<SEC-DOCUMENT>0001628280-26-011226.txt : 20260224
<SEC-HEADER>0001628280-26-011226.hdr.sgml : 20260224
<ACCEPTANCE-DATETIME>20260224171857
ACCESSION NUMBER:		0001628280-26-011226
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		131
CONFORMED PERIOD OF REPORT:	20251231
FILED AS OF DATE:		20260224
DATE AS OF CHANGE:		20260224

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ARVINAS, INC.
		CENTRAL INDEX KEY:			0001655759
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				472566120
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38672
		FILM NUMBER:		26673002

	BUSINESS ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511
		BUSINESS PHONE:		203-535-1456

	MAIL ADDRESS:	
		STREET 1:		395 WINCHESTER AVE
		STREET 2:		5 SCIENCE PARK
		CITY:			NEW HAVEN
		STATE:			CT
		ZIP:			06511

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS INC.
		DATE OF NAME CHANGE:	20181001

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ARVINAS HOLDING COMPANY, LLC
		DATE OF NAME CHANGE:	20151015
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>arvn-20251231.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:bad37b98-383d-4e3d-a5b5-927fa1eba41c,g:852a4cd9-135e-4322-96de-ff3159237791,d:234a6a5dabee4a7a8fb9427be68ac044-->
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2025" xmlns:us-gaap="http://fasb.org/us-gaap/2025" xmlns:srt="http://fasb.org/srt/2025" xmlns:stpr="http://xbrl.sec.gov/stpr/2025" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:cyd="http://xbrl.sec.gov/cyd/2025" xmlns:ecd="http://xbrl.sec.gov/ecd/2025" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:arvn="http://www.arvinas.com/20251231" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>arvn-20251231</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-33">0001655759</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalYearFocus" id="f-34">2025</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:DocumentFiscalPeriodFocus" id="f-35">FY</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" format="ixt:fixed-false" id="f-36">false</ix:nonNumeric><ix:nonNumeric contextRef="c-48" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-393">1</ix:nonNumeric><ix:nonNumeric contextRef="c-49" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-394">1</ix:nonNumeric><ix:nonNumeric contextRef="c-50" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-395">1</ix:nonNumeric><ix:nonNumeric contextRef="c-51" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-396">1</ix:nonNumeric><ix:nonNumeric contextRef="c-52" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-397">1</ix:nonNumeric><ix:nonNumeric contextRef="c-53" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" format="ixt-sec:duryear" id="f-398">1</ix:nonNumeric><ix:nonNumeric contextRef="c-209" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-937">http://fasb.org/us-gaap/2025#ResearchAndDevelopmentExpense</ix:nonNumeric><ix:nonNumeric contextRef="c-210" name="us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" id="f-939">http://fasb.org/us-gaap/2025#GeneralAndAdministrativeExpense</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="arvn-20251231.xsd"/></ix:references><ix:resources><xbrli:unit id="usd"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="shares"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="usdPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="subsidiary"><xbrli:measure>arvn:subsidiary</xbrli:measure></xbrli:unit><xbrli:unit id="number"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="sqft"><xbrli:measure>utr:sqft</xbrli:measure></xbrli:unit><xbrli:unit id="vote"><xbrli:measure>arvn:vote</xbrli:measure></xbrli:unit><xbrli:unit id="product"><xbrli:measure>arvn:product</xbrli:measure></xbrli:unit><xbrli:unit id="segment"><xbrli:measure>arvn:segment</xbrli:measure></xbrli:unit><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-2"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-3"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2026-02-20</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-4"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-10-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-5"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-6"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-7"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-8"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-9"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-10"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-11"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-12"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-13"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-15"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-16"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-17"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-18"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-19"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-20"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-21"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-22"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-23"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-24"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-25"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-26"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-27"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-28"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-29"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-32"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-33"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-34"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-35"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-36"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-37"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-38"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-39"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-40"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-41"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-42"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-43"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-44"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-45"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-46"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-47"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-48"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-49"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-50"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-51"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2029-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-52"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2030-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-53"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"><us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2031-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain></xbrldi:typedMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-54"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-55"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryAndSalesBasedMilestonesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-56"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-57"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-58"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-09-01</xbrli:startDate><xbrli:endDate>2021-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-59"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-60"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-07-01</xbrli:startDate><xbrli:endDate>2021-07-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-61"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-62"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-63"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-64"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-01-01</xbrli:startDate><xbrli:endDate>2018-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-65"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-66"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-67"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2017-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-68"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-69"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-70"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-71"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-72"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2017-11-01</xbrli:startDate><xbrli:endDate>2017-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-73"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2015-09-01</xbrli:startDate><xbrli:endDate>2015-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-74"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-75"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-76"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-77"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-78"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-79"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-80"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-81"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-82"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:RemovalOfCombinationTrialsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-83"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:UpdatedResearchTimelinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-84"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:UpdatedResearchTimelinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-85"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:ExpansionOfDevelopmentProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-86"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:UpdatedResearchTimelinesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-87"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-88"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-89"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-90"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-91"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-92"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-93"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-94"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-95"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-96"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-97"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:A101CollegeStreetLLCMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-98"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-05-04</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-99"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="arvn:ContractTerminationAxis">arvn:OneTimeCashTerminationFeeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-15</xbrli:startDate><xbrli:endDate>2024-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-100"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="arvn:ContractTerminationAxis">arvn:WriteoffOfPrepaidRentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-15</xbrli:startDate><xbrli:endDate>2024-08-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-101"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PledgedStatusAxis">us-gaap:AssetPledgedAsCollateralMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-05-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-102"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-103"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-104"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-12-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-105"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-106"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-04-01</xbrli:startDate><xbrli:endDate>2021-04-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-107"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-108"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-109"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-110"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arvn:PreFundedWarrantMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-111"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arvn:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-112"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-11-01</xbrli:startDate><xbrli:endDate>2023-11-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-113"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2025-09-17</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-114"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-08-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-115"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-116"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-11-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-117"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-118"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-119"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-120"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2018-09-01</xbrli:startDate><xbrli:endDate>2018-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-121"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-122"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-123"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-124"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-125"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-126"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2018-09-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-127"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-128"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-01-01</xbrli:startDate><xbrli:endDate>2019-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-129"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-130"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-131"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-132"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-133"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-134"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-135"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-136"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-137"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-138"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-139"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-140"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-141"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-142"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-143"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-144"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-145"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-146"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-147"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-148"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-149"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-150"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-151"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-152"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-153"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-154"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-155"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-156"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-157"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-158"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-159"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-07-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-160"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-161"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-162"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-163"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-164"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-165"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-166"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-167"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-168"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-169"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-170"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:MA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-171"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-172"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NY</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-173"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">arvn:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-174"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">arvn:NewYorkCityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-175"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NJ</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-176"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:PA</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-177"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-178"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-179"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-180"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-181"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-182"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-183"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-184"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-185"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-186"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-187"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-188"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:MilestonePaymentOnFirstAnniversaryOfSigningMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-189"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2025-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-190"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-07-05</xbrli:startDate><xbrli:endDate>2013-07-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-191"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2013-07-05</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-192"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:LicenseFirstLicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-07-05</xbrli:startDate><xbrli:endDate>2013-07-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-193"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:LicenseSecondLicensedProductMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-07-05</xbrli:startDate><xbrli:endDate>2013-07-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-194"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2013-07-05</xbrli:startDate><xbrli:endDate>2013-07-05</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-195"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-196"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-197"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-198"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arvn:PreFundedWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="c-199"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-200"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-201"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-202"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-203"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-204"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-205"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-04-01</xbrli:startDate><xbrli:endDate>2025-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-206"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-09-01</xbrli:startDate><xbrli:endDate>2025-09-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-207"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-208"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">arvn:StockCompensationAndBonusExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-209"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-210"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-211"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-212"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-213"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-214"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-215"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-216"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-217"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-218"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-219"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-220"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-221"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-222"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-223"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-224"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-225"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-226"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-227"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-228"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-229"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-230"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-231"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-232"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2025-01-01</xbrli:startDate><xbrli:endDate>2025-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-233"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="c-234"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001655759</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-12-31</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_1"></div><div style="min-height:14.4pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000;padding:0 1pt"/></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">UNITED STATES </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION </span></div><div style="margin-top:4pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Washington, D.C. 20549 </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">________________________________________________</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%">FORM <ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">10-K</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">________________________________________________</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">(Mark One) </span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:1pt;font-weight:700;line-height:120%"> </span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentAnnualReport" format="ixt:fixed-true" id="f-2">x</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">For the fiscal year ended <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-3"><ix:nonNumeric contextRef="c-1" name="dei:CurrentFiscalYearEndDate" format="ixt:date-monthname-day-en" id="f-4">December 31</ix:nonNumeric>, 2025</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">OR </span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:3.293%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:94.507%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:DocumentTransitionReport" format="ixt:fixed-false" id="f-5">o</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM &#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;TO&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; .</span></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Commission File Number: <ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-6">001-38672</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________________________________________</span></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:14pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-7">ARVINAS, INC.</ix:nonNumeric></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">(Exact name of registrant as specified in its Charter) </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________________________________________</span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:48.900%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-8">Delaware</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-9">47-2566120</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(State or other jurisdiction of</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">incorporation or organization)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">(I.R.S. Employer</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:115%">Identification No.)</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-10">5 Science Park</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine2" id="f-11">395 Winchester Ave</ix:nonNumeric>.</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-12">New Haven</ix:nonNumeric>, <ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" format="ixt-sec:stateprovnameen" id="f-13">Connecticut</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-14">06511</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(Address of principal executive offices)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:114%">(Zip Code)</span></td></tr></table></div><div style="margin-top:3pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Registrant&#8217;s telephone number, including area code: (<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-15">203</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-16">535-1456</ix:nonNumeric></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">________________________________________________</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(b) of the Act: </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6pt;font-weight:400;line-height:120%"> </span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:38.900%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:19.051%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:38.749%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title of each class</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Trading<br/>Symbol(s)</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:2.28pt;padding-right:2.28pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name of each exchange on which registered</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-17">Common stock, par value $0.001 per share</ix:nonNumeric> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%"> </span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-18">ARVN</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-19">The Nasdaq Global Select Market</ix:nonNumeric></span></div></td></tr></table></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">Securities registered pursuant to Section 12(g) of the Act: </span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:120%">None </span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:7pt;font-weight:700;line-height:120%">(Title of class) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8.5pt;font-weight:700;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. <ix:nonNumeric contextRef="c-1" name="dei:EntityWellKnownSeasonedIssuer" id="f-20">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or 15(d) of the Act.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Yes</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityVoluntaryFilers" id="f-21">No</ix:nonNumeric></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant: (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric contextRef="c-1" name="dei:EntityCurrentReportingStatus" id="f-22">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric contextRef="c-1" name="dei:EntityInteractiveDataCurrent" id="f-23">Yes</ix:nonNumeric> </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">x</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"> No </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company,&#8221; and &#8220;emerging growth company&#8221; in Rule 12b-2 of the Exchange Act.</span></div><div style="margin-top:2pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:20.718%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:2.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:44.506%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.384%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.902%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Large Accelerated Filer</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">o</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" id="f-24">Accelerated filer</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:right"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">x</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Non-accelerated filer</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%">o</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Smaller reporting company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntitySmallBusiness" format="ixt:fixed-false" id="f-25">o</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Emerging growth company</span></td><td colspan="3" style="padding:2px 1pt;text-align:right;vertical-align:top"><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt:fixed-false" id="f-26">o</ix:nonNumeric></span></td></tr></table></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. </span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%">o</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report.</span><span style="color:#000000;font-family:'Wingdings',sans-serif;font-size:8pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:IcfrAuditorAttestationFlag" format="ixt:fixed-true" id="f-27">&#9746;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <ix:nonNumeric contextRef="c-1" name="dei:DocumentFinStmtErrorCorrectionFlag" format="ixt:fixed-false" id="f-28">&#9633;</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive officers during the relevant recovery period pursuant to &#167; 240.10D-1(b). &#9633;</span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes &#9744; No <ix:nonNumeric contextRef="c-1" name="dei:EntityShellCompany" format="ixt:fixed-false" id="f-29">x</ix:nonNumeric></span></div><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">As of June 30, 2025, the last business day of the registrant&#8217;s most recently completed second fiscal quarter, the aggregate market value of the Common Stock held by non-affiliates of the registrant was approximately $<ix:nonFraction unitRef="usd" contextRef="c-2" decimals="-5" name="dei:EntityPublicFloat" scale="6" id="f-30">469.0</ix:nonFraction>&#160;million, based on the closing price of the registrant&#8217;s Common Stock on such date. The number of shares of registrant&#8217;s Common Stock, $0.001 par value per share, outstanding as of February&#160;20, 2026 was <ix:nonFraction unitRef="shares" contextRef="c-3" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" format="ixt:num-dot-decimal" scale="0" id="f-31">63,960,997</ix:nonFraction>. </span></div><div style="margin-top:2pt"><span><br/></span></div><div style="margin-top:2pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:120%">DOCUMENTS INCORPORATED BY REFERENCE</span></div><ix:nonNumeric contextRef="c-1" name="dei:DocumentsIncorporatedByReferenceTextBlock" id="f-32" escape="true"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant&#8217;s 2026 Annual Meeting of Stockholders, which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December&#160;31, 2025.</span></div></ix:nonNumeric><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:91.666%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="height:14.4pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_7"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Table of Contents</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:78.748%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:6.931%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Page</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_13">PART I</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_16">Item 1.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_16">Business</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_16">7</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_19">Item 1A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_19">Risk Factors</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_19">65</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_22">Item 1B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_22">Unresolved Staff Comments</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_22">117</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_25">Item 1C</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_25">Cybersecurity</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_25">118</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_28">Item 2.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_28">Properties</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_28">119</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_31">Item 3.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_31">Legal Proceedings</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_31">119</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_34">Item 4.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_34">Mine Safety Disclosures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_34">119</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_37">PART II</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_40">Item 5.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_40">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_40">120</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_43">Item 6.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_43">[Reserved]</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_43">122</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_46">Item 7.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_46">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_46">122</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_64">Item 7A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_64">Quantitative and Qualitative Disclosures About Market Risk</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_64">143</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_67">Item 8.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_67">Financial Statements and Supplementary Data</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_67">143</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_70">Item 9.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_70">Changes in and Disagreements With Accountants on Accounting and Financial Disclosure</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_70">143</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_73">Item 9A.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_73">Controls and Procedures</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_73">143</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_79">Item 9B.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_79">Other Information</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_79">146</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_82">Item 9C.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_82">Disclosure Regarding Foreign Jurisdictions That Prevent Inspection</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_82">146</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_85">PART III</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_88">Item 10.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_88">Directors, Executive Officers and Corporate Governance</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_88">147</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_91">Item 11.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_91">Executive Compensation</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_91">147</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_94">Item 12.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_94">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_94">147</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_97">Item 13.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_97">Certain Relationships and Related Transactions, and Director Independence</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_97">147</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_100">Item 14.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_100">Principal Accountant Fees and Services</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_100">147</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_103">PART IV</a></span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_106">Item 15.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_106">Exhibits, Financial Statement Schedules</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_106">148</a></span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:4.22pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_109">Item 16.</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_109">Form 10-K Summary</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_109">152</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_10"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS AND RISK FACTOR SUMMARY </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this Annual Report on Form 10-K, including statements regarding our strategy, future operations, future financial position, future revenues, projected costs, prospects, plans and objectives of management, are forward-looking statements. The words &#8220;anticipate,&#8221; &#8220;believe,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;might,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;project,&#8221; &#8220;target,&#8221; &#8220;potential,&#8221; &#8220;goals,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; &#8220;could,&#8221; &#8220;should,&#8221; &#8220;continue&#8221; and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The forward-looking statements in this Annual Report on Form 10-K include, among other things, statements about: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ini</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tiation, timing, progress and results of our current and/or future clinical trials of ARV-102, ARV-806, ARV-393 and ARV-027, including statements regarding the period during which the results of the clinical trials will become available or the forum in which we will present such results;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the initiation, timing, progress and results of our current preclinical studies and any future preclinical studies or clinical trials of our other programs, including ARV-6723 and our pan-KRAS degrader, including statements regarding the period during which the results of preclinical studies or clinical trials will become available or the forum in which we will present such results;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief, based on data from our preclinical studies and clinical trials, that PROTAC protein degraders may have distinct advantages over traditional small molecule inhibitors, antibodies and gene-based medicines;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that PROTAC degraders offer distinct advantages that enable perturbation of protein targets traditionally considered undruggable by conventional therapeutics;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans with respect to market preparations for vepdegestrant and our plans, together with Pfizer Inc., jointly select a third party for the commercialization and potential further development of vepdegestrant;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of, and our ability to obtain, marketing approval of our product candidates, including vepdegestrant, and the ability of our product candidates, including vepdegestrant, to meet existing or future regulatory standards;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans to pursue research and development of other product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential advantages of our platform technology and potential advantages and therapeutic benefits of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that and the extent to which our targeted protein degradation approach may provide distinct advantages over existing therapies and address a broad range of targets, including historically undruggable proteins, in areas of significant unmet need;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential achievement of milestones and receipt of payments under our collaborations, including our collaboration with Pfizer Inc. entered into in July 2021;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential receipt of payments based on the achievement of milestones related to luxdegalutamide (ARV-766) and future royalties under our license agreement with Novartis Pharma AG;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">favorable clinical trial results in our ongoing oncology and neurology programs providing further validation of our platform as a new therapeutic modality for the potential treatment of diseases caused by dysregulated intracellular proteins;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that our leucine-rich repeat kinase 2 ("LRRK2") degraders are particularly well positioned to be evaluated in neurodegenerative diseases where there are currently no disease modifying therapies available, including Parkinson's disease ("PD") and progressive supranuclear palsy ("PSP");</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that the data from our preclinical studies of ARV-102 further support the potential of PROTAC-induced LRRK2 degradation as a treatment for patients with neurodegenerative disease;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that ARV-806</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> has the potential to address high unmet need in solid tumors, such as pancreatic, colorectal and non-small cell lung cancer ("NSCLC"), with KRAS G12D mutation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that ARV-806 has the potential to be developed as a monotherapy and in combination with chemotherapy in pancreatic ductal adenocarcinoma and in combination with standard of care ("SOC") treatments in colorectal and non-small cell lung cancer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that preclinical data for ARV-806 supports intermittent clinical dosing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that PROTAC-mediated degradation has the potential to address the historically undruggable nature of the</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> B-cell lymphoma 6 protein ("BCL6") </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and that ARV-393 PROTAC-mediated degradation of BCL6 may provide an important novel therapeutic option for patients with non-Hodgkin lymphoma;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that ARV-393 can be an attractive combination partner for development of novel therapies for lymphoma, i</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ncluding chemo-free combination regimens and/or &#8220;all oral&#8221; treatment options</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that the totality of our preclinical data for ARV-393 provides a compelling rationale to evaluate ARV-393 in combination with bi-specifics, oral pathway inhibitors, and potentially other standards of care, in the larger diffuse large B-cell lymphoma indication;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that vepdegestrant has the potential to be a best-in-class monotherapy treatment </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for advanced/metastatic breast cancer </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients in the second-line estrogen receptor 1 mutant setting;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the potential receipt of revenue from future sales of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the rate and degree of market acceptance and clinical utility of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding the potential market opportunity for our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to manage the transition of a new chief executive officer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our commercialization plans, and sales, marketing and distribution capabilities and strategy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish and maintain arrangements for manufacture and testing of our product candidates;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to enter into additional collaborations with third parties;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our intellectual property position;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our plans with respect to our strategy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our estimates regarding expenses, future revenues, capital requirements and needs for additional financing, and statements regarding our cash, cash equivalents and marketable securities, including their sufficiency to fund planned operating expenses and capital expenditure requirements into the second half of 2028;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that the </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">One Big Beautiful Bill Act,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is not expected to have a material impact on our business or financial condition;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that there are not currently any risks from known cybersecurity threats that have materially affected or are reasonably likely to materially affect us;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that our facilities are sufficient to meet our current needs and that suitable additional or alternative space will be available as and when needed on commercially reasonable terms for any future growth;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our belief that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the impact of government laws and regulations; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our competitive position.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">You should read this Annual Report on Form 10-K and the documents that we have filed as exhibits to this Annual Report on Form 10-K completely and with the understanding that we may not actually achieve the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements we make. We have included important factors in the cautionary statements included in this Annual Report on Form 10-K, particularly in the &#8220;Risk Factors&#8221; section, that we believe could cause actual results or events to differ materially from the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments we may make.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not assume any obligation to update any forward-looking statements except as required by applicable law.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Annual Report on Form 10-K also contains estimates and other statistical data made by independent parties and by us relating to market size and other data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such data and estimates. In addition, projections, assumptions and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. Cross-trial comparisons are not based on head-to-head studies and no direct comparisons can be made.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Throughout this Annual Report on Form 10-K, the &#8220;Company,&#8221; &#8220;Arvinas,&#8221; &#8220;we,&#8221; &#8220;us,&#8221; and &#8220;our,&#8221; except where the context requires otherwise, refer to Arvinas, Inc. and its consolidated subsidiaries, or any one or more of them as the context may require, and &#8220;our board of directors&#8221; refers to the board of directors of Arvinas, Inc.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Arvinas name and logo are our trademarks. This Annual Report on Form 10-K contains references to our trademarks and service marks and to those belonging to other entities. Solely for convenience, trademarks and trade names referred to in this Annual Report on Form 10-K, including logos, artwork and other visual displays, may appear without the &#174; or &#8482; symbols, but such references are not intended to indicate in any way that we will not assert, to the fullest extent under applicable law, our rights or the rights of the applicable licensor to these trademarks and trade names. We do not intend our use or display of other entities&#8217; trade names, trademarks or service marks to imply a relationship with, or endorsement or sponsorship of us by, any other entity.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risk Factor Summary </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our business is subject to a number of risks that if realized could materially affect our business, prospects, operating results and financial condition. These risks are discussed more fully in the &#8220;Risk Factors&#8221; section of this Annual Report on Form 10-K. These risks include the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have incurred significant losses since our inception. We expect to incur expenses and operating losses over at least the next several years and may never achieve or maintain profitability. Our net losses totaled $80.8 million, $198.9 million and $367.3 million for the years ended December&#160;31, 2025, 2024, and 2023, respectively. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have never generated revenue from product sales and may never be profitable. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We will need substantial additional funding to continue our operations. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research, product development programs or future commercialization efforts.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our approach to the discovery and development of product candidates based on our PROTAC technology platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We do not have any product candidates that have been approved for commercialization.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Positive data from preclinical or early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive data from our preclinical or early clinical studies of our product candidates in our future clinical trials, we will be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We are developing and plan to continue to develop our product candidates in combination with other drugs. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs, or revoke their approval of such drugs, or if safety, efficacy, manufacturing or supply issues arise with the drugs we choose to evaluate in combination with our product candidates, we may be unable to obtain approval of or market our products.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We have an ongoing collaboration with Pfizer related to vepdegestrant, but have announced that we and Pfizer have agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant. If our collaboration with Pfizer or another party is not successful, we may not be able to capitalize on the market potential of vepdegestrant.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We currently depend, and expect to continue to depend, on collaborations, license arrangements, and other strategic alliances with third parties for the research, development, and the potential future commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely and expect to continue to rely on third parties to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We rely on third-part</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">y CMOs or CDMOs for the manufacture and testing of both drug substance and finished drug product for our product can</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">didates for preclinical testing and clinical trials and expect to continue to do so for commercialization. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired, and we may not be able to compete effectively in our market. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of any or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and our failure or the failure of our collaborators,CROs, CDMOs, contractors, consultants and other third parties to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our future success depends on our ability to retain key employees, consultants and advisors and to attract, train, retain and motivate qualified personnel.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Our internal computer systems and those of our collaborators, CROs, CDMOs, contractors, consultants and other third parties are vulnerable to cyber attacks, cyber intrusions and security breaches, which could not only materially disrupt our business operations and result in the loss of confidential information, but also damage the integrity of our clinical trials, impact our regulatory filings, compromise our ability to protect our intellectual property, and subject us to regulatory actions that could result in significant fines or other penalties.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The price of our common stock is volatile and may fluctuate substantially, which could result in the loss of all or part of our stockholders&#8217; investment. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_13"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART I</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_16"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1. Business. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_684"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Overview</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through our PROteolysis TArgeting Chimera, or PROTAC, protein degradation platform, we are pioneering the development of a new class of therapeutics designed to harness the body&#8217;s ow</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We have designed and optimized our proprietary PROTAC Discovery Engine for the discovery of PROTAC therapeutics to address diseases caused by abnormal proteins or aberrant protein expression. We believe that our targeted protein degradation approach is a novel therapeutic modality that may provide distinct advantages over existing therapies and address a broad range of targets, including historically undruggable proteins, in areas of significant unmet need. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In the past five years, seven of the programs developed using our PROTAC protein degradation platform have progressed to clinical trials in oncology and neurology indications after demonstrating potent and selective protein degradation in our preclinical studies. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The U.S. Food and Drug Administration, or FDA, has accepted our New Drug Application, or NDA, for vepdegestrant, our most advanced product candidate from the platform, for the treatment of patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), or ER+/HER2-, estrogen receptor 1, or ESR1,-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy, and has assigned a Prescription Drug </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">User Fee Act, or PDUFA, action date of June 5, 2026. We believe favorable clinical trial results in our ongoing oncology and neurology programs would further validate our platform as a new therapeutic modality for the potential treatment of diseases caused by dysregulated intracellular proteins.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently progressing the following product candidates through clinical development programs: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-102, targeting the leucine-rich repeat kinase 2, or LRRK2, protein for the treatment of neurodegenerative diseases, including Parkinson's disease, or PD, and progressive supranuclear palsy, or PSP;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-806, targeting Kirsten rat sarcoma, or KRAS, -G12D protein for cancers with the G12D mutation, including pancreatic, colorectal </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and non-small cell lung cancer</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-393, targeting the B-cell lymphoma 6, or BCL6, protein for the treatment of relapsed/refractory non-Hodgkin lymphoma, or NHL;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vepdegestrant, targeting the estrogen receptor, or ER, for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also advancing several preclinical candidates through early stage development, in a broad range of intracellular disease targets, including proteins that currently cannot be addressed by existing small molecule therapies, commonly referred to as &#8220;undruggable&#8221; or under-drugged targets. These preclinical candidates include ARV-6723 targeting hematopoietic progenitor kinase 1, or HPK1, and a pan-KRAS degrader targeting multiple variants of KRAS while sparing other RAS isoforms. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the programs above and our early-stage collaborations</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, including with Pfizer, Inc., or Pfizer, and Genentech, Inc. and F. Hoffman-La Roche Ltd., or Genentech, we are conducting exploratory research and development work on multiple other undisclosed targets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_674"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Our Strategy</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our mission is to improve the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of novel protein degraders. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;We are currently developing PROTAC degraders to address targets within oncology and neurology, and we believe there is the potential for applicability in other therapeutic areas as well. The key elements of our strategy are to:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Advance our current oncology and neurology pipeline through anticipated data milestones to evaluate safety, efficacy, and biological activity, with the objective of demonstrating therapeutic differentiation to existing therapies. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These clinical data will inform development priorities, resource allocation, and subsequent clinical and regulatory strategies. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Create medicines using new therapeutic modalities that have potential benefits over current modalities.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We aim to develop therapies with the potential to deliver meaningful benefits relative to traditional small molecule inhibitors, or SMIs, antibodies, and gene-based medicines.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Utilize our PROTAC Discovery Engine to expand our pipeline with a focus on historically undruggable and difficult-to-drug targets. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This approach is designed to leverage targeted protein degraders to address disease biology that may not be amenable to traditional small-molecule or biologic approaches. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Selectively collaborate to realize the full value of our pipeline and platform. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our preclinical and clinical programs advance, we continue to assess opportunities where a partner may be able to accelerate any such program's development, enhance such program's probability of success, or expand such program's commercial potential. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:14.5pt">Expand the capabilities of our PROTAC Discovery Engine and the breadth of our intellectual property portfolio to support the discovery and optimization of next-generation targeted protein degraders. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We seek to broaden and strengthen our intellectual property portfolio to protect platform innovations, novel targets, and product candidates, supporting long-term value creation.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_525"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Our Focus - PROTAC Degradation and its Potential Benefits</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our disciplined target selection and proprietary discovery platform aim to enable the rational design of innovative degrader medicines across major protein classes. We focus on potential first- and best-in-class target opportunities in areas of high unmet need, particularly where we believe targeted protein degradation, or TPD, may offer the most effective or only path to potentially meaningful clinical outcomes. This includes addressing genetically defined targets or those under-drugged targets that are key regulatory points within pathways that are clinically validated targets, such as transcription factors and scaffolding proteins. With our integrated capabilities we aim to accelerate discovery of TPD therapeutics, translating biological insight into efficient drug design.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Areas of Unmet Need and PROTAC Capabilities</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We are seeking to address areas of significant unmet need for patients, including neurology and oncology, with PROTAC targeted protein degrader therapeutics as further described in "Our Clinical Programs" section.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PROTAC protein degraders are small molecule therapeutic agents consisting of two ligands joined by a chemical linker. One ligand binds to an E3 ligase and the other ligand binds to a disease-causing protein of interest. PROTAC protein degraders facilitate formation of a ternary complex, leading to transfer of ubiquitin to the protein of interest and subsequent degradation by the proteasome, as shown in Figure 1 below</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="text-indent:36pt"><img src="arvn-20251231_g1.jpg" alt="PROTAC.jpg" style="height:269px;margin-bottom:5pt;vertical-align:text-bottom;width:553px" id="i-1"/></div><div><span><br/></span></div><div style="text-align:center;text-indent:54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Figure 1</span></div><div style="text-indent:54pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PROTACs have the potential to bring together certain useful features of SMIs, antibodies and gene-based medicines, while also having an iterative mechanism of action, which is referred to as &#8220;event-based pharmacology,&#8221; allowing one PROTAC to potentially lead to the degradation of many molecules of the protein of interest. Based on data from our preclinical studies and clinical trials, we believe that PROTAC protein degraders may have distinct advantages over traditional SMIs, antibodies and gene-based medicines, as shown below</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">:</span></div><div style="text-indent:54pt"><span><br/></span></div><div><img src="arvn-20251231_g2.jpg" alt="PROTAC Advantages.jpg" style="height:359px;margin-bottom:5pt;vertical-align:text-bottom;width:624px" id="i-2"/></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe PROTAC degraders offer distinct advantages that enable perturbation of protein targets traditionally considered undruggable by conventional therapeutics. Unlike inhibitors, degraders can eliminate proteins such as scaffolding proteins, transcription factors, oncoproteins, and oligomer-forming proteins using PROTACs with the potential for oral dosing and systemic distribution, in contrast to genomic and antibody modalities that only work extracellularly. Because degradation is a catalytic and durable process, PROTACs have the potential to achieve therapeutic effect with lower drug exposure and less frequent dosing than traditional approaches. PROTAC molecules are also compatible with established small-molecule manufacturing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">processes, offering potential advantages in scalability and cost. Importantly, PROTACs can be chemically engineered to selectively degrade disease-relevant proteins, including mutant or pathogenic isoforms, while sparing wild-type or healthy proteins, and can overcome challenges posed by protein amplification or overexpression. We believe these capabilities support therapeutic strategies aimed at oncoprotein removal and immune reactivation within the tumor microenvironment in oncology, as well as the removal of key amplified scaffolding and pathologic proteins in the brain and muscle in neurodegenerative and neuromuscular diseases. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Discovery Platform &#8212; PROTAC Discovery Engine</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Our PROTAC Discovery Engine is an interlocking suite of tools and expertise that assists with our goal of creating and advancing clinical-stage programs with the potential to help patients, as shown below:</span></div><div style="text-indent:36pt"><span><br/></span></div><div><img src="arvn-20251231_g3.jpg" alt="PROTAC Discovery Engine.jpg" style="height:322px;margin-bottom:5pt;vertical-align:text-bottom;width:660px" id="i-3"/></div><div style="text-align:center;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Defined terms used in the figure above include: PROTAC, proteolysis targeting chimera; ANGLE, Arvinas Next Generation Linker Enablement; LEAP (Library-Enabled ANGLE PROTACs; EM, electron microscopy; AI/ML, artificial intelligence/machine learning; HTS, high throughput screening; DEL, DNA-encoded libraries; CADD, computer-aided/assisted drug design; PK/PD, pharmacokinetics/pharmacodynamics; and cryoEM, cryogenic electron microscopy.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional details regarding certain tools we use in our PROTAC Discovery Engine are included below.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Target Selection</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We focus on targets that we believe are poised to make a PROTAC protein degrader that has the potential to provide benefits over SMIs, antibodies and gene-based medicines, and address unmet need for patients with cancer and neurodegenerative diseases. These targets are selected because they are genetically defined targets or are under-drugged targets that are key regulatory points within pathways that are clinically validated. We focus on differential target biology that drives disease via scaffolding functions, gene amplification and protein overexpression, isoform expression or mis-localization, protein oligomers, resistance mutation, and where targets have been underdrugged due to incomplete target coverage, inadequate biodistribution, or lack catalytic binding pockets.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">E3 KnowledgeBase</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We have deep and long-standing experience in understanding and exploiting E3 ligase mechanisms in order to match the right E3 ligase to the right target. The human body has more than 600 E3 ligases, and we select ligands for E3 ligases from our growing proprietary ligand library, E3KnowledgeBase, for incorporation into our PROTAC targeted protein degraders. We are expanding our capabilities to include the development of novel PROTACs that recruit E3 ligases with targeted expression patterns, such as tumor or central nervous system, or CNS, localized E3 ligases, that may be beneficial for the development of targeted oncologic and neurologic therapies.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Advanced Screening Capabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We have high-throughput and DNA-encoded library, or DEL, screening abilities, that power our ability to identify new domains, which are the building blocks of proteins, including domains for the &#8220;undruggable&#8221; targets, and new binders for E3 ligases. Unlike traditional libraries, our DEL is designed specifically to facilitate incorporation into PROTACs and optimize their drug-like properties.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">ANGLE: Arvinas Next Generation Linker Evolution</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: Our chemical linkers incorporate learnings from our long history of designing PROTACs, allowing increased potency and selectivity, as well as desirable pharmacokinetic properties to drive oral absorption and blood-brain barrier penetration, right from the start.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">LEAP: Library-Enabled ANGLE PROTACs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We have enhanced our ability to deploy ANGLE on our projects by evolving it into a library format, where we can now make hundreds of PROTACs at one time and screen them all in a direct-to-biology format. We have also created a proprietary software tool to accelerate LEAP library design.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">PROTACify</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We have built PROTACify, a proprietary computational, machine-learning, or ML, solution for modeling PROTAC ternary complexes to enable selection of the best PROTAC designs for synthesis. With our deep experience in trimer structure-based computational modeling and design algorithms, we frequently create potent degraders in the first chemical series.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">Proteomics Capabilities</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: PROTACs are often far more selective than the protein-binding domain within the targeted protein. Our proteomics capabilities enable us to understand that specificity in precise detail and iterate quickly to optimize the selectivity of our degraders for the drug target.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:14.5pt;text-decoration:underline">Arvinas Rules</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">: PROTACs are not intrinsically "drug-like" and frequently do not following classical guidance for probable oral absorption, such as the "Rule of 5". We have established and refined our own "beyond the Rule of 5" Arvinas Rules to discover PROTACs that have the potential for oral bioavailability and crossing the blood-brain barrier. We have consolidated our large, proprietary preclinical pharmacokinetic, or PK, data set into ML models in order to enhance our potential for success in finding PROTACs with the desired pharmacokinetic properties from the outset of the process.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="padding-left:36pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt;text-decoration:underline">PIVOT (PROTAC In Vivo Optimization Tool)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: In contrast to traditional small molecule agents, which follow an occupancy-driven mechanism of action, PROTACs are event-driven, and as such can display profound nonlinear PK, pharmacodynamic responses. We have developed PIVOT as a desktop tool to enable our scientists to develop a deep, intuitive understanding of relationships among PK, pharmacodynamic and efficacy. We believe our understanding of molecular features that impact PROTAC biodistribution and target degradation kinetics in the body enables us to create PROTACs with drug-like properties and activities.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">11</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_520"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Our Pipeline</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our pipeline, which includes an overview of our most advanced clinical and preclinical programs, is summarized below. </span></div><div style="margin-top:6pt;padding-left:144pt;padding-right:144pt;text-align:center;text-indent:36pt"><img src="arvn-20251231_g4.jpg" alt="Pipeline for 10-K.jpg" style="height:299px;margin-bottom:5pt;vertical-align:text-bottom;width:700px" id="i-4"/></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:15.2pt">The agents included in the graphic above are currently under investigation; their safety and effectiveness for these investigational uses have not been established. </span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:15.2pt">Defined terms included in the graphic above: AR, androgen receptor; BCL6, B-cell lymphoma 6; ER, estrogen receptor; HPK1, Hematopoietic Progenitor Kinase 1; I-O, immuno-oncology; KRAS, Kirsten rat sarcoma viral oncogene homolog; LRRK2, leucine-rich repeat kinase 2; mCRPC, metastatic castration resistant prostate cancer; mHSPC, metastatic hormone sensitive prostate cancer; NSCLC, non small cell lung cancer; NDA, new drug application; NHL, non-Hodgkin lymphoma; polyQ, expanded polyglutamine; PSP, progressive supranuclear palsy; SBMA, spinal bulbar muscular atrophy.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:112%;padding-left:15.2pt">Footnotes included in the graphic above: (a) Includes relapsed/refractory angioimmunoblastic T-cell lymphoma, or AITL, and relapsed/refractory mature B cell NHL; (b) PDUFA date of June 5, 2026; and (c) Phase 1/2 combination clinical trials with palbociclib, atirmociclib, abemaciclib, ribociclib, samuraciclib, everolimus. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_763"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Our Clinical Stage Programs</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-102: Oral PROTAC LRRK2 Degrader Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-102 is an investigational, orally bioavailable PROTAC designed to cross the blood-brain barrier and specifically target and degrade LRRK2, which is a large, multi-domain scaffolding kinase with GTPase activity. ARV-102 is our first oral PROTAC protein degrader in clinical development to treat neurodegenerative diseases.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Traditional SMIs only block LRRK2&#8217;s kinase activity, and thus only modify disease processes regulated by the LRRK2 kinase. By degrading the entire protein, LRRK2 degraders are designed to eliminate all of the ways LRRK2 interacts with disease pathology: the scaffolding function, GTPase activity, as well as kinase activity. We believe our LRRK2 degraders are particularly well positioned to be evaluated in neurodegenerative diseases where there are currently no disease modifying therapies available, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PD, where increased LRRK2 expression and activity contributes to neurodegeneration and pathogenesis of PD; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PSP, where genetic variations in LRRK2 are associated with PSP progression and accelerated time to death. PSP is a primary tau-driven disease, and tau uptake by human neurons requires LRRK2 activity. Additionally, we have published data associating the tau pathology of PSP with LRRK2-mediated endolysosomal dysfunction.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Population and Market Opportunity</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">PD is the second most common neurodegenerative disease after Alzheimer's disease. It is estimated that PD affects approximately 1.1 million people in the U.S. and more than 10 million people worldwide. Approximately 90,000 people in the U.S. are estimated to be diagnosed with PD each year. PD is a neurodegenerative disease characterized by a complex array of motor and non-motor symptoms. It is commonly thought of as a movement disorder because patients can experience tremors, slowness of movement, stiffness and difficulty with walking and balance. In addition, PD patients can have other non-motor type problems such as constipation, depression, sleep disorders and cognitive decline. PD is a progressive brain disorder that damages dopamine-producing neurons and is likely caused by a combination of genetic and environmental risk factors. Current management for PD is limited to symptomatic interventions and there is no approved disease modifying agents. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Mutations in the LRRK2 gene are one of the most common genetic risk factors for PD. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">LRRK2 is a multidomain GTPase/kinase that acts, in part, as a scaffolding protein to interact with components of downstream signaling pathways regulating lysosomal function, mitochondrial processes, neuroinflammation and alpha-synuclein a</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ccumulation to negatively impact neuronal survival. Human genetics in the form of a protective PD variant (N551K/R1398H), produces approximately half the levels of LRRK2 in the CSF and reduces the risk of developing PD.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Preclinical animal model data suggest that a reduction of 50% of LRRK2 protein, but not kinase inhibition, may impact pathology and dysfunction in PD. Therefore, reduction of LRRK2 in the brain may be beneficial for the treatment of PD.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">PSP is a rare, progressive neurodegenerative disease that affects brain cells that control balance and coordination, eye movement, speech, swallowing and thinking. Emerging research suggests that LRRK2 plays a role in PSP by contributing to disease mechanisms such as neuroinflammation and cellular dysfunction. LRRK2 is involved in immune system regulation and may influence tau protein accumulation, a hallmark of PSP. It also plays a role in autophagy and inflammation, which could contribute to neurodegeneration seen in PSP. Additionally, variants in the LRRK2 gene have been associated with PSP progression and survival. PSP has an estimated annual prevalence of approximately five to seven per 100,000 persons globally. It is estimated that approximately 20,000 to 25,000 people are in the U.S. living with PSP each year, based on data from 2023. There are currently no FDA-approved disease-modifying therapies that halt or delay PSP progression and which often leads to patients progressing with a time to death of five to seven years following diagnosis. Based on 2021 published data, g</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">enome wide association studies have identified LRRK2 variants that are significantly associated with reduced survival in PSP. Based on data from a third party study in 2025 comparing PSP and control participants, higher levels of baseline monocyte LRRK2 levels were associated with a greater one-year change in PSP rating scale scores. We believe these data support a role for LRRK2 variants that impact its expression levels in modulating survival in PSP.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Preclinical Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In preclinical studies, ARV-102 was shown to cross the blood-brain barrier and degrade LRRK2 in cerebrospinal fluid, or CSF, in non-human primates, or NHPs. Our preclinical studies also showed that ARV-102 and other similar LRRK2 PROTAC degrader molecules pharmacologically enhanced lysosomal degradative capacity and number, and reduced pathologic forms of tau </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> in vivo</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We believe the data from our preclinical studies of ARV-102 further support the potential of PROTAC-induced LRRK2 degradation as a treatment for patients with neurodegenerative diseases.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Clinical Development</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been evaluating ARV-102 in Phase 1 clinical trials in healthy volunteers and patients with PD. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Healthy Volunteers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We initiated the first-in-human Phase 1 clinical trial for ARV-102 in the first quarter of 2024. We completed the single ascending dose, or SAD, and multiple ascending dose, or MAD, cohorts of the ARV-102 Phase 1 clinical trial in healthy voluntee</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Patients with PD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We completed enrollment in the SAD cohort of the ARV-102 Phase 1 clinical trial in patients with PD in the second quarter of 2025. We received Clinical Trial Application approval in the Netherlands to initiate a multiple dose cohort of the Phase 1 clinical trial in patients with PD in </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the second quarter of 2025, and we initiated this multiple dose cohort in the third quarter of 2025. In the fourth quarter of 2025, we completed enrollment in the multiple dose cohort.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2025, we presented data from the first-in-human Phase 1 healthy volunteer clinical trial of ARV-102 at the 2025 International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases, or AD/PD, 2025, including results from the randomized, double-blind, placebo-controlled SAD cohort, and initial results from the MAD cohort. The ARV-102 Phase 1 clinical trial was designed to assess the safety, PK, and pharmacodynamics of orally administered ARV-102 in healthy male volunteers. This clinical trial was a single-center, randomized, double-blind, placebo-controlled trial evaluating outcomes in both SAD and MAD cohorts. In the SAD cohort, volunteers were randomized three to one, to either placebo or a single dose of ARV-102 (10 mg, 30 mg, 60 mg, 90 mg, 150 mg, or 200 mg) on day 1 with follow-up until day 10. In the MAD cohort, volunteers were randomized to either placebo or a once daily dose of ARV-102 (10 mg, 20 mg, 40 mg, or 80 mg) for 14 days with follow-up until day 28.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The ARV-102 Phase 1 clinical data in healthy volunteers demonstrated substantial reduction of LRRK2 in CSF with a promising safety/tolerability profile and favorable pharmacodynamic outcomes. Key findings from the clinical trial indicated brain penetration, substantial central and peripheral LRRK2 protein degradation, and downstream LRRK2 pathway engagement. The specific data presented at AD/PD 2025 are outlined below.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Safety Profile</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">At the time of data cutoff (March 13, 2025), the SAD cohort of the Phase 1 clinical trial was completed and the MAD cohort was ongoing. Based on evaluation of the available data from single and multiple oral doses, ARV-102 was well tolerated in healthy volunteers.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Of the 47 volunteers across all SAD dose levels, the primary treatment related adverse events, or AEs, were headache and fatigue. Headaches occurred in 17.1% (6/35) of treated individuals compared to 0% (0/12) in placebo controls. Fatigue occurred in 8.6% (3/35) of the treated individuals compared to 25% (3/12) in placebo controls.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Procedural pain associated with the lumbar puncture occurred in 28.6% (10/35) of treated individuals compared to 41.7% (5/12) in placebo controls. Post lumbar puncture syndrome was only observed in the treated cohort, at a rate of 17.1% (6/35).</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">No serious adverse events, or SAEs, were reported in either the SAD or MAD cohorts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">ARV-102 Exposure in Plasma and CSF</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-102 exhibited median maximum concentration six hours after oral administration.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The area under the concentration-time curve in the first 24 hours post dosing and the maximum plasma concentration increased in a dose-dependent manner and the median terminal plasma half-life was 73 hours.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-102 levels in CSF increased in a dose dependent manner in both the SAD and MAD cohorts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Pharmacodynamic Evaluation</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">At single doses of greater than or equal to 60 mg and repeated doses of greater than or equal to 20 mg, LRRK2 reduction of greater than 90% in peripheral blood mononuclear cells was observed.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-102 at single doses of greater than or equal to 30 mg induced greater than 50% decreases in peripheral phospho-Rab10T73, a LRRK2 substrate and biomarker for downstream LRRK2 activity; as of the date of presentation, data for this endpoint in the MAD cohort was pending.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-102 at single doses of greater than or equal to 30 mg resulted in greater than 90% decrease of bis(monoacylglycerol)phosphate in urine, a biomarker of lysosomal function; data for this endpoint in the MAD cohort is pending.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In CSF, ARV-102 induced dose-dependent LRRK2 reduction, with greater than 50% LRRK2 reduction at single doses of greater than or equal to 60 mg and repeated doses of greater than or equal to 20 mg.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fourth quarter of 2025, we presented late breaking positive Phase 1 data from our clinical trial of ARV-102 in healthy volunteers, and from the SAD cohort of our Phase 1 clinical trial of ARV-102 in patients with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">PD, as well as CSF Proteomic Data from the Phase 1 clinical trial of ARV-102 in healthy volunteers at the 2025 International Congress of Parkinson&#8217;s Disease and Movement Disorders, or MDS. Data presented at MDS included the following:</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Data from the Phase 1 SAD and MAD Clinical Trial in Healthy Volunteers</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Safety: ARV-102 was generally well tolerated at single doses up to 200 mg and multiple daily doses up to 80 mg, with no discontinuations due to AEs or SAEs observed in the study population.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmacokinetics: ARV-102 exposure increased in a dose-dependent manner in plasma and CSF, the latter indicating brain penetration.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmacodynamics: Repeated daily doses of greater than or equal to 20 mg resulted in greater than 90% reductions of LRRK2 protein in peripheral blood mononuclear cells, or PBMCs, and greater than 50% reductions in CSF.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pathway Biomarkers: Repeated daily doses of ARV-102 resulted in reduced plasma concentrations of phospho-Rab10T73 and urine concentrations of bis(monoacylglycerol)phosphate, a sensitive biomarker for modulation of the lysosomal pathway downstream of LRRK2.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Interim SAD Data from the Phase 1 Clinical Trial in Patients with PD and CSF Proteomic Data from a Phase 1 Trial in Healthy Volunteers </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Safety: The SAD cohort of the Phase 1 clinical trial in patients with PD included 15 patients treated with ARV-102 and 4 patients treated with placebo. In the trial, single doses of ARV-102 (50 mg or 200 mg) were well tolerated with only mild treatment-related AEs including headache, diarrhea, and nausea; no SAEs occurred.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmacokinetics: In patients with PD, ARV-102 exposure increased in a dose-dependent manner in both plasma and CSF, the latter indicating brain penetration.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pharmacodynamics: In patients with PD, treatment with ARV-102 resulted in median PBMC LRRK2 protein reductions of 86% with the 50 mg dose and 97% with the 200 mg dose.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CSF Proteomics: In healthy volunteers treated with ARV-102 at 80 mg once daily for 14 days, unbiased proteomic analyses of CSF showed significant decreases in lysosomal pathway markers and neuroinflammatory microglial markers previously shown to be elevated in patients with PD harboring LRRK2 variants.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe these data presented at MDS highlight the potential of PROTAC-mediated LRRK2 degradation, which supports the development of ARV-102 in ongoing studies of patients with PD and we plan to present data from the multiple dose cohort of the Phase 1 clinical trial of ARV-102 in patients with PD i</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n the first quarter of 2026 in an oral presentation at 2026 AD/PD. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We also believe these data support development in PSP, and pending regulatory feedback, we plan to initiate a Phase 1b clinical trial of ARV-102 in patients with PSP in the first half of 2</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">026 and have the potential to initiate a registrational trial of ARV-102 in PSP in late 2026, pending regulatory feedback.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_1101"></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">ARV-806: Novel PROTAC KRAS G12D Degrader Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-806 is an investigational novel PROTAC designed to selectively target and degrade mutant KRAS G12D in solid tumors. KRAS is one of the most frequently mutated human oncogenes and G12D is the most common mutation of the KRAS protein. In normal cells, the KRAS protein regulates cell growth and functions as</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">a molecular switch, cycling between a baseline &#8220;OFF&#8221; state and only turning &#8220;ON&#8221; when conditions are appropriate for growth. Mutations, including G12D, lock KRAS in the &#8220;ON&#8221; form, leading to uncontrolled cell growth and cancer. ARV-806 is designed to degrade both the ON and OFF forms of KRAS G12D and by removing this oncogenic protein, has the potential to shut down the constitutive growth signal and lead to death of the cancer cells</span><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">. We believe ARV-806 has the potential to address high unmet need in solid tumors, such as pancreatic, colorectal and non-small cell lung cancer, or NSCLC, with KRAS G12D mutation. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Patient Population and Market Opportunity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patients with metastatic cancers harboring KRAS G12D mutations have poor survival outcomes with no approved KRAS G12D-targeted therapy. Key tumors harboring KRAS G12D mutations include pancreatic ductal adenocarcinoma, or PDAC, colorectal carcinoma, and NSCLC with respective prevalence of KRAS G12D mutations of 35-40% for PDAC, 12-15% for colorectal carcinoma and 3-4% for NSCLC, based on published data from 2021 and 2022.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">There are approximately 60,000 newly diagnosed PDAC patients per year in the U.S., based on 2026 estimates, with only an approximate 3% five-year survival rate in metastatic setting, based on data from the Surveillance, Epidemiology, and End Results, or SEER, Program, part of the National Cancer Institute. There are approximately 158,000 newly diagnosed colorectal cancer patients each year in the U.S., based on 2026 estimates, with only an approximate 16% five-year survival rate in metastatic setting, based on data from SEER. There are approximately 195,000 newly diagnosed NSCLC patients per year in the U.S., based on 2026 estimates, with only an approximate 10% five year survival rate in metastatic setting, based on data from SEER, as reported for combined NSCLC and small-cell lung cancer.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Due to the high unmet need of these patient populations, we believe ARV-806 has the potential to be developed as a monotherapy and in combination with chemotherapy in PDAC and in combination with SOC treatments in colorectal and non-small cell lung cancer.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Development</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Preclinical Development</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the preclinical setting, ARV-806 demonstrated high potency and selectivity, with robust antitumor activity through dose-responsive degradation of KRAS G12D in KRAS G12D mutated cancer models, including pancreatic and colorectal models. ARV-806 formed a ternary complex with both the active "ON" and inactive "OFF" forms of KRAS G12D, achieving potent and durable elimination rather than inhibition of the target. As a result, in preclinical studies, ARV-806 achieved </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> potency more than 25 times greater than</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical stage </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">KRAS G12D "ON" and "OFF" inhibitors and more than 40 times greater than the leading KRAS G12D clinical-stage degrader.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2025, we presented preclinical data for ARV-806 at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, or the 2025 Triple Meeting. Key highlights from the presentation at the 2025 Triple Meeting include the following:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In vitro, ARV-806 degraded KRAS G12D with picomolar potency across pancreatic, colorectal, and lung cancer cell lines, but did not induce degradation of wild-type KRAS or other RAS isoforms.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The preclinical data demonstrated that ARV-806 is differentiated from other KRAS G12D targeting agents in development and we believe ARV-806 has potential to be a best-in-class therapy for KRAS G12D mutated cancers due to:</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Catalytic activity, which may allow it to overcome upregulation of KRAS G12D, a common mechanism of resistance to inhibitor treatment.</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Compared with clinical-stage KRAS G12D ON and OFF inhibitors and another clinical-stage KRAS G12D degrader, ARV-806 demonstrated:</span></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">more than 25-fold greater potency in reducing cancer cell proliferation (versus clinical-stage KRAS G12D &#8220;ON&#8221; and &#8220;OFF&#8221; inhibitors);</span></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">more than 40-fold greater potency in degrading KRAS G12D protein (versus the comparable clinical-stage KRAS G12D degrader); and</span></div><div style="margin-top:6pt;padding-left:126pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">more than 10-fold lower concentrations required to induce pro-apoptotic BIM (Bcl-2-interacting mediator of cell death, a pro-apoptotic factor) expression.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Following a single intravenous dose in a colorectal tumor xenograft model, ARV-806 degraded greater than 90% of KRAS G12D for seven days, with parallel suppression of c-MYC (a key driver of cancer cell proliferation) and induction of BIM for greater than or equal to five days.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-806 demonstrated robust efficacy responses at low doses in tumor models including: &#8805;30% tumor volume reductions in pancreatic and colorectal cell line-derived xenograft (CDX) models and a patient-derived xenograft (PDX) model of lung cancer.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These preclinical data demonstrate sustained pharmacodynamic activity consistent with long-lasting target degradation, which we believe supports intermittent clinical dosing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%;text-decoration:underline">Clinical Development</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We filed an investigational new </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">drug application, or IND, with the FDA for ARV-806 in the first quarter of 2025 and received a safe-to-proceed letter from the FDA in the second quarter of 2025. We initiated enrollment in a Phase 1 clinical trial of ARV-806 in patients with advanced solid tumors harboring KRAS G12D mutations in the second quarter of 2025 and this trial is currently ongoing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2026, we announced that we had completed dose escalation for once-weekly administration ahead of plan based on faster-than-anticipated enrollment of the Phase 1 clinical trial evaluating ARV-806 in patients with solid tumors harboring KRAS G12D mutations. We plan to continue enrollment in this clinical trial and anticipate sharing initial clinical data i</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">n patients with solid tumors harboring KRAS G12D mutations </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">in 2026.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_768"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-393: Oral PROTAC BCL6 Degrader Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-393 is an investigational, orally bioavailable PROTAC designed to specifically target and degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentiation processes. Deregulation of BCL6 function (e.g., via chromosomal translocation, mutations) may lead to malignant transformation and development of NHL.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Also as a lineage defining transcription factor of T-follicular helper cells, BCL6 has been implicated in nodal T-follicular helper cell lymphoma, or nTFHL, including the angioimmunoblastic type, formerly angioimmunoblastic T-cell lymphoma, or AITL.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During B-cell development, tightly controlled BCL6 protein expression regulates more than 600 genes to facilitate rapid B-cell proliferation and tolerance of somatic hypermutation and gene recombination for antibody generation. Deregulated BCL6 expression is common in B-cell lymphoma and promotes cancer cell survival, proliferation, and genomic instability. We believe that PROTAC-mediated degradation has the potential to address the historically undruggable nature of BCL6 and that ARV-393 PROTAC-mediated degradation of BCL6 may provide an important novel therapeutic option for patients with NHL. Furthermore, we believe current preclinical data suggest that ARV-393 has the potential to be an attractive combination partner for development of novel therapies for lymphoma, including chemo-free combination regimens and/or &#8220;all oral&#8221; treatment options.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Population and Market Opportunity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">It is estimated that there were approximately 80,000 new cases and approximately 19,300 deaths in the U.S. related to NHL annually in 2025 based on data from SEER. NHL is a heterogeneous group of diseases, with large B-cell lymphoma, or LBCL, and follicular lymphoma, or FL, being the most common subtypes. Diffuse large B-cell lymphoma, or DLBCL, is another subtype of NHL, often associated with deregulated BCL6 expression and/or functions. It is estimated that approximately 30,000 to 33,000 patients are diagnosed with DLBCL each year in the U.S., based on data from 2025 and 2026.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment for DLBCL is largely devoid of oral options and there are currently no approved BCL6-targeted therapies on the market in the U.S. </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Each subtype has a distinct biologic and clinical characteristics and requires different approaches to treatment. Despite significant progress made with treating B-cell NHL and nTFHL, many patients will ultimately experience disease progression or relapse. Thus, there remains unmet need, including managing aggressive subtypes, treatment resistance, and improving outcomes for older patients.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We believe our PROTAC BCL6 degrader could be a potential therapy for many NHLs, including FL and nTFHL (formerly AITL). NHL originates from B cells, T cells, and/or natural killer cells, with those of B-cell origin </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">constituting approximately 80%&#8211;85% of all NHL cases. BCL6 may also be a clinically relevant therapeutic target in other hematologic malignancies, some solid tumors and B-cell driven autoimmune diseases.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Preclinical Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on our NHL preclinical studies, complete tumor stasis, which correlates with 90%-100% degradation of measurable BCL6, was achieved when ARV-393 was dosed as an oral monotherapy at low daily concentrations. This robust activity was seen in models of multiple NHL subtypes including multiple DLBCLs representing various genomic backgrounds of activated B-cell and germinal center B-cell lymphomas, Burkitt's lymphoma, and transformed FLs. In addition, ARV-393 significantly reduced tumor burden in a CHOP-relapsed patient derived xenograft, or PDX, model of AITL (now known as nTFHL), a cancer that has no standard of care, or SOC, and high unmet need. This is the first demonstration, to our knowledge, of preclinical evidence of BCL6 as a tractable therapeutic target in a human-derived model of this type. In our preclinical studies, we have also demonstrated that ARV-393 combines well with SOC therapies including CHOP, R-CHOP or rituximab, and with the newer biologics glofitamab, tafasitamab, and the antibody drug conjugates loncastuximab tesirine and polatuzumab vedotin. This potential for broad combinability extends further to investigational SMIs that target BCL2 (anti-apoptosis), EZH2 (chromatin regulation) and BTK (B-cell receptor signaling pathway). Combinations such as these that target multiple oncogenic drivers, have the potential to provide benefits for patients with lymphomas that progress aggressively with the acquisition of multiple genetic or epigenetic aberrations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2024, we presented preclinical data for ARV-393 at the European Hematology Association 2024 Annual Congress, which showed anti-tumor activity in preclinical models of B-cell lymphoma. In these preclinical models, ARV-393 potently and rapidly degraded the BCL6 protein and inhibited cell growth in DLBCL and Burkitt cell lines. ARV-393 showed tumor growth inhibition, or TGI, including tumor regression, in various DLBCL cell line-derived xenograft models and in multiple patient-derived xenograft models of NHL including germinal center B-cell-like, or GCB, activated B-cell, or ABC, GCB/ABC, and BCL not otherwise specified subtypes of DLBCL, and Burkitt lymphoma. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2025, we presented preclinical data of ARV-393 in combination with SOC chemotherapy and biologic agents, as well as oral, investigational SMIs in high grade and aggressive DLBCL in vivo models at the American Association for Cancer Research, or AACR, Annual Meeting. Based on these preclinical data, in aggressive DLBCL models, ARV-393 showed strong synergistic antitumor activity, including complete regressions, in combination with SOC chemotherapy and biologics, as well as investigational oral SMIs. In particular:</span></div><div><span><br/></span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-393 in combination with SOC chemotherapy (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone, or R-CHOP), induced significantly greater TGI, compared with rituximab, CHOP, R-CHOP, or ARV-393 alone, with complete tumor regressions in all mice treated with the ARV-393 and R-CHOP combination;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-393 in combination with SOC biologics targeting CD20 (rituximab), CD19 (tafasitamab), or CD79b (polatuzumab vedotin), resulted in tumor regressions and demonstrated significantly stronger TGI compared with either agent alone;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In preclinical models, ARV-393 increased CD20 expression, providing additional support for the exploration of combinations with CD20-targeted agents and in the context of low or loss of CD20 expression; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-393 in combination with investigational SMIs targeting clinically validated oncogenic drivers of lymphoma, such as BTK (acalabrutinib), BCL2 (venetoclax), or EZH2 (tazemetostat), resulted in superior TGI compared with each agent alone, with tumor regressions in all mice treated with the combinations.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, in the second quarter of 2025, we presented new data from preclinical studies of ARV-393 at the European Hematology Association 2025 Congress in Milan, Italy. In these preclinical studies, ARV-393 demonstrated significant single-agent activity in a PDX, model of nodal T-follicular helper cell lymphoma, angioimmunoblastic-type, or nTFHL-AI (which is also known and referred to as AITL), and PDX models of transformed follicular lymphoma, or tFL. In addition, in these preclinical studies, in combination with oral SMIs, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ARV-393 demonstrated enhanced antitumor activity, including tumor regressions, in cell line-derived xenograft, or CDX, models of high-grade B-cell lymphoma, or HGBCL, and DLBCL. We believe these preclinical data potentially suggest the broad utility of ARV-393 across NHL subtypes with unmet need beyond DLBCL and provide a compelling rationale for considering combination strategies including chemotherapy-free approaches. Key findings from these preclinical studies included:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Single-agent ARV-393 significantly reduced tumor burden in peripheral blood, bone marrow and spleen in a systemic PDX model of nTFHL-AI derived from a patient who relapsed post chemotherapy.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-393 monotherapy treatment resulted in robust (&#8805;95%) TGI in two PDX models of tFL.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-393 in combination with five classes of SMIs targeting potentially cooperative oncogenic drivers (tazemetostat, palbociclib, everolimus, acalabrutinib, or venetoclax) demonstrated increased TGI in CDX models of HGBCL and aggressive DLBCL compared with the respective monotherapy treatments. Tumor regressions were observed when ARV-393 was combined with tazemetostat, palbociclib, acalabrutinib, or venetoclax.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">RNA sequencing studies carried out to further characterize downstream mechanism of action suggested that ARV-393 inhibits tumor cell cycle progression and promotes differentiation, driving antitumor activity and broad combinability in preclinical models.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fourth quarter of 2025, we presented preclinical data for ARV-393 in combination with glofitamab, a CD20xCD3 bispecific antibody and an emerging SOC option for DLBCL, in models of aggressive high grade DLBCL at the 67th American Society of Hematology 2025 Annual Meeting and Exposition.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">These preclinical data showed that in a humanized high-grade B-cell lymphoma, or HGBCL, CDX model, the combination of ARV-393 and glofitamab resulted in significantly enhanced TGI and increased rates of tumor regression compared with either agent alone. These preclinical data suggest mechanistic synergies between BCL6 degradation with ARV-393 and T-cell engagement.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Specifically, key highlights from the poster presentation included the following:</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In a humanized HGBCL CDX model, ARV-393 (3 mg/kg) combined with glofitamab (0.15 mg/kg) achieved 81% TGI with concomitant dosing and 91% TGI with sequential dosing (ARV-393 followed by glofitamab), versus 38% for single-agent ARV-393 and 36% for glofitamab alone.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">At a higher ARV-393 dose (6 mg/kg) combined with glofitamab (0.15 mg/kg), an increase in tumor regressions was observed with concomitant (10 of 10 mice) and sequential dosing (7 of 8 mice) versus single-agent ARV-393 (5 of 11 mice) or glofitamab (0 of 11 mice).</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">RNA sequencing and biomarker analyses revealed that ARV-393 upregulated CD20 expression and genes that promote interferon signaling and antigen presentation, while downregulating proliferation-associated gene sets. We believe these collective effects likely contributed to the observed synergistic antitumor activity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe the totality of our ARV-393 preclinical data provides a compelling rationale to evaluate ARV-393 in combination with bi-specifics, oral pathway inhibitors, and potentially other SOCs, in the larger DLBCL indication. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;text-decoration:underline">Clinical Development</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated the monotherapy cohort of our first-in-human Phase 1 clinical trial of ARV-393 in patients </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">with relapsed or refractory NHL in the second quarter of 2024 and are currently recruiting patients for this clinical trial. This is an open-label, multicenter, Phase 1 dose escalation trial to evaluate the safety, tolerability PK, pharmacodynamics, and pre</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">liminary anti-tumor activity of ARV-393 as a single agent in adult patients with relapsed/refractory NHL. We announced previously that there have been multiple responses in early cohorts in both B- and T-cell lymphomas in the first-in-human Phase 1 clinical trial. Dose escalation in the trial is ongoing and the safety profile of ARV-393 supports continuing dose escalation. We also believe these early data support an emerging, and differentiated, therapeutic benefit of ARV-393. We plan to share updated clinical data from the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">19</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ongoing Phase 1 clinical trial of ARV-393 in patients with relapsed/refractory NHL at a medical congress in the second half of 2026.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also plan to initiate enrollment of a glofitamab combination cohort in patients with DLBCL in the ongoing Phase 1 clinical trial of ARV-393 in the first half of 2026.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_1206"></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-027: Oral PROTAC polyQ-AR Degrader Program</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ARV-027 is an investigational, oral, peripherally restricted PROTAC designed to selectively target and eliminate the polyQ-AR in skeletal muscle. ARV-027 is a product candidate specifically selected for potent in vitro reduction of cytosolic and nuclear polyQ-AR and for favorable skeletal muscle exposure following oral administration.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The polyQ-AR protein is the pathogenic driver of spinal bulbar muscular atrophy, or SBMA, a rare, X-linked, genetically defined neuromuscular disease caused by a CAG trinucleotide repeat expansion in the androgen receptor, or AR, gene, causing protein misfolding and leading to progressive degeneration of the neuromuscular system in men. SBMA leads to progressive muscle weakness, dysphagia, and functional decline, and currently has no disease-modifying therapies approved by the FDA or EMA, representing a significant unmet medical need.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Population and Market Opportunity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Due to limited disease awareness, historical underdiagnoses, and the absence of approved therapies, few large-scale epidemiologic studies have been conducted in SBMA. Published data estimates suggest that SBMA has an estimated population prevalence of approximately one to two per 100,000 individuals worldwide. Based on those estimated prevalence rates, roughly 3,500 to 7,500 individuals are currently living with SBMA in the U.S.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Preclinical and Clinical Development</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the fourth quarter of 2025 at the International Congress of the World Muscle Society, we presented new preclinical data demonstrating induced robust degradation of polyQ-AR in human myotubes derived from SBMA patient-induced pluripotent stem cells. The preclinical ARV-027 data presented also showed dose-dependent degradation of AR in mouse skeletal muscle that was sustained for more than 24 hours (single oral dose), and reductions in muscle monomeric polyQ-AR levels between 40-60%, improved muscle grip strength, and restored muscle endurance to wild-type levels in SBMA mouse model.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We initiated a first-in-human Phase 1 clinical trial in ARV-027 in healthy volunteers in the first quarter of 2026.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_773"></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vepdegestrant: Oral PROTAC ER Degrader Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant is an investigational, orally bioavailable PROTAC ER degrader being developed for the treatment of ER+/HER2- locally advanced or metastatic breast cancer. We chose ER degradation as a therapeutic focus given the well-documented biology of ER signaling as a principal driver in a high percentage of breast cancers. In July 2021, we announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has accepted our NDA for vepdegestrant for the treatment of patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy, and has assigned a PDUFA date of June 5, 2026.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Patient Population and Market Opportunity</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Breast cancer is the most commonly diagnosed cancer diagnosed in women in the United States, excluding non-melanoma skin cancers, and the second leading cause of cancer death among women, based on 2026 estimates. Approximately one in eight women in the United States will develop invasive breast cancer in their lifetime. For 2026, the American Cancer Society estimates that there will be approximately 322,000 new cases of invasive breast cancer diagnosed in women in the United States. Approximately 70% of all breast cancer cases, including males, are ER+, based on SEER data. In addition, there are approximately 20,000 </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">patients in the U.S. with ESR1 mutated, ER+/HER2- advanced or metastatic breast cancer in the second line plus setting, based on SEER data from 2023.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treatment options for breast cancer depend on many different factors, including the stage of the cancer and whether the cancer cells contain hormone receptors. Patients with locally advanced or metastatic breast cancer are treated with systemic therapy, including hormone therapy, chemotherapy and targeted therapy, either as single-agents or in combination. Patients with locally advanced or metastatic ER+/HER2- breast cancer are often treated with hormone therapy, such as an aromatase inhibitor, typically in combination with targeted drugs such as CDK4/6 inhibitors. In patients with aggressive disease or whose disease continues to progress with a hormonal treatment regimen, chemotherapy may be prescribed. Treatment with chemotherapy is generally postponed for as long as possible due to the potential for severe side effects including neuropathies, nausea, diarrhea, decreased mental capacity and increased risk of infections. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A current standard of care for patients with ER+/HER2- locally advanced or metastatic breast cancer who experience progression on first-line therapy is fulvestrant, a selective ER degrader, or SERD, administered as a monthly intramuscular injection, either as a single-agent or in combination with another targeted therapy. While fulvestrant has validated the importance of ER degradation as a therapeutic intervention, up to 50% of ER can remain when compar</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed to baseline levels after six months of treatment with fulvestrant, providing an opportunity for more potent ER degraders. In January 2023, the FDA approved elacestrant, a SERD, for postmenopausal women or adult men with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. In September 2025, the FDA approved imlunestrant, a SERD, for adults with ER+/HER2-, ESR1 mutated advanced or metastatic breast cancer with disease progression following at least one line of endocrine therapy. </span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Clinical Development</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, along with Pfizer, have several ongoing clinical trials of vepdegestrant, for which enrollment of patients is complete, which are summarized below.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VERITAC-2, a Phase 3 clinical trial of vepdegestrant as a monotherapy, for the treatment of patients with metastatic breast cancer previously treated with endocrine based therapy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VERITAC, a Phase 2 dose expansion clinical trial of vepdegestrant as a monotherapy, for the treatment of patients with previously treated metastatic breast cancer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TACTIVE-K, a Phase 1b/2 clinical trial of vepdegestrant in combination with Pfizer's cyclin-dependent kinase 4, or CDK4, inhibitor, atirmociclib; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TACTIVE-U, a group of Phase 1b/2 clinical trials of vepdegestrant in combination with multiple targeted therapies including abemaciclib, ribociclib or Carrick Therapeutics, Inc.'s, or Carrick, cyclin-dependent kinase 7, or CDK7, inhibitor, samuraciclib.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We, along with Pfizer, also have completed two clinical trials of vepdegestrant:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TACTIVE-N, a Phase 2 clinical trial of vepdegestrant as a monotherapy in the neoadjuvant setting; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TACTIVE-E, a Phase 1 clinical trial of vepdegestrant in combination with everolimus.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, VERITAC-3 a clinical trial with a study lead-in of vepdegestrant in combination with palbociclib for the treatment of patients with first-line metastatic breast cancer, is ongoing and enrollment of patients is complete. As previously disclosed, VERITAC-3 will not proceed beyond the study lead-in.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">VERITAC-2 Clinical Trial, New Drug Application</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the first quarter of 2025, we, along with Pfizer, announced positive topline results from the Phase 3 VERITAC-2 clinical trial in the estrogen receptor 1-mutant, or ESR1m, population, and in the second quarter of 2025, we, along with Pfizer announced detailed results from this clinical trial. These detailed results, which are included below, were presented in a late-breaking oral presentation at the American Society of Clinical Oncology, or ASCO, 2025 Annual Meeting and were highlighted in the ASCO press briefing and selected for Best of ASCO, and were also simultaneously published in the New England Journal of Medicine.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on the results from VERITAC-2, in the second quarter of 2025, we and Pfizer submitted an NDA to the FDA for vepdegestrant for the treatment of patients with ER+/HER2- ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This represents the first NDA submitted for a PROTAC. In the third quarter of 2025, we announced that the FDA accepted the NDA for vepdegestrant and assigned a PDUFA date of June 5, 2026.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Trial Design</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Phase 3 VERITAC-2 clinical trial is a global randomized study evaluating the efficacy and safety of vepdegestrant as a monotherapy compared to fulvestrant in patients with ER+/HER2- advanced or metastatic breast cancer. The trial enrolled 624 patients at sites in 26 countries who had previously received treatment with a CDK4/6 inhibitor plus endocrine therapy. Patients were randomized to receive either vepdegestrant once daily, orally on a 28-day continuous dosing schedule, or fulvestrant, administered intramuscularly on Days 1 and 15 of Cycle 1 and then on Day 1 of each 28-day cycle starting from Day 1 of Cycle 2. The primary endpoint was progression-free survival, or PFS, in the intent-to-treat, or ITT, and ESR1-m populations as determined by blinded independent central review, or BICR. Overall survival, or OS, was the key secondary endpoint.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Clinical Trial Results</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">The Phase 3 VERITAC-2 trial met its primary endpoint in the ESR1m population, demonstrating a statistically significant and clinically meaningful improvement in PFS compared to fulvestrant. The results exceeded the pre-specified target hazard ratio of 0.60 in the ESR1m population. The trial did not reach statistical significance in improvement in PFS in the ITT population.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">OS was not mature at the time of the analysis of data, with less than a quarter of the required number of events having occurred. The tr</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ial has continued </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">to assess OS as a key secondary endpoint. In the trial, vepdegestrant was generally well tolerated and its safety profile was consistent with what has been observed in previous studies.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Detailed results from the Phase 3 VERITAC-2 clinical trial included the following:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">PFS</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Vepdegestrant demonstrated a statistically significant and clinically meaningful improvement in PFS among ESR1m patients, reducing the risk of disease progression or death by 43% compared to fulvestrant [Hazard Ratio, or HR=0.57 (95% CI 0.42&#8211;0.77); 2-sided P&lt;0.001]. The median PFS, as assessed by BICR, was 5.0 months with vepdegestrant versus 2.1 months with fulvestrant in the ESR1-m population.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Investigator-assessed PFS was consistent with the BICR-assessed PFS.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">In ESR1m patients, vepdegestrant demonstrated a consistent PFS benefit over fulvestrant across all pre-specified subgroups.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The trial did not reach statistical significance in improvement in PFS in the ITT population, with a median PFS of 3.7 months for vepdegestrant versus 3.6 for fulvestrant [HR=0.83 (95% CI 0.68&#8211;1.02); 2-sided P=0.07].</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Tolerability and Safety Profile</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Vepdegestrant was generally well tolerated in the clinical trial, with a safety profile consistent with what has been observed in previous studies, and mostly low-grade treatment-emergent adverse events, or TEAEs, were reported.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Rates and severity of gastrointestinal treatment emergent AEs were low with vepdegestrant (nausea, 13.5%; vomiting, 6.4%; diarrhea, 6.4%). Grade 4 TEAEs were reported in five patients (1.6%) in the vepdegestrant arm versus nine&#8239;patients (2.9%) in the fulvestrant arm.</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">The three most common TEAEs observed with vepdegestrant were fatigue (26.6%), increased alanine transaminase (ALT) (14.4%) and increased aspartate aminotransferase (AST) (14.4%).</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">TEAEs leading to treatment discontinuation occurred in 2.9% of patients taking vepdegestrant versus 0.7% of patients taking fulvestrant.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Other Data Points</span></div><div style="margin-top:6pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9702;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Additional secondary endpoints include clinical benefit rate, or CBR, and objective response rate, or ORR, and duration of response by BICR. In patients with an ESR1 mutation, CBR was 42.1% with vepdegestrant versus 20.2% with fulvestrant [odds ratio 2.88 (95% CI: 1.57&#8211;5.39); nominal P&lt;0.001] and ORR was 18.6% with vepdegestrant versus 4.0% with fulvestrant [odds ratio 5.45 (95% CI: 1.69&#8211;22.73); nominal P=0.001]. The median duration of response was not reached.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We believe that, based on these strong data from VERITAC-2, vepdegestrant has the potential to be a best-in-class monotherapy treatment for advanced/metastatic breast cancer patients in the second-line ESR1m setting.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our global collaboration with Pfizer, we and Pfizer presented patient reported outcomes, or PRO, data from the VERITAC-2 clinical trial in the fourth quarter of 2025 at the European Society for Medical Oncology, or ESMO, 2025 Congress. In the VERITAC-2 clinical trial, in patients with ESR1-m disease, vepdegestrant demonstrated a reduced risk of deterioration compared to fulvestrant which was statistically significant in several PRO domains including overall health status, pain severity, and functioning (including role, cognitive, emotional, and social functioning), and vepdegestrant consistently showed reduced risk of deterioration versus fulvestrant across all PRO domains. These PRO data from the VERITAC-2 clinical trial support the clinical benefit of vepdegestrant in patients with ESR1-m, ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Clinical Trials and Information</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In the second quarter of 2025, we announced that we and Pfizer removed two planned Phase 3 combination trials of vepdegestrant from the agreed-upon joint development plan: a first-line Phase 3 combination trial with Pfizer&#8217;s novel investigational CDK4 inhibitor, atirmociclib, and a second-line Phase 3 combination trial with a CDK4/6 inhibitor.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in the second quarter of 2025, Pfizer added a vepdegestrant combination cohort to its ongoing Phase 1 clinical trial evaluating Pfizer&#8217;s investigational KAT6 inhibitor in combination with endocrine therapies following CDK4/6 inhibitor treatment. This clinical trial is being operationalized and funded solely by Pfizer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our global collaboration with Pfizer, we and Pfizer presented results of the TACTIVE-N Phase 2 clinical trial which evaluated neoadjuvant vepdegestrant in postmenopausal women with ER+/HER2&#8211; localized breast cancer in the fourth quarter of 2025 at the ESMO 2025 Congress. The results presented showed that neoadjuvant vepdegestrant demonstrated biological and clinical activity in this treatment-na&#239;ve, predominantly ESR1 wild-type population of postmenopausal women with ER+/HER2- localized breast cancer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as part of our global collaboration with Pfizer, we presented five posters at the San Antonio Breast Cancer Symposium further supporting the potential of vepdegestrant as a potential treatment option for patients with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy potential.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We, along with Pfizer, continue market preparations for vepdegestrant in advance of the PDUFA date. While we continue to believe that vepdegestrant has the potential to be a best-in-class monotherapy treatment for advanced/metastatic breast cancer patients in the second-line ESR1m setting, given our and Pfizer&#8217;s decision to remove the two planned Phase 3 combination trials of vepdegestrant from the agreed-upon joint development plan as noted above, we determined that it is no longer viable for us to build out our commercial infrastructure as we had previously planned. As such, in the third quarter of 2025, we announced that we and Pfizer have agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_758"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Our Preclinical Programs </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have active preclinical programs in neurology and oncology. We aim to take a disciplined target selection approach and leverage our proprietary discovery platform to rationally design innovative degrader molecules across major protein classes. Our focus is on potential first- and best-in-class opportunities in high unmet need areas where targeted protein degradation may provide the most effective, or only, path to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">meaningful impact to the target that is either genetically defined or historically an under-drugged regulatory target or target protein that contains non-enzymatic sites involved in the disease causation.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exploratory and research activities in neurology focus on programs aimed at degrading proteins with strong human and mouse genetic validation demonstrating that protein mutation potentially drives disease pathology. Examples include Tau in Frontal temporal dementia with expansion into Alzheimer's disease, alpha-synuclein gene amplification in accelerated forms of Parkinson's disease and Multiple System Atrophy, and mutant Huntingtin protein in Huntington's disease.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our exploratory and research activities in oncology focus on degrading oncogenic drivers, such as pan-KRAS, as well as tackling key immune regulatory targets like HPK1, a negative regulator of the tumor microenvironment and T cell activation.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Neurologic Diseases</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Neurologic diseases, in particular, neurodegenerative diseases, are generally progressive in nature and result in the degeneration and often death of neurons in the periphery and the brain, leading to cognitive decline, functional impairm</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ent and eventually death. These diseases affect a rapidly growing patient population and represent one of the largest unmet medical needs of our time. Alzheimer&#8217;s and PD encompass the largest patient populations among the neurodegenerative diseases. The Alzheimer&#8217;s Association estimated that 7.2 million Americans aged 65 and older, about one in nine individuals, were living with Alzheimer&#8217;s dementia in 2026, with 74% aged 75 or older, and the Parkinson&#8217;s Foundation estimated in 2026 that approximately 1.1 million Americans are living with PD and approximately 90,000 people are newly diagnosed every year. Alzheimer&#8217;s disease is marked by the progressive accumulation of aggregated tau protein, while aggregation of alpha-synuclein is thought to cause PD.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Antibody-based therapies targeting only extracellular forms of these proteins thought to be the cause of these neurodegenerative diseases have failed to show clinically mea</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ningful benefit to date. While some existing products provide symptomatic relief to Alzheimer&#8217;s and PD patients, they have significant side effect risks and over time gradually lose their effectiveness in treating the symptoms of the disease. Further, while there are now amyloid-directed antibody therapies that modestly impact extracellular A-beta with vascular side effects that can be severe, there are no approved disease-modifying treatments targeting intracellular tau or alpha-synuclein for Alzheimer&#8217;s or PD.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Developing PROTAC Targeted Protein Degraders that Cross the Blood Brain Barrier </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Engineering PROTAC degraders that cross the blood-brain barrier is necessary to achieve targeted elimination of disease-causing intracellular proteins from within the CNS. The ability of a targeted therapy to cross the blood-brain barrier is a highly desirable characteristic in developing effective therapeutics for patients with neurodegenerative diseases as compared with therapies delivered directly into the CNS via invasive intrathecal delivery. Any product candidates for neurodegenerative disease must reach their intended intracellular targets in the brain at exposure levels that will provide a therapeutic effect, while having an acceptable safety profile. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Importantly, we have achieved brain penetration in preclinical models following parenteral administration of PROTAC degrader molecules. These PROTAC degrader molecules achieved concentrations in the brain sufficient to induce degradation of the aggregated proteins, widespread penetration into different parts of the brain, and brain/plasma ratios of 0.5 to 5.0, comparable to approved therapeutics with CNS activity. Our research efforts are aimed at designing PROTAC degraders to either specifically target pathologic oligomers or monomers of mutant huntingtin, tau, and alpha-synuclein, for the treatment of Huntington's disease, Alzheimer&#8217;s</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> disease (tauopathies) and PD (synucleinopathies), respe</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ctively, or to impact pathway proteins contributing to their pathology in these diseases.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to our tau and alpha-synuclein programs, our neuroscience pipeline includes a program directed to mutant huntingtin, or mHTT, a key protein target for Huntington&#8217;s disease. In preclinical studies, we have identified ligands that bind to mutant mHTT protein without binding to wild-type HTT protein in preclinical studies. This selectivity differentiates these ligands from other small molecule splice modulators that reduce </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">both mHTT and wild-type HTT protein. We believe that our discovery of selective mHTT PROTAC degraders has the potential to eliminate the toxic mHTT protein.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Oncology, ARV-6723: Oral PROTAC HPK1 Degrader Program, and pan-KRAS Degrader Programs</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition to neurological preclinical programs, we are exploring oncology and immuno-oncology preclinical programs. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">ARV-6723 is an investigational, preclinical oral PROTAC designed to degrade HPK1 in solid malignancies. Preclinically, ARV-6723 has shown potent, selective HPK1 degradation and strong anti-tumor immune responses with superior tumor control in low- and high- immunogenic murine syngeneic tumor models. In solid tumor malignancies, such as NSCLC, melanoma, and renal cell carcinoma, or RCC, HPK1 acts as a negative regulator in T-cell receptor signaling, contributing to T-cell exhaustion and suppressing antitumor immunity. In addition, HPK1 has a regulatory role in other immune cell types that can be co-opted by tumors, thus enabling these cancers to resist immuno-oncology therapy. Degrading HPK1 and thus eliminating both its kinase and scaffolding functions has the potential to unleash an immune response with potent anti-tumor effects and minimum off-target toxicity.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We presented preclinical data at the Society for Immunotherapy of Cancer annual meeting in the fourth quarter of 2025 that we believe supports the potential of ARV-6723 to provide sustained anti-tumor immune response as a single agent or in combination with standards of care with improved clinical benefits, including that: ARV-6723, as a single agent, demonstrates anti-tumor efficacy superior to anti-PD1 or a clinical HPK1 inhibitor and combines with anti-PD1 to further enhance response; and ARV-6723 single agent activity outperforms the HPK1 inhibitor and anti-PD-1 efficacy and reinstitutes the tumor microenvironment. We believe these preclinical results support future investigation of ARV-6723 alone or in combination with other agents in patients with high- or low-immunogenic tumors. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, we presented preclinical data for ARV-6723 at the AACR Immuno-Oncology Conference in the first quarter of 2026 that support clinical investigation of ARV-6723 in patients with solid tumors harboring high- or low-immunogenic tumor microenvironments, or TME, including immune checkpoint inhibitor-resistant tumor settings. This preclinical data showed robust single-agent antitumor and proinflammatory activity in multiple syngeneic tumor models, including those with immunosuppressive TMEs, and showed greater preclinical activity than an investigational HPK1 inhibitor or an anti-PD-1 antibody.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Pending regulatory feedback, we plan to initiate a Phase 1 clinical trial of ARV-6723 in patients with advanced solid tumors in mid-2026. Upon initiation of the clinical trial, ARV-6723 will be our first clinical candidate in immuno-oncology. Additionally, we plan to present preclinical data evaluating antitumor and unique immunomodulatory activity of ARV-6723 in immuno-oncology-resistant models compared to SOC checkpoint inhibition in the first half of 2026.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Our preclinical oral pan-KRAS program targets multiple variants of KRAS that drive solid tumors such as PDAC, colorectal cancer, NSCLC, and esophageal cancer, while sparing other RAS isoforms. We believe selectively targeting KRAS for removal may have benefits to tolerability compared with a pan-RAS approach. The poster presented at the 2025 Triple Meeting in the fourth quarter of 2025 showed that orally bioavailable pan-KRAS degraders have been identified that potently degrade multiple variants of KRAS and spare other RAS isoforms. A tool pan-KRAS PROTAC demonstrated robust single-agent activity and superior combination efficacy with immune checkpoint blockade compared with a pan-RAS ON inhibitor (seven complete responses compared with two complete responses). We plan to present preclinical data evaluating the activity and selectivity of a novel pan-KRAS degrader in multiple KRAS mutants and differentiation over RAS (ON) or pan-KRAS inhibitors in the first quarter of 2026 at the AACR Special Conference in Cancer Research: RAS Oncogenesis and Therapeutics. We also plan to p</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">resent preclinical data evaluating the efficacy of a novel pan-KRAS degrader in a KRAS syngeneic model, as well as associated immune microenvironment changes in the first half of 2026.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_748"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Other Programs: Luxdegalutamide (ARV-766) and bavdegalutamide (ARV-110)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had been developing luxdegalutamide and bavdegalutamide, each an investigational, orally bioavailable, AR degrading PROTAC targeted protein degrader, for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC. Both luxdegalutamide and bavdegalutamide demonstrated </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">activity in preclinical models of AR overexpression and AR mutations, both common mechanisms of resistance to current standard-of-care agents in men with prostate cancer. We believed that the differentiated PROTAC pharmacology of luxdegalutamide and bavdegalutamide, including their iterative activity, had the potential to translate into significantly improved clinical outcomes over current SOC agents. However, a comparison of clinical data from separate studies of luxdegalutamide and bavdegalutamide showed that luxdegalutamide&#8217;s tolerability and efficacy was more promising than that of bavdegalutamide</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result, early in the fourth quarter of 2023, we determined to prioritize the initiation of a Phase 3 clinical trial with luxdegalutamide in mCRPC instead of the previously planned Phase 3 clinical trial for bavdegalutamide. Clinical trials for bavdegalutamide (ARV-110-101 and ARV-110-103) were completed in the second quarter of 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2024, we completed a transaction with Novartis Pharma AG, or Novartis, which comprised a license agreement, or the Novartis License Agreement, and an asset agreement, or the Novartis Asset Agreement. Pursuant to the Novartis License Agreement, we granted Novartis an exclusive worldwide license for the development, manufacture and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization of luxdegalutamide, and we completed the transition of our ongoing and planned clinical trials of luxdegalutamide to Novartis in the fourth quarter of 2024. Pursuant to the Novartis Asset Agreement, we sold Novartis all of our rights, title and interest in our PROTAC protein degrader targeting AR-V7, a splice variant of the AR. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_515"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Intellectual Property</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part upon our ability to secure and maintain patent and other proprietary protection for our platform protein degradation technologies, including our PROTAC degrader programs, product candidates, and know-how related to our business, defend and enforce our intellectual property rights, in particular our patent rights, preserve the confidentiality of our trade secrets, and operate without infringing valid and enforceable intellectual property rights of others. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent positions for biotechnology companies like us are generally uncertain and can involve complex legal, scientific and factual issues. In addition, the coverage claimed in a patent application can be significantly reduced before a patent is issued, and its scope can be reinterpreted and even challenged after issuance. As a result, we cannot guarantee that any of our product candidates will be protected or remain protectable by enforceable patents. We cannot predict whether the patent applications we are currently pursuing will issue as p</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">atents in any particular jurisdiction or whether the claims of any issued patents will provide sufficient proprietary protection from competitors. Any patents that we hold may be challenged, circumvented or invalidated by third parties.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, our patent estate that we own, co-own and in-license includes 71 issued U.S. patents, 318 granted foreign patents, and 620 pending patent applications (118 U.S. and 502 foreign). All dates noted for patent term expiration below exclude any potential patent term extensions or adjustments, assuming all appropriate maintenance fees are paid.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_646"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-102</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, we have three families in our LRRK2 patent portfolio directed, in part, to the composition of matter of ARV-102, as well as other LRRK2 PROTAC degraders. These families include granted U.S. and foreign patents as well as pending U.S. and foreign applications. Any granted patent in these families will expire between 2041 and 2044. In addition, the LRRK2 portfolio includes pending U.S. and PCT applications directed to manufacturing methods for and crystalline forms of PROTAC LRRK2 degraders. These additional applications, if issued, will expire between 2044 and 2045.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_641"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-806 and KRAS G12D</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, our KRAS G12D patent portfolio, including ARV-806, includes a composition of matter patent family, which includes a granted U.S. patent as well as pending U.S. and foreign applications. In addition, the KRAS G12D portfolio includes a pending U.S. method of treatment application. Any granted patents in this family will expire between 2044 and 2</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">045.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_657"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-393</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, our ARV-393 patent portfolio includes a composition of matter patent family, which includes an issued U.S. patent and an issued foreign patent, as well as pending applications in the U.S. and certain foreign jurisdictions including Europe, China, and Japan, and a method of treatment patent family with pending U.S</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. and PCT applications, as well as one pending foreign application. Any granted patents in these families will expire between 2042 and 2045. In addition, the ARV-393 BCL6 portfolio includes pending U.S. applications directed to drug treatment combinations, and drug formulation. These additional families, if issued, will expire in 2045</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_1222"></div><div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-027</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, our ARV-027 patent portfolio includes two patent families, one directed to a composition of matter and one directed to a method of treating SBMA, both of which have issued in the United States and are pending in select foreign jurisdictions. If issued, these families will have a natural patent expiry between 2037 and 2044.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_662"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vepdegestrant</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, our vepdegestrant patent portfolio includes a family with issued composition of matter patents in the U.S. and in foreign jurisdictions, including China, Japan and Europe, as well as pending applications in U.S. and certain foreign jurisdictions. Any granted patents in this family will expire in 2037. This patent portfolio also includes patent families with pending applications directed to methods of treatment with a combination of vepdegestrant and palbociclib; methods of treating breast cancer with ER mutations; crystalline forms; formulations; manufacturing methods; dosage regimens; drug treatment combinations; and drug-drug interactions in the U.S. and certain foreign jurisdictions. Patents from these additional families, if issued, will expire between 2040 and 2046. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_621"></div><div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-6723</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, our HPK1 patent portfolio includes two composition of matter patent families, which includes pending US and PCT patent applications. Patents from these families, if granted, will expire between 2044 and 2045.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_616"></div><div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Luxdegalutamide (ARV-766)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The intellectual property rights related to ownership of inventions, patent prosecution and maintenance of licensed patents, as defined in the Novartis License Agreement, are outlined in the Novartis License Agreement, including that, we own the licensed patents and Novartis has first right to file, prosecute and maintain all licensed patents and joint patents specified in the Novartis License Agreement, throughout the world. The luxdegalutamide patent portfolio includes a patent family directed to the luxdegalutamide composition of matter, which includes an issued U.S. patent and two foreign patents, including China. In addition, there are pending composition of matter pending applications in the U.S. and certain foreign jurisdictions including Europe, Japan, and China. Any granted patent in this family will expire in 2040. This patent portfolio also includes pending method of treatment applications in the U.S. and one foreign country, as well as a pending PCT application. This additional family, if issued, will expire in 2043. In addition, this portfolio includes patent families directed to crystalline forms, drug formulation, manufacturing, and drug-drug interaction, in the U.S. and one foreign jurisdiction, as well as pending PCT applications.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_636"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PROTAC Platform</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our PROTAC platform patent estate that we own, and in-license, covers constructs that have ligands for the Von Hippel Lindau, or VHL, E3 ubiquitin ligase, the cereblon, or CRBN, E3 ubiquitin ligase, the inhibitor apoptosis protein, or IAP, E3 ubiquitin ligase, and the human mouse double minute homolog (MDM2) E3 ubiquitin ligase. As of December 31, 2025, the VHL patent portfolio, which we exclusively license from Yale University, or Yale, includes composition-of-matter patents in the U.S., as well as certain foreign jurisdictions, as well as pending applications in the U.S. and foreign jurisdictions including Europe, China, and Japan. Any granted patents in this family will expire in 2033. As of December 31, 2025, the CRBN patent portfolio that we own includes issued composition of matter patents in in certain foreign jurisdictions including Europe China, and Japan, as well as pending applications in the U.S. and certain foreign jurisdictions. Any patents in this family will </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">expire in 2035. As of December 31, 2025, the IAP patent portfolio that we own has pending composition of matter applications in the U.S. and Europe. Any granted patents in this family will expire in 2036</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:line-through">.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> As of December 31, 2025, the MDM2 patent portfolio that we own includes an issued composition of matter foreign patent, and pending composition of matter applications in the U.S. and Europe. Any granted patents in this family will expire in 2036.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_611"></div><div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Co-Owned Patent Portfolios</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We co-own with Yale six patent families describing composition of matter claims of PROTAC targeted protein degrader compounds addressing certain discovery and other potential protein targets, and associated methods of use. As of December 31, 2025, one or more U.S. patents have been issued in all of these families, and one or more patents have been issued in certain foreign jurisdictions for two of these families. There are also pending patent applications in the U.S. and/or certain foreign jurisdictions in four of these families.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also co-own with Yale a composition of matter patent family that covers constructs that have ligands for the VHL E3 ubiquitin ligase. This family includes issued patents in the U.S. and certain foreign jurisdictions including Japan, and pending patent applications in the U.S. and certain foreign jurisdictions. Our rights to several of these patent applications are governed by the Amended Yale License Agreement described below in "</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business&#8212;Licenses and Strategic Collaborations"</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We co-own four patent families with Genentech directed to PROTAC targeted protein degrader compounds addressing a specific protein. Our rights to these patent applications are governed by the Genentech License Agreement described below in "</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Item 1. Business&#8212;Licenses and Strategic Collaborations"</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The term of individual patents depends upon the legal term of the patents in the countries in which they are obtained. In most countries in which we file, the patent term is 20 years from the earliest date of filing a non-provisional patent application. In the United States, the term of a patent covering a drug approved by the FDA may be eligible for a patent term extension under the Hatch-Waxman Act as compensation for the loss of patent term during the FDA regulatory review process. The period of extension may be up to five years beyond the expiration of the patent but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. Only one patent among those eligible for an extension may be extended. Similar provisions are available in Europe and in certain other jurisdictions to extend the term of a patent that covers an approved drug. It is possible that issued U.S. patents covering vepdegestrant and others may be entitled to patent term extensions. If our product candidates receive FDA approval, we intend to apply for patent term extensions, if available, to extend the term of patents that cover the approved product candidates. We also intend to seek patent term extensions in any jurisdiction where they are available; however, there is no guarantee that the applicable authorities, including the FDA, will agree with our assessment of whether such extensions should be granted, and if granted, the length of such extensions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The United States also offers Patent Term Adjustment, or PTA, whereby a particular patent&#8217;s term is automatically extended beyond the 20-year term if the United States Patent and Trademark Office caused delays during the underlying patent application&#8217;s examination. However, potentially available PTA will be reduced by any amount of delay caused by the applicant.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_606"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trade Secrets</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also rely on trade secrets, technical know-how and continuing innovation to develop and maintain our competitive advantage. Our policy requires inventors who are identified on any company-owned patent applications to assign rights to us. We also rely on confidentiality agreements with our employees, consultants and other advisors to protect our proprietary information. Our policy is to require third parties that receive material confidential information to enter into confidentiality agreements with us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">28</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_601"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Trademarks</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We own U.S. trademark and service mark registrations for ARVINAS in word and logo form for pharmaceutical preparations and pharmaceutical products development of cellular proteins for treatment in the fields of oncology, immunology, inflammatory diseases, and central nervous system disorders. The ARVINAS word mark is registered for pharmaceutical products development services in Australia, China, the EU, Japan, Norway, South Korea, and Switzerland, and is pending registration in several other countries. The ARVINAS word mark is also registered for pharmaceutical products in Australia, Brazil, China, Colombia, the EU, Hong Kong, India, Indonesia, Israel, Japan, Mexico, New Zealand, Norway, Singapore, South Africa, South Korea, Switzerland, Taiwan, and the United Kingdom, and is pending registration in several other countries. The ARVINAS logo mark is registered for pharmaceutical products development services in China, the EU, and the United Kingdom, and is pending registration in several other countries. The ARVINAS logo mark is registered for pharmaceutical products development services in Australia, China, the EU, Japan, Norway, Switzerland, and the United Kingdom, and is pending registration in several other countries. The ARVINAS logo mark is also registered for pharmaceutical products in Australia, Brazil, Colombia, the EU, Hong Kong, Indonesia, Israel, Japan, Mexico, New Zealand, Norway, Singapore, South Korea, Switzerland, Taiwan, and the United Kingdom, and is pending registration in several other countries. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also own U.S. service mark registrations for our &#8220;degrading dots&#8221; logo mark in both black and white and color form for pharmaceutical products development of new small molecules aimed at degrading disease-causing cellular proteins for treatment in the fields of oncology, immunology, inflammatory diseases, and central nervous system disorders.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with our vepdegestrant pipeline product, we have filed trademark applications in the U.S. and internationally for a number of brand name candidates.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_510"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Licenses and Strategic Collaborations</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_593"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pfizer Vepdegestrant (ARV-471) Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into a collaboration agreement with Pfizer, or the Vepdegestrant (ARV-471) Collaboration Agreement, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound vepdegestrant (ARV-471), or the Licensed Products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Vepdegestrant (ARV-471) Collaboration Agreement, we received an upfront, non-refundable payment of $650 million. In addition, we are eligible to receive up to an additional $1.4 billion in contingent payments based on specified regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer share equally (50/50) all development costs (including costs for conducting any clinical trials) for the Licensed Products, subject to certain exceptions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with its terms, the Vepdegestrant (ARV-471) Collaboration Agreement will expire on a Licensed Product-by-Licensed Product and country-by-country basis when such Licensed Product is no longer commercialized or developed for commercialization in such country. Pfizer may terminate the Vepdegestrant (ARV-471) Collaboration Agreement for convenience in its entirety or on a region-by-region basis subject to certain notice periods. Either party may terminate the Vepdegestrant (ARV-471) Collaboration Agreement for the other party&#8217;s uncured material breach or insolvency. Subject to applicable terms of the Vepdegestrant (ARV-471) Collaboration Agreement, including certain payments to Pfizer upon termination for our uncured material breach, effective upon termination of the Vepdegestrant (ARV-471) Collaboration Agreement, we are entitled to retain specified licenses to be able to continue to exploit the Licensed Products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to specified exceptions, we and Pfizer have each agreed not to directly or indirectly research, develop, or commercialize any competing products outside of the Vepdegestrant (ARV-471) Collaboration Agreement anywhere in the world during the term of the Vepdegestrant (ARV-471) Collaboration Agreement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2025, we announced that we and Pfizer have agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_556"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pfizer Research Collaboration Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into a Research Collaboration and License Agreement with Pfizer setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of targets, referred to in this section as Targets, using our proprietary platform technology that are identified in the agreement or subsequently selected by Pfizer, subject to certain exclusions. We refer to this agreement as the Pfizer Research Collaboration Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pfizer Research Collaboration Agreement, Pfizer has designated a number of initial Targets. For each identified Target, we and Pfizer will conduct a separate research program pursuant to a research plan. Pfizer may make substitutions for any of the initial Target candidates, which substitutions are limited subject to the stage of research for such Target.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer are obligated to use commercially reasonable efforts to complete our respective activities set forth in a research plan, including, in our case, the obligation to provide certain deliverables at the end of each stage. Under the research plan, we are required to provide compound formulation and conduct pharmacokinetic/pharmacodynamic and drug safety research and development activities in support of screening and other activities conducted by Pfizer relating to a Target. Following the provision of the deliverables by us for a stage, we will suspend the conduct of any further activities until Pfizer has exercised its right to proceed. If Pfizer does not exercise such right within the applicable time period, we will cease activities for such Target and such Target will no longer be part of the collaboration. Each party will bear its own costs in the conduct of such activities, except that any additional work that we agree with Pfizer to perform outside of the research plan will be paid for by Pfizer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer has the right to exercise an option to obtain an exclusive worldwide license with respect to each Target for a specified period of time after receipt of the applicable deliverables for such Target. If Pfizer does not exercise its option for a Target, such Target is no longer subject to the Pfizer Research Collaboration Agreement. If Pfizer exercises such option, Pfizer will have an exclusive license to develop and commercialize compounds directed against such Target, subject to certain diligence obligations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the term of the Pfizer Research Collaboration Agreement, we and our affiliates are not permitted, either directly or indirectly, to develop or commercialize any pharmacologically-active agent whose primary mechanism of action is, by design, directed to a Target, or grant any license, covenant not to sue or other right to any third party for the conduct of such activities. There are no restrictions on Pfizer from developing, manufacturing or commercializing products, programs, technologies or processes that are similar to or may compete with any covered by the Pfizer Research Collaboration Agreement, subject to certain limitations on Pfizer&#8217;s right to use our confidential information or know-how.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2018, we received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in exchange for use of our technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. We are eligible to receive up to an additional $3.8 million in non-refundable option payments if Pfizer exercises its options for all targets under the Pfizer Research Collaboration Agreement. We are also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as mid- to high-single digit tiered royalties, which may be subject to reductions, on net sales of PROTAC targeted protein degrader-related products. Pfizer selected additional targets and initiated additional services totaling $1.0 million and $3.5 million in December 2022 and 2021, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Pfizer Research Collaboration Agreement will expire upon the expiration of all royalty obligations thereunder. The royalty period for each product developed under the Pfizer Research Collaboration Agreement will expire on a country-by-country basis upon the later of (1) the expiration of the last-to-expire valid patent claim that claims or covers the composition of matter of a compound contained within such product or (2) ten years after the first commercial sale with respect to such product. Pfizer has the right to terminate the Pfizer Research Collaboration Agreement for convenience in its entirety or with respect to a specific target on 60 days&#8217; prior notice. Either we or Pfizer may terminate the Pfizer Research Collaboration Agreement, in its entirety or with respect to a specific target, if the other party is in material breach and such breach is not cured within the specified cure period. In addition, either we or Pfizer may terminate the Pfizer Research Collaboration Agreement in the event of specified insolvency events involving the other party. If Pfizer terminates the agreement in its entirety or as a result of our uncured material breach or our insolvency, Pfizer retains its license with respect to Targets for which it has exercised an option (unless Pfizer elects otherwise), subject to reduced payment obligations.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_581"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Novartis Transaction</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, we entered into the Novartis License Agreement and the Novartis Asset Agreement collectively referred to as the Novartis Transaction. The Novartis Transaction closed in May 2024 upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, at which time the Novartis License Agreement and the Novartis Asset Agreement became effective.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Novartis License Agreement, we granted Novartis an exclusive worldwide license for the development, manufacture and commercialization of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">luxdegalutamide (ARV-766)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, our second generation PROTAC AR degrader for patients with prostate cancer. Pursuant to the Novartis Asset Agreement, we sold to Novartis all of our rights, title and interest in our PROTAC protein degrader targeting AR-V7, a splice variant of the AR.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of and as consideration for entering into the Novartis Transaction, we received a one-time, upfront payment in the aggregate amount of $150.0 million from Novartis. Under the Novartis License Agreement, we are also eligible to receive up to an additional $1.01 billion as contingent payments based on specified development, regulatory, and commercial milestones for </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">luxdegalutamide (ARV-766) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">being met, as well as tiered royalties based upon worldwide net sales of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">luxdegalutamide (ARV-766)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, subject to reduction under certain circumstances as provided in the Novartis License Agreement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025, we received $20.0&#160;million upon the achievemen</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t of a development m</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ilestone pursuant to the terms of the Novartis License Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Novartis License Agreement will expire on a country-by-country basis (or, in certain cases, a region-by-region basis) until the expiration of the applicable royalty term for such country (or region, as applicable). The Novartis License Agreement contains customary termination provisions, including that either party may terminate the Novartis License Agreement (a) upon the material breach of the other party or (b) in the event the other party experiences an insolvency event. Additionally, Novartis may terminate the Novartis License Agreement for convenience or upon a safety or regulatory issue.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_566"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Amended Yale University License Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, we entered into an Amended and Restated License Agreement, or the Amended License Agreement, with Yale, pursuant to which the parties amended and restated the license agreement dated July 5, 2013, as amended to such date, or the Original Yale Agreement. Pursuant to the Original Yale Agreement, Yale granted us an exclusive, worldwide license under specified intellectual property rights for the treatment or prevention of any human or animal disease in which a product mediates degradation of one or more target proteins, which we refer to as the Field, subject to certain exceptions. These licensed intellectual property rights arose from the research conducted by Dr. Craig Crews at Yale.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Original Yale Agreement, we paid to Yale an upfront payment of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.1&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and we were responsible for paying Yale an annual license maintenance fee in varying amounts (ranging from the low tens-thousands of dollars to the mid to high tens-thousands of dollars) until the first sale to a third party of any licensed product, which is creditable against our royalty obligations for the given year. As of December 31, 2023, we paid a total of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.7 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in license maintenance fees to Yale. In connection with the signing of the Amended License Agreement, our obligations under the Original Yale Agreement to pay Yale minimum annual royalties and certain other annual fees were eliminated, and Yale agreed to release all claims arising previously under the Original Yale Agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Also in connection with the signing of the Amended License Agreement, we made a payment of $14.95 million to Yale, comprising both an upfront payment connected to the Amended License Agreement and an amount related to the collaboration income under the Novartis License Agreement and Novartis Asset Agreement (see Note 3,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Research Collaboration and License Agreements</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, for a description of the agreements). We made another $5.0 million payment in June 2025 on the first anniversary of signing. Thereafter, we will also pay to Yale (1) up to $15.0 million if it secures approval of the first and second royalty products (as defined in the Amended License Agreement), (2) a low single digit percentage royalty on certain, more narrowly defined &#8220;collaboration products,&#8221; and (3) a lower single digit royalty on its aggregate worldwide net sales of certain newly defined &#8220;meaningfully involved products.&#8221;</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other provisions of the Original Yale Agreement remain materially unchanged under the Amended License Agreement, including the requirement to pay to Yale a minimum license maintenance royalty totaling $0.1 million per year until the first sale to a third party of any licensed product, followed by success-based milestones for the first two licensed products for the development of the protein degradation technologies totaling approximately $3.0 million for the first licensed product and approximately $1.5 million for the second licensed product, certain of which milestones have already been satisfied. We are also required to pay to Yale low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to minimum royalty payments that range from $0.2 million to $0.5 million. We are also responsible for costs relating to the prosecution and maintenance of the licensed patents. Finally, subject to certain conditions, all payments made by us to Yale (except patent costs) will be tripled during the pendency of any patent challenge made by us against Yale. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Amended License Agreement remains in effect until (a) for certain products, the date on which the last claim of the licensed patents expires; and (b) for certain products, 10 years after the sale of such products. The expiration of the last to expire patent right licensed from Yale, if it issues as a patent and all appropriate maintenance fees are paid, is currently expected be in 2039. Either we or Yale may terminate the agreement for the other party&#8217;s uncured material breach of certain provisions, we m</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ay terminate the agreement for convenience upon six months&#8217; prior notice, and Yale may terminate the agreement if we fail to make a payment when due, fail to obtain or maintain adequate insurance coverage or fail to achieve specified financing or regulatory milestone events. The agreement will automatically terminate if we become insolvent. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_561"></div><div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genentech License Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, we entered into </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an Option and License Agreement with Genentech focused on PROTAC targeted protein degrader discovery and research for target proteins, referred to in this section as Targets, based on our proprietary platform technology, other than excluded Targets as described below. Pursuant to this agreement, Genentech had an option to obtain an exclusive worldwide license to the applicable PROTAC targeted protein degraders directed against an applicable Target, which we refer to as Licensed PROTACs. Each such option was required to be exercised within a specified time after we deliver the data package for such Licensed PROTAC to Genentech. Once Genentech exercises an option, it is responsible, at its cost, to use diligent efforts to develop and commercialize the Licensed PROTAC through first commercial sale in the United States, the European Union, or EU, and Japan. This collaboration was expanded in November 2017 through an Amended and Restated Option, License and Collaboration Agreement, which we refer to as the Restated Genentech Agreement. Simultaneous with entering into the Restated Genentech Agreement, Genentech exercised its exclusive option with respect to a PROTAC targeted protein degrader. We receive annual updates on research and development activities related to this option.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Restated Genentech Agreement, Genentech had the right to designate up to ten Targets for further discovery and research utilizing our PROTAC platform technology and also had the right to remove a </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">32</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Target from the collaboration and substitute a different Target that is not an excluded Target at any time prior to us commencing research on such Target or in certain circumstances following commencement of research by us. The research phase of the collaboration with Genentech has ended. As such, Genentech is no longer able to nominate new Targets into the collaboration, and there are no active Targets in the collaboration for which we are conducting research activities. The only Target that remains part of the collaboration is the PROTAC targeted protein degrader for which Genentech exercised its exclusive option for as noted above. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Restated Genentech Agreement, we received $11.0 million in 2015 and an additional $34.5 million in 2017 in upfront payments and expansion target payments. We are also eligible to receive payments aggregating up to $44.0 million per Target subject to the achievement of specified development milestones; payments aggregating up to $52.5 million per Target (assuming approval of two indications) subject to the achievement of specified regulatory milestones; and payments aggregating up to $60 million per Licensed PROTAC subject to the achievement of specified sales milestones. These milestone payments are subject to reduction if we do not have a valid patent claim covering the Licensed PROTAC at the time the milestone is achieved. We are also eligible to receive, on net sales of Licensed PROTACs, mid-single digit royalties, which may be subject to reductions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated, the Restated Genentech Agreement will expire upon the expiration of all royalty periods for any Licensed PROTACs. The royalty period for each Licensed PROTAC expires on a country-by-country basis upon either (1) the expiration of the last-to-expire valid patent claim covering such Licensed PROTAC or (2) ten years after the first commercial sale with respect to such Licensed PROTAC, depending on whether the sale of the Licensed PROTAC is covered by an applicable valid claim. The expiration of the last to expire patent right licensed to Genentech, if it issues as a patent and all appropriate maintenance fees are paid, is currently expected be in 2042. We could also obtain rights to additional patents, including through the issuance of pending patent applications, with later expiration dates, or new Licensed PROTACs could be added to the agreement that are subject to additional royalty terms with later expiration dates, which in either case could extend the term of the Restated Genentech Agreement. Genentech has the right to terminate the Restated Genentech Agreement for convenience in its entirety or with respect to a specific Target on 60 days&#8217; prior notice. Either we or Genentech may terminate the agreement, in its entirety or with respect to a specific Target, if the other party is in material breach and such breach is not cured within the specified cure period. In addition, either we or Genentech may terminate the agreement in the event of specified insolvency events involving the other party. If Genentech terminates the agreement for convenience or if we terminate the agreement as a result of Genentech&#8217;s uncured material breach or Genentech&#8217;s insolvency, all licenses we granted to Genentech terminate (either in its entirety or with respect to a specific Target, as applicable based on the nature of the termination). If Genentech terminates the agreement as a result of our uncured material breach or our insolvency, all licenses that we granted to Genentech terminate (either in its entirety or with respect to a specific Target, as applicable based on the nature of the termination), except that Genentech has the right to elect to retain its licenses, in which case it would no longer be obligated to use diligent efforts to develop and commercialize the applicable Licensed PROTACs and its payment obligations to us would be reduced. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_505"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Competition</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on intellectual property and proprietary products. While we believe that our technology, expertise, scientific knowledge and intellectual property estate provide us with competitive advantages, we face potential competition from many different sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions that conduct research, seek patent protection, and establish collaborative arrangements for research, development, manufacturing, and commercialization. Not only must we compete with other companies that are focused on protein degradation, but any product candidates that we successfully develop and commercialize will compete with existing therapies and new therapies that may become available in the future. Moreover, our industry is characterized by the existence of large numbers of patents and frequent allegations of patent infringement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our platform and product focus is the discovery and development of protein degradation therapies using our small molecule PROTAC targeted protein degraders. Other companies researching chimeric small molecules for protein degradation include Accutar Biotechnology, Inc., C4 Therapeutics, Inc., Cullgen Inc., </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">33</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Foghorn Therapeutics, Inc., Kymera Therapeutics, Inc., Nurix Therapeutics, Inc. and Proteovant Therapeutics, Inc. Further, several large pharmaceutical companies have disclosed preclinical or clinical investments in this field, including AbbVie Inc., Amgen Inc., Astellas Pharma, Inc., AstraZeneca plc, BeOne Medicines Ltd., Boehringer Ingelheim, Bristol Myers Squibb Company, GlaxoSmithKline plc, Genentech, Novartis AG, Pfizer and Sanofi. Since 2020, some of these biotechnology and pharmaceutical companies have announced the initiation of clinical trials for targeted protein degraders. In addition to competition from other protein degradation therapies, any products that we develop may also face competition from other types of therapies, such as small molecule, antibody, or gene therapies. Additionally, other novel targeting mechanisms could ultimately address similar patient populations, such as SERDs, in breast cancer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additional competitive information related to our specific product candidates is summarized below:</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-102</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate, ARV-102, is a PROTAC LRRK2 degrader and in development to treat PD and PSP. With respect to PD, we are aware that several companies have candidates in the clinic designed to degrade or inhibit LRRK2, including IONIS Pharmaceuticals, Inc., Brenig Therapeutics, Inc., Biogen Inc. and Denali Therapeutics, Inc., Neuron 23, Inc. and Oncodesign Precision Medicine. There are also several companies who are developing product candidates to treat PD that are not LRRK2 inhibitors or degraders, including Genentech, a member of the Roche Group, Ventyx Biosciences, Inc., and Prevail Therapeutics, Inc.. No LRRK-2 targeted therapy is currently in the clinic for PSP. However, several companies do have product candidates in the clinic to treat PSP, including Novartis AG, Aprinoia Therapeutics, Inc., Transponson Therapeutics, Inc., Ferrer Internacionale, S.A., , Alzprotect SAS and GemVax &amp; KAEL Co., Ltd.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-393</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate, ARV-393 is a PROTAC BCL6 degrader and in development to treat relapsed/refractory NHL. We are aware of four companies with BCL6 degraders or inhibitors in the clinic, including Bristol Myers Squibb Company, Treeline Biosciences, Inc., Haisco Pharmaceutical Group, and Eli Lilly and Company. We also believe there may be several non-BCL6 degrader or inhibitor companies with product candidates to treat relapsed/refractory NHL, including F. Hoffman-La Roche Ltd. and AbbVie and its partner, Genmab.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-806</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate, ARV-806, is a PROTAC KRAS G12D degrader in development to treat cancers with the G12D mutation, including pancreatic, colorectal and non-small cell lung cancers. We are aware that several companies have KRAS G12D or related inhibitors or degraders in the clinic, including Astellas Pharma, Inc., Incyte Corp., Genfleet Therapeutics, Inc., Verastem, Inc., Revolution Medicines, Inc., and Kumquat Biosciences Inc. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARV-027</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate, ARV-027, is a PROTAC poly-Q AR degrader targeting polyQ-AR in skeletal muscle. We are aware that several companies have poly-Q AR or related inhibitors or degraders in the clinic, including AnnJi Pharmaceutical Co., Ltd.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vepdegestrant</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidate, vepdegestrant, targets breast cancer. In the second quarter of 2025, we and Pfizer submitted an NDA to the FDA, for vepdegestrant for the treatment of patients with ER+/HER2- ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This represents the first NDA submitted for a PROTAC. In the third quarter of 2025, we announced that the FDA accepted the NDA for vepdegestrant and assigned a PDUFA date of June 5, 2026.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The most common methods of treating patients in oncologic indications, including breast cancer, are surgery, radiation and drug therapy, including chemotherapy, hormone therapy and targeted drug therapy. There are a variety of available drug therapies marketed for cancer, including breast cancer. In many cases, these drugs are administered in combination to enhance efficacy. Some of the currently approved drug therapies are branded and subject to patent protection, and others are available on a generic basis. Many of these approved drugs are well established therapies and are widely accepted by physicians, patients and third-party payors. In general, although there has been considerable progress over the past few decades in the treatment of cancer </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">34</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and the currently marketed therapies provide benefits to many patients, these therapies all are limited to some extent in their efficacy and frequency of adverse events, and none of them are successful in treating all patients. As a result, the level of morbidity and mortality from cancer remains high. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to currently marketed drugs, including elacestrant, an oral SERD, imlunestrant, an oral SERD, and fulvestrant, a first-generation SERD, there are also several product candidates in late stage clinical development for the treatment of metastatic ER+/HER2- breast cancer. These products in development include, in the case of metastatic ER+/HER2- breast cancer, SERDs, including camizestrant, giredestrant, and may provide efficacy, safety, convenience and other benefits that are not provided by currently marketed therapies. As a result, they may provide significant competition for vepdegestrant for which we obtain market approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates are approved for the indications for which we expect to conduct clinical trials, they will compete with the foregoing therapies and the currently marketed drugs and potentially any drugs in development. It is also possible that we will face competition from other biologic or pharmaceutical approaches as well as from other types of therapies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The key competitive factors affecting the success of all our programs, if approved, are likely to be their efficacy, safety, convenience, price, level of generic competition and availability of reimbursement. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_500"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Commercialization Plans</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our produ</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ct candidates are still in preclinical and clinical development. Other than our discovery collaboration agreements, to date, we have retained commercialization rights for all of our development programs including global co-commercialization rights for vepdegestrant through our collaboration with Pfizer. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In past years, we had begun the process of establishing our own focused, specialized sales, marketing, and market access organization to support the commercialization of our product candidates, including vepdegestrant, in the United States. However, in September 2025, we announced that, with Pfizer, we have agreed to jointly select a third party for the commercialization and potential further development of vepdegestrant.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As our other product candidates progress through clinical development, we will revisit our commercial plans. We would expect to utilize a variety of types of collaboration, co-promotio</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n, distribution and other marketing arrangements with one or more third parties to commercialize our product candidates in markets outside the United States or for situations in which a larger sales and marketing organization is required. However, as product candidates advance through our pipeline, our commercial plans may change. In particular, some of our research programs target potentially larger indications. Data, the size of the development programs, the size of the target market, the size of a commercial infrastructure and manufacturing needs may all influence our strategies in the United States, Europe and the rest of the world. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_495"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Manufacturing and Supply</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely on and expect to continue to rely on third-party contract manufacturing organizations, or CMOs, and contract development and manufacturing organizations, or CDMOs, for both drug substance and finished drug product as well as for the synthesis of compounds in our preclinical research and development activities. We have engaged third-party manufacturers to supply the building blocks and drug substances for ARV-102, ARV-806, ARV-393, and vepdegestrant, as well as ARV-027, and we have also engaged third-party manufacturers to develop and manufacture finished drug product for ARV-102, ARV-393, ARV-806 and vepdegestrant, as well as ARV-027, that we are using and plan to use in our ongoing and planned Phase 1/2 and pivotal clinical trials, as well as for part of our IND-enabling plan. We currently obtain our supplies from these manufacturers on a purchase order basis and do not have long-term supply arrangements in place. Should any of these manufacturers become unavailable to us for any reason, we believe that there are a number of potential replacements, although we may incur some delay in identifying and qualifying such replacements. Pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer, Pfizer has primary responsibility to manufacture the commercial supply of vepdegestrant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are organic compounds of low molecular weight, generally called small molecules, but which are larger than traditional small molecule therapeutics. We have selected these </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">35</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">compounds not only on the basis of their potential efficacy and safety, but also for their ease of synthesis and reasonable cost of goods. In particular, our lead product candidates are manufactured using reliable and reproducible synthetic processes from readily available starting materials. The chemistry is amenable to scale up and does not require unusual equipment in the manufacturing process. We expect to continue to develop product candidates that can be produced cost-effectively at contract manufacturing facilities or with partners. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_490"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Government Regulation and Product Approvals</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Government authorities in the United States, at the federal, state and local level, and in other countries and jurisdictions, such as the EU, extensively regulate, among other things, the research, development, testing, manufacture, pricing, quality control, approval, packaging, storage, recordkeeping, labeling, advertising, promotion, distribution, marketing, sales, reimbursement, post-approval monitoring and reporting, and import and export of pharmaceutical products. The processes for obtaining marketing approvals in the United States and in foreign countries and jurisdictions, along with compliance with applicable statutes and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Approval and Regulation of Drugs in the United States </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, drug products are regulated under the Federal Food, Drug, and Cosmetic Act, or FDCA, and applicable implementing regulations and guidance. A company, institution, or organization which takes responsibility for the initiation and management of a clinical development program for investigational products, and for their regulatory approval, is typically referred to as a sponsor.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The failure of a sponsor to comply with the applicable regulatory requirements at any time during the product development process, including nonclinical testing, clinical testing, the approval process or post-approval process, may result in delays to the conduct of a study, regulatory review and approval and/or administrative or judicial sanctions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A sponsor seeking approval to market and distribute a new drug product in the United States generally must satisfactorily complete each of the following steps before the product candidate will be approved by the FDA: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preclinical testing including laboratory tests, animal studies and formulation studies, which must be performed in accordance with the FDA&#8217;s good laboratory practice, or GLP, regulations and standards; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">completion of the manufacture, under current Good Manufacturing Practices, or cGMP, conditions, of the drug substance and drug product that the sponsor intends to use in human clinical trials along with required analytical and stability testing;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">design of a clinical protocol and submission to the FDA of an IND for human clinical testing, which must become effective before human clinical trials may begin; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">approval by an independent institutional review board, or IRB, representing each clinical site before each clinical trial may be initiated; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">performance of adequate and well-controlled human clinical trials to establish the safety and efficacy of the product candidate for each proposed indication, in accordance with good clinical practices, or GCP; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">preparation and submission to the FDA of an NDA for a drug product which includes not only the results of the clinical trials, but also, detailed information on the chemistry, manufacturing and controls, or CMC, for the product candidate and proposed labeling for one or more proposed indication(s); </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">review of the product candidate by an FDA advisory committee, where appropriate or if applicable; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of an FDA inspection of the manufacturing facility or facilities, including those of third parties, at which the product candidate or components thereof are manufactured to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the product&#8217;s identity, strength, quality and purity; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">satisfactory completion of any FDA audits of the clinical trial sites to assure compliance with GCP and the integrity of clinical data in support of the NDA; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">36</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">payment of user fees pursuant to the PDUFA and securing FDA approval of the NDA to allow marketing of the new drug product; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">compliance with any post-marketing requirements. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preclinical Studies </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Before a sponsor begins testing a product candidate with potential therapeutic value in humans, the product candidate enters the preclinical testing stage, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> and animal studies to assess the safety and activity of the drug for initial testing in humans and to establish rationale for therapeutic use. Preclinical tests include laboratory evaluations of product chemistry, formulation and stability, as well as other studies to evaluate, among other things, the toxicity of the product candidate. These studies are typically referred to as IND-enabling studies. The conduct of the preclinical tests and formulation of the compounds for testing must comply with federal regulations and requirements, including GLP regulations and standards and the United States Department of Agriculture&#8217;s Animal Welfare Act, if applicable. With passage of the FDA&#8217;s Modernization Act 2.0 in December 2022, Congress eliminated provisions in the FDCA that required animal testing in support of an NDA. In April 2025, the FDA released a roadmap to replace animal testing in preclinical safety studies with scientifically validated new approach methodologies, such as organ-on-a-chip systems, computational modeling, and advanced </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> assays. Some long-term preclinical testing, such as animal tests of reproductive adverse events and carcinogenicity, and long-term toxicity studies, may continue after the IND is submitted. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The IND and IRB Processes </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An IND is a request for FDA authorization to administer an investigational product to humans. Such authorization must be secured prior to interstate shipment and administration to a trial subject of any product candidate that is not the subject of an approved NDA. In support of a request for an IND, sponsors must submit a protocol for each clinical trial and any subsequent protocol amendments must be submitted to the FDA as part of the IND. In addition, the results of the preclinical tests, together with manufacturing information, analytical data, any available clinical data or literature and plans for clinical trials, among other things, must be submitted to the FDA as part of an IND. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA requires a 30-day waiting period after the filing of each original IND before clinical trials may begin. This waiting period is designed to allow the FDA to review the IND to determine whether human research subjects will be exposed to unreasonable health risks. The FDA&#8217;s primary objectives in reviewing an IND are to assure the safety and rights of patients and subjects in the study, and to help assure that the quality of the investigation will be adequate to permit an evaluation of the investigational product&#8217;s safety and efficacy. At any time during this 30-day period, the FDA may raise concerns or questions about the conduct of the trials as outlined in the IND and impose a clinical hold or partial clinical hold. In this case, the IND sponsor and the FDA must resolve any outstanding concerns before clinical trials may begin. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following commencement of a clinical trial under an IND, the FDA may also place a clinical hold or partial clinical hold on that trial. The FDA imposes clinical holds whenever there is concern for patient safety and may be a result of new data, findings, or developments in clinical, nonclinical, and/or CMC. Thus, occasionally, clinical holds are imposed due to manufacturing issues that may present safety issues for the clinical study subjects. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No more than 30 days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise demonstrating to the satisfaction of the FDA that the investigation can proceed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the foregoing IND requirements, an IRB representing each institution participating in the clinical trial must review and approve the plan for any clinical trial before it commences at that institution, and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">37</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the IRB must conduct continuing review and reapprove the study at least annually. The IRB must review and approve, among other things, the study protocol and informed consent information to be provided to study subjects. An IRB must operate in compliance with FDA regulations. An IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the product candidate has been associated with unexpected serious harm to patients. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an IND application takes effect, the sponsor of the IND may amend the application as needed to ensure that the clinical investigations are conducted according to protocols included in the IND. The FDA has indicated that sponsors are expected to submit amendments for new protocols or changes to existing protocols before implementation of the respective changes. However, there is no official timeline for an IND amendment. New studies may begin, however, when the sponsor has submitted the change to FDA for its review and the new protocol or changes to the existing protocol have been approved by the IRB with the responsibility for review and approval of the studies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, some trials are overseen by an independent group of qualified experts organized by the trial sponsor, known as a data monitoring committee, or DMC. This group provides authorization for whether a trial may move forward at designated check points based on access that only the DMC maintains of available data. Suspension or termination of development during any phase of clinical trials can occur if it is determined that the participants or patients are being exposed to an unacceptable health risk or for other reasons.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expanded Access to an Investigational Drug</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Expanded access, sometimes called &#8220;compassionate use,&#8221; is the use of investigational drug products outside of clinical trials to treat patients with serious or immediately life-threatening diseases or conditions when there are no comparable or satisfactory alternative treatment options. The rules and regulations related to expanded access are intended to improve access to investigational drugs for patients who may benefit from investigational therapies. FDA regulations allow access to investigational drug products under an IND by the company or the treating physician for treatment purposes on a case-by-case basis for: individual patients (single-patient IND applications for treatment in emergency settings and non-emergency settings); intermediate-size patient populations; and larger populations for use of the investigational drug product under a treatment protocol or Treatment IND application. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When considering an IND application for expanded access to an investigational product with the purpose of treating a patient or a group of patients, the sponsor and treating physicians or investigators will determine suitability when all of the following criteria apply: patient(s) have a serious or immediately life-threatening disease or condition, and there is no comparable or satisfactory alternative therapy to diagnose, monitor, or treat the disease or condition; the potential patient benefit justifies the potential risks of the treatment and the potential risks are not unreasonable in the context or condition to be treated; and the expanded use of the investigational drug for the requested treatment will not interfere initiation, conduct, or completion of clinical investigations that could support marketing approval of the product or otherwise compromise the potential development of the product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There is no obligation for a sponsor to make its drug products available for expanded access. However, if a sponsor has a policy regarding how it responds to expanded access requests, it must make that policy publicly available. Specifically, sponsors are required to make such policies publicly available upon the earlier of initiation of a Phase 2 or Phase 3 clinical trial; or 15 days after the investigational drug or biologic product receives designation as a breakthrough therapy, fast track product, or regenerative medicine advanced therapy. We received Fast Track designation for bavdegalutamide for mCRPC in 2019 and for vepdegestrant for ER+/HER2- breast cancer in the first quarter of 2024. In October 2025, the FDA issued final guidance further clarifying the statutory and regulatory requirements governing expanded access.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to and separate from expanded access, the Right to Try Act was signed into law on May 30, 2018. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without needing FDA permission under the FDA expanded access program. There is no obligation for a drug manufacturer to make its investigational drug products available to eligible patients under the Right to Try Act.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">38</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Human Clinical Trials in Support of an NDA </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical trials involve the administration of an investigational product to human subjects under the supervision of a qualified investigator in accordance with GCP requirements which include, among other things, the requirement that all research subjects provide their informed consent in writing before their participation in any clinical trial. Clinical trials are conducted under written clinical trial protocols detailing, among other things, the objectives of the study, inclusion and exclusion criteria, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Human clinical trials are typically conducted in three sequential phases, but the phases may overlap or be combined. Additional studies may also be required after approval. The FDA has issued regulations that define the three principal types of trials. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 1</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials are initially conducted in a limited population to test the product candidate for safety, including adverse effects, dose tolerance, absorption, metabolism, distribution, excretion and pharmacodynamics in healthy humans or in patients. During Phase 1 clinical trials, information about the investigational drug product&#8217;s pharmacokinetics and pharmacological effects may be obtained to permit the design of well-controlled and scientifically valid Phase 2 clinical trials. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 2</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials are generally conducted in a limited patient population to identify possible adverse effects and safety risks, evaluate the efficacy of the product candidate for specific targeted indications and determine dose tolerance and optimal dosage. Multiple Phase 2 clinical trials may be conducted by the sponsor to obtain information prior to beginning larger and more costly Phase 3 clinical trials. Phase 2 clinical trials are well controlled, closely monitored and conducted in a limited patient population. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Phase 3</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> clinical trials proceed if the Phase 2 clinical trials demonstrate that a dose range of the product candidate is potentially effective and has an acceptable safety profile. Phase 3 clinical trials are undertaken within an expanded patient population to further evaluate dosage, provide substantial evidence of clinical efficacy and further test for safety in an expanded and diverse patient population at multiple, geographically dispersed clinical trial sites. A well-controlled, statistically robust Phase 3 clinical trial may be designed to deliver the data that regulatory authorities will use to decide whether or not to approve the drug product, and, if approved, how to appropriately label the drug product: such Phase 3 studies are typically referred to as &#8220;pivotal studies&#8221; or "registrational studies."</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A clinical trial may combine the elements of more than one phase and the FDA often requires more than one Phase 3 trial to support marketing approval of a product candidate. A company&#8217;s designation of a clinical trial as being of a particular phase is not necessarily indicative that the study will be sufficient to satisfy the FDA requirements of that phase because this determination cannot be made until the protocol and data have been submitted to and reviewed by the FDA. Moreover, a pivotal trial is a clinical trial that is believed to satisfy FDA requirements for the evaluation of a product candidate&#8217;s safety and efficacy such that it can be used, alone or with other pivotal or non-pivotal trials, to support regulatory approval. Generally, pivotal trials are Phase 3 trials, but they may be Phase 2 trials if the design provides a well-controlled and reliable assessment of clinical benefit, particularly in an area of unmet medical need.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some cases, the FDA may approve an NDA for a product candidate but require the sponsor to conduct additional clinical trials to further assess the product candidate&#8217;s safety and effectiveness after approval. Such post-approval trials are also referred to as post-marketing clinical trials. These studies are used to gain additional experience from the treatment of a larger number of patients in the intended treatment group and to further document a clinical benefit in the case of drugs approved under accelerated approval regulations. Failure to exhibit due diligence with regard to conducting these clinical trials could result in withdrawal of approval for products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has issued numerous guidance documents to specify how particular types of clinical trials should be conducted. This includes, but is not limited to, the guidance below:</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2022, the FDA finalized guidance entitled &#8220;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#8221; which outlines how sponsors can utilize an adaptive trial design in the early stages of oncology product development (i.e., the first-in-human clinical trial) to compress the traditional three phases of trials into one </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">39</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;padding-left:54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts are included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to product development and reduce developmental costs and time.</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In December 2022, with the passage of Food and Drug Omnibus Reform Act, or FDORA, Congress required sponsors to develop and submit a Diversity Action Plan, or DAP, for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for DAPs. Unlike most guidance documents issued by the FDA, the DAP guidance when finalized will have the force of law because FDORA specifically dictates that the form and manner for submission of DAPs are specified in FDA guidance.</span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">On January 27, 2025, in response to an executive order issued on January 21, 2025, relating to Diversity, Equity and Inclusion programs, the FDA removed the draft DAP guidance from its website. That action, along with similar actions by the Administration to remove many other healthcare webpages, is currently the subject of ongoing litigation. On July 3, 2025, the U.S. District Court for the District of Columbia ruled that the actions to remove these webpages, including the draft DAP guidance, are unlawful under the Administrative Procedure Act. The court ordered the restoration of many of these webpages. In late July 2025, the FDA restored the draft DAP guidance to its website with a statement that &#8220;information on this page may be modified and/or removed in the future subject to the terms of the court&#8217;s order and implemented consistent with applicable law.&#8221; Accordingly, in light of these ongoing actions, there is considerable uncertainty surrounding the draft DAP guidance and how the FDA will consider DAPs in connection with its review of NDAs. </span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In September 2025, the FDA issued final guidance with updated recommendations for GCPs aimed at modernizing the design and conduct of clinical trials. The updates are intended to help pave the way for more efficient clinical trials to facilitate the development of medical products. The final guidance is adopted from the International Council for Harmonization&#8217;s recently updated E6(R3) guideline that was developed to enable the incorporation of rapidly developing technological and methodological innovations into the clinical trial enterprise. </span></div><div style="margin-top:12pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In October 2025, the FDA issued final guidance that focuses on patient-focused drug development.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The guidance outlines how stakeholders, such as patients, caregivers, researchers and medical product developers, can submit patient experience data in support of the development and approval of drug products. To that end, the guidance provides an overview of clinical outcome assessments, or COAs, in clinical trials, and the role that COAs may play in in evaluating the clinical benefit of a medical product.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Studies Outside the United States in Support of FDA Approval</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with a clinical development program, a sponsor may conduct trials at sites outside the United States. When a foreign clinical study is conducted under an IND, all IND requirements must be met unless waived. When a foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with certain regulatory requirements of the FDA in order to use the study as support for an IND or application for marketing approval in the U.S. Specifically, the studies must be conducted in accordance with GCP, including undergoing review and receiving approval by an independent ethics committee, or IEC, and seeking and receiving informed consent from subjects. GCP requirements encompass both ethical and data integrity standards for clinical studies. The FDA&#8217;s regulations are intended to help ensure the protection of human subjects enrolled in non-IND foreign clinical studies, as well as the quality and integrity of the resulting data. They further help ensure that non-IND foreign studies are conducted in a manner comparable to that required for IND studies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The acceptance by the FDA of study data from clinical trials conducted outside the United States in support of U.S. approval may be subject to certain conditions or may not be accepted at all. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the U.S., the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">40</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even where the foreign study data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the study is well-designed and well-conducted in accordance with GCP requirements and the FDA is able to validate the data from the study through an onsite inspection if deemed necessary. Many foreign regulatory authorities have similar approval requirements. In addition, such foreign trials are subject to the applicable local laws of the foreign jurisdictions where the trials are conducted. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In December 2025, in the context of negotiations involving reauthorization of PDUFA, the FDA proposed cutting fees for companies conducting clinical development programs in the United States, rather than abroad. It is unclear whether and how this proposal will be adopted and finalized.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Interactions with the FDA During the Clinical Development Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the clearance of an IND and the commencement of clinical trials, the sponsor will continue to have interactions with the FDA. Progress reports detailing the results of clinical trials must be submitted annually within 60 days of the anniversary dates that the IND went into effect and more frequently if serious adverse events occur. These reports must include a development safety update report. In addition, IND safety reports must be submitted to the FDA for any of the following: serious and unexpected suspected adverse reactions; findings from other trials or animal or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">testing that suggest a significant risk in humans exposed to the product; and any clinically important increase in the occurrence of a serious suspected adverse reaction over that listed in the protocol or investigator brochure.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, a sponsor is given the opportunity to meet with the FDA at certain points in the clinical development program. Meetings at other times may also be requested. There are five types of meetings that occur between sponsors and the FDA. Type A meetings are those that are necessary for an otherwise stalled product development program to proceed or to address an important safety issue. Type B meetings include pre-IND and pre-NDA meetings as well as end of phase meetings, such as end-of-phase 2 meetings. A Type C meeting is any meeting other than a Type A or Type B meeting regarding the development and review of a product. A Type D meeting is focused on a narrow set of issues and should not require input from more than three disciplines or Divisions. Finally, INTERACT meetings are intended for novel products and development programs that present unique challenges in the early development of an investigational product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has indicated that its responses, as conveyed in meeting minutes and advice letters, only constitute mere recommendations and/or advice made to a sponsor and, as such, sponsors are not bound by such recommendations and/or advice. Nonetheless, from a practical perspective, a sponsor&#8217;s failure to follow the FDA&#8217;s recommendations for design of a clinical program may put the program at significant risk of failure.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Manufacturing and Other Regulatory Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Concurrent with clinical trials, companies often complete additional animal studies and must also develop additional information about the chemistry and physical characteristics of the drug as well as finalize a process for manufacturing the product in commercial quantities in accordance with cGMP requirements. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity, and potency of the final drug. Additionally, appropriate packaging must be selected and tested and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the FDA&#8217;s regulations require that pharmaceutical products be manufactured in specific approved facilities and in accordance with cGMPs. The cGMP regulations include requirements relating to organization of personnel, buildings and facilities, equipment, control of components and product containers and closures, production and process controls, packaging and labeling controls, holding and distribution, laboratory controls, records and reports and returned or salvaged products. Manufacturers and other entities involved in the manufacture and distribution of approved pharmaceuticals are required to register their establishments with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">41</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the FDA and some state agencies, and they are subject to periodic unannounced inspections by the FDA for compliance with cGMPs and other requirements. Inspections must follow a &#8220;risk-based schedule&#8221; that may result in certain establishments being inspected more frequently. Manufacturers may also have to provide, on request, electronic or physical records regarding their establishments. Delaying, denying, limiting, or refusing inspection by the FDA may lead to a product being deemed to be adulterated.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes to the manufacturing process, specifications or container closure system for an approved product are strictly regulated and often require prior FDA approval before being implemented. The FDA&#8217;s regulations also require, among other things, the investigation and correction of any deviations from cGMP and the imposition of reporting and documentation requirements upon the sponsor and any third-party manufacturers involved in producing the approved product. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The PREVENT Pandemics Act, which was enacted in December 2022, clarifies that foreign drug manufacturing establishments are subject to registration and listing requirements even if a drug undergoes further manufacture, preparation, propagation, compounding, or processing at a separate establishment outside the U.S. prior to being imported or offered for import into the U.S. In May 2025, the FDA disclosed plans to expand its use of unannounced inspections of foreign manufacturing facilities that produce drugs and biologics distributed in the U.S.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Subsequently, in August 2025, the FDA introduced a &#8220;PreCheck&#8221; program with the intention of supporting companies as they build new facilities in the U.S. The PreCheck program provides manufacturers with more frequent FDA communication at critical development stages, including facility design, construction, and pre-production. These FDA initiatives flow from an executive order issued on May 5, 2025, calling for actions to reduce regulatory barriers to pharmaceutical manufacturing in the U.S.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pediatric Studies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently conduct any pediatric studies. In the event that we ever do conduct pediatric studies, we will be subject to additional government regulation, including compliance with the Pediatric Research Equity Act of 2003, or PREA, and the FDA Reauthorization Act of 2017.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Expedited Review Programs</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA is authorized to expedite the review of applications in several ways. Under the Fast Track program, the sponsor of a product candidate may request the FDA to designate the product for a specific indication as a Fast Track product concurrent with or after the filing of the IND. Candidate products are eligible for Fast Track designation if they are intended to treat a serious or life-threatening condition and demonstrate the potential to address unmet medical needs for the condition. Fast Track designation applies to the combination of the product candidate and the specific indication for which it is being studied. In addition to other benefits, such as the ability to have greater interactions with the FDA, the FDA may initiate review of sections of a Fast Track application before the application is complete, a process known as rolling review. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any product candidate submitted to the FDA for marketing, including under a Fast Track program, may be eligible for other types of FDA programs intended to expedite development and review, such as breakthrough therapy designation, priority review and accelerated approval. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Breakthrough therapy designation. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To qualify for the breakthrough therapy program, product candidates must be intended to treat a serious or life-threatening disease or condition and preliminary clinical evidence must indicate that such product candidates may demonstrate substantial improvement on one or more clinically significant endpoints over existing therapies. The FDA will seek to ensure the sponsor of a breakthrough therapy product candidate receives intensive guidance on an efficient development program, intensive involvement of senior managers and experienced staff on a proactive, collaborative and cross-disciplinary review and rolling review. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Priority review. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A product candidate is eligible for priority review if it treats a serious condition and, if approved, it would be a significant improvement in the safety or effectiveness of the treatment, diagnosis or prevention compared to marketed products. FDA aims to complete its review of priority review applications within six months as opposed to 10 months for standard review. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Accelerated approval. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Drug products studied for their safety and effectiveness in treating serious or life-threatening illnesses and that provide meaningful therapeutic benefit over existing treatments may receive accelerated approval. Accelerated approval means that a product candidate may be approved on the basis of adequate and well controlled clinical trials establishing that the product candidate has an effect on a surrogate endpoint that is reasonably likely to predict a clinical benefit, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">42</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or on the basis of an effect on a clinical endpoint other than survival or irreversible morbidity or mortality or other clinical benefit, taking into account the severity, rarity and prevalence of the condition and the availability or lack of alternative treatments. As a condition of approval, the FDA may require that a sponsor of a drug product candidate receiving accelerated approval perform adequate and well controlled post-marketing clinical trials. In addition, the FDA currently requires as a condition for accelerated approval pre-approval of promotional materials.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">With the passage of FDORA in December 2022, Congress modified certain provisions governing accelerated approval of drug and biologic products. Specifically, the new legislation authorized the FDA to: require a sponsor to have its confirmatory clinical trial underway before accelerated approval is awarded, require a sponsor of a product granted accelerated approval to submit progress reports on its post-approval studies to FDA every six months (until the study is completed); and use expedited procedures to withdraw accelerated approval of an NDA or biologics license application after the confirmatory trial fails to verify the product&#8217;s clinical benefit. Further, FDORA requires the agency to publish on its website &#8220;the rationale for why a post-approval study is not appropriate or necessary&#8221; whenever it decides not to require such a study upon granting accelerated approval.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In March 2023, the FDA issued draft guidance that outlines its current thinking and approach to accelerated approval. The agency indicated that the accelerated approval pathway is commonly used for approval of oncology drugs due to the serious and life-threatening nature of cancer. Although single-arm trials have been commonly used to support accelerated approval, a randomized controlled trial is the preferred approach as it provides a more robust efficacy and safety assessment and allows for direct comparisons to an available therapy. To that end, the FDA outlined considerations for designing, conducting, and analyzing data for trials intended to support accelerated approvals of oncology therapeutics. Subsequently, in December 2024, the FDA issued additional draft guidance relating to accelerated approval. While these guidance documents are currently only in draft form and will ultimately not be legally binding even when finalized, sponsors typically observe the FDA&#8217;s guidance closely to ensure that their investigational products qualify for accelerated approval and comport with FDA&#8217;s current thinking.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Commissioner&#8217;s National Priority Voucher Program</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. On June 17, 2025, the FDA announced the creation of a new voucher program to expedite the development and approval of new drug products. Vouchers issued under the new program, which is known as the Commissioner&#8217;s National Priority Voucher, or CNPV, Program, may reportedly be redeemed by sponsors to shorten the review time of an NDA from approximately 10-12 months to 1-2 months. The FDA has indicated that the new CNPV process will convene experts from the FDA&#8217;s offices for a team-based review rather than using the standard review system of a drug application being sent to numerous FDA offices. Clinical information will be reviewed by a multidisciplinary team of physicians and scientists who will pre-review the submitted information and convene for a 1-day meeting. Vouchers under this program will reportedly be given to companies aligned with U.S. national priorities. As with the FDA&#8217;s other programs for expediting review and approval of new drug products, there is no guarantee it would result in approval of our marketing applications or that such approval, if granted, would be on an expedited basis.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Rare Disease Evidence Principles</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. In September 2025, the FDA introduced a framework intended to streamline the approval of new therapies for ultrarare diseases. The Rare Disease Evidence Principles, or RDEP, are intended to allow sponsors to rely on a single-arm trial in support of approval of drugs and biologics that treat rare diseases with very small patient populations and where the disease is linked to a known genetic defect and characterized by progressive functional deterioration leading to disability or death in a short period of time. The targeted diseases should also lack adequate alternative therapies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of these expedited programs changes the standards for approval but they may help expedite the development or approval process of product candidates.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Review and Approval of an NDA </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to obtain approval to market a drug product in the United States, an NDA must be submitted to the FDA that provides sufficient data establishing the safety and efficacy of the proposed drug product for its </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">43</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">intended indication. The application includes all relevant data available from pertinent preclinical studies and clinical trials, including negative or ambiguous results as well as positive findings, together with detailed information relating to the product&#8217;s CMC and proposed labeling, among other things. Data can come from company-sponsored clinical trials intended to test the safety and effectiveness of a use of a product, or from a number of alternative sources, including studies initiated by investigators. To support marketing approval, the data submitted must be sufficient in quality and quantity to establish the safety and efficacy of the drug product to the satisfaction of the FDA. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The NDA is a vehicle through which sponsors formally propose that the FDA approve a new product for marketing and sale in the United States for one or more indications. Every new drug product candidate must be the subject of an approved NDA before it may be commercialized in the United States. Under federal law, the submission of most NDAs is subject to an application user fee, which for federal fiscal year 2026 is $4,682,003 million for an application requiring clinical data. The sponsor of an approved NDA is also subject to an annual prescription drug product program fee, which for federal fiscal year 2026 is approximately $442,213. Certain exceptions and waivers are available for some of these fees, such as an exception from the application fee for products with orphan designation, an exception from the program fee when the program does not engage in manufacturing the drug during a particular fiscal year and a waiver for certain small businesses. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following submission of an NDA, the FDA conducts a preliminary review of the application within 60 calendar days of its receipt and it must inform the sponsor by that time or before whether the application is sufficiently complete to permit substantive review. In the event that FDA determines that an application does not satisfy this standard, it will issue a Refuse to File, or RTF, determination to the sponsor. The FDA may request additional information rather than accept the application for filing. In this event, the application must be resubmitted with the additional information. The resubmitted application is also subject to review before the FDA accepts it for filing. In October 2025, the FDA issued internal guidance clarifying that &#8220;materially incomplete or inadequately organized&#8221; applications that would not permit timely, efficient and complete review will be the subject of an RTF.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The internal guidance also provides that the agency will issue an RTF for an application that relies on a single adequate and well-controlled investigation to support approval if prior communications with the FDA determined the need for more than one clinical study and any justification for a single investigation is inadequate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once the submission is accepted for filing, the FDA begins an in-depth substantive review. The FDA has agreed to specified performance goals in the review process of NDAs. Under that agreement, 90% of applications seeking approval of New Molecular Entities, or NMEs, are meant to be reviewed within ten months from the date on which the FDA accepts the application for filing, and 90% of applications for NMEs that have been designated for &#8220;priority review&#8221; are meant to be reviewed within six months of the filing date. For applications seeking approval of products that are not NMEs, the ten-month and six-month review periods run from the date that the FDA receives the application. The review process and PDUFA target action date may be extended by the FDA for three additional months to consider new information or clarification provided by the sponsor to address an outstanding deficiency identified by the FDA following the original submission. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with its review of an application, the FDA typically will inspect the facility or facilities where the product is or will be manufactured. These pre-approval inspections may cover all facilities associated with an NDA submission, including component manufacturing, finished product manufacturing and control testing laboratories. The FDA will not approve an application unless it determines that the manufacturing processes and facilities are in compliance with cGMP requirements and adequate to assure consistent production of the product within required specifications. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Under the FDA Reauthorization Act of 2017, the FDA must implement a protocol to expedite review of responses to inspection reports pertaining to certain applications, including applications for products in shortage or those for which approval is dependent on remediation of conditions identified in the inspection report. Moreover, with passage of FDORA, Congress clarified FDA&#8217;s authority to conduct inspections by expressly permitting inspection of facilities involved in the preparation, conduct, or analysis of clinical and non-clinical studies submitted to FDA as well as other persons holding study records or involved in the study process.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a condition of approval, the FDA may require a sponsor to develop a Risk Evaluation Mitigation Strategies, or REMS. REMS use risk minimization strategies beyond the professional labeling to </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">44</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ensure that the benefits of the product outweigh the potential risks. To determine whether a REMS is needed, the FDA will consider the size of the population likely to use the product, seriousness of the disease, expected benefit of the product, expected duration of treatment, seriousness of known or potential adverse events and whether the product is a new molecular entity. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may refer an application for a novel product to an advisory committee or explain why such referral was not made. Typically, an advisory committee is a panel of independent experts, including clinicians and other scientific experts, that reviews, evaluates and provides a recommendation as to whether the application should be approved and under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">The FDA&#8217;s Decision on an NDA </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">After evaluating the application and all related information, including the advisory committee recommendations, if any, and inspection reports of manufacturing facilities and clinical trial sites, the FDA will issue either a Complete Response Letter, or CRL, or an approval letter.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To reach this determination, the FDA must determine that the drug is safe and effective and that its expected benefits outweigh its potential risks to patients. This &#8220;benefit-risk&#8221; assessment is informed by the extensive body of evidence about the product&#8217;s safety and efficacy in the NDA. This assessment is also informed by other factors, including: the severity of the underlying condition and how well patients&#8217; medical needs are addressed by currently available therapies; uncertainty about how the premarket clinical trial evidence will extrapolate to real-world use of the product in the post-market setting; and whether risk management tools are necessary to manage specific risks.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with this assessment, the FDA review team will assemble all individual reviews and other documents into an &#8220;action package,&#8221; which becomes the record for FDA review. The review team then issues a recommendation, and a senior FDA official makes a decision. In connection with this assessment, the FDA review team will assemble all individual reviews and other documents into an &#8220;action package,&#8221; which becomes the record for FDA review. The review team then issues a recommendation, and a senior FDA official makes a decision.</span></div><div><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA reviews an application to determine, among other things, whether the product is safe and whether it is effective for its intended use(s), with the latter determination being made on the basis of substantial evidence. The FDA has historically interpreted this evidentiary standard to require at least two adequate and well-controlled clinical investigations to establish effectiveness of a new product. In February 2026, however, the Commissioner of FDA and the Director of Center for Biologics Evaluation and Research published an editorial in the New England Journal of Medicine in which they declared that, in most cases, the new default requirement for FDA approval of a new product will be one adequate and well-controlled pivotal clinical trial plus confirmatory evidence, rather than two pivotal clinical trials.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In determining whether to rely on one trial, the FDA will focus on the single trial&#8217;s quality, including magnitude of effect, appropriateness of control arms, endpoint selection, statistical power, blinding, handling of missing data, biological plausibility and alignment with intermediate biomarkers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA has long had authority to approve new products on the basis of one trial plus confirmatory evidence and, in recent years, the agency has exercised that authority with respect to certain types of products. The FDA now takes the position that this will be the new official default standard for most product candidates.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">A CRL indicates that the review cycle of the application is complete, and the application will not be approved in its present form. A CRL generally outlines the deficiencies in the submission and may require substantial additional testing or information in order for the FDA to reconsider the application. The CRL may require additional clinical or other data, additional pivotal Phase 3 clinical trial(s) and/or other significant and time-consuming requirements related to clinical trials, preclinical studies or manufacturing. If a CRL is issued, the sponsor will have one year to respond to the deficiencies identified by the FDA, at which time the FDA can deem the application withdrawn or, in its discretion, grant the sponsor an additional six month extension to respond.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA has committed to reviewing resubmissions in response to an issued CRL in either two or six months depending on the type of information included. Even with the submission of this additional information, however, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval. For those seeking to challenge the FDA&#8217;s CRL decision, the agency has indicated that sponsors may request a formal hearing on the CRL or they may file a request for reconsideration or a request for a formal dispute resolution. The FDA has taken the position that a CRL is not final agency action making the determination subject to judicial review. While CRLs were previously treated by the FDA as confidential and were only disclosed in action packages for approved products, the agency announced in September 2025 that it will now release CRLs promptly after they are issued to sponsors. Since that announcement, the FDA has posted a number of CRLs on its website.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">45</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An approval letter, on the other hand, authorizes commercial marketing of the product with specific prescribing information for specific indications.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">That is, the approval will be limited to the conditions of use (e.g., patient population, indication) described in the FDA-approved labeling. Further, depending on the specific risk(s) to be addressed, the FDA may require that contraindications, warnings or precautions be included in the product labeling, require that post-approval trials be conducted to further assess a product&#8217;s safety after approval, require testing and surveillance programs to monitor the product after commercialization or impose other conditions, including distribution and use restrictions or other risk management mechanisms under a REMS which can materially affect the potential market and profitability of the product. The FDA may prevent or limit further marketing of a product based on the results of post-marketing trials or surveillance programs. After approval, some types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are subject to further testing requirements and FDA review and approval. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Post-Approval Regulation </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If regulatory approval for marketing of a product or new indication for an existing product is obtained, the sponsor will be required to comply with all regular post-approval regulatory requirements as well as any post-approval requirements that the FDA may have imposed as part of the approval process. The sponsor will be required to report, among other things, certain adverse reactions and manufacturing problems to the FDA, provide updated safety and efficacy information and comply with requirements concerning advertising and promotional labeling requirements. Manufacturers and certain of their subcontractors are required to register their establishments with the FDA and certain state agencies, and are subject to periodic unannounced inspections by the FDA and certain state agencies for compliance with ongoing regulatory requirements, including cGMP regulations, which impose certain procedural and documentation requirements upon manufacturers. Changes to the manufacturing process are strictly regulated and often require prior FDA approval before being implemented. Accordingly, the sponsor and its third-party manufacturers must continue to expend time, money and effort in the areas of production and quality control to maintain compliance with cGMP regulations and other regulatory requirements. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an approval is granted, the FDA may withdraw the approval if compliance with regulatory requirements is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-market studies or clinical trials to assess safety risks; or imposition of distribution or other restrictions under a REMS program. Other potential consequences include, among other things: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">restrictions on the marketing or manufacturing of the product, complete withdrawal of the product from the market or product recalls; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">fines, warning letters or holds on post-approval clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">refusal of the FDA to approve pending applications or supplements to approved applications, or withdrawal of product approvals; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">product seizure or detention, or refusal to permit the import or export of products; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injunctions or the imposition of civil or criminal penalties. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug products placed on the market. This regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities, and promotional activities involving the Internet and social media. Promotional claims about a drug&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a drug product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information. In the United States, health care professionals are generally permitted to prescribe drugs for such uses not described in the drug&#8217;s labeling, known as off-label uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of an approved drug product for any off-label uses. In September 2021, the FDA published final regulations which describe the types of evidence that the agency will consider in determining the intended use of a drug product.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">46</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On September 9, 2025, the President issued a Memorandum directing the Department of Health and Human Services, or HHS, to &#8220;ensure transparency and accuracy in direct-to-consumer, or DTC, prescription drug advertising, including by increasing the amount of information regarding any risks associated with the use of any such prescription drug required to be provided in prescription drug advertisements.&#8221; To that end, the FDA announced that it is initiating a rulemaking process &#8220;to eliminate the &#8216;adequate provision&#8217; loophole that allows pharmaceutical advertisements to hide safety information by placing it in another format or location.&#8221; In this context, the FDA declared that it will no longer tolerate what it characterized as &#8220;deceptive practices&#8221; in prescription drug advertising and that the agency would &#8220;aggressively deploy&#8221; its available enforcement tools, with &#8220;heightened scrutiny&#8221; of fair balance and disclosures in social media promotions. The FDA also issued a generic &#8220;notice letter&#8221; directing companies to &#8220;remove any noncompliant advertising and bring all promotional communications into compliance.&#8221;</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in nonpromotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information. With passage of the Pre-Approval Information Exchange Act in December 2022, sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite patient access upon product approval. Previously, such communications were permitted under FDA guidance but the new legislation explicitly provides protection to sponsors who convey certain information about products in development to payors, including unapproved uses of approved products. In addition, in January 2025, the FDA published final guidance outlining the agency&#8217;s non-binding policies governing the distribution of scientific information on unapproved uses of approved products to healthcare providers. This final guidance calls for such communications to be truthful, non-misleading, factual, and unbiased and include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription drugs may lead to investigations and enforcement actions alleging violations of federal and state healthcare fraud and abuse laws, as well as state consumer protection laws. If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the Department of Justice, or the Office of the Inspector General of HHS, as well as state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil and criminal fines and agreements that materially restrict the manner in which a company promotes or distributes drug products. The federal government has levied large civil and criminal fines against companies for alleged improper promotion, and has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, the distribution of prescription pharmaceutical products is subject to a variety of federal and state laws, the most recent of which is still in the process of being phased into the U.S. supply chain and regulatory framework. The Prescription Drug Marketing Act, or PDMA, was the first federal law to set minimum standards for the registration and regulation of drug distributors by the states and to regulate the distribution of drug samples. Today, both the PDMA and state laws limit the distribution of prescription pharmaceutical product samples and impose requirements to ensure accountability in distribution. Congress enacted the Drug Supply Chain Security Act, or DSCSA, which made significant amendments to the FDCA, including by replacing certain provisions from the PDMA pertaining to wholesale distribution of prescription drugs with a more comprehensive statutory scheme. The DSCSA now requires uniform national standards for wholesale distribution and, for the first time, for third-party logistics providers; it also provides for preemption of certain state laws in the areas of licensure and prescription drug traceability. For wholesale drug distributors, the final DSCSA deadline was August 27, 2025, marking the date for mandatory transition to a fully electronic, interoperable system for tracking prescription drugs at the package level throughout the United States.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">47</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Section 505(b)(2) NDAs</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">NDAs for most new drug products are based on two full clinical studies which must contain substantial evidence of the safety and efficacy of the new product for the proposed use. These applications are submitted under Section 505(b)(1) of the FDCA. The FDA is, however, authorized to approve an alternative type of NDA under Section 505(b)(2) of the FDCA. This type of application allows the sponsor to rely, in part, on the FDA&#8217;s previous findings of safety and efficacy for a similar product, or published literature. Specifically, Section 505(b)(2) applies to NDAs for a drug for which the investigations made to show whether or not the drug is safe for use and effective in use and relied upon by the sponsor for approval of the application &#8220;were not conducted by or for the sponsor and for which the sponsor has not obtained a right of reference or use from the person by or for whom the investigations were conducted.&#8221;</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Section 505(b)(2) authorizes the FDA to approve an NDA based on safety and effectiveness data that were not developed by the sponsor. NDAs filed under Section 505(b)(2) may provide an alternate and potentially more expeditious pathway to FDA approval for new or improved formulations or new uses of previously approved products. If the Section 505(b)(2) sponsor can establish that reliance on the FDA&#8217;s previous approval is scientifically appropriate, the sponsor may eliminate the need to conduct certain preclinical or clinical studies of the new product. The FDA may also require companies to perform additional studies or measurements to support the change from the approved product. The FDA may then approve the new drug candidate for all or some of the label indications for which the referenced product has been approved, as well as for any new indication sought by the Section 505(b)(2) sponsor.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Abbreviated New Drug Applications for Generic Drugs </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 1984, with passage of the Hatch-Waxman Amendments to the FDCA, Congress established an abbreviated regulatory scheme authorizing the FDA to approve generic drugs that are shown to contain the same active ingredients as, and to be bioequivalent to, drugs previously approved by the FDA pursuant to NDAs. To obtain approval of a generic drug, a sponsor must submit an abbreviated new drug application, or ANDA, to the agency. An ANDA is a comprehensive submission that contains, among other things, data and information pertaining to the active pharmaceutical ingredient, bioequivalence, drug product formulation, specifications and stability of the generic drug, as well as analytical methods, manufacturing process validation data and quality control procedures. ANDAs are &#8220;abbreviated&#8221; because they generally do not include preclinical and clinical data to demonstrate safety and effectiveness. Instead, in support of such applications, a generic manufacturer may rely on the preclinical and clinical testing previously conducted for a drug product previously approved under an NDA, known as the reference-listed drug, or RLD. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, in order for an ANDA to be approved, the FDA must find that the generic version is identical to the RLD with respect to the active ingredients, the route of administration, the dosage form, the strength of the drug and the conditions of use of the drug. At the same time, the FDA must also determine that the generic drug is &#8220;bioequivalent&#8221; to the innovator drug. Under the statute, a generic drug is bioequivalent to a RLD if &#8220;the rate and extent of absorption of the drug do not show a significant difference from the rate and extent of absorption of the listed drug.&#8221; Upon approval of an ANDA, the FDA indicates whether the generic product is &#8220;therapeutically equivalent&#8221; to the RLD in its publication &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; also referred to as the &#8220;Orange Book.&#8221; Physicians and pharmacists consider a therapeutic equivalent generic drug to be fully substitutable for the RLD. In addition, by operation of certain state laws and numerous health insurance programs, the FDA&#8217;s designation of therapeutic equivalence often results in substitution of the generic drug without the knowledge or consent of either the prescribing physician or patient. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Hatch-Waxman Amendments, the FDA may not approve an ANDA until any applicable period of non-patent exclusivity for the RLD has expired. The FDCA provides a period of five years of non-patent data exclusivity for a new drug containing a new chemical entity, or NCE. For the purposes of this provision, a NCE is a drug that contains no active moiety that has previously been approved by the FDA in any other NDA. This interpretation was confirmed with enactment of the Ensuring Innovation Act in April 2021. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. In cases where such NCE exclusivity has been granted, an ANDA may not be filed with the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification, in which case the sponsor may submit its application four years following the original product approval. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">48</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical investigations, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. This three-year exclusivity period often protects changes to a previously approved drug product, such as a new dosage form, route of administration, combination or indication. Three-year exclusivity would be available for a drug product that contains a previously approved active moiety, provided the statutory requirement for a new clinical investigation is satisfied. Unlike five-year NCE exclusivity, an award of three-year exclusivity does not block the FDA from accepting ANDAs seeking approval for generic versions of the drug as of the date of approval of the original drug product. The FDA typically makes decisions about awards of data exclusivity shortly before a product is approved. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA must establish a priority review track for certain generic drugs, requiring the FDA to review a drug application within eight (8) months for a drug that has three (3) or fewer approved drugs listed in the Orange Book and is no longer protected by any patent or regulatory exclusivities, or is on the FDA&#8217;s drug shortage list. The FDA is also authorized to expedite review of &#8220;competitor generic therapies&#8221; or drugs with inadequate generic competition, including holding meetings with or providing advice to the drug sponsor prior to submission of the application. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In October 2025, the FDA introduced a new program to expedite review of ANDAs and approval of generic drug products. Under this new initiative, a sponsor of an ANDA would qualify for faster review and approval if it conducts bioequivalence studies in the U.S., exclusively sources the active pharmaceutical ingredient in the U.S. and manufactures the finished drug product within the country, as well.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Hatch-Waxman Patent Certification and the 30-Month Stay </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Upon approval of an NDA or a supplement thereto, NDA sponsors are required to list with the FDA each patent with claims that cover the sponsor&#8217;s product or an approved method of using the product. Each of the patents listed by the NDA sponsor is published in the Orange Book. The FDA&#8217;s regulations governing patient listings were largely codified into law with enactment of the Orange Book Modernization Act in January 2021.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">When an ANDA sponsor files its application with the FDA, the sponsor is required to certify to the FDA concerning any patents listed for the reference product in the Orange Book, except for patents covering methods of use for which the ANDA sponsor is not seeking approval. To the extent that the Section 505(b)(2) sponsor is relying on studies conducted for an already approved product, the sponsor is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA sponsor would. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, the sponsor must certify with respect to each patent that: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the required patent information has not been filed; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the listed patent has expired; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the listed patent has not expired, but will expire on a particular date and approval is sought after patent expiration; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the listed patent is invalid, unenforceable or will not be infringed by the new product. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A certification that the new product will not infringe the already approved product&#8217;s listed patents or that such patents are invalid or unenforceable is called a Paragraph IV certification. If the sponsor does not challenge the listed patents or indicates that it is not seeking approval of a patented method of use, the application will not be approved until all the listed patents claiming the referenced product have expired (other than method of use patents involving indications for which the sponsor is not seeking approval). </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If the ANDA sponsor has provided a Paragraph IV certification to the FDA, the sponsor must also send notice of the Paragraph IV certification to the NDA and patent holders once the ANDA has been accepted for filing by the FDA. The NDA and patent holders may then initiate a patent infringement lawsuit in response to the notice of the Paragraph IV certification. The filing of a patent infringement lawsuit within 45 days after the receipt of a Paragraph IV certification automatically prevents the FDA from approving the ANDA until the earlier of 30 months after the receipt of the Paragraph IV notice, expiration of the patent, or a decision in the infringement case that is favorable to the ANDA sponsor. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">49</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that the Section 505(b)(2) sponsor is relying on studies conducted for an already approved product, the sponsor is required to certify to the FDA concerning any patents listed for the approved product in the Orange Book to the same extent that an ANDA sponsor would. As a result, approval of a Section 505(b)(2) NDA can be stalled until all the listed patents claiming the referenced product have expired, until any non-patent exclusivity, such as exclusivity for obtaining approval of a NCE, listed in the Orange Book for the referenced product has expired, and, in the case of a Paragraph IV certification and subsequent patent infringement suit, until the earlier of 30 months, settlement of the lawsuit or a decision in the infringement case that is favorable to the Section 505(b)(2) sponsor. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pediatric Exclusivity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we do not currently conduct any pediatric studies. pediatric exclusivity is another type of non-patent marketing exclusivity in the United States and, if granted, provides for the attachment of an additional six months of regulatory exclusivity to the term of any patent or existing regulatory exclusivity, including orphan exclusivity.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Orphan Drug Designation and Exclusivity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Orphan Drug Act, the FDA may designate a drug product as an &#8220;orphan drug&#8221; if it is intended to treat a rare disease or condition, generally meaning that it affects fewer than 200,000 individuals in the United States, or more in cases in which there is no reasonable expectation that the cost of developing and making a product available in the United States for treatment of the disease or condition will be recovered from sales of the product. A company must seek orphan drug designation before submitting an NDA for the candidate product. If the request is granted, the FDA will disclose the identity of the therapeutic agent and its potential use. Orphan drug designation does not shorten the PDUFA goal dates for the regulatory review and approval process, although it does convey certain advantages such as tax benefits and exemption from the PDUFA application fee. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If a product with orphan designation receives the first FDA approval for the disease or condition for which it has such designation or for a select indication or use within the rare disease or condition for which it was designated, the product generally will receive orphan drug exclusivity. Orphan drug exclusivity means that the FDA may not approve another sponsor&#8217;s marketing application for the same drug for the same condition for seven years, except in certain limited circumstances. Orphan exclusivity does not block the approval of a different product for the same rare disease or condition, nor does it block the approval of the same product for different conditions. If a drug designated as an orphan drug ultimately receives marketing approval for an indication broader than what was designated in its orphan drug application, it may not be entitled to exclusivity. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The period of market exclusivity begins on the date that the marketing application is approved by the FDA and applies only to the disease or condition for which the product has been designated. Orphan drug exclusivity will not bar approval of another product under certain circumstances, including if the company with orphan drug exclusivity is not able to meet market demand or the subsequent product is shown to be clinically superior to the approved product on the basis of greater efficacy or safety, or providing a major contribution to patient care. This is the case despite an earlier court opinion holding that the Orphan Drug Act unambiguously required the FDA to recognize orphan drug exclusivity regardless of a showing of clinical superiority. Under Omnibus legislation signed by the President on December 27, 2020, the requirement for a product to show clinical superiority applies to drug products that received orphan drug designation before enactment of amendments to the FDCA in 2017 but have not yet been approved by FDA.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA and the U.S. Congress may further reevaluate and revise the Orphan Drug Act and its regulations and policies. For example, in September 2021, the Court of Appeals for the 11th Circuit held that, for the purpose of determining the scope of orphan drug exclusivity, the term &#8220;same disease or condition&#8221; means the designated &#8220;rare disease or condition&#8221; and not the &#8220;indication or use&#8221; for which the product is approved. Subsequently, in another case, a federal district court in Washington, D.C. followed the reasoning of the 11th Circuit decision and that decision was appealed to the U.S. Court of Appeals for the D.C. Circuit. On February 3, 2026, the Consolidated Appropriations Act of 2026 was enacted into law. It overruled these court decisions and codified the FDA&#8217;s longstanding interpretation of the scope of orphan drug exclusivity to apply to &#8220;the same drug for the same approved use or indication within such [designated] rare disease or condition.&#8221; This change, which applies retroactively, expressly authorizes the FDA to approve multiple versions of the same orphan drug for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">50</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">different sub-indications and subpopulations, such as adult and pediatric patients or multiple variations of the same disease that are caused by different genetic variants. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Term Restoration and Extension </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A patent claiming a new drug product, its method of use or its method of manufacture may be eligible for a limited patent term extension under the Hatch-Waxman Act, which permits a patent restoration of up to five years for patent term lost during product development and the FDA regulatory review. The restoration period granted on a patent covering a product is typically one-half the time between the effective date of the IND for the clinical investigation is begun and the submission date of an application, plus the time between the submission date of an application and the ultimate approval date. Patent term restoration cannot be used to extend the remaining term of a patent past a total of 14 years from the product&#8217;s approval date. Only one patent applicable to an approved product is eligible for the extension, and the application for the extension must be submitted prior to the expiration of the patent in question. A patent that covers multiple products for which approval is sought can only be extended in connection with one of the approvals. The United States Patent and Trademark Office reviews and approves the application for any patent term extension or restoration in consultation with the FDA. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Federal and State Data Privacy and Security Laws</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are multiple privacy and data security laws that may impact our business activities, in the United States and in other countries where we conduct trials or where we may do business in the future. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the health care industry generally, under the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, the HHS has issued regulations to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also regulates standardization of data content, codes and formats used in healthcare transactions and standardization of identifiers for health plans and providers. HIPAA also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. HIPAA may apply to us in certain circumstances and may also apply to our business partners in ways that may impact our relationships with them. Our clinical trials are regulated by the Common Rule, which also includes specific privacy-related provisions. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that may be applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. State attorneys general also have authority to enforce state privacy and security laws. New laws and regulations governing privacy and security may be adopted in the future as well.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, California has enacted legislation that has been dubbed the first &#8220;GDPR-like&#8221; law in the United States. Known as the California Consumer Privacy Act, or CCPA, it creates new individual privacy rights for consumers (as that word is broadly defined in the law) and places increased privacy and security obligations on entities handling personal data of consumers or households. The CCPA went into effect on January 1, 2020, and requires covered companies to provide new disclosures to California consumers, provide such consumers new ways to opt-out of certain sales of personal information, and allow for a new cause of action for data breaches. In November 2020, California voters passed a ballot initiative for the California Privacy Rights Act, or the CPRA, which went into effect on January 1, 2023, and significantly expanded the CCPA to incorporate additional GDPR-like provisions including requiring that the use, retention, and sharing of personal information of California residents be reasonably necessary and proportionate to the purposes of collection or processing, granting additional protections for sensitive personal information, and requiring greater disclosures related to notice to residents regarding retention of information. The CPRA also created a new enforcement agency &#8211; the California Privacy Protection Agency &#8211; whose sole responsibility is to enforce the CPRA, which will further increase compliance risk. The provisions in the CPRA may apply to some of our business activities.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">51</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to California, at least eighteen other states have passed comprehensive privacy laws similar to the CCPA and CPRA. These laws are either in effect or will go into effect sometime before the end of 2026. Like the CCPA and CPRA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering additional laws that will go into effect that could go into effect in 2026 and beyond. Other states will be considering similar laws in the future, and Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, the State of Washington passed the My Health My Data Act in 2023 which specifically regulated health information that is not otherwise regulated by the HIPAA rules, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering such legislation. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Plaintiffs&#8217; lawyers are also increasingly using privacy-related statutes at both the state and federal level to bring lawsuits against companies for their data-related practices. In particular, there have been a significant number of cases filed against companies for their use of pixels and other web trackers. These cases often allege violations of the California Invasion of Privacy Act and other state laws regulating wiretapping, as well as the federal Video Privacy Protection Act. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our current or future business activities, including certain clinical research, sales and marketing practices and the provision of certain items and services to our customers, could be subject to challenge under one or more of such privacy and data security laws. The heightening compliance environment and the need to build and maintain robust and secure systems to comply with different privacy compliance and/or reporting requirements in multiple jurisdictions could increase the possibility that a healthcare company may fail to comply fully with one or more of these requirements. If our operations are found to be in violation of any of the privacy or data security laws or regulations described above that are applicable to us, or any other laws that apply to us, we may be subject to penalties, including potentially significant criminal, civil and administrative penalties, damages, fines, contractual damages, reputational harm, diminished profits and future earnings, additional reporting requirements and/or oversight if we become subject to a consent decree or similar agreement to resolve allegations of non-compliance with these laws, and the curtailment or restructuring of our operations, any of which could adversely affect our ability to operate our business and our results of operations. To the extent that any product candidates we may develop, once approved, are sold in a foreign country, we may be subject to similar foreign laws. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Health Care Law and Regulation </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care providers and third-party payors play a primary role in the recommendation and prescription of drug products that are granted marketing approval. Arrangements with providers, consultants, third-party payors and customers are subject to broadly applicable state and federal fraud and abuse laws and regulations (including anti-kickback and false claims laws), patient privacy laws and regulations, and other health care laws and regulations that may constrain business and/or financial arrangements. Restrictions under applicable federal and state health care laws and regulations, include the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Anti-Kickback Statute, which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchasing, ordering, leasing, arranging for, or recommending the purchasing, ordering, or leasing of, any good or service for which payment may be made, in whole or in part, under a federal health care program such as Medicare and Medicaid; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal civil and criminal false claims laws, including the civil False Claims Act, and Civil Monetary Penalties Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, false or fraudulent claims for payment or knowingly making, using or causing to made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">52</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal laws that prohibit, among other things, knowingly and willfully executing, or attempting to execute, a scheme to defraud any health care benefit program or making false statements relating to health care matters; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, and the regulations promulgated thereunder, including 45 C.F.R. Parts 160 and 164, imposing rules regarding privacy, security, and data breach notifications; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FCPA, which prohibits companies and their intermediaries from making, or offering or promising to make improper payments to non-U.S. officials for the purpose of obtaining or retaining business or otherwise seeking favorable treatment; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the federal physician transparency requirements known as the Physician Payments Sunshine Act, under the Patient Protection and Affordable Care Act, as amended by the Health Care Education Reconciliation Act, or the Affordable Care Act, or the ACA, which requires manufacturers of drugs, medical devices, biological and medical supplies covered by Medicare, Medicaid, or State Children&#8217;s Health Insurance Program to report annually to the Centers for Medicare &amp; Medicaid Services, or CMS, within HHS, information related to payments and other transfers of value made by that entity to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">analogous state and foreign laws and regulations, such as state anti-kickback and false claims laws, which may apply to health care items or services that are reimbursed by non-government third-party payors, including private insurers. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government in addition to requiring manufacturers to report information related to payments to physicians and other health care providers or marketing expenditures. Additionally, some state and local laws require the registration of pharmaceutical sales representatives in the jurisdiction. State and foreign laws also govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Insurance Coverage and Health Care Reform </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and other countries, patients who are prescribed treatments for their conditions and providers performing the prescribed services generally rely on third-party payors to reimburse all or part of the associated health care costs. Significant uncertainty exists as to the coverage and reimbursement status of products approved by the FDA and other government authorities. Thus, even if a product candidate is approved, sales of the product will depend, in part, on the extent to which third-party payors, including government health programs in the United States such as Medicare and Medicaid, commercial health insurers and managed care organizations, provide coverage and establish adequate reimbursement levels for the product. The process for determining whether a payor will provide coverage for a product may be separate from the process for setting the price or reimbursement rate that the payor will pay for the product once coverage is approved. Third-party payors are increasingly challenging the prices charged, examining the medical necessity and reviewing the cost-effectiveness of medical products and services and imposing controls to manage costs. Third-party payors may limit coverage to specific products on an approved list, also known as a formulary, which might not include all of the approved products for a particular indication. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to secure coverage and reimbursement for any product that might be approved for sale, a company may need to conduct expensive pharmacoeconomic studies in order to demonstrate the medical necessity and cost-effectiveness of the product, in addition to the costs required to obtain FDA or other comparable marketing approvals. Nonetheless, product candidates may not be considered medically necessary or cost effective. A decision by a third-party payor not to cover a product could reduce physician utilization once the product is approved and have a material adverse effect on sales, results of operations and financial condition. Additionally, a payor&#8217;s decision to provide coverage for a product does not imply that an adequate reimbursement rate will be approved. Further, one payor&#8217;s determination to provide coverage for a product does not assure that other payors will also provide coverage and reimbursement for the product, and the level of coverage and reimbursement can differ significantly from payor to payor. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">53</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The containment of health care costs also has become a priority of federal, state and foreign governments and the prices of products have been a focus in this effort. Governments have shown significant interest in implementing cost-containment programs, including price controls, restrictions on reimbursement and requirements for substitution of generic products. Adoption of price controls and cost-containment measures, and adoption of more restrictive policies in jurisdictions with existing controls and measures, could further limit a company&#8217;s revenue generated from the sale of any approved products. Coverage policies and third-party reimbursement rates may change at any time. Even if favorable coverage and reimbursement status is attained for one or more products for which a company or its collaborators receive marketing approval, less favorable coverage policies and reimbursement rates may be implemented in the future. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There have been a number of federal and state proposals during the last few years regarding the pricing of pharmaceutical and biopharmaceutical products, limiting coverage and reimbursement for drugs and biologics and other medical products, government control and other changes to the health care system in the United States. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2010, the ACA was signed into law. In addition, other legislative changes have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for spending reductions by Congress. A Joint Select Committee on Deficit Reduction, tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, was unable to reach required goals, thereby triggering the legislation&#8217;s automatic reduction to several government programs. These changes included aggregate reductions of Medicare payments to providers of up to 2% per fiscal year, which went into effect in April 2013 and will remain in effect through 2030 under the Coronavirus Aid, Relief, and Economic Security Act, or the CARES Act. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The American Taxpayer Relief Act of 2012, among other things, reduced Medicare payments to several providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Consolidated Appropriations Act, which was signed into law in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the Consolidated Appropriations Act delays the 4% Statutory Pay-As-You-Go Act of 2010 (PAYGO) sequester for two years, through the end of calendar year 2024. Triggered by enactment of the American Rescue Plan Act of 2021, the 4% cut to the Medicare program would have taken effect in January 2023. The Consolidated Appropriations Act&#8217;s health care offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into fiscal year 2032 and lowers the payment reduction percentages in fiscal years 2030 and 2031.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Since enactment of the ACA, there have been, and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. For example, with enactment of the Tax Cuts and Jobs Act of 2017, which was signed by the President on December 22, 2017, Congress repealed the &#8220;individual mandate.&#8221; The repeal of this provision, which requires most Americans to carry a minimal level of health insurance, became effective in 2019. The U.S. Supreme Court, on June 17, 2021, dismissed an action challenging the constitutionality of the ACA after finding that the plaintiffs do not have standing to bring the action.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. Further, with adoption of the One Big Beautiful Bill Act, or OBBB Act, in July 2025, Congress further restricted certain provisions in the ACA by eliminating enhanced premium tax credits, halting provisional coverage, removing repayment caps, reducing subsidies for lawfully present migrants, and tightening enrollment verification requirements.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pharmaceutical Price Reforms</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2020, the President issued several executive orders intended to lower the costs of prescription products and certain provisions in these orders have been incorporated into regulations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These regulations include an interim final rule implementing a most favored nation </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">54</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">model for prices that would tie Medicare Part B payments for certain physician-administered pharmaceuticals to the lowest price paid in other economically advanced countries, effective January 1, 2021. That rule, however, has been subject to a nationwide preliminary injunction and, on December 29, 2021, CMS issued a final rule to rescind it. With issuance of this rule, CMS stated that it will explore all options to incorporate value into payments for Medicare Part B pharmaceuticals and improve beneficiaries' access to evidence-based care.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program to import certain prescription products from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America, or PhRMA, but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Several states have passed laws allowing for the importation of products from Canada. On January 5, 2023, the FDA approved Florida&#8217;s plan for Canadian product importation. That state now has authority to import certain products from Canada for a period of two years once certain conditions are met. Florida will first need to submit a pre-import request for each product selected for importation, which must be approved by the FDA. The state will also need to relabel the products and perform quality testing of the products to meet FDA standards. On May 21, 2025, the FDA announced that it would offer individual states the opportunity to submit a draft proposal for pre-review and meet with the agency to obtain initial feedback from the FDA prior to formally submitting their section 804 importation program, or </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">SIP, proposal. The intent of these meetings is to assist states in developing their proposals by further clarifying requirements, enhancing the quality of proposals submitted to the agency and ultimately shortening the review timeline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The final rule would also eliminate the current safe harbor for Medicare drug rebates and create new safe harbors for beneficiary point-of-sale discounts and pharmacy benefit manager service fees. It originally was set to go into effect on January 1, 2022, but with passage of the Inflation Reduction Act of 2022, or IRA, has been delayed by Congress to January 1, 2032.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the IRA was signed into law. The new legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of enrolling in a plan providing outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare (beginning in 2026), with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (beginning in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS may negotiate prices for ten high-cost drugs paid for by Medicare Part D starting in 2026, followed by 15 additional Part D drugs in 2027, 15 additional Part B or Part D drugs in 2028, and 20 additional Part B or Part D drugs in 2029 and beyond. Drugs and biologics that have been approved for a single rare disease or condition were originally categorically excluded from price negotiation. With passage of the One Big Beautiful Bill Act on July 3, 2025, which was signed into law on July 4, 2025, Congress extended this exemption to drugs and biologics with multiple orphan drug designations. Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare beneficiaries' out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The first cycle of negotiations for the Medicare Drug Price Negotiation Program commenced in the summer of 2023. On August 15, 2024, HHS published the results of the first Medicare drug price negotiations for ten selected drugs that treat a range of conditions, including diabetes, chronic kidney disease, and rheumatoid arthritis. The prices of these ten drugs will become effective January 1, 2026. On January 17, 2025, CMS announced the selection of 15 additional drugs covered by Part D for the second cycle of negotiations. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">55</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This second cycle of negotiations with participating drug companies will occur during 2025, and any negotiated prices for this second set of drugs will be effective starting January 1, 2027.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 6, 2023, Merck &amp; Co., Inc., filed a lawsuit against HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the U.S. Constitution. Subsequently, other parties, including the U.S. Chamber of Commerce, or Chamber of Commerce, Bristol Myers Squibb Company, the PhRMA, Astellas Pharma US, Inc., Novo Nordisk Inc., Janssen Pharmaceuticals, Inc., Novartis Pharmaceutical Corporation, AstraZeneca L.P. and Boehringer Ingelheim Pharmaceuticals, Inc. also filed lawsuits in various courts with similar constitutional claims against HHS and CMS. HHS has generally won the substantive disputes in these cases or succeeded in getting claims dismissed for lack of standing. Most of these cases are now on appeal. On October 30, 2024, the U.S. Court of Appeals for the Third Circuit heard oral arguments in three of these cases. In April 2025, the U.S. Court of Appeals for the Second Circuit and the U.S. Court of Appeals for the Third Circuit heard arguments in an additional three cases. On May 8, 2025, the U.S. Court of Appeals for the Third Circuit rejected AstraZeneca L.P.&#8217;s challenge to the Medicare price negotiation program, finding that the program did not violate the company&#8217;s due process rights under the Constitution since there is no protected property interest in selling goods to Medicare beneficiaries at a price higher than what the government is willing to pay in reimbursement. Litigation involving these and other provisions of the IRA will continue with unpredictable and uncertain results.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On April 15, 2025, the President issued an executive order that directs HHS to take steps to reduce the prices of pharmaceutical products. The new executive order repeats many of the proposals advanced during the current President&#8217;s first term, including directing the FDA to streamline and improve its existing drug importation program so as to make it easier for states to obtain approval without sacrificing the safety or quality of drug products. Other provisions of the executive order relate to the 340B program. Specifically, one provision calls on the Secretary of HHS to determine the hospital acquisition cost for covered outpatient drugs at hospital outpatient departments and to consider and propose any appropriate adjustments for Medicare payment. The other provision directs HHS to condition grant funding to certain health centers on those centers passing through the 340B discounts they receive on insulin and injectable epinephrine products to patients who meet certain requirements. With respect to the IRA&#8217;s Medicare drug pricing program, the executive order, among other things, calls for alignment in &#8220;the treatment of small molecule prescription drugs with that of biological products, ending the distortion that undermines relative investment in small molecule prescription drugs, coupled with other reforms to prevent any increase in overall costs to Medicare and its beneficiaries.&#8221; </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, on May 12, 2025, the President issued an additional executive order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the United States. The executive order directs the Secretary of HHS to communicate most-favored-nation, or MFN, price targets to pharmaceutical manufacturers to bring prices in line with comparably developed nations. The executive order further provides that if such actions do not lower the costs of pharmaceuticals, the Secretary of HHS would pursue other actions, including proposing a rulemaking that imposes MFN pricing in the United States. Subsequently, on May 20, 2025, HHS indicated that the proposed MFN pricing will apply only to brand products without generic or biosimilar competition and the reference foreign countries will include only those in which the branded product similarly does not have generic or biosimilar competition. Second, HHS indicated that the MFN target price will be the lowest price in a country that is a member of the Organization for Economic Co-operation and Development, or OECD, with a gross domestic product, or GDP, per capita of at least 60% of the U.S. GDP per capita. Based on previous estimates, there are likely at least 22 OECD countries that would satisfy this criterion. The implications of these actions remain unclear and are likely to result in litigation if the administration pursues an MFN regulatory pricing requirement.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">More recently, on July 31, 2025, the President issued letters to 17 pharmaceutical companies reiterating the requirements of the May 12, 2025 Executive Order and demanding that such companies extend MFN pricing to Medicaid patients, guarantee MFN pricing for newly-launched drug products, return increased revenues abroad to American patients and provide for direct purchasing at MFN pricing. The letters also urged these companies to stipulate that they will not offer other developed nations better prices for new drugs than the prices offered for such products in the U.S. The letters called for engagement with the FDA and CMS within 60 days to implement these changes and threatened to use &#8220;every tool in our arsenal&#8221; to address what the letter characterized as &#8220;abusive drug pricing practices.&#8221; Virtually all of these pharmaceutical companies have entered into agreements with the administration to provide for lower prices on certain pharmaceuticals. On February 5, 2026, President Trump launched TrumpRx.gov, a website that directs individuals to pharmaceutical manufacturer websites that are offering price discounts based on the administration&#8217;s pricing agreements with pharmaceutical manufacturers. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">56</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On December 23, 2025, CMS, through its Center for Medicare and Medicaid Innovation, proposed two five-year pilot programs to implement a &#8220;reference pricing&#8221; regime for drugs paid for under Medicare for 25% of covered beneficiaries. The programs are referred to as the Global Benchmark for Efficient Drug Pricing Model for Medicare Part B drugs, referred to as GLOBE, and the Guarding U.S. Medicare Against Rising Drug Costs for Medicare Part D drugs, referred to as GUARD. Under the proposed pilot programs, a manufacturer would owe rebates to Medicare if prices for their drugs exceeded the prices paid by other economically comparable reference countries, defined in the proposed regulations as OECD countries with a GDP of $400 billion and a per capita GDP that is at least 60% of the U.S. per capita GDP (an initial list of 19 reference countries is included in the proposed rule). Comments are due on the proposed pilot program rules on or before February 23, 2026, and the pilot programs are proposed to go into effect beginning October 1, 2026 for GLOBE and January 1, 2027 for GUARD.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A number of states, for example, require drug manufacturers and other entities in the drug supply chain, including health carriers, pharmacy benefit managers, wholesale distributors, to disclose information about pricing of pharmaceuticals.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, regional healthcare organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription pharmaceutical and other healthcare programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Review and Approval of Medicinal Products in the EU</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market any product outside of the United States, a sponsor must also comply with numerous and varying regulatory requirements of other countries and jurisdictions regarding quality, safety and efficacy and governing, among other things, clinical trials, marketing authorization, commercial sales and distribution of products. Whether or not it obtains FDA approval for a product, a sponsor will need to obtain the necessary approvals by the comparable regulatory authorities of foreign countries or economic areas, such as the 27-member EU, before it can commence clinical trials or marketing of the product in those countries or jurisdictions. The approval process ultimately varies between countries and jurisdictions and can involve additional product testing and additional administrative review periods. The time required to obtain approval in other countries and jurisdictions might differ from and be longer than that required to obtain FDA approval. The EU/European Economic Area, or EEA, applies harmonized regulatory rules for medicinal products, for the approval process and requirements governing the conduct of clinical trials, and for the regulatory approval of medicinal products. However, pricing and reimbursement for medicinal products varies greatly between countries and jurisdictions and can involve additional testing for health technology assessments.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulatory approval in one country or jurisdiction does not ensure regulatory approval in another, but a failure or delay in obtaining regulatory approval in one country or jurisdiction may negatively impact the regulatory process in others. Specifically, however, the process governing approval of medicinal products in the EU generally follows the same lines as in the United States, as further detailed below. It entails satisfactory completion of preclinical studies and adequate and well-controlled clinical trials to establish the safety and efficacy of the product for each proposed indication. It also requires the submission to the relevant competent authorities of a marketing authorization application, or MAA, and granting of a marketing authorization by these authorities before the product can be marketed and sold in the EU. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Non-clinical Studies</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-clinical studies are performed to demonstrate the health or environmental safety of new chemical or biological substances. Non-clinical (pharmaco-toxicological) studies must be conducted in compliance with the GLP principles as set forth in EU Directive 2004/10/EC (unless otherwise justified for certain particular medicinal products &#8211; e.g., radio-pharmaceutical precursors for radio-labeling purposes). In particular, non-clinical studies, both </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vivo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, must be planned, performed, monitored, recorded, reported and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">57</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">archived in accordance with the GLP principles, which define a set of rules and criteria for a quality system for the organizational process and the conditions for non-clinical studies. These GLP standards reflect the Organization for Economic Co-operation and Development requirements.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical Trial Approval </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On January 31, 2022, the Clinical Trials Regulation (EU) No 536/2014, or CTR, became effective in the EU and replaced the prior Clinical Trials Directive 2001/20/EC, or CTD. The CTR aims at simplifying and streamlining the authorization, conduct and transparency of clinical trials in the EU. Under the new coordinated procedure for the approval of clinical trials, the sponsor of a clinical trial to be conducted in more than one Member State of the European Union, or EU Member State, is only required to submit a single application for approval. The submission is made through the Clinical Trials Information System, a new clinical trials portal overseen by the European Medicines Agency, or EMA, and available to clinical trial sponsors, competent authorities of the EU Member States and the public. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The main characteristics of the CTR include:  a streamlined application procedure via a single entry point, the "EU Portal ad Database", a single set of documents to be prepared and submitted for the application as well as simplified reporting procedures for clinical trial sponsors, and a harmonized procedure for the assessment of applications for clinical trials, which is divided in two parts. Part I is assessed by the appointed reporting Member State, whose assessment report is submitted for review by the sponsor and all other competent authorities of all EU Member States in which an application for authorization of a clinical trial has been submitted, or concerned member states. Part II is assessed separately by each concerned member state. Strict deadlines have been established for the assessment of clinical trial applications. The role of the relevant ethics committees in the assessment procedure will continue to be governed by the national law of the concerned member state. However, overall related timelines will be defined by the CTR.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CTR did not change the preexisting requirement that a sponsor must obtain prior approval from the competent national authority of the EU Member State in which the clinical trial is to be conducted. If the clinical trial is conducted in different EU Member States, the competent authorities in each of these EU Member States must provide their approval for the conduct of the clinical trial. Furthermore, the sponsor may only start a clinical trial at a specific study site after the applicable ethics committee has issued a favorable opinion.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The CTR foresees a three-year transition period. The extent to which ongoing and new clinical trials will be governed by the CTR varies. Clinical trials for which an application was submitted (i) prior to January 31, 2022 under the CTD, or (ii) between January 31, 2022 and January 31, 2023 and for which the sponsor has opted for the application of the CTD remain governed by said Directive until January 31, 2025. After this date, all clinical trials (including those which are ongoing) will become subject to the provisions of the CTR.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Parties conducting certain clinical trials must, as in the United States, post clinical trial information in the EU at the EU Clinical Trials Register.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PRIME Designation in the EU </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In March 2016, the EMA launched an initiative to facilitate development of product candidates in indications, often rare, for which few or no therapies currently exist. The PRIority MEdicines, or PRIME, scheme is intended to encourage drug development in areas of unmet medical need and provides accelerated assessment of products representing substantial innovation reviewed under the centralized procedure. Products from small- and medium-sized enterprises, or SMEs, may qualify for earlier entry into the PRIME scheme than larger companies. Many benefits accrue to sponsors of product candidates with PRIME designation, including but not limited to, early and proactive regulatory dialogue with the EMA, frequent discussions on clinical trial designs and other development program elements, and accelerated marketing authorization application assessment once a dossier has been submitted. Importantly, a dedicated EMA contact and rapporteur from the EMA's Committee for Human Medicinal Products, or CHMP, or Committee for Advanced Therapies, or CAT, are appointed early in PRIME scheme facilitating increased understanding of the product at EMA&#8217;s Committee level. A kick-off meeting initiates these relationships and includes a team of multidisciplinary experts at the EMA to provide guidance on the overall development and regulatory strategies. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">58</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pediatric Studies </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently conduct any pediatric studies. In the event that we ever do conduct pediatric studies, additional regulation will apply. For example, prior to obtaining a marketing authorization in the European Union, sponsors must demonstrate compliance with all measures included in an EMA-approved Paediatric Investigation Plan, or PIP, covering all subsets of the pediatric population, unless the EMA has granted a product-specific waiver, a class waiver, or a deferral for one or more of the measures included in the PIP. The respective requirements for all marketing authorization procedures are laid down in Regulation (EC) No 1901/2006, the so-called Paediatric Regulation. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing Authorization </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To obtain marketing authorization for a product under EU regulatory systems, a sponsor must submit an MAA either under a centralized procedure administered by the EMA, or one of the procedures administered by competent authorities in the EU Member States (decentralized procedure or mutual recognition procedure, or MRP). A marketing authorization may be granted only to a sponsor established in the EU. Regulation (EC) No 1901/2006 provides that prior to obtaining a marketing authorization in the EU, sponsors have to demonstrate compliance with all measures included in an EMA-approved PIP covering all subsets of the pediatric population, unless the EMA has granted (1) a product-specific waiver, (2) a class waiver or (3) a deferral for one or more of the measures included in the PIP. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The centralized procedure provides for the grant of a single marketing authorization by the European Commission that is valid across the EEA (i.e. the EU as well as Iceland, Liechtenstein and Norway). Pursuant to Regulation (EC) No 726/2004, the centralized procedure is compulsory for specific products, including for medicines produced by certain biotechnological processes, products designated as orphan medicinal products, advanced therapy medicinal products and products with a new active substance indicated for the treatment of certain diseases, including products for the treatment of cancer. For products with a new active substance indicated for the treatment of other diseases and products that are highly innovative or for which a centralized process is in the interest of patients, the centralized procedure may be optional. The centralized procedure may at the request of the applicant also be used in certain other cases. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the centralized procedure, the CHMP is responsible for conducting the initial assessment of a product and for several post-authorization and maintenance activities, such as the assessment of modifications or extensions to an existing marketing authorization. Under the centralized procedure in the EU, the maximum timeframe for the evaluation of an MAA is 210 days, excluding clock stops, when additional information or written or oral explanation is to be provided by the applicant in response to questions of the CHMP. Accelerated evaluation might be granted by the CHMP in exceptional cases, when a medicinal product is of major interest from the point of view of public health and in particular from the viewpoint of therapeutic innovation. If the CHMP accepts such request, the time limit of 210 days will be reduced to 150 days but it is possible that the CHMP can revert to the standard time limit for the centralized procedure if it considers that it is no longer appropriate to conduct an accelerated assessment. At the end of this period, the CHMP provides a scientific opinion on whether or not a marketing authorization should be granted in relation to a medicinal product. Within 15 calendar days of receipt of a final opinion from the CHMP, the European Commission must prepare a draft decision concerning an application for marketing authorization. This draft decision must take the opinion and any relevant provisions of EU law into account. Before arriving at a final decision on an application for centralized authorization of a medicinal product the European Commission must consult the Standing Committee on Medicinal Products for Human Use. The Standing Committee is composed of representatives of the EU Member States and chaired by a non-voting European Commission representative.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU medicines rules expressly permit the EU Member States to adopt national legislation prohibiting or restricting the sale, supply or use of any medicinal product containing, consisting of or derived from a specific type of human or animal cell, such as embryonic stem cells. While the products we have in development do not make use of embryonic stem cells, it is possible that the national laws in certain EU Member States may prohibit or restrict us from commercializing our products, even if they have been granted an EU marketing authorization. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The decentralized marketing authorization procedure requires a separate application to, and leads to separate approval by, the competent authorities of each EU Member State in which the product is to be marketed. This application is identical to the application that would be submitted to the EMA for authorization through the centralized procedure. The reference Member State, or RMS, prepares a draft assessment and </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">59</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">drafts of the related materials within 120 days after receipt of a valid application. The resulting assessment report is submitted to the concerned EU Member States who, within 90 days of receipt, must decide whether to approve the assessment report and related materials. If a concerned EU Member State cannot approve the RMS's assessment report and related materials due to concerns relating to a potential serious risk to public health, disputed elements may be referred to the European Commission, whose decision is binding on all EU Member States. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The MRP similarly is based on the acceptance by the competent authorities of the EU Member States of the marketing authorization of a medicinal product by the competent authorities of other EU Member States. The holder of a national marketing authorization may submit an application to the competent authority of an EU Member State requesting that this authority recognize the marketing authorization delivered by the competent authority of another EU Member State.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketing Authorization under Exceptional Circumstances</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission may grant a so-called &#8220;marketing authorization under exceptional circumstances&#8221; under Article 14(8) of Regulation (EC) No 726/2004. Such authorization is intended for products for which the sponsor can demonstrate that it is unable to provide comprehensive data on the efficacy and safety under normal conditions of use, because the indications for which the product in question is intended are encountered so rarely that the sponsor cannot reasonably be expected to provide comprehensive evidence, or in the present state of scientific knowledge, comprehensive information cannot be provided, or it would be contrary to generally accepted principles of medical ethics to collect such information. Consequently, marketing authorization under exceptional circumstances may be granted subject to certain specific obligations, which may include the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the sponsor must complete an identified program of studies within a time period specified by the competent authority, the results of which form the basis of a reassessment of the benefit/risk profile; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the medicinal product in question may be supplied on medical prescription only and may in certain cases be administered only under strict medical supervision, possibly in a hospital and in the case of a radiopharmaceutical, by an authorized person; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the package leaflet and any medical information must draw the attention of the medical practitioner to the fact that the particulars available concerning the medicinal product in question are as yet inadequate in certain specified respects. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization under exceptional circumstances is subject to annual review to reassess the risk-benefit balance in an annual reassessment procedure. Continuation of the authorization is linked to the annual reassessment and a negative assessment could potentially result in the marketing authorization being suspended or revoked. The renewal of a marketing authorization of a medicinal product under exceptional circumstances, however, follows the same rules as a &#8220;normal&#8221; marketing authorization. Thus, a marketing authorization under exceptional circumstances is granted for an initial five years, after which the authorization will become valid indefinitely, unless the EMA decides that safety grounds merit one additional five-year renewal. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conditional Marketing Authorization</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The European Commission may also grant a so-called &#8220;conditional marketing authorization&#8221; prior to obtaining the comprehensive clinical data required for an application for a full marketing authorization under Article 14-a of Regulation (EC) No 726/2004. Such conditional marketing authorizations may be granted for product candidates (including medicines designated as orphan medicinal products), if (i) the risk-benefit balance of the product candidate is positive, (ii) it is likely that the sponsor will be in a position to provide the required comprehensive clinical trial data, (iii) the product fulfills an unmet medical need and (iv) the benefit to public health of the immediate availability on the market of the medicinal product concerned outweighs the risk inherent in the fact that additional data are still required. A conditional marketing authorization may contain specific obligations to be fulfilled by the marketing authorization holder, including obligations with respect to the completion of ongoing or new studies, and with respect to the collection of pharmacovigilance data. Conditional marketing authorizations are valid for one year, and may be renewed annually, if the risk-benefit balance remains positive, and after an assessment of the need for additional or modified conditions and/or specific </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">60</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">obligations. The timelines for the centralized procedure described above also apply with respect to the review by the CHMP of applications for a conditional marketing authorization. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Data Protection in the EU </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, innovative medicinal products approved on the basis of a complete independent data package qualify for eight years of data exclusivity upon marketing authorization and an additional two years of market exclusivity pursuant to Directive 2001/83/EC. Regulation (EC) No 726/2004 repeats this entitlement for medicinal products authorized in accordance the centralized authorization procedure. Data exclusivity prevents sponsors for authorization of generics of these innovative products from referencing the innovator&#8217;s data to assess a generic (abridged) application for a period of eight years. During an additional two-year period of market exclusivity, a generic marketing authorization application can be submitted and authorized, and the innovator&#8217;s data may be referenced, but no generic medicinal product can be placed on the EU market until the expiration of the market exclusivity. The overall ten-year period will be extended to a maximum of 11 years if, during the first eight years of those ten years, the marketing authorization holder obtains an authorization for one or more new therapeutic indications which, during the scientific evaluation prior to their authorization, are held to bring a significant clinical benefit in comparison with existing therapies. Even if a compound is considered to be an NCE so that the innovator gains the prescribed period of data exclusivity, another company nevertheless could also market another version of the product if such company obtained marketing authorization based on an MAA with a complete independent data package of pharmaceutical tests, preclinical tests and clinical trials. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In this context, it should be noted that the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products was published in April 2023 and includes, among other things, provisions that would potentially reduce the duration of regulatory data protection. The European Parliament requested several amendments in April 2024. On December 11. 2025, the European Parliament and Council reached a provisional political agreement on the legislation which is expected to be adopted by mid-2026. Key changes include updating regulatory data exclusivity to a new system with 8 years data exclusivity and reduced market exclusivity period to 1 year which can be extended if specific conditions are fulfilled, adding launch/supply obligations, incentivizing antibiotic innovation with transferable vouchers, and streamlining approval procedures in the EU. This measure, and others, are expected to be adopted by mid-2026 and, following a transition period of 24 months, will likely take effect in mid-2028.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Periods of Authorization and Renewals </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A marketing authorization has an initial validity for five years in principle. The marketing authorization may be renewed after five years on the basis of a re-evaluation of the risk-benefit balance by the EMA or by the competent authority of the EU Member State. To this end, the marketing authorization holder must provide the EMA or the competent authority with a consolidated version of the file in respect of quality, safety and efficacy, including all variations introduced since the marketing authorization was granted, at least six months before the marketing authorization ceases to be valid. The European Commission or the competent authorities of the EU Member States may decide, on justified grounds relating to pharmacovigilance, to proceed with one further five-year period of marketing authorization. Once subsequently definitively renewed, the marketing authorization shall be valid for an unlimited period. Any authorization which is not followed by the actual placing of the medicinal product on the EU market (in case of centralized procedure) or on the market of the authorizing EU Member State within three years after authorization or if initially placed on the market, is no longer actually present on the market for three consecutive years, ceases to be valid (the so-called sunset clause). </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pediatric Exclusivity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently conduct any pediatric studies, and therefore regulations related to pediatric exclusivity do not currently apply </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Orphan Drug Designation and Exclusivity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Regulation (EC) No. 141/2000, as implemented by Regulation (EC) No. 847/2000 provides that a drug can be designated as an orphan drug by the European Commission if its sponsor can establish: that the product </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">61</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is intended for the diagnosis, prevention or treatment of (1) a life-threatening or chronically debilitating condition affecting not more than five in ten thousand persons in the EU when the application is made, or (2) a life-threatening, seriously debilitating or serious and chronic condition in the EU and that without incentives it is unlikely that the marketing of the drug in the EU would generate sufficient return to justify the necessary investment. For either of these conditions, the sponsor must demonstrate that there exists no satisfactory method of diagnosis, prevention or treatment of the condition in question that has been authorized in the EU or, if such method exists, the drug will be of significant benefit to those affected by that condition. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once authorized, orphan medicinal products are entitled to 10 years of market exclusivity in all EU Member States and in addition a range of other benefits during the development and regulatory review process including scientific assistance for study protocols, authorization through the centralized marketing authorization procedure covering all member countries and a reduction or elimination of registration and marketing authorization fees. However, marketing authorization may be granted to a similar medicinal product with the same orphan indication during the 10-year period with the consent of the marketing authorization holder for the original orphan medicinal product or if the manufacturer of the original orphan medicinal product is unable to supply sufficient quantities. Marketing authorization may also be granted to a similar medicinal product with the same orphan indication if this product is safer, more effective or otherwise clinically superior to the original orphan medicinal product. The period of market exclusivity may, in addition, be reduced to six years if it can be demonstrated on the basis of available evidence that the original orphan medicinal product is sufficiently profitable not to justify maintenance of market exclusivity. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Patent Term Extensions in the EU and Other Jurisdictions</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The EU also provides for patent term extension through SPCs. The rules and requirements for obtaining a SPC are set out in Regulation (EC) 469/2009 and are similar to those in the United States. An SPC may extend the term of a patent for up to five years after its originally scheduled expiration date and can provide up to a maximum of fifteen years of marketing exclusivity for a drug. These periods can be extended for six additional months if pediatric exclusivity is obtained, which is described in detail above. Although SPCs are available throughout the European Union, sponsors must apply on a country-by-country basis, and SPCs are valid. Similar patent term extension rights exist in certain other foreign jurisdictions outside the EU.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Regulatory Requirements after a Marketing Authorization has been Obtained </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In case an authorization for a medicinal product in the EU is obtained, the holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. These include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Compliance with the EU&#8217;s stringent pharmacovigilance or safety reporting rules must be ensured. These rules can impose post-authorization studies and additional monitoring obligations. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The manufacturing of authorized medicinal products, for which a separate manufacturer&#8217;s license is mandatory, must also be conducted in strict compliance with the applicable EU laws, regulations and guidance, including Directive 2001/83/EC, Directive 2003/94/EC, Regulation (EC) No 726/2004 and the European Commission Guidelines for Good Manufacturing Practice. These requirements include compliance with EU cGMP standards when manufacturing medicinal products and active pharmaceutical ingredients, including the manufacture of active pharmaceutical ingredients outside of the EU with the intention to import the active pharmaceutical ingredients into the EU. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The marketing and promotion of authorized drugs, including industry-sponsored continuing medical education and advertising directed toward the prescribers of drugs and/or the general public, are strictly regulated in the EU notably under Directive 2001/83EC, as amended, and are also subject to EU Member State laws. Direct-to-consumer advertising of prescription medicines is prohibited across the EU. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pricing Decisions for Approved Products </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, pricing and reimbursement schemes vary widely from country to country. Some countries provide that products may be marketed only after a reimbursement price has been agreed. Some countries may require the completion of additional studies that compare the cost-effectiveness of a particular product candidate to currently available therapies or so-called health technology assessments, in order to obtain </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">62</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reimbursement or pricing approval. For example, EU Member States have the option to restrict the range of products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. EU Member States may approve a specific price for a product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the product on the market. Other EU Member States allow companies to fix their own prices for products, but monitor and control prescription volumes and issue guidance to physicians to limit prescriptions. Recently, many countries in the EU have increased the amount of discounts required on pharmaceuticals and these efforts could continue as countries attempt to manage health care expenditures, especially in light of the severe fiscal and debt crises experienced by many countries in the EU. The downward pressure on health care costs in general, particularly prescription products, has become intense. As a result, increasingly high barriers are being erected to the entry of new products. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU Member States, and parallel trade, i.e., arbitrage between low-priced and high-priced EU Member States, can further reduce prices. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any products, if approved in those countries.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Brexit and the Regulatory Framework in the United Kingdom </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2025, the Medicines and Healthcare Products Regulatory Agency, or the MHRA, is responsible for approving all medicinal products destined for the UK market (Great Britain and Northern Ireland), and the EMA will no longer have any role in approving medicinal products destined for Northern Ireland. The MHRA relies on the Human Medicines Regulations 2012 (SI 2012/1916) (as amended), or the HMR, as the basis for regulating medicines. The HMR has incorporated into domestic law the body of EU law instruments governing medicinal products that pre-existed prior to the United Kingdom&#8217;s withdrawal from the EU. On April 28, 2025, the UK Parliament adopted amendments to improve and strengthen the UK&#8217;s clinical trials regulatory regime; they will take effect on April 28, 2026. These changes were needed since the current UK requirements are based upon the now-repealed EU Clinical Trials Directive (2001/20/EC), which has been replaced by the European Clinical Trials Regulation (Regulation EU No 536/2014). Since the UK left the EU prior to the date on which the EU CTR took effect, the UK legal framework did not benefit from the same revisions as occurred at EU level.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of January 1, 2024, a new international recognition procedure, or the IRP, applies which intends to facilitate approval of pharmaceutical products in the United Kingdom. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators, or RRs. The RRs notably include EMA and regulators in the EEA member states for approvals in the EU centralized procedure and MRP as well as the FDA (for product approvals granted in the United States). The RR assessment must have undergone a full and standalone review. RR assessments based on reliance or recognition cannot be used to support an IRP application. A CHMP positive opinion or a mutual recognition and decentralized procedure positive end of procedure outcome is an RR authorization for the purposes of IRP. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">General Data Protection Regulation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are significant privacy and data security laws that apply in Europe and other countries. The collection, use, disclosure, transfer, or other processing of personal data, including personal health data, regarding individuals who are located in the EEA, and the processing of personal data that takes place in the EEA, is subject to the EU&#8217;s GDPR which became effective on May 25, 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, and it imposes heightened requirements on companies that process health and other sensitive data, such as requiring in many situations that a company obtain the consent of the individuals to whom the sensitive personal data relate before processing such data. Examples of obligations imposed by the GDPR on companies processing personal data that fall within the scope of the GDPR include providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, appointing a data protection officer, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR also imposes strict rules on the transfer of personal data to countries outside the EEA, including the U.S., and permits data protection authorities to impose large penalties for violations of the GDPR, including potential fines of up to &#8364;20 million or 4% of annual global revenues, whichever is greater. The GDPR also confers a private right of action on data subjects and consumer </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">63</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. Compliance with the GDPR is a rigorous and time-intensive process that may increase the cost of doing business or require companies to change their business practices to ensure full compliance.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Following the July 2020 Court of Justice of the European Union judgment invalidating the so-called EU-U.S. Privacy Shield, the European Commission adopted an adequacy decision for the EU-U.S. Data Privacy Framework in July 2023. This adequacy decision permits U.S. companies who self-certify under the EU-U.S. Data Privacy Framework to rely on it as a valid data transfer mechanism for data transfers from the European Union to the United States. However, some privacy advocacy groups have already suggested that they will be challenging the EU-U.S. Data Privacy Framework, and there is currently one pending litigation against the EU-U.S. Data Privacy Framework before the Court of Justice of the European Union, or the CJEU, C-703/25 P &#8211; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:112%">Latombe v. Commission</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-style:italic;font-weight:400;line-height:112%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"> If these challenges are successful, they may not only impact the EU-U.S. Data Privacy Framework, but also further limit the viability of the so-called standard contractual clauses and other data transfer mechanisms. The uncertainty around this issue has the potential to impact our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the EU, commonly referred to as Brexit. Following the withdrawal of the United Kingdom from the EU, the U.K. Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. The United Kingdom government has already determined that it considers all European Union 27 and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the EU/EEA remain unaffected. The European Commission decided in June 2021 that the level of data protection in the United Kingdom is &#8220;essentially adequate&#8221; for purposes of data transfer from the EU to the United Kingdom. On December 19, 2025, the European Commission renewed this decision until December 27, 2031. The United Kingdom and the U.S. have also agreed to a U.S.- United Kingdom &#8220;Data Bridge,&#8221; which functions similarly to the EU-U.S. Data Privacy Framework and provides an additional legal mechanism for companies to transfer personal data from the United Kingdom to the U.S. Switzerland has also taken an adequacy decision in relation to the Swiss-U.S. Data Privacy Framework (which functions similarly to the EU-U.S. Data Privacy Framework and the U.S.-UK Data Bridge in relation to data transfers from Switzerland to the U.S.). Any changes or updates to these developments have the potential to impact our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Beyond the GDPR, there are privacy and data security laws in a growing number of countries around the world. While many loosely follow the GDPR as a model, other laws contain different or conflicting provisions. These laws will impact our ability to conduct our business activities, including both our clinical trials and any eventual sale and distribution of commercial products. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_485"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Employees and Human Capital Management</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had approximately 246 full-time employees. Of these full-time employees, 188 employees were engaged in research and development activities, with over 167 employees possessing advanced degrees, and approximately 50 employees were engaged in general and administrative activities. None of our employees is represented by a labor union or covered by a collective bargaining agreement. We believe that we maintain good relations with our employees.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize that identifying, attracting, incentivizing, integrating, retaining and promoting talented employees is vital to our success. We aim to create an equitable, inclusive and empowering environment in which our employees can grow and advance their careers, with the overall goal of developing and retaining our workforce to support our current pipeline and future business goals. Our efforts to recruit and retain a talented, passionate and inclusive workforce with different experiences, perspectives, and backgrounds include providing competitive compensation, including equity incentive compensation, and comprehensive benefits that provide resources to help employees and covered dependents manage their health, finances and life outside of work. Our aspiration and efforts to represent the communities we serve also extend to the leadership of the Company, including the board of directors and our senior leaders.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Training and educating our employees is key to our organizational success. We endeavor to provide in person and virtual trainings, as well as experiential learning through cross-functional exposure via presentations or shadowing opportunities. In addition, we value our employee's opinions and thoughts and provide virtual and onsite forums where our employees can provide feedback on corporate initiatives, recognize each other&#8217;s contributions and accomplishments, and provide other suggestions for improving our evolving workplace. We </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">64</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">prioritize employee feedback, and conduct an employee survey to measure employee engagement and to inform future talent initiatives. Similarly, we have introduced technology that enables employees to provide anonymous real-time feedback.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we are committed to our employees&#8217; health, safety and well-being. In March 2020, initially in response to the COVID-19 pandemic, we adjusted our workplace policies to allow employees to work from home and we remodeled our work paradigm to one that is flexible and designed to accommodate a range of work profiles from office based to hybrid to fully remote, allowing us to maximize productivity and performance. We have, and plan to continue to, leverage remote hiring supported by virtual processes through which we provided a high level of interpersonal engagement and continued to expa</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nd our robust onboarding program to ensure all new hires are grounded in our business and culture.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With the goal of ensuring every employee is included, supported, and treated equitably, our employees have formed various employee resource groups which help to support and guide us as an inclusive, and culturally intelligent workplace. These groups are comprised of a mix of employees from various functions and positions and have worked to identify areas for growth and education in order for the company to develop processes, systems and actions that will enable us to continue to build an inclusive and welcoming workplace. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also believe in the importance of our employees engaging in our community. In past years, we have hosted an IMPACT day, a company-wide community service day benefiting organizations in the Greater New Haven area and beyond. Giving back to the communities in which we work and live is an integral part of our corporate values and over half of our employees participated in person or virtually. The activities selected supported important priorities for Arvinas, including science, technology, engineering, and math, or STEM, initiatives, and the Greater New Haven and patient communities. We plan to continue IMPACT day in future years. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_480"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Available Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our principal executive offices are located at 5 Science Park, New Haven, Connecticut 06511. Our telephone number is (203) 535-1456. Our website address is www.arvinas.com.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We make available, through our website and free of charge, our Annual Reports on Form 10-K, Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and any amendments to those reports filed or furnished pursuant to Sections 13(a) and 15(d) of the Exchange Act of 1934, as amended, or the Exchange Act, as soon as reasonably practicable after we electronically file such reports with, or furnish such reports to, the U.S. Securities and Exchange Commission, or the SEC. In addition, we regularly use our website to post information regarding our business, product development programs and governance, and we encourage investors to use our website, particularly the information in the section entitled &#8220;Investors and Media,&#8221; as a source of information about us. The information on our website is not incorporated by reference into this Annual Report on Form 10-K and should not be considered to be a part of this Annual Report on Form 10-K. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_19"></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">65</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1A. Risk Factors. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">We face a variety of risks and uncertainties in our business and investing in our common stock involves a high degree of risk. You should carefully consider the risks and uncertainties described below together with all of the other information contained in this Annual Report on Form 10-K, including our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K, before deciding to invest in our common stock. Additional risks and uncertainties not presently known to us or that we currently believe to be immaterial may also become important factors that affect our business. If any of the following risks actually occur, our business, prospects, operating results and financial condition could suffer materially. In such event, the trading price of our common stock could decline and you might lose all or part of your investment. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_839"></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Financial Position and Need For Additional Capital </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have incurred significant losses since our inception. We expect to incur expenses and operating losses over at least the next several years and may never achieve or maintain profitability. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our net losses totaled $80.8 million, $198.9 million and $367.3 million for the years ended December&#160;31, 2025, 2024, and 2023, respectively. As of December&#160;31, 2025, we had an accumulated deficit of $1,612.4 million. We have historically incurred losses, and expect to continue to incur losses in the future. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of our equity, proceeds from our collaborations, grant funding and debt financing. We are still developing our product candidates, and we have not completed development of any product candidates. We expect to continue to incur significant expenses and operating losses for at least the next several years if and as we: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our ongoing and planned clinical trials of our product candidates, including ARV-102, our PROTAC protein degrader designed to target the LRRK2 protein, ARV-806, our PROTAC protein degrader designed to target KRAS G12D for mutated cancers, ARV-393, our PROTAC protein degrader designed to target the BCL6 protein, ARV-027, our PROTAC protein degrader designed to target the polyQ-AR protein, and vepdegestrant, for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress our preclinical programs, including</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ARV-6723 and our pan-KRAS degrader program;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress additional PROTAC protein degrader programs into IND- or CTA-enabling studies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">apply our PROTAC Discovery Engine to advance additional product candidates into preclinical and clinical development;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand the capabilities of our PROTAC Discovery Engine; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make decisions with respect to our personnel, including retention or future hiring of key employees, and establishment of a sales, marketing, market access, and distribution infrastructure to launch commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make decisions with respect to our infrastructure and capabilities, including to support our operations as a public company and our research, product development and future commercialization efforts;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make or maintain arrangements with third-party manufacturers, or establish manufacturing capabilities, for both clinical and commercial supplies of our product candidates; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand, maintain and protect our intellectual property portfolio.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our expenses could increase beyond our expectations if we are required by the FDA, the EMA, or other regulatory authorities to perform trials in addition to those that we currently expect or anticipate, or if there are any delays in establishing appropriate manufacturing arrangements for or in completing our clinical trials or the development of any of our current or future product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">66</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of the numerous risks and uncertainties associated with pharmaceutical product development, we are unable to accurately predict the timing or amount of increased expenses we will incur or when, if ever, we will be able to achieve profitability. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would depress the value of our company and could impair our ability to raise capital, expand our business, maintain our research and development efforts, diversify our product offerings or even continue our operations. A decline in the value of our company could also cause our stockholders to lose all or part of their investment. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have never generated revenue from product sales and may never be profitable. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never generated revenue from product sales. Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaboration partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, product candidates we may identify for development. We do not anticipate generating revenues from product sales for the next several years, if ever. We may never succeed in these activities and, even if we do, may never generate revenues that are significant enough to achieve profitability. To become and remain profitable, we must succeed in developing, obtaining marketing approval for and commercializing, either alone or with collaboration partners, products that generate significant revenue. This will require us to be successful in a range of challenging activities, including completing preclinical testing and clinical trials of our product candidates, discovering additional product candidates, establishing arrangements with third parties for the manufacture of clinical supplies of our product candidates, obtaining marketing approval for our product candidates and manufacturing, marketing and selling any products for which we may obtain marketing approval, either alone or with collaboration partners. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If one or more of the product candidates that we develop is approved for commercial sale and we decide to commercialize such products ourselves, we anticipate incurring significant costs associated with commercializing any approved product candidate. Even if we are able to generate revenues from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will need substantial additional funding to continue our operations. If we are unable to raise capital when needed, we may be required to delay, limit, reduce or terminate our research or product development programs or future commercialization efforts. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses in connection with our ongoing activities, particularly as we continue our ongoing and initiate our planned clinical trials of ARV-102, ARV-806, ARV-393, ARV-027 and vepdegestrant, advance our other oncology programs and neurodegenerative programs and other preclinical programs, including ARV-6723 and our pan-KRAS degrader program, continue research and development and initiate additional clinical trials of and potentially seek marketing approval for our lead programs and our other product candidates and decide to commercialize such products ourselves. In the third quarter of 2025, we announced that we and Pfizer have agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant. However, if we decide to commercialize any other product candidates ourselves, and obtain marketing approval for any of these product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution. We continue to incur significant costs associated with operating as a public company. Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on acceptable terms or not at all, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents and marketable securities of approximately $685.4 million as of December&#160;31, 2025. Based on our current operating plan, we believe that our cash, cash equivalents and marketable securities as of December&#160;31, 2025 will enable us to fund our planned operating expenses and capital expenditure requirements into the secon</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d half of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2028</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. We have based this estimate on assumptions </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">67</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that may prove to be wrong, and we could </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope, costs and results of our ongoing and planned clinical trials of ARV-102, ARV-806, ARV-393, ARV-027 and vepdegestrant;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope, costs and results of preclinical and clinical development for our other product candidates and development programs, including ARV-6723 and our pan-KRAS degrader program;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of, and development requirements for, other product candidates that we pursue, including our other oncology and neurology research programs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the success of our collaborations, including with Pfizer and Genentech; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval and which we choose to commercialize ourselves; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish additional collaboration arrangements with other biotechnology or pharmaceutical companies on favorable terms, if at all, or enter into license, marketing and royalty arrangements, and similar transactions for the development or commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Identifying potential product candidates and conducting preclinical testing and clinical trials is a time-consuming, expensive and uncertain process that takes years to complete, and we may never generate the necessary data or results required to obtain marketing approval and achieve product sales. In addition, our product candidates, if approved, may not achieve commercial success. Our commercial revenues, if any, will be derived from sales of products that we do not expect to be commercially available for many years, if at all. Accordingly, we will need to obtain substantial additional funds to achieve our business objectives. Adequate additional funds may not be available to us on acceptable terms, or at all. In addition, we may seek additional capital due to favorable market conditions or strategic considerations, even if we believe we have sufficient funds for our current or future operating plans. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although we may receive potential future payments under our collaborations with Pfizer and Genentech and our out-license of luxdegalutamide to Novartis, we do not currently have any committed external source of funds. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, our stockholders&#8217; ownership interests will be diluted, and the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights as common stockholders. Debt financing and equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be acceptable or favorable to us.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">68</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our limited operating history may make it difficult for our stockholders to evaluate the success of our business to date and to assess our future viability. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies, establishing arrangements with third parties for the manufacture of initial quantities of our product candidates, conducting Phase 1, Phase 2 and Phase 3 clinical trials for our product candidates, and preparing for commercialization. However, we have not yet demonstrated our ability to successfully complete any clinical trials, obtain marketing approvals, manufacture a commercial scale product, or arrange for a third party to do so on our behalf, or conduct sales, marketing and distribution activities necessary for successful product commercialization, or arrange for a third party to do so on our behalf. Consequently, any predictions stockholders make about our future success or viability may not be as accurate as they could be if we had a longer operating history. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as a business with limited operating experience and no history of revenue-generating commercial activity, we may encounter unforeseen expenses, difficulties, complications, delays and other known and unknown factors. If we choose to commercialize any of our approved products ourselves, we will need to transition at some point from a company with a research and development focus to a company capable of supporting commercial activities. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect our financial condition and operating results to continue to fluctuate significantly from quarter to quarter and year to year due to a variety of factors, many of which are beyond our control. Accordingly, stockholders should not rely upon the results of any quarterly or annual periods as indications of future operating performance.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our cost savings plan and the associated workforce reductions implemented in April 2025 and September 2025 may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2025, we committed to and approved a reduction </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in our workforce by approximately 33% across all areas of our company, as part of our decision to streamline operations across the organization and enable the efficient progression of our portfolio. In addition, in September 2025, we announced further reductions to our workforce by an additional 15% to streamline operations, with the most significant reductions being roles related to vepdegestrant commercialization. We may not realize, in full or in part, the anticipated benefits, savings and improvements in our cost structure from our cost savings plan and associated workforce reductions due to unforeseen difficulties, delays or unexpected costs. If we are unable to realize the expected operational efficiencies and cost savings from our cost savings plan and associated workforce reductions, our operating results and financial condition would be adversely affected. We also cannot guarantee that we will not have to undertake additional workforce reductions or restructuring activities in the future. Furthermore, our cost savings plan may be disruptive to our operations, including conducting clinical trials and potentially commercializing our product candidates, including vepdegestrant, which could affect our ability to generate product revenue. In addition, our reductions in workforce could yield unanticipated consequences, such as attrition beyond planned staff reductions, or disruptions in our day-to-day operations. Our workforce reductions could also harm our ability to attract and retain qualified management, scientific, clinical, manufacturing and sales and marketing personnel who are critical to our business. Any failure to attract or retain qualified personnel could prevent us from successfully developing and commercializing, if approved, our product candidates, including ARV-102, ARV-806, ARV-393, ARV-027 and vepdegestrant, in the future.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income, sales, use or other tax laws, statutes, rules, or regulations could be enacted or amended at any</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">time, which could affect our business or financial condition, including causing potentially adverse impacts to our effective tax rate, tax liabilities, and cash tax obligations. For example, the Inflation Reduction Act, or IRA, was signed into law in August 2022, and the One Big Beautiful Bill Act, or OBBB Act, was signed into law in July 2025. The IRA introduced new tax provisions, including a 1% excise tax imposed on certain stock repurchases by publicly traded corporations. The 1% excise tax generally applies to any acquisition by the publicly traded corporation (or certain of its affiliates) of stock of the publicly traded corporation in exchange for money or other property (other than stock of the corporation itself), subject to certain exceptions. Thus, the excise tax could </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">69</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">apply to certain transactions that are not traditional stock repurchases. The OBBB Act </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">is not expected to have a material impact on our business or financial condition, however, this could change in the future and we will continue to assess the impact of the OBBB Act on subsequent periods. The recent changes under the OBBB Act include tax rate extensions and changes to the business interest deduction li</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">mitation, the expensing of domestic research and development expenditures (in contrast to the continued capitalization and amortization of foreign research and development expenditures), the bonus depreciation deduction rules, and the international tax framework. Regulatory guidance under the IRA, the OBBB Act, and other tax-related legislation is and continues to be forthcoming, and such guidance could ultimately increase or lessen the impact of these laws on our business and financial condition. In addition, it is uncertain if and to what extent various states will conform to the IRA, the OBBB Act and additional tax legislation.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">In the future, we might not be able to utilize a significant portion of any net operating loss carryforwards and research and development tax credit carryforwards we may have. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, we had $533.6 million of federal net operating loss carryforwards, $563.2 million of state and local net operating loss carryforwards, $44.7 million federal tax credit carryforwards and $22.3 million of state tax credit carryforwards. To the extent they expire unused, these net operating loss and tax credit carryforwards arising after 2017 will not be available to offset our future income tax liabilities. Federal net operating loss carryforwards may be carried forward indefinitely, but the deductibility of such carryforwards is limited to 80% of our taxable income in the year in which carryforwards are used. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, under Sections 382 and 383 of the Code, and corresponding provisions of state law, if a corporation undergoes an &#8220;ownership change,&#8221; which is generally defined as a greater than 50% change, by value, in its equity ownership by certain stockholders over a three-year period, the corporation&#8217;s ability to use its pre-change net operating loss carryforwards and other pre-change tax attributes to offset its post-change income may be limited. We may experience ownership changes in the future as a result of subsequent changes in our stock ownership, some of which may be outside of our control. If we determine that an ownership change has occurred and our ability to use our historical net operating loss and research and development tax credit carryforwards is materially limited, it would harm our future operating results by effectively increasing our future tax obligations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is also a risk that due to regulatory changes, such as suspensions on the use of net operating losses, or other unforeseen reasons, our existing and any future net operating losses could expire or otherwise become unavailable to offset future income tax liabilities. In addition, state net operating losses generated in one state cannot be used to offset income generated in another state. For these reasons, even if we attain profitability, we may be unable to use a material portion of our net operating losses and other tax attributes.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_834"></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Discovery and Development of Our Product Candidates</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our approach to the discovery and development of product candidates based on our PROTAC technology platform is unproven, which makes it difficult to predict the time, cost of development and likelihood of successfully developing any products. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our PROTAC technology platform is still a relatively new technology. Our future success depends on the successful development of this novel therapeutic approach. Prior to the initiation of our Phase 1 clinical trial for bavdegalutamide in 2019, no product candidates that use a chimeric small molecule approach to protein degradation, such as our PROTAC targeted protein degraders, had been tested in humans. No product candidates of this type have been approved in the United States or Europe, and the data underlying the feasibility of developing chimeric small molecule-based therapeutic products is both preliminary and limited. We have not yet succeeded and may not succeed in obtaining marketing approvals of our product candidates. There may be adverse effects from treatment with any of our current or future product candidates that we cannot predict at this time. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these factors, it is more difficult for us to predict the time and cost of product candidate development, and we cannot predict whether the application of our PROTAC Discovery Engine, or any similar or competitive protein degradation platforms, will result in the development, and marketing approval of any products. Any development problems we experience in the future related to our PROTAC Discovery Engine or any of our research programs may cause significant delays or unanticipated costs or may prevent the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">70</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development of a commercially viable product. Any of these factors may prevent us from completing our current or future preclinical studies or clinical trials or from commercializing any product candidates we may develop on a timely or profitable basis, if at all. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We do not have any product candidates that have been approved for commercialization. If we are unable to commercialize our product candidates or experience significant delays in doing so, our business will be materially harmed. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of our product candidates are in clinical or preclinical development. We are developing ARV-102, an investigational PROTAC designed to degrade the LRRK2 protein, ARV-806, designed to degrade the KRAS G12D, ARV-393, designed to degrade the BCL6 protein, ARV-027, designed to degrade the poly-Q AR protein, and vepdegestrant, designed to degrade the ER protein. In the second quarter of 2025, we and Pfizer submitted an NDA to the FDA for vepdegestrant for the treatment of patients with ER+/HER2- ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In the third quarter of 2025, we announced that the FDA accepted the NDA for vepdegestrant and assigned a PDUFA date of June 5, 2026. We also announced in the third quarter of 2025, that we and Pfizer have agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to generate revenue from product sales, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of one or more of our product candidates. The success of our product candidates will depend on several factors, including the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully completing preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt and related terms of marketing approvals from applicable regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making or maintaining arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">for products we choose to commercialize ourselves, establishing sales, marketing, market access and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining third-party coverage and adequate reimbursement; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of the products following approval; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">With respect to vepdegestrant, success will depend on our and Pfizer's ability to identify and successfully execute a commercialization arrangement with a third party and on the terms of any such deal. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we do not achieve one or more of these factors in a timely manner or at all, we could experience significant delays or an inability to successfully commercialize our product candidates, which would materially harm our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Drug development involves a lengthy and expensive process, with an uncertain outcome. We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have product candidates in clinical development and preclinical development. The risk of failure for each of our product candidates is high. We are unable to predict when or if any of our product candidates will prove effective or safe in humans or will receive marketing approval. Before obtaining marketing approval from regulatory authorities for the sale of any product candidate, we must conduct extensive clinical trials to demonstrate the safety and efficacy of our product candidates in humans. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">71</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">planned INDs in the United States or similar applications in other jurisdictions. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA or similar regulatory authorities outside the United States will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our programs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Clinical testing is expensive, difficult to design and implement, can take many years to complete and is uncertain as to the outcome. A failure of one or more clinical trials can occur at any stage of testing. We may experience numerous unforeseen events during, or as a result of, clinical trials that could delay or prevent our ability to receive marketing approval or commercialize our product candidates, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or IRBs may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may experience delays in reaching, or fail to reach, agreement on acceptable clinical trial contracts or clinical trial protocols with prospective trial sites; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">clinical trials of our product candidates may produce negative or inconclusive results, and we may decide, or regulators may require us, to conduct additional clinical trials or abandon product development programs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of patients required for clinical trials of our product candidates may be larger than we anticipate, enrollment in these clinical trials may be slower than we anticipate or participants may drop out of these clinical trials at a higher rate than we anticipate; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may have to suspend or terminate clinical trials of our product candidates for various reasons, including a finding that the participants are being exposed to unacceptable health risks; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulators or institutional review boards may require that we or our investigators suspend or terminate clinical trials for various reasons, including noncompliance with regulatory requirements; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our product candidates may have undesirable side effects or other unexpected characteristics, causing us or our investigators, regulators or IRBs to suspend or terminate the trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen global instability, including political instability or instability from an outbreak of pandemic or contagious disease, such as the COVID-19 pandemic, in or around the countries in which we conduct our clinical trials, could delay the commencement or timing of completion of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the cost of clinical trials of our product candidates may be greater than we anticipate and could be exacerbated by macroeconomic conditions such as inflation; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the supply or quality of our product candidates or other materials necessary to conduct clinical trials of our product candidates may be insufficient or inadequate, or their cost could increase dramatically making them financially infeasible. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are required to conduct additional clinical trials or other testing of our product candidates beyond those that we currently contemplate, if we are unable to successfully complete clinical trials of our product candidates or other testing, if the results of these trials or tests are not positive or are only modestly positive or if there are safety concerns, we may: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be delayed in obtaining marketing approval for our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">not obtain marketing approval at all; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval for indications or patient populations that are not as broad as intended or desired; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtain approval with labeling that includes significant use or distribution restrictions or safety warnings; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">be subject to additional post-marketing testing requirements; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">have the product removed from the market after obtaining marketing approval. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">72</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product development costs will also increase if we experience delays in preclinical studies or clinical trials or in obtaining marketing approvals. We do not know whether any of our preclinical studies or clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. Significant preclinical study or clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our product candidates or allow our competitors to bring products to market before we do and impair our ability to successfully commercialize our product candidates and may harm our business and results of operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, cancer therapies are sometimes characterized as first-line, second-line, or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. Our current clinical trials </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for ARV-393 and ARV-806</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> are in both first- and second-line settings. Subsequently, for those products that prove to be sufficiently beneficial, if any, we would expect to seek approval potentially as a first-line therapy, but any product candidates we develop, even if approved, may not be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, we do not know whether clinical trials will begin as planned, will need to be restructured or will be completed on schedule, or at all. In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies governing clinical trials, our development plans may be impacted. For example, in December 2022, with the passage of FDORA, Congress required sponsors to develop and submit a DAP for each Phase 3 clinical trial or any other &#8220;pivotal study&#8221; of a new drug or biological product. These plans are meant to encourage the enrollment of more diverse patient populations in late-stage clinical trials of FDA-regulated products. In June 2024, as mandated by FDORA, the FDA issued draft guidance outlining the general requirements for DAPs. Unlike most guidance documents issued by the FDA, the DAP guidance when finalized will have the force of law because FDORA specifically dictates that the form and manner for submission of DAPs are specified in FDA guidance. On January 27, 2025, in response to an Executive Order issued by the President on January 21, 2025, on Diversity, Equity and Inclusion programs, the FDA removed this draft guidance from its website; however, they have since been restored with a note that they could in the future be modified or removed. In light of these ongoing actions, there is considerable uncertainty. This action raises questions about the applicability of statutory obligations to submit DAPs and the agency&#8217;s current thinking on best practices for clinical development.</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similarly, the regulatory landscape related to clinical trials in the EU evolved. The CTR, which was adopted in April 2014 and repeals the EU Clinical Trials Directive, became applicable on January 31, 2022. While the Clinical Trials Directive required a separate clinical trial application to be submitted in each member state, to both the competent national health authority and an independent ethics committee, the CTR introduces a centralized process and only requires the submission of a single application to all member states concerned. If we are not able to fulfill these new requirements, our ability to conduct clinical trials may be delayed or halted. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any of these events could prevent us or our collaborators from achieving or maintaining market acceptance of the affected product candidate, if approved, or could substantially increase costs and expenses of development or commercialization, which could delay or prevent us from generating sufficient revenue from the sale of our products and harm our business and results of operations. Significant clinical trial delays also could shorten any periods during which we may have the exclusive right to commercialize our products, allow our competitors to bring products to market before we do or impair our ability to successfully commercialize our products, which would harm our business and results of operations. In addition, many of the factors that cause, or lead to, clinical trial delays may ultimately lead to the denial of regulatory approval of our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If SAEs, undesirable side effects, or unexpected characteristics are identified during the development of any product candidates we may develop, we may need to abandon or limit our further clinical development of those product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any product candidates we develop are associated with SAEs, or undesirable side effects, or have characteristics that are unexpected, we may need to abandon their development or limit development to certain uses or subpopulations in which the AEs, undesirable side effects or other characteristics are less prevalent, less severe, or more acceptable from a risk-benefit perspective, any of which would have a material adverse effect on our business, financial condition, results of operations, and prospects. Many product candidates that </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">73</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">initially showed promise in early-stage testing for treating cancer or other diseases have later been found to cause side effects that prevented further clinical development of the product candidates or limited their competitiveness in the market. It is impossible to predict when or if any product candidates we may develop will prove safe in humans. There can be no assurance that our PROTAC technology will not cause undesirable side effects.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A potential risk in any protein degradation product is that healthy proteins or proteins not targeted for degradation will be degraded or that the degradation of the targeted protein in itself could cause adverse events, undesirable side effects, or unexpected characteristics. It is possible that healthy proteins or proteins not targeted for degradation could be degraded using our PROTAC technology in any of our ongoing, planned or future clinical studies. There is also the potential risk of delayed AEs following treatment using our PROTAC technology.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Positive data from preclinical or early clinical studies of our product candidates are not necessarily predictive of the results of later clinical studies and any future clinical trials of our product candidates. If we cannot replicate the positive data from our preclinical or early clinical studies of our product candidates in our future clinical trials, we will be unable to successfully develop, obtain regulatory approval for and commercialize our product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The results of preclinical studies may not be predictive of the results of clinical trials, and the results of early-stage clinical trials may not be predictive of the results of the later-stage clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. In particular, the small number of patients in our ongoing early clinical trials may make the results of these trials less predictive of the outcome of later clinical trials. For example, even if successful, the results of the ongoing and planned clinical trials of ARV-102, ARV-806, ARV-393, ARV-027 and vepdegestrant, may not be predictive of the results of any future clinical trials of these product candidates or any of our other product candidates. Moreover, preclinical and clinical data are often susceptible to varying interpretations and analyses, and many companies that have believed their product candidates performed satisfactorily in preclinical studies and clinical trials have nonetheless failed to obtain marketing approval of their products. Our current or future preclinical studies and clinical trials may not ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for product candidates proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving encouraging results in earlier studies. Any such setbacks in our clinical development could materially harm our business and results of operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Interim top-line and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we have published and may in the future publish interim top-line or preliminary data from our clinical trials. Interim data from clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. For example, the initial safety, tolerability, PK and efficacy data that we have disclosed in connection with our ongoing clinical trials of ARV-102, ARV-806, ARV-393, and vepdegestrant may not be indicative of the full results of those trials obtained upon completion. Preliminary or top-line data also remain subject to audit and verification procedures that may result in the final data being materially different from the preliminary data we previously published. As a result, interim and preliminary data should be viewed with caution until the final data are available. Adverse differences between preliminary or interim data and final data could significantly harm our reputation and business prospects. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we experience delays or difficulties in the enrollment of patients in clinical trials, our receipt of necessary marketing approvals could be delayed or prevented. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to initiate or continue clinical trials for our product candidates if we are unable to locate and enroll a sufficient number of eligible patients to participate in these trials as required by the FDA or similar regulatory authorities outside of the United States. In particular, we are conducting and planning several clinical trials of ARV-102, ARV-806, ARV-393, ARV-027 and vepdegestrant. We cannot predict how difficult it will be to enroll patients for trials in these indications. Therefore, our ability to identify and enroll eligible patients for </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">74</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our clinical trials may be limited or may result in slower enrollment than we anticipate. In addition, some of our competitors have ongoing clinical trials for product candidates that treat the same indications as our product candidates, and patients who would otherwise be eligible for our clinical trials may instead enroll in clinical trials of our competitors&#8217; product candidates. Patient enrollment is affected by other factors including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of the disease under investigation; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the eligibility criteria for the trial in question; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the requirements of the trial protocols;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the perceived risks and benefits of the product candidates under study; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efforts to facilitate timely enrollment in clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of competing therapies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the patient referral practices of physicians; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the burden on patients due to inconvenient procedures; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the ability to monitor patients adequately during and after treatment; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the proximity and availability of clinical trial sites for prospective patients.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For example, in April 2020, we announced that, as a result of the COVID-19 pandemic, two trial sites for our ongoing Phase 1/2 clinical trial of bavdegalutamide had publicly announced pauses in patient enrollment for clinical trials, including our trials. In addition, one trial site for our ongoing Phase 1/2 clinical trial of vepdegestrant had a pause in patient enrollment for clinical trials, including our trial. We also experienced a short delay in the enrollment for one cohort of one of our vepdegestrant trials as a result of screening slowdowns attributable to COVID-19. In addition, we may engage in conversations with regulators regarding clinical trial protocols, which could result in delays to our anticipated timing to enroll patients in our studies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our inability to enroll a sufficient number of patients for our clinical trials would result in significant delays and could require us to abandon one or more clinical trials altogether. Enrollment delays in our clinical trials may result in increased development costs for our product candidates, which would cause the value of our company to decline and limit our ability to obtain additional financing. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may expend our limited resources to pursue a particular product candidate or indication and fail to capitalize on product candidates or indications that may be more profitable or for which there is a greater likelihood of success. </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Because we have limited financial and managerial resources, we focus on research programs and product candidates that we identify for specific indications. As a result, we may forego or delay pursuit of opportunities with other product candidates or for other indications that later prove to have greater commercial potential. In addition, our resource allocation decisions may cause us to fail to capitalize on viable commercial products or profitable market opportunities. For example, in September 2025, we announced that, with Pfizer, we have agreed to jointly select a third party for the commercialization and potential further development of vepdegestrant instead of commercializing ourselves. Furthermore, our April 2025 and September 2025 workforce reductions may cause us to reprioritize our portfolio and evaluate future strategic decisions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our spending on current and future research and development programs and product candidates for specific indications may not yield any commercially viable products. If we do not accurately evaluate the commercial potential or target market for a particular product candidate, we may relinquish valuable rights to that product candidate through collaboration, licensing, marketing or other royalty arrangements or similar transactions in cases in which it would have been more advantageous for us to retain sole development and commercialization rights to such product candidate. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">75</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are developing and plan to continue to develop our product candidates in combination with other drugs. If the FDA or similar regulatory authorities outside of the United States do not approve these other drugs, or revoke their approval of such drugs, or if safety, efficacy, manufacturing or supply issues arise with the drugs we choose to evaluate in combination with our product candidates, we may be unable to obtain approval of or market our products. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently conducting clinical trials of ARV-102, ARV-393, ARV-806, ARV-027 and vepdegestrant and intend to conduct other clinical trials for each of these and potentially other product candidates. We may conduct clinical trials in combination with other therapies, and have conducted combination clinical trials of vepdegestrant and preclinical combination studies of ARV-393. We are planning to initiate enrollment of a combination cohort of ARV-393 with glofitamab in patients with DLBCL in the ongoing Phase 1 clinical trial in the first half of 2026. We did not develop or obtain marketing approval for, nor do we manufacture or sell, any of the currently approved drugs or therapies that we are or may study in combination with our product candidates. If the FDA or similar regulatory authorities outside of the United States revoke their approval of the drug or drugs in combination with which we determine to develop with our product candidates, including ARV-102, ARV-806, ARV-393, ARV-027 or vepdegestrant, we will not be able to market our product candidates, including ARV-102, ARV-806, ARV-393, ARV-027 or vepdegestrant, in combination with such revoked drugs.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If safety or efficacy issues arise with any of these drugs, we could experience significant regulatory delays, and the FDA or similar regulatory authorities outside of the United States may require us to redesign or terminate the applicable clinical trials. If the drugs we use are replaced as the SOC for the indications we choose for ARV-393, ARV-102, ARV-806 or vepdegestrant, the FDA or similar regulatory authorities outside of the United States may require us to conduct additional clinical trials. In addition, if manufacturing or other issues result in a shortage of supply of the drugs with which we determine to combine with ARV-102, ARV-806, ARV-393, ARV-027 or vepdegestrant, we may not be able to complete clinical development of ARV-102, ARV-806, ARV-393, ARV-027 or vepdegestrant on our current timeline or at all. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if any of our product candidates, including ARV-102, ARV-806, ARV-393, ARV-027 or vepdegestrant, were to receive marketing approval or be commercialized for use in combination with other existing drugs, we would continue to be subject to the risks that the FDA or similar regulatory authorities outside of the United States could revoke approval of the drug used in combination with our product candidates, including ARV-102, ARV-806, ARV-393, ARV-027 or vepdegestrant, or that safety, efficacy, manufacturing or supply issues could arise with these existing drugs. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our other product candidates for use in combination with other drugs or for indications other than cancer. This could result in our own products being removed from the market or being less successful commercially. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have conducted, and may in the future conduct, clinical trials for product candidates at sites outside the United States, and the FDA may not accept data from trials conducted in such locations. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted, and may in the future choose to conduct, one or more of our clinical trials outside the United States. To date, we have conducted clinical trials in the United S</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tates and Spain, Germany, France, Georgia, the United Kingdom, the Netherlands, Canada and Denmark. Although the FD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A may accept data from clinical trials conducted outside the United States, acceptance of these data is subject to conditions imposed by the FDA. In cases where data from foreign clinical trials are intended to serve as the sole basis for marketing approval in the United States, the FDA will generally not approve the application on the basis of foreign data alone unless (i) the data are applicable to the U.S. population and U.S. medical practice; (ii) the trials were performed by clinical investigators of recognized competence and pursuant to GCP regulations; and (iii) the data may be considered valid without the need for an on-site inspection by the FDA, or if the FDA considers such inspection to be necessary, the FDA is able to validate the data through an on-site inspection or other appropriate means.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, even where the foreign trial data are not intended to serve as the sole basis for approval, the FDA will not accept the data as support for an application for marketing approval unless the trial satisfies certain conditions. For example, the clinical trial must be well designed and conducted and performed by qualified investigators in accordance with ethical principles. The trial population must also adequately represent the U.S. population, and the data must be applicable to the U.S. population and U.S. medical practice in ways that the FDA deems clinically meaningful. In addition, while these clinical trials are subject to the applicable local laws, FDA acceptance of the data will depend on its determination that the trials also complied with all </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">76</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">applicable U.S. laws and regulations. If the FDA does not accept the data from any trial we conduct outside the United States, it would likely result in the need for additional trials, which would be costly and time-consuming and would delay or permanently halt our development of the applicable product candidates. Even if the FDA accepted such data, it could require us to modify our planned clinical trials to receive clearance to initiate such trials in the United States or to continue such trials once initiated.</span></div><div style="margin-top:12pt;text-indent:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other risks inherent in conducting international clinical trials or using international trial sites include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign regulatory requirements, differences in healthcare services, and differences in cultural customs that could restrict or limit our ability to conduct our clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the administrative burden of complying with a variety of foreign laws, medical standards and regulatory requirements, including the regulation of pharmaceutical and biotechnology products and treatment; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the failure of enrolled patients to adhere to clinical protocols or inadequate collection and assessment of clinical data as a result of differences in healthcare services or cultural customs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">foreign exchange fluctuations; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">diminished or loss of protection of intellectual property in the relevant jurisdiction; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">political, economic, environmental, and health risks relevant to specific foreign countries, including risks related to natural disasters or disease outbreaks.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may not be successful in our efforts to identify or discover additional potential product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A key element of our strategy is to apply our PROTAC Discovery Engine to address a broad array of targets and new therapeutic areas. The therapeutic discovery activities that we are conducting may not be successful in identifying product candidates that are useful in treating cancer or other diseases. Our research programs may initially show promise in identifying potential product candidates, yet fail to yield product candidates for clinical development for a number of reasons, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product candidates may, on further study, be shown to have harmful side effects or other characteristics that indicate that they are unlikely to be drugs that will receive marketing approval or achieve market acceptance; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">potential product candidates may not be effective in treating their targeted diseases. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research programs to identify new product candidates require substantial technical, financial and human resources. We may choose to focus our efforts and resources on a potential product candidate that ultimately proves to be unsuccessful. If we are unable to identify suitable product candidates for preclinical and clinical development, we will not be able to obtain revenues from sale of products in future periods, which likely would result in significant harm to our financial position and adversely impact our stock price. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We face substantial competition, which may result in others discovering, developing or commercializing products before or more successfully than we do.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The biotechnology and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition and a strong emphasis on proprietary products. We face and will continue to face competition from third parties that use protein degradation, antibody therapy, inhibitory nucleic acid, gene editing or gene therapy development platforms and from companies focused on more traditional therapeutic modalities, such as SMIs. The competition is likely to come from multiple sources, including major pharmaceutical, specialty pharmaceutical and biotechnology companies, academic institutions, government agencies and public and private research institutions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For specific information regarding competition t</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">o our product candidates, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">see &#8220;Item 1. Business&#8212;Competition&#8221; in this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Many of our current or potential competitors, either alone or with their collaboration partners, have significantly greater financial resources and expertise in research and development, manufacturing, preclinical testing, conducting clinical trials, obtaining regulatory approvals and marketing approved products than we do. These competitors also compete with us in recruiting and retaining qualified scientific and management </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">77</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. Smaller or early-stage companies may also prove to be significant competitors, particularly through collaborative arrangements with large and established companies. These competitors also compete with us in recruiting and retaining qualified scientific and management personnel and establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our programs. Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient or are less expensive than any products that we may develop. Our competitors also may obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market. In addition, our ability to compete may be affected in many cases by insurers or other third-party payors seeking to encourage the use of generic products. There are generic products currently on the market for certain of the indications that we are pursuing, and additional products are expected to become available on a generic basis over the coming years. If our product candidates are approved, we expect that they will be priced at a significant premium over competitive generic products. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_829"></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Dependence on Third Parties</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We have an ongoing collaboration with Pfizer related to vepdegestrant, but have announced that we and Pfizer have agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant. If our collaboration with Pfizer or another party is not successful, we may not be able to capitalize on the market potential of vepdegestrant.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into a collaboration agreement with Pfizer, or the Vepdegestrant (ARV-471) Collaboration Agreement, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound vepdegestrant, or the Licensed Products. Although pursuant to the terms of the Vepdegestrant (ARV-471) Collaboration Agreement, we and Pfizer share equally (50/50) all development costs, including costs for conducting clinical trials, for the Licensed Products, subject to certain exceptions, our control over the amount and timing of resources that Pfizer dedicates to the development or commercialization of the Licensed Products is limited, including with respect to oversight and management of CMOs, CDMOs and CROs. Our ability to generate revenues from the Vepdegestrant (ARV-471) Collaboration Agreement will depend, in part, on Pfizer&#8217;s ability to successfully perform the functions assigned to it in such agreement.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our agreement with Pfizer is ongoing, and we, along with Pfizer, continue market preparations for vepdegestrant in advance of the June 5, 2026 PDUFA date, in the third quarter of 2025, we announced that we and Pfizer have agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We cannot predict the success of our collaboration with Pfizer, or any efforts by Pfizer and us to engage a third party for commercialization of vepdegestrant. We cannot guarantee that our collaboration with Pfizer or the engagement of a third party commercialization partner, if we and Pfizer are successful in doing so, will lead to development or commercialization of the Licensed Products in the most efficient manner or at all. We have yet to determine how any potential transaction with a third party commercialization partner will impact us under the existing terms of the Vepdegestrant (ARV-471) Collaboration Agreement. Further, we cannot predict the potential terms of any third party arrangement with respect to the commercialization of vepdegestrant. In addition, Pfizer has a right to terminate the Vepdegestrant (ARV-471) Collaboration Agreement for convenience, subject to certain notice periods. As a result of any of the above, we may not receive any of the $1.4 billion in contingent payments based on specified regulatory and sales-based milestones for the Licensed Products under the Vepdegestrant (ARV-471) Collaboration Agreement.</span></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We currently depend, and expect to continue to depend, on collaborations, license arrangements, and other strategic alliances with third parties for the research, development, and the potential future commercialization of certain of the product candidates we may develop. If any such collaborations are not successful, we may not be able to capitalize on the market potential of those product candidates. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">78</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have, and anticipate in the future seeking additional, third-party collaborators for the research, development, and potential future commercialization of some of our PROTAC programs. For example, in September 2015 we entered into a research collaboration with Genentech, which we amended and restated in November 2017; in December 2017 we entered into a research collaboration with Pfizer; in July 2021 we entered into a development and commercialization collaboration with Pfizer; and in April 2024 we entered into an out-license agreement with Novartis. In addition, in the third quarter of 2025, we announced that we and Pfizer have agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our likely collaborators for any other collaboration arrangements include large and mid-size pharmaceutical companies and biotechnology companies. Any such arrangements with third parties will likely limit our control over the amount and timing of resources that our collaborators dedicate to the development or commercialization of any product candidates we may seek to develop with them. Our ability to generate revenues from these arrangements will depend on our collaborators&#8217; abilities to successfully perform the functions assigned to them in these arrangements. We are unable to predict when, if ever, we will enter into any additional strategic collaborations because of the numerous risks and uncertainties associated with establishing them, and we cannot predict the success of any collaboration that we enter into. We may enter into strategic collaborations that we subsequently no longer wish to pursue, and we may not be able to negotiate strategic collaborations on acceptable terms, or at all. At the current time, we cannot predict what form any future strategic collaboration might take, and we are likely to face significant competition in seeking appropriate strategic collaborators, and strategic collaborations can be complicated and time consuming to negotiate and document. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any collaborations involvin</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">g our research programs or any product candidates we may develop, including our current collaborations with Pfizer and Genentech and out-license to Novartis pose the following risks to us: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborators and licensees have significant discretion in determining the efforts and resources that they will apply to these collabor</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ations or licenses. For example, our research collaboration with Pfizer are managed by a joint research committee composed of an equal number of representatives from us and our respective collaborative partners, with the collaborative partner having final decision-making authority. In</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> addition, following our out-license of luxdegalutamide (ARV-766) to Novartis, Novartis is responsible for worldwide clinical development and commercialization of ARV-766 and therefore has full decision-making authority with respect to the luxdegalutamide (ARV-766) program. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborators or licensees may not pursue development and commercialization of any product candidates we may develop or may elect not to continue or renew development or commercialization programs based on clinical trial results, changes in the collaborator&#8217;s or licensee's strategic focus or available funding or external factors such as an acquisition or business combination that diverts resources or creates competing priorities. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborators have broad rights to select any target for protein degradation development on an exclusive basis, even as to us, so long as not excluded by us under the terms of each collaboration and may select targets we are considering but have not taken sufficient action to exclude under the collaboration. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborators and licensees may delay clinical trials, provide insufficient funding for a clinical trial program, stop a clinical trial or abandon a product candidate, repeat or conduct new clinical trials, or require a new formulation of a product candidate for clinical testing. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborators and licensees could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates if the collaborators believe that competitive products are more likely to be successfully developed or can be commercialized under terms that are more economically attractive than ours. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborators with marketing and distribution rights to one or more products may not commit sufficient resources to the marketing and distribution of such product or products. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborators and licensees may not properly obtain, maintain, enforce, or defend our intellectual property or proprietary rights or may use our proprietary information in such a way that could jeopardize or invalidate our proprietary information or expose us to potential litigation. For example, </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">79</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pfizer, Genentech and Novartis have the first right to enforce or defend certain intellectual property rights under the applicable collaboration arrangement or license agreement with respect to particular licensed programs, and although we may have the right to assume the enforcement and defense of such intellectual property rights if the collaborator does not, our ability to do so may be compromised by their actions.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Disputes may arise between the collaborators or licensees and us that result in the delay or termination of the research, development, or commercialization of our products or product candidates or that result in costly litigation or arbitration that diverts management attention and resources. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We may lose certain valuable rights under circumstances identified in our collaborations and licenses, including if we undergo a change of control. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaborations and licenses may be terminated and, if terminated, may result in a need for additional capital to pursue further development or commercialization of the applicable product candidates. For example, each of Genentech and Pfizer can terminate its agreement with us in its entirety or with respect to a specific target for convenience subject to specified notice periods, in certain cases as short as 60 days, or in connection with a material breach of the agreement by us that remains uncured for a specified period of time. Novartis may terminate its agreement with us upon our material breach or for convenience or upon a safety or regulatory issue, subject to specified notice periods. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Collaboration or license agreements may not lead to development or commercialization of product candidates in the most efficient manner or at all. If a present or future collaborator or licensee of ours were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration or license could be delayed, diminished, or terminated.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our collaborations and licenses do not result in the successful development and commercialization of products, or if one of our collaborators or licensees terminates its agreement with us, we may not receive any future research funding or milestone or royalty payments under the collaboration or license, as appropriate. If we do not receive the funding we expect under these agreements, our development of product candidates could be delayed, and we may need additional resources to develop product candidates. In addition, if one of our collaborators or licensees terminates its agreement with us, we may find it more difficult to find a suitable replacement collaborator or licensee or attract new collaborators or licensees, and our development programs may be delayed or the perception of us in the business and financial communities could be adversely affected. All of the risks relating to product development, marketing</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval, and commercialization described in this Annual Report on Form 10-K apply to the activities of our collaborators.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek to establish additional collaborations or out-license the development of our product candidates. If we are not able to establish collaborations or enter into these out-licenses on commercially reasonable terms, we may have to alter our business development plans or product development and commercialization plans. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">To realize the full potential of our PROTAC Discovery Engine and accelerate the development of our PROTAC programs, we plan to continue to selectively pursue collaborations with companies with particular experience, including development and commercial expertise and capabilities. For example, </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">in the third quarter of 2025, we announced that we and Pfizer have agreed to jointly seek a third party collaborator for the commercialization and potential future development of vepdegestrant. We face significant competition in attracting appropriate collaborators to advance the development of any product candidates for which we may seek a collaboration. We also may choose to out-license product candidates at any time. Whether we reach a definitive agreement for a collaboration or out-license will depend, among other things, upon our assessment of the potential collaborator&#8217;s or licensee's resources and expertise, the terms and conditions of the proposed collaboration or license, and the proposed collaborator&#8217;s or licensee's evaluation of a number of factors. Those factors may include the design or results of clinical trials, the likelihood of approval by the FDA or other regulatory authorities, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge, the terms of any existing collaboration or license agreements, and industry and market conditions generally. The collaborator or licensee </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">80</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">may also have the opportunity to collaborate on other product candidates or technologies for similar indications and will have to evaluate whether such a collaboration could be more attractive than one with us. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">s and licenses are complex and time-consuming to negotiate, document and execute. In addition, consolidation among large pharmaceutical companies has reduced the number of potential future collaborators. Our existing collaboration and license agreements limit our ability to enter into future agreements on certain terms with potential collaborators. For example, we have granted exclusive rights to Genentech and Pfizer for the discovery, development and commercialization of PROTAC targeted protein degraders directed to certain protein targets, and during the terms of those agreements, we will be restricted from granting rights to other parties to use our PROTAC technology for those targets. In addition, we granted an exclusive worldwide license for the development, manufacture and commercialization of luxdegalutamide (ARV-766) to Novartis and during the term of the Novartis License Agreement, are restricted from granting rights to other parties related to luxdegalutamide (ARV-766). Any collaboration or license we enter into may limit our ability to enter into future agreements on particular terms or covering similar target indications with other potential collaborators or licensees.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may not be able to negotiate collaborations or licenses on a timely basis, on acceptable terms or at all, including the collaboration we are seeking to establish with a third party for the commercialization and potential future development of vepdegestrant. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate or license, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any sales or marketing activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate revenue from product sales, which could have an adverse effect on our business, prospects, financial condition and results of operations. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely and expect to continue to rely on third parties, including CROs, to conduct our clinical trials, and those third parties may not perform satisfactorily, including failing to meet deadlines for the completion of such trials.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently rely and expect to continue to rely on third-party CROs and other third parties to conduct our ongoing and planned clinical trials. We currently do not plan to independently conduct any clinical trials of ARV-102 or ARV-806, ARV-393, ARV-027 as well as ARV</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">-6723 and our pan-KRAS degrader program, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and have not independently conducted any clinical trials of our product candidates, including vepdegestrant, to date. Agreements with these third parties might terminate for a variety of reasons, including a failure to perform by the third parties. If we need to enter into alternative arrangements, that would delay our product development activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our reliance on these third parties for research and development activities reduces our control over these activities but does not relieve us of our responsibilities. For example, we will remain responsible for ensuring that each of our clinical trials is conducted in accordance with the general investigational plan and protocols in the applicable IND. Moreover, the FDA requires compliance with GCPs for conducting, recording and reporting the results of clinical trials to assure that data and reported results are credible and accurate and that the rights, integrity and confidentiality of trial participants are protected.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, these third parties may have relationships with other entities, some of which may be our competitors. If these third parties do not successfully carry out their contractual duties (including those governing confidentiality and privacy), meet expected deadlines or conduct our clinical trials in accordance with regulatory requirements or our stated protocols, we will not be able to obtain, or may be delayed in obtaining, marketing approvals for our product candidates and will not be able to, or may be delayed in our efforts to, successfully commercialize our product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We rely on third-party C</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">MOs or CDMOs for the manufacture and testing of both drug substance and finished drug product for our product candidates for preclinical testing and clinical trials and expect to continue to do so for commercialization. This reliance on third parties may increase the risk that we will </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">81</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, which could delay, prevent or impair our development or commercialization efforts.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not own or operate, and currently have no plans to establish, any manufacturing facilities. We rely on and expect to continue to rely on third-party CMOs or CDMOs for both drug substance and finished drug product as well as the building blocks used to manufacture drug substance and the testing of the same. This reliance on third parties may increase the risk that we will not have sufficient quantities of our product candidates or products or such quantities at an acceptable cost or quality, w</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">hich could delay, prevent or impair our development or commercialization efforts. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may be unable to establish agreements with third-party manufacturers or to do so on acceptable terms. Even if we are able to establish agreements with third-party manufacturers, reliance on third-party manufacturers entails additional risks, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reliance on the third party for regulatory, compliance and quality assurance; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible breach of the manufacturing agreement by the third party; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible misappropriation of our proprietary information, including our trade secrets and know-how; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the possible termination or non-renewal of the agreement by the third party at a time that is costly or inconvenient for us. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have development and supply agreements in place with respect to our clinical product candidates, and these arrangements do not extend to commercial supply. We acquire many key materials on a purchase order basis. As a result, we do not have long term committed arrangements with respect to our product candidates and other materials. If we receive marketing approval for any of our product candidates, we will need to establish an agreement for commercial manufacture with a third party. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Third-party manufacturers may not be able to comply with cGMP regulations or similar regulatory requirements outside of the United States. Our failure, or the failure of our</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> third-party manufacturers, to comply with applicable regulations could result in sanctions being imposed on us, including clinical holds, fines, injunctions, civil penalties, delays, suspension or withdrawal of approvals, license revocation, seizures or recalls of product candidates or products, operating restrictions and criminal prosecutions, any of which could significantly and adversely affect supplies of our products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and any products that we may develop may compete with other product candidates and products for access to manufacturing facilities. As a result, we may not obtain access to these facilities on a priority basis or at all. There are a limited number of manufacturers that operate under cGMP regulations and that might be capable of manufacturing for us. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any performance failure on the part of our existing or future manufacturers could delay clinical development or marketing approval. Some of our manufacturers are based outside of the United States, including the manufacturers of the building blocks for our drug substances which are based in China and India. For example, as a result of the COVID-19 pandemic, in the first quarter of 2020, the production of certain building blocks for the drug substance used in the manufacture of vepdegestrant was delayed at one of our China-based manufacturers. While this production delay did not delay the overall clinical development of our product candidates, other delays in the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> manufacture of building blocks, drug substance or drug products for our product candidates could arise, which could have a material adverse effect on our clinical development.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If our current contract manufacturers cannot perform as agreed, we may be required to replace such manufacturers. Although we believe that there are several potential alternative manufacturers who could manufacture our product candidates, we may incur added costs and delays in identifying and qualifying any such replacement manufacturer or be unable to reach agreement with any alternative manufacturer. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our current and anticipated future dependence upon others for the manufacture of our product candidates or products may adversely affect our future profit margins and our ability to commercialize any products that receive marketing approval on a timely and competitive basis. </span></div><div><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">82</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:115%">Disruptions at the FDA and other government agencies from funding cuts, personnel losses, regulatory reform, government shutdowns, leadership changes and other developments could hinder our ability to obtain guidance from the FDA regarding our clinical development programs and develop and secure approval of our product candidates in a timely manner, which would negatively impact our business.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The FDA and comparable regulatory agencies in foreign jurisdictions, such as the EMA and Committee for Medicinal Products for Human Use, play an important role in the development of our product candidates by providing guidance on our clinical development programs and reviewing our regulatory submissions, including INDs, requests for special designations and marketing applications. If these oversight and review activities are disrupted, then correspondingly our ability to develop and secure timely approval of our product candidates could be impacted in a negative manner.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">For example, the recent loss, replacement and retirement of FDA leadership and personnel could lead to disruptions and delays in FDA guidance, or review and approval of our product candidates. Pursuant to an executive order, on March 27, 2025, the Secretary of HHS announced a reorganization and an approximately 24% reduction in force at HHS and an approximately 18% reduction in force at the FDA. Subsequently, the FDA indicated that roughly a quarter of those employees who received reduction in force notices had been reinstated. On July 14, 2025, following litigation reaching the U.S. Supreme Court, the administration began to carry out these layoffs across HHS, including the FDA. There are also ongoing deliberations within the administration and Congress over potentially substantial proposed cuts to the overall budget for HHS and funding of the FDA for the 2026 federal fiscal year.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Further, while the FDA&#8217;s review of marketing applications and other activities for new drugs and biologics is largely funded through the user fee program established under the PDUFA, it remains unclear how the administration&#8217;s reduction in force and budget cuts will impact this program and the ability of the FDA to provide guidance and review our product candidates in a timely manner. For example, while the FDA reduction in force did not reportedly specifically target FDA reviewers, many operations, administrative and policy staff that help support such reviews were affected and those losses could lead to delays in PDUFA reviews and related activities. There have been several reports in which the FDA failed to meet a PDUFA goal date for approval of an NDA, or Biologics License Application due to heavy workload and limited resources. In addition, while currently unclear, there is a risk that the reduction in force and budget cutbacks could threaten the integrity of the PDUFA program itself. That is because, for the FDA to obligate user fees to be collected under PDUFA in the first place, a certain amount of non-user fee appropriations must be spent on the process for the review of applications plus certain other costs during the same fiscal year. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">There is also substantial uncertainty as to how regulatory reform measures and leadership changes being implemented by the current administration across the government &#8212; and in particular at the HHS and FDA &#8212; will impact the FDA and other federal agencies with jurisdiction over our activities. For example, since taking office in January 2025, the President has issued a number of executive orders that could have a significant impact on the manner in which the FDA conducts its operations and engages in regulatory and oversight activities. If these orders or executive actions impose constraints on the FDA&#8217;s ability to engage in oversight and implementation activities in the normal course, our business may be negatively impacted. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Similarly, actions by the U.S. government have significantly disrupted the operations of U.S. government agencies such as the National Institutes of Health, National Science Foundation, Centers for Disease Control and Prevention and FDA, which have traditionally provided funding for basic research, research and development, and clinical testing. These and other future U.S. government actions could, directly or indirectly, significantly disrupt, delay, prevent, or increase the costs of our research and product commercialization programs, including our ability to develop new product candidates, conduct clinical trials, implement research collaborations with other companies or institutions, and obtain approvals to market and sell new products.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, government funding of the SEC and other government agencies on which our operations may rely, including those that fund research and development activities, is subject to the political process, which is inherently fluid and unpredictable. During the last several years, the U.S. government has shut down several times and certain regulatory agencies, such as the FDA and the SEC, have had to furlough critical FDA, SEC and other government employees and stop critical activities. If a prolonged government shutdown occurs, it could significantly impact the ability of the FDA to timely review and process our regulatory submissions and could impact our ability to access the public markets and obtain necessary capital to properly capitalize and continue our operations. </span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">At the same time, disruptions at the FDA and other government agencies may result from public health events similar to the COVID-19 pandemic. For example, during the pandemic, a number of companies </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">83</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">announced receipt of CRLs due to the FDA&#8217;s inability to complete required inspections for their applications. In the event of a similar public health or other emergency in the future, the FDA may not be able to continue its current pace and review timelines could be extended. Regulatory authorities outside the U.S. facing similar circumstances may adopt similar restrictions or other policy measures in response to a similar public health emergency and may also experience delays in their regulatory activities.</span></div><div style="text-indent:24.5pt"><span><br/></span></div><div style="text-indent:24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Accordingly, if any of the foregoing developments and others impact the ability of the FDA to provide us with guidance regarding our clinical development programs or delay the agency&#8217;s review and processing of our regulatory submissions, including INDs and NDAs, our business would be negatively impacted. Further, any future government shutdown could impact our ability to access the public markets and obtain necessary capital to properly capitalize and continue our operations.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in U.S. and international trade policies, particularly with respect to China, may adversely impact our business and operating results.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In 2025, the current administration initiated a series of tariff-related actions on U.S. trading partners, including China and India, where the building blocks of our drug substances are manufactured. The current tariff on goods from China is 20%, which may be increased in November 2026, and the current tariff on goods from India is 18%. There are certain product exemptions for pharmaceutical-related products, including an exemption relating to pharmaceutical-related products for clinical use.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 25, 2025, the President announced that, beginning October 1, 2025, all branded or patented drugs imported in the U.S. would face a 100% tariff. The President indicated that the tariffs could be avoided by building pharmaceutical manufacturing facilities in the U.S. Thereafter, the President delayed the October 1st effective date of the tariffs and announced that the administration had begun preparing tariffs on manufacturers that do not build in the U.S. or enter into an MFN drug pricing agreement with the current administration. Certain trading partners, including the European Union, South Korea and Japan, negotiated exemptions from the Section 232 tariffs on pharmaceuticals.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">A host of other U.S. tariff actions remain possible, including an additional 25% tariff on products from countries that do business with Iran. In February 2026, the U.S. Supreme Court held that the International Emergency Economic Powers Act does not authorize the President to impose tariffs, invalidating both the &#8220;reciprocal&#8221; tariffs and certain country-specific tariffs. However, the President announced plans to impose new tariffs under other authorities.</span></div><div style="text-align:justify;text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of changes in tariffs that have been announced and/or implemented, and the underlying uncertainty currently surrounding international trade, we could experience a negative impact to our costs of materials and production processes, and supply chain disruptions and delays as a result of any new tariff policies or trade restrictions. If we are unable to obtain necessary raw materials or product components in sufficient quantity and in a timely manner due to disruptions in the global supply chain caused by macroeconomic events and conditions, the development, testing and clinical trials of our product candidates may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business. We cannot yet predict the effect of U.S. tariffs on imports, or the extent to which other countries will impose quotas, duties, tariffs, taxes or other similar restrictions upon imports or exports in the future, nor can we predict future trade policy or the terms of any renegotiated trade agreements and their impact on our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, some of our manufacturers and suppliers are located in China. Trade tensions and conflicts between the United States and China have been escalated in recent years and, as such, we are exposed to the possibility of product supply disruption and increased costs and expenses in the event of changes to the laws, rules, regulations and policies of the governments of the United States or China, or due to geopolitical unrest and unstable economic conditions. Certain Chinese biotechnology companies may become subject to trade restrictions, sanctions, other regulatory requirements or proposed legislation by the U.S. government, which could restrict or even prohibit our ability to work with such entities, thereby potentially disrupting their supply of material to us. For example, the U.S. Department of Commerce&#8217;s Bureau of Industry and Security, or BIS, published an interim final rule in September 2025, referred to as the &#8220;Affiliates Rule,&#8221; which expands the scope of BIS export restrictions to include entities with 50% or greater ownership, in the aggregate, by one or more entities listed on the BIS entity list. While the Affiliates Rule has been suspended until November 10, 2026 as </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">84</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">part of the U.S.-China tentative framework agreement, escalating tensions between the United States and China may prevent or hinder the export of materials or technical information between us and Chinese manufacturers and suppliers, and other Chinese third parties we may interact with in the future. In addition, other third parties with which we interact may require voluntary compliance or supply chain requirements that go above and beyond potential legislation to address perceived risk of &#8220;pass through,&#8221; which could make it difficult for us to operate our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, on December 18, 2025, as part of the National Defense Authorization Act for Fiscal Year 2026, the President signed into law the BIOSECURE Act which limits U.S. government procurement from and grants to biotechnology companies of concern, or BCCs. Under the BIOSECURE Act, U.S. government agencies cannot (i) buy or obtain biotechnology equipment or services provided by a BCC; (ii) enter into, extend, or renew a contract with any entity using biotechnology equipment or services provided by a BCC to perform a government contract; or (iii) expend loan or grant funds for biotechnology equipment or services provided by a BCC. The BIOSECURE Act does not name specific companies as BCCs but treats any company on the U.S. Department of Defense 1260H list of Chinese Military Companies as a BCC. This list currently includes BGI Group, BGI Genomics Co., Ltd., Forensic Genomics International, and MGI Tech Co., Ltd., but does not include the WuXi entities. The legislation allows for other biotechnology companies, possibly including WuXi entities, to be added to the federal funding prohibitions at a later time. The 1260H list was updated by the Department of Defense in January 2024 and January 2025. On February 13, 2026, the Department published an updated list, which included WuXi AppTec but then abruptly withdrew the list. The implications of this action remain unclear. This law could have the potential to severely restrict the ability of companies like ours to contract with certain Chinese biotechnology companies of concern without losing the ability to contract with, or otherwise receive funding from, the U.S. government. It is possible some of our contractual counterparties could be adversely impacted by these or similar supply chain restrictions.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Any unfavorable government policies on international trade, such as export controls, capital controls or tariffs, may increase the cost of manufacturing our product candidates and platform materials, affect the demand for our product candidates (if and once approved), the competitive position of our product candidates, and import or export of raw materials and finished product candidates used in our preclinical studies and clinical trials, particularly with respect to any product candidates and materials that we import from China, including pursuant to our manufacturing service arrangements with WuXi. </span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">If any new tariffs, export controls, legislation and/or regulations are implemented, or if existing trade agreements are renegotiated or, in particular, if the U.S. or Chinese governments take retaliatory trade actions due to the recent trade tensions, such changes could have an adverse effect on our business, financial condition and results of operations.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_824"></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to the Commercialization of Our Product Candidates </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if any of our product candidates receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of our product candidates receives marketing approval, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors and others in the medical community. For example, current cancer treatments, such as chemotherapy and radiation therapy, are well established in the medical community, and doctors may continue to rely on these treatments. If our product candidates do not achieve an adequate level of acceptance, we may not generate significant revenue from product sales and we may not become profitable. The degree of market acceptance of our product candidates, if approved for commercial sale, will depend on a number of factors, including, but not limited to: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the efficacy and potential advantages as compared to alternative treatments; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the prevalence and severity of any side effects of our product candidates, in particular as compared to alternative treatments; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to offer our products for sale at competitive prices; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the convenience and ease of administration compared to alternative treatments; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">85</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the strength of marketing, sales and distribution support; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the availability of third-party coverage and adequate reimbursement; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the timing of any marketing approval in relation to other product approvals; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">support from patient advocacy groups; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">any restrictions on the use of our products together with other medications. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to establish sales and marketing capabilities, we may not be successful in commercializing our product candidates if and when they are approved. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have a sales or marketing infrastructure and have no experience in the sale, marketing or distribution of biopharmaceutical products. To achieve commercial success for any product for which we obtain marketing approval, we will need to establish sales, marketing and distribution capabilities, either ourselves or through collaboration or other arrangements with third parties. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In past years, we had begun the process of establishing our own focused, specialized sales, marketing, and market access organization to support the commercialization of our product candidates, including vepdegestrant, in the United States. However, in September 2025, we announced that we and Pfizer have agreed to jointly select a third party for the commercialization and potential further development of vepdegestrant. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other than with respect to vepdegestrant, we currently expect that we would build our own focused, specialized sales, marketing and market access organization to support the commercialization of our product candidates in the United States for which we receive marketing approval and that can be commercialized with such capabilities. There are risks involved with establishing our own sales and marketing capabilities. For example, recruiting and training a sales force is expensive and time-consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. These efforts may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Factors that may inhibit our efforts to commercialize our products on our own include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our inability to recruit, train and retain adequate numbers of effective, knowledgeable and experienced sales and marketing personnel;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability of such sales personnel to obtain access to physicians or persuade adequate numbers of physicians to prescribe any future products;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage to companies with more extensive product lines; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to establish our own sales and marketing capabilities and, therefore, we enter into arrangements with third parties to perform these services, our revenue from product sales and our profitability, if any, are likely to be lower than if we were to market and sell any products that we develop ourselves. In addition, we may not be successful in entering into arrangements with third parties to market and sell our product candidates or may be unable to do so on terms that are acceptable to us. We likely will have little control over such third parties, and any of these third parties may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish sales and marketing capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we are able to commercialize any product candidates, the products may become subject to unfavorable pricing regulations, third-party reimbursement practices or healthcare reform initiatives, which would harm our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulations that govern marketing approvals, pricing, coverage and reimbursement for new drug products vary widely from country to country. Current and future legislation may significantly change the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">86</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval requirements in ways that could involve additional costs and cause delays in obtaining approvals. Some countries require approval of the sale price of a drug before it can be marketed. In many countries, the pricing review period begins after marketing or product licensing approval is granted. To obtain reimbursement or pricing approval in some countries, we may be required to conduct a clinical trial that compares the cost-effectiveness of our product candidate to other available therapies. In some foreign markets, prescription pharmaceutical pricing remains subject to continuing governmental control even after initial approval is granted. As a result, we might obtain marketing approval for a product candidate in a particular country, but then be subject to price regulations that delay our commercial launch of the product, possibly for lengthy time periods, and negatively impact the revenues, if any, we are able to generate from the sale of the product in that country. Adverse pricing limitations may hinder our ability to recoup our investment in one or more product candidates, even if our product candidates obtain marketing approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to commercialize any product candidates successfully also will depend in part on the extent to which coverage and adequate reimbursement for these products and related treatments will be available from government healthcare programs, private health insurers and other organizations. Government authorities and third-party payors, such as private health insurers and health maintenance organizations, decide which medications they will pay for and establish reimbursement levels. A primary trend in the U.S. healthcare industry and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, government authorities and third-party payors are requiring that drug companies provide them with predetermined discounts from list prices and are challenging the prices charged for medical products. Coverage and reimbursement may not be available for any product that we commercialize and, even if these are available, the level of reimbursement may not be satisfactory. Reimbursement may affect the demand for, or the price of, any product candidate for which we obtain marketing approval. Obtaining and maintaining adequate reimbursement for our products may be difficult. We may be required to conduct expensive pharmacoeconomic studies to justify coverage and reimbursement or the level of reimbursement relative to other therapies. If coverage and adequate reimbursement are not available or reimbursement is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There may be significant delays in obtaining coverage and reimbursement for newly approved drugs, and coverage may be more limited than the purposes for which the FDA or similar regulatory authorities approve the drug outside of the United States. Moreover, eligibility for coverage and reimbursement does not imply that a drug will be paid for in all cases or at a rate that covers our costs, including research, development, intellectual property, manufacture, sale and distribution expenses. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. Reimbursement rates may vary according to the use of the drug and the clinical setting in which it is used, may be based on reimbursement levels already set for lower cost drugs and may be incorporated into existing payments for other services. Net prices for drugs may be reduced by mandatory discounts or rebates required by government healthcare programs or private payors and by any future relaxation of laws that presently restrict imports of drugs from countries where they may be sold at lower prices than in the United States. Third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own reimbursement policies. Our inability to promptly obtain coverage and adequate reimbursement rates from both government-funded and private payors for any approved products that we develop could have a material adverse effect on our operating results, our ability to raise capital needed to commercialize products and our overall financial condition. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of any products that we may develop. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We face an inherent risk of product liability exposure related to the testing of our product candidates in human clinical trials and will face an even greater risk if we commercially sell any products that we may develop. If we cannot successfully defend ourselves against claims that our product candidates or products caused injuries, we will incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">decreased demand for any product candidates or products that we may develop;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">termination of clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">withdrawal of any marketing approval, recall, restriction on the approval or a &#8220;black box&#8221; warning or contraindication for an approved drug;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">87</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failure to enroll clinical trial participants or withdrawal of clinical trial participants;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">significant costs to defend the related litigation;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">substantial monetary awards to trial participants or patients;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">loss of revenue;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">injury to our reputation and significant negative media attention;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">reduced resources of our management to pursue our business strategy; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the inability to commercialize any products that we may develop.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Although we maintain product liability insurance coverage, it may not be adequate to cover all liabilities that we may incur. We may need to increase product liability insurance coverage as we expand our clinical trials and if we commence commercialization of our product candidates. Insurance coverage is increasingly expensive. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_862"></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Intellectual Property</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to obtain and maintain patent protection for our technology and products or if the scope of the patent protection obtained is not sufficiently broad, our competitors could develop and commercialize technology and products similar or identical to ours, and our ability to successfully commercialize our technology and products may be impaired, and we may not be able to compete effectively in our market. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends in part on our ability to obtain and maintain patent and other proprietary protection in the United States and other countries with respect to our proprietary technology and products. We seek to protect our proprietary position by filing patent applications in the United States and other jurisdictions related to our novel technologies and product candidates. Any disclosure to or misappropriation by third parties of our confidential proprietary information could enable competitors to quickly duplicate or surpass our technological achievements, thus eroding our competitive position in our market. Moreover, the patent applications we own, co-own or license may fail to result in issued patents in the United States or in other foreign countries. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent prosecution process is expensive and time-consuming, and we may not be able to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner or at all. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection. Moreover, in some circumstances, we do not have the right to control the preparation, filing and prosecution of patent applications, or to maintain the patents, covering technology that we license from third parties. Therefore, these patents and applications may not be prosecuted and enforced in a manner consistent with the best interests of our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. In addition, the laws of foreign countries may not protect our rights to the same extent as the laws of the United States. For example, European patent law restricts the patentability of methods of treatment of the human body more than United States law does. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. Therefore, we cannot know with certainty whether we were the first to make the inventions claimed in our owned, co-owned or licensed patents or pending patent applications, or that we were the first inventors to file for patent protection of such inventions. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">88</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, we may be subject to a third-party preissuance submission of prior art to the United States Patent and Trademark Office, or the USPTO, or in addition to interference proceedings, may become involved in opposition, derivation, reexamination, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review, post-grant review or other post-grant proceedings challenging our or our licensors&#8217; patent rights or the patent rights of others. An adverse determination in any such submission, proceeding or litigation could reduce the scope of, or invalidate, our patent rights, allow third parties to commercialize our technology or products and compete directly with us, without payment to us, or result in our inability to manufacture or commercialize products without infringing third-party patent rights. In addition, if the breadth or strength of protection provided by our patents and patent applications is threatened, it could dissuade companies from collaborating with us to license, develop or commercialize current or future product candidates. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our owned, co-owned and licensed patent estate includes patent applications, many of which are at an early stage of prosecution. Even if our owned, co-owned and licensed patent applications issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors from competing with us or otherwise provide us with any competitive advantage. Our competitors may be able to circumvent our owned, co-owned or licensed patents by developing similar or alternative technologies or products in a non-infringing manner. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The issuance of a patent is not conclusive as to its inventorship, scope, validity or enforceability, and our owned, co-owned and licensed patents may be challenged in the courts or patent offices in the United States and other jurisdictions. Such challenges may result in loss of exclusivity or freedom to operate or in patent claims being narrowed, invalidated or held unenforceable, in whole or in part, which could limit our ability to stop others from using or commercializing similar or identical technology and products, or limit the duration of the patent protection of our technology and products. Given the amount of time required for the development, testing and regulatory review of new product candidates, patents protecting such candidates might expire before or shortly after such candidates are commercialized. As a result, our owned, co-owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in patent laws or patent jurisprudence could diminish the value of our patents in general, thereby impairing our ability to protect our product candidates. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents. On September 16, 2011, the Leahy-Smith America Invents Act, or the Leahy-Smith Act, was signed into law. The Leahy-Smith Act includes a number of significant changes to United States patent law. These changes include provisions that affect the way patent applications are prosecuted and may also affect patent litigation. The USPTO developed new regulations and procedures to govern administration of the Leahy-Smith Act, and many of the substantive changes to patent law associated with the Leahy-Smith Act, and in particular, the first-inventor-to-file provisions, became effective on March 16, 2013. Accordingly, it is not clear what, if any, impact the Leahy-Smith Act will have on the operation of our business. However, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition. Furthermore, for applications in which all claims are entitled to a priority date before March 16, 2013, an interference proceeding can be provoked by a third party or instituted by the USPTO to determine who was the first to invent any of the subject matter covered by the patent claims of our applications. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, the U.S. Supreme Court has ruled on several patent cases in recent years limiting where a patentee may file a patent infringement suit, narrowing the scope of patent protection available in certain circumstances or weakening the rights of patent owners in certain situations, and there are other open questions under patent law that courts have yet to decisively address. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending on decisions by Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways and could weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future. In addition, the European patent system is relatively stringent in the type of amendments that are allowed during prosecution, but the complexity </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">89</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">and uncertainty of European patent laws has also increased in recent years. Complying with these laws and regulations could limit our ability to obtain new patents in the future that may be important for our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors, or other intellectual property, which could be expensive, time-consuming and unsuccessful. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Competitors may infringe our issued patents, the patents of our licensors, or other intellectual property. To counter infringement or unauthorized use, we may be required to file infringement claims, which can be expensive, time-consuming and unpredictable. Any claims we assert against perceived infringers could provoke these parties to assert counterclaims against us alleging that we infringe their patents. In addition, in a patent infringement proceeding, a court may decide that a patent of ours or our licensors is invalid or unenforceable, in whole or in part, construe the patent&#8217;s claims narrowly or refuse to stop the other party from using the technology at issue on the grounds that our patents do not cover the technology in question. An adverse result in any litigation proceeding could put one or more of our patents at risk of being invalidated, held unenforceable or interpreted narrowly. Even if we successfully assert our patents, a court may not award remedies that sufficiently compensate us for our losses. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may need to license intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms or at all. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A third party may hold intellectual property, including patent rights, that are important or necessary to the development of our products. It may be necessary for us to use the patented or proprietary technology of a third party to commercialize our own technology or products, in which case we would be required to obtain a license from such third party. A license to such intellectual property may not be available or may not be available on commercially reasonable terms, which could have a material adverse effect on our business and financial condition. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The licensing and acquisition of third-party intellectual property rights is a competitive practice, and companies that may be more established, or have greater resources than we do, may also be pursuing strategies to license or acquire third-party intellectual property rights that we may consider necessary or attractive in order to commercialize our product candidates. More established companies may have a competitive advantage over us due to their larger size and cash resources or greater clinical development and commercialization capabilities. We may not be able to successfully complete such negotiations and ultimately acquire the rights to the intellectual property surrounding the additional product candidates that we may seek to acquire. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our commercial success depends upon our ability, and the ability of our collaborators, to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights of third parties. There is considerable intellectual property litigation in the biotechnology and pharmaceutical industries, as well as administrative proceedings for challenging patents, including interference, reexamination, and </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review proceedings before the USPTO and oppositions and other comparable proceedings in foreign jurisdictions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may become party to, or threatened with, future adversarial proceedings or litigation regarding intellectual property rights with respect to our products and technology, including interference, derivation, reexamination or </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">inter partes </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">review proceedings before the USPTO. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our product candidates may give rise to claims of infringement of the patent rights of others. There may be third-party patents of which we are currently unaware with claims to materials, formulations, methods of manufacture or methods for treatment related to the use or manufacture of our product candidates. Because patent applications can take many years to issue, there may be currently pending patent applications which may later result in issued patents that our product candidates may infringe. In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">90</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found by a court of competent jurisdiction to infringe a third party&#8217;s intellectual property rights, we could be required to obtain a license from such third party to continue developing and marketing our products and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. In addition, even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors access to the same technologies licensed to us. We could be forced, including by court order, to cease commercializing the infringing technology or product. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees if we are found to have willfully infringed a patent. A finding of infringement could prevent us from commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with our obligations in our current and future intellectual property licenses and funding arrangements with third parties, we could lose rights that are important to our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are party to an amended and restated license agreement with Yale that provides us with the foundational intellectual property rights for our PROTAC targeted protein degradation technology. This license agreement imposes diligence, development and commercialization timelines and milestone payment, royalty, insurance and other obligations on us. If we fail to comply with our obligations, including achieving specified milestone events, Yale may have the right to terminate this license, in which event we might not be able to develop, manufacture or market any product that is covered by the intellectual property we in-license from Yale and may face other penalties. Such an occurrence would materially adversely affect our business prospects. For a variety of purposes, we will likely enter into additional licensing and funding arrangements with third parties that may also impose similar obligations on us. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Termination of any of our current or future in-licenses would reduce or eliminate our rights under these agreements and may result in our having to negotiate new or reinstated agreements with less favorable terms or cause us to lose our rights under these agreements, including our rights to important intellectual property or technology. Any of the foregoing could prevent us from commercializing our other product candidates, which could have a material adverse effect on our operating results and overall financial condition. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the above risks, intellectual property rights that we license in the future may include sublicenses under intellectual property owned by third parties, in some cases through multiple tiers. The actions of our licensors may therefore affect our rights to use our sublicensed intellectual property, even if we are in compliance with all of the obligations under our license agreements. Should our licensors or any of the upstream licensors fail to comply with their obligations under the agreements pursuant to which they obtain the rights that are sublicensed to us, or should such agreements be terminated or amended, our ability to develop and commercialize our product candidates may be materially harmed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, we do not have the right to control the prosecution, maintenance and enforcement of all of our licensed and sublicensed intellectual property, and even when we do have such rights, we may require the cooperation of our licensors and upstream licensors, which may not be forthcoming. For example, under the Yale license, any patent applications and issued patents under the agreement remain the property of Yale, and Yale has the right to choose patent counsel. Our business could be adversely affected if we or our licensors are unable to prosecute, maintain and enforce our licensed and sublicensed intellectual property effectively. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to claims by third parties asserting that our employees, consultants, contractors or we have misappropriated their intellectual property, or claiming ownership of what we regard as our own intellectual property. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We employ individuals who were previously employed at universities as well as other biotechnology or pharmaceutical companies, including our competitors or potential competitors. We have received confidential and proprietary information from collaborators, prospective licensees and other third parties. Although we try to ensure that our employees do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these employees or we have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such employee&#8217;s former employer. We may also be subject to claims that former employers or other third parties have an ownership interest in our patents. Litigation may be necessary to defend against these claims. We may not be successful in defending these claims, and if we </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">91</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Even if we are successful, litigation could result in substantial cost and reputational loss and be a distraction to our management and other employees. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, while it is our policy to require our employees, consultants and contractors who may be involved in the development of intellectual property to execute agreements assigning such intellectual property to us, we may be unsuccessful in executing such an agreement with each party who in fact develops intellectual property that we regard as our own. Such assignment agreements may not be self-executing or may be breached, and we may be forced to bring claims against third parties, or defend claims they may bring against us, to determine the ownership of what we regard as our intellectual property. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Intellectual property litigation could cause us to spend substantial resources and distract our personnel from their normal responsibilities. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses, and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future sales, marketing or distribution activities. We may not have sufficient financial or other resources to conduct such litigation or proceedings adequately. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could compromise our ability to compete in the marketplace. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Obtaining and maintaining our patent protection depends on compliance with various procedural, documentary, fee payment and other requirements imposed by governmental patent offices, and our patent protection could be reduced or eliminated for non-compliance with these requirements. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Periodic maintenance fees on any issued patent are due to be paid to the USPTO and patent offices in foreign countries in several stages over the lifetime of the patent. The USPTO and patent offices in foreign countries require compliance with a number of procedural, documentary, fee payment and other requirements during the patent application process. While an inadvertent lapse can in many cases be cured by payment of a late fee or by other means in accordance with the applicable rules, there are situations in which noncompliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of a patent or patent rights in the relevant jurisdiction. Non-compliance events that could result in abandonment or lapse of a patent or patent application include, but are not limited to, failure to respond to official actions within prescribed time limits, non-payment of fees and failure to properly legalize and submit formal documents. In such an event, our competitors might be able to enter the market, which would have a material adverse effect on our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to seeking patents for some of our technology and product candidates, we also rely on trade secrets, including unpatented know-how, technology and other proprietary information, to maintain our competitive position. We seek to protect these trade secrets, in part, by entering into non-disclosure and confidentiality agreements with parties who have access to them, such as our employees, corporate collaborators, outside scientific collaborators, contract manufacturers, consultants, advisors and other third parties. We also enter into confidentiality and invention or patent assignment agreements with our employees and consultants. Despite these efforts, any of these parties may breach the agreements and disclose our proprietary information, including our trade secrets, and we may not be able to obtain adequate remedies for such breaches. Enforcing a claim that a party illegally disclosed or misappropriated a trade secret is difficult, expensive and time-consuming, and the outcome is unpredictable. In addition, some courts inside and outside of the United States are less willing or unwilling to protect trade secrets. If any of our trade secrets were to be lawfully obtained or independently developed by a competitor, we would have no right to prevent them, or those </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">92</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to whom they communicate it, from using that technology or information to compete with us. If any of our trade secrets were to be disclosed to or independently developed by a competitor, our competitive position would be harmed. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we are not able to obtain patent term extensions in the United States under the Hatch-Waxman Act and in foreign countries under similar legislation, thereby potentially extending the term of our marketing exclusivity for our product candidates, our business may be impaired. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depending upon the timing, duration and specifics of FDA marketing approval of our product candidates, one of the U.S. patents covering each of such product candidates or the use thereof may be eligible for a patent term extension under the Drug Price Competition and Patent Term Restoration Act of 1984, or Hatch-Waxman Act. The period of extension may be up to five years beyond the expiration date of a patent but cannot extend the remaining term of a patent beyond a total of 14 years from the date of product approval. The Hatch-Waxman Act allows a maximum of one patent to be extended per FDA-approved product. Similar patent term extension also may be available in certain foreign countries upon regulatory approval of our product candidates. Nevertheless, we may not be granted patent term extension either in the United States or in any foreign country because of, for example, failing to apply within applicable deadlines, failing to apply prior to expiration of relevant patents or otherwise failing to satisfy applicable requirements. Moreover, the term of extension, as well as the scope of patent protection during any such extension, afforded by the governmental authority could be less than we request. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are unable to obtain patent term extension or restoration, or the term of any such extension is less than we request, the period during which we will have the right to exclusively market our product may be shortened and our competitors may obtain approval of competing products following our patent expiration sooner, and our revenue could be reduced, possibly materially. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We only have limited geographical protection with respect to certain patents and we may not be able to protect our intellectual property rights throughout the world. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Filing, prosecuting and defending patents covering our product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In-licensing patents covering our product candidates in all countries throughout the world may similarly be prohibitively expensive, if such opportunities are available at all. And in-licensing or filing, prosecuting and defending patents even in only those jurisdictions in which we develop or commercialize our product candidates may be prohibitively expensive or impractical. Competitors may use our and our licensors&#8217; technologies in jurisdictions where we have not obtained patent protection or licensed patents to develop their own products and, further, may export otherwise infringing products to territories where we and our licensors have patent protection, but enforcement is not as strong as that in the United States or the European Union. These products may compete with our product candidates, and our or our licensors&#8217; patents or other intellectual property rights may not be effective or sufficient to prevent them from competing. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we may decide to abandon national and regional patent applications while they are still pending. The grant proceeding of each national or regional patent is an independent proceeding which may lead to situations in which applications may be rejected by the relevant patent office, while substantively similar applications are granted by others. For example, relative to other countries, China has a heightened detailed description requirement for patentability. Furthermore, generic drug manufacturers or other competitors may challenge the scope, validity or enforceability of our or our licensors&#8217; patents, requiring us or our licensors to engage in complex, lengthy and costly litigation or other proceedings. Generic drug manufacturers may develop, seek approval for and launch generic versions of our products. It is also quite common that depending on the country, the scope of patent protection may vary for the same product candidate or technology. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The laws of some jurisdictions do not protect intellectual property rights to the same extent as the laws or regulations in the United States and the European Union, and many companies have encountered significant difficulties in protecting and defending proprietary rights in such jurisdictions. Moreover, the legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets or other forms of intellectual property, which could make it difficult for us to prevent competitors in some jurisdictions from marketing competing products in violation of our proprietary rights generally. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">93</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, are likely to result in substantial costs and divert our efforts and attention from other aspects of our business, and additionally could put our or our licensors&#8217; patents at risk of being invalidated or interpreted narrowly, could increase the risk of our or our licensors&#8217; patent applications not issuing, or could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, while damages or other remedies may be awarded to the adverse party, which may be commercially significant. If we prevail, damages or other remedies awarded to us, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license. Furthermore, while we intend to protect our intellectual property rights in our expected significant markets, we cannot ensure that we will be able to initiate or maintain similar efforts in all jurisdictions in which we may wish to market our product candidates. Accordingly, our efforts to protect our intellectual property rights in such countries may be inadequate, which may have an adverse effect on our ability to successfully commercialize our product candidates in all of our expected significant foreign markets. If we or our licensors encounter difficulties in protecting, or are otherwise precluded from effectively protecting, the intellectual property rights important for our business in such jurisdictions, the value of these rights may be diminished and we may face additional competition in those jurisdictions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In some jurisdictions, compulsory licensing laws compel patent owners to grant licenses to third parties. In addition, some countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors are forced to grant a license to third parties under patents relevant to our business, or if we or our licensors are prevented from enforcing patent rights against third parties, our competitive position may be substantially impaired in such jurisdictions. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_857"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Regulatory Approval and Marketing of Our Product Candidates, Our Industry and Other Legal and Compliance Matters </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The regulatory approval process of the FDA is lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain marketing approval for our product candidates, our business will be substantially harmed. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The time required to obtain approval by the FDA is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained marketing approval for any product candidate to date and it is possible that none of our existing product candidates, or any product candidates we may seek to develop in the future, will ever obtain marketing approval. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates could fail to receive marketing approval for many reasons, including the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may disagree with the design or implementation of our clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate to the satisfaction of the FDA that a product candidate is safe and effective for its proposed indication;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of clinical trials may not meet the level of statistical significance required by the FDA for approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may disagree with our interpretation of data from preclinical studies or clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">data collected from clinical trials of our product candidates may not be sufficient to support the submission of an NDA to the FDA or other submission or to obtain marketing approval in the United States;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the FDA may find deficiencies with or fail to approve the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies; and</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">94</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the approval policies or regulations of the FDA may significantly change in a manner rendering our clinical data insufficient for approval.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The lengthy approval process as well as the unpredictability of future clinical trial results may result in our failing to obtain regulatory approval to market any of our product candidates, which would significantly harm our business, results of operations and prospects. The FDA has substantial discretion in the approval process, and determining when or whether regulatory approval will be obtained for any of our product candidates. Even if we believe the data collected from clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has traditionally required sponsors to conduct two adequate and well-controlled studies in support of approval of an NDA. In February 2026, however, the Commissioner of FDA and the Director of Center for Biologics Evaluation and Research published an editorial in the New England Journal of Medicine in which they declared that, in most cases, the new default requirement for FDA approval of a new product will be one adequate and well-controlled pivotal clinical trial plus confirmatory evidence, rather than two pivotal clinical trials.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining whether to rely on one trial, the FDA will focus on the single trial&#8217;s quality, including magnitude of effect, appropriateness of control arms, endpoint selection, statistical power, blinding, handling of missing data, biological plausibility and alignment with intermediate biomarkers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA has long had authority to approve new products on the basis of one trial plus confirmatory evidence and, in recent years, the agency has exercised that authority with respect to certain types of products. The FDA now takes the position that this will be the new official default standard for most product candidates. The implications of this decision and how it will impact our clinical development programs are unclear at this point.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if we were to obtain approval, regulatory authorities may approve any of our product candidates for fewer or more limited indications than we request, may not approve the price we intend to charge for our products, may grant approval contingent on the performance of costly post-marketing clinical trials, or may approve a product candidate with a label that does not include the labeling claims necessary or desirable for the successful commercialization of that product candidate. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of any or all of our product candidates. If we are not able to obtain, or if there are delays in obtaining, required regulatory approvals, we will not be able to commercialize our product candidates, and our ability to generate revenue will be materially impaired. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our product candidates and the activities associated with their development and commercialization, including their design, testing, manufacture, safety, efficacy, recordkeeping, labeling, storage, approval, advertising, promotion, sale and distribution, export and import are subject to comprehensive regulation by the FDA and other regulatory agencies in the United States and by the EMA and similar regulatory authorities outside of the United States. Failure to obtain marketing approval for a product candidate will prevent us from commercializing the product candidate. We have not submitted an application for or received marketing approval for any of our product candidates in the United States or in any other jurisdiction. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a company, we do not have experience in filing and supporting the applications necessary to gain marketing approvals and expect to rely on third-party CROs or other third-party consultants or vendors to assist us in this process. Securing marketing approval requires the submission of extensive preclinical and clinical data and supporting information to regulatory authorities for each therapeutic indication to establish the product candidate&#8217;s safety and efficacy. Securing marketing approval also requires the submission of information about the product manufacturing process to, and inspection of manufacturing facilities by, the regulatory authorities. Our product candidates may not be effective, may be only moderately effective or may prove to have undesirable or unintended side effects, toxicities or other characteristics that may preclude our obtaining marketing approval or prevent or limit commercial use. New oncology drugs frequently are indicated only for patient populations that have not responded to an existing therapy or have relapsed. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The process of obtaining marketing approvals, both in the United States and in other jurisdictions, is expensive, may take many years, if approval is obtained at all, and can vary substantially based upon a variety of factors, including the type, complexity and novelty of the product candidates involved. Changes in marketing </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">95</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">approval policies during the development period, changes in or the enactment of additional statutes or regulations, or changes in regulatory review for each submitted product application, may increase costs or cause delays in the approval or rejection of an application. Regulatory authorities have substantial discretion in the approval process and may refuse to accept any application or may decide that our data is insufficient for approval and require additional preclinical, clinical or other studies. In addition, varying interpretations of the data obtained from preclinical and clinical testing could delay, limit or prevent marketing approval of a product candidate. Any marketing approval we ultimately obtain may be limited or subject to restrictions or post-approval commitments that render the approved product not commercially viable. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, principal investigators for our clinical trials may serve as scientific advisors or consultants to us and receive compensation in connection with such services. Under certain circumstances, we may be required to report some of these relationships to the FDA or comparable foreign regulatory authorities. The FDA or a comparable foreign regulatory authority may conclude that a financial relationship between us and a principal investigator has created a conflict of interest or otherwise affected interpretation of the study. The FDA or comparable foreign regulatory authority may therefore question the integrity of the data generated at the applicable clinical trial site and the utility of the clinical trial itself may be jeopardized. This could result in a delay in approval, or rejection, of our marketing applications by the FDA or comparable foreign regulatory authority, as the case may be, and may ultimately lead to the denial of marketing approval of one or more of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, under the PREA, an NDA, or supplement to an NDA for certain drugs and biological products must contain data to assess the safety and effectiveness of the drug or biological product in all relevant pediatric subpopulations and to support dosing and administration for each pediatric subpopulation for which the product is safe and effective, unless the sponsor receives a deferral or waiver from the FDA. A deferral may be granted for several reasons, including a finding that the product or therapeutic candidate is ready for approval for use in adults before pediatric trials are complete or that additional safety or effectiveness data needs to be collected before the pediatric trials begin. The applicable legislation in the EU also requires sponsors to either conduct clinical trials in a pediatric population in accordance with a PIP approved by the Paediatric Committee of the EMA or to obtain a waiver or deferral from the conduct of these studies by this Paediatric Committee. For any of our product candidates for which we are seeking regulatory approval in the U.S. or the European Union, we cannot guarantee that we will be able to obtain a waiver or alternatively complete any required studies and other requirements in a timely manner, or at all, which could result in associated reputational harm and subject us to enforcement action.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we could be adversely affected by several significant administrative law cases decided by the U.S. Supreme Court, including </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Loper Bright Enterprises v. Raimondo</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Corner Post, Inc. v. Board of Governors of the Federal Reserve System</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Securities and Exchange Commission v. Jarkesy</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. These decisions could introduce additional uncertainty into the regulatory process and may result in additional legal challenges to actions taken by federal regulatory agencies, including the FDA and the CMS, on which we rely. In addition to potential changes to regulations as a result of legal challenges, these decisions may result in increased regulatory uncertainty and delays and other impacts, any of which could adversely impact our business and operations.</span></div><div style="margin-top:12pt;text-indent:24.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Finally, there is currently litigation ongoing challenging FDA's approval of another company's drug product, mifepristone. Depending on the outcome of this litigation, our ability to develop new drug product candidates and to maintain approval of existing drug products could be delayed, undermined or subject to protracted litigation. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we experience delays in obtaining approval or if we fail to obtain approval of our product candidates, the commercial prospects for our product candidates may be harmed and our ability to generate revenues will be materially impaired.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Failure to obtain marketing approval in foreign jurisdictions would prevent our product candidates from being marketed outside of the United States and may limit our ability to generate revenue from product sales. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In order to market and sell our products in the EU and in other jurisdictions outside of the United States, we, and any collaborators, must obtain separate marketing approvals and comply with numerous and varying </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">96</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory requirements. The approval procedure varies among countries and can involve additional testing. The time required to obtain approval may differ substantially from that required to obtain FDA approval. The marketing approval process outside the United States generally includes all of the risks associated with obtaining FDA approval. We, and any collaborators, may not obtain approvals from regulatory authorities outside the United States on a timely basis, if at all. Approval by the FDA does not ensure approval by regulatory authorities in other countries or jurisdictions, and approval by one regulatory authority outside the United States does not ensure approval by regulatory authorities in other countries or jurisdictions or by the FDA. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In many countries outside the United States, a product candidate must also be approved for reimbursement before it can be sold in that country. In some cases, the price that we intend to charge for our products, if approved, is also subject to approval. Obtaining non-U.S. regulatory approvals and compliance with non-U.S. regulatory requirements could result in significant delays, difficulties and costs for us and any collaborators and could delay or prevent the introduction of our product candidates in certain countries. In addition, if we or any collaborators fail to obtain the non-U.S. approvals required to market our product candidates outside the United States or if we or any collaborators fail to comply with applicable non-U.S. regulatory requirements, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed and our business, financial condition, results of operations and prospects may be adversely affected. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we could face heightened risks with respect to obtaining marketing authorization in the United Kingdom as a result of the withdrawal of the United Kingdom from the European Union, commonly referred to as Brexit. The United Kingdom is no longer part of the European Single Market and EU Customs Union. As of January 1, 2025, the MHRA is responsible for approving all medicinal products destined for the United Kingdom market (i.e., Great Britain and Northern Ireland). On April 28, 2025, the UK Parliament adopted amendments to improve and strengthen the United Kingdom&#8217;s clinical trials regulatory regime; they will take effect on April 28, 2026. These changes were needed since the current United Kingdom requirements are based upon the now-repealed EU Clinical Trials Directive (2001/20/EC), which has been replaced by the CTR. Since the United Kingdom left the EU prior to the date on which the EU CTR took effect, the UK legal framework did not benefit from the same revisions as occurred at EU level. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, as of January 1, 2025, a new international recognition procedure, or IRP, will apply, which intends to facilitate approval of pharmaceutical products in the UK. The IRP is open to applicants that have already received an authorization for the same product from one of the MHRA&#8217;s specified Reference Regulators, or RRs. The RRs notably include EMA and regulators in the EU/EEA member states for approvals in the EU centralized procedure and mutual recognition procedure as well as the FDA (for product approvals granted in the U.S.). However, the concrete functioning of the IRP is currently unclear. Any delay in obtaining, or an inability to obtain, any marketing approvals, as a result of Brexit or otherwise, may force us or our collaborators to restrict or delay efforts to seek regulatory approval in the UK for our product candidates, which could significantly and materially harm our business.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, foreign regulatory authorities may change their approval policies and new regulations may be enacted. For instance, the EU pharmaceutical legislation is currently undergoing a complete review process, in the context of the Pharmaceutical Strategy for Europe initiative, launched by the European Commission in November 2020. The European Commission&#8217;s proposal for revision of several legislative instruments related to medicinal products (potentially reducing the duration of regulatory data protection, revising the eligibility for expedited pathways, etc.) was published on April 26, 2023. On June 4, 2025, after almost two years of negotiations among the EU Member States, the Council of the European Union adopted its position on the proposed overhaul of the EU general pharmaceutical legislative framework, which is known as the new Pharma Package. On December 11, 2025, the European Parliament and Council reached a provisional political agreement on the legislation which is expected to be adopted by mid-2026.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The revisions may have a significant impact on the pharmaceutical industry and our business. They would, among other things, set a baseline period of 8 years of data exclusivity and one year of market exclusivity with possible extensions for new indications up to a maximum of 11 years total. There will likely be a transition period of 24 months, with the changes taking effect in mid-2028.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that we will be subject to additional risks in commercializing any of our product candidates that receive marketing approval outside the United States, including tariffs, trade barriers and regulatory </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">97</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirements; economic weakness, including inflation, or political instability in particular foreign economies and markets; compliance with tax, employment, immigration and labor laws for employees living or traveling outside of the United States; foreign currency fluctuations, which could result in increased operating expenses and reduced revenue, and other obligations incident to doing business in another country; and workforce uncertainty in countries where labor unrest is more common than in the United States.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may seek certain designations for our product candidates, including Breakthrough Therapy, Fast Track and Priority Review, designations in the United States, but we might not receive such designations, and even if we do, such designations may not lead to a faster development or regulatory review or approval process.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may seek certain designations for one or more of our product candidates that could expedite review and approval by the FDA. A Breakthrough Therapy product is defined as a product that is intended, alone or in combination with one or more other products, to treat a serious condition, and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over existing therapies on one or more clinically significant endpoints, such as substantial treatment effects observed early in clinical development. For products that have been designated as Breakthrough Therapies, interaction and communication between the FDA and the sponsor of the trial can help to identify the most efficient path for clinical development while minimizing the number of patients placed in ineffective control regimens.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may also designate a product for Fast Track review if it is intended, whether alone or in combination with one or more other products, for the treatment of a serious or life-threatening disease or condition, and it demonstrates the potential to address unmet medical needs for such a disease or condition. In the first quarter of 2024, the FDA granted Fast Track designation for the investigation of vepdegestrant for monotherapy in the treatment of adults with ER+/HER- locally advanced or metastatic breast cancer previously treated with endocrine based therapy. For Fast Track products, sponsors may have greater interactions with the FDA and the FDA may initiate review of sections of a Fast Track product&#8217;s application before the application is complete. This rolling review may be available if the FDA determines, after preliminary evaluation of clinical data submitted by the sponsor, that a Fast Track product may be effective.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also seek a priority review designation for one or more of our product candidates. If the FDA determines that a product candidate offers major advances in treatment or provides a treatment where no adequate therapy exists, the FDA may designate the product candidate for priority review. A priority review designation means that the goal for the FDA to review an application is six months, rather than the standard review period of ten months.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These designations are within the discretion of the FDA. Accordingly, even if we believe that one of our product candidates meets the criteria for these desig</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nations, the FDA may disagree and instead determine not to make such designation. Further, even if we receive a designation, as we have with the</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">investigation of vepdegestrant for monotherapy in the treatment of adults with ER+/HER- locally advanced or metastatic breast cancer previously treated with endocrine based therapy, the receipt of such designation for a product candidate may not result in a faster development or regulatory review or approval process compared to products considered for approval under conventional FDA p</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rocedures and does not assure ultimate approval by the FDA.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, even if one or more of our product candidates qualifies for these designations, the FDA may later decide that the product candidates no longer meet the conditions for qualification or decide that the time period for FDA review or approval will not be shortened.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Even if we obtain regulatory approval for a product candidate, our products will remain subject to regulatory oversight.</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Even if we obtain any regulatory approval for our product candidates, they will be subject to ongoing regulatory requirements for manufacturing, labeling, packaging, storing, advertising, promoting, sampling, record&#8209;keeping and submitting safety and other post&#8209;market information. Any regulatory approvals that we receive for our product candidates also may be subject to a REMS, limitations on the approved indicated uses for which the product may be marketed or to the conditions of approval or contain requirements for potentially costly post&#8209;marketing testing, including post-marketing clinical trials, and surveillance to monitor the quality, safety and efficacy of the product. For example, the holder of an approved NDA is obligated to monitor and report adverse events and any failure of a product to meet the specifications in the NDA. FDA guidance advises </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">98</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that patients treated with some types of gene therapy undergo follow&#8209;up observations for potential adverse events for as long as 15 years. The holder of an approved NDA also must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling or manufacturing process. Advertising and promotional materials must comply with FDA rules and are subject to FDA review, in addition to other potentially applicable federal and state laws.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, product manufacturers and their facilities are subject to payment of user fees and continual review and periodic inspections by the FDA and other regulatory authorities for compliance with cGMP requirements and adherence to commitments made in the NDA or foreign marketing application. If we, or a regulatory authority, discover previously unknown problems with a product, such as AEs of unanticipated severity or frequency, or problems with the facility where the product is manufactured or such regulatory authority disagrees with the promotion, marketing or labeling of that product, the regulatory authority may impose restrictions relative to that product, the manufacturing facility or us, including requiring recall or withdrawal of the product from the market or suspension of manufacturing.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we fail to comply with applicable regulatory requirements following approval of any of our product candidates, a regulatory authority may:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">issue a warning letter asserting that we are in violation of the law;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">seek an injunction or impose administrative, civil or criminal penalties or monetary fines;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">suspend or withdraw regulatory approval;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">suspend any ongoing clinical trials;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">refuse to approve a pending NDA or comparable foreign marketing application, or any supplements thereto, submitted by us or our collaboration partners;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">restrict the marketing or manufacturing of the product;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">seize or detain the product or otherwise require the withdrawal of the product from the market;</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">refuse to permit the import or export of products; or</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">refuse to allow us to enter into supply contracts, including government contracts.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and adversely affect our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, FDA policies, and those of equivalent foreign regulatory agencies, may change and additional government regulations may be enacted that could prevent, limit or delay regulatory approval of our product candidates. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the U.S. or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained and we may not achieve or sustain profitability, which would harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The FDA, EMA and other regulatory authorities actively enforce the laws and regulations prohibiting the promotion of off-label uses.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We must also comply with requirements concerning advertising and promotion for any of our product candidates for which we obtain marketing approval. Thus, we will not be able to promote any products we develop for indications or uses for which they are not approved. The FDA and other U.S. or foreign agencies, including the DOJ, closely regulate and monitor the post-approval marketing and promotion of drugs to ensure that they are manufactured, marketed and distributed only for the approved indications and in accordance with the provisions of the approved labeling. The FDA imposes stringent restrictions on manufacturers&#8217; communications regarding off-label use, and if we, or our collaborators communicate about any of our product </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">99</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">candidates for which we, or they, receive marketing approval in a way that regulators assert goes beyond their approved indications, we, or they, may be subject to warnings or enforcement action for off-label marketing. In addition, following a memorandum from the President regarding disclosure of risks in direct-to-consumer prescription drug advertising, the FDA indicated it would increase enforcement on this topic.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:112%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Alleged violations of the FDCA or other statutes, including the False Claims Act, or the FCA, relating to the promotion and advertising of prescription drugs as well as an increase in enforcement may lead to more investigations or allegations of violations of federal and state health care fraud and abuse laws and state consumer protection laws, which could put us and other drug companies at increased risk for allegations of non-compliance.</span><span style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:112%"> </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">We will also need to carefully navigate the FDA&#8217;s various regulations, guidance and policies, regarding communication about products in development and distribution of scientific information on unapproved uses of products to healthcare providers. For example, the Pre-Approval Information Exchange Act was enacted in December 2022, which allows sponsors of products that have not been approved may proactively communicate to payors certain information about products in development to help expedite patient access upon product approval. In addition, in January 2025, the FDA published final guidance outlining the agency&#8217;s non-binding policies governing the distribution of scientific information on unapproved uses to healthcare providers. This final guidance calls for such communications to be truthful, non-misleading, factual, and unbiased and include all information necessary for healthcare providers to interpret the strengths and weaknesses and validity and utility of the information about the unapproved use. </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Violations of the FDCA and other statutes, including the False Claims Act, relating to the promotion and advertising of prescription products may lead to investigations and enforcement actions alleging violations of federal and state health care fraud and abuse laws, as well as state consumer protection laws.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Failure to comply with regulatory requirements, may yield various results, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">restrictions on such products, manufacturers or manufacturing processes; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">restrictions or warnings on the labeling or marketing of a product; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">restrictions on product distribution or use of a product; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">requirements to conduct post-marketing studies or clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">warning letters or untitled letters; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">withdrawal of the products from the market; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">refusal to approve pending applications or supplements to approved applications that we submit; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">recall of products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">fines, restitution or disgorgement of profits or revenues; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">suspension or withdrawal of marketing approvals; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">refusal to permit the import or export of our products; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">product seizure or detention; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">injunctions or the imposition of civil or criminal penalties; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">damage to relationships with any potential collaborators; </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">unfavorable press coverage and damage to our reputation; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-align:justify;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:13.8pt">litigation involving patients using our products.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Similar restrictions apply to the approval of our products in the EU. The holder of the marketing authorization is required to comply with a range of requirements applicable to the manufacturing, marketing, promotion and sale of medicinal products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we are found to have promoted such off-label uses, we may become subject to significant liability. The U.S. federal government has levied large civil and criminal fines against companies for alleged improper promotion of off-label use and has enjoined several companies from engaging in off-label promotion. The FDA </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">100</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">has also requested that companies enter into consent decrees or permanent injunctions under which specified promotional conduct is changed or curtailed. If we cannot successfully manage the promotion of our product candidates, if approved, we could become subject to significant liability, which would materially adversely affect our business and financial condition.</span></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our relationships with health care providers, physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other health care laws and regulations, which could expose us to civil, criminal and administrative sanctions, contractual damages, reputational harm and diminished future profits and earnings. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Health care providers, physicians and third-party payors will play a primary role in the recommendation and prescription of any drugs for which we obtain marketing approval. Our future arrangements with third-party payors, health care providers and physicians may expose us to broadly applicable state and federal fraud and abuse and other health care laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell and distribute any drugs for which we obtain marketing approval. These include the following: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Anti-Kickback Statute, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">which prohibits, among other things, persons and entities from knowingly and willfully soliciting, offering, paying, or receiving remuneration, directly or indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchasing, ordering, leasing, arranging for, or recommending the purchasing, ordering, or leasing of, any good or service for which payment may be made, in whole or in part, under a federal health care program such as Medicare or Medicaid; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">False Claims Act</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - the federal civil and criminal false claims laws, including the civil False Claims Act, and Civil Monetary Penalties Law, which prohibit individuals or entities from, among other things, knowingly presenting, or causing to be presented, to the federal government, false or fraudulent claims for payment or knowingly making, using or causing to made or used a false record or statement material to a false or fraudulent claim or to avoid, decrease or conceal an obligation to pay money to the federal government, or knowingly concealing or knowingly and improperly avoiding or decreasing an obligation to pay money to the federal government; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the federal Health Insurance Portability and Accountability Act of 1996, or HIPAA, which created additional federal criminal statutes that prohibit, among other things, executing a scheme to defraud any health care benefit program or making false statements relating to health care matters, and apply regardless of the payor (e.g., public or private); </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">HIPAA and HITECH - </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">HIPAA, as amended by the Health Information Technology for Economic and Clinical Health Act, or HITECH, and their implementing regulations, which impose obligations on HIPAA covered entities and their business associates, including mandatory contractual terms and required implementation of administrative, physical and technical safeguards to maintain the privacy and security of individually identifiable health information; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Transparency Requirements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - the federal physician transparency requirements known as the Physician Payments Sunshine Act, under the Patient Protection and the ACA, which requires manufacturers of drugs, medical devices, biological and medical supplies covered by Medicare, Medicaid, or State Children&#8217;s Health Insurance Program to report annually to the CMS within the United States Department of Health and Human Services, information related to payments and other transfers of value made by that entity to physicians, other healthcare providers and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Analogous State, Local and Foreign Laws</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - analogous state, local and foreign fraud and abuse laws and regulations, such as state anti-kickback and false claims laws, which may be broader than similar federal laws, can apply to claims involving health care items or services regardless of payor, and are enforced by many different federal and state agencies as well as through private actions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government and require drug manufacturers to report information related to payments and other transfers of value to physicians and other health care providers or marketing expenditures. State and foreign laws also govern the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">101</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not pre-empted by HIPAA, thus complicating compliance efforts. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Efforts to ensure that our business arrangements with third parties will comply with applicable health care laws and regulations will involve substantial costs. It is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other health care laws and regulations. If our operations are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and/or administrative penalties, damages, fines, individual imprisonment, disgorgement, exclusion from government funded health care programs, such as Medicare and Medicaid, contractual damages, reputational harm, administrative burdens, diminished profits and future earnings, additional reporting obligations and oversight if we become subject to a corporate integrity agreement or similar agreement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations. If any of the physicians or other health care providers or entities with whom we expect to do business is found to be not in compliance with applicable laws, they may be subject to criminal, civil or administrative sanctions, including exclusions from government funded health care programs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The provision of benefits or advantages to physicians to induce or encourage the prescription, recommendation, endorsement, purchase, supply, order or use of medicinal products is also prohibited in the EU. The provision of benefits or advantages to physicians is governed by the national anti-bribery laws of EU Member States. In addition, payments made to physicians in certain EU Member States must be publicly disclosed. Moreover, agreements with physicians often must be the subject of prior notification and approval by the physician&#8217;s employer, his or her competent professional organization and/or the regulatory authorities of the individual EU Member States. These requirements are provided in the national laws, industry codes or professional codes of conduct, applicable in the EU Member States. Failure to comply with these requirements could result in reputational risk, public reprimands, administrative penalties, fines or imprisonment. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If the FDA or comparable foreign regulatory authorities approve generic versions of any of our future drug products that receive marketing approval through the NDA pathway, or such authorities do not grant such future products appropriate periods of data exclusivity before approving generic versions of our products, our sales could be adversely affected.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Once an NDA is approved, the product covered thereby becomes a &#8220;reference-listed drug&#8221; in the FDA&#8217;s publication, &#8220;Approved Drug Products with Therapeutic Equivalence Evaluations,&#8221; commonly known as the Orange Book. Manufacturers may seek approval of generic versions of reference-listed drugs through submission of ANDAs in the United States. In support of an ANDA, a generic manufacturer need not conduct clinical trials to assess safety and efficacy. Rather, the applicant generally must show that its product has the same active ingredient(s), dosage form, strength, route of administration and conditions of use or labeling as the reference-listed drug and that the generic version is bioequivalent to the reference-listed drug, meaning it is absorbed in the body at the same rate and to the same extent. Generic products may be significantly less costly to bring to market than the reference-listed drug and companies that produce generic products are generally able to offer them at lower prices. Thus, following the introduction of a generic drug, a significant percentage of the sales of any branded product or reference-listed drug is typically lost to the generic product.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The FDA may not approve an ANDA for a generic product until any applicable period of non-patent exclusivity for the reference-listed drug has expired. The FDCA provides a period of five years of non-patent exclusivity for a new drug containing an NCE. For the purposes of this provision, an NCE is a drug that contains an active moiety that has previously been approved by the FDA in any other NDA. This interpretation was confirmed with enactment of the Ensuring Innovation Act in April 2021. An active moiety is the molecule or ion responsible for the physiological or pharmacological action of the drug substance. Specifically, in cases where such exclusivity has been granted, an ANDA may not be submitted to the FDA until the expiration of five years unless the submission is accompanied by a Paragraph IV certification that a patent covering the reference-listed drug is either invalid or will not be infringed by the generic product, in which case the applicant may submit its application four years following approval of the reference-listed drug. The FDCA also provides for a period of three years of exclusivity if the NDA includes reports of one or more new clinical trials, other than bioavailability or bioequivalence studies, that were conducted by or for the applicant and are essential to the approval of the application. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">102</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Generic drug manufacturers may seek to launch generic products following the expiration of any applicable exclusivity period we obtain if our product candidates are approved, even if we still have patent protection for such product candidates. Competition that any such product candidates of ours may face from generic versions of such products could materially and adversely impact our future revenue, profitability and cash flows and substantially limit our ability to obtain a return on the investments we may make in those product candidates.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compliance with global privacy and data security requirements could result in additional costs and liabilities to us or inhibit our ability to collect and process data globally, and our failure or the failure of our collaborators, CROs, CDMOs, contractors, consultants and other third parties to comply with such requirements could subject us to significant fines and penalties, which may have a material adverse effect on our business, financial condition or results of operations. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The regulatory framework for the collection, use, safeguarding, sharing, transfer and other processing of information worldwide is rapidly evolving and is likely to remain uncertain for the foreseeable future. Globally, virtually every jurisdiction in which we operate has established its own data security and privacy frameworks with which we must comply. For example, the collection, use, disclosure, transfer, or other processing of personal data regarding individuals in the European Union, including personal health data, is subject to the EU GDPR, which took effect across all member states of the EEA in May 2018. The GDPR is wide-ranging in scope and imposes numerous requirements on companies that process personal data, including requirements relating to processing health and other sensitive data, obtaining consent of the individuals to whom the personal data relates, providing information to individuals regarding data processing activities, implementing safeguards to protect the security and confidentiality of personal data, providing notification of data breaches, and taking certain measures when engaging third-party processors. The GDPR increases our obligations with respect to clinical trials conducted in the EEA by expanding the definition of personal data to include coded data and requiring changes to informed consent practices and more detailed notices for clinical trial subjects and investigators. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the GDPR also imposes strict rules on the transfer of personal data to countries outside the EU, including the United States and, as a result, increases the scrutiny that clinical trial sites located in the EEA should apply to transfers of personal data from such sites to countries that are considered to lack an adequate level of data protection, such as the United States. The GDPR also permits data protection authorities to require destruction of improperly gathered or used personal information and/or impose substantial fines for violations of the GDPR, which can be up to four percent of global revenues or 20 million Euros, whichever is greater, and it also confers a private right of action on data subjects and consumer associations to lodge complaints with supervisory authorities, seek judicial remedies, and obtain compensation for damages resulting from violations of the GDPR. In addition, the GDPR provides that European Union member states may make their own further laws and regulations limiting the processing of personal data, including genetic, biometric or health data. Similar laws and regulations have been approved, or are expected to be approved, in several jurisdictions beyond the European Union.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are ongoing concerns about the ability of companies to transfer personal data from the EU to other countries. In July 2020, the Court of Justice of the European Union, or the CJEU, invalidated the EU-U.S. Privacy Shield framework, or Privacy Shield, one of the mechanisms used to legitimize the transfer of personal data from the EEA to the U.S. While we were not self-certified under the Privacy Shield, this CJEU decision has led to increased scrutiny on data transfers from the EU to the United States generally and increased our costs of compliance with data privacy legislation as well as our costs of negotiating appropriate privacy and security agreements with our vendors and business partners.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the CJEU decision, in October 2022, an executive order implemented the EU-U.S. Data Privacy Framework, which would serve as a replacement to the EU-U.S. Privacy Shield. The European Commission initiated the process to adopt an adequacy decision for the EU-U.S. Data Privacy Framework, or DPF, in December 2022, and has now adopted an adequacy decision to permit data transfers from the European Union to the United States going forward. This development permits data transfers at this point under this framework and more broadly has made international data transfers more straightforward, but these provisions are being challenged in court. The recent election in the United States and the new administration may also impact whether the DPF remains an adequate data transfer framework. The continuing uncertainty around this issue may further impact our business operations in the EU.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">103</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 23, 2016, the electorate in the United Kingdom voted in favor of leaving the EU, commonly referred to as Brexit. As with other issues related to Brexit, there are open questions about how personal data will be protected in the United Kingdom and whether personal information can transfer from the EU to the UK. Following the withdrawal of the UK from the EU, the UK Data Protection Act 2018 applies to the processing of personal data that takes place in the United Kingdom and includes parallel obligations to those set forth by GDPR. While the Data Protection Act of 2018 in the United Kingdom that &#8220;implements&#8221; and complements the GDPR has achieved Royal Assent on May 23, 2018 and is now effective in the United Kingdom, it is unclear whether transfer of data from the EEA to the United Kingdom will remain lawful under the GDPR. The UK government has already determined that it considers all</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">27 EU and EEA member states to be adequate for the purposes of data protection, ensuring that data flows from the United Kingdom to the EU/EEA remain unaffected. In addition, a recent decision from the European Commission appears to deem the United Kingdom as being &#8220;essentially adequate&#8221; for purposes of data transfer from the EU to the United Kingdom, although this decision may be re-evaluated in the future. The United Kingdom and the United States also have agreed on a framework for personal data to be transferred between the United Kingdom and the United States, called the UK-U.S. Data Bridge. The UK-U.S. Data Bridge may be challenged in the future. Continuing uncertainty about these data transfers, including the possibility of future changes, may impact our business operations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are multiple privacy and data security laws that may impact our business activities in the United States. These laws are evolving and may increase both our obligations and our regulatory risks in the future. In the health care industry generally, under the federal HIPAA, HHS has issued regulations to protect the privacy and security of protected health information, or PHI, used or disclosed by covered entities including certain healthcare providers, health plans and healthcare clearinghouses. HIPAA also imposes certain obligations on the business associates of covered entities that obtain protected health information in providing services to or on behalf of covered entities. HIPAA may apply to us in certain circumstances and may also apply to our business partners in ways that may impact our relationships with them. Any clinical trials we conduct will be regulated by Subpart A of 45 CFR 46, also known as the Common Rule, which also includes specific privacy-related provisions. In addition to federal privacy regulations, there are a number of state laws governing confidentiality and security of health information that may be applicable to our business. In addition to possible federal civil and criminal penalties for HIPAA violations, state attorneys general are authorized to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorney&#8217;s fees and costs associated with pursuing federal civil actions. In addition, state attorneys general (along with private plaintiffs) have brought civil actions seeking injunctions and damages resulting from alleged violations of HIPAA&#8217;s privacy and security rules. State attorneys general also have authority to enforce state privacy and security laws. Moreover, new laws and regulations governing privacy and security may be adopted in the future as well.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to potential enforcement by the HHS, we could also be potentially subject to privacy enforcement from the FTC. The FTC has been particularly focused on the unpermitted processing of health and genetic data through its recent enforcement actions and is expanding the types of privacy violations that it interprets to be &#8220;unfair&#8221; under Section 5 of the FTC Act, as well as the types of activities it views to trigger the Health Breach Notification Rule (which the FTC also has the authority to enforce). The agency is also in the process of developing rules related to commercial surveillance and data security. We will need to account for the FTC&#8217;s evolving rules and guidance for proper privacy and data security practices in order to mitigate risk for a potential enforcement action, which may be costly. Finally, both the FTC and HHS&#8217;s enforcement priorities (as well as those of other federal regulators) may be impacted by the change in administration and new leadership. These shifts in enforcement priorities may also impact our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are also increased restrictions at the federal level relating to transferring sensitive data (including certain kinds of clinical data) outside of the United States to certain foreign countries. The DOJ recently finalized a rule implementing Executive Order 14117, which creates restrictions related to the transfer of sensitive US data to countries such as China. The &#8220;Preventing Access to Americans&#8217; Bulk Sensitive Personal Data and United States Government-Related Data by Countries of Concern&#8221; regulations establish a new regulatory regime that may have a significant impact in connection with the transfer of sensitive U.S. personal data to &#8220;countries of concern&#8221; (i.e., China (including Hong Kong and Macau), Cuba, Iran, North Korea, Russia, and Venezuela). This Rule prohibits (1) U.S. data brokers from licensing or otherwise transferring a wide variety of sensitive U.S. persons data to China (among other locations) and (2) all U.S. persons from knowingly engaging in any &#8220;covered data transaction&#8221; with &#8220;countries of concern&#8221; or &#8220;covered persons&#8221; involving access to bulk human genomic, epigenomic, proteomic, or transcriptomic data, or with human biospecimens from which such data can be derived. The DOJ</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Rule defines six categories of &#8220;sensitive personal data&#8221;: covered personal </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">104</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">identifiers, precise geolocation data, biometric identifiers, human genomic data, personal health data, and personal financial data. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, the Protecting Americans&#8217; Data from Foreign Adversaries Act, or PADFA, which also passed in 2025 and is now in effect, prohibits data brokers from selling, licensing, transferring, disclosing, trading, or providing access to &#8220;personally identifiable sensitive data&#8221; of Americans to foreign adversaries, namely China, Russia, Iran, and North Korea, or entities controlled by a foreign adversary. Although the DOJ Rule and the PADFA share a common purpose, the PADFA focuses more on categories of data rather than transactions. The Act includes 16 categories of &#8220;sensitive data,&#8221; including biometric information, precise geolocation information, and genetic information. Collectively, the DOJ Rule and the PADFA, as well as other similar provisions that may be passed in the future, may create both operational challenges and legal risks for our business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">New laws also are being considered at the state level. For example, the California Consumer Privacy Act, or CCPA&#8212;which went into effect on January 1, 2020&#8212;is creating similar risks and obligations as those created by GDPR, though the CCPA does currently exempt certain information collected as part of a clinical trial subject to the Federal Policy for the Protection of Human Subjects, known as the Common Rule. The CCPA also has been amended through a recent referendum in California that creates additional obligations beginning in 2023. In addition to California, at least eighteen other states have</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">passed comprehensive privacy laws similar to the CCPA. These laws are either in effect or will go into effect over the next few years. Like the CCPA, these laws create obligations related to the processing of personal information, as well as special obligations for the processing of &#8220;sensitive&#8221; data, which includes health data in some cases. Some of the provisions of these laws may apply to our business activities. There are also states that are strongly considering legislation that could</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">go into effect in 2026 and beyond. Congress has also been debating passing a federal privacy law. There are also states that are specifically regulating health information that may affect our business. For example, Washington state passed a health privacy law in 2023 that regulates the collection and sharing of health information, and the law also has a private right of action, which further increases the relevant compliance risk. Connecticut and Nevada have also passed similar laws regulating consumer health data, and more states are considering, such legislation. These laws may impact our business activities, including our identification of research subjects, relationships with business partners and ultimately the marketing and distribution of our products. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A broad range of legislative measures also have been introduced at the federal level. Accordingly, failure to comply with federal and state laws (both those currently in effect and future legislation) regarding privacy and security of personal information could expose us to fines and penalties under such laws. There also is the threat of consumer class actions related to these laws and the overall protection of personal data. Even if we are not determined to have violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, which could harm our reputation and our business. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Given the breadth and depth of changes in data protection obligations, preparing for and complying with these requirements is rigorous and time intensive and requires significant resources and a review of our technologies, systems and practices, as well as those of any third-party collaborators, service providers, contractors or consultants that process or transfer personal data collected in applicable jurisdictions. These changes in laws or regulations associated with the enhanced protection of certain types of sensitive data, such as healthcare data or other personal information from our clinical trials, could require us to change our business practices and put in place additional compliance mechanisms, may interrupt or delay our development, regulatory and commercialization activities and increase our cost of doing business, and could lead to government enforcement actions, private litigation and significant fines and penalties against us and could have a material adverse effect on our business, financial condition or results of operations.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Current and future legislation may increase the difficulty and cost for us and any collaborators to obtain marketing approval of and commercialize our product candidates and affect the prices we, or they, may obtain. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States and some foreign jurisdictions, there have been a number of legislative and regulatory changes and proposed changes regarding the healthcare system that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities and affect our ability to profitably sell any product candidates for which we obtain marketing approval. The pharmaceutical industry has </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">105</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">been a particular focus of these efforts and has been significantly affected by legislative initiatives. Current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we receive for any FDA approved product. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, or the MMA, changed the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for prescription drugs purchased through a pharmacy by the elderly and disabled and introduced a new reimbursement methodology based on average sales prices for physician-administered drugs. In addition, this statute provides authority for limiting the number of drugs that will be covered in any therapeutic class, subject to certain exceptions. Cost reduction initiatives and other provisions of this statute could decrease the coverage and price that we receive for any approved products. While the MMA applies only to drug benefits for Medicare beneficiaries, private payors often follow Medicare coverage policy and payment limitations in setting their own reimbursement rates. Therefore, any reduction in reimbursement that results from the MMA may result in a similar reduction in payments from private payors. In March 2010, the Patient Protection and Affordable Care Act was signed into law, as amended by the Health Care and Education Affordability Reconciliation Act, or collectively the ACA, which substantially changed the way healthcare is financed by both the government and private insurers. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, other legislative changes have been proposed and adopted since the ACA was enacted These changes include, the Budget Control Act of 2011, which, among other things, led to aggregate reductions to Medicare payments to providers of up to 2% per fiscal year, which will remain in effect through 2031. Under current legislation, the actual reductions in Medicare payments may vary up to 4%. The Consolidated Appropriations Act, which was signed into law in December 2022, made several changes to sequestration of the Medicare program. Section 1001 of the Consolidated Appropriations Act delays the 4% Statutory Pay-As-You-Go Act of 2010 (PAYGO) sequester for two years, through the end of calendar year 2024. Triggered by enactment of the American Rescue Plan Act of 2021, the 4% cut to the Medicare program would have taken effect in January 2023. The Consolidated Appropriations Act&#8217;s health care offset title includes Section 4163, which extends the 2% Budget Control Act of 2011 Medicare sequester for six months into fiscal year 2032 and lowers the payment reduction percentages in fiscal years 2030 and 2031. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since enactment of the ACA, there have been and continue to be, numerous legal challenges and Congressional actions to repeal and replace provisions of the law. Litigation and legislation over the ACA are likely to continue, with unpredictable and uncertain results. For example, with adoption of the OBBB Act on July 4, 2025, Congress further restricted certain provisions in the ACA by eliminating enhanced premium tax credits, halting provisional coverage, removing repayment caps, reducing subsidies for lawfully present migrants, and tightening enrollment verification requirements. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the EU, on December 13, 2021, Regulation No 2021/2282 on Health Technology Assessment, or HTA, amending Directive 2011/24/EU, was adopted, or the HTA Regulation. The HTA Regulation began to apply in January 2025 for oncology and advanced therapy medicinal products, with all new medicinal products set to be incorporated from 2030 onwards. The HTA Regulation intends to boost cooperation among EU member states in assessing health technologies, including new medicinal products as well as certain high-risk medical devices, and provide the basis for cooperation at the EU level for joint clinical assessments in these areas. It foresees a joint clinical assessment, or JCA, to be conducted by EU member states with one uniform clinical assessment of the new medicinal product and will serve as a basis for national HTA procedures of individual EU member states. While individual EU member states will continue to be responsible for assessing non-clinical (e.g., economic, social, ethical) aspects of health technology, and making decisions on pricing and reimbursement, a negative JCA can have a substantial detrimental effect on all pricing and reimbursement in all EU member states.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">106</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that these healthcare reforms, as well as other healthcare reform measures that may be adopted in the future, may result in additional reductions in Medicare and other healthcare funding, more rigorous coverage criteria, new payment methodologies and additional downward pressure on the price that we receive for any approved product and/or the level of reimbursement physicians receive for administering any approved product we might bring to market. Reductions in reimbursement levels may negatively impact the prices we receive or the frequency with which our products are prescribed or administered. Any reduction in reimbursement from Medicare or other government programs may result in a similar reduction in payments from private payors. Accordingly, such reforms, if enacted, could have an adverse effect on anticipated revenue from product candidates that we may successfully develop and for which we may obtain marketing approval and may affect our overall financial condition and ability to develop or commercialize product candidates. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The prices of prescription pharmaceuticals in the United States and foreign jurisdictions are subject to considerable legislative and executive actions and could impact the prices we obtain for our drug products, if and when approved.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The prices of prescription pharmaceuticals have also been the subject of considerable discussion in the United States. There have been several recent U.S. congressional inquiries, as well as proposed and enacted state and federal legislation designed to, among other things, bring more transparency to pharmaceutical pricing, review the relationship between pricing and manufacturer patient programs, and reduce the costs of pharmaceuticals under Medicare and Medicaid.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in October 2020, HHS and the FDA published a final rule allowing states and other entities to develop a Section 804 Importation Program to import certain prescription products from Canada into the United States. That regulation was challenged in a lawsuit by the Pharmaceutical Research and Manufacturers of America, or PhRMA, but the case was dismissed by a federal district court in February 2023 after the court found that PhRMA did not have standing to sue HHS. Several states have passed laws allowing for the importation of drugs from Canada. On January 5, 2024, the FDA approved Florida&#8217;s plan for Canadian drug importation. That state now has authority to import certain drugs from Canada for a period of two years once certain conditions are met. Florida will first need to submit a pre-import request for each drug selected for importation, which must be approved by the FDA. The state will also need to relabel the drugs and perform quality testing of the products to meet FDA standards. On May 21, 2025, the FDA announced that it would offer individual states the opportunity to submit a draft proposal for pre-review and meet with the agency to obtain initial feedback from FDA prior to formally submitting their Section 804 importation program, or SIP, proposal. The intent of these meetings is to assist states in developing their proposals by further clarifying requirements, enhancing the quality of proposals submitted to the agency and ultimately shortening the review timeline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, HHS finalized a regulation removing safe harbor protection for price reductions from pharmaceutical manufacturers to plan sponsors under Part D, either directly or through pharmacy benefit managers, unless the price reduction is required by law. The final rule would also eliminate the current safe harbor for Medicare drug rebates and create new safe harbors for beneficiary point-of-sale discounts and pharmacy benefit manager service fees. It originally was set to go into effect on January 1, 2022, but with passage of the IRA has been delayed by Congress to January 1, 2032.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On August 16, 2022, the IRA was signed into law. The legislation has implications for Medicare Part D, which is a program available to individuals who are entitled to Medicare Part A or enrolled in Medicare Part B to give them the option of enrolling in a plan providing outpatient prescription drug coverage. Among other things, the IRA requires manufacturers of certain drugs to engage in price negotiations with Medicare, with prices that can be negotiated subject to a cap; imposes rebates under Medicare Part B and Medicare Part D to penalize price increases that outpace inflation (first due in 2023); and replaces the Part D coverage gap discount program with a new discounting program (which began in 2025). The IRA permits the Secretary of HHS to implement many of these provisions through guidance, as opposed to regulation, for the initial years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, with respect to price negotiations, Congress authorized Medicare to negotiate lower prices for certain costly single-source drug and biologic products that do not have competing generics or biosimilars and are reimbursed under Medicare Part B and Part D. CMS has published the negotiated prices for the initial ten drugs, which will first be effective in 2026, and has published the list of the next 15 drugs that will have negotiated prices go into effect in 2027. Negotiated prices for 15 additional Part B or Part D drugs will go into </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">107</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">effect in 2028, and negotiated prices for 20 additional Part B or Part D drugs will go into effect in 2029 and beyond. This provision applies to drug products that have been approved for at least 9 years and biologics that have been licensed for 13 years. Drugs and biologics that have been approved for a single rare disease or condition were originally categorically excluded from price negotiation. With passage of the One Big Beautiful Bill Act on July 3, 2025, which was signed into law on July 4, 2025, Congress extended this exemption to drugs and biologics with multiple orphan drug designations. Nonetheless, since CMS may establish a maximum price for these products in price negotiations, we would be fully at risk of government action if our products are the subject of Medicare price negotiations. Moreover, given the risk that could be the case, these provisions of the IRA may also further heighten the risk that we would not be able to achieve the expected return on our drug products or full value of our patents protecting our products if prices are set after such products have been on the market for nine years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, the legislation subjects drug manufacturers to civil monetary penalties and a potential excise tax for failing to comply with the legislation by offering a price that is not equal to or less than the negotiated &#8220;maximum fair price&#8221; under the law or for taking price increases that exceed inflation. The legislation also requires manufacturers to pay rebates for drugs in Medicare Part D whose price increases exceed inflation. The new law also caps Medicare beneficiaries' out-of-pocket drug costs at an estimated $4,000 a year in 2024 and, thereafter beginning in 2025, at $2,000 a year.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On June 6, 2023, Merck &amp; Co., Inc., filed a lawsuit against HHS and CMS asserting that, among other things, the IRA&#8217;s Drug Price Negotiation Program for Medicare constitutes an uncompensated taking in violation of the Fifth Amendment of the U.S. Constitution. Subsequently, other parties, including the U.S. Chamber of Commerce, or Chamber of Commerce, Bristol Myers Squibb Company, the PhRMA, Astellas Pharma US, Inc., Novo Nordisk Inc., Janssen Pharmaceuticals, Inc., Novartis Pharmaceutical Corporation, AstraZeneca L.P. and Boehringer Ingelheim Pharmaceuticals, Inc. also filed lawsuits in various courts with similar constitutional claims against HHS and CMS. HHS has generally won the substantive disputes in these cases or succeeded in getting claims dismissed for lack of standing. Most of these cases are now on appeal. On October 30, 2024, the U.S. Court of Appeals for the Third Circuit heard oral arguments in three of these cases. In April 2025, the U.S. Court of Appeals for the Second Circuit and the U.S. Court of Appeals for the Third Circuit heard arguments in an additional three cases. On May 8, 2025, the U.S. Court of Appeals for the Third Circuit rejected AstraZeneca L.P.&#8217;s challenge to the Medicare price negotiation program, finding that the program did not violate the company&#8217;s due process rights under the Constitution since there is no protected property interest in selling goods to Medicare beneficiaries at a price higher than what the government is willing to pay in reimbursement. Litigation involving these and other provisions of the IRA will continue with unpredictable and uncertain results.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, while it is currently unclear how the IRA will be effectuated, we cannot predict with certainty what impact any federal or state health reforms will have on us, but such changes could impose new or more stringent regulatory requirements on our activities or result in reduced reimbursement for our products, any of which could adversely affect our business, results of operations and financial condition.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On April 15, 2025, the President issued an executive order that directs HHS to take steps to reduce the prices of pharmaceutical products. The new executive order repeats many of the proposals advanced during the current President&#8217;s first Administration, including directing the FDA to streamline and improve its existing drug importation program so as to make it easier for states to obtain approval without sacrificing the safety or quality of drug products. Other provisions of the executive order relate to the 340B program. Specifically, one provision calls on the Secretary of HHS to determine the hospital acquisition cost for covered outpatient drugs at hospital outpatient departments and to consider and propose any appropriate adjustments for Medicare payment. The other provision directs HHS to condition grant funding to certain health centers on those centers passing through the 340B discounts they receive on insulin and injectable epinephrine products to patients who meet certain requirements. With respect to the IRA&#8217;s Medicare drug pricing program, the executive order, among other things, calls for alignment in &#8220;the treatment of small molecule prescription drugs with that of biological products, ending the distortion that undermines relative investment in small molecule prescription drugs, coupled with other reforms to prevent any increase in overall costs to Medicare and its beneficiaries.&#8221; </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Further, on May 12, 2025, the President issued an additional executive order calling on pharmaceutical manufacturers to voluntarily reduce the prices of medicines in the United States. The executive order directs the Secretary of HHS to communicate MFN price targets to pharmaceutical manufacturers to bring prices in line with comparably developed nations. The executive order further provides that if such actions do not lower the </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">108</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">costs of pharmaceuticals, the Secretary of HHS would pursue other actions, including proposing a rulemaking that imposes MFN pricing in the United States. Subsequently, on May 20, 2025, HHS indicated that the proposed MFN pricing will apply only to brand products without generic or biosimilar competition and the reference foreign countries will include only those in which the branded product similarly does not have generic or biosimilar competition. Second, HHS indicated that the MFN target price will be the lowest price in a country that is a member of the Organization for Economic Co-operation and Development, or OECD, with a gross domestic product, or GDP, per capita of at least 60% of the U.S. GDP per capita. Based on previous estimates, there are likely at least 22 OECD countries that would satisfy this criterion. The implications of these actions remain unclear and are likely to result in litigation if the administration pursues an MFN regulatory pricing requirement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">More recently, on July 31, 2025, the President issued letters to 17 pharmaceutical companies reiterating the requirements of the May 12, 2025 Executive Order and demanding that such companies extend MFN pricing to Medicaid patients, guarantee MFN pricing for newly launched drug products, return increased revenues abroad to American patients and provide for direct purchasing at MFN pricing. The letters also urged these companies to stipulate that they will not offer other developed nations better prices for new drugs than the prices offered for such products in the U.S. The letters called for engagement with the FDA and CMS within 60 days to implement these changes and threatened to use &#8220;every tool in our arsenal&#8221; to address what the letter characterized as &#8220;abusive drug pricing practices.&#8221; Since that time, virtually all of these pharmaceutical companies have entered into agreements with the administration to provide for lower prices on certain pharmaceuticals. On February 5, 2026, President Trump launched TrumpRx.gov, a website that directs individuals to pharmaceutical manufacturer websites that are offering price discounts based on the administration&#8217;s pricing agreements with pharmaceutical manufacturers.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On December 23, 2025, CMS, through its Center for Medicare and Medicaid Innovation, proposed two five-year pilot programs to implement a &#8220;reference pricing&#8221; regime for drugs paid for under Medicare for 25% of covered beneficiaries. The programs are referred to as the Global Benchmark for Efficient Drug Pricing Model for Medicare Part B drugs, referred to as GLOBE, and the Guarding U.S. Medicare Against Rising Drug Costs for Medicare Part D drugs, referred to as GUARD. Under the proposed pilot programs, a manufacturer would owe rebates to Medicare if prices for their drugs exceeded the prices paid by other economically comparable reference countries, defined in the proposed regulations as OECD countries with a GDP of $400 billion and a per capita GDP that is at least 60% of the U.S. per capita GDP (an initial list of 19 reference countries is included in the proposed rule). Comments are due on the proposed pilot program rules on or before February 23, 2026, and the pilot programs are proposed to go into effect beginning October 1, 2026.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the state level, individual states are increasingly aggressive in passing legislation and implementing regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement constraints, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. This is increasingly true with respect to products approved pursuant to the accelerated approval pathway. State Medicaid programs and other payers are developing strategies and implementing significant coverage barriers, or refusing to cover these products outright, arguing that accelerated approval drugs have insufficient or limited evidence despite meeting the FDA&#8217;s standards for accelerated approval. In addition, health care organizations and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other health care programs. These measures could reduce the ultimate demand for our products, once approved, or put pressure on our product pricing. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our product candidates or additional pricing pressures.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In other jurisdictions, particularly in the EU, the pricing of prescription pharmaceuticals is subject to governmental control. In these countries, pricing negotiations with governmental authorities can take considerable time after the receipt of marketing approval for a drug. In addition, there can be considerable pressure by governments and other stakeholders on prices and reimbursement levels, including as part of cost containment measures. Political, economic and regulatory developments may further complicate pricing negotiations, and pricing negotiations may continue after reimbursement has been obtained. Reference pricing used by various EU member states and parallel distribution, or arbitrage between low-priced and high-priced </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">109</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">member states, can further reduce prices, and in certain instances render commercialization in certain markets infeasible or disadvantageous from a financial perspective. To obtain reimbursement or pricing approval in some countries, we, or our collaborators, may be required to conduct a clinical trial that compares the cost-effectiveness of our drug to other available therapies. If reimbursement of our drugs is unavailable or limited in scope or amount, or if pricing is set at unsatisfactory levels, the commercial launch of our products and/or product candidates could be delayed, possibly for lengthy periods of time, we or our collaborators may not launch at all in a particular country, we may not be able to recoup our investment in one or more product candidates, and there could be a material adverse effect on our business.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We are subject to anti-corruption laws, as well as export control laws, customs laws, sanctions laws and other laws governing our operations. If we fail to comply with these laws, we could be subject to civil or criminal penalties, other remedial measures and legal expenses, which could adversely affect our business, results of operations and financial condition. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operations are subject to anti-corruption laws, including the FCPA, the Bribery Act, and other anticorruption laws that apply in countries where we do business and may do business in the future. The FCPA, the Bribery Act, and these other laws generally prohibit us, our officers and our employees and intermediaries from bribing, being bribed or making other prohibited payments to government officials or other persons to obtain or retain business or gain some other business advantage. We may in the future operate in jurisdictions that pose a high risk of potential FCPA or Bribery Act violations, and we may participate in collaborations and relationships with third parties whose actions could potentially subject us to liability under the FCPA, the Bribery Act, or local anti-corruption laws. In addition, we cannot predict the nature, scope or effect of future regulatory requirements to which our international operations might be subject or the manner in which existing laws might be administered or interpreted. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also subject to other laws and regulations governing our international operations, including regulations administered by the governments of the United States, United Kingdom, and authorities in the European Union, including applicable export control regulations, economic sanctions on countries and persons, customs requirements and currency exchange regulations, which we collectively refer to as Trade Control Laws. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There is no assurance that we will be completely effective in ensuring our compliance with all applicable anti-corruption laws, including the FCPA, the Bribery Act, or other legal requirements, including Trade Control Laws. If we are not in compliance with the FCPA, the Bribery Act, and other anti-corruption laws or Trade Control Laws, we may be subject to criminal and civil penalties, disgorgement and other sanctions and remedial measures, and legal expenses, which could have an adverse impact on our business, financial condition, results of operations and liquidity. The SEC also may suspend or bar issuers from trading securities on U.S. exchanges, including The Nasdaq Stock Market, for violations of the FCPA&#8217;s accounting provisions. Likewise, any investigation of any potential violations of the FCPA, the Bribery Act, other anti-corruption laws or Trade Control Laws by U.S., U.K. or other authorities could also have an adverse impact on our reputation, our business, results of operations and financial condition. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could significantly harm our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Although we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We maintain workers&#8217; compensation insurance to cover costs and expenses we may incur due to injuries to our employees resulting from the use of hazardous materials, but this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us. In addition, we may incur substantial costs in order to comply with </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">110</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">current or future environmental, health and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts, which could adversely affect our business, financial condition, results of operations or prospects. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Social media platforms and AI-based platforms present new risks and challenges to our business.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As social media continues to expand, it also presents us with new risks and challenges. Social media is increasingly being used to communicate information about us, our programs and the diseases our product candidates are being developed to treat. Social media practices in the biopharmaceutical industry are evolving, creating uncertainty and risk of noncompliance with regulations applicable to our business. For example, patients may use social media platforms to comment on the effectiveness of, or adverse experiences with, a product or a product candidate, which could result in reporting obligations or other consequences. Further, the accidental or intentional disclosure of non-public information by our workforce or others through media channels could lead to information loss. In addition, there is a risk of inappropriate disclosure of sensitive information or negative or inaccurate posts or comments about us, our products, or our product candidates on any social media platform. The nature of social media prevents us from having real-time control over postings about us on social media. We may not be able to reverse damage to our reputation from negative publicity or adverse information posted on social media platforms or similar mediums. If any of these events were to occur or we otherwise fail to comply with applicable regulations, we could incur liability, face restrictive regulatory actions or incur other harm to our business including quick and irreversible damage to our reputation, brand image and goodwill.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Additionally, AI-based platforms, including generative AI, are increasingly being used in the biotechnology and biopharmaceutical industry, including by us. The use of AI platforms by our employees or third parties on which we rely, including our vendors, suppliers and contractors, with access to our proprietary and confidential information, including trade secrets, may continue to increase and may lead to the unauthorized release of such information, in contravention of our internal policies, data protection laws, and other applicable or contractual requirements. The misuse of AI-based platforms or solutions may give rise to liability, lead to the loss of trade secrets or other intellectual property, result in reputational harm, or lead to outcomes with unintended biases or other consequences. The misuse of AI-based platforms or solutions could also result in unauthorized access and use of personal data of our employees, clinical trial participants, collaborators or other third parties. Any of these events could have a material adverse effect on our business, prospects, operating results, and financial condition and could adversely affect the price of our common stock.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_852"></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Employee Matters and Managing Growth </span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our future success depends on our ability to retain key employees, consultants and advisors, as well as our ability to attract, train, retain and motivate qualified personnel.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our ability to compete in the highly competitive biopharmaceuticals industry depends upon our ability to attract, retain and motivate highly skilled and experienced personnel with scientific, medical, regulatory, manufacturing and management skills and experience. Although we have employment agreements with each of our executive officers, each of them may terminate their employment with us at any time. We do not maintain &#8220;key person&#8221; insurance for any of our executives or other employees.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Recruiting and retaining qualified scientific, clinical, manufacturing, sales, marketing and market access personnel has been and will continue to be critical to our success. The loss of the services of our executive officers or other key employees could impede the achievement of our research, development and commercialization objectives and seriously harm our ability to successfully implement our business strategy. For example, in July 2025, we announced that John Houston, Ph.D., our Chairperson, President and Chief Executive Officer notified us of his plans to retire from his role as our President and Chief Executive Officer following the search for, and the appointment of, a new Chief Executive Officer. We announced in February 2026 the onboarding of our new Chief Executive Officer and President, Randy Teel, Ph.D. Dr. Teel was also appointed as a member of our board of directors, and Briggs Morrison, M.D., our lead independent director, was appointed as chair of our board of directors. Dr. Houston remains as board member. Any significant leadership change or executive management transition, such as our transition to a new president and chief executive </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">111</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">officer, involves inherent risk and can be difficult to manage. Initially, such changes could be disruptive to our daily operations or relationships with employees and collaborators, make it more difficult to hire and retain key employees or impact our public or market perception, any of which could have a negative impact on our business or share price. In addition, although Dr. Teel was our Chief Business Officer and Dr. Houston remains on the board of directors, management transitions inherently cause some loss of institutional knowledge, which could negatively affect strategy and operation execution during the transitional phase. Management transitions may also create uncertainty and involve a diversion of resources and management attention, which could negatively impact our ability to operate effectively or execute our strategies.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We may also need to grow the size of our organization in the future based on how our organization evolves. Managing future growth will involve implementation and improvement of our managerial, operational and financial systems and procedures and recruitment and training of additional qualified personnel. Any inability to manage growth could delay the execution of our business plans or disrupt our operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, attracting or replacing executive officers and key employees, consultants and advisors may be difficult and may take an extended period of time because of the limited number of individuals in our industry with the breadth of skills and experience required to successfully develop, gain marketing approval of and commercialize products. For example, we may have difficulty identifying and attracting a qualified candidate to serve as our new chief executive officer which may materially impact our corporate strategy and business.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our April 2025 and September 2025 workforce reductions could also harm our ability to attract and retain qualified management, scientific, clinical, manufacturing and sales and marketing personnel who are critical to our business. In addition, we may not be able to retain our existing employees or hire new employees quickly enough to meet our needs. At the same time, we may face high turnover, requiring us to expend time and resources to source, train and integrate new employees.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we offer remote and hybrid work arrangements, allowing us to seek talent from outside our New Haven headquarters area, we still may not be able to attract or retain qualified personnel in the future due to the intense competition for a limited number of qualified personnel among biopharmaceutical companies. Many of the other biopharmaceutical companies against which we compete have greater financial and other resources, different risk profiles and a longer history in the industry than we do. Our competitors may provide higher compensation, more diverse opportunities and/or better opportunities for career advancement. We also experience competition for the hiring of scientific and clinical personnel from universities and research institutions. Any or all of these competing factors may limit our ability to continue to attract and retain high quality personnel, which could negatively affect our ability to successfully develop and commercialize our investigational products and to grow our business and operations as currently contemplated.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we rely on consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategies. These consultants and advisors may be employed by employers other than us and may have commitments under consulting or advisory contracts with other entities that may limit their availability to us. If we are unable to continue to attract, train, retain and motivate high quality personnel, our ability to pursue our corporate growth strategy will be limited.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our internal computer systems and those of our collaborators, CROs, CDMOs, contractors, consultants and other third parties are vulnerable to cyber attacks, cyber intrusions and security breaches, which could not only materially disrupt our business operations and result in the loss of confidential information, but could also damage the integrity of our clinical trials, impact our regulatory filings, compromise our ability to protect our intellectual property, and subject us to regulatory actions that could result in significant fines or other penalties. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our internal computer systems and those of any collaborators, CROs, CDMOs, contractors, consultants or other third parties that we work with, are vulnerable to damage from computer viruses, unauthorized access, natural disasters, terrorism, war and telecommunication and electrical failures. Such systems are also vulnerable to service interruptions or to security breaches from inadvertent or intentional actions by our employees, third-party vendors and/or collaborators and other business partners, or from cyber-attacks by malicious third parties. In recent years, cyber-attacks have increased in their frequency, sophistication and intensity, and have become increasingly difficult, time co</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nsuming and costly to detect and we have experienced certain attacks, though minor, related to third-party vendors. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Cyber-attacks could include the deployment of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">112</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">harmful malware, ransomware, denial-of-service attacks, unauthorized access to or deletion of files, social engineering and other means to affect service reliability and threaten the confidentiality, integrity and availability of information. Cyber-attacks also could include phishing attempts or e-mail fraud to cause payments or information to be transmitted to an unintended recipient. These types of incidents continue to be prevalent and pervasive across industries, including in our industry. In addition, we expect information security risks to continue to increase due to the proliferation of new technologies, including AI, and the increased sophistication and activities of organized crime, hackers, terrorists and other external parties, including foreign state actors.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are increasingly dependent on information technology systems and infrastructure, including mobile technologies, to operate our business. In the ordinary course of our business, we collect, process, store and transmit large amounts of confidential information, including intellectual property, proprietary business information and personal information. It is critical that we do so in a secure manner to maintain the confidentiality and integrity of such information. The size and complexity of our information technology systems, and those of third-party vendors with whom we contract, and the volume of data we retain, make such systems potentially vulnerable to breakdown, malicious intrusion, security breaches, ransomware, phishing, and other cyber-attacks.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While we have not experienced any material system failure, accident or security breach to date, if such an event were to occur, or if we were unable to implement satisfactory remedial measures, it could result in diversion of management's attention and a material disruption of our development programs and our business operations, whether due to a loss of our trade secrets or other proprietary information or other similar disruptions. For example, the loss of clinical trial data from completed or future clinical trials could result in delays in our marketing approval efforts and significantly increase our costs to recover or reproduce the data. To the extent that any disruption or security breach were to result in a loss of, or damage to, our data or applications, or inappropriate disclosure of confidential or proprietary information, we could incur liability, our competitive position could be materially harmed and the further development and commercialization of our product candidates could be delayed. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our employees, independent contractors, vendors, principal investigators, CROs, CMOs, CDMOs, and consultants may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements, privacy laws and insider trading laws, which could materially harm our business. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to the risk that our employees, independent contractors, vendors, principal investigators, CROs, CMOs, CDMOs, and consultants may engage in fraudulent conduct or other illegal activity. Misconduct by these parties could include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">intentional, reckless or negligent conduct or disclosure of unauthorized activities to us that violate the regulations of the FDA or similar foreign regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">healthcare fraud and abuse laws and regulations in the United States and in other jurisdictions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">violations of U.S. federal securities laws, including those related to trading in our common stock;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">violations of applicable US and international privacy laws; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">failures to report financial information or data accurately. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In particular, sales, marketing and business arrangements in the healthcare industry are subject to extensive laws and regulations intended to prevent fraud, misconduct, kickbacks, self-dealing and other abusive practices. These laws and regulations regulate a wide range of pricing, discounting, marketing and promotion, sales commission, customer incentive programs and other business arrangements. Other forms of misconduct could involve the improper use of information obtained in the course of clinical trials or creating fraudulent data in our preclinical studies or clinical trials, which could, among other things, result in regulatory sanctions and cause serious harm to our reputation. We have adopted a code of conduct and implement other internal controls applicable to all of our employees, but it is not always possible to identify and deter misconduct by employees and other third parties. In addition, the precautions we take to detect and prevent this activity may not be effective in controlling unknown or unmanaged risks or losses or in protecting us from governmental investigations or other actions or lawsuits stemming from a failure to comply with these laws or regulations. Additionally, we are subject to the risk that a person could allege such fraud or other misconduct, even if none occurred. If any legal, regulatory or administrative actions or proceedings are instituted against us, and we are </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">113</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">not successful in defending ourselves or asserting our rights, such actions could have a significant impact on our business, including the imposition of civil, criminal and administrative penalties, damages, monetary fines, possible exclusion from participation in Medicare, Medicaid and other federal healthcare programs, contractual damages, reputational harm, diversion of management attention, general costs of litigation or proceedings, diminished profits and future earnings, and curtailment of our operations, any of which could adversely affect our ability to operate our business and our results of operations. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_875"></div><div style="margin-top:18pt;text-align:center;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Risks Related to Our Common Stock</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">The price of our common stock is volatile and may fluctuate substantially, which could result in the loss of all or part of our stockholders&#8217; investment. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and likely will continue to be volatile. The stock market in general and the market for smaller biopharmaceutical companies in particular have experienced extreme volatility that has often been unrelated to the operating performance of particular companies. The market price for our common stock may be influenced by many factors, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the degree of success of any competitive products or technologies; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">results of or developments in preclinical studies and clinical trials of our product candidates or those of our competitors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">regulatory or legal developments in the United States and other countries; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">developments or disputes concerning patent applications, issued patents or other proprietary rights; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the recruitment or departure of key personnel; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the level of expenses related to any of our product candidates or clinical development programs; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the results of our efforts to discover, develop, acquire or in-license additional technologies or product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">variations in our financial results or those of companies that are perceived to be similar to us; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">changes in the structure of healthcare payment systems in the United States and other jurisdictions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">market conditions in the pharmaceutical and biotechnology sectors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">general economic, industry and market conditions, including geopolitical conflicts, inflation and high interest rates; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the other factors described in this &#8220;Risk Factors&#8221; section. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If any of the foregoing factors were to occur, or if our operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We may be subject to securities litigation, which is expensive and could divert management attention. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our stock price has been and likely will continue to be volatile. In the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation and shareholder derivative litigation. Such litigation, if instituted against us, whether successful or not, could cause us to incur substantial costs to defend such claims and divert management&#8217;s attention and resources, which could seriously harm our business, financial condition, results of operations and prospects.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our executive officers, directors and principal stockholders, if they choose to act together, have the ability to significantly influence or control all matters submitted to stockholders for approval. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our executive officers and directors, combined with our stockholders who own more than 5% of our outstanding common stock, in the aggregate, beneficially own shares representing approximately 34% of our capital stock. As a result, if these stockholders were to choose to act together, they would be able to significantly </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">114</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">influence or control all matters submitted to our stockholders for approval, as well as our management and affairs. For example, these persons, if they choose to act together, could significantly influence or control the election of directors and approval of any merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership control may: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">delay, defer or prevent a change in control; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">entrench our management and the board of directors; or </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">impede a merger, consolidation, takeover or other business combination involving us that other stockholders may desire. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Provisions in our organizational documents and under Delaware law may have anti-takeover effects that could discourage an acquisition of us by others, even if an acquisition would be beneficial to our stockholders, and may prevent attempts by our stockholders to replace or remove our current management.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Provisions in our certificate of incorporation and our bylaws may discourage, delay or prevent a merger, acquisition or other change in control of our company that stockholders may consider favorable, including transactions in which stockholders might otherwise receive a premium for their shares. These provisions could also limit the price that investors might be willing to pay in the future for shares of our common stock, thereby depressing the market price of our common stock. In addition, because our board of directors is responsible for appointing the members of our management team, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors. Among other things, these provisions: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide for a classified board of directors such that only one of three classes of directors is elected each year; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">allow the authorized number of our directors to be changed only by resolution of our board of directors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit the manner in which stockholders can remove directors from our board of directors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">provide for advance notice requirements for stockholder proposals that can be acted on at stockholder meetings and nominations to our board of directors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require that stockholder actions must be effected at a duly called stockholder meeting and prohibit actions by our stockholders by written consent; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">limit who may call stockholder meetings; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">authorize our board of directors to issue "blank check" preferred stock, which could be issued without stockholder approval, may contain voting, liquidation, dividend and other rights superior to our common stock, and could be used to institute a &#8220;poison pill&#8221; that would work to dilute the stock ownership of a potential hostile acquirer, effectively preventing acquisitions that have not been approved by our board of directors; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">require the approval of the holders of at least 75% of the votes that all our stockholders would be entitled to cast to amend or repeal specified provisions of our charter or bylaws. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Moreover, because we are incorporated in Delaware, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, which prohibits a person who owns in excess of 15% of our outstanding voting stock from merging or combining with us for a period of three years after the date of the transaction in which the person acquired in excess of 15% of our outstanding voting stock, unless the merger or combination is approved in a prescribed manner. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If securities or industry analysts do not publish research or reports about our business, or if they issue an adverse or misleading opinion regarding our stock, our stock price and trading volume could decline. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The trading market for our common stock is influenced by the research and reports that industry or securities analysts publish about us or our business. If any of the analysts who cover us issue an adverse or misleading opinion regarding us, our business model, our intellectual property or our stock performance, or if </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">115</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">our trials or operating results fail to meet the expectations of analysts, our stock price will likely decline. If one or more of these analysts cease coverage of us or fail to publish reports on us regularly, we could lose visibility in the financial markets, which in turn could cause our stock price or trading volume to decline.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">If a significant portion of our total outstanding shares are sold into the market, the market price of our common stock could drop significantly, even if our business is doing well. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Most of our outstanding common stock can be traded without restriction at any time. As such, sales of a substantial number of shares of our common stock in the public market could occur at any time. These sales, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have a significant number of shares that are subject to outstanding options and restricted stock units, and in the future we may issue additional options, restricted stock units, or other derivative securities convertible into our common stock under our equity compensation plans. The exercise or vesting of any such options, restricted stock units, or other derivative securities, and the subsequent sale of the underlying common stock, could cause a further decline in our stock price. These sales also might make it difficult for us to sell equity securities in the future at a time and at a price that we deem appropriate. Such sales of our common stock could result in higher than average trading volume and may cause the market price for our common stock to decline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We currently have on file with the SEC a universal shelf registration statement on Form S-3 which allows us to offer and sell registered common stock, preferred stock, debt securities, depository shares, units and/or warrants from time to time pursuant to one or more offerings at prices and terms to be determined at the time of sale. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, we entered into an Equity Distribution Agreement with Piper Sandler &amp; Company, or Piper Sandler, and Cantor Fitzgerald &amp; Co., or Cantor, as agents, pursuant to which we sold </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1,449,275</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of common stock in at-the-market offerings, resulting in net proceeds of approximately $36.0&#160;million.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we amended and restated the Equity Distribution Agreement with Piper Sandler and Cantor, pursuant to which we may offer and sell from time to time, through the agents, up to an additional approximately </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$262.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the common stock registered under our universal shelf registration statement pursuant to one or more &#8220;at-the-market&#8221; offerings. During the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, since the amendment and restatement of the agreement, no shares were issued under this agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Sales of substantial amounts of shares of our common stock or other securities by our stockholders under our universal shelf registration statement, including pursuant to our "at-the-market" offering program, or otherwise could also dilute our stockholders.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">We will continue to incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to any new compliance initiatives and corporate governance practices. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a public company, we incur significant legal, accounting and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act of 2002, or Sarbanes-Oxley, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of The Nasdaq Global Select Market and other applicable securities rules and regulations, including those promulgated by the SEC, impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. Moreover, we incur significant legal and financial compliance costs as a result of these rules and regulations, and these rules and regulations have made some activities more time-consuming and costly. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to Section 404 of Sarbanes-Oxley, or Section 404, we are required to furnish a report by our management on our internal control over financial reporting. To achieve compliance with Section 404, we are engaged in a process to document and evaluate our internal control over financial reporting and internal controls, which is both costly and challenging. In this regard, we will need to continue to dedicate internal resources, potentially engage outside consultants and carry out a detailed work plan to assess and document </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">116</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the adequacy of internal control over financial reporting, continue steps to improve control processes as appropriate, validate through testing that controls are functioning as documented and implement a continuous reporting and improvement process for internal control over financial reporting. Despite our efforts, there is a risk that we will not be able to conclude that our internal control over financial reporting is effective as required by Section 404. If we identify one or more material weaknesses, it could result in harm to our reputation or an adverse reaction in the financial markets and it could restrict our future access to the capital markets due to a loss of confidence in the reliability of our consolidated financial statements which would materially harm our business. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware will be the exclusive forum for substantially all disputes between us and our stockholders. Our certificate of incorporation further provides that the federal district courts of the United States are the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. These choice of forum provisions could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees or other stockholders. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our certificate of incorporation provides that the Court of Chancery of the State of Delaware is the exclusive forum for any derivative action or proceeding brought on our behalf, any action asserting a breach of fiduciary duty owed by our directors, officers, other employees or stockholders to the company or our stockholders, any action asserting a claim against us arising pursuant to the Delaware General Corporation Law or as to which the Delaware General Corporation Law confers jurisdiction on the Court of Chancery of the State of Delaware, or any action asserting a claim arising pursuant to our certificate of incorporation or our bylaws or governed by the internal affairs doctrine. Our certificate of incorporation further provides that, unless we consent in writing to the selection of an alternative forum, the federal district courts of the United States shall, to the fullest extent permitted by law, be the sole and exclusive forum for the resolution of any complaint asserting a cause of action arising under the Securities Act of 1933, as amended. These choice of forum provisions may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that such stockholder finds favorable for disputes with us or our directors, officers, other employees or other stockholders, which may discourage such lawsuits against us and our directors, officers, other employees or other stockholders. Alternatively, if a court were to find this provision in our certificate of incorporation to be inapplicable or unenforceable in an action, we may incur additional costs associated with resolving such action in other jurisdictions, which could adversely affect our business and financial condition. Neither of these choice of forum provisions would affect suits brought to enforce any liability or duty created by the Exchange Act or the rules and regulations thereunder, jurisdiction over which is exclusively vested by statute in the United States federal courts, or any other claim for which United States federal courts have exclusive jurisdiction.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Because we have never paid and do not anticipate paying any cash dividends on our capital stock in the foreseeable future, capital appreciation, if any, and any cash expended via our share repurchase program, will be our stockholders&#8217; sole source of gain. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our capital stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business, other than any cash we have expended with respect to our share repurchase program. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors. As a result, capital appreciation, if any, of our common stock and any cash we have expended via our share repurchase program will be our stockholders&#8217; sole source of gain for the foreseeable future. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_22"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1B. Unresolved Staff Comments. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">117</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_25"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 1C. Cybersecurity.</span></div><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock" id="f-39" continuedAt="f-39-1" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock" id="f-37" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementProcessesIntegratedFlag" format="ixt:fixed-true" id="f-38">We have processes for assessing, identifying and managing cybersecurity risks, which are built into our information technology function and are designed to provide protection for our information assets and operations from internal and external cyber threats, including protecting employee and patient information from unauthorized access or attack, as well as secure our networks and systems.</ix:nonNumeric> These processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine reviews of our policies and procedures to identify risks and enhance our practices.</ix:nonNumeric> As part of our overall risk mitigation strategy, we maintain cyber insurance coverage; however, such insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches. <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag" format="ixt:fixed-true" id="f-40"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementThirdPartyEngagedFlag" format="ixt:fixed-true" id="f-41">We have engaged external parties, including consultants, computer security firms and risk management, and legal and governance experts, to enhance our cybersecurity oversight.</ix:nonNumeric> We also employ processes to identify material risks from cybersecurity threats associated with our use of third-party service providers.</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag" format="ixt:fixed-false" id="f-42">Based on an assessment using the previously described risk mitigation strategy, we do not believe there are currently any risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition.</ix:nonNumeric> See &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our internal computer systems and those of our collaborators, CROs, CDMOs contractors, consultants and other third parties are vulnerable to cyber attacks, cyber intrusions and security breaches, which could not only materially disrupt our business operations and result in the loss of confidential information, but could also damage the integrity of our clinical trials, impact our regulatory filings, compromise our ability to protect our intellectual property, and subject us to regulatory actions that could result in significant fines or other penalties&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1A. &#8220;Risk Factors&#8221; for additional information.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock" id="f-44" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-43" escape="true">Our Audit Committee of our board of directors, or the <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag" format="ixt:fixed-true" id="f-45">Audit Committee</ix:nonNumeric>, provides direct cybersecurity risk oversight, and provides regular updates to the board of directors regarding such oversight.</ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock" id="f-46" escape="true">The Audit Committee receives quarterly updates from management and the Cybersecurity Board, as discussed in further detail below, regarding cybersecurity matters, and is notified between such updates regarding significant new cybersecurity risks, threats or incidents. We also provide updates to the full board of directors regarding cybersecurity risks, threat landscape and risks, as appropriate.</ix:nonNumeric></ix:nonNumeric> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskRoleOfManagementTextBlock" id="f-48" escape="true"><ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock" id="f-47" escape="true">We have a cross-functional <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag" format="ixt:fixed-true" id="f-49">Cybersecurity Board led by our Senior Vice President, Information Technology Systems &amp; Security, or SVP ITSS, serving as the chair and consisting of executive-level and non-executive level leaders, including among others, our chief financial officer and general counsel.</ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock" id="f-50" escape="true">This board is responsible for reviewing, engaging and making decisions related to the execution and continuous improvement of cybersecurity strategy, processes and governance impacting our information systems, employees, partners and patients. Our SVP, ITSS, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks.</ix:nonNumeric></ix:nonNumeric> <ix:nonNumeric contextRef="c-1" name="cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock" id="f-51" escape="true">Our SVP, ITSS, is an experienced senior leader with more than 25 years of experience in information technology within the pharmaceutical industry leading a team of employees and consultants with a breadth of experience including security management experience along with Certified Information Systems Security Professional, or CISSP certification.</ix:nonNumeric></span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-39-1">In an effort to deter and detect cyber threats, we periodically provide our workforce, including all employees and contingent staff, with a privacy, data protection, cybersecurity and incident response, and prevention education and awareness program, which includes annual and supplemental training covering a range of timely and relevant topics. Past topics have included social engineering, phishing, password protection, confidential data protection, asset use, and mobile security. This education and awareness program functions to educate employees on the importance of reporting all incidents immediately. In addition, we perform monthly phishing test campaigns to reinforce identification and reporting training. We automatically assign online reinforcement training upon initial phish test failure and may follow-up one-on-one as needed, including providing additional training. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs. Lastly, we perform annual penetration tests conducted by independent, third-party cybersecurity firms and ongoing vulnerability assessments conducted by the internal security team</ix:continuation>.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">118</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_28"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 2. Properties. </span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">31, 2025, we</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> leased approximately 73,500 square feet of office and laboratory space in New Haven, Connecticut under leases, as amended, that expire in December 2029. We believe that our facilities are sufficient to meet our current needs and that suitable additional or alternative space will be available as and when needed on commercially reasonable terms for any future growth.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_31"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 3. Legal Proceedings. </span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, we may become involved in litigation or other legal proceedings arising in the ordinary course of business and regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors. We are not currently a party to any material litigation or legal proceedings.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_34"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 4. Mine Safety Disclosures.</span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not applicable.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">119</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_37"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART II</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_40"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Market Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our common stock is publicly traded on the Nasdaq Global Select Market under the symbol &#8220;ARVN.&#8221;</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Holders</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">of Febr</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">uary 20, 2026, there were approximately 18 holders</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of recor</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d of our common stock. This number does not include beneficial owners whose shares are held by nominees in street name.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Dividend Policy </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have never declared or paid cash dividends on our common stock. We currently intend to retain all of our future earnings, if any, to finance the growth and development of our business. We do not intend to pay cash dividends in respect of our common stock in the foreseeable future. Any future determination to pay dividends will be made at the discretion of our board of directors and will depend on various factors, including applicable laws, our results of operations, financial condition, future prospects, then applicable contractual restrictions and any other factors deemed relevant by our board of directors. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Recent Sales of Unregistered Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We did not issue any securities that were not registered under the Securities Act of 1933, as amended, or the Securities Act, during the year ended December&#160;31, 2025.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Purchases of Equity Securities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2025, the Company announced that its board of directors authorized and approved a share repurchase program for the repurchase of up to $100.0&#160;million of the then-currently outstanding shares of the Company&#8217;s common stock. Share repurchases under the share repurchase program may be made from time to time through a variety of methods, which may include open market purchases, privately negotiated block trades, accelerated share repurchases, other privately negotiated transactions or any combination of these methods. Repurchases may also be made under a Rule 10b5-1 plan, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws. The share repurchase program is funded using the Company's working capital. The share repurchase program has no time limit and can be modified, suspended or discontinued at any time without prior notice. Repurchased shares are recorded as treasury stock, at cost, and are eligible to be reissued under the Company's stock plans and for other corporate purposes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information about purchases by us during the three months ended December&#160;31, 2025 of equity securities that are registered by the company pursuant to Section 12 of the Exchange Act.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:18.445%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.930%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:22.539%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%"><br/></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Period</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(a)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Total Number of Shares (or Units) Purchased</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(b)<br/>Average Price Paid per Share (or Unit)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(c)</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">Total Number of Shares (or Units) Purchased as Part of Publicly Announced Plans or Programs (1)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:112%">(d)<br/>Maximum Number (or Approximate Dollar Value) of Shares (or Units) that May Yet Be Purchased Under the Plans or Programs<br/>(millions)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">October 1, 2025 - October 31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.48&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6,667,168&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">November 1, 2025 - November 30, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.61&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">782,560</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">December 1, 2025 - December 31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">120</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1) In September 2025, our board of directors approved the repurchase by us of shares of our common stock having a value of up to </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$100.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in the aggregate. Share repurchases under the Program may be made from time to time through a variety of methods, which may include open market purchases, privately negotiated block trades, accelerated share repurchases, other privately negotiated transactions or any combination of these methods. Repurchases may also be made under a Rule 10b5-1 plan, which would permit shares to be repurchased when we might otherwise be precluded from doing so under insider trading laws. The Program is funded using our working capital. The Program has no time limit and can be modified, suspended or discontinued at any time without prior notice. Repurchased shares are recorded as treasury stock, at cost, and are eligible to be reissued under our stock plans and for other corporate purposes. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe we have met our objectives for the stock repurchase program. As of December&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we suspended the program and have no further plans to repurchase additional shares.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the twelve months ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, we repurchased </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">10,009,758</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> shares of our common stock, at an average price of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$9.09</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share, for an aggregate purchase price of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$91.0&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, plus commissions and excise tax of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.9&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Performance Graph</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following performance graph shows a comparison of cumulative total shareholder returns on our common stock with the Nasdaq Composite Index and the Nasdaq Biotechnology Index from December 31, 2020 through December&#160;31, 2025. The graph assumes an investment of $100 on December 31, 2020 in our common stock, the Nasdaq Composite Index and the Nasdaq Biotechnology Index and assumes that any dividends are reinvested. All index values are weighted by the capitalization of the companies included in the index. The comparisons shown in the graph below are based upon historical data. The stock price performance included in this graph is not necessarily indicative of future stock price performance. The following performance graph and related information shall not be deemed to be &#8220;soliciting material&#8221; or to be &#8220;filed&#8221; with the Securities and Exchange Commission, or SEC, for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, nor shall such information be incorporated by reference into any future filing under the Exchange Act or Securities Act, except to the extent that we specifically incorporate it by reference into such filing.</span></div><div style="margin-top:12pt;text-align:center"><img src="arvn-20251231_g5.jpg" alt="2602" style="height:380px;margin-bottom:5pt;vertical-align:text-bottom;width:613px" id="i-5"/></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">121</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_43"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 6. [Reserved]</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_46"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">The following discussion and analysis is meant to provide material information relevant to an assessment of the financial condition and results of operations of our company, including an evaluation of the amount and certainty of cash flows from operations and from outside sources, so as to allow investors to better view our company from management's perspective. You should read the following discussion and analysis of financial condition and results of operations together with our consolidated financial statements and the related notes appearing elsewhere in this Annual Report on Form 10-K. This discussion contains forward-looking statements that involve risks and uncertainties. As a result of many factors, such as those set forth in the section titled &#8220;Risk Factors&#8221; and elsewhere in this Annual Report on Form 10-K, our actual results may differ materially from those anticipated in or implied by these forward-looking statements. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_49"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Overview </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_947"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Our Business </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases. Through our PROteolysis TArgeting Chimera, or PROTAC, protein degradation platform, we are pioneering the development of a new class of therapeutics designed to harness the body&#8217;s ow</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. We have designed and optimized our proprietary PROTAC Discovery Engine for the discovery of PROTAC therapeutics to address diseases caused by abnormal proteins or aberrant protein expression. We believe that our targeted protein degradation approach is a novel therapeutic modality that may provide distinct advantages over existing therapies and address a broad range of targets, including historically undruggable proteins, in areas of significant unmet need. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the past five years, seven of the programs developed using our PROTAC protein degradation platform have progressed to clinical trials in oncology and neurology indications after demonstrating potent and selective protein degradation in our preclinical studies. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The U.S. Food and Drug Administration, or FDA, has accepted our New Drug Application, or NDA, for vepdegestrant, our most advanced product candidate from the platform, for the treatment of patients with estrogen receptor-positive (ER+)/human epidermal growth factor receptor 2-negative (HER2-), or ER+/HER2-, estrogen receptor 1, or ESR1, mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy, and has assigned a Prescription Drug User Fee Act, or PDUFA, action date of June 5, 2026. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe favorable clinical trial results in our ongoing oncology and neurology programs would further validate our platform as a new therapeutic modality for the potential treatment of diseases caused by dysregulated intracellular proteins.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are currently progressing the following product candidates through clinical development programs: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-102, targeting the leucine-rich repeat kinase 2, or LRRK2, protein for the treatment of neurodegenerative </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">diseases, including Parkinson's disease, or PD, and progressive supranuclear palsy, or PSP</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-806, targeting Kirsten rat sarcoma, or KRAS, G12D protein for cancers with the G12D mutation, including pancreatic, colorectal and non-small cell lung cancer; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-393, targeting the B-cell lymphoma 6, or BCL6, protein for the treatment of relapsed/refractory non-Hodgkin lymphoma, or NHL; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ARV-027, targeting the polyglutamine-expanded androgen receptor, or polyQ-AR, in skeletal muscle; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vepdegestrant, targeting the estrogen receptor, or ER, for the treatment of locally advanced or metastatic ER+/HER2- breast cancer. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">122</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also advancing several preclinical candidates through early stage development in a broad range of intracellular disease targets, including proteins that currently cannot be addressed by existing small molecule therapies, commonly referred to as &#8220;undruggable&#8221; or under-drugged targets. These preclinical candidates include ARV-6723 targeting hematopoietic progenitor kinase 1,</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> or HPK1, and a pan-KRAS degrader targeting multiple variants of KRAS while sparing other RAS isoforms.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition to the programs above and our early-stage collaborations, including with Pfizer, Inc., or Pfizer, and Genentech, Inc. and F. Hoffman-La Roche Ltd., or Genentech, we are conducting exploratory research and development work on multiple other undisclosed targets</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_897"></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Clinical Stage Programs</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_1170"></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-102: Oral PROTAC LRRK2 Degrader Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-102 is an investigational, orally bioavailable PROTAC designed to cross the blood-brain barrier and specifically target and degrade LRRK2, which is a large, multi-domain scaffolding kinase with GTPase activity. ARV-102 is our first oral PROTAC protein degrader in clinical development to treat neurodegenerative diseases. We believe our LRRK2 degraders are particularly well positioned to be evaluated in neurodegenerative diseases where there are currently no disease modifying therapies available, including :</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PD, where increased LRRK2 expression and activity contributes to neurodegeneration and pathogenesis of PD; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">PSP, where genetic variations in LRRK2 are associated with PSP progression and accelerated time to death. Additionally, we have published data associating the tau pathology of PSP with LRRK2-mediated endolysosomal dysfunction.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have been evaluating ARV-102 in Phase 1 clinical trials in healthy volunteers and patients with PD.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Healthy Volunteers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We initiated the first-in-human Phase 1 clinical trial for ARV-102 in the first quarter of 2024. We completed the single ascending dose, or SAD, and multiple ascending dose, or MAD, cohorts of the ARV-102 Phase 1 clinical trial in healthy voluntee</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;padding-left:14.5pt">Patients with PD</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">: We completed enrollment in the SAD cohort of the ARV-102 Phase 1 clinical trial in patients with PD in the second quarter of 2025. We received Clinical Trial Application approval in the Netherlands to initiate a multiple dose cohort of the Phase 1 clinical trial in patients with PD in the second quarter of 2025, and we initiated this multiple dose cohort in the third quarter of 2025. In the fourt</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">h quarter of 2025, we completed enrollment in the multiple dose cohort.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2025, we presented data from the first-in-human Phase 1 healthy volunteer clinical trial of ARV-102 at the 2025 International Conference on Alzheimer&#8217;s and Parkinson&#8217;s Diseases, or AD/PD, 2025, including results from the randomized, double-blind, placebo-controlled SAD cohort, and initial results from the MAD cohort. The ARV-102 Phase 1 clinical data in healthy volunteers demonstrated substantial reduction of LRRK2 in CSF with a promising safety/tolerability profile and favorable pharmacodynamic outcomes. Key findings from the clinical trial indicated brain penetration, substantial central and peripheral LRRK2 protein degradation, and downstream LRRK2 pathway engagement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2025, we presented late breaking positive Phase 1 data from our clinical trial of ARV-102 in healthy volunteers, and from the SAD cohort of our Phase 1 clinical trial of ARV-102 in patients with PD, as well as CSF Proteomic Data from the Phase 1 clinical trial of ARV-102 in healthy volunteers at the 2025 International Congress of Parkinson&#8217;s Disease and Movement Disorders&#174;. Data from the Phase 1 SAD and MAD clinical trial in healthy volunteers showed that ARV-102 was generally well tolerated, with no discontinuations due to adverse events, or AEs, or serious adverse events, or SAEs, observed in the trial population, favorable pharmacokinetics and pharmacodynamics. Interim SAD data from the Phase 1 clinical trial in patients with PD showed single doses of ARV-102 were well tolerated with only mild treatment-related AEs, including headache, diarrhea, and nausea, with no SAEs, and favorable pharmacokinetics and pharmacodynamics. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We plan to present data from the multiple dose cohort of the Phase 1 clinical trial of ARV-102 in patients with PD in the first quarter of 2026 in an oral presentation at 2026 AD/PD. Pending regulatory feedback, we plan </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">123</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">to initiate a Phase 1b clinical trial of ARV-102 in patients with PSP in the first half of 2026, and have the potential to initiate a registrational trial of ARV-102 in PSP in late 2026, pending regulatory feedback.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_912"></div><div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-806: Novel PROTAC KRAS G12D Degrader Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-806 is an investigational novel PROTAC designed to selectively target and degrade mutant KRAS G12D in solid tumors. KRAS is one of the most frequently mutated human oncogenes and G12D is the most common mutation of the KRAS protein. We believe ARV-806 has the potential to address high unmet need in solid tumors, such as pancreatic, colorectal and non-small cell lung cancer, or NSCLC, with KRAS G12D mutation.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted preclinical studies of ARV-806 and in the preclinical setting, ARV-806 demonstrated high potency and selectivity, with robust antitumor activity through dose-responsive degradation of KRAS G12D in KRAS G12D mutated cancer models, including pancreatic and colorectal models. These preclinical data demonstrate sustained pharmacodynamic activity consistent with long-lasting target degradation, which we believe supports intermittent clinical dosing. In particular, in the fourth quarter of 2025, we presented new preclinical data at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics highlighting ARV-806's high potency and clear differentiation from both KRAS inhibitors and degraders currently in the clinic while also demonstrating dose-dependent, selective, robust anti-tumor activity, with regressions across preclinical models of KRAS G12D-mutant cancers; </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> potency approximately 25 times greater than KRAS inhibitors and 40 times greater than the leading clinical-stage degrader, and degradation greater than 90% for seven days after single dose and significant efficacy in models of pancreatic, colorectal, and lung cancer.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe ARV-806 has the potential to address high unmet need in solid tumors, such as pancreatic, colorectal and non-small cell lung cancer. We filed an investigational new drug application with the FDA for ARV-806 in the first quarter of 2025 and received a safe-to-proceed letter from the FDA in the second quarter of 2025. We initiated enrollment in a Phase 1 clinical trial of ARV-806 in patients with advanced solid tumors harboring KRAS G12D mutations in the second quarter of 2025 and this trial is currently ongoing. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2026, we announced that we had completed dose escalation for once-weekly administration ahead of plan based on faster-than-anticipated enrollment of the Phase 1 clinical trial evaluating ARV-806 in patients with solid tumors harboring KRAS G12D mutations. We plan to continue enrollment in this clinical trial and anticipate sharing initial clinical data i</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">n patients with solid tumors harboring KRAS G12D mutations </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">in 2026.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_902"></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-393: Oral PROTAC BCL6 Degrader Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-393 is an investigational, orally bioavailable PROTAC designed to specifically target and degrade BCL6, a transcriptional repressor and a key regulator of normal B-cell maturation and differentia</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">tion processes. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deregulation of BCL6 function (e.g., via chromosomal translocation, mutations) may lead to malignant transformation and development of NHL. Also as a lineage defining transcription factor of T-follicular helper cells, BCL6 has been implicated in nodal T-follicular helper cell lymphoma, or nTFHL, including the angioimmunoblastic type, formerly angioimmunoblastic T-cell lymphoma, or AITL.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We believe that PROTAC-mediated degradation has the potential to address the historically undruggable nature of BCL6 and that ARV-393 PROTAC-mediated degradation of BCL6 may provide an important novel therapeutic option for patients with NHL. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Furthermore, we believe current preclinical data suggest that ARV-393 has the potential to be an attractive combination partner for development of novel therapies for lymphoma, including chemo-free combination regimens and/or &#8220;all oral&#8221; treatment options.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have conducted preclinical studies of ARV-393 alone, in combination with SOC chemotherapy and biologic agents, as well as oral, investigational small molecule inhibitors in high grade and aggressive diffuse large B-cell lymphoma, or DLBCL, and in combination with glofitamab, a CD20xCD3 bispecific antibody and an emerging SOC option for DLBCL, in models of aggressive high grade DLBCL. We believe the totality of our ARV-393 preclinical data provides a compelling rationale to evaluate ARV-393 in combination with bi-specifics, oral pathway inhibitors, and potentially other SOCs in the larger DLBCL indication. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">124</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We initiated the monotherapy cohort of our first-in-human Phase 1 clinical trial of ARV-393 in patients with relapsed or refractory NHL in the second qua</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">rter of 2024 and are currently recruiting patients for this clinical trial. We announced previously that there have been multiple responses in early cohorts in both B- and T-cell lymphomas in the first-in-human Phase 1 clinical trial. Dose escalation in the trial is ongoing and the safety profile of ARV-393 supports continuing dose escalation. We also believe these early data support an emerging, and differentiated, therapeutic benefit of ARV-393. We plan to share updated clinical data from the ongoing Phase 1 clinical trial of ARV-393 in patients with relapsed/refractory NHL at a medical congress in the second half of 2026. We also plan to initiate enrollment of a glofitamab combination cohort in patients with DLBCL in the ongoing Phase 1 clinical trial of ARV-393 in the first half of 2026.</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_932"></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-027: Oral PROTAC polyQ-AR Degrader Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-027 is an investigational, oral, peripherally restricted PROTAC designed to selectively target and eliminate the polyQ-AR in skeletal muscle. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the fourth quarter of 2025 at the International Congress of the World Muscle Society, we presented new preclinical data demonstrating induced robust degradation of polyQ-AR in human myotubes derived from spinal bulbar muscular atrophy, or SBMA, patient-induced pluripotent stem cells. The preclinical ARV-027 data presented also showed dose-dependent degradation of AR in mouse skeletal muscle that was sustained for more than 24 hours (single oral dose), and reductions in muscle monomeric polyQ-AR levels between 40-60%, improved muscle grip strength, and restored muscle endurance to wild-type levels in SBMA mouse model. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We initiated a first-in-human Phase 1 clinical trial in ARV-027 in healthy volunteers in the first quarter of 2026.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_907"></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Vepdegestrant: Oral PROTAC ER Degrader Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Vepdegestrant is an investigational orally bioavailable PROTAC estrogen receptor, or ER, degrader being developed for the treatment of ER+/HER2- locally advanced or metastatic breast cancer. We chose ER degradation as a therapeutic focus given the well-documented biology of ER signaling as a principal driver in a high percentage of breast cancers. In July 2021, we announced a global collaboration with Pfizer for the co-development and co-commercialization of vepdegestrant. The FDA has accepted our NDA for vepdegestrant for the treatment of patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer who have previously received endocrine-based therapy, and has assigned a PDUFA date of June 5, 2026.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We, along with Pfizer, have several ongoing clinical trials of vepdegestrant, for which enrollment of patients is complete, which are summarized below.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VERITAC-2, a Phase 3 clinical trial of vepdegestrant as a monotherapy, for the treatment of patients with metastatic breast cancer previously treated with endocrine based therapy;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">VERITAC, a Phase 2 dose expansion clinical trial of vepdegestrant as a monotherapy, for the treatment of patients with previously treated metastatic breast cancer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TACTIVE-K, a Phase 1b/2 clinical trial of vepdegestrant in combination with Pfizer's cyclin-dependent kinase 4, or CDK4, inhibitor, atirmociclib; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TACTIVE-U, a group of Phase 1b/2 clinical trials of vepdegestrant in combination with multiple targeted therapies including abemaciclib, ribociclib or Carrick Therapeutics, Inc.'s, or Carrick, cyclin-dependent kinase 7, or CDK7, inhibitor, samuraciclib.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We, along with Pfizer, also have completed two clinical trials of vepdegestrant:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TACTIVE-N, a Phase 2 clinical trial of vepdegestrant as a monotherapy in the neoadjuvant setting; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">TACTIVE-E, a Phase 1 clinical trial of vepdegestrant in combination with everolimus.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, VERITAC-3 a clinical trial with a study lead-in of vepdegestrant in combination with palbociclib for the treatment of patients with first-line metastatic breast cancer, is ongoing and enrollment of patients is complete. As previously disclosed, VERITAC-3 will not proceed beyond the study lead-in.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">125</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">VERITAC-2 Clinical Trial, New Drug Application</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2025, we, along with Pfizer, announced positive topline results from the Phase 3 VERITAC-2 clinical trial in the estrogen receptor 1-mutant, or ESR1m, population, and in the second quarter of 2025, we, along with Pfizer announced detailed results from this clinical trial. These detailed results were presented in a late-breaking oral presentation at the American Society of Clinical Oncology, or ASCO, 2025 Annual Meeting and were highlighted in the ASCO press briefing and selected for Best of ASCO, and were also simultaneously published in the New England Journal of Medicine.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Based on the results from VERITAC-2, in the second quarter of 2025, we and Pfizer submitted an NDA to the FDA for vepdegestrant for the treatment of patients with ER+/HER2- ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. This represents the first NDA submitted for a PROTAC. In the third quarter of 2025, we announced that the FDA accepted the NDA for vepdegestrant and assigned a PDUFA date of June 5, 2026.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our global collaboration with Pfizer, we and Pfizer presented patient reported outcomes, or PRO, data from the VERITAC-2 clinical trial evaluating vepdegestrant versus fulvestrant for previously treated patients with ESR1 mutated- ER+/HER2- advanced breast cancer in the fourth quarter of 2025 at the European Society for Medical Oncology, or ESMO, 2025 Congress. In the VERITAC-2 clinical trial, in patients with ESR1-mutated disease, vepdegestrant demonstrated a reduced risk of deterioration compared to fulvestrant which was statistically significant in several PRO domains including overall health status, pain severity, and functioning (including role, cognitive, emotional, and social functioning), and vepdegestrant consistently showed reduced risk of deterioration versus fulvestrant across all PRO domains. These PRO data from the VERITAC-2 clinical trial support the clinical benefit of vepdegestrant in patients with ESR1-mutated, ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:115%">Other Clinical Trials and Information</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2025, we announced that we and Pfizer removed two planned Phase 3 combination trials of vepdegestrant from the agreed-upon joint development plan: a first-line Phase 3 combination trial with Pfizer&#8217;s novel investigational CDK4 inhibitor, atirmociclib, and a second-line Phase 3 combination trial with a CDK4/6 inhibitor.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Additionally, in the second quarter of 2025, Pfizer added a vepdegestrant combination cohort to its ongoing Phase 1 clinical trial evaluating Pfizer&#8217;s investigational KAT6 inhibitor in combination with endocrine therapies following CDK4/6 inhibitor treatment. This clinical trial is being operationalized and funded solely by Pfizer.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">As part of our global collaboration with Pfizer, we and Pfizer presented results of the TACTIVE-N Phase 2 clinical trial which evaluated neoadjuvant vepdegestrant in postmenopausal women with ER+/HER2&#8211; localized breast cancer in the fourth quarter of 2025 at the ESMO 2025 Congress. The results presented showed that neoadjuvant vepdegestrant demonstrated biological and clinical activity in this treatment-na&#239;ve, predominantly ESR1 wild-type population of postmenopausal women with ER+/HER2- localized breast cancer.</span></div><div><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">In addition, as part of our global collaboration with Pfizer, we presented five posters at the San Antonio Breast Cancer Symposium further supporting the potential of vepdegestrant as a potential treatment option for patients with ESR1-mutated ER+/HER2- advanced or metastatic breast cancer previously treated with endocrine-based therapy potential.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">We, along with Pfizer, continue market preparations for vepdegestrant in advance of the PDUFA date. While we continue to believe that vepdegestrant has the potential to be a best-in-class monotherapy treatment for advanced/metastatic breast cancer patients in the second-line ESR1m setting, given our and Pfizer&#8217;s decision to remove the two planned Phase 3 combination trials of vepdegestrant from the agreed-upon joint development plan as noted above, we determined that it is no longer viable for us to build out our commercial infrastructure as we had previously planned. As such, in the third quarter of 2025, we announced that we and Pfizer have agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">126</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_892"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Our Preclinical and Other Programs </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have active preclinical programs and in neurology and oncology. In 2025 we announced two new product candidate nominees, ARV-027 and ARV-6723. As described above, we initiated a Phase 1 clinical trial for ARV-027 in the first quarter of 2026. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_927"></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">ARV-6723: Oral PROTAC HPK1 Degrader</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-6723 is an investigational, preclinical oral PROTAC designed to degrade HPK1 in solid malignancies. Preclinically, ARV-6723 has shown potent, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">selective HPK1 degradation and strong anti-tumor immune responses with superior tumor control in low- and high- immunogenic murine syngeneic tumor models. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We presented preclinical data at the Society for Immunotherapy of Cancer annual meeting in the fourth quarter of 2025 </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">that we believe supports the potential of ARV-6723 to provide sustained anti-tumor immune response as a single agent or in combination with standards of care with improved clinical benefits, including that: ARV-6723, as a single agent, demonstrates anti-tumor efficacy superior to anti-PD1 or a clinical HPK1 inhibitor and combines with anti-PD1 to further enhance response; and ARV-6723 single agent activity outperforms the HPK1 inhibitor and anti-PD-1 efficacy and reinstitutes the tumor microenvironment.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> We believe these preclinical results support future investigation of ARV-6723 alone or in combination with other agents in patients with high- or low-immunogenic tumors. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, we presented preclinical data for ARV-6723 at the American Association for Cancer Research, or AACR, Immuno-Oncology Conference in the first quarter of 2026 that support clinical investigation of ARV-6723 in patients with solid tumors harboring high- or low-immunogenic tumor microenvironments, or TME, including immune checkpoint inhibitor-resistant tumor settings. This preclinical data showed robust single-agent antitumor and proinflammatory activity in multiple syngeneic tumor models, including those with immunosuppressive TMEs, and showed greater preclinical activity than an investigational HPK1 inhibitor or an anti-PD-1 antibody.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pending regulatory feedback, we plan to initiate a Phase 1 clinical trial of ARV-6723 in patients with advanced solid tumors in mid-2026. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Additionally, we plan to present preclinical data evaluating antitumor and unique immunomodulatory activity of ARV-6723 in immuno-oncology-resistant models compared to SOC checkpoint inhibition in the first half of 2</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">026. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_1161"></div><div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pan-KRAS Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our preclinical oral pan-KRAS program targets multiple variants of KRAS that drive solid tumors such as PDAC, colorectal cancer, NSCLC and esophageal cancer, while sparing other RAS isoforms. In the fourth quarter of 2025, a poster presented at the 2025 Triple Meeting, showed that orally bioavailable pan-KRAS degraders have been identified that potently degrade multiple variants of KRAS and spare other RAS isoforms. A tool pan-KRAS PROTAC demonstrated robust single-agent activity and superior combination efficacy with immune checkpoint blockade compared with a pan-RAS ON inhibitor (seven complete responses compared with two complete responses). We plan to present preclinical data evaluating the activity and selectivity of a novel pan-KRAS degrader in multiple KRAS mutants and differentiation over RAS (ON) or pan-KRAS inhibitors in the first quarter of 2026 at the AACR Special Conference in Cancer Research: RAS Oncogenesis and Therapeutics. We also plan to p</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">resent preclinical data evaluating the efficacy of a novel pan-KRAS degrader in a KRAS syngeneic model, as well as associated immune microenvironment changes in the first half of 2026.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_887"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Programs: Luxdegalutamide (ARV-766) and bavdegalutamide (ARV-110)</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had been developing luxdegalutamide and bavdegalutamide, each an investigational, orally bioavailable, AR degrading PROTAC targeted protein degrader, for the treatment of men with metastatic castration-resistant prostate cancer, or mCRPC. Both luxdegalutamide and bavdegalutamide demonstrated activity in preclinical models of AR overexpression and AR mutations, both common mechanisms of resistance to current standard-of-care agents in men with prostate cancer. We believed that the differentiated PROTAC pharmacology of luxdegalutamide and bavdegalutamide, including their iterative activity, had the potential to translate into significantly improved clinical outcomes over current SOC agents. However, a comparison of clinical data from separate studies of luxdegalutamide and bavdegalutamide showed that luxdegalutamide&#8217;s tolerability and efficacy was more promising than that of bavdegalutamide</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As a result, early in the fourth quarter of 2023, we determined to prioritize the initiation of a Phase 3 clinical trial with luxdegalutamide in mCRPC instead of the previously planned Phase 3 clinical trial for bavdegalutamide. Clinical trials for bavdegalutamide (ARV-110-101 and ARV-110-103) were completed in the second quarter of 2025.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">127</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2024, we completed a transaction with Novartis Pharma AG, or Novartis, which comprised a license agreement, or the Novartis License Agreement, and an asset agreement, or the Novartis Asset Agreement. Pursuant to the Novartis License Agreement, we granted Novartis an exclusive worldwide license for the development, manufacture and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">commercialization of luxdegalutamide, and we completed the transition of our ongoing and planned clinical trials of luxdegalutamide to Novartis in the fourth quarter of 2024. Pursuant to the Novartis Asset Agreement, we sold Novartis all of our rights, title and interest in our PROTAC protein degrader targeting AR-V7, a splice variant of the AR.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_882"></div><div style="margin-top:18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Our Operations</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We commenced operations in 2013. Our operations to date have been limited to organizing and staffing our company, business planning, raising capital, conducting discovery and research activities, filing patent applications, identifying potential product candidates, undertaking preclinical studies and clinical trials, establishing arrangements with third parties for collaborations and for the manufacture of initial quantities of our product candidates and preparing for potential commercialization. To date, we have not generated any revenue from product sales and have financed our operations primarily through sales of assets and equity, proceeds from collaborations and a licensing arrangement, grant funding and debt financing. Since inception through December&#160;31, 2025, we raised approximately $1.7 billion in gross proceeds from the sale of assets and equity interests and the exercise of stock options, and had received an aggregate of $933.1 million in payments primarily from collaboration partners and a licensing arrangement.</span></div><div style="margin-top:12pt;text-indent:30.6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are a clinical-stage company, with product candidates in clinical development and other drug discovery activities in the research and preclinical development stages. Our ability to generate revenue from product sales sufficient to achieve profitability will depend heavily on the successful development and eventual commercialization of one or more of our product candidat</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">es. In June 2025 we announced the submission of an NDA to the FDA with our partner Pfizer for vepdegestrant for the treatment of patients with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer previously treated with endocrine-based therapy. In August 2025 we announced the FDA's acceptance of this NDA for review and that the FDA had assigned a PDUFA date of June 5, 2026. In September 2025, we and Pfizer announced our plan to jointly select a third party for the commercialization and potential further development of vepdegestrant.</span></div><div style="margin-top:12pt;text-indent:30.6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Any delay or failure to obtain regulatory approvals would materially adversely affect our product candidate development efforts and our business overall. Because of the numerous risks and uncertainties associated with product development, we are unable to predict the timing or amount of increased expenses or when or if we will be able to achieve or maintain profitability. Even if we are able to generate product sales, we may not become profitable. If we fail to become profitable or are unable to sustain profitability on a continuing basis, then we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We regularly review our operations and make decisions we believe best support our business strategy. In April 2025, as part of our decision to streamline operations across our organization and enable the efficient progression of our portfolio, we committed to and approved a r</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">eduction of our workforce by approximately 33% across all areas of our company. The workforce reduction was aimed at reducing internal costs while minimally impacting our targeted clinical stage programs to drive value over the next several years by aligning our operations with long-term program development objectives. The workforce reduction was substantially completed by the end of the second quarter of 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, we announced an update on our collaboration with Pfizer and further actions to support value creation by optimizing organizational and cost structures and streamlining operations in advance of multiple anticipated upcoming value inflection points, including: further limiting additional expenditures on the vepdegestrant program supporting activities required for commercialization readiness and identification, with Pfizer, of a third party for the commercialization and potential further development of vepdegestrant; reducing our workforce by an additional 15%, with the most significant reductions being roles related to vepdegestrant commercialization; and proactively managing pipeline cost by seeking strategic business development opportunities and by identifying further efficiencies acro</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ss the business. The September 2025 workforce reduction was substantially completed in the first quarter of 2026.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">128</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognized restructuring charges of $3.7&#160;million related to the two actions noted above, including $15.3&#160;million of cash severance and other one-time employee related termination benefit related to the workforce reductions, partially offset by a reversal of $11.6&#160;million of non-cash stock compensation and bonus expenses. We expect to achieve annual operating cost savings of $100.0 million, on a run-rate basis. Refer to Note 14, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Activity,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in this Annual Report on Form 10-K for further details.</span></div><div style="margin-top:12pt;text-indent:30.6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2026, we announced the appointment of Randy Teel, Ph.D., as our President, Chief Executive Officer and as a member of our board of directors. Dr. Teel, who previously served as our Chief Business Officer, succeeds John Houston, Ph.D., who is retired from his role as President, Chief Executive Officer, and Chair of Arvinas&#8217; board of directors. Dr. Houston will continue to serve as a member of the Board and has entered into a consulting agreement with us whereby he will provide consulting and advisory services. Briggs Morrison, M.D., our lead independent director, has been elected to serve as Chair of our board of directors.</span></div><div style="margin-top:12pt;text-indent:30.6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since inception, we have incurred significant operating losses and, even in light of our workforce reductions and cost optimization decisions, expect to continue to incur operating losses for at least the next several years. In addition to any additional costs not currently contemplated due to the events associated with or resulting from our workforce reductions, our ability to achieve profitability and our financial position will depend, in part, on the rate of our future expenditures, potential collaboration revenue, our ability to successfully implement cost avoidance measures and reduce overhead costs and our ability to obtain additional funding.</span></div><div style="margin-top:12pt;text-indent:30.6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect to continue to incur significant expenses associated with: our ongoing and anticipated preclinical and clinical activities, development activities, research activities in oncology, neuroscience and other disease areas, managing our employees and retaining key talent in research, clinical trials, quality and other functional areas, expenses incurred with CMOs and CDMOs to supply us with product for our preclinical and clinical studies and expenses incurred with contract research organizations, or CROs, for the synthesis of compounds in our preclinical development activities, as well as other associated costs including those related to partnering with us on our clinical trial portfolio and the management of our intellectual property portfolio.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not expect to generate any revenue from product sales in the near future, if ever. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accordingly, we will need to obtain substantial additional funding in connection with our continuing operations. If we are unable to raise capital when needed or on attractive terms, we could be forced to delay, reduce or eliminate our research or product development programs or any future commercialization efforts, or to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or to grant licenses on terms that may not be favorable to us.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, we had cash, cash equivalents and marketable securities of $685.4 million. We believe the existing cash, cash equivalents and marketable securities on hand will be sufficient to fund our operations into the second half of 2028, which will enable us to execute on multiple data readouts across our programs. We have based this estimate on assumptions that may prove to be wrong, and we could exhaust our available capital resources sooner than we expect. See &#8220;Liquidity and Capital Resources&#8221; below.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_52"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Operations Overview </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_986"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Revenue </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, we have not generated any revenue from product sales and do not expect to generate any revenue from the sale of products in the near future. Our revenues to date have been generated through research collaborations, a licensing arrangement and an asset sale. Revenue is recognized ratably over our expected performance period under each agreement. We expect that any revenue recognized in the near term will be derived primarily from our current collaboration agreements and licensing arrangement and any additional arrangements that we may enter into in the future. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025, we received </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">a development m</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ilestone totaling $20.0&#160;million, pursuant to the terms of the Novartis License Agreement. To date, no other development, regulatory and commercial milestone payments or royalties have been received under any of our other collaboration agreements or licensing arrangement.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">129</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_976"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Vepdegestrant (ARV-471) Collaboration Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound vepdegestrant (ARV-471), or the Licensed Products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Vepdegestrant (ARV-471) Collaboration Agreement, we received an upfront, non-refundable payment of $650 million. In addition, we are eligible to receive up to an additional $1.4 billion in contingent payments based on specified regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400 million in regulatory milestones are related to marketing approvals and $1.0 billion are related to sales-based milestones.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We and Pfizer share equally (50/50) all development costs (including costs for conducting any clinical trials) for the Licensed Products, subject to certain exceptions.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Unless earlier terminated in accordance with its terms, the Vepdegestrant (ARV-471) Collaboration Agreement will expire on a Licensed Product-by-Licensed Product and country-by-country basis when such Licensed Product is no longer commercialized or developed for commercialization in such country. Pfizer may terminate the Vepdegestrant (ARV-471) Collaboration Agreement for convenience in its entirety or on a region-by-region basis subject to certain notice periods. Either party may terminate the Vepdegestrant (ARV-471) Collaboration Agreement for the other party&#8217;s uncured material breach or insolvency. Subject to applicable terms of the Vepdegestrant (ARV-471) Collaboration Agreement, including certain payments to Pfizer upon termination for our uncured material breach, effective upon termination of the Vepdegestrant (ARV-471) Collaboration Agreement, we are entitled to retain specified licenses to be able to continue to exploit the Licensed Products.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Subject to specified exceptions, we and Pfizer have each agreed not to directly or indirectly research, develop, or commercialize any competing products outside of the Vepdegestrant (ARV-471) Collaboration Agreement anywhere in the world during the term of the Vepdegestrant (ARV-471) Collaboration Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the third quarter of 2025, we announced that we and Pfizer have agreed to jointly select a third party for the commercialization and potential future development of vepdegestrant.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_971"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Pfizer Research Collaboration Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, we entered into a Research Collaboration and License Agreement with Pfizer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of targets, using our proprietary platform technology that are identified in the agreement or subsequently selected by Pfizer, subject to certain exclusions. We refer to this agreement as the Pfizer Research Collaboration Agreement. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Pfizer Research Collaboration Agreement, Pfizer has designated a number of initial targets. For each identified target, we and Pfizer will conduct a separate research program pursuant to a research plan. Pfizer may make substitutions for any of the initial target candidates, subject to the stage of research for such target. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the year ended December 31, 2018, we received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in exchange for use of the technology license and to fund Pfizer-related research, as defined within the Pfizer Research Collaboration Agreement. As of December&#160;31, 2025, there remains a single target under the Pfizer Research Collaboration Agreement, and, in accordance with the terms of such Agreement, we are eligible to receive up to an additional $3.8 million in non-refundable option payments if Pfizer exercises its option for such target protein.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as mid- to high-single digit tiered royalties, which may be subject to reductions, on net sales of PROTAC targeted protein degrader-related products. In 2021 and 2020, we received payments totaling $1.2 million and $4</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.4&#160;million, respectively</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Pfizer selected additional targets and initiated additional services totaling $1.0 million and $3.5 million in December 2022 and 2021, respectively.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">130</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_981"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Novartis Transaction </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, we</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> entered into the Novartis License Agreement and the Novartis Asset Agreement, with Novart</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">is, collectively referred to as the Novartis Transaction. The Novartis Transaction closed in </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">May 2024 upon the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, at which time the Novartis License Agreement and the Novartis Asset Agreement became effective. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the Novartis License Agreement, we granted Novartis an exclusive worldwide license for the development, manufacture and commercialization of luxdegalutamide (ARV-766), our second generation PROTAC AR degrader for patients with prostate cancer. Pursuant to the Novartis Asset Agreement, we sold to Novartis all of our rights, title and interest in our PROTAC protein degrader targeting AR-V7, a splice variant of the AR.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of and as consideration for entering into the Novartis Transaction, we received a one-time, upfront payment in the aggregate amount of $150.0&#160;million from Novartis. Under the Novartis License Agreement, we are also eligible to receive up to an additional $1.01&#160;billion as contingent payments based on specified development, regulatory, and commercial milestones for luxdegalutamide (ARV-766) being met, as well as tiered royalties based upon worldwide net sales of luxdegalutamide (ARV-766), subject to reduction under certain circumstances as provided in the Novartis License Agreement. During the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025, we received $20.0&#160;million upon the achievemen</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t of a development m</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ilestone pursuant to the terms of the Novartis License Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Novartis License Agreement will continue on a country-by-country basis (or, in certain cases, a region-by-region basis) until the expiration of the applicable royalty term for such country (or region, as applicable). The Novartis License Agreement contains customary termination provisions, including that either party may terminate the Novartis License Agreement (a) upon the material breach of the other party or (b) in the event the other party experiences an insolvency event. Additionally, Novartis may terminate the Novartis License Agreement for convenience or upon a safety or regulatory issue.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_1006"></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Genentech License Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2015, we entered into an Option and License Agreement with Genentech, focused on PROTAC targeted protein degrader discovery and research for target proteins, or Targets, based on our proprietary platform technology, other than excluded Targets as described below. Pursuant to this agreement, Genentech has an option to obtain an exclusive worldwide license to the applicable PROTAC targeted protein degraders directed against an applicable Target, which we refer to as Licensed PROTACs. Each such option must be exercised within a specified time after we deliver the data package for such Licensed PROTAC to Genentech. Once Genentech exercises an option, it is responsible, at its cost, to use diligent efforts to develop and commercialize the Licensed PROTAC through first commercial sale in the United States, the European Union and Japan. This collaboration was expanded in November 2017 through an Amended and Restated Option, License and Collaboration Agreement, which we refer to as the Restated Genentech Agreement. Simultaneous with entering into the Restated Genentech Agreement, Genentech exercised its exclusive option with respect to a PROTAC targeted protein degrader. We receive annual updates on research and development activities related to this option.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">Under the Restated Genentech Agreement, Genentech had the right to designate up to ten Targets for further discovery and research utilizing our PROTAC platform technology and also had the right to remove a Target from the collaboration and substitute a different Target that is not an excluded Target at any time prior to us commencing research on such Target or in certain circumstances following commencement of research by us. The research phase of the collaboration </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">with Genentech has ended. Genentech is no longer able to nominate new targets into the collaboration, and there are no active targets in the collaboration for which Arvinas was conducting research activities. The only Target that remains part of the collaboration is the PROTAC targeted protein degrader for which Genentech exercised its exclusive option for as noted above.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">At the time we entered into the original agreement with Genentech, we received an upfront payment of $11.0 million, and, at the time we entered into the Restated Genentech Agreement, we received an additional $34.5 million in upfront and expansion target payments. We are eligible to receive payments aggregating up to $44.0 million per Target upon the achievement of specified development milestones; payments aggregating up to $52.5 million per Target (assuming approval of two indications) subject to the achievement of specified </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">131</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">regulatory milestones; and payments aggregating up to $60.0 million per PROTAC targeted protein degrader directed against the applicable Target, subject to the achievement of specified sales milestones. These milestone payments are subject to reduction if we do not have a valid patent claim covering the licensed PROTAC targeted protein degrader at the time the milestone is achieved. We are also eligible to receive, on net sales of licensed PROTAC targeted protein degraders, mid-single digit royalties, which may be subject to reductions. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_966"></div><div style="margin-top:18pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Bayer Collaboration Agreement </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, we entered into a Collaboration and License Agreement, or the Bayer Collaboration Agreement, with Bayer, setting forth our collaboration to identify or optimize PROTAC targeted protein degraders that mediate for degradation of Targets, using our proprietary platform technology, that are selected by Bayer, subject to certain exclusions and limitations. The Bayer Collaboration Agreement became effective in July 2019. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the Bayer Collaboration Agreement, we and Bayer conducted a research program pursuant to separate research plans mutually agreed to by us and Bayer and tailored to each Target selected by Bayer. During the term of the Bayer Collaboration Agreement, we were not permitted, either directly or indirectly, to design, identify, discover or develop any small molecule pharmacologically-active agent whose primary mechanism of action is, by design, directed to the inhibition or degradation of any Target selected or reserved by Bayer, or grant any license, covenant not to sue or other right to any third party in the field of human disease under the licensed intellectual property for the conduct of such activities.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the terms of the Bayer Collaboration Agreement, we received an aggregate upfront, non-refundable payment of $17.5 million and an additional $12.0 million in aggregate from inception through 2023. We were also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated Targets. In addition, we were eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which were subject to reductions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to notice from Bayer AG in accordance with the terms of the Bayer Collaboration Agreement, the Bayer Collaboration Agreement was terminated, effective August 12, 2024.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_961"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Operating Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our operating expenses since inception have consisted solely of research and development costs and general and administrative costs. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_1033"></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses consist primarily of costs incurred for our research activities, including our discovery efforts, and the development of our product candidates, and include: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">employee related expenses, including salaries, benefits, stock-based compensation expense and travel, for personnel engaged in research and development functions; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expenses incurred under agreements with third parties, including CROs and other third parties that conduct research, preclinical and clinical activities on our behalf as well as third parties that manufacture our product candidates for use in our preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs of outside consultants, including their fees, stock-based compensation and related travel expenses; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs of laboratory supplies and developing preclinical studies and clinical trial materials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">facility-related expenses, which include direct depreciation costs of equipment and allocated expenses for rent and maintenance of facilities and other operating costs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">costs incurred in the development of intellectual property; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">third-party licensing fees. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">132</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expense research and development costs as incurred. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We typically use our employee and infrastructure resources across our development programs, and as such, do not track all of our internal research and development expenses on a program-by-program basis. The following table summarizes our research and development expenses for the years ended December&#160;31, 2025, 2024 and 2023: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Program-specific external expense:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vepdegestrant (ARV-471) (*)</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-102</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-806</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-393</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Bavdegalutamide (ARV-110)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Luxdegalutamide (ARV-766)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other programs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total program-specific external expense</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">115.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">127.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">159.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Non program-specific external expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Unallocated internal expense</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Compensation and related personnel expense </span></div><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(including stock-based compensation)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">145.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">134.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other research and development expense</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:24pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total unallocated internal expense</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">120.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">158.2&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">148.0&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total research and development expense</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">285.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">348.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">379.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*)&#160;&#160;&#160;&#160;Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we continue to conduct our ongoing clinical trials of vepdegestrant, ARV-102, ARV-806, ARV-393, ARV-027 and continue to discover and develop additional product candidates. Research and development expenses related to vepdegestrant are shared equally with Pfizer since July 22, 2021, the effective date of the Vepdegestrant (ARV-471) Collaboration Agreement. We may receive reimbursement from, or make payments to, Pfizer to satisfy the cost sharing requirements. These payments are accounted for pursuant to ASC 808, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaborative Arrangements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which are recorded as an offset or an increase to research and development expenses.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We cannot determine with certainty the duration and costs of ongoing and future clinical trials of vepdegestrant, ARV-102, ARV-806, ARV-393, ARV-027 or unexpected costs of ongoing clinical trials for any other product candidate we may develop or if, when, or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The successful development and commercialization of our product candidates is highly uncertain. This is due to the numerous risks and uncertainties associated with developing drugs, including the uncertainty of: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">successfully completing preclinical studies and clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">receipt and related terms of marketing approvals from applicable regulatory authorities; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining patent and trade secret protection and regulatory exclusivity for our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">making or maintaining arrangements with third-party manufacturers, or establishing manufacturing capabilities, for both clinical and commercial supplies of our product candidates; </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">133</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">establishing sales, marketing, market access and distribution capabilities and launching commercial sales of our products, if and when approved, whether alone or in collaboration with others; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">acceptance of our products, if and when approved, by patients, the medical community and third-party payors; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">obtaining and maintaining third-party coverage and adequate reimbursement; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">maintaining a continued acceptable safety profile of the products following approval; and </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">effectively competing with other therapies. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A change in the outcome of any of these variables with respect to the development of a product candidate could mean a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time on the completion of clinical development. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_1028"></div><div style="margin-top:18pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses consist primarily of salaries and other related costs, including stock-based compensation for personnel in our executive, finance, business development and administrative functions. General and administrative expenses also include legal fees relating to intellectual property and corporate matters; professional fees for accounting, auditing, tax and consulting services; insurance costs; travel expenses; and facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We expect that our general and administrative expenses will increase in the future as we manage our personnel, including retaining or hiring of key employees, and, as a result of any future need to increase our headcount to support research and development activities relating to our product candidates, develop our infrastructure and build out commercial operations for any potential launch of commercial sales of our products. We also expect to incur increased expenses associated with being a public company, including costs of accounting, audit, legal, regulatory and tax-related services associated with maintaining compliance with Nasdaq Stock Market and Securities and Exchange Commission requirements; director and officer insurance costs; and investor and public relations costs. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_1023"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income consists primarily of interest income from marketable securities and money market accounts and losses on the disposal of fixed assets.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_1018"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;text-decoration:underline">Income Taxes </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception in 2013, we have not recorded any U.S. federal or state income tax benefits for the net losses we have incurred in any year or for our federal or state earned research and development tax credits, due to our uncertainty of realizing a benefit from those items.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025, we </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">had $533.6&#160;million of federal net operating loss carryforwards, all of which may be carried forward indefinitely, but the deductibility of such carryforwards is limited to 80% of our taxable income in the year in which carryforwards are used, $563.2 million of state and local net operating loss carryforwards which expire at various dates beginning in 2035, $44.7 million of federal tax credit carryforwards and $22.3 million of state tax credit carryforwards as of December&#160;31, 2025 which expire at various dates beginning in 2035.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, Arvinas, Inc. had four wholly own</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ed subsidiaries organized as C-corporations: Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc., Arvinas Estrogen Receptor, Inc., and Arvinas Winchester, Inc. Prior to December 31, 2018, these subsidiaries were separate filers for federal tax purposes. Net operating loss carryforwards are generated from the C-corporation subsidiaries&#8217; filings. We have </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">134</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">provided a valuation allowance against the full amount of the deferred tax assets since, in the opinion of management, based upon our earnings history, it is more likely than not that the benefits will not be realized. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_55"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Accounting Policies and Use of Estimates </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management&#8217;s discussion and analysis of financial condition and results of operations is based on our consolidated financial statements, which have been prepared in accordance with generally accepted accounting principles in the United States. The preparation of our consolidated financial statements and related disclosures requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities, costs and expenses and the disclosure of contingent assets and liabilities in our consolidated financial statements. We base our estimates on historical experience, known trends and events and various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Our actual results may differ from these estimates under different assumptions or conditions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">While our significant accounting policies are described in more detail in the notes to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K, we believe that the following accounting policies are those most critical to the judgments and estimates used in the preparation of our consolidated financial statements.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue Recognition </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We recognize revenue under Accounting Standards Codification, or ASC 606, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our revenue is primarily generated through research collaboration and license agreements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Under ASC 606, we evaluate whether the license agreement, research and development services and participation in research and development steering committees represent separate or combined performance obligations. We have determined that these services within our existing contracts represent combined single performance obligations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We also generated revenue through the sale of assets based on fair value.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research collaboration and license agreements typically include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration that are not initially recognized within the transaction price as they are fully constrained under the guidance in ASC 606. We continually assess the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized ratably over our expected performance period under each respective arrangement. We make our best estimate of the period over which we expect to fulfill our performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, the transaction price allocated to the combined performance obligations identified under the individual research collaboration and license agreements was recognized as revenue on either a straight-line basis over the estimated performance period under the arrangement or over the estimated performance period based on our best estimate of costs to be incurred. Straight-line basis was considered the best measure of progress for certain agreements in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">135</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our contracts may also call for certain sales-based milestones and royalty payments upon successful commercialization of a target. In accordance with ASC 606-10-55-65, we recognize revenues from sales-based milestone and royalty payments at the later of (i) the occurrence of the subsequent sale, or (ii) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). We anticipate recognizing these milestones and royalty payments if and when subsequent sales are generated by customers from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liabilities in our accompanying consolidated balance sheets. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Contract Costs and Accruals</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As part of the process of preparing our financial statements, we are required to estimate our accrued research and development expenses. This process involves reviewing open contracts and purchase orders, communicating with our applicable personnel to identify services that have been performed on our behalf and estimating the level of service performed and the associated cost incurred for the service when we have not yet been invoiced or otherwise notified of actual costs. The majority of our service providers invoice us in arrears for services performed, on a pre-determined schedule or when contractual milestones are met; however, some require advance payments. We make estimates of our accrued expenses as of each balance sheet date in the consolidated financial statements based on facts and circumstances known to us at that time. We periodically confirm the accuracy of these estimates with the service providers and make adjustments, if necessary. Examples of estimated accrued research and development expenses include fees paid to:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">vendors in connection with clinical development activities;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CROs and investigative sites in connection with preclinical, non-clinical, and human clinical trials; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">CMOs and CDMOs in connection with drug substance and drug product formulation of preclinical and clinical trial materials.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We base the expense recorded related to external research and development</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> on our estimates of the services received and efforts expended pursuant to quotes and contracts with multiple CMOs, CDMOs and CROs that supply, conduct and manage clinical trials on our behalf. The financial terms of these agreements are subject to negotiation, vary from contract to contract and may result in uneven payment streams. Th</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ere may be instances in which payments made to our vendors will exceed the level of services provided and result in a prepayment of the expense. In accruing service fees, we estimate the time period over which services will be performed and the level of effort to be expended in each period. If the actual timing of the performance of services or the level of effort varies from the estimate, we adjust the accrual or the amount of prepaid expenses accordingly. Although we do not expect our estimates to be materially different from amounts actually incurred, our understanding of the status and timing of services performed relative to the actual status and timing of services performed may vary and may result in reporting amounts that are too high or too low in any particular period. To date, there have not been any material adjustments to our prior estimates of accrued research and development expenses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">New Accounting Pronouncements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For information on new accounting standards, see Note 2, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to our consolidated financial statements appearing elsewhere in this Annual Report on Form 10-K.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">136</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_58"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Results of Operations </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Comparison of Years Ended December&#160;31, 2025 and 2024</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Years Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">$ change</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">262.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">263.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(285.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(348.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">63.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">General and administrative expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(95.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(165.4)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other income</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">38.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(13.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(198.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">118.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Reconciliation of GAAP and Non-GAAP Information</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',serif;font-size:8pt;font-weight:700;line-height:100%">Year Ended December&#160;31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:100%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Research and development reconciliation</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP research and development expenses</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">285.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">348.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: restructuring expense</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: stock-based compensation expense (*)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">30.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP research and development expenses</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">252.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">298.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative reconciliation</span></td><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GAAP general and administrative expenses</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">95.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">165.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: restructuring expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less: stock-based compensation expense (*)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Non-GAAP general and administrative expenses</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">126.9&#160;</span></td><td style="background-color:#ffffff;border-bottom:0.75pt solid #000000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">    </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Excludes restructuring related stock-based compensation. See Note 14, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Activity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, to the consolidated financial statements for further details.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenue</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenues for the year ended December&#160;31, 2025 totaled $262.6 million, compared with $263.4 million for the year ended December&#160;31, 2024. The decrease of $0.8 million </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">was primarily due to a decrease of $162.4&#160;million of revenue from the Novartis License Agreement and the Novartis Asset Agreement as we completed the technology transfer of our ongoing and planned clinical trials of luxdegalutamide (ARV-766) to Novartis in 2024, a decrease of $5.1&#160;million of revenue from the Pfizer Rese</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">arch Collaboration Agreement due to changes in estimates of the performance period duration under the agreement resulting from updated research timelines and a decrease of $3.8&#160;million in revenue from the Bayer Collaboration Agreement as a result of the termination of the Bayer Collaboration Agreement in August 2024, partially offset by </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">an increase in revenue from the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer of $150.5&#160;million related primarily to changes in total program cost estimates resulting from the removal of the first-line Phase 3 combination trial with Pfizer&#8217;s novel investigational CDK4 inhibitor, atirmociclib, and the removal of the second-line Phase 3 combination trial with a CDK4/6 inhibitor from the development plan and the recognition of $20.0&#160;million </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">for achieveme</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">nt of a development </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">milestone pursuant to the terms of the Novartis License Agreement.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Research and Development Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses for the year ended December&#160;31, 2025 totaled $285.2 million, compared with $348.2&#160;million for the year ended December&#160;31, 2024. The decrease of $63.0&#160;million was primarily due to a decrease in compensation and related personnel expenses of $35.8&#160;million, which are not </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">137</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">allocated by program, and a decrease in external expenses of $25.4&#160;million. External expenses include program-specific expenses, which decreased by $11.7&#160;million, driven by decreases in our luxdegalutamide, vepdegestrant and bavdegalutamide programs of $19.7&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$14.2&#160;million and $5.8&#160;million, respectively, partially offset by increases in our ARV-806, ARV-102 and ARV-393 programs of $11.2&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:12pt;font-weight:400;line-height:120%">, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$8.0&#160;million and $4.3&#160;million, respectively, and our non-program specific expenses, which decreased by $13.7&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP research and development expenses for the year ended December&#160;31, 2025 totaled $252.2&#160;million, compared to $298.5&#160;million for the year ended December&#160;31, 2024, excluding $2.3&#160;million of restructuring expense for the year ended December&#160;31, 2025, and $30.7&#160;million and $49.7&#160;million of non-cash stock-based compensation expense for the years ended December&#160;31, 2025 and 2024, respectively. We define non-GAAP research and development expenses as GAAP research and development expenses excluding restructuring and stock-based compensation expense.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">General and Administrative Expenses </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">General and administrative expenses totaled $95.9 million for the year ended December&#160;31, 2025, compared with $165.4 million for the year ended December&#160;31, 2024. The decrease of $69.5 million was primarily due to a loss on the termination of our laboratory and office space lease with 101 College Street LLC in August 2024 of $43.4&#160;million, a decrease in personnel and infrastructure related costs of $18.9&#160;million and a decrease in professional fees of $6.6&#160;million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP general and administrative expenses for the year ended December&#160;31, 2025 totaled $71.2&#160;million, compared to $126.9&#160;million for the year ended December&#160;31, 2024, excluding $1.3&#160;million of restructuring related reversal of previously recognized expense for the year ended December&#160;31, 2025, and $23.4&#160;million and $38.5&#160;million of non-cash stock-based compensation expense for the years ended December&#160;31, 2025 and 2024, respectively. We define non-GAAP general and administrative expenses as GAAP general and administrative expenses excluding restructuring and stock-based compensation expense.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Income </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Other income totaled $38.0 million for the year ended December&#160;31, 2025, compared with $51.9 million for the year ended December&#160;31, 2024. The decrease of $13.9 million was primarily due to lower interest income of $16.4 million from marketable securities and money market accounts, partially offset by a loss on the disposal of fixed assets of $2.4&#160;million related to the termination of our laboratory and office space lease with 101 College Street LLC in August 2024.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Tax Expense </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Income tax expense totaled $0.3 million for the year ended December&#160;31, 2025, compared with $0.6 million for the year ended December&#160;31, 2024. For the year ended December&#160;31, 2025, we generated a taxable loss primarily due to losses from operations. For the year ended December 31, 2024, we generated a taxable income primarily due to the Novartis License Agreement, the Novartis Asset Agreement and the required capitalization of research and development expenses, partially offset by operating losses.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Results of Operations &#8212; Years Ended December&#160;31, 2024 and 2023</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Discussion and analysis of the results of operations for the year ended December&#160;31, 2024 compared to the year ended December&#160;31, 2023 is included under the heading "Comparison of Years Ended December&#160;31, 2024 and 2023" in Part II, Item 7, Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations, in our 2024 Annual Report on Form 10-K as filed with the SEC on February 11, 2025 and incorporated by reference into this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Financial Information </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We use the non-GAAP financial measures non-GAAP research and development expense and non-GAAP general and administrative expense, to evaluate our ongoing operations and for internal planning and forecasting purposes. We believe that non-GAAP financial information, when taken collectively, may be helpful to investors because it provides consistency and comparability with past financial performance. However, non-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">138</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">GAAP financial information is presented for supplemental informational purposes only, has limitations as an analytical tool, and should not be considered in isolation or as a substitute for financial information presented in accordance with GAAP. Other companies, including companies in our industry, may calculate similarly titled non-GAAP measures differently or may use other measures to evaluate their performance, all of which could reduce the usefulness of our non-GAAP financial measures as tools for comparison. Investors are encouraged to review the related GAAP financial measures and the reconciliation of these non-GAAP financial measures to their most directly comparable GAAP financial measures and not rely on any single financial measure to evaluate our business.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_61"></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Liquidity and Capital Resources </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Sources of Liquidity </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We do not currently have any approved products and have never generated any revenue from product sales. To date, we have financed our operations primarily through sales of assets and equity interests, proceeds from collaborations and a licensing arrangement, grant funding and debt financing. Since inception through December&#160;31, 2025, we had received an aggregate of $933.1 million in payments from collaboration partners and a licensing arrangement, grant funding and forgivable and partially forgivable loans from the State of Connecticut, and raised approximately $1.7 billion in gross proceeds from the sale of assets and equity and the exercise of stock options, including:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">October 2018: completion of our initial public offering in which we issued and sold an aggregate of 7,700,482 shares of common stock for aggregate gross proceeds of $123.2 million, before fees and expenses; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">July 2019: sale of 1,346,313 shares of common stock to Bayer AG for aggregate gross proceeds of $32.5 million; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">November 2019: completion of a follow-on offering in which we issued and sold 5,227,273 shares of common stock for aggregate gross proceeds of $115.0 million, before fees and expenses; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">September - December 2020: sale of 2,593,637 shares of common stock in an &#8220;at-the-market offering&#8221; for aggregate gross proceeds of $65.6 million, before fees and expenses; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">December 2020: completion of a follow-on offering in which we issued and sold 6,571,428 shares of common stock for aggregate gross proceeds of $460.0 million, before fees and expenses;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">September 2021: issuance of 3,457,815 shares of common stock to Pfizer for aggregate gross proceeds of $350.0&#160;million.</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">July - September 2023: sale of 1,449,275 shares of common stock in an &#8220;at-the-market" offering for aggregate gross proceeds of $37.2 million before fees and expenses;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">November 2023: sale of 12,963,542 shares of common stock and pre-funded warrants to purchase 3,422,380 shares of common stock in a private placement for aggregate gross proceeds of $350.0 million before fees and expenses; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">April 2024: sale of AR-V7 to Novartis under the Novartis Asset Agreement for $20.0 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, we amended and restated the Equity Distribution Agreement with </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Piper Sandler &amp; Company and Cantor Fitzgerald &amp; Co.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, pursuant to which we may offer and sell from time to time, through the agents, up to approximately </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$262.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the common stock registered under our universal shelf registration statement pursuant to one or more &#8220;at-the-market&#8221; offerings. During the years ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025 and 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, no shares were issued under the amended and restated agreement.</span></div><div style="margin-top:8pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, we entered into the Vepdegestrant (ARV-471) Collaboration Agreement with Pfizer, pursuant to which we granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing our proprietary compound vepdegestrant. Under the Vepdegestrant (ARV-471) Collaboration Agreement, Pfizer made an upfront, nonrefundable payment of $650.0&#160;million.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">139</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Cash Flows </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our cash, cash equivalents and marketable securities totaled $685.4 million and $1.0 billion as of December&#160;31, 2025 and 2024, respectively. We had an outstanding loan balance of $0.6 million and $0.8 million as of December&#160;31, 2025 and 2024, respectively. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes our sources and uses of cash for the period presented: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years Ended December 31, </span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash used in operating activities</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(273.8)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(259.3)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(347.8)</span></td><td style="background-color:#CFF0FC;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash provided by investing activities</span></td><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">407.6&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">34.7&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td colspan="2" style="padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">203.5&#160;</span></td><td style="padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(91.4)</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.9&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#CFF0FC;padding:0 1pt"/><td colspan="2" style="background-color:#CFF0FC;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">374.7&#160;</span></td><td style="background-color:#CFF0FC;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">42.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(216.7)</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="padding:0 1pt"/><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">230.4&#160;</span></td><td style="border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Operating Activities </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December&#160;31, 2025 increased by $14.5 million, compared with the year ended December&#160;31, 2024, primarily due to a decrease in deferred revenue of $141.6 million, driven by changes in total Vepdegestrant (ARV-471) Collaboration Agreement program cost estimates resulting from the removal of two Phase 3 combination trials from the development plan and a decrease in non-cash charges of $39.5 million, partially offset by a decrease in our net loss of $118.1 million, changes in accounts payable and accrued liabilities of $19.5 million, prepaid expenses and other assets of $12.3 million and accounts receivable of $10.4 million. The change in non-cash charges was primarily due to a decrease in stock compensation expense of $44.2 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in operating activities for the year ended December 31, 2024 decreased by $88.5 million, compared with the year ended December 31, 2023, primarily due to a decrease in our net loss of $168.4 million and a net increase in non-cash charges of $16.4 million, partially offset by changes in accounts payable and accrued liabilities of $38.5 million, deferred revenue of $26.4 million, prepaid expenses and other assets of $21.1 million and accounts receivable of $6.7 million. The change in non-cash charges was primarily due to an increase in stock compensation expense of $16.7 million.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Investing Activities </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the year ended December&#160;31, 2025 increased by $372.9 million, compared with the year ended December&#160;31, 2024, primarily due to a net decrease in purchases and sales of marketable securities over maturities of $373.0 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by investing activities for the year ended December 31, 2024 decreased by $168.8 million, compared with the year ended December 31, 2023, primarily due to a net decrease in maturities and sales of marketable securities in excess of purchases of $170.1 million, partially offset by a decrease in purchases of property and equipment of $1.1 million.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Financing Activities </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash used in financing activities for the year ended December&#160;31, 2025 decreased by $99.3 million, compared with the year ended December&#160;31, 2024, primarily due to repurchases of common shares of $91.9 million, including commissions and excise tax, under our share repurchase plan and a decrease in proceeds from the exercise of stock options and issuance of ESPP shares of $7.6 million.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Net cash provided by financing activities for the year ended December 31, 2024 decreased by $366.8 million, compared with the year ended December 31, 2023, primarily due to net proceeds from the issuance of common stock and pre-funded warrants to purchase shares of our common stock in a private placement in 2023 of approximately $334.1 million and net proceeds from the issuance of common stock under our "at-the-</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">140</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">market" offering program in 2023 of approximately $36.1 million, neither of which reoccurred in 2024, partially offset by increased proceeds from the exercise of stock options and issuance of ESPP shares of $3.8 million.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Share Repurchase Activities</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2025, we announced that our board of directors authorized and approved a share repurchase program for the repurchase of up to $100.0 million of the currently outstanding shares of our common stock. Share repurchases under the share repurchase program may be made from time to time through a variety of methods, which may include open market purchases, privately negotiated block trades, accelerated share repurchases, other privately negotiated transactions or any combination of these methods. Repurchases may also be made under a Rule 10b5-1 plan, which would permit shares to be repurchased when we might otherwise be precluded from doing so under insider trading laws. The share repurchase program is funded using our working capital. The share repurchase program has no time limit and can be modified, suspended or discontinued at any time without prior notice.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December 31, 2025, we have utilized approximately $91.9 million to repurchase shares of our outstanding common stock pursuant to our authorized share repurchase program. We believe we have met our objectives for the stock repurchase program. As of December&#160;31, 2025, we suspended the program and have no further plans to repurchase additional shares.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Funding Requirements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Since our inception, we have incurred significant operating losses. We expect to continue to incur significant expenses and increasing operating losses for the foreseeable future as we advance the preclinical and clinical </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">development of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Specifically, we anticipate that our expenses will increase substantially if, and as we: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">continue our ongoing and planned clinical trials of our product candidates, including ARV-102, our PROTAC protein degrader designed to target the LRRK2 protein, ARV-806, our PROTAC protein degrader designed to target KRAS G12D for mutated cancers, ARV-393, our PROTAC protein degrader designed to target the BCL6 protein, ARV-027, our PROTAC protein degrader designed to target the polyQ-AR protein, and vepdegestrant, for the treatment of patients with locally advanced or metastatic ER+/HER2- breast cancer;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress our preclinical programs, including</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> ARV-6723 and our pan-KRAS degrader program;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">progress additional PROTAC protein degrader programs into IND- or CTA-enabling studies;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">apply our PROTAC Discovery Engine to advance additional product candidates into preclinical and clinical development;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand the capabilities of our PROTAC Discovery Engine; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">seek marketing approvals for any product candidates that successfully complete clinical trials; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make decisions with respect to our personnel, including retention or future hiring of key employees, and establishment of a sales, marketing, market access, and distribution infrastructure to launch commercial sales of our products, if and when approved, whether alone or in collaboration with others;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make decisions with respect to our infrastructure and capabilities, including to support our operations as a public company and our research, product development and future commercialization efforts;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">make or maintain arrangements with third-party manufacturers, or establish manufacturing capabilities, for both clinical and commercial supplies of our product candidates; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">expand, maintain and protect our intellectual property portfolio.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">141</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We had cash, cash equivalents and marketable securities of approximately $685.4 million as of December&#160;31, 2025. We believe that our cash, cash equivalents and marketable securities as of December&#160;31, 2025 will enable us to fund our planned operating expenses and capital expenditure requirements into the second half of 2028. We have based this estimate on assumptions that may prove to be wrong and we could use our capital resources sooner than we currently expect. Our future capital requirements will depend on many factors, including: </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope, costs and results of our ongoing and planned clinical trials of ARV-102, ARV-806, ARV-393, ARV-027 and vepdegestrant;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the progress, scope, costs and results of preclinical and clinical development for our other product candidates and development programs, including AR</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">V-6723 and our pan-KRAS degrader program</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the number of, and development requirements for, other product candidates that we pursue, including our other oncology an</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">d neurology res</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">earch programs;</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> success of our collaborations, including with Pfizer and Genentech; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs, timing and outcome of regulatory review of our product candidates; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of future commercialization activities, including product manufacturing, marketing, sales and distribution, for any of our product candidates for which we receive marketing approval and which we choose to commercialize ourselves; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the revenue, if any, received from commercial sales of our product candidates for which we receive marketing approval; </span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">the costs and timing of preparing, filing and prosecuting patent applications, maintaining and enforcing our intellectual property rights and defending any intellectual property-related claims; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">our ability to establish additional collaboration arrangements with other biotechnology or pharmaceutical companies on favorable terms, if at all, or enter into license, marketing and royalty arrangements, and similar transactions for the development or commercialization of our product candidates.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of these anticipated expenditures, we will need to obtain substantial additional financing in connection with our continuing operations. Until such time, if ever, as we can generate substantial revenue from product sales, we expect to finance our cash needs through a combination of equity offerings, debt financings, collaborations, strategic alliances and marketing, distribution or licensing arrangements. Although we may receive potential future payments under our collaborations, including with Pfizer and Genentech, and our out-license to Novartis, we do not currently have any committed external source of funds. Adequate additional funds may not be available to us on acceptable terms, or at all. If we are unable to raise capital when needed or on attractive terms, we may be required to delay, limit, reduce or terminate our research, product development programs or any future commercialization efforts or grant rights to develop and market product candidates that we would otherwise prefer to develop and market ourselves. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">To the extent that we raise additional capital through the sale of equity or convertible debt securities, the terms of these securities may include liquidation or other preferences that adversely affect the rights of our common stockholders. Debt financing and preferred equity financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making acquisitions or capital expenditures or declaring dividends. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If we raise additional funds through collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs or product candidates or grant licenses on terms that may not be favorable to us. </span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Borrowings</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, we entered into an additional Assistance Agreement with the State of Connecticut, or the 2018 Assistance Agreement, to provide funding for the expansion and renovation of laboratory and office space. We borrowed $2.0 million under the 2018 Assistance Agreement in September 2018, of which $1.0 million was forgiven upon meeting certain employment conditions. Borrowings under the agreement bear an interest rate of </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">142</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.25% per annum, with interest only payments required for the first 60 months, and mature in September 2028. The 2018 Assistance Agreement requires that we be located in the State of Connecticut through September 2028 with a default penalty of repayment of the full original funding amount of $2.0 million plus liquidated damages of 7.5% of the total amount of funding received. As of December&#160;31, 2025, $0.6 million remains outstanding under the 2018 Assistance Agreement.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_64"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 7A. Quantitative and Qualitative Disclosures About Market Risk. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We are exposed to market risks in the ordinary course of our business. These risks primarily include interest rate sensitivities. Our interest-earning assets consist of cash, cash equivalents and marketable securities. Interest income earned on these assets tota</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">led </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$38.5 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in 2025.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Our interest income is sensitive to changes in the general level of interest rates, primarily U.S. interest rates. As of December&#160;31, 2025, our cash equivalents consisted of bank deposits and money market funds and our marketable securities included interest-earning securities. Such interest-earning instruments carry a degree of interest rate risk. Our outstanding debt totaled $0.6 million as of December&#160;31, 2025 and carries a fixed interest rate of 3.25% per annum. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_67"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 8. Financial Statements and Supplementary Data.</span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our financial statements, together with the report of our independent registered public accounting firm, appear on pages F-1 through F-31 of this Annual Report on Form 10-K. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_70"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure.</span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_73"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9A. Controls and Procedures.</span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Evaluation of Disclosure Controls and Procedures</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer (our principal executive officer and principal financial officer, respectively), evaluated the effectiveness of our disclosure controls and procedures as of December&#160;31, 2025. The term &#8220;disclosure controls and procedures,&#8221; as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, means controls and other procedures of a company that are designed to ensure that information required to be disclosed by the company in the reports that it files or submits under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the Securities and Exchange Commission&#8217;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by a company in the reports that it files or submits under the Exchange Act is accumulated and communicated to the company&#8217;s management, including its principal executive and principal financial officers, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure. Our management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and our management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December&#160;31, 2025, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Management&#8217;s Annual Report on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management is responsible for establishing and maintaining adequate internal control over financial reporting for the company. Internal control over financial reporting is defined in Rule 13a-15(f) or 15d-15(f) promulgated under the Exchange Act as a process designed by, or under the supervision of, the company&#8217;s principal executive and principal financial officers and effected by the company&#8217;s board of directors, management and other personnel, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of consolidated financial statements for external purposes in accordance with generally accepted accounting principles and includes those policies and procedures that:</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Pertain to the maintenance of records that in reasonable detail accurately and fairly reflect the transactions and dispositions of the assets of the company;</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">143</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance that transactions are recorded as necessary to permit preparation of consolidated financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and</span></div><div style="margin-top:6pt;padding-left:54pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Therefore, even those systems determined to be effective can provide only reasonable assurance with respect to financial statement preparation and presentation. Projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our management assessed the effectiveness of our internal control over financial reporting as of December&#160;31, 2025. In making this assessment, management used the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission (COSO) in Internal Control - Integrated Framework (2013). Based on that assessment, our management concluded that, as of December&#160;31, 2025, our internal control over financial reporting was effective.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deloitte &amp; Touche LLP, the independent registered public accounting firm that audited the consolidated financial statements included in this Annual Report on Form 10-K, has issued an attestation report on the effectiveness of internal control over financial reporting as of December&#160;31, 2025, included below.</span></div><div style="margin-top:18pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Changes in Internal Control over Financial Reporting</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">No change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act) occurred during the quarter ended December&#160;31, 2025 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_76"></div><div style="margin-top:18pt"><span><br/></span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">144</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the stockholders and the Board of Directors of Arvinas, Inc.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the internal control over financial reporting of Arvinas, Inc. and subsidiaries (the &#8220;Company&#8221;) as of December&#160;31, 2025, based on criteria established in</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission (COSO). In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December&#160;31, 2025, based on criteria established in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by COSO.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the consolidated financial statements as of and for the year ended December&#160;31, 2025, of the Company and our report dated February&#160;24, 2026, expressed an unqualified opinion on those financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s management is responsible for maintaining effective internal control over financial reporting and for its assessment of the effectiveness of internal control over financial reporting, included in the accompanying Management&#8217;s Annual Report on Internal Control over Financial Reporting. Our responsibility is to express an opinion on the Company&#8217;s internal control over financial reporting based on our audit. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audit in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether effective internal control over financial reporting was maintained in all material respects. Our audit included obtaining an understanding of internal control over financial reporting, assessing the risk that a material weakness exists, testing and evaluating the design and operating effectiveness of internal control based on the assessed risk, and performing such other procedures as we considered necessary in the circumstances. We believe that our audit provides a reasonable basis for our opinion.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Definition and Limitations of Internal Control over Financial Reporting</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A company&#8217;s internal control over financial reporting is a process designed to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles. A company&#8217;s internal control over financial reporting includes those policies and procedures that (1) pertain to the maintenance of records that, in reasonable detail, accurately and fairly reflect the transactions and dispositions of the assets of the company; (2) provide reasonable assurance that transactions are recorded as necessary to permit preparation of financial statements in accordance with generally accepted accounting principles, and that receipts and expenditures of the company are being made only in accordance with authorizations of management and directors of the company; and (3) provide reasonable assurance regarding prevention or timely detection of unauthorized acquisition, use, or disposition of the company&#8217;s assets that could have a material effect on the financial statements.</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">/s/ Deloitte &amp; Touche LLP</span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Boston, Massachusetts</span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;24, 2026</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">145</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_79"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9B. Other Information. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">(a) </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">On February 24, 2026, we issued a press release announcing unaudited financial results for the quarter and year ended December 31, 2025, which was furnished on a Current Report on Form 8-K filed on February 24, 2026, or collectively, the Earnings Materials. We also held a conference call and webcast discussing such results. Subsequent to presenting our Earnings Materials, we made an immaterial adjustment to the fourth quarter 2025 basic and diluted net loss per common share. The amount reported for fourth quarter 2025 basic and diluted net loss per common share in the Earnings Materials was reported as $(1.10) and should be $(1.04). </span></div><div style="margin-top:18pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"> Director and Officer Trading Arrangements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None of our directors or officers <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-52"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrAdoptedFlag" format="ixt:fixed-false" id="f-53">adopted</ix:nonNumeric></ix:nonNumeric> or <ix:nonNumeric contextRef="c-4" name="ecd:NonRule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-54"><ix:nonNumeric contextRef="c-4" name="ecd:Rule10b51ArrTrmntdFlag" format="ixt:fixed-false" id="f-55">terminated</ix:nonNumeric></ix:nonNumeric> a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement (as defined in Item 408(c) of Regulation S-K) during the fourth quarter of 2025.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_82"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9C. Disclosure Regarding Foreign Jurisdictions That Prevent Inspection </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Not Applicable. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">146</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_85"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART III </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_88"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 10. Directors, Executive Officers and Corporate Governance. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference from the information that will be contained in our Proxy Statement for our 2026 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have adopted a Code of Business Conduct and Ethics that applies to our officers, including our principal executive, financial and accounting officers and our directors and employees. We have posted the text of our Code of Business Conduct and Ethics under the &#8220;Investors and Media &#8211; Corporate Governance&#8221; section of our website, www.arvinas.com. We intend to disclose on our website any amendments to, or waivers from, the Code of Business Conduct and Ethics that are required to be disclosed pursuant to the disclosure requirements of Item 5.05 of Form 8-K. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="ecd:InsiderTrdPoliciesProcAdoptedFlag" format="ixt:fixed-true" id="f-56">We have adopted an Insider Trading Policy</ix:nonNumeric> governing the purchase, sale and/or other dispositions of Company securities by our directors, officers and employees and other covered persons. We believe the Insider Trading Policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, and Nasdaq listing standards. A copy of our Insider Trading Policy is incorporated by reference as Exhibit 19.1 to this Annual Report on Form 10-K for the fiscal year ended December&#160;31, 2025. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_91"></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 11. <span id="i14cc16fae9d542459e8f71aaf9be2ad5_469"></span>Executive Compensation. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">The information required by this Item (other than the information required by Item 402(v) of Regulation S-K) is incorporated by reference from the information that will be contained in our Proxy Statement for our 2026 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_94"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference from the information that will be contained in our Proxy Statement for our 2026 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_97"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 13. Certain Relationships and Related Transactions, and Director Independence. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference from the information that will be contained in our Proxy Statement for our 2026 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K. </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_100"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 14. Principal Accountant Fees and Services. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information required by this Item is incorporated by reference from the information that will be contained in our Proxy Statement for our 2026 Annual Meeting of Stockholders, which we intend to file with the SEC within 120 days of the end of the fiscal year to which this Annual Report on Form 10-K relates pursuant to General Instruction G(3) of Form 10-K. </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">147</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_103"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">PART IV</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_106"></div><div style="-sec-extract:summary;margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 15. Exhibits, Financial Statement Schedules. </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Financial Statements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The following consolidated financial statements are filed as part of this Annual Report on Form 10-K:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_121">Report of Independent Registered Public Accounting Firm (PCAOB ID No.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><ix:nonNumeric contextRef="c-1" name="dei:AuditorFirmId" id="f-57">34</ix:nonNumeric></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_121">)</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_121">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_124">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025 and 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_124">4</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_127">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ended December 31, 2025, 2024 and 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_127">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_130">Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ended December 31, 2025, 2024 and 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_130">6</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_133">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ended December 31, 2025, 2024 and 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_133">7</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_136">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="-sec-extract:exhibit;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_136">8</a></span></div></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Financial Statement Schedules</span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All financial statement schedules have been omitted because they are not applicable, not required or the information required is shown in the consolidated financial statements or the notes thereto.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%;padding-left:23.78pt">Index to Exhibits</span></div><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a list of exhibits filed as part of this Annual Report on Form 10-K.</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Exhibit</span></div><div style="margin-top:0.75pt;text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Number</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Description</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518289513/d615527dex31.htm">Restated</a></span><span style="color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518289513/d615527dex31.htm"> </a></span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518289513/d615527dex31.htm">Certificate of Incorporation of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on October 1, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575923000073/exhibit31-secondamendeda.htm">Second Amended and Restated Bylaws of the Registrant (incorporated by reference to Exhibit 3.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on June 21, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518262944/d564688dex41.htm">Specimen Stock Certificate evidencing the shares of common stock (incorporated by reference to Exhibit 4.1 to the Registrant's Registration Statement on Form S-1 (File No. 333-227112) filed with the SEC on August 30, 2018)</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518262944/d564688dex41.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.2</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518262944/d564688dex43.htm">Second Amended and Restated Put Agreement among the Registrant, Connecticut Innovations, Incorporated and the other parties thereto, dated March 29, 2018 (incorporated by reference to Exhibit 4.3 to the Registrant's Registration Statement on Form S-1 (File No. 333-2271121) filed with the SEC on August 30. 2018)</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518262944/d564688dex43.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.3</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312523282934/d906900dex102.htm">Registration Rights Agreement, dated November 24, 2023, by and among the Company and the other parties thereto </a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312523282934/d906900dex102.htm">(incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on November 27, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:8pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">148</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.4</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000156459020011004/arvn-ex44_268.htm">Description of the Registrant&#8217;s Securities Registered Under Section 12 of the Exchange Act (incorporated by reference to Exhibit 4.4 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 16, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.1+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex107.htm">Incentive Share Plan, as amended by First Amendment, dated October 16, 2015, Second Amendment, dated December 22, 2016, Third Amendment, dated September 8, 2017, and Fourth Amendment, dated March 29, 2018 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-227112) filed with the SEC on August 30, 2018</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex107.htm">).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.2+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518262944/d564688dex102.htm">Form of Incentive Share Award Agreement under Incentive Share Plan (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Registration Statement on Form S-1 (File No. 333-227112) filed with the SEC on August 30, 2018</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518262944/d564688dex102.htm">).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.3+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex103.htm">Form of Restricted Stock Agreement under Incentive Share Plan (incorporated by reference to Exhibit 10.3 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex103.htm">).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.4+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex104.htm">2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.4 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex104.htm"> </a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.5+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex105.htm">Form of Stock Option Agreement under 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.5 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex105.htm"> </a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.6+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000156459019009357/arvn-ex106_781.htm">Form of Restricted Stock Unit Agreement under 2018 Stock Incentive Plan (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 26, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.7+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex106.htm">2018 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September&#160;14,&#160;2018)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex106.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.8+*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108-arvinasxformo.htm">Form of Restricted Stock Unit Agreement under 2018 Stock Incentive Plan</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit108-arvinasxformo.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.9+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575924000009/arvinas-optioninducement.htm">Form of Inducement Stock Option Award Agreement </a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575924000009/arvinas-optioninducement.htm">(incorporated by reference to Exhibit 99.3 to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-276519) filed with the SEC on January 16, 2024).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.10+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575924000009/arvinas-rsuinducementgra.htm">Form of Inducement Restricted Stock Unit Award Agreement </a></span><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575924000009/arvinas-rsuinducementgra.htm">(incorporated by reference to Exhibit 99.4 to the Registrant&#8217;s Registration Statement on Form S-8 (File No. 333-276519) filed with the SEC on January 16, 2024).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.11+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex107.htm">Form of Director and Officer Indemnification Agreement (incorporated by reference to Exhibit 10.7 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018)</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex107.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.12+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex108.htm">Employment Agreement between the Registrant and John Houston, Ph.D., dated September 13, 2018 (incorporated by reference to Exhibit 10.8 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.13+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575924000118/exhibit101-saikemploymen.htm">Employment Agreement between the Registrant and Andrew Saik, dated June 17, 2024 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on July 30, 2024).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.14+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575924000060/employmentagreement-noah.htm">Employment Agreement between the Registrant and Noah Berkowitz M.D., Ph.D., dated March 18, 2024 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on May 7, 2024).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.15+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">Amended and Restated Employment Agreement</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">, </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">dated </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">November 4</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">,</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm"> </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">2025</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">, by and between the Registrant and Angela Cacace</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">, </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">Ph.D.</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm"> </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">(incorporated by reference to Exhibit </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">10.1</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm"> to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">November 5</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">, </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">2025)</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit101-arvinasxamend.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.16+*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1016-arvinasxamen.htm">Amended and Restated </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1016-arvinasxamen.htm">Employment Agreement</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1016-arvinasxamen.htm">, dated </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1016-arvinasxamen.htm">February 12, 2026</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1016-arvinasxamen.htm">, by and</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1016-arvinasxamen.htm"> between the Registrant and </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1016-arvinasxamen.htm">Randy Teel</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1016-arvinasxamen.htm">, </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1016-arvinasxamen.htm">Ph.D.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">149</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.501%"/><td style="width:0.1%"/></tr><tr style="height:6pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.17+</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/exhibit101-iansconsultin.htm">Consulting Agreement, dated June 6, 2025, by and between Arvinas Operations, Inc. and Ian Taylor, Ph.D.</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/exhibit101-iansconsultin.htm"> </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/exhibit101-iansconsultin.htm">(incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/exhibit101-iansconsultin.htm">1</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/exhibit101-iansconsultin.htm"> to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/exhibit101-iansconsultin.htm"> </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/exhibit101-iansconsultin.htm">August 6</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/exhibit101-iansconsultin.htm">, 2025</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000139/exhibit101-iansconsultin.htm">).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.18+*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="exhibit1018-arvinasxcons.htm">Consulting Agreement, dated February 12, 2026, by and between Arvinas, Inc. and John Houston, Ph.D. </a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.19+</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000162828025049527/exhibit102-arvinasxamend.htm">Amended and Restated Employment Agreement, dated November 4, 2025, by and between the Registrant and Randy Teel, Ph.D. (incorporated by reference to Exhibit 10.2 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on November 5, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.20</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1012.htm">Lease Agreement between the Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated December 31, 2017, as amended by First Amendment to Lease, dated May 23, 2018, and Second Amendment to Lease, dated September 4, 2018 (incorporated by reference to Exhibit 10.12 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.21</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312519076853/d723460dex101.htm">Third Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated March 12, 2019 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Current Report on Form 8-K (File No. 001-38672) filed with the SEC on March 15, 2019).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.22</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000156459020011004/arvn-ex1014_313.htm">Fourth Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated January 31, 2020 (incorporated by reference to Exhibit 10.14 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 16, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.23</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000156459021009857/arvn-ex1034_590.htm">Fifth Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated January 4, 2021 (incorporated by reference to Exhibit 10.34 to the Registrant's Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 1, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.24</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575923000079/arvinassixthleaseamendme.htm">Sixth Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated June 13, 2023 (incorporated by reference to Exhibit 10.11 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on August 8, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.25</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1024-building5sev.htm">Seventh Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated December 13, 2024</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1024-building5sev.htm"> </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1024-building5sev.htm">(incorporated by reference to Exhibit 10.</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1024-building5sev.htm">24</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1024-building5sev.htm"> to the Registrant&#8217;s </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1024-building5sev.htm">Annual </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1024-building5sev.htm">Report on Form 10-Q (File No. 001-38672) filed with the SEC on </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1024-building5sev.htm">February 11</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1024-building5sev.htm">, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.26</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1025-arvinas5sp8t.htm">Eighth Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated December 31, 2024</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1025-arvinas5sp8t.htm"> </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1025-arvinas5sp8t.htm">(incorporated by reference to Exhibit 10.2</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1025-arvinas5sp8t.htm">5</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1025-arvinas5sp8t.htm"> to the Registrant&#8217;s Annual Report on Form 10-Q (File No. 001-38672) filed with the SEC on February 11, 2025)</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1025-arvinas5sp8t.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.27</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1026-fullysigned9.htm">Ninth Amendment to Lease between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated Februar</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1026-fullysigned9.htm">y 10, 20</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1026-fullysigned9.htm">25</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1026-fullysigned9.htm"> </a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1026-fullysigned9.htm">(incorporated by reference to Exhibit 10.2</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1026-fullysigned9.htm">6</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1026-fullysigned9.htm"> to the Registrant&#8217;s Annual Report on Form 10-Q (File No. 001-38672) filed with the SEC on February 11, 2025)</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1026-fullysigned9.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.28</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit1031-4sparvinasle.htm">Lease Termination Agreement between Arvinas Operations, Inc. (formerly Arvinas, Inc.) and Science Park Development Corporation, dated January 15, 2025 (incorporated by reference to Exhibit 10.31 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on February 11, 2025).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.29&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575924000118/exhibit106-amendedyaleag.htm">Amended and Restated License Agreement between Yale University and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated June 18, 2024 (incorporated by reference to Exhibit 10.6 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-36874) filed with the SEC on July 30, 2024).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">150</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.30&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1016.htm">Amended and Restated License and Option Agreement among Genentech, Inc., F. Hoffmann-La Roche Ltd and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated November 8, 2017 (incorporated by reference to Exhibit 10.16 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018)</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1016.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.31&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1017.htm">Research Collaboration and License Agreement between Pfizer Inc. and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated December 22, 2017 (incorporated by reference to Exhibit 10.17 to the Registrant&#8217;s Registration Statement on Form S-1/A (File No. 333-227112) filed with the SEC on September 14, 2018)</a><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312518273347/d564688dex1017.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.32&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000156459020011004/arvn-ex1024_312.htm">Amendment No. 1 to Research Collaboration and License Agreement between Pfizer Inc. and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated December 9, 2019 (incorporated by reference to Exhibit 10.24 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on March 16, 2020).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:5pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.33&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575922000016/pfizerarvinasamendmentno2r.htm">Amendment No. 2 to Research Collaboration and License Agreement between Pfizer Inc. and Arvinas Operations, Inc. (formerly Arvinas, Inc.), dated January 14, 2022 (incorporated by reference to Exhibit 10.1 to the Registrant&#8217;s Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on May 5, 2022).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.34&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575923000010/arvinaspfizzeramendmentno3.htm">Amendment No. 3 to Research Collaboration and License Agreement between Pfizer Inc. and Arvinas Operations, Inc (formerly Arvinas, Inc.), dated December 21, 2022 (incorporated by reference to Exhibit 10.32 to the Registrant&#8217;s Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on February 23, 2023)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.35&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000119312521221390/d160222dex101.htm">Collaboration Agreement by and between Arvinas, Inc., Arvinas Operations, Inc., Arvinas Estrogen Receptor, Inc. and Pfizer, Inc., dated July 21, 2021 (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-38672) filed with the SEC on July 22, 2021)</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.36&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000119312521221390/d160222dex102.htm">Stock Purchase Agreement, dated July 21, 2021, by and between Arvinas, Inc. and Pfizer, Inc. (incorporated by reference to Exhibit 10.2 to the Registrant's Current Report on Form 8-K (File No. 001-38672) filed with the SEC on July 22, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.37&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;background-color:#ffffff;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/0001655759/000119312521221390/d160222dex103.htm">Investor Agreement, dated July 21, 2021, by and between Arvinas, Inc. and Pfizer, Inc. (incorporated by reference to Exhibit 10.3 to the Registrant's Current Report on Form 8-K (File No. 001-38672) filed with the SEC on July 22, 2021).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.38</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312523272580/d555260dex12.htm">Amended and Restated Equity Distribution Agreement, dated November 7, 2023, by and among Arvinas, Inc., Piper Sandler &amp; Co. and Cantor Fitzgerald &amp; Co. (incorporated by reference to Exhibit 1.2 to the Registrant's Registration Statement on Form S-3 (File No. 333-275377) filed with the SEC on November 7, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.39</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000119312523282934/d906900dex101.htm">Securities Purchase Agreement, dated November 24, 2023, by and among the Company and the other parties thereto (incorporated by reference to Exhibit 10.1 to the Registrant's Current Report on Form 8-K (File No. 001-38672) filed with the SEC on November 27, 2023).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.40&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575924000118/exhibit104-novartisxarvi.htm">License Agreement by and among Arvinas, Inc., Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc. and Novartis Pharma AG, dated April 10, 2024 (incorporated by reference to Exhibit 10.4 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on July 30, 2024).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">10.41&#8224;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575924000118/exhibit105-novartisxarvi.htm">Asset Purchase Agreement by and among Arvinas, Inc., Arvinas Operations, Inc., Arvinas Androgen Receptor, Inc. and Novartis Pharma AG, dated April 10, 2024  (incorporated by reference to Exhibit 10.5 to the Registrant's Quarterly Report on Form 10-Q (File No. 001-38672) filed with the SEC on July 30, 2024).</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.1</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit191-insidertradin.htm">Registrant's Insider Trading Policy</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit191-insidertradin.htm"> (incor</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit191-insidertradin.htm">porated by reference to Exhibit 19.1 to the Registran</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit191-insidertradin.htm">t's Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on </a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit191-insidertradin.htm">February 11, 2025)</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575925000016/exhibit191-insidertradin.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="arvn-20251231x10kxex21_1.htm">Subsidiaries of the Registrant</a><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="arvn-20251231x10kxex21_1.htm">.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">23.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="consent-form10kfy25.htm">Consent of Deloitte &amp; Touche LLP, independent registered public accounting firm.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.1*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="arvn-20251231x10kxex311.htm">Certification of Principal Executive Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">151</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div style="-sec-extract:summary"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:8.972%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.529%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:73.498%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.501%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">31.2*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="arvn-20251231x10kxex312.htm">Certification of Principal Financial Officer Pursuant to Rules 13a-14(a) and 15d-14(a) under the Securities Exchange Act of 1934, as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.1**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="arvn-20251231x10kxex321.htm">Certification of Principal Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.2**</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="arvn-20251231x10kxex322.htm">Certification of Principal Financial Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</a></span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">97.1*</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="https://www.sec.gov/Archives/edgar/data/1655759/000165575924000018/arvinas-exchangexcompliant.htm">Arvinas, Inc. Dodd-Frank Compensation Recovery Policy (incorporated by reference to Exhibit  97.1 to the Registrant's Annual Report on Form 10-K (File No. 001-38672) filed with the SEC on February 27, 2024)</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">.</span></div></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.INS*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Instance Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.SCH*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Schema Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.CAL*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Calculation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.DEF*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Definition Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.LAB*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Label Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">101.PRE*</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Inline XBRL Taxonomy Extension Presentation Linkbase Document</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cover Page Interactive Date File (formatted as Inline XBRL and contained in Exhibit 101)</span></td><td colspan="3" style="padding:0 1pt"/></tr></table></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">____________________</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">*&#160;&#160;&#160;&#160;Filed herewith.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">**&#160;&#160;&#160;&#160;Furnished herewith.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8224;&#160;&#160;&#160;&#160;Portions of this exhibit have been omitted pursuant to Item 601(b)(10)(iv) of Regulation S-K.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">+&#160;&#160;&#160;&#160;Management contract or compensatory plan or arrangement.</span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_109"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 16. Form 10-K Summary</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">None.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">152</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_112"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">.</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:46.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.596%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:46.629%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">ARVINAS, INC.</span></td></tr><tr style="height:15pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Date: February&#160;24, 2026</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Randy Teel, Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Randy Teel, Ph.D.</span></div></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">President and Chief Executive Officer</span></div></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant in the capacities and on the dates indicated.</span></div><div style="margin-top:6pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:32.687%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:45.263%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:17.236%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Name</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Title</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Date</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Randy Teel, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">President and Chief Executive Officer, Director</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 24, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Randy Teel, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(principal executive officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Andrew Saik</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chief Financial Officer and Treasurer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 24, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Andrew Saik</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(principal financial officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ David K. Loomis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vice President and Chief Accounting Officer</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 24, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">David K. Loomis</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(principal accounting officer)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Briggs Morrison, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Chair of the Board of Directors</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 24, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Briggs Morrison, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Sunil Agarwal, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 24, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Sunil Agarwal, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Linda Bain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 24, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Linda Bain</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Everett Cunningham</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 24, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Everett Cunningham</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ John Houston, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 24, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">John Houston, Ph.D.</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Edward Kennedy, Jr.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 24, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;Edward Kennedy, Jr.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Leslie Norwalk, Esq.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 24, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;Leslie Norwalk, Esq.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">/s/ Laurie Smaldone Alsup, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Director</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">February 24, 2026</span></td></tr><tr><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laurie Smaldone Alsup, M.D.</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr><tr style="height:3pt"><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">153</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_115"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Index to Consolidated Financial Statements</span></div><div style="margin-top:12pt"><span><br/></span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:89.203%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.597%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Page</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_121">Report of Independent Registered Public Accounting Firm (PCAOB ID No.</a></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">34</span><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_121">)</a></span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_121">2</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt 0 10pt;text-indent:-9pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_124">Consolidated Balance Sheets</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">December 31, 2025 and 2024</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_124">4</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_127">Consolidated Statements of Operations and Comprehensive Loss</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ended December 31, 2025, 2024 and 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_127">5</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_130">Consolidated Statements of Changes in Stockholders&#8217; Equity</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ended December 31, 2025, 2024 and 2023</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_130">6</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_133">Consolidated Statements of Cash Flows</a></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Years ended December 31, 2025, 2024 and 2023</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_133">7</a></span></div></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline"><a style="color:#0000ff;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline" href="#i234a6a5dabee4a7a8fb9427be68ac044_136">Notes to Consolidated Financial Statements</a></span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">F-<a style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:none" href="#i234a6a5dabee4a7a8fb9427be68ac044_136">8</a></span></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 1</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_121"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM </span></div><div><span><br/></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To the stockholders and the Board of Directors of Arvinas, Inc. </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Opinion on the Financial Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have audited the accompanying consolidated balance sheets of Arvinas, Inc. and subsidiaries (the "Company") as of December&#160;31, 2025 and 2024, the related consolidated statements of operations and comprehensive loss, changes in stockholders&#8217; equity, and cash flows, for each of the three years in the period ended December&#160;31, 2025, and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company as of December&#160;31, 2025 and 2024, and the results of its operations and its cash flows for each of the three years in the period ended December&#160;31, 2025, in conformity with accounting principles generally accepted in the United States of America.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the Company's internal control over financial reporting as of December&#160;31, 2025, based on criteria established in </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Internal Control &#8212; Integrated Framework (2013)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> issued by the Committee of Sponsoring Organizations of the Treadway Commission and our report dated February&#160;24, 2026, expressed an unqualified opinion on the Company's internal control over financial reporting.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis for Opinion</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">These financial statements are the responsibility of the Company's management. Our responsibility is to express an opinion on the Company's financial statements based on our audits. We are a public accounting firm registered with the PCAOB and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Critical Audit Matter </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The critical audit matter communicated below is a matter arising from the current-period audit of the financial statements that was communicated or required to be communicated to the audit committee and that (1) relates to accounts or disclosures that are material to the financial statements and (2) involved our especially challenging, subjective, or complex judgments. The communication of critical audit matters does not alter in any way our opinion on the financial statements, taken as a whole, and we are not, by communicating the critical audit matter below, providing a separate opinion on the critical audit matter or on the accounts or disclosures to which it relates.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses &#8211; Research and Development Accruals - Refer to Note 2 in the Consolidated Financial Statements</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Critical Audit Matter Description</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into contracts with third parties to perform research and development activities. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. These accrued expenses are based on management&#8217;s estimates of the work performed under </span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">service agreements, milestones achieved and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We identified the valuation of certain research and development accruals as a critical audit matter due to the judgments necessary for management to estimate the level of services provided and the costs incurred for the service when the Company has not yet been invoiced or otherwise notified of actual costs. This required a high degree of auditor judgment and an increased extent of effort when performing audit procedures to audit management's estimates of such expenses.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">How the Critical Audit Matter Was Addressed in the Audit</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our audit procedures related to research and development accruals included the following, among others:</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">We tested the effectiveness of controls over the estimation of research and development accruals.</span></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">For a sample of projects, we read the related contracts and any amendments to the contracts, purchase orders, statements of work and other contractual documentation. We tested the completeness and accuracy of the information used to develop the estimates and evaluated the significant assumptions used by management to estimate the recorded amounts by performing the following:</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Performed corroborating inquiries with the Company&#8217;s research and development personnel to understand the nature and progress of the studies.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Inspected information from third-party service providers to evaluate the progress of the activity.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Obtained corresponding invoices and evidence of payment to third-party service providers.</span></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#9642;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.46pt">Compared the estimated accrual balance as of December 31, 2025, to the invoices received after year-end to evaluate the Company&#8217;s ability to estimate the accrual.</span></div><div style="padding-left:36pt"><span><br/></span></div><div style="padding-left:36pt"><span><br/></span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">/s/ <ix:nonNumeric contextRef="c-1" name="dei:AuditorName" id="f-58">Deloitte &amp; Touche LLP</ix:nonNumeric></span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:AuditorLocation" id="f-59">Boston, Massachusetts</ix:nonNumeric></span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">February&#160;24, 2026</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have served as the Company's auditor since 2016.</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 3</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_124"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Assets</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Current assets:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-60">142.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-61">100.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-62">542.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:MarketableSecuritiesCurrent" scale="6" id="f-63">938.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-64">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-65">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other receivables</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="f-66">5.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OtherReceivablesNetCurrent" scale="6" id="f-67">8.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Prepaid expenses and other current assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-68">8.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="6" id="f-69">14.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total current assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AssetsCurrent" scale="6" id="f-70">700.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AssetsCurrent" format="ixt:num-dot-decimal" scale="6" id="f-71">1,067.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-72">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-73">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease right of use assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-74">8.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="6" id="f-75">9.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Collaboration contract asset and other assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="f-76">3.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="f-77">8.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total assets</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Assets" scale="6" id="f-78">717.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Assets" format="ixt:num-dot-decimal" scale="6" id="f-79">1,091.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Liabilities and stockholders' equity</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Current liabilities:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable and accrued liabilities</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-80">69.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-81">71.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-82">71.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityCurrent" scale="6" id="f-83">156.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Current portion of operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-84">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="6" id="f-85">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total current liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-86">142.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:LiabilitiesCurrent" scale="6" id="f-87">229.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-88">134.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityNoncurrent" scale="6" id="f-89">292.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Long term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-90">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-91">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease liability</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-92">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="6" id="f-93">7.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total liabilities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:Liabilities" scale="6" id="f-94">284.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:Liabilities" scale="6" id="f-95">529.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Commitments and contingencies (Note 12)</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-5" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-96"></ix:nonFraction></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"><ix:nonFraction unitRef="usd" contextRef="c-6" xsi:nil="true" name="us-gaap:CommitmentsAndContingencies" id="f-97"></ix:nonFraction></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Stockholders' equity:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Preferred stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-98"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-99">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-100"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-101"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:PreferredStockSharesIssued" format="ixt:fixed-zero" scale="0" id="f-102"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:PreferredStockSharesOutstanding" format="ixt:fixed-zero" scale="0" id="f-103">zero</ix:nonFraction></ix:nonFraction></ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2025 and 2024, respectively</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-104">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:PreferredStockValue" format="ixt:fixed-zero" scale="0" id="f-105">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Common stock, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-106"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-107">0.001</ix:nonFraction></ix:nonFraction> par value, <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-108">73.5</ix:nonFraction> shares issued and <ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-109">63.5</ix:nonFraction> shares outstanding as of December&#160;31, 2025, and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-110"><ix:nonFraction unitRef="shares" contextRef="c-6" decimals="-5" name="us-gaap:CommonStockSharesIssued" scale="6" id="f-111">68.8</ix:nonFraction></ix:nonFraction> shares issued and outstanding as of December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-112">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CommonStockValue" scale="6" id="f-113">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated deficit</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-114">1,612.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" sign="-" name="us-gaap:RetainedEarningsAccumulatedDeficit" format="ixt:num-dot-decimal" scale="6" id="f-115">1,531.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additional paid-in capital</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-116">2,136.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AdditionalPaidInCapital" format="ixt:num-dot-decimal" scale="6" id="f-117">2,092.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accumulated other comprehensive income</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-118">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" scale="6" id="f-119">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Treasury Stock, at cost (<ix:nonFraction unitRef="shares" contextRef="c-5" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-120">10.0</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:TreasuryStockCommonShares" format="ixt:fixed-zero" scale="0" id="f-121">zero</ix:nonFraction> shares at December&#160;31, 2025 and December&#160;31, 2024, respectively)</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:TreasuryStockCommonValue" scale="6" id="f-122">91.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:TreasuryStockCommonValue" format="ixt:fixed-zero" scale="6" id="f-123">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total stockholders' equity</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-124">433.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-125">561.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total liabilities and stockholders' equity</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="6" id="f-126">717.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:LiabilitiesAndStockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-127">1,091.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 4</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_127"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Operations and Comprehensive Loss </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per share amounts)</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Consolidated Statements of Operations</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-128">262.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-129">263.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-130">78.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Operating expenses:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-131">285.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-132">348.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-133">379.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-134">95.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-135">165.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-136">100.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total operating expenses</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-137">381.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-138">513.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-139">480.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Loss from operations</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-140">118.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-141">250.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:OperatingIncomeLoss" scale="6" id="f-142">401.5</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other income (expense)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other expense, net</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-143">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-144">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:OtherNonoperatingIncomeExpense" scale="6" id="f-145">1.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-146">38.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-147">54.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-148">38.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total other income</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-149">38.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-150">51.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:NonoperatingIncomeExpense" scale="6" id="f-151">37.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net loss before income taxes and loss from equity method investment</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="f-152">80.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="f-153">198.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" scale="6" id="f-154">363.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-155">0.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-156">0.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-157">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Loss from equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-158">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-159">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-160">2.5</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 2.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-161">80.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-162">198.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-163">367.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per common share</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Basic and diluted</span></div></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-164"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-165">1.14</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-166"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-167">2.77</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-168"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-169">6.62</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Weighted-average common shares outstanding</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Basic and diluted</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-170"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-171">70.9</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-172"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-173">71.9</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-174"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-175">55.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:52.233%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:700;line-height:114%">Consolidated Statements of Comprehensive Loss</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Net loss</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-176">80.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-177">198.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-178">367.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other comprehensive loss:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Unrealized gain on available-for-sale securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-179">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-180">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-181">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Comprehensive loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-182">80.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-183">194.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:ComprehensiveIncomeNetOfTax" scale="6" id="f-184">351.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 5</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_130"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS, INC. AND SUBSIDIARIES</span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Changes in Stockholders&#8217; Equity </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:24.205%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:8.333%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.779%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.243%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:7.787%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:27pt"><td colspan="3" style="padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Common</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated Deficit </span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Additional<br/>Paid-in Capital</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Accumulated <br/>Other<br/>Comprehensive<br/>Loss (Income)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Treasury</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" rowspan="2" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Total<br/>Stockholders'<br/>Equity</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr style="height:14pt"><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions)</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Shares</span></td><td colspan="3" style="border-top:0.75pt solid #000000;padding:0 1pt"/><td colspan="3" style="border-top:0.75pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Amount</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance as of December&#160;31, 2022</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-9" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-185">53.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-9" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-186">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-10" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-187">965.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-11" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-188">1,549.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-12" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-189">19.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-190">564.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-191">71.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-192">71.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-15" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-193">367.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-194">367.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-195">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-196">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-197">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Common stock issued, net of issuance costs of $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" scale="6" id="f-198">17.0</ix:nonFraction> million</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-16" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="6" id="f-199">14.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-14" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-200">370.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-201">370.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unrealized gain on available-for-sale securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-17" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-202">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-203">16.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance as of December&#160;31, 2023</span></div></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-18" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-204">68.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-18" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-205">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-19" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-206">1,332.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-20" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-207">1,995.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-21" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-208">3.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-209">660.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-210">88.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-211">88.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-24" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-212">198.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-213">198.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-25" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-214">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-23" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-215">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-216">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unrealized gain on available-for-sale securities</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-26" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-217">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-218">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance as of December&#160;31, 2024</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-27" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-219">68.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-27" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-220">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-28" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-221">1,531.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-29" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-222">2,092.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-30" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-223">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-31" decimals="-5" name="us-gaap:TreasuryStockCommonShares" format="ixt:fixed-zero" scale="6" id="f-224">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-31" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:fixed-zero" scale="6" id="f-225">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-226">561.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-227">44.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="6" id="f-228">44.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">Net loss</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-33" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-229">80.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-230">80.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of common stock under equity incentive plans</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-5" name="us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation" scale="6" id="f-231">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-32" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-232">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation" scale="6" id="f-233">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Issuance of common stock for pre-funded warrants</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-34" decimals="-5" name="arvn:StockIssuedDuringPeriodSharesExerciseOfWarrants" scale="6" id="f-234">3.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Share repurchases (Treasury stock)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-35" decimals="-5" name="us-gaap:TreasuryStockSharesAcquired" scale="6" id="f-235">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-35" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-236">91.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:TreasuryStockValueAcquiredCostMethod" scale="6" id="f-237">91.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:115%">Unrealized gain on available-for-sale securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-36" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-238">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" scale="6" id="f-239">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:700;line-height:114%">Balance as of December&#160;31, 2025</span></div></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-37" decimals="-5" name="us-gaap:CommonStockSharesOutstanding" scale="6" id="f-240">73.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-37" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-241">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-bottom:3pt double #000000;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-38" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-242">1,612.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-39" decimals="-5" name="us-gaap:StockholdersEquity" format="ixt:num-dot-decimal" scale="6" id="f-243">2,136.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-40" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-244">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="shares" contextRef="c-41" decimals="-5" name="us-gaap:TreasuryStockCommonShares" scale="6" id="f-245">10.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-41" decimals="-5" sign="-" name="us-gaap:StockholdersEquity" scale="6" id="f-246">91.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:StockholdersEquity" scale="6" id="f-247">433.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 6</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_133"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-align:center"><span style="background-color:#ffffff;color:#2e2e2e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="background-color:#ffffff;color:#2e2e2e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INC</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. AND SUBSIDIARIES</span></div><div style="margin-top:6pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Cash Flows </span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years Ended December&#160;31,</span></div></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Cash flows from operating activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-248">80.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-249">198.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-250">367.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:21pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Adjustments to reconcile net loss to net cash used in operating activities:</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Depreciation and amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-251">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-252">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-253">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net accretion of bond discounts/premiums</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="f-254">12.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="f-255">21.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" scale="6" id="f-256">16.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:25.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Loss on sale of marketable securities</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="6" id="f-257">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" format="ixt:fixed-zero" scale="6" id="f-258">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss" scale="6" id="f-259">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Amortization of right-of-use assets</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-260">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-261">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense" scale="6" id="f-262">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Amortization of collaboration contract asset</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="f-263">4.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="f-264">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:CapitalizedContractCostAmortization" scale="6" id="f-265">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Net loss on disposal of property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="6" id="f-266">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="6" id="f-267">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" format="ixt:fixed-zero" scale="6" id="f-268">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Stock-based compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-269">44.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-270">88.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:ShareBasedCompensation" scale="6" id="f-271">71.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Changes in operating assets and liabilities:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accounts receivable</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-272">4.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-273">5.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsReceivable" scale="6" id="f-274">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Other receivables</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="6" id="f-275">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="6" id="f-276">0.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:IncreaseDecreaseInOtherReceivables" scale="6" id="f-277">0.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Prepaid expenses and other assets</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-278">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-279">7.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="6" id="f-280">14.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Collaboration contract asset</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:fixed-zero" scale="6" id="f-281">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" scale="6" id="f-282">3.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:IncreaseDecreaseInContractWithCustomerAsset" format="ixt:fixed-zero" scale="6" id="f-283">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Accounts payable and accrued liabilities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-284">1.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-285">21.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="6" id="f-286">17.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Operating lease liabilities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="f-287">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="f-288">1.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInOperatingLeaseLiability" scale="6" id="f-289">2.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 26.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-290">242.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-291">101.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:IncreaseDecreaseInContractWithCustomerLiability" scale="6" id="f-292">74.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 46pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Net cash used in operating activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-293">273.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-294">259.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="6" id="f-295">347.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Cash flows from investing activities:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Purchase of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="f-296">354.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="f-297">652.1</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="6" id="f-298">956.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Maturities of marketable securities</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" scale="6" id="f-299">731.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" scale="6" id="f-300">644.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="arvn:ProceedsFromMaturitiesOfMarketableSecurities" format="ixt:num-dot-decimal" scale="6" id="f-301">1,103.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Sale of marketable securities</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:ProceedsFromSaleOfMarketableSecurities" scale="6" id="f-302">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:ProceedsFromSaleOfMarketableSecurities" scale="6" id="f-303">44.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="arvn:ProceedsFromSaleOfMarketableSecurities" scale="6" id="f-304">58.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Purchase of property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-305">1.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-306">1.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="6" id="f-307">2.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Proceeds from disposal of property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-308">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="6" id="f-309">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" format="ixt:fixed-zero" scale="6" id="f-310">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Net cash provided by investing activities</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-311">407.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-312">34.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="6" id="f-313">203.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Cash flows from financing activities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Repayments of long-term debt</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-314">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" scale="6" id="f-315">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:RepaymentsOfLongTermDebt" format="ixt:fixed-zero" scale="6" id="f-316">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Proceeds from issuance of common stock and pre-funded warrants</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:ProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:fixed-zero" scale="6" id="f-317">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:ProceedsFromIssuanceOfCommonStockAndWarrants" format="ixt:fixed-zero" scale="6" id="f-318">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="arvn:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="6" id="f-319">387.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Payment of common stock offering costs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="6" id="f-320">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" format="ixt:fixed-zero" scale="6" id="f-321">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="f-322">17.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Repurchase of common shares, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" scale="6" id="f-323">91.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="0" id="f-324">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:9pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:PaymentsForRepurchaseOfCommonStock" format="ixt:fixed-zero" scale="0" id="f-325">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Proceeds from exercise of stock options and issuance of ESPP shares</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" scale="6" id="f-326">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" scale="6" id="f-327">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" scale="6" id="f-328">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 34pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Net cash (used in) provided by financing activities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-329">91.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-330">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="6" id="f-331">374.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Net increase (decrease) in cash, cash equivalents and restricted cash</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-332">42.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-333">216.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="6" id="f-334">230.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 22pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">Cash, cash equivalents and restricted cash, beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-335">100.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-336">317.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-337">86.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Cash, cash equivalents and restricted cash, end of the period</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-338">142.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-339">100.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-340">317.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;text-indent:-9pt;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Supplemental disclosure of cash flow information:</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-top:0.75pt;padding-left:22.5pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:115%">Purchases of property, equipment and leasehold improvements unpaid at period end</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-341">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" scale="6" id="f-342">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:CapitalExpendituresIncurredButNotYetPaid" format="ixt:fixed-zero" scale="6" id="f-343">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">See accompanying notes to the consolidated financial statements</span></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 7</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_136"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt;text-align:center"><span style="background-color:#ffffff;color:#2e2e2e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ARVINAS</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">, </span><span style="background-color:#ffffff;color:#2e2e2e;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">INC</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">. AND SUBSIDIARIES </span></div><div style="margin-top:12pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Notes to Consolidated Financial Statements </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_139"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">1. <ix:nonNumeric contextRef="c-1" name="us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock" id="f-344" continuedAt="f-344-1" escape="true">Nature of Business and Basis of Presentation</ix:nonNumeric></span></div><ix:continuation id="f-344-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins. Arvinas, Inc. has <ix:nonFraction unitRef="subsidiary" contextRef="c-1" decimals="INF" name="arvn:NumberOfWhollyOwnedSubsidiaries" format="ixt-sec:numwordsen" scale="0" id="f-345">four</ix:nonFraction> wholly owned subsidiaries; Arvinas Operations, Inc. formed in 2013, Arvinas Androgen Receptor, Inc. formed in 2015, Arvinas Estrogen Receptor, Inc. formed in 2016, and Arvinas Winchester, Inc. formed in 2018 (collectively, "Arvinas" or the "Company").</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="f-346" escape="true"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and include the accounts of Arvinas, Inc. and its wholly owned subsidiaries. <ix:nonNumeric contextRef="c-1" name="us-gaap:ConsolidationPolicyTextBlock" id="f-347" escape="true">All intercompany transactions have been eliminated upon consolidation. The accounting policies used to prepare the Company's consolidated financial statements are the same as those used to prepare the consolidated financial statements in prior years.</ix:nonNumeric></span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:UseOfEstimates" id="f-348" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and notes. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements and notes are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the Company&#8217;s revenue recognition, uncertain tax positions and research and development expenses.</span></div></ix:nonNumeric></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_145"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2. <ix:nonNumeric contextRef="c-1" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="f-349" continuedAt="f-349-1" escape="true">Summary of Significant Accounting Policies </ix:nonNumeric></span><ix:continuation id="f-349-1" continuedAt="f-349-2"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></ix:continuation></div><ix:continuation id="f-349-2" continuedAt="f-349-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="f-350" continuedAt="f-350-1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-350-1">The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents and are considered Level 1 financial instruments.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="f-351" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount which was canceled in connection with a lease termination agreement the Company entered into with 101 College Street LLC in August 2024.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock" id="f-353" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" id="f-352" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total amounts shown on the consolidated statements of cash flows for the years ended December 31, 2025, 2024 and 2023:</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-354">142.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-355">100.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="6" id="f-356">311.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="6" id="f-357">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:RestrictedCashCurrent" format="ixt:fixed-zero" scale="6" id="f-358">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:RestrictedCashCurrent" scale="6" id="f-359">5.5</ix:nonFraction></span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-360">142.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-361">100.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="6" id="f-362">317.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 8</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-349-3" continuedAt="f-349-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ConcentrationRiskCreditRisk" id="f-363" continuedAt="f-363-1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protect its proprietary technology. If the Company does not successfully obtain regulatory approval for its product candidates, it will be unable to generate revenue from product sales or achieve profitability. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of assets and equity, proceeds from collaborations and a licensing arrangement, grant funding and debt financing. The Company had cash, cash equivalents and marketable securities of approximately $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities" scale="6" id="f-364">685.4</ix:nonFraction> million as of December&#160;31, 2025.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-363-1">The Company maintains its cash in financial institution accounts that may at times exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $<ix:nonFraction unitRef="usd" contextRef="c-42" decimals="-3" name="us-gaap:FederalDepositInsuranceCorporationPremiumExpense" format="ixt:num-dot-decimal" scale="0" id="f-365">250,000</ix:nonFraction>. Cash may also be maintained at commercial institutions that are not insured by the FDIC.</ix:continuation> </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, one collaborator represented <ix:nonFraction unitRef="number" contextRef="c-43" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-366">92.0</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-44" decimals="3" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-367">62.0</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-45" decimals="2" name="us-gaap:ConcentrationRiskPercentage1" scale="-2" id="f-368">97</ix:nonFraction>% of the Company's revenue, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:MarketableSecuritiesPolicy" id="f-369" continuedAt="f-369-1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities </span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-369-1">The Company's marketable securities are classified as available-for-sale securities and are carried at their fair value based on the quoted market prices of the securities, with unrealized gains and losses reported as accumulated other comprehensive income (loss), a separate component of stockholders' equity. Realized gains and losses on available-for-sale securities are included in other income in the period earned or incurred.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="f-370" continuedAt="f-370-1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Equipment, and Leasehold Improvements </span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-370-1">Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from <ix:nonNumeric contextRef="c-46" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-371">three years</ix:nonNumeric> for office equipment to <ix:nonNumeric contextRef="c-47" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" format="ixt-sec:durwordsen" id="f-372">five years</ix:nonNumeric> for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation is removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeLeasesPolicyTextBlock" id="f-373" continuedAt="f-373-1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease and Rent Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases under Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use ("ROU") assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of the term of the lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the lease term unless there is reasonable certainty of renewal.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a </span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 9</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-349-4" continuedAt="f-349-5"><ix:continuation id="f-373-1"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">similar term, in a similar economic environment. The Company's weighted average incremental borrowing rate at December&#160;31, 2025 totaled <ix:nonFraction unitRef="number" contextRef="c-5" decimals="3" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="f-374">7.0</ix:nonFraction>%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease payments are not included within the lease right-of-use asset and lease liability on the consolidated balance sheet, and instead are reflected as expense in the period they are incurred.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" id="f-375" continuedAt="f-375-1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-375-1">The Company monitors its long-lived assets for indicators of impairment. If such indicators are present, the Company assesses the recoverability of affected assets by determining whether the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found not to be recoverable, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, with the fair value generally determined based on the present value of the expected future cash flows associated with the assets.</ix:continuation> <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="0" id="f-376"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="0" id="f-377"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="INF" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" format="ixt:fixed-zero" scale="0" id="f-378">No</ix:nonFraction></ix:nonFraction></ix:nonFraction> such impairments were recorded during 2025, 2024 or 2023.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueFromContractWithCustomerPolicyTextBlock" id="f-379" continuedAt="f-379-1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition and Deferred Revenue </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues from Contracts </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s revenue is primarily generated through research collaborations and licensing arrangements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Under ASC 606, the Company evaluates whether the license agreement, research and development services and participation in research and development steering committees represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent combined single performance obligations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also generated revenue through the sale of assets based on fair value.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research collaboration and license agreements may include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company continually assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized ratably over the Company&#8217;s expected performance period under each respective arrangement. Management makes its best estimate of the period over which the Company expects to fulfill its performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. Management evaluates changes in the duration of the performance period at each reporting period and adjusts revenue as necessary. Changes are accounted for prospectively as a change in accounting estimate. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, the transaction price allocated to the combined performance obligation identified under the individual research collaboration and license agreements was recognized as revenue on either a straight-line basis over the estimated performance period under the arrangement or over the estimated performance period based on the Company&#8217;s best estimate of costs to be incurred. Straight-line basis was considered the best measure of progress for certain agreements in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. For agreements accounted for under the costs to be incurred method, revenue is recognized as program costs are incurred by measuring actual costs incurred to date compared to the total expected costs to satisfy the performance obligations. Management evaluates estimates of expected costs to satisfy the performance obligations at each reporting period and adjusts revenue as necessary. Changes are accounted for prospectively as a change in accounting estimate.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 10</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-349-5" continuedAt="f-349-6"><ix:continuation id="f-379-1"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale, or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by customers from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liabilities in the Company&#8217;s accompanying consolidated balance sheets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses direct and incremental costs to obtaining and fulfilling a contract as and when incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as collaboration contract assets and amortized as general and administrative expenses over the total estimated period of performance of each underlying contract.</span></div></ix:continuation><ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsPolicy" id="f-380" continuedAt="f-380-1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Method Investments </span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><ix:continuation id="f-380-1" continuedAt="f-380-2"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Equity Method and Joint Ventures</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-380-2">. The Company recognizes its pro-rata share of income and losses in the investment in &#8220;Loss from equity method investment&#8221; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment in the consolidated balance sheet until such investment is reduced to <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="INF" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="f-381">zero</ix:nonFraction>.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxPolicyTextBlock" id="f-382" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. The Company provides a valuation allowance to the extent that it is more likely than not that all or a portion of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the authoritative guidance under ASC 740 for recognizing and measuring uncertainty in income tax positions taken or expected to be taken in a tax return. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="f-383" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures employee and board of director equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards. Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies equity-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="arvn:DefinedContributionPlanPolicyPolicyTextBlock" id="f-384" continuedAt="f-384-1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">401(k) Savings Plan</span></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-384-1">The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis.</ix:continuation> Under the 401(k) Plan, the Company made discretionary matching contributions on behalf of eligible employees </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 11</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-349-6" continuedAt="f-349-7"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">totaling $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-385">2.6</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-386">3.4</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:DefinedContributionPlanCostRecognized" scale="6" id="f-387">3.1</ix:nonFraction>&#160;million for the years ended December&#160;31, 2025, 2024 and 2023, respectively.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="f-388" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include (i) employee-related expenses, including salaries, benefits, stock-based compensation expense and travel; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites and consultants; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into consulting, research and other agreements with commercial entities, researchers, universities and others for the provision of goods and services. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#8217;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.</span></div></ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueMeasurementPolicyPolicyTextBlock" id="f-389" continuedAt="f-389-1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Inputs used in the valuation techniques to determine fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below, with Level 1 having the highest priority and Level 3 having the lowest. The three levels of the fair value hierarchy are as follows: </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;&#160;&#160;&#160;&#160;Inputs are based upon observable or quoted prices (unadjusted) for identical instruments traded in active markets. The Company&#8217;s Level 1 financial instruments consist of cash equivalents.</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;&#160;&#160;&#160;&#160;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#8217;s Level 2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;&#160;&#160;&#160;&#160;Inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models and similar techniques. </span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-389-1">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerSharePolicyTextBlock" id="f-390" continuedAt="f-390-1" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Common Share </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common shares.</span></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 12</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-349-7"><div style="margin-top:12pt;text-indent:36pt"><ix:continuation id="f-390-1" continuedAt="f-390-2"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average number of common shares included in the computation of basic and diluted net loss per common share gives effect to pre-funded warrants. See Note 9,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note 13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-390-2">.</ix:continuation> </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="f-391" escape="true"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2023, the FASB issued ASU No. 2023-09, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted the new standard on January 1, 2025 and presented disclosures on a retrospective basis. The adoption of the standard did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In November 2024, the FASB issued ASU No. 2024-03, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," which requires disaggregation and disclosure of specified information about certain costs and expenses in the notes to the financial statements. The requirements of the ASU are effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact ASU No. 2024-03 will have on its consolidated financial statements.</span></div></ix:nonNumeric></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_1047"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">3. <ix:nonNumeric contextRef="c-1" name="us-gaap:CollaborativeArrangementDisclosureTextBlock" id="f-392" continuedAt="f-392-1" escape="true">Research Collaboration and License Agreements</ix:nonNumeric></span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_1072"></div><ix:continuation id="f-392-1" continuedAt="f-392-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vepdegestrant (ARV-471) Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a collaboration agreement with Pfizer (the &#8220;Vepdegestrant (ARV-471) Collaboration Agreement&#8221;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#8217;s proprietary compound vepdegestrant (the &#8220;Licensed Products&#8221;). Under the Vepdegestrant (ARV-471) Collaboration Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-54" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-399">650.0</ix:nonFraction>&#160;million. In addition, the Company will be eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-55" decimals="-8" name="us-gaap:ContractWithCustomerAssetNet" scale="9" id="f-400">1.4</ix:nonFraction>&#160;billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $<ix:nonFraction unitRef="usd" contextRef="c-56" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-401">400.0</ix:nonFraction>&#160;million in regulatory milestones are related to marketing approvals and $<ix:nonFraction unitRef="usd" contextRef="c-57" decimals="-8" name="us-gaap:ContractWithCustomerAssetNet" scale="9" id="f-402">1.0</ix:nonFraction>&#160;billion are related to sales-based milestones. There were no regulatory or sales-based milestone payments received through December&#160;31, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Pfizer share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will be the marketing authorization applicant in the United States and, subject to approval, can book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with the execution of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant (ARV-471)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Collaboration Agreement, the Company and Pfizer entered into a Stock Purchase Agreement (the "Pfizer Stock Purchase Agreement") for the sale and issuance of <ix:nonFraction unitRef="shares" contextRef="c-58" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-403">3,457,815</ix:nonFraction> shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;) to Pfizer at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-59" decimals="2" name="us-gaap:SharesIssuedPricePerShare" scale="0" id="f-404">101.22</ix:nonFraction> per share, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-405">350.0</ix:nonFraction>&#160;million (the &#8220;Pfizer Equity Transaction&#8221;), less financial advisor fees of $<ix:nonFraction unitRef="usd" contextRef="c-58" decimals="-5" name="us-gaap:PaymentsForBrokerageFees" scale="6" id="f-406">4.6</ix:nonFraction>&#160;million, which was consummated in September 2021. Pursuant to terms of the Pfizer Stock Purchase Agreement, Pfizer has agreed not to sell or transfer the Shares without prior written approval of the Company for a specified time period, subject to specified exceptions.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 13</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-392-2" continuedAt="f-392-3"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant (ARV-471) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement and the Pfizer Equity Transaction entered into with Pfizer concurrently should be evaluated as a combined contract in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined the fair value of the shares sold under the Pfizer Equity Transaction to be $<ix:nonFraction unitRef="usd" contextRef="c-60" decimals="-5" name="arvn:SaleOfStockFairValueOfSharesSold" scale="6" id="f-407">85.4</ix:nonFraction>&#160;million less than the contractual purchase price stipulated in the agreement. In accordance with the applicable accounting guidance in ASC 815-40, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that the sale of stock should be recorded at fair value and therefore allocated the excess consideration received under the Pfizer Equity Transaction to the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant (ARV-471) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement, which, along with the non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-61" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-408">650.0</ix:nonFraction>&#160;million, is being recognized as revenue over the total estimated period of performance based on the Company&#8217;s best estimate of costs to be incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant (ARV-471) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $<ix:nonFraction unitRef="usd" contextRef="c-62" decimals="-5" name="arvn:DirectAndIncrementalCostsIncurredToObtainTheContract" scale="6" id="f-409">12.9</ix:nonFraction>&#160;million. In accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $<ix:nonFraction unitRef="usd" contextRef="c-63" decimals="-5" name="arvn:CollaborationContractAssetAndOtherAssets" scale="6" id="f-410">12.9</ix:nonFraction>&#160;million in collaboration contract asset and other assets in the consolidated balance sheet, which is being amortized as general and administrative expense over the total estimated period of performance under the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant (ARV-471) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the Company announced that the Company and Pfizer have agreed to jointly select a third party for the commercialization and potential further development of vepdegestrant. The announcement did not have an effect on revenue recognition for the year ended December 31, 2025.</span></div></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_1067"></div><ix:continuation id="f-392-3" continuedAt="f-392-4"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pfizer Research Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the "Pfizer Research Collaboration Agreement"). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $<ix:nonFraction unitRef="usd" contextRef="c-64" decimals="-5" name="us-gaap:ProceedsFromCollaborators" scale="6" id="f-411">28.0</ix:nonFraction> million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized over the total estimated period of performance. As of December&#160;31, 2025, there remains a single target under the Pfizer Research Collaboration Agreement, and, in accordance with the terms of such Agreement, the Company is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-65" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-412">3.8</ix:nonFraction> million in non-refundable option payments if Pfizer exercises its option for such target protein under the Pfizer Research Collaboration Agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also entitled to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-66" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-413">225.0</ix:nonFraction> million in development milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="c-67" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-414">550.0</ix:nonFraction> million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. There were no sales-based milestone payments or royalties received through December&#160;31, 2025.</span></div></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_151"></div><ix:continuation id="f-392-4" continuedAt="f-392-5"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Novartis License and Asset Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company entered into a transaction (the "Novartis Transaction"), including both a license agreement (the "Novartis License Agreement") and an asset purchase agreement (the "Novartis Asset Agreement") with Novartis Pharma AG ("Novartis") for the worldwide development, manufacture and commercialization of luxdegalutamide (ARV-766), the Company's second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer and for the sale of the Company's preclinical AR-V7 program. Under the terms of the agreements, Novartis is responsible for worldwide clinical development and commercialization of luxdegalutamide (ARV-766) and has all research, development, manufacturing, and commercialization rights with respect to the Company&#8217;s PROTAC protein degrader targeting AR-V7, a splice variant of the AR. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, Novartis paid to the Company a one-time, upfront payment in the aggregate amount of $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-415">150.0</ix:nonFraction>&#160;million in accordance with the terms of the Novartis License Agreement and the Novartis Asset Agreement. Under the terms of the Novartis License Agreement, the Company is eligible to receive up to an additional $<ix:nonFraction unitRef="usd" contextRef="c-68" decimals="-7" name="arvn:RevenueRemainingPerformanceObligationContingentPayments" scale="9" id="f-416">1.01</ix:nonFraction>&#160;billion as contingent payments based on specified development, regulatory and commercial milestones for luxdegalutamide (ARV-766) being met, as well as tiered royalties based on worldwide net sales of luxdegalutamide (ARV-766), subject to reduction under certain circumstances as provided in the Novartis License Agreement. During the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025, the Company recognized as revenue $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-417">20.0</ix:nonFraction>&#160;million upon the achievemen</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t of a development m</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ilestone pursuant to the terms of the Novartis License </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 14</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-392-5" continuedAt="f-392-6"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement. There were no development, regulatory or commercial milestone payments, or sales-based royalties received during the year ended December&#160;31, 2024.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Novartis License Agreement will continue on a country-by-country basis (or, in certain cases, a region-by-region basis) until the expiration of the applicable royalty term for such country (or region, as applicable). The Novartis License Agreement contains customary termination provisions, including that either party may terminate the Novartis License Agreement (a) upon the material breach of the other party or (b) in the event the other party experiences an insolvency event. Additionally, Novartis may terminate the Novartis License Agreement for convenience or upon a safety or regulatory issue.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Novartis License Agreement and the Novartis Asset Agreement entered into with Novartis concurrently should be accounted for as a combined contract in accordance with ASC 606, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined the fair value of the assets sold under the Novartis Asset Agreement to be $<ix:nonFraction unitRef="usd" contextRef="c-69" decimals="-5" name="us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax" scale="6" id="f-418">20.0</ix:nonFraction>&#160;million, which was recognized at the time of sale as revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the fair value of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis License Agreement to be $<ix:nonFraction unitRef="usd" contextRef="c-70" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-419">130.0</ix:nonFraction>&#160;million, which was recognized as revenue over the total estimated period of performance during the technology transfer period, as defined in the agreement, based on the cost incurred input method. Under the Novartis License Agreement, Novartis will also reimburse the Company for development costs incurred during the technology transfer period, which will be recognized as revenue as costs are incurred. As of December 31, 2024, the technology transfer period ended as the Company completed the transition of its ongoing and planned clinical trials of luxdegalutamide (ARV-766) to Novartis.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the Novartis Transaction, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:CapitalizedContractCostGross" scale="6" id="f-420">3.0</ix:nonFraction>&#160;million. In accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $<ix:nonFraction unitRef="usd" contextRef="c-71" decimals="-5" name="us-gaap:CapitalizedContractCostGross" scale="6" id="f-421">3.0</ix:nonFraction>&#160;million in collaboration contract asset and other assets in the consolidated balance sheet at inception of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis License Agreement and the Novartis Asset Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was amortized as general and administrative expense over the total estimated period of performance under the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis License Agreement and the Novartis Asset Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_1057"></div><ix:continuation id="f-392-6" continuedAt="f-392-7"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genentech Modification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the "Genentech Modification") with Genentech, Inc. and F. Hoffman-La Roche Ltd (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Genentech Modification, the Company received upfront, non-refundable payments of $<ix:nonFraction unitRef="usd" contextRef="c-72" decimals="-5" name="us-gaap:ProceedsFromCollaborators" scale="6" id="f-422">34.5</ix:nonFraction> million (in addition to $<ix:nonFraction unitRef="usd" contextRef="c-73" decimals="-5" name="us-gaap:ProceedsFromCollaborators" scale="6" id="f-423">11.0</ix:nonFraction> million received under the previous agreement in 2015) to fund Genentech-related research. Upfront non-refundable payments were recognized as revenue over the total estimated period of performance, which concluded during the first quarter of 2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-74" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-424">44.0</ix:nonFraction> million per target in development milestone payments, $<ix:nonFraction unitRef="usd" contextRef="c-75" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-425">52.5</ix:nonFraction> million in regulatory milestone payments and $<ix:nonFraction unitRef="usd" contextRef="c-76" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-426">60.0</ix:nonFraction> million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received through December&#160;31, 2025.</span></div></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_1062"></div><ix:continuation id="f-392-7" continuedAt="f-392-8"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the "Bayer Collaboration Agreement") setting forth the Company&#8217;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras, or PROTAC targeted protein degraders, that mediate for degradation of target proteins ("Targets"), using the Company&#8217;s proprietary platform technology, which Targets were selected by Bayer AG, subject to certain exclusions and limitations. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $<ix:nonFraction unitRef="usd" contextRef="c-77" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-427">17.5</ix:nonFraction> million in exchange for the use of the Company&#8217;s technology license. The Company also received an additional $<ix:nonFraction unitRef="usd" contextRef="c-78" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-428">12.0</ix:nonFraction> million from Bayer AG from inception through 2023, including $<ix:nonFraction unitRef="usd" contextRef="c-79" decimals="-5" name="us-gaap:ProceedsFromCollaborators" scale="6" id="f-429">1.5</ix:nonFraction> million received during the year ended December 31, 2023. These payments were recognized over the total estimated period of performance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to notice from Bayer AG in accordance with the terms of the Bayer Collaboration Agreement, the Bayer Collaboration Agreement was terminated effective August 12, 2024.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 15</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-392-8" continuedAt="f-392-9"><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was also eligible to receive up to $<ix:nonFraction unitRef="usd" contextRef="c-80" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-430">197.5</ix:nonFraction> million in development milestone payments and up to $<ix:nonFraction unitRef="usd" contextRef="c-81" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-431">490.0</ix:nonFraction> million in sales-based milestone payments for all designated Targets. In addition, the Company was eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which were subject to reductions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no development or sales-based milestone payments or royalties received through August 12, 2024, the termination date of the agreement.</span></div></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_1082"></div><ix:continuation id="f-392-9" continuedAt="f-392-10"><ix:nonNumeric contextRef="c-1" name="us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock" id="f-432" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's contract balances were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:67.990%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.053%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-433">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" format="ixt:fixed-zero" scale="6" id="f-434">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" scale="6" id="f-435">21.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" scale="6" id="f-436">12.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" scale="6" id="f-437">25.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" scale="6" id="f-438">6.7</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-439">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AccountsReceivableNetCurrent" scale="6" id="f-440">5.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts payable related to collaborations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" scale="6" id="f-441">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" scale="6" id="f-442">13.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentAdditions" scale="6" id="f-443">46.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentAdditions" scale="6" id="f-444">48.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentPayments" scale="6" id="f-445">34.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrentPayments" scale="6" id="f-446">56.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" scale="6" id="f-447">16.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="arvn:AccountsPayableContractBalancesCurrent" scale="6" id="f-448">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-449">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-450">9.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" format="ixt:fixed-zero" scale="6" id="f-451">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" scale="6" id="f-452">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:CapitalizedContractCostAmortizationDuringPeriod" scale="6" id="f-453">4.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:CapitalizedContractCostAmortizationDuringPeriod" scale="6" id="f-454">4.6</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-455">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ContractWithCustomerAssetNet" scale="6" id="f-456">7.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-457">448.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-458">549.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" format="ixt:fixed-zero" scale="6" id="f-459">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" scale="6" id="f-460">130.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-461">242.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ContractWithCustomerLiabilityRevenueRecognized" scale="6" id="f-462">101.0</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances not held at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" format="ixt:fixed-zero" scale="6" id="f-463">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="arvn:ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" scale="6" id="f-464">130.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-465">205.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:ContractWithCustomerLiability" scale="6" id="f-466">448.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, the Company updated its estimate to satisfy the performance obligations under the Vepdegestrant (ARV-471) Collaboration Agreement due to the removal of the first-line Phase 3 combination trial with Pfizer&#8217;s novel investigational CDK4 inhibitor, atirmociclib, and the removal of the second-line Phase 3 combination trial with a CDK4/6 inhibitor from the development plan. The change in accounting estimate resulted in an increase in revenue of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-467">150.2</ix:nonFraction>&#160;million, an increase in operating expenses of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-468">2.6</ix:nonFraction>&#160;million, a decrease in net loss of $<ix:nonFraction unitRef="usd" contextRef="c-82" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-469">147.6</ix:nonFraction>&#160;million, and a decrease in basic and diluted loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-82" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-470"><ix:nonFraction unitRef="usdPerShare" contextRef="c-82" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-471">2.08</ix:nonFraction></ix:nonFraction> for the year ended December 31, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, the Company also changed its estimate of the duration of the performance period under the Pfizer Research Collaboration Agreement as a result of updated research timelines. The change in accounting estimate resulted in a decrease of $<ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="f-472"><ix:nonFraction unitRef="usd" contextRef="c-83" decimals="-5" name="us-gaap:NetIncomeLoss" scale="6" id="f-473">6.6</ix:nonFraction></ix:nonFraction>&#160;million in revenue, an increase in net loss, and an increase in basic and diluted loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-474"><ix:nonFraction unitRef="usdPerShare" contextRef="c-83" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-475">0.09</ix:nonFraction></ix:nonFraction> for the year ended December 31, 2025. The reversed revenue will continue to be recognized in future periods as the Company continues to advance on the performance obligation under the updated collaboration timeline.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 16</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-392-10"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company changed its estimate of the duration of the performance period under the Pfizer Research Collaboration Agreement as a result of updated research timelines. The changes in accounting estimate resulted in a decrease in revenue and an increase in net loss of $<ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-476"><ix:nonFraction unitRef="usd" contextRef="c-84" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="f-477">2.4</ix:nonFraction></ix:nonFraction>&#160;million, respectively, and an increase in net loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-478"><ix:nonFraction unitRef="usdPerShare" contextRef="c-84" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-479">0.03</ix:nonFraction></ix:nonFraction> for the year ended December 31, 2024. The reversed revenue will be recognized in subsequent periods as the Company continues to advance on the performance obligation under the updated collaboration timeline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2023, the Company had a change to its estimate to satisfy the performance obligations under the Vepdegestrant (ARV-471) Collaboration Agreement due to the expansion of the development programs. The changes in accounting estimate resulted in a decrease in revenue and increase in net loss of $<ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="f-480"><ix:nonFraction unitRef="usd" contextRef="c-85" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-481">35.0</ix:nonFraction></ix:nonFraction>&#160;million, respectively, and an increase in net loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-482"><ix:nonFraction unitRef="usdPerShare" contextRef="c-85" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-483">0.63</ix:nonFraction></ix:nonFraction> for the year ended December 31, 2023. The reversed revenue will continue to be recognized in future periods as the Company continues to advance on the performance obligation under the collaboration.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company also changed its estimate of the duration of the performance period under the Bayer Collaboration Agreement and Pfizer Research Collaboration Agreement as a result of updated research timelines. The changes in accounting estimate resulted in a decrease in revenue and an increase in net loss of $<ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" sign="-" name="us-gaap:Revenues" scale="6" id="f-484"><ix:nonFraction unitRef="usd" contextRef="c-86" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-485">10.6</ix:nonFraction></ix:nonFraction>&#160;million, respectively, and an increase in net loss per share of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-86" decimals="2" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-486"><ix:nonFraction unitRef="usdPerShare" contextRef="c-86" decimals="2" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-487">0.19</ix:nonFraction></ix:nonFraction> for the year ended December 31, 2023. The reversed revenue was recognized in subsequent periods as the Company continued to advance on the performance obligation under the updated collaboration timelines.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" id="f-488" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of December&#160;31, 2025 totaled $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-489">205.6</ix:nonFraction>&#160;million, which is expected to be recognized in the following periods: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-48" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-490">71.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-49" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-491">20.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-50" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-492">114.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RevenueRemainingPerformanceObligation" scale="6" id="f-493">205.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_157"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">4. <ix:nonNumeric contextRef="c-1" name="us-gaap:FairValueDisclosuresTextBlock" id="f-494" continuedAt="f-494-1" escape="true">Marketable Securities and Fair Value Measurements</ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock" id="f-495" escape="true"><ix:continuation id="f-494-1" continuedAt="f-494-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available for sale marketable securities measured at fair value on a recurring basis.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hierarchy</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-496">528.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-497">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-498">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-87" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-499">529.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-500">13.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-501">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-502">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-88" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-503">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-504">541.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-505">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-506">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-89" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-507">542.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:31.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:11.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.085%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hierarchy</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-508">934.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-509">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-510">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-90" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-511">935.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-512">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" format="ixt:fixed-zero" scale="6" id="f-513">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" format="ixt:fixed-zero" scale="6" id="f-514">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-91" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-515">3.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis" scale="6" id="f-516">937.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="6" id="f-517">1.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="6" id="f-518">0.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-92" decimals="-5" name="us-gaap:AvailableForSaleSecuritiesDebtSecurities" scale="6" id="f-519">938.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 17</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-494-2"><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities approximate their </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair values due to the short-term nature of these assets and liabilities.</span></div></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_160"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">5. <ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="f-520" continuedAt="f-520-1" escape="true">Property, Equipment and Leasehold Improvements </ix:nonNumeric></span></div><ix:continuation id="f-520-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="f-521" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-47" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-522">21.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-93" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-523">20.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-94" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-524">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-95" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-525">9.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-46" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-526">3.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-96" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-527">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-528">33.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentGross" scale="6" id="f-529">32.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-530">28.2</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="6" id="f-531">25.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-532">5.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:PropertyPlantAndEquipmentNet" scale="6" id="f-533">7.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-534">3.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-535">4.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-536">4.8</ix:nonFraction> million for the years ended December&#160;31, 2025, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company wrote-off leasehold improvements totaling $<ix:nonFraction unitRef="usd" contextRef="c-97" decimals="-5" name="arvn:PropertyPlantAndEquipmentWriteoff" scale="6" id="f-537">2.4</ix:nonFraction>&#160;million resulting from the termination of the Terminated Lease, as discussed below in Note 6, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right-of-Use Assets and Liabilities.</span></div></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_163"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">6. <ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeasesTextBlock" id="f-538" continuedAt="f-538-1" escape="true">Right-of-Use Assets and Liabilities</ix:nonNumeric></span></div><ix:continuation id="f-538-1" continuedAt="f-538-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company entered into a Lease Termination Agreement with 101 College Street LLC (the "Landlord"). Under the terms of the Lease Termination Agreement, the lease, by and between the Company and the Landlord, dated May 4, 2021 (as amended, the "Terminated Lease"), for certain leased premises of approximately <ix:nonFraction unitRef="sqft" contextRef="c-98" decimals="-3" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-539">160,000</ix:nonFraction> square feet of laboratory and office space, was terminated in full, effective August 15, 2024. The leased premises were expected to be occupied by the Company in 2025. In connection with the Lease Termination Agreement and as consideration for the Landlord&#8217;s agreement to terminate the lease for its laboratory and office space at 101 College Street in full, the Company agreed to pay to the Landlord a one-time cash termination fee in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-99" decimals="-5" sign="-" name="us-gaap:GainLossOnContractTermination" scale="6" id="f-540">41.5</ix:nonFraction>&#160;million and wrote-off $<ix:nonFraction unitRef="usd" contextRef="c-100" decimals="-5" sign="-" name="us-gaap:GainLossOnContractTermination" scale="6" id="f-541">1.9</ix:nonFraction>&#160;million of prepaid rent, both of which were recognized in general and administrative operating expenses on the consolidated statements of operations. The Company also cancelled its previously issued letter of credit in the amount of $<ix:nonFraction unitRef="usd" contextRef="c-101" decimals="-5" name="us-gaap:DebtSecurities" scale="6" id="f-542">5.5</ix:nonFraction> million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its corpor</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ate office, laboratories and certain</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> equipment, which expire no later than December 2029. The leases have a weighted-average remaining term of <ix:nonNumeric contextRef="c-5" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" format="ixt-sec:duryear" id="f-543">4.0</ix:nonNumeric> years.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LeaseCostTableTextBlock" id="f-544" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-545">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-546">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-547">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 18</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-538-2"><ix:nonNumeric contextRef="c-1" name="arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" id="f-548" escape="true"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.263%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.557%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-549">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-550">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:OperatingLeasePayments" scale="6" id="f-551">2.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-552">1.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-553">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" format="ixt:fixed-zero" scale="6" id="f-554">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, the Company, entered into a Seventh Amendment and an Eighth Amendment to its lease (collectively the &#8220;Seventh and Eighth Building 5 Lease Amendments") with Science Park Development Corporation for certain premises in New Haven, Connecticut (the &#8220;Building 5 Premises&#8221;). The Seventh and Eighth Building 5 Lease Amendments extend the term of the original lease to December 31, 2029, resulting in an increase in the Company's ROU assets of $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-555">8.5</ix:nonFraction>&#160;million, and, effective on January 1 2025, expand the Building 5 Premises to include approximately <ix:nonFraction unitRef="sqft" contextRef="c-6" decimals="-2" name="us-gaap:LandSubjectToGroundLeases" format="ixt:num-dot-decimal" scale="0" id="f-556">11,200</ix:nonFraction> square feet of additional laboratory and office space resulting in an increase in the Company's ROU assets of $<ix:nonFraction unitRef="usd" contextRef="c-102" decimals="-5" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="6" id="f-557">1.5</ix:nonFraction>&#160;million. The annual base rent during the extended term will range from $<ix:nonFraction unitRef="usd" contextRef="c-103" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-558">2.2</ix:nonFraction>&#160;million to $<ix:nonFraction unitRef="usd" contextRef="c-104" decimals="-5" name="us-gaap:OperatingLeaseCost" scale="6" id="f-559">2.6</ix:nonFraction>&#160;million.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="f-560" escape="true"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of December&#160;31, 2025 were as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="6" id="f-561">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="6" id="f-562">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="6" id="f-563">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="6" id="f-564">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="6" id="f-565">9.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="6" id="f-566">1.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:OperatingLeaseLiability" scale="6" id="f-567">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_169"></div><div style="margin-top:18pt;text-align:justify"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">7. <ix:nonNumeric contextRef="c-1" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="f-568" continuedAt="f-568-1" escape="true">Accounts Payable and Accrued Liabilities </ix:nonNumeric></span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="f-569" escape="true"><ix:continuation id="f-568-1"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-570">24.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AccountsPayableCurrent" scale="6" id="f-571">13.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="arvn:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="f-572">18.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="arvn:AccruedResearchAndDevelopmentExpenseCurrent" scale="6" id="f-573">25.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-574">17.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="6" id="f-575">22.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="f-576">4.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AccruedIncomeTaxesCurrent" scale="6" id="f-577">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative and commercial expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="arvn:AccruedGeneralAndAdministrativeAndCommercialCurrent" scale="6" id="f-578">3.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="arvn:AccruedGeneralAndAdministrativeAndCommercialCurrent" scale="6" id="f-579">5.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccruedProfessionalFeesCurrent" scale="6" id="f-580">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AccruedProfessionalFeesCurrent" scale="6" id="f-581">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-582">69.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent" scale="6" id="f-583">71.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div></ix:continuation></ix:nonNumeric><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 19</span></div></div></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_172"></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">8. <ix:nonNumeric contextRef="c-1" name="us-gaap:DebtDisclosureTextBlock" id="f-584" continuedAt="f-584-1" escape="true">Long-Term Debt </ix:nonNumeric></span></div><ix:continuation id="f-584-1"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDebtInstrumentsTextBlock" id="f-585" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt obligations consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:36.475%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.051%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:14.054%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Assistance Agreement Debt</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-5" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-586">3.25</ix:nonFraction>%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-587">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-588">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current installments included within Accounts Payable and Accrued Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-589">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:LongTermDebtCurrent" scale="6" id="f-590">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-591">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:LongTermDebtNoncurrent" scale="6" id="f-592">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into an Assistance Agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. In September 2018, the Company borrowed $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-593">2.0</ix:nonFraction>&#160;million under the 2018 Assistance Agreement, of which $<ix:nonFraction unitRef="usd" contextRef="c-106" decimals="-5" name="arvn:DebtInstrumentLoanForgiveness" scale="6" id="f-594">1.0</ix:nonFraction>&#160;million was forgiven by the State of Connecticut in April 2021 as the Company met certain employment conditions, as defined in the agreement. Borrowings under the 2018 Assistance Agreement bear an interest rate of <ix:nonFraction unitRef="number" contextRef="c-105" decimals="INF" name="us-gaap:DebtInstrumentInterestRateStatedPercentage" scale="-2" id="f-595">3.25</ix:nonFraction>% per annum, with interest-only payments required for the first <ix:nonNumeric contextRef="c-107" name="arvn:DebtInstrumentInterestPaymentsTerm" format="ixt-sec:durmonth" id="f-596">60</ix:nonNumeric> months, and mature in </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 2028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028 with a default penalty of repayment of the full original funding amount of $<ix:nonFraction unitRef="usd" contextRef="c-105" decimals="-5" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="f-597">2.0</ix:nonFraction>&#160;million plus liquidated damages of <ix:nonFraction unitRef="number" contextRef="c-107" decimals="INF" name="arvn:PercentageOfLiquidatedDamages" scale="-2" id="f-598">7.5</ix:nonFraction>% of the total amount of funding received.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" id="f-599" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt as of December&#160;31, 2025 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:84.809%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.991%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" scale="6" id="f-600">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" scale="6" id="f-601">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" scale="6" id="f-602">0.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LongTermDebt" scale="6" id="f-603">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2025, 2024 and 2023, interest expense was immaterial.</span></div></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_175"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">9. <ix:nonNumeric contextRef="c-1" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="f-604" continuedAt="f-604-1" escape="true">Equity </ix:nonNumeric></span></div><ix:continuation id="f-604-1" continuedAt="f-604-2"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025 and 2024, the Company had authorized <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-605"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-606">5,000,000</ix:nonFraction></ix:nonFraction> shares of preferred stock, at a $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-607"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="f-608">0.001</ix:nonFraction></ix:nonFraction> par value per share. Preferred stock may be issued in one or more series upon authorization of the Company's board of directors. The board of directors is authorized to fix the designations, powers, preferences and the relative, participating, optional or other special rights and any qualifications, limitations and restrictions of the shares of each series of preferred stock. The authorized shares of the Company's preferred stock are available for issuance without further action by the Company's stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025 and 2024, the Company had authorized <ix:nonFraction unitRef="shares" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-609"><ix:nonFraction unitRef="shares" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockSharesAuthorized" format="ixt:num-dot-decimal" scale="0" id="f-610">200,000,000</ix:nonFraction></ix:nonFraction> shares of common stock, at a $<ix:nonFraction unitRef="usdPerShare" contextRef="c-5" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-611"><ix:nonFraction unitRef="usdPerShare" contextRef="c-6" decimals="INF" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="f-612">0.001</ix:nonFraction></ix:nonFraction> par value per share. The holders of shares of common stock are entitled to <ix:nonFraction unitRef="vote" contextRef="c-5" decimals="INF" name="arvn:NumberOfVotesPerCommonStockShareHeld" format="ixt-sec:numwordsen" scale="0" id="f-613">one</ix:nonFraction> vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. The holders of shares of common stock are entitled to receive dividends, if and when declared by the board of directors. No dividends have been declared or paid by the Company since its inception.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company completed a private placement offering with certain institutional investors in which the Company issued and sold <ix:nonFraction unitRef="shares" contextRef="c-108" decimals="INF" name="us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction" format="ixt:num-dot-decimal" scale="0" id="f-614">12,963,542</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-109" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-615">21.36</ix:nonFraction> per share and, to one investor, in lieu of common stock, pre-funded warrants to purchase up to <ix:nonFraction unitRef="shares" contextRef="c-110" decimals="INF" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" format="ixt:num-dot-decimal" scale="0" id="f-616">3,422,380</ix:nonFraction> shares of common stock at a price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-110" decimals="INF" name="us-gaap:SaleOfStockPricePerShare" scale="0" id="f-617">21.359</ix:nonFraction> per pre-funded warrant. Each pre-funded warrant has an exercise price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-111" decimals="INF" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-618">0.001</ix:nonFraction> per share, is exercisable immediately and is exercisable until exercised in full. The aggregate gross </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 20</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-604-2" continuedAt="f-604-3"><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds from the issuance of common stock and pre-funded warrants totaled approximately $<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="arvn:ProceedsFromIssuanceOfCommonStockAndWarrants" scale="6" id="f-619">350.0</ix:nonFraction>&#160;million,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before deducting placement agent fees and offering costs of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-112" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="f-620">15.9</ix:nonFraction>&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2025, all outstanding</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pre-funded warrants had been cashless exercised for no consideration and the Company issued <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="arvn:StockIssuedDuringPeriodSharesExerciseOfWarrants" format="ixt:num-dot-decimal" scale="0" id="f-621">3,422,186</ix:nonFraction> shares of common stock to the holders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2025, the Company announced that its board of directors authorized and approved a share repurchase program for the repurchase of up to $<ix:nonFraction unitRef="usd" contextRef="c-113" decimals="-5" name="srt:StockRepurchaseProgramAuthorizedAmount1" scale="6" id="f-622">100.0</ix:nonFraction>&#160;million of the then-currently outstanding shares of the Company&#8217;s common stock. Share repurchases under the share repurchase program may be made from time to time through a variety of methods, which may include open market purchases, privately negotiated block trades, accelerated share repurchases, other privately negotiated transactions or any combination of these methods. Repurchases may also be made under a Rule 10b5-1 plan, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws. The share repurchase program is funded using the Company's working capital. The share repurchase program has no time limit and can be modified, suspended or discontinued at any time without prior notice. Repurchased shares are recorded as treasury stock, at cost, and are eligible to be reissued under the Company's stock plans and for other corporate purposes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, the Company repurchased <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="us-gaap:TreasuryStockSharesAcquired" format="ixt:num-dot-decimal" scale="0" id="f-623">10,009,758</ix:nonFraction> shares of its common stock, at an average price of $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:TreasuryStockAcquiredAverageCostPerShare" scale="0" id="f-624">9.09</ix:nonFraction> per share, for an aggregate purchase price of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:TreasuryStockValueAcquiredCostMethodNetOfCommissions" scale="6" id="f-625">91.0</ix:nonFraction>&#160;million, plus commissions and excise tax of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="arvn:ShareRepurchaseProgramCommissionsAndExciseTax" scale="6" id="f-626">0.9</ix:nonFraction>&#160;million. As of December&#160;31, 2025, the Company has </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">suspended the program and has no further plans to repurchase additional shares</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Distribution Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company entered into an Equity Distribution Agreement with Piper Sandler &amp; Company (&#8220;Piper Sandler&#8221;) and Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to $<ix:nonFraction unitRef="usd" contextRef="c-114" decimals="-5" name="arvn:MaximumAggregateOfferingPriceOfCommonStock" scale="6" id="f-627">300.0</ix:nonFraction>&#160;million of the common stock registered under a universal shelf registration statement pursuant to one or more &#8220;at-the-market" offerings. During the year ended December 31, 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-115" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:num-dot-decimal" scale="0" id="f-628">1,449,275</ix:nonFraction> shares of common stock under this agreement resulting in gross proceeds of approximately $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:StockIssuedDuringPeriodValueNewIssues" scale="6" id="f-629">37.2</ix:nonFraction>&#160;million, less offering costs of approximately $<ix:nonFraction unitRef="usd" contextRef="c-115" decimals="-5" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="f-630">1.1</ix:nonFraction>&#160;million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company amended and restated the Equity Distribution Agreement with Piper Sandler and Cantor, pursuant to which the Company may offer and sell from time to time, through the agents, up to approximately </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-116" decimals="-5" name="arvn:MaximumAggregateOfferingPriceOfCommonStock" scale="6" id="f-631">262.8</ix:nonFraction>&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the common stock registered under a universal shelf registration statement pursuant to one or more &#8220;at-the-market&#8221; offerings. During the years ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025 and 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, <ix:nonFraction unitRef="shares" contextRef="c-117" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="f-632"><ix:nonFraction unitRef="shares" contextRef="c-118" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" format="ixt:fixed-zero" scale="0" id="f-633">no</ix:nonFraction></ix:nonFraction> shares were issued under this amended and restated agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the "2018 ESPP"), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of <ix:nonFraction unitRef="shares" contextRef="c-119" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-634">311,850</ix:nonFraction> shares of the Company's common stock. The number of shares of the Company's common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to <ix:nonFraction unitRef="number" contextRef="c-120" decimals="2" name="arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" scale="-2" id="f-635">1</ix:nonFraction>% of the Company&#8217;s then-outstanding common stock, effective as of January 1 of each year. As of December&#160;31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-121" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-636">3,577,025</ix:nonFraction> shares remained available for purchase. During the years ended December&#160;31, 2025, 2024 and 2023, the Company issued <ix:nonFraction unitRef="shares" contextRef="c-122" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-637">110,412</ix:nonFraction>, <ix:nonFraction unitRef="shares" contextRef="c-123" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-638">120,834</ix:nonFraction> and <ix:nonFraction unitRef="shares" contextRef="c-124" decimals="INF" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" format="ixt:num-dot-decimal" scale="0" id="f-639">78,528</ix:nonFraction> shares, respectively, of common stock under the 2018 ESPP.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 21</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-604-3" continuedAt="f-604-4"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s board of directors adopted, and the Company&#8217;s stockholders approved, the 2018 Stock Incentive Plan (the "2018 Plan"), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#8217;s initial public offering. The number of common shares initially available for issuance under the 2018 Plan equaled the sum of (1) <ix:nonFraction unitRef="shares" contextRef="c-125" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-640">4,067,007</ix:nonFraction> shares of common stock; plus (2) the number of shares of common stock (up to <ix:nonFraction unitRef="shares" contextRef="c-126" decimals="INF" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" format="ixt:num-dot-decimal" scale="0" id="f-641">1,277,181</ix:nonFraction> shares) issued in respect of incentive units granted under the Incentive Plan that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each year beginning with the year ended December 31, 2019 and continuing to, and including, the year ending December 31, 2028, equal to the lesser of <ix:nonFraction unitRef="shares" contextRef="c-127" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-642">4,989,593</ix:nonFraction> shares of the Company&#8217;s common stock, <ix:nonFraction unitRef="number" contextRef="c-128" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" scale="-2" id="f-643">4</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on the first day of the year or an amount determined by the Company&#8217;s board of directors. As of December&#160;31, 2025, <ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" format="ixt:num-dot-decimal" scale="0" id="f-644">2,966,406</ix:nonFraction> shares are available for issuance under the 2018 Plan. Common shares subject to outstanding equity awards that expire or are terminated, surrendered, or cancelled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the strategic restructuring actions initiated by the Company in the second and third quarters of 2025, as further discussed below in Note 14, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Activity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company modified the vesting terms of certain restricted stock units previously granted to employees. The incremental impact of the modification for the year ended December 31, 2025 totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" scale="6" id="f-645">5.3</ix:nonFraction>&#160;million, as a decrease to compensation expense.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, the Company recognized compensation expense of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-646">44.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-647">88.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-648">71.6</ix:nonFraction> million, respectively, related to the issuance of incentive awards, including $<ix:nonFraction unitRef="usd" contextRef="c-130" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-649">0.5</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-131" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-650">0.7</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-132" decimals="-5" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="f-651">0.8</ix:nonFraction>&#160;million, respectively, related to the 2018 ESPP.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="f-652">30.4</ix:nonFraction> million of compensation expense that is expected to be recognized over a weighted-average period of approximately <ix:nonNumeric contextRef="c-133" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" format="ixt-sec:duryear" id="f-653">1.5</ix:nonNumeric> years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="f-654" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during each of the years ended December&#160;31, 2025, 2024 and 2023 was determined using the Black-Scholes option pricing model at the grant date with the following range of assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:39.960%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.021%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:2.678%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.024%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-134" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-655">72.1</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-134" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-656">80.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-657">72.0</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-135" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-658">75.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" scale="-2" id="f-659">71.3</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-136" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" scale="-2" id="f-660">75.0</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-137" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-661">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-138" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-662">5.7</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-139" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-663">5.4</ix:nonNumeric> - <ix:nonNumeric contextRef="c-140" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-664">5.5</ix:nonNumeric></span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-141" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-665">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="c-142" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" format="ixt-sec:duryear" id="f-666">7.0</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-134" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-667">3.7</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-134" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-668">4.4</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-669">3.5</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-135" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-670">4.6</ix:nonFraction>%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" scale="-2" id="f-671">3.4</ix:nonFraction>% - <ix:nonFraction unitRef="number" contextRef="c-136" decimals="3" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" scale="-2" id="f-672">4.8</ix:nonFraction>%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-134" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-673">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-135" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-674">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-136" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" id="f-675">0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-143" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-676">6.61</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-144" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-677">17.70</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-145" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-678">24.19</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-146" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-679">47.00</ix:nonFraction></span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-147" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-680">16.21</ix:nonFraction> - $<ix:nonFraction unitRef="usdPerShare" contextRef="c-148" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" scale="0" id="f-681">36.27</ix:nonFraction></span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Expected term is calculated based on the Company's historical experience.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant.</span></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company calculated volatility of its common stock by utilizing a weighted-average of a collection of peer company volatilities and its own common stock volatility as the Company&#8217;s common stock had not been trading for a sufficient period of time. The expected term was calculated utilizing the simplified method.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 22</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-604-4"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-683" escape="true"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="f-682" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the 2018 Plan as of December&#160;31, 2025 is presented below. Included in the table are stock options granted to employees, directors and consultants under the 2018 Plan, as well as options to purchase <ix:nonFraction unitRef="shares" contextRef="c-1" decimals="INF" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" format="ixt:num-dot-decimal" scale="0" id="f-684">255,611</ix:nonFraction> shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:40.112%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.994%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">except weighted-average exercise price)</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term (Years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-149" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-685">7,892,330</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-149" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-686">44.16</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-150" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-687">6.7</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-149" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-688">3.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" format="ixt:num-dot-decimal" scale="0" id="f-689">2,253,860</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="f-690">12.41</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-151" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-691">1,515,115</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-151" decimals="2" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="f-692">46.07</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-693">8,631,075</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="f-694">35.89</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-151" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" format="ixt-sec:duryear" id="f-695">6.5</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="6" id="f-696">5.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and exercisable as of December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" format="ixt:num-dot-decimal" scale="0" id="f-697">5,607,194</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" id="f-698">44.41</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-151" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-699">5.3</ix:nonNumeric></span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" format="ixt:fixed-zero" scale="6" id="f-700">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and expected to vest as of December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-129" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" format="ixt:num-dot-decimal" scale="0" id="f-701">8,304,964</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-129" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" id="f-702">36.55</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-151" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" format="ixt-sec:duryear" id="f-703">6.4</ix:nonNumeric></span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-129" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" scale="6" id="f-704">4.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2025, 2024 and 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-705">8.15</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-706">27.35</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-707">21.99</ix:nonFraction>, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-708">3.6</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="f-709">1.4</ix:nonFraction> million, respectively. There were <ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" format="ixt:fixed-zero" scale="6" id="f-710">no</ix:nonFraction> options exercised during the year ended December&#160;31, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock" id="f-711" escape="true"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit ("RSU") activity under the 2018 Plan for the year ended December&#160;31, 2025 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing <ix:nonFraction unitRef="shares" contextRef="c-152" decimals="INF" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" format="ixt:num-dot-decimal" scale="0" id="f-712">170,365</ix:nonFraction> shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:69.506%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested RSUs as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-153" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-713">2,311,291</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-153" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-714">42.25</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-715">3,440,614</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-154" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-716">12.34</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-717">1,253,564</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-154" decimals="2" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" scale="0" id="f-718">40.06</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="shares" contextRef="c-154" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" format="ixt:num-dot-decimal" scale="0" id="f-719">874,290</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-154" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" scale="0" id="f-720">22.81</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested RSUs as of December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-155" decimals="INF" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" format="ixt:num-dot-decimal" scale="0" id="f-721">3,624,051</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usdPerShare" contextRef="c-155" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" id="f-722">18.59</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs granted during the years ended December&#160;31, 2025, 2024 and 2023 was $<ix:nonFraction unitRef="usdPerShare" contextRef="c-152" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-723">12.34</ix:nonFraction>, $<ix:nonFraction unitRef="usdPerShare" contextRef="c-156" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-724">44.43</ix:nonFraction> and $<ix:nonFraction unitRef="usdPerShare" contextRef="c-157" decimals="2" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="f-725">32.27</ix:nonFraction>, respectively. The total intrinsic value of RSUs released during the years ended December&#160;31, 2025, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" scale="6" id="f-726">17.7</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" scale="6" id="f-727">13.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" scale="6" id="f-728">4.3</ix:nonFraction> million, respectively. The total fair value of RSUs vested during the years ended December&#160;31, 2025, 2024 and 2023 was $<ix:nonFraction unitRef="usd" contextRef="c-152" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-729">44.3</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-156" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-730">13.1</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-157" decimals="-5" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" scale="6" id="f-731">6.9</ix:nonFraction> million, respectively.</span></div></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_181"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">10. <ix:nonNumeric contextRef="c-1" name="us-gaap:EquityMethodInvestmentsDisclosureTextBlock" id="f-732" continuedAt="f-732-1" escape="true">Equity Method Investments</ix:nonNumeric></span></div><ix:continuation id="f-732-1" continuedAt="f-732-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company and Bayer CropScience LP ("Bayer LP") formed Oerth Bio, a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. Pursuant to the terms of the joint venture agreement, the Company made an in-kind intellectual property contribution to Oerth Bio in the form of a license to certain of the Company&#8217;s proprietary technology and Bayer LP committed and subsequently made cash contributions to Oerth Bio totaling $<ix:nonFraction unitRef="usd" contextRef="c-158" decimals="-5" name="us-gaap:EquityMethodInvestmentAggregateCost" scale="6" id="f-733">56.0</ix:nonFraction>&#160;million, as well as an in-kind intellectual property contribution. The Company and Bayer LP each held an initial ownership interest in Oerth Bio representing <ix:nonFraction unitRef="number" contextRef="c-158" decimals="2" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-734">50</ix:nonFraction>% of the ownership interests. A <ix:nonFraction unitRef="number" contextRef="c-159" decimals="2" name="arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" scale="-2" id="f-735">15</ix:nonFraction>% ownership interest of Oerth Bio was </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 23</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-732-2" continuedAt="f-732-3"><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled <ix:nonFraction unitRef="number" contextRef="c-160" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-736">42.9</ix:nonFraction>%, <ix:nonFraction unitRef="number" contextRef="c-161" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-737">43.6</ix:nonFraction>% and <ix:nonFraction unitRef="number" contextRef="c-162" decimals="3" name="us-gaap:EquityMethodInvestmentOwnershipPercentage" scale="-2" id="f-738">45.0</ix:nonFraction>% as of December&#160;31, 2025, 2024 and 2023, respectively, as a result of vested incentive units.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the joint venture agreement, the Company has no obligation to provide additional funding and the Company&#8217;s ownership interest will not be diluted from future contributions from Bayer LP. The activities of Oerth Bio are controlled by a management board under the joint control of the Company and Bayer LP. As Oerth Bio is jointly controlled by the Company and Bayer LP, the Company accounts for its interest using the equity method of accounting. The Company determined that Oerth Bio is a variable interest entity and, accordingly, the Company has evaluated the significant activities of Oerth Bio under the variable interest entity model and concluded that the significant activities consist primarily of research and development activities and, as the Company does not have the sole power to direct such activities, the Company is not the primary beneficiary.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses and net loss of Oerth Bio for the years ended December 31, 2025, 2024 and 2023 totaled </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-739"><ix:nonFraction unitRef="usd" contextRef="c-163" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-740">1.1</ix:nonFraction></ix:nonFraction> million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $<ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-741"><ix:nonFraction unitRef="usd" contextRef="c-164" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-742">3.7</ix:nonFraction></ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" name="us-gaap:OperatingExpenses" scale="6" id="f-743"><ix:nonFraction unitRef="usd" contextRef="c-165" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-744">8.3</ix:nonFraction></ix:nonFraction> million, respectively. The Company recognized <ix:nonFraction unitRef="usd" contextRef="c-166" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="f-745"><ix:nonFraction unitRef="usd" contextRef="c-167" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="f-746">no</ix:nonFraction></ix:nonFraction> equity method losses for the years ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognized equity method losses of $<ix:nonFraction unitRef="usd" contextRef="c-168" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-747">2.5</ix:nonFraction>&#160;million for the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and 2024, the Company&#8217;s carrying value of the investment was <ix:nonFraction unitRef="usd" contextRef="c-160" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="f-748"><ix:nonFraction unitRef="usd" contextRef="c-161" decimals="-5" name="us-gaap:EquityMethodInvestments" format="ixt:fixed-zero" scale="0" id="f-749">zero</ix:nonFraction></ix:nonFraction>.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><ix:continuation id="f-732-3" continuedAt="f-732-4"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides Oerth Bio with compensated research and development and administrative services through a separate agreement. The se</span></ix:continuation><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-732-4">rvices rendered by the Company during the years ended December&#160;31, 2025, 2024 and 2023 were immaterial.</ix:continuation> </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_184"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">11. <ix:nonNumeric contextRef="c-1" name="us-gaap:IncomeTaxDisclosureTextBlock" id="f-750" continuedAt="f-750-1" escape="true">Income Taxes </ix:nonNumeric></span></div><ix:continuation id="f-750-1" continuedAt="f-750-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" id="f-751" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, income tax expense totaled </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-752">0.3</ix:nonFraction>&#160;million, $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-753">0.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-754">0.9</ix:nonFraction>&#160;million, respectively, and consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-755">0.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:CurrentFederalTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-756">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:CurrentFederalTaxExpenseBenefit" scale="6" id="f-757">1.7</ix:nonFraction>)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-758">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-759">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:CurrentStateAndLocalTaxExpenseBenefit" scale="6" id="f-760">2.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-761">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-762">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:CurrentIncomeTaxExpenseBenefit" scale="6" id="f-763">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-764">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-765">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:DeferredFederalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-766">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-767">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-768">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-769">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-770">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-771">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:DeferredIncomeTaxExpenseBenefit" format="ixt:fixed-zero" scale="6" id="f-772">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-773">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-774">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-775">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generated a taxable loss for the year ended December&#160;31, 2025 primarily due to losses from operations. The Company has not recorded any income tax benefits for the net operating losses incurred in the period due to its uncertainty of realizing a benefit from those items.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generated a taxable income for the year ended December 31, 2024 primarily due to the Novartis License Agreement, the Novartis Asset Agreement and the required capitalization of research and development expenses. The taxable income for federal purposes has been partially offset by losses from operations.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 24</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-750-2" continuedAt="f-750-3"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generated a taxable loss for the year ended December 31, 2023 primarily due to losses from operations. The Company has not recorded any income tax benefits for the net operating losses incurred in the period due to its uncertainty of realizing a benefit from those items.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, H.R.1, commonly referred to as the One Big Beautiful Bill Act, was signed into law in the U.S., which includes a broad range of tax reform provisions, including extending and modifying certain key Tax Cuts and Jobs Act provisions, and provisions allowing accelerated tax deductions for qualified property and research expenditures. The tax impacts of this legislation do not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s losses before income taxes were generated in the United States.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="f-776" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2025, 2024 and 2023 were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"/><td style="width:30.918%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.558%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.673%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:9.683%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></div></td><td colspan="3" style="padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Federal statutory tax rate</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-777">16.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-778">21.0</ix:nonFraction></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-779">41.6</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-780">21.0</ix:nonFraction></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" scale="6" id="f-781">76.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="f-782">21.0</ix:nonFraction></span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State and local income taxes, net of federal income tax effect</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-783">0.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-784">0.1</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-785">4.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-786">2.3</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes" scale="6" id="f-787">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="f-788">0.6</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="f-789">6.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-790">8.5</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="f-791">9.1</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-792">4.6</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:IncomeTaxReconciliationTaxCreditsResearch" scale="6" id="f-793">28.0</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="f-794">7.6</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="f-795">16.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-796">20.6</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="f-797">43.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-798">22.1</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="6" id="f-799">98.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" id="f-800">26.9</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nontaxable or nondeductible items</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-801">7.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-802">9.3</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-803">2.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-804">1.1</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="6" id="f-805">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" scale="-2" id="f-806">1.2</ix:nonFraction></span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="6" id="f-807">0.2</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-808">0.1</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="6" id="f-809">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-810">0.4</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther" scale="6" id="f-811">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" scale="-2" id="f-812">0.2</ix:nonFraction></span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective tax rate</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-813">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-1" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-814">0.4</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-815">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-7" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-816">0.3</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-817">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="number" contextRef="c-8" decimals="3" sign="-" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" id="f-818">0.3</ix:nonFraction></span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2025, state and local income taxes in Connecticut, Massachusetts, and New York comprised the majority of the state and local income taxes, net of federal effect. For the year ended December&#160;31, 2024, state and local income taxes in Connecticut comprised the majority of the state and local income taxes, net of federal effect. For the year ended December&#160;31, 2023, state and local income taxes in New York comprised the majority of the state and local income taxes, net of federal effect.</span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" id="f-819" continuedAt="f-819-1" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes income taxes paid, net of refunds received for the years ended December&#160;31, 2025, 2024 and 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US federal &#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxPaidFederalAfterRefundReceived" scale="6" id="f-820">0.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxPaidFederalAfterRefundReceived" scale="6" id="f-821">0.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncomeTaxPaidFederalAfterRefundReceived" format="ixt:fixed-zero" scale="6" id="f-822">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US state and local &#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-169" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="6" id="f-823">1.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-170" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="6" id="f-824">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-171" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="6" id="f-825">0.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-172" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="6" id="f-826">2.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York City</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-173" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="6" id="f-827">0.5</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-174" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="6" id="f-828">2.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-175" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="6" id="f-829">1.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-176" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="6" id="f-830">1.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-177" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" format="ixt:fixed-zero" scale="6" id="f-831">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-178" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="6" id="f-832">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-179" decimals="-3" name="us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived" scale="6" id="f-833">1.0</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income taxes paid, net of refunds received &#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-3" sign="-" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="f-834">0.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="f-835">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-3" name="us-gaap:IncomeTaxesPaidNet" scale="6" id="f-836">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr></table></div></ix:nonNumeric></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 25</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-750-3" continuedAt="f-750-4"><ix:continuation id="f-819-1"><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The amount of income taxes paid during the year does not meet the 5% disaggregation threshold.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and tax reporting purposes. <ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="f-837" continuedAt="f-837-1" escape="true">Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities were as follows as of December&#160;31, 2025 and 2024: </ix:nonNumeric></span></div><ix:continuation id="f-837-1"><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:70.112%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.992%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="f-838">145.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="6" id="f-839">31.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="f-840">131.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment" scale="6" id="f-841">161.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="f-842">81.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsDeferredIncome" scale="6" id="f-843">155.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="f-844">62.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwards" scale="6" id="f-845">55.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-846">56.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="6" id="f-847">60.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-848">4.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsOther" scale="6" id="f-849">8.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="f-850">482.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsGross" scale="6" id="f-851">472.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="f-852">0.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment" scale="6" id="f-853">1.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="f-854">0.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredIncomeTaxLiabilities" scale="6" id="f-855">1.4</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-856">481.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="6" id="f-857">471.4</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred income tax liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="6" id="f-858">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:DeferredTaxLiabilities" format="ixt:fixed-zero" scale="6" id="f-859">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company has provided a valuation allowance against the full amount of the deferred tax assets since</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> it is more likely than not that the benefits will not be realized. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This assessment is based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All, or a portion of, the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to utilize these potential tax benefits. The valuation allowance increased by $<ix:nonFraction unitRef="usd" contextRef="c-180" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="f-860">10.0</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-181" decimals="-5" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="f-861">63.5</ix:nonFraction> million in 2025 and 2024, respectively, due to increases in net operating loss carryforwards, revenue recognition for tax purposes from the Vepdegestrant (ARV-471) Collaboration Agreement and the mandatory capitalization of qualified research and development costs in 2024.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-862">533.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-863">111.0</ix:nonFraction> million of federal net operating loss carryforwards as of December&#160;31, 2025 and 2024, respectively. Federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such carryforwards is limited to <ix:nonFraction unitRef="number" contextRef="c-184" decimals="2" name="arvn:OperatingLossesCarryForwardMaximumDeductibilityPercentage" scale="-2" id="f-864">80</ix:nonFraction>% of the Company&#8217;s taxable income in the year in which carryforwards are used. The Company had $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-865">563.2</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:OperatingLossCarryforwards" scale="6" id="f-866">129.0</ix:nonFraction> million of state and local net operating loss carryforwards as of December&#160;31, 2025 and 2024, respectively, which expire at various dates beginning in 2035. The Company had $<ix:nonFraction unitRef="usd" contextRef="c-182" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-867">44.7</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-183" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-868">37.7</ix:nonFraction> million of federal tax credit carryforwards as of December&#160;31, 2025 and 2024, respectively. The Company had $<ix:nonFraction unitRef="usd" contextRef="c-185" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-869">22.3</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-186" decimals="-5" name="us-gaap:TaxCreditCarryforwardAmount" scale="6" id="f-870">22.4</ix:nonFraction> million of state tax credit carryforwards as of December&#160;31, 2025 and 2024, respectively, which expire at various dates beginning in 2035.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has performed a Section 382 analysis through December 31, 2024 to determine whether an ownership change occurred for tax purposes. Based on this analysis, the Company determined that ownership changes occurred on July 31, 2018 and December 31, 2020 due to various equity offerings, vesting of restricted stock awards and stock option exercises. These ownership changes resulted in Section 382 limitations on the Company&#8217;s net operating loss and tax credit carryforwards generated before these dates. However, because the amount of the Section 382 limitations (including carryover of the unused Section 382 limitations and realized built-in gains) exceeds the amount of the Company&#8217;s carryforwards generated before these dates, the limitations will not affect the Company's ability to fully utilize these carryforwards.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 26</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-750-4"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company complies with the provisions of ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. As of December&#160;31, 2025 and 2024, the Company recorded net uncertain tax positions of $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="arvn:UnrecognizedTaxBenefitsNet" scale="6" id="f-871">5.9</ix:nonFraction> million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="arvn:UnrecognizedTaxBenefitsNet" scale="6" id="f-872">5.4</ix:nonFraction> million, respectively, relating primarily to state income tax filing positions in various jurisdictions. </span></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" id="f-873" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's gross unrecognized tax benefits were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period balance - gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-874">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-875">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-13" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-876">4.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for tax positions taken during the current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="f-877">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" format="ixt:fixed-zero" scale="6" id="f-878">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" scale="6" id="f-879">1.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period balance - gross</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-880">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-881">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:UnrecognizedTaxBenefits" scale="6" id="f-882">5.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense. The Company's accrual for interest and penalties as of December&#160;31, 2025 and 2024 totaled $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="f-883">1.6</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" scale="6" id="f-884">1.0</ix:nonFraction>&#160;million, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to file income tax returns in the U.S. Federal and various state jurisdictions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Company&#8217;s net operating loss carryforwards, the Company&#8217;s federal and state statutes of limitations generally remain open for all tax years until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization. The Company is currently under federal income tax examination for the year ended December 31, 2023, and state income tax examination with the state of New York for the years ended December 31, 2021 through December 31, 2023.</span></div></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_187"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">12. <ix:nonNumeric contextRef="c-1" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="f-885" continuedAt="f-885-1" escape="true">Commitments and Contingencies </ix:nonNumeric></span></div><ix:continuation id="f-885-1" continuedAt="f-885-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the&#160;ordinary&#160;course&#160;of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount, which could differ materially. Legal fees and other costs associated with such actions are expensed as incurred.&#160;As of December&#160;31, 2025, 2024 and 2023, the Company accrued <ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" format="ixt:fixed-zero" scale="6" id="f-886">zero</ix:nonFraction>, $<ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="f-887">5.0</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="usd" contextRef="c-22" decimals="-5" name="us-gaap:LossContingencyAccrualAtCarryingValue" scale="6" id="f-888">15.2</ix:nonFraction>&#160;million, respectively, for such matters, related to the Amended License Agreement with Yale University ("Yale"), as further described below.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical and Preclinical Development and Licensing Arrangements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, under licensing and related arrangements to which the Company is a party, the Company may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Yale University License Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the Company entered into an Amended and Restated License Agreement (the &#8220;Amended License Agreement&#8221;) with Yale pursuant to which the parties amended and restated the license agreement dated July 5, 2013, as amended to date (the "Original Agreement"). In connection with the signing of the Amended License Agreement, the Company made a payment of $<ix:nonFraction unitRef="usd" contextRef="c-187" decimals="-4" name="arvn:PaymentsForCollaboration" scale="6" id="f-889">14.95</ix:nonFraction>&#160;million to Yale, comprising both an upfront payment connected to the Amended License Agreement and an amount related to the collaboration income under the Novartis License Agreement and Novartis Asset Agreement (see Note 3, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 27</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-885-2"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreements,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the agreements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company made another $<ix:nonFraction unitRef="usd" contextRef="c-188" decimals="-5" name="arvn:CollaborativeArrangementRightsAndObligationsMilestonePayment" scale="6" id="f-890">5.0</ix:nonFraction>&#160;million payment in June 2025 on the first anniversary of signing. Thereafter, the Company will also pay to Yale (1) up to $<ix:nonFraction unitRef="usd" contextRef="c-189" decimals="-5" name="arvn:CollaborativeArrangementRightsAndObligationsMilestonePayment" scale="6" id="f-891">15.0</ix:nonFraction>&#160;million if it secures approval of the first and second royalty products (as defined in the Amended License Agreement), (2) a low single digit percentage royalty on certain, more narrowly defined &#8220;collaboration products,&#8221; and (3) a lower single digit royalty on its aggregate worldwide net sales of certain newly defined &#8220;meaningfully involved products.&#8221; </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Original Agreement to pay Yale minimum annual royalties and certain other annual fees have been eliminated and Yale has agreed to release all claims arising previously under the Original Agreement. Other provisions of the Original Agreement remain materially unchanged under the Amended License Agreement, including the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirement to pay to Yale a minimum license maintenance royalty totaling</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="arvn:AnnualLicenseFeePayment" scale="6" id="f-892">0.1</ix:nonFraction> million per year until the first sale to a third party of any licensed product, followed by success-based milestones for the first <ix:nonFraction unitRef="product" contextRef="c-191" decimals="INF" name="arvn:NumberOfLicensedProducts" format="ixt-sec:numwordsen" scale="0" id="f-893">two</ix:nonFraction> licensed products for the development of the protein degradation technologies totaling approximately $<ix:nonFraction unitRef="usd" contextRef="c-192" decimals="-5" name="arvn:RequiredMilestonePayments" scale="6" id="f-894">3.0</ix:nonFraction>&#160;million for the first licensed product and approximately $<ix:nonFraction unitRef="usd" contextRef="c-193" decimals="-5" name="arvn:RequiredMilestonePayments" scale="6" id="f-895">1.5</ix:nonFraction>&#160;million for the second licensed product, certain of which milestones have already been satisfied, and low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to minimum royalty payments that range from $<ix:nonFraction unitRef="usd" contextRef="c-190" decimals="-5" name="us-gaap:PaymentsForRoyalties" scale="6" id="f-896">0.2</ix:nonFraction> million to $<ix:nonFraction unitRef="usd" contextRef="c-194" decimals="-5" name="us-gaap:PaymentsForRoyalties" scale="6" id="f-897">0.5</ix:nonFraction> million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During each of the years ended December&#160;31, 2025, 2024 and 2023, the Comp</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any recognized expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the license agreement totaling</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usd" contextRef="c-195" decimals="-5" name="us-gaap:PaymentsForRoyalties" scale="6" id="f-898">0.7</ix:nonFraction>&#160;million, <ix:nonFraction unitRef="usd" contextRef="c-196" decimals="-5" name="us-gaap:PaymentsForRoyalties" format="ixt:fixed-zero" scale="6" id="f-899">zero</ix:nonFraction> and $<ix:nonFraction unitRef="usd" contextRef="c-197" decimals="-5" name="us-gaap:PaymentsForRoyalties" scale="6" id="f-900">0.3</ix:nonFraction>&#160;million, respectively, under the license agreement. The payment made in the year ended December 31, 2024 included the payment made in connection with signing the Amended License Agreement, as summarized above.</span></div></ix:continuation><div id="i234a6a5dabee4a7a8fb9427be68ac044_190"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">13. <ix:nonNumeric contextRef="c-1" name="us-gaap:EarningsPerShareTextBlock" id="f-901" continuedAt="f-901-1" escape="true">Net Loss Per Share </ix:nonNumeric></span></div><ix:continuation id="f-901-1" continuedAt="f-901-2"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" id="f-902" escape="true"><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share was calculated as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-903">80.8</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-904">198.9</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-905">367.3</ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;- basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-906"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-907">70.9</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-908"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-909">71.9</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-5" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" scale="6" id="f-910"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-5" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="6" id="f-911">55.5</ix:nonFraction></ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per common share<br/>&#160;- basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-912"><ix:nonFraction unitRef="usdPerShare" contextRef="c-1" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-913">1.14</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-914"><ix:nonFraction unitRef="usdPerShare" contextRef="c-7" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-915">2.77</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(<ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareDiluted" scale="0" id="f-916"><ix:nonFraction unitRef="usdPerShare" contextRef="c-8" decimals="2" sign="-" name="us-gaap:EarningsPerShareBasic" scale="0" id="f-917">6.62</ix:nonFraction></ix:nonFraction>)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:nonNumeric><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury shares are not considered outstanding and are excluded from the calculation of basic and diluted loss per common share.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average number of common shares included in the computation of basic and diluted net loss per common share for the years ended December 31, 2024 and 2023 gave effect to pre-funded warrants which allowed holders to acquire a specified number of common shares at a nominal exercise price of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$<ix:nonFraction unitRef="usdPerShare" contextRef="c-198" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-918"><ix:nonFraction unitRef="usdPerShare" contextRef="c-22" decimals="3" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" id="f-919">0.001</ix:nonFraction></ix:nonFraction></span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share and were classified as equity. The shares underlying the pre-funded warrants were exercisable for little or no consideration and therefore the underlying shares were considered outstanding at the issuance of the pre-funded warrants for purposes of calculating the weighted-average number of common shares outstanding in basic and diluted net loss per share for common share. As of December&#160;31, 2025, all outstanding</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pre-funded warrants had been cashless exercised for no consideration. See Note 9,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 28</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="f-920" escape="true"><ix:continuation id="f-901-2"><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported net losses for each of the years ended December 31, 2025, 2024 and 2023, and therefore excluded all stock options and RSUs from the computation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:55.415%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.990%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.993%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(shares in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-199" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-921">8.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-200" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-922">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-201" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-923">7.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-202" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-924">3.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-203" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-925">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-204" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-926">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-1" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-927">12.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-7" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-928">10.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonFraction unitRef="shares" contextRef="c-8" decimals="-5" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="6" id="f-929">9.1</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/></tr></table></div></ix:continuation></ix:nonNumeric><div id="i234a6a5dabee4a7a8fb9427be68ac044_1184"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">14. <ix:nonNumeric contextRef="c-1" name="us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock" id="f-930" continuedAt="f-930-1" escape="true">Restructuring Activity</ix:nonNumeric></span></div><ix:continuation id="f-930-1" continuedAt="f-930-2"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2025, the Company committed to and approved a reduction of the Company&#8217;s workforce by approximately <ix:nonFraction unitRef="number" contextRef="c-205" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-931">33</ix:nonFraction>% across all areas of the Company, as part of the Company&#8217;s decision to streamline operations across the organization and enable the efficient progression of the Company&#8217;s portfolio. This decision was made following a strategic review aimed at reducing internal costs while minimally impacting the Company's targeted clinical stage programs to drive value over the next several years by aligning the Company's operations with long-term program development objectives. As of June 30, 2025, these restructuring activities were substantially completed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the Company announced an update on its collaboration with Pfizer and further actions to support value creation by optimizing organizational and cost structures and streamlining operations in advance of multiple anticipated upcoming value inflection points, including: further limiting additional expenditures on the vepdegestrant program supporting activities required for commercialization readiness and identification, with Pfizer, of a third party for the commercialization and potential further development of vepdegestrant; reducing the Company's workforce by an additional <ix:nonFraction unitRef="number" contextRef="c-206" decimals="2" name="us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" scale="-2" id="f-932">15</ix:nonFraction>% to streamline operations, with the most significant reductions being roles related to vepdegestrant commercialization; and proactively managing pipeline cost by seeking strategic business development opportunities and by identifying further efficiencies across the business. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The September 2025 workforce reduction was substantially completed in the first quarter of 2026.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Components of Restructuring Charges</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, the Company recognized net restructuring charges of $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-933">3.7</ix:nonFraction>&#160;million, including $<ix:nonFraction unitRef="usd" contextRef="c-207" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-934">15.3</ix:nonFraction>&#160;million of cash severance and other one-time employee related termination benefit related to the workforce reduction, partially offset by a reversal of $<ix:nonFraction unitRef="usd" contextRef="c-208" decimals="-5" sign="-" name="us-gaap:RestructuringCharges" scale="6" id="f-935">11.6</ix:nonFraction>&#160;million of non-cash stock compensation and bonus expenses, of which $<ix:nonFraction unitRef="usd" contextRef="c-209" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-936">2.3</ix:nonFraction>&#160;million of charges are reflected in <span style="-sec-ix-hidden:f-937">research and development expenses</span> and $<ix:nonFraction unitRef="usd" contextRef="c-210" decimals="-5" name="us-gaap:RestructuringCharges" scale="6" id="f-938">1.3</ix:nonFraction>&#160;million of a reversal of previously recognized expense reflected in <span style="-sec-ix-hidden:f-939">general and administrative expenses</span> in the accompanying consolidated statement of operations. The Company recognized <ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="0" id="f-940"><ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:RestructuringCharges" format="ixt:fixed-zero" scale="0" id="f-941">no</ix:nonFraction></ix:nonFraction> restructuring charges during the years ended December 31, 2024 and 2023.</span></div></ix:continuation><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-930-2">The Company's restructuring accrual totaled $<ix:nonFraction unitRef="usd" contextRef="c-5" decimals="-5" name="us-gaap:RestructuringReserve" scale="6" id="f-942">4.4</ix:nonFraction>&#160;million and <ix:nonFraction unitRef="usd" contextRef="c-6" decimals="-5" name="us-gaap:RestructuringReserve" format="ixt:fixed-zero" scale="0" id="f-943">zero</ix:nonFraction> as of December&#160;31, 2025 and 2024, respectively.</ix:continuation> </span></div><div id="i234a6a5dabee4a7a8fb9427be68ac044_193"></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">15. <ix:nonNumeric contextRef="c-1" name="us-gaap:SegmentReportingDisclosureTextBlock" id="f-944" continuedAt="f-944-1" escape="true">Segment Information </ix:nonNumeric></span></div><ix:continuation id="f-944-1" continuedAt="f-944-2"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations are organized into <ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfOperatingSegments" format="ixt-sec:numwordsen" scale="0" id="f-945"><ix:nonFraction unitRef="segment" contextRef="c-1" decimals="INF" name="us-gaap:NumberOfReportableSegments" format="ixt-sec:numwordsen" scale="0" id="f-946">one</ix:nonFraction></ix:nonFraction> operating and reportable segment focused on </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the discovery, development and commercialization of therapies that degrade disease-causing proteins. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The segment develops protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing protein through the Company's PROTAC (PROteolysis TArgeting Chimera) protein degrader platform. The Company is progressing multiple product candidates through clinical development programs, including </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-102, targeting the leucine-rich repeat kinase 2 protein for the treatment of neurodegenerative diseases; ARV-806, targeting Kirsten rat sarcoma G12D protein for cancers with the G12D mutation, including pancreatic, colorectal and non-small cell lung cancers; ARV-393, targeting the B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyQ-AR in skeletal muscle and specifically selected for potent </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 29</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-944-2" continuedAt="f-944-3"><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduction of cytosolic and nuclear polyQ-AR and for favorable skeletal muscle exposure following oral administration; and vepdegestrant, targeting the estrogen receptor for the treatment of locally advanced or metastatic ER positive / human epidermal growth factor receptor 2 negative breast cancer</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company's tangible assets are held in the United States and all of the Company's revenue has been generated in the United States. The Company manages all business activities on a consolidated basis. The Company's chief operating decision maker is the Chief Executive Officer. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating segment's revenue is primarily generated through research collaborations and licensing arrangements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Revenue is recognized ratably over the Company&#8217;s expected performance period under each respective arrangement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also generated revenue through the sale of assets based on fair value. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have intra-entity sales or transfers.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the operating segment are the same as those described in Note 2, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The chief operating decision maker evaluates the performance of the operating segment and allocates resources based on net income/ loss that also is reported on the consolidated income statement as net loss. The measure of the operating segment assets is reported on the consolidated balance sheet as total assets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chief operating decision maker uses net loss to monitor budget versus actual results and to analyze cash flows in assessing performance of the segment and allocating resources.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 30</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:45pt;width:100%"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div></div><ix:continuation id="f-944-3"><ix:nonNumeric contextRef="c-1" name="us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock" id="f-947" continuedAt="f-947-1" escape="true"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the reportable segment's financial information: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:58.142%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.081%"/><td style="width:0.1%"/><td style="width:0.1%"/><td style="width:0.406%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:12.084%"/><td style="width:0.1%"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="padding:0 1pt"/><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years Ended December 31,</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"/><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-948">262.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-949">263.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:Revenues" scale="6" id="f-950">78.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Program-specific external expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vepdegestrant (ARV-471) (*)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-214" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-951">62.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-215" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-952">76.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-216" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-953">104.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-102</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-217" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-954">21.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-218" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-955">13.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-219" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-956">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-806</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-220" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-957">13.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-221" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-958">2.3</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-222" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" format="ixt:fixed-zero" scale="6" id="f-959">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-393</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-223" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-960">11.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-224" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-961">6.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-225" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-962">1.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Bavdegalutamide (ARV-110)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-226" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-963">2.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-227" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-964">8.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-228" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-965">26.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Luxdegalutamide (ARV-766)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-229" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" format="ixt:fixed-zero" scale="6" id="f-966">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-230" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-967">19.7</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-231" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-968">24.2</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-232" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" scale="6" id="f-969">4.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-233" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" format="ixt:fixed-zero" scale="6" id="f-970">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-234" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseProgramSpecific" format="ixt:fixed-zero" scale="6" id="f-971">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non program-specific external expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseNonProgramSpecific" scale="6" id="f-972">49.1</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseNonProgramSpecific" scale="6" id="f-973">62.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="arvn:ResearchAndDevelopmentExpenseNonProgramSpecific" scale="6" id="f-974">72.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Compensation and related personnel expense</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(including stock-based compensation)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="f-975">109.6</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="f-976">145.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:LaborAndRelatedExpense" scale="6" id="f-977">134.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" id="f-978">11.0</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" id="f-979">12.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:OtherResearchAndDevelopmentExpense" scale="6" id="f-980">13.8</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total research and development expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-981">285.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-982">348.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:ResearchAndDevelopmentExpense" scale="6" id="f-983">379.7</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-984">95.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-985">165.4</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:GeneralAndAdministrativeExpense" scale="6" id="f-986">100.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other segment expense, net (**)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-987">0.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-988">2.9</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:SegmentReportingOtherItemAmount" scale="6" id="f-989">1.2</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-990">0.3</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-991">0.6</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" id="f-992">0.9</ix:nonFraction>&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Loss from equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-993">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:IncomeLossFromEquityMethodInvestments" format="ixt:fixed-zero" scale="6" id="f-994">&#8212;</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" sign="-" name="us-gaap:IncomeLossFromEquityMethodInvestments" scale="6" id="f-995">2.5</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Plus:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-996">38.4</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-997">54.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#cceeff;padding:0 1pt"/><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"><ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" name="us-gaap:InvestmentIncomeInterest" scale="6" id="f-998">38.8</ix:nonFraction>&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-211" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-999">80.8</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-212" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-1000">198.9</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="background-color:#ffffff;padding:0 1pt"/><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(<ix:nonFraction unitRef="usd" contextRef="c-213" decimals="-5" sign="-" name="us-gaap:NetIncomeLoss" scale="6" id="f-1001">367.3</ix:nonFraction>)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"/><td colspan="3" style="display:none"/></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*)&#160;&#160;&#160;&#160;Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.</span></div></ix:nonNumeric><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"><ix:continuation id="f-947-1">(**)&#160;&#160;&#160;&#160;Includes loss on disposal of fixed assets, realized gains/ losses on sale of marketable securities and refundable research and development credits from the State of Connecticut.</ix:continuation>  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense totaled $<ix:nonFraction unitRef="usd" contextRef="c-1" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-1002">3.0</ix:nonFraction> million, $<ix:nonFraction unitRef="usd" contextRef="c-7" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-1003">4.6</ix:nonFraction> million, and $<ix:nonFraction unitRef="usd" contextRef="c-8" decimals="-5" name="us-gaap:DepreciationAndAmortization" scale="6" id="f-1004">4.8</ix:nonFraction> million for the years ended December&#160;31, 2025, 2024 and 2023, respectively.</span></div></ix:continuation><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">F - 31</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>2
<FILENAME>exhibit108-arvinasxformo.htm
<DESCRIPTION>EX-10.8
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit108-arvinasxformo</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exhibit108-arvinasxformo001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit108-arvinasxformo001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">    Exhibit 10.8    Arvinas, Inc.  RESTRICTED STOCK UNIT AGREEMENT  Arvinas Inc. (the &#8220;Company&#8221;) hereby grants the following restricted stock units pursuant  to its 2018 Stock Incentive Plan.  The terms and conditions attached hereto are also a part hereof.  Notice of Grant  Name of recipient (the &#8220;Participant&#8221;):   Grant Date:   Number of Restricted Stock Units (&#8220;RSUs&#8221;)  granted:    Number, if any, of RSUs that vest  immediately on the grant date:    RSUs that are subject to vesting schedule:   Vesting Start Date:   Vesting Schedule:           All vesting is dependent on the Participant remaining an Eligible Participant, as provided  herein.    This grant of RSUs satisfies in full all commitments that the Company has to the  Participant with respect to the issuance of stock, stock options or other equity securities.   Arvinas, Inc.         Signature of Participant           Street Address  By:       Name of Officer  Title:        City/State/Zip Code    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit108-arvinasxformo002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit108-arvinasxformo002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Arvinas, Inc.   Restricted Stock Unit Agreement   Incorporated Terms and Conditions  For valuable consideration, receipt of which is acknowledged, the parties hereto agree as  follows:  1. Award of Restricted Stock Units.  In consideration of services rendered and to be rendered to the Company, by the  Participant, the Company has granted to the Participant, subject to the terms and conditions set  forth in this Restricted Stock Unit Agreement (this &#8220;Agreement&#8221;) and in the Company&#8217;s 2018  Stock Incentive Plan (the &#8220;Plan&#8221;), an award with respect to the number of restricted stock units  (the &#8220;RSUs&#8221;) set forth in the Notice of Grant that forms part of this Agreement (the &#8220;Notice of  Grant&#8221;).  Each RSU represents the right to receive one share of common stock, $0.001 par value  per share, of the Company (the &#8220;Common Stock&#8221;) upon vesting of the RSU, subject to the terms  and conditions set forth herein.    2. Vesting.  The RSUs shall vest in accordance with the Vesting Schedule set forth in the Notice of  Grant (the &#8220;Vesting Schedule&#8221;).  Any fractional shares resulting from the application of any  percentages used in the Vesting Schedule shall be rounded down to the nearest whole number of  RSUs.  Upon the vesting of the RSU, the Company will deliver to the Participant, for each RSU  that becomes vested, one share of Common Stock, subject to the payment of any taxes pursuant  to Section 7.  The Common Stock will be delivered to the Participant as soon as practicable  following each vesting date, but in any event within 30 days of such date.  Notwithstanding  anything herein to the contrary, in the sole discretion of the Board, the Company may, with  respect to any applicable vesting date of the RSU, deliver to the Participant cash having a fair  market value equal to the number of shares of Common Stock underlying the portion of the RSU  that vested on such date, payable within 30 days of the vesting date, less applicable taxes.  3. Forfeiture of Unvested RSUs Upon Cessation of Service.   In the event that the Participant ceases to be an employee, director or officer of, or  consultant or advisor to, the Company or any other entity the employees, officers, directors,  consultants, or advisors of which are eligible to receive awards under the Plan (an &#8220;Eligible  Participant&#8221;) for any reason or no reason, with or without cause, all of the RSUs that are  unvested as of the time of such cessation shall be forfeited immediately and automatically to the  Company, without the payment of any consideration to the Participant, effective as of such  cessation.  The Participant shall have no further rights with respect to the unvested RSUs or any  Common Stock that may have been issuable with respect thereto.  If the Participant provides  services to a subsidiary of the Company, any references in this Agreement to provision of  services to the Company shall instead be deemed to refer to service with such subsidiary.    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit108-arvinasxformo003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit108-arvinasxformo003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">4. Restrictions on Transfer.  The Participant shall not sell, assign, transfer, pledge, hypothecate or otherwise dispose  of, by operation of law or otherwise (collectively &#8220;transfer&#8221;) any RSUs, or any interest therein.  The Company shall not be required to treat as the owner of any RSUs or issue any Common  Stock to any transferee to whom such RSUs have been transferred in violation of any of the  provisions of this Agreement.  5. Rights as a Stockholder.  The Participant shall have no rights as a stockholder of the Company with respect to any  shares of Common Stock that may be issuable with respect to the RSUs until the issuance of the  shares of Common Stock to the Participant following the vesting of the RSUs.    6. Provisions of the Plan.  This Agreement is subject to the provisions of the Plan, a copy of which is furnished to  the Participant with this Agreement.    7. Tax Matters.     (a) Acknowledgments; No Section 83(b) Election.  The Participant  acknowledges that he or she is responsible for obtaining the advice of the Participant&#8217;s own tax  advisors with respect to the award of RSUs and the Participant is relying solely on such advisors  and not on any statements or representations of the Company or any of its agents with respect to  the tax consequences relating to the RSUs.  The Participant understands that the Participant (and  not the Company) shall be responsible for the Participant&#8217;s tax liability that may arise in  connection with the acquisition, vesting and/or disposition of the RSUs.  The Participant  acknowledges that no election under Section 83(b) of the Internal Revenue Code, as amended  (the &#8220;Code&#8221;), is available with respect to RSUs.     (b) Withholding.  The Participant acknowledges and agrees that the Company  has the right to deduct from payments of any kind otherwise due to the Participant any federal,  state, local or other taxes of any kind required by law to be withheld with respect to the vesting  of the RSUs.  To the extent the Participant has not previously executed and delivered to the  Company effective durable automatic sell-to-cover instructions that by their terms would cover  any taxes required by law to be withheld with respect to the vesting of the RSUs, at such time as  the Participant is not aware of any material nonpublic information about the Company or the  Common Stock and is not prohibited from doing so under the Company&#8217;s insider trading policy  or otherwise, the Participant shall execute the instructions set forth in Schedule A attached hereto  (the &#8220;Durable Automatic Sell-to-Cover Instructions&#8221;) as the means of satisfying such tax  obligation.  If the Participant is required to but does not execute the Durable Automatic Sell-to- Cover Instructions prior to an applicable vesting date, then the Participant agrees that if under  applicable law the Participant will owe taxes at such vesting date on the portion of the award  then vested the Company shall be entitled to immediate payment from the Participant of the  amount of any tax required to be withheld by the Company. The Participant further agrees and  acknowledges that the Company will not (and is not obligated to) deliver any shares of Common  Stock to the Participant until it is satisfied that all required withholdings have been made.    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit108-arvinasxformo004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit108-arvinasxformo004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">8. Miscellaneous.  (a) No Right to Continued Service.  The Participant acknowledges and agrees  that, notwithstanding the fact that the vesting of the RSUs is contingent upon his or her  continued service to the Company, this Agreement does not constitute an express or implied  promise of continued service relationship with the Participant or confer upon the Participant any  rights with respect to a continued service relationship with the Company or any affiliate of the  Company.  (b) Section 409A.  The RSUs awarded pursuant to this Agreement are  intended to be exempt from or comply with the requirements of Section 409A of the Code and  the Treasury Regulations issued thereunder (&#8220;Section 409A&#8221;).  The delivery of shares of  Common Stock on the vesting of the RSUs may not be accelerated or deferred unless permitted  or required by Section 409A.  (c) Participant&#8217;s Acknowledgements.  The Participant acknowledges that he  or she:  (i) has read this Agreement; (ii) has been represented in the preparation, negotiation and  execution of this Agreement by legal counsel of the Participant&#8217;s own choice or has voluntarily  declined to seek such counsel; (iii) understands the terms and consequences of this Agreement;  and (iv) is fully aware of the legal and binding effect of this Agreement.  (d) Governing Law.  This Agreement shall be construed, interpreted and  enforced in accordance with the internal laws of the State of Delaware without regard to any  applicable conflicts of laws provisions.      </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit108-arvinasxformo005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit108-arvinasxformo005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Schedule A    DURABLE AUTOMATIC SELL-TO-COVER INSTRUCTION    This Durable Automatic Sell-to-Cover Instruction (this &#8220;Instruction&#8221;), which is being  delivered to Arvinas, Inc. (the &#8220;Company&#8221;) by the undersigned on the date set forth below (the  &#8220;Adoption Date&#8221;), relates to the Covered RSUs (as defined following my signature below). This  Instruction provides for &#8220;eligible sell-to-cover transactions&#8221; (as described in Rule 10b5- 1(c)(1)(ii)(D)(3) under the Securities Exchange Act of 1934 (the &#8220;Exchange Act&#8221;)) with respect  to Covered RSUs and is intended to satisfy the affirmative defense conditions of Rule 10b5- 1(c)(1) under the Exchange Act.  I acknowledge that upon vesting and settlement of any Covered RSUs in accordance with  the applicable RSU&#8217;s terms, whether vesting is based on the passage of time or the achievement  of performance goals, I will have compensation income equal to the fair market value of the  shares of the Company&#8217;s common stock subject to the RSUs that are settled on such settlement  date and that the Company is required to withhold income and employment taxes in respect of  that compensation income.   I desire to establish a plan and process to satisfy such withholding obligation in respect of  all Covered RSUs through an automatic sale of the number of the shares of the Company&#8217;s  common stock that would otherwise be issuable to me on each applicable settlement date in an  amount sufficient to satisfy the applicable withholding obligation, with the proceeds of the sale  delivered to the Company in satisfaction of the applicable withholding obligation.  I understand that the Company has arranged for the administration and execution of its  equity incentive programs and the sale of securities by participants thereunder pursuant to a  platform administered by a third party (the &#8220;Administrator&#8221;) and the Administrator&#8217;s designated  brokerage partner.  Upon the settlement of any of my Covered RSUs after the 30th day following the  Adoption Date (or if I am an officer of the Company on the Adoption Date, after the later of: (i)  the 90th day following the Adoption Date or (ii) two business days following the disclosure of the  Company&#8217;s financial results in Form 10-Q or Form 10-K for the completed fiscal quarter in  which this Instruction was adopted (or, with respect to this clause (ii), if sooner, the 120th day  after adoption of this Instruction) (the &#8220;Cooling-Off Period&#8221;), I hereby appoint the Administrator  (or any successor administrator) to automatically sell such number of shares of the Company&#8217;s  common stock issuable with respect to such RSUs that vested and settled as is sufficient to  generate net proceeds sufficient to satisfy the Company&#8217;s minimum statutory withholding  obligations with respect to the income recognized by me in connection with the vesting and  settlement of such RSUs (based on minimum statutory withholding rates for all tax purposes,  including payroll and social security taxes, that are applicable to such income), and the Company  shall receive such net proceeds in satisfaction of such tax withholding obligation.    I hereby appoint the Chief Executive Officer, the Chief Financial Officer and the General  Counsel, and any of them acting alone and with full power of substitution, to serve as my  attorneys-in-fact to arrange for the sale of shares of the Company&#8217;s common stock in accordance  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit108-arvinasxformo006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit108-arvinasxformo006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">with this Instruction. I agree to execute and deliver such documents, instruments and certificates  as may reasonably be required in connection with the sale of the shares of common stock  pursuant to this Instruction.  Unless the third and final box in the definition of Covered RSUs below is checked, if I  have previously adopted an automatic sale or sell-to-cover instruction relating to Covered RSUs,  this Instruction shall be void ab initio.  I hereby certify that, as of the Adoption Date:   (i)  I am not prohibited from entering into this Instruction by the Company&#8217;s insider  trading policy or otherwise;   (ii) I am not aware of any material nonpublic information about the Company or its  common stock; and  (iii) I am adopting this Instruction in good faith and not as part of a plan or scheme  to evade the prohibitions of Rule 10b-5 under the Exchange Act.            ________________________________          Print Name:  _____________________          Date:  __________________________        Covered RSUs:    The following restricted stock units (&#8220;RSUs&#8221;) are covered by this Instruction.    Check all applicable boxes:    &#65533; The first award of RSUs granted to me on or after ______________ [insert date of grant of  current RSUs the grant of which is triggering the execution of this Instruction; if instruction is  being executed in advance of a grant of RSUs, insert the Adoption Date] and any RSUs that may,  from time to time following such date, be granted to me by the Company, other than any future  granted RSUs which by the terms of the applicable award agreement require the Company to  withhold shares for tax withholding obligations in connection with the vesting and settlement of  such RSUs, and therefore do not permit sell-to-cover transactions.    &#65533;  Any outstanding RSUs that were granted to me by the Company prior to the Adoption Date  that (1) are not subject to any prior automatic sale or sell-to-cover instruction and (2) for which  the next vesting date is after the Cooling-Off Period, other than any previously granted RSUs  which by the terms of the applicable award agreement require the Company to withhold shares  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit108-arvinasxformo007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit108-arvinasxformo007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">for tax withholding obligations in connection with the vesting and settlement of such RSUs, and  therefore do not permit sell-to-cover transactions.      &#65533;  With respect to any RSUs, whether or not granted to me by the Company prior to the  Adoption Date, that already are subject to an automatic sale or sell-to-cover instruction (a &#8220;Prior  Instruction&#8221;), I elect to have such sales effected pursuant to this Instruction and confirm that  doing so does not modify or change the amount, price, or timing of such sales from those  provided by the Prior Instruction (and, as a result the Cooling-Off Period is not applicable to  sales pursuant to this Instruction that were previously subject to the Prior Instruction).  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.16
<SEQUENCE>3
<FILENAME>exhibit1016-arvinasxamen.htm
<DESCRIPTION>EX-10.16
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit1016-arvinasxamen</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exhibit1016-arvinasxamen001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1016-arvinasxamen001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">EXECUTION VERSION  AMENDED AND RESTATED EMPLOYMENT AGREEMENT  THIS AMENDED AND RESTATED EMPLOYMENT AGREEMENT (the &#147;Amended  Agreement&#148;), is made effective as of February 12, 2026 (the &#147;Effective Date&#148;) by and between  Arvinas, Inc. (inclusive of its subsidiaries, the &#147;Company&#148;), and Randy Teel, Ph.D. (the  &#147;Executive&#148;) (together, the &#147;Parties&#148;).   RECITALS  WHEREAS, the Executive has been employed by the Company since May 14, 2018;  WHEREAS, the Parties are currently party to that certain Amended Employment  Agreement, dated November 4, 2025, by and between the Parties (the &#147;Existing Agreement&#148;),  and pursuant to the terms of the Existing Agreement, the Executive is employed as Chief  Business Officer;   WHEREAS, the Board of Directors of the Company (the &#147;Board&#148;) desires to continue to  employ the Executive with the Company and appoint him as Chief Executive Officer and  President of the Company;  WHEREAS, the Parties desire to amend the Existing Agreement as set forth in this  Amended Agreement to reflect appropriate employment terms in light of such appointment;  WHEREAS, the Executive has agreed to accept such employment on the terms and  conditions set forth in this Amended Agreement; and  WHEREAS, this Amended Agreement shall amend and restate the Existing Agreement in  its entirety.  NOW, THEREFORE, in consideration of the foregoing and of the respective covenants  and agreements of the Parties herein contained, the Parties hereto agree as follows:   AGREEMENT  1. Agreement. This Amended Agreement shall be effective as of the Effective Date.  Following the Effective Date, the Executive shall continue to be an employee of the Company until such employment relationship is terminated in accordance with Section 7 hereof (the &#147;Term of Employment&#148;). 2. Position. The Executive shall serve as the Chief Executive Officer and President of the Company, and shall serve on the Board, subject to his reelection thereto from time to time by the Company&#146;s stockholders, working out of the Company&#146;s office in New Haven, Connecticut, and travelling as reasonably required by the Executive&#146;s job duties. 3. Scope of Employment. The Executive shall be responsible for the performance of those duties consistent with the Executive&#146;s position as Chief Executive Officer and President. The Executive shall report to the Board and shall perform and discharge faithfully, diligently, and to the best of the Executive&#146;s ability, the Executive&#146;s duties and responsibilities hereunder. The Executive Exhibit 10.16 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1016-arvinasxamen002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1016-arvinasxamen002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">2  shall devote substantially all of the Executive&#146;s business time, loyalty, attention and efforts to the  business and affairs of the Company and its affiliates. Membership on boards of directors of any  other companies will be permitted only with the express approval of the Board; provided,  however, that the Executive may engage in community and charitable activities or participate in  industry associations and serve on the boards of up to two (2) community, charitable or industry  organizations, without the approval of the Board, provided such activities do not create a conflict  of interest or otherwise interfere with the Executive&#146;s performance of the Executive&#146;s duties  hereunder.  The Executive agrees to abide by the rules, regulations, instructions, personnel  practices and policies of the Company and any changes therein that may be adopted from time to  time by the Company.   4. Compensation. As full compensation for all services rendered by the Executive to the  Company and any affiliate thereof, during the Executive&#146;s Term of Employment, the Company  will provide to the Executive the following:   (a) Base Salary. Effective as of the Effective Date, the Executive is entitled to receive a  base salary at the annualized rate of $680,000 (the &#147;Base Salary&#148;). The Executive&#146;s Base Salary  shall be paid in equal installments in accordance with the Company&#146;s regularly established  payroll procedures. The Executive&#146;s Base Salary will be reviewed on an annual or more frequent  basis by the Board and is subject to change in the discretion of the Board.  (b) Annual Discretionary Bonus. Effective as of the Effective Date, the Executive will be  eligible to earn an annual performance bonus of 60% of the Executive&#146;s Base Salary (the  &#147;Target Bonus&#148;), based upon the Board&#146;s assessment of the Executive&#146;s performance and the  Company&#146;s attainment of targeted goals as set by the Board in its sole discretion.  To the extent  the Executive&#146;s Base Salary is changed during the year to which the performance bonus relates,  the Target Bonus shall be calculated based on base salary actually paid during such year (and not  solely on the Executive&#146;s Base Salary at the end of such year). The Board may determine to  provide the bonus in the form of cash, equity award(s), or a combination of cash and equity.   Following the close of each calendar year, the Board will determine whether the Executive has  earned a performance bonus, and the amount of any performance bonus, based on the set criteria.   No amount of the annual bonus is guaranteed, and the Executive must be an Executive in good  standing on the date of payment in order to be eligible for any annual bonus, except as  specifically set forth below. The annual performance bonus, if earned, will be paid by no later  than March 15 of the calendar year after the year to which it relates.  The Executive&#146;s bonus  eligibility will be reviewed on an annual or more frequent basis by the Board, and is subject to  change in the discretion of the Board.   (c) Equity Award.  The Executive will be eligible to receive equity awards, if any, at such  times and on such terms and conditions as the Board shall, in its sole discretion, determine.   (d) Paid Time Off. The Executive shall receive twenty (20) days per annum of paid time  off vacation time plus sick time, consistent with the Company&#146;s policies, during each full year of  employment with the Company (allocated ratably for any partial year worked by the Executive)  that must be used in accordance with the Company&#146;s paid time off policies as in effect from time  to time.    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1016-arvinasxamen003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1016-arvinasxamen003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">3  (e) Benefits. Subject to eligibility requirements and the Company&#146;s polices, the Executive  shall have the right, on the same basis as other Executives of the Company, to participate in, and  to receive benefits under, any medical, vision and dental insurance policy maintained by the  Company and the Company shall pay a portion of the cost of the premiums for such medical,  vision and dental insurance that is consistent with the Company&#146;s then current Executive benefit  policy if the Executive elects to participate in such plans.   (f) Withholdings. All compensation payable to the Executive shall be subject to  applicable taxes and withholdings.   5. Expenses. The Executive will be reimbursed for his actual, necessary and reasonable business  expense pursuant to Company policy, subject to the provisions of Section 3 of Exhibit A attached  hereto.   6. Restrictive Covenants Agreement. The Executive hereby acknowledges that the terms and  conditions of the Proprietary Information and Assignment Agreement that the Parties previously  entered into remain in full force and effect.  7. Employment Termination. This Amended Agreement and the employment of the Executive  shall terminate upon the occurrence of any of the following:   (a) Upon the death or &#147;Disability&#148; of the Executive. As used in this Amended Agreement,  the term &#147;Disability&#148; shall mean a physical or mental illness or disability that prevents the  Executive from performing the duties of the Executive&#146;s position for a period of more than any  three consecutive months or for periods aggregating more than twenty-six weeks. The Company  shall determine in good faith and in its sole discretion whether the Executive is unable to perform  the services provided for herein.   (b) At the election of the Company, with or without &#147;Cause&#148; (as defined below),  immediately upon written notice by the Company to the Executive. As used in this Amended  Agreement, &#147;Cause&#148; shall mean a finding by the Board that the Executive:   (i) performed his duties, in the good faith opinion of the Board, in a grossly negligent  or reckless manner or with willful malfeasance;   (ii) exhibited habitual drunkenness or engaged in substance abuse;   (iii) committed any material violation of any state or federal law relating to the  workplace environment (including, without limitation, laws relating to sexual  harassment or age, sex or other prohibited discrimination) or any material  violation of any Company policy;   (iv) willfully failed or refused to perform in the usual manner at the usual time those  duties which he regularly and routinely performed in connection with the business  of the Company or such other duties reasonably related to the capacity in which  the Executive is employed hereunder which may be assigned to the Executive by  the Board;   </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1016-arvinasxamen004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1016-arvinasxamen004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">4  (v) performed any material action when specifically and reasonably instructed not to  do so by the Board;   (vi) breached the Executive&#146;s Proprietary Information and Assignment Agreement or  any similar agreement with the Company;  (vii) committed any fraud or used or appropriated for his personal use or benefit any  funds, properties or opportunities of the Company not authorized by the Board to  be so used or appropriated; or  (viii) was convicted of any felony or any other crime related to the Executive&#146;s  employment or involving moral turpitude.    (c) At the election of the Executive, with or without &#147;Good Reason&#148; (as defined below),  immediately upon written notice by the Executive to the Company (subject, if it is with Good  Reason, to the timing provisions set forth in the definition of Good Reason). As used in this  Amended Agreement, &#147;Good Reason&#148; shall mean (without the Executive&#146;s consent):   (i) a material diminution in the nature or scope of Executive&#146;s duties, responsibilities,  or authority;    (ii)  the Company requiring Executive to report directly to anyone other than the  Board;  (iii) a material diminution of the Executive&#146;s base compensation;  (iv) the Company&#146;s requiring Executive to relocate Executive&#146;s primary office more  than fifty (50) miles from the Executive&#146;s then-current primary office; or    (v) any material breach of this Amended Agreement by the Company not otherwise  covered by this paragraph;    provided, however, that in each case, the Company shall have a period of not less than thirty (30)  days to cure any act constituting Good Reason following Executive&#146;s delivery to the Company of  written notice within sixty (60) days of the action or omission constituting Good Reason and that  the Executive actually terminates employment within thirty (30) days following the expiration of  the Company&#146;s cure period.   8. Effect of Termination.   (a)  All Terminations Other Than by the Company Without Cause or by the Executive  With Good Reason. If the Executive&#146;s employment is terminated under any circumstances other  than a Qualifying Termination (as defined below) (including a voluntary termination by the  Executive without Good Reason pursuant to Section 7(c), a termination by the Company for  Cause pursuant to Section 7(b) or due to the Executive&#146;s death or Disability pursuant to Section  7(a)), the Company&#146;s obligations under this Amended Agreement shall immediately cease and  the Executive shall only be entitled to receive (i) the Base Salary that has accrued and to which  the Executive is entitled as of the effective date of such termination and to the extent consistent  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1016-arvinasxamen005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1016-arvinasxamen005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">5  with general Company policy, accrued but unused paid time off through and including the  effective date of such termination, to be paid in accordance with the Company&#146;s established  payroll procedure and applicable law but no later than the next regularly scheduled pay period,  (ii) unreimbursed business expenses for which expenses the Executive has timely submitted  appropriate documentation in accordance with Section 5 hereof, and (iii) any amounts or benefits  to which the Executive is then entitled under the terms of the benefit plans then-sponsored by the  Company in accordance with their terms (and not accelerated to the extent acceleration does not  satisfy Section 409A of the Internal Revenue Code of 1986, as amended, (the &#147;Code&#148;) (the  payments described in this sentence, the &#147;Accrued Obligations&#148;).   (b) Termination by the Company Without Cause or by the Executive With Good Reason  Prior to or More Than Twelve Months Following a Change in Control. If the Executive&#146;s  employment is terminated by the Company without Cause pursuant to Section 7(b) or by the  Executive with Good Reason pursuant to Section 7(c) (in either case, a &#147;Qualifying  Termination&#148;) prior to or more than twelve (12) months following a Change in Control (as  defined below), the Executive shall be entitled to the Accrued Obligations. In addition, and  subject to Exhibit A and the conditions of Section 8(d), the Company shall: (i) continue to pay to  the Executive, in accordance with the Company&#146;s regularly established payroll procedures, the  Executive&#146;s Base Salary for a period of twelve (12) months and (ii) provided the Executive is  eligible for and timely elects to continue receiving group medical insurance pursuant to the  &#147;COBRA&#148; law, continue to pay (but in no event longer than twelve (12) months following the  Executive&#146;s termination date) the share of the premium for health coverage that is paid by the  Company for active and similarly-situated Executives who receive the same type of coverage,  unless the Company&#146;s provision of such COBRA payments will violate the nondiscrimination  requirements of applicable law, in which case this benefit will not apply (collectively, the  &#147;Severance Benefits&#148;).   (c) Termination by the Company Without Cause or by the Executive With Good Reason  Within Twelve Months Following a Change in Control. If a Qualifying Termination occurs  within twelve (12) months following a Change in Control, then the Executive shall be entitled to  the Accrued Obligations.  In addition, and subject to Exhibit A and the conditions of Section  8(d), the Company shall: (i) continue to pay to the Executive, in accordance with the Company&#146;s  regularly established payroll procedures, the Executive&#146;s Base Salary for a period of eighteen  (18) months; (ii) pay to the Executive, in a single lump sum on the Payment Date (as defined  below) an amount equal to 150% of the Executive&#146;s Target Bonus for the year in which  termination occurs or, if higher, the Executive&#146;s Target Bonus immediately prior to the Change  in Control, (iii) provided the Executive is eligible for and timely elects to continue receiving  group medical insurance pursuant to the &#147;COBRA&#148; law, continue to pay (but in no event longer  than eighteen (18) months following the Executive&#146;s termination date) the share of the premium  for health coverage that is paid by the Company for active and similarly-situated Executives who  receive the same type of coverage, unless the Company&#146;s provision of such COBRA payments  will violate the nondiscrimination requirements of applicable law, in which case this benefit will  not apply, and (iv) provide that the vesting of the Executive&#146;s then-unvested equity awards shall  be accelerated, such that all then-unvested equity awards vest and become fully exercisable or  non-forfeitable as of the termination date (collectively, the &#147;Change in Control Severance  Benefits&#148;).  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1016-arvinasxamen006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1016-arvinasxamen006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">6  (d) Severance and Release of Claims Agreement. As a condition of the Executive&#146;s  receipt of the Severance Benefits or the Change in Control Severance Benefits, as applicable, the  Executive must execute and deliver to the Company a severance and release of claims agreement  in a form to be provided by the Company (which shall, at a minimum, include the Executive&#146;s  release of all releasable claims, reaffirmation of continuing obligations, including those  obligations set forth in the Form of Proprietary Information and Assignment Agreement, and  confidentiality, cooperation, and non-disparagement obligations) (the &#147;Severance Agreement&#148;),  which Severance Agreement must become irrevocable within 60 days following the date of the  Executive&#146;s termination of employment (or such shorter period as may be directed by the  Company). The Severance Benefits or the Change in Control Severance Benefits, as applicable,  will be paid or commence to be paid in the first regular payroll beginning after the Severance  Agreement becomes effective, provided that if the foregoing 60 day period would end in a  calendar year subsequent to the year in which the Executive&#146;s employment ends, the Severance  Benefits or Change in Control Severance Benefits, as applicable, will not be paid or begin to be  paid before the first payroll of the subsequent calendar year (the date the Severance Benefits or  Change in Control Severance Benefits, as applicable, commence pursuant to this sentence, the  &#147;Payment Date&#148;). The Executive must continue to comply with the Proprietary Information and  Assignment Agreement and any similar agreement with the Company in order to be eligible to  continue receiving the Severance Benefits or Change in Control Severance Benefits, as  applicable.   (e) Change in Control Definition.  For purposes of this Amended Agreement, &#147;Change in  Control&#148; shall mean the occurrence of any of the following events, provided that such event or  occurrence constitutes a change in the ownership or effective control of the Company, or a  change in the ownership of a substantial portion of the assets of the Company, as defined in  Treasury Regulation &sect;&sect; 1.409A-3(i)(5)(v), (vi) and (vii): (i) the acquisition by an individual,  entity or group (within the meaning of Section 13(d)(3) or 14(d)(2) of the Securities and  Exchange Act of 1934, as amended) (a &#147;Person&#148;) of beneficial ownership of any capital stock of  the Company if, after such acquisition, such Person beneficially owns (within the meaning of  Rule 13d-3 under the Exchange Act) fifty percent (50%) or more of either (x) the then- outstanding shares of common stock of the Company (the &#147;Outstanding Company Common  Stock&#148;) or (y) the combined voting power of the then-outstanding securities of the Company  entitled to vote generally in the election of directors (the &#147;Outstanding Company Voting  Securities&#148;); provided, however, that for purposes of this subsection (i), the following  acquisitions shall not constitute a Change in Control: (1) any acquisition directly from the  Company or (2) any acquisition by any entity pursuant to a Business Combination (as defined  below) which complies with clauses (x) and (y) of subsection (iii) of this definition; or (ii) a  change in the composition of the Board that results in the Continuing Directors (as defined  below) no longer constituting a majority of the Board (or, if applicable, the Board of Directors of  a successor corporation to the Company), where the term &#147;Continuing Director&#148; means at any  date a member of the Board (x) who was a member of the Board on the Effective Date or (y)  who was nominated or elected subsequent to such date by at least a majority of the directors who  were Continuing Directors at the time of such nomination or election or whose election to the  Board was recommended or endorsed by at least a majority of the directors who were Continuing  Directors at the time of such nomination or election; provided, however, that there shall be  excluded from this clause (y) any individual whose initial assumption of office occurred as a  result of an actual or threatened election contest with respect to the election or removal of  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1016-arvinasxamen007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1016-arvinasxamen007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">7  directors or other actual or threatened solicitation of proxies or consents, by or on behalf of a  person other than the Board; or (iii) the consummation of a merger, consolidation,  reorganization, recapitalization or share exchange involving the Company, or a sale or other  disposition of all or substantially all of the assets of the Company (a &#147;Business Combination&#148;),  unless, immediately following such Business Combination, each of the following two (2)  conditions is satisfied: (x) all or substantially all of the individuals and entities who were the  beneficial owners of the Outstanding Company Common Stock and Outstanding Company  Voting Securities immediately prior to such Business Combination beneficially own, directly or  indirectly, more than fifty percent (50%) of the then-outstanding shares of common stock and the  combined voting power of the then-outstanding securities entitled to vote generally in the  election of directors, respectively, of the resulting or acquiring corporation in such Business  Combination (which shall include, without limitation, a corporation which as a result of such  transaction owns the Company or substantially all of the Company&#146;s assets either directly or  through one (1) or more subsidiaries) (such resulting or acquiring corporation is referred to  herein as the &#147;Acquiring Corporation&#148;) in substantially the same proportions as their ownership  of the Outstanding Company Common Stock and Outstanding Company Voting Securities,  respectively, immediately prior to such Business Combination and (y) no Person (excluding any  Executive benefit plan (or related trust) maintained or sponsored by the Company or by the  Acquiring Corporation) beneficially owns, directly or indirectly, fifty percent (50%) or more of  the then-outstanding shares of common stock of the Acquiring Corporation, or of the combined  voting power of the then-outstanding securities of such corporation entitled to vote generally in  the election of directors (except to the extent that such ownership existed prior to the Business  Combination); or (iv) the liquidation or dissolution of the Company.  9. Absence of Restrictions. Notwithstanding the Existing Agreement, the Executive represents  and warrants that the Executive is not bound by any employment contracts, restrictive covenants  or other restrictions that prevent the Executive from entering into or continuing employment  with, or carrying out the Executive&#146;s responsibilities for, the Company, or which are in any way  inconsistent with any of the terms of this Amended Agreement.  10. Notice. Any notice delivered under this Amended Agreement shall be deemed duly delivered  three (3) business days after it is sent by registered or certified mail, return receipt requested,  postage prepaid, one (1) business day after it is sent for next-business day delivery via a  reputable nationwide overnight courier service, or immediately upon hand delivery, in each case  to the address of the recipient set forth below.   To Executive:   At the address set forth in the Executive&#146;s personnel file   To Company:   ATTN: Corporate Secretary  Arvinas, Inc.   5 Science Park   New Haven, CT 06511    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1016-arvinasxamen008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1016-arvinasxamen008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">8  Either Party may change the address to which notices are to be delivered by giving notice of such  change to the other Party in the manner set forth in this Section 10.   11. Applicable Law; Jury Trial Waiver. This Amended Agreement shall be governed by and  construed in accordance with the laws of the State of Connecticut (without reference to the  conflict of laws provisions thereof). Any action, suit or other legal proceeding arising under or  relating to any provision of this Amended Agreement shall be commenced only in a court of the  State of Connecticut (or, if appropriate, a federal court located within the State of Connecticut),  and the Company and the Executive each consents to the jurisdiction of such a court. The  Company and the Executive each hereby irrevocably waives any right to a trial by jury in any  action, suit or other legal proceeding arising under or relating to any provision of this Amended  Agreement.   12. Successors and Assigns. This Amended Agreement shall be binding upon and inure to the  benefit of both Parties and their respective successors and assigns, including any corporation  with which or into which the Company may be merged or which may succeed to its assets or  business; provided, however, that the obligations of the Executive are personal and shall not be  assigned by the Executive.   13. At-Will Employment. During the Executive&#146;s Term of Employment, the Executive will  continue to be an at-will Executive of the Company, which means that, notwithstanding any  other provision set forth herein, the employment relationship can be terminated by either Party  for any reason, at any time, with or without prior notice and with or without Cause.  14. Acknowledgment. The Executive states and represents that the Executive has had an  opportunity to fully discuss and review the terms of this Amended Agreement with an attorney.  The Executive further states and represents that the Executive has carefully read this Amended  Agreement, understands the contents herein, freely and voluntarily assents to all of the terms and  conditions hereof, and signs the Executive&#146;s name of the Executive&#146;s own free act.   15. No Oral Modification, Waiver, Cancellation or Discharge. This Amended Agreement may  be amended or modified only by a written instrument executed by both the Company and the  Executive. No delay or omission by the Company in exercising any right under this Amended  Agreement shall operate as a waiver of that or any other right. A waiver or consent given by the  Company on any one occasion shall be effective only in that instance and shall not be construed  as a bar to or waiver of any right on any other occasion.   16. Captions and Pronouns. The captions of the sections of this Amended Agreement are for  convenience of reference only and in no way define, limit or affect the scope or substance of any  section of this Amended Agreement. Whenever the context may require, any pronouns used in  this Amended Agreement shall include the corresponding masculine, feminine or neutral forms,  and the singular forms of nouns and pronouns shall include the plural, and vice versa.   17. Interpretation. The Parties agree that this Amended Agreement will be construed without  regard to any presumption or rule requiring construction or interpretation against the drafting  Party. References in this Amended Agreement to &#147;include&#148; or &#147;including&#148; should be read as  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1016-arvinasxamen009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1016-arvinasxamen009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">9  though they said &#147;without limitation&#148; or equivalent forms.  References in this Amended  Agreement to the &#147;Board&#148; shall include any authorized committee thereof.   18. Severability. Each provision of this Amended Agreement must be interpreted in such manner  as to be effective and valid under applicable law, but if any provision of this Amended  Agreement is held to be prohibited by or invalid under applicable law, such provision will be  ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder  of such provision or the remaining provisions of this Amended Agreement. Moreover, if a court  of competent jurisdiction determines any of the provisions contained in this Amended  Agreement to be unenforceable because the provision is excessively broad in scope, whether as  to duration, activity, geographic application, subject or otherwise, it will be construed, by  limiting or reducing it to the extent legally permitted, so as to be enforceable to the extent  compatible with then applicable law to achieve the intent of the Parties.   19. Entire Agreement. This Amended Agreement, together with the Proprietary Information and  Assignment Agreement, constitutes the entire agreement between the Parties and supersedes all  prior agreements and understandings, whether written or oral, relating to the subject matter of  this Amended Agreement.   20. Counterparts. This Amended Agreement may be executed in separate counterparts, each of  which shall be deemed an original, but all of which taken together shall constitute one and the  same instrument. A signed copy of this Amended Agreement delivered by facsimile, e-mail or  other means of electronic transmission shall be deemed to have the same legal effect as delivery  of an original signed copy of this Amended Agreement.    [Signatures on Page Following]     </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1016-arvinasxamen010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1016-arvinasxamen010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">10  IN WITNESS WHEREOF, the Parties hereto have executed this Amended Agreement as of the  day and year set forth above.           THE COMPANY:         By:  ___________________________      Name:  Jared Freedberg                Title:  General Counsel         EXECUTIVE:           _________________________________  Randy Teel, Ph.D.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1016-arvinasxamen011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1016-arvinasxamen011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">11  EXHIBIT A  Payments Subject to Section 409A  1. Subject to this Exhibit A, any severance payments that may be due under the  Amended Agreement shall begin only upon the date of the Executive&#146;s &#147;separation from service&#148;  (determined as set forth below) which occurs on or after the termination of the Executive&#146;s  employment.  The following rules shall apply with respect to distribution of the severance  payments, if any, to be provided to the Executive under the Amended Agreement, as applicable:     (a) It is intended that each installment of the severance payments provided  under the Amended Agreement shall be treated as a separate &#147;payment&#148; for purposes of  Section 409A of the Internal Revenue Code (&#147;Section 409A&#148;).  Neither the Company nor  the Executive shall have the right to accelerate or defer the delivery of any such payments  except to the extent specifically permitted or required by Section 409A.                                  (b) If, as of the date of the Executive&#146;s &#147;separation from service&#148; from the  Company, the Executive is not a &#147;specified Executive&#148; (within the meaning of Section  409A), then each installment of the severance payments shall be made on the dates and  terms set forth in the letter agreement.     (c) If, as of the date of the Executive&#146;s &#147;separation from service&#148; from the  Company, the Executive is a &#147;specified Executive&#148; (within the meaning of Section  409A), then:     (i) Each installment of the severance payments due under the Amended  Agreement that, in accordance with the dates and terms set forth herein, will  in all circumstances, regardless of when the Executive&#146;s separation from  service occurs, be paid within the short-term deferral period (as defined  under Section 409A) shall be treated as a short-term deferral within the  meaning of Treasury Regulation Section 1.409A-1(b)(4) to the maximum  extent permissible under Section 409A and shall be paid on the dates and  terms set forth in the Amended Agreement; and     (ii) Each installment of the severance payments due under the Amended  Agreement that is not described in this Exhibit A, Section 1(c)(i) and that  would, absent this subsection, be paid within the six-month period following  the Executive&#146;s &#147;separation from service&#148; from the Company shall not be  paid until the date that is six months and one day after such separation from  service (or, if earlier, the Executive&#146;s death), with any such installments that  are required to be delayed being accumulated during the six-month period  and paid in a lump sum on the date that is six months and one day following  the Executive&#146;s separation from service and any subsequent installments, if  any, being paid in accordance with the dates and terms set forth herein;  provided, however, that the preceding provisions of this sentence shall not  apply to any installment of payments if and to the maximum extent that that  such installment is deemed to be paid under a separation pay plan that does  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1016-arvinasxamen012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1016-arvinasxamen012.jpg" title="slide12" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">12  not provide for a deferral of compensation by reason of the application of  Treasury Regulation 1.409A-1(b)(9)(iii) (relating to separation pay upon an  involuntary separation from service).  Any installments that qualify for the  exception under Treasury Regulation Section 1.409A-1(b)(9)(iii) must be  paid no later than the last day of the Executive&#146;s second taxable year  following the taxable year in which the separation from service occurs.     2. The determination of whether and when the Executive&#146;s separation from service  from the Company has occurred shall be made in a manner consistent with, and based on the  presumptions set forth in, Treasury Regulation Section 1.409A-1(h).  Solely for purposes of  Section 2 of this Exhibit A, &#147;Company&#148; shall include all persons with whom the Company would  be considered a single employer under Section 414(b) and 414(c) of the Code.     3. All reimbursements and in-kind benefits provided under the Amended Agreement  shall be made or provided in accordance with the requirements of Section 409A to the extent that  such reimbursements or in-kind benefits are subject to Section 409A, including, where  applicable, the requirements that (i) any reimbursement is for expenses incurred during the  Executive&#146;s lifetime (or during a shorter period of time specified in the Amended Agreement),  (ii) the amount of expenses eligible for reimbursement during a calendar year may not affect the  expenses eligible for reimbursement in any other calendar year, (iii) the reimbursement of an  eligible expense will be made on or before the last day of the calendar year following the year in  which the expense is incurred and (iv) the right to reimbursement is not subject to set off or  liquidation or exchange for any other benefit.     4. The Company makes no representation or warranty and shall have no liability to  the Executive or to any other person if any of the provisions of the Amended Agreement  (including this Exhibit A) are determined to constitute deferred compensation subject to Section  409A but that do not satisfy an exemption from, or the conditions of, that section.     5. The Amended Agreement is intended to comply with, or be exempt from, Section  409A and shall be interpreted accordingly.           [Remainder of page intentionally left blank.]      </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.18
<SEQUENCE>4
<FILENAME>exhibit1018-arvinasxcons.htm
<DESCRIPTION>EX-10.18
<TEXT>
<HTML>
<HEAD><!-- Document generated by Workiva Inc -->
<TITLE>exhibit1018-arvinasxcons</TITLE>
</HEAD>
<BODY bgcolor="white">
<DIV align="center">
<DIV style="margin-left:1em;width:1055;"><!-- exhibit1018-arvinasxcons001.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1018-arvinasxcons001.jpg" title="slide1" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">EXECUTION VERSION  CONSULTING AGREEMENT  This Consulting Agreement (this &#8220;Agreement&#8221;), effective as of February 12, 2026 (the &#8220;Effective  Date&#8221;), by and among Arvinas, Inc., a Delaware corporation (inclusive of the Subsidiaries (as defined  below), the &#8220;Company&#8221;) Stonington Biotech Advisors LLC, a Connecticut limited liability company (the  &#8220;LLC&#8221;) and John Houston, Ph.D. (&#8220;Dr. Houston&#8221;) the sole member of the LLC , both with an address as  set forth in the signature page of this Agreement (together the &#8220;Consultant&#8221;).  WHEREAS, on July 9, 2025, Dr. Houston, Chairperson of the Board and President and Chief  Executive Officer (&#8220;CEO&#8221;) of the Company notified the Company of his plans to retire from his role as  President and CEO of the Company following a search for, and the appointment of, a new President and  CEO of the Company;   WHEREAS, effective February 12, 2026, Dr. Houston has tendered his resignation (1) as President,  CEO and Chairperson of the Company, to the Company, (2) as President and CEO of each subsidiary of  the Corporation (each, a &#8220;Subsidiary&#8221;, and together, the &#8220;Subsidiaries&#8221;) to each such Subsidiary, and (3)  as director of each of the Subsidiaries, to each such Subsidiary;  WHEREAS, effective February 12, 2026, the Board of Directors of the Company (the &#8220;Board&#8221;)  determined that Dr. Houston will continue to be a valuable director of the Company and asked that he shall  no longer serve as chairperson of the Board, but Dr. Houston shall remain as a director of the Company;  and  WHEREAS, in addition to his Board seat, in order to assist with a transitional period following his  resignation as President and CEO, the Company desires to engage Dr. Houston to provide certain consulting  services in his capacity as an independent contractor for the Company, and Dr. Houston desires to perform  such services for the Company in accordance with the terms and conditions set forth in this Agreement.  NOW, THEREFORE, in consideration of the premises and the mutual covenants set forth herein  and for other good and valuable consideration, the receipt and sufficiency of which are hereby  acknowledged, the parties agree as follows:  1. Consulting Services.  Consultant shall render the services described in Exhibit A (the  &#8220;Consulting Services&#8221;) to the Company (or its designee).   2. Term.  This Agreement shall continue until expiration or termination in accordance with  the provisions of Section 11. Consultant&#8217;s obligations set forth in Sections 4-10, 12 and 13 shall survive  termination of this Agreement.  3. Payment; Reimbursement of Expenses.  The Company agrees to pay Consultant the  compensation described in Exhibit A for Consultant&#8217;s performance of the Consulting Services in accordance  with the terms of this Agreement. The Company will reimburse Consultant for reasonable and customary out- of-pocket business expenses incurred by Consultant in the ordinary course of performing the Consulting  Services and in compliance with the Company&#8217;s policies covering such expenses. With respect to his  consultancy, anticipated expenses in excess of $500 will require the prior written approval of the Company.  No more than once per calendar month, Consultant may submit to the Company a statement of such business  expenses, accompanied by appropriate supporting documentation. The Company shall reimburse such business  expenses within thirty (30) days following its receipt of such statements. The parties hereby acknowledge and  agree that the compensation contemplated under the terms of this Agreement (i) constitutes fair market value  for the Consulting Services; (ii) is not being given in exchange for any explicit or implicit agreement by  Consultant to recommend, provide, prescribe, or order favorable status for any of Company&#8217;s products or to  reward or influence any formulary or clinical practice guidelines committees or prescribing or dispensing  Exhibit 10.18 </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1018-arvinasxcons002.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1018-arvinasxcons002.jpg" title="slide2" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">decisions; and (iii) has not been determined in a manner that takes into account the volume or value of any  referrals or business or potential referrals or business that might be generated by Consultant.  4. Confidential Information.  Consultant acknowledges that, in relation to this Agreement or the conduct of the Consulting Services, Consultant may receive, become exposed to, or generate  information: (a) applicable to the business, technology or products of the Company or (b) applicable to the  business of any client or customer of the Company, in each case whether provided prior to, on or after the  Effective Date (&#8220;Confidential Information&#8221;).  Confidential Information includes any and all technical and  non-technical information including patent, copyright, trade secret, and proprietary information,  techniques, sketches, drawings, models, inventions, know-how, processes, apparatus, equipment,  algorithms, software programs, software source documents, and formulae related to the current, existing  and contemplated products and services of the Company and includes, without limitation, information  concerning research, experimental work, development, design details and specifications, engineering,  financial information, procurement requirements, purchasing, manufacturing, customer lists, business  forecasts, sales and merchandising and marketing plans and information.  Confidential Information also  includes proprietary or confidential information of any third party who may disclose such information to  the Company or to Consultant in the course of the Company&#8217;s business, provided that such information is  identified as confidential or is of a nature that a reasonable person would understand to be confidential  under the circumstanced of disclosure.  Notwithstanding the foregoing, Confidential Information shall not include information that: (i) is  or becomes generally available to the public through no act or omission of Consultant; (ii) was lawfully  known to Consultant prior to disclosure by or on behalf of the Company; (iii) is independently developed  by Consultant without use of or reference to Confidential Information; (iv) is lawfully received by  Consultant from a third party without restriction on disclosure; or (v) is required to be disclosed pursuant  to applicable law, regulation, or court order, provided that Consultant gives the Company prompt notice (to  the extent legally permitted) and cooperates in seeking confidential treatment.  Confidential Information does not include Consultant&#8217;s general skills, experience, know-how, or  residual knowledge retained in the unaided memory of Consultant, provided that such residual knowledge  does not include any trade secrets of the Company.  5. Ownership and Nondisclosure of Confidential Information.  All Confidential Information of the Company shall remain the property of the Company or its applicable licensors.  Nothing  in this Agreement shall be deemed to transfer to Consultant any ownership interest in such Confidential  Information.  Ownership of inventions, works of authorship, and other intellectual property, if any, shall be  governed exclusively by the applicable intellectual property provisions of this Agreement.  During the term  of this Agreement and for a period of five (5) years thereafter (or, with respect to trade secrets, for so long  as such information remains a trade secret under applicable law), Consultant (i) shall keep in confidence  and trust all Confidential Information, with no less than a reasonable degree of care, and (ii) shall not  disclose any Confidential Information to any person or entity other than the Company or use any  Confidential Information other than in connection with Consultant&#8217;s performance of the Consulting  Services for the benefit of the Company, in each case, without the prior written consent of the Company,  except as expressly permitted under this Agreement. Consultant shall notify Company promptly upon  becoming aware of any unauthorized use or disclosure of Company&#8217;s Confidential Information. The  obligations set forth in this Section shall not apply to information excluded from the definition of  Confidential Information as provided elsewhere in this Agreement.  6. Ownership and Return of Materials.  All materials (including, without limitation, documents, drawings, supplies, products, models, apparatus, sketches, designs, lists, and all other tangible  media of expression) furnished to Consultant by the Company (&#8220;Materials&#8221;) shall remain the property of  the Company.  Upon termination of this Agreement, or upon the Company&#8217;s written request prior to  termination, Consultant shall promptly (and in no event later than five (5) business days after the earlier of  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1018-arvinasxcons003.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1018-arvinasxcons003.jpg" title="slide3" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">such termination of this Agreement or the Company&#8217;s written request) return or destroy, , at the Company&#8217;s  option, all Materials and all tangible media which are in Consultant&#8217;s possession that contain or embody  the Company&#8217;s Confidential Information.  Notwithstanding the foregoing, Consultant may retain one (1)  archival copy of such Materials solely for legal, regulatory, insurance, or compliance purposes, subject at  all times to Consultant&#8217;s continuing confidentiality obligations under this Agreement.  At the Company&#8217;s  written request, Consultant shall provide the Company with written certification of Consultant&#8217;s  compliance with Consultant&#8217;s compliance under this Section.  7. Intellectual Property and Innovations. (a) As used in this Agreement, the term &#8220;Innovations&#8221; means all information fixed in any tangible medium of expression (whether or not protectable under copyright laws), know-how,  improvements, inventions (whether or not protectable under patent laws), works of authorship, techniques,  software, code, objects, development tools, methods and protocols, instructions and routines, comments,  user interfaces, support logs, scripts, design notes, supporting technical and user documentation,  discoveries, data, ideas (whether or not protectable under trade secret laws), specifications, designs, trade  secrets, combinations, formulae, developments, artwork, copyrights, regulatory and other governmental  filings, documents, descriptions, processes, methods, procedures, trademarks, trade names, service marks,  domain names, web addresses and web sites, all other subject matter that may be protectable under any  patent, copyright, moral right, mask work, trademark, trade secret or other laws and all goodwill associated  with any of the foregoing and any registrations and applications therefor, but only to the extent conceived,  created, developed, or reduced to practice by Consultant in the course of performing the Consulting Services  during the Term of this Agreement.  Innovations expressly exclude Consultant&#8217;s pre-existing inventions,  works of authorship, methodologies, tools, software, templates, know-how, and other intellectual property  developed or acquired by Consultant prior to or outside the scope of this Agreement (&#8220;Background IP&#8221;).  (b) Consultant hereby agrees to promptly disclose and describe to the Company, and Consultant hereby assigns to the Company all of Consultant&#8217;s right, title, and interest in and to, each of the  Innovations and all associated intellectual property rights that Consultant solely or jointly conceives,  reduces to practice, creates, derives, develops or makes that (i) relate to the Company&#8217;s business,  technology, products or actual or, (ii)  was materially developed of the Company&#8217;s time or funding or with  the use of any of the Company&#8217;s equipment, supplies, facilities, Materials or trade secret information or  (iii) results from any work Consultant performed for the Company including the Consulting Services (collectively, the &#8220;Company Innovations&#8221;).  For clarity, all deliverables expressly identified in writing as deliverables generated in the performance of the Consulting Services shall be deemed Company Innovations. To the extent any Company Innovation does not qualify as a &#8220;work made for hire&#8221; under applicable law, Consultant hereby assigns such Company Innovation to the Company. Notwithstanding the foregoing, Consultant retains all right, title, and interest in and to  Consultant&#8217;s Background IP.  To the extent any Background IP is incorporated into a Company Innovation  or deliverable, Consultant hereby grants the Company a non-exclusive, perpetual, irrevocable, royalty-free  license to use, reproduce, modify, distribute, and display such Background IP solely as incorporated in, and  as necessary to use, the applicable Company Innovation or deliverable. Consultant shall not knowingly  incorporate any third-party proprietary information into any of the Company Innovations or any of the  Company&#8217;s products or any of the deliverables in a manner that would require the Company to obtain a  license or incur obligations to such third party, without the Company&#8217;s prior written consent.    (c) Consultant hereby agrees to perform, during and after the term of this Agreement, all acts reasonably requested by the Company to permit and assist the Company, at the Company&#8217;s expense,  in obtaining and enforcing the full benefits, enjoyment, rights and title throughout the world in the  Confidential Information and Company Innovations.  Such acts may include, but are not limited to,  execution of documents and assistance or cooperation (i) in the filing, prosecution, registration,  memorialization and assignment of any applicable patent, copyright, mask work or other property right  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1018-arvinasxcons004.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1018-arvinasxcons004.jpg" title="slide4" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">protection, (ii) in the enforcement or defense of any applicable patent, copyright, mask work or other  property right and (iii) in any other legal proceedings, provided that such assistance does not unreasonably  interfere with Consultant&#8217;s other professional obligations.  In the event that the Company is unable, after  reasonable effort,  to secure Consultant&#8217;s signature to any document required to file, prosecute, register,  memorialize or assign any patent, copyright, mask work or other property right or to enforce any patent,  copyright, mask work or other property directly related to the Confidential Information or the Company  Innovations, Consultant hereby appoints the Company as Consultant&#8217;s attorney-in-fact to act solely for the  limited purpose of executing such documents, provided that such power of attorney shall terminate  automatically upon completion of the applicable filing or proceeding.    Consultant agrees to promptly provide Company with copies of all data and results and all  supporting documents that constitute deliverables generated during the performance of the Consulting  Services.     8. Relationship; Reporting.        (a) In Consultant&#8217;s performance of the Consulting Services, Consultant shall act in the  capacity of an independent contractor with respect to the Company, and not as an employee or authorized agent  or representative of the Company.  Consultant in his capacity as a consultant, shall not have any authority to  enter into contracts or binding commitments in the name or on behalf of the Company.  Consultant will not use  the Company&#8217;s logo or marks without prior written approval, and then such use shall be only for the benefit of  the Company and at the direction of the Company. Consultant, in his capacity as a consultant, shall not be, nor  represent himself as being, an agent of the Company, and shall not be, nor represent himself as being, authorized  to bind the Company.        (b) Consultant acknowledges that Consultant shall not have the status of an employee of  the Company and Consultant shall not participate in any employee benefit plans or group insurance plans or  programs.  Consultant agrees that consistent with Consultant&#8217;s independent contractor status, Consultant  will not apply for any government-sponsored benefits intended only for employees, including, but not  limited to, unemployment benefits.      (c) The Company shall issue Form 1099 records for its payments to Consultant made  pursuant to this Agreement.  Consultant is solely responsible for all taxes, withholdings, and other similar  statutory obligations.  Consultant agrees that the Company may report all payments and transfers of value  made in connection with this Agreement as required by applicable payment reporting laws including the  Physician Payment Sunshine Act, if applicable.    (d) In connection with this Agreement and the Consulting Services hereunder,  Consultant shall not make any payment or transfer of value to any health care professionals that would  require reporting under the Physician Payment Sunshine Act or other similar payment reporting laws.     9. Consultant&#8217;s Representations, Warranties and Covenants.  Consultant agrees, represents  and warrants, to the best of Consultant&#8217;s knowledge and belief, that:        (a) All action necessary for the authorization, execution, delivery and performance of  all obligations under this Agreement has been taken and this Agreement constitutes a valid and legally binding  obligation of Consultant that is enforceable against Consultant in accordance with its terms. The authorization,  execution and delivery by Consultant of this Agreement and the performance of Consultant&#8217;s obligations  under this Agreement will not, to Consultant&#8217;s knowledge, (i)  result in any violation of any permit, law, rule  or regulation, or any judgment, decree or order of any court or other governmental agency or instrumentality  to which Consultant is a party or to which Consultant is subject or (ii) result in a violation of any agreement,  policy contract, indenture or other instrument to which Consultant is a party or to which Consultant is subject.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1018-arvinasxcons005.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1018-arvinasxcons005.jpg" title="slide5" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">Consultant&#8217;s performance of Consultant&#8217;s obligations under this Agreement will not, to Consultant&#8217;s  knowledge, infringe upon or violate any right of any person or entity.  (b) During the term of this Agreement, Consultant shall not knowingly be bound by any agreement, nor assume any obligation, which would in any way be inconsistent with the Consulting Services.  (c) In performing the Consulting Services, Consultant will not knowingly use any confidential or proprietary information of any other person or entity or infringe the intellectual property rights  (including, without limitation, patent, copyright, trademark or trade secret rights) of any other person or entity  nor will Consultant disclose to the Company, or bring onto the Company&#8217;s premises, or induce the Company  to use any confidential information of any other person or entity.  (d) Consultant shall comply with all applicable laws, statutes, ordinances, regulations, rules and orders as applicable to the Consulting Services performed under this Agreement.  Consultant shall  comply with Company&#8217;s instructions and applicable policies (as communicated to Consultant by Arvinas),  only to the extent they are lawful and consistent with Consultant&#8217;s independent contractor status.   (e) Consultant has not, and shall not, knowingly (a) take any action in violation of any applicable Anti-Corruption Laws (as defined below); or (b) corruptly offer, pay, give, promise to pay or give,  or authorize the payment or gift of anything of value, directly or indirectly, to any government official, for the  purposes of: (i) influencing any act or decision of any government official in his or her official capacity, (ii)  inducing such government official to do or omit to do any act in violation of his or her lawful duty; (iii)  securing any improper advantage; or (vi) inducing such government official to use his or her influence with a  government, government entity, or commercial enterprise owned or controlled by any government (including  state-owned or controlled veterinary, laboratory or medical facilities) in obtaining or retaining any business  whatsoever. &#8220;Anti-Corruption Laws&#8221; shall mean all applicable anti-bribery and anti-corruption laws and  regulations, including, where applicable, the United States Foreign Corrupt Practices Act, the United  Kingdom Bribery Act 2010, and the local laws and regulations of any countries in which products,  payments or services will be provided in connection with the Consulting Services.  (f) Consultant will not subcontract any of Consultant&#8217;s obligations under this Agreement without the prior written consent of the Company.  (g) Consultant shall maintain, at Consultant&#8217;s own expense, reasonable insurance coverage appropriate for the services performed hereunder.  (h) Consultant is not, to Consultant&#8217;s knowledge, (a) debarred and is not subject to a pending debarment pursuant to applicable law (including section 306 of the United States Food, Drug and  Cosmetic Act, 21 U.S.C. &sect; 335a); (b) excluded, debarred, suspended, or otherwise ineligible to participate in  federal health care programs or in federal procurement or non-procurement programs; (c) listed in the FDA&#8217;s  Clinical Investigators &#8211; Disqualification Proceedings Database, including for restrictions; or (d) convicted of  a criminal offense that falls within the scope of 42 U.S.C. &sect; 1320a-7(a), but has not yet been excluded,  debarred, suspended, or otherwise declared ineligible. If, during the term of this Agreement, Consultant  becomes the subject of any investigation or proceeding that could lead to Consultant becoming debarred,  excluded, suspended or convicted, Consultant shall immediately notify Company. This provision shall survive  termination or expiration of the Services Agreement.  (i) Consultant shall adhere to all applicable data protection and data privacy laws, rules and regulations (including, where applicable, the United States Health Insurance Portability and  Accountability Act of 1996 and the EU General Data Protection Regulation).  Consultant shall perform all  applicable collection, handling, processing and transfer of personal data or protected health information in  accordance with applicable laws, rules and regulations, to the extent Consultant is responsible.  Consultant  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1018-arvinasxcons006.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1018-arvinasxcons006.jpg" title="slide6" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">shall promptly notify the Company of any breach of the foregoing, including any unauthorized access to, or  transfer of, such data or information. The Parties incorporate Exhibit C, which is attached hereto.   (j) Consultant shall forward to the Company any information, including initial and follow-up reports, that become known to Consultant from any source in any form relating to an adverse event,  suspected adverse event, or other safety concerns regarding products of the Company (each, an &#8220;AE&#8221;) to the  extent known or reasonably available to Consultant as soon as it becomes available, but in any event within  one (1) business day of becoming aware of such information.  Without limiting the foregoing, Consultant  shall provide to customer a safety reporting form completed with all applicable information including, to the  extent available, (a) information on the person or entity contacting Consultant regarding such AE, (b)  information about the applicable patient or person impacted by such AE, (c) the products suspected to be  related to such AE and (d) details of the suspected AE.  Consultant shall reasonably cooperate with the  Company in seeking any additional follow-up information with respect to such AE.  (k) Consultant acknowledges that the Company&#8217;s common stock is publicly traded. Consultant is aware of, and will abide by, the restrictions imposed by securities laws on the purchase or sale  of securities by any person who has received material, non-public information regarding the issuer of such  securities and on the communication of such information to any other person when it is reasonably foreseeable  that such other person is likely to purchase or sell securities in reliance upon such information.   (l) Consultant acknowledges it has read and understood Pfizer&#8217;s International Anti- Bribery and Anti-Corruption Principles, attached hereto as Exhibit B.  10. Indemnification.  Consultant shall indemnify and hold harmless the Company and its affiliates from any third-party claims, losses, liabilities, damages, and expenses arising solely from  Consultant&#8217;s gross negligence or willful misconduct in the performance of the Consulting Services.  The  Company shall indemnify and hold harmless Consultant from any third-party claims arising out of (i)  Consultant&#8217;s performance of the Consulting Services in accordance with Company instructions, (ii)  Company-provided information or materials, or (iii) Company products, operations, or regulatory matters.  In  no event shall Consultant&#8217;s indemnification obligations exceed the total compensation paid to Consultant  under this Agreement.  Nothing herein shall limit Consultant&#8217;s rights to indemnification and advancement of  expenses under the Company&#8217;s certificate of incorporation, bylaws, or applicable D&amp;O insurance policies in  Consultant&#8217;s capacity as a director.  11. Expiration; Termination.  This Agreement expires upon March 1, 2027. Notwithstanding the foregoing, if Consultant is actively engaged in Consulting Services that were assigned and commenced  prior to March 1, 2027, this Agreement shall continue solely for the completion of those assigned services, but  in no event longer than 30 days following March 1, 2027, unless mutually agreed in writing.   12. Non-Competition and Non-Solicitation; No Disparagement (a) Consultant agrees that while Consultant is engaged by the Company and for six (6) months thereafter (the &#8220;Non-Compete Period&#8221;), Consultant shall not knowingly provide advisory, management, or consulting services directly to a company whose primary business activities directly compete with the Company&#8217;s current or actively planned products or services. The Company and the Consultant agree that Dr. Houston acting as director to the Company or any other company for which Dr. Houston acts as a director as of the Effective Date does not violate the terms of this Section 12(a). (b) Notwithstanding Section 12(a), nothing herein shall prohibit Consultant from being a passive owner of not more than five percent (5%) of the outstanding stock of any class of a  corporation which is publicly traded, so long as Consultant has no active participation in the management  or operations of such corporation; provided that, the Company and the Consultant agree that Dr. Houston&#8217;s  equity ownership in the Company does not violate the terms of this Section 12(a).    </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1018-arvinasxcons007.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1018-arvinasxcons007.jpg" title="slide7" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">  (c) During the Non-Compete Period, Consultant shall not directly or indirectly  through another person or entity: (i) knowingly induce or attempt to induce any employee or independent  contractor of the Company to leave the employ of or engagement with the Company, or in any way interfere  with the relationship between the Company, on the one hand, and any employee or independent contractor  thereof, on the other hand; (ii); knowingly induce or attempt to induce any customer, supplier, independent  contractor, licensee or other business relation of the Company to cease doing business with the Company,  or in any way interfere with the relationship between any such customer, supplier, independent contractor,  licensee or business relation, on the one hand, and the Company, on the other hand; or (iv) knowingly solicit  any customer of the Company with whom Consultant had material direct contact during the Consulting  Services, for the purpose of providing services that are directly competitive with the Consulting Services.    (d) Consultant shall, upon reasonable request, disclose the existence of the restrictive  covenants  contained in this Section 12 to a prospective employer or engagement partner only to the extent  reasonably necessary to confirm compliance with such restrictions.      (e) Consultant agrees that the provisions of this Section 12 are fair and reasonable and  do not unreasonably limit Consultant&#8217;s ability to earn a livelihood.  However, Consultant does not waive  any rights to challenge the reasonableness of this Section under applicable law.  Notwithstanding the  foregoing, if, at the time of enforcement of this Section, a court holds that the restrictions stated herein are  unreasonable under the circumstances then existing, Consultant and the Company agree that the minimum  modification necessary to render this Section enforceable shall apply,  such that the restriction is limited in  duration, scope, or geography to the extent required by law, while remaining enforceable to the extent  consistent with protecting the Company&#8217;s legitimate interests.    (f) In the event of a material and willful breach by Consultant of any of the restrictions  contained in this Section, the Non-Compete Period may be tolled only for the duration of such material  breach, and only to the extent reasonably necessary to protect the Company&#8217;s legitimate interests.  Any  dispute regarding the existence or duration of a breach shall be resolved in good faith between the parties.   Minor, inadvertent, or promptly cured breaches shall not extend the Non-Compete Period.    (g) Consultant agrees not to make any statements, written or verbal, or cause or  encourage others to make any statements, written or verbal, that defame, disparage or in any way criticize  the Company, its practices, products, services, reputation, employees, officers, or directors.    13. Records.     13.1 Consultant shall maintain complete and accurate records, as appropriate, of the Consulting  Services. Such records shall fully and properly reflect all work done and results achieved in the performance  of the Consulting Services in sufficient detail and in good scientific manner appropriate for patent and  regulatory purposes. Consultant agrees that Company or its designee shall have the right, no more than once  per calendar year, during normal business hours and upon reasonable prior written notice, to inspect and review  all such books and records maintained by Consultant.     14. Miscellaneous Provisions.      (a) This Agreement shall be governed by and construed and enforced in accordance  with the laws of the State of Connecticut, without reference to principles of conflicts of laws. The parties  hereby irrevocably and unconditionally consent to the exclusive jurisdiction of the state courts in New  Haven County in the State of Connecticut or the federal courts in the United States District Court with  jurisdiction over New Haven County in the State of Connecticut in connection with any matter or dispute  arising under this Agreement and waive any objection they may have to such jurisdiction or to the venue  of any such matter or dispute and any claim that such matter or dispute has been brought in an inconvenient  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1018-arvinasxcons008.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1018-arvinasxcons008.jpg" title="slide8" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">forum.  (b) It is the desire and intent of the parties hereto that the provisions of this Agreement be enforced to the fullest extent permissible under the laws and public policies applied in each jurisdiction in  which enforcement is sought.  Accordingly, if any particular provision of this Agreement shall be adjudicated  by a court of competent jurisdiction to be invalid, prohibited or unenforceable for any reason, such provision,  as to such jurisdiction, shall be ineffective, without invalidating the remaining provisions of this Agreement or  affecting the validity or enforceability of this Agreement or affecting the validity or enforceability of such  provision in any other jurisdiction.  Notwithstanding the foregoing, if such provision could be more narrowly  drawn so as not to be invalid, prohibited or unenforceable in such jurisdiction, it shall, as to such jurisdiction,  be so narrowly drawn, without invalidating the remaining provisions of this Agreement or affecting the validity  or enforceability of such provision in any other jurisdiction.  (c) This Agreement shall be binding upon, and inure to the benefit of, the parties hereto and their respective heirs, successors and permitted assigns; provided, however, that this Agreement and  Consultant&#8217;s rights and obligations are not assignable by Consultant without the Company&#8217;s prior written  consent.  Any assignment made in violation hereof shall be null and void and of no force or effect.  (d) All notices, consents, waivers or other communications given under this Agreement shall be delivered to the address of the applicable party set forth in the signature page of this Agreement (or  such other address as notified by the applicable party in writing) by (i) certified mail, return receipt requested  (or the equivalent), (ii) hand delivery with receipt acknowledged or (iii) overnight courier service that provides  a delivery receipt. Notice shall be deemed to have been given upon delivery, as confirmed by the applicable  return receipt or delivery receipt.  (e) Except as expressly set forth in Exhibit D attached hereto, which lists all equity award grant agreements, including stock option grant agreements and restricted stock unit grant agreements, this  Agreement contains the entire understanding of the parties regarding its subject matter related to the Consulting  Services and supersedes all prior understandings or agreements between the parties with regard to such subject  matter. For the avoidance of doubt, all rights, terms, and obligations under the equity award grant agreements  listed in Exhibit D are fully preserved and remain in full force and effect, and this Agreement shall not be  construed to limit, modify, or supersede any such equity awards. Any equity awards, stock options, restricted  stock units, or other securities that were previously granted in connection with employment with the Company  are hereby confirmed to be fully retained by Consultant and are no longer contingent upon employment or any  future employment relationship with the Company. This Agreement may only be amended, modified, or  supplemented by a written instrument executed by both parties.  (f) If any action at law or in equity is necessary to enforce or interpret the terms of this Agreement, the prevailing party shall be entitled to reasonable attorneys&#8217; fees. Equitable relief, including  injunctive relief or specific performance, shall be available only for material breaches, and the party seeking  such relief must provide written notice and a reasonable opportunity to cure.   Nothing herein shall be construed  as prohibiting either party hereto from seeking monetary damages for any breach.  (g) No failure on the part of any person or entity to exercise any power, right, privilege or remedy under this Agreement, and no delay on the part of any person or entity in exercising any power,  right, privilege or remedy under this Agreement, shall operate as a waiver of such power, right, privilege  or remedy; and no single or partial exercise of any such power, right, privilege or remedy shall preclude  any other or further exercise thereof or of any other power, right, privilege or remedy.  No person or entity  shall be deemed to have waived any claim arising out of this Agreement, or any power, right, privilege or  remedy under this Agreement, unless the waiver of such claim, power, right, privilege or remedy is  expressly set forth in a written instrument duly executed and delivered on behalf of such person or entity;  and any such waiver shall not be applicable or have any effect except in the specific instance in which it is  given.  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1018-arvinasxcons009.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1018-arvinasxcons009.jpg" title="slide9" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">(h) In the event of a breach by Consultant of the provisions of this Agreement, the Company may set off amounts only for undisputed obligations of Consultant to the Company, and shall  provide written notice of any proposed set-off, giving Consultant a reasonable opportunity to dispute the  claim prior to application.  (i) WAIVER OF JURY TRIAL.  The parties acknowledge that they may have a right to a jury trial for disputes arising under this Agreement. Except as may be mutually agreed in writing at the  time of a specific dispute, no party shall be required to waive its right to a jury trial. This Section shall not  be construed to limit any other rights or remedies available to the parties.  (j) This Agreement may be executed in counterparts, each of which shall be deemed to be an original and all of which, taken together, shall constitute a single agreement binding on all parties. The  parties agree that signatures delivered by electronic transmission (including electronic signature programs and  scanned .pdf documents by email) shall have the same force and effect as an original signature.  [The remainder of this page is intentionally left blank]  </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1018-arvinasxcons010.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1018-arvinasxcons010.jpg" title="slide10" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">[Signature Page to Consulting Agreement]  IN WITNESS WHEREOF, this Consulting Agreement is entered into as of the Effective Date.  ARVINAS, INC.  By: Name:  Jared Freedberg  Title:    General Counsel  Address: 5 Science Park, New Haven, CT  06511  CONSULTANT  Name: John Houston, Ph.D.  Title:  Consultant  Address: [***]  Stonington Biotech Advisors LLC  Name: John Houston, Ph.D.  Title:  Member  Address:[***]   </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1018-arvinasxcons011.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1018-arvinasxcons011.jpg" title="slide11" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">EXHIBIT A  CONSULTING SERVICES AND COMPENSATION  1. Consulting Services.  Provide expertise and assistance in the following: a. Mentoring the President and CEO in the role and providing relevant business advice; b. Acting as Chief Scientific Advisor to the CEO; and c. Answering questions for senior leadership of the Company based on Consultant&#8217;s historical knowledge of the Company. The Company and Consultant agree that Consulting Services are expected to be provided for no  greater than 8 hours per month.  Consultant shall be compensated in accordance with Section 2(c)  below for each hour in excess of 8 hours per month.   The Consulting Services do not include the roles and responsibilities required of Dr. Houston in  his capacity as a director.   2. Compensation. a. Provided that Consultant timely elects coverage under the Consolidated Omnibus Budget Reconciliation Act of 1985 (&#8220;COBRA&#8221;), the Company will pay Consultant an amount of $27,914.40, equal to 12-months of premiums for health coverage that is paid by the Company for active and similarly-situated employees who receive the same type of coverage, inclusive of any dependents, and the Company shall pay this amount within 45 days of the Effective Date. b. $457,000, to be paid on or about March 15, 2026 as an up-front fee for the anticipated Consulting Services. This payment is not contingent on Board approval or any future performance, and is intended to replace the bonus Consultant would have earned for the 2025 corporate goals. c. To the extent Consultant performs Consulting Services for more than 8 hours per month, the Company shall Compensate Consultant $500 per hour. Consultant shall submit to the Company a written invoice for such amount each month. Payments will be net 30 days from receipt of invoice by the Company. d. any equity that had been granted to the Consultant under and in accordance with the terms of the Company&#8217;s existing 2018 Stock Incentive Plan and Incentive Share Plan, as applicable, as of the Effective Date, will continue to vest in accordance with such plan terms. Except as expressly set forth in Exhibit D attached hereto, which lists all equity award grant agreements, including stock option grant agreements and restricted stock unit grant agreements, this Agreement contains the entire understanding of the parties regarding its subject matter related to the Consulting Services and supersedes all prior understandings or agreements between the parties with regard to such subject matter. For the avoidance of doubt, all rights, terms, and obligations under the equity award grant agreements listed in Exhibit D are fully preserved and remain in full force and effect, and this Agreement shall not be construed to limit, modify, or supersede any such equity awards. Any equity awards, stock options, restricted stock units, or other securities that were previously granted in connection with employment with the Company are hereby confirmed to be fully retained </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
<!-- exhibit1018-arvinasxcons012.jpg -->
<DIV style="padding-top:2em;">
<IMG src="exhibit1018-arvinasxcons012.jpg" title="slide12" width="1055" height="1365">
<DIV><FONT size="1" style="font-size:1pt;color:white">by Consultant and are no longer contingent upon employment or any future employment  relationship with the Company.  NOTE:  With respect to the Consulting Services, Consultant will continue to use the existing  Company provided laptop and perform all Consulting Services within the Company environment.  Consultant will be provided with a company email address to use in connection with performance of  the Consulting Services. The Company acknowledges that Consultant may also use such Company  provided laptop in connection with the performance of services as a member of the Board.   </FONT></DIV>
<P><HR noshade><P>
<DIV style="page-break-before:always;">&nbsp;</DIV>
</DIV>
</DIV>
</DIV>
</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>5
<FILENAME>arvn-20251231x10kxex21_1.htm
<DESCRIPTION>EX-21.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i83d24108a638456dbc156dbee682f3a4_1"></div><div style="min-height:72pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%">Exhibit 21.1</font></div><div><font><br></font></div><div style="margin-bottom:0.12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:45.053%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:4.028%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:47.619%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">Name of Subsidiary</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:100%;text-decoration:underline">State of Incorporation</font></div></td></tr><tr style="height:13pt"><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Arvinas Operations, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Arvinas Androgen Receptor, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Arvinas Estrogen Receptor, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Arvinas Winchester, Inc.</font></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:0.12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:100%">Delaware</font></div></td></tr></table></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>consent-form10kfy25.htm
<DESCRIPTION>EX-23.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i04abaf66dea340fabe2fafd9c714f06b_1"></div><div style="min-height:72pt;width:100%"><div style="text-align:right"><font style="color:#000000;font-family:'Calibri',sans-serif;font-size:11pt;font-weight:700;line-height:100%">Exhibit 23.1</font></div></div><div style="margin-bottom:8pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:700;line-height:125%">CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:107%">We consent to the incorporation by reference in Registration Statement Nos. 333-234031, 333-234035, 333-251326, 333-275377 and 333-275945 on Form S-3 and Registration Statement Nos. 333-227555, 333-231388, 333-237215, 333-253721, 333-263095, 333-270010, 333-276519, 333-278044, 333-280537 and 333-284848 on Form S-8 of our reports dated  February&#160;24, 2026 relating to the consolidated financial statements of Arvinas, Inc. and subsidiaries (the &#8220;Company&#8221;) and the effectiveness of the Company&#8217;s internal control over financial reporting appearing in this Annual Report on Form 10-K for the year ended December&#160;31, 2025.</font></div><div style="margin-bottom:0.08pt;margin-top:12pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:120%">&#47;s&#47; Deloitte &#38; Touche LLP</font></div><div><font><br></font></div><div style="margin-bottom:0.08pt"><font><br></font></div><div style="margin-bottom:0.08pt"><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">Boston, Massachusetts</font></div><div><font style="color:#000000;font-family:'Times New Roman',serif;font-size:12pt;font-weight:400;line-height:125%">February&#160;24, 2026</font></div><div><font><br></font></div><div><font><br></font></div><div style="height:72pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>arvn-20251231x10kxex311.htm
<DESCRIPTION>EX-31.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i0a9bbc2c49a546bfaed65d3f431eb8a1_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 31.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Randy Teel, Ph.D., certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Annual Report on Form 10-K of Arvinas, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;24, 2026</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Randy Teel, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Randy Teel, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>arvn-20251231x10kxex312.htm
<DESCRIPTION>EX-31.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i5a41eaacc8984e70bd4d52247bce63fa_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 31.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">RULES 13a-14(a) AND 15d-14(a) UNDER THE SECURITIES EXCHANGE ACT OF 1934,</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">AS ADOPTED PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">I, Andrew Saik, certify that&#58;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">I have reviewed this Annual Report on Form 10-K of Arvinas, Inc.&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report&#59;</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles&#59;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(c)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:24.34pt">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Disclosed in this report any change in the registrant's internal control over financial reporting that occurred during the registrant's most recent fiscal quarter (the registrant's fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant's internal control over financial reporting&#59; and</font></div><div style="margin-top:12pt;padding-left:36pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5.</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:27.67pt">The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions)&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(a)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(b)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;24, 2026</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Andrew Saik</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Andrew Saik</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Chief Financial Officer and Treasurer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>arvn-20251231x10kxex321.htm
<DESCRIPTION>EX-32.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i4105db67e5c142618e78d75809cee447_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 32.1</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Arvinas, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;24, 2026</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Randy Teel, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Randy Teel, Ph.D.</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">President and Chief Executive Officer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Executive Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.2
<SEQUENCE>10
<FILENAME>arvn-20251231x10kxex322.htm
<DESCRIPTION>EX-32.2
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2026 Workiva -->
<title>Document</title></head><body><div id="i871fafa5abeb4b88a1d90a6a19eca9d6_1"></div><div style="min-height:45pt;width:100%"><div><font><br></font></div></div><div style="margin-top:12pt;text-align:right"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Exhibit 32.2</font></div><div style="margin-top:12pt;text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CERTIFICATION PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</font></div><div style="margin-top:12pt;text-indent:36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the Annual Report of Arvinas, Inc. (the &#8220;Company&#8221;) on Form 10-K for the period ended December&#160;31, 2025 as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), I certify, pursuant to 18 U.S.C. &#167; 1350, as adopted pursuant to &#167; 906 of the Sarbanes-Oxley Act of 2002, that&#58;</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(1)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934&#59; and</font></div><div style="margin-top:12pt;padding-left:72pt;text-indent:-36pt"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(2)</font><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:23.78pt">The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.</font></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:46.778%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.293%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:46.629%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date&#58; February&#160;24, 2026</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">By&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#47;s&#47; Andrew Saik</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:top"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Andrew Saik</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:112%">Chief Financial Officer and Treasurer</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(Principal Financial Officer)</font></div></td></tr></table></div><div style="height:45pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><font><br></font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>11
<FILENAME>arvn-20251231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:bad37b98-383d-4e3d-a5b5-927fa1eba41c,g:852a4cd9-135e-4322-96de-ff3159237791-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:arvn="http://www.arvinas.com/20251231" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2024-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.arvinas.com/20251231">
  <xs:import namespace="http://fasb.org/srt/2025" schemaLocation="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd"/>
  <xs:import namespace="http://fasb.org/us-gaap/2025" schemaLocation="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/dtr/type/2024-01-31" schemaLocation="https://www.xbrl.org/dtr/type/2024-01-31/types.xsd"/>
  <xs:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/cyd-af-sub/2025" schemaLocation="https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2025" schemaLocation="https://xbrl.sec.gov/dei/2025/dei-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/ecd/2025" schemaLocation="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/stpr/2025" schemaLocation="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20251231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20251231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20251231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="arvn-20251231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="Cover" roleURI="http://www.arvinas.com/role/Cover">
        <link:definition>0000001 - Document - Cover</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AuditInformation" roleURI="http://www.arvinas.com/role/AuditInformation">
        <link:definition>0000002 - Document - Audit Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheets" roleURI="http://www.arvinas.com/role/ConsolidatedBalanceSheets">
        <link:definition>9952151 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedBalanceSheetsParenthetical" roleURI="http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical">
        <link:definition>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofOperationsandComprehensiveLoss" roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss">
        <link:definition>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquity" roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity">
        <link:definition>9952154 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofChangesinStockholdersEquityParenthetical" roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical">
        <link:definition>9952155 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ConsolidatedStatementsofCashFlows" roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows">
        <link:definition>9952156 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentation" roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation">
        <link:definition>9952157 - Disclosure - Nature of Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPolicies" roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies">
        <link:definition>9952158 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreements" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements">
        <link:definition>9952159 - Disclosure - Research Collaboration and License Agreements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurements" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements">
        <link:definition>9952160 - Disclosure - Marketable Securities and Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovements" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements">
        <link:definition>9952161 - Disclosure - Property, Equipment and Leasehold Improvements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilities" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilities">
        <link:definition>9952162 - Disclosure - Right of Use Assets and Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilities" roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities">
        <link:definition>9952163 - Disclosure - Accounts Payable and Accrued Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebt" roleURI="http://www.arvinas.com/role/LongTermDebt">
        <link:definition>9952164 - Disclosure - Long-Term Debt</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="Equity" roleURI="http://www.arvinas.com/role/Equity">
        <link:definition>9952165 - Disclosure - Equity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestments" roleURI="http://www.arvinas.com/role/EquityMethodInvestments">
        <link:definition>9952166 - Disclosure - Equity Method Investments</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxes" roleURI="http://www.arvinas.com/role/IncomeTaxes">
        <link:definition>9952167 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingencies" roleURI="http://www.arvinas.com/role/CommitmentsandContingencies">
        <link:definition>9952168 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShare" roleURI="http://www.arvinas.com/role/NetLossPerShare">
        <link:definition>9952169 - Disclosure - Net Loss Per Share</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringActivity" roleURI="http://www.arvinas.com/role/RestructuringActivity">
        <link:definition>9952170 - Disclosure - Restructuring Activity</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformation" roleURI="http://www.arvinas.com/role/SegmentInformation">
        <link:definition>9952171 - Disclosure - Segment Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesPolicies" roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies">
        <link:definition>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesTables" roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables">
        <link:definition>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsTables" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables">
        <link:definition>9955513 - Disclosure - Research Collaboration and License Agreements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsTables" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables">
        <link:definition>9955514 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsTables" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables">
        <link:definition>9955515 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesTables" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables">
        <link:definition>9955516 - Disclosure - Right of Use Assets and Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesTables" roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables">
        <link:definition>9955517 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtTables" roleURI="http://www.arvinas.com/role/LongTermDebtTables">
        <link:definition>9955518 - Disclosure - Long-Term Debt (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityTables" roleURI="http://www.arvinas.com/role/EquityTables">
        <link:definition>9955519 - Disclosure - Equity (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesTables" roleURI="http://www.arvinas.com/role/IncomeTaxesTables">
        <link:definition>9955520 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareTables" roleURI="http://www.arvinas.com/role/NetLossPerShareTables">
        <link:definition>9955521 - Disclosure - Net Loss Per Share (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationTables" roleURI="http://www.arvinas.com/role/SegmentInformationTables">
        <link:definition>9955522 - Disclosure - Segment Information (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NatureofBusinessandBasisofPresentationDetails" roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails">
        <link:definition>9955523 - Disclosure - Nature of Business and Basis of Presentation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesCashReconciliationDetails" roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails">
        <link:definition>9955524 - Disclosure - Summary of Significant Accounting Policies - Cash Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>9955525 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails">
        <link:definition>9955526 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails">
        <link:definition>9955527 - Disclosure - Research Collaboration and License Agreements - Schedule of Contract Balances (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails">
        <link:definition>9955528 - Disclosure - Research Collaboration and License Agreements - Schedule of Transaction Price Allocated to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails_1" roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails_1">
        <link:definition>9955528 - Disclosure - Research Collaboration and License Agreements - Schedule of Transaction Price Allocated to Performance Obligations (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="MarketableSecuritiesandFairValueMeasurementsDetails" roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails">
        <link:definition>9955529 - Disclosure - Marketable Securities and Fair Value Measurements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails">
        <link:definition>9955530 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails">
        <link:definition>9955531 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails">
        <link:definition>9955532 - Disclosure - Right of Use Assets and Liabilities - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofComponentsofLeaseExpenseDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofComponentsofLeaseExpenseDetails">
        <link:definition>9955533 - Disclosure - Right of Use Assets and Liabilities - Schedule of Components of Lease Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails">
        <link:definition>9955534 - Disclosure - Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails">
        <link:definition>9955535 - Disclosure - Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1">
        <link:definition>9955535 - Disclosure - Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="AccountsPayableandAccruedLiabilitiesDetails" roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails">
        <link:definition>9955536 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofLongTermDebtDetails" roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails">
        <link:definition>9955537 - Disclosure - Long-Term Debt - Schedule of Long Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails">
        <link:definition>9955538 - Disclosure - Long-Term Debt - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails">
        <link:definition>9955539 - Disclosure - Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails">
        <link:definition>9955540 - Disclosure - Equity - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails">
        <link:definition>9955541 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofStockOptionActivityDetails" roleURI="http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails">
        <link:definition>9955542 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityScheduleofRestrictedStockDetails" roleURI="http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails">
        <link:definition>9955543 - Disclosure - Equity - Schedule of Restricted Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="EquityMethodInvestmentsDetails" roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsDetails">
        <link:definition>9955544 - Disclosure - Equity Method Investments (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails">
        <link:definition>9955545 - Disclosure - Income Taxes - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeTaxExpenseDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails">
        <link:definition>9955546 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails">
        <link:definition>9955547 - Disclosure - Income Taxes - Schedule of Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails">
        <link:definition>9955548 - Disclosure - Income Taxes - Schedule of Income Tax Paid, Net of Refunds (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails">
        <link:definition>9955549 - Disclosure - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails">
        <link:definition>9955550 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="CommitmentsandContingenciesDetails" roleURI="http://www.arvinas.com/role/CommitmentsandContingenciesDetails">
        <link:definition>9955551 - Disclosure - Commitments and Contingencies (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareScheduleofBasicandDilutedLossperCommonShareDetails" roleURI="http://www.arvinas.com/role/NetLossPerShareScheduleofBasicandDilutedLossperCommonShareDetails">
        <link:definition>9955552 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Loss per Common Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/NetLossPerShareAdditionalInformationDetails">
        <link:definition>9955553 - Disclosure - Net Loss Per Share - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails" roleURI="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails">
        <link:definition>9955554 - Disclosure - Net Loss Per Share - Securities Excluded from the Computations of Diluted Net Loss Per Share (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="RestructuringActivityDetails" roleURI="http://www.arvinas.com/role/RestructuringActivityDetails">
        <link:definition>9955555 - Disclosure - Restructuring Activity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationAdditionalInformationDetails" roleURI="http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails">
        <link:definition>9955556 - Disclosure - Segment Information - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType id="SegmentInformationScheduleofFinancialInformationDetails" roleURI="http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails">
        <link:definition>9955557 - Disclosure - Segment Information - Schedule of Financial Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
  <xs:element id="arvn_AuditInformationAbstract" abstract="true" name="AuditInformationAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_CollaborationContractAssetAndOtherAssets" abstract="false" name="CollaborationContractAssetAndOtherAssets" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" abstract="true" name="IncomeStatementAndStatementOfComprehensiveIncomeAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" abstract="false" name="StockIssuedDuringPeriodSharesExerciseOfWarrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arvn_ProceedsFromMaturitiesOfMarketableSecurities" abstract="false" name="ProceedsFromMaturitiesOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ProceedsFromSaleOfMarketableSecurities" abstract="false" name="ProceedsFromSaleOfMarketableSecurities" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ProceedsFromIssuanceOfCommonStockAndWarrants" abstract="false" name="ProceedsFromIssuanceOfCommonStockAndWarrants" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" abstract="false" name="ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsAbstract" abstract="true" name="ResearchCollaborationAndLicenseAgreementsAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_DefinedContributionPlanPolicyPolicyTextBlock" abstract="false" name="DefinedContributionPlanPolicyPolicyTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" abstract="false" name="ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType"/>
  <xs:element id="arvn_NumberOfWhollyOwnedSubsidiaries" abstract="false" name="NumberOfWhollyOwnedSubsidiaries" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arvn_SummaryOfSignificantAccountingPoliciesTable" abstract="true" name="SummaryOfSignificantAccountingPoliciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arvn_CollaboratorOneMember" abstract="true" name="CollaboratorOneMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_LaboratoryEquipmentMember" abstract="true" name="LaboratoryEquipmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_SummaryOfSignificantAccountingPoliciesLineItems" abstract="true" name="SummaryOfSignificantAccountingPoliciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" abstract="false" name="CashCashEquivalentsRestrictedCashAndMarketableSecurities" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsTable" abstract="true" name="ResearchCollaborationAndLicenseAgreementsTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arvn_NovartisPharmaAGMember" abstract="true" name="NovartisPharmaAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_PfizerIncorporationMember" abstract="true" name="PfizerIncorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_BayerAGMember" abstract="true" name="BayerAGMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" abstract="true" name="GenentechIncorporationAndFHoffmanLaRocheLimitedMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CollaborationAgreementMember" abstract="true" name="CollaborationAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_RegulatoryAndSalesBasedMilestonesMember" abstract="true" name="RegulatoryAndSalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_RegulatoryMilestonePaymentsMember" abstract="true" name="RegulatoryMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_SalesBasedMilestonesMember" abstract="true" name="SalesBasedMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_StockPurchaseAgreementMember" abstract="true" name="StockPurchaseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_OptionPaymentsToLicenseAgreementMember" abstract="true" name="OptionPaymentsToLicenseAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_SalesBasedMilestonePaymentsMember" abstract="true" name="SalesBasedMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_DevelopmentMilestonePaymentsMember" abstract="true" name="DevelopmentMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ResearchFundingPaymentsMember" abstract="true" name="ResearchFundingPaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CommercialMilestonesMember" abstract="true" name="CommercialMilestonesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_UpdatedResearchTimelinesMember" abstract="true" name="UpdatedResearchTimelinesMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ExpansionOfDevelopmentProgramsMember" abstract="true" name="ExpansionOfDevelopmentProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_RemovalOfCombinationTrialsMember" abstract="true" name="RemovalOfCombinationTrialsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ResearchCollaborationAndLicenseAgreementsLineItems" abstract="true" name="ResearchCollaborationAndLicenseAgreementsLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_RevenueRemainingPerformanceObligationContingentPayments" abstract="false" name="RevenueRemainingPerformanceObligationContingentPayments" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_SaleOfStockFairValueOfSharesSold" abstract="false" name="SaleOfStockFairValueOfSharesSold" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" abstract="false" name="DirectAndIncrementalCostsIncurredToObtainTheContract" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" abstract="true" name="ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" abstract="false" name="AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" abstract="true" name="ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_AccountsPayableContractBalancesCurrent" abstract="false" name="AccountsPayableContractBalancesCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AccountsPayableContractBalancesCurrentAdditions" abstract="false" name="AccountsPayableContractBalancesCurrentAdditions" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AccountsPayableContractBalancesCurrentPayments" abstract="false" name="AccountsPayableContractBalancesCurrentPayments" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" abstract="true" name="ChangeInCollaborationContractAssetAndOtherAssetsRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" abstract="false" name="ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CapitalizedContractCostAmortizationDuringPeriod" abstract="false" name="CapitalizedContractCostAmortizationDuringPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ChangeInContractWithCustomerLiabilityRollForward" abstract="true" name="ChangeInContractWithCustomerLiabilityRollForward" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" abstract="false" name="ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" abstract="false" name="ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_A101CollegeStreetLLCMember" abstract="true" name="A101CollegeStreetLLCMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_PropertyPlantAndEquipmentWriteoff" abstract="false" name="PropertyPlantAndEquipmentWriteoff" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ContractTerminationAxis" abstract="true" name="ContractTerminationAxis" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:dimensionItem" type="xbrli:stringItemType"/>
  <xs:element id="arvn_ContractTerminationDomain" abstract="true" name="ContractTerminationDomain" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_OneTimeCashTerminationFeeMember" abstract="true" name="OneTimeCashTerminationFeeMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_WriteoffOfPrepaidRentMember" abstract="true" name="WriteoffOfPrepaidRentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" abstract="true" name="CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" abstract="true" name="SupplementalNonCashInformationRelatedToLeasesAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_AccruedResearchAndDevelopmentExpenseCurrent" abstract="false" name="AccruedResearchAndDevelopmentExpenseCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" abstract="false" name="AccruedGeneralAndAdministrativeAndCommercialCurrent" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_TwoThousandAndEighteenAssistanceAgreementMember" abstract="true" name="TwoThousandAndEighteenAssistanceAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_DebtInstrumentLoanForgiveness" abstract="false" name="DebtInstrumentLoanForgiveness" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_DebtInstrumentInterestPaymentsTerm" abstract="false" name="DebtInstrumentInterestPaymentsTerm" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:durationItemType"/>
  <xs:element id="arvn_PercentageOfLiquidatedDamages" abstract="false" name="PercentageOfLiquidatedDamages" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_AtTheMarketOfferingMember" abstract="true" name="AtTheMarketOfferingMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_PreFundedWarrantMember" abstract="true" name="PreFundedWarrantMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_PiperSandlerAndCantorMember" abstract="true" name="PiperSandlerAndCantorMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_EquityDistributionAgreementMember" abstract="true" name="EquityDistributionAgreementMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_TwoThousandEighteenStockIncentivePlanMember" abstract="true" name="TwoThousandEighteenStockIncentivePlanMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_NumberOfVotesPerCommonStockShareHeld" abstract="false" name="NumberOfVotesPerCommonStockShareHeld" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions" abstract="false" name="TreasuryStockValueAcquiredCostMethodNetOfCommissions" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ShareRepurchaseProgramCommissionsAndExciseTax" abstract="false" name="ShareRepurchaseProgramCommissionsAndExciseTax" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_MaximumAggregateOfferingPriceOfCommonStock" abstract="false" name="MaximumAggregateOfferingPriceOfCommonStock" nillable="true" xbrli:periodType="instant" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" abstract="false" name="IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AggregateIntrinsicValueAbstract" abstract="true" name="AggregateIntrinsicValueAbstract" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:sharesItemType"/>
  <xs:element id="arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" abstract="false" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType"/>
  <xs:element id="arvn_BayerCropScienceLPMember" abstract="true" name="BayerCropScienceLPMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_OerthBioLimitedLiabilityCorporationMember" abstract="true" name="OerthBioLimitedLiabilityCorporationMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" abstract="false" name="FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_IncomeTaxDisclosureTable" abstract="true" name="IncomeTaxDisclosureTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arvn_IncomeTaxDisclosureLineItems" abstract="true" name="IncomeTaxDisclosureLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" abstract="false" name="OperatingLossesCarryForwardMaximumDeductibilityPercentage" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:percentItemType"/>
  <xs:element id="arvn_UnrecognizedTaxBenefitsNet" abstract="false" name="UnrecognizedTaxBenefitsNet" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_NewYorkCityMember" abstract="true" name="NewYorkCityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CommitmentsAndContingenciesTable" abstract="true" name="CommitmentsAndContingenciesTable" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrldt:hypercubeItem" type="xbrli:stringItemType"/>
  <xs:element id="arvn_YaleUniversityMember" abstract="true" name="YaleUniversityMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" abstract="true" name="UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" abstract="true" name="MilestonePaymentOnFirstAnniversaryOfSigningMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" abstract="true" name="MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_SuccessBasedMilestonePaymentsMember" abstract="true" name="SuccessBasedMilestonePaymentsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_LicenseFirstLicensedProductMember" abstract="true" name="LicenseFirstLicensedProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_LicenseSecondLicensedProductMember" abstract="true" name="LicenseSecondLicensedProductMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_CommitmentsAndContingenciesLineItems" abstract="true" name="CommitmentsAndContingenciesLineItems" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="xbrli:stringItemType"/>
  <xs:element id="arvn_PaymentsForCollaboration" abstract="false" name="PaymentsForCollaboration" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" abstract="false" name="CollaborativeArrangementRightsAndObligationsMilestonePayment" nillable="true" xbrli:periodType="instant" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_AnnualLicenseFeePayment" abstract="false" name="AnnualLicenseFeePayment" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_NumberOfLicensedProducts" abstract="false" name="NumberOfLicensedProducts" nillable="true" xbrli:periodType="instant" substitutionGroup="xbrli:item" type="xbrli:integerItemType"/>
  <xs:element id="arvn_RequiredMilestonePayments" abstract="false" name="RequiredMilestonePayments" nillable="true" xbrli:periodType="duration" xbrli:balance="credit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_StockCompensationAndBonusExpenseMember" abstract="true" name="StockCompensationAndBonusExpenseMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ReportableSegmentMember" abstract="true" name="ReportableSegmentMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ARV471Member" abstract="true" name="ARV471Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ARV102Member" abstract="true" name="ARV102Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ARV806Member" abstract="true" name="ARV806Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ARV393Member" abstract="true" name="ARV393Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ARV110Member" abstract="true" name="ARV110Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ARV766Member" abstract="true" name="ARV766Member" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_OtherProgramsMember" abstract="true" name="OtherProgramsMember" nillable="true" xbrli:periodType="duration" substitutionGroup="xbrli:item" type="dtr-types:domainItemType"/>
  <xs:element id="arvn_ResearchAndDevelopmentExpenseProgramSpecific" abstract="false" name="ResearchAndDevelopmentExpenseProgramSpecific" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
  <xs:element id="arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" abstract="false" name="ResearchAndDevelopmentExpenseNonProgramSpecific" nillable="true" xbrli:periodType="duration" xbrli:balance="debit" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType"/>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>12
<FILENAME>arvn-20251231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:bad37b98-383d-4e3d-a5b5-927fa1eba41c,g:852a4cd9-135e-4322-96de-ff3159237791-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arvn-20251231.xsd#ConsolidatedBalanceSheets"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_14783569-e9c8-4713-bba2-06ae4b472c60" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_261b1af3-10f1-49dc-bd1a-3159e3bb67f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14783569-e9c8-4713-bba2-06ae4b472c60" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_261b1af3-10f1-49dc-bd1a-3159e3bb67f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_9db31c12-7bdd-4152-8520-c2c840c4558b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14783569-e9c8-4713-bba2-06ae4b472c60" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_9db31c12-7bdd-4152-8520-c2c840c4558b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_a34224ee-5547-4dd6-89c1-db47b613014c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14783569-e9c8-4713-bba2-06ae4b472c60" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_a34224ee-5547-4dd6-89c1-db47b613014c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_f36670fc-fa53-431d-acba-dfb21b50f2f0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14783569-e9c8-4713-bba2-06ae4b472c60" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_f36670fc-fa53-431d-acba-dfb21b50f2f0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b1f10839-8ef6-4a23-acf0-510a69b114e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AssetsCurrent_14783569-e9c8-4713-bba2-06ae4b472c60" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_b1f10839-8ef6-4a23-acf0-510a69b114e9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_ec5ee881-2240-4c91-b3c4-45d0411485e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_45ab85d8-ae64-4c0d-a6cd-87a1614802b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ec5ee881-2240-4c91-b3c4-45d0411485e7" xlink:to="loc_us-gaap_AssetsCurrent_45ab85d8-ae64-4c0d-a6cd-87a1614802b3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_69ddea73-df4e-4ecd-8df0-5d28409d4f41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ec5ee881-2240-4c91-b3c4-45d0411485e7" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_69ddea73-df4e-4ecd-8df0-5d28409d4f41" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_c9748d2c-3fb3-4674-9896-9c8ac7221eac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ec5ee881-2240-4c91-b3c4-45d0411485e7" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_c9748d2c-3fb3-4674-9896-9c8ac7221eac" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_942859bc-f513-4ea1-8ef2-c0a4fa146e64" xlink:href="arvn-20251231.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Assets_ec5ee881-2240-4c91-b3c4-45d0411485e7" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_942859bc-f513-4ea1-8ef2-c0a4fa146e64" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_97de3201-07d4-4495-8527-0bf0132a616f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c6e7c9b8-e6c4-4861-ab9d-2140206baac2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_97de3201-07d4-4495-8527-0bf0132a616f" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_c6e7c9b8-e6c4-4861-ab9d-2140206baac2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_762dae6d-0ff4-4b47-b28e-08ad3dd6c4a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_97de3201-07d4-4495-8527-0bf0132a616f" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_762dae6d-0ff4-4b47-b28e-08ad3dd6c4a9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_64cc05dd-d55c-483b-b59b-35864870ab75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_97de3201-07d4-4495-8527-0bf0132a616f" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_64cc05dd-d55c-483b-b59b-35864870ab75" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_cccc4e59-ee10-4003-ae7a-19eccc9cde94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_Liabilities_97de3201-07d4-4495-8527-0bf0132a616f" xlink:to="loc_us-gaap_LiabilitiesCurrent_cccc4e59-ee10-4003-ae7a-19eccc9cde94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_7b0116eb-6eb5-4cbe-bf62-3a87c07c6e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6f6c45fa-f804-4576-9912-99f6c2c6fb72" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7b0116eb-6eb5-4cbe-bf62-3a87c07c6e1e" xlink:to="loc_us-gaap_PreferredStockValue_6f6c45fa-f804-4576-9912-99f6c2c6fb72" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cfb1ff7c-5322-45d5-b0d0-e85e476eb82a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7b0116eb-6eb5-4cbe-bf62-3a87c07c6e1e" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_cfb1ff7c-5322-45d5-b0d0-e85e476eb82a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_692375fa-d4fc-4d3f-a187-b0d2f5c9ac16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7b0116eb-6eb5-4cbe-bf62-3a87c07c6e1e" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_692375fa-d4fc-4d3f-a187-b0d2f5c9ac16" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_cb3b6920-c1fd-4e65-86f5-0bfd898a23b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7b0116eb-6eb5-4cbe-bf62-3a87c07c6e1e" xlink:to="loc_us-gaap_CommonStockValue_cb3b6920-c1fd-4e65-86f5-0bfd898a23b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_fc24c87b-d082-4c74-964b-36d19d2ace63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7b0116eb-6eb5-4cbe-bf62-3a87c07c6e1e" xlink:to="loc_us-gaap_AdditionalPaidInCapital_fc24c87b-d082-4c74-964b-36d19d2ace63" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_019c0af5-0fba-7e24-9996-6fff8c10904a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:calculationArc order="6" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_StockholdersEquity_7b0116eb-6eb5-4cbe-bf62-3a87c07c6e1e" xlink:to="loc_us-gaap_TreasuryStockCommonValue_019c0af5-0fba-7e24-9996-6fff8c10904a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_3cb2fdab-86fa-4c4c-9be9-d8586802f139" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_0bd88521-05b3-4814-8010-5a1129a77902" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3cb2fdab-86fa-4c4c-9be9-d8586802f139" xlink:to="loc_us-gaap_Liabilities_0bd88521-05b3-4814-8010-5a1129a77902" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_126cfb80-957f-4072-9a87-0f3391a3bf9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3cb2fdab-86fa-4c4c-9be9-d8586802f139" xlink:to="loc_us-gaap_CommitmentsAndContingencies_126cfb80-957f-4072-9a87-0f3391a3bf9a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_0e33a377-0941-4f39-808e-e1c0455eddf6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity_3cb2fdab-86fa-4c4c-9be9-d8586802f139" xlink:to="loc_us-gaap_StockholdersEquity_0e33a377-0941-4f39-808e-e1c0455eddf6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_9dc82097-8368-491d-8d48-3d4ea9face3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3976e0cc-5f78-4e1d-9e71-184abd41be00" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9dc82097-8368-491d-8d48-3d4ea9face3a" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_3976e0cc-5f78-4e1d-9e71-184abd41be00" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4ad171de-b12e-4892-a2e0-43d4aebec8fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9dc82097-8368-491d-8d48-3d4ea9face3a" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_4ad171de-b12e-4892-a2e0-43d4aebec8fc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_29dc07c2-7a3d-4460-bfe5-9ea60826459e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LiabilitiesCurrent_9dc82097-8368-491d-8d48-3d4ea9face3a" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_29dc07c2-7a3d-4460-bfe5-9ea60826459e" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arvn-20251231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_3c27147a-6d50-46ba-941e-9324db73d01a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1fd6e958-4d97-4d9d-a95a-9bb4c800db82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3c27147a-6d50-46ba-941e-9324db73d01a" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1fd6e958-4d97-4d9d-a95a-9bb4c800db82" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_fe71de7b-8159-4680-9d42-8dba4f84ef31" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3c27147a-6d50-46ba-941e-9324db73d01a" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_fe71de7b-8159-4680-9d42-8dba4f84ef31" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e3357127-5e09-45bc-85fd-b254cfe78ffe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetIncomeLoss_3c27147a-6d50-46ba-941e-9324db73d01a" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e3357127-5e09-45bc-85fd-b254cfe78ffe" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_3834b67b-5515-4cf9-a005-66a9e6cd718d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_f937260f-76d5-45dd-9e72-79b348a7cc9b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3834b67b-5515-4cf9-a005-66a9e6cd718d" xlink:to="loc_us-gaap_Revenues_f937260f-76d5-45dd-9e72-79b348a7cc9b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_ce3c1f7b-a793-4e45-bf8f-71b4bb9fc948" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingIncomeLoss_3834b67b-5515-4cf9-a005-66a9e6cd718d" xlink:to="loc_us-gaap_OperatingExpenses_ce3c1f7b-a793-4e45-bf8f-71b4bb9fc948" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_26d8558d-1dc1-4aca-841d-897cbcbe61e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_c95289ad-45d9-4563-9c09-07572fc793ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_26d8558d-1dc1-4aca-841d-897cbcbe61e9" xlink:to="loc_us-gaap_InvestmentIncomeInterest_c95289ad-45d9-4563-9c09-07572fc793ca" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_71c2910d-d276-4496-908e-8a28146c73f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NonoperatingIncomeExpense_26d8558d-1dc1-4aca-841d-897cbcbe61e9" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_71c2910d-d276-4496-908e-8a28146c73f3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_fd07a150-3800-4969-8258-99282e4ba4fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_6faa6286-6d9d-4da2-8f1d-9206c32df8ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_fd07a150-3800-4969-8258-99282e4ba4fa" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_6faa6286-6d9d-4da2-8f1d-9206c32df8ce" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d2570b9b-56e2-4724-93b7-0b58af082cff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax_fd07a150-3800-4969-8258-99282e4ba4fa" xlink:to="loc_us-gaap_NetIncomeLoss_d2570b9b-56e2-4724-93b7-0b58af082cff" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1c89e4e6-eaf3-4f9e-b025-e3898af8804d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_adab81de-0006-4368-9a4c-8a23ec7aeec1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1c89e4e6-eaf3-4f9e-b025-e3898af8804d" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_adab81de-0006-4368-9a4c-8a23ec7aeec1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_45c8f750-4b68-4d5c-a64a-9f3ef20342cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_1c89e4e6-eaf3-4f9e-b025-e3898af8804d" xlink:to="loc_us-gaap_OperatingIncomeLoss_45c8f750-4b68-4d5c-a64a-9f3ef20342cb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e509f50d-45b2-4ba6-991e-7037b51561ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_ef18f1ba-9923-412c-a14f-0957f30177bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e509f50d-45b2-4ba6-991e-7037b51561ed" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_ef18f1ba-9923-412c-a14f-0957f30177bb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_64ec42a7-3106-40a9-8e4a-2d95a9275d4d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_OperatingExpenses_e509f50d-45b2-4ba6-991e-7037b51561ed" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_64ec42a7-3106-40a9-8e4a-2d95a9275d4d" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arvn-20251231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a77f9ad0-c022-407d-aedd-1ccc24701bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_79885833-5e25-487e-9ec6-9d2113579e45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a77f9ad0-c022-407d-aedd-1ccc24701bb6" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_79885833-5e25-487e-9ec6-9d2113579e45" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants_663ed034-b2da-4e23-bb44-c8b2f4d53c6f" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a77f9ad0-c022-407d-aedd-1ccc24701bb6" xlink:to="loc_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants_663ed034-b2da-4e23-bb44-c8b2f4d53c6f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_98948018-d462-4724-a21d-111e7e721bfc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a77f9ad0-c022-407d-aedd-1ccc24701bb6" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_98948018-d462-4724-a21d-111e7e721bfc" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3d561bc4-0c78-48e5-8afe-65cbb05517e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a77f9ad0-c022-407d-aedd-1ccc24701bb6" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_3d561bc4-0c78-48e5-8afe-65cbb05517e8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_019c0ae5-121d-7e9c-a1df-af5bf5eeb462" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_a77f9ad0-c022-407d-aedd-1ccc24701bb6" xlink:to="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_019c0ae5-121d-7e9c-a1df-af5bf5eeb462" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ab7464cf-8507-4aa0-a72b-c278fd0ed422" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_700484be-2253-4dbc-9c41-3abc0d846fa5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ab7464cf-8507-4aa0-a72b-c278fd0ed422" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_700484be-2253-4dbc-9c41-3abc0d846fa5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f383a00-3766-4f35-91f1-486cf7cfa8f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ab7464cf-8507-4aa0-a72b-c278fd0ed422" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_0f383a00-3766-4f35-91f1-486cf7cfa8f5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d3afb7d-406a-438a-adb1-c845e07dc8b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_ab7464cf-8507-4aa0-a72b-c278fd0ed422" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_7d3afb7d-406a-438a-adb1-c845e07dc8b8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc8cd4ca-c24c-4fb4-90df-18cb0be2205e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d61176c3-65c8-43d3-a0a8-6c6108014f32" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc8cd4ca-c24c-4fb4-90df-18cb0be2205e" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d61176c3-65c8-43d3-a0a8-6c6108014f32" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_f6f526cb-b744-4e13-ad99-e4dabde75e78" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc8cd4ca-c24c-4fb4-90df-18cb0be2205e" xlink:to="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_f6f526cb-b744-4e13-ad99-e4dabde75e78" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromSaleOfMarketableSecurities_3a379dee-92c8-4e20-a1a0-32df97087532" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromSaleOfMarketableSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc8cd4ca-c24c-4fb4-90df-18cb0be2205e" xlink:to="loc_arvn_ProceedsFromSaleOfMarketableSecurities_3a379dee-92c8-4e20-a1a0-32df97087532" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a4e876d8-755e-4d62-952e-c98a001757c0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc8cd4ca-c24c-4fb4-90df-18cb0be2205e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_a4e876d8-755e-4d62-952e-c98a001757c0" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_cdeff767-189f-4ec8-962b-1929dd0dd64d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_bc8cd4ca-c24c-4fb4-90df-18cb0be2205e" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_cdeff767-189f-4ec8-962b-1929dd0dd64d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_1f646ac6-6ad4-473a-8518-9810172faffd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_NetIncomeLoss_1f646ac6-6ad4-473a-8518-9810172faffd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_053faa85-283c-41a3-ba51-2c95f3fd045d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_DepreciationAndAmortization_053faa85-283c-41a3-ba51-2c95f3fd045d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_61e1dc63-c42f-4e55-bdba-497706ca47b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_61e1dc63-c42f-4e55-bdba-497706ca47b9" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_e867fbe7-4e3b-4fbb-bb60-7e09a661f41b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:calculationArc order="4" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_e867fbe7-4e3b-4fbb-bb60-7e09a661f41b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_27582335-fec1-42c2-84d1-cb3c007570e6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_27582335-fec1-42c2-84d1-cb3c007570e6" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_5beaf0b4-be8e-4270-b66a-aa454658949f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_5beaf0b4-be8e-4270-b66a-aa454658949f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_79067f6a-b620-4519-88fb-96bb7754831b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_79067f6a-b620-4519-88fb-96bb7754831b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_26580655-cdd3-4ca2-bd4d-f941220239cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:calculationArc order="8" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_ShareBasedCompensation_26580655-cdd3-4ca2-bd4d-f941220239cf" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_538eeb71-3d5e-4b4e-985d-4bcd6ea5ffaa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:calculationArc order="9" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_538eeb71-3d5e-4b4e-985d-4bcd6ea5ffaa" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e72df7d3-7675-4891-84df-19416122dd74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:calculationArc order="10" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_e72df7d3-7675-4891-84df-19416122dd74" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a3b6e5db-1e6e-421c-8027-15829d30700d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:calculationArc order="11" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_a3b6e5db-1e6e-421c-8027-15829d30700d" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_ee4cbb16-ba61-4ccd-94af-77abe814e48a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:calculationArc order="12" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_ee4cbb16-ba61-4ccd-94af-77abe814e48a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c06c47e0-6691-44fb-b2d3-b61817255212" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:calculationArc order="13" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_c06c47e0-6691-44fb-b2d3-b61817255212" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_af0b4f68-5151-474d-b6ed-e94d08a324be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:calculationArc order="14" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_af0b4f68-5151-474d-b6ed-e94d08a324be" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6a9c8252-68b5-4fcd-be60-e402ae9c3d59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:calculationArc order="15" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_2ddb0473-6269-402b-a787-2c7eff6d7138" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6a9c8252-68b5-4fcd-be60-e402ae9c3d59" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#SummaryofSignificantAccountingPoliciesCashReconciliationDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c36ea723-ab29-4857-9fcb-27439a4df3e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54d2c04b-f250-4ed2-8f40-fd00c597acf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c36ea723-ab29-4857-9fcb-27439a4df3e8" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_54d2c04b-f250-4ed2-8f40-fd00c597acf5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_3dc6aa60-cc9d-4174-aa3d-41e8cefdb78f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c36ea723-ab29-4857-9fcb-27439a4df3e8" xlink:to="loc_us-gaap_RestrictedCashCurrent_3dc6aa60-cc9d-4174-aa3d-41e8cefdb78f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#MarketableSecuritiesandFairValueMeasurementsDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_55ba64d4-f1fa-41ea-b3f6-6bee63e9afc3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4a05f588-80c7-4f6e-98db-6eb4cf339727" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_55ba64d4-f1fa-41ea-b3f6-6bee63e9afc3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_4a05f588-80c7-4f6e-98db-6eb4cf339727" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7645943b-8b29-4cb9-abd2-2b595b217264" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_55ba64d4-f1fa-41ea-b3f6-6bee63e9afc3" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_7645943b-8b29-4cb9-abd2-2b595b217264" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c589266e-5547-43d0-a053-472245f84787" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_55ba64d4-f1fa-41ea-b3f6-6bee63e9afc3" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_c589266e-5547-43d0-a053-472245f84787" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8f1c4570-b54f-411e-a6cf-3ae79423d918" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_b36b351b-7a16-49b6-96be-bdf604106719" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8f1c4570-b54f-411e-a6cf-3ae79423d918" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_b36b351b-7a16-49b6-96be-bdf604106719" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ee97f542-3af3-4b6a-a1f0-e75df7727ed3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet_8f1c4570-b54f-411e-a6cf-3ae79423d918" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_ee97f542-3af3-4b6a-a1f0-e75df7727ed3" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b48ad2fb-d99b-46da-8c77-56f08ad830a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6f3e808e-c46c-46f2-9494-848b655caed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b48ad2fb-d99b-46da-8c77-56f08ad830a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_6f3e808e-c46c-46f2-9494-848b655caed8" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_aef3b91c-0897-4740-aa25-a92ce8931421" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b48ad2fb-d99b-46da-8c77-56f08ad830a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_aef3b91c-0897-4740-aa25-a92ce8931421" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c0dcfaed-576e-4b61-9a16-74a1f8dc4da2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b48ad2fb-d99b-46da-8c77-56f08ad830a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_c0dcfaed-576e-4b61-9a16-74a1f8dc4da2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c8463f9d-efa6-4f69-94bb-0d35cc9aac5f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_b48ad2fb-d99b-46da-8c77-56f08ad830a4" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_c8463f9d-efa6-4f69-94bb-0d35cc9aac5f" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="simple" xlink:href="arvn-20251231.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9e95a27-becc-4a31-966e-4a80123b2125" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_aed8e55b-48f3-48b2-81d9-5f4865afbe8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9e95a27-becc-4a31-966e-4a80123b2125" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_aed8e55b-48f3-48b2-81d9-5f4865afbe8e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_11e0a022-8246-4298-82dc-b77458b0f0e9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_d9e95a27-becc-4a31-966e-4a80123b2125" xlink:to="loc_us-gaap_OperatingLeaseLiability_11e0a022-8246-4298-82dc-b77458b0f0e9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6d033445-1107-41b5-a6fc-80e8ab0c48da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6569dc44-708e-4cf0-a6e2-cd21e587ee50" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6d033445-1107-41b5-a6fc-80e8ab0c48da" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6569dc44-708e-4cf0-a6e2-cd21e587ee50" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_9cb0f4e4-30cb-4112-a53e-6af621c2d643" xlink:href="arvn-20251231.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6d033445-1107-41b5-a6fc-80e8ab0c48da" xlink:to="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_9cb0f4e4-30cb-4112-a53e-6af621c2d643" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9f3b99ff-a69a-4817-a63d-9b21f6e12a94" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6d033445-1107-41b5-a6fc-80e8ab0c48da" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_9f3b99ff-a69a-4817-a63d-9b21f6e12a94" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_e3c38d90-223d-47a3-8e0d-99e3b3665b1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6d033445-1107-41b5-a6fc-80e8ab0c48da" xlink:to="loc_us-gaap_AccountsPayableCurrent_e3c38d90-223d-47a3-8e0d-99e3b3665b1c" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_e7800000-0ffe-4478-9cf9-d7c961831db2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6d033445-1107-41b5-a6fc-80e8ab0c48da" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_e7800000-0ffe-4478-9cf9-d7c961831db2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_bf8d0a8c-5fec-4ba5-bc5a-3968d83f6283" xlink:href="arvn-20251231.xsd#arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_6d033445-1107-41b5-a6fc-80e8ab0c48da" xlink:to="loc_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_bf8d0a8c-5fec-4ba5-bc5a-3968d83f6283" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_d339cac1-4d2f-49c9-84d7-63e06d647dfe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_5f6c3adf-9947-4d6d-a0a0-78f49d7d1f6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d339cac1-4d2f-49c9-84d7-63e06d647dfe" xlink:to="loc_us-gaap_LongTermDebtCurrent_5f6c3adf-9947-4d6d-a0a0-78f49d7d1f6b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_ea390d52-c37a-4f9c-9e86-9623543bc7d2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_d339cac1-4d2f-49c9-84d7-63e06d647dfe" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_ea390d52-c37a-4f9c-9e86-9623543bc7d2" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_bd6fb4b7-9c35-478d-ae31-050ce38201af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d47d4493-2b72-4320-aba9-05853dcb629b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_bd6fb4b7-9c35-478d-ae31-050ce38201af" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_d47d4493-2b72-4320-aba9-05853dcb629b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_409d013e-41fc-4723-b9e4-96072fdc976b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_bd6fb4b7-9c35-478d-ae31-050ce38201af" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_409d013e-41fc-4723-b9e4-96072fdc976b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8c09d3be-8557-41c7-9053-e947d4710194" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_LongTermDebt_bd6fb4b7-9c35-478d-ae31-050ce38201af" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_8c09d3be-8557-41c7-9053-e947d4710194" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxesScheduleofIncomeTaxExpenseDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a99dc478-4802-4e7a-a14e-fac42cf5eb70" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_330ee9df-d97d-452b-bbab-b7e76c73d80f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a99dc478-4802-4e7a-a14e-fac42cf5eb70" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_330ee9df-d97d-452b-bbab-b7e76c73d80f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0e8c7ea9-9ea4-41e6-93a8-0c9cce5e8214" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_a99dc478-4802-4e7a-a14e-fac42cf5eb70" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_0e8c7ea9-9ea4-41e6-93a8-0c9cce5e8214" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b76f649e-73ff-40bf-8bf1-a76f8fcfa463" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_62cf34e4-de12-4338-ba20-78a5bbac9053" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b76f649e-73ff-40bf-8bf1-a76f8fcfa463" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_62cf34e4-de12-4338-ba20-78a5bbac9053" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4451b119-f66b-49b8-a8de-b489cfa51506" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_b76f649e-73ff-40bf-8bf1-a76f8fcfa463" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_4451b119-f66b-49b8-a8de-b489cfa51506" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_7125f81e-24d1-4c05-8472-0f197ffc996a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_44c90d21-f61d-4511-a8d2-116e33c5f581" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7125f81e-24d1-4c05-8472-0f197ffc996a" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_44c90d21-f61d-4511-a8d2-116e33c5f581" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e3247dfc-4eaf-4e5a-9c4d-22dba97da893" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_7125f81e-24d1-4c05-8472-0f197ffc996a" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_e3247dfc-4eaf-4e5a-9c4d-22dba97da893" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c4691-ea0b-74ee-8c14-5a3eada55d78" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c4691-ea0b-731b-a107-2f2d517b100f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c4691-ea0b-74ee-8c14-5a3eada55d78" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c4691-ea0b-731b-a107-2f2d517b100f" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c4691-ea0b-77a1-88bf-b35c96f94fe1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c4691-ea0b-74ee-8c14-5a3eada55d78" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c4691-ea0b-77a1-88bf-b35c96f94fe1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c4691-ea0b-72af-a6a1-f9e03fa4686b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c4691-ea0b-74ee-8c14-5a3eada55d78" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c4691-ea0b-72af-a6a1-f9e03fa4686b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c4691-ea0b-795e-b3f9-4e33173fa472" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c4691-ea0b-74ee-8c14-5a3eada55d78" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c4691-ea0b-795e-b3f9-4e33173fa472" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c4691-ea0b-7760-8d23-0bb40fafc255" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c4691-ea0b-74ee-8c14-5a3eada55d78" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c4691-ea0b-7760-8d23-0bb40fafc255" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c4691-ea0b-7013-a0bb-05125746abbd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit_019c4691-ea0b-74ee-8c14-5a3eada55d78" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c4691-ea0b-7013-a0bb-05125746abbd" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7a1aa909-eed4-42a7-9f9c-c67b065766a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_748e4411-73f4-410b-af51-0c1224cf15a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7a1aa909-eed4-42a7-9f9c-c67b065766a0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_748e4411-73f4-410b-af51-0c1224cf15a1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8b9a4d1f-66f8-41ed-ba9e-221c32470874" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7a1aa909-eed4-42a7-9f9c-c67b065766a0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_8b9a4d1f-66f8-41ed-ba9e-221c32470874" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_a41166f0-186f-4eb9-937d-f796e8ad9aa4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7a1aa909-eed4-42a7-9f9c-c67b065766a0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_a41166f0-186f-4eb9-937d-f796e8ad9aa4" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bea4700e-82e8-4acb-893c-c70ad80ed09e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7a1aa909-eed4-42a7-9f9c-c67b065766a0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_bea4700e-82e8-4acb-893c-c70ad80ed09e" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_db2ba725-0b2f-42cc-9300-370d51f78477" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7a1aa909-eed4-42a7-9f9c-c67b065766a0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_db2ba725-0b2f-42cc-9300-370d51f78477" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_c357db7f-7e45-4eda-a276-805693804802" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_7a1aa909-eed4-42a7-9f9c-c67b065766a0" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_c357db7f-7e45-4eda-a276-805693804802" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019c469e-56e7-7e50-981d-05d3b449eac0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c469e-56e7-7525-aa1c-d65ca1ae89a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_019c469e-56e7-7e50-981d-05d3b449eac0" xlink:to="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c469e-56e7-7525-aa1c-d65ca1ae89a7" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c469e-56e7-7eec-99d0-7b43b7cf2228" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_IncomeTaxesPaidNet_019c469e-56e7-7e50-981d-05d3b449eac0" xlink:to="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c469e-56e7-7eec-99d0-7b43b7cf2228" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_653a2f43-678f-4177-b235-68a31d6e8600" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fe0233b4-fcd6-4234-a364-197b4b071b46" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities_653a2f43-678f-4177-b235-68a31d6e8600" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_fe0233b4-fcd6-4234-a364-197b4b071b46" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_ac6e5825-0ce6-471c-b1f1-f94309b097f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_98b115af-71b3-480e-acbf-174657c3e690" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ac6e5825-0ce6-471c-b1f1-f94309b097f9" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_98b115af-71b3-480e-acbf-174657c3e690" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_258a263e-2881-49a5-a953-28648cbc459a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ac6e5825-0ce6-471c-b1f1-f94309b097f9" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_258a263e-2881-49a5-a953-28648cbc459a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_64f791de-6e8a-4567-9bc8-9024ce2b30d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxLiabilities_ac6e5825-0ce6-471c-b1f1-f94309b097f9" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_64f791de-6e8a-4567-9bc8-9024ce2b30d1" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_c1d96892-5e24-4f8f-9731-e42415efcf92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9d5e2568-9d9c-437e-a71f-32babdfa9833" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c1d96892-5e24-4f8f-9731-e42415efcf92" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_9d5e2568-9d9c-437e-a71f-32babdfa9833" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_ce606dbf-ee77-4c10-b098-b4a7eca66c8b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c1d96892-5e24-4f8f-9731-e42415efcf92" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_ce606dbf-ee77-4c10-b098-b4a7eca66c8b" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_de26154c-5536-43a9-b1cc-b5aa6f5c138a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c1d96892-5e24-4f8f-9731-e42415efcf92" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_de26154c-5536-43a9-b1cc-b5aa6f5c138a" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bc0f791b-1dd8-471b-85f3-1fd43c151ec2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c1d96892-5e24-4f8f-9731-e42415efcf92" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_bc0f791b-1dd8-471b-85f3-1fd43c151ec2" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_204f3236-6de6-4e05-98e7-e89b9f03dcbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c1d96892-5e24-4f8f-9731-e42415efcf92" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_204f3236-6de6-4e05-98e7-e89b9f03dcbb" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_4c3bec1e-6132-44d1-aee2-d51f3be7aec9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_DeferredTaxAssetsGross_c1d96892-5e24-4f8f-9731-e42415efcf92" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_4c3bec1e-6132-44d1-aee2-d51f3be7aec9" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#SegmentInformationScheduleofFinancialInformationDetails"/>
  <link:calculationLink xlink:role="http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_93ed041e-2a45-4422-a373-c4223a28778d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific_e7fb0206-798a-490a-b635-03e826bddce3" xlink:href="arvn-20251231.xsd#arvn_ResearchAndDevelopmentExpenseProgramSpecific"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_93ed041e-2a45-4422-a373-c4223a28778d" xlink:to="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific_e7fb0206-798a-490a-b635-03e826bddce3" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_da1ab157-041c-42fb-a0f6-aadf5b6db1d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_93ed041e-2a45-4422-a373-c4223a28778d" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_da1ab157-041c-42fb-a0f6-aadf5b6db1d5" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_074a3ba5-a0a8-47ef-b152-f7cf84ec1199" xlink:href="arvn-20251231.xsd#arvn_ResearchAndDevelopmentExpenseNonProgramSpecific"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_93ed041e-2a45-4422-a373-c4223a28778d" xlink:to="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_074a3ba5-a0a8-47ef-b152-f7cf84ec1199" xlink:type="arc"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_dbdeff0c-5626-4406-b060-62b9a4102b53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense_93ed041e-2a45-4422-a373-c4223a28778d" xlink:to="loc_us-gaap_LaborAndRelatedExpense_dbdeff0c-5626-4406-b060-62b9a4102b53" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>13
<FILENAME>arvn-20251231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:bad37b98-383d-4e3d-a5b5-927fa1eba41c,g:852a4cd9-135e-4322-96de-ff3159237791-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member"/>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="arvn-20251231.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_101eb52d-4bb4-4d0b-a6f3-95e63c5cb137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f26f7966-c39e-453f-a29f-ea4aafdcf856" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_StatementLineItems_101eb52d-4bb4-4d0b-a6f3-95e63c5cb137" xlink:to="loc_us-gaap_StatementTable_f26f7966-c39e-453f-a29f-ea4aafdcf856" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40a47dd5-f5f5-4bf7-a49e-090b81c9391c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_StatementTable_f26f7966-c39e-453f-a29f-ea4aafdcf856" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40a47dd5-f5f5-4bf7-a49e-090b81c9391c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_40a47dd5-f5f5-4bf7-a49e-090b81c9391c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40a47dd5-f5f5-4bf7-a49e-090b81c9391c" xlink:to="loc_us-gaap_EquityComponentDomain_40a47dd5-f5f5-4bf7-a49e-090b81c9391c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40a47dd5-f5f5-4bf7-a49e-090b81c9391c" xlink:to="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f14437cf-2ea7-48f4-bafb-2e186e6448a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:to="loc_us-gaap_CommonStockMember_f14437cf-2ea7-48f4-bafb-2e186e6448a2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ac8742ae-eb45-43b1-993e-989849276934" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:to="loc_us-gaap_RetainedEarningsMember_ac8742ae-eb45-43b1-993e-989849276934" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6b62f533-50b9-4ff0-bf50-e166385d7e99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6b62f533-50b9-4ff0-bf50-e166385d7e99" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_68f42f24-71bd-48cc-8746-559ff403f899" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_68f42f24-71bd-48cc-8746-559ff403f899" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_019c0b05-2da6-7cdd-aff8-d40af5d48e57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:to="loc_us-gaap_TreasuryStockCommonMember_019c0b05-2da6-7cdd-aff8-d40af5d48e57" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StatementLineItems_101eb52d-4bb4-4d0b-a6f3-95e63c5cb137" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f83c15e7-3077-4df8-973b-6ecf5f30332f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f83c15e7-3077-4df8-973b-6ecf5f30332f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019c65cb-176b-77db-b89c-87e8274cc240" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019c65cb-176b-77db-b89c-87e8274cc240" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bc30de12-0ac4-4429-af11-8ae6e50456ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_StockholdersEquity_bc30de12-0ac4-4429-af11-8ae6e50456ba" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0474228c-fbdc-4634-a509-4ee6f5f09be2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0474228c-fbdc-4634-a509-4ee6f5f09be2" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f39fc2e7-d5e1-484b-924b-6cf27684890f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_NetIncomeLoss_f39fc2e7-d5e1-484b-924b-6cf27684890f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2dc006ae-86ff-45d3-9e7e-0194406b1d82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2dc006ae-86ff-45d3-9e7e-0194406b1d82" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_99c8cbb9-a758-4123-923c-7c210091ee5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_99c8cbb9-a758-4123-923c-7c210091ee5c" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_019c68df-c2aa-7576-b16a-4d5ca81f665c" xlink:href="arvn-20251231.xsd#arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_019c68df-c2aa-7576-b16a-4d5ca81f665c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6c1e93c0-9d93-447a-baa7-dd410ab68796" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6c1e93c0-9d93-447a-baa7-dd410ab68796" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4a0bc71e-d408-43e3-85f8-57f027b93776" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4a0bc71e-d408-43e3-85f8-57f027b93776" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019c0afe-281f-7923-b4a1-12e0560ffc06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019c0afe-281f-7923-b4a1-12e0560ffc06" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019c0afc-c8f6-7faa-9e6c-726bbfc3ade4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019c0afc-c8f6-7faa-9e6c-726bbfc3ade4" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5f196019-d851-4265-ae72-40203c190656" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5f196019-d851-4265-ae72-40203c190656" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d437d4df-7934-40a1-be47-c236293e4a08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019c65bd-aae3-7ea0-aaeb-37fd1cabd947" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_db11c431-e746-4a51-9db3-15993c94a984" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:href="arvn-20251231.xsd#arvn_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:href="arvn-20251231.xsd#arvn_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_37f082d6-0aa4-40d3-a2d6-ae753c953989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_37f082d6-0aa4-40d3-a2d6-ae753c953989" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_37f082d6-0aa4-40d3-a2d6-ae753c953989_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_37f082d6-0aa4-40d3-a2d6-ae753c953989" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_37f082d6-0aa4-40d3-a2d6-ae753c953989_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_df581fb2-8caa-4de5-9c4e-2c026f18a8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_37f082d6-0aa4-40d3-a2d6-ae753c953989" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_df581fb2-8caa-4de5-9c4e-2c026f18a8a6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_3997ae20-f360-4244-946f-a1db37f3d57d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_df581fb2-8caa-4de5-9c4e-2c026f18a8a6" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_3997ae20-f360-4244-946f-a1db37f3d57d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b951406c-a865-4fc2-981c-7b043c57dc63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b951406c-a865-4fc2-981c-7b043c57dc63" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b951406c-a865-4fc2-981c-7b043c57dc63_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b951406c-a865-4fc2-981c-7b043c57dc63" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_b951406c-a865-4fc2-981c-7b043c57dc63_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c19264a-5079-4e61-b5ce-4a05386f6e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b951406c-a865-4fc2-981c-7b043c57dc63" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c19264a-5079-4e61-b5ce-4a05386f6e91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_f5c1b601-3a21-4a00-9a0e-848cf5f660fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c19264a-5079-4e61-b5ce-4a05386f6e91" xlink:to="loc_us-gaap_SalesRevenueNetMember_f5c1b601-3a21-4a00-9a0e-848cf5f660fa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96a38bcb-0ac8-4e26-9f89-95d2d0844e61" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96a38bcb-0ac8-4e26-9f89-95d2d0844e61" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_96a38bcb-0ac8-4e26-9f89-95d2d0844e61_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96a38bcb-0ac8-4e26-9f89-95d2d0844e61" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_96a38bcb-0ac8-4e26-9f89-95d2d0844e61_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_eaa5ef25-5d89-4ca2-934e-bf5af90c9fbf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96a38bcb-0ac8-4e26-9f89-95d2d0844e61" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_eaa5ef25-5d89-4ca2-934e-bf5af90c9fbf" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaboratorOneMember_fb396892-25e8-4d21-8ceb-d6586ccfbdc0" xlink:href="arvn-20251231.xsd#arvn_CollaboratorOneMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_eaa5ef25-5d89-4ca2-934e-bf5af90c9fbf" xlink:to="loc_arvn_CollaboratorOneMember_fb396892-25e8-4d21-8ceb-d6586ccfbdc0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e660ae00-1857-406e-8036-a3c7a10bf5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e660ae00-1857-406e-8036-a3c7a10bf5ab" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e660ae00-1857-406e-8036-a3c7a10bf5ab_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e660ae00-1857-406e-8036-a3c7a10bf5ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_e660ae00-1857-406e-8036-a3c7a10bf5ab_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d5ab930b-c64b-4fd2-a7ec-07027a08859f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e660ae00-1857-406e-8036-a3c7a10bf5ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d5ab930b-c64b-4fd2-a7ec-07027a08859f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_ea586282-f73d-4c9b-a6f5-6b1b25f9bcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d5ab930b-c64b-4fd2-a7ec-07027a08859f" xlink:to="loc_us-gaap_OfficeEquipmentMember_ea586282-f73d-4c9b-a6f5-6b1b25f9bcdc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_5d5c5475-ab69-4745-864b-e0e968f1104e" xlink:href="arvn-20251231.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d5ab930b-c64b-4fd2-a7ec-07027a08859f" xlink:to="loc_arvn_LaboratoryEquipmentMember_5d5c5475-ab69-4745-864b-e0e968f1104e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6051b771-c777-4ab0-91bc-61fe7b298a30" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:to="loc_srt_RangeAxis_6051b771-c777-4ab0-91bc-61fe7b298a30" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_6051b771-c777-4ab0-91bc-61fe7b298a30_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_6051b771-c777-4ab0-91bc-61fe7b298a30" xlink:to="loc_srt_RangeMember_6051b771-c777-4ab0-91bc-61fe7b298a30_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1eac6f45-91f1-48ad-a47f-f970c20f7090" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_6051b771-c777-4ab0-91bc-61fe7b298a30" xlink:to="loc_srt_RangeMember_1eac6f45-91f1-48ad-a47f-f970c20f7090" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e8298f68-09aa-4f76-a0c4-184fcaa51c75" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_1eac6f45-91f1-48ad-a47f-f970c20f7090" xlink:to="loc_srt_MaximumMember_e8298f68-09aa-4f76-a0c4-184fcaa51c75" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_f6cd78ac-2452-4e6c-909d-132a4c1ff8fd" xlink:href="arvn-20251231.xsd#arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_f6cd78ac-2452-4e6c-909d-132a4c1ff8fd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_22f64c7d-7c8f-4648-ae95-aafdaffe39c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_22f64c7d-7c8f-4648-ae95-aafdaffe39c1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4809bf08-b20b-464f-950a-15e69687f6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4809bf08-b20b-464f-950a-15e69687f6bd" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_97a8fc46-8052-45b2-8ab4-7681676d053f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_97a8fc46-8052-45b2-8ab4-7681676d053f" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6e61833a-fd79-4df1-becb-b1ae62009ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6e61833a-fd79-4df1-becb-b1ae62009ab9" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_0ebb0919-ca57-452a-bf4f-c23d30d41d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_0ebb0919-ca57-452a-bf4f-c23d30d41d1f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2511b45a-64c9-4467-a126-42ee0e39a94f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_EquityMethodInvestments_2511b45a-64c9-4467-a126-42ee0e39a94f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_ceb3875f-4205-498f-afa0-5540b10d3c67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_ceb3875f-4205-498f-afa0-5540b10d3c67" xlink:type="arc" order="7"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:href="arvn-20251231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:href="arvn-20251231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ab8c0af1-4470-4cf8-bbfd-d24a3ec38848" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:to="loc_srt_CounterpartyNameAxis_ab8c0af1-4470-4cf8-bbfd-d24a3ec38848" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab8c0af1-4470-4cf8-bbfd-d24a3ec38848_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_ab8c0af1-4470-4cf8-bbfd-d24a3ec38848" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_ab8c0af1-4470-4cf8-bbfd-d24a3ec38848_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99539a10-05bb-46dc-9f8e-d4bb27fac802" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_ab8c0af1-4470-4cf8-bbfd-d24a3ec38848" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99539a10-05bb-46dc-9f8e-d4bb27fac802" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NovartisPharmaAGMember_11d65a12-88bf-42f7-946c-bb538d1bcffd" xlink:href="arvn-20251231.xsd#arvn_NovartisPharmaAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99539a10-05bb-46dc-9f8e-d4bb27fac802" xlink:to="loc_arvn_NovartisPharmaAGMember_11d65a12-88bf-42f7-946c-bb538d1bcffd" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_7ece09cc-46fb-44c3-9560-d579e97adb52" xlink:href="arvn-20251231.xsd#arvn_PfizerIncorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99539a10-05bb-46dc-9f8e-d4bb27fac802" xlink:to="loc_arvn_PfizerIncorporationMember_7ece09cc-46fb-44c3-9560-d579e97adb52" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember_033c9926-bc36-47ae-a0df-6ac8e1f5f3af" xlink:href="arvn-20251231.xsd#arvn_BayerAGMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99539a10-05bb-46dc-9f8e-d4bb27fac802" xlink:to="loc_arvn_BayerAGMember_033c9926-bc36-47ae-a0df-6ac8e1f5f3af" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_f3b417e1-4f7e-49b8-9d8c-1b93bc2241b5" xlink:href="arvn-20251231.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99539a10-05bb-46dc-9f8e-d4bb27fac802" xlink:to="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_f3b417e1-4f7e-49b8-9d8c-1b93bc2241b5" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3b5a6093-8d25-47bf-b153-a09bb284541d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:to="loc_srt_ProductOrServiceAxis_3b5a6093-8d25-47bf-b153-a09bb284541d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_3b5a6093-8d25-47bf-b153-a09bb284541d_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_3b5a6093-8d25-47bf-b153-a09bb284541d" xlink:to="loc_srt_ProductsAndServicesDomain_3b5a6093-8d25-47bf-b153-a09bb284541d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_08a170e1-bbe4-438a-aa84-72441966caa5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_3b5a6093-8d25-47bf-b153-a09bb284541d" xlink:to="loc_srt_ProductsAndServicesDomain_08a170e1-bbe4-438a-aa84-72441966caa5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_81ff7a3a-8b22-462c-89f3-b7b5df39358b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_08a170e1-bbe4-438a-aa84-72441966caa5" xlink:to="loc_us-gaap_LicenseMember_81ff7a3a-8b22-462c-89f3-b7b5df39358b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2848fd18-6552-4f89-ba3f-5a2920879ab9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:to="loc_srt_RangeAxis_2848fd18-6552-4f89-ba3f-5a2920879ab9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_2848fd18-6552-4f89-ba3f-5a2920879ab9_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_2848fd18-6552-4f89-ba3f-5a2920879ab9" xlink:to="loc_srt_RangeMember_2848fd18-6552-4f89-ba3f-5a2920879ab9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8e79fa39-3a4c-46f5-a9d7-eb6d103873e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_2848fd18-6552-4f89-ba3f-5a2920879ab9" xlink:to="loc_srt_RangeMember_8e79fa39-3a4c-46f5-a9d7-eb6d103873e3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3e2ce744-e03d-4cc0-96cd-41feb742a37c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_8e79fa39-3a4c-46f5-a9d7-eb6d103873e3" xlink:to="loc_srt_MaximumMember_3e2ce744-e03d-4cc0-96cd-41feb742a37c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_40c2a9d2-e668-4989-aaf1-648893bd2c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:to="loc_us-gaap_TypeOfArrangementAxis_40c2a9d2-e668-4989-aaf1-648893bd2c6a" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40c2a9d2-e668-4989-aaf1-648893bd2c6a_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40c2a9d2-e668-4989-aaf1-648893bd2c6a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_40c2a9d2-e668-4989-aaf1-648893bd2c6a_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40c2a9d2-e668-4989-aaf1-648893bd2c6a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember_cb27ff3c-5be9-4849-aa79-15cb8aefabcb" xlink:href="arvn-20251231.xsd#arvn_CollaborationAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_CollaborationAgreementMember_cb27ff3c-5be9-4849-aa79-15cb8aefabcb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_7f810a3a-0e82-4087-bf92-c0028e801d15" xlink:href="arvn-20251231.xsd#arvn_RegulatoryAndSalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_7f810a3a-0e82-4087-bf92-c0028e801d15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember_96ad7ca2-c2d0-4d8d-aa8b-66ccaa08fa58" xlink:href="arvn-20251231.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_RegulatoryMilestonePaymentsMember_96ad7ca2-c2d0-4d8d-aa8b-66ccaa08fa58" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonesMember_019b30c4-e3e6-7cab-840e-de554ceea5f6" xlink:href="arvn-20251231.xsd#arvn_SalesBasedMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_SalesBasedMilestonesMember_019b30c4-e3e6-7cab-840e-de554ceea5f6" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockPurchaseAgreementMember_f4861722-7d7d-4459-8ff6-489a13fa9185" xlink:href="arvn-20251231.xsd#arvn_StockPurchaseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_StockPurchaseAgreementMember_f4861722-7d7d-4459-8ff6-489a13fa9185" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember_c140db45-8497-4084-a3bc-c71ab0bfca3f" xlink:href="arvn-20251231.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_OptionPaymentsToLicenseAgreementMember_c140db45-8497-4084-a3bc-c71ab0bfca3f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember_278cb0eb-8382-4242-9cf9-0de556c42278" xlink:href="arvn-20251231.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_SalesBasedMilestonePaymentsMember_278cb0eb-8382-4242-9cf9-0de556c42278" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember_db04600f-964c-4430-96f8-62f07454a0df" xlink:href="arvn-20251231.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_DevelopmentMilestonePaymentsMember_db04600f-964c-4430-96f8-62f07454a0df" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember_a57e056b-f4ac-4afa-a4ba-9ea109582e3c" xlink:href="arvn-20251231.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_ResearchFundingPaymentsMember_a57e056b-f4ac-4afa-a4ba-9ea109582e3c" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember_e6045fd0-9dbe-4afb-a809-9097cd1d751e" xlink:href="arvn-20251231.xsd#arvn_CommercialMilestonesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_CommercialMilestonesMember_e6045fd0-9dbe-4afb-a809-9097cd1d751e" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a3e5118d-cc10-4f3f-bd0d-52e2e2604519" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a3e5118d-cc10-4f3f-bd0d-52e2e2604519" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_a3e5118d-cc10-4f3f-bd0d-52e2e2604519_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3e5118d-cc10-4f3f-bd0d-52e2e2604519" xlink:to="loc_us-gaap_EquityComponentDomain_a3e5118d-cc10-4f3f-bd0d-52e2e2604519_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_edaea17b-5389-4c06-ab30-27e823314264" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3e5118d-cc10-4f3f-bd0d-52e2e2604519" xlink:to="loc_us-gaap_EquityComponentDomain_edaea17b-5389-4c06-ab30-27e823314264" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3165b41b-2cea-4699-af6f-8c94e630595a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_edaea17b-5389-4c06-ab30-27e823314264" xlink:to="loc_us-gaap_CommonStockMember_3165b41b-2cea-4699-af6f-8c94e630595a" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_7c011872-b764-4b5b-beee-1bfa4128ccd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_7c011872-b764-4b5b-beee-1bfa4128ccd2" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_7c011872-b764-4b5b-beee-1bfa4128ccd2_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_7c011872-b764-4b5b-beee-1bfa4128ccd2" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_7c011872-b764-4b5b-beee-1bfa4128ccd2_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d9097981-507c-4357-881b-3a7c74d3925b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_7c011872-b764-4b5b-beee-1bfa4128ccd2" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d9097981-507c-4357-881b-3a7c74d3925b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UpdatedResearchTimelinesMember_9fd2c0f4-f2f8-46d1-baab-c55d9b5cbefa" xlink:href="arvn-20251231.xsd#arvn_UpdatedResearchTimelinesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d9097981-507c-4357-881b-3a7c74d3925b" xlink:to="loc_arvn_UpdatedResearchTimelinesMember_9fd2c0f4-f2f8-46d1-baab-c55d9b5cbefa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ExpansionOfDevelopmentProgramsMember_173485b3-7254-489b-b7ea-7accb713b557" xlink:href="arvn-20251231.xsd#arvn_ExpansionOfDevelopmentProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d9097981-507c-4357-881b-3a7c74d3925b" xlink:to="loc_arvn_ExpansionOfDevelopmentProgramsMember_173485b3-7254-489b-b7ea-7accb713b557" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RemovalOfCombinationTrialsMember_019c2373-086e-7771-9d22-641c7df2442d" xlink:href="arvn-20251231.xsd#arvn_RemovalOfCombinationTrialsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d9097981-507c-4357-881b-3a7c74d3925b" xlink:to="loc_arvn_RemovalOfCombinationTrialsMember_019c2373-086e-7771-9d22-641c7df2442d" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019b30cb-f9bc-7c7b-83d5-860a6ddc82f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019b30cb-f9bc-7c7b-83d5-860a6ddc82f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RevenueRemainingPerformanceObligationContingentPayments_019b30cb-f9bc-7ccc-b23f-e53bcac527ca" xlink:href="arvn-20251231.xsd#arvn_RevenueRemainingPerformanceObligationContingentPayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_arvn_RevenueRemainingPerformanceObligationContingentPayments_019b30cb-f9bc-7ccc-b23f-e53bcac527ca" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b30cc-2f26-7786-b8c6-fc81a2e2f359" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b30cc-2f26-7786-b8c6-fc81a2e2f359" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_019b30cc-2f26-75d1-8e97-1f0770b7728d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_019b30cc-2f26-75d1-8e97-1f0770b7728d" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_019b30cc-2f26-705e-ac84-b80b58d1d66c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_CapitalizedContractCostGross_019b30cc-2f26-705e-ac84-b80b58d1d66c" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_019b30cc-6102-7549-b54d-b55ff6c57790" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_019b30cc-6102-7549-b54d-b55ff6c57790" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019b30cc-902f-7648-b720-4ebba6b8b5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019b30cc-902f-7648-b720-4ebba6b8b5f7" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_019b30cc-902f-74fa-a407-2883a4d2ad5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_019b30cc-902f-74fa-a407-2883a4d2ad5d" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019b30cc-902f-7c2a-9c8c-3c7148f4b5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019b30cc-902f-7c2a-9c8c-3c7148f4b5a4" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForBrokerageFees_019b30cc-902f-72b3-b81e-cc50e4149e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForBrokerageFees"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_PaymentsForBrokerageFees_019b30cc-902f-72b3-b81e-cc50e4149e6b" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SaleOfStockFairValueOfSharesSold_019b30cc-c965-7907-8657-f03f715f21a9" xlink:href="arvn-20251231.xsd#arvn_SaleOfStockFairValueOfSharesSold"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_arvn_SaleOfStockFairValueOfSharesSold_019b30cc-c965-7907-8657-f03f715f21a9" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_019b30cc-c965-775f-b7fb-b3e2803aa089" xlink:href="arvn-20251231.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_019b30cc-c965-775f-b7fb-b3e2803aa089" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_019b30cc-c965-751f-8d6a-95d1a795c4e1" xlink:href="arvn-20251231.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_019b30cc-c965-751f-8d6a-95d1a795c4e1" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_019b30cc-f73d-7fb3-99f4-558cf7d96c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_ProceedsFromCollaborators_019b30cc-f73d-7fb3-99f4-558cf7d96c0e" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019b30cd-8e55-7735-b13f-7698b2f56bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_Revenues_019b30cd-8e55-7735-b13f-7698b2f56bc5" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019c2373-086e-7f61-a65a-dd9a4b52ddb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_OperatingExpenses_019c2373-086e-7f61-a65a-dd9a4b52ddb5" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019b30cd-8e55-7ebf-b16c-2b2bd790aee9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_NetIncomeLoss_019b30cd-8e55-7ebf-b16c-2b2bd790aee9" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019b30cd-8e55-7c30-8fdd-03fd3f29c448" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_EarningsPerShareBasic_019b30cd-8e55-7c30-8fdd-03fd3f29c448" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019b30cd-8e55-7a08-b021-91c34fc080dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019b30cd-8e55-7a08-b021-91c34fc080dc" xlink:type="arc" order="18"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1d5338f0-c73a-4aeb-82de-f03dc3d1528b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ad08dae6-3378-4a14-a835-8acde4263d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1d5338f0-c73a-4aeb-82de-f03dc3d1528b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ad08dae6-3378-4a14-a835-8acde4263d3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_14857f1f-122e-4176-afbb-8086060cbf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ad08dae6-3378-4a14-a835-8acde4263d3a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_14857f1f-122e-4176-afbb-8086060cbf7f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d2d09636-b7ca-4462-b0cf-c52171db51a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1d5338f0-c73a-4aeb-82de-f03dc3d1528b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d2d09636-b7ca-4462-b0cf-c52171db51a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f3ad7b6d-fcad-4dca-8f0a-2ae5c20b9d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1d5338f0-c73a-4aeb-82de-f03dc3d1528b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f3ad7b6d-fcad-4dca-8f0a-2ae5c20b9d3c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="simple" xlink:href="arvn-20251231.xsd#ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails_1"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails_1" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1d5338f0-c73a-4aeb-82de-f03dc3d1528b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ad08dae6-3378-4a14-a835-8acde4263d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1d5338f0-c73a-4aeb-82de-f03dc3d1528b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ad08dae6-3378-4a14-a835-8acde4263d3a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d2d09636-b7ca-4462-b0cf-c52171db51a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1d5338f0-c73a-4aeb-82de-f03dc3d1528b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d2d09636-b7ca-4462-b0cf-c52171db51a3" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f3ad7b6d-fcad-4dca-8f0a-2ae5c20b9d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1d5338f0-c73a-4aeb-82de-f03dc3d1528b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f3ad7b6d-fcad-4dca-8f0a-2ae5c20b9d3c" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#MarketableSecuritiesandFairValueMeasurementsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_952caf71-36bb-4971-90bf-5a0568acfb24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67e0f8f1-892c-439f-ac7d-057d774e740e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_952caf71-36bb-4971-90bf-5a0568acfb24" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67e0f8f1-892c-439f-ac7d-057d774e740e" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb14d1fd-d7d7-45a5-b8e6-a098d2d2e653" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67e0f8f1-892c-439f-ac7d-057d774e740e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb14d1fd-d7d7-45a5-b8e6-a098d2d2e653" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bb14d1fd-d7d7-45a5-b8e6-a098d2d2e653_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb14d1fd-d7d7-45a5-b8e6-a098d2d2e653" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_bb14d1fd-d7d7-45a5-b8e6-a098d2d2e653_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_edfc9666-b3dd-4ff3-ba98-8a04a2bb1319" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb14d1fd-d7d7-45a5-b8e6-a098d2d2e653" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_edfc9666-b3dd-4ff3-ba98-8a04a2bb1319" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1cf4f472-35d1-4789-af76-0340e37f0e61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_edfc9666-b3dd-4ff3-ba98-8a04a2bb1319" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1cf4f472-35d1-4789-af76-0340e37f0e61" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7982b4d1-3137-4253-85f6-14d53f331760" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67e0f8f1-892c-439f-ac7d-057d774e740e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7982b4d1-3137-4253-85f6-14d53f331760" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_7982b4d1-3137-4253-85f6-14d53f331760_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7982b4d1-3137-4253-85f6-14d53f331760" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_7982b4d1-3137-4253-85f6-14d53f331760_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_66b09fc8-8cfb-4cff-be91-b0b3048aab58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7982b4d1-3137-4253-85f6-14d53f331760" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_66b09fc8-8cfb-4cff-be91-b0b3048aab58" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4ee9857a-2c7c-4a95-a9a6-9d64c7a228f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_66b09fc8-8cfb-4cff-be91-b0b3048aab58" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4ee9857a-2c7c-4a95-a9a6-9d64c7a228f8" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f8f60448-ffdc-49ab-9050-41fa22e2b206" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67e0f8f1-892c-439f-ac7d-057d774e740e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f8f60448-ffdc-49ab-9050-41fa22e2b206" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f8f60448-ffdc-49ab-9050-41fa22e2b206_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f8f60448-ffdc-49ab-9050-41fa22e2b206" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_f8f60448-ffdc-49ab-9050-41fa22e2b206_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06c57444-a0b0-4906-bb54-d1ab1e943b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f8f60448-ffdc-49ab-9050-41fa22e2b206" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06c57444-a0b0-4906-bb54-d1ab1e943b7b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_c7faf820-a654-411a-952f-6c893aa68821" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06c57444-a0b0-4906-bb54-d1ab1e943b7b" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_c7faf820-a654-411a-952f-6c893aa68821" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_e19623f2-8e76-4a7c-b620-2e40860f0118" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06c57444-a0b0-4906-bb54-d1ab1e943b7b" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_e19623f2-8e76-4a7c-b620-2e40860f0118" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_39ee6781-c4c8-4f81-99fc-900edeb4a7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_952caf71-36bb-4971-90bf-5a0568acfb24" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_39ee6781-c4c8-4f81-99fc-900edeb4a7c1" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b7fd15b7-fa90-4710-b5c8-2353732d1317" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_952caf71-36bb-4971-90bf-5a0568acfb24" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b7fd15b7-fa90-4710-b5c8-2353732d1317" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d6a8c04f-60b4-47b0-bbbc-3ba6d85ab99b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_952caf71-36bb-4971-90bf-5a0568acfb24" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d6a8c04f-60b4-47b0-bbbc-3ba6d85ab99b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fbe7f9e9-7a69-499b-b155-92e05a7f5d79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_952caf71-36bb-4971-90bf-5a0568acfb24" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fbe7f9e9-7a69-499b-b155-92e05a7f5d79" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f63c2d06-c4a4-4f1c-96ab-fa5691311b77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61dea112-2232-4fe5-a69a-bf9851c422e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f63c2d06-c4a4-4f1c-96ab-fa5691311b77" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61dea112-2232-4fe5-a69a-bf9851c422e3" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deb8eeca-7045-4de5-bb33-42735d4cecb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61dea112-2232-4fe5-a69a-bf9851c422e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deb8eeca-7045-4de5-bb33-42735d4cecb4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_deb8eeca-7045-4de5-bb33-42735d4cecb4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deb8eeca-7045-4de5-bb33-42735d4cecb4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_deb8eeca-7045-4de5-bb33-42735d4cecb4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cda5ae8-57fe-4231-a128-056aafb04466" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deb8eeca-7045-4de5-bb33-42735d4cecb4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cda5ae8-57fe-4231-a128-056aafb04466" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_b228e387-fb14-44db-9982-1da6d7a62e4e" xlink:href="arvn-20251231.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cda5ae8-57fe-4231-a128-056aafb04466" xlink:to="loc_arvn_LaboratoryEquipmentMember_b228e387-fb14-44db-9982-1da6d7a62e4e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_738a62c5-08a2-461d-8bfa-44ab7920db98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cda5ae8-57fe-4231-a128-056aafb04466" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_738a62c5-08a2-461d-8bfa-44ab7920db98" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_cd42c80e-c137-49ba-b4e8-651eeb11ba13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cda5ae8-57fe-4231-a128-056aafb04466" xlink:to="loc_us-gaap_OfficeEquipmentMember_cd42c80e-c137-49ba-b4e8-651eeb11ba13" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_691788e4-aac1-4c27-8d71-edf020a97d53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f63c2d06-c4a4-4f1c-96ab-fa5691311b77" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_691788e4-aac1-4c27-8d71-edf020a97d53" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0ba9d92f-0568-4a89-8d86-11b13ad3de22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f63c2d06-c4a4-4f1c-96ab-fa5691311b77" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0ba9d92f-0568-4a89-8d86-11b13ad3de22" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8e6891c7-7dc2-48dd-8a60-4d3359c70654" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f63c2d06-c4a4-4f1c-96ab-fa5691311b77" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8e6891c7-7dc2-48dd-8a60-4d3359c70654" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00d9d8f9-66c6-4143-84b6-2643b3c7c5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943dca39-c534-4fbc-b181-464f718d2e54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00d9d8f9-66c6-4143-84b6-2643b3c7c5a1" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943dca39-c534-4fbc-b181-464f718d2e54" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4b45749d-398f-459c-af6b-ce5d43a25e34" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943dca39-c534-4fbc-b181-464f718d2e54" xlink:to="loc_srt_CounterpartyNameAxis_4b45749d-398f-459c-af6b-ce5d43a25e34" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b45749d-398f-459c-af6b-ce5d43a25e34_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4b45749d-398f-459c-af6b-ce5d43a25e34" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4b45749d-398f-459c-af6b-ce5d43a25e34_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a479c476-14b0-4a5b-9f79-131201e98d8e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4b45749d-398f-459c-af6b-ce5d43a25e34" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a479c476-14b0-4a5b-9f79-131201e98d8e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_A101CollegeStreetLLCMember_9b6bf3e1-eae8-4282-a8e8-009caceb4050" xlink:href="arvn-20251231.xsd#arvn_A101CollegeStreetLLCMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a479c476-14b0-4a5b-9f79-131201e98d8e" xlink:to="loc_arvn_A101CollegeStreetLLCMember_9b6bf3e1-eae8-4282-a8e8-009caceb4050" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ab0028f1-d131-4084-ab00-acc1e38a1953" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943dca39-c534-4fbc-b181-464f718d2e54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ab0028f1-d131-4084-ab00-acc1e38a1953" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab0028f1-d131-4084-ab00-acc1e38a1953_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ab0028f1-d131-4084-ab00-acc1e38a1953" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_ab0028f1-d131-4084-ab00-acc1e38a1953_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e170c0e-47c8-4284-a1cf-5715c6bad648" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ab0028f1-d131-4084-ab00-acc1e38a1953" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e170c0e-47c8-4284-a1cf-5715c6bad648" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4b49e290-4be2-450e-a78d-bbf608f958a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e170c0e-47c8-4284-a1cf-5715c6bad648" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4b49e290-4be2-450e-a78d-bbf608f958a7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_019c4685-74dd-7733-8330-c3080d2bc3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00d9d8f9-66c6-4143-84b6-2643b3c7c5a1" xlink:to="loc_us-gaap_DepreciationAndAmortization_019c4685-74dd-7733-8330-c3080d2bc3cc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PropertyPlantAndEquipmentWriteoff_0a63d23f-2b2b-466b-bb7b-905f503b55e4" xlink:href="arvn-20251231.xsd#arvn_PropertyPlantAndEquipmentWriteoff"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00d9d8f9-66c6-4143-84b6-2643b3c7c5a1" xlink:to="loc_arvn_PropertyPlantAndEquipmentWriteoff_0a63d23f-2b2b-466b-bb7b-905f503b55e4" xlink:type="arc" order="1"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#RightofUseAssetsandLiabilitiesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9e7d959f-262e-48e2-b770-c823be139b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9e7d959f-262e-48e2-b770-c823be139b0a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractTerminationAxis_5b3e4602-989e-4327-a7ab-2cb9ad955993" xlink:href="arvn-20251231.xsd#arvn_ContractTerminationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e7d959f-262e-48e2-b770-c823be139b0a" xlink:to="loc_arvn_ContractTerminationAxis_5b3e4602-989e-4327-a7ab-2cb9ad955993" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractTerminationDomain_5b3e4602-989e-4327-a7ab-2cb9ad955993_default" xlink:href="arvn-20251231.xsd#arvn_ContractTerminationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_arvn_ContractTerminationAxis_5b3e4602-989e-4327-a7ab-2cb9ad955993" xlink:to="loc_arvn_ContractTerminationDomain_5b3e4602-989e-4327-a7ab-2cb9ad955993_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractTerminationDomain_c58ac74a-cc30-4430-bbb0-27b5775b72d6" xlink:href="arvn-20251231.xsd#arvn_ContractTerminationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_arvn_ContractTerminationAxis_5b3e4602-989e-4327-a7ab-2cb9ad955993" xlink:to="loc_arvn_ContractTerminationDomain_c58ac74a-cc30-4430-bbb0-27b5775b72d6" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OneTimeCashTerminationFeeMember_75c3d5b6-baed-4ddb-a04c-9a3372c7b542" xlink:href="arvn-20251231.xsd#arvn_OneTimeCashTerminationFeeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ContractTerminationDomain_c58ac74a-cc30-4430-bbb0-27b5775b72d6" xlink:to="loc_arvn_OneTimeCashTerminationFeeMember_75c3d5b6-baed-4ddb-a04c-9a3372c7b542" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_WriteoffOfPrepaidRentMember_8ec40d64-9704-4697-9e39-45fc28cd7f0f" xlink:href="arvn-20251231.xsd#arvn_WriteoffOfPrepaidRentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_ContractTerminationDomain_c58ac74a-cc30-4430-bbb0-27b5775b72d6" xlink:to="loc_arvn_WriteoffOfPrepaidRentMember_8ec40d64-9704-4697-9e39-45fc28cd7f0f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusAxis_ee56c486-bc71-48c7-bd95-bd61d3b33709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgedStatusAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e7d959f-262e-48e2-b770-c823be139b0a" xlink:to="loc_us-gaap_PledgedStatusAxis_ee56c486-bc71-48c7-bd95-bd61d3b33709" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusDomain_ee56c486-bc71-48c7-bd95-bd61d3b33709_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgedStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PledgedStatusAxis_ee56c486-bc71-48c7-bd95-bd61d3b33709" xlink:to="loc_us-gaap_PledgedStatusDomain_ee56c486-bc71-48c7-bd95-bd61d3b33709_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusDomain_d08c31a9-22ec-4572-9c50-ed811654a546" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgedStatusDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PledgedStatusAxis_ee56c486-bc71-48c7-bd95-bd61d3b33709" xlink:to="loc_us-gaap_PledgedStatusDomain_d08c31a9-22ec-4572-9c50-ed811654a546" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetPledgedAsCollateralMember_1b9eff82-bd61-4db0-b5e9-a34dc0d39819" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetPledgedAsCollateralMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PledgedStatusDomain_d08c31a9-22ec-4572-9c50-ed811654a546" xlink:to="loc_us-gaap_AssetPledgedAsCollateralMember_1b9eff82-bd61-4db0-b5e9-a34dc0d39819" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeAxis_d4642c2f-cdb1-4e51-b537-09e2b12ef04c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e7d959f-262e-48e2-b770-c823be139b0a" xlink:to="loc_us-gaap_PledgingPurposeAxis_d4642c2f-cdb1-4e51-b537-09e2b12ef04c" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeDomain_d4642c2f-cdb1-4e51-b537-09e2b12ef04c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PledgingPurposeAxis_d4642c2f-cdb1-4e51-b537-09e2b12ef04c" xlink:to="loc_us-gaap_PledgingPurposeDomain_d4642c2f-cdb1-4e51-b537-09e2b12ef04c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeDomain_9948218a-0456-46bb-b8b0-1bc1141fb484" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PledgingPurposeAxis_d4642c2f-cdb1-4e51-b537-09e2b12ef04c" xlink:to="loc_us-gaap_PledgingPurposeDomain_9948218a-0456-46bb-b8b0-1bc1141fb484" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_c1bbe2d5-3d07-4684-91a9-ae7e04812f86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PledgingPurposeDomain_9948218a-0456-46bb-b8b0-1bc1141fb484" xlink:to="loc_us-gaap_LetterOfCreditMember_c1bbe2d5-3d07-4684-91a9-ae7e04812f86" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a6cb6ee2-3c40-4bfd-ab04-2622ad0a1198" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e7d959f-262e-48e2-b770-c823be139b0a" xlink:to="loc_srt_RangeAxis_a6cb6ee2-3c40-4bfd-ab04-2622ad0a1198" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_a6cb6ee2-3c40-4bfd-ab04-2622ad0a1198_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_a6cb6ee2-3c40-4bfd-ab04-2622ad0a1198" xlink:to="loc_srt_RangeMember_a6cb6ee2-3c40-4bfd-ab04-2622ad0a1198_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56d9e0c6-431d-4c44-9fc0-0565909c55bb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_a6cb6ee2-3c40-4bfd-ab04-2622ad0a1198" xlink:to="loc_srt_RangeMember_56d9e0c6-431d-4c44-9fc0-0565909c55bb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_955a245f-3faf-42bf-b89b-691579604d17" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56d9e0c6-431d-4c44-9fc0-0565909c55bb" xlink:to="loc_srt_MinimumMember_955a245f-3faf-42bf-b89b-691579604d17" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee4ec83a-86c0-4325-903c-b2165a53556b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_56d9e0c6-431d-4c44-9fc0-0565909c55bb" xlink:to="loc_srt_MaximumMember_ee4ec83a-86c0-4325-903c-b2165a53556b" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_d57e4751-f133-4747-a25f-07dc1f972dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_d57e4751-f133-4747-a25f-07dc1f972dae" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_827ae165-1709-46e1-b886-bce802fabae7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:to="loc_us-gaap_GainLossOnContractTermination_827ae165-1709-46e1-b886-bce802fabae7" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecurities_6ace69f8-4c8d-4ea8-84c8-d982b2b703f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecurities"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:to="loc_us-gaap_DebtSecurities_6ace69f8-4c8d-4ea8-84c8-d982b2b703f4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_81f4eaee-a59a-482d-ae6d-82b77e405ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_81f4eaee-a59a-482d-ae6d-82b77e405ddc" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bc3495d4-cdc3-4595-9728-cce7a4ff18fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bc3495d4-cdc3-4595-9728-cce7a4ff18fb" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c56265d5-185c-4818-9d94-f7191837a710" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:to="loc_us-gaap_OperatingLeaseCost_c56265d5-185c-4818-9d94-f7191837a710" xlink:type="arc" order="5"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b2382231-3391-4b7b-a5d4-e6053415dc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:to="loc_us-gaap_DebtInstrumentTable_b2382231-3391-4b7b-a5d4-e6053415dc9d" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_50a0b34b-e1c2-4300-b4c7-a02d7d2b5e64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b2382231-3391-4b7b-a5d4-e6053415dc9d" xlink:to="loc_us-gaap_DebtInstrumentAxis_50a0b34b-e1c2-4300-b4c7-a02d7d2b5e64" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_50a0b34b-e1c2-4300-b4c7-a02d7d2b5e64_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_DebtInstrumentAxis_50a0b34b-e1c2-4300-b4c7-a02d7d2b5e64" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_50a0b34b-e1c2-4300-b4c7-a02d7d2b5e64_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b6566896-20a6-419f-9fd7-3c8a9e6a887c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_DebtInstrumentAxis_50a0b34b-e1c2-4300-b4c7-a02d7d2b5e64" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b6566896-20a6-419f-9fd7-3c8a9e6a887c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_b5ce70d4-ac95-45bd-b15f-b61c442dfc38" xlink:href="arvn-20251231.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b6566896-20a6-419f-9fd7-3c8a9e6a887c" xlink:to="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_b5ce70d4-ac95-45bd-b15f-b61c442dfc38" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5d1449ef-13dd-4935-847c-ae63fbf89b11" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_DebtInstrumentTable_b2382231-3391-4b7b-a5d4-e6053415dc9d" xlink:to="loc_srt_StatementGeographicalAxis_5d1449ef-13dd-4935-847c-ae63fbf89b11" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_5d1449ef-13dd-4935-847c-ae63fbf89b11_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_StatementGeographicalAxis_5d1449ef-13dd-4935-847c-ae63fbf89b11" xlink:to="loc_srt_SegmentGeographicalDomain_5d1449ef-13dd-4935-847c-ae63fbf89b11_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_66c5708c-5641-4206-a140-13b54a352273" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_StatementGeographicalAxis_5d1449ef-13dd-4935-847c-ae63fbf89b11" xlink:to="loc_srt_SegmentGeographicalDomain_66c5708c-5641-4206-a140-13b54a352273" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_75f17150-3aad-42b9-bf8d-a39fc17ca805" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CT"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_SegmentGeographicalDomain_66c5708c-5641-4206-a140-13b54a352273" xlink:to="loc_stpr_CT_75f17150-3aad-42b9-bf8d-a39fc17ca805" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6e335476-498f-446d-8405-a8c132fcd7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6e335476-498f-446d-8405-a8c132fcd7bc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness_677e52a8-6f05-4ec0-86f0-88537a9eb996" xlink:href="arvn-20251231.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:to="loc_arvn_DebtInstrumentLoanForgiveness_677e52a8-6f05-4ec0-86f0-88537a9eb996" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ba52ced7-a6d5-44ab-bfe9-cb54289b071f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ba52ced7-a6d5-44ab-bfe9-cb54289b071f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm_41c4fa8e-c49e-4f87-85b4-2358f3adc628" xlink:href="arvn-20251231.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:to="loc_arvn_DebtInstrumentInterestPaymentsTerm_41c4fa8e-c49e-4f87-85b4-2358f3adc628" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages_a00742dd-2db8-449d-85ae-dd77cc5b6d42" xlink:href="arvn-20251231.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:to="loc_arvn_PercentageOfLiquidatedDamages_a00742dd-2db8-449d-85ae-dd77cc5b6d42" xlink:type="arc" order="4"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#EquityAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1b96cfa3-8652-4c1e-81eb-640c2a790c27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1b96cfa3-8652-4c1e-81eb-640c2a790c27" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_1b96cfa3-8652-4c1e-81eb-640c2a790c27_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1b96cfa3-8652-4c1e-81eb-640c2a790c27" xlink:to="loc_us-gaap_EquityComponentDomain_1b96cfa3-8652-4c1e-81eb-640c2a790c27_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_afcee1e8-2174-4ad5-8453-47ec57a1e491" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1b96cfa3-8652-4c1e-81eb-640c2a790c27" xlink:to="loc_us-gaap_EquityComponentDomain_afcee1e8-2174-4ad5-8453-47ec57a1e491" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3640cc71-3b50-43cc-9410-5772a03571be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_EquityComponentDomain_afcee1e8-2174-4ad5-8453-47ec57a1e491" xlink:to="loc_us-gaap_CommonStockMember_3640cc71-3b50-43cc-9410-5772a03571be" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_77463358-1847-4635-8e39-775a8d2f005f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_77463358-1847-4635-8e39-775a8d2f005f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_77463358-1847-4635-8e39-775a8d2f005f_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77463358-1847-4635-8e39-775a8d2f005f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_77463358-1847-4635-8e39-775a8d2f005f_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b6ffb21-b8aa-46fd-ad90-1878ffc5b860" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77463358-1847-4635-8e39-775a8d2f005f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b6ffb21-b8aa-46fd-ad90-1878ffc5b860" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_fbb0c789-0054-4188-9a5b-a4e1eb9b3a41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b6ffb21-b8aa-46fd-ad90-1878ffc5b860" xlink:to="loc_us-gaap_PrivatePlacementMember_fbb0c789-0054-4188-9a5b-a4e1eb9b3a41" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_019b3121-af2f-77f4-b623-40169b5b4af5" xlink:href="arvn-20251231.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b6ffb21-b8aa-46fd-ad90-1878ffc5b860" xlink:to="loc_arvn_AtTheMarketOfferingMember_019b3121-af2f-77f4-b623-40169b5b4af5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_83445903-ff48-47d9-9aa1-92604826b154" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_83445903-ff48-47d9-9aa1-92604826b154" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_83445903-ff48-47d9-9aa1-92604826b154_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_83445903-ff48-47d9-9aa1-92604826b154" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_83445903-ff48-47d9-9aa1-92604826b154_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_be87100a-f31b-407f-968b-7a42fa0b0a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_83445903-ff48-47d9-9aa1-92604826b154" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_be87100a-f31b-407f-968b-7a42fa0b0a2e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PreFundedWarrantMember_390e57d7-e378-4b66-b734-283c55db1245" xlink:href="arvn-20251231.xsd#arvn_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_be87100a-f31b-407f-968b-7a42fa0b0a2e" xlink:to="loc_arvn_PreFundedWarrantMember_390e57d7-e378-4b66-b734-283c55db1245" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4598c1cb-e02b-49b6-aa73-e165429c8a3b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_srt_CounterpartyNameAxis_4598c1cb-e02b-49b6-aa73-e165429c8a3b" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4598c1cb-e02b-49b6-aa73-e165429c8a3b_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_4598c1cb-e02b-49b6-aa73-e165429c8a3b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_4598c1cb-e02b-49b6-aa73-e165429c8a3b_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a0cf858-0f4c-47c7-8e92-a31dafffe246" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_4598c1cb-e02b-49b6-aa73-e165429c8a3b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a0cf858-0f4c-47c7-8e92-a31dafffe246" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerAndCantorMember_c52bb586-4501-4795-8c4b-16d23effecbc" xlink:href="arvn-20251231.xsd#arvn_PiperSandlerAndCantorMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a0cf858-0f4c-47c7-8e92-a31dafffe246" xlink:to="loc_arvn_PiperSandlerAndCantorMember_c52bb586-4501-4795-8c4b-16d23effecbc" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_29bbbf31-9e36-4495-a6fe-0be9f2a7c748" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_us-gaap_TypeOfArrangementAxis_29bbbf31-9e36-4495-a6fe-0be9f2a7c748" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_29bbbf31-9e36-4495-a6fe-0be9f2a7c748_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_29bbbf31-9e36-4495-a6fe-0be9f2a7c748" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_29bbbf31-9e36-4495-a6fe-0be9f2a7c748_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a1ed2e1-e9e5-4850-95bc-df2bbd06d3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_29bbbf31-9e36-4495-a6fe-0be9f2a7c748" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a1ed2e1-e9e5-4850-95bc-df2bbd06d3e1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember_ecb14f6c-6aba-482f-9c22-0ed25dc812f7" xlink:href="arvn-20251231.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a1ed2e1-e9e5-4850-95bc-df2bbd06d3e1" xlink:to="loc_arvn_EquityDistributionAgreementMember_ecb14f6c-6aba-482f-9c22-0ed25dc812f7" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_32dcfbca-5a55-47d0-b3bf-a289254d895e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_us-gaap_AwardTypeAxis_32dcfbca-5a55-47d0-b3bf-a289254d895e" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32dcfbca-5a55-47d0-b3bf-a289254d895e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_32dcfbca-5a55-47d0-b3bf-a289254d895e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_32dcfbca-5a55-47d0-b3bf-a289254d895e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c921de5-ab56-40cd-a1c8-0d0c9021ab53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_32dcfbca-5a55-47d0-b3bf-a289254d895e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c921de5-ab56-40cd-a1c8-0d0c9021ab53" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_fbe483d3-39ec-4b17-b849-677df8e1ef8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c921de5-ab56-40cd-a1c8-0d0c9021ab53" xlink:to="loc_us-gaap_EmployeeStockMember_fbe483d3-39ec-4b17-b849-677df8e1ef8d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5732020a-0dbd-43ab-bd38-8a5fe08a481d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c921de5-ab56-40cd-a1c8-0d0c9021ab53" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5732020a-0dbd-43ab-bd38-8a5fe08a481d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0899721e-d9c5-4d27-af55-359d16390e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_us-gaap_PlanNameAxis_0899721e-d9c5-4d27-af55-359d16390e3e" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_0899721e-d9c5-4d27-af55-359d16390e3e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_0899721e-d9c5-4d27-af55-359d16390e3e" xlink:to="loc_us-gaap_PlanNameDomain_0899721e-d9c5-4d27-af55-359d16390e3e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_469b0116-40da-47e9-8082-4f26491a1e57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_0899721e-d9c5-4d27-af55-359d16390e3e" xlink:to="loc_us-gaap_PlanNameDomain_469b0116-40da-47e9-8082-4f26491a1e57" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_7db80dbf-b5d6-4e73-96be-4d03d4bef4a4" xlink:href="arvn-20251231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_469b0116-40da-47e9-8082-4f26491a1e57" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_7db80dbf-b5d6-4e73-96be-4d03d4bef4a4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_641076c9-88ce-4de3-8ffd-5894683bccd1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_srt_RangeAxis_641076c9-88ce-4de3-8ffd-5894683bccd1" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_641076c9-88ce-4de3-8ffd-5894683bccd1_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_641076c9-88ce-4de3-8ffd-5894683bccd1" xlink:to="loc_srt_RangeMember_641076c9-88ce-4de3-8ffd-5894683bccd1_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20062d62-f550-4361-b1f8-47b1eab0fbb8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_641076c9-88ce-4de3-8ffd-5894683bccd1" xlink:to="loc_srt_RangeMember_20062d62-f550-4361-b1f8-47b1eab0fbb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a97e4cab-5744-4eeb-88d5-4f1727a28488" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_20062d62-f550-4361-b1f8-47b1eab0fbb8" xlink:to="loc_srt_MaximumMember_a97e4cab-5744-4eeb-88d5-4f1727a28488" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5e7368bf-6297-485c-a46f-ee0a87c546ab" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_20062d62-f550-4361-b1f8-47b1eab0fbb8" xlink:to="loc_srt_MinimumMember_5e7368bf-6297-485c-a46f-ee0a87c546ab" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_cac6a0ff-f263-47e7-b97e-58d27aa92a89" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_20062d62-f550-4361-b1f8-47b1eab0fbb8" xlink:to="loc_srt_WeightedAverageMember_cac6a0ff-f263-47e7-b97e-58d27aa92a89" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9c23fa2f-a80b-42a6-9bd3-130a65452647" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9c23fa2f-a80b-42a6-9bd3-130a65452647" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ad3e2245-a027-4842-84ae-b8e7726eec41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ad3e2245-a027-4842-84ae-b8e7726eec41" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8c02bd04-46a9-464a-bd01-a1b3d760f81c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8c02bd04-46a9-464a-bd01-a1b3d760f81c" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7b9ed1b7-7807-42b2-8a48-09b577965949" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7b9ed1b7-7807-42b2-8a48-09b577965949" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfVotesPerCommonStockShareHeld_0f02c0c9-c931-4494-b4c2-32de90e748f5" xlink:href="arvn-20251231.xsd#arvn_NumberOfVotesPerCommonStockShareHeld"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_NumberOfVotesPerCommonStockShareHeld_0f02c0c9-c931-4494-b4c2-32de90e748f5" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47613cf7-710e-4be6-b862-ee5ac1387ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47613cf7-710e-4be6-b862-ee5ac1387ab7" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_16ce6b6c-2a09-4d9b-aaa9-2702b76b2f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_16ce6b6c-2a09-4d9b-aaa9-2702b76b2f1c" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_aab405d6-98b2-4b0e-920d-46777b7875fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_aab405d6-98b2-4b0e-920d-46777b7875fc" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aec1d360-db0d-45b4-9bc4-cb2427864d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aec1d360-db0d-45b4-9bc4-cb2427864d3e" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants_1512dcd9-06fc-4702-80ae-70bbca23825f" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants_1512dcd9-06fc-4702-80ae-70bbca23825f" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4af634a4-5e52-475a-8779-014c7280cae8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4af634a4-5e52-475a-8779-014c7280cae8" xlink:type="arc" order="10"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_019c235b-ff93-753b-8cac-c838f06a0701" xlink:href="arvn-20251231.xsd#arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_019c235b-ff93-753b-8cac-c838f06a0701" xlink:type="arc" order="11"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019c235b-4dbb-7384-9636-ad03f86783b2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019c235b-4dbb-7384-9636-ad03f86783b2" xlink:type="arc" order="12"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019c7cac-35a9-79e5-b6f8-4c96d04eb568" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019c7cac-35a9-79e5-b6f8-4c96d04eb568" xlink:type="arc" order="13"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_019c235b-4dbb-7e32-bd87-875dffc3da0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_019c235b-4dbb-7e32-bd87-875dffc3da0f" xlink:type="arc" order="14"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions_019c235b-4dbb-7ad1-ab33-11ac8ae5f415" xlink:href="arvn-20251231.xsd#arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions_019c235b-4dbb-7ad1-ab33-11ac8ae5f415" xlink:type="arc" order="15"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareRepurchaseProgramCommissionsAndExciseTax_019c235b-4dbb-7645-9c38-9eaea8563406" xlink:href="arvn-20251231.xsd#arvn_ShareRepurchaseProgramCommissionsAndExciseTax"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_ShareRepurchaseProgramCommissionsAndExciseTax_019c235b-4dbb-7645-9c38-9eaea8563406" xlink:type="arc" order="16"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_019b3145-d39d-7f42-b8e2-4e0d11698e4d" xlink:href="arvn-20251231.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_019b3145-d39d-7f42-b8e2-4e0d11698e4d" xlink:type="arc" order="17"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6fc8526e-f763-41d7-b4bd-c7e88117e49a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6fc8526e-f763-41d7-b4bd-c7e88117e49a" xlink:type="arc" order="18"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f6a4c8a5-2697-4041-9d02-24eacfea1c83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f6a4c8a5-2697-4041-9d02-24eacfea1c83" xlink:type="arc" order="19"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_63169ebd-c99f-4a7c-84da-dce1684ce057" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_63169ebd-c99f-4a7c-84da-dce1684ce057" xlink:type="arc" order="20"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_2599dca9-2928-4560-a7ea-4d7c6d014cd2" xlink:href="arvn-20251231.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_2599dca9-2928-4560-a7ea-4d7c6d014cd2" xlink:type="arc" order="21"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3aec5a5e-6240-41f8-9a89-528702b90db9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3aec5a5e-6240-41f8-9a89-528702b90db9" xlink:type="arc" order="22"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f7a0cbe7-bb6e-41be-b9e2-b63ca1e65b88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f7a0cbe7-bb6e-41be-b9e2-b63ca1e65b88" xlink:type="arc" order="23"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_8b8aaf77-15b2-4583-b779-02c89c71e70a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_8b8aaf77-15b2-4583-b779-02c89c71e70a" xlink:type="arc" order="24"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_5464f7bc-5c63-4e13-9d98-6c602d826f49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_5464f7bc-5c63-4e13-9d98-6c602d826f49" xlink:type="arc" order="25"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_019c235a-2178-794f-abea-ac051e980b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_019c235a-2178-794f-abea-ac051e980b9a" xlink:type="arc" order="26"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc61a285-48ce-455e-aa87-2480daf34197" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc61a285-48ce-455e-aa87-2480daf34197" xlink:type="arc" order="27"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6ae59693-03ac-44a6-bbb8-3d9627fa88a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6ae59693-03ac-44a6-bbb8-3d9627fa88a5" xlink:type="arc" order="28"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_87e6a3e2-1d1e-4658-bb3c-66e70c6947af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_87e6a3e2-1d1e-4658-bb3c-66e70c6947af" xlink:type="arc" order="29"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_bfc6993b-5a35-4c9c-9d0a-f260f380df7d" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_bfc6993b-5a35-4c9c-9d0a-f260f380df7d" xlink:type="arc" order="30"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60c2fe50-8ef6-4c01-8e10-587ef521c1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60c2fe50-8ef6-4c01-8e10-587ef521c1ba" xlink:type="arc" order="31"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_77905ea7-365e-4d4a-bd65-9026b4bffe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_77905ea7-365e-4d4a-bd65-9026b4bffe2f" xlink:type="arc" order="32"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_b44f76be-f87c-4d82-ac6e-d540b9ddd4bf" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_b44f76be-f87c-4d82-ac6e-d540b9ddd4bf" xlink:type="arc" order="33"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_364f1186-2992-45a2-88a6-c0e2e958fe7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_364f1186-2992-45a2-88a6-c0e2e958fe7b" xlink:type="arc" order="34"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_34947d97-e6ea-40fe-93f4-06d6660f7a6c" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_34947d97-e6ea-40fe-93f4-06d6660f7a6c" xlink:type="arc" order="35"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_59f801af-b4bc-4002-b37b-71ae8a917bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_59f801af-b4bc-4002-b37b-71ae8a917bf7" xlink:type="arc" order="36"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29901eff-6e02-4101-8339-bb33b4be5b89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29901eff-6e02-4101-8339-bb33b4be5b89" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cec5b68b-7d28-4438-89a2-89ba41a84fff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29901eff-6e02-4101-8339-bb33b4be5b89" xlink:to="loc_us-gaap_AwardTypeAxis_cec5b68b-7d28-4438-89a2-89ba41a84fff" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cec5b68b-7d28-4438-89a2-89ba41a84fff_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_cec5b68b-7d28-4438-89a2-89ba41a84fff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_cec5b68b-7d28-4438-89a2-89ba41a84fff_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_885ddef5-e24e-4db3-a96f-4e6842608ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_cec5b68b-7d28-4438-89a2-89ba41a84fff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_885ddef5-e24e-4db3-a96f-4e6842608ebe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ec4202e3-9274-4f0b-b4cf-fb694a9645a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_885ddef5-e24e-4db3-a96f-4e6842608ebe" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ec4202e3-9274-4f0b-b4cf-fb694a9645a0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ded8e77b-eaf3-4332-b9ca-5c920d14f006" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29901eff-6e02-4101-8339-bb33b4be5b89" xlink:to="loc_srt_RangeAxis_ded8e77b-eaf3-4332-b9ca-5c920d14f006" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ded8e77b-eaf3-4332-b9ca-5c920d14f006_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_ded8e77b-eaf3-4332-b9ca-5c920d14f006" xlink:to="loc_srt_RangeMember_ded8e77b-eaf3-4332-b9ca-5c920d14f006_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4289795f-7f89-4d46-91c6-86831a815a4e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_ded8e77b-eaf3-4332-b9ca-5c920d14f006" xlink:to="loc_srt_RangeMember_4289795f-7f89-4d46-91c6-86831a815a4e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_01aa7f4b-553b-473c-ab83-4526876828ab" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4289795f-7f89-4d46-91c6-86831a815a4e" xlink:to="loc_srt_MinimumMember_01aa7f4b-553b-473c-ab83-4526876828ab" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ae7a0ad0-ff33-4bef-a03f-4e951525a702" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_4289795f-7f89-4d46-91c6-86831a815a4e" xlink:to="loc_srt_MaximumMember_ae7a0ad0-ff33-4bef-a03f-4e951525a702" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_197edb91-99c1-4fcb-9fd3-a6993389d521" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_197edb91-99c1-4fcb-9fd3-a6993389d521" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_8cb9c944-39d6-4fa0-bbf3-7eeb994d75b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_8cb9c944-39d6-4fa0-bbf3-7eeb994d75b8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c5252675-1de6-47d4-bb2b-8e84dc05328e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c5252675-1de6-47d4-bb2b-8e84dc05328e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6c0da7cb-c4ba-4d54-88a6-08af06959ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6c0da7cb-c4ba-4d54-88a6-08af06959ed8" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8d2b0df2-7141-4215-9d24-95a0155d6d74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8d2b0df2-7141-4215-9d24-95a0155d6d74" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a58503f5-df75-4290-9e8f-bc45d4c0b1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a58503f5-df75-4290-9e8f-bc45d4c0b1c6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_bc92d4cf-d6fe-433b-93cb-ecbbf3ab3e51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_bc92d4cf-d6fe-433b-93cb-ecbbf3ab3e51" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#EquityScheduleofStockOptionActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c1677f3-fb2a-4d49-bf86-becd316c50a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c1677f3-fb2a-4d49-bf86-becd316c50a9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c634823f-5b65-4d4b-8e12-953416c888b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c1677f3-fb2a-4d49-bf86-becd316c50a9" xlink:to="loc_us-gaap_PlanNameAxis_c634823f-5b65-4d4b-8e12-953416c888b3" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_c634823f-5b65-4d4b-8e12-953416c888b3_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_c634823f-5b65-4d4b-8e12-953416c888b3" xlink:to="loc_us-gaap_PlanNameDomain_c634823f-5b65-4d4b-8e12-953416c888b3_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d254102e-1bfa-49e5-a77f-9343ae6fa3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_c634823f-5b65-4d4b-8e12-953416c888b3" xlink:to="loc_us-gaap_PlanNameDomain_d254102e-1bfa-49e5-a77f-9343ae6fa3e5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_a18d9da6-5d98-4edc-8e11-d920edbf3e14" xlink:href="arvn-20251231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_d254102e-1bfa-49e5-a77f-9343ae6fa3e5" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_a18d9da6-5d98-4edc-8e11-d920edbf3e14" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35faf6de-be8e-48e5-b252-e6667204e9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35faf6de-be8e-48e5-b252-e6667204e9c4" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_43be4298-2562-4b4f-80fa-f936d0755f91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35faf6de-be8e-48e5-b252-e6667204e9c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_43be4298-2562-4b4f-80fa-f936d0755f91" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_327ddfc0-692a-4621-b98f-fc406dac8f84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35faf6de-be8e-48e5-b252-e6667204e9c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_327ddfc0-692a-4621-b98f-fc406dac8f84" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_22ea392a-340f-494d-bb13-2c57394f8415" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35faf6de-be8e-48e5-b252-e6667204e9c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_22ea392a-340f-494d-bb13-2c57394f8415" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2161fc2e-d422-4a34-92ff-fc4d8ea874e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4ff05dbc-c9aa-4ad1-8aea-84be74096304" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4ff05dbc-c9aa-4ad1-8aea-84be74096304" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8e374500-01bc-421c-bd5a-e63191f21471" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8e374500-01bc-421c-bd5a-e63191f21471" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c29b1225-c360-45f1-98a2-c3f529664625" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c29b1225-c360-45f1-98a2-c3f529664625" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cbbc87e1-7f1f-4a7c-addf-e539d4e3524f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c29b1225-c360-45f1-98a2-c3f529664625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cbbc87e1-7f1f-4a7c-addf-e539d4e3524f" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_22d4d2ca-3398-4b44-bb53-64a42ffa8460" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c29b1225-c360-45f1-98a2-c3f529664625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_22d4d2ca-3398-4b44-bb53-64a42ffa8460" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_11056029-3085-4ebb-a782-61ecd650e82a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c29b1225-c360-45f1-98a2-c3f529664625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_11056029-3085-4ebb-a782-61ecd650e82a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_42828290-8e0d-442b-ba42-306e4858e52f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_90936d3c-8e4b-45e0-925e-657ae4a5b65e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_90936d3c-8e4b-45e0-925e-657ae4a5b65e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e212bf67-abc0-489e-8015-a8dd4904d814" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e212bf67-abc0-489e-8015-a8dd4904d814" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a80cbacf-2cfc-438c-b4af-b8bb9c03abcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a80cbacf-2cfc-438c-b4af-b8bb9c03abcb" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b062cc4e-eb6c-4765-aa75-c5322a9e8797" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a80cbacf-2cfc-438c-b4af-b8bb9c03abcb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b062cc4e-eb6c-4765-aa75-c5322a9e8797" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_897e2cb6-bf11-48e0-99f4-a3e8c295a163" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a80cbacf-2cfc-438c-b4af-b8bb9c03abcb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_897e2cb6-bf11-48e0-99f4-a3e8c295a163" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_954a8d7f-0695-4003-91bc-2e0d54ac7794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a80cbacf-2cfc-438c-b4af-b8bb9c03abcb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_954a8d7f-0695-4003-91bc-2e0d54ac7794" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AggregateIntrinsicValueAbstract_555b6d07-d213-4985-adc5-0f45985b83f8" xlink:href="arvn-20251231.xsd#arvn_AggregateIntrinsicValueAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_arvn_AggregateIntrinsicValueAbstract_555b6d07-d213-4985-adc5-0f45985b83f8" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_842d52fc-a60d-421f-b4d4-c26fa4b22eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_555b6d07-d213-4985-adc5-0f45985b83f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_842d52fc-a60d-421f-b4d4-c26fa4b22eb8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c640baaf-f633-44d5-8524-a49f385ea08a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_555b6d07-d213-4985-adc5-0f45985b83f8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c640baaf-f633-44d5-8524-a49f385ea08a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_dca16a73-00bc-4349-869e-729b5926348f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_555b6d07-d213-4985-adc5-0f45985b83f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_dca16a73-00bc-4349-869e-729b5926348f" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#EquityScheduleofRestrictedStockDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13baf050-5a5d-4be1-af70-d360521f51e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bcf9771-9fcb-4c25-8ad7-41019afb5a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13baf050-5a5d-4be1-af70-d360521f51e3" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bcf9771-9fcb-4c25-8ad7-41019afb5a7b" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d9e3e2e8-80f3-4abf-b6f9-3e9c40f7dafb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bcf9771-9fcb-4c25-8ad7-41019afb5a7b" xlink:to="loc_us-gaap_PlanNameAxis_d9e3e2e8-80f3-4abf-b6f9-3e9c40f7dafb" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d9e3e2e8-80f3-4abf-b6f9-3e9c40f7dafb_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_PlanNameAxis_d9e3e2e8-80f3-4abf-b6f9-3e9c40f7dafb" xlink:to="loc_us-gaap_PlanNameDomain_d9e3e2e8-80f3-4abf-b6f9-3e9c40f7dafb_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_96dde6de-af51-4d57-b293-5c3420c0f60e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_PlanNameAxis_d9e3e2e8-80f3-4abf-b6f9-3e9c40f7dafb" xlink:to="loc_us-gaap_PlanNameDomain_96dde6de-af51-4d57-b293-5c3420c0f60e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_b3b9902c-4592-4a72-9fe7-b7c278b01399" xlink:href="arvn-20251231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_PlanNameDomain_96dde6de-af51-4d57-b293-5c3420c0f60e" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_b3b9902c-4592-4a72-9fe7-b7c278b01399" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05fe02c6-d27f-4e32-8115-fc25e21e5394" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bcf9771-9fcb-4c25-8ad7-41019afb5a7b" xlink:to="loc_us-gaap_AwardTypeAxis_05fe02c6-d27f-4e32-8115-fc25e21e5394" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05fe02c6-d27f-4e32-8115-fc25e21e5394_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AwardTypeAxis_05fe02c6-d27f-4e32-8115-fc25e21e5394" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_05fe02c6-d27f-4e32-8115-fc25e21e5394_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_125b4a88-4393-4da5-96d4-e9845c827110" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AwardTypeAxis_05fe02c6-d27f-4e32-8115-fc25e21e5394" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_125b4a88-4393-4da5-96d4-e9845c827110" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3d7fac9b-45c4-4aae-b552-13b0c5e892aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_125b4a88-4393-4da5-96d4-e9845c827110" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3d7fac9b-45c4-4aae-b552-13b0c5e892aa" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0cfdd9d8-1b60-4858-8915-8ec7d0a77294" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13baf050-5a5d-4be1-af70-d360521f51e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0cfdd9d8-1b60-4858-8915-8ec7d0a77294" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae4ff707-c7ac-417f-9dfb-b836b8333298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0cfdd9d8-1b60-4858-8915-8ec7d0a77294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae4ff707-c7ac-417f-9dfb-b836b8333298" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fdfdf5d3-1c44-4bd1-af7f-103387d974b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0cfdd9d8-1b60-4858-8915-8ec7d0a77294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fdfdf5d3-1c44-4bd1-af7f-103387d974b6" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_9cce467e-3512-47c8-958f-5c616b4e69a9" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0cfdd9d8-1b60-4858-8915-8ec7d0a77294" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_9cce467e-3512-47c8-958f-5c616b4e69a9" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1906f142-dcac-4d67-a272-de464e42eb52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0cfdd9d8-1b60-4858-8915-8ec7d0a77294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1906f142-dcac-4d67-a272-de464e42eb52" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5826a72b-cc53-40b8-a3e2-a642c17b0410" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b774617-f38d-4563-865b-3a3eb0b42c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13baf050-5a5d-4be1-af70-d360521f51e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b774617-f38d-4563-865b-3a3eb0b42c4a" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_570ba4de-e0bc-4bc3-873e-a978ef20525e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b774617-f38d-4563-865b-3a3eb0b42c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_570ba4de-e0bc-4bc3-873e-a978ef20525e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ad8d8846-f3cd-4505-936a-72371c2b597f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b774617-f38d-4563-865b-3a3eb0b42c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ad8d8846-f3cd-4505-936a-72371c2b597f" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue_fffffb80-7b29-47f0-aac2-0a87425bcb1a" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b774617-f38d-4563-865b-3a3eb0b42c4a" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue_fffffb80-7b29-47f0-aac2-0a87425bcb1a" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ee306605-9b29-4d4d-8887-f598568a515e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b774617-f38d-4563-865b-3a3eb0b42c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ee306605-9b29-4d4d-8887-f598568a515e" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fed31327-55f6-4ab3-b08a-f5b7debfba06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#EquityMethodInvestmentsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8276f581-4107-485e-8dd6-42924d5005d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8276f581-4107-485e-8dd6-42924d5005d5" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5ed7bb97-2835-410f-b890-e613da383c44" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8276f581-4107-485e-8dd6-42924d5005d5" xlink:to="loc_srt_CounterpartyNameAxis_5ed7bb97-2835-410f-b890-e613da383c44" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ed7bb97-2835-410f-b890-e613da383c44_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_5ed7bb97-2835-410f-b890-e613da383c44" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_5ed7bb97-2835-410f-b890-e613da383c44_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82daaa45-5ffe-44cc-9e98-add59acb3585" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_5ed7bb97-2835-410f-b890-e613da383c44" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82daaa45-5ffe-44cc-9e98-add59acb3585" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember_7a22b93b-baa9-46b6-804f-dd0e3891c912" xlink:href="arvn-20251231.xsd#arvn_BayerCropScienceLPMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82daaa45-5ffe-44cc-9e98-add59acb3585" xlink:to="loc_arvn_BayerCropScienceLPMember_7a22b93b-baa9-46b6-804f-dd0e3891c912" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_179f1ea1-b869-412f-8d43-8e8861962965" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8276f581-4107-485e-8dd6-42924d5005d5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_179f1ea1-b869-412f-8d43-8e8861962965" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_179f1ea1-b869-412f-8d43-8e8861962965_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_179f1ea1-b869-412f-8d43-8e8861962965" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_179f1ea1-b869-412f-8d43-8e8861962965_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_de309276-fa03-4088-9c6d-6c7b057d43fe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_179f1ea1-b869-412f-8d43-8e8861962965" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_de309276-fa03-4088-9c6d-6c7b057d43fe" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_3fcd51cc-c150-47d7-b151-84473553ddf2" xlink:href="arvn-20251231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_de309276-fa03-4088-9c6d-6c7b057d43fe" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_3fcd51cc-c150-47d7-b151-84473553ddf2" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bca6c2ed-afef-407b-a6dd-bf990e1c24ea" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8276f581-4107-485e-8dd6-42924d5005d5" xlink:to="loc_dei_LegalEntityAxis_bca6c2ed-afef-407b-a6dd-bf990e1c24ea" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_bca6c2ed-afef-407b-a6dd-bf990e1c24ea_default" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_dei_LegalEntityAxis_bca6c2ed-afef-407b-a6dd-bf990e1c24ea" xlink:to="loc_dei_EntityDomain_bca6c2ed-afef-407b-a6dd-bf990e1c24ea_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_57397d9c-18e9-48c3-9ce7-346634cbb1c2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_dei_LegalEntityAxis_bca6c2ed-afef-407b-a6dd-bf990e1c24ea" xlink:to="loc_dei_EntityDomain_57397d9c-18e9-48c3-9ce7-346634cbb1c2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_b000cb2b-7297-4471-99b7-b615c28b726c" xlink:href="arvn-20251231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_dei_EntityDomain_57397d9c-18e9-48c3-9ce7-346634cbb1c2" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_b000cb2b-7297-4471-99b7-b615c28b726c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_360be3d6-54a6-4efd-a401-3084da5f082b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_360be3d6-54a6-4efd-a401-3084da5f082b" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_29f2c60c-106f-4f60-a07e-eac818c9655e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_29f2c60c-106f-4f60-a07e-eac818c9655e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_659fb8b5-ad3c-40d1-98f4-6633bbadfb6a" xlink:href="arvn-20251231.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_659fb8b5-ad3c-40d1-98f4-6633bbadfb6a" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_90c8f786-34d2-42fc-b201-22bf4dcd172b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_us-gaap_OperatingExpenses_90c8f786-34d2-42fc-b201-22bf4dcd172b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d01893ec-6de2-4fd4-984e-2a0f18021c10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_us-gaap_NetIncomeLoss_d01893ec-6de2-4fd4-984e-2a0f18021c10" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_370f24cc-973f-423a-8683-51c40bde0eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_370f24cc-973f-423a-8683-51c40bde0eb9" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_cb145eb4-4c45-40b5-90c1-c0453f0a66e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_us-gaap_EquityMethodInvestments_cb145eb4-4c45-40b5-90c1-c0453f0a66e1" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:href="arvn-20251231.xsd#arvn_IncomeTaxDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeTaxDisclosureTable_784682c1-b37d-4e9d-a283-4c3fba0e79bf" xlink:href="arvn-20251231.xsd#arvn_IncomeTaxDisclosureTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_arvn_IncomeTaxDisclosureTable_784682c1-b37d-4e9d-a283-4c3fba0e79bf" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_ff6273ea-913f-403c-aaca-c759cc721234" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_IncomeTaxDisclosureTable_784682c1-b37d-4e9d-a283-4c3fba0e79bf" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_ff6273ea-913f-403c-aaca-c759cc721234" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_ff6273ea-913f-403c-aaca-c759cc721234_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ff6273ea-913f-403c-aaca-c759cc721234" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_ff6273ea-913f-403c-aaca-c759cc721234_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_44f46b2a-19f6-4f22-8897-f0dc11d3a540" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ff6273ea-913f-403c-aaca-c759cc721234" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_44f46b2a-19f6-4f22-8897-f0dc11d3a540" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_b93fa4b6-a9fe-457a-99a6-2fc41c508074" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_44f46b2a-19f6-4f22-8897-f0dc11d3a540" xlink:to="loc_us-gaap_ResearchMember_b93fa4b6-a9fe-457a-99a6-2fc41c508074" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f6aac83b-a7a1-4d13-b389-261574a129a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_IncomeTaxDisclosureTable_784682c1-b37d-4e9d-a283-4c3fba0e79bf" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f6aac83b-a7a1-4d13-b389-261574a129a4" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_f6aac83b-a7a1-4d13-b389-261574a129a4_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f6aac83b-a7a1-4d13-b389-261574a129a4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_f6aac83b-a7a1-4d13-b389-261574a129a4_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4ab65026-065a-4f68-8809-30195bf29975" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f6aac83b-a7a1-4d13-b389-261574a129a4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4ab65026-065a-4f68-8809-30195bf29975" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_61e6f98d-4759-427f-bf1c-15746d6c7472" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4ab65026-065a-4f68-8809-30195bf29975" xlink:to="loc_us-gaap_DomesticCountryMember_61e6f98d-4759-427f-bf1c-15746d6c7472" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6da9ba72-2967-4471-900a-63ae51b2d4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4ab65026-065a-4f68-8809-30195bf29975" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_6da9ba72-2967-4471-900a-63ae51b2d4e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_19bc7152-0d79-4a19-9ce9-a80078ae641d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_19bc7152-0d79-4a19-9ce9-a80078ae641d" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ba886422-4631-45b9-8b63-bb780219082c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ba886422-4631-45b9-8b63-bb780219082c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c0ffc21d-b33c-4d90-a517-420b13a97a45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c0ffc21d-b33c-4d90-a517-420b13a97a45" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_c75d6a1f-9be1-4e00-a838-e7fa92e7469b" xlink:href="arvn-20251231.xsd#arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_c75d6a1f-9be1-4e00-a838-e7fa92e7469b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_4e7f8a3f-c188-4f15-82f3-df14f3640d76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_4e7f8a3f-c188-4f15-82f3-df14f3640d76" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UnrecognizedTaxBenefitsNet_03d9de3b-a1ba-4b0a-9746-6fa81017878f" xlink:href="arvn-20251231.xsd#arvn_UnrecognizedTaxBenefitsNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_arvn_UnrecognizedTaxBenefitsNet_03d9de3b-a1ba-4b0a-9746-6fa81017878f" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_59cf82d9-eeb3-4260-92b7-ed8dc8bc3626" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_59cf82d9-eeb3-4260-92b7-ed8dc8bc3626" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c469d-ec70-7e41-8619-1ebee0dc0aae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c469d-cc1f-758f-b15a-6db29e729ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c469d-ec70-7e41-8619-1ebee0dc0aae" xlink:to="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c469d-cc1f-758f-b15a-6db29e729ae7" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c469d-ec70-7804-ac07-9c15f3943a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c469d-cc1f-758f-b15a-6db29e729ae7" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c469d-ec70-7804-ac07-9c15f3943a6d" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c469d-ec70-7804-ac07-9c15f3943a6d_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c469d-ec70-7804-ac07-9c15f3943a6d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c469d-ec70-7804-ac07-9c15f3943a6d_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c469d-ec70-7af0-af6d-e039bf3156a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c469d-ec70-7804-ac07-9c15f3943a6d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c469d-ec70-7af0-af6d-e039bf3156a0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c469d-ec70-7af0-af6d-e039bf3156a0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_019c469d-ec70-7157-ab6b-1b9819b8a220" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_stpr_CA_019c469d-ec70-7157-ab6b-1b9819b8a220" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_019c469d-ec70-7f3f-82c2-ac9434b6d037" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_stpr_MA_019c469d-ec70-7f3f-82c2-ac9434b6d037" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_019c469d-ec70-7bb7-8cdc-91ff88dee7a4" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_stpr_NY_019c469d-ec70-7bb7-8cdc-91ff88dee7a4" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NewYorkCityMember_019c469d-ec70-7781-b95b-7ba09bb0119f" xlink:href="arvn-20251231.xsd#arvn_NewYorkCityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_arvn_NewYorkCityMember_019c469d-ec70-7781-b95b-7ba09bb0119f" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_019c469d-ec70-7a57-8c90-6bd67d52ec3c" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NJ"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_stpr_NJ_019c469d-ec70-7a57-8c90-6bd67d52ec3c" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_019c469d-ec70-718d-886c-3ed43db8073f" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_PA"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_stpr_PA_019c469d-ec70-718d-886c-3ed43db8073f" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c469d-ec70-7170-bb78-d968d39e0713" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignTaxJurisdictionOtherMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c469d-ec70-7170-bb78-d968d39e0713" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c469d-ec70-7fdf-a31d-9e9b8bc56ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c469d-ec70-7e41-8619-1ebee0dc0aae" xlink:to="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c469d-ec70-7fdf-a31d-9e9b8bc56ed0" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c469d-ec70-7021-afa6-ebefe5b2ebd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c469d-ec70-7e41-8619-1ebee0dc0aae" xlink:to="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c469d-ec70-7021-afa6-ebefe5b2ebd8" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019c469d-ec70-7359-a007-afacae9769d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c469d-ec70-7e41-8619-1ebee0dc0aae" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_019c469d-ec70-7359-a007-afacae9769d5" xlink:type="arc" order="2"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#CommitmentsandContingenciesDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:href="arvn-20251231.xsd#arvn_CommitmentsAndContingenciesLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesTable_702aea73-e2f7-4f31-869b-0714e2e5fc81" xlink:href="arvn-20251231.xsd#arvn_CommitmentsAndContingenciesTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_arvn_CommitmentsAndContingenciesTable_702aea73-e2f7-4f31-869b-0714e2e5fc81" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e0489e43-ba61-412f-ae1a-671f5928f3a9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_702aea73-e2f7-4f31-869b-0714e2e5fc81" xlink:to="loc_srt_CounterpartyNameAxis_e0489e43-ba61-412f-ae1a-671f5928f3a9" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0489e43-ba61-412f-ae1a-671f5928f3a9_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_CounterpartyNameAxis_e0489e43-ba61-412f-ae1a-671f5928f3a9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_e0489e43-ba61-412f-ae1a-671f5928f3a9_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_902c71c5-4f4d-4913-8ec8-432456637083" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_CounterpartyNameAxis_e0489e43-ba61-412f-ae1a-671f5928f3a9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_902c71c5-4f4d-4913-8ec8-432456637083" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_YaleUniversityMember_808244e1-dcf8-4da9-88b2-313426391518" xlink:href="arvn-20251231.xsd#arvn_YaleUniversityMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_902c71c5-4f4d-4913-8ec8-432456637083" xlink:to="loc_arvn_YaleUniversityMember_808244e1-dcf8-4da9-88b2-313426391518" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3d23324c-2d5d-4ba3-b839-0257ab8c1354" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_702aea73-e2f7-4f31-869b-0714e2e5fc81" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3d23324c-2d5d-4ba3-b839-0257ab8c1354" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d23324c-2d5d-4ba3-b839-0257ab8c1354_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3d23324c-2d5d-4ba3-b839-0257ab8c1354" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3d23324c-2d5d-4ba3-b839-0257ab8c1354_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02c620fb-19fb-473e-9018-292ea9f7d7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3d23324c-2d5d-4ba3-b839-0257ab8c1354" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02c620fb-19fb-473e-9018-292ea9f7d7a5" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_23e23400-d0d7-4dcc-930d-ac10673aa817" xlink:href="arvn-20251231.xsd#arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02c620fb-19fb-473e-9018-292ea9f7d7a5" xlink:to="loc_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_23e23400-d0d7-4dcc-930d-ac10673aa817" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_82ba5ffb-d359-408b-a45f-43ba12e9a9a1" xlink:href="arvn-20251231.xsd#arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02c620fb-19fb-473e-9018-292ea9f7d7a5" xlink:to="loc_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_82ba5ffb-d359-408b-a45f-43ba12e9a9a1" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_fb7565c7-c600-472b-b700-ce9325098c19" xlink:href="arvn-20251231.xsd#arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02c620fb-19fb-473e-9018-292ea9f7d7a5" xlink:to="loc_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_fb7565c7-c600-472b-b700-ce9325098c19" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SuccessBasedMilestonePaymentsMember_c4dba16c-d4e3-49d2-8907-abb744d30263" xlink:href="arvn-20251231.xsd#arvn_SuccessBasedMilestonePaymentsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02c620fb-19fb-473e-9018-292ea9f7d7a5" xlink:to="loc_arvn_SuccessBasedMilestonePaymentsMember_c4dba16c-d4e3-49d2-8907-abb744d30263" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f204d28-f505-4c24-a46e-0820094f7ad0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_702aea73-e2f7-4f31-869b-0714e2e5fc81" xlink:to="loc_srt_RangeAxis_0f204d28-f505-4c24-a46e-0820094f7ad0" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_0f204d28-f505-4c24-a46e-0820094f7ad0_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_RangeAxis_0f204d28-f505-4c24-a46e-0820094f7ad0" xlink:to="loc_srt_RangeMember_0f204d28-f505-4c24-a46e-0820094f7ad0_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad84248f-c007-4bf8-b436-4415f3340763" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_RangeAxis_0f204d28-f505-4c24-a46e-0820094f7ad0" xlink:to="loc_srt_RangeMember_ad84248f-c007-4bf8-b436-4415f3340763" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f31b0e7e-dfe5-44f4-af64-6e0e492eb924" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ad84248f-c007-4bf8-b436-4415f3340763" xlink:to="loc_srt_MaximumMember_f31b0e7e-dfe5-44f4-af64-6e0e492eb924" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b760430d-5eb6-4784-b64a-4e985ecc7ec4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_RangeMember_ad84248f-c007-4bf8-b436-4415f3340763" xlink:to="loc_srt_MinimumMember_b760430d-5eb6-4784-b64a-4e985ecc7ec4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4c35f10c-3ee5-4103-b523-7aab7b33a645" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_702aea73-e2f7-4f31-869b-0714e2e5fc81" xlink:to="loc_srt_ProductOrServiceAxis_4c35f10c-3ee5-4103-b523-7aab7b33a645" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_4c35f10c-3ee5-4103-b523-7aab7b33a645_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_4c35f10c-3ee5-4103-b523-7aab7b33a645" xlink:to="loc_srt_ProductsAndServicesDomain_4c35f10c-3ee5-4103-b523-7aab7b33a645_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ed96e9fc-5f42-4060-a337-060d0eeb7060" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_4c35f10c-3ee5-4103-b523-7aab7b33a645" xlink:to="loc_srt_ProductsAndServicesDomain_ed96e9fc-5f42-4060-a337-060d0eeb7060" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseFirstLicensedProductMember_d769e484-3329-4104-9762-79a60a3957fb" xlink:href="arvn-20251231.xsd#arvn_LicenseFirstLicensedProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ed96e9fc-5f42-4060-a337-060d0eeb7060" xlink:to="loc_arvn_LicenseFirstLicensedProductMember_d769e484-3329-4104-9762-79a60a3957fb" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseSecondLicensedProductMember_2c6fa20a-1390-4626-84d9-aa499452b04e" xlink:href="arvn-20251231.xsd#arvn_LicenseSecondLicensedProductMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_ed96e9fc-5f42-4060-a337-060d0eeb7060" xlink:to="loc_arvn_LicenseSecondLicensedProductMember_2c6fa20a-1390-4626-84d9-aa499452b04e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_5336be66-2024-46a8-9ac4-5055e0c69f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_5336be66-2024-46a8-9ac4-5055e0c69f1f" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PaymentsForCollaboration_b47326dc-53f7-45b2-84b8-d24d395fc795" xlink:href="arvn-20251231.xsd#arvn_PaymentsForCollaboration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_arvn_PaymentsForCollaboration_b47326dc-53f7-45b2-84b8-d24d395fc795" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_57530897-e618-4757-9f61-60703212bcbe" xlink:href="arvn-20251231.xsd#arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_57530897-e618-4757-9f61-60703212bcbe" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AnnualLicenseFeePayment_13ec3170-c36c-482e-a518-257b0565967b" xlink:href="arvn-20251231.xsd#arvn_AnnualLicenseFeePayment"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_arvn_AnnualLicenseFeePayment_13ec3170-c36c-482e-a518-257b0565967b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfLicensedProducts_b1871f38-0ea0-4ee3-9bf6-13a4aea8f1a7" xlink:href="arvn-20251231.xsd#arvn_NumberOfLicensedProducts"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_arvn_NumberOfLicensedProducts_b1871f38-0ea0-4ee3-9bf6-13a4aea8f1a7" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RequiredMilestonePayments_41f182df-9011-462f-bc40-016aba405834" xlink:href="arvn-20251231.xsd#arvn_RequiredMilestonePayments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_arvn_RequiredMilestonePayments_41f182df-9011-462f-bc40-016aba405834" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_3dd4d07e-805b-4ed7-816c-894106750fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_us-gaap_PaymentsForRoyalties_3dd4d07e-805b-4ed7-816c-894106750fa6" xlink:type="arc" order="6"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#NetLossPerShareAdditionalInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/NetLossPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019b315c-efae-7ce7-ba28-e4bba4993b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019b315c-efae-7f45-82dd-19e4c9c8186a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019b315c-efae-7ce7-ba28-e4bba4993b3b" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019b315c-efae-7f45-82dd-19e4c9c8186a" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019b315c-efae-7ccd-af8e-1adf7dec8601" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019b315c-efae-7f45-82dd-19e4c9c8186a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019b315c-efae-7ccd-af8e-1adf7dec8601" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019b315c-efae-7ccd-af8e-1adf7dec8601_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019b315c-efae-7ccd-af8e-1adf7dec8601" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019b315c-efae-7ccd-af8e-1adf7dec8601_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019b315c-efae-7f72-932a-4cf83ee83cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019b315c-efae-7ccd-af8e-1adf7dec8601" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019b315c-efae-7f72-932a-4cf83ee83cd4" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PreFundedWarrantMember_019b315c-efae-74e8-bbed-502428764286" xlink:href="arvn-20251231.xsd#arvn_PreFundedWarrantMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019b315c-efae-7f72-932a-4cf83ee83cd4" xlink:to="loc_arvn_PreFundedWarrantMember_019b315c-efae-74e8-bbed-502428764286" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019b315c-efae-7672-aa12-942e8f7bb49d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019b315c-efae-7ce7-ba28-e4bba4993b3b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019b315c-efae-7672-aa12-942e8f7bb49d" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0f4b6cc2-1f02-46df-a9b0-495219369deb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59c5b7a5-c962-493b-8d68-d4d597455e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0f4b6cc2-1f02-46df-a9b0-495219369deb" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59c5b7a5-c962-493b-8d68-d4d597455e91" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_404a611a-2fec-4e85-bbc6-067452aea4de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59c5b7a5-c962-493b-8d68-d4d597455e91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_404a611a-2fec-4e85-bbc6-067452aea4de" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_404a611a-2fec-4e85-bbc6-067452aea4de_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_404a611a-2fec-4e85-bbc6-067452aea4de" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_404a611a-2fec-4e85-bbc6-067452aea4de_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc1a1f6c-7a72-4745-8743-dd18abad2db2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_404a611a-2fec-4e85-bbc6-067452aea4de" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc1a1f6c-7a72-4745-8743-dd18abad2db2" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e0a1f65d-664b-4d5d-aeb1-f7156da20cff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc1a1f6c-7a72-4745-8743-dd18abad2db2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e0a1f65d-664b-4d5d-aeb1-f7156da20cff" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_88ab55b8-a872-4126-aaa8-b4bb731c59e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc1a1f6c-7a72-4745-8743-dd18abad2db2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_88ab55b8-a872-4126-aaa8-b4bb731c59e0" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_21975872-d0f5-4a41-91d2-40d9049e1140" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0f4b6cc2-1f02-46df-a9b0-495219369deb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_21975872-d0f5-4a41-91d2-40d9049e1140" xlink:type="arc" order="0"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RestructuringActivityDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#RestructuringActivityDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/RestructuringActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_019c68f6-e714-76e8-9dc4-837b849d5fea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c68f6-e714-75e1-91f5-a4c8a48d2bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c68f6-e714-76e8-9dc4-837b849d5fea" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c68f6-e714-75e1-91f5-a4c8a48d2bb9" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_019c68f6-e714-78a9-95b0-e4c86124df9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c68f6-e714-75e1-91f5-a4c8a48d2bb9" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_019c68f6-e714-78a9-95b0-e4c86124df9c" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_019c68f6-e714-78a9-95b0-e4c86124df9c_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_019c68f6-e714-78a9-95b0-e4c86124df9c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_019c68f6-e714-78a9-95b0-e4c86124df9c_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_019c68f6-e714-7b03-89f2-ddff108d533e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_019c68f6-e714-78a9-95b0-e4c86124df9c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_019c68f6-e714-7b03-89f2-ddff108d533e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_019c68f6-e714-706d-9de1-e81c1d53dbea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_019c68f6-e714-7b03-89f2-ddff108d533e" xlink:to="loc_us-gaap_EmployeeSeveranceMember_019c68f6-e714-706d-9de1-e81c1d53dbea" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockCompensationAndBonusExpenseMember_019c68f6-e714-7822-9cb7-49b7acbb8891" xlink:href="arvn-20251231.xsd#arvn_StockCompensationAndBonusExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_019c68f6-e714-7b03-89f2-ddff108d533e" xlink:to="loc_arvn_StockCompensationAndBonusExpenseMember_019c68f6-e714-7822-9cb7-49b7acbb8891" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019c68f6-e714-765c-bed9-abc51a135e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c68f6-e714-75e1-91f5-a4c8a48d2bb9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019c68f6-e714-765c-bed9-abc51a135e1e" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019c68f6-e714-765c-bed9-abc51a135e1e_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019c68f6-e714-765c-bed9-abc51a135e1e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019c68f6-e714-765c-bed9-abc51a135e1e_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019c68f6-e714-7367-bfd9-29f78b301444" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019c68f6-e714-765c-bed9-abc51a135e1e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019c68f6-e714-7367-bfd9-29f78b301444" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019c68f6-e714-76fc-a5c9-38a9bca91e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019c68f6-e714-7367-bfd9-29f78b301444" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019c68f6-e714-76fc-a5c9-38a9bca91e2c" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019c68f6-e714-7655-9a50-c641022fb681" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019c68f6-e714-7367-bfd9-29f78b301444" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019c68f6-e714-7655-9a50-c641022fb681" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019c68f6-e714-7f78-816c-ecfb86b87c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c68f6-e714-76e8-9dc4-837b849d5fea" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019c68f6-e714-7f78-816c-ecfb86b87c6e" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c68f6-e714-7378-ba31-0a4459f7e344" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c68f6-e714-76e8-9dc4-837b849d5fea" xlink:to="loc_us-gaap_RestructuringCharges_019c68f6-e714-7378-ba31-0a4459f7e344" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_019c68f6-e714-7c66-9c64-b48799928136" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c68f6-e714-76e8-9dc4-837b849d5fea" xlink:to="loc_us-gaap_RestructuringReserve_019c68f6-e714-7c66-9c64-b48799928136" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019c6900-1c40-7eec-af80-7ef61f6a9f09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c68f6-e714-76e8-9dc4-837b849d5fea" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019c6900-1c40-7eec-af80-7ef61f6a9f09" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#SegmentInformationScheduleofFinancialInformationDetails"/>
  <link:definitionLink xlink:role="http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3b6d5b89-419d-47da-b58c-6998ba0bb235" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5193414e-3e38-4c06-82d4-4a81bdd32a95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b6d5b89-419d-47da-b58c-6998ba0bb235" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5193414e-3e38-4c06-82d4-4a81bdd32a95" xlink:type="arc" order="1" xbrldt:closed="true" xbrldt:contextElement="segment"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fe035549-a54b-4743-bfc5-02bae5208080" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5193414e-3e38-4c06-82d4-4a81bdd32a95" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fe035549-a54b-4743-bfc5-02bae5208080" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_fe035549-a54b-4743-bfc5-02bae5208080_default" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fe035549-a54b-4743-bfc5-02bae5208080" xlink:to="loc_us-gaap_SegmentDomain_fe035549-a54b-4743-bfc5-02bae5208080_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0b3769c9-3ccf-4483-8ef8-aea5e65e3800" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fe035549-a54b-4743-bfc5-02bae5208080" xlink:to="loc_us-gaap_SegmentDomain_0b3769c9-3ccf-4483-8ef8-aea5e65e3800" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ReportableSegmentMember_96cb4336-94c6-4a83-94f0-8038eb303f36" xlink:href="arvn-20251231.xsd#arvn_ReportableSegmentMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentDomain_0b3769c9-3ccf-4483-8ef8-aea5e65e3800" xlink:to="loc_arvn_ReportableSegmentMember_96cb4336-94c6-4a83-94f0-8038eb303f36" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d644cc42-04b9-418b-8ee0-ccb6541b2314" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5193414e-3e38-4c06-82d4-4a81bdd32a95" xlink:to="loc_srt_ProductOrServiceAxis_d644cc42-04b9-418b-8ee0-ccb6541b2314" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_d644cc42-04b9-418b-8ee0-ccb6541b2314_default" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="loc_srt_ProductOrServiceAxis_d644cc42-04b9-418b-8ee0-ccb6541b2314" xlink:to="loc_srt_ProductsAndServicesDomain_d644cc42-04b9-418b-8ee0-ccb6541b2314_default" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="loc_srt_ProductOrServiceAxis_d644cc42-04b9-418b-8ee0-ccb6541b2314" xlink:to="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV471Member_9c92c626-6b66-42bb-9c79-ad20cdb20990" xlink:href="arvn-20251231.xsd#arvn_ARV471Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_ARV471Member_9c92c626-6b66-42bb-9c79-ad20cdb20990" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV102Member_cf0a7f7d-ea57-4f36-bd47-856619290955" xlink:href="arvn-20251231.xsd#arvn_ARV102Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_ARV102Member_cf0a7f7d-ea57-4f36-bd47-856619290955" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV806Member_019c46ac-dc8a-7624-afbf-f35d5dae0e7b" xlink:href="arvn-20251231.xsd#arvn_ARV806Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_ARV806Member_019c46ac-dc8a-7624-afbf-f35d5dae0e7b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV393Member_7d536514-2046-4654-8198-f8a9316ea72b" xlink:href="arvn-20251231.xsd#arvn_ARV393Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_ARV393Member_7d536514-2046-4654-8198-f8a9316ea72b" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV110Member_e27a5c24-bac3-4e17-b0df-fb02b06a6e18" xlink:href="arvn-20251231.xsd#arvn_ARV110Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_ARV110Member_e27a5c24-bac3-4e17-b0df-fb02b06a6e18" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV766Member_d1f529cc-f86c-42e0-b04c-25f76120ee98" xlink:href="arvn-20251231.xsd#arvn_ARV766Member"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_ARV766Member_d1f529cc-f86c-42e0-b04c-25f76120ee98" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OtherProgramsMember_dd3ed1d8-fe33-46fc-8af6-41f05456a731" xlink:href="arvn-20251231.xsd#arvn_OtherProgramsMember"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_OtherProgramsMember_dd3ed1d8-fe33-46fc-8af6-41f05456a731" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2b9ae023-0e23-4eca-a552-03c88105cb13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b6d5b89-419d-47da-b58c-6998ba0bb235" xlink:to="loc_us-gaap_Revenues_2b9ae023-0e23-4eca-a552-03c88105cb13" xlink:type="arc" order="0"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b6d5b89-419d-47da-b58c-6998ba0bb235" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific_bb6f6c7e-2cbf-4b4a-95ee-998da2c9358e" xlink:href="arvn-20251231.xsd#arvn_ResearchAndDevelopmentExpenseProgramSpecific"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific_bb6f6c7e-2cbf-4b4a-95ee-998da2c9358e" xlink:type="arc" order="1"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_9c231d38-ed2c-40b6-a057-7d6045a62577" xlink:href="arvn-20251231.xsd#arvn_ResearchAndDevelopmentExpenseNonProgramSpecific"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_9c231d38-ed2c-40b6-a057-7d6045a62577" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_9d7eda2b-4d49-46b7-b5a4-8a5ee7af635e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_LaborAndRelatedExpense_9d7eda2b-4d49-46b7-b5a4-8a5ee7af635e" xlink:type="arc" order="3"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_f598497b-7c0c-436e-ac8b-7ec84f10b9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_f598497b-7c0c-436e-ac8b-7ec84f10b9b8" xlink:type="arc" order="4"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_50e8f4e7-2476-4605-be5c-3d6415f225d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_50e8f4e7-2476-4605-be5c-3d6415f225d6" xlink:type="arc" order="5"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0ece782a-e264-4e2a-85b1-25daa88b7b63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0ece782a-e264-4e2a-85b1-25daa88b7b63" xlink:type="arc" order="6"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_5b5b5472-b8d2-41a7-afb2-eb2934aeae35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_5b5b5472-b8d2-41a7-afb2-eb2934aeae35" xlink:type="arc" order="7"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5ff07229-047f-48a8-843b-ee3f461b3117" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5ff07229-047f-48a8-843b-ee3f461b3117" xlink:type="arc" order="8"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_71566b60-b24a-4de2-b824-eae64428648d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_71566b60-b24a-4de2-b824-eae64428648d" xlink:type="arc" order="9"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ccddcf16-04c1-408a-bb0d-cdbcc51c863b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b6d5b89-419d-47da-b58c-6998ba0bb235" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ccddcf16-04c1-408a-bb0d-cdbcc51c863b" xlink:type="arc" order="2"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dadce0b5-7c37-4a7a-ab7c-c2c03dd6e39b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b6d5b89-419d-47da-b58c-6998ba0bb235" xlink:to="loc_us-gaap_NetIncomeLoss_dadce0b5-7c37-4a7a-ab7c-c2c03dd6e39b" xlink:type="arc" order="3"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd#eedm"/>
  <link:definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:definitionArc xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="691"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>14
<FILENAME>arvn-20251231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:bad37b98-383d-4e3d-a5b5-927fa1eba41c,g:852a4cd9-135e-4322-96de-ff3159237791-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_c591536a-5a86-484d-b083-798843065cdf_terseLabel_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary of Significant Accounting Policies</link:label>
    <link:label id="lab_us-gaap_SignificantAccountingPoliciesTextBlock_label_en-US" xlink:label="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="lab_us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeMember_edc8e1c0-fd58-42b2-ac38-4a913d6eed1d_terseLabel_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:label id="lab_srt_RangeMember_label_en-US" xlink:label="lab_srt_RangeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeMember" xlink:to="lab_srt_RangeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_b24c46f6-796f-4ee4-9ba2-c6afc2aac48f_terseLabel_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities:</link:label>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_label_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]</link:label>
    <link:label id="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_documentation_en-US" xlink:label="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash paid for amounts included in the measurement of lease liabilities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:href="arvn-20251231.xsd#arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:to="lab_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_7865c53f-fffd-46e4-affd-d4edfcfa2e77_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Available-for-Sale Marketable Securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_6fb8270a-7e7c-41ef-975f-9f33715a07bd_verboseLabel_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Restricted cash</link:label>
    <link:label id="lab_us-gaap_RestrictedCashCurrent_label_en-US" xlink:label="lab_us-gaap_RestrictedCashCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Cash, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedCashCurrent" xlink:to="lab_us-gaap_RestrictedCashCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined</link:label>
    <link:label id="lab_ecd_AwardTmgPredtrmndFlag_label_en-US" xlink:label="lab_ecd_AwardTmgPredtrmndFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Predetermined [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgPredtrmndFlag" xlink:to="lab_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_536c5f10-f582-4285-89f4-039d0d711e50_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_04196770-79af-4a4a-8a67-26961f68503d_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_7f7a419f-c3ea-412f-a8f9-3ed501659a0d_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapitalMember_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapitalMember" xlink:to="lab_us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_f1315ade-c705-4c7a-b4e2-15c0f05c95d7_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:to="lab_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_9a1fc2ad-3535-4a33-88c1-f0e31295e673_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss from equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_5c78d907-89d8-4611-9d82-dd7361ae73ba_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss from equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TabularListTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tabular List, Table</link:label>
    <link:label id="lab_ecd_TabularListTableTextBlock_label_en-US" xlink:label="lab_ecd_TabularListTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tabular List [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TabularListTableTextBlock" xlink:to="lab_ecd_TabularListTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeasesAbstract_4d13ee7f-5cab-4c04-8abe-6c84d5c97fe5_terseLabel_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:label id="lab_us-gaap_LeasesAbstract_label_en-US" xlink:label="lab_us-gaap_LeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leases [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeasesAbstract" xlink:to="lab_us-gaap_LeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_UpdatedResearchTimelinesMember_22b9ea7f-76af-4411-9d59-e69997743b70_terseLabel_en-US" xlink:label="lab_arvn_UpdatedResearchTimelinesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Updated Research Timelines</link:label>
    <link:label id="lab_arvn_UpdatedResearchTimelinesMember_label_en-US" xlink:label="lab_arvn_UpdatedResearchTimelinesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Updated Research Timelines [Member]</link:label>
    <link:label id="lab_arvn_UpdatedResearchTimelinesMember_documentation_en-US" xlink:label="lab_arvn_UpdatedResearchTimelinesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Updated Research Timelines</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UpdatedResearchTimelinesMember" xlink:href="arvn-20251231.xsd#arvn_UpdatedResearchTimelinesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_UpdatedResearchTimelinesMember" xlink:to="lab_arvn_UpdatedResearchTimelinesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_0012ea52-da84-4c32-98f3-cf4cc0f6e9b4_terseLabel_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements</link:label>
    <link:label id="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="lab_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OneTimeCashTerminationFeeMember_d39c5c02-d5e1-4af9-a586-d404e25d6f47_terseLabel_en-US" xlink:label="lab_arvn_OneTimeCashTerminationFeeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">One-Time Cash Termination Fee</link:label>
    <link:label id="lab_arvn_OneTimeCashTerminationFeeMember_label_en-US" xlink:label="lab_arvn_OneTimeCashTerminationFeeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">One-Time Cash Termination Fee [Member]</link:label>
    <link:label id="lab_arvn_OneTimeCashTerminationFeeMember_documentation_en-US" xlink:label="lab_arvn_OneTimeCashTerminationFeeMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">One-Time Cash Termination Fee</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OneTimeCashTerminationFeeMember" xlink:href="arvn-20251231.xsd#arvn_OneTimeCashTerminationFeeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OneTimeCashTerminationFeeMember" xlink:to="lab_arvn_OneTimeCashTerminationFeeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgedStatusAxis_7875545e-8e67-4658-a78f-6212f259e544_terseLabel_en-US" xlink:label="lab_us-gaap_PledgedStatusAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pledged Status [Axis]</link:label>
    <link:label id="lab_us-gaap_PledgedStatusAxis_label_en-US" xlink:label="lab_us-gaap_PledgedStatusAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pledged Status [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgedStatusAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgedStatusAxis" xlink:to="lab_us-gaap_PledgedStatusAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_019c46aa-f82d-7071-98df-bf65a0e4b357_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:label id="lab_us-gaap_TypeOfRestructuringDomain_label_en-US" xlink:label="lab_us-gaap_TypeOfRestructuringDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Type of Restructuring [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfRestructuringDomain" xlink:to="lab_us-gaap_TypeOfRestructuringDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_b42aa086-7c98-44a0-a95f-aad2835fb5e0_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Royalty payment</link:label>
    <link:label id="lab_us-gaap_PaymentsForRoyalties_label_en-US" xlink:label="lab_us-gaap_PaymentsForRoyalties" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Royalties</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRoyalties" xlink:to="lab_us-gaap_PaymentsForRoyalties" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c4691-77c7-73f5-bcfd-74cf245b59a6_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_IncomeTaxReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LicenseMember_1e96f329-2910-4cd4-9d20-a84ff2cef4e3_terseLabel_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License</link:label>
    <link:label id="lab_us-gaap_LicenseMember_label_en-US" xlink:label="lab_us-gaap_LicenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LicenseMember" xlink:to="lab_us-gaap_LicenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_78ad6178-5d3f-431b-beb7-7a090b56d68e_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Losses</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrByIndTable_terseLabel_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual</link:label>
    <link:label id="lab_ecd_TradingArrByIndTable_label_en-US" xlink:label="lab_ecd_TradingArrByIndTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangements, by Individual [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="lab_ecd_TradingArrByIndTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_281f29fd-3e27-48af-8793-1a9263eb435b_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share - basic (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_3c45c4cb-6070-4beb-9c5a-44ba2152ebf2_verboseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share - basic (in usd per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareBasic_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareBasic" xlink:to="lab_us-gaap_EarningsPerShareBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAxis_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation:</link:label>
    <link:label id="lab_ecd_AdjToCompAxis_label_en-US" xlink:label="lab_ecd_AdjToCompAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="lab_ecd_AdjToCompAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote</link:label>
    <link:label id="lab_ecd_NamedExecutiveOfficersFnTextBlock_label_en-US" xlink:label="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Named Executive Officers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:to="lab_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_2831a1fa-5dfe-4ee6-bfab-062b8231437f_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Payable and Accrued Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_3336ec59-d7c7-4847-8c0f-c5254f93b29d_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for issuance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_label_en-US" xlink:label="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Capital Shares Reserved for Future Issuance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="lab_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement And Statement Of Comprehensive Income [Abstract]</link:label>
    <link:label id="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_documentation_en-US" xlink:label="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income Statement And Statement Of Comprehensive Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:href="arvn-20251231.xsd#arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:to="lab_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_104afc4e-bd69-417c-b3ac-6cdca37c2306_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_7189197e-b222-4c3e-8871-444a51dc1970_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred income tax assets</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsGross_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsGross" xlink:to="lab_us-gaap_DeferredTaxAssetsGross" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_13eb2ce0-5b28-4190-a0fe-924f9746a533_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reportable Segment Financial Information</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_5efe13ea-2d2c-44c3-b12c-07fff9d35a25_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Employee Stock Purchase Plans</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_651ef7d7-d1d7-497c-89f8-dc46f7e58bcb_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_defce9c6-ea93-4ec1-9950-4f9481b601ec_totalLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_b5218722-5aad-4f5a-9d65-86422069690d_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligation_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligation" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation, Amount</link:label>
    <link:label id="lab_ecd_AdjToCompAmt_label_en-US" xlink:label="lab_ecd_AdjToCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToCompAmt" xlink:to="lab_ecd_AdjToCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_7b9838b2-0e40-4f5a-8200-832fdaf27959_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration risk, percentage</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskPercentage1_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskPercentage1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskPercentage1" xlink:to="lab_us-gaap_ConcentrationRiskPercentage1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_019baff8-5489-732d-aae5-0e138fe7c9b0_terseLabel_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidation</link:label>
    <link:label id="lab_us-gaap_ConsolidationPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Consolidation, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConsolidationPolicyTextBlock" xlink:to="lab_us-gaap_ConsolidationPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensation_6718410b-5e50-4de1-9d10-19b733dd6160_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Noncash Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensation" xlink:to="lab_us-gaap_ShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AnnualLicenseFeePayment_cc2135bf-7621-4032-9466-836a5d090972_terseLabel_en-US" xlink:label="lab_arvn_AnnualLicenseFeePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual payment for license</link:label>
    <link:label id="lab_arvn_AnnualLicenseFeePayment_label_en-US" xlink:label="lab_arvn_AnnualLicenseFeePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Annual License Fee Payment</link:label>
    <link:label id="lab_arvn_AnnualLicenseFeePayment_documentation_en-US" xlink:label="lab_arvn_AnnualLicenseFeePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Annual license fee payment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AnnualLicenseFeePayment" xlink:href="arvn-20251231.xsd#arvn_AnnualLicenseFeePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AnnualLicenseFeePayment" xlink:to="lab_arvn_AnnualLicenseFeePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_44112a96-a807-409c-8e58-172ac117974c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock options</link:label>
    <link:label id="lab_us-gaap_EmployeeStockOptionMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockOptionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockOptionMember" xlink:to="lab_us-gaap_EmployeeStockOptionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiDiscTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:to="lab_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_36ce7bd2-b39b-427e-9007-bc0eb237786a_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Property Plant And Equipment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="lab_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_85b7c544-aa82-4787-9196-37f2077bfb16_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expenses</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpensePolicy_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_019bafe6-23d8-716b-8c97-9332dcf37288_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="lab_us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CommitmentsAndContingenciesTable_3f101547-e199-4cc8-a294-c0d540fd7a0d_terseLabel_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesTable_label_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Table]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesTable_documentation_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesTable" xlink:href="arvn-20251231.xsd#arvn_CommitmentsAndContingenciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CommitmentsAndContingenciesTable" xlink:to="lab_arvn_CommitmentsAndContingenciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c4692-ade3-7bf7-8f21-90b2f77cb3fc_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percent</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_b74374f5-c3f1-449b-be74-46987c9d73b9_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquity_35bab8c3-7c87-46d5-8306-94be44ecb1c2_totalLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_c09606a6-1d1f-4c94-985d-3bb476799f48_periodStartLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_e8ff574e-8d11-4f7b-8ffa-9a5a116ed6c2_periodEndLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_StockholdersEquity_label_en-US" xlink:label="lab_us-gaap_StockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquity" xlink:to="lab_us-gaap_StockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_6ad1ffe2-ba71-4ea0-a6dd-7d1017afa0b4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByMeasurementFrequencyAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:to="lab_us-gaap_FairValueByMeasurementFrequencyAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SummaryOfSignificantAccountingPoliciesTable_a35578d3-ba23-4f67-97ae-0504b662fe7d_terseLabel_en-US" xlink:label="lab_arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arvn_SummaryOfSignificantAccountingPoliciesTable_label_en-US" xlink:label="lab_arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Table]</link:label>
    <link:label id="lab_arvn_SummaryOfSignificantAccountingPoliciesTable_documentation_en-US" xlink:label="lab_arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of significant of accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:href="arvn-20251231.xsd#arvn_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:to="lab_arvn_SummaryOfSignificantAccountingPoliciesTable" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingPoliciesProcLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="lab_ecd_InsiderTradingPoliciesProcLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NY_019c469d-ec70-7d8b-bacd-611675a1f426_terseLabel_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New York</link:label>
    <link:label id="lab_stpr_NY_label_en-US" xlink:label="lab_stpr_NY" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NEW YORK</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NY" xlink:to="lab_stpr_NY" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_bd8fb125-689e-4ef2-9874-b857979d0df8_terseLabel_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense</link:label>
    <link:label id="lab_us-gaap_AllocatedShareBasedCompensationExpense_label_en-US" xlink:label="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="lab_us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_4e863570-28e3-47ed-8da9-0ac007258581_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesAuthorized" xlink:to="lab_us-gaap_CommonStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_ae32118f-2387-4374-a87d-c7d8438e5373_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Property, Equipment and Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_52a8f884-ef17-46ef-a464-8e6a2bdf8a9e_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued, net of issuance costs (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_0dc2ea83-c364-49fd-8269-219c10430230_verboseLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:label id="lab_us-gaap_AssetsCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrentAbstract" xlink:to="lab_us-gaap_AssetsCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_a7c383db-02bd-48d2-81c8-a3144f9a5ed6_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_63b92a1b-8b09-4272-bea2-136d8136a649_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquity_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_2fca87e0-7e57-4929-af55-aa6ed3c3e9bb_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_d8997300-7990-461f-b04e-65e0b5342357_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value, Measurements, Recurring</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsRecurringMember_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsRecurringMember" xlink:to="lab_us-gaap_FairValueMeasurementsRecurringMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_1f9a3a39-88b5-4b15-b691-5a4f7cfb6f6c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_fb717158-5a6e-4672-bf87-f57824097603_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByBenchmarkAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:to="lab_us-gaap_ConcentrationRiskByBenchmarkAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_23d58e86-7b91-4466-a0b4-560bf9671468_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration of Credit Risk and Other Risks and Uncertainties</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskCreditRisk_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskCreditRisk" xlink:to="lab_us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_b932f428-b8cd-4dcb-a102-33271db8f98b_terseLabel_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-based Milestone Payments</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Based Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales-based milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember" xlink:href="arvn-20251231.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SalesBasedMilestonePaymentsMember" xlink:to="lab_arvn_SalesBasedMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_9766d830-8b83-41e8-8b7e-82210b9971b8_verboseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Liabilities and stockholders' equity</link:label>
    <link:label id="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities and Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="lab_us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_7f8072cb-9b4b-4638-8bea-b6035c1f11a9_terseLabel_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US state and local &#160;</link:label>
    <link:label id="lab_us-gaap_StateAndLocalJurisdictionMember_label_en-US" xlink:label="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember" xlink:to="lab_us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_c72ed7ef-a85f-405f-95c1-d98abb54019b_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other income (expense)</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense) [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpenseAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_0fdf8187-0b56-4ac9-b222-4d9f27bb2d7a_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_075e09ea-b0ac-4f20-a78f-bda7ed269623_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOther_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Other</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOther" xlink:to="lab_us-gaap_DeferredTaxAssetsOther" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_d75b866e-dad0-4603-91b8-cc5255fe6cba_terseLabel_en-US" xlink:label="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Future grant of incentive units to service providers, percentage</link:label>
    <link:label id="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_label_en-US" xlink:label="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Future Grant Of Incentive Units To Service Providers Percentage</link:label>
    <link:label id="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_documentation_en-US" xlink:label="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Future grant of incentive units to service providers, percentage.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:href="arvn-20251231.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:to="lab_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MaximumMember_d4d2592e-499e-4967-b0d2-e2d0591595f7_terseLabel_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maximum</link:label>
    <link:label id="lab_srt_MaximumMember_label_en-US" xlink:label="lab_srt_MaximumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MaximumMember" xlink:to="lab_srt_MaximumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_019c46aa-f82d-7d07-ad91-ebab50221196_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpenseMember_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_b0ba7c34-c0bc-422a-8184-5699f7255d9d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_add0fd30-d62c-41e7-9615-bf59f856d7d9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Equity Method Investments [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_2e35cb9e-1c40-47a8-b1c6-2d763c5c3fec_terseLabel_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:label id="lab_us-gaap_AccountingPoliciesAbstract_label_en-US" xlink:label="lab_us-gaap_AccountingPoliciesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountingPoliciesAbstract" xlink:to="lab_us-gaap_AccountingPoliciesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_PA_019c469d-ec70-7ccd-aad8-3e8890c1beb6_terseLabel_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pennsylvania</link:label>
    <link:label id="lab_stpr_PA_label_en-US" xlink:label="lab_stpr_PA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PENNSYLVANIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_PA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_PA" xlink:to="lab_stpr_PA" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_08585cdb-0371-4675-ab35-4c5eba7f1076_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from exercise of stock options and issuance of ESPP shares</link:label>
    <link:label id="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_label_en-US" xlink:label="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares</link:label>
    <link:label id="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_documentation_en-US" xlink:label="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:to="lab_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ce908a5e-2ac7-41aa-9d21-f60bf07b5e4d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Operating Lease Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_21ed7bb3-d7e0-4b33-a9a0-e9fdfb46f488_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskTypeDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain" xlink:to="lab_us-gaap_ConcentrationRiskTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgTotalCompAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:to="lab_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_71355f03-f281-466e-8916-3cb59b85ec50_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentLineItems_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentLineItems" xlink:to="lab_us-gaap_DebtInstrumentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_03beacb4-aa06-4ae6-826d-ea1d92e42604_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_019c0b05-2da6-7dc5-b55b-ee280f41b469_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonMember_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonMember" xlink:to="lab_us-gaap_TreasuryStockCommonMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_59374f78-cbc3-4f41-83a9-507f608e58ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total fair value of RSUs vested</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote</link:label>
    <link:label id="lab_ecd_AdjToNonPeoNeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Non-PEO NEO Compensation Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:to="lab_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PayVsPerformanceDisclosureLineItems_label_en-US" xlink:label="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="lab_ecd_PayVsPerformanceDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_f5672cb3-5c91-4634-9f86-029afbace875_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightAxis_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis" xlink:to="lab_us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_93e97ab3-3d57-4c77-9935-92cd8fb41230_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiability" xlink:to="lab_us-gaap_OperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_c898c768-e05a-4962-ba6e-ad9826c570e1_terseLabel_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_label_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Additions</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_documentation_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:href="arvn-20251231.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:to="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Disqualification of Tax Benefits, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:to="lab_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_0fe0ee90-f128-4f84-b07e-d4c8dce81cfc_terseLabel_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_DepreciationAndAmortization_label_en-US" xlink:label="lab_us-gaap_DepreciationAndAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation, Depletion and Amortization, Nonproduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DepreciationAndAmortization" xlink:to="lab_us-gaap_DepreciationAndAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityShellCompany_27d7b3f2-b0d4-4961-a0b7-51b5e43c1695_terseLabel_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:label id="lab_dei_EntityShellCompany_label_en-US" xlink:label="lab_dei_EntityShellCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityShellCompany" xlink:to="lab_dei_EntityShellCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentTable_5b3bd680-60e5-4353-85dc-7b15e981b388_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Table]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentTable_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentTable" xlink:to="lab_us-gaap_DebtInstrumentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_7383d53b-174d-4273-9a73-93dbd230bc54_periodStartLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_f0e0e120-cbfc-4074-9bc4-63e98b9d7701_periodEndLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_label_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Contract Balances, Current</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrent_documentation_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable, Contract Balances, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrent" xlink:href="arvn-20251231.xsd#arvn_AccountsPayableContractBalancesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsPayableContractBalancesCurrent" xlink:to="lab_arvn_AccountsPayableContractBalancesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_01f40482-966d-4601-aba7-ccc23cc63549_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from disposal of property, equipment and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Sale of Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="lab_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_7be5f1f6-0fa7-4a51-8eec-f9983282c422_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfStockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="lab_us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_019c4695-696d-72af-b4cd-bd06e725da80_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income Tax Paid, Net of Refunds</link:label>
    <link:label id="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_b3ebf2cc-4980-4230-bd5a-6b212d31ee67_terseLabel_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Oerth</link:label>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_label_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Oerth Bio Limited Liability Corporation [Member]</link:label>
    <link:label id="lab_arvn_OerthBioLimitedLiabilityCorporationMember_documentation_en-US" xlink:label="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Oerth Bio LLC.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:href="arvn-20251231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:to="lab_arvn_OerthBioLimitedLiabilityCorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_1f772750-4bc3-43ed-a9d0-7c4036090099_negatedLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: current installments included within Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_LongTermDebtCurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtCurrent" xlink:to="lab_us-gaap_LongTermDebtCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_5f0a6b0d-32d5-4445-a4c8-37d798ce505b_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfCashFlowsAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract" xlink:to="lab_us-gaap_StatementOfCashFlowsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureAmt_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureAmt" xlink:to="lab_ecd_CoSelectedMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_4087a626-7d26-4296-9b72-746324a89c51_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgMnpiCnsdrdFlag_label_en-US" xlink:label="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing MNPI Considered [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:to="lab_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_b8561ba4-d3bc-4ef8-a127-9ab396066d79_totalLabel_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Comprehensive loss</link:label>
    <link:label id="lab_us-gaap_ComprehensiveIncomeNetOfTax_label_en-US" xlink:label="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="lab_us-gaap_ComprehensiveIncomeNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureName_terseLabel_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_MeasureName_label_en-US" xlink:label="lab_ecd_MeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureName" xlink:to="lab_ecd_MeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringReserve_019c46aa-f82d-7e01-bad8-2cba9a234916_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring accrual</link:label>
    <link:label id="lab_us-gaap_RestructuringReserve_label_en-US" xlink:label="lab_us-gaap_RestructuringReserve" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Reserve</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringReserve" xlink:to="lab_us-gaap_RestructuringReserve" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LetterOfCreditMember_51d0be4c-b539-49ea-aa15-836d73634cd2_terseLabel_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Letter of Credit</link:label>
    <link:label id="lab_us-gaap_LetterOfCreditMember_label_en-US" xlink:label="lab_us-gaap_LetterOfCreditMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Letter of Credit [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LetterOfCreditMember" xlink:to="lab_us-gaap_LetterOfCreditMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_0c7ec0c5-2e32-4cdc-bacc-fe50f6194a36_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current portion of operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_ae6ad242-a867-48b1-9a4b-bbabac45f76c_terseLabel_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument interest payments term (in months)</link:label>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_label_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Interest Payments Term</link:label>
    <link:label id="lab_arvn_DebtInstrumentInterestPaymentsTerm_documentation_en-US" xlink:label="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt instrument interest payments term.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm" xlink:href="arvn-20251231.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DebtInstrumentInterestPaymentsTerm" xlink:to="lab_arvn_DebtInstrumentInterestPaymentsTerm" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_2d8b29f6-29c2-432d-b807-9fcf8621c4b1_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalPeriodFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalPeriodFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalPeriodFocus" xlink:to="lab_dei_DocumentFiscalPeriodFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing Method</link:label>
    <link:label id="lab_ecd_AwardTmgMethodTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgMethodTextBlock" xlink:to="lab_ecd_AwardTmgMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AwardTypeAxis_a0c2d296-5ccc-4561-801a-d762cf5c801c_terseLabel_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:label id="lab_us-gaap_AwardTypeAxis_label_en-US" xlink:label="lab_us-gaap_AwardTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="lab_us-gaap_AwardTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_380d199d-a80d-4c52-abb4-772e9e7383ca_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebt_8f81c741-9385-4aa1-b3c9-d357379bbabc_totalLabel_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:label id="lab_us-gaap_LongTermDebt_label_en-US" xlink:label="lab_us-gaap_LongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebt" xlink:to="lab_us-gaap_LongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_bc4dde7e-7e57-4ee3-9b55-d8956d80b4c8_terseLabel_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Development Milestone Payments</link:label>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Development Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_DevelopmentMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Development milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember" xlink:href="arvn-20251231.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DevelopmentMilestonePaymentsMember" xlink:to="lab_arvn_DevelopmentMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LegalEntityAxis_891a3dc3-841e-4ec8-9bdf-d5d701fce2a0_terseLabel_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:label id="lab_dei_LegalEntityAxis_label_en-US" xlink:label="lab_dei_LegalEntityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LegalEntityAxis" xlink:to="lab_dei_LegalEntityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Assets_db4c3b02-a833-42c6-9fc7-e2dc1e6efc86_totalLabel_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:label id="lab_us-gaap_Assets_label_en-US" xlink:label="lab_us-gaap_Assets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Assets" xlink:to="lab_us-gaap_Assets" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_f63347fe-48ed-47d5-92e0-11dd754ba5c6_terseLabel_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_label_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Distribution Agreement [Member]</link:label>
    <link:label id="lab_arvn_EquityDistributionAgreementMember_documentation_en-US" xlink:label="lab_arvn_EquityDistributionAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Equity Distribution Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember" xlink:href="arvn-20251231.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_EquityDistributionAgreementMember" xlink:to="lab_arvn_EquityDistributionAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_5daede5c-a448-41b8-ba96-b5dbb7890b13_terseLabel_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:label id="lab_srt_EquityMethodInvesteeNameDomain_label_en-US" xlink:label="lab_srt_EquityMethodInvesteeNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_EquityMethodInvesteeNameDomain" xlink:to="lab_srt_EquityMethodInvesteeNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_b1f96cb9-364e-44bb-927d-5f8de92428ea_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity-based Compensation</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="lab_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_b0a10a0d-0eb3-4f1d-9771-47f4e91ff7d4_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_43b5f184-4fe0-47dc-bce3-8ff5550c9025_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2029</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Four</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RequiredMilestonePayments_f0cd6eea-be34-4c7a-a199-7c79f09fa9a8_terseLabel_en-US" xlink:label="lab_arvn_RequiredMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Required milestone payments</link:label>
    <link:label id="lab_arvn_RequiredMilestonePayments_label_en-US" xlink:label="lab_arvn_RequiredMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Required Milestone Payments</link:label>
    <link:label id="lab_arvn_RequiredMilestonePayments_documentation_en-US" xlink:label="lab_arvn_RequiredMilestonePayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Required Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RequiredMilestonePayments" xlink:href="arvn-20251231.xsd#arvn_RequiredMilestonePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RequiredMilestonePayments" xlink:to="lab_arvn_RequiredMilestonePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_bbb513a8-9f4a-491b-a50f-db72c23b07a3_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restricted Cash</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="lab_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_11eaa9ac-2f47-4c9f-9917-1bf5c7f4d2f6_terseLabel_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract liabilities: Deferred revenue</link:label>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_label_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:href="arvn-20251231.xsd#arvn_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:to="lab_arvn_ChangeInContractWithCustomerLiabilityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_SegmentGeographicalDomain_bc94557a-d828-4891-9eab-e6e4dcb63d30_terseLabel_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:label id="lab_srt_SegmentGeographicalDomain_label_en-US" xlink:label="lab_srt_SegmentGeographicalDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_SegmentGeographicalDomain" xlink:to="lab_srt_SegmentGeographicalDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_c0de08bb-46a8-4681-9971-1fe21029f577_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowance</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod_019b30d0-b5f3-7045-a999-1b3de3d1cf90_negatedLabel_en-US" xlink:label="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Amortization</link:label>
    <link:label id="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod_label_en-US" xlink:label="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Amortization During Period</link:label>
    <link:label id="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod_documentation_en-US" xlink:label="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Amortization During Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:href="arvn-20251231.xsd#arvn_CapitalizedContractCostAmortizationDuringPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:to="lab_arvn_CapitalizedContractCostAmortizationDuringPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_a2a06995-15bb-4027-a2f1-e39e98303ff4_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPolicyTextBlock" xlink:to="lab_us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_418359d1-6e89-42ba-a870-26158b0a2f80_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive plans (in shares)</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_0776de16-7ea6-4db1-a7a8-1f097b7b50d4_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecurities_e478bf56-b4fe-44e1-9e65-6b3b834fbb80_terseLabel_en-US" xlink:label="lab_us-gaap_DebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt securities</link:label>
    <link:label id="lab_us-gaap_DebtSecurities_label_en-US" xlink:label="lab_us-gaap_DebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecurities" xlink:to="lab_us-gaap_DebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_f09459c1-2a36-4dfb-9bcf-cceedfb7a4f3_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from operating activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_ee4fc3e6-b042-4c2f-8a6b-3be9e31cbaad_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_3507a29d-64dd-4b49-9d6d-b75ed97c6ab8_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other segment expense, net</link:label>
    <link:label id="lab_us-gaap_SegmentReportingOtherItemAmount_label_en-US" xlink:label="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting, Other Segment Item, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingOtherItemAmount" xlink:to="lab_us-gaap_SegmentReportingOtherItemAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_b383c81e-b2e0-4cf1-bc6d-ace7a6069ce3_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis" xlink:to="lab_us-gaap_ConcentrationRiskByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:label id="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt_label_en-US" xlink:label="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO Average Compensation Actually Paid Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:to="lab_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_019c46aa-f82d-7e33-a1f4-55906a5b097d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationDomain_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationDomain" xlink:to="lab_us-gaap_IncomeStatementLocationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_16caa1d7-8f5c-471f-a135-4e25db3ef61c_terseLabel_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">RSUs</link:label>
    <link:label id="lab_us-gaap_RestrictedStockUnitsRSUMember_label_en-US" xlink:label="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestrictedStockUnitsRSUMember" xlink:to="lab_us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Other Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractTerminationDomain_2c1c4a00-1677-4a9c-aee3-cd1435f1c665_terseLabel_en-US" xlink:label="lab_arvn_ContractTerminationDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Termination [Domain]</link:label>
    <link:label id="lab_arvn_ContractTerminationDomain_label_en-US" xlink:label="lab_arvn_ContractTerminationDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Termination [Domain]</link:label>
    <link:label id="lab_arvn_ContractTerminationDomain_documentation_en-US" xlink:label="lab_arvn_ContractTerminationDomain" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Termination [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractTerminationDomain" xlink:href="arvn-20251231.xsd#arvn_ContractTerminationDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractTerminationDomain" xlink:to="lab_arvn_ContractTerminationDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_cd4f92ab-8bf4-487a-8272-f077e26c8a53_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_b3beca7b-7f41-4a03-bca9-ec85749bb272_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2028</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Three</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_6dc3595c-517d-4736-a110-15b5edb7195a_terseLabel_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Common Stock Shares Outstanding</link:label>
    <link:label id="lab_dei_EntityCommonStockSharesOutstanding_label_en-US" xlink:label="lab_dei_EntityCommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCommonStockSharesOutstanding" xlink:to="lab_dei_EntityCommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_18ca2c99-b4b4-46ed-beb0-2d8f8893945b_terseLabel_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right-of-use assets obtained in exchange for new lease obligations</link:label>
    <link:label id="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="lab_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_7a1d2d63-513c-4531-b84d-6a177ea6384a_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_51c873fa-f08d-44fb-b4d4-98bc8cb33006_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year</link:label>
    <link:label id="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:to="lab_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_c59c7f17-72bc-4faa-add4-5ca308214ba3_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Level 2</link:label>
    <link:label id="lab_us-gaap_FairValueInputsLevel2Member_label_en-US" xlink:label="lab_us-gaap_FairValueInputsLevel2Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Inputs, Level 2 [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueInputsLevel2Member" xlink:to="lab_us-gaap_FairValueInputsLevel2Member" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_da429c68-d917-46d9-a10e-c82af0901cb5_terseLabel_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction</link:label>
    <link:label id="lab_dei_DocumentFinStmtErrorCorrectionFlag_label_en-US" xlink:label="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Financial Statement Error Correction [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFinStmtErrorCorrectionFlag" xlink:to="lab_dei_DocumentFinStmtErrorCorrectionFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c8b0a-8bd1-7ad5-8cf0-2a3b37385712_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income taxes, net of federal income tax effect</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestments_dc84a075-9370-4d76-84a6-768b089f3fab_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity method investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestments" xlink:to="lab_us-gaap_EquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Not Adopted [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:to="lab_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_6a448584-e425-450e-8ab5-9ea936c914b8_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_a6626cf6-5d7c-4269-888c-87feec447c68_periodStartLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_b3fd6d7f-d1f6-4f6d-bcff-2f0ae8a5b16c_periodEndLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesOutstanding" xlink:to="lab_us-gaap_CommonStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetPledgedAsCollateralMember_cd2b85a6-32d3-4b9d-9d70-51ed7c7de8ef_terseLabel_en-US" xlink:label="lab_us-gaap_AssetPledgedAsCollateralMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Asset Pledged as Collateral</link:label>
    <link:label id="lab_us-gaap_AssetPledgedAsCollateralMember_label_en-US" xlink:label="lab_us-gaap_AssetPledgedAsCollateralMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Asset Pledged as Collateral [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetPledgedAsCollateralMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetPledgedAsCollateralMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetPledgedAsCollateralMember" xlink:to="lab_us-gaap_AssetPledgedAsCollateralMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PiperSandlerAndCantorMember_e39499dc-b14f-43f5-bea7-9b51c702227a_terseLabel_en-US" xlink:label="lab_arvn_PiperSandlerAndCantorMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Piper Sandler and Cantor</link:label>
    <link:label id="lab_arvn_PiperSandlerAndCantorMember_label_en-US" xlink:label="lab_arvn_PiperSandlerAndCantorMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Piper Sandler And Cantor [Member]</link:label>
    <link:label id="lab_arvn_PiperSandlerAndCantorMember_documentation_en-US" xlink:label="lab_arvn_PiperSandlerAndCantorMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Piper sandler and cantor.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerAndCantorMember" xlink:href="arvn-20251231.xsd#arvn_PiperSandlerAndCantorMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PiperSandlerAndCantorMember" xlink:to="lab_arvn_PiperSandlerAndCantorMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_A101CollegeStreetLLCMember_6975a5ad-beba-48de-b902-a2a9ba107fa0_terseLabel_en-US" xlink:label="lab_arvn_A101CollegeStreetLLCMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">101 College Street LLC</link:label>
    <link:label id="lab_arvn_A101CollegeStreetLLCMember_label_en-US" xlink:label="lab_arvn_A101CollegeStreetLLCMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">101 College Street LLC [Member]</link:label>
    <link:label id="lab_arvn_A101CollegeStreetLLCMember_documentation_en-US" xlink:label="lab_arvn_A101CollegeStreetLLCMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">101 College Street LLC</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_A101CollegeStreetLLCMember" xlink:href="arvn-20251231.xsd#arvn_A101CollegeStreetLLCMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_A101CollegeStreetLLCMember" xlink:to="lab_arvn_A101CollegeStreetLLCMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_0758509a-a18a-4545-acb2-2bd1835facbe_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Income Tax Expense</link:label>
    <link:label id="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameAxis_e56f5107-6c14-4e86-9b3d-28761e2da195_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:label id="lab_us-gaap_PlanNameAxis_label_en-US" xlink:label="lab_us-gaap_PlanNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameAxis" xlink:to="lab_us-gaap_PlanNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_c83e749e-04df-4baf-81ca-a4920f76fbf9_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Equipment, and Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock_0d9ff341-1e48-496b-b991-dd93c9699949_terseLabel_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Supplemental Cash Flow Information Related to Leases</link:label>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock_label_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule Of Supplemental Cash Flow Information Related To Leases Table [Table Text Block]</link:label>
    <link:label id="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock_documentation_en-US" xlink:label="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental cash flow information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" xlink:href="arvn-20251231.xsd#arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" xlink:to="lab_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoMember_terseLabel_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO</link:label>
    <link:label id="lab_ecd_PeoMember_label_en-US" xlink:label="lab_ecd_PeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoMember" xlink:to="lab_ecd_PeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncomeTaxDisclosureLineItems_020f8f8d-767a-4b81-b708-632661e28085_terseLabel_en-US" xlink:label="lab_arvn_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_arvn_IncomeTaxDisclosureLineItems_label_en-US" xlink:label="lab_arvn_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Line Items]</link:label>
    <link:label id="lab_arvn_IncomeTaxDisclosureLineItems_documentation_en-US" xlink:label="lab_arvn_IncomeTaxDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income tax disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeTaxDisclosureLineItems" xlink:href="arvn-20251231.xsd#arvn_IncomeTaxDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems" xlink:to="lab_arvn_IncomeTaxDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_019c46aa-f82d-7a12-aba3-2d1928cd256c_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee Severance</link:label>
    <link:label id="lab_us-gaap_EmployeeSeveranceMember_label_en-US" xlink:label="lab_us-gaap_EmployeeSeveranceMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Severance [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeSeveranceMember" xlink:to="lab_us-gaap_EmployeeSeveranceMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_LicenseSecondLicensedProductMember_137da1ab-e387-4981-8b87-f1fb989ed81c_terseLabel_en-US" xlink:label="lab_arvn_LicenseSecondLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, Second Licensed Product</link:label>
    <link:label id="lab_arvn_LicenseSecondLicensedProductMember_label_en-US" xlink:label="lab_arvn_LicenseSecondLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, Second Licensed Product [Member]</link:label>
    <link:label id="lab_arvn_LicenseSecondLicensedProductMember_documentation_en-US" xlink:label="lab_arvn_LicenseSecondLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, Second Licensed Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseSecondLicensedProductMember" xlink:href="arvn-20251231.xsd#arvn_LicenseSecondLicensedProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_LicenseSecondLicensedProductMember" xlink:to="lab_arvn_LicenseSecondLicensedProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OtherProgramsMember_1d14dce7-97d1-48e8-ba43-63f5aac91b9a_terseLabel_en-US" xlink:label="lab_arvn_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other programs</link:label>
    <link:label id="lab_arvn_OtherProgramsMember_label_en-US" xlink:label="lab_arvn_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Programs [Member]</link:label>
    <link:label id="lab_arvn_OtherProgramsMember_documentation_en-US" xlink:label="lab_arvn_OtherProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Other Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OtherProgramsMember" xlink:href="arvn-20251231.xsd#arvn_OtherProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OtherProgramsMember" xlink:to="lab_arvn_OtherProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments_b683a5c7-c339-42df-9a76-3a26d50ca9b1_terseLabel_en-US" xlink:label="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contingent payments</link:label>
    <link:label id="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments_label_en-US" xlink:label="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Contingent Payments</link:label>
    <link:label id="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments_documentation_en-US" xlink:label="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Contingent Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RevenueRemainingPerformanceObligationContingentPayments" xlink:href="arvn-20251231.xsd#arvn_RevenueRemainingPerformanceObligationContingentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RevenueRemainingPerformanceObligationContingentPayments" xlink:to="lab_arvn_RevenueRemainingPerformanceObligationContingentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_f38467e4-e994-4199-bc13-9a3ce35b47ce_terseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_12560fe5-c025-43c5-984d-efcbacc36db7_verboseLabel_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest income, net</link:label>
    <link:label id="lab_us-gaap_InvestmentIncomeInterest_label_en-US" xlink:label="lab_us-gaap_InvestmentIncomeInterest" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment Income, Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_InvestmentIncomeInterest" xlink:to="lab_us-gaap_InvestmentIncomeInterest" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_a177994b-4ab5-4a38-afd2-c046625bd1a3_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss before income taxes and loss from equity method investment</link:label>
    <link:label id="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_label_en-US" xlink:label="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:to="lab_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_0f654813-51f7-4a36-9395-3ad486b2d754_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current:</link:label>
    <link:label id="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c469d-ec70-77c4-a1d5-13e5ea785d2d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Paid, by Individual Jurisdiction [Line Items]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, by Individual Jurisdiction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:to="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_5e00320e-c33f-47c2-ac26-6b269d3ac1cd_terseLabel_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">(Decrease) increase in valuation allowance</link:label>
    <link:label id="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_label_en-US" xlink:label="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="lab_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_659d5048-cdc1-461e-86f9-708f227b5998_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income taxes</link:label>
    <link:label id="lab_us-gaap_AccruedIncomeTaxesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Income Taxes, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedIncomeTaxesCurrent" xlink:to="lab_us-gaap_AccruedIncomeTaxesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_46f3092e-1765-4bf3-8570-a73064ea54ad_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_NovartisPharmaAGMember_7f40361e-9399-4d2b-a808-519acdf61729_terseLabel_en-US" xlink:label="lab_arvn_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Novartis Pharma AG</link:label>
    <link:label id="lab_arvn_NovartisPharmaAGMember_label_en-US" xlink:label="lab_arvn_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Novartis Pharma AG [Member]</link:label>
    <link:label id="lab_arvn_NovartisPharmaAGMember_documentation_en-US" xlink:label="lab_arvn_NovartisPharmaAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Novartis Pharma AG</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NovartisPharmaAGMember" xlink:href="arvn-20251231.xsd#arvn_NovartisPharmaAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_NovartisPharmaAGMember" xlink:to="lab_arvn_NovartisPharmaAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year</link:label>
    <link:label id="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember_label_en-US" xlink:label="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:to="lab_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c468a-f54a-757b-a93a-4a085cc81719_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changes in valuation allowance</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_2cc41fe5-9765-4847-9973-46d17f24742b_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Property, Plant and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsMember_f122b36f-683a-4961-b14b-c3a71674c388_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsMember_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsMember" xlink:to="lab_us-gaap_RetainedEarningsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_2223f57d-504a-4bd1-bffa-dfeffb14a331_terseLabel_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other current assets</link:label>
    <link:label id="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_label_en-US" xlink:label="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid Expense and Other Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="lab_us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_f3f7648a-1d13-4347-91d7-27161b8ad58d_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityAxis_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis" xlink:to="lab_us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_026e94a4-e259-4997-a819-1f57920d2afd_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgedStatusDomain_34d53b4e-c2f2-454c-9f25-6c0caecfa844_terseLabel_en-US" xlink:label="lab_us-gaap_PledgedStatusDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pledged Status [Domain]</link:label>
    <link:label id="lab_us-gaap_PledgedStatusDomain_label_en-US" xlink:label="lab_us-gaap_PledgedStatusDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pledged Status [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgedStatusDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgedStatusDomain" xlink:to="lab_us-gaap_PledgedStatusDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_82981c75-77dd-4066-b733-ed8abedd12d1_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Accrued Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_6f753f81-cb7a-4126-9e30-529536d2374e_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDeterminationDate_terseLabel_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:label id="lab_ecd_RestatementDeterminationDate_label_en-US" xlink:label="lab_ecd_RestatementDeterminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDeterminationDate" xlink:to="lab_ecd_RestatementDeterminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_116c96b1-57e8-4f93-a4d9-ad7231059484_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Abstract]</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_487d6321-a36e-4b99-b9b1-1a091d849c2c_periodStartLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, beginning of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_14d476e3-f6d1-413d-8711-3e449d284a11_periodEndLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash, end of the period</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_027c8c3c-0008-407b-93c2-38911039e5b2_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_6477fec9-2270-4d9d-a99e-d2481832abd8_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Operations</link:label>
    <link:label id="lab_us-gaap_IncomeStatementAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeStatementAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementAbstract" xlink:to="lab_us-gaap_IncomeStatementAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_c6d5abce-17c1-46c7-9009-18bad474f97e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_6926a5d7-9d77-41f9-b938-a80e2377f9de_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_1a6d4d39-4ba5-43ab-94ea-d09054e4c68d_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_aa766983-087e-47cb-b572-53b6492c8e41_verboseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Income tax expense</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_b81cc40d-f7a7-4a49-9dd7-134d2eda8c2a_terseLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of inducement grants (in shares)</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_20f9f6e1-3d8c-4ee2-8587-bbe199ec8e71_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of marketable securities</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquireMarketableSecurities_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="lab_us-gaap_PaymentsToAcquireMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_efc49156-8adb-4c70-b0f5-395ef06971fc_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNameOfTransactionDomain_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="lab_us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_4db6bf93-5e5e-4a4c-985d-baaa9b04810f_negatedLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Released (in shares)</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Released In Period</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Released In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_bfc7d3f5-2192-4af8-9920-efa7cb369fee_terseLabel_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration agreement direct and incremental costs incurred</link:label>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_label_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Direct And Incremental Costs Incurred To Obtain The Contract</link:label>
    <link:label id="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_documentation_en-US" xlink:label="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Direct And Incremental Costs Incurred To Obtain The Contract</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:href="arvn-20251231.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:to="lab_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AggregateIntrinsicValueAbstract_615f8c0b-8af7-4820-849c-9a39ac4d5402_terseLabel_en-US" xlink:label="lab_arvn_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:label id="lab_arvn_AggregateIntrinsicValueAbstract_label_en-US" xlink:label="lab_arvn_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value [Abstract]</link:label>
    <link:label id="lab_arvn_AggregateIntrinsicValueAbstract_documentation_en-US" xlink:label="lab_arvn_AggregateIntrinsicValueAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AggregateIntrinsicValueAbstract" xlink:href="arvn-20251231.xsd#arvn_AggregateIntrinsicValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract" xlink:to="lab_arvn_AggregateIntrinsicValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_3252a2ad-9a56-4f8f-982f-a0155739cb69_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase in reserved shares of common stock (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_fd36305d-5c69-4344-be06-f8edb72d090c_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesIssued" xlink:to="lab_us-gaap_PreferredStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsSvcCstMember" xlink:to="lab_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PaymentsForCollaboration_aab1b908-204b-4892-9a8f-39b423b73d8a_terseLabel_en-US" xlink:label="lab_arvn_PaymentsForCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments for collaboration</link:label>
    <link:label id="lab_arvn_PaymentsForCollaboration_label_en-US" xlink:label="lab_arvn_PaymentsForCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments For Collaboration</link:label>
    <link:label id="lab_arvn_PaymentsForCollaboration_documentation_en-US" xlink:label="lab_arvn_PaymentsForCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Payments For Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PaymentsForCollaboration" xlink:href="arvn-20251231.xsd#arvn_PaymentsForCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PaymentsForCollaboration" xlink:to="lab_arvn_PaymentsForCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductsAndServicesDomain_594bb333-65a9-44a3-a018-39bcbfd83287_terseLabel_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:label id="lab_srt_ProductsAndServicesDomain_label_en-US" xlink:label="lab_srt_ProductsAndServicesDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductsAndServicesDomain" xlink:to="lab_srt_ProductsAndServicesDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_5a951125-9028-4e08-adf1-3e99b650de0e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:label id="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis_label_en-US" xlink:label="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="lab_us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_b81e2157-606b-4fb4-92cb-5a93622e9a99_terseLabel_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk</link:label>
    <link:label id="lab_us-gaap_CustomerConcentrationRiskMember_label_en-US" xlink:label="lab_us-gaap_CustomerConcentrationRiskMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Customer Concentration Risk [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CustomerConcentrationRiskMember" xlink:to="lab_us-gaap_CustomerConcentrationRiskMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_47d12117-e69a-4138-8f74-350e5d13a4d7_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total property, equipment and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentGross_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentGross" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_be54571c-bcc9-43c2-941a-0c3e9ccb1f34_terseLabel_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash, cash equivalents, restricted cash and marketable securities</link:label>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_label_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</link:label>
    <link:label id="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_documentation_en-US" xlink:label="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalents, Restricted Cash and Marketable Securities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:href="arvn-20251231.xsd#arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:to="lab_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_terseLabel_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement does not require Recovery</link:label>
    <link:label id="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock_label_en-US" xlink:label="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Does Not Require Recovery [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:to="lab_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PreFundedWarrantMember_ef319436-9e4e-411b-9712-af17fab51dbb_terseLabel_en-US" xlink:label="lab_arvn_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant</link:label>
    <link:label id="lab_arvn_PreFundedWarrantMember_label_en-US" xlink:label="lab_arvn_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant [Member]</link:label>
    <link:label id="lab_arvn_PreFundedWarrantMember_documentation_en-US" xlink:label="lab_arvn_PreFundedWarrantMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pre-Funded Warrant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PreFundedWarrantMember" xlink:href="arvn-20251231.xsd#arvn_PreFundedWarrantMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PreFundedWarrantMember" xlink:to="lab_arvn_PreFundedWarrantMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_e9eb7909-21c0-4a94-a528-717b45794204_terseLabel_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:label id="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_label_en-US" xlink:label="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Organization, Consolidation and Presentation of Financial Statements [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="lab_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c469d-cc1f-7832-bf4e-e271da25c2e1_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Paid, by Individual Jurisdiction [Table]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, by Individual Jurisdiction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:to="lab_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_019c46aa-f82d-7403-9949-8d785070b3c2_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Activity</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_92bec018-0def-4e0f-a99d-ef115af19802_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of right-of-use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset, Periodic Reduction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Company Selected Measure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_bd2afe29-7fda-4416-8ebb-55b92dc0fd9e_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered</link:label>
    <link:label id="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock_label_en-US" xlink:label="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing, How MNPI Considered [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:to="lab_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c469d-ec70-7a25-87ed-985e1ee36d53_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US federal &#160;</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, Federal, after Refund Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:to="lab_us-gaap_IncomeTaxPaidFederalAfterRefundReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_813e3a86-c33f-4809-bf90-ecc97f934912_terseLabel_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payments received</link:label>
    <link:label id="lab_us-gaap_ProceedsFromCollaborators_label_en-US" xlink:label="lab_us-gaap_ProceedsFromCollaborators" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from Collaborators</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ProceedsFromCollaborators" xlink:to="lab_us-gaap_ProceedsFromCollaborators" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllTradingArrangementsMember_terseLabel_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Trading Arrangements</link:label>
    <link:label id="lab_ecd_AllTradingArrangementsMember_label_en-US" xlink:label="lab_ecd_AllTradingArrangementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Trading Arrangements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllTradingArrangementsMember" xlink:to="lab_ecd_AllTradingArrangementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:to="lab_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Vs Peer Group [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:to="lab_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_2c06ecc5-9c57-4b97-becc-f4e88984e83d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in Years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific_addda0ae-ed55-4316-bc0a-8578ec4849d1_terseLabel_en-US" xlink:label="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Program-specific external expense:</link:label>
    <link:label id="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific_label_en-US" xlink:label="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Program Specific</link:label>
    <link:label id="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific_documentation_en-US" xlink:label="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Program Specific</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific" xlink:href="arvn-20251231.xsd#arvn_ResearchAndDevelopmentExpenseProgramSpecific"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific" xlink:to="lab_arvn_ResearchAndDevelopmentExpenseProgramSpecific" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_3931652b-6e33-4b61-a561-79ac1ddb1811_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_14ac942c-051e-49f5-a210-ec0dbf06287e_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_fdec508b-17db-4f4a-aa5b-d6e6f0ada813_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_9e644363-1e92-4dd9-8732-f4ddd272750f_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Contract Balances</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:to="lab_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_7d5f78c3-9602-4d02-859f-08379b21e66b_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred income tax liability</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilities" xlink:to="lab_us-gaap_DeferredTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_912280b9-8716-4787-8c63-2d0d626488be_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from investing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a3513aad-a13e-46f9-9246-5925d247b666_terseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_a11aff49-d09c-43ce-a940-c13fb2f1938f_verboseLabel_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">General and administrative expense</link:label>
    <link:label id="lab_us-gaap_GeneralAndAdministrativeExpense_label_en-US" xlink:label="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GeneralAndAdministrativeExpense" xlink:to="lab_us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTable_terseLabel_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure</link:label>
    <link:label id="lab_ecd_PvpTable_label_en-US" xlink:label="lab_ecd_PvpTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTable" xlink:to="lab_ecd_PvpTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_da3f05de-1239-4bf4-9ae8-598c5cc9b481_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Operating Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_cde7ac65-7e67-49d2-a5cd-a4825e590541_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:to="lab_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ARV102Member_9ff0d7f3-6132-4b8b-b84e-c31d6ef10850_terseLabel_en-US" xlink:label="lab_arvn_ARV102Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ARV-102</link:label>
    <link:label id="lab_arvn_ARV102Member_label_en-US" xlink:label="lab_arvn_ARV102Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARV-102 [Member]</link:label>
    <link:label id="lab_arvn_ARV102Member_documentation_en-US" xlink:label="lab_arvn_ARV102Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARV-102</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV102Member" xlink:href="arvn-20251231.xsd#arvn_ARV102Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ARV102Member" xlink:to="lab_arvn_ARV102Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_24b710e1-ee9c-4f42-86a5-3b9335d4bd15_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property and equipment, estimated useful life</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_95dc95c8-f7ec-4d6b-89a3-877f9e73aab8_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_PreferredStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_PreferredStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_b7f06073-2109-4602-a54a-79cd27c23248_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_1beac79d-a2bc-4130-ab70-2fa9d93f0cca_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Equity Method Investments [Line Items]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Equity Method Investments [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:to="lab_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote</link:label>
    <link:label id="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock_label_en-US" xlink:label="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Valuation Assumption Difference, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:to="lab_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_16cffdf0-fd2d-4f85-81ab-3fdf067465a9_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Components of Lease Expense</link:label>
    <link:label id="lab_us-gaap_LeaseCostTableTextBlock_label_en-US" xlink:label="lab_us-gaap_LeaseCostTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease, Cost [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseCostTableTextBlock" xlink:to="lab_us-gaap_LeaseCostTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoTotalCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoTotalCompAmt_label_en-US" xlink:label="lab_ecd_PeoTotalCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Total Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoTotalCompAmt" xlink:to="lab_ecd_PeoTotalCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_1da6de37-0bd4-4655-93a3-a2580e0e0b7a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_42f12cd1-be65-46a3-a99c-921980355a0f_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Federal Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredFederalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_25b86ddf-c9b2-4b46-888c-8926b96c902e_terseLabel_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementEquityComponentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementEquityComponentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementEquityComponentsAxis" xlink:to="lab_us-gaap_StatementEquityComponentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_49a12e81-1ab0-4ed9-a215-50af76b8be6a_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property Plant And Equipment [Line Items]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentLineItems_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_beef0dff-5e92-43c4-a19c-9241a3306f3a_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_label_en-US" xlink:label="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:to="lab_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_bbccb82a-3c50-48ef-af1c-d7686a2bc447_terseLabel_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Assistance Agreement</link:label>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_label_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand And Eighteen Assistance Agreement [Member]</link:label>
    <link:label id="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember_documentation_en-US" xlink:label="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand and eighteen assistance agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:href="arvn-20251231.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:to="lab_arvn_TwoThousandAndEighteenAssistanceAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorName_d422eafa-a19a-4c43-99eb-74699fc17027_terseLabel_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:label id="lab_dei_AuditorName_label_en-US" xlink:label="lab_dei_AuditorName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorName" xlink:to="lab_dei_AuditorName" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_NonRule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:to="lab_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_LicenseFirstLicensedProductMember_813e1c9f-56fe-4ccf-8432-a1acfa04d43d_terseLabel_en-US" xlink:label="lab_arvn_LicenseFirstLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">License, First Licensed Product</link:label>
    <link:label id="lab_arvn_LicenseFirstLicensedProductMember_label_en-US" xlink:label="lab_arvn_LicenseFirstLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">License, First Licensed Product [Member]</link:label>
    <link:label id="lab_arvn_LicenseFirstLicensedProductMember_documentation_en-US" xlink:label="lab_arvn_LicenseFirstLicensedProductMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">License, First Licensed Product</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseFirstLicensedProductMember" xlink:href="arvn-20251231.xsd#arvn_LicenseFirstLicensedProductMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_LicenseFirstLicensedProductMember" xlink:to="lab_arvn_LicenseFirstLicensedProductMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_afb87c5b-b97d-41d4-bc86-4af5e5c77e31_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of reportable segments</link:label>
    <link:label id="lab_us-gaap_NumberOfReportableSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfReportableSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Reportable Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfReportableSegments" xlink:to="lab_us-gaap_NumberOfReportableSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RemovalOfCombinationTrialsMember_019c2373-086e-734b-aa31-4eac0c093c1f_terseLabel_en-US" xlink:label="lab_arvn_RemovalOfCombinationTrialsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Removal Of Combination Trials</link:label>
    <link:label id="lab_arvn_RemovalOfCombinationTrialsMember_label_en-US" xlink:label="lab_arvn_RemovalOfCombinationTrialsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Removal Of Combination Trials [Member]</link:label>
    <link:label id="lab_arvn_RemovalOfCombinationTrialsMember_documentation_en-US" xlink:label="lab_arvn_RemovalOfCombinationTrialsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Removal Of Combination Trials</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RemovalOfCombinationTrialsMember" xlink:href="arvn-20251231.xsd#arvn_RemovalOfCombinationTrialsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RemovalOfCombinationTrialsMember" xlink:to="lab_arvn_RemovalOfCombinationTrialsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_148193b3-a832-44ed-80e8-7fec44cd77db_terseLabel_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of cash flow information:</link:label>
    <link:label id="lab_us-gaap_SupplementalCashFlowInformationAbstract_label_en-US" xlink:label="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Cash Flow Information [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="lab_us-gaap_SupplementalCashFlowInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_9e5f4f3b-95e3-4a7a-bb85-cef492f42715_totalLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Amortized Cost</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Amortized Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_019c46aa-f82d-74a3-bd5d-01e3126a2c2b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveLineItems_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost and Reserve [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems" xlink:to="lab_us-gaap_RestructuringCostAndReserveLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_terseLabel_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:label id="lab_ecd_OtherPerfMeasureAmt_label_en-US" xlink:label="lab_ecd_OtherPerfMeasureAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Performance Measure, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OtherPerfMeasureAmt" xlink:to="lab_ecd_OtherPerfMeasureAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_cbff9270-01d6-4b9e-b343-f0775334c400_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of restrictions on cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restrictions on Cash and Cash Equivalents [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_604a01c8-eef0-45ab-88b8-933a1c06cb31_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_334f45e1-eff1-45af-8c81-e43b9ae9aa44_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesPolicy_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesPolicy" xlink:to="lab_us-gaap_MarketableSecuritiesPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_91c3d710-625f-4a2b-a95f-fdf2dfeb669e_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Security, Excluded EPS Calculation [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_b1435a82-2988-44a7-8d78-ec396caaca0b_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Measurement, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:to="lab_us-gaap_FairValueMeasurementPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_551b046e-9f4d-4bf3-8621-71e1d95258ec_totalLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrent" xlink:to="lab_us-gaap_LiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c4690-c6d0-73b0-9cd9-e3ac974e847c_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amount</link:label>
    <link:label id="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:to="lab_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019c46aa-f82d-7884-bf7f-549c1b198c1b_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reduction in workforce (as a percent)</link:label>
    <link:label id="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Cost, Number of Positions Eliminated, Period Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:to="lab_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CommercialMilestonesMember_ece51e7c-edb2-40bc-a351-099b2cf24f5a_terseLabel_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commercial Milestones</link:label>
    <link:label id="lab_arvn_CommercialMilestonesMember_label_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commercial Milestones [Member]</link:label>
    <link:label id="lab_arvn_CommercialMilestonesMember_documentation_en-US" xlink:label="lab_arvn_CommercialMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commercial milestones.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember" xlink:href="arvn-20251231.xsd#arvn_CommercialMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CommercialMilestonesMember" xlink:to="lab_arvn_CommercialMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_50c5ca53-c9f5-4807-bd36-57b1c53e36a3_terseLabel_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration contract asset and other assets</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_label_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Contract Asset And Other Assets</link:label>
    <link:label id="lab_arvn_CollaborationContractAssetAndOtherAssets_documentation_en-US" xlink:label="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Contract Asset And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets" xlink:href="arvn-20251231.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaborationContractAssetAndOtherAssets" xlink:to="lab_arvn_CollaborationContractAssetAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_90b46822-ddc7-4086-b9d6-2c788e56472a_terseLabel_en-US" xlink:label="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable related to collaborations</link:label>
    <link:label id="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounts Payable, after Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Accounts Payable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:href="arvn-20251231.xsd#arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:to="lab_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_IndividualAxis_terseLabel_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Individual:</link:label>
    <link:label id="lab_ecd_IndividualAxis_label_en-US" xlink:label="lab_ecd_IndividualAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Individual [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_IndividualAxis" xlink:to="lab_ecd_IndividualAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ReportableSegmentMember_5784d8ac-76f9-45d2-a233-9316bca43a19_terseLabel_en-US" xlink:label="lab_arvn_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:label id="lab_arvn_ReportableSegmentMember_label_en-US" xlink:label="lab_arvn_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Reportable Segment [Member]</link:label>
    <link:label id="lab_arvn_ReportableSegmentMember_documentation_en-US" xlink:label="lab_arvn_ReportableSegmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Reportable Segment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ReportableSegmentMember" xlink:href="arvn-20251231.xsd#arvn_ReportableSegmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ReportableSegmentMember" xlink:to="lab_arvn_ReportableSegmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_7cc167f5-4877-4617-bc58-7a040c53b240_terseLabel_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Discretionary matching contributions</link:label>
    <link:label id="lab_us-gaap_DefinedContributionPlanCostRecognized_label_en-US" xlink:label="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DefinedContributionPlanCostRecognized" xlink:to="lab_us-gaap_DefinedContributionPlanCostRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AuditInformationAbstract_label_en-US" xlink:label="lab_arvn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Audit Information [Abstract]</link:label>
    <link:label id="lab_arvn_AuditInformationAbstract_documentation_en-US" xlink:label="lab_arvn_AuditInformationAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Audit Information</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AuditInformationAbstract" xlink:href="arvn-20251231.xsd#arvn_AuditInformationAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AuditInformationAbstract" xlink:to="lab_arvn_AuditInformationAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SuccessBasedMilestonePaymentsMember_b1cd3d9b-adbb-4d13-8878-acc72b93f2e6_terseLabel_en-US" xlink:label="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Success-Based Milestone Payments</link:label>
    <link:label id="lab_arvn_SuccessBasedMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Success-Based Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_SuccessBasedMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Success-Based Milestone Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SuccessBasedMilestonePaymentsMember" xlink:href="arvn-20251231.xsd#arvn_SuccessBasedMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SuccessBasedMilestonePaymentsMember" xlink:to="lab_arvn_SuccessBasedMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_a0d0db58-c0c1-48b5-a199-b4c824407882_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity interest</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentAggregateCost_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Aggregate Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentAggregateCost" xlink:to="lab_us-gaap_EquityMethodInvestmentAggregateCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_a42c1f6a-6f89-4df7-8444-0c5f2715e032_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOtherReceivables_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Other Receivables</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:to="lab_us-gaap_IncreaseDecreaseInOtherReceivables" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_16060d9e-7cff-4952-bee1-58bd55f72503_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxAuthorityDomain_label_en-US" xlink:label="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Jurisdiction [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain" xlink:to="lab_us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentAnnualReport_c0f2782a-4237-4917-b0e2-f51ed5e8faa7_terseLabel_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:label id="lab_dei_DocumentAnnualReport_label_en-US" xlink:label="lab_dei_DocumentAnnualReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentAnnualReport" xlink:to="lab_dei_DocumentAnnualReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_019c46aa-f82d-7933-890f-70141a719644_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpenseMember_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_71d82f84-42cd-4665-beda-801ff6ee9b54_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate by Type [Axis]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Change in Accounting Estimate, Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:to="lab_us-gaap_ChangeInAccountingEstimateByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityDomain_b6467e40-a416-455d-adf2-b13b8c728a66_terseLabel_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:label id="lab_dei_EntityDomain_label_en-US" xlink:label="lab_dei_EntityDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityDomain" xlink:to="lab_dei_EntityDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_b4bece0c-071b-4d29-9138-b00c14f6158d_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Investing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_022f0033-842d-48ac-919c-0424abc01666_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue, remaining performance obligation, expected timing of satisfaction, period</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentFiscalYearFocus_4d0044cd-da35-4d7e-9503-a4c1b366b6d2_terseLabel_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:label id="lab_dei_DocumentFiscalYearFocus_label_en-US" xlink:label="lab_dei_DocumentFiscalYearFocus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentFiscalYearFocus" xlink:to="lab_dei_DocumentFiscalYearFocus" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019b3057-2efc-7d38-9e71-a374c70e9411_terseLabel_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="lab_us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_37863a83-13ea-461a-9ee3-29ae36e8013c_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease right of use assets</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseRightOfUseAsset_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Right-of-Use Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="lab_us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Explanation of Impracticability [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:to="lab_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_1dff15e4-d8be-4a72-be9a-909e5b1bd64e_terseLabel_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_83a9d0e7-be25-4ea6-bdb8-49d67391188e_verboseLabel_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">2018 Plan</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_label_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Two Thousand Eighteen Stock Incentive Plan [Member]</link:label>
    <link:label id="lab_arvn_TwoThousandEighteenStockIncentivePlanMember_documentation_en-US" xlink:label="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Two thousand eighteen stock incentive plan.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:href="arvn-20251231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:to="lab_arvn_TwoThousandEighteenStockIncentivePlanMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_ea5dd17b-f99d-4ddb-a885-f82846f9896f_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repayments of long-term debt</link:label>
    <link:label id="lab_us-gaap_RepaymentsOfLongTermDebt_label_en-US" xlink:label="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Repayments of Long-Term Debt</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RepaymentsOfLongTermDebt" xlink:to="lab_us-gaap_RepaymentsOfLongTermDebt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_c942c053-75cb-4553-b2f4-f57b286f2953_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized research and development</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Asset, In-Process Research and Development</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:to="lab_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_3cb98852-239c-42dc-8e86-2c7e9399d352_totalLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Effective tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_5cb1e317-ba86-4c35-8b05-ac25f421addc_terseLabel_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:label id="lab_dei_EntityInteractiveDataCurrent_label_en-US" xlink:label="lab_dei_EntityInteractiveDataCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityInteractiveDataCurrent" xlink:to="lab_dei_EntityInteractiveDataCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseCost_cc638e32-c546-49ce-9137-abbd12dffe8e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease cost</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseCost_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseCost" xlink:to="lab_us-gaap_OperatingLeaseCost" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration_019b30d0-b5f3-700f-860b-8b26d117f46f_terseLabel_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from balances not held at the beginning of the period</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration_label_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized From New Collaboration</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration_documentation_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized From New Collaboration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" xlink:href="arvn-20251231.xsd#arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" xlink:to="lab_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PlanNameDomain_dad4acc1-9eed-4148-8b45-c927e2d679f8_terseLabel_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:label id="lab_us-gaap_PlanNameDomain_label_en-US" xlink:label="lab_us-gaap_PlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PlanNameDomain" xlink:to="lab_us-gaap_PlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_0b76b5e5-e98f-4727-a502-739cd9764beb_terseLabel_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions to collaboration agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_label_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_documentation_en-US" xlink:label="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:href="arvn-20251231.xsd#arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:to="lab_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_c9248ded-e6f9-42bc-81da-e129781a3d71_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense not yet recognized, period of recognition (in years)</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_c6aecf76-ad29-4fbf-a431-59e8d8c81658_negatedLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less valuation allowance</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsValuationAllowance_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="lab_us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_fc537683-f87f-4832-b6f5-ddeaa60d4816_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsDeferredIncome_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Deferred Income</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:to="lab_us-gaap_DeferredTaxAssetsDeferredIncome" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_52196d3d-c36b-4dd7-bb81-437c8e3d3d66_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Recognition and Deferred Revenue</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_7f247c9f-485d-47f2-b287-57ce9e51c5d6_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c68eb-cd17-7ca2-9f78-25641d3c9358_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock compensation</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_5d9094b4-22b2-4558-8f2e-6f9f22a2772e_terseLabel_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Less:</link:label>
    <link:label id="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_label_en-US" xlink:label="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:to="lab_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_1c36d585-4af3-4ff6-a3b1-6e4258ec1d84_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Information</link:label>
    <link:label id="lab_us-gaap_SegmentReportingDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingDisclosureTextBlock" xlink:to="lab_us-gaap_SegmentReportingDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ARV471Member_a9124609-db87-4233-8a66-681a0f7ef507_terseLabel_en-US" xlink:label="lab_arvn_ARV471Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vepdegestrant ARV-471</link:label>
    <link:label id="lab_arvn_ARV471Member_label_en-US" xlink:label="lab_arvn_ARV471Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARV-471 [Member]</link:label>
    <link:label id="lab_arvn_ARV471Member_documentation_en-US" xlink:label="lab_arvn_ARV471Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARV-471</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV471Member" xlink:href="arvn-20251231.xsd#arvn_ARV471Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ARV471Member" xlink:to="lab_arvn_ARV471Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_64002530-b06b-4204-87f1-918722d49442_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_fe88641a-5f8a-40a7-8ddb-61dd36ec287a_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss carryforwards</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_2c0e1afb-ad4f-4142-a90e-84017af11b15_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal</link:label>
    <link:label id="lab_us-gaap_CurrentFederalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Federal Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentFederalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ae795741-96bd-4a1e-b8c9-e59e96ec49dd_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_3603e997-d57b-458e-bd59-cf47ff916cca_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Stockholders' Equity [Roll Forward]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="lab_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Total Shareholder Return [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_cd435cc8-f05d-41fd-985a-b6bab0cd8e40_terseLabel_en-US" xlink:label="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating losses carry forward, maximum deductibility percentage</link:label>
    <link:label id="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_label_en-US" xlink:label="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Losses Carry Forward Maximum Deductibility Percentage</link:label>
    <link:label id="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_documentation_en-US" xlink:label="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Operating losses carry forward, maximum deductibility as a percentage of taxable income.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:href="arvn-20251231.xsd#arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:to="lab_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_WeightedAverageMember_92ac664d-4954-4570-8555-02ece1f0f3fa_terseLabel_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted Average</link:label>
    <link:label id="lab_srt_WeightedAverageMember_label_en-US" xlink:label="lab_srt_WeightedAverageMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_WeightedAverageMember" xlink:to="lab_srt_WeightedAverageMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_f4e43d02-5dc6-4d99-9f18-e33befb5332f_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]</link:label>
    <link:label id="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_label_en-US" xlink:label="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value, Recurring and Nonrecurring [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:to="lab_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_2d6a3c64-28e0-41bd-bbe1-113b5bcd211d_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease and Rent Expense</link:label>
    <link:label id="lab_us-gaap_LesseeLeasesPolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Leases [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeasesPolicyTextBlock" xlink:to="lab_us-gaap_LesseeLeasesPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_2e6ff435-806e-4aae-87da-7735bf951561_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoName_terseLabel_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:label id="lab_ecd_PeoName_label_en-US" xlink:label="lab_ecd_PeoName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoName" xlink:to="lab_ecd_PeoName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_b073bf6e-c3e8-478a-a4b9-502dd1c4927c_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Minimum Future Payments on Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Maturities of Long-Term Debt [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Revenues_fdc04f21-1feb-4cad-bf00-dfd80d1fd562_terseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_d19b00dd-c5ce-424c-a046-f936aa1670a9_verboseLabel_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_Revenues_label_en-US" xlink:label="lab_us-gaap_Revenues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Revenues" xlink:to="lab_us-gaap_Revenues" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year</link:label>
    <link:label id="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember_label_en-US" xlink:label="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:to="lab_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_NumberOfWhollyOwnedSubsidiaries_0a478882-a49a-4a82-8363-e52e1e6cf98d_terseLabel_en-US" xlink:label="lab_arvn_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of wholly owned subsidiaries</link:label>
    <link:label id="lab_arvn_NumberOfWhollyOwnedSubsidiaries_label_en-US" xlink:label="lab_arvn_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number Of Wholly Owned Subsidiaries</link:label>
    <link:label id="lab_arvn_NumberOfWhollyOwnedSubsidiaries_documentation_en-US" xlink:label="lab_arvn_NumberOfWhollyOwnedSubsidiaries" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of wholly owned subsidiaries.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfWhollyOwnedSubsidiaries" xlink:href="arvn-20251231.xsd#arvn_NumberOfWhollyOwnedSubsidiaries"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_NumberOfWhollyOwnedSubsidiaries" xlink:to="lab_arvn_NumberOfWhollyOwnedSubsidiaries" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_f7af7c89-1d4c-47a5-9a60-745e7d1f0d83_terseLabel_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Supplemental non-cash information:</link:label>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_label_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental Non Cash Information Related To Leases [Abstract]</link:label>
    <link:label id="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_documentation_en-US" xlink:label="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Supplemental non-cash information related to leases.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:href="arvn-20251231.xsd#arvn_SupplementalNonCashInformationRelatedToLeasesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:to="lab_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingAggtErrCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingAggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingAggtErrCompAmt" xlink:to="lab_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrDuration_terseLabel_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Arrangement Duration</link:label>
    <link:label id="lab_ecd_TrdArrDuration_label_en-US" xlink:label="lab_ecd_TrdArrDuration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Duration</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrDuration" xlink:to="lab_ecd_TrdArrDuration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_50ef8ef1-defd-4d6e-9b59-e4ee00bacb5d_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Segment Reporting Information, by Segment [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:to="lab_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_5da93c1e-26c3-4bff-8622-a32dc8aa3f8c_terseLabel_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Funding Payments</link:label>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_label_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Funding Payments [Member]</link:label>
    <link:label id="lab_arvn_ResearchFundingPaymentsMember_documentation_en-US" xlink:label="lab_arvn_ResearchFundingPaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research funding payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember" xlink:href="arvn-20251231.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchFundingPaymentsMember" xlink:to="lab_arvn_ResearchFundingPaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ARV806Member_019c46ac-dc8a-71f3-b2c1-941e030d06a7_terseLabel_en-US" xlink:label="lab_arvn_ARV806Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ARV-806</link:label>
    <link:label id="lab_arvn_ARV806Member_label_en-US" xlink:label="lab_arvn_ARV806Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARV-806 [Member]</link:label>
    <link:label id="lab_arvn_ARV806Member_documentation_en-US" xlink:label="lab_arvn_ARV806Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARV-806</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV806Member" xlink:href="arvn-20251231.xsd#arvn_ARV806Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ARV806Member" xlink:to="lab_arvn_ARV806Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_efe63d9b-3b4e-4c31-99ad-8deb25c741ce_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, maximum (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_6031b5e5-6274-4626-86ff-2a2520485666_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityCurrent_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_2f693653-527b-4e95-a770-08fa800038b2_terseLabel_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:label id="lab_us-gaap_StatementBusinessSegmentsAxis_label_en-US" xlink:label="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis" xlink:to="lab_us-gaap_StatementBusinessSegmentsAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_cae90435-3cbc-467e-88a7-62c419ee922f_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrant exercise price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="lab_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_ef9905c7-afec-4d07-85db-e3e8d32a35b2_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses and other assets</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Prepaid Expense and Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="lab_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardExrcPrice_terseLabel_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise Price</link:label>
    <link:label id="lab_ecd_AwardExrcPrice_label_en-US" xlink:label="lab_ecd_AwardExrcPrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardExrcPrice" xlink:to="lab_ecd_AwardExrcPrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFilerCategory_9cd10785-7f4a-44cc-bdfd-50e84950b62e_terseLabel_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:label id="lab_dei_EntityFilerCategory_label_en-US" xlink:label="lab_dei_EntityFilerCategory" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFilerCategory" xlink:to="lab_dei_EntityFilerCategory" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_8a4c8cf5-885b-4c0c-87d5-6528620ac5a8_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_terseLabel_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure</link:label>
    <link:label id="lab_ecd_Additional402vDisclosureTextBlock_label_en-US" xlink:label="lab_ecd_Additional402vDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional 402(v) Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Additional402vDisclosureTextBlock" xlink:to="lab_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_ef3f577e-9469-4ca8-86a9-1142b55f960c_terseLabel_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:label id="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember_label_en-US" xlink:label="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:to="lab_us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_ab08c69a-8c5a-44b7-8e89-82e0a4e18372_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PropertyPlantAndEquipmentWriteoff_2f604392-f50f-42ca-b6f4-ab2c1fd910ad_terseLabel_en-US" xlink:label="lab_arvn_PropertyPlantAndEquipmentWriteoff" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvement written-off</link:label>
    <link:label id="lab_arvn_PropertyPlantAndEquipmentWriteoff_label_en-US" xlink:label="lab_arvn_PropertyPlantAndEquipmentWriteoff" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant And Equipment, Writeoff</link:label>
    <link:label id="lab_arvn_PropertyPlantAndEquipmentWriteoff_documentation_en-US" xlink:label="lab_arvn_PropertyPlantAndEquipmentWriteoff" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Property, Plant And Equipment, Writeoff</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PropertyPlantAndEquipmentWriteoff" xlink:href="arvn-20251231.xsd#arvn_PropertyPlantAndEquipmentWriteoff"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PropertyPlantAndEquipmentWriteoff" xlink:to="lab_arvn_PropertyPlantAndEquipmentWriteoff" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_97ba645b-17bd-45f6-85dd-cf0b0349abec_terseLabel_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity</link:label>
    <link:label id="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_label_en-US" xlink:label="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="lab_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_be1191b5-0952-45b5-865d-532f6b3dbfe7_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Maturities of marketable securities</link:label>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_label_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Maturities Of Marketable Securities</link:label>
    <link:label id="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities_documentation_en-US" xlink:label="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from maturities of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:to="lab_arvn_ProceedsFromMaturitiesOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsAbstract_d1d82c23-4de2-4e97-8e1e-1ba4af1f825f_terseLabel_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Assets</link:label>
    <link:label id="lab_us-gaap_AssetsAbstract_label_en-US" xlink:label="lab_us-gaap_AssetsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsAbstract" xlink:to="lab_us-gaap_AssetsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_6f871bf9-0f9f-48e5-960f-95fd02b6e164_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_ee0833e1-3c00-41b0-9268-2d8aac98d568_verboseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Total long-term debt</link:label>
    <link:label id="lab_us-gaap_LongTermDebtNoncurrent_label_en-US" xlink:label="lab_us-gaap_LongTermDebtNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Excluding Current Maturities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtNoncurrent" xlink:to="lab_us-gaap_LongTermDebtNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_terseLabel_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change</link:label>
    <link:label id="lab_ecd_UndrlygSecurityMktPriceChngPct_label_en-US" xlink:label="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underlying Security Market Price Change, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:to="lab_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_1dd8954b-b9e8-44a2-bf84-90968445695c_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightDomain_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain" xlink:to="lab_us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_f188a019-1cdc-4ab8-b875-16bb71272fb8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentAxis" xlink:to="lab_us-gaap_DebtInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_be9c2f9a-19df-45a6-b430-fcb283b0b189_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_ed443c3c-82ba-4bf6-bc87-4bc85eb4d09e_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable Securities and Fair Value Measurements</link:label>
    <link:label id="lab_us-gaap_FairValueDisclosuresTextBlock_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresTextBlock" xlink:to="lab_us-gaap_FairValueDisclosuresTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_fd97a28b-bd40-4140-8a1a-c9cc91134043_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax assets:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="lab_us-gaap_DeferredTaxAssetsNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_6240453b-bf57-4c56-b027-143cf73a3bf1_terseLabel_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stockholders' equity:</link:label>
    <link:label id="lab_us-gaap_StockholdersEquityAbstract_label_en-US" xlink:label="lab_us-gaap_StockholdersEquityAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity, Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockholdersEquityAbstract" xlink:to="lab_us-gaap_StockholdersEquityAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_terseLabel_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year</link:label>
    <link:label id="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember_label_en-US" xlink:label="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:to="lab_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_60e8952b-7675-4e49-b1b5-4fd4b363d86d_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine2_28574cd1-9c19-47f5-9ea6-5b0a897f672b_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine2_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine2" xlink:to="lab_dei_EntityAddressAddressLine2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_019c0afe-9a60-767e-b863-16b38450edbf_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Share repurchases (Treasury stock)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockValueAcquiredCostMethod_label_en-US" xlink:label="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:to="lab_us-gaap_TreasuryStockValueAcquiredCostMethod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_d009e92b-187b-42c2-b193-e087fca37341_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_4414767c-a134-4e60-a19f-f53186ec4bf9_totalLabel_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total research and development expense</link:label>
    <link:label id="lab_us-gaap_ResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_63a9bd27-43e8-4735-8b04-3c9b9211156b_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Loss (Income)</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">AOCI Attributable to Parent [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_f3c84676-3509-4fc3-b889-619f66ff8006_verboseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Interest Rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_ea8f3ebc-d632-42d8-991e-a3fe86990ce8_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument bearing interest rate</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Interest Rate, Stated Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:to="lab_us-gaap_DebtInstrumentInterestRateStatedPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_a2fff465-c8e1-4feb-b055-c614e935848c_terseLabel_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:label id="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_label_en-US" xlink:label="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Investment, Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:to="lab_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_415fc57c-956c-47c4-affc-1a5e8dc99ee6_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liability</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseLiabilityNoncurrent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Liability, Noncurrent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="lab_us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityVoluntaryFilers_0e8db482-7d65-4c45-8877-0e07b2366447_terseLabel_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:label id="lab_dei_EntityVoluntaryFilers_label_en-US" xlink:label="lab_dei_EntityVoluntaryFilers" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityVoluntaryFilers" xlink:to="lab_dei_EntityVoluntaryFilers" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_cf76ed47-6516-4629-ab48-69d77329a8b3_terseLabel_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loan forgiveness</link:label>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_label_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument Loan Forgiveness</link:label>
    <link:label id="lab_arvn_DebtInstrumentLoanForgiveness_documentation_en-US" xlink:label="lab_arvn_DebtInstrumentLoanForgiveness" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Debt Instrument Loan Forgiveness</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness" xlink:href="arvn-20251231.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DebtInstrumentLoanForgiveness" xlink:to="lab_arvn_DebtInstrumentLoanForgiveness" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_83812443-86d2-4eed-a4d3-8fce1faf86d1_terseLabel_en-US" xlink:label="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">General and administrative and commercial expenses</link:label>
    <link:label id="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_label_en-US" xlink:label="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued General And Administrative And Commercial, Current</link:label>
    <link:label id="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_documentation_en-US" xlink:label="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued General And Administrative And Commercial, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" xlink:href="arvn-20251231.xsd#arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" xlink:to="lab_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_a43d17ee-0b0c-4a52-b217-1ce5a6ae7220_terseLabel_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Genentech</link:label>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_label_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Genentech Incorporation And F Hoffman La Roche Limited [Member]</link:label>
    <link:label id="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_documentation_en-US" xlink:label="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Genentech, Incorporation. and F. Hoffman-La Roche Limited.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:href="arvn-20251231.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:to="lab_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems_2b56841e-ebdf-4c48-9681-0847546f745a_terseLabel_en-US" xlink:label="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems_label_en-US" xlink:label="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary Of Significant Accounting Policies [Line Items]</link:label>
    <link:label id="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems_documentation_en-US" xlink:label="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Summary of significant accounting policies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:href="arvn-20251231.xsd#arvn_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:to="lab_arvn_SummaryOfSignificantAccountingPoliciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_b3eda560-1721-47a3-9895-aeaac16ab948_terseLabel_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Agreements [Line Items]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Agreements [Line Items]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:href="arvn-20251231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardGrantDateFairValue_terseLabel_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value as of Grant Date</link:label>
    <link:label id="lab_ecd_AwardGrantDateFairValue_label_en-US" xlink:label="lab_ecd_AwardGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardGrantDateFairValue" xlink:to="lab_ecd_AwardGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_05b8a502-d224-477f-857d-ec7d6977718b_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentAbstract_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_b5fb7e92-0d07-44aa-b594-89fb51a299aa_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_8e49d9d5-2bc7-4501-b793-9a5e8a17d1f6_terseLabel_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of liquidated damages</link:label>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_label_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Percentage Of Liquidated Damages</link:label>
    <link:label id="lab_arvn_PercentageOfLiquidatedDamages_documentation_en-US" xlink:label="lab_arvn_PercentageOfLiquidatedDamages" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of liquidated damages.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages" xlink:href="arvn-20251231.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PercentageOfLiquidatedDamages" xlink:to="lab_arvn_PercentageOfLiquidatedDamages" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_terseLabel_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method</link:label>
    <link:label id="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock_label_en-US" xlink:label="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Price or TSR Estimation Method [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:to="lab_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_3d2c72b8-9bc6-423b-85b4-6a7b7023c2f2_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal net operating loss carryforwards</link:label>
    <link:label id="lab_us-gaap_OperatingLossCarryforwards_label_en-US" xlink:label="lab_us-gaap_OperatingLossCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Loss Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLossCarryforwards" xlink:to="lab_us-gaap_OperatingLossCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_8f2e9778-cfe6-490a-a95f-e837bcd313db_verboseLabel_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Compensation and related personnel expense (including stock-based compensation)</link:label>
    <link:label id="lab_us-gaap_LaborAndRelatedExpense_label_en-US" xlink:label="lab_us-gaap_LaborAndRelatedExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Labor and Related Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LaborAndRelatedExpense" xlink:to="lab_us-gaap_LaborAndRelatedExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_c2d752ff-4a57-4459-9e02-65737e7727fd_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Long-Term Debt Instruments [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:to="lab_us-gaap_ScheduleOfDebtInstrumentsTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_8d01cb21-1bd6-41a7-b20c-1f6e7c25124f_terseLabel_en-US" xlink:label="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment Upon Approval Of First And Second Royalty Products</link:label>
    <link:label id="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_label_en-US" xlink:label="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment Upon Approval Of First And Second Royalty Products [Member]</link:label>
    <link:label id="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_documentation_en-US" xlink:label="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment Upon Approval Of First And Second Royalty Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" xlink:href="arvn-20251231.xsd#arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" xlink:to="lab_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_e6388e88-380c-4e8a-9ef4-dd6b01e7b0e3_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SaleOfStockFairValueOfSharesSold_4c2c012d-a0fb-4d44-ad34-c2c7af3b90df_terseLabel_en-US" xlink:label="lab_arvn_SaleOfStockFairValueOfSharesSold" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair value of the shares sold</link:label>
    <link:label id="lab_arvn_SaleOfStockFairValueOfSharesSold_label_en-US" xlink:label="lab_arvn_SaleOfStockFairValueOfSharesSold" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale Of Stock Fair Value Of Shares Sold</link:label>
    <link:label id="lab_arvn_SaleOfStockFairValueOfSharesSold_documentation_en-US" xlink:label="lab_arvn_SaleOfStockFairValueOfSharesSold" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sale of stock, fair value of shares sold.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SaleOfStockFairValueOfSharesSold" xlink:href="arvn-20251231.xsd#arvn_SaleOfStockFairValueOfSharesSold"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SaleOfStockFairValueOfSharesSold" xlink:to="lab_arvn_SaleOfStockFairValueOfSharesSold" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_e37c1860-b6fd-445b-aa40-995b15bedeb3_negatedLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_f4660b41-db02-4e06-86c5-8ef764bf03b3_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation expense not yet recognized</link:label>
    <link:label id="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_label_en-US" xlink:label="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="lab_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_580e923f-57e1-4015-8d50-b91aea211706_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock, offering costs</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote</link:label>
    <link:label id="lab_ecd_ChangedPeerGroupFnTextBlock_label_en-US" xlink:label="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changed Peer Group, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:to="lab_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_3d60a629-271e-40a4-bf85-11d35e5023c5_terseLabel_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:label id="lab_srt_RepurchaseAgreementCounterpartyNameDomain_label_en-US" xlink:label="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="lab_srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_73a1d315-7785-488d-8212-704605417856_terseLabel_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of operating segments</link:label>
    <link:label id="lab_us-gaap_NumberOfOperatingSegments_label_en-US" xlink:label="lab_us-gaap_NumberOfOperatingSegments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Operating Segments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NumberOfOperatingSegments" xlink:to="lab_us-gaap_NumberOfOperatingSegments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_6cca813c-98c9-4c52-be78-8c715b6ea2c8_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_68f826ab-8b01-48fa-945c-58cd9fdf165d_negatedLabel_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Net accretion of bond discounts/premiums</link:label>
    <link:label id="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_label_en-US" xlink:label="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accretion (Amortization) of Discounts and Premiums, Investments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="lab_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote</link:label>
    <link:label id="lab_ecd_AdjToPeoCompFnTextBlock_label_en-US" xlink:label="lab_ecd_AdjToPeoCompFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment To PEO Compensation, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AdjToPeoCompFnTextBlock" xlink:to="lab_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_14553f0f-c5f1-43b2-873b-c126f5f6100e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_737c81a6-b2d7-4327-aed5-f95dec14df99_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_0839b091-290c-4619-b248-110c360b4b75_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndTitle_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title</link:label>
    <link:label id="lab_ecd_TrdArrIndTitle_label_en-US" xlink:label="lab_ecd_TrdArrIndTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Title</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndTitle" xlink:to="lab_ecd_TrdArrIndTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_PeerGroupTotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:to="lab_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_de803be9-df64-4ec9-a85b-86934f843702_terseLabel_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:label id="lab_us-gaap_TypeOfArrangementAxis_label_en-US" xlink:label="lab_us-gaap_TypeOfArrangementAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement and Arrangement Other than Collaborative [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TypeOfArrangementAxis" xlink:to="lab_us-gaap_TypeOfArrangementAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RestatementDateAxis_terseLabel_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restatement Determination Date:</link:label>
    <link:label id="lab_ecd_RestatementDateAxis_label_en-US" xlink:label="lab_ecd_RestatementDateAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restatement Determination Date [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RestatementDateAxis" xlink:to="lab_ecd_RestatementDateAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_2b8e8581-c7d6-4ef8-9950-23903e2fb722_terseLabel_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of long lived assets</link:label>
    <link:label id="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_label_en-US" xlink:label="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Impairment of Long-Lived Assets to be Disposed of</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="lab_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_74df900e-938e-4ca8-b6c6-6c54878e6b2f_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock under equity incentive plans</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonPeoNeoMember_terseLabel_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-PEO NEO</link:label>
    <link:label id="lab_ecd_NonPeoNeoMember_label_en-US" xlink:label="lab_ecd_NonPeoNeoMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-PEO NEO [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonPeoNeoMember" xlink:to="lab_ecd_NonPeoNeoMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_f6540d3e-7e73-4804-89b1-dcdf9a78906f_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Outstanding</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaborationAgreementMember_cef1ff2a-5548-4504-a024-5688a6be10d0_terseLabel_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:label id="lab_arvn_CollaborationAgreementMember_label_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaboration Agreement [Member]</link:label>
    <link:label id="lab_arvn_CollaborationAgreementMember_documentation_en-US" xlink:label="lab_arvn_CollaborationAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaboration Agreement</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember" xlink:href="arvn-20251231.xsd#arvn_CollaborationAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaborationAgreementMember" xlink:to="lab_arvn_CollaborationAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_d9c80210-6a98-4ed9-ad63-43d3e1d50a1a_terseLabel_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:label id="lab_us-gaap_SubsidiarySaleOfStockAxis_label_en-US" xlink:label="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis" xlink:to="lab_us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CommitmentsAndContingenciesLineItems_2b1d18b1-14da-4f23-91f5-e03a54b51fb4_terseLabel_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesLineItems_label_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments And Contingencies [Line Items]</link:label>
    <link:label id="lab_arvn_CommitmentsAndContingenciesLineItems_documentation_en-US" xlink:label="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Commitments and contingencies.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesLineItems" xlink:href="arvn-20251231.xsd#arvn_CommitmentsAndContingenciesLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems" xlink:to="lab_arvn_CommitmentsAndContingenciesLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_20b43ebe-85c4-4cea-a1cf-80ca2e84c8f1_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Gross Unrealized Gains</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="lab_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrIndName_terseLabel_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_TrdArrIndName_label_en-US" xlink:label="lab_ecd_TrdArrIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrIndName" xlink:to="lab_ecd_TrdArrIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_ce24125e-1174-4b0a-9f46-71bff27edcab_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_ab59abe8-b577-4c44-a42a-e6e3e683de6a_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="lab_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_a10c907b-4dfc-419c-8dd1-880017643e0d_terseLabel_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Leasehold improvements</link:label>
    <link:label id="lab_us-gaap_LeaseholdImprovementsMember_label_en-US" xlink:label="lab_us-gaap_LeaseholdImprovementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Leasehold Improvements [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LeaseholdImprovementsMember" xlink:to="lab_us-gaap_LeaseholdImprovementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentPayments_5feba424-c54b-4552-8b90-0c91500c693e_negatedTerseLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments made</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentPayments_label_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Contract Balances, Current Payments</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentPayments_documentation_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable, Contract Balances, Current Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:href="arvn-20251231.xsd#arvn_AccountsPayableContractBalancesCurrentPayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:to="lab_arvn_AccountsPayableContractBalancesCurrentPayments" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote</link:label>
    <link:label id="lab_ecd_PnsnBnftsAdjFnTextBlock_label_en-US" xlink:label="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Benefits Adjustments, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:to="lab_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock_019b3145-d39d-7481-b236-5fc83c0a2b82_terseLabel_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock aggregate offering price</link:label>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock_label_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price Of Common Stock</link:label>
    <link:label id="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock_documentation_en-US" xlink:label="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Maximum Aggregate Offering Price Of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:href="arvn-20251231.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:to="lab_arvn_MaximumAggregateOfferingPriceOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Amount</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryCompAmt_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryCompAmt" xlink:to="lab_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_693c2fc5-dabe-481c-82c1-9c0698cf6cb8_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred:</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_c8459a52-dc4e-479f-bd8d-ce8d1a3e8b9c_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt instrument face amount</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentFaceAmount_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentFaceAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Face Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentFaceAmount" xlink:to="lab_us-gaap_DebtInstrumentFaceAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_985dd28d-3109-4396-bc8b-72b352c2b84f_terseLabel_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_DebtInstrumentNameDomain_label_en-US" xlink:label="lab_us-gaap_DebtInstrumentNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Instrument, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtInstrumentNameDomain" xlink:to="lab_us-gaap_DebtInstrumentNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_6fdd4019-2243-47a2-9458-7ca16300106a_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected dividend yield (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_66e2bd83-e4fc-4592-a56c-22011c36f682_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Consolidated Statements of Comprehensive Loss</link:label>
    <link:label id="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Comprehensive Income [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:to="lab_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_RecoveryOfErrCompDisclosureLineItems_label_en-US" xlink:label="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Recovery of Erroneously Awarded Compensation Disclosure [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="lab_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019b30d0-b5f3-7841-81a5-39adde4a9a46_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized from balances held at the beginning of the period</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability, Revenue Recognized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:to="lab_us-gaap_ContractWithCustomerLiabilityRevenueRecognized" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants_9a8725aa-0efb-4bab-b182-40542e4500fb_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from issuance of common stock and pre-funded warrants</link:label>
    <link:label id="lab_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants_label_en-US" xlink:label="lab_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:label id="lab_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants_documentation_en-US" xlink:label="lab_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds From Issuance Of Common Stock And Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:to="lab_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_NumberOfVotesPerCommonStockShareHeld_167129db-52df-4b46-9ca1-269d3dc47d98_terseLabel_en-US" xlink:label="lab_arvn_NumberOfVotesPerCommonStockShareHeld" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of votes per common stock share held</link:label>
    <link:label id="lab_arvn_NumberOfVotesPerCommonStockShareHeld_label_en-US" xlink:label="lab_arvn_NumberOfVotesPerCommonStockShareHeld" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of votes per common stock share held</link:label>
    <link:label id="lab_arvn_NumberOfVotesPerCommonStockShareHeld_documentation_en-US" xlink:label="lab_arvn_NumberOfVotesPerCommonStockShareHeld" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of votes per common stock share held</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfVotesPerCommonStockShareHeld" xlink:href="arvn-20251231.xsd#arvn_NumberOfVotesPerCommonStockShareHeld"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_NumberOfVotesPerCommonStockShareHeld" xlink:to="lab_arvn_NumberOfVotesPerCommonStockShareHeld" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_019c235b-ff93-7fc7-9a20-72d32dbdec05_terseLabel_en-US" xlink:label="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Issuance of common stock for pre-funded warrants (in shares)</link:label>
    <link:label id="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_label_en-US" xlink:label="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:label id="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_documentation_en-US" xlink:label="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, Exercise Of Warrants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:href="arvn-20251231.xsd#arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:to="lab_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_terseLabel_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value</link:label>
    <link:label id="lab_ecd_MnpiDiscTimedForCompValFlag_label_en-US" xlink:label="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MNPI Disclosure Timed for Compensation Value [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:to="lab_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscIndName_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:to="lab_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_500f91a4-b67e-4740-b48e-99c76cbb5097_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_cd10db6d-ea4e-403e-8ce8-72acfeae235f_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_019c46aa-f82d-7cde-8fd3-2872fbdb01e0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:label id="lab_us-gaap_RestructuringCostAndReserveAxis_label_en-US" xlink:label="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Type [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis" xlink:to="lab_us-gaap_RestructuringCostAndReserveAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c2331-d759-79f6-ac57-543d100546e9_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding Reconciliation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined</link:label>
    <link:label id="lab_ecd_AggtErrCompNotYetDeterminedTextBlock_label_en-US" xlink:label="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Not Yet Determined [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:to="lab_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeStockMember_262178ad-96f6-4051-8c2e-6a06d00d08ac_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ESPP</link:label>
    <link:label id="lab_us-gaap_EmployeeStockMember_label_en-US" xlink:label="lab_us-gaap_EmployeeStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeStockMember" xlink:to="lab_us-gaap_EmployeeStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_b761288b-77cb-4117-871e-1aa5887e3f76_terseLabel_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:label id="lab_dei_IcfrAuditorAttestationFlag_label_en-US" xlink:label="lab_dei_IcfrAuditorAttestationFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_IcfrAuditorAttestationFlag" xlink:to="lab_dei_IcfrAuditorAttestationFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_2274050a-1ab7-4a1f-90f0-1429a0689140_terseLabel_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference</link:label>
    <link:label id="lab_dei_DocumentsIncorporatedByReferenceTextBlock_label_en-US" xlink:label="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Documents Incorporated by Reference [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:to="lab_dei_DocumentsIncorporatedByReferenceTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_cc94872b-73bb-488b-9483-87da27e0e39a_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">APIC, Share-Based Payment Arrangement, Increase for Cost Recognition</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="lab_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_e132f118-1d55-4177-b3e7-ca1e0f3fd7d6_terseLabel_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated other comprehensive income</link:label>
    <link:label id="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_label_en-US" xlink:label="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Other Comprehensive Income (Loss), Net of Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="lab_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_f044b2c3-9d22-4c7c-a12a-21f744096fe4_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2026</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_9fe59001-b3fd-4313-a9d2-217a5cac2d97_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_cab037bb-a5df-4648-8c16-461d05d39b9e_terseLabel_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:label id="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_label_en-US" xlink:label="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instruments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="lab_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_bf11ea01-4746-46ad-81ce-1bab91c80264_negatedTotalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Total deferred income tax liabilities</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxLiabilities_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxLiabilities" xlink:to="lab_us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorFirmId_eb80907e-69cc-492f-912e-c957e5ccd429_terseLabel_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:label id="lab_dei_AuditorFirmId_label_en-US" xlink:label="lab_dei_AuditorFirmId" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorFirmId" xlink:to="lab_dei_AuditorFirmId" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentDomain_908f76bb-106c-4870-bec8-4c2aece2218b_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:label id="lab_us-gaap_SegmentDomain_label_en-US" xlink:label="lab_us-gaap_SegmentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segments [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentDomain" xlink:to="lab_us-gaap_SegmentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_019c46aa-f82d-7e9f-987f-9d45f47578e3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:label id="lab_us-gaap_IncomeStatementLocationAxis_label_en-US" xlink:label="lab_us-gaap_IncomeStatementLocationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Income Location, Balance [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeStatementLocationAxis" xlink:to="lab_us-gaap_IncomeStatementLocationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ProceedsFromSaleOfMarketableSecurities_8d6a8406-8fbd-4fed-8a20-aecfd09c66ad_terseLabel_en-US" xlink:label="lab_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of marketable securities</link:label>
    <link:label id="lab_arvn_ProceedsFromSaleOfMarketableSecurities_label_en-US" xlink:label="lab_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds From Sale Of Marketable Securities</link:label>
    <link:label id="lab_arvn_ProceedsFromSaleOfMarketableSecurities_documentation_en-US" xlink:label="lab_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Proceeds from sale of marketable securities.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromSaleOfMarketableSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:to="lab_arvn_ProceedsFromSaleOfMarketableSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost</link:label>
    <link:label id="lab_ecd_AggtPnsnAdjsSvcCstMember_label_en-US" xlink:label="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Pension Adjustments Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="lab_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_YaleUniversityMember_600cd39e-7c67-4594-a3f6-ce71a7948f66_terseLabel_en-US" xlink:label="lab_arvn_YaleUniversityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Yale University</link:label>
    <link:label id="lab_arvn_YaleUniversityMember_label_en-US" xlink:label="lab_arvn_YaleUniversityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Yale University [Member]</link:label>
    <link:label id="lab_arvn_YaleUniversityMember_documentation_en-US" xlink:label="lab_arvn_YaleUniversityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Yale University.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_YaleUniversityMember" xlink:href="arvn-20251231.xsd#arvn_YaleUniversityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_YaleUniversityMember" xlink:to="lab_arvn_YaleUniversityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_ae0f43ca-67c0-485f-846b-a8907ec1c985_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Transaction Price Allocated to Performance Obligations</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_78ec8555-b854-4188-a9a5-837e1a729fe2_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Hierarchy and NAV [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="lab_us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c468b-a684-7cbb-9dcb-e5dfce4d1400_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgingPurposeDomain_8726a226-4597-47e0-9a87-f458e39eb8f8_terseLabel_en-US" xlink:label="lab_us-gaap_PledgingPurposeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pledging Purpose [Domain]</link:label>
    <link:label id="lab_us-gaap_PledgingPurposeDomain_label_en-US" xlink:label="lab_us-gaap_PledgingPurposeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pledging Purpose [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgingPurposeDomain" xlink:to="lab_us-gaap_PledgingPurposeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareRepurchaseProgramCommissionsAndExciseTax_019c235b-4dbb-7f9d-8246-d6f723c56c71_terseLabel_en-US" xlink:label="lab_arvn_ShareRepurchaseProgramCommissionsAndExciseTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program, commissions and excise tax</link:label>
    <link:label id="lab_arvn_ShareRepurchaseProgramCommissionsAndExciseTax_label_en-US" xlink:label="lab_arvn_ShareRepurchaseProgramCommissionsAndExciseTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program Commissions And Excise Tax</link:label>
    <link:label id="lab_arvn_ShareRepurchaseProgramCommissionsAndExciseTax_documentation_en-US" xlink:label="lab_arvn_ShareRepurchaseProgramCommissionsAndExciseTax" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Repurchase Program Commissions And Excise Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareRepurchaseProgramCommissionsAndExciseTax" xlink:href="arvn-20251231.xsd#arvn_ShareRepurchaseProgramCommissionsAndExciseTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareRepurchaseProgramCommissionsAndExciseTax" xlink:to="lab_arvn_ShareRepurchaseProgramCommissionsAndExciseTax" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_f29ab332-ab02-4e94-9c23-274a7df85576_terseLabel_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants to be purchased (in shares)</link:label>
    <link:label id="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_label_en-US" xlink:label="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="lab_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_MinimumMember_343d9ce2-ccb8-468d-934b-2c27c21a272b_terseLabel_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Minimum</link:label>
    <link:label id="lab_srt_MinimumMember_label_en-US" xlink:label="lab_srt_MinimumMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_MinimumMember" xlink:to="lab_srt_MinimumMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_f38a0571-941f-4d97-aa31-2ee2eede2a94_terseLabel_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Agreements [Abstract]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:href="arvn-20251231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_701c8e17-9a49-4fd6-ad10-bd0fc1e45223_negatedLabel_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: accumulated depreciation and amortization</link:label>
    <link:label id="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="lab_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_18b496fb-67ba-452c-a104-079db49822f5_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerSharePolicyTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="lab_us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CoSelectedMeasureName_terseLabel_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:label id="lab_ecd_CoSelectedMeasureName_label_en-US" xlink:label="lab_ecd_CoSelectedMeasureName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Company Selected Measure Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CoSelectedMeasureName" xlink:to="lab_ecd_CoSelectedMeasureName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_7a926ed8-4eec-4862-8b84-367c0cbb7320_terseLabel_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Government securities</link:label>
    <link:label id="lab_us-gaap_USGovernmentDebtSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">US Government Debt Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_USGovernmentDebtSecuritiesMember" xlink:to="lab_us-gaap_USGovernmentDebtSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_5fe395e3-f8b2-409f-9080-159373a3b3c1_negatedTerseLabel_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Payments received</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_label_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received</link:label>
    <link:label id="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_documentation_en-US" xlink:label="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:href="arvn-20251231.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:to="lab_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_6cc8bfeb-6de0-4d95-9dd9-58f01e901cea_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Term Debt</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureTextBlock" xlink:to="lab_us-gaap_DebtDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockValue_5c539c19-8c56-45b5-a590-f9b1ea09a337_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, $0.001 par value, zero shares issued and outstanding as of December&#160;31, 2025 and 2024, respectively</link:label>
    <link:label id="lab_us-gaap_PreferredStockValue_label_en-US" xlink:label="lab_us-gaap_PreferredStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockValue" xlink:to="lab_us-gaap_PreferredStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_terseLabel_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Available</link:label>
    <link:label id="lab_ecd_TrdArrSecuritiesAggAvailAmt_label_en-US" xlink:label="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement, Securities Aggregate Available Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:to="lab_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_a266182a-ea57-4159-8c5f-84ca1b4b7f42_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:label id="lab_us-gaap_AccountsPayableCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableCurrent" xlink:to="lab_us-gaap_AccountsPayableCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_68946e14-060e-4bf3-82ed-79377f59d7c6_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred income tax liabilities:</link:label>
    <link:label id="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract_label_en-US" xlink:label="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Liabilities, Net [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="lab_us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeasePayments_756c4030-ab34-432e-a73c-9c614c57785e_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating cash flows from operating leases</link:label>
    <link:label id="lab_us-gaap_OperatingLeasePayments_label_en-US" xlink:label="lab_us-gaap_OperatingLeasePayments" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeasePayments" xlink:to="lab_us-gaap_OperatingLeasePayments" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_terseLabel_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs)</link:label>
    <link:label id="lab_us-gaap_StockAppreciationRightsSARSMember_label_en-US" xlink:label="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Appreciation Rights (SARs) [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:to="lab_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_terseLabel_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Executive Categories</link:label>
    <link:label id="lab_ecd_AllExecutiveCategoriesMember_label_en-US" xlink:label="lab_ecd_AllExecutiveCategoriesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Executive Categories [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="lab_ecd_AllExecutiveCategoriesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_4f43bcf3-d148-49d1-9a1f-74d46cc45324_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Income Tax Benefits and Liabilities</link:label>
    <link:label id="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockValue_7c8769c5-fd50-4caa-b71b-e244d46c3815_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value, 73.5 shares issued and 63.5 shares outstanding as of December&#160;31, 2025, and 68.8 shares issued and outstanding as of December&#160;31, 2024</link:label>
    <link:label id="lab_us-gaap_CommonStockValue_label_en-US" xlink:label="lab_us-gaap_CommonStockValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Value, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockValue" xlink:to="lab_us-gaap_CommonStockValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_bb210f04-884c-44e0-9e2e-ea3f963aa0aa_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected volatility, minimum (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_ba75b14e-3037-4d05-b99c-6541881e5e77_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="lab_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_f4b95759-d769-41ca-875e-ffcf1225c1e2_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding - diluted (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="lab_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_95c72747-d9ea-4741-a26f-43442cbda6f4_terseLabel_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Commitments and contingencies (Note 12)</link:label>
    <link:label id="lab_us-gaap_CommitmentsAndContingencies_label_en-US" xlink:label="lab_us-gaap_CommitmentsAndContingencies" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommitmentsAndContingencies" xlink:to="lab_us-gaap_CommitmentsAndContingencies" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_d15f573e-0dfb-4af0-a3fa-26b9bf8e69c2_terseLabel_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract assets: Collaboration contract asset</link:label>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_label_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Collaboration Contract Asset And Other Assets [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Collaboration Contract Asset And Other Assets</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:href="arvn-20251231.xsd#arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:to="lab_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_terseLabel_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description</link:label>
    <link:label id="lab_ecd_NonGaapMeasureDescriptionTextBlock_label_en-US" xlink:label="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-GAAP Measure Description [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:to="lab_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntitySmallBusiness_62727411-7538-4571-b79b-b923bc24cfc3_terseLabel_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:label id="lab_dei_EntitySmallBusiness_label_en-US" xlink:label="lab_dei_EntitySmallBusiness" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntitySmallBusiness" xlink:to="lab_dei_EntitySmallBusiness" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_ddff644c-1c4b-45bf-92c5-050670697ce3_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of common stock offering costs</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_3a3aee60-2153-45e3-8086-e0d8923d77af_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fees and expenses</link:label>
    <link:label id="lab_us-gaap_PaymentsOfStockIssuanceCosts_label_en-US" xlink:label="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments of Stock Issuance Costs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="lab_us-gaap_PaymentsOfStockIssuanceCosts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_787b383f-05e3-4543-a702-6ce441f613e7_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract" xlink:to="lab_us-gaap_IncomeTaxDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_97397918-5496-4f99-9423-75252e001fcf_terseLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Inducement grants (in shares)</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_ce422f44-3453-4e3d-b1ad-4226cf8a517d_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares outstanding (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesOutstanding_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesOutstanding" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Outstanding</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesOutstanding" xlink:to="lab_us-gaap_PreferredStockSharesOutstanding" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_d43f33b0-986c-41d8-9721-719be5008b5a_terseLabel_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current State and Local Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:to="lab_us-gaap_CurrentStateAndLocalTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentTransitionReport_fac28364-4805-4539-b5ac-9bc76752c827_terseLabel_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:label id="lab_dei_DocumentTransitionReport_label_en-US" xlink:label="lab_dei_DocumentTransitionReport" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentTransitionReport" xlink:to="lab_dei_DocumentTransitionReport" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_7571c249-b4de-4128-b060-0118ab02e994_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsPolicy_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsPolicy" xlink:to="lab_us-gaap_EquityMethodInvestmentsPolicy" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_StockPurchaseAgreementMember_aa47ebf5-00d9-4594-83b7-343b03fd0823_terseLabel_en-US" xlink:label="lab_arvn_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement</link:label>
    <link:label id="lab_arvn_StockPurchaseAgreementMember_label_en-US" xlink:label="lab_arvn_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Purchase Agreement [Member]</link:label>
    <link:label id="lab_arvn_StockPurchaseAgreementMember_documentation_en-US" xlink:label="lab_arvn_StockPurchaseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock purchase agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockPurchaseAgreementMember" xlink:href="arvn-20251231.xsd#arvn_StockPurchaseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_StockPurchaseAgreementMember" xlink:to="lab_arvn_StockPurchaseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_6397b40a-1dae-4ee6-aac1-2ec221c4d997_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Ownership interest, percentage</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investment, Ownership Percentage</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:to="lab_us-gaap_EquityMethodInvestmentOwnershipPercentage" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_terseLabel_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underlying Securities</link:label>
    <link:label id="lab_ecd_AwardUndrlygSecuritiesAmt_label_en-US" xlink:label="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Underlying Securities Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:to="lab_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityComponentDomain_a25ae12c-48bd-4a41-b2f2-5dc74f5db20c_terseLabel_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:label id="lab_us-gaap_EquityComponentDomain_label_en-US" xlink:label="lab_us-gaap_EquityComponentDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityComponentDomain" xlink:to="lab_us-gaap_EquityComponentDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_3c10e249-4e0b-4c90-8ddf-b4bfee422cdc_verboseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_terseLabel_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:label id="lab_ecd_PeoActuallyPaidCompAmt_label_en-US" xlink:label="lab_ecd_PeoActuallyPaidCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">PEO Actually Paid Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeoActuallyPaidCompAmt" xlink:to="lab_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_BayerCropScienceLPMember_0d434864-3cae-4a6c-93e4-9137dfb52bd9_terseLabel_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bayer LP</link:label>
    <link:label id="lab_arvn_BayerCropScienceLPMember_label_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bayer Crop Science L P [Member]</link:label>
    <link:label id="lab_arvn_BayerCropScienceLPMember_documentation_en-US" xlink:label="lab_arvn_BayerCropScienceLPMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bayer CropScience LP.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember" xlink:href="arvn-20251231.xsd#arvn_BayerCropScienceLPMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_BayerCropScienceLPMember" xlink:to="lab_arvn_BayerCropScienceLPMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_d452c7b1-ff6c-40b7-a9ca-e937f42d2359_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Taxes</link:label>
    <link:label id="lab_us-gaap_IncomeTaxDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="lab_us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_0b746eab-a1fe-470d-89a5-8efeb5fe9e71_terseLabel_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development expenses</link:label>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_label_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Research And Development Expense Current</link:label>
    <link:label id="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent_documentation_en-US" xlink:label="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accrued research and development expense current.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:href="arvn-20251231.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:to="lab_arvn_AccruedResearchAndDevelopmentExpenseCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_5d091e4a-aef2-4175-8f63-6f0c928eb815_terseLabel_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Option Payments To License Agreement</link:label>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_label_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Option Payments To License Agreement [Member]</link:label>
    <link:label id="lab_arvn_OptionPaymentsToLicenseAgreementMember_documentation_en-US" xlink:label="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Option payments to license agreement.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember" xlink:href="arvn-20251231.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_OptionPaymentsToLicenseAgreementMember" xlink:to="lab_arvn_OptionPaymentsToLicenseAgreementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_edc1386f-0834-4dd7-bbc6-b097d37488ee_terseLabel_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_label_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in Accounts Receivable, after Allowance for Credit Loss [Roll Forward]</link:label>
    <link:label id="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_documentation_en-US" xlink:label="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Change in Accounts Receivable, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:href="arvn-20251231.xsd#arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:to="lab_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures, Table</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RegulatoryAndSalesBasedMilestonesMember_e7f5967e-6e47-4aa9-ba26-e1356a7a793a_terseLabel_en-US" xlink:label="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory and Sales Based Milestones</link:label>
    <link:label id="lab_arvn_RegulatoryAndSalesBasedMilestonesMember_label_en-US" xlink:label="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory And Sales Based Milestones [Member]</link:label>
    <link:label id="lab_arvn_RegulatoryAndSalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory And Sales Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:href="arvn-20251231.xsd#arvn_RegulatoryAndSalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:to="lab_arvn_RegulatoryAndSalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_9c83f319-d1ec-4f7f-b9f6-de3d08531eb6_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerAbstract_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_StockCompensationAndBonusExpenseMember_019c46aa-f82d-7e23-804d-5f26077abb39_terseLabel_en-US" xlink:label="lab_arvn_StockCompensationAndBonusExpenseMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non Cash Stock Compensation And Bonus Expense</link:label>
    <link:label id="lab_arvn_StockCompensationAndBonusExpenseMember_label_en-US" xlink:label="lab_arvn_StockCompensationAndBonusExpenseMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Compensation And Bonus Expense [Member]</link:label>
    <link:label id="lab_arvn_StockCompensationAndBonusExpenseMember_documentation_en-US" xlink:label="lab_arvn_StockCompensationAndBonusExpenseMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Stock Compensation And Bonus Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockCompensationAndBonusExpenseMember" xlink:href="arvn-20251231.xsd#arvn_StockCompensationAndBonusExpenseMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_StockCompensationAndBonusExpenseMember" xlink:to="lab_arvn_StockCompensationAndBonusExpenseMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_52d27725-0591-46b4-9eb7-b2c7d11caa1e_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable (in years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractTerminationAxis_9a5c064b-b56c-4190-b3a3-ed1fbcbfb0f6_terseLabel_en-US" xlink:label="lab_arvn_ContractTerminationAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract Termination [Axis]</link:label>
    <link:label id="lab_arvn_ContractTerminationAxis_label_en-US" xlink:label="lab_arvn_ContractTerminationAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract Termination [Axis]</link:label>
    <link:label id="lab_arvn_ContractTerminationAxis_documentation_en-US" xlink:label="lab_arvn_ContractTerminationAxis" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractTerminationAxis" xlink:href="arvn-20251231.xsd#arvn_ContractTerminationAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractTerminationAxis" xlink:to="lab_arvn_ContractTerminationAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_db63d590-462c-40b2-a60a-ef537fa819f3_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits</link:label>
    <link:label id="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_e2e7f176-e3bf-46b7-978a-4785193085b3_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease liabilities</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Operating Lease Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInOperatingLeaseLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_019c235b-4dbb-7a5e-8119-6eff6ccaa2ff_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program, average price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare_label_en-US" xlink:label="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Acquired, Average Cost Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:to="lab_us-gaap_TreasuryStockAcquiredAverageCostPerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_BayerAGMember_36b5efd9-cdce-428e-9229-773a2bdb8eee_terseLabel_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bayer</link:label>
    <link:label id="lab_arvn_BayerAGMember_label_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Bayer A G [Member]</link:label>
    <link:label id="lab_arvn_BayerAGMember_documentation_en-US" xlink:label="lab_arvn_BayerAGMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Bayer AG.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember" xlink:href="arvn-20251231.xsd#arvn_BayerAGMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_BayerAGMember" xlink:to="lab_arvn_BayerAGMember" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_d63503e4-f41e-4f03-ba35-8ed8f75a92fe_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_d7747c63-0443-4ee6-8e7a-2b53aaad7eca_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net Loss Per Share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareTextBlock" xlink:to="lab_us-gaap_EarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_OutstandingRecoveryIndName_label_en-US" xlink:label="lab_ecd_OutstandingRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Outstanding Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_OutstandingRecoveryIndName" xlink:to="lab_ecd_OutstandingRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_UnrecognizedTaxBenefitsNet_e1e566e2-fcf4-4aa0-96e2-07546e738395_terseLabel_en-US" xlink:label="lab_arvn_UnrecognizedTaxBenefitsNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net uncertain tax positions</link:label>
    <link:label id="lab_arvn_UnrecognizedTaxBenefitsNet_label_en-US" xlink:label="lab_arvn_UnrecognizedTaxBenefitsNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Net</link:label>
    <link:label id="lab_arvn_UnrecognizedTaxBenefitsNet_documentation_en-US" xlink:label="lab_arvn_UnrecognizedTaxBenefitsNet" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UnrecognizedTaxBenefitsNet" xlink:href="arvn-20251231.xsd#arvn_UnrecognizedTaxBenefitsNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_UnrecognizedTaxBenefitsNet" xlink:to="lab_arvn_UnrecognizedTaxBenefitsNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_794b46d6-19c1-4ff0-bb47-63ec7c84e2fe_terseLabel_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:label id="lab_us-gaap_AdditionalPaidInCapital_label_en-US" xlink:label="lab_us-gaap_AdditionalPaidInCapital" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid in Capital</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdditionalPaidInCapital" xlink:to="lab_us-gaap_AdditionalPaidInCapital" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CA_019c469d-ec70-70c2-97d6-bc0cbe4fc568_terseLabel_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">California</link:label>
    <link:label id="lab_stpr_CA_label_en-US" xlink:label="lab_stpr_CA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CALIFORNIA</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CA" xlink:to="lab_stpr_CA" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_ProductOrServiceAxis_7ba65a2c-0bf8-49d6-a456-1c381b16c359_terseLabel_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:label id="lab_srt_ProductOrServiceAxis_label_en-US" xlink:label="lab_srt_ProductOrServiceAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Product and Service [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_ProductOrServiceAxis" xlink:to="lab_srt_ProductOrServiceAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_989ef1ba-ab8d-435c-98a9-c88b32023086_terseLabel_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Office equipment</link:label>
    <link:label id="lab_us-gaap_OfficeEquipmentMember_label_en-US" xlink:label="lab_us-gaap_OfficeEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Office Equipment [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OfficeEquipmentMember" xlink:to="lab_us-gaap_OfficeEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_c7f2d064-dbc2-4c26-b2e6-541c66ab6763_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue recognized</link:label>
    <link:label id="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_label_en-US" xlink:label="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue from Contract with Customer, Excluding Assessed Tax</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:to="lab_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllIndividualsMember_terseLabel_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Individuals</link:label>
    <link:label id="lab_ecd_AllIndividualsMember_label_en-US" xlink:label="lab_ecd_AllIndividualsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Individuals [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="lab_ecd_AllIndividualsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_3bd9040e-82c7-445c-897c-4078a386b693_terseLabel_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in Accounting Estimate, Type [Domain]</link:label>
    <link:label id="lab_us-gaap_ChangeInAccountingEstimateTypeDomain_label_en-US" xlink:label="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effect of Change in Accounting Estimate, Type [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:to="lab_us-gaap_ChangeInAccountingEstimateTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_FairValueDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract" xlink:to="lab_us-gaap_FairValueDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_bf08b476-e54c-4258-af09-8b30d584ab54_negatedLabel_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Purchase of property, equipment and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_label_en-US" xlink:label="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments to Acquire Property, Plant, and Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="lab_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_011bd894-bad1-468b-9235-8e170a4b53a5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Name</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryIndName_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryIndName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery, Individual Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryIndName" xlink:to="lab_ecd_ForgoneRecoveryIndName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AssetsCurrent_0cd39333-1fca-4f57-a4d5-e71fbadaa70d_totalLabel_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:label id="lab_us-gaap_AssetsCurrent_label_en-US" xlink:label="lab_us-gaap_AssetsCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Assets, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AssetsCurrent" xlink:to="lab_us-gaap_AssetsCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_RangeAxis_b6ac69f9-d6e2-42f4-9a51-ca7dd207c5d7_terseLabel_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:label id="lab_srt_RangeAxis_label_en-US" xlink:label="lab_srt_RangeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_RangeAxis" xlink:to="lab_srt_RangeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_terseLabel_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember_label_en-US" xlink:label="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:to="lab_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_5f8d7a72-ae24-45b6-8244-959b7a21fbfd_terseLabel_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Loss contingency</link:label>
    <link:label id="lab_us-gaap_LossContingencyAccrualAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Loss Contingency Accrual</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:to="lab_us-gaap_LossContingencyAccrualAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_019c235b-4dbb-78ec-9722-32eaeca30f08_terseLabel_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program, authorized amount</link:label>
    <link:label id="lab_srt_StockRepurchaseProgramAuthorizedAmount1_label_en-US" xlink:label="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Repurchase Program, Authorized, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:to="lab_srt_StockRepurchaseProgramAuthorizedAmount1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_71b6c7a8-3cd2-403e-9554-8f93812b7221_terseLabel_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other receivables</link:label>
    <link:label id="lab_us-gaap_OtherReceivablesNetCurrent_label_en-US" xlink:label="lab_us-gaap_OtherReceivablesNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Receivables, Net, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherReceivablesNetCurrent" xlink:to="lab_us-gaap_OtherReceivablesNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_7c1e825f-0640-41d6-8efc-ac4da1254f8d_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Annual increase in reserved shares as percentage of outstanding common stock</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AggtErrCompAmt_terseLabel_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:label id="lab_ecd_AggtErrCompAmt_label_en-US" xlink:label="lab_ecd_AggtErrCompAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Erroneous Compensation Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AggtErrCompAmt" xlink:to="lab_ecd_AggtErrCompAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_3c29e50b-b542-4177-8599-9689b602eee8_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Intrinsic value of options exercised</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PrivatePlacementMember_65eaa46d-ee55-4389-849d-1b52424c98d6_terseLabel_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Private Placement</link:label>
    <link:label id="lab_us-gaap_PrivatePlacementMember_label_en-US" xlink:label="lab_us-gaap_PrivatePlacementMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Private Placement [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PrivatePlacementMember" xlink:to="lab_us-gaap_PrivatePlacementMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_46006fb8-1451-4e0d-a464-fbd8ee357b79_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Capitalized costs</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostGross_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostGross" xlink:to="lab_us-gaap_CapitalizedContractCostGross" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote</link:label>
    <link:label id="lab_ecd_PeerGroupIssuersFnTextBlock_label_en-US" xlink:label="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Peer Group Issuers, Footnote [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:to="lab_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_16449958-0f58-4e86-9129-732a86171e0a_terseLabel_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Marketable securities</link:label>
    <link:label id="lab_us-gaap_MarketableSecuritiesCurrent_label_en-US" xlink:label="lab_us-gaap_MarketableSecuritiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Marketable Securities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_MarketableSecuritiesCurrent" xlink:to="lab_us-gaap_MarketableSecuritiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_eef08ae0-bda6-422b-baae-5bac42225410_terseLabel_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lease for laboratory and office space (in sq feet)</link:label>
    <link:label id="lab_us-gaap_LandSubjectToGroundLeases_label_en-US" xlink:label="lab_us-gaap_LandSubjectToGroundLeases" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Land Subject to Ground Leases</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LandSubjectToGroundLeases" xlink:to="lab_us-gaap_LandSubjectToGroundLeases" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_terseLabel_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis</link:label>
    <link:label id="lab_ecd_ErrCompAnalysisTextBlock_label_en-US" xlink:label="lab_ecd_ErrCompAnalysisTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneous Compensation Analysis [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompAnalysisTextBlock" xlink:to="lab_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_WriteoffOfPrepaidRentMember_3cf862db-32ec-4777-8955-5324a4a2fd3e_terseLabel_en-US" xlink:label="lab_arvn_WriteoffOfPrepaidRentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Writeoff Of Prepaid Rent</link:label>
    <link:label id="lab_arvn_WriteoffOfPrepaidRentMember_label_en-US" xlink:label="lab_arvn_WriteoffOfPrepaidRentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Writeoff Of Prepaid Rent [Member]</link:label>
    <link:label id="lab_arvn_WriteoffOfPrepaidRentMember_documentation_en-US" xlink:label="lab_arvn_WriteoffOfPrepaidRentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Writeoff Of Prepaid Rent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_WriteoffOfPrepaidRentMember" xlink:href="arvn-20251231.xsd#arvn_WriteoffOfPrepaidRentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_WriteoffOfPrepaidRentMember" xlink:to="lab_arvn_WriteoffOfPrepaidRentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_dd91f48c-42d5-426e-81fa-68a608ef858f_terseLabel_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:label id="lab_us-gaap_LiabilitiesCurrentAbstract_label_en-US" xlink:label="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities, Current [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract" xlink:to="lab_us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_769c06ae-86e6-4fb1-9d57-bd9268fc9a63_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Remaining Contractual Term (Years)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_StatementGeographicalAxis_0dcb9300-52eb-4092-9e4c-74b67964a972_terseLabel_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:label id="lab_srt_StatementGeographicalAxis_label_en-US" xlink:label="lab_srt_StatementGeographicalAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Geographical [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_StatementGeographicalAxis" xlink:to="lab_srt_StatementGeographicalAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_615bd865-2afc-496a-8f24-bfc446b28cb0_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Lease Description [Line Items]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionLineItems_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems" xlink:to="lab_us-gaap_LesseeLeaseDescriptionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpenses_e3df89c2-12b9-49db-90ab-9d3f1517b6fe_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_9fcc6172-37ca-4da9-9060-f12f29375b0f_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses</link:label>
    <link:label id="lab_us-gaap_OperatingExpenses_label_en-US" xlink:label="lab_us-gaap_OperatingExpenses" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpenses" xlink:to="lab_us-gaap_OperatingExpenses" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated</link:label>
    <link:label id="lab_ecd_Rule10b51ArrTrmntdFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Terminated [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:to="lab_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_CT_a8883bb0-d797-4001-a13d-4c8b0c4f5e7c_terseLabel_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State of Connecticut</link:label>
    <link:label id="lab_stpr_CT_label_en-US" xlink:label="lab_stpr_CT" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">CONNECTICUT</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CT"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_CT" xlink:to="lab_stpr_CT" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6f0de3cb-66f9-41b7-a01e-33ba697323e9_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate, minimum (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_cd93a816-d271-4242-a7dc-5e081e867578_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax credits</link:label>
    <link:label id="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_label_en-US" xlink:label="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Tax Credit Carryforwards</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:to="lab_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_77d70904-8728-440e-af97-68bdd7f2b193_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share - diluted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareDiluted_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareDiluted" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Diluted</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareDiluted" xlink:to="lab_us-gaap_EarningsPerShareDiluted" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_152d14c0-99bc-4915-9b9e-c752e0d2303a_terseLabel_en-US" xlink:label="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal deposit insurance corporation premium expense</link:label>
    <link:label id="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_label_en-US" xlink:label="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Federal Deposit Insurance Corporation Premium Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:to="lab_us-gaap_FederalDepositInsuranceCorporationPremiumExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ErrCompRecoveryTable_terseLabel_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery</link:label>
    <link:label id="lab_ecd_ErrCompRecoveryTable_label_en-US" xlink:label="lab_ecd_ErrCompRecoveryTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Erroneously Awarded Compensation Recovery [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="lab_ecd_ErrCompRecoveryTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_2c5a6034-c751-4907-ac85-30e6a4c4929a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_27c6a3da-b793-4b64-954f-038b16fc2a8b_periodStartLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_afcf1ac5-7869-4cdc-a0fa-b4613d768280_periodEndLabel_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_AccountsReceivableNetCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsReceivableNetCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Receivable, after Allowance for Credit Loss, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsReceivableNetCurrent" xlink:to="lab_us-gaap_AccountsReceivableNetCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_a352f504-b47e-4abd-b9d3-57cab554bd4e_terseLabel_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:label id="lab_us-gaap_ConcentrationRiskBenchmarkDomain_label_en-US" xlink:label="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk Benchmark [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:to="lab_us-gaap_ConcentrationRiskBenchmarkDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_a83fa6ef-1c34-4ea6-bdd4-4dc73c627b5e_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_a137073a-9084-4749-a364-e79a78d79eb7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Lessee Lease Description [Table]</link:label>
    <link:label id="lab_us-gaap_LesseeLeaseDescriptionTable_label_en-US" xlink:label="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Lease, Description [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable" xlink:to="lab_us-gaap_LesseeLeaseDescriptionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_f499bd09-c3c4-4e78-a691-38dc852f0681_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amortization of collaboration contract asset</link:label>
    <link:label id="lab_us-gaap_CapitalizedContractCostAmortization_label_en-US" xlink:label="lab_us-gaap_CapitalizedContractCostAmortization" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized Contract Cost, Amortization</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalizedContractCostAmortization" xlink:to="lab_us-gaap_CapitalizedContractCostAmortization" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_0e0c33d6-4226-48af-8619-faaebca10bf4_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other comprehensive loss:</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="lab_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_a2ae6eeb-0e08-4801-9a73-4c1420db7a9c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of shares issued in transaction (in shares)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_label_en-US" xlink:label="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Number of Shares Issued in Transaction</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:to="lab_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_019c0af5-a7a1-793d-a34f-de9ea968b940_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Treasury stock, shares (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_019c65cb-3543-7edd-bc2b-25c3ce7a6c6f_periodStartLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_019c65cc-0e93-7100-9ebf-088426b0d9d5_periodEndLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonShares_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonShares" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Shares</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonShares" xlink:to="lab_us-gaap_TreasuryStockCommonShares" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_SalesBasedMilestonesMember_6d4257f1-d936-4dbf-a335-79cebd5733a2_terseLabel_en-US" xlink:label="lab_arvn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sales-based Milestones</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonesMember_label_en-US" xlink:label="lab_arvn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sales Based Milestones [Member]</link:label>
    <link:label id="lab_arvn_SalesBasedMilestonesMember_documentation_en-US" xlink:label="lab_arvn_SalesBasedMilestonesMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Sales Based Milestones</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonesMember" xlink:href="arvn-20251231.xsd#arvn_SalesBasedMilestonesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_SalesBasedMilestonesMember" xlink:to="lab_arvn_SalesBasedMilestonesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_46af18b1-9193-4711-be54-405382a9e29a_terseLabel_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss per common share</link:label>
    <link:label id="lab_us-gaap_EarningsPerShareAbstract_label_en-US" xlink:label="lab_us-gaap_EarningsPerShareAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EarningsPerShareAbstract" xlink:to="lab_us-gaap_EarningsPerShareAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c469d-ec70-7c86-99be-04b66707b3f3_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">US state and local &#160;</link:label>
    <link:label id="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_label_en-US" xlink:label="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Paid, State and Local, after Refund Received</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:to="lab_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_f5fd9e61-c25d-4cc0-9ba0-017bbda78567_terseLabel_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Nature of Business and Basis of Presentation</link:label>
    <link:label id="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_label_en-US" xlink:label="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Business Description and Basis of Presentation [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:to="lab_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_5dbf5604-ff2c-4d8b-baf9-666b06b27f3b_totalLabel_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total other income</link:label>
    <link:label id="lab_us-gaap_NonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_NonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonoperatingIncomeExpense" xlink:to="lab_us-gaap_NonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AuditorLocation_a1a79be8-cffb-4f5a-993f-8f485531ad46_terseLabel_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:label id="lab_dei_AuditorLocation_label_en-US" xlink:label="lab_dei_AuditorLocation" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AuditorLocation" xlink:to="lab_dei_AuditorLocation" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaboratorOneMember_612724f9-8981-432d-a0c5-bf04073f3061_terseLabel_en-US" xlink:label="lab_arvn_CollaboratorOneMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Collaborator One</link:label>
    <link:label id="lab_arvn_CollaboratorOneMember_label_en-US" xlink:label="lab_arvn_CollaboratorOneMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborator One [Member]</link:label>
    <link:label id="lab_arvn_CollaboratorOneMember_documentation_en-US" xlink:label="lab_arvn_CollaboratorOneMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborator one.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaboratorOneMember" xlink:href="arvn-20251231.xsd#arvn_CollaboratorOneMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaboratorOneMember" xlink:to="lab_arvn_CollaboratorOneMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_f85f8c64-d6d9-4d5b-b387-7f2a6a687ec0_terseLabel_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock reserved for issuance represented as percentage on outstanding common stock</link:label>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_label_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock</link:label>
    <link:label id="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_documentation_en-US" xlink:label="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:href="arvn-20251231.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:to="lab_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_b7a47358-08d5-4f28-be4d-aff6829bb625_terseLabel_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Method Investments</link:label>
    <link:label id="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Method Investments and Joint Ventures Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:to="lab_us-gaap_EquityMethodInvestmentsDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentAdditions_bd9e9901-3b8f-411f-a174-5181c8569233_terseLabel_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentAdditions_label_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Contract Balances, Current Additions</link:label>
    <link:label id="lab_arvn_AccountsPayableContractBalancesCurrentAdditions_documentation_en-US" xlink:label="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Accounts Payable, Contract Balances, Current Additions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:href="arvn-20251231.xsd#arvn_AccountsPayableContractBalancesCurrentAdditions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:to="lab_arvn_AccountsPayableContractBalancesCurrentAdditions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_d2608d8d-00ea-40f5-8c66-6ed294073ea9_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Securities Excluded From Computation of Diluted Net Loss Per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="lab_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_3d6adbfa-faba-4498-ad27-94cbdc89c51d_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Federal tax credit carryforwards</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAmount_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAmount" xlink:to="lab_us-gaap_TaxCreditCarryforwardAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_6e7b85d2-dd8f-4f9e-9c5f-7b056866f537_terseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred revenue</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DomesticCountryMember_019c7cb1-b587-7b52-b654-4c84a7ff9918_verboseLabel_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction</link:label>
    <link:label id="lab_us-gaap_DomesticCountryMember_label_en-US" xlink:label="lab_us-gaap_DomesticCountryMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Jurisdiction [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DomesticCountryMember" xlink:to="lab_us-gaap_DomesticCountryMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_NewYorkCityMember_019c469d-ec70-707a-a94f-4d6dfe5d1f35_terseLabel_en-US" xlink:label="lab_arvn_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New York City</link:label>
    <link:label id="lab_arvn_NewYorkCityMember_label_en-US" xlink:label="lab_arvn_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New York City [Member]</link:label>
    <link:label id="lab_arvn_NewYorkCityMember_documentation_en-US" xlink:label="lab_arvn_NewYorkCityMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">New York City</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NewYorkCityMember" xlink:href="arvn-20251231.xsd#arvn_NewYorkCityMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_NewYorkCityMember" xlink:to="lab_arvn_NewYorkCityMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_8744e18a-c29c-482a-87bd-3cf8fc3af04f_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_8fac0ff0-9934-4e44-9532-6e0330ff5f66_terseLabel_en-US" xlink:label="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone payment the Company will make</link:label>
    <link:label id="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_label_en-US" xlink:label="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payment</link:label>
    <link:label id="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_documentation_en-US" xlink:label="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement, Rights And Obligations, Milestone Payment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:href="arvn-20251231.xsd#arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:to="lab_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_a1a96b4c-2ce0-483c-abb5-4b990b5e1eae_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercise price (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_ddc6efbf-3ed7-49dd-9529-41c71b832f41_negatedLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Less: imputed interest</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_520ac0f0-3f80-435a-b2d7-fa4340e3cb34_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardAxis_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis" xlink:to="lab_us-gaap_TaxCreditCarryforwardAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_019c469e-3bc0-7a64-881f-cafa195a8623_totalLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total income taxes paid, net of refunds received &#160;</link:label>
    <link:label id="lab_us-gaap_IncomeTaxesPaidNet_label_en-US" xlink:label="lab_us-gaap_IncomeTaxesPaidNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Taxes Paid, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxesPaidNet" xlink:to="lab_us-gaap_IncomeTaxesPaidNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019c468b-e492-76ab-8a51-822c436d6a4d_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_019c0afe-281f-78f9-bc23-50a3323a7805_terseLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchases (Treasury Stock) (in shares)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockSharesAcquired_label_en-US" xlink:label="lab_us-gaap_TreasuryStockSharesAcquired" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Shares, Acquired</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockSharesAcquired" xlink:to="lab_us-gaap_TreasuryStockSharesAcquired" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_a5cb459c-b7cc-44d2-a7d1-edc4e9a87130_terseLabel_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Corporate bonds</link:label>
    <link:label id="lab_us-gaap_CorporateBondSecuritiesMember_label_en-US" xlink:label="lab_us-gaap_CorporateBondSecuritiesMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Corporate Bond Securities [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CorporateBondSecuritiesMember" xlink:to="lab_us-gaap_CorporateBondSecuritiesMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_5cb57153-4b7d-4327-a0ba-6e910b98e6f0_terseLabel_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Restricted Stock Grant Activity</link:label>
    <link:label id="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nonvested Restricted Stock Shares Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:to="lab_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions_019c235b-4dbb-7be4-8502-08acbe0e1577_terseLabel_en-US" xlink:label="lab_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share repurchase program, acquired, value net of commissions</link:label>
    <link:label id="lab_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions_label_en-US" xlink:label="lab_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method, Net Of Commissions</link:label>
    <link:label id="lab_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions_documentation_en-US" xlink:label="lab_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Treasury Stock, Value, Acquired, Cost Method, Net of Commissions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions" xlink:href="arvn-20251231.xsd#arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions" xlink:to="lab_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardTmgDiscLineItems_label_en-US" xlink:label="lab_ecd_AwardTmgDiscLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Timing Disclosures [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="lab_ecd_AwardTmgDiscLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_88ccde15-d3ea-49ac-b59b-371934bb4e68_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_24e18873-cdfc-4d32-aea9-15e1f7158840_terseLabel_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:label id="lab_dei_EntityWellKnownSeasonedIssuer_label_en-US" xlink:label="lab_dei_EntityWellKnownSeasonedIssuer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityWellKnownSeasonedIssuer" xlink:to="lab_dei_EntityWellKnownSeasonedIssuer" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_36b17a74-6918-4979-91fb-0c28e2b07f4f_terseLabel_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Employee expenses</link:label>
    <link:label id="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Employee-related Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="lab_us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_1331bed3-48ad-4a0b-84b7-55455dfd3be4_terseLabel_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:label id="lab_us-gaap_FairValueMeasurementFrequencyDomain_label_en-US" xlink:label="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measurement Frequency [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain" xlink:to="lab_us-gaap_FairValueMeasurementFrequencyDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ARV110Member_cafa2669-9ea5-4f78-9c3a-d409db49d496_terseLabel_en-US" xlink:label="lab_arvn_ARV110Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Bavdegalutamide (ARV-110)</link:label>
    <link:label id="lab_arvn_ARV110Member_label_en-US" xlink:label="lab_arvn_ARV110Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARV-110 [Member]</link:label>
    <link:label id="lab_arvn_ARV110Member_documentation_en-US" xlink:label="lab_arvn_ARV110Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARV-110</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV110Member" xlink:href="arvn-20251231.xsd#arvn_ARV110Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ARV110Member" xlink:to="lab_arvn_ARV110Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_67b85db6-ea25-4941-b2b7-3de937b2e90e_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Equipment and Leasehold Improvements</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_2f2936df-c333-42ef-b21b-b20b9805a860_totalLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total lease payments</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Lease, Liability, to be Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="lab_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_85ff82fe-0c63-461e-b075-c94eb33c2474_terseLabel_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other research and development expense</link:label>
    <link:label id="lab_us-gaap_OtherResearchAndDevelopmentExpense_label_en-US" xlink:label="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Research and Development Expense</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherResearchAndDevelopmentExpense" xlink:to="lab_us-gaap_OtherResearchAndDevelopmentExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_eaa39e0f-c176-45a5-a61e-b376150c7a27_terseLabel_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local</link:label>
    <link:label id="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred State and Local Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_0c6d1f72-40e4-455d-82b0-f4c5f1353c0f_terseLabel_en-US" xlink:label="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non program-specific external expense</link:label>
    <link:label id="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_label_en-US" xlink:label="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Non-Program Specific</link:label>
    <link:label id="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_documentation_en-US" xlink:label="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research And Development Expense, Non-Program Specific</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" xlink:href="arvn-20251231.xsd#arvn_ResearchAndDevelopmentExpenseNonProgramSpecific"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" xlink:to="lab_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetIncomeLoss_34a5e3d6-db6f-40ac-8305-2fe505a17d8a_totalLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_b4d18097-ec23-496a-8578-cb73dbbab73a_terseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_f66aebed-c69d-4f70-9a38-53637e1ec782_verboseLabel_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Segment net loss</link:label>
    <link:label id="lab_us-gaap_NetIncomeLoss_label_en-US" xlink:label="lab_us-gaap_NetIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net Income (Loss) Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetIncomeLoss" xlink:to="lab_us-gaap_NetIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_PfizerIncorporationMember_91a84e77-3f7c-4c58-821c-58fc88774ff1_terseLabel_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pfizer, Inc.</link:label>
    <link:label id="lab_arvn_PfizerIncorporationMember_label_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pfizer Incorporation [Member]</link:label>
    <link:label id="lab_arvn_PfizerIncorporationMember_documentation_en-US" xlink:label="lab_arvn_PfizerIncorporationMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Pfizer, Incorporation.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember" xlink:href="arvn-20251231.xsd#arvn_PfizerIncorporationMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_PfizerIncorporationMember" xlink:to="lab_arvn_PfizerIncorporationMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrExpirationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expiration Date</link:label>
    <link:label id="lab_ecd_TrdArrExpirationDate_label_en-US" xlink:label="lab_ecd_TrdArrExpirationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Expiration Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrExpirationDate" xlink:to="lab_ecd_TrdArrExpirationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_156a91a6-d959-4ab6-9ed5-a4b5eb82c1da_terseLabel_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Agreements [Table]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_label_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Collaboration And License Agreements [Table]</link:label>
    <link:label id="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable_documentation_en-US" xlink:label="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Research collaboration and license agreements.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:href="arvn-20251231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:to="lab_arvn_ResearchCollaborationAndLicenseAgreementsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_681763bd-82a2-4526-a615-47fa73b42792_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_9e4f9e3a-00b0-4811-9bb6-b04657600f02_terseLabel_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrealized gain on available-for-sale securities</link:label>
    <link:label id="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_label_en-US" xlink:label="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:to="lab_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_14f8e553-b6d3-4827-bcdc-cbe605847ebc_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and leasehold improvements, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_15dd8446-067a-492f-aeee-cf69f49ecba4_totalLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Property, equipment and leasehold improvements, net</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentNet_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Net</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentNet" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_3cf1c8e3-5a3e-4869-b155-bde1d2f4bf23_terseLabel_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:label id="lab_us-gaap_SegmentReportingInformationLineItems_label_en-US" xlink:label="lab_us-gaap_SegmentReportingInformationLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting Information [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems" xlink:to="lab_us-gaap_SegmentReportingInformationLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringCharges_019c6902-bf21-7e1f-bda9-e34e6b3b0eb9_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring charges</link:label>
    <link:label id="lab_us-gaap_RestructuringCharges_label_en-US" xlink:label="lab_us-gaap_RestructuringCharges" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringCharges" xlink:to="lab_us-gaap_RestructuringCharges" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_ded0cc98-4d56-4be8-8e0c-5e4f52188639_terseLabel_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Preferred stock, shares authorized (in shares)</link:label>
    <link:label id="lab_us-gaap_PreferredStockSharesAuthorized_label_en-US" xlink:label="lab_us-gaap_PreferredStockSharesAuthorized" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Preferred Stock, Shares Authorized</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PreferredStockSharesAuthorized" xlink:to="lab_us-gaap_PreferredStockSharesAuthorized" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_019c0af0-3826-70d7-9b16-6d1c077625e1_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Repurchase of common shares, net</link:label>
    <link:label id="lab_us-gaap_PaymentsForRepurchaseOfCommonStock_label_en-US" xlink:label="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Repurchase of Common Stock</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:to="lab_us-gaap_PaymentsForRepurchaseOfCommonStock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrAdoptionDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adoption Date</link:label>
    <link:label id="lab_ecd_TrdArrAdoptionDate_label_en-US" xlink:label="lab_ecd_TrdArrAdoptionDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Adoption Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrAdoptionDate" xlink:to="lab_ecd_TrdArrAdoptionDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_72a0dd46-8ac0-4be1-9475-832edd1d2090_terseLabel_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share price, issued and sold (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SharesIssuedPricePerShare_label_en-US" xlink:label="lab_us-gaap_SharesIssuedPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharesIssuedPricePerShare" xlink:to="lab_us-gaap_SharesIssuedPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_terseLabel_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income</link:label>
    <link:label id="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock_label_en-US" xlink:label="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Compensation Actually Paid vs. Net Income [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:to="lab_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_64ba1e6d-52e5-4e8d-9522-04b62aa1bb5e_negatedLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Accounts receivable</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInAccountsReceivable_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Accounts Receivable</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:to="lab_us-gaap_IncreaseDecreaseInAccountsReceivable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_aa18bab6-92eb-4693-993e-fcc580dd302a_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract revenue receivable if milestones achieved</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_22efd4ef-d3a1-4d86-9bd8-455303d1eb88_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_7abbf844-6bf8-4209-846d-31736949da49_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerAssetNet_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerAssetNet" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Asset, after Allowance for Credit Loss</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerAssetNet" xlink:to="lab_us-gaap_ContractWithCustomerAssetNet" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c46aa-f82d-78ab-a4cf-db2620446bee_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:label id="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_label_en-US" xlink:label="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Cost [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:to="lab_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCurrentReportingStatus_478e74d2-fdce-49e2-8dd2-5631ce87741c_terseLabel_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:label id="lab_dei_EntityCurrentReportingStatus_label_en-US" xlink:label="lab_dei_EntityCurrentReportingStatus" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCurrentReportingStatus" xlink:to="lab_dei_EntityCurrentReportingStatus" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_terseLabel_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures</link:label>
    <link:label id="lab_ecd_AwardsCloseToMnpiDiscTable_label_en-US" xlink:label="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Awards Close in Time to MNPI Disclosures [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="lab_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_e60ef79a-f9af-4393-8976-2a626e2d4d76_totalLabel_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:label id="lab_us-gaap_OperatingIncomeLoss_label_en-US" xlink:label="lab_us-gaap_OperatingIncomeLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Income (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingIncomeLoss" xlink:to="lab_us-gaap_OperatingIncomeLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_f3b21178-3dc3-416e-8779-18b453a4926c_terseLabel_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:label id="lab_us-gaap_RetainedEarningsAccumulatedDeficit_label_en-US" xlink:label="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings (Accumulated Deficit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="lab_us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_NumberOfLicensedProducts_e06aa648-7c42-47e0-b200-10c719b0c2cf_terseLabel_en-US" xlink:label="lab_arvn_NumberOfLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Number of licensed products</link:label>
    <link:label id="lab_arvn_NumberOfLicensedProducts_label_en-US" xlink:label="lab_arvn_NumberOfLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Number of Licensed Products</link:label>
    <link:label id="lab_arvn_NumberOfLicensedProducts_documentation_en-US" xlink:label="lab_arvn_NumberOfLicensedProducts" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of Licensed Products</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfLicensedProducts" xlink:href="arvn-20251231.xsd#arvn_NumberOfLicensedProducts"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_NumberOfLicensedProducts" xlink:to="lab_arvn_NumberOfLicensedProducts" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c4689-4c7a-75aa-a0a5-fa735e9196eb_terseLabel_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">U.S. Federal statutory tax rate</link:label>
    <link:label id="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_label_en-US" xlink:label="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:to="lab_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_c9598f91-a35d-4d41-a87a-79921fa2f643_terseLabel_en-US" xlink:label="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements</link:label>
    <link:label id="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_label_en-US" xlink:label="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements [Member]</link:label>
    <link:label id="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_documentation_en-US" xlink:label="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" xlink:href="arvn-20251231.xsd#arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" xlink:to="lab_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ExpansionOfDevelopmentProgramsMember_2f470c0b-9db2-4e02-964f-5a3b727ca644_terseLabel_en-US" xlink:label="lab_arvn_ExpansionOfDevelopmentProgramsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expansion of Development Programs</link:label>
    <link:label id="lab_arvn_ExpansionOfDevelopmentProgramsMember_label_en-US" xlink:label="lab_arvn_ExpansionOfDevelopmentProgramsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expansion Of Development Programs [Member]</link:label>
    <link:label id="lab_arvn_ExpansionOfDevelopmentProgramsMember_documentation_en-US" xlink:label="lab_arvn_ExpansionOfDevelopmentProgramsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Expansion Of Development Programs</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ExpansionOfDevelopmentProgramsMember" xlink:href="arvn-20251231.xsd#arvn_ExpansionOfDevelopmentProgramsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ExpansionOfDevelopmentProgramsMember" xlink:to="lab_arvn_ExpansionOfDevelopmentProgramsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_43610167-142f-4187-bd1d-386e60a335fa_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Net loss on disposal of property, equipment and leasehold improvements</link:label>
    <link:label id="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_label_en-US" xlink:label="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Disposition of Property Plant Equipment</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="lab_us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_171fbf00-2857-4f89-9315-702f3cbf3495_terseLabel_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:label id="lab_us-gaap_FinancialInstrumentAxis_label_en-US" xlink:label="lab_us-gaap_FinancialInstrumentAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Financial Instrument [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_FinancialInstrumentAxis" xlink:to="lab_us-gaap_FinancialInstrumentAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_1da00832-c1d1-401a-b21d-7f798f07a7eb_terseLabel_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:label id="lab_us-gaap_StatementOfFinancialPositionAbstract_label_en-US" xlink:label="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract" xlink:to="lab_us-gaap_StatementOfFinancialPositionAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_terseLabel_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested</link:label>
    <link:label id="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember_label_en-US" xlink:label="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:to="lab_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_terseLabel_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Executive Category:</link:label>
    <link:label id="lab_ecd_ExecutiveCategoryAxis_label_en-US" xlink:label="lab_ecd_ExecutiveCategoryAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Executive Category [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="lab_ecd_ExecutiveCategoryAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_c078b1e3-ed3e-4697-94e7-8b1d7ebff6cb_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and development tax credit</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_1cc192f5-a920-4a23-825b-88e878fc35d9_terseLabel_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">State and local income taxes, net of federal income tax effect</link:label>
    <link:label id="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_label_en-US" xlink:label="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="lab_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_019c235a-2178-770e-a2f2-696ee93325f5_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Decrease in compensation expense</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Plan Modification, Incremental Cost</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_c5334fbb-f401-4af0-a0b8-4738da228fa6_terseLabel_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:label id="lab_dei_CurrentFiscalYearEndDate_label_en-US" xlink:label="lab_dei_CurrentFiscalYearEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CurrentFiscalYearEndDate" xlink:to="lab_dei_CurrentFiscalYearEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_f788cf01-c4fa-42fa-97b5-17979cca534d_terseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Expected term (years)</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:to="lab_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_639654bf-7d9b-4d3e-8338-a56af33ddacb_terseLabel_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:label id="lab_us-gaap_PayablesAndAccrualsAbstract_label_en-US" xlink:label="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payables and Accruals [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract" xlink:to="lab_us-gaap_PayablesAndAccrualsAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_03b388b7-39d0-4bc8-ad2f-53ee02118e15_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Grant Date Fair Value Per Share</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_778b48ef-94ca-44a3-802b-bcf1ac96ea21_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares remained available for purchase (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementTable_05b3e244-e3b4-4043-b8b0-ae7f64354260_terseLabel_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:label id="lab_us-gaap_StatementTable_label_en-US" xlink:label="lab_us-gaap_StatementTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementTable" xlink:to="lab_us-gaap_StatementTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_9d4dc7d4-30c8-4055-ba0b-216fa8cea238_terseLabel_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other expense, net</link:label>
    <link:label id="lab_us-gaap_OtherNonoperatingIncomeExpense_label_en-US" xlink:label="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Nonoperating Income (Expense)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpense" xlink:to="lab_us-gaap_OtherNonoperatingIncomeExpense" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_40294dbc-1758-4645-903f-9a03d483b627_totalLabel_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total deferred</link:label>
    <link:label id="lab_us-gaap_DeferredIncomeTaxExpenseBenefit_label_en-US" xlink:label="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred Income Tax Expense (Benefit)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="lab_us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_70049f79-b289-4a94-bbb6-4ec69099cba2_terseLabel_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:label id="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="lab_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_3c762372-283c-4f30-adf2-bc2649920d6e_terseLabel_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research Collaboration and License Agreements</link:label>
    <link:label id="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock_label_en-US" xlink:label="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Collaborative Arrangement Disclosure [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:to="lab_us-gaap_CollaborativeArrangementDisclosureTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_90df30e5-185a-4038-8979-fe1d1c338ef0_terseLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash flows from financing activities:</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_5707eb26-55c5-4cfc-a4c2-ea9cff3ba52c_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted average grant date fair value of options granted (in usd per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_terseLabel_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in Compensation Table</link:label>
    <link:label id="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember_label_en-US" xlink:label="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="lab_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_36c47abc-f3fb-4312-8355-e44ec0f98727_terseLabel_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue</link:label>
    <link:label id="lab_us-gaap_SalesRevenueNetMember_label_en-US" xlink:label="lab_us-gaap_SalesRevenueNetMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue Benchmark [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SalesRevenueNetMember" xlink:to="lab_us-gaap_SalesRevenueNetMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ForeignTaxJurisdictionOtherMember_019c469d-ec70-71e4-8f06-d351089b5477_terseLabel_en-US" xlink:label="lab_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:label id="lab_us-gaap_ForeignTaxJurisdictionOtherMember_label_en-US" xlink:label="lab_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Foreign Tax Jurisdiction, Other [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignTaxJurisdictionOtherMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:to="lab_us-gaap_ForeignTaxJurisdictionOtherMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ARV766Member_2b2f277f-244f-440d-bf43-66657e46db61_terseLabel_en-US" xlink:label="lab_arvn_ARV766Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Luxdegalutamide (ARV-766)</link:label>
    <link:label id="lab_arvn_ARV766Member_label_en-US" xlink:label="lab_arvn_ARV766Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARV-766 [Member]</link:label>
    <link:label id="lab_arvn_ARV766Member_documentation_en-US" xlink:label="lab_arvn_ARV766Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARV-766</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV766Member" xlink:href="arvn-20251231.xsd#arvn_ARV766Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ARV766Member" xlink:to="lab_arvn_ARV766Member" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_3592319c-9339-42f8-9de4-c740a58c9289_terseLabel_en-US" xlink:label="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Milestone Payment On First Anniversary Of Signing</link:label>
    <link:label id="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_label_en-US" xlink:label="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Milestone Payment On First Anniversary Of Signing [Member]</link:label>
    <link:label id="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_documentation_en-US" xlink:label="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Milestone Payment On First Anniversary Of Signing</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" xlink:href="arvn-20251231.xsd#arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" xlink:to="lab_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_8906d1e5-6f31-41fa-965e-47c701bdd963_terseLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Contract with customer, liability</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_a3614304-2ec7-449b-b732-07a99990fc48_periodStartLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_1f7cb55a-c3b4-4347-a6db-408c69f3a523_periodEndLabel_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance</link:label>
    <link:label id="lab_us-gaap_ContractWithCustomerLiability_label_en-US" xlink:label="lab_us-gaap_ContractWithCustomerLiability" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract with Customer, Liability</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ContractWithCustomerLiability" xlink:to="lab_us-gaap_ContractWithCustomerLiability" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_dfd7d703-6b13-4db4-9c29-ecd1db613538_periodStartLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning of period balance - gross</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_c52df205-2288-47cb-a8f4-bd3bfe92802a_periodEndLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">End of period balance - gross</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefits_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefits" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefits" xlink:to="lab_us-gaap_UnrecognizedTaxBenefits" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_e6670259-9403-4f79-8ec3-68eb0e21fff0_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="lab_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_MA_019c469d-ec70-70ce-8c05-1dec471eb55a_terseLabel_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Massachusetts</link:label>
    <link:label id="lab_stpr_MA_label_en-US" xlink:label="lab_stpr_MA" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">MASSACHUSETTS</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MA"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_MA" xlink:to="lab_stpr_MA" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_AllAdjToCompMember_terseLabel_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation</link:label>
    <link:label id="lab_ecd_AllAdjToCompMember_label_en-US" xlink:label="lab_ecd_AllAdjToCompMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">All Adjustments to Compensation [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="lab_ecd_AllAdjToCompMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ARV393Member_9812f021-183a-4360-a790-dcb274d05a01_terseLabel_en-US" xlink:label="lab_arvn_ARV393Member" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">ARV-393</link:label>
    <link:label id="lab_arvn_ARV393Member_label_en-US" xlink:label="lab_arvn_ARV393Member" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ARV-393 [Member]</link:label>
    <link:label id="lab_arvn_ARV393Member_documentation_en-US" xlink:label="lab_arvn_ARV393Member" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">ARV-393</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV393Member" xlink:href="arvn-20251231.xsd#arvn_ARV393Member"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ARV393Member" xlink:to="lab_arvn_ARV393Member" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_f0d08865-1d8e-4dc2-8ee3-fc4000cadb55_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_459fc42a-0d17-4fb7-b28a-3411a2c7833a_terseLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_04ed99bc-6978-4772-8a79-334ec2ab6e72_totalLabel_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Accounts payable and accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_label_en-US" xlink:label="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable and Accrued Liabilities, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:to="lab_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_5db6c68a-bce5-40ad-9b87-b8c656884683_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_90e859bd-a0c2-4399-b900-eb19ab66fd0c_terseLabel_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Sale of stock, price (in usd per share)</link:label>
    <link:label id="lab_us-gaap_SaleOfStockPricePerShare_label_en-US" xlink:label="lab_us-gaap_SaleOfStockPricePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock, Price Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SaleOfStockPricePerShare" xlink:to="lab_us-gaap_SaleOfStockPricePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_a8adc425-936f-41ec-a5e2-cae12fe475d3_terseLabel_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">2027</link:label>
    <link:label id="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_label_en-US" xlink:label="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Term Debt, Maturity, Year Two</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:to="lab_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_019c65c8-d502-76dc-b7b6-68ed7e5e8eef_negatedLabel_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Treasury Stock, at cost (10.0 and zero shares at December&#160;31, 2025 and December&#160;31, 2024, respectively)</link:label>
    <link:label id="lab_us-gaap_TreasuryStockCommonValue_label_en-US" xlink:label="lab_us-gaap_TreasuryStockCommonValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Treasury Stock, Common, Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TreasuryStockCommonValue" xlink:to="lab_us-gaap_TreasuryStockCommonValue" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_a20db49d-5e87-45e5-94f7-b684fcf97cd0_terseLabel_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Regulatory Milestone Related to Marketing Approvals</link:label>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_label_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Regulatory Milestone Payments [Member]</link:label>
    <link:label id="lab_arvn_RegulatoryMilestonePaymentsMember_documentation_en-US" xlink:label="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Regulatory milestone payments.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember" xlink:href="arvn-20251231.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_RegulatoryMilestonePaymentsMember" xlink:to="lab_arvn_RegulatoryMilestonePaymentsMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_87d04f0b-1737-477b-b6ca-9526d76f2aa7_terseLabel_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Right of Use Assets and Liabilities</link:label>
    <link:label id="lab_us-gaap_LesseeOperatingLeasesTextBlock_label_en-US" xlink:label="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lessee, Operating Leases [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="lab_us-gaap_LesseeOperatingLeasesTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TrdArrTerminationDate_terseLabel_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Termination Date</link:label>
    <link:label id="lab_ecd_TrdArrTerminationDate_label_en-US" xlink:label="lab_ecd_TrdArrTerminationDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement Termination Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TrdArrTerminationDate" xlink:to="lab_ecd_TrdArrTerminationDate" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_1cffa59c-170d-418e-be11-36559f20653b_totalLabel_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash (used in) provided by financing activities</link:label>
    <link:label id="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities_label_en-US" xlink:label="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash Provided by (Used in) Financing Activity, Including Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="lab_us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_b8c6e526-909a-4e2c-81dc-26ca3366d036_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Collaboration contract asset</link:label>
    <link:label id="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_label_en-US" xlink:label="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Increase (Decrease) in Contract with Customer, Asset</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:to="lab_us-gaap_IncreaseDecreaseInContractWithCustomerAsset" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock_b6b23d19-c008-4bde-9ce2-629e03877a6f_terseLabel_en-US" xlink:label="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">401(k) Savings Plan</link:label>
    <link:label id="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock_label_en-US" xlink:label="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Policy [Policy Text Block]</link:label>
    <link:label id="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock_documentation_en-US" xlink:label="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Policy</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DefinedContributionPlanPolicyPolicyTextBlock" xlink:href="arvn-20251231.xsd#arvn_DefinedContributionPlanPolicyPolicyTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_DefinedContributionPlanPolicyPolicyTextBlock" xlink:to="lab_arvn_DefinedContributionPlanPolicyPolicyTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted</link:label>
    <link:label id="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag_label_en-US" xlink:label="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Policies and Procedures Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:to="lab_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_a8e95404-d68b-46cf-ac78-740146f3f345_verboseLabel_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted-Average Exercise Price</link:label>
    <link:label id="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_label_en-US" xlink:label="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:to="lab_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_b144d10c-c2d0-40e7-9bd7-fb41a9b16a16_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued liabilities</link:label>
    <link:label id="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_label_en-US" xlink:label="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Liabilities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:to="lab_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MeasureAxis_terseLabel_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Measure:</link:label>
    <link:label id="lab_ecd_MeasureAxis_label_en-US" xlink:label="lab_ecd_MeasureAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Measure [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MeasureAxis" xlink:to="lab_ecd_MeasureAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_603fb890-2ae5-4db5-b1f7-2829ec50aba8_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, weighted average discount rate, percent</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Discount Rate, Percent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_b7214c4f-b23a-4b08-bcdb-7795422cebb6_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Stock Option Activity</link:label>
    <link:label id="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_ea8e950e-de92-435c-92fd-4e0f4d722f76_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Unrecognized tax benefits, income tax penalties and interest accrued</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue_97e6f167-3616-4124-94d4-718ba37079fa_terseLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Released (in dollars per share)</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Released, Weighted Average Grant Date Fair Value</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Released, Weighted Average Grant Date Fair Value</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_32fe2bcd-d724-46f7-a8cf-2f09c9bf010f_terseLabel_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:label id="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain_label_en-US" xlink:label="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Long-Lived Tangible Asset [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="lab_us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_b7dad94f-6a6d-4f29-b0c0-469181744c31_terseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Weighted-average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3d902f58-c53b-45f8-8230-49e7a87920eb_verboseLabel_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Weighted average common shares outstanding - basic (in shares)</link:label>
    <link:label id="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_label_en-US" xlink:label="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted Average Number of Shares Outstanding, Basic</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="lab_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:type="arc" order="1"/>
    <link:label id="lab_stpr_NJ_019c469d-ec70-7407-8ebc-df1ccb981062_terseLabel_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">New Jersey</link:label>
    <link:label id="lab_stpr_NJ_label_en-US" xlink:label="lab_stpr_NJ" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">NEW JERSEY</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NJ"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_stpr_NJ" xlink:to="lab_stpr_NJ" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_cac8c956-5a55-45e9-93c0-1cb736141185_terseLabel_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Schedule of Basic and Diluted Loss per Common Share</link:label>
    <link:label id="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_label_en-US" xlink:label="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:to="lab_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_722ff477-561d-4ea7-a331-b469c596135d_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Vested and exercisable, ending balance (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_SegmentReportingAbstract_label_en-US" xlink:label="lab_us-gaap_SegmentReportingAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Segment Reporting [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_SegmentReportingAbstract" xlink:to="lab_us-gaap_SegmentReportingAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PvpTableTextBlock_terseLabel_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pay vs Performance Disclosure, Table</link:label>
    <link:label id="lab_ecd_PvpTableTextBlock_label_en-US" xlink:label="lab_ecd_PvpTableTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pay vs Performance [Table Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PvpTableTextBlock" xlink:to="lab_ecd_PvpTableTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_cbe7138d-4d8f-4191-ba0c-193fd7561de7_terseLabel_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:label id="lab_us-gaap_DebtDisclosureAbstract_label_en-US" xlink:label="lab_us-gaap_DebtDisclosureAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Disclosure [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtDisclosureAbstract" xlink:to="lab_us-gaap_DebtDisclosureAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Violation of Home Country Law, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_72b2ecd2-5c40-4c26-a389-60f51ff38504_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_2c7052ca-73d6-461e-8c08-db781fcbfa4e_terseLabel_en-US" xlink:label="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Additions</link:label>
    <link:label id="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_label_en-US" xlink:label="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:label id="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_documentation_en-US" xlink:label="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:href="arvn-20251231.xsd#arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:to="lab_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_b7a26466-7ae9-4a2f-a829-38fe58558f5d_negatedLabel_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on sale of marketable securities</link:label>
    <link:label id="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_label_en-US" xlink:label="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale, Realized Gain (Loss)</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:to="lab_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_74fce644-95ef-4b8a-a4f6-68d5a9c7f44c_periodStartLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Beginning balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_2f582b99-d9f8-4a0f-9d69-c050e135734c_periodEndLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Ending balance (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract_label_en-US" xlink:label="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring and Related Activities [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:to="lab_us-gaap_RestructuringAndRelatedActivitiesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_terseLabel_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:label id="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt_label_en-US" xlink:label="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forgone Recovery due to Expense of Enforcement, Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:to="lab_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6c399ce1-e5b5-417c-abf1-9eb0402b3a9e_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_f2546426-b647-4fc5-a3c5-b0ef647e29dd_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_CommonStockParOrStatedValuePerShare_label_en-US" xlink:label="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Par or Stated Value Per Share</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="lab_us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_84169485-76b5-4c5e-babc-db0ab8b7c5c6_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:label id="lab_us-gaap_CommonStockSharesIssued_label_en-US" xlink:label="lab_us-gaap_CommonStockSharesIssued" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock, Shares, Issued</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockSharesIssued" xlink:to="lab_us-gaap_CommonStockSharesIssued" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_43691d2c-3b72-4622-af5f-47d33e586a22_terseLabel_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total intrinsic value of RSUs released</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_label_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period</link:label>
    <link:label id="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_documentation_en-US" xlink:label="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" xlink:to="lab_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_26d90593-0b7a-416a-b570-ad9d4b8a931d_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating lease, weighted average remaining lease term (in years)</link:label>
    <link:label id="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_label_en-US" xlink:label="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Lease, Weighted Average Remaining Lease Term</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="lab_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_7cdb33f0-911d-438b-b6ac-40a8f6a62d69_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_83af2f27-6545-46d4-887f-663a4fde2504_terseLabel_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Laboratory equipment</link:label>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_label_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Laboratory Equipment [Member]</link:label>
    <link:label id="lab_arvn_LaboratoryEquipmentMember_documentation_en-US" xlink:label="lab_arvn_LaboratoryEquipmentMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Laboratory equipment.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember" xlink:href="arvn-20251231.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_LaboratoryEquipmentMember" xlink:to="lab_arvn_LaboratoryEquipmentMember" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_31ebb258-a98d-4844-bb77-66b0938aecf7_terseLabel_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">At-the-Market Offering</link:label>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_label_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">At The Market Offering [Member]</link:label>
    <link:label id="lab_arvn_AtTheMarketOfferingMember_documentation_en-US" xlink:label="lab_arvn_AtTheMarketOfferingMember" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">At the market offering.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember" xlink:href="arvn-20251231.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_AtTheMarketOfferingMember" xlink:to="lab_arvn_AtTheMarketOfferingMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UseOfEstimates_019b3057-9755-798a-acfe-d7f54faa1530_terseLabel_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Use of Estimates</link:label>
    <link:label id="lab_us-gaap_UseOfEstimates_label_en-US" xlink:label="lab_us-gaap_UseOfEstimates" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UseOfEstimates" xlink:to="lab_us-gaap_UseOfEstimates" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityPublicFloat_5cdd3824-6e4f-4a2a-86bb-fdd893b2977e_terseLabel_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:label id="lab_dei_EntityPublicFloat_label_en-US" xlink:label="lab_dei_EntityPublicFloat" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityPublicFloat" xlink:to="lab_dei_EntityPublicFloat" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TradingArrAxis_terseLabel_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Arrangement:</link:label>
    <link:label id="lab_ecd_TradingArrAxis_label_en-US" xlink:label="lab_ecd_TradingArrAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Arrangement [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TradingArrAxis" xlink:to="lab_ecd_TradingArrAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_terseLabel_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:label id="lab_ecd_TotalShareholderRtnAmt_label_en-US" xlink:label="lab_ecd_TotalShareholderRtnAmt" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Total Shareholder Return Amount</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_TotalShareholderRtnAmt" xlink:to="lab_ecd_TotalShareholderRtnAmt" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_InsiderTradingArrLineItems_label_en-US" xlink:label="lab_ecd_InsiderTradingArrLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Insider Trading Arrangements [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="lab_ecd_InsiderTradingArrLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_174d7a26-3b9f-4835-a197-dbf822aacb85_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_1e0ce2b5-e3ed-4678-96d9-50007d31a08e_verboseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in dollars per share)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_Liabilities_b05d8861-8df5-4223-a8fe-1b44ab4314ad_totalLabel_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:label id="lab_us-gaap_Liabilities_label_en-US" xlink:label="lab_us-gaap_Liabilities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liabilities</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_Liabilities" xlink:to="lab_us-gaap_Liabilities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_f697f19b-b357-4375-b3fb-0b887d6298a6_terseLabel_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_AntidilutiveSecuritiesNameDomain_label_en-US" xlink:label="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="lab_us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_7ee85277-2800-4283-b005-5b2b27c9507b_terseLabel_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Purchases of property, equipment and leasehold improvements unpaid at period end</link:label>
    <link:label id="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid_label_en-US" xlink:label="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capital Expenditures Incurred but Not yet Paid</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:to="lab_us-gaap_CapitalExpendituresIncurredButNotYetPaid" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_terseLabel_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost</link:label>
    <link:label id="lab_ecd_PnsnAdjsPrrSvcCstMember_label_en-US" xlink:label="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pension Adjustments Prior Service Cost [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:to="lab_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_80fe3fc1-f992-43c6-8d7a-aeb79b9c018c_terseLabel_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Increases for tax positions taken during the current period</link:label>
    <link:label id="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_label_en-US" xlink:label="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:to="lab_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PledgingPurposeAxis_ba444ffa-ef1c-49a4-a6cd-ecb95d6d9b96_terseLabel_en-US" xlink:label="lab_us-gaap_PledgingPurposeAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pledging Purpose [Axis]</link:label>
    <link:label id="lab_us-gaap_PledgingPurposeAxis_label_en-US" xlink:label="lab_us-gaap_PledgingPurposeAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pledging Purpose [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PledgingPurposeAxis" xlink:to="lab_us-gaap_PledgingPurposeAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_arvn_IncomeTaxDisclosureTable_998a68ca-8552-432a-bcd5-2872fcfacf30_terseLabel_en-US" xlink:label="lab_arvn_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:label id="lab_arvn_IncomeTaxDisclosureTable_label_en-US" xlink:label="lab_arvn_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Table]</link:label>
    <link:label id="lab_arvn_IncomeTaxDisclosureTable_documentation_en-US" xlink:label="lab_arvn_IncomeTaxDisclosureTable" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Income tax disclosure.</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeTaxDisclosureTable" xlink:href="arvn-20251231.xsd#arvn_IncomeTaxDisclosureTable"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_arvn_IncomeTaxDisclosureTable" xlink:to="lab_arvn_IncomeTaxDisclosureTable" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_4851b895-6b4f-4e9c-8d13-71b2f239e320_terseLabel_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:label id="lab_us-gaap_OperatingExpensesAbstract_label_en-US" xlink:label="lab_us-gaap_OperatingExpensesAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating Expenses [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_OperatingExpensesAbstract" xlink:to="lab_us-gaap_OperatingExpensesAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_terseLabel_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement</link:label>
    <link:label id="lab_ecd_MtrlTermsOfTrdArrTextBlock_label_en-US" xlink:label="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Material Terms of Trading Arrangement [Text Block]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:to="lab_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_PaymentsForBrokerageFees_21920d48-0c0c-4918-b824-6d14e6bbc9b1_terseLabel_en-US" xlink:label="lab_us-gaap_PaymentsForBrokerageFees" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Financial advisor fees</link:label>
    <link:label id="lab_us-gaap_PaymentsForBrokerageFees_label_en-US" xlink:label="lab_us-gaap_PaymentsForBrokerageFees" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Payments for Brokerage Fees</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForBrokerageFees" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForBrokerageFees"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_PaymentsForBrokerageFees" xlink:to="lab_us-gaap_PaymentsForBrokerageFees" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_9db6709b-230b-4329-82ca-2b76251df058_terseLabel_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common stock issued, net of issuance costs</link:label>
    <link:label id="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues_label_en-US" xlink:label="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Value, New Issues</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="lab_us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_955b99f2-1fe6-40c3-951e-b54318df82a2_negatedTerseLabel_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Lease termination costs</link:label>
    <link:label id="lab_us-gaap_GainLossOnContractTermination_label_en-US" xlink:label="lab_us-gaap_GainLossOnContractTermination" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Gain (Loss) on Contract Termination</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_GainLossOnContractTermination" xlink:to="lab_us-gaap_GainLossOnContractTermination" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_StatementLineItems_203fa13f-86df-4384-8447-5bec1c342221_terseLabel_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:label id="lab_us-gaap_StatementLineItems_label_en-US" xlink:label="lab_us-gaap_StatementLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_StatementLineItems" xlink:to="lab_us-gaap_StatementLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_510d39fb-963b-4d58-b051-1026eab5ec86_terseLabel_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</link:label>
    <link:label id="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_label_en-US" xlink:label="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:to="lab_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_terseLabel_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted</link:label>
    <link:label id="lab_ecd_Rule10b51ArrAdoptedFlag_label_en-US" xlink:label="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Rule 10b5-1 Arrangement Adopted [Flag]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:to="lab_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_1defbe34-d7a6-4678-b1e3-ce242abfd71c_terseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_c4442293-5f35-4e34-b043-4b5a4352a342_verboseLabel_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:label id="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue_label_en-US" xlink:label="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalent</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="lab_us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc" order="1"/>
    <link:label id="lab_srt_CounterpartyNameAxis_e0ab8cbe-3e0e-449a-835d-619182f104af_terseLabel_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:label id="lab_srt_CounterpartyNameAxis_label_en-US" xlink:label="lab_srt_CounterpartyNameAxis" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_srt_CounterpartyNameAxis" xlink:to="lab_srt_CounterpartyNameAxis" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019c46d7-ffba-7ee6-8b83-537e3e620fa0_terseLabel_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:label id="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_label_en-US" xlink:label="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:to="lab_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ResearchMember_c13b08be-c770-4b95-8511-7fc0746e0aae_terseLabel_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Research and Development Tax Credits</link:label>
    <link:label id="lab_us-gaap_ResearchMember_label_en-US" xlink:label="lab_us-gaap_ResearchMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research Tax Credit Carryforward [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ResearchMember" xlink:to="lab_us-gaap_ResearchMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_0d6acd80-65ae-4b8d-9145-f4385f06a13b_terseLabel_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Risk free interest rate, maximum (percentage)</link:label>
    <link:label id="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_label_en-US" xlink:label="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:to="lab_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CommonStockMember_eb2e9e20-3c6e-4211-91dd-d2235951bf22_verboseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Common</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_f4830d3e-55d3-43c1-9207-262eeb487e93_terseLabel_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Common Shares</link:label>
    <link:label id="lab_us-gaap_CommonStockMember_label_en-US" xlink:label="lab_us-gaap_CommonStockMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CommonStockMember" xlink:to="lab_us-gaap_CommonStockMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_00ad7ff3-cb18-4932-9881-d282227c48d3_terseLabel_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Fair Value</link:label>
    <link:label id="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities_label_en-US" xlink:label="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Debt Securities, Available-for-Sale</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:to="lab_us-gaap_AvailableForSaleSecuritiesDebtSecurities" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_5c708788-dc70-47c4-ac50-cf4d7ee5e2e2_terseLabel_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:label id="lab_us-gaap_TaxCreditCarryforwardNameDomain_label_en-US" xlink:label="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Tax Credit Carryforward, Name [Domain]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain" xlink:to="lab_us-gaap_TaxCreditCarryforwardNameDomain" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3b1a5aa4-d534-49b9-a3ab-4a6e8883d9e1_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_ecd_NonNeosMember_terseLabel_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Non-NEOs</link:label>
    <link:label id="lab_ecd_NonNeosMember_label_en-US" xlink:label="lab_ecd_NonNeosMember" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Non-NEOs [Member]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_ecd_NonNeosMember" xlink:to="lab_ecd_NonNeosMember" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_49ccfda4-659d-47c9-bdef-71260460df95_totalLabel_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase (decrease) in cash, cash equivalents and restricted cash</link:label>
    <link:label id="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_label_en-US" xlink:label="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="lab_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc" order="1"/>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_4cef5aba-4206-41c0-b206-a685ae98d462_terseLabel_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Professional fees</link:label>
    <link:label id="lab_us-gaap_AccruedProfessionalFeesCurrent_label_en-US" xlink:label="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued Professional Fees, Current</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_us-gaap_AccruedProfessionalFeesCurrent" xlink:to="lab_us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>15
<FILENAME>arvn-20251231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2026 Workiva-->
<!--r:bad37b98-383d-4e3d-a5b5-927fa1eba41c,g:852a4cd9-135e-4322-96de-ff3159237791-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.arvinas.com/role/Cover" xlink:type="simple" xlink:href="arvn-20251231.xsd#Cover"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/Cover" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_088a0e74-ef86-4fc8-ad64-e33e1eb2887c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_DocumentType_088a0e74-ef86-4fc8-ad64-e33e1eb2887c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentAnnualReport_750dd07f-9d8d-41e9-9c62-17d979563808" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentAnnualReport"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_DocumentAnnualReport_750dd07f-9d8d-41e9-9c62-17d979563808" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_4fe41998-5c6b-4cd7-b5b9-f0c0bf2c5980" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_DocumentPeriodEndDate_4fe41998-5c6b-4cd7-b5b9-f0c0bf2c5980" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CurrentFiscalYearEndDate_4cdc9310-1ad7-4b95-9719-d076f504b3a6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CurrentFiscalYearEndDate"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_CurrentFiscalYearEndDate_4cdc9310-1ad7-4b95-9719-d076f504b3a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentTransitionReport_0c175128-4a3b-4867-8023-b836abbac2a9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentTransitionReport"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_DocumentTransitionReport_0c175128-4a3b-4867-8023-b836abbac2a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_06e6b2c6-ffef-485a-ae6a-3ca2390b3c78" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityFileNumber_06e6b2c6-ffef-485a-ae6a-3ca2390b3c78" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_bf252062-2977-4276-99d7-5d3ed16f6382" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityRegistrantName_bf252062-2977-4276-99d7-5d3ed16f6382" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_f346d007-a6d2-4330-b543-45e955adccf4" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityIncorporationStateCountryCode_f346d007-a6d2-4330-b543-45e955adccf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_5735afff-5878-45d9-8bbc-86a1783b2466" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityTaxIdentificationNumber_5735afff-5878-45d9-8bbc-86a1783b2466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_cd531c58-92a5-48d6-a836-c6f9952574ac" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityAddressAddressLine1_cd531c58-92a5-48d6-a836-c6f9952574ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine2_85ac9583-5abe-4c97-90eb-30b818fd0015" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressAddressLine2"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityAddressAddressLine2_85ac9583-5abe-4c97-90eb-30b818fd0015" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_183b0245-4988-4c8e-8baf-47c3d876ac54" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityAddressCityOrTown_183b0245-4988-4c8e-8baf-47c3d876ac54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_d84cf95f-7abf-4c83-8c11-f32986faf97c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityAddressStateOrProvince_d84cf95f-7abf-4c83-8c11-f32986faf97c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_7632b93a-5a8b-4f07-abee-1b3d9d0f1f3b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityAddressPostalZipCode_7632b93a-5a8b-4f07-abee-1b3d9d0f1f3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_a9bde751-475c-4fbb-a9ca-b59909aaa5fa" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_CityAreaCode_a9bde751-475c-4fbb-a9ca-b59909aaa5fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_af0d70d4-5b8f-4373-bc7c-a84d0289cf1c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_LocalPhoneNumber_af0d70d4-5b8f-4373-bc7c-a84d0289cf1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_ebeebd1a-5e31-4674-95c6-87ef97a0f07e" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_Security12bTitle_ebeebd1a-5e31-4674-95c6-87ef97a0f07e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_31b8819d-901f-450e-8fe5-16b3fdb1f3df" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_TradingSymbol_31b8819d-901f-450e-8fe5-16b3fdb1f3df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_bad5af1f-0af4-47f9-83c5-14d0005275ed" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_SecurityExchangeName_bad5af1f-0af4-47f9-83c5-14d0005275ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityWellKnownSeasonedIssuer_5d0b1b7a-81a6-450a-b642-01b73f69a48d" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityWellKnownSeasonedIssuer"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityWellKnownSeasonedIssuer_5d0b1b7a-81a6-450a-b642-01b73f69a48d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityVoluntaryFilers_f74ae8f7-066e-4a28-9737-904867c95c9c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityVoluntaryFilers"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityVoluntaryFilers_f74ae8f7-066e-4a28-9737-904867c95c9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCurrentReportingStatus_c85bf2a4-2277-4b80-a3a0-3d7bb55ac4cf" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCurrentReportingStatus"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityCurrentReportingStatus_c85bf2a4-2277-4b80-a3a0-3d7bb55ac4cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityInteractiveDataCurrent_de768c8d-6a3d-45dd-9f87-34a21cf8d96b" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityInteractiveDataCurrent"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityInteractiveDataCurrent_de768c8d-6a3d-45dd-9f87-34a21cf8d96b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFilerCategory_37e303db-6808-40e5-96c5-072362792b53" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityFilerCategory"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityFilerCategory_37e303db-6808-40e5-96c5-072362792b53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntitySmallBusiness_c20d2605-2422-46d5-b60b-e0f8ab4f18b2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntitySmallBusiness"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntitySmallBusiness_c20d2605-2422-46d5-b60b-e0f8ab4f18b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_d8e4fc64-a2ab-4c63-b0d0-2369086eb886" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityEmergingGrowthCompany_d8e4fc64-a2ab-4c63-b0d0-2369086eb886" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_IcfrAuditorAttestationFlag_683ea841-bbb1-4ce7-a568-54726a120568" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_IcfrAuditorAttestationFlag"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_IcfrAuditorAttestationFlag_683ea841-bbb1-4ce7-a568-54726a120568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFinStmtErrorCorrectionFlag_b8b9b399-bb1b-4245-955c-ae94043c806f" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFinStmtErrorCorrectionFlag"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_DocumentFinStmtErrorCorrectionFlag_b8b9b399-bb1b-4245-955c-ae94043c806f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityShellCompany_8ad52d67-3250-4935-b82b-b9e0e3554d47" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityShellCompany"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityShellCompany_8ad52d67-3250-4935-b82b-b9e0e3554d47" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityPublicFloat_c1a9095f-f264-4681-b67a-9614e98f4fcd" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityPublicFloat"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityPublicFloat_c1a9095f-f264-4681-b67a-9614e98f4fcd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCommonStockSharesOutstanding_6c04fa92-aa10-451b-bd89-221f118466a9" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCommonStockSharesOutstanding"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityCommonStockSharesOutstanding_6c04fa92-aa10-451b-bd89-221f118466a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentsIncorporatedByReferenceTextBlock_dec8362a-2f5e-4d82-89b4-e23c00b244b3" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentsIncorporatedByReferenceTextBlock"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_DocumentsIncorporatedByReferenceTextBlock_dec8362a-2f5e-4d82-89b4-e23c00b244b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_ea6c7876-bb88-4707-95af-56dc2c46cd57" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_EntityCentralIndexKey_ea6c7876-bb88-4707-95af-56dc2c46cd57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalYearFocus_9573b858-b12c-4cd2-8578-ea45213f66b8" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalYearFocus"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_DocumentFiscalYearFocus_9573b858-b12c-4cd2-8578-ea45213f66b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentFiscalPeriodFocus_71f73910-91ff-4f66-87f8-6e1035a892d7" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_DocumentFiscalPeriodFocus"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_DocumentFiscalPeriodFocus_71f73910-91ff-4f66-87f8-6e1035a892d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_4fc88e2b-8886-4637-bde6-d5bb0fed153c" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_81037fb9-56a3-4ca6-84b9-17933bf6490f" xlink:to="loc_dei_AmendmentFlag_4fc88e2b-8886-4637-bde6-d5bb0fed153c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AuditInformation" xlink:type="simple" xlink:href="arvn-20251231.xsd#AuditInformation"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AuditInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AuditInformationAbstract_0538a83b-f048-43c6-9d77-87e7e3689c8c" xlink:href="arvn-20251231.xsd#arvn_AuditInformationAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorName_1f0882dc-054b-4152-88e0-6e142cd59a88" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorName"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AuditInformationAbstract_0538a83b-f048-43c6-9d77-87e7e3689c8c" xlink:to="loc_dei_AuditorName_1f0882dc-054b-4152-88e0-6e142cd59a88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorLocation_e749a10d-adb6-4756-9cb8-faf559cfa7eb" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorLocation"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AuditInformationAbstract_0538a83b-f048-43c6-9d77-87e7e3689c8c" xlink:to="loc_dei_AuditorLocation_e749a10d-adb6-4756-9cb8-faf559cfa7eb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AuditorFirmId_264a80b1-e784-494a-8ced-61ad919c3be6" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_AuditorFirmId"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AuditInformationAbstract_0538a83b-f048-43c6-9d77-87e7e3689c8c" xlink:to="loc_dei_AuditorFirmId_264a80b1-e784-494a-8ced-61ad919c3be6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedBalanceSheets" xlink:type="simple" xlink:href="arvn-20251231.xsd#ConsolidatedBalanceSheets"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ConsolidatedBalanceSheets" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_359ecef9-fb74-4809-b430-c5015ef84244" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsAbstract_bde7019c-5b32-4571-8729-a35f478733d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_359ecef9-fb74-4809-b430-c5015ef84244" xlink:to="loc_us-gaap_AssetsAbstract_bde7019c-5b32-4571-8729-a35f478733d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrentAbstract_20472989-bbf7-4adb-ae27-4d3593447992" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bde7019c-5b32-4571-8729-a35f478733d5" xlink:to="loc_us-gaap_AssetsCurrentAbstract_20472989-bbf7-4adb-ae27-4d3593447992" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03e469a2-3dc7-4a32-97f0-ac75f6485a35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_20472989-bbf7-4adb-ae27-4d3593447992" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_03e469a2-3dc7-4a32-97f0-ac75f6485a35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesCurrent_787edf74-7eda-438e-89f8-48c079428f30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_20472989-bbf7-4adb-ae27-4d3593447992" xlink:to="loc_us-gaap_MarketableSecuritiesCurrent_787edf74-7eda-438e-89f8-48c079428f30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_9cb332b5-60f2-4e3a-8056-b63808a17a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_20472989-bbf7-4adb-ae27-4d3593447992" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_9cb332b5-60f2-4e3a-8056-b63808a17a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherReceivablesNetCurrent_071daa35-5557-432e-89db-8f289d35ef36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherReceivablesNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_20472989-bbf7-4adb-ae27-4d3593447992" xlink:to="loc_us-gaap_OtherReceivablesNetCurrent_071daa35-5557-432e-89db-8f289d35ef36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c86484be-69b0-4411-83fd-73a9c651cc7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_20472989-bbf7-4adb-ae27-4d3593447992" xlink:to="loc_us-gaap_PrepaidExpenseAndOtherAssetsCurrent_c86484be-69b0-4411-83fd-73a9c651cc7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetsCurrent_19f5eb65-3f63-4d92-b37f-cf1156af62e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetsCurrent"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsCurrentAbstract_20472989-bbf7-4adb-ae27-4d3593447992" xlink:to="loc_us-gaap_AssetsCurrent_19f5eb65-3f63-4d92-b37f-cf1156af62e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_921229d3-609c-44a5-b68b-ed62b852b854" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bde7019c-5b32-4571-8729-a35f478733d5" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_921229d3-609c-44a5-b68b-ed62b852b854" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAsset_639dbb01-14ec-4008-916c-b67d815f722e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAsset"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bde7019c-5b32-4571-8729-a35f478733d5" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAsset_639dbb01-14ec-4008-916c-b67d815f722e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_ad87f2ae-cebd-457d-8f3b-ddb2936b60fa" xlink:href="arvn-20251231.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bde7019c-5b32-4571-8729-a35f478733d5" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_ad87f2ae-cebd-457d-8f3b-ddb2936b60fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Assets_84aaf37b-7d30-4092-bce1-9c303627d56e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Assets"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AssetsAbstract_bde7019c-5b32-4571-8729-a35f478733d5" xlink:to="loc_us-gaap_Assets_84aaf37b-7d30-4092-bce1-9c303627d56e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0920496-e08b-4e37-bf7b-4cd04f97a1e8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_359ecef9-fb74-4809-b430-c5015ef84244" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0920496-e08b-4e37-bf7b-4cd04f97a1e8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrentAbstract_c989da90-4538-4bb0-a5a5-e567276e1c16" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrentAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0920496-e08b-4e37-bf7b-4cd04f97a1e8" xlink:to="loc_us-gaap_LiabilitiesCurrentAbstract_c989da90-4538-4bb0-a5a5-e567276e1c16" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aee2b17d-516e-4680-bfb8-164263671aca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c989da90-4538-4bb0-a5a5-e567276e1c16" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_aee2b17d-516e-4680-bfb8-164263671aca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e5f1b542-46df-4269-b33e-f16e221bebf5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c989da90-4538-4bb0-a5a5-e567276e1c16" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityCurrent_e5f1b542-46df-4269-b33e-f16e221bebf5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityCurrent_322c02bb-666a-4320-a4f1-471b6e18ca6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c989da90-4538-4bb0-a5a5-e567276e1c16" xlink:to="loc_us-gaap_OperatingLeaseLiabilityCurrent_322c02bb-666a-4320-a4f1-471b6e18ca6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesCurrent_6d6560ed-e072-43aa-b20a-9c5aed0d8afb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesCurrentAbstract_c989da90-4538-4bb0-a5a5-e567276e1c16" xlink:to="loc_us-gaap_LiabilitiesCurrent_6d6560ed-e072-43aa-b20a-9c5aed0d8afb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7dd92736-b13e-41d0-8929-2951595981f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityNoncurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0920496-e08b-4e37-bf7b-4cd04f97a1e8" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityNoncurrent_7dd92736-b13e-41d0-8929-2951595981f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_2d30eabf-df03-4aa0-a8c9-d2717f4a1258" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0920496-e08b-4e37-bf7b-4cd04f97a1e8" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_2d30eabf-df03-4aa0-a8c9-d2717f4a1258" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cc8c7e51-b94e-4042-8c4e-10b466bfa1cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0920496-e08b-4e37-bf7b-4cd04f97a1e8" xlink:to="loc_us-gaap_OperatingLeaseLiabilityNoncurrent_cc8c7e51-b94e-4042-8c4e-10b466bfa1cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Liabilities_6cb52b6f-ee87-40d7-bf3f-c0f9fd9b40c7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Liabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0920496-e08b-4e37-bf7b-4cd04f97a1e8" xlink:to="loc_us-gaap_Liabilities_6cb52b6f-ee87-40d7-bf3f-c0f9fd9b40c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingencies_72ed2b34-8bb8-4486-9de2-223ff30e54a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingencies"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0920496-e08b-4e37-bf7b-4cd04f97a1e8" xlink:to="loc_us-gaap_CommitmentsAndContingencies_72ed2b34-8bb8-4486-9de2-223ff30e54a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquityAbstract_5dd4330d-0208-40bb-aa1a-6863806f4df3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquityAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0920496-e08b-4e37-bf7b-4cd04f97a1e8" xlink:to="loc_us-gaap_StockholdersEquityAbstract_5dd4330d-0208-40bb-aa1a-6863806f4df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockValue_6cd0ecc5-6181-41d1-8162-0fcfe489d658" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dd4330d-0208-40bb-aa1a-6863806f4df3" xlink:to="loc_us-gaap_PreferredStockValue_6cd0ecc5-6181-41d1-8162-0fcfe489d658" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockValue_e12350e7-629f-40c3-aa44-8aebaa17801f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dd4330d-0208-40bb-aa1a-6863806f4df3" xlink:to="loc_us-gaap_CommonStockValue_e12350e7-629f-40c3-aa44-8aebaa17801f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsAccumulatedDeficit_376d67af-573f-487a-b975-4bb6cf45659c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsAccumulatedDeficit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dd4330d-0208-40bb-aa1a-6863806f4df3" xlink:to="loc_us-gaap_RetainedEarningsAccumulatedDeficit_376d67af-573f-487a-b975-4bb6cf45659c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapital_94176ead-4c0b-4984-81b0-194553cd862c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapital"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dd4330d-0208-40bb-aa1a-6863806f4df3" xlink:to="loc_us-gaap_AdditionalPaidInCapital_94176ead-4c0b-4984-81b0-194553cd862c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b965808-e643-488f-a361-629f225e3165" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dd4330d-0208-40bb-aa1a-6863806f4df3" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_4b965808-e643-488f-a361-629f225e3165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonValue_019c0af4-54f2-7ba8-89f4-b802b69a2663" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonValue"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dd4330d-0208-40bb-aa1a-6863806f4df3" xlink:to="loc_us-gaap_TreasuryStockCommonValue_019c0af4-54f2-7ba8-89f4-b802b69a2663" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_f568a094-9af7-482b-95e2-9cb3da23f765" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StockholdersEquityAbstract_5dd4330d-0208-40bb-aa1a-6863806f4df3" xlink:to="loc_us-gaap_StockholdersEquity_f568a094-9af7-482b-95e2-9cb3da23f765" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LiabilitiesAndStockholdersEquity_0997aadc-8b9e-40be-aab5-72f7e79c493d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LiabilitiesAndStockholdersEquity"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LiabilitiesAndStockholdersEquityAbstract_a0920496-e08b-4e37-bf7b-4cd04f97a1e8" xlink:to="loc_us-gaap_LiabilitiesAndStockholdersEquity_0997aadc-8b9e-40be-aab5-72f7e79c493d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="simple" xlink:href="arvn-20251231.xsd#ConsolidatedBalanceSheetsParenthetical"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfFinancialPositionAbstract_f3ca6ea5-8cc0-4871-9e04-be94d8a9c23c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfFinancialPositionAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c5027e49-7d1e-4017-b642-8fcdc3b8343f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f3ca6ea5-8cc0-4871-9e04-be94d8a9c23c" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_c5027e49-7d1e-4017-b642-8fcdc3b8343f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesIssued_6ba08cf3-2882-44c7-a6bb-dc5349f62565" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesIssued"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f3ca6ea5-8cc0-4871-9e04-be94d8a9c23c" xlink:to="loc_us-gaap_PreferredStockSharesIssued_6ba08cf3-2882-44c7-a6bb-dc5349f62565" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesOutstanding_5de4b8d9-af3e-468c-9c21-8fd123b52ce1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f3ca6ea5-8cc0-4871-9e04-be94d8a9c23c" xlink:to="loc_us-gaap_PreferredStockSharesOutstanding_5de4b8d9-af3e-468c-9c21-8fd123b52ce1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_e0ad4c6c-3687-4f58-aed3-d331bc8ab2ff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f3ca6ea5-8cc0-4871-9e04-be94d8a9c23c" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_e0ad4c6c-3687-4f58-aed3-d331bc8ab2ff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesIssued_f913faaa-4e52-4cb1-ad84-99730ea9e87a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesIssued"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f3ca6ea5-8cc0-4871-9e04-be94d8a9c23c" xlink:to="loc_us-gaap_CommonStockSharesIssued_f913faaa-4e52-4cb1-ad84-99730ea9e87a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_9cc69609-eb3c-42b9-ad08-72ed07e19782" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f3ca6ea5-8cc0-4871-9e04-be94d8a9c23c" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_9cc69609-eb3c-42b9-ad08-72ed07e19782" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019c0af5-a7a1-7b95-bab8-de79120a05ec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfFinancialPositionAbstract_f3ca6ea5-8cc0-4871-9e04-be94d8a9c23c" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019c0af5-a7a1-7b95-bab8-de79120a05ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="simple" xlink:href="arvn-20251231.xsd#ConsolidatedStatementsofOperationsandComprehensiveLoss"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_00fe812f-1471-4143-8a58-e1473fb58e0e" xlink:href="arvn-20251231.xsd#arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementAbstract_291a5dab-ee66-4bbf-a168-95e17b2ad750" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_00fe812f-1471-4143-8a58-e1473fb58e0e" xlink:to="loc_us-gaap_IncomeStatementAbstract_291a5dab-ee66-4bbf-a168-95e17b2ad750" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_ad758a82-e0f3-412a-b08d-7ce27b5045da" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_291a5dab-ee66-4bbf-a168-95e17b2ad750" xlink:to="loc_us-gaap_Revenues_ad758a82-e0f3-412a-b08d-7ce27b5045da" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpensesAbstract_7596f67e-8fc0-4ee9-b9cd-64df25a9c457" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpensesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_291a5dab-ee66-4bbf-a168-95e17b2ad750" xlink:to="loc_us-gaap_OperatingExpensesAbstract_7596f67e-8fc0-4ee9-b9cd-64df25a9c457" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_cc6954eb-4fb8-4306-8fda-8c5ebf1c66d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7596f67e-8fc0-4ee9-b9cd-64df25a9c457" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_cc6954eb-4fb8-4306-8fda-8c5ebf1c66d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_4b75b3eb-053a-43c6-b9e7-cb2d7aa5aca9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7596f67e-8fc0-4ee9-b9cd-64df25a9c457" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_4b75b3eb-053a-43c6-b9e7-cb2d7aa5aca9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_e2a7f51c-9f34-44eb-bf27-69559923e5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OperatingExpensesAbstract_7596f67e-8fc0-4ee9-b9cd-64df25a9c457" xlink:to="loc_us-gaap_OperatingExpenses_e2a7f51c-9f34-44eb-bf27-69559923e5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingIncomeLoss_8fa97c66-852c-4e83-886d-2e4d86d31009" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingIncomeLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_291a5dab-ee66-4bbf-a168-95e17b2ad750" xlink:to="loc_us-gaap_OperatingIncomeLoss_8fa97c66-852c-4e83-886d-2e4d86d31009" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0472a550-6ed6-4068-9b4a-d2227ade2a0b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpenseAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_291a5dab-ee66-4bbf-a168-95e17b2ad750" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0472a550-6ed6-4068-9b4a-d2227ade2a0b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherNonoperatingIncomeExpense_61e4c301-e216-48a7-bbe3-c9eae8692295" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherNonoperatingIncomeExpense"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0472a550-6ed6-4068-9b4a-d2227ade2a0b" xlink:to="loc_us-gaap_OtherNonoperatingIncomeExpense_61e4c301-e216-48a7-bbe3-c9eae8692295" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_17ab956e-13b8-46d6-b1c7-2330749a6406" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0472a550-6ed6-4068-9b4a-d2227ade2a0b" xlink:to="loc_us-gaap_InvestmentIncomeInterest_17ab956e-13b8-46d6-b1c7-2330749a6406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonoperatingIncomeExpense_9b067787-e4c1-4784-afed-fe1aa125be89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonoperatingIncomeExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherNonoperatingIncomeExpenseAbstract_0472a550-6ed6-4068-9b4a-d2227ade2a0b" xlink:to="loc_us-gaap_NonoperatingIncomeExpense_9b067787-e4c1-4784-afed-fe1aa125be89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ceb929c0-96e7-4596-b11c-a63e02302beb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_291a5dab-ee66-4bbf-a168-95e17b2ad750" xlink:to="loc_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments_ceb929c0-96e7-4596-b11c-a63e02302beb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_00a65ea4-2800-4153-8dbf-112120d23abe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_291a5dab-ee66-4bbf-a168-95e17b2ad750" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_00a65ea4-2800-4153-8dbf-112120d23abe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e44c2bff-02d6-4e6d-8c38-576aeed67639" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_291a5dab-ee66-4bbf-a168-95e17b2ad750" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_e44c2bff-02d6-4e6d-8c38-576aeed67639" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f3618b4c-de15-4e34-a6ff-72fb3547cdf4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_291a5dab-ee66-4bbf-a168-95e17b2ad750" xlink:to="loc_us-gaap_NetIncomeLoss_f3618b4c-de15-4e34-a6ff-72fb3547cdf4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019c2331-57a7-7f08-8d2f-2b1adae77b0d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_291a5dab-ee66-4bbf-a168-95e17b2ad750" xlink:to="loc_us-gaap_EarningsPerShareAbstract_019c2331-57a7-7f08-8d2f-2b1adae77b0d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_ecb47a62-261e-4cd2-bc8b-345376d4f74e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c2331-57a7-7f08-8d2f-2b1adae77b0d" xlink:to="loc_us-gaap_EarningsPerShareBasic_ecb47a62-261e-4cd2-bc8b-345376d4f74e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_8dddeb65-f316-48ca-b1a7-51fa9b1747b7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019c2331-57a7-7f08-8d2f-2b1adae77b0d" xlink:to="loc_us-gaap_EarningsPerShareDiluted_8dddeb65-f316-48ca-b1a7-51fa9b1747b7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c2331-d759-7bfe-b02d-90d8e82ce567" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementAbstract_291a5dab-ee66-4bbf-a168-95e17b2ad750" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c2331-d759-7bfe-b02d-90d8e82ce567" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3c4dc80c-eb92-40e6-8f20-45cf1e84cce8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c2331-d759-7bfe-b02d-90d8e82ce567" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_3c4dc80c-eb92-40e6-8f20-45cf1e84cce8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb2156f3-f28e-4d25-95d3-56a7d5c3d41b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract_019c2331-d759-7bfe-b02d-90d8e82ce567" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_bb2156f3-f28e-4d25-95d3-56a7d5c3d41b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9b772d8b-52bd-4395-8682-671cc7ab5856" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract_00fe812f-1471-4143-8a58-e1473fb58e0e" xlink:to="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9b772d8b-52bd-4395-8682-671cc7ab5856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_6ef72c33-c2f5-4512-89fb-3152ca63d662" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9b772d8b-52bd-4395-8682-671cc7ab5856" xlink:to="loc_us-gaap_NetIncomeLoss_6ef72c33-c2f5-4512-89fb-3152ca63d662" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_397c7323-d227-40e6-a760-2de1a0867deb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9b772d8b-52bd-4395-8682-671cc7ab5856" xlink:to="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_397c7323-d227-40e6-a760-2de1a0867deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_9bc040f7-8628-4b30-9f9e-b0ec39d089e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_397c7323-d227-40e6-a760-2de1a0867deb" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_9bc040f7-8628-4b30-9f9e-b0ec39d089e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ComprehensiveIncomeNetOfTax_cdaef8d9-2d2a-4f6d-add2-a527eb08b1af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ComprehensiveIncomeNetOfTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract_9b772d8b-52bd-4395-8682-671cc7ab5856" xlink:to="loc_us-gaap_ComprehensiveIncomeNetOfTax_cdaef8d9-2d2a-4f6d-add2-a527eb08b1af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="simple" xlink:href="arvn-20251231.xsd#ConsolidatedStatementsofChangesinStockholdersEquity"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_a1fc8a99-e62b-4469-9929-5533ae9d2a8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementTable_f26f7966-c39e-453f-a29f-ea4aafdcf856" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_a1fc8a99-e62b-4469-9929-5533ae9d2a8d" xlink:to="loc_us-gaap_StatementTable_f26f7966-c39e-453f-a29f-ea4aafdcf856" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_40a47dd5-f5f5-4bf7-a49e-090b81c9391c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f26f7966-c39e-453f-a29f-ea4aafdcf856" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_40a47dd5-f5f5-4bf7-a49e-090b81c9391c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_40a47dd5-f5f5-4bf7-a49e-090b81c9391c" xlink:to="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_f14437cf-2ea7-48f4-bafb-2e186e6448a2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:to="loc_us-gaap_CommonStockMember_f14437cf-2ea7-48f4-bafb-2e186e6448a2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RetainedEarningsMember_ac8742ae-eb45-43b1-993e-989849276934" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RetainedEarningsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:to="loc_us-gaap_RetainedEarningsMember_ac8742ae-eb45-43b1-993e-989849276934" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdditionalPaidInCapitalMember_6b62f533-50b9-4ff0-bf50-e166385d7e99" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdditionalPaidInCapitalMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:to="loc_us-gaap_AdditionalPaidInCapitalMember_6b62f533-50b9-4ff0-bf50-e166385d7e99" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_68f42f24-71bd-48cc-8746-559ff403f899" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:to="loc_us-gaap_AccumulatedOtherComprehensiveIncomeMember_68f42f24-71bd-48cc-8746-559ff403f899" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonMember_019c0b05-2da6-7cdd-aff8-d40af5d48e57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_9a077366-8e29-4d79-a4b7-57f1c2b79127" xlink:to="loc_us-gaap_TreasuryStockCommonMember_019c0b05-2da6-7cdd-aff8-d40af5d48e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementLineItems_101eb52d-4bb4-4d0b-a6f3-95e63c5cb137" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementTable_f26f7966-c39e-453f-a29f-ea4aafdcf856" xlink:to="loc_us-gaap_StatementLineItems_101eb52d-4bb4-4d0b-a6f3-95e63c5cb137" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementLineItems_101eb52d-4bb4-4d0b-a6f3-95e63c5cb137" xlink:to="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_f83c15e7-3077-4df8-973b-6ecf5f30332f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_f83c15e7-3077-4df8-973b-6ecf5f30332f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019c65cb-176b-77db-b89c-87e8274cc240" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019c65cb-176b-77db-b89c-87e8274cc240" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_bc30de12-0ac4-4429-af11-8ae6e50456ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_StockholdersEquity_bc30de12-0ac4-4429-af11-8ae6e50456ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0474228c-fbdc-4634-a509-4ee6f5f09be2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_0474228c-fbdc-4634-a509-4ee6f5f09be2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_f39fc2e7-d5e1-484b-924b-6cf27684890f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_NetIncomeLoss_f39fc2e7-d5e1-484b-924b-6cf27684890f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2dc006ae-86ff-45d3-9e7e-0194406b1d82" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation_2dc006ae-86ff-45d3-9e7e-0194406b1d82" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_99c8cbb9-a758-4123-923c-7c210091ee5c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation_99c8cbb9-a758-4123-923c-7c210091ee5c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_019c68df-c2aa-7576-b16a-4d5ca81f665c" xlink:href="arvn-20251231.xsd#arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_019c68df-c2aa-7576-b16a-4d5ca81f665c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6c1e93c0-9d93-447a-baa7-dd410ab68796" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6c1e93c0-9d93-447a-baa7-dd410ab68796" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4a0bc71e-d408-43e3-85f8-57f027b93776" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_4a0bc71e-d408-43e3-85f8-57f027b93776" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019c0afe-281f-7923-b4a1-12e0560ffc06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019c0afe-281f-7923-b4a1-12e0560ffc06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019c0afc-c8f6-7faa-9e6c-726bbfc3ade4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockValueAcquiredCostMethod"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_TreasuryStockValueAcquiredCostMethod_019c0afc-c8f6-7faa-9e6c-726bbfc3ade4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5f196019-d851-4265-ae72-40203c190656" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent_5f196019-d851-4265-ae72-40203c190656" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesOutstanding_d437d4df-7934-40a1-be47-c236293e4a08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesOutstanding"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_CommonStockSharesOutstanding_d437d4df-7934-40a1-be47-c236293e4a08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockCommonShares_019c65bd-aae3-7ea0-aaeb-37fd1cabd947" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockCommonShares"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_TreasuryStockCommonShares_019c65bd-aae3-7ea0-aaeb-37fd1cabd947" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockholdersEquity_db11c431-e746-4a51-9db3-15993c94a984" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockholdersEquity"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_a8489626-7039-4612-a0f7-e6d0aaff8aee" xlink:to="loc_us-gaap_StockholdersEquity_db11c431-e746-4a51-9db3-15993c94a984" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="simple" xlink:href="arvn-20251231.xsd#ConsolidatedStatementsofChangesinStockholdersEquityParenthetical"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfStockholdersEquityAbstract_c85a2998-4527-4fca-b5a4-63f060147ed7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfStockholdersEquityAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_99cf41fd-8f71-49c1-9cbd-fe53f26afd11" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfStockholdersEquityAbstract_c85a2998-4527-4fca-b5a4-63f060147ed7" xlink:to="loc_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts_99cf41fd-8f71-49c1-9cbd-fe53f26afd11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows" xlink:type="simple" xlink:href="arvn-20251231.xsd#ConsolidatedStatementsofCashFlows"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementOfCashFlowsAbstract_ca15a6b9-6345-4762-a343-52d45da09657" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementOfCashFlowsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_535a8c4b-8ae9-4bd7-8055-13822b5762ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ca15a6b9-6345-4762-a343-52d45da09657" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_535a8c4b-8ae9-4bd7-8055-13822b5762ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d12da97e-5c72-4f22-a845-e7863b47dc7d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_535a8c4b-8ae9-4bd7-8055-13822b5762ab" xlink:to="loc_us-gaap_NetIncomeLoss_d12da97e-5c72-4f22-a845-e7863b47dc7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96af51a5-c416-4603-92f8-021295b6214f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_535a8c4b-8ae9-4bd7-8055-13822b5762ab" xlink:to="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96af51a5-c416-4603-92f8-021295b6214f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_fc470c31-e1e3-410d-a9eb-fe6768a66f7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96af51a5-c416-4603-92f8-021295b6214f" xlink:to="loc_us-gaap_DepreciationAndAmortization_fc470c31-e1e3-410d-a9eb-fe6768a66f7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4179799c-1d43-40cc-9789-ef797abe3dd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96af51a5-c416-4603-92f8-021295b6214f" xlink:to="loc_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_4179799c-1d43-40cc-9789-ef797abe3dd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_014798bb-bf6a-4f61-a953-30c454fd3b6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96af51a5-c416-4603-92f8-021295b6214f" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss_014798bb-bf6a-4f61-a953-30c454fd3b6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_174153fa-046e-4197-813c-5e7411e3f6bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96af51a5-c416-4603-92f8-021295b6214f" xlink:to="loc_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense_174153fa-046e-4197-813c-5e7411e3f6bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostAmortization_ff31207c-e235-4566-b6e7-5b0bfe44db0c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostAmortization"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96af51a5-c416-4603-92f8-021295b6214f" xlink:to="loc_us-gaap_CapitalizedContractCostAmortization_ff31207c-e235-4566-b6e7-5b0bfe44db0c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ea5b4e72-d5f5-47f8-8934-2de7ab15cb27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96af51a5-c416-4603-92f8-021295b6214f" xlink:to="loc_us-gaap_GainLossOnSaleOfPropertyPlantEquipment_ea5b4e72-d5f5-47f8-8934-2de7ab15cb27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensation_139ee3c2-c17d-4541-a6ce-3168c31eba7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensation"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_96af51a5-c416-4603-92f8-021295b6214f" xlink:to="loc_us-gaap_ShareBasedCompensation_139ee3c2-c17d-4541-a6ce-3168c31eba7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dea38a7f-3c71-4970-8823-5fa0bd6e61ae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_535a8c4b-8ae9-4bd7-8055-13822b5762ab" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dea38a7f-3c71-4970-8823-5fa0bd6e61ae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_54036f79-f9e7-408b-b9f4-238e9da3ccb0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsReceivable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dea38a7f-3c71-4970-8823-5fa0bd6e61ae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsReceivable_54036f79-f9e7-408b-b9f4-238e9da3ccb0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOtherReceivables_5c5fcd84-2462-481f-97c0-fca6bb8fb33e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOtherReceivables"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dea38a7f-3c71-4970-8823-5fa0bd6e61ae" xlink:to="loc_us-gaap_IncreaseDecreaseInOtherReceivables_5c5fcd84-2462-481f-97c0-fca6bb8fb33e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2b8ec74b-26a5-4e9c-bcb5-7277dae04163" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dea38a7f-3c71-4970-8823-5fa0bd6e61ae" xlink:to="loc_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_2b8ec74b-26a5-4e9c-bcb5-7277dae04163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_35349981-5792-4d37-88b5-194e7e0bf9e7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerAsset"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dea38a7f-3c71-4970-8823-5fa0bd6e61ae" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerAsset_35349981-5792-4d37-88b5-194e7e0bf9e7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f51bdb63-36b1-4996-afe7-fb7c953f0165" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dea38a7f-3c71-4970-8823-5fa0bd6e61ae" xlink:to="loc_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_f51bdb63-36b1-4996-afe7-fb7c953f0165" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_997d094f-8131-46d8-a2b3-babbd0fae9de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInOperatingLeaseLiability"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dea38a7f-3c71-4970-8823-5fa0bd6e61ae" xlink:to="loc_us-gaap_IncreaseDecreaseInOperatingLeaseLiability_997d094f-8131-46d8-a2b3-babbd0fae9de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fdbb56f2-b812-40c7-92a9-5a97dd6614c2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncreaseDecreaseInContractWithCustomerLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_dea38a7f-3c71-4970-8823-5fa0bd6e61ae" xlink:to="loc_us-gaap_IncreaseDecreaseInContractWithCustomerLiability_fdbb56f2-b812-40c7-92a9-5a97dd6614c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2c27fc7-e465-4c9d-a45f-3d2f1386df40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_535a8c4b-8ae9-4bd7-8055-13822b5762ab" xlink:to="loc_us-gaap_NetCashProvidedByUsedInOperatingActivities_c2c27fc7-e465-4c9d-a45f-3d2f1386df40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceebbc65-6dca-4a13-834d-923361d7601e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ca15a6b9-6345-4762-a343-52d45da09657" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceebbc65-6dca-4a13-834d-923361d7601e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d8932ff8-5e83-42b8-bab9-eb51ba4629e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquireMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceebbc65-6dca-4a13-834d-923361d7601e" xlink:to="loc_us-gaap_PaymentsToAcquireMarketableSecurities_d8932ff8-5e83-42b8-bab9-eb51ba4629e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_df0cefc8-ff12-4703-af89-c799dab65af7" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromMaturitiesOfMarketableSecurities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceebbc65-6dca-4a13-834d-923361d7601e" xlink:to="loc_arvn_ProceedsFromMaturitiesOfMarketableSecurities_df0cefc8-ff12-4703-af89-c799dab65af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromSaleOfMarketableSecurities_6693a0ff-1465-408e-8257-d6d3ca4a8a12" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromSaleOfMarketableSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceebbc65-6dca-4a13-834d-923361d7601e" xlink:to="loc_arvn_ProceedsFromSaleOfMarketableSecurities_6693a0ff-1465-408e-8257-d6d3ca4a8a12" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_32ae8a95-b1ed-4b1a-aa45-9cd719c3b076" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceebbc65-6dca-4a13-834d-923361d7601e" xlink:to="loc_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_32ae8a95-b1ed-4b1a-aa45-9cd719c3b076" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_09dd9394-fb77-417f-8259-01b0abb42c8e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceebbc65-6dca-4a13-834d-923361d7601e" xlink:to="loc_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment_09dd9394-fb77-417f-8259-01b0abb42c8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_116eaa94-604c-48d1-8995-88b51a4ea4d7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_ceebbc65-6dca-4a13-834d-923361d7601e" xlink:to="loc_us-gaap_NetCashProvidedByUsedInInvestingActivities_116eaa94-604c-48d1-8995-88b51a4ea4d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_59105ce3-9a25-4e3e-bb9b-bc5fa371b7e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ca15a6b9-6345-4762-a343-52d45da09657" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_59105ce3-9a25-4e3e-bb9b-bc5fa371b7e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RepaymentsOfLongTermDebt_59fcc18d-222a-47ed-920c-de5dcb016893" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RepaymentsOfLongTermDebt"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_59105ce3-9a25-4e3e-bb9b-bc5fa371b7e0" xlink:to="loc_us-gaap_RepaymentsOfLongTermDebt_59fcc18d-222a-47ed-920c-de5dcb016893" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants_658c8a94-2bec-4b44-92f8-0737d927832b" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_59105ce3-9a25-4e3e-bb9b-bc5fa371b7e0" xlink:to="loc_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants_658c8a94-2bec-4b44-92f8-0737d927832b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_1fc80262-dcfa-46a8-adee-dbee7d0c1319" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_59105ce3-9a25-4e3e-bb9b-bc5fa371b7e0" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_1fc80262-dcfa-46a8-adee-dbee7d0c1319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c0adf-317a-744a-aad3-5bd761f17c96" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRepurchaseOfCommonStock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_59105ce3-9a25-4e3e-bb9b-bc5fa371b7e0" xlink:to="loc_us-gaap_PaymentsForRepurchaseOfCommonStock_019c0adf-317a-744a-aad3-5bd761f17c96" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_04cfae29-7a95-4849-bd06-8e0f6baaeafe" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_59105ce3-9a25-4e3e-bb9b-bc5fa371b7e0" xlink:to="loc_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares_04cfae29-7a95-4849-bd06-8e0f6baaeafe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_474d62c7-23d0-4942-823e-edea3b9adf51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_59105ce3-9a25-4e3e-bb9b-bc5fa371b7e0" xlink:to="loc_us-gaap_NetCashProvidedByUsedInFinancingActivities_474d62c7-23d0-4942-823e-edea3b9adf51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_202f085d-755f-4edd-9806-bff92455bc36" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ca15a6b9-6345-4762-a343-52d45da09657" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_202f085d-755f-4edd-9806-bff92455bc36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_276a5b65-1ab3-451f-9de4-9fcceeb353a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ca15a6b9-6345-4762-a343-52d45da09657" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_276a5b65-1ab3-451f-9de4-9fcceeb353a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4271499-2e9c-4a3e-873a-1d69a8535cf2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ca15a6b9-6345-4762-a343-52d45da09657" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_c4271499-2e9c-4a3e-873a-1d69a8535cf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SupplementalCashFlowInformationAbstract_9a0a8604-8105-462e-9d5a-fde85df87efb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SupplementalCashFlowInformationAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementOfCashFlowsAbstract_ca15a6b9-6345-4762-a343-52d45da09657" xlink:to="loc_us-gaap_SupplementalCashFlowInformationAbstract_9a0a8604-8105-462e-9d5a-fde85df87efb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1de532b8-1a6e-4671-9b03-2e1882d2db9f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalExpendituresIncurredButNotYetPaid"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SupplementalCashFlowInformationAbstract_9a0a8604-8105-462e-9d5a-fde85df87efb" xlink:to="loc_us-gaap_CapitalExpendituresIncurredButNotYetPaid_1de532b8-1a6e-4671-9b03-2e1882d2db9f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation" xlink:type="simple" xlink:href="arvn-20251231.xsd#NatureofBusinessandBasisofPresentation"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62a6ca4b-dd82-4fa5-9462-e8d2b4494b2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_126799f6-5767-4219-aade-1cbce21f5f76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_62a6ca4b-dd82-4fa5-9462-e8d2b4494b2e" xlink:to="loc_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock_126799f6-5767-4219-aade-1cbce21f5f76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies" xlink:type="simple" xlink:href="arvn-20251231.xsd#SummaryofSignificantAccountingPolicies"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_aa91bd90-cdc1-4d98-b498-ef7b8c9c7552" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4d8dac18-2d1d-4090-a83b-15d68c3fd428" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SignificantAccountingPoliciesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_aa91bd90-cdc1-4d98-b498-ef7b8c9c7552" xlink:to="loc_us-gaap_SignificantAccountingPoliciesTextBlock_4d8dac18-2d1d-4090-a83b-15d68c3fd428" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements" xlink:type="simple" xlink:href="arvn-20251231.xsd#ResearchCollaborationandLicenseAgreements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_9b88ca4b-8286-4139-aa76-42a92bf8d21b" xlink:href="arvn-20251231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_a277bbd8-ef53-40a9-b7df-8de65e744f26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CollaborativeArrangementDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_9b88ca4b-8286-4139-aa76-42a92bf8d21b" xlink:to="loc_us-gaap_CollaborativeArrangementDisclosureTextBlock_a277bbd8-ef53-40a9-b7df-8de65e744f26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="simple" xlink:href="arvn-20251231.xsd#MarketableSecuritiesandFairValueMeasurements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_3c6d5ddb-696e-4d8a-bbc5-edd84850842d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresTextBlock_1cf4a011-45f1-4e6a-9323-e8ba0594efb2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_3c6d5ddb-696e-4d8a-bbc5-edd84850842d" xlink:to="loc_us-gaap_FairValueDisclosuresTextBlock_1cf4a011-45f1-4e6a-9323-e8ba0594efb2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements" xlink:type="simple" xlink:href="arvn-20251231.xsd#PropertyEquipmentandLeaseholdImprovements"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_480734f9-b58c-4d47-9231-d49151267668" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a0d291d3-7212-4774-aebd-676dc29f4b75" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_480734f9-b58c-4d47-9231-d49151267668" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_a0d291d3-7212-4774-aebd-676dc29f4b75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilities" xlink:type="simple" xlink:href="arvn-20251231.xsd#RightofUseAssetsandLiabilities"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_7ec854db-8248-448d-b813-9c901acabdbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeasesTextBlock_7eb6a0e7-bbc9-4175-9df9-981eb2208480" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeasesTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_7ec854db-8248-448d-b813-9c901acabdbf" xlink:to="loc_us-gaap_LesseeOperatingLeasesTextBlock_7eb6a0e7-bbc9-4175-9df9-981eb2208480" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities" xlink:type="simple" xlink:href="arvn-20251231.xsd#AccountsPayableandAccruedLiabilities"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_3c3dc454-c2db-4650-9039-870899de6291" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_f6c20c95-568c-4861-ba61-77a8822239d1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_3c3dc454-c2db-4650-9039-870899de6291" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_f6c20c95-568c-4861-ba61-77a8822239d1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebt" xlink:type="simple" xlink:href="arvn-20251231.xsd#LongTermDebt"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebt" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_f81c05dd-868a-4f5b-a052-1a2e75c7aced" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureTextBlock_eed68e89-a351-454d-b78e-0e1f8fd06fe2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_f81c05dd-868a-4f5b-a052-1a2e75c7aced" xlink:to="loc_us-gaap_DebtDisclosureTextBlock_eed68e89-a351-454d-b78e-0e1f8fd06fe2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/Equity" xlink:type="simple" xlink:href="arvn-20251231.xsd#Equity"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/Equity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce37b275-09ad-4c13-913f-1c9eee760638" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_10bfe3b6-a5ea-42ed-999b-35b12c1f01dd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_ce37b275-09ad-4c13-913f-1c9eee760638" xlink:to="loc_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_10bfe3b6-a5ea-42ed-999b-35b12c1f01dd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestments" xlink:type="simple" xlink:href="arvn-20251231.xsd#EquityMethodInvestments"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestments" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4d6b1851-0642-4f06-917d-e6b970597bc6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_88936b55-1fb8-41d2-8721-f847e10be788" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_4d6b1851-0642-4f06-917d-e6b970597bc6" xlink:to="loc_us-gaap_EquityMethodInvestmentsDisclosureTextBlock_88936b55-1fb8-41d2-8721-f847e10be788" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxes" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxes"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxes" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_40bed6a3-9555-4714-b2b4-283017ac0d90" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureTextBlock_520ce43f-a09d-422f-b0f7-d950eb140618" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_40bed6a3-9555-4714-b2b4-283017ac0d90" xlink:to="loc_us-gaap_IncomeTaxDisclosureTextBlock_520ce43f-a09d-422f-b0f7-d950eb140618" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CommitmentsandContingencies" xlink:type="simple" xlink:href="arvn-20251231.xsd#CommitmentsandContingencies"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CommitmentsandContingencies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1207077b-7bb8-461c-a533-9ef383a6642f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f2c1bd65-b321-45b7-a88d-fb3e4c87a744" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_1207077b-7bb8-461c-a533-9ef383a6642f" xlink:to="loc_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_f2c1bd65-b321-45b7-a88d-fb3e4c87a744" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShare" xlink:type="simple" xlink:href="arvn-20251231.xsd#NetLossPerShare"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShare" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_357ba17d-b9e1-488a-9664-90295a6233e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareTextBlock_e850d931-2113-4980-a5ff-48a47a9fb7cf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_357ba17d-b9e1-488a-9664-90295a6233e4" xlink:to="loc_us-gaap_EarningsPerShareTextBlock_e850d931-2113-4980-a5ff-48a47a9fb7cf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RestructuringActivity" xlink:type="simple" xlink:href="arvn-20251231.xsd#RestructuringActivity"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RestructuringActivity" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c46aa-f82d-774d-b80b-fa22b1e3083c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_019c46aa-f82d-799d-b8b9-597861dcc90d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c46aa-f82d-774d-b80b-fa22b1e3083c" xlink:to="loc_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock_019c46aa-f82d-799d-b8b9-597861dcc90d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SegmentInformation" xlink:type="simple" xlink:href="arvn-20251231.xsd#SegmentInformation"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SegmentInformation" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_c7b07386-d195-4638-99a5-dae65e78605b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingDisclosureTextBlock_72578df3-1f09-4bd9-9e8a-f342a8dd11d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingDisclosureTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_c7b07386-d195-4638-99a5-dae65e78605b" xlink:to="loc_us-gaap_SegmentReportingDisclosureTextBlock_72578df3-1f09-4bd9-9e8a-f342a8dd11d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="simple" xlink:href="arvn-20251231.xsd#SummaryofSignificantAccountingPoliciesPolicies"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019b3062-4136-7900-8624-0d28a4597a97" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_BasisOfAccountingPolicyPolicyTextBlock_019b3062-4136-7900-8624-0d28a4597a97" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConsolidationPolicyTextBlock_019baff8-5489-79e3-a187-016896e39d59" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConsolidationPolicyTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_ConsolidationPolicyTextBlock_019baff8-5489-79e3-a187-016896e39d59" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UseOfEstimates_019b3062-50d4-7dcf-bef8-e010d4661965" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UseOfEstimates"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_UseOfEstimates_019b3062-50d4-7dcf-bef8-e010d4661965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_019bafe6-23d8-7154-b49f-ff1424f46001" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_CashAndCashEquivalentsPolicyTextBlock_019bafe6-23d8-7154-b49f-ff1424f46001" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_30984041-67e7-4ba3-a0c4-7b6f441966a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_30984041-67e7-4ba3-a0c4-7b6f441966a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskCreditRisk_75ce8d1b-bfe7-4452-a72c-abf408a48166" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskCreditRisk"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_ConcentrationRiskCreditRisk_75ce8d1b-bfe7-4452-a72c-abf408a48166" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_MarketableSecuritiesPolicy_b2a2d36f-3b4a-4ea9-9f2c-f7d920c62f89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_MarketableSecuritiesPolicy"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_MarketableSecuritiesPolicy_b2a2d36f-3b4a-4ea9-9f2c-f7d920c62f89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_faf2fd41-40b4-4d94-b4ec-d24e1555b305" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_faf2fd41-40b4-4d94-b4ec-d24e1555b305" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeasesPolicyTextBlock_31d57578-914e-4c37-bb70-42f2972f2af7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeasesPolicyTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_LesseeLeasesPolicyTextBlock_31d57578-914e-4c37-bb70-42f2972f2af7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_2681b71d-2afe-4318-8eff-c643171ebb92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock_2681b71d-2afe-4318-8eff-c643171ebb92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_530c6862-8290-4aeb-bb68-6701cc25dd53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_530c6862-8290-4aeb-bb68-6701cc25dd53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsPolicy_0347ce82-105e-469f-93a9-7f2e0ea4b508" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsPolicy"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_EquityMethodInvestmentsPolicy_0347ce82-105e-469f-93a9-7f2e0ea4b508" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPolicyTextBlock_59b5d108-98ea-46d0-aab5-7d21a78ffbf0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPolicyTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_IncomeTaxPolicyTextBlock_59b5d108-98ea-46d0-aab5-7d21a78ffbf0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c0fd5569-856c-4062-8c3e-fe25623f8c07" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_c0fd5569-856c-4062-8c3e-fe25623f8c07" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DefinedContributionPlanPolicyPolicyTextBlock_c8c58aa2-2d9f-4472-8193-babcf8ead3c7" xlink:href="arvn-20251231.xsd#arvn_DefinedContributionPlanPolicyPolicyTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_arvn_DefinedContributionPlanPolicyPolicyTextBlock_c8c58aa2-2d9f-4472-8193-babcf8ead3c7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_52580c21-0a9a-46e4-937c-ec529d4fc988" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpensePolicy_52580c21-0a9a-46e4-937c-ec529d4fc988" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e7514c44-24c0-4136-8bcb-1c50ed753aa1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementPolicyPolicyTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_FairValueMeasurementPolicyPolicyTextBlock_e7514c44-24c0-4136-8bcb-1c50ed753aa1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerSharePolicyTextBlock_67f7e78a-574a-44c0-908d-e95a75b2d2f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerSharePolicyTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_EarningsPerSharePolicyTextBlock_67f7e78a-574a-44c0-908d-e95a75b2d2f9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6c8c1ba9-e340-4296-833d-ffa4bcbdc7be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_d62c083a-3864-4dbd-865a-b79e8331a852" xlink:to="loc_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_6c8c1ba9-e340-4296-833d-ffa4bcbdc7be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="simple" xlink:href="arvn-20251231.xsd#SummaryofSignificantAccountingPoliciesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_07c03b09-8af1-41e6-8b4c-c63cd3bf3e1a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_586fea96-df0a-47af-b6b8-0501acfddfb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c03b09-8af1-41e6-8b4c-c63cd3bf3e1a" xlink:to="loc_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock_586fea96-df0a-47af-b6b8-0501acfddfb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_2bd502f8-a0ea-4b13-8704-69baf1b0c9a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_07c03b09-8af1-41e6-8b4c-c63cd3bf3e1a" xlink:to="loc_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock_2bd502f8-a0ea-4b13-8704-69baf1b0c9a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables" xlink:type="simple" xlink:href="arvn-20251231.xsd#ResearchCollaborationandLicenseAgreementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_04c91dd5-c83e-4399-87ed-7d61f7bee45e" xlink:href="arvn-20251231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_5485b758-ff21-4c0a-9240-419f0e77e4bb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_04c91dd5-c83e-4399-87ed-7d61f7bee45e" xlink:to="loc_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock_5485b758-ff21-4c0a-9240-419f0e77e4bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_e88361e3-5bcf-430a-9c7c-ddc2c4a63509" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_04c91dd5-c83e-4399-87ed-7d61f7bee45e" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_e88361e3-5bcf-430a-9c7c-ddc2c4a63509" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="simple" xlink:href="arvn-20251231.xsd#MarketableSecuritiesandFairValueMeasurementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_03ec0b92-dd0d-400a-abe7-a9eaf6ccc227" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019b30e2-9d29-7556-8bde-bd82dd32e01c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_03ec0b92-dd0d-400a-abe7-a9eaf6ccc227" xlink:to="loc_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock_019b30e2-9d29-7556-8bde-bd82dd32e01c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables" xlink:type="simple" xlink:href="arvn-20251231.xsd#PropertyEquipmentandLeaseholdImprovementsTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5fc8e4ef-e198-4c21-8424-e512ec71cd7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3d0ab85f-82b4-4ab6-be62-d7c81c14b1f2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_5fc8e4ef-e198-4c21-8424-e512ec71cd7b" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTextBlock_3d0ab85f-82b4-4ab6-be62-d7c81c14b1f2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables" xlink:type="simple" xlink:href="arvn-20251231.xsd#RightofUseAssetsandLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_3232c9c2-0819-4042-a08f-e084ce27ed10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseCostTableTextBlock_da49045f-f0d8-4aaa-a70d-970eb343cf63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseCostTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3232c9c2-0819-4042-a08f-e084ce27ed10" xlink:to="loc_us-gaap_LeaseCostTableTextBlock_da49045f-f0d8-4aaa-a70d-970eb343cf63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock_29c9fd02-4580-4063-a5ca-47ff6a90cca2" xlink:href="arvn-20251231.xsd#arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3232c9c2-0819-4042-a08f-e084ce27ed10" xlink:to="loc_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock_29c9fd02-4580-4063-a5ca-47ff6a90cca2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ebf31bc8-896a-4095-9dcd-9ebcfbef1131" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_3232c9c2-0819-4042-a08f-e084ce27ed10" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ebf31bc8-896a-4095-9dcd-9ebcfbef1131" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="simple" xlink:href="arvn-20251231.xsd#AccountsPayableandAccruedLiabilitiesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_0561883d-9e9b-44b3-87a0-9fb7cb8f285f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c1bfbd94-61e9-49a6-842c-38ab4182ace3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_0561883d-9e9b-44b3-87a0-9fb7cb8f285f" xlink:to="loc_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_c1bfbd94-61e9-49a6-842c-38ab4182ace3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtTables" xlink:type="simple" xlink:href="arvn-20251231.xsd#LongTermDebtTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_d0e3da50-48ea-4076-b690-1c3bf94ee3d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7f4c3417-7c9a-4891-97dc-b790fe155a9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDebtInstrumentsTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d0e3da50-48ea-4076-b690-1c3bf94ee3d9" xlink:to="loc_us-gaap_ScheduleOfDebtInstrumentsTextBlock_7f4c3417-7c9a-4891-97dc-b790fe155a9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0d2a1de3-9ff1-4998-8b42-3968e8cb71cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_d0e3da50-48ea-4076-b690-1c3bf94ee3d9" xlink:to="loc_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock_0d2a1de3-9ff1-4998-8b42-3968e8cb71cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityTables" xlink:type="simple" xlink:href="arvn-20251231.xsd#EquityTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5b98118-04eb-41fb-b38d-7d07bbdb5bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e8ed72f6-dda1-4df3-ac6f-c134eab4b716" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5b98118-04eb-41fb-b38d-7d07bbdb5bb8" xlink:to="loc_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_e8ed72f6-dda1-4df3-ac6f-c134eab4b716" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fdd7fe90-b79c-4d7a-9ee3-0e363f8a3216" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5b98118-04eb-41fb-b38d-7d07bbdb5bb8" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_fdd7fe90-b79c-4d7a-9ee3-0e363f8a3216" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_4b2d6d80-1d7c-4847-be9d-251134efe51c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_e5b98118-04eb-41fb-b38d-7d07bbdb5bb8" xlink:to="loc_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock_4b2d6d80-1d7c-4847-be9d-251134efe51c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesTables" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxesTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_2b12681d-69a3-4ef1-8cd7-c4e2e7f656f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8b443976-5dca-4d5b-924b-e2c64db87bac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b12681d-69a3-4ef1-8cd7-c4e2e7f656f6" xlink:to="loc_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock_8b443976-5dca-4d5b-924b-e2c64db87bac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_61ce157f-7863-4abe-b9bd-98bb8aca5718" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b12681d-69a3-4ef1-8cd7-c4e2e7f656f6" xlink:to="loc_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_61ce157f-7863-4abe-b9bd-98bb8aca5718" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_019c4695-696d-7207-a309-e8ead359ddcc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b12681d-69a3-4ef1-8cd7-c4e2e7f656f6" xlink:to="loc_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock_019c4695-696d-7207-a309-e8ead359ddcc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c3e349cd-3683-499a-b677-198ea70e8206" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b12681d-69a3-4ef1-8cd7-c4e2e7f656f6" xlink:to="loc_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_c3e349cd-3683-499a-b677-198ea70e8206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_d78f6ea2-e632-41f1-8d39-f55dde080471" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_2b12681d-69a3-4ef1-8cd7-c4e2e7f656f6" xlink:to="loc_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock_d78f6ea2-e632-41f1-8d39-f55dde080471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareTables" xlink:type="simple" xlink:href="arvn-20251231.xsd#NetLossPerShareTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShareTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_468429d9-913c-41b0-813b-9a178b892a15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1c9dcf05-f7e8-4f7b-a939-b393c18fdaef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_468429d9-913c-41b0-813b-9a178b892a15" xlink:to="loc_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock_1c9dcf05-f7e8-4f7b-a939-b393c18fdaef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a197fc2f-9ee4-4445-9a41-3c69ab1ce7b2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_468429d9-913c-41b0-813b-9a178b892a15" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_a197fc2f-9ee4-4445-9a41-3c69ab1ce7b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SegmentInformationTables" xlink:type="simple" xlink:href="arvn-20251231.xsd#SegmentInformationTables"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SegmentInformationTables" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_ed55fe0a-3a5f-4394-ad64-c9bc9401d9c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_c7b7367c-8e13-4018-9691-ca0525a28138" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_ed55fe0a-3a5f-4394-ad64-c9bc9401d9c5" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock_c7b7367c-8e13-4018-9691-ca0525a28138" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#NatureofBusinessandBasisofPresentationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_922c5631-2d91-4993-bc84-220c24257b0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfWhollyOwnedSubsidiaries_c41d2736-e08b-4fc0-b25e-926933a4746d" xlink:href="arvn-20251231.xsd#arvn_NumberOfWhollyOwnedSubsidiaries"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_922c5631-2d91-4993-bc84-220c24257b0f" xlink:to="loc_arvn_NumberOfWhollyOwnedSubsidiaries_c41d2736-e08b-4fc0-b25e-926933a4746d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#SummaryofSignificantAccountingPoliciesCashReconciliationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_a34990f2-47a1-44c0-8b21-4e6d643ba439" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0af7106a-0467-41fa-8aef-9c70f631e4f6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a34990f2-47a1-44c0-8b21-4e6d643ba439" xlink:to="loc_us-gaap_CashAndCashEquivalentsAtCarryingValue_0af7106a-0467-41fa-8aef-9c70f631e4f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedCashCurrent_c9df7b2d-eee5-4d16-b028-577bcde41a68" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedCashCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a34990f2-47a1-44c0-8b21-4e6d643ba439" xlink:to="loc_us-gaap_RestrictedCashCurrent_c9df7b2d-eee5-4d16-b028-577bcde41a68" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1a8682b-bce5-4046-86b4-9311940ec512" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_a34990f2-47a1-44c0-8b21-4e6d643ba439" xlink:to="loc_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_d1a8682b-bce5-4046-86b4-9311940ec512" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountingPoliciesAbstract_5791946b-912e-4523-a570-cda3f1dd459a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountingPoliciesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:href="arvn-20251231.xsd#arvn_SummaryOfSignificantAccountingPoliciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccountingPoliciesAbstract_5791946b-912e-4523-a570-cda3f1dd459a" xlink:to="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByTypeAxis_37f082d6-0aa4-40d3-a2d6-ae753c953989" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:to="loc_us-gaap_ConcentrationRiskByTypeAxis_37f082d6-0aa4-40d3-a2d6-ae753c953989" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskTypeDomain_df581fb2-8caa-4de5-9c4e-2c026f18a8a6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByTypeAxis_37f082d6-0aa4-40d3-a2d6-ae753c953989" xlink:to="loc_us-gaap_ConcentrationRiskTypeDomain_df581fb2-8caa-4de5-9c4e-2c026f18a8a6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CustomerConcentrationRiskMember_3997ae20-f360-4244-946f-a1db37f3d57d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CustomerConcentrationRiskMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskTypeDomain_df581fb2-8caa-4de5-9c4e-2c026f18a8a6" xlink:to="loc_us-gaap_CustomerConcentrationRiskMember_3997ae20-f360-4244-946f-a1db37f3d57d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b951406c-a865-4fc2-981c-7b043c57dc63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskByBenchmarkAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:to="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b951406c-a865-4fc2-981c-7b043c57dc63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c19264a-5079-4e61-b5ce-4a05386f6e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskBenchmarkDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskByBenchmarkAxis_b951406c-a865-4fc2-981c-7b043c57dc63" xlink:to="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c19264a-5079-4e61-b5ce-4a05386f6e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SalesRevenueNetMember_f5c1b601-3a21-4a00-9a0e-848cf5f660fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SalesRevenueNetMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ConcentrationRiskBenchmarkDomain_9c19264a-5079-4e61-b5ce-4a05386f6e91" xlink:to="loc_us-gaap_SalesRevenueNetMember_f5c1b601-3a21-4a00-9a0e-848cf5f660fa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96a38bcb-0ac8-4e26-9f89-95d2d0844e61" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96a38bcb-0ac8-4e26-9f89-95d2d0844e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_eaa5ef25-5d89-4ca2-934e-bf5af90c9fbf" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_96a38bcb-0ac8-4e26-9f89-95d2d0844e61" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_eaa5ef25-5d89-4ca2-934e-bf5af90c9fbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaboratorOneMember_fb396892-25e8-4d21-8ceb-d6586ccfbdc0" xlink:href="arvn-20251231.xsd#arvn_CollaboratorOneMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_eaa5ef25-5d89-4ca2-934e-bf5af90c9fbf" xlink:to="loc_arvn_CollaboratorOneMember_fb396892-25e8-4d21-8ceb-d6586ccfbdc0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e660ae00-1857-406e-8036-a3c7a10bf5ab" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e660ae00-1857-406e-8036-a3c7a10bf5ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d5ab930b-c64b-4fd2-a7ec-07027a08859f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_e660ae00-1857-406e-8036-a3c7a10bf5ab" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d5ab930b-c64b-4fd2-a7ec-07027a08859f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_ea586282-f73d-4c9b-a6f5-6b1b25f9bcdc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d5ab930b-c64b-4fd2-a7ec-07027a08859f" xlink:to="loc_us-gaap_OfficeEquipmentMember_ea586282-f73d-4c9b-a6f5-6b1b25f9bcdc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_5d5c5475-ab69-4745-864b-e0e968f1104e" xlink:href="arvn-20251231.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_d5ab930b-c64b-4fd2-a7ec-07027a08859f" xlink:to="loc_arvn_LaboratoryEquipmentMember_5d5c5475-ab69-4745-864b-e0e968f1104e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_6051b771-c777-4ab0-91bc-61fe7b298a30" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:to="loc_srt_RangeAxis_6051b771-c777-4ab0-91bc-61fe7b298a30" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_1eac6f45-91f1-48ad-a47f-f970c20f7090" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_6051b771-c777-4ab0-91bc-61fe7b298a30" xlink:to="loc_srt_RangeMember_1eac6f45-91f1-48ad-a47f-f970c20f7090" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_e8298f68-09aa-4f76-a0c4-184fcaa51c75" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_1eac6f45-91f1-48ad-a47f-f970c20f7090" xlink:to="loc_srt_MaximumMember_e8298f68-09aa-4f76-a0c4-184fcaa51c75" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:href="arvn-20251231.xsd#arvn_SummaryOfSignificantAccountingPoliciesLineItems"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesTable_c6b0c161-ff86-42c2-9f45-4d48755543ee" xlink:to="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_f6cd78ac-2452-4e6c-909d-132a4c1ff8fd" xlink:href="arvn-20251231.xsd#arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities_f6cd78ac-2452-4e6c-909d-132a4c1ff8fd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_22f64c7d-7c8f-4648-ae95-aafdaffe39c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FederalDepositInsuranceCorporationPremiumExpense"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_FederalDepositInsuranceCorporationPremiumExpense_22f64c7d-7c8f-4648-ae95-aafdaffe39c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ConcentrationRiskPercentage1_4809bf08-b20b-464f-950a-15e69687f6bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ConcentrationRiskPercentage1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_ConcentrationRiskPercentage1_4809bf08-b20b-464f-950a-15e69687f6bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_97a8fc46-8052-45b2-8ab4-7681676d053f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentUsefulLife_97a8fc46-8052-45b2-8ab4-7681676d053f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6e61833a-fd79-4df1-becb-b1ae62009ab9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_6e61833a-fd79-4df1-becb-b1ae62009ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_0ebb0919-ca57-452a-bf4f-c23d30d41d1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_0ebb0919-ca57-452a-bf4f-c23d30d41d1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_2511b45a-64c9-4467-a126-42ee0e39a94f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_EquityMethodInvestments_2511b45a-64c9-4467-a126-42ee0e39a94f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DefinedContributionPlanCostRecognized_ceb3875f-4205-498f-afa0-5540b10d3c67" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DefinedContributionPlanCostRecognized"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SummaryOfSignificantAccountingPoliciesLineItems_e549dfec-1134-4883-9685-503f586248be" xlink:to="loc_us-gaap_DefinedContributionPlanCostRecognized_ceb3875f-4205-498f-afa0-5540b10d3c67" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c4bc595b-1466-41d4-ab09-43a3400e7d84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:href="arvn-20251231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueFromContractWithCustomerAbstract_c4bc595b-1466-41d4-ab09-43a3400e7d84" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_ab8c0af1-4470-4cf8-bbfd-d24a3ec38848" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:to="loc_srt_CounterpartyNameAxis_ab8c0af1-4470-4cf8-bbfd-d24a3ec38848" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99539a10-05bb-46dc-9f8e-d4bb27fac802" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_ab8c0af1-4470-4cf8-bbfd-d24a3ec38848" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99539a10-05bb-46dc-9f8e-d4bb27fac802" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NovartisPharmaAGMember_11d65a12-88bf-42f7-946c-bb538d1bcffd" xlink:href="arvn-20251231.xsd#arvn_NovartisPharmaAGMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99539a10-05bb-46dc-9f8e-d4bb27fac802" xlink:to="loc_arvn_NovartisPharmaAGMember_11d65a12-88bf-42f7-946c-bb538d1bcffd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PfizerIncorporationMember_7ece09cc-46fb-44c3-9560-d579e97adb52" xlink:href="arvn-20251231.xsd#arvn_PfizerIncorporationMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99539a10-05bb-46dc-9f8e-d4bb27fac802" xlink:to="loc_arvn_PfizerIncorporationMember_7ece09cc-46fb-44c3-9560-d579e97adb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerAGMember_033c9926-bc36-47ae-a0df-6ac8e1f5f3af" xlink:href="arvn-20251231.xsd#arvn_BayerAGMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99539a10-05bb-46dc-9f8e-d4bb27fac802" xlink:to="loc_arvn_BayerAGMember_033c9926-bc36-47ae-a0df-6ac8e1f5f3af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_f3b417e1-4f7e-49b8-9d8c-1b93bc2241b5" xlink:href="arvn-20251231.xsd#arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_99539a10-05bb-46dc-9f8e-d4bb27fac802" xlink:to="loc_arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember_f3b417e1-4f7e-49b8-9d8c-1b93bc2241b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_3b5a6093-8d25-47bf-b153-a09bb284541d" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:to="loc_srt_ProductOrServiceAxis_3b5a6093-8d25-47bf-b153-a09bb284541d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_08a170e1-bbe4-438a-aa84-72441966caa5" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_3b5a6093-8d25-47bf-b153-a09bb284541d" xlink:to="loc_srt_ProductsAndServicesDomain_08a170e1-bbe4-438a-aa84-72441966caa5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LicenseMember_81ff7a3a-8b22-462c-89f3-b7b5df39358b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LicenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_08a170e1-bbe4-438a-aa84-72441966caa5" xlink:to="loc_us-gaap_LicenseMember_81ff7a3a-8b22-462c-89f3-b7b5df39358b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_2848fd18-6552-4f89-ba3f-5a2920879ab9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:to="loc_srt_RangeAxis_2848fd18-6552-4f89-ba3f-5a2920879ab9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_8e79fa39-3a4c-46f5-a9d7-eb6d103873e3" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_2848fd18-6552-4f89-ba3f-5a2920879ab9" xlink:to="loc_srt_RangeMember_8e79fa39-3a4c-46f5-a9d7-eb6d103873e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_3e2ce744-e03d-4cc0-96cd-41feb742a37c" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_8e79fa39-3a4c-46f5-a9d7-eb6d103873e3" xlink:to="loc_srt_MaximumMember_3e2ce744-e03d-4cc0-96cd-41feb742a37c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_40c2a9d2-e668-4989-aaf1-648893bd2c6a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:to="loc_us-gaap_TypeOfArrangementAxis_40c2a9d2-e668-4989-aaf1-648893bd2c6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_40c2a9d2-e668-4989-aaf1-648893bd2c6a" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationAgreementMember_cb27ff3c-5be9-4849-aa79-15cb8aefabcb" xlink:href="arvn-20251231.xsd#arvn_CollaborationAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_CollaborationAgreementMember_cb27ff3c-5be9-4849-aa79-15cb8aefabcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_7f810a3a-0e82-4087-bf92-c0028e801d15" xlink:href="arvn-20251231.xsd#arvn_RegulatoryAndSalesBasedMilestonesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_RegulatoryAndSalesBasedMilestonesMember_7f810a3a-0e82-4087-bf92-c0028e801d15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RegulatoryMilestonePaymentsMember_96ad7ca2-c2d0-4d8d-aa8b-66ccaa08fa58" xlink:href="arvn-20251231.xsd#arvn_RegulatoryMilestonePaymentsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_RegulatoryMilestonePaymentsMember_96ad7ca2-c2d0-4d8d-aa8b-66ccaa08fa58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonesMember_019b30c4-e3e6-7cab-840e-de554ceea5f6" xlink:href="arvn-20251231.xsd#arvn_SalesBasedMilestonesMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_SalesBasedMilestonesMember_019b30c4-e3e6-7cab-840e-de554ceea5f6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockPurchaseAgreementMember_f4861722-7d7d-4459-8ff6-489a13fa9185" xlink:href="arvn-20251231.xsd#arvn_StockPurchaseAgreementMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_StockPurchaseAgreementMember_f4861722-7d7d-4459-8ff6-489a13fa9185" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OptionPaymentsToLicenseAgreementMember_c140db45-8497-4084-a3bc-c71ab0bfca3f" xlink:href="arvn-20251231.xsd#arvn_OptionPaymentsToLicenseAgreementMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_OptionPaymentsToLicenseAgreementMember_c140db45-8497-4084-a3bc-c71ab0bfca3f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SalesBasedMilestonePaymentsMember_278cb0eb-8382-4242-9cf9-0de556c42278" xlink:href="arvn-20251231.xsd#arvn_SalesBasedMilestonePaymentsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_SalesBasedMilestonePaymentsMember_278cb0eb-8382-4242-9cf9-0de556c42278" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DevelopmentMilestonePaymentsMember_db04600f-964c-4430-96f8-62f07454a0df" xlink:href="arvn-20251231.xsd#arvn_DevelopmentMilestonePaymentsMember"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_DevelopmentMilestonePaymentsMember_db04600f-964c-4430-96f8-62f07454a0df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchFundingPaymentsMember_a57e056b-f4ac-4afa-a4ba-9ea109582e3c" xlink:href="arvn-20251231.xsd#arvn_ResearchFundingPaymentsMember"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_ResearchFundingPaymentsMember_a57e056b-f4ac-4afa-a4ba-9ea109582e3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommercialMilestonesMember_e6045fd0-9dbe-4afb-a809-9097cd1d751e" xlink:href="arvn-20251231.xsd#arvn_CommercialMilestonesMember"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_94011327-40f1-4a48-891b-f90723f0c641" xlink:to="loc_arvn_CommercialMilestonesMember_e6045fd0-9dbe-4afb-a809-9097cd1d751e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_a3e5118d-cc10-4f3f-bd0d-52e2e2604519" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_a3e5118d-cc10-4f3f-bd0d-52e2e2604519" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_edaea17b-5389-4c06-ab30-27e823314264" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_a3e5118d-cc10-4f3f-bd0d-52e2e2604519" xlink:to="loc_us-gaap_EquityComponentDomain_edaea17b-5389-4c06-ab30-27e823314264" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3165b41b-2cea-4699-af6f-8c94e630595a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_edaea17b-5389-4c06-ab30-27e823314264" xlink:to="loc_us-gaap_CommonStockMember_3165b41b-2cea-4699-af6f-8c94e630595a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_7c011872-b764-4b5b-beee-1bfa4128ccd2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateByTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:to="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_7c011872-b764-4b5b-beee-1bfa4128ccd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d9097981-507c-4357-881b-3a7c74d3925b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ChangeInAccountingEstimateTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateByTypeAxis_7c011872-b764-4b5b-beee-1bfa4128ccd2" xlink:to="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d9097981-507c-4357-881b-3a7c74d3925b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UpdatedResearchTimelinesMember_9fd2c0f4-f2f8-46d1-baab-c55d9b5cbefa" xlink:href="arvn-20251231.xsd#arvn_UpdatedResearchTimelinesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d9097981-507c-4357-881b-3a7c74d3925b" xlink:to="loc_arvn_UpdatedResearchTimelinesMember_9fd2c0f4-f2f8-46d1-baab-c55d9b5cbefa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ExpansionOfDevelopmentProgramsMember_173485b3-7254-489b-b7ea-7accb713b557" xlink:href="arvn-20251231.xsd#arvn_ExpansionOfDevelopmentProgramsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d9097981-507c-4357-881b-3a7c74d3925b" xlink:to="loc_arvn_ExpansionOfDevelopmentProgramsMember_173485b3-7254-489b-b7ea-7accb713b557" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RemovalOfCombinationTrialsMember_019c2373-086e-7771-9d22-641c7df2442d" xlink:href="arvn-20251231.xsd#arvn_RemovalOfCombinationTrialsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ChangeInAccountingEstimateTypeDomain_d9097981-507c-4357-881b-3a7c74d3925b" xlink:to="loc_arvn_RemovalOfCombinationTrialsMember_019c2373-086e-7771-9d22-641c7df2442d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:href="arvn-20251231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsLineItems"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsTable_f139e6c4-add2-4b6f-bb22-b02296347dae" xlink:to="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019b30cb-f9bc-7c7b-83d5-860a6ddc82f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019b30cb-f9bc-7c7b-83d5-860a6ddc82f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RevenueRemainingPerformanceObligationContingentPayments_019b30cb-f9bc-7ccc-b23f-e53bcac527ca" xlink:href="arvn-20251231.xsd#arvn_RevenueRemainingPerformanceObligationContingentPayments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_arvn_RevenueRemainingPerformanceObligationContingentPayments_019b30cb-f9bc-7ccc-b23f-e53bcac527ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b30cc-2f26-7786-b8c6-fc81a2e2f359" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax_019b30cc-2f26-7786-b8c6-fc81a2e2f359" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_019b30cc-2f26-75d1-8e97-1f0770b7728d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_019b30cc-2f26-75d1-8e97-1f0770b7728d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CapitalizedContractCostGross_019b30cc-2f26-705e-ac84-b80b58d1d66c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CapitalizedContractCostGross"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_CapitalizedContractCostGross_019b30cc-2f26-705e-ac84-b80b58d1d66c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_019b30cc-6102-7549-b54d-b55ff6c57790" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_019b30cc-6102-7549-b54d-b55ff6c57790" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019b30cc-902f-7648-b720-4ebba6b8b5f7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_019b30cc-902f-7648-b720-4ebba6b8b5f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharesIssuedPricePerShare_019b30cc-902f-74fa-a407-2883a4d2ad5d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharesIssuedPricePerShare"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_SharesIssuedPricePerShare_019b30cc-902f-74fa-a407-2883a4d2ad5d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019b30cc-902f-7c2a-9c8c-3c7148f4b5a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_019b30cc-902f-7c2a-9c8c-3c7148f4b5a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForBrokerageFees_019b30cc-902f-72b3-b81e-cc50e4149e6b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForBrokerageFees"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_PaymentsForBrokerageFees_019b30cc-902f-72b3-b81e-cc50e4149e6b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SaleOfStockFairValueOfSharesSold_019b30cc-c965-7907-8657-f03f715f21a9" xlink:href="arvn-20251231.xsd#arvn_SaleOfStockFairValueOfSharesSold"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_arvn_SaleOfStockFairValueOfSharesSold_019b30cc-c965-7907-8657-f03f715f21a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_019b30cc-c965-775f-b7fb-b3e2803aa089" xlink:href="arvn-20251231.xsd#arvn_DirectAndIncrementalCostsIncurredToObtainTheContract"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract_019b30cc-c965-775f-b7fb-b3e2803aa089" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborationContractAssetAndOtherAssets_019b30cc-c965-751f-8d6a-95d1a795c4e1" xlink:href="arvn-20251231.xsd#arvn_CollaborationContractAssetAndOtherAssets"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_arvn_CollaborationContractAssetAndOtherAssets_019b30cc-c965-751f-8d6a-95d1a795c4e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ProceedsFromCollaborators_019b30cc-f73d-7fb3-99f4-558cf7d96c0e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ProceedsFromCollaborators"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_ProceedsFromCollaborators_019b30cc-f73d-7fb3-99f4-558cf7d96c0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_019b30cd-8e55-7735-b13f-7698b2f56bc5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_Revenues_019b30cd-8e55-7735-b13f-7698b2f56bc5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_019c2373-086e-7f61-a65a-dd9a4b52ddb5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_OperatingExpenses_019c2373-086e-7f61-a65a-dd9a4b52ddb5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_019b30cd-8e55-7ebf-b16c-2b2bd790aee9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_NetIncomeLoss_019b30cd-8e55-7ebf-b16c-2b2bd790aee9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_019b30cd-8e55-7c30-8fdd-03fd3f29c448" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_EarningsPerShareBasic_019b30cd-8e55-7c30-8fdd-03fd3f29c448" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_019b30cd-8e55-7a08-b021-91c34fc080dc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsLineItems_12a1ed66-0754-42a6-b7cf-698f20445590" xlink:to="loc_us-gaap_EarningsPerShareDiluted_019b30cd-8e55-7a08-b021-91c34fc080dc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_019b30d0-b5f3-76ba-a0fd-30f20ae76a1f" xlink:href="arvn-20251231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_019b30d0-b5f3-72bf-8c8a-486328f025d6" xlink:href="arvn-20251231.xsd#arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_019b30d0-b5f3-76ba-a0fd-30f20ae76a1f" xlink:to="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_019b30d0-b5f3-72bf-8c8a-486328f025d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_019b30d0-b5f3-714b-abdf-90a6f788c352" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_019b30d0-b5f3-72bf-8c8a-486328f025d6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_019b30d0-b5f3-714b-abdf-90a6f788c352" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_019b30d0-b5f3-756c-b698-e03bc2f90b40" xlink:href="arvn-20251231.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_019b30d0-b5f3-72bf-8c8a-486328f025d6" xlink:to="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions_019b30d0-b5f3-756c-b698-e03bc2f90b40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_019b30d0-b5f3-7d90-94ee-5287552e84e4" xlink:href="arvn-20251231.xsd#arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_019b30d0-b5f3-72bf-8c8a-486328f025d6" xlink:to="loc_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived_019b30d0-b5f3-7d90-94ee-5287552e84e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsReceivableNetCurrent_019b30d0-b5f3-7ab9-9710-5855d123a952" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsReceivableNetCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward_019b30d0-b5f3-72bf-8c8a-486328f025d6" xlink:to="loc_us-gaap_AccountsReceivableNetCurrent_019b30d0-b5f3-7ab9-9710-5855d123a952" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_019b30d0-b5f3-7da9-bd7a-57611082dce4" xlink:href="arvn-20251231.xsd#arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_019b30d0-b5f3-76ba-a0fd-30f20ae76a1f" xlink:to="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_019b30d0-b5f3-7da9-bd7a-57611082dce4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrent_019b30d0-b5f3-73e2-8696-41dfbd3b7f24" xlink:href="arvn-20251231.xsd#arvn_AccountsPayableContractBalancesCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_019b30d0-b5f3-7da9-bd7a-57611082dce4" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrent_019b30d0-b5f3-73e2-8696-41dfbd3b7f24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentAdditions_019b30d0-b5f3-75c0-9a70-008b1f1eeae9" xlink:href="arvn-20251231.xsd#arvn_AccountsPayableContractBalancesCurrentAdditions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_019b30d0-b5f3-7da9-bd7a-57611082dce4" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrentAdditions_019b30d0-b5f3-75c0-9a70-008b1f1eeae9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrentPayments_019b30d0-b5f3-7c25-8ef6-897080a4eb11" xlink:href="arvn-20251231.xsd#arvn_AccountsPayableContractBalancesCurrentPayments"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_019b30d0-b5f3-7da9-bd7a-57611082dce4" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrentPayments_019b30d0-b5f3-7c25-8ef6-897080a4eb11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccountsPayableContractBalancesCurrent_019b30d0-b5f3-7508-87a8-4317671ffc4d" xlink:href="arvn-20251231.xsd#arvn_AccountsPayableContractBalancesCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward_019b30d0-b5f3-7da9-bd7a-57611082dce4" xlink:to="loc_arvn_AccountsPayableContractBalancesCurrent_019b30d0-b5f3-7508-87a8-4317671ffc4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_019b30d0-b5f3-70d8-9141-e3079a243288" xlink:href="arvn-20251231.xsd#arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_019b30d0-b5f3-76ba-a0fd-30f20ae76a1f" xlink:to="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_019b30d0-b5f3-70d8-9141-e3079a243288" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_019b30d0-b5f3-78c0-8ab7-61fded7bd036" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_019b30d0-b5f3-70d8-9141-e3079a243288" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_019b30d0-b5f3-78c0-8ab7-61fded7bd036" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_019b30d0-b5f3-734b-abb2-df1ad8615439" xlink:href="arvn-20251231.xsd#arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_019b30d0-b5f3-70d8-9141-e3079a243288" xlink:to="loc_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements_019b30d0-b5f3-734b-abb2-df1ad8615439" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CapitalizedContractCostAmortizationDuringPeriod_019b30d0-b5f3-7642-b587-a24f4679ef79" xlink:href="arvn-20251231.xsd#arvn_CapitalizedContractCostAmortizationDuringPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_019b30d0-b5f3-70d8-9141-e3079a243288" xlink:to="loc_arvn_CapitalizedContractCostAmortizationDuringPeriod_019b30d0-b5f3-7642-b587-a24f4679ef79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerAssetNet_019b30d0-b5f3-74c2-af08-6009c9d1e4b5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerAssetNet"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward_019b30d0-b5f3-70d8-9141-e3079a243288" xlink:to="loc_us-gaap_ContractWithCustomerAssetNet_019b30d0-b5f3-74c2-af08-6009c9d1e4b5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_019b30d0-b5f3-73c2-aa30-ecdd00daca2b" xlink:href="arvn-20251231.xsd#arvn_ChangeInContractWithCustomerLiabilityRollForward"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_019b30d0-b5f3-76ba-a0fd-30f20ae76a1f" xlink:to="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_019b30d0-b5f3-73c2-aa30-ecdd00daca2b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019b30d0-b5f3-71c0-879b-cd50ea582884" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_019b30d0-b5f3-73c2-aa30-ecdd00daca2b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019b30d0-b5f3-71c0-879b-cd50ea582884" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_019b30d0-b5f3-7841-85ea-b302b814fb43" xlink:href="arvn-20251231.xsd#arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_019b30d0-b5f3-73c2-aa30-ecdd00daca2b" xlink:to="loc_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements_019b30d0-b5f3-7841-85ea-b302b814fb43" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019b30d0-b5f3-72fc-be00-df6d065fbef7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiabilityRevenueRecognized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_019b30d0-b5f3-73c2-aa30-ecdd00daca2b" xlink:to="loc_us-gaap_ContractWithCustomerLiabilityRevenueRecognized_019b30d0-b5f3-72fc-be00-df6d065fbef7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration_019b30d0-b5f3-795a-b673-d7aa7f443ac7" xlink:href="arvn-20251231.xsd#arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_019b30d0-b5f3-73c2-aa30-ecdd00daca2b" xlink:to="loc_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration_019b30d0-b5f3-795a-b673-d7aa7f443ac7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ContractWithCustomerLiability_019b30d0-b5f3-7632-85d0-f1851d34a09b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ContractWithCustomerLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ChangeInContractWithCustomerLiabilityRollForward_019b30d0-b5f3-73c2-aa30-ecdd00daca2b" xlink:to="loc_us-gaap_ContractWithCustomerLiability_019b30d0-b5f3-7632-85d0-f1851d34a09b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_f81ff8d5-a792-47a4-9ce1-7147e8be96a8" xlink:href="arvn-20251231.xsd#arvn_ResearchCollaborationAndLicenseAgreementsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ad08dae6-3378-4a14-a835-8acde4263d3a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ResearchCollaborationAndLicenseAgreementsAbstract_f81ff8d5-a792-47a4-9ce1-7147e8be96a8" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ad08dae6-3378-4a14-a835-8acde4263d3a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_14857f1f-122e-4176-afbb-8086060cbf7f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ad08dae6-3378-4a14-a835-8acde4263d3a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis_14857f1f-122e-4176-afbb-8086060cbf7f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1d5338f0-c73a-4aeb-82de-f03dc3d1528b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable_ad08dae6-3378-4a14-a835-8acde4263d3a" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1d5338f0-c73a-4aeb-82de-f03dc3d1528b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligation_d2d09636-b7ca-4462-b0cf-c52171db51a3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligation"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1d5338f0-c73a-4aeb-82de-f03dc3d1528b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligation_d2d09636-b7ca-4462-b0cf-c52171db51a3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f3ad7b6d-fcad-4dca-8f0a-2ae5c20b9d3c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems_1d5338f0-c73a-4aeb-82de-f03dc3d1528b" xlink:to="loc_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1_f3ad7b6d-fcad-4dca-8f0a-2ae5c20b9d3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#MarketableSecuritiesandFairValueMeasurementsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueDisclosuresAbstract_410e54d7-7cf6-4598-927d-73a62fda1c7a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueDisclosuresAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67e0f8f1-892c-439f-ac7d-057d774e740e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueDisclosuresAbstract_410e54d7-7cf6-4598-927d-73a62fda1c7a" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67e0f8f1-892c-439f-ac7d-057d774e740e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb14d1fd-d7d7-45a5-b8e6-a098d2d2e653" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67e0f8f1-892c-439f-ac7d-057d774e740e" xlink:to="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb14d1fd-d7d7-45a5-b8e6-a098d2d2e653" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_edfc9666-b3dd-4ff3-ba98-8a04a2bb1319" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByFairValueHierarchyLevelAxis_bb14d1fd-d7d7-45a5-b8e6-a098d2d2e653" xlink:to="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_edfc9666-b3dd-4ff3-ba98-8a04a2bb1319" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueInputsLevel2Member_1cf4f472-35d1-4789-af76-0340e37f0e61" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueInputsLevel2Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementsFairValueHierarchyDomain_edfc9666-b3dd-4ff3-ba98-8a04a2bb1319" xlink:to="loc_us-gaap_FairValueInputsLevel2Member_1cf4f472-35d1-4789-af76-0340e37f0e61" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7982b4d1-3137-4253-85f6-14d53f331760" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueByMeasurementFrequencyAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67e0f8f1-892c-439f-ac7d-057d774e740e" xlink:to="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7982b4d1-3137-4253-85f6-14d53f331760" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementFrequencyDomain_66b09fc8-8cfb-4cff-be91-b0b3048aab58" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementFrequencyDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueByMeasurementFrequencyAxis_7982b4d1-3137-4253-85f6-14d53f331760" xlink:to="loc_us-gaap_FairValueMeasurementFrequencyDomain_66b09fc8-8cfb-4cff-be91-b0b3048aab58" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueMeasurementsRecurringMember_4ee9857a-2c7c-4a95-a9a6-9d64c7a228f8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueMeasurementsRecurringMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueMeasurementFrequencyDomain_66b09fc8-8cfb-4cff-be91-b0b3048aab58" xlink:to="loc_us-gaap_FairValueMeasurementsRecurringMember_4ee9857a-2c7c-4a95-a9a6-9d64c7a228f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FinancialInstrumentAxis_f8f60448-ffdc-49ab-9050-41fa22e2b206" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FinancialInstrumentAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67e0f8f1-892c-439f-ac7d-057d774e740e" xlink:to="loc_us-gaap_FinancialInstrumentAxis_f8f60448-ffdc-49ab-9050-41fa22e2b206" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06c57444-a0b0-4906-bb54-d1ab1e943b7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FinancialInstrumentAxis_f8f60448-ffdc-49ab-9050-41fa22e2b206" xlink:to="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06c57444-a0b0-4906-bb54-d1ab1e943b7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CorporateBondSecuritiesMember_c7faf820-a654-411a-952f-6c893aa68821" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CorporateBondSecuritiesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06c57444-a0b0-4906-bb54-d1ab1e943b7b" xlink:to="loc_us-gaap_CorporateBondSecuritiesMember_c7faf820-a654-411a-952f-6c893aa68821" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_USGovernmentDebtSecuritiesMember_e19623f2-8e76-4a7c-b620-2e40860f0118" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_USGovernmentDebtSecuritiesMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_06c57444-a0b0-4906-bb54-d1ab1e943b7b" xlink:to="loc_us-gaap_USGovernmentDebtSecuritiesMember_e19623f2-8e76-4a7c-b620-2e40860f0118" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_952caf71-36bb-4971-90bf-5a0568acfb24" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable_67e0f8f1-892c-439f-ac7d-057d774e740e" xlink:to="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_952caf71-36bb-4971-90bf-5a0568acfb24" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_39ee6781-c4c8-4f81-99fc-900edeb4a7c1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_952caf71-36bb-4971-90bf-5a0568acfb24" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis_39ee6781-c4c8-4f81-99fc-900edeb4a7c1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b7fd15b7-fa90-4710-b5c8-2353732d1317" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_952caf71-36bb-4971-90bf-5a0568acfb24" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_b7fd15b7-fa90-4710-b5c8-2353732d1317" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d6a8c04f-60b4-47b0-bbbc-3ba6d85ab99b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_952caf71-36bb-4971-90bf-5a0568acfb24" xlink:to="loc_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_d6a8c04f-60b4-47b0-bbbc-3ba6d85ab99b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fbe7f9e9-7a69-499b-b155-92e05a7f5d79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AvailableForSaleSecuritiesDebtSecurities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems_952caf71-36bb-4971-90bf-5a0568acfb24" xlink:to="loc_us-gaap_AvailableForSaleSecuritiesDebtSecurities_fbe7f9e9-7a69-499b-b155-92e05a7f5d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_837818c7-bb1a-4bad-b521-232bfe0604ad" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61dea112-2232-4fe5-a69a-bf9851c422e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_837818c7-bb1a-4bad-b521-232bfe0604ad" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61dea112-2232-4fe5-a69a-bf9851c422e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deb8eeca-7045-4de5-bb33-42735d4cecb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61dea112-2232-4fe5-a69a-bf9851c422e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deb8eeca-7045-4de5-bb33-42735d4cecb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cda5ae8-57fe-4231-a128-056aafb04466" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_deb8eeca-7045-4de5-bb33-42735d4cecb4" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cda5ae8-57fe-4231-a128-056aafb04466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LaboratoryEquipmentMember_b228e387-fb14-44db-9982-1da6d7a62e4e" xlink:href="arvn-20251231.xsd#arvn_LaboratoryEquipmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cda5ae8-57fe-4231-a128-056aafb04466" xlink:to="loc_arvn_LaboratoryEquipmentMember_b228e387-fb14-44db-9982-1da6d7a62e4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_738a62c5-08a2-461d-8bfa-44ab7920db98" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cda5ae8-57fe-4231-a128-056aafb04466" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_738a62c5-08a2-461d-8bfa-44ab7920db98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OfficeEquipmentMember_cd42c80e-c137-49ba-b4e8-651eeb11ba13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OfficeEquipmentMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_9cda5ae8-57fe-4231-a128-056aafb04466" xlink:to="loc_us-gaap_OfficeEquipmentMember_cd42c80e-c137-49ba-b4e8-651eeb11ba13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f63c2d06-c4a4-4f1c-96ab-fa5691311b77" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_61dea112-2232-4fe5-a69a-bf9851c422e3" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f63c2d06-c4a4-4f1c-96ab-fa5691311b77" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentGross_691788e4-aac1-4c27-8d71-edf020a97d53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentGross"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f63c2d06-c4a4-4f1c-96ab-fa5691311b77" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentGross_691788e4-aac1-4c27-8d71-edf020a97d53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0ba9d92f-0568-4a89-8d86-11b13ad3de22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f63c2d06-c4a4-4f1c-96ab-fa5691311b77" xlink:to="loc_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0ba9d92f-0568-4a89-8d86-11b13ad3de22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentNet_8e6891c7-7dc2-48dd-8a60-4d3359c70654" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_f63c2d06-c4a4-4f1c-96ab-fa5691311b77" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentNet_8e6891c7-7dc2-48dd-8a60-4d3359c70654" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d122654d-55f0-477b-8c07-f72b67637620" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943dca39-c534-4fbc-b181-464f718d2e54" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentAbstract_d122654d-55f0-477b-8c07-f72b67637620" xlink:to="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943dca39-c534-4fbc-b181-464f718d2e54" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4b45749d-398f-459c-af6b-ce5d43a25e34" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943dca39-c534-4fbc-b181-464f718d2e54" xlink:to="loc_srt_CounterpartyNameAxis_4b45749d-398f-459c-af6b-ce5d43a25e34" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a479c476-14b0-4a5b-9f79-131201e98d8e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4b45749d-398f-459c-af6b-ce5d43a25e34" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a479c476-14b0-4a5b-9f79-131201e98d8e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_A101CollegeStreetLLCMember_9b6bf3e1-eae8-4282-a8e8-009caceb4050" xlink:href="arvn-20251231.xsd#arvn_A101CollegeStreetLLCMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_a479c476-14b0-4a5b-9f79-131201e98d8e" xlink:to="loc_arvn_A101CollegeStreetLLCMember_9b6bf3e1-eae8-4282-a8e8-009caceb4050" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ab0028f1-d131-4084-ab00-acc1e38a1953" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943dca39-c534-4fbc-b181-464f718d2e54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ab0028f1-d131-4084-ab00-acc1e38a1953" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e170c0e-47c8-4284-a1cf-5715c6bad648" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentByTypeAxis_ab0028f1-d131-4084-ab00-acc1e38a1953" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e170c0e-47c8-4284-a1cf-5715c6bad648" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeaseholdImprovementsMember_4b49e290-4be2-450e-a78d-bbf608f958a7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeaseholdImprovementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentTypeDomain_8e170c0e-47c8-4284-a1cf-5715c6bad648" xlink:to="loc_us-gaap_LeaseholdImprovementsMember_4b49e290-4be2-450e-a78d-bbf608f958a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00d9d8f9-66c6-4143-84b6-2643b3c7c5a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PropertyPlantAndEquipmentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_943dca39-c534-4fbc-b181-464f718d2e54" xlink:to="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00d9d8f9-66c6-4143-84b6-2643b3c7c5a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_019c4685-74dd-7733-8330-c3080d2bc3cc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00d9d8f9-66c6-4143-84b6-2643b3c7c5a1" xlink:to="loc_us-gaap_DepreciationAndAmortization_019c4685-74dd-7733-8330-c3080d2bc3cc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PropertyPlantAndEquipmentWriteoff_0a63d23f-2b2b-466b-bb7b-905f503b55e4" xlink:href="arvn-20251231.xsd#arvn_PropertyPlantAndEquipmentWriteoff"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PropertyPlantAndEquipmentLineItems_00d9d8f9-66c6-4143-84b6-2643b3c7c5a1" xlink:to="loc_arvn_PropertyPlantAndEquipmentWriteoff_0a63d23f-2b2b-466b-bb7b-905f503b55e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#RightofUseAssetsandLiabilitiesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_8b52cc78-c085-4735-ac4e-b3769987055a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionTable_9e7d959f-262e-48e2-b770-c823be139b0a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_8b52cc78-c085-4735-ac4e-b3769987055a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionTable_9e7d959f-262e-48e2-b770-c823be139b0a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractTerminationAxis_5b3e4602-989e-4327-a7ab-2cb9ad955993" xlink:href="arvn-20251231.xsd#arvn_ContractTerminationAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e7d959f-262e-48e2-b770-c823be139b0a" xlink:to="loc_arvn_ContractTerminationAxis_5b3e4602-989e-4327-a7ab-2cb9ad955993" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ContractTerminationDomain_c58ac74a-cc30-4430-bbb0-27b5775b72d6" xlink:href="arvn-20251231.xsd#arvn_ContractTerminationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ContractTerminationAxis_5b3e4602-989e-4327-a7ab-2cb9ad955993" xlink:to="loc_arvn_ContractTerminationDomain_c58ac74a-cc30-4430-bbb0-27b5775b72d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OneTimeCashTerminationFeeMember_75c3d5b6-baed-4ddb-a04c-9a3372c7b542" xlink:href="arvn-20251231.xsd#arvn_OneTimeCashTerminationFeeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ContractTerminationDomain_c58ac74a-cc30-4430-bbb0-27b5775b72d6" xlink:to="loc_arvn_OneTimeCashTerminationFeeMember_75c3d5b6-baed-4ddb-a04c-9a3372c7b542" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_WriteoffOfPrepaidRentMember_8ec40d64-9704-4697-9e39-45fc28cd7f0f" xlink:href="arvn-20251231.xsd#arvn_WriteoffOfPrepaidRentMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_ContractTerminationDomain_c58ac74a-cc30-4430-bbb0-27b5775b72d6" xlink:to="loc_arvn_WriteoffOfPrepaidRentMember_8ec40d64-9704-4697-9e39-45fc28cd7f0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusAxis_ee56c486-bc71-48c7-bd95-bd61d3b33709" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgedStatusAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e7d959f-262e-48e2-b770-c823be139b0a" xlink:to="loc_us-gaap_PledgedStatusAxis_ee56c486-bc71-48c7-bd95-bd61d3b33709" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgedStatusDomain_d08c31a9-22ec-4572-9c50-ed811654a546" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgedStatusDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgedStatusAxis_ee56c486-bc71-48c7-bd95-bd61d3b33709" xlink:to="loc_us-gaap_PledgedStatusDomain_d08c31a9-22ec-4572-9c50-ed811654a546" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AssetPledgedAsCollateralMember_1b9eff82-bd61-4db0-b5e9-a34dc0d39819" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AssetPledgedAsCollateralMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgedStatusDomain_d08c31a9-22ec-4572-9c50-ed811654a546" xlink:to="loc_us-gaap_AssetPledgedAsCollateralMember_1b9eff82-bd61-4db0-b5e9-a34dc0d39819" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeAxis_d4642c2f-cdb1-4e51-b537-09e2b12ef04c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e7d959f-262e-48e2-b770-c823be139b0a" xlink:to="loc_us-gaap_PledgingPurposeAxis_d4642c2f-cdb1-4e51-b537-09e2b12ef04c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PledgingPurposeDomain_9948218a-0456-46bb-b8b0-1bc1141fb484" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PledgingPurposeDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgingPurposeAxis_d4642c2f-cdb1-4e51-b537-09e2b12ef04c" xlink:to="loc_us-gaap_PledgingPurposeDomain_9948218a-0456-46bb-b8b0-1bc1141fb484" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LetterOfCreditMember_c1bbe2d5-3d07-4684-91a9-ae7e04812f86" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LetterOfCreditMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PledgingPurposeDomain_9948218a-0456-46bb-b8b0-1bc1141fb484" xlink:to="loc_us-gaap_LetterOfCreditMember_c1bbe2d5-3d07-4684-91a9-ae7e04812f86" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_a6cb6ee2-3c40-4bfd-ab04-2622ad0a1198" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e7d959f-262e-48e2-b770-c823be139b0a" xlink:to="loc_srt_RangeAxis_a6cb6ee2-3c40-4bfd-ab04-2622ad0a1198" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_56d9e0c6-431d-4c44-9fc0-0565909c55bb" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_a6cb6ee2-3c40-4bfd-ab04-2622ad0a1198" xlink:to="loc_srt_RangeMember_56d9e0c6-431d-4c44-9fc0-0565909c55bb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_955a245f-3faf-42bf-b89b-691579604d17" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56d9e0c6-431d-4c44-9fc0-0565909c55bb" xlink:to="loc_srt_MinimumMember_955a245f-3faf-42bf-b89b-691579604d17" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ee4ec83a-86c0-4325-903c-b2165a53556b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_56d9e0c6-431d-4c44-9fc0-0565909c55bb" xlink:to="loc_srt_MaximumMember_ee4ec83a-86c0-4325-903c-b2165a53556b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeLeaseDescriptionLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionTable_9e7d959f-262e-48e2-b770-c823be139b0a" xlink:to="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LandSubjectToGroundLeases_d57e4751-f133-4747-a25f-07dc1f972dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LandSubjectToGroundLeases"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:to="loc_us-gaap_LandSubjectToGroundLeases_d57e4751-f133-4747-a25f-07dc1f972dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GainLossOnContractTermination_827ae165-1709-46e1-b886-bce802fabae7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GainLossOnContractTermination"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:to="loc_us-gaap_GainLossOnContractTermination_827ae165-1709-46e1-b886-bce802fabae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtSecurities_6ace69f8-4c8d-4ea8-84c8-d982b2b703f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtSecurities"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:to="loc_us-gaap_DebtSecurities_6ace69f8-4c8d-4ea8-84c8-d982b2b703f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_81f4eaee-a59a-482d-ae6d-82b77e405ddc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:to="loc_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_81f4eaee-a59a-482d-ae6d-82b77e405ddc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bc3495d4-cdc3-4595-9728-cce7a4ff18fb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_bc3495d4-cdc3-4595-9728-cce7a4ff18fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_c56265d5-185c-4818-9d94-f7191837a710" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LesseeLeaseDescriptionLineItems_6cda08d6-2921-4e15-8f73-52c3a430301d" xlink:to="loc_us-gaap_OperatingLeaseCost_c56265d5-185c-4818-9d94-f7191837a710" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofComponentsofLeaseExpenseDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#RightofUseAssetsandLiabilitiesScheduleofComponentsofLeaseExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofComponentsofLeaseExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f3a65ec0-939c-493a-931f-9139b22c1486" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseCost_5cb06e61-75fa-42e0-877f-e7ce1ebf187c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f3a65ec0-939c-493a-931f-9139b22c1486" xlink:to="loc_us-gaap_OperatingLeaseCost_5cb06e61-75fa-42e0-877f-e7ce1ebf187c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_a57cc0e4-fc81-4ce4-891a-0f38ef78a56a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_ea8e4e20-a7b9-4244-953c-7e7de632208d" xlink:href="arvn-20251231.xsd#arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a57cc0e4-fc81-4ce4-891a-0f38ef78a56a" xlink:to="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_ea8e4e20-a7b9-4244-953c-7e7de632208d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeasePayments_4178e5b1-40f5-45a0-b79d-92d7aab224db" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeasePayments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract_ea8e4e20-a7b9-4244-953c-7e7de632208d" xlink:to="loc_us-gaap_OperatingLeasePayments_4178e5b1-40f5-45a0-b79d-92d7aab224db" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_520625e2-952c-40ca-9b41-99a390b652df" xlink:href="arvn-20251231.xsd#arvn_SupplementalNonCashInformationRelatedToLeasesAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_a57cc0e4-fc81-4ce4-891a-0f38ef78a56a" xlink:to="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_520625e2-952c-40ca-9b41-99a390b652df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_960a19a7-3324-46a0-96b4-de752376c42e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract_520625e2-952c-40ca-9b41-99a390b652df" xlink:to="loc_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_960a19a7-3324-46a0-96b4-de752376c42e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LeasesAbstract_f897d381-0d80-4957-9da8-7d52d3af0216" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LeasesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_17048061-493b-4699-92ab-9ba9e69bc158" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f897d381-0d80-4957-9da8-7d52d3af0216" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_17048061-493b-4699-92ab-9ba9e69bc158" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_db7920dd-86ba-40d8-9924-88f0c0a2d363" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f897d381-0d80-4957-9da8-7d52d3af0216" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_db7920dd-86ba-40d8-9924-88f0c0a2d363" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_21f087b7-4e1c-4d52-8f7a-5f41c531bf26" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f897d381-0d80-4957-9da8-7d52d3af0216" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_21f087b7-4e1c-4d52-8f7a-5f41c531bf26" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fc15b940-7a7f-4dfd-82ca-4184ccd1541c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f897d381-0d80-4957-9da8-7d52d3af0216" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_fc15b940-7a7f-4dfd-82ca-4184ccd1541c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4d7e570-aefd-434b-8359-952b78e31bb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f897d381-0d80-4957-9da8-7d52d3af0216" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_f4d7e570-aefd-434b-8359-952b78e31bb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3708d3ab-ce9e-4567-9598-3086af0ceb9e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f897d381-0d80-4957-9da8-7d52d3af0216" xlink:to="loc_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_3708d3ab-ce9e-4567-9598-3086af0ceb9e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLeaseLiability_b0a89d98-343b-42b5-b4c2-c4b07d582bb6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLeaseLiability"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_LeasesAbstract_f897d381-0d80-4957-9da8-7d52d3af0216" xlink:to="loc_us-gaap_OperatingLeaseLiability_b0a89d98-343b-42b5-b4c2-c4b07d582bb6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#AccountsPayableandAccruedLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PayablesAndAccrualsAbstract_9b98ca34-8146-44e8-bac5-783f07b32d65" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PayablesAndAccrualsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableCurrent_c02a9050-1818-42ec-9933-35c6afc3b3f3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9b98ca34-8146-44e8-bac5-783f07b32d65" xlink:to="loc_us-gaap_AccountsPayableCurrent_c02a9050-1818-42ec-9933-35c6afc3b3f3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_399b609c-1b1b-4664-9e62-e9c6aaae9c40" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9b98ca34-8146-44e8-bac5-783f07b32d65" xlink:to="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_399b609c-1b1b-4664-9e62-e9c6aaae9c40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_2ab886b8-ebd0-438d-906e-a9d84a407bf3" xlink:href="arvn-20251231.xsd#arvn_AccruedResearchAndDevelopmentExpenseCurrent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_399b609c-1b1b-4664-9e62-e9c6aaae9c40" xlink:to="loc_arvn_AccruedResearchAndDevelopmentExpenseCurrent_2ab886b8-ebd0-438d-906e-a9d84a407bf3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_68feafa6-e989-4081-acfa-8c18b5c23d79" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_399b609c-1b1b-4664-9e62-e9c6aaae9c40" xlink:to="loc_us-gaap_EmployeeRelatedLiabilitiesCurrent_68feafa6-e989-4081-acfa-8c18b5c23d79" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedIncomeTaxesCurrent_8736a9a5-f2cd-4bd0-903a-25000359d09d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedIncomeTaxesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_399b609c-1b1b-4664-9e62-e9c6aaae9c40" xlink:to="loc_us-gaap_AccruedIncomeTaxesCurrent_8736a9a5-f2cd-4bd0-903a-25000359d09d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_32d5af20-1986-4d79-856b-7036d322fcdd" xlink:href="arvn-20251231.xsd#arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_399b609c-1b1b-4664-9e62-e9c6aaae9c40" xlink:to="loc_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent_32d5af20-1986-4d79-856b-7036d322fcdd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccruedProfessionalFeesCurrent_6cb7769f-1e43-4dee-aadc-400cc33afa29" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccruedProfessionalFeesCurrent"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract_399b609c-1b1b-4664-9e62-e9c6aaae9c40" xlink:to="loc_us-gaap_AccruedProfessionalFeesCurrent_6cb7769f-1e43-4dee-aadc-400cc33afa29" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_82d831f1-40e6-4c25-9a8f-9051dcebedbf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PayablesAndAccrualsAbstract_9b98ca34-8146-44e8-bac5-783f07b32d65" xlink:to="loc_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent_82d831f1-40e6-4c25-9a8f-9051dcebedbf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#LongTermDebtScheduleofLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_cbf4bdd9-f3e2-4802-82b7-8d657756022c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f529c39-e25e-4b2f-a15a-e559e9a452aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cbf4bdd9-f3e2-4802-82b7-8d657756022c" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_6f529c39-e25e-4b2f-a15a-e559e9a452aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_c303977b-b424-4d5d-b499-0c0acf841df3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cbf4bdd9-f3e2-4802-82b7-8d657756022c" xlink:to="loc_us-gaap_LongTermDebt_c303977b-b424-4d5d-b499-0c0acf841df3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtCurrent_0e12d3d9-8616-4a08-a229-02fca302fcb4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtCurrent"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cbf4bdd9-f3e2-4802-82b7-8d657756022c" xlink:to="loc_us-gaap_LongTermDebtCurrent_0e12d3d9-8616-4a08-a229-02fca302fcb4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtNoncurrent_1753009a-589c-45ee-9c33-0eaf32450ac0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtNoncurrent"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_cbf4bdd9-f3e2-4802-82b7-8d657756022c" xlink:to="loc_us-gaap_LongTermDebtNoncurrent_1753009a-589c-45ee-9c33-0eaf32450ac0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#LongTermDebtAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_09f3025b-2f2c-46d8-9b14-343b80805cac" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentTable_b2382231-3391-4b7b-a5d4-e6053415dc9d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_09f3025b-2f2c-46d8-9b14-343b80805cac" xlink:to="loc_us-gaap_DebtInstrumentTable_b2382231-3391-4b7b-a5d4-e6053415dc9d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentAxis_50a0b34b-e1c2-4300-b4c7-a02d7d2b5e64" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b2382231-3391-4b7b-a5d4-e6053415dc9d" xlink:to="loc_us-gaap_DebtInstrumentAxis_50a0b34b-e1c2-4300-b4c7-a02d7d2b5e64" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentNameDomain_b6566896-20a6-419f-9fd7-3c8a9e6a887c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentAxis_50a0b34b-e1c2-4300-b4c7-a02d7d2b5e64" xlink:to="loc_us-gaap_DebtInstrumentNameDomain_b6566896-20a6-419f-9fd7-3c8a9e6a887c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_b5ce70d4-ac95-45bd-b15f-b61c442dfc38" xlink:href="arvn-20251231.xsd#arvn_TwoThousandAndEighteenAssistanceAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentNameDomain_b6566896-20a6-419f-9fd7-3c8a9e6a887c" xlink:to="loc_arvn_TwoThousandAndEighteenAssistanceAgreementMember_b5ce70d4-ac95-45bd-b15f-b61c442dfc38" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StatementGeographicalAxis_5d1449ef-13dd-4935-847c-ae63fbf89b11" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StatementGeographicalAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b2382231-3391-4b7b-a5d4-e6053415dc9d" xlink:to="loc_srt_StatementGeographicalAxis_5d1449ef-13dd-4935-847c-ae63fbf89b11" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_SegmentGeographicalDomain_66c5708c-5641-4206-a140-13b54a352273" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_SegmentGeographicalDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_StatementGeographicalAxis_5d1449ef-13dd-4935-847c-ae63fbf89b11" xlink:to="loc_srt_SegmentGeographicalDomain_66c5708c-5641-4206-a140-13b54a352273" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CT_75f17150-3aad-42b9-bf8d-a39fc17ca805" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CT"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_SegmentGeographicalDomain_66c5708c-5641-4206-a140-13b54a352273" xlink:to="loc_stpr_CT_75f17150-3aad-42b9-bf8d-a39fc17ca805" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentTable_b2382231-3391-4b7b-a5d4-e6053415dc9d" xlink:to="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentFaceAmount_6e335476-498f-446d-8405-a8c132fcd7bc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentFaceAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:to="loc_us-gaap_DebtInstrumentFaceAmount_6e335476-498f-446d-8405-a8c132fcd7bc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentLoanForgiveness_677e52a8-6f05-4ec0-86f0-88537a9eb996" xlink:href="arvn-20251231.xsd#arvn_DebtInstrumentLoanForgiveness"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:to="loc_arvn_DebtInstrumentLoanForgiveness_677e52a8-6f05-4ec0-86f0-88537a9eb996" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ba52ced7-a6d5-44ab-bfe9-cb54289b071f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtInstrumentInterestRateStatedPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:to="loc_us-gaap_DebtInstrumentInterestRateStatedPercentage_ba52ced7-a6d5-44ab-bfe9-cb54289b071f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_DebtInstrumentInterestPaymentsTerm_41c4fa8e-c49e-4f87-85b4-2358f3adc628" xlink:href="arvn-20251231.xsd#arvn_DebtInstrumentInterestPaymentsTerm"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:to="loc_arvn_DebtInstrumentInterestPaymentsTerm_41c4fa8e-c49e-4f87-85b4-2358f3adc628" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PercentageOfLiquidatedDamages_a00742dd-2db8-449d-85ae-dd77cc5b6d42" xlink:href="arvn-20251231.xsd#arvn_PercentageOfLiquidatedDamages"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtInstrumentLineItems_e104e1e9-c316-4dea-8721-65ec11cf4e22" xlink:to="loc_arvn_PercentageOfLiquidatedDamages_a00742dd-2db8-449d-85ae-dd77cc5b6d42" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DebtDisclosureAbstract_0d49ef79-afda-4a16-8af2-df12953f8319" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DebtDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a32d9d8a-f81c-4841-bca3-470e75b26cc4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0d49ef79-afda-4a16-8af2-df12953f8319" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths_a32d9d8a-f81c-4841-bca3-470e75b26cc4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ec931938-24d6-4a65-8fd7-ea1b2d180aa7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0d49ef79-afda-4a16-8af2-df12953f8319" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo_ec931938-24d6-4a65-8fd7-ea1b2d180aa7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e89d6b4f-1500-4370-9241-8744629f3eae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0d49ef79-afda-4a16-8af2-df12953f8319" xlink:to="loc_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree_e89d6b4f-1500-4370-9241-8744629f3eae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LongTermDebt_e8029a5e-0f9f-4eaf-a976-1368f1751af2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LongTermDebt"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DebtDisclosureAbstract_0d49ef79-afda-4a16-8af2-df12953f8319" xlink:to="loc_us-gaap_LongTermDebt_e8029a5e-0f9f-4eaf-a976-1368f1751af2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#EquityAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ab61ba9-c7cc-407c-b19e-3e7992c052a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_6ab61ba9-c7cc-407c-b19e-3e7992c052a4" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementEquityComponentsAxis_1b96cfa3-8652-4c1e-81eb-640c2a790c27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementEquityComponentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_us-gaap_StatementEquityComponentsAxis_1b96cfa3-8652-4c1e-81eb-640c2a790c27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityComponentDomain_afcee1e8-2174-4ad5-8453-47ec57a1e491" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityComponentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementEquityComponentsAxis_1b96cfa3-8652-4c1e-81eb-640c2a790c27" xlink:to="loc_us-gaap_EquityComponentDomain_afcee1e8-2174-4ad5-8453-47ec57a1e491" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockMember_3640cc71-3b50-43cc-9410-5772a03571be" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityComponentDomain_afcee1e8-2174-4ad5-8453-47ec57a1e491" xlink:to="loc_us-gaap_CommonStockMember_3640cc71-3b50-43cc-9410-5772a03571be" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SubsidiarySaleOfStockAxis_77463358-1847-4635-8e39-775a8d2f005f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SubsidiarySaleOfStockAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_us-gaap_SubsidiarySaleOfStockAxis_77463358-1847-4635-8e39-775a8d2f005f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b6ffb21-b8aa-46fd-ad90-1878ffc5b860" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNameOfTransactionDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SubsidiarySaleOfStockAxis_77463358-1847-4635-8e39-775a8d2f005f" xlink:to="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b6ffb21-b8aa-46fd-ad90-1878ffc5b860" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PrivatePlacementMember_fbb0c789-0054-4188-9a5b-a4e1eb9b3a41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PrivatePlacementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b6ffb21-b8aa-46fd-ad90-1878ffc5b860" xlink:to="loc_us-gaap_PrivatePlacementMember_fbb0c789-0054-4188-9a5b-a4e1eb9b3a41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AtTheMarketOfferingMember_019b3121-af2f-77f4-b623-40169b5b4af5" xlink:href="arvn-20251231.xsd#arvn_AtTheMarketOfferingMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SaleOfStockNameOfTransactionDomain_6b6ffb21-b8aa-46fd-ad90-1878ffc5b860" xlink:to="loc_arvn_AtTheMarketOfferingMember_019b3121-af2f-77f4-b623-40169b5b4af5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_83445903-ff48-47d9-9aa1-92604826b154" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_83445903-ff48-47d9-9aa1-92604826b154" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_be87100a-f31b-407f-968b-7a42fa0b0a2e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_83445903-ff48-47d9-9aa1-92604826b154" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_be87100a-f31b-407f-968b-7a42fa0b0a2e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PreFundedWarrantMember_390e57d7-e378-4b66-b734-283c55db1245" xlink:href="arvn-20251231.xsd#arvn_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_be87100a-f31b-407f-968b-7a42fa0b0a2e" xlink:to="loc_arvn_PreFundedWarrantMember_390e57d7-e378-4b66-b734-283c55db1245" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_4598c1cb-e02b-49b6-aa73-e165429c8a3b" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_srt_CounterpartyNameAxis_4598c1cb-e02b-49b6-aa73-e165429c8a3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a0cf858-0f4c-47c7-8e92-a31dafffe246" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_4598c1cb-e02b-49b6-aa73-e165429c8a3b" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a0cf858-0f4c-47c7-8e92-a31dafffe246" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PiperSandlerAndCantorMember_c52bb586-4501-4795-8c4b-16d23effecbc" xlink:href="arvn-20251231.xsd#arvn_PiperSandlerAndCantorMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_0a0cf858-0f4c-47c7-8e92-a31dafffe246" xlink:to="loc_arvn_PiperSandlerAndCantorMember_c52bb586-4501-4795-8c4b-16d23effecbc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_29bbbf31-9e36-4495-a6fe-0be9f2a7c748" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_us-gaap_TypeOfArrangementAxis_29bbbf31-9e36-4495-a6fe-0be9f2a7c748" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a1ed2e1-e9e5-4850-95bc-df2bbd06d3e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_29bbbf31-9e36-4495-a6fe-0be9f2a7c748" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a1ed2e1-e9e5-4850-95bc-df2bbd06d3e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_EquityDistributionAgreementMember_ecb14f6c-6aba-482f-9c22-0ed25dc812f7" xlink:href="arvn-20251231.xsd#arvn_EquityDistributionAgreementMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_3a1ed2e1-e9e5-4850-95bc-df2bbd06d3e1" xlink:to="loc_arvn_EquityDistributionAgreementMember_ecb14f6c-6aba-482f-9c22-0ed25dc812f7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_32dcfbca-5a55-47d0-b3bf-a289254d895e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_us-gaap_AwardTypeAxis_32dcfbca-5a55-47d0-b3bf-a289254d895e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c921de5-ab56-40cd-a1c8-0d0c9021ab53" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_32dcfbca-5a55-47d0-b3bf-a289254d895e" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c921de5-ab56-40cd-a1c8-0d0c9021ab53" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockMember_fbe483d3-39ec-4b17-b849-677df8e1ef8d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c921de5-ab56-40cd-a1c8-0d0c9021ab53" xlink:to="loc_us-gaap_EmployeeStockMember_fbe483d3-39ec-4b17-b849-677df8e1ef8d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_5732020a-0dbd-43ab-bd38-8a5fe08a481d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_4c921de5-ab56-40cd-a1c8-0d0c9021ab53" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_5732020a-0dbd-43ab-bd38-8a5fe08a481d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_0899721e-d9c5-4d27-af55-359d16390e3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_us-gaap_PlanNameAxis_0899721e-d9c5-4d27-af55-359d16390e3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_469b0116-40da-47e9-8082-4f26491a1e57" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_0899721e-d9c5-4d27-af55-359d16390e3e" xlink:to="loc_us-gaap_PlanNameDomain_469b0116-40da-47e9-8082-4f26491a1e57" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_7db80dbf-b5d6-4e73-96be-4d03d4bef4a4" xlink:href="arvn-20251231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_469b0116-40da-47e9-8082-4f26491a1e57" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_7db80dbf-b5d6-4e73-96be-4d03d4bef4a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_641076c9-88ce-4de3-8ffd-5894683bccd1" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_srt_RangeAxis_641076c9-88ce-4de3-8ffd-5894683bccd1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_20062d62-f550-4361-b1f8-47b1eab0fbb8" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_641076c9-88ce-4de3-8ffd-5894683bccd1" xlink:to="loc_srt_RangeMember_20062d62-f550-4361-b1f8-47b1eab0fbb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_a97e4cab-5744-4eeb-88d5-4f1727a28488" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_20062d62-f550-4361-b1f8-47b1eab0fbb8" xlink:to="loc_srt_MaximumMember_a97e4cab-5744-4eeb-88d5-4f1727a28488" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_5e7368bf-6297-485c-a46f-ee0a87c546ab" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_20062d62-f550-4361-b1f8-47b1eab0fbb8" xlink:to="loc_srt_MinimumMember_5e7368bf-6297-485c-a46f-ee0a87c546ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_WeightedAverageMember_cac6a0ff-f263-47e7-b97e-58d27aa92a89" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_WeightedAverageMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_20062d62-f550-4361-b1f8-47b1eab0fbb8" xlink:to="loc_srt_WeightedAverageMember_cac6a0ff-f263-47e7-b97e-58d27aa92a89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_088da93b-8a62-45f7-8dbf-d64b8084f8ba" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockSharesAuthorized_9c23fa2f-a80b-42a6-9bd3-130a65452647" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockSharesAuthorized"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_PreferredStockSharesAuthorized_9c23fa2f-a80b-42a6-9bd3-130a65452647" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ad3e2245-a027-4842-84ae-b8e7726eec41" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PreferredStockParOrStatedValuePerShare"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_PreferredStockParOrStatedValuePerShare_ad3e2245-a027-4842-84ae-b8e7726eec41" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockSharesAuthorized_8c02bd04-46a9-464a-bd01-a1b3d760f81c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockSharesAuthorized"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_CommonStockSharesAuthorized_8c02bd04-46a9-464a-bd01-a1b3d760f81c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockParOrStatedValuePerShare_7b9ed1b7-7807-42b2-8a48-09b577965949" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockParOrStatedValuePerShare"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_CommonStockParOrStatedValuePerShare_7b9ed1b7-7807-42b2-8a48-09b577965949" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfVotesPerCommonStockShareHeld_0f02c0c9-c931-4494-b4c2-32de90e748f5" xlink:href="arvn-20251231.xsd#arvn_NumberOfVotesPerCommonStockShareHeld"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_NumberOfVotesPerCommonStockShareHeld_0f02c0c9-c931-4494-b4c2-32de90e748f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47613cf7-710e-4be6-b862-ee5ac1387ab7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction_47613cf7-710e-4be6-b862-ee5ac1387ab7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SaleOfStockPricePerShare_16ce6b6c-2a09-4d9b-aaa9-2702b76b2f1c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SaleOfStockPricePerShare"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_SaleOfStockPricePerShare_16ce6b6c-2a09-4d9b-aaa9-2702b76b2f1c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_aab405d6-98b2-4b0e-920d-46777b7875fc" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_aab405d6-98b2-4b0e-920d-46777b7875fc" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aec1d360-db0d-45b4-9bc4-cb2427864d3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_aec1d360-db0d-45b4-9bc4-cb2427864d3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants_1512dcd9-06fc-4702-80ae-70bbca23825f" xlink:href="arvn-20251231.xsd#arvn_ProceedsFromIssuanceOfCommonStockAndWarrants"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants_1512dcd9-06fc-4702-80ae-70bbca23825f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsOfStockIssuanceCosts_4af634a4-5e52-475a-8779-014c7280cae8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsOfStockIssuanceCosts"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_PaymentsOfStockIssuanceCosts_4af634a4-5e52-475a-8779-014c7280cae8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_019c235b-ff93-753b-8cac-c838f06a0701" xlink:href="arvn-20251231.xsd#arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants_019c235b-ff93-753b-8cac-c838f06a0701" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019c235b-4dbb-7384-9636-ad03f86783b2" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_StockRepurchaseProgramAuthorizedAmount1"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_srt_StockRepurchaseProgramAuthorizedAmount1_019c235b-4dbb-7384-9636-ad03f86783b2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockSharesAcquired_019c7cac-35a9-79e5-b6f8-4c96d04eb568" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockSharesAcquired"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_TreasuryStockSharesAcquired_019c7cac-35a9-79e5-b6f8-4c96d04eb568" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_019c235b-4dbb-7e32-bd87-875dffc3da0f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TreasuryStockAcquiredAverageCostPerShare"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_TreasuryStockAcquiredAverageCostPerShare_019c235b-4dbb-7e32-bd87-875dffc3da0f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions_019c235b-4dbb-7ad1-ab33-11ac8ae5f415" xlink:href="arvn-20251231.xsd#arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions_019c235b-4dbb-7ad1-ab33-11ac8ae5f415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareRepurchaseProgramCommissionsAndExciseTax_019c235b-4dbb-7645-9c38-9eaea8563406" xlink:href="arvn-20251231.xsd#arvn_ShareRepurchaseProgramCommissionsAndExciseTax"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_ShareRepurchaseProgramCommissionsAndExciseTax_019c235b-4dbb-7645-9c38-9eaea8563406" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_019b3145-d39d-7f42-b8e2-4e0d11698e4d" xlink:href="arvn-20251231.xsd#arvn_MaximumAggregateOfferingPriceOfCommonStock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_MaximumAggregateOfferingPriceOfCommonStock_019b3145-d39d-7f42-b8e2-4e0d11698e4d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6fc8526e-f763-41d7-b4bd-c7e88117e49a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesNewIssues_6fc8526e-f763-41d7-b4bd-c7e88117e49a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f6a4c8a5-2697-4041-9d02-24eacfea1c83" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodValueNewIssues_f6a4c8a5-2697-4041-9d02-24eacfea1c83" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_63169ebd-c99f-4a7c-84da-dce1684ce057" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_63169ebd-c99f-4a7c-84da-dce1684ce057" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_2599dca9-2928-4560-a7ea-4d7c6d014cd2" xlink:href="arvn-20251231.xsd#arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock_2599dca9-2928-4560-a7ea-4d7c6d014cd2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3aec5a5e-6240-41f8-9a89-528702b90db9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant_3aec5a5e-6240-41f8-9a89-528702b90db9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f7a0cbe7-bb6e-41be-b9e2-b63ca1e65b88" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_f7a0cbe7-bb6e-41be-b9e2-b63ca1e65b88" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_8b8aaf77-15b2-4583-b779-02c89c71e70a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod_8b8aaf77-15b2-4583-b779-02c89c71e70a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_5464f7bc-5c63-4e13-9d98-6c602d826f49" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum_5464f7bc-5c63-4e13-9d98-6c602d826f49" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_019c235a-2178-794f-abea-ac051e980b9a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost_019c235a-2178-794f-abea-ac051e980b9a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc61a285-48ce-455e-aa87-2480daf34197" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AllocatedShareBasedCompensationExpense"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_AllocatedShareBasedCompensationExpense_bc61a285-48ce-455e-aa87-2480daf34197" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6ae59693-03ac-44a6-bbb8-3d9627fa88a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_6ae59693-03ac-44a6-bbb8-3d9627fa88a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_87e6a3e2-1d1e-4658-bb3c-66e70c6947af" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_87e6a3e2-1d1e-4658-bb3c-66e70c6947af" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_bfc6993b-5a35-4c9c-9d0a-f260f380df7d" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants_bfc6993b-5a35-4c9c-9d0a-f260f380df7d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60c2fe50-8ef6-4c01-8e10-587ef521c1ba" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="32" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_60c2fe50-8ef6-4c01-8e10-587ef521c1ba" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_77905ea7-365e-4d4a-bd65-9026b4bffe2f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue"/>
    <link:presentationArc order="33" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_77905ea7-365e-4d4a-bd65-9026b4bffe2f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_b44f76be-f87c-4d82-ac6e-d540b9ddd4bf" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants"/>
    <link:presentationArc order="34" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants_b44f76be-f87c-4d82-ac6e-d540b9ddd4bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_364f1186-2992-45a2-88a6-c0e2e958fe7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="35" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_364f1186-2992-45a2-88a6-c0e2e958fe7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_34947d97-e6ea-40fe-93f4-06d6660f7a6c" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod"/>
    <link:presentationArc order="36" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod_34947d97-e6ea-40fe-93f4-06d6660f7a6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_59f801af-b4bc-4002-b37b-71ae8a917bf7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue"/>
    <link:presentationArc order="37" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_147121f8-575e-41e7-967a-864d9bbe14bd" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_59f801af-b4bc-4002-b37b-71ae8a917bf7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e833f5b-7200-4faa-a9ee-3675da2f40f9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29901eff-6e02-4101-8339-bb33b4be5b89" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1e833f5b-7200-4faa-a9ee-3675da2f40f9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29901eff-6e02-4101-8339-bb33b4be5b89" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_cec5b68b-7d28-4438-89a2-89ba41a84fff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29901eff-6e02-4101-8339-bb33b4be5b89" xlink:to="loc_us-gaap_AwardTypeAxis_cec5b68b-7d28-4438-89a2-89ba41a84fff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_885ddef5-e24e-4db3-a96f-4e6842608ebe" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_cec5b68b-7d28-4438-89a2-89ba41a84fff" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_885ddef5-e24e-4db3-a96f-4e6842608ebe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_ec4202e3-9274-4f0b-b4cf-fb694a9645a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_885ddef5-e24e-4db3-a96f-4e6842608ebe" xlink:to="loc_us-gaap_EmployeeStockOptionMember_ec4202e3-9274-4f0b-b4cf-fb694a9645a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_ded8e77b-eaf3-4332-b9ca-5c920d14f006" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29901eff-6e02-4101-8339-bb33b4be5b89" xlink:to="loc_srt_RangeAxis_ded8e77b-eaf3-4332-b9ca-5c920d14f006" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_4289795f-7f89-4d46-91c6-86831a815a4e" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_ded8e77b-eaf3-4332-b9ca-5c920d14f006" xlink:to="loc_srt_RangeMember_4289795f-7f89-4d46-91c6-86831a815a4e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_01aa7f4b-553b-473c-ab83-4526876828ab" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4289795f-7f89-4d46-91c6-86831a815a4e" xlink:to="loc_srt_MinimumMember_01aa7f4b-553b-473c-ab83-4526876828ab" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_ae7a0ad0-ff33-4bef-a03f-4e951525a702" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_4289795f-7f89-4d46-91c6-86831a815a4e" xlink:to="loc_srt_MaximumMember_ae7a0ad0-ff33-4bef-a03f-4e951525a702" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_29901eff-6e02-4101-8339-bb33b4be5b89" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_197edb91-99c1-4fcb-9fd3-a6993389d521" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum_197edb91-99c1-4fcb-9fd3-a6993389d521" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_8cb9c944-39d6-4fa0-bbf3-7eeb994d75b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum_8cb9c944-39d6-4fa0-bbf3-7eeb994d75b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c5252675-1de6-47d4-bb2b-8e84dc05328e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_c5252675-1de6-47d4-bb2b-8e84dc05328e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6c0da7cb-c4ba-4d54-88a6-08af06959ed8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum_6c0da7cb-c4ba-4d54-88a6-08af06959ed8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8d2b0df2-7141-4215-9d24-95a0155d6d74" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum_8d2b0df2-7141-4215-9d24-95a0155d6d74" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a58503f5-df75-4290-9e8f-bc45d4c0b1c6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_a58503f5-df75-4290-9e8f-bc45d4c0b1c6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_bc92d4cf-d6fe-433b-93cb-ecbbf3ab3e51" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_6cd22cf7-920d-4856-8184-94bb020759cb" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_bc92d4cf-d6fe-433b-93cb-ecbbf3ab3e51" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#EquityScheduleofStockOptionActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a66ae7b6-4d1a-4e2d-b6e1-b7230fa515d9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c1677f3-fb2a-4d49-bf86-becd316c50a9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_a66ae7b6-4d1a-4e2d-b6e1-b7230fa515d9" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c1677f3-fb2a-4d49-bf86-becd316c50a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_c634823f-5b65-4d4b-8e12-953416c888b3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c1677f3-fb2a-4d49-bf86-becd316c50a9" xlink:to="loc_us-gaap_PlanNameAxis_c634823f-5b65-4d4b-8e12-953416c888b3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_d254102e-1bfa-49e5-a77f-9343ae6fa3e5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_c634823f-5b65-4d4b-8e12-953416c888b3" xlink:to="loc_us-gaap_PlanNameDomain_d254102e-1bfa-49e5-a77f-9343ae6fa3e5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_a18d9da6-5d98-4edc-8e11-d920edbf3e14" xlink:href="arvn-20251231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_d254102e-1bfa-49e5-a77f-9343ae6fa3e5" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_a18d9da6-5d98-4edc-8e11-d920edbf3e14" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_4c1677f3-fb2a-4d49-bf86-becd316c50a9" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35faf6de-be8e-48e5-b252-e6667204e9c4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35faf6de-be8e-48e5-b252-e6667204e9c4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_43be4298-2562-4b4f-80fa-f936d0755f91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35faf6de-be8e-48e5-b252-e6667204e9c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_43be4298-2562-4b4f-80fa-f936d0755f91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_327ddfc0-692a-4621-b98f-fc406dac8f84" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35faf6de-be8e-48e5-b252-e6667204e9c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_327ddfc0-692a-4621-b98f-fc406dac8f84" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_22ea392a-340f-494d-bb13-2c57394f8415" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35faf6de-be8e-48e5-b252-e6667204e9c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_22ea392a-340f-494d-bb13-2c57394f8415" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2161fc2e-d422-4a34-92ff-fc4d8ea874e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_35faf6de-be8e-48e5-b252-e6667204e9c4" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_2161fc2e-d422-4a34-92ff-fc4d8ea874e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4ff05dbc-c9aa-4ad1-8aea-84be74096304" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_4ff05dbc-c9aa-4ad1-8aea-84be74096304" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8e374500-01bc-421c-bd5a-e63191f21471" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber_8e374500-01bc-421c-bd5a-e63191f21471" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c29b1225-c360-45f1-98a2-c3f529664625" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c29b1225-c360-45f1-98a2-c3f529664625" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cbbc87e1-7f1f-4a7c-addf-e539d4e3524f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c29b1225-c360-45f1-98a2-c3f529664625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_cbbc87e1-7f1f-4a7c-addf-e539d4e3524f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_22d4d2ca-3398-4b44-bb53-64a42ffa8460" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c29b1225-c360-45f1-98a2-c3f529664625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_22d4d2ca-3398-4b44-bb53-64a42ffa8460" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_11056029-3085-4ebb-a782-61ecd650e82a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c29b1225-c360-45f1-98a2-c3f529664625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_11056029-3085-4ebb-a782-61ecd650e82a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_42828290-8e0d-442b-ba42-306e4858e52f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract_c29b1225-c360-45f1-98a2-c3f529664625" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_42828290-8e0d-442b-ba42-306e4858e52f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_90936d3c-8e4b-45e0-925e-657ae4a5b65e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_90936d3c-8e4b-45e0-925e-657ae4a5b65e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e212bf67-abc0-489e-8015-a8dd4904d814" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice_e212bf67-abc0-489e-8015-a8dd4904d814" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a80cbacf-2cfc-438c-b4af-b8bb9c03abcb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a80cbacf-2cfc-438c-b4af-b8bb9c03abcb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b062cc4e-eb6c-4765-aa75-c5322a9e8797" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a80cbacf-2cfc-438c-b4af-b8bb9c03abcb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_b062cc4e-eb6c-4765-aa75-c5322a9e8797" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_897e2cb6-bf11-48e0-99f4-a3e8c295a163" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a80cbacf-2cfc-438c-b4af-b8bb9c03abcb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_897e2cb6-bf11-48e0-99f4-a3e8c295a163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_954a8d7f-0695-4003-91bc-2e0d54ac7794" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_a80cbacf-2cfc-438c-b4af-b8bb9c03abcb" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1_954a8d7f-0695-4003-91bc-2e0d54ac7794" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AggregateIntrinsicValueAbstract_555b6d07-d213-4985-adc5-0f45985b83f8" xlink:href="arvn-20251231.xsd#arvn_AggregateIntrinsicValueAbstract"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_76f76dd7-5e38-4b0b-bc93-6e482b65835c" xlink:to="loc_arvn_AggregateIntrinsicValueAbstract_555b6d07-d213-4985-adc5-0f45985b83f8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_842d52fc-a60d-421f-b4d4-c26fa4b22eb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_555b6d07-d213-4985-adc5-0f45985b83f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_842d52fc-a60d-421f-b4d4-c26fa4b22eb8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c640baaf-f633-44d5-8524-a49f385ea08a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_555b6d07-d213-4985-adc5-0f45985b83f8" xlink:to="loc_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_c640baaf-f633-44d5-8524-a49f385ea08a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_dca16a73-00bc-4349-869e-729b5926348f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_AggregateIntrinsicValueAbstract_555b6d07-d213-4985-adc5-0f45985b83f8" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_dca16a73-00bc-4349-869e-729b5926348f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#EquityScheduleofRestrictedStockDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a001fbf-b462-45f6-a960-90f7b04d3742" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bcf9771-9fcb-4c25-8ad7-41019afb5a7b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_1a001fbf-b462-45f6-a960-90f7b04d3742" xlink:to="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bcf9771-9fcb-4c25-8ad7-41019afb5a7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameAxis_d9e3e2e8-80f3-4abf-b6f9-3e9c40f7dafb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bcf9771-9fcb-4c25-8ad7-41019afb5a7b" xlink:to="loc_us-gaap_PlanNameAxis_d9e3e2e8-80f3-4abf-b6f9-3e9c40f7dafb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PlanNameDomain_96dde6de-af51-4d57-b293-5c3420c0f60e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameAxis_d9e3e2e8-80f3-4abf-b6f9-3e9c40f7dafb" xlink:to="loc_us-gaap_PlanNameDomain_96dde6de-af51-4d57-b293-5c3420c0f60e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_b3b9902c-4592-4a72-9fe7-b7c278b01399" xlink:href="arvn-20251231.xsd#arvn_TwoThousandEighteenStockIncentivePlanMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_PlanNameDomain_96dde6de-af51-4d57-b293-5c3420c0f60e" xlink:to="loc_arvn_TwoThousandEighteenStockIncentivePlanMember_b3b9902c-4592-4a72-9fe7-b7c278b01399" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis_05fe02c6-d27f-4e32-8115-fc25e21e5394" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bcf9771-9fcb-4c25-8ad7-41019afb5a7b" xlink:to="loc_us-gaap_AwardTypeAxis_05fe02c6-d27f-4e32-8115-fc25e21e5394" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_125b4a88-4393-4da5-96d4-e9845c827110" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis_05fe02c6-d27f-4e32-8115-fc25e21e5394" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_125b4a88-4393-4da5-96d4-e9845c827110" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_3d7fac9b-45c4-4aae-b552-13b0c5e892aa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_125b4a88-4393-4da5-96d4-e9845c827110" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_3d7fac9b-45c4-4aae-b552-13b0c5e892aa" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13baf050-5a5d-4be1-af70-d360521f51e3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_9bcf9771-9fcb-4c25-8ad7-41019afb5a7b" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13baf050-5a5d-4be1-af70-d360521f51e3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0cfdd9d8-1b60-4858-8915-8ec7d0a77294" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13baf050-5a5d-4be1-af70-d360521f51e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0cfdd9d8-1b60-4858-8915-8ec7d0a77294" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae4ff707-c7ac-417f-9dfb-b836b8333298" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0cfdd9d8-1b60-4858-8915-8ec7d0a77294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_ae4ff707-c7ac-417f-9dfb-b836b8333298" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fdfdf5d3-1c44-4bd1-af7f-103387d974b6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0cfdd9d8-1b60-4858-8915-8ec7d0a77294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_fdfdf5d3-1c44-4bd1-af7f-103387d974b6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_9cce467e-3512-47c8-958f-5c616b4e69a9" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0cfdd9d8-1b60-4858-8915-8ec7d0a77294" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod_9cce467e-3512-47c8-958f-5c616b4e69a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1906f142-dcac-4d67-a272-de464e42eb52" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0cfdd9d8-1b60-4858-8915-8ec7d0a77294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod_1906f142-dcac-4d67-a272-de464e42eb52" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5826a72b-cc53-40b8-a3e2-a642c17b0410" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward_0cfdd9d8-1b60-4858-8915-8ec7d0a77294" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_5826a72b-cc53-40b8-a3e2-a642c17b0410" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b774617-f38d-4563-865b-3a3eb0b42c4a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_13baf050-5a5d-4be1-af70-d360521f51e3" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b774617-f38d-4563-865b-3a3eb0b42c4a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_570ba4de-e0bc-4bc3-873e-a978ef20525e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b774617-f38d-4563-865b-3a3eb0b42c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_570ba4de-e0bc-4bc3-873e-a978ef20525e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ad8d8846-f3cd-4505-936a-72371c2b597f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b774617-f38d-4563-865b-3a3eb0b42c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_ad8d8846-f3cd-4505-936a-72371c2b597f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue_fffffb80-7b29-47f0-aac2-0a87425bcb1a" xlink:href="arvn-20251231.xsd#arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b774617-f38d-4563-865b-3a3eb0b42c4a" xlink:to="loc_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue_fffffb80-7b29-47f0-aac2-0a87425bcb1a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ee306605-9b29-4d4d-8887-f598568a515e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b774617-f38d-4563-865b-3a3eb0b42c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue_ee306605-9b29-4d4d-8887-f598568a515e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fed31327-55f6-4ab3-b08a-f5b7debfba06" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward_7b774617-f38d-4563-865b-3a3eb0b42c4a" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_fed31327-55f6-4ab3-b08a-f5b7debfba06" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/EquityMethodInvestmentsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#EquityMethodInvestmentsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/EquityMethodInvestmentsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f1611037-48fb-45ee-b0e7-fead66b2e725" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8276f581-4107-485e-8dd6-42924d5005d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract_f1611037-48fb-45ee-b0e7-fead66b2e725" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8276f581-4107-485e-8dd6-42924d5005d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_5ed7bb97-2835-410f-b890-e613da383c44" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8276f581-4107-485e-8dd6-42924d5005d5" xlink:to="loc_srt_CounterpartyNameAxis_5ed7bb97-2835-410f-b890-e613da383c44" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82daaa45-5ffe-44cc-9e98-add59acb3585" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_5ed7bb97-2835-410f-b890-e613da383c44" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82daaa45-5ffe-44cc-9e98-add59acb3585" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_BayerCropScienceLPMember_7a22b93b-baa9-46b6-804f-dd0e3891c912" xlink:href="arvn-20251231.xsd#arvn_BayerCropScienceLPMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_82daaa45-5ffe-44cc-9e98-add59acb3585" xlink:to="loc_arvn_BayerCropScienceLPMember_7a22b93b-baa9-46b6-804f-dd0e3891c912" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_179f1ea1-b869-412f-8d43-8e8861962965" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8276f581-4107-485e-8dd6-42924d5005d5" xlink:to="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_179f1ea1-b869-412f-8d43-8e8861962965" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_EquityMethodInvesteeNameDomain_de309276-fa03-4088-9c6d-6c7b057d43fe" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_EquityMethodInvesteeNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis_179f1ea1-b869-412f-8d43-8e8861962965" xlink:to="loc_srt_EquityMethodInvesteeNameDomain_de309276-fa03-4088-9c6d-6c7b057d43fe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_3fcd51cc-c150-47d7-b151-84473553ddf2" xlink:href="arvn-20251231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_EquityMethodInvesteeNameDomain_de309276-fa03-4088-9c6d-6c7b057d43fe" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_3fcd51cc-c150-47d7-b151-84473553ddf2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LegalEntityAxis_bca6c2ed-afef-407b-a6dd-bf990e1c24ea" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_LegalEntityAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8276f581-4107-485e-8dd6-42924d5005d5" xlink:to="loc_dei_LegalEntityAxis_bca6c2ed-afef-407b-a6dd-bf990e1c24ea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityDomain_57397d9c-18e9-48c3-9ce7-346634cbb1c2" xlink:href="https://xbrl.sec.gov/dei/2025/dei-2025.xsd#dei_EntityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_LegalEntityAxis_bca6c2ed-afef-407b-a6dd-bf990e1c24ea" xlink:to="loc_dei_EntityDomain_57397d9c-18e9-48c3-9ce7-346634cbb1c2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OerthBioLimitedLiabilityCorporationMember_b000cb2b-7297-4471-99b7-b615c28b726c" xlink:href="arvn-20251231.xsd#arvn_OerthBioLimitedLiabilityCorporationMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_EntityDomain_57397d9c-18e9-48c3-9ce7-346634cbb1c2" xlink:to="loc_arvn_OerthBioLimitedLiabilityCorporationMember_b000cb2b-7297-4471-99b7-b615c28b726c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfEquityMethodInvestmentsLineItems"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsTable_8276f581-4107-485e-8dd6-42924d5005d5" xlink:to="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentAggregateCost_360be3d6-54a6-4efd-a401-3084da5f082b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentAggregateCost"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_us-gaap_EquityMethodInvestmentAggregateCost_360be3d6-54a6-4efd-a401-3084da5f082b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_29f2c60c-106f-4f60-a07e-eac818c9655e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestmentOwnershipPercentage"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_us-gaap_EquityMethodInvestmentOwnershipPercentage_29f2c60c-106f-4f60-a07e-eac818c9655e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_659fb8b5-ad3c-40d1-98f4-6633bbadfb6a" xlink:href="arvn-20251231.xsd#arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage_659fb8b5-ad3c-40d1-98f4-6633bbadfb6a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingExpenses_90c8f786-34d2-42fc-b201-22bf4dcd172b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingExpenses"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_us-gaap_OperatingExpenses_90c8f786-34d2-42fc-b201-22bf4dcd172b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_d01893ec-6de2-4fd4-984e-2a0f18021c10" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_us-gaap_NetIncomeLoss_d01893ec-6de2-4fd4-984e-2a0f18021c10" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_370f24cc-973f-423a-8683-51c40bde0eb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_370f24cc-973f-423a-8683-51c40bde0eb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EquityMethodInvestments_cb145eb4-4c45-40b5-90c1-c0453f0a66e1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EquityMethodInvestments"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems_730177a4-4152-4e31-bf2a-a0ab6f151766" xlink:to="loc_us-gaap_EquityMethodInvestments_cb145eb4-4c45-40b5-90c1-c0453f0a66e1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxesAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_92159b3b-8550-44be-9428-48f462e71931" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeTaxDisclosureTable_784682c1-b37d-4e9d-a283-4c3fba0e79bf" xlink:href="arvn-20251231.xsd#arvn_IncomeTaxDisclosureTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_92159b3b-8550-44be-9428-48f462e71931" xlink:to="loc_arvn_IncomeTaxDisclosureTable_784682c1-b37d-4e9d-a283-4c3fba0e79bf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAxis_ff6273ea-913f-403c-aaca-c759cc721234" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureTable_784682c1-b37d-4e9d-a283-4c3fba0e79bf" xlink:to="loc_us-gaap_TaxCreditCarryforwardAxis_ff6273ea-913f-403c-aaca-c759cc721234" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardNameDomain_44f46b2a-19f6-4f22-8897-f0dc11d3a540" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardAxis_ff6273ea-913f-403c-aaca-c759cc721234" xlink:to="loc_us-gaap_TaxCreditCarryforwardNameDomain_44f46b2a-19f6-4f22-8897-f0dc11d3a540" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchMember_b93fa4b6-a9fe-457a-99a6-2fc41c508074" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TaxCreditCarryforwardNameDomain_44f46b2a-19f6-4f22-8897-f0dc11d3a540" xlink:to="loc_us-gaap_ResearchMember_b93fa4b6-a9fe-457a-99a6-2fc41c508074" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_f6aac83b-a7a1-4d13-b389-261574a129a4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureTable_784682c1-b37d-4e9d-a283-4c3fba0e79bf" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_f6aac83b-a7a1-4d13-b389-261574a129a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_4ab65026-065a-4f68-8809-30195bf29975" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_f6aac83b-a7a1-4d13-b389-261574a129a4" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_4ab65026-065a-4f68-8809-30195bf29975" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DomesticCountryMember_61e6f98d-4759-427f-bf1c-15746d6c7472" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DomesticCountryMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4ab65026-065a-4f68-8809-30195bf29975" xlink:to="loc_us-gaap_DomesticCountryMember_61e6f98d-4759-427f-bf1c-15746d6c7472" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_6da9ba72-2967-4471-900a-63ae51b2d4e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_4ab65026-065a-4f68-8809-30195bf29975" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_6da9ba72-2967-4471-900a-63ae51b2d4e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:href="arvn-20251231.xsd#arvn_IncomeTaxDisclosureLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureTable_784682c1-b37d-4e9d-a283-4c3fba0e79bf" xlink:to="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_19bc7152-0d79-4a19-9ce9-a80078ae641d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_19bc7152-0d79-4a19-9ce9-a80078ae641d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ba886422-4631-45b9-8b63-bb780219082c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_ba886422-4631-45b9-8b63-bb780219082c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OperatingLossCarryforwards_c0ffc21d-b33c-4d90-a517-420b13a97a45" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OperatingLossCarryforwards"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_us-gaap_OperatingLossCarryforwards_c0ffc21d-b33c-4d90-a517-420b13a97a45" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_c75d6a1f-9be1-4e00-a838-e7fa92e7469b" xlink:href="arvn-20251231.xsd#arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage_c75d6a1f-9be1-4e00-a838-e7fa92e7469b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TaxCreditCarryforwardAmount_4e7f8a3f-c188-4f15-82f3-df14f3640d76" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TaxCreditCarryforwardAmount"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_us-gaap_TaxCreditCarryforwardAmount_4e7f8a3f-c188-4f15-82f3-df14f3640d76" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UnrecognizedTaxBenefitsNet_03d9de3b-a1ba-4b0a-9746-6fa81017878f" xlink:href="arvn-20251231.xsd#arvn_UnrecognizedTaxBenefitsNet"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_arvn_UnrecognizedTaxBenefitsNet_03d9de3b-a1ba-4b0a-9746-6fa81017878f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_59cf82d9-eeb3-4260-92b7-ed8dc8bc3626" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_IncomeTaxDisclosureLineItems_c02017f7-5f3c-445a-bb51-f7de679ea51b" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued_59cf82d9-eeb3-4260-92b7-ed8dc8bc3626" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxesScheduleofIncomeTaxExpenseDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_5335d328-f156-4df9-84d7-3151850bd655" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_21b1b726-c72d-42a5-95dc-9f2e03b43edf" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5335d328-f156-4df9-84d7-3151850bd655" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_21b1b726-c72d-42a5-95dc-9f2e03b43edf" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6ebef992-6281-4e84-965e-4fa46d86a62a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentFederalTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_21b1b726-c72d-42a5-95dc-9f2e03b43edf" xlink:to="loc_us-gaap_CurrentFederalTaxExpenseBenefit_6ebef992-6281-4e84-965e-4fa46d86a62a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6b5ade72-84f6-4e51-9546-f8ac01f62f4b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentStateAndLocalTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_21b1b726-c72d-42a5-95dc-9f2e03b43edf" xlink:to="loc_us-gaap_CurrentStateAndLocalTaxExpenseBenefit_6b5ade72-84f6-4e51-9546-f8ac01f62f4b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_545a0a45-295f-430b-865c-de4381940c5a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CurrentIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract_21b1b726-c72d-42a5-95dc-9f2e03b43edf" xlink:to="loc_us-gaap_CurrentIncomeTaxExpenseBenefit_545a0a45-295f-430b-865c-de4381940c5a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_769e9d14-aa2f-4dbc-bc71-ed649ad562b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5335d328-f156-4df9-84d7-3151850bd655" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_769e9d14-aa2f-4dbc-bc71-ed649ad562b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0d23ec4d-8c32-4205-b94b-9780ffaa9813" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredFederalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_769e9d14-aa2f-4dbc-bc71-ed649ad562b9" xlink:to="loc_us-gaap_DeferredFederalIncomeTaxExpenseBenefit_0d23ec4d-8c32-4205-b94b-9780ffaa9813" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4303eb9a-f0b8-4c97-878d-44e5d41331c5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_769e9d14-aa2f-4dbc-bc71-ed649ad562b9" xlink:to="loc_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit_4303eb9a-f0b8-4c97-878d-44e5d41331c5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a372fb34-d10b-4538-a6b6-867644b25c3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract_769e9d14-aa2f-4dbc-bc71-ed649ad562b9" xlink:to="loc_us-gaap_DeferredIncomeTaxExpenseBenefit_a372fb34-d10b-4538-a6b6-867644b25c3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_4cc3c3ca-3b5b-4dce-a344-0a05c9b2e514" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_5335d328-f156-4df9-84d7-3151850bd655" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_4cc3c3ca-3b5b-4dce-a344-0a05c9b2e514" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_cbd85cce-a6f9-4b7f-9ebe-6c891a15e840" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c4690-c6d0-7f25-9c9b-5ff9477e6104" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cbd85cce-a6f9-4b7f-9ebe-6c891a15e840" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c4690-c6d0-7f25-9c9b-5ff9477e6104" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c4691-056d-735d-b154-a31112d985ef" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c4690-c6d0-7f25-9c9b-5ff9477e6104" xlink:to="loc_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate_019c4691-056d-735d-b154-a31112d985ef" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c4691-056d-76e2-8bdf-41c568e2ce6c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c4690-c6d0-7f25-9c9b-5ff9477e6104" xlink:to="loc_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes_019c4691-056d-76e2-8bdf-41c568e2ce6c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c4691-056d-7100-98a2-cf5845cfadec" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c4690-c6d0-7f25-9c9b-5ff9477e6104" xlink:to="loc_us-gaap_IncomeTaxReconciliationTaxCreditsResearch_019c4691-056d-7100-98a2-cf5845cfadec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c4691-056d-700c-a4bf-35afaf8712a1" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c4690-c6d0-7f25-9c9b-5ff9477e6104" xlink:to="loc_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c4691-056d-700c-a4bf-35afaf8712a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c4691-056d-740c-9176-eb1118cd5580" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c4690-c6d0-7f25-9c9b-5ff9477e6104" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost_019c4691-056d-740c-9176-eb1118cd5580" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c4691-056d-780a-b807-a86801521e08" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c4690-c6d0-7f25-9c9b-5ff9477e6104" xlink:to="loc_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther_019c4691-056d-780a-b807-a86801521e08" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_019c4691-056d-7f48-b7bd-9ffaaa241bbb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract_019c4690-c6d0-7f25-9c9b-5ff9477e6104" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_019c4691-056d-7f48-b7bd-9ffaaa241bbb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c4692-ade3-7088-8b5f-c33ae3b98345" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_cbd85cce-a6f9-4b7f-9ebe-6c891a15e840" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c4692-ade3-7088-8b5f-c33ae3b98345" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019c4693-028a-7324-a486-6bf55078cd7e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c4692-ade3-7088-8b5f-c33ae3b98345" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_019c4693-028a-7324-a486-6bf55078cd7e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019c4693-028a-79fe-84d8-29451fdfca5b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c4692-ade3-7088-8b5f-c33ae3b98345" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_019c4693-028a-79fe-84d8-29451fdfca5b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019c4693-028a-7a40-817a-725533944dae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c4692-ade3-7088-8b5f-c33ae3b98345" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_019c4693-028a-7a40-817a-725533944dae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c4693-028a-7c37-815f-91b377f9f003" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c4692-ade3-7088-8b5f-c33ae3b98345" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_019c4693-028a-7c37-815f-91b377f9f003" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c4693-028a-7c72-9def-cae2a0b01d27" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c4692-ade3-7088-8b5f-c33ae3b98345" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost_019c4693-028a-7c72-9def-cae2a0b01d27" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019c4693-028a-7d3c-9036-14c0829543ed" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c4692-ade3-7088-8b5f-c33ae3b98345" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther_019c4693-028a-7d3c-9036-14c0829543ed" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c4693-028a-79d8-ab4c-9239a86f53bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_019c4692-ade3-7088-8b5f-c33ae3b98345" xlink:to="loc_us-gaap_EffectiveIncomeTaxRateContinuingOperations_019c4693-028a-79d8-ab4c-9239a86f53bd" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_019c469b-e4ac-7b18-b8af-2bae97e322eb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c469d-cc1f-758f-b15a-6db29e729ae7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_019c469b-e4ac-7b18-b8af-2bae97e322eb" xlink:to="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c469d-cc1f-758f-b15a-6db29e729ae7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityAxis_019c469d-ec70-7804-ac07-9c15f3943a6d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c469d-cc1f-758f-b15a-6db29e729ae7" xlink:to="loc_us-gaap_IncomeTaxAuthorityAxis_019c469d-ec70-7804-ac07-9c15f3943a6d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxAuthorityDomain_019c469d-ec70-7af0-af6d-e039bf3156a0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxAuthorityDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityAxis_019c469d-ec70-7804-ac07-9c15f3943a6d" xlink:to="loc_us-gaap_IncomeTaxAuthorityDomain_019c469d-ec70-7af0-af6d-e039bf3156a0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StateAndLocalJurisdictionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxAuthorityDomain_019c469d-ec70-7af0-af6d-e039bf3156a0" xlink:to="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_CA_019c469d-ec70-7157-ab6b-1b9819b8a220" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_CA"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_stpr_CA_019c469d-ec70-7157-ab6b-1b9819b8a220" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_MA_019c469d-ec70-7f3f-82c2-ac9434b6d037" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_MA"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_stpr_MA_019c469d-ec70-7f3f-82c2-ac9434b6d037" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NY_019c469d-ec70-7bb7-8cdc-91ff88dee7a4" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NY"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_stpr_NY_019c469d-ec70-7bb7-8cdc-91ff88dee7a4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NewYorkCityMember_019c469d-ec70-7781-b95b-7ba09bb0119f" xlink:href="arvn-20251231.xsd#arvn_NewYorkCityMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_arvn_NewYorkCityMember_019c469d-ec70-7781-b95b-7ba09bb0119f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_NJ_019c469d-ec70-7a57-8c90-6bd67d52ec3c" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_NJ"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_stpr_NJ_019c469d-ec70-7a57-8c90-6bd67d52ec3c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_stpr_PA_019c469d-ec70-718d-886c-3ed43db8073f" xlink:href="https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd#stpr_PA"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_stpr_PA_019c469d-ec70-718d-886c-3ed43db8073f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c469d-ec70-7170-bb78-d968d39e0713" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ForeignTaxJurisdictionOtherMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StateAndLocalJurisdictionMember_019c68ee-5d40-7c19-a1bd-13b97a845df6" xlink:to="loc_us-gaap_ForeignTaxJurisdictionOtherMember_019c469d-ec70-7170-bb78-d968d39e0713" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c469d-ec70-7e41-8619-1ebee0dc0aae" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionTable_019c469d-cc1f-758f-b15a-6db29e729ae7" xlink:to="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c469d-ec70-7e41-8619-1ebee0dc0aae" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c469d-ec70-7fdf-a31d-9e9b8bc56ed0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidFederalAfterRefundReceived"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c469d-ec70-7e41-8619-1ebee0dc0aae" xlink:to="loc_us-gaap_IncomeTaxPaidFederalAfterRefundReceived_019c469d-ec70-7fdf-a31d-9e9b8bc56ed0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c469d-ec70-7021-afa6-ebefe5b2ebd8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c469d-ec70-7e41-8619-1ebee0dc0aae" xlink:to="loc_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived_019c469d-ec70-7021-afa6-ebefe5b2ebd8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxesPaidNet_019c469d-ec70-7359-a007-afacae9769d5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxesPaidNet"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems_019c469d-ec70-7e41-8619-1ebee0dc0aae" xlink:to="loc_us-gaap_IncomeTaxesPaidNet_019c469d-ec70-7359-a007-afacae9769d5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_b6ef34df-4da0-4cb9-be44-4682077fc5fa" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsNetAbstract_a162a089-e0b7-4b71-a756-be8126299f03" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsNetAbstract"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b6ef34df-4da0-4cb9-be44-4682077fc5fa" xlink:to="loc_us-gaap_DeferredTaxAssetsNetAbstract_a162a089-e0b7-4b71-a756-be8126299f03" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4052a792-3d2f-483a-926b-e8c81ab3836b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a162a089-e0b7-4b71-a756-be8126299f03" xlink:to="loc_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_4052a792-3d2f-483a-926b-e8c81ab3836b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_7453522d-6816-4a9a-a6da-4c628fd5a8f4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a162a089-e0b7-4b71-a756-be8126299f03" xlink:to="loc_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment_7453522d-6816-4a9a-a6da-4c628fd5a8f4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsDeferredIncome_b4fb929c-8f07-4777-9bb0-f898ef99ee7c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsDeferredIncome"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a162a089-e0b7-4b71-a756-be8126299f03" xlink:to="loc_us-gaap_DeferredTaxAssetsDeferredIncome_b4fb929c-8f07-4777-9bb0-f898ef99ee7c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_e6e61ef7-bfea-4dc1-bb15-e26c80f08681" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwards"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a162a089-e0b7-4b71-a756-be8126299f03" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards_e6e61ef7-bfea-4dc1-bb15-e26c80f08681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3baa930f-a58b-4638-91cc-bdd936543e37" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a162a089-e0b7-4b71-a756-be8126299f03" xlink:to="loc_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_3baa930f-a58b-4638-91cc-bdd936543e37" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsOther_97a8560a-36aa-469b-a956-cd8addc23091" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsOther"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a162a089-e0b7-4b71-a756-be8126299f03" xlink:to="loc_us-gaap_DeferredTaxAssetsOther_97a8560a-36aa-469b-a956-cd8addc23091" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsGross_b8413d7a-eeac-48c6-a305-a12291b6a6b9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsGross"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxAssetsNetAbstract_a162a089-e0b7-4b71-a756-be8126299f03" xlink:to="loc_us-gaap_DeferredTaxAssetsGross_b8413d7a-eeac-48c6-a305-a12291b6a6b9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1eb6b786-b717-4b38-a34c-94c18082dc3e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b6ef34df-4da0-4cb9-be44-4682077fc5fa" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1eb6b786-b717-4b38-a34c-94c18082dc3e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_38d1d612-f824-41d9-bdf9-09197ea62407" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1eb6b786-b717-4b38-a34c-94c18082dc3e" xlink:to="loc_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment_38d1d612-f824-41d9-bdf9-09197ea62407" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredIncomeTaxLiabilities_a992b1bf-1c40-462e-a0ae-0973bb49a0c3" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredIncomeTaxLiabilities"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_DeferredTaxLiabilitiesNetAbstract_1eb6b786-b717-4b38-a34c-94c18082dc3e" xlink:to="loc_us-gaap_DeferredIncomeTaxLiabilities_a992b1bf-1c40-462e-a0ae-0973bb49a0c3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b7188db3-108f-4431-9038-16f27968eea9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxAssetsValuationAllowance"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b6ef34df-4da0-4cb9-be44-4682077fc5fa" xlink:to="loc_us-gaap_DeferredTaxAssetsValuationAllowance_b7188db3-108f-4431-9038-16f27968eea9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DeferredTaxLiabilities_fbdf2c38-8243-4c79-881a-80f4f340c2e4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DeferredTaxLiabilities"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_b6ef34df-4da0-4cb9-be44-4682077fc5fa" xlink:to="loc_us-gaap_DeferredTaxLiabilities_fbdf2c38-8243-4c79-881a-80f4f340c2e4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxDisclosureAbstract_0525b052-05b2-48b7-ad89-30c1c51b3142" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_bb06a451-dc1c-4837-9de7-548c4acf7125" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeTaxDisclosureAbstract_0525b052-05b2-48b7-ad89-30c1c51b3142" xlink:to="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_bb06a451-dc1c-4837-9de7-548c4acf7125" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_610c52f8-78bb-4c3a-b94d-fa7fb63496ca" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_bb06a451-dc1c-4837-9de7-548c4acf7125" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_610c52f8-78bb-4c3a-b94d-fa7fb63496ca" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6fef3f0f-0a8c-4b59-bbb2-469dbb1392e2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_bb06a451-dc1c-4837-9de7-548c4acf7125" xlink:to="loc_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions_6fef3f0f-0a8c-4b59-bbb2-469dbb1392e2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_UnrecognizedTaxBenefits_2c55b78c-6365-44d8-a226-28904fcac0f5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_UnrecognizedTaxBenefits"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward_bb06a451-dc1c-4837-9de7-548c4acf7125" xlink:to="loc_us-gaap_UnrecognizedTaxBenefits_2c55b78c-6365-44d8-a226-28904fcac0f5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#CommitmentsandContingenciesDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/CommitmentsandContingenciesDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6e968cb7-c921-4537-8134-09c5186dbb30" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesTable_702aea73-e2f7-4f31-869b-0714e2e5fc81" xlink:href="arvn-20251231.xsd#arvn_CommitmentsAndContingenciesTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_CommitmentsAndContingenciesDisclosureAbstract_6e968cb7-c921-4537-8134-09c5186dbb30" xlink:to="loc_arvn_CommitmentsAndContingenciesTable_702aea73-e2f7-4f31-869b-0714e2e5fc81" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_CounterpartyNameAxis_e0489e43-ba61-412f-ae1a-671f5928f3a9" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_CounterpartyNameAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_702aea73-e2f7-4f31-869b-0714e2e5fc81" xlink:to="loc_srt_CounterpartyNameAxis_e0489e43-ba61-412f-ae1a-671f5928f3a9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RepurchaseAgreementCounterpartyNameDomain_902c71c5-4f4d-4913-8ec8-432456637083" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RepurchaseAgreementCounterpartyNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_CounterpartyNameAxis_e0489e43-ba61-412f-ae1a-671f5928f3a9" xlink:to="loc_srt_RepurchaseAgreementCounterpartyNameDomain_902c71c5-4f4d-4913-8ec8-432456637083" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_YaleUniversityMember_808244e1-dcf8-4da9-88b2-313426391518" xlink:href="arvn-20251231.xsd#arvn_YaleUniversityMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RepurchaseAgreementCounterpartyNameDomain_902c71c5-4f4d-4913-8ec8-432456637083" xlink:to="loc_arvn_YaleUniversityMember_808244e1-dcf8-4da9-88b2-313426391518" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfArrangementAxis_3d23324c-2d5d-4ba3-b839-0257ab8c1354" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfArrangementAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_702aea73-e2f7-4f31-869b-0714e2e5fc81" xlink:to="loc_us-gaap_TypeOfArrangementAxis_3d23324c-2d5d-4ba3-b839-0257ab8c1354" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02c620fb-19fb-473e-9018-292ea9f7d7a5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfArrangementAxis_3d23324c-2d5d-4ba3-b839-0257ab8c1354" xlink:to="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02c620fb-19fb-473e-9018-292ea9f7d7a5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_23e23400-d0d7-4dcc-930d-ac10673aa817" xlink:href="arvn-20251231.xsd#arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02c620fb-19fb-473e-9018-292ea9f7d7a5" xlink:to="loc_arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember_23e23400-d0d7-4dcc-930d-ac10673aa817" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_82ba5ffb-d359-408b-a45f-43ba12e9a9a1" xlink:href="arvn-20251231.xsd#arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02c620fb-19fb-473e-9018-292ea9f7d7a5" xlink:to="loc_arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember_82ba5ffb-d359-408b-a45f-43ba12e9a9a1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_fb7565c7-c600-472b-b700-ce9325098c19" xlink:href="arvn-20251231.xsd#arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02c620fb-19fb-473e-9018-292ea9f7d7a5" xlink:to="loc_arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember_fb7565c7-c600-472b-b700-ce9325098c19" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_SuccessBasedMilestonePaymentsMember_c4dba16c-d4e3-49d2-8907-abb744d30263" xlink:href="arvn-20251231.xsd#arvn_SuccessBasedMilestonePaymentsMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ArrangementsAndNonarrangementTransactionsMember_02c620fb-19fb-473e-9018-292ea9f7d7a5" xlink:to="loc_arvn_SuccessBasedMilestonePaymentsMember_c4dba16c-d4e3-49d2-8907-abb744d30263" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeAxis_0f204d28-f505-4c24-a46e-0820094f7ad0" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_702aea73-e2f7-4f31-869b-0714e2e5fc81" xlink:to="loc_srt_RangeAxis_0f204d28-f505-4c24-a46e-0820094f7ad0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_RangeMember_ad84248f-c007-4bf8-b436-4415f3340763" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_RangeMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeAxis_0f204d28-f505-4c24-a46e-0820094f7ad0" xlink:to="loc_srt_RangeMember_ad84248f-c007-4bf8-b436-4415f3340763" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MaximumMember_f31b0e7e-dfe5-44f4-af64-6e0e492eb924" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MaximumMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ad84248f-c007-4bf8-b436-4415f3340763" xlink:to="loc_srt_MaximumMember_f31b0e7e-dfe5-44f4-af64-6e0e492eb924" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_MinimumMember_b760430d-5eb6-4784-b64a-4e985ecc7ec4" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_MinimumMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_RangeMember_ad84248f-c007-4bf8-b436-4415f3340763" xlink:to="loc_srt_MinimumMember_b760430d-5eb6-4784-b64a-4e985ecc7ec4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_4c35f10c-3ee5-4103-b523-7aab7b33a645" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_702aea73-e2f7-4f31-869b-0714e2e5fc81" xlink:to="loc_srt_ProductOrServiceAxis_4c35f10c-3ee5-4103-b523-7aab7b33a645" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_ed96e9fc-5f42-4060-a337-060d0eeb7060" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_4c35f10c-3ee5-4103-b523-7aab7b33a645" xlink:to="loc_srt_ProductsAndServicesDomain_ed96e9fc-5f42-4060-a337-060d0eeb7060" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseFirstLicensedProductMember_d769e484-3329-4104-9762-79a60a3957fb" xlink:href="arvn-20251231.xsd#arvn_LicenseFirstLicensedProductMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ed96e9fc-5f42-4060-a337-060d0eeb7060" xlink:to="loc_arvn_LicenseFirstLicensedProductMember_d769e484-3329-4104-9762-79a60a3957fb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_LicenseSecondLicensedProductMember_2c6fa20a-1390-4626-84d9-aa499452b04e" xlink:href="arvn-20251231.xsd#arvn_LicenseSecondLicensedProductMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_ed96e9fc-5f42-4060-a337-060d0eeb7060" xlink:to="loc_arvn_LicenseSecondLicensedProductMember_2c6fa20a-1390-4626-84d9-aa499452b04e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:href="arvn-20251231.xsd#arvn_CommitmentsAndContingenciesLineItems"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesTable_702aea73-e2f7-4f31-869b-0714e2e5fc81" xlink:to="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LossContingencyAccrualAtCarryingValue_5336be66-2024-46a8-9ac4-5055e0c69f1f" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LossContingencyAccrualAtCarryingValue"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_us-gaap_LossContingencyAccrualAtCarryingValue_5336be66-2024-46a8-9ac4-5055e0c69f1f" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PaymentsForCollaboration_b47326dc-53f7-45b2-84b8-d24d395fc795" xlink:href="arvn-20251231.xsd#arvn_PaymentsForCollaboration"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_arvn_PaymentsForCollaboration_b47326dc-53f7-45b2-84b8-d24d395fc795" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_57530897-e618-4757-9f61-60703212bcbe" xlink:href="arvn-20251231.xsd#arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment_57530897-e618-4757-9f61-60703212bcbe" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_AnnualLicenseFeePayment_13ec3170-c36c-482e-a518-257b0565967b" xlink:href="arvn-20251231.xsd#arvn_AnnualLicenseFeePayment"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_arvn_AnnualLicenseFeePayment_13ec3170-c36c-482e-a518-257b0565967b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_NumberOfLicensedProducts_b1871f38-0ea0-4ee3-9bf6-13a4aea8f1a7" xlink:href="arvn-20251231.xsd#arvn_NumberOfLicensedProducts"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_arvn_NumberOfLicensedProducts_b1871f38-0ea0-4ee3-9bf6-13a4aea8f1a7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_RequiredMilestonePayments_41f182df-9011-462f-bc40-016aba405834" xlink:href="arvn-20251231.xsd#arvn_RequiredMilestonePayments"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_arvn_RequiredMilestonePayments_41f182df-9011-462f-bc40-016aba405834" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_PaymentsForRoyalties_3dd4d07e-805b-4ed7-816c-894106750fa6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_PaymentsForRoyalties"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_arvn_CommitmentsAndContingenciesLineItems_7fea21c4-8cd2-435c-8399-3e4ba08165d7" xlink:to="loc_us-gaap_PaymentsForRoyalties_3dd4d07e-805b-4ed7-816c-894106750fa6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareScheduleofBasicandDilutedLossperCommonShareDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#NetLossPerShareScheduleofBasicandDilutedLossperCommonShareDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShareScheduleofBasicandDilutedLossperCommonShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_8257bc18-2acb-418a-940b-6973984505ce" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_a7aed214-0780-4226-93b9-b7c9ca61d440" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8257bc18-2acb-418a-940b-6973984505ce" xlink:to="loc_us-gaap_NetIncomeLoss_a7aed214-0780-4226-93b9-b7c9ca61d440" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c492c035-5ef8-4356-bf93-38c776d1fa92" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8257bc18-2acb-418a-940b-6973984505ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_c492c035-5ef8-4356-bf93-38c776d1fa92" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd96a70f-55f7-45c4-b30a-1eaf1ecce121" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8257bc18-2acb-418a-940b-6973984505ce" xlink:to="loc_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_dd96a70f-55f7-45c4-b30a-1eaf1ecce121" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareBasic_c2bc50c6-5dad-401d-b146-dabd7324d88c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareBasic"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8257bc18-2acb-418a-940b-6973984505ce" xlink:to="loc_us-gaap_EarningsPerShareBasic_c2bc50c6-5dad-401d-b146-dabd7324d88c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareDiluted_1569778f-81c0-4c15-bdf3-d71f975747df" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareDiluted"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_8257bc18-2acb-418a-940b-6973984505ce" xlink:to="loc_us-gaap_EarningsPerShareDiluted_1569778f-81c0-4c15-bdf3-d71f975747df" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#NetLossPerShareAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShareAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_019b315c-efae-7207-b004-1fe910fce783" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019b315c-efae-7f45-82dd-19e4c9c8186a" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_019b315c-efae-7207-b004-1fe910fce783" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019b315c-efae-7f45-82dd-19e4c9c8186a" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightAxis_019b315c-efae-7ccd-af8e-1adf7dec8601" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019b315c-efae-7f45-82dd-19e4c9c8186a" xlink:to="loc_us-gaap_ClassOfWarrantOrRightAxis_019b315c-efae-7ccd-af8e-1adf7dec8601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightDomain_019b315c-efae-7f72-932a-4cf83ee83cd4" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightAxis_019b315c-efae-7ccd-af8e-1adf7dec8601" xlink:to="loc_us-gaap_ClassOfWarrantOrRightDomain_019b315c-efae-7f72-932a-4cf83ee83cd4" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_PreFundedWarrantMember_019b315c-efae-74e8-bbed-502428764286" xlink:href="arvn-20251231.xsd#arvn_PreFundedWarrantMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ClassOfWarrantOrRightDomain_019b315c-efae-7f72-932a-4cf83ee83cd4" xlink:to="loc_arvn_PreFundedWarrantMember_019b315c-efae-74e8-bbed-502428764286" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019b315c-efae-7ce7-ba28-e4bba4993b3b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_019b315c-efae-7f45-82dd-19e4c9c8186a" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019b315c-efae-7ce7-ba28-e4bba4993b3b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019b315c-efae-7672-aa12-942e8f7bb49d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_019b315c-efae-7ce7-ba28-e4bba4993b3b" xlink:to="loc_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_019b315c-efae-7672-aa12-942e8f7bb49d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EarningsPerShareAbstract_df205d37-3813-46ee-9bd2-bce80c3e0cb8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EarningsPerShareAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59c5b7a5-c962-493b-8d68-d4d597455e91" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_EarningsPerShareAbstract_df205d37-3813-46ee-9bd2-bce80c3e0cb8" xlink:to="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59c5b7a5-c962-493b-8d68-d4d597455e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_404a611a-2fec-4e85-bbc6-067452aea4de" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59c5b7a5-c962-493b-8d68-d4d597455e91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_404a611a-2fec-4e85-bbc6-067452aea4de" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc1a1f6c-7a72-4745-8743-dd18abad2db2" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_404a611a-2fec-4e85-bbc6-067452aea4de" xlink:to="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc1a1f6c-7a72-4745-8743-dd18abad2db2" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember_e0a1f65d-664b-4d5d-aeb1-f7156da20cff" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc1a1f6c-7a72-4745-8743-dd18abad2db2" xlink:to="loc_us-gaap_EmployeeStockOptionMember_e0a1f65d-664b-4d5d-aeb1-f7156da20cff" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestrictedStockUnitsRSUMember_88ab55b8-a872-4126-aaa8-b4bb731c59e0" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestrictedStockUnitsRSUMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesNameDomain_fc1a1f6c-7a72-4745-8743-dd18abad2db2" xlink:to="loc_us-gaap_RestrictedStockUnitsRSUMember_88ab55b8-a872-4126-aaa8-b4bb731c59e0" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0f4b6cc2-1f02-46df-a9b0-495219369deb" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_59c5b7a5-c962-493b-8d68-d4d597455e91" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0f4b6cc2-1f02-46df-a9b0-495219369deb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_21975872-d0f5-4a41-91d2-40d9049e1140" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_0f4b6cc2-1f02-46df-a9b0-495219369deb" xlink:to="loc_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_21975872-d0f5-4a41-91d2-40d9049e1140" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/RestructuringActivityDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#RestructuringActivityDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/RestructuringActivityDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c46aa-f82d-7e8f-beb6-43fb7d936b5e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedActivitiesAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c68f6-e714-75e1-91f5-a4c8a48d2bb9" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfRestructuringAndRelatedCostsTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringAndRelatedActivitiesAbstract_019c46aa-f82d-7e8f-beb6-43fb7d936b5e" xlink:to="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c68f6-e714-75e1-91f5-a4c8a48d2bb9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveAxis_019c68f6-e714-78a9-95b0-e4c86124df9c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c68f6-e714-75e1-91f5-a4c8a48d2bb9" xlink:to="loc_us-gaap_RestructuringCostAndReserveAxis_019c68f6-e714-78a9-95b0-e4c86124df9c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_TypeOfRestructuringDomain_019c68f6-e714-7b03-89f2-ddff108d533e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_TypeOfRestructuringDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveAxis_019c68f6-e714-78a9-95b0-e4c86124df9c" xlink:to="loc_us-gaap_TypeOfRestructuringDomain_019c68f6-e714-7b03-89f2-ddff108d533e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeSeveranceMember_019c68f6-e714-706d-9de1-e81c1d53dbea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeSeveranceMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_019c68f6-e714-7b03-89f2-ddff108d533e" xlink:to="loc_us-gaap_EmployeeSeveranceMember_019c68f6-e714-706d-9de1-e81c1d53dbea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_StockCompensationAndBonusExpenseMember_019c68f6-e714-7822-9cb7-49b7acbb8891" xlink:href="arvn-20251231.xsd#arvn_StockCompensationAndBonusExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_TypeOfRestructuringDomain_019c68f6-e714-7b03-89f2-ddff108d533e" xlink:to="loc_arvn_StockCompensationAndBonusExpenseMember_019c68f6-e714-7822-9cb7-49b7acbb8891" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationAxis_019c68f6-e714-765c-bed9-abc51a135e1e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c68f6-e714-75e1-91f5-a4c8a48d2bb9" xlink:to="loc_us-gaap_IncomeStatementLocationAxis_019c68f6-e714-765c-bed9-abc51a135e1e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeStatementLocationDomain_019c68f6-e714-7367-bfd9-29f78b301444" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeStatementLocationDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationAxis_019c68f6-e714-765c-bed9-abc51a135e1e" xlink:to="loc_us-gaap_IncomeStatementLocationDomain_019c68f6-e714-7367-bfd9-29f78b301444" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019c68f6-e714-76fc-a5c9-38a9bca91e2c" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpenseMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019c68f6-e714-7367-bfd9-29f78b301444" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpenseMember_019c68f6-e714-76fc-a5c9-38a9bca91e2c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019c68f6-e714-7655-9a50-c641022fb681" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpenseMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_IncomeStatementLocationDomain_019c68f6-e714-7367-bfd9-29f78b301444" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpenseMember_019c68f6-e714-7655-9a50-c641022fb681" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCostAndReserveLineItems_019c68f6-e714-76e8-9dc4-837b849d5fea" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCostAndReserveLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfRestructuringAndRelatedCostsTable_019c68f6-e714-75e1-91f5-a4c8a48d2bb9" xlink:to="loc_us-gaap_RestructuringCostAndReserveLineItems_019c68f6-e714-76e8-9dc4-837b849d5fea" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019c68f6-e714-7f78-816c-ecfb86b87c6e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c68f6-e714-76e8-9dc4-837b849d5fea" xlink:to="loc_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent_019c68f6-e714-7f78-816c-ecfb86b87c6e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringCharges_019c68f6-e714-7378-ba31-0a4459f7e344" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringCharges"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c68f6-e714-76e8-9dc4-837b849d5fea" xlink:to="loc_us-gaap_RestructuringCharges_019c68f6-e714-7378-ba31-0a4459f7e344" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringReserve_019c68f6-e714-7c66-9c64-b48799928136" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringReserve"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c68f6-e714-76e8-9dc4-837b849d5fea" xlink:to="loc_us-gaap_RestructuringReserve_019c68f6-e714-7c66-9c64-b48799928136" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019c6900-1c40-7eec-af80-7ef61f6a9f09" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_RestructuringCostAndReserveLineItems_019c68f6-e714-76e8-9dc4-837b849d5fea" xlink:to="loc_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration_019c6900-1c40-7eec-af80-7ef61f6a9f09" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#SegmentInformationAdditionalInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_7e0c972e-8220-4fc3-bd85-894ab77ce5bd" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfOperatingSegments_86f9c4ec-c693-4db4-91a1-f299b692ccd6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfOperatingSegments"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7e0c972e-8220-4fc3-bd85-894ab77ce5bd" xlink:to="loc_us-gaap_NumberOfOperatingSegments_86f9c4ec-c693-4db4-91a1-f299b692ccd6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NumberOfReportableSegments_59b3fadb-d7a9-4189-b6cb-035802800881" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NumberOfReportableSegments"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7e0c972e-8220-4fc3-bd85-894ab77ce5bd" xlink:to="loc_us-gaap_NumberOfReportableSegments_59b3fadb-d7a9-4189-b6cb-035802800881" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_DepreciationAndAmortization_019c46ae-de77-7cbf-ac21-9db269b8aec5" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_DepreciationAndAmortization"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_7e0c972e-8220-4fc3-bd85-894ab77ce5bd" xlink:to="loc_us-gaap_DepreciationAndAmortization_019c46ae-de77-7cbf-ac21-9db269b8aec5" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails" xlink:type="simple" xlink:href="arvn-20251231.xsd#SegmentInformationScheduleofFinancialInformationDetails"/>
  <link:presentationLink xlink:role="http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingAbstract_9e6a0b72-209b-4016-9f8b-c8f26c5baec7" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5193414e-3e38-4c06-82d4-4a81bdd32a95" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingAbstract_9e6a0b72-209b-4016-9f8b-c8f26c5baec7" xlink:to="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5193414e-3e38-4c06-82d4-4a81bdd32a95" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StatementBusinessSegmentsAxis_fe035549-a54b-4743-bfc5-02bae5208080" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StatementBusinessSegmentsAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5193414e-3e38-4c06-82d4-4a81bdd32a95" xlink:to="loc_us-gaap_StatementBusinessSegmentsAxis_fe035549-a54b-4743-bfc5-02bae5208080" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentDomain_0b3769c9-3ccf-4483-8ef8-aea5e65e3800" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_StatementBusinessSegmentsAxis_fe035549-a54b-4743-bfc5-02bae5208080" xlink:to="loc_us-gaap_SegmentDomain_0b3769c9-3ccf-4483-8ef8-aea5e65e3800" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ReportableSegmentMember_96cb4336-94c6-4a83-94f0-8038eb303f36" xlink:href="arvn-20251231.xsd#arvn_ReportableSegmentMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentDomain_0b3769c9-3ccf-4483-8ef8-aea5e65e3800" xlink:to="loc_arvn_ReportableSegmentMember_96cb4336-94c6-4a83-94f0-8038eb303f36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductOrServiceAxis_d644cc42-04b9-418b-8ee0-ccb6541b2314" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductOrServiceAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5193414e-3e38-4c06-82d4-4a81bdd32a95" xlink:to="loc_srt_ProductOrServiceAxis_d644cc42-04b9-418b-8ee0-ccb6541b2314" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:href="https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd#srt_ProductsAndServicesDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductOrServiceAxis_d644cc42-04b9-418b-8ee0-ccb6541b2314" xlink:to="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV471Member_9c92c626-6b66-42bb-9c79-ad20cdb20990" xlink:href="arvn-20251231.xsd#arvn_ARV471Member"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_ARV471Member_9c92c626-6b66-42bb-9c79-ad20cdb20990" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV102Member_cf0a7f7d-ea57-4f36-bd47-856619290955" xlink:href="arvn-20251231.xsd#arvn_ARV102Member"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_ARV102Member_cf0a7f7d-ea57-4f36-bd47-856619290955" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV806Member_019c46ac-dc8a-7624-afbf-f35d5dae0e7b" xlink:href="arvn-20251231.xsd#arvn_ARV806Member"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_ARV806Member_019c46ac-dc8a-7624-afbf-f35d5dae0e7b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV393Member_7d536514-2046-4654-8198-f8a9316ea72b" xlink:href="arvn-20251231.xsd#arvn_ARV393Member"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_ARV393Member_7d536514-2046-4654-8198-f8a9316ea72b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV110Member_e27a5c24-bac3-4e17-b0df-fb02b06a6e18" xlink:href="arvn-20251231.xsd#arvn_ARV110Member"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_ARV110Member_e27a5c24-bac3-4e17-b0df-fb02b06a6e18" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ARV766Member_d1f529cc-f86c-42e0-b04c-25f76120ee98" xlink:href="arvn-20251231.xsd#arvn_ARV766Member"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_ARV766Member_d1f529cc-f86c-42e0-b04c-25f76120ee98" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_OtherProgramsMember_dd3ed1d8-fe33-46fc-8af6-41f05456a731" xlink:href="arvn-20251231.xsd#arvn_OtherProgramsMember"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_srt_ProductsAndServicesDomain_b3b4f41f-2892-4aa1-9029-228ac8c06e36" xlink:to="loc_arvn_OtherProgramsMember_dd3ed1d8-fe33-46fc-8af6-41f05456a731" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingInformationLineItems_3b6d5b89-419d-47da-b58c-6998ba0bb235" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingInformationLineItems"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable_5193414e-3e38-4c06-82d4-4a81bdd32a95" xlink:to="loc_us-gaap_SegmentReportingInformationLineItems_3b6d5b89-419d-47da-b58c-6998ba0bb235" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_Revenues_2b9ae023-0e23-4eca-a552-03c88105cb13" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_Revenues"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b6d5b89-419d-47da-b58c-6998ba0bb235" xlink:to="loc_us-gaap_Revenues_2b9ae023-0e23-4eca-a552-03c88105cb13" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b6d5b89-419d-47da-b58c-6998ba0bb235" xlink:to="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific_bb6f6c7e-2cbf-4b4a-95ee-998da2c9358e" xlink:href="arvn-20251231.xsd#arvn_ResearchAndDevelopmentExpenseProgramSpecific"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_arvn_ResearchAndDevelopmentExpenseProgramSpecific_bb6f6c7e-2cbf-4b4a-95ee-998da2c9358e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_9c231d38-ed2c-40b6-a057-7d6045a62577" xlink:href="arvn-20251231.xsd#arvn_ResearchAndDevelopmentExpenseNonProgramSpecific"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific_9c231d38-ed2c-40b6-a057-7d6045a62577" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_LaborAndRelatedExpense_9d7eda2b-4d49-46b7-b5a4-8a5ee7af635e" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_LaborAndRelatedExpense"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_LaborAndRelatedExpense_9d7eda2b-4d49-46b7-b5a4-8a5ee7af635e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_OtherResearchAndDevelopmentExpense_f598497b-7c0c-436e-ac8b-7ec84f10b9b8" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_OtherResearchAndDevelopmentExpense"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_OtherResearchAndDevelopmentExpense_f598497b-7c0c-436e-ac8b-7ec84f10b9b8" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ResearchAndDevelopmentExpense_50e8f4e7-2476-4605-be5c-3d6415f225d6" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ResearchAndDevelopmentExpense"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_ResearchAndDevelopmentExpense_50e8f4e7-2476-4605-be5c-3d6415f225d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/totalLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_GeneralAndAdministrativeExpense_0ece782a-e264-4e2a-85b1-25daa88b7b63" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_GeneralAndAdministrativeExpense"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_GeneralAndAdministrativeExpense_0ece782a-e264-4e2a-85b1-25daa88b7b63" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_SegmentReportingOtherItemAmount_5b5b5472-b8d2-41a7-afb2-eb2934aeae35" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_SegmentReportingOtherItemAmount"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_SegmentReportingOtherItemAmount_5b5b5472-b8d2-41a7-afb2-eb2934aeae35" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeTaxExpenseBenefit_5ff07229-047f-48a8-843b-ee3f461b3117" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeTaxExpenseBenefit"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_IncomeTaxExpenseBenefit_5ff07229-047f-48a8-843b-ee3f461b3117" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_IncomeLossFromEquityMethodInvestments_71566b60-b24a-4de2-b824-eae64428648d" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_IncomeLossFromEquityMethodInvestments"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract_47e5ba8e-6464-4c2f-97a4-b49a30d1ed15" xlink:to="loc_us-gaap_IncomeLossFromEquityMethodInvestments_71566b60-b24a-4de2-b824-eae64428648d" xlink:type="arc" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_InvestmentIncomeInterest_ccddcf16-04c1-408a-bb0d-cdbcc51c863b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_InvestmentIncomeInterest"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b6d5b89-419d-47da-b58c-6998ba0bb235" xlink:to="loc_us-gaap_InvestmentIncomeInterest_ccddcf16-04c1-408a-bb0d-cdbcc51c863b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_NetIncomeLoss_dadce0b5-7c37-4a7a-ab7c-c2c03dd6e39b" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_NetIncomeLoss"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_SegmentReportingInformationLineItems_3b6d5b89-419d-47da-b58c-6998ba0bb235" xlink:to="loc_us-gaap_NetIncomeLoss_dadce0b5-7c37-4a7a-ab7c-c2c03dd6e39b" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#AwardTimingDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgDiscLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgDiscLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiDiscTextBlock"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiDiscTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMethodTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgPredtrmndFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgPredtrmndFlag"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgPredtrmndFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgMnpiCnsdrdFlag"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgMnpiCnsdrdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardTmgHowMnpiCnsdrdTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardTmgHowMnpiCnsdrdTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MnpiDiscTimedForCompValFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_MnpiDiscTimedForCompValFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTableTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscTable"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_AwardTypeAxis" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_AwardTypeAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardsCloseToMnpiDiscTable" xlink:to="loc_us-gaap_AwardTypeAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_AwardTypeAxis" xlink:to="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_EmployeeStockOptionMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_EmployeeStockOptionMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_EmployeeStockOptionMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:href="https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd#us-gaap_StockAppreciationRightsSARSMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="loc_us-gaap_StockAppreciationRightsSARSMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardsCloseToMnpiDiscIndName"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardsCloseToMnpiDiscIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardUndrlygSecuritiesAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardUndrlygSecuritiesAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardExrcPrice" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardExrcPrice"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardExrcPrice" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AwardGrantDateFairValue" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AwardGrantDateFairValue"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_AwardGrantDateFairValue" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_UndrlygSecurityMktPriceChngPct"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AwardTmgDiscLineItems" xlink:to="loc_ecd_UndrlygSecurityMktPriceChngPct" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ErrCompDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/ErrCompDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RecoveryOfErrCompDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompRecoveryTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompRecoveryTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompRecoveryTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDateAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDateAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_RestatementDateAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ErrCompRecoveryTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonNeosMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonNeosMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllIndividualsMember" xlink:to="loc_ecd_NonNeosMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDeterminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDeterminationDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDeterminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompAmt"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ErrCompAnalysisTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ErrCompAnalysisTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ErrCompAnalysisTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_StkPrcOrTsrEstimationMethodTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_StkPrcOrTsrEstimationMethodTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingAggtErrCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingAggtErrCompAmt"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingAggtErrCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtErrCompNotYetDeterminedTextBlock"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_AggtErrCompNotYetDeterminedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryIndName"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryIndName"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OutstandingRecoveryCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OutstandingRecoveryCompAmt"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_OutstandingRecoveryCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_RestatementDoesNotRequireRecoveryTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_RecoveryOfErrCompDisclosureLineItems" xlink:to="loc_ecd_RestatementDoesNotRequireRecoveryTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#PvpDisclosure"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/PvpDisclosure" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PayVsPerformanceDisclosureLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ExecutiveCategoryAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ExecutiveCategoryAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_ExecutiveCategoryAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllExecutiveCategoriesMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllExecutiveCategoriesMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_ExecutiveCategoryAxis" xlink:to="loc_ecd_AllExecutiveCategoriesMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_PeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllExecutiveCategoriesMember" xlink:to="loc_ecd_NonPeoNeoMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAxis"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_AdjToCompAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllAdjToCompMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllAdjToCompMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AdjToCompAxis" xlink:to="loc_ecd_AllAdjToCompMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AggtPnsnAdjsSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsSvcCstMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnAdjsPrrSvcCstMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AggtPnsnAdjsSvcCstMember" xlink:to="loc_ecd_PnsnAdjsPrrSvcCstMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_AllAdjToCompMember" xlink:to="loc_ecd_EqtyAwrdsAdjsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsMember" xlink:to="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember" xlink:to="loc_ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureAxis"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PvpTable" xlink:to="loc_ecd_MeasureAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PvpTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PvpTableTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PvpTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NamedExecutiveOfficersFnTextBlock"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NamedExecutiveOfficersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupIssuersFnTextBlock"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupIssuersFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_ChangedPeerGroupFnTextBlock"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_ChangedPeerGroupFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoTotalCompAmt"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoActuallyPaidCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoActuallyPaidCompAmt"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoActuallyPaidCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToPeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToPeoCompFnTextBlock"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToPeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgTotalCompAmt"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgTotalCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonPeoNeoAvgCompActuallyPaidAmt"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonPeoNeoAvgCompActuallyPaidAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToNonPeoNeoCompFnTextBlock"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToNonPeoNeoCompFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EquityValuationAssumptionDifferenceFnTextBlock"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EquityValuationAssumptionDifferenceFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsNetIncomeTextBlock"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsNetIncomeTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnVsPeerGroupTextBlock"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnVsPeerGroupTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CompActuallyPaidVsOtherMeasureTextBlock"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CompActuallyPaidVsOtherMeasureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TabularListTableTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TabularListTableTextBlock"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TabularListTableTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TotalShareholderRtnAmt"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_TotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeerGroupTotalShareholderRtnAmt"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeerGroupTotalShareholderRtnAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_CoSelectedMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_CoSelectedMeasureAmt"/>
    <link:presentationArc order="23" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_CoSelectedMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_OtherPerfMeasureAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_OtherPerfMeasureAmt"/>
    <link:presentationArc order="24" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_OtherPerfMeasureAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AdjToCompAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AdjToCompAmt"/>
    <link:presentationArc order="25" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_AdjToCompAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PeoName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PeoName"/>
    <link:presentationArc order="26" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PeoName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MeasureName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MeasureName"/>
    <link:presentationArc order="27" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_MeasureName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonGaapMeasureDescriptionTextBlock"/>
    <link:presentationArc order="28" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_NonGaapMeasureDescriptionTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Additional402vDisclosureTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Additional402vDisclosureTextBlock"/>
    <link:presentationArc order="29" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_Additional402vDisclosureTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_PnsnBnftsAdjFnTextBlock"/>
    <link:presentationArc order="30" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_PnsnBnftsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_EqtyAwrdsAdjFnTextBlock"/>
    <link:presentationArc order="31" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_PayVsPerformanceDisclosureLineItems" xlink:to="loc_ecd_EqtyAwrdsAdjFnTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingArrangements"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingArrLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingArrLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrByIndTable" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrByIndTable"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TradingArrByIndTable" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TradingArrAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TradingArrAxis"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_TradingArrAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllTradingArrangementsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllTradingArrangementsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrAxis" xlink:to="loc_ecd_AllTradingArrangementsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_IndividualAxis" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_IndividualAxis"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_TradingArrByIndTable" xlink:to="loc_ecd_IndividualAxis" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_AllIndividualsMember" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_AllIndividualsMember"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_IndividualAxis" xlink:to="loc_ecd_AllIndividualsMember" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_MtrlTermsOfTrdArrTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_MtrlTermsOfTrdArrTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndName" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndName" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrIndTitle" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrIndTitle"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrIndTitle" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrAdoptedFlag"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrAdoptionDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrAdoptionDate"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrAdoptionDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_Rule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_Rule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_NonRule10b51ArrTrmntdFlag"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_NonRule10b51ArrTrmntdFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrTerminationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrTerminationDate"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrTerminationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrExpirationDate" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrExpirationDate"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrExpirationDate" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrDuration" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrDuration"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrDuration" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_TrdArrSecuritiesAggAvailAmt"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingArrLineItems" xlink:to="loc_ecd_TrdArrSecuritiesAggAvailAmt" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="simple" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#InsiderTradingPoliciesProc"/>
  <link:presentationLink xlink:role="http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTradingPoliciesProcLineItems"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcAdoptedFlag"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcAdoptedFlag" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:href="https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd#ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_ecd_InsiderTradingPoliciesProcLineItems" xlink:to="loc_ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>arvn-20251231_g1.jpg
<TEXT>
begin 644 arvn-20251231_g1.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" $- BD# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"]_X2WQ)J=UXIOKLZ@#KD5H\HB@FVI'-(H6-045B.Y'J:Z/QEXM\:W'BC6=
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M^OYC=2=6+3DW_7Z?D<K\;]7T^R\!:E;7.NMHMU.BBW\B0">9MPQ&J;@6#="
M1P3S7SAX-O;KP1>1WNF3>5?H"(XBB%0&&#USP3Z=,5U/[4#:!XW\1:39Z>\D
M_B'3)S!=NN]1;0XW=" I);'.?I6);:59ZK<0RI(KP6PV&.,'YLCJ&]CVKNMH
M?.XFL_:V70^B/A_\2/\ A)?(T[4XX[36C")@L3[HYE &64]CG.4Z@5W5?-GV
M==.BCGM)9+:[@_U,]LY5SN&,!AR=W3\:^AM'BGMM)LXKJ5YKE(4621^K-@9)
M_&I/0P]5U5J7J*I:GJUIHUE+>7US%:6L0R\TS!54>Y-<->?$G7]8!'A+PA=Z
ME$?NW^J.+*W;W4-\[#WP*VIT9U=8[=V[+[V:5*T*>DM^RU?W(]&HKR.Z\2?&
M"SS)_P (MH=S&.3';W;%_P!6%9MO^T?-HMZMEXM\*WVB3G^*/YA]0& R/H37
M9'+Z\U^[M+T:;^Z]SD>/HP?[R\?5-+[SVZBL3PSXRT;QA9_:-(U"*]0#YE4X
M=/\ >4\C\16U7GRC*$G&2LT=\91FN:+NA:***DH**** "BBB@ HHI#0!F>)]
M>@\+^']1U:Y!:"R@>=E!P6VC.!GUZ5\FZ]\4=3^+GBXYLK/3[.TC*V^V3?(P
M/*[CQNR<'&,#'O7HG[4_C.Y&F)X-MHC:MJ,2W+WTS[49$?)1 /O'(!(;C!'7
MMX;X+\C1+>74M0@B,LD1,;R/M\P*/X2>F,_C6D5I<\+'8AJ7LHO3J=+X>\=:
MCH.LG3HM9>VDFVYDM9#&<J3PZ<\CKSV-?27PW^(8\2*VFZC)$NKP# *' NE
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MQM\T>;1S.NY<ME+\SZW#9'7.>E>-^//VDO#>C:;J5O8+>:E?(9;4^5&8HXY
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MHP*6B@!#7GGB'XNZ=X?^(1\.7CVUG:6NEG5;_4+R5XQ$A8JBI\A5B2#G+#J
M,DXKT,]*X+QO\*D\9:A?7HU66PN)K.U@A*0JXAEM[G[3%*0>&&_ *G@@=12$
MQ\WQ3\ ZQI^FF;6M/O+;4[EK:UAE3>99D(#)Y9&0R[E)! (!!Z<U3^(OQ/\
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M))/H,  CT+2]1L];TZUU"QN([RRNHUFAN(6W)(C#*L#W!%3B"-79Q&H=L!F
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M "T444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %(>12T4 5C;P6LDUWY<:R,O[R4*-Q [$]<"OES]G.)O%7QFUW
MQ!*=S+'<7 ;_ &I9,#_QW-?1WCV^.F^"-?N@=IBL)V!]#L.*\6_9"TL1:9XA
MOBOS/+# &]E4L?\ T(5]!@W[/ 8FIU?+'[WJ>%BU[3&X>GT5Y'O.DZ+9Z'#+
M#90+;Q2S/.R)P-[G+$#MD\U>HHKP&VW=GN))*R"BBBD,**** "BBB@ HHHH
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MUBYX W5\A^&OB-KNE:WJ-E?0O#I]\-LMK=+CRI">"-QXX(X'M7UK^RM^S?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %13V\=RFV1
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M,=S6,P)@)[[<<QGZ9'M6]151DX[$RBI;F&?$HM 1JEG/IQ'60KYD/_?:]/\
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MAZ=/VEJR;72QQB:I/X>\">&I-.TC2;36=/EGGN;PV:2SQ)Y@\O[XP"<DYY/
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M:W[:E!%H\=K>7%W/.DT<]N;=XDD5H3'D;3,N0<,,K@,"2,XXB459)6V^6O\
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MT7S1V2ZK7J_(\Z\5:2;Z6Z9XKFYMS"^(8KA4D7"@'YMIQWR,<U[=^S;)H_\
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MN]U$ F9$ <90EA\PQGCUXKAM1^'VF0:7JIGO[R6*YUI/$-TL:J[RO"T;K"%
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MEM8&DC8QI'E9MOFA,1C"[L#D=.*]"%,08I:**!A1110 4444 %%%% !1110
M4444 %%%% !1110 R6&.>,I*BR(>JN,@_A3L4M% "44M% "8HQ2T4 )12T4
M<SXR\477A];*VL=&O-;O;URB16P 5% &YG=OE7 /&>M>:6WP>\3WNM7L,_B"
MYBT&.]BE^RW 'EW:#'F*J1L!&A' &,YYKW&DQ5*36Q<9..QR/AG1K'P5K-UH
M^FV%ZMK?M)J)E"#[+;M\JF,'L206 ^M=<.E&*6I);OJPHHHH$%%%% !1110
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M#6OELDRE&DXRA5MK*P/(Y_3O@.]YX@SK6D:*^CGQ)?ZW<K&=YOU='6U$B>6
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L4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>arvn-20251231_g2.jpg
<TEXT>
begin 644 arvn-20251231_g2.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %1 DD# 2(  A$! Q$!_\0
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MQJ1L+(E+>*<($615_O!0!NZGK4QH8GVC4I/ETZ^G]7T_RJ5;#\GNQUUZ>O\
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M?3_V;?"$GC^97T[4YO"%S8Z/=PRW&L);/8M?#Y8F<1,TSY!V@* <')%?./\
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M):X2"X91*3U+8/)/K7J6D>'M.\0_M-:_8ZA:QW4"7]_-%8M\J7$J;VCB/L6
MX[XQ6ROA#4?BK9>%CJUWIUE;7FK-8S6]IHHL;BR=86D:(-@;UP,#.>: /%M.
M\8Z]H]A]AL-:O[.RWF3[/!<,B;B,$X!QR*2R\6ZYIMU;7-IK%[;7%M#]GADB
MG96CBSG8/]G)Z=*]5C^%W@>^UAS;ZA>O8P:1>7]W:6MRLTD,D!& )2BAMP/3
M'!XJU%\%_"\U]<ZHMQ>1Z F@VNLK975TL4H,SE-C3!" JX)R%[@4 >2_\)QX
MB\N^C_MW4-E^2UTOVAOWY(P2W//  ^G%8E=KXQ\#Z3I>H:W)HOB33[O3+-U^
MSQ7$Q6ZG4JIPJ[?FP6(SQG%<50 4444 /;[Q^M>O_LH?\EJTC_KE/_Z*:O(&
M^\?K7K_[*'_):M(_ZY3_ /HIJ /$OV\O^3F?$W_7*U_])XZ;^SO\ -%^*^CQ
MMKD.H63ZG=SV.GZI'J$,,2R1Q;R$@92\[#C< 5 !ZDT[]O+_ ).9\3?]<K7_
M -)XZ\I\*?%OQKX$TU]/\.^*-2T:Q>;SS;VDVU/,QC<!C@D<''7O7Z?2A4J8
M&G&D[/E7Y'YU5G3AC*CJJZN_S/HGX9?"[PQX*\-W4SV^L:EXFU7X?:AK4EX\
M2'38XW!41+D9$B[<[L]3C%<UK_[-&@Z=H<>O:?/JNHZ5KS:-!X7MX'0SW<UT
M-UPA8@*QC".!T&2N>]>/6?QA\<Z?X97P[;>+-5AT$))$-.2X/D[) 0ZX_NG)
MXZ<\5G2_$+Q-)I&AZ6^OW_\ 9VARF;2[;SB$LY"<[H\?=.::PV(4W+GW?X?U
MIZ7$Z]!Q4>3;\_Z_&Q](7O[+O@MM9\./]HU73=-O(=:6_M8=0AOY89;"(/E9
M515W$Y#)C@C&:E\$?!_X8PZDNI-I&M:UH6M^ ;KQ#9V-Y/']IM)(G*/AE7!?
MC*G&%R<@UX#JOQN\?Z[>17>H>+]5N[B)9DCDDF&469-DP'' =>#ZU1T?XH>+
MO#U]H]YIGB/4+&ZT>V:RT^6&7!M8&)+1)_LDDG!S4_5L2XV=3\7Y_/MKY%?6
M,.I74/P7E\NY[/H_[.>@:]\(M0UOR=5T77H-+AUJW-W?PSFXMY)Q&H^RHNY5
M(/RN6RQ!^45U/B/]E?P#!XV\+^![#5=1L_$>HZM+:S2SWT4X>RAA,CW C5!Y
M;NP*+&QR".<UX#9_'3QU:6-MI\OB?4+O1X&!;3+B;,$J>8)#&XZE"PZ9[G&*
M[/XJ_M3:U\2;*"&VL'T.XCU;^VA>B_DN)X)]NT+;NP!AC'7:/SJ)4<9SZ2T=
M^NW;??O8J-7"<FL==.F_?;;U.F@^"?PKN?'.C6B^)V6SOK"Y=M*&J(^R^CD"
M10/>B+8BR@YW%/E(VUQO@OX,66L?%;QKH6N0:GING^%;.]U&ZTVW=);Z18,?
MN%<#:6.1\X&,<XKFI/CS\1)O$,6NOXQU-M8BMS:I=EUW+$3DIC;C!(!Z=:Y_
M2O'/B+0_%!\2:?K=]:>(#(TK:E',?/9V^\2W?/?/6NF-'$)-.?3OU^[\=S"5
M6@VFH]?P^_\ X![W/^S-X=\1VI'A>?5H]7UGPU;>)-"TB_96F0?:/*N(9=JC
M?A2'5@!P#Q6K:?LT?#B&;7;Z_P#$MQ%X>M_$)\-07DE_' 89(X5,UP<H?-_>
M;@L0VY /S<5\_K\6?&B>,O\ A+5\4:F/$^PQC5?//GA",%0>@7!Q@#%)X5^*
M_C+P+_:!T#Q-J.DC4&,EV()>)G.?F8$$;N3\W7GK6;P^*M95/Z];>6GSN6J^
M'O=T_P"O3^NECN/'OPV\%^!O@[X:U@7.JZGXH\0-=K:SPNBV");W31&0J1N.
M] ,#L>3Z5T7@_P" OACQ?X'\$ZCILM]JEW?:E9VOB"YAO$C_ +*\^8QB,VQ3
M<0PP5F#$$\8KPW4_$VK:UING:??ZC<7ECIPD%G;S/E8/,;?)M]-S')]ZVXOB
MYXU@T72M(B\4:E'IFE2QSV-JDN$MY$.8V7C^$\C.<=JVE1K\B49ZW;^71?=^
M/<RC5H\UW'2R7S/H?1OV=?A/K%_H-M%<^+0=5\17WA.,O+  +J#D73<<)T'E
MCD^HKD]"_9ST>_\ A9KFHZC'J-AKUKI-_J]G>/?P^7=QVTI3Y;0*7\ML8\PL
M"#VQ7C=K\2O%=E+:2V_B&_ADM-0DU6W99.8KR3_63KQ]]NYJW%\8/'$'AR30
M(_%6J+HDJRH]B)OW;++GS%(Q]ULDD=,FL?J^)6U3JM[^?_ -?;X=[P_K3_@G
MT/\ M!6%K!\._B0\5K#$R:GX8"LD:J5!TX$@8'&3R?6N6^"7P%\#^/?#7@A]
M?NM<AUCQ9J6HZ9;/I[QB"V:"-765PPRW7&T=<]1BO$=7^('B77K.\M-2UR\O
M;:]>"2YBFDRLS0IY<);U*)\H]J-'^(/B;P\FDIIFNWMBNDSRW6GB"3'V660!
M9'3T+  &G'"U84?9QG9]_P#MVWYZB>(I2J\\HW7;_MZ_Y:'N]E^SQX(\1KX=
MU[2;GQ!%X:GT75=2O;&8QR7TSV#[&6$J-J^9D'&#M&>M;NA_"O0O#_@[QG?Z
M$+F+3?%/@*+4K6SUG:]SI[-?1Q$,X R.X; R,U\X:7\2O%FARZ/)I_B+4+)]
M':5]/:";;]E,IW2[/]X\D'(-.U/XH>+M:OM7O;_Q'J-Y=:O;"SOY99LFX@!#
M")O]D$ @# I2PV(D[.>G_!O_ ):^5AK$4$KJ&O\ P+?YZ'OWB_\ 98\&:;XN
MTGP;I_BIX/$G]NVFCW*RW*3O<QRKEYUA51Y)0]$9FW @YKC+WX5^#]>T[XCW
M?AO3_$^GOX7TU9;>UU9D>2XG%VL#OA4!*;3G;_">YKSS6?C!XW\0Z;INGZGX
MJU2]M--D26SCEGR8'081@WWLKV))Q5R3X[_$6;Q&/$#^--7;6Q:FR^W>?^\\
M@G)CZ8P3STZ\]:<:&*BE>=WZ^?IU_#H*5;#MNT++T\O7I^/4^@YO@-IVEZ7X
MP^'UA/);K?ZUX5A%[?JK2V[7,;M)S@8P6/'L :\C^/\ \,/!OP_L;1_#.L-/
M?I?7.GWNF37J74B"/&R<LB*$+<@QG)4CJ:X/4OB9XMUDWAO_ !'J-VUX]O+<
M-+.2TKP#$#,>N4'W3U%'C3XG>+/B*EHGBCQ!>ZZMH"(!>.&V9QD\ 9)P,DY-
M.CAZ\)J4IW77[DOT%5KT9P<8PL^GWMGT;XQ^$GA"2+4/$/BZYUF\M=&T+PV4
M@TA;>W>7[4C*R'"!>,#YR"W7.36Q#\(/!7A/PWXG\"^(3JM]I2_$2STRSNM/
M,4=U^^M1L,CL#\JA\D <D=LU\KWWQ)\4ZK97-I=^(+ZYM;B*V@FA>7*R);_\
M>ZGVCR=OI4M[\4O%VI3RRW7B34+B:2_CU61WER6NXU"QSGC[ZJ  ?2LOJE=J
MSG_2MM^/WFOUJBG=0_K7_@?<?5?PI^&EKX3U;PUI-U/)J=K;:[XJTQD6TB9V
M6&SVAU^7<SD<A68@'H!7%Z;\*/#>C:)<>(?#SZSI^CZUX$U34&T[68X9+R-H
M)5B<;BF 'P2& !'8UX9!\6O&EK>17</BC4X;J*YN+V.9)L.D\XQ/(".C..":
M-9^+/C3Q#J5UJ&I^)]2OKVZL6TR:::;)>U;[T)[;#CD#K0L)7YK\ZUW^]O:W
MGOY>8GB:/+;EVV^Y+]#Z'^(_P:^',OBS4[VRT36M,T/P[X/LM=O=/TZ5#)J!
ME6-4$;%3L(WDR/@Y(R *RM7_ &>? 'A#3?%WB+6+GQ!=:'IVDZ1K%EI]M)$E
MXHO?,'D3,5QN4J/FP..W->*V7QJ\?:=<Z1<6WB_5H9](MVM+"19^;> XS&,C
ME>!P<]!69J7Q#\3ZPNMK?Z_?WBZXT;ZF)YBWVPQG,?F9Z[2>!VJH8;$)*+J:
M:=7W5_UU\[=!2Q%!W?)KKT79_P# T\K]3T;XA_![1M-^&/ACQ%X.BU#7_MDD
M-O?7Z7*R>7=O$7:U:U""2-UQ\K98. 3QQ7C+*58JP(8'!!Z@UZ-X=_:#\<:!
MJ6B7<NM7&JKH<;KI=M>OF&TD,1B64*,;F13\N[/0=J\ZDD>:1Y)&+R.Q9G;J
MQ)R2?QKMH1JPO&IKYG)6E3E9PT&U^E_["/\ R:EK?_7Y?_\ HE*_-"OTO_81
M_P"34M;_ .OR_P#_ $2E>/GO^Z?-'KY'_OB]/\CYSF_UK_[QIE/F_P!:_P#O
M&F5\@?T":_@^".Y\7:'#+&)8I+Z!'C89# R#((KZ%U63PQ?_ !-T#1)DT74M
M9C\3R*$TZQ$2060W 03?*%=@V.QZ=:^:+:YEL[F*X@D:*>)Q)'(IP58'((]P
M:MQ>(-2@US^V8[Z9-6\XW'VP-^\\TG)?/KDFHE&YR5J#JRNG;1GT+<>&=$\5
M>)OA\+NWT[5TO9KYY+_3K06<%UY0)CM608^8%<$X&0>]<O'XIO;_ .'_ (@\
M1ZGX?TK3]4T34((M-F_LN.-"9"RR6[)C#@*,Y()%>2Q^)M6ALHK2/4KF.VAN
M3>QQH^ DY&#(N.0WN*L^(_''B'Q>D*:WK-YJD</^K2XDRJGUQTS[]:GD9BL-
M)-)NZ_X+?XK1GTA=6DEY\1M;N4T/19=.\/6-M):VC6L%O'+<W$:9#N=H.%WL
M 3Z8KE;_ ,$P?#N_^)>K:?IMMJ=_I[VTVE17$"W$<-M<,6,H3D-M^Z#R!BO$
M]5\6:UKEM/;ZCJES>P3R)++',^5=T38C'U(7@>U6;'Q_XETV_M;VUUV]M[NU
MMUM(9DEPR0CI'[J,]#FDH-$1PM2*TDMEIZ6_/7[SM8?"]IXX\+Z_K\]F1XIB
M#SRZ99%;)+>!$4^>(67]XI.=P4C'4#FO*QR*Z.Z^(_BF^L[ZUN-?OIK>^8O<
MH\N?-) !R>N#@<#CBN<K1)K<[:491OS?(*=']]?J*;3H_OK]15&YZ[^T9_R*
MOPQ_[ 4?\A7AU>X_M&?\BK\,?^P%'_(5X=7EO=GYY5_B2]6%>^_"SPWI7B7X
M*2Z/-I]JVKZWJ5Y:V-](@$J7$4"2Q*'QD D,N/\ :KP*M2P\5:QI=O9V]GJ=
MQ;0V=U]MMXXWP(9\ >8OHV !GVI&1]$:O\,M(UKPIX5\%VT-O8WUIKL>F7^J
M1QJ9I)?LIFG&[^(AB5 SC*BL;P#X*T"TU_0]?T:WU&WM+I=6L)+'6-DC[X;=
MCYJD 9!STQP1UKQ)O%^N,A4ZM=X-[_:/$I!^TG_EMG^_[U=U#XE>*M4U6#4K
MSQ#?7&H0Q/#%.\OS(C AU'89!.>.: .]U3X0>'-(\%V;S:SY/B&YTVVU&%I+
ME2DS2E?W0A"[@ &SOW=01BK=Q\(O#/\ PL"\\(P)K8NM,M+I[B]E*^5=2QP>
M8IB 7@9_AYR*\Q;Q[XB/AK_A'VUJ[;0PNW["TF8PN<[?7&><9Q5F7XG>+IY]
M,FD\1ZB\VF?\>4AFY@XQP?IQSGB@#TWP;X(MM"\,ZC-Y<GVK5O \M],EVH_=
M2FX" J",J, &L?XI_"KPWX"T>[AMM7:37K"6"-X9+A7-VLBY9Q&%!BVDC ).
M1S7!WWQ \3:G+/+=Z[?7,D]LUG*TLNXO S;FC/\ LEN<4W5?'GB/7='M]*U'
M6KR^TV#:8K:=]RK@87GJ<#IDT 85%%% 'T#^Q9_R4[4/^P9)_P"C(J\O^,7_
M "5/Q7_V$KC_ -&-7J'[%G_)3M0_[!DG_HR*O+_C%_R5/Q7_ -A*X_\ 1C4
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MXUZ]&F1Q^2EKO&T("&"],X! (&>*EF^*7BZZU:TU1_$5ZU_:HT<$X< HK?>
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M'_&C[7)ZG_OH_P"-']M8W^9?<@_LC"?RO[V? _\ P[$\6_\ 0XZ+_P!^9O\
M"OJG]GWX%ZI\%/@MJ?@^\O[;5;Z>6YF26V#*A\R-55?F[Y7]:]/^UR>I_P"^
MC_C5YY&_LNY<$AA&Q!ST^6N;$9EB<5#V=5W7HCJPV H86I[2DM?4^*9/V5_B
M"SL1IL&"2?\ CZB_^*IO_#*OQ!_Z!L'_ (%1_P#Q5>\W&OZBD\BB]N  Q 'G
M-_C4?_"0ZE_S_7'_ '^;_&N;VDS[?ZYB?+[G_F>%?\,J_$'_ *!L'_@5'_\
M%4?\,J_$'_H&P?\ @5'_ /%5[K_PD.I?\_UQ_P!_F_QH_P"$AU+_ )_KC_O\
MW^-'M)A]<Q/E]S_S/"O^&5?B#_T#8/\ P*C_ /BJ/^&5?B#_ - V#_P*C_\
MBJ]U_P"$AU+_ )_KC_O\W^-'_"0ZE_S_ %Q_W^;_ !H]I,/KF)\ON?\ F>%?
M\,J_$'_H&P?^!4?_ ,51_P ,J_$'_H&P?^!4?_Q5>Z-XCU%%+-?SJHZDS, /
MUI?^$BU+_G^N/^_S?XT>TF'US$^7W/\ S/"O^&5?B#_T#8/_  *C_P#BJ/\
MAE7X@_\ 0-@_\"H__BJ]U_X2'4O^?ZX_[_-_C1_PD.I?\_UQ_P!_F_QH]I,/
MKF)\ON?^9X5_PRK\0?\ H&P?^!4?_P 52K^RM\058'^S(.#G_CZB_P#BJ]T_
MX2'4O^?ZX_[_ #?XTY/$.I%U!OKC&?\ GLW^-'M)A]<Q/E]S_P S%^(?[-^M
M_$3PYX,MUU"STVXTC3$M)XYMS_. ,X*C!%<+_P ,0>(/^ABTS_OW)_A7L7Q.
MUO4+#1?#CV][<0/);%G:.5E+'"<G!YZFO._^$OUO_H+7O_@0_P#C7*]SYJ;;
MDVS!_P"&(/$'_0Q:9_W[D_PH_P"&(/$'_0Q:9_W[D_PK>_X2_6_^@M>_^!#_
M .-'_"7ZW_T%KW_P(?\ QI$F#_PQ!X@_Z&+3/^_<G^%'_#$'B#_H8M,_[]R?
MX5O?\)?K?_06O?\ P(?_ !H_X2_6_P#H+7O_ ($/_C0!@_\ #$'B#_H8M,_[
M]R?X4?\ #$'B#_H8M,_[]R?X5O?\)?K?_06O?_ A_P#&C_A+];_Z"U[_ .!#
M_P"- &#_ ,,0>(/^ABTS_OW)_A1_PQ!X@_Z&+3/^_<G^%;W_  E^M_\ 06O?
M_ A_\:/^$OUO_H+7O_@0_P#C0!@_\,0>(/\ H8M,_P"_<G^%'_#$'B#_ *&+
M3/\ OW)_A6]_PE^M_P#06O?_  (?_&C_ (2_6_\ H+7O_@0_^- '5_ ?]G35
M/A)XMN=6O=5L[Z*6T>W$=NKA@2R'/(Z?+^M<CXW_ &0-<\5>+]9UB+7=/ABO
MKN2X2-TDW*&8D X'7FNP^%WB+4]0\8V<-SJ%U/$=V4DF9E/R-V)K+\8^)]7M
M?$^IQ1:G=QQK<2!56=P -QX S0!Q'_#$'B#_ *&+3/\ OW)_A5W1?V._%WAW
M4HM0TWQ7I]G>Q!@DT<;Y4,I4]1W!(_&M'_A+];_Z"U[_ .!#_P"-'_"7ZW_T
M%KW_ ,"'_P : %M/V7_B%81:-%;^.;6./1F=M/4(Y%L7SO*_+WR>OK3[?]F/
MXA6N@/HD?C:P_LME=/L[P%]JO]\*2I*@Y.0"*C_X2_6_^@M>_P#@0_\ C1_P
ME^M_]!:]_P# A_\ &@"W<_LY_$R\T-='F\?VTFFB%;?R&C;#1J054G;DX*C&
M3QBG0?L[?$VWEU22/Q_:AM3;?>9B8^:VW;NP5X.WC(P:I?\ "7ZW_P!!:]_\
M"'_QH_X2_6_^@K>_^!#_ .- !>?LN?$#4+.>TN/&]G+;310021M&^&2'_4K]
MW^'M5VV_9V^)EI?:A>1^/;-KB_=)+HR0%UE=1M5BK*1N X! JB/&.M,,C5KP
MCU%R_P#C2_\ "7ZW_P!!:]_\"'_QH &_9=\?OH$VBGQI8#3)B?-@6!E\P%M^
M&8+N(W<XSC-8/_#$'B#_ *&+3/\ OW)_A6]_PE^M_P#06O?_  (?_&C_ (2_
M6_\ H+7O_@0_^- &#_PQ!X@_Z&+3/^_<G^%)_P ,0>(/^ACTS_OW)_A6_P#\
M)?K?_06O?_ A_P#&C_A+];_Z"U[_ .!#_P"- 'R@WWC]:]?_ &4/^2U:1_UR
MG_\ 135Y WWC]:]?_90_Y+5I'_7*?_T4U 'V_J?^N_'^@KPOX@^"=2N?C99^
M)U\-ZOKVEQZ)'9HVCZHMHT<ZW+2'S%,B;UVD<'(]J]TU/_7?C_05FSWMO:R0
MI/<0P/,VR))9%4R-Z*">3["@#Q.W^%_B-?&UAJ;V:+:Q^-=4UIV\Y<BUGTXP
MQMCU,AQCJ.M<OX'_ &9ETW3/!$>J^$]+>>R\(W^GZGO6.3??2LAC+?WS_K,.
M<[<G&*^DH]1LYI;B*.\MY);?F:-9E+1?[XSE?QITEY;Q(SR7$,:(GFLS2* J
M?WB<\+[]* /FY_@;XGU'0+BPU'38KI;FQ\*6TT<TZL)/L4A-VK<\A5/_  *M
M'Q1\*_$6FWFN6>@^&K.3PW?>(9KV.WM8+5Y8(GLHTWP1S@Q1AI0X<XS@Y YK
MW./Q%:2ZJMDFYXVM/MJWRE3;%-^W DSC=GGTQWJU_:=E]FEN?MMM]FB)62?S
MEV1D=0S9P".^: /G3P7\%_$N@#P@U[H<+ZJ/ \OAV;54DB>32[W>S1RLQPQ4
M*=H9,D=, 5T'[._PMU+P1?)=ZOI^JZ?J-OHT.E2F=[,6DY1@Q:,0 ,YSDB23
MG#$=2:]MAO[6YMC<0W4$UN/^6T<JLG_?0.*1-2LY8Y)$O+9XXW,;NLRE5;NI
M.>#['F@#YS;X=7/C"Y\2^&9]/BU!;+XH0:_J%O<\)+I\L:R!R#PXQE<#KM([
M&K^J_#/Q7J'QGT>_3P_:6>@Z7X@BN89[&*UB@;3A;-&=YQYS29.TIP@4# ->
M]IJ-@\T 2[M&FNEW0A94W3J.Z\Y8#VS5#1/&F@^(XM2ETW5[2[CTVXDM+QTE
M&()8SAU;/3![]/>@#P3PA\"KV*'X?Z/JG@ZQAT_P[XKU'4-0=_):"\MY([GR
M)@HY;!EB7:PR,=,"L.?X!^*K?3]#@N]-O;O28+/5],;3=*>SDDMDGOGEA=5N
M 4"F$JN4PR8 Z5]/2:_;)J5C:*'F2\@EN$O(MK6ZHFW.Y\\9W<=<X-6EU*S>
M*>1;RV:.WXF<3*5BXS\QSA>.>: /+?A+\)!X0\<^+]<U'3$DN;D:=!IFI7;I
M/=^1#8QQ2 N.AWJV2,;NO2N6^*/PBU?6]7^+ZZ9X8M[I_%WAV"VL=41HD*W"
M*Z20R$D,"^4.X<''/05] 03Q74*302I-"XW))$P96'J"."*?0!\^^(OA3KWA
M[6/$K^%?#5A_8E\-$Q:00V[G]P)5N9889?W?G &(!GX/N16=X ^ FK)-X%A\
M4Z%:WFFZ1_PD1FMKQH9EB^U3(UL-B@(3MW<*,+VQQ7TG10!XR_PZ\13?LFKX
M)EMQ)XG_ + 73S;O,"/-!&%W],8 YK,U/X*7MUKGBC6TT6T;6KGQ9I.J6&H%
ME\];6!;992K]5P$F&WOGOFO>:* /FO2_@'K&DZ9HL]KHEI:ZU_:WB2?4;F)T
M$DMO=I="W#OU8,7@^7^' ]*R-;^"/B1XKV"7P+:>(+C4/ VD^'+:^DNH5_LR
M]A1Q(YW'(12RMO3)R@P.:^JZ* /G;7?@YKGDSW=SH4'BB:U\;VNMK;R&(R7E
MHMI'#*R[_E#%@3M)&=M=[\-U?4?B=\5-5A4P6;75EID3 <--!;?O6'KM,@3_
M (!7IE(J*@(50H)R0HQD]S0!\IZ7\#?$\=GI-H/!=IIVHZ9X=US2;[7%N82^
MJW%S'B*3CYF5F^8L^""Q&.,UUT/PQ\3V7C*SET?3'L&O-'BL=6U*^:"6W1TL
M##'):L#YT4JR$*5'R,H)ZU[_ $4 ?+'A3X-^+/#G@Z[,'A^[E\10:3::5+!J
M0T][*Z1)T>1X40 2R !W1I^YP>II+;X.^+]/\'7VWP_>3ZXOB2^U31D=[&2&
M%)H(D NK<@0^6Y#[A&,IR1R<GZHHH ^<Q\&O$-S\5KS4=:M]1N+:[UFSU>VO
M](>T6"U\J&-?*9I!YZJC*X"H2&5O<U[KX:T2]T*UGBOM=O=?DDE,BSWR1*T:
MG^ "-5&![C-:]% !1110 4444 %:3_\ ((NO^N3?^@5FUI/_ ,@BZ_ZY-_Z!
M0-;GB5U_Q\R_[Q_G452W7_'S+_O'^=15T'N!1110 54DU:RB2Z9KN$"U7=/\
MX/E#_:]*MUYAXI^%USJGB_SM/<6FD:@H.I!6V[BK9( [ENOYU22>YK3C&3M)
MV-?1FN/B)=?VE=*\'AR)_P#1+,\&Z8'_ %DGJN>@KN*CM[>*T@C@A01PQJ$1
M%Z*!P!4E)NXIRYGIL%%%%(S"G1_ZQ?J*;3H_]8OU% &C\6?^0%X8_P"O4_R2
MO,:].^+/_("\,?\ 7J?Y)7F-<YXDMV%%%%!(4444 %%%% !1110 4444 =I\
M(O\ D=['_@?_ * U9'CC_D;=6_Z^9/\ T,UK_"+_ )'>Q_X'_P"@-61XX_Y&
MW5O^OF3_ -#- &%1110 4444 ,-Q$LZPF5!,PRL98;B/4"N8NM4G\4:M+I>F
MRM#86YQ>7L9Y8_\ /-#_ #-1>.O"UUJDMGJ&D_NM4B;RS(#MRA&,D^W]:W?#
MNB1>'M(@LHL$H,R/_?<]30!=M;6*RMXX($$<,8VJH["I:** "BBB@ HHHH ^
M:&^\?K7K_P"RA_R6K2/^N4__ **:O(&^\?K7K_[*'_):M(_ZY3_^BFH ^X-3
M'[[\?Z"O$_%OA*\?XSMK6H>#7\::/=:=:6NGR*\6-)GCF=I7(D8%-P9&WID_
MN\5[S*80YW;LYYQG^GX4S=;_ .W_ ./4 ?(NG_"WQUK/CC4;RY\.0Z"MUHVN
MZ;<R6L5O!:R23@"U(=&,DX.-Q>3[I)P!4\_@'Q/XQCGEU[P=K>EV4'A73-'6
M*UN+:6YENK>Y$C.L9<H\8(!VN?G7(QSBOK/=;_[?_CU&ZW_V_P#QZ@#Y&U_X
M5>/?$WA?5Q<:!:V5_=^ YM%CM=/*6\0N3?\ F1H$5ML;&+#,%.U22 :J_%WP
M-=>!-8N$T71[&RT/5M8T,V=E-Y:V-Q/##<?:/-1V5,'$>[>1N(')-?8>ZW_V
M_P#QZH+VRTW4[9[:\MDO+=_O0W$1D1OJ""* /E22+3+/]A_QM::-#-"EI8:E
M#-O5(PUP)6,AC,9*&/<<*RDC:!SQ5:;X-ZIXL:[>U\"MX6\/7<^@QW&B23Q?
MZ6;><O<W)$;$%?+8+N)W. <BOK066FBR^QBUC%GL\O[,(OW6W^[MQC'MBIP;
M8  ;P!VPU 'RSXS^$6JS:]XJT_3?!J3SZE?6$WA_Q+;O%'#H=M$(P8P"0\6P
MI(P1!A_,YZFLW5?@WX@M-(\6:=I/A8VA;QK_ &X\UG%;$:OIS.6$2*YVNR$[
MC%( N1[U]<;K?_;_ /'J-UO_ +?_ (]0!\J6GP>U^WMK(Z=IVII;'1?$L+0Z
MD8(7@GO%B\F-8XCLC1F5BJC[O.<9J2_^!;Z7IS6=IX<O;?3+GPOI=O>0Z&83
M+)J,%QO+M'(=DQ4?>#9WKD9-?4^ZW_V__'J-UO\ [?\ X]0!Y[\*K76;/X?:
M-!K^G6FDZK'&RRV=C$L448WML^1251BNTLJD@$D UU>*U]UO_M_^/4;K?_;_
M /'J ,C%&*U]UO\ [?\ X]1NM_\ ;_\ 'J ,C%&*U]UO_M_^/4;K?_;_ /'J
M ,C%&*U]UO\ [?\ X]1NM_\ ;_\ 'J ,C%&*U]UO_M_^/4;K?_;_ /'J ,C%
M&*U]UO\ [?\ X]1NM_\ ;_\ 'J ,C%&*U]UO_M_^/4;K?_;_ /'J ,C%&*U]
MUO\ [?\ X]1NM_\ ;_\ 'J ,C%&*U]UO_M_^/4;K?_;_ /'J ,C%&*U]UO\
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MM%>S?:?AK_SS;_OF:C[3\-?^>;?]\S4 >,T5[-]I^&O_ #S;_OF:C[3\-?\
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M[TJRB1X5F6^>U=DE8AL;U/WOE"?,3P:[)?B[+-K_ (7T.U\,WE]J>N6CW_\
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M)9WEOJ-I#=6D\=S:SH)(IH6#)(IY#*1P0?6@#7_M7V_\=_\ KT?VK[?^._\
MUZSJ* -'^U?;_P =_P#KT?VK[?\ CO\ ]>L[&*C:XB2>.!I46:0%DC+ ,X'4
M@=3C(S]: -7^U?;_ ,=_^O1_:OM_X[_]>LZB@#1_M7V_\=_^O1_:OM_X[_\
M7K.HH T?[5]O_'?_ *]3R73?8)YEP&1"R\?[.:QZTG_Y!%U_UR;_ - H&MSS
MN;XBZK'*Z"0$*2!E%_PIG_"R-6_YZ+_WPO\ A7,W7_'S+_O'^=15O9'L>RAV
M.K_X61JW_/1?^^%_PH_X61JW_/1?^^%_PKE**+(/90['5_\ "R-6_P">B_\
M?"_X4?\ "R-6_P">B_\ ?"_X5RE!X&3P/4T60>RAV.K_ .%CZM_ST7_OA?\
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MVBFD:6JS:DXW2.W*6Z?WF]_04 >R_P#"\M<_YXV?_?IO_BJ/^%Y:Y_SQL_\
MOTW_ ,57F=I UM;1Q/,]PZC#2OU8^O%2T >C_P#"\M<_YXV?_?IO_BJ/^%Y:
MY_SQL_\ OTW_ ,57G%% 'H__  O+7/\ GC9_]^F_^*H_X7GKG_/"S_[]-_\
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M (4CIO\ T'5_[]C_ .*H_P"%(Z;_ -!U?^_8_P#BJ\@WGU_2C>?7]*!'K_\
MPI'3?^@ZO_?L?_%4?\*1TW_H.K_W['_Q5>0;SZ_I1O/K^E 'K_\ PI'3?^@Z
MO_?L?_%4?\*1TW_H.K_W['_Q5>0;SZ_I1O/K^E 'K_\ PI'3?^@ZO_?L?_%4
M?\*1TW_H.K_W['_Q5>0;SZ_I1O/K^E 'K_\ PI'3?^@ZO_?L?_%4?\*1TW_H
M.K_W['_Q5>0;SZ_I1O/K^E 'O'A+X7V7AO7(+Z'5A<O'NQ$$ SE2/[Q]:IZU
M\(;#5M6N[R36A$\TK2%-@^7))Q][WKAOA&Q/C>QS_M_^@-61XW8CQ;JV/^?F
M3_T(T >A_P#"D=-_Z#J_]^Q_\51_PI'3?^@ZO_?L?_%5Y!O/K^E&\^OZ4 >O
M_P#"D=-_Z#J_]^Q_\51_PI'3?^@ZO_?L?_%5Y!O/K^E&\^OZ4 >O_P#"D=-_
MZ#J_]^Q_\51_PI'3?^@ZO_?L?_%5Y!O/K^E&\^OZ4 >O_P#"D=-_Z#J_]^Q_
M\51_PI'3?^@ZO_?L?_%5Y!O/K^E&\^OZ4 >O_P#"D=-_Z#J_]^Q_\51_PI'3
M?^@ZO_?L?_%5Y!O/K^E&\^OZ4 >O_P#"D=-_Z#J_]^Q_\52?\*0TW_H/#_OV
M/_BJ\AWGU_2C>?6@#YF;[Q^M>O\ [*'_ "6K2/\ KE/_ .BFKR!OO'ZUZ_\
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MPN,D9VDJ=M9MQ\&?&>K?$B+7-6UJUO;.TN=3DMY&NIBQAN8'BBC$&/+C\O<
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MG->L:#X/GTCXA>)M?:2'[+JMEI]M'$@PRM;K(&+=L'>N/I0!UE%%% !1110
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M:9]IM_[B_FO^- &7]GE_YYM^5'V>7_GFWY5J?:;?^XOYK_C1]IM_[B_FO^-
M&7]GE_YYM^5'V>7_ )YM^5:GVFW_ +B_FO\ C1]IM_[B_FO^- &7]GE_YYM^
M5'V>7_GFWY5J?:;?^XOYK_C1]IM_[B_FO^- &7]GE_YYM^5'V>7_ )YM^5:G
MVFW_ +B_FO\ C1]IM_[B_FO^- &7]GE_YYM^5'V>7_GFWY5J?:;?^XOYK_C1
M]IM_[B_FO^- &7]GE_YYM^5'V>7_ )YM^5:GVFW_ +B_FO\ C1]IM_[B_FO^
M- &7]GE_YYM^5'V>7_GFWY5J?:;?^XOYK_C1]IM_[B_FO^- &7]GE_YYM^5'
MV>7_ )YM^5:GVFW_ +B_FO\ C1]IM_[B_FO^- &7]GE_YYM^5'V>7_GFWY5J
M?:;?^XOYK_C1]IM_[B_FO^- &7]GE_YYM^5'V>7_ )YM^5:GVFW_ +B_FO\
MC1]IM_[B_FO^- &7]GE_YYM^5'V>7_GFWY5J?:;?^XOYK_C1]IM_[B_FO^-
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MM"_Z%R'_ +Y3_P")H_X6]H7_ $+D/_?*?_$T >3>3)_<;\J/)D_N-^5>L_\
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MHHHH)"BBL_Q!+?P:/<RZ:(S>(NY1*,@@=1CUH MW=W#8VTEQ<2+##&-S.QP
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M9,8.%Z8!ST-<=_PI#Q!_>L_^_P ?_B:P/&ENSSVBO0O^%(>(/[UG_P!_C_\
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M*/$MU92:A'9!"?W"'#,S8POL"<G% '6?;IO^>C?G1]NF_P">C?G54R( 274
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MT+C;^?2G(ZR*&5@RGH5.0: +/VZ;_GHWYU=,[KIMQ(&.]4+ GG!VYK*K2?\
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MOPB_Y'>Q_P"!_P#H#5D>./\ D;=6_P"OF3_T,T :G_"VO$W_ $$6_P"_<?\
M\31_PMKQ-_T$6_[]Q_\ Q-<=10!V/_"VO$W_ $$6_P"_<?\ \31_PMKQ-_T$
M6_[]Q_\ Q-<=10!V/_"VO$W_ $$6_P"_<?\ \31_PMKQ-_T$6_[]Q_\ Q-<=
M10!V/_"VO$W_ $$6_P"_<?\ \31_PMKQ-_T$6_[]Q_\ Q-<=10!V/_"VO$W_
M $$6_P"_<?\ \31_PMKQ-_T$6_[]Q_\ Q-<=10!V/_"VO$W_ $$6_P"_<?\
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MWW&/'=S7U#10!\M3>'?$'C2W9=6\.>*M#TZU\'Z?I,CI LLLMY%<J\@6'?\
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MT9/J: -/[-:_WV_,U,T</V25"Q$14AF)Z#'^%8V3ZFM%_P#D$77_ %R;_P!
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MU[_A%?AY_P!!D_\ ?X?_ !-'_"*_#S_H,G_O\/\ XFO(<T9H ]>_X17X>?\
M09/_ '^'_P 31_PBOP\_Z#)_[_#_ .)KR'-&: /7O^$5^'G_ $&3_P!_A_\
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M&Y_[\M_A7UA10!\G_P!AZC_SXW/_ 'Y;_"C^P]1_Y\;G_ORW^%?6%% 'R?\
MV'J/_/C<_P#?EO\ "D_L34/^?&Y_[\M_A7UC10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>arvn-20251231_g3.jpg
<TEXT>
begin 644 arvn-20251231_g3.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" * !1X# 2(  A$! Q$!_\0
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M.S@7?+/.X1$7U+'@5\G?&/\ X**^$?!TLNG^"K)O&&H+P;QG,-DA]FQND^@
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MJVJW4VI:M?S&26:0EGD=CT'\@!TX K[6_9D_8GMM-MK;Q=\1K99IB!):Z)(
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MAL/=2\<#_9&06/8>Y%?D=\2OB7K_ ,6/%MYXA\17KWE[<.2JD_)"F?EC0=E
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M;-K?4FTE(+UHV+3+''(6!C=E*XD'(/45Y[XO^)VK:A 9+F]EN(E.?+'RQ_\
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M7,'BFTP=IRF$,@_UF=[#DL<IPQ ..Q_;XL+B^_9F\0M;Q-*+>XM)I=O54$Z
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MPM\AHSX<T0P%=I38"NWTQG&/:NIM9]"T_3(+&U^R0V-K$L44"8V1QJ,!0.P
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MD>8/H@KA/^"?7C]O"/Q]M=)D?;9^(;:2R<=O,53)&?S0K_P.OKO]O?PRFO\
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M?PZ]KJBW1/WY9%4!N<[@78GG@U]'_LDZ)XJ\/? /PQ9>,#<+JZ)(5AO"3-#
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M:^'_ (>ZAI?Q>\4>#-?\=^,=0F\*W5I=:]XHR]O<J8CM5)&B21W40H/F'"X
M]OM.BL'F+=*,+.Z26^C2\K7_ !^1LL"E4E.^C;>VMWYW_0^8_P#@G<A3]G.
ME2 VJ71!(Z\J,_I^E7O^"@*EOV:-:P"<7EH3C_KLM?1U%<SQ=\7]:Y>M[?\
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MTSQ+8/8ZOIUIJMDYRUM>P+-&WU5@0:OT4W.3M=[!R15]-S!\,^ ?#'@KS?\
MA'O#FDZ#YHQ)_9EC%;;_ *[%&:E\/^#/#_A*&ZBT/0M-T:*[D,MPFGV<<"S.
M>"SA -Q]S6S10YR=[O<2A%6LMCD[/X2>!M/U<:K:^#/#UMJ@;>+V'2H$GW>N
M\)NS^-:?B7P;X?\ &EK';>(="TW7;:-MR0ZG:1W"*?4!P0#6S13]I-M.[N@Y
M(I6MH9.G^$M#TG1'T:QT;3[/1W5D;3[>U1+=E/!!C VX/?BLFW^$O@:UT:[T
MB#P9X?ATF[=9+FPCTN!8)F7[K/&$VL1V)'%=91252:V;#DB^AEWGA;1=0T)-
M$NM(L+G1DC6)-.FMD>W5% "J(R-H    QQBJOAGP%X9\%"4>'O#NDZ")?]8-
M,L8K;?\ 78HS6]11SRM:^@^6-[VU,?2_!V@:'J]_JNG:'INGZIJ!W7E]:VD<
M<]R<YS(Z@,_//)-+H7@_0?"T]]-HVB:=I$U_)YUW)86D<#7$F2=\A4#>V6/)
MR>3ZUKT4G.3W8*,5L@KSS]HB=[;X"_$22,E7&@7P!';,#C^M>AUQ?QKTDZ[\
M'?'.GKD/<Z'>Q+CKDP/C]:THM*K%ONOS(K*].279GXFU^V/A^W2TT:P@B&(X
MXE51[ 5^)U?M#\/]6_MSP3H.I9#"[LH;@$=,,@8?SKZWB%.U)^OZ'RV0M7J+
MT_4ZAC@5SGCVVNM9\':KINEW!BU:6+$2H^UR,Y(_$9KI,98 <Y]:Y7Q#XCTS
M23 VHZA%$(V>01G]V9"JAMA^89."" >"2.M?'1E*$E*"NULCZN:BXM3=D?'=
MYX>U>&*7_B72L5.#M(8G)QD ')KT[3=0:;P]8P3Q2P_9X]N;H 2D>^":^A-9
MT33_ !)8;[RPMIU8>8)H\;QQV=3S^&:X>3_A'O"&K0VESH$?V6[4^1J-QAT1
MT4,5D+D;-P+;?78PKZ*KG$:JCSP=UVZ:;GAT\KE'FY)*UC1\(7.H7W@"S:ZA
M"L'9+>3!4R1* %)/Y@>H%6_ 7AIX-7N=2NU8R?ZN+><G!Y)Y_+\ZJ^%-6L]3
MU'5[+3]9@U.T69+BTB@G)%K$T8#QE2W.) [# P%8"NVTQMK8[UX,JW.Y..S/
M5I14HQ:=['1Q#Y .U?#OB+Q E]XL\07,IW2'4)<%O7<V/R%?<$9S'UQ7YY?$
M.VN=.^)&L:8%(4:FX/N26Q^@_6OH<CIQJRJ1?E]U_P#ACQ\YJRHQA./G]]OZ
M9TFO3S:;-<P7L6R\A0%D)!.#@\GZ$5]B?"J_;4_AQX<N78LSV,8)/? Q_2OB
MWX\6UWHOQ2U2SQE6AB+$^A2(?XG\*^T?A38-IOPV\-V[C#K8Q$_B,_UK7-80
MCA*3CULU_P" ZF66U9U,544G>R:?REH6/&>@+K>G90?Z5"WF1$=?<?B/UQ5K
MP[;S6U@B3@A@N/F8D_K6JYYI!_2OEN=\O*?2<JYN8\J_:EMDN_V?O'2R+N"Z
M7<2 >ZQL0?S%?CNCM&ZLI*LIR".QK]=_VP-6&C?LZ>,Y6<)YMH;?)_Z:$1X_
M-P/QK\D=*L6U35+.S3)>XF2%<=<LP']:^WX?TH3;VO\ H?'YYK6@EO;]3]T]
M/D,UA;2,<L\:L2>^0*L4R*)88DC7.U%"C/H*?7PS/LD%%%%(9Y;^U'<O:?L[
M_$)T;83H\\>?9EVD?B"17XX6T7GW,473>X7CW-?LG^T[8'4?V>OB'$ 25T6Y
MFX_V$+_^RU^-<$S6\T<J?>1@P^H.:^ZX?_@5/7]#XS//XT/3]3]MM+@2WL;6
M*-0L:(%51V':M!NE9NBW<=]I=G<Q,&BEC5U8'(((XK385\,S[,S-9/\ Q*[W
M_KB__H)KRK]E@X_9Y\#_ /7A_P"SM7JVM#_B57O_ %Q?_P!!->4?LL_\F\>!
M_P#KP_\ 9VKJC_NTO\2_*1RR_P!XCZ/\XF?^RVV/@GI?_7]J7_I=/6I\>V)^
M"OCL?]02\_\ 1+5E_LMC/P4TO_K^U+_TNGK4^/8/_"EO'9_Z@EY_Z):MY_[\
M_P#'^IE#_<U_A_0S9_"EYX[^!FF:%8:Y=^'+J[TJS5-2LL^9%A(V.,%3@@%3
M@C@GFN>_:/T^71_V7O$.GSWLVHS6NGVT#WEP<R3LLL0,C?[38R?<UZ/\/A_Q
M0/AG_L&6W_HI:X?]JT8_9Z\9?]>\7_H^.BA.7UF$.G.G^*%6@OJ\Y]>5K\#V
M:!N!7GG[3QS^SWXZ_P"P<W_H2UZ'"*\]_:>'_&/7CK_L'-_Z$M<^%_WBGZK\
MSHQ/\"?H_P CUG0SG2K+_KBG_H(K6C[5DZ&/^)59?]<4_P#016Q".E<SW-UL
M6%KQ?]LFS6^_9Q\8(V/EMA)S_LL&_FHKVA:\3_;1U!--_9N\7R.<!X4B'U>1
M4'ZL*Z<+?ZQ3MW7YG/B?X$[]G^1^3>@7C:=KNFW2_>@N8Y1CU5@?Z5^Z]?A7
MX:L'U7Q'I5E%S+<W<4*_5G '\Z_=2OI^(K7I?/\ 0^>R':I\OU"BHKJYBLK6
M:XG?RX84,CMC.% R3^5?"%C^U!X\^*>E>+O%VE_%/PI\.;+3))!I/A/4$M'N
M=15$#X9ICO&X$ ,HP6R  !FOF\-A)XF[BTDK:N_7;9,]^OB88>RDKM]K=/5H
M^]**^-/&'[0WQ)\2?LT^%?BYX0O8]/FTZY:+Q'I*6L4L-PBR!"ZEU9U7(7(5
M@0LI.?ES74_ ?X[^+?VB_C7J.J:)=3:3\+M&L(EEL);6(M=7DD?W6D*;P59F
M/R,!B).,.<[2R^K&$JC:M&]_)K2WJ^AC''4I3C!)WE:WFGU]%U/J*BOAWX&_
M$SX]_M Z#XMBTGQKINCRZ'=2&+4)M*MY9[IV7]U:[=HC1!L8F0J6R_?'&EX5
M_;=U@_LJZMXUU*SM[OQ?I^I+HT?[O9!-*ZATF95Z87>2HQDIVW<:3RRM&3BF
MFTTFETOMT(CF-*24FFDTVF^MM^I]H45\(W'[3/COX8CP5XDU7XK>%/B)I^KW
M$46K^&M,2T6;35D&[Y6B/F-M&068 !@ 0<@UT/Q6^,/QFO/VI]9^&7P^UBPM
MXI[*$VHU"VA\NQ)ACEDGWF,LQ^\,$./GX7(&#^S*O-;F5K-WUMH[/I?KV#^T
M:=K\KO=*VE]=NI]:ZGXQT#1=8L-)U'7--L-5U XL[&YNXXY[DYQ^[1B&?GC@
M&N-^(?Q[\/?#3Q]X0\(:G9ZI<:IXGG6WLY+.W5X8RTBQ@R,SJ0,MSM#$ $D=
M,_&/QP\+?$E/VAO@W;>)?&\+^*[Y+5;>]M]+A:/2YA*JLRJ JS@R R?,%^]M
MQ@5[5\8OBE\0_A/\5/@;X/'BU=476KV&UUN[.F6\7]H!KJ*,G9M;ROE<CY"/
M6MEE\$Z=I*7,F[:K:_6VVG]+4R>-DU.\7'E:71[VZ7\_Z>A]745\5^(OV@O'
M'B7X^>,?!\7Q)T;X56VBW'V?2[;5=+CF34V!Q\\TH^3< &!!Y#@ 'K77_M&_
MM!^*OAWJ/P_\":;K&AZ%XHUVWBFU3Q+?;?L-DOW6=/,&W:660@MV4#&6R.;^
MSJO-&%U>2OUT5K]ORN='UZERRE9V3MTU=[=_SL?4M%?)_P %OCYXE@_: 'PU
MU[QSHGQ/TO4K%KS3O$6CQV\91U5F:-U@8H#A'RIRP^4YP:]F_:+\87_@KX/Z
M]>:1*8-;NQ%IFGR*<,EQ<2K CJ>Q7S-X_P!WOTK"IA)TZL:3^U:S]?6S_ VA
MBH5*<JJ^S>_R/2J*^?/BKXSO/A_\1/AIX2N?B+/X/\.7.E7@OM7NI;/S9Y8%
MA$3/->12#<Q+9[L2>]=U=WL:_#.+4;;XLI'I#3K--XQNO[/D_<;]I2*18TME
M)?";VC?JPQN(99>'DHQE?26V_=KMY%*NFY1MK'?;LGW\STFBO(O@)XRUGQ9?
M^-(I]=;Q?X6L-0CAT3Q,\$41OE\L&= 842.18I,H)$4!CGDXXP?C-\=;OX3_
M !C\/V-Q<37&B7>AW,J:+:P(]QJ-_P"='';Q1?*7+L7VA5..22, D"PM255T
MHZNU_P +_>)XF"IJJ]%_P;'O=%>0Q_$+6/@]\/[37_BC>3W^H:OJT4!L]'LT
MECTOSVQ' @0!YEC'WF^=V.=H;@5T/A3XP:?XAUS4]%U+2-5\(ZM86*:G):Z\
ML*;K1B1YRO%+(FT%2&RP*D<@5#H32<EJEU1:K0;2>C[,[VBO*K#]HC1;R'1-
M2FT/7=/\+:W>+8Z=XEO(8$LYW<L(F*"8SQI(5PKR1*IW+D@,";]U\==!M- \
M9ZH]GJ3-X5U+^RKRP2.,W,TQ,8B,2^9AED,J;"Q7.3D @T/#U4[<O];?F"KT
MVKW_ *W/1J*X#4?BWI$]]H.CV2WEQ>^(M'N-7M)H%79!;I&C"24[@5W&10NT
M-SGIUKS_ ."OQ?.B_ /X9S:P=8\5^*-?@:*UM+=A<7MZZLQD<O*ZJ%1>6>1U
M  ZYP#2PU1PYK=?\_P#)DNO!2Y;_ -:?YH]_HKS?_A??AFU\&^(/$&I)?:0^
M@7)LM2TB[A4WL%P2HCB"1LRN9-Z%"C,K!Q\W!QPD?Q,U;Q#^T]X,T>2P\0^%
M[?\ L2_FN=&U1T6.?_5&*;$,LD3X^<?>+*000N1EPPU25[JUD_P5_P"O5!+$
M0C:SO>WXNW]>A]!T5XXO[36EW,GAV6Q\)>)M0TCQ%?MIVD:S#'9I:WDBEQD>
M9<JZ*1&Y7>BE@N5!XK6\0?'S1]"O->\K1-<UC1_#TBQ:WKFG6\;VFG-UD#AI
M%ED,2$/)Y,<FU3SSD"?JU5.W+_6WYZ>N@_K%)J]_ZW_+7T/3:*^?_BG\4'T[
MXV>&M#G^)">!O"-_X>FU$W\4FGHL\XF18\2W44BX*,QPO7&16]\%_BAK.N?"
M>XU_5DN_%1BU6ZL-,O=+LE6;6+=)S%!<>6"J1[R.68I&H!9BJY-7+"SC353H
M[=^M_*W3N2L3"4W3[?I;Y]3V*BO.=.^.FB2)XO76K#4O"U[X5M%O]3L=56%I
M5MFC9UF0P22I(I",,*Q8,,$ D9N:/\6K.Y\.ZCKFN:)K'@_3+&R747N-;CAV
M/;LK-O5H)95W *<QDAQE?E^89R="HMU_3[=_D:*M!]?Z_0[JBO._"_QIL?$&
MO:-I-[X?UWPU<:W:M=Z2^L0PJE\BJ'8+Y4LA1PA#&.4(V,\9! SO@AK>H)K'
MQ!\(:K>W>H7/AS7&%M<7LOFR&RN8UN(%+DDL5\QUYZ!5'; ;H32;?37Y7M^>
M@E6BVDNOYVO^1ZK1117.;A1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%>0?%?]J_X:_!YY
M;;6->2]U:,D-I>E 7%PI]' .U#[.RU\J^.O^"G&MW4CQ>#_"-EI\707.L2M<
M.P]=B% I_P"!-7IX?+<5B5>$-.[T//KX_#8=VG+7LM3]":*_(W7_ -MOXS:_
M*[-XPDL(FZ0V%K#"J_0A-WYDUS#?M-_%AB2?B'XAR>>+^0?UKU5P_B+>]-+[
M_P#(\R6>4$](O\#]F:*_'G2_VO/C%H[HT'C[4Y"O077EW /U$BMG\:]1\(?\
M%(OB3HLJ+KEAH_B.W'WRT)MIC]&0[1_WP:SGD.*BKQ:?S_S+AG6&EI)-'Z:T
M5\M_#+_@H9\.?&C0VVOI=>#;^1MO^F?OK7/_ %V4<?5E45]-:9JEEK5A!?:?
M=P7]E.N^*YMI!)'(OJK*2"/I7B5\-6PSM5BT>Q1Q%*NKTI)EJBBBN8Z HHHH
M *BN;:.\MI8)E#Q2H4=3W4C!%2T4 ?AMX\\,R^#/&VOZ!,C))IE_/9D-U^20
MKG\<9S7Z8_L9>,D\7_ +P^OF%[C3%;3IA_=,9P@_[]^6?QKY5_X*&?#9_"'Q
MM/B""WV:=XCMEN=ZYV_:$&R4>QP$;_@=:/\ P3Z^*2>'?&NI>#[V4):ZPGVB
MUW'&)T'S*/\ >3G_ +9#UK[W,%]>RZ-:.ZL_T?\ 7D?%8%_4\?*C+9W7^7]>
M9^AS7R6ODL\,\P.<^1$7QCUQ7Q#\=OA-X_UWX@:AJ4EK<:CIUU(9;>9_D6*,
M] RG[O\ GZ5]P0-@D>M+>6QU&W%F4CE@E^2>.0G#H<Y QW]_:OB*>(GATY0C
M=GOYCEM/,X1IU).*3OI_D>-_!#PUXN\$_#Z/3KAK:^964K'=W#(4&23M&TD<
M%1SC(&<5K?$+PAK?C_PU'9N;6SN%+%;=)6;D],MM .,#TX)KK;CQ58Z/;Q3:
MG>0VMO,0@5R%)*Y!;;_#C R-Q)![5:MO$^FZQ'*UI*;F-6)B\CYCC Z 9SR3
MT[=<5Y,LQP^+GRR:4I=.IZ,,I>&PGL&FX)6O_P $\ ^&GP>\2>%/&.G:MJZI
MIUE:N97\IO.:0#'R83.,Y[U]#Z=*'"N 55QN 8$$ ^H/(IACD:W27/[LL5 #
M@\@^Q(IT(*L*ZJ5.-.-H&.&PL,)%PA?YG26\@*=:^4O'WA.+6?CI<0Q@;[C5
M;8M_X[G^M?4-K*0N*^95:]N/VE(HL,0=5,I'8*K=?RKZ#*VXSJ2B]H_\$Y,P
MC&481DKZ_P# _4E_:1\,12_$@WK@%;JRB(^JDH?Y"OI[2$6'2K*./ C2!%4#
MI@*,5\X?M2QSV_BG098$*0RP,C%!U;>23^M?07A5Y#X8TDR\2?9(MWUV"EBY
M2EA*#D^_X67Z!A8QCB:JBNWXW?ZFHQS03UI!R<TC2*BLS$*J@DD]A7C'K'R+
M_P %(O&RZ1\+-*\.(^+C5[U69,]8HOG8_@_E?G7QC^RWX0;QO^T#X'TT1&6)
M-12\F Z".',S9]L)C\:ZK]M?XK+\3?C5?16LWFZ7HB_8(-IRID!S*P]]WR9[
MB,&O8?\ @F?\-'N_$/B/QU<Q8M[.$:99NV?FD<AI"/HJJ/\ @=?>T8_4,K<I
M:-J_S>WZ'Q-5_7<R48[)V^2W_4_0>BBBO@C[8**** ,SQ1HJ>)/#6K:1)@1W
M]I-:MNZ8="IS^=?AG?64^FWMQ9W,9BN;>1HI8SU5E."/P(K]WZ_)']MCX<2?
M#S]H'Q 5B\NPUIO[6M6"X4B4GS /I('_ $KZWA^LHU)T7U5_N_X<^8SRDW"%
M5=-/O/OS]F/Q:GC3X%>$-05MTB6*6LISD^9%^Z<GTRR,?QKU@<J#ZU\,?\$Y
M_B:AAUSP->3A71O[0LE8_>4X651]"$('^VU?<T7<?E7A8^@\/B9PZ7NO1ZGL
MX&LJ^'A/R_%%#6E_XE5Z?^F#_P#H)KRC]E=,_L\>!O\ KP_]G:O5O$UW;Z;X
M=U2[NYX[:U@M999IYF"I&BH2S,3P  "237SY^S9\9_ 'A_X$^#=-U3QIH.GZ
MA;V6R:UNM1BCDC;>QPREL@U-.$YX>7*K^\ORD5.<85X\SMH_SB;W[+*9^">E
M_P#7]J7_ *7SUK_'Q,?!/QY_V [S_P!$M7G_ .S;\8? 7A_X0Z=8:IXST+3[
MU+W4&:WN=0BC<*U[.RD@MG!5@1Z@@UJ_&WXS_#[6/A!XUL;#QMX?O+VXT:[B
MAMX-2A=Y',3!54!LDD\ "NJ=&K]=;Y7;F[>9SPJT_JB7,K\O?R-FX\;6_P -
M?@5I?B2YL;O48++2;1FM[)-TC;D11]!D@D]ADUSW[2>I1Z]^RWXCU6*&:WBO
M=/MKE(;E-DJ!Y8F"NO9AG!'8UN>!/C=\.;+P-X=M[CQUX>@N(M.MHY(I-3A5
MD81*"""W!!KC?VG?B[X$\1? ?Q;IVD^,=#U+49X(Q%:VNH1222$31DA5#9/
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M25O,^LJ4(U9*;9\VGX:?%3_H4/@U_P" EW_\;IA^&GQ3S_R*'P;_ / 2Z_\
MC=?2A2FF/VK3ZY/^5?U\S/ZK'^9_U\CYL_X5I\5"?^10^#G_ ("77_QNG?\
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MEW)(C#!!%7Z*:;3NA-)Z,_)_]JC]DK5O@/J[:II:3ZKX+NG_ '%YMW/:,?\
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MB<;L<XQCBOI?P=\"?B%HVK:*VO?&O6=?T729DEBTV'38K-YPAR$GG5F>53@
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MX;\&WUP9WTF&PC>XCSP?+NBX:,XP-RJ,X!.36SXM_99U:X^+&M^._!/Q&OO
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M?J%P#QD L0#BOI#Q-^RUJ,'Q/U;QU\._B!>?#_5]8'_$QA73H[^WN'[MY<C
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M&'DE2C;?U^\[2BBBO..\**** "BBB@ HHHH **** "J&O1B;0]1C/1K>1?\
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MN:4L?4J1=1I)67?=O;;5^GD?2GAGQKX>\:V\L_A[7M,UZ"(A9)=,O([E4)Z
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M)'L>*^:I/%FL6G_!/>"T@O)Q;3^,CITJAC@6WD-/Y?'\)D ..G-=A^W)\'?
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M=/L7Q-!;Z_IY<8\PJ#',H/<@\X] :\;#ZTZJ6]OU5SUJ^E2DWM?]'8]3\?\
MC+3OA_X3U3Q#JTODV%A"99#W;T4>Y. /<UX)X.^%]]\<+NW\>?$Z-Y[.?$^C
M>%78_9K2$@%'E7^.0C!.?7GT&_\ M0H?$?B+X7>"Y<G3];U]9;U,X$D4"^84
M/U//X5[++&J*%50JJ,  8 %4I/#48RA\4KZ]EMIZNY+BJ]5QE\,;:=WOKZ:&
M1:V-II5NMO96T-I;H,+%!&$51[ <53U;2-/URW:WU&QMK^!NL5U"LBG\"#7,
M^._B[HOP\\3Z1I6NQ7EG;:F-L6K- 39I)NP(WD_A)Z\\=*[ @,,_K7)*,X)3
M?79G4I0E>"Z;H^>_BM\"8_!'A[6O$_PQN-0\,ZTD#-+I>DJ9;>^!X*>1R V#
MP5''85?\/_LR6C_#;P<VG7DWA'QUI5C'LURRC_>+(WSO'*F0)%W,PP?Y9%>[
M*O-6H5R177]>K\BC?5/?J^EGW6^YR_4J/.Y6T:V_5=GZ'@6C>*?C/:ZWJNC:
M7X@\#^.[_2=@O+-UEM+J(M]W=M^09&>__P!?I/\ A?'Q%\,@MXF^#6KM"GW[
MC0+R*^4@#DA!@_@:]3TOPSHNB:IJ6L6FG6EEJ%_M:]O8XE22?:."[=\#/6O.
M?%7[3&GIJ[^'?A_IDWQ!\4 [6ATX_P"B6Q_O33XV@ ]<'UZ5M&:Q$K1HIKJ]
MK=]4TDO4QE%T(WE5:[=?3=-L]&^%7Q5T#XN^'7U?099=D4K6]S:W,?ESVTHZ
MI(AZ'D'Z&NTD7* ^]>2? 'X7ZYX(/BCQ!XHN+-O$GBF\6^O;7301;6Q52%1,
M\D\G)[GUZUZZXRE<->-.-1JD[H[:,IRIIU%9GQ/_ ,%*=)63P[X-U+:-T-U-
M;Y[_ #H&/_HH5XE^P+JAL/VG/#L SB]MKRW./06[R?\ M,5[]_P4FN8U\ >%
MK<_ZUM3\P?[HBD!_]"%?./[#4$D_[4?@KRQ]PWCL?1?L<V?\/QK[+!:Y3-/M
M+]3Y/%Z9I%KO']#];J***^%/LPHHHH **** "BBB@ HHHH Q/%_AB#Q7HTEI
M(3%.I\VWG7[T,H^ZP/L:H> /$TVM6,]AJ*^5K6FL+>[3^\>T@]F'-=57GWQ!
MMY?"VK6GC&R0L+?]QJ,2_P#+6 \!OJI.:UC[RY'\C*7NOF7S.SUV0PZ)J#C(
M*V\AXZ_=-8/PI3R_AWH0X_X]P>/<DT_Q=XMT6T\-7K3:I:QFXM7\I6E 9\J<
M;1U.:\T\/?'32_"W@O2[!;&ZOKZWMPCJH$<88=MQY_(5<82E!I+J3*<8S3;Z
M'NE%06%P;RQMYV3RVEC5RG]W(SBIZYS<**** "BBB@ HHHH **** &R2+#&T
MCL$1069F.  .I-<]XTU2%? FM7D$J31?8Y"KQL"#E2.OXUH^))/*\.ZH_P#=
MM93UQ_ :^<?".A)J=HNG+>75C;WD821+>0A'.,\H>#R/3-=5&BZB<D]CFK55
M3:B^I]!> [8V?@O0X3P5LXO_ $$&L3QKKUYJNIQ^%=#?;?W"[KRZ7I:P'()_
MWCVKDM5^+]_X(,^BW%I!J-Q;P*L-U;$QA6V_*'0Y[8)P?PK?^$.IZ'+I;O#J
MT-]KMXQFO6<[96<GIM;!P.G'%$J<J?[R2] 4XSM"+]3MM T&T\-:5!864?EP
MQ#KW=N[$]R:T:**YF[N[.A*VB"BBBD,**** "BBB@ HHHH *Q_&'BBR\$^%=
M7U_47V6.F6LEW,0>2J*3@>YQ@>YK8KY;_P""B7CQ_"WP+31K>0I<>(+Z.U;;
M_P \4!D?]50?\"KJPM'ZQ7A2[O\ X<Y\15]A1E4[(_-OQ[XRO_B'XSUGQ+J;
M;K[4[I[F3T7<>%'LHP![ 5^BO[$'P9C^'GPOAUV]@VZYKZK=2%U^:.''[I/;
MY3N/NY!Z"O@/X)^!C\2?BMX9\.E"\%Y=J;@#O"F7D_\ '%:OV,LK1+6&&!%"
MI&H4!1@ #VKZO/:_LX0PL-$]7Z+;^O(^8R6A[2<L1/6VB]>O]>9/%'M7)ZFG
M$T]N!43' KXH^O&LU1EJ61L=:IW%[# ,O(J^Y--*Y6Q8,F!GI7E7Q<^+,'@G
M3KNX:<116T;2RR>@ [>_H*ZCQ%XVL=.L9BDZM* < &OC+XB:E-\8?B1!X4C=
MI-)L76\U=U.0YSF.#\3R?\17N9=@_:SYZB]U'D8_%>RARTW[S/3?"G[97AW4
M'5&UN&"0XS'>AH"/Q8 ?D:]BT#XZ:;J<"2K)'-&W DA<.I_$5PQ^ FG>)]'1
MM1L+2[!3"I<0*X4>V1Q7SS\5OA9I'PF\1^&-3T:U.F3MKEM;W(@E<(\3$Y!4
MG'85ZBP^!Q4G"&C/.=;&8:*E/5'Z&:1JD6JVB7$)RC#-:2-7!?"JY6;P[&H;
M)%=VAKY2M#V=1Q['T5.7/!2)B 1FOB'_ (*)?!6.[TFS^(6F6^+FT*VVH^6O
MWH2<(Y]U8@9]']%K[>09K ^(/A.T\<>"M9T&]7=;7]K) _&2 RD$CWP3@^M;
M8/$/"UXU5TW].IABJ"Q-&5-]?S/R1_9R^*TWP;^+^@>(@Y6Q$PMK]<\-;2$+
M)^0^8>ZBOV7BE2>))(W62-P&5U.0P/0@U^%>OZ-<>'-=U'2;L;;NPN9+68#L
MZ,5;]0:_7/\ 9"\>/\0OV?/"=_/*9;VU@.GW#-U+PDH"?<J$/XU]-G]%2C#$
M1]'^:_4^>R2LU*="7K^C.F^-?P6T/X\>#5\->(+F_M;%;I+M9=.D1)0Z!@.7
M1AC#GM7*^"OV9(? ^MZ5?V_Q-^(^HP:<RF/2]2U\2V4BJ,"-XA& 4QVXZ"O:
M**^6CB*L(>S4O=['TLJ%.4_:-:GS_K_[%_A/6WU"&'Q5XUTC1K^5I;G0M/UL
MK82%F+,#&Z-P23QGO7K?P\^'>@?"SPI:>'?#5@FGZ7;9(0$LSN?O.['EF/<G
MV'  %=+114Q-:K'DG)M"A0I4Y<T(V9YIX\^ /AWXB?$KPGXWU.ZU*+5O#3J]
MI#;2HL$A#[QYBE"QY]&6N2\4_L[0>%IOBCXU\%_:=1\;^*=+N+<6.IO%)9EG
M )5$*#D[1@.S+GKQFO>**<,55A9)Z+2WE>]OO%+#TI7=M7U\[6N?E_9?!A8_
MA/#HEC\%/B#;_%M90!XA:*>*Q0^9DL'WA,;/EQL'KOKZ\;]E2#Q_X8\!ZCXU
MUW6M/^(F@Z:EI)X@\/:AY-R<9.PR,K;MI=AN !.YCGFOH2BNZOF=:K9QT=V]
MV]^FO3R.2CE]*E>^NB6R6W73KYGB7@']D;P3\/-6\1W]A=:W>2^(-+DTK4%U
M"]$OFQR$&23=L#^8Q')W8Y. *J>'OV-_!NC>)='UC4-;\4^*AHT@ETW3_$&J
M_:;6S8'(,:; 1@@'!)&0,@U[Q17&\9B&V^=ZG5]5H))<BT/&OB'^RMX2\?>-
MV\80ZEK_ (1\3R1B.;5/#&H?8YI@  -QVMS@ 9&,@#/2NN^%?PCT;X1:7?6F
ME76IZC-?3_:;N_U>\:YN)Y-H4%F.!P !P!7;T5G+$59P]G*3L7&A2C/GC'4\
MU^+7P"\._&77O"&K:Y<ZC!<>&+IKNS2QE1$D9FB8B0,C$C,*?=*GKS7.^,_V
M>K6V\9>./B;X::XO/'VK:++8V]C?O$VGM)]G2) 49!U$2 [V*\G(QT]LHIPQ
M-6"45+1:6\F[M?-BGAZ<VVUJ];^:5DS\OM+^#*6GPI?1#\$OB /BUYKB/Q!'
M!-'81DOE2'#B, )@8V=<_/7UU;?LKQ_$+X:^ (_B#JVJVWCOP]:!!KFB7WEW
M41+;@GFE6#%1M&[&<@D'GGZ'HKOKYG6K6<='=N]V]^BOLO(XJ.74J5T]5:VR
M6W73=^9XO\-?V4O"7PN^(/\ PF>FZGK^H:X]I):SRZK>K<?:"[ M+(2@8OP!
MD,!@#C/-:WPD_9U\,_!C1O$FFZ)=:G<P:]*9KIK^:-V0E2N$VHH PQZ@GWKU
M*BN&>*K3NI2;O;\-ON.V.'I0LXQM:_X[GC/AS]D[P-X?^#NI?#5_[0U;P]?7
M37CR7\R&XCF(3#HZ(H4KL&./4'()%<=??L!?#W5M#AT[4=;\6:F;<)':W=YJ
M:2RVL*Y_<1 Q;$C.>0%SP,$<Y^EZ*N.-Q,6VIO5W^9F\)AY))P6BM\@KS7X2
M? +P[\&=<\7:KH=UJ5Q<^)KI;J\6^E1U1E:5@(PJ+@9F?J2>G->E45S1J2C%
MP3T>YTN$924FM5L>+^._V4O"?C3QQ-XPL]5\1>#/$EPFRXU#PMJ/V.2?C!+?
M*W)  .,9P,Y-<9\>/@4G@W]DWQQX6\'6NM^(]1U&ZMKZ03R27]]=S?:;;>_
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M]J+A?WC=<GIS7H]%%95*DJLN>;NS6$(TX\L%9!1116984444 %%%% !1110
M4444 %%%% 'B?[:7_)L7CK_KW@_]*8J^:_'_ (;TJU_X)O\ ANYATZVBN?-M
MKHS)$ YE:=E9R>I8J2,GMQVK[E\9^#-&^(7AB_\ #WB"S&H:/?*$N+8R/'O
M8,/F0AARH/!'2L#4_@?X)UCX:VW@"[T02^$;946+3A<S+M"-N7]X'#G!YY;G
MO7KX7&0H4X0=])\S]+6^\\O$X25:<Y*VL.7YW/B?XOW&MW'QD_9Y-O)HI/\
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M)/62D]NFZ6IA]0KN'(VM(N*WZ]=CYT^,'PST7P+^PVNI>$M!M],U'4-'TO\
MM2]M(AY]Q$[PR2>8_P!Y@7()YX''"\4GQF/@5?\ @GSH0M#8!FL-..GB#9YI
MOMT7GD?[?^MW]_O=\5]BQ>&=+A\-Q^'Q8PR:+':BR%E*OF1F )L$9#9R-HQS
MFO+M)_8\^#FB:Y'J]IX&LQ>QR"5/.GGFB5@<@^4\A3\-M<U+'PT=5RNI<VG7
MR>O^9T5,%/54[6<>7T\UI_D?*_Q!CU*'Q?\ L?IJ_F#4%331()?OC_2;;:&]
M]N,YY]><UZ!^S])9/^VS\96\0&(Z\KO_ &:;W;Y@@#C_ %>>>(A%T_A]J^F_
M%_PA\(^//$_A[Q%KND+?ZSH$PGTVY,\J>0X=7!VJP5L,JGY@>E9'Q)_9S^''
MQ=U./4?%GA>WU/4(T$8NEFEMY2HZ!FB=2P&>,YQ5?7Z4Z?LY)JZ:;5M+ROIJ
MKK[B5@JD)\\6G9IJ_6T;:Z;_ 'GQKX??3(?'W[5,^CSSVW@TZ+=Q/-I:JT8G
M9L+M"_*1N,XX(&TMR.M<YX/EU+XO?"WX:?#DQ^"?#MAI>H)J#:])XBL_MCJ2
MV5^R!_.20[_F!'S%4^Z!FOM3QQ\"X-)^!'BCP5\+;2S\*7NH6Y6%XBR>8Q9=
MX>0Y8ET#)N))&X= *^6M1_9H^(7BGX8:-X"C^"7AKPQJ5JT:7'C<ZG:O-,%/
MS.0F9<MR2"6&. !P!Z5#%T:J<KI:JUVKJT;<UKJ_IKZ'GUL-5I-1LWH[V3L[
MRO:]G;UT.[_:R#?!#]H?X;_&*V1DT^>7^R]8,8)RH!!)[%C"[X'K"/K6O^P5
MHUSXGC\?_%;5(_\ B8>*M6D6 L.5A1B[;>VTN^W_ +9"N@_:>^$7B[Q/^SEX
M?^'_ (8TG_A+]5MS96\]_<7,,#1K!'AI\R.N6<C& 3P[5[+\(_ -O\+OAGX<
M\*V^"NF6:12,.CRGYI7_ .!.S-^->95Q,/J*@G>;]WSY4[KTU_(]&G0E]<<V
MK16O_;S5GZGS]_P4,\-W$/@+PKX\TX%=2\)ZQ'*L@XV1R%?FR/26.'\Z^;/%
M'BR_\3?$74OVC+0R_P!CZ5XPL-/AB(.#;I#ENW]Q8P>A_>].>/TJ\8>#]'\?
M>&K_ ,/Z_9+J.CWZ>7<6S.R!UR"/F4A@00#D$'BN1M/V=_AY8_#6[\ 0>&XT
M\)7<WVB;3S<SDO)N5MWFE_,!RB\AN@QTXIX3,:="BJ<XMM-K_MUV;7J+$X"I
M6JN<)))V?_;RND_0^5/A%:'QU\/?VG_BM,A*ZW9:K96+D](%MY)"!WQAH1G_
M &#7+)#))_P3/D9$9ECUC<Y49"C[8!D^@R0/J17W3X=^#_A#PI\/;KP/I6C+
M:>%KJ&>">P$\K>8DP(E!D9B_S!B,[LCMC IFC?!CP7X?^'<O@2RT&%/"<RNL
MFFRR22JP=MS99V+9W<YSD8&,8%4\RI\UTG92BUZ15K>I/U"?+9M7Y9)^K=_N
M/F3X_P!S#/\ \$]/":QRI(RZ/H6Y58$CY(QS^*L/J#Z5RW[2?AG2=*_8-^%<
MUGIUM:S*-+N1)%&%;S)K-GF;(YR[<MZD#T%?3^G_ +*7PKTOPAJWA>U\*+%H
M>K313WMK]NN297B),9WF7>,$G@$#FNB\5_!/P7XW\!Z9X,UK11>>&=-$*VEB
M+F:,1")/+C ='#G"DCDG/?-33Q]*E*/+>RFY=-FO4J>"JU%*]KN*C\T_0Z7P
MS-)<^&]*FE=I)9+2)W=CDL2@))-?%7[*W_"/#]KOXY'5OL/]I#4=1-F;O;N$
M?VR7S]F[_9V[O]G/;-?<=K;165K#;P)Y<,*"-%SG"@8 _*OC[X<?L?CQ!\8/
MBYJ/Q-\(P7GAS6-6FO='F:]7>X:YF?<IAD$D>4=<AMN<CCCCGP=2G&G7525K
MI>N_175S;%0J.I1<%>S?IMU/"_ :K_PH']IY]/Q_PCQOK(6'E?ZK'VN3.S_@
M!B_#;7N'PU^&NBZ!^Q!=>*/#N@VUOXPNO#-\[ZK;P@WDF\,)!O/S8VKPHZ8X
M -?2$/P/\#6WPWN/ ,'AZ"W\)7(Q-IT,DB>8=P;<T@8.6RJ_,6SP!G KHO"G
MA'2/!'AFP\/Z+9K9:/8Q>1;VN]I B<\;G))ZGDDFNBOF4:B?(FO>3]4DEKZV
M,:.7R@USM?"UZ-MO3TN?'_PF/@5?^">FM?:S8#=IVH"^SL\XW^Z4P ]_,_U6
MS/;;VKE_ ?P9UWXG_LZ?!NZL?$NG:'XRT*\U"_T"QUHH4O8?M"-PI!+!62,C
M*L,. < K7TS=?L<?!J]UM]5E\"V1NW?S&5+B=82<Y_U(D$>/;;BNL^(?P,\"
M?%72],T[Q1X<MM1L],4I91([V_V92%!5#$RE5PB# ./E'I5/,*49-P;UDY.Z
M3MHU9*^N^NVA*P-1Q2FEI%15FU?5.[=M-O/4^3[KXS:E\2?@#\=M%\1^'M+T
M[Q9H4,<.I:IHL:_9[]O-* LP)RX,;\Y((/ &"*PX6\&+_P $W+GR_P"SO[4,
MR^=C'G&_^UC;GOO\H_\ ?!/;-?2WQ(_9^TK1?V>?&7@OX;>&[:RNM3MOW5K%
M*%:XEW+C?+*W)P."S<5R7P3_ &,?!-O\.O"<WC[P/9OXTLH6%WNN692WFN5\
MQ8I/*D(4J,D-TQVK>.+PRI\ZNDIII*U]%VOLWZV,98;$.IR.S;@U=[:OO;?\
MSYJ\8GQ*+_\ 9EBNSI@8:'$UB/%9?^SO-\T[/-V\[?+%MT[;*]Y\.?"GXBQ?
MM)0>/?$.L> ++7'T:YA?2O"]U<"XO?W+B.7R9E^8AFBRV=N$7C/)^C_'OPJ\
M)?$_0X=(\4:#:ZOI\#;H8I 4,)QC*,I#)QQ\I%8?PV_9V^'7PBU&74/"?A>W
MTN_DC,1NFFEGE"$@E0TKL0#@=".E<\\QA.G9*TK-;)K5WWOI]S-X8"<*EV[J
MZ>[3T5MK:_>?._\ P3[;PK/\&O&C:]_9SZFVJRG6CJNPL8/+CV>=O_Y9[O,^
M]QNW=ZB^/GV1/VU/@7)9>2NFM:6ZVSP8\DIYTNT(1QC!7&.Q%>[^(_V2OA'X
ML\23Z]J?@JSFU.>0S2R1SS0I(YZLT:.J$D\G*\G)-;_Q#^ W@+XK:=IECXH\
M-V^I6VF+LLU622!H%P!M5HF5@N%7C..!4O&T7B'7]ZTD[K32ZMIKK^!2PE94
M%1T]UJSUUL[ZZ:?B?-W[0TJ3_MR_!62-UD1K>$AD.0?](F[UP7Q!\82_LF_M
M#?%N.%'AT_Q?H<U]IH3*!;N3)C?CLLIN%QQU'(K[)C_9]^'\6M^%=73P\BZA
MX7MUM=(E%S/BUB4DJNW?M?!9CEPQYH^)_P"S]X ^,M]8WGC#P^FL75E&8H)?
MM4\!5"<E3Y3KN&>><XY]:JECZ$>2$TW!1L]N]T]Q5,%6ES3@TI.5U]UGT/A+
MXG^ -0^'O["OP_1(VABUO6UU;5"5P"98I#!OQ\VWRU3\0.^*]8\3?"3XD>/M
M;^%NM:GK7PET&PT6^MVT>Y\.W5W"]Q%YD9$,6]2)/NC:@(Y/7DU]?:UX,T/Q
M'X8D\.ZII=M?:&\2P-8SINCV+C:,=L8&#U&!7GW@_P#9.^$W@/Q%!KNB>#;:
MVU2WD$L,\MS//Y3@Y#(LDC*I!Z$#CM369QE%N2M*\GLG\7S5NW70EY?*,K1U
MC:*W:V^3OWZ:GK=?-G_!07P_)K?[-^HW$2%SIE_:WK8'1=QB)_\ (M?2=<I\
M5_!:?$7X:>)O#+CG4]/FMXSG&V0J=C?@VT_A7D86K[&O"H^C1ZF)I^UHSIKJ
MF?CQ\%O$ \+?%OP?JCL$B@U2W\UFZ"-G"N?^^2U?M1#(+B"*4<!U#?F*_"BX
MMY;*YD@F1H9X7*.C##*P."#[@U^QG[-/Q&C^)_P8\-ZSY_GWGV98;LL?F$Z?
M+)GTRRL1[$5]3Q#1?[NLO3]5^I\YD=5+GI/U_P _T/2I%R*\;_:&^%>J^,[#
M2/$WA.9;3QUX8F-YI<CG"3@C$MN_^RZC';G'(!->T,,BJ\J=:^1I5)49J<>A
M]14IQJQ<)'RA/XK/[07B'X<ZSH,(T[Q7X1UG.O\ A^_<17%G$Z;)F"M]\#'R
MD=<]CQ7T5<18KC/BI^SYX;^)E[%K!:Y\/^*;<#[-X@TB3R;J/'0,1PZ\G@]N
MXKASX3^/WA,?9].\5>%_&-FI^677;22VN=OH3%E2?<YSCM7?4]EB(Q5.2C;H
M_6^^S7K9G%#VE"4G.+E?JONVZ?*YG?MC>(K'0O@GJ]E=V4M[/JV+.U1(BX23
M(8.3VV[<Y]0*U/@Q\7?"?C[3+/1-(US^T-9TZQB6ZAFADAE;:JJSA9 "PSCD
M>HJG+?\ [0CC#^&O!+#WO9C_ $JIX5^%_P 0M9^)T/CSQ>F@:=J&F:9-9:=I
M^DO(RRN^>9G(^Z,G@>OM6OLZ2P_LYR5U=IJ2>NFEK>7?S,N>HZ_M()V=DTXM
M:>M_T/8;ETLK::XEW>7"C2-M4L< 9. .2?85XAK?[9O@G3-*EGTVPUS6+T#]
MW:IITD6X^[.  /S/M6OYO[0P/_(,\!G_ +>;G_"G*W[0V,?V1X _&XN?\*SI
M8>G%WJM2_P"WK?HRZM>I+^&FO^W;_J<G\/M'U[]K/2%U_P 1^+$L/!S2&,>&
M?#LQ5BPZI=2D!NA'RCL>U?2?@KP-H7@'1HM*\/Z7;:581CB*W3&X^K'JQ]R2
M:X#]GWX2:Q\.;3Q)J/B&ZLYM>\1:BVH7<.F!EM(#T"Q@_4Y./3KBO8XDQ66+
MK<TW3IOW%LEM_P 'UZFN%I<L%.HO?>[>_P#P/0?&E/=> *>B4V9UC1Y&.%0$
MDUYYW'P%_P %*O$JS^(?!^@HWSV\$]W(OLY54/\ XY)7)_\ !.3PZ^K_ !^E
MU'!\K2M*GG+?[3E8@/R=ORKS/]JCXAK\2OC?XBU&!Q)8VLGV"V(.04BR"0?0
MOO8>S"OK+_@F1X-BL_"'BWQ1( ;J]NX[&//58HU+$CV9I,?\ K[RHOJ>4\CW
M:_-_\$^*IOZUFG,MD_R/MFBBBO@S[4**** "BBB@ HHHH **** "OGSQX^O6
M7B:ZTW6]5N[NQE_>01J_E12Q$GY2%QG&,$'-?0=<K\1?!B^,M":*+;'J%N?-
MM93V< _*?8]*Z*$XPFG-71A6A*<&HNS/)M=L=(U#P)<&PL;>SNK1EF*QH 2!
MP3GN,$UY7,OFLJ<?,P7GW.*[33[R1XYK:96AEPT,L;<%3C#*:Y73H#)KNGVY
M!W->1)QUSO KW[*%.26VYXB;G-7W/LBVC\FWBC_NH%Y.>@J6D P*6OF#Z(**
M** "BBB@ HHHH **** ,3QO)Y/@[6W[BRF_] -?/WA6^73%MKJ0X2 +(WT K
MW?XE2>5X \0-_P!.4@_-<5\SW][Y&CQPJ<-*!GZ"O8P*3C._D>5C7:4?F4=8
MU:34[^ZO9C\\TC2-D],GI^%>L_!/X7F62'Q+J\.,?-90..>X,C#^7YUSOP?^
M&;>,;Y=5U*,_V+;M\B,/^/E^>/\ =!Z^M?2:J$4*H 4< #M4XO$\W[N&Q6%H
M6_>2W%HHHKR3TPHHHH **** "BBB@ HHHH *_/#_ (*>Z^T_C?P5HGF'9:Z=
M->&//&99=@./^V)_6OT/K\Q?^"DLK2?'_3U(P$T&W4?3SIS_ %->_DD5+&)]
MDSQ,XE;"-=VB'_@GAX<CU7XRZAJ4J;ET[37,9_NR.Z@'_OE7'XU^D\2\DU\%
M?\$SH%?6?'DIQN2*R4?0F?/\A7WQ$/E-3G4G+&R3Z6_*_P"I6414<)%][_G8
M1JA:IV%0N,"O"/:..^(7B-_#^EM)&<2'I7R%J'[1'B;Q?<7,?ACPUJ&K1QRM
M";NXE6WMRRG!(8D[A^1KW+]ICQ.- \-ZC=A]K6EK),!ZL%) _$X%<!^RIX&C
M3P+H45S%NW6XN'W=2TA,G/O\V/PKZO!0I4,*Z]2-V?.XJ52MB51A*QYT^A?%
M7Q2"]]K-AX>MVZQZ=;FXEQZ%GX!]P:YKP#J=S\&/'$^@^(CY]OJ]T;JTUN0<
MSR' *2D]^G?@GT;(^^$\-V%O$8TMT (QTKPGX^?"+3/$&B7%K=1CR)OF1E'S
M1.,X=?<?J"1T-=&&S*%>?LI1LF95\NG1C[6,KM'J6B_$;3TT:,RN%=5QMKY=
M_:O\46%WH!N1<Q1W$=[!<00LX#R;9!G:.IP,GCTKA/A^/B'XUTR72+;6[6ST
M_3KF2P;5DB,EU<[#C*@\=,#=P?J<U[;\/?V5["VNEU&[MY=4U)B&?4-5<SRD
M^HSP/P&?>M84,/E]1U92U,IUZ^/IJG&.G<]Y^"SDZ,><BO3XZYCPAX<C\.6"
MP)R>YKIHZ^1Q,U4JRE'9GTU&#A34664/2GE<]>E-C%2GM7*:GY$?MB>'$\-?
MM$>+(8DV0W$L=TON7C4N?Q??7UA_P3&UYKKX<>+]&:0L++5([E4)^Z)8@O'M
MF$_K7@/_  4+@2']H'<N,R:5 [8]?,E']!7JG_!+B=A<_$B'^ II[_B#<C^M
M?=8K]YE"D^BC^:1\7AOW>:N*ZN7Y-GV?\2OB9X>^$GA.Y\1^)KX6.FPL$!"[
MGE<_=1%'+,<'CT!)P 37EGAW]M#P5K'B+1](U31?%'@\ZRP73KWQ'I@MK:ZR
M< HX=N"2!N( Y&2*X'_@HOIMVW@KP3K!M9+K1-+UI9-05.5567Y2P]#AER>[
M ?Q5R?[;7Q$\*_'#0OA]X7\!:K:>)_$U]JZ3VQTR;S'MXS&RD.%Y0EF1B&PR
MB,D@"O#PN"I5:=-R3?-S7:VC;^KZGM8G%U*<YJ+2Y;67\U_ZMH>V_%#]L[P#
M\(O&VL^%M?@UD:EIEM'<%K:VC>.X+A"L<9\P'?A\_,%7"MSTS?U;]J_PM8:/
MX9N[/0_%&OWOB&P74[32-&THW-VL#$@,X#;!R&& QZ'VSXJFGVNH?\%,+O[5
M;Q7'DZ8DT7FH&V2+9IM<9Z$=CVKI/V@?CAXI\-?'/P]\-M$\4:1\,-"N-/%W
M+XCU*SCE3)+_ "J)<1@#9@9(Y)RPX%5]4HMTX1C=N*D]=-O)-_<3]:JI3G*6
MBERK37?S:7WGH.@_M#>%_C;\/O'\.B)J.F:MI&G7*7NE:O;BWNX#Y4@R5#,.
M"I!P<@C!QD9X;_@F^[-^SY<@DD+KER ">@\N$_U->._LUZ@VJ_$WX_W;^(4\
M6/-H-RQUR.U6U6]//[T1+PH/H.*]A_X)O?\ )OMW_P!ARY_]%0UKBJ$</AZL
M(;7@_O3]#/#5I5Z]*<M[27W-'KOQ1^/NB?"S6K'1)M'\0^)-=O(#<Q:9X<TU
MKN?RMQ7>>57&0PQG/!XZ56^%7[2/A+XO67B!]*CU+3M0T$$ZAI.K6P@O(0-V
M<H&(/*L#SP1@XR*\H_:'^.WBW0OCQH'P[TKQ7I7PUT:ZL!>3^)M6M4F5B2_"
M^;^[ &S R1DDY8<"O+_V3M0;5?C1\;[M_$*>+'FTJ5CKD=JMJMZ=_P#K1$O"
M@^@XK&&!@\*ZLE9V3W?5V[6_&YK+&26(5.+NKM;+M?O?\+'LMI^W[\/]2\.R
MZQ8:#XNU"&V!>^BM-+21K"/=M62=A+Y:*QZ?.3["O2M8_:-\#:)\(;/XDW&I
MN?#5ZJBV9(B9II"6'E*A_C!1P1G V-S@9KYC_8R@B;]BWXL,8T+/-JJ.2HRR
MC3H< ^HY/'N:\<UVPNF_8O\ AAJS6TEWHNG>)[LWR*?E 9VV[AZ':ZY[%@/X
MJZWE^'G5=.-U::6^Z:;_ $L<RQU>-)3E9WC?;;5+]3NOVK?CYH_QAUGX5IIF
MF:]H%[9ZG]J:SUVR-K*T4C0^5,F&964[&P0>U?HE7Y^?MI_%7P7\2O%OPJB\
M)ZG:ZY)97BRW%W8J&CA29XC%$S]F.QSY9Y7!R :_0.N''Q4</02BX_%H_4[,
M$W*O6;ES?#JO0_./X1?\)7\2?AI\5O%^J_%WQMHU_P"&'DELA%KL@M&(1W"2
M1L><E0H"LOWAP>E>OZ!\7/&GBG]@G7?%FJ7]U:>(X+6:&WU>W)@FF1)5190R
MXPV-R[EZE2>N:^?_ -FWP/\ !;Q7H?C^?XJ:CI^FWMO>D64T^K-:W"QX8L8H
M@X\PY _@?GC%=M\+M>\3:U^P?\4(]9FNKO1;/-OHUS>9WM #'N12>J*< =@2
MP[8'MXJG!SM;:<-U;1]$^OF>/AJDE"]]X2V=]5U?;R,G6=2\8^!?V9O!?Q9L
M?BUXQD\2ZC=^7)I>J:NUU:3 2R+\D3\\",$YW=3TS7J'[:GQ%\7:;\,OA1>V
M&LZKX4U+6)4;4$TJ[DM'#-#&60E2#A69N#7A7_"'_!BP_9,T[Q/%K%II_P 6
M(T\R-;'6':],XN6"!K<.=@V '<%7'!SSSUO[5&I:[K_[./P,O/&@D&LW$TAO
M6N@8Y&7: K/T(8Q[23QR35>SC+$4W;:<EJDNFENZ7<7M)1HS5]XQ>COUZ]F^
MQZ%J%]XL^!'[57@+P;HOQ \2^-='UX)_:&F^([[[=+ C,59MV!MPJ[P0!C:<
MY!-?:=?G7\5M&\ ?"[XJ?#JY_9ZU>.?Q1=WIBN;'0]4?489(BRX60[WX;Y@5
M+?=&<#&:^M?$GPS^+&I^*[N_TGXS_P!BZ))/YD.C_P#"+6D_DQ\?N_.9MS=_
MF//->)C:4)JE-R4;IZM--V?5)/Y?F>MA*DH.I%1YK/HTTKKHVU\RCXO_ &N?
M!?@OXC:WX&O+'7KKQ'IJP>7::?8BX:_DE1)%BMU5RS/MD!.X*/E//3.S\(?V
MDO!_QEBUL::U]HU]HN3J&GZY"MM/;*,@NPW,H4$$'GC'..*^9I_&WA_P%_P4
MD\4:AXDOK?2[&6RAMH[V[(6*&5K"VVEG/" @,NXX'S<\&N=\.6-[\5/C#^TI
MK_@D27^D7?AN]L;:ZM0P2YG<PD(A PQ<0S8]=P[&MW@*+IIV:]V,N;I=V37]
M,R6-JJ;5T_>DK=;*^I]"7'[=?P]AEGN(]+\4W?AR"Z%G)XHM])+:8DA/ ,FX
M-[XVY(Z"NL^*/[4W@?X1:AX8@UN2^EM/$-NUW::C8PK+;K$ I#.=P;#!AC:K
M9S7QE\*DM?%?[.9\-ZQ^T'I'@S00)8K[PE?:!:O/$?/+_*Y=9I<G:^Y<D9Q_
M#75?%[PW9>'/B%^R?HUKJ7]OZ="]C'#?26YA%U";JV*L8V)*@J1\IR0.#6DL
MOPRJJGKIS=]DKIW<4K^ET9QQV(=+GTUY>W5VV3;MZV9].?#K]JOPG\1?'_\
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M^/\ ^S"KJ'4V.FY5AD']ZE=S\1(UC_X*0?"XHH4R>')F<J,;CY6HC)]> !^
MK'ZG0]FDT^9QE*]_Y6^GR-?K5;VCU5E**M;O;J8/PL_;!\7:U^T#XLTG5?#W
MB[5/#A.RPT&UT&+[;I1,B*'N0N'10"=Q9FP2*^Q]>UW3_"^B7VKZK=1V6FV,
M+W%Q<2_=CC498G'/0=!S7Q?\)_$VD_#O]N;XN-XGU*UT%;R%EMCJ$JQ"8O+
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M10F'P>?FS75T4*<ELP<(O=%/3-'L-$TR#3=.L;:PTZ!/+BM+6%8X8T_NJB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M\-ZS:ZC P&1$_P R$]F4\J?8@'VKK=U?'2BXOEDK,^JC)27-%W1&4]J;Y=3
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M@ZMW9V/=F8EB>Y)K?HHKX*4G)N4GJS[=)122V04445(PHHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M,5V%%%?)2E*<G*3NV?3QC&"48JR04445)04444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%> _'#]M'P%\&9+C3DN#XF\1Q @Z9IL@*QM
M_=EEY5#[<L/[M;T:%2O+DI1NS&K6IT8\]1V1[]61XA\7:%X2MOM&N:UI^C08
MSYNH720+CZN17Y<?$_\ ;L^*/Q#FFBL=4'A'2VR%M=&^23'^U.?WF?\ =*CV
MKY_O]0NM5NY+J]N9KRZD.YY[B0N[GU+'DU]+0X?J25ZT[>2U_K\3YZMGE.+M
M2C?UT/U^U;]KSX.Z*Q%QX^TR0@X_T027(_\ (:M64O[</P1>;RAXX3=G&3IM
MX%_[Z\G'ZU^3FGZ'J.KDBQT^ZO2/^?>%I/Y UI/\/O%,<9D?PUK"(."S6$H'
MY[:[_P"PL)'251W]5_D<?]LXEZQ@ON?^9^O&@_M.?"GQ)*L5CX^T/S&^ZES=
MK;EO8"3;D^U>C6.H6NIVR7-G<PW=N_*S02!T;Z$<&OPGN;2>RE,5Q#)!(.J2
MJ5/Y&MCPGX]\2> [S[5X<U[4=#GSDO87+Q;O]X*0&'L<UC4X>@U>E4^]?Y&M
M//9)VJ0^X_<BBOS9^%'_  4>\8^&G@L_&VGV_BK3P0K7D %O>*/7@;'QZ%5)
M[M7W)\)/CUX)^-NG/<^%=8CNIXEW3V$P\JZ@&<9:,\X_VAE?>OG<5EV(PFM2
M.G=:K^O4][#8^ABM(/7L]ST*BBBO,/0"BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***C-Q$)!'YB^8
M?X<\T 245EZAJXMW:..:W65?X)&Y_F*J3>)I--13?VVP'^*)@?T/^-<\Z].%
M^9VL;*C.2T1OT56L-1M]2A\VWD#KT/J#[BK-;1E&:4HNZ9DTXNS"BBBJ$%%%
M% !1110 4444 %(>GI2T4 <7!\(O#0U*?4;VT;5;^9R[SWSF3GV'3 [<5UMI
M8VUA"(K6WBMHAT2) H'X"IZ*;;>XDD@HHHI#"BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ?,C_L!_"]XBHBU-&_OK>-D?GD?I7+>(/^"<7A2[0G1O$NK:=(?^?H1W"#Z
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MBZM H?'(!GO<C/O@?D*\2\#:/J&J_L9?&2#2XY'%OXAAN)H8<C,"-$7X'4*
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M,?FK:7#,%8C###+RN1SUX-?7OB?P3X=\:P10>(M!TS7H826CCU.SCN50G&2
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M_AU_"OPMU[0[SPSK=_I&HPFWO[&=[:>)NJNC%6'YBOWUG.001D'M7Y]?MO\
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MT9HFGJ@HHHI#"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M/(/VDO!(\1^#'U")MEQ9#GDX*$_T/\S7Q!IFE:G'XG"Q+(@B.Z4*?OICCZYK
M]*?%6CCQ!X=U#3B_EFXA9 WH>H/YU\2?$76]!\,SI:6L/^G6V(WN@>H'85Y&
M8X6G6I.<G:Q^@<.8BI5IRPJ3E^B/#/$%_J\\DHN/.AC9CMA *A1GIBK_ ,/;
MZ6UU..61,;&4JK<9PP->C:^BZGX7N=2GTR2TNHBJN)%*^8N/O 'GCBN%T74K
M>]U"&TLX#-<2, JKAB3_ $KXZ5&G)2IIJR/KE3<EL?H]\.O%6F^)/#-@UG/$
M94A420JPW(V.>/3/>NJKX/\ "^J:GX4U9702VEQ;-AX]V#Z]J^O_ (=_$2Q\
M;:/%()ECOE&V2%V 8GU K[/!XN-5*FU:RT[/T/S/,\IG@_WL'S1?X'8T445Z
MI\Z%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %>)?M8?M!
M0? /X=/<VK1R>)=3WV^EP/SAL?-,1W5,@^Y*CO7M4TT=M#)+*ZQ11J6=W.%4
M#DDGL*_'7]I[XSS?'#XM:KK22.='MV-GI<1)PMNA.UL=BYRQ^N.U>UE6"^MU
M[S^&.K_1'D9GB_JM'W?BEM_F>;7=UJ7BO79)YWGU/5M0GRS'+RSRNWIU))/0
M5^D7[*'[*MC\)=(AU_7HHKSQ;=QY8D!ELU(_U:'U_O,.O0?+][R/]@/X IJ=
MPWQ&UJW#P1,T.E12+D%@</-^>4'T?V-?>J)GKT%>EG.8-R>%I/1;_P"7R//R
MG I+ZS56KV_S(UBSR>!3\A1CI3G-02/FODSZ<<9/>FF3WKG?%'C33_"J1"Z+
MRSRG]W;0+OD8=VQZ#G\JM:/K]CK]DMU87"7$+=U/*GT(Z@^QK5TIJ'M&M.Y"
MG%RY$]36W^]<;\7_ (HV7PC\!:AXBNT-Q-&!#9V: EKJY?B*)0.>3UQT )[5
MU0DKP']J&*/0/$?PO\=WX-SH/A_7%CU"UE.88UG 5+DKTS$R@@^K#WK7"TXU
M:T82V_/R^>QCB9RITI2CO^7G\MR>?XT?&SP]HDFJ:O\ !FUO;6&W-S,UAX@B
M1XU"[FS&RLQ(&> "?K7*^ ?AKK_[4'ANU^)NO^.M0T34KEI'\/6F@.4M]'"2
M,AW X,KDH0V2,CC.,!?H*\^)WA6PT*^UE_$&FRZ?90-<330722 (HR<;2<GT
M'<U\T?L]?#GXL'P/<:AX-\2V'@;PEK6H7&IZ9I6HV O;B"WD;]WECP 552!W
MZ_Q5ZE*:]E.<8QIR36NNN]UK?\%MHSSJL7[2,)-U(M/33RL]+?B]]CUG]GSQ
MQXD^(>G>,=!\9)I^JR^'-3DT5]7LU*Q:@R ^9NC(PI *YQP=W08Y^2?VO_V4
M3\,+J7Q;X5MF;PO.^;JT09^PN3U'_3,DX_V2<=",?<OP+^%;?"+P$NB76HC6
M=2GO+B_O=0$7E?:)I7+%MN3C"[1U_A_"NPUW0K/Q#I-YIFH0)=65U$T,L,@R
MKHP(((]""165/'?5,5*I0^#MT:_3NNQI4P?UK#*G6^+OU7];/N?D;^S_ /&W
M5O@1\0[+7[!WEL'98M2L0V%NK<GYE_WAU4]B!VR#^POA3Q1IOC7PYIVNZ1<K
M=Z9?PK/!,O\ $I_J.A'J#7X_?M%_!NX^"7Q,O]#P[Z7+_I.GSOSOA8G"D]V4
M@J?7 /<5]0_\$W?C5)Y^I?#74IRR$/J&E%S]TC'G1#VZ.!_OU[V;8:&*PZQE
M'=+[U_P#Q,KQ$\-6>$J]?P?_  3[VKY6_P""D/\ R;[:?]ARV_\ 14U?5-97
MB/PKHGC'3O[/U_1[#7+#>)/LNI6J7$6\9PVUP1D9//O7R6%K+#UH56KV=SZC
M$TG7HRIIVNCXO^,_[+7PP\)_LK7OC#2O#'V7Q''I-E<K>_;[I\22-"';8TI3
MD.W&W'/%><_'[_DQ_P""?_7PW_H$M?HWJ/A[2M7T5]'O],L[W29(Q$]A<0))
M R#&%,9!4@8'&.PK,O?AMX1U+1+'1KOPMHMUI%@P:TT^?3X7M[<\\QQE=J'D
M] .M>I1S1QY75O*TN;5]+6L>=5RY2YE3M&\;;=;WN?$OQW^)5]\)/VS=>UW2
M=2TKPM>2:#!;/=>)[6ZN;2^5E3F,6T;R)C8H!Z;H6!."16UX"T[PSIO['?Q>
M?1_&=EXQUC48;G4=5ELHGA2"21!M41R*KA>"=Q49)(QQ7H^O_ #XF^&/CYX@
M^)7@#6O"^H2ZU"(9+3Q;'<$VR[5&V-X@6P-@Q@KP<$'&3L? ']E^;X?ZAXTU
M[QM>:;XAUOQ8Q%]8VEMC3EC+%V01NOS98GJH   QUKJGB:"H0M+5*&V[MT>E
MU;O<YH8>LZTKQT;E\K]5KK?T/&M'@B'_  2ZF/EIEX9G;Y1\S#5FP3[\#GV%
M>G_"KP/\0_%7P-^&=QX0^)__  @]E'H$$<UG_8%OJ'G2<G?OE8%>"!M''&>]
M>_CP/X<7PQ_PC8\/Z6/#NW9_9 LH_LFW=OQY.W9C=\W3KSUK1TO2[+1-.M[#
M3K."PL+9!'!:VL2QQ1(.BJJ@!0/05YM3'<T9**U<W+5)[]+.YZ%/!\KBY/11
M4=&UMYH^)_VZ-*U?P]X?^#$OB'6#KUQI^J2)?ZXUJEJDKDQ,&,:$JF51N!_=
M-'[=OB?1?&K?![4-$U.SUO3'UJXB%U93+-"Y5[<, RD@X/'%?:.O^&])\5Z<
M^GZWI=EK%@Y#-:W]ND\3$="4<$'\JR6^%W@Q[#3;%O".A-9:9(9K&V.FP^7:
MR$@EXEVX1B0#E<'BM:./A3]DY1UAS;6M[US.K@I3]HHRTGR[^5CYG_:J4+^U
M=\ '  <WX!8=2/M$7'ZG\ZR/@_I=GJ?_  41^*+7=K#=-:Z9+/ 9D#>5)NLT
MW+GH=KL,^C'UKZ_U7P?H.NZKI^IZEHFG:AJ6G-OLKR[M(Y9K5L@YC=@2AR <
MJ1T%)9>#M TW7[S7;31--M=;O$\NYU*&TC2YG7CY7D W,/E7@GL/2HCCHQH^
MSMKRN/WNY4L&Y5?:7TYE+[E8^19M=TGX3_\ !0?7M5\7RPZ)HNKZ%%!I%_>M
MY5M&1#;+D.?E49AF3J "WO3OA9?V?Q._;V\3^+O"3+>^&K#2Q!=ZI;DF">4P
MQQ@!NC$L./41$BOK?Q-X,\/^-+:.V\0Z%INNV\9W)%J=G'<(I]0'! / _*I]
M \-Z1X4T];#1-*LM'L5.X6MA;I!$#P,[4 &>!^5#QT.32+YG'DWTMW]06#ES
MZR]WFYO._8_/W]FSXJ^&?AM^R]\5/"7B#44L?$[WM[##I!YN9Y)K6.W18TZL
M?,1@<?=ZFN&>18/V*?!DQAFBDA\:R2)J@!:&RPGWI$ .X'/ QGY?P/Z52?#?
MPE+K\FN/X6T5];DSOU)M/A-RV>#F3;N/YUXY^T'^RY)\0-#\(P> GT3PJWAO
M4'U"#29+(1Z=<.Q0YDCC7&04_NG(=@>M>C2S&A.M=IQYI*3;>FB:ML<-7 5H
MTK)WLK+ONCR;X#>.-,^+/[1^E>,O%?Q*\,:EXEL].;2]*TC0;*\M8Y<J^26N
MHD);$DAVC.2>, 8K2_8]13^U'^T&VT;AJ]R V.0#?3Y_D/RKK(?V<OB+\2?C
M!X3\;_%#6/#$"^&9$GM+/PI%.#.Z.'7S'F (&Y02.> 0 ,U]%:1X/T'P_J6H
MZCI>B:=INH:B_FWMW9VD<4MT^2=TKJ 7.6)RQ/)/K7-B<52C&4(._-%+396=
M[7LK_<;X?#U)2C.>G+)OS=U;N[?>?GM\+U"?LT_M)HH"HM^ %' '[PU:C^+W
M@<_\$^9?"*ZG:+XH&+4Z3A1</,;P2^8$ZE=G._VQUXK[$^*GP2T_Q%\)/&7A
M;PAI6B^';_7X?FEBMEMHI9=P.^4Q(23P><$\UG?!/]GC1? ?PX\*:9XGT'P]
MK7BC1H60ZJMDDS*3*[CRY9$#@ /CM6[Q]"475DG?G4DKZZ17X:&*P5:,E3BU
M;D:;]7^9\G^,]/NOA>?V4-6\41OIMAIZH;R>8'_1AY\4N''52J."1_LL.QKI
M/&GQ#T'XD_\ !0'X<7OAN_CU;3K"V73GOK<AX)9E^TR,(W'#@"9!D<9S7VYX
MA\,Z/XMTYM/US2;'6;!F#FUU"V2>(L.AVN",\GM6?9?#CPEIMUIMU:>%]%M;
MG3%9+&:#3X4>T5L[A$0N4!R<[<9S7,LQ@U><7S6DM]/>;?ZG0\!-.T9>[>+\
M_=LOT/D7P1XDTGX;?\% OB?=^*=2M- M;O2&6WGOYEB28N;-T56)P255L <Y
M4CKQ7TI#\>_#L_QOG^%B6NI'Q##:"\>X\E/LNW8K[=V_=G:P_AQ[UU&O?#SP
MKXJU&WO]:\,Z/K%_;@"&ZO["*>6/!R-K.I(YYXKC?AQ\"X?!?Q)\9>/-4U7_
M (2#Q+XAFPER;;R5LK08"6Z#>V0 J MD9V+P.<\U2O0KKFFFI**2\VK)/TWO
M<WIT:U!\L&K.3?R=V5OVH]!\$^*/A-=:7X\UMO#NCW-U"D6IJ"?(N,DQDX!&
M."#NP,'J#@U\\_!?XA>-X/B1KWP@L?&UG\4O#QT&Y-EKED5S:-Y1$0,RD_Q;
M4(+L 67#<$5]K:OHVG^(-/EL=4L;;4K&7B2VNX5EC?ORK @U0\,^!_#G@J*6
M+P]X?TO08I3F1-,LH[97/N$49J:.*C3H2I25^U[63[[7_'4NKAI5*RJ1=N^]
MVNW;_(^0/V'_ (U>!/A?\$]8TCQ5X@L?#6L:=JMQ+=V5^WESN"J*"L>-SD;2
MI506&SD#BKOC[]HOQ5KOQY\0^$;7XC:1\(_#&D627,.IZCIT=S+? QI("JSX
M!+!\A00<#@,:^I=0^%O@O5]:_MB^\(:#>ZON#_;[C3(9)\^OF%2V?QJ;Q#\.
M?"?BZ^AO==\+Z-K5Y" L5QJ&GQ3R1C.<*SJ2.?2MWB\/*M*LX-N5][.STV35
MN^Y@L+7C2C24U:/:ZNO.S_(^ _V?Y?/_ &7_ -HJ3[3]MW[V^T^7Y?FY1_GV
M_P .>N.V:W/#7QO\2_![]D/X-6WANYL])DU[4+^TN-;OX3+%8H+Z7YBN"/XB
M>0>$; /;[CMO 'A>RL]5M+?PWI$%KJS,^H016,2I>,>IF4+B0G)R6SUHD^'W
MA:7PS'X<?PUI#^'HN4TEK"(VB<EN(MNP<DGIU)K:>8TJDFYPNG)2MZ1M_P $
MSA@*D(I1G9J+5_\ MZ__  #X:\#:M=:O^WG\/GO/B/9?%"YATVYADUG3["&U
MAB(M;QO(7RB4DV[@V\'_ ):8_AQ5_P#9S^(WA;X=?M3_ !RF\4:K::&EYJU^
MEM>WQ$<1*7DK/'YAX#$;2%S\VWC)Q7VAI/PR\'Z!>6-WIGA/0].N[$.+2>TT
MZ&)[<.-K^6RJ"FX<'&,CK4=W\*?!-^FH)=>#] N4U&X^UWJS:9 PN9N3YLF5
M^=_F;YFR?F/K4SS"E43BXNSBHZ66S;OHK?((8&I!J2DKJ3EU>ZMU=SX!^&-I
M+>_L_P#[37B6WADCT#5[B+[!(R%%?9/*S;1TX6:/..G2L_XA6.H1?LU?LW:V
MES+IVCZ=>W@N]26V^TI9N]VK1R-$?E? CE(4\-@CO7Z0?\(CH7_".'P__8NG
M?V"8S$=+^R1_92A.2OE8VXSSC&*6'PEH=MX>708M&T^+0U3RUTQ+5!;!<YVB
M(#;C/.,=:T_M5<_/R?:O\N7E^_J1_9CY.7F^S;Y\W-]Q\B^'?">F>//CM\.]
M:U?]HG2?'_B&QD:73M/TW0K>*26-4:5XW>WD(C^5&/[P9'(')KZ'\!_'OP[\
M1/B1XM\%:9:ZE'JOAES'>37,*+!(0Y0^6P<D\C^)5KH] ^&OA3P=+-<>'/#&
MAZ!>2*5,^GZ;% 3G^]L"DCVS7*_ OX&6WP:LM=GGU-O$/B77KZ2_U36I(/):
MX=F)50FYMJKN8XR>6)] .*M7I5XMRO=)**LEUN]DE;]?P[*5&K1DE&UFVY/5
M]--VW?\ 0]0HHHKRCT@HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ J&]O(-.LY[JYE6"V@C:665SA451DD^P -35Y;
M^U'?W6F_L\^/Y[-F6?\ LF9-R'!"L-KG/^Z6K6E#VE2,.[2,ZD_9PE/LKEU/
MCUX5C\'>%O$=]_:FG6OB9@NE6K:9/<75QE2R8BMUD;YD&\?[)'0\5N^$OB9X
M<\;WM[8Z5?O_ &G98^TZ9?6LUE>PJ0I5VMYT20(0RX?;M/8G!KR+XJ65OINL
M_L\6EHH6UM];ABA53D!%LG"X_ "MOXBQQ']IWX0M8JAU(6FK_;S$!O%CY"[/
M,QSL\\Q[<\9+8[UVNA2DE:ZNI/[K^7EW.-5JB;O;1Q7WV_S['4:5\>/".O7,
ML.F-KFI"*Z>R>>S\-:E- LR/L=3,MN4^5N"=V!ZXKJ--\8Z/K'B;6O#UI=^=
MJ^C);R7UMY3KY*SJS1'<0%;<$;[I.,<XXKPK]E.R\52>'M9FL]9T>#0!XJU3
MS;&?2)9+IA]I;=MG%RJKGMF(X]ZZGX;?\G,?&G_KST#_ -$W-*KAZ<)5(Q?P
MK]4NR[CI5ZDHPE)?$_T;[OL=G\6OB*/AAX.?5X].;6=0ENK>PL-,27RFN[F:
M58XXPVUL<MG.#P#6SI/C'1]<\0:[H=C=^?JFAO#'J$'E.OD-+&)8QN("ME"#
M\I..AP>*\T\9.OCS]HKP=X:5_,L/"EI+XFU"/=E&N'S;V:D#HRYFD&?0'Z\[
MX/L?%=W^T-\;3X<UK1M*C6ZTCSEU32);XN?[.CP5*74.T=>"&S[4E0@Z?O.S
M2YOO:27W:_,;K353175[?<FV_OT^1ZF?B_X9>SO+JUDU34XK/4I])N/[+T6]
MO&BNH3B5&6&%B #QNQM/8FJWA'XX^$/'-NMUI%SJ<NG-'++_ &G<Z)?6MD$C
MW>83<RPK$-I5@<MU!'6N._942ZCT#X@I?30W%ZOCC61/-;Q&*.23SAN94+,5
M4G)"EF('&3UJG^S/X<M/&/[)VG:!J'F?8-5M]4L;CRFVOY<MU<HVT\X.&.#5
M5*%*FIWOHTM^Z?EY$PK59N-K:IO[K>?F>C^$_C!X5\;W]M::3>W3R74+7%H]
MUIMU:Q7D:XW/!)-&J3 ;E.8RW!!Z<T:Y\11I?Q/\,>"[73FO[G5;6ZO[NX67
M:+"VA"A9&7:=V^5TC R,9)] ?/? VO\ C+X0^-?!_P -/%4FG>)=$U2WEM-"
M\0V2-;72_9;?S&CNX"64G8-JO&W.P%AEN*OA&6^\:ZW\9?'^EF2XN5CE\->'
MS$2S!;.-][1$<$27+L1C.=@_$>'A&3E]FVFN]W9=%ZV?8%7DTE]J^NFUE=]_
M2_F>@7WQW\$Z?>7D,FJW$D%E<"TN]2MM-NIM/M9<J&6:\2(P1[2PW[Y $_BV
MX-7D^+OA%_B4_@ :PH\7)!]I.G&"4'R]H;(D*["=IS@-GKQP:Y_]EZ/38_V>
M?A]_93(]LVCP/(R=/M!7,^??S3)GWS7AGQ/TZZL/C)\6_'.DQ-)K?@D^'=:A
M6,?-+;""Y2[ASV5H&DSZ[1]14,/2G4G3U7+^=TETT5WJ3.O4A3A4T=_RLV^N
MKTT/I;Q_\5_"GPN&E'Q1JRZ7_:EP+6S!@EE,LG'&$5L#D?,< 9'/-6[?QWI\
MWQ!O/!SQ7%OJT&G1ZI&TJ+Y5S TC1LT; DY1U 8,%(WH1D'(^2?CCJ]M\7[#
MQ3X_LY%N_#NC7VE>'M#N%^Y,S7UO->3*,]V\F,' XC(]:]V^(JFU_:1^#]Q
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MRX++G72U=W^B/C<9S8O'JBWHK+]6?HGX*\)V/@GPKI>A:;"+>SLH$@CCP,@
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M&N)%=PP1]IB (W $$ G".%G*UK:V_&]E\[&TL3"-[]+_ (6N_E<^F**\7O\
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MM1M[21[>W(FF8B20#:IP0>2.H]:^L:*Y88Z4(QCR[*2_\".F>#C-R=]W%_\
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M+9/AO\4[R>&(KI.LEKRU8#Y5R<.GU!_0U],_LD_M5Z=\9M AT36)8[/Q?91
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M8QSVLHZ212#E&'M7GWP^_8^\'^$-2O;_ %BZOO'%S-9KIL#>(2LPMK53D1(
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M.:^A'_98BF\2Q:A>:U/J9)WS3W0.\^P ->WZ-HZ:+8QVR32S*BA0TA'0#L
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M'=QJVAOKGB"_MKJVGBFF-LB120.0[&(,"1$W13U'X?9-%4L?64G)/5\K_P#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR_R/.6)S/$ZTTTO)6_%_YEIO^"EWQ0,NX:+X4"_W/L=SC_THS6UHW_!3OQC
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M^'C>*=3'B#5$\S3K9_W"2 $32#N1_=7^=?155M.T^WTFP@L[2)8;:! D<:C
M4"K-?-U:CJRYF>_3IJG'E04445D:A1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:EJIUIU(J,GL*%*,).45N%%%%8&P4444 %%%% !1110 4444 %%%% !1110
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MZGF:U4W_ .!?\$Y7P=_P4V\5V4\:>)_"NE:K;#AI-->2UE^OS&12?; KZ/\
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MA,SHXKW?AEV_R/:Z***\4]<**** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH ***^:?VAOVT[3X$^/4\,P>%9?$SPV<=Y?W$5]Y'V17?:JE?*;<<%3U ^=
M1WKHH8>KB9^SI*[,*U>GAX\]5V1]+45QGCKXF6GA+X3ZIX[LX!K%C:Z;_:<$
M22^6+B,H&7#X.,@CG!JM\#/BD/C3\+-#\9C3#HXU/SO]",_G^7Y<\D7W]JYS
MY>?NCK4^QFJ?M;>[>WS*]K#G]G?6U_D=Y17SCIGQ>\6>.?VQK[P9H6I"#P1X
M9T\OJ\*6\3?:+@KP/,92ZD/(BX4C_5-6!\)_V\K3XD?%#3O"=[X.ET&UU&ZF
MLK756U'SU>9!D(4\I<%LJ.&."Z]N:ZOJ%=KFBKV2D_)._P"-E?2YS?7:-[2=
MKMI>;7]=3ZMHKR?]HW]H"S_9\\)6.J2:4^O:EJ%XMG9Z9'/Y+2M@EFW[6P ,
M?PG)91WR.(T3]L2/6?V:=>^+0\)M$=)O5LVT?^T<^83+#&&$WE<#]^#]S^$C
MWK.&#KU(*I&.C=EMN:3Q5&$W3E+5*[WV/H^BN7^%_C<?$KX>>'_%(LSIPU:S
MCN_LIE\SRMPSMW8&['K@5U%<LHN$G&6Z.B,E)*2V84445)04452UN^?3-&O[
MR-5:2WMY)55NA*J2 ?RII7=A-VU+M%?-GP(_:NO/&?[/WBGXE>--.MX$T+4)
M;:2WT*%LO$L<##"RR'+9F(Y8#@=*](A^*.J?$/X''QK\-M(_M'5;ZU:72]-U
M@K#O<2%"LF) HQM8_? .!R,UUU,)5I2<9JUG:_2_J<T,33J14HO=7MUMZ'I=
M%<S\-;_Q1J?@;2+KQIIMKI'BB2(F^LK)P\,3[C@*0[_P[3]X\D\UTU<LH\LG
M'L=$7S),****DH**** "BBB@ HHHH **\U^.7Q]\._L_:'INJ^([74KJVO[K
M[+&NFQ)(RMM+98.Z\8!Z$GVKTJM'3E&*FUH]OEN0IQE)P3U6_P PHKB?C!JW
MCC1?!%S<_#O1+'7_ !.)8UBL]1E$<10M\[$EXP2!VWC\<8/1>%KC5;KPQI$^
MO6T-EKDEG"]_;6[;HHK@H#*B')RH;< <G@=30X6@IW7WZ_<'/>7)9_I]YJ44
M45F6%?!/_!1OXZN9K7X8:5,1$%CO=7=#PQSF*$_3 <_5/2ON+Q1XAM/"/AK5
M=;OW$=GIUK)=S,3CY44L>?PK\2O'/C"_\?\ C#6/$>IOOOM3N7N9<= 6/"CV
M P![ 5]+D>%5:LZTEI'\_P#@'SV<XETJ2I1WE^1U?P!^#EY\;/B'9Z'#OBT^
M/]_?W*#_ %4((!P<8W,2 /KGH#7ZT>&?#=AX5T2RTC2[:.SL+2)8HH8EPJJ!
M@8KPS]B3X1+\.?A+;ZI=PA=9U\+>S,1\RQ$?N4_!3GV+L*^C8TV+SU-<V;8Q
MXFNX1?NQT7ZLZ,KPBP]%2:]Z6K_1 JA1@4UVIS' J!WKPSV0+TTO43/432X[
MT 6?-YIRR9JB9:59N>M &DDE3H]<X?$EI'K,>F$O]H<#!"'8"0S!2WJ0CG_@
M/TIMAK]Y)XNN-+FM1';+"98I=K98#9SNZ')=A@<KLY^\* .L&&'-5=5TFUUK
M3KBPO8([FTN(VBEBE4,KJ1@@@\$$$C!ZURGQ1^*6C_"7PK)KNM2M%:JZQ I&
MTA+$X&%7DUQGP5^-VK>,M=U+2?%=OINDW<[_ &G1(;>X5I+JS.<.0';.,#)&
M,$\@=:GG2=CDGBJ4:JH-^\_UVOVOT/SW_:F^!$WP+^(TUG;H[>']0W7&G2G)
M"KGYH23U*9'<DJRD\DU[!_P3U^/9\(>*KCP#J]QMT?5RUQ9/(QVP7*KEA]'5
M?S ]:^J/VM_@^/B_\(-2M;:$/K-@/MMB<?,9$!^0?[P++Z?-GM7Y,V5Y-IUW
M#=6TC0W$+B2.1>JL#D&OT+"5(YK@G1J_$M/\G_7F?)8J#RS%JK3^%Z_YH_:+
MP5;/XNUNX\77B8A.;?2XF_@A!YD^K&N]KC_@_P",+/Q_\+O"_B"PC6&VOK"*
M3REZ1L!M=/\ @+!A^%=A7PE6ZFXM6MH?9T[."DNNH4445D:A1110 4444 %%
M%% !1110 4444 %%%("",@Y![B@!:*** "BBB@ HHHH **** "BBB@ HK*N?
M$EE:>(;71IG,=Y=0M-"#T<*>0/?O6K0 4444 %%%% !1110 4444 %%%% '#
M_$'X66'CR]TZZE?[--!(!,Z#F:'J4)_D>V35KQ?X&BU72[1]*"6&J:8 UA,@
MQLP.$/\ LGI7745:G)6UV(<(N^FYSO@CQ6/%6E%Y8S;:C;-Y-Y;,"#%(.O![
M'J*Z*N!\96DGA#6XO%MA&3!@0ZI @^_%GB3'JO\ *NTDU2TBTQ]1>XC2Q2$S
MM<%OD$8&XMGTQS3E'9QV8HM[2W1S_P 3/B7H/PE\'WOB3Q%>+::?;84#J\TA
M^[&B_P 3'T'8$] :_)W]H3]H[Q)\?_$TEUJ$SV>A0.?L&D1M^[A7IN;^\YQD
MD^N!@5M?M9_M&7GQZ\>2K:R/%X3TN1XM,MB?OCH9V'3<V,CT! ]<VOV5?V8+
MWXZZ]_:&I+):>$;*0"XF&5:Z<<^4A[#IN;MD <G(^WP.#I9;1^M8GXOR\EYG
MQ^,Q53,*OU?#_#^?F_(YWX$_LT^*OCMJ ;3XO[/T*-]L^K7"908ZK&.-[>V0
M!QDC(S^BOP<_9=\#_!FWBET[3EO=8"XDU2\ DF8]\''R#V4 >N>M>H>'/#6F
M^$]&M=*TFRAL+"VC$<4,"!551T  K3P%%?.XW-*V+;BG:/;_ #[GO8/+J6%2
M;5Y=_P#(A$6U0% 51T XI/*'<FI&:HRXKQCUA#&OH::8E)[BE+"DR* &-">Q
MK"\5>#=&\9Z5-IFNZ7;:G92CYX;F(.I/KSW&>#U':N@W4I (P>133<7=":35
MF? GQ^_8*FTM+G6_ATS7%NN9)-#G<LZC'_+%SRW^ZQSZ,3@5\?V-_J7A76X[
MJUFN-+U6QFRLB$QRPR*<'W!!R"*_;66+ ..5]#7R]^U?^R?9_%'3KCQ+X;@C
MM/%ENA9D0!5OU ^X_P#M_P!UOP/&"OUN79RTU1Q3NGU_S_S/F,?E2:=7#*S[
M?Y&Q^Q[^V#!\7K6W\)>*IH[?QE!%B&<X5=251R1V$F,DJ.H!('!KZJK\*+*]
MU'PMK<5S;23Z;JMA/N5AE)895/H>001T-?K1^R?^T+;_ !\^'<4]V\47BC30
M(-3MDXW-_#,H_NN!GV.1V%89OEJP[]O17NO==O\ @&V5Y@Z_[FJ_>6WG_P $
M]OHHHKY@^B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH BN;F*RMI;B>18H(
MD,DDCG 50,DD^@%?F5HWQ6^'GQ!B^/&M^./$(TW7/%R&UT6W>SN)BD41\R#+
M)&P W1VPP2/]6>!Q7Z)?$_P?=_$#X?:_X;LM6.AW&JVKVG]H+#YQB5^'PFY<
MY7</O#KFLSX(_"BS^"GPSTCPC9W7V\60=I;PQ>4;B1W+LY7<V.3@#)P !FO6
MPF(I8:E*3NY-K;31:WO9K>QYF*H5,14C%644GOKJ]-KKI<^5OA3\2!XZ_P""
M?GC339Y=^H>'-.N=-D!/S&+;OA;Z;6V#_KF:]._90\76?@']B31/$E_S::59
MZG=R+NP7V7ER0H/J2 ![D5)I/['"Z%/\6(;#Q<UOHWCR"6/^SAIV18.SLRN&
M\W]X%#NH&%X;KQ7F'[0WA*^^#_[._P /?@/HFI-K>K^(=4:U%TL/D>;$;DS$
M% S;1YDT0^\<A&_#T92P^*;HTI?%-2ZZ+E?-]VIP15?#)5:B^&#CZNZM]YWW
M[ OA"\C^'NO?$#6%+ZWXSU.6]>9^6:%78 ^O,C3'GJ"I]Z^2/#?A&ZO/V=_%
M7C32LIK/@WQE'J,,R]4C98U;'T<0M]$-?J#X,\*V7@?PEHWA[3U"66EVD5I%
M@8RJ*%W'W.,GU)->1?"']E>S^&?PZ\;^$+[7/[?L_%,LSRR&R$'DK)%Y>T#>
M^XCKG(YQQ65+,(QJ5:KZN-EY)O3[C2I@92A3IKHI7?F[:_>>!:UXXM_VJ_C1
M!JEG^]\,^#?!LVJO'NRBWTUMN*_[R.Z#ZV[<UR'@?_E&K\0O^PY%_P"E-C7U
M+\ _V3+'X'>"?%^AC7CK-YXC0PRZC]B$!BB\MD10F]LX+NV=PSGH,5FZ%^QV
MFB_LU>(/A*?%K3_VM>K>G6!IVWRB)(7"^3YIS_J ,[Q][VKH^NX:+5.$O=C*
M%M'LFVW][,?JF(DG.:]Z49WVW>B7W([W]EO_ )-W^'W_ &!X/Y5B_MHG'[,7
MCK'_ #[P?^E,54/A?\!OB7\-AX>TX?&7^T/"NDF./^Q?^$7MHO-@7_EEYV]G
M7(XW<FO1?C1\-A\7_ACKOA ZB=)&J1I']L$/G>5MD5\[-RY^[CJ.M>0Y4X8R
M-533CS7TOHKWZI?@>FHU)X5TW%I\MM;=O)L^!O'7POL_#W[)'@?XK6NK:P?'
M"S6R)J3WTA,, WQQPQKG"*BQIC'/!YP<#H/CIX+@^!\/P>^(^A:KJ[^,-6N(
MYM5U2[O7EDO2RQR-N#?*%.YEV@!2IP0>M?27BW]E1?%'[.&A_"@>)S:C3&A;
M^US8;_,*,Q/[KS!C.X_QG&.]3_&O]EY/C'X3\"Z&WB0Z2OAAHR9A8^<;D+&B
M8QYB[,[,YRW6O8AF--SCSSTYI7T?PM:+;;R/+E@*BC+DCKRQMM\2W?KYGFVX
M_P##R;&3C^P,?^0*Y_X?NW_#<7QT7<=I\-W1(SQQ]CQ_.O:_BS^S+<>./BEI
M/Q$\+>,KGP/XLL8/LSW45BEXDR ,!F-V49VN5.<@@#CC-9GPL_9#B^&7Q$\2
M>+#XPOM<N==TB73;C[?;@S--*\;R7#2;_FRT?"[1@'&3C)YUB:'L[N6O(HVL
M]T_N-WAZWM+<NG.Y7NMFOO/E?X4^#M(\3_L!_$&\U.T^TW.C>()[ZQ?S73R9
MOLUHF_"D!OE=AALCGI7=>#?ACX:\-_L#:_XPTW33;>(M;T22._O1<2MYRK=D
M*-A8HO"C[H%>^?"C]E#3OAW\#O%'PUU'7'UZRUZ>>>6\6U^S-%YD,<8VKO?E
M3$K D]>U9'AK]DW7]%^$OB'X=WOQ,GU7P[>V+6>G0-H\<8T_=-YI<XDW2G.1
M@L.IQBMZF/I3<DJEESJ776/_  ^MF80P52*BW"[Y&NFC_P"&TNCY?^+M_<V/
M[$/P/NH)GCN(-3FDCD!Y5E>?:1],#%=G^TG\-+7]E[Q#\,_&7A'5=5/B:>_:
M'5+^\O9)6U-AL9GEW,<;LNI4<$'ID9*?MH?#(_"7]F7X9^#XKYM8_LS5)(OM
M8@\HREEE?[FYL<OC&3TKVJW_ &.;G5O&'AC4/&7Q%U/QCX?\,,#I&BW=G'$8
M@""HEF5OWO*IDE06"@9QQ71]9IPA"JY^XW4TL_>3>B_'J8+#U)SE34?>2AK=
M>Z[:_ET.'^.LOP:\4_&+7=-UW1/'OQ-\3K$BR:1X<$MQ!I6V-5S%&CQA3QN;
M.\;G;/H/+OAQXGU76OV#OBWI]_?75W;:5?106:7;$R01&6!C'ST&23CL2:^E
M?$/[*6L+\4/$7C+P3\2M0\$R^(EVZG;1:='=&3IDQNSCR^02" 2"3@CI5/PQ
M^QE#X8^"_CSX>Q>+IKB'Q/>+<IJ$U@"]JJLA567S/WA_=\ME<YZ"N6&+PT*4
M(\][.#UOI9Z]++Y7N=,\-B)5)2Y+74EI;6ZTZW?SV.$_9>^"&C>'/A?9_%WQ
M!XUUF"[O/#MQ;7-QYP2.PLPNQ/*."ZM$L?RG)&<87CGP7XNWGPWL_ 5KXG^&
M7ASXA66MVVH)L\=ZB)A;7.-P93,9"H?."-J*>.?2OO[PW\#]/TKX#0_"_4;^
M74M/&F/ILU[$GD.X;=EU7+;2"V0"3TYS7B6H_L+^(=9^'D/@B^^,.H7'AFQ;
MS--T_P#L:-8X&W[LR$2[I0 6 !8!2V1Z%T,=2=:52K4?Q>=N77HEKZ,5;!U/
M91ITX=/*_-IU;T]4<%^TFEYXX^.7P @GU.[TZYUO3+:*XOM/?RID$[A92A'W
M20[#CIFJ4OP2TCPQ^V/#\,-$U/6=(\%:YIJWFH:=::A*IN L;R&-G)W$,T0)
M.<X9@"!7T;XM_9>3Q5\0?AAXG/B1K;_A"8+>'[*+'=]M\I@P._S!Y>2/1JUM
M0_9^%]^TEIOQ9_MXH;/3S8_V1]CSORDB;_.W\?ZS.-AZ=>:SCCZ<*:A&5K0D
MMOM7NO\ @/H:2P4YS<Y1^U'[K:_UU/G+X':J_P #OCW\<_"&@27'_"-:)H=U
MK%EIMQ,TD<<D(B90"V3_ ,MBN>I &22*\>\*6<'Q/^&FO>(]7\'_ !.\7?$V
M^GFFT[Q5H]A+/96TJ_<C5DD  W<-\A*@_*.,'[C\*_LU6WA[X\^-?B/<ZT-2
M@\36#V$FC/9;%B1S#NS)O._/DXQM'WO:N2\._LD>*?ARM_IO@'XPZKX6\+7<
M[3G29-*AO'BW=1',[ H< #( )QSFMHXZ@FY*5I-1UUULM4[)O]&8RP5:RBXW
MBG+332[T>KM^J/FW]K#1=0U;]G?X4^,?&&F7MI\09 =(OIM1$L5P88S,4$D3
M$ ,W#EBNX[N3VKTS]N/X;>'/@W^S9H.C^#M/.C:</%L-T(5N)9B)3:W&6W2,
MS?PKQG'%>Z_%W]F>R^+WP>TCP1J?B+4'O=+>*:#7[P"YN7E5&5FDR5WA@[9&
M1_#SQ6!\2OV6_$'Q;^$%EX-\4_$J;5=4MM835/[<DT>-"46%XEA$*2* /G+;
MMQ).<YS6=/'4[TG*=E&4FUK:SVMY+[T:5,'4M5M"[E%)/3=;_>>&_&GX!VGP
M7_92\5:K%K^IZ[JGB:32+C49]0=2#,DCL63 R ?.Y#%C\HYJ7XD:QJ7C#3/V
M9/AA)J=UIWAWQ!HFFS:H;2<QR72F*)=C'TPK8SD98'' KZD^-GP03XP_"%O
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M542Z'X>U @99[?5)H,GT"M WO_%7Q[A&-K6;\W_PWYGTBJ3E=NZ5WLK[??\
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M0:GH*6]SY,4]VT4Z; WF((9'QD].4'(]: .5M_A7KD5U.TOQ%\020_NA H9
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M5E"$JDE"*NV:RE&$7*3LD=M167X6\0V_B[PQI&NV<<T-IJEG#>PQW"[9521
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MTW4HVDACO$5)5"NR$,%9@#E3T)I.G-0YVM+V^?8?M(.7(GK:_P CJ****S-
MHHHH ***SM?\1Z3X4TR34=;U2RT?3XR%>[U"X2")23@ NY &3QUII-NR$VDK
MLT:*@LKVWU*RM[RSN(KJTN(UEAG@</'(C#*LK#@@@@@CKFIZ0PHHHH ****
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M\O[8$'G&$G9NQSC/:O&Q,81F^1GK8>4I0]]%FBBBN0Z@HHHH **** "BBB@
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MS9",XS\IP!QFNX^-OP/\=VOQ&^&GQ*\ :3INHZUX:L(M,N] M9ULK?RE#_+
M7*A8\32I@X(&W@\@:3>%]JE:/VK/W;;>[>WG_-KW(@L3[-N\OLW7O7WUM?\
M30\OT&P\7Z5_P40\'67C75+37=5M["=(M4M+<6XNX/L5T4=X@<(_+ @<?+QG
MJ?OBOD#PS\)/BUX@_:Y\*_%+Q;X>L=+TM+:XCFM[*_BF&GI]FGBBB<[@TCEG
M!+(I7YNV,#MOV;?B=XU^*GQ.^)U]>:DM_P##S3]0>PT1A:QQJ661L['50S@(
M%)+$_?6N+'0]NHSC)>Y!7MM>[T5M/ZT.O!R]BY0DG[TG:^]K+5WU)OVR_C7X
ME^#'@S0IO#;PZ?+JNH"TGUB>W\]+%,9W;,$$GGJ#PIP">F-IDGCGQI\$_'KV
M_P 9=%\76C60EL-?TW2(!/&BK(US!/;@[$+H$53G<N6.,@5ZG\;W\7_V)91>
M&?!6C>/[*65DU31=6G2$RQ8!7RVD_=YSG.X'J.*\8_9O_9N\2>&M=^(^LZ[I
M-MX$TSQ19M8VOAG3[Q;M;56!RY93M)7)Q@_Q-P!@5-&5*.%YG923O]EMZKIN
MOR:*JJH\397<6K=4EIWV?YW.8_X)V^'O%C_#FZUBT\6I'X<2^NX1X:ETV,K)
M<^5%MF-SGS .5^0#''O4/Q>^*_Q3^%GAB\\13_'/P7J.OV4\?G>"=,L[5@4:
M0(0C,?/;:6R1M!VJQSQ71_LV?"SXK_#3P/XD^&>J^&+73=*OA?20^+(M6C<)
M)+ (X]L"'S/O*&W'!'I7D<7[+7Q.@^#NI>!4^#WAMM;,S3-XSEU*VDNYT602
M+'#D[HR=NS)*J5)!4$DUZ=Z-3%3J5)1:;7\NJ[W?X_:/.M5AAH0A&2=G_-OZ
M+\/LEW]M[4=>\;>#OA!XPEUE;?2]>MK:Y@T1+-"+.XDA21Y1-G<^0ZKM/ V9
M[FO9_CU\7_&W[-?PMT/3;OQ1:>+O&VNZ@]M;Z]?Z?%8P6T0VDNT2$I\NY1DG
M'S$G.,')^.W[.7C+QW^SI\*M)T>RBE\5>$[2R6YTJ6XC0.5M4251(6V;E= /
MO8(SSTS?^/7P>\?_ +1WPR\/ZK>>&M/\,^-="U)[F'P_>7T=Y;W$!V J\B_(
M2Q0'!XP"#US6,:E"<:,)N/)&4K[?]N^=N[V?4VE"M&564$^9J-M_GY7[=>QS
MWA;]H/Q;X%^-/@KPUK'Q.\-?%K0O%#BTDGT:.UCDTZY)50/W!/R[G7!?[PW8
M (KZ:L_C'X!U#6(])M?''ANYU22;[.EC#JUN\[29QL"!]Q;/&,9KQ/X:^#/%
M5QXTT&:^_9Z\ ^ K2SE$MWK"-9W%QE5)#6P@7=&V[;@L3@9YKVRS^#G@'3]8
MCU:U\#^&[;5(YOM"7T.DVZ3K)G.\.$W!L\YSFO.Q;H.2NK.WV>6S>N]M/N.[
M"JNHO72_7FO^.OWGSGX%^)/Q<_:>\1>,;[P3XPL?A_X7T2Z-E91R:3%>S7C@
M$@R&0'8" "2O3=C#8R>6E^-/CCXW_LL_$VTU'58_#WB;PH\MOK,MK9*Z:G:&
M.56@(8CRBQ!!9><(,#YB*Z3X>_#?XP_LQ^(?&>F^#O!MAX]\-:U=F\L;J35H
MK-[5SD#S5D(+84@$+UV@AAG%7O ?[+_BKP?^SI\3M-OG@U+QYXSBFGEMH)@(
MUD*MLBWL0N[+N2V<9;&2!D^BY8:#O'EM>/+M?SOU_P# NNQP*->:M+FO:7-O
M;RMT^[YB_L175UX%_9]T7Q)XK\?V-IX-NEGAL=+U&""SBT^07DP8_:F8&0NP
M8[6Z;L#I5_\ ;$\367Q&_9V\37G@OQ[I-YIFF>4VK6FEM!?BZ1Y4$<;2*Q,.
M&^?(Y.W'3-=K^SG\''T+]G#POX*^(/ARPNKJS:YDN=,U".&]B5FNII$/\:$[
M74Y!.,UH_%?X!Z-KGP7\9>$O!FA:-X:O-8MEVC3[.*UCFEC8/&)-BCC*[<G.
M-QKBE7I?7G5;UY]]+6OO]W7YG7&C5^IJFE]GSO>VWW]/D?.?AWP]XFTW]@;7
M]0U7Q;_;&AWF@H=.T;^S8H/[. N#N'G*=TN[C[PXQ7.>$?$OQF^&/[)&@>/]
M"\5Z78^&=*8)'H TV.5IX'NC&9)9GRVXROC:F/E(.<UZGX<^'WQ6U#]E3Q#\
M,=6\"PZ3>V6DBSTV==8MYFU&0S%SPK;8@%Q]YN3Z=!>U/X'^-)OV#$^',>CA
M_&0@A4Z<+J$<C4%F(\POY?" G[W;'6O1]O33<9N+O4_NM<K6_;Y_?J</L9M*
M4%)6I^:?-?;O\OT*WQM_:KURRL?A;H_AB^TOPIJGC73K;5KG6]8*FWTRWE52
M/O\ R]=_+?W0,9;(/@]^T+K^F?'B3X>>)?'N@_$C1;W3GO[+Q/I:VT(A,:,[
MI((&*+A8Y,@G(PK9P:S/B=^R_P"+M7\._!KQ#I6B:5KOB'PEH=EIFJ>&-9>-
M[>Y6.)=R;B3&V&,BG)P<@@\<^@_!_P %:W<>,OMFL? KP1\-]'2TEB>6U^RW
M5],[@+M5X$"K&5+A@W4''KGFE]4CAVHI/1]5>]]-_>^[3N;Q^LRKIR;6J[VM
M;7R^_4]:\/\ Q;\#>+-3CTW1/&?A[6=1D#,EII^JP3S, ,DA$<DX )/%?*OQ
M>^)WQ4^&OAK5-?N?CIX*?Q#8R(7\$Z99VKAU+A65'D/GDC<21M!PIY%?3?\
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MGRDGDGFO6J\+%-NO-NV_2UOPT/9PR2HQ2OMUO?\ '4****Y3I"BBB@ HHHH
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M8LB:#H&K6^H_9U5#EY)(6*Y)4<]RS'CH>?\ ^"<GPN\*:]\.-4\4ZEH5G?\
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MOQ/^*7@"^^%WQ USPOJ"GS].N6B#D8$B=4<>S*0?QKZG(:L:E*>&EZ_)Z/\
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M#/X(O(;<Z!=,\J7<9*.;8%EP^P$*7<9!R?+.!SBO1]-C_P")/8_]<$Y_X"*
M,GQ%H\.O:9/87#RI#, &,$A1^"#P1R.E9NK:5->WFF31W"1)9SF9U>(N9 8V
M3 .X;?ODYP>G2NDN(^M4I(\T <#I]M#8_%348]J!KG3$N8CCYO\ 6E91],^6
M?JQKMD%<OXAT:ZL]?B\1(ZM!9P"-X%0F0IN/F'.>1M.[&,Y05U<(6159&#*0
M""IR".U %B(8Q5V 56CC-7H$Z4 68ATJVBU!$F*M*N!0 ,,J:^1_^"D4B+\(
M- C/WVUR(@?2">OKEQQ^-?#'_!2[Q&H@\&:$C@LTD]W(F>5VJJJ?Q\Q_RKU<
MKBY8RFEW_0\S,I*.$J-_UJ?/?['$33?M,> U0;B+R1L>PAD)_05^P%?E5_P3
M\T!M8_:4TFZ"[ETNRN[QN.!F,PC]9A7ZJUZ&?R3Q,5VBOS9PY)&V'D^[_1!1
M17@7QX_:!U_X6_&3X6^$M,L=-N=.\4W\=K>RW<<C31JUQ%%F,JX .)"?F#<@
M5X-&C.O/DAOK^&I[=6K&C'GGM_F>^T445@;!1110 4444 %%<)\=/'E_\,/A
M)XG\4Z9#;W%_IEKYT,5VK-$S;E'S!2I(Y[$57_9^^(FH?%CX/>&O%FJV]M:Z
MAJ4,CS16:LL2E973Y0S,0,*#R3UK?V,_9>V^S>WSM<Q]K'VGLNMK_+8]#HHK
MS3P9\?O#OCGXK>*/A_86NI1:UX>0O=37$2+;R ,JGRV#ECRXZJ*B-.4TW%7M
MJRY3C!I2>^QZ717FOA77?B=>?%[Q'I^O>&]+L/AY! 3I.JP3A[JXEW1@!U\T
MD @RGF-<8 R>_I5$X<C2;3]'<(3YU>S7J%%%%9EC)8DFC>.1%DC<%61AD,#U
M!%4=!\.Z5X5TR+3=%TRST?3HB3':6%ND$*$G)PB  9))Z5HT4[NUA65[A111
M2&%%%% !1110 4444 %%4['6=/U2>]@L[ZVNYK*7R+J."97:"3:&V. ?E;:R
MG!P<$'O5RFTUN).^P4444AA1110 4444 %%%% !1533M7L=7%R;&]M[T6T[V
MT_V>59/*E7[T;8)VL,\J>15NFU;<2=]@HHHI#"BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KXG_X**_
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M\DCK'&@+,[' 4#J2:_-;XLR?"'7/!WBW5?".C?$3Q=XDLYBZ^/9O.FM;>7S
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M'Q5H-YI$K$B.2:/,4H!ZI(/E8<=C7UDHX#.%S)VG]S_X)\PI8W*G9J\?O7_
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MBOG<3G6)KNT'RKRW^_\ X8][#Y1AZ*O-<S\]ON/+O#G[+OPM\,1A;3P7I4A
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M/J(\[N/XMH]:\2^ /P)UOX]>.K;1=-CD@TZ,^9J&I;?W=K$.IST+'HJ]23Z
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&(9F122.YQ47E6G]K!]Z_;/+P4W<[<CG'Y5\8?6FBHIX%(HIRBD!$/\ C_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M6,Q>))XK?23"CRF[>1-Z%0@)"[>2YPH&,D9H4)2U2$YQCHV=-1114%A1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MZDE)<K<M-%TTZ7=WMJK"E3Q7+"+B[I+77OKULM/)W,WPC_RDP\;_ /8'C_\
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M#P 6(KIOC[^R??\ COP!\.O"O@R[T_3[+PI,H/\ :DDBF2((J[@41LN2I)R
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M_M7=OF<-\9_BSK/B3XA?"'0=7\:7OPU\&>(]!BU;4-8TNY^R.]PZ,QB$Y^X
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M*]EF$NI6<?V&]&<MYL>%W-[L-K_\#KZOB"CS1IUX[;?JOU/FLCJ\LIT7OO\
MYGL-M'Y4,:?W5 _2DE6?[1$RN@MP"'4CYBV5P0?3&[\Q4RBH+F-_M$<B2?,J
MD"$M@-EEY/TQZ=Z^+/K2X!Q3P*J"2\_Y]X/^_P"?_B*<LE[G_CW@_P"_Y_\
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M8D6RLL%LL>(PB8^;.22?SJ+1? -Q#J=PZR99VP)B.0M>J^0)% (J>"U5&+8
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M-X;N9!(60O&N'5>'#"3"OM# KP37W1X[^'OAWXFZ"VB^*-*@UC3&D67[//D
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M_$^=OVM[R"P_:8^ 6I7,R0:>FI%'NG8")66YA# MT&,C.>G>LCXLZ]IVM_\
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MSO\ ,K@X9AG!(I)?@WX2N?"NL^'KK3KB^TW60!J+7NH7-Q<W0&-H>X>0RD*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6=K_AS2?%>F2:=K>EV6L:?(0SVFH6Z3Q,0<@E'!!P>>E:-%--
MIW0FDU9D%E96^FV5O9V=O%:VEO&L4,$"!(XT48554<     =,5/112&%%%%
M!1110 4444 %%%% !1110 4444 %8_AWP=H'@^.YCT'0]-T1+F3SIUTZTCMQ
M*_\ >8(!N/N>:V**=VE9"LF[A1112&%%%% !1110 4444 8/B;P%X9\:B(>(
M?#NDZ\(O]6-3L8KG9]-ZG%6?#WA71/"-D;/0M'L-%M"=QM].M4@CSZ[4 %:M
M%7SRMRWT)Y8WYK:A1114%'YF?\%#?@XW@OXG1>,K*$C2O$@S,5'$=VH <?\
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M60QR(?8CFOJ*^!PN:1]O0E:7?_-=SYVCC,3ELO8UHWCV_P F?MZLA&,\^]2
M@GKBOS;^&G_!0?QGX5ABM/$VGVWBBU7 $X;[-< >Y *M]-JD]SZ?1GA/]O\
M^&&NQ0C49[_0)V #)>6K,H;_ 'H]XQ[G'OBOEZV58NB_@NO+7_@_@?1T<SPM
M9?%9^>G_  #Z<"#U!IP4"O)-/_:I^%.HJ6C\;:3&!_S\7"Q'\F(HU#]J_P"%
M&EKOE\:Z7*,9_P!&G$Q_),FN#ZM7O;D?W,[/K%&U^=?>CUP8IX/X5\L^,/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX9()!U212I_(TZSL;G4)A%:V\MS*>B0H78_@*_=N6"*< 21I(!TWJ#BB*".
M$1QI&#U"*!7;_K%I_"_'_@')_8.O\3\/^"?C%X6_9U^)OC-E&D^!M;G1N!--
M:-!$?^VDFU?UKW_X=_\ !-;QGKAAN/%^M6'AFV."]M;?Z9<CU!P1&/J&;Z5^
MD5%<-;/<3-6II1_%_C_D=E+)</#6;<OP_K[SQ_X/_LI_#KX+&*YT;1_MVLH,
M'5M383W&?5> J=/X%!^M>P445X%2K.M+GJ2N_,]RG3A2CRTU9!11161H%%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '__
!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>arvn-20251231_g4.jpg
<TEXT>
begin 644 arvn-20251231_g4.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (+!,<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4Z*** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***^:?C!^WW\/O@
MI\1=7\%ZYH_B:ZU33/)\Z;3[6W>!O,A25=I>=6/RR*#E1R#UZUK3I3K/EIJ[
M,JE6%)<TW9'TM17QO_P]/^%'_0O^,O\ P"M/_DJC_AZ?\*/^A?\ &7_@%:?_
M "573]1Q/\C.?ZYA_P"='V117QO_ ,/3_A1_T+_C+_P"M/\ Y*H_X>G_  H_
MZ%_QE_X!6G_R51]1Q/\ (P^N8?\ G1]D45\;_P##T_X4?]"_XR_\ K3_ .2J
M/^'I_P */^A?\9?^ 5I_\E4?4<3_ ",/KF'_ )T?9%%?&_\ P]/^%'_0O^,O
M_ *T_P#DJC_AZ?\ "C_H7_&7_@%:?_)5'U'$_P C#ZYA_P"='V117QO_ ,/3
M_A1_T+_C+_P"M/\ Y*H_X>G_  H_Z%_QE_X!6G_R51]1Q/\ (P^N8?\ G1]D
M45\;_P##T_X4?]"_XR_\ K3_ .2J/^'I_P */^A?\9?^ 5I_\E4?4<3_ ",/
MKF'_ )T?9%%?&_\ P]/^%'_0O^,O_ *T_P#DJC_AZ?\ "C_H7_&7_@%:?_)5
M'U'$_P C#ZYA_P"='V117QO_ ,/3_A1_T+_C+_P"M/\ Y*H_X>G_  H_Z%_Q
ME_X!6G_R51]1Q/\ (P^N8?\ G1]D45\;_P##T_X4?]"_XR_\ K3_ .2J/^'I
M_P */^A?\9?^ 5I_\E4?4<3_ ",/KF'_ )T?9%%>/? /]JGP-^T7%>KX:FO+
M/4+,YETW58TBN=G9PJ.X*^X/UQ7L-<DX2IRY9JS.J$XU(\T'=!17@7Q^_;1\
M$_LY^,;/PWXDTO7[Z^NK!-1232K>"2(1M))& 2\R'=F)N,8P1SZ>:?\ #T_X
M4?\ 0O\ C+_P"M/_ )*KHAA*\XJ48-IF$L51A)QE))GV117QO_P]/^%'_0O^
M,O\ P"M/_DJC_AZ?\*/^A?\ &7_@%:?_ "55_4<3_(R/KF'_ )T?9%%?&_\
MP]/^%'_0O^,O_ *T_P#DJC_AZ?\ "C_H7_&7_@%:?_)5'U'$_P C#ZYA_P"=
M'V117QO_ ,/3_A1_T+_C+_P"M/\ Y*H_X>G_  H_Z%_QE_X!6G_R51]1Q/\
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M )*H_P"'I_PH_P"A?\9?^ 5I_P#)5'U'$_R,/KF'_G1]D45\;_\ #T_X4?\
M0O\ C+_P"M/_ )*H_P"'I_PH_P"A?\9?^ 5I_P#)5'U'$_R,/KF'_G1]D45\
M;_\ #T_X4?\ 0O\ C+_P"M/_ )*H_P"'I_PH_P"A?\9?^ 5I_P#)5'U'$_R,
M/KF'_G1]D45\;_\ #T_X4?\ 0O\ C+_P"M/_ )*H_P"'I_PH_P"A?\9?^ 5I
M_P#)5'U'$_R,/KF'_G1]D45\;_\ #T_X4?\ 0O\ C+_P"M/_ )*H_P"'I_PH
M_P"A?\9?^ 5I_P#)5'U'$_R,/KF'_G1]D45\;_\ #T_X4?\ 0O\ C+_P"M/_
M )*H_P"'I_PH_P"A?\9?^ 5I_P#)5'U'$_R,/KF'_G1]D45\;_\ #T_X4?\
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M_'.H2_$ZWN1I^DWGP]LS?:O:WT[AWC\N24>241E<E(B1DJ"&7GGC&^'O[/\
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M_8;J6U^W:=-YUM<;'*^9$^!OC;&5; R"#6=72G?4YWIH%%%%,04444 %%%%
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M .$ELK6^(!S]HB@NHW)_WB W_ Q7Z!T4 ?*'_!2Q&?\ 9XM JEB=>M> ,_\
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MUUJC5A-5(I;6LVWUOO:YRNK2E!PDWO?1)=+;7L>F?%/_ )1K?!O_ +&*[_\
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MLD**** "OH;_ ()__P#)W/@/_M__ /2"YKYYKH?A_P#$#7_A=XNL/$_AB_\
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M'5I$>ZG<)L4L%+!0J[NC')<\# KT^Q\=_#I_^"@;: GPNV>-?MTB_P#"7_\
M"07)^?["S%OLFWR^4RF,]\]:_-_PCXMU;P)XFTWQ!H5V;'5].F6XM;D1K)Y;
MCH=K@J?H01710_&WQK!\5#\2$UMAXT,S7']J&VA)WF,QD^7L\O&PD8VX]JXY
MX%-OD>G*UN]V[Z]U_5CKAC&DN;?F3V6R[=C[*_9R\#P']K/X]?$C4IK&PL?"
M>K:LEK>:M+]GM([R>YF56>8\*JH'#<''FJ<=,GQJ^&MUXW_8AM9+KQ?X>^('
MBKP%?274VJ>&M274$-K+(=Z,^U2I".C$$=(!UKX[U#X\>.M5\*^*?#EUKIDT
M;Q/JCZSJ]L+2!3=7;.DC2%P@91NC0[5(48Z=:I^ _C#XN^&6D>)-+\-ZJ+#3
MO$=M]CU6W>UAG2ZAVNNT^8C8XD<97!^8T/"57)5.975K>B\_.[!8FFHN'*[.
M]_5_\,C[,^'7BGPW^U.WA;X1?&3X>ZWI/CNQTTP:9XAM(WMY%A2(D2R(P&P$
M)W5XV;LN0!<^ FE:+\*OV:OVB=)U[31XTT30/$5Q8W-F+E[(7Z1&.//F)EH\
ME0W&?2OF2W_;8^-MKX=30XO'UXE@D MU(MK?SP@7:,3>7YF<?Q;L]\YK ^%_
M[3GQ,^#.GZA8^#_$[:5;7]Q]KN5>SM[DRRX +EIHW.< =#42PE5Q<59*Z=KN
MVCN];:?(N.*IIIN[=FKV7:RZZ_,YOXG>)/"OBGQ*+WP?X._X0?2/(2,Z7_:D
MNH9D!.Z3S90&YR/EZ#'O7N'[(/P3@:^C^,GCJZ'A[X<>$[A;U;V?(:_NHG!C
MBA Y8!PN<9W, @!);;XW\5_C=XU^-^IV.H>-=:_MJ[LH3!;R?98(-B%MQ&(D
M4'GN0375_#_]L#XN?"SPC8>&/"_BW^S-#L?,^SVO]FVDVS?(TC_-)$S'+.QY
M)Z^E=E6%65'DA9/KJ]O6V_JCDISI1J\\]5TT6_I?;YF/^T;\8Y/CS\7]=\8&
MV:RM+IDAL[5\;XK>-0J!B.K$#<>3@L0#@"O,Z[#XH_%OQ9\:/$<6O>,M5_MC
M58K9;1+C[-%!B)69E7;$BKU=N<9YKCZZ*<>2"C:UCGJ2YYN5[W"BBBM3,***
M* "BBB@ HHHH **** "OTA^)'C3X8?#GX=_LO^*/'VG>)M5U72/#EI>Z+;:(
MT(MC+';V;;KC>RM\K",J%.#@[@1Q7YO5U_C;XL^*_B+HOAG2/$6K'4=.\-68
ML-*@-O%']F@"HH3**"W$:#+$GY>M<=>@ZTH:Z*]_FK'71K*C&6FKM;[[GVW^
MSG\8H/BW<?M4_$'7] 2XT^]T&*>YT-+IHQ+:Q6ETGD&91N4M'&%+@9!)(':G
M?"?Q?X(\7_LA?'B7P3\/O^%?VT-@ZW-O_;4^I?:&,+$-NE *8&1@=<U\1>"O
MBSXK^'>A^)M'\/:L=.T[Q+:?8=5A%O%)]IAVNNS<ZDIQ(XRA!^;KTI_A/XP>
M+_ _A#Q'X6T36&LM!\0QB/4[/R(I!.H!7[SJ63@D94@URSP3;DXZ:QMJ]E;I
M\M#ICC$DE+M*^BW=S[4^%W@"\^'7[(7A".Q\8^#_  3XH\4ZY;^*'F\8:O\
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M?\.X_AS_ -![Q1_X$VW_ ,8KS;_AO;X@?] ?PU_X"W'_ ,?H_P"&]OB!_P!
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M  %N/_C]'_#>WQ _Z _AK_P%N/\ X_1_:.)_Y^,.6'8])_X=Q_#G_H/>*/\
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M'$_\_&'+#L>D_P##N/X<_P#0>\4?^!-M_P#&*/\ AW'\.?\ H/>*/_ FV_\
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MZ#WBC_P)MO\ XQ1_P[C^'/\ T'O%'_@3;?\ QBO-O^&]OB!_T!_#7_@+<?\
MQ^C_ (;V^('_ $!_#7_@+<?_ !^C^T<3_P _&+EAV/2?^'<?PY_Z#WBC_P "
M;;_XQ1_P[C^'/_0>\4?^!-M_\8KS;_AO;X@?] ?PU_X"W'_Q^C_AO;X@?] ?
MPU_X"W'_ ,?H_M'$_P#/QARP['I/_#N/X<_]![Q1_P"!-M_\8H_X=Q_#G_H/
M>*/_  )MO_C%>;?\-[?$#_H#^&O_  %N/_C]'_#>WQ _Z _AK_P%N/\ X_1_
M:.)_Y^,.6'8])_X=Q_#G_H/>*/\ P)MO_C%'_#N/X<_]![Q1_P"!-M_\8KS;
M_AO;X@?] ?PU_P" MQ_\?H_X;V^('_0'\-?^ MQ_\?H_M'$_\_&'+#L>D_\
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M]![Q1_X$VW_QBOJRBC^T,5_S\8<D>Q\I_P##N/X<_P#0>\4?^!-M_P#&*/\
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M/X<_]![Q1_X$VW_QBOM7X5Z##X4^'/AW0K:::XM=)LH]/@DN"ID:*$>6FXJ
M"=J#) %<M7>>$_\ D 6WUD_]#:IEB:U?2I*]CULNBE.5C7HHHJ#W0K*\4?\
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MQMI\=CXFL6DD$5RR# FAPG+CK\P7H?[QK%_X9B\3_P#"E_\ A$/[0TC^TO\
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MGI=^-/O;V.^B6>,[]C2+:D;WC4Y)8'&!DXK=^ 7PPU3X5^'M?L-5N+.XEO\
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M **** "BBB@ HHHH **** "BBB@ ILG0?44ZFR=!]136Y</B0ZBBBD0%%%%
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M:#3$A5/F0$1L!YC#Y^&)'..#3N%SZCHKY^\>2MX%_:P\#ZO &CM_%%A+I5V
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M!\1^ _V?/V=O^$?U>YTG[;):QW7V5]AF150A&(Y*\G*]#WS7DO[>&JWVB_M
M>)[#3[VYL;'5K*Q?4+6WF:.*\9(_D,J@X<KCC<#CM7S[?>,M?U2PTRQO-<U*
M[LM+_P"/"VGNY'CM.G^J4G"=!]W'05!K_B35_%FIOJ.MZI>ZSJ#J%>[U"X>>
M5@!@ NY)( X'-)RNK&53$<\7'T_!6/T,^%*>)OB5\,/"'AV6+Q=\,]5T?PTD
MVGZY9;)M"U&W>%5C:<',;N5*N8VPZ_,01S7Q]^R6FF/^T;X$&KB%K/[?E1.
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M%+.V4LQ(5(U ' P-Q&3C)KK:*=@L%%%% PHHHH **** "BBB@ HHHH ****
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M4?\ "F?A_P#]"+X:_P#!1;__ !%'*'*?E117ZK_\*9^'_P#T(OAK_P %%O\
M_$4?\*9^'_\ T(OAK_P46_\ \11RARGY445^J_\ PIGX?_\ 0B^&O_!1;_\
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M'?F:[^;.<7<HZXZ?-QT[=*OUR-G\3M*O?B??>!(X+L:Q9Z>-2DF9%\@QED7
M;=NW9D7C;CKS2N',^YOG18#OS-=_-G.+N4=<=/FXZ=NE!T6 [\S7?S9SB[E'
M7'3YN.G;I7/?$+XN>$OA4E@WBG5AI8OBXM_]'EF,FS;NXC5L8W+U]:F\!?%+
MPK\3[6XN/#&LPZJEN0)E5'C>/.<;D<!@#@X..<&BX<S[FV=%@._,UW\V<XNY
M1UQT^;CIVZ4'18#OS-=_-G.+N4=<=/FXZ=NE7Z\RU/\ :!\.:5?>.+66TU-I
M/"$4<U\4BC(E#XP(LOR>>=VVBX<S[G?'18#OS-=_-G.+N4=<=/FXZ=NE!T6
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M-QT[=*_.C_AKSXM_]#9_Y3;3_P"-4?\ #7GQ;_Z&S_RFVG_QJCF#G9^BYT6
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M.S]%SHL!WYFN_FSG%W*.N.GS<=.W2@Z+ =^9KOYLYQ=RCKCI\W'3MTK\Z/\
MAKSXM_\ 0V?^4VT_^-4?\->?%O\ Z&S_ ,IMI_\ &J.8.=GZ+G18#OS-=_-G
M.+N4=<=/FXZ=NE!T6 [\S7?S9SB[E'7'3YN.G;I7YT?\->?%O_H;/_*;:?\
MQJC_ (:\^+?_ $-G_E-M/_C5','.S]%SHL!WYFN_FSG%W*.N.GS<=.W2@Z+
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MS9SB[E'7'3YN.G;I7YT?\->?%O\ Z&S_ ,IMI_\ &J/^&O/BW_T-G_E-M/\
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MBZ^V2^'HK_;ISR>ICVY_\>X' XK4^('[-^@_$'Q=8^))M;\0:)J-C;I;6O\
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M **** "BBB@ IO\ RU/TIU-_Y:GZ4RX]1U%%%(@**** "BBB@ HHHH ****
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MI\G/7MU[477</85?Y']S+=<C\2OACI7Q3TO3;#5IKN"&PU"+4HFLW56,D88
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M>5Y>W<6&W&XYQMZ^_2N4K"OQ1B\-5E1JT4I+=7_R-Z'#&$Q-.-:E6;B]M/\
M,^O_ /A.?#?_ $,&E?\ @;'_ /%4?\)SX;_Z&#2O_ V/_P"*KY HK#_6^O\
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M $,&E?\ @;'_ /%4?\)SX;_Z&#2O_ V/_P"*KY HH_UOK_\ /I?>P_U2H?\
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MQ^'_ *YC^9JH]27T)J***DH**** "BBB@ HHHH **** "BBB@ HHHH ****
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M>^[Q7SIJ6K7VLW/VC4+RXOKC:%\VYE:1\#H,L2<5<O/%VNZC8_8KO6M1NK/
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MZRR1(8HF;8FTYR68G@\EO3CYGL?%VNZ7###9:UJ%I% K+%'!=2(L88Y8* >
M3R<=34-AXCU;2KN:ZLM4O;.ZF),L]O<.CN2<G<P.3R3UJ8\24_91IRC)M)*]
MU>+4''FAIHVW=_U:Y<.3]K*<912;;M9VDG-2M/75)*R_J_U/IR!?&>BWU_:6
M\/B&X\,SR:G"$ +,&AV[U'OO'X8[5PNB^+=2\:_"G7]2U65)KK^U[*(,D:H
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M^Z^IXV,X=Q%.-.%""G&T5)*R]Y*S?O?S=U[RZ'B]Y=RZA>3W5P_F3SR-+(^
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M_P"/.#_<'\JFJ&R_X\X/]P?RJ:OUJ7Q,_*8_"@HHHJ2@HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "H;K[L?_71?YU-4-U]V/\ ZZ+_ #JH_$B9
M;$U%%%24%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %0C_
M (_#_P!<Q_,U-4(_X_#_ -<Q_,U4>I+Z$U%%%24%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %=%X;_P"01'_UTE_]&-7.UT7AO_D$1_\
M727_ -&-7H8/XF>?B_A1J4445ZIY@51UK_D&3?\  ?\ T(5>JCK7_(,F_P"
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M.FJHDN) BEOW)P">IP#Q[4_P;=1^*?B[K>N:<6;2X;1;8W &%E?Y./<?*3^
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MU0C_ (_#_P!<Q_,U4>I+Z$U%%%24%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %=%X;_Y!$?\ UTE_]&-7.UT7AO\ Y!$?_727_P!&-7H8
M/XF>?B_A1J4445ZIY@51UK_D&3?\!_\ 0A5ZLSQ*L[Z)<K:R1PSG;M>:,R*/
MF'50RD_F*SJ_!+T9I3^./J>8_$?P=-XRT2*&SEBM]0MITN+>6;(4,.H) )'!
M]#R!6^FFV\UQ;WMS:6S:C%'M$X0,R9'S!6(R!R?SJ&2WU@[ME_8KDMMW63G
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M]5LN[/[V'^L^8]U]R/"?^&=O$G_/[I7_ ']D_P#C='_#.WB3_G]TK_O[)_\
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M6#NV7]BN2VW=9.<#C:#^^&<<Y/&<CICDMYA?R-*BLV2WU@[ME_8KDMMW63G
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MSJM/VG+!/E4GUT496U]5=JW8]*6348^SYIM<SBNFKE&^GH[)W[GM]_J=GI4
MFO;N"SA+!1)<2!%)/09)ZU9KR;Q!J<7Q'\3^"]-A(:T:(:K=(#D 8X4^AX9?
M^!5VT7Q$\/3Z^=$34-VIB5H?(\F3[XSD;MNWL>]>U1S"E4G.\DHW2BV[<S:3
M=OO2^\\>ME]2G"%HMRLW))?"D[*_W,TO^$ETC[;]C_M6R^V9V_9_M">9GTVY
MSFIM1UBPT>-9+^]MK%&.%:YE6,$^Q)%>'?$_0UTV.&'_ (16/0])BO.=9MW6
M>:1<D D @C.<X8GVK?\ %5H\OQ"MM<O-"N_$V@36*K;+:P>>$8C()0\>IY_O
M9[5YCS:M%U(."O%Q7VMG>[::O96WM9W/26549*G-3=I*3^SNK:)IVN[[7NK'
MJBZG9O8_;5NX&L\;OM D!CQZ[LXJ+3M=TW6"XL-0M;XI]X6TZR;?K@G%>2_#
M6Q75/#?BNP?26O[:WOS);Z3/-Y>&!.$+=!C SVXJ/PA&MA\8 =0TI/"\\ULR
MVVGP!6BDX.3O4@?PGH,$CUZU#-JDE0GR+EJ-)[Z.[6]K=-$W=]B9Y33BZ\.=
MWIJZVU5D]KWZZM*R[GME%%%?3GS04444 %%%% !1110 445YK\>8A/X7TJ%B
M0DNJ0HV#U!22N+&8CZIAYU[7Y5ML=>#P_P!:KPHWMS/?<]*HKPO6]3N6\!VF
MBW[$ZEHVLP6DI/\ $F&,;_0KT^E=]K/Q$NH/$-UHVB:%+KMW:1B2Y*W"PI'D
M9P"0<GD<?X5P4LVHSNYJWP]V[N]U9*]U9W/0J956C90=_B[)65K.[=K.ZL=M
M17GDWQBMD\)VFMQZ9/+YE^-/FM=X$D3[2QQQ\QP!@<9SVJ[H/Q(>]\076D:Q
MI+:#<0VQNPTUPLBF,8)+$ !>.>O&#FNB.9X24HPC/>UM';7;6UE?S.>668N,
M92<-KWU5]-]+W=O([:BO._BMKNG:S\--=_L[4;6^\OR/,^RSK)LS,F,[2<9P
M?R-</X[\7G4_AAING?V+K%IY:VX^UW5KL@?:F/E?/.>HXYKCQ><4L+*<;7M'
MF6N^K5MG;;<Z\)E%7%1A*]KRY7IMHG?=7WV/?**XS7OB#<VGB.70]&T.77+^
M"(37 6=85B! (&X@Y."./<53'QAL/^$0FUEK*9;F*Y^QM8%AO\[J%SCIC)SC
ML>*[99EA(2E&4[<M[Z.VF]G:S:ZI79QQRW%3C&487YK6U5]=KJ]TGT;LCMWU
M*TBOH[)[J%+R12Z6[2 2,HZD+G)'!Y]JL5XZNO7E]\7M$NM6TF7198-/F+0O
M()04V2-N# <]>F."*T8_C+J%R=-DMO"S26FI3F"SE>_13(P.#E=IV_B?QKCI
MYQAWSNJVK2:7NRO9<NK5KK65M;'74RBNN54TG>*;UC:[YM$[V>BOI<])MM2M
M+RXN(+>ZAGGMR%FBCD#-$3G 8 Y'0]?2K%>,:1XPA\(^,O'3?9WOK^ZO8(K6
MRB.'F?\ >< X. ,]<>E='<W,4GQ7\.&]L9H-5DTUR1'=!HHN)"5*[/F/4;@1
MVX.*='-85(+^;FY6M=+R<5K9ZZ7M^2U%5RN=.3_EY>9/37W5)Z76FMK_ )L]
M$HKRN'XX7$NBQZP?#$XTM91#/<_:EPC$\!1MR_&.>!DXKU**59XDD0[D=0RG
MU!Z5WX;'8?&7]A*]DGLUH]GJD<&)P5?"6]M&U[K=/5;K1L=1117><04444 %
M%%% !7BGCKXS:UX2\6ZEI5G:V$EO ZE6GC<N=R*QR0X'4GM7M=?+'QC_ .2D
MZU_O1_\ HI*^4XDQ5?"8*,Z$G%N26G:TCZCAS"T<7C)0KQ4DHMZ][Q-__AHG
MQ)_SY:5_WZD_^.4?\-$^)/\ GRTK_OU)_P#'*\MHK\U_MO,?^?S/TC^Q<O\
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MRTK_ +]2?_'*\MHH_MO,?^?S#^Q<O_Y\H]2_X:)\2?\ /EI7_?J3_P".4?\
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M=)?_ $8U<[71>&_^01'_ -=)?_1C5Z&#^)GGXOX4:E%%%>J>8%4=:_Y!DW_
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M/Q(F6Q-1114E!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MVG+MM+K4+0R30 # VL&&,  9QGBL[2?B[K^DW_B"])M[R[UN+RKJ6YC)(&"
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MFJ&Z^['_ -=%_G51^)$RV)J***DH**** "BBB@ HHHH **** "BBB@ HHHH
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MJ&@-N))S- <DXR>O? _*N+_8/[G_ )*=O^W_ -[_ ,F+)\(^%1G.BZ.,=?\
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M^Y!]9Q'\[^]F8?"/A49SHNCC'7_1(N/TK6M18Z?;I!;_ &>V@C&%BBVHJCT
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MFR;M^GVK;B2<PJ<DXR>G? _*A]"TV3=OT^U;<23F%3DG&3T[X'Y5.A6I8-W
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M25T8.C;2K*<@C'45/7ZG+?[C\OB%%%%24%%%% !1110 4444 %%%% !1110
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M-[W-_P ,>+#!5_K*<J3]K[7F<]+<E]KWO;E]WE_X<L_":+4)?!/Q$^R7-M!
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M !1110 4444 %0C_ (_#_P!<Q_,U-4(_X_#_ -<Q_,U4>I+Z$U%%%24%%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %=%X;_P"01'_UTE_]
M&-7.UT7AO_D$1_\ 727_ -&-7H8/XF>?B_A1J4445ZIY@51UK_D&3?\  ?\
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MB@ HHHH *A'_ !^'_KF/YFIJA'_'X?\ KF/YFJCU)?0FHHHJ2@HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KHO#?_ ""(_P#KI+_Z,:N=
MKHO#?_((C_ZZ2_\ HQJ]#!_$SS\7\*-2BBBO5/,"LSQ))-%HMR\$(N)1MVQE
M]N[YAW[5IU2UC_D&S?A_,4.*E[KZC3<?>70X5[W4@&VZ6K8+8_TE1G!&.W?G
M\J'O=2 ;;I:M@MC_ $E1G!&.W?G\JU**S^I4>QI]<J]S+>]U(!MNEJV"V/\
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M=^?RK4HH^I4>P?7*O<RWO=2 ;;I:M@MC_25&<$8[=^?RH>]U(!MNEJV"V/\
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M,SDA-KL?4Z/8?UNMW/97O=2 ;;I:M@MC_25&<$8[=^?RH>]U(!MNEJV"V/\
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M3_XJC^S)_P R']=CV/L>BOCG_A._$O\ T,.J_P#@;+_\51_PG?B7_H8=5_\
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MK3_B8ZO)%:3":"&2Y5HXR#DA5VX )Z]_>G[>C)MSUNET78/95$DH^?7S.:\
MZ9JX^+'B13K>6MY$:[;[(G^EKV7&?D^HJCI'Q!U32OAZALA:PZC>ZP]G%*EM
M'''&NU26VJ "<D<D'WZ5Z:?ASIR^+7\0PW5_;7<C*\L$,^V&4@8&Y<9(]LXJ
MHGPCT(>&)="=KJ6U>Y-VLK2+YL<A &5(4#H,<@]34^WI2=Y*^W3MN-4JB5H^
M?4U_"NGZ_IPNH]<U6'5U.PP31P"%QP=P91QC.,&O+]1MM<O/C%XPM]"%B;B6
MP1)1?[L;#%$#MV_Q9QUX]:]0\*^#K;PH+DQ7M]?S7&SS)]0G\UR%!"C.!@#)
MK(UGX5V&L>(;S65U75].O+M%27[!<B)64*%Q]TG&%'&:QIU80G)M[KMZ=#2<
M)2C%+H^_KU/-=%\87/A?X2P_V*S6>H6VK"VN?-"R!R06.,C !P!QR,'FM_Q?
MXL\6>$YM*T,Z@^H:I>LT\EW9:>LDB1X'[N.+@-@ASD\D8Z<UUT_PHT.7PQ!H
M,?VFWLXKD79>.0>8\@!&6)!Z@^G85H>+? NG>,?LKW;W%M=6K%H+NSD\N6//
M4 X/H.W:MG7HN=VM+OI]QFJ511M?M_P3@;/Q[XDLO!OB"?6'N--GMI(5LM0O
M].\EY@S'</*^Z6 4].!NY--\#^/_ !'<>+6TB^DNKY+BR>XMO[1L$LI"P!*D
M!204.",Y_E77-\)]'FT6^TZZN-0OOMCI)+=W5SOGW)G:0Q&.,GMWIFE_"/2M
M-U7^T7OM3U"Y,#VSM>W DWHR[<$[0> <#!%)U:#C)6W\O)!R5;QU_$Y'PEXL
M\4:UK1TO4M?_ +)U2=)5^PW.F*IB(!*M$W23IDAL<=,U:_9]LK]='O;E]2WZ
M?]IEB%CY"C][\A\S?UZ<;>G>NIT+X5Z5H6KVVH_;-1U&>U4I;+?W'F) #_<&
M!CJ:M>%?AYI_@_4+JYT^ZO\ RI]W^ARS[H(RQ4DJN.OR@9))Q2J5J;C*,-+V
MZ+S'"G-23ETOU.HHHHKSCM"OE'XS_P#)3-;_ -Z/_P!%)7U=7RC\9_\ DIFM
M_P"]'_Z*2O4RW^,_3]4<&-_AKU_S+?P#_P"2N>'O]^7_ -$O7<>+/%OAOP5H
MGCO2+#6;C7=5UR]E62U-N\,-D=[;_O<$C)&Y?O87@ 5XOH&OW_AC5[?5-,G^
MS7UN28I=BOMR"IX8$'@GJ*KW]]/J=]<WER_FW-Q(TTKX W.Q))P.!R3TKUZF
M']I5YY/2R_!W//A6Y*?*EKK^*L?6&LR:/XB^*]OX5U+P[IU[%=:3YLE_/'NN
M <':$;^   ].<G.1CGFOAMX3TK1O#OAZWU^QT%IM2NY8(OM&E/>W-V Y'#@@
M18'<@@#!..0/%_\ A:7B?_A)HO$']J'^UXH?LZ7'D1<1X(V[=NWN>U6-%^,7
MC'P]IYL;#6Y8+7S&DV&*-\,QW'!920"23@<<FN+ZG54.2,NW5[Z^7I_P#I^L
MTW+FDN_Z'KGA;PYX7TS7?%&CIINF?VJ^L/!I[:Y9M-:O'M4^0C]%<;CZM@KP
MU2>'?!_AGP7X6U76=>LM,LKF35IK=OM^GR:E!:HKL%B55Q@8'#G&<C/85Y#I
MOQE\9:1/J$MIK3PO?S&XN/W$1#R$ %@"N%. .F.@JKX>^*GBOPK+>R:9K,T#
M7DIGGWHDH>0]7PZD9/<CKQZ5;PM9W][MU_X&GW,2KTE;3OT_X/\ D7/C%::'
M:^-ISX>ADMM/FACF\E[>2 (Q'.U'4$*>".,<\<5Z[\(/LUVNOZ?92Z[!XVGT
MU5NYO$";X4<#'RX^8 %N-_./7D5\]Z[K^H>)M3FU'5+J2\O9<;Y9.IP, 8'
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M::9<W=W:O%$]S<1VTOE^8[*6*,<9P,@8&.E'LH<BGS;NVW_!#VDN9QMMY_\
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MH>OO_@EA92BI)K7_ #L-UXIV:9[+17)_#I]>O=&CU/6]2BO1?P13P010+&(
M021D?>R"O7H0:ZRN:<>23C>YM%\RN%%%%24%%%% !1110 4444 %%%% !111
M0 5\H_&?_DIFM_[T?_HI*^KJ^4?C/_R4S6_]Z/\ ]%)7J9;_ !GZ?JC@QO\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMX);E)+=I&F$N!@'< I7 /&,YQ73?#6[UK4/"-I=Z]+YM]<$RC,:H1&?N@@
M#..?Q%=1153J^T3NM7U%&GR6L]$><:GX-\4V?Q#U'Q)H<ND%;JW6W\O4&ER
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M44\=[)<L(*WJPGA?:.\I'QS_ ,()XE_Z%[5?_ *7_P")H_X03Q+_ -"]JO\
MX!2__$U]C45I_:4_Y49_4H]SXY_X03Q+_P!"]JO_ (!2_P#Q-'_"">)?^A>U
M7_P"E_\ B:^QJ*/[2G_*@^I1[GQPO@;Q(R@CP_JI!Y!%E)S_ ..TO_"">)?^
MA>U7_P  I?\ XFOL"R_X\X/]Q?Y5-1_:<_Y4/ZE'N?'/_"">)?\ H7M5_P#
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M$O\ T+VJ_P#@%+_\31_P@GB7_H7M5_\  *7_ .)K[&HH_M*?\J#ZE'N?'/\
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M$:=:LJU&75I*<=--M))O1]=3[2K#M_'?AJ[\1R>'H/$.E3:_&"7TJ.]B:Z3
MR<Q!MPP.>E?#6L^-_B=\*/"EEXIM=2\;)INE^&)H_$MUXQ,JV]UJDT0CM19Q
M3YDW+<.I)4!=J_7.]\,=2L?AW<Z?H_B'P1HY\5_"SPZ=;F\1WGB6:.*.:^*F
MX$P%M_K9%=WPRR'A5!);->&^''"G*I[3GW24;7OMKS-=7#1:VFGOH_J_9Z7/
MN.BOE:T_;8U:[L=*A_X5M+!XAU739-;L]*EU*5M^GJ2J3,T=H[JTK@JBF/!Z
MLR C/1:-^U3KGC?Q)J.C>#OACJ.N7FF:78:AJ$-WJ,=A):RW*A_LSK(N!(B$
ML>>=K#''/DSR',*=W.FDENW*-EK;5\UK7TN1R2/H>BBBO ("BBB@ HHHH *Z
M#PW_ ,@B/_KI+_Z,:N?KH/#?_((C_P"NDO\ Z,:LJFQ<-S3HHHK$U"J6L?\
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MF1MSQZ9S0!IT5F.=8PVP6).6VY+],C;GCTSFASK&&V"Q)RVW)?ID;<\>F<T
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M;!8DY;;DOTR-N>/3.:P_M.O3I4J6'DZ?(GJFU=N7-?2W:*M_=3#F=E8XJ_\
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M HHHH **** "H;7I+_UT:IJ^:?%7Q<\6:3XIUJSM-6\JV@OIXXT^S0G:HD(
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M3V(F7SUA9F59"F=P0LC@-C!*D=C5R@ KH/#?_((C_P"NDO\ Z,:N?KH/#?\
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MD(B<$E 2V<K@<*>O7'%#I5%>\7IY!SP?4Z6BBBLRPHHHH *^.?'?_(\>(?\
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M"^P([ JWS*1E,=^AJYX.^&FF^(?B_J/A6XN+I-.M;BZB66)E$K")F"Y)4C/
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MCM'^(,LOCRUU1M;,NFW^H36']FFX&V*+"K#)Y>?ERV<G'X\UZD</*2T?2_\
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M64[65K-O[SZVM;V5_P!IN[@,[M$FD;1'O)5<[#C';UKA=$N3JGP8^)K74S7
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M/7 ]JS(/A'I,=KJ,<M]JEW<WS1N]]/<[KA2ARNU\#I[@_I7;T5/M9IMIVO\
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M^U>\1OLEO81:?9RS.K/,,[G<[3P<YZ@9S79445$YN;NRHQ4=@HHHJ"@HHHH
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M]S\?^ 'U'^]^'_!/ARBON.BC^T_[GX_\ /J/][\/^"?#E%?<=%']I_W/Q_X
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M6K7_ ,&B_P#QNCR_%W_0M6O_ (-%_P#C=>C44<[#E1YSY?B[_H6K7_P:+_\
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M6K7_ ,&B_P#QNCR_%W_0M6O_ (-%_P#C=>C44<[#E1YSY?B[_H6K7_P:+_\
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M*CSGR_%W_0M6O_@T7_XW1Y?B[_H6K7_P:+_\;KT:BCG8<J/.?+\7?]"U:_\
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M^A:M?_!HO_QNCR_%W_0M6O\ X-%_^-UZ-11SL.5'G/E^+O\ H6K7_P &B_\
MQNCR_%W_ $+5K_X-%_\ C=>C44<[#E1YSY?B[_H6K7_P:+_\;H\OQ=_T+5K_
M .#1?_C=>C44<[#E1YSY?B[_ *%JU_\ !HO_ ,;H\OQ=_P!"U:_^#1?_ (W7
MHU%'.PY4><^7XN_Z%JU_\&B__&Z[#PO%>0Z) NH6RVEWND9X4E\P+EV(^; S
2P0>G>M:BDY-[C22"BBBI&?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>arvn-20251231_g5.jpg
<TEXT>
begin 644 arvn-20251231_g5.jpg
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.GO]4OI02EO;0QM))(V 3A45B< GB@#1HKYX_P"'L/\ P3N_Z.GT#_OQ<_\
MQJM_X7_\%$/V+/C1X[T_X9?"[]H'1]9U[57=-/TVVBG#SLD;2, 6C X1&/)[
M4 >T4444 %%4/^$I\,_\)-_PA8\0V/\ ;!L3>?V4+I/M/V8.$,WEYW;-S!=V
M,9.,U?H ***X'X1?M0_ +X\^)=>\'_"'XF6.NZGX8F$6O6EHD@:S<NZ -O4
M_-&XXS]TT =]1577-;TKPUHEYXCUV]6VLM/M9+F\N'SMBB12SN<<X"@G\*\"
M_P"'L/\ P3N_Z.GT#_OQ<_\ QJ@#Z'HKS7X)?MB?LO?M'ZA-H_P1^./A_P 0
MWUO$99M.L[S;<K&#@OY+A7*@D L%P,CGD5Z50 4450N?%7AFS\16OA"[\0V4
M>K7MO)<6>F/=(+B>&,@/(D>=S(I906 P"P!/(H OT444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 5XO_ ,%$/CMKW[-?[%OQ ^,?A2X\G5M-T=8-
M*N ,F"YN9X[6*4 \$H\RN >/EYXKVBO&O^"A'P%UW]IK]C3Q]\%_"T8DU75-
M(6;282P7SKJVGCNHHLG@;WA5,G@;N>* /D#_ ((__P#!./\ 9S^*_P"R_;?M
M-?M#> +;QKXA\;:C?2Q2>('>=+:"*YD@.$+8:5Y(I)&D;+?,H!'.?7O@-_P2
M3T7]F+]MF?\ ::^ _P 7)O#OA.6W>*3P!'I[SK/'+%B6%KAY@1$)0LJ JY5E
M49PM>)_\$E/^"EW[//P$_9N3]EK]I_Q9)X)U_P $ZI?16ZZQITX6>&6YDG9"
M40F.:.625&C< X"XS\P7T;]FG_@J-\6_VP?^"@=]\(?V>?!NFZE\(+"S,FH>
M(M2TV>*Z@CCB.;A6W@()IRJ)'(A8K\V%PX !O?M>?\%4?%GPY_:&7]D#]D/X
M#S?$GXA1(#J:&=EM;%R@D,6$YD94(9V+HD>0"Q.X+%^RO_P56\;>*_VBXOV0
MOVS_ ( R?#3QU?@?V+(EPS6E\[*62+#YV%PI".KR([ KD-@'YW^!7Q/\%_L)
M?\%H?B]=_M1:A_85AXV.IR:%XAOXF\A(KR^BO+<E\'$11&B+CA7CVG&&P[]J
MSXG^"?V]_P#@K7\%]&_94U1?$,7@RXL)]=\2Z9&Q@CBM[_[7,RR8 9(HQP_W
M3)+M!)/(![K\7_\ @K9\4/ /[;/BO]C+P!^R[)XQUC3XHX/"L6EZJ8YM0O'M
MH+C]]O7;#"D<DS,^3@1#. 2R\=X0_P""T?[1/A[XK:]^S-\<?V*+D?%&)X[?
MPSX9\-:ED7-W($=(9V<N$C\E_-\]&==J_= .X87P=BCD_P"#BKQX[H"8]%D9
M"1T/]DV8S^1(_&DN((9/^#DF%WC4E-&W*2.A_P"$:89_(T >K_LG_P#!43XW
M^-?VQ&_8H_:\_9UM/ _BJ]MY)=*;3+\RHKI;M<B.3+.KAX58K*CXW*%V\Y7/
M^+7_  5[^)G@+]LOQA^Q]X'_ &79?%^L:9MM?"<.DZDPGU*]:*"7$P*%885C
M>9V<9P(AG )9?//C$ /^#BGP"0.NA1Y_\%-[7!VG[07PO_9M_P""^'CGQW\8
M-5BTW1+MY--EU>="8["2:PMMDKD E5+*$+=%$F3@ D 'T7^S7_P57^+5]^U-
M:_L@?MO?L[1_#OQ1K6T>'[JTNF>"61P3%$X8L&63:R++&[*9!L(')&Y^U)_P
M4(_:A\-_M)W'[+'['7[(EWXTUO3M/%UJ.LZXTEK8L-J,PB+&-&1/,13(90"[
M; "0"?FK]L+XK_#W]MG_ (*W? K0_P!F+Q#!XF7PO>Z;+K&NZ/F2!$@OS>3;
M9 ,.L4*%MP.W<^W.<BMCXG_M<?%S]H[_ (*'^.OV7OB5^VI-\ _ 'A![J"PE
ML+F'3I]2>"2-.;R5D*/*K-,I+[0B@*A)+$ ^@OV"O^"E?Q#_ &B_CUXG_9/_
M &B_@9'X(\?>&;&2[FALKPRP2K&\:21E6R4<>:CJ0[JZDD$8&[R.\_X+4?M$
M^+/BKXY^ ?P._8Z/BGQ;X=U^YM-(ATVYGN(WL[:>:*>ZN$10RX*P!5! )E.6
MR%5O)O\ @E:/AK:_\%@?&=I\+/B7J_B[04\,ZE#I?B;7[[[3=ZJ5:T#S/+M7
MS-S+(0V!E0#[UW__  1GL+:3_@H1^TIJ;Q*9H=7O(HW(Y"OJUP6'XE%_(4 =
M%^T+^T7H-Q^U_P#LQ0_M"_L<:)-X_P#%UEH-T-1NM<O8;CPO//J6%C2(;5=X
MG.\K(,A\H<@9KTK]J#_@I/\ &?P]^UE)^Q)^QQ^S[8^-O&]AIZ76KSZYK*6=
MM!NA2?8@9XP^V*2-F8R+RVT*2":\9_X*C?\ *7S]F3_L):%_Z?&K,_X*(?#[
M_@GU^T)^W1>_#WQS\5O%7P<^*-O91?:O&NJ65O'H-Z8X4-N[O).C"0Q;524-
M&A$6TG< " ?3?[&G[;_[2WQ9^,^L_L[_ +5'[(6K^!]?TFU,RZ[I<4MUI$C!
M5;RGG >.-BC!D82NKX*Y# !N._:>_P""K7C_ $/]H^Z_9#_8G_9[D^)7C72P
MPUNYEN&6TLY4 \R/:F-P0LJO(SQJK_)R>GS_ /\ !/GX\_M+?"+_ (*)Z7^Q
MSI7[647QL\!WMG.U_JMGJ+ZA:VD:VDDJR13NSF$QNJ(RI(T9\S;RY&V#]BWX
MN> ?V#O^"IGQN\(_M5:PGAQO%-]>OI'B/5498722^:ZB9I,?(DT3A]Y^7<@4
MD&@#Z7_8[_X*F^(OBI\?Y_V0_P!K+X&S?#7XC!&;3;=IV:VOV$9D,8#C,;&,
M%T(9TD .&!VAL'XH?\%<?B9X*_;3\7_L<>!_V79?&&L:8BV_A.'2-4*3ZE>-
M#!-B;<NV"%(WF=I.<"(9P"67Q#XH_$/PG^WE_P %K_AAK_[+MX=:TGP+::?)
MX@\26,+"W>.SNI[J9]Y S'B5( YX9VP,@J3TG[/\,4O_  <,_$EY(P3'HERT
M9(^Z?L-D,_D2/QH ]0_99_X*F_&_Q5^V%'^Q9^V#^SA;>!O$^HQR-I<VG7S2
M(CB!KA$D!9U=7C5MLL;D;@%V\DK]PU^9_P"TNJK_ ,'!GPK91@MH=H3CO_H]
M\*_3"@#XD_:7_P""KGQ#TS]H^]_9&_8@_9XD^)7C'1]ZZY=S7#+:6<J8$D85
M,9$98(\CR1JK_)\QYK5_8U_X*F:]\7?CY<_LB_M5_ ^?X;?$B-&:PM'F9K:_
M*Q^:8P'&Z-S'ET.YTD4$A@=H;YE_88^+WP^_8-_X*:_&_P "?M6:U'X;E\2Z
MA=-I/B+5D98)%:]>YC9I,?(D\4BR!SA<H 2#@5<\>?$#PM^W?_P6Y^''BK]F
M"[.L:+X%T^Q;7_$EE"PMY([2>XN)I-Y RA\Z.W#'AF( )4@T >(>-_BA^T)\
M2_\ @JU=?$#XA?L0V?B3QG]B16^$FLLMS#L32U1)&$BE6Q'BX *\$@]0#7[5
M?#JSBT_X?:%80>$K;0$AT>V1="LH5CATX")1]F1% 55C^X    H %?G3IW_*
MR/?_ /8"'_J-QU^E] 'X\_\ !4/XH?!?Q7_P5RL]%^/_ ("UOQAX/\&^&+?3
M-1\,^'&<75]*]I-=QHC1RQLN)KN(NRN#MC(YQBOI/_@E%KG_  2S\=?$G5O$
M/[(_P8U;P+\0M.TF6WU+1_$6LWLUPUDTD?F-$LMW-%(@D6,,<!U.,@!LGJ=5
M_P""C'[+?PD_;_\ $'P3^.'P0TKX?ZW:V+)#\4=5C@4ZDC+$\2-*L(=(9(^=
M[2%0T00C/3Y]_9NUKPY^TG_P7GUOXZ?LV8N_!>C:=/+K^M6,)2VNR=*^QL^<
M 'S+IE(/_+3RFD&>30!^I%Y9V>HV<NGZA:QSV\\;1SP3(&21&&&5@>"""00>
MM?DS>WFJ?\$/?^"AMYJ#6&H7/P7^(]M))%;VJES%$&+*B@G#36DK[1DDM!-G
M[S\?K57PA_P<,Z=I]Q^Q#HVHSV43W%M\0K(6\[1@O&&M;L,%/4 X&0.N!Z4
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M\\4CXY*I8614?@7;\S0!^@<)F,*&X55DVCS%1B5#8YP2!D?A7Y.?#/P#H_\
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M3]IG3OA+IVIW/Q(L;.XN]*GU.2..Q\ZR6Y(1PA+X+;>0.!FO#/\ @L!^V_\
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MI_'3X'6/P&_9[^%_Q,C^'FC>,_#>FOXC\?/8K,]I QA@?87!V+"I,K[<.0R
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M<V(&/PKV7_@EA_RCV^%7_8L+_P"C9* /?Z*** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** /)OC1^PG^R#^T+X@/BWXP_L_\ A[6=58 2ZHULT%S,!C DEA9'DP!@
M;B<#CI77?"'X&?!WX ^&3X/^"_PUT?PSIS2>9+;:19+%YSXQOD8#=(V.-S$G
M'&:ZNB@#A?C?^S+\ /VD=+@TCXZ?"31/$T5KG[))J5F#-;Y^]Y<JXDC!P,A6
M&<#/2F_ []E[]GO]FK3[C3?@5\(]%\-)>8^V3:?:_OK@#H))6S(X'. S$#)Q
MUKO** .+T[]G3X&:1\7[OX_:9\+='@\:7T1CO/$L=J!=S(8UC*L_<;$5?HHH
M/[.GP,/QD'[0I^%NC_\ ";B+RQXG^RC[7L\GR-N_T\KY/IQ7:44 <7J/[.OP
M-U?XOVGQ^U/X7://XTL8A'9^)9+4&[A01M'M5^PV.R_1C7Q%X#_8Z\?^+/\
M@L9\4/'_ ,7?@+<ZC\-/$F@W%L-0UC2Q+IU]NM[,*OS ACNC;'<%,C!%?HC1
M0!YO\"_V0OV9OV9[F\OO@5\&-$\.76H+LO+VS@+3RIG=Y9ED+.$R =@.W(!Q
MQ5#XQ_L-?LC_ +0/C"+X@?&+X":!KNM1(B'4KFW9)9548593&R^< . 'W
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MS%^S_P#'CP58_#OXO_"?1]>T?2PHTRTO;?FSVJ$'DNI#Q?* ORL,@ &N[HH
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M+-?V_ASQ#8W\FE7[66II9W22FTN0B2&&0*3LD"21L5." ZG'(H YCX)?LX?
MG]F_0I_#?P,^%FC^&;2ZD#W8TRU"R7+#.TRR'+R$9.-S'&3BNVHHH Y#XQ?
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M6&,MNV!NNW=DX[$DCJ:E^-/[,?P _:+T"U\-?'#X3Z/XEM;'/V$ZG;[IK;(
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M"=W[1GC[X::-\;_$GC#PKK7B;P];W?A#XF:5I\#:2--N27C^UM+(-T2N=QV
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MLBDD+N0KG. 0#[Y_81_X*.7/[3WCKQ/^S]\;/A1-X ^)O@Z)IM6T&:X,D-Q
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MGW+/Y7DR.DF1<+N(8@$*/6O6/^"'%O O_!-:YQ$O[[7]9,O'WCM1>?P 'X4
M&A?\%+O'O[57_!-SQU\<?@W\%)V\8:-YVCZYH%IJ3$6B/ #)?PRA0VQ(I#(
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M^RUX^N]'EGC^&^E6FB^)&B&1%=I#9RH,C@!GM[D GC( [TW_ (*R?'?X1_\
M!1#XP_ GX!_LO^,8O%-Q>ZA<-?RZ?&Y%K]L>U1%?(&QD2*9Y >449;% 'ZS@
MA@&4Y!Z&B@ * JC '044 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M02,(H&"17J]% !7COQ4_X)^_L7?&SQ>_C[XF_LY>&]3UF:3S+G41:M!)<O\
MWIC"R^<?=]QZ>E>Q44 9?@KP/X-^&_ABS\$_#[PKI^B:/81^79:9I5FD$$"Y
MSA40 #)))XY))-<_\'OV=/@9^S\FI1_!7X6Z/X976)8Y-4&DVHB^TNF[8SXZ
MD;VQ_O&NTHH *^:_VBO^"7_[.'[07QQ\)_&G4O ?AVSFTO6)[SQA:#1 ?^$F
M1XBJ1SE'0;E?#EV5RV,'BOI2B@"CX:\,^'/!F@VGA7PAH%EI6F6$(AL=.TZU
M2""WC'1$C0!54>@&*YGXF?LZ? WXS>(M%\6_%3X7:/KVI^'9?,T.]U&U$DED
M^]7W1D_=.Y$/U45VE% $5_86.JV,^EZI90W-M<PM%<6]Q&'CEC8$,C*>&4@D
M$'@@UY%\/O\ @GY^Q9\*OB$GQ4^'W[-_AC3->AF\ZUOH;,M]ED_OPQL2D+#L
M452.V*]BHH R_&G@CP=\1_"U[X(\?^%[#6M'U&'RK_3-3M4G@G3(.&1P0>0"
M/0@$<BN ^"7[$?[)W[./B*?Q=\%/@5H6@ZK<1M&^I6\+23JC?>1))69HU/=5
M(!P,CBO4Z* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHKP7]O3QY^V#X#\(Z!=_L?>#/[9U*X
MU*5-8B_LY+CRX!'E3AF&/FXS6M"DZ]54TTK]7HAQCS.Q[U7YS_\ !3__ (*?
M_P#(1_9M_9M\0_W[;Q3XILI?P>TMG'XAY![JO<US'QF^-/\ P69\4_#'6=$\
M7?"W5M+TF:R<:I>:)X>CCN%M\?O '1F=05SDJ <9Y S7P=7U>49+3C4]K5E&
M5MDG=>K_ ,CMH8=7YI.Y^C'_  3 _P""G_\ R#OV;?VDO$/]RV\+>*;V7\$M
M+ES^ 20^RMV-?HQ7\Y]?>/P9^-/_  69\+?#'1M$\(_"W5M4TF&R0:7>:WX>
MCDN&M\?NP7=E=@%Q@L"<8Y(Q1F^2TY5/:TI1C?=-V7JOU05\.K\T78_3^BOF
M+]@OXF_M\>//%VOVG[8/P]_L;3;?38GT>7^R8[?S)S)AAE6.?EYQ7<_\% /V
MC(_V5OV1O&?Q@MKL1:I;:6UIX?&>6U"X/DP$#^+:[B0C^[&U?+8BA+#U73;3
MMU3NCCE'EE8^$OVD/BS\:?'WQY^(O_!1SX6^(=3E\*? /Q_HWA[3=)M+IOLV
MK6$#2)JV5!VMF2XC._\ YY3$_P ((_32R^)/A#4OAG%\7M-U07&@3Z$-8@O8
M%+>9:&'SA(H')RG(%? O[.7P=_X*'_"G]BX?LJ1?L1>#M4T37='O4UJ]U/X@
MQPW=Z;X.99)4V'9(%D" <E?+7G(KH_\ @FG\4_&"_L3?%+]D/XNQ&V\9_!FV
MU71[ZTDE#M]B>&=H&##AU5UFC4C(V)&0?F%8$GJ&D_\ !83]BWQ+XIT;PCX0
MUSQ)K5UK5F)X3I/AF>=;=F1G2"7 RDK*A;: < @L5YQ[K\"/CE\./VD?A5I7
MQG^$NLM?Z#K*2&RN)(&B?,<KQ.K(W*L'1@0?2O!?^"+/A70O#O\ P3A\ W6E
M:=%%-JK:C>ZC*L8#7$YU"X0.Q[D)'&@/HBCM7AOA_P".Q_X)GZ9^T]^SN9/L
MZ:%_Q5WPE@QG?%JS);I#&O4I!=20*0.I$I]Z /:_VK_VC_V._P!H?]D[XA3>
M.?BAXRTCP7X4\8PZ%XB\2>$;5H;E-0AN8OW=L[12"5-[1AF52"K\'G->J_'/
M]M?]F_\ 9=UW1?"7QI\=/HTNLZ/<W^GSS6<DD;PVZKO!9%.9"6550 L[, H)
M-?'7[9/[/+_LO_\ !"N/X4ZC 5UA'TB^\1N_+OJ-S?Q37 8]6*N_E@G^&-:]
M(_:N\-Z)XK_X*L_LJZ5X@TZ*ZMX](U^[6*9 RB:WL7GB?![K)&C#T*@T >J?
M!7_@IK^S)\;?BQ:_!*Q?Q/X;\2:G$TNB:?XQ\-3:<=3106)@9\AN%8@-M+8.
M 3Q72?M%_MR? +]F3Q+IW@'QQJ6K:IXIU>V-SIOA/PMHLVHZC- "09?*B!V)
ME6 +%<[6QG:<>,?\%0K.U3]H+]E;6T@47<7QML[>.X ^=8I)(=Z9ZX;8N1WP
M*9\0_CCJTW[>'C#P?^Q+^R9H_BOXG:/X>L[7X@>/O$GB%K*SL+>14D@M OS&
M3("$^7M.4(PVTD 'KW[-O[?W[/O[4'C34?A?X-GUW1?%NE6OVJ]\*>+M#ET^
M_6#*@R!'R& ++D!B1N!(P0:QOBK_ ,%,_P!G#X8?$75OA98Z9XR\7ZOX>D$?
MB1? _A*XU*+29,$E)Y4 56&#D*6*D$'!! ^=_"TO[2?_  ^8^&4_[44O@*+Q
M%<_#+4C!9> 1=&&"RQ=^6DSW/SR2;Q(<@!?2MWPU\'_VT/V??B-\0_B7_P $
MZ?B7\,?BCX)\5^.KW5M=\(ZQJ"_:K#5I=K7%NES"X3>N4&))5*C9F,G+, ?7
MGP#_ &@_A'^TY\.+;XK_  4\7Q:SHMS*\)F6)XY()DQOAEC<!HW7(RK <$$9
M!!/:5\T?\$W?CKX!^+6D>/\ PQIG[.,'PM\9^'/&$G_"Q?#-LR21R:E.&)NA
M*BJ)/,\MQTXV#!9=K'Z7H ^;/^"O>J:GHO\ P3G^)6IZ/J,]I<Q6FGF*XMIF
MC=,ZE:@X92"."1^-;VF?M2_"']FK]F7X1>(?CEXM?3+?Q/I.BZ5::C/&SQBZ
MEL5??,_2- $9FD;@8R:YK_@L;_RC9^)W_7GIW_ISM*\2_;Z\/:1XM_98_9$\
M*^(+*.YL-3^(O@^TOK:5<K+#)8['0CN"K$'ZT >V^&?^"MO['OB3Q_I/@:XU
M/Q1H]OXANUMO#OB77_"ES9Z7J<C$!/*GD4':Q(PS*J_,,D5ZM^TC^U5\#_V3
M_"-MXP^-?B_^SX]0NOLVDV%M;/<7FHS\?NH(8P7D/(R<;5W#)&17S[_P74TV
MP;_@GAK5W]DC$NF^(-)FL'"@&WD^TK'N3^Z=CLO'9C5;XLP6OB3_ (+9_"S2
MO&\:36&E_!^\U#PO#<#,8U-KBZ69T!X\P0HK<<C8I[# !ZY\ _\ @H9^SW^T
M#\1?^%/:7'XE\,>+GM&N[/PWXW\.S:9=WL"@EI(1)E9  I. V["L<85B/<Z\
MK^.NC?LJCXM_#;Q7\=/[,A\7VVMRVWPVNKJZFBG-Y*$#Q1"-@)-P" JX*\^_
M/JE !1110 4444 %%%?/6L_$?_@I3!J]U#HG[-WP\GLDN76SFF\82*\D08[&
M8;>"5P2.U95:JI6NF_1-_D=N#P-3&MJ,X1M_-.,?NYFKE;_@H#_P4!_X86_X
M1+_BTO\ PE/_  E/V_\ YCWV'[+]F^S?],)=^[[1_LXV=\\?./\ Q$!_]6E?
M^7Y_]P5YQ_P6"\3?M/>(O^%=_P##2'PR\-^'/)_M?^QO^$?UIKS[1G[%YWF;
M@-FW$6/7<WI7Q57R&99QCZ6-E"E)J*M9.*OLNZN?NW"? ?#>-X?HUL9152H^
M:\HU)-.TY)6Y)\NB26G5:ZW/VJ_X)_?\% ?^&Z?^$M_XM+_PBW_"+?8/^8]]
MN^U?:?M/_3"+9M^S_P"UG?VQS]'5^3G_  1]\3?M/>'?^%B?\,W_  R\-^(_
M._LC^V?^$@UIK/[/C[;Y/E[0=^[,N?3:OK7VK_PLO_@I[_T;+\./_"TE_P#B
M:]O+<PG5P49U5)R=[M1=MWV5C\ZXLX7H8+B"M1P<J=.FN6T958IJ\(MWYY<V
MK;>O1Z:'T=7Y5?M'_'#]H3]G?_@K'\6/VB_AT^H:QX3\ V_A[_A//#,5TY67
M1[O3;-)9$C)V@I(%?<,;6*L<IOK]3-&EU2?2+2;7+6."]>VC:\AA?<D<I4;U
M4]P&R >]?&OP$T/1_$W_  5X_:?\-^(=,@O=/U#P;X=MKZSN8P\<\+Z;:J\;
MJ>&5E)!!Z@U[.Y\$U9V/4?VV_B9X?^('_!-OX@?%?X8>)_M.FZK\/+B_T?5+
M&4J6C>+<K C!5AGD<%2"#@@TOP#^/WPU^ ?_  3E^&/QE^.OCJ/2M)MOAMH3
M7FI7I>62:5[*'"JJAGED8Y^506/)[$U\5_'36-<_X)U_#OXR?\$_/B!?W$OP
M[\<>$-4U;X*:U=N6%O(P+3Z6[G^($\#/W]K8S< #V;QI\5?A!\/O^"?'[,6@
M^.?@*WQ,\5ZUI?AD?#?PA]N-LDNKQV$.R>20G:J)Y@4[E8'S0"-I9@"/4-(_
MX*W_ +*LWB?2_#_C31_'G@ZUUNZ2WTC7_&/@NYL=.NI'^X%F;. >#N8!0#DD
M#)'IW[2G[87P2_94M])B^)^JZA-JOB"9XO#_ (<T'2Y;[4=29 "_E01 DA01
MEFPO(&<D"OB#_@JSKO\ P4%\4?L2>(-4_:+\$?"?PIX4&HZ<3I6E:C=W^LR7
M!NH_+6.4@0)CYBQ&255@, FO<?VK/@-\0OB+\:_AG\:/V7?VA/"&@?&/PMX0
ME6S\*>+9DE35M+F7$DGE+NE10QD4R*A!+ ;D*Y(!ZO\ LZ_MZ? ']I7QE>_#
M'PI-KVA>+=/LQ>7/A/QAH,VFWXM\@>:J2##KEAG:Q(R"0 0:S/C;_P %'_V<
M/@C\39_@U=#Q-XH\36$"SZSI'@CPW-J<FEQ, 0]P8_ECX(.W)8 @D#(SY#\)
M_P!I+XIZ3^VCX(^'/[?W['GAKP]\0_$&F7MEX"^)/AB\6YM[F.)&DFMU#,\D
M*D,<Y?(,J@H%?=5W_@C)#:ZAX"^,'C'7XT;QAJ/QLUE?%4TH_P!(WH(BD;YY
MVJTDI4= 7?'>@"A^P1\<O"_Q]_X*0?M">/\ X;^-Y=:\*W^@>%YM&D\R01)_
MH$:R 1/@Q.)%=74@,&5@1D&O1?&O_!5K]EWPQXDU;PYX4TOQOXV&@W3VVN:G
MX'\'7&H65C*GWU>X&U#MZDH6'O7FW[-8^&7PO_X*8_M8ZQ9O;V.AV/A[1=3U
MLVPPD#M9FXNW^3G<6,CMCG<S=ZJ?LF_%;]K'QW\'K-O^">G[''P[^'OPON;V
M[?PUJ/Q!\2W4LEXIG<27+6]KF5<R!AM9S]T!6*A30!]6_ _]IKX(_M$_"-?C
ME\*O'=M>^&@LOVN_N ;?[$T0W2I.LH4Q%!R=V!M(8$J03Y'I/_!6K]D#6=7W
M6U_XK3PRVH?88_B#/X1NH_#[W&[8(_MA7:N6XW, O.<XYKXN^'.H>/-)_P""
M5?[7:Z=J-G-JR_%F^BU";08VCM)(Y+BPCO&@4DE86A,N >B8!K]!? ?@CX0:
MA^P'I'@>2QL&\$W/PK@CE38OD-9-IX9I#VR5)<MUS\V<\T =I\ OCM\._P!I
M?X2:3\;?A1J%Q=:!K?G_ &">ZM6@D;R9Y('RC<KB2)QSU SWKR[_ (*6_M7^
M*/V2?V;7\3_#>QCNO&/B76;?P_X/AEC#JM]<!R)2IX;8B.P!^4OL!X)KG?\
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M]X6^'/\ P2N\#?%WXS>.X[#2]-TW49]5UK5[IF"*-4NE7+'+,Q.U5499B54
MD@5YQX3MM/\ #7_!27]JKPUX!C2#1;[X2P:AXAM;08A75C:H0Q X$C++,Y[E
MG<GDFO#KE(-3_P""5'[)'A/Q8^WP?K/QGMK7Q<)#B*2V.J:AE)#TV%?,8@\9
M0'L* /LCP[_P5W_9 UG5]-@UJ;Q?X<T;6KD0:+XO\3>#[FSTB]=ON[+EQA5/
M7<X50.6( ->R?M!_M+?!?]ESX<M\4OC3XRBTO2C,D%H4C:::\G<$I##&@+2N
M0"< 8 !8D $CE/\ @H)X9\!:O^PK\4M(\::?:?V7:^ M1FMXY8U"0SPV[O;,
M@Z!EF2(H!_$ !7Q=\*-0UOQK\8_V#;#XW;I]'/@/4KG3!J/,<^HQ69^RNV[[
MSA8[)D)YW%<?>Y /IJR_X*Y_LAHJ6GC*7Q=X4U.>YMXK+0_%7A&XL[R\2:3R
MTFA0@B2/<1D@Y4')&.:]@T']I3X5>(OVA-<_9>LM3NH_&.@:-%JMY87-DZ)+
M9R>6!+%(1ME ,J*<'AB0>AKYI_X+?:/X*N?@3\/=;UN"W_MFT^+.DQZ'.P'G
M 2>9YT:GKL*(&8=,QH3R!5[_ (*'6S?L[?M1?!;]O;3E,5CINM_\(=X^E7H=
M)OMPBE?_ &(9&E?_ 'FC% 'T;XS_ &BOAAX$^-/A+]G[6]2N7\4^-(+N?1=/
MM+-Y1Y-LF^665AQ$F V"WWBI Y%=S7R'^Q_;R?M(?M[_ !D_; U!#-H_A*5?
MAUX%=OF79;,)+^5#TPTQ!5AU65AGKGZ\H ^)?^"3_P 1_P#A'?@O\?/'OCW7
M;V>P\/?&+Q#<W$LTCSO#:P6T$C*@))P%#$*/PKM-=_X+$?L9Z;I-OKV@7WBS
MQ'8FPBO-4OO#GA.XN8='BD0.OVN3 6)MIR4R67^( \5XM^P)_P F1?M:?]C[
MXS_]-J5[Q_P22\'^&M)_X)Q_#K3K/1;98=4TBYN=1C,((NI)KF;S&D_OY&%Y
MS\H Z "@#V/PS^T3\%/%WP1C_:/T/XBZ=)X(DTQ]0_X2&60QPQP)D.S[P&1E
M965D8!@RE2,\5\H?M,?\%4OV9?BA^R]\1?#GA&\\8:1_;G@?6;7PCXIU?PM=
M6.G:M=_8YO+CMKI@!YC$':&V$D8'S$"OEVWN]1LO^"%5MH<=U/%HDWQE^QZ^
M8W.(].^W%R">R^:L1^I%?HG^WOX,^&UW_P $^?B7X9U/2K"/0M.^'-])I4"1
MJ(;>2WM6>S\H#@;98X=@'< "@#+_ &5OC=X ^#'_  3<^&_QC^-WCJ'2M(L?
MA]IDNI:MJ4K.S,T"  8R\LC,0 J@LQ. ":J?#W_@JI^RMX\\8Z1X.U)?%WA3
M_A([A8/#6K>,O"EQI]AJTC8V+!.X*_-D8W[<Y ZD _'_ .T8?'VK_LD_L->"
M/"-IH5U!J=[ID@L?%;RC2;G4([>V%G'=^7\QC8R3*0.H8CUKU;]M/X9?\%+_
M ([?LXZ[\.OVB!^S+X>\+SM;27/B&?7M4M#ILJ3H8I4GN%,<3%\1@D<B0K_%
MB@#ZT\>?M5?![X8_'/PO^SUX\U6\TS7_ !I$[>&9;FP<6=\ZY#0K<8V"7( V
M$@DO&/XUR_Q!^U)\(?#_ .T)H_[+C:K=WOC36--?4$TO3K!YEL[1<_OKF11L
M@4[3C<03P /F7/SK_P %*-)^':_\$UM'U#X]>*EN?&FF:9I3^"]=\-W!GN;K
MQ.($\I[.3Y6D21P[,PP3%N<#<JXRO^"-YTW5+WXH>(OC8^HO^T$_B4Q?$U?$
M$:)=P6XQ]D2!5^46I4<;,#<H'W%BH ^XZ*** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K\Y_^"G__  3
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M8GG(-?6M% 'C?Q!_8Q\%?%3]I/P=^T%X]\47]]:> +1E\)>"_)B33+*[./\
M3"H&YY1A=O("^7'@?+R[QE^QOX2UW]K#0/VP_"/C#4_#?B?3--;3==ATV.,V
M_B&Q)&(;I6')4#Y7!W#;&?\ EFN/8J* "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
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M% !1110 4444 %8]E_R.][_UY1?S-;%8]E_R.][_ ->47\S0!L4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/X'_P"01+_U
M^S?^A5L5C^!_^01+_P!?LW_H5;% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!Y1^W/_ ,FC^/?^P"__ *&M
M=U\+O^29^'?^P%:?^B4KA?VY_P#DT?Q[_P!@%_\ T-:[KX7?\DS\._\ 8"M/
M_1*4 ;M%%% !1110 4444 %%%% !1110!CV7_([WO_7E%_,UL5CV7_([WO\
MUY1?S-;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 5C^!_^01+_P!?LW_H5;%8_@?_ )!$O_7[-_Z%0!L4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %9OC'_D6+W_K@:TJS?&/_(L7
MO_7 T 7-._Y!\'_7%?Y"IJAT[_D'P?\ 7%?Y"IJ "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#'\2_\ (7T?_K]/_H)K8K'\2_\
M(7T?_K]/_H)K8H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "L>R_P"1WO?^O*+^9K8K'LO^1WO?^O*+^9H V**** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\#_ /((E_Z_9O\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% &/X'_Y!$O\
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M+_R%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_B7_ )"^C_\ 7Z?_ $$UL4 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !6/9?\CO>_\ 7E%_,UL5CV7_ ".][_UY1?S- &Q1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 8_@?_D$
M2_\ 7[-_Z%6Q6/X'_P"01+_U^S?^A5L4 %%%% !1110 4444 %%%% !1110
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MIO\ 9^[KY'G6F_'MYGZT ;7PD_:&_:B^!?[5^A?LC?ME>(?#WB>#QUI5S=^
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M)=7_ .A0O?\ OI:/^$EU?_H4+W_OI: -BBL?_A)=7_Z%"]_[Z6C_ (275_\
MH4+W_OI: -BBL?\ X275_P#H4+W_ +Z6C_A)=7_Z%"]_[Z6@#8HK'_X275_^
MA0O?^^EH_P"$EU?_ *%"]_[Z6@#8HK'_ .$EU?\ Z%"]_P"^EH_X275_^A0O
M?^^EH V**Q_^$EU?_H4+W_OI:/\ A)=7_P"A0O?^^EH V*S?&/\ R+%[_P!<
M#4/_  DNK_\ 0H7O_?2U1\2Z]J=SH-U!-X8NH5:(@RNRX7W- '0:=_R#X/\
MKBO\A4U85EXCU5+.)%\)7C 1* P9<'CK4O\ PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
M"2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PD
MNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK_P#0H7O_ 'TM &Q16/\
M\)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\ "2ZO_P!"A>_]]+1_PDNK
M_P#0H7O_ 'TM &Q16/\ \)+J_P#T*%[_ -]+1_PDNK_]"A>_]]+0!L45C_\
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M?LW_ +/.C:'I%N(;*QM-2U$*H[LQ\[+NQRS.Q+,Q))))->C?M7?LO?'GX^>
M_AA\:O!6L>']!^-GPUFAU6T23S&TFXN98(UO[ MS(()&3"MR=JX)&\NOTM10
M!\<:K\!_VV?VUOBOX&NOVO?A_P"%? 7@#P!X@BU^7P[HFO?VE<^(-3A!$!9P
M L4"Y;*GYL.P.[<&3KOVKOV9OCS!^T;X9_;:_9%DT2Y\8Z-H<F@^)?"WB&X:
MWMM?TIY#*L:S*/W<R2'<"W!PA)Q'M?Z9HH ^4?A'^SO^U)\=/VL-"_:[_;+\
M/^'_  Q!X$TJYM/ '@/0=4-^;>YN5V7%Y<SX",Q3Y5"_W4.%*9?ZNHHH ***
M* /*/VY_^31_'O\ V 7_ /0UKNOA=_R3/P[_ -@*T_\ 1*5PO[<__)H_CW_L
M O\ ^AK7=?"[_DF?AW_L!6G_ *)2@#=HHHH **** "BBB@ HHHH **** ,>R
M_P"1WO?^O*+^9K8K'LO^1WO?^O*+^9K8H **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "L?P/_P @B7_K]F_]"K8K'\#_ /((E_Z_
M9O\ T*@#8HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH *S?&/_ "+%[_UP-:59OC'_ )%B]_ZX&@"YIW_(/@_ZXK_(5-4.G?\ (/@_
MZXK_ "%34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% &/XE_Y"^C_P#7Z?\ T$UL5C^)?^0OH_\ U^G_ -!-;% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 5CV7_([WO\ UY1?S-;%
M8]E_R.][_P!>47\S0!L4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%?%7[6W_!8+_AEK]H/Q!\"/^&=_P"W?["^R?\ $U_X2W[+
MY_G6D-Q_JOLDFW;YNW[QSMSQG Y\3B\/@Z:G6=DW;9O7Y'JY1DN9Y]B7A\#3
MYYI<S5XK1-*]Y-+=KS/KWP/_ ,@B7_K]F_\ 0JV*_-?0_P#@O;_8UHUK_P ,
MI>9NF>3=_P )UC&XYQ_QXFON']DG]H'_ (:E_9\\/_'?_A$O["_MW[7_ ,2K
M[?\ :O(\F[FM_P#6^7'NW>5N^Z,;L<XR<<-F6"QE1PHRNTK[-:?-';F_"?$&
M0X98C'4>2#?*GS0>K3=K1DWLGY'H]%%%=Q\Z%%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 >4?MS_\ )H_CW_L O_Z&
MM=U\+O\ DF?AW_L!6G_HE*X7]N?_ )-'\>_]@%__ $-:[KX7?\DS\._]@*T_
M]$I0!NT444 %%%% !1110 4444 %%%% &/9?\CO>_P#7E%_,UL5CV7_([WO_
M %Y1?S-;% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 5C^!_P#D$2_]?LW_ *%6Q6/X'_Y!$O\ U^S?^A4 ;%%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !6;XQ_Y%B]_P"N!K2K-\8_
M\BQ>_P#7 T 7-._Y!\'_ %Q7^0J:H=._Y!\'_7%?Y"IJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#'\2_\A?1_^OT_^@FMBL?Q
M+_R%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MK8K'\2_\A?1_^OT_^@FMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MHHH **** "BBB@ HHHH *Q_ _P#R")?^OV;_ -"K8K'\#_\ ((E_Z_9O_0J
M-BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K-\8_
M\BQ>_P#7 UI5F^,?^18O?^N!H N:=_R#X/\ KBO\A4U0Z=_R#X/^N*_R%34
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M ,^]:]%%=22BK(\6<YU)N4W=OJ]PHHHIDA1110 4444 %%%% &/X'_Y!$O\
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M+_R%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M2T %E_R.][_UY1?S-;%<I:ZYJ*^*;JZ7PW<L[VT:M &7<H!/)K3_ .$EU?\
MZ%"]_P"^EH V**Q_^$EU?_H4+W_OI:/^$EU?_H4+W_OI: -BBL?_ (275_\
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MZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DN
MK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J_
M_0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\ T*%[_P!]+0!L45C_ /"2
MZO\ ]"A>_P#?2T?\)+J__0H7O_?2T ;%%8__  DNK_\ 0H7O_?2T?\)+J_\
MT*%[_P!]+0!L45C_ /"2ZO\ ]"A>_P#?2T?\)+J__0H7O_?2T 'B7_D+Z/\
M]?I_]!-;%<IKFN:C/J.FR2>&[F,QW)9$9ES(=O05I_\ "2ZO_P!"A>_]]+0!
ML45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+0!L45C_\)+J__0H7O_?2
MT?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\ ?2T?\)+J_P#T*%[_ -]+
M0!L45C_\)+J__0H7O_?2T?\ "2ZO_P!"A>_]]+0!L45C_P#"2ZO_ -"A>_\
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M'O>WC)+&--B?,<9\P<#!KXOK]V?V@?V;O@E^U+_9'_"]_@A>Z[_87VC^RO\
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MU?\ Z%"]_P"^EKN/G#8HK'_X275_^A0O?^^EH_X275_^A0O?^^EH V**Q_\
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MJ+7-O$>ZQ6@Q"B>B,' [&O>])TC2M!TZ'1]#TRWLK2W0);VMI"L<<2CHJJH
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M$I7"_MS_ /)H_CW_ + +_P#H:UW7PN_Y)GX=_P"P%:?^B4H W:*** "BBB@
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M44 %%%% !1110 4444 8_B7_ )"^C_\ 7Z?_ $$UL5C^)?\ D+Z/_P!?I_\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@#RC]N?_DT?Q[_V 7_]#6NZ^%W_ "3/P[_V K3_ -$I7"_MS_\
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M0A4M;F2?WJY^6YG@_P"SLRK83FYO9SE&]K7Y6U>UW:]MKOU"BBBMCA"BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH *S?&/\ R+%[_P!<#6E6;XQ_
MY%B]_P"N!H N:=_R#X/^N*_R%35#IW_(/@_ZXK_(5-0 4444 %%%% !1110
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MD_9^\!;[:U\2R:[=ID?9]#B\U<_]=21'CZ,3[5\[_'?]N_QM\6/#%YX)\/\
MA6#1-)U%/+N)6G:6XFC!&5WX55!QA@%)P<9ZY^6S7C'(\LIR2JJ<TG:,==>S
M:T7G=F%3$TH+>[/?_P!D3]HO3_C0WB/0I(U@N;#5)+BPA(PTEC(V$8CNRD8;
M_?7UKVFOS-^ 7Q7O/@O\5=+\=0,YMX9O*U*%/^6ML_$BX[D#YA_M*M?I987]
MGJMA!J>G7*36]S"LL$T9RLB, 58'N""#7-P5Q!4SO+I1KN]6#U\T]4_S7R\R
M<+6=6&NZ)J***^S.D**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH \H_;G_Y-'\>_P#8!?\ ]#6NZ^%W_),_#O\ V K3
M_P!$I7"_MS_\FC^/?^P"_P#Z&M=U\+O^29^'?^P%:?\ HE* -VBBB@ HHHH
M**** "BBB@ HHHH Q[+_ )'>]_Z\HOYFMBL>R_Y'>]_Z\HOYFMB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HKF?B#\:?A!\)[<W7Q.^*/A_P /H%W :QJ\
M-NS#_95V!8^P!)KQO5/^"GO[-5Y?2:+\(;'Q?\2-1C;:UEX$\)W-V0W8;W6-
M"/<,16%3$X>D[3FD^U]?N/1PF49ICH\U"C*4>Z3Y5ZRV7S9]%45\W?\ "_\
M_@H'\3?D^$_[&FE>$[63_4ZO\2O%*CKW:TM1YR8^IH_X9J_;H^)?S_&/]N#^
MP+63_6Z-\-/#<=KM]=EY-F8?B*S^MN7\.$I?*R_\FM^!U_V(J/\ O6)I4_+F
MYW]U-3U]6O,^A==\1>'_  MIKZQXFUVSTZTC_P!9=7]TD,:?5G( KQCQS_P4
MD_8R\#WO]CK\9[/7M19ML&G>$[:75))F_NJ;=63/U85FZ%_P3#_95AU%-?\
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MA?1_^OT_^@FMBL?Q+_R%]'_Z_3_Z":V* "BBB@ HHHH **** "BBB@ HHHH
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MO]A)?'>M:%X!\,>!V\4>/H_#^H-:7&LRR3+%!9/*GS"("2)R!]X,_=497_\
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M (T?8O&__0;LO_ 8_P"- &Q16/\ 8O&__0;LO_ 8_P"-'V+QO_T&[+_P&/\
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MXF_)\)_V--*\)VLG^IU?XE>*5'7NUI:CSDQ]37ES?L/?MHZ/ +72_%.@O$F
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M-L_0'P-\*_AE\,++^S?AO\.]#T"#;@Q:-I4-LI'N(U&?QK>K\RKWP+_P4!L
M3/\ L]>/6QC_ %.OPR?^@3&LJ\M_VZK$D3_LW_%)L$C]RTLG3_<)KMAC>)DK
M1RQ_*K2_S/'G5QE:;G.+;?5R39^I5%?D_>>+?VS[ %KO]FCXR*H&2XT:_*C\
M0F*RKSXR_M.Z<2NH?!'XJP$'!$UA>K@^G*UJL5Q8]LKE_P"#:?\ F3_M/_/O
M\4?KK17XZ7G[4?QCTX%M0\"^/X !DF9[A>/7D5E7G[;OBS3B5U"V\50$'!$V
MIR+SZ<FM%5XQ>V4S_P#!E/\ S'RXM_\ +M_>C]H**_%^']NVX8_O]3\5+S_!
MJ);^<@JU#^W/IK#]_P"(O&BGOLE#?SN!1[3C+_H43_\ !D!\N+_Y]/[T?LM1
M7XYP_MQ>$V_X^/&7CY>?X((V_G>"K]E^VA\.KK'G_%3QU;9!_P!=I^<?]\7;
M5+K<8K_F43_\#@+EQ?\ SZ?WH_7VBOR7L_VKOA'=8\_]I'Q+;YQ_KM)NSC/^
MY(W3_.:UK+]HSX%W6//_ &S;^VSG_7:'JYQ_WPC5#Q7%Z_YD]3_P*(K8O_GT
MS]4J*_,*S^,_[/\ >X$?[?L*' RLVBZZF,]LFWQ6M9>-/@I?D"#_ (*%Z&N2
M1^^?4H__ $-!4/'\6K?**G_@4?\ (5\3_P ^F?I/17YVV;?"N^ ,'_!1?P<N
M0#^^\03Q_P#H9%:UGX-\#7Y"VO\ P4=^'C,3@(?'2!C^!FS6;S/BB.^4U/\
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M/[M9_P"UT?[Z^Z7^3_\ )3I_X0L?WP\_G.G_ /+(K_P8?3U%?*U_^T-^W/\
ML[-Y'[2/P3B\6:#",/XW^&=L;DH@_CGL7*R)@<LRX0<X!KU+X(_M*_#G]HO3
MOMWP>^-.@:O(B;I]/6(Q7EN._F6\FV1!GC)7![$UI3Q5&I+EO:79Z/\ X/RN
MCFQ638_"TO;64Z?\\'S1^;7PORE9^1ZO16/]B\;_ /0;LO\ P&/^-'V+QO\
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MOKE(D'_ F(%>-?$/_@H'\#/!^^U\-2WGB.Z7("Z?#Y<(/O+)CCW4-7GVE_\
M!/OXH^.KX>(/C=\7C<7+\O'#-)=2X/;S9>%^@5A7JOP__8_^'/PW9+C1?#6D
MW5TG(O=5MC=29]1YA*H?]T"N?ZUQ;F7\"C'#P[S?-/Y16B?E(7-B)[+E]3R1
MOVE?VROCXQM_@Q\.&TBPE.$O8+8-@>AN;C$>?]T U;T/]@+XG?$'4$\0_'_X
MPS33-RT%M,]W, ?X?-EPJ?0*PKZ66P\:HH1-9L@ , "U. /SI?L7C?\ Z#=E
M_P" Q_QIQX2HXF2GF=>>(?9OEA\HQV^\/JZEK-MG%_#S]D+X _#?RY],\"07
M]W'C_3=9/VF3([@-\BGW517I<<:1((HD"JH 55& !Z5D?8O&_P#T&[+_ ,!C
M_C1]B\;_ /0;LO\ P&/^-?287!8/ T^3#TXP79)+\C:,(P5HJQL45C_8O&__
M $&[+_P&/^-'V+QO_P!!NR_\!C_C744;%%8_V+QO_P!!NR_\!C_C1]B\;_\
M0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO
M_P!!NR_\!C_C1]B\;_\ 0;LO_ 8_XT ;%%8_V+QO_P!!NR_\!C_C1]B\;_\
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M */%2?\ #RKX%_\ 0J>+?_ "U_\ DBO7)?@=\%9UV3?!_P +.,YPWA^V(_\
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M>(\YX@]G]?J\_)?E]V,;<UK_  I7O9;A11176>&%%%% !1110 4444 %%%%
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M\8?@A\*/C[X1E\#?%[P/8ZWITF2D=U'\\#D8WQ2+AXG_ -I"#VSBO@KXK?\
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MBB@ HHHH **** "BBB@#'LO^1WO?^O*+^9K8K'LO^1WO?^O*+^9K8H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L?P/_R")?\
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M59OC'_D6+W_K@: +FG?\@^#_ *XK_(5-4.G?\@^#_KBO\A4U !1110 4444
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M!NR_\!C_ (T ;%%8_P!B\;_]!NR_\!C_ (T?8O&__0;LO_ 8_P"- &Q16/\
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MHHH8].L\Y,-K;Q?)#N.=Q!.<G&W<^[WRBB@ HHHH \H_;G_Y-'\>_P#8!?\
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MX@_:J.DA_O#_ (3F[@Q[8LXB/RH_X="?MF>+SGXE?MGB4L?WG_$QU&^Z]?\
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M68_#ZSINW=:K\+DRHU8[H]OHJ.TO+34+6.]L+J.>&50T4T+AE=3T((X(J2N
MR"BBB@ HHHH **** "BBB@ HHHH *Q[+_D=[W_KRB_F:V*Q[+_D=[W_KRB_F
M: -BBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH Q_ _\ R")?^OV;_P!"K8K'\#_\@B7_ *_9O_0JV* "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#RC]N?\
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M4 8]E_R.][_UY1?S-;%8]E_R.][_ ->47\S6Q0 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %8_@?_D$2_\ 7[-_Z%6Q6/X'_P"0
M1+_U^S?^A4 ;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !6;XQ_Y%B]_ZX&M*LWQC_R+%[_UP- %S3O^0?!_UQ7^0J:H=._Y!\'_
M %Q7^0J:@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH Q_$O_ "%]'_Z_3_Z":V*Q_$O_ "%]'_Z_3_Z":V* "BBB@ HHHH ****
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MBB@ HHHH **** ,>R_Y'>]_Z\HOYFMBL>R_Y'>]_Z\HOYFMB@ HHHH ****
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ME38WT<V1_P  )K2K\^-<_P""!_A:1C)X5_:7U&T(Y07WAE)\'ZI/'^>*S?\
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M8_\ (L7O_7 UI5F^,?\ D6+W_K@: +FG?\@^#_KBO\A4U0Z=_P @^#_KBO\
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MA_\ T<%X$_\ "7>@#WJBO!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\
MPEWH ]ZHKP7_ (5]_P %#_\ HX+P)_X2[T?\*^_X*'_]'!>!/_"7>@#WJBO!
M?^%??\%#_P#HX+P)_P"$N]'_  K[_@H?_P!'!>!/_"7>@#WJBO!?^%??\%#_
M /HX+P)_X2[T?\*^_P""A_\ T<%X$_\ "7>@#V*R_P"1WO?^O*+^9K8KY)\/
MW_[>>J_M#>(?A-;_ !N\()J&DZ#:7MQ=OX;S#)'*Q"JH W!ACDGBN\_X5]_P
M4/\ ^C@O G_A+O0![U17@O\ PK[_ (*'_P#1P7@3_P )=Z/^%??\%#_^C@O
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M_P!'!>!/_"7>@#WJBO!?^%??\%#_ /HX+P)_X2[T?\*^_P""A_\ T<%X$_\
M"7>@#WJBO!?^%??\%#_^C@O G_A+O1_PK[_@H?\ ]'!>!/\ PEWH ]ZHKP7_
M (5]_P %#_\ HX+P)_X2[T?\*^_X*'_]'!>!/_"7>@#WJBO!?^%??\%#_P#H
MX+P)_P"$N]'_  K[_@H?_P!'!>!/_"7>@#WJBO!?^%??\%#_ /HX+P)_X2[T
M?\*^_P""A_\ T<%X$_\ "7>@#WJBO!?^%??\%#_^C@O G_A+O1_PK[_@H?\
M]'!>!/\ PEWH ]ZHKP7_ (5]_P %#_\ HX+P)_X2[T?\*^_X*'_]'!>!/_"7
M>@#WJBO!?^%??\%#_P#HX+P)_P"$N]'_  K[_@H?_P!'!>!/_"7>@#WJBO!?
M^%??\%#_ /HX+P)_X2[T?\*^_P""A_\ T<%X$_\ "7>@#WJLWQC_ ,BQ>_\
M7 UXO_PK[_@H?_T<%X$_\)=ZY+X[Q?M]?##X0:_X_P!<^.?@VZM-*L&GGM[3
MPT5ED4$#"EA@'GO0!]0Z=_R#X/\ KBO\A4U?.WA;PE_P4(USPQINM6OQ]\#Q
MQ7EA#/&DGAABRJZ!@#CC.#5__A7W_!0__HX+P)_X2[T >]45X+_PK[_@H?\
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M4/\ ^C@O G_A+O0![U17@O\ PK[_ (*'_P#1P7@3_P )=Z/^%??\%#_^C@O
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M^(FF>/-<\$^._"$LC>&O&OAJ15N;=)!B2"16&V:%N<H<=6&<,X;V>B@#P/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% 'YO_\
M!77X[?MH>-_@E\0;#P)\-;SP%\+O!VJ0V.N>)]6N##?^*I3>Q6RI91K\R6N]
MPYDX$BJ!N +1G[A^(6H_%C3OV:=0U#X&Z'#JGC-?"8_X1JSNIXXXY+TP 1,[
M2LJ;58AB&(!"XSS7A_\ P6X_Y1K>/O\ KYT?_P!.MI7TOX5O;/3O &FZAJ%W
M%!;P:/#)//-(%2-%B!9F8\   DD]* /C_P *?\$J/#^M_!&#XA_M%_'7XAP?
M%NZT7^T=<\;_ /"<SJVAW[1^8Z1+')Y/DP-\O&050E64%=OH/_!,3]I;QO\
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M-T_1M.M](TFQBM;2UA2&VMK>,)'%&H"JBJ.%4   #@ 4 ?!/["OB']JK6/\
M@J7X_7]K74K*+Q#-\)[>ZB\.Z1=F2RT2WDO+=HK1.2I9 QW,"VYV8[FSFOOR
MOCWX7?\ *;7XF_\ 9&-._P#2BUK["H **** "BBB@ KSG]J'XQ?$3X*?#5/$
M/PF^!^K_ !!\1ZAJ4>GZ1H&E.(U$TB.PFN)6XAMUV'<YX!*C(SD>C44 ?"7_
M  3(U7]HVZ_;I_:#TO\ :D\3VM_XMM=.\.O?VVES,UC8":"69+:W4\*D:2+'
MD9W%"Q9R2Q],_:2_9M^/_P"UC^U5IW@7QWK^N^'O@/HOA@W5T/#7B)+2;Q%K
M#2@?9Y_*<3K"L;9&5VYB;!!<$<]^R)_RE<_:H_Z]/"G_ *;A7J_[97[:GA']
MD[0M,T:R\.7GBOQ[XIF-KX)\"Z0"UUJD_3<V 3'"I(W/@^@!.< 'SW)X$?\
MX)]?\% _A!\(_P!GSXB>([SP?\5HM2M?$?@#6M;EU"*P^S1*Z7T!E9GBR6))
MSR()!D@X7U/]LK_B[G[6?P$_9EA_>VD/B6Y\=^)(UY\NWTJ(_90X[I)=3*N#
MQE.>E+^QM^QS\2-!^).H?ME?MB>(+?7?BYXAL_L]O:6AS8>%+ Y(L;09(W8)
M#R GJP!;=))(G[-/_%X_V_\ XW?'V3][8>#[?3_AWX=G[*8%^V:BGL1<RQC_
M (#S0!A7'[ OCW]I[XU>.?B5^W#XUUF70XM9:V^&?A'PQXMN+6QL--0?)=R"
M$H3<OQNST96^\NP*S_@EA\0O&U_XD^,WP)NOB9J?C?P;\.?&L>G^"/%VK7GV
MJ>>"193+:-<?\M_(*1C=_P!->,+M4>J^)],_92_X*,?#?6?A]<>()O$NA>'O
M%,ECKMKIM_>:>\.H01D-!(4,3LH$V<#*,1WVD#PS]@"#5_V8?VW/B;_P3R\)
M^(I=7^'WA_P[;^)/#0O$C-QH\D[0>9:/(B@R;OM&X;\G;&IZLV0#R[_@KS\=
M_P!M'Q[\%/'5MX1^&M[\/_A9X2UZ/3=5U_5KDQ:CXLF6]6!?LL:_-'9[\2;S
M@2JJX;!:.OTCTDDZ7;$G_EW3_P!!%?)O_!<K_E'%XN_["ND_^E\->U_M4?&9
M/V>_V2O&/QE$XCGT'PE--IY;H;QH_+ME_P"!3/&OXT ?,G@RX_:,^)W@K]IG
M]JC]E31(]2\<^,O&R^%_ ,DEW!"L>F:5LL_M<3W#+&,E[J103@R(I(/2G?&'
M_@F5\/\ X.?LSZ_\;(OVA_B)9?$_PQX7N-9N/B+<>-[HR37T$+3,'C+[/)=U
M*[0-VU@-S'D_0?[)'@/P_P#LC?L1>#_#/CO5+?2+?PSX12]\37M]*$CM[AU-
MS>2.QZ 2R2G)YKYZO9OBS_P6#UY-/L;;4_!G[-.G:B&N+N56@U+Q_)#)D*@Z
MPV8=>OJ,\N,0@%/XJ_MF?M ^/_\ @GS\#;3PQKSZ!\1_CKKFG>&I-?M8O+DL
MXY)&BGOX@N-C.%C8%<;1.2I4JI$'[67[)47_  3H^#<?[8_[*OQ.\:IKW@K4
M;*?Q98:[XHGO;;Q592W$<$Z74<AVAR9 ^Y0H4!B &",O5_\ !2GPYH?PS^)/
M[*?B#3-+@TSPQX8^+UAI0C@C"6]C'*L2PKCHJ*D#8] M=S_P6'\0:;X>_P""
M<OQ)?4)E4WEG96ELA/,DLE];J%4=SU;Z*3VH B_:F^'W[0?[8/BSX7^"_AGX
MDUGPY\&]=L7U?X@>)/#^LQ6FH7,;0^9:V2_.)0C\!RBLO[T$_<Q7C?[1GP8T
MK_@FC\6/@_\ $?\ 94^(7BBVC\8_$:R\,^(_A_JGB.XU"UUJUN,[YUCG9BLJ
M$!=XSAIHR,<AOH3QG^TEX _8/_8[\$ZI\7A=3:K;^&=,TC2/#5A'OO\ 5]12
MUC3[-#'U)W#YF/"CW(!X?]F/]EKXU_&SXU67[=7[=5O%;>([.%A\.?AM ^^U
M\(VS_P#+27/^LO&&"2?NGD_,$2$ T/CY^S!\=_VMOVM'\,?%O7M>T+X$Z!X;
MCDL++PUXD6T;Q)JKLI<7/DOYXC168 , ,Q J1O8GSOPOX2N_V#O^"D?PV_9V
M^!OQ%\0ZEX&^*&@ZE)K7@;7-9EOUT:2UADDCO;=I26B5S&5.2<[) 2?D">[_
M +9O[;6@?LN6FE>!?"7A.Z\9?$SQ:QA\%^!=+YFNWY'GS$?ZJW4@Y<]=K <*
M[)S_ .Q=^QIXY^'WC;5_VL?VK/%,'B7XP^+;40WDUN/]"\/67!73[,= HP S
MCKC SEGD /I.BBB@ HHHH **** /GO\ ;+^+G[7%KK%O\!?V0OA!)+K.M:.;
MJ_\ B3K3"/2/#D#.\9;D'S[D;"RQ@'&48JX) Y/_ ((HZWK/B/\ X)Z^%M;\
M0ZM<WUY<ZOJ[W%W>3M))(QU"?)9F))/UKZGUG_D#W?\ U[2?^@FOD_\ X(;_
M /*.'P?_ -A35O\ TOFH SO"?[!?Q'_:N^(7C?XK?\% ]7\401MXGGM?A]X(
MT;QBT&GZ=I"!3#<XLI<&9\D-N(;,9+ [EVR?\$[?%'CKX=_M3?&O]BB?XF:O
MXT\'_#V73;GPOK.N7ANKK3Q=0[WL))SRX0G: ?NF%\ 9*C>_:J_;.^)FO_%"
M?]BW]A;0X==^)LL _P"$B\27(SI?@RW?&9[A\$-. 05CP<$C(=OW9[?]F;]F
MSX9_\$__ (!:[?WGB&YU?4#%<^(/B!XRU(YNM7N4C:6:=R22% #[4). 2269
MF9@#SKPM-X[^+W[<?QV^,WPQM+*\U3X;^!+7P+X$&I2E;.3594:_N?,(!VA)
MVMXW(&=H(K@M?_X)U:;X,_9>UG]H;]J#]I+QM9?&"TT"YUC5/'D'CF>&+2;T
M(TB00(C+%Y*L$CV 9;D(5RH7U#_@GSJND?!?]A%_VEOC;J2Z4_C2_P!3\?\
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M"0>)7U[P;\+[BPN/!VI30QB:R@O(S,UG*\:J)&4MC<0#NCE[$!?LZ@ HHHH
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M+XQ_&;]A/Q-XKU/QO<?#BWMM7^'=_KUZ&O+S3KJW$D=G-.V-WEN\,8=N[O\
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M<7EW/=:PT]U=S-))(W]JW?+,Q))^M?27CG_D2=8_[!5Q_P"BVKYE_P"")/\
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MTOX&_LQ:1^S7X)\47=M'H_AEM+M]>MX5CG$[(V^\5>55S*[2@9(!.,FO1:*
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MRW]K[]E?PO\ MA_")?A!XN\37^DVBZS::C]KTU$:3? Y95PX(P<\]Z]2HHH
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MB9KSX>V;02B*&5BTMM!=R R0PME@4PV0QW;BS$_8%% '@7[1G_!/GX8_'?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
910 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>21
<FILENAME>exhibit1016-arvinasxamen001.jpg
<TEXT>
begin 644 exhibit1016-arvinasxamen001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUO99KB.8V\+A&A**!]Q2 V#ZU6LO 6I7\>HP0J_AO29[FWN(]-<I=!V0'>7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JG;Z3IMI=RW=MI]K#<S?ZV:.%5=_]Y@,G\:N44 %%%% !1110 4444 ,
MEABG"B6-) K!U#J#A@<@CW![T^BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-CMD '\:ZJ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M7_+2$*H"K(.I(&6![=* .CD\07M_XKU#0=)-E%+IT,4MP]V&8N9 2JHJD<
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M!N',/S(?4#.*YZXAO_ FI67A219;GP]J&J6CZ3.?F-JXN8W>!SZ8#%3[=^<
M'KZ[@HW$%L<D# )^E+110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV5O;MYL\R@$;@!PV<@D^O7B@"S\4]5\9>'M0AU7PU?226=M#]IO;)XT=2@<
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M^M7'P)3Q=;S2:;JOD12?NE!4DRJA.U@>"#D?45)H4^MZ[X0TB:W\4WZZ]=6
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M&.#@L!G!XX[T ;5%8MOXJTBYO[:Q$T\-U=$^1%<VLL+2X4L2N]1D  GBMJ@
MHJK+J-G#J5OI\EPBW=RCR0Q$\NJ8W$?3<*AUC6M/T#3WO]3G,%HGWY?+9PG;
MG:#@>YH T**BM;F"]M(;JVE66"9%DCD4\,I&01]16=%XETBXUF\TB"Z,U_9J
M&N(8HG?R@1D9(&,D=LY[4 :U%<_;>--#O1,;2:\N!#*T,IAT^X<(Z_>4X3@C
MN*?-XRT"VMK*YN+_ ,FWO7$<$TD,BHS$D;2Q7"G(/!QTH W:*J:GJ=IH]A+?
M7TC1VT2EI)!&S[ .23M!('O6?J'BW1M*:T2^GG@>\.VW5K2;=(?0 +G/MUH
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M*JW>HV=A+:QW5PD3W<WD0!C]]]I;:/P4TFIZG9Z/8M>WTIB@5E4L$9CEF"J
M%!))) X'>@"W17.#QUX?-U):BYNC<1())(A87&]%/1B-F0/>I9O&>@P+I[/>
M2$:BF^SV6TK^>,9^7"G)P<XZT ;U%95KXCTV[O#:1M<K<"%IQ'+9S1,R*0"5
M#*-V"R\#)YJC!XZ\/7*3O#=SR1V[M'.ZV4Y6)EZJS;,*1WS0!T=%5M/U&RU6
MRCO-/NX;JVD^Y+"X=3^(JGK'B/2]!:V74IWA-S((8<02/YDAZ(-JG+'' ZT
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MWU](T=M$"TD@C9]@'))V@D#WH MT5BW7BS1[*<03S7"S>2+@QK9S,RQDD!F
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M!/H0*]".G:]/>6K7>L6?V6&3S'AMK)HVE(!V@L96PH;!P!SC&<9JE-X0;4-
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MKN[ANO,N)IPT<!CQYLC2$$%FS@N0/853\+^#[#PE-JHTTE+6^N?M"P8XA.T
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MV\A=YE; W8)XYQCO67I_A36=+\3:YK5MK-@7U=H6DBDT]R(_+38N")AVZYH
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M^_@22(,<A<D@8R1CC-+.9](^+L=S?7TEY!#X<N)@SQHKJ%E0L/E !''''YT
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MO"$)$#ZL6#$>B<]1D UM0\2:7IEQ+!<S/YD,0FG$4+R>3&<X=RH.T<'KZ$]
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M\2[R$ Q\H'/3'7FK'AWQYXGUVPT;7;2"ZNX[S4FAN["*R/DVUMN*AQ+MY9<
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M@X.X#((W;=N1UK4N-1\C5;.P^Q7<GVE9&^T1QYBBV@'#MGY2<\>N#0!E>']
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MN9HY&0820892K <'D@^F>:IZCX"CN/!L7ARROS;1"=;B6XDA\QY9!()2QY4
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M+OQQIOBFUU:>UNK2U^R2*8Q)YL?S<Y/1OF/.#VXIVC>!WTGQ]J_BHZF)GU-
MDEO]GVA -NW#;C_=&>.?:NOHH YS1_!FG:+XMUOQ#;C_ $G5=F]=N!'@?-C_
M 'C@GW%8R?#JZT[QGJ&OZ#XBFTV+5#NOK3[,LH=LY+*6/RG))Y!P2>W%=+I?
MB*TU;6=6TN"*X2?2VC6<RIM!+J67;SDC ]!UK7H C$;1VPBB?#*NU6DR_0=3
MSD_G7G_AKX:ZAX5N-:FT[Q(JOJ\@DG=K %HV!8YC^? ^^>H/:NVU758-(MHY
MIHKB7S)5B2.WB,CLQ] /H3[8K$C\>:=-?WMC%8:M)=6*HUS"EDQ:,.,KD#U
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MO9+J!9'D5I4 8%V+MR.",L>U&H>'!?\ BG2M=-[)')IJ2I%"$!5A( 'W'KT
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MNY;R(&*A1"ORXRH!96(9N2<J0.F<\YXP:P\00S?#R[MKU[N:UADAN_)Q&2'
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M2\"/9P1SSB/42D<DIC5OW*_Q!3C\JZ7PUX87PY)J;KJ-U=G4+MKN03*@ =@
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MJZ^-0DEFU01+<0M&H0"-=J;<<C@]R<T 9=[J>I:EX@UG1-*-Y;)I<$*HUEY
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M=J4MAJVFS :5:)M_>Q[%*$(0?,\QMR]\=!@B@#T^F22QPJ&D=44L%!8XY)
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MH!75T4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7EG
MQL\1:WX6TG2KW1=3FLY)[KR)%54967:3T93SQ7J=>-?M"H]WH.C6MO&\\ZWO
MF-%$I=E3:1D@=!DT :'C#Q+KO@KQQX7L[359M3M-6E,,]C<QQEU&Y%W*R*K#
M[QZY&5J/XC>(-<TCXC^$M+TW6+FUL]6G2*YC18SP9%4[2RD@X8UB:QI\OP\^
M)ECXOTVUDU3P]J8\J78AG>U)Z[#R0.XQVW+Z4OQ5DM-5^(W@>X1!>:?%*CW3
M+&9$6,RH3OP#@8!X/:@#TK1H+^37A>VVOW=_I*K/;307 B(69'4!E9%!QPX(
M-<KX;\3ZK\2O%FKI8ZC-IOAO2G$2_90HFNW)."7(.U?E)P,'!%;F@:EH>CWM
MEX8\/J9H;BXGG;RHF$5M&0SD;NGWB% ST/M7%?#NW?X5^)]=T/Q KV^FWDBR
MV&HNA\B0+N&&?HK8(X..0?49 /2;?2]:MO$"HVL7-SHSV<@VRA!+%-N3;\X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8O&]OY\,L"_<4J2.5['- %:U\5>(7AT72M3TUK+6KN.>6Y\A%DVQQ%5#(I;
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M_P!T;B/]I:O:N,Z+?@]/L\G_ *":Q_ >@#PYX2M+,B42N/-D$S;G7( 5"?\
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M HHHH **** "BBB@ HHHH CFMX+E D\,<J@Y"R*&&?QI8XHX8Q'$BHB]%48
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MR55<C<5" G'3/L: .AHKB_ 7C"+5O"NBOK.K6?\ ;5^DC"%G2-Y<2,!M3CC
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MO+:Q@,]W<100@@%Y7"KD].350:_HQM([L:M8_9I7\N.;[0FQFSC:#G!.>,4
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MK9HY5*REF"Y!'&!G)/8"MR">&Z@2>WECFA<922-@RL/4$=: )**** "BBB@
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MZ4Z;3[*Y>%Y[.WE> YB9XE8Q_P"[D<?A0!7T&W@L_#^GVUL+@6\5NB1?:?\
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MOFUS3)X1_91?;-%=1<%L  [>K$YQ@G/-*K:<WAWXM/NMBYFNAG*Y/^CKM_\
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MC'4]'O7O!??9OM%XTH:*6574 )T&X#&<>H[@UZW90644/F6,4"1R@'="H <
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M4 >T:=KVD:O<7-OIVIVEW-;'$R02AS&??'T/Y5RWC[Q:--TN,:1K,$5\M_!
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M>\6.=XU+*-L)^8.2>,GI@]Z /<)?%OAZ"Z6VEUFRCF:#[2J/,!F+;NWC/5<
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M,?R/I0!9:WA>$PM#&T1ZH5!4_A3E14C"1JJ*!A0!P/PK!T/5+&'PW%=OK_\
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MZAJ6C7;:G!:K=07LL#7%IGR;O;C]ZF?7H?=374,JLI5E!!Z@B@ *    .@%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 & .@HHHH **
M** "BBB@ JK96,=D)BK.\L\GFRR/C<[8"YXP. JC@=JM44 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MHH **** "BJ6K:M9Z)IDVHWTC):PXWLD;.1DA1PH)/)':KO6@ HHHH ****
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MSFN&;QAK-YX%N/&NG?96LHC+.EC)&<R6\;E6)?/#E5+#C X&#UKL=#TJ/0]
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M>)MP +8_B! ]#5V7PK<67BE=?T6ZCCFDM%M+NWN59TF5?N/N!R''3/.1Z=:
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MR$%(UDW\C?\ ,QX&<@>WKN?\(]J!\<1>)&O+;"::;$VXA;G+ARV[=ZC&,=*
M.;C\<:V/"-EJ,@LOMJ:V-*N\1-LD'G^670;LJ<<\YYK:O?%5SI?C/4["[\E]
M,M-$.J92,B0$.RE<YP1A<]!UJA_PKZ]/A.\TDZK!]J?5#JEM<+;D+')YOF;6
M7<<C/'4=:N)X.U"[\33ZOJ^I6MQ'=Z4=-N;6*U**5+,QV$N2!SWW9R>G  !!
M9^(/$T]WH=U%8FYL;\K]LB%JT?V567*NLA;Y@.AXYZ@#I5KXHW-[9_#?6[BP
MNOLTJ0'<X3)*G@@'/!(/7M^HC\->%/$6BK;:==^)5O-%LR/L\8MMD[*OW$>3
M.-JX'09.,=.*V_%6A#Q-X6U'13.8/MD)C$H7=L/4''?D4 9<FM7\>NZ7X8BN
M+<WT]I)>3W/D$!(E(4!4W'YB6ZDX&T\<U)X9\0WE[KFN:!JBQ&^TF2,^?"I5
M)XI%W(VTDX;@@C.,]*@N?">I3:AH^N+J5N-<T^-X9'%N5@N(FZQE=Q9<$ @Y
M/.>,<#5T70?[.U'4]5N94EU'4GC,S1KM151=J(H))P!DY/4D].@ -JBBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBL'Q3KDNBVMBEO'ONK^\2SA^7=M+!F)QD9PJM@9'.* -Z
MBO/[W6O&&EZ=XFGDMU^RV5@]Y8WMW"FYF126B=$<9Z<-@>X-1/K_ (IM[KPG
M*;VPEBUU/*>%K8@0N8?,#A@V6Y!R. >G'6@#T6BO.9/$_B'3[+QQ:RW=G<WF
M@0)<P7+6Q59$>(R;60-U&TC.>_2DD\2>*=(G\+ZGJ-Q8W6E:U-!:2VT-N4>W
M>5<HX?/S<]> /0=Z .TTS7]/U>^U"SLY)&FT^18KA7B9-K$9 ^8#/'.1Q6G7
MF4>O1^%]6^)FM2QF5;2:V<1@XWM]G0*,]LD@9K7U37-9\,W'A^ZO[F&]L]3N
MXK*ZC6$)Y$D@^1HR.=H(P0V3R.: .VHKA[/Q/?Z?JOB?3==N4:;3X1=V1AA"
MF:W8$ @<[G#C:>V<<<UUFF)?KI-LNHRQO?\ E SM&F$WXYP/0&@!NKZQ9:'I
M=QJ5_(Z6MLI:5DC:0J ,]%!-6;:XCN[2&YB),<R+(A(QP1D5Y-$VHS_#GXCR
MWVHM=;+C4H/GC )**%!R.@VJ!CM6[IFK:YI>L^#[&YNK6;3]8M'C$"0%6MVC
MA#J0^<MD @Y ^E 'H-,ED6&)I&#E5&2$0L?P R37GQ\3^*-6T=-<\/V,ERIN
MF6.R,<8CF@60H?WA<,'P"V>@Z8/4^B#D4 <]9^-]"U"U^U64M[<V^2/-ATZX
M=<@X(R(^QK:L[N#4+*"\M9!);W$:RQ. 1N5AD'!YZ&O+?AY?:]9_#2YDTK2[
M>Z,=Q>-$6NBKEO,;^#8<_3//M75>--3U3PMIUIJ^G&+^R+.5!J%L(@76#."T
M9SU'IZ>F* .OHKCY_$E_IG@W^V[AXKF:^FB6RB11M19I L08@X8@,"Q! ."
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MK6\SVEPT05XI8@"RL%P&7:01T/;GK0!T6F:I;ZM!+-;"8)%,\#>;$T9W(<'
M8#(SWJ[7E]SXT\11?#75]<6:R^WV.IR6G_'N=C()Q$,#=P><Y.ZMZ'5->M?'
MJZ%?7MK-!?:=+=0-%;;#;2(ZKCECO&&[]QVH [$$'H0:S1K^GGQ)_8'F2?VC
M]F-UL,3!?+#!<AB,'EAT)[US7PKDO[GP<MU?7[73RW5UDN@!W"XDR21USZ=J
MKZQ'>S?&*SCL+B*WF;0)AYTD?F;!YZ<A<C)^IQWYQ@@'6>()M,L])EO=6M!<
MVT&"5^S>>PR0O"@$GKVK2CC2*)8XD5$4855& !Z8KS.Y\:>((/A9JNL+-9_V
MKI=[)9RR& [)=DPCW!=WRD@@]QD=*W=5U;71\0K30;*ZM(;2ZTZ6X#O;EWC9
M71<_>PWWN!QUYSC! .QHKRUO$_B[_A#O$.IC4+ 7'AZ[N('/V0G[8(B#R-WR
M94XXSSW%>EV=Q]KL;>Y"[?.B63;GID9Q0 XVT!N5N3#&9U78)2HW!?3/7%2U
MYU'XLUFUU3P_'>7-O++J%^]G>VL$>^&W.'*A)@.7&T;@2>IX%6!XNGE\6W&B
MSZBFF:A'?(EO974(5+NUW+EXW/WG(W8P>#QM[T =XRAE*L 01@@]ZQAXITAI
M98X)9[D0L4DDM;26:-&'52Z*5R.XSQWK/^)6HW>E?#C7;RQ9DN4MB$=>J[B%
M+#W )/X5?\'6=M8>"]%MK15$"646W;_%E02?J22?QH 8WC+0O+TV6.\,T6I7
M)M;62*)F220,5(W 8'*MU/..,UN.XCC9VSA02<#)_*N \>V2V"^%(M/CCC9_
M$T4JAL[0[K,S$@?[1)_&KND:QKO]N>)]#O+RUN+C3X8;BUN?LQ08D5CM9 W(
M!3USS0!U.EZE!J^F6^H6HE$$Z;T$L91L>ZGD5:9E12S,%51DDG  KSW2?&FI
M:CX=\)AE+:EK<$LTLD$:DHD8RVQ6(&<LH&<X&3@TM_<^)[CP/XMAU:,VWV:W
MG-I=F- US#Y3'#*K$*PZ$\=B!0!T]CXLTK4=4AT^"2837$!N;9G@94N(AC+(
MQ&".1^!!Z4D_B[1K;5Y-)>:Y:_CC\UH([*:1@F<;OE0Y7/&>E1>!XIX_!6B^
M?<";-C 4Q&%V+Y:_+[_6N9N)+V+X\3&QMH;B0^'$!668Q #[0><A6_+% '<:
M=K-EJKSQVKR^9;E1*DT$D3+D9'#J#S5^N?@_MR^TO49?)M],U?S&CA+#SDVK
MRF3@%E.XGMC)K'\#^)-6\3DFZ>.V?30UKJ=N44LUV"<[<'Y4 Y!YSD>AR =Q
M17G9\3^*-6T>/7/#]C)<J;EA'8F.,1S0+(4/[PN&#X!;/0=,'J=1M6UG7KGQ
M##H=S#:OI,GV:!98PPGG$8<[R>B?,%XP>"<]J .PI"0 22 !U)KD;?6]97QU
MI^BWI@1+G1FNYHXUW>5.KHI"MW7YCU%<GX@U_6]3^'6LS/?K#+::\=/+0Q >
M;$MPD>#SQD'G'7ITH ]-GU*ULM2L=.9)1->^9Y6R%B@V#<VY@,+U[]:O5R6H
MZMJ^F>-?"^D-=036FHK=>>?(VN6CCW#!S@#D<8[=>:JV7B74;/5_%&EZQ.KS
MV$:7%CY404S0."%(!SEMXV>F<<<T =O17&SZSJXU:#P\)9&OXM/6[N[FU@1C
MN9BH"JYP%RK9SDXQ]:U_"EWKEYH:-XAL5M-121XV"$;9%!^5P 3C(QQG@YH
MMZAK>GZ9<16]Q,QN9@6CMX8VEE8#J0B M@>N,4:=K>GZK)-%:SDSP8\Z"6-H
MI8\]"R. P!['&#7$_#^5[_QWX\O;OYKN*_2T3=U2! =@'H#U]SS2^,GDL/BO
MX%NK/*W%V;FTN O_ "TA"JV#ZA22WUH ZK6?%6EZ$)S>/,PMD66Y,$+2>0C$
M@,^T' X/X GI5;4O'6A:4AEGFG>W$H@:>"W>2-9"H8(2H/S'(_$@=:P/#-MJ
M+?$?QLIU($JUHK$P#YLP';WXQG\:H^$I=6L/"/C#4(+Z%YK?4M1D19K?<ID1
MR=QPP/..F>,^U 'I-C>1:A86][ '$5Q&LJ"1"C889&0>0>>AJQ7$Z?XHOM2@
M\)Z>LJ17VKZ8+^YN @.Q0B$[%/&XLXQG( !X-.NM;\0:):06>IK;SWU[JAL[
M*>!<EX-I<2,A(&_:K# .,X[<4 =I17 7>M>+],TKQ1/-;J+>PLFN]/O;N%-S
ME4+-&Z(_7CAN![&MWPI)KUW91:CJU]:307=I!+#!# 4,3%<MEL_-G([#OTH
MZ*BN)\6:[J^ERZLT5Y#:QVMA]ILHXXO/DN) &+F1<$K&,*,\=3\W:J]SXHUV
MYOO!*V,EE!%KUL\LRR0LYC80>9D'<,@$]."<=>: .^K,N=?T^TUVQT6:21;Z
M^5V@3RFVL$7<WS8V\#MG/(KC%\<:GHND>)TU-H+Z^TJ_CL[:18_*68S!#'N
M)Q@OSCL*=JMMJ%O\4_!'VW4%NU:.^Q^Y"%7\I=V,?PGC .2,=30!Z)1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 5A>+?#,?BG1ULS=RV=S!.ES:W
M<0RT$R?=8#OU(QZ&MVL[6M<T_P /:9+J.IRR0VD0S)(L+R;1TR0@) YH PG\
M+:W?^'=3L-8\1)=W=[:/9B9;,1QQ1N,,1&&Y8^I/88 YR3>#[V8>%_\ B:P
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MII=E+>WUQ';VT0W22R-A5'UK(G\8Z5:V9O+M;ZUM,9$\]E*BGTZKQGMG&<T
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M&^\T;M_JRW?@\_AC2M_#$UIXMGUV"^C426*6*6[6Y(1$)93NWY)R3GU'IUH
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MWL<BF+RK82B3 .(V!X52<9;L!70C..>M !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MGGBMH))YY4BAC4L\CL%50.I)/05QD7B:2\^*-GIEEJBS:=)ILL\ELJ*-L@9
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M>W\$#*H9][8V \ L>V2#C/7M6A0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %8'C;0/^$F\&ZII(_UTT),!_NRK\R'_ +Z
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M%VR;U &% !'/!X R2*C\.75SI6J>'X-/U"WUSPY?7$GV-' ^UZ<Q1R<D'YE
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M4@.-T2[5/H2>QYS6M\6@?^%8ZN<$A3 [8'0":,D_@ 37816T$./*@CCQG&U
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M..4N( #(R?:"9$SUYC7&.XQ6_8WGAOQ5>V^J:!JEUJ.MQ64RP,9,&U#H1^]
M  ^;: #SGD=":]'5$0810OT&*;%!##N\J)(]YW-M4#<?4T >2^%;WPQKVB^&
M]-O;R^?6],FAQI9<K+!<1?*S%0 =@^8DDXQUYXI()M.;PI\6&\RV+-=WO.Y<
MG_1UV_\ CV<>^:];6"%9FF6)!*PPSA1N(]S2^3%@CRDY_P!D4 >63W%A"GPK
M:.:W3]XN"K*.&MB&_-L ^]4;.\T"ZL==\+>+K^\BOSJ,[26&X@W8>4R1-$ ,
MMD;0,'/ Z"O8?)BX_=IQT^44C00M,LS1(95&%<J-P'L: //]'?3U^+?B$3/
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MG7]+%ZMI]K7S7E,"_*VUI!G*!L;2PP<C.1@^E>?75Y8)=?"XQW%NH4G[KJ,
MVQ7\BW'UXJ.UNIM*UVU;0]3AU71[W66CGT>X -Q93-(QDDC(YVAMS$$8QSWS
M0!Z1K=Q!:Z+>2W&HKIL?DL/MC,H\DD8##=QD=>:HP^(M&TZRTN"\UVW>6YM@
M\,L[JKW"A-QDQQ@$ DG@4WQQ)%%X#\0&5U13IUPH+'&28V 'U)KA3>6#S_";
MS+BW8+$2=S@[3]EP,^GS8'U]Z /2=(US3->MGN-+O8KJ*.0Q.T9^ZXZ@CJ#R
M*P?$>H:A9^.?"%M;WLB6=]/<1W%N%7;)MA9E.<;NOOC@52\&W-M)\0?'4<,T
M39NK9PJ,#G]PH8_]]#!]Z/&5U;P_$+P*LL\:$75R2&8# ,#*#^)('UH Z#2;
MRUN=9UHP:\+\1O&'M@5*V1"X*@@=\$G)XI?^$N\/B2%'U>UB\\9@:9_+6<9Q
MF-FP''3[I/6N,LGL;_Q)\4+5[K$4T,*NUO\ ,X7[+M8J!R2#D<=^*R_#.N:'
MK=SX*BN/$.D1W&CQ;(HHIF$MP[1"-5*LH"\<D MD\#UH Z'1O&,&E:MXHB\1
MZZHAM=2$%LUQM4JGEHV,*!P"W)QW&36]JGC+3-+\0:7H\DA,U\KR!PI*JBKG
M.0.225&/0Y],\*EWI[V'Q78SVQ:0R@'>N6'V8*/K\V1]:EBU&UMM2^%VH7$Z
MBV_LN>$S?>'F&"(!./XB00!U)&* /57=8T9W8*B@EF8X 'J:SK/Q#I-_>+:6
MU[&\[Q^;&A!4R)_>3(&]?=<BL;XFV>HZA\.=:MM+1Y+IX01&GWG0,I=1ZY4,
M,=\UC:W>V7BS4/!-SX?N(YKF#45NG,1!:"V$;>:'Q]S/RI@XYXH EDUZ7Q/X
MIUS0K#7)M,>RC@6SE@B#;IF#,S,&'S 84;>!U]L=I/>PZ;:PF^N 9&Q&"J$M
M*^,G:@R2>"<#/ /I7'>%[^TE^*GC:..ZA9W%B$4."6VQ-NQZX[^E7O'4%K<G
M24;6WT745N&>POAM*+*$(*N&X(921@]?T(!LCQ-HQCMI/[0B"74_V:%FR \N
M=OE\C[V01CKP:M0ZM87&HW&G17*->6ZAY8>C(IZ$CT..M>5ZEJM[<^#])U'6
M(;6(:;XJ@-U>6H/D31I)AK@>BDGD^H-2:I>#7?%OB^+0KCSKB\\-(EF\6<2M
MF7[C=#G. 1Q0!Z/!XBTB]O$L;?48S<S(S0XX\T+]XQDC#X[XSBN4\'^-+6+3
M9H?$6NQ->MJMS:PM.55F592B9"@ =,= ,TOA?Q-X7\16NA)!;I+JNG1 &!X2
MKZ>0FV0L2,(.-OOQCVXJZNK$_!3Q>8YX#(^L3L-K#<Q-R"I]^!D>PH ]TK)M
M?$VC7MW%:V^H1/+,':'J%F"_>*,1A\=]I.*N75S'_94]U$GVN,0M(J1'=YHQ
MG ]<UX[I^MZ=<WOP[O8;N-+>.>6,V5M$?*LBT# 0YP6+YP#DY/4  T >E7'C
MWPG:@--X@T]5,QM]WG C>,9&1Z;AD]!FK=_XIT'2YVAO=7LX)4A\]D>4;A'D
M#<1Z$D >N>*\ZTNXT3^P_B19W[6QFFU:\4P''F2@HH0*.K'=G&._3FETF%="
M\8>!K;79(8KF#PZ\1:=A\DH,8QD]P,C_ /70!Z19>(='U'1CJ]IJ5M+IP!+7
M(D&Q<=<D],>].L]=TR_FG@M[M#/ H>6)P8W13T8JP!VGUZ5Y'J&GW-M:ZYK>
MF0.^@?\ "3VE^\4*Y$T$6WSG51]Y?,P<CKL)Z5V%V]OK?Q,\-:KHUU#<06=G
M=&_N('#)Y3JOEJS#CELL!_LDT :VG>(=&T_1;K4;KQ1#>V?VR0"ZE= J$MQ$
MI7[VWH,9-:-KXGT.]OKJRM=3MYKFT0R31HV2JC@M[@'CC/->17MY9/\ !KQD
MBW$#;]=G*J'!W W2L,#OD#/T%=I>W=B/C#X>$%Q;X;2;B,;'&""T94<>H!('
MM0!J:5\0_#^H:%/K$]['96D4TD>ZX)3(5V4'GNVW..M:/_"7^'A>7-H=8M!/
M;(9)4,F-J@X)]^>.._%>37-_:+\!O$>F/,JWL%U<I+ W#(QNBRJ?<CD#T^E=
MCK=UIK_%+P.8IK5E%K>A2K*0,K'LQ]<''XXH ["P\0:1J>ER:G9ZA!+91EA)
M-NPJ%?O!L_=Q[U%%XHT247?_ !,H(S9H'N!.3$8E/1B&P0I['H:\LNKAY--\
M;2Z=NNEMO$D%[/;VKY>2!/*+E<?[IY_V36_%J'@_64U'7M(NI[VYCTF:":]E
MFEV0QD9$;;^-Q8Y Z\'VR =A:^,/#U[?6ME;:O:RW-W'YD$:OS(NW=Q[XYQU
MQS4&E>,M,U;7M5TN!R&T]E1G92 S;2S8R.@&.>_/:O/$N["'P%\+=L]NC1ZE
M9E\. 5_=2!R?3YB,^YYKIO#FHVEA\0?'%O=3".5YX+E4*DDQ"W7+_P"Z,$9]
M>.I% '::9J=EK.G0ZAIUS'<VDP)CEC.5;!(/Z@BK=9?AW5](US1(+_0Y8Y-/
M?(C,<90#!P1M(!'/M6I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 48%
M%% !BD(!!! (/4&EHH 0      = *6BB@!NQ-Q;:N3C)QZ=*5E5L;E!P<C(Z
M&EHH 1E5QAE!'H10 !T&*6B@ HHHH Y0Z#XCM-7U"XT_6-/EM+Z;SFCU"R:5
MX3M"[599%RN , CCUK=TG3(]*LS"K!Y))&EE<($#.QR2%' 'M[=2>:O44 (R
MJXPRAAZ$9H(# @@$'J#2T4 (      .@I<444 %(JJB[54 >@%+10 8HQS11
M0 8S2%%8@LH)!R,CI2T4 %%%% ";5W%MHW$8SCFEQ110 4BJJ#"J ,YX%+10
M @55)(4 GDX'6EQ110 8&<XY%<WXE\/WNLZGH=S;36\4>F7?VHK("3(=K+MX
MZ<,>>?I7244 9?B#3)=5\-:AI5JT4+7=M);AW!VH'4J3@=<9Z4[0-.ETK0K&
MPG,3S6UO' TD8(#[%"@\_3I6E10 4FQ=^_:-V,9QS2T4 <U9^';R#QSJ>O32
MVSV][;Q0"$*=R>66(;)X).X\=JZ6BB@ I,#G@<]:6B@ QS2;5W;MHW8QG'.*
M6B@ I JKG:H&3DX'6EHH ,4R7S/*;R0ADQ\N\X&??%/HH YWP3X=G\+>%[32
M+F:"XDMMZK/&I7<&<MR#T^]CK71444 )L7?OVC=C&<<U@'1=5NO$376H:K'-
MI,4BS6MBEN%*N%P"[Y^8 Y8#'7![5T%% !1BBB@!" 000,'M0%"J%   Z "E
MHH ,48HHH ,4FU2P;:-PX!QS2T4 %&*** #%)L7=NVC=C&<<TM% !1BBB@ H
MHHH SM=TQ]9T*]TV*\ELWN8C&+B( LF?8]?0CT-8\.@ZY>QI;:[?:3/:(5)%
MI8-&\FT@C)9V"C@9P,^A%=310 8HP/2BB@ I%15)*J 2<G ZTM% !2,H8$,
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MBBB@ HJ.::.W@>:9PD:#<S'L*K:3JUCKFF0ZEILXGLYP3'*%(# $@\$ ]0:
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MT(;./PKK_%?B36=%_M>:+[#;06=G]HLUF0S/>N%9G&U7#(JX )Q_%G.!5!_
M.JO\/;KPN;ZS#SWAN?M.QL*#.)L;?J,=>E6M1\&ZS>:GXBFBU2TCMM=LEMY5
MD@:22 K&4VQMD#:=Q/(ZD\4 )?\ CL6\^AI<7-MI$&J6 N8[N[B:2(RD*1%N
M#*%P"3DGGVKL--DNI=+M)+T1"[:%&G$)R@<J-VWKQG.*YB'PSJ\>BVNE7KZ5
MJEDNGQVDUM<1,B%DR Z_>[8R.Y&05K<\-:*/#OAK3]'6X>X%G"L7FN,%L>W8
M>@["@#E-1\9:SI=[9?:TL4-QK"6+V"J7DC@=]B2M(K$*QX;! R#CJ,UI7?B/
M4KCQ!K^E:<;6W;2+.*<-<QE_/>0.PZ,,( N">3D]L<XO_"O=>&C1:8NMV+1V
MNKKJ=O*]JQDE(E,G[T[^3R1QC.!R*I:N9]7\9:L;35_#IDLXH[*:WU>!@WW=
M[X"NI,;;QUR"01T&2 7AXW\13:%X2U&*UTY6UZZ2$QNLG[M71F!Z_P"R>>XZ
M5HCQ!KD=\-"NYK-=5AM?M-S<6EA-/%AW=8PJ Y'"$DD^PZY%<:=K7BJRT&Z=
M]*A;2-1^T![;>8+I44J/+[JN&(SSRO&15_Q!X7UB7Q+;^)/#>IV]GJ M_LES
M#=Q&2&>(,67.T@@@D\CU[=P"G:>,]7DM-(L]1TUM/UF]\\RJ;:2552+ +K&O
MS$-N3 )XR<YQ@M'C36;#2K@:II@6_?4HM.TZ5HGABNS*<(Y5B67')89_AXZU
M8UKP?K%]'I6I6FN+%XCTZ221;F2',,HD #QF//"8"@<DC&>2<TNK^#M4\1>'
M!#JFL1KK4=S%>6UQ;0E8;:6,Y0*A))'+9).3GV H H^7J,?QGTM;^XMIQ_8M
MP8WAA,9_UD>006;\#GO[9-[XEW6I6FA:>=.O$MO-U.UAEW1%BZM*HQG<,#U'
M<<9%/M?#GB";QAIOB#4[_30]M9R6LD-M;OAPS*206;C[OX=,'K6EXP\/S^(]
M$2TM;F.WN8;J&ZA>5"R;HW# , 0<'&.* *W]MZC>>)IO#MG<6B7-E9I<7=TU
MNS*6<D(JIOXX4DDL>P[Y$O@_Q'/X@M=0BOH(X=1TR\DLKI8L[&9<$.F>=K @
MX/(JM)X9U*V\4Q^)+"[M7O9K06M_!*C)%. <JZD9*%>G.[(]^:T_#N@KH<%Z
MSRB:[O[M[RZD5=JEVQPHYPH  '/;/>@# \6^*-9T)-:N(_L-O#8VPGLXYE,L
ME[A2TG"N"BCA<D=>2<5?3Q'=:MK%MI.FF&VE;34U">69#+L5SA$505R<AB3G
M@ <<\9NJ^"-7O;SQ2+?5K5+/7K<1MYUNSRPD1E JMN V<YZ<9..N:9+X+U^T
MO=)UG2-7LH]8M;%=/NEGMV-O<1 Y7Y0VX%3WSS[=* +R>(M<ACT+2]1L[2TU
M[4Y9D;#&2%$B!9I  <G(VX7/&[D\47?B+7-"LKD:Q:VS2R:A%9Z=/ K%9UDQ
MAFC!9@5^;(!^;'&,YIFN>#M3U*UTJ]M]96/Q%IL[7$5V\/[IRXVO&4SPA7 P
M"3@=2<FG:IX1U3Q#X<EM]6UA(]7,T5Q;W-G"5BM9(SE"B,Q)Y)R2<G/; H K
MMXD\2VLNM))8QSVUMI[7EK?26<MLA=?O0NK$DGN",<5F_P#":^*;'3/#/B#4
M;;2WT;5?LT5Q% KB:!IE&) Q.",G[N,@$#)ZUKW-CXBA\)ZU/XCU.TN94TV>
M...RA:*/&PDNVXG+' ] .?6J'AK0KW7_  )X0M]0DMAIUK;VEW^ZW%Y]B!HT
M8'A0#@DY.[;VS0!;\$W.L77B7Q9]NOX)XK?4O)""W*D 1(5"G>0 ,],$DY.>
M:O>+/%2^'-0TJWN+B&PL[WS%?4+B%GBC==NQ&P0%W98Y)Q\I]<B;1/#M]H_B
M76[U;V!]/U*X%UY/E'S5DV*A&[.-ORYZ9_K;UFPO[VYA\E;*YL##)%=6-X#L
MFW%=IR <8PW4'.[M0!C3>(]9LM3\*6TYTZ5-6FEAG:%&(PJ.ZO&V\C! 7@YZ
M]:KW'CJZTJ;QA]OAMYH]$DMDMA"IC,K3*"JL26_B91D=LG%1K\/[O3M#\/6^
MD7T"WNBWDES%]H1C"PDW[H\ Y  ? Y/2B;X>76IGQ7'JVJ0R0Z\L&?(@*-#)
M$BA6!+= PR!R< <]: .AM'\2PZ]%!>1V5SIDEN6>X@4Q-#,"/EVEV+*1WXQC
MFO.?!NN:WX?^''A"[C%@VE37:64L+(YF(DF9=X?( P3]W:>._8=YH>F^*[>-
M3KFKV-X]LA6 6\#1>:V,;Y22<G&>% '.>>,8</@'5(? >B^&Q?69?3;R.Y^T
M%6Q($D\P#;VR3C.>WOP =GKFK0Z#H-_JUPK-%9P/,RKU;:,X'N>E<Y;:]XC_
M +<TR(V0N[&\1A<.EC-!]C?;E3N<X=2>#P#W]JZ75M+@UO1+S2[T'R;N!H9=
MAY 88.#ZCM7/>&]"\5Z:MO::OKUK>V%D,0&*W:.:? POFMN(P..@R2!D]00#
MGY_&WBI?"&M>(%32 -'OYX)8#%(?/2-PIP=WR'&3GYLGL.^Z?$&O6?C'2--O
M1I[VFLP3O;K$CA[=XU5L,Y8AP0W4*M4F\"ZI)X*\0>'VO;/?J]W-<"<*V(A*
MVXC;WQT'(Z^W.K=^'=2N_$GAO5FFM$72(YDDC&XF7S$"$@]L;<]_ZT <L?&O
MC.3P?>>)H;31FM]-N)UN;;;)OFCBD*L4;=A2%&><YP>G0ZUW>17_ ,3?!U]#
MGRKC2KN5,]=K"(C/YUD>#M*U'7O >K:0L]M%I][J-[%+,,^:D9F8.H7H21G#
M9&,]#CGK+CPQ<'Q?HFJVKV\=EI=K):K;D-N97"C(/08"CCO[4 9#^,M8NO!$
M_C/3H[.33HC),MD\;>9+;QN59O,W85B%+ ;2!TYZU>?Q5?)XJT",FT_X1_6[
M8O:S&%A*)MH=8V;?M&Y<D<=B/>JMIX&O[#PWJ'A.VOH!H-TTJQNRGS[>&0DO
M$!]UNK88D8ST.*/&D6BWNBQ>$[._A@UF)[<Z=!#(#/;NK#9(%ZX5023_ '0:
M &ZWXMU[3])?5+1-.EMI-7CLK</&ZLT1D$98G<03NW8.,8 .#G%2C6O%0\:7
M'AII-(+RV O[>Z$$@$"^9L963?\ O#DC!RG<^U7O$?A.74O#>G:-IDL-O%93
MV\JM,"WRPL"%X]<<FI#H.HGQZOB3S+7RAIIL/L^6SRXDW;L>HQC'3GVH Q]/
M\>7DOARU>\@A&K3:K+I1,,3O'OC+[I @)8C:A.W/7 R.M,OO%GB?3=*\2SO8
M12)IUK]JL[V:TE@CF !+(R,V=P/<'!'I3?\ A7>H/X=FL_[5BM]1CU=]7L;R
M",D12LQ.UE/WE^8CKSGIQSHWGASQ+K/A;5-/UC5;%[V^MFM4^S0ND$*L,%L$
MDLQ]\ 8XQSD BMO$FOP^)?#=KJ"Z>UGKL$I1((W$D#I$).6+88$9_A&/?J4\
M 7.L7>I>*7U"_AN(X=9E@"K;E"-L<0&T[R H'\."<\YJU-X8U.;5O"EZ9[0?
MV&DBR)\Q\[?%Y9Q_=P.>_/'O5KP]X=O=#UK6YOML$FGZC>->K$(B)%D95!!;
M.-HV\<9YZT .U+79SXLM/#6GM#'=2VCWLTTR%Q'$K!  H(RQ8^O 4]:YC5/'
MVLZ;H/BQ#;V)UKPZT9=BC^3/%(,HX7=D'&<C)P1UYKI-:\-W-QXGT[Q+I5Q%
M%J%I$]M+'.#Y=Q QSL)'*D-R#@^X-9>K^!+G5-#\21?:K=-3\0-&+B;:?+A1
M %15'5L 'DXR6)XZ4 68=>URT\;Z9I.IK8/::K:S30"W1P\#Q[259B<."&Z@
M+SVIGQ2N]1LO ]Q-IUVMNQG@BD)CW%D>54(!R,?>Y]N..M6[KP_J5WXLT#6F
MFM$33()HI(AN)D\T*"0<<8VC YS5KQCX?D\3^%[K2H;E;>:1HY(Y73<H9)%<
M9&1P2N/QH YK7$U0?$[PTD,UHU^=-O09FB98E^:/G9N)./3<,^HJ2Q\=7R:!
M<'4(K=M4AUMM%5H(G,<C@C$@0$MC:2=H.21C(SQJ2>'M7G\7:1KMQ=6;FRM9
M8)(T1DWF0@DKR< ;0 #G/K62_P /+RYT;6+274H[>ZNM8;6+*ZMU)-M-D;00
M?O 8QGC.3P* -G0M7URX\17FGW]FTE@L"S6^H+:26X+9PT3*Y)W#J".,50\:
M7.KQ^+/"%M87T,$%S>2AXW@+AF6%R"V&7(]N.><G&*VM L?$,3&?Q%J5I<SJ
MGEQQV4+1Q@9!+-N)+,<#T YQUJ'Q/X>O-8OM$O\ 3[N"WNM+NFF7SXC(CJR%
M&! (.<'(YH R-0\6:S<1:PVA0I--IL[6Z0-832BZD0 N-ZD+'DDJ,YQC)X.*
M;=^)?%%SXGL]&TVUT^T>\T8WZB^5RT$@9 5?:1G!8CCUSVP7CPEXCTGQ!?W?
MA[7+2&PU.43W4%W:F0Q3$ -)%AARV <'C-:(\-7T?C>QUQ+J)[:UTXZ>4E+&
M60%E8N6Z9RHXQSS0!EVVN>+K_7?$.C1-HT%QID%M(DQAD=6:1&8@KN!ZC&<C
M '0YXHV_CGQ!-X>\,^)'ATY-/U.YM[6>T5',@\QMA=7W8&&_AVGC^*NBLO#^
MI67BGQ#K*S6CKJL<*1Q'<#%Y2LH)/?.XD],5C1^ ]4B\"Z%X=6]LR^E7<-QY
MY5L2"-]X&WMGH>3T]^ "U<^,+EO%5_H45W8V5_!+&+:TO8F!O(BJEG1]P!/+
M@  X*\]>.OOI;B#3[F:TM_M-S'$S10;POF. 2%R>!DX&:Y/Q%X0OO$]K=:?J
M+V+VTLZS6USAO/L@-I(0XY.0<'*XSR#C%='K^F/K7A_4-,CN7M7N[=X5G3K&
M6!&: .6TOQ;J<GBK3-'NI;"Y-]8RS.;:-E%O/'MW)OW,KCYL<<@CWK(G\<^*
MHO">L>(/+TD1:/J,UO-#Y<A,Z1R!#M.[Y#C)R=V3V'?7LO!^O1:QX=U*XU+3
M=VDVLEJT,%JRHR,$'RY;@G9UZ#L/6"7P%JDW@CQ!X>:]LP^K7LUSYX5L1"1]
MY7;WQC .1U]N0#<DUR[U'Q5=:%I4D$)L;:.>ZGFB,F&DSL15#+V4DG/H.^1E
M_"GSO^$5O/M&SSO[6O/,\O.W=YS9QGMFIY?"^LVOBS_A(](O;**>[MDMM1MK
MB-GCDV?=D0@@AATP>,5>\&>';WPUIMW:WE[!=&>\FNE,4)3;YCEB#ECGK[8]
M^M '24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 445A^)M<DT:'3XK=8S=
MZC>QV4!D!*(S9)9@,$@*K'&1DX&1G- &Y17&:QX@UOPAINO:EJ\=O>:=:11O
M8S)^[DDD8[?+=>0!N*_,.Q[T[4]<UCPUK&A)J4UM=V6JW(L9#'"8V@G8$H5^
M8Y0D$$'D<'/:@#L:0D $GH*\QG\6>+3X?\5ZI%<:4G]@7\\03[*Y^T1QJC;?
MO_)P3S\V2>V.>D'B.YU?Q';Z+ISI;$:<FH7,SIO90YPB*.F>I).> !CG( +\
M7B[1I]'U'58KB1[/3I7BN6$#[D=,;AMQN.,]A6S%*DT22H3M=0RY&"01GH:\
MHT;5-6T#P!XZU2"2T;4;/6KV5F>)C&Y&W.%W C/;DX]ZV;^[UBY^(WA>*/44
MCMY]-GN#"8-RAP(\D_,,DAB!Z>G)H [2UU6TO=1OK"!W-Q8E%G#1LH!==RX)
M&&X],XJ[7"/XWN]*N/&\FJK!+;: L+0+ A0R!X]X!R3SD@9Z=\5)J7B'6O#H
MT"_U&2UN;+4KF*TNHXHBAMWE'R,AR<J#P0>3U&.E ';T5YO/XE\636_C&2WN
M=+B_L"5C&6M7;SE6(2;2-_RYSRV3]!5O4?'8MCH,EY<II%CJE@MPM[+"9(A.
MP4B)FR HP2><9]1B@#O:*J:7)<RZ39R7CPO=/ C3- <QERHR5]LYQ[5R&B^,
M+C5_$#:<U];VNH07DL=UI-Q"4D$"E@CQL3\^0$8D9&">!0!W5'>O/9O%OB+4
M=*;6?#]BUTJW31Q6)MCB>))3&Q\TL &(4L.,#I@]:L:%-JL_Q4\3QS:@K6MO
M;V6V!H/NHPE(4'=P02<GG/MQ0!VMS<P6=K+<W,J0P0H7DD<X55 R23Z5G:=X
MDTW5-2N-.MY)EO+>-97AG@>)MC=' 8#([9%<Y\7A<_\ "L]7:"=8T$:B12FX
MNI=1@'(Q^M79]7OT\3V'AF.YMS?S6DEY<78M\;(58*JJI8_,6;J20 #QSP =
M91TKS75/'&N:;HOC"W(LCJ_AT1R"8PL8KB&1=R-MW?*V,@\D9'O3/&$WBR'1
M+2:YU6QBANM5L5CCMK9MRHSKE&8M\P!QR,;O8'% '=QZ]ITOB"30DG8ZC';_
M &EHC&P CW!=VXC!Y..#ZUI5YU=0ZJ_Q?$-I=VL=X?#8#W,D!95_T@\B,,,G
MV+<>_2NB\#:[=^(?"\5YJ"Q"\2::WF,((1FCD9-P!Z9QG% &M_:MI_;9T?>_
MVT6_VK;Y;;?+W;<[L;<Y[9S5VN6_MO5#\2)_#^^U%G_9'VV%O*;<KF79AOF^
M8<9XQUKE(?&OBK_A";3Q5/)IGDIJ'V>YM4MWS*AN3#E6+_(1Q@8;IDGG  /5
M*S=8U[3M MXI]1G,4<LJPH1&SY=C@#Y0<<GO5N\69K*86\PAF*'9(4WA3CKC
M(S7CCSZC=_ S1[V\NDNIKB]M)5W(5.XW0)W-DYR3UP/I0![55+2M5M-9LOM=
MD[M#YCQY>-D.Y6*GA@#U!KG=/UC7(O'=WX=U&XLIUDTT7]M+#;M'Y1\SRRC
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)(^D/-)(9H"6N'E4JQR& 0#)P,'' [5UE% '%3>!;B[B\7PW.I1>7XA4?ZN
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\ER2=VIQ$G;/DDECV(R<&J/A2RTZ_P#&OCO[5<SH1J* "&^D@X\L9R$<9^M
M'H6CM?M8YU&:WGF\QMDULFU)(\_*0-S8XQGGK7.Z3XU.H?$'4O#\L'EVR0>9
M83G_ )>#&Y2;'T?C'^R33_[7LM&\("QTB[2>6T,6DVDKL"LEP0J*,Y^;!(+?
M1O0URWC+1=4\*Z)HGB)+NSG_ .$9D1BL-JT<DL#824%C(P)(.3QUR: .N\5>
M)9-)UG0M(BN8+)M6EE7[9<+N6/8H.T#(&]B0!DXZ\'I5[2VUV+6KNTU*6VN+
M)8(WMKB*$QLS%F#*XR1D87ICKTK-\12^%?$T.F:+K"VUS::Q"\]G([[=S+LQ
ML;J&(DR,'H#6'X0CU'PIXTU'PP^LRZGH%OIXO(YKI@TEB=^!$[^A4%AGL. .
MX!Z36!#XKTS4=>U'0;'4+8:A:(F2S!AYC;\J%R"Q4)D@'C(K4TW4['6;"*_T
MV[BNK27.R6)MRM@X//U%<=H5S;6_Q9\8PS311RS16!B1F 9\1R9VCOCOB@"W
MX#\6KK/A/1I]7U&S&KWZ2.(=ZHTF)&'RIG)  [>E;T<DQ\2S)_:UL\ M5QIP
M1?-1MQS(6SG!! QC%>/Z=;6</P9\'WR10K<#6;9_/"C=G[21][KTX^E=;=)9
M1?%3Q#YI\F%_#2O<-",/CS)-S<?Q8Q^E '=6NKZ9?7#06FHVEQ,JEC'%,KL
M#@G .<9('XU<KSGPM-JND>)M)T;5#9:K;2:=*-+U>U&U_(7RR5E7ISB/##@X
M'J:ZWQ/J4FGZ08[:5([^]D6TLRW:5S@-COM&6(]%- &/H'C4ZMXXU?0I8/*A
MBC$VGRG_ )>(U8QRM]!(I ]1S74SWUG:RQ17%U!#)+GRTDD"E\ DX!ZX )/L
M*\P\8Z7J'A"T\/\ B@7-G)!X=D2"2.WM6B=K63$;@DR-N['IUR:UO%2:?J'C
M[P!/MM[B*>6[*O@,)$^SL1SW&<&@#K?^$DT(6 O_ .VM.^QE_+^T?:D\O?\
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M2"3C/0U/-K^C6X)GU>PB E\@[[E%Q)@'9R?O8(XZ\UR/B*6QN?B+X"N[9X)
M\UZ@EC(.X"!A@$=1G]:YHZ;IK>$?BJ_V2V+17=X$.P?)B!",>GS<_6@#UVZO
MK2QC62[NH;=&.T-+($!/7'/THM;VTO8_,M+F&X3 .Z*0.,'H<BO-[K4[?2]>
M\$ZK=:A;$'2)$:"XN$B.&6,F5&<A2V< C()!)'0UO_#S2;73='OIK>XL)WO;
M^>Y8V;K(D0=BRQ;QUV@_F3B@#I]1OH=,TVYOK@D0V\32O@9. ,X'J:P/ GB>
M?Q/H,LU_;BUU.TN9;6]MA_RRD5NG_?)7GZTOB-IM5U:PT"RN((Y@1?W/FH9%
M$<;#8I4,I^:3:>O1&KFHFN?!WQ:C;4;JU:T\4P["88C"BW4( 7@NWWE.,YY)
M% 'H-WJNG6$BQWE_:V[L,JLTRH2,X[GUXI)-5TZ$1F6_M4$F[R]TRC?M!)QS
MS@ D_2O-M6O+.U\4^.--FU#397U6T@B5+N[CA,#&$KL8.<E,$/E0?O$8S27^
MA:7I][\,]//V.[2.1X6G15VS[;<\\=06 /?.: /1I-=TB&PBOY-5L4LY1F.X
M:X01O]&S@U/+J%E!9"]EO+>.U(!$[RJ$(/0[LXYKSR\NM-\/?$AM.O;Y-"TV
M;2XUTYD2&.#B1S*@+H54DLA(&,X&<\5F%](\*WOA*.VU:[M_#&;R.#4)#&R+
M.Q4J=S*5"$>8%; X)P<'- 'J0UC3&T]=0&HVALG.%N!.OEGG'#9QUIHUS2"]
MV@U2R+68S<@7"9@'^WS\OXUY9XLTWP_;_#OQ#<:3>M?Q3ZI;7$ERSHT?G-/$
M'\LH !QUQ].H..@OM,TU/C'HL2V=LJG1Y_D$:@';(FWCVYQ0!W-OJ%E=V(OK
M:\MYK,J6%Q'*K1D#J=P.,<5%;ZUI5W;37%MJ=G-! <2RQSJRQG_:(.!^->0O
M=?V9X7UR6-GBTRS\:N;S[.@;R;<,I)"D$8#%3C&*W-6M?#5_8>*=8L-9.KW4
M^@S+<.LD3PJJJ3&7"* 'ZXSS@'TH ]"@UG2[F[6T@U*SEN7C$RPI.K.4(R&"
M@YVD$<]*I:-XLT?7M0U"ST^]@FDLIO)8+("7(52Q4=2 6QGID&N"2UL[.+X5
M3V\,,4LC(#(B@,P:U.[)[Y.,UN^!+FVC\1^,K1I8UNFUIW6$L-Y3RH_FQUQ[
MT =1JDDR7VF+%JUM9*UQ^\AE16:Z7:?D3)&#G!R,]*?<Z[H]D)3=:K8P"%E2
M4RW"+L9N@;)X)P< ^E<KXZ2$>*O \I5!-_:Q0.0-VWRGXSZ9Q61;:;ILWB?X
MFB2TMG"10CYD4[0UKEL>F2.?I0!Z@K!E#*05(R"#P12US7P\D,OPY\.,S;C_
M &= ,YST0"NEH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHK*\23_9]!N6&M0:*Y "7TZHRQ'/HY
M /&1^- &K16!>>+](T_Q)9Z#<7L*WEQ$TIWR!0@& ,Y[L3P/8UH'6]*6]%D=
M1M1=%_+$)E7<7Z[0,]<=NM %^BD=UC1G=@JJ,EB< #UK/MO$&C7GVC[-JME+
M]G4--LG4^6IZ%N>![]* -&BLN'Q+H5S=VUI!K-A)<W*>9!$EPA:5?51GD<'I
MZ54L?&.BW_B#4='AO;?S[ )YA,H&YB&+*H[[0H)(Z9]J -^BL'2=6M+30H)]
M0\2V6H"69XTOLQQ)*Q<@(H4X)'W>.I%7(_$.BRV4EY%JUD]M'*86E2=2HD'5
M,@_>]NM %W[-!]F-MY,?V<KL,6T;=O3&.F/:EF@BN86AGB26)OO(ZA@?J#6#
MJ_C;0M)T:VU1M0MI[>ZF2"!HI5*R,S!3@CC"YR3VQ6E;Z]H]W>+9VVK6,UTR
M;UACN$9ROJ%!SCWH EBTO3X()((;&UCAD^_&D*A6^H YIBZ+I2PM"NF68B<@
ML@@7:2.A(Q4UO?6=W+/%;74$TENVR9(Y QC;T8#H?8U8H SAX?T4$$:18 C_
M *=D_P *FDTK3IKG[3+86KSYSYK0J6_/&:MT4 5KC3[*[E26YL[>:1/N/)$&
M*_0D<57/A_1223I%@2>I^S)_A6C10!2;1]+:&.%M-LS%&28T,"[4)ZX&.*GN
M+.VNX1#<VT,T0.0DJ!ES]#4U% %,Z1IK6WV8Z=:&#!'E&%=N#@D8QCG _*EM
MM,LK&T>VL;*UM8GSF.*%50D]RHQFK=% &?HVD6VB:>+2U1%0NTC!$"+N8Y.%
M' '8#T Z]:L2V%G/,TTMI!)*T?E%WC!8I_=SZ>U6** */]B:28EB.F67EJVX
M)]G7 /KC'6G_ -E:<)FF%A:^:RE2_DKN((P1G'3'%6Z* *MIIFGV#.UG8VUL
MS_?,,2H6^N!S2W.GV5ZR-=V=O.4^X98PVWZ9'%6:* (+FSM;V(17=M#/&#D+
M*@8 ^N#4(T;2P8B--L\Q?ZO]POR<YXXXYJ[10!2_L?3 92-.M,RC$A\A?G&<
M\\<\TKZ3ILEB;%]/M&M"<F PJ8R?]W&*N44 5'TK3I;>*WDL+5X(1B*-H5*I
M]!C _"E33;".Y%REE;+< 8$JQ*& QCKC/2K5% %!=$TE)GF72[(2R.)'<6Z;
MF<=&)QR>>M27.F:?>7$-Q=6-M//"<Q22PJS1G_9)&1^%6Z* *MYIMAJ(C%]9
M6UT(VW)Y\2OL/J,C@U+!;6]JC);P1PJS%V6- H+$Y)X[D]ZEHH K)I]E%=M=
MQV=NERWWIEB4.?J<9IMQI>GW4XGN+"UFE&,220JS#'N15NB@#@CX6UK^T+S[
M9IGAG6(;BX>5;N^C83(K'A678P;:,*,,. *Z32O#.F:98VT'V*TD>#)63[.H
MV$L6(0<[5!8X&>!@5LT4 5;W3+#4A&+^QMKH1G<@GB5]I]1D<&G7EA9ZA;&V
MO;2"Y@)!,4T8=>/8\58HH J2Z7I\\$4$MC:R0PC$<;PJ50>PQQ1_96G>?Y_V
M"U\[&WS/)7=C&,9QZ<5;HH J1Z5IT5O+;QV%JD$PQ)&L*A7^HQ@TB:1IL=B+
M%-/M%M <B 0J(P?]W&*N44 4_P"R--#Q.-.M-T7$9\E<IWXXXJ:*UMX9Y9HK
M>*.68@RNJ ,Y'3<>_P"-344 5+O2M.U!U>]L+6Y91A3-"KD#VR/>EDTVPEGC
MGDLK9YHP DC1*67'3!QQ5JB@"D-'TL1S1C3;,),,2J(%Q(/]H8Y_&GC3+!<X
ML;89B$/$2_ZL=$Z?=]NE6J* *)T;2S (#IMGY(;<(_(7:#ZXQC-7$18T5$4*
MBC 4#  ]*=10!3BTC38%18M/M(U23S4"0J-K_P!X<<'WZTT:-I:I(@TVS"2?
M?40+AOKQS5ZB@"D='TP^5G3;,^5_J_W"_)SGCCCFG2:9I\M^E])8VSWD8PEP
MT*F11[-C(JW10!4.E:<TTDQL+4RR AW,*[GSUR<<TG]DZ=]B>R_L^U^R2<O!
MY*[&^JXP:N44 5K73K&Q.;2RM[<[0F8HE3Y1T' Z#TIUS96EX8S=6L,YB;?'
MYL8;8WJ,]#[U/10!3DTC3)599-.M'5I#*P:!2"YZL>.I]:<FF6$=RMREC;+.
MHP)1$H8#&.N,]*M44 4!HFDB>2<:79":5P\DGV=-SL.02<<GWJW-!%<PM#/$
MDL3<,CJ&4_4&I** (;>SMK2 P6UM##$<DQQH%7GKP*AMM)TVR@E@M=/M((9L
M^;'%"JJ^>#N &#^-7** *MGIMAI^_P"Q65M;;_O>3$J;OK@<TUM(TU[5K5M/
MM&MF?S#"85*%NN[&,9]ZN44 0+8VBM,RVL :<!92(QF0 8 ;UXXYJ.32]/FL
M!82V%J]F!@6[0J8P/]W&*MT4 1PP16T*0P1)%$@VHD:A54>@ Z4R6RM9YUGE
MMH9)D4HLCQ@LJGJ ?0U/10!1&B:2(3"-,LO*)W%/LZ8)]<8ZTZYTC3;V*&*Z
MTZTGC@YB66%6$?\ N@CC\*N44 &.,=JSFT#1F8LVD6!)Y)-LG/Z5HT4 4QI.
MFK"D*Z?:")'WH@A7"MZ@8X/O3GTVPDNC=/96S7!&#*8E+D8QUQGIQ5JB@"C_
M &+I7V=K?^S+/R7.YH_(7:Q]2,8[U+'I]E%9M9QV=NEJP(:!8E"$'KE<8YJS
M10!4;2M.=H6:PM6:$!8B85)0#H%XX'TI@T;2@DB#3+,+)]\"!<-]>.:O44 <
M;K?AK4Y-8AN=.LM#OM-2V\E=.U",HD+;B6="JL,MP""O\(YK4\.>'DT=[JZ-
MII]G/=A!)!I\6R%0F['8;F^8Y; R,#''.]10!6&GV0O/M@L[<71_Y;>4N_IC
M[V,]*;<Z7I][()+NQMIY%& TL*L0/3)%6Z* .%N/#&M'6;^6;3O#>LVMS.9(
MI-01EE@3  CQL<,J@<8*YY/4UO:3X6TS3M/BMWL+&1T=Y!MME5$+,6(1>=J@
MG@?UK<HH K7NG6.I1+%?V5O=1J=P2>)7 /K@CK3KBQM+NT-I<VL$UL0 89(P
MR$#H-IXJ>B@"HVE:<]I':-86K6T7^KA,*E$^BXP*/[*T[SDF^P6OFH %?R5W
M*!P #CBK=% %6#3+"V25(+&VB648D$<2J''O@<TR'1]+M[-K.#3;.*U<[F@2
M!50GU*@8J[10!2.C:61&#IMGB+_5_N%^3G/''%3I:V\=S)<I;Q+<2 !Y50!G
M Z GJ:FHH K7&GV5Y(DES9V\[I]QI8E8K]"1Q4?]D:9NE;^SK3=-Q(?(7Y^<
M\\<\U=HH BM[6WM(1#;010Q#D)&@4?D*EHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KB/B]Y7_
M  JS7#+LXB3;N]=ZXQ[UV]1S00W"A9HDD4'(#J",_C0!PNKWUK9_%?PW<7-Q
M%%#+I5S'&[L '8M&0J^I/H*RH)[S1=5M)+&ZMM:\.7VN-']FD&+JPN7E;<58
M?>56WD@\@>V37IWV:#]U^XC_ '1S'\@^3Z>E,2PLX[HW4=I MP1@RK& Y'UQ
MF@#F?B8UU'X#OIK5)9!%)#+.D0!=H5E4R  \'Y0V<\8S63:3^$]>U0ZU8ZU)
MJUZNFR1NX=-D4!&<2A5&/FZ!N<YXX./1*K1:?901210VEO''(=SHD8 8^I '
M- 'CMFMG!\+_ (;3(((Y/[9LB7& 22S!LGZ<&NN\/W=I#\4_&MI<31+-<&R:
M*)R-TBB Y('<#!R:[3^SK(J%-G;[0<@>4N!^E2&V@9R[0QEBGEDE!DK_ '?I
M[4 >(*;%_@7I0D: QC6PO)& /MK$_P#COZ5UOBRYLO#7C30+NXE_LK19XKF-
MKJWC18X[E_+(9R5(&Y5(W8SUYQFN^_LZQV[?L=OMSG'E+C/Y5)+:V\]L;:6"
M*2 @ Q.@*X],=* /)O$$&A6?A":_T:\DN+&;Q%:7=S>/(#"TAE3>ZD +MZ9(
MXSGT-=#XTE339M)\>Z</M$=@?)O# -WGV4A 8C'WMK;7';K7<?9H/LWV;R(_
M(V[?*V#;CTQTQ6'J&E:UJ6M"&6[L4\.CRW,"0MY[NAW;2V=NPD#/'(&.^: $
ML+JV\->&3J6NW$=F]Q)]HNY)#PDLK#"9_P!G*H/91714R:&*XC,<T221D@E7
M4$'!R.#[T^@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JF^K:;'J2::^H6JWSC*6
MQF42,,9X7.3QS5RN%^(?AS_A)KK0[2*Z>SO4EFEM+N/[T,JQ[E/TR!D4 =A>
MZG8:8B/?WMM:H[;5:>54#'T&3R:+K4K&QM5NKN\@@@; 6260*I)Z8)ZYK@+7
MQ5+KOA_^R]8A6U\1:9JNGQWUMV)^UPXE3U1NH],_3,NC3OK?QJ\1_;/F30[6
M"&RC;HAE7<[@?WCC&?3B@#N+#5M/U02&PO;>Y\LXD$4@8H?0@=/QJ*'7]'N9
MIX8-6L99;<$S(EPC-$!U+ 'C\:XSXC3/HGB/P?KEE\EW+JD>FS;>LT$N<JWK
M@C(ST-/GV^&?C+%<G"67B:R,4AZ#[3 ,J2?="1]: .SL=9TO5())]/U*SNXH
M_OR6\ZR*OU(/%2V.HV.IPF:PO+>ZB5BI>"4.H(ZC(/6O*_ ^N_\ ".W/BNRD
MMA'!,#KNE0#K)#,<!1Z'<$&/5J].T33O[)T6TL2P>2*,>:X&-\AY=OQ8D_C0
M!:N+F"SMI+BYFCA@C4L\DC!54#J23P!61_PF?A;./^$DT?/7_C^C_P#BJUKN
MT@OK5[:YC$D+XWHW1@#G!]N*X:\ 'QVTP8&/[!F_]'"@#JF\3Z D-O,VN::L
M5Q_J'-VFV7G'RG//((X[BIKW7-)TT1&_U2RM1-CRS/.J;\],9/-<+\1[:#3/
M^$-6UM247Q-#*(8@,LS>8[8R0,EB3^-1?$C49+R'PO')I5[; >(K([YQ'M^\
MW'RL3G\* .[N?$FA64RPW6LZ?!*Z[E26Y12P]0">E.MO$&C7OF_9=7L)_)7?
M+Y5PC;%]3@\"N+\7326WQ;\%2Q6DUTXM[X>5"4#'Y%_OLH_6NJTJ[;4M7O)K
MC29[">U"P(;@H7=& 8G*,RE<CCGL: 'P>+/#EU(D=OK^ERR.=JK'>1L6/H #
MR:O7^IV&E0>?J%[;6D.<>9<2K&OYDUX9INH6]S\*6\*#3WGO]9OKNVLFE4)
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M,Q);'(/0^U4[OQ;J>CVVBZIJEK:_V;J<T4,BP[O,LVE'R%F)Q(,\$@+C/&:
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M>V)W+<VBKO"LV6YR57^$#YNIQ0!V-%%% !1110 4444 %%%% !1110 4444
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MSVJ2W\3:-=:K'ID-\C7<JL\2%6 E"\,48C:^.^TG%:DDB0Q-)(ZI&@+,S'
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MA5%8E/\ :&>XP<XXQDN\->&?%FA1V^C3:W93Z#:,!!((7%VT:G*Q,<[0.@)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%%  0",$9%9EIX<T/3[PWEGHVG
MVUT<YFAM41SGK\P&:TZ* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHILD:31-'(H9&&&![B@
M21) 2CJP!*G:<X(ZBG5P_P *(D@\%O%&H6--1O%51V G< 5W% !2!E+%0P+
M D9Y%5-3OQI]J'$9EGD81P0@X,LAZ*/3H23V )[5Q'@?47L;3QKK.MWWF"VU
M:=9I\?*J0QH"%'91\P Z_4T >AT5QMQXZFM8=%GDT&Y=-:;;9PQ3Q^=DKO7>
MK%57*@G[QQTJ2[\;3PZAK6GVNA75]=Z:(R(K>129BZ[L<], KG_>& : .NHK
MFM4\7PV5OJLUM;K.FE1EKN1YA'&K[=WE*V#NDP1P!CD#.3BK!\31R31VMM;,
M;O[*MW<1SN(EM(V&1YK<[2<$8 )X/89H W:*XT?$"(V/AZY.F7 _MIF6--XW
M(%!)(&,L" ,=,[E]:JS_ !+6#1M5OFT.Y,FFWIM)H%F0_P 2J&W=,EFVA1G)
M4^A- '>45DWNNQP:H-+MHQ/>B'SY07V1P1Y(#2-SC)!  !)P>, D88\?P_V7
MH-\VG2A=7N6@1?,&4"[B7'&67:A88&2"O'- '945RD/C1I;/Q+,^EO;MH?+K
M-.N''EB3EER%(4\CG%7_  C>:IJ/ABSOM7A2*[N5\_8C9"J_S*O08P"%[].M
M &S)+'"A>5U11_$QP*A_M&R_Y_+?_OZO^-1ZEI5EK$$<%_ D\"2K+Y4BAE9E
MZ9!Z@'GZ@5Y_H>AZ1/\ %OQC:RZ7926Z6EEMB:W0HN4;.!C S0!Z,M[:/="U
M6ZA:X,?FB(2 N4X&['7'(Y]Z6ZN[:QMVN+NXBMX5(!DE<(H).!R>.20/QKSD
MVC:#\5[>UT338YY(_# AC1Y1$N%G !=\$] !D GIQZ7-1\;V][\-WUZ\\/1W
M4:7(MKJPGD5ECD6<1]2I# /@CC\J /0**YO4?%,D&OW.BV%M;W%_!9K=B">Y
M\EI@Q8!8QM;<1LY/ &1^'0PNTL$<C(49E#%3U4D=* ',ZH 68*"0,DXY/ %+
M7GWQ'MM3UVUFL-%G>*YTF%=4RG\<RMF&/WSLD./4)ZUT-AXHCU/P-%XFLH//
M62T^T^0KA3D#YDR>X((_"@#H**X)/B%?_8/#NI3>'2-/ULQ11M'=JTJ32(65
M=A4 J<8W%AZD"M"T\:M#>Z[::]8)ITFDVRWKM%<>>DD#!CD':I!&T@C'T)H
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M /5:*QO$&OIH?]G1"'SKK4;M;2WC+;5W$$DLV#@ *3T/85CKXUO!?>(K*31
M9]#A6:8QW0*R!D+IM)4'D ]N".] '8T5Q%GX]NWT6VUG4-$6RT^\M[=[25[U
M3YDTI V$8&T#.=Q_A&<9XJ2W^(%M'J&J6NI101I861O_ +597'VB&2(<,-VU
M<.#_  ]\@T =G17&P>.RVNZ=ITMG;2)J*.89+.]$YB=5W!)0% 3(X!!(SQ[U
MG/\ $J^3PO+XC/AS&GVMV]O=YO1YB!9?++(NWY^>2"5]L]: /0Z*YBW\4WJ^
M+H-#U+2%LTO+>2XM)EN1(6$9&Y74* K88'@L/>LN7XE6RQV%]#;VUQIEW<+"
M##=AKE%8X65H0OW>Y^;(!!QU  .[HKAKCQWJH?Q&EGX<$S:$W[[S+T('3R_,
MR,*?FP>!T]2*9J'BO5KKQ!X+72(+<V&L02W6V:=HV?$.X*V$; &\'OD@=,<@
M'>4R6:.")I9I$CC099W8 */4DU1U[6(= T&]U:=&>*UB,C*O4X_E]>U<[KM_
M/J_@WQ$EU96;V?\ 9,DUO=6]QY\4Q*29 )4<KM![_>% '80S17$$<T,B2Q2*
M'1T8,K*1D$$=013Z\]\,>*+S3].\&:9=Z2(['4K&*"WNQ< OYBP!OFCQPI .
M#N)]0*OZEXYN-+_TFYT<Q6']J#3@TTQCFDRP3S4C*X9,GCYN1S[4 =:+NV-X
M;07$7VD)YAAWC>%SC=MZXR1S1;7=M>(SVMQ%.J,49HG# ,.H..X]*XQ((5^-
M]QB)!YOAU3)A1\Y^T$<^O%.^&$:1:-K4<:JB)KM\JJHP !*< 4 =C]KMC>?8
M_M$7VK9YGD[QOVY W;>N,D<^]35YSJDEW8_&5I=)TN.\O)?#Q_=F585)^T?>
M=\'TQP">G;D:%A\1K6ZTD275F+#5!?MILME<W"JL<ZJ6;,F,;-H)W8YZ $T
M=M17->&_%@UW5-3TR6VCBN+ H?-MY_.@F1QD,CX'(Z$8X/K4VM>)X=,U.+2X
MWL_MLD!N#]LNA!&J [1EL$DDYP .QZ<9 -XD*"20 .235.WUG2[N">>VU*SF
MB@.)I(YU98_]X@\?C7G'BSQ;=Z_\*+V^L[(6Q^TI9WB23G*'SHU(0A<2(P;K
MQP>_2K'C>WO+34?#M[%I.G0WFH:S:0W;QW3?OMGF-&C'RAE1M!W8R" ,' -
M'HEE?V>I6_VBQNX+J')7S() ZY'49!Q5BN'GU^RT&]U:#3;#28]255N]0CDO
MA )9F3.U#L)=MH')"CD=R<7=/\:)K::9'I-DSWE[9F\:&Z<Q"",-L.\A6.=^
M0 !S@GB@#JZA:[MENTM&N(A<NA=(2XWLHX)"]2!D<^]<'KOB[7QH>AW$&D_V
M=<W6MP6-S#=RLK#]Z!A"$Y1]I&_'0\ YXV)=8V^/+'2Y]$MO[0DTV6>.]\T-
MMPRAHU.S=M)(YXZ=* .JHKD=,\9SW^@ZQ>R:7'!?:9=/:-9?:2Q>52 J[M@Q
MN++MX.<BGZIXQ-E=75C!'IS7]G DMQ%<WXA7<P)$:$H2QP.I '*^IP =7169
MX=UN'Q'X?L]7@AEA2YCW>5,N'0@D$'Z$&N?U+QS<:61<7.CF&P.J#3E::8QS
M/E@GFI&5PR9/'S<CGVH [.BN7N/%DK:QJNFZ;9P75SIFSSH'N3',X95?<B;3
ME0&'.>2"/KT-Y=P6%E/>74@CM[>-I97/1549)_(4 3U6OM1L=,@\^_O+>TAS
MCS)Y5C7/U)KEYO&\UEI^E:Q?Z4(-&U&2-%G6XW20"3_5M(FT  Y&<,<9[U0N
M)M2NOC$]C+9V<UH-$(\N2Y;'E//AVQY9&XA0"O3 'S4 =]'(DL:R1NKHP#*R
MG((/0@U&]W;1W4=J]Q$MQ*"8XF<!W ZX'4XKD?'-U<^#OAQ<MX>@MX$M4C@C
M!8KY*,P3*8!R1NXSCUYQ@YOB%KR'XE>#[H:; VI26NH*T4,WRMA8]N9"H. #
MG[O&3@'N >C45QUEX]C?0K^\U*R6RO+'4?[,DM_M 9&F)4+B0@?*=X.2!@9X
MXJQHOC#^TO$UQH<]O;B5+8745S9W/VB&1-VTJ6VKM<''R^G- '22W-O 0)IX
MXR>@=P,_G38[VUE<)'<PNYZ*L@)-<'\8DA/A73I)8A)LU>TXV;CC?R .^1VK
M8MCH=YXEL;:#0Y;:Y@BDO(KE[ V^TKMC*@LHSD2G('I0!T%[JFGZ8(S?W]K:
MB0X3SYECW'T&3SUHFU73K>\BLY[^UBNIO]5"\RJ[_P"ZI.3^%<'8+J&L_$'Q
ME8:AIMA=6OV6T@>&6Z8JL921@!^[YW$Y/3';.*SO#L]O'H7BFZ\1:;92:;8:
MW,P G+LDD1C2)$!11@850Q8>X S0!ZQ17'0>/(DU]--OXK189;:2X2[LKO[1
M&GEC<ZR?*-IV@D=0<&K-KXHU*Y;1[E= E;3-5/[N:*4O) K+N1Y4VX52.OS'
M&10!TSND4;22,J(H+,S'  '4DTV"XANK>.XMY8YH9%#))&P964]""."*X31?
M$>M7<'C&?4M.M+FWT^\FA$$=P3\J11_NP&3!!!)))')/RU,GC'^SO#/A2_MM
M#MX=,U7[/#M6XV+9&0#8,!,%>V>.<=* .YHK U+Q,FE2ZK+=0*-/TZW266X6
M7+%VSB,+C&<8_B_C7UXHV/C7S_%%IHMQ;6K?;87DAN+&\^T*K(,E)/E&TXY!
MY!P: .IEN(8 #--'&#TWL!G\Z2*Y@GSY,T<F.NQ@?Y5Q/QDC23X4:Z716*QQ
ME21G!\U.15K7_!>CZCX6?[-9P6-_#;^9:WEJ@BE@D"Y4AEP<9ZCO0!V-%>?^
M#O&VJ:UX.\-W1T\W-Y?PS?:+F1C'!%Y)*EG8*<%B!@8]?2JVJ^/-1O\ P3IV
MK:1:P027&JQV%P'N"=A$X0A&"_,&Q][ P#G!- 'I-%<OJ/BUK.]?35331J4-
MNL\\=SJ'DQKN+!55RF6)VG^$8&,]16CX7U^+Q/X=M-7BMYK83@[H9AAHV!((
M/KR.#W&* ->H9;NVA?9+<11MUP[@&IJ\W^)RVJ>(?!,UQ;>>HU0AE6'S&9?+
M/&T D]N* /0XKJWG8K#/%(P&2$<$_I4M<A97GAZWEU7Q NEMI@TN%X9IGM3
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MOW?."I!Z8/MS0!W$TT=O"\TTB1Q1J6=W8!54<DDGH*(I8YX4FAD22*10R.C
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MNEHLZYB$@.8V'15SR,9ZFN[FU"RMKN"TGNX([FX)$,+R /(0"3M'4\ ]*LT
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MM#_1,3+_ ,\1%\W/'(SWX]Z@B\-:_:P^ [B"TMY+G0K9[6ZADN-H.Z%8]ZL
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M2#@C@X((_"@#A/\ A&M<U?P;IOA+5[6*..UD@2YO4F#)-#"P(V+]X,VQ0<@
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M<:W=7<UL1<$JJSKM&X[>"/8&NRT*WN+/0=/M;I$2>"W2)PC;ERJ@<' XX]*
M,$^+=2N]._M?2-&^WZ:+LVX6.4^?*@D\MI57&,!@3@GD#/%6W\0WE]JNJZ?H
MEI;W$FF!%G:XF,:O*R[A&N%/;&6/0D#!YQA>'] \7>&OM&@69T^30VN))+:^
M>5A-;1NQ8IY>W#,"3@Y [GTJ_:Z'JWA_Q=K6HZ;!#>V&L%)GB>;RW@G5=I/0
M@HPP3W&.AH J?\+'-SIGAV_T[26G35[LV3QR3A)+>8!MRD8P<%#SD>N*9>^,
M];CTCQA VGV=KK&A6PG!6=I861XV=6!**21M(P0!D=:A'@;4M/T_PQ;68MIW
MT_56U.]D:0H'9]^X(,'N_&<<**LW?A35K[5?&[LMM%;Z[I\=I;/YI+(R1NF7
M&W@$OG@GI0 DVOWECX;\(RZGI5I>M?WEG;^8TY<Q,X&V7YDY;[WI@XY-79O%
M6MS>)]8T'3=%M99[""*>.6:\*)(K[NN$)!^7@ $=<D=Z%]X>\1W_ (:\+V;V
MM@EUI5_:W,RK<L5*0C! .SEFZXQ@>IK3L](U:U\=ZWK;6T#6M[:00PJ)_GW1
M[OO#;@ [O4]* *MIX_>\TWPGJ$6FJ(->G%NP:?#6[[6)XVX890CJ*LOXV2RU
M#Q1!J-HL4&A0PS>;%+O,PD5B!@@8/R@=3R>M<]:>"_$%AX)\+6D<-G+J>@WX
MN3#]H(CG3]X" ^W@XD[CM5F?P5K.LWOB_P#M,V=M;Z[:6\4;03,[021*<<%1
MN )'.5SCIS0!KV?C"YD\3V.DW%E!)%?1.R7%E*TJP.@R4DRH R.C=R,8I/B%
MJ^JZ1I>F-I?DJ;C4[:WE:1RIVM(HP, ]>A/89X/:7PY_PFCO!#XBCTR&.V&'
MGM)6=KLXP#M*@(.YY)R!P!4OCC1+[7-%MH]-\EKNUOK>\1)G*+)Y;ABI8 XR
M.^* 'MK]Y/K<FAV-M:OJ%O:I<7;/,WE1;R0B A<L3M8]!@#/.<5+X6\2)XET
M^XE-LUK=V=S)9WELS;O*F0\@-QN'((..0:RAH>LZ;XTD\2VD-M<#4+-(-0LU
MF*E'0_(\;$88 $J<[?7VK3\*Z ^AP:C-<-&;S4[Z6^G$9)5"V $!(!("@#.!
MDY.!0!RLDVJ6GQ6\1G0],M[NZ?3;1B)Y_)0?-)U(!))[<?4BM*P^(MMJ&C6$
M_P!E%KJ-U<RVCVMS+A;>6($R;F Y P,8')9>G)%J32=7T_QW?Z[9VMO>6U]9
M16Y0S^6\3QEB"<J05.[J.1CH:QKGP'K&GV&GZCHMW:MXAM-0N-1E$V1!<-<9
M\V/CD#& #_L]L\ '1^%_$TVNW.IV=S9>1/82JGFQ$M#<(PRKHQ ST(([$=:3
M7O$-_IEU=1V]A$+>UL_M3WEW*8H7;) B5L'YN,GTR.#FKVAG6Y89+C7([6WF
M? 2UMI#(L8&>2Y RQSZ8  ]S6#J^@Z_<^+[J\A2QNK"XL!;P&YE938R?-N94
M"D-N!'.0>,9 H ;-X]N&L?"EW9:0)H]?VA5:X"M$QC+X^[@CCKG\#TK3\->(
MKS5=5UG2=3L8;6_TN2(/]GF,L;I(FY"&*J<XR",=JYFQ\)^(X-(\$6LT%B7T
M*8//LN6^91&T8VY7D_-GL.V3UKH-#T;4K+QOXEU:YB@6SU,6WD%)=SCRD*G<
M,#&<YX)H M:UXDCTW5+?2X3;B\FA>?=<2%$1%(7)P"223@#V)SQSSW_"QKP:
M/8WAT%A-+K":3/&9R &9@!)$2H\Q"#D$[:O^*-$UY?$FG^)?#1M9;N"![2YL
M[MRB3PLP888 [6##/^<&#7M$\2ZWI>D&9+$WD&KV^H2Q+,1'%'$0?+5MN6)Q
MU(')/;% $L?BGQ _B.^\/'1+$:C';)=V[B^8P&)F*_.WE[@P*XP%.?;K53_A
M8UP?"^BZNFB;Y+_4ETV:W%P,Q2>8R':2,,,J<9(ZBM./2-53XCW&OFW@^Q/I
M:V2KYW[S>LC/G&,8.['6N)U/1M6\/>#O#]C=0VQO!XKAGB"3$HWF3.X!;;D?
M>P>#0!V>D>*[^X\67'AG7]'AL;MK;[7;/#<>?%/%NVD9*KA@3TQ_]?G_  %K
MD>A?"WP[&D(FNKZ\FM+6'=M#.9Y3DG!PH ))P>G2NGBT>]N_%_\ PDEW;I";
M6Q:TM+;S S,68,[,1P/NJ !GN3Z5S%EX#UN#P1H-INM(]:T*_:]@Q*6AF!D=
MBA.W*@J^,XZB@#I4\3W\7B&Y\.W5A;C5#:&\LF6<B&Y4'!4DKE&![8/!S[5!
MIGC2YU3P?;:O%IT*ZA/=BS-@UP<QR^9L96;9D%<%CQT!JQ!H]S>>+8O$VJ11
M68L[)K:"'S0Y!9@SNS8  PH '/<G'2L[1M!B'Q'UC4+2Z$FF*([DP+@HE](A
M5W!]?*VD_P#76@"75_',EJNJMIUM:W3:6Q26%YV62=PH9EC 4\@' SU;(QW,
MLWC=+AU@TV.W2X^Q17CKJ$C0[?,!*1D $[OE.?3CKFJ2:/XM\/>)=5ET&/3;
MW2=5N/M3)>3-&]K,0 YX!W*< XX/TZE;[0O%.C^*/[=T![+4?MEI%;:A;7DA
MAWO'G;*K ''WCD8_/L =)X8UW_A)/#MIJILI[)YE.^WG!#1L"01T&1D<'N,5
MER^*KZ[@UFZT73H;NWTF9X)!).4>>2, R*F%(&,X!/4@C@<UT.G1WL=C&-0E
MCDNSEI#$"$4DYVKGG Z9/)QFN2TS0-<\-W.OVNFPVUW8ZI=27ML\LQ0V\L@^
M=7&#E,C((R>HQWH R_$WB&?7(? VH:.D+Z??ZG#*@FE9&9PDA". I  (ZY/(
MZ=Z[NWL%L;6YEL;*T@O;DF>94.U))BH!+,!D]!SC-<?/X*OM.TSP;I>DI!/;
MZ%=)<3R32F,R85E;: #R2Y/)]J[]22H)&#CD>E 'C.HZKJ>N_ M=6U:."2:6
M\ADC>-R6)-Z,C! V@< #)X]*[VU\5WD7BNYT76=/@LU6P;489HK@RCRE<*P?
M*C##(/&1[FN87P7XE7X7KX3\K3C+!<H8IA<MB1%N/-W'Y/E)  QSZY[5T%_X
M=U#4O'2ZG-!"NFR:/+ITP$W[P&1U8D#;C QCK0!7B^($DD^C3)81S6&J2I$!
M;RL\]L'&4>1=N-O3=@_+GJ:F^*GB"\\-_#W4;[3W,=X^R"*0?\LR[!2WU )Q
M[XJ#PKIOC;2+:TT&_;3'TVQVQQZE'(WG2PI]U/+(P&( 4G/ ]3S71^*/#MIX
MK\-WNB7I98;I,;UZHP(*L/H0#0 NE>'=-TO0(]'CM8I+81[91(@;SB1\S/G[
MQ)R23US69%<P^&'TCPEI,2S7,L<KPK*Y588$/5B 2<;E4#OZBET>7Q=9V45A
MJ.G6-W/"HC%]'=E$E X#,I0LK'N!D9[U7U?PYJH\1Z+XDL)8KJ^LHY+>[AD/
ME">&3D[#SM*MR >HX)[T 5KKQ_<66F>)?.TJ/^U?#ZB2XMA<$1RQ,NY9$?;G
M! /!'!&*?)XRUFWUC1K.;0H#%K,3FS*7GSK(J!R) 5PJXSRI8\=">*K:MX/U
M+4K#Q;=K';IJ>O6R6D4+2G9!&J%06;'))8DX'H.>M6KO0=9N-8\'7BV]L$T<
M2?:@9SDEHO+^3Y><=><4 0R>/=0L]$\3SWFCP?VCX?8>?!%=$QR(R!U97*9Z
M'H1VJ1?&^IVFNZ-;:OH:6NFZR1%:727/F,LI7<JR+M 7=VP3_/&'XJT;4K#0
MOB3J5W% MMJEJLD&R4LP\N((0PP,9QG@FM^/1]0\1)X7:_MXK:UTMX[UBLN\
MS2K&50+QPOS$DG!X QWH ;=^.+O3[C3WO-+2WM[W5/[.CAFF*W.TN46;81@J
M2 <#L0<]JEF\5ZW-XDUO1--T2UEGTZ&&9)9KPHDBN&/.$)!^7 &".N2.,\Z_
M@[Q;)I<-O+%I<]Y;:U'J#7LER^^]592RAOD^3"D#^+ & *Z2PT?6;3QIK^L2
M6]L\%_:V\,02<AMT0;.05X!+>IZ4 5#\09WT#PUKL6EQC3M7ECAGDDN"IM'<
M[1D!#N7<,9R.WK730:G<7'B*[T]+>,VMK#&SW'F'=YCY^3;C'"@$G/1EXYKE
M-.\.0Z=\(_\ A&/$\MM"([.5)9(Y=PP"6$BY .5R#TZBM_P7IUYIWA>T_M.1
MI=4N%$][(PPS2L!P?H J_P# : %U#Q#-8>,='T,VB/#J<<[K.)2&C,2@D%=O
M.=P[UA7WQ O++P[XGU+^R(7ET*[-LT8NB!* JG>#LX^^.,=NM:/BC1]6G\2>
M'M=TF"WN9--,\<MO/,8MZ2J%R&VMR"H.,<USEYX,\2W7ASQGIS)IQFUR[\Z!
MA.P"95 =PVG@;..Y]!0!T4/BG4X_%=GH]_I,$$>HVLL]E(ET7;,>W<L@VX4X
M8'Y2P^M8>B^)M:F\$>)=7U6PLK]+2>\W0>>P5TB)!3!0@+M4XZY[@9K:O-&U
M>[\:>&M7%O;I;:=;W$5P#/ELRJ@^4;>0-G<CK6;:>%M?M/"?BK0?*L774)+T
MVDHG8%O/+8WC;\NW=SC.?;N 0^(9HKU/AQ?);1P&;48'6-!Q&K6[G:/8?TKM
MM=U5-"T&_P!5DB>5+.!YFC3JP49Q7*7GAO6Y]-\%PQV]KYFBSPRW0-P0&"1&
M,A#MYSG/.*Z_5EOFTJY731";PI^Z6<X0MZ-P>#T/% &"/$U^='OM4AM]/O;.
M&R-W!<6UT3',0"63.T[2 !SSG/08J,^,YA:>$;K^SX_*\0&)2//.Z!GB,G]W
MY@,8[5G:?X%,.IZU<6=I'HUEJ>G-:RV4,F^-IVS^]"CY5P.!C&<G@=Z<'AGQ
M;+IO@^UGM-+B_P"$?N(M^+MF\]$B:/>#L^7((XP>O48Y -V?Q;J4^GW>J:+H
MW]HV5K=FV,:2D3S[7V2-&N,84[L9/.T].,Y$SW]O\7]6.D6-O/=2:);MB>7R
MHP?-DY8A6.?H/Q%3:/H/B[PW>:AI6F_V=-HMU=27-O=S2L);,2'<R^7MP^"2
M1R/<]JTX-&U6W^(E]KGD0O92Z;':1_O_ -X61F;)&W !W8ZT :7A+Q /%'AB
MRU@6YMVN%8/"6W;'5BC#/<94\UM5S'@#1=0\.^$;;2M26$7$,DS9AD+JP>1G
M') _O8Z=JZ>@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***R/$6O1Z#9V\C)OFNKA+
M:!#G!=LG)P"<!58\ ]* ->BN#E\<ZK:6_B'S-(6=M+LS>PW*B6&"X0*2RY92
M5<8Z<Y]12MXSUV&Z\.F71[-K;7(]L 2Z(>.7RO,&_*X"G!Z9(]SQ0!W=%<*?
M&VJVECXL6]TRS;4/#T:SND-PPBFC:,R @E<@X!&,=>]1KXXUJSOO#\VK:-;0
MZ/K;QV\,T-P7EAF=<H'7;C#'.,$X[GM0!V=GJFGZA-<PV5[!<26S!)UBD#>6
MQ[-CH?:K=><:=K%IX<\0_$C5KS(MK2>VE<*.3_HZ\#W)X^IK9N_%.HZ+=Z*=
M9L[9+/5IUM0\#L6M9W&45L_?!P1N&,'M0!UU%<EIOBVY>\\2VFKPVUE-HP$G
MR,S"2$H667D#@X(P.A!&:@F\5:_;ZSH&DRZ/9K=:K:2SG-TP$+HJDH?EZ#<.
M1G.#P* .THKST>-O$CZ+KUPFCZ=]JT":5+S==.(Y51 _[KY<Y*G^+&#CKDXU
MI_&23/IUO8JB7%[8+J&Z='=8HVQM!"#)))([ ;3[ @'645Y\?B#JPTG2;E_#
MQCN+O5AI<T4TC1X8Y(>/<HW(P&03C&>^*M#Q7KF_Q/IMQ9V$&J:7:)=P/'*\
MD+HZL1G(!R"A],^U ';T5SG@*ZU"^\#Z-=ZD\<DTUG#)YBDEGR@.6SWSZ5G2
M>*/$5SXKUC0]-T:QD;3A;2>9-=LH>.3=G^#AL#@=.#R> 0#M*J1ZII\VI2:;
M%>P/?1)YDENL@+HN<9(ZCKWKC+WX@W*V)U73=.-]8I<F$V\44K7$D8DV-(A"
M[>H)V]P.H/ FC(7XUW;JI)_X1R,X Y/^D/0!W%-DD2*-I)&"(@+,S'  '4FN
M*M?&U^NM:!8ZC96UO)K'F V@D/VBS*H77S!WR!Z#!]:@\,ZUX@NG\7SW:65R
M++4)88X?,9 -D4>$!VG"XR2<=2>* .ULKJSU*U@U"REBN(94S%/&0P93Z'TX
M_2K-<5I?C(7'A[PJ+6Q@AO\ 74_T>V4[8H55"[L<#HH'0=20..H=+XROK*\U
MW2KNPMVU73;'^T(0LK)%=0<_,#@E"""I'/..?0 [.BN$LO&VKNWA6ZOM+M(M
M.UY4C5HYV:6.1HC("1C&TX(ZD]"?2KMAXNGU;5KNUL/L3/97YM+FR=R+A(P^
MTS8[@]0,8QWSQ0!T=EJNGZE)<)8WL%RUN_ES"&0/Y;8S@XZ'VIUQJ-E:WEK:
M7%U%%<W99;>)V :4J,MM'? YKS2UU/5M&U?XA7VDV-I.+2\6XE%Q,4#*MNC%
M5"@Y8@'DX'3KVZ27Q49]:\'+'IL#V^MQ231W$CYD@_<&3 &WN"!G/KQ0!V%%
M>?/XT\47,6OMIGA^PE;1;MX95DO6_?*J*V$PG+$$]< <=>W7^']:M_$7A^PU
MBU5EAO(5E56ZKGJ#[@Y'X4 6;74;*]GNH;6ZBFEM9/*G1&!,;XSAO0X-6:X:
M+QHUG8>+[ZXTF"%M'NO+<0.6\[Y$.]FV@]&&>#@#OBM_0=4N=4::4RV-U8&.
M-[:]LG)24DMN7&3@KA>Y^]VZ4 ;5%<7XGU36[;QYX5TZP>V6UNS<NZ2%@79(
MCPQ'\/S9 ]0/2H]6\<W<46J3Z18I>#39V@:W*2&2Y9,;PA52%(.0,YR0>G&0
M#N**X:Z\8:]<>(CH^CZ);/+)I2:E"UW<-&<,^W:Z[<JW!&.>>I%-/B_Q'<7'
MB6UM='TY9]$*%O,NW*2 Q>9@$(#DCCH /4T =W5:+4;*;4)]/BNHGO+=5>:!
M6!=%;.TD=LX-<;%XZU)X?#.J2:5;QZ/KDT-NO^D%IXWE0LK$;=NW((ZYQ@\=
M!?M_$%T_BOQ+IR:5:+/IUK!-'*)B#<!MY =MF5QMZ8;&30!UE%>>6/C_ %B?
M2_#.LW.D6D6F:S<Q6K!;AFFC>3(5@-N-N1CKGG/'2K?B?QM?^';75-0FL;>*
MSL)DCCBN)-LMZIV[WB[ #=Z'.T]* .XHKBKS5=:_X6O8Z7 ]M_9YTJ6X\MBP
M+'S8U+''<= /<\\U6O?B#=+8G5=-TXWUBER83;Q12M<21B38TB$+MZ@G;W4=
M0>  =U//#:P//<2I%"@W/)(P55'J2>E,LKVUU&SBO+*>.XMI1NCEC;<K#U![
MUSEQKUYJT^MV>C06TD6F+Y4SW!8>=*4W&-<?=P"N6.>3C'%1?"S_ ))?X>_Z
M]!_,T =-#J-E<7]S8PW43W=J$,\*L"T8897<.V0.*LUR%OXCNCX@\76B:3:+
M/I,%O*CB8@W(=78;VV9& N,8.,GFLZQ\>:Q+9^%M4N])M(M-UR6*V^2X9IHY
M)%)5L;<;<J1UST/'2@#T"BJ6KWL^G:1=WEM92WT\,3/';1?>E8#A1]:YNQ\9
MNGBBYT74C9'R-,;49)[5R1#M8*\;CGD9!SW]!0!V-%<I9>(=<O8M%U*'1TET
MO5&4E4?]]:Q,NY)'SP01C('3/4U'+XIU>\TZ\U70M*CO[2UNVMA;[R)KD(^R
M1D/W5P=V <Y"]LT =?17-MK][J.L:KIFB0VS2:6L8G>Z9MKRNNX1C;TP,9;G
M&<8/-8;?$>XN=&T#4-/TA';4]0_LZ:":XVO;S#=E>%P1E#\V>F#@]* /0"<#
M)JI8:I8:JDSZ?>0720RF&1H9 X5P 2I([@$?G7/6WB'69M2MM!GM+&'6VMWN
M[DI*TD,,(?8A' +%CVXQ@G/0'G?!NH:GI^E>*YH=+6YU!_$\T30PO^[0MY0+
MDXSL&2QXSB@#TZBN+LO&MS<-XHMHX;*\N-#BCF66"<K%<*Z,V,X8J1L8'KVJ
MM9>.-7D3PK>WNE6D6FZ]Y<2F.=FECE>,NI(QC:<$=<XP?:@#O:*Y&?Q1JUW9
MZG?Z#ID5]!I]TUKY#.1+=,C!9-AZ+@Y SG.T].*35?%]Q'>:C9:9!$USI\2-
M*DZ2-OD9=XB&P'!VD?,<_>'!H Z^BLW0M4?6] L]2:SFLI+B(.UO<*5>)NA4
M@X/!_.N0N?'NJ6GACQ'J,FG68OM#O#!-:&9@'3Y2KAL?Q!@0,<].M 'H-5K'
M4;+4X&FL;J*YB61HF>)@P#J<,..X-9D&LW%Y?6,5BMM<036/VN67<R@ X\O'
M!X?YOH$/6N)U;Q;JLWPMU#5M.M+/39TU%K25(V+8!N!$Q4@#YB3G=@=SUH ]
M'.JZ>-4&E_;8/MYC,GV82#S-@Q\VWKCD<U;KSK57U-/BIHC0V]K)J#:/=+@R
M%8A^\CY)P6QCL!U/;J.E\(>()_$.EW,EY;1V][9WDUE<)$Y9/,C;!*D@'!X/
M- &I?ZMIVE(CZC?VMHKG"&XF6,,?;)YJI=Z?HGBB*"25H[Z*VE66)HK@[4D
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M7NK2U>ZMVGCM;C!,J*SMO!)XY/IV)KUJ@ HHHH **** "BBB@ HHHH ****
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MYSDJ>I_B%;6F>'M:TN\\4+']@EM-4N9+N!FE=7WO&J[&&W"@;<Y!.?2NRHH
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M;JTSLNT!%9)/DXRJGD9ZU/X8\)?V'XCU/5+>U@TVUO88U;3[:0M&95+%I<8
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MM[R>1S+&@V[8" N H*G!!/4G;D\>F44 <C/H6N'QGI/B")M/)33WLKR-G<!
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M'G'93^;'K6 ? NM2_#G5O#\DE@E[<W[7D#K*[1\SB8*QV CIC(!]:]'HH Y
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MX#:.IP,\XY&,'I:* "BBB@#S;3/!&O6GQBU'QG*=.-G>0B#R%N',B +&N?\
M5X/^KZ9[]:M^//!FKZMXAT/Q-X=N;6/5=*9AY5V6$<T9ZC(!(ZL/HW48KOJ*
M //?'?A+Q)XU\"_V2\NF0W\MRDSCS'$42J/NJVTESGN0.OM6WXGT+4=<^'MW
MH<'V6.]N+40$O*WEJ>,G(7)Z>E=/10!Y+/\ #?Q%+;^ $633-WAEP\^;B3$V
M'0X7]WZ)W[FMWPOX.U?1_B-XD\0W;V1M-5QY:12LTB;3QD% .1[\>]=[10!Q
MGCCP;/XBU'P_K%A)$NH:+>"X2.9BJ3)E2R$@'!^48.#5#2_ NH6^I^+M>N&M
M?[3UR,PPP+*WEPQ[<#<^W))X)P.,=Z]"HH Y#X:>&-1\'>#8-$U)[626"21A
M);NS*P9BW\2C'6NOHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y#X
MI_\ )+_$/_7HW\Q77US_ (VT6\\1>$=0T:Q:!);R+RO,G<A4!(YX!S^E 'G7
MPSNDUKP1H7A&]TN<Z==:7=R2SRHOER$3!0$.3R-Y/(&#BNH\9^,]6\-^+?#6
MB:?:V5PFKNT69RRE"I49W ]/F';M4?ASPWXM\,^"[/0[-=#>\LXY(X;Z6:4A
M=[%L[/+]Q_%VIFN> ]7U/7_!FH17=HRZ J^<9G??.WR;B,*<?=SD^M &-'\2
M/%DD/C&V%EHWVSPWND>?$OERH-W 3=G<=IYW8]JGUCXIZI9^!_"WB*RT^S=]
M8F6"6WE+85CD$JP/ RIZ@]14L7PYUR*Z\=S?:-/(\2QLD0\Q_P!QG</F^3GA
MR>.X]\UR7Q T"]\,?#?P3HES+;O<VFK*@EBRR-G>0<$ ]^GZT >@Z7XTU6'X
MER^#M>@LO,FM?M5G<68< CG*,&)R>&Y&/N].>/.O ?C&+P+\,O$^L-!Y\O\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"L[5- TC6_*_M73;6]\DYC^T1!]A]1GI6C10 U$6-%1!A5  'H*=110 CHLB
M,CJ&5A@J1D$>E5=-TK3]'M?LNF6-O9V^XMY5O$$7)ZG [U;HH **** "BBB@
M HHHH 0@$$$9!I(XTAC6.)%2-1A548 'H!3J* "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M\/PRPZ1I=K91S',@AC"[S[^M-TGPOH6A7,]QI6D6=E-/_K'@A"EAUQQV]NE
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M/^CW<"AU# 8!4@L1@_RJG::99:=9_"W4K2VCBOIV@BFN%'[R1&M6RK-U(X&
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MK*"U$SF200H%WL>K''4^]17F@:3J%TUU=6$,L[Q^4\A7EX^?D8_Q+R?E/'-
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MN/#5O':^&M/MX;Z6^BBA"1W4OWI5' ;/?(Q@]QS3-4\*:!K<EO)JFCV5X]N
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M9[6VC588R.%?"DX9AGZXSVK'UN)],^.&@ZO<_+8WVFR:='*?NI.&+A2>Q8'
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M9=?\):;?ZI-:QZA=M,/+C.P-LE=?E4DGHH]:RM%BLHOB]XJ+QVZ2&VL6B+
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MD&W2/5]-F.R>!$CW;HGZ?=;=@]\XYKT5#!J6GHSQ!X+B(,8Y4ZJPSA@?KTH
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MMO.(U9RGHJR<8''##UK=\&:G+XPN+75KZT\F?28&LY8W3&V\)Q-CV4*N"/\
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M%"RO9LS;5,A+$%"1C.!C/Y]%JU_J,&K:+#936@MKZ=HI/-A9VP(GD!4AP/X
M.AZT :%GI>GZ=:&TL;&VM;8YS##$J(<]> ,5#I>@:/HAF.E:79V)F.9/LT"Q
M[S[X'-33ZII]M=Q6EQ?6L5S+_JX9)E5W^BDY-!U33A)-&;^U#P@F53,N8P.#
MN&>/QH CAT32K:WN;>#3+.*"Z8M<1I H68GJ6 &&S[T_3](T[2D9=/L;>U#
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M ')?$SRDMO#,LVP(GB&S+.^,*NXYR3VJN;?3]3^,_P"\BM[J >'$>,, Z?\
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M'O77OI.FO>B]?3[1KH=)S"I?_OK&:2/1]+BN)+B/3;-)I,AY%@4,V>N3C)H
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MF&Q>Q.G6ALW.YK?R%\MCG.2N,'GF@!L&LZ5-?KIUO?VKW9A\Y;=)5+&/.-P
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M9&=QZ$D9(XK1551 B*%51@ #  H 6BBB@ HHHH **** "BBB@ HHHH ****
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MCE)#@$<(?6O,Y;>TTSX,^&M8M;1$5(]/?4;BVA5I3;JRM)DD'< W)!R.#D4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !3)H8KB%X9HTEB<89'4,K#T(/6GT4
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M*V@@>5X88XVE;?(44 NV,9..IP!S4M%% !1110 4444 %%%% !1110 4444
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MLEO%/AY&96U[2P5.&!O(^#[\UHV]Q!=VZ7%M-'-"XRDD;!E8>H(X- $M%%%
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M1D$'T(J2@ HHHH **IWFJZ?I\]M!>7L$$UU((X(Y) &E8] HZG\*N4 %%!(
M))P!66/$NAG3[C4!J]E]BMI#%-<>>OEHX )4MG&>1Q0!J44Q)HY(5F1P8F4.
M&SP01G-5]/U2PU:&2;3KR"[BCD,3O"X=0XQD9'&1D4 6Z*** "BBB@ HHHH
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M.N+9KJ&6\P618Q8W';C=S]W&??- ')^/UU'2=6T7Q?:VK7]GI F%Y:+RXCD
M!E0?WE /X$].:O0ZSH5HD>N:0JWESXCDC%M'#A3<,J'D^@4!BQ/3'K@&S!%X
MGLIM3_T?3;V.YN7DMB]R\9C7 55<;#D84'(]<8[USVG> -2\-Q^%I=*EM+R7
M1TN8YX;AVA23SR&9D(5MN#T!'(H Z&\\5OHL.HS:SI\D,5KY*PO 2XNY),@1
MQ @%F!VCL/F[8-._X2.ZM?$.E:1J5C%#+JD4SP>5.9-CQ@,RO\H['J,\C'O4
M7B#0-2URUTJ9WMOM>GZG%?K;[F\M@@(V;\9)^8D-MZ@<"L[Q!!/I#:GXXU5X
MOM&G:?)#IUI$2RQ%NK%B!N=VVKT  XYZT 0/\0M1_P"$;UK78]#@-II5U+"[
M&\($Z1L%9HSY?)SNZX' Y)SC?N/%4'VJ2VM1&6@MENKN:XD\N*UC897><'YC
M@G;Z DD<9P],\'7\_@[1_#6I);P:;;K&]\L<QD>[93O*G*C:K/RW4GIWS4L'
MA74[#QGK&I0V>D7UIJ4L<Z37;,)K5U0)@#80PX!&&7TSWH Z7P[JD^M:!9ZE
M<63V4MPF\P.22HR<'D X(P1D X-9$OB^2>RUF_TJRCN;'2O,62>:8QB9XQEU
MCPIR!C&XX&>!GK741JZQ*LC[W  9@,9/KCM7 VW@W4K7P*O@^2[MK?3R\D<]
M\DA\V6%Y"Q 4J KL&VDDD#)QG/  SQ!K%YXCU'PCIVG10G3M6"ZE,)965VAC
M59-C@*0%+,GKGIP,UW<[VVGVUU>2*D4:J9IW"@9"KR3Z\#]*Y;0]-67QWJ.H
M11".PTRRBTBR ^[Q\\N/I^[7ZJ1VJ]XYTK5]=\)7^D:,]K%/>QF%I;B1E"(<
M;L;5.<C([=: .4^'%[<+I%F+G1;D3>(KNYU*XN)%0PA7RPZ,3ROE@ @=3Z5O
MOKHT#Q!9^$=,TJ)XTT[SXB)]NQ5(10PVX4?>.[)X4\$X!GDM/$HLK+3K&TTJ
MPMHQ'#),MY)))'",!A&/*4;MHP"3Q52^\*:I/<>+=0@GM5U'5;9;.P=F;%O"
M$QR<9!+,[8&>BT 4]-^(USJ.F^&[Q-&4+J]X+63_ $G_ %9.\[D^7YP%3<<[
M<;@.3G&HOBG4[OQ/K6B6&DV\CZ;'$QN)+IEC+."P5L(<'&#@9Z]15;_A$9M.
MU?PNUG):QZ/H-I+&?,)W[V55WXQ@_*'&21@L3STK*\*6>M:UX4U"[@$%F/$5
MU-=M>&0M+' YVIM3;C<(U4#+8&<\]* %U77T\;^"O#4$5NT'_"1WD4<L!;<5
MAC8R3<]QB,C/<,*ZA?$4M_J>HV&C6L5Q_9V$N9YI3'$)<9\I2%)) QN/1<CJ
M>!03PI<6?BK0Y[ 6L>BZ3ISVL,;,QD1V9<D#&#E$"Y)[D\U!:^%M9T_2=:T>
MRN+:*/4KV>X_M NQDC28Y;Y,8+C) .['0^U $EKX\^V67A?48=.']GZY,+<R
M-/B2"0JY V[<,,H1G(^E+K_C.\T*UU2=]*AD6UO(+6WS=[?/,H3T0[2-V2/0
M9S4.L^'HUT?PYH7A]X4DTR^@FB#G<$CBR'9L=^2.V2:T-4\*M?W_ (>021MI
MVG7;WMPLA)DFF"GRVX&#\S,QZ<@8'H 9\GCRZ35-;L?['4/I]HETA>YVY5E9
MCYOR_N\!03C=]X#J:T;?Q;YVBZ#.;)AJ>LPK)!8^9]W*!V+-CA%!Y.,\@8)(
M%8NH>"-4N- \7)%/:G5M?N?]8SL%6V!5%C+;20?+#=CRU6-9\)ZE-XCT?6+6
MVTN_2ULWLI[&\+1QA6(8-&=KX(QCD=* $OO'UQ8Z#K.IKIMO<)87<=K"Z716
M*Z9MH.QBG\+-M/&/E//%:=AXGN[SQ?-HC::L<2Z>+V.<S'<<OL4,FWY=V&(Y
M)P.0#P(]8\-7FN-H4%VUF+&SO1=W,$8(!V*?*C48^8!B"<XSCIV$ \.ZVFJ^
M+]0CGM$GU.!8K!]S$ILBVINX^4!RY.,YW=L<@$W@35]5\0:?>:OJ"P+;7-U(
M+)89"0(D8H."HZE2V>^[H !727EI!?V4]G<H)()T,<B'HRD8(_*N>TW2]=T+
MP;I>F:8FF?:[40PLDS.8A$N ^& !9L G. ,GI744 >?:O#$GQI\,(L:!!IEW
M\H4 ?PTSQ?9QZ9XJ\&?V99Q^8^IW,BQ;MBEV@?))QP,\G /?@FM74O#^KW7Q
M'TGQ!"ME]BL;:6W97G<2-O[@!".,#C-6/$FAZEJ?B/PY?V8M/(TNX>>432LK
M-NC*84!2.^>30!GV_CJXL[3Q&-<LX4O-$GBB9;1V9)O-53%@D9!)< \5;TWQ
M1J,WBF+2;JP\VVN(&ECO;>"54B=>L;[QW'1LC/H*R[[P)J.KW'C);J>VMH=<
M-M):RP2,[P20*H4L"H'WD!X/M[UM^'HO&#/'_P )++I:) N!_9Y<FX;&-S;@
M H[X&><<C&" 8OQG_P"29WIQDBXMB!_VV2MU]1&H:O86%SH-Y K,9TGN%3:C
MQX( *L?F.?R!JM\0_#VI^*?"LFD:8;1))98W:2YD90H1U?@*K9SMQVJ[.?$]
MT88EM-+M(VD7SIDO9)76//S!%,2C<1D D\9S0!C7GC'5[#Q/=>'Y]-M_MDT2
MR:2RLVR\^;#[CCY-@Y/7CGT!T]6\226.IVVCQ>3]ODMC<RR-%(\<:@A1\J\G
M+9QR, 'GH#E^(O"6K^((+F],EK;ZW;7"R:/,D[%+95Q][Y.K?-N&""-H["C6
M-!\4OJ^F>)M)DTR/68;4V=[:32.;>>,MN^5PNX$-R.._Y@#]/\<W=WIUC'/I
M+VNL7E_)81P3!DC8HI=I@64$Q[!D<9)X]Z;K?BO7_#^@:_?WND0$Z44:&8.5
MBO(VQDJ,DH5)P0<T:[X8\1:OIVFZBE_91>(].O/M<(PWV8 KL:'^]M*]6ZDY
MX&<"75O#^O\ BCP9K&G:O/96UY?0>5#%;%FAA(Y!+$ L2<9XX & >20#0OO$
M-U:>,-)T5;>%XM2MIYED+$,C1A3@CN#N%<SH7B+73X*\3ZQJ$-E?M9W-[F$N
MR*PB)!7HWR[5P!W[GO6BFA^)[[Q9X>US4%TJ!=/@GAG@AFD<_O @RK%1G[I.
M"!CU.>(;7PEKMIX9\4Z(KZ<\6I2WCVDAD<']^3]_Y?EVY/3.?;N 6;CQ;>V%
MIX2N?L5JFG:QY$,TF2/LTDB;D '0J3\HZ8XJ_J?BA])75[N:&-[*Q:*"/82'
MEGDV@)WXRZ<C/WCQ\O,-WX5FU3X:IX:O6BCNTL8X5EB<LJ2QJ-C@D \,H/2D
MU'PA-JG@!]!FOBFH2*LS7JK_ ,O0<2F3'IO'3TXH -+\3ZC/XI72+NP,EM-;
MF:*^MX)4C1P>8WWCKCD'//H*M^)_$T7A^?2X)IK>U6_F:(7=UGR8B%+ -R.6
MZ#)'?GC!9X>C\7NZ-XEDTN-85P%T\NWGMTW-N VCK\HSR>HQBK/B"PN]1\B!
M;*PO].=72\M+QL!P<;2ORL,@@]<=: .3\:7-_-IWA"XN[6'[8/$L(6.&3*.!
MYH0ACV90I]LUKV'BO5OMWB/3;_2HI=0TJW2YABL92PN5=6*H-P!#97'3O6/'
MX"U:ST30M/LI+0Q:=K?]IB*:Y?;#$"^V!&V$M@-U..G2KFI^$]?O-9\4WEK=
MVMG_ &MI\=K;31S.9(G0-@D;!@'=C@Y'O0!=TKQ;=3>+K?0+Y+)II[!KLFV<
MDV[JRAHG!)R?F'/'3I7(,J_\*U^* P,?VIJ)_P#'5KH=-\,>(8?$N@ZK+%HU
MK#8V$EE-;6SR$*&*'*$J,YV]"!C/5JB'@[73X2\8:2W]G"?6[RYN(6%PY6-9
M0!AOW><C';K[4 =IHW_("T__ *]H_P#T$5YEHFK^(-$TSQ=?Z1I-G>6EIK]_
M-<++<%)'4,"PC 4C( SR?H#7I^E03VVD6=O<K&)XH5C<1L67(&."0#V]*Y&U
M\,:]8VGB32[=K$VVL7MQ<I>-*V^!9OO Q[<,5[?, >^* ++>.(]1:VBT?8'F
MT^*_,EQ%(ZJLN?+4J@SD[6R<\8[YK7\*ZW<>(/#\&H7>FSZ=<L626VF4@JRG
M&1D E3U!QT-<W<^#]:\/ZO8:CX.ELF2+3XM.N;/4&94DCCSL<,H)##)[8KLM
M,BO8K%/[1GCFO&):4Q B-2?X5!YP!QSR>O>@#E[/Q1XCU/Q)JFF6FD:>(M,O
M88;B22[;F)U#%E^7E@#G!P.V3VJ2?$&[DM+/5M/TUKW3;BX$9@A@E:<1%BHF
M!"[3Z[?3O6OX=T/4]-\3^(]1O%M/LVJ3QRQ"*9F=-D83# H!SC/!K(\.^&_%
M_AR/_A'[>]TQ_#\<C?9[IM_VJ*$DGR]N-I(R0&SQUP>E &A!XNGU#7;[3K V
M1GL;Y+::RF8K<&(E=TPY^[AB0,'('7M5*3Q9XIO-2\0Z?I&A:?)/H\J*?.NV
MQ,K1AP%POWB#WP!ZFC7?!U_XANXY+JVT^*\MK]9K/5X96$\4(DW;" @R=N5Q
MNQSGJ.:VA2:JGC[QX-.MK6;=<6P!GF9-C_9UP2 IR/R/'OP :.E>/H_$5KH"
MZ5 JWFKV\EP5G)*VR1G:Y.,%CO\ E XSR<C%5KWQ]?:?IGB=)M-MVU?P^BRR
MQ><RQ31,NY9%.TGH#E3T(QFH[7X?W/AX^&KS0YX9KO2(9+:XCN"8TNHY#N?!
M .TAR6'!'.#4FK>"]1U33O%4X-FFJZ] EJJ-*WE01(I4?-MRQR6)X'4#MD@%
MRV\5:LGB;1=/U'3K6*UUFWDDMGAF9I(WC0.0X( Y![$X/<]:=H'BZ?Q#=QFS
M-D\*W4L%Y:[B+BS";PK."><LJC&!C=P3C--N/#VLSZ_X1U#98K'H\<R7"_:'
M)8R1A/D^3G&,\XJH/!U_?:_HVL7MMI]IJEA/NN-1LY6WW<6TC8R[%SG*YR3C
M!QUH S?$&M2:QX%^(<$^GVUI)8>; ?);?YI$2L')(&3R.W:M"T\5:UHUYX>M
M=7TJUCTC5/+M;:X@N"\D4I3*"12H'S8/W2<>II1X+U6YTWQK97,MG"-?D>2!
MXY&?R\QA &!4?W<\'O5Y/#^J:L=!CUF*TM[?1Y4N-EO.TIGF1"J')5=JC);N
M2<#C'(!CZ1J]OX>U#XAZI.A:.WU&,[$ZNQAC"J/<L0/QK:T_Q1J4GBFVTJZT
M_P VUNH7D2\MH)52!UY*2%U Y'1N,D8P*S9/ NH:E;^,;2_FMH(=<G6>WEMY
M6=X615"E@57H4!X/M[UL>'8?&1DB7Q)-I0CMUQNL"Y:Y;& S;@ HYS@9R<=
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M)D9C8$G! /L>O Q705QV@^$6T[QA<:]'9VFEI<6GDW%I9REXYY=P;S"-J@8
M(!QD[CG'?L: "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MD-@$-TY(S@ '>4A 92#T/%<1>^*/$L_BN?0M'TW3Q)_9D>H0O>R2+@,Y7:X
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M;<A&[EB3G)XXQQQSVM% ',6.F>)-1TZ[@\2W>GJTUJ]LL>FJ^SYQ@R,7Y)]
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M=@ A7)X/1?6MN@".::.WA>:5MJ(NYCC.!5;2-7L==TN#4]-G\^SG!,<FTKN
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MS4K36-,M]1L9#):W"!XG*%20?8@$?C7$^%+O7I+OQI-+J%M.]MJ4D<:R6S
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MFL=.L=,M_L]A9V]I#G/EP1+&N?H!BK!( ))P!UKS*?Q?XM/A_P 4ZK$^DH-
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M,7-]K-B7T,LJK#:-ME0Q^7SE\[B.^0!Z&KUCX4U'39O$BP:C;M::M/+<QQO
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
1HH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>22
<FILENAME>exhibit1016-arvinasxamen002.jpg
<TEXT>
begin 644 exhibit1016-arvinasxamen002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUO99KB.8V\+A&A**!]Q2 V#ZU6LO 6I7\>HP0J_AO29[FWN(]-<I=!V0'>7
M8J%8^6=H8YV<]<4 ;UM\08;_ ,/1ZG::9.T]S?O8VEK*XC:1EW'<Q(^0;59C
MD' '<T77C35+;3=/?_A'E^WWNHBP2!KT")LQLXD64(=RX7'W0<Y]*Y]/!6LK
M8B;5[=-9^S:Y/??8=D<?VB)Q(I89;:22ZOM8@?*0>M5[[P?J$^FQ21^%F^P-
MKZWPT1)H5,4 MS&?XP@+/\VU6XW?6@#N]!\17.IZIJ&E:CI@L+^R2*1UCN!/
M&R2;MI#X'/RG((':HO%WB]/"RV>+%[V28O)*B/M,5O&-TLO0YV@CCOGK7.Z'
MX3U1=1U*338+KPCI]Q%$!!'+#/(\RLVZ3;ET4%2J^IP/2I4\$:IK'B&^N]7U
M?4X(X+5=.M)H7@#W,1&Z5W&Q@-S$#  X3I0!T.O^)9M,N=/L].L$O[N^222(
M/<K!&$C"EB7(//S+@ <\G@"J-]\0+*T\+:;K4=C=3'4%1HK=5Y0%E5B[#*JH
M+#GOD8SFN:?PUJR66CV>NZ!-K^G:6EQ:+;+-%E\,H@N"K.H;]V"I!.5.3CFM
MM] UE_A9%H\L7F:B#'B$S!BB"<,J%R<$J@ SGG;WH TM6\2ZI;>*$T+2=%@O
MIC9?;'DFO?("KO*8'R-DYIMIXIU/4;*X%EH!;5+.Y^S7EC-=K'Y1VA@P?!#*
M05(.!U]JJZM%K.G_ !!76;+0KG4[1M*%H3!/"A5_-+<B1UXQZ5!'I'B%=#\5
M:DENL&MZTP\BV293]G41K$A+YP6 !<X..PS0 I\>:DVD6=W'X?B:>]U4Z;;Q
MF_'ER85R9!($/R[D9>G.,YQ5N#QE?EM4LI_#TW]KV @/V2UG$R2B8D(1)@;0
M,$MN P!GFJ7C3PL9O#WAW3=-T4ZC9:;?PO)9)(B$PI%(G5V4=67O698Z7XBT
M :UJ'AOPR;!+B&*.#2I;J)]T^XAYSB3:H"8&T-\V!G% '0P^+M2=-1M7\.2G
M6;)X5^QPW*R(ZRYVOYN!A1M;=E>,=\BD7QR$T:YN+C3)%U&"_735LHIED$UP
MP4JJ2< C# DD#&&R.*JZ.FM:9HEY+;^&KMM2>9);IM0N8#+?YX<J4<JI"C"J
M<*. *R(_"NK/93WVFZ.NF):ZG;ZAINC2RH!^[4K*/D)2/>&; !P" 3U- '7Z
M5K.M2ZJ-/UG0A9M)"9HKBUG-Q#P0"CML7:_(P,8/.#Q5$?$+2S=>(E6*9K70
M[=9I;A1D3$EPRQCOAHRN<XSD=LTV2;Q3XE>XM$LI_#E@UI)&UQ.T<MPTK8 ,
M81R%"C=R3DY&!QFL;3O ^KZ;?:Q;RR6VH:7)HL=E# T"P).5,V(R58LN-PRV
M.=_J* -Z+Q=?Q"X@U+P]<0:@MH;NWM+>99VG0$*5! &&!901T&[.3SBWHGB&
M\OM7N=)U721IU]# ERJI<B='C8LH.X 8(*D$8^A-<AI6C:_I]U=:_::/J;WM
MKIC6=I::IJ*3232,Z-PP?:L:[!R2&;)]JZ'P5:W\$EY-JND7\&HW.V2YOKN6
M!O.8<!$6-VV(N3A>@R>2220#KJ*** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JG;Z3IMI=RW=MI]K#<S?ZV:.%5=_]Y@,G\:N44 %%%% !1110 4444 ,
MEABG"B6-) K!U#J#A@<@CW![T^BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJUU:V.HP733QQB/K&@*D%E)'7FMRW)TV^O)Y-<N[VUMX?W\$D:R-$^001Y:
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M0J2O!((R.:\O\)7.A:CI6B^']4TK56\0Z6\*M8SO<[(9(L*)@<^6J@98'WP
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MC1%G(1 =J@GDX '&3TKM)->TY;*TNTG,\=X@>V$"-(TRE=V55021C!ST&>:
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MJ<]H)(8$=MEV?(R_FG!#8 +<D<U?7QYX=?4O[/2]D>Y%VMFR+;2';*W0,=N
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MI;JXV%5"R(%6,D@?-G)*]1MYQD5W=% '#_#J4>?XJ1ED1I==N9XQ)&R[XR$
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M Y=RUP6 '&6XY)&?K76^/+N*YM/"<D DF5=<M)W\N-FV1J6W,P X [YKOJ*
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M8Z49EE6XF:"+SIUMH6E,4?/S-CIT/'4X.!Q7F]C:7%Q\([WP>VGW/]M32W$
MMY;=U"%YV99"Q&W8 0V[..,#GBK4ZIX7\9:G'KFDZGJ&FZC#;FUN[2&28!DB
M$;1NJ<@G;D?4T >EV6H6NI:=#?V<ZSVL\8DCD3D,I&017,7'Q/\ "UO#).]U
M=&"&X:WGE6RE*P,#@^8=OR#/'.,X..E;^@VL-GHEK!;Z>NG0JI*6BX_=*22
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M)_?MD31CWVH6C]/G/]V@#O\ 7]<TE-+UJVOKB^MH;6#%U/;12!HE9<Y5E!Y
MYXZ=ZHW?C"WTG4?#&E06]]<Q:E$SB<Q/(QC2$L.G+.3M)ZX&2:K:Q!=R?"K7
M9IK2;^TM5LIYGMXT:1Q))'A(\ 9)5=B=/X:SKSS[:_\ ASJ9L;Y[:TAFBN/*
MM9&>)WMPJAD R,L".1@=Z '6'B:'P_XQ\;#4;G4;FVMI+5XXD22X,*&'>Y
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MCN*W* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "N.^)EM<WOA(6UG:7%S.UY;.$@B9SM2568
MG XP :[&B@#S[5].NM6^(LYB@NXK6Z\-S6 NS;N$25Y P!.."!S^G6LJ33=2
MUOX3VW@B?2[NVU9%@LI&>!O)18G7,PEQL(VID '.3C%>K44 <1XIT35#XMTG
M5-&5@UW!)I>H2 \QPL-ZR_52K8]V [U%X-\-WVB:YJ&GRQ;-$TZXDETGT(G
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M<AD1AOY^48!Y-<Z;*_?P5\1+0:9?_:-1O[J2TC-K(#,LD:JI''<@_3O7JU%
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M(<E!G+<#\>V:ZK4OM5Y\1_"FH+IU\EM#:W:S.T#$1&0)L#$9 )VGZ=\5W%%
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M],WPW:?<G'2WE'#GVC<*^/K3?'&FO%I/AFRTZRN9H[+5[*4K!$TGEPQ-\S'
M[#\37<44 <5!%>6/Q6U"\;3KN2SO]-MTCN(X\HK(S[@Q['# XZGM7+#0]8NO
M!NL?9M*F>\M_$LFJQ65U$8Q=P^;N"C<,'<N>/45Z]10!Y_;RV.JZ7J%W#X G
MM8_L;PSQ75BD$]P&(S$@'S$8W9/ SMQWQ)X,TR_T?Q#<6EE=:G/X8^QAH4U.
M)UDMIMW$:%P&*;<\<@8'-=Y10!Q?BFSO[3QKX<\206T]W96BSVUW% A>2-9
M,2*@Y8 J,@9..QK%UO1KR_\ ^$XUNWL[O9J6D#3[.#R'$D[A'RQ3&Y1E@HW
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MLPKOJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML2C$<@$>W7BN6^)NO0ZO\-=?>SL+JXLHMT(O490GF*X4D#=N90V5)QUSU'-
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M4S30Q8_U\J$!,D]%RJ9)Z**S;G3=6A;X?:C%I-S.=*1XKNW0H)(R]OY8/S,
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M;&*ZVB.Z5!'\IYXSM/!QVKUBB@#E?"]Q<7\_VA_"7]@HD960SK&)'<XX39_
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M?W<9 9AY+YQD@=/>@"[IWC^RF;6(-6L;K2+S2(Q-<V]SM8F(CAT*$A@>G'?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM)O#MSJ5U93VUS;7S:;)9;E=VN0P41H>C9++@\#G/:L3?,/C78S7NG0V<O\
M8D[/+'*'611(F,M@'*\]1Z8)H ]'HKB6^)6G)-I4K1QG3M3N%MX)X[E6D5G^
MXSQ=55O7)(R,@5/:>-;K4-<O--L_#=])]BODM+J4RQJ(E90?,^]R,'.!DXZX
MX! .OHHJMJ-E%J6F75A,6$5S"\+E3@[6!!Q^!H LTQY8XR@=U4N=JACC<?05
MY?K/AG0;?XL>$["'1K!+26SO#+"+=-DA55VEACDCU-2^*=$T[PYKW@Y]-T\
M?VQ(T<,*#(W0N2BYQA2PS@D 9["@#TZBN4L_'-N;?7FU:RDTV?1&7[3$TBR9
M5UW(58<'=TQZTEAXXMKGQ1;:#<0PQSWD+36TEO=+.K;>61L?=<#G'(/.#0!U
ME%>??&N&)_A;JDSQJ986@,;E<LF9XP<'MD$BKJ6_A*XUC3;2TT,6UZ9?/BF7
M2WMBGE_,?G9%SG@$9Y!- ':45R%WXZ^PZ[?Z-<Z7)'?00)-:1^</].#-M BX
MZY.#G&/IDC1U3Q+%IDUI92K;KJ-S$THBFN1'&BK@$LY'JP P"3Z8!( -ZBN0
MTSXA:?JFD+<PV\GVUM0;3!9AU8FX') 8<%=N6W>@]>*+_P ;SZ5IVNW%]H=Q
M')HP228*^8YHV&0T4A4!B.A! Q0!U](S*BEF8*JC)). !6%<^)A:^(-&TIK-
MV.K0RRPRJX^4QH&8,/\ @0Q7.Z1XIO\ 4O#WBJ\UK1UGM+.YNX'MX95;*1@*
MT>&QD8#$DGG)X[4 =\CI(BNC!D8 JRG((]13JXV+Q9;Z7H_A(VVD>3IVL);P
MVY64*EJ70,B-QTQP".I':M:_\2PZ9+JCW<6RRTZ%))+A7SN=ND87^]T[_P 2
M^O !N45RFG^.+:Z\40:#<0PQW%U T]M);W2SHX7[R,1C:X'..1UP:U]9UAM+
M>QAALY;JXO9_(B5<A%.TL6=L':H"GL>W% &I17)IX]L8_#NLZM>VTL!T>Z:S
MN848/NE!4 (>,ABZX)QUYQ4W_"67$/BB'P_=:+/]LGMC=1M;SQO'Y8.&R7*'
M<"1P >N?6@#IJ*XO2?'[:I U\VA7=KI4#7*W=[-+'MMS#G.5!RV=O5<@'C)Y
MP^W^(-F^MZ5I\\$<::KD6LD5TDK*P&0DJC[A(Z8+#/&: .QHKA[KXF:9;+:7
MA2*32[FY%LL\=TIE7)*B0Q==A(ZYS@@XK5B\4M=W=REA8BY@M;];"X99P)(W
M+*I8IC[HW=<Y(!.,<T ='165XFU.YT;PQJ6IV=NEQ/:6TDRQN^U3M4DY/X=.
M]8VE>*;A/#OA[[;;>9JVJQ1K;Q+*/WQ\H.\C''RJ!DG@XXQDD"@#KJ*PM(\2
MIJ&LW^BW5LUGJEDJR/"7WK)&WW9$; W+V.0"#VJ?5-9ELM2L=.M;%[FZO%D=
M69BD4:H 27< XSN  P<T :DDL<0!D=4!8*"QQDDX ^I-.KROQ7KMGXD\+^&=
M<CL766'Q';1^65#R(Z3%752.N2O&.O%=5I?C*6Z\07.A:CH=WIVHI;FZMXGE
MCD%S$#@[64[0P.,@G\: .GBECGC$D4B2(20&0Y'!P>?K2^;'YHBWKYA7<$SS
MCUQZ<UQ?A_Q3H]MX&L=1T_26LH;N[>UM-/CVAGF,SKM]!DAF)S@#/I6;:3FW
M^--[<W]E#8,GAPR321R!TD43@[]V > ,'(SQZ8H ](ILDL<,;22NJ(HR68X
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M UFVMRKQZ]:1E90"\+B8*ZY''XCJ,5ZG0 4444 %%%% !1110 4444 %%%%
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M"5)8I!N22-@RL/4$=: /+)_"'B*XT?57@L?(U"'Q.==L8IIDVW"C&$)5CM)
M/7CISZ:\FGZYKOC:PU2YT&:PL3I4]E<>=<Q,\;2,IR C-D<<?KBO0** //\
MPC%XQTJRL_#=_HEMY-B%@76%N4*20)P"(_O;]HQSQGGV.EX4T[4K+Q+XIN;W
M3Y+>WU"\2>WD:2-MRB-4((5B0<KGZ5UU% &?H]WJ%Y9-+J>F_P!GSB5U$/GK
M+E Q"MD<<CG':M"BB@#B=:TS5KCXG^']7M],EET^PM[B*:82QCF0 #"E@2!C
MGC\ZL^+M-U*^U[PO<65A)<0V%\;BX=9(UVJ8V3@,P).6S74S7$-L@>>:.)2P
M4%V"@DG '/<FI* /-=3\(ZQK5_XZC^SM9QZLEHUA<O(A7S(%_B"L2 6 [=,_
M2NA\.7_BC4)(EUKP]!I(A4^=(+E)?/;&/W87[JY^;).> .<DCJ:* ..^*&D:
MGX@\"7VCZ39-<W=TT6W]XB*H65'.2Q'93TS6A<ZEK%PL$=MX;NHIC(H\^ZEM
M]D /#/A9&)(4G  YZ5NRW$,+1K+-'&TK;8P[ %SZ#U-"W$#W#VZS1M-& SQA
M@64'H2.H!P?RH X7Q3H6MZZTNL6EK+:ZOH\P;14,D>)>F\N0V-KC*D$C  /4
MD4FLVWB==:TCQ9INB+/<K:-9ZAI,ES&K;&8,&1\E20P[GD>G;OZCBN()VD6&
M:.0Q/LD",#L;K@XZ'D<>] '"^(=*\3ZMIFEZU:V-O!K&FWXO(=-,P(:+84:)
MI!\N\@DYZ#..<9-G6+/Q#XO\$:W9W6FII<UU:-%;6DDZR,7P3EV7Y0"<  $]
MR>N!VM% 'GJV?B34O%/@_5)M -G!IT5S%<K+=1LR%XT4'Y201D<8)/!R!QDT
M_1==L=$\9Z6^E%Q?W5[<6DJ7$?[[S_N#!(VXR<[L=.,UZ%10!Q+>%KK5?A+:
M>'KJ)K348-/ABC)=28KB)5V,&4D8W*._2EU#POJFL?#>ZTVXFCAUV]5;J63^
M!;D,KA>,_*"BIGGA176'4+(7PL3>6_VLC<(/-'F8]=N<XJS0!R_AR_\ $^H2
M1#6?#T.D"%3YSBY2;SVQCY OW5SSDG/ '/)I/&-OK<\^CG3;1[[3TN6.HV<4
MZQ/-'M(7EB 5#8)7//3D9KI8KB&X,@AFCD\MRC[&!VMUP<=#R./>I* /)I="
MU+3O"OC.PO=#LUBU6_#V, N@$E:01JB)M (8%<@G'(';)&MH]UJ%IXCMKS7/
M"^KQW4D/V&"^GN[:<(/O;,1D8W$<L1UQD@5V>LZ)IVOV!L=3MA/!N#@;BK*P
MZ,K*05(]0<U4L/#VEZ&WVHSW4K1CY9K^^EG\L'CY?,8A>.,C!H YOP_X7U&?
MX?:[X>U.U>PEOI;S8[.CC;,S%3\K'IN&15OPQ/XOEAM=,UK0;>R^S*$GU!;I
M)%N HQF-!\P+<9W8QSWXKL8Y8Y55HY$=6&5*L""/44^@#SKPG9^,/#UE#X6E
MT6WFM+5C%;ZU]I3;Y&>"T7WBX'&.A..<<TS5O"U]J&NC5K#29]*UZ*_ &I6\
MZ+#<6PD_Y:J&RV8^,%<YQSCIZ110!F^(K"75/#.K:?!M\ZZLYH(]QP-S(5&?
MQ-<0N@>(19>#-872]FH>'T-O-8&X0M-$\2QN5;.W<"N0">1U(/%>DT4 <MIF
MC7-QXYO/%-U;/:;K"/3X()&4N5#EV=MI(&20 ,GH<XS47B>TUNX\1Z2\&GG4
MM$$<BW5HLZQCS3C8[AB-Z 9^7GKG!(%==10!Y1:^$O$</@^"R;2H5N-/\1+J
M20I<H?/B$[2$(> ." -Q'?(%=9'IEYJ7C&#Q)=6,MK%86,EO;VTCH997D(+$
M[6*@ * /FY).<8&>KHH \FMO"'B2#P+H2Q6 36-$U9[];26=-MRC22,5#@D
M[9.I[@UJSZ-K7B'QC=7MUH\NGZ=>^'Y-,=I;B)I(W=R<[48YX]#Z=.E>B44
M<+X3?QC;VUEHFK:%;0"R"1/JJW*.D\:8 *QCY@S  <XQDGVK5\?Z+>^(?!&H
MZ9IZHUW*(VC5VVABLBN1GMD*:Z6HX;B&Y0O!-'*@8J6C8, 1P1QW% '+RZ=?
M>(O$^AZI=:?-IUMI/FS;+AXVDEE=-@ V,P"@%B23R<<5GS>'I/\ A:+26TZC
M3;J"._U&VQUGB8K"WMN//N8:[J2-98VC<95@5(!QP:R] \-:5X8LFM=*MVBC
M8Y9GD:1V],LQ)P.PZ"@#6KR:3PQXE'PDO_"@T?==K<MY,BW,>V93=&;=R1@;
M>.><]N]>LT4 <7J>DZCJ7Q TW4#ILZ:<NF3VD\IEBRC2%2. V3C:<XS^-4O"
M,/C'1[&T\-7NB6Q@LML*:RMRA1X%Z$1?>W[1C!XSR??T&F2RQPQ-+*ZQQH,L
MS'  ]2: ,+QQ8WFJ>"=8TZPMFN+J[M7@C0,J\L,9)8@8K(\2Z-JVI^!-*BM+
M G4;">TN39O*@+F)E+(&R5R0#@YKM4=)8UDC971@&5E.00>A!IU '#V%IKTO
MQ(D\07.BM;V4NCK;!3<1M(KB5GVD XS@]CCD<]<8-IX3\30> M*CM[%(=;T?
M59+^*VGE0I<*SR$IN4D#*28R<<C\:]6HH Y S^(=5T*[DOO"L$(94C_LN6XB
ME:X4N/,RWW -F<#/)ZXXK-T+0]5\)?VY/H6F71TQH(VL=&N[M.)\MOV-N8(F
M"O!/4'MBO0:9-#%<1-%-&LD;##(PR"/<4 4]&U%M6T.RU%[=K=[F!93"6#;"
M1G&>A^O>N5\.>']0;3?&&G:G92V<>KW]U-#(9(W_ '4J!1]UCAA@G'TYKN0
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M)-$<D<T22Q.LD;J&5U.0P/0@]Q0!QLND:G=_$C^TI].=-/ET-K"29)D(61I
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M(&1^= $E%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML:9:6T=BBQR:A'="3[4J#"[(\94G R6QWP,GC(;P=K.H:)XOLFC%C<ZAJO\
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M2>=Y\@)QM&,#CJ<@#@8K5O-<UA?B?::%#;6S:>VF27+;IRK/^\C4L1M/W<D
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M\-:?#;0:KIMLDYO[4S")#/(V\2$,/G126 !'H<9H TF^(\8\*6FN)I$THEU
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M]W;R&944A=O!SG ^89/Y U@^)/#OB75KKQ7;MI]M?0WUH8]+N9;D*ML#$59
MA!(8L2=PZYY(P!5RST?7!XH\+ZA<Z8$BL-,DM;C9<(VUWV8QR,XV<_7C/6@"
M23XA3Q^$-1UTZ$YETN[DM-0M!< F(H0&96V_,H!!Z#C/I71OK#_VIIEE!!%.
M+R%YWE2;B-%V_,/E^8$NH'3-8WA'0[NUB\2V^KV 2#4]4N+I%9U</#(JC:V"
M<'@Y'OUJ#X;Z+/IFE3O<7?VM$D>RL93U^R12.(Q[GEN>XV^E '1ZUK46CQVJ
MF,S7-Y<+;6T(./,D()Y/8  DGL >"<"N3\6ZC<:KX*\9Z=JFBM;26%@[I*<R
MP39B9E:-RJY*D<\<&M3QSH>J:I;:7J&AF)M4TF\6[AAF;:DXVE6C)[9#'FJ^
MJQ>)O$/@O6[>ZTF.RN;RR>UM[%;E)2&92"[R<#'(X&> 3SG  (M!\4W%K-X9
MT:\TAX+?4K(+:71G5BSQQ!B&0#Y01D@Y/N!5B3QS)!+ILMSI#P66H:D=-A:6
M4K.'W,H<Q%1\A*]=V<$''-5)M%U>34O TXTYPFCJXO,RQY4M#Y7R_-SSS]/?
MBL%_#'BZXT_3C>:3:W&JV6MQ7L]\]XNZ[C61B-O'R*%(&TXQC@'- '4S^,]0
M;6M=TG3_  [+<W.E1Q2$O=)&LJN&;K@XX7@<YSSC%30^.;2[TGP[=6EL[SZ\
M0+6"1]H7"%W+M@X"@'H#DXJMI^F:M:^,O%.J2Z<QM]1M[:.W*3(2S1(X;.2,
M EN,]ASBN8&D:OIGA'P;H0TN*?6]/E:;R4O%BE58U.9(WPR[<N@(8<YQCG(
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MA!+ ;D/J!GCI0!F_#G7(M)^&GABTCMS)?:A/<0VMMNV\B65F+'G"JH))P>V
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M$$GER*Q7<> 2 >M5;G3M8NO'VA:R^G;;:ULIX9]DZ-M:0J0!D@G&WDX[\9H
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MH8Y!VA0JX'.26Y QSS8\(:^/A+%X8^QQ?V@MV)B?/7R]HNO/Z]>G'3K7J%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/>VD5PT:G(4NH; /XUQ.E_\ 'M\3O^ON;_TF2NH\!?\ )._#7_8+MO\ T4M
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MC)->B_MH(8TG*VK12ES)%@89A@;3G/%<9)IMG)\=!*\"ESH(F+9.=XN  ?P
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M D,2+'$BA$1!@* , #'2L35];GAURRT+3Q#_ &A=P2W DG!,<:1[1R 0226
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M/,MV6=T\MNF<*P&<<<UGZAX$\-:IK?\ ;%YIBO>L LCK(ZK*!T$B@A7_ .!
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MIMN(8 2Q&XLS,>I9F)+'W)J_110 4444 %%%% !1110 4444 %%%% !1110
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M!J=PX$R.)HT:*' R(U&5Y(S\W!SFNC&G6)^.%W,;.!I1H<4X8H,F03L V?7
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M_P!L:<6$("@EER20."3@')]!5W7FM_!7Q$@\0?9@;/6;9[28(@R+I 7CQ[R
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MG'-:5 !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!071=
M,2PM[%;*$6MM(LL,07Y8W5MRL/<'FC4]%T[6#;G4+83_ &:030[F(\MQT88/
M##L>HJ_10!G#0M-&K/JHM\7[Q^2UP)&WE/[N<].^/7GK3M+T73M%BDBTZV6W
MCE<R.BL2"QZM@GJ>Y[U?HH XB[\/W5_\5/[6N--N/[.721:)=1W"QLLOFER1
MM<. 5./Z5T-SX8T6\TZWTZ?3XFL[=M\4 R$5LYW8!Y.><]<DGO6M10!0U#1=
M.U6UBM[ZV6=(6#Q%F.^-AT96SN#>X.:FL=/M--A:*TA$:NQ=SDEG8]69CRQX
M'))/%6:* *]O8VMI+<R6\"1/<R^=,5&-[[0NX^^% _"JEMX=TFT^V^38Q@7Y
M)NPQ+"<D8)<$D,2..:TZ* .>M/ OA>RDMG@T6U#6K%X"P+^63_=W$X]AV[5)
M+X,\-SZ^NNRZ+:-J:L&%P4YW#HQ'0L/7&:W:* $95=2K*&5A@@C((K'B\)>'
MX=&DTB/2+5=/D;>T 3Y2V<@_4<8/;'%;-% %.PTJRTSS#:P[7EQYDCNSN^.!
MN=B6..V3Q3=5T;3=<MH[?4[**ZBCD$J+*N=KCHP]#R?SJ]10!EQ^'-)BOY[Z
M*T$=U/&(I)8Y&4L@Z+P>@[#MVJ!_!_AZ30?[#?2;=]+W;EM6!*(<YRO]TY)Z
M8ZGUK;HH HZ1HNFZ#IZV&E6<5I:J21'$N 2>I/<GW-5]1\,Z/J][#>W]DMQ<
MP9\F1W;,>>NWGY<]\=:UJ* ,B'PQHUO/)/%9*)I(6@:0NQ;RR02N2<@' Z>E
M%SX8T6\L;*RN+".2VL65K6,LV(2HPI7G@@<#T[5KT4 86K>#/#>NWL%[JNCV
MMW<P@*DLJY; Z _WA['-2ZWX4T'Q&D"ZOI=O=_9SF(NO*>P(YQ[=*V** ,N_
M\.:/JFE0Z7>:=!)8PE6AA"[5B*_=*XQMQ[4RW\*Z#:27,D&D6B/=1""8B(?/
M&%V[3[8[=ZUZ* ,3_A$- %C:62Z9"MM9R":WC4D".0='&#]X=CU%:=U8VMZD
M*W,"3"&59H]XSM=3E6'N*L44 4-8T33/$&GM8:M90WEJQ#&.5<@$="/0^XI=
M)T;3M!T]+#2K.*TM4)(CB7 R>I/J?<U>HH SKW0M*U*_M;^\L89KNUSY$S+\
MT>?0_4 ^QYJK_P (AH/]G7.G_P!G(;.ZD\V> NVR5R<EF&>23R?7 ]*VZ* ,
M35_"'A_7K:VM]5TN"\CMO]29<ED'H&SG' XSVK6M;6"RM8K6UACAMXE"1QQJ
M%5%'0 #H*EHH S8M TR'5Y=6CMMM_* LDXD;<ZCHIYY [#H*B3POHJ7LEVFG
MQK)),)W4$B-I1_RT*9VE\\[L9SWK7HH SWT/3I-875VM@=06/REGWL&"?W1S
MT[XZ9YJ.T\.:1907D$%C&(;UF>ZC;+K,S?>+ D@D]R>M:E% &;IOA_2])97L
MK41LD?E(S.SF-/[BEB=J\#Y1@<"K8LK9;][X0(+MXEA:;'S% 20N?3+$_C4]
M% %6#3;.VL#8V\"PVWS?NXB5 W$DXQTR23^-9H\'Z NGVM@NFQBSM)?.MX0[
M!(GSD,HSP0<D$=,GU-;E% &!JGAZ,Q:C?Z3! FNSVK017%RS,IX.U7Y.5!YQ
M@CVKB=/\ 6LJQ1IX'31+V, #4(]1!\IA_&FPY8]P& ![UZK10!2BTFP@U>XU
M6*UC6_N(UBEG ^9U7H#5VBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BD!#*&4@@C(([T!@20",CJ/2
M@!:*** "BBB@ HHHH ***0,IS@@X.#S0 M%%,>6.-E5Y%5G.%!."3[4 /HHH
MH **** "BBB@ HJ.:>&VC,D\J11C@L[!1^9I);F"$(99HXPYVIO<#<?0>M $
MM%%% !1138Y(Y03&ZN 2I*G."."* '4444 %%%% !1110 445']H@^T?9_.C
M\XC=Y>X;L>N.N* )***:LB.6".K%#M;!S@^A_,4 .HHHH **** "BHTN())G
MA2:-I4^^@8%E^H[40W$%QN\F:.38=K;&!P?0X[T 24444 %%->2.,H'=5+G:
MH)QN/7 ]>AIU !1110 4444 %%%% !1110 444T2(SLBNI=<;E!Y&>F: '44
M44 %%%% !1110 4444 %%%-:2-&16=59SA03@L<9X]>* '4444 %%%-\R/S3
M%O7S NXIGG'KCTH =1110 4444 %%(S*BEF(50,DDX %"LKH'1@RL,@@Y!%
M"T4WS$\SR]Z[\;MN><>N*=0 44C,J(7=@JJ,DDX % (90000>01WH 6BBB@
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MPG(D+$X;'/ W**G\6VM_=?".'0Y+7R-4OX[:PCM]X<ARR@Y(XX568XX !YH
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M*22TW39D38N_$J%1M)7T+<\4 =;17-:9XJDUB6.6QL8YK%KR2TDE2XS)"4+
ML\>WY02O'S9PRG'/&7JOQ,L--MI=06.WN-.@N3;S,EVOV@8?8SK#C+*&SW!(
M&0,<T =S156^OX=/TNYU&8L8+>%IWV#)*JI8X]>!61I_B2>\MX[Q]/1K"6R:
M\CN+2X\\,%V_)@*/F(;H,]#0!T-59H[/4X9;:0QSHC@2*&R4<88=.58<$=".
M#7/6'C&6?6-&T^^TLVC:Q:O<VO[[<Z!5#%94*C8V&[$\@CM6#X5OH?#EGX\O
M(;"6:.VUR4I:VD>68F.( *H]S^')H ](4;5"Y)P,9)R:A:S@:\6[=-TR*51F
M.=@/7 Z#/<]36%9^*)I?$%_H5UIP34+6T2\5+>X$JR(Q*XRP7:V1T([@YK%L
M?B%JFI^'1KUEX1N9-/\ LLMP7-V@8E&(*!<9)P"0>^"/0D [ZBN?A\3?:M.T
M&[M+:.<ZN5**L_$:E"Y;.WD #GIR0.]7]<U4Z+I,MZMI/=NK(B00+EG9F"CZ
M#)&3V&: -&BN2/B^Z\[Q#IXTZ!=4TBV2Y""Y+0RJRL1\^P$$;3D;?3UJYX'U
M+4-7\&Z5J&I)&)[BUCE+I)N\S<H)8C V\GIS]: .AJ.&>*XB$L$J2QDD!D8,
M,@X/(]""*Y&QUG5-2^(6O:'=65JVF6EM;@*9<Y63S"6*E<$G &WH .IS7+>!
M/%$OAOX=Z#OT>1]+>]DM9+L2JOE&2YD52$ZLH) )X]LT >MT5R>N>.+?2YM2
MAMH[2XETU UQ'->K [$KOV1@@[FVD'G Y SG.-[1M5MM<T:SU2SW_9[N)94#
MC# $="/4=* +U%<?)XY>"33YKC29(;&_U/\ LR%Y)-LV_<4#F(K]PLO7=G!!
MQ3;CQO??VGK^G6/AR>YN-'6-WWW*1K(KH7R#S@X' YSWQ0!V507EI'?6,]I,
M9!'/&T;F-RC $8.&'(/N*Y63Q_$8O#,MII-U<QZ^A:$JZ*4/EE]I!/7C'8=\
MTS_A/9HM(\1W-WHQ@O= .;JU^TA@R%-ZLCA<'*]B!0!U=C86^FVJVULK!%ZE
MW+LQ]68DEC[DU9KG9O%(AUGP]8-9DIK<<CQRB3F,I'YA#+CTXR#5&?QR]J]I
M-/I,D5A=:I_9D<DDFV;>6*!_+*_<+#KNSC!Q0!UGGQ>?Y'FIYVW?Y>X;MO3.
M.N*(9X;F/S()8Y4R5W(P89!P1D=P>*XB&*.W^-FH20P+O?P]&[B, &1O/8<]
M,G  R:M>%];2[\,Q7.A^'4MA+?SPM:B146-E9]\C,H(&2O8'EA0!V-%<;;>/
MXVEUQKNP$5EHPVW%Y#/YD;3<?NERJY89 /8$@=Z?9>/+:7Q-!HMW':H]S;O/
M!/:WBW"?(,LKD ;& Y[@X/- '5S3Q6\?F3RI$@(&YV"C)Z<FI*\I\?:P_B#P
M19:G#I,9TV74;5K6Z>4>:J^<H$FS;\JL!@8;.&&0,G'J%W.UM9S3I"\[1H6$
M:$ MCL"2!0!-17#:?\0;R_\ #ZZZOA:^_LV2T$\4D<JR/)(7"",(/F[YW8Q@
M'M@G03Q7=-JFKZ.^G0+JEC9K=HBW1>*56R "^P%2"O(V^E '4T5PGA[QK<#P
M+HVJZTMNMUJ158/]("K([!F.XD (H )[\#C)P#K>&_&$&OZKJ>E-%%'>:?L9
MC!.)X94<9#(X SZ$$#!H Z6BL:_UTPZW#HEC;I<ZE);M=,DDOEI'$&"[F8!C
MRQP  <X/3%8&H>,)]0\%>)9["V-MJNE1SPW4$DN# ZQDAU8 [AC!4\9]J .P
MAOK2XN);>"Z@EFAXDC20,R?4#D4^6Y@@>)9IDC:5MD89@-[8)P/4X!/X5R_@
MO2+:31-#U:YTRWAU"'38X(IXY"S-$R*3NX'4C.#G'//)KDO$L\>@_$0W7BNP
MCGT&_N8_L^HRQB2*W46[H8'!!V@NV[T.23TX /6J:)$:1HPZEU&2H/(_"O/O
M%&I2Z+IWAOPKH,T[2:M(8HY[<AI$M4&YS&Q.-VT@!B<#.<\5<LKJRU70=?\
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M[@  #T/I5GPGXHM_%FD/?00M \,[VT\3,&V2)U 8<,.001U!H W,C.,C/7%
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M#8I-IMO8+%->^< 4=%55 3&3G!YK>/ Z9]J*CDGBA9%EE1#(VU S ;CZ#U-
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MGOBO1;>ZM[M7:VN(IE1S&YC<,%<<%3CH1W%%S=VUE T]U<100KUDE<*H_$T
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M:))YBEMZ.S$E<]#NQZ^U<J/"'B5/A4/"9L;8W$%RGE2K<C;(BW'FECD#;D
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MQSC)ZT :\7C27[3XBLI=.C:]T6!+ADM[D.DJLK' 8J-K#:001Z55L?'UW/\
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MG@OPU8WMEH\<ND*Z?:=LQ0VD;MDN%"'<B[N@Q@>U7O\ A*A!H&HZ]>VR1:9
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK,U75UT
M^>RLXE$M_?2&.WB)P/E&YG8]E4<GW('4T :=%<UI7B"^N_&FM:'=PVR0V$%O
M+'+$6+/YF_.<]/N]/U-:6N:H^BV)U)XQ)90?-=XSOCC[R#U"\DCTR1R,$ TZ
M*:CI)&LD;!D8 JRG((/<4RYN(;2VEN;B18X8E+N[=% ZF@"6BL7PIXA3Q3X>
MAUF*%H8+B241*_WBBR,@)]"0N<=LUM4 %%%% !1110 45S_AC6KW6IM9-PEN
M+>SOWL[=XE(,FP#>QR3_ !$KQ_=-1>*_$=YH5UHMK8VD%W/JEZ+58Y)2FP;2
MS/P#D*!S]: .EHKF9?$]SI6N:?IFN6,-NFHN8K6[MYS)&TH&?+<%5*DC..H/
MM6S]LN?[:^Q?V?+]D^S^;]MWKLW[L>7MSNSCG.,4 7:*** "BBB@ HJO]MMO
M[0%AYJFZ\HS&,<D)G&3Z9/3UP?0U%IUY<W@NOM.GRV?E7#Q1^8ZMYR#I(,'@
M'T//% %VBBB@ HHHH **** "BN<\5>(;S0Y]'@L;2"ZGU*]6T6.20H5R"Q?@
M'(4+S1I'B:6[\4ZAX<O[-(+ZT@2Y#P2F2.2-CC.2 5(/8_G0!T=%%% !1110
M 444U]VQMF-^/EW=,T .HKC/#?BC7?$D>J/!IVG0_8-0FL&$ERYWM&0"PPG0
MYK0U/Q)<:+X2.JZC9+'>>8L'V=)"5,C2^6N&(!VDD-G'3M0!T=%<A>:_KNCW
ML=EJ,%A(U_>Q6FG7, 95;<K,YDC+$C8$/1OFR.G.-S19=8:"X36X;2.:.=DB
MDM6.R:/C:^TDE3R05R>G6@#3HH) &3Q5._U2TTTVRW4H1KJ=;>%>[NW0#\,D
M^P- %RBJ6[4_[<V[;3^ROLV=VYO/\[=TQ]W9M_'-7: "B@D#J:* "BC(SC//
MI1D>M !111D9QF@ HKF]4UR_?Q!+H&C+:C4([#[<7NU9HR"Y1$PI!&2&RW;
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MFC^(+R_\8^(M&NH+>*'3%MFA>-B6<2AR=V<?W1P!Z\F@#I***,Y&10 4444
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M1/!6@:E ]SJ\=C<W(L+E@+=$=\[Y00264,%4 9Y;IUKT:'PMH<,\,XTZ*26
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MD]: /=Z:LL;LRHZL5.& .<?6L_Q%=6UEX:U2YO9IX;6*UE:66W.)$7:<E/\
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MN8I&3<!VSC/US7*Z#;6?BA_'$'B"&.2[AU*:WS*!N@M@B^24)^Z,98$8YR:
M.M\3:]_85I9%$5KB^O8;&'?]U7D;&X^H R<=\8R,YJ?1VUM3>)K7V%E27_1I
M[4,@DCQG+(Q.T@Y'4Y]J\ME275_A[\.;W7;>.XOYM7LXGEGC#/)$6?:"3R0R
MA2?7->P"TMA9_8Q;PBUV>7Y(0;-O3;MZ8]J .3\2^-'M/ D_B30#;7,<<XB#
M39*L//\ ))7:>><D'/(KL ZLS*&!9>H!Y%>'):V</[.,SPPPQ3RS*)7C4*[
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M.7<OU&<B@"EJ_A+P_K\L$NK:1:7LEN,1O-&&('IGN/8\5L(BQHJ(H55& H&
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M_(J*/PGH,-O:00:7! EIN^S^0#&8MV-VTK@C.!GGG%:J3PRR21QRH[QG#JK
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MKG2%TF;1[%]/0Y2V,"^6A]0N, _2@#.\%Z18:+::C:Z;J+WENUZ\I "^7 [
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M3[Y9ID1-HC7(V*.,'G)W8 QFM^ZFL)/BCX;NII+9HY-'N3YKE2&8-'W[D8-
M'7Z5XETK6;O4+>RNXI7L9S!)M<'+!59L>H&[!/J#5ZTU"ROPYL[RWN AP_DR
MA]I]\'BO)UN=$TWP_P#$@ZI%F'^UI4:&W<1RLC)$H /4*2>3TQFM;2YXQ\81
M%<7.G-YWAT(T5J?D'[\;4))^<X)P<#(/04 =OIMQ/!8W,NJ:E93[+B3$L($:
M1IN^56R3\P& :O17EK//+!%<PR30X$L:."R9Z9'4?C7B5[:6G_"D_$R>3$$M
M]=F\G"@>7_I:@;?3@XX[5V<NF:?8?%_2X;2SMX([G1;E)T2, 2@2)C</XNIZ
MT =M_:=@'B0WUMNF<I&/-7+L#@@<\D'M3XKRUGN)8(;F&2:'B6-) 63Z@<C\
M:\/?2]/3X#7UZEI MS!J+^3.% >+%]@;6ZK@$]/4^M=K>V%MI/Q8T8:5:06T
MDVD7:L(D"^85:,KNQUY]: .Y&H61O?L0O+?[7C/D>:/,QZ[<YI)M2L+<,9[V
MVBV.(VWRJN&/0')ZGTKRCPVNA>(_"&A/J'B">+5;&Z21[9/)2Y6]#$,,;-Y+
M,3GU!Y-.&B:3-:_%(R:?:OY+RF+,8(C/V56)7^Z=W.1W ]* /2=0\2:7IFL6
M&EW5W$EW>[RB,X&U54DL<]!P![D_6M:O*4>V;6OA;=7QAQ)I%PTLLV,,?L\)
MR2?Q-=5\39]0M_AOKDNE^9]J6WZQ_>";AO(]PFZ@#H[?4+*[EDBMKRWFDB.)
M$CD#%/J >*Y2[\27VK^(-7T30-1L+6ZTZ&%HFN )%N)7W'8<'(4!0#CG+>V#
MG^)(K:2]\ ZAX=$:RM?QQ1&  ;K%HV:0<?PA54^QQWJSX:M[8?%7QKMAB#1I
M8%<*,J3&^<>F: .CU7Q#9^'[*RDU>>&*:YFBME16X:1V"G;GL,DD^@J[/JFG
MVR1/<7]K$LW^K:295#_3)YKD?B<D)L?#LDRQ[5U^RW,X& I?G)/:LCQ%>Z5<
MZGXL@LGM(I8=%2.ZFN7W(T;+(42%,@=^6SC)48- 'I<UU;V^WSIXH]X)7>X&
M<#)QGT )^E12:E80VL=S)>VR6\@RDK2J$;OP<X->3VMKIVK77PG-S%;W1DL)
M8YRP#;\6BG:WKSV/K6]?+8>&OB+IZQ+:_8%T1[>/3UECB-N/-!WJ'95(?[IP
M<_+Z4 >@&>(0F8RH(@-Q?<-H'KGTK/O?$>D6&AW&LRZA;M86ZEGFCD5EX[ @
M\GL!ZFO+VTV+P7X)\-+<36T%C+K&_4KFT5'1%;S#$';!#*C%!D@XVCVJYXFT
MK14\->-]0T[5GU&XO-,\RY5#$T*,JD(_R* '(SSU(% 'I4&K6,VEIJ)NH$MF
M0,9&E7:N1T)SCO5F.ZMYK87,4\3VY7<)5<%2/7/3%>::CJME9Z_X.2;4(K+2
M9;*54N(Q&8ENRL97<6!4'86P3S\Q]:SM7ATKP];6$=EJ4EWH-YXDCDU.1V0P
M1LP+;!M 41[PA8=,\>HH [.Q\37%[\1Y='AN[*YTO^ROMD;6XRP?S=A!8,0<
M8[ =:ZN66.")I9I%CC499W. ![DUP=N;&/XZSF!H%DF\/*7V$9=O/XSZG;C\
M,5;^(S>39:%<FYA1(-8MY&MY9 @N0-WR MA<C[XW$#Y/I0!UUO=VUW&)+:XB
MF0Y :-PP_,4R+4+*XN9+:&[MY+B/[\22 LGU .17F=[ILZP^/?%>CQVPOKRS
M5;-8&CDGB*1$.^Y"=I;L >=H)YJ368[6X\(>!-0\/A%NUO;-;-XOO%&'[U#C
M^':&+#_9.>E 'I$FHV,5VEI)>6Z7+_=A:50[?1<Y-8%SK6HP?$FPT3? =.N=
M/FN<",B0.C(.6S@CYO0?C7GGBV_L)_"?BF?3Y(+=(]>C$OVB3?<2W*31*S+R
M/+4!>!R< _=%=G>RQR_&'0GCD5T;1KHJRG((\R/I0!U\>HV,MTUK'>6[W"G#
M1+*I<'T(SFII98X(FEED6.-!EG<X 'J37F'AV2^T35?#5A>QVNKZ/<O)_8^K
MP?+/'NC=MLJ]\KNRP[C)YKI_'UW86VE::E_$93/JEM';J9?+C\[=N0R-S\@V
MY(P<X H Z2VO;6]@,]K<PSQ D>9%(&7(Z\BFVNH65]N^R7EO<;?O>5*'Q]<&
MO+;3[+>:S\2=.O-9MH%N8[5'N;8!41FA*LP7<>G ;GL<XKHO"M[JL/BZ[TGQ
M#I]H-66P21-1L>(KJ!7*C<IY5@6/'3DXX% '9W5Y:V40EN[F&WC)VAI7" GT
MR:;)?6<-H;N6Z@2V'_+9I $_[ZZ5RWBZTU677-+N] O;,:M:P3E;"]4^5=0L
M8P_(Y5@0F#_M<\9KD;+Q%:2ZIX3EN@^@:7/:WD4,;[&CAO%E"LNY@5Q@.%/'
M!P.I% 'I&K^)M)T72HM1NKR'R)I$CA*N#YK,0 %/?KGV )[5IB03VY>VEC;<
MO[N3[ZY['@\C\:\D\0Z1HNE>"IAIE\U[:'Q#;SO)(4,43O-&76,J  GJ!P#D
M>M>MV[0- IMS&8AD+Y>-O!QQB@#E_ _BB36O#EK<:O=6::A/<7$2QH1'OV2N
M@VJ22>%'K72K>VCW)MENH6G'6(2 L/PZUXK!H6CWGP3U.^DLX6U5+FZ^S7*+
M^_6<7+^4J-]X$L5  _O>]=3XB\WP?K&B^-9X"^^W73M:$2;F;< 4D '4B0;?
MHP% 'H<-S!<;_(GCEV':VQPVT^AQTK+7Q'I]UKM[H5K>P?VC;1([AB&"L^["
MD9!)&W)&>A'K4GAS3I-.T>-;A%6\N&:YNMO_ #VD.YAGN 3M'L!7+Z0+.'XP
M>)Q(($D>TL3%NP"6/F9(]Z -'P+XGDUSPIIUYJUS:)J-V\ZB-"$W[)77Y5)R
M>%'K71W6H65B8Q=W=O;F0[4\Z0)N/H,GFO$[6PLH_@QI&J);PB^CUA&2YVCS
M%/VXCANH&">/<UTLT^G:AXQ\8:)X@U=;!IEB6))O*"R6AB ^1I%/1]Y.#P3F
M@#T\Y*G:0#V)YKB-"UWQ+KFL>(K%;C281I-V+>,FRD;S<KN!/[T8ZX[UT?AJ
MVM[/PUIUM:7-Q<VT4"I#-<'+R(.%8G ZC';IBN$\*:5#J?BSQ]YE[>V^-25=
MUK=O%C]V.?E.,^] '5^#?%$GB:RU 7-JMM?:;>R6-TD;[XS(F,LC8&5.>_(K
M<MM0LKQY$M;NWG>(XD6*0,4/O@\5X?:WVH6'PR\;Z;I?^D:=IE^(H=0@4"2Y
MA9QYY9E^^P3J_<'VKNO$<,)\3^!;[01$)9+AHLP !7LC$6?..J#"X[ D8Y-
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MLDU[/87@G\Y<M(HB4H'S][@@X/<F@#U^VNK>\@6>UGBGA;I)$X93^(J6O/\
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M:79&=$V)(;=-RKC& <9 QVKF]9UW7+;XA:3X?LY[%+6_MIIB\MJSNACQQQ(
M<Y]*EL/$NHP>/7\*:LEK-))9?;K:ZM4:,% VTJZ%FP<]"#@T ;?_  CFA?8S
M9_V+IWV4MO,/V5-A;UVXQGWJ7^Q=*^UQ7?\ 9EG]IA4+%-Y"[T Z!6QD#Z4Y
M=7TU[\V*:A:-> D?9Q,IDR.ORYSQ1-JVFVUTMK/J%K%<,0%B>95<D], G/-
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MVM>'M0LI9;.)F$BXF3(ZC@X!^N?I6WI^K6=X5MEO;:2^2)7F@252Z9 Y*@Y
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M#0!91$BC6.-51% "JHP !V IU%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7$?%<HO@@R2
M;0B7]FS,W11YZ9)/85V]1W%O!=P/!<PQS0N,/'(H96'H0>#0!P>HI8:G\7-
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M -&K)B1)$5 0@ P<\=/49E^%NCZ2VASWHL+1KJ'5+U8YO+4O&#*RX4]5&WC
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MYXXYYJJWBSPXA&[7]+7,8E&Z\C&4)P&Z]">]<+I=]9S_ !)\2)/J=G>FYT>
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MB;X6:Z950[8E*EAT.]<8]ZKW\-I9_%;PDMHD,/F:;>)B,!=RCRRHXZCJ?SH
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MF0[>4N6SUSQS46KQZC-IYCTNX2WNFD0><\8<(FX;SM/4[<@>YKC;6^\1W/Q
MU/PY_;P6&TL8KE)?L<98LY(P1TQQ0!T6KV&MH+:'PS)I5A"[,+MI[=F8 @ -
M&%(&X<_>XZ5K6%E#INGV]E;@B&WC6-,G)P!CD]S7$_V]JNC>-M/LM>U>W2R_
ML:6XNB42./S4D1-^[J <],]Z["WUG3+O2AJEO?VTFGE2PN5E!CP#@_-TZ\4
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M-&YDM@89 <J3MX/YU9>TMI)6E>WB:1EVL[("2/0GTJ:@#QB.6"_^ DNC2?\
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M)!QN"L,^I/O756VDZS/K[WFL7]I-8VTSR:?;V\!1EW J#(Q)W$*6 P!]XGT
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MU.G?8?BL0;7F6;)RO(-L/_9L_CFO5VAB=P[1(SCHQ4$TW[+;@$""+GK\@YH
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ML-I%=W*/,_"JS0,%!/J3P* &V7BV/2O&'BV'7M;1-.LS:?9?/"KL$D;.P&T
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M,5@ VXLPP2"!C'?/=7M_;:?$LES)M#ML154NSMC.%502QP"< 'H: +  4
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M)XL+MF"P,RL?ESG/.,X]J .RP,YP,TM<AX<O[^;Q_P"+]/N;Z6XMK3[&;9)
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MEN ;*1!AF.3M"@ XSP>!C)Q7JE% '&_$^WOI_!CO8PR7'V:Z@N9[>,9:6))
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M'C /%;>H77A/5/#/BC6]!:>YEFT6:VEOYI9BK$J=D0\P_,V<].1P.]>J4=*
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M598O])D8+\Q8 D<@8 X)YKKDO;6;XS1W>_;"?#I0/(I3#&<-M.<8;;S@\XH
MZFW\2Z/=:#'KD-_&^G2?<F /)W;=NW&=V[C;C.>,9KFM*UR6^^+=[8Q7UX]D
MFCK*;6>)HA%*9<9"LJG[N.3GKUKB;66>T\,Z5J:0S36&F>*+BZOHHD+,D+/)
MLEVCDJ-P;CZ]JZW3=5L]3^,C7EBTDUK+H"1I.D+[&;SV/WL8Z=_8CJ* .B\4
M>*[?PRVF1RP7$LE_>1VR>7 [JN3\Q)4'G:#A>I/; -8#>)AI?Q*U%;_4[K^S
M#I$-S#;O&Q*NTC@[8U7<3A>>"1SFK7Q)8PP>&;QDD-O::_;33NB%O+3;("Q
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M%NGEDE1_$,J3Q_=KI-:OK'QUX6UR3PO9M/>S:8\!O6MFB9N<B ,R@MGYL@'
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M7MK/J*_:+(*T\4<3R.@.<<*"3T.<9QCG%6%\4:,RZ8RWRLFJ8^Q.J,5F)&0
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MQ5V8X ) ^7G.<XQ@YZ46GC'1;U=1,,\X;3E#W,<EI*DB*02&"%0Q4@'D ]*
M-ZBL;_A*]&^S:3<_:V\C5F1+*3R7VRLXRHSM^4D GYL=*?-XETR&Y,#23-BX
M2U:1+=VC65B $+@8!RP'7 )P>: -:BJVH3PVNG7$US*\,*1DO(@.Y1CJ, G-
M8VCZSI5KX:T=K?4+W4(;F("UFF5Y;BX &=Q&,G@9)(% '1455T[4;;5;);NT
M9VA9W3YXV1@R,48%6 ((92.1VJEJ'B;2M,ENH[B>0M9Q":Z\J%Y/(0YPS[0<
M< GUP">G- &O16)!XOT.YGTZ*&\9FU(L+1O(D"RE5W'#%<=!GDT[_A*M%"ZJ
MTEZ(AI./MQEC=/)RNX9W 9R.1C.<B@#9HK'MO%&E7-U<6HEFBN;> 7$D,UO)
M&_E'(#A2,L,@CC//%9UM\1O"MW$9HM4_<"V>Z,S02*GEJVTG<5QG)'R]>1QS
M0!U-%9%KXFTR[N[FT62:.ZMH5GD@FMWC?RSG#!6 )&01QGGCK6=;?$/PS>"P
M:#4'>*_E\F";[-((S(20$9]NU6)' )!/'J* .HHKF[/Q=#>>-=1\/+:W2FRB
MB8RFWDPSN7SSC 7"C#' ))QG%6!XNT4WUI:FY=3>.8[:9X'6&=Q_"DA&TGCC
MGGMF@#<HK#O_ !=HVF2$7=R\<2S""2X\AS#'(3@*T@&U3D@<G@\'%/U?7-/M
M?M%E)<7(G6#S9?LD+R/"ASACM4[>AQGDX..AH V:*Y+X8WMUJ7PXT6\O;F6Y
MN98F:2:5RS.=[<DFNFO+RVT^RGO+R9(;:!#)+(YP%4#))H GHK&L_%.E7MW)
M:1RS)<I;"[\J:WDC9H2<;U# 9&>..15"W^(GABZ2QDAU!WAO9O(AF%M+Y?F;
MBH5GVX0DC@,03P>AH ZBF3*[PR)'(8W92%< ':<<'!ZXK+U37+"TDELI9KCS
MQ#YLBVD+RO%&<C>=H.WH<9ZX.,X-8_PNOKK4OAQI%Y>W4MU<2K(7FE<LS_O7
M R3[8H U/#VAWFEK)/JNK/JVI2JL;W30+"-BY*JJ+P.68GN2?H!JW4<LUK+'
M#(D<CJ55W0L ?4@$9_,5S=KXJBUGQ'KGA^.*]MVL4C3SQ;NI+LK,3NQA1@+@
MG&><9XK$^'_C>Q;PAX;M]6U&XEU*^7R_/ECD=7E+-A&EQM#D#A2<]/:@#J?"
M&@2>%_"]EHLEVEV+1/+258?+W+G(R-S<\^M;E8VJ^*-*T;SS>33;+8!KAXK>
M258 >07*@A>.>>W/3FM6.2*YMTEBD62*50R.C9#*1P01_.@"2BO./#%Q<:EK
MWBNWU#7[Y(=/U$PVR_: FR/:#C..>O4UT"^(--\,^&[:^U;5Y[BRG<M#>O"\
MF4D;,88HN!PP )QG H Z>BJ,&L65S>WEI%(_FV>//+1.JIE0P&XC:3@@X![U
M2M_%FCW&I6M@MQ(DUXC/:F6!T2X &3Y;, &XYX/3D<4 ;=%8<WB_1+>XBBEN
MV59;G[(D_DOY)FR1L\S&W.01UZ@CKQ3U\4Z0\6J2+<2D:6<7J_9Y-T7R[ON[
M<GCG(!XH V:*Y._\=V-MJ?ARVMH;FY@UI&G2>.UD<>4(BX( &2Q.WC' ))QQ
M5BWU72D\3:V\>IW\US:V\1NK+;(\<"_-AD0+RS<YVYS@4 =)16-;^*='N] B
MURWN))=.F94CE6WD)<EMHPNW=RQQTI-4\5:3HXG:\FF$=N%-Q)';R2+ ",C>
M54A>"#ST!!/% &U148N(6MA<I(KPE/,#I\P*XSD8Z\5S(^(WA=K6"[&H2&UF
MF, N/LTOEH^XIAVVX3+# W8]>E '545B67BW1M0U2;3;>XE-W%"9PC6TB^;&
M#@O&2H$@SW7-,/C/01H*ZX;Q_P"S6E\GS_L\GROOV8(VY7YN.0.: -ZBLG4?
M$NF:6URMS),?LL8EN##;O*(5.2"Q4'' )^G/2J)\70_\)T?#0M;K<EH+AY?L
M\A4EG"K@@8V_>RQXS@9X- '24V1#)$R+(T9(P'7&5]QD$?I7'?$Z[N=/\)+>
MVM_/9O%>VP9XI-F5:9%8,?3!-:ND^,M"UO59]+LKQC>PIYAAEA>(LF<;UW@;
ME]QD4 :]I:0V-K';6Z[8D' )R3W))/4DY)/<FIZPQXNT7[=:6IN74WDABMIF
M@<0S./X4D(VDG!QSSVS6EJ6I6>D:?-?W\ZP6L(R\C9XYP.!R220 !R2: +5%
M8]OXGTNYFO81++'/91K+<0S0.CJC9PP4C)!P>F>F.M4;3X@>&KV33EM[]W34
M7$=M+]GD$;N<X0N5VAC@X4D'VY% '345'-$)H6C+.H88W(Q5A]"*\T\"7[ZO
M\.K;6=<\37\=RWG>;(MPJX"R.JX7'7 ';F@#T^BL(Z]9:)+I&C:M>R-J5VBP
MQR&W?;<2!1N.X+M![XR*M0>(-,N-/N+])V6UMY&CDDDB=!N5MI W ;OFXXSD
M\"@#3HK(LO$VE7M]=6*SO#=VT0FEAN87A81G^/#@97W'3OBHK?Q=HUS?V]DE
MQ*LUU$TUJ)+>1!<(HRQC)7#X!!X[<CB@#<HK ;QIH":!)KC7CC3HY3#)-]GE
M^1PVPAEVY'S<<BH9?%\$?CI?#1MKK<+/[0\WV:0KDNJK@@?=^]ECP..>M '2
MT5R-AXE\/Z9I&LZL=8O[FQAU"07,MQ'+)]FDPNZ-0%RL:Y'; R>:WWUFR3[!
MN>7_ $]MMOB!SN.TMSQ\O )^;'2@"_16'/XNT6VNH89KET6:?[-'.87\EI<X
MV>9C;G((Z]01UXK5O9XK:RFFGD:.)$)=U!)4>HQS0!/17):;XJ\.Z1X=T3?K
M=S<VUZ!':7=X'>2<\\NVT8/!ZXZ5KZ+XDTS7Y+N*PEE,UFX2>&:!X9(R1E<J
MX!P1R#CF@#6HJEJ&JV>F-;I<RD2W,GEP1(I9Y6P20JCDX ))Z #)JC9>+M#O
MTO6AO@HL-WVOSHWC\C;]X-N P10!MT5D6OB;2[O4HM/66:*ZFC,L$=Q;O"9D
M'4IO W8[@<CTJ*\\7:+8&4W%TZP02B":Y$+M#$^0-K2 ;5Y(!R>#P<4 ;E%9
MU_K-E8RQ6TDDKW,Z,\<5O$TLA48RV%!P!D<GC) ZFN;^&6I3ZIHFJSS7MS>(
MNL74<,EPQ+>4& 48/(X[8'TH [6BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KG_&LR1>
M%KH-N+,4"JBEF;YU/ ')XKH** .&\:>';NZEM_%OA<H->L8R H^[?0=6A?U_
MV3V/YC(:&]TI_ASK<\$[:;9:>;:\"QDFV:2% KLHY RN">U>H44 <7H-DUW\
M1M<\0VVX:;-9V]JLF"%N)%+$NOJ%!5<].2!T-)XEU(VWC;2K6>UG@M);27&H
M6MHTLS/N7]P&524! W$CDX&",5VM% 'B-J)8_A7I-@]G>I<6WB%6DBDMWW!1
M=LY/3D!2"2,CGKFNU\Z/_A<_VKYOL_\ PC_E>?L.S?Y^[;NZ9V\XSTKN:* /
M%+*"^ATG3M4CM;F2VTSQ3<W=W;K"V_R)&<+*$QE@ V>!T)]#77269U[XAMK6
MF$O90Z))9R7 !"32.^50$]=H!)QTR!7>T4 >)VM_O\">!-.2QU%KK2]7LQ>Q
MBRDS"4+;@?EY]?ESQ736,J+XM^(DSI(L4\%MY3M&P$NV JP7CYL,<8'>O1J*
M /(-/\VRT+X7WL]M=^58,T5T$MW=X6:W9 &4 L/FXZ5Z!XTTZ]UOP-K&GZ?E
M+NZLW2)2<$DC[I/;/3\:WZ* /,M1D_X2_P .>%;"Q@FBU*VO[2>XB>)D>R\K
M_6%\CY<8*C^]D8S6IILR_P#"X=:<AQ&^FV\*2%"$9U=RRAL8)&X<5W-% '&_
M%"&:7P4[0PRS>3>6LSK$A=@BS(6( Y. ":ISWD=U\6-$O4CG6V_LFX3S)(60
M*S.A4'(^4D D X.*[ZB@#Q9H;[_A'M4O;6QO+A;'QA-J,MM"'26:U)8;H\8)
M^]N&/[M=UX4GT+5M3FU?1M.O0S0"&6^O%F5VY!$8\WE@.22.!Q@G)QU]% '%
M^*M2:T\7Z+;S6LT-I+#-G4;:T,TP?*XA5@K% PY) R=H QUKA+821_#^PL7L
MKY)K?Q2LLD<MNY8(+IG+9(Y 7!)Y'/6O;Z* //Y[B-/BQJ%T=_V8^'4B\X(2
MA<3.Q4'&"VT@XZUS5LKQ?"SP#;M!,)[75K-YXO);?$$D)<LN,@ '))]?>O9:
M* /-'O!I7C;QO%<6]T7U2UMY+'RK=W$X6 HV& P,'KDBL[1-2ELM$\!VES87
MEK#]@>*6^73W>>*0*H\I?D)0/_> YVC![CURB@#Q&59A\'/$6FBROUNAK#E8
M9()"[ W0?C();Y1DD9^M>V1R)+&LD;!D89!'<4ZB@#Q^R@-Q\(]2\)-9RMK<
M\US"ME)"RL&>=F20Y& @!5M_3CKGBMS1Q+X2^(&L_P!L/)]BU*SL_LEZRDQ[
MH8RCQD]F))8 ]<FO1** /&I-*N=,\/:49K>=$NO&2ZE%;F)MT%L92067'RC'
MS'/3=SS7121M=_$KQ&L*.PN-"C@B?:0CR!I,J&Z$@,*]#HH \7M]1$_@[X>V
M45EJ+3Z9J=HEZ@LI<PLD;JP(V\^O&>.N,C.I?I<6&O7.I>&;RX6ZEU15O= N
MHB\=R?,"F:/(RG #EQQQSTKU2B@"GJ[K'HUZ[GY1 _09['M7F&FV%G=?#[P;
M:WMWJ&CZA;6[>1J$*E#:2JH!20$8"L#R&P#C'>O6Z* .;\#W.K77AP'65C-R
MEQ-&L\<7E+<H'.V;9VW]??.>]<9KNIV6B^,O%EN]S<6B:M;01S/)ITUPH?RB
MN^,Q@C 4@%3CD'TY]7KEAX7U:TU2^N=+\2S6]M>SFXEMY[5)MKD '8QP0,*,
M Y Q0!RU[-I=C9?#[4M+FFN]!TJX:W>Y2)W9!Y#1 NH&X?,,'C@U4NM1N8KG
MXD7UOH5Q>^<;)X8+JQ=DE01(K,5(P=H.[8<'CH.WJ>GV,>GVODH[R,69Y)9,
M;I'8Y+'  R3Z  =  *M4 >8:5>1+\45U'=JEQ:7&@;!>W-K(BNXFW'C: @ [
M8 ],D\U]#GN--_9_B$>C_;+JWB*2V-Q:E\9F.2T9&6P#OQWQ7J]% 'F6CWD2
M_%3^T VIW%I<:"J"]NK:15=A,S'JH" #'& /3)/.%;))'\%/#UHUO.+J+5(G
M>#R6\Q MT7)*XR %YSZ&O:J* //-LP^(_B>!8[A&U;2K=+*=86,9*K("=X&!
M@L#R163X2GTJ^T[1M!U/0-5.OZ8T*O;7(G,,+Q87SU8DQA0 2,>N .:]9HH
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ML7/&\9VMSVJ7PQ?:/KYTJ"31-677;'!E2]6?98N!AG#.2O;@#DY' &<>F44
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M\F%^<Y/1<]#G&*NZ'KEAXATM-0TZ1G@9F0AT*,C*<,K*>001T-<3I5A<:/\
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M\P%M@&X@%AR!6K=W*:-XXUB77-#U2ZTW65@FM)[:WDEV,(E1H9%3H?ER/J:
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MF>#QUXJU<^--%M)9A)-*8+>Z6SGN5B8Q13-@!&;URR@GH"<$BN(BA7Q/\/O
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M&T;N"A5R,-D'L3TYQQE?%PD/CKP7*EO<R1V]S</-)' [K&K0LH+$ @9) YH
MN7/Q#\/VHU',E[(=.?9=K%92L8>,EF&W(4#G<>/3-=-;W$5U;17$$BR0RH'C
M=>C*1D$?A7FL*R[/B9FSO/\ 2RQMLVLG[_\ T<)\GR_-\PQQ78^"PZ>!]"CD
MCEBEBL((Y(Y8RC*RQJ""" 000: $O?&&D:>+F2:28VMK+Y-S=1PLT4#\<,P'
M;(R1D#OBF:KXVT31[\6-S-<-<M;-=)'#;22&2,8R4*C#=>V< $G %<9I"7.E
M>!O$7A/4K&[EU,O>);A8&<7JS%F1U8#')?!R?EQSBK.EZ;<Z-XU\'V=Q%<S?
M8-!:SFN5@=HQ+^[P"^,#.T]Z .JO/$VF36<D<;WLA:T6YE^RPOYD$3C*LV!E
M21DX^]P>*Q_A_KNSX:>'KG4;BXNKR[B(7.Z669\L3[G@9)/ [FJFE7D_AOQO
MXHMM5L[YTU2=+JQNH;9YDE7RPACRH.TKCH<<<URFD0WVE>$? NK76BZE<6>G
M0W%KJ%JD$BS1"0J5D"<%@-HR1V- 'I,OC[P_!HMUJLUS-'!:3_9KE6MWWP2Y
M VNN/EY(Y/'(YK4TC7;+7!=&S$^+:7RG,T#QY. <KN R"",$5YWXK@M+[X;Z
MW-HGAZ\@^WS6Y5?LDGGW165&9RF"V  <%L$X/;&?4XI%FB61,[6&1N4J?R/(
MH YO2O%Z:GXMUG1OLES$FG>4GFO"P!9E9B2>BKC;C.,\U83QCH[RV0,LJ07T
MGE6ET\++#.YZ*KD8YP<9P&[9KE9K"]G\4_$'2TM[J&76;2$65SY+>4<6Q0DR
M8VC#8&,YYX%4KJ&X\2?#'2/"Z6-W;:U"UI!-') R_93"Z[Y-V-NW:A((/.0!
MDT =OXX:6/P+KLT%Q/;S0V$TL<L$A1E94)!!'/45D^&O'.CRV^AZ1/=7"WUS
M9Q"*6>"18[AP@W!)"-KM]#U]ZW/%]K/?>"]=M+6)I;B?3YXXHUZLQC8 #ZFN
M-DMSXET+P9IEI;W*W&G75I<W3S6[Q?9A"OS E@/F)^4 =<YZ#- '6ZEXPTC2
M1))=R3+:PS"">[6%FAA<D##.!@<D GH"<'%;C.BQF1F4(!DL3P!ZYKR;31;Z
M=+JOACQ#X8U'4+F2^GEM72!Y(+V.20R*2WW%P6YW8 Q7H>OZ9/J/@[4]*M=D
M5Q<6$MO%M.%5FC*CGTR: (H?%VDS:E96)>>)[]2UG)+ R1W&!D[&(P3CGG&1
MR,US&BWZ6\'C\:KJ.H?8;:^DC\Y9)))((C A.PC++C)/'3K4/A6[T_5_[*M+
MGPGJ$.MV!3SC>6[B*U=1AG61OE.<?+MY.1VR:AMUF&F?$M39WH:[EG:V!M9,
MS VZH-GR_-EACB@#L[76M,L=#T7R[BXG6]AC2R63+SW'[O<"<\D[1DDX YR:
MK2>+M"U'3-73[3?1+91R1WI2UF5[? PW(7[P!S\N>.>G-<?J$HT[P_\ #S4&
MM]0COK"-8\I9/+Y0^S[9%>(8?G&,CIU]C:TR]TBY\/\ C%[*>\N-5U"*6XN(
M7L)8'.8_+01QL,D< 9&>3SC(% "ZMJMOI]_\/+ZUU/46TJ=7SYDLCM<1_9BR
M%T'+N21V))-;S^*=-\3>&->&EW5U!=64$@FC9'M[BW?:2I(.&'3@US,<5Q:Z
M3\,;Z:SO%@TR,1WO^C.6MR;7R_F7&X#=QG&*T)K&2YUKQ;XCAMYTL[C25LH!
MY+;[EU#DN$QN(^95!QS@XXYH U_"FLI;_#_PS->RS3W5U80;5 ,DLS^6&/N>
MY)/XFMG1=>L->@GDL9'+6\S03Q2(4DAD'564\@UYEY=YIGA[P#J\^D:A=V.G
M:>UEJ-K%"XG@+QQC?LX8X:/!]C7?>%%TZ6*[O],T>73X+IU8O/$T4MP0/OLK
M?-CL">3@]L$@&1XKU\Q^,]"T%X[_ .QW*7$ER+>*4-+M1=H5DY(!?)P>PS5Z
MTU?3/"NFSV,M_J>HQ:<2;JYD1IVMU;Y@KN!D[5(]2!@FJ7B!W_X6EX5F%O=/
M!;V]XLTR6[M'&75-H+ 8&=I[U2T"67PW<>+-*UBTNI#=ZA/?6CQV[R+=Q2@8
M12H(W#&TJ?;M0!TNH>--#TR>PAFN9';4(FEM/(@>43*J[OE*@ACC& .3D<<U
MJ:?J=MJ>E0:E 76VFC$JF5#&0ON#R*\QTG1;[P]>?#.PO8+F633X;O[7)'"\
MB0&2/Y59E! Y.WKVKU*_>:+3KJ2W@%Q,L3M'"3@2, <+^)XH R+'QEH^H7=A
M;PR3#^T5=[&5X65+D(,ML)]N><9'(S5*?XC>';>&^E,MXZ6$QANS'8S'R" "
M6<;<JHSU/7!QG%<38W%S=:IX"U)]-U?S+>69+R,6$D4-J[0,HB2/  4,<;L$
M8'S-5U4G/ASXFQ?8KWS+VXN6M5-I)F<- J*4&WYLL".* .]?Q/I::[9Z.9)3
M=WL1FM]L+%)$ R2'QMX&._<5;M=4MKR_O;.'S3+9LJ3;HR%#%0P 8\'@@\>H
MKA]<L;@_#;1-<LXWCU70+>&\B653&Q"1@31,#@C<NX8]0*Z_P[9S6FD(]VNV
M]NF:ZN1UVR.<E<]PHP@]E% #-3\3Z=I5W+:R^?-<0VYNIHK>(R-'""1O..V0
M>.IP<"H+GQKH-K_96^[=EU5/,LV2"1EE7;NX(7KC^'[Q) QS7/>([NZE\6:E
MITVGWZ6\FF 6LMC;,6O)#ORCS*/E"DC"EE'S$D\@5@Z,+C['\+P^G:C&; 2+
M<[[.0>5_HY3+?+P-QP"<9Z].: .[C\=:&^C:CJCRW4,.FN8[Q);21982!GYD
MV[@,$'.,4^S\::-?:K;Z="]R)KJ%IK9I+9T2=5 +"-R,,0",X-<-JT=Q(OQ2
M6.QOF-]#$MIMM)#YY%N$.SY?F^;CBM2Z,C^(_AU,MI>&.VCG\]Q:R8AW6^P;
M_E^7+<<T =*WC71$T._UAIIQ96$[V]TWV=]T3H<,"N,\9'.*L7_BC3;"X^SL
M9Y[@6IO&BMXB[)#G&\CTST'4X. <5YEJ/VJV\'?$'P^=,U&34;G4+NY@2.T=
MEDBD*E7#XVGZ9SGM6]?:A<W&O"RFTS4H;:71T%O);6;K)<R?-F*20#,87@[2
M5')).#B@"YXSU5;S3?".J:3J$XMKO6K(!H)619HG;)##C(.!P:Z?Q*'_ .$7
MU4QS2PR+:2NDD+E'5@I(((Y'(KS*%+H_#/P%;G3=16:SU2R:>,V<FY%C8[V(
MQD*,]3U[5ZEK<,EWX>U&&!"\DMI*B*.K$H0!0!R'@[QYI(T'PQIM]=W/VZ[L
MH$6XGAD\N:;RQE!*1M9\]>>O'7BNDU#Q5IFG-=B0W$J60!O)((&D6W!&?G('
MIR0,D#D@ UPL=G)X@^'GA7PW!:W2:A:O9?:?.MWC^Q^3M,C$L ,_*5&.N[CC
M)K1T"67PU>^+=,UBTNI/MFHSW]I)';O(MU%*HPBE0?F7&TJ?;M0!TU[XRT.P
MN=.@ENW9]2C:2T,4+R+,H7=\K*""<8P!DG(XYJ!?'>A'0K[6'DN8[6PE,-VL
MEK(LD##'#)C<.H[=ZXK1]$O_  _=?#.PO(+F26PCNS=O'"\B0&2([59@"!R=
MO7M3=2TZ^U+2/B?;6MC=F6\D62U5K=U\\+$@.S(&[E2.* /29=?T^'6K+29)
M)%N[Z-Y;<&)MLBH 6^;&. 1P?6HK;Q+I]U=6L,(N&2[D>*WG\EO*E9 Q;#=.
MB-@G&<<9KC7U3^V/'7@F_M-/U,V<-O=QRS264B!&9(P 01D#/&[&WT)P<5]"
MM;K3=>TF7PY+J"Z=>7#F_P!$OH&*V.58M)&S %!NX Z-NXH ]2K-U'7+739#
M"R7%Q.L?G-#;0F1U3.-Q Z#(..YP<9P:AT'Q':^(/MHM[>\MWLYS!)'=PF)B
M1T8 ]5/8UQVNS?\ "/\ Q#N]0U72M0O=(U.T@CBN;**24V\L9?*,J<X8/D'U
M_&@#IF\=>'Q;Z3<K=O);:LZQ6<\<+LCN3@*6QA6R#PV.A]*OQ>(=.EM+^[,S
M16MB[QSS31LB H2&P2/F ((R,\\5RM_I-CJGA>T\*VVB2:9!J+-(BBW8"S0,
M6$A(X64G!"D\$\YP0<64:YK'PMU#P\NG3+K6D21HH-N\<5\L,JL'C) !WA>G
MK]: ._L_$^FWFKG2LSV]Z8/M*0W,+1F2+.-XS[]1U'<5"OC'1S>V5NTDT:WY
M*V<[P,(K@@9PC8P21R/[W;-94.LKXUTR[BT_2;VSN9+&6%[F^M6A,#.N!&"P
MRQW8)VY V\\XK"\)3V5_:Z/I.H>$M037--:(2_:H'\F%X\ S+(?EZ E<<DG'
M3F@#H;CXG^%[:&:9[FZ,,%PUO<2+92E8&! /F?+\@R<<XS@XZ58NO&4,7C.P
MT**VN)H[FS>Z-Q'"SJ1E NTCJ/F)+=!QSZ<=H]Y;R>&?'^E_9I[BZN=8U***
MW2%F\YG^4 '&.O4Y^7J<#FKUEIMYX:\6>#DNK:ZN([?06TYYK>%I%$P,?!('
MR@[3RV!QUH [_5=4LM%TV;4-0F$-M"!O<@GJ0  !R220 !U)JC;^*=+FEU&&
M622UFTZ(3W4=S&4,<9!(?T*X4\@G&.:J>/+N\LO"=Q-9:?\ ;9!)$'3R//*)
MO7=((_XBH^8#U /:N-AV#Q;XDN)-)UK4-.O= 4 W%O*&N@OF;UY VDYP%PIY
MX7'- 'HECKEM?7HM%ANHIC#YZB>!D#1Y R">.XXZCN!6G7GW@VVU#2_$GV"R
MU&\U/PY]B+Q/?PD364FY0(M[ %@1GY3RNT9QW]!H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHJGJ6IV^EPQ//O9YI5AAC09:20YPHSQ
MT!/) P#0!<HKG+WQMI.F:?)>:@MW:QQ72V<@DMVRDA"D9(R /G'S$X/8FETG
MQKI&KZW/H\8N[:^BC\Y8KRV> RQ9QO3<!E: .BHKGQXRTH7FGPR"XCAU%_+L
MKMXL0W#XR%5O< XR &[9INH>--(TU9)IVG^Q0W M9KU(\PQ2DA=I/7@D D @
M'@D'- '145SBW^E-X]GMTDOSJT6F[GA.\0^3YG#*I^5F+<9&>A&:Y&TNXO%K
M^)9M5?6[,:?J3I;W%F71K>*-$.P!<\G+$C!SN]A@ ]1KE;3PCJ&FSS)IWBB_
M@L)9I)S;O##*R,[%FVNRDX))/.>M2:+K6CV?A+1I;*:[GM;I%CL5E)DGG."0
M.>2< DD\ #)P!3T\;Z*;&]N)))87LKE;.>VDC_>K,Q 5 !D$MD8()'OP: -R
MSM(;&U2V@!")GECDDDY))[DDDD^IJ>N>.MVFM6FMZ=']KM;VQBQ<1,3')%N0
MLC!D/0@<%3VK@VNKM_A-X&O3>W8N'OK!9'$[@RAI &#\_-GWS0!Z[161;^([
M*Y\2W.@*EPM_;Q"=P\>U3&3@,&[@GCBK6F:I#JL4TD$<JI%,\!,BXRR,5;'J
M 01GVH NT5BW/B:SMI[A!#=31VTR6]Q-#&&2*1MI"GG/1U)(! SR1S2:MXIL
M=(6[>2*ZGCLE#WCV\6\6ZD9RW_ >2!D@8)&"* -NBN2?QM')XQTW1[.TGN;6
M[L&O1=1)N5U+($*\_=PQ)/T]ZW->U)](T*]OXX9)G@A=U5%W<@$C/MZT :-%
M>=>%[BS&B:!XIO[K5HM0N+6**2,NQ74)I4##$?.X@Y*D8P,]AQU$/BS39'U&
M&5;FWNM.C$MS:R0DRJAZ, N=ZGU7- &[17"WWQ0TU?#EYJNFV.HW:Q6'VR)S
M:LL3C.,;SQP>H!R.>I&*HZSK3KXM\"ZC*U_!'<"Z$]O\^)2(,KB($@G)XXSS
M0!Z1163H/B*Q\107,EHL\<EK.;>X@N(C')$X ."I]B#GWKE=?U0:-\5=,EDD
MOY8)=*N";2#S)O,<.@&V(9&[&>0.G)H ] JCK%@VJZ->:>LPA^U0O"TFS=M5
M@02!D<X-9NF>--%U;19=4MYY%BAF^SRPRQ,LT<V0!&4QG<20 .^:6'7['6+C
M4=%(N[/4((/,DMY,Q2"-NCHRGD9XRIX/7% %[0=,;1=!L=+,_GK9P);I)LVE
ME10HR,GG K1KA/ 6NQVOPQ\.7.HW$T]U=IY<8),DL\A+' SR3@$DG@ $D@"M
ML>,=,^SZH[I=1SZ4H>\M&B_?1*1D-M!.Y<9.5)'!H ?)X=EN/$AU.ZU>\FM%
M*20Z:VT0QR*,!N!N/K@G&>>PQNUSW_"9:9G1,)=%=:4-9,(OE?*[L$Y^4[><
M'^=:MKJ45W?WEG'','M&5969<+EE#  ]S@@^V10!<HIL@9HG5&VL5(!]#7F7
MB/2YM%USP9I\6LZTZWMVT%X[ZG/F8",G^_\ +SS\N* /3Z*\V\:V$GAVPTV>
M/5]2,#^(+-L37LC[(RRAT)+?,GRYP<X)-=;IGBS3=4OK^R47-K<6*+++'>0-
M"?+;.)!N_AX//;'.* -RBL"+Q?ILFIV-C(ES;G4%+64L\16.XP,D*>H..<,
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M!#<0V]E([A6!.X#'W0!DMTY'/- '545BV_BK2KW2;#4;&9KR+4 ?LB0KEY2
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M+;LL/E^\,] !6>;.^7X3>#K(Z9J/VNTOK)IX!9R%XQ'("Y*[<@ =^_:O7**
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MZ (N[CY<MD<XZ9Z8->CT4 <7X-CGC\5^,9);2ZABN;Z.6!YK=XUD41*I*E@
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M!X T.VN+>>WGM[..&6*>)HV5E4 C# '\:Z6BB@ HHHH **** "BBB@ HHHH
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MW.E7^G+:/);PM*UO*CEAE%!;:P)Y .#UQ0!+K?C2)_A]K&MZ*L\D]K%/&RE
MKVLR*<^8K$8VD#(Y[8R#4WA'1[8QVFN)%?VMU+9)#/'-+E+@X5O-903ELY^8
MG/)S7.7>A7T7@[QY=+97)FU^69K2T2)FDP8]BEE'W2Q!)ST!&<'BN]\/L6\/
MZ>&BEB=+>-'26-D96"@$$$4 <XOB6XUK6_%&A/I]Y;P:?#&@F20(0S([[BRM
MN (VXQSZXSBLSP'XQM+7PCX3L;Z._+WT*0)>O$3"TQ!(0N3DL<'G!&>,Y!JS
M#%>Z=XX\9R2Z9?/;ZE!;O;W$4)="$@*,,C^+=@8'/.>G-8<5AJ$?P^\ 63:9
M?_:M/U.TENXA:R;HDCW;V/'09'3KVS0!W>K>+['2(KRXDMKRXM;!@MY<6\:L
MEN< G=D@G ()VAL \UN03Q75O%<02+)#*@='4Y#*1D$?A7F$,#Z'XBUS3]6\
M%W&M0:C>R7=E>06<<RLLF,Q2%L;-IR,MQC]?1DLR=$6QV16S&V$.VW&$B^7&
M$'H.WTH R&\;Z6DE@S1W(LK^Z%I:WVP&&64D@*.=V"00&V[3ZXQ3;CQSI5N\
MS-%=-9P7PT^:\5%,4<Y(&T_-NP"P!(4C)ZU@>!]2UK3M%T_PK?>&[Z/4-/VV
M[7;1C[(8U.!(LF>?E_A'.?3DC"\1Q:[J^BZS#=:%JTFH0:O')"D$6+?[.LZ%
M60 @2,5!)."V2>@H ZR7?'\:[51--Y<F@RNT9E8H&$T8R%)P#CT%:5QXVTRT
M:UDFBNEL+JX%K#J&Q?(:0D@#.=P!((#%=I]<<UES174_Q7LKXV-[':G1)+9I
MC"Q6.5Y48*6&1G /.<>]<_X3M)+#3K;PMJW@0SZG9-Y2:@]E&UI(BGY9C*>^
M.<?>R/4\ '5W7Q#TJW;5E2RU6X;2FQ=K#:',8V[BW)'R@<\\GL#BM:;Q)8+%
MIS6_F7<FI)YMI# !OE3:&+?,0 H!&22.H'4@5QT-O=K<?$9FT^^ OQFT_P!%
MD_?_ .CB/Y>.?F&/UZ5GZ9;ZKH%_X.UR72=0N+.'05TF]AAMV::UD&QM_EXW
M$97!(!Z?2@"[X3\0VNE/XWU/4'O8K2VU1$$=RS22(2B*$&2>KG P<<C!Q761
M>+;)I]3MKBVO;:ZTZ%9Y[=X@[F-LX9=A8,.".#QCFN&\SQ%:P>-+S3M"U /=
MZE!-"7MU+M#MC5VC1OO. "0".#UY&*L6=O=6_C'7+V/1=9%E>Z*B1S3QM(S.
M#)G=DEMQR!MZCT H Z_P]XQL?$SQ?8+/45@EM1<QW,UL5A8$XVA^A8=Q]?2K
M%SXDM;3Q-9Z!+!<BZO(VD@?8/+<*,M\V>H[C&:I?#R&>U\ :+:75M/;W-M:I
M#+%-&49648/!Z_6J_P 1;"67PX-8LBJZGHLHO[5B<;BGWXS[.NY<=R10!K2>
M)+*&34%ECG064R0.Q4$22N%*HF"2S'>O&/XA50>-M*AN-3MM06XTZYTZV^V3
MQ72KGR/^>BE"P89&.#G/&*P?$GAW57\"6CV]G'>ZK;WT>J7-FQ!6Y?<6DCR>
M"/F('LH%1M=W%WH&JZGX;\#-IVHI8O&GV^PCAEE<D'8JCEE !)SP3M SS@ Z
M>Q\66=YJ8TY[6\M;I[/[=$DT:GS8<@%EV,W()'RG!YZ56T3QUIOB"ZMX;"SU
M-DF>:,W#6C"*-HR05=OX2<< ^W2N9TN.Z7XA:3K"Z/KAM9-(E@FN+R,EQ(71
MCN4GY. ?E &?X0:V_AG!<VGAB:VN[2YM9EOKF39/"T9*O*S*1D<Y!% &]JFN
MVVEWME8M%-<7M\7^SV\(7<X098Y8A0 ".I[BN;\1^-0WPTU77M$CN?-CBFB!
M* -;2KE27!/\+#MGMU%6?%=SJ<7B'18DL;Z;2)!*+F73T)E5\#8I889$/.2"
M.0,D#.>/CTW5(_A-XLT<Z'J,5W/>78MX?)+&022$KMP3D8_BZ>A- &D]\OAO
M6- N['2-66?6"MI<1M,A1]JE]^TN<RG&-V>F<\XKKM3\6VFEP7D[V=[/#8J&
MO7MT5A; J&.[+ DA2&(7<0"#W%8/B6.[FC\&ZE;:=>SQV-^CW,4<#>;&IA9,
ME#@X!(S64L4NB>)];@U?P7=:S:ZK<_:[2Y@M([@KO15:&0DX3!7@DXY- '4W
MWC[1[.[M[6.*^O9;FS-[;BTMFD\Z, 'Y.FXX(/'XXK9N-5$/A]]62SN9 +?[
M0+?:$E(VYVD,1@^H)XKDA:7%O\1_#THTN2"UM])EMI#:V[?9X)&9"J @8Q\I
M&>GTKM-1A>XTN[@C&9)(711GN5(% 'F.M^(;C6_ _A'7KB.ZLI)=6L'<+(0C
MHS@G"JWS+_O#/'2NYTWQ=I^HW^H63Q75C<6$:S2I>Q>5F(YQ(.?N_*>N",<@
M5P M]2?X;^#M/;1=3CN=.U"Q-Q&ULQ(6%@9&P,_* .#WSQFM76]'O=;\:>(X
M8+>YBAU#PY]@ANG@=8_.W2'!;'HP_P#UT =/'XPL#JFGV,]O>6O]I FQGGC
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M@ HHHH **** "BBB@ HHJGJ6I0:7;I+,'9I)%BBBC&7E=NBJ/7ZX  )) !-
M%RBN4N/$5GK5KK^BR07=EJ%G:EY;>5@K[&4E75HV((X['CH:Y_1K_28?A]X
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MO(0S$[=S#Y1W[ 9- 'I%%8#^*XH-?TW1KK3+^VNM15V@,@B*?(,L"RN>0,'
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M1F%O&%CY9F8$@8/ R0!DC%=M+XNL6N+6WT^&XU*:YLCJ$:6H3F#( ;+LHY)
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M<T >HT4CML1F()P,X R3^%<=X?\ $&@6GAQKO3+6\B@GU.2W6"4_O)+EI"&
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MEQ;'P>V#ZXSVS7->%M.O-'M$\+ZCX'6ZO;:1HX=6:WB:VECW$K([D[@0#]T
MDX[9X]7HH 9+((HFD8,0HR0BEB?H!R:\C_LC5F^ ]QH/]DWPU8R/BU,)R=UR
M9 <_=^[SU]J]?HH X3QU8WUS/X?\06.CG5H=/DD^TZ:\8\R2*50"55OXE(!Q
M6?K>F7^L>%6O]#\+C3)K:]M;V&QEBCAGNO)?<0X4D#K\H)SP?45Z710!YO\
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MTC$)4DG)YR< #(YJ?XEV%]JO@BZL-.LY;NZFFMV6./ X29'8DD@=%- %J_\
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MM 'K,LL<$+S2NJ1QJ6=V. H'))KFCXXLXH-.O;BRNX-+U&1([:^D"["7^X6
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MU9WC#G9C<<$[@!Z=\4 =[1573;F:]TRVNKFTDLYI8U=[>0@M$2.5)'&15J@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@#&USPS8Z]-:W,TMW;7EIN\BZLYVBD0-C<,C@@X&00>E3Z
M7HL&F$R?:+N[N&7:9[N8R/M]!GA1[ #.!FM*B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBDX&WC9C YP3_$,=%%X#TF&+7(XYKU4UE2MP!-RN4"-M.,Y('5LGD^IK6O\
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MA D>V<A=Q7DHW7&>AZUY)X=U.?P_\*=&EM+FX2?5-7^P-/)*9! KW4@9P&R
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MI97#2)MD;9(I/+*0!D\_+4.K^)=1\/7/Q&N(+J:1=/6R-JLSM(L!E3#, Q/
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M&C.D8+=V9@JC\20/QK@FCN[3Q7#X1AOKV\@73WO]UYJ<D4LA>4KCS47<0@'
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M\BGG+1N/L^\$)T4@CJ.3W)H ],HKS"U;Q#XO\.SZQINH1V.H)?2^7,^H2K'
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M:81O+%UV/@889YZ9JWX>\-6'AFVN(-/-R4N)WN'\^=I/G8Y.,GCK^/?-;%%
M&)>>&+2YUO\ MFWN+JQU%H?(EFM64>;'G(5U8%3CL<9'K4-SX,TJXL-,LD-Q
M;P:;<K=VZQ2<^<"2'8D$L<LQ.>I)SFNAHH R+;P[;6OB.YUU9[EKRYB6&4,R
M["BYVC&.,9/YU+J&CI?WUK>K>7=K<VJ2(CV[+@J^W<&5@0?N+U'%:5% '-W7
M@?2+G2+33U-S;_9+HWD-S!+MF68EBS[NY8LV>,<].E%MX&T2WN-6F>.XN#JL
M2Q7BW%PSK*JKMY&>3C/)YYXQ7244 <WH/@K3_#HQ:WFI3;(S%;_:[IIA:H>T
M:MPO;L3QCI4/_" :5_PC(\/?:+[^SA/YX3S1NW[_ #/O;<_?^;_ZU=510 SR
M@T'E2$R KM8MCYN.<XKEC\.M ;PO_P (]*EU+8HX>$R7#%X"I)7RV_AVY.,>
MO.:ZRB@#F8_ ^G+H-[I,MYJ5RE\GE7-Q<W1EGD3!&S>V<+R>!CJ?4U8U#PG9
M:GH5GI%S<WC6UH\;QD2 .3&04R<<XP/KCG-;U% &,?#=N?$::\;N[^WK:_9
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M4A&B4C!3!!4J1CY2"*VJ* .<O?!&D:AI<EE/]I\R2Z6]:[27;.;A<;9-PZ$
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MQK*A0LA&X ]<9!KG8_ FF0V&C64=S?+#H\HELAYB_(P! R=OS8!(YSUKJ**
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M;5Y,YW&(<'GG'3VK4LO#EM8:]J.LPW%T;K4 @N S*48("$P,<8!/3\<UL44
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MAGF\M2PC@B:1W('0*H)R:Y?X86=Q:^"XI+Z">'4KRXFN[U)H6C82R.2>& /
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M+#Y0.Y)Q0!!?>,I[^V\*:;#%=V]YKL<5Q</#!(?)A\M7D"L!U)94R/N[LDC
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M*[M+5KR17B*J85ZNK'AA]*Q--U/3[3PCHXET34Y]0LK6'9 NE3JXF5 N-Q0
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M-RI3[;Y@96QAP5(^[D]S@<UVMFTG_"V=1OVL[U;1]&AB69K60(761V*YVXR
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M<45S(\=:0WAJU\0*ET=/N9_(#^6-R.9/+&Y<Y^\,<9JW?^)[6QEOD%M=W*V
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M#(K2 , 7*G:5(R<$\CG!%.LO$LNL^+=?\/2:?>0V]C'"GG*P0Y=78MN5LJ"
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M >06XU>\F\&:E<Z%K;7MI?-]O5K<I'"3&Z[8TR%5 2,,!C&,L36@MK>GP_\
M$F'^S;_S=1GN&M$-I)F8/ J*5X[L#_.O4:* //->TZX?X9:1JEM&\&KZ#!#>
M0+,AC;=&@$D3 \X9=RX[\5U_AZQFL='C^U@"]G9KBZP<_O7.Y@#W SM'LHJO
MJ'AJ/4M=@U&XU+4/(B10=/6;%M(RMN5V7&20<=\' S6Y0!R7C?3+'5CIUM?6
MNI !WDAU#35<RV4H VL"@) ()'0C@?46O! UI?#HCUR5YIX[B5(9Y8O+DFA#
M'8[I_"Q'.#SZ\YKHZ* //-(U2+3OB=XZ$MO=R!A8LOV>V>7)$'3Y0<'TSBL;
M1_"^K^$1X.U22SFFALOM:7UK;J97MEN&+J55<EMIP&VYZ<9KT#2_#::9XBU;
M65OIY9=4,9FB=5V+Y:[5VX&1QZDUN4 >?2:9<7.L>+_$4=K=+;W>F)96T1@<
M23LJMEO+QN'+!1D=B>F"<RXM+[_A ?A_:C3;\W%A?6#W40M)"T*Q+ARPQT'Z
M]LUZI10!YU;WFI>$_&FOQW.A:GJ.GZQ,EW:7%C!YN&\M4:.3)&S[HP3QBK>K
MQ7TOCSP3<R:?.%M8[O[4T$+O% 9(U55+ 8Z@C/MG@5W5% 'D^D6K:3)?^&]8
M\#2ZK.UY-):7PLDEM[B.20NIED;A""W.<X XS5GQ3I%P=5U+4=!BU73?$=NL
M<<+6UN[6NI*$7:L@P4P"2F21MQGH*]/HH P[/Q%YWB670+C3KR"XCMA.+EHL
M6\WW=XC;/.TNH-8?C>#4;3Q+X7\1VME<7UIIDLZ7=O;(7E"2H$$BJ.6VXY Y
MP:[%;2%;Q[L)F=U"%V).%]!GH._'6IZ /,TMK_6/$?CAX-*OXH-4TB*"UFN8
M#$KN(Y!CYL$<N.",^N*I0RZC>6/P]CC\/ZNK:3/''>>;:E/+*V[(?O8RN?XN
MG3G/%>LT4 <7X+CGA\1^+WGL[N&.YU 3P/+;NBR((T7*DCGE3QUKD[O3]1F^
M'7CZR32]0-U?ZM<RVL7V20-*CLFU@,=/E/T[U[!10!PVI+/<_$/P?>Q65Z;:
MWM;I)I?LL@6(R*@0,2.,E3].]<A');#3M1T*\TGQ$-"?5I+@QV^EM.NU9MVU
M9D)!0LN[[N1DC)ZU[.RAE*GH1@\XKE=-\$OI4*65KXDUI=+C&U+(O$0J_P!T
M2>7Y@'T;(]: -R4Q:WH#FTG_ '5]:GR9@#]UU^5OR(->>>$$Q9:9H.I^ FCU
MC3S'&][+8H;;]W@><LO=B!D8YW'TR1Z?##';P1P0HL<4:A$11@*H& !3Z /'
M-:77-5TF<WFA:NVHVNN1S&*& BW6!9P0T8! D)7DMAFR3D@5N6=]JGA7Q?KJ
MW?A[5;ZQUF:.\M9K.$2[',:HT4G.$QM&"3CWKT>B@#A;Z.^?XC>%;N73YU2"
MQN4N'A@=XH7D";5W 8_A(S[=JG\ 0W%O<>*?M%I=6XN-<GN83/ T8DB94 89
M [J?>NSHH XKQ0LY^(7@^YCL[R6WLVNS<316SND0>+:N2!W/I^-9THOM+\9>
M,U;2=0N%UBV@>SE@@+1MLA*,&?HI!['D]L\"O1J* /)H[/45\%?#FVDTG44G
MT_4+:2ZC^S,S1(D;JS, #@98<'GVKI;&*X'Q<U2[:TNEM9=+A@2X:!Q&SJ[L
M1NQCHPKM** ,GQ-H4/B7PY?:1.VP7$>$D'6-QRCCW# '\*Y'3-*UCQ3\-=5G
MU$QQZSK-@;=2K94*J%$Y_NLQ=_\ MI76:]H']N_95.JZE8QPLQD2RG\L3J1@
MJ_&<?3!%:L,,=O!'!"BQQ1J$1%& J@8 % 'GWA>Y34FL8IO +Z?J]F 9[FZL
M4CBB8#!,4G5BQX&WUR>G//XUO4+7PM?7F@:T=2L]962^C$!2*%<2#$29"[.5
M^<#_ 'FS7LE% '%^$([B/QCXPFFL[N"*[NX98))K=T615B5#@D8X(-2_$32]
M1U#1=/NM+A:XN-+U.WU VRG#3K&QR@SWP<CZ5U]% '%3VS^(O'GA[6[:VNX+
M32;>Y::2XMGA9VE556,*X#'&&)XP..YH\ )/!<^)UN+.[M_M.M3W4)GMWC$D
M3! &!([X/'7VKM:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "JFHZE!IENLL^YC)(L44:#+
MR.QP%4>I_( $D@ FK=<?\1=*U"_TG3KO3;&/49M,OX[Q[%\8N8PK*R#/&<.2
M,^E $TOCW3+5-8%Y:7]M<Z1$)[FU>-6D\HC(==C%2N ><\=\4W_A8&G+>:=!
M+I^J1)J41DLYFMLI.P7<47!+;L>H /8D5BWJ?VOX+\0OIO@Z?2I+G39K6-);
M-([B>5U("A4)P@/=NI/MRMW:WKS?#UUT^\(T]MUWBW;]R/(,?S<?WCVSZ]*
M-N/Q[IO]F:S>7%GJ-K)HQ_TRUE@!E0%=P;"D@J5YSGM3+7XAZ5<ZOIUA)::E
M:KJ2YLKJYM]D,[8SM5L]?PP>Q.1GE]=M[J)?BG=RVEQ%;7FFI]GF>(JLGEV[
M*^"?0GOU[9J^UI+XJTKP3;06=U$-/N+6_N9IX618Q%&?E5CPY9B!\N1C)]*
M+'AFZM]*\3^/Y[NY:.SM+J&1I)I&81KY"LW))..2<5O1^+K07^GVEW9WMC_:
M6?L<MRBA)FQG;\K$JQ'(# $].O%<9?\ AK4M?B^(VGQV\]LVJO"]E+-&4279
M&@(SV!9<<]CFM348;WQE;>%[=]-O+&YL=1@OKXW$)183$K956/#EF( *DC!)
M.* .BTKQ5::LVK)':W<$FE2&*YCN BD,%W<?,>",$'@'UJF?'=@+K2[4Z?J@
MN=3MFN;:+[.-S*H!P>< X(^F><<UD>)]"NV\<V;Z<R+;:] ;/5H\X)BBPWF
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M#GD,OKQG@UI/8MXN\.:K::?X/;P_<S6$L!GO+:.%S(PP$0KR4SG+' QC@YX
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M&]EI%K=7SV=W/IMG-Y-U=PA"L3 A6^4L&8*3@X!QSUP< '3T5$TX-K]H@0W
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M*TNDM+B6$IB.1MO8L&P-ZY./7K@T ;U%4]5U&/2=*NM0FBEDBMHFE=85W,5
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MSI&ZMTY RP[<C.*UO"FL^(KNULM.U+PY<Z?/:H$O+F9D,+[1C]UM8EBQ [
M9Y/&>QHH \H;PSK=_P"%O%5O#8-%?2>(&U6QBN@ EPBO&R@\X^;81@X[9K?T
MNXNK^PN[B+P*NER16D@:*ZCB#7$FWB)-IY0]V.,\<=<=Q10!Y]X3T"XT7Q.A
MT1-2L_#TMJ[76G7Q.RWGRNT0Y)/][."5XZ],:_C"364O-%%C9W=UI;3N-1CL
MG"S%=O[O!+#"[OO8(.!Z9KJJ* /+M)T2ZM]%\4:9J?A*:;3[W66G^S!D(:!_
M+&4PWWEVENW(&"3TZ#P-I6HZ/-JMJ]U?SZ&'C_LP:@29D&T^8O/S; =H7=SP
M?J>QHH X[6K2\E^)?AJ_BLIY+.TM[J.>=5^5&D";?<_=/0<5SC:1JS^!O'M@
M-*NQ=:IJ%W+9QE1F5) H4YS@=#UQBO5** *.F(SZ':1R1R1/]G5&1AAE.W!%
M>=^$=/U31[.W\,WW@N*6[LV\J/6/+B-N\0/$C'.[=C^'&21U';U*B@#C8;>]
M'Q;NM2:PN18/I$=FMSL^4RK*S$=<XPW7&.*RK?0=0U5_B!8RVEQ9IK9*V<\J
M_*P\@1Y..0,CH<'!KT>B@#S[PJ=0N4M+"_\ !":7?6RA;J_9(O*.!C=$5.YF
M;Z8&>IQ@Q^"9/$WA_2;?PC<Z!.TUDQABU0,GV5H-Q(<_-NW8/W .2!DCG'HM
M% '':-9ZCI_Q)\33RZ=,;+4Q:R0W:LOE@1Q;&!YSG<.F.^:=\3+.]U+P7/8:
M=937=U+/ RQQ =$E1V))( X4UU]% '%ZK#>77Q'\,ZE#I]VUE;6]U'/-Y>!&
MT@0+D'G^$]!Q3(+/4/#OQ$US5&L[B[TS6H8&$MNF]H)8E*;&4<X8'(/3/7%=
MO10!Y3)X6U6PT[2&73YY)YO%9UNYABPWV:)B_!.<$@%<@9YSC-='9P7D/Q0U
M?4WL+H6,NFPP1S[,AW1G9@!UZ,.W-=G10!R/PSL;W2_ UI8:C9RVMU#+.7CD
M Z-,[J002#PPJ*PM=1TWXF:_>/IL\ECJ5M:F.ZC*E$\I7#!AG=GD8 !S79T4
M >12:)K3_"?4=(&CWG]H3:JTZ0;5R8S="7=G./N@]^M=5>6]Y-\4-(U1+"Z-
MC%ILT$D^S 5W9&4$=>BGMQ79T4 >1R^&]=N="UQ[?2F-Y%XG;6+6UN@ EY%P
M-N>0,C=P?:NT\+3/?3-=#PH="B6/8WGQQK+(Y(.%V$_(,'DXR2..*ZBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ KE_'OB&^\-^'1>6%KYTLEQ% 7W*!&'=5S@]3S@?F:Z
MBN5^(FEW^K^$)8--MC<W4=S;SK"&"EQ'*K$ D@9P#U- %^;Q"4OX=,AL)9=4
MDMS<O;>8@\J,-MR[9QR>!C.<'T)J3P_XAM/$5G/-;I+#-;3O;7-O, )()5ZJ
MV"1Z$$$@@USKV>K6'CZ/Q0NF7$ME?Z>+2ZMD9&FM75RR,1G# @X(4G!]1S6E
MX1T.XTZ[UW5+N(P3:M?&X$!()BC"A5#8)&XX).">N.U $+^)=2_X66/#RZ<Y
MLTT[[29%D3+;I0N\@G@+AACJ<].E9]MXMT;1M"\4ZW:Z%>PK8ZE(M_$NSS))
M@J;I/OXQRHX/OBKMU8:G;_%6#6(=.DN;"?219-,DB 0N)BY+ D'&T]@>?SKF
M;O0-=G\'>/K!-&N?M.KZC+-9H9(OWB.L:@YWX'W#U]J .JE\<"#6K73)M"U-
M'OH7DL' C/VDH 64#=E#@@_/MXZXJ6P\;V5QI>J7=[:W%A-IEQ]FN;:4JSB0
M[=@4J2&W;U YZFL_4K+4[GQCX,OX]+N3;6$5R+IRT?[HR1*J@C=D\@YQFL.^
M\*Z[JD/C-8+)K:XNM1M[_3FN&0QS&$1_*P#'&2A'..HH [#3_%]M=^)3H%S;
M/:WS6_VJ',B2)+'G!PRDX8'J#^&:Z.N4\.7NJW\@FNO"8T3R8SYGF/&S2O\
MW8]O\/7YCCMQU(W=&O;O4-)M[J_TZ33KJ0$O:R2!VCY(&6'!R #^- %ZBBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH ***Q-=\0R:0Z06FD7VJW;J9#!:!?D3IN9F( SR .IP<#@T ;=%
M8WAGQ+8^*M(_M"Q6:,+(T,T$Z;)(9%^\CCL1_6MF@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH *J7][!IUL]S*I9CA$1!EY6_A11W)/2K=<_KWA
M*W\07]O>3:IJUK);J5B%E=F$+GJ>!G)Z9]* '^%=$?1-.N#<;/MM_=RWUT$.
M5620Y*CU"@*N>^,]ZW:R="\/P:##.D5Y?WDDSAGFOKEII.!@+N/11SQ[GUK6
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
&BBB@#__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>23
<FILENAME>exhibit1016-arvinasxamen003.jpg
<TEXT>
begin 644 exhibit1016-arvinasxamen003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(\4ZY_P (
MUX9OM8^S?:3:H'\G?LWY(&-V#CKZ5KUSGCW3+W6? ^JZ?I\'GW<T0$<>Y5W$
M,#C+$ =.YH AA\4:G:ZO8V&OZ&FGK?N8;:X@O!<1F4*6"-\JE20IQP0<5JV?
MB71-1U2;3+/5;2>^@SYD$<H++@X/'L>#Z=ZYZY@USQ5J^CB[T2;2-/T^Z^VR
M/<7$3R2NJLJ*HC9L#+9))'3%9&E^'M=>T\.Z'-I1L/[$:1I=4$R%9LQ21@QA
M3ORY<,VX+C!ZG% '8Q>,?#<\MY%%K=B[V:-)<!9A^[5?O,?8=SVJ]=:OIMD9
MA=7UO#Y$(N)?,D"[(R2 QST&01GVKSMM$UZ^\&IX8/A>WM9K32)K/[?++$RL
MYBV+Y)!+ .0"Q8+@=<FI[[2];\03ZG>W7AJ>&.72K>VCMI+V..5Y$F9V*LA8
M*1D%2>"0,X[ '7Q>*-,OK*"[TN]L[N"2[2U9_/VA6)Z=#EN1A>,YI]KXL\/W
MNJ'3+;6+*:^#F/R$E!<L 20!WQM.<=,5Q&GZ!XDN(-MQ#>F!=7L[B)M0:W^U
M[$_UC2-&=K ?+MR2W!]JSO#UW*=6\!:1]BM#'I[SHM];W<<@N +>12ZJIW*"
M<%MP&&('- 'I&G>*] U>]^Q:=K%G=7/E^;Y<,H8E>.>/J/SJEK?B/4K+Q'9Z
M)I6D0W]Q<6LET6FO/(5%1E4C[C9.7%8WASPSJ.FVG@:.6R6)M,MITO '3]VS
MQ@=CSEO3-)XS\/S:CXPTS4)?#4FN:?#8S0O%'-$A21G0J?G=<\*W3UH Z-?$
M/]G:>+CQ0+'1I'D9(T^V>:K@+NX8JO/#<8[5;L=>TG4Q;&RU&WG^U1O+!Y<@
M/F*I 8CZ$@'TKE;30Y9KGPV;?PS)I-GI^HS32V\TL3[0;>11(-CMGYV4>N1G
M&.:SM2\,^(K71GO]&LU.MVFL7UQ:QF5%$D$[N.N<#AD?!Y^3UH [*\\7>';"
M&":[UJRACN"PB9Y@ ^T[6(]@1@GH*C;Q3:1>(+[3KCRH;:SL(KY[QY@$VNSK
MZ8 &S.<]ZXO4/!NHZ/J5FUA!JUU9II,.G_\ $LNXH9 \9<DN), JV_.0<@@Y
M!J.3P3K,9,<%B&2WTS3%2&2X#K*]O<-*\.\@9^7 !( Y% '?0^*_#]QI;:G'
MK%D;%9!$TYF 57/123T/(ZT1^*M FT>35TUBS.GQ-L>X\T;5;^Z?0\CCKR*\
M^\2VVJ3RSZ]/H;VPNM1TJ&'3II8S).T4S$LY4E06WA1R>%YJ;5_#>O:S/<:Z
MFFW=DQU&WN1I\5S$ERZ1PO&7# E!(3(" 3T0<@T >D:;J=CK%DEYIUW#=6SD
M@21,&&1U'U'I7(R?$"ZDQ%8Z*D]T^MSZ1'')>>6I,2LQD+;#C(4\8_&K_@G2
MKG3X=2N+FVO[=[RY$H6_NDFF8!%7<^P;5)QC )X R>U<K'X?\0:?.E[%HTUT
MT/BN[U#R8YHE9X'C=5<%F Y+#C.?:@#KK#Q:PO[S3]>L5TF[M;7[:Q-P)87@
M!PSA\#[IX((&,CUK;O[BZAT]Y]/M%O;@8,<)F$8?)&?F(..,GIVKF;*VUF\\
M37'B>^T>2T^S:<]I::?Y\;S3%G#L2P;8N=BJ!N]22*ZN=YELY)(8M\PC+)&2
M!EL<#/3KQ0!Q=SX\U.RTS6+JY\.(KZ=+!!M6_#+)+*ZKLW!."H=2>#U JWJ/
MBC7M$T+4M6U;P[:PPV=N956'4C(9&R!M_P!4-HP2<\].E4-3\)WT_P )X]"%
MO]HU&9K>:\1G4>9*9TEG))..N\]?I5CQ+X)LX? NO:=X;TJ*.[OK<((XV"^8
M0>!EC@=3WH MP>+-2M]9M],UK0?LLUU!+-;FTNQ<A_+ +*1M4@X(QQ@GC--L
M_&LR37<6N:0^EM!I[ZE@7"S$0K][> !L?GIR#S@\&L'2O#=[!XFLM1T7PLWA
MU8(IEN6N+J-UN@4^2,I&[<!]K;N",<9S27'A[5_$MU?,V@_V!+=Z7<6NH3&:
M-EO)G0*F C$LJG)#, <'&.30!T^B>*+N_P!4CT_5-'?3)KFU-W:YN!*)(P5#
M X VN-Z9'/7K3/#'C2'Q)JNH62V;VP@_>6LC/N%W#O>/S5&!@;D/'/!![US]
M_!XMUI5O8=#DTZ^M-,EL81+<1'=-.T0>12K'Y$5"W."<\"IH? MYX9U;P_?Z
M+?:AJ*V>+":"ZDB"I:,N"5PJYVLJ-C))P<<T ;&A>+;K7+V81:9 EBAEQ.+Y
M6D*JS*K&(#(#;<CGH:R[+XA:FWAZS\1ZCX;6WT2X5)'N(+\3/"C$ .R%%X&1
MG!) YQ572?#]V^K:.8O",.@/IIE:ZNHI(BEP&C9?+0J2S*S,KY<#&T=ZJ6.D
M^*+SX<V7@J?P[-8[K:.TNKZ:Z@9$CR-Y54=F8E<@<#D]: /1M6OI=-TN:[@L
MI[V9 !';P#+2,2 ![#)Y/89/:LO1_$LUW>:E8ZOIZZ9=V$4=Q*!<B6(Q/NPP
M?"XQL;((&,=ZJ:C8^)-&MM3U#2;^ZUFY=2MGIDXA2*(LXP0V%)"KG@MR/?FL
M:V\+ZAKF@WNGW5OJ&DW=S/%/>WUX8)S?XSE"L<AVH, ;>!CCG)H WM%\;V&L
M>'M5UT12V]AI\LJEY1@R1H@?>!V!!R!]*I6/C]KGP-JWB"XTE[6[TR-WGT]Y
MLL,()%&[;_$K*<X[]\5@-X,\3W.G:IHEY=&2SU765DN+B)(XBELJJS.!D\N4
M5 N#C!)&#4VN>"M9M(]?ATR>]U=-;TF6"9KN:(,DZ#$70(,%69>G&!DXH WX
M_%NJ6=SIPUW0$LK34)DMXKFWO1<!)'^XKC8I 8\9&>2,XKJ+R[M]/LIKR[F2
M&W@0R22.<!5 R2:XJYM]?\2_V-87&@3:59V=Y!=W%Q<W,+E_).X(BQLW)8+R
M<8&:EU#P1J^HVBV\_C"\N$6XCGV75I"Z'9DA2JA<C)4X.>5% #1\0I+KPYIV
MJ:?HKR3:AJC:=%;7,_DE2#(-S':V/]7TQQGVJ<^//[/CUA=>TMK*YTR"*=X[
M>87"RB5F5%1L+\Q9<8('4=JY>Z\&^(#X9M[74+(ZR8_$<E]):IY41> M,2V2
MX'S;U;&<C..U/'@?4;R#6?[,TC_A'[:6&WDM[&XN$D$MW%+Y@D.QF"#"JAP>
M<YQQ0!U]EX@UU-1MH-9\."SMKI6*3VUU]H$!5=V)L( N0#R"PSQFH]'\93:E
M<:<]QI#VFGZMG^SKEIU9I?D+KO3&4W(K,.3TYP:=::MXGU35+*%O#[Z39QDM
M?2WDL4F\;2 D01B3\Q!W'' Z<UR^D>#]1?5M.C%EJ>DP:8\\BR2:@L\$9:-X
MT6V3)./GW?.HQM"]S0!V/B3Q#>:->:39:?ID=]=:E,\4:R7/D*NR,N23M;LI
M[4W1_%0O/[7BU6T73+C2"OVO,XEB563>&#X';J" 17,^)?"6J2'0C=1WGBR"
MUO99KB.8V\+A&A**!]Q2 V#ZU6LO 6I7\>HP0J_AO29[FWN(]-<I=!V0'>7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JG;Z3IMI=RW=MI]K#<S?ZV:.%5=_]Y@,G\:N44 %%%% !1110 4444 ,
MEABG"B6-) K!U#J#A@<@CW![T^BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8R<BGZ?XCTW4=3FTR*26.^AC$S6]Q \3F,G <!@,KGC(Z'@T :U4;^VO[B2
MV>H"U5=WFJ8!)Y@(P,$D8(//\ZKZQXFTG09[2#4KHPR7;%(!Y;-O(!.. >>#
MQW[5DP>(]!UO7=!FMM6OTGG2X-M:!)(H[@ 8<R*R]5V\9(P3[T =%ING6VDZ
M;;V%HFR"! B G)/N3W)/)/<FK585_P",-$TU;N2YNG6"SD$5U.D+O'"YQA68
M @'D9],C.,USFJ>(5M?B+H=P-1O/[,NM-N9#;*KD.RL@7;$!N9N3Q@GTH ]
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M58:0]E>K?6EW!'-"UK(&#+=!F X^;"C)(R.E=3J\4FH?$Z5;1F47'AB>UCN
MIV"5Y5*C=C&<<X]*]%HH \I\)7.E:E9:+HVHZ!JO]OZ8\(DM[H3F*W>/ \X.
M28P, E<=<X'6NU\:V]A=^&9;?4TNC:R2Q*TEIN\V$[UVR+M!(VG#9]!70T4
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MSCFL[2FL+:WU#PCXFT35KO4/MD[0P@3O;WZ/*TB."#Y:C+#); &,GG->P44
M96O:.NN>%]0T9F$0N[5[<,.0A92 ??!KE_!7B*/1_#=CH'B&.73M5TZ);5HY
M(FV3*@VJ\; 8<$ =.<YXKO:* ."\:MJ%PGA[7(;&Y:RTS55N+B (3*8"I3S?
M+QG*[B=O7')QR 2)'J?Q$3Q'9N3IUGHTEO/<JIVRL[AE0?WL $G&<$@=37>T
M4 >,0(\?P=\&VKV\XN(-2M&EA\EM\82;<Y9<9  YS[UU4T@?XO7,ZJY@;P[Y
M(E"'89/.9MN[&,[3G'I7>U#=Q2S6DL4,BQR.I57=-P7/?&1G\Z /&M/BA\2?
M K1/#M@I?5)C L:!"&A*S!FE/'RJ%#'=T.<#)-6?&EU/J.G>.M-;3[V"Z4?Z
M/;VEFP%V@1?W\DBK\_0C!. % P37I'A/07\,>&K+16NQ=):)Y:2^5Y9*YR,C
M)YK:H \\M;I)_BEI%[Y4Z6__  C[Q&26%D"N948*<C@E03@\XJ+PKHL'B'P=
MXJT:\CDCCO-6O67?&5(5Y-T<B@X[X8'VKTBLK7=,U#5+>"/3M;GTETE#R20P
MI(9$P05PX('7.?:@#GO DNJ7NGRZSK\16]MHSIPV_/N$+$22#'=W!X']Q:Z'
MP]X@LO$VDIJ-B)UB9BA2>,QNC#L5/3L?H:N65C#I^G0V-MN2*&,(A)RW'<D]
M3W)/4TMG9PV,'E0@X+%V9CEG8G)8GU)H X1HKE?B+XLM%CN89=5TRW2SG6%R
MFY5E5B7 PNTL.I'M6')%+K'P9@\'"TFA\01I!9&T>-@T3QR+^]SC&S"[M^<>
M^>*]?HH HZH"NA7JEBQ%LX)/?Y37E-I%#XE^#OA?0=/4OJ3-:,H"$&WV.&>5
MN/E7:&P>^X8SFO6]1MI+S3KBVAE6)YHVC$C)O"Y&,XR,_G5'PQHK^'?#=CH[
M70N5LXA"DHCV$J.F1D\T >7^-+JXU/0_&^GG3KVWNX[@&&TM+-@EQ&/+Q</(
MJ_.2 >"< *!@GFNIM[J.Y^,-O>+%.L#^'_)622!U <SA@I)'#;><'!KOJ* .
M%T.8Z=\3?&*74%Q&MX;2>&4PMY;(D 5FWXVC!&.O6N/TQ=0L/AQX4U.+3[N<
M:-K$US>V:Q-YHB:28;PA&20) P^N:]JHH X?4=7T_7/"7B2_TS3Y5CGTZ2+[
M5):-%)<OY;!4564,V,XSC&6P,\USSW4-F_PGEN@R)#"\<H9#F-A:;3N&,C!Z
MYZ8R>E>LUS^L^')]5\1Z)JT=_'!_93R.D1MR_F%T*-D[AC@\<=?6@#B-:CN(
MKWQKXHTW2DU"SGM;6V2)X#(ETZM\\H3^-44CZ[3@\5;T:82_%47<7]J75O=Z
M"(TO+FV=1(XF+'JH"#&.,*/3)//IE% 'BE@+^+X5>%VCTS4I9- OEDU&T2*2
M*4H/-1MG0L5WAN#^-=[X3ET/5-0N-7T;3KQ?,A6*6^O%E5Y,'(0>;RP'.3T'
M &><==10!Q'C%L>-O!3A)&6&\F>5E0D1J864%B!P"2!S6/ X\[XFDQR 7/\
MJ,Q-^^'V8)\G'S?-QQGFO3Z* .)\,>)++2O#O@[1[R.Z2ZO+"*%3Y#;(Y$C4
M%7./E.>,'O6AX_O)K#PC<3P:<M]B6(.C0>>(U\Q<R>7_ !%/O >H![5O3V45
MS<033;F\AMZ)GY0V,;B.Y )QGZ]:L4 >7Z3<QQ?$'6[K&IS6UUHT)CN[JVD
ME*M)D\J O4 # SV'-9=NKQ_##X?V[03B>UU:S>>+R6WQ!')<L,9  /)/K7LE
M% 'F&F:BV@ZMXSTO5X+KS]1NY;VQF2W>1;F)XE554J#RNT#!KI/AKO7X<:#%
M)#-#)%:)&Z31-&P('HP''OTKJZ* "BBB@ HHHH **** "BBB@ HHHH ****
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MWC]P9%!,:D#=D$9('(P:XBPAO(OAGX9L)-+U-+FS\0I)-&UI(S*BW3N6X!R
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M-J%Y'+<S>99+;%Q%<$H3AR!M*[><$^E<EXINKO4;SQ=IS:;J*++I8%A]BM'
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MFVO-;N6C:Y4 M# @#2%<\;L$ $].:O:EX1CDT>>'2[V_M+XQGR[C[;*Q9O\
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MS3KBVANI;266-D2XB +1DCAAGC(JIH6C?V-9NDM[/?7<S![B[N,;Y6 "C@
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M/-C:>#:5W ==IXKL]3M;CQ!XTT#5;"SN$CT>&ZE:2Z@>#?))&$2,;@">Y)'
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MQ?S/N, 2J@ <@ EL#I5+38[T^-_#>L?V-KAA_LZ>&ZN+N([ED.PG*Y^0##8
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M*3GIGJ/$>A1>)=!NM'N+B:""Z39*T.W<5[@;@0/RJ_9VYM;.&W,KS&- OF.
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M175Q%;NZJ/L_EJ20.[?EWKN-8MY+O0[^WA7=+-;2(@Z9)4@5=HH \F,.HR^
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M@222"2!F',4A4LOUVDC\B:Y/2O$'AZRA\3:E;V]W;"VO]E]Y^<R3E4 VAF.
M<J!]T?SKJ[2=[FUCG>WEMV<9\J7&Y1VS@D ^U>>V5A,+;QLE_H%U>6NH:FLJ
M6SQ$&X@81HQ7IR &(&0>!0!V]AJK7M[<VDMA=6DUND;GS]A#J^[!4JQ!^X<T
MFH:U#8WL%@D,UU?3HTB6T&W=L7 9R6( 4$@<GDGC-<WX)TK4-'U74;6"ZU&?
MPX(HS9KJ2L)89,MO1=P#% -O7UP,X)J/Q*FK:'X]L/%%GI=SJE@]@VGW<%H
MTT7S[U=5)&[G@T :UKXVTN\TF"^BCN?,GNFLH[-D F,ZDAH\9VY&"2<XP,YI
MT?C&Q\S5+>XM;RWOM-A$\UHZ*TC1'HZ;20R\$<'@]<5A>(;77-0N?#GB>+2Y
M@VF7KR/IV5,WV>1-C$@'!D'+;0>AQU%+>Z9<:GXHU/Q+%:726Z:$VG0(\+)+
M/(SESA"-P ^4<@<D]AF@#0LOB%IMZ^BL+#4H;76-JVMW-"JQ&1E+",_-G. >
M<$>]:)\46[7$B065W<017JV,EQ$$*)*653D%MV 6 )Q7$C3=27P;\/;,Z9>?
M:-,OK62\C$)S"L<;*Q/KR1TSFI=0T6[/B%]7\/VNIZ7KC:BJW$01OL=] ),&
M23/R ^7SGALCH20: .CM=8T&#Q1XGF$%U;WMC;0R:C<2[O+:,*Y4J,GH W(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY*[28TZ*2,C/N<8R:VZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MAAD9PPP17D<VA:__ ,*BUKPP-#NC??:91$0\>V8/<F0,IW=-IY)QZ<]O7J*
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MSE3WP!SSZ]C;6NIV7Q.U'43I=P]EJ&GVZ+.K)MB:,ON5_FSG##& <_J.SHH
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MGB08[&M"BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MNF2VGD[L\8X.>XZ'N*NWOA.SOWU!9[J\-IJ+J]W:>8/*DPJKCD;E!"C.TC-
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M2,=.>E6H_"MI%J.KWT=U>+/JR*ET=ZX(5=J[1M^7"DCC^?- ''V^O:K=^&?
M%[>W$PL+X :I<1,5<MY),>2O(4N,L1CISQFI+*W\2R:9XLETZ^O)5^T^5HXN
M[@@21_*6"LW/)W*KD]QST-)XB\/1:3'X?TN.T\0-H^GI(8KS2I&:XMWP%5"$
M^8IM+\X)Z#IG-_1/#TM]#=0OJ/B1]*F1"O\ :LV)UE5PZM'D!T V\[NO&.E
M$_@C6K74]1U.$+JMC?PQQ"XTK4I'=H#\_P Z,Q.Y6R.1_=![UVE8;>%K25=0
M:>ZO);N_MA:2W9D"2K$-V%4H %P68Y SD\YK6L[9;*R@M4>1TAC6-6E8L[ #
M&6)ZGCDT 34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ML:726;SQQ[HTF9@H4G.>K $XP#QG/%;- !1110 4444 %%%% !1110 4444
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MKOPS+8+=M;N(UF>3(!..#@Y_3KQ0!T"^,]-^VZ=!+%=0PZFVRQNY(P(KAL9
M!SD$CD;@,]LU=\1>(;'POHTNJZEYPMHB QBB+D9( Z=.2.3@5P_A$B:#2])U
M#P%);:QIYC6:\GLD^SJ8\ RI+_$Q XVY.3Z<UK_%TX^%NMD#.%BX'_75* -"
MS\=:3=Z__8IBO[>Z>)IK<W%JR+=(O4Q9Y; YQC..E,TOQ]I&L7$<=I!J/E,\
MT;W+VK+#"T6=PD<\(>#@'VSC(JEJ=N_B+QAX:O[>TNXK?2#/<W$T]L\1&Z/8
ML:A@"Q).3C(PON*S?#FBWVH_#;Q'HCP7-C=WD]\(C<0M'Q*SE&Y'(((SB@#I
MD\9Z:7TYI8KJWM-2<1V5Y-&!%.Q&5 YW+N'3<%SVJSIWB2UU/6M3TF*WNDN]
M-"&=94"CYP2FTYYR 3GIZXKBKJTO_$_@31/#DFF7UGJ<$UJMT9;=EC@$+ NZ
MR$;&!"_+M)SN'OC5\5Z)JG_"7:;JNBHW^GPOI6HLIP8X2"ZS?5"&P?5@* +>
MHZ]HM^WAN:\BU*)KN^4V&T,JM)M;!<J=I4C)P3R.<8K3D\3VJW$D<=M=SPQW
M:64EQ$JE$F9E7:?FW<%ER<8'K6)XUM)!>>$(K*QN)(;+5HII!;P,ZPQ+&ZY.
MT' &X<5BZGI=Y'K\^K>&HM5T_66U!4N;-H':ROXPX4RL2-BG9SN!!X/&2#0!
MUFGZAHTGC/6TA:[34;>WA^V&8NL(3YMI4,<>N2!CWI5\::9G3Y)8[J&RU&01
M6=]+&!#,S?= .=R[NQ8 'M7.7>D7NJ^+_&ULD%S;QZGI$5G;W;P.L9D"R X;
M&.-X^O:JEQ9:AXD^'&D^%)=+O;358GM8+AI;=EC@$+J7D63&Q@50XVDD[@/7
M !U%UX^TNVO-5LTM-3N;G2PC7,4%HQ(#*6R,XXP,Y[Y&,U?3Q187$&FR6*RW
MK:E ;FVCA"AFB 4ECO*@8WJ,$YR>E<U8QW$/C'QW<R6-Z(+N"V%O)]ED(F*1
M,K!>.<$@>_:L2PT**[\%^$]/U2QUS3[^RLG$6H64$HFLIEV@J0JDX8>H(.V@
M#U#3;^+5+"*\A26-),_)*NUU()!!'8Y!K+O_ !;8V(OW6WN[J#3CB]GMHPZV
MYP&(/(+$*02%#8!YH\&G63X5L_[>.[41O#N8]C.N\[&9?X6*[21V)KF="2]\
M,GQ3I.H:;?77VN^N+VRE@MGE2X289V%E!"L#P=Q YSTYH M>-O$KQV?AU=-6
M>XL]5U&V1YK8C;-"VYBBG(.6"C\">:Z'1-&AT>SN38_:D6Z<W"VMS+N6!BH^
M11SM7(S@$C).*X2?0+_0O"7@#1VMKJ[N--U.WN+MK>%Y5B0!]YR!T!<#UQVK
MU!W)MV= <E<J"I!Z>AH \C\/:C;>)]%N](N]8U+3/':+(LT<UW)$_F\XV)G8
M8^GR@<#GKS7I^H:S%8W"VL=O<7EV8S+]GM@I<(#C<=Q  SP,G)YQG!KSWQ7:
M6OC/P=&;[PWJ<7BL6X^RE+*17AN,<?O@-@3=R<MP/0U)JMIJ.@^*=/U;5M"G
M\0V=QI,-E=/:6PN)(;B,L=X3KM;>>1_^L Z^T\9:1J&E6-]922W'VZ1HK>W1
M,2M(N=ZE3C:5P<DD 8Z\BL?7?B)!9^$=5U33K.YEN["X^QSV\BJIMYB0H+\X
M(RP/RDYS]2,K5+6^TB_\.>)]+\+RQV%H]RESI=G HG2.8*!)Y:\%\ID@<X('
M8FKOC+^TO$_PVUDV>BW<+RM"\%M+%MN)0DB,S%,\'"D!3SQ[@4 ;&H:GI4OB
M3PW#?0:C!J,TDQLX\,J B-MWF%3L/RC@9)Y%6+[QAI]C'>SF&[GL["0QWEU!
M&&C@88+9YW-M!&=H;'?H:Q-=DN-1\7^"=0BTW4%@@GN))RUJV85>)D4O@';D
MD<'D=\5GZ-!?Z!H7B;PY?:9?7,\US=2V4L5N\D=VDV2N7 VHV20=Q&.O2@#J
MKWQII-EJ5E8?Z5<3WMNUQ;?9H&D65  ?E(X;J.F<=3@<U<\/^(;/Q)82W5FL
M\9AG>VGAN(]DD4J_>5AZ\C\ZXC2]"O="\2>!;.2"YG33-*GMKFYC@=HTD98\
M#<!C&5;Z8&<5L^ 8;BWNO%/VBTNK<7.MS7,)F@:,21LJ ,,@=U- %CQO9::^
ME7%]K.O7NF6D,1\LVUVUOM?D[OE(+MTPIR..G-7_  :]_)X,T>34[N.[O6M4
M:6>-PZN2.NX<'ZCJ:-3UJTCOI-)O=)U*XCDAW>8FGO/!)G(V%E! /^]@<]:@
M\"Z%+X<\)V^G2J8RLLTJP[MWDJ\C.L>>^T, <<9S0!=O=?@M;Z6Q@MKF^NX8
MA--#:JI:-#D*3N(&3@X .3@\5S'C/QFO_"LKG7/#\LTJW"!([F)<&$F14;=D
M@JPR1TR"*?:QWGAOXC^(+V[M+N?3=9BMY(+BVMWG\IXD*-&P0$C/4'&/?-<[
MJGAW4K+X2ZY9I874E]JNIO?164,1D:)&N%<*=N0,(N3[Y% '?Z%HMI97=SJ5
MI%?6GVM562SGERBLI/SA<G#'N0><#O7%65WIZ?$WQ?8:UK]U;6=LMFUG%-K$
MT*J7B)?;^\&><'VKT^&59X5E0.%89 ="A_$$ BO/=$N)-.^)GC'4;K3M46RO
MULUMIET^9Q(8XRK]%)X)[]: -B#6M,\.^%KO7(KG4=1TAIGF642-<M%&,(2&
M9BS)N4MG)P&]*UK/7+36;AK.WCN&1K:.=IT("*L@RHWJWWL<\<C@]""<O^UF
M32;U++0;M;=IOL]O%-:2#S&D.7D9,96(%^<@=& '2LGP79W7@K5+[PM):W=Q
MI"@75EJ"6K$ L/GB<J.2,?*>>,#/ % &?X"\8VFD>"M+BU+^T91+?3V[WK1M
M)'&[7,@022$]^!GG&1G%=6]QH]WX^ET\F_75AI9+8>2.+R/,'*\@;MQ^\O/!
M&:X)=.U(?!>'2_[*U'^T%U/S3;_9)-X7[9YN<8Z;.?TZUURQSO\ &%+\6=W]
MC.A?9_M!MW">89@^TDC@[>?TZT <]X#\>V&C^!-"CU?^TBLKO%)J,D#O CM,
M^ \I[GCGD#N178-J.DCQY<0I'J$FLPZ7O,8W")H?,XVAB%+%CC(],9KB;#2=
M0O/A /!$FEWL6K2%K>3SK9Q#$#.7\SS<;& 7D;223@8KIHK:>+XOBY%K=FS7
M05M!<F!O+,HFW;=V,9V\YZ?C0!H^!_$TWBSP['J<UC+:^9)+MWXVE1*ZJ 0>
M2 H!X'-:FN:BVE:/<742"2XP([>,_P#+25B%1?Q8@5SGPOAO+#P=!I-]I]W:
M7-E+,DAGCVJY,KL-A_B&"#D<<U;U:+^W/%5EIDT.H165FC7)GC22-'G^ZBB0
M #Y5+D\XR5[B@"E\-]6OY]/U'0M:N#/K&BW;6\\K=94;YHY/H5/'TKK=1U"U
MTK3;G4+V416MM&TLLA!.U0,D\5P%[IMQX5^)^G:KIMKJE[9ZC;-:ZHP26X\O
M:08I"W.><C'89XYKKO%DVI0^$M3ET>T2[U 6[>1 Z;@Y]-IZ\9X[]* ([+Q7
M:7NI?V<;2\@O&L_MT44R+F:'.,J58C.2!@D'D<5RS?$J['P\U;Q(-%NEDMY9
MHX5.S:N)"BECN[8&['?IFHM(BNF^(VD:JFDZX;:729;>2YOHR&$ID1CO!/[L
M8!XP!_=!K-.D:O-\(O$WAU=(O1?I/<NBM'A9@TYD7RS_ !Y7T^E 'H4OB>"&
M>SLS97CZC=1O+'9JJ>9L3 9CE@H&2/XLG/UI+;Q=I-YH5CJUM)+)%?2>3;1!
M,2R2 D% I[@JV<\#:23@9K U'5=2N_$.D;]&UA-&GLY,M;P%9_.W+A)"#NB3
M SU7)QDX%<EI.GZ_H_ACPOJ4>@Z@\N@:E>&ZL?+_ 'DD4SR M&N<N55P1ZYX
M[T =+XW\0VVL_#WQ9%:O>6>H:5'MGA+F*2)B 5R4;#*0>Q(-;^D^+;"XU*ST
M5HKR&YFM?-MY9X"D=P% W;&/7&0>@XY&16)XLN[WQ)\.O$'V70]0@-U;B*VA
MFMB+B9SU)09*KT W8/![8R^_CN+CQQX(NX[*]-O;6UTMQ)]ED B+QHJALCC)
M4_3O0!M7?C72[$PRSQW*Z?-<_95U (#!YN[;@G.X#<"-VW;GO4'B?7[8Z5K=
ME;Q7UP]I;-]IELCM^S$IN&6#!LXP<+D@8R.1GC_"]FVG:?'X4U?P-)>:E:R&
M.+4'LD>TG3<2LK2GI@8)'+<<<G N6)U+P]<>,M'O-(U*Y_M.ZN+ZQNK:V:6.
M594 V%APC+C'S8H ZOX?R/-\//#LDCL[MI\)9F.23L')-='7-^ (;FV\ Z';
M7=K/:W$%G%%)%,NU@RJ >.WXUTE !1110 4444 %%%% !1110 4444 %%%%
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MZZBB@#E_^$%L/^@MXA_\'-S_ /%T?\(+8?\ 06\0_P#@YN?_ (NNHHH Y?\
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M=6JVL_E)).H"SC .],'E><5H444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M]M<6[*@BDCED*MD;<[NASGC' % 'K]%<3IUY>>+M4\30IJ5S8+IMW]AM1;D
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M:CJ6H?#CX@6MW=WJ?V;<2Q0;W7S1'Y:,(W9<[A\Q'4DC@DT >NHZR(KHP96
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M\67,FI-#:16+W6FL95FGA=$)=263YD)QC.2/6J6MMXATGP1;:['XHOGN+MK
M-$T47EIO95<+\N[!W>N>.O- 'J5%>?O'K$7Q'.@CQ'J#65[I;7CEEC\R)UE5
M?W9VX4$-Z'IZ\BC8:WXC/@R^,/VO59M,UR:RG:':+J:UC<@[>@+XQTP2 <<\
MT >G45S/@G6+/6]-O+FQU.XO(?M141W2E9K7"*#$X(!R"&/.>O4]:RO%E]?1
MWNLK;ZG<%K;3/.MK6PX>WDPY,LS'Y<'"X4GD!L*: .[HKS0ZSKFI7GP[*:O-
M:KK=A)+>)%%&07%L'W+E>#ECUR.G'%5F\6:KX=T7Q5;/?R7L]AJL5C97-T%+
M()A'@O@ -MWD^^,4 =W>^(X+'Q1I>A26MP9M125XIQM\L>6NY@><YY';O6S7
MG>IZ<]A\5?!9-_=W*O#? BX<-AA&N6''&<C(''' '->B4 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 5GZWHMGK^ER:??*QB<JRNC;7C=3E74]F! (-:%% &3:
M:$D.IC4[JZFO;Y(/L\<LH5?+0D%MH4  L0"3[#H.*GT73'T?2H;%]0O+]HRQ
M-Q>2;Y7RQ/)P,XS@>P%7Z* ,&P\+Q6/BB^U_^T;V>ZO8DBDCE,?EJB9VA0$!
M&,GOSGFJ7_"O]*.B:QHSW-X^FZI,\[VY=,0.S;R8R%R,, 0"2,UU=(3@$@$^
MP[T 8 \,2R:3)8WNO:I=N\?EBX=HU=%XS@*@4D@?>8$]?4U,GAR#^T+O4)[F
M:6]N;069GPJE(@6.%P ,Y8G)SVZ=*J:=XM;5=%U>_LM'NWGTZZFM/L99!)*\
M>,@$$KU/J>E;XN8P8$E(BFF&5B8C=D#)''I0!SUKX'T^WT/2-):ZNYK?2YX9
MX][+^\,0P@8!<;1P< #)&22<YT/$6@0^(]/ALY[F>W2*YBN0T.W):-@P!# @
MC(';M5JTO;BXU&^MI=/F@AMV017#LI6X!7)*@'(P>#FKM '/77A.*378-9LM
M2O;"\2U%G(T11Q-$#N 82*W()/S=>3G-/U#PI:ZC=Z3<R7EXCZ:\KIMD&93(
MI5MQ()!P3RN",G&.,;U% &+:>&[>T\3ZCKJW-RTU\L2O"S#RT\M2HQ@9Z$\$
MD9).*DL/#MAI^MZEJ\2NUWJ#J\C.V0N$5,*.V0@)[G\!C6HH YG3O!D.E7EZ
MUGJNHQ6%Y<-<R6"L@C$C'+;6V[U!/. PKINE9NK:S#I36<)0RW5[-Y%M"#C>
M^TL<GL JDD^W<X%&B:G/JMG)+<Z9=:=/%,T+PW ')7^)2.&4]CWH RK7P:NE
M7MW-HNK7NFV]W*9IK2-8WB$AZL@=24)[@''M5R^\+V=];VBM-.MS:72WD5UN
M!D\X C<<C!!!*XQC' Q@8CUOQ5;:-!I<ZV\MW!J-[%9QRPLNQ&D; 8Y.<=>@
M/2M^@#+T_0;:QU*ZU-GDN=1N55)+F;&X(O1%  "J#DX Y/)R>:;I7AVPT>^U
M&]MU<W&H7#7$SNV<$@ A1V'RCZXYZ#&M6;K^M1>'M$NM5N+:XGM[6,RRK %+
M!0,DX9AG'UH R]*\&0Z/-=)::KJ*:=<3O<'3]R>6KL<L%;;O"D\X#8_.IY?"
M5E+:>(8?M%R)-=W?:9MR[T!C$85.. %'&<]352W\>Z>\^E1WUCJ&FIJP7[#-
M=I&8YBP!5=R.VUB",!L9KJJ .7E\$6IFT:>WU+4+6XTJ)X(Y8F0M)&P4,K!E
M( ^48V@8[8XQ#'\/-+CTC6],%Y?BUU>=YIU$B@KN*[E!V\@A0,MDXSSS7744
M 8MUX:M;KQ'I^LF>=)+&!X(H(R!'M8J3GC/\"]",@8/&15*V\%6]I!>10ZGJ
M"&ZOS?EPZ91S(),#Y<$;@.H)P,9Q73U2O;VXMKRQAAT^:YCN)"DLL;*%MP%)
MW-DY()&./6@"'3=$@TZ_O]0WO+>W[(9Y6 &0B[5  '  S[\GFB71O.U^WU62
M_NR+>-DCM/D\D%@ 6QMW;N,9W< D="<Z=1F>(7"VYD43,A=4SR5! )^F2/SH
M YZ?P\=.UW4?%=O<7]YJ#61A6R+1".14RRQK\F1\W?/?FN34:S;PW&L:%X@G
MEU:[_?RZ/=:>7#2D?ZH$@21*/NY9L#K7J-% &9;Z)!%X@N-==I&O;BVCMBK,
M"D:*6;"\9Y+$G/H.E4;_ ,*1W7B1->L]3O=.OC +:8VWELLT8.0&5U89!)P1
MS70TC$JI(4L0,X'4T <[JOA"WU&YTR]@U"^LK_32_DW4+J[E7^^KAPP8' ZC
MCM5BZ\,VM]_9QN[J[G:QNUO09''[V55(4L,8P,Y 7:,@4SP]XJM_$=UJ5O;V
M%[ =.N6M9VN!&!YB]0-KDGJ.>E;U '.W/@VQN;3Q%";BZ637N+J8,N]5\L1A
M4XX4 =#GJ:CO_!5K=Q:.T&H7UI>Z06^RWD3(7PPVNK!E*D$ <8P,#&!Q5C5O
M$ILKRYL=/TZ;4KVUMENIX(7"L(R2% SU8[6POMU&1G8M9_M5G!<>5+%YL:OY
M<J[73(SAAV([B@#*N_#%MJ$-E'>W=Y<&UO([TN[KF:1,[0P"X"@D'"A1D#WR
M)X9MT\1:CK0NKKS[Z".!HPX"1A P!7C.?G8\DC)SCI6W10!S5IX-BL/!H\.6
M>K:E;JL:QI>12JDR!2"-I P.F#QSDYY.:Z11M4#).!C)ZFEHH P-9\*0:UKN
ME:O+J%[!/I;N]ND/E[,L-K9W(2<CWJ7Q!X;A\1#3Q/>75O\ 8+N.\B^S[/FD
M3[N[<IXY/'%:QGB6X6W,BB9T+JF>2H(!/T!8?G5;3[VXO'O%GT^:T$%PT49E
M93YZ #$BX/ .3UYXH RV\'V4NN:EJES<W-P=1M!9W%M+L\IHAG P%#?Q'OWJ
MKX=\"P>'I8@NLZM>VEMG[):7<X:.WXQQ@ G ) R3C]:ZNB@#)\2:!#XGT*YT
MBYNKFWMKE=DIMRH9E],LIQ5)O"DLFFQZ=)XCU=[-46-H\6Z[T&!M++$&P0,'
M!!QWKHZ* ,&]\*VFI0ZS%>W-Q.FJ1"!Q((SY,8!PL?R\ $D\YYYK/O\ X?V>
MH:'INGS:KJGVG2VW66I"51<P\8QN"@$8 !R.>]==10!R]SX%T[4/#=QH^IW5
M]?-<,LDE[-*//#K]UE( "[>P QUX.3F;3_"45MI]W:ZCJ>H:NUU UM)->R L
M(F&"JA0 ,]SC)XR>!BQX>\1Q^()-51+.>U;3KUK.19BI+,JJQ/RDC'S>M;)(
M4$D@ <DF@#CK;X>00C1?.UW5K@Z-)NLR[QC8H78$(" $8/4_-[UHVWA*"SU/
M5[VVU&_B&J-YDL"LGEI(5"EU!7.< <$D>W3%SPYXBT_Q3HZ:IIDIDMGD>,$\
M'*L5/'X9^A%:M &/H?ANTT+PU#H$<DUU911&$"YVEBA_A.T $<GM3=,\+:7I
M?A./PTD)ETY8&@=)3DR*V=V3[Y-;54EO;@ZT]B=/F%LMN)1>EE\MF+$>7C.<
MXYZ8H PO#O@:'P]+$!K.K7UK;9%I:W<X:.W&,<8 )P"0,DX'2M'Q+X<@\3Z=
M'8W-W=6\23)/FW* ED8,N=RMQD ULT4 8+>%;:7Q/_;TUY=2SFQ-@\#B/RGB
M+;B"-F<D\]:SM"^'UIH$Z+;ZQJTNFPOYEOILTX:"%LY&.,D \@$D \\GFNOH
MH P]"\,6^@C4UCN[JZ34;J2[G2Y\LCS'QNQM4<' X.:R]#^'MGH-THMM6U5]
M,BD\V#2Y9PT$39R,<;B >0"<9YY-=A10!RX\$VR'588M2OHK#59WN+NT4IM=
MW^_A]N]0P&" ?IBJ?BM[+4[67P+#IEVSW5O&J.ELPMX(]P&_S/N@H%R!Z@#O
M7:5'#/%.&,4BN$<HQ4YPP."/J#0 EM;Q6=K#;6Z".&%!'&@Z*H& /RKG;[P3
M:7NMZAJ:ZCJ%M_:5NMO>V\$BA)U4%5)RI92 3]TC^>>G) !). .IK)\.>(M.
M\4Z0NIZ9*9+9I'C!/7*L5_7&1[$4 8,WPVL&TO1K>#5=3M[W1T\NSU&*51,J
M8"E#\NTK@ 8QV]SF[?>";34-&M]-FU+4?W=TEW)<;T:6>5""K.64CC:.  ,
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M/S28B1*X8,,;,%3N.01]"*ZFB@#+TC0X-)GO[E9'FN[^837,S@#>P4*
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M)1U4=V/4'K[#$UQX"L;WPW<Z+>:GJMRMV4-Q=33J\\H4Y52Q7 4$=% [^IR
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M97<[7+&5U#QRLVXLC*HP=W/_ -;B@#-FT_QEIYUO[!=P-#/9;K"UFO6GECN
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M&..1@8QP.W2NFL(KFS^).I: ^J:C<V%UHZ7C+/<L6CD,K(2C#!0$=EQ@],4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MTYP*[YW$:,[9PHR< D_D.M 'G$FG7:^/]&\/1Z[K$RQ6,M]J<C7LBF4$A(P
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M1D65A^]3<%QR>1CCKWK!%K>_\*'73/[,U+[>+_=]F^PR^9C[=YN=NW.-G.:
M/2].\5Z9J>M2Z1%]JBO$A\]4N+9XA+%G;O0L!N&<#\:C;QCI"75E%(\R0WTW
MD6MVT1$,TG.%5_?!P3PW8FL#5HIKWXGV$D,%XL#Z+<6_VH6LFR.1V0J"VW .
M 3SZ5C>$?L[Z;I?AS5O!UY_;>G&.)GFMF-L#'P)UE/RXP,C')/ ]: .LN?B)
MH-L-1YOI3IK[+L16,K&'C<68;>% YR>#VS6O<:_801V)1VN)+]=]I% NYIEQ
MN+#T4 @DG Y'/(KA8DG$?Q+S87X^V%C;9LY?W_\ HX3Y/E^;YACBJFF/?>']
M7\'ZY>:?J#Z;_P (ZFEW 2UD9[.<%&)>,#< =NW(':@#7\#ZW$LGC"[O+R\^
MR6VK%$%XSL\0\M!Y8#9;[QP%'4GC.:ZBS\4:;=ZI<Z8YFM+ZWA%R\-U'Y9,.
M<>8">"N>#SQWQ7FMQ8ZKJ-AXOFL-)O7E77+?4H()X'B^UQ1B(E5+ <G:>.O'
M3-:MU;6OC'P]J_\ 8'AR\L-0ETV6W^U7]L8) S#_ %*EN3GG)'RC\: )_%?B
M..]U'P=+ITNI0Q76LPJL@#QPW,)5B>,X(R$(W#D<C(S7I%>3ZAK$FL:/X)CB
MT;5X[K3]7M6O8&T^4>1LC=6YVX([Y&>/2O2]5U$:7I5Q>FWN+@Q(66&WB:22
M0XX4*H)R>E '$^*/%>HZ3XSTRZC;'AVUN5T_43G_ ):SKE6/LG[OG_IH17<:
MGJ=GH^GRWU_,(K>/&YL$DDD   <DDD  =2:XJ?P5%K/@&YMK[4-1WWT+SW";
M2%$['>3Y97=@/T'7  K(N=1N]>^#$9UG3=6@U:U:W1T-HZR^<LJA)55@/,!X
M8@<G)'!H [E/%VF'6'TB5+V'44B\XVYM)'/E\X?*!EP<$=>HQUXJKI?Q T#5
M_+>TFN/(>*6;[3);.D2K&2'W.1A2,9P><8]16'H&MZ3?>-6U6]FOTU:6Q^Q0
M1RZ5/:H8U)D8+NSN<D$XST7@=35#0M&U'4O@7>:'#:W-KJ;)<JL-S"T)+&9W
M4?,!PP(YZ<T =Q;>*M-GUBWTMQ<VUU=1-+:K<P-&+A5^\4)[@$$J<'':HV\8
MZ0EU912/,D-]-Y%K=M$1#-)SA5?WP<$\-V)KF-%N+#Q.8%C\*7VGZM#%(LMQ
M>VK(+)F0J?+=OO$G ^7MR<8K.\(_9WTW2_#FK>#KW^V]-,<3/-;,;8&/ $ZR
MGY>@R,<D\#UH ZR?XB:#!#J$P^WRIITIBN_+L928< $LPVY"@'J>N#C.*M0^
M-=%N-6LM/CEG)O@?LMP;=Q!.0NXJDA&TG'/_ -?BN1MDN!I7Q*0V%^&O)IVM
ME-G+F<-;J@V#;\V6!'%)<)<'2/AJ@L-0+V<T#72BSES %MV0[_E^7#$#F@#L
MM3\8:3I"S2W33_9;>40W%TD+-% YP,,P^HR1D#/.*9>>-='L]6FTK_3)[^*
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M:*^F074@;]]"8I9R!R[*>1Z#//&>F*Z"@ HHHH **** "BBB@ HHHH ****
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MA2,C.2,G'.U<MC''(S6N?'.@VT6D2BXEGAU;_CTD@@=U?@G&0.O&-OWL\8H
MZ.BL?0O$MEK\E]#;QW,%S8RB*XM[J(QR(2-RDCT(Y!K/U_Q7+H_BG0M&CTZY
MG&H&9GDC4'Y4C)VKR.<E2?;ZT =117F6E>)8/#>O^-VO/[3O(+:]C?;&KW!@
MB\E69B23M4$DXSZX'%=Q-X@LUCM3:I-?274'VB&*V4%GBX^?YB !\PZD9SQF
M@#5HK-T/7;#Q%I::AITK/"S,C!U*LCJ<,K*>00>U5K_Q/9V4UY&D%W=FQ4/>
M&UC#^0"-PSR,G'.U<G&..1D VZ*R&\2Z:UI87%I*;S^T5W6<=N S3 #)(S@
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MI&T8SC(KG[#P]J.@Z=X#LYK*Z>2UU*:[N5@@:5;9)!(0I*@@8+@?F>E>N44
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MOL=HD#-(1Y/EJQ0#*EFR>0,#&<5Z=10!E>&F8^&=,5XIHI([6)'CFB:-E8(
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MVR0LP<L">0,#!&/>NFMO$FI7WBOP:RW!BL-9TN6[EM-BX5Q'&P^;&[^,]^U
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ML3"@C53;[E93C=N!49)8@^@'%:\&K^(GUGQ[8VDXO+C3HH#ID+HJA7>$OMX
MS\V.OH* .\HKBO!GB2'7=1N(X]4OO/@@ N=+U*%8[BWDSRW"C(/MD#C&,XKH
MO$&J'1M"NKU(S+.JA8(@"3)*QVHN!R<L0.* 'Z;K>GZM=:A;V4XDET^X^S7
M'\+[0V/UQ]01VK0KR327MO!_Q&TPVXO!8Z[;+9WDMS:2P![U,LDA+J 6?+#
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M6PJS>7L#*Q4D<8X!P<>G%-USPZ]_X6LO!J7$]S&YA6\N90 5MT8,<X &6VA
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M$9>2'^Y(NW:PXR..OK5B\\$)<C29XM8OX=2TZ9YEOCL=Y6==K[P5V\K@# P
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M.XDN+FUV+N)D.9%60#(1N01R<$X(J[<^%XI_$FDZQ'=/!_9<+P06R1KY>QP
MP/?HHQCIBM^L:U\1P77BJ\\/BVN([FUMTN&D<+L=6) VX)/4'J!0!GQ>#!%'
MXB0:G,?[=+-.3&O[LE-AV?\  1CG/K39O!$<FD^'[./5+J&;0F4VMU&B;RH0
MQX8,"IRIZXKJZ* .%UD:1XSUFRT%;>ZGET>_6>ZED@=%C5%/&\@!]Y(7 )R"
MQ[5W5(3@$XS["J>DW\FIZ7!>2V-S8O*"3;W2@2)R1\P!([9_&@"[7/W7A<'Q
M*VOZ;>O8WTT M[D",21SH/NEE./F7L0>G!S704R5S'$[K&TA4$A$QEO89(%
M'+ZCX%L[[P?<>&X[NX@M[J0S7-P K2S2,_F,Q)&,ENO'L,5T\"21P(DTOFR
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M_K\IQQBI?^$.QJ'B&\75;E)=;2-9"B*#"47:C(<=0/7/-=/10!B67AX0Z_\
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M$&_=#'<$ -@YY/L*V8[2&*[FNE4^?,%5W)).T9P!Z#DG [DFI418HUC10J*
MJJ!@ #M3J .'\9Z]=:%J\$U\NI1>'FMB'O=/7<;:?=]Z4 $[-N,<$9SD'C&7
MJ EU'QEX!\C5_,:73+O-_ JDR?NXLNN00">O(.,]*[6^T2:ZU*2]@U2YMC+;
M"VDA"(\;*"Q#893\WSGG./4&LZV\#6%E?Z%<V=W=PIHMN]M:P H4*, &W94D
MD[1SD4 <[IVLZNOAGQ#:S:\(Y=-ULV,=_=(&D:',9V@*OS2$.57"\G'%7_#N
MJW\_B;Q5I,[W9L[6VMYK9+S:9$\Q7W<C)P=H(#<C/;I5B?X<V4]GJ$#:KJ(>
M\U%=4$P,8:&X7&&3"8Q\H&#FKEIX+CM-8O\ 55UC4I+N^MD@G9VC(8J& ? 3
M (#'@?+[4 <#'_R0OP=_U^V'_H\5[%,C20NB2O$S @2( 2ON,@C\Q7)_\*^L
M_P#A$M.\.#5-0%I831S0R#RO,)1MR@G9@@'VKJVC=H#&)65RN/, &0?7&,?I
M0!Y#;ZUXE_X5GH?BIO$-PU\;U(I(FBC\F5'N3&=Z@9)P>Q&,#&.M=)_:FI>'
M?'=[97&J76I6+:')J1CN @*21R $)M484@].:N+\.[-?!]KX975=1%E;3B='
M_=>9D2>8 3LQC=STK4?PM#+XICU^6^N9)TLS9&%EC\IXR0QR-N<D@'K0!S>F
M3>+-3M?#NNV=SE+DQ37\<\Z>1)!(N6$:A<JRY&WG/'S$U1U?7]6L&AO8=5EN
MY?[?CM9&MU'V1('EV>2=P&YP#RRY(;()'2N@T/X>VN@W*I;:QJKZ5%+YL&ER
MS P1-G<,<;B >0"<9YYJNWPRLCITFG)K6K1V0O1?6T*O'BVD\SS/ERF2-V>&
MR!GUYH B;^V-4^(>NZ(/$%[:V,5C;SQ"!(@\;.7!"L5/''<$].1WUOAYJ][K
MO@+2=1U"02W<L;++(% WE79=V!W.W-6+;PLEIXBO-;BU.]^TW5LELRMY;*JI
MG:1E<Y&2<DG.:G\+^'H/"N@P:/:W5Q<6\!;RVN-I8!F+$94 =2>U '$>-->U
M;2]/\2ZC9ZK-+<Z=+&UO':*/)M4PF4FW##,V6R 6(!4X%>F.K2P%5D:-F7AU
MQE?<9!'YBN.O_AO8W\6NVQU74XK'69#//:1N@19CC+@[=W\(XSCVZ8ZR%$T^
MP1)KEW6)/GGG89;U9CP/R 'TH \A35/%I^%<?C1?$L[WMB\TC6K0QB&XC2X=
M6#X7.<#@@@   #/-;RV\^L_%/4A!?W.G";0;5V>W"^:,R2$ %@0/?C/TJM\.
M_#ZZS\.K6PO[VX-F;F9[C3V15_Y;NRHQQN"-\K$=3GK@XKM$\,)%XINO$$>H
M7:W-S;+:F/$?EJBDE<#;G())Y)H X9-=\177PJTCQ2NHW#3V,I?4HX40?:K>
M.9DD/*\-M7=D8Z&NGN+_ %/59-9O?#MWYJ6VGA+.,E?*FNF0R!LD= K1=\98
MYZ5%$FF_#S0+/0/+U758KEIE@C%L)BQ8EBC%%  )8XW>_8&KVB>$H-,\!0^&
MU>2V!MC'));M\R.W+%6.>A)P3GH* ,KPGKT>NWUW9QZEJMEJ$5KBXTW4$43V
M\F1^]7<N&4].Z].!FLOP]XLU2_\ "?@B"YOF%[KLTJW%[M7<%0.Q"C& S;54
M<< G'.*[*#PV$U4ZK<7\\^HBT-G'<&-%*1E@Q. N"Q(!Y&.. .<Y/_"M=+_X
M0^Q\._;K\)ITOGV-X'59[=P2058*!W/4?TH -2AUO1-)UHMXE@CMWEA:RFND
MW2VT9($BDX.]CR$X)R0.:9X7U:^D\<ZYI$LEX;&&UM[FW2]P9$+[PW(YP=H.
M&Y'H*M77@2WU#0I;"_U?4KF[DEBF_M!W43(\;;DV@+M !SQCN>YS4]CX/2Q\
M03ZV-8U*:]N+5;>9I&CVN5W8?:$ !&X\#"]\9H S_A)_R3+2?]ZX_P#1\E/M
M=0NO$WBSQ'I:W]S96^D^3#$+8A6:1T+F1B0<XX '3@Y!SQL^%_#L'A70H=(M
M;JXN+>%F*-<;2PW,6(RJCNQ[5#<>%H_^$BFUS3[ZXT^]N8EANO*5&2=5^Z65
M@?F7H#Z<'- '"#Q5XBU#P_X=D_M)K6^/B+^Q[UXH4V3A2X+X(R#\HX! SGC%
M>E:1I]SIVFK:W6IW&H2AF/VF=5#D$D@': . <=.U8UUX$L)M/TBR@O+RUBTN
M\%]$8BA:28%B7<LISDNQ/3K748.W&3G'6@#R2;4O$3^"_%^K#Q)>K<Z)J=VE
MMMCB =8B,+(-G(QQ@8ZD\UO&^U>P\:>%#)J\]S;ZY'.+FU=$$496+S%,8 RN
M#QR3D=36B/ -K_8.MZ.=5U V^LW$MQ<L?*WAI/OA?DP ?H<5:F\(Q3ZAH5Z^
MIWOFZ*K"  1X?<NQM_R<_+QQB@#EX-1\5>)O#Z:]H4QBNC=.T4<LZ"V\I)2I
MC==I/W5.6Z[NA X$X;7-5\6^,M,'B*]MK:QAM9+;R4B#QEXW;&=OW<CTR<#G
MKG2A^'5G::K=3V>K:I;:=>3&>YTN.4"WD<_>[;@K=P",].G%:,/A2.#6M:U2
M/4[T3ZM''',N(RJ!%*KL^3C 8]<T <&]]?\ B.S^&.I76H7,5Q>3'SO(*JI?
MR'R^W&-W'T&3@"M'QEK&JZ;9^)KJTU>>6XTZ*.2UCM%7;:@("WGE@%9F.?EY
M.T@@#K6ZGP^LX=#T33(=4U"(Z+-YMG<J8_,7@J5.4VD88CI4=[\.;&\_MN+^
MU=3BL]97-S:I(FTR;0N\,5+9P!D9P>X(XH KZY*9_B%\/9F #2+>L0/>W!K>
M\:W-W8^"=:O;"Z>UNK6REGBE158AD0L.&!&.*@?P?%)J.@WS:I?M-HR.L.XQ
MGS-Z[6+_ "<Y'I@#M6IKFDQZ[HE[I4T\T$-Y"T,CP[=VQA@@;@1T/I0!Q.MS
MRW2_#6XG<O++?1.['JS&V<D_G5FT61_BAXO$,[P2?V79[94"DJ?WO(# C\Q6
MO<>#(;F'0(VU2^7^Q'5[=E$>795* O\ )S\I(XQ4R>%8X_$.IZU'J5XMQJ$"
M02)B,HBKG;M^3.1N/4GK0!P6FZUXA7PGX)\1SZ]<S3:AJ%M:7-LT<8BDCE<J
M20%SNZ'.<<=!6Y<7_B#Q*WB)=&N)K:XT^\>SLRDR*B2(BG,BE26#,W/;;C S
MDG13X>VD?AS1]#35=0%MI-S'=6[_ +K>61MR!CLP0#[4MYX!@F\0SZQ8:UJN
MERW@47L=G*JI<E1@,05.UL<9&#]#S0!B>(/$>JZ//$WB%[S3[&;3X@FI:8OF
MP6MV=WF&08)VY*;<@C'OFI?$_B2YTB^CDU"YOX-"GL(_LVKZ>HDBAG.[<\H
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 5E>(]?@\,Z)<:O=V]Q-;6Z[I?LX4LJYQG#,,]>
MU:M<?\5/^27^(?\ KT/\Q0!H#Q1)]FM[J3P_JT=M,T8$Q-NP4.0 Q"REL<@G
MC@5T%<KI</B%;;0)'O;!]/5%-RD=NT;[/);;\QD8$;MN>*Y_QGJ6I^&?$EO<
M1ZO)_96K1&V999#MT^1F4"X&/X/F P3@$CD \ 'I5%<=KE]>66M>'_#5K-++
M]LBGDEEEN3'),(@OR[PI()WECM /R\8%9%U?^)?#&GK8ZEJ$)&HZU!9V5P)?
M-FMH)2<[RR@%AM8*2#UYSB@#TBBN)UZPU/1-(\2WMOKMP;4:9)/:0.Y:6":-
M&)<.225/R_*<C-5)=6U%9OAW*+V8'4@JWB[OEF_T8ODCUW<Y% '>?:(V\]8B
M)9(>'C0C(.,@>Q((_.H=+NYK_3+>ZN+*:RFE3<UM,07C/H<<5P7@^QE6\\=/
M'J-\DJ:I*B2&7>1^YC(.&!!(Z#(X'%4CJ>N2?!_0O%$>H7DES:)%=WZH^#=0
M!OWJGT.W)R,=* /5:*XG6O$4EIIFO>)K"=IK2PL +=-Y,4LI7?O([@!HQQ_M
M=Q3K*Q\2Q:[I5_%?1MIDD;+?I<7IF\_<OR/&-@"-GL, @]* .KU"_MM+TZYU
M"\D$=M;1-+*Y_A51DG]*S=+UZXO]3-I-HU[:QO;+<PW+[6B=20-I8'Y7&?N^
MG<UD_%.#SOAIKI\V5/+M'?"-C=QT/J/:LK6%U*QOO!5A8ZY?P07\KQ3C<KDC
MR&;()7.1CCJ!P<&@#T:BN#L9+J3QC_PA\^K7\UOI^F"YDG:79/<N\A +.N#A
M0,<8R3SG%<[JGB/Q!;^$/$ML-5G6\T/5X;6*\55W3PR21X#\?>"O@E<9X]Z
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MS(72190G[L[<("&Y ';C'8 [35KV?3M+GN[:PGOYHP"MM 0'DY XR0/?\*N
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB;:_C*"501AE(V[2I'4%:9<>#[*ZTK5K*:ZNVDU8;;VZRGFRKMV;?N[0 O
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M+;?3Y5VKQQQQ7044 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7"?%JW6;P=&QDF4IJ
M%ICRY60',R YP>>O?H>>M=W69K^A6?B31Y=,OC*(9&5MT3[71E8,K*>Q! H
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MV<C@8Q5NQOKS6_%3Z!J=\4-GI-O/)]@G:(7$TA(>167#;%VC Z?-SGC%_4?
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M.4-U?(0+/:R7<@(WPMGOVSP.@[5V'AS0+7PQHT6E6,L[VL)8QB9@S+N8L1D
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M5]H1 C/U; <C.<GUKIH([RQ^)S:,VK:C<V5_H\ES(LTY)25957=&1C9PQX7
MJX_PXT9M,U#3EN=22UO[S[9,GVG=^\W!N"P./F4'U..2:TKG08(-<7Q*\]_/
M>VMFT"QQ[#YD?WBH4*,L2 >HY]!0!R&D:CJ"Z=?^#KS4;M]?AU(6RW33-YCP
M.3(LP.>,1*XP.-RX/6O2T01HJ DA0 -Q)/XD\FN4T""+7O$;^+9-'NM/?[&M
ME;K>Q>7.5W%W++DX&=H'?ANQ%=;0 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445SGC0ZNNC
MPOHT)N94N4>:U2X\F2XB )9$?C#=#UY"D=Z )O%GB,^%M'&HFQ>[3SHX6"R!
M-N]P@))]V'0&MVO']?U6RUCX8:L]E/J*.NKVJRVNH[C/9OYL(,9W$G&1N'./
MF]JZ*!I]$^)UQ8#5KQK*YT1[V7[9.95CE24+Y@#'"C#'(&!QT% '?5S%GXO>
M[;Q(@TJ99-$D"&/S5+3?('R.PX/J:Y+3+^^M_$'@=H;_ %"YMM1^T)<7=S,P
M6_'DEQ((2Q"+D K]TX.,8K1T;_D,?$K_ *[K_P"DJT =AX=U@>(/#FG:NL)@
M%[;I.(BV[9N&<9P,U9U*\;3],N;Q8&G,$;2>4C %L#.,GBL'X;_\DU\.?]@^
M'_T$5A07#^+;?QK-=7=W#_9]U/86T,%P\8B6.,'>0I 8LQ)^;(P .F<@'9>'
M=7'B#PYIVKK"8!>VZ3B(MNV;AG&<#-7;FZ@LX?.N)5CCW*FYO5B%4?B2!^->
M6^&M2NIM*\#^'HB!#<:$;EE-T]N9G7RU"AT!;@,Q(&,\>F#%XFT74;/P[8VF
ML:FUV8_$EJ;41W<K/#"\JXC=^"[#G#'GT(H ]=HK@IY+K5/%^J>'(GD^SZ?9
M0-$AU.:"1C)OW2;U!9\84<G@^N:R[Z#Q!:-X(TW4/$<\MW)>S6EY/92E5F4)
M(1NX^\  "3W&>M 'J-%>;C2;BS^(>F^'AKVM3:>VC3R.);UB[D3( 2PP<X;&
MX8..]83KJ/\ PKWQ9>'7M7^T:!J%W#82"[8%5B8%=Y'^LZX^?(QTQ0!ZQ<75
M[%JME;PZ>9K282&XNO.51;D %1M/+;CD<=,5=KA=0OKT^/\ P3MO;A(;^UNW
MGMU<B-F6)"IV]R"QZUS$Z:C/X6\?WS:_K GTC4;IK(I=LOE^7$C '&-R]MIX
MZ\9.: /8:*\^_M:^U[Q+;Z,V"G]BPWQC6]DM3(\C$,P:,$D+@#&0!N[\8Z3P
ME::KI^A+8ZSJ,>H7EO(R&=6+-MZJ') )8 CG'/!H T(+J]DU:[MI=/,5G$B-
M#=^<I$S'.Y=@Y7;@<GKFKM<':2WDGCSQI8MJ5YY$=C:R0KYI_<%A(3L'1>@K
MF=-N-2@\(^ /$#:UJ<U[>:A:VUP);EFCDBE+*RLG0GON.3GOTP >Q452UE[Y
M-#U!],56U!;:0VP;&#+M.S.??%>=Z8VH:M<>#)--U#5B98&?6MT\F!B,'+[N
M%;S. !C()Q\HX /4:*\YTV>Z\7:%XGU%]1O;2]M;ZZM[3R+AXQ:^2,("@.UB
M3\S;@<[L=,57\.^*+[Q=K'AW3M1:6VBN- _M.98)&B\^4R",<J0=H 9L _Q#
M.<4 >G5A77B,VOC+3_#[6+G[;;RSK<F0;1Y>,C;U_B'7%<!>^*-7T >(]"%[
M,\=MJUE9VE_,V^2"*Y 9@6;.XH,X+9/(SFMJ[TN'3OB_X9,,UTZR:?> K/</
M+@CR^07)()SS]!0!W&I:A;Z3IEUJ-V^RVM8FFE;&<*HR?T%9FDZUJ5_J"17.
MB/;V<UJMS!=I.)%.<?NW& 5?!S@;AUYK/^)UNEQ\-M?+M*/*LI9%\N5DR0IZ
M[2-PYZ'(]JH2PQ6L/A>QAU#4&$T3RG3HKB1I+K]TO)E9P8T3.2,X)(&,\$ [
M#5;F\L]+N+BPL#?W:+F.U$JQ^8?3<W _&I3=Q)/#;R.J7$R,Z19Y(7&[\LC\
MQ7D\^JZN?@OXFG;4[R*\TV]NH89TN&,BJDN ID/S-@'&>M;EYI\-Q\8]&D>2
MY#/HLKG9=2+RLD>. PP/4=#WS0!TWAKQ&?$1U8&R>T;3M0>Q97D#%BJJ=W'
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MES_#TZ]SFI="\1ZKXKGT33[H#?-H,>H2H+R2T,TC.4+!HU)( 4' P/GSS@8
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MX!)VDCYB< \5O44 <KIWP^T/2M4>\L_ML<+3?:!8"Z?[*LN<[Q%G&<\CL#C
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MWQE@>QR 1Z8J?7/#ECK^EQZ;=&6.TC='$<#;.4(*]N@(!Q[5KT4 8X\.6O\
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M+6SO<%V#%=I+%@=WR\8/ '0"NCHH Y\>#M*:;69+A9;I=9 %]',P*2;5VK@
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M,'S87:,<?+\O'';WYK?HH HZ-I5OH>D6VF6C2&VMD$<0D;<54< 9[XJ]110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MC@<D#!Y#-C<,[0V,\]#0!T=%<I#XMGG\?7&@+IMQ]F@LTG,Z[#OWL0&^]G:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPR>*/%7AC5(+.^MK?23/<W#W-L\+ M'M$8# %B223MR,+UY%<K<:;J4OP?\
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M2RC\R=(&0D,@ZC)(!8<@$XQUKKZJV&GP:9 ;>UW+;@DQQ9^6(?W5]%]!VZ#
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M))8:6^<DQ,1(=WJ5'EQ^VQA6I\2-,O=9^'VK6.GP-/=2(C1Q*1E]LBL0,]\
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M"97!)ZYZ<<W_  S=ZC>2PM>>"ET:>V4FZG98B';:1MAV')R><G QQSFNUHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ JGJ.I0:;'%Y@9Y9Y!%!"GWI7()P/P!)/0 $GI5RN&NIWN?C=I]E*3Y%GH4
MMU$.WF/,L9/_ 'R,?C0!U)O;W^UOL8TQS#]E\[[7YJ^7YF['E?WLXYSC&*?I
MNIP:I#(\.Y)(9##-"XP\4@ZJP_$'C@@@C((KG([R^3XPR:>U].]BVA_:5MF(
MV))YX7(  [#OGJ:K:?/);?&K6;*,GR+O1X+N0=O,5VC!^I7'Y"@#N:*** "B
MBB@ HHKS.UT_6O$>L^,;#_A*=5M18W:+9F!U38QA5ANPO*@G[HQGG.>, 'IE
M%>5>'/%FL>*K;PU8W&T376E2W=SBZ:U,[I*(AAT4D="Q"XSD=A@NUA?%FBZ%
MIEO>:^1<-XB@MXI+>7S&-M(XVI*S("S#\,CKF@#T/6=8M]$LDN+@,QEGCMX8
MUZR2R,%11]2>O89-1Z1JEW?RWL-[I4]A+:RA,NP>.8$9#1N,;AZ\#!XKAO&V
M@?8-.\-PRZMJEX6\26F)+BY)90\F<#;CIV/45KV]R^K>.M4\.275Y%9:590,
MBQW+I),\FXERX(8[0  ,XR3G/& #MJ*\?N?$'B%_"TT!U>YCN],\3II7VM H
M-S%YB %^.3AL'&,XYZUM:M8ZIHOBKPMIT'B;5Y8-0O;KSO/D1CCR68 ':. 1
MP#D#TXH ]&HKS&TM-2N-1\::*WB+5Q:Z48Y;1UN/WRF2'?@R8W%01P.G/.:=
MI?B;5=;M/!VGR2!IM2TE[RY;[2ULT[H$& Z*2/O,Q"XZ#G&00#TRL2/Q&C^-
M)?#9LYDE2Q^VB=F78Z[]F  2>N>N.E<=<7OB3P]!8:'J.IQN^JZTMM;W$<QE
MFM[5@6V,[*,O\I4,03SGJ*N6%@MA\;9T2>YEC?P\&43S-*4_TC! 9B3CC/)[
MF@#I?$'B-/#\^DQR6<TRZC?1V2R(RA8V?."V3GH#T';M6TQ(4D D@=!WKA_B
M6CR1>%4CD,3MXBM ' !*G#\@'BFZ(;ZV\:^)= .KW\]LMG;W,$D\@DDA=]X;
M:2,8^4'&,#M0!U^E7=S?Z7!=7=A+83R+E[:5U9HSGH2O!]?QJY7EFE:QXAN/
MA?X8U98[W5B6:34HK:8I<S1?.,H003AMIP""<8Z9KL?!6J66KZ ;JPO[F\A,
M\@_TK=YL)W9\I]W.5SCGMCKUH WIY&A@>1(7F95)$:$!F]AD@?F169X7U^+Q
M1X;LM:@@>"*[4LL;D%E 8CG'TK!L+N;Q5XF\36LE[=6T&E21VEO';3-$0Q3<
MTK8^\<G !RN%Z<FN0\)WEW8^"_AI]FNIHENKUK>=%<A9$Q*V"O3J!S0![)6=
M=ZG(EC:7>G6;ZC'<21 >2ZC$;G_69)Y !S7":I/=7-U\3-.EO;LVMIIT,MN@
MG8>4S0R,VTYR 2!D9QVZ5#</=Z1\-_!,UAJ-Y"9KG34F42[@Z/L#+DY(7'8$
M#DT >I45P-Y<ZKXD\0^)=*LIC"=-$4,!COY+9HW>(/YA"(=_+8PQQ\G3DU3U
M74_$&B6^F3^(4NM0L(K(QW]SH<S!H+@,0965=K,N!Z8!#<=* /2JJZC<SV>F
MW-S;6<EY/%&72WC8*TI X4$\#-0:!<177AW39X+[[?&]M&5NSUF^4?.?<]36
M9X_N+NS\!:W=V-Y-:7-O:22QRPXW JI/<'].: .@@=Y8(Y)(FB=E#-&Q!*$C
MH<<<5)7G>HW&J3>)_!%I%K-[;V^HV=P;E(V7YBD*D')'7YCR<^HP>:T_ 5S>
M>?XDTRZO;B\CTW5&@MY;E]\@C*(P4MWP6/)H ZR2XBCFCA9U$L@8HF>6QUQ^
M8_.LGPWXC3Q''J3I9S6IL;^2Q=)F4L60+D_*2/XO4]*YO5;%)OC/HY:>Z7=I
M-P^U+AU *R1] #@ ]_7C/2N7>.]M_"?Q U>RU:]LY]/UR\GA6W<*I==A^<8^
M8'I@\>U 'L]%<)-JFH:_XHET:([(H-+@NBD=\]J[/*6RP9%)(7:!C(&6YSQC
MH/"D&LVGA^&UU^\M[S482R23P,2&&?EW<#YMI&>/?O0!MT5YMK>JWYU'QC;7
M5]=V5U:6\<FBQP2,OF9C)!51_K6,@*E2#T QZSVNH:LVM>%_#.J7=TDUSIKW
MU^^\)))* H\H,@7 #,QXP?E'/7(!Z%17D^K^+M7\*+XPTU;F2X2P:T:QNKCY
MV@6X;:0Y/WMAR06R3T.:W]9FO?"WBGPU]CO;NXL]3N6L;NWN9FERQ0LLJEL[
M2-IR!@$=J .A\4Z^GA?PY>:S):374=JF]XX2H./7YB./ID^U:L,GG0QR 8#J
M&QZ9%>/ZU=3>+?@GK?B6>]NDFN%G:.&.8K'%$DI01E/NM\J\D@G)X(P,>MV@
MW:? ,D9B4<'!Z4 8=[XL>*XO$TW2;G4X["X2WO#;,-Z,P5OD0_?VAE)Y'7O@
MXZ2O+O#=N-/B^(%W%JLEE);ZC.J75S,SQQ'R(\.ZDX8@^O/%7-%O[^'Q[ING
M+<:E]AO-'DE?[;(6,LB,@$JJQ8QY#'Y3CW48H [2TU.1[.]NM1LWTZ*VED7,
MSJ0T2?\ +7(/"D<X/-5;[Q&ECXKTG07LYBVI),\=QN78/+4,PQG.>1V'6O,M
M<GO-0^$'C(WVH7=Q)9ZQ<01R-*5)1)E0*=N 1CMC'M72^)=/(^('@>SAO+J(
M&/41YWF;Y0#&A.&;//;/;M0!Z'17'> KJ\,OB/3+J]N+Q--U5X+>6Y??)Y91
M&"EN^"QY-+<:C+JWQ'G\.23SP65IIBW96"5HGF=W*YW*0VU0.@(Y;G.!0!V%
M%>/:EK_B"W\-Z[9+JURMQH^N06<-X NZ:&1TPLAQR0'P2"">,UO[-7\.?$K2
M=/&N:AJ&GZY;W/F)=LKF"6)0V],* H.<;<8_2@#M=,O+F]MY)+K3Y;%UF>-8
MY75BRJ<!QM/0CFKM>/W.L:VGPCUG4$UJ]%]::Q) EQN&YD%TL>T\<#:?X<5T
M\!O]+^*$.F?VO?75K?Z5+<2)<.&"2I(H#(,87ACP!B@#K-,O+F]BG>ZT^6R:
M.=XD21U8R(IP'&T\ ]<=:NUY/!XIU;3_  ==F34)Y;J?Q.^DI>2X9H8S-LW8
MQCA0<<8R>E;]_->^'_'V@Z=:7MW+IVM17$4L4TQF:"2--ZR(SY(SR"/N].*
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M@-D=LD''X8/O64LFHZ3X^\,1'5[VZAUBTN?M4,[@QAHT1E9% ^7J1[CKD\T
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MJ9VDY4YQD\=.:C3PQ!%KU]K*7UZMW>P+;R<Q[0JYVX&S@C)_/FMRB@#FM/\
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MJ"[LT>-6MY=@=&P2C<<C(!XP:H?\()IYT?6=+:^OS;:Q.]Q=Y>/<SOC?@[.
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M2;]6:UNHS')L;#8]0?4=:S/^$/MCJ&D7SZCJ,EQI0?R'DE5BQ<;7+97G(X[
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBN;UK5I)?%&E^&;61HY+
MJ*2[NI$.&2!,# /8L[ 9Z@!L8." #I**YR.\TC_A/)+1)KX:I#IF6@(D$'D^
M8,,%/RLV3C(R< BJ^A_V?K6B:D=#U#4%87\Y$]PS[XK@'D!7YV G&PC'48H
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MVG\0 ?QKMZ;'&D,211HJ1H JJHP% Z "G4 %%%% !7E-ND>CZYKVCZ]X3O\
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M-61W4C +E=I ;'S<UZY10!YZE_)JWQ0T/5+;3-36P_LRXA,\UF\85F=" P8
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M ]<#H"<=>M $]%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8AL<Y' XK=HH Y8>"+:WO]"N=/O[JS_LFS-BJJ%;S8#M^4EAP?D'(YZUF/\
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M#\:V* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M1/?S&XBLS9^4$4(R%@Q)XSG< >M'A?PS%X6L'L+:^NKBU$CM!%/MQ"K,6*C
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M[1OI[*_TB29IIXD7=,C(/-B!4$ [CP1CH0*U[GP':7LWB1KJ^NI(]?C2.YC
M51'L7:I0@9! ]<YHM/!!@UG2]6N->U*ZN["!K?<_EJ)8SM.TA5&.5'(Y/<T
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MK$J/0#L!DT:YX;76]1TJ]:^GMWTR<W$*QJI#.05^;(/&"1QB@#GUNM737/\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %8VC^(X=8U;5].2UN
M()M+E2*7SMOS%EW KM)XP1U]:V:\J>UO9O$/Q)GL]6NM/>V:"9#;!06=;52-
MQ8'Y>.@QGUH ]5HK@;?6;W5].\)SSZA(IO\ 3!<3V-D-MQ<2E$.X,,!$4ELD
ME1DJ,GI6#'XC\0W7P^\-7RZM-#?3:ZEA/)Y<9\V/[0T?SC'7"C.TC//K0!ZY
M17$W=M?Z5>Z9ITWB.^OHYFN)&@ 47=QTV ,@4*B9.22HR5&>U8NG>(O$5Q\/
MK'4##>ZB;?4YH-06UVBZ>V1Y%&W& 6!"9V\D X/.: /4**\Y/B*YNO",6JZ!
M<ZAK=BNHG[9'"-MY' %.Z( X.]6V\?>*]^<U3U/Q)-/X(BU7P]XCNI5;6(("
M98QYD:O(BM#(&7<"N3T()!')SF@#U*BO/O*UA/B/-X>'B/4&L;O23?,S"/S(
MW64(1&=N%!##L>G&.HS].\5ZO%X;M+*6[>XO)?$,VC+=N561HT9R"3C;O(0+
MG'?/6@#U&BO-]8'BW1-#\571U)H+*.P:ZL"TRS3PR(I++EDY0\=<D>M/@O-8
ML/$W@QI=:NKJ+6X)4NH)53RU*P>8K( ,@Y'<G.: /0DFCD>1$=6:)MC@'.TX
M!P??!!_$4^N!^&MK)'/XJD>]NYMFO74.V:3<#@1X8\9S@8],=JTM5U:>Y\?Z
M?X7CGDMH'L);^>2([7EPX14#=0.2QQSP.>N0#K**\FUKQ%KVFZ-X\TM-4N!<
M:$D-Q9WP5#(T<J[A&^5P2N"-W!/'->@Z#IU[9K-<7FL7-^;H)($F50L)V\A-
MH!P3V.>G4\D@&Q17G7C+4]1M1XGFM=5N&FL+%9[6"Q  LRJ,Q:<M\K;B!A3D
M[1PO>K=YK]V^J^%8K^X-GI6HV3S3W"/Y8>XV*RQE_P" 8+,.1G&.Q% '=45Y
M=9>(M?LO#+W%UJ%Q<M>ZZ-,T^>9(D'V<R%5E4A!DLH(!;<,X.,=>HT.T\1V?
MB:Z^USAM$FMPT44]QYLT4X;G:=HRA![DX/3K0!U-%%><#Q%<VWBW^R]>N-0T
MN\EU(BQF(S9WL&_Y(@1PK[>N<'=WYQ0!Z/17FYO?$_BG3]4O-#N#;7EMJ$UO
M:9N L*"*3;MDCVG=N ).>?F&,4[QIK.L^%KS3-<%_P"9IUS&;>[LB_[N"1E^
M6=6"[BBG[WM@@9H ]&HJGI=M)::9;PRWTM](J#=<R8S*?[W' S[5R]E>W7BK
MQ%XEL1J%S8PZ5+':P"V8*P<IN,K<?-R< 'Y<+TYH [2BO)(?%/B'5]#\(S'4
MGL[NXUE],O3#$FR;9Y@+@$<'Y <9QGL17IFDV4^E:5';7.H7.H21[B;FX"^8
MX)) .T < XZ=J +]1O/&DHB+ RLC.L>1N8# ) _X$/S%>9IKNL:K\+)_'-IJ
M4L-\BS7D5OP8!%&[#R63'.57EOO9/! XJ?3WDU7XM6-_]JO(4N/#<=X(/,&U
M-TRY3&.G SW..M '8^'/$4'B2UO)X+:>W^RWDMG)'/MW;XSAONDCK[UL5XKY
MFIZ9X*\::[IVKW-I+I^OWLT4,2IY<A$PR),@E@1Q@$5VEWJ>H:WXIU+1;1IX
MHK*S@D_T>X$+EY=YW9(.0 H '3).<\8 .VHKS&XG\7P7G@K3-3UOR+V\EN;>
M_:S5&239$[*XRG#XQ_LYYQ7H&G6,]EI$-E/J-Q=SQH4-W*%\QC_>/&,CZ=J
M+U%>-I>^*YOAG<^+(_%%U]NTV:Y=8&BC$,\<<S B0!<DE1@8( P,#/-;DD^M
M^(/',FF0:_?:=9W&@PWZ)"D>Z&1I", E>GRC.<GW% 'I%8U]XCAL/$^E:%):
MW!EU(2M#.-OECRUW,#SG/3MWZUS.FWFI>+-/\275OJMS9W%A?3V5D(MH5#"
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^0I]% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MR(2&&X;<<$ \  ]P:@7X>Z<GA>T\/+J&HBQM9Q<1?/'O#!]XR=G(#<__ %J
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M#?W-P_V1;NSE*F&:.4JI 7&=^6!W9)SGIP!ZAK[A/#VHDACFVD "J6))4@
M<DYKDO OAQ+KP1X;&I7%_(+***7[#<JJ+%,HXR-@<[3R 21T]!@ ?I=Q=^,I
M/%!&HW=C+I^HRZ?9"WE*"$QJO[Q@.'W,2<-D8  '7."->NO$WA_X:ZO>HJ75
MQK"B4*, LJ3(6 [ [<_C7<2>$;4:M?ZC97U]I\FH*!>1VK($F(& V&4E6QQE
M2#^/-%YX-TZZBT6&&6XLX-&D66TBMBH5652HSN4D\$C\: .;N/$6HZ+XA\?S
MO=37D&EZ;!=VMO+C;&Q25B!@#@E1D]<#K6QINFW\Z:%K$?B&=HI8 U^DK%DN
M_,0;2@R!&0QXV@<''-:$7A2R36]5U22>XG?5(5@NH)=AB9%!"K@*#T9N_.><
MU3\/^!+#PY+&;?4-5N+:W)-K9W5SOAMLY'R+@= 2!N)QGB@#GK;5=0T>X\3>
M&KV^N;G5&=)-)FFE.Z2*8A(\8_YYOD,1V&:[2#1IH-2L[K^UKYXK>U,#6[N"
MDS$@^8W&=W%86FBW\7>*+'Q"VBWUDNE0S11/?VYAD>1R <*3DJJJW/J_'0UJ
M7>CW4WC33]6@O;^.&"!HYX//'V:12&Q^[Z[]Q4[NF% H WZ*** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHKG=9U>1O$FE^&[20QS7B27-S*
MOWH[=, X]"S,JY[#<1SB@#HJ*YQ;[2T\:RVZZAJ#:C!INYK']X8?*#C]X%QA
MGR=N02>HJ>S\7:-?Z!<:Y;3S/I]N7$DGV:0,"IPWR%=QP?04 ;E%<SJ>L/H>
MOZ0\DDAT[69OLI27.89RI:,C/(#!2I7L=IXYSTU !1110 445@?\)EHGD:M-
MY]QLTEMM[_HDN8>,]-N2,<Y&1CF@#?HK+3Q#ITEOIDZ/,T>ID"U(MY/GRI;)
M&WY1M!.6QP*Y>\O[.X\#^,[O1=9U.26W:[=Y))'5K:=(@QCCW %4'' ]30!W
ME%>;ZA>WR:;\-[A+^[5KJYM8KA1*0)@T#,=_][D \U:UC6UU+X@-X:G?58;%
M-,:4FSCGC<S-*$#;D&=J@'!^[D\YQP =]17*Z?XJT;3/![7]QJUW=VFG,;6Z
MO)[:0R>8AVMO4+G.>"<56U2YN8_BKX<ACO+@6MS8W;26_F$1L5V;3MZ9^8]:
M .SHKSW0O$,>AS^-+O6M0O)+&QU0(KR!YO)0Q(< *"0N2>@P*["37;"*+3I6
M>;;J+B.VQ Y+DJ6&0!E?E!/.. : -*BLKQ+JYT+PYJ&I+&\CV]O)(BI$S_,%
M)&0H.!QR>@KD_#U_:PV&A^(;S5]8%S>VL=O+:2B5DN[AT#[DC8=OF.4PN/84
M >@T5S.H>)=#U#PIJ]U)J%W:6EOYEM=RPQR)/:N!\W 4LK $'.,=#65K]U+%
MK/@-K'4;S[+<W7ENIE($Z>0S N/XCP#S0!W=%8FJ>+-)T<3M=RS"*V95N9HX
M'>. G!&]E! X()] 03@&IK[7;"WD6U$DTT\T)F5+2-I7$?3?\H.!Z'N>F: -
M6BN+^%M_/J7@E+J>\GNV:\N0LT[EG9!,P7)//3'%;]_XAT_3[B6WD,\TT,0F
MFCMH'E:)#G#,%!QG!P.IP< XH U:*P;OQGX?LK#3KZ74%-IJ+K':S1HSI(S=
M!D# Z'KCH?2KVD:U9ZYIWVZR,WD;W0^;"\3 J2""K 'J/2@#0HKFK3QYX>OM
M02RMKJ9YFN7M3_HLH"2(,LK$KA>_7&<'TJS%XNT>74+.S\^5&OL_9))('6.X
MP,G8Y&#QR.>1R,T ;E%>:OJO_"5>)?$NF2W>N6,=C]G2RDLH9XVB/E^8S, N
M"23C#CD 8'//51^,=#_L73-3%[))9:A(D%M<?9W_ 'CLVT X7Y<GU % '045
MD7?B73;*:>.1IV%O(L4[Q0.ZQ.P!56(!P<,I]@1G&:35?$VF:.+@W3SLML@D
MN6@@>40(>=S[0<<<^N.>E &Q165/XATV-+01SM</>Q&6W2U0RM)'@$N ,_+R
M.3QR!U(KG?AGJ,NI:;KLLEY=74::W<QP/<LQ=8QMVKAN1@=N,4 =O17-2>+H
MD\>+X9^R7619_:'F%NY!)=57! ^[][+'C..>M6+KQAHMGO>>XD6VCG^SR78A
M<P1R9V[6D VCG@G. >"0: -VBF22+%$TK$[%&XX!)Q]!UKDU^)WA-TLY1J3_
M &>[D,4=P;:01*^XJ [E<(20>#CC!Z'- '7T5DZIXCT[2/.%P9W,$?G3BW@>
M7RH^?F;:#@<'WX/I5*\\=^';)K59+YI#=VYNK?R8))/-C !)7:IR<$<#GVH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MV4A\K9<%CSC#<<C;GBO<** /*_$<5Q;ZSJNK^&;F\MM8,T:SZ3<0,]OJ@VH
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M)B:1EC5_F;:H).,]A5:&Y63XPF^,-Q';-X?$?FR0.JA_.+[22.&V\XZUWE%
M'B=G#?VGA'2-373;^XATO7;N>\LXD>.;R)6E42*O!. X/'8GWKT/PF^CW]U>
M:MI&EW,"3HB27EW'(DEP1G Q)\Q"COTYP.AKJ:* .%\23_V3\2] U>YAN38F
MQN;4RP6[R[9&9&4$("1G!QQVKG=.M[6]T+Q#::S9:M:Q7'B>>:.>&&1)+?)R
MDRL 1PRX)&0._%>N44 >0ZK;^(KSX<^*+"XD?64M;FW>SOX[?;)>1JT;OD#[
MY4*1N'7'M6N^K#4OB;I>J:?8W\]I_8UQ&DK6DB*SET(4[ERH.,9( ]Z]'HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M(V@G(XXKIM>O;NZ\4WME)INI"SFTL?9);*U<-=2'=E))0 4"Y&%)4<G.<@4
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MFO9Y+:9;8R6]Y')(9%+/]U<%N=W3'K0!Z%>>)K"SENE*7$R6C*MS)!$76%F
M(!QST93P#@$$XHOO$UC8RW:,ES*MGM%T\,1=82P! ;'.<$'@' ()P*X7Q)I]
MS;ZKJ>I>&SJ-AKT1BB:T%N\EGJJA$ X(V\ E-P(V[3G'6G>*;*Z36=5U;P^V
MI6'B&,QHUMY#RVFJC8N 01M.,E-P(V[3G'6@#U&BFH6,:EP ^!N .0#3J "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK"
MO_%=C8M?%8+NZCT__C]EMHPZV_&[!Y!8A2"0H8@$9% &[17"^-O$YCTS0#IG
MGSVFJZC:QM/;8Q)"[;BJMD'+ 8^A/(K?T;2K?0[.\N+1;\Q7+?:!92R;_).W
ME(P3\N2,XSC)["@#;HKR3Q#XIN/$OP;N]<\J\TZ5;E#&RRF,;/M8CVY5OF^3
M@YXS7?:?XKT_4=>ET98KR"[2#[0@N8&C$T6[:73/4 D#G!YH W:*YUO&FEQW
M%@LJ7,=IJ,P@L[YHQY$TASM4'.1NP<$@!NQ-+XY\3#PAX-U'6Q&))+= (D;H
MTC$*N?;)!/L#0!T-%<UI7AEFTJ"35M0U"XU22,//<+>21A7(R0B*P55!X  [
M<YJ6TNV\.:78:=J5U/J&I3221PA<-+<X9FW=@,+@DD@#IZ4 =!17.'QMI$>E
MZI>S?:8CI1(OK9H"9H.,C*KG@CD,"5([U"/'^CB\LK>2'4(Q?Q&2TE:T;9.0
MNXHA&2S8/0#GL30!U-%<Q'X\T@Z7JU]/'?6W]DMB]@EMF\V+Y=P)49X(Y!Z?
M2F6?Q!T6\UBRTW;>P-?INLY[BV9(;@XR51SP3C\#V)R* .JHKFW\<:2DR_+<
MFU:__L[[8$!B^T9V[.N[[W&[&W/>FW7CK2[;4M2TY+;4KF\TY$>:&"S=F*L"
M<KG&1A>O3D8))H Z:BN;;QQI'DZ)/&+F6WUHJEG,D?RLQ&0K$D;3C/!]#Z5K
M)JD3ZU+I2Q3&:*!9W?:-@5BP7G/4E6X]C0!>H(R"*S]1UBVTV>VMF62:[NBP
M@MH0"\FT98\D  #J20.0.I%94GCK1H-%U+4YC=(NF.8[VW,#&:!NN&49X(Y#
M9VGUH @TSP=>Z3"EE:>*=472TR([9HX6=%)SM$I3=CWZ^]=/;V\5I;16T"!(
M8D"(@Z*H& *S=%\0VNNR7*VMO>QI $(EN+=HTE5QD-&Q^\..H_J*9J'B:TT^
M2]3[/=7(L$#W;6Z!O)!&X9!()..> <#KB@#:HK(A\0VL^LZAI$<-P;VQB2:2
M/:/G1L[2IS@YVGTJ"T\8:5?Z'8:K;--)'J#F.TA$>)9G!8$!3Z;6))P !DD"
M@#>HKS;Q[XBMM8^&OB<V,UY:7VF$1SQ;S%)"^Y>"5.&!![$@UU6G^+-/O-<7
M11'=PW+0&>%IX"B7" @,4)ZXR/3KD9% #]!\.-H\LMQ=:M>ZK=N"BSWA7,<>
M<[%"@ #/4]3@=@ -RJ>IZG::19&[O)-D>Y44 %F=V(554#DDD@ "J%OXHM)M
M1N-,DMKNWU*&#[0+.5%WRQ]-R$,5;GCKP>N* -NBO)/$'BFX\2_!VXUWRKS3
MY%ND*,LIC4I]KV;<JWS808.>,UW^G^*]/U'79M&6*\@NXX/M*"Y@:,31;MI=
M,]0"0.<'F@#<HKG6\::7'<:>LJ7,=KJ,H@L[UHQY,\ASM4'.1NP=I( ;L34-
MKX\TF^U-K"UM]2FECO?L4K+9/MB? .7)'RKSC)]#VYH ZBBJ6J:K:Z/:+<7;
ML \BQ1HB[GED8X5%'<D_X]!7#66KR)\6-8=X-2CB@T2.62TF?=A_-;+(-Q3!
M4+]TXX/?(H ]&HKGAXSTIM,T745%P;36)HX+601_QR?=##.1G!Y]JK:9XNDO
M_%^NZ0^FW4<&F+"/,\L,265G+$ DX(V[0 3^= '545ROAK6M"A\(6][ILEZ]
MC+<R1P+<%WFDD,K J QS]X' /0=<8-6(_&FE9U..Y%Q9W6F[#<VTZ 2 /PA7
M:2&#$@#!//I0!T5%9]AJRWUW<VC6EU:W%NJ.Z3JO(?=@@J2#]T]#5#6O%^FZ
M#J=IIUU'>27=VDCP1P6SOYFP9(7 Y/3@9Z\X'- #M6\.-K&JP7$VK7L=BD82
M;3HRHAGPV07XS[$ \@8Z9SNU@'Q;:-9)<06.HSN;9;N2W2#$L,;9P75B,'@_
M*,DX. :;'XSTF[BTUM.:74'U*%[BVBMU&YHUQN8[BH7!(&"0<\4 /G\./-XS
MMO$0OMKP6K6JV_E94HS!FR<YSD#G]*WJP;7Q=I=_I.G7]EYUP-1D:*VA5 LC
MNN[>N&( *['SD@<>XS+_ ,)-8)IAOITN(!]H^R+#)'^]>;=M"*HSDD],<8YS
MCF@#9HK#M_%5C+>WEC-%=6M_:0BXDM)8MTC1'@.@0L'&>/E)P>#BLVS^(VAW
MR:5-%'?BUU.406]T]LPB\QB0J%O4D=L^AP: .NHKF]3\;Z5I;:@95N9+?371
M+ZXBC#);E\$;N=QX()V@XSS6#K&JC1_BW;3,=0N(9=#E86EOYDV]_.0 I&"0
M#@=1@<<T >A45YGXW\367B/X2ZMJFD75W"]M*D3KN>"6&02HK(Z@CG#<@Y'-
M=H_B2SC\4Q>'GBN5O98#<1L4 C9!@$AL\X) QU]L<T ;%%4;'5(M0N;Z"**9
M39S>3([J K-M#?*<\\,/SQU! Q]6\=:5I&K7&ER6^HW%[!;BY:&VLWD9HRVW
M*\?,.O(XXZYXH Z:BN>U/QEINEV]Q=30WDEE:L$N[F*+*6Y..&&=QQN&=H..
M^*R;J8M\7=%:&ZE>WN-(N)-@F9HFPT>&"YVC@]0.: .WHKF[;QQI-U-8>6MR
M+74+A[:SO"@\J:1=V5'.X?=;!( ..*ATKQ<^H>+-=TJ6PGM[;3/*4S2!0H)1
MG+,<\ C;C]<9X .JHKGX_&.G-J.GV<L5U;C4@?L,\T6V.X(&< YRI(Y 8+GM
M7+?$WQ'#<?#W76T\:@5M\P_;K5BD:RA@"N58,PSE2<%<\$\< 'I-%0B0QV8D
MV,Y6/=M49+<=![UROAOQU#JGA:?7=2MIK"WCGE4%U!! E9$4;22S\ 8 Y)P,
MT =A16-:>);2XUD://#<V6H/$9XH;E0/-0'!*E20<=QG(]*J>-O$LOA;0UO(
M;.6YDEGB@7:!A"[A=QR??@=SCMDT =)17GFI:J;+XIZ5<NNH^7/H\[?8@6=F
M<2(!B,$@-C/([<DUTMAXOTK4=$75(3.JM<&U^SO$1,)PVTQ%/[V1],<YQS0!
MO45CZ3XCL]6U"^TY8Y[;4+$K]HM;A0'4,,JPP2&4^H)J>_UB"QNH;,1RW-[,
MK/';0 %RBXW,<D  9 R2.2!UH T:*YR#QQHUUI5E?VSS2_;;DVD%N(\2M,,[
MD() !&TY)(''7I44_C[1;70;_5[D7<4.GW!M;J(P%GBE&/E.W(_B7YL[>1S0
M!U%%<W8>.-(O_$0T,)>6]W)&TML;FV:)+I!U,1/W@.OTYZ46WCC2;J:P\M;D
M6NHSO;6=X4'E32+NRHYW#[K8) !QQ0!TE%<_JOC#3=(2^EECN9K?3R!>SP1A
MDMB0#\W()(!!(4$@$9Q4,FJ:+/XVL(UDO7U(Z?)-!LWB!X25)/\ =8],8S0!
MTU%</IGQ#2;1=9UC4-+OX+/3[N6%MD0<HD9"G=AN2#DG'0>PS72/KUND.ER"
M&=QJ;A( BJ3DH7R>>!M4G/M0!J45B>+[O3;+PIJ,VKM=+8>2PF:U#^8%/4@K
MR/KT]:K7'B[2-)N=+TQUO6FO;<R6J+ \A=54'&?XFP1T)//..M '245D^'_$
M-EXCM)Y[-9XFMYVMIX;B/9)%(N,JP^A!_&FR>([6/Q*- ,%R;YK9KI/D 1XP
M0#AB<$Y(&.O/IS0!L45SUGXQT^^T.YU:""\-O;3FW=#$!)Y@;85"YSD,<8_+
M-<Q;:X-$^(WBYIH]3NT%I9RI:PAYV3(D+[5R0H_$#T[4 >D45R.K>(/#VHZ9
MX;O9I[UK;4+ZW:P>V$BAI6/R!R, #DY5O0\'%:6J^*;+2C>@PW-S]@A\^\^S
M(&^SI@G+9(R< G:,MCG'(H W**\YU'6[=?B1X>U*UN+NYLKW2)YHX8"\@FYC
M*%8^@.#UP/?I79:!K]EXCTYKVR$R!)7@EBGCV212(<,C+V(H U**** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *\
M^T'[7X7OO%6G:CIU]<QWNH3:A9S06SRI.DH'[LE00K*1CYL<<]*]!HH \HE\
M/ZAH/@?P'H[VMU=76GZK;7-U]F@>41(&=GR5!&%W8]\<5ZLC!T5AG!&1D$'\
MCTI:* /&6LM47X(7'AUM%U,:E!=!3&+5CO\ ],\S*X'S#9SNZ=LYKJ=6MKC4
M/B79RPVUZEK)HEQ:FZ^S2!(Y)&4J"<<' )]J[VB@#ROPA&%L--\/:IX$E75]
M/,<37DMDIM<1X F68]3@9 '.?S'8^//#)\7^"]1T5)%CFG0-"[=!(K!ES[$C
M!]C71T4 <KHGBN633X+?5](U6TU:- D\(L99$9P,$I(JE"I/0[OKBL[7[?5;
M;QAX;\3O8S36D$<]K>06ZF62W63!5PJY+8V@-MS[9%=W10!Y?K>D7=ZOCS6[
M>SN_+U+2EL+2#[.XDN'$; MLQN RP4$@=">F";5Y%<O=_#N1;"_*V1+71%I)
M^Y'V<I\WR\?,<?KTKT:B@#R?78IT7XK7$EI=16]UIT9@FDMW1)=ELRMAB,'!
M_P#K5HS6S^*=/\#V]I:74;6%U;7]Q--;O&L211G*AF #%F(&%SQD]*[77](7
M7]"O-)DN)((KN)H9'C +;&&#C.1T-6--LSIVF6UEYS3""-8Q(P + # SCC.*
M /)=7_MK5-*+7FA:P=1M->BF>&"W80) LX(:,# E)7DMACDG) KJM):>'XB>
M*;^?3[^*VN+.T6)VM7(=D5]Z@@$$C<!QG/;-=U10!YEH/AFYU3X(66C7,4VG
MZG:P[X6GC,;6]Q&Y=&^8=,XY]":ZGP1]LN]!36M3B6+4-5"W,L:G(C7: BCV
MV@''JS59UWPXNO7%JTNJ:C;6T0=9K6VF"1W*MC*R<9(XQP1U-;2J%4*H  &
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MA4E%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %<':6NI:;XM\9O)I5U);:D(IK>XC"LC!8 A7&<[MPQC'OTKO**
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBLG6]9GTM
M%6STB]U2Y92WDVNP;5'<L[ #V'4]AP< &M165X<\06?B?0K?5K%94AFW*8YE
MVO&RDJRL.Q!!%:M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
AHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>24
<FILENAME>exhibit1016-arvinasxamen004.jpg
<TEXT>
begin 644 exhibit1016-arvinasxamen004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(\4ZY_P (
MUX9OM8^S?:3:H'\G?LWY(&-V#CKZ5KUSGCW3+W6? ^JZ?I\'GW<T0$<>Y5W$
M,#C+$ =.YH AA\4:G:ZO8V&OZ&FGK?N8;:X@O!<1F4*6"-\JE20IQP0<5JV?
MB71-1U2;3+/5;2>^@SYD$<H++@X/'L>#Z=ZYZY@USQ5J^CB[T2;2-/T^Z^VR
M/<7$3R2NJLJ*HC9L#+9))'3%9&E^'M=>T\.Z'-I1L/[$:1I=4$R%9LQ21@QA
M3ORY<,VX+C!ZG% '8Q>,?#<\MY%%K=B[V:-)<!9A^[5?O,?8=SVJ]=:OIMD9
MA=7UO#Y$(N)?,D"[(R2 QST&01GVKSMM$UZ^\&IX8/A>WM9K32)K/[?++$RL
MYBV+Y)!+ .0"Q8+@=<FI[[2];\03ZG>W7AJ>&.72K>VCMI+V..5Y$F9V*LA8
M*1D%2>"0,X[ '7Q>*-,OK*"[TN]L[N"2[2U9_/VA6)Z=#EN1A>,YI]KXL\/W
MNJ'3+;6+*:^#F/R$E!<L 20!WQM.<=,5Q&GZ!XDN(-MQ#>F!=7L[B)M0:W^U
M[$_UC2-&=K ?+MR2W!]JSO#UW*=6\!:1]BM#'I[SHM];W<<@N +>12ZJIW*"
M<%MP&&('- 'I&G>*] U>]^Q:=K%G=7/E^;Y<,H8E>.>/J/SJEK?B/4K+Q'9Z
M)I6D0W]Q<6LET6FO/(5%1E4C[C9.7%8WASPSJ.FVG@:.6R6)M,MITO '3]VS
MQ@=CSEO3-)XS\/S:CXPTS4)?#4FN:?#8S0O%'-$A21G0J?G=<\*W3UH Z-?$
M/]G:>+CQ0+'1I'D9(T^V>:K@+NX8JO/#<8[5;L=>TG4Q;&RU&WG^U1O+!Y<@
M/F*I 8CZ$@'TKE;30Y9KGPV;?PS)I-GI^HS32V\TL3[0;>11(-CMGYV4>N1G
M&.:SM2\,^(K71GO]&LU.MVFL7UQ:QF5%$D$[N.N<#AD?!Y^3UH [*\\7>';"
M&":[UJRACN"PB9Y@ ^T[6(]@1@GH*C;Q3:1>(+[3KCRH;:SL(KY[QY@$VNSK
MZ8 &S.<]ZXO4/!NHZ/J5FUA!JUU9II,.G_\ $LNXH9 \9<DN), JV_.0<@@Y
M!J.3P3K,9,<%B&2WTS3%2&2X#K*]O<-*\.\@9^7 !( Y% '?0^*_#]QI;:G'
MK%D;%9!$TYF 57/123T/(ZT1^*M FT>35TUBS.GQ-L>X\T;5;^Z?0\CCKR*\
M^\2VVJ3RSZ]/H;VPNM1TJ&'3II8S).T4S$LY4E06WA1R>%YJ;5_#>O:S/<:Z
MFFW=DQU&WN1I\5S$ERZ1PO&7# E!(3(" 3T0<@T >D:;J=CK%DEYIUW#=6SD
M@21,&&1U'U'I7(R?$"ZDQ%8Z*D]T^MSZ1'')>>6I,2LQD+;#C(4\8_&K_@G2
MKG3X=2N+FVO[=[RY$H6_NDFF8!%7<^P;5)QC )X R>U<K'X?\0:?.E[%HTUT
MT/BN[U#R8YHE9X'C=5<%F Y+#C.?:@#KK#Q:PO[S3]>L5TF[M;7[:Q-P)87@
M!PSA\#[IX((&,CUK;O[BZAT]Y]/M%O;@8,<)F$8?)&?F(..,GIVKF;*VUF\\
M37'B>^T>2T^S:<]I::?Y\;S3%G#L2P;8N=BJ!N]22*ZN=YELY)(8M\PC+)&2
M!EL<#/3KQ0!Q=SX\U.RTS6+JY\.(KZ=+!!M6_#+)+*ZKLW!."H=2>#U JWJ/
MBC7M$T+4M6U;P[:PPV=N956'4C(9&R!M_P!4-HP2<\].E4-3\)WT_P )X]"%
MO]HU&9K>:\1G4>9*9TEG))..N\]?I5CQ+X)LX? NO:=X;TJ*.[OK<((XV"^8
M0>!EC@=3WH MP>+-2M]9M],UK0?LLUU!+-;FTNQ<A_+ +*1M4@X(QQ@GC--L
M_&LR37<6N:0^EM!I[ZE@7"S$0K][> !L?GIR#S@\&L'2O#=[!XFLM1T7PLWA
MU8(IEN6N+J-UN@4^2,I&[<!]K;N",<9S27'A[5_$MU?,V@_V!+=Z7<6NH3&:
M-EO)G0*F C$LJG)#, <'&.30!T^B>*+N_P!4CT_5-'?3)KFU-W:YN!*)(P5#
M X VN-Z9'/7K3/#'C2'Q)JNH62V;VP@_>6LC/N%W#O>/S5&!@;D/'/!![US]
M_!XMUI5O8=#DTZ^M-,EL81+<1'=-.T0>12K'Y$5"W."<\"IH? MYX9U;P_?Z
M+?:AJ*V>+":"ZDB"I:,N"5PJYVLJ-C))P<<T ;&A>+;K7+V81:9 EBAEQ.+Y
M6D*JS*K&(#(#;<CGH:R[+XA:FWAZS\1ZCX;6WT2X5)'N(+\3/"C$ .R%%X&1
MG!) YQ572?#]V^K:.8O",.@/IIE:ZNHI(BEP&C9?+0J2S*S,KY<#&T=ZJ6.D
M^*+SX<V7@J?P[-8[K:.TNKZ:Z@9$CR-Y54=F8E<@<#D]: /1M6OI=-TN:[@L
MI[V9 !';P#+2,2 ![#)Y/89/:LO1_$LUW>:E8ZOIZZ9=V$4=Q*!<B6(Q/NPP
M?"XQL;((&,=ZJ:C8^)-&MM3U#2;^ZUFY=2MGIDXA2*(LXP0V%)"KG@MR/?FL
M:V\+ZAKF@WNGW5OJ&DW=S/%/>WUX8)S?XSE"L<AVH, ;>!CCG)H WM%\;V&L
M>'M5UT12V]AI\LJEY1@R1H@?>!V!!R!]*I6/C]KGP-JWB"XTE[6[TR-WGT]Y
MLL,()%&[;_$K*<X[]\5@-X,\3W.G:IHEY=&2SU765DN+B)(XBELJJS.!D\N4
M5 N#C!)&#4VN>"M9M(]?ATR>]U=-;TF6"9KN:(,DZ#$70(,%69>G&!DXH WX
M_%NJ6=SIPUW0$LK34)DMXKFWO1<!)'^XKC8I 8\9&>2,XKJ+R[M]/LIKR[F2
M&W@0R22.<!5 R2:XJYM]?\2_V-87&@3:59V=Y!=W%Q<W,+E_).X(BQLW)8+R
M<8&:EU#P1J^HVBV\_C"\N$6XCGV75I"Z'9DA2JA<C)4X.>5% #1\0I+KPYIV
MJ:?HKR3:AJC:=%;7,_DE2#(-S':V/]7TQQGVJ<^//[/CUA=>TMK*YTR"*=X[
M>87"RB5F5%1L+\Q9<8('4=JY>Z\&^(#X9M[74+(ZR8_$<E]):IY41> M,2V2
MX'S;U;&<C..U/'@?4;R#6?[,TC_A'[:6&WDM[&XN$D$MW%+Y@D.QF"#"JAP>
M<YQQ0!U]EX@UU-1MH-9\."SMKI6*3VUU]H$!5=V)L( N0#R"PSQFH]'\93:E
M<:<]QI#VFGZMG^SKEIU9I?D+KO3&4W(K,.3TYP:=::MXGU35+*%O#[Z39QDM
M?2WDL4F\;2 D01B3\Q!W'' Z<UR^D>#]1?5M.C%EJ>DP:8\\BR2:@L\$9:-X
MT6V3)./GW?.HQM"]S0!V/B3Q#>:->:39:?ID=]=:E,\4:R7/D*NR,N23M;LI
M[4W1_%0O/[7BU6T73+C2"OVO,XEB563>&#X';J" 17,^)?"6J2'0C=1WGBR"
MUO99KB.8V\+A&A**!]Q2 V#ZU6LO 6I7\>HP0J_AO29[FWN(]-<I=!V0'>7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JG;Z3IMI=RW=MI]K#<S?ZV:.%5=_]Y@,G\:N44 %%%% !1110 4444 ,
MEABG"B6-) K!U#J#A@<@CW![T^BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9F "GS')7<>,^W?'M7,)IUWX=TO3M=EL;[^PTU^]O'MK;>DMO:S*R1R;5(8
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M YZV\.74'CB\\1-J$3QW-JEK]F%L055&9@=^_DY8Y^6NAHHH **** "BBB@
MHHHH *AO(II[*>*VN#;3O&RQSA WEL1PV#P<'G!J:B@#'T#1KG2H9)-0U)]3
MU*?:)[MXEBW!1A5"+PJC)./5B>];%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110!@V&@W\>N3:CJFM2:BBR2-8VYMTB6U5^,97ER!\H8]B?6MZBB@
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MGTQ3HHHX(4AB14CC4*B*,!0. !0 ^BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP5OLD5MM*R$YW[\\Y&>,<9]LGL: "BBB@ HHHH **** "BBB@ HHHH ****
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M$OXC:K/'.4&%<!C\K <9Y_GFSJ/A"2YU'0;ZTU6:WN=)$R>9)$)6F64 .3G
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)7,<]RH$K1Y^7<!WZG'4 @'D5NT %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MH)&G9E!]]H-=RV[:=N-V.,],U1TW2XM.-S-N\VZNY/-N)R,%VP !CLH   [
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M*7OAC6-(T'0]1@U%O$.E20@Z;)+.&@GBPOFXSM"@9;/3!QUXKUZDP,YP,^M
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MS^*Q\ZW)E:4 [AEQ]F"C'K\V1]:K1:Q9Z+<^$M5UF>YBT.?P]%9B\MY'"P7
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MBW-Q;:AJT,,UO&)98]K,54G .%!_+V)Z"O.K5EG^"MUX/NXB/$<4;VAT]O\
M6O,9"4D4=64DA]_3J<\5T&G!(?C D-Q,DT\?AJ&V:4\[I1,Q9<_WL8..N.:
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M]MJ=M=31*,26:1J?-$@ZI_=P<9)'6O2Z "BBB@ HHHH **** "BBB@ HHHH
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M SD'/M6K10!5TVPBTS3X;*$LR1+C>YRSD\EF/<DDDGU)JU110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% &!JVA:AJVKQL^M-'HOEJ)]-6V0^<
MP;.3(?F"G@%>X!]:WZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "O.]*O+71O%/C:/589%^V7,<L$+0L3=Q^0JD1C'S\@C S7HE% 'B]EIUYX$
M@\)7&OVU^^FQZ9+9W3V3R%K.5Y1*-WEG)7&%XR,J/:O2/"4.F+I]S<Z1I\UI
M:W=RTX><.'N&(&92K_,,D=^3C/>N@HH \K\4+-9:WK.J>&[^:'5Q+&ESHUS'
MYD&J?(@!12,YVD*67^[SCK6KI-VWAWQ_XG_MO=!#J9@N;*Y<$I(JQ[&C#=-R
MD<+U.<BN_HH Y'X;:1<Z-X02"YB>#S;F>XBMW&##&\A9%(['!!QV)Q6!+>+I
M/C'QY;W4%SYNIV\$EDJ0.PG"VY1L$# PPP<D8KTVB@#R&QM+:[\(^#E?4K_P
M]K%IIA%OJ#1%$0@('BD5P%96P" >NW@TD^HZK:CPKXE\1Z;="S%O=6E\=.65
M#"SR*4GV(0P5P@)';/3.!7K]% 'D^O6]NNAV.O\ AW1[W^S8-=M]1O04D,UW
M&H(:78_SG!*GGD[<] "=2SU:UU7XP6>H6*W,UG)H,D(N!:R!-YG5@"2O' /)
MXSQUKT2B@#B?'\5Y!?>&=9BAEGL=,U'S;R.)"[*C(4\S:.2%W$\<\U2NHX]1
M\>7?B*RD#:;;Z"]I+<J/DFD9]RHI_BP 2<9P6 ZUZ'10!R7PQ 3X;Z%"4:.2
M&V6.6-E*LCCJ"#R#_C5+7M1\OQ\MA/:W%O%+IO[N\M;5GENFWG,'F!244?>Q
MP<G.0!SW5% 'A^D74=IX5^&'VR*:$6NH/',)H&4JPCDYP1T&1ST&#SP:VO$5
MF+V]\=^(;( Z<WAM[0S+]RXF"NQ93_$%7:N>F3CL:[;Q!X<N-:U?1;Z*_CMQ
MI=P;A8VMS)YC%2N"=XP,,>W6KOB'2I-<\/7^E1W"V_VR![=I6CW[5=2I(&1S
M@^M ' S1V_B70? %GI>)+NRNK.[E*+@VL4<>7W_W<\* >I(QG%7_  E&]U/X
M\M[9S#<76HRM;RE2NY3$BJZGN P/(KM-'L9-,T:SL)9UG:VA2'S%CV!@H !Q
MDXZ>M7J /'F1]6^"\7@[[+)%XAC2*R-DR$/'(DB_O?\ <P-^_ICOFMW3]0LM
M+^+7B07]RD9.FV0$L@P&QOR,^I].IQQTKT2N?L/#EQ9>,=3U]K^.1;^&*%K<
M6Y4H(]VW#;SD_,<\?E0!YO%I<FC^'O"D<]M)"C^*CJ"6YC.;:V8R[2PQ\H *
MDYZ;N:[#QC(O_":^"7&2L5Y,\C*"0BM"R@L1T!) R:[BB@#Q7Q9?2:CX=\5V
MIL;RUNH-51EL;6R<(Z+-'_I#L%_>,R@GKC@<<9KK/M!C^+C7)@NTBU#0HHK:
M3[,^-XF<D'CY2 P)#8P*[ZB@#Q[PJ^ER:+8^%->T759M?L'6,VDIN&@=D;Y9
M@V?+"8^;/UP#QFQ::B=%T_QWH.KPW*:C=7-[=6I%N[K=12I\A4@$' &".V/8
MX]9HH X?PUXEL-&\)^#-.OXKR&XO+2"UCWVK@)(J(I#DCY<L0 >^:T?B)I5_
MK?P^UK3M,R;R:WQ&H."^""5_$ C\:WKFRBNY(&F+,D+B18\_*7'*D^N#R.V>
M>H&+- 'G.KW$?C-/" TM)$N[74X+VY0QE6LXT5O,63(^4DD+@]<\9 J[X =#
MK/C'@AIM8>:,E2/,C\M &4GJ,@\BNYHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "H+N\@L;<SW$@1,A1P268G   Y))X
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M-R%B&!'49 -6)O"NJZAX8U33=4U\75[J-N;9[G[($CBC((PD8;K\Q.2>3CL
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MJ[6FJV5N;626YA\];J)CN(D4,ISNRV01R:N>&/#-SH%WK%Q/J?VPZE=F[91
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M9([>5(I67"O(A<+]0",_G7)^&O">N^%O#%MH5AKU@\%LK+'+-IC%_F8MSB8
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M;SQ@Y( Y(!X[];110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 W8F[=M7=ZXIU%% !00#U%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% "%02"0,CH:6BB@ HHH
MH **** "BBB@ HHHH *1D5OO*#CU%+10  8&!THHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MBUVV^VMJUS:6_GLD;.J2%%  P.V/K0!WM%4K_5M/TS;]MNXX2P+*K'YB!U(
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MAIMW\7?&4<HM9I?L]@%5MK'Y5<MQ[$)GTXKK?$FBP^(O#>H:1/@)=P-&&/\
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MG$H(#C&02/3<,GH,]:XCPKJ'A37[/P]8S#4)->TMXC_9TDDP:TFC 5F(^Z$
MSUX(P.IQ5+[3I[^"/BF1-;EY;^\V_,N7S$H3'K\V<>^: /9"ZJA<L @&2Q/
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M[$CL/>O([..POO@G>^' D,NMRW%Q&ECQYXG-PQ0E>HP-K;CT49Z5U?BV&_\
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M*VT+>@KN0Y!PH8$$G&,8[UD^+O%":7K&AZ,MTT'V^X9;B95)9(EC9OEX/)(
MSV&>G45_B_)&GPNUE9'4%UC5 3RQ\U#@>IXJ#QAJ5BOCCP(YO+?9]JN'W>8,
M;3 P!SZ$D 'WH ZC28)](TB8ZGK1O8E=Y8[JX18VCA/*JQZ$C^\0,^E87_"7
M:=X=\+:--+J\NLB]N4M8;PIS-NDVECM& %&?KM'7-=C+-%# TTLB)$J[F=B
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MK3$ DA54%C@ YXXP<XIT/B+2;G2AJ<-XKVAD\H,JMN\S=MV;,;MV[C;C.>U
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M*(Y'4,ZD @G:3CU..#0!U]<WKWA^]U7Q+H.J036Z1:5)+(T<@),OF(4(R.F
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M#@_>Q5B[UFPL6C669F:1#*JPQ/*=@QEL("0O(YZ<T 7F57&&4$=<$4,H92K
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M\PHQ4,3@ D#C)('-']L6']LG2#< 7_DF?R65@3&" 6!(P1D@<&@"ZJA5"J
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M8@997<OSZXP2*L_"-T/PWTZ($;HWG5D[I^^<@$=N"#]"*[>B@#SS0M0@\/\
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MNT9(X%8>A+>^"-0\%7'B<R16":-+9--("4M+AY X#G^'Y J9]O:O9J* ."\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBL3Q7K/\ 8VB2/%($NYR(+8[2VUW(4.0/X5SN)]!0!SEGXOOC\3?[
M/N0%T/489(--D_OSV['S?SRP'J$&.M=5JOB/2-$N;2WU&]2WENV*PJP)W$ D
M\@<< ]:X/QQX5ETWP/;7FG:S>3W&A/%=:='*L)#,F/ERD89BRY'7D]<U8\0Z
MU::U=> ]1AW*AU(3RHZD- /)<'>/X<,P'- '1#Q_X;,%U*+Z7=:/LGA^R3><
MG&<F+9OVXYW8Q[UJ#7],;3+348[H2VUX ;8PHSM-D9&U5!8G )QC@ YZ5R>C
MW-M#\3/&L\KJD3VUF%D;A7V)(' /?&0#BN,TB672?!_@+5KNVOY-,T^*YM=1
M6U,BRVS2$;794(; V\^S>XH ]0?QQX=BT>?59=1$=K!-]GF+Q.KQ29QL9"-R
MG)'!'<59T_Q3HVJZM-I=G>>9>11^:8S$ZAX\XWH2 '7/&5)%>=^+$T:Y^&OB
M&[T*PN1'J,UL?.F64R7CK*A+!9/F("CKWP>PS6WK,HN?BCI364ZAGT6ZB2=>
M561V0H"1QDX) H 9\1O%<47A6=])U.[AN8[R&!9K:)Q&[><JNGF[=N0-W1NH
M([8KL-4\1:;H_F?;)9<Q1^;*(8))C$G/S/L4[1P>3Z'T->0W&JQ_\*27PY-:
M7<6MZ?);0W%F;9V<,MRA+\ @AAR#WSCK6_>ZE8Z-X[UO_A(X-533=86"6QN(
M!<;' B"-$R1\ALC.".] 'H$OB#2XK:SG6Z$RWJ[K46Z-*TRXSE54$D <D]!F
MN<^'.JSZJ?$SRW]S>10ZS+% UP"&1!''\NT@;<$GC YS6%&\'A'QSHM_/IT^
MG^'9M':QM@59Q:2F;S,/U*EEV]>XQVK8^'4ZRZCXO*PW"++K4D\;20.@9#'&
M,@L!W!XZT =?JNHQZ3I5U?RJ66",OL7JY[*/<G 'N:YGX>:_J6J66I:;KQ0:
MYI5X\-T%Z,K'?&P_V2IP/]VI]?FCUCQ'I_AY+V2V\H_;II(E4G<A'EQC>I4G
M<=^,$_NQZUS>I(_@SXI:7JK7UU>V^L0-::@9(TS%MP8I"(T4 9RN2.!GGT .
MZU#Q)I6F2W$5S<-OMHA/<"*%Y/)C.<,^T':.#U[ GH#5.3QQX:BBLY6U6+9>
MDK;LJL1(0,G&!Z?GVKB=<UC3]#\:^*(WO6MEU>RMUE>>SFE0/L90\9C4AE"D
M94D9(/(I;J718[;X<PZ3>B]TZQO GGX)VJD3IN?CY?FQUQ@T =U!XNT:ZTVV
MO[6XFN(;E'>)8;:5Y&5#M8^6%W  \9(ZX]14T/B72+G2K;4[:\6>UNCM@,*,
M[2MSE50#<2,'(QD8.<8-<;XHO8O#_P 1$U/6H]1&B7NG);)=V;38@F21VVN(
MCG#!^#SR/K6;JL5EH,GAW7+/1]2M_#4<MT+A8&F6:/S@FV=E!W@$H<@\X(XR
M<4 =T_C?P[%HT^JRZB([2WF,$Q>)U>*3.-C(1N4Y(X([BD_X3?PZ+^>R-^1<
MQ1^;L,$@,JYQF/Y?WG/'R9KA?%::-<_#3Q%=Z%87*QZC+;D32K*9+QUD4E@L
MGS$ #KWP>PS6_JMS;R_%CPQ/'(CQ+872F1>5!?9L!/0$X./6@#I;'Q1HVI:/
M)JMM>AK2.0Q2,R,C)("!L*$!@V2!MQDY&.M11^+]#==0+WC0MIZ"2ZCN(9(G
MC0C(8HR@D'U Q7F,XNFTWQ%>65M<726?BT:C+;VQ99)[8*@+1XP3SD@@_P -
M=$MWX;U;2M<UK1K6]DD.DS6\M_=>>&.1E85\WECG/3H<#O0!U%EXW\.ZA>V-
MI:ZAOEOX_,M287"2C;NP'*[=V.2N<CN*CT+Q?;:[KNKZ;#;74?V"80AI+:10
MQVAF))&%Z\ X)Z]ZXDRQ)X9^%R9P]M<VQG7',(%NRL7_ +H#$ Y[ULZ!J,6B
M>*O'/VZ&Z3_21>C;;NP:$0+E@0,'E2,=<\4 >@UPUQK7BA-*UUQH-\UW:WH6
M(1NG^D6YDZP^XCQG/.2?3 ZK1=8L]?TBWU.P9VMIP2N]"K @D$$'D$$$?A5^
M@#R[Q'XWU6_\=Z-X&T-FTZZNHUFU"Y95>2W387,:YRN[:.O/)&*Z76- UNVT
MTOH&NWXND*[X[IUF69<C< 6&5;&<$$#/;TXWQ1H%]X;^,VG>/([::ZTB9/)O
MC A=[<^68]Q4<[<;3D>A]LO^(GB;5KK5/#\7@C5KBX-S,5O4T\"8)'E<%A@[
M.K>E 'H>J^*-*T>_BL+F:1[V6-IEMK>%I9/+7JY50<#W/7H,TR3Q?H$7AI/$
M+:G"=*D V7"Y;>2<!0H&2V>-N,Y[5P,]K+X;^.=UKFJ.ZZ3=Z.8;>ZDR5#KL
MS&6_O':Q [[N*X.W\'>(K3X1Z)<W%G<^7!KO]H2VFPF2.W(50Q3KP0QQZ/GU
MH ]_TSQ)I>JW-W:V\[)=V>#<V\\;121 C()5@#@COTKS#XG_ !,5/"EOJ/A'
M5[J*47X@\];8B&9=K;]K.NUL$#H:CN=&U+Q-\2/&>J:*Q:QFT)["&Z4XCFG>
M-<*K=#@CDCIBN,UB:2Z^!&B>'(;"^.K6.IE;FV%K)NC.9B,\=2&''U]#0!]-
M.N]&7)&1C*G!'TKQ_P !ZMKWB7Q/XUTV^\2W\4&E7)BM9(Q$#&N^5<ME"#P@
MZUZ\L\;6PN"VR(IOW."N!C/(/3\:^=?#GA"/Q;K7Q$L)VELY[V[:;3;APR!S
MYDIX_O*05R.>#GM0!Z-\(?&NJ^*_#6H7&N21R-8W!B%Z$$:RJ%R2<< CN1C@
MBNKTSQCH>KWD%K9W;-)<QM+;%XG1;A%.&:,L & ]NW/3FO,/"U[J^K?"O7?
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M*]&4@]O44FK6VE>,?#.NW7A*ROI]1ETTV[7ESYX9@'5_LX\W[Q.&SC@>OS4
M=];^+-&N;U+..XE%Q)"9X8WMI%,T8ZM'E?G_ . Y]::/&&A'1K36!?9T^[E\
MF&<0R;2^_9@_+E?F&.<5F>'_ !3I'BNZL9K72YC?VZ,)VN+-HVL,K\R;V4#)
M( PIY'/05YTMZL/PEM-!-M>-J>GZLGVJ!;9R8@+POD\8.01C&2<^QP >G_\
M"86O_";2^'/L]TK0VHGDF-M(5RS8&"!C;P<L>.V>#5>P\3>']*T&_P!6DUV[
MN]/6^E$MS<(\@@<L,QC"9"*2 .W;-41<K9_&*6XFBN%AO=$AC@D\A]I99G+
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M^9!*,,,X((.001R"" 01R" :DMHY8K=(YIC,ZC!D*@%O0D#C/KC ]ATJ6B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH HZEID>JQQV]TVZT#!Y(<<2D$$!C_=R,D=\
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M@7=(Z1-(0/HH)_'I33K5HM[IUIB8R:A&\D!6%BN%4,=S 87@C&>M &C1110
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M\<9Z&@#3HHI,C.,C/I0 M%4M+U2WUBS-U:B81B1XOWL31G*L5/# '&1UJ[0
M4444 %%%% !1110 4444 %%%% !17/WOC/1].TG4-3NVNHK73[AK:=S:R<."
M!QQRI) #=/>N@!R : "BL:3Q/IL.GZI?3&YCMM,E>*Y=K:3@H 6( &67!^\.
M*D_X2"Q,.DS#SV352OV8K"S#YDW@M@?*,>M &K129&<9Y':J>DZI;ZUIT=_:
M"80R%@HFB:-OE8J<JP!'(- %VBBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MT)54,GVD[PAE(9MFSG ).,]JW/&>N:EX-?3M60QMX;CD$-_ D0\R%2-J,A)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MF(.K>60H WE=_&,XR#U&0#TFV\1:-=S20V^IVLLD<?FLJR@G9_?'JON.*/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MM0_X6/+X>:*V^R?V5]NCD&[S"WFA,$],=>@[UB+XTUD^ O$NM&VL/MNDW=U
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M13"93NYY.,#C%):>*O$":EX5-_%IWV'7HB-D*/YD,GD^8#N+88'!XP,>IZT
M=Y17!?\ "8ZN/"GB_4BEC]JT&\N(8_W3[)4B16Y&_()W'G/X5'=:EK=YX^\+
M1PWUO#;76FS71@:W9@' 3)/SC)PQ ].>N: .TM=6L;W4;ZPMYP]U8E%N8]I'
MEEUW+R1@Y'/%7:X<^.)].N?&CZM! +;0!$T?V?.Z4/'O )/?) Z"I+_Q-K&@
M'0KS54LI;#4[B.UF6WC97M9)!\AW%B'7/!X4]_:@#M**\ZG\6>*Y(/%LEK%I
M$?\ 8$K8\Q)'\Y%B$FWAA@D'[WZ=Z[C2+\:KHMAJ(3RQ=V\<X3.=N]0V/UH
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MZU?U#4O%6E0ZW+/%I\UK:6#7=K>+&5#2*"6B:/S"W;(8$#GO0!UE(S!5+$X
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MI?>&]2O?&4>MBX@MXQI<FGE8V8R*78,74X R".!^/%8ECX$\06]MX7BDU73
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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ME_<6XU&]M1.T*$*3ZE5SG%;<]]9VTT4-Q=012RG$:22!6<^P/6O&]/T^RM?
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M8Y!#.V&!![],5QD=C#J'QPUF.6:XCVZ/;D?9[AXC]\]2A!-;_P!AT&TT#5-
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M:&-'^PNQD$B;^?WHQCI6_9ZC+96CG7K_ $Y&\YEBGC/DI*G&,!G;!'((SVH
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MLZII][=)* ZV2;4MSL7*'))/.3S@X(K1L]3T_43(+&^MKHQG#B"57V_7!XH
MAM-"TC3[EKFSTRSMYV))DB@56YZ\@=^_K3ET72DU![]-,LUO7^]<"!1(WU;&
M33X=5TZXO9+*&_M9+N,9>!)E+K]5!R*E@N[>Z,HM[B*4PN8Y!&X;8XZJ<=#R
M.#0!5M]"T>T:=K;2K&%I\^<8[=%,F>N[ Y_&D70-&73)-,72;%;"3[]JMN@B
M;ZKC%6KN]M;" SWES#;Q X\R:0(N?J::=1L18?;S>6XL]N[[095\O'KNSC%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;,>EZ?#=2745C:I<29#S+"H=L]<G&34EI9VMA;BWL[:&WA!)$<*!%!/7@<4
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MP\RT\.P0):0/RHEE7<TN/[P V@]A0!W-IJFG7ZAK._M;A2VT&&97!.,XX/7
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ME9-J;Z8MU$;Y(A.UN&^<1DX#8],C% '&:1X)OI/AIJ'A35F@@EN&N"DUO(9
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MPLDC1QRNS.756VD@#> #C^'I7;7M@-5T.YTZ^P!=VS03^4>/G4JV,_4U=HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4(
M]$TN'6)M7CT^V74IE"270C'F,H  !;KT _(>E7Z* "BBB@ HHHH *H:GHNG:
MP(1J-JEP()!+$')PCCHP]QV/45?HH 10%4*,X QR<TM%% !1110!A?\ "%^&
M/[1:_P#[ T[[4S;S)]G7EO[Q&,9]^M;M%% !6>VB::^KKJS6JG4%3RUN,G<$
M_N@YZ>W2M"B@ HHHH 0 *    . !2T44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !111TH **0$'."#C@T!@3@$9H 6BD# D@$$CKC
MM2T %%4KDZF-4L1:_8_[//F?:_-+>;T^3R\<=<YSVZ53\5:M<Z'X7U/4[.."
M6XM+:2=8YF(5@BECTY/2@#9HJEI5ZU[HEC?3[$>>WCE?'"@LH)QGMS5WMF@
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M1MLDJ=L*<X4_>"DY' K=FUQ+35;&"X\LV>I?+9W"'@R;=VQO=@"5(ZX(ZXR
M;%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M,F^12V/4@#)[U+XUOS'XK\,:;<SVT.GWIN-QNXO,A>957RU8;E!ZO@$]<<9
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M[NVOGB#3V^Z>UA"KY4D;EQL'\0('7).<UZ)I,\(TZPMCJ NI_LJ/YCX629<
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MYA9*#J Q=D.W[_M\_//''/;CI4,G@[P[*MBLND6SK8*5M0ZY\I3_  C/\/\
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MLK.HX"G!Z#L.W:@#S7PS<P:AX2^'MI>&6]U"5)VMK6:0""41JREIL@YV*1M
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ML37J:N]C+"L@-I/:JR%T(Y#H2<$'C()S[5JU'!!#;0)#;Q)%$@PL<:A54>@
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M56@\7:'/!JMP-0@6WTN5HKB4N-H*JK,1Z@;L?4$4 ;,44<$211(L<:*%1$&
MH'0 =A5*#0M)M9KV:#3+2.2^)-TRPJ#/GKOXYSSU]:=8:O9ZAHT&J1S(EM+"
MLNYV V!E!PQZ C-6%O+5[472W,+6Y&1*'!3'UZ4 5-.T'2M(;=86$%NP38I1
M?NIUVKZ+[#BKEU:V][:RVMU!'/;RJ5DBD4,K ]B#UHCN8)I9(HIXWDB($B*X
M)0^X[4Z26.%0TLBHI(7+' R3@#\Z *&D>'](T"U>VTG3;:SAD;<Z0QA=Q]3Z
M_C52#P5X8MD6.'0=/1%F$ZK]G7 D (#8QVW''IGBMB*Y@N&D6&>.1HVVN$<$
MJ?0XZ&FI>6LER]LES"UP@RT0<%E'N.HH KV6B:9IUW<7=G8P07%P<S2QH TA
M]6/?\:KQ>%= AUMM:BT>R34V))NEA ?)ZG/J?7K3[3Q!IM[KE]I%O<QO=62Q
MF90PX+[L+]0%R?3(I^CO>C32VIW=I<3K))NEM5*QA0QP.2>0, ^X- %J]LK7
M4;.6SO;>*XMIEVR12J&5AZ$&LZW\*^'[22&2WT:QBDAB,,3I"H9$/4 ]1G)_
M,UI6UW;7D7FVMQ%/'G&Z)PPSZ9%);WEK=-(MO<PS&,[7$;AMI]#CI0!F_P#"
M)^'_ .SX]/\ [&LOL4;^8EOY(\M6SG(7H#FJ3V>M:IKBVM_8V<&AV5PD\$B3
MF22X*C* KCY=K8;.>J@>IKHI;B" J)9HXRWW0[ 9^E-6ZMVD:-;B(NN=RAQD
M8ZY% $U8UQX2\.W=S=W-QHEA+/>+MN)'@4M*/<X]A^537L]U+-I[Z??626YN
M,7 E&XRIM/RH0>&SCUZ57/B*TO;S5=,TV[MVU"PC7?O^=5=@QVD @D@+D@'C
M(H =J/A/P]J\-K%J&BV-S': + LD"D1CT'H.!QTJU?Z)I6J6T%O?Z=:W,$#!
MXHY8E98R. 0#TXXK)\$^(WU_PEH]_?S6Z:A?0>:8D.W/)SM4G..*U8C??V[<
MK)=6C6/D(8K=5(F5LG<S'/W3QCCM0!?*JR%&4%2,$$<$5E:1X8T+0)IY=)TF
MSLI)_P#6-!$%+>W';VZ5?6^M'DCC6Z@+R@F-1(,OCK@=\5/TH RU\.:,E^]\
MFFVRW#R><SA!S)_?(Z;O]KK[U(=#TLZC)J/V"#[;*GEO<!/G9?[I;KCVJ>*]
MM[R-_L=W;RL >4<. ??!JKIEW+#I%K_:VH6,MXR?O)H#LC<YY*@GI0!"GA/0
M(H(88=)M8HX'9X1$FSRF;[Q4C&TGN14]QX>T>ZTM=,N-,M);%6WB!X@R!LYW
M8/?))SUY-69]0L[:&>6>[@CC@4O,S2 "-1U)]!573/$&FZKI5IJ,%U$L-U$L
ML8=P#@C(R,\'!% #UT/2EU*/45T^W6]CC$23B,!U0?P@]E]NE,3PYHD:WZII
M-DJZ@2;P"%?W^>N_CGJ>OK6@9HA,(3*@E(R$W#)'TK.US64T:V@(02W5W.EM
M:PYQYDC=,GL  6)[!3UZ4 1V7A3P_ITEM)::-90O:@B!EA&8\XR0>Q.!SUXI
MW_"+Z#Y=['_9%D$OGWW:B%0)V]7_ +W4]?4U6UKQ ^C?V?IZ1K?:UJ#&.W@7
M]VK$#+NQYVHHY/4]!R33->UZY\,>'3>7OD7=[+-';VT4*&)9)9"%5>68XR<D
M^@/% %[_ (1S1O.LY?[,MO,LEVVK^6,P#T0_PCZ5D>(?"ROHE_%H.FZ:MU>2
M(UW'.NU;M P+HS '!901N(.,_C4L.N7UKXGC\/:I);&XO+1KBSN8(F12R'#H
M49FY&58'/(SP,<Z&BZS_ &E+?64ZK'J&GRB&YC4\<@,CK_LLI!'H<CG% '*:
M+X*MEU6TOX_"%AX>FMI1(9[:YWR-CJ@" #:>ASV[<Y'H-,FFBMXFEFD2.-1E
MG=@ /J37,>&O$-YJOB7Q+8W$UI+:Z=) +:6W4@,DD>_).XY/.,CCB@#0/A'P
M^1(HTJW6.4EI(D7;'(3U+(/E/XBKMUH^FWFFC3KBPMI+)0 L!C&Q<=,#MCMC
MI4D.H65Q$\L%Y;RQQG#NDJL%/N0>*?\ :[;R?.^T1>5G&_>,9^M $=EIMEI\
M+Q6EM'$LAW/@<N<8RQZDX &35:P\.Z/I<PEL=-M[=UW;/+3 3=UVCHN>^,9J
MV]_9Q3)#)=P)*XW*C2 ,P]0.]6* ,6\\(>'=0O9[V[T6RFN;A/+FD>($R+C'
M/KQQGK6I;6=M96B6EK;Q06\:[4BB0*JCT ' I([RUFN)+>*YA>>/[\:N"R_4
M=17,ZGXAN[OQ/<^'-'O+.VNX+$7/G3KYBM(SE5CP"/[ISWY&* -RPT#2=+NI
MKFPTZWMIYSNFDB0*TA]6(ZGGO1!H&D6MQ=SV^FVL4MYDW+)$!YV>N_\ O9]Z
MK7VNQ^'_  Y#J'B"6WAG"(DJPL=CS-@;8]V"<GIGMR:S[KQ%>0?$#3M*$UH=
M*NK">Y+A3O5HRHY?=C'S'L* -/2?"V@Z$MPNE:19V@N.)O)A"[QZ'V]NE1VW
M@[PU9B 6^A:?%]GE\Z+;;J-C_P!X<=:UXIX9X%GBECDA89$B,"I'KFFVUW;7
MD9DM;B*= <%HG##/ID4 4K7P[H]E<+/;:=!$Z.TB;5X5SG+ = QR<D<G)]:2
M;PYHUQ?O?2Z;;/<R%3(Y0?O"OW2PZ,1V)SBKUS=6]G%YMU<101YQOE<*,_4T
M\2QF'SA(IB*[MX/&/7/I0!3ET73)]334I;&![Y%V)<%/G5?0-U ]J=IVCZ=I
M/G?V?906OGN9)?*0+O<]6..I]ZBO=?TK3]%N=7GOH/L-NA9YDD#+QV!'4]L>
MM13WES>V^F76F7EG##+.AG$XW%XR#E$(/#Y(]: )[K0M*O=0AU"YL();R$$1
M3NF7C!Z[3U'X4R\\.Z/J%X;N[TZWEN&3RWD9.73^ZW]X>QR*N7%Y:VI07%S#
M"9#A!(X7<?09ZU(\L<90/(JESM4,<;CZ#UH IWNBZ9J,MO+>V$$[VQW0-(@)
MB/JOH?I2Q:-IL&IRZG%8P)?3#$EPJ .X]">I%68+F"ZC\RWFCF3)7=&X89'4
M9%+//#;0M-<2QQ1+]YY&"@?4F@#/@\.:-:WINX--MHYS(9=RH  YZN!T#'N1
MS5Z:UM[B2"2:%)'MW\R)F&2C;2N1Z'#,/QI1<P&V^TB>,P;=WF[QMQZYZ8I8
M[B&9G6*6-VC.'"L"5/7!]* &QVMO#<3SQPHDTY!E<#!<@8&3WP.*H?\ ",Z'
MB\']E6N+[_CZ_=C]_P#[_P#>_&KUQ>6MIL^TW,,.\[4\QPNX^@SUJ1Y8X]OF
M2*FY@J[CC)]![T 9I\-:(19@Z7:D67_'J/+'[C_<_N_A7"MX,GNM0NSK?@C1
M-6NI[B23^T_M(C#J6.W<NPLNU<+QNZ9Y)KT;^T;'[/)<?;+?R8VVO)YJ[5/H
M3G -5]5>]-M;/IUY9P$W$7F/<*65XR?F5<$?,1P#0 NBZ8-(T6UT[>7$$>S.
M20!Z#))P.@R2< 54'@_PX)Y9QHEB)9CNDD\D;G/J3W/UK4FOK2VE6*>Z@BD<
M$JLD@4L!Z T3WUI;2)'/=0Q.X)59) I8#K@&@"E%X<T6"&"&'2[2..WF,\2I
M$ $D/5QZ-[U*FBZ9'J[ZLEA;KJ+KL:Y"#S&7T+=<>U(QOAX@C NK06!MF)MR
MI\YI-P^8'.-H!QTZD59^V6OVO[)]IA^TXSY.\;\>NWK0!GV'A70-+U2;4[#1
M[*VOIL[YXH0K'/7GMGOCK0_A;07UP:V^CV3:F.1=&$;\^N?7WZUHS7=M;[_.
MN(H]B[VWN!M7IDYZ#WJ1'61%=&#(PRK*<@CUH S;OPYHM_JD6IW>EVLU]$NQ
M)WC!<#TS[=O2F-X5\/MI<.EMHM@;"%Q)';F!=BN/X@,=?>M&>\M;5HUN+F&%
MI#M02.%+'T&>M+<7-O:1&6YGCAC'!>1PH_,T 54T73(M4.J)8P+?E/+-P$ <
MK_=SZ>U61:6XO#>>2GVDQB(RX^;8"3MSZ9)-.:XA6#SVFC$. ?,+#;@]\TD=
MS!-+)%%/&\D1Q(BN"4/N.U &;JWA;0=>N8;C5M(L[V:#_5O/"&*CKC)[>W2M
M8 *H   '  [5 E_9R221I=P,\>=ZB0$ICKD9XK&37X_$'AF[OO#NHV:2 R)%
M<7'S1*4<H68 CY3M)!],&@"]+X=T>>]ENY-.@:>9E>5BO^M9<;2XZ,1@8SG&
M!6G65<>(-/LM7L=(N+J+[==1M(J!@,*HY8Y/ ).!Z_@:OB\M3$91<P^6#@OO
M& ?3- &,G@?PJCLR^'].^:7SB/LZD;_7&,"I]0\*>']5OX+^_P!&L;FZ@ $<
MLL*LR@=![@=O2I+SQ#IEEJ]CI<UU&+N]5GC3>.$49+'VZ >I/L:DM6O1J^HB
MYN[1[,",V\,:D2Q#!W&0YYR1QP. : '3Z-IMUJ4&HSV,$E[ ,13L@+QCN%/4
M46&C:;I<T\MC8P6\EPV^9HD"F1O5O4^YJ=+VTDE2)+J%I)$\Q$60$LO]X#N/
M>EEO+6":.&:YACEDX1'<!F^@/6@ AM+>VDGDAA2-[B3S)648+MM"Y/J<*!^%
M9S^%= DUQ=:?1[)M34@BZ,(WY'0Y]??K6O7*VWB*^\0:YJ-CH/V6*STR7[/<
MWUS&TH>?&6CC167[N1EB>IQ@]: -NWT73+34I]1M[&"*]G_UTZ( \GIN/4_C
M63I-KK>HZNFI>(+&SLS9"2.TAMYC-N+D R$D#'R@ #_:;/85<LKC7(]<:RU"
M.UEM#;F6.[MT9-SA@"C*2VW .>IS[8K2%Y:FZ-J+F$W(&3"'&\#UQUH GK.A
MT#1[>2^DBTNS1[\DW9$*_O\ /7?Q\V<GKZU;N+RULPAN;F& .=J^:X7<?09J
M226.&)I)'5(U&69C@ >I- %'3M"TO2#FPL88#L$8*KR$'10>R^PXJQ?V%IJE
ME+97]M%<VLHQ)#*H96'7D&N=T#Q%=ZIXU\0:8\UI-864-M+:R6ZGD2;R=QW$
M$_*!QCZ4SQQXAU7PZ-%;3A9L-0U.'3V%Q$S;#)N^<%6&<8Z?K0!LIX<T6*YM
M[F/2[1)[9/+@D6( Q)_=4CH/84L/AW1K>VN[:+2[18+PEKF(1#;,3U+#HQ/J
M:PH/%.HV/CRV\+:Q!:R&]MFN+6[M R [<[E=&)QP"<AC74S7EK;RQQ3W,,4D
MIQ&CN%+GV!ZT 5-&\/Z1X>MW@T?3K:RBD;<ZP1A=Q]3ZU<NK6WOK:2VNX(I[
M>0;7BE0,K#T(/!I+F]M;(*;JYA@#G"F60+D^@S2W%U;VD0EN+B*&,D /(X49
M/N: *&G>&=%TF19+'3H(63A"!GR_]W/W?PQ3[WP]I&I78N[S3K>:XV>69&3E
MD_NM_>7V.15UKF!+<W#3QK !DR%P% ^O2B.Y@EMQ<1SQO 1N$BN"N/7/2@"K
M=:)I=]/;3W5A;RRVO_'N[H"8O]W^[^%,7P]HZW%W<+IUN)KP;;F0( TP]&/?
M\:N1W=M+-Y,=Q"\NP/L5P6VGH<>GO4K,J*68A5 R23@ 4 <+X@\(K)JWA>'3
M-$B.DZ;<R33Q1E$50T94;5)'()#<8Z<<UU8T/2QI]Q8&P@:UN<F>-TW"4GJ7
MS]X\#D^@JS;WEK>1&6VN89XP<%XG# 'ZBA+VTDECB2ZA:21-Z(L@)9?4#N/>
M@#.MO"GA^SD@DMM&L89((VBB=(5#(C=0#U&?ZFD_X1/P_P#V<NG?V-9?8E?S
M%M_)'EALYR%Z9SS3_$>J_P!E:+>307-I%>I \D"7/(=E4G&T,">G8T>%M1GU
MCPEH^IW6W[1=V4,\NP8&YD#' ],F@#.EL]:U36Q9WMA9P:#9SQSPRK.7DN"@
M!12F/EPX#9S_  @=R:Z>N7U#Q;!/H7B*XT.ZM9;O1UE!\P;T9TC$A& P)'S!
M2<\'/I6CX<U<:IH.E3W$\/VZZL8;F2)6 .60$D+U R: );WP]I&I78N[S3K>
M:XV>69&3ED_NM_>7V.13M0T/2M5CACO]/M[F.!@T22QA@A'0@=B*LM>VBW8M
M&NH1<L,B$R#>1_N]:I#Q!IK>(7T-;F-KZ. 32(&'R G"@^YY./0>XH TD18T
M5$&%48 IU%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)J6GVLSOHEM+-&\89&E,C@L5/!/&,GFM3X2DGX::6NXD1O<1KDYPJSR!1^
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M/?GTN\TC3-1AAAOM.M+J*%@T23P*ZH1P"H(X/TJ"[\-Z'J%Y;WEYH]A<7-N
M(99;=6:,#H 2.,=O2@#A+V33I=1O;2&;S+JV\.1I<W>JMD&!@Q&(^,NW5FR
M/EX/2JFC1ZI?>$?!=[H-]8SZM9:4P;3[TY2XC*Q!QN'W7'R '_:YX->EW.B:
M5>:A#J%UIMG/>PKMBN)(%:1!Z!B,CJ?SJ$>&-!$%O"NC6"1VVX0*ENJ^5N^]
MMP/ESWQUH \[T[68+_6? :MI[:?H\WVU%M)2"D=XA*A,]#C#[/KQR*A\0Z>L
M,WQ,M884.D_V4MRT14;([LQ.25'0,0%8X[D'O7J4^CZ9=:<FGSZ?:R628V6[
M1*47'3"XP,=L=*;_ &)I7]GOIYTVT:R<DO;M"I1B>I*D8)^M 'GB:;8Z=XB^
M&MS9VT4$]Q',D\J+AY@;7/SMU;D \YKJ?B%<Z=;^$I5U..62WFN((A''+Y8=
MS(NT,W.U,@;C@\9K8/A_12UJQTBPS:#%L?LR?N1_L<?+^%6;VQM-2LY+.^M8
M;FVD&'AF0.C=^0>#0!YB@AD\:>-[.]DL)O/T:$R0PJ A<++Q@DY8 #GCIG K
M/M--L;+PC\+M2MK:**^EO[.-[E5_>.KPN&4MU(. ,=, "O4E\-:$GW=%T\?N
M/LV!;)_JLYV=/NYYQTH/AO0F@MX#HNG&&W;=!&;5-L1]5&.#]* //["XM-6T
MCXD)K"POJ$5U=12)-C<ENL?[C&>BX!(/J2>IKL? #*_P[\-[6# :9;@X.>?+
M7BK]YX:T+4;X7U[H]C<7838)Y;=6?;Z9(S5VTL[6PMDMK.WBM[>,82*% BJ/
M8#@4 >7:9%90>'_B<JQV\<XO;]4  #!/LR' [XIEOIUE81_"R^M;:*&[F\M)
M9U7#R*UH<AFZD<#KZ5Z5+H&C33W4\NDV,DMVH2Y=[="9E'0.2/F' ZTA\.Z(
M5ME.C:>5M?\ CW'V5,0_[G'R_A0!Y-K]Y8S^';J^TYX8(!XGC;=</ON9)Q.H
M=@<CRU ! ')V^E=9:K8?\+HOY66V^?1;:2)R%^9C,XW ]R<@9'M74R>%_#\S
MW;RZ'ISO>$&Y9K5"9B#D;^/FY //>K3Z3ITM_!?26%JUY;H4AG:%2\:^BMC(
M'TH N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5E>(/$.G>&M-^VZC.D2%UCC4L 9'8X"C\_P
M&3VK5KA_BP(QX)\R0+M2_LR6;HH\],G/:@"U<>);F'X@6.G_ &RS.BW&FS79
M<#D,C*,F3=@CD]A^-=1%>6MQ:"[AN89+8J6$R."A'KN'&*X34H-/U+XMZ"C1
MV]S;#2;HJN R$B5.W0X(/XCVKD_M:Z3X4O\ #M;Z/:^-98[HPH"L%OOR/E((
MVARAQC\* /9;/4++48C+8W=O=1JVTO!(' /ID'K7,^-O$&K:!<: FG-9;-3U
M.+3W^T0.Y3>&.\;77IMZ?K3?#MEHA\6WVK:9KDFI7=W:H+GRI(FAVJ?D9O+4
M#>1D#/4 ^E9OQ42.63P9%([*K^([8$I(48#:_1@01]0: .IC.O6^HVXNKW3+
MBS8/YPCM7AD0!<A@3*P(S@'CN*N#5],,+3#4;0Q*P4N)UV@GH,YZUEQ6&FZ'
MKL-RM[=//>I]ECMY[N2<L02^5WL2, ,3CL/:N&N(['0/&W]J>6?^$/U"_ FY
M'DQZB/E$V,?ZLL-I/3>N>PH ]1O-1L=/A6:]O+>VB8X#S2JBD_4FGS7EK;VO
MVJ>YABM\ ^:[A4P>AR>*\_U+4;:'XHW]CK.J_P!G0W&F0BP:41>7*FY_-7,B
MD9)*Y QD 9S@5EV4ND>%=?\ !UE_:,TWAI8+R.RN[R12GVC<-IW !<;=ZH?1
MN.#0!Z>NJ:>\<$BWUJ8[@XA83+B0]/E.>?PIS:A9(TRM>6X:!2\P,JYC4=VY
MX'UKS3Q7!H-GX<BGT8I]B_X2>UNKF=9-\0D:5?,96)( &<'' .1US6K;W=C<
M_&Z[2.>"3=X?C0A6!W,)W)'N<8H V5\20>(O"D^H:!K%E:-N(2YN0'2,+(5W
M,N1@,%.,D=16\;^S%W]D-W!]I_YX^8-_3/W<YKQ)A83?LTLI%N]Q %9A\I>-
MOM9 )[@]1^==UX]5=!U71?&R)\NGR_9=0*KDFUE(4GCD[&VL![F@#M%O;1_.
MVW4+>1_KL2 ^7_O>G0]?2DL[^SU&(RV-W!<Q@[2\$@< ^F0>M>>>+9)=(\+Z
M5J5Z9+:&[UF&ZU9U0,8HV!V[@000A$*\@_<%;GARRT3_ (2O4-5TS6Y-2N[R
MVC%UY4D30@*?D9O+4#>1G&>H!H Z>\O[/3XA+>W<%M&3@/-($!/U-/\ M,'V
M7[3Y\?V?;O\ -WC9M]<],>]<?KU_8Q_$'3K7=!!J2:;-*+J\D/DQPEU#!4R
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M84N5O5<Y&-F\EF)[\@\G@UM^'M T6^^(OCA+K3+.<0W5G)&DD2L(V,"L6 /
M);DD=: .\;5]-1HU?4+13)(8D!F4;G'51SR?;K4D=_9S7<MI%=P/<Q#,D*R
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M]Q3J0 *    . !2T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M$H"A4'8# 'T   ] ,5:H Y&;1-;LO'!U^S6ROH[C3X[.9)YF@:-D<MN7"O\
M*=QR.OUJ37=#UC5-6\.7"R6;Q6$\MQ<!RR@2%"L;*N#NV[FX)&>.17544 9O
MB'2SKGAS4])$QA-[:R0"0#.S<I&<=^M<]-X9O=5L-"TK5?LMIINGM"\L$,I<
MW4D0^1!E1A 1N[DX P,5V=5;W3K/45B6\MTF$,GF1[A]UL$9'X$CZ$B@#G?!
M]L]QJWB+Q#*,#4;P16_O;P#RU(]F;>P]00>];VLKJ3Z3<II(@^W/&RQ-/(41
M&(.&)"L>#CC%7$1(HUCC5410 JJ,  =@*=0!SW@[09_#_@JPT2X\I)K:#RW>
MWD+!F/+."5!Y8D]*Q_ _A?5O#6G6NF7-EHZ_9,QC4H69IIX]Q."A0;21U^8C
M/8UW-% '/^&= FTFYUF_O6A>^U.^>=WC)($0PL29('1 /Q)K O/ NHWF@>(;
M5[BV6]U[4A)=3*[?+:!U 0';DL(EQC@98\UW]% '+0^'KV'Q\FK(+5-+M],6
MRMXP3O3YBS +C !Q'SGHN,<Y&)!X)UR;X?W&@7L]DESJ%Z9;Z6*1SNC><R2D
M-M&6*_*!@ >M>B44 <J_AV^_X3J'4X3:Q:9;:7]BME!.^)B^6VKC &%C&<]
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MJ,'C@1@XYYQW-4M%TV\MKCX>:;?7=P+V*%[ZX#3-^ZB5-H0C."6DE4<\\8Z
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MW$[5X' P.!Z5;F@BN8)()XDEAD4H\;J&5E/!!!ZBG[AZB@LJJ6+ *!DDG@4
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MSUP.U26EG;6-I':VL$<-O&,)&BX51]* //\ 1=+T>_N/#/B&QUFU1D4I"ME
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M:#I3W\%^UE$UW;KLAG(RZ+Z ]0* /'=5M+:#X9>.;2.-8K:P\1E+5%X6!3)
M2%'8?,W'N:ZN]\/6?A_XI^%[C0H/LSWR72:BL;$^?&J!@[YZD.1\QY)(J_XV
M\'I<^#=4TWP_I$7VO4)HI)0C*BN5D5V9RQY)"D9Y-=1I^CZ?9YG@L1!+)&(V
MW'<ZI_<!R<*/0'% 'DS7\UAX OW5F2RE\72PZA(IQMMFN?GR>P/"GV8UUFJ:
M?'IWQ0\-#2;>**#4+6[BU*") (Y(412C,HXX9@ ?]K%=7;>'M'L[*YL[?3;9
M+6Z),\(C&R4GJ67H<]_6G6.BZ?I".VG644<GE[ <G.T=%W')"CTZ#TH \XMK
M&/0]2UCX=1VJK;:O.+FQ98^!:R9\]2>Q0*P7/]Y*T8_#^D7'Q>U&RFTZVDLS
MH4#&V9 8B?-<#*=#@ 8R.,"NCT&UUB^OQK/B&QM;*\C@-M!;P3>=L5F#.Q;
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M[=7JV,2W5TNVXF PTH]&/<5!_P (GH']G0Z=_9-K]BA?S(K?9^[1NN0O0'-
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MM5;3].L]*LTL["WCM[:/[D48PJ_0=JLT %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %9VMZW8
M^'].-]J$RQQ;UC4$C+NQPJCU)-:-<-\688)/!:O-'&VR_M/F=0=H,Z ]>G%
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M5T895E.01[&O++>ZE33?A?J$]PLZ+9YEM7E57E8VR@2C>0I*<YR<_/QS71^
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MQR2<G)H [];NV:Y:V6XB,ZC)B#C<!].M4[+7M/U#5;_3;6X22XL2JS!6!PS
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MJ;!A7^RAMP'8[N<^M78]-L=-\0_#6ZL[:*"XN8Y4GF1</,#:YP[=6Y /.<4
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MX'(P ,4S2_#>B:)Y_P#9>DV5E]H_UOD0*F_V.!T]JN2WUI JM+=01JZEU+R
M J!DD>P'.:CDU;38O*\S4+1/.7?'NF4;U]1SR/<4 00>'-$MH+B"#1["*&YS
MY\:6Z*LN>NX <YQWI/\ A&=!,5M%_8NG^7:G-NOV9,0GU08^7\*NB^M"TJBZ
MAW0C,H\P93_>]/QI&O[-+3[6UW MM_SV,@"=<?>Z=: (8=&TNVO9[V#3K2.Z
MN!B:=(5#R#_:;&3^-0Z7X<T30YII=*TFRLI)_P#6-;P*A;V.!T]JN+?V;V7V
MQ+N!K7!;SQ("F/7=TH2^LY;B2WCNH'FB4-)&L@+(#T)'4"@#+;P;X9>>>=]
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M([$].U2W&CZ9=W\-_<:?:S7D'^IGDA5I(_\ =8C(_"H]2>[%QIQM;^UMHS<
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MI7^EZ?JMG]DU"QMKNVR#Y,\2NF1T.",4D.DZ=;/*\%A:Q/,@25DA4%U "@'
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M=^'T]NMLSQZSIZ^9&%)4E,D9'KP?RK5\/O'?>//&UAK,<<DV85BCF (:S,?
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MEN21UKTBJ=MI.FV5U+=6NGVD%Q+_ *R6*%5=_J0,FKE !1110 4444 %%%%
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M@0'SE_>Y_N\_-^%-EUG2X)C#-J5G'*)%B*/.H8.V=JX)ZG!P.^*\?@U73O\
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MW1U&T^SR-M27SUV,>F <X)KD] U#P=KR^%[S3Y+>:_M;<K9PP2_/;*T8$@=
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M.?\ IL?2N7T"30]?\'VVG:]X@NH=8L[XO/IZM"EP+Q9204!3>2Q/7)ZG)X-
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMXUBBC7HJ@8 J._UG3-+*C4-0M;4L-P\^94X]>3T]Z=/JFGVQMQ/?6T1N#B
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MM$$]G =8L/-O5#6J?:4S.#T*#/S ^U2ZAK.EZ2%.HZC:VFX9'GS*F1TSR>E
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M&..<8'7TJM<^*-#MM'N]6?4[9K*TSYTD<@;81_#Q_%TXZ\BC3?$FEZCH%OK
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MQ)^N6P?KBO3%L+-;5;5;2 6R_=A$8V#\,8IITRP.W-C;'8,+^Z7Y><\<>I-
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MQS1+IMA-.\\ME;23.NQI'B4LR^A..1[4 >:_V_8V/C>)M4ULZ?I]_HUN-/O
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MU"34S#HT5N;>YO+?8Z6]PT""/>2& XWKG'&X]*]72V@C=G2&-790K,% ) Z
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MQ<<_=P,YZ5P6I:OI^D_$;7K3Q+JDVF6NH6T#64S,%BEC5"KIN((!#%CC_:J
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MT2RBBEN=5M(HY461':4;2C?=;/0*>Q/%3WVK:?IL:27EY#"K@E-S<L!R2!W
M'7TKS)M0T2Q\1>+/#_BK4I=-2\F#P1DA(KFU:%$"H=IR1M*X!^G.:GL-6TWP
M=XYBBU=Y-/TJYT2WATR>^8@1B,MOB9CT?E20?0>U 'HS:OIRZ?'J'VZW-G*
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M+A9=&GC$D,JL&;S$8+D=\9.* .^O;^TTZ 37EQ'!&6"!G;&YCT4>I/H*J?\
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M2)XE*NAR",=C7C$5XW_"I9+>U;SI-.UMYM4M(_FD6W6[9F#*.1Q@X/4 ^AH
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M&AO;6]RNIV_DW$_V>)]V 9<X\OV;/&T\U.^N:9'>7-FUY&+FVB\^:'G>L?\
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M]WT^E.9E1"[L%51DDG  K*M_$VBW5Q);Q:E!YL<7GE7;9F/^^,XW+_M#(]Z
M-+R(=NWRH\=<;13P H    Z 5A1>-?#,\MG%%K=D[WK%+8+*#YAW%< ^Y! ]
M<<9ID/C'3)O%EYX?$F)K2%))'8$+N8M\H..P7)/3G'8T ;@MH!<&X$,8F(P9
M-HW$>F>M.,,18L8D)/4[1S7'3^+M-\.^$-2UN36SK4*74HB= I&\M\L(*#&
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M+P6LNH0I*9?(!)^7S?[F[[N__9SGVK!\4>*8K/Q3HV@"]:U2[$[W4T8^=%1
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M\UTNBWCQ+!K5SXFDN;"XMEC>TEA4DW. V8RH!Z9^0 ^O:@#KU540(BA548
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M^EWT-U'%(8Y#&<[&'8CM6?K/B_3=%U_2]'N'(GOC(V=IQ&BH3DG'4G:,>^:
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M.,9/U(;'K7HGEIYGF;%WXQNQSCZT[% &'XTC>;P+XABC1GD?3+E551DDF)L
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MO;9F"03-Y9!8KV.TKGL<^AKU7 R3CKUI"BLA1E!4C&TCB@#F_!L&AK;7]YH
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M .I/%>N8I, ]J %!R,T444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1145S<0VEM+
M<W$BQ0Q(7D=C@*H&230!+16/X8\16WBG0HM6M(9HH)9)$5)AA_D=DR1VSMSB
MMB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
&*** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>25
<FILENAME>exhibit1016-arvinasxamen005.jpg
<TEXT>
begin 644 exhibit1016-arvinasxamen005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K(\4ZY_P (
MUX9OM8^S?:3:H'\G?LWY(&-V#CKZ5KUSGCW3+W6? ^JZ?I\'GW<T0$<>Y5W$
M,#C+$ =.YH AA\4:G:ZO8V&OZ&FGK?N8;:X@O!<1F4*6"-\JE20IQP0<5JV?
MB71-1U2;3+/5;2>^@SYD$<H++@X/'L>#Z=ZYZY@USQ5J^CB[T2;2-/T^Z^VR
M/<7$3R2NJLJ*HC9L#+9))'3%9&E^'M=>T\.Z'-I1L/[$:1I=4$R%9LQ21@QA
M3ORY<,VX+C!ZG% '8Q>,?#<\MY%%K=B[V:-)<!9A^[5?O,?8=SVJ]=:OIMD9
MA=7UO#Y$(N)?,D"[(R2 QST&01GVKSMM$UZ^\&IX8/A>WM9K32)K/[?++$RL
MYBV+Y)!+ .0"Q8+@=<FI[[2];\03ZG>W7AJ>&.72K>VCMI+V..5Y$F9V*LA8
M*1D%2>"0,X[ '7Q>*-,OK*"[TN]L[N"2[2U9_/VA6)Z=#EN1A>,YI]KXL\/W
MNJ'3+;6+*:^#F/R$E!<L 20!WQM.<=,5Q&GZ!XDN(-MQ#>F!=7L[B)M0:W^U
M[$_UC2-&=K ?+MR2W!]JSO#UW*=6\!:1]BM#'I[SHM];W<<@N +>12ZJIW*"
M<%MP&&('- 'I&G>*] U>]^Q:=K%G=7/E^;Y<,H8E>.>/J/SJEK?B/4K+Q'9Z
M)I6D0W]Q<6LET6FO/(5%1E4C[C9.7%8WASPSJ.FVG@:.6R6)M,MITO '3]VS
MQ@=CSEO3-)XS\/S:CXPTS4)?#4FN:?#8S0O%'-$A21G0J?G=<\*W3UH Z-?$
M/]G:>+CQ0+'1I'D9(T^V>:K@+NX8JO/#<8[5;L=>TG4Q;&RU&WG^U1O+!Y<@
M/F*I 8CZ$@'TKE;30Y9KGPV;?PS)I-GI^HS32V\TL3[0;>11(-CMGYV4>N1G
M&.:SM2\,^(K71GO]&LU.MVFL7UQ:QF5%$D$[N.N<#AD?!Y^3UH [*\\7>';"
M&":[UJRACN"PB9Y@ ^T[6(]@1@GH*C;Q3:1>(+[3KCRH;:SL(KY[QY@$VNSK
MZ8 &S.<]ZXO4/!NHZ/J5FUA!JUU9II,.G_\ $LNXH9 \9<DN), JV_.0<@@Y
M!J.3P3K,9,<%B&2WTS3%2&2X#K*]O<-*\.\@9^7 !( Y% '?0^*_#]QI;:G'
MK%D;%9!$TYF 57/123T/(ZT1^*M FT>35TUBS.GQ-L>X\T;5;^Z?0\CCKR*\
M^\2VVJ3RSZ]/H;VPNM1TJ&'3II8S).T4S$LY4E06WA1R>%YJ;5_#>O:S/<:Z
MFFW=DQU&WN1I\5S$ERZ1PO&7# E!(3(" 3T0<@T >D:;J=CK%DEYIUW#=6SD
M@21,&&1U'U'I7(R?$"ZDQ%8Z*D]T^MSZ1'')>>6I,2LQD+;#C(4\8_&K_@G2
MKG3X=2N+FVO[=[RY$H6_NDFF8!%7<^P;5)QC )X R>U<K'X?\0:?.E[%HTUT
MT/BN[U#R8YHE9X'C=5<%F Y+#C.?:@#KK#Q:PO[S3]>L5TF[M;7[:Q-P)87@
M!PSA\#[IX((&,CUK;O[BZAT]Y]/M%O;@8,<)F$8?)&?F(..,GIVKF;*VUF\\
M37'B>^T>2T^S:<]I::?Y\;S3%G#L2P;8N=BJ!N]22*ZN=YELY)(8M\PC+)&2
M!EL<#/3KQ0!Q=SX\U.RTS6+JY\.(KZ=+!!M6_#+)+*ZKLW!."H=2>#U JWJ/
MBC7M$T+4M6U;P[:PPV=N956'4C(9&R!M_P!4-HP2<\].E4-3\)WT_P )X]"%
MO]HU&9K>:\1G4>9*9TEG))..N\]?I5CQ+X)LX? NO:=X;TJ*.[OK<((XV"^8
M0>!EC@=3WH MP>+-2M]9M],UK0?LLUU!+-;FTNQ<A_+ +*1M4@X(QQ@GC--L
M_&LR37<6N:0^EM!I[ZE@7"S$0K][> !L?GIR#S@\&L'2O#=[!XFLM1T7PLWA
MU8(IEN6N+J-UN@4^2,I&[<!]K;N",<9S27'A[5_$MU?,V@_V!+=Z7<6NH3&:
M-EO)G0*F C$LJG)#, <'&.30!T^B>*+N_P!4CT_5-'?3)KFU-W:YN!*)(P5#
M X VN-Z9'/7K3/#'C2'Q)JNH62V;VP@_>6LC/N%W#O>/S5&!@;D/'/!![US]
M_!XMUI5O8=#DTZ^M-,EL81+<1'=-.T0>12K'Y$5"W."<\"IH? MYX9U;P_?Z
M+?:AJ*V>+":"ZDB"I:,N"5PJYVLJ-C))P<<T ;&A>+;K7+V81:9 EBAEQ.+Y
M6D*JS*K&(#(#;<CGH:R[+XA:FWAZS\1ZCX;6WT2X5)'N(+\3/"C$ .R%%X&1
MG!) YQ572?#]V^K:.8O",.@/IIE:ZNHI(BEP&C9?+0J2S*S,KY<#&T=ZJ6.D
M^*+SX<V7@J?P[-8[K:.TNKZ:Z@9$CR-Y54=F8E<@<#D]: /1M6OI=-TN:[@L
MI[V9 !';P#+2,2 ![#)Y/89/:LO1_$LUW>:E8ZOIZZ9=V$4=Q*!<B6(Q/NPP
M?"XQL;((&,=ZJ:C8^)-&MM3U#2;^ZUFY=2MGIDXA2*(LXP0V%)"KG@MR/?FL
M:V\+ZAKF@WNGW5OJ&DW=S/%/>WUX8)S?XSE"L<AVH, ;>!CCG)H WM%\;V&L
M>'M5UT12V]AI\LJEY1@R1H@?>!V!!R!]*I6/C]KGP-JWB"XTE[6[TR-WGT]Y
MLL,()%&[;_$K*<X[]\5@-X,\3W.G:IHEY=&2SU765DN+B)(XBELJJS.!D\N4
M5 N#C!)&#4VN>"M9M(]?ATR>]U=-;TF6"9KN:(,DZ#$70(,%69>G&!DXH WX
M_%NJ6=SIPUW0$LK34)DMXKFWO1<!)'^XKC8I 8\9&>2,XKJ+R[M]/LIKR[F2
M&W@0R22.<!5 R2:XJYM]?\2_V-87&@3:59V=Y!=W%Q<W,+E_).X(BQLW)8+R
M<8&:EU#P1J^HVBV\_C"\N$6XCGV75I"Z'9DA2JA<C)4X.>5% #1\0I+KPYIV
MJ:?HKR3:AJC:=%;7,_DE2#(-S':V/]7TQQGVJ<^//[/CUA=>TMK*YTR"*=X[
M>87"RB5F5%1L+\Q9<8('4=JY>Z\&^(#X9M[74+(ZR8_$<E]):IY41> M,2V2
MX'S;U;&<C..U/'@?4;R#6?[,TC_A'[:6&WDM[&XN$D$MW%+Y@D.QF"#"JAP>
M<YQQ0!U]EX@UU-1MH-9\."SMKI6*3VUU]H$!5=V)L( N0#R"PSQFH]'\93:E
M<:<]QI#VFGZMG^SKEIU9I?D+KO3&4W(K,.3TYP:=::MXGU35+*%O#[Z39QDM
M?2WDL4F\;2 D01B3\Q!W'' Z<UR^D>#]1?5M.C%EJ>DP:8\\BR2:@L\$9:-X
MT6V3)./GW?.HQM"]S0!V/B3Q#>:->:39:?ID=]=:E,\4:R7/D*NR,N23M;LI
M[4W1_%0O/[7BU6T73+C2"OVO,XEB563>&#X';J" 17,^)?"6J2'0C=1WGBR"
MUO99KB.8V\+A&A**!]Q2 V#ZU6LO 6I7\>HP0J_AO29[FWN(]-<I=!V0'>7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JG;Z3IMI=RW=MI]K#<S?ZV:.%5=_]Y@,G\:N44 %%%% !1110 4444 ,
MEABG"B6-) K!U#J#A@<@CW![T^BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXZXY &2?SK;DO]+TGQ3XDTOQ7!JHAU6X^T6<D/VDQ7<3Q(ABVQ_Q#;C!']*
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MMPDJRVMLD,RR1,FUQP5Y R1CM0!OQZ]ITU]?6,<SM=6*J]Q"(7W*K9VD#'S
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MF66R5V+)"ORG8SJPSD'H1C/( .YUOQ%H5[X,N-0;7YM/L';RS>VV4EB=7P5
M*E@V1@@KGFMJ_P!7LM.:&&XFD\^8,8HX8FED8#JP103@9&3C'(]:\=N) /A!
MXTL/*NA.=7GV1S0N'?=.K+C(^8X&3C)'4UUEUJT>B?%1=5U)V&D:CI*6]G>J
MI:))%<L4)'0MD')ZX% &C\-M5N-7TS6YI[^>]2/6;F*"6;[WE*5VC&!CCM@?
M2M&3Q?:IXX'AK[/=>8+3[0\OV:0KDNJJ 0,;?O9;[HP!G.:R/AG,LD7B?$4\
M8?7[N5?,A>,,K,,$;@/0\=1WI;F86/QIAFGCF$5UH8MX76)F5I!<$E<@8& 0
M3GH.: +]AXBT&PT_7-5?Q#+=64%\XN)+@EEMGVJ3$F%!V@$' SU/-61XX\-F
M]6S.IHLS1&9-\;JLBCKL8C#D9Z*2?:O/I9HG\#_$^)6!>XU&Z:!0.90T4:J5
M'\0)! (]*V=1N+5_$OPWD62,QQ+.78=(P;?:,_W<MP,]QB@#LM-\3Z-JUA=7
MMI?*;>T9DN6E1HC"5&3O5P"O'/(IUCXCTO4-2?38)Y%O4B$WD3P20NT><;E#
MJ-RYXR,BO,M6AN]0F^)$>E1M<7#7-C<10QL0;A8EC,@0CK]TKQWXKIO#.H>&
M/$FM6FIZ3::C/?VT3+)/>-<9M PY0F0E2Q/89Z$]AD [*_U&UTR 37<PC1G$
M:#!9G8]%51DL3Z $U5M/$6F7R7AMII'>S(%Q!]GD$T9(R,Q%=_(Y''/:N;\=
M"YLO$'A/7#'))I>GWDOVT(I;RQ)&464@=E).3VS26"17?Q0OO$EG/&=(CT9+
M66Y5AY4LWFE\ANC;5&"1TW8]: ,.P\1W.I^%7\8?VAJT%W:2W4SVT=O,UO-$
MC2*D17;MZ*N7'(.<D=NC\&QW&J6NEZ^=7U-FFL4^VVMPCB*65E5MZ!P-H!)^
MY\I&/2N<\,W4*? K4H'?9.+?4%,3##Y=Y2@V]<L",>N:[?P3+'+X'T,(X)CL
M((W'=&$:@J1V(]* *]OXLM]1\6ZGX;BCO(I+2&/-P+9_OOOZ$J5  488\$DX
MSBL#P#XWLAX3T:'7-7>74[N>:$22JS;G\YPBLX&U20!@$CC&*M6-U'IGQ:\1
M?:Q)$MY8VC0.8VV,J"3>=V, #(SDBN+@DC3X':5!]VY35D=HMI#KB\+DE>OW
M>?I0!Z;J/CKPSI5W<VM[JL<<]J4$R"-V*;SA<[0>X_#OBK-]XJT73GF6ZO"B
MP.$GE$+M%"QQ@/(%*H>1]XC&1ZUSFCSVTOQ@UYU=&$NFVJ1..0Y4N6 /0D94
MD"L?1[A-,\*>*_#>N*W]J/<7C)"RDO?+-DHT8_CSNQ@9(QSB@#T0ZYIRZO'I
M1N/]-EA,\<?EM\Z#&65L8.,CH>]0P>)M'N--O=02^1;6QE>&YDD5D\IUQN4A
M@#D9''O7G]O#+X1UOP&^N/(J0:-+8RSA&=5FQ&0A*@^A ]<5G.(;OP!X\6YC
MOK?_ (G\MS&PM7)!\R(HQ&.5#+\P'( /&: /34\3Z/=:B=)2^>#4'3*PR0O%
M+@CA@KJ,CKS@C(Q7)^!O&UE#X:L8==UB26_N+Z>W6696;)\]U16<#:A(  !(
M]J30/$/A_6O'@UB36[4:B-.-E%:K'+$"H;S'?,BKD\=.P!Z]N7,D8^!<T _X
M^3JV\1!3O_X_@^=O7[G/TH ]N=UC1G=@JJ,EB< #UK&LO%FB:A=6]M;WA,ES
M$TUN9(9(UG1>K1LR@. "#\I/!STJWJUQLT"^N8+87^+621+=>1/\I(4>N[I^
M->5Z=J<%SXA^'NH*UR\217,4L<5D\<%HS0 "%%"\ $$<DGCDXH [R3XA^%(H
MFE;5T\M)S;R.L4A6-P0/F(7"C)QN.!G//!K7U#6++3Y(X)YI!/,K-'%!"TTA
M ZL$4$X&1SC&2/6O*)Y(I/AA\1(DP9;C5KUHD ^:4,P*%1U8''!'I[5MP:O'
MH?Q'&HZJ[C3-3TB"&RO-I:-70DM$2/NDEL\]: -GX::I<:OH>I7$]]->JNK7
M44,TQ^8Q*^$XP,<=L"M62^T[_A-5MSK4ZWL5@[MIP;]UY>Y<RMQ]X9 Z]#TK
M#^&$H?3M> BFCSKEY(OFPM'E6D)&-P'Y=N]%W/#'\:;-WD5470Y8V<GY0QF1
M@I/0' )QZ4 :@^(7A4I%(-70QRS?9Q((I"JONVX9MN%R> 6P#V-:FI:]IVDL
M4NYG\Q8C,R0PO,RQCJY5 2%]SQ7D=R\;?!/Q- @S/+JLSI$%^=\W092%ZG*C
M(]A[5TK^(+;PS\1=:N-:64Z5K=M;-8WD<#S1MY:E6B^0'DEBP'O[T :/B?69
M)+WP9>Z3JDAL;_4TC<0,/+GC:-VY.,G[HXSCVKHE\3:2\>I.MRY&F'%XOD2;
MH>-W*[<].<@=.:X[Q.]K!_P@JPV2Z=!'JZ2BV"!/(AV2 %E ^0?,N0>A.*IW
M%_%I7B'XB65TDXN=0A2:T186;ST^S;25(&, @@GMWH ] ;Q!I:Z?97PNM\%\
MJM:^7&SO,&7<-J %C\O/3@=:XK0O$"71\=O?Z]>1Z=;3B**ZD!CDM5,(W;5*
MC:RL3_#G(YK%TF_?1)_ &L:E%<QZ/'H7]GR2O X%K<%8^6&,@-MV[NGOBK$=
M[!/;_%)XUF$=S&3"S0.JRYM0H"DCDD]!U.>* .XC\4:#I5EH]O<ZSO:\ME:U
MEN,F2X4)NWMQP2!GD#)XZ\5;TWQ/HVK6%W?6E\IM[-F2Y:5&B,)49.\. 5XY
MY%<")X#/\*RSKB"(^;G_ )9'[+L&[^[\_'/?BH[M+.]?XJ0W#3FVFCC<&V7<
M[A;<!B@Z-AA@]O6@#OH_%^A/>VUF;TQW%TJO!'-#)&95)P"NY1N'T]13?&'B
M6'PEX8O-8E@EF\E/D2.-FRYX7<1]U<XR3_/ KB="\0:'K?BKP[<7NNVPU'3[
M62UMX(X)HO/ED"AB3(BXX7A.>3U[5T?Q4MY[KX9:[%;PO+*858)&I8D!U)X'
ML": *6O>(&M/'/A.<:A=V^EW4=[Y]O+&T08H@VY0J')RW .<\8%=/I_B?1M4
MTJ?4[2^1K.W=HYGD5HS&R]596 *GD<$=Q7)ZOJ=GJ7Q$\"WENY:W"7QWNA7;
MNC4(3N (W$$#.,]JYN\2ZN+#QI)IL,MTT'B&#4/LT#%7N(8_*+;".3RAY'=>
M.: /4M/\0Z9J=_/86\[B\@0226\\$D,@0\!@KJ"5SQD<5J5Q'A:\\,Z_K::O
MHMM?SW4=L89;R[-Q^Y4D'ROWIP3G)P,@8SGD9[>@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHJO>WUOI]L;BZDV1@A1P6+,3@* .222  .30!8HK#A
M\6:5<)J B:X-QI^W[1:FUD$R;ONGR]NX@^H!'Y5P%IK]S)X B\<?VAJZZG!9
M3S36_E3-:SNRN4!4J4"J0/F7 &.3S0!ZW17$Z%-;VT=CKDFK:R[7=JL$EC.D
MSB>?:',B1NNX'&[[@"X^E;MKXKT6[TR?4([S$-O-]GF62-EDCER!Y90C=N)(
M &,G(QG- %[5+!=4TJ[L&GF@6YA>(RPMM= PQE3V/-8-IX;UHV0TW5?$,5YI
MOE^4T4>GK#)(F,;6;<1@C@[5!]"*FN?&VD06.KSC[4\^E1>;<VGV=UF52NY3
MM('!'\70=R,5G2^)=-U7PSH%]J-]J&EO>W%J4%O'+%YDS;2(\E>8R6P3T([T
M =I167;>(=,O-<NM&AFD.H6B!YHFMY%VJ>AW%0I![8)S2+XCTQ[1;E)9F1IW
MMT7[/('DD4D,JH5W-C:W(&.">QH U:*SM'UW3]=AFDL)BYMY3#/&Z-&\3CJK
M*P!!_"C4=8L[":.TE>9KJ9&=(;>)I9-HZMM4' &1R>,D#K0!HT5Y]X$\30Q^
M%KV_U/4KBXC?6KBVMI)][RR R;8T5<;LX[8XYZ5MZAXXTNS\/:QJL2W,[:5N
M6XMA ZRHX7< RD< @@[NF.<T =-16+:>)+271K&]G$ZRW2C;"+:0.[[=Q"H1
MN('KTQWJUH^N:?KUK)<:?.9%BE:&561D>*1?O(RL 5(]"* -"BLZ_P!<L=/N
M1;2--+<F,R^1;PO*X0'&XJH) SP,]>V:YWQ?XU@L?AS>^(-$N/M!> _99XX6
M=5<G;EN,+@]FQR,>U '9T5@:#IJ17DNI6VHZM);7$2H;2^,F%=3RZB4;E)]!
MP>N*L#Q+IAN4@5YF\RX-LDJV[F-I02&7>!MR"K#KC((ZC% %71?#EUI7B77=
M7EU"*==6>)S"ML4\LQH$&&WG/ YXZUT-88\7:(=,U+4?M4GV;3)6AO&^S2YA
M90"P*[=V "#D#%69]?T^".U8222M=Q^;!%#$TDDB8!+!0,@<CDXZ@=30!IU7
MOH9[BPN(;6Z-K<21LL5P$#^4Q'#;3P<'G!KA/%'B>VNHO"&LZ3K$JZ=<:Q'!
M,8W,:.FV0LK@@'(* 8/Y5UNC>)-,U^2\BL)93-9N$N(9X'ADC)&5)5P#@CD'
M'- ":#H\^E6\CW^HOJ6HSE3<7;Q+'OVC"@(O"J.>/4D]ZL:W82ZKHE[I\,Z0
M-=0/#YKQEPH92"=N1GKZUE>(/%L.@ZYHNF/;7,K:C*ZEX[=Y B+&S'&T$EL@
M<#.!DG%6M3\5:3I"S/=RS".W"M</';R2+ ",@N54[>"#ST!R>* +'A[2Y=$\
M/:?I4MPEP;*WCMQ*L7E[E10H)&X\X'K6E7.:CX[\.:7<M;W-^3,+7[8%BA>3
M=#D#<NT'=USQG@$] ::_CWP\LEW$EU/+-:1I+-%#:2NX5P2IVA<D8!)(X'&<
M9H Z6BN;C\>^&Y7T\17[21:@R);SK!(82[?=0R;=JL?[I(/M3AJ6E+XSO$_M
M2]-]!IX:6Q^<P)'O_P!8%VX+DG&03P,8H Z%@2I ;:2.#Z5A^']"OM,:2YU?
M69-7U%T$0N'@2$)&"2%5%X')Y/? ]!52V^(7AF\_L\P7[O%?R^3;S?9I!&9"
M2 A?;M5CC@$@GCU%6]2\7Z+I4MVEU<R 66PW;QP.Z6^_[N]E!"Y'/L.3@4 :
MC6,3Z@EY(7>2-2L2D_+'GJ0/4X')S[8R<V:YJ\\86]KXTLO#PMKES/:O<-,E
MO(Z\%0H4J#D?,<GH..>:?HVI:3)J/B">WU>ZG\B93>)=.PBM"$'";@ JX&X]
M1SG- '145C6WBK2;J^MK-9I8YKM#):B>!XA<*!D["P ;CG YQSTK/G^(OABW
MBNY6OI62SF,%R8[25_)8 $E\+\J\CYCQ[T =3134=)8UDC8,C ,K Y!![UA>
M,_$R>$O#-UJS6\L[1@+&B1EAO8X7<1T7)&3^ Y(H WZ*RYO$%A"MON-P9;@,
MT5N+:3SF"G#'R]NX <<D <CU%3:3K%AK=E]KTZX$T0=HV^4JR.IPRLI *L.X
M(!H O45Y_J/B%=!^*TZ7^H7AT]M$69+50\H\TS$92- 23M7T/&:Z>R\5:+J.
MAQ:S9WRS64K;$9%8LSYQLV8W;L_PXS0!LT5F:5X@T[69[NWM)7%S9L$N+>:)
MHY(B1E<JP!P1R#T-5]5\7:)HNH+87UX8[MXC,D2PN[,HP.-H.3R.!SSTH VZ
M*Y^S\;>'K_09-:@U!3912^1(3&P=),@;"A&[=D@ 8R<BK-KXCTR^.H11RRI-
M8!?M4,D+I)$&&5.TC)!&<$9SB@#7HKFM"UC1K/P98WT.KW=]I[?)#=W9:2><
MER ,8W,Q/  &>E9.AZQ+??%?6;5+N^:UBTR%_LMRK((I"[9PA Z@+SW]: .[
MHK \3WFFVW]E1:AJ=Y8--J$*V_V4L#-)NPL;$ _(V>0<9'>F7GCG0+*\O[.2
MZF>ZL%5KB&&UED=0V2" JDD8!)(X'&3S0!T5%5M/O[75-/M[^RF6:UN(Q)%(
MO1E(R#67>>,=$L9ITGNG"6TZ6UQ.L+M%#*V,*[@;0?F7OQD9QF@#=HK-U'7;
M#2Y?)G>5YA$9C%!"\KB,=6(4$@>YZ]JB3Q-I$NGV5];W8N8;X9M1 C2--@9.
MU0,\=^..^* *ND^'+K3?%FMZW)J$4R:H(08%MBAC\I2JX;><Y!YXKH:QK;Q5
MHMUI#ZI%>@VL<QMWRC!UE#;?+*$;M^2!MQDY&.M.MO$VEW,]W;B:2.YM(Q+-
M;S0.DBH>C!2,L/<9YXZT :]%<WIWCWPWJK#[)J.Y#;/=^:\+I&(D.&)=@ ,<
M<$YP:PM3\1?:_B1X,@LKO4(K>Z-TTL$D4D,<Z"!BK88#=@\^W!QTH ]!HK"_
MX3'1/M44'VI\2W9LHYO)?RFG!(\L/C;G((ZXR,=:@N_'?A^RN=0MI+J9[C3P
MIN8H;661T# D'"J21@9)' XR>10!TE%9C>(=+&GV5ZESYL-\ ;7R49VFRNX;
M5 R>.3QP.N*BM/%&CWNFSW\-WF&WG-M,K1LLB3 A?+*$;M^2 %QDY&,YH V*
M*R],\0Z=JUY=65M+(MY:;?/MYXFBD0-]T[6 )!]1Q3KO7]-L=9L=(N9I$O;[
M=]F3R'(DVC+?,%VC Y.30!I45C6OBK1[V/4I(+B8KIC,MYNM95,1 R1@J"3C
MGC-5&U72;KQ5I874[^.\>TEEAL@DB1S1G:2[J5^\., X(STH Z2BO.=3\9-K
M_@CQC/8?;]/GTP7*0RB%XFS$@Y+$8#;L_+D-C' YK=\.^+M+NTTK26NY6U&>
MR21#)#(%G*H"^V0C:Y'?!/?WH ZFBL+QCXD3PGX6OM8>WEG,"'9'&A;+'@;B
M/NKGJ3_/%<YK^O&W\;>#KH7U[!I]R+P3V[QR1B0I%\N8R S'<>!@Y.,=J /0
M**QM.\5:/JFEW6HV]T5M[21HKCSXFB>)UQE61@&!Y'&.XI]AXDTW4=4FTR*2
M6.^BC$QM[B!X7,9. X# 97/&1T/!H UJQ_$>B3:YI\,-OJ,UA<07"7,4T:!Q
MO0Y 93PRYYQQR >U9/C7Q'>:9=:+H>E,D>J:U<F&*9UW""-0#))M[D C /&3
M5G4O#NH1Z//_ &/K>I)J7EG;)//YBRGT*M\JYZ94+CK[4 6+'1M3:>";6]6B
MOS;OYD*06@@0/@KN8%F)(!..0.>G3&[67?\ B#3].GDMY6FDFBB$TL=O \S1
MH<X9@@. <''K@XS@U6N/&7A^UL]-NY-2C^S:DZI:2JK,DA/09 P.AZXZ'TH
MW:*YE/'OA^0WB+-=FXM"!+:_89O/P1D,(MF\K@9R!BII?&_AR'3=-U&34XQ:
M:D0MK+L;:Y.>O'R]#G.,8- '045S^E^-O#^L+J!M;_:=.7?=I<1/"T28SN*N
M =N!G-367BO2+^[6UBFF69[;[7$DUO)&98?[Z[@,CD<#GD<4 ;5%<LGQ%\+R
M103)?R-!-/\ 9Q,+:7RTDW;0';;A,MP-V,]>E:L/B+3)_$$^A1S2?VE!$)I(
M6@D4!#P&W%=I&>.#0!J45S6MS/XC\.:A#H>H7]K=0S&(36T11_,1N5!D !&>
M"1QUYK0?58],CM;2^DDGOV@WNMM TA;;@,^U0<#)_7 H U:*KV-[!J5A;WUJ
MY>WN(UEB8J5RK#(.#R.#WK+O_%VC:;(1=W+QQ+,+=[CR7,,<A. K2 ;0<G')
MX/!P: -RBLB^\2Z9I\EPD\DQ^S;?/:*W>18BP! 8J" <$'V!!. :HVGB^"Z\
M::CX?%M<I]BAB8S-;R;69]^><8"@*,,< G.,XH Z6LOQ#HYU[19M/6]FLV<H
MRSP@$JRL&&0>",@9!ZC(JM9>,-%U"[L[:WN7+7P<V<C0NL=QLY;8Q&#@<^XY
M&17'Z%XVL?#UUXICU_5KR5(-9DCC9TDG\F+RX\9VJ0B9)ZX&<^] '6VFB:Q*
MT0US6X;^&*1)5B@LA!N=2&4N2[9PP!XV\CTXKH*XGQ!J$Q\:^")+'49C8WTL
M^^.*7]U.H@9E)Q][L1VZ5HZ?J^C1ZIXDNDUBZD^R&-KV*X9O*M,(?N @8! W
M'&<F@#I:*YO5M;@O=%UBVM)KVTO8+%[@%H'A=1AMK LOJIZ<CVK+\%^,M.FT
M'PSIUY?3R:G>6$6)98I"LTHC#,OFD;6?J2,Y_&@#N**Q-3\6Z/I!E-Y<2)%
MZQSSK [Q0LV,!W *KU'4\9&<9J?4-;L;246C2S/<R0F41VL32R"/IOPH.!GH
M3U/3- &I17&?"[4)]4\$QW5Q>3WC-=W(6:=BS,@F8+U]@.*[.@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQXUS))WDD)R[GW9B3^-<EXTLK>ZUVVEAU>[T+6+>U9K7447="ZEN8I 1M89
M(4G)[=*[NB@#&\)7.HW?A/3)]5M$M+YX!YL*)L"GMA3]W(P<=LXKSC2FL+>V
MO_"/B;1-6N]1^V3M#"!.]O?(\K2(X(/EJ,L,EL 8R><U[!10!Y7XH@FL]8UC
M4O#M[<6FM1>5'/I<T1EM]6'E)@*I')P=FY3QMYQUK3AGN=.^)?B&673KF66]
MTNV:V1(F9)602;EWXVC!(')'6O0:* /&;*^:[N_ 6HFSU%6M[F1+FVBT^2*"
MR9H741(@4# /&>?4D"MW2KF'2I_'-CJ-K.9[W4)9K>U,#$W<;Q(HV<88$@CC
MIWQ7I-% 'E4&E77A^;X8Z=>!WFT_SA=,BEEBW0,HRPX W':#[5806DNO?$@7
M]E<W%A<K; I'&V9T$ 1_+('S$'CCO7IM% 'EM@=2L(M=TX:K+KFAKH\C6U[-
M%F>&0Y46[.!\Y(YQU&!D#(S7R5\*?#"/RI1):75J;A?*;,(6!E8N,?* Q .:
M]:HH \CM);#3]0UWPYXHTC5[F:ZU">>U6%9Y(;Z*5RZ@;3L!&<'=@#')K4L+
MIO"GQ'U0ZK:3PV.IV5HEA+#$\T<9B0JT.5!.<L2..?QKTBB@#B/A677PA)%)
M;W$#K?W3;9H6CR&F=@1N R,'M7;T44 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 5EZYXATSPW:Q7.J3M##+*L*N(V8;F.!D@87KU.!6I7#?%>01>$+>1E9@FJ
M6;%54L3B9> !U/M0!L:5XVT/5]4NM-@GFBN[>/SFBNK=X"T7_/1=X&5]Z=8^
M,M(U"[L;>%YQ_:$;R64CPLJ7*H,L4)]N><9'(KG]6AEUCQQ8:YI-H]PFE:9=
M^8SQE%N)) !'#D@9.0Q/ID9ZUSMA<7%UK'@+4VT[5R\#S1WB?8)(HK5V@*B)
M(\!54-QNQC Y:@#T?3?%6E:M9ZA=6DDYBT^1X;GS('1D=1EEPP!) Q^=4[OQ
M[H5D]K'-)>"6ZMFNH(A92EY(P >!MY."..H[XK US1;VW\>FUL$!TSQ/#MU%
M=V/*,.-[X_VXSY9QW()J]K(<?%?PU*MM<M!#9W4<DR6[M'&S[-H+ 8&=I[T
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MVL)/+NEBLI6,/&2S +PH!'S'CTS5J[\<^'[-M/5[UW_M&$S6AB@D<3(%S\I
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M\YCTZ5X;GS('0HZC++A@"2!Z>M87B 2-\4?"4RV]R\,$%XLLR0.T<9=4"AF
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M2?(0Y088C*X/T^F=#7+,QZ7I.OZ'X>NH;"UUM-0N;586%Q<1["K3&,_,6!/
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M$\R&,YP6!8#)P<*"2<'CB@#:K"T/P[+I=U-=WNKWFJW3!DBDN@H\F,MN**%
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MD2T.("I 9F!(.!GZ\=,5H6_C'3KC7[72/(O8GO$=[.XE@*PW(09;8W4X'/(
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ML5W8QT85U=E:)8VJ6T;R/'&,)YC;BJ]AGJ<>^3[U,ZEXV57*$@@,N,CW&>*
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ML8*S #[W'/7MQ6C/9S^)X/"-I#8WEN-+NX+V[ENK9X?+\I"-@W ;BS$#Y<C
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M!8Y !)QQ4=W9W6@^-]9FO/",NOZ=JSQSV]Q;01RO#((U1D<.1A?E!!S@?G@
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M)"58^4A*,H*/NW  Y/ ]#TKH8->L+2RT>TL;:XFEN[19;6T0@R"%57YF+,
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MV[\;Z?:65QJ)M;R72K:8PSW\2*T2%6VL<;MY56X)"D<'L#7/>$!=,FGZ;?>
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M/+B./.U0S#&"RDDXZ8&>:YG3=9'AGQ7X_FATN^OHH+BWFD2VVGRT%NK,Q+L
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M3(I\DG (WD9)/0?F1Q0!N45A'Q/ _P#9L-O:7$U]J%K]KCM!M5XX\+EG).%
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M+(2H)R""0=N<&M+PAHEQI]WKVJ741@DU:_-PD#$$QQA0J[L9&XX)/U KJ**
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M@YP<@98=1R,U=\,2:G?&WMK[P6FD7<"[;J]98MA(&,PE3N))Y[ #/)XSWE%
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ML%U'<FX,2F)I%0#C?R,C\>PK6^(>EWVK^$GM].MS<7"7-O.(E8*76.578#)
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M$X!1^K8Y_.M75]*UKQQX+U?3VT)- DGMPD232(SR2AE<9*<*GRXYY.[.!CD
M@\0W<U]XY\!W-QH\MH9+N5HY9&4MM\ESL<#[K<@XY'7FNK\<:W=^'/!NIZM8
MVXGN+>%F4,P 7C[QSU ZX'7]:YF\;Q)KNI^$;R;PO=VLNG7;27H>>':,Q,A*
M$.=RY/?!]CVZ;QQI5UK?@?6=,L4#W5S:ND2%@-S8X&3P,T (OB1X8M+M9;*1
MM5OT9HK;S%Y55!:1F!P%Y'J<D#%3Z'XCM]:NM0L3!+:ZCIT@CNK64@E=PRK
MC@JPY!_05S%QIVMC7?#?BJ/29@;6V>RO=/,L9F6-@"'7#;20PY ;)&._ V-
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M.,<U7U73=1U'Q_H=^-,N5L(K&Y@N)O,B!C:79CC?DXVG. :Q+/P]KT?PSN/
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M^YT^2PO],E1)X7D60%77<C!EX.1^6*M:S>SJ8M-L& U"[R$?&1!&/O2D>V0
M.[%1TR0 :@(;H0><<4!@V<$'!P<5XS;:I=Z!\$]1-A<2K=RZK/9Q3LQ+J7NB
MA;=UW8).?7FNHU:.#PEXU\(II4*6]M?M+87448P)0$W1LWJRL#\QYPQ]: .^
MW+NVY&[&<9YI:\46_M;OX/:GKUW-%;^*;.>>66X8A;B&Z24E4R>0-NU0O3:<
M8KTR]UFY3PC;WL2*NHWL,26\9' GE "Y'H"<GV4T ;X.1D45P7PTN;G3UU?P
M?J,[S7FB7)$4LA^::VDR\;GU/)!].*[/4M1M=(TRYU&]E$5K;1M+*Y[*!DT
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M*Z, RLIR"#W!IU8/@C_D0?#O_8,MO_12UYV?^$2TWXE^.7\0V]BEFD-D8Q+
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M  .>M:E% !7GGQ,\ WOB>?2M<T2:*+6](E$D*S'"3 ,&"D]B",CMR?J/0Z*
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M<-TMS^_B8QF4*%'WN2-O.,]>,UUT%G!;332PQ[&G;=(%)PS?WL=,GN>_%3T
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M-L8HHA<BX+29#!V90 %!4# R3DYZ"J%U9>,-9_X15KO08(+C2K]);IVO4*2
M1LA9, G!SG!&1TP>M ':^(+J.Q\.ZC=361O88K:1Y;;Y?WB!3N!W<8QFN;3Q
ME'IVF>$8[+0)/(UJ!!;PP2(JP?NMX09QG &.P_E71^(K>XO/#6IVEK"9;BXM
M9(8T#!<LRE1DDX YKCD\/ZTEIX C_LUBVAA1>8FCXQ 8OE^;GDY^GOQ0!TGA
MSQ++K5[JVGWFG&PU#3)DCFB$PE4JZAT8, .H[8XK/UW7=9M/'^@:/9V]LUI=
M0W$S%YRC.44#!^4X WY[Y/ICF7P_I>HVGCCQ3J5S9F*TU)K8V[^8A)\N/8V0
M#D9/(]O2F^(M)U67QIX=UK3K6*YBLX[F"='F$>P2A-K=#D J<@<T <OIFK7'
MAC4_']UINB"[@M;\7$R),L*H@@1FV\'+=3C'XCC/3W7B'3KKQ'X0!T@7!U2.
M6:ROI-N;<>27.!R<E< ].O4XK,CT'61!X\0Z<P.M%S9_OH^<PB(;OFXY&?I[
M\40Z#K27?P_D;3FVZ);O'>_OH^"8/*^7YOFYY^GOQ0!N6?BN34KJ<:?8Q7%O
M;:@;"X*W/[Z)@^QG:/;PN>1\V2,'Z:>OZU!X>T.ZU6Y&8K=02,XY)"C)[#)&
M3V'-<9?>%+W4/$=MJ]OI3:7K,.HY?4K>=!'<6@D/$BALLS1@#!7KWQ79Z\ES
M+HL\=I90WTC;5:VF("2H6&]3GCE=W6@"A+XG;3[#4+_5;2*&SM8(YH[BWN/.
M2<.6 5257G( YX^8<U0L_'23^)(]$DM;>2>XMWGMGL;U;A'*_>C8X78V.>X/
MK7/_ /"NKJ33?$6G:3Y^C:9?0PO9V5Q,)!#=))YA=0K,$0E4& 3WXX%=1H-_
MXNO-IUS1+?3Q;H?,\BZ68W;XP-@X"+WY.>@]30!CVOQ*GN-#TO7'\/31:7>7
M0M99FN5+0LTIC4A<?,,@9Z8SQGK5ZS\0:O+\1]9TN>&U33;&T@D#>>00&+DN
M1MY/R@8R  .IS7/1^%/$"?"O3O#YTW.H6]^D[@3Q[-BW!EX;/H<?7\ZWVT+4
MSX[U6]-HC:9J^G0V\DIF"O 4WAAMYR2'XQQ[T 1?\+*LO.TF7R;>33]4G2"*
M2&[5YXR_W&DAQ\JG_>)&1D#I3)_B'>K8Z]>0>&II(]#N7BNM]VB_(B*S,O!R
MV#G;Z#KSBD\)0>-M)L[/PW?:=9FTL0L*:PER#YD"\*!#C._: O) '7G&#77P
M]K?]@^/+,Z:PEUN>>2S_ 'T>,21+&-WS<8(R?:@#IW\2K<WMI8Z3;K=7=Q9B
M^Q-*8DCA) 4LP5CDDX  /0],527QM&NCZ?<WEA)IU]?3/ EI?R"$(R9W%G(^
MYA<A@#G(XYK"_L3Q/HFK:-K^E:9'>R+I,>F:AITERD3#8<K(C\J<$G\/KQ?\
M0Z1XINX]%U^QCM'UO3;B24Z>9<1/%(NUHA)@?,  =Q&,Y[8% &MX7\6P^)+G
M4[,PI#=Z;*L<PAF$T3AAE720 ;@0#V!!%=#(7$;&-0S@':K' )[ GG%<K<:O
MXJMO#=[J\FAVD=X@4Q:<]ZI"(#\[O+@#."3@=EZY.*Z6SG:ZL;>X:)X6EC5S
M$_WD)&<'W'2@#R'7-5U'Q-\$O$5]K-I:[DFF\IDD+["EQM  *C& , YR?;-=
M[9^*KC_A*;;0K_27LUNK5[BSG,ZOY@0J&#*!\APP/4UR<WA3Q)_PK37O"ZZ=
M$TT]S,;:9;E<2K),9 Q!QM !QZY[=ZZ+4-*U*^\<^'M3_L^1;*TM+B"X+2IN
M4RA , -SC:<_7C- %:;XFV$2V-XD=M-IEY<K LD5XK3H&.%D:''"$C/WL@$9
M'8=)XFTZ^U;P]=6>FW,5O=OL,;S*6C.UPQ5P.JL 5/L37*^%++QIX?LX?"\N
MGV<MA:GRX-9^TC/D9X!AQDN!QV'3KCGT&@#F;;2?$$?B>QU&>_L)+0:>MO>1
M"%@WFC<2T1S\JL2,@]E'MCC?C3J^M6NE0SZ&V(]&N8+V]<>I8B-?<9&6'H5K
MU65VCA=TC:5E!(12 6/H,D#\ZXVU\*+J^A7Y\0V%XE]?M*UU#%?ML?=PH4*X
M0X0(HW ?=YH UX/%NF2^"4\5O(5T\VGVIB.2HQDK[L#\N/6L?1?'=[J6K:3;
MW7A^6VLM6L3?6UY'*9$C7!8++\H"G;@\$\L![UR?A#P#XGA^'6N>"==B2&VN
M S6-RLRN(R3G:P!R!N /&>K>U='X"LO%UGX=M_#GB'2K6&VLX3;_ &Q+L.9H
ML$*%0#@@8&21P.G/  VT^)LNHG3KZQT">YT2_P!1:PCNHI"TBD' E:,+@(3G
M^+.!GVJ&X^)]_P#\))KWA_3O"LVH:CI:!U2&Z&)5..22HVX##@9))P!WJI\.
MM \9>"$N/#<NGV=UI(N6EM]2-T%V(<9!C +$\9QQR3SCFKWACPQK&F_%?Q-K
M]W9A-/U)%2!Q*A8;=H^8 Y&<4 7H/'UQ)XZB\*2Z*(;N73Q>AVNLA3MSY; )
MP0<C(SZ^U4-)^+>GWWP[O_&%YI\EI!:W!MQ;K*)&D?"X .!U+?A@FF:WX8\0
M0_%^S\5:7907EHVGFTD#W B\I_FPQR"2O(Z GK7,:7\*M>D^#FJ>%;Y(;;4F
MO_MELWFAHWX48)'(^ZPZ=Q0!W,7Q$M[74M1T_7+6.RN++31J9,$_G*\/\0!V
MK\P/&,<UYG\1_$%WXJ\,^$M;FT6*RMKG5$:UD%P))-GS##C:-N<9 !8<<XXS
MW=GX9U?7_!E[I.L:!INB74UBUJT\#)(TLF!A_D'RKD9(R2<]L<\G?^!_&VI>
M!O#/AYM'M8Y=%O0[S->KME1=VTJ!R!@X.><]J /:=3O1INE7E\REUMH'F*CO
MM4G'Z5Y1\&$_X3"RUGQ9KZQW^HW%XUNAG4.L,:JK;$!^Z,OT'H*]=>);FV:*
M>,%9$*R(3D$$<BO.O!/A;6/AO-JFFVUE)JVB7,_VFT>WEC6:(D %761E!X"\
M@]NG/ !A>&=1E\._'/6?!,/S:%>1F:&T;E(',0D(4= IRPVCCIZ5@_#+Q7?>
M#?A?JNJQZ,M[IMMJ[_:7%SY;H&6)?D7:=V,C.2.OUQZ%X4\$7T?CO5O&^OB*
M/4+S]W;6D;[Q;Q8"C<W0MM4#CCKUSQR>E_#[Q59?##5O!SV$/VC5;U;@78N$
M,4"$Q[@XSN+#R_X01SUH L>)[RTU3XQ_#K5+/!AO+=ID?;@LA4E<_@:M^'?$
MN@Z)XB^(NJ/I5Q:SV$BO?2+=&83MEP BE5VY/K_>[ 58U#P)JEMXT\$7&FVO
MG:7X?MA;RRM*BL_&W(4G\35*'P[JF@3_ !(UK5M)MI;#587F@BGN$".%WD+)
MAOESN'0_B.* -F+XG7IN/"\<V@0H/$:&2T(OB=@&#A_W?7#*>.YQ[T:]\5?[
M(@UN\@T9IK/1;R.TNC+,8I'+'&Z-=A##/^T,CG@8SQ?AKQ#IVF77AR;7?"'B
M>%;%$M+*[O8LP6IDP,K\JY!) !8L< 8J_P"*O OCGQ*GBN*\@L;H7$R'2YI+
MK!BA63=LC3&%)&-Q)&2.^<@ W/'/C36+;Q%X,T_1X8OLFL3I/N>8HTH!4B-L
M*=BG<N3SGIC'5T-]IY^.:17ND-!K(TG<UTE\7B5,9(V%!R#D9Z8YQFHO$'@W
MQ%>3^ -3MK.WDN-"VB[M?M '&(^58C!^X<_7C-69/">M77QB'B*XLD&F/IOV
M*5DF7.XJ<D#.=N3CU]J #_A;MO\ V*_B,:63X=74?L/VGS_WQ_Z:^7MQMSVW
M9]NU:.K?$"XL?'MKX3L]$%[/>6GVJWG6["*1AOO97@?(>03QC@]*XK_A6'B$
M> 6\"+"GDG5OM U/S%\O[/USMSOW_P"SC'^U72W7A+5H_C%H_B&VLM^D:?IO
MV(MYR;R=LF"%)Z?.!SCO0 RT^,%K/\/+KQ1/I;P2VU[]A>U\[<HD^7G>%^[A
MLD[<\$8-;-U;)\0O#5Y8:AI]FUNQ1K:XBN6FAD!&1*C *25)/RG'(P>#FN5\
M'>"=<T7P1JVC:MH=M>B]U/SY+5YT*R0,JA@&SPZ[<CISCGTW_ACX.O/!\>M1
M/Y\.FW-T)+&SGE61X4 Y+%25R21T)X49YH VX_!^G)XG?6C AD>Q-G,68L;E
M3M'[P'C@)CISDYJMX*U26:?7-"N)&DET6],$;N<LT# /%N/<@';GOMSU-=97
MG_AZ'4H7\9>)M,LDO+G4;T"Q@>41K,D*B,-N/0$AR#W 'K0!Z!13(B[1(TB!
M)"H+*#D ]QGO3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "LS6]
M T[Q#;1VVI1RR0QR+*JI.\?SJ<J?E(S@C(K3HH 1%"(J@DA1C).3^=+110!D
M:%X7T7PTMPND6*6WVA]\K;F9F.2>K$G&2>.@R?6M>BB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH 9+#%.H66-)%!# .H(R.0:?110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 56O["TU2PGL;ZW2XM9U*212#(859HH QXO#&
MEQF#<MU.L#*\4=S>33(K+]T[78C(Z@D<=JV*** "BBB@ HHHH **** (YX8[
MF%X903&XPP#$9'IQ3HXTBC6.-%1$ 5548  Z "G44 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445GZGJL>G&
MVA"^;=W<GE6T ."[8)))[* "2>P'<D @&A17/Z7XBN+[Q=J^A3V20_V?#!*)
MDFW^:)-W; VXV^]7]8U5=&MA>W$>;%#_ *3*#S"IXWD=U'?T'//- &C12 @@
M$$$'H17)>)?&5WX>M=3OO[%,^GV!1&G-R$,SMM&U%VDGE@.<<Y]* .NHK%T[
M5=3N-6>QOM(6U46XF\Y+D2KDM@*1M&#P3^%;5 !1110 457OKHV5A<78MY[@
MPQM)Y,"[I),#.U1W)Z 4^VF^TVL,YBDB\Q%?RY1ATR,X8=B.] $M%%% !156
M74(4MKR6$/<M:!A)# -SE@H;8!W8@C ]Q3[*Y-Y8V]T8)K<S1K)Y,Z[9(\C.
MUAV(Z$4 3T444 %%9/B;63X>\-:AK B2;['"TOEO(4#X'3(!Y/0<=ZO6$T]Q
MI]M-<PB&XDB5Y8@<A&(!*Y[X/% %BBBD) !)( '4F@!:*YW7_$SZ9::1/I]O
M#>KJEY#;19F*<2<AQA3D!06[<"NBH ***S]:UJP\/Z9)J&HS>5 A"C +,['@
M*JCEF)X % &A17-WFOZS9Z-<:O)X? MH(6G: W@^T[ ,GY A3=CMO_6N@@>2
M2WBDEC\J1D!9,YVDCD9[XH DHHHH **** "BBB@ HHHH **YRW\37-SXOU+0
M(].C!L;=)WN&N<*0^=@QMR#P<^GO5#2/'4NL>%+W7H-+0QP3/!!$MUN-RZMM
MPAVX^8G"^IQTZT =E169;ZG<M?VUC=:9<1336[3O+'^\@B((&PR<?,<YQCL:
M9K.NPZ7H.JZG$89_[.C=Y4:38,JNXJ6 .#@CL>M &M15/2;J>^T>RN[JW%O/
M/ DLD(;=Y;,H)7.!G&<5<H ***BN+B&T@>>XD6.)!\S,>!0!+117/6_B9]7O
M+F#0;-;V*TD,4UW+-Y4'F#JB,%8NP[X&!ZYXH Z&BLC1]6N]0O-1M;O3C:/9
M2)&7$OF)*S*&RIP#@ KU .2>..=>@ HHHH **** "BBB@ HHK!\,Z_<:_P#V
MHTMI';QV5])9QM',9!+LP&;)48^8D?@: -ZBBB@ HJM+>Q*+E8Y(FFMT#R*S
M[0N02-QP<=/2L_PIK4_B+PO8:Q<6@M&O$,JPAR^$).TY(&<K@].] &S1110
M45R>E>*]4UJ;54L=$@9-.O'LW=[[:))$QG;^[/'('..:WM'OI]2TFWO+FR>R
MFE4EK=W#%.2,9'!]?QH O4444 %%%% !147VB'[5]F\Q?/V>9Y>>0N<9^F?Z
MU7TW4#J,,TALKNT\N=X=MU'L9]IQO7DY4]0>XH NT444 %%8OBS7_P#A%_#5
MYK1M?M,=HH>2/S-A*YQP<'GD<5FZGXPN=+U+P_ITFF0M=ZRQ5(Q=\Q$+N8M\
MG( [COQ0!UE%8@UN[.JZA;+IAEM;&(.\\4VYG<KN\I4VC+8QWQ\R^N!>M]3B
METZSO)XY;/[4$VPW*[)%9^B,O9O4>QH NT5A0Z]<3>-[G0%LX_(M[%+I[E9B
M2&=RJH5V\$A6/4]*W: "BL*Z\2H=;?1=+MC?ZC$@>X ?9%;*?N^8^#@GLH!/
M?&.:=!JVJ#78-,O=)CB$T,DPN8+KS8P$*@J<HIW9=>,8QGGC% &W1110 445
MA#7IW\<-X>6TC,,=B+R2Y$I)7+[54KMX)PQZ]%H W:*P_%WB'_A%?#=SK)M?
MM26Y7=$)-C-N8*-O!R<D<57M?%3KXFMM U73FLKV[MVN+9DF$L<@7[RYP"&&
M<],>] '24444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&R8QN(4<_+RQ/&*HS^$]"-AI=L]DWV71_FM(D=_E 0K@@'+_ "DC!SG/.<T
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M7XY6\LD"ESH3RELG)99T /X"N2N].BD\$_$'5?-N4O+'6[V:U>.=T\IU*$,
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MI/.,U=G@2Y@>&0N%88)CD9&_!E((_ U)52]U*UT][5+F4(]U,((5[NY!.!^
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MVEO;@>YK;L;G[986UUMV^=$LF/3(!_K0!E3^$-"N-5N-2DL<W-S$L4Q$KA)
MHPI* [20.AQD=C4EGX5T6PATV*WL@J:82UIND9C&=FS.2?F.WY1G.!TK8HH
MYG5]#>QBU+4_#]F#J]])$;AC)EG0%5?8'.Q6\M>.@) S6)IOA:33-0TX^&?[
M<TRUBF4W%K=W7F6ODC[RA'9B&/0%>!ZUZ#10!AMX0T-M8N-4^R.MS=8-P$N)
M%CG(& 7C#;&./4&MHHK(4(^4C&!Z4ZB@##M/"&A6.F6>G06 6ULYTN($:1VV
MR)]TDDY..P.1T]!5M-#TZ/79=:6W_P")A+&L3REV/RKG&%S@'YFY SR:T:*
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MVEM%;6\2101($CC0855 P !V %25DWNN1I:ZO_9_E7-WIL>Z2)G*J&V[@I8
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MB*1K=F8K@\ D D=*FO-$CT5_ FOZ3+<KJ=Y=VMI=L9V?[3#)&2X8$XPH7(P
M!CV&.K\5>%X3X=\2OI&GRS:MJUF\#[9SF5BA5-V]MN!G ]!TJ[X9\/6ECI>E
MS364T5[;6RQA)YVD\@[0&"#<RKG&/EQQQTH X;5-3OM&A^*NH:9N%Y#);F-E
M'*9@0%A] 2?PK3UZTM]&?P;JWAP!)KG4;>UE:,_\?EO*I+&3^^<#=N.2,$UV
MMKX>TNRN[ZY@M<2W_P#Q]%Y&<3<8^8,2#QQ].*CT[POH^DR0O9VA3R P@5YG
M=8 >OEJQ(3CCY0..* .&F;_A"_%.M:/# C1^(8A-I6]=RBX)$;PG_9!99,=
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M^1/*G5_N[6.TY]!SU[5YO<:=KGPLN;&33=2DU3PK/=Q6SZ=>?-+:[V 4Q/W
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M+&QNO,M8-H*P,T2,2@_AY)/'3->NZ/:VEII-O!9P00Q"-28X4"KD@$\#US0
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MQ_WUC/\ LFNAC\K_ (33X0E-GFG28MY&,D>7QG]?UH ]\>:*-E5Y$5G.%#,
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M-[_9[7IGN8S(@^<(B[0RGDY).> .ASP 7&\)Z"VAQZ(=+@&F(01:J"$)SG)
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M!J=)HI'=$E1F0X958$K]?2L[Q%KUCX8T*ZU?4&86]NN2%&6<DX"J.Y)( ^M
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M$CJ03WJM#X)\-V]E>6<.DP);7I!N8E+!9B#G+#//XUNR2)%&TDC!40%F9C@
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M((]12T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^(7Q5^TVD,H@TB2:(.H(23R@=X'3<#SGJ*](^#;M/\)] >5B[K'*H9N2 )7
M'Y "NC;PGX?:XN[AM'LC->*4N9/*&Z93U#G^(' X-7=-TNPT>S6STVSAM+92
M2L4*!5!/7 % %H*%S@ 9.3BN%^%Q<6'B5.?LZ>(KY;?T\O>.GMG=7:7ANA:N
M+-8S<,,(9#\JG^\>Y ]!U]NHJZ%HUOH&C6^FVQ9DB!+.WWI')+,Y]RQ)/UH
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MWE ^9E4DJ"?0%F_.@#S 6]GXIU/QEH^L:A9VUQ'=&,+<0J98K;RU\MXV9AM
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M^\"?W=W7'M44'AS1K:]-Y!IMO'.9#-E4P!(>K@= Q_O 9H XFU\/Z3JGQ/\
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MMM:VMLXC7<WE,(\D$+&6SNXQ@FK,<"#Q'\0;&Y6R"2:5!(]O;C$8D\N7L>K
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MB'V\KA6ZJ,$\#CDGK7L[:'I;ZF^I-8P_;GC\IKC;^\*?W=W7'M5;_A$_#_\
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MZBM[>"TMX[>VA2&"-0J1QJ%50.@ '2I: "BBB@ HHHH **** "BBB@ HHHH
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M-V<^V/>MBUEUBWU%DU*?3Y;/R"_FP1-$T;A@ &#.W!!.#_LFN2\:VZ7?Q4\
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M5;.\$L\<:QK=)>!R"O(W$L3C'<$"@#V*N3UCQK%I/CC1] >',%\"DMR>D4K
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MPLZ*Y4Y'EJ , ?,=OI71VNCZ/J?Q=UT7%C:74$FE6LI5T#H[%I!O(Z$X[]:
M/1#-$L/G&1!%MW;RPVX]<^E<QHGB*[U+QQK>E--:36%K;6\UM);J<GS"^=S;
MB#C;VQ7G?A_4?*\-?#.TOY/^)-->74<YD/R&2,R"W1B>V[H#W4>E=CX?BM+?
MXP^+$MUBC:2RLW=4P,M^\R2/7&* .]HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M(  R2>U5K74K&^CDDM+VVN$C.':*57"_4@\4 0OH.CR+9J^E63+8G=:@P*1
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MLI+VW2Z?E(&E4.WT7.35"S\3:5?>(+[1;>\A>[LUC\U0X^\VX[1ZD!<GTR*
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MMQ>2D9\M6)"(/]IMK'V"^XIT/]IR3ZJJ:G92LLJFUC6+F ;1\LF#DY.?0X-
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MKFO&ME-?V&GQ6>IQ:?J*WR263S)OCDE578(X]" WOD#'-=+5>]T^RU*$0WUI
M!=1!@P2>,.H8=\$=>30!Y)KVI37?@761J>EP:=J-CKMH;\P/N@=]\)\U2>@*
ME<@\C//6NE%[9R_'"/RKF!V_X1YXR5<'YOM"G;]<<XKLQI6G#3WL!86HLY 0
M]OY*^6V>N5Q@YIEKHNE6+Q/9Z99V[0Q^5$T4"H43).U<#@9).!ZT >*VVA:;
M<? '3;VTM(?[>WI]BN8E'GFX\_"A6Z].,=@/:NUGADM_B[J3V44:WLGA<."B
M@;Y?/8 GUZ <^E=B-$TZTFGOK#2M/BU%@S+-Y"H6<C^)@,\]S67HVC:D_B23
MQ'K,=K!?/I\=B(+65I$ 5V=FW%0>2PP,<8ZG/ !Q/AH>'O$7AGPM+<>(;@:E
M87$+BTC:%;A;L<2*PV;R"2Q;/4<D]ZFT*\\/:OX9U[2O%4\:ZBFJS->PO+Y<
M[N)=T)3!#'Y0BKM],"O1X=$TFWU.34H=+LH[^3(>Z2!1*V>N6 R:631=*EU1
M-3DTRS?4$&%NF@4RJ/9\9_6@#D+-K2'XSZKYWDQ/)I%J8P^ 2QED''J<X'%2
M_%98_P#A$(9)0FU-2LR68<*//3//85V#Z?92WT5]):0/=Q*4CG:,&1%/4!L9
M IUU:6U];26UW;Q7%O(,/%,@=6'N#P: .(TZ\BE^+VH6UP8F@;2H_P"R\8*%
M ["<+VSNVYQSA1Z5-\-8);6SU^W3/]F1:U<IIZ_PK$",A/\ 9#[P/H:ZFZT7
M2KZ"""[TVSGA@_U,<L"LL?&/E!''''%6X88K>%(88TCB0!51% 51Z #I0!YY
MXBM8;WXT^'H)I)D!TJY.89WB;[P_B0@_K7265KI&BW&I:=)>/.+S?>S1W<QF
M\N((D;;V<D[?EXS[]A6;JOA?6-0U.>Y\CPE*C,?+:[TAI90N> S>8,G'L*BB
M\*^(+>&:&&/P;'%. LR)HKA9 .@8"7G\: ,/P9'#X>\66^E7T<J:=<I++X::
MX(_=(S;I(L8R'(VL,Y.TXX.13)--L+ZX^*<MU:P3O&#L:1 Q3_1%.1GH<@<C
MT'I71S^'?$UU]G^T'PC+]G $'F:/(WE ?W<R\=!TI@\,>(AY^%\'C[1Q/_Q)
MI/WO?YOWO/XT 8)6.6/X2WDBHURZQ@S$#<0;0DC/7&:GTW1] U7Q'\0CKEI:
M30QW2;WN%!,49MT)8$_=Z9R,=!Z5K_\ ",>(B(!M\'XM_P#4C^QI/W7?Y?WO
M'X4ZY\-^)+R]6\NO^$0GNE "SRZ/(SC'3YC+F@#D=/M+F'0OA6^IQD:@M[LW
MRK^\$1CD**2>?N[.*ZCPR;2'XH^-HV,*3-+9>4IP&/\ HV3M'X'IZ&K5WH7B
MJ_EBEO)?"EQ)$<QO-I,KE/H3-Q3AH_BX7YOQ<^%A>%/+-Q_94OF%?[N[SLX]
MJ -3Q5>31:2+"RF$6HZD_P!CM6/568$LX_W$#O\ \!KAO%%K?>#-9\.>+)7L
M4L; KI=VMM$R8M9.%)RQR$;! ]ZZ.YT/Q5>SQ3W<OA2>:'_5R2Z3*S)]"9LB
MEOM%\6:G$(K^?PK=QJ<A)]*ED /K@S4 =@K!E#*001D$=Z\3NM3TZXT;PS>:
M?/;VMBWBI)8X99-]R29W$DDC$_+G)^7!P",GM7KVBVMU8Z5#;7?V(2QY&+&
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MD;ZU;:B[W-DTI2Y>[$Q964 AF)R,'ICCH#6MX9EMY]9\>Z?X@\OSVO6>19R
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M'Q>ALI()"]M'($B8'=BV^9@!U^;.?>M2ZU;2[KQ7\-O+OK651#<!R)%(&ZV
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M3[*WD22"TMXG2/RD9(PI5,YV@@<#/;I3;;3+"SN)KBUL;:":<YEDBB56D/\
MM$#)_&N5A\076M>-=:T&#5H],ETT1B*#R5>2XW(&,AW=4&0,+@\9)Y%;>E:A
M=VN@"Y\2SVEO<I-*DL@_=1$"5E0C<> 5VXR3UH O_P!F6']H?VA]AMOMNW;]
MI\I?,QZ;L9Q276E:=?31S7EA:W$L7^K>:%79/H2.*S-7UI)_">K:AH>HVTDM
MK;RLLL>)0DB*3M(SU]C3="UZ(^#-"U+6+Z&.>\LH)'DE94\R1HPQP..>IP*
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MY(&1V].M;_B?Q)8>%-!N-6U"0+'$OR)G!E?LH]R?RZ]J +ITK3C)%(;"U+Q
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MW7%ZXB&UE5CA4"X'RC)P3D5L:A)<W5U::OX7URR_M.'1XVFLKS#6]Y;[GY#
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M-/;0RRQ',;O&&9#[$]*4V=LT_GFVA,V<^84&[/UH \XFCE3Q]XUMM&$<=^=
MA%LD6%(EQ+MP!WR5_2LV]DM]8^"OAZ#264:S#)916D:\2Q7:.JR9'4$ 2$Y[
M9)KUE;2V2<SK;Q+,<DR! &.?>FI8VD5T]U':P)<.,/,L8#M]3U- 'GFCZO9V
MWB?QW8Z_<007LLP>);E@HEM/*"QA<_> ^;('=CW-;'PGGAG^%^@^5*DFRV"/
MM8':P)R#Z&NLFLK6XFCFFMH9)8_N.\8+)]">E2111PQ+%$BQQJ,*JC  ] *
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MMH[F*,7<$,C@9(*[@#WQD4 4=>\1Z9X;THZCJ5U%%"2%CW.%\QCT4$D#GUZ
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M\W&T,^,G@X]ZLZ=K>FV6C:4M[XBM;R6Y15ANI&2,W9_O*HXY]JY+PY?V5O\
M\+!L;FXBCN1J=U.T+MAA$8DPY'93Z]*P8[FQ?X??"U)IK=@-2M P=E/ CD!S
M]"0#0!Z8/&GAEK*XO!KVGFWMW$<L@G7"L>0/Q )'K@UHG5M/&FQZC]M@-G*%
M:.<."CANFT]\]L=:XO2Y=/'QD\2LTEMO&FVNXEER,%]WZ;<_A7%:)JD6F>!O
M >IW%S-'HUI=WD5Y/;'=]F9VD6)FP#@#)&?1O>@#T7Q=XC#?#W6M8\.ZK&)[
M.)R)H@K['7JK!@<'V(S6U:Z]IP>QL+G4;<:E<0)(MNT@$CY&20O4CK7GNO\
M_"._\*_\<:IHMW)=+?VP\^\>7='-*%*@)T!8#&<=<CN#C9\50./"VB^+-+ F
MO-#1+I?+.?.MRH$T8/NF3]5% ';0ZA9W%Y/:0W,4ES;X\Z)6!://3([9J/4-
M7T_28P]_=Q0 @D;SR0.IQUP.Y[52\,12/IKZG.C)<ZG(;MU88**0!&I]"L80
M'W!KD-<UBTT'XG3MK^H3Z=87VG0I978;;%N1W+QEB" 3N![=![4 :_BS7;F
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M&&M7=K'X8N](U%1;7VL6MO(8PCK/#(23AL'J .1ZUULLL<$+RS2+'&@+,[D
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MV\!P94+'=E.0".V..]:7PX\37OBOPNU[J$<0N(;J6V,T((CG"''F*/0_S!H
MZM8HU;<L: ^H%(L$*3-,L4:ROPSA0&;ZFN*\6>,[K0/%.CP1Q@Z2)TAU28X_
M=&8,L//;!4D^Q7UK<\71ZS)X?E_L&_:RU!65HV6V$_F8_@VG@!C@;NPYH VQ
M%&&W!%#>H'-*R*Z%'4,I&"",@USUK'X@3QE(\U^LVCO9C=;?9@@@F&W!63J^
M[YR1VP/453\;:AJ&FWWA<V5[)#%=:S#:W$2JI$D;*Y()(R/NCH10!U?DQ_\
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MW2YP$/&5YZYZ5T5K=0WMNMQ;OOB;.&P1G!QWH Y[6]"UF;6K?4M(O+#RTMS
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MV4\$ !F>.=6$>>F[!X)QT-,3Q5H307DS:G!$EEC[3YY,30Y&1N5L$9[<<]J
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MURTO]2G@B.+N-#\[ 8RX4A"2..#Z&O42 P((!!Z@TH  P!@#M0!P-Y+;:O\
M$SP]J^D7<$UK96-T=0N89 T?E,%\M68<?>RP'L37$PW-C'\![';-;K*-75R
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M^!=1O=3\-";4+6WAN5N9XW>USY,Y$C9E3/\ "YR??.:QUOK3_A><D?VF'?\
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M/T4HWSJ<^G<=N_6MG72]_P"/O%5GI5Q&;ZY\+>5 (W&6EW28 _VL$?3(KU/
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MQ(L+ND!;&/,900G4=2."#TH V:*YK_A,;0^-?^$=6"Y)6T%PTXMI"AW.%7!
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MS9DQ,%<?9=N=^, ;AMZ]:?X8U#0/$)TB Z7JIU^PVEX+PW.VQ<##/ESLQQ@
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M3*DP>25+=)C(F#E,/P.H.?:@#G_ +ZKJMNVJ:[#LOK5#I@YR&,3$2RC_ 'W
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MJK16445[->$L\\JA"S'[J#)"CT&23ZG/)X%6: "BBB@ HHHH **** "BBB@
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M>(=#U2STJ^U"UN8)/)::UC*2+(I!*H7 !ST)!QSUJU'J)TFPTVTU29[G4Y(
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MFU^R@BA8K=-),K/';K:R&8JIPQ\O&X 9') '(]14VD:Q8:]IL>H:;<">VD)
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MFBQ)L\I@)ROF%XP<<MA@,=>: .OL?$-AJ%W';0_:%DE@-S$9;=XU>(%06!8
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M3GCGGVH [*BN*U&XE7XL>'TAO)S:W.G73M")F,3%=FUMN<9PQYJ]HNL:&O\
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M71DO%M9;B26XC@0(A*J7<+EOSX'4G H Z*BO/=1UK[#\4=-G>741:W&CSO\
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M+8P#@$\^E8GA+[,VF:9X;U?P?>G6].,<3--;LUL#'P)Q*?EQ@9XYSP*]8HH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@"K?V,6I6K6L[/Y
M$G$J*<>8O=3['OCKTJRJJBA54*JC  & !2T4 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MI5?Q#X@MO#>B3:K<P3SV\+*K+;A2V2P48#,,_,0,>] &M12 Y4$@@D=#VI:
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MXI^D^(M/UB[O+.W:6.\LRHN+:>(QR1[AE20>H(Z$9% &K1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<1>73WGQHTS3
M9"?(L=&FOHU[&5Y!%G\%W#_@1]:[>N8UK2GM_%FE^)[>-I#;PR6=XB#+&!R&
M# =]KJ"1Z$]Q@@%3[=J?B36?$NGZ?J;Z<VE%+>W,:(=TS1[][[E.5R0 !CH>
MN1BK\0FU"T^%,]]=30G5]/6"Z\Z $()XY$)*YYP3D?0U>U#P4+KQ')K^D:[?
M:3<7D:)>?91&Z7*J,*<.I 8#@,.U.\4:&NKZ%!X3M5?[/.\0NI"2?+MT8,V6
M/5GV[1W.XGL: .GMIOM%K#/C;YB!\'MD9KB==1-4^)GAG0XU M],BEU>X0#C
M(_=Q?CN9C^%=T %    '  KG]-\+M8>*]0\0/J,MQ<7T<<4D;QJ%1$SM"8Y'
M)R<DYH JZUXC2T\30Z#9L(;B6 WMW.L1D=(P0BA$ )9V(P.#@*3@\"L75-<\
M2Z;H=HTL\L5]J&M+;6,;PQF8VS'/[Q0-H;:KGC&,KGG-=%J'A5KCQ1'X@L-5
MN-/O#;"UG$:(ZS1ABPR&!PP).#5J3PY!-K&E:C-<W$LFFK-Y2R,&#/( "YXZ
M@9  P!N.!0!S/B74_%&AQ09U*"6[U/58+>RM[>W7]W&1F126SNP%?YCCL>.@
MS;OQ;X@MV\;DZC!Y&D1(8YUMQB&7RBS1IG[Y+,BC=G&#Z@5WM[H4%_X@TS5Y
MI9"^G+*(8AC;ND 4L>^0 0/]XUC7'@*TG\-WNCB^N$^W:@=0N+@*I>1S*),$
M$8Q\JKTZ 4 076J:U'?^#-,:Y5+^^'F:BHB4J4CB#2'D97+E5&/6LN_\5ZNM
M]XV:WU!8M.T6%=DS0*WER",NRK_>;)51G.,'/49ZIO"\;>*;77#?W6^WLOL@
MA+ AAO#EBW7)(7.",X';(-*X\"6D_A6^T(7MPHOKQKRXN,*7D=I1(01C&. O
MT% $5KK>K7']A:$SHFLW&GI>:E<!!BW3 !*KTW,Y('888X.,'(?Q/JD?ACQK
MJLFI,UOITSVNG2QQ1[V=% )^[@EI&"],?+P*Z.;PB'\2+K,.K7L#/9K9W,:E
M3YZ*Q8'<1E3ECRN.O&*SX/AU;6_A"'P['J=UY,5VET)"B<E9?-VE<8(W=<\]
M.P H IJNK>';7P=X?BU*66^O;G-Z9D1]T:H9)SG;GEN,]?GZGBM2RUN[\1:A
MK1M;LZ?I.ES-:?:$16>:9!F1OG! 1<XZ9)!Y&,5=F\+QS^)-.UEM0N]UC;-;
MK$6!W[F5BQ;&<G:,XQD<=,@USX+@^R:EIR7T\>EZC<R7-Q;H &)D.9$#]0C'
M.1C/) (% ',P^-M:U'0_ T\&(M1UJ<^= L8VR11JQ=AD$J#A.>P8^E=%X0U/
M5=1U;Q)'?7D=U:6=ZMM;ND(CPPC4RJ,<D!FP,DG@\UI1^&[*'Q!::K'E?L=B
M;*VMU $<2%@25'8X51]!2>&O#L?ANSN+=+N>Y,]Q+<,\N!\SNSG@>['GJ>/0
M  &%XS6?5_%/AC0+21$*SOJEPS+NV)",(2.^9'7'NM9T^M^)(=,\<P0ZH)I=
M" DM+UK9,R?N/-:-@ %)' R!WKKI_#^[Q')KEM>-%=R6JV;;T#A8PQ;Y.F#D
M\YR.!QQ5"XATRTL[WPK9+-+?WD#R2;D8ES+N5I9),;>N2>>P 'W10!9L[^]U
M+5-*GM[E!926'GW4'E _,^TQD/U!^_QW /M67\0#=7K:%H-G?3VSZK?"*=8@
MOSVZ*7ER2#V4#CKNYR.*Z+0-&AT#1;;3HI'F\F-$::3[TA50N3^  ]@ *K:A
MX<34/$NG:TUY/&]E#)$L28PP<J2<]0?D X[4 <CJ-_+<?$:_:.XVIX>T?$MW
M*@80O+\[O@8!?9&@ X'S$]!@V+'QAJ4?A_PK:7TL?]N:Q;?:)IC%D11 !B^Q
M>K$,JA1_$<]!BMFY\$VMQH?B'3A>W"-KDTDMQ<  NNX!=HX^Z%4*!Z9I;_P:
M)[_2M1LM5NK+4-.B>!9PJ.)8FP65E(QC(!&,8[=J +/AN75YYM2EOS,;$S*+
M#[3&L<Y0*-S,J@8!;. 0&QUKFKACKGQO@L;KFST33/MD$)Z-/(VWS,=\+P/0
MUWEI;&UAV-<37#D[FDE8$L?H  /H !6+K/A2+4M:M=<L[V;3M7MHS"MS"JL)
M(B<F.16X9<\]B#T- &U>BV^R.]V%\B+$S%NB["&#?@5!_"N!O?%NKM\.[WQJ
MDXLX@OGV%D8U821;@$\TD$EG_P!DC&X=3R>PBT=YHY!JMXU^SQM'M*".-588
M;"CN1QDDGKC&3G-M_!=NNGZ7IMY=RW>FZ64-M;,H4-LXC,I'W]O&.@R,D$T
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M5?RH_P"'!W29ZCH:@UFSN-.MO!7A%II;^[FNQ=SF0CY_)7S#N('W3*5))R<
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M4I4*ENAY(C3G&3R222<=<<5/X?T2W\.Z#9Z3:L[Q6R;=[_><DDLQQW)))^M
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M>L=;LM2GT[4+2)[?S(T5UEB8@E&5AZ@$&MJTMC:P;&GFG<G+22MEF/X8 ^@
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M+>N=JX_$T[0/#L>@RZE(EW/<-?WDEVXDP A<YP .N  ,GL!0!M4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %,E<QQ,ZQM(5&0B8RWL,D#]:?534[G[%I-Y=DX$$#R?\
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M?$.H^&]$O++5!_;NJ7RHVG101NEM%N(<,I&\;%&2Q(^;ZXH ]4HK.O\ 48M
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MOK5K&Z@6U9%6>50$GW+G*$') Z'..:X<:GK-KK7@R_DU>>:/7,QW5FR((5S
M9 4 &X$$=2QS2C5M9%Q\1(/[7GW:7'&]E)Y<>8<V_F8QMP1GU&<=Z /1**\Q
MLM2URT3P!JDVMW-T-96*"[MI$01$/;EPPPNX,",DY.<GH.*;K6OZOI^+Z#59
M;J5->CMG:W4?98X&E">2=P&YP#R5R0V>1TH ]-\V/SA#O7S"N[9GG'3./2JN
MFW\FH)<-)8W5F8;AX0+A0#(%. ZX)^4]C7&V-K,_QEUK_B8W@5=,MI FY2HR
M\@V@%>%XSQWZYK,A\8:OI_A/5I)KYKB]/B632+>YE1?W2&4(&*@!?E7)Z8SU
MH ]2HKB;^]U'P]XXT'3DO[FZT_6EG@=9MK/!*B;Q(AQW&00>!C(%<FVM>)(O
MAU>>)V\173W6G:F\:Q>5$(YD%R(R) %R?E/;:!QQWH ]BHJCK6I#1]!U'5&C
M,BV=M)<%!U;8I;'Z5P.IZWK.D_#_ $GQJFI2W$S"VGO;4A?)ECF*@HBX^4KO
M&T@YXYSF@#TRBN(ANM4\63>)X[#59=.GTV[:QLA&!A75%;S) 0=P+,1CIA>F
M>:EBU&]U7Q:WAV>_:$6>EQ7,\EIA#/*[%25)R0B[<X'=AGIR =E17G]S<^(M
M%U#P997^M"ZN+B]EMKUXHU5)T$;NI(QPV N<8J"^UG68I_B/##JLZ#2;6*>R
M;9&QB)MVD(Y7D%AWR: /1Z*\Z'_"46G@VVUR#4;_ %>:Z@LY9[.)(U=(\ R^
M3QDL5/<D]<<XQO>"=:L]<LKZXLM4N+R(7.T0W2;9K3Y%!B<$ YW!CDYZ]3B@
M#IZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH *J:G81ZKI-YITKND5U \#L
MGW@&4J2/?FK=% &/=^&=+N[+2K)K=5L],GCF@MU'R9C4A 1Z#(/U45)XCT.+
MQ)X>O='GGF@ANTV/)#C<!D'C((YQCZ&M2J6HWL]E]D\C3Y[SS[A(7\DJ/)5L
MYD;)'RCOCGF@#,O/"=O>:CH]X]]>*^F"8(%=?WOF !MQQQTP-N, D# I)?"%
MG+9^(H?M-RLFO;OM$X*[T!C$85>. %'&<]36W)<HCR1I^]G2/S/)0C<0<@=2
M!R01R1TK-\+^((?%/AZWUBW@E@BG:0+'+C<NQV3G!(_AH I3>#+25]!/VZ]4
M:/O$05U'F[DV'=QQQD#;MQDXQ4TGA.TDA\1*+FY$VN@K<3 C=&OEB-0G'  Y
M&<\DUI"]G_MLV'V"?[.+?SOMN5\LMNQY?7.['/3&*NT 4M)TV+1]*MM/ADDD
MCMXUC5I""Q &!T  X'0 "LS6/"J:SKNEZK+J5W$VF2-);P1B/R]S+M)8%22<
M9QSQFN@J.&:*XC\R&173<5W*<C()!'X$$4 5=9TN'6]%O=*N6=8+R!X)"A^8
M*PP<>_-4IO"NF3:EI%X8V7^R8GBMH5.$PVSJ.^/+&/?GJ!6W10!SMWX367Q,
M^O6.JWNG74T*P7*P"-DG522I(=6PPR1D=JDOO"MM?:KH]^UY>(VF"4(BR9\S
MS  VYB"V>.H(/)J3Q5XCB\*>'Y]8GM)[F&$J'6$KD;F"@G<1QDCID^U;5 &1
M?>'+'4M?T_6+D.T]C')'$F[Y#O*'+#O@H,=L\]0,5+_PHMQXE77[+5+W3KQH
M!;3_ &<1LLT8)(R'5@""3@BNBHH BMX%MK=84>1@/XI&+,3ZDFL.;PE;WFG:
MU87]]=74&KMNGW[%*_*J84JHP,*O7-:VH:C!IMNLLY8F1UBBC09:5ST51Z_H
M "3@ FJ&O>)K3PW96MQ?P7)^T31P!88RX5W(49;@ 9/<_2@"IJ/@RUO[S1I8
M[VYM(-'<26EK L?E*0NT9!4DX&<<\9JS-X;3^V+[4[.^N+*>_BCBNC$%._9D
M*PW [6 8C/3&..,U:UK68M%M4E:VNKN:5]D-M:1[Y96P3@#(   ))) 'K6=H
M/C&T\0Q:@EM8WL&HZ>P6YT^Z01S(2,KWVD$ X.<'VH >O@W28H-%MH$DAM=(
MN#<PP*V5>3:P#.3DL07+9SG/)I/^$1MCJ&OWGVV\\S68Q'* R@1 1^6"G'4#
MD9S@D^IK8T_4+;5+*.[M)-\3Y'(P00<%2#R""""#R"#5F@#FX/!=C%IVAV4E
MU=31:1-'/$'9<.R(43< , *,$ 8Y )R<Y)_!L$^I:S?C4KZ*751"'\ME'E",
M #9\OUZY'S'BNDHH RK+0HK;6KC6)IFGOYH$MC(5"@1J2P  [Y8DD^W056\3
M>%X_$\=G%<7]U;PVMS'=". )AW0Y7=N4Y&>U;U% "*"% +%B!R3WKFV\&6AM
M]2LEN[J/3=1N'N;FU0@!V?[ZAL;@K'D@'/)P0.*G\3>*;;PUX>N]8:WEO(;5
M@DJVY7*DD+SDCH2,XR?:MX<B@#"G\*V<NO:9JD<T\ TZV:VAMH=JQ;"5/ID?
M<4<$9 QTR#7@\$Z>EIKUK<3W5U;ZU--+/'(P 3S  0N .@  )R1@8KI:KWU[
M;Z;87%]=R".VMHFEE<_PJHR3^0H RH?"\!NM/N-0NI[]].7%HLP55C;&WS"J
M@9?'&3TYP!FK0T*S_P"$F;7V4M>FT6T4GHB!F8X]R6_3ZU6TOQ!/J.I+;2Z-
M>VT,MJ+J"Z<*T3J2/E8@_*_(.WTSSQ6I?77V&PGNO)DG\E"YCBQN8 9P-Q _
M,T 9.F^$[#2?"TV@V<D\<,T4D;3[LR?.",@]!C/ Z#%0VW@NQ@L-!LWN;J:+
M1I4FA5V7$CI&8T+ #&%!R ,<C)R<YK_\)Y:_V%X=U8:?=&#7+B&WBP4_<M*<
M+OYSZ] >E=90!R6IZ:_ARXUOQ+8+=WMY?- 'M\;DB5=L9<*HW,%4LV.3UQC.
M:Q=(@U71+RQ@T/Q%_;EG+<JMS;W-HID2-C\\C3IC##D_/DGIUKT>B@#-\0:)
M;>(] O='O&D6WNXS&[1G#+W!'N"!60G@F)M;TO6+K5M0NKZPB>+S9"@\T-MZ
M[5&T?+_#C.3G.3G<NKV>WU&QMH]/GGBN2XDN$*[+?:N06R<\G@8S5V@".XMX
M;NVEMKB-9894,<B,,AE(P0?8BN<TKPC-HEJNGZ?X@U&/3(^(K9UC=HE_N+(R
MEMOIG) Z&NGHH QV\-V3:UINIYEWZ=#+%;Q;LH#)C<YSR6PN,D]SZUDS_#ZP
MN-'UC3I+^^QJ=Z;UI0ZAH9-X<;>,<%5ZY.!BNNHH YJW\&P1>);?7YM3OKB^
MBM3;.TA0"4%@V3M4;>0.%P/4')S'+X%L9/"W]@K>7:1->?;)9\H9)9/.\T[L
MK@Y;VZ 5H7WB2VM=772+:WN+_4O+\U[>V"YB3. SLQ"J#V!.3V!JO)XL2"YG
MM)])U&*[BLY+SR2L9WQH5!VL'VD_,.,Y'?&1D YW5HYM1UR19-:N= ETIO)L
MO.A$Z72,JDRGS 0YSE1M.X8;)^; OQ:+?^,/"T<'B&5[>]M;[S[.]M(S ^8V
M_=S>6^=I(SE3G@^]='H&L1>(/#]AJ\,3Q17D*S*CD;E!&<'%:- %'3["6S4M
M<7]S?3D8,LVU>/0*@"C\L^I.!5/5/#<&JZ]I>K2W5S&^G+*J11, K^8%!R<9
M'"XX(ZFMJB@#F;GP58W&A:[I?VJZ4:U/)/<S@KY@+X&T<8VA5"@$'BN@M+9;
M2UCMU=W"#&YSDG^GX# '8 5-10!SEWX2C;Q!+KNEZA<Z9J%PBQW1A"/'<A?N
M[T8$9'0,,'%6;KPU:ZEI%[I^J33WHO83#-+(0K;3V4* %P>>!UQG-:&I74MC
MIMS=06<MY+%&72WA(#R$=AGC-3Q.TD*.T;1LR@E&QE3Z'% &/%X:A:_L;[4+
MJ:_GL%*VOFA56,D8+[5 !<CC)Z<X R:I7/@:PN?#6K:(;JZ5-4NGNKF<%3(S
M,X8CIC&%"XQT%=167K.OV6B&UBG\R:[NW,=K:0+NEF8#)VC@8 Y)) '<B@"K
M+X6MYO$%AK#7MYYMG;-;B/>,.&=7))QD'*C.",CCIQ5O1M$M]%%\8))9'O;N
M2\F>4@DN^.. .   /855?Q*;6ZL[>_TF_M&O)A!"["-TW$$X+(S;> >N,]LU
MNT <V_@VT,.IVB7EU%I^IW#W%U;1D#>SX\P!\;@K8Y .>3@C.*FG\*6<NMZ5
MJ,<TUNNF6[V\%M#M6/8VWCID?<4<$<#'3(.]4<\T5M!)//(L<4:EW=C@*!R2
M: *UA8264MX[WUS="YG,RK.P(A! &Q, 848[^M9OBGPM#XJMK2WN+^ZMH[:Y
M2Z06^S)D0Y4G<IX]JWZ* ,#4O"XU/6](U634[N.XTOS#"L:Q[6+KM8L"ISD>
MF*OZYHUKXAT*\TB]W_9KN(Q2&,X8 ]P?4=:J^(_$<7AN&QEFM)YTN[R*T#1%
M<1M(P4%LD''/8&MJ@#E;3P0EOK6F:O/KFJ75Y8P-;[Y6C EC)4[6"H.A4<C!
M/<FMW5](L==TN?3=2MUGM)UVNC<>X((Y!!Y!'2K,TT4"!YI%12RH"QQEF(51
M]22!^-9,'B.*;QA<>'#:3QSP6BW?G.5V.A;:-N"3U!ZXZ4 <KK>C^)X[N#3K
MNZN-7\(RKY=TL 5;T+CHY S(G8[,.0>_.>BU?PU9Z_INF+:SW&FOITRSV4MO
M&$:$JI7;L=<8P2,$5T5% '&7'PWT^\37EN]3U*;^VXXDNBTB9W1@;7&%X;(S
M@?+VQ@"K=KX+$&OVNMRZYJ=S?PVC6CR2M&!*A8,,JJ #! /&,]\\YZBHYIHK
M>%I9I%CC7JS' % ')_\ "OK3_A$-0\--JE^UG?3/++(?+\P%VW, =F,$^U7]
M3\*+JMSHT\NJ7B2:3()8=BQ_.^TKE\KZ$C QUJ=_$<2>,8O#;6DXFELWNUN"
M5\ME5E4@8.<Y;N!^-;5 '$:__9_C+4X?#,FGW<K6%[%<7,\MNR1(J#=\KD8;
M?G9@=F8]!6[XD\.1>)(+.&:\N;9;6ZCNT,&S)=#E<[E/&:VJPO$?BFW\,MIX
MN;&\N/M]TEI ;<1D&5\[5.YUQG!YZ>] "1>&%A\3W>OIJ5U]JNK9;9D*Q[%5
M22I VYR"2>O>N/UW08/"WA[0M"2^UU-,AO)+AM2MHA(]L1N8!U1#D,[GDJ0,
M?2NVAUV5M0MK2YT74K3[266.67R63<%+8)21B.%...U;% '%>$?[0;4B\'B#
M4M7TDPMO:_LEAV297;L;8A;C=G@CIR#793(\D3(DK1,1@.H!*_GQ3Z* ,'PG
MX7@\(Z1_9EK>W5S;B1I%^T;"REB6;E5'<FLN'X=6=KJUW<6>KZI;:=>3&>YT
MN*4"WD<_>[;E#=P",].G%=E10!AV?AJ.S\57VOK?7337L2120,$\L*F=N,+G
MC)[]ZHIX'@33/$%A_:E\8M=DDDNB1'E3(H1MGR<?* .<UM:AJ;6VD3WUC:2Z
MD\1*K;VS+ND8-M8 D@9!SGZ&KX.0"1CV- ',R^#(91X?W:I>C^PR#;D"/YR$
MV?/\G/RG'&*/^$+A\_Q%-_:=[NUY ESQ'\@";!L^7CY>.<UT]% '*MX'@:S\
M/6O]J7P30F1K4@1Y8JFQ=_R<_*2.,51D^&5D^G3Z<NM:K'9->B^@@5X\6\OF
M>82I*9(SGAB0,],\UW%8NH^(XM-\2Z/HLEI.SZH91%."OEKY:%R#SNS@#MCG
MK0!%_P (K"OB===AU"]BG-JEK-&K*4G5"2I;*EL@D]",]^,YI1_#_3#H6K:/
M=W-W=VVIW;WDAD*J\<S-N+(548PP!'6NLIDKM'$[K&TC*"0B8RWL,D#\S0!B
MVOAO9?6U_?ZC<7]Y:0O%;2S(B^5N #-A0 7( !)_ #)SE-\.[1_"5WX;;5=0
M-G=7!N)'_=>9N,GF$ [,8W<]*4_$.T'@*'Q:--O&M)9?+\H%-\?[[R@6^;IN
MQTSUKKY'*1,ZQM(R@D(N,M[#) _,T ,:W66T-M<8G1T*2;P/G!&#D#CFN:LO
M MI::?;:4]_=W&CVLRS06,VTA=K;D0MC<R*V" 3V )(XK2\+^((?%/A^#6+>
MWEMXIGD41S8WKLD9#G!(ZKZUL4 <E>^ X)O$=SK-AK&IZ7)>A1?16<BJEQM&
M 3E25;'&5P?H>:?K/@6TU'4;'4M/O[W1]0LH/LJ7%DRY:'_GFP8$$#J,]ZZJ
MB@#FM2\&6U]ING6\5_>VUUIUS]J@O597E\P@AF;<"&W;CD8Q^'%5O^$ M]VO
ML=8U)FUR!8+MF:,D@)LR,IP2"W3@9X P*ZZHY9HH IED5 [!%W'&6/  ]Z ,
M<>&S'H6FZ9#JEY$VGF,PW*A/,(12H#?+M((.#QS4^DZ%!I=YJ%]YC37NH2))
M<S%0N[:H50 .  ![GD\U82]G;6I;$Z?.L"0+*MX2OENQ)!0<YR,9Z=ZH>)/%
M%MX=\,WFNF"6]M[7(D6V*Y!#;3U(Z,,'J?:@#<HI$;>BMZC-+0 45BZ9XCBU
M+Q'K&BBTGAFTL0F1Y2N)!(&(*X)XPO?!YZ5K2311/$DDBJTK;(P3]YL$X'O@
M$_A0!)1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 5RWQ!&IP^$KG4=)N;B*ZL,7)2%L>=
M&I!D0_50<8YSBNII'19$9'4,K#!!&010!YNWBV.U^(%K=MJ%R_AR^T]BC,_[
MJ.Y"";'KS"0<=,].>DVMS:SI&E^$I#J=Y'/>:W;QW<3,&RDA9C$21G"X"\'G
M!SG-;B> =!C\.:;H0MV-EI]REU"&;+;U8MR>X.2#['%7M?\ #EOXA_L_[1=W
M4'V&[2\B\@H,R)G:3N4Y R>* .9T2S)^,'BF0W=V?+M;-PAF)7YA+\N/[H[#
MW-<CHDNHZ/\ "W0]<L]6NXC#JGE?95VB%XWO&1E88RQ.X\YXXQBO4&\+6W_"
M2S:]#>WL%U/ D,R12*(Y-F=C$%3R-Q[X]0:S5^'FGKX4@\.#4M2^PPW N$.Z
M+?N$GF#G9TW\_P#UJ &"[U _%FYTK^T;C["^ABY2'"8BD,VS<OR\G _BSWKC
M8=4U^/X:V?BF3Q#?RWEOJ?E&,[!'*ANS$0X"\Y!]L8& ._I'_",P_P#"4-X@
M_M"]^VFS^Q8_=[/+W;NFSKNYSG].*S/^%>:?_P (G_PC?]I:E]@^T?:,[HM^
M[S/-Z[.F_G_ZU '47L/VBQGB\R2/?&1OB;:PX[$=#[UY%HZ:EIWP/T?7M/U"
M_P#-LU2[N85F)$L"R'S4]OER<CGBO8E3$01F+\8+-C+>YQQ6)X?\*6/A[1'T
M>">ZN;$AD6*ZD#A(SGY!@#CYCUR?4G H Y0^*ET_X@SR37UU-H%Y8.]J?,S&
M+B-!)(J=SF-E(]P0.G%R>[U6TU#P]X;DGDDN;RUGNKMWNC&SLFS]VL@!( WG
MI@X0<]<Z\?@71(]$T32?)=K;1YX[BVW'+%USRQQSDDDU-XG\)6'BF.T:XGNK
M2[LI#):WEG)Y<T+$8.#@\$=010!P_C"UUZP^%/B>UUR[AN0L\;V;"4R2K 9D
MPLC%5R00>>_X5T?B2[O-#\;>'[][VX_L:^E:QN(-_P"[CG8?NG^A(*D=.0>M
M7+SP-97_ (7N-"NM1U*6.Z=7N;IYE:>8J01EBI 'RKP .GUK2UOP]9^(O#\V
MC:FTDT$H7>^0KY4@A@0  <@=!0!R^I:U?6>G65S;W,G_ !/]72WMS)+@0P$,
M5V$@[=X3(X./,]AC6\/V/B#3]?OQ?74;Z1-&KVL$ETT\T,@X;#,H)0Y!Y)P?
MK6CK_AG3/$FAMI%]$PMOE,9A;8\++]UD/8CM3- \.)H2NTFIZCJ=RRA/M&H3
M>8ZJ/X1@  =SQD]R<"@#!U6X>Y^,?A^P<GR+73;F\0=C(Q$>?J%+?]]&G_%+
M_D5+;_L*67_H]*TM?T>1]=T?Q%:1F2XTXR1RQ+]Z6"088#U*D*P'?!'4U9\0
M>'[;Q5IT%M<7=W! LL=P/(VJ2RD,N=RGH0#CCWH U9Y(+>-KF=HXTB0EI7P
MB]3SV''Z5@>'M+8ZWJ_B2>)HI=3\J.*)AAD@C!"EAV9B6;'8%0>0:L>(/#2^
M(K*VM9]5U*U2%Q(6M)$C:1AC!;Y3T(S@8&>>PQ%I/AR/P]-/?RZQK6IOY6P"
M]G\[8,Y.Q54<G ]3P* ,CP?/)%X_\=Z4I/V:"[MKJ,=@\T(9_P!5S^)IWB&;
M4C\1O#^FV^KW5M97UI=M-%$$X*!,$$KG/S'KG';!YK5\,:++I\NJZI>)MO\
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MV5PMTGD,NYY5;>&8LK9.XECZDU+#H]Y'XVDU5=0U!K1K3R9;>:8& N"NUHT
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MGMY68L61E4=V/4'K["K%SX"L[[PW=:->ZKJMR+LH;B[EF5IY ARJY*X"@CH
M._J<@%.*34=)^)]EI[ZM=WEIJ.G332Q7&W:DD;I@H !M&&(Q_,\TSXKPF7PK
M:D3SQXU.T!$4A4-F91SCKCJ/?GM6])X9AF\26.NR7]ZUU9P- B_NPC*V-VX!
M,Y) Z$=.,5/XBT"T\2Z/)IMY)-%&SI(LL#!7C=&#*RD@C(('4&@#D=4T^27X
MKZ3917]U /[#N TZ,#*1YL?1B#@^^,^F#R,_3_%&K6_AV+3Y+U[BY;Q++HJ7
M<SA9#&K,02VTC<0NW..^>M=FOA.!?$%KK1U+4'N[:U:U7>Z,K(Q#-G*9R2 >
MHQT&!Q5%_AUH\VA:CI%S/>W$%]>-?,[NJR13L=Q>-E4;3GZ_E0!-X?L?$&GZ
M_?B^NHWTB:-7M8)+IIYH9!PV&902AR#R3@_6L;XK"4P^$1"R+*?$MGL9U+*#
M\^"0",CVR*Z?0/#B:$KL^IZCJ=RRA/M&H3>8ZJ/X1@  =SQD]R<"H_$GA6W\
M3M8&YOKVW%A<I=P"V,8Q*F=K'<C9QD\=/:@!]M%KB:QNU*[LY; VY5?L\30D
M2EE'.YVSD=,8[^HKC!=ZI8^/9?"EYK=RUI?3)=6=Z93YD:J"6M<XQN/!!/.P
MD]=M=H/#\DE[;7%WK>IW:VSF1(9/)6,M@@%@D:EL9R,G&0#VJE?^!['4M#73
M+F^OV9;S[<+Q6C%P)@VX,&"8&.@P.@ Z<4 4+V]U#6?%NJZ%;221PZ?:0,/*
MO&@<O)O._(4E@ H '3.<@Y&*>G:AKS:OH/A37[^+[8UC/<WMQ92%?M!1PB(&
MP"IPVYL8.5[#-;&L^!+35]3M=575-4L-5@A\AKVRF6.2:/.=KC;M(SST%+JW
M@+3-4M--1+F_LKO369[:_MI\7"EOOY9@=VX\G(YH P_$7]M^'/#MONUZ:YG7
M7((XI5X86TDJ@12==Y )^8\UI2W%W)\4;O1OMURMA-H7VCREDQLD,Q3<IZJ=
MH[5H7G@S3[[PU)HMQ=7S^9(L[7C39N#*I!63<1C(VKVQ@8QBBP\'6UEXB37I
M-2U&ZOQ:?9'>>5<2)N+9*JH .<<# XZ9)) /.K"?4-)_9S&K:?JM[!>+!Y@<
M.&Q^^((&X'&<G)&#GO79^);N\T/Q=X=U)KVX&C7<QLKN#?\ (DKC]T_L-PVG
MMR#4H^'.F+X1N?# U#4_[,F/"&5"8TWE]BDIP,GKR>V:V]9\/VFO^'9]%U)I
M9K>9 KR9 ?(((8$# ((!X% '+ZIK5]9:;;WEO<R?\3W6([6U,DN%AA;."A(.
M-X0D'!QY@]!6KH-AX@L/$5Z+RZC?1IX5>WMY+MIYHI0<-AF4$H01U)P?K6CK
MOAG3/$.@-HM["1:87R_*.QHBOW60]B,<5'X?\-)H09I-4U+4[AE""XU"?S'5
M/[JX  '<\9.!DG P 8_C75;[1[^RNY;34;C05AD%VVFN1-!)E=DC!2&* !^G
M'<@X%85_*NJZS\-I++67NEF^U[=051OD'V<Y;!& W7J.#VXQ7>7NCM=:G'J$
M&I7EG,L)A*P["CJ3GE64\@]#_B:RXO NFVTVA/:W-Y NB^8;5$9-I:0$.S94
MDELGICKQB@#G+74]3L],\:::_B%X?[,O8X[;4+T>:\:2(C%>!\S?,0O!.2.M
M:7AW4KU?B'J>D,;Y=/\ [-ANXH;Z3S'1B[*2"22 0!\I/'H.E6[SX>:9?Q:U
M'<7VHM_:TT=Q,PD13')'C8R$(,$;1UR.*LVG@RWM->.MC5=4EOVM!:R22S*1
M( 20Q7;C(R>  OMGF@#SD?\ )M,?_7RO_IP%>UUR/_"O-._X0L>%/[0U'^SA
M() =\?F?ZSS<;MG3?ST]NE=9&I2-59V<@8+MC+>YP * /$M*AUC3?@\OB73-
M?N[:;39+J>.SPGV>1%N9-RNN,L3SSGCC'K77-J6K>*]5URPLI)+4V,,"Q".\
M,#1R2Q"3>P"G=RV,'CY3QS6O:^ ]/M; Z6+V]DT<S&?^SI&0Q9+[RI.W>5W'
M.TL<]#D<4NL^!++5=>76[?4M3TK4#&(9I=/G$?GH.@<$$''8]?R% &OX?&J+
MH-FFM2V\VII'LN9+8Y1W!P2.!Z<\#G-<):77BGQ3X<B\0:->0VUV;IW3SKUA
M (DE*F)X@A'W5.6^]GG(' ]&L[2&PLXK6W4B*)=J[F+$^Y)Y)/4D\DURT/PY
MTRUU>YN[74-4M[.ZF,]QI<5SBUE<]25QG![@'!Z=.* ,@KJ^J>*_&VG-XBU&
M"VL8K:2V$!16C+Q.V =O3(^IXR365<W5UXBT;X9:E>WERMQ=W<8F,,A0,WDN
M2^!QNR.O;)QUKO8O"D$.K:SJ4>H7RSZNB)<#,950BE5VC9Q@$CG/O5/_ (0'
M3UT#2-(2_P!0C32)UFL[A'02QD @#.S!&&(Y% %6VFOG^)FJZ++J=V]C_8\4
ML:;@IB9I&4E2 #G"]3D^]</! 4_9FOIVGGE::VD)$LA8 BX;IGIGOZUZE;>&
M+>U\3R:\MY>/<R6JVC1R,K)Y:DD#[N[.23G.>:RU^'6F+X3N_#2ZAJ8TRY8_
M)YJ$Q(7+E$RO R3R<GWH BU#4;[4?%Y\.VY988-,2[81W36[NSNRY#*I.%V]
M!@9;G-9D&H^([.]\,^$]:U&)KV^FN6GO+5_G>") ZIG:,.=R@D ' )')S6]K
M?@:SUNXL+TZEJ5EJEE&8H]0LY5CF9#U5OEVD=\8I=0\":;?Z?80?:KZ&[L)C
M/;ZC'-FY60_>8LP(;=W!&,8&  * ,GPC:&R^)WC6'[1-,HBL"AF?>R@I)\NX
M\G'J>:/&=F;GXA^"%^U742R2W:E8I2H&(&.0/7DC/IQ6]H_A.#2-<OM8&HW]
MU>7T<:3M<.NUM@(4[54 'D]..>E3ZYX:M==NM-NI;F[M;G3I6E@FM7"L-RE6
M4Y!X(./7T(H Y_2[F[\7WGB=!J5W8G3;YM/LQ;R;?+*(I,K#^/+,>&R, <=2
M=3X?Z]=^)O ^FZK?HJ7<JNDVT8#,CLA8>QVY_&I&\(V\>KWFI:?J%]ITM\BK
M=K;LA68J,!SO5L/CC<,9[\\UKZ;IUII&FV^GV,*PVMO&(XHQV _G]: +5%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M&NI+[0]/NYL>;/;1RO@<9903_.@"[1110 4444 %%%% !1110 4444 %%%%
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M\SPD*%P"1C;M !4C![@GFM;3=&M],FNKE9)9[R[*FXN9B"\FT84?*   .@
MY)ZDUCIXOGF\4:AH%OHL\MW8QQRR,)XPA5_ND$D']*V=+U&>_P#M27.GS64M
MO+Y921E;>"H8,I4D8YQ]0: .5\9Z?>ZOJED/["UJZBT^9+FVGLKNUB3S0.&Q
M(VXD9(YXJNC>(#?6]W<^'O$MT]L6:));^Q"*Q4KNVJP!(!.,YQ7H5% 'F5[I
ME_J&B0:7<>$?$!6"[^V)<#4+(3>;N+;M^_KDGD<]NE6MFLGQ''KQ\+>(#?):
M?8P3>V.TQDACD;NI8 Y_IQ7H=% 'E;Z%>2>'+W0G\)^(S97MR;J8?VA8[BY<
M.<'?P"P!Q_2M"[CUFYUB#6(_"WB&UU*.V^RM<PWUCF6+=NVLK.5ZDG( -=]<
MW4%G$);B58XRZH&;^\S!5'XD@?C4$MU>IK%M:QZ>9+*2)VEO/.4")AC:NSJ<
MY/(Z8H X*_TZ[O\ PT^@GP3KD-E++YTQBU"S\R5]^\LS&0DDL 2?Z<58NX]4
MO-<L=8D\'Z^M[:0F#?'J-HGG1DABK@2<C(!XQ^5>A44 <-KEYK>O:7)I\_A#
M7(()<>9Y%]9J7']TDR'@]_7ITJ74-2UW4M'N--N/!VL^7<0F&61;RRWLI&&_
MY:8Y&>W>NTJ*ZDEAM)I;> SS)&S1PA@OF,!PN3P,GC)H Y[P/93Z7H2Z:^G:
ME96]KA+=+^XAF;9Z!HR>![\_A4-_\/-'U";66DN-0CAU<9N[:*Y*Q,^W;O Q
M][ 'J..E=)8S3W%A;S75L;6XDC5I;<N'\IB.5W#@X/&15B@#GHO"%G#JVG:D
MM[?FXT^W:VAWRJX*-C=NRI))('?C'&!55_A]HTVDZIIMR]W<6^I71O9?,D 9
M)R0?,0J 5/ ]N.G)KJZ* .:LO!5I:ZU9ZQ-J>JWM]:0-;I)<W.<H2#A@H /0
M?7OFM'Q!H%GXDTLV%ZTR)YB2I)"^QXW1@RLI]016I10!@P^%+:#7UUI+Z_-X
MMG]B!>16'E[MW.5.3NYS_3BJ#_#K1)?#<NASO=S6KW)NT=I0)89BQ8NC*!@Y
M)/X^E=;10!D:#X>@T&&15O+^^GDP'N;^X,TK 9PN>P&3P .I/>JOB/P=I_B2
MZL[R6>\LK^SSY%Y8S>5*JGJN<$$'T(_G4OB_Q$?"GAF[UK["]XML 6C20)P2
M!DD]LD= :W <@&@#G[KP;I5WI-K8.;D-:SBY@NQ,3<),#GS-YSECDYSD'IC%
M2?\ "+VK0ZAYUU=37=_"+>>\<IYOEC.$7"A5'S-T7J2>O-;E% ',GP18G3]$
ML?MM^(=%D22SPZ95D4JN3LYPI(Y]:BN? &F37VJ7$%YJ-G'JJL+VVM9PL4S$
M8+D$$AO4@C/?-=710!S*^"-.2+0HX[N_1-$P;,>:&P=NWYMRG/R\8Z>U6XO"
M]G;^(+_6K>XO(;F^5?.1)?W9=5V!]I&-P7CG(]LUMT4 <M#X T>+PM!X>+W3
MVEM-Y]K(T@$MO(&+!D< $$,2><]<=.*T(/#D,<MQ<RWEW<7\\ MC>2[/,2,$
MG:H50HY)/W>3US@8N:I=7MG9B6PT\W\WF(IA$RQX4L S9;C@9..^*F>[A2X^
MS!@USY1E$(/S%00,^@Y('- '.+X"TY="TK1EO;];32[A+BU =-RNARF3LY )
M/!_'-6;CPA:7:74%S>WTUE=3BXFLW=#&[!@W]W<!E02 0/S.9?"GB+_A)]'>
M_P#LC6A2YFMS$SAR#&Y4G(X[5N4 175M!>VDUK<Q++!,ACDC<9#*1@@_A6%I
M_@ZQL([" W=[=6FG.'LK:YD5D@(!"X(4,VT$@;BV/P%)XE\6PZ#X=?6;>V-_
M EPL#>7(%"L91$<D^C'' /2NCH Q;?PU;VWB:ZU]+R[-W<Q+#*C,GEE%)*J!
MMXQD\YSS5G6=%MM=M8K>Z>>-8IEG1H)3&RNN=I!'/!.:T:AN[JWL;2:[NIDA
MMX4,DDCG 50,DF@#*A\,P_VK;:C?7][J-Q:!OLWVDQA82PP6"HB@MCC)R<$X
MZUF1_#K1X-9N+^WN=2@@NI?/N-.BNBMK-(>2S1CKD]1G![C'%7;'Q'>ZI9)J
M-CH5Q)I\B[XFDE2.69.S+&>QZC<RGVK2T75(]:TBWU&*&6%)@2(YEPZX)&&'
M8\=* ,;4O >F:AK\FM1W>IV%W.BQW7V"Z,*W*KP!)CK@<9!!]ZN7?A/3;K5=
M-U%3<6TVGPFWB%M*8U:(X_=L!U7Y1TQ6Y10!@6_@_38I]:>9Y[I-9_X_(9RI
M1_EV\ *"/EXZ_K2:?X1L['[ LEY>WL.G<V45TZLL!VE01A06(4D L6(!KH**
M .9'@BQ%AK=G]MOS#K3O)> NF6+KM;'R<94 <5N:=8IIFFVUC')))';QK$C2
M$%MH&!G ':K5% !114<\C0V\LJ1/*R(6$:8W.0.@SQDT 245D^&];/B#1DOG
ML+BPEWO%);7 &^-U8J1QUZ5K4 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<M\0DT^X\*/8W
M\,DIO;B&VM5C?8PN'<"-@W\.&P<\\ \'H>IJEJNE6>M6#6=[&7B+*ZE6*LCJ
M0RLK#D," 010!YUH]UK/AO6-9T_Q!_I^MKI3SZ?JX'%Q!$/]65_@8,P)_O9R
M2<"ELM;G\+?L]VFKV9!NEL8W61ANQ)*X!<^N&<M^%=_;Z+;Q7C7D\LUY=&$P
M"6XVDK&3DJ H  ) SQDX&>@K(T3PU#9>';CPEJ%M]ITM1(D#-RLENS$A&/9E
MSM]P 1SG !@ZYI$6G^// 4D5W>3EKBX5S/<O*)#]G;Y\,2 >O3 Y]AB]J<TE
MK\:-"\DG%[I5Q#./548.I/T)/YFKMM\/=)MY=,=[O5;@Z6Y:S$UZY\H%=NT8
MQQCCZ<'(XJU:Z0]YXKN/$5U&R;;3[%9Q'AA&6W.Y]"QV@#J HS@D@ '15P&F
MZ?!_PNC79=]SN&G6LN/M,F"Q:0<C=@CC[IX'I70^$="?P]H[V33W,D9G:2)+
MF8RO$AQ\I;N<@L>P+$#.,U+/X9L)_$7]NAKF*^, @8Q3%4=025++T8@DD9H
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M:A;2M/\ !,6IZUIVG:M?S7<B--;6TC3NQ^52P5FY/ ).<\4 97AG6G\5PZ#
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MQN+AOBE-8'4;B>RE\/Q7!43-L:0S,ID49PI( ^[BM"]\ :+>Z]-J^Z^MIKD
M7<5K=O%%=8X'F*I^;CCW[U;U'PEIVHZS;:J9+NVNH(3;;K2=HA)#G/EMMZKG
MGC% 'F,YFU;X>>')K^[O+B9/%*0B1[J3=L^ULHR0W)   )Y';%=I>&XM/BEH
M5A%?7GV*;3+DO;O<,RDH4 8Y.2W)Y))J\GP^T*/P\=$C6Z2U^TB[0K<,'BE#
M[PR'/RX/H!5X^%['^V['5O.NOM5E"T$),NX;&QN#9R6)P"23GWH Y"SO;W2=
M4\3>%;B^O)KVXD2;299KEW?R9OD&TDYQ$P8G'.!5V>2[U'Q?J'AJ-Y7M]/T^
M!HU?4YK>5RY?=(70%G(VJ.3@'USQUD^B:?<Z[9ZU+ &OK.*2*&3^ZKXS_+CZ
MGUK-\0>"M*\1:A;:C.]Y::A;*8X[RQN6@EV'DH67J/\ Z_K0!9\*6VJ67AVV
MM-:U"+4+^#='+<Q$G?@G&<@?,!@'W%/\5&5?">KR07$MO-'9RR)+"VUE94)!
M!^HK.U#PG%)<: -/DN[8:7/YBLERP4J6!<2 G,C/@C)_O,2<\'>U*QCU33;F
MPF>18;B-HI#&<,5(P0#VR,B@#S>2YU*XT[X8E=7OX6OXHTNC',<RYM2Q+9SN
M.>YSZ]:W?!CW%IXL\7:(U[=W-G8SVSVWVN=IG3S8MS+O8DD9' )XK2'@O3A%
MHL8GO NBX^P_O!^[PNT9X^;Y>.<\5=T_P]::;K6HZM#+<-=:CL-SO<%6V#:N
M!CC XX_'- &3XA?S_%&GV*WMW*QM99#I=I(T)?E0)GE5EVHO(QSDMP"17)^'
MO$NHWGAWP1I]_?SYU2\NX+FZ\TB1UA,FQ-_!!8J@W<$X/<UWNI^%=.U76[75
MY7NX;VWB,'F6UPT1DB)R4;:>1GFLT_#?PZ?#O]B>3<_94N#<P-]H;?;R;BP,
M;9^3!8]/4YS0!E^(YKSP7HFJ2PZY/)%=WMLD0G8R-IT<KA'8.Q)(^\1G@&KF
MNPW'A"VU?Q!9:I=30Q:7(4TRYE>96F3+"4,[$CC@@<'K6M'X.T@:#=Z/=I<7
M]O>#%S)>SM-+-Z9<G/'&,8QVI-$\':;H<$D2RWM\'B,&=0N6G*Q'_EFH;A5Z
M9 '.!G.!0!R>KW-]HOA3PWXFL-2O;B[EFM!=))<.\=XDV PV$[5.6!7:!CH.
M*ETRPN]5\=>*X;G7=86VTR\M)K>&&Z*CF(.RD=T))&WIS],=-I_@S3-.CM($
MDNI;*RD\VTM)I=\<##."O&XXR<!B0.V,"K6G>';33-9U'58)KEKG42K7/F."
MK%1M4@8XP../QS0!Y9KLS^)_@1?^)[N\NC>78,Q1+AQ%&HGVB(1YVX"@#D9)
MYZUU/BJ:6:_UR.VU&^GFM=*#I;6LS6Z6+8=A*[JPW,V!A<$X7I@YK0G^&>@3
M6FH6*R:A#IU\_FRV,5TRP!R0257MDCIT]NF+<_@31KC4;B]9KY7N;9;:Y1;R
M0+<(H(7S.<L0"1DGZYH Y22^U/4O^%9RMJU[ VJ6^;SR)-HE)M2Y)&,9SGZ=
M1R*JW.OZAX4T_P =6L.H74L.G7MI':SW<IG>W6X6/>=SY)"[R1G-=K;^!=*M
M4T589KX#1L_8RTY;;E=ISD'/R_+CH!T J;_A#=)>767N%EN5UD*+Z.9\K)M7
M:N  -I &!C'Y\T 9VJVDWAA+_7[+5KJ2"'2YB-.N9GF6>9%+JX9F)!PI! ZC
MZ5GZ58ZY=_\ ".Z];:I'% ZQO>-)J,LR7B2 <",J$1MQR-N,$XZ5T&@^#-,\
M/HRPRWUV/+,*?;KEIQ%$>L:!N%7@=!S@9Z56T/X?Z)X>O1/8O?\ DQN7@LY;
MMWMX&/4I&3@'D\G.,T 3^.K#4+[PA?\ ]DW5S;:C!&9[=K>9HRS+SL.TC(8
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M;NY5;R"X%P@G;;+BVW LN<$@\YQF@#OZ*\N\.6DTD?B?6)M2U6XET76;W[)
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MU-O,R&U544I(%!&2S%CD]1QT%2V\TZ_%'3;4:E<7-M/X?>63]ZPCF<21@2!
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M>-[@HR,F=K9!ZD$^^ !0![71110 4444 %%%% !1110 4444 %%%% !1110
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MG!8<<?6N@H XG3?!T>HZ/-9:K)K#Z<UPD]M;W]Z7GC*X.6=23C< 0I)QC/?
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;%I+6]#$2,,A50KT/'4_G6'<:5#J%Q\39I9KI'MI!+#Y-P\021;52'^4C)!
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M=S'>Y.XDG=GD\GGFC6? N@:_/:7%_:RM=6B>7%<1W,D<NS^Z75@S#KU/<^M
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M%E43QB=8F2/G++G[QS@!1R2:YBX@34/'5UX6D:S2TM-+@>SM+N%I5D#,XDD
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M^T[>,W#7#DE'G*LF,XVD'GCGO7L^I6$.J:;<6-QN\J>,HQ4X(SW![$=0?44
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MSUS0![51110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %4M4TFQ
MUNP>QU&V2XMW()1LC!!R"".00>A'-7:J:GJ=II%B]Y>RB*%2JY/=F("@>Y)
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MG(/;&":U]&\">&?#^HO?Z7I4=O<,6((=V5,]=BDE4S_L@<<4W1O%3WWB2_\
M#NHV(L]4M(EN (Y?-BFB8X#JV%/7@@@?C724 9FG^'M*TO4+R_LK-8;F\<R3
MN&8AF.,D G )P,X S@9J/5_#&DZ[<VUQJ,$LLMJV^!DN98_+;^\NUA@^_6M>
MB@#(M?"^CVFIIJ2VK2WR*42YN9GGD0'J%:1F*_A3+GPGHMW?7-Y):.LMVH6Z
M$4\D:7  P/,16"OQQ\P/''2MJB@#+N/#VEW.JV>IRV[?:[)2ELZ3.HB4C! 4
M$#! &>.<5 GA#0TMM3MOL1>'5"6O$DFD<3$C!)W,<'@<C!X'I5[46U-3:?V;
M':N#<*+K[0S#;#SN*8'+], \5=H Y^S\$^'K"\L[N&P)N;-62":6:21U!QG)
M9B3T&,YQCC%3Z?X6TC3&M3;6\F+0$6R2W$DBP9&#L5F(7@D<=B1T-;-% %'5
M]'L==TZ73]1B::TEXDC$C(''H=I!(]JKW7AK2;[3;?3[FV>2"V=7@+3/YD3+
M]UEDW;E(]0:UJ* ,D^&M*;3KRQ>WD>&]&+HM/(9)AC;AGW;B,<8STXZ5=T_3
M[;2K"&QLT9+:! D:-(S[5'  +$G JR>E<EHWB'6]<TOQ$;>SL(]2T[4)K*WC
M>1S$Y15(+-C/.X] .U &S>>'=)O]8M]6N;0/?V\?EQS!V4A<YP0" 0#R,YP>
M1S5,^"/#YTF[THV4AL;R4S7$)NI2)')R2?FSR>3ZUO1E_*0RA1)@;@IR,]\>
MU5K_ %.TTT6YNI0AN)TMXE[N['  'YGZ T 9.L^!_#OB VCZGI_GRVB[89O.
MD615]"X8,1[$FMNUM8+&TBM;6%(;>%0D<:#"JHZ "IJYS6?$%YIGB[PYI,=M
M UKJLDR22LYWH8XF?A<8YP.<^O% $%C%J>O:_!?:OH8TV'2WE^R^9,DKS.WR
M"0;?NKLW<'DEA_=YT/$'A+0_%*0+K%@MP;=MT,@=HWC)ZX92".W&:VJ* ,*Y
M\&^'[NPL+&33E$%@_F6HBD>-HF[D,I#<YYYY[YJ!_ 'A>2UOK4Z2BP7[B2YC
MCE=%D(QV## X!P."0#7244 ,AA6"%(D+E4&!O<N?Q)))_&LW_A&]+_M>YU40
MS+?7,7DRS+<R LG88#8 '.,=*L(VI_VU*KQVO]E^0IC<,WG&7)R",8VXQ[YJ
M[0!SX\$>'QH]KI(LI!86LHF@@%U*!&X.01\V>#R/0UOJ JA1G &.3DTM5M1U
M"UTK3KG4+V58K:WC,DCL> H&: (?[%TW.I'[)'_Q,O\ C\X_UWR!.?\ @( _
M_74=]X>TO4M"&B75KNTT(L?V=9&1=B\!3M()' X]JT4<21JXZ, 1FG4 9+>&
MM*?4;'4'AF:[L4*6TK74I,:G@C[W.<#.<YQS3+;PIHEK:ZC:QV6ZWU)VDNXI
MI7E69F^\Q#$\GCGV'I5Z?4[2WU&TT^24"ZN@YBC[D*,L?H./S%8_ACQ!>:UJ
M.OVMY;00'3+[[,GE.6W#8K9)('/S>@H ?I/@GP]H=G<6FG6!@BN$\N0^?(S[
M/[H<L65?8$"E_P"$+T'^SK"P^R2BUT^59K2,74N(77[I'S=NWI6_10  8&**
MYRZ\32S>)9?#VC6T=S>V\2S7DLTA6*V5ON@X!+.W4*,<<DBE?5M<MM32PN-,
MM7$EK++%=1SL(V="N$8%<J2&)[_=_( Z*BL+P;KLWB7PAINLW$4<,MW%YC1Q
MYVKR1@9^E;M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M[P<J-V3G)SCK6[X_OY;:Y\,V3L4T_4-6CM[Q@<!EVDK&3Z,P /J!CH:WM/\
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M)!ZXXSUQQTH \JTS3K:P\&_#36;=7349-0M+=[C>Q8Q.KAH^OW>G'_UZV8[
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MSA2<GD =30!T%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M7B_2M8LXI397"6=O!*-WD6GE#R]F>5S\S9'.>>PK!M;K4+SP!\.YM2E>:?\
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MDN)(R^6)_#H*Z175B0K X.#@]*\:U*3_ (1R?XH2:0@MEB;3V(@7'EHZ#S6
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M,^$TN8_/9K=0W&XK]E.1GKC./QQ0!Z3:ZM:7]W?VEI*LDUDXBFQR%<KNV_4
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MQ)#+%-A2VPC@J000?>L:.RLXOB]K]S'86KW4>DV\\.Z)<F4O(,@_WCP,]>E
M'HFY=VW<-V,XSS2UXR4AO_@6OB2-L>(8E-U]N4?Z0+H2X(W=>3\FWI@@8QBO
M2]>O-1M/ ^I7MNF-3BTZ25%49Q*(R>!WYH V@REBH8%AU&>1064,%+ ,>@SR
M:X/P]IWAJ^TOPIK]M<%+M8P(Y8'&^ZD=,2++QESD%CGH5)/0USUA%;Z_\)O$
M.KZFJKKT$E[+-<GB:UGB9C&%;JNU0@ ';ZT >ND@=2!5+5-7LM&TYKZ]F5(
M54'/WF8@*H]220*\WL]/76O'OAQM=M1)<7?A<R7L,F=KR;XLAEZ$9)X/''M6
M'=V=K_PJ[5K1H(WM]/\ %+6]JCJ&$,?VM!M7/08)'T- 'LER=3&J6/V8V?\
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MA9U19HRSC*@,,D>HH:XA681--&)",A"PR1]* ,^]\.:1J-Z;RZL8WN&C\IY
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MA:X\H3L2,EF.1G&>3Z8JQH&GW%I#=7E]'"FHW\WVBY6([E0[0BH&P,[451G
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MFI+O0]-O]0MM0NK1);NUSY$Q)W19Z[>>,]\=:N">$S&$2H90,E-PW >N*DH
MQ]<\*Z#XE\DZSI5M>F$_NVE3)7VSUQ[=*=JGAG0]:TR+3=1TNUN+.''E0M&
ML>!@;<?=XXXK26>%I7B66,R(,L@897ZCM2B6,@D.I ZD'I0!0/A_1VT/^Q#I
MMJ=+V;/LGE#R\9ST^O.?7FJ]CX2T#3=&FTBRTJW@L)\^=#&N!)G@[NYXXY[<
M5K27$,,8DEFC1"<!F8 ?G3BZJ5!8 L<+D]3UXH K6^FV5IIJZ=!;HEDL?E"#
MJH3&-N#VQQBB33+*72O[,>W3[#Y0A\@<+L QMX[8XQ3;W5K#3]*N-3N;J)+.
MW0O)+N!4 =?Q[8]:GM+J.]LX;F+[DJ*X!Z@$9YH S?\ A%M$V6*?V?'ML/\
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M* H;GH>:YZ=+.'X:_$Z&18$5-6O=B,  K%$VX'8^E>J:?X?TC29!)8:=;V[
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MB;^\HZ ^XJ0>'='6[:Z&G6XF:43,P3[T@Z.1T+#L3R,4 <+;QV</B+XH12I
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MM:6I)+111A58GJ3Z_C0!Q/B*SM+35? ^H>&XH8I)KY+8?9U $UD\;,X./O*
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M)?#.JV>OZ\UEJ-OJ4SW<:B);B.59B8RA*ES\H15QGCY1Z5["F=BY))P,D]:
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M'?,)(L[Q_%@YZ],>PH ]0AFBN(5EAD22-QE71@0P]014-[=P6<&Z:ZM[8O\
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M0G/6@#U:H#?6BW8M#=0BY(R(3(-Y'KMZU2T.%;7PQ8PVEQ-=)':JL,UR?GE
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MANK>X>1(+B*5HFVR*CABA]#CH:HZ7<SQ60&JZC8S7#32*KP?(I&XX7!)^8#
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M&V><)U*;O3=G&?:IC?6BW(MS=0"=EWB(R#<5]<=<4 0V^CZ;!:RPQ:=;1Q7
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MZPS*Y7ZX/% %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "N4^)@0_#3Q$7"G%C)C/8XKJZ@N[
M*UOX/(O+:&YBSGRYHPZY^AH \_O[C[+XK^'ZSA4TF6&4*V,1_:C$OEY[9QN"
M^Y-97B&P5;WXFB&)&TMM'$TJ$ HMYY3G('0-M"DXYY4UZ@^DZ;+8&PDT^T:S
M/_+NT*F/_OG&*!I.FBP^PC3[06><_9_)7R\_[N,4 9/@W2=-L?#NFW=G96\4
M]Q8P>=-&@#RX0$%FZMU/)]:PY+*TOOC9<)=V\4ZIX?B(250P!\]QG![X/ZUW
M-M;6]G L%K!%!"OW8XD"J/H!Q4#:3IKW;W;:?:&Y<%6F,*[V!&""V,D8H \;
MTG45TOP7X.DNKJ2TT6'6;R*XG0*5A.^80EMP("AL=1@<'L*W-9C\*:9HOB?4
M5O[C6(=0DM?MBI<QK!YI<*GSQJ F>"_7C&1R,^C)HVEQV4MDFFV:VDO^L@6!
M0C_5<8-+%H^F0::VFQ:=:)8,"#:K HB(/7*XQ0!PN@7J?\+AU5)=0LIII](M
M\BVPJLXDD^4#<22%[]<>E<Q:&(?!3PE-(4\M-<A+.V,*OVQLDGL*]ACT?2XB
MICTVS0K#Y"[8%&(\YV#C[OMTI%T72EL9+%=,LQ9R'+VX@7RV^JXP: .,G@T_
M4OC-9!X[>Y@'AZ1T! =,BX49 Z'O5KX6!(_#-_;Q +#!J]['$B]$43-@ =AS
M75?V/IGVD7/]G6?GA=@E\A=P7&,9QG&.,5)9Z=8Z<KK96=O;*YRP@B5 Q]3@
M<T <%#JNEI\0O&&E^);BW@%Q;0+:_:Y!&LEH8R'5"2.-Y?..Y]N(]/DM;'XD
M>';*)9(]$_L%X](\XD@RB0;L%N=QB"D9YVGW-=[?:/IFIR0R7^G6EV\)W1-/
M"KE#ZJ2./PJ2]TZRU* 07]G;W408,$GB#J".AP1UH \[TWPS'KC?$+02 -$N
MKM5M,#*QSF(-*5^DA4\=P?>M'P9J5]XGL8+V\@*7VD0/92+(N ;T?+(?P"K@
MC_GJP[5W%O;P6D"06T,<,*#"QQJ%51[ =*6*&*$,(HT0,Q=MJ@98]2?<T >0
M>&CH'B+PAH<6I^(+N/5K"[1WLE:%+E;U6.X8V;SN8DGGD$Y/!K:\-Z+H]Q\0
M?&[7&G6DWV:\M)8@T0;RF\A6W*.QW<Y')(KNTT;2X]3;4TTVS6_88:Z$"B4C
MW;&?UIUOI>GVES)<VUA:PSR??ECA56;ZD#)H \<75=,DTSP)>6-S:VFG_P!N
M[X;=Y=\\:-YV]I9">I)Y&.,XR:U-3>WDOO'VBO>:?<R:KL2*2XNXX_(9H0 K
MAB&VIE6!4-U(Z@UZ4N@Z.@8)I-BH:83L!;H,R#HYX^]R>>M<A+X5U9]5OGOM
M!\,:Y'<W+2QWE[E)8T/W4*^4X.T  8(SCU)H S;E[/PQXI\+Z==ZFMAI8TEX
M;:\B2)8GN=R[R2RE5+*,Y]R,\G/6>"=-TG3-,O8M%OI[RSDO9)O-=T9 [8+"
M,H NP'/ Z'<*M6'A?3+?P[#HUU96=U:(S/Y+P*8E9F+85#D!06( [# K7@@A
MM8$@MXDBAC&U(XU"JH] !T% '#Z/):P?%_Q0DKPQRRVEB8E8@%SB3.WU_"N'
MM+.RB^"NB:DD$(O%UF-UN-HW@B](X;KTS7M4NFV,]U]IFLK:2X\LQ>:\2E]A
MZKDC./:H/^$?T7[.+?\ LBP\@-N$7V9-H;UQC&: /,O&E_I]Q:?$.&V>WMID
MM4CO#<ONDN'$.4$:$@(H!Z\Y.>!C-:,][8MXR\ WDUQ;F%],NP9G<;68)%GG
MU&#7?OHNE23O.^F6;3/%Y#2- I9H\8V$XR5QQCI3VTO3W2V1["U9+4@VZF%2
M(2.A3CY?PH R_',,,_@+Q L\:.@TZX;#@$ B-B#SW!KDX[74YM&\&W?A[4;2
M/6;;104LKQ28KJ%DAWC(Y4@A.1Z\\5Z-<VUO>0-!=013PM]Z.5 RGZ@U4DT'
M1YHH8I-)L7CA!$2-;H1'GKM&./PH SO ^H1:IX/L+N'3SIZMYBFUW;A$RNRL
M%/=<@X]L5P^D:!X<OI/B)%J5E9F&*_DR71?W"&%"67^YR"<C'(]J]6BBC@B2
M*&-8XT 5408"@= !V%<=X>\(O;ZWKU[K6FZ;,+Z^^U6S\2O&-JKM.Y!@_+G@
MT <OX8O?LP\)V6I/';:Y'X?:1[K4)#LCMV=1M"$C=(0JYR1@#G/2LB%K2?X
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M;6'_ #ZF!3%US]W&.OM4BZ;8)IW]G)96RV.W9]F$2B/;Z;<8Q[4 <3'/I_\
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MFF;[)#<(',DHY&\,68!21\Q//%<]J-Q93_#CXF0F[M[J0:J\Z,-O.1" Z@=
M3G!'7U- 'M UW2#<W-L-5L3/:ION(OM";H5]7&<J/<U-9ZG8:C9?;;*^MKFT
MY_?PRJZ<=?F!QQ7#:YI^FK\3_!,:6ML$>UO<J$&&"K&RY'?!R1[\US-_,]CH
MWCIK17%I;>(X)KJ.W4$B#]R92%P1V.<C! .>,T >NV.KZ;JAE&GZA:79B($@
M@F6383TS@\50UWQ7I'AVZT^UU"\ABGOIA'$KR!<#DESGHHQU]<"L30?^$<U7
MQ;'K>F:_+JVH-8F%VBDB*)#N# 2!%7!W= >>OH<,^($\5KK?@NXN)4A@36/G
MDD8*JYADQDG@4 =9:ZOIE[<O;VFHVD\Z#+Q13J[*/< Y%-76])<*5U2R8/(8
ME(N$.YQR5'/4>E<7XIGD\*^*;+Q;IMLUU;ZI"-/NXHAS)*03;/\ BWR9]&%4
M_%>BV.G2^ K2^6"4_P!J[+B611B9WCD9\Y[,Y)QT.: /0]/U73M6A:;3;^UO
M8D;8SVTRR*&]"5)YIMGK.EZA<26]EJ5G<SQC<\<,ZNRCU(!R!7E7B?2KBRU_
MQO+X9MRD#:%$+N.U7:#<;R2 !QN\D$\<_,/6NBT6X\+>(M>T'6-/\03ZC?V\
M,@MX(VA4PQ,GS"5$12%& !NZ-C'6@#O9IXK:%YIY4BB09=Y&"JH]23TJM;ZQ
MIEW;37-MJ-I-!!GS98YE98\#)W$' X]:Y3XC7,EE+X8NIN-)BUB(WS'[J#!$
M;/\ [(<@Y/&0*/L[GXS)=6!'DG1B-1*'Y2?,_<[O]K&['? /:@"/0_$5_P"+
MKJ2[TC7+.$6NI21/8%4D$MJC["_'SAFZAL[>0,'K79WNH66G0B:^NX+6(G >
M:0("?3)KD?A;(DGAW4BCJP_MF]Y!S_RV8_R(J#5M;MM$^+MJVMW$=K87&D&.
MRN)V"Q+-YN9%W'@,5"?D!0!VO]HV)L!?_;+?[$5WBX\U?+*^N[.,5%'K6E36
M,M['J=F]I$=LDZSJ40^A;. ?K7G6IOI6DW/@R728Q%X475YC-(&+1&5U;RI
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MHC5O"%E>#3QIY8R*ULK;E1ED96VGNI()'L17+:7>6T.M?$>UEGC2X>;>L3,
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M?:6$2J1R#RH '8^];'B34;,Q^.+%IK:SU&/2(X[YYGW27K_9V*B)2<*HW8)
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M%%=6!<(V%=B%;;NV'H#SC(KL=/U[2[^[?3[?4[2?4($#3V\<RM(GKE0<CDT
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M.ZGM_EE6"59#$>G(!]?Y4 .T;3GTVP\N>83W4LC37$RKM#R,<G YP!P ,G
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M "BBB@ HHHH **** "L#QKH;^(O"5_I\)VW>SS;5QU29#NC(/;Y@/P)K?HH
M\?;7-5DOM"^(-M8R;;^$:1)9[,,Q891CW ^T;DS_ '<'O6WXVM+?2--\$VKR
MH7A\068,KX!=OG+,?<DDGZUZ%Y4>Q4\M=BD$+C@8Y%)+;P3D>;#')CIO4'%
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M?V@^"GC&Q-S$+N&[O?,AW#<F;@XW#MG/&>M=5J!LX/B5X&6T:WCWZ?>H!'@
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M%-PR<+)N&/;(S]:I^$K*[LM9NO!LL+_V=HUX;V"4CY7@?YH(_<JY<_\ ;(4
M=KJ'B'1]*D"7^HP6[?+N\QL!-W"[CT7/;.,U2U8:Y_PDFC/IMZ@T\LRWEJUM
MN#KC[_F?PXXP.Y/<9QP8U'0H=7\6>'?&%]=6DMY?22QPEF"WEO(JA-F!EB
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M LB*-8Q&(U" 8"@< ?2A(HXX_+CC1(_[JJ /RK,D\2Z-%?Q64E_&DTLI@C+
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MY!%N=3$4EB# [6V2+T.."00:YCP)X]TR[\-Z!:ZOKD#ZY>P LDC ,[DG ..
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M* "BBB@ HHHH *XGXIH&\(PN\9>&+4;22;Y=P6-95+,WL!UKMJ* /-];M?\
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M*H& /R%>(W.NV-[HV@7",+!;7Q/$\^EPPD+9#SGR93@G><YZ@'=@#C->YT4
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M)\4=(O%U47D$^A2QI.D.R'=YL;%8\#[H ).22N.3Q6"]S9#X#ZBJ30"4ZL7
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M ]>!]/0*0  D@#)ZT >3V<NC7EC\0H-0O6BLY=90M-;R /&"(564'T5QG/\
MLFH+W6]0T_0_$EMK*6'BBTM8+4IJ<<7RR(TIPLP0X)C^^0IZ'MG->P4@4 8
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M1G&  %&"< Y.,XJU'XIT634+>Q6]Q-<EEMRT3K'.5ZA)"-KGV!-<<CR-X_\
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M.%VDG920P6,+NX(.>.*Q?&OBX/\ #'5M>\,ZH4GM" )$0;HW#JK(Z.O!YY!
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M16;KFLQZ'I_VEK6ZO)&<1Q6MH@>69CSA02 < $GGHIH TJ*R]!UB76[%KJ72
M=0TPB0H(;]%21L ?, K'CG'X&M2@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *P/%'A*S\4QVWVB\U"SGM2S6\]E<F)XV(QGC@_CZGUK?K(U30/
M[2U&WO4U75+*2%"FRTG"QR*3GYD8$$^^ ?>@#-\"W>KR:;J&GZU<"ZN]+OGL
MQ=A=OVA J.KD>N' /N*ZFJ]E8V^G6JV]LA6,$L<L6+,3DL2>22222>35B@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
# /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>26
<FILENAME>exhibit1016-arvinasxamen006.jpg
<TEXT>
begin 644 exhibit1016-arvinasxamen006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUO99KB.8V\+A&A**!]Q2 V#ZU6LO 6I7\>HP0J_AO29[FWN(]-<I=!V0'>7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JG;Z3IMI=RW=MI]K#<S?ZV:.%5=_]Y@,G\:N44 %%%% !1110 4444 ,
MEABG"B6-) K!U#J#A@<@CW![T^BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M22]0R6P!+"50NXD$9&,#CUX R2*GT77],\0VTMQIESYR0RF&4-&T;1N.JLK
M,#R.HKS#1=.N="D^%NGZJ=MU:"[:</SY(>)MBL>V"0H]QQ74>"Y8V\:^-MC
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MVNY4':?,"JD6>[ [F([8YQD5M>+?#LOBC2$TY+U;11/',SF'S"2CAU ^88Y
MS6X@<1J)&5GP-Q48!/L,G'YT <3\*7>#P5!I<]O<PW=E-.DZS0L@5C/(P )
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M0X#2':2>!A>2.3C%<O,DC?!#5K-;>X-T^J.Z0>0WF,#>!P0N,XV\Y]!7M5%
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MS(+2 0L4B!;(#G^!FW#@]"<5UE5Y[**YG@EFW,(&WHF?EW=F([D9..W?K@T
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ME-_:OL@A:1MJS*S'"@\  FHYG8_&&TO!;W1M1H<D)G^SOY8<RJP4MC&< G%
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M2$1!H"@W_+\N6XYQ3O$.C:E!XZBN-+B<V?B"V^P:DR<>44^99<^OE^8@]]M
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MS"WD&7)&S?C'4$9Z9&,YKBO#=I=Z=K>CGP[-J TB\=VO=&OX&_XEI*,=T;L
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M261HP&<A6 . "#DX'('7BN,\106DWA6"XT?P_>VT5SK5K<E!:2&:94D4O*Z
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M;E5&6*$CG@@\XR.1D5SOA#6X]*TKQ9>:QJ,[6MEKUS"LMQ(TK*@\M40=2>2
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MJ6,-M=1W&F.$N$F55(8C(Q\W((Y!Z>] &U15+2=2BUC2K?48(I8X;A!)&)0
MQ4]#@$]1S6!H>L/KM[K6JA)9;33KJ2RLX(NKF, 228) +%B5&>@7C[QR =91
M7*CQ_I;Z%IFLI;7K66I7 MH&"+D2%BH# M\N6!&3T[XI_BO4$FT;7]-1+N.:
M#2WN3/$^P+E7VX96W9RAX]O3J =/17"^#_%]G'HWA32;F&^6:]T^%(;J2$B&
M6180S*')R3@'G&#C@FM#3M8T"+7/%-RDEU!-9^2VI271=8U C)4JK'@;1DX
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MD5>=S%N&.,X/)[9JQ!XELYM&_M5XKB&V:01Q>8@W3$MM78%)W;F( ]<@].:
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MD#-;= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;M7BT>YAEC%NYDC81PJ<H!N.",< ^O3FO5JQ+[PW'?>*-.UYKZY2:P22.*%
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M[1MVYSA0#R>,D8SS7-6/AW5KWX46W@2YTNXMKSY8+F>0+Y,<8EWF16!.[@<
M<Y(S@9->K44 <=%9WL?Q7N=3-C<?V>=&2T6XP"ID65G(QG/0CG%<NVE7D/PO
MUS3]0T>X^U7.JR2VUN9%21_,N T;(<XW#[V,]5P>#7K-9>O:%8:_8);W_FHL
M,HGBFAF:)X9%SAU8'((R?SH X[2=1D?Q+]MO=$UZWUFXM#8VMUJ,$2P# ,@3
M,3'!8C))'.,#'2LF#3_$=W/X1U.]\.ZA)JEE>LVI3SS1$L6C=<Q_/@1 G.!@
M#C )KT#2="M+*:.8ZE>ZC,J[HGO+KS=@/&5 P,XR-V,X)&>36TS*BEF8*HZD
MG H X?0[/5-*U;QA#-I5PT-[>/>6]PC(4D5HD4*!G=NRIX( ]_7!T[PYKNG^
M&O >HIITS7WAUG2[L"RAWCD4HY3G#$ Y SSSWKU>B@#@;_1[S4_$.L^)$L;B
M-#H3:9;0.H62=V9G+;2?E )4#./XCTP3GG2=6'A;X>VG]E71GTFZMGO4 7]T
ML<3(QZ\\D=,UZ=2%U5E4L 6. ">M 'FE]H%Y)XC_ +8T.QO](UPZD%N3&?\
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M1GKWQ74LRHI9F"J.I)P*6@#C)[*Y\2^+O#FL&PNK*WTA+B63[2H5VDD0((P
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MFA'2[6!U"R3LS,Y;:3\HR549QW/3&>_HH \S;2M6'AWX>6W]E71FTFXMWO5
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M8W!^9L#![1J:RO#VE7_ACXBZS!9Z;>-X>U-8Y_/9]XBNAP_WFW$,.2W/.*]
MHH \STKP_>6WB33=4T6QO]&FN)V;6K!S_H;J5;+J,D;BVW&WGGD#FC3= O+;
MQ)IVJZ+8W^C7$]R6UJR8_P"AR)M;=(!DC<6VXV\\\@<UZ8"" 0<@TBLKC*L"
M,D9![B@#S#^SKF#PGX_CU+1Y&34+^>XM89G""X5T1$ (/#%EX'!SCUJ;1[\Q
M:]I5UKFA^)4N;:'[#;7=Y!"8HS(54EC$Q.YB%7<1CITR:[K6M%LM?TQ]/U"-
MV@9E<&.0HR,I!5E92""" 0:IZ=X8@L)DEFU'4]0:,YC%]=&0(?4#@$^Y!(H
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M:P8J& *D9[@_CM^);/7?$?P[UNV@\.&SN;V)(K>R\V+S.&R7=MP4#T&2>/?
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MB2V*N9N =H]#@G/T.,\9N+XZ\VXT?38=)G76]2M#=FPN'\HV\8!SYC8."2,
M8Z]<5B6N@:Q_PO2X\2_V;(='ET\6T=UYL>"V%.=N[=C@CI57QOX6U=/B7I7B
MVPT2/7;%;;[)>6+%-P&6PP#\'[P_[Y]\T ;T/Q,TB]T31+ZQBEFN=9N#;6MF
MQ"L) </O/.%7N1GJ, YJ*]^)]E8^&-7UB33Y6ET:\^QW]JL@W(^X*"IZ,I)&
M#QQGTQ7.>-O!&IW5OX;UG0_#5A')I5T\TNB1^6JO&Y4D''R%ODYQ_>XSC)N>
M+_#=_K?PRU:RT;PA!IE]J$D!%I$8(Y#MD5B\C A>Q &2?SP #03XII_;FE:9
M-X=U"-M7M1<6!WQEI<C(!7/R].I/UQVO>'_B/I^KZ;K]U?6LNF/H,KQWT<CA
M]NW/(*]>588]17+2^%_$4GC7P!J0T:86ND:>D%ZQFAS&^PJ1C?SCVJMI'@'7
MKNT^)%E?6+V(UZX:>QEDEC8-\[LH;8Q(ZKGCUH [;2O'T.HZEI5E-I\EH^LV
M;7FFF24'S4 SM? ^1MN&Q\PQWSQ7.'XUVQ\/W6MKX<OVLK.\%I=2>;&-A..1
MSECST_7FI_AWI%_9:?IUMJ_@BTLM0TN,Q'42(6:4!2H\LJ=VXC&2<#KSSBN)
MC\ >+A\*_$&A'0I1?WNKK=0I]HAP8_ER2=^!C;T]Q0!W/CCQSJ>F^)?">E:3
M9F2#59TE,OF!6F0$'RQG[N=RY)^GK6NW@FVO+O7;RXM71=9M4CN;3[8^)' Y
M)8?<Q]WY<\9]<5SGBGPQKUUJOP_UBSTN2X_L<@7ELLL:R)PG3+!3]T]#Z5ZG
M&7:)#(H1RH+*#D ]QGO0!PFLHW@'PYHNII.\BZ>]O9WS$D^=;L0ASGJ5+*5)
MY&",\FN]KBOBC9OJ_A)-!A&;C5;VWMT [ 2"1V^@1&)^E;46N7;>,)M$FTF6
M*V%MY]O?^:K+-@H'7:.5P7')ZX- &W1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !116'XJ\1?\
M(OI2:D]FUQ;"9(IF60+Y(=@H<Y'W02,^E &Y3'ECC*AW52YVJ&.-Q]!6&GB4
MGQJWAJ6S\N7[']L2<R@K)'NV\#&<@]1Z<UR'B>_%_JG@?63IA$QU61(1&5=Y
M8_*DVX;CY6(!&2!@@G'8 ]-)"@DD #DD]J2.1)8UDC=71@"K*<@CU!KE+;Q:
M-0L_$5M?Z)/'=:2N+JR\Q)/-C=-RD-D*05SP?2ETCQ'81^&_#<>EZ<(GU2W5
MK&P5@HC0(&.YL<*H(R<$Y(X.: .IDECAC:25U1%&2S' 'XT^O+_B'J8USX8^
M(/MNDRVEUIUW%$1,FY2PEC^>)\#<I#=< \D8KK;+Q5)/XK.@WNDSV4DEJUU:
MR22(PE16"L"%/RL-P..>* .CIJNC@%65@>A!S7)?$B#59O#,3Z79M?K!>13W
MEBC8:ZMU)+QCUSP<=P",'.#G>#[[PAXDUF'5O#HBLKVVADBN]/\ +\B1=VWE
MXQP2"N-PSUQF@#T"BN'U#XF:980I?%(I-+-S]F>=+I?-7YMGF>5U*;N^<XYQ
MBMFQ\2M=>+=0\/2V)MY[2!+A9&E!$\;$@,HQG ((.>A]: -^BN8;QC#'9:?)
M+###<ZB9&M8YKD(C1I_RT9R.%(*D8!/S+QUQDM\4;)-#N]0_LVXDELK];&ZB
MAD1PC,P"L&!^=3D8(&?84 =[6-?^%],U/7;;5[M9Y+BV0*D?GN(CAMREHP=K
M$'D$CT]!BBGBC4FN;>RE\-W5M>W4\R0I/,OE^7&H;S'=-P7.X #!.<_6J,WQ
M%MX?![>(/[+NG6*\-E/"CJ3%()?+/.?F&XC! ).>@H [&>WANH6AGC62)OO(
MPR#]1WJ2N:LO%IE\2W&BZCIDVG2)9F^ADEE1EDA#;6)VD[2"1QD\4R#Q?+.=
M(N4T>Z?2]5D$=O<QG<RA@2CR(!\B,!D')QD9 H ZBBN(U;XE:=I5M-?^7%/I
MMO<FWGD2Y7S@0^QG6+JRAN.H/!(!')[965U#*05(R".XH 7('XUG:[HMMXAT
M>XTN]:46MPNV58FVEE],XX_"N&^(U[JHF&K:3(YA\+2Q7MS$O_+PS??3VVPL
M6/M(*[6^\1:=8>%Y/$4LQ;3DMA=!T&2R$9&!ZG(Q]: +]I;BTM(K<2/(L2A0
MTA!8@=,X J:N6;QA/;Z]I>D76BSB?4X3-;M!/&ZA5QO#[BN"H8$@;L]LU5T[
MQ[)J,]RRZ!>0V-E>3VM]=RRQA;;RER6(!^8<'[N<<<GI0!V=%<9#\1+)M5TB
MVFAC2WU9O+M98[E)'1R,JLJ#[F>V"W/!Q4>J?$O3=,MWU I%+I<5S]FEE2Y7
MSEP^PN(NI0-QG.<<@$<T =O17)2>,[J36=:TG3_#]U=7>EI%(09HT659 Q!!
MR<<+QW.>@P:J0_$>.?3M%U9-&NQI&IS10?:WD0&*20[0"F<E0W!/'MD4 =Q1
M7)ZYXZM=);4E@BAN3IBYND:[2)\[0Y6-3]]@I!QP.0 2<@1GQ]#/J&DVNG:5
M=WG]JV37EK(K(BL %.#D_+C<,YQCMD\4 =8EO"D\DZQJ)9  [XY('09]!Z>Y
M]:DKSO7/']\?A[JNKZ?IQMM0L;LZ?<Q32@_9Y-ZH64@8?[ZD=N?;GOH)9WM1
M)/;^5-@DQ*X;'L#P* )J*X*7XE/'H5]K2^';TV6G7<EM>,9HPT01@K$#/S$'
ML./>M:/Q=)_PDUGH]SI$]LNH0RRV%Q)*I$WE@%@RC)3@@C/Y \4 =/17&S>/
MXX?!^J^(3ILI32[J6VN(/-&XF-]C%3C!Y]<<5I7WB9HM5NM,L+-;N\M;1;N6
M$SB-V1BP C&#N/R'.< 97GF@#H*;)+'#&TDKJD:C+,QP /<UQ\GB75V^(UCH
MT5BGV*32WNVS-AB3)&N2,<;<D8[Y[8J#XP00R_##5GEB1VB\IT)7)4^:G(]#
MC- '<T5R<'C5T\46^B:MHMWIGVU'>QN)I$9)]@RRG:3L;'.#51_B7IL<FF3F
M.)M-U&X6WAGCN5:12WW&>+JJ'UR2,C(% ';T5R^H>,6@MM1O+#2I]1L]-G\B
MY:%OWC."-XB3!W[<\Y*]#C.*MS>(GFU2XTW2;+[9=VL"3W"R2^2L8?.Q,D$[
MR 3C  '4C(H W:RO$'A^T\2:>MC?23K;B192L+[264AE).,\$ U@R?$:Q.BZ
M5J=OI]Y,E]J":<\?RJ]M,6VE7&<Y!!Z9SZC-21^,[Z36K[1/^$;NAJD$*7,4
M)N(]DL+$C<7SA<$8(Y.>F1D@ ZU%*HJEV<@8+-C)]SCBG5R=IX]T^[\-:?JQ
MB,$M].UM';3R*A652P<,W0 ;&.?0< D@59\-^+[;Q!J.J:;Y217VFL@F6.82
MQNKC*LCC&1U[ @]: .@:6-)$C>1%>0D(I."V!DX'?BGUS.N:C86_C+PU8W>D
M&XNKEY_LEZ=N+=EB)?'.<D#'3'/7BJMCXWN]3U*[M++PQ?RBROS97+^=$/+P
MH;=RV#UZ \<9ZXH M1>!=)MKJ62TN-4M(99&EDM;;4)8X2S'+$*&^7)ZXQ71
M0016T$<$$:QQ1J%1%& H'0"N,TSXB?VAIQU:70KRUT>);@W-[+(A$)B)&-H.
M6SCMD9..>:L6_CR"3Q#9:--;PI-J,4CV;17:2@L@W&.3:/D;'IN'7!- '7T5
MRNF^,_[1\/:IJ?\ 9SPS:=<26LEF\H\PRH0-G QDDC;ZY'3-6Y/$4\NHW6FZ
M=IZW=]90QRW:&X")&7!*QAL'<Q )Z 8QDC- &_17+V?CG3M3TK3+JPBEEN=1
MF>W@M'PCK(@)D#]=H0*<GGMC.1D/C"2#3M5FN]$OH[K3[A+<P1J76=G*A&C?
M W*=PR<#'.10!TY( ))P!U)I(Y$EC62-U=& 964Y!!Z$&N+U;6X]8T[Q7X?U
M'3XX[JRTXS.H<31.CHQ4@D Y!4\$#'&,UD^&/&DFB^&/!]MJ&B7D&EW5G:6D
M6I%T*>:8U"[D!W*I/ 8_EB@#TH2QM*T8=3(H!90>0#T)'X'\J=7G^C2V6C_$
M?Q_>2^7;VT5M97$[A<  1R%F./IFK]O\0+1]<TO3KB".--5#"UDBNDE*L!G9
M*H^X2.F"PSQF@#L:*P_%?B+_ (1;1CJCV;7-NDB),5<+Y09@H<Y_A!(SZ4P>
M)2/&J^&Y;/RY'LS>1S^:"LB!MI &,[@>WIS0 FM>%])U'4HM3FN+JQO]HMQ<
MVEX\#2+DD(<'#<DX!!K4T[2[;2X6CM_-9G.9)9I6ED<^K.Q)/].U<KK'B*SF
ML-#N-4T W$-UK,5O:MYB.L<GF%8YN<'!Y88!XQG&:EMM=U._^(FK:#/80MIM
MM:0M@R@[A(7RS#'.=N-OM[T =='+',NZ-U=<D94Y&0<$?G1YL?G>3YB>;MW;
M,_-CIG'I7D_@?Q.?"_@#32^CSOI8U&:WENT=56'?=.JD(>6 ) ..F>,\UV9U
M.Q_X6/)8?V,_]J1Z2TZWV4S)#YH'EKSG[QSSCD?C0!U%%<"GQ,WZ'%K;>'[Q
M-,%V;6YG>6/,!\WR@=N<MSC..!G@G!KN+JYBLK.>ZG;;%#&TCGT4#)_04 2L
MRJ,L0!ZDTR95DB:-G9 _RY5MI_ ]0?I7EWA[Q1:W%M9^*/%=C=C^U;C99SRQ
M!K6R0DB-!SE2P )DVX)/7 %:ND10>+O&?B\:K"EQ;6#QZ?:Q2#(B&S=(R^C,
MQ'S=?E'I0!W=O;PVEO';V\2Q0QC:B*, "FWEI;WMN8;I \>0W)P5(.0P(Y!!
MY!'(KE_AEK%UK7@.QGOI6FNH6DMI)6ZR>6[(&/J2 ,^^:B\3:V-5T+Q+9V6F
M+J%K8PR07;O(%'F>7N*HI!W,H()R5YX!)S@ [&)TDA1XY!(C*"K@@AAZY%/K
MA?">LS6G@_P?IEI8/<W5SI$<H9V,<4:I&F=S[3@DL !C\JD?XB0_\(MIOB"/
M3)FL[NZ%I,7E5?LK^88]SGGY-P^\/;CF@#MJ*Q-3\1)I=[<Q36[-;VE@]_<S
M(V3&BYP-N.2VUL?[K>G*Z3K=QJ4UOOL42VN;;[3#<PW E1AE1M)P,-\V>X]"
M: -JHH+JWNE9K>>*95.TF-PP!].*X[XJ7U[9>"IA9QY6:>"&5Q)M(5ID4KC'
M(8$J?8U9ADL=)\0F&PT:&/Q#JD'G7$*3[8Q%$=H=V ('+ #"Y.?09 !UCNL:
M,[L%51DL3@ 4WSHAY>94_>_ZOYA\_&>/7CFO/?%6N6?B;X;>+[>:T,-[IL$T
M=S:S ,8I A964]"".5;^5,OX(O\ A+?AE<>4GG%)T,FWYBOV0G&?3- 'I%%<
MQ=>+F$&JW>G:9)?V>E2-%=.DH5V9 #((U(^<J#SDKR"!FD3QI;3ZMH5M:VYE
MM-;@>:TO/,PAVKN*D8R&QV^OI0!U%,\V,3"$R)YI7<$S\Q'3./2N7LO&GVS3
M]?N#IQCGT:X:VDMC,"\K@ C;QT;("^I]*7^U+0_$&"QGT-EU;^R7G6\W(?W>
M]08E.<_>/?'3WH ZJBN!/Q,(T.36CX>O5TVVO&M;N5I8P8<2>7D+G+8)&<<>
MYYQT5YXA*:^^AV%J+J_CM/MDBO+Y:*A;:HS@Y8D' QCCDCC(!N45B>%/$L7B
MS0X]6M[*YM;>1F5!<%-S;25;A6.,,".<'BLFUUS4]0^(>L:#/80MIMM:0G!E
M!W"0OEF!'.< ;?;WH ZZ.6.9-\3JZY(RIR,@X(_.GUY)X&\3GPQ\/M*WZ1.^
ME_VA-;2W:.JK"7NG52$ZL 2 <=/?FNRUOQK;Z5/?P6\<%S-I\8DN8Y+M86Y7
M<$0'.YMN#C@<CF@#I+JUAO;.:TN8Q)!/&T<B-T96&"#]0:PCX2TJ#2EL+FYN
MY-)A0*+6XN28@B]%8GDJ,#AB1CK6GHNKVNOZ+9ZM8LQMKN(2Q[A@@'L1ZCI7
MGOQ(UL:_\,=?N+33%NM,BW1)=-(-Q='VF1$QRH8$;L@\$@$=0#U 8P,8QVQ2
MUS-]XEFT]Y;2UTR2Y:ST\7LTCR>4FSD!5;!#/\IXX'O65J'C2^N+_P &-H]D
M)++6]TQ,L@1RH@9PF,''8D^V.] '=T5R&M^/K724U)XH8;E=,XNT-VD<F0H9
MA&I^^0",]!V!)R!TMAJ%MJ>EVVHVTFZUN85GC<\91AD$^G!H M5'-/%;1-+/
M*D4:_>=V"@?4FN3G\>PV^B1^(FT^0^'GE"&\60;U0ML$ICQ_JR>^=V#G;5#Q
M%>WT_P 2_#U@MC%<V)M;J9(VF&V4X0;B""/E#,!_O&@#O4=)$5T961AE64Y!
M%(\L<90.ZJ7.U0QQN/H/6N9UO9X$^'VH2>'[")4L+>6:*!I#L3JY/.3@$D[?
MPX'3E]>N)Y;WX>:I=V&Z_-V0/+*O)(#;L<9X R><' '>@#U&BN4L_'-N;;76
MU:RETV?16474+2+)D.H:,JPX.[.,>M%AXXMKGQ1;Z#<0PQW%W TUM);W2SHV
MWED;&-K@<XY!YP: .D^QP&]%XR;IPFQ&8YV*>H4=LX&?7 ]!3TMX4GDG6-1+
M( '?') Z#/IUX]SZU)10 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 51UK2K?7-$O=*NAF"[@
M>%_8,,9'N.M7J1G5/O,%^IQ0!Y>W@CQ'/HV@ZC+<HGB>WE6"ZG5L[;9D\EP#
MGDA<2?[^['6N@\4:/>S:MX3.F::\MII=YYTOER1J(XQ&R  ,P)ZC\!77":,G
M D0G_>%/H X2+2=8C\0^.+PZ5,8=4MX$LR)8LR,D3(01O^7D@C/;\JR8_#GB
M;2]$\%:G8::LVJ:!;-:76G23HOGQNBJQ1\E<@H",G_"O4:* ."\767B3Q-\/
M]1M/[($5[=O$(;);B-C$JR*Q+N2%R<'@$XX]ZNW5AJ=Q\2M(UA=-F6Q@T^:W
MED:2+*.[*PX#9.-ISC]:["B@#)UZ75X%L)=(M1=,ET#<PF0)NAV.#@GC.2I
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MX.U>TT73U@L3<7<WB9=<O(XI4"PKYA8H"Q&2%VCCJ0:WXK#4T^)]WK1TR;[
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M4//*>?#MV?:O.SNWX^[Q]?SK7EM?$_A_QCJ>H:;H2ZOIFL^5,\?VJ.&2TF5
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M88[<#/*GZF#QIH/D^#M-32Y1%J6D36W]F2.,YD!6,(?4,#M/U]J7Q7X:O9O
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MY'% &5J7C"]MO%,_AZP\/SWMZED+R,FX2-'4N4Y)SM&0>O/3CN*^G_$:PO=
MBOI;<V=ZU\VG/9W,JIY5PH)96?H%"@MG'3MGBJEU<W%M\;I&@L9;L'PY&&6)
MT5A_I#X/SD C\:I7'@G7;;3QK.F?9AKZZW+K'V61_P!VPD4QF'=Z[,?-TSGM
MS0!>E^)L4&G^()6TT3W6BHLLB6ETLD4T;#(=)"!TZ$8R#ZTOB'Q3*GA+4K_6
M_![3:6A@,<<UQ$ZW"NRX9EZKM8KP033M=MO%/B?P-K-I<Z/%8W5Y;FWM[);M
M)2&/5WDX '0 #/?UXG\9:1JNN?#5](L[$_VA,D"F)Y4 0HZ,<MG&,*<8SU%
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M9RHSNR,889(QCC)J?2/#$O\ PI\>'/$L45GY-FT4CK*'$87D29' ((W=^@H
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MA/IZ/J!EN%"PR!V<&W; WL%[G)STYKL?&>D7&O>#-8TJT*"YNK5XXMYP-Q'
M)[5S]UIFO7VJ^#;V721$-+DD>Z1;E&*!H3& #D9.3DXXQW)H O6GCN);#7)M
M8L3I]SHTZPW$*S"4,7"F/:^%'S;@.<8[T[3/&T5YXI309X;4336YG@GL[L7$
M;;3\R,=J[6'7'(([U@ZAX.UG5Y?&JB/[$VJ3VMSI\[NK 20*F-P!)&60>O!]
M>*Z;P]>^*]0=/[=T>UTI(5_>>5="<W#XQ\H ^1>_))Z#UR =)1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 445PWQ3UF]TSP[8V5A.]M<:OJ,.G?:
M$.&B5R=S*>QP,9]Z .O&I6+7ALUO;8W0ZPB5=X_X#G-65974,K!E89!!R"*R
M?^$7T3^Q/['_ +,M_L&S9Y6P?GGKN[[NN><YJC%J+:7=V'A/38TO+ZVT]99'
MGD,:)$N(U)(#'<Q!P .QYZ9 .EHKA+SXD?9?"^I:G_9#&]TN\6SOK,S@>6Y=
M5#*V/F4[@0<#(]*MR^+=7@\4#0I?#\8GN;5KFR<7H*L%8!A+\OR$9!^7?[9H
M ["BN"F^(TUMX0U#69]$/VG3=0.GW=LER"JN'5-ROMRP^=3]W-7K7QE?1^,+
M;0-:T-M/^WQ22Z?.MR)1+L&61@ -K <X!(]Z .OHKC+?QQ<_VAH,-]I'V./6
MI)(X8Y)B+B':&*F2,J, A>Q."1UJK<>/]5%IXBN+;PVLBZ%.Z7'F7P7>BH')
M7"'+8/3I[]J .]ICRQQE [JI=MJACC<>N!ZG@_E7,2^,7CUOP];#3U_L[7(]
MT%Z]QMVMLWA"FT_,1T^;G!J^LP\0OK&F7-H@L8)!;K.DQ+2/M5B0-HVE2PP0
M3AAV(H VZ:[I$A>1E1!R68X KFO &N7&O^$H)[UMU];R26ERP&-TD;%2WX@
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MI(8#U /)%5O"FN^$?$&KW/B#2BMEJ$%H\.H6DL7E3( RMEU[[=I&1GKC/&*
M.]HKAT^(D;7&C2"TMY;#59DA1K>Z\R>#>,HTL87Y5/&?F.W/>M#3?%LMS?\
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MQE'$BHBZ_+A5& /W47:H/'W]J:7KVC>(X=(?6=+L$E2ZLHANDB+;<3(I^\0
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MES.R@*,9[G.: /;**YO4/$R:;<VFEB>QDU"2U^T/)<W(@BVC"YS@DEFS@ =
M>>F<5/B5))I.E7D>A3-)>:I_9<L7G@>7+SRA( =2!D'@<CI0!WU%<A:^-V@G
M\0P:]8)I\FBP)=2&&?SUDA<,00=JG=\I&,=<<TEMXW9_$6G:7/:6K)J".8IK
M.\\_R749V2@*-N1T()&01[T =)=ZMIMA-%#>:A:VTLQQ&DTRHSGT )YJ:UN[
M:^MDN;.XBN+>0926%PZMVX(X-><Z%#>:]K'C:UUC2+"^MVODCD@>Z+ ;(4*(
MN8P",\YR,$G@]XY/%MXW@'PIJ/A[2[/3K;4M3@MS;"38(E:8C:NU,8;:<G'
M)X.: /4**Y2\\6746J7FDVEC:3:I:6:73VCWA1IBP8[8ODRV-O7 Y(&!75*2
M5!(P2.E "T5EZUJ=SIPLDL]/DO)KNX$ P2$B&"2\C ':H"^G)('>N?A^(4 \
M/ZWJ5U;11MI-Z+*7R[C?$S%D"N'V\)^\!)QD8/7% '3:QI%CKVE7&F:E!Y]G
M< "2/<5R 01R"".0*DT[3K/2;"*QL($@MH1A(UZ#G)]R2<DD\DFJVE:A>7LL
MXN+6!(52-X+BWG,L<ZMGD':,8Q[]15;5M:O;/4TLK33ED7[*]S)=W,IBMT"D
M (7"M\QSG'& ": -RBN$'Q',VA>&M4M=%FF77)_LZQB=08I,-QR/FY0\\#O2
MQ?$"]@FUVQU70#:ZII=F;];>.[$B7$ SEE?:,8(P1CK0!W501WMK-//!%<PO
M-!CSHUD!:/.<;AVS@]?2N)C^(=]$V@7>H^'FM='UHPQ17@N@[1RR*"H9-O"D
M\ Y]R!TI/#ZBU^(7Q -M;(Y L6$2X0.?(/?WH [BUN[:^MH[FTN(KBWD&4EB
M<.K#V(X-35Q6@>+K.3PEX=ET[2(;6;5V:.RTZ)PD:8W,Q+!>%"J22%ZG&.:N
M-XGU6WL]5-SX;NC=V4\<,*0%GCNA(0 Z/M!VC/S<';@]: .GDDCAC:25U2-1
MEF8X 'J33;>XANK>.XMYHYH9%#))&P96!Z$$<$5QTWB%=93Q5X?OK.V$^GV0
MD8Q3>='(KHQ'500P*G((]#6!X9\87_AWP9X2-_H3+H<]M;6IU!;E2\;LH"LT
M8'"$]]V?8=* /3H[RUENI;6.YA>XA :2)7!= <X)'49P?RJ:O/\ 3I[32?B9
MXVOIMD-O#IUI<3L%Q@!92S''4X%7+?Q]OU?2+:2SMVMM4.V.2UNQ-);MC*B5
M N%STR"0#Q[T =I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5SOC7PLGB[P\U@+@VUU%
M*ES:7 &?*F0Y5L=QU!]C7144 <]8:AXGDMU@O=#MXKP#:UPEV&MR?[P&-_OM
M(]L]ZS[K0=4TWQQ;^)K%1J"RV L;^ LL;MM;<LJ9PN<Y!!(X/%=C5>ZO[2Q\
MG[7=0P>?*L,7FN%\R1NBKGJ3V% 'GNM>"=5N_#'B)8(86U77;^*Z:/S0$A2-
MD*J6[G:AS@=6]!FMV[TS4[CXAZ3K:66+*VL9K>7=*N\-(5(P,\@;<'GZ9KHU
MU*Q:^DLEO+<W<2>9) ) 71?[Q'4#W-.LK^SU& SV-U#<Q!BADAD#KN'49'<4
M >3>*-)U/2/AWXP-Y;)&U]KD=];_ +T,-KSP@!L=#\O/4<]Z[2\T?4=>\2Z7
MJL]O_9ZZ5#.80[K(SSRH$SA21L49//))' Q6GJ]IH/B0OH6HRQ7+J!-)9K<L
MK@!@0S*K X!QC/?%;$:"*-44L0HP"S%C^)/)H \NM/"OBL0>&I)].T[[=IE^
M9KRX:\+/=DHZF4MLS_$.#D]N *TD\.ZT-,\=6YLE#ZY)*UI^^7 #PB,;_3IG
MC->@T4 <%XAT=V^%5O8W+"UU;3;:![5E8,4NHL"/;CKN8!1_O5U&F6Z>'_#J
M"\G7,$;37<YX#.<O(_XL6-%SX9T6\U^WUVXTZ&74[>/RXKAP247)(P.F02><
M9YJ_<P6\T0^TJK11D2$.?E!'()[''7GN >U '$>"]/US1/"&GM;V$3W6HZB]
MY?17$AC,$,KEB1QRX7;\OKFN]J"SO+;4+2*[L[B*XMI5W1RQ.&5AZ@CK38M1
MLI[V:RANX)+J !I84D!>,'IN Y&<'K0!RSZ/JI^+$?B$6:_V:NE'3RWFKOW&
M7?OV_P!W\<^U6-;TG4;OQYX:U6WME>STU+E9V,@#'S551M'?&WGI[9KJJ* /
M-)_!>N7UEXF5/+LKRZU:/5=-F9PZJ\83:' Z?<[9Z]\5U?A^X\47KB77]/L]
M-6--OE6]QYQF?CYLX&Q1S@9).>3QST%% &/K(UI+S3[C28H9HHV?[5#+,8]Z
M$<;3@C<#@C/'!&1FN>D\)RZ[XS;7KO3QID7]G2V+J)%::Y\SC+[,J HSCDDD
M]L5W-% '"^%+3QMI5K9^']0M]/-C8[8UU6.<EY84^ZOE;>&*@*23@<GD];FN
M^$Y]1\9:9J]K,L5NT)M=30]9H5821C'^^-I_V7(KKJ* .+\1Z3XAM/%UKXG\
M.0VUZ_V3[#>6%Q-Y7F1ARZLCX(# LW7L:CU[2?$>KP^'II;6W>YM-6CU"XBC
MF 2*-59?+1B 7;YLY( )ST&*[BB@#D-7TS79O&]GJ$-K:WVE+9^6L%Q/L%M<
M;\^;MVG<=N ,<CG&,G/-V'A#Q):>#/"6D2V=LT^CZK'=RF.X!#1(SGC('S'?
MP.G')[5ZG10!P&J^$+_7?$'B?[1%Y%AJ^EQV44V]69'3<=Q4'IEAW[=JT/#L
M?B^>U@T[Q#9V-O#;Q^5-=6]R9&O,+M&%VC8#U))SQ@ 9XZ^B@#@/"NG>-=!M
M+?PU-!I\FF6A\N'5A.?,\@'A?*V_?QQG.!UYQSVFIB9M,N4MX3-,\;*B;@N2
M1@9)Z"K=% 'GGA[2/%.C?#FW\-#2+)[N.V>W\Z:\_<_,6^8@*21\W3'/K56+
MP%K?A;1?"TGAZX@O=1T-)HIH;AC&EU',=SJ&YVX8#;GTY]*]-J"[O+73[9[F
M\N8;:W09>69PBK]2>* .+\3Z5XG\3>![NSGL[6&_NI86CM4N T<")(KG=(0"
MS':>@QT'J39U#0[_ %+QY:ZF]F5TW^RIK&8F5=X:1E.0 3P ,=:[".1)HDEC
M</&ZAE93D$'H13J .#\*6/C;1[2T\.WL&GMI]EMBCU9)SOD@7[J^5M^_M 7)
M.!UYQS?TG3-4L_'WB'5YK+_0M0AMHX2LJEP8E<'<,\9W<<GWQ76T4 >9-X,U
MRX^&^OZ&T$$5_=ZA)>VX:8%&#3B4*2.AXQTQTK8\0Z)<^)8EM]=\-V]Y;-;A
MH_(N5\ZTGW-]UVVG&-F2.XZ$5VM5WOK2*^BL9+J%;N9&>.!G =U7&2!U(&10
M!2\-Z?>Z;X9TZPU.[^UWL%NL<\^2=[ <\GD_4\GK7&Z?X4UW3/ ^H^!XX8I;
M.43P6FH&482"4DG>OWMZ[FP "#QR*[^]O[/3;5[J^NH;6W3[TLT@11]2>*G5
M@ZAE(*D9!'<4 <99>'+W3?'UA>VUJ#I%IHHTM7,HWY#JP;;Z87'KGM73:U8O
MJ>A:C81LJO=6TD*LW0%E(!/YU-:7]I?B8VEU#<"&5H93$X;9(OWE..A'<58H
M \X?P]XCF\->#;&73K=9M%O;6681W08-'#&4)!('S-G('0#O4^I^#[_7-=\6
M?:(OL]CK.G16D,P<,R/'N^8J#TRP[]NU>@56_M&R_M$:?]K@^VF,R?9_,'F;
M!@%MO7'(Y]Z .<\-R>-93;VOB"ST^V2V&);NWN#(;L@8&$VC8">22<\8 &>+
M?C3PM'XN\.R:=YYMKA)%N+6X SY4R'*MCOW!]B:Z&B@#G;#4/%#6Z6]]H=M'
M> ;6N8[L&W8_W@,;_?;M]L]ZIS:/JH^(>FZQY/GVEMILEI++O57=W96W!?3Y
M?UKJYIHK>%YIY$BB099W8*JCU)/2L^R\1:)J5R+:QU:QN9R&(BAG5F^4@-P#
MGC(S]: .#'A?Q1#HE_#!;0[I_$3ZE+:FY"K=6KL282PZ'ID="!CG)%6$\,^(
M$G\:,-.L8XM;LHXK:.&XXC<0&+;@J.!G)/MP#V]'HH X"3P]K36G@6,62[M#
M:-KO]\O.V$QG9Z\G/..*QY+/5=2U'7Y[#PY:ZMH^H7A#^1JWV:.?R\(=Z%#D
M[E8,00&QSD8SZO7.MX%\--?2W@TM$EF<O*L<CI'(QZED!"MGOD<T <]<0^(9
M]7TWQEX<T^"1Y;+[#>Z5=3B/Y5D8J4D *\,6YZ$$8ZUVNE?VB;(2:KY*W4C%
MVB@;<D0[(&(!;'<XY)/08JXB)%&L<:JB* JJHP !V IU '(0:5JEOX^US6?L
M0>TN[&&WAQ*NXO&6/([ [N/ITK @\):]#\//#&A_8XVO=+U""XG(G784CD+G
M:>I)!P,@=_Q].ILDB11M)(ZHBC+,QP /4F@"KJ>G6^LZ/=:;>1DV]W"T,JYY
MVL,'\>:YCPS;^)O#&E0:%<Z='J=O9J(;6^@N%C+1#A1(C8*D# ^7=TKK+.]M
M=0M4NK*XBN+=\[)8G#*V#@X(X/(-3T <=XE\.ZQJ?]C:O;26[:OI5[]J2W+%
M8GC8;7B#8SG;T8CKV . 3Z%?ZCX@N_$4]GY,RZ4VGVEHTJER6;<S.0=HYV@8
M)XR>^*[&B@#S9?"VNIX.\&:5]B0W.BWUM<7/[]=K)$&!V'N3NXSCH:UK;1M:
MT_Q=XGOH[2">QU9(9(W\_;(K)#Y>S:1CJ <YQCU/%=G10!YU%X'U*^^#]KX6
MNFCL]4M(T\J4/OC\R-PZG(YVG&#QD<]:UI=)U/Q'J^@7FK6*6":3(US(@F$G
MFS%"JA,?P#).3@\ 8ZFNOHH Y7P?I.HZ5?\ B.2^MEBCU#4WO8"L@;Y&5% ;
M'0_+GN.>M7]1;7;?78;FQMHKO3OLY2> S[)-^[*L@(VGC(.2O4<\5MU3CU73
MI9+J.._MG>TQ]I"RJ?)SG&_GY>AZ^E '"S^ )=<N_%5[- FD_P!M6:6J01L&
M;>I+>=)M^7=G P"> ><FMOPW+XTF:"#Q#9:?:I;#$MS;W!D-V<8&$VC8,\DD
MYXQCGCI;2\MK^UCNK.XBN+>0926)PRL.G!'!IEOJ-E=W5Q;6]W!-/;8$\<<@
M9HLYQN Z9P>OI0!S1\)SI\0Y-9BF5=+NHDFNK?N]U%E8V^FUL_5%JI?:9XHT
M/QI?ZSH%I9ZG9:LD0NK6XN?(:&6-=@=6VD%2N,C&>*[FB@#C-2T?7;GQ/X3U
M)XHK@::UP]XZ.$&94*@1@\D+GOC@#O577- \0WWB+6V6WL[RQO; 06,MQ.5^
MPML97PFTY+%@<C'0 G%=[5>SO[34(6FLKJ&XB5VC+Q.& 93@C([@T <%9^'-
M?B_X0(SV, _L*)H[H1W ;@P>4-N0,GN>@'0$U!J?@C6=7E\6LHCLI;^[M;W3
M9VD#!9(%4 .!TR5[9X/M@^F44 <E#:>(_$VBWUAXCLK72H;BSDM62VN//:1G
M7:7S@!5 SA<DG/)&.8/"T?C:WAM-)UFUT^.WL@J-J4-P7:Y1>% C*_*3@9)/
MK@>G6?;K3^T/[/\ M4/VWRO.^S[QYGEYQNV]<9XSZU8H P/&VG7NL>#=5TO3
MX1+<WMN\";G"JI88R2>WTS7/:GHWB75OA^GA5--LK=Y+2.TFN9[K>B*  655
M7+'C@''..:] HH \^N_"^O>'-1T75/#*P:B;+3$TJZM+J;RC/$ARKJ^" P.>
MO8U9UW2?$>L6_A^::VMVN;75XM0GABF&R&-%8>6K$ NW.<D 9ST&*[BHKFY@
MLX&GN9HX85^\\C!5'XF@#A=3\'W^N:]XK^T1>18:QIL5G#,'5F1TW_,5!Z98
M=^W:M+PW)XUD-O:^(+/3[=+48EN[>X,C7A P-J%1L!ZDD^P SQTEAJ-EJEHM
MUI]W!=6[$@2P2!U)'49%6: .0\,Z;JVE:QXFN[K3_P!WJ-Y]JM@DRDX$:KM;
MG@_+GC(YK M?!NO6_P ,_#VD"WMSJ>C:A#=M$9\),$E+X5\<9#=QVKTZB@#@
M?%?AF\\3Q7,5_H<$ETL2G3=0MKD)):3;><OPVP-SD YY^7I6S;7^MV/B+3=&
MNK>&YLGL1OOA+^]:9!\S%.RGCGU85N+J-D^H-IZW<#7JIYC6XD!D5,@;BO4#
M)'-3B.-9&D"*'8 ,P') Z9- ',^,M-UC4#I+:;%#=VL%UOO;"6;REN8]I !.
M"" Q#;3P<5C:9H/B/35\3[M,TN=-1OH[B. SY22,B-9(R"F -BN,D<G' %>@
MU!=WMII]N;B]NH;:$'!DFD"*#]3Q0!RW@WPLWAW5-6FM+>33](N_+:#37E#B
M*0;O,< $A0V5X!/3MP*=K6EZ[-XWLK^"VM;_ $E+0QB"XG*"WN-^?.V[3N.W
M"CN.<8R:Z>VO;6]0/:W,,Z%0P:*0,,'.#QVX/Y&IZ /&WTG6?#7ASP#I=[:V
M[7EIKVU$BGR)%*S-G) P2#P/ID\\=+K^C7,X\4>)[R#[,QT";3[: L&<( \C
M,Y4D EB  ">![X'6:IH&FZS<6D]]#)))9R"6 K/(GEN/X@%8#/)Y]ZM:AI]M
MJEA-8W:,]M,A21%D9-RD8()4@X(H X+2M)O_ !/X+\&V5Q9BVM+1+.\FG,JL
M)1&@**@'/S';G<!@9QFM?2M*U2Q\8>*]5DL@;?4EM_LP65=Q,490[AGC).1U
MXZXKI=.T^VTJP@L;-&2V@0)$C2,^U0,  L2< 5:H \MM?!?B.P\&^%39I;+K
M_AV5V6&27]U<(^X.H8=,JW!(X(/UK;UJS\8ZWX8G98;6QO7FA;^SH[HD/"K9
MD1I@HP7'' P ,9Y-=O10!P&G^&=:7Q+K-T]AI]E8ZEI<=JD<,Q/D,H<!<!0#
M]\$D8 [9IEIX6U>_\&Z+X4U*TBMK>P:W%W<K.'6=(2& C Y^8J,[@,#/6O0J
M* .&F\+7NH^)O%K7</E:;K6G1V,<RR NNU74L5_X'Q].<5-X63QM!#::5K5K
MI\<%F%1]1AN"[7*KP (RORDX&23ZX'/'9T4 87AK5=5U(:C'JUA!:S6MVT*>
M1+YB.F P.?7!Y'_ZANTV...% D2*B#HJC %.H **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y
M_P 8^(;GPOHG]JPV4=U!%*BW.^8Q^5&S!=_"G(&<D<<5T%5=3T^WU;2[O3KI
M=UO=0M#(/56!!_G0!AKXIE'C_P#X1F:VMD1['[;#<"X):1=VTKLV\$=>O3\<
M9VH^*)UT_P .7EYHEG-%J6JQ6\),^_R0Y/ES %.I4$]B,CGK68?AWJ<OAS1%
MFU)?[=LYU%Q>)P6MRGDNB_\ ;(#_ ($,]ZZ#QAH5_JL>@1Z7#;[-.U2"]D$D
MFP>7'GY5P#SSQT'% %&"-!\;;["*-_A^(MQU_?OUIWPN4)X<U%5 "C6+T #L
M/.:KD>CZHGQ*N-?,,'V&32TLE F_>;UD9\XQC'S8ZT[P-HNHZ%I5[:ZE' LD
MM_/=(892XVR.6 .0.1G% &#J<FHVOQDG;1[""YO'\.IQ--Y48_TAN68 GVX!
M_#K5[3_B+%=:,LEU8BSU8:BVERV<LWRQSJI9B7 Y3:"V0.>E7;[2-5MOB GB
M.RMX+NW?3!820F;RW0B4N'&001SCJ#]:QKWP'JJZ7]OTV\MH_$:ZNVL ODP,
M[*4,.<9V[,+G&21GC/ !O^'/$\^KZMJ>F75FL<EGL:.Y@+-!<(PZJ2!A@>".
M?K46M^*-3T_Q79Z#8:1%=2WEK+/#*]UY:@H5!##:<#YNHR?:M'06\07"O<:]
M#9VCD!8[6UE,H'JS.0,D\8 ' [G/'-^(9+F+XM^&GM;=9V&G7FZ,OL)7='T)
MXSTZX^M $VF>.M0OM-U.)] E&O:;>1V<]C#)O3+D;9=X&?+P2Q.,@ U:TWQ;
M-J%]XBTS[+:3W6DI&^Z&XS%.'5C@G!*D%2".:R-3\':Y<6FL:A:O;+J>J:C;
MW-Q:-*5BDMH0JB!G S\RCYCC')'3DV],T#7[+Q-KNIO:::EOJ-C!%'!#.W[I
MXU=0GW "/FSNP.F,4 /TCQC#)X5\,R66F007>M?)9V$;;8XP 68D@<*J@G@<
MG [U5\,_:O\ A;7BD7D$$4OV&SY@8E9!F3YN0"#VQ[=35&W\$>(+#PWX0EM?
ML9UOPVSJ(6F/DW,;KM==VW*DC&"1P:WM#TC78_'>IZ[J%K906U[9P0B..Y:1
MT9"Q_N '[WM^- &MJ^O?8-5TW2+6))M0U#S#&KOM1$09=V(!/<  =2>W)&'<
M>.[FRMO$D-SID7]JZ%!]J>!;@B.XA*E@Z-MR.A!!'![]ZN>)?#]_<^(]$\1Z
M28GO--,D<EM*^Q9X9!A@&P<," 1V]:SM4\)ZEJ</BG4#% FI:QIXT^WA:;Y8
M8PK#+L!R2S$D '  &: -WPWJVL:O%]JO]*AL[.:"&:V=+GS&?<N6#+@;<<=S
MUJ.\\07DVIZGIVBV<-S<:;"DD_G2E 7=2R1K@'D@9)/ R.O.-'0;:YL_#^GV
MEXB)<06\<4@C?<N54#(.!QQZ5R]YHGB;1O&VH:YX>BL+VUU:.);NVNYVB,4L
M:[5=6"MD;>HQF@#23Q7/<3:/I\6FM;ZOJ-LUU);73[?LL:X#%\ DG<P '&>>
MF*S+SX@7%CH_B5Y=*C.K>']K7-K]H(22-EW)(C[<D$=B,C!%3ZAX<UB/Q%HO
MB6TE@N]0M8)+6^A<^4L\3G=^[/.TJW0'J.">]4=8\&:GJ>E^+KE$MUU37XH[
M=(FE.R"-$VKN;')Y8G [@<XS0!=F\8:U;:[I-A+H=N4UB&1K(I>?,KH@<B7Y
M<*,'.5+=.]0MX[U"VT#Q/<W6D6_]H^'W(G@CNCY<B; X97*9Z'H1VJQ>Z'K%
MSXA\(:@MO;"+2%F%RIG.27B\OY/EYQUYQ69?>$]>N;?QW$D%F#KX46I-P?DQ
M$(SO^7CIGC- %^3QEK-OJ^BVLNA6YBUJ)S:%+SYUD6/?B0%<*I&>5+'CH3Q3
M[7QT]O9^(3K=E%;7>B31Q2I;3&1)?-"F+:S!<9+ <CBFW>@:S/JO@V[6WM@F
MC"3[4#<')+0F/Y/EYZYYQ5"^\#ZIJ\_C-)WAM(]9>VELYHY2[120JNTL,#^)
M >">* -.V\87TGB$:2VGV]P9[9IK>XM9G:(.O6.1BGRG'(;OZ5FV/Q%U.ZT;
MP]KDVAP0Z7JMU':N1=EI8VD<JK!=N"H(&>0>>E;6BOXTFCSKMMID+01D 6D[
M-]J?& 3E?D7OCDYQT P><@\&>((/AYX;T#R;)KO2[^"XE;[0=C)')O\ E.W.
M3G'2@#I+SQ-J$QUDZ%IL=\-(;RI5>4JT\H4.T<8 /(##D]SC'>F7GB]A="QM
M8;>"]6SCNIH[^4QB,R9VQG:#\WRMGTXZYK.AT7Q7X?\ $^K7&AQ:==:9K$PN
MG2[F:-K2<J%<_*IWJ< XX/&..I=J&A>*-)\4)KWA][/4#<V<=KJ%M>2&'S&C
MSME5@#@_,<C'_P!8 Z+PMKI\2>'K75&LI[*24$26TP(:-@2".@R.,@]P17,Z
M/XJU*#4O&5YK9METW2)\'RI&)C18E<!5*_,3GDY')Z=*[/38[V.Q3^T98I+M
MLM)Y0(123]U<\D <9/)QGC-<;)X+U"\N_&&GW1MAI.O'S$N%D)EC;RE3&S&.
M&4'.[VQSP 7KCQA>Z6FC7FJZ;%#IVJRQP!XIBSVSR#,8D!4 @]"0>#Z]:L?$
M9%?X;^(]ZAL:=.1D9P0AYK,_X1S6]9T31-%UN&UCCTZXAEN+F*8N+D0_=VK@
M$;B 3GISC-=+XGTJ37?"VJZ3#(D<MY:20([_ '5+*0"<=N: .4T_Q;JFCOX;
MM-6T6.#2M26*TMKN.YWNDI3Y!(FW W8.,$XJ34?B(UO92ZG8645[907)@>&.
M5C<R*LGELZ(%(.""0,\@9R.E64T#5-8A\/6NK6T%I;Z/-%<OY<_FF>6-2J;?
ME&%R=Q)YX QWJEH^A^,O#EQ=Z-IS:;-H<UQ)-;7DTC":T61BS+LQAR"3CD>Y
M[  [:^NI+;3)[N"(3/'$9%C9]@; SC.#C\JX)/B3JL>BZ+XAO?#T<.@W[1)+
M.MWNE@,AP'*;<%,X&<Y]ATKO-2&-(NQDG$#\G_=->;>&='U#Q1\)_#FBSV\4
M-@\=O)/<>;N+Q(X<*JXSN)4 YX')R>E &_XE\;WGAZUU74)=+C2QTZ9(A]HE
M,<EX"%+-%Q@@;O?)4]*OW>LB+X@:7I+Z7;L;FSFFBOB^9$"[=R ;> <COSBN
M7U_P;XGU6T\76(73I_[5?=:7TT[>9'%\N(-NW@ J>0<<DX)-;\VC:U<^.-"U
MJ6"T6"SLYH+@).20TFT_+E>0-O4XSZ"@#G/'>NW/B+X6^(;^PLK:320LD,<D
MDI$D@1]C2J,8 # X!.2!GCI7I5GD:=;X&3Y2X&?:O,SX+\4V7@36/!-I#87&
MGR"46%[)<LC+&[EMCIM.6!)YSC'TQ7I=BEQ%IUNERD8N$C"NL3EER!V) ./P
MH X-O'4NF^#M?UR#P_:QOIVJRVL]O'/M#L'5#)N"?,2S9Y X[UNVGB741XS3
M0=3TR&V6YM'N[26*X,APC!660;0 WS \$CW-<S=^"_$-QX)\3Z,(;);G5=6>
M^A8W)V*C2J^&.S.1MQP.]='<Z1JMS\0=)UP6\"V=M92VTH,_S[I"IR!MP0-O
MJ.M $?Q%U;5='\/V\VE&%7FOK>"1W<@A7D5<+@'KG!/89X)K)U)]0B^+>FR6
M]C;2:C)H,X*&8K$#YR<L^W=@>RD\].XZ'QSH=[K_ (<%MIQA^UQ74%S&LS%4
M<QR*^TD XR ><54_LC6Y?']AK\UM:""+39+25([@E@[NK\949 VXR<9ZX'2@
M"*R\?++X<2]O+2.WU ZD^E-;^=F/ST9@?GQG;A2V<9P,8)J]X>\43ZKKFH:3
M=6:J]JB2Q7=NS/!.C=@2!A@>".?6N8_X0;Q VA7@AEL[75H=?EUJP;S"\;%B
MW[N3Y01\K,#C-=EH#^(KC=<:_!96;!=B6UI*903W=F('IP!TYR3G@ P/B5<:
MA$GAR*U2!H9M<LU??*R[V#EE4@*?ERH.?;H:GBNH;#XB0V!\/:=#?W]A)=RW
M\+Y=F4HI0G8#CD<YYP.*L^-=&U36O[#&FQ6[BQU2"^E,TQ3*QDY484\G-)=Z
M/JLWQ"TW74MX/L=M82VT@,WS[G96X&W&!MQU[T 9VG^.=:OK:^U ^'HET[3;
MB[AO'2\W2#R%)^1=HW9(QVZ^V:TM.\2:CJVG?;;"+3;FVELFGAN(;EG191M_
M=O\ +D<$\]3@C JOX:T77M&T'Q! R6D=]=WEW>6;+*70-*2R!\J,8.,\&H-(
M\&O:^*I=8MK"'1HKBR>&]M;:;?'<3$@APH  V_-S@$[N@YR 7_AUJ>IZSX(T
MW4=4\II;F+S?,20L7R23D$#;[ $U6U#Q9KJ^*M0T#2]!M[JXM;6.Z1Y+WRUD
M1F*X/R<'@X'/U];O@+2-5T#PG9Z1JJ6JO9)Y,;6\K.)%!/S'*C&>..?KS@1V
MNC:I%\2;_7'AM_[/N+".T4B8F0,C,V2NW&#NQU[4 9^J?$%[:TO+[3[*&]M[
M.Y:!X%E;[1-M?8[1J%(X.< GD ].*U9/$T]WK\VC:3;1R7$%BEZ[7+% =Y(1
M  ,Y.#D]N.#VQ=-T7QCX<U+4-/TK^S+C1;RZDNH+BYD99+,R,6==@&' )) R
M/<BJVM0:K?>.+F31+2SU!["QCL[ECJ#VDZLY+E69%.X;=I'3&3CDG !;LOB)
M=7F@^'M9_L>*.VUG48[%5-V2\>XL-Q^0 X*L,?3FMVSUZ2]\8:KX=N+*,):6
MT5PLPDW>8LA88*E1@C;ZFN9GTS4M:\+:?:Z?HUIIM]X>U:"5+ 7.Z&01 -M6
M0+QD2=2,@@Y]:T]+TCQ#!XWU/7[NVL!%=V$,(ACN&+(Z%CC)3##YN3Q]#0!D
M?#W4;S3OA3X62QL&NI+F1H2W(C@7?(3(Y .% 'XD@9&:MS?$6>+PGXBU:+3[
M:YGT.Y:"18KK]U,H"D.K;3V8<>QYJA8^#O$VG^"O#.E".PN'TNZ9[RS>Y80W
M<9+$9;9_"6!P1C(]A27O@OQ-<Z)XST_R],SKDPE@99V 0E$!!^7H-F,]\]!0
M!W.BWNKWK7+ZEID-E#E&M2EQYC2(1D[A@;2/3D>YQDX5WXLUV3Q-J^@Z5H-M
M<7-C#%.DDU[L1U?=U^3(/RX Y'7)'?K+(3"R@%Q&L<P0!T5MP!]C@9_*N%M)
M[V#XO>)3:6:W(.G6893*$(/[S;U&,=<]QQP: +ND^.;G7M'TRZL=(>*:YFF@
MO#.Q\JP:('?YC <Y( '3.>W2JQ^(%[)X'U+Q#9Z1!=R:9=2V]U#'=':RQMAI
M(V"G<,8;D#C/XU4\%:YI@T5[7[#?JE[=7NIV<TS112S3'*NIVMD1G.,CWX/3
M7\):+?Z%;ZY!KAL/(O\ 4Y[F,QR$B02G.TA@,>F,G/\ , U9-<GEOM+M]/@M
MKI;RV>Z:3SRJI& N"/E.0Q< =.Y[5S>E_$'4+K0W\0WVBPVFB6ZW/VJ87>^1
M&B9E 5=HW!B,9R.<\  $V/AUHC:1HUU,EPUY$99(-/9SC%I&[^4N>XRS$'N"
MM0:3X)O9OAKJ/A36?)A>Y>X*RV\AD \R1I%/('0D<=\4 :-SXLOM)GT636-.
MAAL=6F2W22&8NUO,XRBN"H!!Y&X=#Z]:H>'H8C\0OB!'Y:;&^Q97'!_<'M4K
M:!K>NZ?H.G:Y#;0KIEU#<W$\,Q<7+1 [=BX! 8X)STQ@9SD6=+T;5['Q9XJU
M62WMV@U00?9E6<[LQQE/F^7C/7C- $?PG_Y);X?_ .O;_P!F:L2WN-8LOB-X
MX.@:3;7LY2P=EFN/(7B)N 0"2Q[=!ZD=^I\!:-?>'O!6FZ/J*PBYM(S&QA<N
MK<D@@D ]_2JD>DZUI/C37=7L[6VO+?5HK<(&N#&T+Q(5^8;3E3NSD9(QTH A
ML?B)::GH^D7%O"MO=ZEYP\FZDVB Q';)N(&3AB  !SD=.<11_$1HM#O[J\TQ
MDO+6^2Q1$<^3<-(P5'20J/D.>>,C!Z\52E\":QHEEH5[X>NK:;6-,DN'G2YR
MD5V)VW2C(R5^8#;]!FK'BD:Q>>$&M-6CTM=2U2ZAM[:P,K&(88,5$F =^U6;
M< ,8&!D9(!K0>)=3_P"$TD\,S:=;-*EF+T7"7!56C)*@;2IYWC'7H<^U8B>.
MI;#P!<^(+;P_;1>3J+VTMI%/M ;S_++@A!N)8Y/ ^M6="DUC3?$,?]J^&[>&
M?4$, O8]4:Y<^6K.JD.H(3@\CC+#(R<UF2>"_$+_  ZO_#_DV(O+C4S=JWVD
M[ AN!-@G9G/&.E '26GB;5#XNET"_P!*MX)9+%KVS>.Z+AE5PA23Y!M;)!XW
M#W-8=M\1M5F\-Z=XBET&"+3)[P6MQ_IA:6/,QB#(-F& .,Y()YXQR=JXTG5Y
M/B%9Z^EM ;2'3)+1D,^'WLZOP-N,#;CKWKG5\%^(5^%]MX:\FR^VQ7PN"_VD
M^65%QYW79G...E '3_VRW_"Q)]&_LFV^T+I/VJ*]\SYY%\W:(S\N5&[)ZGL:
MP(OB/JK^&;;Q'+H,$>F_;?LMU_IA,B?O_)#(-F& .,Y*GKQCFMK^R-6_X60?
M$/V>#[%_9'V+;Y_[SS/,\S.-N,=NM<Z?!?B$_"Z3PSY-E]N:^^T!_M)\O;]I
M\_KLSG''2@#J[KQ'<R^([[0]+M89;FRLUNI6GD*JQ<D(@P#UVG+=N.#VF\'^
M(G\5^&K;6FLUM([G+1QB7S#M!QR=HP<@C'/3K7)ZS%JVI^-KVYT;3["\:ULH
M[.Z4:C):2QLV79&9%.\8*$=,9..2:ZOPC<-)HQLWTB+2FL)/LOV6&82QKM52
M-C #(PP'(!R"#0!D^)O&M[X>MM7OGTN-;+3610;F8QO>9 +>3Q@[0<=\D$<8
MJKXTN]2;Q5X,CM(K=[>6^>1%DF9-[B!R-P"G  .0>>>W>J6O^#_$VJ1^+K0+
MITZZJO\ H=[/,PDACVC$ 3;P,@G(./FR036OJVBZ]?:GX3O%MK+.E2M-=*+@
MC.Z,IM3Y><9SDXSB@"EH-]>V/Q \46CVNG6FFVT,%U,L#L &<2,\I^3YG;:,
MDXX4=:L1_$"62?1ITL(Y[#5)4B @D9Y[8.,H\B[<;>F[!^7/4U8;PUJ+>--:
MO"EL^E:S8PV\[&4B6(H'4@+MPV0_7(Q[]#6\*Z;XVTBVM-!OVTQ]-L=L<>HQ
MR-YTL*?=3RR,!B %)SP.F3S0!/HOBS7=;U6\MX=!MTMK#5'L;N4WN2JJJG>@
MV#=R>1QU'7G#_B!J^K:3:Z+_ &7Y ^UZM:VTK2.RDJT@^48!P#C!/H3P<\3^
M#]&U/1[OQ ^H16ZQZAJ<E]"8IBY"LJKM8%1@_+GC/6G^-]$O];TRP_LT0-=6
M.HV]\L<[E%D$;9*[@#C([X- '/W3ZE#\8=UE8VLFH2>&QN5YRD2M]H.27VEB
M.W"Y/'3J-*P\?QW7AK3K^:UCM[^]NY+(6[S?(DL9?>2^/N@1L>GH.]31:/K0
M^(@\036]I]F_LC[$RQSG=YGF>9D K]WMG@]\#I7/0^!_$=OX:M/LLME;ZYIN
MK3:C:;I&>&59&?=&YP",JY&0.WOP =5X;\3SZSJFIZ;=68CEL2A2Y@+-!<(P
MR"K$#D=".WJ:R/'::UINNZ-XFT_2VUBST])DN;&/_6+OV_O8QW8 $>N"?4D=
M'H+:_.CW.O0VEK(0%CM;60RA?5F<@9)XX P .ISPW4EUV'7(+O3HK>XL1;LD
M]O+,8W+;@59.",@9&#C.>O% '.:!XI\(/I^O>,-)D")Y*/J%L(MDJ21[_O+_
M 'FW;?0[>O6KMOXQO&\0V.F2V-O*E_%(8Y[29I%MY%&=DIVC /9AW&,5G7'@
M&37;WQ-?WT<6FMK-BMFL,#;R"I)\V0@ %L[>!V7KSQK^&U\:LT%OXB73(XK4
M8>XM96=[L@8!VE0$'<\Y)&, 4 1:9XSN[[0-9NYM-A@U+3;M[,V0N"V^4$!!
MNV#&\LN#@]12ZIXQFMI]0M+.&RDO-.B5IXYKAE#R,F_RTPI)X(^8@?>''7#V
M\)2CXA-KL4ZKI]Q CW5O_P ]+F+*QO\ 0*Y_%%JE=Z/XIT7QCJ&K>'8]/O;+
M5A&US;7DS1&&5%"!U8*<@J!D8SQ0 2^/-0FN/#D.GZ#N?7+>:6)+J<Q-$\:
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MKC6\:R+KGA:U"V;6.OP-)%<!R&5@@?;M_P!K/!S[5/=>+9[.$%K:&22\U/\
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M!2 9)G"*"3@<GCK7(>!-"MK&]UK4;.X,VG3WDBZ>O!2*/.Z39_LF4O\ 4*M
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MO?V^IE\.8QA)0R#.[!P1TZ^O !8B\4ZPFM>%;'4-,BLWUF*<W$#/N>W>)-V
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M5[*2:;F*,3KND_W1GG\*U:\@^(FH7%Y\/=-LKG1[O3;>1[4MJ]QY;I98*GS
M(G=P3]T< ?-U%=KJ/B>3^V/[(TR5?-2S2[>Y-G+=+ARP0!8L==K$DGIC .>
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MU"6Q@'AMAVAE/O\ 0UV&C6^I06C/J]U%<7LK;G^SH4BCX "H"2<<=2<DD].
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M]=S:/#J$$,4<6]@RF(-@D[<<[OP]ZW['3[/3+86UA:06L"G(B@C"*/P'%6*
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M!E50O7[V"BGMTI#X5\47U[X=NM3UC37ET>=I-\=J^9P4*9;+C#$'MP#SSTH
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M<?,#D;<X/ J+6?"FO:_X4GT[4-6M&O[F:&222.!EAB6-U<*B;B>2O))R<^P
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M2JDQW:ID!N1G;G!Z5U-WX5UC^W='U:SUB&2>S@F@G^V0%U?S&#-(BJPVMD8
MS]W K*;X>ZH?A_J/A;^UK9Q=7;31SM;D;%,WF\@'YF)XXP!0!MZIXBN6\076
MBZ<_DRVEM'/+,;*2Y^:0L$7:A&!\A))/.0!WK%_X2_Q5M\*13Z5:6-YJL\MO
M=07"OE&1&8,I!^Z=H.#SVSWK1UCPOKC>)(O$?A_5+6RU![9;:]@N86E@G4$E
M3P00P)/X>G.9+[PMJEWJ'AV\?4H9I=+N)+F9Y8R//=U*D* ?D4!N!ST'7DD
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MS?,Q*=_S=2.,9P.171Z;X>O[/QKJ6NS75O)#>VT-N8E0AE\O=AL].=QX[>M
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M=7+PK*D/EO!.J[@.IRC#(]1CJ: -W2-=T[75O&T^9I19W#6LVZ-D*R* 2N&
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M;[(?+#YSY;KO^9>!W!R!4\G@;59;GQ/-)KD#-K]FEO*/L6!&PC:/*_/]W#'
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MM8K PI;SO;6+++)&H P&:1@N0.3@UVE4=1U6VTR*VDG69UN9TMX_)B:3YG.
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M'-9^(517BCA*-#LCV ABQR< 'IU%3>&_#_B/36@BUGQ(NHVEH-L"I:^4\G&
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MEO'<020&9<9RGF*-W'/&: ,*X\"ZE?ZCK5Y>Z['NU;2Q82B"U*>61NPR?.2
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M-&U^PU];QK!Y&%G<M:3>9$T9610"1A@#QN':@#3HHHH **** "BBB@ HHHH
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MF=I[S[*6-X'^^KKO'#'G&3@XQC%-N/!>JV_B2\U;0/$C:9'J)5KZV:T697D
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MN1I5U;6]F-@4DS*F-V",@,X].!6IIMWXH3Q3'!<VL\^C36[&2XG2&-[>8=
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M&,;?LY?& _WO,"G.<XR#\M='H7AF?2=3UVZN;Z&[BU:?SWA%L4V':$QG><C
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MF(H@7[VXY&U>>!S^59&DQ:)XL\=Q^*](F-Q;6MGY+3ID1S3$D+P0,LB%P?\
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MJ-Z]ZP$ CV,P (ZG(^44 =%1110 4444 %%%% !1110 4444 %%%% !1110
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M]:-M-XQ77=.*Q3S:;<1NMZUTMLJV[[<H\0C?<5SP5))QWH [.DW*&"[AN()
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MP7,PFG2 "WA,A4L<!F Z*.Y[5=KE?'&KZEHUOHTVGSQQ+<:M:VLX:+<6CD<
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MM[/F?Z-_J<Q^7\OS\_*._?GVJ,^!Y5A\,>3K#PW.@1-;Q3);J?-B:,1D%22
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M3C ]R>I-<]J/PWEOK'Q#IR>()X=/UFY-VT(MT9HY25)^8\E<J/EXZ=?7O:*
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MK,T%K=6GV:-4/F1,V\$#<&!7/!Q["N@^*EU=V7PPU^:R++,+?;E>H5F"N?\
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MMQJFIZ!X\T329[Z74-/UF.9%,R()()HEWY!15!5AG@C@CKCBF?#;_CV\3?\
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MW$DTKJ6=HRWS)$H#9D;H!@]: -VBO,?^$BUN/2OB!$E[<Q2:)$)[*2YBC:5
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M4+=RI!]Q78T4 9L6E20ZV+Z._N%M5M!;+IXQY*D-G>!C.[''TK2HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MYQNC^7]X,\93-4?#WCG3]<T*359([BUA6X>%1);2 M^],: <?,Y('RKD@G%
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M((R*6@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M+P1:12_&CQQ/<6P:*X"I"\D?RRKD;PI/##@9QZ5Z]10!XS<VTWAWXG>-K[5
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M=6A@0R22V4RQJO)8E" !]:U** /(3?V]SX8^&:*)0;.\M!<"2%D\O9;LK$Y
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M&XO+<,A/VR"51M$?]]@!M*C)' JK)X9U;2_A!H4FQFU[P\J7\29R?E)+P_\
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M1N\73<BD9;GC YSVKB]+U9O$HU;4Y[[7+6;3=7E$(M(IPA@B95$;)M*L6Y+
M@L,D\ <:?AK4-!UW5(-3L=&U*.[MH6$USJ,<RFV!',8,A.YB>H7(P"2>F8/
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M-KB.\L\>=;75N\$JJ>C;7 .#6AJ.K6NF>0L[,TUP_EP0QJ6>5L$D*!Z $D]
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]-OK+>(I8 KJ5?&X,C@AA\H]QZU8TS2);2;[3?:E/J-X$,:RRHB!%)!(54
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MN&N'7<6<)C<0,JH..><5/\+8YK;X<Z-9W-M<6US;PE)8KB%HV4[F[,!78T4
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M&#VS5OQ3<7M_J/BS37TS4@DFF :>;*U<"])B;)DE4?PL=H1F QGAB0*].HH
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M7=RW.2<<#'O7944 <?XROKJSUCP^@L[IM/EEE%U>6=JT\T!V855VJS(')(+
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M&(4$@$$@9%<Y;6=WX'\6/)IUA=7'AC66,LD-M SM87..6" 9$;CJ,<$=NAS
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MWL22Q8]"<COCI3M0%[>?#WP? FD:HL]G?:>9HFLWWHL.WS&*@9 &#UQG'&:
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MZ]-^Y26'?CZU%H5Q=:UXPLDUZPCLM?T>W=VGA.8[Z&0; T9[IGYB#RK;?4X
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MT]Y(KG*]%D V ]B6*X- %75-;O\ 3M!\.V#7$;ZUJSP6AN(L%58INEE4="
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MQ7 .5"\YZ'/!)KI-8T^ZU;XB7P@M[N.WN_#,MBEVUO((UF>3(!;'!P<_IUH
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MKR+XA_9K((=*\10B74DSRC6Y7+ >DBLL9^N: .]M+D7EG#<K')&LJ!PDJ[6
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M8-YAV+VX &6[G)Z8 TO"NM1ZMH,_BZ_F$5M.97@\PX6WM48@'ZD+O)]P.@%
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MG)4DG''3.>.;T[7X_#?BOQW)+;ZG?0V]Q;R%( TS11^0&9B6; &23C.?0<4
M>FT5CMXCLW@LGL8YK^2]M_M4$-N%W-%@'>=Y4 ?,O4CK4F@:_8^)--^W6#2;
M%D:&6.5=KQ2*<,C#L0: -2BO,M?U^QTWXBW%GXPDNK;2;B"(:3<"5X[<-@^9
MN*$8?.,$] .V>>LTQHO#>A2276HS7T$ER3;2O*9I)5D8>6@/5CR%'YYH Z&L
M/0/#2Z&TLTNIZAJ=U(-OVB_E#NB9)"+@  9/U/'H,10^,M,-[J-E?K/IMUI]
MO]JGCO H_<?\] 59E*\8X.0>U+#XNM9-7MM,EL;ZVNKN![BT69$'VA5P2%PQ
MVL 0</M/- '045R__">:5_PBT7B/R;S^SWG^SL?+7=&WF^5\PW=-_'&:35/'
M>G:9J]UI7V#5;N]MH%N&AM+0R,R%MN5'&0#G)Z?CQ0!U-%<=!KNDVVJ>+;RP
ML=1FU&RCA>^B<E1)B-B@0.P ^4$DX&?>J$GB>QU3X>Z1J?B2POXX[Q[5P+?@
M-(Q4J04;A-Q'WB/I0!Z!161J7B"+3Y9X8K.[OY[>(3SQ6BJ6C0YP3N902=K8
M R>.E5K;QAINHP6,FE+-J)O;9KJ)( H;RE(4L=[*!AB!CKG/'!H Z"BJVG7T
M>IZ;;7T22)'<1K*JRKM901G!'8^U8,GCK2XY<^3=M9_VA_9IO51?*$^[;M/S
M;L;OEW;<9[T =/17,77CBPM]5U+2XK#5+N]T^-))8K>UR65LX*Y(!'RGDX!X
MQFK,7B[2[C1M,U.U:6X35,"SAC7]Y*Q!) !( P 222 ,')H WJ*X#P;=/<_$
MKQL&CO( B6/[BZ?<8R5E)Q\S#!Z_*<5W] !1110!!<VD-X(UG4NB.'"Y."0<
MC([X///>IZ** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X[XBZ9?WVDZ=>:=
M8)J,NF7\=Y)8M@_:(PK*RC/&</D?2NQHH \VU!4U?P7XADTOP;<:7)<Z;+:H
MLMBL5S/(RD!0J9.P>IXR?:I;B"[?5OAY,NGWICL$D^UG[,_[G=;F,;N/[W'Z
M].:]$HH \\TRWU#3I/'5G/I5Z1>7<UU;S)%N25'A15"D<EL@C ''?%9PT[4[
M?P7\/7_LJ]DETBZ@-Y;I"?-C B="=IQD D<BO5** .$\<6.I)=Z)XAT0+#JZ
MO]@>.0CYXI^,''78^U^/[K5V6GV,.FZ=;6-N"(;>)8DR<G &.?>LV#PS!%XB
MFUF74-1N79M\-M/<;H+9MNTF-,<$C([]3ZUMT <%H2WOA3Q!XGM[VPO;FUU&
M];4;.>V@:42;U :)MH.P@J -V 1WK$TWPWJ/AR#X>6,MI<S-IT]Q/>-!$TB0
M>:LF!D#!PSXX],]*]8HH *\6TZ:WCT:+2;W1/$@T.WU%[V*.WT[SXPJRLZ@3
M(QW1Y^;A<]LD=?9IH4N()(91F.12C#.,@C!Z5S.G^"4TZ!+./Q!K;Z9&NQ+&
M2="BH. F\()-H'&-W2@"CIIDN/BK>:I%;7+:=<Z/!%#=^0PC=@[/@-C^ZP.>
ME5="COO"]SXHTV^TV]NTO;^>_LIH(&D2=90/W;,!A&!&/FP.<YQ7?HBQHJ(H
M5% "J!@ >E.H \IL?#VI>#6\ R365W?QZ;:75M>&SC,K122A6' Y*Y!&>V!6
M5K\.H6WP[^(;WNEW5H+K5A=0^:% ="\ &,'DY4]./<U[76/XG\.P>*M"GTBZ
MNKBWMYROF-;[0QVL& RRG'(% &'J%I)XE\9>&KZ"TNH;?26GN)Y;B!HCETV+
M&NX#<23DD9&%Z\BF?$^UD?1=(U%03%I.LVE_/CM&K%6/T ?)]A7:1(T<2H\C
M2,!@NP +>YP *)8HYHGBE17C=2KHPR&!Z@CN* .?\=:-/K?A*[BLO^0A;[;N
MR8=1/&=Z8^I&/QKE9_#&MRZ_IFK"$K)KL#6NNQ[B1#&<2*![J@:+/JP/>O1;
M*T2PM4MHGD:*/A [;BJ]ESU('ODU8H XSQ+;W$GQ!\'7,-G<R6UF]T;B6.%F
M2(/%L3) [G\N^*R[>VU&PD\?V<FE7S?;Y9+BVFCBW)(KP*BA2.2VX8QCCJ<5
MZ/10!Y<;.^'AWX<0?V;?>;IMQ;M>*+9\PA(&1B>/[Q'3ZU>C@NX_$OQ!N&T^
M]\F]M;=+5Q;.1,R0LC!>.?F('Z].:]#HH \K-E?KX/\ AU:G3;_S]-O;22\C
M%L^85CB9&)X[%ATZ]J[SQ;93ZEX-UNQM4\RXN+">*),XW,T9 'YFMBB@#S%A
M?W0^'SG1]2B&G2C[4'MFS&!;F/) S@;CCUXSC'-5]7T#5=9O/B%!9V<R27QL
MI;%[B%ECN&@52RY(QRR[>>N?2O5J* .)\+7,&J7UO.G@9]%N;=3Y\]W9QQ%"
M1C;$PY;)[X P#W-2_$6WN;K3='CM;2XN7CU>UN'6")GVQQR!F8X'8?GVKL:*
M .*5)Q\7)-2-G>?8?[#6V^T?9GV^8)B^WIUVG^G7BN-@T76(/#VGZBN@3WKZ
M9K=W<SZ9/!AI[>8N-R!AAF 8$"O9Z* /.;ZYOCX9O=2\-^$)=,>22!71K*..
M\D0/^\98QD95?N[N<Y..!F+2[>ZM/&NN7R:)J\=C>:3$L<TZF1V93)G=EBVX
MY V]?4 5Z710!Y+%I^HQ_#OP)8MI=_\ :M/U.TENHA;.6B2,G>QXZ#(Z=>U=
M#:I<0_$?Q)?O8WHM)M.MXXI1;.5D=-^X#CD_,/K7<T4 >0V^FZE%\,/!>GOI
M=_\ ;+'4[66YA%LY:-(Y"S,>.F".G7M5K6;F2S\8>)EM-+UQK?4K>""ZEL+(
M72LWEXW#Y@8W",!@@] <<BO5*YD^#5BU.[O-/UW6-/6[F,\]O!+&T;N>K 2(
MQ4G'8B@"YX4FTZ3PS91:5%<0VEM&+9(;F-HY8MGR[75N01C^M<KH<-_X9'BC
M2+W3;V[%Y?7%[8S00-(EPLPSL9@,(P/!WD#G/2N\LK.&PM5MX VP$DEV+,S$
MY))/))))S5B@#RVX\/7^A^%_ .CBVN;R;3-1@N+M[>%I%C4*^\Y Z O@#KCM
M7ITCL;9GC!W%"5!7!SCC@U)10!Y=XKLX?&?@U(]0\,ZC'XJ%N/LQ%HRM#/C@
MB<#8$W<G+=.V:74+'4/#_BJ'4M5\/R^)+.\TVWMKB6VMEGE@N(MV6"-_"V\G
M([UZA10!YKJUGJ6DWWAKQ-IOAIEM+(W,=SI-E&OG1Q3;<.%4[2X*@L!ZXYQF
MK?C#^U?$G@"]EMM%NXF^TVTT-I(@%Q(B2HS,5!X. <+UX]\#OZ* .&U@W5_X
M\\&:BFFWR6]N+PW#- 3Y(DC"INQD DCIV[XK.T>UU'0- \2>&[O3+RZFFN+J
M2QEBA9X[I)LE=SCY48%B&WD>O->E44 >:Z9H-YH7B;P1:/!<SQ:7I,UK<W4<
M+-&LC"/ SCIE3].,UL> 8+FVG\4?:;2YMQ<ZW/=0&:%D$D3*@##(]5/'6NRH
MH X[XH6UU?\ @.]L;*TN+JZFD@,<4$1<G;,C-TZ<*>M;VIZTNF64%V-/U&[C
MED"%;6V9WC!!^9DX; QS@$\CBM.B@#A!X8_M36/$VJVEL]C#JNEBQ"R1F-II
M</F5E/(P&51D G!XZ9R!I6H>(O@!::7IR8U&&UBB\ASC,EO( T9]"3&1SWKU
M*JMOI\%I=W%Q &C^T'?+&#\C/TWX[' &<=>] '!7FH7^O^+/!FI0^'=8@CM)
M;@W:SV_E^27A*X)8C(R>HX/;TIWB31YO$7Q(DMK<X6V\/7$4DG97N"413[X5
MC^%>BU5LK""Q$IC!:69_,FE<Y:1L 9)^@  Z   4 <MX*U%K'X5:3<&RNKB6
MRLU@EM;= TN^,^6ZA21R"IX]J/[/C\0^-=#\16UA<V@T^*83S7-NT#R[TVK$
M58!C@DMGH,<$Y-=3;Z?!:7=Q<0!H_M!WRQ@_(S]-^.QP!G'7O5J@#B-1M7U#
MXQ:+)$#LTO3)YIV'0>:P1%/N=KG_ (":F\=:;J,MUX>UK3[>2[_LB_\ /GM8
M^7DB92C%1W90<@=^:Z>SL(+)IG3<TT[[YI7Y:0XP,^P   ' JU0!PES8RZGX
MSG\316MW'9VVC/9IYENZ23R.^[ C(#84 =1U;CH:TOAS;W%G\/M&LKNVGMKF
MVMUBEBFC*,K#Z]1[BNIHH Y/XF6US?\ P]UBQLK:>YNKF'RXHH8RY9LCTZ?4
MU=U30U\3:7I__$PU+3C ZSHUN!&^X*5PPD0],GMUP:WZ* /--&\%:E;>/]>G
MGU?69K22RAC2>X:,K<DK(I5L(,[,@C&.3SFJ^DZ'?ZW\ I?#EOB+5(H);-XV
M.,2QRG*$]L[?R:O4ZJQ:?!;W\]W"&C>XP9E4_+(P  8C^]@8R.HQG.!@ \\O
M]1U/7KCP;.OAK5X9K'4 ][');[!$?*=3AB0&7)X8<8]^*T/$FG/K?Q0T""(D
M+8:=>S3N/X1,HB0?4D,?^ GTKO:JVEA!9R3S)N>>X8-+*_+/C@#Z = ./S-
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M?://X<U*ZC,>U6,*&"Y#+RH;=@=<'=BL?3OAX(O#V@V4^M:G:W6EVA@\RPN
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MVFO;Q;ZWGG,*9W,)A)*_MD[C^--U?2+O5_B!>NEM<QV-WX;DTX79B(5)7DW
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MK(0/E5B%49 R3SD] .0"7PMK21Z%X<TN*TN;J=M*MY)7AV;(%\M0-Y9@1GG
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M2>10GF,<[4Z[5]!GGW[YJU7):)XAT:S\)>'CI5E-'#J"+'IU@I!D(VEL$DX
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MHVC6Y@294D&"NY00#[\UY6^F>*+^T\/7>H^';R?6K#6DN+Z=IXB'0;Q^Y^?
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M8'A_X>6W]DW1FTB:W:]7*?N@D)C8_>YY/;/%=?XQ_ML>$[__ (1U=VJ;5\D
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M,TF[O_):86T32M&K %@HR<9XS@5S5Y9WGB^;0Y+S1+G2_P"S[Y+YWNGB9@R
MX1-C-G)(R3@8'K72ZO9OJ&BW]E&P5[BWDB4GH"RD#^= &*?&=N+3PU=?8I_(
MU]HTA;<N8F>,N PSZ ],U0N?B"\?]NBW\.ZC.VBOBZ&^)<($WE@=V#\O( R?
M7%<_!IGB:?1? ]F_AR:%]"NX!=>9<Q?,L<3(73#'*\CK@\C@]:TXM(UE3X_+
M:1./[6R;+][%^\_<"/\ O_+R,\XX_*@#I&\4VTW]E1:=$UW=:I;_ &JWBW!
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MO3M5SP/K<^KZ3=V]Y)YE]I5]-IUQ(1@R&-N'^K*5)]\U7\%Z=JFCWWB&UOK
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M\T#/S*0GW< '/^T.* .ZIKR)$A>1U11U+' J"QGGGT^"XNK?[-,\8>2'?O\
M+)&=N<#)%>._#:9/BAXGUWQ)X@1;RVLY5BTZQF&Z&!3N.[8>"V O)'4GVP >
MU!E8 A@<C(P>HI:YEM TCPYJ\WB6'98VEO83)<PQC;%C<C^8$' ("') R<CT
MK#L_BG!+;:%J-YI;6FDZW<O;6EP9]SJP8JID3: H8@]&;'>@#T*BN!O/B/=1
M>,M8\,6GAY[N\TZU-UO%VJ(Z81N25RO#@=^?;D9#?&I%\)Z=XF_X1VX&F7%T
M+2X=KE0T+\YVC'S@ =3MH ]5HKB]?\>R:+XWTWPQ%HSWD^HPF6"2.X"] W#
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MP_<B:]'VB+H)$/R_-R2%->UT4 >6Z?X:UJP^(/C77[NP,6G:C9,D$GFH3E5
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M.%C R"W )0_F,XKD9_AOXMD^#5KX672A_:46J&Y;_28MGE[6YSNZY;I7OU%
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MNUKJ%O;QVY65-S-$K@Y&[C);CZ<XH DB\>V%SHNB7T(ACEUB$RP17=P(40*
M7W/@]"0. 221QC)%>R^(MI<Z;=22696_@OUTY+:&82)<3.?D,<F "A&3D@8"
MGCBN?T_PGXJT3P]X3O-/M;>36-"BEMKBQEG"I=12$9VN,@$%5(SCO^.OXBT7
MQ1XCT6QU$V]I9ZOIVH17]KIYGWH0@(*/( /F8,>0,# 'J: (;/[2?CB&N]/M
M[69O#[DO!+Y@E'GIR254Y'3D>E=)XM\22^%M.@U#["MS:M<1PSR&?R_(#L%#
MGY3E03S_ %K(LK'Q!>?$6T\076D165H-*:SD1[M7=6,H?HH(/W?7OU[5U.LZ
M5;:YHM[I=VNZWNX6A?V!&,CW'6@"K>ZZMAJ%Q'/'&ME:61O+JY,I_=+S@;=O
M.=K'K_"?;.3+XUELK;2=1U'2OLVDZI)'''<"XWR0F09C\U-H"@\ D,V":BTK
MPE?7'P]N]%UZZ#ZE?VS6]S<1\XPGEH1ZX55)]26]:HMX>US6_"FD>&=7L4@%
MG+;_ &N\696CFCA((,8!W;FVK]X#&3UP 0"]HFO:[>^-O$]C/:6S6NG&".-(
M[@[@&C+@@% "6W#.2,8[XR:%CXXM=.\ :7K.G^&_L]I=7QM19V\B*(2T[1YX
M !).3@#J>O>M33-+U?2_'GB/4/L<<VG:F()4E68!P8XMA3:>Y('.0,=ZYJ'P
MGX@C^&NE:$=.!OK75%NI )TV;!<&;@YZX..G6@#K=.\5SS>);[1-4TO^SYH+
M07T3BX$HDA+%23@#:P(Y'/UK-?XA2C2M%U:/1FEL-9N5MK0K<@2;G)\O>I4
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MF.>GL.<'CV>21(HVDD=411EF8X 'J36>WB'1ETQ-2;5;(6,C%$N3.OEN02N
MV<$Y!'% 'G\O@G7SX\\9ZVL%L;76=,:SMAY_S!_+1 6&. =I/>K7ACPQ#H_P
MOM_!'BFXLX+B\$]NBB<'S=S,X*9P25R#]17I%9>L>'=(U\VIU6QBNC:OYD)?
M(*$\'IV/<=#0!@?"S0;C0/ =A#>3&:ZE7S&<G.$Z1J/8(%X]S79D9&#TH
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MLL\8(CDN)Y)VCR,':78[<CCC%:5 !1110 4444 %%%% !1110 4444 %%%%
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M2HZ ]3BM.#Q+='QW)X>N;2"*%[/[9:7*S$F==VTC&T $9!/)X(-8$/@[6Y/
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M'R]-NX](A>&YM);EUB9R!LF4[#DK@\%>,\>M,_X0;Q%_PAVHZ6SZ<UU_;/\
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M2)Y.#ND8KD#C  !P">3QBKX<\(G2?%MWK5M8PZ3:W-H(I[&WEW1RS[L^;@
M8&0,#)W'('< V-6UYK36M/T2SB274+U))1YC$)%$F-SMCD\D #OGJ,5F6_BF
M^O!X@THVD%OK>DJK,IE)BDC==R2*VW/0'C'!&,]ZD\0^'[^;Q1H_B723"]W8
MI);SVTSE%GA?J V#A@1D<8/M3;?P]?)?>(=;DB@_M+5(4MXK?S3LBC12 &?;
MU)8DX'' &<9(!1^&EG]L\#>'+W4+.T>:WM0]I<9+R+O4ASD@;2<\X)S4UOJN
MM3_%34-*<6ITZWT^*58][ @.[ L>,%OEZ< #OUK4\$Z5?:%X/TS2-16 7%G
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M'VR[7CS(&C\F1!_VS"C/JN>IK?\ %^AZCJ[>'QIL5MLT[5(;V02RE,H@8;5
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MPS6PT_\ LJ2X\M@V2?-C4D^I]/3)]: .IT[5=/U:.633KR"[CAE,,CPN'57
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M3M3N;NWL;R&XEM'"7"Q-N\MB,@$],U>H **** "BBB@ HHHH **** "BBB@
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M\2>(-5U&>R9-5DAD6*W#DH4C"8)/T].>O'2NJH **** "BBB@ HHHH ****
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M=YBLB]"W"Y;IDGWKB);K5[[X4>.I]3OH;G;/?0_+ 4;*-M!SO("X4 +CCU-
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M3;^,+F_\2WFCV]SI]O>VE\L1TZZC99I;?*[I48N V5+,,*>F#6E\0-=F\-^
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M/TY=32:S1E_=98,C!F.6!7@C&?04 =/J.MZ;I$MG%?W<<$EY.MO;HV29)&.
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M" =O+,>WK@^E<AI5UK%WJWCQ+V_@FM[5O)6,6Y4A?(#*%.\@ ;CG(.3D\=*
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M3L=%NY89FLX_+66+(#C).2"..OJ:TM'UBPU[2X=3TR?S[.;=Y<NTKNVL5/!
M/4&KU '&^*?"=[XGMM3TZ[73I[*Y93:32AO.L3L52R#'S'(+#E>N#D5+-X:U
M:V\9#6M*OK413V$=E<K=HSN-C$JZX(!/S$$''K76U2TW5K+5EN6LI3(+:X>V
MERC+MD0X8<@9^HXH XBS^'^JV?@[0]+&I6DEYHVI_P!H0L86"2?-(=C'.?\
MEH?F [#BMQ_#NHW-_J&MR7-O;ZS+8&RL_*R\=LN2V22 7);!/ X4#'4GJ**
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M,42Y.X7"VY?<8BN-I/5=^>G\-=L;N 7@M/,!G*;R@!)5>Q/H#@XSUP<=*GH
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M97%]#'%J%O<VYFAD*#"NN&!# <=>:ZVPMGM+**"6X>XE49>9^"[$Y)QT')/
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MD*DL=R9!!SST/M4&F>,+C5/$4^EK>V=K?VU\\4NEW,)25K=6($D;%AN)7#Y
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MG>6ZQE)[=AY$N"#(@R?4$+D$8^]R: .HB,IMD+A1*4&[T#8_QKSB[\<:_!X
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MM'MY+4Q06957C957C+\-\G7IZ#U #POXPN/$6H10B]LXKJ.61=1TJ6$QW%L
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M*EBQWC#=<+SV%9T'B_Q!J%GI.L:9I[W5I>S(9;,6;JT=N_1Q*3M+ 8)&,')
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M)0!UL_,6XP#^[VDG:&XRV>!DY'6NE;>8SM*A\<$C(!IU0&[@%X+3?F?9YA4
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M+6"]TV_?RI(;2- Y&W)=0,,3GD]:LZ?XY\4PZ[X!:^U&"YM?$4&9[9;54"'
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MI]W('&<@Y]^E<GI.HZWH'PV.NV.HI';VNKRJ]F8%83H]X48,QY!^;C;CIW[
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5R_C^ZU?3?"MQJNC74D,UB5N)HTC1O-A4CS!\RG!VY((
M]*ZBF2Q)/"\4J!XW4JRD9!!X(H X(^+GMOB);PRZK))X?O-/:6%C'&(TG51(
M5+A=W^J(?&>_?M2\0)JDDG@1KJ\?[=/JK2;YHES"&AD(3:H4$J"![D5NI\.=
M&7POI>@L97@T^Z2Y21CEW*GE6/H5)3']W [5IZ[X<.MZEI%Y]M: Z9<?:(D6
M,,'?:5^;/;!/3% ''7/C'5?"EGXY6^NVU4Z']F>TEGC1&)G485]@4$!CV .*
MU]:U'5_"FJ>')I=3DU&SU*]33KJ*6*,;7D!VR1E5! !!R#G@^O-79/ ]I=WW
MB*:_N&N8->CCCN;<H%""-=JE2.0<'/.><'BI;/PHZG2UU/4Y-1BTIM]HLD00
M[PI57D(^^P4G!  YR03C !9\7KK'_"*ZA)H-TUOJ<,32P$1J^]E&=A# CGI]
M<5R?_":3R^(O"-S!J4[:+JUNJW$9CBQ%-(I,.YMN<LR2*0.Z]NE>D5QY^'&C
M'PK?>'U,J6UU=M=[U.&B;S-ZA#V"X 'X^M $5QJ.J_V-:WXUI8+>^U'*M)&I
MD%J2VQ(55#O=P%/()PQ],UG6'B/Q'-H?BU+9+F]OM+OA%:J\:"<Q%48C &TN
M%9L9')QD&NF\0>%DUI=*>VO9=.N=+G$UK+"BL%^4J5*L,$%3BJ-OX'>SDUB6
MWU^_674KB*Y+LL9,<J%#N^Z,YV 8Z8)&* '>"]?MO$#WTUGK,]Y%&(T:TNXE
MBN+23YMRNH5>O&"<]#S4'B._UJ/Q[X>TFQU3[+::C!=&51 CE3&JD,"1U^8^
MW R#TK9TSP^MEK=[K5Q,DVH7D4<,CQQ>6FQ,X^7).?F.22>@' %,U'PZ;_Q3
MI6N?;6C?34E2.$1@JXD #;CUZ*,8Z>] '&1^,M7TGP_K5O=78O+ZUUY=(M;N
M:)5^6385=PH )4.W0#.!6Y?:EJOA[QIH>FOJ$M]8:RLT.9XTWV\R)O# HJY4
MC((/3''I3W^'UG=:?KME?WDL\.L77VQRJA&@F^7#1D=,;5QG/3WK2MO#LQU&
MSU'5-0^WWEC$\=JYA$:H7 #.0#RY QG(&"< 9H \_G\1>*8_ASJOB;^WV^TZ
M5?S(L0M8@DZ)/LVO\N>G3:1^-=4U[K6D_$32=.N=6:]M-6M;EVA>!$6!XMA!
MC*C=@AL88M]:'^'J2>#M2\-/JLQMM0N'GEE\I=ZEWWL!VQGVZ5JW7AJ6\\2:
M1K<NHGS]-BDC2-80%D$@ <GG.?E&,=/>@#B;_P 3^(K?P%XXOTU7%[I.JRP6
MTWV=.(E$>%QC'\1Y.:Z!;[6M+^(FDZ?=:JU[9ZK9W$C0- B+!)'L(*$#=@AL
M88M]:6?X>K<Z#K^D2:M+Y.MW;7=PXA7<C-MR$]!\J]<]ZT[KPP]YXATK6)]0
M8RZ=#)"L:Q +()  Y/.0?E&,=* .5_X236[2]\.O)JGVUKW5FLKT01*;/:WF
M;5C<J&++M'()&0P)Z"BRO;C1O%GQ%U6;4+RYBTN*&<6[E-KJ+8R;/NY !)Q@
MCWSS6A;_  S%OI>E:<OB+4?L^DWBW5D/+BS&!N^4_+\Q^8\G\JV%\'VX\0ZM
MJ37D[V^K1)'>6+!3'(5C,8).-V-IZ9Z\T 9-A<^+9[S0]0A-Q-8W"AM1CNOL
MZQ!&7(>'82XP3T).1UYYKF?$VI7_ (L^"NL>)/[1EAAN5D:&S1$,8A678%8E
M=Q8A<DY&"?3@]AX>\#3:"\-NWB+4;W2;4YM+"<)MBQ]T,X&YPO8$X&!QP*HR
M_#)?[%U/0;37KRVT.^9G%D(D;R"S;F".1D+GG'Z]<@':O<)::8US)G9##YC8
MZX"Y->>7/B77E^&D/CN"_)E"K=R:<43R&A+X,8.W>"%/WL]1TP<#T:WM_)LX
M[>25[C:FQGE"Y?Z@ #]*Y2V\ 06VCOX?&H2OX>:7S!8M&"RKOW^5YG7R\]L9
MQQNH SIKSQ%K7CF_TC3_ ! VG6ATN"]@86D;M&SNPQANN0O.?PQ72^+]<D\.
M>%[G48E#S*T44>X# :218P3R!@%L]1TZBD@\-F#QE<>(A?,7GM5M&M_+&P(I
M++@]<Y)Y_2KVNZ+9>(M$N](U!"]K=)L<*<$=P0>Q! (]Q0!AZ8/%$/BF/S?M
M4NB2VY$OV\VXDBF'0IY752."#T/2N3\,ZW/I/@S3K6U5S/J6OW=JK1A-R#S9
M7)7>0N["8&>,G.#C![+0/"]]I!5K_P 1WVKM A2U%TB 0C&,G: 7;'&YCG!/
M3)K/_P"%;V<GA5M"FU&Z;9>-?VUW& DUO.6+;E(XZL>W0F@"CJ&O>)_"FE^(
M=1U"-YM.BCB.G/>M%YJ2.P0JXB."@9@<]<9&:Z)=+\01:LG_ !/FFTV6U9)O
M,CC69)OX7BPF,8SD-GH*@C\%K=Z)?:=XAU6ZUIKR'R'FF5(]B=0$5  #G!SR
M20,] *D\.^%KO1S%]O\ $%]JZVR[+5;A$41+C&3M +MCC<Q/!/J: .*\):U?
MZ3\,/#DJW=U=76L7WV52_E%HBTDK,RE@,L0I^^3R1]#JZIXA\2^$-.\0:K?Q
M2W&EPVZ/8F]:$2K.S!-C>5P4RP.>HP15Z/X:60\(MX<EU.^DMHIO.L9 522S
M8.74H0.2"QY/;TJVG@@7NB7NG>(M7N]:-W#Y!EF5(_+3(/R*@ !R%.XY)*CT
MH Q->L+ZT\=> VNM6FO2UU.)%DC15W_9W^9=J@@=>#GM[YZWQ9=ZG8>&[FZT
MBVEN+N,H?+A4-(8]Z^9L!X+A-Q /?'!Z5C1>!;QKG1)[[Q/?73Z/(SV[>3$K
M,"A3#':=QP<$]_8\UTNKZ?+J5AY$%[)9RB2.5)HU!(*,&Q@\$'&"/0F@#SV_
M\82S> ?$>N:!XCGFDLD1HXY[>-9K5QPT<B%!P?7'KSQ71:AJ^HVWCSPO81W;
M?8]1MKI[B HF"T:(5(.-PY8]ZEN/ ]GJ$&OC4)O,N-;@2"YE@C$854!";5R>
M1N)R2<\=ABHK?P3<?VQHFJWWB&]NKO2DEC0^5&BR*X48( P.%Y/4YZC % '$
MZ6OB.T\#Z_K6C:VMK_9VI:A<"S:V1TG"2LS!V/S<@$#;C%;.L>-KF%K6YO[F
M]T33-1TV":ROXH%E@CN'!++,2K$8RF.@QG\-V+P,L-EJ.E+JDYT;4+B2>>V,
M:[SYC;G02#HC$D'C.#P15W4?#,MX+ZWBU#R=/OK<6TMHUNKJBA2N4Y&UL''.
M1P.* ,JXUK4=4U^]T:PEO%6RLH)6GT_[.6>24,0V93@J HQ@<Y.>U0V>M^)'
MF\.^'=7:*RUF\AGFO;BWV-A(B -@.5#-N4G@XPV!TQ:O_A]&;ZPO]"UB\T6]
MM+1+'S(%602P+]U75P02.Q_^M4NJ^!8[Z/2IK35KRRU73'=X=0&V21S)_K-X
M(VL&ZXP .V!Q0!@7>N:[81_$*!=9FD;0[6*>QE>&+<I,+2$-\F&YP.G0#ODU
MJSZYJD>M^!$6\;R=6CD%Y%Y:8D(MS("#C(.[T.*R?#UA::EXM^(.BWE^]XMY
M#:P2REE#R P%7(P !@G' P.*V;;P%.EQH-Q=^([ZXET4M]G(BC0%2FS:1@@_
M+U)R3VQ0!EC6O%?B'1'UCP\MR+@7DBP0/]G%J\<<I0JY)\S)52<C&#TXJPMS
MXBU;QGXGT>/7GLK>TMK6:W,5M$SQ-(KDC+ @C*C.03P,$5<A^'QL]5O)-/U_
M4+/2;Z9I[K2XPAC=V^]M8C<@;N%P?<=M.W\,/:>(M7UF'4")=2ACA:,P@K&(
MP0FWG.?F.<]?:@#@Y-5U/Q)HGPVU.?4;BWGO;U5G%N$"LXCD^?!4C.5Z'@9/
M%>GZG'*=$NHX[J:*40,!/'M#@@=1QC/X5S,/P]BM_#FAZ3#JUS&^BW(N+2Z6
M-"_1AM8$%3PY[>GX]>8%:U\AV9U*;&+'EAC'/O0!Y=X;UJ]TKX?^"K2*_F>Y
MUR6* 33*C?9TPS.5^7ECC W;N3GG&#TMMJNI:5\1(_#MW=O?6-]8M=6TLJ*)
M(71@&0E0 5((()&0>*9#\.K9/"UGHDFJWLG]GS)-I]UA%DM60DIC"X/4@YSD
M?A6W8Z"8=8.L7]U]KU'[/]F218A&D<>=Q"KD\DX)))Z#&* ,[QKK5]H<-A=1
MPWITSSF&H36,0DEA3:=K;2#\N[[Q R *Q9_$EXNE^$[W3?$(U&WU'6A:R3K%
M'B:!VD8!AL!5U554XQR#Q79:EIUU=7EI=V>H-:RVX<%3&)$E#8X89!XV@C!!
MK!N/A_:/H<=E;7LMK=Q:G_:R74<:_+<EB20AXVX8C;Z=SUH S=3\7ZAH.M>-
M'FF-U::5IT%W;0.BC:[[\KN4 D95>N<5O65EX@34M+O/[:CNK"2%OM\,T:C+
ME04:':HP,Y!#$\8ZGFJT7@.W;4M6O-1U*ZOQJMFMI=Q2*BK(H##/ ROWCC;C
M'N>:=X>\'76AK#%-XBO]1MK-2MC!<H@6'@J"Q4 R$ X&3@>G3 !P.F7VLZ%\
M-9=>L-5:*.SUB4&S$*%)T:\*,'8@MGYC@J1CWZUZ]JE_'I6D7NHS*6BM('G<
M#J0BECC\JY1OAXC>#+CPR=6F^RSW)N6E\E?,!,OFD#MC</3I782VR75D]K=J
MLT<L9CE&,!P1@\>AH \K\2/J>J>!O"^N7>IR,U]J.GW,EJL:>4JR2*RJOR[O
MER!DDYYSVQI^--?UK2H/$EW:ZKB73XHYK2VM(ED6)0H+&X++@%CG #9VX(&:
MM#X:2#1+?1/^$EO_ .S+.YCGM(C%&7B"-N5=Y!+ 'ID<>]3WWPZ2]&OPC7+Z
M*SUL;KBW5(S^]V!=X;;G!P"5&!QZ<4 4]1%W>?%/PTRZE=P1S:7<3>5'L**0
M8\X#*>N>2>>."*C;6?%/B'2KO4O#PN4N8KV6*VA;[/\ 9G2*4H5DW'S,L%)R
M,8)&..3OS>#O,O\ 1+]=8O$N],A>W,H6/,\;XW _+A?NC! &/UJDOP_:UUF]
MN=-\0:C8:=J$QGO-.A"%'=OO%6(W1[N^WGT(XP =-J+,V@W;.NUS:N67.<':
M>,UY1IE[XB\,_#/PQXDMM8$MA#%:QW&EFV0(T+LJ95_O[P6!SG'MV/L$MO'+
M:/;%=L3H8\+QA2,<5S&G^"%M=+T_2+K4I;S2=.D1[>W>)59MAR@D8??"G!
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M,"10<;7QQGD'N#0!P>LZU>^+?AGX?U:XFDL[EM7MH+B* )L:1;@(7&Y2>JY
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M7!&X="#78T4 <]-X5$^OZ3K$FJ7CW&F1R1H&"$2>9C>6^7J<#I@#L*I?\(%
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MYVNI&#@\@C!!KH** .4O_ EE?:#+I7VVZB$]X+ZYN$V&2:8,&W'*X'*KP .
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MW)X=U/XH:M"JM+;/:-&'^Z&-N@!/L"<GZ5Z-IEB=-L(K5KNXNV08,URP+O\
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M%@%B,0&&=<8?<V20V1C &.M:9\"6?]E:%IPU/41!HDT<UH08MVY%*KN/E\@
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M6(LYK:32YU@D\UE)<E0P(VDC&".]<WXHL5N/BMX0S<72"6WOLB.X= -JQXP
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MB>&R,*..N>>M_$VL7/A#PKXPO;J:-+>^^RZM'$Y6*6/S&A\T@>C[6X]2.@H
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MA +>PR0*S?"^O)XG\,V&M1P-;I=Q^8L3-N*C)'7\* &Q>&[>*#41]JN6NM1
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M]>!BQ>>#M+U'PE'X;OC/<V44:)$[N!*FS&Q@R@888'./KGFN@HH Q- \-0Z
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M>Y!_L%9L+=2*-PN,= V-N /E^Z>I&:ZG0O#UKX?%Z+2:X<7MR]W-YS!LRO\
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MQ7CAS$<91CG[O X&,=L4 <-?W][J'P(OFU">2>>'4EM_,D?>Q5+Y54%CRQ
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M  *]B2<_TH \PL;O5X_AKX>\3/KVJ2Z@-32)@]R?+DC:Z:-E=.C9!ZG)'&,
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MN(\.6LFO^%_#GB;^W[J"\=X[J[D$K-'/NR'@*$[0NX[1@9!4=ZJ^#M*@2_\
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MQK4J*W@2VMTAC,A1!@&21I&_%F))_$U+0 4444 %%%% !1110 4444 %%%%
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M-,Z6?VES;1R'^-8L[0?3CCMBKL?A33(-2U*_@^TQ3ZCS.$N&";MH4N$SM#$
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M;FP1@C/!K:HH P9O!VBS2Z3(MO) =*C,-J+>9XP(R "AP?F4[1P?3ZUO444
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M$ ]#C([$5#=^#='N]/T^Q\N:&VT^=;FW2&9E(E!)#D]6.23DDY)).:WZ* $
MPNW)/&,]ZRM&\.V.A/?-9M.?MT[7,XEE+AI6^\W/3.!TXK6HH Y72OA[X?T7
M4S>6,=U&GF&9+,W+FVCD/\2Q9V@^GIVQ5A/!>EI8ZO9A[OR-7=Y+U3.?WC.,
M,<_PY  XQ7144 8#^$--D_L?=)=G^R,&S_?'Y"!MY_O?+QSGBDE\&Z5)=7\R
M?:8(]1.;ZWAF*17!Q@EAV)'!*XSWS7044 4-2T:PU;1)]'N[=6L9XO):)?E
M7'&,=,<8],5!K7AO3=>TF/3;R)U@A=)(3 YC:%T^ZR,.016M10!SMMX*TBTO
M[R^A-XMU>0+!/*UW(Q< $!CDG+8)&3R >,5I:)HUIX?TB#2['S!:6XVQ+(Y<
MJOID\XK0HH Q+GPKI\^K7&J0R75I=W48BNGM9C'YZC@;AZ@9 888#O3=1\(Z
M3J6F6.FO'+#96+QR6\-O(8PC)]P\<\5NT4 -C4I&JEF<@8W-U-.HHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJ.K:O9:)8&\OI
M=D>X(H52S2.3A451RS$] * +U%5;&YGNH/-GLY+3/*QRNI?'OM) /XFK5 !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 5YWXD@N-7^+WA_3FNY+:
MVM-.GOHF158F;<(\@,"N0IR,@XR:]$K,U30[75;FSNW>6"\LG9K>Y@(#Q[AA
MAR""".H((Z=P* ,/P=JVJS:UXCT'5I_M<FD7$8BO/+5&ECE3>H8* NX#@D ?
M2NOJCINE6VEK.8=[S7,IFN)Y#EY7P!DD8'0       "KU !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
G %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 ?_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>27
<FILENAME>exhibit1016-arvinasxamen007.jpg
<TEXT>
begin 644 exhibit1016-arvinasxamen007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUO99KB.8V\+A&A**!]Q2 V#ZU6LO 6I7\>HP0J_AO29[FWN(]-<I=!V0'>7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JG;Z3IMI=RW=MI]K#<S?ZV:.%5=_]Y@,G\:N44 %%%% !1110 4444 ,
MEABG"B6-) K!U#J#A@<@CW![T^BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MNR2O3.!UQD5H+XIT=K/4;L73>3IKE+P^1)F$@;CN7;G@'.<8Q7)ZM(FF^-O
M]X^GR6=FEI=P+##"6$+,L>R/"# . 1@<<'%9%W?1::/B9I5RDXO;T2SVT2PL
MWFQM:@;@0,8!!R<\8H ]%F\2Z3#':,;EY#>0_:+=((9)7DCP#O"(I;'(YQW
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M(L,$+S2%1U;:@)QD@9QC)K,\!M&? 'A]8\ QZ?!&Z@8*N(U# CL0<YK$-R=
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M!,T$F^%XR' !/# $C!'/3FN='BU-<?Q/IELE]:/IR&-)Q Z-N$>\MN*X7J,
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M_('SE02&P""!V)! .RHJO:7L%[I\%];N7MYXEFC91G<K#(./H:\]UGQF^O\
MP]\5WFGG4-.GT_[0D,BQ/$P\K Y<C );/R@Y QGO0!Z517-Z'XMTJ]FL=)%U
M*U_):B5/,A=5F"J-Q20C:^,\X)_G5B]\7:-ITNVZN72+SQ;M<>2YA20G&UI
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MW=V]A9S7=W,D-O"I>21SA5 ZDFL^T\2:9>:FNG+)-#>/%YT<-S \+2(.K+O
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M%@K9VL X!*G!P1Q0!KT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !7#?%AUC\(6\CJ61=3LRRJI8D"9> !U^E=S6#XL\
M.R^)M-@LH[U;18KF*Y+&'S"3&P91]X8&1S0!S.NZ:WBKQI:7FBN-MII-Y!->
M+D(7E4+%'N[D'<Q';OC(K.\)W6DZE9Z+I&H:!JO]O:8\/F6]T)S%;O'@&8.2
M8P, E<=<@#K7JB!@BAR"^/F(& 3].U+0!P'@=T2'QIYEO(WF:S=7"QO&5\Z(
MJN"N1R#@C(K(T&SO[2_M=+\/:K<7FAWEE.!!>QGSM';9\@WD;@,D*$;GCC."
M:]6HH \?\J;5/@PG@QK.6+Q!'''8FS>,@JZ2+B7.,;,#?OZ>^>*Z33'6V^*V
MM2S%_*&E6T7GNA"NR,Y8!L8) ()%=Y10!Q?PG5XOAQIEO+')%-$9E>*1"C+F
M5R,@\C@@_C6?X?NAX<U7Q=INNQ2YO-1EO[5_*9Q=0R*H")@'<R[=NWKTXKT2
MB@#R'3M)O_"ME\,_[3M[EA8/=+<F*)IC"98GV(0H)X+!?PK7L957Q;\0YI(Y
M$CGM[81,T9Q)M@*L%./FPQQQGFO1Z* /%K%YM%T?P-K%_9:E+I=OI;Z?>BU$
MJRVDC>60S*F&QE,'\/:M'Q/#ILO@.YGT;2;J&&]U2VG^>&4RW6V5"\I1@7Q@
M'D\G&>A&?6** &HZR1JZ,&5AD$=Q7G5E,=/\0^/[>YM[I&NF6>%O(<HZ?9U7
M(;&#\PVXSG/:O1Z* /(%W)X"^&L)AF$UIJ5FUPGE-NA58W#EQCY0"1DGUJKX
MONY]3\/^,+,Z=>V]W#J*F.SM+)U26-9(_P#2'=5_>,R@GD]AQD9KVFB@#@K:
M[CE^+\U]LF2V;0$C$LL+(-PF9RI)'#;2#@\^U6/A8&C\&>3)')%(E[=$QR(4
M(#3.RG!'0@@UVM% '"VDQTWXM:Z]U!<+%>Z?:F"40LT;"/S-^7 VC&1U(KCH
MUD7X'V5I]GN!=IJH<P>0_F ?;3)G;C.-G.?2O:Z* /++N\M-%\;:]%XAL]5E
MT_6&BGL;FS$\D<H\I8VB98CU^7C(Y!^E>A:';06.A6D$%C]@@CC^2VSGREZA
M3[XZ]>?6M&B@#R?P^FA/XL\:3:WIJ317%\K6[W&GM*)$" ':2AR,CM67%X=\
M0WG@'QE::;:WD6F2WD<NBV%T&63RD<.ZJK?,JL!A5./IS7ME% 'G^K2Q^,M8
M\(7&DK*'LKW[9<N\;(;:,1L&C?(X9B57;UX)Z"N3OK^74-)TR>73K^UN;/Q)
M%+<Z?;6$BPVB"<DM\J_O&888GYB2QP!7ME% '"^&9%;XG^,)3%*BW$5EY3O&
M5#[(V#@$C!() (%<7]KFLOA!K_A'4+2]_M^W%RK(+:1_M.^5G$JL 00=W7/;
MZ5[=10!SMMXHL(+_ $;1I8KR.ZO[;?"9+9U0;5.58D#:WRG@^GN,T?B78:C?
M^$"=-@>YFM;J"[:VCY:=(Y S(!W/&<=\5U$ME%/>07,NYF@R8E)^5&((+8]<
M$CZ$XZFK% '!:@\/B?QEX4U/2V=H-,^T7%U<%&41(\841MD##$]5Z@*2:F^%
M_P N@ZC&T<D4G]JW<A62,H2KRDJV"!D$=#7;T4 <-XL@DB^)'@74F!^S1S7E
MJ[=E>6'Y/SV$4[Q0W_%R?!+A)"D+7AE=4)6/?#M7<0,#)X&:ZS4=.M]4LVM;
ME24+*ZLIPR.IRK*>S @$'VJQ"KI"BR2>8X&"^W&[WQ0!Y[I$JIK/Q$D=)%CF
MD1XF,; 2@6X0E>/F^88XSS2Z5,ME\ _])5HVM]#DCECD4JRL(B"I!YSGBO1*
MI:AIL6IB**Z8M;(XD:#'$C*05W>H! ..Y SQQ0!G^"K&?3/ VA6-T"MQ!80I
M(IZJP09'X=/PKSQVEA^'GC_2'M+P7KWM^Z)]F?#B1\Q[3C#;@<C&>!7L%% '
MG-Y*K^+OAW+&LACA@N1*XC;$6Z!54,<?+EACGN*Q-(-A#97GA#Q+HFJW>IK=
M3>5#B=K>^5I3(C@@^6HY!).,$9ZU[#10!@^,M,N]6\#ZSIMAQ=7%E)%$ <;F
M*_=S[]/QK'\,^)K/Q''ID"Z-=1:I:1[;C[39,GV!MFUL.RXR2, *<D'G !KM
MJ* /(-.2>+X0:EX*OK29M?CCN+1;<QL3<.[L4E0XP4.X$MT&#G%;>F0/IOQ1
MLH[EWD%MX82TDN2AV-*LH)&[&,D#=CKBO1** /']*L[&[\&16FI/J.GR?V]=
M2V][;JT;VCEI624\<(5)&3Q\U2:D^NW'@5I]4'V_^S-?MY1?6UL5:\MHW0F;
M8O4CD9'!"Y''->N44 >=VNJ0W?Q8N-2C@O!82>'T1+E[6148B9VZD<<9QG&<
M<9XSS4"2)\%?"UH]O.+F'4;8R0>2V] MQN8E<9 "\Y]#7M-% '"/<1I\9/M;
M;OLP\/F(S[#LW^?OV[L8SMYQZ5R$*2+\"]$LFMIQ=1ZA"7M_(;S%"W6\DKC(
M&WGZ5[510!YUK-RZ?$Z6]MK-KT+X9GC1 A*32^8'6+=C&6 Z>AK#TZ]-UX@^
M'^HBWU%Q$EQ%<(MA)%#:NT&T1(@4!5!R,\\#EN*]AHH \XT&8V"^/;&ZM[J.
M:34;JZ3=;OM:-XT"D-C!R1@ '/M6-I"7FF6'PXUJ:WN#I^GV<EG?*(FW6KO&
MJAV7&0 5P3C@'WKV"B@#RS6[-[RZ\=Z[:)(UC=Z&+&$JA/VN<(_*#&6QE5!'
M4D@=#4LSCSOADPCDQ;#]_B)OW(^S%/GX^7YN.<<UZ=10!R/Q+T[4=3\$7,>E
MPM/<0S0W'V=>LRQR*Y0>IP.G?&*H:B\7BWQ5X1OM)\QET^:6YN9C&RF%#'M\
MMLCAF) V]< GM7>T4 <-X-F4^-?&;%9%6XO87A9T*B51"JDJ2,, 01Q5GQMJ
M+V&H^'PUJXM9;J03:A%:^?):?NSMV#:VTN3MW8.!GUX["B@#@OAKN@G\4VSV
MU]$6UJ:=#=1."T;)'M.YNI.#QG([XXJ6Z<+\9K*9E<1+HDL+2[#L#F5&"EL8
MS@$XKN** /'75G^&/Q MU@F,UUJE\\$7DMNE#L"A48R0>Q'I5V]OHM#\70:I
MJUMJ<FBZEI=O#'=V?G?N)8R^4=8SNYWYY'7\:]5HH \NO[>QLK[P0-/TF:PL
M8]3EN/),3DQHT;@22#G9N8@\],\X.<7?%NIVWA[XB:=J[-<1R/IDMO*QM)9X
MG3S%90/+!*L&R<GC&!WX]$KF]0\-ZC)K\NKZ3K\UC+/$D,\,ENL\3*A8KM!P
M5/S-T.#GI0!P,J6:>!]-N?#TUUK,6E:S]NU.*".2"=@_F%]L9PRX\P$#T'4\
MFM>ZFT/5/"WB;5-%TV^+W&DS6S7ES',))G*$+$HD^9L'TXR0!GG'>:;IIL1)
M)-<R75W-@RW$BJI;'0 *  HYP/<]22:OT <A8>(;+PU\-]&U"]BNC#%:6\+I
M#;LSHVP Y7&1@@YKHM1B?4=#NX;24+)<VSK#(#T+*0I_45+>V<=_:O;3%O)D
M&)%4XWKW4^Q]JG    & .@% 'G/@G7H+G0M$\.7FA70UO2UB@E@GLVV0&,;3
M,)"-H^4$@@Y).!US4&BS-HNB^+/#^M03->RW=W- OE,WVZ.;)4I@?,3G! Z=
MZ].HH \KTK3+K1/$7P[L+T.\UAI=Q#<R!2R1.R1[5+#@="!ZXJ&U@T^[T_Q;
M:ZI'?QVUSXC,L4]LKI)$"L>R="!T#+]X<<$]*]:HH \>U"U\47GAC5;<3'78
MM+U&TNK:[BA"2:A"A#O&0.'9,#D=2,=>*Z6^,7BCQOX4U/2F=X--%S-=3[&4
M(KQA1&<@?,3U7J ISCBN\HH \@^9_AU\1H!#.9KK4[YK>/RFW2JX&PJ,98'!
MP1Z5I2WKZ)XU\.Z]>0W#:+/H?V#SDA9Q;3[U?+@ E=P4+G'4>U>FT4 >.C4Y
M[33_ !G=0Z/<7$<VNQ3!KC3Y'5(B(@9@A7YBFTL!U! )%:FB9D\?>(C#'J<\
M=_I,'D7-U Z^:1YF3DJ HR0 ,#V&*].HH \9>9I?@CH=@+2]%U:SV4<L3VLB
ML&CF4O@$9(4 DD<>]=1;W#:#\3]:O=2++INL6ELUG=[28T:(,&B+#[I.XL,]
M?K7?44 >-7&E7.G^'8))+>=8[[QDNI06_E-NBMO.!W,N,J,#<<]-PSS74"[C
MMOBWJE^R3-;)H,8\Q(F8,R2.[*I ^9MI!P.:[VD=2R,H8J2,!EQD>XS0!G:#
MK=IXBT>#5+$2B";< LT91U*DJ0RGH00:TJ@M+2&QME@@4A 68Y.268DL23U)
M)))]ZGH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M" <D#CUXQ5Q(M.\8Z3J?]B:#?66H2Z9/:_;-0@>)HF="!$"_)Y.3C@8ZY(H
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MEWBQ8!86DW8@Y7Y0<MSTZGMFL2UT.]T+PUX!L9[*Z\VWUHWDT44+2"VB?S2
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MS3;)=,NB\9E8IE6CP0N< \GD"NKU/4[31]/DOKV7RX(\ D DDD@*H Y))(
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MC<W F-]8AF$S#>&E (;!^;\<T >PT5C0>)+6?Q3<>'OL]S'>P0"X)= $:,G
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M>V[0[I(\KO!^0D$%3G.<>N*+/QOIM[JUAIZVU_$^H0M+9RS0;(Y]J[F523U
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M:/O4<KN'!) .#T)]\:!\>Z1X:TGPI;79U2[&KVT0M+DQ"1Y3M3EP&SN.]2<
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M'HPZ?T-=IJ.GZA;?'2W\2-IM[)I$>F"![B&W:3:[;R!L4%CVS@'&1G%>HT4
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M_>Z-8?#_ $N*VN;S^R+F-[N:&,LJ*(F0GW&YN@YQVKT:53-;.J\%T(&1CJ*
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M;>N"=H.>IZ8I] 'GL_A^6XD\3:MJ&A->P:W-:PMII*^9]GB 4R'D /RS@9R
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M0KCP='JBR7<TUCJ@$1B*2.7_ 'Q;Y@5+'. 2>PZ9]/C4I&JG&0 .!@?E3J*
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MY=W/)"GG"Y[C)P*ATK2]5M_'NGZY%X9N;:T;29+6<S7,3S>9YB/ND.XEB0I
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M0RJQ*1H@,>&P#GYF))[D5=T_Q5I5EX6\.M9VL-FNI6RM96DDRQ)&@0,=SGH
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M9FCDBE&'BD4X9&'8@B@#5HKG)/%+/?:C;V%B+O\ LV>."Z43A95+!6W*F.5
M<<DCHV <4^V\2M=:UKVDI8D7.DQPR$F4;9A(&9<'&0<*<Y'6@#H*QM;T*QU.
MZL+^]NIH3ILOGP,LBHJ/@C<<CG@D<\5GZ?XVM]4T?0[NTM)&N]91GM;5W"X5
M1EF=N<*.,D G)  .:YCXA:F-<^&6NM>:3+:76G7L,)69-PW":/YXFP-RD-U
M!Y(Q0!ZA17.6/BF2X\5MH-[I,]C*]J;NVDDD1A+&&"MD*?E8$CCGBL;XR012
M?"S6I'C5I(HT:-R.4/F)R#VH [RL:V\+Z9;>(;C7%6=[V<Y_>SNZ1G&TE$)P
MI(&,@>W0UYMXQNM&M=/T6+PO -,\1S7,*VDR6S6:$9&\2,RJK*1GY3G.>!7H
MP\0D^,)?#AM")UL/MT<WF?(Z[]FT\9!S]>* -RF2RQP1F261(T'5G. /QKE+
M7QY:W6C6E[]E\B:ZU%]-BBGF"KYJEP<O@X'R-C@D\#'-0^*]>@M_!FI7.O\
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MMAVXRIQC!X[]0*BN?%C[=5FTS37O[?29&BNF64(S.JAG6-2/G*@C.2O/ )-
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MEELQYT1\P-$L8!^?Y3D9Y[?E7H%% '#MX>-U\'X=$UA3836FF1H\C.I\B6%
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M<$=Q76TV.1)HDEB=7C<!E93D,#T(/<4Z@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFO'VJ
M6FC>#+^]O](75;.,+YMJY7:P+  G=G@''8UTM<O\1-)O]>\#:EI.F0":[NE1
M$!<(HPZL223Z"@!=3\57%CXJM_#UKHLMS//9O<Q2>>J(=I48/7 ^;D_D#5>S
M\>P3^')-1N;"2"]CU Z6;%9 [-=!]@16X!!)!SQ@9/:BXT[5)_B+I>MC3I!9
M0:=+;2DRQ[E=V5AQNY VX)]ZYF7P9XAFT:^D@MHX-2M_$S:[8QRRJ4F7/$;%
M2=IP3[9QSZ %^$W0^-L,EUID%O.= E.ZWE\P3?ODQ\Q53D=.1Z<^DD'C>STC
MP)?Z_9^&S;PP:C+#-:PNB_O/-",Y(')+'L#5FVM/$-Y\0K'Q!<:(MG:QZ7):
M21O=H[J[2*W 7(/W>.>_)'2L2?PIX@E^&NLZ&NF8OKS5'NH@9X]NQK@2\G/!
MP,?6@#J9?&%Q9.L&J:7'IMS<7#QV:W5]&$EC50QD9AG8!D#&"<D=1S5:P^(M
MG=VEX)+7;?VU]'8+;P3"5)Y9/]68Y, %2,G) P%.1Q3_ !=IFNW%[H?B+0;>
M.34-,,H>PN)0@GBE"AUWC(##:I!Z?R-3Q!I'BCQ-X?@O/L]KIVKV-]#?65BT
MWFKNCW9620 #+!B..!@<\DT :%[XGUBUMM=C?0A%=Z=9_:H93*S6LXP3@2;
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M.TZOYBH0&#*!\A&X'J?K65)\3;&/^SKI8K>73+ZX6!)(KQ6G0,<+(T..$/\
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M&XOO(\VWDO+<;_+W*9(@>,XZC/(S7+:?\0(M1T?3YHM/=-3OKM[**R>3 \Q
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MAM;F&<1.8Y#$X;8XP2IQT/(X]ZYZ+Q<FJ7&GV6DV@FNKRQ%^Z73F(00G &_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0TJY%Y-MF#B:94*J(\?P98L2V#P!CN*VFZ!KFFVGB^Q-K;RPZE=W5U:RK/\
M,YF4 *5(^4#G)S] :ZK^W-).GIJ U.S-D\GE)<><OEL^[;M#9P3NX^M:% 'G
M4?AK7(](\"6OV)#)H4D;7>)UP0L1C^3USG/.*??V5YI%_P".M:OK:U6QU*TA
MCM_M+AD9DC:,+(HYPS,  ,YSVKT*J]]86FIV4ME?6T5S:S+MDBE4,K#W!H \
MYT:'6M!GT>35_"9:*R5+*"[&L+.;82%4)6,JN<G:.I..!QQ6[\5O^26^(?\
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M_;%5H]_TV')]6 /:NNHH XZWT;5?#_C36=5L;47^GZPL4DD2RJDD$Z+MS\V
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M4DGH* .7\>63:CX-WHPM=6M)(;FPR0S)<A@(UXZ[B=GT:NCT?3AI6D6UEO\
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M168ERRI\IS]\ 9Q]WWK<TS1M3MOB#K6LS10"QOK:"&,K*2X,>[DKC&#N]>U
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MY1<R0WDS1M:S[0K,"JG<IV@XZ\=NI[6W2>"RC263[1<)& SXV[VQR<=LG\J
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M]LW.CQL5&U=HW D8SQSGC &9GT?4=9\1:/K6IV<-J=(CF:*!)_,,DTBA2<X
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M445P7Q9U.ZL_#FGZ=:3/ VL:G!ITDT9PR1N3NP>Q(&/H30!U:^(=%>Z-JNL6
M!N VPQ"Y3<&],9SGVK0CD2:))8G5XW4,K*<A@>A!JG_8NF_V+_8_V&#^SO*\
MG[-L&S9C&,5BQZB]AJ=GX0TGRWN;33DFEGN<E8XP1&G P69B#W& ,^@H ZBB
MO/;WXC7=IX6U>^&E0G4M'O5LKVV:<[06=55T.WYE(8$ [>_ISH3>)O$-OXM3
M09-*L#)>6CW-G(MTVU-C ,)?E]&!^4'GCW !TVH:KI^E1QR:A>P6JR.(XS-(
M%WL3@ 9ZGV%7*\G\4>(;G7OAY>->6<<5_INO064T<#[D=TGCY0MC@AAUKI[7
MQ3K5MXPAT#7=*LX&OX))M/FM;EI$<QC+1N2H(8 @Y Q0!T]CJ-EJ<+S6-U%<
M1I(T3-$P8!U.&7Z@U:KSH^/+RS^'^H>(8=$LTDM=1DMI+9)B%SYPC+ [1N)8
MY.=N:V[/Q)JB>-/[!U33[:)9[)KRU>WF+G"N%9'R -WS Y''\Z .JIKNL:,[
ML%11EF)P /6N)M_&U^FL:!9ZC96UN^L/(AL_,/VBS(5F3>.^0O/ P3WJ/0-9
M\07.N>,/M"V=PEA<B*&'S&0 ")6"@X/7<<G'7MB@#M+&^M-3L8;VQN([BUF7
M='+&V58>H-6*XC2?&8N/#7A9K:P@AO\ 705MK53MBA55+.QP.BJ.@ZD@<9R)
MG\87UEJ.M:/>6-N^J6%C_:-N4E9(KJ#D$]"4(88(Y[<T =C17!67CC6)(_"M
M]>Z7:1:;KQCA!CG9I8Y7C+J<8QM.TCKG&#[5N^.->?PQX)U;6(@#-;0$Q9&1
MO)"KGVW$4 ;B3Q2R21QR*SQ$!PISM)&<'T.*DKC=6O[OP+X%L[JWMX[J.V\H
M7SS.0V'($DW .X[F+'UR>:M+XIF7X@_\(U.EJL,EA]M@G60EI &VE<= 1UZ\
MB@#<NM5T^QN;:VNKV"&XNGV01/( \K>BCJ:M2.D4;22,%1069F.  .I->:^*
M;^]O[;P1J,EK$9IM=1X(T<@,ACEV$D],C!/IGOBMW3?$^JW%UXDTR^TZS_M'
M2$CE589V\J9)$+*-Q7((VD'B@#I[&^M=2LH;VRN([BVF7?'+&V58>H-1ZEJN
MGZ/:_:=2O8+2#.W?-($!/8#/4^U<MHWB]K[0_#$=G8V\%]K4#2Q0 XBMXT4%
MCQR0,J !C)/:L?X@7NJ7GPN\1QZOI@M9K6ZABC=&RER@FB*R)GD9ST/0CK0!
MZ6$4.SA0&; + <G'2G5RUGXCU1?&RZ!JEA:PI<V;W=K)!,SD!&"LCY &?F!R
M./KUJWXJ\21>&K*SGF>*%+J[2U-Q/GRH-P8[WQV^7'4<D<B@#2O]5T_2DC?4
M+V"U65Q''YT@7>Q. HSU/L*N5YOX^NKRZ\#K-=PP,R:O9^0]L^Y)T\V,JZD]
M,Y(Z\>IZUNV/B;5%\67V@ZIIUNLJ6 U"V-G,9-Z;RA0[@OS9Q[<T ;>K:'IV
MN1PQZC 9TAD$L:^8RA7'1N".1V/:FPZ]HSVMU-%JMHUO9-Y=Q+]H4K$0!PS$
MX!Y'4USECXSOCXBT'2M1M;6*;5X99#;1R'SK)D3S D@/7(R,X7D=*R]*5?*^
M)RX&#=R\?]NRT >AVMU!?6D-W:RI-;S()(I$.5=2,@@^A%1Q:C93ZA<V$5U$
M]W;*C3PJP+1ALE21VS@UC^ /^2=>&O\ L%VW_HM:SQXFNTU[Q;;)I-F)])M8
M)T<3$&Y#*[ ,VS*X"\#!ZGF@#LJ*X&Q\<ZQ)#X5U"\TJTBTW7FCA!CG9I8Y'
MC+J<8QM^4CKG&#[5H7'B?5KNTU2]T#38KV'3;IK;R&<B6Z="!)L/1<$D#.<E
M3TXR =&=5T\:H-+^VP?;S&91;"0>9L&/FV]<<CFK=<-?EG^+^AN$V2-HMUPP
MZ'?'P<5%<>/[Z#P#K/B/^S[<S:7>36SP>:VV01R;"0V,C/7I0!V6JZ=8:MI=
MQ8ZG!'/92KB6.7[I YY^F,_A4.@R:,^DQQ:"]HVGP$PQBT(,:E3R!CCK5&XU
MVXN?$DV@Z4D!N+6V6XNII\E(]Y(1 HP23M8YR, #KFN,\%>(#HGA%_.@07M]
MK]W;QP@ED1][LW(&2JA6Z#G Z9H ]11%C!"*%!). ,<DY)IU<SX<\1WVJ:OJ
M6F7U@R?9 CPWD<4B0W",.V\9#*>",FNE;.T[<9QQF@!:*\^NO'VJ6GA7Q#J<
MNG68OM#O#;SVAF8!D^7#AL?Q!@0,<].M=+%K%S=W]G#8+:W$$MC]KDEWLH&[
M CQP>'^;GL$/6@#2L-1LM5M!=6%U%<VY9E$D3!E)4D$9'H0::NJZ>VJG2UO;
M=K]8S*UL) 9%3(&XKU R1^=><7_BW5;OX7VNKZ;:V>FR3ZF+6:*,DA5^TF,[
M2 .3W..YXSTO7SZHGQ=M#;6]I)J#>'9 =\A6)?\ 2%Y)P6(]@.I[=: /1:*X
MBQ\?//X<L[F>QC35KG4VTE;993Y?GJ[*3NQG8 I;IGM5U?$M_;>)W\.7\%L+
MR:T:[L;F/<(I@IPR,IY5AP>I!!SQTH ZJBN$A\>W<W@[PUX@6PA U:\@M983
M(?W?F2;-RG'.,="*GT[4]:N/BCK6G2R6QL+6TMVCC!;*JYD.?=CCGM@#\0#J
M=0U73]*B234+V"U21PB&:0+O8\ #/4^PI7U&RCU*+3GNHEO98VEC@+#>R @%
M@/3FN3^*H!\% D<C4+/'_@0E:%SK<T7Q"L]%.G6Q6;3YKB.[,A\SY64%,;?E
M!)'<YP* .FHKSB;X@:\OAG5]=31;$0:1?36]S$UTQ9UC<*VP[>O4Y./I6U'X
MHU2'Q=I6EW^GVT=GJ\4SVCQ3%I$,:AB)!@#E3_"3@\9/6@#H[34;*^EN8K6Z
MBFDM9?)G5&!,;X!VGT."*6_T^SU2RELK^UAN;648>*9 RL/<&N#O?%>J'PKX
MXN[*RLK"_P!(FECWJQ</MB5O,)P,M@\9'8=<5KV^KZS:Z5HD3PVRK/:F6XU&
M5B8;=51=N_)!+,6]1T)YH UM*\*:%H<OFZ=IL,,H&T/RS*/0%B2!["KTFHV4
M.HP:?)=1)>3HSQ0%@'=5QN('?&17G6I^-M6U7P/I.J:<MM:RW&LQ6-SARX.)
M]AV,/X6V\D]CCWKII];NK?QUHVC76GV9:ZLYY1=HY+(4V[E *\ Y'<YQTH Z
MFBN)E\:7\WAJ]\4:;8P7&D6DDO[MG(EGBB8K)(IZ#[K$*0<@=1G <_C+4+SQ
M+8Z7H]A:3P7^E?VC;7,UPR@KN0#<H7(&&[9)XZ<D ':45@>#_$$_B+1YI[NV
M2VO+6[FL[B.-RR>9&Q4E2<'!Z\UN2N8XG<(SE5)"+U;V% #ZSK[0M.U*_M+Z
M[@:2YLR6MY!*Z^63P2,$#)'!]1Q7-67C2^_X2#0-,U&TM89=8CE8VJ2'S[)E
MC\P+(#URH(SA>1WKH?$.MQZ!I?VMXC-+)-';P0AMOF2R,%1<]AD\GL,]: -6
MBN8G\0ZEHD^I2:[8QC3+2Q-X-0MB=I()W1%6.=W<'H<]JJ77B[4=)AT74-5L
MK=--U2:.!O)<F2T>0?)N)X<9X)&,'UH [*BN)M?%/B34O$6JZ98Z-IY72[R&
M&>26\8;HW0-N7Y/O8.<$8'OVRG^(/B5O#=[X@@\.V3V6FW,T5Y']L8R,D;E6
M,?RX. ,DMCZ4 >E,JNI5@"I&""."*P+3P/X8L;L7-KHMI$X;>JJOR*W7(3[H
M/T%00^*7UK53IV@B!FCLHKV6>XSM42Y,:;1R20"2<\#'7/&)/\1[I?#BW\&D
M1F\@U9=)OK5KC!BEWA3L.W#@Y!!.WK0!Z%17*-K7B6W>&#4-.T^T\QYFDO1.
MTEM!$@79N)"G<Q;&./ND^U<YJ_C;5=4^'%IK&G+;VDTNI)97&'+C G$9V,,<
M-CJ>@)[\T >B2:C90ZC!I\EU$MY.C210%AO=5QN('?&15JN6FUN[@\=:/HUW
MI]F6NK.>87:.2RE-NY0"HP#D=SG%4I?&M]-X9O?%.FV,%QI%H\O[LN1-/#$Q
M6213T'W6(4@Y ZC.  =+::%IUCJMUJ=O R7EWM$\OFN3)M&%R"<' X'IVK1K
MBW\9:A>>);+2]'L+2>"_TK^T;:ZFN&48W*!N4+D##=!DGCIR1J^#_$$_B/1I
M;B[MDMKRVNIK.XCC<LGF1L5)4G!P>M &_17,MXAU!/&T_AZ2WM8U>Q-Y93L[
M?OL-M92,<%203C/!!JAH'C6[\0>%+'4K>WM!?W-\;,VWF,RH58[_ )L<X16?
MIR..^: .ILM5T_49;B*RO8+E[9@DPAD#>6WH<=#[4ZZU&RLI[6"ZNHH9;J3R
MX$=@#(V,X7U.!7F]OJ.K:3XB^(=YI-E:3FVN(;B3[3*4!5;9254*#EC@]<#Z
MUT%UXL,LO@RXCTR"2VUQE9)97S);EH2XP-O7'&<COQ0!V54UU73WU5M+2]MV
MOUC\UK99 9%3(&XKU R1^=<]<^)M6NX-7N= TZ&]CTNX:V,+N1)=2)CS%0]%
MQG )SD@\#@G(OY;\_%^VDT^TB-Y)X;;Y+F38L?\ I"GYBH)..F!W].M 'HE%
M8/@_Q!+XDT'[9<VR6UU%/+;7$2/N421N5.TGJ#C/XUF^)_%>I:&FL7*V=M#:
M:;;+-')>2%?MS;69HXB.A 7&><D].] '845R%SXUC.I:580R6EG+J-@+V!KY
MB%E)QB)2,?-SD]<<8![=/I\MQ/IMK-=PB"YDA1IH@<B-R 67/?!R* +%%<->
M>-[_ $Z[TXWMC;V\=]J@L$LY),7*HSE%G]"I(!QCH1S75ZS>S:=HM[?6\"3R
MV\+RB*20H&VC.-P!QT]* +U%<)9>-]6_X1VUU_4M*M(;&]MK8VBQ7#-(\\I5
M0K#;PN6SD9('8G@2?\)O?V5[JD-YI4ES!:Z<]_#=6D,JHY3.83O'#\9!R<CL
M.E ';T5R=EXFO;_29]3LI-+OK(637$=Q;.VWS%P3$PY(.._7V&.:_P#PFUT=
M$\(:H+*'9KT\$$D?F',)E0MD''.-I':@#J;;5=/O+ZYLK:]@FNK7;Y\4<@9H
MLYQN Z$X/!]*MUY_9O<0?$?QS+9B+[2NGV3)YH.W<%EZXY-:WPZO]2U3P-I=
M_J<D<DUQ )=ZD[FSDDMGISZ4 =539)$AB>65U2- 69V. H'4D]A7//KU[J&N
M:II6BQVIETQ(_/DN2VUI'4LL8"]/EP2W.,C@\UQWB_Q1/XD^$<^I64*VI-S'
M;7L$KDO%(+A$9 0,$9SSW!_"@#T73]:TS5I)X["^@N)+<@3)&X+1YY&1U&>Q
M[U?JE962QRM>W%K:)J,JA)IH%Y=5)V@L1D@9[^IKG="\6W'B*Y0V/V%XENI;
M>[MBY%Q9A-X5G'?+*O&!C=P3UH Z^BN#E\=WT?@OQ%KGV"W,^BWT]JT/F-ME
M$3!20<9!.<]ZVI-?NKS6'TC2HX/M4%HEU<27!)2/>2$0 <DG:QSD8 '7- &M
M<:KI]I?6UC<7L$5W=$B"!I 'DP"3M7J>AJY7F>O:AJ5_?_#^_NM'-GJ;W\P:
MREE'R-Y,@Y<9^4XSG!..V>*ZCPQXAOM4U+6]*U2UMX+_ $J>-'-M(7CD21 Z
M$;@"#@X(]J .DHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L'QAX7@\7>'Y--EF
M:WE#K-;7"#+0RJ<JX'?TQZ$UO44 <]83>+OLZV]_9:2)U&UKR*Y<HW^T(M@.
M?]G=_P "JE=^&]2LO&5MXETJ2*ZD:Q%C>P7,AC,JAMRR*P4@,#G(Q@@]JZZB
M@#SS6/ FIWWAG7H(&LAJNMWT5U.9)6$42QLA5 0A+85,9P.6)]JVKO1-6N/'
MVEZZ([);6ULI;>1#.V\M(5.0-F"!M]1G/:NIHH \WE\"ZW<:!X@LGDT^.>^U
ML:K;$2NR\.C;'^0$?<ZC/7I71KHU_J?B6PUW5(;>!]-@E2UMH9C)F20 .[.5
M'&%P !W)]JZ6B@#S27P-X@E^'VK>'\Z8+J]U)KQ)/M$FQ5,XEP?W><\8Z>_M
M6[?Z!K-YXWM-:C:S@@BTV:S8B9FD5Y"K;E&S! *]R,^U==5;4-0M-*T^>_OI
MT@M8%WR2OT4>M 'G=CX,\50VWAA93HRS:->-+-()97-UN1E:5B5!WG=DKSD_
MQ#I6[8^']:TW7_$UQ#]@ELM5<3Q%Y'60/Y03:0%( R,[LGTQSD=='(DL:21L
M&1P&5AT(/0TZ@#SBT\!ZQ9^&_"?E360UOPXY\O\ >,8;B-AM="VT%2R]\'!'
M>M:Y\-:AJ.I:KK<\=K%J%QI1TRU@$S%$0EF9G?;G)8C@#@+[\=C10!Y^?".N
M_P#"/^"]/ TXRZ#<02SL;A\2".-DPO[OONSSTQ70^-]!?Q/X*U;1HB!-<P$1
M9.!O!#+GVW 5OT4 8ED;?Q1X/2*[C/EWEJ8+F)AAD8KMD0CLP.1]17)GX;WL
MOAO1+>?4P=8LKA3<7J\%X"GDR(/3,0 ^JY[UZ&D$4<DDB1JKR$%V P6(&,GU
M.*DH Y?Q5H.H:K=^'GTY+-8M,U!+N032LF5567:H"'^][=*KP>']8@\4^*-4
M"6+0ZK;0PVZ_:'#*8U9<M\G .[MG&.]=A10!YI%X&\1:?H/A2;3[C3UUWP\C
MP['=S;W,3@!E)VA@> 1QP:U/$GA_Q+XE\$7VG7$FG)J-Z\1\M97$$"(ZO@-M
M+,3M.3@=1Z<]5<:QIUKJ=KIL][#'?7>[R+<O\\F 22!UP #S5V@#EI]$U:X^
M(&F:\4LUM+:QEMI$\]B^YV5L@;,$#;CJ,Y[5IZ_:WMY;6\-K;65W 9<7EM>'
M"30E6! ^5N=Q4\C'%:U(S*B%F8*JC)). !0!YI)\/-2@\+7.DZ9]CABFU>._
MAM9;AS':QHR-Y:ML).2I/0 ;N^,G:U#PYK=YXSN=9@FM+6*71'TU)$F8RQ2E
M]XD V $ ^_O[5MIXJ\/R E=:L"H!.[SUVD#DX.<'&.U:] 'F^G>$/$T%SX0G
ME71H3HGFI.(I)&\[S(]C2Y*C+$\E3U/\7/&E9>&M:MD\8AUL"=:E>6VQ</\
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M.*QM:\)^(;_5/%/DRZ=+::S8?9;>:Y=_-M!Y11D50N-K,=V01@G)#8Q7?T4
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MDYJUH6AZEI_C'Q+JUT+7[+JK0-"(I69T\N/9\P*@<]>#73T4 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 5QWQ,U#4]-\*";3+B.!GN[>&5F4DE'E52!@C'7D^
MF?J.QKGO&N@7/B3PS+I]E-%%=":&>)IL["T<BOAL<X.W'% &7JOB+Q+:^*+3
MP]966ES7-S82W*3RR.B;T91\R@$A?F[$D^U5_$'C'7/#^F:C?7EIIUM]@BC9
M8)'+&^;:&E\I@05522 2IZ<XK0;0M;F\<:7KTYT\QVUE):S(DC@DNRL2H*]M
MH')YZ\=*R-9\$^(-0/BVWBO=.:VUM (I[@.9H0$"B+ & F1D$$XR?E.: -74
MO$^KIXLTS1M/L;-H]0LI+F.:>5@5*[?O #I\W09S[=:SXOB!<P>%KV_U2WM[
M>YL-6.EW4T89X(R' ,V/O;,,#C/7N*O1^'=;_P"$IT'5YWT]ET^QDM9E1W4L
M7V\J"IX&T#D\]>.E0Z5X<\0:5!JP3^RY3?ZQ)?M%)*Y1X9%PT3?)UX'.#]/4
M O\ ]MZP=#GO+2"QU-FN8X[2>T?$+PMLS,WS'A27R ?X>HSFLR#XA1VR^*3?
MM;74.AQ0S+<V60MPLBDJH!+8.Y=N=Q'/:J,WPYOX=+U&+2'L;$76IP7RZ9O=
MK3;&!NC8[0<.1D@+C@#%3W'@+4]7OO$QU6[L5M-=LH(6%LCEX9(@P7&>" 2#
MGOCH* .@CN_%*:K;6\UC926MS;N[7$.0+.4 %4<%LR YQE0O3H*X_1O$^O6O
MP=O?$EXMEJ,R&ZE,<H9 0)Y V>N1T 7CCC-=5X;L?%\7V>/Q%?:;)%:KM5K(
M/ON3C:&DW8 XY( .3@Y&,'#B\$:[#\-]4\)?:=.=9C-';39<?))(SEGX/(W8
MP/SH WY?$4]QKECH-@($OIK#[?-+,I9(8\A1A006)8D=1@ GVKG]2^(FHZ?X
M:\23G3K4ZQH$Z17,1D81NKD;)%XS@@YVDC&#S6I/X8U2'Q#I/B/3VM/[0M['
M^S[RVEE81319W#:X4D$-SRO.<<50UOP'?ZIX>\2QQRVBZMX@FB>9V=O*A2/:
M$4';EL!>N!DL>G2@#5M_$.KP>.+?0]4M+-(+ZTDN+5[=V9T,;*&5\C!X8'(Q
MZ<]:T?$FOC0;:R"1++=W]W'96L;-A3(YZL?0 $GZ8[U0N]$U6[\<:/KI6S2"
MRM9H)8Q,Q8F3;DK\F.-O?&<]JG\8^&I?$>G6GV2Y6VU#3[R.^LY74E!(F<!@
M.=I!(/UH J_\)%J=GXJ'AN^6T-S=VCW&GW<<;+&[)]Z-T+$@C(.0W(]*PI?B
M)J$'@S3M>GBL8)'U'[!J,+JQ^RD2%&(^;YBH7<1QD<\8KI8-#O;[Q19Z_JZ6
ML,UC;206T%M*TH#2$;W+,J]E  QZG//% ^ +>?6/$4MS-OTW5HSLM0.(I9$"
M2R?4A$(/;YO6@"UKOB'4]-M]?N[."TN+?2K+SB)"R%I=I=DR,]$"GISO'(QF
MJ%GXNUL:MX934+&Q2QUZ(^7Y+L98I!%YF6SP00",#IZFK$7A34(/AG<>'?M4
M-QJ=U9/!/=2L0K2.FTL2 20!@#CHHZ5#)X7UAY?!KC["/["'[\><_P"\_=&+
MY?D]#GGZ>] $FC^+[C7-4FM[26P$EM?26UWI\@9;F"-691)RWS9PIX7 #=3C
MFU\1;_4-+\ :S?:9.D-S#;LPD92Q48P=O(PWH>WH:SKKP=?ZMJ^E:AJ$6G17
MVG7PG74K:1O/DA!)$3+L'4$*<L1U('.*Z#Q9HK^(_">J:/'*L,EY;M$DC#(4
MD<9]LT <?KS:BGB/X>LRV\][YMSLQF-#FV;&2<GW/TK0MO'5W9V'B$:U:VYO
MM'NXK8+:%MDYE">5C.6&2X!Z^V>E2S^'O$%WJOA6_N&TS?I#2-.D<D@#;XC'
MA<J<XSG)QZ8'6J=YX"O]5/BZ.[N8+9-:E@GMI8'9GMY(54(2"HSR@/!]O>@#
M5TOQ#J\GBE=+N]/>:RFMS+'?PV4T"1.#S&XDSU'(8$9]*Q_B5<R76M>$?#3L
M18ZMJ!-X <"6.(!O+/LQ/(]JW_#UMXNWHWB6[TLB%<(NG*X\YNF]RV,<9^4#
M&3G/ %.\7^%5\3V-KY-T;/4K"X6ZL;H+N\J1?4=U/0B@#3U;1[+6=%N-)NX5
M:TGB,13 ^48X(]"."/3 K*;7+W4O$&IZ-HYM4ETN*)KB:Z1G5I) 65 JD8^4
M ELGJ.#4UL?%-Q"(+Z'2[0D8>ZM;B24GU*QM& I],LV/]JJ \.ZEI'C+4-=T
M8VL\.J0Q)>6MU,T9$D8VI(KA6S\O!!'OGM0!DM\1KV?0M(OK72X1<3ZRFD7U
MO+,<P2[]K!2!STX)QU'!J[#XB\42>)]1\.&STD7L5M'>07'F2>4(V9EPR_>9
M@R]L CGCH:USX#OH](TRVLIK22YCUP:U>RRLR"23>795 4X'( )[*.M:\6B:
MI'\0+OQ#MLS;3:<EFL?G-ORKLX8_)C!+8]NO/2@##'Q"U23PIX?U:'2;9[C4
M=373;B(SD!'\QD)3CD$H>2>,CK5VR\6Z[;>);_0-;TJU>]6P;4+ Z?*Q6X53
M@Q_.!A\X&>GTKF-6T+5/#?A+POIL[6<ETOBF&6)DD8HQ>61P&RH(P6QQGU]J
MZW4?"NI:U?ZCJ=Q<PV%])I<FG61MI&D\C><M(6*J<YV@ #@ \Y/ !%I_C#4&
M\3Z9HUZEA)/?V<D[1V[$-:3(%)BD.6!^]C( /'3FLF3X@^(8_"M]XB;3--6T
MTV_DMKJ+SG+R(LHC)0XP",YR>OH.]NP\(^(X=4\+WTLFC1#1[::VD@@$FUE=
M4&Y20.3MZ$#&?XJ@F\"ZY-\/=<\.&33UN-2O9;A91,Y5%>7S""-F21C'O[4
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M0DCYVG# E6QSM8 J<=B:R+#P[X@A\:Q^()WTE(_[*%B]K ) $*N74*2.G/7
MQ_=/6@#B) /^&;=0&./M,W_I<:]J9@BEF("@9)/85YP? FMM\*KKPD9=/%U-
M.[B?S7V!6G,W39G/;]?:O1%5I;?;<1H&9<.BMN7GJ,X&?R% '#S>-]1_X0X^
M,[:TMY='5C(;4AA.UN'VF0/G;NP-VS;TXW9JOK]SJ%W\2?!\EA<VIMIK6\FM
M_,C8C'EQY+889X/'3&34EIX(U>T\'77@L7-H^C2%XHKPR-Y\=N[%BACV[2P!
M(#;@.0<<8.I?^'-0?Q?X?U*Q2S6PTBWF@$3RL'82*J\84@8V#OS[4 6_%+S:
M%X(UFZT1;:TGM[6:Y0B'Y0P!=CM&/F)R<^IR<UQFKR:B=%^',T_DW-VVHV[1
MX)0-FV?&XG)SGJ?TKT37M-.L^'=3TM9!$;RUEMPY&=I=2N<?C7)R>%O$4^G^
M$X9WTLRZ)<QS2;))%5U2,Q@ E3R<DYXQTQWH D@\<7>G?\)3%KUM;^?H:PR@
MV9;;.LJDHH#<ALC;Z<U:LO$>LGQ19:=<Z<\]E>1.QNX+*>);611G9(9!A@1P
M&&.1TYJE?>!KO5]3\7&^EMX[+7;>"&-H9&:2%H@0K$%0#R0<9[5I>'+/QE&\
M*>([_2Y(;885[%7$ER<8!DW8"]<D*.3CD 8(!D?%F^N(]'T71X97ABUK5K>P
MN9$."(7)W 'MG&/IFNUDTNQETIM+>TA-@T7DFWV#9LQC;CTQ6;XN\+V_BW0F
MTZ:9[>5)%GMKF,9:"93E7 [_ $]":99'Q<8%MKZ+1Q(!M:]AGD.?]KR2@ /M
MOQ_*@"M#J4Z:Q_PBFC/")-,L8GGN;I#(!G*QIM4KDD*23GCC@YXQ+CXBWZ^&
MI+V+2[<:A9ZLNE7\#S':CEU7<AQ\P(8$9QC/?%:\OAK4=.\8GQ#H\L$YN;1+
M2]M[R5D\S9]R0.JM\PY!&,'VK,U#P'?R^'KBUM9;0W]]JZZK=R2,RH&#JP1<
M*20 BKDX[GOB@"W_ ,)%XF7Q?/X;>RTHW$MC]NMIUDDV1H'V,KC&6.2,8VY]
MJSW^(6JQ>#TU0Z7:O>Q:M_9=W&LS!-XE\LM'D<Y]R,>];K:)JA^(47B+;9_9
METMK$Q><V_<9%DW?<QC*X_7VKB?$>A:GH'@>YAN6LS-=>)8KV$QNS*IEN%8*
MV5'0]QU]J .IM?%6NV?C%= U[3;,&\M9+G3Y;&5F#E/O1-O ^;!SG@?GQ'9>
M,]2'B'0-+U"&Q6;5HYC):Q,?-L9$C\P)(=Q#9 (Z+SVJ]>>'-1UG6EU6]E@L
MI[:QGM;(6LC2F.24 -*6*KR H &/4Y],/3_!?B6W?PE)+/HR-H+2HPB60^<K
MQ&,R$D#+G.2/7)W'.* &S^._$HT'Q%JT6EZ8(]"OYH)D:9R94C"D[3@?-@DY
M/'08[UO7/B:]M?%VBV,L5NFDZO"S07!#;Q*%#>4><#(R0?8C'>LD^#-:;PKX
MNTDOIXEUR\N+B)Q,^V(2@#!^3DC;VZY[5+XOM[>[\(6^AR7]K#XB@-N]DD$H
M:2.X5@(W4'!VYSDXX7=Z4 ;UL\WB*UU>"YBLI+#[0]M;^9!YBR!.&+J3@X<,
MN/\ 8SWP,_5M7L_ UEH.D1S065G*?LJ7EVI:*'8F5#8*C+8XY Z_2NDTRPBT
MO3+:PA),=O&L89NK8'4^YZGW-4-=L;Z_>"**VT^\L&21+NTO20L@.W:00K<C
M!ZCO^( +>D3WESID<M^L G+.,VYRC*'(1EZ\,H4_C7)>*_&FI^&[75K^2VLX
M;:PD006]PQ\V^3Y=[H0WR@;B.5;[O..VWX-\.GPOH TWS 4\^66.)&+) CN6
M$:D\D*#C)QGDX%<MK7@7Q%J5IXML([[36@UJ3S8KF<.9D "XA.!@(-O!!.,G
MCF@#:UCQ=);>)9="MI[&UO19I<6J7P8"]=BPV(P8 8VC/WC\W3CENJ>+I[;Q
M#_8:36%G?FR2XMTO@P6[D8L#&C!@!@J,_>/S=..8]?\ #&J^(M.NM/U2TT:^
MMYK=1"TCNC6LV""R?(Q(Z$<@\'UX9K'@^_U31FT2\AT[5;$64<,,][(R313*
MFTR@A&Y/!X(.0>>: +=]XHO6U"YTRPCC2]M+:*:=I+2:=?,<$K'B/[O"Y+$]
MQ@'G&#>>)?$6IW/@>6.W_LAM1N)A<V5W"^]9$CDX;D'9QD<#/RGVJXWA#Q-H
M>KV^I^&]3LKB22Q@L]0BU0.%G,2[5F#)DAL$Y'2M#6/#6LWC^';Z"^M)M1TN
MZ>>4W"LL<@D1E8*!D@#=\H/8#)[T 1GQ=<W'B+4-&M)M/CO[*:-!8W(99;F,
MJC-+&=P&,,V  ?N\D9XZ/7=7@T#0KW5KD,T-I"TK*O5L#@#W)P/QKE?$G@[4
M?$\4MM?1Z:72X26QU-'9+FT4%2=HV\G(;'S@<C/3GI_$.BP>(O#U_H]P[)%>
M0M$77JN1PP^AP?PH PK7Q+K8\1Z?8SZ8UQ9WL;EIX;*>(6<BC(61G&&4] P"
M\CI7-Z_XLUFX^&WBV]M8[33[JPU*6P<P[GRH9$+!N/F.\_-C\,UU'ARP\9P&
M"#Q!J&ES6]J,+)9K();H@8!DW<+ZD+G) [9SCR^ ]6N_!_BO19[BRBFUC4);
MZ"1'9E0LRL%;*CILQD>O2@!?$IU*/XA^",+:S7_E:B ?FCB^Y'R>IP!^?MVL
MV?CNZBT;5'U2T@_M*PU4:6$MBYCFD<IL8#!8##@D<G@XSTJY=:%KM]XJ\-ZU
M<G3A_9B7"SI'(XW&957Y<J?N[>IQG/:LJ;P#J=]8>(X)KNWM)]0U--3L;B!V
M<V\J;-NX%1G[GZF@"Z/%>NP7^IVLFE"YB@L&O+>^^RSVL+,IYB?>&PV.00>1
MZ5=\':SK^OV%EJFH6>GV^G7EC'/$(9&,HD;!(((QMQR.<^OM';:?XQO=)O(M
M<N-(-P]L\$,5D9%C=F&#)(S GCLH&.3STQI^$M+N]$\*:9I-Z8&FLK=+<O"Q
M97"@ 'D C..E $5[KEQ)XH3P[IGD+=+:_;+B>=2ZQ(6VJ H(+,QSW& .^17!
M:1K6H>'_  )XZU8V5G<75MKMV\T+N1$?N XXR1[''UKK=6\.:O#XVA\4:#+9
MM*]I]BO+2\=D22,-N5E958A@3Z8(K'?P-KTOA#Q7H\ESIIFUN^FN8W4NJQ"0
MKG/!)^[T]^M &KK7B;7+;Q+I6BZ986$CZC9S3QRW$S *Z!3\P X7YATR3[=:
MAN/%NLM'?V]I:V[:EID2+<QI:SSQS7!C#M&C(!M&&4!CDY/3C)MSZ!J\_B_P
M_K!%BL.G6LL$R><Y9C(%R5^3MM[]<]JJW?ASQ/I?BV_U?PS>:8;75-C7EKJ*
MR8CD50OF1E.N0!D''3KZ %JR\57NM7=GIUE9_P!GW\FGK?72W\3,;;<Q58R@
M*DL2&YR, 9YS6-X@UOQ2=+\*M-;P:3=WFLQ6MW;D^;NPS%2&5ON'8#CK@XSU
MS>U/PKXAMO$5EXAT#4;.7419_8KZ/4 RQ7";BX8;,E6#$X'3&!];&O>&M:U7
M2M(87MI)JMAJ<6HL9 R0N5W QKC)50&XZ],GJ: *KK-_PN:V!:/[1_PC,@+!
M3MW?:$YQG.,]L_C3]-\8ZE<>'-:FN[>UBUK3;MK/[&@8JTI($0R3DB3<N#QU
M[XJ[_8>J+X_M_$4TED;6+2C8R@.RL6+K(7 P0!E<8)_&LZ#3--UKXF+K>EW\
M<]K'9H]ZMNZO%+,"RP$D<%@ID/MA#Z4 =E+<BQTU[J^D0""$R3N@(4!1EB!R
M<<&N-N_&^I6'A2Q\7W%I;'1+@Q22P*&\^""0@))NSAC\RDKM'4\G&3VE[:0Z
MA87%E<*6@N(FBD /56!!_0UP\/@K5YO!L/@S49[.728FCC-XCMYTENCAE0Q[
M<*V%"D[CQSB@"R/$OB:^\6:SHNFZ=I>W36M7\V>=_GCD!)Z+][ XXP,'DYKM
MJYC2-"U&P\;Z]K$WV3['J26Z(J2,73RE91D%0.=WKQCO73T %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 445QGQ.O=2L?"8ETV[2W+W=O#*6C+%D>55(!R,=>>
MN1D<=: .D.M::-;71OMD?]HM$9A;CEM@QDGTZCK5^O.]7&J+\5-#6![1[\Z/
M= RNC+$/WD?S;,DGZ;N?45'<>/M;M_ M_JQLK!]1TW5#IMRJEQ&Y$JQ[D&<\
M[@<$T >D45Q\FOZ]9:M8Z)?+I8U+4[B9K5X!(T<-M&@9F<'!9\G;@$ YSQC%
M4[SQGJNG'Q/IUS%9G5-'L3J,$JQL(KJ#:3]W=E6!7:?F/K[4 =Y17'R^*K]+
MSP<HBMC#KJXG7:VZ-O),F5.<8R,8(_&J&I>.-3CT;Q1J]A!:"'0;M[8VTZMO
MGV!2[;@PVYW?+P>GOP =@^M:;'K46CM>1C498VE2W'+%1U/M^-7Z\WU6;4[C
MXA>$)HH[5;^;3+P_.6\M,^6<D<,<#MQSW'6ND\&:]?:Y8ZBFI1VZ7NG:A-83
M-;@B.0I@AE!)(R&'!)H Z2BN<GUR[O?%5UX?TI[:*6RM4N+F>XB:0 R$A$"A
ME[*23GT&.>.:N/B)JB^&WNHM/M!J5EK":3?0N[;-Q=5W1]\$,",]/?% 'I%%
M<9%XKU+3/$VJZ9KZ61@MM+.JQRV:N-L:L59&W'YB,9!&,^E16OBO79KW1)DT
MUKFPU%E6XCBL)XVLPPRKF5OE=1T) 'J* .XJLNH6C6\MP+B,00DAY6;"#'7Y
MCQQT)]01VKF_B3J]SI'@V;['*T5U>31644J\&,RN%+#W"EB/?%=!)8VL.BM8
MI!&+6*#RTB*Y4*!@#'X4 +%JMA/IBZG#=1RV++O$\9W(5SC=D=O?IWJVK*Z*
MZ,&5AD$'((KD/A7_ ,DN\/?]>@_F:9X&O7CU3Q/X>)S%I-^/LP_N0RKYBH/9
M26 ]!@=J .SHKG;O7;F?Q9_PCFF-!'<16?VRXGGC,BHI;:BA0RY)())SP .N
M>.9O_B'JMIX6UFZ%A:?VMHM_'97<19O+<.ZJLB#KA@X.">,'K0!Z116;HYUL
MI<_VT+ -YQ^SBS+D"+ P'W?Q9SR.#QTKEG\2^)[O5?%6GV,.DQ/HOE-&\PD<
M2!HO,P0".3P,\8]#V .[HKSR'QOKCV'A76Y+2P32]:N(+5[=2YFC:4'#A\A<
M C[N.G?TUX]?U;6Y]<70/L2KI5P;0"ZC9S<3JH9ER&&P#<%SAN<G'&" =917
MG:?$+4=6@\(W&BV5H(M>::-UNF;=#)&C$CC&0&4^Y [9J\/$NN&XET>0V4>K
MV=M'+=RP6-Q=0&20ML50N&487)+'OP#@T =M161X8U2^UGP[:7VI:;+IM[(I
M$UK*""C D=^<'&1[&L'3O&%SJVNW6G6USI\5U:7[03Z;/&RW'D*V/-4E@&RN
M'X7&#C.1R =/J&CZ;JQA.H6,%UY#B2+SD#;&'1AGH?>FMK.F0ZQ#HQNXQJ$D
M9D2W!RVQ>I]OQKEU\7:J=$\971CLOM&@33)$1&VR54B$GS#=D$YQP:RM2O=2
MU'QKX)OK".U%]=:/<RCSRWE(66(DD#D@9Z<9]1UH ]-JO?W]MI>GW%_>RB&U
MMXS++(02%4#)/'-<$GQ U.PTO78M;LK>+4]%NH(;J6V1W@$,Q&V?;G=@*22N
M<\=1GC1O/$^HP^"]:UVTFTG4X;6%I[6:#<(I45,L& 9CN!R,9';I0!TEK8:3
M->#7+:SM3=W,2_Z8L0$DD>!C+8SC&/TJ&/Q/HLMIJ5U'J$3P:86%Y(F2(MJ[
MCG YP/3-97_"375W?Z+H]D+=-0OK#[?/)(A9(8AM'"@@DEFP.> ">>AY;1]1
MU/1;3XDZD8[.>^L[QIF4AEB<);J>F21D#IGOUH ]/MKF&\M8;JW<20S(LD;C
MHRD9!_(U+7*2Z_JC6&AW"+96EM>6@GNKZX&8XG*J5C5-ZDEBQQST7OFL(?$'
M6)?!>B:S;V%FUQ>:JNG3QLSJN?.,>4[C.W//3/?% '>7NK6.G7%E;W=PL4M[
M+Y-NI!_>/@G Q[ ]:N5Q5WKOB72-2\/V>JP:1(=1U%[=I+;S/ECV,RD!NC8&
M#R146I^,=5ECU>70;47#:;<-;K;-8SRFZ=,;P)$^5#DD#.[ID]: .ZJ%+J"2
MYEMED!GB +Q]" >AQW'7GID$=C7%7WCBY&K'2XFM-+OY+"*YL[?5(F!NI'!)
MC#;E"E2 I')R>G%3^/[V31(M"U^+Y9;;48H)L?Q03'9(A]L[6^JB@#M*BBNH
M9Y98HI [PD+)MY"D\XSTS[=>1ZBL?QGK4GAWP9J^KQ &:VMG:+(R-^,+GVR1
M65/J7_"%?#FPN<%_+2 7-PZ-($,C#S)W Y;EF8^IH [*BN#UCQ?JFF^"=3\1
M6ESI.HPV\D9MI8%8QSQL44YPYVL&9NYZ#CFM>^\0W5CXZL-&<6YL;JRGN3)M
M(>,QE>^<$'=Z=J .EJAIVM:;JTUW%87D=P]I)Y4_E\A'QG&>AX]*YVPU_P 1
M:OINDZYIMC:3Z=?3KOM3E9HK9B0)?,+;2P&&*!>^ 3C)YN&^UO3-6^(E_HZ6
M&;2Z6XD^UAVWA;96* *1@D#[Q/X'L >JT51T?4!JVAV&I)'L%W;1W 0G[N]0
MV,_C7'Z7XL\27TFKW<\&DPZ9HVI7%O>-F0R-#'&&RG;=SWX.>V.0#M[RRM=1
MLY;2]MXKBVE&V2*5 RL/0@]:=;6MO96T=M:P1P01+MCBB4*JCT ' %<5:^+=
M=GNM#N(M-:YL-1=5GBBL)T>S5QE7,K?(ZC@' 'J*ETGQA<ZUK,]C;W.GQ7-K
M?207.F31LMQ'$K,!("7 ;("MPN,-C.1R =K5"ZUK3;+4[/3;B\CCO;TL+> \
MM)@$G ], \FN3'C'5O\ A%_&&H&.R^TZ!=W$,?[M]DR11J_(W9!.XCK46NW+
M7WB7X<7;JJO//-(0O0%K5B0* /0"<#)JGI6JV.MZ9#J.FW"W%I,"8Y5! ;!(
M/7GJ#7(>&+O7[KQ=XO2:]M)UM+F.&*-H&0 >4&4 [C@#<<\$DYZ=!1M_'NM3
M>#/"FLPV%@9M8U!+.6(LZJFYW V]<<)U.>N<'I0!Z317&V'BK5+76/$6G:W#
M:RMI=FE]$]BC+YD;!R5(8GY@4QGOGH*HCQEKIMO"=W'#ILL7B+:!%AU-N6C\
MP?,"=V "#P.1GVH ] HK)\3:];^&/#=]K5RC/':Q[MBG!=B0%7/;+$#/O6-?
M^(M7\/:IH::PME-9:M<+9EK:-D:WN&!*#ECO4D$9PN.OM0!U]%<1H/B#Q3KF
MKZA$MMI$5IINK/9W!+2%WB"*<IVW9;OP<]L<]!XAO[_3[."2PA@8O<(D\\[
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M1B^&8L6!VX[D8_'VJ'PSX?\ %ND1VNE:AK=C<:/9;1#)%"ZW4J+]Q'.=H P
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M")"RQ8V^F%)W8QSC-=M10!P-[X,UPOXLM;"^L$T_7U>3,J.98I&B$97CC:<
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MLHLJA2AR!G@=??I7644 <3X9\.^+=&CM=)O=;LKC1;(J()(X76ZD1?N(YSM
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY!'0_*&XR<@\$=-\.-7U25]3T'5/#MCI#Z9Y9 T]PT+;P3C@G#<9/.?FYQW
M..^(%T^M?'3PIX:ON=)B"7)@;[DLAWG)'?[@7\_6O8-6TFSUK3)=/O8@\$@'
M&.5(.0P]"" 1]*YKQMX @\5W>G:K:WK:=K>FN'M;Q4WC@[@KKQD9]^Y]<5J0
M6WB:Y$<>H7NGVT:D&5[&-R\N.P+G" ]_O''0@\T <O?>-M4U#QMKV@:.]O;1
MZ)IYN9)I8O,,TV 0F,C"<\]\CJ*PM:^+FJ+\+-'\7:7;VL=S<7OV2YMYHV=0
MV'R5(8'^ $=?O>U=3J/@.Y3Q7K&O:+=6\4NL6)M+J*X5L*V !*I'4X RIZ^H
MK(UCX0_:?AWI/A'3=22!+*Y%U+<S1%C*^&S\H/ )<]^  .>M $GBOQ)XZ\*>
M%M=UZ]&C*D,D!L88T>3"NVUUD.1R-R\CJ0>*B_X3OQ#I'B/P?'K#6$^G^)85
M 2WA9&MI2$QABQW#,BYX'?TJY\;2_P#PJ#5?-VB3=;[MIXSYR9Q5?2/!-]X@
MN/!FM:O?VSV6C64<MI#!$RO([(A!<DD#&U>G7';.* *MS\2-8O8?&6I:5]EB
MLO#<BQ1Q2Q%S=$,0Y9LC:/EXQZ\YZ4_Q!\3=5A_X06[T2VMI+?Q&P62WG4[E
M.Z,8#@\<N1G!Z9]JN7GPQN57Q39Z5?P0Z?XCD62?S8R7MFR2^P X8-DX!QCW
MJ76?AH]U<>#1I=Y#;VOAEU>..9"S3D%#R01C.SKZDT 37FL>.=$TB-]3M=,N
M)IM3\N2ZM,B*TLSC]XP<CD<]3@<9S65X>\>ZQK5IXXLQ<6IN-##-:7RVYQ(F
M'(+)G&?DZ].>G'/1^/O!]]XOMM+CLM56Q-E>+<LDD7FQR[>1N7(S@]CQR:S]
M ^'5UI.M^*KNYUA+JW\0)B51;[)%8ALD'. /G;C'ISQR <)I.JZO#^SQ>ZY>
M36.I1O([M;7MH9/,9KK#%VW_ #<MN& ,$#K76IXXN_M?@7PSIL-K:76LZ?'=
M3R+%E+>(1%ML:9QSM8#.0 .]-@^%^JP_"VZ\$MK5H\4C_NIQ;,"J^;YA+#<<
MDD8XP /6M _#R>&Y\)ZK;W=O_:_A^V%H2RL(KF((4P>ZG!)!YZGK0!D+\3-5
MD\(>,9@EH-9\-7)A9_*)BG7>55MN[()VMQGM^%1:?\0_$RZ]X(74?[.DL_$=
MON>&"%E:%L#!#%CGD@XQQR.>M:B?"Z2/PEXET\:A$=4\17#3W=R8SLCRY8*J
MYR0,GJ>_X5&/AEJ/VSP7.=3M?^*:B$>WRF_?\CW^7@#UYH [.7PU92IJ>50/
MJ)43.(EX49P ,8R,L<G)R<^@&!XSE7PW=^$=0LE$:QZE%ICH.AMYE*E3ZX*H
MP]UKN*Y+Q5I[>(M=T#3(QF&QODU.[<=$$8/EJ?=F(X]%8T =!K%Q<6FC7MS:
M"(W$,+R()02I(&><$'M7$MXRUUM \$WT$.GM+KLD45PKJX"L\;/E<'@?+WS7
M<:I;2WFE7=K R++-"T:L^=J[AC)Q]:Y!/!.IQZ-X2L!>VA/A^:.4N4;]_L0H
M!C^'(8^M &AX8UO5KKQ'K^A:NUI+-II@>.XM8FB5TE4D JS-@@J1UYI/%?BM
M?#VK:9:W-U#IUG>+)G4+B$O$LJE=L9(("Y!8Y)_AQ[BQI6@7ECXRUO6Y9X'A
MU-($$*J=T?E!@#GH<[CZ8JSK&G7][<J(Q8W.GO T5Q8WBDK(200V<'&.>,'.
M>V* ,A_$6LVFO>$;"X.GRQZN)UN6A1C@QQ-(&C;>1M.!U!X[US_BS7+[4_"/
MQ&TV\%N5TM!%"\,;*65HE?YLL>1G'&*U$\ 7FF:5X8CT?4(!>Z#-*\;74;-%
M(LH8.N <@ /A>3@ 4K> ;^ZM_%T%]K$+)X@5<M';$&)A&$S][IQ]WKC'S$T
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MDD:PPC4+K[2;6V&(8#M5<+TZ[<DX')Z#% &.;C5W^,C60OX?L4>CK.L+6Y.
MTVU@"''S'8/F.0/3UY73M;UOPWX.\1:W8?839V.O7;S031LSSJ;C#!6# )@'
MCAL^W?OKOP[?'QW#XCLKV"-#8"RG@EB+%E$A<%6!&"22#D'BL.7P#J<W@?7?
M#K7]H'U2\ENO/$;8C$DF\KMSS@C&<CK0!J:EXDO)M;U#2=*812V,$;O*UC+<
MAI) Q5<(1M "@DDY.[C&*H3>+?$$.F>$KF[TR&PN-4U!+*^M9U8O$3OR4YX!
MV9&<\,*GU'PKK\?B0>(/#^K6=G>7-NEO?V]S TL$VS.UQ@A@PR1U_P#KV=9\
M+:CJ4.@*-1BDETS4%OYI9T.9W&[*@ _*/G..N  .: *5OK?BO4O%^N:19G2(
MX-*N+7+RQR$R12)O8<-]['?IQTYR-WQ7X@'AS1UNDC66YGN(K2VC8X5I9&"K
MD^@R2?857T;0+[3O%NOZQ-<6[PZJ82(D5@T7E)L')ZY'/08JQXM\-Q>*M DT
MUYWMI0Z36]P@R894.5;'?GMZ$T 9MSKVK:-XMTS1=0DM9X=7CE6UNHH&0PSQ
MKN*NN\[E(Z8(/&/>N?N_'NOV7@C4M3F&G#5=)U)[2\MQ;2%60,/F0>9G_5GS
M,DXP#TQFNJBT&^O];TO5M<EM6FTQ)!!':JVUI' 5I"6Z?*" O;)Y/&&_\(;:
MOXPU#6Y7WP7MJD4EH1\C2@,AD/OY;;/H30 7FM:B[WDNES6,MK:Z:+DO)$Q#
MRL"R@$/TVKDC&?F7GFN?L?&'B/[#X.U>]7338Z[+#;2V\,3B1'DC9@X<MC&5
M^[MX'<]:W=#\)2:!X(ET&"[\^X>-X_M$V>01L3(_V4"+C_9K._X0G4QX>\*:
M6+VTSH%S#<&0HW[_ ,I2H&/X<ACSS0 V_P#%NM75OJMQX?MA.]A=/;1VK64L
MGVEHSM<>:"%3)W =<8!/7 2Z\0^++SQ9+H>EQ:9:NVDQ:A&;V-R8V:0J4?:W
M)^4CCI[U+'X1\1:3KVHS:!KMM;:5J=P;FXM[FV,KP2M]]HCD#GKAL@'L:T;;
MPW>6WCLZ\+J)K7^S4TX0L&,F%<N'+=SDD$8_&@#-B\875UXGN=$%Y8V>HV]Y
M'&+"ZA96N+<E=\D;E@&)!<@ '&,$=ZR4EUJ#QM\0Y]&ELHI85LY2UU&T@;;;
M9"A59<9_O9X]#VW=;\'WGB%/LNI2V4D4=\+JUO C"YMD$@?8OOQMW9& >AQ4
MD/A?48=8\57XN;5O[<CC1$VL/)V1^6"3_%D'/:@"G)XSU&72_!.HV\%JD.NS
MP17*.&9H]\;.=AR!_"1SFF-KOC'4_$'B72-)&C1/I30^3)<1R-YF^/>%(##D
M]-W;'0YX<O@C4TT+PEIRWMH3H%Q',7*-^_V(R 8S\N0QYYJMHW]IGXF>._[.
M:TY:R4_:-WR-Y'##'7O\O&?44 =+X*\1GQ7X2L=8>W^SS3!EFASD)(C%& ]L
MJ<5OUE>'-"@\-Z!::3;NTB0*=TC#!D=B69C]6)/XUJT %%%% !1110 4444
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MK)UB(?STP6C9MV/NY8<#.".U:GAR]O-2TY[ZYDC>&>9VM-D>W]QN(1CR<E@
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M<GS$=MI&_D\ ;L\8^[SP:3XVO-?M_"]I;+#;7^KV37MS)MW+#&@ ;8">2S'
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M\6:)#JS6%QI6M2- BV\3*]I+MW*"Q)W@X()P/H.A@N/%^LZ??Z0+N2T,UYK
MT^YL84\Q;>-RP0^:IP),!6*GKN/ Q0!W$FEZ?->I>RV%J]VF-L[0J77Z-C(J
MW7GTVN^*KK5?%]C:7>F0#1A$\$C6K.7#1&3:1OX]"V>W"\\+-XQU9=*\(>(&
M-K#H^J>2FHJ8BS0-*ORLK;L!=Y"G(XR* /0*R-2\3Z1I.HVVGWUTT5W='%O'
MY+L93Z+A3D\C@4FFWMY>ZYJH\R,Z=;.L$0$>&,H4,YW9Y R!TZAO2L7XF:/<
M:AX5_M'3A_Q-=&F74;,@<EH^67W!7(QW.* .DU76+'1+/[9J,QAM]P0R>6S
M$G SM!QDD#ZD"KB.)(U=0P# $;E*G\0>1^-<G;ZO;>,FT V9W64D2:K<#KC!
MQ$A]_,RWUA-3?VU>ZQXKU?0M-N([0:5#"T\SQ>8S2RAF50,@;0H!/<[N,8Y
M.HSCK5)M5M$UJ/2"TGVR2!KA5\MMNP,%/S8QG)'&<UYEJOBG6-=\.Z0PFCL+
MVW\40:7J$<499'D24<J2<[.%;'4],^O7#6=7B^(=OX?EFM)+632'NPZP%6\U
M9$3GYC\O).!CKUH ZRBO*G\:>*X_!=[XF>;3-FFZC)!-;+;-_I"+.(SAB_R<
M'(^]TZ]JZV[UJ^N?&\GANUE2S$>F_;?/:/>9&+E  #QM&.>YR.1W .HK,O\
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M^]QG/2MJ'P[?Q^-KCQ&U_;-YVGI9>0+=AC:Q<-NW^K'C'2NEHH X!OA[?O\
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M_P"8_,>1M]\]O1J* .6M/"]_:>(/$.JKJ5NYU>&&((UL?W7EJR@DA_FSN)/
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M0[O2-2C,EK<IM< X([@@]B" 1]*R]+TSQ1I]I'82ZU8W4,2A$NI;1O/*CIN
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MTT/5O"\'AC2-%U-7LK5F2\@>VW&9&;);=G]V%RV!W^4<UVU% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !7*_$#6M4T#PVM_I3VZS"Z@B99HRVY7D5.#
MGY?O=<'Z5U58'B_P[-XHT4:=%?)9CSXIC(T'FG*.'  W+W44 9%QJFOZ;JUK
MH5U>+>W=\9[I9[.U6-H;=-@"!7<J6W/]XYX'0]:J3>(_%6D>&[NYUG3IU%OJ
M"Q?:X8D>0V9/,WE*6 9>A'3OCC%;/BCPG<Z])IFH66K-IFM::6,%W'"'0A@
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MV0/ \K1>9M5E(.!N'//K6#+X-U>Z\)1>&)_$$":<MLEI(]M8%)I(E4+C<TC
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M%),8],@M]KVQ13()D7,I8CH,\ <9QGH13]*OO$VKZ;H.NVD]HUO?LDUU92*
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO/[5CGLK;3VN;*62-//29$8LK (%*' ]^:@E\1:HLW@.07 V:R MY'Y:X8F
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M-KA57 )*C.#T/)H ]&HKA=6UG6O#0\/:C<WXOK74+N&SO(#"BB-I1\KQ%0"
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M4GD@/FQE&W(<-P>1SZUR\:7K_&FZB.J7/V>/1XIEAVIM4&9@5'R]#M!)Z^^
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M*W[L?,2<<<9([YJ>,O$5WX \*:Q#<6T5Y?ZI%976Z#(<&9HR1S\N=O./7C%
M'J-%<187OB#_ (2[6_#5QJZS.+"*\M+H6R*8&9F4J5Z,N5!YYQW[U7T3Q+JF
MK^&;"U>[,7B(ZB;&]Q&A\IHV+2_+C&WRQE3ZLO/- '?X _&BL7Q;KZ^%O">I
M:TT?G&TA+JAXWMP%!]LD5@ZOK&L^&+CP]=W5_P#;[34KR*QNX3"BB)Y1\KQ%
M0"%##!#%N#USS0!W%96M>(;'038B]\[-]=1VD/EQ%AYCMA<GHHY[G\ZY?0+W
MQ3K7B#6(GUJVBM=*U?R6C6R!,\7EJQ3).5^]][).?;BI?B>)3I>@"$H)?^$@
ML=A<$J&\SC(':@#N**X*"_\ $VG>-3X;U'5X[N+4K&2YLKQ+18WMY$(!4KR&
M7Y@>>>WO3-%\2:MJ7AF&RGN_+\2KJ9T^YVQIA&5BSD+C&WR@6![Y'- 'H%9.
MK>(]/T5].2Z:4_VC=1VMNT4192[GC+#@#ZGMQFCQ*;A/"NJ-;7<MO/':2.D\
M87<I"DY&01V]*\VN8[I?AO\ #EOM;332:EI;QF=1A,Q\#Y0"0/<Y]Z /7Z9+
M#%.FR:-)%_NNH(_6O/W\5ZIX;U'Q;;ZK=+J<6EZ='J-NWDK$WS!P8SMXQE1@
M]>><UH6=QXO77=*D\BXN-,N$87_VC[,BPG;E7BV,6(SQAMQQWH [)5"J%4
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M?723VVJ6*V,]J(=N(QNP0VX\_,>WY5'X<\(:GHI@@O?%%WJ>G6G%I:RP(A0
M87>XYDVCIG S@]ACK:* "BBB@ HHJGJ>IVVDV@N;IR%:1(D51EI)'8*JJ.Y)
M('_UJ +E%9>CZY'J\EY"+.\LY[.7RIHKJ,*<D9!!!*L".X)K4H **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ8IVVK:_9^(?!QN]6^UVVN0R+/;&W1%C98/,5D(&[.00<D@YX Z#=7P?!%X
M/A*WNG2!K0VKW#+N=@P(=NOWCDG\:9)X1EDNO#EP=2^;0@1$! ,2Y3RSN^;^
M[Z8YY]J ,32_%5U<>*4TC5-1N=,U9;R7_0+F!%@N[<%MGDOMRQQL/WLY#<>G
MH=<N?"#W+:='J.H_;+;3KP7EL&@"RJX)*J7S]T9Z  G R3SFSX=L]5M;_6&O
MM1N+RSEN-]I]HC"-&#G<J@?P#Y0,]<$]""0"K=ZO=:AX[/AJUNGLXK:P%Y<3
M1*ID<L^U$&X$ #!).,].G.>&L[_5M ^'/CV^LM0VZA9ZY=O]I:%27(V G;C:
M"?ICVKO=8\)-?>)+7Q#INIRZ;J<,)MI'6-9$GA)W;'4^AY!!K-/P[#>'->T9
MM;NGCUJZDN9Y'B3*%R"VW ')VCD\>@% $>NW_B"3QGH>CZ?K"V5OJ-A<2.PM
MD=D= F&&>IRW3I]:A_M+Q%J3ZQI=A>7KWNDK':K<V\5LJSW'E*YDD60\*2P&
MU<< \GC&]+X7GF\1Z1K+ZE^]TV!X%C$ "R*X 8GG(/RC&.GO5/4_!$TWB6;7
M=%U^]T:YNT1+U(8TD2X"C"G:X(5@.-W/\\@$%AK.M:MKMOX?OI?[+O8-*2\O
MC:['9I7<H%0L& 4;23P3\RC/!SD>)[?Q#%I_@V'5]9(OFUV*">2Q5524?.R.
M0R?> 53C[N<\'C&]JO@1;C4-/U31]7N])U2S@-M]J15F\Z(G<5D5^&.[+9]2
M35C4_!J:CI.GVHU.Z2[LKU+]+U@KN\RYR6!&T@AB,  #@#@8H RY8G_X7);P
M_:)!)_PC,B^?A=^?M"?-C&W/?ICVJKI?B'6GT35=%O=19O%%KJ(L4E$,8R)#
MNBE";<;?+RQ!R?D:NAD\/_9/%">)Y=2D8VVG&S>-H=VZ/<'9B1R7R.PQVQ69
MH4>D>*O&/_"8Z='*UO%9"VCGDB>,32%F)(5@"2BDKN_VV':@#I]5U!=#\/WN
MHS%YUL;5YWS@,^Q23T&,G'85P^I>(M<T?P/I/C-]0-RDHMIKVQ\I!%Y4Q48C
M(7>"I<8)8YP<^WH=S;PW=K+;7$:R0S(8Y$;HRD8(/X5RUGX&6#2;30[C4Y;K
M1+.9)8;:2(;R$;<D;OGYD4@8& ?E )(XH SX+CQ-JWCKQ'I,'B!;.UTYK.6+
M;9HYVN&9D.>Q QGKTQCG.[XZO[_2O!&KZCIMP+>[M;9YD<QA^5&>AXI^F^''
MT_Q5JVN?;C(=36)98#$ J",$)M.<]"<YZ^U6O$>C?\)#X?O=(:X-O'>1&&21
M4W$*>#CWH Y;4=6UYO$GA"PM=46"#5;.=[C_ $=6.Y(E;<,]\L?;ID'H<Z/Q
MEJ^D:#KT%W=+?:A9ZTFEV=U-$J[O,V;6D5  =N\DXQG Z5U#>$Y7U?P_J+:E
MF3189(8U$ Q*'4*Q;GKA1C'?\JHS_#NUOK'7K._OI98]8N1>,T:"-K>8!0K1
MG)Z;1US^M %"_LKNT^+7A/S]3GO%:ROMOGI&"C!8\GY%7@\<=L>]4;CQ/XBB
M\!>-]074U^W:1J=Q!;S?9TXC0)A=N,=SR<UT<'@V^;7='U?4?$=S=W6F1RQI
MBVCC60.%!W#!_N\X_#'>&3P 9= \0:0^K-Y6N74EU.X@&Z-GQN"<XQ\HQG/?
MK0!7NM1U[2+G3+6XU62^FUR<")8;:*-K14A9W"%B Q)  W]!GJ:@O->\4>&=
M,UJXU)#);&>WBTJ>\\KS 96",)1$=I"DY!X)'!K>U[PA'XAT*RLKF_G@O;&1
M)K6_M@$DBD48# <CD=1T/M4,G@E-3\.W^E^(=5NM6EO46.2Y=$B*!3E-BJ-J
MX/.>23UR,"@"2?3O$-O=W?\ Q/GETN2Q8;G2-;F*X!^\A6,+M*]B#@CBO/YT
MG_X9PMYY[R>X::.T?$NWY/\ 2$S@A03_ ,")/O7HFA^&;W3U_P")MK]YK+)&
M883/&D8C0\$X4?,Q'&YB3Z8R<Y9^'>? O_")G6[EK,,@21X4W1HCAU48P,Y
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M MG9YZ('(..Q"J#]<UWVI^'X;VYTV]MG%I>Z:6^RRJFY0K+M9&7(RI&. 1R
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MB!DC!<H7<9P%&,DY.!5"TU&\\2^)_$%A!J$]C;:2T=O'Y 7<\K)O9VW Y R
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M<?A716U.:SGN8ED2-A"5&TNP4$Y(XRPZ9K;KRKQ7:ZY8_"?5K77KR"[FCU&
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MCMN3GJA P,<9+9XVT >CT5Y]I,FI^,?#4VMVFN2Z=?B_E$7),,$44Q7RWCR
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MN-.NTN2S10XR$G8J-PX(W$$XYSQ5KP1?R>+=)O-3NKFZMIY?]$ET]9W4V3H
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MEBSGMY=*DBCD,I7Y]Z[P1M)XQC\^U<WXOLA<_$SP4#<W48D^V@B*9D VPY!
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ME9(B4!4\'(! QR!Q6'X9O=3?Q?/X5U76;B5M/FDNH;H2D-J$1P!&<<?NR?G
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M1BR;4+,K+R >OIZUT%UX)TN]\/WVD3O<L+^<7-Q=!P)GE#*P?(& 1M4  8
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M4=Q=0OI<3PVT2,I0*X ;=N4L2<#G.:FT/PY;Z#<:E-!=74S:A<FZF$Y0CS"
M"1M48X &/:GZMK8T^^LM-MX1<:C>B1H(6DV+MC +,S8.!RHZ'DCW(ETC4I=0
MT>.^O+"?393N\VWN2-T94D'D<$<9![@@T 5=2\,VM_K=OK4-S<V.IP1&#[1;
M%<R1$YV.'5E89Y'&0>E6],T:STJREMH59Q/(\T[RD,TTC_>9NQ)^F ,   8J
MAJ?BF+3]1T&V2TDN(M8F\J*Y5U")\A<$CJ<@>GXUOT <S'X#T&/P[INA"W8V
M6GW*74 )R=ZL6Y/?.2#['%7=<\.6^O7.FSSW=U"VGW(NH1 4 \P @$[E.>"1
MCWK9JAK.LV.@:7-J.I3B&VBQDX))). H Y))X % &:?!VG2:IK-[<RW%R-8A
M6"[MY2GELB@A0 %!& Q[]ZKZ!X%M?#Q40ZOK%TD*E+2.\N1(EJ",?NUVXR <
M MG X[G,UWXGO+#29M4NO#NH):11&5E5XVF50,Y9 W'X$D>E=!%(LT*2+]UU
M##Z&@#G].\&6>F>%Y/#\%]?_ &1G9TD,B"6,E]Y*L%'\1)Y!I9_"%M=F^EN[
M^]GNKRR^P/<MY:NL!))5=J!>23DXS]*Z*B@#F3X)LS;Z#!_:%_LT,JUI\T>?
ME78-WR<_+Q_]?FJ6N>'8-+TOQ?JL-Q>SW6KV3K+$0KAG6(H@157.<8'O79T4
M <3X0\/17/A7PS)?W-]/]@MX9([2Y556&98P.1M#$KD@;B<=>H!KJ]4TRSUK
M2[G3=0A$UI<QF.6,]P?Y'WJW10!R^B>"(-#B9(]:UFZ*QF*V:\N1+]E4C'[L
M%<9QQD@G''3-.NO!%A=6^BH+R^AFT=S);7,3()2Q&"7)0YW<[N/FSSFNFHH
MP)/"5K+KM]J[WEXT][9_8I4W)L\OG&!MR""Q.<]Z?:>&((+^QO;F^O+^>PB>
M*U:Z*$QAP QRJJ6)"@9.?S)-;E% '(I\.=$'AFY\/2R7LVG2R&2)))N;8[BX
M\H@#;AB3DY/8DCBK%GX'T^+2KO3]1O-1UE+N$P22:E<>8XC_ +JD !>><@9)
M )/ QTU% ''P?#VTB?23/K>LW0TF3?9B:=/D&TKM)5 6&#C))/O1\4HY)_AM
MK=M!#+-//!LBBBC+L[;AP  37844 <_IV@V\TFGZE/?7E[):PE;0W 0>3N7#
M, $&6QQELG&?4YFT'PU!X>@OHK6]O)!>7$ETYF*$K*YRS+A1WYP<BMJB@#E8
MOA_I$?A<^'Y)KR:T$YN8I'D42PRER^]&51@AB3WZXZ<5HVOAY(+QK^:_N[K4
M/(^SI=S"/?$F<D*%0*,D DD'.!V %;-% &1X:\/6WA;1(=)L[BYFM82WE_:&
M5F4$EB,A1GDGK3-:\,VFN:AIM]+<7=O<Z<[M#);2;"0Z[74\'@@#I@^A%;5%
M '.OX/M%U+4+VROKZP.H@?;(K9DV3,!C?\RDJV."5(S]>:V[&RMM-L8+*SA6
M&VMXUCBC7HJ@8 J>B@#EW\"Z>8M=ACO=1BM]::1KF%)5V*T@"R%05."P'?..
MV*E;P;:O)H3G4+_=H@Q:\Q\_+L^;Y.?EX[?GS71T4 <A_P *ZTI-:NK^WOM4
MMK>\E,UWIT%SMMIW/4LN,\]P" >G2NLFC:2%D25XF(P'0#*_3((_2GT4 <EI
M?@*'1M%.CV.O:S#8$N?+62$-\Q);#^7N&23T-6+CP+HDGA2#PY;1RV5G;2)+
M;O;/B2*16W!PQSEL\Y.>M=+10!RJ^ [ ZA=W\VHZG/=7>GG3YY))QET.[YL!
M0 WS<8&!@8%7[?PU%%J$.H7&H7EY>6]N]O;S3^7NB5L;B-J %CM7E@>GN<[=
M% '(+\/-.3PU!H"ZCJ0LH+K[6AWQ[]^_S.NSIO)/_P!:M-O"]K)XE.NRW5U+
M<-9_87B?R_*>+.X@KM[GGK^G%;E% '):%\/=-\/W2M:ZCJTEC$YDM].GNMUM
M V<Y5<9X/(!)P>>O-6T\(6N;5+B_OKJVM;O[9!;SLA5)02R\A V%)) )].PQ
M7144 <ZOA"U)MTN+^^NK6VO/ML-M,R%4E#%EP0@;"L<@9].W%=%110 4444
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MEQ>)##%.R)#'%N4(4!VMD#)+ GYN,8&.[7P?8)J&C7JW-Z)-(B:*U!E# *P
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MR010B$^9*Z$AMH[@%3\W3CK4NBZ_8:_!/)8R/NMYF@N(I4*20R+U5E/0_H:
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M6\LL8"21@J,@@G!^=3@X//2J/C#Q/)X:ATOR;*:Y>^U""TR@!"!G&<Y(Y*Y
M'K7.^$M,O-'\2V<.B2ZJ?#DUM(T]CJ<#K]@<;=BQNX!Y)(V@D#&>XK6^(MM=
M3:9HUQ:VEQ="RUFTNIH[>,R/Y:-\Q"CDXST% &9/JYTWXM22,NI2QS>'UF6Q
M3?*WF&<@[8\D*<*,XP.*Z.'QKH]SH>GZK \TD>H3_9K:$1XE>;)!3!Q@@JV<
MD 8/-8\+3O\ %LZFVGW\=HV@+!YKVK[1)YQ?9D C.TYZ^W6N;TF36=*\)Z9
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M\,8\F>3G"J<YYP<$@ ]B:H:/XZCO6\13W]G<65GI-T\)ED0<*B(3G!/S$L<
M=L=ZSO!&KZI%HNE>&;[PUJ$.I::L=M+/+!BU"1_+YBR]&RHX YR?3)JO96\M
MH/'.G:EX?O[RWO-0DN=B0,4N('2-<(PZMPW Y!':@#N;'5UO+Z:R>SN[6>*-
M)2LZK@JQ(!!4D'[IXSD=ZT:\Z\.+J7AF\U06\FLZMX<M[ 3V\=W;/]JCE!/[
MB/>%9QM'0]#@>M=MHNJQ:WI%OJ,,,\"3 YBN$V21L"0RL.Q!!'X4 8T/CW2+
MG59-.MX-2FGBO%LYBEE)B)R,@OQ\J\]3[]AFIG\::7%<6(E6YCM-0F%O:7S1
MCR)I#G"@YR,X."0 >Q-8_A:UN)-7\;126UY:K?7IDMYI;=T5T,2IN4D#."#6
M'X0B5-/T[P[JO@27^V-/*1-=RV2FU(3@3B8\$X&<#G/'N #O#XFM/M!2.WNI
M8!=BR:YC0&-9BP7:>=PPQP3C&>,UD67CI9M6\1Q76G7D%GH[*K2"'>?N;RQ"
MY/((P,=.3CG&!<Z;>6_B-]4\-1ZK8W\NJ[+[3IK=S9W<?FX:?+#:I*#?N!]L
M9/-A8KVQUKQ_!)I>H.NH*LMM-%;L\<@^S!, CJ=PQ@<\YQC)H T[GQQH&L>&
M[^66+5TTQM.^TR7,=K*H,3CG8ZC[P[XZ<\\&MJ+6K&ST_2H;=;FXDNK=6M+=
M?FF= H)8EC@8!&68]2.<D5S"V]T?@.=-^PW@OQH?V/[*;9_,\WR=FW;C/7OT
MJE*^I^']6\+^)%TC4;VP&C#3;R"WMV:>V;*,&\O[Q&5P?I]* -C5/B+:II&G
M7NEVMS<FZU6/395,8!@?S KJP)^]C( &>2#G%:+ZEI4OC:Q@==135_L$DD<)
M#K%Y>5W9&=A;.!QG'>L3Q:;_ %3P]I6I0Z+>1I;:Y:WIM5AS<>2C@L[1KD[L
MY..N,9P<@6;G[1<?%31+\:??);+I<\3R-;MMC=V0JK, 0#A3WX[T ;5AXNT[
M4=)U/4H8[E8--DDBN1)&%97C&7&">P_^MFIKKQ%#;@*EE>W%R(!<26T,8,D4
M9S@L"0 3@X&<G!P#@US5QX?U"#XAW$=K"3H6M1QW=\W:.: @$>G[P&,$=P&J
MGKB2:%\0;S4M0\-W6M:3J=M"B2VEK]H>VECW J5ZA6#9SZT =WH^KV.O:3;:
MIILXGL[E-\<@!&1T/!Z$$$$>U9>I^-=)TJ*YN;@7#6-I,(+J\CC#10.2!ACG
M)P6 )4$#.#CFK_A^VBM=%@CATN+2XB6=+.-%3R@6)&0O 8YR<=R>O6N'\.7V
MJ>&GU3PS?>'=1O97OYY[*YB@W6T\<KEP9).B$%CG/X9H [2]\16UK=SVD-O=
M7UQ;Q":>.T0,8D.=I.2.3@X498XZ53N/'&C0Z7I>IQ/-<V6IS)!;3P1Y4R,<
M*K9QM.<CG&",'%8VF"\\,^//$<VHVMW-9:MY%S;75M;23 ,B;'C8("5/ (SP
M1WS4&E>!IKCX8:AH=ZIMKF_FGNX4)YM7:0O$..A4A2<=\T =G/K%M;:A):3!
MT\JW-S),V!''&,C+'/'0_D?0UGIXPT[^U+2PN(;RUDO8WELVFAP+D*,D+C)#
M8YVL ?:L&+2-;\2?#753J,/V77=7L3$T3\>60FU4/H"=S>WF&HO#%W;:G-8B
M?P)<:=JEF-UQ<7-@$C@8##&)^KECP-O8Y/3D TU^)>@/91WRIJ'V)KG[-)<F
MT<1P/OV#S"?NY;\1D9 R*TM4\7:?I=Q?0-%<W+Z?;BZO?LZ!OL\1SAFR1GA6
M.%R<#I7G4UAJ+_!G6=-72M1-]-J4DD=O]CDWLINA("!MZ;>?_KUK^)9M3U/4
MO$NGR:1JCVTVF :8;2W9$N&,;;O-?CYE8X",0,9^4DT =7>^--&L;G2H'>YD
M;58VEM##;NXD4)OX(')(Q@#GD<5G:A\0K2+P?K6M65E>23Z67BFM)HO+DCD
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MQNSMPH  !.<\#BJ%CXM\-Z%X3U+6[>#4EL(M0F6X#HSN)BX#<,?E7<<<D 4
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MM/\ 5 *&+G)'R@'Z\' P* .PHKD=2\8RP>*- TRRTZ>ZMM3AEN1<1E/G14!
M4,P_O*23CC&,\XZZ@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M,GW(  )) %<;H&IPS^,8K[5-(\06VJ7%M]A@N+^R2*$*,R%049@&8@DD]=H
MQTK2\>:3J-XNB:IID+7,^D:BEV]JI ::/!5PN>-P#9&?>@"_#XLMY-1O-,FL
M;RWU.VMQ<_9)/+W319QOC(8J1G@\@@U OCK37T70M76VO3::S<16T#;$RCR-
MM7>-W SZ9JG_ &7-KWCJWUY;>>VM+339;53<1F-Y9)&&1M/.U0.I')/&<5Q]
MK8:^/ _A/1?^$;U#[5HNK6KW1.P*RQR$DQDM\PQSDX'O0!W&D>*+[4?'6N:+
M)I<\=MIZVZK+OC(!=78NWS9PP"@  D8YQFG^,_$EYX=32!:6$ERU_J4%HSJR
M#:&;D ,1EF ('8=21QFII-KJ-A\3/$5Q)IMP;/5(;1HKD%?+3RT96#<YSDC
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MCSLE,JN%.TGG:IZ9&>,YH MO\1=,C\,0:_\ 8-1-H]S]DF41H'MI=^S$@+@
M;N,@D=*WY=62+6K72_LMP\MQ"\_F+MV1JI4'=\V>K # .>?0UR7A/P^U]X2\
M0:-K-C/!%?ZA>/LE3!,4KDJP]\'/J"*M_#JUU,Z,;_6I4GOB!9QRH<AX("R*
M_P!7.]\]PPH V==\1V_A^;3DNK6ZD2_NDM(Y80A5)&^Z&RP(!YYP?Y4RS\3P
M7GB'4]%%E=Q76GQI+(TOEA'5L[2AWY(.#V&.^*3QCH;>(O">H:;&=MR\>^V?
MH4F0[HSGM\P%<;/X7U^[OM%UPQB+4=51[37$5O\ 56\B @#T*! H_P!IB>]
M'5Q^,;><Z=%;Z;?R7FH6S7<-KB-7$*X^9B7VC.Y<#.>>@YQ7D^(.F)X>TO7(
M[._EL=1G6W5T1 89"^P"3<PV_,",\CCKTS%KYU5?%FG6PTR\N_#[6C@I9,J_
MZ1N&!*2R_N]O;."3R#BLWP?X8FO?A5+X6US3I;(M]HB8/M/WI7973!Z#*D$X
MY% ':/JJ+KL6DBVG:5X#<-*NW9&H.,-\V<D]..<'T-7ZY'X>PZE-H"ZKK3I+
MJ-VB1F1#D-%&"J$'N&.^3_MI774 %%%% !1110 4444 %%%% !1110 4444
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MF*82<.524[7^[PQ'7(ZCD5+:>(K[4?'VL>'IM,D^P6MM#\^]#G?OR[<YP0
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M::]1D(1M^PMLW;BH?Y20/H".: .MHJEJM])I^CW=]#;FZ>")I%B5PN_ SU/
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MQ ]1SGB@#JP01D'(]J6N8^''_)-O#G_8/A_]!%1^/$O]3T9O#VD7!@U'4HY
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MM*T#ZMJ<-BTZ_>C1LEBN>C$+M'IG/:@"^OB-6\;'PT;*9)!8&^%PS+L90X3
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MS"&59##(8I-O\+  D?J*@NKJ]AU&Q@M]/-Q;3LXN+@3*OV<!<J=IY;<>..E
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MZ!>:/J$EYJ<5ZH6XGO[@RS.%Y7YN,;3R,8P<GJ31I'@NUTBTGA75-6NY)(3
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M>[O[&ZND6.[6TF")<A1@;P0>0.-RX/O5%_AIH+>&=/T,27Z)IS^99W:7)%Q
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M&M[P_P"%K+PZC^1<W]W*RA/.OKIIW5!T12WW5]ACWJ/Q#HLEWJ.DZU9H'O\
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M4K/PU:VNL:DUWY?B*U:U$=Y*SPPO*N$=S@N1SACSZ5T\1FM?BRFE1W=X;%]
M:4P274CKO$ZKN^9B=V.,]:U)O!6DW'AXZ-,;N2(RK<-</<NUPTJD$2&0G)8;
M1^  Z4Z]\':;>WUC>^??P75G$T"S07;H\L;$$H[9RP)&>N<\YH \\GU'5F^'
M4MQ'K.H1W$/B1K5)?/9F\O[4$"DGD@+V)K:UO2KO1O$WA>QM?$.MF'4-0N#.
M);LN<&%CM&1T!' .<9R.U;O_  KO0QI$FEQF]CM)+S[:R+<'_6[MP(_N@'G
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M?VE:Q[X)"N5:55((Z$8/0\4 =K17F&I?;O _CB)M/O=0O[._TN\N)[2[N&F
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQ  SAB?F.!D]3W--U#PII6I:Y#K$Z3K>QP_9R\-P\8EBSNV.%(#+GG!K;HH
MR] \/:=X9TM--TN.2.U1B55Y6DVY.< L3@>PXK4HHH **9*9%A<PHKR ?*K-
MM!/H3@X_(UB^#O$#^*O"EEK4EL+5KGS,PA]^S:[+UP,_=]* -VBBB@ HHHH
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MZ80UFD$SQ+"0, @*0.G'-;1&1B@#QR[DN5^&/Q#9;^^$EGK%V()?M4GF(J[
M%W9R1CC!.*V=2TI;7QYX3BAO=11=7M[J._Q>2?OPD:NO?Y><_=VX!P,5U!\#
MZ VF:CIK6TYM-2F,]W&;N4^:YZDG=D9P,XZXJU)X7TN:_P!-OI([AKG359;5
MS=2_NPPPW\6#D<'.: /-;WSK'P?\2=.MKR]C@TR<O9XNI-\.84<J&SG;DG@G
M'-:E]I@MO&/@Q8;[44_M:"XBOR+R3]^JP!P.N%Y'\.,9XQ76R^"-!FBU2*2W
MN&356#7JF[F_?$#'/S<< #C''%3R>%=)EN],NGCN&GTP%;1S=2_NP1M/\7.1
MQSGB@#SF?5;CPO9^,K&TNYHK"TU:RACDEF=_LL4XC\TAB=P'S-CG@G(K>O['
M4/"<FJ>(K34(! NE3.-+C#LDTL:EUE&YC@XX) Y!YYKIE\(:&'U5GLVE&K "
M]6:9Y%FP,#(8D# X&,8IF@>"]"\-)*FG6C@2)Y9\^9YL1_W!O)POL.O>@#@M
M7L;:;PEX#UCSY9[VXU?39IKEI23,SL&;=S@C)X'\.,#%;L=R;/XD^*O.U">"
MTCT>&X+R2LZV_,FYU4D@8 S@<<5IQ_#;PQ'!';K:W(M8K@7,-O\ ;9O*AD!R
M"B[L+R<\8K3/A71VU.\U![9WN+RW^S7!>>1EDBP1L*EMN.3V[F@#@M*>>U\4
M^!?LS7*VNHVMRLT\TY\V_ A#K)*G(!)^8<DC=CCI5"PF7PQX'\;:GI^Z":'7
M;BV$H=CY4331J6QGJ 2<]>*[ZU^'WANS;3FCLIB^G,3:M)=RN8P1C8"S'Y,?
MP_=]JN0^$M#@GU.5;$'^TRQNXWD9HY"V-YV$[06P,D 9P,T 9.FZ!<V'BBSU
M6#5;>&RN(&ADLXB[K=-@LL@+,?F !.[J1U-<KHFB7>M_!N1=-FFBU*WO+R>U
M,4C)O=;B0[#@C(8#;@^OM7<Z#X'T'PT9#I=K+$70Q@O<22&-#U5-S'8.G3'0
M>E1-:KX(TB&V\.Z!>:A%+<G=;Q763'NRQ?,K=-W7GOF@"GX:U:V\9ZA9ZY9[
MUL[2S"; Y ^T28+(PZ$QJ .?^>A]*3XA/)!)X6FAEDBD;7[2%FC<KN1BV5.#
MR#@<&M[PWI T71DMS'$D\LDES<"(87S9&+OCV!.![ 5+K>AZ?XATXV.I0M)#
MO612CLC(ZG*LK*000>XH XJ]:3_A./&%LES<QQ#0XIU6*=TV29DRRX/RG@=,
M5SCV-UI_@#PAXNLM2U%]9S8I()+IW2Y20JAB*$[<?-V&>,DD\UWUYX1TG3+7
M4]1L;.YDU*:Q:VW^=)*\HP<!LD[CD_>.3[\55\#>%X+;PGH"ZA;7:W=A"A^S
MW,KE(9@N"RJ3C/)P>@SQB@"EHL:^,I?%PU*:>.YM-3EL;8I*R-:1HB['3!&"
M22V[OTZ#%<]I>H:EXC7X:76I7E[%/?I=I="&X>,3!(F"L0#@$@9W#!^;@CBO
M2+KPII-UJ5S?F*:&XNHQ'=&WN'B%PH& '"D D#C/7'&<5)<>&-)N;W3+M[9D
METP%;/RIGC6$$;2 JD#IQR.E '/^ U:RUSQ;I$<TSV5EJ$?V9)96D,8>%&*@
ML2<9).,]Z@\4V<=_\4O"MM*\JQ/97V_RI"A88BXW#D#Z$5U>G>'].TK4+Z_M
M(Y5N;Y@]RSSNXD8# .&) P...U)=>'M.O-<M=9FCE-]:*R0R+/(H16^\-H.W
MG SD=J /.].N4M?#&OZ7/JE_#;V_B4V-FL3F2:1"T;+;JS'.&RRY)X!.3BI(
MFNXKSXBZ>3+8PV^G07-O;VUT^+=VBE)*,,;22BD@<9'>NOE\!>'9[*]M)+29
MHKRZ%Y-FZE+>>,8D5MV5;@<C%.'@3P\LUY,+27S;VW%M<O\ :I=TJ $?,=V2
MV"1N^]@D9YH XBS@?3H/AKJT-Y>M>7_DV]TTER[++&]L6VE2=O! (P.O/)YI
M[O'XK\#>.=3U!Y&N[>6^MXE$C*;5(D(15 /&<9;^]N.<CBNY/@W16M]*@,%Q
MY6E%6LE^UR_N2!@8^;G XYSQQ4%YX#\/WM]?W;VT\;Z@A2\2"ZDBCGR,9=%8
M*QP>I% %SPA_R)6@_P#8.M__ $6M>97SQ^*O@MXA\0W[R-J,GVICB1@;<)(5
M6(#/"[0,CODDYS7KFFZ=:Z3IT%A91F.V@01Q(79MJC@#+$FL&Z^'GAN[EU%G
MM)TCU$EKN"*ZECAE8]6,:L%W>^/?KS0!A":76_%C^'YW@\B#1[:>"WF9P)-Y
M8/(-I&2,( >W;&35+5K&\TO1/!.GW^K?VK<6WB6",W1!!( DPIR3D@<9SV]:
MZ[5? 7AW68K%;NSDWV"[+::*XD26-?[N\-N(^IJS<^$=%NK33K62U=8--E6:
MU2*>2,1R#.&^5AD\GDYZGUH PK>,R?%W5[*2:X>UET6&0PO.Y56:5P2HS\O
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MA$EK,FQX\E05]..156W\/:9;M,WV=IWFA^SR-=2O.6BY^3+DG;R<COWK3HH
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MYN)%B/S,A7$6PY(R<[CC@8YSPWP7>>)[+2M.\-ZAX>F@GT]$MY-0,B&V>%,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M:O<&YN5F=>)3CYU*J"I^5?RJWX>\+0>']S?VEJ>HS;/+6;4;DS-&G7:O  '
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MKW'F&,C<J[5(&SC Q^7.:SC\/M,/A.3PT;W4#I\D_GM\Z;]WF>9][9TW\_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 5F^()5B\/:B2';-M(H5$+,25.  .2:TJ* .*^'<$[?"O3+!EFM+M
M+,PNLL;(\3\CD$ ^]<K%;W-Y\&G\$S:?.FO1QBQ^S-"V-PD&V4-C;LQAMV<?
MC7K]% &?>Z4M_P"';C2)Y69;BT:UDD[D,FTGZ\UQO@;5V\,>'K;PSXB@N+._
MTX&!)/(=X;F,$[7C=00>,<=<]J]"HH X/QRNIZEI&E:K8V%S)%I>KV]\]L$/
MG3P)D,0F,Y&[(4\\=,\4^9$UOXAZ-KUCYGV#3+&X%S<&)E#F3:$C&0"2,,Q'
M;C/)KN:* /%HX;@? BQL#8WOVU;]&:W^RR>8 +SS"=NW.-G.:[&9S)\8]/N4
MBG-O_8LL)F$+[ [2HRJ6Q@$@$XKN*9*)#$PB94D(^5F7< ?<9&?SH \6TA8]
M>^ L?ARTA>;4KIWABB\IN&-RQ\PG&-JCDMTXQUXK3\52W=TOC/1Y-/U!91IX
M2S%G:/B__<G]Y)*H^;!^7:6 XQAB<5WOA'P\WA7P[;Z,+S[5';ERDACV-AF+
M'/)!Y8^E;E 'F=C,TWC'P3<?9+Q(H='FBE>2UD41NPC"ALCY2=IQG^M6O"6E
MP:QIWC;2]0MIEMM0UBZ8"6)DWQ.B .NX<\@X([BO0JS-=TR]U6QC@L-8N-*E
M657,]NB.S*,Y7# C!S^@^E ',_#V'5KB%[C7 &N=+5])AD!SYHC?#R_\#VQ@
M^\9KJ=(U>'6;>>:&"ZA6&X>W(N83&24."0#U4]C4VG6$.F:?#9V^XQQ#&YSE
MF).2S'N2223ZDU:H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9X@U!IHX+,7]A(D*(9(0"'  '+JV!COD<4 =U15#14OX]&M!JLWG7YC#3L%
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M$V@WDCW<JHZ+'M&/*8D -N<(V!D8C-=Y0 !T% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M;<!G.,C-:ECHUQX-T?PSX;AUAOL\4<PFCMTS<W4A^8>6,':@9F))(Q\N3UH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M@(2!C4;4P%\_W03DX_K3M'\26.N7^IV=HEPLFG2K%/YT)C^9EW# //3U ZT
M:]%9%YXDL;'Q'INA2I<?;-0\PPD0GR\(FYLN>.G89/(K7H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M4LU1D$L>P%HR5R,DGKG'8=ZUOA_?WUU9:U9W]Y+>-INKW%E%/-CS'C7:5W$
M GYL9QVJ\_A*T_M[3-6BN[J%]-MVMH($*&/8V-V<J6).T<Y[5EWG@I[/0M9M
MM,UC64N=2O#>F2"6..19CC.&"C:IV@'KQ^1 .MO6F6PN&MAF<1,8QZM@X_6N
M&^"QC;X6Z9(&W3O).UPQ^\9/-?.[WQC]*[NV26.TA2>3S9E11)(!C<V.3CW-
M<]%X-CT_4[J]T35+S2UO)#+<VT(C>%Y#U<*ZG:Q[E2 >XH Z$00"Y>8(GG,%
MW-CG SC^9KAO"7_)6/B%]=/_ /1#5VEE8I9(_P"]EGFD.9)YB"[GMG   ]@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBL'7_$_P#8=Q!;PZ+JNJS2J79-/A5_*4'
M+EF &3G'K@^E &]16#X9\4)XE^W :5J.GO92B&6.^1%;<5#8&UF[,I_$5O4
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !4-W<PV-G/>7#!(8(VD
MD<]E4$D_EFIJI:MID&LZ7/IURT@M[@!9/+(!9<@E>0>".#[$T 9O@VUF@\-P
MW-TA2\U!WOKA3U5Y3OVG_=!5?^ UOT44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
=110 4444 %%%% !1110 4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>28
<FILENAME>exhibit1016-arvinasxamen008.jpg
<TEXT>
begin 644 exhibit1016-arvinasxamen008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUO99KB.8V\+A&A**!]Q2 V#ZU6LO 6I7\>HP0J_AO29[FWN(]-<I=!V0'>7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JG;Z3IMI=RW=MI]K#<S?ZV:.%5=_]Y@,G\:N44 %%%% !1110 4444 ,
MEABG"B6-) K!U#J#A@<@CW![T^BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *Y;XBWU[I7@+5M2TZ[DM;NUA\R.1
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MDVJ66L^;'+!<I'YD)10?,5D5>.>0<]#^#OC,P;X7ZK;+E[B?R1%$HRSXF0G
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M(WDDJK;A/,,AZ;<9S7BFFZKX=3P_8>&M1UK[%8Z=JK7*&YM9DG"I,SK&Y*[
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M$F:U-O);X2)0BJHD +9Z%O5ATXKO]?\ #]SJMY87]AJ\^G7MEO$;+&LL;AP
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MMUOM&\X^7+<<XY%8LH:3X;_$2!8)C-=:K>O!'Y+;I@Y78RC&6!P<$>E>Q44
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %,EEC@B:65U2-!EF8X %/HH H:/K6GZ_IRW^EW N+5G=%D"D E6*G&0.X
M-,M]?TN[UNXT:WNTEO[>,2S1*"=BDX&3TSGMG-<Y\*^/!1_["%Y_Z4/1;?\
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M'ILVHZC*T5I"-TDBQL^T>I"@G'O65H.HZK?ZQ>K(4GTF.*,17?D&+S9LMO"
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MEL)8D6&R\E1Y+#.YM_5L\<'I4-WI=W=Z[9WCWT7V&UW,+,VY):0C <ONZCG
MQCD]\$:U% ')7NE'2/%5[XUOM5@6VBTXVS0&WV[(E8R</O\ O9]N?2L?PCX=
MO-8\!0)J&H1+::PS7]['!$1)+YS;VC,FXC&"%.%!QQQUKT&7R6VQS;#O.%5\
M?,<9X!Z\ FG)&D:[4157T48% 'G^DB76?B%KE[I%Y90P:5;1:3 ##YH''F2%
M0KKC!*+_ ,!]JU;[P+%-X?BTNUOGB?\ M"/4+JXFC$K74BN'.\9 Y(7V   &
M!74QP0Q$F.)$)ZE5 J2@#GIO#,LWBZPUPZE)LM+(VH@:,%F)=6+[\\$[5!XZ
M>E5]%\*WVA->6MKK"_V5<74ERL/V;]]&9&W,HEW8VY)_ASSU[UU-9&A>(K3Q
M VHBTCN(S87;6DHGCV$NJJQP,YQ\PZXH Q[CP7=2:KXAN(-;>"UUJ-?-A6 %
MTD6/RP0^[[N "5QGW%%MX':UTOPW:KJ(=]"8/$'@_=2,(C&"4# @@$D'<>23
MS713ZCY&K6EA]CNY/M*2-]HCBS#%MQP[?PDYX]<&KM '-W_A0W]AK6^^*ZGJ
MEH;1KP1<0QX("HF>%!8GKDD]>F*M_P""II[/0&LM5^S:CHC;K>X:W#QE2FQD
M,>X?*5X&&R,=2>:ZZB@"K8V]S!&3=W?VF=L;F5/+0>RKDX'U)/OTK U;POJ.
MH^+=.UZ+5[>(Z='*EO;R61D4&089B1("3@ =JZFB@#CM9\%ZAXATW4[?4]=#
M2W21);-!:;$MMD@DX4N2VYE7.3T4#BIH_"-VWBVQ\0WFLF>XM[5K=D6W"J2S
M*Q*?,=@^7!')()YZ8ZNB@#"'A>U/B#5=8=V>;4+9+8J1\L:J&!(]2=W7V^M0
MV.@S>&_!)TK2[B66^BLQ#%<LJEVD"!$;!^7 P.#Q@<YYKHZR(/$5G<>*+CP^
ML=PMY;VRW+,\>$*%MHP<Y/(/;'% %[3H[N+3+2._F6>\2%%GE1=H>0 ;F [
MG)KE[CP1=WZ:C8ZAKT]UI-_?&ZEMW4F39P1 '+86/*] H)'&1W[&B@#GM;\,
MRZKKFBZE;ZB;,:8)E\M80VX2*%RI)PK  @'!^\>*RA\/L:%KND_VJX@U:[:9
MML."D99<Q_>RQV*$W9Z=LYSVU% &;>:QINDS6UC+,B7,R-]FM4^_*%P"$7OC
M(_\ U UG^#?#/_",Z%#:2S&:X (+'HBEF8(OL"QY[_D!T.U2P8@;AP#CI2T
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MER"V#U 'T)YKN:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YWQ;K<^E)I-
MK:N(I]4U".R68@'R@P9F8 \%L*0,\9(X/2NBK%\4^&;3Q7I L+J6:!XY5GM[
MB!MLD$J_==3ZCG\Z ,#Q%JNN>"-$U_5[B_BU"R2.+^STG4"6.5F"'>5504W,
MI]>H]*?K&HZMX5USPZ9-2EU"QU.[73[F.:.,%)'4E)$**,#*G(.1CWYJ^G@U
M+S1+W3_$.IW.M->1>1)-,J1[4Z@(J !3G!SR20,G@ 26GA:02Z8VJ:G)J(TL
M[K0/$J'?M*AY"/ON%) (P.2<9P0 <;/JWBF;0O&]\GB)X7T*\G^S!+6+YUCB
M1PCY4_+R>F#D]>U:>N>+[K3VTJ\U*2^T[1+S3TD-_90+*D-PW.)<JQ"X(QQ@
MDG.>VHO@<C3/$=B=4<QZ]+)+<-Y(S&74(P3GIM QG-6H_#-Y!#%%#J^8A8)8
M2136RNCJF[#XR,/AL'L>XH YJ[6\N_'_ (*(UZ>19],N)&DMO+,4C*L>74%"
M/FW'GTZ8JQHLGB;7/$6O6[>)'M[;2]42-5CM(B9(C&K%"2./O<'K]>*U?^$#
MM+=O#S:??W=F=$@>VB*;6,L3A0P;<#R=H.1TY_"]H7AQM%U75[[[<T_]ISBX
MEC:,*$<*%^4CM@#@YH XH>*M>/PBM]?_ +3;^TEU#R7E\F/$B?:_*P5VX'R^
MF.:V[_5]8UC6]?TO27O8'TP1Q1O:^1S*\8D#/YO)7YE& .S<GC$4OPS671+K
M1!K]]'I<EW]J@MTCC'D-YHE(W8RPW9QG@9Z' J]J7@:6?Q =<TKQ!?Z5?31)
M#>/"D;K=*HPI967:' XR!QZ4 5+'6]=U'7]+\-:C(NGZ@FE&_P!1>UVL6;S/
M+54)! !(9CQGH/6D^&L4L%QXPBGN&N)%U^8&5E"E_P!W'@D  9QZ "M"_P#
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ME!^^&.2>A!Y&*CO_  1#J.CZU:37LGVK6MHO;L1C<5"A55%Z* !@=>IZDYH
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M+>.T@O())HD1XR[.K+\B@$?*",C(J-?A^RZ#HVDG7+J2+2;J&YMW>),_N?\
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M+*>?F[Y ]*Y74O$?BC2?"OC.PDUF234- NK<07_E1[IHIMI"N-N,A6/(P>E
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MEEOKJX_XFMXFV9E;I*1NSC))QSS0!WE%<G=ZM<:C\03X9BN9;6W@TW[;*\.
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M9V6K.TEW:QA2I=AAV0D90L.O7U&#4[^$;0:YH^I6]S-;+I-NUM;6T:KY8C8
M$'(ST5>_:NAHH XNZ\&S6.BZY%IVLZLESJEW]M+VYC2193MR%;:-JD* <]!7
M6VL<Z6$,5U*);@1*LLBC 9L<D#W-3T4 <W9>$4@GTB2]U&XO_P"QU869F1 X
M)39EV4#<=O';U.3@UE7/PSM;C2M0TC^V]2CTN[N?M26J&,"!S()&VMMR1D'
M8D#/0G!KN:* ,$^&5/BNV\0-J-TUS!:&S$9";&0D,2<+G)(!XQ]*=X?\,P^'
M9KXVU[=RV]U<27*V\I79"TC;FVX )R?4G';OG<HH PM5\,Q7^N6FN6UU+9:I
M;1M )XP&$D3')C=2.5SR.A![U1U'P'9:EX>OM(DO;N/^T+@75Y=)L\V:0,K
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MD:1W=O*%V;50H N "/E/K71T4 <CH7@P^&U0G6M6U2ULU/V*RN)$*Q<$  @
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU"[NKL><3;37<2QSM%@8\Q0!@YW=@<8R <T <A92-I/CSX@ZJ]S>3+I]I;7
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MC!1QMVLIP.,=>1BHM0\#:?J6@ZGI=Q=7G_$TD$E[=(R"68C  R5(  50  ,
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M6MNR>5*Y7!?YE)5B.I4C- '.^'M4O)]-\(>';4LJ/X=CO)=D_DO)@1H ' )
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M[@$#(9U!\L[AD9.#TQFJGB'3GAN? %Y)J-W=32ZM"9C+,625FB<[PO1.^ H
MP?84 >GT5YL)/$?B^QUBYTB]6TO;74IK6UD-\Z)!Y3[0KPA"K[@,G=D_-QC
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M>]O+N^C^+.GV"ZA<"RGTF>4VX*[%=70!@,<GD]<T =C17C%U?:Y%\//$>O\
M_"1:D;W2-5N%MAYBA&6.8+AP!\P(XQT'8#G/LDB":!HRS*'4@E&*D9]".AH
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M\$A/[OS5[\]_U/2KFBVJV_Q%\>W(OYH3;I:NLD\[-&FZ!R2P)P54G('0=L4
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MN6F!)WL64ECEF)]2>:Z6N=\1>+(-#T:+4X;9KZ"2Z2V+12!0I:3R\DGKAN.
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M=SZQK-Y-I1?[*UQ<K\H9=I!VJ,\<9///)-;^F75Y=P2O>Z>UBZ3O&B-*LF]
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M@BA%7/!;MZ\U4\%>'(W\)>&SJ+:@SV%O$ZV=XNQ8)U0 G:5#'!)QN) [=!@
MY[Q9JE]::7KVJZ?JM]=7%EJD2K<Q2M%;VJ^9&AM]F[$I&3N.W'S<G(Q6W?0W
M=_\ %F727U?48M/DT/[0T$$YC ?S]N5(Y7@#D<^^"0;UW\-]"O(=4@DDOUMM
M2G^TS6\=TRQK,6#%U7H"2 ><BM.+PM:0Z\NM1W5X+Q;3[$&:4./*SNP=P.3N
MYR<G/?'% '!VS:]J7PJ>]M=3OYM3T>]GV$7#J]W%#,P,<A!^8E%QGKD#U-=?
MH>IP^*-935]/NIVTR"S15596"22R@.=RYP2B%>O>0]P*8(X/ .G1VNG:7K.J
MQW=T[;+=5E,;OEBS$E=JD]SP,]JTO"FAQ>'?#MM81PQ1/\TLR1?=$CL68#V!
M) ]@* *?BN;;>Z+;"_N(_.N'S8VN5EO0(R=H<,NQ5.&)R!Q@]>>!O=6UE/AC
MXLE&IWMO<Z9KC6UNXN"[I'YL0V&0_,P =AG.?>O2]<\,6.OW.GW5Q)=075@[
M/;SVLQC==PPPR.Q'!K*D^'.AR:=J>GB2_6UU*Y%S<1BZ8Y<%3D$Y(R54D]3C
MDXH S99[KPY\1TB&HZA>6EUH]Q=3P7$Q<>9$RX9!T3()&% 'M7-:_P";KGP9
MM?$=W?74E[=SVUQ(JW#>3\UP@\L1YV@+P!QG*Y)SG/IC^&[:7Q!:ZW+<W3WE
MM UNA++M*-@L"H7!R0#_ "Q6(_PPT)M.N=+2?4HM+FF$PL8[LK#$P</\@Z@9
M'3..>,'F@#KKN!+FTF@D+A)$*L8W9&P?1E((^H->*V]JL?[/FBRI)-YD]S:$
MEY6<*?M0^ZK$A?H,9KVZ.,1Q+&"Q51@%F+$_4GD_C7*+\.M%CT!=$CFOUL%F
M69(OM).PJV]57.<*&.<#\<T 8\M[>>&/'FK6\5]?7MK_ ,(])J9@NYS(/.CD
MQ\N?N@@]%P/:C2;7Q!J5KX;\06NJ11++Y4MZ\FHRRQW4<@&Y1$4"(V3\NW&#
MQS76?\(U:-XC779)[F2\%I]C.YEV-$3N*E=N.6YS_3BLW1?A[HN@WPGLI=0%
MNDAEAL'NW:VA<\[ECZ9],YQU% %[QM_R(?B+_L&7/_HIJP/"-IX@D\"^%&@U
M*T%JMK9/)"EJRR-$%0E=YD(Z=?EYP1QFNOU?3(M9TJYTZXEE2WN8VBE\H@,R
M,""N2#C(/;FL>/P7;1:-'I$>JZLEA'"(%B6Y"XC P%W!=V,<=: .=\?7][X=
MU"P\1Z=J,\UG-&\5U9^=(\2QE>+I54]$R"<<$$8P3FKVLWLNE0^%=%L;Z6YB
MU.<QO=SWC*TRK$S@>: Q!=@OW?H,9XZ4:#:_:KR<O*WVJW%J8VVE(XP#@(I'
M Y.?7OG K(;X>Z'+X4B\-S&[FL+=Q);%YSYMNPZ%'ZC&3CKZ=.* .>UBY\0>
M"]&UNYGU.(6MQ/;+9HUR]S)8K(XCD8O(H)7DE<Y /%=%=Z%+I]U=W4.N7RV<
MM@\?V*2XD=C,N6$J2,^Y3@$$#@]:LV_@O28]#O-)NS=ZE#>J$N9;^X::611]
MT%CR .HQC!YZ\TN@>$+#P^K".YU"];R_)1K^Y:8QQ_W$!X5>!T'.!GH* .+C
MU;4G\"_#K4#J%W]JN]1LH;F3SF_?(X;<'&<-G ZUI^&=-B_X67XX*S7:LDEI
MM(N9#C? 2>"2#C/&0<=L5H0_#30XK.RL_M&IO;6-TMS:1M>-B KDA4QR!D_7
M@<XK7C\+V,/B&[UN"2ZBO+J-$F"3'8Q52JN5/!8 XYR/;- '!:>-=U?X+?;[
M75-0?6+26YF247+AYQ'.^8V(/(*KM'IQC%="OB%-3L)_$^FR3266GZ2TZ1"9
MMDLS1^8%=0<$JH7K_P ]/45T/A[P_:>&M*73;%YVME=G59GW%2S%FYQW))_&
MG:-H&FZ#I1TS3[=8[0O(YC/()=BQ'TYQ] !0!Q^DVGB"_B\-Z_;:I%%%((I+
MUI=1EECNXY ,@1% B-D_+MQ@\5N^.M9N-%T.W>V=8WNKZWM&E9]@C61P&.[!
MV\9&<'&<]JBT3X>Z+H%\)[*74/LZ.9(;&2[=K:!S_$D9XSR<9SCM6YK.C6'B
M#2+C2]3MUGL[A=LB$X[Y!!'0@@$'VH Y4V.M:)>ZM>S:W!I^E2Z;(5CGO)+P
MV\Z_\ME,@!V@$97.,CWK,TO4+ZP\9>'X4FU*2SO-)G>7[9.SFZ>,(1*(V9O+
M)W'C@\X(&*Z2P\!:39Z7>:?//J&HQ74#6SM?W;3,L1ZHA/W1TZ<\#T%%IX"T
MJTO=+O?M.I37.F(T<$DUX[$H<?*WJHVCCCWS0!C>'$O/%'A+1?$Z^(+BSO))
MA=W+"1F@:,,P>#RRP0*!\N<9!7/)S69)ISW_ (I^)#+J%]:&%;:1#9SF([Q:
MY!++R<8Z9QZ@\8ZK3_A]HNEZJ]Y:/?1P/-]H_L\73?91+G.\1=,YYQT! XX%
M6T\)6<=WK-TMU>"76%5;L[UY 7:-OR_+A>./Y\T /\&ZA<:KX)T._NWWW-Q8
MPR2O_>8H"3^)KF-+%[XUT'4]1CUVZTS48M2FBADBD;R[18I,!&BW!7RHR=W]
M_P!  .TT;28-"TBVTNT>5K:V01Q>:P)51P!G'.*Q)/A]HK:Y<ZI&]] +M_,N
M[."Z9+>Y?^])&.&SW'0]P<F@"CI]TWBOQ9XGT^YO+N&WTPP06Z6MP\)&^/>9
M24(R23QG( 7IR<\M%KFO:EX?\*M/JUW#=#Q$=*N)X"%%RB>8-Y&,$_(/;(/%
M>C77A>SGUM]8MKBZL;^6(0SRVKJ/.0= X8$$CLV 1ZU#<^#=*GM-*M8_/MX-
M*G%Q:I"X&)1GYV)!+'YFSGKDYS0!S%K_ &S::UXXT'2]4N99(K.WFT]KZX,A
MAFD1P0';) )48'0&J(\9'3M)\17"P:KIVNZ?IGF/I6HRO,JD$@31LS$.N2 2
M.N!7:S^#M/N+_5;V2XO?.U2%8;DK*%^5<[=N!\I&3@CGFIX_#%B;B>XOGFU&
M::U-F[W>T_N"<E,*H&">I(R>.: ,*TTG7$UO2M2M]42+3I(F2[1]2EN?M6Y<
MHZ!T"HP//RX!!QC%<9+<ZM#\,]3\1?V_JK7^FZK*L!-R=A5;H)M=1PX*G&#D
M#MBO0M \!Z7X<E#65UJ4B1!A;0W-VTL=KD8/EH> <$C)R<$CN::W@#27\-W>
M@-<7QT^[G,\R>:-S.7WGYMN1EL&@#*M-/A/QMU23S+G<-(MY<"YD"[O-<8QN
MQMX'R]/;FJ?AC6;F+Q#IFD^(_P"T[+6SYA$K7#RV>IC:<M&<[5/1@N!@<>F.
MQ;PO8OXA@UQI;K[=';K;NRS%5F16++O48!P2346G^$K*P.FAKF\NX],!%E'<
MR*PA)79D$*"QVD@;B<9H P_BO;)<>&K NTH*ZK9@>7*R=9E!SM(S[9Z=1S4J
M7#:C\0;KPS)<7<=AI^FQSHB74BO,[N06:0-O(4  <]2<]L='KVA67B/2GTZ_
M$GDLZ2!HG*.CJP964CH00*J7/A.QFO;*_BGN[;4;2(PI>12YE>,G)5]X8.">
M>0<'D8H S? 6HZA<#7M+OYY+K^R=3DM(+F3EY(L!E#'NP#8)[\50BT^%OCC=
MN9+D'^Q(9L"YD W>>XQC=C;@#Y>G?'-=EIFE6ND6K6]HA >1I9'=MS22,<L[
M'N2?\.@JG=^&;&[\1PZZ7N8KZ.#[.6BF*JZ!MRAEZ'#'(_7(H \IQ=Z=\-M?
M\06>IWUO=:?K=S)!'#,4B_X^@&#J.'!!/WL^V.<]I>W-_P"(/%^O:)$Y2/3[
M> 1JFH2VK R*S&3]VI+<X')P-O3FM%O &E/X=O=!>>]:PO9S<3H91N9RV]OF
MVY&6P>*=K/@33-:U&VU.2ZU&UU*"+R?MEE<F"62/KM<KP1^% &EX8AU.W\.6
M<&LWL%[J,2F.>X@^[(58C/0<X !]\UP\UYJ"0_$Y#J=\QTZ/S+1_/96A/V7S
M!MQC W'./SKNYV@\.:"6MK&ZN(+5!MM[5#+*XSS@$Y8\Y)SD\GDUA>'M%-W?
M^*[^]MY!8ZW.@CAG1HW:)8%C;<IP5R=PP<'CWH RY=1OA-\-YA?7(:^"I=#S
MFVS#[,7^9<X)W<YZTWPQI]]K&O\ B%KKQ#K&S3-;*V\:7&%*^4AV,,8*_-]W
MI^9K9MOAWI%O_9>^ZU2<Z6^ZT,UXQ,8V[0@QC"@<<=>,YP*U=(\.6VBW6HW%
MK<732:A*9Y_,=6!D( W 8XX &.G'2@#A])N_$5UX%U)K&>XU&^@UV>/RY;HI
M+/!'-S&DG\)*@XQCO4,OC.*/P[/_ &7<ZG:W=WK-M83P:B6,VF>:%5OOD\85
MF4Y(RWMBNRM?!5A9Z>]G;W=_&K7IOQ(LPWK,226!QT))R#D>V,TZZ\%:/J&G
MZE::C')>'4F1[J:5@)'9  A!4 +M &, ?J: .>GTR/3_ (PZ&(;B[99-*NAB
M>X>;:0T?(+DD9R,]N/K63;^)-2TWPKJWF:E<.[^*WTL7DS[FMX#,J$C/ PN<
M=@3FNSM/!%A;:K8ZI+?ZK=WME$T,,MQ=ECM;&00, ]!UZ]\TJ>!=&_L75-(N
M%FNK+4YWN;F.=\YE8Y9@0 0<@'CH1QB@"CK7A][2UUQQK5ZUA<:7(!827$C,
MLB DR+(7W 8(!4<>O6N8D^T:5\&?"MUI]_>V\CG3=^VX<[@YC5EY)PN#]T8'
MM7=Z/X0T_2+6: W%_?F:(P-)?W33.(C_  *3]U?IUXSG JI_P@.D_P#".V^A
M?:-0-E;R))&&N"S#804 )!PJX& ,#US0!5@O'\1>/_$.BW5Q=0VNE6]L(8[>
MX>$R-*K,TA9""<851S@<]S7(OK>O7'AVQ@EU:\CN;'Q<FCM=1D*;F(2@;GXP
M3@X/8X.<Y->CWGABTNM8BUB*YNK34DA^SO<V[*&ECSG:X*E3SR.,CMBH;KP9
MI5SIMC8 W$,%E="\C\J3YFG#%A(S$$L=Q)YZD\YH R=!^TZ9\2]7T4:A>W5D
M^G07JK=SF4QR%W5MI/0' .!QZ59\4:K.GB[POX?662"VU22X>>2)RC,(H]PC
M##D9)!.,'"X[UKP^';:'Q++KPN+EKV6W%L^YEV&,$D# '8DG/7FGZWX?L=?A
MMUNQ(DMK,)[:XA?9)#(/XE/Z$'(/<4 <UICW5O\ $#6/"LMU>3Z7)I\5_ SW
M#F2W)<HR"3._!*Y'/'(Z4SX/VD</PWTN=7F+RK)N#S.RC$K_ '5)POX 9KJ+
M/0H+-KN=+BX>]NPJS7CE3*P484#Y=H R<  #DGJ2:;X=\/VGAC2(M+L))VLX
ML^4DSABF26.#C)Y)ZYH Y#QMJ=]I.K7=QJ$6J-X?DM5C2^TN=@VG2_-N>2-2
M"PY4Y.<!<8YJ[9WTD_Q1CM8-0GFTVY\.BZ""9C&S&8*)%&>"5],5O7WAJ"_N
M;V5KV]A2^B$-S#%(NR1 ",8*DJ<$C*D'WX%07O@W3+N_L+V)[NRFLK?[+&;.
M<Q;H./W;8_AX'3!'K0!Q&E^(]070M)LI]0N,:AXDN-/DNGE)D6)7D*H'/()V
MJH/4 G'.#6KXQTF;2?!GC0G5Y[FTN=/:2WLKAVD:VPA#D.S%BK'!P> >G6M?
M_A7/AX^'KG1&AN&M)[DW7,[;HI2Q;=&?X"">WXYJ=?!&G'0;S29[O4KE+U!'
M<W%S=&2:5!G";VZ+R>!CJ?4T <[;"[T?QCX+6+4[Z:+5K2>.Z@FF+1'9"KH5
M3[J$'C@=.N:ZCQE<?9_#[8U1].,D\,8DB0O))EP/+0 @[G&5!'(SGMFE?PI9
MR7VCWCW5XTVD*R6IWK@!EVMN&WYLK@<_SYJSX@\/V/B7318WWFJBRI-')#(4
MDBD4Y5E8="* .;\(WE\/'/B?3)C=):016D\%M=7!F:$NK[OF).,[0<9(':KO
MB'4Y#XS\/>'C/);VU^ES-*T3F-Y3&J[8PPP0/F+'!!^4#IFKVF^$=.TK7)M8
M@EO7O)X4BF::Y9Q)MSAF!/)Y(]!V I_B3PKIOBFVMX[[SXYK:3S;:YMI3'-
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MK1+.:UGF8RM9B=PCC<V20.64'.,>E=C/I$6C7LFJP^(;FTLS821O%<2M/&6
M+B?+L>54$G'4=: .I)(!(&3Z>M8?A?Q$WB.WU&1[(VCV6H36+(9-^XQX!;(
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M72]%M+2XN9;FXCC'G32RM(7?^(Y8DXSG ["M"@ HHHH **** "BBB@ HHHH
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MX9TW5VA$!O;=)S$&W;-PSC/&:U: "BBB@ HHHH **** "BBB@ HHHH ****
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M+DB,*S;>OMU-0^';2:[U*\\27^EG3[R\BB@2"0J9$B3)&\KD;BS-QGH%[\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHJGJVHQZ3I5S?RJ76",L$7J[?PJ/<G 'N: ,JU\7V-WXXOO"R BZM
M;9)]Y/#DGYE'NH*'_@1]*Z&O(/$EEK/AJPT+Q3-IJ+<Z+<M-J,\5QO,T4[?O
M_EP.,MD<_*![5UOC&XGDG\,SP,UQI$U\/M<,&6:=#&Q0A1RZ@_,5&>!G& :
M.RHKRRXT:[M?#_Q U$OJ-K8FWF?2HS=31>4JP[F*Q[@$7S <# .,]C3+N"+P
MYX,T+4X+NXBEUA]/MM0NI[B1E6,KDDC< @/"DKC@]J /5J*\P\066H^"M/\
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M%T_3M1U"_M8/+N=0='N7WL=Y5=J\$X''IBM"B@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MD<[03M&6QVY&<KX:V1MO!5M=R1"*;4Y)-1D0# 7S6+* .V$V#\*X]M-\4O\
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MR3 !R\S2 @$.60+C Z],4 =?:^+M/N]>M]'2&[6XN+=[A'>+"80J&7.?O L
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M+#6'O+XVLNG75JWDB='D*,CJ3C *L>1W^HZUR4-G?Q>(O'MW)H<UU;7\5O\
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MHG&?+*\E5<G' YQVKH['QS;WEQHP;3[J&UUII%LIWV_,5!;YUSE=P!(Z^^*
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MZU:^(M!LM8LMXM[N(2('&&7U!]P<C\* -&BBB@ HHHH **** "BBB@ HHHH
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M6+*Z[CM/+," :O:MI1UK1K2UUKPJ'L[B9I)+>V9?-L<*-C[E89;.<[,XW8Y
M.>XIHD1I&0.I=0"R@\C/3/Y4 <[X(L-6TS09+75;FYN-ES)]D:Z8-,+?/R"0
MCJW7\"/I7)>+-)\2:W'XMT^XT6:^$T.-(F\^,6\:;!D;2V1+NSSM[XR!7I[R
M1QE0[JI=MJ[CC<?0>].H X*TL=8;QSH.J3:-<16T&CR6LS&2-O+D9D(!PV3P
MO.,C)ZFL"7POXC?1KRYM],=+ZS\5OKEM:S2Q@7418X4$,0I()ZXZ5ZT9$$BQ
MEU#L"0I/) Z\4Z@#A+1=7U#XEV.NMH%[:6 TF2T=KAX@R.TJORH<\?*>G/M5
M_P"(&F7^HZ/I[Z=:-=S66J6MXT",JLZ1N"P7<0,X]2*ZRFI(D@)1U8 E3M.<
M$=10!QEM:ZJWQ/EUN;2+B*R?1$M=_F1MB42L^W ;/0@9Z9[]ZY:U\,>)+/PI
MHUU#HPEU+1]4NKEM.N)(\7,,S29"L"5#;7!&>X/X^O44 <5<+JFK^#=>">&C
MITMW8R6]M9[HO.D=D898@[0,D8!.>"3VK._LK65D^'C?V/<G^R(R+[#Q?NB;
M?RO[_P WS<\9XKT4D*,D@ =S2Y![T -=BB,P4L0,[5ZGV%><:1X4U:]^$>I>
M&KNU?3[^9KDQ^:Z,I+S-(ARA/'(!_&O2:* .+\,W>N7LD":AX0BTB>W4_:;A
MFB99&VD8BVG/)P<G  R.:RO#_AN\L?$VF:GI6G7FAQSAVUO3VD4VI8H<&-0Q
M&[?C!7C .<=#Z3374O&RJ[(2,!EQD>XSD4 >1^'(;[6OA/J7A^TTZ9IKVZO+
M=)WV^2JM.X+DYR-N3QC)(X'.:T_[(U?PEXJO7M?#AU_2=0B@V-&\8EMY8XEB
MPV\CY6"@YSQ7:^'O#]KX:TYK&REN'MS(\H69@Q5F8LV#@=22:UJ //=4L?$6
MB^*-*\3V6D)J"FP:PO["S=5:(&3S%:/=@-@G:>F>N.>+'BBSU_5]&T:^&DL;
MFSUFWOFL(Y4,BPID%=Q(4OSGKCG&3C)[JB@#C7L]4F^*&G:NVES)9)I,EM++
MYD9"2/(CA?O9. I!(&,U')X7OH_B++>6^T:)J,<=U?)G_EY@.(\#MNRA/KY7
M/6NVHH \]U:RUG0_'=]J]MX=_M[3-5AA61(VC$MM+&"HP'(!5ACOU'Y]MI27
M":;"+JWAMYCEFAA^['DDA<]R 0">YR:N44 >:W'AR]D\3Q:QI&FWFCZP=3Q>
M/'(OV6\M1(<NZAB"2F#T#;CT[AEYI>NVG_">Z;!HD]TNM"6>TNDDC$7S0!"K
M9;<&R, 8.<CD#FO3:* /+[;3_$OAS5-#UV#0I[V,Z+#I=_8QS1^="\9RKJ2V
MUADD8S[UH^(K/Q.][X>\56NEK/>:=).)]*29=_D2JJD!S\I==H/IDD D#)[U
M)$E0/&ZNAZ,IR#3J .$\2V/B+Q3X7%U!IJ6=]:W<-Y9Z?=2*QD\LY*R$$J-P
M)&,G&!DC)Q+;7&JZEI%[,_@F.R MFC-C<-$7NV)&4!!P$QN&6QDD<8'/;44
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M+B M,CD@1JN"%)P>/\,]:34=*U/3?B+#XGLK1[ZTN+#[!=P1.HDC*OO21=Q
M(Y((SGOS0 R[^(]G:>&-0U=M-O#+IMT+2]M 4WP2%@HSSRI+#!7.0>G7'1Z1
MJ5YJ(NC=Z1<:=Y4NR(3NC&5, AQM)QUZ'IBN U[PAK%UX9\52VVGO)J6O7\$
MZ6HEC'DQQ-'C<Q8+N(1B<$\L![UZ=$[21*[1M$S#)1R,K['!(_(T <R/&,AG
M\16PTF7[3HB+))#YJYG1E+!D]B >N.>*GLO$ZZII>A7=O9>;'K R$\T'RD*%
MBS<<X P?<@=ZS_$/A>\OO&6GZE9,BVES;/8ZL"?OP!A(H [DD,A]G-)X-\+W
MGAZ^U1)RK6%O/(FDQJ1F."0B5Q_WV0HS_<]Z .7\->)!X/T#Q%<KHT\VF6GB
M"\$\L+(BP1^:%&U2<MCC@#IWKM;S4=.'Q!TFQFTIGU"2TGDMK\[<*@V[U'.>
M<CJ!7(3^&O$$WPZ\7Z0-'F%[JFI7-Q;1F>'!260,"3OP, <C^==%=:?JMQ\0
M/#FJ+I<RV=K93PW$C2Q?NVDV8&-^3C:<XS^- %F;QIBU34;72KF\TDW?V0W,
M!W.3OV%UC R8PP(SD'C(!&">=M;J71OB7XUETS1I+V9K6RE:&%DC!.V0L2S8
M&3^))_$B?PI9^+O#%HWA8:1'/9PS2?9-7^TH$6%W+9>/[Q==QX P>!D#FM*Q
MT_5;7QWXIU-]*G-I>VUM';.LL7[QHU<'C?D9W#&<?A0!T6@ZS;>(=!L=7M Z
MP7<*RHKCYESV/N#Q7/S>.I_M.O6UGX=O;B?1BOGJ98T#*4WY!R1]WH.3ZXJS
M\.],O]%\!Z5I>IVK6UY:Q&.1"ZOSDG(*DC'-9EGI>KP:WXYNGTF?RM4$1LR)
M8LR;81&1]_CGGG''Y4 6HOB!%*="N?[(O$TG69(X;>]=D&)'4LJE,[L'!&?4
M>F"9-7\<II,&J7KZ9.^G:7<);W4Y;8Q+;<M&A'SJ-ZY.1WQFN>/A_7E\$^!]
M-&CS&ZTB^M)KM!-#\J1 AB#OP<YXQ^E5/%/A[Q3KNE^*[&?11>W4\^_3+M[J
M,1I;@H5C12<J_!R<#.>6X H [O\ X24IXU7PW-8O$\EJUU#<M(-DJJ0"%'7<
M"1D>G-7=)U1M46[?[,8HH+F2W1]X82E"59A[;@1]0:YKQW8WUYHNE:O8B.SU
M^QO(FM%<[QND81M$Q'4%6YQ_=ZX&:ZO3+"+2]+MK"$ED@C"!FZL0.6/N3R?<
MT 9%WXI*7^J6MC8_;)-+"?:HUF"R#<H<;5Q\PVD'.1W R14MOXB-SXEU/0EL
MF%U901W 8R#9*KE@O.,@_*<\5RWB_P ,7FMZC?7=EI%S9ZY;L@TO6+2=(]R[
M5)$OS9*AMP(*GCIZ5H-8ZWI?Q%N=4@TLW]MJ&GPV[3),D:PRQLV2X8YVD-G*
MAC[4 7-,\<VNK:+H][:V<OVK5VD6UM'8 _NRP=F;H%&WD\]0 "34D?C**.PO
M9K_3KNTN;6\6Q%N5S]HE8@)Y3' 8-N&#QCG.,5P^D^%_%FB>'O"6HV^E)+J>
MAO=1SZ>;A 9X9V))5L[0P^4X)_\ K]'XDTSQ+XG\,QW<5G%8:I97L%]8V,LR
MOEHCG;(Z\9;)X!(&!SR< &N?%HLKG4X=9T^:P6PM1>-< F2%X^?NO@?.",;<
M?3-5[7QU:OXDL=&NX$ADU"-Y+62.Y28$H-S(^W[C8Y[@\X-5=0M/$'C?PIJF
MGW^EC0OM%J8XHY;A9F:;((8E. @(QZG)X&!F70+GQ/JB1VFN>'8=+\M"EU<K
M<)()SM(_=*O*Y)SD] ,<YR ".7XDZ;"VG7+1HVF7]PMO%<I<(SJ6)"NT?4(<
M=<Y&1D"H?&&MKJWA/Q3;V>F"_M+*WGM[B5G Q*(R6V*1\Q3().1R,#)%5O"-
MOXNT6QM?#%WH-NT5EB&+61<)Y;0 \'R_O;]O&.F>IQ56'1O$>BZ7XM\/1:-)
M?VVI/=W%C>Q3QJH\Y3E) S!@03U .<]J .R\&\>!?#_&?^)9;\?]LEK!T'QM
M<O9^)]3UZW2TL=+OYX=Z2!]@C5!L QEB22<^K8KHO"EM=V/A+2+.^@\BZMK.
M*"2/>&PRH%/(X[5Q$_@S6=2T'QKX=FMA;QZGJ,M]9WQF4HY8QLB[1EARF#D#
MVS0!U;>*VL]5TRRU;39+%=4)2TE,H<>9C/ER8^ZY'3&0<$9JYXJN[6P\*ZI=
M7U@]_9QVTC7%NFW+QA3N'S$#&,^]8%YIVK>+&\-KJ6E2Z<=,OH]0NWDDC96D
MC5@$CVL206;.3C@>O%;GC"TNM0\&ZS8V-NUQ=75E+!%&K*N6="HR6( '- '/
M7?B:^L]2\$V&D:6BV&IQ._E^:%(5+<LL0XX RIS_ +.*V1XI:XO+N*QL/M45
MG>QV5R5F D1V*@MLQ]P;^3D'@X!'-8-SHVMQMX#U"#2GFET='BN[;SXU9-\'
ME[L[MI /)P2<=JKZYX8O]3UAM4L-)GTOQ%%=J(M3MIT$,\ <9\Y0V6&S(P5R
M<#MP #O]3U"+2M*N]0G25XK:%IG6)=SL%&< =SQ6+8^+#-KL6D7^GO9SSV!O
MX2)!(#&" RMP"KC<..1[U>\3QZM+X8U*/09%CU5H&%LS$##]NO /IGC-<7IN
MBZW#XRTC68?#9M(AIDUM<&:[C>42ED;=(027SM.#DD]]M '4:-XH;68K"\AL
M?^);?Q-+#<I,'V #($B@?*Q] 3C!!.:-&\4-K46GWEO8YTV_1GANDF#; !D"
M1<?*Q],G&""0>*YK0O"][8^)K#5M+TJXT)98I&UBR\]&MIG*?+L16(W;\'(
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MM^QLXW!2,9QR#7JM% '+Z;HUS<^.+GQ3=VS6A.GII\%O(RL^T.9&9MI*C)(
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M(T> W,BF.0)!Y95PI) 8]@#D'UXK*T5-7T7^Q)-;\(WY@TQ%MX+@ZE!.MKO
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MX/' %9]YIFIV?A'P;H"Z?;SZU9,C^1]K$4F(8R#)%( 0!DH#D<AL8YH W?\
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MX682"U<(QRI9 Q)48Z#KU-<Y/X,\17OA+QOI<T5E'/K%\]W:E9R0<B/Y3\O
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M<W5B2;=Y"?D)P>F<'D#J#TK6HHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHIDKM'$SK&TC 9"*
M0"WL,D#]: 'T5A>%?$@\3>'_ .U39O:#SIHC"S;V'ENR=AU^7H,_C6;_ ,)A
MJ5KXDTW3M4\.O9V>INT=I="Z61@X4MMD0#Y"0#T+4 =?1110 45B7?B:SMO%
M>G>'5_>7UW'),P!_U4:C[Q^IP /J>W.LUU MVEH95%PZ-(L?<JI )^F6'YT
M2T4URXC8QJK/@[0QP"?<X./RK@_^%DRI\/;KQ?-I,,5M#*T:0M>_-+M<QG!\
MO&=PX'?VH [ZBL"36]3$FDP1:5!)<WJF2:/[60+=  2Q.SD9(7H.2.V2'WGB
M%[71=;U%]/F@&F>;_P ?9\M9U1=Q=2-WRGG!QU'2@#<HKD[CQ3J-OIOA>1M.
M@^V:U/#%) 9B# &0NY'R_-M4'/2NK;<%.T MC@$X!- "T5Q^B>+-:\0Z1-J>
MGZ!:- DTL,8?42IF\MBI*_NL8)!QDC\*Z;3;J2^TNTNYK<VTL\*2/ S9,98
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M9K=QVBAY(O.\LD9 X.T^OM0!NT5SZZMKWV>UN6T2T:"9X@_DW[,Z([ %MIB
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M746U>YBEM84T]8T,$ZRY=W.=P*XX XYS0!=HHHH **** "BD8L$8J 6QP"<
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MD:K\5H8^#!H>GE^.T]P< ?41QM_WU6EXWUH^'O!6KZFA(FAMV$..OFM\J?\
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M+&[%HHFL5D6V8$@1^9C><9P2<=3SU]351O"&AO;:O;M9DQZLSO> RO\ O"P
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MHY79VD;CYF<DL6X&#G(P,=* ,/7]!M-(TKQ1/:7L\8N-+DECL%?$<+QH?WJ
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MNW)  X K0@T^7QQ;^)!/JMK9W]GJ<\(N&@8W%BL;_NRC^8NU=H!X !RV<\T
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MAU,@^SL3G!Z\?>Z^]:NBZ!:7.O>/?"R&2'3/]%>&-9&/D/)"2SH2<@Y /UH
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MF+>5'M1@HSV!8_G5;5-.@O\ XQ6UK<M.]M-H4K20^>X1B)D'3. /4#KWH ]
MHKQ"72K<?#'Q?/YER9=$U*]CTQS</FU6.3*!.>,9Z]<<=*ZJ:=_$/CB31+^6
MR,8TB"XM[:\MS*LI<OYKJ Z_,,(,\D<XQSD ]%HKS2#3HK%O#GAVYU:7Q!>6
M[77EP2@)!,J\$S%M^1'G:,;CGMP<<[<&=_@[J*O<S*]EKS6\)BF8!$^V*NT<
M\J 2 #F@#VVBO.X[*'1/BM+;6,TMM!>:#+<7!:5I 94E4"4[B<L QYJMX3EF
MTGQ-I>CZ_I"V^J-;2I:ZI9OO@U)0%9F?N),+N^;/5N>>0#T/4-1M=+MUGNY1
M'&TJ0J3_ !.[!5 ]R2*QXO$-VWQ"F\-R6L*VZZ:+Y)UD+,V9-F", #H?7MS6
M+\5+.VNM)T-IX(Y"NMV:@NN<!I0&'XCBJUUHMA?_ !?.GSPYLE\-J/(1BJL/
MM+#!P1D>W2@#T6H;N[@L+.:[NI5BMX$,DDC' 50,DFO*=!N89? ^@:;=W%U/
M)_;4]O:V@<$72Q22[8Y6;/[M5 )Z_= P>!52[@W^ _B987,4/DV=S(\%NA+1
MP'R4;"9 P QR.!SV% 'L<$R7-O%/'G9(@=<^A&14E9>@06EEH5A#;I%"KPH0
MBX&6*@GCUK-^(B;OAWX@8/(C1V$TB-'(R$,J$CD$?E0!TU%>7P6$.E>+/A]=
M6CS+/J-O-%>.TS-YZBVW@,"<<, 0!T[56L53Q)\,]?UV^=H]=@EO9/M(8K+9
MR1,QC16ZJJJJ\#KDYZF@#T^34;6+4[?3GE NYXWECC[E%P&/TRP_.K5>5:=;
MQZQX_P#"FH:O90F]N_#1GN=\8YDW1<D>V3],U2U#3&C/BGP) I^W7DZ7VCR%
MRK*D@);#=0L9C<?0@=Z /8JR$U2XTW2+B]\0BUM?+F95\B0LK(6Q'U ^8Y''
MJ:YWP=?V_C%+'61;B);*Q%LR(-GEW+8\U>.FP*H'^^:X>ZM8;CX27?VA?/,'
MB4K&\Q+LH^V!>IY^[Q]#0!Z?<>(;N#Q]9>'C:P_9;FREN1/YA+Y1E&-N,#[W
MJ?PKHJ\\UC2;*X^*6@Z>8MMF-(NP88F**1YD?RG';U'?O63I%IJ4_A'5M*TF
M:!FL/$MQ#:6=Y(WESPQMO^SD\G&,]?3GB@#T_4M1M=)T^:^O91%;PKN=C^0
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M\XKH<YHR/6@"MI^GVFE6$-C8VZ06T(VI&@X'?\\\Y[U5'A_2EUU];%D@U&1
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M^&WTZ.P;3<VT5Q]JC7SY,QR\Y=6W94G)S@\YJ:#P?X>M?[0$.DVZ#44\NZ4
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MD\@ \F@#DO!'AO2[W7/$EW<P/+-I_B*9K0M,_P"Z(CCY'/.<\YSG ]*T/BE
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M >9:.TVB>(]%AUO38+J*YNY&TWQ#9D9G:1)"$G!^;)5CSDC('H:JZ/8KXO\
M"":S=:Q9V&J6MX\MS>):DW=M*DAS&6\SIC"A<8*D "O2++PSI&GR0O;6>SR&
M+PH9'9(F((+(I)52<GD 'D^IJN?!7AIO$']O'1K7^T]V_P"T;>=W]['3=[XS
M0!SOA;3=/B^*?C:5;.V26*2S:-Q$H92\!+$''!;G/KS4GQ?M+:X^'UU+/;Q2
M213VWENZ E-UQ&&P3TR.#76#0M+76VUH6,(U)D$;7&WYB ,#\<$C/7'%+J^B
MZ=KUI]DU.V6YMMP8Q.Q"DCD$@'G!]: .0N([3_A:5AX;GL[=-&31Y+FUM/+
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MS3;>8^S=G.<9ZYY^O-/N?"/A^]OVOKK2H)[IH1 \LH+%T P V3\Q]SD^] '
M"TL]4U[X87&H6UO=2W.E3&XDGC5S(1;1L-Q/7!)//J:?#81^-AXJMK_4;*VO
M;34I8_.DMR;BSB0CRGC?S!L7: 00,9W=<FN[/@_P\UE869TBU-O8-NM4V<1D
MC!QZY[YZ]Z9J/@KPUJ^L1ZM?Z-:W%]'C$SKR<=-PZ-CWS0!S&AR0:_X\UG3-
M:9-02PT^S%DES$,2I(A,LP0_Q%BH)ZC %7/A)&D/@"&*/.R.\NU&3DX$[]ZZ
M+4_"^BZS?07U_I\4UU "L<V2K!3_  D@C*^QR*GTC0]+T&U:VTJQAM(6<NRQ
M+C+'J3ZT <+'X<TKQ)\2_&=KJ]M]IMQ;V&(S(RKDI)S@$<CL>W.*P[72KV[^
M%]CK2JU]?^'KZ6:R>7YFNK6*5AL)[@H#CW5<5ZA>>&M(O[]KZ>S'VIT\N26-
MVC:1/[K[2-Z^S9%5M:EUNQ6SL/#VBVTT$B-$T[W"Q)9X "'R\9<=>!Z8[T 5
M?#$UGXAU"Z\5VR*T%Q&EM92E<%HDR6;ZEV9?I&*SO%-X9?'^B:+=RVD=C=6<
M[Q)>0F6*:X#( I7<H+!2Q&<]3QG&.NTK3;?1])M--M5VP6L2Q(,=@,9^M0:Y
MX=TCQ+9"SUFPAO(%;>JR#E6]01R#]* /-?%F@Q:%\*?$EE'J9NTAO4ECCC4Q
MI9[Y(R85&X_* W )X#5NSZ;I\GQRCEFL[9G_ +!,V]XE)\Q;A0'R1]X#@'J*
MZ=_"FA/H*:&=,A&EJ01:KD(3G/(!YYYYSSS4UQX=TF[O;.]N;&.:ZLUVP32$
MLZ#KU)R>0#SWYZT >0W^E6<_P_\ 'VJ21DWUEK=[+:S;SF!UD4ADY^4^I')K
MJ[B;^WO']UHFI26#)_95O+:6U];&990Q?S70;U&[.T$\G XQSGJ_^$0T'[!=
MV'V ?9+R0RW,)D?;,YZLPSR3W]<#/2FZMX,\.Z[;6L&J:5#=):#$!D+%D'H&
MSG'MF@#@=1T&&SC\":9)JT^J)%JLEJ;DLRET"293J<@8VYSG QFO3M(TBQT+
M3(=-TV#R+.'/EQ[F;;DECR23U)JM<>&-&N5L5DL$":?C[(J,R" C@% I !]Q
M6JRAE*G.",<'!_.@#RSPMH\^MWOC^R35+BR@GUF6*;R$0N5**#AF!VDCC-:M
MWH^C6&M>'O#5C;&X>TL9F@L;AQ]F6/*J99,@EGR2!C^\W0<UUFF>'M*T>XN;
MC3[7R);ES).RR,?-8_Q-D\GW/-)JGAS1]:NK:ZU'3X+F>USY+N.5!ZCW!]#Q
M0!Y%#']K^%_A9)9Y&:+Q*ENCQRL-L?VMU '/0 #'I@8KH=8\)>'M+^('@RUM
MM)M5MYY;]Y4D7S Y\K=SNSP#D@=!VKL?^$(\-_9OLZZ1 D/VC[5L0LH\W.=_
M!Z@YQZ9XQ5[4M TK6!:C4;&*Z^ROOA,HW%#C'7OD=<]>] '":C)%X"\<7ES!
M:)):>([;;;(%X%\G2(>BR!@?J#7=Z%I$6AZ)::=#M/DQ@.X7&]_XF_$Y-9,<
M&L:UK\?]K:/!9:=I=T\UK)]I69KIMI5'V@?( &8X)SG'I73T %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !6?KNK0Z#H%_JTZEX[.W>=D4\MM!.!]>E:%<C\3[:"X^&V
MO&>&.4Q6<DD9= VQ@IPPST//6@"_I%UX@FNTGU#^S6TJ:T697A#))%*<$H06
M(9<'.[CITK>5U= ZL"I&00>*\VN5MK3Q)X%TAK6"'1[N":5XEC"Q37(B79O
MX)QDC/4X/4"LO7;$6DWQ(TVVB T==&%X(5&(X+HQO]T= 2%#$#O@T >N*Z/G
M:RMC!X.>O2AY8X\;W5=QP-QQDUS?@K0-+TS1++4+.T6.\O;&W^TS9):7:G!.
M3UY/^0*YOQ6NGZCK'BJ*.-)[JTT95NWOB&BMT99&41)C.YNK'( PO4\4 >DE
M@" 2 3P/>D61'4,KJRGH0<BO(H+6VU:[^%#W@\]Y]/E6=F8YD'V,'#>HYY!Z
MY.>M7M&\+:;JZ^/O"I@CAT[[>OV>)% 6W=H$.Y!_#AN>* /4,CU'-#,%4LQ
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M2N>0*\3ET+2Y?AW\0KB2SB>:RU6_:U=ADVY7:04_NG@=,9P!712Z=::=XZ\
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MA?XG/%:VT4R7FHQ(R1JK!/LZ':.^.^.E 'I.@:B^J:!IE[.8UN+JSBN)$3@
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MPJH^2%0J@D9/ ^N:\HL/">@ZOHWC\ZA;H?LNK7A@D9S_ *-B)&#IS\IR.O<
M \"@#V%G5/O,%^IQ5,-J)US[]F=*-ME0-WGF;=U_N[-N/?->56.F+KFM^ 1K
M]OY\]YH,_P!L64G,V%CQO]>N?K6Y%80Z)\5;B#2+54\GPJ!#",D$K,54?DJC
M\* /1?,3S/+WKOQG;GG'TH:1$^\ZK]3BO&Y$AO?@5!XBMS_Q/X0MRMZH_?\
MVOS=K GJ23E=OH0,=*V/^$<TS7?BIJ]KK%A',DNC6LLT))VF3S'RW!ZC'!H
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M\O?#7B&PUFTC*H4A2QMPC72NOS))\Q+8P6.>002:]!AN(;E"\$T<JABI9&#
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M[#PWHVF3K-9:=! R%C&$'RQEOO;%Z+GO@#-(/#6C+]MQIT ^W?\ 'WQ_K_\
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M%O#=VLMM<1K+!,ACDC89#*1@@^Q%,:QM&EMI#;QE[7/D-MYCR-IV^G'%6**
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M(A=JNJL0<$$X8$#-=W10!0GT33+G4X-2FLHGO8!B*<CYXQW"GL*4:-IPU?\
MM;['%_:!3R_M./GV?W<^GMTJ]10!E1^&M%BOFO(].@6=Y?/8A?E,G]_;TW_[
M6,^]3)HFF1ZL^JI91+J#KL:Y ^=E]"?3VJ_10!6O]/M-4LY+.^MTN+:08>*0
M95AZ$=ZJ'P[I!FLIC80F2Q&VU<CF >B'^'CCCM6I10!E2>&M%FOY+V33H#<2
MLK2MMXD9?NLR]&([$@D8J>\T73-0OK6]O+"WGNK0DV\LD89HR?0]N@_*KU%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYB8D&.(]N[=M)^]QT&.020 <R-3O=7^+&B#S&334T^YNX(,8W#*QK*W^]N;
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MC.,#&/3BO4II&BA9TA>9@,B-" 6^F2!^9KD?ACI&I^'O ]MI.K636]U;O*Q
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M\43;ECR>%!P-V!@$]SGITKCK.RUK3_B3KNN'0KJ:QO;:""$Q30;\Q@Y)#2#
MYXH O:7<66F^%[_6?#6ALT4L\LS6$:?9V8QGRF*H5&&/E@[2 ?QJSX;\7)XH
M%M-I]LKV;VRS37 FR(7;/[HC;RXQR.W?J,N-[X@%GJ$UOH7DON5+.V:6(L2<
MEY7PVW&6^Z&R=I_O<9.@Z!JGA3Q7<6UA;S77A[4$$\[R2H&@NCP[@9!*OP2
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M+>0R.%6(/A5VC<S9SVZX[9JA>>%;Z]\26^LV>DRZ3K,>H_O[^"=!#=6@D/\
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MTN)AT>0* Q_$YH \PUC5]0\3_"?QC/K%C; 02W4<6V3>(VC;:  5'3'WN_/
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY;[5=2M1;(MO92+$)Q+GS'*AB-N!C 8=SU^M &E1110 4444 %%%% !1110
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M&-G=VD$4)65-S-%NSP3P#NX^G.*ZBTO+:_M8[JSN(;FWD&4EA<.C#V(X-34
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MB.I9< D YS@C()Z'DCTFB@"CJ\VH0Z3<OI=LMQ?^61!&SA5WXX+$]@>M<Z?
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MH[*9U-^?)>-DWJ5?R]Q8C/!4#CDCI5R/QW:7.EZ'<6ZPQ3ZO;&ZC2[G\M(D
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MB@ HHHH **** "BBB@ HHHH ***1F5%+,0% R2>@% #1+&9FA$BF55#,@/S
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M SG&1UKH-(U+6+CQ'K%CJ%O9BSMS&UI-;.Q8JV?EDSP'X!P.@(]03O$@#).
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M1! CKMP%RN=V3QVYX7P]X1.E^+[G6[>Q@TFWN+3RKBRMI=T<TVX'S,  # !
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M8<8YQSCF;Q!H7BC7_#MM%,-.%_\ ;X+IH1.ZQ0I$X;8&V$L3@Y.!U]N>YHH
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MXRCLPD  ._AN02OUK$M? FO6W@71-*%QISZAI.JKJ$>6<1R@2.^TMMR#\YZ
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M[@"5(P0<?RKFIO"GB?3[K1=9T.XTT:G:Z:FFWMK<NY@GC4Y4JP7<&!R>G?\
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M]C"%E;C]WG)VX]O>@#2D\3:Q97<.EZE;64.I7+32Q&V\VXC2W38 [ *&+%G
MQP."<]JK6OCR[_L[;J&E2VVHOJ)T^$-#*(I\*7\Y05W%-JL<8SD8SSFK7BGP
M_K=YJFD^(/#]Q:0:O8(\3P718P3Q/C<A8#(P5!!Q5?6O#/B/7-&M+J34;.V\
M165XMY:^4K&VC*J5\LY^9E8,V6QGGI@4 :/ASQ#J&I:OJ6FW^GN@M0CP7R6\
MD4-PK#D .,AE/!&35G6M5O[+4(+>WBM[>U:%Y9M1NS^YB(*A4P"/F;/KT'>G
MZ#'XA97N/$+V"3%0B6]@7,:^K%FP23QQC  [YK/UG1-;G\::=K-A)8S6D%J]
MNUO>,X\EV8'SHPH.6P-N#CCC(S0!3TGQX^L:!X?GAM(TU+6I988X6<F.,Q%_
M,<G&2H"$@=3D#CDBIXMU[Q18>!_%$KVL%G<V"X@O4R4N(V'+HN2589QR2 >>
M>E4+7X?>(['PWHR6M_IR:UH=[/<6;X<PS1RLY=).,C<'QP#C'4YR.@U7P_KW
MB3P7K&G:K<V4-]?V_E11VV]H(<<C+$;F)/4X'&,#C) .ETS[2=.A-V8C-M&3
M%G&.W7FK=8=JOB9)-(69=*%N%<:BJ-(67"CR_*) S\V<[@..E;E !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MH 3Q0!M45RNK>(M1\-76ER:NEI-87]TEFTENK(UO(^=A.XG>N1@GY<=<5U5
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M22,'GB@"[1110 4444 %%8&K>)1::U;Z%IUM]MU>>,S>5OV)!$#@R2-@X&>
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M%;M;IHEFL+3BX*"/CS <@_@23CIR:T%T;34U8ZJME"+\Q"'SPOS;!G ]NIH
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MA=O&WI[5L>-UL;ZS\>W%JBS3VELBW%Q>,#]GD6/<B6Z@97J"6)'S'@&O0O\
MA$= _LN+3/[+@^P1/YD=MSY:-G.0N< YY^M)<^$/#UY>3WESH]I-<W$7DS2R
M1[FD7;MY)ZG'&>N.] ''^(H8=)D\->/O*20VJ1P:G)M!+02*%\PGU1B#ZX)K
MJ_"EI&;2YUDP+'<:O,;ICLPWED 1 ^^P*2/[Q;UJEJ6EZC,5\+V.BV5OX:D@
M6.6Z$X!5,_/$L07JR\9SQN)Y(Q76 !0   !P * %HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJ%F/#>O:UX)MK98[;Q$WVG3V2/B-7PMROI\B@NH]P*].6.VTW3PD:+#:V\6
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M % 'J7FQ[2?,3 ZG/2J-]KFGZ??:=97%P@N-0D:.W3(RVU"Y/T 7KZD>M<%
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M$.;6K2VE$6JW7[Z506A41(=RD_=.><C&<#TI9K._TCP9X0\:7D#OJNBV\8U
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MC0_&7C'0;]A%>W6I/J5MO.//ADZ%?7;C!QT->C111P1)%#&L<:*%1$& H'0
M#H*J:EHNEZRB)J>G6MX(SN3SXE?8?49''X4 9OBW4+F'PWK4.DLS:K'I\LL2
MQC+(=IVGV)/0=\'T-<1JL=M<?#CP9J6@A!J$=S9?8I(OOLS8$JD]3D;]X/H2
M>E>G66GV>FP>18VL-M%G.R% HSZX'>H+70M(LKMKNUTRS@N&)8RQPJK9/4Y
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MFTO^RY-(L6T\'(M3;IY8/J%QC-*_A_19+""Q?2+!K.W.88&MT*1GU5<8'X4
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M:=+)?R>9!*T*>9;%5\IT+H2<*!C!X(]Z /3[K5-/LBXN[ZUMRB>8PEF5-JY
MW')X&2!GWJT"& (((/((KS"WT+2+OXJ6]G=6:W4+>%HRRWL:L\A$VW=(,8+X
MX)Q75^._M\'P]UH:,K+=I9.(1$,,HQSMQW"YQB@#:M]4T^[NI+6VO[6:XC^_
M%',K.O..0#D5RM_XFFU3Q1?^'='U>SLKFUM$DCF?9)YL[LP$9![ +R!\WS=L
M<X^NBUOM!\ WWA_RQ<"_M19M#U$!0^:O'\.P'</:M32$A_X7%XD 6/<-.LSC
M R#F3)_44 ;NJ^([;PSH=K=:]<V\=Q(8X2L;8629L A-W.W))YZ 9-9<OB:>
M+XA6U@U]9_V'+I,M[Y@ &&61%R9-V",$],?C5?XJ^6OA.VEDVA(]4LV9FZ*/
M.7))["JUY%I^I?&'20R6]S;C1)V08#(2)D&<=#W_ "H [A=1LFL!?K>6YLRN
MX7 E7R\>N[.,54N_$>C6>BW&L2ZE:FPMP3)/'*K*"/X00>3VQUS7E^G7>FZ=
MX:DM;B!&C7QG-!8H93%#!()69"Y'\ P3M[G XZALUQ#+!\6H#>VMU*UHL@\@
M *Q^RG<RKD]#P3D].30!ZSI6IVVL:9!?6LB/'*BM\CAMI(!VDCN,TZZU33[&
M:.&[O[6WED^XDLRHS=N 3S5+PK/;7'A?3&M98I%6UB#&)@0&\M3@X[\BN0\.
M-:ZA'\0+#Q (_/\ [1G^TK-C/V0H/)//\.T''XF@#T"XOK2T95N;J"$N&*B2
M0+D*,DC/H 2?84^">&Z@2>WECFAD4,DD;!E8>H(X(KQO2=/>ZG^%2Z_;I+>2
MVUXLHG4%G00YC#YZX7;P>]>L2Q6.BZ#,D5L(+&UMV(AMEV[4 )(4#&#]* )8
M-5TZZNWM;>_M9;E,[X8YE9UP<'(!R.:;+K.EP?ZW4K./][Y'SSJ/WF =G7[V
M"..O(KR6PU#3QJOPUG@NK&WL0)_)MEEWO!$UNV!+(3RQ(&> ,@CG&::VDZ8W
M@3XH2&RMB\.I7HB/EC]WB*-AM]/FYXH ]@.HV2W@LS>6XNC_ ,L#*N_IG[N<
M]*?%=VT\TL,-Q%)+$<2(C@LA]P.E>?\ B1&TO3O#?CJ%3)+ID,:7Y RTMI(H
M$A]25)#CZ&NL\,6[C37U&>,I=:G*;N56&&4, $4^ZQA%/N#0!HWFHV6G1B2^
MO+>UC8X#3RJ@)^I-4-<\3Z5X?L;:[O;N)4N9HX8/G'[PNP (]0,Y)[ 9KGK&
MY;_A<6M6FH@?O-,@.FA^AB!;S@OON*Y]@/2N)D@-GX,D5RHTF#QFGV!F^XEL
M+A?NG^X&WX[4 =^WB:>+XBC3Y;ZR_L-M%>_60 +AA*B9,A8@C!/IUKJ4O;62
MR%Y'<PM:E=XG60%"OKNZ8]ZX6>'3]2^,]D&2WN8!X>D= 0'3(N%&0.A[UR-M
M?+I/@^Q9YGMM%M?%MQ'<O"JE8(M\FPD$$!0Y0].N* /8X=6TVYLWO(-0M);6
M/(>=)E9%QURP.!4EO?V=W)+';7<$SQ8\Q8Y Q3(R,@=,CFO+O$^F^'I?#?C7
M4]/U5M6N+K3-]RP>%X5=5(C;Y% $F,^^/PKOO#&DZ;I^D6MQ8V5O#+<VL)FE
MB0!I<+P6;JQY/)]: -"ZU73K(N+N_M8"BAV$LRKM4G )R>!D@5!9R7#:WJ2R
M:E:SVX6(PVD: 26^0<ESGG<1D<#H:XR?1=)U'XTWUO>Z?:W$<GA^)WBEC5E=
MO/<%B#P3C SUI-)MH(O'/Q&@MY([%6M++,L8"^43#)E\#N.M '=)JNG2W#01
MZA:O,F=T:S*67!P<C.>O%<UH_BB9?$?BBSUS4+*&UTZY@AMY&Q"N)(@^"68Y
M/..O;H*Y#0K2P\3:7X%LI)=)/]D8>5C<12_:%$94*B9+9<[6(8*1CN:NG3[&
M^UWXHO=6T$[)'$%,BAMH^R#.,].GZ#TH [G5/%6D:/JNG:;>7L$=S?LWEJT@
M7:JHS%SGH/E ]R16U7D=I<0(WPDN[V6)8_L$HDEF8 9^R#&2?>O4K;4K&\N;
MFVMKN&:>U*K/'&X+1%AD!AVR* +)( ))P!U)KD?!GC3_ (2B_P!:M);?[/)9
MSJ]NI&#+:R*#%)_P(9/MD5>\7323:?%HEI,D=[J[FV1FYVQ[2TK8!!X0$<$<
MLM<?XB2]\'>-= \5WD]B+&8C1[T6T#1*L;Y,;'+MPK#KZ4 >GR2)#&TDKJD:
M LS,<!0.I)JF=:TI84F.IV0B<E5<SKM8CJ <\GFKO##L0:\:NM&O9+'7OA_I
M\6R:PNCJNFS%/ECA.98U4^OG93_=W>E 'K_VVT^T"W^TP^>4WB/S!N*^N.N/
M>H[/5-.U!W2RO[6Y:/[ZPS*Y7ZX/%<'_ &Y9:SX UGQCJEG<&SN=-\CR(\I)
MY84^8 >JYD9USZ(IJGIEY;CXHZ#OOM.*R:%)"L5JX*(N^,I'N)RYYX/&?04
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MO8([RY1I-KRA0B@<$Y[DD #OSZ4 :']CZ9]GAM_[.L_(A<211^0NV-O[RC&
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M*!S5NN-T[Q--J'Q-N-)MM2M;O2ETD72K %.R7S=I!8$Y.!TXZ]*[*@ HHHH
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M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ J"[O+:PMFN+NXB@A7
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MVTDN3&LTJH6 !)(!/( !)^E9D>L66J:QI4NF^)K-K:6.5OL41CD-V.@8-G<
MA#=/QK"\?_8SXI\#K=>3SJK<28Z>4^.O^UC\<4W68K&Q^*W@JWMX[>W MM0
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MIDL.W2\JDT%Q&-K$J%#;!\Q))QCKS0!Z1'XGT&6YCMH]9L'GEF:".-;A27D
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M\L%YJME;RPQ&:1)9U5DCR!N()X&6 S[BO+]-G@G^"_B+1]8*G6X6O([N!_\
M6O=-(SQ$#J2Q*;2.O&*T]+@\OXH^'X=6,,FI0^%<3LY!;SA)&"?K][GZT >C
M6-_::G917EA<Q7-K*,QS0N&5ATX(JQ7G/@'6M*T;PQK$]W>P6]G'K]W"C%OE
M7=,=H&.F<UZ-0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M>WMMIMC/>WDRPVT"&261NBJ!DDT 3T5'!/%<V\=Q XDBE0.CKT92,@C\*DH
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MDD\R-D@9(SQ6W?>$]0O-.\17?VJ :]JUH;2*3YO*MHL$+&IQG&6)+8Y)S@8
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ML9'*D-R#@^E4M8\!7&I^'=>M%O($U+7+B.:ZN3&2B!-NQ%7.2 $ R3R23[4
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MKK3;Y+N,S1&1'PK*5(!!Z-Z]J .:6/6'^*?B"/2[BRBNSI-INGN(6= =TG1
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M'K4\OB+Q/HOB#P^^JOI]QI.MRBV\NWA99+65EW)\Q)W@X.3@?04 =_17G_\
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MS P?\L]\A"CYN".>>_I36\7:S/X ?QM8?9OLD>^==.:+[ULCE3E\Y#[06SC
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M ^!CH><<5SP\(W$VN3:Y//91ZD^GO8^9;V[*LFX@EY!NR<;1@9XYY/&.MHH
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MQO<J7)).T#J,#([YJKHOA"YT?P/<>&QJD4WF+,J7!M2NP2LS-E=_."YQR.U
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MAO\ 5M-_M"[N%0'RT"KD(IR,LS=\@ '@\5BV&KW7AC5/B!>3NMY=I?V4,3%
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M<$X!Y/3/&:O?>7Y6ZC@B@!:*\WL=<\5W\_BX6VIV0;1+EH[=)[3*R@)OPY#
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MEZL+;)#;S+($/H<'B@"]16?:Z]I%[<R6UKJEG-/&GF-'',K,%_O8!Z>]0?\
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M%PC:I:V=YY+/%YS+D>AVDCC/'IFH/ ^IW>L^!]&U*^E\V[N;5))7VA=S$<G
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MGVULLZV\5NB1"X/[P(  N[/?&*M2V-I.\3S6L$C0G,1>,$I_NYZ?A4Q 8$$
M@\$&@#RWPGI.F^(?$GCZUNIIGA?5-DD4%V\8="@!#!&&1P1^8K5UBYT;0O&&
MA:3"EGI4D6GS?9[V=ML<46Y 8HUR%+G .3G 7H<UV\5E:0/OAM88WQC<D8!_
M2GRV\,SQO+#'(T9W(64$J?4>AH \*M)M.G^&7AJVFE@D\GQ2B2K)@%%-U(<,
M.V5.2..#7<>*/[.T7X@>"9V%M8VGF7Y=\+&F]H1U/ R3^)KN6L+-QAK2!ADM
M@Q@\GJ>G4U(]O#(L:O%&PC(9 5!VD="/2@#S*Z$\GB[XDPZ20-0DT:W\A8^'
M,GERXQ_M9*_F*7PY>^%?$J^&)XM8N;G4[#:;>P4QI):MM"R!U5 0@ (.>#@8
MR2*]*2TMHYC,EO$LISEP@#'/7FDBL[6">2>&VACFE_UDB1@,_P!2.M 'F?A^
MXO-&U+P[!;W5MKOAN^N9!I\A&V[L7*.2&QPZ@%U)/(SSVKIOB'J%CIV@V<E_
M;1S1OJ-LD;S2,D4$F\%99""/E4C)'0\#OFNEAT^RMIVF@M((I6&&=(PK$>A(
M%2S0Q7$3131I+&W#(ZA@?J#0!Y9I%U9W?BSXA6\FMQN;O3[8BZA Z"&4.Z!>
MH7(YR>PR35;P[<:3XA3P-;RZQH:2:-$!Y4=[&\LY\KRU18^HSP6!Z$8&>M>E
MZSI+W^C7MI87 T^[N(#"EW'&"T8[>G Y[\9XQ7.P>%-0OD2WUC3_  W%"A4F
M6QMF\QMI!&W<!Y?3KEB.W/( ,_PM96%UXP\=^7;VDMS%J$+PED5O+80KM8>F
M&SSZUA>&+OP]KOA?1-*U?6+S^VM.N8\Z5NC2X6[C8Y8 ('(SEBV<8)+'K7KL
M5G;02&2&WAC<C!9$ )_$4@L[5;MKM;:$7+#:TPC&\CTW=: /);>]T.]@\3^&
MO%NLSV=R^ISM+9/Y:M<QL^Z)H\H7;*[  I)^4>U>MVB>790)B0;8U&)3EAQ_
M$>Y]:22SM9;F.YDMH7GC&$E:,%E^AZBIZ /"UOK*3]G6.S-S"9X+F))XMXW1
MDWN<,.QP"<'M78ZA+9Z=\6X&CB01KX:GW10 !G595(4 >P.*[MK&S=2K6L!!
M8N08QRQZGZ^]*MC:)(LBVL D7&UA&,C' YH \:L-9TN2\^'%U;7UE;V4<LJQ
MV4,F\6:M X5)'8EBY/'.,GH.]=CX!N[=->\96#3QB\.NS3" M\^PQQ8;'7;[
M]*[1+&TC"A+6!0K^8 L8&&_O?7WJ188DE>58T$CX#.%&6QTR>] '#^-;JWL/
M'/@>[NYX[>V2YNP\TK!44FW8 $G@9-9]FMC<^-_B0\JP2$6EJN7 )"FW;<.>
M@X&?I7I$D,4P42QHX5@R[E!P1T(]ZB.GV19V-I;Y?[Q\L?-WYXH \CAF@;P)
M\*9'DC,@U*S0,2,X$4@(_/ _*M'7I[S1;_6M7TJZMM5TMK^(:IHMP,31S?NU
M#0L.<G$9"GTXKTHZ=8E0ILK<J.@\I<#]*4Z?9-=+=&TMS<+]V4QC>/H<9H =
M=W=O86<UW=3)#;PH7DD<X"J!DDUY[=>&-3\7>"=2+W]A&FMC[:%>U9GB.%,0
M\P2@ JJH,[>QZUZ++%'/&8Y8TD0]5=00?PI%MX4@,"PQK$01Y84!<'KQ0!Y+
MJWB>#Q9^SWJ-]<21->QVGDW2D@E9U8*3[9ZCZUL:S;Z=_P +%\ (L5MM-O>;
M5"K@@1H5_7D>]=Y_9MB%*BRMMIY(\I<']*=]@L]RM]D@W)]T^6/E^G% 'CFI
M7+6EOXWEM-YM;3Q':W-Y'; ,PA B,A"X(/*Y.1C@Y[UU%N_A;6+^_P!;T_67
MU>[.DR0SS!XS%'#]X+(%4 -G) //!]*[V*SM8&9HK:&,L,,40#(ID6GV4$#0
M0V=O'"YRT:1@*Q]2 ,4 >06JV=O\.?AC-&((Y#JUEEUP"25<-S^AK4TW5[*'
M_A8FG:[<00ZE)=SNL=RP4RVIB"P[<_>7 Q@=S[UZ6=.L2H4V5OM'('E+@?I2
MRV-G/,DTUK!)*BE5=XP64'J 3T% 'CNCZY;:9:^ +R^U1[/2'T1K07D6QDAN
MOW9*N65@N54C/!X/;-6;]]&T2]T'4=/NY9_#4VOR7-_>.X:!KAH\(X*@*$#G
MJ/E##VKUN6SM9K7[++;0R6^ /*9 4P.@QTI6M;=K;[,T$1M]NWRB@VX],=,4
M <%HVH:;<?&C6C:7=K(TVDV^#%(I\QE=\].I Q70>+[[;I\6CV]W';W^KR?9
M(&8\J""9' R#\J!B/?:.];D%I;6O_'O;Q1?*%_=H%^4=!QVY-$MI;3NKS6\4
MCKT9T!(_.@#S'QE!>>#M5\/>+[B\L3;:?*NGW,=M:M#_ *+)QWD;<$(! &*T
MO$VL:?I'Q"T'6)-4LA')IUQ%Y=S<+$FPLA$B.WREB<#&>1SVKO9K:"Y $\,<
MH'0.@;'YURVL>'M8?7%O=-_LBYLC;B#[!J,+!(2&)+1LH."V1D%?X1S0!PFM
MZ?I=C\&=6>+4-,O/M.II</)9S+)'$7ND;RU<==JGV[UTGC:6S\-ZQX9U $:=
MHOVJ47=S:0IMCE:()$[?*1C&Y=Q' -=-HWAJWLC<7%U::=]IN=GF1VML$B7;
MG& >I^8Y8\GC@8%;36T#VYMWAC: C:8RH*D>F.F* /)M>.DV6CWVO:%?W=_9
MOJUG=:O=P%)494)W% J[25^1FP".F>AK7SX8U1];UK3M8;5KF31I(;F<21M"
MD8^95<*H ?.<9YP#[5Z'%;P00""&&..%1@1HH"@>F!Q4<6GV4%LUM%:6\<#'
M)B2,!2?7&,4 >120:>?AW\+PT=MA]1L ^0OS9B8.#ZY[_K5GQ,EP?$_CVVT<
M?Z9+X?@(CAX9R#(#@#^+:<#OR*]3.G6)4*;*W*CH/*7 _2GI9VL<WG);0K+_
M 'P@#?G0!Y_HE[X3\4ZKH&I6>LSW^H6L;^1;*8U:V1DPXE1$7"\ ?-QG&.M<
MC,E@GP-\17$:VZR#5Y")%QD$7@V\_3I[5[9%8VD#3-%:P1M,<RE(P#)_O>OX
MTG]FV.TK]BM]I.<>4N,_E0!QCWMK:_&[]_<1Q_:?#\4<&Y@/-;[2_"^IY'2N
M@\8Z%_PDGA/4=+4[9Y8MUN_39,OS(V>V& K7%M K1L((PT0(C(090'L/2I:
M/'6U_5))]!^(<=A+MDC72+FS"8>0N/O?07&$'TSWK;\;V4.E>'_"4$TD;31Z
M_9,\S8!>0R%I'_%BQ/UKT3R8M@3RTV A@NT8!!SG\^:;-:V]SM\^"*7;TWH&
MQ^= '&"6/_A>13S%W?\ ".#C//\ Q\T?#*6.33_$)C=6'_"07Q^4YZR9%=C]
MBM/-\W[+#YG]_P L9Z8Z_2G0VMO;;O(@BBW==B!<_E0!PVH)8M\;+,WZVY4Z
M XA\\#!<3C.W/?:3T[9KCY4;0=*NM4MO.M_# \5BX#6Z!E2WV;3*JD$>6)<$
M<$?*".U>SW5E:WJ!+NVAG0'(66,. ?7FI3&C1F,HI0C:5(XQZ8H Y'PPOAZ\
M\1ZAK&C:K)JMU<01I=W*2(T7R_<4[ %WXS[@=<9&:&O:U;Z!\5M,N=:G6VTJ
M?2I+>VN9CMBCN/,#."QX4E O)],5W5M:V]G"(;6"*"('(2) JC\!1<VMO>0F
M&Z@BGB)SLE0,,_0T >8ZW+I>G)X8O](B6/PPFNM-=RH28F=P0LV2?]6)&//W
M<@$<8-7M1MTF^)>IWEJT;6/_  CS)J+ @QM)O)BW=MVW<?7'U%>A-%&\)A:-
M#$5VE"HVD>F/2HHK&S@MC;16L$=N?^621@+^72@#QZU6SM_AM\,IHQ!'(=7L
MB77 ))#!LG]#6KJ=Q>:+J-_J>F75MJ^BRZO&+_29QB>WN/,10T3#J=P1@I[=
M*]+.G6)4*;*WV@Y \I<#]*!I]D+D7(L[<7"])?*7</QQF@#@+2[LH?'GQ!M+
MN:%))X;5HXI& ,BBV.2 >H&.3VK(M=.LY/V<7N+2T@:Z.ANK2QH"Y ^9@3UZ
MC)'M7K,EK;RNSR01.S+L+,@)*YSCZ9IT5O!!&8X88XT/)5% !_ 4 >:76NZ3
M>>.?AV]MJ-M,@@NU+I("H9H$PI/3<?3KT]:Q]&NM#U?PO)X>\2ZQ=QZO;7S^
M?I8:-)I+@2EU:+Y-[%B0<@]^3BO7X;"SMA&(+2"(1YV;(PNW/7&.F<#-*;.U
M-V+LVT)N0-HF\L;P/3=UQ0!YOI6KV=OJOC_3]>N((-0EN7=%N6"^;:&(+$%S
M]X#YN!W;WKH?A=/#/\,O#YAE20)9HC;6!VL!R#[BNGFLK2XF2::UADEC!".\
M8+*#UP3TJ6.-(HUCC1411A548 'H!0!YKK&G2VOC35_#\4#-8^+K4.&"Y6&5
M,).WH"8RK#/5@!WJY\/GO]1@B@U:-O.\/+)IC.PXFE!P7&>O[M8^?^FC5WQ1
M2X<J"R@@-CD ]?Y"@1H-V$4;SEL#J?>@#Q6\\M_A'\1TM]K!=:O#B/G \U#V
M[8KJ-?O-,U7XA^ 9(I[:[MW-\R,K!T8B)<$=C@C\Q[5WL=E:Q*ZQVT**XPX6
M, ,/0^M)]@LR4)M(,H $/ECY0.@'I0!XUJ[3)HOQ"33U\R"'78)KJ"'DM!MB
M,O ]<'/L#78:XT.J^._!5]HL\<TB^?)-+"P(-H8^=V/X2VT#/<UV\5I;0,6A
MMXHV88)1 "?RI+:QM+(.+6UA@WG<WE1A=Q]3CK0!XCJ6I6,'P@\8:9+=0K?I
MJUSNMMP\P#[2&R5ZXQSGI7;/J5E'\9[6=[N$0W7A[9;OO&)F-P,!#_$>>@KM
MVL+-Y)9&M("\N/,8QC+XZ9..<8%2M#$\B2-&C21YV,5!*YZX/:@!]%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 53U#5=/TF))-0O;>U21PB&:0+O8] ,]3["KE<
M'\79+9/ Q6Y>)5:^M.)"!D><A/7VSGVH Z>#Q-H=S9R7=OJMI-!',;=GCE##
MS!R4&.K8YP*FM];TNZTM]3@U"V>Q3.^X$HV)CKD]L=\]*XCQG>6>@>*O#NJ7
M,CV>A2)<12W=J %BG<1['<@'J%*Y_I6;KUKX='@#7=1T>_E%K/J$%V][*S/#
M/<"1/_'"0H9AP.>NTB@#T6W\0Z/<WHLHM2MOMA.!;-(%E/&?N'#=.>G2BV\1
M:/>7B6EMJ5M)/(&,:JX_>!?O;3T;'?&<5Q>E:KHVL>,-0\1Q:KI=W<)I'V5=
M-L+H322*K-(S=%.>=HP.A//.*YFPUS2Y[WX<WD%]:Q6D<TJ"RM_F2R#0,%B9
MCEC)G Y(W'HM 'JD?BWP[+=16L6MV$D\LYMXT2=27D !*C!Y(!'YBN=\>>+5
ML+"V&D:S%%>#48+>1$"OY@,BJZ9((R 3D#D5F>$T@O$^(!T[[-+J8U>Y>V8;
M697\E0C#T^8M@_6N<NM?T6?X-Z!9?:H([^QN[)+JVD8":&5)E$K,IY'.XDG^
M][T >U7EY;Z?937EU*(H(4+NY[ 5D:%XMTO6_#D>MI<PPVS*'?S) /*!/ ;T
M)XX]ZU+PB?2[@Q$.'@;85YW97C%>.V&J1CX=> +R.99=.TN]@_M78<BWX909
M/0*Q!(/3Y3Z4 >OV&KZ?JAF6RNXIGA8+*BGYHR>0&7J,CUJ2]U"STV))+RXC
MA5W")N/+L>BJ.I/!X'I7'QQK??%^'4M+E22VCT=HKZ6%@R,3(#$I(XW?>/KC
MZBI?&^K6.F:WX96[%M;R2W,WDZE=$B.T(B.>X!9@2HW''4\XQ0!OMXFT)-,&
MI/J]FED7,?G-,H7>#@KS_%GC'6EMO$FB7EW=VMMJMI-/9J6N(TE!,8'4GV'0
M^E>,W]]9'X9^/[9[Q99?^$@,G[X!796E@(8C  SACT&<'T-=Y=3V,?QDT%()
M;==VC7$:JC 9&^,J!CMP2!0!UD'B'1[G29-5@U.TET^/.^Z24&-<=<MTXJX]
MW;QVGVMYXTM@F\RLP"A?7)XQ7G%MIUWIOBN]\%1V['1M1G&JQ2 ?+%!NS/#]
M#($&/[LIKT>[ :SG! (,;<'Z4 94/C#PW<7MK90Z[I[W-TNZ")9U)D!Z8YYS
MV]>U.N?%OAVTN)(+C6[".6*1(9$:=<H[YVJ>>"=IX]J\EMK33]6^ NA66G?9
MWUIYH!:"+'FK<"8;FXY!"!B3V45V6A+IUW\7/&<<HM9I?(L0JMM8_*K%L#V(
M7/I@4 =?<^(='L[U+.YU*VBG=Q&$=P/G/(4GH&/8'DTZ[UW2K&<PW5_#%(I4
M,&;&TM]T$] 3V!Y/:O*=/N_#][I&J^%?%E[>IJBZA/YNG;BK71:8R1M$ ,MG
M*XP>W85?\0W%SHVH:YJFB:C;WT2SPIJV@7F"TC[(U#0L/F#%=F.H)'J,4 >D
MKK6F/->0I?V[2V0!N4$@W0@YP6';.#U]*A/B70Q#9R_VO8^7>G%LWGKB;_=Y
MYZ'I7(6^J6.D?%;Q,NHW,=L][8636R2'#3[?,4A!U8Y(&!DUQVDW>GR_#WX8
M1R3V[;-8C5U=AQ@2YR#[E?S% 'JX\:>&#8SWHU[3S;02>7+()UPK8R!^(!/O
M@U;D\0Z-%%:2R:K9*EX ULQG4"88SE>>1CG(KD=)ETX?&#Q6[R6H<:?:;B67
M(QOW9_#;G\*XG2YK!_AS\-FNI+=K>/7-DAD(*J,SX#9Z#IUH ]:B\8^';C2+
MW5;;5[2YL[($W$D$@?9[8'.3V]>U9Q\3V&M^%]+U&#Q!#H[7CV[@ED=BS;6,
M&&ZD@XXY&:YZ_P!/2?QSXKO])16M6\.-;W9@&5DNB6*CCJX0#/H&'K65J&K:
M;<?!GPB8[RW?R)]+C<AQA'0Q[USZCG([=Z /5-0UK3=*(%]>PP-M+[6;D*.K
M$=E'KTI)]>TBU6T:?4[.-;P@6Q:9?WV>FSGYOPKD-(U"/3?B;XKBUB>*$7L-
MM/82S,%26W1"&"D\?*Q)(_VLUQR6L=AX3\)6]\8TLY?%WFV4,^!BU+2[.#_"
M0<_1A0![!I6O:3KBS-I6HVUX('V2F"0/L/OC_)JQ>7UKI\(FNYXX8RP4%SC<
MQZ >I/H.:XS0[BV_X7%XHCCFBWO869*JPR67S >/4 C]*7Q9<OIOQ#\):A>M
MLT=1<P-,W"0SNH"%CVR 5!]SZT =.OB+1FTR74O[4M!90L4EG:956-AU5B>A
M]CS3M.U[2=7N)X-.U&VNIK<*TJ12!B@897('3->:>((T\[XEZG;2Q_V7/HPA
M9PP\N6Z$3@[3T+ %0<=R!UKT#PA%9#PKI,]FD&'L8%,D0'S (."1UP2?S- $
MNH>*M TJ::&_UFQMY8$$DJ23J&120 2,\9)&/6I8O$.C36UU<Q:I:/#:8^T2
M+*"(LC/S'MQSS7(3_P!G7/QS,%Q]FE8^'=GER;6R3.<C![[2>/0UER:E8:7K
MOQ)LKNXB@N;F.-[:!CAYE^RXRB]6 (.<=,<T =)XEUNZAU7PA-I>HJ;#4K]8
MI!&J.DT9C9P0V"<<#H:W]0\0:1I4HCO]1M[9OESYC@!<G W'^$$]"<9KS)-0
MLSX:^$Y%U#\MQ;AOG'!%LRG/T/'UI_\ :.AQ:QXM\/>+]1N;*2[O7E2%F*K=
MVSJJILP"6( VX'/ Q0!ZS)+'%$TLCJD:C<SL< #U)]*R[/Q5X?U"ZAMK/6;&
M>:9'DC2.=6+JI(9A@\@$'GV/I5K3(H;+0[.)4D@@@MD4+.V610H&&)[@#DUY
M/H5H+[X"ZC_8\,4^H*;SB$ R$&=BRC'.6C &.XQ0!ZG9:_I&HWC6EGJ-O-<*
MGF>6CC<4Z;@.Z^XXJ.[\4:%8S-%=:M:0NC;&WR  /_=STW?[/7VKC-+U#PSX
MJO\ 3M4T34;J_P!:M;:8VZ-(<VF^,@B5<  9PN#WQCUKE;GQ#I5U\#(M(%PJ
MZQ:R6T=W9OGSHYEND\QG7J,G)W'@EL9R: /9EU?3GN[FT6^@-S:KOGA#C?&O
MJPZ@5EZKK6G7>C6EU9^)[6QAN+A!#=H\<@GP^&C7/!)P5XY%8#ZE9:/\8]0?
M4;J*U6ZT: 6_FMCSF65P53^\W(^4<\]*XNWOK,_ [1 UQ"'CUJ,,K, 5/VPL
M<@]/EY^E 'KE_P"*_#^ERS17VM6-O) H:5))U!C!.!D9XR34%IJMB-6UFX;Q
M-:W%K D)DMM\82QX8$LXY^;&?F/&*YS.FWGQPN(IC:SEO#T:A'VMD^>Y(Q]"
M/P-5K6[LD\<?$D-/ H^PV>X%P.D,@/Y9 /U% '9V_BOP_=WUM96^LV4MU=1^
M9!$DP+2+C.0/IS].:GO=>TK39'CO+^"!HPK2;WP(PQPI<]%!/0G&:\HAGL(/
MAY\+V66VC9=5LRQ#*"#L</G\3S^M6M8U/3+'7O'6BS:UI<)U=(T8ZC.86A=H
M AP-IWH%*D8(YR/>@#U>TO;6_MEN+.YAN8&R%EAD#J<<'!'%5+CQ!I%I>+:7
M&HVT4Y=8MK.!AS]U2>@8]@>31X>BM;?PYIL%C=I>6T5M'''<HP82A5 W9'!S
MC-><>&=:T%_#M[X5\41K+K<.HS&:PE4^;=R-,9(W0?Q Y7GH .<"@#TK4-;T
MS2FVWU]# VSS"';D)_>/HON>*2XUW2+3[+]HU.SC^UX^S[IE'F@C.5YY&.<B
MN/T6_BTSXA^+[;79HK=[KR+BU>X8*DMLL>TA2>"%.<CU8GO7(6UJFG^&/ MK
MJ)1(7\2-+:PW& 5MCYVS(/;!4_\  A0!ZYI_B+1M5M+BZL-4M+BWMB1/+'*"
ML>!D[CV&.<U7NO%VAV>GWMY)?Q^790^=.HSO53G!V]><''KBN%O)-'F\7?$:
MUU"\\FSFL+);AX7 =!M=6?ZKD$TCW6M?V?XJT34KBTUHCP_++;:M:)M>1"KA
M8Y5&1N))(QU&: .VL/&>AW>DZ?>S:G9VS7L:LL4DZY#%0Q7WQGFK6G^)]"U5
MX([#5[.Y>=6>)8Y02ZJ<,0.X!ZUYOJ&J:1?>&?AGB\M9HX]1LT<EP0"MNP(/
MT8@'T/!YK=\2SZ?H7Q)\)7=S);6%A]GOH_-<B.(.PC;!/ !/)]^: .SM]9TR
M[M;FYM]0MI(+9V2>191MB91E@Q_A(!&<U4?Q7H:6=]='4H3'8IYEP <LBGH=
MO7GMQSVKRB;4<Z#XJN[4/<06GBY+Z\MT4[WM5,18[>N/ES^!KN)]3\-^)+76
M=1T'RK^]?2)89+RW!.U<$K$3_>))..HQSCB@"T?%%AKGA;2]1@\00Z.UX]NX
M)9'8LVUC#ANK$'''(S707^L:=I>T7MY%"64N%8\[1U;'7 [GH*\IO]5TVX^"
MOA/R[RW<P2Z7$Y#CY'0Q[USZC!R.W>NFT[4$TWXL>(EU:>.&*_L[633996 1
MXHU82*K'C(=BQ'H<T =;-K^CV\-G++JEFD=ZRI:L9EQ.6( "<_-G(Z4:7K^D
M:V;@:7J5K>&W8++Y$@?83TSCUYP>]>/R6L5EX2TF.[,2Z;<>-DFL(Y<!?LAF
M., _PD;F],-GO7;:=<6W_"ZM8CBFBW/HUOE589+"1^WJ 1^&* .SO+ZUT^$3
M7<\<,98*"YQN8] /4GT'-5%\1:,VFRZC_:EH+*%BDLS3*JQL.JL3]T^QYKF/
M%MR^F_$'PCJ%ZVS1U^TP/,W"0SN@"%CVR-R@^Y]:Y[7XT^T_$K4[:6/^RY]%
M$+N&'ERW0B<?*>A8*5!QW('6@#TK3M>TG5[B>WT[4;:ZF@56E2*0,4##*Y';
M-5I+V#_A+%A_M^)3%9NTFE_)G[RGSF/WE !QZ<TSP?%9#PGI$]FD&'L8%,D0
M'S (."1UP2?S-8%W<VR?&^P5IHE?^P9E(+ '/G(0/R!/YT =!_PF7AG=;J->
MTXFXD,4.+A3YC XP.>>>/KQ3)_%^EP>,(O#;SH+M[9IV+' 4[T54]V;<3CV]
MZ\IN)M/'P0\6/');;VU>=MRLN2?M0*G\N1[5V]UJ%I:_&?3YY[F-(KK0'AMW
M+<3/]H0[5_O''.!0!UDWB'1[>_2QFU*VCN7D$2HS@9<C(3/3=_L]:@N/%WAR
MUGD@GUS3XY8Y4A=&N%RLC9VJ>>"<'CVKS#1KK0-1\.S>%_$][?#6H+V02Z8'
M*R3S>:71X\#)W$@Y![DGCFNG\.KIMW\5O&Z2"UFEVV&U6VL?EC.<?0A?H0*
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MV<$,TURFR? AV9=I>,_(JY+<<\ \<T 6?*CR3Y:Y/7BFR6T$L?ER01NA_A9
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M%=+XIO=.U?PSJ>M^&+-KR,75G<WUQ:(5:\2*0%E4\%BJ@<CZ=0:].P",8XI
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MUFT9QN *D3$N3Z8!Y^M=3)>:>?B?XI$\B2PG08A(D;C<P!D+ >^TC\Q7I%%
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MED[X3(3C?R"<GG ]JTOA9<P3:7KRP'A=<O& VE<*9"1P:[LJK8W '!R,BE
M' Q0!R.KW46N^+;30[34XH)-.7[;.%VNQDY6-=IZX^=CZ$(>]<Y#<IX(^+C0
MWNIQR6OB2V#R,P6/RKF/A20.%#*<9[FO4:* /'-9U72=/U?QSH-QK5A:+J[!
M7;4"Z/"SPJK,@"D2* 01RO((Z<UK:A<:.GC+X;16^H6UW:PP72Q3F16##R%5
M&SZDCCWKH(/#_B6PO;Q;36M.GLKJY>X/VZP:2:,L?NAED4, , 9'  ':NATO
M3H=*T]+2'E59G9L ;F9BS' X&68G XH \YU'4])\/?$'6K;Q+/<:?I^HV]N=
M/G1Y$A=$0J\7R< AB2!_M'U&:UY)I7A#5?#5U-#J&G>%?L$]I!+YDH-L[RJZ
MF0YW*'4#@]. <8X]:*JV-P!P<C(H90RE6 (/4&@#R'Q"GARW\-:?/I(*6-]X
MGM;II;B1B+EMZF25=YSM[$].">G)Z!+JP_X7C-)Y]OD>'E&[>O#>>Q(SZ[>?
MI7?XHH \,L;]+/P;I>I@S2Z7IOB2ZEOA:,=T43M*JR?+SM&\'CUK=UJ;PM>>
M#/&6LZ%++<M>:8T,]])-(R3.$(1%WG!8>W3(%>K8I%554*H  Z "@#S"XN[!
M/$?PO,5Q;A%BG'RN, &UVCZ M@?6M3X>7<$>I^+=-=]MX->NIS"0=PC;9M8^
M@/;UY]*[RB@#@_%EW!IWQ,\'7EV_E6_DWT/F$$@NRQ[5X[G!P.I[5F:%?VFF
MV?C71O$<L<5Y+?W4_ES'!NH)5 0H#]_@;<#., 5Z?2%5+!BH)'0D=* .=\ V
M%_I?@'1++4]PO(;1%D5NJ>BGW P/PKHZ** .!MKVSC^-.K%[F%-NB0ABS@8*
MRN2#[@$$^U<39W-C%\#O#0$T"2+J\+D;@""+HDD^X7GZ5[I10!YA;>(=)T3Q
M=XLTKQ2X2/5I4GM'EC9TO+=HE3RUP#NQ@C;WW'%6=8FL[3QO\.85CCL8XUN@
MELQ"F%#;[44CMV7Z\5Z*54D$@$CID=*6@#QB]U2SL/"_Q/T>YF":E->WEQ':
MX)D:)X4VN!_=X//05IV>N6VD>.]&U'5KA;?2;SP]';65W-\L23!PSH6/"L0%
MZ]=H%>IE%))*@DC!XH95888 CKR* /$!>_\ %/\ B"]LTGGM;/QBU]=QVP8.
MUL-N77&#P<-_P'/:N\\*S^%=9U^;6] EN+ZX:T$$]\TLK(J[@RQG?P6ZG@9&
M.<9&>S  Z#%"JJC"@ >@% "UQ'Q):XMK?P_J01WT^PU>&XOP@)VQ#(WD#J%)
M!/Y]J[>B@#@)GMM0^*%GK>G7<#V%KI$L=_=1R Q$,P,:%AQG[S8[#ZBI/@^+
M5OAEHIA$1ECC='V@;E)D8D'N#T/Y5W2JJ+M50!Z 4M !7"_%F>&'P9&)9$0G
M4+0J&(&<3(3CZ $UW5% ' "[L&^.#R&XMR5\.J Y=>#Y[-P?7:<_2N+TS4ET
MWPKX?UCF;2=+\0W<E\L(W^3&[2JDA4?PKO#?B*]SHP,8Q0!Y[KFJ>'M3\$^,
MM5T=866ZTR1)M01=JW,@B=40$@;R 0/^! =<XS+K4;.QF^&&KW5S%%IT,$L4
MMTS 1QL]J%4,W09((Y]*]4"A0   !T H*AA@@$>AH \1U>YFU'2_B-_9<<UP
MQU&UN'A2-@TMN$BWX!'(*@_4?6NBU#Q-H>M_$/P'>Z9?P74.+T%XOFV;H5PK
M8^Z<]CS7IH '0=::$5?NJ!]!0!X[/>V;>$?BJJW,),EY<% ''S9A11CURP(^
MHK6N+NP3Q/\ # Q7%N$6&X VN, &VV@?0L /K7IU% 'B-[J&A_8_%?A"\\06
M%G!>ZQ)*TMXSI/$"ZN^$VX;YE.UMPXP>W/M5O+%/;1302K+"Z!DD1MP=2.""
M.H/K7)Z=X<\3:;$U@NN:=<V!D=Q+=:>SW'S,6.2) K')/)7\*Z?3[&'3-.M[
M&W!$,$8C3/7 ^E %FO*)KJ;2==EN=!U2'4;&YUOR[W0;H S13F;#20D?,,,/
M,P>,9->KTFU=V[:-V,9QS0!Y5#=6#7GQ49I[8ET R77YE%J%Q[C=D?7BH-"O
MQIVI^ =5OIE&COX>%BMPS?NX+HB,D,>BE@FWGN,5Z[2%0RE6 (/4$4 >.>(=
M.GN]&^*&H:<IETV]C@-OY7*RR1QCSG3'4= 2.I4^E;%QXATK5OB1X)N=/O$N
M;<VMZ@EC!*;BD?RYZ9]1VXS7I@  P.E(%5<;5 QP,#I0!XG>2S7G@OX@KIG^
ME.OB%IY8(#N:6W!A+X Z@A6^H!%=!J'B70];^(G@2]TR_@N8<7H+Q?-L+0KA
M6Q]TY['FO3::$5?NJ!]!0!QOQ8B:;X:ZFJQM(!);,RJN[Y1<1ECCT !)]A5'
M5HK?Q#X\\.7WAV>WF:QMKHW%W;,&1(WBVQ(6'!RYR%] 37H5(JJ@PJ@#T H
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH ***R]1UN.QU&STV*![F_NU=XX58* B8W.Q/0 LH[DD].
MN #4HK-T?68-82["1R0SV<YMKB&3&8W !Z@D$$,I!'8^N16E0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
C "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH _]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>29
<FILENAME>exhibit1016-arvinasxamen009.jpg
<TEXT>
begin 644 exhibit1016-arvinasxamen009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUO99KB.8V\+A&A**!]Q2 V#ZU6LO 6I7\>HP0J_AO29[FWN(]-<I=!V0'>7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JG;Z3IMI=RW=MI]K#<S?ZV:.%5=_]Y@,G\:N44 %%%% !1110 4444 ,
MEABG"B6-) K!U#J#A@<@CW![T^BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH *P/%WBB'PIHPOI8)IFDE2&-8XF<;F
M8*"Q X'/X]!R:WZXSXIQR-X'ED2.200WEK,XC4L0BSH6.!SP 30!4U'Q$;'X
MD:8\VHW<>E7&E3RFUDB9?G5T Q'M#EN3P03Z5U%IXFT:^T,ZU;W\;:>"5,S
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M4CBGMHQ++&(W<JI. ?E!_P @GM7GMM_I'P5N?!MS P\111M9FP8?O'E\S*R
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MW=03LW,S,1A1R,9P3U[T =-16+;>*](NM3MM.6>6.XND:2U$T#QK<*!DF-F
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M_EG3+J/SU0E49]A0%L8!.#@&N]HH \@\*/ILNCZ=X6UO0=5DU[3W2(VTWGM
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M_=D0A9HC"B,1GJ,@C(KO:S];L;W4=+DMM/U233+EF4K=1Q+(5P02-K<'(XH
MX_P%8ZHEW+I^JY>'PVSV%G,3GSPV&5SZ%8C&O_ FK6\?W\NG:):31V(N$-_
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M%=BYCLI5DW[&V\*".,],C'I7.^(]+N/^$1\>W\-O.8-8O[=[*W6)B\H0QAY
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M7U>\O!H\DUHEY86T;ZM>1H3&DKC(CC!([?,2>@QQ\W !T6H7T.F:=<7USO\
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M.Y<9#$G!XP/6@#H-$U^P\0074VGM*R6UR]K)YD31D2)C<,, >,]Q6F2 "2<
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M\0Z98ZUJ.IVAM6:YBEM8[7:7*RLJL&S\N-N,8/'N: .ZHHHH **** "BBB@
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M Z=*O44 <//X N;C1O$VG-K,877KAIY'%F<Q;@JD#]YSPHZ^]:4_A>[N=?\
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MX5OWG ^=NGM5Z?P.E_JOB*XU"\6>TURVCMIK=("AC5 P4J^X\_,3TZXKKJ*
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MZ2ZI<6"!IDD:-"KD 9V9+EL>W;@]AX8O8]0\.VEW#J@U2*4,R7@ 'F+N.,@
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ME?R0A\S:P8*VX'Y<@9'<<5J52U:^ETW2Y[N"PN+^6, K;6^-[Y('&2!WS^%
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MS!R"YY;D]LDX]L4:[X:M];N=/O1/+::CITADM;J'!9-PPRD$$%6'!'\JVZ*
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MM8MFQGV; X)7<.,9 (SCGCBGV_@>"VN?#LRZK?,=!A:"V#B,AU9 AWX09^4
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MK5-4O++5KRT752K7<2!#\P4)N1BN5.T =_;!I;SP98SC0H[6>:Q@T2026L,
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M*1 _EO+)(3\VX<X4 <#C).<\5N:'HBZ+;NK7UY?W,A!ENKR0/(^.@X   R<
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M&\\5>)_#MGXBT>ZC@N9+@RA9KO%OY*R$&)HPA_A&-WWL\Y'0>C6EK#8VD5K
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M?189381Q6'B'QC9:L0TC:8]B72*9B6*EI(MNW<3\S/@]<UZ[ LIM(UN=C3%
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M2^(6C.FZI';P7]VOF2B)Q&Q0;1\S_,RKP3DBNMN/"L-SK.CZI+J5\;C2DD2
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MDJ VS<0#T#$X% %.:[\0>*3XB&CW36MS87KV=FRW/EK&Z*IRZ;#O#$\YSQC
M!R3%/_PD6J>.;?1)O$-Q9+/X>^U3"Q"%8Y_-528V*YQGN<G&<8S6U>?#^SG\
M03ZQ9ZMJVF2W847D5E<!$N=HP"PP2&QQE2#^/-:$?A2T@\3P:[#=W<4L%D+%
M+=?+\D0Y#;<;=W4#G/:@#;A1HX8XVD:1E4 NV,L0.IQQS3Z** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M418\*., <GH!6TLFHZ3X^\,1'5[VZAUBTN?M4,[@QAHT1E9% ^7J1[CKD\T
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MC!!''7YCUSCM@U@0Q:K-I_C:R;Q'JP31)G:RD6?$H_<B0!WQEP#T![$YSQ@
M]5HKSJS\0ZGKT_AK3&8;KS0EU*XVW36QF<[!@.BE@!EC@8ZCG P:6JCQ7HNC
M:/;7NOG[0WB2"V22WD$C-;2,"J2ED!9A^1&,YS0!ZE6)X@\1IX?GTF.2SFF7
M4;Z.R61&4+&SYP6R<] >@/3M7'SZW?>#]>\6Q&^N]2MK/1TU*&.\DWE9<NI
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MU:ZAIA'G17 0;@>-R%6.1T_,4[Q7XQT[PA#8M?1W$TE[<+;P0VZJ79CW^8@
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MFE3V-]/;%M6M(9!$0!(CR %2<9QCT(H V]5UM=/O;/3H(?M&HW@D:"#?L!5
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MKD]1G!H [U9XGN)(%D4RQJK.@/*ALXS]<'\JDKS[P7IZP?$'QF3=7DI@N;8
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MLX=4):]MK=U$<S$89N5+*Q'!*%<]>O-7]2\/Z=J?AN;0)H FGRV_V?RX^-B
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M"Z_;/!NF=7@B>5<1LP;+XYPS<\\8Q75W_@+1]1T;3-.EDO$.E "QNX9_+G@
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M1=W,EU+CO(YY/_UJ .$TNY\0W/A3Q0EA=3WU_;>(9H84GN=CR0I(F8E?^ E
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MNA</YJ"5=QB+YW$+VR2<'Z5T&I1-H>MZ!IW]JZDT&OWA^V2S73'!2$D)&?\
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M/,)+CZ@Y]#6-:Z]?Z3X<O=/%],\4?BQM(CN+FX;?';DA@#*<L.NW=U /'04
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?NLKCD,/6MJB@#"M_"&D0Z'=:1-%->V]VNVY:]F>:2;L-SL<\=L=.V*J:9X
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M+EQ;/+G.\Q9VDYY],]JZJB@#!FTBUT:_U7Q+;6][=:A/ /-ABDW&8(#L15/
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M>V^HV<=W:2K+;RC*2+T8>H]J ,]/#.EFRU"UN(/M:ZC_ ,?KW!W-/QM&3V
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M7$JA2H&-V%P"0,8Q4]MX=T^WN&N'66YF: VV^ZE:4B(G)3YL\$XSW.!DG H
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MR <$ MVR*SK73YM(\&[-9O-5A>_UE8[2V-P\DLT/FDPVY#MA R@ANGR]>F*
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M(5T2T\(:SH,DGVBXO[6VF82%OML,H^;S/[Y_B#')&#6_\3/^29^(O^O&3^5
M'2VDQN+."<@ R1JY [9&:FKS"^T?_A'M<\&ZKI%S>_:]0NX[2]B>Y>1;B)HF
M9F*DD#;MR,  ?E573;.\\8^%'UO^V[;3M3@O)9)+SRG::T,<IS&?W@&S8 -N
M,$'."3D@'K-%8OBW4+K2?!NLZC9#-U;64LL7&<,J$@X]NM<OIF@M<3Z!X@L]
M=MX8'C"RF!)-VH+(O1V,ARP/.[&00?2@#T*L76=<:PU33-)MDC>_U(R^2920
MB+&NYF..3U48]_:O)I[0Q?"O6]<%W?-J6FZO,;2=KN0F+;=!?7!R,@DY)_ 5
MV7BG2[*Y^*OA#SH _GP7_F<GYMJ1X[]J .QT6YU*ZTQ)-7L$L;T,RO#',)5X
M) 96'8C!P>1GFM"O.M%AB\8CQ?\ VJ[K=VNISV5NP<JUG&BKY;1X^Z3RVX=3
MZ@5@V=U?^)+/X976JW-VD]^;B.Z$<[QB91"^&(! RP .1@_-P10!['17G>EV
M.GR^,]3\(W7F/8:;IT!L+:>9GW*Y<R298DLP.Q03]WMC)J*Y+V>K>%O"AU;[
M99R072^?J ,GVJ:)E4(^"N[:"_!ZD#J10!Z36/XIUB?P_P"&-1U>WMH[E[.!
MIC%)(4!"C)Y /Y?J*XR?2QX?L%TB\UZ>[6YUF)[73[9"O# M]E)9CB(XW')&
M ,<Y .7.UQ#X<^*FG2*D,%M"3%;12%XX=]J&8)D# )YQ@#.: /5M.N6O=,M+
MME"M/"DA4= 64''ZUC^'_$-SJ^M:_I]S:16YTJX2%3'*7\P,@?/(&.".*XNZ
MT?\ L";P1K6DW-Z+^]N[:SO$>Y=UN(7C)?*$X&T+D8  Q["H[W5+K15^*.H6
M;,D\-Q;[749* PQ@L/< D_A0!ZS5:^O[;3H$FNI5C1Y8X5)[N[!5 ^I(KDM-
M\/O;>(])UNSUFTBM)HFB>WMHWVWX9"R,2TARPP6W8)(SDU#\4K.WNK'PZT\0
M<KKUD@)[!I #^8H [RBN#MO(U7XCZOH&H1!K#3M/MS9VKD[&#[M\F.Y!"J#V
MYQC)JS\.;F^?3]:L+N:6XATS5[BRM)IF+.T*D;06/+$9*Y]O:@#J&U"#[?)I
M\4B/>K!Y_E%L84D@$G!P"0>W8UE^#?$$WB?P\NI7%JEM(9YH3$CEP/+D9.I
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M_P ,+G446[G;5K>%I)AO8H5E!4D]CM7\A78QP1VWQJ@C@++"?#KD1AR47$Z
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M0=P&<*Q(&2,$]ZQO^$:EF^)[WSZ7=0Z4FD1V4%Q!<>3M=9&8@;'#[<$=L9%
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MWM[CRH+V13#,JD(99CM.XJ?E7 /7TYKE(S)<_#C0;6:=R(_%L=NC(YRB"Z8
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M>0KD'.[A6;H<CU%=19^%+2/Q!!?KJ-@+._M&@DL+.U*17BXW"0_O&&1_>QW
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M&](O-$_L::R4Z<>MNK,JMSGYL$9R>3GJ>:OVMM%9VR6\.\1H,*'=G('U))H
M\QT33;"VB^),D-I!')'=7"(RH 54VZD@?4Y-4M/T^#3-*^%VK6OF)?7+6UM-
M*9&)>)[9B4(SC:,# [8KTB7PIH<UY?W;:>@N+]-ETZNRF08QS@\9'!(Y(X--
M/A'1#;Z?;FT?R=.8-9I]HDQ 0, K\W&!P/0<4 <);Z>WC>R\1FYU6TLM0L]3
MGC-RUN3<6*QO^[*/Y@VKL4'@ '+9SS7J%F6:RMRTOG,8U)DV;=YQUQVSUQ6)
M?>!?#&IZXNLWFCV\NH#&93D;\=-R@[6Q@?>!Z"M^2,2QLC%@&&#M8J?P(Y%
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M!2&Q[CG/%0/X]LWO]+M+'3KZ^.J6;7EI)"$"R* #CYF&T_,,[L >M '64FX
M@$C)Z#UKE[+QU87'AZZU6XMKFUDM;QK":S<*TOV@,%$:X.&)++@@XY[5A>=(
M_P :M-DN=.:RE_L:<LYD5E<;TQR.XY!_K0!Z-17(2?$+3HI-,EDMY!IVISK;
MVUX)$(+-G860'<JMC@^XR!5#QQKD6J>"_%4%IITM[;6=O/!-<*RA4E"'.T$Y
M;82"3VP<9(Q0!WH(8 @@@\@BEK(\*_\ (H:)_P!>$'_HM:P/B*NK:II3:)H,
M[0Z@8FOF=.H6(AD4>A>3:![!J .VHK%\+^(;?Q'X3L-<0JB7$ DD&>(V'#C\
M&!'X5D/\0;9+#2M172KV:PU:<6]E)$8]TCG.S<K,-H;!(Y^N#Q0!V-%<E)XY
M)UW4-(MO#VJW-U8/ )Q&(\!)<X<'?T  XZ\GC )#=5^(6G:5:RZA);R2Z5!<
M?9I[N.1/D(?86"9W,H;@D<\$@$<T =?17,ZQXTM=,74'@M7O4TU0]V8I44K\
MH<A0Q&Y@I#8]QSGBHF\>6<FH:7:6.GWM[_:EFUY:21! LB@ XY8;3\PSNP!Z
MT =717#_ /"QU.BZAJ*^'=48Z7+)%J40,0-MLY8Y+8?@Y^7/'7'&=JZ\4VR/
M!#8Q_:[B:U%VJ>:L0$3?=)+$8W<@#V/3% &]17%I\2]+FTG1]1M[&_FBU.[^
MQ*$12T,PSE'&[.?E/3(]ZE_X3>1[/Q$HT6Z@U/181,]G/)'\Z,I9&#JQ7&%.
M<$D8[T =?16'X/U2\UGPEI>H7T#1W$]I%(S$KB0LBDL I. 23P<&KVLWTNF:
M+>WT-L;F2WA:180X7=@9ZGI0!>HKC]#\822>#]"O]3M93?ZFD*01(4S<2.FX
ME><*N-Q.<8 K0L_%EI)J6H:9J$,FGWUA +J6.4AE>#G]XC#JH((/0@]J .@H
MKD&\?0I%HMP=(OGMM:.+!XVCW.2NY0P9@%W+R.3^!XJ36?'5GI$%_="UENK3
M3I/+NY(I$!0C&[:I(+[<\_B!D@@ '5T@8'."#@X.*XV'Q7=:AX_31H+$RZ7)
MI2WBS*Z?O%D<*'()R% !XZG/3I7,>%/$\7A'PUJTTFDWDNFV^NW:3W,.P);H
M9MH.&8,V,C.T' H ]:HK"U3Q-'8W<]G;6S7EW;PB>6-94CVJ<[1EB,L=IP/;
MDC(SD+\2M.N8=!ET_3M0O4UM)6M#$J#YHU)9#EN&!&.?E[YP* .THJE87T][
MH\5Z^GW%M/)'O-I,5$BG^Z><9_&N9/Q&LU\*1>(3I=\+4W9M)HV,8>W?S/+S
M(-V -W'4]10!V=(K!E#*05(R".]8NI:RD4UY92:9<W*0V7VF?RBA&UMPV<L.
M3M;VX/-<J_BH:9X8\&'PYH[Q:=JEQ!!'&9%W11D%@@R>20I&2<#US0!Z)N&[
M;D9QG%+7FJ74NF?%C6YK/1[BZNIM'MI#;0LBG=O?)9F8*.@'7GMFNW\.Z[:^
M)= L]8LUD6"Z0L$D&&4@D%3[@@C\* -.D#!AE2"/45Q^GZ]>ZQXU\1Z#=Z8?
M[/LHK= 2Z$?.LC%F&<_,-H &<8YQFN9^'OBM=#^'_A:"YTR]-E<S?9/MPV>6
MDKRN%!!;<1G@MC'O0!ZO17,ZSXSMM*747BM)+Q-,&Z\,<J*4^4.54,1N8*0Q
M'N!G/%;>GWUIK&E6U]:N);2[A66,D?>1AD9!]CTH MT5X?;+H$-I\0?M]VMK
M>6^IW"V!BN"D\9" H(@#G[QX X[5U^B^,M4TG0O"MAK^E:A<ZWJELY'EJ@+.
MBEMK98$.1MSD  DY(P: /0:*YR#Q4]U)!:0:3=?VFUJ+J:SE9$-NA) #MG&X
MD' &>ASBJ,WQ'TN+0[?55L[YTDOQITT2QKYEK/NVE)%W9R#_ '=V>/6@#L:"
M0!DG %<GI_CA+K7+K1;O1=1L-1BMS=06\_EYN8LXRA#[<YZ@D8_.J,'CNVU_
MPW/?MX:U6719M/FGDE(C"NBDJ\>"X.<9/O@XS0!W((8 @@@\@BEKE[#Q#IMG
MX>T!-/M#&+ZS22RLS(J[(@BGYF)P H91GDY(ZUAZO\2'?PW-=:382"]@U./3
M;N*1TS;LSJI(.2'R#\I''.3C&* /1**YV]\4/:WCV46DW,UY%9&^FBWHH2/<
M5 W9P6)4X XXY(JG/\0+%+;P_<6^G7]U'KJYM3&J?>V%MC MPW&/[OJ0!0!U
MU%<M9>,VGUK3-)O=#U#3KG48))HOM)CVC8?F7AB=PX.,="#6SIVJ#4;O4(4M
MI8TLY_(,K%2LK;0QVX.<#< <XYR.U &A17G?B&TMV^,WA56B0K-:7;RKCB1E
M4;2PZ$C)QFM"Y^(0B&N>1X?U2<Z*^+L*8EVJ$WE@2^#\O( R?84 =ITIJ.LB
MAD8,IZ$'(K@?&^O2W%AX5:PMI;C3]5U*U+D,@$T;*SB,@D==JDYXQP:T].DT
M[0M0O-,T'1Y#?3J-0O+2.95C@+\ <G:K,5/"\'!)QP: .MHKCIOB-ID>@V>K
MQV=]+%/?+821JB^9;3%MI61=V<@_W<YX]13F\=O!J&G6%YX:U>VNM0FGB@1_
M*;<8U+=0YZC&#TZ\X&: .OHKBT\?R20:JL?AO4VO]*<B\M T68UV[PP??M;*
MG( )/MWK2'BZVN8M%.G6L]U)K%NUS;+PBK&JJQ+L?N_>48YY/XT =%2;E#!2
M1N/(&>37!:O\0)G\)Z=JVD:?,6NM3CL95E9 T#><$=<9P2<$#!QSDGM6I<:C
MIS^.]%M;S1IX]6DM)WMKEV0K&@V^8ORL<G[O;Z&@#JJ*Y:[\<6UMIUWJT5A=
M7.CV<S13WD14XV-M=U7.613D$CT. 12W7C6&+7H-'M-,O;Z>YL3?6TD!C\N9
M,J!ABPQ][JV!QQG(R =116/X:\0P>)=*-[%;S6SQS26\]O-C?%*C;64X)!Y'
M453U?Q<FF7&IPPZ=<W?]EVJW=XR%4"H0Q 7<?F;",<<#WSQ0!TE%<M=^.+6"
M^T2U@TV_NCK-NUQ9O$J8<*@?'+#!PR]<#GKQ19>.K";0]3U&]MKBQ?3+DVMU
M;2;6<2_+M5=I(;=N4#!Y)H Z@L 0"0">@]:6O.+V::?XP^%GN-+DLIFLKPEV
M=7#C:F!E3U7G(Z?,,$UZ/0 4444 %%%% !1110 4444 %%%% !1110 4444
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M<5Q?Z5"MPLK(I1F'!=,#Y<J"#C(((K7_ +"M-9F\'0Z1 I\*6,37JLK?*[!
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M<Q(P;@-N'WAC(K"T.P\0>'I+KP\_A6'4(3<RR6.K%X_+$<CE_P!Z#\V5+'@
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MT>9C=@2Q'8OE,F?O\\MG SQ[\5ZO10!R/Q%T^6X\.)J5DRIJNE7$=W8L?XI
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M7)82C+;I0N\C';:P [YKEI_#/B&;X6:_H:Z-*-0O=0EFAC,\."CSB0$MOP,
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M(,<<<C)S0!JV?CX3:7%JEWHUW9V%S!;R6LTLL>)Y)< 1@9XP3U.!CG@4MO\
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M'?S]X8Q^E6;"U\4^&=<U:RM?#\.K:;J%[)>VMX;I(OLYD.620'G ;)RH/'Y
M [R*^MIM/2_29?LKQ"82G@;",Y^F.:Y1?B-8"]TA9(56SU>58+6=+A'<.PR@
MDC'*!NW)QQD"NEO+!K_0KC3IY?FN+9H))$7'++M) [=<XKD/"/\ PEUG:6.@
MZGX?MX18A(FU9;A&CFB3 !5!\VY@,<XQG/M0!)/\1I$LM;NX?#E_+%HMP\5Y
MF6)2JHJLS#YL,<$G SP.2,BIK_Q5J)\:>'].T^S673[^TEN_,,H5I  N.".
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MCD*X!VL<-Q]/>GZ[9ZY<>,X"=+_M/06LMB1&=$CBN=YR\JL<L-N,$!L<X&:
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M76? _BJ.STP7ME9P3V\L[.HQ*J'<44CY@AZG(Y!QG%=9X9_Y%31_^O&#_P!
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX"S+.6\M3&\A?&WYB>,],8'7ND7Q%M&U/2+>2"#[/JS>7;R07BRR1N1E5EC
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M');@  ]#TQ7/:GXPGU#P'XFN=/MFM=4TN*XANH))<-;NL;'>K '<.A4\9]J
M.RAOK2YGE@@NH)9H3B2-) S)]0.GXU8KE/!VD6S:1HVK7&F6\&H1:=';Q312
M%F:$JIYX'4C.#G'KR:ZN@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *X?XK,Z^$;=HD
M#R#5+,JI.-Q\Y<#/:NXK,UO0-/\ $5K%;:DDLD,<JS*L<SQ_.IRI^4C.",T
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MEN&X('4<XK!B\'>(V\'ZCHR16]K>6NJOJ.G733!DF<3^:F5 RHQP<]Z]/HH
MY&WNO%>KZ1>KJ>@1::WV5XEMX[M)FGD88!!X"(.>IR<^W-_P387FE>"](TW4
M+<P75G;)!(N]6!*@#(()X-;]% ''ZEH^IV'Q"@\4:?;&^MY['[!>6R2*LB@/
MO21-Y"GDD$$CU&:H3^%]1/A[QI.EINU/Q&LBI;"10(5,/E1AF)QGJS8)ZX&<
M9KOZ* ,SPY#<6WAS3K6[MV@N+>VCAD0LK?,J@'!4D$9%:=%% !1110 4444
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M=OD;Y5QC.>"1U_&[K6B^)?''@[4M/U2VM=%GEC3[-#'<>?\ O4=7#NP48&5
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MYB>4QA@H)/.#SQZ4 :]%5M-NC?:7:7;*%:>%)2HZ#<H./UJS0 4444 %%%%
M!1110 4457L;ZVU*S2[LY5EMY,[)%Z-@D9'MQ0!8HHKG]5\0W&G>+] T46<;
MP:KYX-QYIW1F.,OC;COQSGUXH Z"BJNI27L.FW,FG6\=Q>+&3#%*^Q7;L"V.
M*GA,C01M,BI*5!=5;(!QR >] #Z*** "BBB@ HHHH **** "BJUC?VVI6WVB
MTE66'S)(]Z]"R.4;\F4BK- !1110 4444 %%%5[N^MK)K=;B54:XE$,0/5W.
M3@?@"?P- %BBBB@ HHHH ***KWE];6$<3W,JQB69((\_Q.[!5 _$T 6****
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MB6ZO)9U3'0@.Q&1V/44MSX9TF[N+N:6W?-X%%TB3.J3X&!O4$!N.#D<C@Y%
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MC' ]*L-HM@^OIKC0G^T$MC:K+O; C+;B-N<=>^,T :%<#\./^0UXY_[#TO\
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ML&M@)G#PGU5\[A^= '(:BE_X3T^QT.76VGM=2\016[M&61K.WD!?R Y8L,X
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M((5<]NV,G/17/@[0[S0CHMS:RRV!F,YC:YE+%RQ?<7W;OO$GKUJ+6O _A_Q
M]G)J-G)+/:+LAN%N)$E"^AD5@Q'U)ZF@#E-/-S:>(/#7A'6M9.J6XL[IS.P*
MB\FC<*L;\G=L7=D$G)&3R*/%.FIX?\,Q0V>J7<YBU^W*%Y3NMDDE0F$$<[ I
M'!SP1[5U^J>"_#^L:5::;=Z<GV:S(-MY3M&T)'=64AA[\\]ZDE\):)-X<?0'
ML0=.?EH][;BV=VXOG=NR =V<YH YN^B2?XK:A82,[6D_ALR2P;R$9O/*[B,X
MS@ 9]*YC0KD:3\,O T4$BVL6K74<%W,[-M(VR%5."" S*H.".,CO7I%CX/T3
M3]4CU."UD-\D'V?[1+<22.R9)PQ9CN.3U.3P/05"G@3PTF@3Z'_9:-ILYRT$
MDCN!R2-I))4 DD!2,9..M '&^)8]3\!Z'XAU"UUB-(KM8/+M(8V"V6Z18WE3
M<QVY#$XP!D9[&K^K:/8:;\3? DEBA3?]M5CYA828M^&.3RW)^;J>Y-=1IW@S
M0-,TBZTN"P#VETNRX6>1I6E7& "SDG [#/':J]GX!\/64^GSQVUR\FGEOLAF
MO)I/)!&"%W,<+CC'2@!GQ(WCX=:]+'--#)%9R2(\,K1L& R.5(X]NE<_JEL;
MOQAX#@>[O$AN[&Y$\<5RZ+)MA0C@'@_,>1@\]:[S5M*L];TR;3M0C:6TG7;+
M&LC)N'H2I!Q5+_A%=(-[IMX89S<::ACM'-W*?+4C!'WN<@ '.>E &'\/ UK/
MXHTQ)96M+'5WCMDDD+F-#&C;022<9)_.JOC9]1LM:?46TMM:T5+$)<6UO-MN
M;([G)GC7N2.."#\G!'-=;I?A_3=&N;VXL8I8Y;V3S;@O/))O?INPS$ X ''I
M3;WP[I]_?27LHN4GE@%O*T-U)&'C!8A2%8 \LW/7D\T <3;W\?B3Q)::-#=0
MS:=_85O=VB7:O_I <L&DP&'S *G7.,G&*HWFD7NG7/@O1[KQ'>WK#4I[:6>&
M9XRT?E.P1OF.67[N[[P]017<:QX&\.Z[!8Q7NG*!8*$M6@D:%H5QC:K(00,#
MITK!\4^'5_M+PA9Z=IES_9VG7;RS&U++Y*E& ;<"&)W')QD]2>M &%.B^$M8
M\8:/'K-_9:%_945XLPD::2RE=VCQ&6).6QD#/7'2M;1HY[;XH'3?LSV%E<^'
MS,UJER22ZS*H=MN LF&()4GZFNMD\*Z-/IU_8W-I]HAU#'VLS2,[S8&!EB<\
M8&,'CMBJ]MX(\/VE];WT5G+]K@A,"3O=2M)L/."Q;+8P,$YQ@8Q@4 <!X:L+
M./X8S>)-1UO4[6Y@2^A%Z+F20Q(9G480G#-D#!/.3UZ8UM(@EM_B5!IK6K6=
MC=Z [R6OGEC(RRHH>0#@288@D$]>IKK;;P?H5KX?N=!CLB=+N=WFV\D\D@.X
MY."S$C).>".>:99>"?#]A?V=_!9.;NTC,44TEQ)(VPX.&+,=P&!C.<8XQ0!Y
MMH%RN@_"+0YK5Q:+?ZL;2ZN"S!8XC=2CD@C:. I(QP>O>N]T/P_<Z+XJN;C^
MTX%M+RUXTR&-@@D5AF5<L<<, 0 ,Y!J[%X)\.PZ9?::NF(UE?,S3P2.[H23N
M.T$G8-QSA<<\U+X?\*:-X7BDCTJU:+S  SR3/*Q Z+N<D@#)P!Q0!D>(K\2>
M/?#N@W;E-/O(+F9HR<+<2H%VH?4 %FV]"<>E8VO*?"T.G:/::I=266I>(8XK
MC=)S:12#=Y"L.54D #G(#>XKL_$'AG2/%%G';:O:"=(G$D3!V1XV'=64@@_0
MTS_A$]#.@-H;6"/I[G<T;LS,S9SN+D[BV0#NSGCK0!S4]L=*^)=KI5BK?V3J
MFF3275F"?+C>,KB11_"3N"G&,\'K7-6EW<R?"7P'>O=3FZ;5;1&F,K;V5IR&
M!.<D$#D'TKU/3]$LM-G>XA6:2Y=!&T]Q,\TFP<A=SDD#)S@=^>M8R_#GPNL(
M@_L^0P+<"YCB-U*4B<-N_=C=A!GG"X!_"@#GX]'@UCQ_XVL;VYOI+1+:S=(1
M>2!59DE)(PV1@C('3VX&,*W0:YH'PLO-2+W-S+<^5)*[G<R^5)U.>IVC)ZG%
M>GQ>%])AU"^OXHITNKY%CN9%NI1O51A1C=@8!.,8QFJW_"#^'_[&LM)%E(+.
MQF$UJHN90T+C/*ONW#J>,XYH Y8VL_B[6O%>D-=P02V$J6ULK[S):QF%2DJ;
M7&"6+'/4X S@5!>:7)>^+_"6F7VL7=[%<:5=1W<T%Q)$ER4" /@-\I.225Z^
MI%=9JW@'PUK6HPW]YIH^U11B(20RO$60=%;81N'L:O2^&=)FU:RU-K=UN[&,
MQ6S1SR(L2$ %0@8+@@#C'84 <-8^%[._\=^(=!NKS5)--MM/LA'"=0EX.'&=
MV[/;.,XSR0>,4_#MY<7>AZ#I>J7UW?W$6J7EM;6Y88U&.'<H:5C_  )U/7)4
M<$UOVNARW?Q/UZ_N;74(+2>TMX;>YBE>(.4W;QE2#CD8)].*Z"\\':#?6NG6
M\ECY:::2;,P2O"T.1@X9"#SWYY[T >87\UZ/A7XO5KJX@DT_7W@MQ#<OB%/.
MB'E@\;D&]@ 1CGI6YXU\*Z7ITOAMHQ<RM=>);=I&GN9)#EE8-C)XSM!XKJG^
M'WA>2ROK,Z85MKZ83W$4=Q*BNX(.<!ACE0<# R!Z5I:IX>TW6M.AL-0ADFAA
MD26(F=PZ.OW6#@[LCUSF@#@O%CSZ'J6IW6H:?+?>'"D42WEE,3<:3M10<IG)
M4Y#D@]#SD8KT^.1)8U=&#*RA@1W!Z&L27PAHLK7.Z"81W007$*W,@BE"J$ 9
M-VT_*H!XY YS3(?#-O#XVF\111^3-):?9I")6/G#*[<K]U0NTXQR<GICD S?
M&FHS1:YX:TGSHH;74;B5)6ESLD98\I&V"#AB>F>2H'()!R+[2V\-Z/KEM>>(
MYH[6\N+9K:TL4(DMR[[3%&6<X$A4C&0%^;M7;:]X?TKQ-IC:=K%FEU;%@X5B
M058=&5A@@^X-4!X&\.CP_+H;6!>QE<22!YG:1G&,,9"=V1@8.>,8H X>YU74
M_#>I>.FLK=+7[-HT-Y!:1R&2.*3$@W@8 !P 2 ,''4]:ZS2M&TTR^']=LM4N
M$+0;6VR[AJ/F)D&3.2Q&"P/4<]JT;3P;H-EJ+:A%89NW@^SR22RO(9$Y^_N)
MW'!(W')P<9Q46B>!O#OAVX>?2[%H78,%!GD<1!NHC#,0F?\ 9Q0!Y?<V:P_#
M7Q5KD4]U'J%AKEU+:R1SNHB87(Z*" <Y.<@]:]IOKB2VTRYN8HO-EBA:1(Q_
M$0I('XUC'P-X>;1KO2&M)C87DQGN(3>3$2.3DDG?GD\GGFM^&)8(4B0L50!1
MO8L<>Y/)_&@#R.YGFD^#%KXSM+R7_A((XX[PW8<DR2&0!XF'=.2NSH.,#BMN
M?3+6Y^,]@\]N5>30I)W7S&X<31^_;\JZ>#P=H=K(QAM'6$S_ &G[-Y[^0)<Y
MW"+.T'//3&>>O-3R>&],EU]-<>*;^T4B\E9A<R !,Y*[0VW&><8H UJ*** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBN5^(FCS:MX/NWLUSJ%D!=VV/XF0[BA]0P!4CH<
MT =57.^(/$-WH^N>'[&*UADM]3NS;O*TA#1D(S<+C!^[US^%<(?%%G;^+].\
M:009T+4K,V3,.?\ 2MGFJ5'3<>8N.2P(/2M#Q!HJV4G@33Y<I))JK/<F%BN9
M&AD+[2.0,D@8Z# &,4 >DSF46\A@5&F"'RU<X4MC@$]AFHM.:]?3;9M1CABO
M3&IG2%BR*^.0I/)%>=Z9916.I_$71;5IH=/@B@FAB29QY3/ S,5.<C)4'K53
M2-2W:=\,M)OY/^)=J-@[3*Y^6>5(D\M']0=S'!ZD#TH [;QQXAN_"WA6YUBT
MM8;EH&0,DLA4 ,ZKD8!SRW3CZUT5>7>/-'LM$^&OBFTL;N9XY+F&?[.S I:[
MYH_DC&/E7C.WMGWK2BL(=$^+]C%8F5$O]*G>Z#2L_FNDB;7;)/S<D9]Z ._K
MG?&7B&[\-:3!>VUK#<![N&WD\R0KL$CA<@ <]?45'XWM-2N]+LUTK[)+<QWB
MR?8KMML=ZJHY,1/_ (\,\909K@M8O[/4?AY>1V^GW.E7$6O6L=W8RD9MI?,B
MR$(X*XP01QSTQ0!['17G"PVGASXFZG#!/-9V$WAUKVZ;S&?$B2E?-^8G+!2>
M>^*S-)4V?BCP!-9QM!;7]O<JT\DF;B^3R-X>< 8R3ANK$9[=* .KL_%NHW-M
MXK=M/MA/HDS1QQB=MLH$8?);;QU_N_XUM^&M4DUSPOI6JRQK')>VD5PR)T4L
MH) _.N+TG_FIO_7U)_Z2K72_#_\ Y)UX;_[!EO\ ^BUH 7PYX@N]8U?7[&ZM
M88#I=TL"^5(7W@H'R20/7IC\ZZ*O+;'POI?B;Q)X[BU0SA$OH_+9)WC$3?9T
M^< $#</4YQCW.<_PWJ^I:Y'X.TO6[FW(O-(FF47\)E2[E60*NY=R[F\OYAG/
MWB<9P0 >Q5'.TJP2- B/*%)17<JI/H2 <?D:P/!VCR:!87NG/JW]H)'=NT:B
M,J+56 80C+,2%SD9/0BL32OL_BCQGXNM-7C68Z=)#;6UN_\ RQC:/=YBCLS,
M2=PYX'/% '0>#-?E\4>$=/UJ>!()+I&8Q(20N&(QD]>E;U>*^%KYU\)_#O1Y
M)X(K*_2[#_:8R\4LB,=B, RYSN8@$X) X-:VL6]QX)T>ZMUUR,V5YJUKYL:P
MLD6G0R-AP/G)"-MZ C )QC- 'JE%><W_ (8.E+K]U'JT,,%YH\S?V=80M;IO
M09$ZD2'!Y ., Y&:PSI<,&@?#74X9;J.^O);2UN+A+AP[PR6[%DSG@<#&.G4
M<\T >Q45Y)>S3>$K_P"(<6A!X8[?2H+R&(,6$4K+(&D4'.#@ GUQ6Y8:%''J
M6B>)-.UFT2%HF7RK2V8?VDK)E0[&1MS#!;<03US0!N^./$%UX6\)WFLVEK#<
MO;[<I+(5&&8+G@'/7IQ]:Z*O#]46U\0_ *Z\27@6?5YV\Z:YS\Z/]H"F,'J%
M ^7;TP.G>O:KN:.WLIYYI?)BCC9WD'\"@9)_"@":BO(M,'V;7?A_=62O';WW
MGJUU+)_I%]&8&</, ,<D!@"6(SV/%4Y]'MKCPA\1KN:2Z>?3M2NY+1VN9"86
M2)&5ASUSW/;B@#VFBJ6E3R7&AV-Q(=\LEM&['^\Q4$UY9;L-:^#%]XJGE:+Q
M%$MS=F\4XF@FCD8B,'J% 4+LZ8/3F@#V"J4+ZD=7NDFAMETX1H;>17)D9^=X
M9<8 '&.:\X.E)XE^(=K;:TMR$O/"RSW5LMQ(BB0RJ#P#Q@]ACD"M71;>2V^)
M7BVUM)I!MTZS\GSI6D",1)@_,3QP.* ._JE$^I'6+A)8;8::(D,,JN3*TF3N
M#+C '3'/_P!;R_3-&O-;T3PAY5M>1ZE'=;]6O0[QB>'#;R9E(\T.=A7:3U!X
M KH+&V5_BIXGM6EN##)I=LQ7SWRI+2 [3G*]!TQ0!WM%>':59I!\.? FOK+<
M'5#J=K&;AIV),;S%73&<;2#R,<]>M7_&\D4F@^,=5TUY+BXL;U%.H3R;7M)4
M,8\J# SM&>22HRQ^]S0!Z!?>(;JS\<Z1H/V6$VU_!/+Y_F$N#&%XVXP/O#G)
M_"NBKB=;.?BSX0/_ $YW_P#**NT5U?.U@V#@X.<'TH Y\^(+M?B&GAQ[6$6S
MZ:]ZLXD)<D2*FTK@ ?>/<]NE=%7GNMZ5::U\8+6SOED>V;P_,7C21D#C[0G!
M*D$CV]JY.>&;3-'U#3XIYY+'2_%5K!8322%FBC9HR\08\E06Q0![=573M1M=
M5LDO+*42V[LRI(O1MK%21ZC(/-<;)#!/\8KVRD17MI_#H:: _==C.02R]"<8
M'TIWP?M;:#X9Z/+#"B2S1$R,HP6P[ 9H [JN=UWQ#=:3XD\/:;':PR6^J3O"
M\S2'=&5C9^%Q@].N?PKE?&"6NH7?B\0!KVZL=*4RFY<+'IY\MW4PX!/F-PQ(
MQT7YNU)/<2W;?"NYGD:2:4AY'8Y+,;0DD^^30!U>C^(;K4/&'B#1+BUABCTQ
M+9HI(Y"QD$H<Y.0,?=''/?DUT5<5X>_Y*MXU_P"O?3O_ $"6E\77SGQIX1T6
MXR-+OY;EKA3]V5XX\QQMZ@DDX/4@4 =I7*:-XCU?7ET[5-/L+:71+R66-B9"
MLT**S*LG/#!BOW1R,CD\UF:39BT^(^N>'HH@^@S:?#>&U/,<$S.R[5'10P7=
M@<9%.^#UE;0?#;2KB*!$FF1_,=1R^)7QF@#O**\^\4-:^&?'>GZ]=H#I>I6T
MMA>*1N590-\;;?[S!63WXK'\)1R&.;P)J5N%O+6_6[ERQ<FT.)E)<\M\Q$)/
MI0!V^A^(;O4_%'B+2+FUAA72G@5'CD+^8)$+Y.0,<8XQZ\FM6_?4DELAI\-M
M)&TX%T9G*E(L')3 .6SC@UYQ+HMEJ_BSXD)>H[I%%:,B"1E56^R\-@$<C'!/
M2HVN;B[\,_"V_GN)WN9KRU25C*V) 87)+#."<J#D\T >L5SLOB&[B^(%MX=:
MUA%K/827:SB0ER595V[< #[WJ?PKG-/MK/QI>^,K+6)66\M+YK:!E8"2S@"*
M8Y(\_<).YMW<]> *9>6%IJGQ+T"VFGFN[5_#\V79RIG7S(^6(QG/4CC/Z4 >
MD55.HVHU5=,\T&[: W'ECJ$#!<GTR3QZX/I7*?#(M%HNKV(=VM[#6KRUMU=B
MVR)9/E7)YP,U4&G6!^.5Q,]M#O&A1SERHSY@G8;OK@ 9]J /0*YW0?$-UJOB
M/Q%I=S:PP?V5-#&C1R%_,#Q[\DD#'!'&/SKSX21K'X/U?2VD>*Z\0"+^TYWQ
M<WD<AEW!P!_J^, $YPJ\"FZCJ?V'Q_XL@OXV30+R_LX-1O(V^: &V38#_=5F
MX+CE>V"00 >RT5P.MM%_PF^C>&E-C!ILVGS2PP7$'F0SS!E&W:&4,0N2,YZD
MXS@C!\0Z%+H?A*&P_MR:[\KQ%;>4(B\0M4DD0^3C>VX '(SG&10!ZY56^U&U
MTU(6NI1'Y\Z6\0/5W<X4#_/0$UQFD64.B_%Z^T^P\R.TN=$CNY8FE9PTPG9-
MYW$\D<$]Z/B98VEU/X1:XMXY&_M^WBRZY^1E?*_0X'Y4 =[17G^DQ6GB#QMX
MJTG5;:.6WTU+:"RM7'RQ1-&270=B3_$.1@#/%8-A>:U<^"M$6ZFFO+6U\0-:
M3@MNEO;5'=5XZR8(!(&20AZ\T >O45Y7?6NI>'[+QWXBT^*ZM;46ZG2XF9T$
M1$?[Z182<*-W(R!RI/0\Z^G^'(&U;1-=L]9LH[6:)HGBM;9@-21TR/,)D;<P
MP6W$$]<F@#1\4^,?[(\':EKNDQ07WV&4PN'D*KN#A&Q@'.">G'0\UU@Y KPQ
M["SM?@3XH>WMXHI#>W$>44 [5N\ ?0<5V$UG'H/Q3TW^SA-NO]*NFN5:5G\]
MXRA4MD_>Y(SZ'% 'H=%>3Z!ITGB?PKH?B<:]:6E_%,D]Q>1VK&=I,X>!V\SD
M$G;MQCI@=*O:'X>L=5^('BT7K7<RV&H6D]LINI,1OY*OG[W/)/!R,<#J: /2
MJYWQMXAN_"_AR35;6UAN#'+%&ZRR%<!W5,@ '/+=,BF^-;34;W1H(M+>U:[%
MTDBVMTQ$=V%RS0DCU )]/EYXKS[7=0M;[X8>)((M,N-'OH=3M1>6$A!%O(9(
M,>61P4( 88]3Q0![+17G@MK7P[\5BMM++;VMSH4UQ=EI6?<Z2KB0[B<L 3S6
M)IN+;6/ %Y8JZV][),IO)I/])OXVA9]\P QR0& ))''0\4 =G8>*-0O+[Q5:
M-86RRZ*Z+$HG;$NZ/S,LVWC@CM^?6M+PGK,GB+PIIFL31)%)>0+*T:$D*3V&
M:YG1/^1J^(__ %U@_P#25:T_AE_R3+P[_P!>4?\ *@#K**\YT^VL_&EWXRL]
M8F9+VTOVMH75@)+. (ICDCS]PD[FW=SUX J33Y8-<^(%YHVI-]NL+32+:6R2
MY&Y9P^=\Q4C!;[HSCCG&,F@#T*BO$[UKT^$;VQFN[MH-,\61V5E-Y[;O(\U/
ME)S\^W<0"<]/:NE2RBT7XE:Q8:=<R6-M=>'?M4KM*SA9A*R^<=Q/('4]\4 >
MCUD2ZI/J/AZ6_P##@MKN=BRV_GN5B<J^TG< 3C@X(Z\5Q/AE1;>((/#_ (ET
M".TU-]/EA2YMV#VNI1@H79N^_P"4'#<_,>>17-)9V\'[,375NI@N&M@[20N4
M+$3$?-@C(P2,'B@#V>34;:'4;;3Y)5%W<(\D<0.257&X_0;@/QJW7G^KZ987
M'QGT=Y[6%V?2;AF9E!R5>/:3],G\ZPFVIX ^)JEMHM=1O# ,_P"J(B0KM_NX
M/3% 'J<FHVL6IP:<\H^USQO+''W*+@,?IEA^=6J\PMM/LKGXF>&9Y[:*223P
MZTCNZY+,K1;23ZC)JI8V$WC3PW?ZE+K5IIVJ6NH3F6\^S,UQ8F.8X3=Y@PNP
M ;<8()R"<F@#UJBL/Q7J-YI7@K5]1L1OO+>RDEB.W^(*3G'MUQ[5Q&K0IIW@
M_P *>(]#9O[4>XL@TRL2]\LV ZRG^/.[/.<$<8H ]3HKR=]#L]2UCXD0WC7,
MT5L(G@1[F0B-C;;MPYZ@G(ST[8IVG:I<ZQ)X)TO4;JW,5]H(N<7T1E2ZN (\
MAAN7<P4L><]2<9P0 >K45SG@[1I- LK[3FU;[>D=V[QH(RHM58!A",LQP,Y'
M/1JXOQMY%Y:^-[JS+W5S8VR;[B=]HL'2/<%M\#=N/#$Y R1R<8 !ZO17FFHV
MJZGXZ\%K=37+)>:7<M<(L[JLA"1GD \?>.<8SWR*PCJ<V@>%M<TZVN);?3T\
M6+IWF"0YM;5S&7"MG*CE@#VW4 >C77B"ZMO'FG: ;6'[+=VDUP)_,)?*%1C;
MC ^]UR?PK8U'4;72K)KN\E$4*E5R>[,0J@>Y) _&N'GTFPTOXQ>'S8VT=NLN
MEW09(AM4X,>#@<9YY/4X'I4_Q9M+>Y\)VS3PI(8]2M-I89VYF4''U!(_&@#9
ME\0W<7Q MO#K6L(M9["2[6<2$N2K*NW;@ ?>]3^%=%7G>JZ18W/Q6T?3VBVV
M8T2Y!AC8HK#S8_E..WMWKGK75)M(\*'3EN_(TY/%TVF&28LZPVP=BJ,=P.S<
M%4\C@D=* /9:*Y/P_P"'6T+Q/?3)J=N(+V!7_LRVMC%%&RD RJ-[!<YP0 ,]
M>U=90 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% &8GA[2(],M=-2PA6SM)4F@A
MXC=6W*P]PW-.U'0M.U:ZM+F]@>2:S?S+=A,Z>6WJ-I'..,UHYH!!&0<B@#'_
M .$7T@7.HW(MY!-J2!+MQ<29F4# !^;L.!CH#BH;KP7X>O?#\.A7.FI+IL!!
MAA>1SY1'3:V=RX]C6]D>M&<]* ,)O!V@/H']AG3U_LTMO: 2.-[9!RQSECD
MY)/0>E63X>TQM6M]5:&5KZWC,44S7$A*H>HY;!!QSGKWK4R#T/2J6JMJ:V).
MD+:-=[TP+MF";-PW?=YSMSCWQ0 :EI-EJZ0)>1NWV>43Q,DKQLC@%=P92"#A
MF'7O5&X\):)=V)LY[-I(&G^TN#/)N>48P[-NRQ&!@DG&!CI6WFC(QG/% &3)
MX:TF74VU*6U:2[:W-JTDDSMNA/5""<%3UP1UYJC;> /"]I]B,.D1 V3E[<L[
ML8R1C ))^7D_+T]JV-2U2TTFT%S>3".-I$B7U9W8*JCU))%7,@=30!CQ>%M'
MA741';2*-2)-Y_I$G[TD8)/S=<<<=N.E7=-TVTTC3X;"QC,5K"H6.,NS!%'0
M#))Q[5;HH Q;GPIHMU?7-Y):,)KH!;GRYY(TN !@>8BL%?CCY@>.*=KGA70_
M$EC#9ZMIT5Q! P:$9*&,C^ZRD%?P-:^1C.1BEZ4 4],TNQT;3X['3K9+>VCS
MM1??DDD\DD]2>35&_P#"6AZEJZ:K=6(-\J>69HY7C+I_=<*0'7V;(K:R,9SQ
M29'/(XZT <\_@3PQ)X<3P^^CP-I:-O2 EOE;^\&SN!Y/.<\U:MO"FA6F@RZ'
M%ID/]FS ^; ^7$F>[%B2QX').>!Z5<TS4[36+!+VQE$ML[.J2#HVUBI(]1E3
M@^E7* .>TSP/X<T?3+K3K#31!;7:>7.!-(6=.?EWEMVWD\9QR?6IF\(Z(]II
M]JUK)Y&G,KV:?:90(6484K\W8<#T'%5/%_C*T\(#3&N8RZWETD,A'2&(D*TK
M?[(+(/\ @0KIJ ,R+P]I<6JW6IK;$W=V@CG=Y782(.BE2<8&3@8XS5+1/ _A
MKPY>R7FD:5%;3R9&X,S!0>H4,2%!_P!G%= 2!UJE?MJ8FLO[/6T:(S@79N&8
M$18.=F/XLXZ\=: ,6X^'OA6Y:]\W25*7K^9<0K-(L3OD'=Y8;:&R.H&?SKHE
MM8%M/LHA3[/LV>7C*[<8QBI<@=3UHH YJW^'_A6V2U6+1X@+27S8-SNWEGD8
M&3]WD_+]WGI5D>#]#%GJ%H+1_L^HNTEVGVB7$S-]XM\W?H?6MS.>E (/0T 0
MV=I#86<-I;JRPPJ$16<M@#H,DDUEGPEH9NY[@66#<2B>>)97$,L@P=[1!MC-
MD Y(Z@55\7^(+SP]!IDMI!;RK=:C;V<OFL<HLCA<@#J>O4_G724 9IT#36UT
M:V8'_M$1>2)O.?\ U><[<9QMSSC&,\U4OM B@;5=5TFVC_MN[MFC$EQ*YCD8
M*=@<9(V@GICCFMW(SC-&1G&>: /)=,\#6[VT5O;^#M4T34HT"B_&JCRHG ^^
MHCE.[GD+L /0X%>B_P#".:6-4NM3$$BWMU'Y4TRW$@+(.@X;  [8Z=JU20.M
M% & /!>@#2K72Q8L+&TE$UO"+B4+&X.01\W8\CT-1W7@+PQ>RWTESI,4C7__
M !\AG?$AZ;L9P&_VA@^]='10!D?\(SI O[&^%H5N+%#';.LKCRU/4  XY[YZ
M]\U!X=\-6OA^YU6>UA2 :A<>>\,<C.H;G+9;^)B23C ' '3)W@<C(KDM'\0:
MUKZ6&K:;;63Z-<7,T,D<A99XXT=D$H;.ULE,[<#&1SUH VM1\/:9JE[!>W,#
MB[@4I'<03/#(JGJN]"#M]LXIMSX:T>[T)]$GL(GTZ3[T/(R=V[=D'.[=SNSG
M/.<U9?5+5-7CTKS5-]);O<K%G^!6523Z<L /Q]*R/"'B"\U^'5S?000R6.J3
MV*K"Q((CV\Y/4G)[#Z4 6+'PCH6FZC'J-KIZK>QP^0L[.SOLR3R6)R<GJ>>G
M/ JSHWA_2O#\,D.E6:6L<CEV522,DDX&2<#))P.!D^M2W#:F-6LQ;K:'3BLG
MVII&;S0V!LV <$=<Y_"KN1G&>: ,.]\'^']1U.?4;O3(I;J>+R9F+-B5 , ,
MH.UB.Q(R.U)'X-T&*/38XK$QIIG-F$FD7RCC&1AN3CC)R<<5NUS+>,K1?B"G
MA0QD2/:M*LY^Z91AC$/]H(P?Z$4 :MMH6G6>L76K00,E]=A1/+YSGS OW003
MCC)QQQVI^JZ-I^MVJVVHVPFC2198SN*M&XZ,K*058>H(-7J,CGGI0!GVVBV-
MG!<101R*;@YFE,[M+(<8&9"=QP.!SQ1HVAZ=X?L%L=+@-O:IG9%YC,JY))P&
M)QR2>*T* 01D'B@"K?:=9ZE%%'>6Z3)%,DZ!Q]UT8,K#W!%*NGVB:G)J2P(+
MR2%8'F_B**20OYL:LY%<]XWUZ[\,^$-0UBQ@@GGM8_,V3L0I&<=N3UZ<?6@"
MTOAC2%N=1N%MY!-J2A;MQ<29E &!GYNPX&.@XZ5#_P (?H7V33[46;B#3G$E
MF@N)0(6'0K\W;H/2MJ)]\*.V!N4$_C3^E '/ZIX'\-:UJZ:KJ&DPS7JJ%,FY
MEWJ.@< @./9@:NRZ!ILVLQZN\#_;XHC"DJS.NU#U4 '&/;%9_A[Q!>:KXA\1
M:;=V]O$NESQ1QF)BV\/&'R2<<\CM71,P52S$!0,DGH* ,_2M#T[1%N%T^!H1
M<S-/,#*[[Y&^\WS$\GN>]-NO#^E7NLV^KW%DDE_;IY<<Q)!"YW8(!P0#R,YP
M>16;X-\86WC"RO9X(FA:UNW@,;\,4ZQO@] R$'\ZZ4D#J: .87X>>$TA6%=%
MA\M+@7*)O<B.3).5&?E&2?E& ?2K;>$-"8:D&LBPU-0MX&GD(F &!GYNPX'M
MQTK<I,C&<C% &!?^"/#FIZ-;:3?::)[.U(-NKRN6BQP-K[MRCV!J1_!^@R:1
M;:4=/"V-M()8HDE=0'!R&)!R6SSDY.>:W*,@C.>* ,U- TV/6_[96&3^T/)\
MCSS.Y)CSG;@MC&><8Z\]:?J^B:=KUFMKJ=LMQ"DBS("Q4JZ]&!!!!'J#5_-
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M 4W\)Z%))ISMIL6[3E*6N"1Y:G&5X/(X'!S5:?P)X8N=?_MR71X&U$L':7+
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M3CY1V&*TO%/AN'1/!OC<1ZDCK/:K="PM8C#%:O@C<H#'&_!)'0D9KO/^$/\
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M>V9KFR4K;2M,Y:('@@'/<<'U'6D@\-:/;_;]EBA&H9^UK(2XGR,?.&)!XXH
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MC+ R+_=+9SCD\9QR?6@#SM;.S\/?";1O$-L&AN[NTTZWU"]9W8BV9TWY 8<
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MK\$7>YV87 ((^<$D-P2.: //M(A73_&_@@VMO%9V]YI=RK!7!EGC5(V1YR
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M!4P;2#A ..=N.>G7DUT$D:2QM'(BNC JRL,@@]010!P=CH=K%K.D>(M*U.P
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5MR^0Y"G/49YQZU0TSPUHFK_ !-\71W=E%/!&FGSQ)D[5?8Y#@ ]>.ON?4T
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MTR0W_P "5\0QG_B?PC[2+U1_I NQ+@C/7)/R[?0@8QB@#V1I$0$NZK@9.3C
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MWNJ[C@;CC)]*\DM;2T\7Z5XBBU;5K.ROK74Y_M$S0@7-H(Y28F20L"JA H!
MQU]ZMK'#XE\4>)]#U>]LQ*D,*0+>VH:3[.T*DO'EAM.\L3@<'&>@H ]1+*"
M2 3TR:;YT6Q7\Q-K'"MN&#]*\M&BV#^-?!5I+<-JD#:7=Q/<3_\ +TB>6%+=
MF&#[@CGG-9J>'=(D\(?$>)["%H]-N[PV*,,K:X@5QY0Z)\QS\N* /97=(T+R
M,JJ.I8X I<C;NR,8SFO+H]1:_P#$GAO3M4NK58KGP]%/;_;H?-CFN"1YF 6
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MQ?:PZ"4V\>8XRV-[$@*,^F2,^U.TK^W1J5R+^YT^ZTYD5K>6W1HY _.Y6!+
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MNI+")I9F5IB<XE*@!2XSAL #&0<8HG\.:1<WDUW-81--.5:<\XF*@!=XZ-@
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MS%GEGD1<!Y78N[ =@68X]L5HT44 %%%% !1110 4444 %%%% !1110 4444
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MP2%V;2>V.,UHBUO/&MUXJL_MT=M=V5ZUK;N6D$MFH13'(@5AC)RV>_()P
M>E-N",4 +8X!. 3]:Y'1/%NK>(#JHL]#M5.FWTMA*)=0(W21XR5Q$>#D8SBN
MCTCS?[&L?/NTO)?LZ;[E%VK,=HRX'8'K^->:>$-+U/4H_'::?K,MB7\0WJ!%
MB1@3\O))&X9Z<'CJ* /3-+NYK[38+FYM'M)W7]Y;NVXQL#@C/?IUJIXGU>;0
M/#.HZO!:I=-9P/.8FE\L,J@D\X/8>E8.JWK7WQ0T_P .W98::=+EO!%N(6XF
M\P+M;^\%7)QTYSV%<U?37=KH7Q1T%I99M.TZT+V;2N7,8EMR[1[CSA3C [ T
M =?/XLN(=2\*VOV"-HM<4EI?..82(C)@+MYZ8SG\*ZJO.+[_ )"WPO\ J_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M*1Y+Z$0W0^TR!)P%V@NH;#,!T8C(ZYS71T4 8#>"]!9-+4V;_P#$K5EM2)Y
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH ***RM1UN.RU&VTR&![K4+E'E2"-
M@-L:X#.Q)X7+*/4D\#K@ U:*R]#UZUUZWG>!)(9[6=K>YMY0 \,B]5."0>""
M""0016I0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<AK6C:O;^
M/-/\4:5#'>(MD]A=VK2B-MA<.KH3P2&'(..*Z^J.I:8NJ0F":ZN8[=QMEBA<
M()!W!8#</^ D4 <;\-S<:AK'B[Q \:QVNH:@L=N$?<KB%/+9U.!D$]\=C7H%
M16MK!96L5K:PQPV\2A(XXU"JJCH !T%2T %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
>1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>30
<FILENAME>exhibit1016-arvinasxamen010.jpg
<TEXT>
begin 644 exhibit1016-arvinasxamen010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUO99KB.8V\+A&A**!]Q2 V#ZU6LO 6I7\>HP0J_AO29[FWN(]-<I=!V0'>7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JG;Z3IMI=RW=MI]K#<S?ZV:.%5=_]Y@,G\:N44 %%%% !1110 4444 ,
MEABG"B6-) K!U#J#A@<@CW![T^BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-IQD1=Q01+@$( &PV\],FJ>AW3Z_I6FZKX=\5W5^//A-]%*8SO4L-X*[08F
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M3(9F<J,84*2,^N!UH K>&=5N_';ZEJ8O9[31X;I[6SAMF"-,$ZRN^,\D\*,
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MK"-2Q"K.C,<#G@ G\*I7FH6EY\5O#=W&_P"Y_LVZ =T*X+,FW.1P6 )&>HH
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M,-ORGH#@L!Z,*J6%S;1?%[Q#-++&D?\ 9EL@D8X7*LY89]0",B@#ICXFT?\
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MSA54<DD]A67;^*=(N;V6RCGF%W'#YY@DM98Y&CZ;D5E!<9X^7-9_Q$LK^_\
M FIPZ9"\UV!'*L*$AI DBNRC'.2JD<>M8V@:OX3UO4[;6;&VU%[NQA<SW%\U
MQ_H2E?F0F0E2Q/&T9Z$]J .EL_%^A:A:VES:7K30W<[6T#)!(=\B@DKC;G@
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MT()Z*@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6JZQ#/+K-PFE*BB;3$B39,RMN!9R-V.@('4#'0G.]0!YE)J.D:CI&KZ[X?\
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M#..5/3I5VB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M/I]C(85EC<.FX_,45N^T,HS[XZ@UREVR^$/B]=:[J9\K1];LHX/MK?ZN">/
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MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH 0
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HK)N/$^AVE^UA
M<:K:Q7BKN,#R /CUV]<>]6[#5+#586FT^]M[N)6VL\$H< ^AQT/M0!;HHHH
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MZ3&_V;:%$#.$)C&/O%%< GJ2Q]:]@M[JWNU=K>>.94=HV,;!@K*<%3CN#VH
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MG.:YSX>7=]I_BBU\3:^Z0P^*(W@AEFE(9Y00ZG!X"-\RH/15X^;D ]NHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1"3QQGDGGGL*I^(/"-KKU[;WZWU_INH6Z&);NPF$;M&>2C9!!7//3@\BI/\
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M@DMG\N2!U^ZR$?=(K'F^'.CWFC7EC?W%[?3W@59[^YD#W#*KA@@)&%7*CY5
M'X\UU]% &1XC\-V'BC09-%O_ #%LY&C9UB;:2$<,%^AVX/MZ5PVN32:KX^\)
M0V;+'8VFHRQVT2KQ((8F$TGT4[8Q[[O45Z>>00#CWKD_"G@V30YH[O4;U;V[
M@MOL=NRQ[%CBW;F."3EW."Q]@!TY .MHHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^ 4?^%'_  AWAC_H7=)_\ H_\*VZ* ,3_A#O#'_0NZ3_ . 4?^%'_"'>&/\
MH7=)_P# */\ PK;HH Q/^$.\,?\ 0NZ3_P" 4?\ A1_PAWAC_H7=)_\  */_
M  K;HH Q/^$.\,?]"[I/_@%'_A1_PAWAC_H7=)_\ H_\*VZ* ,3_ (0[PQ_T
M+ND_^ 4?^%'_  AWAC_H7=)_\ H_\*VZ* ,3_A#O#'_0NZ3_ . 4?^%'_"'>
M&/\ H7=)_P# */\ PK;HH Q/^$.\,?\ 0NZ3_P" 4?\ A1_PAWAC_H7=)_\
M */_  K;HH Q/^$.\,?]"[I/_@%'_A1_PAWAC_H7=)_\ H_\*VZ* &QQI%&L
M<:*B( JJHP !T %.HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR"SCD5MV>^YB,8S0!KT444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MSUH T*;))'#&7E=40=68X IU>=^$I(_&OB?Q%J^IHMQ;Z9J#:=I]M*-T<(C
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M)H R&C_M_P 6Z'K=[''IT>D13E8I;F)WDEE4)QL8C:%!Y)!)(XXKD9-'UU/
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M^ $7_P 30!K?VA9?\_EO_P!_5_QH_M"R_P"?RW_[^K_C63_P@WA+_H5]%_\
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M[46NGV=O:6X)(BMXQ&H)ZG XJS0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q_Q
M2RGPWUNXC=XYX+<O%+&Q5D;(Y!'(KL*Y#XHK)+\-];MX8GDEFMRJA1P.0223
MP!CUH SK ^%KR#1+2"^;^T[DQM&8;IRV]$\TEANZ?(00>N<4SX@Z)<Z?+;>,
M-($\LNF2>=>Z>LS".Z@_C.S.-ZC+ X[=\"FV_BK6+G2=*&C^#[N\6.-!'<W+
MB)5?9MW <DK@GGC(--OM3\9:W<)IL_A)$M4?=.&O,1W('1"VS[I/)'\0&.A.
M=/92ZV^]&?M(]/R9LZ#':^++Z/Q:-XLVCV6$0D(#J#S+(H."Q(P ?N@>IP.8
MTR31H?B9XUL]7NQ%;0&R-K#)<NJ)NB)?:,X&3@FE\&Q>)O"NOWFFGP[)'H=Y
M=><B1S>8ED6^_L.T94GG&./SKB_"VO:Q8?$#4]2$MW=2ZCJODFW0JYN((O/5
M@4SN#(%CVG Z$=ZF4>5V9<7?8[[7_$,?ASP$+SPS.[-K6H+;:?).QD$32?+N
M&XDE?D9@#W(XQQ751>#M,CL/)+73793#:@;A_M);'WO,SD'/..G;&.*\>U?Q
M7>^,O"TL$FGVEFUM<VVH6,L$OR6TC3!?WYR=HS(_)V_=;Y1BNA;XQ:A!I$D]
MYIUK!<I8W+KR3%+<12! $;=AD()SM).> 34C-+7-.DL?%WPXTZ>XDD9EF@O"
MLC!;DQP+@N,_-\PSS75^,K:*?2K,N&!74;- R,5.UKB-67([%2017F/B34M6
M@^)6EZD]U!J:V.I")+6UF FA$D2JT8MVP23R0X8@@]1BF7_Q$U>[TG3+=;:U
M5(OLM[-)=RL'F;[5\JQ@MEL%!G&>_*X&0#K/B3H5OI?@3Q%J]O/=+?[1)'*E
MS(HBY50JJ&P  /3U-='I?A?3XUMKU#/^\L_*FB>XD=)-VQMQ#,0&!7@CGDUY
MYXY\5:SJWAK6=-GLK9[*Y>_MHOLP;SE^RR9W-DXP54YQTQGVK1L?B1J:Z'8+
M)#IEN7N&MA>2RYAV)"),$(S%7/W>3VW8QQ0!+\/M'_X27X+Q13W5P+Z\%P!>
MF9_-1Q+(J-NSGC X]/K6IX'\00_\*Q>74(F^UZ2LEGJ$))9VFC^4@YY+/P?<
MM7+^%M4OM$^#WA8P2+8RG4(U>6YRL+1RR.V2W=<$9Z?AUK.%[J0\20:C:I;>
M7K]TNZ!0S6]S>6TYB$B'.0A!2;KR(VYXH"YT/CO27\-_!B8B>9-2A:!Y+E9W
M+B1Y4#@-G.WD@#/0"NDC'A6YUBPM=-O";_S//C^SW+M\J8+;ANP5(^7!_O>U
M4/B/;ZEK_P /=3TVQA34;V6[58DL1D*L<RL0Y)P& 7!Y'/:N@NM9GG>V%KH-
M^]T956.2>$*D&[AG8[N@4DX'7I[T :-KJANM8O\ 3_L%["+,1G[3+%MAGWC/
M[ML_-C&#Z&M"L^UU"XN-8O[*33;B""U$9BNW(\NXW#)VX.?EZ'-:% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9PH6&.9DB8*VX H#@_-S[]\USUKXG\3Z9H>BZ[K8TZYT[4# +E+:W>&2S\[
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MN(M/MW'0K$"&P?<X/XUZ77!_"'2X--\#[[9=L5Y>W%PF3D[=Y1<GN=J+7>4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M9QVUI>Q/'*4&68L""[,>6;G.2<U4\.^'=4AFM;_Q)>V][J%I +>V%NK".,8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@!DL,4R[98TD7T=014/]GV7_/G;_\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>31
<FILENAME>exhibit1016-arvinasxamen011.jpg
<TEXT>
begin 644 exhibit1016-arvinasxamen011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUO99KB.8V\+A&A**!]Q2 V#ZU6LO 6I7\>HP0J_AO29[FWN(]-<I=!V0'>7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JG;Z3IMI=RW=MI]K#<S?ZV:.%5=_]Y@,G\:N44 %%%% !1110 4444 ,
MEABG"B6-) K!U#J#A@<@CW![T^BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH ***P-2\::!I&K1Z5?7KQ7\HS%!]GE9I!S
MRN%.[H>GI0!OT5F:/XATCQ!'*^E:A#=>2VR54;YHV]&4\J>#U':M.@ HHHH
M**** "BBB@ HIID02K$742,"P7/) QDX]!D?F*=0 457O[^TTNQFO;ZXCM[:
M%=TDLAPJBL^W\4Z1<7MO9^?+#=7)/D0W-M) TN 2=H=1NP!DXZ4 ;%%%96L^
M)=(\/R6J:K>"V-W)Y4!9&(=_[N0",_6@#5HHK*TCQ)I&O7%_!IEZES+I\WD7
M*J"/+?GCD<]#R..#0!JT444 %%-\Q/-\K>OF8W;<\X]<>E*S!5+,0% R2>U
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M-199I])E!AN0H4RQ-_> XW#CD  YZ"GZKX"FU6W\/W,VIH=9T.998+H6^(W
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M3'A%Q:;"$FCWJX9U7G!!_BJZ\6OPO:.-6LI0\T8>%[3873/SA3OX8+N/0]*
M-ZBJ UW2"]P@U6Q+6P+3K]H3,0'!+<_*/K7/Z[XANK/Q;X4BM+^V_LC46N//
M(52&5(6<,'S@#@'CTZT =?166^K6.I:%=7>EZS9"+8Z+?1R)+%$^/O'G!P<'
M!-<YJ&O:CINO^"[=M7M9]/OXIOMEP(E59]EN7$@;)"J3\W'YXH [>BLS^UK'
M4M%N;O3-8LC#L=5O8Y$ECB;'4G.#@X.":RI_%VEZ%::%;:IK5I<W6H*BK<JR
MQI*-F3-UPJ'''.,D 4 =112*RNBNC!E89!!R"*X[Q=XU;PWK^BV@@WV<UPBZ
MC/VMTDW)$3Z9<'GT0^M '94444 %%44UK2I+_P"P)J=FUYDK]G$ZF3(ZC;G.
M1WJ.Y\1:)9"4W6L:? (7$<IEN478QZ*<G@G!XH TJ*IR:MIL-W#:2ZA:)<S
M&*%IE#R ]"JYR?PJ5+VTDO)+2.ZA>YB4-)"L@+H#T)7J!0!/152]U33].V_;
MKZVM=X)7SY53..N,GW%)<ZMIMG9QWESJ%K#:R %)I)E5&!&002<'CF@"Y16>
M^NZ1&EL[ZK8JMT,V[-<(!*/]GGYOPJS]MM?MOV/[3#]JV[_(\P;]OKMZX]Z
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M!QB660*ISTY/% %FBH;2[MK^UCNK.XBN+>0926%PZL/8C@U-0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5R7Q08+\,?$1) _P!#
M<<UUM0W%I;WD8CN;>*= <A94##/K@T 43JECI/AR'4+^[BMK..&,O/(V%7.
M.?<D#\:TP0RAE((/(([U UA9M9FS:T@-J1CR#&-G7/W>G7FK% !1110 4444
M %>?:YX?\,>.M1OG%TVF^(=(E,7VVUF\N>' !5CTRN#W]P".:]!JE=Z/IE_M
M^V:=9W&TEAYT"O@GOR.M 'E%QJVIZA\--!U#79XY6L_$5NKW^-J30QS[1-Z
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MVOA5OM]I/KS(RMJKB:(.,,L &(A[97Y\=BYJ+5](UFYFCT[2I-,LM"FB:.\
MB87 R>?+VD*,KQD]"<\UT2(D4:QQJ%10%50,  =J .&\5P:FOB9K_P .ZE9C
M5;?3A]HTR^7]U=6Y=R"#G*L"&&>G(S7/V_B2TC\1^'+R_N9O#VDWWA^-;%G\
MORXI ^7C+R*0,IY>#QD**]1NM,T^^=7O+&VN&7A6FB5R/ID4Z[L;._@\B\M8
M+B'(/ES1AUR/8\4 >=W?A>PD^',Y\*337,FGWK:IIL[L&5YD;>1'M !1CO7C
MC)/:K=S=WOB+X>Z]XDTN*9+K4=.9;% ")%B5#@#_ &BS2$$=05]*[]$6-%1%
M"HHPJJ, #T%$<:0QK'&BI&@"JJC 4#H * /-]#G\)^)[KPY?VVN37M]:QL+:
MR1H5:!63;(LB(@(0 8.>.F,Y&<OPW!H-I\+->U2\TN*[6WN-1#^2H$NPNZE5
M<<IE2!QV.:]4ATRPMY)Y(;&VC>X_US)$JF3_ 'B!S^-.@L+.U1TM[2")).'6
M.,*&^N!S0!Y?INHV4GQ(\,LVI:?+'+HLT"1VS QH"8]L6XDESCUZ]<#-8=Q:
MV"?!3Q7<QPVZRIJ\^R55&5VW0VX/; /'UKVJ/3+")8ECL;9%B#",+$H"!OO
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MQ;6<GQSMO,AA9SX>D?YE!)87" 'ZXS7&S6=@OPB\?ND%N#%JEZD;!1\@6;*
M'L!G('O7LSZ=927!N'L[=ISUE,2ENF.N,]*C&CZ8(VC&G6@C8@LOD+@D="1C
MW- ' ZMJVG2>(]0MO.M[.]_L*,37=R^YKB)MY6.)"=I.2<M@]0,&L^RM'U'X
M.>&=:TEDN-6T""*Z@"');8H\V$X_O)D8]<5ZD-.L5DAD%G;AX5*Q,(ES&#U"
MG' ^E8VL:9K<K6^GZ)-IMCH[Q/'=9B;SD![P[2%!QGKT///2@ \)S#5K:?Q(
M8W3^U"K0!QAEME&(P?KEG_[:5B>*8;.?XJ>#TOHX7B:VO@JS %2^(B.#P3W'
MTKNH88[:"."% D4:A$1>BJ!@ 5'=V-IJ$/DWMK!<Q9SLFC#KGZ&@#QO5;9](
MC\97^E121^'5U>PEE6U0%<(5-T47!!&=H/!'RL#P#7;:!_PCFJ>+AK>EZ]+J
M^H-8^3(\4D1C2'<&42!%7#9SC//!]*[)(8HH%ACB1(E7:$50% ],>E16=A9Z
M?&T=E:06R,VYEAC" GU( ZT <7XWU!=.\;>"Y=0<1Z-]HN!-))Q&EP8\0ECT
M')?&>_/:L"XGL;GQ%\4X;.:WEEN='AVK$X)D803!L8ZD9 /X5ZM<VMO>V[6]
MU!%/"_WHY4#*WU!XIMO8VEIG[-:P0Y 4^7&%R , <=A0!Y2VM:7+#\+?+U"V
M?RFC$A64'RR;5EPQ_A.>,'N#Z5%:7.AZKIGB+P[XKUV>SO!J<YN+%C$CS9EW
M1-%E"[978%VDG@ <8KU>#2M.M@@M["UBV.9%\N%5VL>K# X)]:=)IUC+>QWD
MEG;O=1C"3M$I=1[-C(H 9-&S:-)$%D9C;E0)#EB=O?U->.6^L:;_ ,*T^',/
MVZW\VWU:Q,R>8,Q;68,6_NX/KBO;ZJ)I6G1,S1V%JA:7SF*PJ,R?W^GWN3SU
MYH \]L;+39_&WQ'+V]K(!;6O55. UNV[Z9XS6-X?U5;/_A6$FIS*FE-ILB1R
MR-^[6ZV!5W$\ [=P7/J:];.E:<6D8V%KND_UA\E<OWYXYH?2M.DLS9O86K6I
M.3"85*$^NW&* /']7O8_.^)YTF1)F\VQF>.U969X@J>>0.0>-X/XYKKM(;PK
MX@\26&L66O2:O>K:/'L5HML<#<D3*B+@9Q@-SGMUKMX+.UM=WV>VAAWXW>6@
M7=@8&<>@ 'TJ*#2M.M8YH[>PM88YCF58X542?[P Y_&@#B/@_IVF_P#"O='O
MHK2V-T!.OV@(I< S,"-W7& O'L*G\7W5O8_$;P1<W<\<$"_;PTDC!5!,*X&3
MZUVMM9VUFA2UMX8%)R1$@4$_A2S6T%QL\^&.7RV#IO4-M8=",]#[T >9I;6-
MWX@^*4D\,$K+#"NYU!*K]D&1STY'Z>U9NG:RFFCX?W.JZI+I^F3: ((KP;"B
M7.(R0[.K!<JI&>._/6O5_P"R=-S(?[/M<R??/DK\W.>>.>:5]+T^2S-G)8VK
M6I.3 T*E,_[N,4 8G@JQT>RL;]M#O)KRTN+V2=IV=6C>1@"YC*@+MSZ<9!KI
MJ9%%'!$D4,:QQH-JH@P%'H *?0 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M6)XJUZ'P_HDEPUQ!%<RD06@F<*&F<A5SGL"03Z $T 8=GXSN)?B7+H<\032[
MF!TT^?\ YZSPL?/ /MG'_;/WKJ;[6M+TRX@M[[4+:VFGSY4<LH5GP"20#V !
MR:\W\<>'[W0O!5CJUOJ\,LGAV2.\M=\(C,N#\X+[N=X))_O&K7BC7]&UR\\
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M9!L.TATVG)Z8)QW.&ZE_8MA;_#*RBU6TOK6VO%1+GS%*R!867=UZ;@![' H
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MJ>FVDH:2QE$1)X\QMH+$#T&0,]^:\^6[TZ#PO\*"EQ:QE;JVSAU&,V[!\_\
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MDT*6,ZA%J%I+''&1YELJ#$NX#E0JY4@]\#N*9976FM>?%)FGM3DX8EUY7[,
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M>;,[!47/U(SZ#- &O@'M2;1Z#\JSVNHM&T^)]4OM\KL%+E>9)#_"B#GZ*,G
M[\FN8\)^()-0\6^,4FU1[C3K%K;R?/41^0#&S."-JXP<YW#/'- ';X'H*1D1
MT*,JLIX*D9!K*M_$^CW-Q-;Q7H\^&'SVB:-E<Q_WU! ++[KD53\.>,],\0Z
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M R_,.1D<BK-[?VVGQ))<R;0[A$55+,[8)PJ@$L< G '0'TH G5%5 BJ H&
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M,.!ZJ30!I211R[?,C1]IR-R@X/K3B >HK*E\2Z-!>I:2W\:RO-]G4D'89?\
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M 9Y/O2T4 )@#H!2)%''NV(J[CN;:,9/J:=10 P11K(T@11(PP6 Y(^M/HHH
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ME:OC#%CKNH7^AZY;Z=JUM8H+C3KQ5-M?PC<54+P0W+#*\\@=Z],I" <9 .*
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M\U._LXOBWILL+138T&X41Q,"9/G1E0>Y .!7*66MV%R_P_O8IQ%!%>NCV-M
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MI[$'C-5UO(=4UWXFBS\R;[5I4'V?;&W[W%O(,KQR/F&/7(QUKU<@$8(R*,4
M>0ZIJVGW/PO\$M%<H1#?:8KD\8,>S?U_N\Y].]=%XT6[T7Q#HWBW2K8W4C9T
MRYAC_P"6L<I_='/H)=O/HYKO** /-_&,?_"+KX4OKLW4ND6$\HU&>W+!T>2,
MCSSLYQN+DX_OGUK>\'CP]=76IZMX>6>6.],?GWTDDK+<.H(&W>>=HP"1P<XZ
M@XZKK0  , 8% '(>.H+2Y_LE)-:DT6_6X9[&_7:420(05<-P5921@XST[\S^
M ]0U'4="G?4X;87,5Y+";BT!$5V%/^N3V8Y_$&NH(!&",BCI0 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5!=WEO86S7%S*(XE(&3W).  .I))  '))J
M>N*^)7VF#2=*U**WN;FUT_4H[F\BM682&':ZLR[2#E2P;CTH V1XPT 6M_<2
M:@L*:?C[6MQ&\3PY&1N1@&Y'3CGM4:^./#37<5K_ &K$LLL1FCWJRJZ@9.UB
M-I('50<CN*XS4[CPQJGA+Q5K&@Q7,\EQH\UM)?SM/^]8H=D2B7ECGTZ9 [TZ
M]N+0S_#$^9$5B8%^1B,?9RO/I\V!SWH [2#QGX>N-,O-174XUM;)]ERTJM&8
MFQG#*P##CIQSVIMEXW\-ZCK$>DVNK0R7TJ;XXL,-XQD[21@D=P#D8.1Q7 ZQ
M-$US\6]KJ1)IL13!X?;;,&QZX. <=#5RYCL_$6G?#^VTAHI;RQN[6ZD\KK;0
MI&?,#_W,G:N#C)QZ4 ;_ (6U"[;Q1XRM[_4)9[>QNH1$9RH$2&$.1P  ,D_U
MK;M?$^CWE[!9PW9$]PADMQ)$\8G4<DQE@ XQS\I/'/2O-]2M+O6H?BE8:2^^
M\NFA,"H>956% X7USAE^IQ6MJ]Y;>,H/!PT5@;VVU.WNYXU&'LXD5O,60=4_
MN8.,DCK0!VNG>(M+U9;PV-PTWV)S'< 0N#&XZJ01G</3K57_ (37PZ#:J=3C
M#7<)G@4HP:2,?Q 8SSQCUR,9S7+^(-.U#3/&S1Z7&_V/Q5$+6Z9#C[/,@YE'
MH3#O'^\JU9UHVMO\5?!T2>6D=O:7D>!P(]RQA![9P0/7% &N?B%X573OMYU9
M/LXD:-R(I-T;*<'>NW<F,CE@!S6Q=ZQ8V4<3RS,_G*6B2"-IGD4#)*J@)(&1
MR!CD>M>:6\]K_8'Q2 DCS/<7)C&1F4&W51M_O9;(&.]0#4[?1+SPMJ^L&]&A
MSZ!#9&ZM7E MKA2&(D\LY (XY[K[< 'H1\:>&ULK*\;6+86][)Y5NY)^=LX(
M/<8P<YQC'.*2/QIH5QI^IWEM=23II@S=1QP2>8G&1\A&2"!P<8/K7"ZU%HEM
MIWAA])M)+6QG\40WG[\ONE7:V^8B3YE4G')P.A[UH2,MQX^\;0VY$CSZ+#'&
M$Y\QPLN5'J1N''O0!V/AC7H_$GAZRU2.*2(W$*2,CQLNTLH. 6 W#GJ,BMBN
M%\&^)M,T_P"'GAD7#SJ3';:=Q;N<3E0NT\=B"">@]:[J@#)U+3=1OM0A>#6;
MFPM(XV#I;)$6D<D8)+HV  #TZY]JXWP/)XC\2>&TU.7Q->_:8]0DC,9A@\N2
M..7!4@1YY4$9!'->BRRQP1-++(L<:C+,YP /<UP/P>FC/@R6+=B5;^Y=D;A@
MK2$@X/."#0!%X>\9VND2>)5\1ZW(ZV^MRP0O,I8QQA(\9V+A5R3R0!DUV]_K
M%CIP3[1*Y9U+I'!$\SLHQE@J G R.<8Y'K7EIFMW\%_%%0Z&2XOKLQ#O*#$H
M0K_>!8$#'>IIM6M-#\0Z3JNM->KHE]H=O;17MK)*%AG1F)1_*.>=W?N/8X /
M4=-U*RUC3X;_ $^YCN;689CEC.0>WYYXQVKCM6UX:EX]_P"$7-SJ%K;#3FE,
MEI%*DGGM*$4[@OW5 )S]TD\YQ6]X2M-,M-$']CV,MG82RO+$LI?<^X\N0_S+
MN.2 >V#QFL$7<'_"[W_?(!_8*P;L\>9]H)V9Z;L$''6@#8MO$.FZ-90V>IZT
MUS-;LMM/?O RQF7@8=U&Q&)(X)')JEJE[?0?%+P_9I?3?8KJSNGDMN A9-F#
MP,G[QZDUR&FRK!\)M;\(ZJA/B&-;R#[(P_>W4LCNT<B#JX)=3N' P<]*UA&^
MG>// EE>SJ]S:Z1/!<2%L_O"D0&3ZL5;'K0!K>$-2NCJGB]-2U&2:"PU'9')
M<,H$4?E(Q'   &36[:>)M)O;V.SBNF%Q+&984EA>,S(.K1[E&\=/NYZUYCJ%
MI>:SH/Q-LM(_>WDU^DL42'F:-5BW!?4$*R\=3Q70:S=VOC*_\&S:'*'N+74D
MO+C;]ZU@$;>8DG]PDE5VGDGZ&@#ICXT\/KI5UJC7Y%E:3&"XF,$@$4@X*M\N
M1@D ^A(J_)K-C%-:Q22NCW,;21!HG&5498DX^7 (SG'6N$U+0;I_&.M>'(X9
M!H_B6%;R:9!Q R82<#W<>5_WT3VK2^'W]ISZ:+K78S%<Z9&VEAW/#^4Q$DH/
MH^U/^^* +NF>)-!TSPXVH3>(WO+)[N1%N[DY.\N1Y:X49 )P,"M33?$^C:OJ
M5QIUC?)-=P()'CVL,H3C<I( 9<\97(KR:>:%_@MJUON#2/K;,L6,LRF]5\XZ
MXV9/TKM9[FV?XSZ<\<T;(VARQ[U8$%C*C*N1W(!('I0!OS^,?#]J%:?4DCB>
M9H%G9&$32#(*"3&TMD$8!Z@^AK5EO+:"R:\EF1+94\PRL<*%ZYKQ32]7\.#0
M-+\-ZAKL5E9Z;JIN4:Y@ECGVI,S(CY7:IR>6W=.V>:]IOIXH]-GFDD18A$Q+
MD\8QZT <^/B-X29"ZZQ&R+;_ &IF6*0A8LA=Q(7@9(_,>M;+ZWIT>J6FFO<;
M;N[1I+>,HP\U5&6*G&#@$9Y[BO--/M7O/V;'L[2$O=)I<B-"B_.'!)88ZY[X
M[U<?7K#5_'/@&ZL&FGMU@O$:5('*AC%&,9QV/!],\T ;?@W5+GSO%QU74I)H
M;#5I(TEN64"*(1(V.   ,GM6]:>)M(O+V:RCNC'<PQ>>\5Q$\+>7_? <#*^X
MR*\RFCNK_P ._$*/2T:YNO[;6[2")B&GB0PLVW')R$8 CJ>*V;34?!OB-)]5
MLK+4K^:VL)UN7G>XW6\10[HLN<%FZ8&>Y[<@'<66OZ=J%VEK;RRF9X3.BR02
M1[XP0-REE (RR]/6K%]J-KIRQ&Y=@TK[(T2-I'=L$X"J"3P">!T%<#X.DO=/
M\36FEVFL)X@T)K*1H+B11]HL "F(Y''4-Q@$!ODZ?+6QXZMK*Z?2DFU>?1KY
M)9)++4HR-L4@7!5P?E*L"1@XSC&>: *?C#Q"?L?AO4M+U6:"TEUV"UN>/+5T
MWL)%?< PP4(/3OFNDT[Q3HFJB^-I?HWV#FZ\Q6C,0P2&.X#Y2 3NZ''6O-]0
MU*]O?#?AG^V5M?M$/BJ+,\";8[F)';-P%[*<Y)Z=^A%7]5OX[?QMXTGBLTU(
M'08@+3JMRR^9N3CKP1D#G!H [NP\2Z3JEXEG:W3&XD@^T1I)"\9DBSC>F]1N
M7D<C/45Q=EJ>KMX/^(4K:O=M=:;?WJVMP=F^-8X495 VX SGH!U-9^E:E;W'
MCWPA>QW-Q=12Z;<0ATM&CAC<^7B- %X"\YR21CD\4^PNH#X/^)R^:NZ6_OWB
M&>9%:!%4KZ@L"!CJ: /0O#$\MUX3T:XGD:2:6Q@>1V.2S&-22??-1OXLT2.\
M%LU\ YN?L@?RG\KS_P#GGYF-F[MC.<\=:;X.D23P5H91@=MA K8[,(P"#Z$'
MC%>5ZUJT5]H<S>3-92VGB*.2;3;>T8+"HN!F61@N69OO9S@YP!QF@#T_4?''
MAK2I[N"\U:%)K0*9XU5G9-V<<*"2?E)P.F.:DD\8^'(K*QO'UBU%O?\ _'M)
MOXDZY^F,'.>F#FN6LM5TRS^+GB">^N(K82Z79F-[C]WQER1EL8/3Y>O'3BN7
M%@NA>'?"<E[$;:RE\7/=012ICR8&$I3(/W>,-[9YQ0!Z=8>)M(\3V6H)HFJ[
MIK<%)3&FV2$D'!VNOMP<8-8?@SQ=;P^ O#5SKVH2->ZD@1)'C=S-*6.%RH/)
M["HX8[>Y^)>J^([.6,Z9'HBVMQ<HP\N6?S"PPW1BJ  D=-P%9_AG0O\ A)/@
M9INF12>5?PVX>W?HUO<QL60GN""!GV/O0!Z(=2M5U1=-,C?:VB,P3RVQL!P3
MNQCKQUJ&]US3M/U*RT^ZN#'=7I*VR>6Q\PCJ 0,<#D\\#FL7P-<WFMZ<WB34
MK4VUW?1QQ+"W_+-(P01^,AD8>Q7TIOQ%L)[CPP=2L4W:AH\R:E; =6,?++_P
M)-PQ[T ;%KXCTN]FOXK>X=Y-/.+I?(D!B.,X.5ZXYP.:H/K&E7_B#0C#KD\4
MLT4LL%B@*K=H5SN=2N<*!D=.O?-<?)8:PGBN*Z6"80>,+?RKU.GV39RN?1OL
MY9/]\5M>(Y(8OBCX)4,BK%'>JV.B;HT"@^F2"!ZXH 2Z\9IKGA[Q<-,>]LKC
M2EN$BG^SLI)CA5B<NN!\S$8/.!GC-7?"?B_2[S3=!TV?4Q+J]SI\4A#ACYKB
M-2^'QM+#DD9R*Y>WNXK/2/B;IUP)([J6ZO)T1HV 9'MT"$'&/F(P!U-(UQ;I
M8?"S;)&#"T7F8/\ JQ]F*G=Z?-P<]Z /2M5U:PT33I=0U*Z2VM8AEY'Z#^IJ
MA:^,- O?MGV;4HY3:-&LP5&R&?[@ Q\Q.. N>>.M4/B6RCX;Z^A/S26;QHO=
MF(X '<U@^*YOL_AKPEK5O!/<Z7I\\<EXEDS!UB,+1[QL(/R%N0/\: .RM_%&
MC75O>31WH LG$=RDD;QR1,?N@HP#9.1CCG/&:CG\7:':6=Y=7=]]FAL]OGFX
MB>(INR5^5E!.<'&!7&7*^#-9T35]3M$U'['>?9HKG5EDG#[Q*HC*F3)/EG:Q
M;&!TYYQDZS=:LW@+QO8ZA?V^L6UM8Q_9M8AC"F8'<?+?;\I9.N1_>YZT >CV
M/C+P]J6M-H]IJD,M^%+B'##<!UVDC#8[X)Q@^E2W'BG1;2[CMI[WRVDF^SK(
M8G\HR]-GF8V!L\8SG/%<CJ,=GXAUKP0=&:*6;3Y_M$TD/_+M (B&1L?=+-M7
M:>>#QP:P-!FT271F\'^)['4Y]>M[AU-@9+G9=-YA9)5*G8%.02QP!R: /3]3
M\2Z3H[2B]NBGDH))BD3R"%3T9RH(0'!Y;'0^E4)O&E@GB^ST"-)I3<6;77GQ
MP.Z8W($VD @@[B2W08&3S7+6FN6/AWQ3XJT7Q1;S%=5N_M-HQM7F2\B>)4\H
M!5.2NW&T^M7)I4TSXH>'YYK-[.WFT*2UABCB+*DGF1D1#:, @#Z<4 =/XN\2
M0>$_#-[K,\4LH@0E(XT+;F_A!Q]T9ZD\"K#:]I\=K;SR22K]H8K%$;>3S9".
M2%CV[S@ GITYK#^*5O-=?#'7X;>)Y93;9"(,DX8$\?0&LB^U6.+Q]X>\2N[G
MP_/ITUFMTZ,L<$K,K!FR!M#!0H8\<4 =SIFKV&LVS7&GW"S(CF)Q@JT;CJK*
M<%6'H0#1J&K6>G-%'<RL)9\B***-I9'P,DA%!) [G&!D5S'A&S9_&GB[6K<_
M\2N_DMEMV'W)GCCQ(Z^HR0,C@E35+5=27P]\6XM1U@M%I5YI(M+:[928XIA+
MN9&/\)88.3UP!VH I:%XABN_!WBRZU;Q-=V]I'J]Q;PZCD++%& FT*-O!Z\!
M?7C-=Y<:S8:>L4<T\LCF'S0$A>5]@_C8(IP/<@"O)I[F*;X:_$B-$E#7&KW3
MPJT++YF[9MVY'))!XZ\5T7B+[//J-E?Z5XC&BZU#IB-#-+AK:[B+-^[<'@D%
M3TY&[H>P!T-YXYTZWUS1M-B6XF&IPM<I,EO(R^4%!!&%Y)++]!UQD5,OCOPP
MUZMFNL0-.UU]D"J&(\W .W.,#@]>GO7(MJ,Z^(/AYJ^J:>]AOT^ZBDACA8B*
M1DCVQ@ $C.#@'GMVK4\ S6S:[XS*O&6?5VE4\?-'Y: ,#W&0W/UH S_%&KF'
MX;:]JF@>)[VYDAO_ /7[E_=EI4#0J=OW%#<8Y]ZZ^P\9>'M4U.?3K'4XY[R!
M#(T*JV64?Q)Q\X]US7F5Q&U]\+/'D%K&\\C:[/,L<:%F:,W"-N ')4J"<^@-
M==?_ &3Q-XY\*7^B2Q7,>F^?+<W4!!6.-H]JQEAQN9B/EZ@ G H Z$^+M"71
M1K!OQ_9QE,1G\I]JN&VX;C*_-QSCFJ[^,+-?&I\-F*X$B6OGR2F!]H)<*H!Q
MC'WLMT'3/7'EM[J$-O\ "77] =)SJEOJKF6V6%BR*;Q75CQT((P>^>*[AKR*
MV^,B7,RS+#>Z#'% YA?#N)V)'3@@$$YQ@<F@#<T+5-*&FZK?Q:^]]9Q7DS37
M%RXVVY&"8U. -B]NO7K5RU\1Z5>7DEG'<M'<I%YQAN(GA<Q_WP' )7W'%>5/
M%=WO@GQ4VF1O<O!XJDOI+:(9:>!9E?Y1_$"!D>NWBNKU&>U\3>-O"6IZ+=1S
MQ:?]HGN[B,\11-&%".>Q+8^4\\$XXH VA\0/"I6%QK$)26;R%<(Y4/NVX8XP
MH)X!. >QKI:\0N9(6^"7BB%"IFDU69DC ^=\W092!U.5&1[#VKV*_$E_HETN
MGSJ)9[=Q!,K<!BIVMGZXH I_\)5HOVF& WH!GF,$4IC<122 D;%EQL+9!& <
MY!%8&O>(EF\<V7AEIKZWM7LYIYWM8I5D9PR*@5E7.T;B21QG )['E)&76/@K
M;>$XHS'XCB2"S^PL,3131R+^\(ZA< OOZ8[UTUW<PQ?&;2EDG7*:--"SDX&\
MR(0I/0$@$XH V[S43X*\%27FK7EUJC6,+,\XA_>38R1D*,#C +=.,FN>U7Q1
M*?$'@F^&H7%KI]X9_M<#H8XV*VY89W*&/)XYP>,<UT'C^"6Y^'OB&""-I97T
M^8*B#)8[#P!WKD;C5+&_USX;SQ2;H8C-O9T*A?\ 1MH)R.!NX!]1CM0!W>F^
M)M&U;3[F_L[^-K:U=DN'D!C\EE&2&# %<#GD4ZQ\1:7J.HR:?;W#B]CC$K03
M0O"Y0G&\!P"RYXR,BO,-42ZO6^(JZ5&US,+^RND@A8AITC6(R!".3]QAQWXZ
MUU'AG4/"OB37+;5=&M[^YOK>%DDN+I[C_15/6,^8<%B?X1GH3Z9 .QOM1M=.
M6(W,C ROLC1(V=W;!.%502> 3P.@)JO'K^F2Z<+];@_9S*81F-PYD#%2@0C<
M6R",8SQ6%XZMK*[.E)/JUQH]XDSR66I1$;89 N,/GY2K D8. >G>N-N]2UA=
M(T/7-:M7N+/2]6N8[VXTL/'Y\3(R+=J$(.,L<XZY..#0!Z$_C7P]'IMUJ$FH
M>7;6DODW)>&16@?L)$*[D[=0.M:4FJV<3V2.\@:].(!Y+_,<;L'CY> 3SCH:
MY;1=.\+>)K37)M+M;B6TU:!8+J^F:;_2<*R@#S>3M!'S#CG'8XB\ QZO=V(7
M6(WCNM&C?2HY&'^M=6PTP]056+!]=_K0!T<GBG18;Z&TDO=DD\QMXG:)Q$\H
MXV"3&PMD$;<YR".M5IO'/AFWOFLI-7A%REPELR*&;$C_ '5X&/3GH,C.,UY[
MX6GT*ZT.Q\*:_I^IR^(K"14;3Y)+G8TB-\LP(.P)_%N[<]>,]/X5EMW^)?CE
ME*,TLEF8R,?.$A ;![X;@^AH Z./Q7HDUY!;)? O<3-!"_E.(I9%SN19,;&8
M8/ /8^E5KOQYX8LC>+-JT6ZS8+<"-'<QG&>0H/ '4]!QG%>8MK$%]I7A6Z\F
M>T-KXBC:?3+>S98K ;I,AL+DN203SR2< 5T-I<VIUKXFR-)&%FCBV%N-X%MM
M./7#<?7B@#T"?6M/M[:VN&N0Z70!MQ"K2M,"-V4502W'/ Z<U%;>(](N]*.I
MP7J/:"0Q%@#N$F=NS;C=OSQMQG/:O+])U<>&QX&UW45E.C#0?[.FF2-G%G.?
M+;+@ E<[-O3M6MXHN+<:/I?B#2M)N5T>VUC[9=K:1/#+/&T;(UP%7:_#/G/4
M@9Z4 =[I>NZ=K+W,=E<%YK5PD\,D;1R1$C(W(X##(Z$CFM&N1\)2>'-3U*\U
MGP_#<S>?$D<^H3M-^](^Z@\WD[1U(Z9 ]<==0 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 445FZQKVF>'[>*?5+M;:*658D9@3EF. .![]>E &E16#I/
MC/0-;U"ZL+'4 ]U;)YDD<D;QG9_?&X#<ON,CIZTZR\7:+?W=I;6]TY>\1Y+1
MF@D5;A5Y8QL5 ; YX/3D<4 3^)=)EU[PWJ&D0W"6YO8'@:5XR^U6!!(&1SSZ
MU9TFSET_2+.RFE2:2WA6(R(A0-M&,X)..GK533O$^DZM:7UU97$DD-C(T5R3
M;R(8W499<,H)([@57D\:Z!'-:0O>N)KN W$$9MY-\B#N%VYSR,#J<C H WZ*
MY8_$7PN--:_^WRF".1HYL6DQ: J<'S5"[HP/5@!6Q>:W862Q%Y))6EC,L<=M
M"\SL@QE@J G'(YZ<CUH HZ1H6H6VIRW^KZTVJ2CS$M!]F2%;>-F!(POWF^51
MN/8>YSOUS[^./#:6&GWS:K%]EU"3R[:3:V';G@\?*1@YW8Q@TU/&VBSZ=JMY
M;R7,QTM=UU +619ER,CY&4'! X.,=\X!H Z*BN<T;Q?::EX<TK4YTGBFOXHR
ML MI-S.T>\A!MRP S\PR,#K6QIVI6NJVGVJT=VBWO&=\;1L&5BK JP!!!!'(
MH MT5'/-';V\DTK;8T4EFQG KS_5_%,&A?"4:EH>IW^I!T\NUO[F-Y78M*$+
MNVW (W'&X#. .: /1**P]"TX075S?V^HZI+9W2J%M+\R'RG4D%E\T;QGCCIW
M'6A_&&AI=+;M=M\UW]B$HA<Q>?T\OS,;=V>.O7CKQ0!N45SUYXX\/V-W?6DM
MZ[7-BJM<0Q6\DCJ&S@@*I)'!R1G'?%2OXPT)%TIOMI9-6Q]A=()'6;(R "%(
M!QV.#0!N45474[5M6?2P[F[2(3,GE-@(20#NQMY(/&<\'TJW0 45S.@^,K77
M-0UJ 0W%O'IMRT/F3V[QJ0J*S,S$87ECP2#@9Q5VV\5:/=7MK:)<R)+=J7M3
M-!)&MP ,GRV90&XYX/3GI0!LT5RWQ&GNK3X>ZU=V5Y/:7$%LTB2P-M8$>_;\
M.:=HOC70=0O;71H]1WZD\ =5>-U$V!\Q1R-KXYSM)[T =/16)=^+=%L;A8KF
MZ>-6G^S>>87,(ESC89,; <\<GKQUK2O[^UTNPFO;V80VT*EY)""0H'4\4 6:
M*YJT^('AB^U&RL(-3!GOD#VVZ)U27(#!0Y7;NP1\N<@\8SQ3I?'GAN'47L&U
M$FZCN([5XU@D;;(_W02%Z'(YZ<CGF@#HZBN8?M-K-!YDD7F(R>9&<,N1C(/8
MBLFX\7:):N1-=LD0G^SM<^2Y@63.-IEQL!SQR>#QUXJPOB#3&\0MH(FD_M(0
M^>83!(!Y><;MVW:1GC.>O% &+IOAC7K/3H])N/$<,^EQQ" !=/"3F,#&TOO*
MYQQG9FNJBB2"%(HE"QHH55'0 < 5S/B+7=%ET.Y^U:Q?:;#'=) ]S;))'()
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MDC12 J5:-UZJRL 58>A - %ZBN;OO%T%GXTM/#AMKHO-;/</*MM(RC#*J@$
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M2Y]5.F17)>[^R_; BQ.0\.0-ZMC##)'0F@"]:6L-C9P6EN@2""-8XT'\*@8
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ME &O169)XATJ.]TJT-VK2ZJKO9;%++,JJ&)# 8 VD'D\]JTZ "BBB@ HHHH
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M7:U<'<0(HU)VG#<YY_73:Z@D^,MI=J^;<Z!)&)L'8',Z,%W= =H)QUQ7=T4
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M.F1ZBO3:KWMG'?VKVTS/Y,@VR*IQO7NI/H?;% #;N<C2I[BWA^U'R&>.(?\
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MBBB@ HHHH **** "BBB@ HHKFM,U1]?\5:M%&["PT>1+8*IP);@KN<MZA05
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M/^6D><[6'< \CN#G'4@@'DAFU/4++PK>W.B:RM_9ZXDE[;1V3QPVJ_O!MC0
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M./E4C<.">>V>*/B):WB/H6LV^F2ZI;Z9=L]W90KND>)XV0LJ_P 17.<5V]%
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MA\.^)-&@U74+NVN#;W42F6X+VK@[^N<;3@@<9)]J .TO=?MK34QID<,]W?\
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M]$O8]*GBBOQ::G*((+I[8B(2,2%0MZDCMD=C@U/I?BJ?4?'&M:&=-N(X=/2
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MLS.BA9XAC)7!.#AE.&P>>E<SJ(U6+QUXCU'3=+GG=] 6&U,UNXBEG5G;820
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MMPJ$@(@;@$ +C').: .L\/>-AJD6O75_93V%IIMY+!YDH4A5C" @[226)+'
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M.YCCTG[1<2RW,#P\O'L6,;@"22<G&0 ON*Y(#6K^W\*7]YH&M'4K/6%DOHQ
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MUS<IIC)(0+=(!\F%S@[F!+9Z@X/ % 'IU%>:Z3XD/B_Q1H5G?@QV5UX?74A
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M'JZ2MIUQ)&H2X\LG.!NRN<<;@.HZ5C^$_B#J'B>]\4>=I%_%9V4C0Q^0\68
MBMG<2XRY(., @<<]Z /3**\N\&>,=!\/_"^#5&U'5[ZV>\>"$WH4W,TK-PB@
M,1^9]3Q76V/C.RO-1U32WM;F#5=-B$TUE)LWLA (9"&*L.0.HP3SB@#I*Q/$
MGAR/Q)!9PRWD]LMK=1W:&$+DO&<KG<#QFN2C^-/A^32;/5O[.U=--N;O[&;I
MX$"128S\WSY/&3\N>GKQ7I% "*"% )R0.3ZTM>0_$3Q/J4OBKPA:Z?,T.D3:
MW'$\B,0;ETD0-T_Y9@L1[D'L 3)JFLW'B#XM:_X?EGF33])T1Y8XXI&3]^PC
M;S,@C) ? ],9% 'K5%?/:?$36=4\"^"$NKN5%O-7%EJ=TC%&DC1T^4L.1N5^
M3WVGU-=EX.UB\L/C%XI\'^?+-I<4*WELDCE_()$9*J3R%/F=.@QQ0!ZE17E'
MQ/\ '6H^&/$F@W%JC_V/97@34I%Z,SH<1GW$9+_4KZ5W/BC2?^$E\,R6MK<W
M,;2A9()K2X\HYZJ2P_AZ$]>!QS0!O5C>*?#L7BK09]'N+J>WMYROF- %W':P
M8 ;@0.0.U45\+R-XI.HRWM[)!)8"VN(WN#Y<KC;M94'W&&&.X8.6X[T[PCK,
MU\VK:3>2&2]T>\-L\C=98R T;GW*D ^X)[T =%$K)$JO(9& P7( )]^*?17,
M^/[/[5X+U-TN+BVN(;=WAGMYGC:-@.#E2,_2@"UIWAJ.PUFZU274M1OII7=H
M4NYMZ6P<@LL:@# X YR0!CUSN5PW@[Q!=WKW?A#Q1A=?L$^=P2HO8>BS(1CK
MWQT/IT%WPSJ,.F>"_#P?[3=WE];1LD?F>9+,YC#,<NW89))('Y@4 =917#ZS
MXO\ #VH^$=>.J6NH""P8V^HV:KB>,]1RC8P>"&#8]ZM:AXIN;#Q=H>A6NE7,
MMO=V\DYE5H\LJ  *-S#IN!)/MC/- '745Y=HWB*'POJ7CB::TU.]M[;4_,D,
M"F4PQ"%"69G8<#DX!)]L"N[F\06P%JMG#-?S74'VF*&VVAC%Q\Y+LH ^8 9/
M.>.AP :U%<@?B1H?]F:??!+YDO+S[ $6W)>*?)!1QGAN#P,Y[9K?TC5/[7TT
M7GV"^LR6=?L]Y%Y<H*DCIDC!QD'/(H T**\PU/Q+=^)OA_XW>?3[NQ%@;N&%
MQ*J[#$@&TE'R6W9)X*]LFM_P]XMM"VAZ)-:7T,MW9*;6XEBVQ7!2,%PISG('
M/( (Y&: .PI#D@@'!]:YO4?&^FZ7 ;VXM[LZ6MQ]FDU%%4PQONV'/S;MH?Y2
MP4C/>M;7-5BT/0=0U:92\=G;O.R@\MM4G'XXQ0!3\/>&T\/-J1BO9[@7]Y)>
MR"8+\LCXW;=H'' XK;KB?!NEMK_AFRU[7Y9;O4-1C%SCS76.!'Y1(U!PN%(Y
MZD\DUI0,GA&TF2]O;J]^UW^VR1W,LSEU&V(%CSC#<D\*,D]30!TE8>N>&TUS
M4=*O'OKB!M-G^T0I$J$,^"OS9!.,$CC%,A\763W.H6<]M>6U_80BXEM)(PTC
M1'HZ;"P89&.#P>N*S(_B3I+VNDWK6.J1V&J,L<%VUN/+$C9VH<$MDXQP",\9
MH [*BN;M/&EE<76IVDUCJ-I=:?"MP\$\ WR1'.'0*3D9!'8CN!6=!\4-%F&E
M3-::I#8:FRQP7\MMM@$C=$9L\'MD C.>>#@ [6BN8U+QUIFF?VE));WDMKID
MJ0WUS$BE(&;:>06#' 92=H.,_6I;_P 8V5EX@;0ULM1N;\6GVM(X(,B1-P7"
MDD#.3U.!QUZ9 .BHKDG^(>E+X<M-=%I?M9W%Q]E<"-0UO+OV;9 6&WYN,\CW
MY%;TFJI'K5MI?V>=IIX7GWJ%V1JI .[G(.6 & <_@< %^BL7Q!XGL?#;6 OH
M[IA?7*VL1@A+@.V<9Q]#P,DXX%0Z9XPT_4)]5@G@NM.FTM%EN4OD5"L; D2
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MB\@=3Q@"M?P^SZRD-K<>!FT;4(HV2ZO)K6)8XVVD$PN#EB3TQ@ 9R>F?0J*
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MN<?437EGJ&DZYI6N7?A2XU;3Y](AL;FU2&.:XM)8RQ#!2<$'<0<'Z^E>IT4
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M@4!VG& 0V.E+XLLM9O)O#_B"WL'D;2M0,SV*$&5H&38QZX+C). >^.O7N:*
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MF./3<..M8FM^'[_7_$?C*VA@N((M2TB&UMKF2)EC:5-Y()QT^8#/UQFO3**
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M) /,NFOZ'XETOQ+%H%[>VEQI,>GWEG R&XMW1BRMC=@@[B" >*L^(H?$AO\
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M:L]U;O*N!)&410>O!RIX.#0!<L?&MEJ/A)O$4%C?"!9#%]F98Q.7#^7MV[\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MH\%S;W9AD1=KRHN&^<CY=P/OCL>E=GH_AVVT2\U"ZM[BYDDU";S[@2LI#28
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MI8] 2>@]:N)#XB\*>-=9N+30Y=8TS6&BF1[>:-&MYE0(P<.1\IP#D=*]!HH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M9PX1TP <GDCJ.#F@#T2VOK2]\S[)=03^6VU_*D#;3Z''0U.S*BEF8*H&22<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M*?'=N-+L[*VURR2.T$<X*HXM_+V%0HQSU/3TS7IE% 'G%UI'BR*V\,ZY8:9
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M1'4DJ#G&7!'TYQ5SPM)XP:TM-+UO2;:T2T01S7T=TLGVH*,#8@&5SP26QCG
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M79@HP,H  ,\$Y[5J^'KGQ9>-%_;^G6>G+ N)#!<^<;E\8R!@;%ZG&2<X[9R
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M<BZ. 50.5V[.<@C!R,^U5?%/B86W@[7-1OM @U#3[2<P^0\P9;A5<*68,F
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MDXJS/HVK3>)_!VH"QQ!I5M/%=9E3(:2-$&T9Y *Y/3@_A6>/#6MGPQXXT\V
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M^36%C%IB9,DK"(OFYXYY[\>_% &D/&<%Q'X;6QMC)<:_"9[9)7V*D:QB1BQ
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MBBB@ HHHH **** "BBB@ HHK&UB>:\N$T6RD:.:9=]S,AP8(,X)![,V"J_\
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M?%4[VT2263S6C^7()8V>-A\Z-@9!!!''>M37HT_X6!\/9-B[\W8W8YQ]FZ4
M=[17"2^.-:>'Q(]IH%L[:%,RRB6^*B1%C#G:0A^8@]" />IX_&]ZUUX=GFTA
M(M(UUDCMYOM.9D=XS(NY N " >C$^N.E ':45P^K_$ V<&H76GVEO>PV%PT$
ML'V@K<3%6VOY:!2#@YP">=IZ<9G;Q?JMUXEN-$TO1899%L([Z&:XNC&K*Y(&
M\;"5/!X /X4 =C17FVJ>-]4U+P5X<UG2K:*U;4=4@M;B.68[D(GV,@(7H2C
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M1(GE^9\N$)W$'IC'O0!W5%<S!XM&IG1X-*MUDN]3L!J(6=]JPP$+RQ ))RX
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M409D6^.[')'D B@#LK:_L[R2>.UNX)W@;9,L4@8QMZ-CH?8T27]G%>PV4EW
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M.12N&7)R!GD<Y'2@#M:*XNUUS6'^)FKZ=.+0:99V4,H_?,"BL7RY&W!;Y>G
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M45V-10V\-NK"&-4W,7;'5F/4D]S0!C^&-3U?48M076+.UMY[:[:%#:R%XW3
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MSSVKOJS7T'3I-;366@<Z@D?E+-YS\)G)7&<8SSC% '&7_@[73I][>6AMFO\
M4-8CO[VR:8K'-;H-HMR^.X ).,$Y'(ZZ7AW1M6TCQ;K^JZA%IUO8:C';%!#,
M3Y1C39LP5 QSUX^G/'9U3U72;#7--FT[4[9+FSF $D3]&P01^H!H Y/P5X?3
M3M?UZX@N/-TR*[DBTZ+'RP;]KSA?;S!CV*$57B\,ZXN@^.+)K:W$NNSW$EJ?
M/X42Q",;^.",9XS7<V5E:Z;90V=E;QV]M"NR.*-=JJ/0"IZ .$N/#NM2)X)V
MVUOG1&5KK,_7$1C^3CGKGG%1Z5HWC+PW?7VEZ8FFW.BW5U)<6UU/*RR68D8L
MRE /GP22.1GN1V[^B@#DK'1]5LO'FL:RUO'):7-E!;Q'SAYC-'N.6&, '=7/
M6?@OQ!9^!_"NGK#9OJ.AZFMV\9N"(YDS)D!]I(.)!U'8UZ=10!Y_XL\)W_B=
M+N.ZTRT^W+L.EZK!/Y<EHVQ=VXX#;0^X@#.0>@ZUVUREVNDRQVTJM>B K%)(
M.#)MX)_&K5% '!Z7X3N++Q8FOV>EPZ2[6LB7]K;S@Q7DIQL( &  =QW$ G/3
MK6;!X-\00_#?0?#_ -GM3>Z??Q7$K?:/D9$F,G!VYR0<=*].HH \TU[PGXGU
M4>++?R;"==4BVV5W/.P>W38!Y 3:0!N!.00.<G/2M>YT37+GQ%X/U)[:U":5
M'.+M4G)YDC" )E?FQC))Q7:44 <MX9T?4M-\2>);V\AB2WU.Z2> I+N("QJF
M&&!@\9XS1XDT?4KCQ/X=UW3X8K@:6;A9;=I?+9UE15RI((R,=#C/K74T4 <!
MJO@2]UNUU^^>YCL]8U%[:2U*G>MM]G(:($XY);); XS@9QD[OAZ7Q9=.K^(;
M73[)8EV[+.8RF=_[W(&Q>O'))/48YZ*B@#EO&>CZCK#:#_9\,3BPU6&^F\R7
M9E$W9 X.2=WL.*9;:3JD'Q#U/76MHC9W%A%;1@3?/N1F;)&, '=CK7644 >7
M:;X0\4:=H7ARR:WL+F/3[RYEO+%[HK%<"1V:-MVPYV%LX(Z\]A1+X!\07>AZ
M]:/+86]W)K?]LZ?*CLRF3*D*XQPORD9YZYP,<^HT4 <(=*\2ZOXPT+6;_3+"
MT@M+6XM[F(7I=OWFP97"<_=X'ZBH_"^D>-/#]M#X;?\ LZ72+5MD&I^:WG"#
M/"^5MP7QQG.!UYQSW]% &%XR\.KXL\):AHAF\AKE!LEQG8ZL&4GVW*,UES:-
MK'B.7P__ &Y:V]J-)NEO9FBFW^?.B,J[.!A<L6.<'@#'>NQHH \Y/A376\*>
M--,-M;"?6[RXGMC]H^55E55&\XX(VYXSUKNM)BFM]'LX+A%2:*%$=5;< 0 #
M@]QQ5RB@#S"[\&>(W\$>)O#<<-BPO[R::UG-PPW+)*)/F&WY<#(XSD^G?H;S
M1]5N_''A[6!:PK:V-K/#.#-\V90OW1CD#;ZCK7744 >?>&]%\9>&X?\ A&X1
MITNBQ2-]FU)I6$T,)8G:8\89QD@'('3.>E=-XO\ #X\4^$]2T0S>2;N+:LF,
M[6!!4GVR!6W10!YY/I7C+5I_"\M]I^FQ3:1>"6X<7K%9@(V0LH"<9SG!_P#K
MUGZCX/\ %=YI>JVCP:;<74FJ)>1WTMRP>>)9E=(R-GR!5&.I QP.<UZG10!Q
MW_"/:M_PG%[J3Q6CZ?J>G16MT1,P>)D+[@J[?F!#\'(Q^AJ>%=,\:Z):VOAV
MZ_LV32[+$<6IK*WFM I^5/*QC=C"YS@>^.>\HH \_P!5\(WVLZS;Z@^GV]EJ
M]KJ(DBU>VFVEK429V.H +,8_EVG([Y[5TOB_3]4U7PGJ-CHMT+74)HP(I2Q4
M=02,CD9 (R.F:VZ* ."T[0=>M?&=MK8TK3+2T72#8M:07))B/F;Q@[ &ST[8
M]^^=#X-\00_#;0_#WV>U-[87T5Q*WVC]V528R<';G)!QTKTZB@#AK/1/$.@>
M*]:N=.MK2\TS6G6X99K@Q/:S;0K9^4[E.!TY_G6G\/\ 1M1\/>"-,TC5$@6Y
MM8RA\B0NI&21R0.>??ZUTU% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV8WAT0Y W!6 (YSV]P 6AXMU33]7D74[)Y](6RENGOH=/GMQ;M&"Q1Q)D-D
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M0=_T% %.\\9:KI7AW2O%%];VATB\:$W$$:L);6.; 1M^[#XW+D;1UX/',O\
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M[1@L582$[@0#@COQ6!XJO=8U;PYX2U:Y:SCM;W6;"?[*D;;XE:0,GS[L,<$
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M *YGQ+X5?5]2T[6M-O%L=:TTMY$[1[TD1AAHY%R"5/L<CJ*Z:D) !). .I-
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MTZ]_L^:RNRIMI)58RV+;%4LG'S'(+#E>O.0<5TEYI[7.AW&FQW4L32VS0+<
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M2UP\JE6/! 0?,2  <<#H*2U\,ZO87_B>_M=4MDN=8*O WV8D6[I&$4G+'<.
M>U '36@N!9P"[:-KD1KYS1 A"^/F*@\XSG%35#:)/'9P)=2K-<+&HED5=H=L
M<D#L">U34 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !2*JHH55"@= !BEHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$$\-S9"0!L$%UPX )ST(/W1[YVM/TVWTW1[72X@S6UM;I;H)#DE%4*,^O H
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M66)R"1@D8(*@@\_0UBR?#>9O#NIZ.-><QW^IG46DDM@Q0^:)-HPPSRHR>_.
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M\5ID4@Y!XYSQCWR,B@#MZ*XV]U346\2-X;M;C4':VL5NI;JW6V\YV=V5<^8
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M>*-%)C3>=I^9@<MDXSU/-9VLZKXST3P-XGO+F7R9;(^;I]W-'"\LD1ZAU0[
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MX*5 9]QRH!Z  G R3CFE9?#Z73+ZYCL/$-]!H-S,TTNDB-"N6.659"-R(3U
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M,K&(P0I'S9)^8Y]?:M73M1.H&[S97=K]FN'M_P#28]GF[<?.G)RASP?8U=H
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M76)I&78NU21QDNS''/ QQF@#T>BN?\)Q:_;6EY;Z_-'.R7+&TDWAI# ?NB3
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M'!<?*#CJ <'/-=5X+UBTUO2[F[L=5FU" W+!1<+MEM\*N8G& <@YZ]B.3UH
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M@8 H ]%HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M8  &=N.@QG%)=>$()[C2KZ*^N8-3TV(PQ7B!"TD9&"DBXVLIQGH,'D8KHZ*
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MH=@CD070C(D 7YLJ?8#C '.?2K3PVD-Y;WMWJ-YJ%W:PM#;37/EYB#8W$!5
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M7M#LM5M3FWO(5E4'G (Z'W'0_2N6^%-Q))X/ELW)*:?J%S9PD_\ /-)#M'X
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M9ZG<M<S SJQ4EMQ"EE/!(!R<GWH B\1?\E1\#?\ 7/4/_125)\6/^26^(/\
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MLT31?<8';M) XY%-MO!-I:ZEJ6H)J>J-<ZC;I!<.\RL&*@@/C;C=ACQ]T9X
MH B^&7_),O#O_7C'_*L74+Z]TOQ/XCTF[U2]$=YIZWFDNLGS1N#L:-/5M[1D
M YX8"NR\/Z)!X<T.UTFUGGFM[5-D1G*E@HZ#*@9_*DU+P_I^K:II>HW<1:XT
MR1I+<YXRRX.?4=#]5!H Y+PCJ]YX@TO0K2:ZN8]1LGE_M?\ >G=YD1,91O\
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M8 NLF/C";!M^3CY>.<_GS0!SUEXCU/7I/#6G;L27NA+J=SLN#;M*YV#"LH)
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MF,2R*AD<1H"?O,>P]^#^5<?XDEEF\03VL6H7DA33"Z6%C(T+0N6/[^20,..
M IST) /-<GYL_B&Q^%VH:A=7+75U*1,\<[Q[CY#G=A2 &XZCGDCH: /4UO+I
MM:DLSI\BVBP+(M[O7:SEB"FWKD  YZ<U=K@IM5O=)^(>MQM=W5S96N@+>QVK
MOE0X=P<<=2$')R:Q[_5=4M/A38^.;?4[F35%CAO)XS*Q@F5V4/%Y>=H #8!
MW?*.<YH ]5HKSV.WO]9^(7B/2I=<U2"R2RM98XX)A&8F??G:0,CH.G)P,DBM
MGX<:I>:U\/=&U"_F,UU+ 1)(>KE6*Y/N<4 6Y?$I?5+RPTW3+G4)+':+IHGC
M149EW! 78;FP0?09'-7M$U>+7-*COX8)X%=Y$\J==KJ4=D(8=CE37&:YX8UR
MV\0WWB;P-JD2WTK*NH:9=<P7+*HQS_ ^W'/?U'.:MOXYFUK2M"@M;+^S+F_U
M6:QOX'F,?E2HKNZ"0*2"S8Y SR1P>0 >FT5YIK%WXC\%:-KUY<:C";.:2W%@
MDER]S)9[W6.1B\B@LHW;AG.",=*Z2;P_-;W\TJ:[>_V=<63026<MP[.\O42)
M(6W(=N00N!WH U;_ %22+1Y;[2[-M4D5MJ00R*ID^?:V&;CCD_A6E7C%L]WI
M/[.MIJ6G:C>VUT(8'WI.3UF"D#.=HPQ^[BNVDU"36?B->^'I9[B"SL=.CN-D
M$S1--)(Q&XLI#84 # .,DYSQ@ [&BO'M0UW7X_"FLVO]K72W.CZ_%8Q7BX#3
MPM)'@2'')"O@XQGC-=3IK7NE_%6;2#JE[=V=UHYO62ZEW[)5F"97@!00W08%
M '9W,XMK:28QR2!!G9$NYF]@*S_#>O6WB?P_::S9QRQV]T&:-90 P 8KR 3Z
M5JUQ7PC_ .26:%_UR?\ ]&-0!VC,%4LQ  &23VK T+QCI>O:9JFI0,T5EIUS
M)!)-,-H8(JL7'^SAN]4?&6L?9KBTTR;3M5N+"X!DNWL;*2?<@(Q$=@.-QZY_
MA!'\61YJ^K'4/AU\2[>SL]0BD?4+BYS+:O&JQGR@RDD8#A0<KU H ]7L?%UM
M=W&FI-:7-I%JBE["6?;B; W8(!)5BOS 'J >AXJ.\\96UK!J%Y'975SIVFRF
M*\NHMI$97&_"D[F"9^; ['&2#7/>.,/IW@%;/ECKMB8MO]P(Q;\-M4-1@U;P
M-X0\6VD]I#>:==27$UG<"?#$S\")DP26W-@8R#GM0!ZC#-%<P1SPR+)%(H='
M4Y#*1D$>V*R_#GB73O%-A->Z9+YD,-S);,?]I&QGZ$88>Q%<\(K_ $+X9Z)H
M(2:359[6&P"0E=ZG9^]*DD#*('(R<9 ]:R-"E_X1;XI26 TRXTW2?$-N&MXI
MMF%N85PP78S  I@\\DB@#U"L6_\ $MKI_B72M#DM[EKC4C((I0G[M=B%VRQ/
M7 [9ZU#=>*?LNNC2_P"P=<FS(D?VN*SW6_S8^;?GH,\G'&#65XI_Y*/X$_Z[
M7O\ Z3F@#J=1U*#38XC(&>6>00P0I]Z5R"<#\ 23T !)Z5G67B3[5XLO?#[V
M,L,UK:QW)E9U*N')'RXYQD'K@^U8=Y.]S\;M,LI"?(M-#FNXAV\QY5C)^NT?
MK5&[TI]8^+>KVHU*^L4.BVQ9[*01R']Y)CYL$@=^/Y<$ [G4]4BTF)+FZ4BT
MW!99P>(<D ,P_NY.">W4\9(=J.I0:9!&\VYGED$4,2<M+(>BK^1/H "3@ UQ
MGABXOM8\!>(M+UJX-Y)8W%[IANG&#/&@(#-[X.#]*YWP7JUWK>O^ 5OF9O(T
M":Y4M_')N$.X^IV@_P#?1]: /4=6U>WT/1)]4U [(H(][JGS$GLJ^I)X'KFJ
M</B>VD\/:;KLD,D6GWL,<K2,1_HXD *E_;G!(Z=3QDCDO%_B%&N=8@O=)UIH
M;*VECM#%ITKQ-(T1#3%P-N &*CT^8]QB[X2F@UOX,VUL]O<1Q#2!:R"XA:/?
M^X ++G[RG/##@T =Y4<=Q#++-%'(K/"P610>5) (!_ @_C7-_#B_N-3^'.@7
M=TQ:9K1%9FZMM^7)^N,UQ-E>MX5T?XCZY:M<S7-EJ4HB66X>123'%@L"<'!/
M4\X&.E 'KU-=UCC9W8*B@EF)P /6O/\ 6Y[[PU'X7U:QU*\N_ME];V=[%/,T
MB7"3#&\*>$8'!&S YQTK7^)<(F^&WB#+R+LL97!CD*$D*3@X/(]1T/>@"YJ7
MBB+3]7T*Q6TEFCUB0I%<JRA$PA?D9R<@>F/>M^O,-9L?+E^'5O!<W$9DNB?-
M:0R.N;9LX+YQ[=AZ5#-XAU'PM;>.[9-0N+F/2Y[06DM[+YCPBX5 Q+$'(4L2
M,YQB@#U6BN1T_2M?L?%-M=_;HDTF6%H[BUFU"6Y:23&5>/>@VG@Y .,<XXJ+
MXA7-_:)X<:QU&XLS/K=K;2B(C#H['(.1STZ=/4&@#LZ*\[MK"];XA:MX<;7]
M7.G/IT-[@W)\Q)"[H0KXRJG .!CGVX-30]9OK_P+X?\ MNLW/VA]2FMG6,$W
M%^D;RJ(U8$%3A5+-D<*<D<T >GT5Y]X7_M#7-/\ %>DW.H7]JUIJ4D-I-]H+
M36RF-&4%\_-@L>I/IDTSX<ZI>:Y+*NJ7\IO])B6U>!)GV7(.2MT0?O!Q]WMP
M3W& #M["\NKJ:]2YT^2T6"<QPN[JPG3 .\8Z#)(P>>*NUY7)J6KKX0^(T@UF
M]^T:;>7'V6?>-\:K"C!1Q@#)/0"K%RNJ6NN^"S%K^I_\3F*2&\5I0R$"#>"B
MD85@1UZ\\YH ],HKR/4K_4]*T7XBV$.KZ@XT;R9[&>6X9IHR\(<C?U90<X!S
M72:A?7D7C?P5#'>7"17]M=?:8Q(=LA2%64E3QD$DT =Q17CT\VL2>!_&FIGQ
M%JHNM'U2\%HR3!0!$5VA@!AACC:>/;-;[3:AI_C;PA+_ &M>SIK45PMY!+)F
M+*P^8I1.B8(QQVZYZT >A4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4C LA 8J2,!AC(]
M^:6B@#DV^'^F-X7N_#K7E^=/NYFFE!D3<69][?-MX!;FM&;PS!<:]IVLS7MX
M]W81O%%R@4J^-^X!><X'Y<8K;HH Y&Q^'6CZ;JLEW:7.I16LDWVAM,6Z(M/,
MSG=Y?UYQG' XXIEW\-M%O(-5MGN=22UU*X-U+;QW16-)BP8NHQU) .#D>@%=
M7+=00300RRJLD[%(E/5R%+''X FIJ ,*/PM;0^(1K:7M]]L6S^Q M(K#RL[N
M<J23NYR3G\.*SV^'VF-X;GT!KW4#8S7/VIQYB;B^_P SKMZ;P#_]:NMJ&YNH
M+.'SKB58X]RIN;^\S!5'XD@?C0!E+X9A7Q&=>^W7AOC:"S))3;Y8.[ILZ[N<
M_P!.*Y/Q#X:BT+P_8Z7:Q:[<Z:VHFZN+BQ?=<VK?,^Y @!.7(SP<#.!TQZ/1
M0!PWA2SN4U9+BRU;Q-=:?L83KK:%03_#L#HKYSWZ8SWQ72:[X>LO$$-L+HRQ
MSVLPGMKF!MLD,@[J<$>Q!!![BM6B@#*L]"ALY;NY%U<RW]VJI+>R;#)M7.T
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M\+V<OB>V\0+<7,-[!!]F_=,JI)'G.UQMY&?R[8K6ENH(9X(9)566=BL2GJQ
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_8QM8;%BSN"A<8^]SGK^'%4!X"T;^P)-&+79M7NOMBMYY$D<V_?O5AR#NYH
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M"<[A@8] ,=.*EL?!^F6FD7NG2R7M\E["8+B:^N7FEDC((V[B<@ $X QU)ZT
M<IJHGTKPYX$:QOKZ%9]4L(ID^TNPD1URRG))V_*.,X]JT=.F?Q7XG\565W=W
MEO'ILL=K;QVUR\)C!CW&3Y2,DD\9R %'OG4?P1IDFFZ98-<7[1:;<)<V[-<%
MF$B#",2<YP. .GM5FY\+6<VLR:O;W%U97T\0AN);60+YZ#IO!!&1SA@ P[&@
M#SJVUO7=6T/P9+<ZK=P7,FM2:=<RV[!!<HGFC>1C!)V#KQD'BNK\(&XLO&WB
MS13?7ES96OV2:W%W.TS1F1&+@,Q)QE0<9XK7N/!VE30Z3#&)K:'29!+9QPO@
M(X!&XY!W'D]<YR<U9LO#UI8:]?ZS%+<&[OU1;C>X*L$!"8&., GIZ\YH Q?%
M>KR0:Q:6$VC:O>:<J"YF:QLVF65PWR1L1T (W$=_E'3(KS"XU%]0^#GBN&.Q
MOX436'GE:: HIC:[!90?[R@?,.U>_P!95CX<TRPTN\TV.WWVEY+-+/%*=P<R
MDEQSV.3Q0!S'CD-+XO\  :6_,IU-Y!M_YYB([_PQ7-ZS8:WX-^&>L>&6MK6]
MMKF26UTV99R)9?M#G">7MY<%V/7&!GM7I&G^&[+3[N&ZWW%S-;0FWMFN9-Y@
MC.,JO'? RQRQP,DU,NB6K:G'J-RTMW=1 B!YR"(0>NQ0  3TW8SCC.* .?U>
M&XLO"NC^&4AEO+FXACMIT@90S01JOG$%F48(^3.1S(*QO#-S)X>^)VJ:1-83
MZ?8:^IU"RBG,?$Z "8#8S#D8;KVKN?[%A_X2 :R;BY-P(3 $+CRPA() 7'&2
M <]>!SCBJNM^%;#7]1TZ_NY;I+C3G,EJT$NS8QZGISG &#Q[=: +7B"X%KX=
MU*<Z@FG;+:0B\=-P@.TX?;WQUQWKB='N;ZW\>Z18K-J265[H\KN+RY9VE=&3
M$NQF;RR=QXSGGD#%=YJ>EVFLZ3<Z9?Q^=:W,1BE4G!8$>HZ'Z5B6O@32K6_T
M^_%QJ4EY81-%%-+>.[%#CALG! VC Z>H- 'G<\VJ1?#36/$']O:LU_IFJS+;
M$W;;=JW(3:ZCAP5XPV0.V*[>&\;Q#\0M=T>YN+B*TTFVM_+A@G>$R/*&9I"4
M()P H S@<GKBK;> =(?P[>:"TMZ=/O)S/.AFY9RV\_-C(RV#Q_C5B^\&Z=>Z
MO;ZO]HOK?48H?(>YMIS$\\?7;)@8(S[ T 8_PFC,/@DQ&1I"FH7BEW.6;$[\
MGWK-\5ZK=Z-KNI2:TNIQZ),8EM-5T^X?;8':H*S1JPX+9.X@Y# >F.U\/>'-
M/\,V,EGIWG^5)*\S>=,TGS,23C)XY/:J][X3LK^74//N;PVVHLK7EH)!Y4N%
M5,8(RH*J =I&>] '*II:ZU\3/%L)OKRWB.GV1W6<YB8G$F#O7GCT!P>^:KZ%
MK%UK'A'P3+?:I=RW5U'(9+.W)66_**5R9 R[57AF)."<#J0#VL/ABTM]9O\
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M" $[2H8X);&20.V,"K%W\.- O(M4@D-\MOJ4_P!IF@2[=8UE+!BZKG 8D T
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M]G?S63)YN_)C(!;.!U-8-OJ3^(?'W]C7LDBVMKI$5V((Y&C$TDC8+G:02%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %95GJ[:H]ZVGQI);VS/
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M:*\"69SM)7YS\KD'Y>F0>* /6ZY[QOXANO"OA*]UJUM(KI[8*3'+*4&"P7/
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MF\.26T"VRZ8+Y)E<EV)DV8(P .A]>W-:VJ-J:VT9TJ.U>;SD#BY9E41Y^<C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M.=082M=Z=K-XUG,TSEH"CKM*\\'WZD<5[;!;06MK':V\20P1($CCC&U44#
M Z"LC_A#]!_L^\T_[#FTO93-<PF:3;*YZLWS<D]_7 S0!SD,Z:Y\3+G2=9AC
MGM8-'AGM;:90T<A=B))-IX)'RKGL,^IKC;^U,N@W&GWD8NK+3/&$-I8/<#>4
MA,B;HP3R5&2OTX[5ZW=>&M)O/L9FMF\VS4K;S),Z2QJ1@@2*P;!],TZY\.:/
M=Z*='GT^%]/)#>3@@;MV[=D<[MW.<YSS0!9D":?I<GV*W3;!$WE0QK@9 .%
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MQM)O&?@&S1 MF9;M56%M@V?9SP"O8CT[5UK^'M+DL[^T>V+0:@Q>Z1I'(E)
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M-<[O/7>VZ;=P2[9W,2."2>1Q5>;PIH=SI=GIL^GQR6=DZO;1NS'RBHP-ISD
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MS3L9));&%I&;G<2@))KRI+"PM?AM\27@M+:&9=0U&%62-581@KA!CG:...E
M'L-C<&YLK>5RHDDB1V5>V1FI]ZAPFX;B,XSS7F@TRSTCQ_X%GL(%AFO[2ZCN
MY%)W7 6%&7>>K8/3-9>CV<'BWP@NIWVKV=CJEI>O+<W,=K_IEO.LA^0N7SR,
M*%V\J0 * /8*:'# [&4GGOWK.\1P_:?#6J0?;38^;:R)]J'_ "QRI&_\,YKC
M?"V]/$LVA:_X?M;'53IQQ<6!'V:]@5U!., JP)'![$^U '<:2=2.EP'6#:?;
M\'SOL>[RLY.-N[GICKWS5VO(=#T33M>^ .EP7X/GB)S:2HH:59S*VS9GJ2V
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M9+:8D[H'4H0R?W3GJ1R>]>S6I^U:9 9?F\V%=_OD<T 6-ZY W#)X SUH9U0
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M$""Z>-8FEQ\Q122%SZ98G\:+2RMK&U6UM8$A@7.(T&%&22>/J37)>)O&IM_
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M65E-/_K'@A5"PZXX[>W2@#6HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M4=E%\9]9,J0([:7:LA8 $L9)!D>Y.!0!I^"/$LVM^'8+K5I[1+Z:ZN(52/Y
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M#L#D>6H .!R=H[5TWB::'P=XOM/&-M;^?8ZG#]AOA NXO)C= XQU)(V9]UH
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M]L_[/>V8F#;F5WR,.K9QM /IW%>.Z:;2;X9^ Q(T$OD^)(XV)P=J>?, /9<
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M#=0QZ38I%=Y^T(MN@$V>N\8^;\:FN=4T^RGB@NKZU@FE.(XY9E5G^@)R:MT
M9Q\/Z*1:@Z18$6@Q;?Z,G[D?[''R_A4MOI.FVEY->6VGVL-U/_K9HX55Y/\
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M'48HH4N+XKYIAB$8(4L06Q]YLNV6/7CTH Y?Q1):VWQ2\'S73PQ1?9K\%Y2
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MBO,#?VE_\$?%B:H\/]M+-=&_CF(#B?S#Y?!YX4(%_P!W Z5[4B)'&L<:JJ*
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M:)5&TGKU[XK>M;:&RLX;2W01P01K'&@Z*H& /R% '(^*K75G\1VE[X=OK/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MZ?2UU.*_MGL&7<+E908R,XSNZ=>*-/U73]5CD?3[V"Y6)]DGE.&V-Z'T/L:
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M=<$2M$I88Z<XS2_8+/[7]J^R0?:?^>WEC?Z=<9J*74[2QLX)KZ[B@\Q0 9&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *9*_EQ/(59@JD[5&2<>E/HH \.@US29K/
MP%=VMY:6EE%JWRV$3[OL:LDO$KL2V\GUP#DX!QFM>)-/>V^*[E;8G,BDX7./
MLPX_[ZS^->J+:6R_=MXA\_F<(/O_ -[Z^])]BM/F_P!&A^;K^['- 'E>CZQ%
MI_B;P1<ZM<I'I<WAE8;2XE8"-;L["X+'@,44#GZ5N?#J\L9]=\:):3P2;M8:
M8")@=RM&GS#'4$YYKN)+*TEM_(DM87ASGRVC!7/KCI4D<4<6[RXT3<<G:H&3
MZT <#J<=@?C=I?VQ+<E]$F\OS0/F<2KC&>IQN_6N8C;3] M=6N#:P'1[KQ7%
M_9LDC%;>VD &Z<[2,QJZL,9 )&.!S7?7OAJZO?'\&MS16,VGQZ>]DT,K%F;=
M(K[L%<<;<8S^-=*]M!);_9WAC:' 'EE05P.@QTH \R\.W]E)XK^(,<FI0W?G
M06THD.T+(HMR&8 <;0<#//;DUCZ9J2:=X<^%=[>2JNAQ;UNI2?W<<QB*PEST
M&&+<GH:]E-M =V88SO 5OE'S = ?I2&TMFMVMS;Q&%_O1E!M/U'2@#A/#>H:
M=<_%[Q2;2[MI3/9694Q2*?,*APQ&.N. ?2I_B,\$=]X,:1HU?_A((,%B <;)
M/ZD5VL-M!;_ZF&./@#Y% X'0<>E++;P3D&6&.0CIO4'% 'FUFFGOXR^)C.ML
M2+>W4D[>%-L=P^F1S]*Z3X;2B7X:^'6#A\6$2D@YQA0,?A71?8[7+'[-#EOO
M?NQS]:DCBCA7;%&J+UPHP* /$?$FM:9<^&M:^S3V^GB'Q"CRV.[=,SK<('FD
M+$E5/4   <<G.*]NBFCF@2>-U:)U#*X/!!Y!IAM+9C(6MXB9<>82@^?'3/K4
MI4,I5@"",$'O0!XC'/#_ ,*BBN?,0P6WB7SIG!R(T%Z3N/H,$'\:ZNVUC2[W
MXU,\%];312>'@BNL@*.1<$D*>C8'7&>A]#7?"TMA$\0MXA'(,.FP88>X[T):
M6R#"6\2C8(\! /E'1?IR>* /$(QIX_9XM& M@?[24Y^7K]N(S]=GZ>U=M=?8
MX_C+IT,?D*'\/S)L7 ! E0J,>F,X'UKN/L5IMV_98=N<X\L8S3)K6-49X+6W
M,X7";AM&<8'(!(_*@#Q*TT_3M2_9[TZ&RCMVUEYD6T,0'G?:?/P,$<Y"]?11
MZ"O8_$*VI\*ZJNI2.EF;*87+Q<,(]AW%??&<5E^!O"[^&/#5CI][%9R7MJC1
M_:8!DNI8GJ0".N,<]*Z=E5U*L 5(P01P10!YMHLVLV^KOH6H3V>MQ/I$LEAJ
MULNV3RLJ-DJ@D<G;AAUP??'-0:YI;?#SX<0"_MS+:ZK8_:%#C,&W>#O_ +O/
MKCH:]IM[.VM-_P!FMX8=YRWEH%W'U..M(EE:1DE+6%29/-)6,#Y_[WUYZT >
M?:4-.D\=_$9G^S,/(M0Q.W[IMSN_#IFN<MVLX?A1\.I5:!&&KV+%P0#NWD,<
M^N.M>R_8[7+'[-#EOO'8.?K2?8K0J%^RP[0<@>6,"@#%\=Q:A<> ]<BTG>;U
M[.01"/[QXY"^Y&<>]<AK$]GK_AKP-)H,D9O$O[1[98B-\,:KB8$#D*J@AA[
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M]_:#X%^*K$W,7VN&ZNQ+#N&Z,FZ. P[9[9ZUV%^;*W^*?@U;4P1J^G7B 1D
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M5ZAX6GBN?"6D2P2I)&UG%AD.1]P"M"2QM)I3++:P/(4*%VC!)4]1GT]JG
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M-N;*:\AOH'M8&999MXV(5X8$]!@]:2PUO3-4DN([.]BEDM\>=&#AH\\@LIY
M/8]Z\TO_ !);:M\,-.OM,MWCCTF_MSJMC;-ND@6)_P!YCJ6P0'![@9]:-;71
MO$NA^(-3\(7=UJFK2:0UN]Q'([#R]P;RB.!O(W8&,]>F1D ]&MO$>C7=PUO;
MZC!),(S,$5N70=67^\ON,BD/B71!ID>I?VK:?89'\M+CS1Y9;.W&[IG/'UK
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M9\+W?AS5O#FE>'];N+\Z_I\Z*^EM(ZR"YC;AP .G\1;. "<T >C(-=7QP_\
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M3T&9&87$>Z>4G)4-C(QM X&3G%=C:ZE9P_&.\:6X1!?:+;?9=W!FQ))G:.^
M<GT'/2@#I-#O[5['4;O_ (2&+4[9+N5C<90);KP?+W+P0H[GGUJU:Z_I-[+-
M%!?P-)#'YLB%MK*G]_!Q\O\ M=*\CDEDG\">*Y=.Q<Q6_BV6YNX8#N+VRSJS
M8 ZC S[@&NOU::UUOQ_X0U+1KN&=;:.YFN[B%PRK;-&  Y'8MC /H3V- '1I
MXS\-226B)KM@S7;F.WVSJ?,8,5P/^! @>I'%;,LJ0Q/+(P6-%+,QZ #J:\--
MQIZ? 6[=)K99/[7WY5E!S]N!!^NSGZ>U>YB6,Q"4.IC*[MX/&/7/I0!YS8>*
MCKYO]27Q3#I46G:I(ABD6,PR6L;!3NW8.6Y(;=QD8KL;;Q3H-Y]J^SZO9R?9
M8UEG(F&(D894MZ9KSG2]0L9/A=\0MMW P-WJQ'[P<[@VW\\C'KFI]9$<'PW\
M&ZK8Q1O86EQIT^HM H;-N@R2<=0KD,1VP3ZT >BVNO:5>?:!!?PEK8!IU9MK
M1 \@L#@@'U/%5$\9>&I)+-$URP9KUBEMB8'S3N*\?4@@>I'%<]=M!J/Q3T35
M=*NH9+>VTVX&HW$4@*>4VWRE9AQ][<P'H":X9)M._P"&>;-?,M<G4E)&5Y/V
MW_XC]/:@#V/3O$6C:M>7%GI^IVMU<6_,L<4@8J.F?IGO5N\O;:PA$MU,L:%@
MBYY+,>@ ')/L*XF:YLU^-FF+%/ "V@RH KCG]ZA4?ED@5I>.K>WN;;2HVUE]
M'OA?!K"\ 4JDXC?A@W!!7>,=\B@#=BUK3)K"2^2^@-K&YC>7=@*P."I]\G&.
MN>.M5QXJT$V%S>MJUHEO:OLG>20)Y3?W6!P0?8]:\SO]<U,:)9:IK-NJ0:5X
MA*:G=Z6&,<R"(H+A1R<!F7/7E?7I/XCD\+W7@WQEK.C7CWDEWIWE7%Z\Q,<C
M@$(@SP7 ].1D9ZT =\WC7PPK3*VNV ,,BQ29F'RNPRJGW.#Q['TK3FU2QM[B
M*WFNHHY98VD1';!95Y8\]AW]*YRZ\/:?XE^')T^T$""[L8Q#/"!\KHH,;9']
MU@/UIG@?4;OQ!IZ>(-5@:VGC@%F4D&-KH?W[CT!D&/\ MF* -30]1M(_#[WL
MOB&+4[599";]BBIC>0%RO!Q]W/?%7K+6M-U%+AK6]BD^S'$XSAHCC/S \KQS
MSVKQS3]22Q\!Z%JJGS]+T[Q+/-J A^?RXC++M<@=E+*WY&NH\3W.F:]X3\2Z
MEX2@6^NYH(3=75J"?M"QN"8@?XF\L."!TR!WH [FQU_2=2NWM+._AFN$02&)
M6^;8>C 'JON.*L7NH6FFPK+>7"0HSB--QY=CT51U)/H.:XGP]J'A+Q/XATW5
M]*OKK4=2MX7 +2-_HT;#D2#@#)P #SGD< FKGCO5K+2[[PX+Q+>$RWS"+4;H
MGRK-A&WS'D LP)49.,G/:@#=?Q1H4>E/J<FK6D=E&YC>9Y0H5QU0YZ-_L]:D
ML_$.CZAJ<^FV>IVL][;C=+!'("RC."<>QX/H:\8U*_L_^%>_$NU:]\Z5M4,B
MF4!6<,(=K8  YP<<#."1TKM=7N;-/BCX56QGM5=M,O(X@C+CD1[!QVX.![&@
M"Q\2?%JZ3X4U!])UE+;4[>2-!L57RQ=0R$D$!MI)QU[UWE>#W.N:<WP"O-'O
M+B./7+5PEY9S']^)A<AF8KU.<[MW3FO:[R[A_L6XO$0W<(MVD"1<F5=I.%]<
M_P!: (+7Q'H]]>):6VHP2SR!FB56_P!:%^\4/1@.^,XJK/XU\,6T;R3:_IZH
MDWD,WGJ0' !*Y]MPSZ9YKS+3M;TRXU7X<7D%];I:H\T8L[89CLMUNP6$L<L9
M,X7!.2>BBK0GTYO#/Q9;S;4N\]T =RY;_1U"_7YLX]\T >I/KFEQZK'I;W\
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M[3K=C&;5E2<&8$QL<X!QWX)Q[5S_ ,0[BWAUGP4)9HD8:XC?,P!V^7(,_3)
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6&8(P4D[UXR2>."..E=KI_B71]1U%]+MM1@FOXH]\D*GG&<$CL<'@XZ&@#6
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M74BR+P@D/.U>I48_[Y..B^(L^FBQ\+.DEKY$FOV4@(*[612<M[J!CGH!7H(
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M3%G!C0L."1\S>PQZBL+1X8KC]FR:.TC22=-*G1EC7+!LL6! YSWQ7KH 48
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MJQ270\OR4\I2RD87;@Y!! /'-=/8>(=,U+4)K"WN'%Y$@E>WFA>&383@,%<
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M9E8/\R@L0>>F03C.*] N?$FEV7B*RT&:9DO[V-I8%\MMK 9)^;& >#QGM]*
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MQ!'*Z/&R[69 Q + ;ASU'!K/M?%=MJWBC5_#L O();*.)3<"W8?.X<G!92H
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MD.('$#A9-H))1RNUL=<@D5R'@WQK9VFD21>(-:9[MM5N+9))P2<"4H@8J-J
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M1UD171@RL,A@<@CUK$3QAH;W4$"WC'[1<-:0S>2_E23#.463&TG((Z]01U%
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M*8KDQ6TK^40 26VJ<*,CYNGO5J'QCH-QJ]MID5]ON+H$V[")_*FP,D))C8Q
MZ@'- &[16+J7BS1M):3[;=/''%(L4TX@=HH6;& \@!5>HZD8R,]:BO/&N@6-
M_=6,MZ[7=M&))((K>21]IS@@*I+=#TSC'- &_574K+^TM+N[$SS0"XA>+S86
MVNFX$94]B,\5SNK>/=-LM-T2^LA->V^KW44$$L,#NNUC\Q.!G=@-A?O$CIP:
MT[SQ1I5BDKSR7 6&)9IBMK*WDJPR-^%^4XYP<$=\4 9MIX:UPV TO5-?MKO3
M/*\EHXM.$,LD>,;6;>5 (X.%!],5MZYI\NK:%?:=#.D#74#P>:\9<(&4J3M!
M&>OK5YW6-&=SA5!)/H*X2[\46>B_#75-:T?4K[5?+-R8+BYC>4K+EN#\HPBG
M@9P, #- '5^'],ET7P]I^ES7"7#6=O';B5(S&'"*%!VY.#@>M:5<SX9LB\J:
MO%JFK20S6JQRVEZ)-IE&"95$@#+W&%PISTXJU=^,-#L9IHY[QE6"=;>>987:
M**1L85W VJ?F7J>,C.,T ;E%85]XQT+3]2FTV>\?[=#$)FMXX))'*DX^4*IW
M'KP,G@^E3P^)]&N-!AUN&^5]/GP(I55B78MM"A<;BV[C;C.>,4 :U%<)HNLR
MW_Q7U:TCO+U[./2XI/LMPC1B*0R,#A& _A"\\]>M;/B?Q9#X;N=)MWMKB634
M;M;=6C@>14')8_*#DX!PHY[XP#0!T5%95YXCTVQ<I*\[2+")WBAMI)'CC.<,
MZJI*]#U /!]#5VQOK74[&&]L;B.XM9U#QRQG*L/44 6**Y:T\50ZSXFUKP[%
M%?6[621)YXMG!WN'8G<5*J,!<%L9).,\5A_#WQQ8OX/\.0:QJ<TNIWP,?G2I
M(ZO*6;"-)C:&(Z*3GIQTH ]%HK'U7Q/I.C><;V>4+;J&G>*WDE6 'H7**0O'
M//;GI6FEQ#):K<I*KP,GF+(IR"N,Y!'48H EHKE_^%B>%OLT5S_:3&VDF,'G
MBWE\M'W;<.VW"<\ MC-7['Q7HVI:P^DVUTS7BQF54>%T$B X+(S *XR>JDB@
M#9HK#@\8:'<W5M!%>,?M<KPV\IA<132+G<JR$;2?E/0\X.,TT^,M"6;4X6NY
M%ETM%>\1K:4-$K=#C;SGMC- &]17/:MJ.F'5M CGU6]L[B><O;6T8=!<G8?D
MD4KT R<''(IMUX\\.6CWZ27TCOIY NDBMI9&CR,Y(52=H');H.,GF@#HZ*Y^
M/QMX>FOK&UBU#>U_@6TJQ.8I&(W!1)C9NQ_#G/M5E/$VDR'4PMQ(6TO'VQ/L
M\FZ+(W#Y=N3QSQGB@#7HK!D\:>'XDTQWU%0NJ1^99GRW_>KM+9Z<<#H<'MUJ
MM_PL+PU]DN;@7D_^BN4GA^QS>=%@9):+9O"X(.XC'O0!T]%0V=W;ZA907EI*
MLUM/&LD4B'AE(R"/PK+U+Q9HVD-)]MN7CCA=8YIE@=HH6;& [A2J]1U(QD9Z
MT ;5%8[^*='CUI](>Z=;Y+=KDQ&"3F(=7#;<,/H36;K7CFQTS3M'O((+NXBU
M6[AMX6%I+C:[#+$;<YVY*C&6., C- '545DWWB73-.B\R=[CB$7#I':RN\<9
M_B=54E!P?O =#Z&J\_C3P[;MIXDU.(_VC&9;0HK,)5"[B00".G;J3@=30!O4
M5RE]X_T>#PEJ>OV?VBZCT\O'+"+>1)$E SM=64%!R,D@ "M_2[]=2TV"[5)4
MWH"1)"\9SCGY6 ./>@"Y17!7/C(:]X?\8)8B_L9M+%Q'#-]G>-LQPJV2S+A3
MN)^4X; !P,U<\)>,-,NM+\/:9<7\DFJ76GQ.&DCD(F<1*7 D(VLPY)&2>N:
M.QHK#E\8:'!=&"2\88NA9-*(7,2SG_EF9 -H;) Z]>.M5T\7V[^.)?#0MKH/
M#;+,TOV:0J69L#! P%X/S'C/&>#0!TE%8'C#Q/%X3T3[=);S3L\J0QK'$S@,
M[!06(' Y_'H.37/7?B+[#\3[9YK^^73)M$EF%FT4G,@F105AV[RV,\8)Z]J
M/0**Q(?%NAW&AP:Q%?!K*>401,(VWO(6V[ F-V[((VXS4-UXSTF#0]6U.,W$
MXTH-]JMUMW$J,%W8*$ @8YW'C'.<4 =#169X>U<:YH5GJ'ER1M-"CNKPO'AB
MH)V[@"1SP1D'UK3H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M"[:)CDQH5 C3\$"Y]RWK6-XP=5\>>"6(8K%=7#2,%)$:M"R@L>P+$#FNW
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M%MH0W)161G+('/4@$>]>@44 >*:<)(/ACX+E>WN NG^(5FNE$+%X8_-F^9E
MR!AE[=Q6QXJW+J>K:SH&H7-CK*PQ^;IMU 7AU5/+!5/+(SOPQ3Y>1CD#.:]3
MHH AAE<V<<UR@A?RPTBELA#C)&?:O(H6_P"+'>);;9)]HEGO5CA\MM[EY6*8
M7&3D'(]J]CHH HZ//'<:/9R1.&7R4'T.T<'T->1^,+V34?#WC&R-C=VMU#J"
ME+*ULV"S(LD?^D2.%^<L 3UQ@#@D9KVJB@#@;:\@E^,,M[\Z6[>'T022QL@#
M"9F*G(&&VD'!YQVKCM.:ZL/"_AG5/LMS+8Z5KUU-?0)$Q>.-WE"2[,9( ?/
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[>>"7R&\IT$"J3OQM^\,8SG/;K2_$@2/:^'A%!/,8]=LYW$,32%8T?+,=H.
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M'(L\'F%2K[!AB 5Y]C0!ZE;>+M%N=*NM16[,<-I*8+A)8V62*7(&PH1NW$D
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M!9F66S@*X$ZQE259BO!*G 8<9XH [X^)-)O](U:0W-S ECNAO0(G6:W.W.<
M9Z$$$9'>FZ=K.E6'A;1YX[VZN;:YAB2S>8-)<7.5RN1C)8@9/'&"3@"N-T??
M;W?Q"4V6J+'<QI+ ]Q!*6E!MPHP2,DEOX>HZ8&,"G:F]T>P^&^MSV5X^GZ98
MO:7\:6[F2V=XE4.4QNP"I!..!]: .C\':I+?^/\ QG%]IO7MX/L8C@NBP\AB
MCEP%;H">>.#QU&*ZJ?7+"VURTT::5TOKM'D@0Q-MD" %L-C;QD<9[URGA.Y^
MT_$CQ==I:WB6UW%9&":6UDC239&P;EE']X<'KFG^,)#IWCOPCK,\%RUA;K>0
M32P0/+Y;2(FS*H">2I'2@#6N/'.@6NE:EJ4UU,MMILYM[LFUES'( #M(VY_B
M'/3GK5BQ\6Z1J&MG2()IA=F(S1^9;NB3(" 6C9@ X!(Y!->8ZFMW<^"?B1;K
MIFHK/>ZB9+:,VCDR@K$!MP""?E.1U'?%=9J[M<_$?PG/;QW'E)97B/.('VQ,
MZIL#'& 20>#Z4 5?B;XHA7P+JKZ9>7\4T$JPK=VBNJ"42 ,GF 8]0><9XSGB
MNSU+7[+2RZ2BXFECB\Z2.V@:5DCY^9@H.!P<=S@XS@UY%+<74/P2OO"%UIFH
MC7K/]R\"6DCB7]^&$BN%VL"#G.>OX5T.HWD6C>/-0OM8TO59])U>W@:UN;6&
M8^4Z*5:)T3Y@3G(R.Y]\ '63^//#ENNG-]N:5=1B::T,,$CB957)VX7ENVW[
MV2!BMG3=1MM5TRWU&U+_ &>>,2(9$*'!]0<$5Y_-:P67BKP"MGHTUA8VQOF,
M"0,5MED0[-Y (4L3R,\$D5Z-<O)':3/%%YLBHQ2/.-YQP/QH Q;/QEHM_=6,
M$$\N-0+BSF:%ECN"F2VQB,= 3[@<9K6O[^VTRRDN[N3RX4P"<$DDD   <DDD
M  =2:\BM;N>[E\#Z@^FZJLUM?,+NVCT^2*&S)B=1&D84# )QNYXZL*](\906
M-UX5N[?4K6YN+.5HDD6U#&109%&]=H)RAP_ _AH LQ>(;!UO6E:6V^PHKW N
M(FCV*V<'D8;H>F?3K5=/%^D?;+BSF>XM[F"W^U&&>VD1VASC>H(RP!Z@<CN!
M7GUWIWB>Z\-^(M+MKN77K:U^R7&GW<R;)KC9+YCP,XQO("_>'=L=>!N:3>Z)
MKQ?4+#0-1AN[>TE66XU"&1&M\J<QJ7^\2>H7(P#D],@&M;_$GPO=7&GQ1WTF
MW4"%MIVMI%B=ST3>5VACZ$Y]:NZAXST73)+L7,\GEV3I'=S)"S1V[/C:'8#
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HI"< GT]*Q]!\26WB"?5(K>WN86TZZ-K*)T"EF"AL@9Z?,.M
M &S16+<^);:U\56/AY[>Y^TWD4DL<NS$6$ +#)/)Y'0=ZVJ "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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E** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>32
<FILENAME>exhibit1016-arvinasxamen012.jpg
<TEXT>
begin 644 exhibit1016-arvinasxamen012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MUO99KB.8V\+A&A**!]Q2 V#ZU6LO 6I7\>HP0J_AO29[FWN(]-<I=!V0'>7
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ JG;Z3IMI=RW=MI]K#<S?ZV:.%5=_]Y@,G\:N44 %%%% !1110 4444 ,
MEABG"B6-) K!U#J#A@<@CW![T^BB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:BQL&8@@84$@$]*NZ'?1^'?&/BRVUZ00+?W*WEG<2CY+B(QA=BGNR[<;>O/
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M%/<P,OFJ+:0%L[0 ,]!@>PQ5EH[7Q'X1\ 6&E,DM]:W%C<N(Q\UJD: R,_\
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M:66VD0$[=S$DKA>HP#R>HR"*\YCU6*\LO!EY]GN;<VVLCS]/M[%TAL<K*-@
M7);)')))R2  <5V/AF\BT[QOXS@O!)"TMW'<JSQL$,7D*-V[&,9!'7K0!MZ%
MJNE6GA"RO$UJ?4+)ODBO;G+2W#%R ,!06.>  ,G ZU;@\3Z//'>N+SRS8@&Z
M2>-XGB!&061P& /8XY[5Y5H:W5I\/_A]J?DRR6>D7KG4850EH0V]1(R]?EW9
MZ=#FNGNUAU#QW?>(K&='TN#0'M9[J-LQRR,Y94#=&( ).,XW =Z .CM/'7AJ
M^NK"WMM35WOQFV/E.$D.,[=Q7:&QSM)!]JZ"21(HVDD=4C0%F9C@*!U)->.Q
M2Q1_#CX;Q$A9+?5;-IDQ\T04-O+#^$#/)/K[UWWQ!TV_UGX?:U8:7EKN>V(C
M53R_()4?[P!'XT 7K7Q1H]Y>V]G%=,)[E#);B6&2,3J.28V90'XY^4GCGI7+
MW&KOXE\9ZSX>6]U6PCM+6 6TMK#-&RS.7)=CMQM&U0 WRGGKVK:O=0>,K;P>
MFD9%[;:G;W<\84A[..-6\Q9!_!_=P>I(QFKV@W4!^+7BK]XN);6S2,]G9!)N
M"GH2,C('2@#MK:.2&UABFF,\J(JO*5"ER!RV!P,]>*EHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MY;<0-HYR<8S0!U%%8L?BG3)1J*I]I-QIT8DN+8VSB4*P)4A",L#@\CTKG?\
MA+]*U[P-9:IJ-YJ.D1W<L15[:.6-MQ<%$#;2&!X!(X.3R* .KU_39=9T"_TR
M*X2W:\MW@,K1^9M#J5)V[AD\^M+H>G2Z1H-CILMPEPUI D E6,H&"J%!V[CC
MIZTE_KEEI]R+:1II;DQF7R+>%Y7" XW%5!(&>.>IZ9JC/XU\.V^E66J/J<?V
M*]E6&"8*Q5G)Q@\?+SUW8Q@YZ4 -\-^'+G0;W6;B;4(KI=3O&O"J6QC\MBJK
MC.]LC"CTKH:Q])\3Z5K=]=V5E-+]JM0K2Q3020MM;.U@' RIP>1Q3]8\2Z1H
M$EK'JEXMNUT^R+<C$,<$]0,#@'K0!JT5S^F>-O#^K0:C-;7^P:<-UXMQ$\+0
MK@G<RN 0, G.*FLO%6E7]X;2&2=;C[-]K2*2VD1I(<XWJ"OS<XX'/(XYH VJ
M*Q+/Q;HM_H-SKEM=2/IUMO\ .F-O(NW9][Y2H8XP<X':M1KR)+'[8PE$(3S"
M/)??CK]S&[/MC- $]%88\7Z&VFZ9J(O6-GJDJ0VDP@D*R.QPH/R_+D_WL54U
M#X@^&M-FOH+B^D,UB5%Q'';2NR9!.<*IXP,D]!D<\B@#IZ*RO^$CTEM-LK^*
M[6:WOL"U,*EVF)!.%4#). 2>.,'.,5 /&&A_V9?W[WC1PZ>Q6\5X7$D! S\R
M8W#CG.,$<B@#<HK L?&FA:CJ=KI]M=R&>[B,ML6@D5)@!E@CE=K$ \@'(_"M
M34M2L](T^6_OYU@MH@"[D$XR<  #DDD@ #DDT 6Z*Q[?Q1I5P]_'YLL4U@BR
M7,,L#HZ(P)5MI&2#@],]*HVGC_PW?2Z<EO?2,NHL$MI3;R")W.2$WE=H8X/R
MDY]J .FHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M_FWAL[MV?O%B223U)- '+?$PEM&TA4221AK%I*1&A<A%D!9L = .IILDB_\
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MRVVHSB/:&., G:>#7.W$$-QX)^(,=Q'>*)-<>Y@,,+%F&8=DB@CYEWKDXSD
MU[%61XBT,Z]I\5O'?W%C-#.EQ#/!@[70Y7<K AAGL?04 <AX?UW1-9\>0ZE/
MJA_M4V)L;>V-C/;JPW>8YS(!ECMX7L >O6M3XGPS2>#UDBAEF$%_:SR+$A=@
MBS*6.!R<#GBM:PT74!/#-K&LG46@;?$B6RPH&P1N(&22 3CG'.<9QC<H \^M
M[UM+^)E[J]^D\>DZQI\*VMU+$RK$\9;,;9&4+;BPW8S]>*T? &ESV$.O7<D;
MPP:EJ\]Y;1.I4B-L ,5/(W%2V#V(KL** /+_ !=#);ZWK.J>'[^YL]<B6-)=
M/FA,MOJR^6I50A'+8)3*G(QSC.:9>7L>A^.=7?Q-8:H+'6([>6UFL_/DC#+$
M$>%A$>N1D<<YKU.B@#R^^_L_1/&'P] L?[,LHX=0V0,"?(5D0C=UV]>>P)Z]
MZK:FEQ93>-/$MEI8N["_GL8XU>V,JL(\"2X$>/G"DY![E,].:[G4_#D^H>+-
M'UQ;^.(:8LRI ;<MO$J@-EMP_NC''YUT% 'E5G<)'XWU^Y U2:WN]"C\JZN;
M:0>:09,G[H"]0 ,#.>!S4EI>3Z;\#=(,>E_:98(K:*XAEM3(;?#KND,1&6*?
M> ]0#TKU&B@#S+0R9/B)KC0IJ<\5]I$(AN;JW=1*09,G)4!1R !A1Z"L5I7D
M^!>DZ<+2]6\M9K2.6%K616#).I< $9. "21Q[U[/10!P,-PV@_%#5[_42PTS
M6+*V^R7FTF-&B# QDC[I.XL,]?K7,7>E7-AX;\V2WG6._P#&*ZE!!Y3;H[?S
ME.XKC*C"EN>FX9YKV6B@#A[=P_QGN9E5S"^A1Q"78=C2"9V*[L8SM(./2F?$
M>>*VO_!L\X/EIKL98A2V!Y4G.!Z=:[NN?\1^')]=O='N([]+8:9=B[56@,GF
M.%9<$[A@88T <?KD<TWB/Q)XHTG3$U.UBT 67E-'NCO9C(6( _Y:!4P#CKG:
M.13-(N5F^)&@:A$-4NH)](F@^TRV;QH)"\9VA=H"* #VQ[DUZG39%9XV57*,
M00& &5/KS0!YV^CWMEX^NM#MXLZ%K3KJLQS_ *EXR/-3'I(WE9]B]>AS*7AD
M0=64@?E6-X>T&XTA9)M1U:?5M0D58VNIHTCPBDE5"J, 98DGJ2>3P,;E 'B%
MI>,/ASX/TD6.HF^TO6+07L0LY"8=DI+?P_-QSA<\5U6D:KI]A\3?')O7\L2)
M8E=T9.\" Y4<<MS]WJ?2O1:Y_2?#D^F^*=:UI[^.8:KY.^$6Y7R_+7:N&W'/
M!YX_*@#SO0]%U/PBO@C4KZUG73K8WJ7,2H6-D+ABT991T & Q_AK0URR>[F\
M?:Y:)(UC>Z(+* HA/VN81OR@QEL;E4$=3G'2O5** /,IW!OOAFZI)MMU;SB(
MV_<@VQ3Y^/E^;CG'-=/X_O)[#PC<3P:<M]B6(.C0>>(U\Q<R>7_$4^\!Z@'M
M7344 >7Z3<QQ?$'6[K&IS6UUHT)CN[JVD D*M)D\J O4 # SV'-9=NKQ_##X
M?V[03B>UU:S>>+R6WQ!')<L,9  /)/K7LE% " @@$'(-+110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %!.!FBB@#C['Q/X>TO2->U@:AJ,UG;ZA(+MKB.5S!+M7<BJ5RJ#(XQ@$FM
M&S\8Z/?:NFF0O<"XEA:> R6SHDZ+C<8V(P^,CIFO/KF&ZD\ _$>V73[\SWNJ
M7+VT?V23=,KK&%91MY!*GD>E=!J#/-XY\!W$=K=M#!;W0FD%K)MB+Q(%#G;\
MN2".?2@#I;'Q9I.HZ7J&HVTDQMM/>2.Y+V[HT;(,N-I .1WXJ6?Q#90O#"J7
M,MS-#]H6VB@8RB/IN9?X>>.<$G@<URL^AW]K\0KNTMH"VAZ\B7EXX^[%+"0'
M7T_>#RP?7YO2IF-QX?\ BEJ&I7T4S:7JMC#'#<I&SK#)$6S&VT';G<6!/!Z=
M: (/'VNPZE\+;O6=#U*= LD026WD:)@?.1&5AP0<$@J:Z[^WK#^WVT/?*-06
MV-WY?E-AH@P4L&Q@\D#&<UYCK&B7UO\ #;Q:Z65VSZQK7VRUM([=VD$9FC.2
M@&5)",V". 1GFNDU6Z_LSXI:;K4UK>/87.C26:2P6LDN)3,CA6"@E<@'J* -
MB7QYX?AT?^U9+J5;071LV=K>0;90VTJW'R\\9.!4]GXOTN_OKVQ@%Y]KM(1<
M&"2TD1Y8R2 \88 L"1C(KS-XKUOA[J5LVE:DMRWB<W A^QR,QC^U!RPV@@@
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MG7"[<X*G.:ZWQI%=R_\ "+:]8VUQ<VFF7RSW-O'$WF>4R%"X3&XE=V<8SR:
M.@M_%.ESO?Q,T\-S8()+FVD@82HAZ,% )93ZKFLZ/XC>&Y(M.G^TSI:Z@0L%
MT]M(L)8YPI<C:&.#QFLR>#^T_'DWB2U2?^S[71'M'E\EP9Y'?<%48RVT#)P.
MI ZYQSD4%U'\*_ UHVGW_P!IM-3LGGA^R2%XECDRY9=N0 .] 'I&D>*--UK4
M;O3[;[3%=VJJ[PW-L\+%&SM<!P"5.#S5N_U6WT^6WAD$DEQ<%A%#$NYWVC+'
MV '<^H[D5R\'F/\ &:XN1;W/V9M"C@$YMW$9D$SL5W8QG:0>M2^.-/L=1N=+
MBN9M1L+F/S9+75;$-FU<!1M<@$;6!/WN#MQWH VT\1Z?)I\%XAG(N)7AAA\E
MA*[J6#*$(R"-K9SC &3BLZ7Q_P"'H-)N=1GN9HHK2X^S7*/;OOAE) "NN/ES
MD8)X.>M<3=MXABL?#.OZWIMQJ,.GW%Y;WHLX&CEEBD($=SY0P1G9N(]&]ZE\
M4PV5]\/M8N-$\/7L/VZXM2,VDGGW12569BF"VT*."V,X/;&0#L?^$^T(/&KM
M?1^;>BQC+V,JAYB 5 )7H0<@]#6K=ZQ9V]S/9S&X$D=OY\ACA=ML9)&<J#SD
M' '/!]*H^+M%_P"$I\(7=G;L4N'036DA!4QS(=T;<\CY@/PS5;PW->7'AJ77
M=7M9+>_OX5DDM]A9HE5,*@ &>NYL8SES0 _0]:T:T\):3-:7UY>6ER/+LWN-
MTMQ<'D]"-Q. 3[ 9. *N6GBO2+RSO;E;AHQ8S?9[F*6-EDBDR $*XR221C&<
MY&,UYEI*:IH7A?X?ZVVE7\L&CI/;ZC:+;OYT0E&T.$(!.W'..QKHO%+77B#P
MJ^J:+HEP5M[^WO?(DA,$U\L; O\ *<-TQC/)V\#ID ZFWUW3M;O+O10]U:W\
M40E>&16AE$9/$BGN,C&1GG@U'X4UR75K>_M+Q@=0TN[>SN& QYFW!63';<I4
MX]<CM6;X5N-'UC5/[4TS0+VUD2W,4EW?6[Q2#)!\I=_+#.2<< @>M96@7HT?
M4_'WB22VN[BS;4DA2*UB,DCF-%C<JHZ_,2#_ +I]* /1Z*13N4'!&1GD8K$\
M5ZE-I^B.EHER;NZ9;>%X('E\HN0ID.T' 4$MSZ4 <S8>+-0'Q-6WNV T+5X9
M(-+.>/-MV.\_\#RQ![A5KJM8\3Z5H5Y96FH321S7K%8 L+L'(!)&0,9XZ=3Q
M@5Q?CGPC)9^"K>XTB\U*>\T9X;G3(-@D^:,C"A43=RN1_.K.MZB^LZMX%U&+
M3]0C5;QIKA'LY0UN#"RX?Y>/F8#/]* -^/QSHDFE:EJ#-=QQ:8^R\CDM)%E@
MXSEH]N[&#G..E:#>(+ 66G7>9FBU%D2VVPL2Y92PR ,C@$Y/0"N;\/0>=\0/
M&XN+2?[+>?9 C36[K',JP[' )&&P>#57P-I6HVFJ7&DWWSV'AN5[?3Y2VXR"
M50R$^C1Q,$^CF@#K?$MU8V?AO4)M2N+FVLQ XFGM0_F1J0<LI4$@CKGM5!O%
MFAZ1'HUE-=71>^M]UH7ADD>953=RP!W/C''WB2..:?X[5Y/ .OPQ12S33:?/
M%''%&SL[LA   !/4URS"4Z[\-919WFRUMIA<-]EDQ"6MP@#_ "_+EN.: .LL
MO&.CWVEW>H1RS1QVD_V:>*:!TECE) "%",Y)9<#'.1577/&MMI&@:OJ LKUY
M]-B#O;M 5.6!*\]-O'+ D#Z\5RGV:VN9?'<6J:9J4MA>:C;,OE6TJNR8B3S8
MR%R=C#=QG[M17%CX@G\'>,]'^U7.N6:V(73KR:'%Q*2K%HB<#S"O'/JQ'7@
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MU5KB"&SE=P&!(( 7E<#)8<<CGD56U7QW9V@\.R6,4]Y;ZU,HBGBA9E$>TMT
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MVX^S6MW'#O2:3) "A27Y(."5 ./<9T+7Q-:W>HZII\5M=_:]-CCDFB9%!99
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MIFE/FQ('5P6).YAN4^O![4 =U17D)UF[F^#Z^.X;^?\ MJ)C=.?/;RR1-M:
MIG;LV_+C'H>O->C:QJTEMX=^UVJ#[7<JD=I&W>63 0'V!()]@30!L45Q?PUU
M:]NM#NM'U:9I=7T2Y>RN78\R ',<GT9<<]\&NTH **XN[ENHOB_I< OKEK6;
M2[B1K8O^[#*Z $*.^">3DU=O-3;4_'$7AN-BMM;6?VV]*G'F;FVQQ'V.&8^N
M .A((!T]%>8:=XDB\,^*_&_GV^KW\4-W ^RWC>X,*>0K,22?E7)/&?7 XXW_
M !#X@AB\)Q>--&G,]O;HD[!"=MQ;EAO4@]" 21W!&.A((!V%%<I-K*ZWXQM]
M!M9<V45B-0NW0_ZT.VV*//H?F8^N .A(.;ISMXMUSQ=:7EW=6\NGW*VMJL,[
MQFW3RP5E 4C+,Q8Y.> !TH [TYQQUK!\-^'9/#\FJLUZ+D:C>R7SCRMFQWP"
M!R?E^48[^]<GIWBC4+[X2V'C8DG4+.%I+E5X6YCC<K(".G*JS ]C[9!WI]<3
M7/%>GZ%9RG[&]A_:=TZG!DC8A8H\]@Q)8^RXZ$T =917-6E_H[>-]5BA2]&J
M6]E$;C<K^68\MMV+T)SGE1SZU@R:OX37X6W=XT>K?V"\\HD ,IGW><=W.[<H
MWCN1QP: /0Z*Y;Q9J1\,"RUU'86GVF*VOHR<J8I#L$GLRL5Y[C(/;'17MW'8
M6,UW,)#%"A=A&A=L#T Y- &3J_AV76-4@FEU>\CT]8]D^G1A1%<?-GYCC=CL
M0#R!CN<[M<?'\2-%>#2KIK?48[+4RJ07;VQ\O>P)5"02=QQQ@$9XSFKMGXRL
MKR?4[86.H0W>GQ+/);3PA'>(YPZ9;!'![@\=* .CHKG1XTTPZ;H>HA+DVFLS
M1PVLFP</)]T,,Y&<'GGI4\OB>U2XECCM;NXBANTLYKB%5*1RL5&"-V[C>N2
M0,^QH VZ*Y;2/%5SJ?C76]%;3+B*#3A"@E.S&65V+-AL@$;0  ??&>,SX@W(
ML-<\'WAEN0HU39)'"SL)%\ISCRU^\<@8XS0!WE%<YI'C?2=6;4HW6YT^XTU?
M,N[?4(O)>./&0^,D%< \YJ2'Q;9-K-EI=S:WEG-?HTEDUS&%6X"C) P25(!S
MM8*?:@#?HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M:2%F<@9P,$<'!]JO>+4UK5O^$PTV;1]3F62SQI?V6/;#*#%RSMD;G#<;6SC
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MZ:ZTN_E34)8)K-H+9I5F"PJA7<H*H=PQ\Y7UZ5FWVB7'ACX"W.B3JLEZUH\
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M% '"_%")M8\ #2[=7^T:K=6MM"K(58$RJQ)!Y&%5B?0 UUVK$KH][A)'/D.
ML:%F8D$  #DTY]/@DU&.]EW22Q*1"&^[%GABH]2.,GG' QDYM4 >3"PU!/AU
MX#LCIE_]JL-1LI+J(6KEHEC)WL>.@_7MFMYK2ZN?B?JTZVERMM<:&EI'</ Z
MQF4.[%=Q&.C"N[HH \<MH]7?P9X)TL>'=6%SH^JVIO UOM"B/>"5)/S+WW#Y
M??) K3U?2KP:[<ZOX<@U73==-\B36WDNUG?QAP-[DC8/DR=V0<@]20:]0HH
MXO1H+VP^)WB=Y=/NC;:DMI)!=*G[K$<15LMG@YP,=>?3FI/'-K=O?>&=0@M+
MBY@T_4Q/<BWC,CI&8W7<$'S-RPX )KL** /-]<\,7OBW4?$>I6D<EJESH?\
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M3@*=V"0J'VSP":Z^YM9?$OB[P_JD=G=6UGI GFD>YA,3O)(FP1JIY.,DD].
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MW6[U>2ZMVEC*B2,HB@C\5/!YKLJ "BBB@ HHHH **** "BBB@ HHHH ****
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ML&V'.TL%8$<^HZUZY10!R-IID^J?$)/$S6TUK:VVFFSB6==CRNTFYCMZA5
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M$P .>,G@GFNXL+B6[T^VN)[9[6:6)7>WD(+1,1DJ2.,CI5BB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*&#.=I(' QU(H ZJF>;&9C#YB>:%W%,_,!TSCTKA-1\<7MTG@ZYT6R#6FMS
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M_#?B*S\->!"=*$EYH<W^DVJW*!MAB9-P8G;P2#C->F17$$[2K#-'(T3;) C
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MR^(>N:H=+F-A/96\$#K+%EVCWYX+Y&=PQG\<5ULMQ#!L\Z:./S&")O8#<QZ
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M5X$C9E>0,PX=MI*C'H"<YY-8+Z%K>O>&]%\/ZO8"V-E/;O=W8F1HYEA((\L
M[LN5'W@N 3UP,@%J;QW?D>(!9^&Y9GT23;.)+M$W*$#D@@'G!X'YD5)%X[=Y
M] F?1I8M)UMDBMKMYUWB1T+J&C'0$ \Y_"JMMHNL12>.7;3G_P")NQ:S EC^
M;]R(_F^;CD9^GOQ567P]K9\,^!+%=-8SZ+=6TMV/.CQMBB:-MIW<DELCV]*
M+EQX^U)I-;CT[PI=7CZ/-Y=PIND3*[ ^5ZY;!X49Z<D< Z-KXR&K6VDSZ+I[
MW*:E:O="6=S%%"JX!5W"MALG&,=CSZX/AZ[U"#Q5X\2RTQ[MGOT\MA*BJK^0
MG#[B"%Z<@,>O'3+;+PAK7A__ (1O38+:'5]'LK%XIX))Q$BW18-YS*0=R_>
M&"1G.,T :+?$:(^$=(\00Z3<2QZA>+9M$LJYB<RF,\_Q<@XP.>.E7K/Q7?W&
MM:GHL^A_9]2MK1;RWB-TK+<1,Q4?,!A6RN,<CWQS7)V_A/Q+!X%TO19-,B-Q
M9:VMX3'<J0T2W#2D\XQD$ #\\5U4.F:E_P +0FUMK)DT^324LQ(9$R)!*S\J
M#G&&QGU]N: %T_QF=3\'VFN6^GCSKFX6W6S:?#*YD\LJ3MX(.21C@ FM/Q5#
M'<^#]8CN(DD4V4Q*,-PR$)[^]<[H_AYK;XD:Q+#.&TF-EOA; <1WLJ%7.?\
M<&['_36NIU^">Z\.ZE;6L)EGGMI(HT# 99E(')( '- '%>$O%-QIF@>"=/NM
M(>.QU"S@M8;SSU)\T0[@#'C(4[3@Y_ 5K:IXYDTJ.XO)M(=--M]16P>664QR
MN2RKYB1E<,F6Z[N0":R3X>UO^PO =H--8RZ)/ ]Y^^CQB.(QG;\W.2<CVK.U
MOPOXKU32]=M9M+MKN]DU%9[6^DNU!:W69'6) 1\F N".!U/)- '97GBN1=4U
M73].L8KRYTR)))H&N?+E<,NX;%VG<,8YR.>*Z&>>*UMY;B=Q'#$A=W;HJ@9)
M/X5Y]XL\+WWB1[J5]$\C6(@ATO5K.Z5&@;8N0[9#%0^[^$Y!X -=M?Z;_:>@
M7.EW4Q/VJU>WEE48)W*5) _$F@#G9O'9M-)T_7;O3#%H-\\:K=>=F2))#B.2
M2/;@*<CHQ(W#CTM7_BNY1-6ETC26U./2G\NY"2E7>0*&9(E"G>P##KCDX'>N
M?_X1G7=4^']IX)U.R6-8?(MYM025#$\$3J04&=^\J@&"H ))S5BST[Q7X7\2
MZRFE:7:ZGI6K71O8Y9+L0FUE8 .'!!++D C;S0!T$GB.2>_73]+L?/OA:+>2
MQW,A@$*/D(K':Q#DAN,<;3DCC-&V\:R2R^&TGT6ZM#K3RQ>7<G9+;O&K,0R$
M<@[>#GG(.*S[_2O$^A^,E\0:1:0ZS'>64=I?V[3K;OYD9.V52>,?,<K4WB#2
MO$-S)X:UF.TAO+_3;QYI[.*8(-DB,FU'; )4$<G&<$\=* +%UXX:TC\5%]*=
MY/#RJ\JQS@B56C\S() QA>O7\:IWOQ U#3O#TNN77A:X2PVVSP2"Z0F02D#E
M1\RX+#C!)SVZ5GW'AWQ)<#Q^TFFP Z];1Q6HCN5.&^S^7SG' )Y/L< UH>)-
M$UC5/A?:Z+;:>3J(2U5XVF0*IB=&;YLXP=AQCU'2@#0E\87%DZ6^J:7%IMW<
M3R):)=7T826)%#&1G&=OW@-N"<D=1R*UE\1K&XTK4+B:V*W=E>+8_9X)1*L\
MKD"/RGX#!B>I Q@Y'%.\6Z9KLNHZ)XCT"VCFO].\U)=/N)1'Y\4H7<N_D!@5
M4CM_(U/$>C>)O%'AN"Z:WM;#5;*^@O[.Q:?S$W1$G:\@ Y;)Z<# ]S0!7'VI
MOC9ICWFG6]K,VC3DR03>8)1OCZDJIR/IW'/IUOB#7X= ALFE$>^]NEM(3-+Y
M<8<JS?,V#@84]CDX'>N>AL_$6H^/](UZYT1+&VAL)K:=)+Q'=&=E/&W(/W>/
MUQ6YXILFU'3X+1]'BU:REGVWEM(5!\K8WS+N(&X-L[COS0!RGQ%GFO/",<]_
MIBP7-IK-JD85O-W#S8_F1L#@@X[>AKH;'Q9/)XBOM%U'2);.X@LQ?P[)A,9H
M=Q4\*.&!&-O/7K7)S>#-;M_!TFD6<,\T']L175E;7%RK-:VR.C;"Y;GE6P 3
MC(YZUN:AI.NS^/+K6+&V^SI)H+V$$\CH?+N"Y=6*@GY1QZ\]L<T 6K'QI+-J
M^AV-[I1M/[;@DFM09]TD>Q0^V5"HVG:>Q/((KG-*LK7[!\3;;[-#]G^V3'RM
M@VY^SH>G3KS1IOASQ(FJ>$-1ET2VAGTTS+J$CWH>2=WBV&5FP2>><9)YQP!6
MI8:+K$$7C<2:<P.K322V@\V/Y@T0C /S<'(S]/?B@#:\ _\ )._#7_8+MO\
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M"7*AD4-N5T9L*3GJ./;/6@"EX-UJW\/6GBVYO+6*S9O$;0);+(H02,D8 #<
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MD5SND. S'!Z<#CW) -6S\57UQXCO-!N-%^RWR67VVU#W099H]VS#%5.PAL9
MW=>]1_#K6]3\1>#[75-3BA5[@R.K1R%L_O'XP0-H& !R>!2#3=2?XH1:Y]A=
M=/\ [(-D7,B;A(91)]T-TP,9]?;FCX=:3JN@>%(-&U2UBB:R9T22.8/YP+LV
M[&/E&".O/7IW +C>)+A?&$WATZ>BR_8C>6\S7&%G 8*5QMX()YZ\$'FJ6D>-
M7UGPO#J]OIR">6]^QBS:Y^97$FPY8+U&"QQGY1G/:G^,O#M_K%SH]_I$XM[^
MRN"C3'J+>52DN/<###W456T/P;)HOC2_N;<I'H3*ES;6J]([HIY3L!_N*/\
MOL^E $L&M1MXH\46]GH4,6J6-K!(]Q+(%^U AR@+*"0HVGKD\]!7&:MJ5[KO
MPN\-:UJMK"]T^IV4T<D;;V.Z89P"!M], GZUV5CHVI+X\\2ZA+:F.RU&T@@@
ME,BGF,."2H.0#OX^G.*YQ/#/B4?#G0M!DTJ/[5IMY;.VRZ0ATBDW%LG&,@#
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M3C[F1G[V<$'':K.OZVVK:5XCLK#2XM0MK")X+III@H:39N*(NTABH*DY*C)
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M8'4XY.>@XH N4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !117/^+_$K^%M+@OET
M][Q9+F*W95D"E=[!0>ASUZ?RH Z"BN.L_&6H_P#"4MX?U;0?L-U/;-<V#+=+
M*EP%^\I( VL.I'(]^F:>E?$2[OO#T?B.[T VFBF"1VG^UJSB19-BH$P,[CP&
MR!G/;!(!WM%<?:>.-WB./2;JUMV6>V>>*XL+G[2@*#+(_P J[6QR.N:L:!XI
MN_$-K97ME96<MC>0-*LL5X6,3@ B.0!/E;DYQG!!'U .HHKAT^(4C^!=.\3C
M25V75T+:2W-SS'F<P@@[/FY&<8%7)_%6J/XIU+P_8:)'-<VMK'<QRS7@C20.
M6'.%)7[I['/MUH ZRBO/H_B1=R>&=/\ $G_"/[-*EG2"[9[L>9"QE\HE%"D.
MH?C)*D^G>M&]\7ZL/$VI:#I?AX7=W:6\=PCR7BQ(ZL6')VG;]WCKGV'- '85
M#]LMOMOV+[1%]J,?F^1O&_9G&[;UQGC-><WWC_4=5T#P]?:19QVTEWK46GWL
M%Q,5>&0/\T>0I&#MP6]#]WGCHXM9C_X6$-+N]'MH;Q=(-T=060,=GF!3&#M!
MV[B3SCH#B@#J:*XJX\>R0>&T\4C2P_A\R#=,LY\]82^P2^7MP1GG&[.#GKQ4
M\_B[47\4W6@Z9HL=S-'9)>0SR7@CCD5F*C.%) X/0'/'3K0!UU%<5:_$.WN_
M#VA:B;>.TEU:X>V5+J?9'#(F_<&< YY0@<<Y'2NHTNZN[NT9[ZS6TG65T,:R
M>8I 8@,&P,@C!Z=Z (-,\/:=H]]>WEFDRSWS^9<,]P[AVQC.&) . !QVK4KE
MY?%DTNL:KIVFV=O<W&F/&LT#W)29PRJQ=$VG*@-Z\D$<<9@UKQNMA-JD5C%9
M7$NF >=%/>"%Y'V!]D8VMN.TCK@9./7 !U]5[^QMM3T^XL+R/S;:YC:*5,D;
ME88(R.1Q7$R^+=6U#Q7X6CTRVA73M2LIKOR[B5HI"55<JX"'&W?TYR>XP*ZW
M7KB[M=!OKBQ2-[B.%V7S)"@& ><A6Y'IC\J *N@Q>'=&3^P-%FLHW@!9K6.<
M/*.Q+ DL3VR:VZ\R\,WMOI_@?P?J6HZ7:S:H\4-KI;K,6D=YD^8LQ0;,C+-]
M[@'J>O3Q>*;F+Q%-H%_IR1:B;4W=IY4^Z.Y0'##<5!5@>HP>.: .FJ":\M;>
M:&&:YACEG;;$CN TAQG"@]3CTKSJ;X@^(M1\ W/B33?#T%M:'3I;F.YGO0Q1
MU)&-@7+< D'@$CG P3'KLMXU]\/+ZYLHI-0-TP BFWM(#;L1EV5<9/)ZX]Z
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MUD^*-1O;#Q-8^.EG?^Q]/O3I4T0^Z;=CLDF/TF 'OL4T >JT$@ DG '>DW*
M#N&#T.:P?&UO!>>!M=2:-9$%A.P!Y&1&V#^!H W4=)8UDC971@&5E.00>A!J
M"XU&QM%9KF\MX51@K&255P3T!R>I[5QDGB!O"_P0L]9C4-+;:-;>4#T\QD14
MS[;F%4OB!I<>F?"Z")T\^X@NK-GE8 N\IGCWOD_Q,2<_6@#T>21(HVDD=41
M69F.  .I)I000"#D'H17-Z;XFO)_%\_A[4M*2SE-G]MMY$N?-#Q[]A##:-K
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M'7&.>]='K44\^B7T%M%YL\L#QHFX*"6! R3T'-7JH/K>DQ.R2:I9(ZG!5KA
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M\MO-5)8I8P0C#)VD;201GKR,UV-44UK2I+6XNDU*S:WMG,<\PG79$P )#-G
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M[E)@Z7 AY7RQ]X;B!G<!@9ZUH^&M*U*P\5>)KZ[M5CMM3N(IK=A*&("1A"&
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %<M\0=*U36/"DD&D)%-=Q3Q7'V:8X2Y5'#&)O9L=^#TK
MJ:RM>AU:6VMFT9H!=17*2,MP[*CQ@'<I(!/(.!P<'![4 <AX=\3>'_%GB:R-
MQ8R:/XJTY7#V5U%LE*%"&56XW+T;UXZ &K.I?$1K>RFU*PLHKVRM[DP/!'*Q
MN9%63RV=$"D'!!(!/(&<BK-[X?OO$/BO0M6O=/@L%TB1Y?-6822S$J5"# &$
MR<DGDXQCDFJ.D:'XR\-W-WH^G'39M$GN9)[:[FD836BR,69=F,/@DXY'N>P
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MC=QZAI]M>Q B.XB65 >N& (_G7#KX7US^QO&]H8+02:[+,]L?M!P@>(1C?\
M+QC&>,UU^@VUS8^'=.M+I$6XM[:.)PC[ERJ@<' XX]* .)\=>#-*;P]#;Z;9
M1)X@N+V(V=\J 7!FWAGD9QR<*'8]L#Z5Z*S+&A=V 51DD] *X01_$%=3N;[^
MR?#\DSY2!I+^7$,6>% $?? +'J3CL !VQ@,UC]GNB)"\6R4J,!LC!QZ4 <?<
M>/+B'PNGBQ=-2302^6Q*?M @+[1+MVX/KMSG'?/%5M=O=3E^*/AE+2.TEMC9
MW<T >X90^5C!9L(<$ D#&>">E0VO@_7(_ <W@:;[.]ES!'J0E^;[,7SS'C_6
M!<KC..ASVK7O=!U+_A.M"U.SMK?^S=-M)K8AIR)#O"XP-N,#8.I[T 6/$S/X
M3\ ZM/X>M;2V:TMYIXTV[40\LQ"@<G.3CIFN5UN:_?\ X5W=W%M%+?&\7:$F
MW%P;=L%G8#&3R>OXUWGB?2Y=<\*ZMI4+K'+>6DL",_W0S*0"?;)KEYM \1W<
M?@]YK2P231YQ+<(ETQ!41&/"DIR>2>P'3GK0!<L_%=_<P^)K._TFU&H:*JM)
M!'<EH9XWCWKAB@(XR""M0VOC6V@T'PHRP66G?VU;AH5E?9!!A WE@@=3D #C
MH?3!6/P_K,>N>,[W[/;&/68(8[4>><@I$8_G^7@'.>,U%:^&M1C\'Z%H&J:1
MI^IV5M9_9KZW:4'+*$"/&64<\/W7&>O% '7Z7<7=U8)+?6JVUSO=7B1]ZC#D
M AL#(( (X'6O/XYX;;XV:^TEA-=;M+MN(80Y!R>376>"]"N?#GAJ'3+F<R>7
M)(T2F0R>3&7)2/<>6VJ0,^U8\6C>(+3XBZKXABL;*6UN[2*V1&O"CC8<[C\A
M'.?6@#1L+J4^'[_6-$T,+>S32EK*=O(,K1,T8S@'#$(/TYJ+PKXNF\6QV\]K
M81I:>1F\=Y6W07&2#!M*C<1CD\8R/6K3-XI:VU"6.UT^&=@J6< N"RKUW2.V
MP9/(PN/X>O)K+TOPSJ?AOQ=)<Z.L<FC7\0:_BGN#YGVD?\ME^4@EA][D9/-
M',:-XAU#PKX?\5:G:Z5!<:?9^(+Q[DM<>6^SS #Y:A2"0#GDK[9KMKW643QY
MH^E2:7;R"\M)Y8;UFRZ!0NY0-O .5[\XZ5SDO@[7YO OBO13#9K=:Q?W%S W
MV@E$25@WS';G(QV!K;N-%U>X\:>'=7^SVRVVGVDT$X\\EMT@7[HV\@;?4=:
M./\ #OB#6?#7A36+^QT&*\TNRU:^DNC]I$<@C$S;C&FT@[1R<D=.!WKLCXDA
MN?&.AVL.FV\L>H:?+=VM^S_O%0!"5QMRH.Y>_;I69:>%]>M?#^N^&Q':"#4[
MFY=;\3$[(IV);,>W.\!B ,X)[BK[>&;VV\9>';NQAA_LK2;"2R.^8^9A@@!
MVX. @[CK0 G@+5]:U>37GU06Q6#5;BV4Q2,=GE[5"A2OW< G.<DD\<UT6N:F
M-'T:YOMH=XUQ%&3CS)&(5%_%BH_&L7PEHFJZ%?Z[%=+:M8WFI3WT$L<C&0^:
M0=I7: ,8/.3FK6M:;>ZKK6F12V=K/HT#M-.LLGS/)M*I\A4@J,D\GKM/:@#E
M? C3^&O&6K^$[V^-Y]K1=5M;AFSYC-@3C_OL;@/0FO2JX7Q5X/N6U70=5\*Z
M?IUM?:;=F21F/D+)"RE7C.U3G(QR>G-;4>J:T/&2Z=-96@TR2S\Y9(Y2TR2
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M7KADBC597\-R'#<9/VA, XI&^(-ROP_?Q1_9468KLVTMM]I/:?R<JVSGGG!
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MF1:<]O8OJ,,UO<&:.6!/O\E5(8>F.?RRSXGF9=/\.&W1'F'B&Q,:NVU6;><
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M2H7;D8SNSWP.E7[CP]J&H:SJ>OS6\,5Y+I1TVTMO.SA2Q9F=@,#)(X&<!??
MS&\)Z[_PB/@W2A!:&XT2\M9[@_:#M=800=IV\DY[XH W]"\1W]YXDU/0=6L+
M>UN[2&*Y1K:<RI)&Y8#DJI!!4CI5/QMJ^L:=JOAFVTT6_DWVHK#-YDC*SX1F
M"Y .%^7D\GMCK5BRT;4XOB-J&N2PP+8W-C%:IB4F0,C,V2N,8.[U[4OC'1=2
MU270KS2UMY)],U%;IHKB4QK(FQE(W!6P?FSTH YZ*35+;XI>)#I.GVL]Z^F6
M;,LLYCB!S)G+!223VX^I%:UG\0+:_P##V@W\<,<-SK*.T<4\N$BV#]X2P&2
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MBI^\A8 E2,$''\JQ]7\:W47]KG1[2.Z;2W,;0NDI>Y=5#,B%5(4@$ $YR<\
M<D [6BN,;QAJEQX@TO2[+2(E&HZ8U]&UW,T;QD;<K(NW*XW=LDGTZUF'QYXA
M_P"$8UC55T;3_,T*YF@OU:Z;;+Y6"WE?+G[I!RV/3!H ]&JEJ&HZ;HMK)>ZC
M=6UG#D;YIG" GL,GJ?:N8N_%VKR^*(-$TG2K24W6E?VA!/<7+(H^=5^<!20!
MN/3<2<=.2.9\4^)IO$OPA\5QZA8K9:GILHM+N!7WJ'61"&4]U(((H ]:HKG[
MK79G\2+X>TU83>):?:YY9\E(D+;5&T<EB0>XP!GG@5@7/C_48_#&KZA#I,+:
MAH=T8-2M#*Q 48)EC8#E=IW8(' /IR =_16%-KQ74+&.!K>6SDLWO;FXR<1Q
M#&UAZ[LG'LI]*P8O'=]-)HMW%I;7&GZG*D92&*4S6J.,I(YV[2O3=C&,\%J
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M17GTOQ'NCH%K?6^D(;H:PND7UL]Q@P3;PIVG;AQSD$E>H]ZVM&\1:G-XNO\
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MS;>N.1S7+_$&[O?#W@E!H0M[6-)[>VVA2NR-I%3:@' X./8=/;/UAM23XIZ
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M,8S6C110 4444 9FC^'M'T!;@:3IUO9_:)/,F,28+MZD_B>.U:=%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !7.^--!NO$.@I:V4D*7,-U#=1^<2$8
MQN'VD@$C.,9P?I7144 <I<>&KCQ#K$>HZY%#!'!93VD%M!*9"#, )'+%5_A
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M(U.\%S%Y,S.R_(J88% /X<\'O4OC;0KSQ!H"0:<\*WMM=P7<(G)".T;AMK$
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MME>Y:)XE( VM\C C()XZ9Z&N87X<ZEIGAW3CHU[:0:Y8:A+J,096^S9ER'A
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M%[916SQ33M$T;(S$'(1@0=WL1[UU,D:31-%*BO&X*LK#(8'L12JJHBHHPJC
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M:?H6G2:AJEW':VL?WI)#Q]/4GV%8<FNZG;>.])T*XBLWANK&:=YXU8/O0J"
M">%^;WZ5R7C+7-1\3_"77]8L39II4B2QPQO&QDEB2389-^["DE20-IXQSSP
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M$^+O$L+^%YY;72Y+;746-8E,BO%*T7F!BV2"O!R-N1ZF@#T&BN$A\;WVE_\
M"5PZ]#:RS:$D,JO9*R+.LJDHNUBQ!W#&<GK5JV\0>(?^$BM+%K 7=G=PR$W*
M6$]LMK*HR YDSN5N@( .>W- '8T5YC:^/?$DGA'2O$\]II:V4U\+6Y@3S#(5
M:<Q;D.<#''!!SR>.E:^GW>LS_%C6;.2^@:QMK*W=(?LYX5V?(!W_ 'LCEB#G
MC@8H [>BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8U+1_/\ (-Y;M#YNW=LR.N,C-947AW4=1FT4ZVUFL.D.)HX[5F;SIE0HKL6
MV@ D[1GDCGCG:TG6].UV">?3;D3QP3M;R,%9<2+C<.0.F:T* ."TGPEXGT&>
MXTO3=:LE\.33O*@DA<W5LKL69(R"%ZDX8YQG.#6C:^'M4M?$WB;50UFZ:M%#
M'%&9&!C\I&4%CMYSNSQTQCGK7644 ><1> -<L-"\-G3-3M(-<T&-X(Y'5G@N
M8GQN5QP1T'3.,?EL:OX>U_6_!6IZ7>WUD^I:C&8G>-72"!<8PB\D]^2<DGT
M%=?10!R.N^'-6U?2_#]NCV4<VF7UO>2$NQ63ROX1\O&?7M[T[_A&M6@\7:SJ
M]E?6T<&J6L4;JR,9(Y(U95*G.,?-DDC/'3O7655U'4+72=-N-0O9/*M;:,R2
MN%+;5'4X )/X4 <S9>$[AO%MAXBO8K"VOK:WDAN);$MF]+  %P0, 8) RQR1
MSQS5^)_G?8_#/V<H)O\ A(K+RS)G;NRV,X[5V\,R7$$<T3;HY%#J<8R",CK5
M:^TG3=4,1U#3[6[\IMT?GPJ^P^HR.#0!AR>'[Z\UNYUR[%JMZ+!K&T@21FCC
M5CN=F<J"22%X"\ =\UG1^ I;KX7P>$=0NHTGMHT6&[M\G:Z,&1\''<<C]>>.
MX "J   !P .U+0!S"Z#J6JZKH]_KS68;2B\D:6K,PFF9=N\[@-H +87GD]>.
M5N?"23^/+;Q&DY2-;;R[FW XFD4YB8_[NY_QV^E=-10!S5]H-_<^/-+UZ-[8
M6MG;2V[1LS;V\PJ21Q@8VCCO[5S#?#[7[;PAJW@^QU'3CHMQYGV22='\Z!7;
M<8R!P0"3AOT]/3** .&O?"OB2TUV#7= U33TOI+1+6_@NX7\B<)G:X"G<K#)
M'6I-4\(ZS)J.C:[8:I;OKE@)$F-RC""YCD.63 R4 /W>N,<YZUVM% '+>&_#
MVJZ9XEU_5M0NK.1=5>%Q%!&P*%(PG4GIQZ<]>.E.\1Z!J=[XAT37-(GM$N=.
M$T;Q78;9)'*%!Y7D$;01ZUT-U=065K+=74J0P1*6>1S@*!WJEIGB#3-7N[NT
MLYW-U9E1/!+"\4D>X94E7 .".AZ4 <5=_#_6[GPSXJTEM2L7;7+TW0D,3+Y6
M=F>YS]P8';/4UO7WA_4=0\7Z/K,OV-8+.UFMYH1(Q+^:%R0=O;;^.>U:5SXJ
MT.SN)H;C4(T,#;9I"&,<+>CR8VH>1P2.M:EO<17=M%<P2"2&5!)&Z]&4C((_
M"@#S63X>^(T\#7G@R#5-.;2]X^QW$T;^<D?FA]C <'&#SWZ8'4:]]X8\2V?B
MB77O#VIZ<DU]#'%J-M>PN8G9!A9$VMD$#C&?QKMZ* .1O_#6K7&N>&=0%Y;S
MG27FDG:8LK3M*A5MH (4#)P,GL.V:ZZJ6H:M9:6]FMY,8S>7"VT&$9M\C D#
M@''0\G J[0!YN_@#6_\ A7=WX16_L&A:X+6\Q1P50S^=E^N3GY<# '7)K>O/
M#M_?^-+'6IA:"UAL);.6 2,682%2Q!VCIMQCO[5U5% '"^&_"_BK08X=%;6[
M.;P_;-^X?R6%YY0.1$6SM [;L$XZ8XQUFL1ZC-I-S%I4L,5[(A2*6;.V,D8W
M8 YQUQ5ZJ5AJ^GZG8O>V5W%-:H[HTRGY04)#<^@(//2@"HFC)_PB0T5[6 I]
MD^RF'>2A7;MQNQGIWQ7(1^"/$9\ :;X:N;[3YI;"Y@DCNB7&Z.)PZH5QUX"Y
MST[5V^GZYINJR&.RNEE<() N"I9#T=<@;E/9AD>]1R>(](BO1:/?1K*91!D@
M[!*>D9?&T/\ [.<^U &8VAZD?B!'XCS:>2NF&P,/F-NR9!)NSMQU&,?C[5@_
M\*]U23P_<VO]HP6NIQZS)K%A=0@NL<C,3L92!E<,1[YZ<8/HM065[;:C:1W=
MG.D]O(,I(AR&YQQ^(H Y>;1?%&J^&=5L]8OM-:]O+22TC2T21((@ZD%SNRS-
MS[ 8P.I-0R>%=6?_ (0\B2R!T''F_._[[]T8OE^7C@YYSZ>]=K10!YT? NO6
M6B^(O#VFW^GG1M4%P\!N$?S;9I0=R<<,N3P>HST-3W'@[Q%97FDZOH>JV":K
M:V":?=QW,+_9[F)3E3@$LK D\YYSVZ5WU% '$ZOX1UJ]DT768-5MSXATR623
M?+&PMY5D4*\6T$E5P!@\GC)Y.:MZ#X?UBQ\7:QKFH75BRZE# A@MXWRAC5@/
MF)_VCVY]JV[/7--U#5+[3+6Z$MY8[/M,84CR]^=O)&#G:>E:% &+J^G:A?ZQ
MI4D?V4Z?:3>?-'(S!Y'VD+C (PI.[GJ0.F*SO&_AF_\ $*:3+I4]M:W^FWJW
M<5Q-N.,#!3 '(;//(Z5U=% 'FGB)[_5O&Z06%[H<5_IUBHE@OFD4JTIR3&Z,
MKL"J@'C X[DXDDTK6?%'@Z704CT2U:SO(=DUB[FV*QLLFU5QD$$;2,X'KG('
M;ZCH6D:NR-J>E6-ZT?W#<VZ2%?IN!Q5V&&*WA2&&-(XD&%1% 51Z #I0!RWB
MGPWJNJW>DZUHM[;V.MZ;O"B93)!*C@;XWQ@XX!!Z\?E7UCPEK>O:%"UYK$,&
MOVUTEY:SVT1$$#H" H5B25(9LD\G/H *[2B@#D9=&\4:IX:U6TUB^TUKV\M)
M+2-+1)$@B#J07.[+,W/L!C ZDU7G\*:M);>$(EDLMV@NCR$N^)ML9CP/EXR#
MGOZ>]=M10!P]YX&GU;4_%C7\T"V6O6\,*B)F,D)B4A6Y&#R<X[8QS5W0-.\8
MVPC37=5TZ[CM%(A-M&\;W+8(!F8D@=<X4=<'M@]2[K&C.Y 5022>PJEI&M:?
MKUC]MTRX%Q;>8T>\*5^93AAR >HH XE/ >L)\.K7PQ]IL3-!>"Y-QN?:0)_.
MQMV^O'7W]JWHO#^I0>.Y]?AN;5;:\LXH+F%D9G5HRQ&P\#!W8R1^%=/10 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5SWC'Q"WAK1X;[&V!KE(KBX,32+;1MG,A5>2!@#VW
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M:UMRK6L\84*PRQR/EZ?K71^'[#Q'"_G>(M5M;N5$\N-+. Q(<XR[Y)RQP.F
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MQ/!+&S23(]T4.U@P"$;N.&SC\*[Z;P[?IXZ/B*RO8$BFL4M)X)8BS'8[."K
M\9W8.0?\,*3P!J<GP_U#PP=0M ]W>-<_:1&V%#3"4C;GGD8SGI0!?\5>(M9T
M=]5DB:RM8+2R^T68E0S/>2 ,SKL5@RJN%!./XLYP*R[[6-8U3Q3X"FM+R&UM
M]3M)[LV[P&0*X@4\D,I;B0@=,=>>VA?^#M8N]7U^YBU6UCM];L4MITDMVD>
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MDW-]'=00V["29(=V"A+':<@<'/?GL #T6J5AJMIJ<M[%;-(6LYS;S;XV7#@
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M R!U5LD^@]<BK=>*O%]GHN@2W=A9VE_=ZPFG7$<L9Q(C%MLB$,=@(7H03R:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MK#&_YL <'(I+WP3JZ7NEZMHNN166KVEDMC<,]MO@NHE.0"F[((.3G/>NXHH
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MW)Y))XZ#9HH P[[2]6.O#5-.U&")/LRP26L\)=),,S!MP8%2-W'7J>.F,MO
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MXO7,%E?Q6]P?#L(>Z>#S#_KWY"9 R3Z\#THTGQQJ5_X:\.B2,-JVJ7-Q:R/
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ML02S99B6X&/3W[)X<\*ZWI(@M]2\42ZE86@Q;0FU6-^!A?,<$E\#ITY )Z4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M3S2JDJ)"!MQTSS@C@Z.H2>*-&T'Q/<RZA:SI:P-<:;<21 RX6,LRR*H5>&&
M1V/- &[+K=G!H]OJ4_FPQ7 C\N.2,K(7DP$3;UW$D#'8UGZ7XPLM5UJ72([+
M4H+R#=YPGM65(RN."XRI)# C!.17(>*);[5?#/P_OY;^5)KK4M.:38B8,C*6
M+\KUSVZ>U=$^JZK:?$?3M$DO5FT^;2Y;A@85#F1&1=Q8?[QX  H ZZH+RZBL
M;*:ZG#F*)"[^7&7; ]% )-<!;>(/%NN:/I^OZ':7$J7$X<V<GV98&MRQ! 8M
MY@<+SGIG/RXJ^=5U#Q,?%"V-^;*VTN1[&)5B1O-E6,,[/N!.W+!0%P>"<\C
M!TF@WFFZMI%KJVF0+';W<0DC/EA&*GID"IK;4X[K5+ZP6"Y22S\O?))"5C?>
M,C8QX;'?'0U@_#+_ ))EX=_Z\8_Y51BUW6WUKQS9&\@_XE4$$ED?L_";XF<Y
M&<L> .O;IVH [FBO,K'Q'XEBT[P/K-WJ<,\&M2P6US:"V51F2)F#ANNX%>G
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M^Z .A(&3[8YLV7C'4-9M?#-M!%,EWJ>EG4+E[01;U V#""4[>6?/.< 8QSD
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MS!&*HWS'.!VX J^UYXFB\?MX=.MQ-!=Z:UZDWV-0ULRR!"J#."#N'WMV,=Z
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MIJ/@J.>R\/6.G7:V-IH=Q%<01F'S"[1J5 8[AQACGOGG-=24+Q;)""2N&(&
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MU59/_"16?_"5+X=V7'VUK1KL,8\1[ RJ<,>IRPZ4 <5X:^TW_C7QW'IFL6T
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MO^);#PYI7]HW@FDMQ*L)-NF_#%@G/8?,<<FMB@ HHHH **** "BBB@ HHHH
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M*ZFPMI+/3[>VEF$SPQA#)MV[L# .,]:X[Q.VB^-=3B\*A)Y[NQO8I[H^2ZK
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M]KITJIB,@Y4&3&YE4\@9 X'6NRH **** "BBB@ HHHH **** "BBB@ HHHH
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M;#3+C4KF\TO3I4EM;:95R"AS&KL!EE4XP..@SG%=57,ZCXQ72?"L>O7^CZC
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M,IC>6( K  I.Y\GIQCCUH NT444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<UXQUFYTJ#2
MK:T.V;4M0CLQ)N *@JS'!((!.S:,@_>KI:R/$OANP\5:.VFZAYJIO66.6%]D
MD,B\JZ-V84 <W):^(K.S\3IJ$PDTB73I'M(YI_-FB<(0XSM&5.0>22*RDO\
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M$4 >/^&=5NO#OPFT::VO)A/J6I_8(WDVLEOYEU(#(!CK@$\Y&<?2NNN;V_\
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M;J:T2T97,;*$4DJ>5SG))R2<YH X[1/%VKZCX:\'VLLQDOM5DNHYYU98VD6
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MGC.3G YSBG:-J5^_C^]T1;G4H["72$NXOM@4RI)YC(77=D@$8^5QP1T%7Y?
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MZO"838-GR<?+QSFM30])CT'1+/2H)YIH;2)88WFV[MJC !V@#H/2@#0HHHH
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MK)V,-H^WYA,BGNQZL#P1C'6M:QO+B?XFZOIGVR=]/;2H+A(Q*<*[NX+*>HR
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MH);MKU)6D598)RQ8O&RJ,')/KUK7T'P]'H44F=0U#4;B0 /<W\WF2%1T48
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M^@P.*AUO2)%\2:7XDM(S)-9I);7,2#YI+>3!./4JP5L=QN YQ4OB3Q1!X?\
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M3VUL;6."/8(A$2"5QMSU []JW** "BBB@ HHHH **** "BBB@ HHHH ****
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MC&W<!R, #D?S-6K_ ,%Z;J/AAO#\T][]CD8-,WG;I9V#!MSNP))R ?PQTXH
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M#85L@#EACCKSB@#4HHHH **@:\MUOX[$RJ+F2)IEC[E%*@G\W7\ZGH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KC?$.KW<'B2"&7P[K-
M_I]JJS1M90HZ23'."VYU^X.0/[QS_"*[*B@#S[X-7[77@&W@-C=P""6?$LR
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MF632;B:X=Y#!-\I(8G/[G#D\] *[B?PQIDVL6NL213O?VL/DI(+AP70'<%<
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MYO!I4,WV34(7NI&C5).$F(+$?*Y )/9O:N@\,*;F*\UEI)6349S+ C2,RI"
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M+8J&E.;:.6128 1_!@]#G@CVK2EB6?XLZII\C.UG/X>226#S#L9C,ZDXSU(
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MQ1R74JQK)-' F?XG=@J@?4D5QUK(GB+XB>)M)U53);:;;VJVENS$*1(K,\@
MZMG"[NHQQC)KBIQ/J?AW1;?5GENVTWQHNFV]S*Y+RP+*5!)[GC;GK\M 'IT7
MB*X;Q]-X;DLXTB33A?)<+*6+@R;,%<#'0]SVKH*\ZNM'M+_XOMI\WG"T7PVB
MF..9DW 7#  L"&(_'ZUAZ/K5['X4\+:9/>D6USK-U8R3W+L=R1M+Y4;,""<E
M4'7D#!X)H ]AHKRCQ9H=YH'@[QBZZTRQ26R7-M96K21BT8?*Q4[R=KG/R],@
M\5WWA_0[728YKB"6ZDFO1').T]PTF6"XR 3A<^@P/R% &S17F[:)!KWQ-\2Z
M;?W>H-8BQM9!;I>R(H9C)R,-D#C.T?+GMTK"T/6=4-EX>T"_O_-MY-6O[$75
MT6(N5@R(E<@@G))'7G8 <\@@'LM%>1^,-%O?#W@7Q2%UR0J9+>XM;6V>2/[&
M'D"LH.\Y1L'"G@<\5NZ_X=O-',$^@P/JVZX>ZO=+O+UB;L; I9"Y(RI(.T\9
M(]!0!W]%>4V_B*UOCX/TJR-];Z7?ZE>1WT5T666.1 [BV<YSC>P&,\A0.F15
MG4$N-+\5>)=#LYKB/29O#[:BJ1S,OV6<,R?NR#E P&<#C(/O0!Z;45RTR6LK
M6\:R3A"8T9MH9L< GL,]Z\FL;=M/TKX9ZS#=WAOKV2VMKEY+EV$D3V[$J5)V
MXR!CCKSUYKTGQ.A?PKJP$DL;"TE97BD:-E(4D$,I!'(H KZEK\NA^&(-2U2U
M1+U_)B-M%)N7SY&50H;'3<W7'0'K5C2;K69;N^@U73H8(X67[/<P3;TN%(.?
ME/S*5/!SUSQ7F^MVT=]\'O!EQ<[Y9MVF NSMD[FCW9YY)]:]7@@ALK58HALA
MC'&6)P.O4T 345Y!%.\3^#=3T^>XFBO-9,+ZG/*5FOHW$I.Y!QY? VY.1M&%
M%6WTB+4]>^(EO=W5^\-JL+VZ?;)0(V-OOR/FSPW(!X'I0!ZI17E-U+>+X#\'
M>.'EN)YM.M[>;44$C$7$#(!(S+G#,N=X)]#7:>'/*U*]U'7XGWPW<GDVI#$J
MT4?R[P.GS-N.1U4)0!T55=2OX-*TN[U&Z)%O:PO/*0,D*H)/Z"N3NKK^U?BH
MWA^_!:P@T@7<5NQ^2:1I=K,1_%M   /3)-<S<K/+X(^(VCW<DUS9:0;@6,LL
MC,R*8-XCW9RP3=CG/! H [S1M6UK4+NVDN-*@CTR[LUN8[F*XW-$QP1&ZD D
MX.=PXX-:-QJD8-_!9^7<7MG$LCPE]H&X$J"V#C(4]CV]:J>$K."S\*Z8L"%0
M]K%(V6)RQ1<GDUR?AS3;2'Q_X_ECBVO%);E#N/!>V!8]><DGK0!UOA+7'\2^
M%-.UEX%@:\B$IB5MP7D\9[ULUXEHUH-.\"?#K6;:XNEO9-1M+5V\]]IAD9E:
M/9G;C'M[UT*VEWXWN?%5J;^*VO+._>UMW._S;-55?+=-KC&3EL]^03@   ],
MHJCIR/-H5HEQ>?:W>V0/=19C\X[1EQ@Y7/7@\9KQF/39F^"R>*X]6U-=;T]Y
MIK>X:\D8#;<.-A7.&##KD$G/7'% 'NE%>9'1T\0?$G5;#4;C4$MWTBUN&MXK
MV5 DID;)&&R,8Z#CVJ;1XU\867BZ749IH[VUU*XL[=UE9&LTC4",I@_*?XB1
MU)YR.* /1ZKW[W46GW$EC"D]VL;&&*1]BN^. 6[ GO7E;:CJ$G@SP9X^OS+Y
MMHT?]IH&(66!\Q^:RC@E25<<=S6]KT0N? GBW7HIIXFN+2>6UDAF9"L<<9",
M"I'#%2_N& .<4 =S;-,]K"US&L<[(ID1&W!6QR >X![U7OYM1BGLEL;6&>)Y
M]MTTDNPQ1X/S*,'<<XX]ZX34?[772?#>H6NG+KEG!IB_;-,\[;*=RIB9 >&8
M;6&#SR<<FJUS?6MW8_#N^TF\OC:3:DL&)I7#.H23*R+G#,&7!)SR.M 'J-%>
M>:+$GC+_ (2_^TY94N[74YK*V99&1K2-%78Z8/RDDEMPZ_08K TN]U#Q&WPS
MNM3NKR.;4(;Q;H17#QB8)$VUB < D<Y&#\W!Z4 >Q45Y986FHI8^-]"T:\\K
M[+J<(LDNIW*@,L3M#O)W!7^9>O\ %6]X&U.WN]1U:U?2KK1M4@$/VK3I6W1I
MG=M>)AP5;GICD=.: .UJ"^O(=.T^YO;ABL%M$TTA SA5!)_05R.H7?\ :7Q4
M@\/7P)TY-':\2%CA)Y3*$.X?Q;5' /\ >)[#'/.DS>'?B1H5R\UQI^DI(UB\
MDC,4#VYD\O=G)"$C .>#B@#M-%UK6=3GL;B7284TF^LQ<QW$=QEX20"$=2!D
MD'JO ((]ZU9=1C-Q=6=J8YKZWA69H6?: &+!<G!QDHW8]*S/!%G!9^"]&\A"
MOFV4$CY8G+&-<GDUSN@Z;:+\6O&,PBQ(D%E(IW'[S))D]>: .F\'Z^_BCPGI
M^M26XMVNT+F)6W!,,1C.!GI6Y7AVBV@L/AKX%UNWN+I+X:G;0[A.X7RGF963
M9G;M(/IFNG-M<^-=2\6Z>][#;W5G=?9K<MO\VT3RU*2IM88)8LV>^,$X % '
MI58'B_Q;8^#=(BU&^5FCDN(X=J]0&/S-]%7<WX8[UHZ*)5T2Q6>]6^F$"![I
M5VB<X&7 [9Z_C7*:Q:S>)]6U6#^S!>Z;#;/IJDSJF)' ,S#(Y('EJ#V*O0!W
M"L&4,I!!&01WI:\^\!ZA<ZA\/[S1=3>2/5=%\S3KKRY2C_(/D<,I!Y7'(/.#
M7+6]JZ> / 6MI?WZZG/?6=O)<BZ<DQR,5=<$[<$'TZ\T >U45Y?<RS>$O%WB
MF+2&G,2>'/[26"69Y@;A6D&[YR3D@#/K5O2=%FO8_#GB.UUV&&-E0SR1^8S7
MZR  HY+X+9/!QE3TQB@#T6D8L$)4 MC@$X!/UKQ"[M'7X;>+M7^WZ@;_ $O6
M+HV4S7DA,.R8 ?Q?-QQELG%=O#=+X@^)6IZ/J0WVNGZ?!)!;,2%D:0DO(1W(
MPJCTYQR: -KPCXAF\2Z5<7<]HEK)#>3VIC23>/W;E<[L#.<>E;]>+Z+?2:1X
M8L=-CN?)M;SQ5=6<TTSL<KND*JS @_,RJ"<\\YZUK>)$U3P#X?\ $^J6>JQ!
M9X8F@L8HVVV;%UC:5-S' ^;.,8R/K0!V6L>(;C2_%/A_25LXY(-5DEC,YE(:
M,I&S_=QSG YS^%=!7F^LZ/I^G>/? ,UB&^>:Y5G\TMYW^CL0[$GYF_VCR<UZ
M%=W4-C93W=S((X((VDD<]%51DG\A0!BR>+K"+QU!X58'[5-:-<+)GY<@C]W_
M +VW+?0#UKH*\@\3V&O1>&H?$PT8QZMI]\=9>3[0I;81AHBN,X$053_N5U7B
M[4YM0\*:+J>DR22:?<WUI+<K"?WDUJY&44#DDY7*CDC(H [6BO/;/1;A]>\3
MWL?]I6NBM:HMG%Y\]NJR[&\QDCRNT?=YQUSCO7.60.B_"G2/$XO[T7UY;VEI
M=74UU(R1PO,@9MN<*0,C<,'G.<G- 'LM%>>7^FZAX6?5?$%AJ5NJ?V1.R:9#
M&Q266-2ZRC+'!Z X'.1GFDTG19KQ/#GB*UUV&&-E0SR1^8S7ZR #:Y+X+9/!
MQE3TQB@#T2BO$[BR+_#?QEJ37VH->:9JMX;*8WDFZ'RY!MQ\W/ QDYXKJ);;
M^ROB)X0FMKBZ\S5H+I;XR3NXGVQ*ZDJ3@8;., 8Z=* /1**\GTNUO_&'A*/7
MTUJWT_4H;J2:2\VNTEN4D.8F&\#9M&-N,8.<$G)L?V1#JOBSX@6EY=7[VT$5
MJ\,7VR0"-F@9LC#9X/('0>E 'I%S?6UG-:Q3RJDEU+Y4*GJ[;2V!^"D_A5BO
M'88UUR+X4WNI;KBYN$=)96=MSC[,QY.>I(!)[U["JA5"CH!@4 +1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M5+>VD^WK;BV,\EQ)([IDGYBS'<<GJ<G@>@K<HH YH> ?#:Z%-H@L'&FS.'>
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M#3A-IL)&F@K:!<J(E( *@ C*D  J>#CI4MOX>TNUU"^OXK8_:;\!;IFE=A,
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M8R0NYR2 "2>#UYZU#9>"_#VGWUK>VVF(MU:QF**9G=V"G'!+$[L8&,YQCC%
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M"74&AFBO90%DN+>YDA=E P 61@2!Z=* /.YO&>MMX.O(-:$%E?V.M0:;J-[
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M6E_)$LDMN6N+2)0/*DC?S!L&!NR!C.[.<T[QEI\UK!H?B'0W:^\06ML6D98
M3>6_EXDD="?O#(*]\D+SG@ ]1HSFO,]8U#2M.\'^$QHL\$/A^_OXHYKB12R,
MC(Y'FX*]7"ALD=P>,BJ_B3PS#HWAOQG+%J46VZTMKG^S[.$PQ0NBD"4 .<%N
MXX#8SSB@#U3-%>4W>AV$'B'P!+#&\<NH1RP7DB2L&N(_LV[:YSDC('';H.*H
M:C8V^G:3\5=*LE:WL+.**>W@B<JL3M;!F*@'@%N<=* /9:H0:I#J*:BFFRQR
MSV<K6S;C\@F"*VTD=AN /ISZ5YM?:!;Z+J'@;6]'\U-3O;N&UO&\UF-U \19
M]X)P0H7([#\!B;PKI&F)HWC[R[.WA==5OH4>)!&RH(T8("N"%SS@<4 >D:<;
MUM-MCJ2VZWQC'GBW),8?'.TGG'UJU7D>E7CMIGPLTF[YTJ_M&-PK_<ED2 &-
M&]1DDX/4@>E2ZM9G3M9\<:19*T>C-H'VXPQ,52WN2) -H'W=P3<0.I&: /5\
MTR65((7ED.$12S'T Y->3VFFVNF/\,=3M$9+Z[6."XGWDM+&UJ3M;)Y4$# Z
M#'&*]*U^UM[S0+^&Z@BGB,#DI*@9<@$@X/H>: ,;0-<US7%TG58[6R_L3486
ME8999[88RF3DA\\ @ 8)[UU6:\4?2K)/@[X,F@@6WFFN].\R6W_=LY9U!+$=
M3[G.*Z.XTS3M(^(.A>&XK18=%O(KN]^SNS/'<77R]0Q.<+E@.F3G&10!Z11F
MO'-=MGLK#XF:/;[UT>TLHKJVB1BJV\SQLS(F.BG ;;T&>G-7[W0M/@\6> WA
MB>-]2BGAO725@UR@MMX5SG)&0./3CI0!ZI17!>"8K71?$_C73;?9:Z99W<$D
M4.[;'#O@5GQG@ GFN\!#*&4@@C(([T +17D=C'!XB^%OB#6]2 37K>2]D>ZZ
M36DL3,8U5NJ!5"<#'!/J:='IJ>)?&7AM-?AD=[_PPTE] 9&57<F+((!&.3G
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MEE4SRVZ2$$\M\HR<?4_K0!=HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MQR?XOFZC-9^OVUEX9T/6KG3]5>>SN=2LY=42%%,-O&S@2;57CYE W+W!'8T
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MS?#2+HZ;-:PW@0F*2Z!,2GU;!!Q4[7,5O'$;F>%&?"@E@H9O;)KD?BU!#/\
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M8R>@ZUTRR1O$)5=6C(W!@<@CUS7 :II>GZO\9H;74K6&ZM_^$>9O)F7<C$7
MZJ>#^/U[5R(D/AW2KFU28P>%D\6>0'<;XXH-ARO/'EB; ],@^] 'M<%Q#<Q^
M9;S1RIG&Z-@PS]11-/%;Q&6>5(HQU=V"@?B:Y7PYI.F6/BG4KZPU87,U]!&]
MQ;VX00KCA7(7HQ&1[@'TK.\1W\:?$W3=/U&\AM;.;39&M&N(U:-Y_, <?-QN
MV;<=\$COR =T;F!55FFC"N,J2XP1[4Y98W<HLBEEZJ#R*\SN_"&@MX O='M[
MV2]87SMILJJI,%R<,J0XXVALY'0#?DC!Q'9ZG=?\*Z\6W$,7D^,;:.9=3V*!
M()@GRLN/X-@!3'IW.20#TZ.Y@FEDBCGC>2/AT5P2OU':D:ZMU95:XB!9]@!<
M<MZ?7VK@-(T[P[JE]X;UNPUJ%F2-HK>"UCC4S1NGS1R@<D*!D@]"/6N/N=&T
MP?!_QA=BR@^T6FIWGV:7:-T&V?Y=A_A_#% 'N*SPO,\*RHTJ %D# LN>F1VI
M&NK='5&GB#.VQ5+C);T'O7G]]I=AIOQ-\'M96D,#7UI?)=,B@&X 2-AYAZN<
MDG)R<UREOX9T*[^%OBV\GM(5NK*]U!K6X'W[=HY&:-4/\/..!C.: /7GUW3X
M_$$>B&X3[<]NUSY>X95 RJ,^F2W'K@T_6M5AT/1+[5+CF*T@>=E!P6VJ6P/<
MXK@-+MT/Q.T>;5X(!?-X626=I47/GB5 6Y_B!XSUKJ/B'!#/\.O$7G11R;-.
MN'3>H.UA&V",]#[T &A:AKEY+9W]W<Z6^E7EHDA6,,DL,[;2$!R0XP?8Y'O7
M0&\MEM_M!N(1 /\ EJ7&WKCKTZUY?XATC33X:^'F+.!/-U6Q5S&@4L&B;<,C
MUP,^N!6C'8V&E?%;3M"2Q@MM(_LF:>QMP@$1NC+^]('3<$_($XZT >A&:(0^
M<94$6W=OW#;CUSZ4T7$!DDC$T9>,9==PRH]QVKQ+Q-8B#P=\2;%(E.D6=] ]
M@I&5AE;RVE5/[H#-T'3)]ZZO6?#^D1?%3PU#'I]NL=Y97HND"<7 7RV'F?W^
M23\V>: /1(IHIXEEAD22-NCHP(/XBGUY_P"!)K#1/^$QCDEM['3;37) @=UC
MBA#)&<#. HW'IZFN_5@RAE(((R".] '%Z5XEUSQ'I%WK.BC3'ABFFBBL)5?S
M7\MBN'D#81FQD#8< CGFNHM+]7T>VOKQXX/,A220L=JJ2 2.>G)KSC5?"]O/
M9W/CKP/J[:/J#1O/<QA@;:X9<EUE3H&R""?7)QGFD3Q&^L>(O"TNM20Z;#J.
MB&>!;B,-$;EF7>HW\9V8QGG!([\@'J8DC,7FAU,>-V_/&/7-9^I:]IFE:'<Z
MQ<W<0L;="[2JX(..P]23P!ZUYK=Q:;X6AT"Q34FNO#<FOR"[>3;Y,;-&62(8
M^7RA(<XZ @@]*M^/=+T"'P5XVGTW9)/<01W%PB,'CCD VJRCHK$ DXYZ$]10
M!WUU/>3-ITNGW-FEN\P^TB<%B\94_*A!P&SCK[U>EN8(&19IXXVD.$#N 6/H
M,]:\_P#%%II\6K^ Y+2"V1DU4(&B51@&%V(X]3@TOAV&TU_4_'=EX@ABEN$U
M!H&68#*6?EKY6,]!]]LCN2: /0FD1"H9U4L<*"<9.,\?@#20S17$?F0RI(A.
M-R,"/S%>+:1:R:K;?"R77(O/NIC=QO)*/FEA$4FP,>I!7:<'KGGJ:[+P-;0:
M?XP\;Z?9Q);V<-[;O'!$H5$+P*6P!P,F@#NJ*** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***:[
MI%&TDC*B*"S,QP !U)H =17'^&_&,^LZ_P")(;F!+73M-CMY;=V!#M'(CL7?
MTR%! QD \\]*2>.+Y/#5EXNN8K=-$NKA$,&QA+# [[$E+[L$Y*DKMZ-UXY .
M]HKEO[<U/6-9UJPT1[.+^R2D3-<Q-)YTS+OV\,NU0"!GDY)].=#PIXAB\4^&
M;/6(HFA\]2)(6.3&ZDJRY[X8'F@#9HKDO"_C5/$/B/7-*:#R?L3J]HQ_Y>+<
MC;Y@]1O5N?0K76T %9FI>'=%UBYAN=2TJSNYX01')/"KLH],GM[5:74;%[TV
M2WEN;H<F 2KO'_ <YHGU&QM1(;B\MXA%M\SS)579NZ9R>,X.* &WNF6&HZ<^
MG7MG!/9. K6\B H0""!CIP0/RJT %    '  J.:Y@M[=KB::.*%1DR.P50/7
M)XKF?#'B&\U?Q1XFL)KBTGM-/DMQ:R6RX#+)'O.3N.3R!GVH ZNBH+J]M+)5
M:[NH;=7.U3+($!/H,US>K>(+VS\;^&K"&>U;2]3CN7E.S+?NXPP(?=C:<^G;
MK0!U=%00WEK<6OVJ"YAEM\$^:D@9,#KR.*CCO8=1M)7TR]M9F&5616$J*WN%
M(S],B@"W5'4M&TO68TCU/3[6]1#N5;B)9 #Z@$5P(\;:[)\)=*\4*UHM[<3Q
M).IA)7:\_E_+\W! /?->DS"4PN(71)2/E9U+*#[@$9_,4 5KK2M/OK#[!=V5
MO<6?'[B6,,G'3Y3Q47]@:1]IM;G^S+/S[4;;>3R5W0CT4X^4?2L7P+XH?7O"
M>E7FJ7-HFI7@E/E(0F[;(R_*I.<84>M='=:A96/E_:[N"W\P[4\Z0)N/H,GF
M@"D/#.A#6O[9&D67]I_\_7D+YF>F=V,YQQGK5Z[L[:_M9+6\MXKBWD&'BE4,
MK#T(/!J>LRPFN8FU)]0U"SFACN&,?E#9Y$>T';(23\PY.>."* +<%C:6UD+*
M"VBBM578(40! OH!TQ6<GA'PW'9RV::#IJVLS!Y(1:H$<CH2N,$UHQWUI+<-
M;QW4#S*H=HUD!8*>A(ZX]ZHZ-XCTO7Y+U-.NHIOLL[0,4<'<5"Y(]@6QGU%
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M$?79D?P\GY>E6S?6BQ1RFZ@$<APC&088^Q[U8H ;'&D4:1QHJ1H JJHP% Z
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M!<1Q,'C$B ^6PZ%?0^XJ.70=(GTS^S9M,M)+'.[[.\*F,G.<E2,$YY^M:%%
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M6'1M,M]2FU&'3[6.^G&);E(E$D@_VFQD_C5ZB@#)T[PQH.D74]UIVCV-I/<
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M62^'M$FTP:9+I%@]@&W"V-LGE@^NW&,U+9:/IFFR/)8Z=:6KN%5V@A5"P4
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M!9"GT)'% $7AFVM[/PSI]K:7-Q=6L4"I#/<D%Y$'"DD 9R,8XZ8KRZXLK-?
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M98Y""R@,1SCZ5'#XC27QG/X;-G-'+%9"\\]V7:Z%]@V@$GJ#UQTZ4 ;=%%%
M!16)<^(TMO%]AX>:SFWWD$LZ7&Y=F$QD8SG/S#J!^-;= !16%K/B-]$O[&&?
M39GMKR[BM([A)$P'DZ97.<#!K=H **** "BBB@ HHHH **** "BBB@ HHHH
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M1R<'KUR>*T[RVU&U^)%EI*:_J9L]3T^>6X5I%)5HV3!CXQ'D-@X'3WYK8N?
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M<9H X.2_UR+X;:CXD/B'4GOM-U21(5,@".BW(3:Z@?,"IQCH., <YZ@6*O\
M'"X8W%T/^)'',%$[;0?/88QG&W@?+T[UI-\/M-?PQ>>'FOM0-A=SFXE&]-Y8
MOO.#LX!;FM&;PM:3>(K776NKU;Z"W%LS)*%6>,-O < <X;GC'H<CB@#A&\5Z
MMHWA+QA=-?S7%S;^(&L;:>?#>0C&)0<8 PNXD#&,_6M[6);WPSXL\-I9WUY/
M9:K,]E=07$QF(;8665"V=I&#D#Y2.U:D/@?2DT[6;"Y:XO+36)WN+N*X92#(
MV,LNU01]U<>F!BK-CX8@M;BTN+B_O;^:RC:.T>[9"80PP2-JC+8XW-DXSZG(
M!YK=7FN)X!\4ZY_PD>I_;-'U6Y6UQ(H4K'*  X ^8$<8Z>@KJ_$MU<3:EJ$<
M.HWDCQ:5YL=G8R&(VSG<?.D<, 0< !3G.TX4\UH-X TY_#^J:(]]J#6>IW#W
M%SETW%W.YL'9P"<?TQ4DW@;3Y]5EU!KW4EEN+5;6[6.<(MRB@A2X4#D GE<?
MSH Y6\U"YU;P[\,-0O'\RYN=1M997QC<QMY"3@>IK5AMOM?Q7\26_G2PF31[
M51+"VUT.^3D'U%:,7@'3H=-T6P2_U(1:/,L]J6E5CO4%5SE3P%)&!@>V>:M7
M&D6VCZOJ7BL/J-S<O:A);:%5?S$3)540*"3DG'/.: .6T#5=0O\ 1H/#%W>W
M(\06NI&VO9Q*P<QQGS#*.<[7CVJ.V7'I7H5X,:?<#TB;K]*YWPW9PZCKM_XM
M;2Y[&6\@BMHDNH_+F,:9)9US\I)(&#VC4]ZZ6Z@^U6LL'F/'YBE2Z8W#/ID$
M?I0!Y7X9U6[@\%?#[1;4JO\ :<$GF,9S"66-"VP.JDJ22#D#.%(R,UM3Z3KE
MKX9\66VKZ@LMF;=Y[!([R26>%?+;<CN54LNX<9SQD'I6E-\.]&G\*V7A^2:]
M\BP<265RLH2>W8="CJ!TR>H/\JNV_A.V@T.\TQM1U*=KQ#'<7EQ.))W4@C&X
MC &"<  8R3U)- 'GMWID8^'_ ,-W%U>_OK[2PP^U/@!D&<#/&,#'IVKUY(Q#
M;K$&=@B;078LQP.Y/)/O7/3>"=/G\-:?H;W=]Y&G20R6<RR*)83%PF"%P<#C
MD&NAAA6"W2$,[*BA=SL68^Y)Y)H \0TR+5M%^"VE^*]-UV^CN-/02"QW+]FE
MC\XJR,F,DG)Y)SGICC';R2[/C%>2^8D!'AA&WR?=3_2)#D^PK5L/ NFV%C!I
MJW5[-I-O*)H=/F=6B1@VX#.W>P#<@,Q&?H*LW/A*QO-?NM7N)[F26ZL3I\L)
M9?+: DG;C;GJQ.<YYH XW2]5U&#Q)X+6/4+^Z@U..X2[N9W(BO2L.\21QL24
M&X<8"Y![BJ<\FLW'AWQ[>MXDU19=&OKAK,I(JX\N%' ; Y7MMX')X)KK;7X=
M:9:G1S_:.KRMI#'[(TEW]Q"NWR^ /EQQQS[U8'@>Q&GZY8_;K\PZU(\EYEH\
MEG4*VWY.,J /PH XWQ7XDFTKQ#X3\0/:/<R#1;F:1(APNX0[F('.U<DG&3@&
MO1/#ULD.DPS)J<VI?:%$OVIY2RN#R"@R0%YX'IC))YJC'X-LX]1TJ^:]O9)-
M,MFM8%<QE3&P 8,-G.0HY]J@M/ EG8>'+G0K/5=6M[*9]Z>3<*CP'<&(C8*"
MH)'3I@GUH A^('W/#/\ V,%G_-J["N,\:&2]O/#]C:VE[-+;ZS:W$K+:R&-8
MU)RQDV[>,C/-=G0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !12$X!/IZ5CZ#XDMO$$^J16]O<PMIUT;643H%+,%#9 ST^
M8=: -FBN,U3XBVND3>==Z-JBZ,)A"VK>6OD*Q.W=C=NV9XW8P>V>*[/J,B@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
@0 4444 %%%% !1110 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>33
<FILENAME>exhibit1018-arvinasxcons001.jpg
<TEXT>
begin 644 exhibit1018-arvinasxcons001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=S",;5)QT!/ &3FL-M(UFQN+2\CTJ6Z,&O7=X88I8@QBD2158;F _C'&<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 5B^+-9N/#WAJ]U>WABF-JGF-%(2NX9'0CI6U7*_$G_ ))SKO\ U['^
M8H N1WVOR65M=K:6$B2^6S1K*X8(Q&2.,$@$G'?%4?$/B?4O#VM:;'<VEK_9
M%[.(&OC(P\ACT#KCOTSG'KBGV>F&VT_2-3N-:N_L]E$)Y(Y2GEE?)9?X5!XW
M9'/:K/BJ.#5]-?P\84GGU&,KL<<1(,9E;N-IQCU; XY( )_[2OI_$3V-G%;R
M6<" W,[,P,;GD1@="V.>HP",]16;8^(=8U#Q/K>BPVMBITOR,RN[_O!*I8<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA.H(X/:I9X?$ES:26MQ8Z)+!(AC>.2>5@RD8(.4YKHJ* ,%6\4HH5;710 ,
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBCI0 45YYX6\0:E\0-6U2[M[^73]#LIO(M
MX[95\RX;KN=F!P,8.!CK[<Z&O:WJ/@G2-9U74+HZA:QQQ"Q5U5&,C%@5;:!G
MDJ<X''N.0#LZ*X6T/B*Z^'PUYM:E759;3[:D:Q1^2N5WK'MVYQC )SG/.:SE
M\5:YXO\ AW::MX=N?L&L-/Y#Q!4:-I #E?G4X!&"/3/- 'I=%>;^'/'%QXH\
M,M!)=2Z=X@L;B&"\C5$W',JH6"LI&#D@\<'\*?J_C.+3_B#-H6LZI<:59+;1
MM:3JJA9G/WF=BIQCH.B\'/:@#T6BO/\ QEJNNZ!\-+K5(=6#7\$P,=S''&5E
MC:8!2001]QAT[UJ)=ZC-\.K'4/[3G2^EM8)WN D>2SA2PP5VXY/:@#K**\Y\
M6ZYK6E_$/PQI%GJLT=GJ!VW">5$2<''!*9&:[O4HKR;2[B&PN/(NVC*Q3E0V
MQO[V",''7% %NBO,KS5=>M?BWI?A==?O&L+BR,TC&&#S"P$AX/EX'W!VIGQ%
MUCQ+X0\'V%Q;ZW(U\U^T#S&"(^9&?,9<C9@,%"CC'0T >H45P'C^Y\5Z7!:3
M^&M0DDDAADGN+>2*-_.1"F<?+G/S\@$<#CFK>B^*X_%]CH6HZ;?2VPEN3#>V
MJA&VL(I'*G<I/51@C&1^@!VE%>?:5XDU#QEXWU;3;&[>QT?2#Y<CPJOFW$I)
M'WF!VKE6Z<\=>>.GM;+5[37U+:D]UI+6S_),B;TEW)M^8 9&W=].Y.1@ VJ*
M:[K&C.[!44$LQ. !ZUQ'@CQM-XBU[7]+O8C!/:S"6VB==K?9R !D>O0G_?%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MF)4-MYXP1DXQD<=S6KH3WEAX_M+6^U&YD_L+0@;J+SB5>8IG8%[_ "\Y]1]
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M@XXH ]7HKG_!FDR:/X?6&:_%[++*\SR(Q,:EC]V//\(Z"N@H **** "BBB@
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M/96NH1O<P)YCH05^3^\"0 R^XR*DCU[3KA7"7+IB S[WA=!Y?]\%EP1R.F:
M+-WIEC?NCW=G!.R A3)&&P/3GMP./85!J&@:-JTRRZCI5C>2(NU7N+=9"!Z
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MWQ-FU ^";ZQTJRN[N]O%$*K;PL^$)^<D@8'RY'XUV-->1(P#(ZJ"0H+'&2>
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M6D=K;J1'&,#<Q8GN22>22<DD]2: ,_Q2UROA;4C9V$=_<>0VRUD3>LI]"O\
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M;:V<B20,KAPA!!)7>,#/10*UO#26DTEYJ-KI-Y9?:?+#RWH99IBH(Y#$G !
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M_AW!<6O@73+:ZM9[:>)&5HID*,/F)Z'V-=1110 4444 %%%% !1110 4444
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M<#KUZ=ZFUZ*,?$7PE,$7S"MXI?')'E#C/I5SP_HVHZ=K&M7]]-:L-1FCE6.
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M&,GC%;ZZ/>GQM_;;FW%N=/\ L9C#DN#OW[NF,=OU]JR+2QLO#?@D>'O$^HV
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MTB9+B6T:YO+:V)$UQ:V[R1(1UPP'S8[[<U4A^('AV;2[G58Y;C[/ Z)*YM)
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M9(.XD9). 2P(QD8QS3=:\8Z[%K'C2>SU$QZ7H]NL43/"C*MPV!@<9)W?+R2
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M6\"&221NBJ!DFJFGZS'?WEQ:?9;NWF@5'(GBP&5LX96!(/0\9R.X%<!X@O\
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M7M0UTV^HVGV Z4\LR31L6$T2HS*KYR0<E<XP, ]3B@"YIGAJVTP0K]LO[I(
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MXR/F .!QQ6VEU;RS/#'<1/*G#(K@LOU':H-/GN?[.\W4IK/S59][VS'R@ Q
MY;N!C/OF@"T4/D[/,?=MQOXS]>F,_A69I'AZUT/3Y;*PFN$AD=I/F<,59CEB
M"1W-:*7,$D'GI-&T."?,# K@>]*EQ!+(T<<T;R( 656!*@],B@##@\&:1!X>
M30U2=K&*3S80TIWPON+!D?J#N)/7]*NQZ#9A;O[1YEW)>0^1/+.V6>/!&S@
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MNFB::U+_ +I_+"A>,9 ^1<X(SCG-">$-(76-3U-HI'GU-!'<J\A*, I3[O\
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M.LB*Z,&1AE6!R"/6G4 8[^&=,GT>;2[J*2ZMYI#+(T\K-(SYR&WYR",#!'3
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MG;1V*V\(GT61G$6!YA$R$$XZG!;GKUKL_L\'/[F/GK\HH$$2L&$2!AT(49%
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M.0 .BL!TR,XH :L4)M_*2.,PE<! !MQ].E>16,NG/\./"%OYEOO75[6.Y0,
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M>U7M/U*SU6T6[L+F.X@8D!T.>1U!]"/0UQM@VH+\3?%O]GPVLC?9K+/VB5D
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M(I5%9L8!^7.$(&>Y'7I4VJ1Z^/#7BJ+4;EUM5LY)+.0F+SROEMO1PJ[<9'!
M!P>N: .CL/$%CJ5]]D@\\2- +F,R0LJRQ$X#*2,$<CCKSTK5K(\+1/#X7TP/
M<23DVL3 R!05&P?*-H' ]^?>M>@ HHHH **** "BBB@ HHHH **** "BBB@
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M-NH_*FFB,]N<\2*,!A[,NX9'<$$=P #%UJR^UZ?'X/&FWUU;301JU](%\J-
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M!Z?6@"MIE@-,TZ&S%S<W(B&/.NI/,D;G/S-WJGJOAZ#5]0T^]FNKF.2PD,L
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MA]1GH:0V5J8/(-M#Y(.[R_+&W.<YQTZ\T <?8V>GW7Q#\06IAA>VN-+M=\8
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M/D9)(/OS]:Y]+6RC^$?A>X2"!)#<V#&15 );S5!)/<XS7J/V"SS(?LD&9?\
M6'RQ\_?GCFF_V;8>4(OL5MY8.0OE+@'UQB@#S_5)-*U'Q!XETGQ)J<5@[&,V
MQF"*?(,:X:)G'4.'/'>K5A/92^+M5T_7Y%=(].MA8_VA@%X2A\UN>-Q;[V/0
M>E=Q+8VD\D4DUK!(\)S$SQ@E/]TGI^%+/9VMS)%)/;0RO$=T;21ABA]03TH
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M9TVV!U!#/#)<19,BV_VH^8H(Z#8"?;D]ZZJXM;3_ (3?P_)HJ0?9+JSN!>I
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M8&P4-(AMMP81LLC!@I'!7(./;%;M-1$C14C5411A548 'H*=0 4444 %%%%
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M&4_= R021DXQC%4)=%UE/"WB?2X&O[ZRGM!%IJ7F//#LK!D+'!* E<%O?ZD
M[&75K6W2VMD:XGN)H/,CCC7=(4 &7/8=1R>I.!FL'P7KI?PG#<WMS<W4TU[<
MQ0[P6EDQ*^U<'T5>^, <XQ44<&J:5XLM-7&F7-W9W.EQV<B1;?,MY$8L,J2/
ME.X\@]16+;Z+K=KI&FWK:"]R]AJ5W+-I\K1EIH9G8[DY(W+D'!QGF@#L&\:Z
M)'9BYDFF0?;!8NC0/NBF) VN,?+U!R>#VS39_&>GQZ9K%U%!>/+I4?F3VSP-
M')@J64X8#Y2 >?8UBZII]Q>:19RV'AHV!;5K:Z>W2.-9=D;@L\FTXS@<#)/3
MZ!^HZ3J-]JGC,164H34=)2VM9&P%DD5)01UXY<=: .LTB_;4])M;QHGC:6-6
M960KR0"< ]JIS^*M+M[B2)WE*1726<LZQDQQS-C:A/K\R\]!D9(JQX?:<Z!8
MK<VDMK*D*(T4I7<"% /W21U]ZXC7['7M1BU6*31[N66/5(9K4PR(L+0+)&<@
M;AND(!R6''J!@4 =3>>,M)LKG4+=Q>23:>JO<I%:2,45@3NZ<KA2<]*NRZY9
M!+3R'>XDO8O.MT@7<SQX!W\\ <CD^H'4XKG/L>H'6?%]PVG7 2_L8([?[I\Q
MUC=64<^K@9/%4=)L=8T/4?#^I/I=S<0+H<6F7,,6TR6\J$'=@G!4],@]@: -
MKP#?SZCHEY-/<SW&W4KF.-Y\[PBR$*"#TP,<4ESJMUJWC>7P[:7#VUK96RW%
MY+%CS'9S\D8)^Z,<DCGH!BI/!-K?6=AJ27UC+:M+J=S/&)&4[D>0L#\I/K5:
M\TR^T7QS+XCLK.2]L[^V6WO882/-C9#\DB@D;AC@@<]^: -E-+O(-4C:/4;E
M].,$B/!(^XJY*E7#_>Z!A@D]:XWPOK$>I>%4FU/Q5/%J4DTL  N(PX/FLB83
M')^[VYKNH+^>Y)E%E/%;JI),R8=SV"KG/XG'MGJ.1\(P7>D^#DT[4_#U]).D
MTTOEJL9SF5G7!WXSR/QH T)M5O-1\9IX9AN6@BM+);J^GCP'D8G"QJ3]T=6)
M'/0#%%]J5QX9\4Z/9O<2W.F:L[VX6=M[P3 94ACR5;D$'..H]*C;2]1L/%T'
MB=;0S"[L5M=0MH2"T3 [E=<GY@.5(Z]P#TJ:]TVX\2^)](O)+:6VTW2G><&8
M;7GF(PH"]0J\DDXR<8'>@#I+R\M]/LY;N[E6*")2SNW0"J4&OV<U^U@R3PW@
MA\]()HBK21^J^ON.HR,@53\:Z1>:WX5NK.P*_:PT<T2L<*[(ZOM)]]N*J/:W
M&M^*-$UAK*XLXM-AG,@G4!F>1578 #SC!)/3IC/8 J^'KJX\37EU>O=:E:R6
M>IS(J+E8GA1M@C93\I)ZDXW ]ZV-5\1C3?$6E:2+2>4WPD8R)&6"JBYP,=3D
MK]!57P7;7=G::I'>6<UL\NIW-Q&) /FC=RRG@GL>E+X@M+[_ (2SPYJ5M92W
M4-K]ICF\ME!3S$4*3N(XRIS0!DZ/XJBTE]?&KW=[/%!K#PK,T;2+!&5C"[B!
MA5R3^OO74:GK]EI8G,PGD%O'YMQY,1?R4Y^9L?0G R<#.*XK4-(U6X\)>-+*
M/3+@W&HZ@\MJGR_O$81@'.<#[AZXJY>6EW9>*]0NY_##ZSI^JQQ,A5(B]NZH
M$*.'(PI !SGCF@#N+>XAN[:*YMY%D@F021NIR&4C((_"N5\.WUQXP:_U*2ZG
M@TV*Z>VLX+=_+WJAP9'8?,23G R  .]=/80?9M/MX?(A@V1JOE0#$:<?=7V%
M<EX<M+[P9)?:5)I]S=:9)=/<6=S;*'V*YR8W7.00>^"#GM0!MPRRZ%'>2:KJ
M+W%N]P@M6=09,,%41@*/F.[..,G-+_PD^FHFH>>T\$NGQB6YA>%C(B$9# #.
MY>#R,C@UF>)[+5M4LM.O[6T/FZ=J,5XMF7422QJ"&&<[0V&) SVZY.!4U32[
MO5-4U;6H;.X16T1]/AA=0LDTCL6Z9X X&3CJ>W) -6/QKH\DUI'F['VR'SK9
MC:R8G& 2J''S-@C@4I\::*NDR:E++/#!%<_9)1);N&BER!M<8^7[PY/'(K&A
MT_4%G\"%M/N -.A9;LX'[HFW\OGGGYO3/K6-KEO>67A[Q)+/93(+G7[:YMPV
M!YJ&2!1CG@Y4]<4 =K:>,=&NIK^$S36TEC";B9+J!X6$7_/0!@"5XZU+;>)M
M/N9I(<7$<JVPO CPMN>$G =0,D\]NH]*PM7L-4U#6KO7-,LL36^D2VMNET@7
MSY78-@J?X1M[\$MZ9JMIEIJ4?BN#5'T?4A#)H[6\CW$B,XEWAN0&. << <>P
M% &]8^--&U&73TMWN-FH _9IGMW6.1@"=H8C&[ /'MCKQ5BV\3Z==6.I7D9G
M$6FN\=UOB*LC*,L,'DX&#Q^%<C8:1JD'AKP/:2:;<"?3;M)+M?E_=J(Y%)SG
MGEATS6IJ.C3_ /"=QBU=!8:I")=1B[Y@9=K#_>W*A]0* .PCE$D"RA74,N[:
MRX8>Q'K7#6.K'6;G6+Z\O]0TV+2M1;:ZY2(0QJA9'4_*2V6)R,\C'2N\[5YU
M+X?U74_#/B[3DMI+6YO=3>\M#-@+*H,94$@\9*$8/K0!V%OKUG=:@NG-Y]M=
MRQ&:))XRAD3NRYX.,C(ZCN*X>74M37X:7]X-3N_M5OJS1+-YGS%/M8CVD^FT
MXXQ70R6UUKWB+P_JCV%Q9+IBS2S"8 -O=-GEK@_-U))'' ]:P9='U9_AUJ6G
M#3+C[9-JK3QP_+DQFZ$N<YQ]T'OUH [B]URULIY8-L\\T,0FECMXR[1H<X8@
M>N#@=3@X!Q4*>)]+EN-,AAF:;^TT:2TDC0E) HR?FZ @=CS65;P7VC^,]8U%
MK*XNK'588'C:%06BDC4J492<C(P0>F<YQ6<OA34=.\ Z=#:QJ^L:;=?;X(@W
M&XR,S19]"CLM '2P>)]/N;&[O(A<&.UN/LLH,+!A+N"[0O4G) _&JZ:UIEMJ
M^NS/>7[/900O=0/&YCA7#D,B[<G(!)(R.!69IOAG4-/\5NQ<2Z9=(E]=,3]Z
M\3*G [!LJ_L8Q3;JPOSKGC&9;"=HK[3H8+9@!B5U20$#GCEQR<=Z -FP\6Z5
MJ-[9VL#7"M>P^=;/) R)*  Q"L1@D @D47'B_2;95ED><V[7)M%GC@:16F!(
MV#:"2<@C.,9&,YK!M=.U%)_ 9;3[@#3;=H[PX'[HF#RQGGGYO3/K6/;,(;8P
MW.B:R^BP:G)J$+6T<4L>%D9E(</N*9^?&W/;)'4 ]0::..!IG;9&J[V9N,#&
M<G/2LK3_ !-IVI7=O;PF97NK?[5;&2,J)HN/F4_\"'!P>1Q5Z^>=]*N7L422
MX,#&!9/NL^T[0?;.*X?1[+5SXD\.ZC<:1?H8[*:"\DGDC^21O+Y"AL*GRM@*
M!]* .YOK^#3X%EG)^=UC15&6=V. H'J354:Y:&!I&6='6?[/Y+1D2-)C.T#O
MP<Y'&,G..:@\464.HZ2MK<6$UY \R^8L#;9(@.1(IR#E2 >.?KTKD)]%\11Z
M;;7#12ZTFF:FTMO;WNT3W-J8BAW9X+@LV-V"0/PH ZU/%NDM;S2&21)8;E;-
M[=XR)1,Q&U-O?.1@],<YZTV?QAI%MI5[J%P\\45C-Y%RAA8M$_& 0 >/F'/3
MGK6)=IJ']E+>:3X8.GK->0FY@2.);MH5SN?@[0W0#G(&3P<8Q[[1-8?0?&%E
M#HMV&U"ZBFM0TJ.7&V/(+%CR-K9)/XF@#N(O$UA."(TNO-,S01PM;LCRD*&)
M4,!E<$'=T]ZP->\2Q7,7A[4=-O[B.W;6%M;F-05)PK[D9<9)!4<=_?-6_$4>
MIV^O:+XAL-/FOH;:.:"YM(R!*$DVD,H) )!09&:BUN+4]27P_<+I,L7E:NEW
M)"NTM%$$<$O@X+9;.!GKWQ0!T&D:Y9ZU]I%MYR2VLOE313Q-&Z-@$94\X(((
M-97C#6IM,_LFVA2XQ?7\<$KPH<^60S,%(Z,=N..<$XI=!M+N'Q=XFNIK66*W
MNY8&@D8#$@2((W?(Y'>D\7VUW=7/A\VMG-<"VU2.YF,8&$C".I/)YY8<#F@!
M]MJ5IH,%U;R7>I7X@_TF7S$,KVL3<A6/4XP3@Y;'M4U[XQT:R:T4RS3M>0-<
M6PMX'D\Y% )V[1R<$<#G\*SK."_T3Q+K\TEA<7EIJACN+=X@"0XC"-&X)&WH
M,$\8/45FZ-X<U#0[[P;;-;R3QZ=:7,=U.F"D;R[2!R<D @C@>E '>V\Z7-M%
M<1APDJ!U#J58 C/(/(/L:JW^K6VG36UO)O>YNF98(8URTA4;FQV  [DBH;;5
MY)]?O-+DL)X1!&LD=PQ!293UQ@Y&"<<]<'TJAXD.I_VKI MK*XN=/+2BZ-JR
MK*IVC8 Q((4G.2"#P.V<@$K>,=%33K&^,\OD7T_V>$B!R?,!(*GC@@J1@^G&
M:EM/%&EW5MJ$YEDMET\XNEN8FB:/C<"5(S@@Y'K7%V6CZQ;Z!HME)I%RDEGX
M@:ZD 96 A\R1MP.>1AU]SSQ4VN:!K&IW'B_[':.K7+V4UH9"%2X,."RYSQDC
M'./RH UEU>>X^)-A:H]]#;OILTK6TRE$)#H%8#UY;KR/05K^*-?_ .$<TE;S
M[-).SS1PJ$7(!=@N3[<_B:QH7U'4_'&D:J=$OK6VCL)X93/Y8,;LR$9&[)'R
MGI6AXXL;O4/#+1V5NUQ/'<V\_E(0&94E1F R0,X!H S9]=DL?'\HEDU"6T?1
MUG2S2)G8/YI!(0#.<#J?ZUT$7B'3[G3K*]M7>Y2]3?;)$A+R#&3QVQWSC!XZ
MFLB&.]/Q!?59-.N8[5M(6#<0IQ()&?;P3S@CVSQFN8T_1=8TK1?#%Y-H+WQT
M^*XM;W3VV&0+(X8.F3M)&T=^A^M 'HNDZO9ZW9?:K*0L@=HG5E*M&ZG#*P/(
M(/:J>H^*=,TR6[2X>4K9!&NWCC++ '^Z6^O7C.!R<5-H,*Q6#NFDQ:6LTIE%
MLB(K#('+[.-QQS@GC'I7'>+]/UW5D\36"Z5<S1RVZ#3W@D1(F&T;M_S L^[(
M ((Z8QR: .HU#Q=I>FW\UA(+N6\BA$YA@M9)&*$D;A@<C@\C@8J,^-M"-MIM
MQ'=22QZDK&U,4#OYA4$E>!][@C;USQBL>*^D@^)CRRV-T"^@P[HT4.R'SI,
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M P,C<C]X&W?< ..G<<UR/B232[KPI>:GI%LWV:74K2YGN5C8"8K+'N< \D
M9(&.#Z&M#[3;3?%2PGB9<2:-*NXC!8F6,J.>Y )'L* .G35M-DL_MB:A:-:[
MMOGB92F>F-V<9I9M5TZVNH[6>_MHKB0@)$\JJS$]  3DYKDM%T^YL?$5[X;\
MAAI4%R-4@DQ\FQR6$7MB8,P]E]ZQWFTZ>ZUWP[XC;4!=7&H2306T:-B[C+!H
MBC!>H 5>HQMYX% ':>,-6O-"\*W^JV0@::UC\P),A96 [<$8I;677&EL))+K
M3I89AOFB2W:-PFWJI,ASABH/'0UG_$=E7X=ZQ&6^>2W*(N<EF..!ZFK>BZ18
MQV<&HZ<Q\^2S\H.9F=3G![DXP1VH U!JEA)>-8Q7]J;W!_<"52XQU^7.>.]8
M7ACQ3'?6GEZOJ%C'J+WMQ;Q1!Q&9 DC(-J$DGI[US7A:;2]2MM$TW4#J)U_2
MI5+VCJRF&5>&D+!<%""3R?FSCDFJ3V%G>^"M<TA;>(Z_+JEP;>';B=7,Y,<G
M]X*!SNZ8SS0!Z9/K>DVTS0SZG912JZQLCSJI#-G:"">IP<#O@T\:MIK013C4
M+0Q3/Y<4@F7:[9QM4YY.>,"N3T:VL)_B-XE$\5M-*(K,H60'+J'W$>X.W..A
MQ7,F]@@\(+I;[_MMIXB#SPB-BT:_;-X8X'0J01Z]J /4YM5TZWNEM9K^UCN&
M(58GF4.2>@P3GGM3+C6M*M)6BN=3LX9$959))U4@MG:"">IP<>N#7FOBG4()
M[+Q-#%%):31:A;2/ L+M).%:']\Q(.U,#  Q]WD\XKH--BTV^^)>MN\,$N^R
MM&C$D8R6!<G@C[P^0GN.* .LCU?3);.2\CU&T>UB.))EG4HGU;.!5DN6AWPE
M')7*?-\I].1VKAAIUS9>*[OP]% 3I&JR#4MP^[$%(\Z/Z,WE\>DC5W;,J(7=
M@JJ,DDX % '/^&M<OM7\,RZC/;1-=I-<1B& D*QCD90 3Z[1S5.#6/$6G^*=
M.TS68].GMM267R9+)74PNB[BK;B=P([C'/:H? E]:VO@ZYGFF5(X+R[DD/\
M=4S.P..O(((]:32/%.B:SKT-SY\DE](I@M+86\G[E#RQ)*X#':"3G@* ,\Y
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M'<\<<D &QIGC IX5O]4UV!+>?3KB2UN%M\LLDB,%'EYY.XD  ]S6WI4NH7,
MGO\ [/$SC_CVBRQB/]UGS\Q'?  ^O6N)UB/3M7\'6G]C+/>Z?IVJ07%X6A8-
M<*'W2G! +'YMQP,=<>E7K1+#3O&=]K6FM%%H::3NO6M5S$TJME2 O!8(&SCG
M!'J* .W<.481LJOC@L,@'Z9%<=X<UGQ-K_AYM3CDTD3":6-;<V\BAMCE?O\
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M#YA )!8\_,>?6NCH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML/ DCERK1[268%CCD \9Q7;5CQ^+- E@@G35K5HKBX^RQ.'X:7^Y]?\ $>M
M'/W>@ZM/;>-8EM!G65VVI,JX_P!2(_FYXY&>_%6[;2-5M_$^DZDMM$84TK[#
M<!IL&)@ZMN& =P^4@?TKJ(+F&Y1FAD#A6*-ZJPZ@CL:EH Q?%-OJMUHK1Z.P
M%SYL;.GF>69(PP+H'_A)7(S7*7'A?67MO%T,&F6<$>L6L:6Z13C",(RA!^4>
MN2?Y]:]%HH X^\T*_P!0US3)GMS%:QZ9/93OYB[E:0(,@9Y VG\Q67%H?B?^
MP?#^CRZ?:EM&OK=OM(NL)-%%D @8)!QC(/?U[>B44 4]5TV#6-(N]-N@?)NH
M6B?;U 88R/>L30%U_1M+M](O-.2\-J@AAO89U5)$484NK?,IQC. U=/5.+5;
M&?5)],BN%:\@022Q '*J3@'/3L: .>\2:7J]]?>'IX+=+AM/O/M5P?," C:R
M[5S_ +W?TZUHSVUWK37%E>Z:EMI]Q;/#<.95:23(P%&.@ 9CG/7'O6Y10!S&
MBPZWH&A0:.UBM]):)Y-M=+,J1N@X0R _,I P#@-TXJYX6T >'=(:W>4375Q.
M]U=3 8#RN<L0.PZ >PK;HH YA=,U'2?&.I:M:6_VRTU2&(2QK(JO%+&"H/S$
M J0>><@CH:RW\*:A8^'M"T^VB2XFM=534+IA(%4?O&=E7/7[V!TZ<XKKUU6Q
M?5WTI;A3?)#Y[0@'(3.,YZ=35R@".2,7%N\;AE$B%6&>1D5R'A?3_$FE6]IH
MM[8V!M;'$::DDN6EB7[H\O;D-@ $DXZGFNCO-<TVPG,%S=HDBJ'=<$^6IZ,V
M!\HX/)P.*MVUU!>VT=S;3)-!(-R2(<JP]0>XH X"#P]XEDN-$NKVRM)K^QU!
MY;F[:ZRTZ%74%?E^50&'R^W3O6CH&G>)-!>;18[:UETS[3)+;Z@9\-'&[ERI
MCQ\S@L<'..?;!Z?4]5L='M?M.H7"P0EE0,P)RQ. ./<U<H X2\\/:O<:;XTM
MUM%#ZPY-J3*N,&)8_FYXY7/>NSL5D33[=)4V2+&JLN0<$#'45+-*D$$DTK;8
MXU+,<9P ,FF6=W!?V4%Y;/YD$\:R1O@C<I&0<'GI0!R&F^&[N#Q+::M!9G2Y
M6:0ZFL,P,%V"I"D(#]_=ALX&.>36;!X;\10Z'I6D+8VI73-76Z$[7.!-&)6?
M( &5X;!SW['MV/\ PDNC_P!G7E^+U3:V<WD3R*C$(_ QP,G[PZ>M:U ''KI.
ML6EWXEBAM(I4U>3S()_- 2+,2QGS ?FXVY^4'/M5'5?!COI]M86MD_VG3[&.
M#3=5@G$4L4B@CY^<[,X.!NZMQ7?44 <?=^'M0O\ Q+<RW'_'K<:&=->Y5@&\
MPL26"^G/Y^W-9T>C^)Y=*\-:=/IUJ'T:]A9YQ=?)-'&C(&4;<C((R#W_ $]!
MHH X>ZT;Q$K^+9].5;>XU&:"2T<S $JB(CJ2.5)"M@]LCI4 \.ZNMWXAEATJ
MUMX=3TM+:...Y!*R 2#YN!D_."3_ #-=_10!S\6F0R^!H=&UI4A0V*VLX9Q@
M$)@D'\,@^U)X+L[NW\.6]QJ,_GW]TJR2RE<%@%"IP>GRJI(]2?6I]:C\/WVH
M:;INL0VUQ<R2-):0S1[LLJDDCC'0'K6U0!SFOZ3>RZ_HNNZ>BS2:>98Y;8L%
M,L4@ .TGC<"H(!P#SR*S[OP[?7%CXMNT@ O==@$$4!D'[M5B,:EVZ9RS$XSQ
M@<UT5WKNEV-B;VZO8HK;?L$C'ACZ+_>Z'IGH?2I(-7T^YL(+^"\BEM)R!'.C
M90DG YZ#GCGOQUH 31XIH-&LH+B+RYHH$C==P/(4 X([5>HHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ KE?'\UY#HEH;2Z-N7U&UC?"@[E:51CZ?SZ5U59FO:+%K^E_8I)Y8")8
MYHY8L;D=&#*>00>1WH YBXAU)_B3=Q65Y##<_P!A0[IY(-XSYTO1<CJ?>GZ9
MXNO]9T_08X8"MYJ%B]W.T"H=@0JIVAV Y9L\YP!TYR-N+PZT6O2:N-1G>XDL
MULSO12-JL6#< ?-EB?3VK+'@""'2=)M;35;VUN])#+:7L>WS C?>5@1M8'T(
M["@#:\.SZQ/I?_$\M$M[U)73Y"I$B _*^%9@N1U&>N:Y[PO(U]\1?%]Q=<SV
MC06L"M_RRAVEN/0,>3]*ZS3K'^S[01-<37,I.Z6>8C?(WJ<  = ,    5G7W
MAM)M:&LV%Y-8:@T8BE>-59)T'0.I'..Q&#[T -\3W]MX<TJ^\1_9P]S!;B(<
MXWY8! Q]-S?ADU5NM5U31_$6D6%U/#<P:H)(A((=I@F5-PP >4(!X/(QUK1N
MO#\&IZ;=6>JRO>K=1&*0L H5?10.G.#GDY YX&([7P\T<]G/>:A+>S6,;1VK
MRHH*%AM+MC[S8XSP.3QS0!R:>(_%3>!;SQ,;S30+>*Y_<?9&.YHY64-G?QPI
M&.>W6M*;Q!K6A^(-.35Y;6XT[4H)G46\)1[9XX_,(R2=X*@\X'/8=*BU_0O[
M"^%NL:3;S3W>^*;R5* N6D8L5 4<\L>U;EAHL=VUCJ%[<M>FWMS';J\84*'
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M6T)=ER0!]XG'L#CIQ4EG!8_#OP[INEVUIJ5] TYBWP0^:X9R6+N%QQVR!Z4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MDLPNH1P+Y,&YBAC4C[Q R/F]/RH OZGK L;^PTZ&)9KV^+^4C/L4*@RS,<'
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MQGK\V2<]=QX[5=U_PIJNH^-M/UZPO[>!+:SDMF65&9D+9^9,<9YQD],=#TH
MY?0_#UOXX\3>)M;O;:-/+OX[6V='/[IH1\[H1C))Q@GCG)!QBN[3PI9)>:Q<
MH#"^I;"YC9LK(N[$HR>'RW;'W14'@+PW=>%/"T.EWDT$TZN[N\(."68G))Y)
MY]!T'U.]>W<=C9RW,N2L:YVJ,LQ[*!W)/ '<F@#*\':S+K_A2QU"X %RRM'/
MM&!YB,48CV)4G\:W:P?!FC3:#X3L;"YQ]I :6< Y D=B[#\"V/PK>H ****
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M[D4KR5/(SD<C.: /3**Y.WN[W6=?US28]2N+4:4D$4<B*F]Y'3?YC97![#
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M)=:BP9\-M;[:>> "<GDY/Y5N7OB#4O#EUXIBEOI+Y+.S@NK=[E4!C:0NI!V
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MA<YQT(QTZ9YK2\3Z[J=C#J][9W\DC64]N$BAC7RH%8IN24M]YFW'A<D KTH
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M@^[AU&7R+F_^QR6FQ/+*.\G.<;MP(!SG'M0!ZI62-?T^74-2L]DQFTM$EFS
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M36E]IM]DC^?'LC.';>,)]?2L;0==GU76=;LY%M_*L)HDADA8MO5XP^2?Q[4
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M#)&/7!S21W,$LKQQS1O)'PZJP)7ZCM0!EKX:LTO+ZZ2>Z$M[ MO,3)G**"%
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MJ-_?1S7*SWT2PS'>"-J@A<9'&,GGWYK0%Y;&)91<0F-_NOO&#]#3S-$'"&5
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MRVVF:9,P)T]-3MSJ'' @R<EO]G=MS[5U MX58,(8PPZ$*.*>0&!! (/!![T
M<=;PPGXC7DUH86TR32E-\%P8FF\SY">V[9N_#'M3OA@+;_A -,D@$6YE?>R
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MP+J9AAA/B)=5G6S=,?:$F^T$H ?O 8.<=,9/O7K\,,=O!'!"@2*-0B*.@ &
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M+%8_*\FWU\C6$0#,<'VB7'F =%SL.#V]J]:2"*.1Y$B17?[[*H!;ZGO3A'&
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M:\Q([8!2\HD<!@!U;!X/7I5[PR_AO5M7TO4]*U6>>\AM6B-M&(E\J,CE9E5
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MNR0ZD=$D_?7Q)!B9P!&J$C=(0%SW &,'-0:+_9VHP?#47!M[AO)GADWD$D"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%8^H>(H--U[3=)FM+II-1+K!,H3R\J-S DL"#CVY[4 ;%%8VG^(X-1
MU_4=&6SNX;FP"-*TP0*P?)4KAB2#CTX[U5U#QC;Z9HM_JUQIM^+6QF,,A41$
ML0P4E1OY )Q^?I0!T=%8NN>)(= T9-3O+&\:(LB,D8C+H68*N?G ZD=":9?^
M)DT_5]/TM],OI+J_21X%C\K!V %@27&" 10!NT5D'7&2*^>;2K^%K2)9F1_*
M)D4[OND.1D;#D$CMZUG6_CJPDM-,O;BROK.RU-E2VN9UC*%F^Z&V.Q7/N!0!
MU%%8NJ^(XM*U?3],:PO+BXU#S!;^3Y>TE%W,"6<8XJW9:D]U=RVTNG7=H\:*
MX,_ED."2."C-R,<YQU% %^BLV77;"'Q%;:$\N+ZXMWN$7MM4@?F>2/\ =-.U
M35X=+-K&T4L]S=R^5;P18W2,%+'J0  H)))[4 :%%9NGZQ]NOKJRDL;JTN+9
M$=UG"X8.6 *E20?N&M*@ HJK97,UR)S-9RVOES-&@D93YBCHXP3P??FK5 !1
M110 45E:)K<>MB_*6TUN;*\>T=92N2RA23\I(Q\WK21:ZLOB&]T=;2<36MLE
MQN)7$@8L %Y]5/7% &M15.UOO-L[26[A:SGN0 +>5@65\%MO'!. >GI3H+F:
M6_NK=[.6**'9Y<[,I6;(R=H!R,=#G% %JBBB@ HIDTT=O!)/,ZI%&I=W8X"@
M#))IX.1D4 %%%96CZY'K%QJ<*VTT#6%S]F<2E<L=JMD8)XPPH U:*JM<S+J<
M=J+.5H&B9S<AEV*P( 0C.<G)/3'%6J "BL;6_$4.AW%A!+97=PU].+>$P;,>
M802 =S#' /-.MO$5M-K(TBXM[FROVB,T<5PJ_O4!P2K*S*<=QG/M0!KT444
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M*REEP2.2I(YQG\: +5%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7
M*?$.RFE\,'4K1<WND3)J$'OY9RP_%-PKJZ:Z+(C(ZAD8$,#T(H \NN]7?3]?
MT_QW$LLECJHDL?*QSLVY@P/5G1CGTD%:_CVR;3_A!J5L[!Y4@0RO_?D,BEV_
M%B3^-=@=*L38VUD;6,VUJ8S#'CA#&04Q],"DU32;'6K)K+48//MGQNB+L%;!
MR,X(SR!0!QGQ%AU)/!3M<7MM+%]IM<HEL4)_?)WWG^56?%*32?$;P<MO,(9#
M'?8<INQ^[3M72W^@Z;JE@EC?0-/;(01&\K\D'().<G'O3+KPYIE[=V]W<0RO
M<VRE89?M$@:,$8."&XSW]: *LT=U:Z3K,-_?K<S31RRPX39MC$:J1CV;/YUY
M]IB2S:+X'M=>D3_A'9(H7A>%-F+I1F-)B2<J>Q&,GK7IJ^']-1;D>3(QNHQ'
M,SSR,SH,X7<6SCD\ ]Z0>'-(_L,Z*;)'TTKM^SNS,H .0!D\8(XQTH YWQ<D
MLGCWP6L$PAD,EYARF['[GTKHK!;FQFNUU+44N&E<S0_*$V1*J!N/0-DY_P!J
MF3^&-)N9;26:"9Y;0$6\AN9=T61@[3NR,CBG'PWI;)<J\$DGVF/R9FDN)&9D
M_NY+9QST'6@#A/$$>I2:6OBV#3)?M=I=C4HI?,7)M0-OEXSD Q<D?WB:ZC7M
M/TWQ=INF>5J$MI<R?Z7IMY <.C;<Y'J"K<CN,UO/I]M)IQT]T8VQC\LH9&R5
M]-V<_K5%/"VBQ65M9I9;8+5BUNHE?,)/4H<Y7\/4^M &-X8U76H?$%WX?\1I
M;37L%JMQ%J%NNT7$.XK\P_A8'/'3K]3V'#+D'@C@BLL^'].2SOH5M?--[$8I
MS/,[M*N"-K.Q+8P3WXR<5/H^F1Z/H]MIT1S' FU>N /09)( Z#D\8H \]N[S
M4%\%Z]*FJ7RS6WB$P12B<[A'Y\:;<^FTGCI71Z4)M/\ B%J&F+>7<]K)IL-W
MLN9VDVR&1U)7)^4$ <# ]JU&\*Z*UG/:-9DV\\_VF5#,^'ESG>?FZY /U JW
M'H]C%JAU-8F^V&(0F4RL24'(4Y.,9R?J<T 87B&1I]<^Q0W=RTRZ=)*;2&9H
M%0%@!,TBG/8J% /.3QUK&T/6[O5W\(Z;?74P2[TEKR:19"C7$JA0%W+@\ LQ
M Z\=J[*^\/Z5J5_%?7EE'+<Q(8U=L\H3DJ0#AAGG!R*JMX/T Z?:6(TY$@M'
MWV_ENR/$WJK@AA^?84 </9WLFC6M_90W$R1WOBXV4EPTA+I&R*3\YYR=H7=U
MYSG/-;$5DMIX]\0Q0SW(#:-"ZLT[,R'?+]UF)(Z9_$UT0\(Z +"\LO[+@-O>
M/YDZ')WO_>SG.>.HI;?PKHMK-)/%9D3R0^0\S2NSLG/&XDGN><Y[4 <1:HVJ
M6_PUN+RXNI)YE?S)/M,BLQ^S.<Y!'.>_7MTJUJVMZEHLWCZYMKB>9K*"U>V2
M1BZPET;<5!X &=WX5U[>&-&:PL[%K%&MK-P]NA9CY1P1P<YQ@D8Z8J>+1-.B
MN[RZ6V!EO5"7)9F82J!@ J3C ''3I0!SEZ9]*\0^&_[/O;N>VU(R6]RDEPTH
M=?++B4;B=I&.HQD'Z5SMK-?Q>%]+U@ZMJ,ETFN_9OGN6*-$;IHRC+G#?+W.2
M.,$5Z'8Z!IFF[/LMNR>6ACBW2N_E(>JIN)V#@<+CH/2H!X5T86"6(M"+9)OM
M"Q^=)@29W;OO=<\_7F@#,^)<2R_#K6MQ<;;<L-KE>01UP>1['BF&4R^-K?PZ
M\UTEC'I9NU N9 TLADVG+[MQVCMG^+V&.HN[*VO[&6RNX5FMID,<D;\AE/4&
MJ+^'-)>&TC^R[/L>?L\D<CI)'GKAP0W/?GGO0!G>"KN]GM-4M;V:2<6&I36D
M$\AR\D2X*[CW(R5)[XKD-2CFBTWQ]J5O?7EM<65\9H/(F:,!UAB.6 ^\#TPV
M1[5Z?:6EO8VRV]M$L42Y(5?4G))]22223R2:SG\,:1)!?0O:EHK]M]TIF?$I
MZ9;GT 'X4 9+W5S_ ,+$L8_M<RP3:--,T)<^6'$D8#;>F<$U2\+W]Y#KEKIN
MMI>0ZDUH^R87+36M^ 4)E3)PK#&=N!@-Z8KJ1H6G"^AO?(8W,,)@20RN2(SU
M7KTX'Y46.A:=IKQ-;0,IAC,46^5W\I#C*IN)VC@=,=!Z4 <WX_61[[PDL,@C
MD.M1[79=P!\M^V1FJ=W]JTWXK:&^J3)J!O;>>&R\I/*^R%0&<E<G=N&!G/'I
M78:EH6G:Q)!)?0-*UNV^$B5UV-_>&TC!]^M%IH6FV5ZU[#:@W;+L-Q*S22;?
M3<Q) ]LT <$VK:A<_#-O%T-Y<IJ\<S2^4)F\O(F*>28\[<;?EZ9SSG-2^*M2
MNX[77M0T^_NWEL;FW7<)FBCM6S'NB"@XD)W9;( ^;&3C%=JOAS24NY+A;0*T
MDPG= [>6THYWF/.W=D YQG(!J"\\(:!?SW<UUID4CWF//R6 <CH< X#<=1S[
MT 8DEG/J?Q#U.QDU74H;6.RMKA(H+ED ?S'SC'8A0"._?M7/:K<-X@^%UYKE
MS<W'VM[X;HA,P2(+=!!&4SMX4 \C.>:]'MM#TZTU%K^WM_+N6B$)<2-R@Z+C
M.,#MQ5&X\%^'KN6Z>;34;[6XDG0.X21P0=Q0';NR.N,F@"YKZWCZ#>1Z?/'!
M>.FV&21BHWDX R.1GID=,UP\WB>6STS45>*^TN^CN+.&\@O+AI4MXY)-IECD
MR?E(R,CH1FO0;K3[6\L&L9X0]LRA3'D@8'3I]!5?^P=,-O=026HG2[0)/]H9
MI3(HZ EB20,G [9- '+ZC!>:);:O<7'B%[2SN+9/*C1WN)(9-P7=&7.?FW!<
M9QDYJA<O=-+XSTVX:YCM4TB.XC@>\>1HV*RY^;.1G:,J"1]<FNKMO!OAZTTF
MYTN'2XA9W( FC8LV\#H,DD\=N>.U36_A?1+6X>XBTZ(3/!]G=VRQ=.>&R3GJ
M>3SSUH C\)11V_A'1U5W.^SA;]Y*SG)C7IN)P/8<"J7Q"FN+7P7>7-K<SV\T
M3Q%7A<H>954C([8)J>3P?I0?21:VB0)ILWFPNKMN3I\HYY!"@'.>!@#GC5U/
M2[/6+)K._A\ZW8@M&6(!P<C.",\@'\* .7N[6;4/B)>Z;)J6H1V;:1'/Y4%R
MT8#F5UR"I!'"CIU[YK2\"7USJ7@;2+N\F::XDMQOD;JQ!(R??BM'^P]/&H/?
M^5)]K>$0--Y[[C&.B]?4D_4YZU-INF6>D6,=E80^3;1YV1AB0OTR3@4 >>/J
MVH77PTE\6PWES'K$4SR^4)6\L%9BODF/.W&W"],YYSFM:UM;C4O'.O13:EJ<
M<%HME<16\-R54,0Y*X_NG&".A_ 8Z1?#FDK=R7*V@#22B=T#L(VD'(<QYVEL
M@'.,Y -30:18VVIW&I0PLMW<@":3S&.\#H""<<9./3- 'F]W.VN_#O2]?N+J
MX>[N-3MY)$$[>6O^DA?+V9V@+P.F<C/4FMF5M1\27/B&"WU3[!=:?=^5"XN'
M3[.@565B@PK!OF/S9SR.U;TG@KP[*\[/IB$3RB>2,.X0R YW;,[0<CJ!SWJ2
M]\(Z!J.IQZC=:7!)=QJ%$G(W = P!PP'N#0!@6UK<ZMXXU.VGUC4%@AM+*Y1
M+>X:--Y+DX'93MY7N#ST&+7Q MTGM]!WM*/^)U:+\DK)P7P?ND<^AZCM711:
M18PZK-J<<)%Y,H223S&.Y1T!&<8&3CCC-/U+2[+5[3[+?P+-#O5PI)&&4Y!!
M'((/<4 <S:,^N>)/$6E3W=Y!'IR00VPAN71E#Q[O,)!RQ)XRV?N^YSH>"=4O
M-5\%:=J&I,/M+QMYCXP'VL5#_B #^-79_#VEW$Z3M:[)4B\@/#(\1,?]P[2-
MR^QR*T8H8H($@BC1(D4(J*,*JC@ #TH \[TR_N_[;\*307]W<VNH27*R7$\S
M 7:B-G5O*R5100-O0X["K6EZC>6GB&TL]9%W'-<23-:7\5PTMI>*59@I7.$8
M+@@8_A.#706_@SP[:M;F'2H5-M*98>6/EL<YQD\#D_+T]JM6WA_3+1XWAMV_
M=%C&K2NZQELABJDD*3D\@#J?6@#EO#5[>)K%OI>N+?0:C)9R!+A+II;:^&4)
ME0Y^1QC.,# ;TQ5/2;O7+GP)H-W;--J<RRSO=6[79BGN8P[KE7SR5)4XS@\#
MTKM;/0--L/+^SP.OE1&&+=,[>4AQE4R3L' Z8Z#TJ.'PQI%O:VUM!;/#%:LS
MP".>13&6^]@ALC//'N: .+WV6M:IX)N89]1:-[F]C(N)Y$FC*QR91L-G<I&W
M.<D#KBNQ\66-[?\ AF]CTVXG@ODC,EN\,K(2Z\A201D'&/QJ:;PYH]Q;6MO+
M8QM%:R&6$$G*N<Y.<Y).3G/7)SFM2@#S2/Q8!KMCKD3W4FCZC9?9UB-PY47F
MSS H7.,D?)_O#'!SG8NHKS2_$?@RS.H7<GF-<)<AIV99F$#-ELGGYN1GIQZ5
MTB:+IJ6L%JMG$(+>;[1$@'"2;BVX>^23^-.NM)LKV^M;VXA+W%H28'$C#RR1
M@X ..1P?;B@#S*YM(H/ 'Q ='F)%_=1@/.[C V=B2,^_7WKJ;(3Z=\0K>S2^
MNYK>[TIYY8YYF=?,21 &4'A.&(PH ]JV9_"NB7'V[S;!"+\[KD!F E/&<@'O
M@9]<#.:L+HE@FHPWXA<W4,7DQRM*Y(3NO)Y' _*@#,U^3S==TNPCN;@RR1S2
M?8H9#$)0 HWO(I!55ST&<EAQQ3? -[=7_@G3[B\G>>X/FHTCMN9MLC*,GN<
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M%6+C6=,M+D6UQ?6\4VY5V/( 06^Z#Z$]L]>U>816MIJOPZU;2;6)'U:;59Q
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MC&![;0.* /3KW5].TU5-]>P6^5W?O7"X'3)]!GOTI;O5].L>;J]@A&S?EW
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MMD"GE#C.".QP0<'UKAI4\.:SI^I:E:KJP2XCAAN+[$RNA$BE-JN.2A^8D X
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MHA\2:'<W%O;P:O9237.?(1)U)DP2#MYYY!_(U@&YAE^)6GW?S+"=%E4R2(5
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M67,J X(YZ$BL[Q]J-DWABWBLC<PR)>6Z(RPRQ84R*&&X@=1GOS0!UGAS1/\
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M</)O )(=%SCL!D_7/M3)O&=K#IZ:NUK(=&:?R#>AA\OS[/,*]=F[C/7OC'-
M'345GZYJR:%HEWJDD$L\=K&972+;NV@9/4@5DVOC%)-;M-.O=,N[%;Z)I;.X
MF*;)MJ[F'!)4XYPV./3I0!TU%<I#X\T^:]TZ)4#0:BQ2VECF1FW8RN],Y7<.
MF?;.*DTSQ;<:QO:ST&]\E))H7EDDC4+)&VTJ?F[\\C(]^N #IZ*\Y\*W5M_8
M6@Z_?V<C:U>9AADCE :[:3<QWX."H )^;[H''85T%SXRAL8-8%U83K>:5"+B
M:W1E.^(@D.C$@%>"#T((Z=* .FK"NM NFUB?4;#6KJS:X5%FB\M)4;:" 5#
ME3R>AQ[52E\9R6Z6DMQH.H1PWES#;V\FZ,^9YBY!QNR.AX(^N*1O&<X.JPC0
M+PWFF //")8\>65+!@V[!) / YR* .BLK-+*$HKO([L7DEDQND8]2< #L.@
M& !5FJVGWT.IZ;:W]N28+F%)H]PP=K $9_ U9H **** "BBB@ HHHH ****
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MSC[1,L$>V-FR[9QG .!QU/%6J .8.DZDOBO6=26&%K>[L([:(>;AMR%SDC'
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MXT_QE;K%;AM:8FV)F.%!B6/YN./NYXS7<51U75[+1;075_*8H2ZQ[@C-\S$
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MWZB-FWQ2^5);3$Y'EMC. ,#.0?E!P<XKH[W4+>P^S_:&<?:)E@CVQLV7;IG
M.!QU/%6J .0@T'68=5\+W-Q+'>'3+.6&ZG:0AY'=4&0,<\IU)'6HK3PI?S^#
M=:T2]>*VFO+J>>&6)]X7?(9%SP.AQFNTJ!+VVDOI;))D-S$BR21 \JK$A2?K
MM/Y4 8%F?%USIMPFI6VEPW"6[I&(Y6D2YEQ@%@5^1/;D\]L8,?AKPVVBZS>7
M5K;_ -G:=<0J#IZ3;XQ-DEG4=%&,#C&?08KJJ* .>O\ 2=0;QII^L6JV\ENM
MG+:3K)(59 SHVY0 =WW2,<?6L.#PAJ2^#9/!LPA;3_-V)>B3YOL_F;\%,??Q
ME?3OGM7>T4 <[X[ 'P_U\#H+";_T U331;G7I-"GOX4M[>P@9L+)N,KO%LXX
MX4 L>><XXKI[VRMM1M7M;R!)[>08>-QE6'H1WI\$$5M D$*!(D&U5'0#TH Y
M7PU8^*M*M;;1KQ;![&R41QWL<A\R:)?N+Y97"G  )S]/6K7AC3-2T?1[^"Z@
MA,\EY<7$2QS9#"1RP!) P1G!X-=)10!P-IX1U>V\*^&X1]G75="F$BKYI,4Z
MX*LN[&1E6X..#5K6/#.H:NNO7_E117NH:9_9MO"TO"+\Q+.P'7+]!GA??CM"
M0.M% '*ZMH^J7VE^'8HH(/.L+R"XN%:; Q&""%..2<\=*:=%U0:QXINA# 8]
M3MHH;?\ ?<Y1&7YN. =V>,]*ZRB@#*\-6-QIGAC2]/NU03VEK' ^QMRDHH7(
M.!P<5JT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 5B>*-1O-*TR.ZM+>XEC$ZBY-M&))8XL'+JI
MSD@X['@DXXK;JGJ%@U\+<I=SVLEO-YJO#MY.UEPP8$$$,?TH Y0>)9Y+70+N
MPU:*_MK_ %7[*\@B S$5=@", JXV@'I]*2[\5WVFW7B.%WCE^R7EI:VAD0 (
M9U3EL8R%+Y[<#'O6I/X,LIK#R([FY@N!?_VB+J+8'$_3=@KMQCC&.GOS3'\#
M:=<1ZQ'>7-Y=)JPC^T"5UX9% 5U(48;Y0?3T&.* *WB:#5K?PUXH6ZO(KK3V
MTJ4PEU"S*_EMN!V@*5Z8[U%I&H:I8:UX=L+B[BGL]2TYW6)80ODM$L9&&SDY
M#X.?3MTK27PBC:->:?>:QJ5X;J!K9KB=T,B1$8*K\N!GN<$GCG@8G3PQ"NH:
M1>F^NVDTN%X(5.S#*P4-NPO)PJ],=* &>*M6NM'M;6YCBNC9^=B\FM8A+)#'
MM.&"D'(W;<G!P,\5F0^))KS^R+*QO3?&^BN+C[9:+&&:-' 4 /A0WSC.0<;3
MQW'2WVGO>36TT5Y/;2P%B#%M(<$8(8,#D?ER*P[GP)ITUG:1V]S>6=W:SRW$
M-[;NJRJ\A)D[;<,3RN,<"@#-NM6\665IH\-V]K;W-SJ_V)G:-7,D)5V20A6P
MK87E1W[BKAO]7T+Q%I%KK&J)=6-[%+$TPMUB N%^9<]< H&XSU7T.*O3^$H+
MB'3UDU&_,EE="\$Q9&>64 KN<E3V)&!@8QZ5?US0[+Q!8+9WR%HEFCF&TX(9
M&!_7D'V)H P=0U?5[*RT&Y6Y7;J.JQQ2))"-P@D)*KQC!V@9X/)/2I$U'6==
M35Y=&NX+>6POC:0PS(#'(4V[S(<%AG)QMQC@\YK7UK0XM;^P^;<W$'V.Z2ZC
M\G;RZYQG<IXY-4)?!EJVM76H6^H:A:QWI#7EI!*!%<,!C)&,@D<':1F@"E>:
MQKFISZS%H2N)].F$$*XB,<K[%<^9N8,%._ VXZ9R>@AU3Q/>V.JK;:E,^D+-
M'";29HEDMI)"/G1Y,':<\#D#'/-:=YX.MY]<EU6TU+4=.EN%5;J.TE"I<!1@
M%@0<''&5P<5-?>%;:_AN[26ZN!I]V$$MF A3"A1A25RN0HSS],'F@#9N4DDM
MW6*9H7(XD4 E?P/%><^%-4N=-\$>$;..X+3:JZPH[HI$"@,S$<<D@8&<\GOC
M!]'FC,L#QK(T188#H!E?<9!'Z5ST7@FPB\.6.C"ZNRFGR++9W!9/-@=22""%
MP>I'(.0: ,G5_$>L:/)XDTX7$<L]CIG]I6=S)""2GS HX&!G<O! Z'IQ72:
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M+2\B=!*J'JA^7:RGW%6=1\&V>H65G']MOH;RSD,T.H1RCSP[<,22,$'H1C&
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M1,5"KY?W"N%!!'7J>:2U\)^3J=CJ,^M:E=W-E"\$;3&/E&QD-A!D_*.>I[T
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M62,1P_:&:>%X@(_[V6 &*KGQ3I8>XBWW'GP6YN3 UM(LCQC^)%*@L,\<=.]
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M@#G? =M<6?@?2+2Z@E@N(+<1R1RJ5*L/K71444 %%%% !1110 4444 %%%%
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M92468RX;KR2<<=,=\U;U'PA-J^HZ[)=3QQVVJ6<5L/*)+Q-&6*OT /+9Q[4
M.?Q9J$%Q>12:.9%BLGNXYHVD$1*_>C9FC&&QR#@Y]JT?#>K:EK5E%?7>G16E
MK<6T,\#+<;V;>N6!&!C'&.3D'\*I0:5XGN-)NK35]2L)Y&MG@B,$31ARPV^9
M)DGD#^$ #K[8U] L9M+\/Z?IUPT;R6END!>/.&V*%SSTSCI0!DZGXKEM9=>6
MTLTF&B0)-<"24H9-R%R%X.,*.IZGCWJ2W\23W]Q9V-K:0B^N++[<ZO,=D41.
M$YVY);TP,8/MGE]6F%]XIUEH=1\/QJ@CM9K?4V>)F55W<A7 ="6."P/<=.N]
M;:9J-WJ=AXGMUMH;XVC6=S;,S"*:(.2K(V,KS\PRIX;!Q0 ZU\;1W<%O"MIL
MU66_DTYK1I/E26,%G.['*A1D''.1P.RS>-(]-;6+?5;7RKO34CD"0ON6X20[
M4*$@8);Y2#T/<BH)/!+K'!>6UW&FL1:D^I>:R'RW=QM:,CJ%*87/7C/M3M5\
M%'7X=6FOKA8+Z^AABB:#++;B)MZ8)QN^?D\#C ]R 5G%V?BGH\EY:VT,CZ9<
M_/ Y;=\T?RDE1T]>^>@KN*Y6WT/79_$>EZQJ5WI^ZSMI8)$@B?\ >;RIR"3Q
M]W\/?MU5 &/J^JW5A<Q0P6T7E-$\CW5S+Y<*$$!4S@_,Q/Y ]>E8T/C:XO+7
MPU/9Z4KC7%?:KW&TQ,L;-@_+R/EZ]<=CTK1U/1=1N/$]EJMI=VXBAMW@:&XC
M+A"Q!\Q,$?-@8Y[5D:5X.U/3K;PO ]W:2C1'D)(5E\Q61D [\@,3G\,=Z +=
MOXS<:;=M>6*)J,&I#3%MXIMR2S-M*X<J"%(8$DC@ \&JVFK<+\6+\W-O;Q2-
MH\1W0,2)/WK<G(!SV[]!] RZ\$WUU!J9^VP074NJIJUG*H+"*5550K XW#"_
MK[5IZ?HNKCQ:==U"YL?GL%M'@MXW/(=FR&)]_3V[9(!TM8DVNSVWB^UT6:SC
M2WN[>26"Z\XY=TQNCV;>N#GKT%;=8?B?P_\ \)!9VJ1W+6MS;7*313I]Y1T<
M#ZH6'U(H B.OWS6MI,MA"D5S)+_I+SGR8HESMD8[1]_C ]^M<YK>KQ>)?!VB
MZJULD<@UJWCP&W[&6YV,5; X.WVX-=)K&AWMSJ6C7>G7%M%%IY<&VGC+1D,H
M4, "/F7!Q]3TK'3P9JD?AR'2OMMI(8=4%^LA1ERHF,NT]>23CV]Z -5O$MP+
MWQ':BQC+Z/!',I\\XF#JS8/R_*1M]^M1-XHNI-+L+Z&PBBBNM/%ZTUS/MB1B
M%*Q!L<L=QYP.!T/2F7WAO5)-9UBZLKNTC@U:S2"=949GC9%905QP00W?ICH>
ME5K3PEJ]G+I)74K.1;33!I[K) Q"$8_>1C=]X@ '/I^% &=>:H^KZ[X'US3[
M!&NKRUNG2.20)C,2G#/@G R>@/TJ+Q1K;:[X \06VHZ>EKJ6F7$4<T._S%!+
MH5=&P."I] >M:NG^$=4TVS\-%;NTFNM$22+849$E1U"_>Y((QG.#UZ5+JG@^
MYO\ 0M9MUN(!J&KSI+/,P.Q FW:JCJ0%0#MDDGCI0!=U?Q-+:W=[::?:+<W%
ME"LLB,7&\L"0B[5;D@=3ZCKSC9TR]_M+2[6]^SS6YGC5S#,I5XR1]U@>A%<_
M>:#KL'B*36=$OK*![R)([VVNXVDC+)D*Z%2IR <8X!KI;:)X;:..29II%4!I
M&X+GN<=OI0!!JNI6^C:3=ZE=DB"VB:5]HR2 ,X'O6:=;U"RF>35--6"P6S>Z
M>ZBEWB$KR48$#G'((]#5_6M*AUS1+W2[@LL5U"T3,O5<CJ/IUK&L="UNYTJ7
M3/$>HVMU:FW:V_T6)D>8,NW=(23S@G@#&3GTH #XKN+==&NKZP2*PU:1(HG2
M4L\+R#,8<8QST)!X/KUK/G\<:C!IVIZBVC0?9=+OS:7)^UDL5!4%D&SD_-G!
MQ^-7+7PQ?R6&C:9J=S;S6NDS1RQRQ@AY_+!$>Y3PN."<$YQVS52Y\'ZE<>'/
M$&E_:+17U:^:Z63+$1!BIVD8YQLZ\=?;D U+GQ.PU^ZT>UCMFN[<1MY$TQCD
MF5N2T8P=P49^I!''4P-X@L]/U_Q&]Y80VPTZSAGEO(SNDGC.\@'@=-IP,GK3
M-?\ "]UXB$L5XMD 9(Y+6Z7<)[(@+NV''.2"1R.O.>E+?>$9-4U/Q ]W-&+/
M5[..UQ&3OCV;L-R,'E\X]N] &=J$MY=>-O!=W=V-O!YK7#*4DW.@,#'8W ]<
M\<9S]3?3QG+/)87%KIDESI]Y<B /$LADC4D@2D;-NSCGG@$'VID'ASQ#+>^'
MY[_4-/8Z0[Y>.%\SJ8RF2"0 <'Z9_*GZ%X<UW0W&F1:K:MH,4I>$&%OM*(6W
M>5NSMVYXSC./3C  ZP\4:Q?SZ@8M"C:WT^ZGMIS'=;G8H@9=B[1N+$@<XQD=
M>:DT_P 475YK9T=[6U2\;3S>*J7!81,&53%)\N006'/UXI++PWJ,.E^([1KV
M."359YIXIX"VZ R*%[XSC .1C\*BTGPQJMEKFF:C/=:>JVNGM8O#;P,HVEE8
M%26ZDK_]8]: ,JS\1WEQ\/=+U;5],L[\75U""'DX4O-@-M*'&TD8&>W6NEFU
MVZN+_4[32;.*YDTU5\[S92F^1EW"-< \[<<GN0/7&+'X,U2+P7:>'OMMFXM+
MF*2.78RY2.7S!GKR< >@]ZU(]"U#3O$&I:GIDML4U-4,\,Y;$4JKM#J0/F!&
M,J<9QU% %.+QO)J,NA#2M.2>/6+>:6)YI_+\MHP-RL-IZ$XR,]#Q6OX:UJ37
M-/GEN+9;>YMKJ6TGC1]ZAXVP2K8&0>O05E67@^32KWPX;*6)K71X)HF$A(>4
MRXW-P,#D9Q[]JB33=?\ #^EWIL)K%[JZU5[P(R.P=9"28ATP<X^;IC)(&* .
MSKG/'6IW^C^$;R]T[RQ.I1-SDC:&<*2,#K\W]?:NCK'\4Z-)X@\-WFF13+#)
M,%*2,N0&5@PR/3*T <Y<_;HOB='+:V-HVH2Z&^]3,5CR)UP6?;N/''W?TYJ_
M9^-4OM'TFY2U\N[U'S0(69F6/RB5D)*J20#@#CG(Z59CT;5!XKBUN:6T<KI[
M6C1IN7+%P^X=<#@#]?:L>#P5JUEHVD"RU&VBU;2IYWAE9&:&5)F+.CKP0.1R
M/[OY '1^'=8GUFSG>ZL);.>WN'@97#;9,='0L 2I!]/45L=JI:7#?Q6I.IW$
M4UV[;G\A"L:<8"J"2<<=2>23TZ"[0!QUMXROGCU*]N=)AATW3+BYANYA=;G'
ME+D%%VC=D\=NM3IXNG@OQ'J&G/'9&UDN6NH5D98=@W,K[D '&<$=<8I;'PI*
M='\0:9J4D30:M<SS9A)S&)1TY')'KW]*-/T+7I]-ETSQ#JEK=6?D/;AK:%DD
MF5E*[I"21G!/ '7G/% %FUUS49)+&>?2PFG7=NTYG2;<;8!0P$@P.H/;.",<
M]:IVGB^XN[O2V32Y7L=1^[)&LA: %=R-)\FW!'4@\'UZU)H6A:[9V<6F:MJ=
MK=:=;1&&(PPLDLR;2H\PDXX![#D@'/JSP[H/B#1HX-,N-6M9](M,"W9866X=
M!]U';.W X&0,D#M0!17Q8=-T+5=1@T*WC:#6&M)X89@/,<NB&3.T;B2PZX^M
M69/%FJV^HZAI5YI5O:WR6+WMDXN#)%*JG!#':"&'' Z^O>L7Q+I%YHW@O6!/
M-;E[W6H;R-ER0A>XC^4YQG&.O?VKJI- FU'59M2U!HHY?L+V4,<)+A YR[DD
M#).% &.,'DYX )?"-Y>ZAX2TJ\O]AGFM8I"ZN6WY0'<>!@DD\<_6MNLCPSIM
MYH_AZRTV]G@F>UB2%7A0J"JJ%&<D\\9-:S#*D D9'4=J .5M_%UP=9TNPN["
M.W?46F583-F:#8K,ID7'1@I^GO5)_'&HQZ?>:B^C0+9V.I&QN3]K)? D6/<@
MV?-RV>=M-T_P;K5I_87F:E8R-I5S+(7\A]UP'5E+N=WWSN_/G)Z4^?P?J<WA
MK6-*^T6BOJ&I->B3+$1@RK)MQCG[N,\=?:@"_K&JR:C%KNFV-G;W*6,&VY,[
MX#.R;MBC!Y"X))[D#UQ8\#?\B#X?_P"P?!_Z *I/X;U:VUC5KO3KJT6VU>-3
M<PSJS&*4)LW(1C((QD''3\*V/#>F3Z+X;T_3+B:.:2T@2'S(T*@A1@<$GTH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L[6-$LM<@@BO!*#;S+/#)#(T;QN,@$,.>A(_&M&B@#GV\%:$]
MKJ5K);22P:BX>X22=VRX &X9/#?*#N'.1UI1X.TLZ+<Z7*]Y/#= +/)/=/))
M(HZ*7)R%'H,#KZFM^B@#'7PU8QZJVIQO<QWC0+;O(DI&]!TW#H2,]2,U!%X/
MTJ'3]-L8_M"V^FS">U7SC^[<9P<]3C)X.>M;]% &))X5TN2>\?9*D5Z_F7=N
MDA$4[>K+[X&<8W=\U?OM*LM2:S:[@60V<ZW$&?X7 (!_4U<HH IVNEV=E>WM
MY;PA)[UU>=QU<JH4?H/YUFMX.T:32K[39H))K6^G:XF624D^:3DNIZJ<\\5O
M44 8,?@_2!HUSI5PEQ>07( F>[N'ED8#[OSDY&WMC&*A;PK!8&34K$W5WJT5
MF]O;M=WDA# \A6YZ9 _GUYKI** /.]#T"ZA^Q16EOXFTV6W,8876HJ]LH4C<
MH3S&W @$ !?RKI$\&:-%K4NJ11W$<DTOG2P)<.L$DG]]HP=I.>>1UYZUT%%
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MS.,C YK0HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI,2"H.2H8-_%CH1QZUU6A#7+"QT?3M1@^UN+3_3+[SA\DB@87:>6SS\WM[T
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MXVC)&2 R].^?:K$VC7LNH>*FNM"^V66I36Q2%Y8QYL:JJ/CYN&&"PSCH.AH
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ML/"6JZ"FC7MIIUMJ\D"7$=[9,ZJ#YT@DS&7X^5N.<9'I5^^TK64OM"UZSTF
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MN84LK6<6L9,IBSYA<@%MJ]!D \]LUTO_  D-I+;6DMG'->-=V_VF&*$*&:+
M.X[BH'W@.3GGV-8JZ?JO_"1>(KU]-D$5[I\,,.V6,[G4/D?>!Q\XP2!T-8MO
MH&MZ5;^';T:%%J36VF+IUY822Q!D*X(D1F.T\Y'7H1^ !W>C:Q9Z]I<.HV+L
MT$F1AEVLK D%2.Q!!%7ZHZ3%+#IZ":T@LW8EC;P8VQY/ R."?4^N:O4 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MU8[P)3G'3/S$C! &, ')Z @'K%%<9K'C"]L_$DND0P6\"6FF-J-W=7 +*%'
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M_A%M._Y[ZK_X-;K_ ..5M44 8O\ PBVG?\]]5_\ !K=?_'*/^$6T[_GOJO\
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MN.5&>F!T'OGIZ* "N?.GMJ?C.WU5@1;:;;R0P$C[\LA&\CV"J!GN6/I7044
M8^OZ&VM#3WBNVM9[&[6ZBD$8<$A64@@]B&-4QX6FMKW4Y=/U(V\.I@&ZC>$.
M1)MVF1#D!6(QG((R <=JZ2B@"MI]C;Z9IUM86B;+>WC6*-?10,"N8/@>4:$V
MCIJ[?91>B[B#6X)3$OF[<@C/S'KZ=AUKL** .:O/",>IZGJES?7(D@U&Q6RE
MA2+;M52Q#!MQYRQ[>E3Z%H6I:9L&HZ_/J:0KL@5X5CVCIEB.7;'&3[\9YK>H
MH Q]?\/0ZXMI+Y\EK?64OG6EW$ 6B;&#P>"I'!!ZU-;66I%HSJ.HPSB,@A;:
MW,(8CINR[9^@Q6E10!RB>"EBTV[T9+[&B74S2M:F+YT#-N:-7W<(3G^$G!//
MI=7P[-'K6JZE'>QJ;^VCM_+,&1&$W;3G=S]X_I6]10!RD7@^2WTWP]9C4EV:
M)(LD;&WYDVH4 ;YN.&/XUC>'-.?7;+Q18?VA&MA=:O<B:-(\R-&S#.U]V &'
M&<'O@^GHE% '(:GX&-^^MQPZM);6FK0)'+ L"ML*)L7:Q_AP!E?R(K0M_#UU
M!X@75SJ2RRBP%EM>WX(#;MW##N>GI[\UOT4 <-<V5AH'A!/!]V\VH37D,T5L
MB6SCS223@L,JI!8<DC &>U=9I&G+I.DVMBKM)Y,85I&.6D;JS'W)R3[FKM%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M'\K;\P,JC!R#]?YY'%=96=K>C6^O:=]BN9)H@)$E22%@'1T8,I&01U'<&@#
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MO<X 'Y"GU0M],,&H_;/MU[)_HZP>3)+F/@D[\8^^<X)].U7Z "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ.10!O45CV_BC2;O1YM5AGE:SAD,3M]FD#!@=I&PKN)SQTK74[E!&<$9Y&*
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MS ZT :5%5=.U&TU?3X;^PG6>UF7='(O0CIWY!SQ@U:H **** "BBB@ HHHH
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M;N,Y+8)XPO0$\Y8GL,[_ /P@4G_0X^*__ Y?_B*/^$"D_P"AQ\5_^!R__$4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDP-<Q%V=4BS*S8!')XYZ=!6\/#]__P )'I>JR7T<WV.WEAEWH0TID*LQ'.%
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MM_[5U+Q3=:;<ZW<)&='M[@FR9542LSABAVYVDKD=_?'% '7_ -EZ?_SX6O\
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MB\O9A6' !SG(Y)S0!VU[>VVG64UY>3I!;0KNDD<X"BLJ;Q/!;6)O[FPU"&R
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M4X/S=\^V*H13Z[K=EJ,^G:E';W6G7\ENLL]R0BK"V")(PF#N4%B<Y^;C &*
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MFS=OM$@S">JX!]><]<]ZOKJ%D_D;;RW;[0,PXE4^8/\ 9YY_"E&H61CFD%W
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M5&IZ>9EA%];&5G\M4$J[BV,[0,]<<X]*6#4;*YN)+>"\MY9XO]9''*K,G;D
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M50JPR2,Q4 Y&&)R,=N>*?J'B?1].L+:]FU"W:"ZF2"%TE4AV9@O!S@@9R3V
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M .N>@JZ;^S%F+PW< M6&1-Y@V$?[V<4T:E8&&*87ML8ICMB?S5VN?13GG\*
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MC3-1L2T:LJW#R!XHW _CP>W?FICJ5I;0K]KO[1'6$2NQD"C;P"W)X7)'/N*
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MD/$3(F>A"C#8Z;3[U;N(])EU_P ?M(MF_P#H$)!;:>3$^XCWSMS[XKTL  8
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M8=3Q^7//%=#533K!-/@= _F22N9)9-H7>Y &<#@< #\.YYJW0 4444 %%%%
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M8VE@@50)-J_>+;B -I(!YZD 9I+?Q797=I;RPV]R9YVD1;5U5) 8SA\[F"@
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M&JP@LDJE@58 ]<HW3/2L>'0-<TYK5H[9;BUO-0NKW4;..<1X,IS&"Q^\J_Q
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M;>:>,*DJJ 6 P200&'4#/;-36_B>TFMEO)(+B"Q>T:\6ZDVF,Q+MR?E8D'#
MX(S6*VE:M_:'A6=-/;&G64T,^Z2/"NT:J/XN1E>?8UF'P1>7$%[:Z?#-HME?
M6$B7-F\ZR0+<DJ4:)5)VC.[/3(QQZ '2R^--.M;J6WOXKFR9+1[Q3,$(DC3E
ML;6/(]#@UJ6.IF]N)86L[BW:...4-+L*NK[L;2K$'[IS]1ZUSEC%KUQILZ7O
MA?3;:XCMW1@)4=;MRN-H 'RH>^[Z8/)J/1]'U/PXVI3:/87/V VZ&VTFZNU.
M)\G=L;+!$QC@GKVH [:N.\>RW&EQZ5KL5U=1VMG>QB^BCG=4>!SM)*@X.TE3
M^==@A8HI9=K$<C.<&J>KZ;#K&CWFFW _=74+1-[9&,_AUH Y*/4&L/BX;%KN
M\DLKZS/E(\[M%'<K\S*H)QS&0V.V>.M2WUS96OA75M7U-]3EL+JXW*D%PY9(
M@P5"AW#:&*[N"/OXZ52F\%:M-X&TJW^U!?$-K<Q7+70(R'X1N>^(^/?:*W/&
M&C7%[X&N=&TFV\R1HXXH8]X4*JLIY)(XPM #;C7+BY\4:AH!L;A((;%9OM$<
MJJ<N6&[(8,!\N..<YXQBLSP3XH1/#WAFQO8+XR7UN$CO95!CDE"EBI).[. >
M2,'UK0FL-4B\976J0V'FVMWID<!_?(K1NC.<$9YR''0X]ZRK'0-8M]#\%VCZ
M>WFZ3<*]UB6/ 41NF1\W/+ _@: /0*YY_%UL-;N=*BT[4IKBUDA29HH05029
MPY.?NC')_0X..AKF+#2[T>+/$EQ<6KQV>HQ01Q2AU.=B,K< Y'WN/Z4 3IXP
MTYKS3X6CG2#46*6ET=OERMC('#;AD#(R!FG0^*K:XM$O([.\:SDMWN8IU5&6
M1%QT 8D$YR 0._H:QO"NFZ[IL-II%]HE@J6(6,:HDB'SHU^Z0F-P8@ '.,<G
MGI5.U\/7NGR2WUM92Z3!+8SG4K,3J]O)*4X:)0QVG.3G X[4 ;5GX\TZ[N=+
M0V>H6\&J*OV2ZGA"Q.Y7<$SDD-^&#C@FK$WC'3H)[421SBUNKG[)%>#88S)D
M@#&[< 2" VW'O@@USVA:==Z]X0\%P/9M!;V/V6\>=W4AQ''\H4 DY)(SD# S
M4_AS2-;T8IHLVBV,MM!,3#JQD3)BW%AE,;MX!QZ=\\<@&\_BNS62!EMKN2TG
MN_L:7<:!HS+DKCKNQN!7=C&>^.:9X9U^YUR75!-82VR6M[);(69"/D"@@X8G
M=G)Z8YZFLOPS9^)-"B_L!K"&2QAG=H=3^T#F%G+8,?WMXR1Z>_'.CX8T[4-+
MO=;ANK95M[C4);N&<2@[U?;@;>H(P<Y]L9H V-5O6TW2;N^6W>X-O$TGE(P!
M; SU)P*Q]*\4&YT71IKFSF_M#48%DCMTV9D^169Q\V @S_$0>0,9(K8U.V>]
MTF\M8R \T#QJ3T!*D#^=<98:)KEE_P (OJ9L 9]+LSI]U9K.A9XRBC>A)"YW
M)G!/([YXH ZW2-:M=9CN/)62*:UF,%Q!, 'B<=C@D=""""00>M4?&Y=? VMR
M1RRQ2164LB/%(R,K!21R"#2Z!I$UIJNMZM<)Y4NJ3QN(-P)C1(PBY(XW'!)P
M2.1S4WBNSN=1\)ZK86<)EN+JUDAC7<%Y92 221QS0!2T?Q+#)-9Z7+:7L4[V
M(GADE0!;A5"AMO.<@D<,!UJ/0]?TM-$L#817SK>W$\<$,[@RLRNY?)=N@VMC
MGIBH1INI?\)%X;O?[/D$-C8303_O(\AW"8 &[G[A_,5FV/AFY?PI9Z1K&A-<
MHMU<2N(YT62$M(SQR1MN'(W8/([]>X!W%A>"^M%N!#+!EF4QS !E*L5.<$CJ
M/6K-8_ABSU&PT""VU2YDN+A&<!Y6#2>7N.P.PX+!< GU]>M;% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M[LA<("0H51D?Q;N2> /?()M;\0Z7-H#ZQ%I\-O>3&UO3$C-Y<ISY95MV K$
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M//2K4WBB9?%4NC27%O8SBXB6WANH6 NX3M+M')D MRP ]NASP ==5$Z/8MK
MU8Q-]N$7DB7S6^YG.W&<8SSTZU!XEUM/#OAV]U9X_,^SH"J9QN8D*HSV&2.:
MSKC6-4TKQ#I6G7SVT\.J+)''+%"4,,R+NP1N.Y2,^A&.O/ !K3ZYIEM?164U
MY&D\L@B0'.#(1D)NZ!B.0N<G-2:AJECI4*RWUS' K'"[CRQ]AU/X5R_@:&YF
M&N->RV\Z+K-S@>001(K## EC@<<#&1ZTGCK3=4CF@\0:5Y<[6T#6]Q9R''FQ
M,Z-\A[/E1UZT ;NI6^@>(=&\R_-I>:;$WGF1I 8U*9RQ8'''.?QS4^FZQH^H
M6KMI>H65Q;VX"N;:962,8X!P<#@5@XC\9>%93H-U_9SR76ZY2YM=Y252"\;H
M2,'(&>N1GKFN:UG4;W_A$+_1KZQM;.]BU*UM+QK-=L4T4CJ0X] R\$'WH ]*
ML]1LM15C9W44X3&[RV!QGD'Z'L>]);:I87EP\%M>02RIDE$<$\'!^N#P?0\5
MP'Q O[K2/$'VC3V9)I-!O1(4[! &1O\ @))Q]35C4%&FZ;\/6L_E=;RWMAM[
MQO"P<?0X!_"@#M=3TFRUB&.&^B:6..19542,N&!R#\I'(/(JX!M4 9P!CDYK
M*\376IV'AV]O-(2"2\MXC*L<Z,RN%&2N P.2.G-8D?C!CXGT^V:YM#I-]IQN
MXIA"P8/C=M+;L % S8QGC\: .HGU"TMKRUM)IU2XNRP@C/60J-S8^@YJD_B;
M1(["YOFU.V%K;3&"67?\JR#'RY[GD=*R1K>L0ZOX8MKM;3;JGG&95A97CVQE
MU RQP>@/T-<MJ@_XH+Q__P!AB7_VC0!ZK12'.TXQG'&:X*W\5Z\ND7NLW?\
M9QM;2[GLS#'$X>1Q*(HV!+$ ;B,CGOSZ '?45QE[XEUO0_M]UJ.G^?IL5J)(
MIP@A/GEPHB(WMP2P(;MSG-6Y]2UNR\4:3I4UQ92)J$,[LRV[*8WC53@?/RIW
M#WXZ\\ '456MM0M+NXNK>WG626U<1SJ.J,0& /X$5R%GXNU2X\-^%]49+,2:
MI?):W*"-L!6+C*?-P?E[YZU%JGBS6+'2O%MS$MB9M(N8TBS$V'1D0_-\WWOG
MZ]..E '>T5RDNKZW;:LFD3M:R75PDMTCVUNS>5"I10I5G&YMSGYLXP.G/&MX
M>N]5N]*#ZS9+:WB2.A"XVR*#\K@9. 1V)XH O7=Y;6%I+=7<\<%O$NYY)&PJ
MCW-/M[B*ZMHKB!P\,J!T8=&4C(/Y5P-[/J4]_P"/H9[R.2UM[!52+R2"JM [
M  [N.2<D@Y]JGT/6=3TP^%K.[>T?3[_3256.-A)"8HE;)8MALC/\(Q[T =W4
M%[96NHV<MI>V\=Q;RC:\4B[E8>XKE=.\0:_J7]C:A;:>)=.ORK31^6%,$3C*
MN'+_ #8XR-O.>,5I^,M7O=!\-3ZE8+ \T3QKMF4D$,ZIV(P?FS0!;T[P]I6D
MR>99V@1P,*SNSE1Z*6)P/I5J^U"TTRU^TWLZPP[U3>W3<Q"@?B2!7(W?B'Q#
MI&M7&G7XTZ7S[":\LI8HG 1HL%HW!;YA@CYACZ=A!+XB\2P>#[3Q!.VEM%=)
M9,L*P/E?-95?)W8_B!'ITYZD [ZBN9.LZEJE[K=OI#VT9TMEA43QE_.EV!R#
MAAM7D#USD^QR+;Q?K.O3:(NCK96Z:KITUR#<QLYADC*@@X8;ADD=O7V(!WM%
M5+D:@-*D^S-;_P!H"+Y"Z$Q&3'<9!P3[UQUKXVO9O^$4FD:T6WU4F&]7R'W0
MS#Y< [\*#("G.>?T .\JL=0M!J8TTSK]L,)G$/?RP=N[Z9.*Y74/$&N0MI+V
MS:>T6I:DUK%OA?*Q;7*OG?SG9GMD$=.M2P:GKT?B0:)>S:>93I#W7GPV[#$@
MD"C@MR,'./6@#KJHZEI%EJZ0I?1-(L,JS1@2,FUUY#?*1R.U>=V&H:_-X9\$
M3'5(<W]ZHEW6Y)?*2/\ .=_S<KGC;V]*W[GQ%KUU%>SZ)8K=&RNVMOLYBP)]
MC!9/G+C8<[L<'H,YSP =D!@ >GK2UPE_XC\1(WBLVS:=&NB*LJ"2!V,J^2)2
MAPXP><;N?I79V-S]MT^VN@NWSXEDVYZ;@#C]: +%%<6?%&J0:OID$_V1OMFH
M2V<L$2,P@ #E#YH.TOA 2O7YN@Q6?/XJ\4IH6K:U&FEO!I-[/#-!Y;AIXXWP
M2K;OE.,GOGVZ$ ]$HKB/[=\3:IJ6N6NCG3$%BD$L!GA<F421EPA 88/;=V].
M>*]GXNUS7YM'32A86XU/2Y+L&XC=_*D1E4CAAN&21V]><8(!W]%<6WB75[G0
M=7UFQ^R&/2Y98S T;?OQ#_K#NW?+DAMO!Q@9SGB>V\4W#>(+-+E[:+1]1TTW
MUG(8F5]P 9D8[B.%8-T'?TH ZVJESJ=C9WEK:7%U''<73%8(B?FD(!)P/H#6
M#+JNM)%IXGDL[8W,,DK,(&:0/P4C6(,6) )+$9^[VZUBG6)=?@^'^JSQI'-<
MWC.ZIG:#Y$H.,]N* /0Z*R?$NMKX=\/7>J-'YAA"A$)P&=F"J">PW,*SY]7U
M/2_$FF:7>O;3Q:HDJQ31PE/)F1=V"-QRI&<<@\=>: -:;7-,M[^*RFO(TN)9
M/*13G!DQD)NZ;L8.W.>:ODA022 !R2>U<;X$AN9H=8:\DMYT76;H@>001(),
M;@2QP/08R/6I]7N-3'Q"T.T@O(X[62UN)&B:$L"5*#)(89.&('ISP: .BT_4
MK+5;=KBPN8[B$.T9>,Y&Y3@C/UJ6YMHKNVDMY@3%(I5P&*D@]1D<UYKI6JZK
MH>AW>H6[6ALD\0SPS0O&QDD62ZV$AMP"D;NF#G'X5OWWB'6[K^TWT&S6X:PN
M?LZPO'D3LH4N"^\;/O$#@],G.<  Z>PL+;2[&*RLXS';PJ$C0L6VJ.@&23BH
M9];TNUN'MYK^W25 #(A<90>K?W1]<4S6;VXL_#.H7\,1%S#9R3)&>2'"$@'\
M165\/((XO FDRJV^6ZA%S/*3EI)7^9F8]SDX_"@#HK>Y@NX!/;31S1,2 \;!
ME.#@\CW!%2US1N5TW6[/PQI*Q6YEAGOG=TW"-/,Y"J".2\A]@!6-<>,M7AMI
MH/*L_M]EK$&GW!*,$E21EVNO.5)5NAW8]Z .^HKC5U3Q+)K>KZ*MUI@FM;>.
MZBN?LKXVON&PIO\ 5/O;NG8]JMIXLUS5W\-I9+80'5].DN7:6-W\ITV9P PW
M#YNG'UH [RBN(T_Q1K-Q936]XMC!>V6IFQO+@9V%-NY7C0G+,V5 7).3G!Z5
M7_X3'6'TB&>*.T:==>&E2>9$Z!T,@4-@G*-@\@Y^G:@#OZ*XLZUXF\SQ+IT!
MTZYU+3(H;BV;[.ZI,LBL=A7?D'*$ [NXXK3TO7I=:?29+"6![:>S^U73&(Y7
M. JCYOE);?US]PT =#1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MADU&W6>*$MD\H'(]\ ]?\: *,?ARYL[4KIVKR6US+=M=W4K0(XN&88(*GH.
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MBPC>.V<P[,%@ 7;D[FP,9&!R>.:UH;F&XDG2*17:"3RY0/X6VAL'\&!_&I:
M,?0-#?0X[R,W?VA;JZDNVS'M*O(<L!STST_G1J>@F_UK3M5BO9;:>R62/"HK
M"1'VY!ST^Z.1[U9U;58=(M8I9%+O-/';0H#C=([!5&>PR<D^@/6ETR\O+M)Q
M?:>UE+%*8P/-$BR+@$.K8!P<]P#D&@# ;P26T&XTHZD?+GO_ +<TGD#<'\T2
MX'.,;A^52OX0GCUJZO\ 3]<N["&^8/>VT*(5D<  LA8$QD@<D<UU%% #1&@B
M$04>6%V[>V/2N>TSPS<Z$C6FD:J8=-+EDM9X!+Y&3DB-L@@9)P&W8KH)G:.%
MW2,R,H)" @%CZ<UG>'=97Q#X?LM62$P+=1[Q&S;BO)'7\* *MYX92:^L-2M;
MN2#4;(.JSNOF"57^\LB\9!/(P1@CC XJM=>#H[FT,8O&2XDU"/49Y_*!,DJ$
M%1C/"C:HQZ#KG)K0\1:Y_P (_IJ7IM7N%:>*$A7"[=[A 3GW8=*UZ ,-= E3
M7K_5EO5\V\MDMBAA^5 NX@CYNN6-<JND/H?BKPEI5IJ"G[#8W40FDBR,'R]J
MN 1R<'&",XKT:@]* .6E\&(S6US;ZC-!J$-\]\]R(U822.I1@4/&-ORCT '6
MH1X%*QO&NL3LK:JNJCS(D.) P;'&."1S^F._3:?/<W-A#->69L[AQEX#()-A
MSTW#@U9H YN>"'PWJ>J>)+RYEDCO%@BEBAM6<IL)52 N3_&<\?E3O"FBQ:=8
M7MQ!#+;'4+F2X6-Q\T2,257!^[U+;>Q<BNBHH JZ;;7%GIT%O=7CWL\:X>X=
M ID/J0.!5JBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "LCQ+C^Q>>GVFV_]'I6O5:]L+748!#>0
MK-$&#;&Z9!R#^! - 'G'B.VG\"VVJ0VT3R>&M6CD18T&?L-RZD# [1N3^!/;
MOT,;C6O'.NZ3J)D$%I:VYM(ED9,APV^08(^8-A<]L<8R:ZF:T@N;1K6>)98'
M78R.-P(]\U7O='T_4)XY[JU22:-2JR<A@IZKD<X/<=* ,GP)>7U]X1M9-0E:
M:97EB$[?>E1)&57/N0!SWZ]ZXF_CE3P=XJU%;Z_^UZ=K$OV20W<A,05T '7D
M8..<\5ZO%%'!"D,4:QQ(H5$08"@=  .@K-/AK1FM+BT;3H3;W,GFSQ$965_[
MS#N?<^@H Y#6IKKPWXEU-M+DN9';P]<7ACEF:4-,CJ%?#$\X8\# J68O:6_@
M[4]*N9Y9;^XA@N<RLWVF*2)F=FYY9=NX'MSVKL1H^GK?I?"U3[7''Y2S')8)
M_=SZ>U,L]"TO3Y-]I910D;MNP8";OO;1T7/?&* /.H_-L?"6N:\M[?M=V.HW
M=O&[W,CB.$SA&.W/S;5R03SQUX&.MT;33:^($OH-<AFM;NSXLH48I(0PQ,"T
MC<X.">^1WK;M-'TZP@G@M;.*.&X8M-&%^60GJ2.Y/?UJ+2/#VCZ")1I6FVUG
MYQS)Y* %O3/M[4 <_K=G;R?$WP[)*#DV5V2?,9?NF(CH?<URXA-KX7O=7AN+
MF.[M_$L@B*3,JA6O K J#@@ACG(->GWNE:?J,UO->6<,\MLQ:%Y$!,9/4@]N
MWY"JQ\,Z*;1[0Z=!]F>7SFBQ\K29SN(]<\YH XCQ/>L+?6]1L+J=Y;/5+:'[
M1),4\A@T0:*)1U7#'=G&=QZXJ6_LQ>ZOXZ66\OC';6L,UNJ7<BB-S"[97!]1
MG'3VKL)_"N@W4MQ+<:1:2R7(43,\8)DQC&??@<^U2#P]I"FZ*V$*FZ01S[1C
MS% P%;U ' 'IQ0!'HEW<7'A#3KU\SW,EA%*<]7<Q@_J:X<7EU+\.M(\46ES,
M^M-<0F0B0_OG>8(\++G&WYB N.,#&*])M+2"QM8[6UB6*")=J1KT4=@/:JL6
MA:7!=M=16,*3&0RD@<>8>K@= Q]<9H \YU2"0Z)X[O/MU^)M-O6>T;[7)^Z8
M11L,<\\GH<@#ICFMV.6/Q%K_ (BTO4;R6W>VMX/LICE,9B1XMQF3_:#DC=VV
M@?7I6\.Z.\5W$UA"8[QMURI'$Q]6'?\ &F7GA;0M1DMI+W2K6X>U 6%I8PQ4
M#H.>H]CQ0!RA+^(=8U71GUD1FWLK<VDLJL)&1H\F==KI\V[.3CC Z9KK;='?
MPM&DM\]V_P!D -W'F(RG;]\8.1GKP:75/#>B:W-#-J>EVMW)!_JVEC#%1Z?3
MVZ5=NU?[#,D,>YS&51 0.<8'TH \OL+>ZM_#'@OQ!;:A?R:G<7%K!.)+EW6>
M-^'4H3MX&3G&>"3D\UH:8+CQ#IZZLVO1V-_::DXGQ&[2(5E*B!AY@!4K@ ;>
M<@\GFNA\'>&DT7P_ID%Y:1K?V<7EEE?>H;&&9.PSW( )YS6C_P (UHG]M?VS
M_95I_:/7[3Y8WYZ9SZ^_6@#G/"6FI=ZOK5Y/=WTDECK4Z0*]W(55?+08()^8
M<]\XP,5>UF^5_'&D:/>R%+&YM9Y$3<5$\RE %/KA2QQZX]!6]9:58Z:\[V=L
MD+3OYDQ3_EHW]X^I]Z9JNBZ9KELMMJEC!=PJVY5E7.T^H]#0!RK06L%]I6B0
MZE=ZFZ?:F6"XFQ&R@C_6/C)$>[: ,G)Y^[D8UC=S7GA'P)+<W#3R_P!N!#([
MEB0OGJ,D\G@#GVKOYO#FBW$=G'+I=HZ67%LIB&(AW"CL/:F+X8T1(HHTTRV1
M(IC<1JB;0LA_C&/XO>@#CD%QXB@U>Y;7H]-OM/U*53)Y;M);I')\BX\P JR
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MKXU(PI&Z?:( T;81^ 6(!( .<K]* /0K'5K'4I)XK6</+;D":)E*/'D9&58
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M",#FK-]XQNK>ZUV"WT.6<Z.B2RLUPJ!T*%\CKS@<#OWQW .J=6:-E5RC$8#
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MT+:X G_>QDXR^S;]SGKGGK5?XA7M[I_@75KBQ(658&!D\PJR \97 ///M]:
M.E5U?.U@V#@X.<&E)"C)(';FN5L_LVFZY):Z=I%K'K%Q:+-<I'<%(1&K%4).
MW[QR>B] <G@5DZ[J]KXATO0+V.!HI[?Q#;V\L4@&^"59,.F1^'3J,4 >@9&X
MC(R.2*6N$MM0LO#_ (M\;ZC<+L@BBLI'"+RS%'& /4D@?4UN-XAN+;6+;2[[
M3T@N;V)WLRL^])&09:-CM&UL<]",9YH WZ0L%&6( ]37(Q^.0^EZ-?M8+''J
M-[]A97N,&WEW,N&^7GE2..^/K3_$NM01Z5?F_P!'6]L+>\@@_P!:,.Q=,-@C
MC:S*.,\@^E '65DV6A)9:_J.KK=SO)?K&LD3!=BA 0N,#/\ $>I-9M[XKNX=
M5U;3[31)+B73H([@LUPJ*ZMN/'7!^0X]?:IX/%<-\=(BL+<R3ZG9F]C25]@2
M,!?O$ \Y<# ![T 6Y="27Q-!KANYUFAMVMUA 7848@G/&<Y4=ZU0P)(!!(ZC
MTK(\-Z]_PD6F&]%G):J)7BV2.K'<C%6Z>A!KG-7\0G3;?QI=Z9I4<&I6"1&:
M:60?OLQY5^ ?NKC [^U '=T5S<GB2>"ZATTVMN^IM9_:O(-UM\Q<D 1DI\S<
M<C QD<UL7M\UGH\U_P#9WD,4)E,((#' R1DT 7*JZGI\&K:9<Z?<[_(N(S&^
MQBK8/H17.VOC2273[.]NM+^QP7Z0FR>:Z0"5G0NP/=0H4G)'(Q@9XIUKXV@G
M\^![0B]CNTLXXXI=\<[."RLDF!E<!B3C(VGC/4 T;/098'3[9K.H:C'&P:..
MY\H*"#D$[$4L0>>2>>>M;#,%4LQ  ZDUSTGBAK*.Z&IZ>]I-%<QV\1:3]S<%
MQD%)"!P.=W'&#UK'U?QA9W&@:_%J&CK>1V"H9HHIQ)#/&W(*R$#.".1C(/K0
M!W5%<Q>^*+R'6[K1]/T*:\N;>U2Y7]^D:NK%AU/3[I'K[8YK.C\:7>K7GA=]
M*M8Q:ZDUQYR7$A1U>)&#1G"G&#SGO@=* .XHK/UC5X=(MH7D0R2W$Z6T$0.#
M)(YP!GL.I)[ &J,7B&=]6N]&ELHXM4AMQ<Q)YY,4T1.W<'VY&#P05].N: -P
M.I<H&!8<D9Y%.KB/A]8QZCX?T?7KZSB_M+R&9;M)"7E\PDL7X&>>QW8[8K8M
MO$C7]_<06-K%,EO=-:S?Z1B2)AGYF3;PI(X.>A!Q0!OT5RH\: Z!#JQT\A&U
M#[#)'YO*MYWE;@<<C//;BK-WXEF1+^;3M+EU"&PF$$XA;]XS_+N$:8._:&&<
MD=#CI0!T&021D9'44M>=IJ4V@^*/&]Y9Z6;I(1;7$RK*L0"B'<Q&<Y8\G&.>
M<D=^ZBOX9M+344W&!X1...=I7=T]<4 6J*Y-_%MW<>&KC6-/L;::$6$EW#*+
MK<@*@'8^%X;!Z<]",]ZELM?U(:3I1FL$DN+BR^T23M,4@4!5^\^SAF+<+CL>
M>* .GHKB5\87VIW?A233+2(6FK+-(ZS2E6RD9RG"D8!YSWQVJU=>.K6!UECA
MCGL_M?V5VCG!F4ABA?RL<H&!YSG'.,4 =917'77CFXM[/6KM-#E>'1[@Q7)-
MPBG8%5BRCG)PV<>W7M5Z/Q44UI+&^L&M()[62[M[AI0VY$QNW*/NG# ]30!T
M=%<I;^-HKB_T^!;19(M01F@>"X61T(7<%E7 "9'3DC/!Q4-CX[DN[32+Y]&E
MAL=1NOL@E:=2R2%F5?E'4$K@G(QGH>M '8T5Q5KXOO+9?$5WJD%NEII^H+:Q
ME9SA,B(+N)7A<ON+=N>#BNHTV\GO$F,]LD01P(WCE\Q)5*@AE; XY(Z=C0!=
MHJKJ.GP:I9-:7(+0NR,R@XW;6#8/L<8/M7#:7H.E77Q"\46$UC"UK%;6GEQ!
M<",LK[BN/NDX'(]* .NU_18O$.G?V?+=2P)YD<K&';NRK!E^\#QE16HH(4 M
MN(')]:\YM;J7PUXD\82V.FM>);06DLH\U8_E6%BQSCEC@G&.><D5T=QXOMML
M*V8MY)I;-+T)<W(@'EOG8,X.6.#QC'')'&0#I*1EW(RY*Y&,CJ*SM'UB/6M!
MM]5M[>95GCWB&0;7!&05.>,Y!%<U!\0GDT_3=5FT*XATF\F$#71F4F%RY0$J
M.2N1@G^?!(!TFBZ*FCPN#>7=]/)@/<WD@>1@,[1D # R>,=SZUIUS-WXM:RO
M($N-.>*VFU$:=&\DFV1F)P)%0CF//&0>G.*B7Q9J-W=ZC;6'A]Y#87#0322W
M2(J_NPX;@$D<@8&2,_A0!U18+C) R<#/>EK@K37WOO#?A2^UO2HKJ2_O(##(
MDG$4K E9,$ @CYL 9^M:.I^.;;3Q<S1PQW-O:7'V><).//R&"L4BQE@I//(/
M!P/4 ZRD)"C)( ]ZPH/$GVS4KFULK:.=;6Z6VG GQ*F<?/Y>W[O/7/.#6=\0
MT3^R])F,7F21:Q9E, ;O]:N0,^M '7T5S">,4@?6(]4LFLY=,$3LHE602++D
M)@\ $L,8/ /?%5YO'*VS:E')8+,]G8M?*UI<B6.1%^\-Y VL/3!XZ9H Z^D)
M"]2!DXYKEX_%\HBMWN]-6R%YL^Q-/=(%E!0NQ8CE N,<@DY''ISVN:]'K1T.
MY73V%[8^($MRD;AQ)^[D(\N0X#*W')QTYZ4 >E45QTGCBZM[76%N-!ECU'2H
MUGFM!.K>9 V?WB,!@XP<C Z5NQ:OY]YI\%O%',EW;&Y:5)>$0;<$<<Y+#'3H
M?2@#4HK,U/5)[*ZM[>WLC,TJ22--(YCAB5 /OOM."<C QV/I6;I_B^'5K#29
M;*U+76I)))'!))M"+&<.68 \ X P#G(XZX .D) QD@9.!GO2UY]K6I+<ZIX4
MU+4+)M-E@U*>*7[1QM589,L&.,H<9!XS6YJ7BFYTO0VU:XT>3R?/2*-!* [*
M[A%<@@%<Y!QR>><4 =+17,'QC'9W6JP:Q9/8?V?:K>[O-$GF0DL,\=&RI&.?
MJ:G;Q)/;:E865_IXMFU%&^R.)]RF0+N\N3Y?E;'IN'!Y]0#H*0D*"6( '4FN
M0'CG&CV.HR:>L2W&H'3YHY+C!MI-Y3YOEZ9';U'X5?B%<?;?!^O0O;)Y=F\
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M_?/\O'ITKKZ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH *P?%6BWNK6EG+I=S%;ZE87*W5LTP)C9@"
MI5\<[2K$<<UO44 <^MOXENK K>/8133NJ2I;2N%BB_B*,5R7(..P''ISS6L:
M)?>'O!7BVR0VYT-K6:2QC$C&2WRA+)@KC;NR1SQGOV]%J&ZM+:^MVM[NWBN(
M6^]'*@=3]0>* .7&@7.OKH\NJ)!%;6=L^%AD+M(\D7EYY4;0%+>O)'IR[P[I
MOBK2[:WTR]N=-FL;)0D,\9<33HHPBN",+VR1GI[YKJ888K>%(8(TBB085$4*
MJCT '2GT <);>$M9@\+Z#I9-@9M-U);R1O/?:ZK(SX'R9S\V/PJU+X4NKOQ%
M:ZM+!9VMW!=.SWEK(P>XMSNVQ.NT G!4$DG&WBNQJO>WT&GV<]U<,PB@0R2;
M$+L%'?:H)['\J .8\.:+XET..'1WNK"31K5L07 W?:#$#E8RN-OMNST[9YI+
M#PM=)XEL=;EAL[.\C5UO9;.1L7H*D#>FT#.<-GDY&/IU%C>0ZCI]M?6Y)@N8
MEFC)&"58 CCZ&K% &/XHT:37-!FM+>18;M66:UE;I',C!D/TR.?8FLZU\("S
M\3VVIQ7'[@6P6YC(YGG4G9*WOB20GWVUU 8'."#@X..U1W%Q';0O+(6VHI<A
M5+-@=< 9)_"@#EKKPQJ%Y?>+6=[5(-:LDMH6#L6C*QNF6&T#G?G@]J2VT'6_
M[6\.7MRNG@:9:RP2K',Y+;U097*<_<SSCKCMD])I>I6VL:9;:C9L6MKA!)&S
M+@E3[&K= '!OX1UIM"N;$&P\V;6_[2!\]]H3SA+M^YUXQ5Z3P]JSWOBN8"RV
MZQ;I% /.;*%8RF6^3WSQGI7744 9^AV<^G^']/L;GR_.M[:.%S$Q9254+D$@
M'MZ5R5GX2UVVT'P[IC-IS?V/?I/O$KCS(U#@?P<,=_3H,=3GCO:* .)U'PMJ
M]XOB]4-BHUN-(X"TS_N]L?EDM\GX\9]*OVNBZI%XLLM5D6S%O#IGV*15F8MN
M+*VX?( 1\N.HZUT]% '+Z=8MX>N=<DU2ZT^/2[^]:X1Y9-K%I%5=C!L*/NGN
M<Y[4WP)I"Z;H\DBW#SPRR,EH[]5M59O)4>HP20?1JZ.[LK6_@\B\MH;B'(;R
MYHPZY'0X-3@   # '04 <QK5DUMXQT77O^6"1RV5RW]P/@HQ]MRX/^\*L:I:
M:SJL&I:7+!IZ:?=1M"EP)G,BHRX;,93!;DX^;'2MYE#*58 J1@@C@B@ *H50
M  , #M0!SSZ!-I^NP:KI*PL18BQE@FD*!D4YC8,%/(Y!XY!]N<O4-!DTKX>W
M>@V[B?4=3\R,L!CS)IF)=L=E4,Q]@M=9>ZA#8P)+(LLBO*L(\F,R$,S;>0.@
M!ZGM5C8GF"3:N\# ;'./3- &1JGAV'4O"$_A[S6CBDM1;+)C)7 P#COT%8B:
M+XGN]1\/75^=,1]*,HEDBF=C-NC*;@"@VGG.,GZUVE% ' :?X4\06L^@W%U+
MIC3:9<327$^]V>Y#QLAD8E1\WS?=Z?[0'%7;"QLM2\>3ZOIM]'<6/D1R3K"P
M>-KD!D1MPXR(R<C_ '#Z5V1 (P1D&H+2RM;"W%O9VT-M""2(X8PB@GKP.* .
M6O\ PM=:CKMMJ3PV=O>6UZ)4U"WD997MPV?*=0H#97Y>21CGV.IXPTF[U[PK
M?Z59&!9KI/+#3N551D<\ D]*W*0L 0"0"3@>] '-2Z+J</BB'Q!:+:M++9_9
M+RU>9@I ;<KH^T\@DC!'0UGS^#[Y=/MDMGM6NFUL:O=EY&5<[]Q1,*2>,#)Q
MTSWQ7;44 <3J?@R\UFY\4+<RP0V^K16ZP21NS/$\.2I8%0,;L'@]JTTTC4=2
MU?2-0UA;6)],61E6VD9Q+*Z["W*C:H&[CGD^W/1T4 <5>^!/M?\ PD,9N0+>
M_P S6<8_Y=YV"EI/^^T1AZ?-ZU;UKPY?WO@J/1K>6W>[:2&6::9BBNZRK*[<
M*?O,#QVS6WI>L6>L?:_L;2-]DN&MI=\;(0X )&& /\0J\S!5+,0 !DD]J .8
M_L351K^NZAML_+U"RBMXE\]LJR!^6^3H=_;TKFWL-0L9?#>B0R:2VJ:5IQWB
M6ZDA+*=J HZKN(.ULKC'0GM7IE4M1TO3=1C!U'3[:\6++*)H!+CZ @_I0!F^
M$I)%TR2S>QM;3[)*8P+2X,T3Y&XD,0"3ECG/.>]96H>$]2U ^,$:2UCCUJ&-
M+=@[,4*1[/G&T<'KP3CWKH]"U#3]4T>"[TM=MDQ9(@(C'C:Q4C:0,<J>U:-
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ME4 '<RX(P<=3@C.:YVQ\&^(=)L=%N+*YTYM3TMKB+RW+B&X@E;<03C*L#@C
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MO9R\FT'*@$8VX/.0,YY.: *-[J.J:3XGMM*-\]S;ZC9SR0RRQ)O@EB )/R@
MJ0PX(Z]\<5C66M>(9-(\'ZFVL!FU>1+>>%K9-@W1NV\8 .X%?7'M781>'XDD
M,TU[=W-T+<VT=Q,4+QH<9"X4#)P,D@DX%58_!]E%8:19)=7@ATF42VHW)D,
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M7J6.JW%G>7%G"AG,,98*X3&#SMW8'3I73)X6L(;S2[BV::W&F1-#;11D; K
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MG\Z /0'=8U+.P51U).!2E@,9(&>E>2:+J<)M/"D.N7T<%A/HNV"6Z56B:8,
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MP.3YO(*,,?*W!X.#QQ3E\36-W:KY"WWFRPM*8EMF$T2!BI9E(R.0< \G' -
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M1U"S\5ZA:V4[2:HEK!;6^ '<1')=@3\O4@9P?E]ZWGANF^(EOJ0L[C[&NDO
MTNS@2&17"XZ]%/:NIHH \TTS2=5@LO#,4NF7*O9ZQ<W,X('R1N9MK=>?]8O
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M7'6DLC:KX[LH[&>YDN)U2,*H*.S6R#:3T7MDG P>]=_'%'#&L<2*D:C"JHP
M/I5#3]%MM,OKZ[@>8RWSB2?>^0S   X[< #B@#F/#VAWNB^*=/B>"62VM=!B
ML#= ?(95?) [XQWQCM531-,NK%FT/4/"<5Y)'=.\&J/'$T+1ERX=R3N#C/0
MDD#D=:]#HH X"'0[Y-;6?24O].2ZN)AJ5I*=UMM(?]]'G[KD[3A3GGD#!JWX
M2FUJRTJPT&_T&6*734$37I*- \:# :/!W%F7 Q@8R<^A[2H?MEM]L^Q_:(OM
M6PR>3O&_;D#=MZXR1S[T <3ING:C%\,M9TV33YTO9A?+'"0,OYK2%,'./XAW
MXJ2SM+ZPUS0=2ET^Y:WBT8V4PC4,T4NZ,X*@YQ\IY&1796UU;WL(FM9XIXB2
MH>)PRY!P1D>A!%+<7$%I;R7%S-'#!&I9Y)&"JH'<D]!0!YS/X;U337M];725
MO]VIW5W<Z9E"RQS!0-N?E+KL4D9ZL0#WKH8-2_L:SANHO"TEG#?7BH\4*1I)
M$&PHDE"G&2<# ).,=^*ZE65U#*0RD9!!R"*;)#'*R-(BL4.Y=PS@^OUH Q?&
M6CW.O^$-2TRTD"7,\7[LL< L"& /L<8_&LV:"[U[6?#VHRZ?<V7]F&6>Y$JC
M(=H]GEK@_-R<Y'&!UYKJ7O+:.[CM7N(EN9 2D)<!V ZD#J:FH YKP%:7>G^$
M;:SOK62VN(I)MT<F.C2LP.02.C"H[^TO;#Q[!KJ6\MS83:>;*80C<\+!]ZMM
MZD')!QGH*ZFB@#SB3P_J-LMK<+8S.UQXF_M62%,$P0X*Y/.,]"0,]3Z5L"+4
MM&\>:E?_ -G7-]8:I;P*DEOM)@DC##:P8C .[.>F:Z^B@#RK2]'UG2=*\.7U
MSX=DOEM(+BUN[%O+:15>0.LB G!^Z 02#S6W)I]Q_;/AJ[M?#_V&VANY[B>&
M&-%,2O$R!GVG!8DY.,X'TKM)[JWMGA2>>*)IG\N(.X4NV"=HSU. >/:IJ $)
MP">>/2O/;>WUVR\.:DMOI=P)Y=<DN6CVH9#;/-N+1Y.W?CIGD?E7H=% '$Z#
MHTTFL>*8+_2KF+3M36+8UQ*KEU\H(RD[B=W7U^M,L/#6KW?@C4]+U*95OWM7
MTVWESP8DW*CG_>SD^V*[FB@#B&LM0URU\,07&GSV<^EW4=S=LX&U3'&R[4(/
MS[F(Z=LYP<"H+&UUVQ\!:O#:::XU(WL\T4,JH2\;SELKDE2VPD@'N!D5W#W=
MO'=16KSQ+<2JS1Q%P&<#&2!U.,C/UHN+RVM/+^TW$4/F.(X_,<+O8G 49ZDG
MM0!YU=Z'JU[/XI6VTF]1-4T=(8'NIU9C(HDX8ES@G<..@'ITK<6RN=7U7P[=
MM97%K'I*R22M.H5BYCV"-0"<]221QP,$YXZ^JPU"R+7*B\MRUJ-UP/,'[H<G
M+?W>AZ^E 'G$.BZQ;:+IUW_8K74EAJEW/-I\NW,T,S/AER<%@&!Q]:[?P]%'
MY$US'H::0L[ ^28T25\#[TFPD9[ 9)P/? UH9HKB".:&1)(I%#HZ-E64\@@C
MJ*?0!PGB72;V?5KN_P!&AOK/64$:03Q'-O>K@?+,IXP,L,G!QC!/2F7]KK]E
M?^,'T[2S/+?""6UE;88VVQJC##'[W!P",=,UWU% 'G+Z1J=WJFNO#I5_'%J.
MA?9HI+N96;S?WG#?,<$[AP.![586#5(9_!^I-HMZRV%M+:W$"[#*A:- &QNQ
MC*$=?0UWU% 'F]MH=Q<6%Y;:OH^H0K+K=S=Q7-K*!+;[B2LJ%3N]1T[]"*Z[
MPK%JL&A)%J\K37"2R!)'4*[Q;CL9P. Q7!/Z\YK:HH XNZTJ]O\ Q3XD3R)X
M+;4-*2SANBOR[QYF3USQO'..U5DTS4M6T#PWI%SI\UK=:7=6TES(V-BB =48
M'YMV!C'3=SC%=[10!S/@ZUNK0ZX+JTFM_M&JSW,7F ?/&V,$8/L>#S3_ !*=
M2&IZ1]FLKBYL"\@NS:LJS*=HV88D%5)SD@@\#G&:W8[JWFN)K>.>)YX-OFQJ
MX+1[AD;AU&1R,U-0!YCI^D:O;Z?H=K)I%S&;+Q!+=R'<K 0DS88$')'[Q?<\
M\5T.FZ0]WKGBZ/4+*06&IO$J%P,2H(1&V/3D'K76U1U;2;76K,6MV9A&'63,
M,S1-D=/F4@T 87@:SOXM/DFU.99YH2;""4?QPPLRAS[L<D^N!4GB:QOO[=\/
MZW9P/<QZ=+*MQ;QD;BDJ;=Z@]2N,XZD$XKH[>WBM;:.W@C6.&)0B(HX4#@"I
M* .%O='O+B/QEJ<5I-NU:R6UM;? #N5B9=Q&>,E\<XX'/6NIT%9(] T^*:)X
MI8K>.-XW&"K!0"/SK1HH XS3[&]\)^)-8D6QGO-)U6X^V+); ,\$Q&'#+G)!
MQD$9QT-3^*;/5=>T,/8VC)+:74%W!;S,%:<QN&*GG"@@<9[]<5UE% '&W]C<
MZQKT>LQV5S#%:Z9/ $D3;)+))C";<]%VGGIDC&>:H6NF:E%I'@.!].N!)ICH
M;P8'[H"%D/?GDCIFO0:* /+/$UO>6MCXKNI;*98KK5;"6W) 'FA7A0XYXY4]
M<5MZY8:IJ.KW6MZ58_OK;29;6!+I OGRNP.W:W4*%/7@EO3-=1K.C6NNV0L[
MPR^1O60K&^W+*0R\CG@@&KZC:H!8L0,9/4T >=+8:FVN7-\NCZGY5SH3VV^Y
MD1I/.W$X(W'&<C ''L!5BST[48D\ *^GW .F0E+S@?NC]G,?///S>F>.:[67
M4+*&:2&6[@CECC\YT>0 JF<;B.PR",U)')#=VR2PR++!,@9)(VR&4C@@CL1W
M% '(PZ-/#X]NK>%D_LB?R]4FB[K<#* 8]&*A_P#>CKK+W<;&XV0B9O*;$3='
M./NGZ]*S_#^FZ1IEK-;Z3()524QS.UP9G#C^%F))!'IVK7H XOPMI-YI6LA+
M'[?%H36I+6=\=QM9MRX2)CDE<;L@$KP.?23QA,8/$GA"4122[;^7*QC+8\A\
MD#OCKZ\<5V%9VH:+;:E?V-Y.\PFL7,D&Q\!6(*DD=^"1S0!Q&O:#J%Y;>)]0
MM;"=I-4GLA!;@ .R0,I9V!(VY^; /.%'K6]J-M>VOC>P\0Q6TUQ9/8/93QQK
MEX<N'5]O4@D8..1Q7544 >:R^'M7L-3B\26]E+/C69;V33T9?,\EXO*W 9P7
MZMC/?'6DU;2-8UB/QJ8=)N8AJ-O:FU\XHID:->5QN."?_P!>*]+JN=0LQ--"
M;N 2P)YDJ>8-T:_WF'8<=30!PVIZ?JGB37KF5-+N[*VO- GL1+.4!CD=@1N
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MW>H_#NB7&B#4A/=17 O+V2\&R(IL+G)7ECG&.O%6?$&F2:UX?O\ 2XYU@-W
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
B%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>34
<FILENAME>exhibit1018-arvinasxcons002.jpg
<TEXT>
begin 644 exhibit1018-arvinasxcons002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K,\0:L="T*
MZU(0?:#  1%OV;B6 ZX..OI6G6%XQL;K4O"=_:6,)GN9%79&&"EL.IQDD#H.
MYH 9#X@OX-4M++6=(6R%XQCMYX;D3(9 I;8WRJ5) )'!!Q6A;:[I-[?26-KJ
M5K-=1YW0QR@L,<'CV[^E85U!J_B74--6?29M*L[*<W3R3S1/([A&5%41LV!E
M\DDCI[UF6NA:O<:9X?T5M-:Q;2<B6_\ ,0H^(7CS'M;<=Y8,<@8YSDT =9'X
MET.5K@1ZO9,;92\V)U^10<$GGH#P35JXU*QLS*+F[@A,47G2>9(%VIG&XYZ#
M/&:XB;1]7U#PBNA#P_%;3VNEO:BYFDC(:3:J@1%22%8C)+!>W>I=1L-5UR]O
M[R;P_<1P/I\4"02W<:2LZS;SM9&(4CJI)P2.<"@#IU\06-S%;RZ?=6EU'+<B
MW9A< ;203CW;@?+UYI\7B'1I[\V,6J6;W>\Q^2LREBPR2 ,\D8.?3%<E::-K
ML\T#SPW)@CU2"='O/(%SY:QNK,YC.U@"5 ZMUK/TJ60-X(TO['$PM+J0+>QS
MQNLX6"4%T )8 G!;<!@X'- '>V/B'1M2NOLUCJMG<SE/,$<4RL2O'(P>>H_.
MJ>JZY?6NNVVDZ=ID5Y/-;27):6Z\D*J,JD?<;)RXK)T3P_?V-AX*CDM%C?38
MG6[ 9?W9:$J>AYRQ'3/K1XJT:6]\46%])H$VKV45E+"R131H4D9XR#\[KD85
MNGK0!O+K0LK(3^(/L>ENSE44W8=6 &>&*KSUXQVJU::OIU^(3:7UO/YZ-)%Y
M<@;>JD!B/7!(!]":YJUTB26[T!X- ETVVL;V:22&>6-RH,#@.-KM_$P'7/?&
M.:JW6@:U;6%S>Z9;)_:L&JW-Q:HTB@212Y4Y.< <A\'G*"@#J+GQ'HMG%'+<
MZK9Q1R,RHSS* Q4X;'/8C!]*9_;]JFJWUK.T<-O:6D-TUT\H"%9&D'T 'E]<
M]ZY2Z\+WVD:C;R6":C<6JZ9'9 6,D"OO1F)+^;QM?=DD=QR#Q47_  B6J6\2
M"*S#I;6NF[8&N%82F"61WBW''0,N"0 3CWP =FGB+19+!KY=5LS:H_EO-YRA
M5;T)SP?8TY->TB339-174K4V<;;7G\T;5;T)['D<>XKA_$%O?27DFMRZ0\*7
M%[IL,5E*\?F3-'*Q+-M8J"=X49/\/.*FU/0-8U.[GUF.SN;3_3[><6:2Q"=T
MCC="^23&'RX(!/1!R#T .[LK^TU*V%S8W,5Q"20'B8,,CJ..]<Y-XPN"88K+
M2UGN)M3GT]$DN?+7,2NQ<MM/4(>,=^M6?"FG7%F-2N;F&[A>\N!)B[FC>1@$
M5=S",;5)QT!/ &3FL-M(UFQN+2\CTJ6Z,&O7=X88I8@QBD2158;F _C'&<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M-3N8HI)EVMY:OA01@8X[8%7Y]0LX_%*V[ZA=+<QV3RFR6,F-DW+F3[O+ D#
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MK>3?$4#Q?:/+(+,,= 20#QT- 'H5%9-IXETJ\^W;+AXS8 &X6>%XBBD$AL.
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M_';%M3CU&#5;FT5AE]IYB!/!*KM ]2E=O4<L\,!032QQ^8P1-[ ;F/0#/4T
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MNS'NPPP?F^^<KQTZU1'@Z?39-!ET:[A633$FB?[5&6$HE(+M\I&&W#..G)%
M#!XZ5;&.:[BM[(OJ<VG&:64F&,QEAN9L#&XK@ XZ]:L7>L3+J'AQ+[2;-Y+R
MZEC282[_ ""J.0Z?+SN5>N1PU1:?X7U/3[.XM9+FPOK>XO;BXFMYX"%D25BV
MTGD9!P<XQU&.]1VG@N>PCT**VN81#IEY-=>6P8@"3>!&GHJA\ G.<=J (9_'
M&IPZ;J>HMI%L+73-0-I<_P"E$LRAE4L@V<GYL\X]*T-5\5W-O)J2Z9I[7K:<
MP22,)(6F?:'*(54@$*PZ]3Q@=:IW/@W4+CP[KVE_:[96U6^:[$FUB(@S*=N.
M_P!P<\=:LOX>UVSU^[U#1]4M((-1*/=V]Q THCD"A2\9!') '!XXH >OBYKG
M5Y-.M888[J-89!:W;F*:5) &+*"/X02"/52.*EM/$[7^MW.GVRVQDM;HP3V[
MRE9T0?\ +4+CE3QCV.<]JKZWX3GUM6MKF2WDB66*2UNW!^TVNT+NVL.I)4G.
M1][G/2G7GA:?4M6L[R\:T\VROOM,%Y$I6<1;B1"?48."<XQVSS0!K:SK*Z6]
MC;I&);N_N!! C-M&<%F8GG@*I/Y#O6!JGC6ZTB'7(;C3X7O]+MENU43%8YX6
MR-P.TD$$$%3^=;'B+07U@6%Q;7"V]_I]R+FWD9=RDX(9&']U@2..:R]8\(W6
MM6VLRS3V\=_J5FMB"H+)!$"3QT+$EB>W;TY -[2KG4[F.9]0LH+8;@8!',7+
M(0#\W P<\8&?J>IY6X\<ZQ%IFI:HF@P/9:7>2V]WB[)<JC ,T8V8..O.*[:V
M22.UB2;9YBJ Q3."1Z9KS_0M.NM<TKQ5I:3VZ65WK-W%+(,F1$+ , .A)'0Y
M&,]#0!T(\27&HR:B-#MH;I;!4+F60IYSL@?8N <?*5Y/<XQWK,L_%=YK?B/0
M'TWR1I=]I\MT4D8J^0R*=V 1E<D >N>>E:-OX<O-'U?4;K19[=+?4$3?#.K'
MR9$7:'7'4$ 94XY'45!:^#&TJ[T%]+NHTATVTDLY%FC+&1'*L6&",-E?IS0
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MAL/&=F"OS<-\@Y/'/3M0!J^)-<N-#33G@LTN1=WT5HP,NPIO. 1P<_F*RO\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 $ C!&144-M;V^[R((HMW78@7/Y5+10 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %1K;P+,TRPQB5NKA1N/XU)10 4444 %%%% !4<EO!+(LDD,;NGW69
M02OT-244 %%%% !1110 4444 %%%% !2,H92K %2,$$<$4M% "*JHH55"J!@
M #  I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MFNK3^U6=8+:382#(-K CHN0.<8P*]&_X1CQ9_P!#[=?^"VW_ ,*/^$8\6?\
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M)MF>@4?>XV\X%7=2OK2#Q#XZ::$WB#28 ]M%)M:4!9=R@CD<$9(Z9KT7 SG
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M=7?Q%JVBWCV<DT%M%<VTT43(H#EQM8%CG!7J",CTK>L!>+I\ U!H6O @\YH
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MK#)F/=N!D&!U'&1R._3(H ZJBN:35M3U+5-6T[3I;2.;2TC1Y)8699IF3?C
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M%9(HF0PS!=PZL=RG!'8C'OQ'X2U77]<A6^O&T]+,2W$#QQ1N'+)*55@2Q &
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M:Z;4O$TVD^);RUN%B;3[?1Y-2)5") 48 C.<$8SV% '3T5SUE<^(KIM/N/\
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M+'_"\JJP&",9W=?K]: -\ZC82ZD^DFXA>\\DRO;YRPCR!DCTY'6K:J%4*H
M& !VKB+N/4S\2H([:XM5O#H3AIY(6*#]^O(0-D_3=[^U/TWQC>:CI.ACR$74
M-1$_F&.,NJ"%MKE5+#J<8R> 3UQ0!VM5;S4K+3_+%W=10M(<(KL SGV'4_A5
M+P[=ZM=V4_\ ;-F+>XBN'C1E&!/&/NR!<G;D'D$]17/^"Y6U+Q3XMU&[^:ZA
MOS8Q;O\ EG!&!M ] 223ZF@#K;34;*_+BTNX9R@!<1N&*YSC..G0_E5JN?\
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MU(I,Q/ODC:,/Q\V PW#GH?08Y?XFNWD\3>&-%SB"]N)9YA_>6%-X4^VXJ?\
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M,,.CK(L4;)N,OF##ECD<GKQW)^E=)573Y[FYLUEN[,V<Q9@83('P Q .1QR
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M.PUF>TO])C:&"\2)3OB;&4=#PPX'XBMRUUP7/B:^T4VKQM:P1S^:S APY8#
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MRW7@UJ2Z3=P-?S6'B2"%;[3BL$*[S&)-P"SAB[$9W!21UR#U%=2NBZ:EQ=W
MLXS+>+LN68;O.7& &SU&..>U5;+PGH&G65S9V>DVL-O=<3QJG$@]#ZCVH Y6
M"ZO[JTUC34MGT;742V)@FN&>VD!D(!C<'($G*'&""?7-;G@^_6Z;4[>6QN=/
MOH)E^T6<TOF)$2@P8VZ%"!GC'.>*U3H.EO;3026B21S;/,\PEV;8<IEB<_*>
M1SQVJU:6-M8B06\6TR-ND8DLSG&,LQR3P .>PH YB)_[<\;>(-*U!YEAL[>W
M^RQI*T?RNK%I!@CYMWRY[;>,9-<T[W.L>#_"%SJLDLMS_;44'G>8RF5!(ZJY
MP1R0H.>O?O7HUYHVGZA<)<7-JCSHI1902K;3U7(P2I]#Q276BZ;>Q6T5Q9Q/
M':LK0)C"Q,OW2H'0CL>U !JDL.G:!>2O<O;0V]LY,XR[1J%/S#.<D=?>N-T1
MID\7V%F9)X[2[T-I&1KIF>4AXPLCX.%D(8\J3UZUWLD$4UN]O+&LD+H4='&X
M,I&"#GKQ67;^%=!M&@>WTJVB>!62)T3#(&ZX/7L* . T8W$7AOP3J_V^^DO;
MC4EMYGDN78/&QD!4J3M/0'.,Y'6M>YDN-#\0:KH8GN7_ +<02:9))*[F)SA)
M4!)X"9$F!VSZ5U2^&=&2UMK5;");>UD\V",9"Q/_ 'E&>#UY'J?6H;*TU2\U
MG[;J]O9PI:&1+-8)#(6#$#>Q(&T[1C _O'VH N7K2:7X?N6LU:66UM7:)78N
M795) )/))(KGO#D5I?6/AW7(]7N3/-!B4"7<+MV3+!U]5()&,;<$<"NQK*L/
M#.B:5>SWMAI=M;7,^?,DB0*3GKCTS[4 <!<O+#\-O$L\$\T,L>MW!5X960\W
M0!'!Y!!(P:W-0,VO>*]:T22_2U:"UB:U4[PP#*2TJ;77D-QGG&!TR<]&?#6C
M&QFL3I\1M9Y/-EA.=KOG.XC/)SS]:34_#&AZRUNVIZ9;W;6XQ$TR[BH],GDC
MV- '*P6<EYXPTRPN]7N[V"30G::2*=XDN&62-=^ WRY'.5//N#6/ AU'P[X*
M>]FGGD37);82/,VXHK3J 3G.<(HSUXKTIM'T]K];XVRBZ6+R5E4D,J?W1CH/
M:H/^$9T0Z>M@=-MS:++YRPLN55\YW =CDG\SZT 5O&&H76C^"M4OM.!-Q!:L
MT1^]MX^][X'/X5C7:G3]:\+3:3<SR0ZBS07*F9G$\1B+B0Y/WAC.X<\XKM3&
MAC\LHOEXV[<<8],50LM"TS3B#:6:0X4HFTG]VIZJG/RCIP,#@4 <UX"T\3V;
M:I<7E]/<PWEY GFW3LNP3, "I.#C'4\^_ Q<U&\2Y\?VNAWLC+9R:<\\4>\H
M)I=^"#C&2J\@>Y/88W]/TNRTJ)XK"W2"-W+LJ="QZGZFH=7T'2M>BCBU6P@N
MTB;='YJY*GV/44 <J(VT[Q#X.LX=6N[R+?>02S2S$F;;&Q ?'#%3P#UXJI9O
MJ=WIFNPZ==+--#XAD2*WN;A@LT:HK&$-R5&-QQTXP>":[6[T#2;^RM[.YT^!
M[>V(:"/9@1D# VXZ<<<5&/#.B(CHFF6\8>43L8TVGS ,!LCD$=O3M0!P5_+:
M:OIFCEK6]M)H/$L,$]K<3,6@<@%E5@>5P05(Z \8K=L@NO>(/$NFWD\\:V A
MBM D[*8HVCW"4$'EBV?F]@*Z270=*N+ V,]C#+;-)YK)(-VY\YW$GDMGOUHN
M=!TJ[F2::QB,B1>2&4;<Q_W#C&5_V3Q0!P.DW>H:W-X&DU*ZNUDOK*[^TK'.
M\:S!0NQB 1@D'.1@\U4NXY;;P5XCO([^_P#/T?598[%C=R'RD61"!U^8?,1\
MV>.*]-ETC3YKRVNWM4-Q:J5@<9!B!ZA<= >A]:KMX9T9K2YM&T^)K>YD\V>(
MY*RO_>89Y/N?0>E ',WHG\0^)/$6COJ2V<MK'$+7.\/&K1AO.3:Z\AR1GG[H
M%0+IS:MXQM]/N]7OKB"30(Y7DM[B2%99!(!Y@4-\N< X''UKJ]1\+:%J\UO+
MJ.EVUU);@+$\R;B!Z$GJ/8U:_LFP_M0:G]F3[:(_*$W.X)_=^G?'2@#'\=ZG
M<:1X4GN;9VB/FPQ23*>8HVD578'L0">>W6JD\,FF^.]*LK%YC8:C9W'VN RL
MRKY>S;(,G*DE]I(ZY'>NLG@BN8)()XDEAD4J\;J"K ]00>HJK9:/I^G*PM;<
M1Y01[MQ+!!T4$G( [ <"@#F_AW:0P:7J,D>_<=4O$^:1F&!,V."<9]^M))9P
M-\7EE;>'_L;?GS&'(F '&>GMTKI]/TFQTI'CL+9;=)&+LJ9P6/4X]3ZTESI&
MGWE[!>W%G%)=0*5BF9?F0'K@T >9:?$UIX4TG58+FY2Y7Q"81MG8)Y;W;JRE
M =I!!/49]^E:\@N?$DOB)#K::;=Z?>E4D(??:QJ%*L ' VL,DY'.3G.!CK1X
M9T46:6@T^(6R2^<L0SM$F<[@,]<\Y]:+OPQH=_JD.IW>E6LU[#C9.\8+#'3/
MKCMGI0!7\66UY?>!M6M[,L]W+8R*@52"Y*G@#L3TQ[T>"KJVO/!.BR6C*8EL
MXH\#^%E4*RGW!!%;U91\-:,;J6Y&GQ)),VZ79E5D/JR@X8_4&@#&N[Y+[QUI
MVD.Y&F2V$UR@1BJW$PD4$''W@%+-CH<Y]*YJ[GU"/3+NT-]>"&Q\2V]K:SB=
MMQB9XR48Y^<+N(^;/3VKT>]TJQU!(5NK9'\AMT+#*M&<8RK#!7CCBHIM"TNX
MLXK26RB:WB?S4CQ@!\YW?[V><]<\T <E'I$4GC'7M(:ZU#[!]A@N1#]MEXE8
MR*6#;MW\(XSC/..E9FFS76LQ> !=ZA??Z=97 N?+N73SML8QG!Z]?F'/)YKT
M+^Q=.^US7?V8?:)H_*EEW'<Z?W2<]*Y[4/"JG7O#OV'3T32]-\_>J2["AD4!
M=@SD8(SP1[9H PK:633FU/1)=0OY;.'6X+>Q'FEGFWH)#;F1CG8.<G.<9'/0
MU=0N;R/P?XRB^US0/9:HBP""Y<^2I\G**W!*_,W!&.>E>BS^'])NM.%A/I\$
MEJ)/-$;+GY\YWYZ[LD\]>34+>%- >.XC.DV@CN2IF58P!)MQMR!UQ@?E0!A1
M6*P_$"\TE;J]-I>:/Y\JM=2,?,$NW>I)RIP?X<=!5;PY/<W;VWAB\FN&O=&N
M7:]F,K;IHU&8F)SD[]ZG!Z['%=5=:5%#)+J5C9PR:LEN8H7FD8;ACA"W)VY_
MQZTW1;*[B-Q?ZE' FH794RI 2RQJHPJ!B 6Q\QSCJQ[4 :<<L<N[RY%?:Q5M
MIS@CJ#[UR\GF'XHBW,]QY$NB.[1"9@H;SD&X#/RG'<8K7T?0[71Y;^2VBCB-
MY.9W2,84,>_N3U)_PJ>32+&34?[1:W'VSRS#YP)#!#_#G/3OCUYH \UTOSXO
M"_A/5_M]\][)K"VSO)=.P>)II%92I.#D=R,\=:[CQKJ4^D>$KV]MW,;(8U:0
M DQHTBJ[<>BDG\*LKX9T9;."T73XEM[>7SH8AD+&^<[E&>#GG/N?6M.6&.>%
MX9HUDB=2KHXR&!Z@@]10!PM] NBP:GJ;>)3!8W&F,?*M$9RK @"="SM\WS <
M8!R#GC-4I]1U'0]6UT6B-$8O#PO(K8SF;$JLX#G/&[ &0,YQU-=E9>%- TVR
MNK.STBTBM[L8GC6,8D'H?4<GBI+/PWHMA<17%KIEK%-%$8DD6,;@A[9H R]%
MM;&1]&U:TU:Y;[3:E3&9BZW9*AM[ Y^9<'GC&<>U<;X>A:P\+>!-1M[FY6>>
M_6UD'GML:)A+E=F=O8'.,Y%>B:?X7T/27N'T_2[:U>X!$K0IM)![ CH/84J^
M&M&2VMK9+")8+63S;>,9"Q/_ 'E&>#UY'J?6@"CXXU2;2/#$EU%*T*&>".:9
M>#%$TBJ[ ]CM)Y[9S5#6X=/T73]7NX]<O;6&XLT/EP2>9Y1W;1)'GHS%@,Y&
M>O;(ZZXMX;NWDM[B))89%*O'(H96!Z@@]:S+7PKH-EIEQIMMI-K'9W'^NA$8
M(D^OK[>E '*1-?QZ]XETR&Z73=^E0R0@W#2);RMYB[\GH>%SCTSSUJG<Z_=Z
M3I6MI<65QI.JP0VIF59C-!Y)E*-/$<Y'#-GH?E'<$UVR>%= CW;=(M 6@-NQ
M\L9,9SE3ZCD_G5J'1]/@CF1;5&6=!'+YN9"Z#.%);.5Y/'3D^M &/HVFR6?B
M!KJ/68I;6[M,K91!F1B&'[X,SMCA@#CKP:@\72'2-3T?7WGE2QAG^S7R>:PC
M\N0;5D89Q\K[><=&-;6D>'M(T!)4TG3K>T$IS)Y2X+>F3^)XJ[<VL%[;M;W,
M22POC<CC(.#D?J* //M ENI;Z\\,W;7:327::A&SSN9%LV^<+N)SPR^41G^*
MJ>K6@>/XB7JW%U%/9R+- T,[1['6V0AOE(ST'7/\Z].^RP"[-WY2?:#'Y1DQ
M\VW.<9],G-46\.Z2ZWBM8QE;TYN@2<3?[W//''- '*R7$_B#Q#<:/<7J6Y_L
MR":W1MX+%]V^1=KKR"%'?&.,9.8+:P4>-O#7VO4&U"9-*N ]X&:/SBCQ@-@-
M]>^#UYKK-0\*Z#JL-M%?Z7;7*6HQ")5W%!Z ]<>W2K5QHVFW<MI+/8P226?_
M ![L4'[KI]WTZ#\AZ4 >9RPM:^&->UB"YN8[RT\22&$I.RJ,W2*P*@X;(8@Y
M!K<NEN/$FL>)=.;5DL+BRD1;<_.'@C\I6$JX=1]XMDD=L'BNH/AG16LYK0Z?
M$;::7SI8CG:\F<[B,\G/.?4"DO\ POH6JW<%W?Z7;7-Q  (Y94W, .@)/4?7
M- '+QZ>=6\<26=WJ=]+!_8UM<DPW$D*O+YCC>%!^7.T?*./6M7XC22P^"KN>
M"YGMY8Y8-LD,A0C,J*>G48)X/%;RZ38IJC:FMLHO63RS/D[BO]WZ>U97C?2K
MO7/"MSIEE"DLL[Q'$C!5PLBN<_@I'XT 85S83:/XT^R65]?O::AIEQ+=1R74
MCF.1"NV16)RI.['&!Q65;/-IO@/P[JWVZ_:;5&L;:^N)+IR$B9OF8<X4_P .
MX8/.>O->AP:18QPR@6NTSQA)=[EF*CHA;).!D\ XY-+'HNFQ:2=*6RA_L\J4
M-L5RFWTP>U '-O:20^.I-&MY;@:7?:6\LT2S,/)D5PH=#G*D@GIU*Y]:K^$Y
M[B_BM=$O)9FO=#GD2^D\ULR%<B(DYR0X8/S_ '#7866F6>G;OLL 1G #.268
M@= 6.3@9.!VS4L5K!#///%"B2SD-*X'+D# S] ,4 >;3:O=Z7HWB'%Y<+&?$
MBV;W#S,S6\#^4&(8G(P"0/3-6M53^PO&VI76F(QFC\,3311ERX+K(", D]2!
MGUKLTT#24@O(!80F&]8M<HPW+,3U+ ]3[U'8^&=$TVXCN+33+>.>./RDEVY9
M5] 3S0!R]DDT=OIOB.QUM)T:SE)MD5V^W-Y98!LN<,I4G(&>HK,D6&_\-^!]
M::YDGO+K5+22>8RDAW8,6!&<8#9 ';&!7>:;X9T/1KR:[TW2[6UN)OOR11@$
MCJ1[#V%0CP?X=64R#1K//G>?@QY4/_> Z#\* *?Q$DEA\ :Q/!/-!-% 722&
M1D8'([@BLR73Y=*\=Z,EI?7TL&JV]P+^.6Z=P=B@K(O/R'<P'RX'(QBMSQGI
MEWK/A#4=,L8U:XNHO+3<P51SU)]*NV.D6=O%O6T\F5XA$V7+,J_W <\+[# H
M \]TZS=OA%=:\^HZFVHG2KC]Z;V3@JS,#C.,@CKU/.<YK=MKI]1\66&C7K2&
MS&B)=1IO*B:0L%8D@\E1CCMN)]*Z2/0-*BTEM*CL8ET]\AK89V$'J,>A]*=-
MH>FW$5K'):*1:?\ 'NP)#1<8PK Y QQP: /.WGU&33K.UFO[T);>*O[/AG6X
M8/+;@GACGYB#E<G)^7UKTBPTR#3M-6PA>=X5W &69G?#$G[Q.>_'/%13Z#I=
MQ;VUO+8Q&&U<20(!@1N.C #H??KR:T1P,4 >3Z/<?V1X&T5+=Y(8K[7&M+J1
M96&R+[1+TY^7) 4D8Z^M=79M+I7Q"N=/AE<:5)I@NY(Y')6"42;<J3]T,N>.
MF5)]:VE\.Z,EM>6ZZ9:B&\8O<1^6,2DG.2/KS]>:5M#L!I]W:):1,EU&8Y1*
M2WF#&,,2<D 'UH T5970.C!E89!!R"*\P:_O+SX:77B=+F>/7K>XD?B1OD=9
MBHA*9QMVX7;CG.>O->B:3IT6D:5;:?!_JH$"+Q@?@.P]NU1?V#I8O7NQ91"9
MY!*Y ^5G'1RO0L./FQF@#C+FT;4/$'C"&YNKY8X;"VFCB2[D412%)22,'C!'
M3I[=*ZWPK=37WA#1KNYD,D\UC#)(YZLQ0$D_C4[:'IKW%W<-:+YUV@2X?)S*
MHZ!N>1[59L[.WT^TCM+2)8K>(;4C7HH]!Z"@#S5K^\O/AE-XHCN)X]>AN'DX
MD;Y76<KY!3.-NW"[<=\]>:V++3O[4\?:]%=7=^L=LMC<10I=R!4<AR> >G'3
MISTZ5U T'2UO7NQ91"9Y!*Y ^5I!T<KT+?[6,U+#I5C;ZC/J$5NJ7<X EF!.
MYP.@/KCMZ4 9GBN>*.VT^![B='N+Z*..&%MIN#R?+9NRD DGT&.<X/(DR7'@
M?Q[:W4C%;.:Z$,:SLPB @5MH/!*@L>#QSTKT'4M*L-8MA;ZA:Q7,*N)%61<[
M6'0CT-5AX9T18KJ)-+MDCNP!<*B;1* , ''48[=* ..N=+M!JW@$$2X=9MQ,
M[Y_X]2>#GCD=J%^U>(X=:G&NIIU[I^HR*)-KE[9(W^0;0X!5D'/&#N/6NUFT
M#2KBUMK:>PAE@M6#0)(NX1D# QGIQQBHI_#&AW6L1ZO/I5K)J$>"MPT8W9'0
M^Y'8]J .=TW3AJ'CSQ"MQ>WYCLI[.:");N0(K&/<1C/*DY^4\<GBK'Q"MHKB
MTT(RACC6K11ARN 9 #T/7W[5TEOI5C:7]Q?06ZI=7./.E!.9,=,^N.WI3M0T
MZSU6T:UO[:.X@8AC'(N1D'(/U!H XJYTNWO_ !QKMN\MPL*:-;;1%<.A)#2X
M)8')Q[GZYJII>L7>IV_A"POKU%2_TEI2T^XBYG78,$AE).TL<9YSG&0*[E=!
MTM+B6=+.-)98A"[(2I:,=%X/0=A4-QX6T*[TF+2[C2[>6QA.8H67*QG_ &?3
M\* &^&+.;3M*:RGU4ZDT,SJLQ4@JN<A"226VYQG/MVK9J&TL[:PM(K2T@C@M
MXEVI'&NU5'L*FH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ KG/'6JWNA>#[_5=/E5+BU574.@96RP
M&"/H:Z.N2^)D<MQ\/M5MK>":>>9%6.*&-G9CO4] #0!JI'J<5U9YU5)0YW20
MO JETQSM(Z$$J:PI?$%QJVM:O8V&K"P.G-#Y;&W$BRY7>^\$9Q@X&"#QGFK=
MLV@VM_9W&FZ0Z7SC[.##8/" K%2Q=M@  VYY],=34>@2^7XR\6S213I%++;M
M'(\+A9 L*JQ4D<X((XH B\/Z_<:W:P:ZVKI;V:RS+<V3PC;LWLD6UL!MWRKW
M.22,#BNDM];TRYMKBXCO8O*MF*SESL,1'9@<%3]:\[M(KZ+X<Z)*EA?R-IVI
M-<7=HB/%.8C)+RHX)(WJP ]*M:G!#=:7-KOA_2-1D*WMG=70G$HEO$A;)54D
M.3M&,'OC SB@#J]2\7Z3IVC:CJ)G,@L%S+"%(D#$94%2,C/8D8[]*D?5;:XU
M32EAUB.$S"5OL6P%[D!3Z_,H4@G(Z]*YSQ#)!XC\&>([G1])N/.N++89I+5H
MI9V7.$"L S;1GGIS@9YQ9O[C[=XL\'7<-M=^0HN2[O;.NP-%M7=D?+D\#.*
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M=A\V/7IS0!ZF^K6VEVUK%K%_:Q7;0AI#NVAB -S 'D+GN>F17.^,/%-U!:Z
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MUF^-E=G\.[(9I?+UF"5_+B9]B -EC@' &1R?6L.^A=Q\2,6EP6NX EOBW?\
M?'[-LPO'S?-QQ0!W=[JUCIRJUU<*FY2X !8[1U; R=HR,GH,UBZCK-POBGPS
M'97D;Z;J(G,@10PD"Q%E(;TZ=*P+._DT+7;>\U*QO9M.O]'MK=)8[5Y3%)'N
MW1L@!8;MV>G:KUW"(?$O@O[/ILEI;0?:<Q1PG;;JT15 VT84GICUH Z0^(=)
M%D]X;^(6R3>0\I/"29QM/H<G'/>F:YK%MIUE<J;Q(+E8&E4[-^P<X9AV7/<X
M%>?:F9XO"_BG2/L%\]Z^M-<JD=J[!HFN$=6# 8.1V!S[5LK=RZ=XD\41ZA:W
MC)J<4<EC,EL[K(@BVF/@':0<\''4F@#<\/Z^LG@[1M1U6Y!N;JT25R$RSL5!
M8A5'X\#BM(:WIK6EO=1W<<L-PI:%H<R;U'4@+DX'<]N]><Z9)/H]IX6OM1L-
M5_LY='%E,;>.99+:8%3ED7#;6QC.#T%:ESI5G#;:6=(.H>'YD6XEM)S&\J ,
MR%DF5LXWG#!20>.QXH [VVN(;RUBN;>19()4#QNIR&4C((_"J<&O:5<W2V\-
M[$TCAS'U D"\-M)X;'?!.*B\/SWTOA>QFOK);>\^S@O;(-H! X !^[GC@],X
MK@M+FFEU/P==G3K^W6WDN(Y[5+%XXK,M$P"#Y<D9ZL21WR.E '=+XM\/O+#&
MFKVC--+Y,>V0$,^<8STZ\#U-7+?5["ZO;JS@N4DN;3'GQ*"6CSTR.V>WK7F\
MT$I\":U$EC=>?+X@:=$%J^]D^U*X<#&2-H)SZ"NA\2VM_9^(;'5-&&'U5/[-
MN<'!7(+1S8[E,/\ @: .MM+RWO[5+FUE$L#C*NO1OI56#7M*N;I;:&]B:1PY
MCZ@2!>&VGHV.^"<5:A@CL;%+>VB_=P1A(XP<<*, ?I7F>E332ZGX.NSIU];I
M;RW$<]JEB\<5F6B8!!\N2,]6)([Y'2@#NE\6^'WEAC35[1FFE\F/;("&?.,9
MZ=>/<TGB+6X-,TR]"WJ07D=LTJG9O\O@X9AT )&,G KA)X)3X$UR)+*Z\^7Q
M T\:"U?>R?:U<.!C)&P$Y]!6FUU+I^I^+[6_M;MVU)/.LIDMWD2:/R0H3*@X
M*D'@XZYH Z[PS>3ZAX5TB]NGWW%Q90RRO@#<S("3@<#DT^WUW2[N[2U@O8WE
MD#&,#.)-IPVP]&QWP3BJ?A'S(_ VC(T$J316$2-%*AC8,J $$,!W%<3I4TTV
MI^#KHZ=?VZV\MQ'-:I8O'%9LT3 (/EY&>K$D=\CI0!IW'B#6HO"'C&\6^7[7
MI=[/';R>2N%1$0@8Z'[QY.:[E)PEBMQ,V (P[MCVR>!7G%U%/)X,\?0+:71F
MN;^X:!/L[[I0R(%*C'()!Y'I7H]DXDL+=AD QKPP(/3N#R* ,O1_%.FZQHBZ
MK')Y=NS%1O!!/S%5XQR3@<#GG%6X=<TRXLI;R*]B,$3^7(Q."CYQM8'D-DC@
M\\BO.+);ZS\%^&Y'TW4G71[Q_M]M%')'*%82KN3&"VW<#\O8_6KVHQ0K;6WB
M'0]'U%[:/5(;J]$BRF:Y14="XCD^8[=RD=,X]@: -SQ5XD,7A.]U#1+]%N+2
M>*.4&/+(6D52K*PRIPV>16S!XCT:Y^U^5J=LPLP&N#Y@ C!Z$D]N#STKD?%4
MMKK'@S5[G3-(N ;R6VR_V-UEN2LBY)0KN(51U(]?2K.HDGQQJ$Z07!@?P_Y0
MD6!RK/YC$*#CEL'IUYH Z2T\2Z+?W<%I:ZE;RSSQ>;$BMRZXSD?@0<=<4S3=
M2MGCU.Y;6X+RVAN6#. JK:@*N8RPZXZY/KCM7&Z=#)#8?#E/LERCV@Q<#[.X
M,)-NRG?Q\OS$#FH;BWU!M-\236=C<S-#XBCO_L_E,IN84\HD)D#=DH>G7% '
M?QZ]I4L5U(+V)%M #<>9E#$",@L&P0".A[U#/K$%WINI?V==J+JUB)8,A#1'
M:2I9&P><<9ZUSNKZK:ZEX>U35=-\.RW3M%$DK7-BRM+AQQL(#.$!+>G& >N*
MMC)(/$?B:<QZE-%=Z7 8KB:T=?,*B4' VC'+ !< GT/6@#K/"M]<:GX2TB^N
MW\RXN+.*65\ ;F902<#@<U,FNZ7)>I:)>1F9W:-!SAW7[RJW0L,'(!R,&J7@
ME7C\#Z)#+')%+%911R1R(596"@$$'GK7$">XN#H$QTN_MFM=<=I[*&R<16X/
MFC.=OSEBP)8$CYOX: .[?Q=X>C)#:Q:<3_9R1("!)QP3V^\.>G-6M2U2TL4:
M*6\6"9HV=3M+E%'5R!T4>IXKSS4K>67PAX_A2RN6GN]0D:!!;/NF!2,*5X^8
M95N1Z5N6M\^F>.M7FU"VNWM-3MK8V,Z6SR+A%8-&< E3N8M@XZF@#8\$ZG=:
MSX,TO4;Z027-Q#OD<*%!.3V'%;]<M\.4EB^'^CPS0302Q0['CFC9&!R>Q X]
MZZF@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBL?Q'KQ\/V=O<_8I+H37,5OA'"[2[!0>>O)_P#U
M4 ;%%<POC&.V?6DU>R:Q;2H4N'Q*)?,B?=M(P!\V5(QZXY-6#XCFM=6L+#4M
M/^SMJ",;5DF$@+J-QC;@;6QTZ@X/- &_17&V_CN6:SLK]]%EBL;B_-C)*;A2
MT;^:8P=H'S#(&>1C/>NN>3"L(RC2@':I;&3Z'KC\J )**XO0?%]R_A:VU+5H
M[9)KR[EM[<+/A6;S)!@DJ-H54Z\DA>F>*M6_C:!UO8YK0K=6]S%;1I#)YD=P
MTOW-DF ".N>/EP: .I)"J68@ <DGM2UP7CF\N+_P1XHL]0TIK=K2W5XYLF2*
M7(R"C%1R,$$8XX]:V[7Q'<'6VTBXTJ2&4V1N[8B96,JJP4@CHK98=R.>M '1
M4@922 02.HSTKD-.\<R7T&AWDFCR06.K2^1',9U9DD(8J"H'0[3SD<]L<U)!
MX@TVPN_$]R^FM:RV<\*7#J0SW+LB^7CMD[E4<]^<4 =916#)KU]:27R7FAW/
M^C6GVJ-K0F99NH,8.U?WG'W?0YS3;'7EU+6KK0;ZRB2=+1+AE2;S4*,2I5LJ
M,,".F.A% &^&##*D$>HI:Y3X:C'PZT4?],3_ .AM75T 5;:S@M+B<P$H)F\U
MX@1M#'JP';/?L3D]22;5<PVJVT'BO6$32#]NM=/CF:<.NZ>/<^U1Z $-UJ+3
M?&DM]+H+3:1);VFLQY@F,ZL5?RR^TJ!T(!P<]N@H ZIG12H9E!8X )ZTZO.F
M>&_USQ;)XDL[9]/TYH&+^>Q:W5(1(/+PH/))/!')QS71_P#"3R6]YI<6H:>;
M:'5/EMI%F#D2;=PCD&!M8C.,%AD$9H Z*L/6_#,.ORE;V^O/L,D:QS6*.!%+
MM??D\9R2 #@].*RX/&E[<VE]>1>'9S:6+W,<\GVF,%6ASP >N<'D=/>GQ>,[
MJ2?1U;0Y FKVYDM&%PI)<('*L,#:,9.[)Z=,\4 =8B+&BHBA548  P *6N:L
M_%<]UI]T_P#9$WVZVOQI\EM&_F*KDKARX'W,."6QP,\5EZUXUNU\*>([FPMX
M$O\ 2G\ASY^^,952'5@OS$;AP0.0: .X+*&"D@$]!GK2US=W?1KXKT"UO])C
M-],EP8+E)=ZP84;@"0"<C;V%17'C2.#2&UP61DT1)S$]RLOSA0^PR!,<IN_V
MLXYQ0!U-%<K>>+KJ+4-9L[/17N7TR&.=F-PJ+(C!CQP><+P._?%=!IE_%JNE
M6>HP!A#=0).@;J%90PS^= %JD#*20""1P0#TI:XQ_$MKI4/BS48=$99M.F4W
M0610UP?+4AB>@^4CUH [.BN<M_%+?VT+#4-/:RCDLVO89FF#[D0@,& ^Z1N!
MZGC\JDL_$%S>S::PTB;^S]21GBN%;<8UV[E,JXP@8=.3SP: ':UX:M_$$S+>
M7]VUBR+'-8HX$4FU]_/&02< X(R!BMQ55%"J J@8  P *\]T#5D\-Z#JDZ6@
MD@_X2*>WV(VW8'G"*0,= 2...*Z6X\4V]CJNJ6E]%Y,.GV2WKSA]P:,EATQP
M?D/'/:@#=+ $ D G@>] 96S@@X.#@]#7!ZA/<W?CSP9=7.FI;>9]J9&$N]P#
M QVN,#!YZ D=>?6:/Q3::3H6N:I;:$\7V;56@N8DD4&20E%,A/N6'3/2@#MZ
M*YZW\3LNKW^GZE8/9-;6@OE;S1)OAR02<=&!7IS]:KP>,));C04.EMY>MQF2
MU99P2JA0_P X(&#L.>">A'U .IHHK(\3:X/#FA3ZHUK)<I"5#(C 'YF"YY]R
M.F: ->BN8A\6S)KLFE:EHUQ9RM;/=6A$BRFX1/O* O1QD?+S]:=8^*9KK5H=
M+ET]8+NXL#>PQM<9*X*C9*-N4;YAV/?TH Z6JU[91:A;FWN-Q@;_ %D8Z2#^
MZWMZCOT/&17*:#XON9?"MAJ.JI;)<7]P\5N!/A2=TAPQ*C:JJAYY) ]3BG3>
M/1;Z;?W+Z6\DMC=16\BPS!HW$C *Z.0-P^;IC(((- '9=!@45R\GBF]2?6+)
M]*6"^LK,7L*27 9)8SN')4':05.1S]:T/"M[>ZEX6TN]OUC$\]K%*61]V_<B
MG<>!@DD\<X]: -BBBJ>JZG;Z-I<^H76[RH5R0HRS$G 4>Y) 'UH N45@2^(Y
MM.DO3K&FO:6UM9_:S=1N98BH)!0G:,/_ +/.<]:;_P )-+;7^FV^HZ<;=-2!
M%LZ3!_W@7=Y;C VL1G&"1D$9H Z&BN'?XARQZ7_:\N@7":7%=-;W5QYZ$PXD
M,>[:.6&<9QTSWK;M_$1?7=4TNYMDMFLH%N4E>;(FB;/SCC@#:0?0^M &[2!E
M+%01N')&>E<I-XOOTN-.M(O#\LMY?V3W<47VE5 V[?D)(X.&')'7CFGVFM64
M6NZ_+<Z4;*YLK*">[GW!VD3:Y X_N[6^N: .II P;."#@X.*YB+Q9++>Z+:R
MZ40FLPF:W99PVU0H9@X(&"%8' )[_CSWAS7'\.:1=$:87TT:[<6\DRRJOE;[
M@HNU/X@"1GI[9H ])HKF]+UC4[OQKK>FRP6ZV5DEOL*RDL-X=MV-O)/ (SQC
MO724 %%%<;#XHU2&Y\5SW5C%);:0WRQPS_,5$0D[J <@Y//'3!ZT =E17,VW
MB;4KFUM[C_A'ITCNVA%L_G!E(="S,^T$QJN.I'.1^"6WC2VGTJ6Z-O\ Z0FH
M'34@CE#B6?( VO@94@YR0, 'CB@#IMPW;<C.,XI:X"&_72OB#X@U'4K:.T2#
M1X993"_F!P'D^8'"DGMR.U;MAXI%UKT6ERVT:F> S136]P)D&.J.0!M;G/<'
MGF@#HJ**RM:UR'1GL8Y/*$E[/Y$332^7&&VEN6P<9VX QR2* -6BL"X\2&U2
MTAN;>&WO[DR[89[@(@6-L%B^.ARN,#)W#CJ17L/&4>HVULL5DZZA<7,MJMN[
MX7=&,NV_'*8P0P'.X<4 =/17+7?B^YL+**:ZT*Z25]373C'O&"68 2(Q WJ<
M\<#N#BGOXIGA*VES86]KJ?E-,UM<7RJ@3<54[P#DM@D#'&#G'< Z:BN)3Q??
MZGJ/AC^S[)8[74UG>2.YD*2!HU(*$;3@ G.>^!T'7MJ "BBL36M>GTN65(K
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ME::K!<17-F+?<\,<D9)&XD MNR0>.!CKSGJ;JX2TM)KF179(4:1A&I9B ,\
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M&I:W93,H8^6FV2-$7.,D +DG'<\5Z-5:\T^RU!%2]L[>Y1&W*LT8< ^HR.M
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M2=0'CEM;06QM?[.^R!3*P<MOWYQMQCMU]_:N@JJU]$FIQV!2;S9(FE#")B@
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MAV*6N4-Q*,)N!& ?O'J.!WR.OB\,V\<EHTEW=SBS=I+5960B%F!7(.W)P&(
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M+01+M$8B!R%QC/7GK^E57\(Z>SWZI-<Q6FH2&2[LT9?*F8_>)R-PW8YVD9H
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M3RT>E1:6LLAD%LB*K+GN^WC<>IQGL,\5IU"]W;17,5M)<1)/+GRXF<!GP,G
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M(@H(]VT[L\_>/:@#F_!VILCZGI.F"W>[&L7<LR.<+##YK ,0.Y(P!WYZ=:]
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MS+L*@JX( S\X/'TYZUGQ>-+ZXL-"U&WL;:2VUFZ-M%$\K(\)^8J6(#9X0Y
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MEBTBW>HVENT2>9()9E4HN<9.3P,D#/O0!6G\,Z3=6-W9W%N\L5V0;C?.Y:7
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M0Z"IWRKCYO,)[]]O/T/I7>44 >1:!?#3--\$7MX672+8W<4[D$K;S,2(R_\
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MMK>B1945MJ29W)&78HIST(4J,=NE=)110 4444 %%%% !1110 4444 %%%%
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M_JJZM8^&[^!+RU)UV"&2&7,; AV#*R@X897KR/2MN7Q7:Q)KK-97F[15#7*
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MOA2&R@N(UN/,M;PW(4/&9Q+AEQD,.?;W]0#JM8\766C_ &TM%)<+8J&NO*=
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MHKIN'W&.WKZ'K4$_A'5[C3O&-G'965I'JT<;6JQS9"L(U7:0%&.5.3ZGOUH
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MA@I(PQ(()'# 'GI7/:[X8U'5K/Q->16P2\U6UBM(+=Y%^14S\SD$C)+'@$\
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M&!3G+N>@&*N5Y3#-J%WX!\%W=Q<I/<SZM;2!G7'S$N3N(////:NDBUW6X?\
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MW_*<,>>>?3'(!Z)5;3]0M=4M%NK*82P,S*' (Y5BIZ^X-3MN:,[" Q'READ
M^XKA;?QAJ"^#M/UB^3:DEY-#>W%K;EQ;QJ\BAPG)QE5!/.,F@#O**SM"O3J.
MCPW9O+:\$A<K/;#".NX[3C)P<8R/7-:- !1110 4444 %%%% !1110 4444
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MNMRZQI=])87EPJI<A4#Q7 7[I93_ !#H""#BMZH;N[@L;26ZN9%B@A0N[MT
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MUTU5?.N_[4$'V0?8_)W_ &GS1GS-V-FS&>G.?PH ?:0R6]K'%+<R7,BCYII
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M/[6T2PU'RO*^UV\<_E[L[=RAL9[XS5V@#!M?#(2]TVZO+U[N335=;9WC"O\
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MX<$>M7>IPW;(UQ:):>5Y8*HBY*X[Y^8UN44 9N@Z0F@Z'::5',\T5K&(T=P
MQ4=,XXK)NO!D=W:Z_;OJ$P36G#3D(N4^4+A?P4=<UHZ#K;:TVJ*]J;=K"^>S
M(,F_?M5&W=./O]/:M>@#$_X1]CKMGJQO7,UK:M:JGEC:RL023WSE1TJFG@JT
M;0M1TB[NIKBWOKE[IGP$>.5GW[E(Z8;D<?G73T4 8L6@R&[2^O+YKJ^AMVMX
M)3$JB,-C<VT=6.U<GIQP!SFB?!D1\#KX5^WS_9554$VQ?,V!MP'3'4=<=/SK
MJ** ,8Z$[>)(];-ZWVA+-K3R_+&PJ6#$^N<J.]9=OX&6TBTT6^KW<4VGW$\T
M4P1"2)B3(I!!!ZG!QQ6_K.JP:)I%SJ5R&,4"[BJ]6). ![DD#\:IVNHZW)K)
ML[K0DBM!DF]2\#H1C(PI4,3G(/ QP>: ,X>!H4TN2R75+S/]HC4892$)BEW[
M^/EP1DGKFKY\-QR:\^ISW4D_F6/V"2&1%VO'DDDX[DD^WM4OB76V\/:0=0%J
M;E1+'&RB39C>ZH#T/=A6O0!SECX1BM;6PL9;Z:YT_3I5EM8)%&5*YV!F_B"Y
MXZ=!G.*AG\%QW&DZYISZC-Y6L7#7$[!%W(2%!"^V%7KFNIJ&:[@@GMX99%62
MX<I$IZL0I8X_!2: '(DBP!#(&D"XW[>I]<5@Z;X7ETC3;2TL]5F'V::64,\:
ML)/,+,RN!C(RQ(Q@\#FMBWFNY+R[CGM!%!&RB"82AO.!7).W'RX/'/7K4EY.
MUM9S3I%YK1H6";L;L#IGM0!4T71K?0[!K6WY#S23N<  N[%FP!P!D\#L*T:S
MM U4:YH%AJHA\D7<"S>7NW;<C.,X&:T: "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y3XC%T\%74T
M<LL4D<T!5HY&3K,@(.#R,$\&NKJM?:=9:G;?9[^UAN8"0QCF0,N1T.#0!RT<
ML6L^./$.F:F28[*V@^R1%BN%=27E7_:W8&[J-HQC-<QX:O<Z-X+TJYN+>&RN
MM-F91<(6CFF5E 4@,N2%+$ GKVSC'I%WH.DW\\$]WIMK/-;KMB>2(,5'H#Z>
MU1R>&="FTI-+DTBR:P0[EMS"NQ3Z@8Z^] '%7.G-9'PS8C6[F]C_ +8DA,D<
MKQ@1F*1O+SN.[:1C=G(QC((K.UVVBB\*^.=.R[6EE?0-;I)(S>5N6)C@DYQE
MB<>]>EG0]):.TC.FVNRS_P"/9?*7$/\ N_W?PH_L+2=MVO\ 9MKB\&+D>4/W
MW^__ 'OQH Y^_C2T^('AB&UDD6![>]#1"5BA*A,?+G&06;GK6?HFG6J3^.#$
MK1M'=LB/'(RLH^SQG@@Y'-=BFAZ5'-:S)IUJLEHNRW=8@#$OHOH/I21Z'I4/
MVGRM.MD^U9^T;8@/-SUW>OXT <%IVHR2V/@K3KV[ACM;W2"^Z[4ND\X6/"M\
MRY.TL1D]>V<8G0MIFI>'?#]QJ[7^FW-Y=!Y3E5)5 T=N6+'<H+'@GG:%/0BN
MSN/#NBW6EIID^EVDEC&<I;M$-B'V';\*?/H6DW.F1Z9-IMJ]C'CR[<Q#8F.F
M!V_"@#GO!UO!:>)O%]O;C$:WT)"YSMS AP/0=0!VZ5=\32P/JNB6+EY9IY96
MCM"X6&8+&<^:<'A<@@ ')QQQD:]CH^F:9)+)8V%M;22X\QXH@I; P,D=>E+J
M&DZ=JJQ+J%C;W0B??&)HP^UO49H \^TEM3OO"=M'8SVMY<6NK706RN93LNHE
M:0",-ST'*YR/E'I77^#[V"]T -#;7%J8YYHY;>X;<T,@D;<F>X!.![8JW_PC
MNC!2JZ9:KF8W&4B"GS3U?(YW<GGKS5ZWMH+2!8+>)(HESA$&!R<G\SS0!R5U
M/;:GXYU/1-6EV0KIT4EG&7VAMQ<22#_:&$ /;!QU-5[22.Y\6Z?H5S=2WVF)
MHWFV\EPV?M4@DVL['@.0H4C_ 'B>^:ZK4]!TG6C"=3TVUO#"<QF>(/M^F:DO
M-*L+]81=6D,OD',19>8SC'RGJ...* /-F:]?3[.UFO+OR+;Q8+*VE$[AGMP3
M\I.?FP<KD\_+6O9VD,.H>-])!D:QBBAFCA>5F",T3%B"3GDJ#783:+I=Q!;P
M2Z?:O%;,'@1H@5B8="H['W%(=$TLRW4AT^V,EVNVX;RQF8>C'^(?6@#S^.!+
M3X=>"9K=I(7DNM-,GERL ^XH"&&<$>QJY<RQ:Y_PG,>I$F>P#16\1<@PQ>2&
M5U]"S%CN[X Z"NR/A_1VM(;0Z9:&V@8/%"8ALC8="HZ _2FWGA[1M0NA=7FF
M6L]P$\OS)(@6V^F?2@#AM,N1>2>'M%N[FVBM9/#UO+ ERA9)9,8?&'7Y@H4C
MJ1DD8J5=.9-8\':=-K5WJ,16]AEG$KQB=47C(#<XZ;LY..M=E=>&="O;""QN
M=(LI;6 YAA:!=L?^Z,<58;1]->>UF:PMC+:+MMW\H9A'3"_W1]* /,;NWC?P
MK=6LI:2"Q\5)!;B1RWEQ^<GR@DYQAB/H:ZB62*Q^(PVW$L=HF@2NRB1F5-LJ
M#<%.0" .PKH?^$?T;[)<VO\ 9=G]GNGWSQ>2NV5LYW,,<G('-2+HVF)=I=+I
M]LMQ'%Y*2"(!EC_N@]E]NE '!:)<>3XB\(R6\K+;W]C<,[RS;IKI=J,KS <;
MLDXZXR1GM70>!?\ 4:__ -AR\_\ 0ZUK;PSH5FT+6VCV,30.9(BD"@HQZD<<
M&K=EIECIHE%C:0VPE<R2") N]CU8XZGWH Y[7;II/&^@Z3=?\@ZYAN)"A^[-
M*H7:K>H"EC@]3SVKE-9-Y;Z1XGL8[JZ6RL=6LTLI%F8%!(T1DCSGE5WX .0,
M^U>FWNGV>I0K%>VT4Z*P=1(N=K#H1Z'W%0S:'I5Q8K8S:=:R6H;>(7B!7=G.
M<'OGG/K0 [3-+M=)MY(+02A'D:4^;,\AW-UY8D_A7-W3M%\2YP+J6*-M!>0Y
M<LL;"4#>%)P#CTZXKL%54144 *HP .PJI)I.G2WS7TEE;M=M&8C,8P7*'JN>
MN/:@#D?"LMS8Z]!I>K6(BO\ ["QBO;:4O!?(&3=(0>1)RN<]=QYZ5I^.M0GT
M[1+5XY'B@FO[>"[F0E3' T@#G(Z<<9[9K;LM)T_3FW6=G#"0NP;%QM7^Z/0>
MPXJQ<6\-U;R6]Q$DT,BE7CD4,K ]B#UH Y,6ILOB"FG6:D:9>:8\EU; GRT=
M7"JX'\)8,0<=<9[4GPSM8(?!T,L2!7DGN QR>0)Y *Z6UTJPL8GCMK2*)9 %
M?:O+ = 3Z#L.U.L-,L=+@,.GV<%K$3G9"@1<_04 87B)[>?Q!I&GL6FG>.>5
M;21PL#J H+R<$G;GY0.Y)XQD-^'5U)=^!K!YK@SR*TR;V<L2JRNJ\GGH /PK
M<OM(T[4Y('O[&VN7MV+1&:,,4)ZXSTJ2RT^RTV)XK&UAMHW<R,L2!06/4G'>
M@#E=4LH[[XEVEI/+<&VETB9I(5G=48B6,#@'CKVQGO6-HETL^@^'=/N)Y[F=
MK^\B@MI)<1SI$T@ E8@DJJX(')) X[CT&32K":^%])9P-=JAC$Y0;PI[;NN/
M:JK>&-">U2V;1[$P1R^<D9@7:K]V QUH \XPE]X5TU+J19Q;>*E@C.\L$C^T
MD  DYQC@>U= IA@\2>+K;S-EHNEVTB(9#M7B7+#GCH.1Z"NJ;P]HS6MQ:MI5
MF8+F3S9H_(7;(^<[F&.3GO2W&@:1=74-S/IEI)/!'Y44C1#*)_='H/3TH X"
MS@_M5/A[#=75VT=YIDPN%6Y=?-Q"AYP>N2>1S[U8:VCU2]U_1)M6BL)-.,<=
MHTV]I;> 1(5E1S(.=VXEN2>Y(P*[:/P]HT+VKQ:79HUH"+<K"H,6>NWCC/M1
M?>']'U.\AO+[2[2YN8/]7++$K,O<<GWH MV)8Z?;%YC,QB7,I387.!\VWMGK
MBO,9;2TM_"GQ(:.-4D%S=(.>=ODQD_KS7JM9TV@:/<2W4LVEV<DEV MPS0J3
M*!T#<<]!U]* .1A2+1?%VDR1W$\<5UHT\EV6E9PQC\LAL'(R,MC Z<=*I:/,
M$\0>$FAE<6VH6-R7>6;,UTNU&5YL<;LDXZXR1GM7>C1=+6XAG&GVWG0)Y<3^
M6-T:_P!T'L/:H;;PSH5FT#6VCV,30.9(BD"@HQZD<<&@#"^&UK;6WAV;R45'
M-]=*0#_"L[@#'M5SQ$]O/K^D6#EIIW2>1;21PL#J H+R<$G;G@ =3GC&1N6F
MF6-A+<2VEG!!)<OYDS11A3(WJQ'4]?SIE]I&G:H\#W]C;W30-NB,T88H>^,]
M* ,/X=74EUX'L'FN#/(K3)O9RQ*K,ZKR><8 'X51UO38M4^(MG87,UU]EGTF
M<R11W+HK$21@=#QU[8Z<UUUEI]EIL3Q6-K#;1NYD98D"AF/4G'>FOI=A)J":
M@]G U[&NU+@H"ZCT#=0* //]G]N#7H9]<BTV\TV^9(Y61FGMHD(\ME)D'RLH
MYX^;)SFH?%=X#9>(-0L[F1KBRO+:,W,LFQH) 8\QPJ.0I#$G)Y+$<UW]QX?T
M>[U2+4[C2[26^BQLN'B4NN.G/MV]*;<^&]$O+BXN+G2;*::Y4)-(\"EI .@)
MQST'Y4 <GXEN)]/U:]U.YMUU'1@\*R2VTN+C3F 4\#^)#D,0.?F.<BG1E=<_
MX3(:E*\5W87#QV[!RK6L0B5HW3'W<G<V>_0\#%=<="THS^=_9]L)#LR1&!G9
M@+D=#MP,9Z8XI;K1=,O;K[3<V%O+/MV%W0$LO4 ^H]C0!PFEK<ZYK_AS^UY+
MG?=^'WENH1,Z*[;HN2H(QG.2!CWINB72S:%X?TZXGGN)FU&\B@MI)<1SI$TH
M E8@DJJX('))"\>GH,FE:?-?+?26<#7:H46<H-X7T!ZX]JJMX8T)[5+9M'L3
M DOG+&8%VA_[P&.M 'G2R/=^%]/MI;EG6+Q8($:.4Y2,3L%"MG( '2MAK$Z-
MKGB73K"6=M+;13<R122M((9SO'!8DC<H)(SVKL#X?T<V]Q;_ -EV?DW$GFS)
MY*XD?^\>.3[U,FDZ?'9RV:V</V>;/FQE 1)D8^;UXXYH X&PO-\/@[2+JXMX
M;.YT-7C6Y0M'-,%C&T@,N2%)(!/?IG&.P\+6;:?HHLSJC:DL,KJLY!X&?N9)
M.=OW<Y/3':I[GPYHMYIL>FW&EVDME%@QP-$"B8_NCM^%7K>W@M+>.WMH8X8(
MU"I'&H55 [ #I0!QFH:;!JOQ+FT^[FNFM)-&65H$NI$4MYQ7. 1CC'3':L'2
MM2O(X-"TG4;]3I\EY?VT5S>@NMP(G"PASN7.1OQDX)4=>*ZZY\/37OCS^UKF
MVMY+$:>+529#Y@?>6SC'0@XZUM7>BZ9?Z:NG7>GVTUDH 6!X@47'3 [8]J .
M"U+36L++2+--;N+I#XCCCS#(\8BC<%C"/F.0.Q)R,XXQ4WB+39-#6<6=J=2T
M:WL=MQ:_:6^U68+2,9HF8G.03WS\@P>*[,^']':TM;0Z7:&WM6W6\7DKMB;U
M48X/O4ESHVFWMP9[FR@EE*"-G9.60$G:?5>3P>.: .7L)X/$WBO7+._WM;16
MEJ]C&Q*XCD0LTB^C;N-W4;0.*P=*DOM6/@7^T[NZ=YS>Q2,L[IY\:(X1B >I
M4 YZG/7FO1[S1].OY8Y;NR@FDC4HKL@R%/5<^A].E++I.G3W%M<2V-N\UJ,0
M.8QF(=/E/;\* ,#P+F*#7;,/(T%GJ\\,"NY;8F$8*">< L:3QH/[-FTGQ'N8
M0V%TJ7B[CM,$GR%B.^TL&]L&NBL],L=.:9K.TAMS,^^4Q(%WMZG'4^]37%O#
M=V\EO<1)+#(I5T<9# ]B* /.M&:4ZK?^'+B*1%U&XCU*V+,Q9+1CEE)ZK@IM
MQV,@JW%LUM?&*ZC(\-W87#QVS*Y1K6)8E:-TQ]W)W-GOT/ Q7=&WA-RMR8D\
M]4,8DQ\P4D$C/ID#\JJ7.BZ9>W7VFYL+>6?:$+N@)91R ?4>QH XOP_>7EWX
MET";4R4FO/#K2W*,=JR/OC^8KTS@GZ9K-MYS/\/] =IFE_XJ2-0S/N^47K <
MGMC%>CW^C:9JDD$E_86]R]NQ:(RQABA/7&?P_*HCX=T4VZP'2K,Q++YP3R5Q
MYF<[^GWO?K0!R%Q+%KC>.(M2),]@K16\1<@PQ>3N5U]"S%CN[X Z"NH\'D'P
M3H)'_0.M_P#T6M3WGA[1M0NENKS3+6><)Y8DDB!;;Z9]*NVMI;6-LEM:6\4$
M$8PD<2!54>P% '#SR+'K/CV*24I"EC!*BLY 1C'(2R^AR!R.]4[*'^T-0\"Q
MW%S=/'=:([3H+AP)"(X<$X/7YCD]3WS7=7>@Z3?WJWMWIUM-=+&8Q+)&"P4]
ML_B?SI(M T>&2WDBTRTC>V4I R0J#&IZA<#@?2@#SVRU*6UT_3-*EN)5TV3Q
M'<V,DCR$D1(SF.(L3G!(4=>0,=*74IO^$>U+QW-II,'EP:>Q\O)\I&+!RH!X
MPI8\8Q7?GP[HQL9[$Z79_99VWRP^2NUVZ[B/7WZTZTT#1[%I&M=,M(FD3RW9
M(5!9?[I..1[4 <C=:=%#;:K?6>NQ-#<Z1*PM;$,B,5&1.&$A(;D#(QG/.:C@
MT6=/".BWNES+-J-W%:R36]]<N8[T+"Q,?4A3@EN!CY!FNNM/#.AV%I<6MII%
ME#;W/^OC2%0LGLP[CVJ9M%TQK*"S-A;_ &:W8-#&$ 6)@" 5Q]T@$]/6@#SV
MY:QU6T\,LUA-:R0^(6MY[:X?<87*R,R!AP5SC&.V*/$]W$;+7=0TZX=I+._M
MHA<R38:!@8@8X0/X<,223SD\'K7H4VB:5<6*V4^G6TMJK^8(I(@R[\YW8/?)
M)S[FHI_#6AW4UQ-/I%C++<*$F=X%)D Q@'CGH/R% '*76GP:GXR\36]Q-<R6
MPTVWE6,7+A0Q\WD8/'0<=.^*JZ!JLNJW?A'3M6E,EM<:&;K$AXN;@;!AO[V%
MW-@]SGL*[D:'I0FEE&G6HDEC$4C"( N@X"GU'M4<WAO1)[&"RETJS:UMVW0Q
M>4-L9]5';\* ,/X?11V]KK\$))CCUNZ5<L6(&5XR:9XGL[6;Q_X3DN(U.5NP
MS,<<",$?U-=18Z5I^EB06%E;VHE;?)Y,83<?4XZTMYIMCJ)A-[9P7!@?S(C+
M&&V-ZC/0T >?/.^J>#_%6JW$\D.L:?=77E2JY#VQBYC1?12 N1T;<<YS7H.F
M2W$^E6<MVGEW+P(TJ8QM<J"P_/-12Z+IDUZ;R2PMVN6VEI"@RQ7[I/J1VSTJ
M_0!Y9+I-K=Z3XYOY;FYM[FRU*XEMY8KAX_*=88V#  @$DX'.?2K<<USX@U.Z
MTG6KR"SNQI=M)''/&VY2Z$R21X=<,'XSU&![UW+Z'I3WK7C:?;&Y8AFD\L98
MCH3ZD=B>E-U/0-(UIX7U/3+2\:$YC,\0<K],]O:@!VB*R:)9(]\;YEA5?M17
M:9L#[^/?K[UQ\#V6OGQ*FJZA+9WMAJ+*DL<NR6VA3:8RF>@8 YX^;)'/%=\
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M[>ZN]*LYY[< 0R20J2@'0#CH.U '(KIT>I^,M1M+VZNKB!M%MY6'G21JSEI
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M;P)]V*)0JK] .E3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBLRZ\0:;9:Q:Z7=3-#=79(MP\3!)"!D@/C;G
MVSF@#3HJG=ZG;6-U:V\WF^9=.4BV0LP9@"Q&0,#A2>?2KE !12;EWA-PW$9
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M.".H/M0!)16?H^L6FN6CW5GYGEI,\)\Q"AW(VUN#SU'>M"@ HHJI<ZA';M:
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M%% !1110 4444 %%%% !1110 4444 %<IXMT&T\1ZAI^G7>Y5:"X:.5#AXI
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M<-K9R#NR#@Y^O7F@# -QX@U";5]*T_46^V:4D4"7#&-/,E,0?S)%V'().,#
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M\# X^M64T.!==763/</=BW^S99AM,>=V, >O.?Z<4 4_%5[J-A:6L]C;7-Q
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M.1XL:!!=,T<BH[9 08+*W QD\=QVX/1W7@_3KG4;F]26\MY;N$0W0@N"HN%
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M,-NSCCCY>./Y\T :EA.UWIMM<-A6FA5SM[$@'BO+KR.<?#7QB\M]<7!&J3Q
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M.?"[-^X$#@2 $],FNZ\(6>FV6E3II%Y-=V4EU)+'([*4RV"PBV@#8#G&.^:
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M^+$UH4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^%2JBH@1%"JHP !@ 5P_B/Q#]JF\.2Z=+>QV]QJ\,0GC^6*X3)W#@Y(..,@
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MU679[9#'GGZ5LQ00P0B&**..(<!$4!1^%94/B2UG#".VO?.\UHHX7MS&\NT
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M0U#%:6T"NL5O%&LARX1  WU]:QKG0+TZ1,EMK=^NJ-$0MVTN5+XZ^7]P#/H
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MC>AE\HPK*'$@.<YVC&W&<^W-;6L>'KJZ\617-NJ_V=J%J;;5%)QN5&W)QWW
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M.=V/N]NN:OWVC7[^(3JFDVMYI^HM>1B9A(IMKR %=S2+DX8+D= V1QZCNJ*
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MDCDM;9H8(U56WO/(P 4D9X&]#P,_,?3FA<>+KW2!JD^J6+R6%K:"XBNX[:2
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MOOB 2(A0V<XRQXZ<UK7=G/JGQ"N-.?5=2@M#I,5QY=O<M'B3SF&1CIPHSZT
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MAXI%#HPZ,",@T^LCPK D'A72U1I"&M(F.^1G.2@[L3@>W2M>@ HHHH ****
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M6@M9&V)*9EVLV<;0<\G/&.M-37](FM?M,6I6LD/FF$.DH8&0=5&.I]J $L]
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M6F^V,GFLGF-EWSG<QSECD Y)/(%9GBOQ"UIX.UC4M$OK62YL5.YAB4(XQE2
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M]B0,T 6J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M>!I5DP1W#+P>OX'([4 :M%%% !1110 4444 %%%8WBG6Y/#OAVZU6*U6Y-N
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M;J6.,X&6'OWQBFWEMJMIX;\8Z!+I5]<7-Y-<SVD\,1>.=)>1\W0,.F#Z#&:
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M$NBQ:E##+$LI8A9(V7C<0.2,'@#.,C-7M1U&TTG3YKZ^E\JVA7=(^TMM'K@
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M9('3. !4U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1ZJ8'A>+)>!X0-K'/!Y /;T]Z[*B@#!AT:\O-9T[5-7:V\_3XI$A2WW%6>0
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M[/\ MRTL+J 6&KR23-YH.^VDD&)"H'#@]0"1@^M32>&IH-6\.S6#0)9:-!)
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %8'B;Q =&6TMK:2P&H7CE8$OKCR8R%&6.<$Y
MY   ZD>];]8.OR>%KJ7^R]??3FDDB+K%=E02F<94GW';F@#3TQM0?3XVU2.V
MCO#G>ELY=!SQ@D GC':K=<OX;FC\/>%M.MM4NV027+6UF;C.]U:1O)4]]VS;
MUZ5U% !1110 4444 %<E_P )?)J7C.X\-:+#$\EG'YE[=SY*1'C"*HP6;GU
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MMTF@Z<M\2;L6T8GSUW[1NS^.:O4 53J=@+T61O;;[6>D'FKO/_ <YILNJZ=
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MKV'-0S:[=OXITVQL8[&XTVXB=Y[@72^8C ':%3.6!QV![],5XU.!-\ O#\I
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MRL!8PJ<'."$&1714 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MC()P#T/MVZ\41>+=.GDT80K/)'K"[K24( APNXAB3P0 3C\LT 9'_",^./\
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M;2XG^S$+"X8+EL\@9('K[5=M_%%A-J%U92QW5K+;VYNB;F$H'A!P77O@'J"
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M .>_X1GQQ_T4+_RBP?XTUO"_C9OO?$ 'ZZ)!_C76:=J$>I6S3Q1RH@D>,>8
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M\N?:-QQSD<<C<!D=,TA\5Z>MS9(Z7"6]](8K6Z*#RIGP2%!!SS@X) ![$\4
M;6Q 0=BY'?%.KF!X\TDQF;R+\6Z7GV.6<VY"0R;@GSD]!N('MWQD5I2Z_;QW
M<MND%Q,(9X[::2)5*Q22;=H(SGHZDD @ ^QH U:C2"&.1I$BC5V^\RJ 3]36
M1>^*+&Q6\E:*XFMK%MMW<0H&2 X!.><G ()V@XSS4-_XRTZQOOL207UY.;47
M:+:6YD\R/(&5Q][KGC^>!0!O/%'(RL\:LR'*DC)'TI2B$Y*J3ZD5EP^(+>>Y
M6.&"Y>)KAK7SU5=@D7.Y3SN&"I&2,9K6H 9Y4>,;%Q]*7RTR#L7(Z<=*R/%:
M2?\ "*ZG-#<3V\\%K++%+#(496521TZCCH:Q=#UV[N[+4/#VN,8=>L(26>-B
MGVF/'RS1D8Z]\=#^5 '8&&(N7,2%SC+;1DXZ4K11NZNR*S)]UB,D?2L.PU6.
MSTK2;=OM%W?75JLJQ*V^1P%4NQ+$ #+#J1R0!5+4O&T$.CP7NGVLUP[ZA'82
MQD!6@D,@5E<$CGGCW([<T =28T))*+D]>*-B8 V+@'(XZ&N)DUJ73?'NHF2/
M4IX3I,,XLH\R%&,D@8A<[5X49Y_.M2XUW2;Y_#ERMQ>[+^4269@W*DA,;'$G
M;&,_*>XH Z+RTY^1>>#QUH\M!_ O3'3MZ5S5SX\TJVCOY6@U!HK"?R+J1;8X
MAX!W'/\ #\P]_;%:=[KUK:7;VB1S7-REN;IXH "5BS@,<D=2#@#DX/% &F%"
MC"@ >U+5'2-6M-<TV+4+$R-;3#,;/&4W#U (Z5>H **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KFO'
MVGWVK^"M2TW3K5KBZN8PB*'50/F!R2Q [5TM5[V^M=.M6NKVXCMX%(#22-M4
M$D <^Y(% '.7-GJ,_BWPYJ"Z;,MO:6MQ'.QDCRC.$ &-W/W#TSVK#NM"UN7P
M)XATU-*E-W>ZE+/!&98N4>8."3OP.!TKT>B@#E;FRU&U\;0>((;*:XM;BP^Q
MW$"LGF0LKEU;EL$')! /H:QI?#6J06]M-#8O+-/XD&KSQ))&/)CSC&2P!; !
M.,\D_6O0)IHK>%YIY$BB0;F=V"JH]23TIEK=V]]:Q75K,DT$J[HY$.58>H-
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MD< R.3@*H[GGM5F@#SR^T/6;CP_XVM$TN7SM4N6>T!EB^=3&BY)W<<J>M/\
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M:4,@@WC?M&/FQUQR.: .8?3]4MO$OB2Y325O+;4;*(1;Y$",\:2 QN"<_,6
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M8[,?9_LUQ@O&5]2"0<Y!R#WK9JIIC6+Z; ^FM$UFR[HFB.58'N#WSUSWJW0
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M<T<Z!X?L])-P+A;6,1K)LV$@=,C)YK4H **** "BBB@ HHHH **** "BBB@
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MRYFCC#.K>8@Z.,= ?0\U:KS%=8O;'1KN/[9<F*7Q4;"2X>9F>&W,@! 8G(&
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M C$*<Y R3QTK4%K=:/XX\/M:ZA?3PZI%.M[%<3M(IV1AED4'A/FP/EP.0,4
M=S134=)$#HRLIZ%3D&O-Y[^;[7I.HV-[<S0W'B V[74DY7S4+.K1",<>6NW
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M/X9M+FPTC['=ZG_:,D$KH)R#D#.0A))+%<XSGMSS6Q0 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !5
M34M+LM7LVL[^ 3VS_>B8G:WU Z_C5NHKFY@L[=I[F5(HD^\[G '8?K0!3_L/
M3OM5K<F F>U0I!(9'+1J>H!ST/'Y"H6\+Z,]A/8O8JUK<2F::$NQ61R<EF&>
M3GGZU8MM;TN[N)+:&_MVN(@3) 7 D0#J60\CJ.H[T6VMZ9>3-%;WL,DBQ^;M
M#<E/[P]5]QD4 %UHNGW@MS/ 7>V),,OF,)(\\'#@[AGOSS3)] TJXMK:WDLT
M,-K()844E0CYSN&#][))SUY/K3HM<TN?3VOX;^WDLU;:TZN"@.<8S]>*6[UO
M3+&58KJ^AA=BH^=L %ONY/09[9ZT .DTBQEU)-1>$F\2,Q)-O8,J'J!STJK_
M ,(OHQL6L39+]E:7SC%O;:9,YW8SUSS]>:=<^)M#M+E[:XU:SCFC=(W1IE!5
MGSM!]"<'\J:GBG0))H(DUBR=[B0Q1!9@=[ XP/Q!'N: &7/A+0+R:YEN=+MY
M9+H 3,X)+XZ$^_'7K5HZ%I?VZ*]%C"MU%#Y$<JC:RIV QTQDX],TM[K6F:=(
M$O+V&!N,[VP%R<#<?X<G@9QFH]8U:VT^UE5[V&WN/*:1"XW;0/XB/[N>YP*
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M=L9D$\J&1(R>648R1[#(_,57M]9T^_N'M+._@>Y$?F*H.25Z;@/XESW''O0
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MX^'$Z[8_<G/ ]Z=:>)-%O[_[!::I:379C$@A24%BI&<X^A!H '\.Z4_V[=:
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MN8+RVBN;:5)H)5#QR(V593T(-2T %%%% !1110 4444 %%%% !1110 4444
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M%+_9OVRXC,=S?.;F5&ZIN VH?=4"K_P&N7N&>UU_QO'+;W ^V6<30,(6*N!
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M\+K8W-II&CZKI>JG7-*F0LDAG$2.G'G!\["I&3COG&.:]* "J%4  #  [4M
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ME$C&XM@@\ =>*SWNH;WXA:)?)%+]G73+@"62!E"LSIC.X?*2 V,XX^M=H %
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MN.U,,L\#1A]B,&X;!SR."*D\1K,?%WA>:.UN98;:>=YI(H&=8PT+*,D#U(H
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M@=IY0DBEG=>2  ,#/)Q]*V]>CFE\8^%+B*VN)(8)+AI9$A8K&&B*KN..,DT
M:UQXCTJUF,<UUL"RB!I?+8Q+(>BM)C:#R!@GJ<4S6M9M;&VNH3=2Q7*6YES#
M"96B7G#L K!1D'EAC@^AKC%TW4!X$UKPG<V-S+J$LTZP2^2QBF$LA=93)C:,
M;LG)R-O3I5VUCO\ 0?$.O07EG?7D.HP0FUNH(&E#%(MA1R/N'(R,X')YH Z'
MP=>W&I>#-'O;N4RW,]I'))(0 68CD\58D\1Z5#.L4EUMW3?9Q(8V\KS<XV>9
MC;NSQC/7CK5+P+#/;>!]&M[JVFMYX;5(WCE7:P(&.E<DFDZC+\-[KP;<6=R=
M4$K1),86,4@,V\3>9C;C!R><Y&,9Q0!T&J:S+>>+QX=AN;VS4V+3>?!;L6\T
MN%4Y*D;1R<].>3Q5OQ/K-SX7\%7%ZTANKZ"W"B40':\N,;V5<A1GGKCMFJZQ
MS)\3EG-O=-;#2!;_ &CR&V&3S=V-V,=.?2I/B%!/=>!M3M;6WFN+B:,)'%#&
M79CN!Z#Z4 0VTH@\26(D\37[)=AV@TVXM=ID*HV\DE P'&X#CD<9!Q6S!XBT
MNYL;V]AN&:WLG9+AO)<&-E^\"",Y'?CBL?6!+<^,/"=U#:W300M<F63[.^(P
MT6U=W'&3ZU$^BWL'C:X2"+.C:H$N[INR31$ C_@?[O/J%:@#=O\ Q#IFFHSW
M<[QHB*\C"%V$2GH7P#L'^]CH:T&GB6W-P9%\D)O+YXVXSG/IBN#O8I+#Q3K<
M&IZ'J>I6&JLDD$EGN=#^Z6-HI & 7[O5N"#R:ZJ\TUYO"-QI<$20.]@UO'&A
MRL9,>T 'T% %"VU^=_"4_B4P32K+"9[6TBC+-L_Y9\ 9)88)],^V34\'7T^M
MVUU<?\)6VI*!Y9B6R2V>VD]U(SGTR,?6IO#FJ"P^'6C71L[NX,-I##)#;1;Y
M%90$;Y>IVD'..>#Q5G3+%+CQ3=:_#;RVT4]HEN?-C,;3L&)W%3@C P 2,G)[
M 9 +6@:NVIQ7<$X47MA<M:W 48!88(8#L&4J<=LD<XJQ#K-A<:K<:9%,QO+9
M0\L1B8;5/0Y(P0>V#6%X3@=O$7BS40"+>YOUBC_VC%&J,1_P+(^JFH_%UE?V
M^KZ9K&C%1?2DZ;*"<;HY,E6]_+8;\>FZ@#>&OZ<UK'<)+*Z2EA&J02,[[3AB
M$"[B!ZXQT]:8GB72);2TN8;P31WFX6XAC9WDV_>PJ@MQCGCCO7-Z[92Z'KND
M7L.FW][I$-DUB\=B7,L!RI5]JD%@=N#],TUXWL;C1EL_#]U::=,]P[O!!ON(
MF;;@,>3'OY+$'L 2.: .B?Q7H<=E97CZC&+>];9;OM;YVYR,8R#P>N.AI$\6
M:+)8_;([J1X/*\YF2WD.Q,L-S +E1E6ZX^Z?2N&T^SOX?#7ABSFTG4$ELM?>
M>96MV<K'OF._(SD?.O/?/&:V?%EC<R:I=7VDG4;75H[15C,=NTUM?+\Q$4BX
M*\$D9)& ^<^@!V=[=QV%C/=S"0QPH781H7; ] .37%WGBR6ZM/"6K07$UG:W
MUTBW,,D6U65H6?&67)Y Y4X/O77W,<]SHLT;HHN9;=E**> Y7H#]:X*UBO&T
M'P' ^EZA')IUS$+E7MF^0) R%C@=-Q'/?KTH [6S\1:5?V-Q>077[FWD,4WF
M(R-&XQ\I5@&!Y&!CG(Q4+^*]%BM[Z::\,*V(!N5FB='C!&02C -@]B!S7&ZE
MINJW$WBB:SL+IV&J6E[#$RM%]J2)8]RJQQSE3CW J?5(8M6\*:]<Z?X=U2WN
M[FP:V#7<3^?*QZ(%))VCU/'/'>@#KK?Q/H]TDK079D\J01$)$Y9F*[@%&,O\
MO/RYX!]*6/Q-I$MD+M+S,9N/LH7RV\SSO^>>S&[=[8SCGI7/>(HKQ(/#FK6^
MG7MW:V6Y;JTMPR3A70+N5>"2I'3T-07.Z"TL[S3O#MW;VUSJ(DN)&MC+=H-A
M'G!#N*L3A<\D+DXY% &UK7BVUM/"&IZSI[-.UJDJ!?)?Y)E!^5UQE<$<YQ^M
M9UKK[:=KVFP37NIW<>JQ$B*:Q<>4R*2S*0@)R2ORXP.3P,5BFROU\$>-K#^R
M]1$UW=SM;(\;.THD10N""<]#D]!ZUNZDMS_;WA'4HK"\E@@2>.8)"=T;/&H7
M<#@@9!&3P* -ZY\1:5:7*03W)0M,( YC?RQ(>B%\;0WL34(\6Z&VI?V>M^K7
M7GBW,:QN<2$9 )Q@<=^E<CI]F\,EYX?U?P[J-[*;V6:"XR[6DJ/*9%=CNVJ5
M+<C&>.,FM[PU%+'XI\4RR6MQ$EQ=120R20LJR*L2J<$CGD&@"]XJUF31]-@6
MV*_;;ZZBLK8L,A9)#C<1W"C+?A5U[BST:W@@EED+.2J##2RRMC). "6/<\<5
MSWCZW?'A[40/W-AK%O+.>RQL2A8_0L*EUN&[L_&VCZT()KC3TMIK280QF1H6
M<JP?:N20=N"0..* -.3Q5HD6FKJ$FH1I:M-Y&]@P*R9V[6&,J<\$$#'>KFF:
MK9:Q;-<6,QEB61HF)1EPRG!&& ->?:MH]X=.UR[BLKIH]2UFUN(;98&+>7&T
M>]RN,KG:QP<' 'K7=7>MQ6>J:=8O:7C"^W!+A(28HR!D!S_"3V&.U $VHZM9
M:2+<WLQB%Q*L,1\MFW.W 7@'!/;-,CUS3YKR^M$F<SV*AKE/*<>6",CMSD D
M8SFH/%&D'7/#=[81MLG=-\#_ -R53N1OP8"N272==N]3T_5I+=XGURW^RZK
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M0NF\. R,5.&'4<9!]*SY=9U0>/O[(CMH6LTT[[3Q+AW)D"YP5QD8( SWR3Z
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M()+=M[1R12<E64X.#T([@CJ#6K0 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;<V< 8[8H Z"N#MO$&JIK.@J]^+N&^NY[><Q1*+;A791$Q <D;0">0>>:[O
MQCM7+VW@+3+1+"..\U+R]/G,UJAN.(@0P*# ^[AC[^] &!<?\@#XG?[\_P#Z
M2)7=Z-_R ]/_ .O:/_T$5FMX2LWMM:MVN[PQZPS-=?,G=0IV_+Q\H _^O6Q9
M6JV5E!:K(\BPH$5GQN( P,X % '':4[3_&'7_M7W[?3[=+,-VB;ER/\ @?6N
MB\0WL&C:3>:Z\ EGL;25HQT)& Q7Z$HOY4FJ>';34[ZWU 2W%IJ%NI2*[M6"
MR!3U4Y!5E[X8$5-'H\312I>S37YEC,+M<[>4/5<*JJ >_&3QGH* .=N-6U;2
MCX;O)+XWD&JSQVMQ$8D 1I$+*\94 @ CH2W'OS61+KWB&'0=3U<ZL&_L[6FM
M! +:,+-$)UCPQQD<'@C!^O;KK#PM:6*V49N;NX@L"39Q7#JRP':5!&%!.%)
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MT,_VB&Q=E,4;AMPQ\N[ ;D L0#VXI9?"5G-'K2/=WFW61BZ 9.FW9\OR\?*
M/_KT ;%E.;JQM[@@ RQ*Y [9&:BU:*]FTFZ33KC[/>F-O(DVJP#XXR"",9ZU
MG0:'/;:[97,-_?&VMK3[.\4DP,4@'W3L ^_ZMQP .<G&[0!YY:>,+F6[\+73
MWLHL;V+R=01HXP(;@@A-QVY&721<#N!T[Z&H:IJ]II^@W:7S8U#5HHW1X4S]
MGD8E4Z<':!D]<D\UJ2^#=%FTR_T][8FWO[K[7.,\F3<&X]!D=/<^M7-8T.#6
M19":>>(6=PES%Y)4?.OW2<@\#TH Y()<MK/C[S+^YECA@14C?9M"M;EL?=R
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M:1,#(%! *#@;0.!^?O6Q5'2-,CT?3(;&*>XFCA4(KSON;   '0#@ #I^M7J
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***Y+Q[>_8[;1A<-LTR;4XH[]S]T1$' ?T4L%!SQC@]:
M+]KKEU=>)=6TE+>WVVEK%/!()"?,+EQ\W''*]LUJV<DYL+=[X0QW+(OFB)R4
M#XY"DXR,UP21Z2/&'B^"V^RB.;287:.,KAB!+DX'_ 2:AL[:\N?"WA"737L+
MF[AT@$Z;?#]W<QE(PQ4_PN, 9QCYCGB@#TLNJKN9@%]2>*Q=7UJXTW6]$L4M
MXGAU&=X7D9SN3$;/P,<_=ZY_"N.T[6M)GU?1(M4A2TT:?0T^P0WQ'EK(&VNN
M3P6V!,'TSCK5VXAL;2Y\"6^G2R264=[*L#RN6+((9 "">H]#Z8H [XLH8*6
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M[4 >AEU4 LP / R>M!(&,GKTK@M(FM-:\4ZE;ZM;*;633+273X+M1Q R$R$
M]#N(#'V'I6)I=JUY_P ($FJYG+S7L:-*3NEMQ')Y>[U!7;UZ@\]: /6%8, 5
M((/<4M<AX#BBM3XCLK95CMK?694AB3A8U*1MA1V&2>/>MGQ/+?0^%=5ETP,;
MY+20P;1EM^TXQ[^E &J&4D@,"1U /2C<N<;AGTS7G;16CP>"-0T$1BXGGCCE
M:+[TMN8F,WF?WL$ DGHWN:M>!-&TQI]5OQ;1M=6FM7L<$N>8E+XVCT&.U '=
MTFY=^W<-V,XSSBEKRW0SIFM6]C)J&KBV\06FHEI8(U1;HS!R"AS\S(0?IM]
M. #U$NH."PSG'7O58:C:MJC:<LJFZ2(3/&#RJDX!/U.?R->4:GIU@O@_QS>K
M!']ILM8E>VE[P,!"04_NG/IUZ5U26^FCXM7IGAM1)+I4#1EU7<[&20$CU.,#
M([4 =&-4>PL8Y=::V@FENA;QK"Y8,6DVQ@9 .2",^G/I6ID>M>0QV]D? &C-
M/% T,/B7:6D *HANV!R3T&,9KH=92'POXBM/$.EV44UKJ4'V!XX$&#+C,##'
M9C\A/3E: .]ZT51T?3(M'TFWL8@O[M/G95 WN>6;'N<G\:PO'MU):Z9ICMD6
M#:G;IJ#=A 2<[O\ 9W;0?8D4 =/)<0Q6[W$DJ+"BEFD+ *H'4DU@W7B5EO\
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M$WSQY&T<$9SQTR*Q])N;"#0M'T^?;M76[R*T6:3;;H$:7 DSU !^5>,G;R*
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MX.#TKSO4M/L/#_C!+S2TDAM9-(NIM4%JQ+.B@%)/=R2V&ZG!]ZJ:!-IZ^+M
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M266VADDC^X[Q@E?H>U3US[^,M)CTRZU!S<K;VES]EG)@;,<F0,$=<98<].:
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MG^#=']J\L@GO\HY /4UUEIXFTR[DU",O-;O8())Q=0M$5C()#_,!\ORGGVH
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M=%4],U.TUC3XKZQ=Y+:4;HW:)H]P]0& ./>KE !1110 4444 %%%% !1110
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M07$4\1D D0;5D4AASC@@]<#D57MO!PT^[\/-97:I;:-'*@CDB+-,9  S%@P
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M#WQFN8\-:G<G5/[,U>/4+/5H[)C)%-,9H+K!4&:)LXZ]5P,;NG%8VFO=Z?\
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M[NUGE@N(+=I(Y(G*E6'3I0!T5%<G-<W1\=:;:)>3I#<Z3-)(BOD;U:,!@#D
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MT//7FNCAT73[?5[C58H-MY<A1*X=L-@8!VYVYQQG&<4DFNZ1"P635;%"9?(
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MIUW9R7EMJ%K-:QDAYHYE9%(ZY8' Q2+K.EO;27*ZE9M!$VV243KM0^A.< T
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M1SV\J[9(Y%RK#T(JA9>'=/L/+6+[4T<9!CBFNY943'3"LQ'';T[5=-_9K/)
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MPR?:K>(PQ2>?(<(>2"-V#D@$DY)/-5FTU?#UE?7.A:9)=W<\OG/;M>,OFNQ
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MT8%6![@CK3Z "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:2[K9"091M.5!'(R.XYK4HH \STF_LY?&=G</<I-:S: T898"L*[9%.Q21R
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MW[TG[Q&#_P#6/>LRV@2T^%?A[4+.T)-LUJ^H&VB!F\I#EQTR2K$-@^E>J44
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MTL=SO")\[B&8G.#R 220/0ULT44 %%%% !1110 4444 %%%% !1110 4444
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M+DQ,JJ-\;( @)!.">^.!ZU6NM&U234_%\R69:/5+*.WM3YB<LJ.ISSP,N#]
M?I0!HV'B^WOK_3K4V%[;KJ-N9[2:95"RX4,R\,2" >X .#C-8]QXGATOPQJ^
MI:1I]V9$U1K>=;B0$I,SJC,,L?ERPP!Q[ <U/!HVJ)>>#9&LB$TJW>*Z/F)P
M6B$8V\\C(S]/?BJ4WAK6+CPIXBL1:HEU=ZL;^W5Y5PZ><D@4D9P<(1Z<CF@#
MH&U"S?Q?I]O/9WL.H/9RR1,T@\L(&7<"%8@MG;V/UIK>,;%+>VO6@N!I=Q.(
M([["^7N+;02,[@I/ ;&.G8@U!<Z;J-[XOTS49K/R[:.QGMYRLRDHTA0C'0G
M7DXZGC-9,'A;59?!,7@V[@7R8I43[>LB['@24."%SN#X 7&,9YS0!KWOC>WL
MY-70:3J4QTG:;LQHF%0IOW@EQD;><=?:ND@GCN;>*XA;=%*@=&]01D&N-N=$
MU663QL5LCC5X%CM#YJ<D0>5\W/'//T]^*ZC189K;0["WN(_+FAMTC=<@X*J
M>1]* $U'58=/EM8&1Y;F[<I!!'C<Y +,>2   ,DD_J0*R+SQ6'T/79;2UG34
MM+C<36TFS=$VPLKGYL%2.003D=L\4_Q%I-[/K6AZWIZ":;3))1);%@OFQ2J%
M;:3QN& 1G //(JC<:!>S1^*M06V(N]8M5MH;8NN458V52YSC)+$G!. !UH M
M>$=/C>PL=9:.[ANY[&-)A+,&6<D*WFD!B"Q.>3@X)S73UG:!!/:^']/M;F$Q
M3P6\<3KN##*J <$'IQ6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !2.ZQHSNP55&2Q. !ZTM<3\2
MYG_L[1+ DK9ZAK%M;79[&(DDJ?8X% '0#Q-HWEB4W\2PG[LS K&_^ZY&UOP)
MK6JO>6-O?6$ME<1*UO(FQDQV]O3':N=_MC4]6EUX:5-# =*E-O$DD>X32A [
M;^<A?F"C&#P3D]* .JK&U?0M!N9&U/4[.W$D2?/<L=A"#GYF!&0/>N>L_%6J
MZ[?Z"NGO;6MOJNFRW1\R$NT3H4!_B 8?,<=/7GI6;KFJ:EK'PLO)[F>)+F"^
M^RSM''A9=ETJ9 S\N< D<]Z .PT[Q#H#7Z:'8S+%=1@@6?D/$4  /W2HP,$$
M>O;-:&I:K8Z1 D]_<+!&\BQJ2"<LQP!Q[FL:YU#4+#QAHFFO+;R07T%P\SB#
M:Y:(*1SD\?/TQV]ZYC7]3O?$/@&#6UGCCL[C4+<I;>7G$0N5526Z[R0">V"1
MCO0!Z917'WNMZ]?2:N- MO,DTZX^SQQL(]DSA59@Y9P5'S8&!QC.3G 9+JWB
M*Z\0:GID$]G9B#3X;M-\!D9&;?E#\V&Y7KT]N] '9U5M]0M;N[N[6"7?-:,J
M3KM(V%E##DC!X(Z5P\>LZGK>H>!;M;I;9=0MYIY85CW+Y@AZ\G./F( [>]:8
MU_5_-\60B2P\S3)(UMGF!BC56C5R7))Z;O49QVH ZJXN(;2VDN)Y!'%&I9W/
M0 4VQO;?4;&"]M)!+;3H)(G (W*1D'FN6L=;NKV_\0Z7-(TT%M91SPS20&)R
M'5P01QD93@X'7OUJ_P" _P#D0- _Z\(?_0!0!I6FM:=?7L]G;722W-OCSHE!
MW1YZ;AVS[U?K@;">>U\5?$.XM6C6>);:1#(I9<BWSR 1Z>M3:5X@UM[GPE+>
MSVLEOKEL2\4<)4Q.(?,#!L\YP01@8S0!TU_X@TO3)A%>70B.Y$8[&*H6.%WL
M!A<]MQ%:5><6^I3:%<>.M6O)5NHK.=&:'RL>8P@CVC.3@9P._K6Y<ZQJND:G
MH:7<T-S;ZJYMW*Q;?(F*%E*\\H<$8//0YH ZNBN M=<\47/AS5=:^V::JV'V
MU/)^R,?,,3,%.=_'W<8Y]<GM/'K7B+^T?#L1N[(IK5J[8-N?W#K&K[@=WS9R
M1CCM0!W%%<79>(-7DT>_6>XLQ<6.KFPENF78&B!4[E3)S)AL!>Y]>E9&M^(-
M5O/!/BE5NFBET^\6V6;R=CR1-Y9PRG[IPY!.!]!0!Z#+J%K!J%M822[;FY5W
MB3:?F"8W<XP,9'6K5<W<ZGJ5CXNT32Y)X);:\M[EY6$)5]T>W'.2,?/TQVK&
ME\7ZB/!2>,X3$UD)-[61CY-OYFS(;.=^/F].V.] '>T5P]]K?B%]0\4P6EW9
M0QZ3!%/ 6MBQ8-&S[3\WMC/Z5U>CWS:GHEA?L@1KJVCF*CH"R@X_6@"[17$V
M'B74SKVAVES-!,-1-PEPL,9,4+(I8".3^/&,'KSZ=*FT+Q--J6N#3[JY%K?Q
MO+]HTVXAV,$&=C1-_&O R><YSQTH ["BN<\5:KJ>F3Z+'IS6H^W7RVK^?&6P
M"CMD$$=-O3OZBN=U'Q3XBT:S\46=S-937VEVT=Y;70MRJRQOD89-W# J1G)^
ME 'HM%<G)JNL6>K:;I-S=VKSZM+(\4D<!7[/%'&&9>2=S9( )QU)QVJK/KOB
M#9XETNU,$NJZ2D=Q;RF+Y;F-U+!2H/#?*PR#C.#B@#MJJZ?J%KJME'>64OFV
M\A(5]I&<$@\$ ]0:RM-U>76VLIM.N4-K)8BXD9X\_,_^K'!'H^1[#IFL72/%
MNH:CI'AR&1H4U+6)KA6E6/Y(TB+EBJYZX50,GODYQ@@'6VFJV-_=W=K:W"RS
M6;!)U /R$C('Y5<KSBVU.YT#6_&$TC+=73WUC;Q-M"@F1$12PR!P&&>0#CMG
MC3O_ !#KOAZVU:]U*Q,NGPVZ/:S2&-',S,$\M@C-\N2IW8&!GK0!U$FJV,6J
MP:8]PHO9T:2.'!RRKU/IWJY7$W4-]#\2/#7VR[2XW6=Y]V+9M;$>['/W>F >
M1SR:VM=U>>ROM,TZTC9KB_>0!E"DJJ+N8@,0">G4^IYQB@#0U+5;'2+=;B_N
M%@B9UC5F!.68X X]S5RO//$L^M2^!K]-;M1%)%J5LMO*"F9HOM$6UBJLP5NH
M(SVK3U?Q--8^)'TRXN1IH<Q"QEGAS!=9^^ID[/U &1V/.<4 =A17&WFN:_?G
M5'T"T\U["Z-O'$PCV3,H4N'9G!7J0,#C /.<!;S7=6L]8U2QGEA@)TT7NG[H
MMV&!(=&P?F(8ITQD-0!U[NL<;.[!549)/857TW4K/5["*^L)Q/;2YV2*" V"
M0>ON#6!X<UZ[UZST>59461X'DU!/+^XZG9L'/RG>'QUX0US'A?4]5TCPKX7F
MCFMVL;K46LGMS$=V'ED^??GJ".F.E 'J%%<7-KWB'4(KR[T*R,_V6^>V6W;R
M@DRQOL?+LX96X8CC'3@U)%JNO77BC6K1;RRALM+EMW;_ $9F>2)DWLOWN#CO
M].!0!V%5=0U"UTJR>\O9?*MT*AGVDX+$*. ">I%<QIFM>(]3&BZG;6/F:??;
M7N(V\I1#$ZY5E;?N)'&01SS@#I6EXSU6]T3PS/J%@T(EBDB4B5"P*M(J''(P
M?FSWZ=* -^JVH:?:ZI926=[%YMO*,/&6(##T.#R/:N<O-1UV?QA?:+9W=G;P
MQZ?'=12M;%V4L[K@C=@_=Z\?3O6GX4U>;7O"FFZI.B)/<P*[JGW0W0X]LT 3
MZA>:;H.BO+?7!MK&%-I<NQ*CMR/F_K4VF:99Z19)9V$/DVRDE8PQ(7)R<9/'
M/->:ZE)?S_#WQU)>7OVC9>W$(S&%/RE%'X8 &*ZZUU+5X?&+:-=W%K+%<:<U
MW"4@*^2RN%VGYOF'S YXZ=J -4C2?%>B,CHE[IUP2K*ZD!MK8/!P>&7]*O6U
MM!9VT=M;0I#!$H5(XUPJ@=@*X>W\7ZB/!NEZQ?*PCFNIH[ZYM+<O]GC5Y%#!
M.3C*J"><#-=9H5Z=0T:"[^V6]X)"Q6XMQA'7<=IQV.,9'KF@"W<W4%G$);F5
M(HRZIN<X&YF"J/Q) _&IJXCQQ##X@\W0G>Y1(K<S[X(9'Q.<B')0'IAF(/\
MLU;T?Q5/??#EM=6V::_MK63S[;&&\^,$,I'49(Z>AH ZRBN-LM;U>YUW2+2W
MO+2XMK[3S>2R?9RWE$;<8VL,*V[C.3\IZ]J-CXGU]?"[^(KV>RDA626V%M'
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M*J!HXCU"@*!D]V.2<#TJTOAP#5M+U!KZ5I-.MWMXUV* ZMM!+<=?E'3%;E%
M'.V'A5M+TD:=9:S?10K<^=&0$RB[RYC^[R"202<FNBHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;\2
M^)TTF^LM+AN+:"[NPTC3W+ 1V\*_>D;D9.2 !D9)]JZ2N4OK*2Q^(EMKLD$L
MUI+IK63/%&9#"XDW@D $X8$C/J!GK0!T.GR1RV,<L5]]NC<;EN 4(<>Q0 $5
M:KC_  U#)X:TR826-X8=0UB5K:"&$L;:*1OE+C^!>"Q]-W/-=A0 4444 %%%
M% !7"V?BJ^\2^/\ 4=!TV?['I^E+BYN$16EEESC:NX$* <]B?E[9KNJ\VTC1
M;OP;\2];U"6VGFTC6095N((FE\J7=N*NJ@D#);G&.GO@ OV_BZ[TCXAOX4U>
M3[3%<6_VFRNA'B0C!)1U48)^5L$ =!QS6L?'WA@:3_:O]IC[")OLYG\B3:),
M9VGY>#BN<@T*\\1_%N/Q1);36VEZ;;B"W:>,QM</AN0K8(4;SR0,X&*R[GX=
MWEWJ'C/2]I72;H+>V*D8'VI@>0?0$$$>A6@#T6^\2Z5ID%U/>7#PQ6JHTSM!
M)A _W>=O_P"KO46F^+]!U;4ET^QU!9;IX1<(FQEWQG^)20 WX'U]#7%ZEI6K
MR?!">WN;:XN-9O+>$R11Q,TA8%  5'((1!GW!JOIFG:@OQ#\(71TZ]2WMM 2
MVFE:V<+%+L?Y6)'!Y% 'H,?B;1Y=06Q2]4S-,T"G8VQI5&60/C:6 [9SU]*H
MS>/_  O;RS13:LB2PW MI(VC<,LA)&,;<]NO05PG@;09((XM"\0:1J[7VFZE
M]JMYQO6V8YR)=_W?[W'?^6SX$TJ:+QEXTN;W39XX[N]62WDN+=E61 SG*EAC
MJ0?RH ["+Q+I,]_]BBN6>;SVMLB%]GFJ"S)OQMW  \9[5Q?AWXBQ6]_XCA\2
MZFBQ6.IM:6[^0>$#,H+E%P.@Y.!5.RT74=,^(D5[H27T=C?7TIU*QNK=_*3!
M;]\CD;<-U7!SSCD9 Y^_T35YO"_CZ"/2-1,VH:PLUJGV23,J><6W#CI@9_\
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M>:6(5V0.//(1 RHV,;N#CU(JQX'M]6\+/K4,G]H:EH5G KV326C+<'J3$BL
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MSVCNF6"[:#R7N8PJX=T['.5SQG:#0!IZSJMOH>C7>IW1/DVT1D8#J<= /<G
M_&LV[NY+73]-.IZO_9]W<W47RHBL'8D?N%!!X/3=U[Y%5?B1:3WO@#58[="\
MB(DVP=65'5V'Y*:;XSWWNFZ+):03W*_VI:7&8(FDQ&KABQV@X&* -&[\7Z#8
MRW<5QJ4:R6>/M"JK,8\Y.2 #QQR>W?%7;G6+&UCB>2?<)D,D:PHTK.@ )8*H
M)(Y'.,<CUKD9H9SK'CJ3[%=E+JRAC@;[*Y$Q$3J0O'/+ <53TV:_\/WVA:C<
MZ5J-Q92Z%!8RB"V=Y;:9#DADQN .<9QU H W=3UQY=7\*3:7J ?3M1N'201A
M6251$[ YQD<KV-:K^)=(CT^ZOGN]MM:3&"X<QO\ NG&,AAC(ZC\ZY_4H'&H^
M$&M](FMH(+R65X8+<E8$:.15W; 0I)89'J3]:PM9@OHM!\<:.NEZA-=7MZ]S
M;^5;,R21LL8!#XP3E2,9S[4 >A:EJMG9JT$MT\4S1&0>3$9'1>F\@*<#W(Q7
M->'==DO_  QX6N=1ULPWUX^XJ(U)NS\WR8QP.^1CI1;7-UI7CC5;F\L+^2SU
M6VMS:2Q6SR>68U(:)PH.PY8MS@<GFL32K6]C\*> X)--ODEL[]7N$-J^8E"2
M#<V!P,LOYT =I<>,_#UL9Q+JD0^SR^3,0K,(VX^\0.!R.>G/6K]YJ]C82".X
MF(D,;2[(T:1@@ZL0H) YZ]*X2_M+J72/B%$FGWK27LA^S 6LF9OW*H-O'/S
MU-J%Z^F>)K._M[743+)HZP3;-/DN HWDIE%PRL#OZ\$<=L@ [G3]2LM5M1=6
M%S'<0,<"2,Y!_'\:M5Q^@:OI.A>']$TVSBU.>V,@LO->U93#)D#]\" 4R6&.
M.X[5V% &8^OZ9'<7UNUPPEL8Q+<KY3DQH>C'CD<'IZ'TI\6MZ?-;V4\<Y:*^
M_P"/=_+;$@QNSTX& 3D]AFL+Q'IFH#Q-I^H:7&3]MA?3;UA_RSC.767_ ("0
M_7NP'>F>#M(OM+FN;*\C86>DO);Z<YR3)$Y#@^^U=J ^S"@"1_%5EI.A/?\
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MBQ:9-J,NH1QVL,GE2LX*M&_]UE(W!O8C-36.O:7J=[/9V=VDMQ H=T (^4G
M89&&7(ZC(K@O$6DWESIWC._MK.Z>/5/LD=M MN^^1H\;GV8R!VR0/N_2M^5Y
M(_B,-06SO'M5T1T\Q+9\%_,#A <8W8!X_"@#KZ*HZ/JL6M:5#?PPW$*2;@8K
MB/9(C*Q4JR]B"#5Z@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MZ+L^9%#=>,[3T[@%'_A7MM_T,?B?_P &TE'_  KVV_Z&/Q/_ .#:2NPK O\
MQ!=V_B6/1+73!/-+9O=1RO<"-/E95(/!('S=<'Z>@!G?\*]MO^AC\3_^#:2C
M_A7MM_T,?B?_ ,&TE1Q>.[E]*M-4DT0QV;W8LKIC= M#(9?*RH"_.H;OE3[5
MJ7/B2<MJO]F:>MXFEG9<$S^66<*'9$&TY(4CJ1R<4 9__"O;;_H8_$__ (-I
M*1? %HX)7Q+XF;!P<:LYP?2K\'BF#5WLH-(A2[>\L_MI$TGEJD1.T;B%8Y)R
M,8_A;TYYWP=K,.C>%XX7ABBGN=5O(HH&D"(F)'8@L <  8X!YQQS0!IOX M(
MU+/XE\3*HZDZLX I?^%>VW_0Q^)__!M)61XJUE/$'@353/8B"XL;ZWCSGS$;
M]]'AXW(&002.@/45T]UXE*:U=Z5:6\,]U:QI(T,EQY<DBMSF-=IW #WZ\4 9
M_P#PKVV_Z&/Q/_X-I*/^%>VW_0Q^)_\ P;25V%8^KZQ<Z?<"*"Q61?(>=[B>
M;R84VD (7VM\Q)X'H#0!C_\ "O;;_H8_$_\ X-I*/^%>VW_0Q^)__!M)3E\;
MO<1>'WL=(DG.MPO)$&F5/+94W%3Q^OIZ]*KGX@20Z;=RW.B2QW]E?16=U:+.
MK;3(5".K8&X$,".!0!-_PKVV_P"AC\3_ /@VDH_X5[;?]#'XG_\ !M)4T/B^
MZCU34-,U'0Y[>\M[-KVWB@E$YN8@<$+@##YP-O/7K4MKXJFFU:YTN:PC6\AL
M1>!(;G?QG!1LJ-K X]>#0!4_X5[;?]#'XG_\&TE:.B^%(=%OC=)J^M79*%/+
MO;YIDY(YVGOQU^M4--\7:GJ6CV^J1^&Y?LUU'$T!6X#DL[[3N 7*JH.XMSQV
MJGK'C6['A?Q//806R7VD?NRZW'F1X9 P=6"C)&[[I Y'6@#NJ*PDUVZCU^RT
M>YLHEENK62X62.X+J-A48.4'7<.?K5"+QQ"VFVMS/;Q6SW&H2V \ZXVQ*\9<
M9+[>,[#CCDD4 =915;3[BXN;-9;JV%O-N=3&'WCAB 0<#(( (X[U6U[68=!T
ME]0G \M9(XR6;:J[W"@LV#A1NR3C@"@#0=UC7<[!5]2<"G5P?C.Y:_\ "JW%
MW:V\?D:I:>1+'+YJ.ADB.]6P,#YB/P-;Y\1K'I]]JTL"KI%NA>*Y63+7  ZJ
MN!P3P#GGJ."#0!NT5R@\77+7LUDNGP-+]D>X@EBN&DB++U21@@V'OWS3-!\3
M7L_A[P^;J"&74]5A#Q*LQ"LH0.[L=ORXSC #<D?@ =8SJ@!=@H) &3CD]!3J
M\_\ %-Y/?V&C7-YI$EM>6GB*WB5"0V_#_>C8@95AC!./?I6S%XP\A=;75;$6
MDVD^6SK%-YJR+(/DVDA>2>,'H>] '3T5R;>-A;3W\=W892UL7O5FM)3,CA?O
M(257:_?'(([UL:/JLNJAY/*MC:F-)(;FVN?.CEW;LC.T8(P/^^A0!J4UG5!E
MV"@D#)..3P*5F"J68@*!DD]J\[\3:H^NZ9X=U*+3XOL$FM6C6]PTO[T+YH ;
M;MX#8_O9P1D=< 'HM%<GJGC:.Q%Y);6BW<-G/Y$R)-B9B" QCCVG=MSW(S@^
MV;:^)_M.L76G65O#-):S11S1M<;)MCA"9%3:<J _7(^Z?Q -\.C,R!E++]Y<
M\C/K4-G9Q6%N+>W!6%3\D>>(Q_=7T'H.W0<8%<Y'K]A8:GXLN9M,%L^FQQ2W
M5Q&0SW*^667C'91@9/?M4L?BB[.L:=ITNE*'O[4W43QW.X!5QN!RHY&Y?:@#
MIJ*XNU\=7,]EIVH2:(8K&[OOL+R&Z!:-S(T:D+M^9<@9Y!&>AZUJ0>)3>:M=
M65G;0RFTNEM[A#<;9D!Q^\\O;]WGKGG% '04TNH<(6&\@D+GD@?_ *Q3JY&>
M)$^+5K*D2^8^B3;B  6Q-'C)H ZQ'20$HRL 2"0<\C@BG5Q>G^*M/L-!6[33
MK?3DGU66S*/,%C67>^YW<+QDJ>QY('O4NMZ_K5LFBB&RMH6O-3%K(&N"05^9
ME*L$^ZP7.<< XQW !U]8EYX;CN-5DU*VU/4;"XF55F^S2+MD"],JZL 1GJ,5
M#'XF>XU>ZTZVM8)9K.>*&XB-SME4.$)D5-O* /UR,[370T 4X=+M88XUVO(4
M?S-TCEBS_P!YO4^GIVQ5RN?U[Q%<:-]K9-.$D%K:?:7GGF\E'.3B-#M(+_*>
M..H]:@E\63OJ.EV=CI1G.I637<#R3B,  *<-P<??'(S]#0!T]-#J7*!@64 D
M9Y&>G\JYFS\9+=Z59R_8BFHW5Y)8I9F7($L98/E\?= 0G./PS5/PHLB^//%_
MG6L5M(?L998GW*Q*/\V<#K[CK^= ':4C.JE0S %CA03U/M6+K6NW&ERR+%8+
M)'%:M</<3S>3%P<",-M;+GTXK U"\M]8UKP#K$4.S[5))(A8#<JM;.VTF@#N
M ZLS*&!9?O 'D4ZN1\)Q1P^*?&"1(J)]OB.U1@9,"$_J36Q=ZRZZT-(L;>.X
MO1;_ &EQ+*8T1-VU<D*QR3G QV/MD UJ:'4N4# L "5SR >G\C7$7OC*]N[#
M2I=,M8XI9=873KR&>4AHI%)+("%((.W[WH1QSQ6CO+O1_&7C&[L=*BN)%M;.
M>:,3B)>$E+?-M)+'MQSCDB@#T*BN:?Q?;R0V/V-(6FO+);Y5NI_)58VQM!(5
MCDG/;L?;--/'-Q<1Z)]ET*=IM5$P6*:81&.2-22IR.AQ][TYP>E '8T5GS7E
M['X?>]-G'%?+;^:UM)+E4?;DJ74'(![@<UA:)XAU6;PQH5U<6*37%_ LCSB8
MK%&OE[R\C;/DR> ,$9/6@#K:*X]?'?F:)INHQ:6TIO-0_L]HXYU(1]Y3*L1A
MA\I(Z=NE3KXR^RV_B!]6L#:RZ*BR2I#-YPD1UW*5.%Y.",$<'O0!U-,\Z(KN
M$B;=VW.X8SG&/KGBL"+Q'=_\)%;://I:++/:&[62.YW*%! (.5'()'YUR6I7
M5G?>&]$OK31H[5X?$J*MO&5)WB=E8AN "Q'TH ]/IN4FBRK;D=>&5NH/<$5Q
M]QKTFJ6^OZ#K&DK9WD-@]PL9E$T<T1! 8' Y##!!'!INA:_'IOA/PS8H(&NY
MM)BE GF\I BH@R6"L<DL,#'KZ4 =A!!';0K%"@1%Z ?YZU)65X>UK^WM)6]-
MK+:R;VCDADYVLIP<' W*>H/<&M6@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "L#Q5H5SK-M8S:?<1
MP:AI]VEW;F4$QLP!!5L<X()&1S6_10!P]YX.U'7+K6WU:6S@AU2PBMBELS.T
M3H6(8$A<C+ ]!Z>]:0T+4-4N=(EUPVA_LW<_^CNS>?(4*;B"HVC!8XYY(YXY
MZ:B@#DO#6A>(=#@@TB6_LI='M&_<2JK?:6C!RJ,/NC'0D9R!C ZUG7G@[7)=
M*U;2;>YT];6ZU+[?#*^_?S,LI1@!@8(.""<\<#K7?5CIXEL98]5:&.ZE;2VV
M7$:6[;RVT-A5QEN"* *,>B:G'K^N:CFT9=0M(H(U\Q@59 XR?E/!W^^,=ZHV
M_A75(-+\)VA>S+:)(KRMYC8D"QLGR_+Q][//I79(XDC5P" P!PPP1]13J .0
MTC0/$6BW$NG6U_8MH33O-$[H_P!IA5V+-&/X3R3ACTST[5#=>%-5N-*\5V8>
MS#:U*SQ-YC8C!14^;Y>?NYX]:[6J.H:K!IS11NLLUQ,&,4$*[G<*,L0/88_,
M#J10!CKH>IQ^)[;5XI;15_LT64Z$L2I#[@R<#.<D<XQUYZ54LO#%Y::RNNE-
M.LKY;.2.Z:V=O+O)"!M>1=J@ $$]SSUXKJ-/OX-4T^"]MM_DS+N7>A1OQ!Y!
MJS0!FZ!<:C=:+;RZJD"7IW"3R PC;#$!E#<X( //K7)77@S7%T/7M LKFP;3
M=1DDE@EG9Q) 9&W,A4 AAG.#D'GH:[^B@#G;31]2B\8MK$[6AA?3DLV5&;=N
M5V?< 1C'S8QGMGVK$/A#7V2!6N].D>WU<:@+B17,DZ[FP']"H;  R, #(Q7>
MT4 <]>^&%O/%<&K-*OV<VWDW=N1Q.RMNB)_W2SG_ +YI/#GAV;P[H$U@LXN9
MMSK$TC$ 1#*Q(3C. N/QS7144 <18>$]5L].\)VI>S8Z)(6E82-^\&QD^7Y>
M/O9Y]*J:[IT^EZ3XB-]-IT::W?1" S%FC4L$3#D@;>$)W \'IR!GN-/ODU*Q
MCNXXIXDDSA+B(QN,$CE3R.E3S0Q7$3131I)&PPR.H((]P: .(THZO%>W-NL>
MBO>7=LRI=VMY+</&54^69!("=F3V/4].35BW\.7>BW>J:QIT>FZ;/<6@3[.D
MCM;-,#GS7 5<>G YR:ZBWL[/3+=ULK**!!EC';Q*NX_08YJ2UNH;RW2XMY!)
M$_1A[<$'T(.01V(H BTN:ZN-)M)KZ)8KMX5::-00%8CD#/(^AKG-.\+7,?B*
MRUNYCLK:\BB=+R6S=O\ 321@%UV@#!^;/)SBNDOM0@T](C,27FD$4,:C+2.0
M2%'O@$_0$TS2]3@U>R^TP)-& [1LDT91T93@@@^_X4 <;:>#M>M])T+3#<Z=
MY&CWZSQR#>6EC&_&1@;6^8# R.^1T+-(M-0U-/&NG6WV9(;K5)H6F=VW1[HH
MU8A0,-P>.1S7H55[;3[*R:1K6TMX&D.7,484L?? YH XRUMY]-^(\EGID,$D
M=OH%O$J3RE,*LD@7D*WIZ58/@^[M]/T*VM9;>1['4CJ-S)(S)YCMOW!0 <#,
MAQGL!70NNGP:["!IW^FW$;M]J2VS@+C(:0#C.> 3SS6A)((HVD8,0HR0JEC^
M ')H Y&\\(7.IW?B@7,T45MK$4*1/$Q+Q-$N%8@@ \X/7MCWJW8VOBYM/G34
MKW2_M20,ENULC[9)",*\F>@_V0.Y]JU]'U:UUS2H-2LB[6TX)C+KM) )'3MT
MJ]0!QEOX=N]#GU;5M,CTW39KFV51;*[M;&8$GS6 5<'! PHY_&NITR6ZN-+M
M)KV)8;J2%&FC7.%<@9 SSUI-3U&WTG3;C4+LN+>WC,DA1"Y"@9)P.:DMYHK^
MQBG5=T,\8<!QU5AGD?0T >>^&=)N_$'P_32I1;)ITU],990[&0HMTS%0NW&2
M5QG/ /2NHT_0[J'Q!X@N[L6[6FJ^7M1'8LH2/80?E Y'/!X]ZV;.TL[*-HK*
MW@@0-\R0H%&?<#O5B@#B[;PAJ'_"-6OAB]FMI=+MIHR+A6;S9(8W#JA3;@'@
M D,>!TJ*Y\):U#:^)=,T^>Q?3M:,TRM<,ZR02RKAQ@ AE)Y'((ST-=E>7EMI
M]I+=WD\<%O$-SR2' 45G-XET^*.*2=;N"*5UCCDFM9$5F8@*.1QDD=<4 9:^
M']9M=:TS4[6:Q>2+3O[/N5EW@ ;@P= ,YY!X)&?45EVO@K7-.TG1'L[ZQ_M;
M299RF]7\F:.9B61B.0>F"!VZ5Z!10!R^JZ'K.J:78M+<V9U*VU"*^V880C9_
MRS!Y;&.^.3V X%?6_"M[KMR)+E+!9XIXI+348F9)[<*%W@#;R"0^ 6Q\WM78
M44 9&EW6JS:OJL-ZMHUG$Z?9)+?=G!SN5\\%A@'CCYJ@N-(OG\:VVM1_9S;0
MV,EJ4:1@Y+,K9^Z1CY<=>]7M:UFTT'3FO[XRB!6528XRYRQ '3IR1R>*O[E#
M!=PW$9 SSC_)% '#'PAJY\)-I&^R\YM3^V[_ #7V[?/\[;]SKV_7VK1AT#5-
M,U+69=->T:VU9O.9)W8&WF*[6884[U. <';TZ\\=310!Q=KX.O/#VI:9>:!+
M;R+;Z>NGW$%VS()$5MP<,H.&R3QC!SVJK%X+URVTV"6VU"RCU:SU*>]MFV,8
MG64MNC?O@ANW3'?K7>[E+%=PW  D9Y /_P"HU0O]9M-.OK"SN#*)KZ4Q0[8R
M5+!2W+=!P#0!AZSHFO:YX5N+&[GL!?7$L3$1EQ#$J.KX!(+,3MZG'7VY9XD\
M+7?B/S4GAL5<%'L[U9&6>S8 ;MI"_-R"1R,YY]NOHH R+*YU5_$6H6UP+5].
MC1#;R1;O,5L<K)G@GJ>.@QGJ*IZMHVJ77B:UU&UGM&M8[9X##<ACY3DY\U .
M"V/EY(X[\FNB9E499@!D#)/<\"J%MK-I=:S>:5$9?M5HB22AHRHP^<8)Z_=/
M3B@#A(=*U/0+_P  Z7(]G/=6OVN,;69491#ZX)SCGI[>]2^+='GL-"U'496A
M_M#4M6LI&"DF- DD:(N< G &2<#J>*[Z;3[*XN([B>TMY9XO]7*\89D^A(R*
M+JQM+Y%2\M8+A%.0LT8< ^O- '.:IX;U+5[B^OVNHK"^?3GL;1H'9_*W'<SE
ML*<DA1P. "<\\5[+PWK5MK,.HG^RHU72S8M;0;PJG=N!!QT)[XX]#UKHKK6+
M&PNH['+R73)O6VMXR[A.FXA1\J]LG IUCK%GJ-S<6T#2"XME1IHI(F1D#9VY
M# ==IH YI?"VKQ> M,T..YM!=63P[P68PW,:-DH_&0&'48/X@U%<^#=4O;7Q
M5!-=6,:ZU%&(Q$C?NG6-4P<_PC;^/7 Z5W-% '+7>C:Y+K&CZQ$^GF\MH);>
MXB<N(]KE3E#@DD%1UQG/:JNG^%]4M-&?3KM-+U"WFO;B:>"8,$DCD9F')5L,
M"0>GX]Z[.B@#C]/T[5_"]AI.FV#VLUNUX_G02L[O' SY"Q-W"*>2W7';(%=%
MJT%U<V#16BVSNS+OCN1^[D3/S*>#U&1T-7J* .!E\"7*:+>Z?8BSMX+G4(;M
M+,RNT,"H49E7Y?XBI., #/M5J+P=>+I6L>'VGA30KQ3]D578RV989*CC!0-R
M!D8'Z=I10!SFE6/B:6V:WU^\T]E6)HU:S1]TQ(QO?=P..P[GKQBL:+PAKUKH
MWA\VUY8+JVA Q0;@YAFB*A&5SU!( / X([]:[&;4K6WEECDEP88_-E(&1&O8
MMZ9P<#J:D2[B>=8 6\TQB4H5.54]"WIG!X/H?0T <YJNB:WJMCIOGSV374&H
MPWLJAG6-5C((1."3GU/<GCL(+_PA=ZI>>)3<3PPP:M# D+Q.6>%XLE6(( /)
M!Z]JV8_%.CR^(V\/K=,-45"Y@:%U^7&<AB,'CWI-6\5:-HFHV>G7UV4O;PX@
M@CB>1WYQT4''/K[^E %2SM?%SV$ZZE>:6+I82D!MT?9(_9Y-W3I]T#N?:J$'
MAZ\T&36-5TM--TV6Y@0+:AW>V\X$YD8!5()! PH[>]=D#N4$9Y&>1B@D @$@
M9X'O0!4M/.OM&@^WPB*>>W7SXE/"LR_,!]"37%Q^$/$46@:=H8NM-DM=,O89
M[>Y<OYCQQON"L@& >V03GVZUZ!10!R$&@^(]*U>_&EW]A_9>H3FY?[0CF:WD
M;&\Q@<,">0">#Z]S6O"ESK-^DTJ6:2V]S'+::BCLMS#&I4LA 7YLX8<MCYNG
M'.[H^O:=KR7;:=.91:7#6TV4*[9%ZCD<]>M7KB>.UMI;B8D11*7<A2Q  R>!
MR: ..U6TN-$7Q?K5Y)9I:ZA;QK%N!DV%4\L;U( ()89YP._'-5- 6_TS4-/5
MH="O T0M8Y+34)I94CQGY0X("9 S@CMUP!77Z/J]AXCTB/4+!C-93[E1GC*[
MP"5/##.,@UE+KGAC1)=6C@@CM9-/5'NUM[,J2&Q@C:OS]1TSB@#+C\(ZO'X7
ML-*WV)EMM4%\7\U]K*)S+M^[UYQ^OM5S4/"UUJFL6M]/'90W5K>K-%J$#L)_
M)#9\IAM 8$97DXP<X]>BL]5L[YD6WEW&2%9X\C'F1L 0Z^HY'T[]15R@#(T:
MZU2XN]334%M##%<%;66VW89/[K;NK#C)'&21V-03Z1>OXWM]:0VYMHK&2T*,
M[!R6=6S]W'\..O>KVM:S::#IKW]\91 K*I,<9<Y8@#ITY(Y/%:% ''V'AS5+
M/1);":+3+I)]0FN9X)F8QRQ2%VV<H<$,RGH<[>U5T\%7MGH^GVUC/;H]EJW]
MH0V\KNT44>&'E*V,X 8D''6NW9@B%CG &3@$G\AUK!'C'26T2WU<-<?9+BX^
MS1GR&SO\PQ\C^$;AWQ0!GZMX5O-9OX;BX2Q2YM[J.6VU*%F2>.-2"R;=O(.&
M'+8PW0XYV-)NM4FU358;Y;1K6*1?LDMONR5.<J^>K# SCCYL=JUZ* .2UOPY
MJVH:S?SP7-FUK=Z>;1!<!BULQ# L@'!W;ADY!X'7&*;IWAS5[74O#UU.]DXT
MS3WLY CN-Y8(,C*]M@^N>U=?10!P2>"]7AM+:X@N;--3LM5GO[?+,T3K*6W1
MO\H(X;&0#TZ5M:)H^J6GB35]6OWLPFH) !% 68H8U(^\0,CGT_*NCJMJ%ZFG
M6$UY)%/*D2[BD$9D=OHHY- &#K&A:K>^(OMMO<6C6C6+6WEW(8F!R3F1 ."2
M" >1TZ]JI67A;5[:U\(Q22V+G1,B7:SC>/*,8V_*>QSDX]/>NT!R :* ,'1-
M(O-/US7;VX,!BU&=)HQ&Y++MC5,'(']W/XTR]T2]B\6Q^(--:!Y'M?LES;SN
M45U#;E96"MA@21C'(/:MF[O8+*UGN)F;9 GF.$4NP7GG:.>Q_*FZ=?P:KIEK
MJ%L6,%U$LT>X8.UAD9'T- '+3^#KM=.@:UGMSJ UG^UYO,W"-W).4!'( 4@
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MF7EHC@13,>I(QD9P,[2,]\U9GT*WGURUU8S3I<6L;11*A4($;&X8QWP/RXH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M#;/=1NJE6EWN&8CH3[^E8.DP64/@WP'J2+$+UM4AA-SQYA3]XI3=UVX &.E
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MX3D=1UQ[4 >HL]X-6C1?LWV$PL6RQ\[S,C&!TVXSGOG%6$FBD=D25&93A@K
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MX/L]OXG;J!MC3[6H/T&W]*WI/[.B^)3R6B62O+H2&R(50'D$K@%/4].G;VH
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M#PPK"9F$@PRJ!DY';BL73==6/PS;Z_J;R*=0\MHH%YVB0@11J/[Q#+D^I/(
M& #>%G:A@PMH0P& 0@R!1!:6ULSM!;Q1%^6,:!=WUQUK%N/&.F6FG:G>7*W,
M7]F.([J(Q;GC) 8?=R,$$'.<>]6+/Q+8WNK2::JW$,Z0?:%,\)198\X+*3U
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M+ $$$C^$\=15?4O$%IIMTUJT<\]PELUU)'"H)2('!8Y([]ADG'2@#5 "@
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M.Y9B3S@ ':.3Z^V77VCZJ^A>%;JWM'-YH\D4DUDSJ&=1&8W"G.W< 21SBNT
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M)%/HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
G"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>35
<FILENAME>exhibit1018-arvinasxcons003.jpg
<TEXT>
begin 644 exhibit1018-arvinasxcons003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=S",;5)QT!/ &3FL-M(UFQN+2\CTJ6Z,&O7=X88I8@QBD2158;F _C'&<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M;RA+G&TOC:#GCKUXZ\4 :]%85YXQT6QN+ZWFGF,UBJM<1QVLKE%()W853\N
M23T''/(K8@N(;FUCN89%>"5!(C@\,I&0?RH EHK)A\2Z5/<6L*7##[62+:1X
MF6.<@9PCD8/'(YY'(S6 VI7'B'Q/K&D07VH:>;)8!;2PV[@!R&9F?<N"#@ !
MN".G7- ':T5AZAXCBL/$FGZ*T%PTEW')(94A9E 7 XP#SEAGL!UZUA:!XL@L
MAJD6LZA<2LFLS6L<SPLRQKN"H'9%VH"3@9Q0!W-%8O\ :%DOBBYA;4YUF@L1
M)+:.NV%$W'][DKUZCKT'2K=EK%I?SB&'S@YB$R^9 Z!D)P""P /\Z +]%4M6
MOO[-TR>Z5/,D4!8H_P#GI(QVHOXL0/QK(\$ZS=:OH31ZD5_M6PG>SO0!@&1#
M]X>Q&#^- '245C77BK1[,N9KEQ&D_P!F:5879!+_ ',@$9[?7CKQ4<OC'1(;
MY[)[B;[2AB#QK;2DKYAPI/R]/?H.,]: -VBLE_$NEQWD%L\[J;B8V\4IB81/
M*,_('QMSP1UZ@CK1<>)=+M;F.&:=U$D_V99O*;RO-SC9OQM!SQUZ\=>* -:B
MN?N?&V@VHO&EN9L64OE7)6UE;R3@'+87A<$?,>/>K5KXDTN\U4:;#.YN&C,L
M>Z%U25 0"4<C:X&1]TGK0!K45D#Q-I1O+>V\]PUR66W=HG$<Q7DA7QM)P.QY
M[9JK'XWT"4Q;+N4I)<?9?,^S2!$EW;=K-MPI)X&<9H Z&BL.Q\20WWB?4M&6
MWN%:R6+,C0L%9F#$\XP!@#!.,\XS5^\U2UL9HX)6D>>16=(8HVD<JN,G"@G
MR.?<#O0!=HK$D\7:'%86=\U\/LUY+Y,+B-SF3.-IX^4\'@X/!JU#K=G<Z(VK
MP"X>V57;'D.LAVD@C80&SD'M0!HT5P-[XKEO=-\)ZQ#/<6=O>WT:7$)C*JR-
M$[XR5RW0<J<'WKJ+/Q)I=]9W5U%.Z):2>5.LT+QO&_& 48!LG(QQSD8H UJ*
MSK#6['4;RXLX))%NK<*989HFC=5;HV& R#ZBL>XU>[U7QI+X=L;AK6"RMEGO
M;A%!D9G/R1KN! XR2<$]ACK0!U-%9,5I?V6JI*VI23:8+>3S$G"923*E6W
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MXLP!YDX#!EDDR"%'!"YP<GKTKMM/T2#3=2U"^BGG>6_=7G$A4@LJA01@#&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMVK03GRY00V5S@[2"A'?/'2ET[Q7?W&H:%%>:=!#;:S:M+ \<Y9T98PY##:
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M9EBNHC&67JN>A'N#@UDZ=I?B5;.2#5M6L[HI"T4)A@:,R$C&^4Y.3CL !^F
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M+"9UWHBL6^0_=)R!R1@X[9Q5ZD "@   #@ 4M !1110 4444 %%%% !1110
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M_!-_?7,S7,NI6BR.C[=QWD;L#OQUH [W2+J&]^TRKID]A/',8I5GA5&8C!W
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M&1@"K*<@CU%.KDOAO-))X.BA<EEM;B>VB8]XTE95_( #\*ZV@ HHHH ****
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M''2KL=]:F9+5KRW:Z*@^6KC<>,Y"YSBD;4K!(7F>]MEB1]CN95 5O0G/!]J
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M=FA=)60KN&&'RD9!'!!X-:%9T-XT=YJ375_8FUA*%%4[6@&WGS"3CDY(Z<4
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M](U1HO$/A^_U.U73--GT4PVR2-B*"?>"RY/3<BKMSU Q7HI (P0#00",$9%
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MW0;@.XR#D]!CFNPL_#6H1V":9?:Q'=Z:B"+R_L2I*Z 8VL^XCIU(4'W!KI<
M]A0!POVZW/CSP[(DBO\ \2:?"@\DDQ$ #U.#CZ5@:/JEA-JG@B>V=(;=)+J(
M6D:LWV8M$V(W<Y)D)Z@X^G>O6J* /)I)Y$\,:U!"KR&U\227&H6Z(2_V7[1N
M.1Z%<'W /O6YJ)M-1\7'4K">WFT_^QYDOYD8-$_(,2L>A;[Q'<#ZUWM(  ,
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MBO0M0^P2"WM+"6"8F2/*N^S'&[G[A_,4 8 N8]9TO7]4UN'6(8].OKG]Y:7
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MQ[#(! [D5NWNGZC'X\L]7M[59[4Z>]I*?-"F,F17S@]> 1QW].M<\/#^M?\
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MU:2"[L735(T4QR\,@N_+*X1LM\HP01@GIFNMM_%=C)/J<-U#<V#Z=$L\PND
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M+V6HZ?H45MJ=S+<3(\FQYG#R"+<=@=AP6"XR?7UZULT %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M45@^+M5O]#T8:G9B Q6\J&[$L;.1"6 =EPPY4'/.>E &]17'GQ7<P^)-;TV:
M2V:*VM!<61CA;=(<<J26PQ!9!@8SO'2DNM4\4?\ "21Z';2Z4L[:7]K,TD$F
MT2"15(P'Z<G'IGOC! .H@U"TN;RZM(9T>XM2HGC'6,L,KGZCFK-<)JVO:O\
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MCI5L+B_NHK>(L$#2-C+$X 'J:K^(-0N-*T*ZOK6V>XEB"GRT0N=NX!FVCEL
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M5\=<*,G^5 &7)X3T*2^EO#IT8FF;?+M9E61NY90=K$^XYK950JA5 "@8  X
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M%IUK#<P22P.Q8.KMM8!QUVCGMZ'/'2Z'J)U?0-.U)D$9N[6*<H#G:74-C]:
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MP/*0@#YL8Y/&.3DYJ35KN+P5HMDEO&8K W+"YN5@,@MPV]RY1,8!? XX&>E
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MD_M/6KU+X*=4MT@9##D1J@8 CGDX8_I6CHNF_P!CZ)9:9YWG+:0I CE=I*J
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M/:IX_#>D0VUO;PV*116[,T B)3RBW4J0<KGV]3ZU?MK:"SMTM[:)8HD^ZBC
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MG6TD%JP:",QC;&0,#:.W'% '"ZOJVH:.WQ!N;*>=Y+:.U: ,[2>2&3YF4'.
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M+G[L:X.\@9)Y'I2:A\0'M_$T6B6&C2:A-<V O;5HIPOF@@D [@ O0\Y_4XH
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M 0_Q;-O\73&>*N444 %%%% !1110 5Y4D^F1?%:7Q2_B;PV+5H/LQA_M)?,
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M.#7FVDV-M::UX<U2[\9>%9I].>8W3B^R\V_/SEB<NV#WQC _#UO_ (1S0_\
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M,2-I(.-H&T$\GGCWKT[_ (1S0_\ H#:=_P" J?X4?\(YH?\ T!M._P# 5/\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MD L 3T!/6O(M8DL+;P5X\LI&MXYEU:1XH#@,,K$0RK],G(]ZV?$\C0WNHZQ
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M'3GCCB&7"HQ*C"L=V"3_  @\<57DDLSJ'C:U,^GM'+HL<HBM<"/>J2Y(&>2
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M\1Z=+?O8R/+;7"P?:0ES&8]T0X+C/8=^X[@5''XHTV6ZCME^T>=- UQ;JT#
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M&_/K2S6=K<2))-;0R2)]QG0$K]">E9*^*].=M0C1;LSV,/GO"ULZ.\9SAD#
M;@2",]*G\.:Q_;V@66I&%X6N(4D*,I !90>,]1SUH M?V5IVUE^P6NUSEAY*
MX8^IXIW]FV/FI)]BM_,0 *WE+E<=,''%5O$+RQ>&]3E@G>":.UD=)(\;E(4D
M$9^E9ND^((8/#VA)=//<W]UIT=QLC4O(X"*7<_BP^I/&: -QK"S>\%XUI ;I
M1@3&,;P/][K2K96BW#7"VL(G;K((QN/X]:S8O%.DSOI0AGDD&JJ6LW6)MLF
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M2UDC1$&2S%2 /S-<I:Q:O!'X;M)=*NVLX]+$$_V<JDB7 "#:[;@0F%)^4X)
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M;E0F-_*DL>/GZ'.?;I3+?PIJ4:>&Q-J=M(=%/&VV*B5?*,0'WS@X.<\\]@*
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MN5\[S+=/-:1X8V'",[ %N0<$\XH W**CN)##;2RJA<HA8*.K8'2O.FU?4?\
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MKB1D52'!8M][C"XXZE;S4KC0/$.EZCJ%])-INH6312>7(QB6Y5=X9%ST=0P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MWJE?Z[8RZ;=?V?KVF0W"0B19I95=(P>C,-P^4]CF@ ;PGHK6-Y9-:.T%[/\
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MKS]:T+S5-/T]D6]OK:V+_=$TJIGG'&3ZTVZUG2[%I%N]1M(#$@>02SJI12<
MG)X&2* (!X>TU;RZNQ%,+B[B6&>3[3)ET&<#[W;)Z>IJ)/"NCQV^GVZVT@BT
MY@]HHN),1$# Q\WH2.>QI=0\4:1IL^FQ3WT .H,?(;S!M*[2V_/3;QC/J15Q
M]5TZ.\6T>_M5N68*L+3*')(R!C.<D<T 9X\'Z"-;?6%T]5O7<2.RR,$9QT8I
MG:6[YQG//6GOX5T>6'4(7MI&CU%MUVIN),2G&.?F] !QV%.@\3:5<ZU?:5%>
MP?:;-5,H,@X)W$CKR5"Y/IFI-.OECT."ZO\ 5+*X^7Y[N(A(7.<<<D>W7K0
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M&)3Q1!=@>2?]<MQY^[SAWVD$MOZ8)YK2U!;IM:\>6%GYBZA>V,)M JD&3$+
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M"VA6*WBCBB&2$C4*HR<G@>YS6+XUBU"?P5K$6EAS>/;,(Q']X^H'OC.*WJ*
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MKD<XW$'/7KWK0N=)UB+Q'I?B)8X[F=+:2UO+6)P,([!QY9; )4@#G&1SQTH
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M3[%K2R(2/4UE!:2)3\H\O;D/C )S@=>>]*^\-:X_A?Q/H\5I"YO[^6XMI1.
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MFM^!'C@C21@SJH#,%V@G')QVKSRW\.>(H=#T?2!86VW2]66Y\]KD 31B1WR
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M>Z@+1K) "N[:06&6"\D#/ZBDM?%,E]XN@TZUM'DL)=.6]2X5D^=78!6P2"%
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MWD8Y)S6Q;Z9XAT?6M3@M-.L;W3[^Z:ZBNIIMC6S/]X,N"7 .2,?3([ &Q?\
MBFWLTO9(+2ZO8K$*;I[8*VS(#8 )!8A2&('8^O%,74+%_&;0):7AU :9YRN6
MQ&\.\<!2V-V[N0#[XK-@T_Q'H7B'5#IUI:WVGZG*MP));CRC;2[%1MPP=RG:
M",?2KJZ;J">/4U1H3):+I?V0RAE!:3S ^=N>G&/K[<T <J)[;5]"US6->L-4
M*V-]=9DMIU1_)0E/*^60' 4<CH3D@DUVW]MPPK;6EG:W%U<&T%P($8;DBZ L
MS$<D\#DDD'T)KG8M!U?_ (0GQ+I3V06ZU&>[D@'FJ5Q,25R<\8SS^F:EDTS7
M]+URRUK3;&*[$FG1V-Y9R7 C9"A)5U;!!'S,"* ->/Q5!=0V+6=A>S2WEL]R
MD31B-D12 0VX@ Y8 #O].:H3^,VGD\,RZ98SW%KK#.V[**X41LVW#,/FR!DY
MQP<9S3[^Q\07&K:>]Q;VM[8FW=9[;SMD<<Q8%6((_>*%^49'7G&:R-+\-:]I
M^C>$5:TMGN=&FD$L0N,!D:-DW;MOJV<<\4 ;D&M:1::OXEN)8[FUDL4A>^EF
M<E&782I10QQP.P!)/K5M/$D:ZG:Z?=V-U:3WD;26HEV$2[1EDR&.' YP?SZU
M@:EX3O\ 6KCQA!*HMH=6AMUMI]X.&B7^( Y +8_#/3I6@VG:EK.H:'>:E9?9
M6TLO-*%E5O.E*% $P?N\DY;!X QUP -MO'EI<P65U_9FHQV=U=FR^T2*@6.7
M>4 8;LX+#J 0,]<YK47Q#%+>30V]K//'!=+:32QE<1N<=1G.!N'./TYKE8_#
MFLIX/L=--B/M,&L"]8"9-OEBX,O!SUP<8]:N7OAR\N_$,6JVMDVG:DEXA>]@
MF CN+8-RLJ Y9MORC@\X.1V .VK,OM6CAOTTR&"6YO)(6F,43!2D8.-Q8D8R
M>!W)^A(9I.I7U[>ZG;WMBEN+6?9$\<WF"5#R">/E;&"1VW"LN_TW5K'QNNO:
M?;)>VUQ9BSN(#*(WC*N65U)X(^8@CKWYH S?!>N167A*%KDSM/<:A=1PQ32#
MS#B5SAF9L#"CDD]NY(SKVOC;3KR'Y(Y5NOMWV V[L@(FVEL;L[2"H)!!YZ=>
M*YVW\,>([+2[&[AM;-]0L-1NK@6CSY2>*9F++NVX5N1@^W/I6Y?:=>ZQH\<.
MK>'[26&><>=81S*6BC"MAE?Y07W8Z$8'0^H!)J^L63VNE2:CIVH1^;JD<$2!
MPICF$A56?:_*$@GN",<58U'Q7::>VJ8MKBX32D62]:$+^[#+NX!(R0OS'';W
MXK!?PWK4>@Z799FN_LFLQWB">=6DBMD?*HS$_,V/P[9XJOJ-M?7^O^(#IVD"
M^L+KR[2[%OJ"0^:53YE<,I^;#;<J1Q@=10!T3>+XOMMI9Q:5J$MQ>6K74"*(
M_F4$#&=^ ?F!Y('OGBG6GB^ROM/T^XA@F$U]-);QVTA5761-V]6)..-AZ$YX
MQ5"SAN[_ ,2:/K<&FO#8P:?-;/&9$RC%UP!@X*CRR,C@Y!'%4;3PS<OX?&EZ
MOH:7EN]]<W$B+,H>,.[.CHV1AANP>1WY/< [6PNS?6BSFWEMR693%,!N4JQ4
MYP2.W8UG^*]8GT#PMJ.J6]OY\MO"SJNX  XZG/8>W-96FOKGAW3]&L+B(Z@L
MMR\4LLUP#-#&6_=CI^\8*?F(Z!3UZUK>*]+GUKPGJNFVQ03W-L\<>\X&XCC)
MH I77B[[#-8V<NCZE+>WEO)-%%&L9+[ -PR'P#R#^/KQ1<^,K:TBGGFT^^2W
MMI(8KF1E4>4\@7 QNR<;USC.,\9Q5<V&KW'B7P[J,VGK%'9VT\5P%G5MAD"
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M+;3J'CD (# ]^:L5S7P]_P"2>:#_ ->:?RKI: "BBB@ HHHH **** "BBB@
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M]?Q!]HO)636XEBF55 \O:NU2I^GKGFM[[5 +T6?F+]H,9E\OOMSC/YG^=34
M8+^'KI[<POJ\LR26OV:=9X$=9!S\VT8 ;#8]/4&FV6C76FZOI\5E>7 TFTL1
M;&UDVE/EX4@_>+=,GI@>]=!61>:VUIXGTW1S:EEOHII%G\S[OE@$C;CG[PH
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ME^#!I%T4M=8OAI(F,\>F$)Y:,3NP&QNVYYVYQZYK?U":ZM[":6RM!=W*KF.
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M".-W #%1TSCBM*BB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI +'N2<  =222  .234]<KXW@OO)T>_L[::[CT_48[FXMX5W.\8# E5_B(+
MX]J &:1KTEUXUUZWDO9#86EI!*L<\7E>06+[LY4'& #D]JV[;7],NKD6\=SB
M5HC,BRQM'OC'5EW ;ATY&>HK@]9L-0\1WWBM=.L[V(7^DP1V\L]NT*R,C.63
MY@""0<<XZ^E;<XE\0ZQX9OH;*[M3I[R3W7G6[QF(&,J8QD#<2Q'W<C"Y],@&
MJOC3PZX@9=4CV3RF%)-C;-X)&TMC"G(.,D9[59M/$FCWOVWR;Y/]"7?<>8K1
M^6N"0WS ?+@'YAQQUK@_L=Y_PKP6ATV^^T?VWY_E?9)-WE_:_,W8V]-G/Z5I
M:T+X>)O$%W9Z1+>B30DBBCFMF\J>0/(2AR,'AAQWZ4 =;:Z_IEY++%%<D21P
MB=DEC>,^6<X<!@,KP>1Q6=I_B/2+/0].ENM>%VET[1PW<RA#,VYNP  Q@C.!
MTK$T7[0OCF'46LM6:VET;RC/<6I3#B3<5V8&SCHH SVSUK,T^SO(_"'@RWDT
MV^6:TU@33QFTDS$@,OS$8X'SK^?L: /0M+UK3]9CF>PN/-\B3RI5*,C(V,X*
ML 1P1VI-1UO3=)DMX[^\C@>X8K$'S\Q )_D#6-X?CF3QGXJF>VN(X;B6W:*2
M2%E60+$%;!(P<$8H\6Q2RZMX8:*VN)E@U(32M%"SB-/+=<D@''+"@#3@\3:/
M<Z;/J$=ZOV:WD\F5G1E9'R!M*D!LG(P,<Y&*&\3:/'9WMU+>B**R.VY\V-D:
M(D9&5(#<@Y''-<;=_;[:X\53PZ/<7"3ZG:R)OLV?]V%C5Y8U(P[*5) ]0#R*
MK7EK>O;>/(X]-U60:A9Q?97E@8M,?**_@<]L#'<"@#MAXNT(W+V_]H+YJQ^:
M%\M\NN<93CY^3C"Y.:LVVOZ7=Z6FI6]VLEJ[;%8*VXOG&W;C=NSQMQFN=D25
M_%_A2X6SN_)@L+A)9/LS@1LPCVACC@_*U8'V/4X+%[^/2]0F2T\1W-Y):QH\
M4LL$@=0\?0L0'S@>] '?P^(=*N+:2>*ZRL4WD.GEN)%D_N%"-V[GIBK=E?6^
MH1/);.S*CF-@R,A5AU!# $5Q<]AIFI:9+<)H^LV*7=U$QNE607:R(K;9MIW,
M O"\CN>,8S;TK6M0T/1V?7(+N]#:@;>*[@L]CO%@8FE3C:!@J3CL..: .PD=
M8HVD;=M4$G:I8_@!R:R4\4Z-):V5REX6@OI/*MG$+D2OR-HXZ\'\CZ5L5YK?
M>&-7>'6]+M$:*ULKDZKI4@XW3M\ZQCV5Q)D?[:T =Z^K6,;W2O,5-J5$N48
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MWGC&33UUN"ZTX"_TNT^V^2D^4G@P?F5BH(P5(((Z^M '5TUW2-"\C*JCJS'
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M1L[N5XZ.=P [#!)/IUM]>V^G64MW=2".",99B,]\  =R20 />H-.U:+49KJ
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M*+;[Q%&.[$G))/IP!BKDFCZC)XKT[6"+41VUE);/'YK9)<J<CY>@V?K7144
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M_3%=EI-UJ%MXWU'1[G4);VW^Q17D9F1%,;,[JRC:H^7Y1US]:E?P3I3:?<6
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M7M#;QA+B);@H0Q"Y#8Z$$=.F>:Z[P_HL4.E:1=7ANY)[*U58HK@<P-L"M@
MD\$9.3CH>><OP?X=,F@F#5$O447\UPUG,-L;'SF=&Z9(^Z<9QD<B@"S:*[_$
M7Q&(Y&B<Z;:;74 E3F7GGBL_0O$FH:EIOA"TN;QEN=6MYIY[E54,WE@':O&
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M6C3B&486?/IF/YAG^('UK4^(6A3ZI\.]1TO2X1YBQHT4"#&X(RMM ^BX ^E
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M[,(!:-&\DH7;G[-PI)]^@]:@U;4]->43P3V]L8?%$1F69]T^X2JKR,2?D3'
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MM5N?^7B+H#]\=^17G<\/AC4+#6]4TS5OM[2:++'-&GE>2J@$H9%5!AP>F><
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M<[5 R<G ZFHTMH(Y9)4@C623[[J@!;ZGO7$^,H]0TBPM[N'6;\37.JPQ$+(
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M @ A5 R ,#]*DKB_%_B.^T?5+&XML?V783QG53_L2Y1?^^?O$>ZT =?%:V\
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M3Y)8&GB0^8JK&I9AMR0V6)'H ":U8-9LX+'38H3<W<MS;"6"/[TTD85<NQ)
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M6\B,S*>6"E3O(.#[UVE% ')ZE::I<Z]X5NVT\E;2::2Y\EUVPAXV51R06QD
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MC/*^[<>&&T'>?7''I3M;\&)KNLW5Y=749@GL/L:P^2=T9#[UD#[OO!L'IVH
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M;[8-C.X4HK.=QR0">@&3S[4 8.FZP/#^G>*K[R_W:^(7623866%6$0:1@O)
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MB$)3;E A&=QR, =A0!4T_P 1:K=ZAI9_LYI;"_C+2,EO*AM#MW+N9OE<'ID
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MLN,GEAZ4 =)HMW<W^E0W=RL:M-EXPBD?NR?D)!)Y*X)';..U:%( %    '
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MZ\LHRYPPVGODCMB@#U6BN#U+4+S3?$;R:FMVVF3WT(MM0L[ABD!RB^3-$"
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M3RT,@^;)(49ZG&.]=?X=L;W3I-0MKO41=(9A+#$79VMT8?<+L<L,@D9Z9^E
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MW"E=@"IOYYSR,=N_6H/&<"/X$UR,F3":?,01(P.0A(R0<GIWZ]ZYJ:Q1M0\
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MF2_9][M%$Q02.TC$@$C)8DGGWH J3Z_9P1W$I),$$H@:3("M*2%V D]B<$\
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MU^ZMO* 5>"=N[!4Y/&2!TZKH=OXCEUS1&>ZU:+3;>P6;59[N1E$UP?FV!7[
M]=H QQGI0!Z517DGAN_U>Y\,3^,[O6K\:=:7-U>)9ERWVB, JL9)/"@@8]]Q
M/8A8=:\03GP5-]NF;5M9O/M=Q#&Q$26?4KLZ8VD')YSGF@#UJBO%K_QG?6MM
MXTU:'4+IU>[_ +-TJ 2EE1QP\B@].H(/N!6WK5SK*Z_X+\.V6IW!O!!]IU"8
M3G$B*!\SX/(+!N._3O0!Z=@9SBL76/$UMHNK:3ILMO<2SZI*8H3$%(7&-Q;)
M!  .> :\VTSQEJNF^!]=UT7\U]->ZH;;2A=,&VJ255L8  X8X  RM:>@6PU#
MXL,&O9[U- L!"\TTI??=29WLN>F5W# X&V@#T/5M2BT?2;K4IXY)(;6)I9%C
MV[MJC)QD@=!ZUAQ^.;"7P:_BDV%^FG*NX!UC#LN=NX#?TS[Y/:LCXQ:E):^"
M#IUODW6J7$=I&HZD$Y/\L?\  JROB1:FR\'>'/!%BP$M_/#:# ZHF,L?^!%#
M^= '1CXD::#9I)INJ137]J;JQB:)"URN,A5VN?F(Z XZCU%:5OXKBNI]-BCT
MW4 -0@:6*1X@J*X#'RF.>'PK>W'6LZ'P&LWB*SUC5KY;DV$'V>RMK>$PQ0KC
M&?O,2>>N1V]*ZM+2WC:)DA13$FR/ P$7T [=!^5 #+&^@U&U$\#';N*,K##(
MRG#*P[$$$59KD?#DKQ^.O&5J#BV26UF4=@[P_/\ ^@J:ZZ@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ JIJ>EV.LV+V6HVR7%L^"4?U'((/4$>HJW10!D6OAC1K.>:>*Q1I9
MH?(E>5FD:1.?E8L3GJ1S1HWA?1?#S2-I5A';-)PQ#,QQG.!DG SV'%:]% %>
M&RMK>ZN;J&%$GN2IF<#ERHP,_0<5FQ^$M!BUMM933(5OW;>THS@M_>VYV[O?
M&:VJ* ,Z/0=,CDOI!:JQO_\ CZ$C,XFXQ\P)(Z<?3BDL]&L-)7S+.UD:2.+R
MXPTK2,J==BEV^4<#@$#@>E:5% '(>"?"XTOPWIL&IV;)?6A9MC3F2-7)/SJH
M8J#@]< ]:U9_"6@W.M#6)M,A:_!!,O(W$="R@X8CC!(/2MJB@#&OO"FB:C>S
MWEU8JT\\7E3,KLGFKC&'"D!L#IG.*TK.SM]/LXK2TB6&WA4)'&O10.U3T4 9
M=OX=TFUN/.AM A\TSB,.WEK(>KB/.T-R>0,\U-9Z18V%[=7EM"R7%V0T[F1F
M\P@8!()QP./I5ZB@#/U+1--U=[:2_M5F>V8O"^2I0D8."".".HZ&JC^#_#[Z
M9<:<VE6_V2>4S21 $#?G.0<Y7DG&,8R<5MT4 9#>%M$?1&T9].B:P8[FB;)R
MW]XMG=N]\YK(TGPX=/\ %VI.FF[-)N+&*V4LZOO*ERVX%BQR' R?2NNHH P[
M3PAH-C+:2V^G(LEIN^SLSLQCR , DGC X';MBGMX4T5[*XLVLRUO<3_:)HS-
M)AY,YW'YNN0#]0/2MFB@#+U?P[I.O6D5MJEFMS'"P:,NS;T/J&!W _CS3;CP
MQHMUIEOITMA']EMF#P*A*&)A_$K A@>3R#DYK6HH SM-T+3-(FN)K&T6&6Y(
M:9\EF<@8R22?2B[T+3KZ]%[- PN?+\HRQ2O&S)G.UBI&X<G@Y%:-% &#K%MJ
M+P1:-IFG6HTVX@:":<RA!;+C;A8]IW?+G X&<9XK:@ACMH(X(4"11J$11T50
M, 5)10!GZEHFG:L\,EY;!Y8"3%,CM')'GKM=2&'X&I;?3+2VADB2(NLHVR&9
MVE9QZ,SDDCD\$]ZMT4 9ECX?TS32AM;<IY:%(@TKL(E/4("3L' X7'05#_PB
MNB_8#8_8S]F,WVCR_.DQYF=V[[W7//UYK9HH S/^$?TS[0TQMV9GE69U:9RC
M2+C#%"=I(P.<=AZ5!>>$=!O[F[N+K3DDDNU"SY=@LF!@$J#C..,XSCO6U10!
MG1Z'IT6HQ7\=MLN88?(C=78;8^NW&<8SSTZU4;P?X?:U-M_9L8B\_P"T@*S*
M5DR3N4@Y7[S<# Y/K6Y10!AMX/T PW,(TV-8[F599D1F4.ZXP>#[ _49ZU<&
MB:>-1>_,!:Z>'[.\CR,VZ/\ ND$X(Y)_&M"B@"GIFE6.C62V>GVZP0+R$4D_
MJ?RKFM \,G[7KLFK6$BK>:D]S&K3Y22,A=H=%;!(*DX(/45V-% %$:18KJ[:
ML(3]N:/RC+YC<IUVXSC&><8Z\U%'X?TJ-+Y!:*R7Y)NDD9G64D8)(8D=./PK
M3HH SK30]/LE8012 M'Y.]YW=U3^ZK,25'L"*FTS2[/1[%+*PA\FVCSLC#$A
M?89)P/:K=% %&;1]/N-5AU.6U1KV%/+24YR%SG'H>>1GH:AM_#FDVEQYT%H$
M(E,RQAV\M9#U=8\[0W)Y SR:U** (KFV@O+:6VN8DF@E4I)&ZY5@>H(JG9Z%
MI]B"+>*0'RO)#M.[LJ?W59B2H]@1T%:-% %/3-+LM&L4LM/A\FV3.R,,2%SR
M<9)Q4=YHFGW]Y'>3PL+F-#&LT4KQ/L/)4LI!*Y['BM"B@#,O/#VDW]E;6<]D
MGD6K!K=8R8_*(&!M*D$<<<5$/"FA"SO;0:9"+>]8-<(,X<C&#UXQ@=/2MBB@
M#)?PUI,F[-J0KQ"&15F<+(@S\K@'##D]<YR?6K T:P&JG4_(_P!,,/D&3>W^
MKZ[<9QC/.,=:O44 8$/@KP[ 8?+TQ L,WGPH7<I&_/*J3A>IX Q^52GPEH+:
MX=9.F0_;RP<RC(RPZ,5SM+#UQFMJB@""\L[?4+*:SNX5FMYD*21L.&4]15&+
MPWI4%Q:SQ6I26UC,<+"5\HIZCKW[YZUJT4 8TGA/0Y=+GTR73TDLYY3-)%([
M,"Y.2P).0<\Y%7-+TFQT6S%II]NL$();:"22?4DY)/3D^E7:* ,V30--FNI;
MB2W9GFD6653*^QW4 *S)G:2-J]1V'I4%QX4T*ZUD:O-IL+7WRDR\C<5^Z67.
M&([$@XQ6S10!F7?A_3+V\>[FMCY\D?E2LDC)YJ?W7"D!QR>&SUK'U+0YKOQQ
MI=X+*0:?:V4L'FPS"(HS%",;6#8 4@_6NKHH R[KPYH][HYTFYL(9;$G=Y39
M^]G.[/7=DDYSG)/-3Z7I-CHUF+33[=8(02VT$DD^I)Y)]S5VB@#-N] TR^O&
MNY[<_:'C\IWCD>,R)_=?:1N'L<TMWH>G7KVCSV^39D-;A'9!$0, J%( XX^E
M:-% $<\$5S;26\\:R0R(4=&Y#*1@@_A69#X7T>V:Q:&SV-8Y^S$2O^[R,''/
M.1QSVXZ5KT4 8S^%=&DL[NT>S+6]Y+Y]Q&9G(E?CYC\W7@?D/2II_#VF7,LD
MDT#N945)09GVRJO #C=AA]<]ZTZ* (+RS@O[.6TN4+P2KL= Q7<O<9!!Q3#I
M]L=-.GE&-L8_+V>8V=O3&[.?UJU10!QFN^$XTL=,L=.T6"\TJUE>22R:Y:-U
M8KA3&Q/ &6R,C.1[U+I7@^S:TNX+O3I+:PNE56L&OI)@2"3N8EL#L, XXYSQ
MCKJ* ,S4_#^E:SIR6&I6BW-O&0R"1F+*1T(;.X'WSFHYO"VAW&AC1I=-A?3U
M.X0G/#9SNSG.[D\YSS6O10!CCPKHJZ;#IRV(6UBE$RHLCC]X#D,3G)(P.23T
MJ?\ L/3_ +?/?"*074\0ADE$S@L@Z#KVR?S-:-% &'<>#O#]UI%OI<^FQO9V
MS;H(R[9B/^RV<K^!J?\ X1O2/+L8ULPB6+;[94=E$;<Y88/4Y/)Y.3ZUJT4
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MKWFDWTDTD;3D(Z.)!D-M/3S!QCL:['6+>>[T*]MH55YYK=XU!.T;F4CKV'-
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M%%<RYC"1*Z[@Y.[E<8Z<^WKR6GB_M]-CU(Z#;WNC1W4FI6Y@U(*@RS,KK$R
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M=627?V.2> !L/NVDA>I56X)]C@&LK4O#-U?:_'J4-HEEJ4-VC+J-O-M\VV#
MLDJC[Q*Y4#!'0Y'2G:/I?B30KJ\TNWCLY=*FNI+B"]:8B2!9&+,ACVG<02<'
M('//I0!?B\5O<:U=Z9;:)J$KV=PD%Q(#&%0,FX-][D8(Z<^N._+:E>6,_AS1
M+[3;.[MHD\1H# TA9V?SV#@C<0<L#@9Q75:)IM_9>(_$-[<0((+^:.6#;("W
MR1JA!';.W/>L.+PMK">&K:V,5O\ :[76O[26,S?+(GG-)MW8X;#8Y&,T ;%O
MXUM1)J4&J65SI=SI\0GDAN-C%XB<*RE20<GCKUXJ;3?%EIJ&O-HS1^7=?9_M
M,965)5=,X(RI.&!QD?D369K'A.[\1R:I>SNMC<W%BEI:*&WF/9)YNYR..7"\
M#/ ]\#7T.7Q'.0=;L[*T$:;2+:8R^>_][E1L7KQR>>V.0"'Q)KM[I.H:);6E
MF9EOKOR7;>H( 1FP >YV]:?=^*$@349;>QGNX=-.+QHBN4(4,RJ"?F*J03TZ
MX&3Q2>)]+O[^XT6[T^.&633[X3O'+(8PRE'0X(!Y&X'I6?;Z)J^DS>(+>UA@
MN;;5I7N8I&EV^1*ZA7#@C)7(!&,GMCO0!U-I>07]C#>VKB6">,2Q,O\ $I&0
M:\XU_7+W7/AYK]S=VKVQM;\PQF.7(&R=4V_*<GOG/!S7?Z'I<>B:%8Z7$Y=+
M2!(0YZM@8S^/6N-N_"^N/X6U[18X;5OM>HO<V\OGD;E>82?,-ORX QWR: .B
MA\50#4[ZRO[.>P:UM?MN^<J0\&2"_P I.,$<@\U%9>,[&[UNSTMHS')?1-+;
M,)4<-M&65@I.UL<XZ=>:IZMX<O-:\0WLTL:PV-YHKZ<S[P71V8MG;W SCKUJ
MYX='BE5@M=:M[&)+5=K7,$Q<W6!@':5&SU/)Y'2@"'QOJ]W8Q:3IEA,8+G5K
MY+3SU^]%&>79?]K' ^M7;KPO:-9>7923VMPI5EG2=]SD$'#G.7!Q@YSUIOBS
MP])K]C:M:3I!J-A<I=V<K@E1(O9@.=I&0:L6USK=S&L<^G164G'F2_:!*H]=
M@ R?^! ?CT(!7O/%$=NFI36]E/=V^F,5NY(BN5(4,P4$_,54@GIZ#)XIC^+H
M7U.WL;"PN;U[JQ^W6\D10)*F5'!+#'WN^/QJC#H>K:7)XAM+2*&YM-6FDN89
M7EVF"210'#C'*Y&1C)[8[TNF^&KK1O$&D26\8EL-/T@Z?O+@.[;D.[;Z?)Z]
MZ '0^/();"ROSI-\EG/<BTFF?8/(E+^7M(W98!N"0,<_4!U]XV-M=:M;P:%J
M5T^EE3<^7Y?"%=^X9;GCL.?85E?\(QK7_"&C2OL\'VH:K]LSYWR[/M'G8SCK
MCCIUJ:PDO_\ A,O&<=I9K,TOV55+RA0CF ?>_P!GZ9/M0!L/XNMY;6*XT^TG
MO(I+ ZAO&$41>F3QO//R^QR137\8VYDT9+73[RY_MBV:YM2@0 @*&P<MP<,.
MO'O6,OA'5;".RTN 6U]I<&EBU47$I017&3NEV;3NR",=QCMDFI-)\/:U:R^#
MFN+:W"Z/9R6]QY<^[.Z-4!7(&?NY/UXS0!>;QQ!'H?\ :DFFW:I'>FQNHRR9
MMI ^S+'."N2.1GJ*WEU#?K#Z<L#DQP+,\N1M7<2 /7)VM^5<[IVC+;:-K]CK
MXMX;74[VYF&9A@QR<XR<88 $T_PY;ZGIG@@W;R1WFJRP^;ON&\I7PH6/<?X?
MD52?<MZT =97._\ "6PB[M$DL;B.VN[U[&&9\ F5=W)4\A248 _3@9K6TJZF
MOM)M+JY@\B::)7>('(4D<C-<0_AKQ),]A+<V]A/>V>K_ &I[Q[EMT\67V@#9
M\@4,!M''% &K=>/([:#5;@Z-?M!I5QY-X^8_D "DL/F^;ALX&3@<XXK6O-82
M2\FTRTM9+V>. 33K'($V(V0HW$CYFPV![<D<9YN\\-:O<:)XPLE@A$FL7#26
MQ,W"@QHGS<<?=SQGK5VWTK6]*\57.JV=K;W-OJ5M#'<Q23[&@EB!4$'!W*0>
M>] $OPV=I/A[H[NS,S1L27.3]]NM=57/^"=*OM$\)6.FZBD*W$ 8'RI"X(+$
MCG YY]_K704 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MV( VB-,'/<L<< =NM &W17 P>,=0/A#1]7O8YHX)99H[^ZM(-Y@",ZJVSYL
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MPSP0<GO[4 =7117#ZGXDU2PU"-A<0R ZQ%9-!#'OC2%V"C<^.)><XSQQQWH
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M:6\NK7[&;C:JF.(YR%&,#).23GG'H!447A.&%]!87]T?[%0QVX(3YP4V?/\
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M+$;B54\V588P>K.QP *GH YF#P5;6UGHD$.H7J-H^Y;>4%-S(R[65OEQT[@
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M\GCDEM%LQ$JIL2-22N.,Y!8]36W10!FZ!HT7A_1+72H)I9H;9=D;2XW8]#@
M?I69'X,LXK6?3DN9_P"R)I_/:P(78"6W%0<9"%N2N?7G!Q72T4 9!T%3XH_M
MX7DXF^S?9?)POE[-V[TSG/?-/UW1(M=M8(9+B:W>WN([F&:';N1T.0<,"#WX
M(JU:RWDEQ=+<VR11)(! ZR[C*NT$DC'R\Y&.>E6J ,%?"Z+J&I7HU"[,NH6R
M6TNX(0%0$ CY>OS-USUJC)X$MQ::2EGJE_9WFEP_9X+R$IO:+ &QP5VL.!VZ
MUUE% %:PLEL+-+=9992,EI96R\C'DLQ]3[<#H,"K-%% !1110 4444 %%%%
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MCY?PH PO!G_(0\5_]AI__1457O&5U;6GA2^DNY[F&$A(R]LP63+.% !/ R2
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M9QD&.!X%*)]%Q@4 <1;R6^EZGX=T6^U7[?HT@NU2:?\ U<LRE=D;$DA@H+@
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MX3;#?Y;",(T4B[@ #C.3QR:O:?92VGCZT==.DM[6+1%M08XF,4;B0-Y8;&,
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MC<!(V.),G#$]>O7-3V#1:K;27$_@Z^AO+>TE287@/)*$-%$Q8EMQXR.,>^*
M.ML]7L[^<PP&;S!&)<20/'E"< C<!FKU<;X4LK_3M8DMH9[ZXT(6H,(U&$K-
M;2;A^Z5F ++MSZXP.:[*@#A-:\727_A3Q3-ICWEE<Z69(XY3 5R412>67 Y8
MC'WL 'BNBTSQ)IE]<?88[HF[CMQ.P>-D#)P"ZL0 RY[J2*X^_L=17P[XZTP:
M9>/->W4TULR1;EE#H@7:1U.0<^F.<5IW<=XWBS2[RVT^>58M'GB_>0LJ>:Q0
MJC$CC.T_2@#?M/$VDWT\4-O<.SS0M/#F%P)HUQED)'S]1TSU'K3/#7B*'Q+I
MSWD,$\2B:1 )8F7A790<D8)^7) SCH:Y'2(=1DU[PE?2Z3J4?DVUQ#=;X1''
M [+'A53("H-I ('( Y8UO^!(;JQT273[RSN+>6"[N"6D7"N&F=@5/<8(Y]Z
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MU\]U<-.T<4I@"R2@D[1L3/.,G [=>AJKX)CU&;3FO]8*/>X%H'4Y#QPDKO\
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ME^8?LZD@$ \GGMR:Z"Q\0G4H]%DLX894U& W#D3']U& ,D?+\QW,%P<=?8T
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M]?PZ=#*('.D07K%)O*9GEW L/D;(7:..GS<YK>?PQI[OJS,UQG55"7?[T_.
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M^HY^]S0!G>([RZ6_F@MK^<-'IKS+;6H"NCY.)78\;1C 7OSP<<8\,]WJ^M>
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ML]S&)WVDM]_ S\NX]<5--X<LII[.Y5YXKNTB,,5S')B3RSU1CT8<#J#SSUH
MXQ=>UVXL],A;49(KB+Q$^DSS)$F+B-0^'QC@\#IQD'CM71^&+F]77?$6DW5[
M->16,\/DRS[=X62)7*DJ " 2<<5>E\+Z9+!8PA)8TLKC[5#LE(/F\DNQZL26
M;.<YR:LV6C6MAJ=]J$)E^T7Q4SEG)#%1M7 [8''% &9KFJ3)XFT+0XY6@CU
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ME(.Q!<QDM[#&3GTJWK6I_:O$GB670+E)KN3PZGV9X&R9&#RY*$?>('IGD>U
M'6ZAXB>#Q5HNEVDEI-#>2S1W&&W21E(V<=#QRO?WK3M+F=1>O?W%EY<<[+&T
M+$;(\# DR?O\\]N17!+JGA^ZUSP!/IMQ:;8_.CPC#=$#;L C=P=W&#WK*U'^
MSO\ A!/&L:FV"1Z\6C"E1M.Z'E?3^+I[T >N17,$TDD<4T<CQ';(JL"4/H1V
MI([NVEE>*.XB>1/OHK@E?J.U<3Y6GVOQ'NK:QD@LUGT EC;@ [A*<-@=2 <^
MM8OAJ71=;E\'12:CH[3:3"R^69T:2X8H%7"'D'/SG/(8=^M 'JU<KK?C"&'P
MYKE_HLUK<W.E;E=9#E2RJI/0Y(&['U!KJJ\EOI[*W\'_ !$M"\$=V+RY;R^
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MR&( VG@DD#.!W% %ZXTV.[O+::<AHK5O,BA"X DP1N/K@$X';.>3C%PJ&&&
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M%5G.6(&"?K2"&(.7$2!B<EMHR3TS45]?6^FV4MY=R>7#&,LV"3R<  #DDD@
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M1V=\RY5LGA5P,'H>.:T?#^KZ;%X=@EM9]0NDENI8(A=L6GEE#MN7G_=8\X
MYQB@#HUAB0Y6-%.2V0H')ZFE"(,X11GKQUK$B\6Z9);WCR>=!-9SK;36TB#S
M1*V-B@ D-NR,8)!_.LS2K^XN/B5J<#B]AB3387^S7#Y57,CY90&*\@+T]* .
MN\M./D7C@<=*3RH\8V+^58^OWME;76CQ7DE[&\U\BP?9RRJTF&PKD<%<9.#U
MQ52[\<Z99G4MUMJ$@TUPMVT=L<1 J&W'./EP0?7T!H =/H.JKJMW<VFIV36U
MTZLT-]8F8Q84+A&#KA>,X(/)/K6SIMA%IEBEK#]U69B=H7+,Q9C@<#DG@58$
MJO )8_WBLNY=O\0QD8KGU\::<VF6NH"WN_(N;O[$N44%)=^S# M\OS C)_J,
M@'0O&DBE716!&"&&<BA(TB0)&BH@Z*HP!6-J_BFQT2"_GNX;KR;((99(X]PR
M_0#!_/.,9'J*I7FOZ?=3Z<MS#K%HQU-8+?,3PK-)M)&3T:,@DX/7'3B@#I5A
MB12J1HJDY("@ FG !1@  >@KF+?Q.;R^\0VMQ87<%MII$;2)@L<QAB1M).2&
M&,#ZX/ +/Q1I5CIN@01_VC.NHVX:T+QM+(X$>[YV[L0/\CF@#I]J[=NT;?3'
M%-:&)X_+>-&3^Z5!'Y5B0>+M,FT>XU%Q/ MO<?9)898\2K-D*$P"<DEEQ@XY
MJQ9>(;6]UBXTGR+J&]MU5Y8Y(^%5A\IW*2O.#W[&@#4>-)$*.BLAX*L,@TCP
MQ21^6\:,F,;2H(Q]*I:AJ\&GW5I:&.6>ZNR_DPQ ;F"C+'+$  #'4]ZJVWBB
MPO;&PN;19IC?,Z00A0LA9,[P=Q &W:<\_3- &R      .@%+5>QO$O[1+A(Y
M8PQ92DJ[64J2I!'U!JQ0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !7*^.K5WM-(U%03'IFJ07<WM$
M"5=OP#;OH#754A 92" 0>"#WH Y/6K;6-/\ &%MK^F:>=2MY+,V5Q;1RJCIA
M]ZNNX@'DD$9IMY8:ROB+1O$7V03-%#-;7=G#(NZ-'(92I8@,05 ;GGM7165U
MIPGDTRSN(6EM5'F0(^XQ YP".PX.!Z"K4LL<$32RR+'&@RSN<!1ZDT <!K/A
MG4[K0?%4MO9,U[K5Q$\5KYB HD8106);;D[6)P3U%;%[IM]>>-[:]^Q3)9'2
MIK62;?'E'=D(XW9X"GD9K<&M:8UI:W0OK<V]W(L5O)O&V5VS@*>Y.#5Z@#A/
M"NF:K8PV6DZAX9LHI+$+'_:JM&5E1. R@?.'( ZXQR<]JG\)0>(M%L;?P[<Z
M6IALW*)J7GJ8Y(=V1\F=V_'&,8[Y['M** .#;1M930/&>EKIK.VH374MK(LT
M>V7S4 4<MD8.<YQ[9J_K&C:C=^%])FL81%K6EM#-!'*PQN4;71B"1AE+#@^E
M=;5:#4;*YO+BT@NH9;FVV^=$C@M'G.-P'3.#0!R_B/0+Y+'1;C3;2+4YM+F+
MRVDY5?M2NI5SEN ^3NY[YJOK>EZEJG@J^@M/#T=E<W,L)2SC>(/A)%8L[ A<
MX!P 3V]>.PGU&RMKRWLYKJ&.YN21#"S@/)@$G ZG !JS0!R7C#3[N>32-1TR
M46NJI/\ 9D+<DQRC#@XZE0/,_P"V9K3NKR30I='T^TTMYK&5A;-*DJC[.  $
M^4\MGVZ $U9CT'3(M<FUE;5?[0F4*\Q9CP!C@$X''&0*O&*-I%D9%+H"%8CD
M9ZX- &)XUTNZUKP9JNG62![F> K&I8#<<@XR>!TJB]OJEUXTTC5GTF:*WBL9
MXI<RQ$HSLA4'#<\*<XR.>M=910!YFGAS7;?2K.[71X[BYL=5NKEK">2/%Q#,
MS=#DJ& 8$9[@UVV@QRBVDFETB'2O-8$6R;"^ .KE.,^PS@#KS@:U% !7 ^*_
M#>IKX^T3QAI=I]O^Q1M;W%H)%1RA#C<A8@$CS#P2.@KOJ* .?OVUC6?#^IPV
MUF^G32VDD=N+AU\SS"I /R,P4#ZD^PQSR>C^";^YM/"-A>VILM/T-1=3QLRE
MI[K.<#:2-H;)R>N<8KTRB@#QVZ\!^(=1TC53/9>7J&NZPK79\]#]GLU;<,'/
M/..!D\#TJ_<V-_X1U7Q;XGGM(X+*WT]+73'$H/RA0  .HR^TG/OUS7J=8>HV
M.@^,K*?3[ETO[:"4+-%#<, KC!PVPCD<'!H X;0/!EY?^'/">EW-J]MI]A(-
M2O'E9=T\QRRHH!)Q\QR3CC Z],NX\(>+[G1M0TZ?2@XU#7_M%Y*MRFZ>WSD8
MR>%&!QUY' Q7LT,2P0I$F[8BA1N8L<#W/)J*"^M;JXN((+B.26V8),BMDQL1
MD ^G!H X:\\.:U>>.-1UY[),6.E_9])3S5VO.5))QGC#$C+ =CVK$U#P[=Z7
M\![G0IK=1J7[IG@C<2.SO.I&<=R>!C/ %>N5F#P]I(UY]<^Q(=2= AG)).!P
M.,X!QQG&: $T.RGM[1;B^51?31H)0#D(%'RH#WQDGZLQ[UR?B/0]8USXD^'K
MM],D.B:6S2-+YL>6E/((7=G *IVSUXKOV8*I9B H&23VJ"RO[34K?[18W,5S
M!N*B2)@RD@X(R/>@#@-1\,ZY=^*/%.OBS!N!IXLM&!F7G*G<W7Y3NY&<=:J2
M^"-6N/"/A#PTUDL=E;W"SZH4F7Y0O)'7)+,S?=SCCZUZE10!YK'X5\0/>^.;
MH6T5M/J,)M=.<2K_ *I5VH% ^Z",9SC! IVD>#+VY_X1*"\MC9:?H$"S/$S*
M7GNR 3]TD!58$YSSGIWKTBB@#A],\(7B^,_$M]>&-=*U">WD2$<M,8USSZ+N
M/3J=OIUXZX\(>+[G1M0TZ?2@XU#7_M-[*MRFZ>WSD8R>%&!QUY' KVF@G R:
M //TTC7U^(6M:X=-0K'IBVNG/YR[,[=Q '4'S..0!@GGUP;;P/KB^"?#.GSV
M)/V?55N]3MO-0O*I8DL>=IQG&,],'KP/4;/6-.U"XEM[2]@FFB4,Z(X)"GHV
M/0^O2KM 'FVH^%M>F@\6:[%;A]9U: 65G:B51Y%OPIRQ.W<1\QP>".":2S\$
MZAI_B?PE'#:(^DZ/9,SRM*.;E^')'4G !'&.G3%>E44 >?:=X<U(^/;#Q)%9
M2:8;BW==8@:1&CE<+A"NUCDYYS_L^I.?0:** .3GMI;OXEQWD*%X]-TMT?!Q
MF65P53/KM0GVR/6NBTZXN;K3H)[RS-G<.@:2W,@<QGTW#@U+!;Q6RLL2!0S%
MF/4L3W)[FI: *>JK*^DW<<$+32O"ZI&I4%B00.6('ZUD^#--N=/\(:18ZC:&
M"[LH0A5F5L, 1D%21T)_.NBHH X*+1-7L]!\1^'18M<)J$MPUI=^8GEA9\Y\
MS)W J6.< Y[5?TK1KW3?&<<@M96T^+1H;!;EG3YGC9CRN[=R".W6NNJI?ZI8
MZ7#YM]=16Z8)R[8X'4_0=SVH S/&.DWFL^&YK?3F07L<D5Q )#A6>-U<*?8[
M<5#]JUO5]#OQ<Z(]B[6KQI;O/&[R2,,<$':%'J3DYZ#'/0Q2QSQ)+$ZR1NH9
M'0Y# ]"#W%/H X6SL=?MK3PU93:7++8V^G"WNH([B-"LZA "YW?-'@-P,]>0
M>!5'1]"UVSTOP=;SZ0ZOI5W*]QMGB("%9%!'S#/WQP.P_"N_LM1LM2CDDLKJ
M&Y2.0Q.T3A@''49'<9%6: .;DL;X_$:#4A9N;%=,>V:?>F YD5AQNW8PI[5G
MZ!X=GD\ 3^&];M#;J%EB,GF*P8%V82+@\8RI&<'(Z<<]I6=JVA:;KJ0)J5J+
MA()/,C4LP ;&.0",C!/!XH Q/#AU:U\'-JUS -1UBXA64QHXC$H50J ,WW<@
M;CGNS5T.EWIU+2K2^,+0FXA67RV()3(SC(Z_6H)-7T1R]I)J%@Q'R/$TR'&.
MQ&?TK15E9%9""I&01T(H \X&E>);J?1;J^TAY+^RU5I;B8W4>QHR) IB&?E0
M!ER, \=&.36A)I&K-#XY4:;+G5 19_O8_P!Y^X$?][CD9YQQ^5=Q10!GZ%#-
M;Z!IT%Q"T,\5M'')&Q!*LJ@'D$CMZUP$NA^(K?P+?^%%TB2YD2YWVUXL\8CF
MC,XER<L&#<D$8QQUKT^HKJZM[*VDN;J>."",;GDE8*JCU)/2@#B)M-U2P\3Z
ME<?\(S!J]EJC1S([R1![:01JC(^[JOR@Y7..>#6E'INH0^.K*^^PYLX=(:T:
M6$HJ"0NC852V0,*>WI7303Q7-O'/ ZR12H'1UZ,I&01^%1V]]:W4]Q!!<1R2
MVSA)D5LF-B 0#Z<$4 <KHOAN>Z\%:GHFKVCVQN[BZ89=&(621G1AM)Y&0?J*
M:_AW6-4^']W9W\D2Z[=QHTC$Y3?'MV ^QV#/NS5VE% '%VL&I7NE7OF>$;?2
M[G[))%A'A9Y9&&,(5. O?+$=N*#::_:>!_#MG:V,WGVHMX;^WCFC64Q(FU_+
M?=@'('.X'&>0:[2H;J[M[*!I[N>*"%>LDKA5'XF@#SN3PSK4FA>)[*+2EA-U
MJ4-[;+YZ'S%4PL5SGAOW;9S@9/4]:Z46-UJ'BFWUV6QFMH[.RDABAD9/,E=R
MI/1B  %P,GDD]AD[=GJ5CJ 8V5Y;W(7&[R9 ^.O7'3H?RJU0!YE:^'-<L/#?
MA>;^QH[NZTD30W.G321GS4DQED;)7(P",^];5[H_]J:3!#>^&!#!+<&4PVDB
M)/:D+\LFY6 +YS]TG@CK@UV=!( R>!0!C>%K74[+0X[?5KB2>=)) CS$&0Q;
MCLWD<%MN,D5S4.D:IINM:I:MX:L]4M;Z[>ZM[^1H\1;^2LBM\Q"G.-N<BNWL
MKVUU&SBN[*>.>WE&4EC;*L/8U/0!Q?B71M5U2<:E96ABO]&96TP,8\7).-X8
M[OE4CY0#@CKSQB.\O+G_ (6'H-Q)ILZROI5SYENKHS1_/%GG=@\^A[UW%9\N
MBV,VLPZL\<AO88S''()G "G&1M!V\X';M0!QDWAK5(H(9XM/>2:X\1KJTT*2
M1CR8A@8)+ %L $XSR3SWJ_KNFZC;>+AK-OH46M6=S:);30,T:R0LC,59=_!!
MWD$9]Z[2HYYXK:!YYY4BB0;G=V"JH]23TH XO6?#\M_#;*VCRVMS!;L]K=Z3
M,D;VLK,3Y?++N7&W/&"<],U6U?0-7O[>">2UN(_$5O81K#JMA,B!IL'<D@+#
M*;L'E<8)Q[]W:W4%]:Q75K*DT$JAXY$.0RGH0:FH Y>WL-37Q^FHSVI:V_LA
M;5[E60*91)O.%W;L?A5;1=%EM/&6IQI*K:3!+]L@B'_+*YF4AQ^ RV/^FU;U
MSJ.C7EIJ-M/?6KP0(8[T>< (@P((8Y^7C-.T.QTNPT>WCT>-%L7021%&+!P1
MD-N.2<C')H ;XBMY[OPUJEK:PM-<3VLL4<88#+,I Y) '6N6MM,UO2-5T'5X
M],ENDCTA=-O+6.6,20L"&#KE@K#(P?FZ8KM[FY@L[:2XNIHX((QN>21@JJ/4
MD]*6WGBNK:*X@D62&5 \;J<AE(R"/PH \W/AW7A827:Z1%)<VVO7&H)93RH5
MN89-RD9R0&PV1FM'5],U/5/"TR6GAN.QGFNK9Q:QO$'VQRJ[,[ A>@( !/ZX
M'=T4 <=>Z3J5YXIUBY6R=+:[T46<<KR)CS,R'! 8G'SCG'K5,Z9K4WAWP?;-
MI$J3:9=VSW*>=$=J1Q%&;.[!R3P!GCTZ5WM5K34;*_:=;.ZAN# _ER^4X;8V
M,[3COR.* ,*TL]0B\?ZIJ+V$HLIK*&".;S(_F9&<GC=D?>&.*YM/#>N1>&[&
M1=*CEO=/U:XO/L-Q)&5N(I&DR 02H;;)QGH17I5% '!ZII&JZCI-K?V&@V^G
MW5GJ$%ZFG[XP\XCW AG7Y02&XY.,=><#0TR'4[CQY<:O/I,]I9S:9% #-)&6
M5UD=B"%8]F[9KK** .;\66-]?3Z";*S>X%KJ<=S,5=%VHJL"?F89/S#@5CWF
MC:O-;^.HTTV4G5EVV?[V+Y_W CY^;CD9Y[5WE5DU&RDU!]/2ZA:\1/,>!7!=
M5SC)'84 ,TI)8M(LXYHFBE2%%=&()4@ $9!(_6N0U#P5=:A>:_9&18]*O/\
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ME8L<CD[F/3J?PJ*T\(W>GZE=?8M=GATBZG:XDL/)4D,QRX23JJD]@.YP1UH
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MPC>1;<Q ($X^?GA1^- $MEKFJCQ5;:7J$=GY%[8O=0F -NC*,H*L2<-D.#D
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M Y&>22<]JE7PE=>;KTTNKF276+9()";8!8RJ%,@ ^C' SZ9)[@&19W6J)=^
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M),,2%P&Y P..E '<45Q?A6]GBUJ33-6M+FQU2*S#L#<M-;W"!@#*C$\')Y!
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MXMPQ5RR@X9E&&R?[I]:[70&^V_:]66:1X;R7-NID8H(E&U64$X&X@OD=0PH
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ME+/>2Z3>VS6QB>XDD$=PHW)@,3RX!7Z@>M=1HMG-8:3;P7,LDMQMW3.\C/\
M.>6 +$G )P!Z8H OT5P?B^X:6;Q +2[N7N+'2?-*+.T*6C8D97!7EG.T<8P
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ JIJ6EV6KV;6FH0">V?[T3$[6^H'7\:MU!=WEM8P^==3)%'N"@L>K$X
M 'J2>@% %7^PM.^U6MR8"9[5"D$AE<M&IZ@'/0\?D*@_X1;1?*\K[$/+^T?:
MMOF/CSLY\SK][/.>M3?\)!I L_M;:E;+!YOD[GD"_O,XV8/.[/;K3+;Q-H5X
MEV]OJ]E(EG_Q\,)EQ$/4G/ ]^E $R:)IR7=U=?95::[01W#.2WFJ!@!@3@@
MGCW-)8:)IVF,IM+81E$\M"69O+3^ZN2=J\#@8' J*T\3:'?WZ6-IJMI-=/&)
M5A24%F4C(('T.?I6'8ZY=RZ7XG;4-9M[%K+4);:"\>)0D*B-"IVDX;ECU/-
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M!>@V4;K??\?2R$L)N,?,"<'CBG_VUIIO5LA?0_:78HB;OO..J@]"P[CK7/\
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M6FI!IMO9S02%7&=SLA!Y.2 $Q^6*Z"77-+@NA;2WT*2EUCVENCM]U2>@8Y&
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M:M;NR,=Y'=VK2[;H20A752IP5*X&-VW((/'>K+:WIBWBVC7T(F:3RE4MU?\
MN9Z;O]GK0!9>TMY+R*[>%&N(D9(Y".55L%@/KM'Y4EO96UK \$$"1Q.[NR*.
M"SL68_B23^-4+KQ/H5DUPMSJUG&UL0LP,HS&3G /H>#^52Q:_I$VH"PBU*U>
MZ*>8(EE!)7&<C\"#].: $LM TO3F5K2T6+8&6,!F(B!ZA 3A ?1<4D/A_2X+
M&ZLHK4+;73,T\8=L2%OO$\]^_KWJ'_A+?#OGP0?VW8&2=S'$HG4[V!Q@<^O'
MUXJU=:WIEE<&"YOH8I 5#!FX3<<+N/1<GIG&: (D\.Z3'-9S):!9;*/R[9P[
M9B3^Z#GIVQZ<5H3P1W,$D$H+1R*58 D9![<5GWGB31=/EFBN]4M(I(%#2HTH
MW(#TR.O8U)_;FE^?9P"_MS+>IOME#@F9<9ROJ,<\4 1+X;TE8;*);,".R;=:
MJ)&Q">F5YXXXIL_AC1;E+Q9[".5;UE:X#LQ\QE^Z3SU&!@]JT(KRVGN)[>*9
M'F@($J \H2,C/X5/0!E0^&=$MWN'BTNU5KF(0S?NP?,3T;/7W]>]1V7A/0M/
MN+>>VTV%)K92L+G+&,'&0"2<#C\.U;-% &18^%M"TW5)=2LM+MH+R4DM*BX.
M3UP.@SWQ6JZAT9#G##!P2#^8Z4ZB@#+A\.Z1!I<NEI8Q?8)<[[=LLAR<G@].
M>>._-21Z'IT=M/ ("4N$$<I>1F=U'12Q.XCD\9QR?6M"B@"O965OIUG%:6D?
ME6\2[8XP20H[ 9Z#VJ.\TJRO[FVN+F#S)K9M\+;B#&W3(P>N.*N44 9+^&M'
MEAO(9+(-'>MON5+L1,?5N>>WY5,FB:?'J$5^L!^UQ1>2DID8L$_N\GI[5H44
M 9%QX6T*ZUE-7GTNV?4%((G*\DCH3V)'&">F!6O110 5C77A30;ZYNKBYTR"
M66Z $Y8'Y\#&2.F<<9ZXXK9HH SDT'3([MKN.U$<[0B O&[*?+'1>#P!Z57?
MPIH<FFV^GMIT7V6V?S($!(\IO5#G*_@:V:* ,F/POH4=I>6JZ5:^1>'-PA3(
ME/OGZ5'#X1T"#2)-)BTR%+"5MTD(SB0]MW.6Z#KZ"MJB@!L<:Q1+&F=JC RQ
M)Q]3S3J** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *YKQE=&TMM,D-F9D^WQ[IQ"TIM!AOWH49R>
MP/0;LG/0]+10!Y!J),7A+Q;'<07A5M=@G!N+9E,B,]N <;0"3@\ 9]A70:O:
M17WB.\U;3U'V6'0;BWN)E7"R,V"B9[D ,3Z<>M=3XBT0>(-+-@]R]O&9(Y&9
M%!8E&#CK[J*N7UH]]I<]F9MC3Q&)I%7ID8) H \]TZU@U?0/ $>G1?Z58M;W
M$SK&5\F,1'S-QQQO.!C^+.>1S3;E7D\(?$&%89C)<7EPT">4V90T2*I48^8$
M@\CTKT#1]._LC1K/31,9DM85A1V4 E5  SCO@5>H X%]2_L3Q7#?ZA;74NEW
MVE0V\4\5N\HBD5F+(RJ"1NW#MSC':G7$D5IK&FV<&CSZ;;OILBPRV]H7DP7&
M(. 0F0 QR/Q&":[RB@#RO0U:#3OA]=7=K<1V]C'/%</+;N!"YCPI;(X&> >G
MO3]=TR5?#/C:\MK65;;4[F%K2!(CND*A [A ,_,P8].0,]#7J-% 'G^JW5O8
M^,+^36+?4I=+U2TA2VGM%F9/E#!HF$?.3NR,CN:['1K6"PT2TMK>V>TMXH@(
MX)'+-&O8$DGD#W.*OT4 >7V-RUEX<@,EA*P_X2&=VF:V=VM5:20K,$QDY! !
MP0-V>>E6]'TAM:T;QEH\R7D<EUJ$DT,US"T9R8XS')G &=RYP.F.@KT6B@#S
M1$\17-WI'B$6TL%WJD']F7<(&#;KMRLI_P!UQ(WT=17;'5+#3=5L-!"2QR30
MG[/MB;R\*#\N[H#A2<>@K5J%[:*2YCN'!9X@?+R>%)X) ]<'&?3/J: .6\=:
M7>3MHNLV%N]U+I%Z+A[:,9>2(C#[1W8#D#O6S;>(;&_118>;<2MC]WY3H4_W
M]P&S'O\ AD\5K44 >>('M=/\9Z/JEO-)=7MS<36RB(M]JCD0",(<<D8"D=L#
MM4FC6DVG>,](CU#<\UIX<6WFN"I*^:'4D;NF< GKG%=_10!Y9H]IN\)Z"@OK
MO1M1MI+PP71@.R/,I.R56&-K*5(SCIP:NK=WL5WX,UC5[%K81B\BN/L\#LJ,
MX 0[0"P#[<@$<9Q7HU% 'E-WYTG@3Q5%]CNUEFUUI(XVMWW.IGC;*C'/"G..
MF*Z.YF>V^(=U<BSGN([G1$2#9$Q25EDD8KNQ@<,.OK79T4 >7:/<F36_!MW]
MFO(HHK:YAEA6R>.*S8HF(QE<X&""Q)Z9R.E0QQ%/ 5M&+:59QXA$Y00,'"_:
MRV_&,XV<Y]*]7HH Y+1&:#Q_XE22&<"[^S2PR>4VQU6+:3NQCJ,=:-:"GXB^
M&I&C9DAM[O=)L)6-F";<G& 3@XKK:* /*$%S:Z<+\6=[+96?B2[N+B&W5UD\
MB3S%610,$@;P>.V:M:]!I5SX5O[O2=/O62^OK1Y'G29GN"DJ;F"/EL!1UP,X
M/I7IM% '#^))DTKQ5IVJW-O>OH\MI) \UB),P2,RL&81_-A@,9YY JG+8V.G
M7GA2\M--N;72(;VYF<S)(YC\R-MKN&R4RYSSTR,X/%>B44 </9^&H=8F\7&2
M)H=-UAXU@^7:2RQX:91V^?!![[<]"#5[P8^I:A;-J6L1A+V)?L P<AO*8K)(
M/]]P?P5:V]7TZ;4[1(8-2NM/99%<RVI7<0.J_,",'Z=JLVEK%8V<5K I6*)0
MJ@G)P/4]S[T <UX@NS!XKTJ-K::-'MY@+^"V:9PQ*?NEP"%W8R21_#@8ZURN
MBVK-X0\.1?;+[1-4LUN5BNI+<^6AWC='(K#!5@1CIRO!SQ7JM% 'F\AO[FPT
MN_:X?0M>BLW(Q 6M9UWG,;(1QNVJP'##<<9Q5V&2XF\4^#)[FP:TE&FSB>)$
M.R!V6+"$]OND 'TKNZ0C((]?2@#R>WO=*B@32+^]GM;2RUN2\626RFW_ "S,
MVTN%V %L_/N^[Q@'IK7"H^J_$!_)9A<6421-Y1/FX@92%./FY(&!WKH+'PI+
M8VRV UW49=,5=BVL@B^Y_=,FS>1^.?>NB "@   #@ 4 >93QS+I6EW>GWT]C
MJT&B0H8I[<R07B@-F!E(SO# ]/F^;H:[F5C-X3=KZR=2]B3/:1G+#,?S(/?J
M!6K10!YO:VVJ-8ZOI$%TVL:>^C2K:74L.R>%B-JP.<#<3UY (QR.126-Z+W5
M/ K6]O>[;:TGAFD:TD BD\E%P<CL1C/3WKTFB@#S[PA>0MI.EZ!JFCW+:UID
MWSB6V;8C G,XE(V\@D@YR2?QK)O(RW@;Q6B6TQGFUUI8U$+;Y%\]&#*,9(P"
M<CT->KT4 9'B32_^$A\*ZCIL4@4W=LR1N>@)'RD^V<5E^&?$,,.AV6GZG#<6
M>IVL*036SP.69E 7*8!#J<9!7/6NKHH XZ]FN;+Q[INKWT$D>FS:=):AL;A;
MRF0/\^/N[E4#/3(QFN=O-.F@TV:5K>7[+>>*8;R"'RF)$(=-[E<9"DAFY['/
M>O4Z* .)3RE\=^)+AXCY<FF0(LAC.'(\S<H..3RO ]JY_2)(;1_AO]O1HS#9
M72.)8R#$X2,?-D?+CU->K5DWVA_;?$&FZL;ID>P618X@@*L)  V3UZ 8Q^M
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MPI1LF3S]XG#8^[@[MWU'7BO4Z* ."*J/$7CEY(G(ELH$1S$<2$1.&"G'S<D
M@=\53LD\JU^&X$$BM;)B<>4P,1-LRG?Q\OS''/>O2:0YP<'![&@#R=;>VU3P
M/XHT>& 2ZC<ZO=+#&(SN:3SOE?..B]VZ#!J3Q:UQ/8>*]/%G=QW(2 J+>T9O
MMH54S*SX(P,8 !&-O.<XKO\ 0=$&A6]U"MR\ZW%S)<DNH!#.Q9@,=LGBM:@#
MBX98)?B1>WKPR"!M%B0220,HSYCL5Y'7:5)'7VK'L-/N?^%2Z+?P1M'JNAQB
MZC24%&RF=\;9Y 9-P_$5Z965JFB'5;RWDEU"[CM8U*RV<;*(YQD'Y^,XXZ C
M(X]<@%2SNQI&@G5=0@G$UY*)YHXXC(ZM(0JJ0O\ =78I/^S70444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 50L=:T[4;RYL[6Y#75KCSX65
MD=,],JP!P?6K]>?ZUH=]-XBU+Q!H1VZWI[QA(R<+=1&-2T+?7J#V/Y@ [6/4
M[6749;!'<W,2AW0Q, %.<')&,':<<\X-6ZX*V\:64UIKOB6UC9Q;:5 TEN_#
MQRJ]QF-O0@\?K5ZYU;5=(N?#TT]V+NVU65;6=/+5?*D="RM'@9VY!!#;N,<T
M =?D'.#TZT5YMI\^NV_@WQ#J-EJ<\][:ZC=,%ECC;S%CD((^[U*CCL"!@8XK
M2'B[R_%*JUZ\FC7.FFYMW6-?]:JAV3.,D^6RL![]Z .MGOX+:]M+20OYUT6$
M6V-B/E&3D@87CUQFH]7UBQT/3)M0U"5H[6'_ %CJC/M_!036#+J&LV.N^%;"
MYND<7RSB\'E+DNL188(X !]!VKDM1^U/\.O'<ES?SW)6^N(@)0O\+( > .P
MQTXZ4 >LT5R8U'6[/Q?<:6]Q%>B;2Y+R",Q",1RJX78".2IW#KD\=:RK?Q'<
MZIHNKQKJMW:ZE:Z:\D]G<6Z13V\H&=R_+@H>1GGMSD\ 'H(((!!R#WHKB=,N
M+ZU\.^%X5U-A'<VBL^U%>Y;]TNU8UV$$ DEF8<#&3S5*W\3Z[=^'/"]XEQ!%
M<7^IM8W!:#.X!I1NP#Q_JQD#UX(H ]#JC_:]E_;8T?S6^W& W C,;8\L$ G=
MC'5AWKCY?%6IZ/%X@M+J>.\N;.]MK:UG>((#YZH1O"X&%+'IC(%6%MKN#XJ6
MRR7[7!;1)MC2QJ"I\Z//W0 1TXZ]>: .LT^_@U.S6[MBYB9F4>9&R'*L5/#
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M^"[+QBLX>"22-YK#8NT0O($ 5L;MXR#DD@D'CT34=8\0^9XQ^SZG#"NBHLT
M%J#O'D^;M.3T[$]?3'< [^BN%UKQ5=V:VLUS--IEC=V$<D%\D EA2X;.5F)!
M*K]S'3.6Y]-.+5+V;Q;JFF+=YM4TZ&ZA944E6=G!P<<CY1US0!LWNKV6GWEE
M:7,K)->R>5 /+8AFP3C(&!P#UJ]D9QGD5YR-3N=9TKX>ZE>,K7-S?+)(57 )
M,$O:IM/N=3MF\:72:LGFV]Z4B:^VB%/W49!)"YX!( '7OR<T >@45PI\0ZK'
M+XGMHKF1A8Z<EY:2W=N%?)63(*@+QE.,@$9/6GZ?J^MC5/#*W=_'-#K5D[/&
ML"KY+K$KAE/4YR<YX] .E ';@@]#17)?#W[5)H5S-=7T]T[7UTN90O\ #,XS
MP!UQ]/3%6?&&I:EIL6DG39XHFN=2@M9/,BWY5SCUX_SR* .DHR!C)Z]*XXWV
MM+JDF@?;9[B[M[07+W=M!"C,7D<("KMMPH7G'7(Z=Z)DUZX\2^#TU6Y:TNY(
M+MKFWMRC1^8@4;AD'J&/<XSQCF@#OZJP7]O<7UU9QE_.M=GF[HV ^89&&(PW
M'IG%<?=>(=4M=3L3]LCG2?6?L,L<,8,"1-N"C>0&,@P"<$@'(('%27NO:Q _
MC=4N8<Z3;I-:$P<+F)G(//)R,9_2@#MJ*XRPU;68=?\ #\-Y>QW,&KV,DK1"
M$)Y3HJ-D$<G.X@Y_#'2E\+^([C4M62QU"ZFMM3C@<W>F7,"H0^5P\3 ?-']X
M=3U% '94V218HFD;.U1D[5)/Y#DU4U>XGM=&O;BVDMHYXX7:-[IML2L!P7/9
M?6N?T/6KZ;Q9-I4T\MQ:G3H[N.2>$1MN+E6P  =IQQD9_"@#47Q5H[Z;I^H+
M<L;74)E@MI!"_P [LVT#I\N3ZXK9KRJQ_P"27>#?^PM:?^E!KU6@ JKI]_;Z
MG9K=6Q<Q,S*-\;(<JQ4\, >H-<SI%UX@U77=7B.JV\5OIVH>2(Q: ^8AB5MI
M.[(P6!SG/6J5IXIU0^"M)U&XD3S;K4S:W5T(P%@B\YTWXZ#[JKD\#.3F@#L=
M4U.TT;3IM0OI&CMH5W2.$9]H]<*":M1R++$DB'*NH8'V->=:W?ZG>^&?',,]
MTESIUG;O%;3"( R$QAFRPX.TDJ<#]0:U;&]U:V\1Z=I4]^LEM?Z8\J!(54V[
MIL VGG(P_P#%GD?A0!V0(/0YHKD_APUS+X+L[FZO)KF29I7)D"Y!\U\G( )R
M>>:ZR@"*>XCMK>6>0G9$A=]JEB !D\#D_2DM;J*[M(+F(MY4Z+(FY2I((R,@
M\@X[&N'TR?4[>/QQ>)J<DDUK=R^4)XU91M@C8<  \=,9QWP333=ZCJ6L> YG
MU&:,WEE)/,D:IM,@A4[L%3UWL/;MB@#LK'5[+4KF\M[65GELI!%.K1LNUB,@
M<@9X(.15ZO/1J[:'J'C>^C0/(-0M(D!Z!I(XD!/(X!;/4=.HKHM*?7DUV>*\
M21]*: /')<^4)4E!P5Q&<%2.<GD'B@#H***X[Q7K.IZ=_:TEI>HGV/3_ +3!
M!!&)'+#>6,VX85,* ,$$_-C)% '8T5QKZMK-_P")].T^WO8K6WO-(:[;$ =D
M<,@R"3S]X]>/8U5TKQ7J-_8>'[&69%U#4;JZ@EN5C PEN7W,JGC<VU?89)QQ
MB@#KK+5[+4+V]L[:5FGLG5+A3&R["PR.H&>.>*EU"_@TNPEO;HN(8@"QCC9V
MY('"J"3UKE_"D4T/C'QA'/<&X<3VW[QE"DCR1C(  SCC@"M#QQJ=]HWA&^U'
M3I4BN( I!>/?P6 /'KS[T =#02!U-<G>WFM7'CB?1+748[6V.F+=*XMP[HQD
M*]S@]._'MWK!BU74]>M_ =Y+?R6\MW<2K.L"KM9UBD&[!!].G3GITH ]*HKB
M9M9\0ZHFHS:%&YELKYK:.)_)$,@C8!Q(2=X)^8@KC''!J6"^UZ_\6ZS9)J<-
MM9Z>UK,$%J'9D=69TSGN!C=],>X!V-%<5I6L>(M7@T76+.)VL[QU:YAE\D1)
M"W="#OWKQUZ\\#I2Z5XANKS7AI5_>3Z?J6^;=93P*%DC&[8\#[?GQ\I.2>_'
M% ': @]#FJM]?V^GQQ/<%PLLR0KLC9_F8X&< X&>YX%<Y\.3<R^$H[BZO9KE
MY;BX),H7@B>3)R .O7G\,5<\6ZG?:5;Z7+92H@FU*VMY@T>XLCN%(![<4 =#
M17#7VJ>()=5\5VUMJ<-O'I=O%/;XM@QRR.VTY)R/EY/Y8KJM$OGU/0-.U"10
MLEU:Q3,J] 64$@?G0!?HKCO%>LZGIQU5[2]1/L>GFY@@@C$CEQO),VX85,*
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M/$FFM:C2;53KGV6)I)I=0L1Y\WFD;1O7:V00S<[3C  P.G<4A(4$D@ =2>U
M'(6.@R:SI=Y8ZI>:G=Z=)Y;VTE[$L-Q%(I)++M52,?)C<,Y![==NVT18;M[V
M:]N+B^,'V=;F0(&C3.2% 4+R<$\'.!V&*NV-[;ZC917EK()()1NC<=&'J/:K
M% ',VW@FRM=/T:RBO[_RM(F\ZVRT9);!'S?)R,,P_&J>OZ ;+3=:N+4ZI=OJ
MTT1ND@9-\:C:I:,!020BXV\Y]#S7944 <3HMK?O<'[+JWB":S9'6==1M4A*Y
M4X,9,:-OW8YY7&<]JZ30+*ZT[1+>TO+J>ZFCW?O;AP\A4L2H9AU8*0"?:M*N
M9M/$FI7VMZSIEOI-L9-+:-79[U@)-Z;UV_NSV]>] &CK6@6FM_9I)FF@NK1_
M,MKJW;;+"Q&#@D$$$<$$$'N*EM=,DBD22[U"XOG3[GG*BA3C&<(H!./7/MBH
M?#VOV_B+3GNH8I(7AF>WGAEQNBE0X93C@_4>M:U '.VW@ZQM;9;%+BY;2TN!
M<1V#%3$C!MX .W=M#?-MSC/MQ3I?"5M,VNEKZ]']M($N0#'\H";/E^3CY>.<
M_G5WQ%JDNB^';_5(8$N&M('F,;2; P49/.#Z5=LYS<V5O<%0IEC5R!VR,T 8
MS^%8WM&M/[3OOL\EDME+&?+(>-=P!^YPV&(R,=N.*)O"=HVIQ7MM=W=F4M%L
MWBMW4++$I)53D$C&3RI!YZUOT4 <U;^"K.VL-%LX[^_\O1Y/-MR6C))P5^;Y
M.1AB.,=:+[P3I]__ &NLEU?)%JCI++%'( J2KMQ(ORYS\B]21QTKI:* .:;P
M7;R3WT\NJ:E)-?68L[AS(GSJ-PW8V8!PQ' QWQGFIX_"MO'<:),+Z]+:/&T5
MN"8\,I4*=_R<_* .,5O44 96BZ#!H8NDMKBY>&>=YQ%*P*Q%V+,%P <$DGG-
M+K>APZXMFLUU<P?9+E+J,P%!ET.5SN4\>U0Z)K<VJZAK-K-;)"=.NA "DA?>
M"BONZ#'WNE1S>(+B+QE!X?6QC82VK70N#<$856"D;=O7)'>@!-9\*6^KZE;:
ME'?WVGZA!&8A<V<@5GC)SL8$$$9YZ=:?/X7M)I]+G2YO(9M.\SRY$D!:028W
MARP.=V,DC!ST(K)/C6_":[,-#22#193'<^7>9D8!0Q9%* '"G."174:;J%OJ
MVF6NH6C%K>YB66,D8.TC(R* .>'@*Q$4<*ZEJ:P0WWVZWB65=L,FXL0ORY()
M8]2<9XQ5N?PC:SR:X[7UZ/[9B6&Y ,>%4*4&WY./E)'.?SK6T^2]DLE?4((H
M+G<VY(I"Z@;CCD@=1@]*M4 80\+VXO-(NC?7C/I<+PP F/#*P"G=\G)PHZ8Z
M4ZR\-0VMU87$UY<WDEA$T-LUQLRBL "254$G  Y_GS6C:27KR70NX(HD64B
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M::QMVMXU/E[65L9W87.?E'0CI6S5>"^MKJYN;>&57DMF"3 ?P,1D ^^"#^-
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M_P!3^X7]W_N\<?A7)1^"KJ9)+;4['P[>^8SEM1DM,W#[B3N*D8W<]=V!Z=J
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M4= 3U(H \\NC:V=CJ.N^&=6MIKQM)D*6VGQ!48 9$KJ"?G7. 3SVH*Z*NM^
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MWD5 $;:P+%< Y_AZ\CCD5A^&(I"FGVVH>$7M=0TY );R1%:(%5QNB8$LQ;T
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MX7,<JS9(9GZ*5+'.<=.,U<\0:/?:9:Z!>:3,AU2R":<6DZ31R (<^NU@LG_
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M0Y[=* .BHKGM,UV_N=>;3KK39%@:W\Z.\CAE6,-G!C;>H^;N#W'85T#E@C%
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MHBFXRY+(>3G/. /US77R2)#$\LCJD: LS,<  =2:K7-R$O[.U:SGF$Q=O.5
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M]2W@#72LDD96RD8&-RIX4G&1V]1WJW_8$*^)+;58081;VOV8*DK!63LNS[H
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M:1+>1,[>8]M+&P&0S Y4[AP<X(XQ699W.K-:^"+HZW>F35X5BN@2I4@VY?<
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M\9^&;**^N6M+A+KSHG8,'*H"I)QDXSZXZ5='@[0_+U)&M'==20)=!YY&\P
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MNCVP%PX>%E^Z5?.X8Z=:8/!VA^5J$1M'9-0VFY5YY#O*XPW+<-\H)8<DC)-
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MI'):(5U08O/63Y GX<#MWYIVIZ'8:OIRZ?=Q,;52C"..1HP"I!7[I'0@'\*
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MD+?VK8**<3*<%_N#KW[>M-.LZ6()9SJ5F(87V22&==J-Z$YX/M7G>IV>B1>
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M!++$HW2$)_$1R2"3U]30!LW5Y:V48DN[F&WC)P&E<(,_4T&]M%2%S=0A)O\
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M% !1110 445S/C;7+K1]-LH-/94O]3O8K""5EW"(N>7QWP ?QQ0!TU(0&&"
M1Z&L*[\.$Z9)%9:EJ$5YM^6X>[D<LW^T"2,'V QGC%27OB2VLVOA':W5VM@
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M);W21ZBDCV<SHNV8)R< $L..1D#(H MZSI=]J9@CMM5>RM?F6ZBCA5FG5AC
M8\H1SR/6M..-(HUCC4*B@*J@8  [5RZ>/-.>)9_L.HK:_;#92SM" D,F_8-W
MS9P6XR <=\5J6NOP76LZCI0M[B*XL4620RA0KJV=I4[N0<'GC'?% $?B'0YM
M;.F^5>1VXLKV.\^:$R;RF<+]X8'-;*@*H   'H*K:;?+J>G6]]'%+%'.@D19
M0 VT\@G!/4<UFWOBBTLUOI1;75Q;Z>VV\G@566$X#'()!;"D$[0<9]>* -PC
M(P>E9'B716\0>'+S2([E;47*>69#%OVCV&1_.L3Q!K,D^N^'+&VM[BZTZ_\
M-E<P2(!<*(B5 )<''(8YQG ZUT-K:C0M$\B W=X+=69!+*'E89)"[F(Z9P,G
MH!S0!=@C:.%%D*,X'S,B[03ZXR?YU)7F]WXANM5T7P?K<D5W:M<ZG%OCBD)6
M5&21L!58[AD#[PSQ75VGBNQN+;4)9H;FSEL)EAG@N%'F!FQL VD@[MRXP>]
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M  SCJ36JT4?AV2^U2YU&?^RUMU)BGE:3RF4MDKG).[<!CGD #TH W*0@,,$
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MO;6.55($S^83&6P#M/'.,@4D_AW7;G0O$*?V>B7%SJ\>HVT1N%)D56B.TD<
MXC/7N?QKT6D9@JEF("@9)/04 <#J7AW6/$6IZV\]DMC!J.CI:1N\ZLT<BN[
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M26$0V1>;;AIT0=%$F<' XR5)IT_AO;K<&KZ;=?9;M+;[+)YB&5)HLY&X9!W
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M=W_EB8Q1>6AV @';D\_,<DGT]*P&\^7XK7AL[R*%O[(BC)DB\Q682R$CJ/F
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MX!X&2>]_1M$?2;[5+DW8F&H7'VED\O;L;:%P#D\844 0>(=7O=&O=(D3[/\
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M:8G0MO\ 3Y>?3M^=5-$\(W&B,EM%KMW+I$+%[:QDC7]WSD*9/O,H/0<=!UH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M^CO'?VENEU%#YZMY\;%@.0,*V5(QR,XY[U)I_B8:GI.C7UM;*QU-]HB\WF(
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M;'<QLENC,CL[KP6!S]T=0?;'6M3P?JMQKGA#2M3NMOVBXMU>0J, MT)QVZ4
M;=4=7U:TT/2Y]1OF=+:!=SLD;.0/HH-9WB+5YK*_T73+=_*EU.Z,1GP#Y:*A
M<XSQN. !G/6N3\6ZG?1Z5XQT"\F-U'#IBW=O<,JJ^QR5*-M !(*G!P..M 'I
M2,'16'1AD4 AAD$$9QQ7%_:=<TOQ-I%E<:I]JLM7BEC"K;HC6LB1[PR'!R,
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M@#NZ*RO#IU?^R537/*-]&[*7C(^=<_*Q X#8QD#C-:M !1110 4444 %%%%
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MOISI>W%U.#(3"UYL\X1X'#[ !G.X^N",\U?N[AHK">>W6.5XT9E5GVJ2!T)
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MGGI6Y:VL5E:QV\((CC&!N8L3ZDD\DGJ2>IJ4LH."PSG'7O065<;F R<#)ZT
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MM;!_O>1$J9^N!3CI]D;S[8;2 W6,>?Y8WX_WL9H X,Z38:AXO\6Q:A:03?\
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MTVQ@MFMH;*VCMW^]$D2A3]0!B@:9IX,9%C;#RO\ 5XB7Y._''% '"Z&9=/\
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M.:V["9-2\9K9ZRD<\$NBPR623J&20DGSB >"W*Y[X]J[$Z7IY\S-C;'S/O\
M[E?G^O'-+-IEA<01P36-M)#&<I&\2E5^@(XH \MC@B_LSPPVIB*6RB\03P6L
MUR V;4+*(P6;JIP,9Z@+[5ZU&4,:F/&S V[>F.V*9+:V\\2Q30121J051T!
M(Z8!]*EH Y(A)/BQ+&^&#:" 5/<>>:X^T@MI/ /A0,!A?$812&P0#<R9 (YZ
M5ZJUC:/<&X:U@:8C!D,8+$8QC/7I4?\ 9.F^6L?]GVFQ3N"^2N ?7&.M '!#
M0=';Q%XSL6L+;[''9V\R6VP>6DC1R9<)T#?*/FQG\Z;I[B=OAA=2MON'@<-(
MQRS?Z(W4]^:]!.FV!>1S96Q:08=C$N6'OQS0-,T]3&18VP\K_5XB7Y._''%
M'F!DMM*T'QA)9QPQ7$6M-YX@0>:MIOA\S '.W:6]NM6-6-G9:-KVL^%]7%S=
M2::HDBT\((T4./WA"=) A?!ZX4^E>F+;0)++*L$8DEQYC!!E\<#)[TRUL;.Q
MB:*TM8+>-CN9(HP@)]2!0!PKMH">//!\^DO9+'-:W2JT+*-Z[$V9QU/7&>>M
M>A$9&#52WTO3K1E:VL+6%E)*F.%5()QD\#O@9^E6Z /(C)!IGACQ*;*.&*1-
M>D6[\A0)$M/.7?TY"[3^1-=4\4&G_$'3IM*\F&RFTV:34!%A8MBE?*<XXSDL
M ?0'L*ZY;6W1Y76")6F_UK! "_;YO7\:B@T^SM()(;2TMH$?.Y8X@JD^X&,T
M .LKZUU*SCN[*XBN+:4926)@RL.G!%6*J:9IUOI5BEI;(%C5F;"J%&68L< <
M 9)X'2K= !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %5[R]@L85DG8_,P1%52S.QZ* .I__7T%6*YC
MQMIU]>66G7>GV:7TNGWBW+V;D 3IL9&49XW8?(SZ4 3R^,M)@L+^[F-R@TYP
MEY$8&,D&1D%E&?E(YR,C'>K]OK=E<-<;'81V\:RRS,N(U!4,/FZ9VD$^@^HK
M%M3(=-N[BT\*K8O>E(?)DBC$C#D%Y0IP44'@9R<'ID5DV7AS4K30->\&1Q2?
MV?)!(NG7[[0/G4YC?'/#'KCD<=J .J@\2:?-J,=BYFMYY83/"+B(QB6,=2I/
MID9!P1GI3(?%.FSWEK;(9M][&\MFS1$+<JHRVP_0@\XR.1D5SME87.N:9+9W
M/A2+1[\6DMO+>ND1"L\93]R5);!)R3P,#'-:/A:\UE[.PT[4=!ELYK&(13W,
MC(8WVKM!BP23G /(  S[4 :$7BO2IM/TZ_224VVH3BV@?RFYD+%0",9'(/7T
MJI!XJAO;K7[6:"\MH--/EM,L+%ON!BPP"?XA@8SQFN6MM,UN'PYH>D?V'=M+
MIFLI/-)OC"/&)7?<A+<_*PZX]*W(+/4;75?%ZMIT[Q7Y$UO,I0J_[A4V]<[M
MP/;'?- &OI^L6$&B:08;BZO/M=NIM?,&^>=0@.YNG.,$DX&3[BFR^,=%ATMM
M0DGD6%+@6LH,+;HI=P7:XQ\O)')P.1ZBN;TO2=5TK_A$-2:QG<6.FG3[ZV7!
MDB)5/G49^8;DP<<XQC-1ZMX?U*:QUN\@L9FEU/5;2XCMAMW)%"T>6;G )V,<
M=>G?@ '9:;X@L=5OKJR@%Q'<VH5GCN(&B8JV=K ,!D'!_*M2N9M;:[_X6+>Z
M@UI,MG+IL,"3,  75W8C&<]&':NFH HWFJV]G<QVI62:ZD1I%@A7<Y1<9;T
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M2]O9/+@CP"<$DDD*  .I)('XU;K$\6'4QH$ATFW,]QYD99%"E_+WC>4W?+N
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MABN!:RAH6W12Y VN,?+R1R>.1S3K#Q;I%_=7MJ)9K>>SC\Z5+N!X#Y7_ #T
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MV-L]Q=7$)CCC3&23[D@ 56U:WO+OQ%X4NX;&X,-K),]PQ 'E!HF09YYY/;-
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MD(4QHX93SG=DC&!7/Z1H>LZ;I'@V]:PF,VCF>*\LP5W[)01O7G#;>#@')!-
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M<7UE8P)/>6$*/*!;RR++(REA&NP'9QCDYZCBH8_$VM7VM0Z9:Z5;VTLVEK?
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MN+RYO+^ZN8/[0FL38Q-'$?+B0DEC@MEB3CN.@'J3T5% '*7/A*[G\&:=X?\
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MF,H7?@G*KE@Q!W'N#6Y-X;GN?$-[J4U['Y=WIPL&A2$@J,L=P;=ZL>,5T5%
M&7X=TRYT;0;/3;J[CNFM8EA21(O+&Q5"KQD\X')S^5:E%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
84 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>36
<FILENAME>exhibit1018-arvinasxcons004.jpg
<TEXT>
begin 644 exhibit1018-arvinasxcons004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=S",;5)QT!/ &3FL-M(UFQN+2\CTJ6Z,&O7=X88I8@QBD2158;F _C'&<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MEM+H^9I=J=B0F1E.Z3Y2%S@G\N.M=Q69!HD%OKUSK"SSFYN(UBD5BNS:N2H
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M P*H6-A?1:1X!A>PNA)ITB_:QY+?N@(70Y_X$1TKT:HVGA2=(6EC660$I&6
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M7D:E9UC#;O)/J#T)SC';/- $"^)XM/M_$][)I4%NVG7B1S-"<^;E4_>.0H/
M89X) 7O47B'Q'JD?@^\U'3WL7430QPW4$Q=9(W95++CHP+$=3C&?:K]MH&J6
M<VN3P7=JLNHW<=RFY&*H%"*4;U!5",\=:H3> _,TC7+:U>WL&U*:&=((5+0P
MO&RMG''WBO. .WIR 7]<\1ZAHT-S))96RI;6AN#)+.0D[C=^ZC.,[L+G)'<<
M4V3Q3?3:KI=C8:;#(-1L&O(I)K@J%QLX8!3Q\_;.?;K4&H>%M8OK^_G.IVFV
M_P!.^QR[[=B83\V3%\W .[G.?NCK4NG^&M2M-3T2\ENK67^S=/:R951EW[MG
M(Y.,;!]>>G2@ T[QA)?Z?IP^QHFIWMU-:>1YF41H2WF-NQDJ F1QDY ]ZGD\
M27ME;A-1TWR;R2^-G;!6+I.-I?S!@%@NT-QC.1CWK)'@C48M.MFMM1@AU2RU
M&:^M9_++1D2EB\;KG."&(R#FM#4_#>K:MI<#SZM%%K5M<K=6\\,)$,3*"NS8
M225(9@<G)SZ "@"_H&LW>ISW]O>:?+;/:2*J3>6ZQW"L,ADW@'CD$<X/?FJN
MIZK+J,FLZ78VMO.+& "Y^T,0K.ZEA&  ?X<$D],C@\XT](M]5BA>36+NWGNG
MP-MK&R1(!GH&)))SR<^G'%9$OAO4K7Q#JFH:7>VR6^JQJ+J&XC9BDBKM#H01
MU&,@^G6@#.\'ZR\?AKPOHMG'&][-I2W+&1B%CC4*N3CDDLP 'U.>.;L/C96M
MY(9K3R]4CU Z>]N&9U\P*7W@A<E"@+=,]O>H--\&7VD)H-U;WMO)J&F6ALI-
MT;)'<0G!VGDE2" 0?TI][X)FN+2:XM[];?6GU :DERL>460+L";2>4V?*?7)
M/M0 2>-9[*ROY=2TY[46MU% +J1)%MW23I)EE! 7D,.QQSSFNCTJ\GOK9Y9E
MMRN_$4MO)O25, AP??)X]NIZUFII_B"2Q#7M]837;2+YD*PLMNT8!!3!).3G
MEO8<<<R>&?#T?AZWO8XA'''<W37"VT.?+@R -J9[<9Z#DG@4 9-_XNU:";Q&
MEMI-JXT0+)(SW1'FH8_,.,)]['8\>YK23Q$^H7\-AI<4;3O8I?.T[$+&CG"+
MP"23@_0#O52?PQ?32>*F%Q;@:Y$(TX;]SB+R\G^]QSV]/>BU\,7VFZE8:I9W
M%NUU'8)8744FX1S*G*N",E6!SV/!Q[T 9MWXPU"_M-%DT^"*VEEUC^SKZ"60
MY21-Q*!@/NG;UQR"..374Z_JDVB^'+[5%@CFDM(&G:(N5#;1D@'!]/2L2;P9
M,NGVBVEY$M]#JQU6662(E)9&W;AM!R!AL#G^$5OZOIG]K^'[W2Y9=IN[9X&E
M"]"RD;L?CG% &>WB&<:WI.GK:1E=1LY;E',I!1D"':1MZ'>.?;I619>-]1N-
M/TC4YM)MXK*^O_L+[;DM(CF1HU8#;@KE1G)!YZ>MFU\.:V-6T74;R_L6?3;:
M6W,44+ 2!@@!R6R#\G)[>G>H(?!NH1>&M+TK[7:E['4A?&7:P#XE,NW';EL9
MSVH M1>)]4FUK5+5=,M4M=+N$2ZG:Z.1$8P^Y1LY(!Y''U/8LO%EY=WNEXTF
M9K'45R)(XY"UME=RF0E=N".,@\'U'-6M.\/SP:GK\]Y)#);ZNRL8TR"@$8C(
MSWR!GM5;P_H&OZ3##IMUK4$^E6@VVY2 K<,H&%5VSMP..@R<#W! &VOBVY;6
M]*T^\LHH'U$S*(/-S-;%%++Y@Z?,JGZ>_6IM(\5_VO,[1?9?(AEECNH_-(GM
M=F[!=2.^W\,]^M9FG>#-8LSH)DU2S<Z3/*^X6S;IU=65F<[OOG=U]>>>E71X
M2DN]9L-1U'[(;FU61)+FW4K)=HR% D@] "#U/(XQ0 U_&4T6CZ?K\MD@T:\E
M1-PD/FQ([;4D88P021D Y&>]07_C'5K=?$4D.D6KIH;@S%[LCS(_+$AV_)][
M!Z' ]S4EMX.NDT"V\-W5W#-I%M.CH^TB5XT<.D;#IP0 6'4#H,YI]SX5OIX/
M%47VFV UT;5.&_<CRA'S_>X&>U $^M>*+G3K:6[@M(A:QV(NUEN9=@G8@GRD
MQGYL+G/N.*QKJ[N+KQUHNI:390/=7FARR*L\GEJ 7B(WL 3QG' /X=:NW'A'
M59IK@KJ-J([G2ET^020LYBP&!:/D8#9R0?0=<5-:^&=3L;G1+V.[M)KK3[!K
M&1'1D213L^8$$D$;!U!SD]* ,36]:_X2'PK;S75B+6_L=>MK6XB+!_+D69,[
M6QR""#GWKJ8_$,L?BB_TB^MX;:.&U%W;S^:3YT>2&)&!MVG&>3U%4+SP=/+H
MQM8+J+[5-J::E<S.A"O(KJV%4'@855'/0=S46OQ:7XGU[3=/@O%;4;"X/VM(
M6R4@9#YB/_LO\J_4^QH Z?2;JXO=*MKJZMUMY9D$AB#%M@/(!) YQUJY110
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MMW(\L;(49=@ X(Y'OWJ31+C7-=TW1/$%OJ$$"3RJ]VKW3,CQL2IB$>S:K*2
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M?:M?17UI=VNH7%PC^($M'F!VP>4S[#"$R=Q7N^!R#SVJ+4Y]6<>.G77+Z/\
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MH#;2JDMS]K&VYD!CER6W1D-\AR2?EQUI)/!.@S0W\3VLICU#;]I'VF7]YM
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M+.&VBM!=6Z6T)@B\NZD&(R<[>O(^O([8K1FU&QM[A+>>\MXIWQLC>559L],
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MQ'YJ[BX&2N,YR 0<>AH L1H(XU0%B%& 68D_B3UIU%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M<9\21:'0K#[5Y6/[3M<>9CA?-7=C\,Y]J[.B@#S_ %NYT_PWXNLI;B7^R]%N
M+)TBN+>%/*6<ON<-\I W+MY[[:@@DT;1;SP]8VGFVT#0W1L[Z\W'Y69<I&G
M+-U7(X X!SBO1B 1@@$4M 'DV@2!_"'AK[#K,6G:K:_:EA^UI^XDP^&B<'&#
M@KC'(P:T-+U21-;\,ZEJ=I'IVFRV%Q#&N[]S#<F0<ACP R*=I/8X%>D$ C!
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M_MS/F%=V!Y<7\(_A)!!_&O4\#.<#/K6?K>F2:OIIM8KR2SD$B2)+&H;#*P8
MJ>&7(Y'>@#CM+OM U[Q7<:Q)J.C23+I@MOLL4PD. Q9G.Y5X ..G0G/I6'H_
M]GVWA3X>3QFWCN1J""1Q@/@QR!MQZ]=H.?:O1K/2;W[5#<ZK?PWDMN2T/DVH
MA"DJ5).68DX)'4#GITQL4 >27FK6,K6+PLMHMOXH#SVF&:2-C(X:25CG&[.0
M!@8..<5I3LLG_"Q].52;R>-I(H0IW.IM5 ('ID8^O%>DT4 >:VVL:7?^(/!#
MP7,4T*Z?<QR,.5#>7%E2>F>.1V[]:H:;902?"K4+G2K.&;4(KBX#&!%,OE?:
M270<=&C'3H>*]8  Z "EH X[PU<Z#K6O?VSI6H75]<_8_(ED*A$C3<"$<!5&
M_.<#J #4GQ!=(=)TNYE(6&WU>SEED/1$$HRQ] *ZP #H,4M '#6E_9P^,O$2
MZU)$EK?6UNUD]Q\J2VX0AT7/HQ)*]?FS6KX!MKVS\#Z7!?\ F"9(VPLN=RQ[
MB4!SW";1CM71D XR <4M 'DWC34;22U\86T>+2YCDMWEB(9Y;G:(R)1G(6,#
MC@=1DD9Q6R#HUW\1M7EE%H\3Z-"V9 N"=TF3SWVD?@17H%% 'E]A!(WPN\-Z
M_9 2ZAH<*S@ Y9HP"LL7ME,\>H%=WH$3FP:^FC*7%_(;F16&"H( 13[J@0'W
M!INJZ1=ZI=0K_:CPZ;L*W-FL*GSQGIO/*C'! Z@GI6O0!QFM:E%I7Q'TRXU:
M58-+?3Y(K>>4XC2Y+@G+'A24& 3[CO7*6=RD%BMQ"/\ B4VOBN>2\"KA4B+-
ML<C^X&VGVP#VKUX@'J,T8H \O\20W=U>^*;[P_FXLY=,MQ.+=LK/,)"7"D=6
M\D8./[P%;+WOA_Q-8:E?:%']JO'TB6V:6-6 1""5B8=-V3TQD8/X]L  , 8'
MM2@ =!B@#R_3M7TV\N_AV(;F.40VTL,Q7D1O]F"E&/0'/&.O2LR=-+'PYUIT
M%J)%UYC&R[0P'VL$;3U VY(QVS7L0 '0"EH \UUI /%FM6NA&&.ZF\,E84MR
M%+2!WVXQ_%@C'L14^AW?AG7;K3[Z*\N9[JRM'BEMY46-;6,KADE 11@$  'O
MR.,FO0Z0 #. .>M 'D.D?V?;>$/A]/&;>.Y&IH)'& ^-DH;)ZX^Z#GVKK_!L
M\,>M^*K)F"W7]K/-Y9'/EF./#?0X./7!KL** .+\>K8MJ'A878@_Y"R9\S'W
M/+DSG/\ #G;GMTK-U.?2]"\67NGZK.VEZ3>6,<5F8H4$# %_,CY0@$ELX&,Y
M^E>C4A /4 T >=V-[8>&O%6G07SSVVEG24ATR6\SPWF'<I)'#E?+X.#@ =>*
MR;66"U\(Z%>OB&SMO%$LDCLNU84\V9<M_=&2!STS7K3 E3C&>Q(S@UC^&]#D
MT'3);.6Z2Y#W$LX81;,>8Y<C&X]R: .'O+RPO%^)3!XWCDM(WB+#A_\ 1<*5
MSUYQ@CKD8ZU.L>E7OB;P4EPMI.LFDS(ZN%8.=D04$=^C8!]#7I6** /+[B72
M!J/B#PYXBN;JT%S<!K:VBB7;<0;$$8B(0G*E<8!X(X[U:34+:PU_Q38:[((I
MKFUB6R%T0?/@$6"BG^(ARV0.I->BX!(..100#U - '.^ )$D\ :%L.=ME$I]
MB% (KG;][E?$/CJSL7*:I=6$#62#AG(A<$K]#QGU(KT6B@#SKS;75X/!+:(R
M"]M+B/S8X^'MX!$PF1QU49"K@]\5Z%-)'%"\DSJD:C+,YP />G  $D <]:6@
M#R(2V;? O3BSPF2.6#&2-RL+D$^X.,_AFNCU&<R_$:YCL;B/[6_AV18,./\
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MU"\%HT=K<Z*+)9'=.)-[MR 2<?,!GU%-TF[UK0/#WAVPN=%!*^38W!6Z4F(
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M1110 4444 %%%% !1161KNKOIK:=;0!#<ZA="VB:0$JGRLQ8@$9P%/&1DD4
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M-J1":C>F\DD$'S(Q<.0OS=,J.O;-377A.Z.NS:MINN7.G2W:(M]'%$CI,5&
MRA\[&QQGGM717$K06TDJQ-*R*6"*0"WMSQ5+P_JZZ]H%EJJ0F%;J(2B-FR5!
M[9H K6_A[[-XF&L)=':+);(0%,_(K%@=V<[LD\^GYU8\1NJ>&=4+$ &TE SW
M)4@#ZYK3HH X[POH[7_ASPS/>W:SQV%M%)#"(MNV41;?G.>2N6&,#GKS5^R\
M)P0Z-JNE7L_VNUU*:::4;-A4RDE@.3QD\=Q[UT5% '/VOAUH3ISZEJ/VR/2@
M3;%XPASM*[Y#DAF"DC("CDG&<8YSPCI!UKPK/975V#8/J,\DML(L.R^>SA=V
M?N-@'ID@GGFO0Z* .8F\)3IKMUJ.F:Y=Z?#?$->6T<:.LC 8W*6'R,0 "15V
MST V?B2ZU=+K*W%O';F#R^%6/.W!SG/S'-:%W/<PR6JV]F;A9)0DK"0+Y*8)
MW\_>Y &!SS5J@#F(X+7P7'?WEQ>7<UG>WK3+#';&0QO*V3]P%B,_EG%6/"&B
M1:'HICC@>#[1-)<>4YR8E9B53VVKM&/8UM&YA6Z2U,B^>Z-(J=RH(!/YL/SJ
M6@#(\1:!%XAL(H&N);:>WG2YMKB+!:*5>C8/!ZD$'J#5&#PO=)JMYJ<^L/-=
M75DMHX%NJH "Q#8Z_P 1XS_A702W,,$L$<LBJ\[E(E/5F"EL#\%)_"L[1M<&
MKW>JV_V5[=M/N?L[;V!W_(K9XZ<,* ,RV\'M:P^'8DU'(T//DDP\R H4^;G^
MZ3T[U)?^%9Y?$$FL:5K5SI<]RBQW:1Q)(LP7A3A@0K <9Y^E=+10!S%YX0?^
MUX=3TG5[G3;D6ZVLY"+,)XU^[N#_ ,0R?FJU-X:5M6TO4(+^>&6QB>!LA7,R
M.5+;B1P25!R/4TZU\0G5'G;2;%[NV@D:)KDR*B.R\,$SRV#QG@9[U=TK4EU6
MT><6\]NR2O$T4X =2K$'."1VR,'H: ,B**W\&PZE?WMS-/#?WWGL(K5G*.X"
MX 3)V_*.W\ZE\(:)#HNCN(H'@^U3R7/DN>8E9B43VPN!CL<UT%% &3XCT0^(
M-*^P?:C;KYL<I<)N.4<.!U]5%5=<\,RZK>V6I6>J2Z=JMHK1K<PQAE=&QN5D
M;@C(!'I7044 <]>>&9+R#2U?4I&EL;Q;UII(PS32 $<@8 7#$8'MZ50NO K7
M$>H0)K5S%;W5^NH+&(D;RY0ZL>2,D97@=O>NPHH YY_"<,NJZG=37DTEOJ=L
MEO=VS*N)-JL@.[&1PQX&.?RJ+2?"<]E;?8M0UNZU.P2)H8+>:-%VH5*X9E&7
M.TD<^O3ICIJ* ..A\#7$=GI=BVOW+VFE723VBF!-ZJH8*C-WP&P#@<=CQCK9
MHEN()(7SLD4HV/0C%244 <G!X)%OI>D0)JDQO-';-E=-$OR)MVE&48W*5X/.
M3ZBMK3=(6QN[V^ED$U[>LAFE";1A1A549. .>I)R3S3-1UV&RU"WTV&&2ZU&
MX0R);Q8!5!P78DX5<\9[G@ TL&KS-JT6FW6GS6\LD+S+*&5XB%*@@,.<_,."
M!T- $>M:%_:UYIEY'>26EQI\S21NB*V0R%&&#QT/7M6?/X/:>U\0V[:CA=;.
M9B(>8_D"?+S_ '0.O>NHHH Y6Z\(7)U&WU+3=;GTZ^6W2UN'CA1TN$7[N4;(
M##)P?>NDM;=;6UC@5W<(,%Y#EF/<D^I/-344 <_+X:>#7+C5]'O_ +#<7847
M43Q>;#,5X#%<@AL<9!&>]2ZEX;BUK1[FQU*YEE>XVGSHQL,3*<J4'.,'GG)/
M<FI;K7!:^)M.T9K5R;V*61)]PVCR]N1CK_$/2M&"YAN?,\F17$;F-RO9AU'X
M4 9,>A3O>QW]]>I<WT%N]O;R"#8L8;&YMNXY8[5R<@<< 9-9]OX,-OI.@Z>F
MHDQZ-.L\3&'F0@,H#<^C'I[5U=% &+9:%-9:[JNJ)>JSZB(]T;0\1[%*KCYL
M]^<]?:LF/P(L&BZ1:6^J2Q7ND2O)9WHB&0&SN5ESA@02#T[?CLZKKJ6&A2ZM
M:6LVHQ1DY2V(R5!PS#) P,'\JU8W$D22 $!@" 1@\T <I+X%BO5UL:AJ=Q.V
MK&%W,:+'Y4D:J%=,#((*@CGZYZU,?"U]<Z'?:?J>OSWTMU;M:^>\")Y<;##8
M5<98^IST'OGIZ* ,!?#D@U71K]KX%M,MWMU00X$@<*"3SP?D7]:H-X'_ .*6
MN?#ZZK-]DEG\V,M$I,2^;YNT=,_-W/;L.M=(-2LS:I<BX0PO*(5?/#.7V #_
M (%Q5J@#E=2\&-J-SK$G]K3PQZO:K!=1)$I&50J&4G) P>GZU:B\-R1ZOI.H
M/J+2OI]L]N T0_>!]NXG!&/NC''YUT%% %;4+5[W3[BU241&:-H]Y7=M!&"<
M9'-<]'X.>/1M"TU=2_=Z//'/"Y@Y?8"%#?-TPQSC':NJHH Y[_A&9!=Z]<"_
M ;6$5''D_P"JVIL!7YN?E]>_Y5$?" &F:)"E\R7NB[19W8B&=H385=<_,&7@
MX(]L5TU5;F>YBNK2.&S,T4KE9I1(%\D!20<'ELG P/6@#"U+P<FJ:9JUO/>$
M76K;!<W"18PB?=5%SP![D]3^%W4]#EU.ZTBYDO5233I_/&V'B1MI7GG@88UM
M44 <U+X3>6/Q$AU# UQ=LN(?]6/+$?R_-_='?OS[5 W@IS,[IK$\:S:<NGW"
MI$O[Q%#!2,YVGYCG'7VJ_>^(9H[V\M=.TU]0DL3%]J1)0CC?R-@(PQ"\D$C@
MC!-;M ',0>$&MSH,B:K/YVD0-;"3RT_>QL%!!&./N+@_7K39?!5O=6>MVMY=
MO)'JMR+HF--C0R *%*')Z;%//]:ZFHK>YANXC+!(LB!V3<O3<K%6'X$$?A0!
MDQ:%.][%J%]>I<WT%N]O;R"#8J!L;F*[CECM7/('' &36?;^##;Z3H.G)J),
M>C7"SQ,8>9" P ;GT8]/:NF6YA>ZDMED4S1*KN@ZJ&SM)^NT_E4M %>_LK?4
MM/N+&ZC\RWN(VBD7U4C!K%L_"[Q1Z9#>Z@UY!I;;[17B"MN"E5:0Y^8JI.,!
M?4Y-=%10!D:!HC:'%>H;K[0+J[DNSF/;M:0Y8#D\9Z?UIWB#1!KMC#!]I>VE
M@N8KJ&55#;7C;<,@]16C<7$5I;2W-Q(L<,2%Y';HJ@9)-/!! (Z&@#!3PY-'
MK%]J0U'=+=VB6K!X1P%W8;@CG+'/;Z5F_P#""-!8Z.NGZS/9ZAI4)MX;M(E;
MS(CC*.AX;H/QYKL:* *NGV;65HL4ES)<RDEI)Y<!I&/4X& /8#H *S-1\-BX
MUJ/6]/O'L-26+R9) @>.:/.0KH<9P>A!!'K4^DZX-4U+5K(VKP/ITZPL78'?
MN0.",=."*O7UR;*PN+H1-,88R_EJ0"V!G'/% %&;1?[1L;FVUB<7:W,+0.J)
MY:!6Z[5R3GIR2>G&*JV?AJ2/^S%OM0-['I?-H&B"MNVE TAS\S!20,!>N<9K
M1T34UUG0K#4UB,2W=NDXC)R5W '&>_6K] ')R>"FD\.WNCMJ1\N[O3>O((!N
M5C*)2!SC&X#\/SJ36M':*ZU'7YKU=QTI[,Q>7A2.6!!SG.X_TZ\UI:EK+VM^
MFG65J+O4'MWN5A:7RQL0J#\V#R2P &/7)%7[.=[JR@N)+>2W>2,.T,N-T9(^
MZ<<9% ')>$]';4/"WAB2^NQ-#8012Q0+%M*RB/:-YR<E<G P.<9SBG0^ WAM
M[&V77+H06%^;RV7RH\KDN2I)'S'YVY/Y&NRJ*XN8;5%>>18U9UC4GNS,%4?B
M2!0!S-QX,-SI.O:>^HD1ZS.T\K"'F,D*I"\^B#K[U#K\-EXCN;;PW-'<2W=K
M/#/-,L#QQH@&6(?H=RDI@$GYSZ'&W9ZX+OQ)J.C&U>-K***7S68$2!]V, =/
MN]ZUJ #I1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !7)?$_P#Y)MKG_7 ?^A"NMJIJ.F66K6C6
MM_;I<6[?>B?E6^H[T <KK$!N?&OAJU-U=I;W-E=>=%%<.BOM$>. >#\QY&#[
MU@>;=#PY:6ZW]ZHMO%8LHW%PV[R?M& K$GY@!_>STKT3^P]-^TVUQ]E'G6JE
M()"QW1J>H!SP#4/_  C&B^5Y7]GQ>7Y_VG;DX\WKYG7[WOUH X?5;^\\-+XY
MCTV>Y*6MO9S0B25IC"9-RR.I8D]!N^HK;O8CIWBWP['IDTSV>I)/%=Q&9G61
M%CW++DDX8' W=3N^E=*FC:='=W-T+2,SW2;)W;),J] &SU')X-)8:+IVF$&S
MM4B*IY:X).Q.NU<_=7V&!0!Q^BF9+N\\'W%Q<R7%M??:!.\SF1K,GS%._.3S
MB(\U2UN]<&YU"PN[B1H->@MVN9)BA0[T1X$0<% "<YQDD\'K7HPM8%O&NQ"@
MN&C$32X^8J"2!GTR3^=9L_A30+F6YEGTBTD>Z8/,S1@[V!!R??('UQ0!@Z-8
M6S_$'Q:<RJS):D%)W4Y:-\]#^7IVQ6-H&JW4^C^ [&[N)FMM1%P;F5I#NE=%
M)1&;.>3DXSSMQZBO0#HFF&^:]^PP"Z:+R3,JX;9T R/8D5&/#VD#2X]-%A"+
M*-P\<('$; Y!7^Z<\Y&* //O$4U]8Z9XWL(+R[2SL1:S6CK.P:%I,;XPV<E>
MAVG@!OI6W+%)IGC>^M+;4;B&*YT.2XDDGF:14E60*)<,2!@,>!@<=*ZB70=+
MGTZ2PFLHY+65M\L;Y(D;U;/+'@=<]!Z42:#IDMR;F6T228P&W+N228CU3D_=
M/I0!S7A>]FM=9ETW6+.6QU*&R\QG6X,MM<QJP!E4D_*V3SGGD9)Q78R;I;5_
M(<;G0['!R,D<&L]_#VFBRN+9+*)EFA\AEE+,/+_N<G(7GH,"K.E:=%I.E6VG
MP?ZJWC"+QCIZ#L/;M0!ROPI94\!6MBXV7EE+-!=Q-]Y)?,8D-[X(/XU:\2:G
MMUO0-/20I97M^\-Y)&2NYEB)2,L/5@ ?7;CU%;-SX>TFZOFO9+)!=, 'FC)1
MG Z!BI&X?7-3W.E:?=V L9[.%[5<%8B@"J0<@CT(/0B@#SOQ')>Z?;>-M/M;
MJZ6RMK"*[MV6=P;>1@V45LYVG;G;G S[UK"-]+\;6\<%_<I'>:-/-.TTS2+Y
MB,FV3:3@$!CP,#':NI?0M,DL)K&2S1[:<[ID?+>:?5R>6Z#KGH*&T+3'N([A
MK1&FCB,*.Q)*QGJO7H?2@#A[.XN[:.\TK5K6XM=4729GCN;>Z9X+T+MS*ISE
M9 <=>?FZ]*GLKV=Y_ANYO)C)=6K>>#,W[[%J6RPS\WS<Y/>NTL]&T^P.;:U5
M,1^4N26VI_<7.=J].!@<54M?"7A^S:%K?2+1# YDB_=@[&/<9Z=\>G:@#S_6
M(8YO!/CHN"=FO%AAB.?W [?6M[Q'Y)N]1L[2XN))+/2'D,37+)';9+D2AN6:
M0D8'H%ZC//4CP_I*VUY;_8(3#>L6N8V&1*QZE@>I]^O%1OX7T*26&5])M&>&
M+R8R8@<)G.WW&23]3F@#D(&FU74_! N;Z\*WVCRR72QW+H)6$<)R<'@Y<\C!
MYK+EB^T^'+"WN)9YDLO%HM(6DF8LL8N" "V<G X!/(KT6#PWH]J]H]OI\,36
MB%+<Q@KY2GJ%QTSW]>](?#6C&QFLFTZ!K:>7SI(F&0TF<[^?XL\YZT +K:+'
MX6U%$)*+92@98G@(>YZUQ6APMI]U\/Y8+FYS?V!CN5:=F1U6V#J-A.T8(XP!
M7H4ME;3V+64D*FV9/+,0&%V]-N!VQQBJB>']*1K)ELT!L1BUY/[D8QA>>../
MIQ0!Q>@_:M?TO2M>.NI:7:7@^U*%<LQ+E6MV7?@#D ?+Q@$5#:QW$&D^+-:B
MN[^:]TF^OOL:/=.Z*!&, J3A@,YYST%=M%X8T.'6GUB+2K5-1<DFX$8#9/4_
M4^O6K-EI-AIIG-G;)%]H<R3;<_O&/5CZD^M '+Z99%KK3=8M=>C>UN;5T:!
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M73;D6BRV<16S(:W4# B(& 5 Z$#CBHF\.Z0Z7B-8QE+TYN5).)C_ +7//XT
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M&6RIQG(P>M '=V=]::C;BXLKJ&Y@)P)(9 ZG\12W5W!9QJ\\FT,P50 26;T
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MU&./2#I0ND#(!AS)MZXW'@=/K5CX@0S3^$)O(AEF:.XMI2D2%VVK,C,0!R<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6<4<\FV.5@I;>LA S'M!.<9X(QFJT'CBU:"[^TP+#<6]TEJH$P:&5G&599,
M%< DG&1M/&>H!U=)N&X+D9(SBN5B\<6RQZD+JVVS63Q(HMY1+'<F4X01O@9)
M;@@@8^E4H&N1\6#)<6$44QT)S^YEWB7]\F.2%Y[<^W- ';JP894@CU!I:XC3
M/%5I8>%M!GT[09(K74;MK6*VBD4>4Q=_7KDJQ].>M7AXTCMK#79]4L7M9M&*
M^=%'()=X90R%6P.N0.>AH ZFBL&#Q#<'Q.FA7.F^7.]K]K$L<X= F=ISD Y#
M8& #U!K>H IZK8#5-*NK!I7B2YB:)W0 L%88.,\9P:73+$:;I=K8B5I5MXEB
M5W !(48&<<9P*MT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !6;K&D
M-JZ0)_:-[9I&Y+BUD">:I&"K'!./I@UI44 ,BB2&)(HD"1HH5548  X %/HH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
ML+Q1I>HZI:V2Z>]N?)NDEGM[EF6.XC .48@$XR0>A''-;M% '!R^#=8FT7Q%
M8M/8*^H7R7UL4W[59?*.UN.!F+&1GKGCI5]-!UF[\276J7QL88[K2A8M'"[N
M8VWNV02HW#YNO'ICC)ZVB@#A[7PIK-M8^&9_,L?[2T)# J*[^5/"R!&!;;D,
M=H(X(!&.>M+K/@^_U33?$+HUHFHZSY"%6D;RXHXL;1NVY8_>/0=<=LGMZ* .
M>?2M2;QK!K>RT$$>G/:,GG-NW,ZOD?)C'RX_'/M6':>%-?L]/TN /ITR6M]<
M7$]K),_E3K(S,I)V=4+9 (()YXXKO:* .#7P?K2:));>?8/<1:W_ &I!RZHX
M\TR%6."5ZXX!QCJ:TKKPY>ZCXDN;R\-M]BNM(.G2B.1M^2Q)8 KC'..M=510
M!ROA_3/%%E8PZ9J-Y8?9K2+RHKFW#&68!=J%U887'!."<D5FZ7X4U^VN_#UQ
M<OIADTUIA<R(\C/<[TVF4DJ,N>X/Y]J[RB@#AKCPEJ\_A;Q-I6ZQ6;5KR6>)
MO.<JBOMX;Y.HV]O6K'BV*'4[6PL(=0AMO$,%S#);K!('DB).'.#@E?++DY'0
M5V-0"RM!>M>BUA%VR;#.(QO*^F[KCVH =;6\5G:PVT"!(84$:*.R@8 KBM5\
M*:W<1>*;&S>P^R:U^\269W#QN8U0J5"XQ\N<YX]#7=44 <+'_:-O\2T2.&VF
MF70(UD4RLBY\Y^0=I_E_A4D/@N[TZ32=2L9X)-3M+BXFN$D)2*<7!S(H(!*X
M.-IQVYZUUHTZQ%^;X65N+PKM-P(E\S'INQG%6: .(U?P?J&I:=KTD;6B:CJ\
MMN6#2-Y<4<)7:-VW+$X)Z#[WMSKII.H'QP-;<6RVITX6A596+AM^_.-H&.W7
MW]JZ"B@#F?$&BZK+KFGZ[H<MJ+VUCDMY8+LLL<T3D$C<H)!!4$<5'?Z!JUU>
M:-K(N+5]6T^21FB)987CD4*T8."1@!2&(.2#P,X'544 <3K/A"_U33?$+HUH
MFHZSY*;6D;RXHXL8&[;EC]X]!U [9.J^E:D_C2WUO9:""/3WM63SFW;F=7R/
MDQCY<?CGVKH:* /,KO2=2T*P\+64PM)+D>(7F39*VQ@XG?!)7(^]CH:WM0\,
M7VH6_B2X8VR7^KV8LHT\QBD485@"6VY)RY)X]![UTUUIUC?2127=E;W#Q'=&
MTL2L4/J"1Q5F@#C9M \0V6H:=JND2Z>;M+%+&\M;EW\J15)*LKA<@@D]1T-6
M[[1-8N-3T#4EN+26ZL&G^T"3<J$2KCY, GY<# .,@<D5T]% '$WW@R]U5/%,
M-S/! FK30SVTD3LS1/$J!2P*CN@/![X]ZTQI&I:AK&EZIJ<=I'/ID4OE1P3,
MRR2R*%+$E1M7 /&"?F]N>CHH X2V\(ZS;^&/#^F$V!FTS45NY&$S[7579L#Y
M,Y^;]*Z'Q3H3>(M!DL8YQ;W"NDT$I&0DB,&4D=QD8/UK:HH YY-)O[[7K#6=
M2BM8IK"WECAA@E9PSR;=S%BHP,+@#!ZFG>$M)O\ 1=-N+6^^S%I+N:X4P2,P
MQ(Y?!RHZ9Q6_10!STVD:C'XV.M6IM6MY;!;61)6974J[.", @@[L>W7GI6+;
M>$=9@\+Z#IA-@9M.U);R1O.?:ZB1GP/DSGYL?A7=T4 <?9Z)XDTC4[^WT^ZT
M]M(O;E[D/-O\^V:0Y<* -K#))&2,9YS6UXFT^_U3P[=V6F72VUW(%V2.2!PP
M)4D<@, 5R.>:UJ* //-5T+4["P\4ZG,FG0VMSH;0^1;%CY31I)P,@ CY\YX]
M,=ZT]+TF\U:S\+W%\MO%;Z=$EP@BD+M+)Y6U>JC: &)ZGG ^O5W-K;WEN\%U
M!%/"XPT<J!E;Z@\416MO!;+;0P11VZKM$2( H'I@<8H \[\.:3>>(? +:0ZV
MZ:?/?W'F3>82_EBZ9F4+MQDD$9SP#GVKIH='U*#Q5K6J!;5H;VUBAB4RL&!C
MW\M\N #O[9QBMNSL+/3HC%96D%M&3N*0QA 3ZX%6* .!MO!^NZ;I/AN6PGL?
M[6T6)[=DD=_)N(G # L%RI^4$<'FM/4M'\07PTN=YK"9X;AI;JR=G6!U*[5
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M>6$<0R;&.Y@H&[L,D9/IFN3M+B%/$7BNW@U.PM#-H\3I)9\1Q.%E!< $[BH
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MZ]_2E#*6*@@D=1GI7D.I:9IY\'^/KG[/$9[34YGMY,<PL$B(*'^$Y],5TO\
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M,DR?9?M'[P9],#\!FNLFL+8>/M-33(8#8WFFS?VC#$H\IXP5\IB!P226 /<
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M2VQDB*"91U*$C!(R#@\XYQBN8T?5U_X0*"?6-5U"-GU*2$74.3(Q%TRHI(!
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M%9N@Y.,] >"0:S?&.OQVOAS7$LY[I;NTM79IK:,MY$FPE QP<=B<= 03@'-
M'4;$\SS-J[P,;L<X],U&EG;1SM.EM"LS_>D" ,WU-0:/(\VB6$DC%W>VC9F8
MY))49)J._P!5MK:8V>9WN6B,I2VC+NB=-^,<<]/7!P#@T 3C3+ ","QM@(O]
M6/*7Y.<\<<<U)#:6ULS-!;Q1,_WBB!2WUQ7(^"?$B2>%] 34KN>:]U)IEBED
M5F\PJSG!., [5[XZ5KW'C#1K2QO[R>:9(;"X%M<$P/\ NY#C /'3YEYZ<]:
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MUZ+10!YWHNF7-D[Z'J/A-+R2.Z>2#4WCC>!HS(7#N2=P89Z $D@<CK7HE%%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%8.J:W);^);#18Y8+9KN"299YT+!V4J/+49'S8))YZ#IS
MD &]167X>U.75]'2\FC5&,DB!DSLD"N5$BYYVL &'L>IZUJ4 %%%% !1110
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "N-\7V-GK>KVFDZXHBT=[>25+C.P_:00% ?^$A2S =
M_?!%=E10!ROAW5IM-\.V::[=-([WK6-K<^4<W*[RL3D <;@.O3OGFNJHHH *
M*** "BBB@ KQN_LCJWQMU:*&_GLO.TWR8;RWD*;9=J8 8'D_[->R5R+^$]>9
MV8>.-44$Y %O#Q_X[0!P_A22^M?!_B?P>]C]D\20Q3;944@WI*GY@W\3>GL0
M?6KG@@:5?Z9I=^;[4%U/2=.DLY[5HU2.%=N"'.P<9 (^8G/T-=5_PB.O_P#0
M]:K_ . \/_Q-'_"(Z_\ ]#UJO_@/#_\ $T >;:)<Q:=\,/#8N+">2ZBUG,;@
M28M7W$AW5/F;@\+WJUI=O=3>&_B;:+#=23RW$DJ*\#(T@)8YVX&"1SC]*[__
M (1'7_\ H>M5_P# >'_XFC_A$=?_ .AZU7_P'A_^)H&<%K]Q'<_#CP$D6YFM
M[NU$HV$;=B88\CH"<$],U-K$<UGJ7Q'34<F;4K6+^SL\^>N& 6/^\02HP*[?
M_A$=?_Z'K5?_  'A_P#B:/\ A$=?_P"AZU7_ ,!X?_B: .+GL[JW\3?#.WU1
M-T]M:D7'F#/EMM&T,>QR,?452T#3K;4?!'B.PNKR73Q)KQD@N$4XB/!1R/[F
M5Z]NO:O0?^$1U_\ Z'K5?_ >'_XFC_A$=?\ ^AZU7_P'A_\ B: /.M=NM7U#
MX1:O#JD<4]XFJ)$MU;#(O=NT>8,?>X7&0.=OJ#70:.T%O\9KB6/9':'040.N
M F1Y9QGIPHS]!72_\(CK_P#T/6J_^ \/_P 31_PB.O\ _0]:K_X#P_\ Q- '
MD$BF/X%0Q2H5==<!9&7D @XX]Z]"TXIJ'QKFU'2!NTZ#2A#=2Q*0A?/"?[P&
MWCJ-OM5K7/AKJ?B"S2TO_&=_/ L@DV26T1&X=#QCU-:2^$?$(4;O'>J%L<D6
MT('_ *#0!)\/K_P_?:/=_P#"/:9-IT$=TPF@FCV-YA .[&3U&/IC%<G\04CN
M?BIX35I72*,,)I8G*F+)X)8?=-='#X'UFWDGDB\;:HKSOYDK>1#EFP%R?E]%
M _"IO^$1U_\ Z'K5?_ >'_XF@1RO@KS_  CX\U;1-;1I[J^/FVFLRJ6:=>R,
MY^G3U!'I5#P':07<=KH^MW>IP:[I6K-=?94C WL3RY;9DH<G/S=/J*[G_A$=
M?_Z'K5?_  'A_P#B:/\ A$=?_P"AZU3_ ,!X?_B:!GF/VBQ31OB9:3!3=W6J
M.EO'LRTK>:VT+QR0><#IUKH[*UU#1?&GA&]U]S%9PZ$+<S3'"13A3N5B> Q&
M/KCVK7TGX:ZIH]Q>S6OC2^C>]E,]P8[6,%Y"<ECG/J>E:G_"(Z__ -#UJO\
MX#P__$T >57FG:A;_!&PM[R*9&FUGSK>$J0ZPD-SCJ!G)_$>M=O\5="M(/AQ
M='1=-B027$,TOV6(?.HX#';UXQS6]_PB.O\ _0]:K_X#P_\ Q-'_  B.O_\
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M:=&$8$$3KE75O,RQ'&1CGG % '95FV^OZ7=Z@+"&[5KED,B*58"10<$H2,,
M>N":YG2=2\2ZUHMY?R7MA#%$UW 4CMFW$QN55@=_'"D8Y]<GH*?AC4KFUT'P
M7I220&YU&RW1S&'F")(E+ <\L25&>!U.#C% 'HE%>?ZKXOUK3;37[8"T>_TF
M>U E:(A)X9V 7@'Y6&2">1QTYJ_<ZAXFL?$6DZ7+>Z;*-1:Y(D6T=?+5$#+Q
MO.>I].@YH [&BO.I_%'B2V\-ZSJ33V#-HE\]O*/L[?Z4JE?]KY/E;WY%:'BO
MQ-J>B1:M=0R6P6RACF@@6,RM*#]\RX_U8[+TZ$\]* .UHKC[K5M?N/$FKZ79
M7-C!';6,5U#(]NSL"Q?Y2-P!^[UXQZ=Z31O%%YXA&DVL)BM+BZTI=0N)-F_;
MDA0J G^]N.3G@ =\@ [&BN2&LZ[]HL='N88DU5[22YN7M KJ KA%VAV7KG)S
MG'3OD;/AZXU:YTB-];LTM;\,RNB,"K 'AA@G&1@XSQ0!J56O+^VL(U>XD*[B
M0BJA=G(!)"JH)/ )X'0&N:?7M4U&SU^]TM[>-=)N)+>.&6,MY[1*"^XY&,DD
M#'3&3G.*S9]0N=;\4^"M1M)U@AO;.YGCC>+<4S'&2#\PR><=L>] ';V&H6FJ
M6,5[8SI/;3#<DB'@CI_/BF/JMC'JD6F-<H+V5&D2'^(J.I_6LWQA)<6'@G6)
M]/E%K-!:2RHZ(/E(4DX]"?6N;DCU ^)O""17, N6TRZQ,\)*J,0_P[N3^(_I
M0!Z%17#Z?XMU&YLK&SDC234YK^ZLGDA0 $0%LNJLP&2 .">,D\XQ6_X>N-;F
MCNX]:M!"T4Y6WE!4>=%CABJLVUNH/- &A>ZA::=$LMY<1PHS!5+MC<W8 =S[
M"H[75]/O+G[-!=1M<;2YA/RR!00,E3R!R.W>N5LI&OOC#J:77(T[3HA9HW1?
M,.7<#UX"Y].*WO$5U9Z)I]SXCF@\R;3[63;C@LIP=F?0E5H V:*Y.YUK5M)O
MM#%Y+;SV^K/]G;9$5\B8H64KS\R<$$'GOGM61:^*?$+:+IFL7$M@89=5^P30
M) P+*9VBW!BWRD8'&#TZ\\ 'H=%<?'XGGE\42://=1V%VMR5BM;B @7$&.'B
M?.&;OCZC'>JDGBS5H_"5YJF;4W%KJYL2/*.UXQ<"+.-W!P<]>M '7P:I8W.H
MW.GPW*/=VRJTT2]4#9QGMV-/N=0M+.YM;>>8)+=N8X%()WL%+$?D#UKB-4FN
M;;Q/XRN+.?R+B+1()$DV[MI7SCT]>*LV&JZI86O@JV,]O-#J*".4F$AP!;EQ
M@[O4<\<T =O17G=SXI\10:+K6JF;3S'I.J-;-$+=LSQAD7KO^4X8GOS6KJ_B
M._AO_$-O;R0VITFP2[B\Y-PN"0Q.>1\@VA>.<GKVH Z^LZZU_2;*X>"YOX(G
MCQYFYL"//3<>BY]R*=HEQ=W>B65U?JBW,\*RR(D90(6&=N"2<C.#SU%<7>R:
MSX,O=5NSIZZWX:OKB2YN!#@SVQ;AP5/#IQT[#KC% 'H$4L<\*31.'CD4,K#H
M0>0:?7'PZ\;MK/2_#I=[<:9'=).$5SL8E8QAV7^X<]^@XJJ=;\727F@Z=-#8
M:=?:A:W+3I)'YOE21;<,"KX(;<#C/'<G&* .ZJL^H6B:E'IS3 7<L33)'@Y*
M*0"<].I%<Q;Z_JEAJ^K:9K$MO)-!91W5FUO"4\X'*L,%CDB3  _VAZU+-KNI
M:9XDM;'4)+:2W_LF:\G:&$JWF1E <98_+\QP/UH ZNBN8T_4M;NK/2M9+6C:
M==6YN+J'!#0(R;TV-_$1T.>O48JMIFM>(]2_L;4H-/$FG7X5[A#Y:^1&ZY5E
M;?EB.,C'/8#I0!V%%<AX9\3S:SJ0M;BYC@O8XW-YIDT)CEA;(VE"3\R8SSSG
M(/'2NOH J7FJ6.GO&EU<I')+GRX^KOCKA1R?P%%GJ=CJ#R):744SQ &14;+)
MG.-PZ@\'@^E<GX)D:_\ $_B^_NN;N/439)NZI!&/D ] <D^YYK6\17L/A]?[
M1MX4-_J,]M8*S#Y2Q<A2V.H7>Q]\8XH Z&BN.U+7]6T;5[C3))+><RZ=+>6=
MPT)&UX_O(ZAAD8((((_&HM+\0ZV]YX4>]EM)+?7+4LT44)5HG$(DW!MQSGD8
MP,<=>M ';45PVE^*[O4C<1-=PVNI6]O*]SIMQ;E9(7'W2N2-Z=<D9SD'(Z5/
M:>)]2GMO!EPWV<#6E ND$9X/DM)E#GCD=\T =-I^J6.JK.UC<I.MO,8)2G17
M !(_45<KRN\GO+;PYXKDLKG[.Q\2B-R$R65V@4CV^]_2N@\2Z_J^BV^IR+<V
MI:RLEN(42$NT[#<7,B@_NTX !SUSSQB@#M**X]M7UV_\4/I5E<65M"^EQWL<
MCV[.R,SE<$;@&Z=>/H:R;;7=6UVZ\"W8NH[;[<EP\T2Q;D,B1,,]<XY.!GC/
M>@#T:J>I:K8Z/:?:M0N4MX=P7<W<DX X]Z9K=W=V.B7EU8VS7-U%$7CA49+$
M>@[_ $[]*X+Q%KD>N^ -8FM=1AO8$DM0JF,Q2Q/YZ[ED7L>F.!^.,D ],IDT
MT<$+S2N$C0%F9C@ 5RO]LZW9^(-5TN=[*ZD33/M]J=AA56W,NQR6/&0#NX[T
MW1_$%Y=>(WTJ>:.YA?3!>"983&-^_:P4GAD.00?U- &VGB/2)(-/F2^C,>HL
M$M#S^]//08]C6I7EFF?\B-\-_P#L)0?^BYJ])U.:XMM+NY[58FN(X7>-9GV(
M6 )&X]AZF@"U17!/XVN-+N-1^U,M[;6VD#4%=(3%N?<5*J3PR$XPWZFMBZ;Q
M)!#/)]KLVMVL7D,JQ8:&<#(VC)#*1GKZ=^E '2U6CU"TEU&;3TF!NX(UDDCP
M<JK9VG/3G!K(\#O<R^"=&FNK@3R2V<+[MN#@H#SR<GWK/U#Q!JUMJGB>VB:T
MVZ=IJ7EMNA8\D2$A_FY^YVQUH ["BN,TW7M:_M;PVE]+:2VVLV;R&.*$JT+K
M&KYW%CN!R>PQQ5KXB3W=KX(OYK*Y-O(#&K,%R2K.JD>V0W6@#=75+%]6?2TN
M4:^2+SFA'54SC)_&KE<-<0ZF_P 2C%;7EO'='0ANN'@+*/WYZ)N'\Z72O%^H
M:QIVAQ1P!;Z^M9KB=H54A1&X0[0[ <LV>2< =.X .XHK)\.W&L7&F$ZY9K;7
MB2NGR%<2H#\KX#-MR.V>#FM:@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BD.
M0#@9/851MM0<6ED=2A6RO+IM@MO-$F'P6VAAP>%)_"@"_1110 445@V?B"YU
M&YB>QTWS]->YEMGN1. T9C)4L4(Y7<I&0<].* -ZBBB@ HJ*Y>6*UFDMX?.F
M5&:.(MMWL!PN>V3QFBV>62UB>>+R9F0%XMV[8V.1GO@\9H EKEHO#ZPW'B#2
MY1)_9VN,\PDCZQNZ!)5)[9P&!]R.W/4UD:3K;:GJVL6#VI@;39DB+&0-YFY
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M@MM:GC@NY9)&5XD<Q;V)(C/;J?O;JWJADNH(KF&V>11-,&,:=V"]3^&1^8H
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MD1O52,@_E4E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %<OXTU(Z>FBI+*8;"ZU*."[E#;0$*L0">
MP+!03Z9'>NHJ"\LK74;22TO;>*XMY!AXI5#*P]P: ..U2#3-+)M(-0NW%[J=
MOLL8Y0(@Y!/E9Q\L;;"S#GV'.#SEW/.FAZY +R2#[-XC@CB6WN&"Q(S0[E7U
M4%CP1C)Z"O1AX:T,:4NEC2;/[ K[Q;^2NP-_>QZ^]8_B?PC#>Z2]MI&F6$<L
M]S;RW!*B,.D3J=IPISPN .E &!JT<7A;7]7CAU#4+?2I]%>XN2DS2O#+Y@17
M0N3AFR1UZC/;B'4=0U#0=1U\:>J6\D?AY;F.WBE\P+('<;SQ@OMY.!S@=>M>
MAQZ/IZVL\!L8?+N5VSHZ[O,&,8;/48XIEIX>T:QEBEM=+LX9(HS$CI"H*H>2
MH..E &186.C336E_I^I7&V[L601Q7!Q<+P?-<CYMXZ;\@Y;%<?I<$5_IGPWG
MO<S22-,KR2.22/)D/)SZ@5Z-8>'-%TM;A;#2K2V%S_KO*B"[QZ'';VI3X>T8
MV,-D=*LS:0/YD4)A79&WJHQ@'D_G0!Q]QYNB>(-3T&,R-'KZ"33I"Q;RV.$E
M4$] @/F =,9K9\;7<V@^")GL6DB6(PQ-*I.Z*(NJNP/7(4GGMUJ]8V6JW&KF
M]UA+)5MC(EFEL6;*L1\[%@,-M &!ZMZ\;$L4<T3Q2HLD;J59'&0P/4$=Q0!R
M%S;"P\<Z1:Z=G[!J-G<"]@5B4VH%V28SPQ+;=W?-+\-K2"'PR\L28=KRZ4G)
M.0)Y *Z.ST?3M/1DM+.&%638=BX^4=%^@STZ4^PTNPTN)HK"SAM8V.XI"@4$
M^N!0!YWJ-XK75MJ%C<2-GQ-%;-=32XD/[P(\*J.D0&1@GG&<=Z@U2U$NE>/K
MK[7>&2PG,MHPNI/W3"!'!'/KZ].U>@2>&-!FEN))='L7>X<23,T"DNP.<GCD
MY&:D/A[1VCN4.F6I2Z.;A3$,2G_:_O?C0!4U]WF\":C,9)$E_LZ20/$Y1@PC
M)R""".:Y:TMA?Z]X3@N)[IH;C07::,7#JKD"'&0#[G..O>N]?3[.6P-@]M$U
MH4\LP%04*^F/3VJ"/0=)AE@ECTZV22WC\J%UC ,:?W5/8>PH \\T?4I0/#NB
MW5Q(=.FU34+=VDD)WB)F\F)F/)!]#UV@=.*9=7*Z!>^+!:R_9K0ZO81SRY)$
M,3QQ[CP00O..", \8P*]"?PUHDE@]BVE69M'D\UH?*&TO_>QZ^_6G0>'M&MD
MN4ATJS1;E0DX$*_O5 QAN.1@=* .!\4Z>=+\/ZY<VFN_)*EM*MK9;HXX3YJJ
M7'SL &!/'0XSVJ;7X;SPKX@N)M!FNI&N-&N[BXAEF:8"2,+LEPQ."2V/0XK<
M\0>#X'\&WFB>'M.LK8W+HS+CRT.'5B6P#GA<5T5CIUI9@O!:1PR2* ^WDX'1
M<^@R<#I0!Q=K8V]S'9ZM9^($\JXLI5:&U#JUUE-P9V\PD.I&=W7D@GFL[18V
MM;3X?:BEQ<M=7H$-PSSLPD0V[-M()QP5!Z=>>M=Y:>&-"L&N6M-(LH&N@5G,
M<*KY@/4'';VIZ^']'1+5%TRU"VAS;J(AB$^J_P!W\* /-KJ6+6OAC#KEVQ;5
M'U*(SL7(:-OM2KY1'957&%Z< ]>:U;@'Q#>^)+6ZUJ#3;NQN\12,K>;;1!59
M)$/F* #R3QSDYR,5U\WA70+BXGGFT:QDEG8/*S0*=[ YR>.3D5)<^'-%O;Z"
M^N=*LY;JW $4KPJ60#I@X[=O2@#AKBQ6^U#QLMS=7DHM[&WFB_?R($D,+MN"
MY^7D9QT'I4NC)%>^,O#E_>8>XF\-+,\K,<L^^'G]3^==NVAZ4\MU*VGVQDNU
MVW+&,9F'HW]X?6A="TE6LV&FVH-D,6I\H?N1_L?W>@Z>E &)KE]'_P )OHVD
MZ@X73KFVG=48X2:=2F%;UPI8@>I'H*S!Y-GXAT#P^+ZXN])E-V=T\FX22K@K
M$6_B506P#GE?]FNQU/2-.UJU%MJ=E!=PAMP29 P!]1GH:271M-GL8;&2PMS:
MPD&*+RP%C(Z%<?=(]10!YOJQO+==9T^.ZNEL;/7+%+1UF8%!*8VDCSGE5W<
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MEA;S1; ^QE+[,% !QC:>XZT <G:WMUI4BZ//?E=%77IK..XNRTB[!#N2)FW
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MK&RDAB,'!(_I6;X5B6>'2=.U'PYJ<>J:6%5I;DR&WC*+M\R-RVTY'0+Z^G-
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MNL33EEAW(P24K]X(Y&UB.> 3TJ[=7<%C;-<7,JQ1+C+-ZDX ]R20 .Y->?\
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M,<>Z8[C@=/G7\ZN7']HZ?;>,(4T2>\EFU%+J)7M3)&\16$%E!X=EVL0HYRM
M'7OXHT:*VO9YKT0I9;?M(FC>-H]PRN58 \CIQS1#XHT>YN)[>"[\V:&'SVC2
M)R6CZ;EX^?GCY<\\5P.IVU[,/&GDZ=K$XU+2X%MI);9BTK 2 \8^4Y8?+@8]
M *Z%HYI/&F@3I:70A32YH7D-LX5&8Q[58D<?=/7TH WO#FO0^(]&@U*"*6-)
MAN"R(R\9..2,'CTR*@.LZ?:ZMJTD^M@QVD$;3VS*-ML/F^;<!DEL=,GI53X>
MI/;^"=-LKJTN;:XM(A#*D\93Y@3G&>H]QP<UD:M!<MK?C-DL;QTN='C@@9;9
MR)9 LH*J0.3\Z_G0!U-CXFT;4;Z.SM+Y))Y(O.C7:P#IQDJ2,'&1D Y'>J'C
M?4+O2M$@N[.[:V87MO'(0JD,CRJK Y!QP3R,5CV\-P-4\!M]BO MK9RQW!-L
MX$),*J W'R\@CGTK4\?0S7'AZ&&"VGN'^W6SE(86D.U959B0 >  : +_ /PD
MFD7MGJ7V?4UB-FG[^4H5,.0=KX8<CN#R#CO3K;6K&VTFQ>6_DN_,M5F$XA9F
MD3:/WC*J_*#G/0#FN<U".=O$_B:=+*\:&?14AC=;60B20>9E1QR?F7\ZS_[/
MN#H>AR6S:MI>LV6CQ)'/':/(CD##0RQ[3GE01G'7(H ](AE2>&.:)MT<BAE;
MU!Y%9Z>(=*DOH;-;L>;.S+"2C!)67[P5R-K$8/ )Z'TIUDEY<>&[=+F-+2^D
MM%$B1_=BD*<@>P/\JY;PC=7 TC2M$OO#ETFI:6@B:6>WQ"FP;?,24\$L.FWG
MYO3)H Z6#Q)I%S<Q017BEYMYB8HP279]_8Y&UL<YP3TJHGC?PU)-;1)JT!:Y
MD,41PVUG!*[=V, Y!QD\]JX_3OM\VH>$KR71M1@>UN9UN;=+0Q0VI:-U"HO
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MKW5I#+J$SLRF.3F0-;,>20-HSR0,XQWH ].HKE;?QFOV&Z:^LTMKVWU#^SC
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6%XIT2[UFSM7TZZ2UU&QN5NK:21=R%@"I5@.=I5B#BMVD9E1=
MS,%'J3B@#DM3T3Q%K6C1Q7T^G"[%W!.4A+B)%B</@$@DLQ')X XXXY-2\+W^
MIZEK\SRVT4.J:6+!<,S-&P#_ #$;0"/G]>U;UMK5I=ZS>Z5%YOVJS1'E#1E1
MA\XP3U^Z>G%:% '%R>'?$EO<Z9JNGW>FKJ=O:?8KF"4/Y$L0((P1\P8')SCO
MCZW9M$U>?7=!U*:>UE:P\\W'+)N,J@808. N.,GG]:Z>LMM?L?M<UK!Y]U+
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MW(J948/3;GGKGM77UD:GXCLM+>99$N)C;JCW'V>(R&%6)"LP'..#T!.!G&*
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M2Y93'-&BQP/&(\%2 #MPQSDGZU'H^M:G_P )#X?MY;Z6[M]1LYWFE:-5BE=
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M&BW-K#:7$.Q-L<K1CRWW;=V"?E/.,D5T,_A>SN;K4KB2XNO,U&W%M<8=0&C
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MUUZ+[%)M3(6Z&3$[?[)!8-] :ZBP_LS1Q9:!!-$DR6^8H,@.Z+@%L?4\GZT
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MQX;'?ZT :GAW7I=4_M);Y;>"2UU&6SC5'/SA0ISSU/)K:DGBB*"25$+G"AF
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M "BBB@ HHHH **** "BBB@ HHHH **** "FR1I*A21%=&X*L,@TZLW6M=L=
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MF^TV\M[$TEH\D>P3J!DE#V(!!P<''.* -1;2W7?MMXAO!#80?,/?UHAM;>V
M$$$46%VC8@7 SG'';)/YUYW;>(M1LOA58W9ENKB\N+HP&Y)WL UT4.2>^TX'
MX5UD3VOAS3;S4[J]O_L<CJXANW,C0DX4*N<MRQ'!)Y/&* -MH8GD21XD:1,[
M6*@E<]<'M2"W@58U$,8$?^K 4?)]/2LI?$^GXOQ,)H)K%XTGAD3Y@9,>7C!(
M.XD 8/6KME?I?&XC$,\$D#A)$E4 @E01@@D$8(Y!- %J2..5"DB*ZG^%AD5$
M;*U)8FVA);[Q,8Y[\UPNA^,+;1H-576+C4)HHM8N(/M3Q/)' @?:@=\84?Y[
MUU.I>)K#2TN)9A/)!:[3=30Q[U@! (+=^A!.,D @G@B@#1>RM9(EBDMH6C0[
ME1HP0#Z@5/7.MK>E1:_>R_;+YY(-/2>2%5=H?*W$B1% ^9CR,C/ ]J?8>,-+
MU&[T^"$72_VA$9;622!E27"[BH8\9 Y_ T ;"V=JDAD6VA61FWEA& 2W3.?7
MD\^](;&S.<VL!R<G]V.:R)_&&E6Z1S.;AK62Y-I'<1PM(CS D; %RQY!&<8)
M'6MX'<H(SSSR,4 1R6MO-!Y$L$3P_P#/-D!7\NE$MM!/!Y$L,<D7 \MT!7CI
MQ61-XKTR"Y>-C,8H[M;&2X5,QI.V,(3U_B49Q@$]:KWGC?2+-]15TO7.G,!=
M^7:.?*!7=N/'W<'.>_;- '0M#$ZJK1H50@J"HP".F*:EO!&[/'#&KM]YE4 G
MZU7OM6LM.TI]3N9@MHJJV]03G<0%P!UR2 /K51/$VG!-3-RTEHVF*KW:3K@Q
MJP+*W&000#T)Z8ZT :,=E:PQ/%%;0I&YRR+& &/N.]'V&TX_T6#CI^['%9L7
MB:Q?54TR6.Z@NWA^T*DD#8,7]\L,JHSP<D$'ZTU?%6G&\M;=UN8_MD;26CM"
M=MP%&3LQDYQS@@$CIF@#9DC26-HY$5T8896&01]*C6TMDMQ;K;Q+".D80!?R
MZ5@V7CC1[\Z<8?M7DZ@YCMYWMV6-GY^3<>YVGC^M3>'_ !$VN7FK0_8IX%LK
MMK=6=<;MJH3GGKECQZ8H VXH8H%VQ1I&N<X10!FF/:6TA8O;Q,6.XY0')Z9K
M,O?$^GV NWD$[P6;!;N>*/<D!P#\W?@$$X!P#SBLG7-8>?Q1I&CQB\-E=6\\
MTDEJQ4R8";2KJ0<#>2<'TH ZI+6WCD$B01*X& P0 _G1#;06V_R((XMYW-L0
M+N/J<=37.W>KR>&9] T8K>ZD]T[Q-<R ,Y549N2,9;@=NF2>>N3I7BF+19_$
MAU6>_G@M]6,8D*-*MO&4CQN/15R3^O'6@#NY(TEC:.1%=&&"K#((^E,M[6WM
M(_+MH(H4SG;&@49^@K/U/Q!9Z6MPTB3S+:QB6Y,$>_R4Y^9OP!.!DX&<52\4
M>*8M#\&SZ]:A+H-&AM0#\LC.0$/TY!^E &ZEK;QSO/'!$DLGWY%0!F^I[TS[
M#:;2OV6#:3DCRQ65'H5Z=,_>ZU>C5&C^:Z5_D5R.T7W-H/;&<=\\T\ZTEA"M
MK.D]U>VULDMVMLF\Q@C[Q]<D-@#)..E %K4-,CN-/N(K>"W2>2)HT=DQMR,9
MX&>!4'AO15T31;*S=+<W%O;I \\28,H10 3W[=.:A?Q?HX?3DBFEN/[1B:6U
M,$+.)%49."!U]NH[XJK_ ,)[HPL6O&6]6&*8P7)-JW^BN&VD2?W>2/7KF@#H
M1:VX)(@B!+^8?D'+?WOK[TW[#9[2OV6#!.2/+%8M_P"-=*T^[O[5H[Z:>Q5'
MGC@M'<JK G=TY4!>3TZ5,?%FEO%;O:-)>?:+4WB+;KD^2, N<X[D#'7/;@T
M/ATJ_;63<WM[#)8P.7LK6*#88R5VY9LG=@%@.!U^F-8Q1F42E%,B@J'QR >H
MS^ K#?QCI ;3EC>XF;48#<6HBMW;S4 !XXZ\CCJ.^*:GC32GL[*Z"W6R[NC9
M*#"04G#;?+<'[IR#UXH Z @,I5@"#P0>]0V]E:V886UM# &.6\J,+GZXIB7\
M4FJ3:>J2>;#$LKMM^7#$@<^ORMQ[?2DU/4K72-/DOKR0I!'@$@$DDD*H '4D
MD#\: )OLMO\ :?M/D1>?C'F[!NQZ9ZTTV5J2Q-M"2WWCY8Y[\UCW'C#2[.TU
M.>[6YA.F;?M41A+.@894_+D$$=\X]<5/9>)=/O=5?3D%Q%.L'VA#-"T:R1YP
M64GJ 2/S]* - V%F6C8VD!,9RA,8^7Z<<4^2VMY9!))!$\@4J&9 2 >HSZ5Q
MFN^(#=:CX7DT^6^CMKK4E02J"L5S%L<GW(R%(SC(Y&175WFIPV=Q#;;))KF9
M7>.&( L57&YN2!@;E_,4 6#:VY9&,$19  IV#*XZ8]*&M;=T='@B97;<P* A
MCZGU-<;<Z\4\;:5<QRW[V5WI,LRVB(Q+-OCVGRQ_%@GKTYZ5MP>*],NK'3[F
MV,TK:@[QV\ 3$C.F[>I!Q@KM;.2.GTH UGM+:0DO;Q,6.3N0')QC/Y4+:VZ/
MO6")7QC<$ -<AX@UU=0T?1=0TN[N84?6;>WE528R?WVQT<?4$$?SJ]HT]PWC
M[Q+;27,TD$4-H\43N2L982;MH[9P/RH VI=*M9;NTG,:#[(2855 -I((Z^F"
M>.GZ8LRV\,^/.ACDQTWJ#C\ZPKSQEI=E=:C;-'>RS:>JO<)%:NVU6!.[IR %
M)ST],U=;7[(BV%MYEW)<P?:8H[=<L8N/GY( '(QD\]LT 7?L-IS_ *+!\W7]
MV.:>8(3#Y)B3RO[FT;?RKFKWQK:I!HTVGPS7<6I7?V<.B8\L@,64@X(;Y2,>
MQS[L\:WTNGCP_=1W-S C:K#',D1/[Q"K$J5'+=!Q0!TOV*T^7_18?E^[^[''
MTI#86;1M&;2 QMR5,8P?PQ658^+])OH[X[I[:6Q*BX@N8&CE3=]T[2,G=VQU
MJS8Z]:7VIW&F[)K>^@C65H)TVL8V. XP2",C'!X/7% &E'&D4:QQHJ(HPJJ,
M #V%,%M +@W AC$Y&TR;1N(],]:K:QJ]IH6E3ZE?&06T"[G,<9<@?0?SZ54M
M/$^G7FIOIX\^&98#<JT\+1K)$" 64GJ 2/SSTH T_LL +,((MS-O)V#EAT)]
M_>L3P]X=;2I]0GNUM9I;F^ENXY$3YH]^,KDCMCKWSTJ>+Q1ITLUDA\^*._S]
MCGDC(2?C.%/4$CD @9'3-,TWQ;INK7XM+..]=O-EA:0VKJD;Q_>5F(^4^@//
MYB@#8>V@D=W>"-F==C$H"67T/M1);02O&\D$;O$<QLR E#[>E8TWB[38M7GT
ML1WLMU \22K%:NP3S"0K$X^[QRW3FG_\)5IHN;2)_/6.]++:W!B)CG8#.%(Y
MR0"1D#=VS0!K_9X/.\[R8_-_O[1N].M9>K:7J%WY-OI]]#8V3AUNT6#+N&_N
M-D;3UYP>N>U9T7Q!T&46D@:[6VNIC ER]JZQ+)N*A68C"DD=#^.*M+XPTM]4
MFT^-+QYH)Q!,1:OMB8KN!<X^5<=SQ^% &['&D4:QQJ%1 %50,  =!3'MK>1W
M9X(F9UVL2@)9?0^HK)3Q5IIO+:WE,T NXVEM99H]J3JHW,5/L.<'!QS4D/B*
MRDC\V19K> VQNUFF3"-$,?,#D^HX.#STH T39VK7"W!MH3,OW9"@W#Z'K3Y8
MHYXS'+&LB-U5QD'\*Q)?%VFVTUQ#=I=6TL-L;ORY(&W/".K*!G..XZCN!26?
MC#3+ZZM+>)+L->6YN+9GMV59@%#$*3U(!% &XL4:,S(BJS8W$#!..F:;);02
MRQRR0QO)'RCLH)7Z'M6/X6U]O$NC?;C:S6VZ65%#@=%D=!SD\X49]ZY_PYXJ
MBTZUO8M4GOIP-:N+1;ET:1(AYNR-6?H!T'MD=,T =Q-:V]PR-/!%*8SE"Z!M
MI]1GI0]M;R2>8\$3/_>9 3^=81UO3+/6=<F>ZU!GL;:*2ZA9':.-/G(:-<<D
MX.2,C@>E)'XUTEYK2+9>K]MA\ZU8VKXGX#%4XY;!'% &TVG63QF-K.W9#U4Q
M*0?PQ4CVUO+&D<D$3HA!160$*1TP.U9-KXJTZ\L_/B$_F?:C9?9GCV2B8#)0
M@\ [>>N,5.NO6S01LL-P9I)'B2V\O$C,F=W!.,#'4G'3GD9 +S6ELZ[6MXBN
MXM@H,9/4_6G>1#NW>4F=NS.T?=]/I[5QFN>($U*VT*[TN\N80-=AL[F($QL#
MN(>.1?P'']#3KJ\GUWQAJ6A-)J5I!;VD1BEM7,921F?,A(/(^5< Y'7CF@#K
MA9VH0(+:$*J[0-@P!G./I1]BM!MQ:P_+]W]V.*S+_P 166D/+;3&XN);6U^U
M7!C0,8XAD;VZ==K<#G@\4ZX\26,,;/&LURJ6JW<A@3=LA;.UB,@G.UL 9/'2
M@"WJ&E6NHV<UK-&@BG/[["#+CZ^O;/7TQUJV\:21F-T5D/56&1^5<QX^NYK+
MPW'=V]W-;,E[;!FB<KE6E16!QVP35RR\7Z3=W-[;.T]I-9Q>?*EY T)\K_GH
M PY7WH U5L+-81"MI (E.0@C&T'Z4X6=L&+"WA!(P3L'(Z8K+'B6Q:]DL)DN
M[:X^SFX1)(2&EC'!9 ,DD<?+]X>E9^G>*-&LM)T.)+G4;I-0C;[)+-$\LDH5
M2WS,!RV!TZ].* .D%I;!0HMX@H78!L& OI]/:D^PVF /LL'R]/W8XK*M_%FE
MSZ7-?;IHEAN?LCPRQ%91,2 (]OJ2RX^M3V.OV=_JEUIB)<1WMJ 9XI(6P@89
M4EQE>1TP>Q]#0!HRP0S@":)) .F]0<?G2);6\<GF)!$K_P!Y4 /YU%J6HVND
MZ=/?WLOE6T"[W?!.!]!U-9DOBRPMXM2:XBN89--B6>YB>,%DC8$AQ@D$?*>A
MSQ0!L06MO;;OL\$46\Y;RT"[CZG%/2..($1HJ DL0HQDGJ:S)/$%G'>VMGMG
M::[MWN(%6//F*H!('O\ ,.#ZUQ]WXKGU71O#.LI]LL8Y]72.2-<@21$R?*0,
MEONKQZT >@&UMVN1<F"(SJ,"4H-P'IGK1+;03O&\L$<CQG*,Z E3ZCTK)M_%
M>ESVM_/(TUM]@D$=Q'<0LDBLP!7Y>IW;AC'7-/'B6Q6XN;:X2XM[FW@^TO!)
M$2[1=-ZA<[AG@XY'?% %T:=!_:IU$J#.(C"I"@84D$\]3DJ.O3''?,SVMO))
MYCP1,_\ >* G\ZY.^\8Z+J6AM,9=7MK-U@E6[@MY(]V]QM"OC'7Y3]<5L:IX
MFLM(CO)KN*Y%O9X\Z81?(N5#<'OPPZ=SB@#3^QVODO#]FA\I_O)L&&^H[T?9
M+;R%@^SQ>2GW8]@VCZ"LNZ\3V5K:/<M#=O'% MQ<!(26@C(R"XZ@X!.!D\=*
M6XU^QFB\JU>>Y,EL+DFS7<R0M]U\^^#@#DX. <4 ;"(L:!$4*HX  P!2US7P
M_N[B_P# >CW5W/)/<2P;GED8LS')Y)-=+0 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7->-K.]O\
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M*[@K@DXPPZXKG)]%UF3P7K-BNE7'VJYUHW<4>^/YHC<K)G.[ ^4'CKFO2:*
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M+5YHDFPV2 2N5R.I&![^O2K-IK-M'HUA<ZC=PPRSVJS-O8+GY06;'H,\GH*
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M\P(+[!M#1G^,$ 'Y<]:[.B@#C-0NYK7QUI&K7T4D.DR6,ULKR#"P2LZL&?\
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M,T;&&15! &1R0/Q%=QXMBM[C0A'<W-Q9@SQ%+F 9:"0,"KD=, @9SQC-;U%
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MW,<G@C2,;T\BRBBD\Q"FUE0!AR!T.1GIQ70T4 >2P")/ FG80+.OB,3L-N'
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M*P[J0@R#Z$>E:U%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M8?,+%?F)*GJ>,]>U-L_#.LVWACPGIS6\)GTF^2XN")AM9%#CY3CD_..N.AH
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M?:&X"I*DB,A4X<,#@X(Y!Y^M9&FPZ7"OA+5+_2KP:C>B&%+A9QL>4Q;_ #9
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MSSAB3GIQGM6CJ6L1:?=V-GL:6[OI&C@C!P#M4LQ)[  >_;BL_P *Z;?:9_;
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M'XU=KS>;5;K6_"O@W4;TH;B77(=Y1=HX:1>!] *OV=SJL7B'QK*E_%(UF(A
MEUA(ES!O4,P^ZH+'/XT =S17%V/B#4I-;N].6Y6=!I2WL,\UL5 DW%3@#;N0
M\$?S-5=)\1Z[)%X1OKRYMI(-9'ERP)!M*,8F<.&SURO3&,'\: .^HKDO [WT
MLFOR7=\]SLU:>(;D ^[M /'L ,5IZ[>W5M=:?%#<QV\$SN)65=\[$+E1&F#G
MGDG' 'X@ VJ*X6T\7:C-X5T6\G6..:\U(V-S<!,+$HD=-^.0"=@'/ +?A4%_
MXD\06FB>++N*YM)$TAREK,UL3YORJQR0P4D;BIP,9'X4 >@T5R4^I:U8W]EI
MT]PES/J322Q&V@5&AC1%+*-[88[F')[9X](4USQ!:+::=J5IMOKR^EAMY8_+
MW/ J%P^W=M#X&,9QWP>E '9T5Q=QK/B72]*N9=1L9VABO547$$:/-]E()+F-
M2PW*< ^QSCBM[PYJ2:MI(O(M1AOX7D;RYXEVY7/ 8=F'0].>PH U68(I9C@
M9/TJIIFJ66L62WEA,)K=F9 X4C)5BIX(!Z@USLK7S_%2* 7SK:KI+2B'8"!F
M90WXG YKG-"U'5='\-:?>V]Q!]C?7)+62V,.2ZR73J6W9X()R !VY]@#U&BN
M'U_Q)J>E2WDZ7$+BWO[>%;:*/>GDNR*3*^/ED)<D 'IMX.<U:TAKZ3XC^(DD
MOG>WAM[39"4& K"4X'ISSGO0!UU%8_B/5Y-)M;,0A//O;R*SB9QE4+G[Q'?
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MRJ>-S$+C.0,GKC%4++4[K0M3\5LS"YNYM7M+6-]@7)DCC521D#(!]0"1VSP
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M6'W=I!\QNH[UU%% #0F(PF2<#&2<FL6R\-1VUYI]U<WDUY-I\+0VTDJJ&"L
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MF">.<:=:":-/+23R5W*O]T'' ]JHW>G7UA;0V_ABVTJS1Y"9_,B*A01]Y53
M+9]>OK0!7\,W<'B"27Q+#&5AN8TAMMPP=B\L2/7>67Z(*E\:PQ3^"-<$T:N$
ML)W7<,X81M@UK6%G%IUA;V<.?+@C"*3U.!U/N>M.NK2VOK=K>[MXIX7X:.5
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MJ4)BO8FG:1E$ZJHQD X.,XSW'J#63>6,-OX(\5W$33++I&J2K8-YS?Z,%9&
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M8\@ ]*] O].L=5M3:ZA:074!.3'/&'7/K@TR31],ETP:9)I]J]@ %%L85,8
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MCVJ.ST32M.EGELM-M+:2X_US0PJAD^N!S0!YQ:,(O!V@3AMA3Q.5+@XPINY
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MJT'EC8P/4%>AS4-IH>DV#Q/::99P/$GEQM%"JE%R3@$#@9)/XT 8GPYCMH_
M6C>0L:L]I&TFS&2VWJ??BH/%-LESXU\*12/,(YGNDD1)64,!"3@@'_/2NILK
M"STV P6-I!:Q%BY2",(I8]3@=Z;/IMC=74-S<6=O+<0?ZJ62(,T?^Z2,C\*
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% #)8EFB:-P2K#! )&?RI418T5$4*B@!548 'H*=10 4444 %%
M%% !69::)#9ZY?:LEQ<-/>JBRHQ79A,[< #(QD]^_-:=% !1110!EQZ%;)KD
MNK-/=RS/C9%+.S10G;M)1.BDCJ?<^IK4HHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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ML=0U"+4<S6U_&GEK=6TAC<IUVMV89YP0: *GC+5AX>\.7VL0)&;V*()&S#.
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M0220W+J9D'02'.6^IY]ZJR> ]#?1[#352ZB33R6M)X[EUFA)Z[7SD ^G3VH
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MJ"'QT5\#)Z8;T!J>(Z!K6J>(=<%YH\YETP1?9XYHYG7:&W2,1TSN5?H!GTH
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MA2X;]^$ XSY6-V/7UKH;G[#?^-= O-)DMI;1K*X%^T1!C:VVKY8?MC<> ?\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M*>V.*$C2) D:*B#HJC %9AU^W-T\4<%Q+''<BUDGC52B2G'!YS_$.<8YK5H
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M^R*0P0EE8Q(60Y4E1D?2N7O/&\7]E:3?:=97$ZW]^EF5955HFWD.K D?-\K
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M()"CU/!H P?!>E7-GX*@TK5K(PR+YJ2Q.RN&5G8]5)&"&JOX&TNYLK:X^U7
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M>=FF=MY P#@D@< #BK] '!WVEWT?PWTAVA%IK6CQV[VR.X;,R )L)7@A\E<
M_P 0JYKFB7PT+1;.TMWO)[?4;>[N71D7)63?(_S$<DDG'O6]<:#IEUK,&KSV
MHDOH$\N.1F;"C)(^7.,Y)YQFM*@#DDL=13Q9X@OO[.F-O=V,,,#"2/YW3S,C
M&[(^^.N.]<_:>']:TJR\-WC:!'J36FG?8+RPDDBWI@@B1"25/((Z]#^7IM%
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M>?,<KH7DDD"C:-K$8 4\DCDC'>NHJJNIV+WLUFMY US GF2Q!P6C7U8=OQH
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M9.A110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.3Z=*O:%K&J6=SX:TRZCM&L]1TXM#Y>[S(VCC0_,2<$$'L!CWJ]=^$YIKGQ
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M^/EW=,^]<[K?A>375NK:\O8WL9Y8Y5C:WS) 5"@^6^[Y<[<YQQN-=$VXJ=I
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M3M;>TU'2H3;QW0MPRRPG&4>,MST!Z]: -_P]?:AJ&DI-JEB;.\#LCQX(#8.
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MGD P"2!^'7O0!V-%>;^-+Z9;;Q1<V%[=/<:=#"=PG,26;XW (!]]FR"<@#!
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M%JZZ7>SQR6GV4 7$4<I4Y;.5..F/3DG/&AXF\2ZIID&JWUK=H1:>0\-M%&'
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MP))&<@]"H..GKFGPZAJ6LZAKEG87QMGTLI!&QB1O.E*!BS@C[N2!A<=#STP
M=516/X5UMO$?A?3]6>'R7N8MSQCHK D''MD'%<[XK\0ZII":Q=6UW&WV'R6B
MMH8PZA3MW>>2/E)R<!6!Q@X- '=45R%W>ZY=>,M0T>UU**UMX].CNHW%L'9&
M9W7N<'[H_P .]4(?$^JMX?\ "WB*>=8["Z,<>IHD:X4O\JR D95=^ ?8\8H
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M[92!@-\RG:V.,C'Y\UN44 8B>%[.'5-/OK::>W_L^V:UMX(]GEK&<9&"I/\
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M/R\<8K>;.T[0"V. 3BL?PSK4NO:2UY-;K;NMQ- 8U?>!Y;E,YP,]/2@#-M/
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MMOB-6)!WJ5!P<#'W?YFM'0-"BT:.X9+:SMGN&5GALHO+B7 QP.Y]6P,\<<4
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M[&:EN;2VO83#=6\4\1.2DJ!E_(T <YI/ANWNQH6KWMW<W<EE:J;6)]@CB+(
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M Z/IA6W4Z=:;;9MT \A<1'U7CY3]*3^Q=*Q&/[,L\1L70>0ORL3DD<<'/.:
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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ML\T<:QL7DM2A(0R@=FQ[8]365%\4=7;PG-XE?1[3[#:7WV6Y19V,C#Y1N7C
MY8=>OM0!ZG17"ZEXXU*/QC'H&E:9!>M<Z?\ ;;:1I3&.<X#<=.#S[@>]17OC
M^\M+J;3I+6S@U.RTP7MW%+-D-+@$01XZL1WY[<&@#OZ*\\G^)?F:O;6%M!#;
M2W-A'=VZ7Q9//=_^60;HI'3)ZGCCK5C6OB']BU36K2RAMY#H\<32QRR8DN6?
MDI$!W"]\'GC'>@#NZ*X"]\>:E_PDTVD:;I]K*O\ 9?\ :,4MQ(R87&<, #S6
M)K_C[5=2^'F@:MI\<5HVJWJVLXW$E<,P(4^AV')ZX./>@#UJBN*\0^+M6T,7
M2/I\,?V73VO&NY=WV>:0'_4HW'S$#/K[=ZP_$?C75;W2O!5UIB16L6LWL'FJ
M[$MD.IV9 ^Z3U/4C]0#T[SHC,8?,3S0NXIN&['KCTI]>;KJ]GI_Q3U.34=.A
M2\M=$-Q/>PRN<QKM)4(>/QZ\"K&G_$6>4>'+N^LHHK+7YI(8!&Q+P,&VIN)X
M;=[8Q[T >@45Y???$W6+:T\2W,6E63Q:#>+;RLTS R@N4^48X/?D\>]:>K_$
M,V>N6FF01VT#W6GK=V[7K%5G=ONQ!APIXZG(SQ0!WM1&Y@$GEF>,/G&TN,Y^
ME2*25!(P2.E>4_%"V_X1SQ3X?\<V\((MYQ;WF%^\AS@_7:7&?]V@#U);JW=P
MBSQ,QZ*'!-.26.1F5)$9EX8!@2/K7C6HWEOX>^,6G^)+>.-='U9C923KC:[X
M4,X]!N*_78U=U)J$VCZ%<:[9:3+>W6IW2R;($R1&V%1VQS@1JI(]2>G6@#KJ
M*X72O'<^H-XIMO*M99]$3S8YX&)BN%VLP[DC[N.IZTS0/&7B'7]%M]9CT2UA
MTU[6>1Y6N,L)$+  +UVG&,_7T&0#O:*X+PSXUU_Q'I=GJ\?A^,::\<[3M'/N
MDWINVJB]\D ?7/3 RFE_$"[N/%.C:/>V,4+:I;O*8@2);1U!;9(#UX'HIY'%
M '?45Y9>?%#6+;3]?O4TFR>'1-0%I,3.P,HWE,J,<'OR>/>KVL>(M:F^)OAW
M2K%K=+.>T>\5)"PWDHX^<CTP< =^3[ 'H2312.Z)(C-&<.%8$J?0^E/KRK3O
M%FF^'+CQ]JC:4D4UE=QK,T4S$W4C,ZKPV0G//'J?2M.\^(\VFV6L-+9PWDUC
M:174<EFQ,3AV"LI/."A;GGD<X% 'H5%87A?73X@L9+Q)K2XMLKY,]L2 _'(9
M3RC \;3['O7,^)?B+>^'A>W$NEB*WM+U;=8KC*2749ZRQ'I@'V/;D=* /0Z*
MXK5_&&IVGCB/PW86%I,TU@;R.::5D"XW##  Y^[V]?QK-B^*+S>!=+UA-/3^
MT=1N_L45N9#Y8DW$;B<9VXP?7G'O0!Z(LT3NR)*C.O50P)%.)"J68@ <DGM7
MF'AL7*_'77_M:0+/_9B;C!G:W,7//(SZ?J:9XVO9=:^*?A[P?<.RZ2Z?:;F(
M' N" Y"MZK\G3W/M0!Z9!>VMRI:"YAE53@F.0, ?3BIZQ[OPSI5U)92I:0P3
M64R2PO%&%*[3G;Q_"1V^A[5R$GQ/8:3=^($LXVT6UU(6##<?.=<#,H[=Q\N.
M?44 >CT5Q@\:3P>.KKP_J$-O;VXLFO+6ZR3YR 9Z=L -G_=--OO&MQ9:CINC
MSI96VJ7-DU[.9W(BA'.U!R"S$C'48P3STH [6BO/)?B/>.OA1[324W:ZSQF*
MXD9#!(C!3DX.1D]<=![U-I?C[4;S0/$%RVB-=:EH]XUJ;:R+,)B&VY'&<=2>
M#P* .]HKB-)\<3W_ (AUO1&CM9);"T%U%<0D['X&589.""<'![&L;3OBCJ=U
M9^'-0GTFUCLM7OC9$).S2*V[:&'&,?X=J /4**\YL_$>N2_$[Q%:R+#)9Z5:
M*5MT+9*D!\KQRYR!SQQ6KX(\:/XOC6=/L9C\HM-'$S"2WDR $93U!&2&'!P>
M!0!V-([K&A=V"JHR6)P *6N)OI3K7Q3AT6[&_3[#3OMP@;E99F?:&8=PHZ9Z
M'F@#L(+NVN4#P7$4JDX#1N&!/IQ4U95YIFFPWL6MR1I!+9(Y:55QF/:<@^H'
M7VQ[FL<^+[B#3M(UFYLHUTK4I(T!5R9(!+_JW88P0<C('3/>@#K:*X>]\::M
M;6>OW::1:F'1;DQSYNFS(@56)7Y/O8;O@#CKVT;_ ,5&+6I-*M1;"[%LD\$-
MU(8VNMV?EC/3(Q[\GMUH Z>HGN((IHH9)HTEE)$:,P#.0,G [\<U@GQ%<_VC
MXBLA:P[M)MXIXV\PXE#J[8/'RXV8[]:QKB]75]<^'VKF!8I;M992!R5#6Q;;
MGN!F@#O**XO1M=UV2T\174MI%>RVNI26\$$,A7[OEJ!R.% )8GKUXIY\9S+;
M>)#'!:7<FBP+<!X9B(YD9&; .#@C8P[YXZ4 =C17*V?B;4I-8TRSN]/MHH]4
MLWN+5DG+,K(%)5QMP 0XZ$].]2>!=2U+5O#HO-2:%I'N)P&C)[3.N,'H!@ <
MG@4 =-17)WGBVZL-2MH;FSACCN-2%BD+2_OBC$JLV!QM)'3T[]JCU3QG/9V&
MNZA:V44MOHUP+>6.20J\IPI8@@':!O&.#G!Z4 =A17)S^(M>/B&31;72+)[A
M+**\+/>-LPSE2,^6#GY3CCGVZ4QO&5U*;>ZL=+FN[&2[-NPBAE,@0,4,H(7:
M1D9QGISG/% '7T5R%QXRNMINK#2YKVS2[-LZ10RM(RJY1I%(7;@$'C/('4=*
MM67B=M0UNYT^V%KYEK=&">V>0K.B#_EJ!W4\8QV.<]J .EHHKC(/&.I&/5+Z
MYTNVBTW2KFXANY%N2SXC3(*+M&<G YQUH [.BN2;Q3JD-VT;Z,TD36DEPDJI
M+&D;H,F-V9,<CHPZD8Q56U\:ZIL\/WM]I$$6F:UY44<D=R6DCED3<NY=N-I/
M P2>YQTH [>BN*MO&>I-97^IW6E6\6G6$]Q;SE+DM(7C;:NP;0"&;CG'7IQS
M/-XNU"RFO/M.C3RP0V+W:300RJNY.L3%T'/<$=>>* .NHKED\7*ND3ZGNM+V
MS/DI;2V<A82RR/LV$8)4@E,]3@].U5+[QEJFG6VL22:,95L;3[7%.5EABD X
M9"73AQUQW'I0!VE%<Q;^(=4?7H=,N+"UB-[9/=6CK.6P5*@K(-HQ]\'C/<<]
M:Q]&\97<'@[1-1UB6VC;4IBANY&811$[V^?TY 4#..>O% '?T54TV>XNK!)K
MF.*.5BW$3[T(#$*P/<$8/XU;H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BLVZUNWL
M]<T_29(IS/?"0Q.JC8-BY;)SZ8[=ZTJ "BBB@ JCJ4%]=P-;6EPEJLBX>X W
M2*.^P= <="2<>AJ]10!DPZ3+I=CIEAHCP6MG:R 2I(A<O%@Y .>&).<G/>M:
MBB@ HIJ2)("4=6VDJ<'.".HIU !139)$BC:21U1$!9F8X  ZDTZ@ KR&ZUSP
MEIWC2?Q)H7BJRMKNX4Q7MI<02-%-TY! RK9 YY_4Y]>K*UO7K/0=+GU"X266
M*!U218%#,I8@#.2,?>7\Z .(O/&_A/7-+OK'6?%%H8;N P^3;0R!8\_Q98$L
MP.,=![5AZ;JWA"+4?#]QJ/BRRF30+9H+58H9%\UB,!WR., #@9YYSVKVC ]*
M,#TH ^?YE\,3>%M3T4^-=/'V[4OMYE^RR_)QRN._;FMKQ5K/A#Q9$8+SQ+IF
MS=&T4XMY?.M<!=X1L<AL'@],YY[>IW6M6UIKMAI$D4WGWJR/$X4;/D&6R<]>
M1V[UIX'I0!XGJ^J>%[SQ'K>I6/C.Q@BUC3C93I+:RNR?*%RI&.H Z^]0-?>&
M#IGA.T'C'3\Z!.)MQMY?W^&# =/EZ>]>YX'I3'>., NRJ"0H).,DG 'YT >0
MV^O^%K+Q-XAU2S\:VT,6LQ ,/LLADA<*5!5NG!.>G;'O61I,WAO3K_P[>2>.
MK"632'E+#[#(/-$A)))SDMR>3[<<<^\8'I1@>E '@UU-X7N=,\4V9\9Z>O\
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MUG ]*8[QQE=[*NX[5R<9/H* //K;XF:)++$U_P"*-,BC0Y9+6&4F0^[,.![
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M6*NPB9H?D9L9./,;G.?<U9UC7M1\)WWB4+>3W\=OI<5["MSAO+E9W0XP!\O
M./;C%=(W@C0GBNHC;SB.ZG6XE474GS2+C#?>ZY523W(&<XJW+X;TN>^N;R>!
MYIKFV^RS>9*S*\7/RE2<=SV[T <Y>61M?'G@^0WUQ=%XKO>TK[@S>4/G _AS
MGH,#IQ6IXTN+O3--MM8MKB:.&QN8Y+R-#Q);E@'S] =WX&I;/P9H]E<6$\8O
M&>PW"U\R\E<1!A@J 6Z8&,>E;5U;0WMI-:W"!X)HVCD0]&4C!'Y&@#A(=;N_
M[>UK2Q>7#"^56T>5I,X&[RI"OJ$?Y^^5]J9XLU.^TZRU^XL-2NIIM-BA,?EG
M:EJ0 2)"3B1GSG&#@$=,YKM$T33HYM.E2U0/IT316I'_ "R4J%('X "J%_X,
MT34KB_FN;>5CJ"!;E%N)%20@8#%0<;@ .<=J ,JXCU+4O'M]IBZY?6MHEA;W
M2+!L!5S(X(!*G@A><Y/OCBLZQFU-]&UW5KKQ3=6QT^\O;:-Y8T:)55BJ,RA<
ML1Q@#'...N>PM?#VGV>IG485G%T8!;EVN';*#) ()(/))SUR342^%-'72]0T
MPV\CVFH2/+<1R3.VYV.68$G()//&.: .9;4=3M]4UVQCN;ZWB31%O8?M#K)(
MDF9 6YW8SM'R\X]J32[O4X[SP7++JUW.-8LF%U'(5VY%N) R@#ALCKWS71#P
M9HPF>8QW3S26IM))7NY69XSGAB6Y/)YZ@'BIX_#&EQMI;)',#I:E;/\ TA_W
M8*[<=>?EXYSQ0!QF@KJEKX),^F_:KV3^U;@3V_VG;)+$LTFX1L?XSP3SDX/-
M==X3U.WU72))[>XNI0MPZ,EXI6:!@>8W![KG\L<FEC\):3!N\A+B$FY-VICN
M9!LD.[)49PH.YL@<'/(J*]\*6DWV(6_FQ207PO6F$[AF?(W%@/OD@;<'@#V&
M* *?Q+0MX%O2LLL95X?]6Y7.95!!QU&#TI8IY=1\7:AH+WEU#;V%G#(A24K)
M*\A;+ENI"X  Z9)SGC'0ZIIEIK.FSZ??1>;;3KM==Q7OD8(Y!! -4Y/#6G/<
M6]RHN(KJ"(PK<1W#B1D)R59LY89YYSSS0!4\%ZG?:KX>+:BV^ZM[F:U>8*%\
MWRW*[\#@9QV[YKA;NW:/X>^,6-Q<2,-9EC'FR%Q@7" 'GO7JMG9V^GVD=K:Q
M"*",851^?7N2>23UK'N/!NB7,5_#)!-Y5_-YUQ&MS(JL^020 V%R0"<8S@4
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ME5)I6F</,SY=CEC\Q/4TS4] T_5IX+BXC=+JWSY-S!(T<L>>H#*0<'N#Q[4
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MO)#)?SWL<]T"%DD2W9@%R.A;"Y(YP#C&<UK>$(#;>*/%\)FDEVWD.&E;<V#
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MRFAGFB<:E:+F*1EW*TR@@X/((/0T6#RK\3-7@\^9H?[.MY!&\C,JL7D!*@G
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MC+O\NU&.[A0.1U' KJH/%VGO;ZG)<Q7-D^FNJ7$-P@WC< 4P%)!W9 &#G/%
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MV$^9]P!F'S<<+WXZUHW_ (@M[V+5=(:.\L=0CL'ND5G"LT>"-Z/&QZ-P>0:
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MK^TTRSDO+ZYBM[>,9>25MH%(=2LA>6UH;F,7%S&TL,>>75<9(^F10!:HHHH
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M=(5EE6%"YQN=CA5'N35F@#C=6L_$'BKPS=03:=#I=RICE@@FF68/*CJ_S%>
MORX]3DD@8YT?#HU"5S/>^'K71BL>PHDB2/(V1R"@X48[\G/08YZ!W5$9W8*J
MC)8G  K.CU_29;.UO(]0@:VNI_L\$JME9)-Q7:I[G((_"@#-\1Z7?2ZYH6MV
M$7VA]-DE66VW!3)'*H5BI) W# (!(SSS6?=Z#?SP^+M02T<76LVBVL%L73<H
M6)E#,<[1DN>A. !WXKM** ,_0HI[?0;"WN86AFAMXXW1F!P54 \@D8K0HHH
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MYH90I)^;@X4=.^?I4VH^'Y+OQ!::Q;:C+:S0P/;.JQJX>-B&.-WW6RHYY^E
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M8#CCNJD=.*N7-M+IMEX@O+J[U*ST^ZNH8=/CCF;>%8H&5$9MJ!GR >" 3T%
M'>W,DL5I-)!#Y\R(S1Q;@OF,!PN3P,GC-+;O++;1230^3*R!GBW!MC$<KD<'
M'3->=^;<Q?\ "?69E:V2VLHIH8K>Y?$#F%R=C<$9*@D# J2"%K[6_"%O-=WG
MDW6B2-/&ERZB0JL6"<'@_,>1@GO0!Z)44MS#!+!%)(JR3N4B4]6(4L0/P4G\
M*\XTTZO-X=ABL674&L-4O(_L-U<%6N8$=E"[SG)7*D;N.!Z"FPMI^K:WX,N4
MCO(U,E_&\=U*PDB95;<A.?X6R,YY &: .^UC6;30[(75VSD/(L44<:[GED8X
M5%'<DU5GUN\LT@EO-'F2*::.$&*59#$7<*"XXP!GG;NK \>YMM>\(:E.<:=;
M:B5N'/W49UVQLWH <\]LUVD\L,<6Z9E"$@#/.23P!ZG.* ):*\U>ZFU/P7XG
MUF6ZF@U?3[FZ,3K(0;<PDF.,#.,%0N1CYMQSG-68+636?%UW;ZE->HDNAVT\
MMLEU(BI*S.&P >,8Z#CCI0!Z#17F-A=ZU>>%/#NI+#_;*IIN;RR-P8YVR0!,
MA_B<;2.>>>#DUI:%>P7GBVP-M<W+Z=<^'%E"SR$;_P!XHW,,XW8X)H Z76M<
M_L:XTN(VKS+?WBV@<. (RP)R>Y^Z:TH[F&:>:&.16D@(611_"2,@'\"#^->8
MV-Q)=>#? \TT\D[G7@/,D<NQ :<#D\G@"IE6QTQ/'5Q)=W5EB_6(36\A,@+Q
MQ<+DXW$G&3TSU% 'IM%>97DMS;2^-K02/9I#H\=S%#;W3GR9-DO(/&"=JD@<
M''>KEE;FT\1>% ES=N-4TV=;P27#L)-L<94X)PI!)^[CK0!WEO<PW<1EMY%D
MCWLFY>FY6*L/P((_"HK.>ZG:Y%S9FV$<Q2(F0/YJ ##\?=SDC!YXKF/AC;PP
M>"+0Q AG>;<-Y/2:0#@GC\*YS4)+E/"'BQDOKU9+?Q"L<4GVERRJ7@7;DGE<
M,1@Y% 'JE%<AID/]F_$B^L()[AK6;2XKIXYIWD_>^:ZEAN)QD =/2LOQE<"3
M_A*&M;F=[G3]-5R6F,26;;793'CDNW!/3@ 9[4 >AT5PMI=IK_B*[TG5+F1
M-*MY;55D*;BX;S)1CJP(4 ]L<=326<L.H>)?^$?OM1GN;:/2(GM)'D*M<DLR
MO-D8W,-JX/;)(ZYH [NBN%L9!<>*[+P_<WT]]I\.D>;#+*YS=2"38S,1C<0
M,?[V?0UB&2_EM].M)[^]\J#Q4^GQ3+<.&EM@KG:Q!^8@C;N//R]<T >IR,RQ
MLRH78#(4$ D^G-9GAS6E\0Z!:ZJL#0+<!B(F;<5PQ7K^%<YI=M;R>+M1\.3R
M7!L].LH6LX9+ARSB0N7DW$Y)!VJ#GY<<8S6+X3:&;P[X5TX2RSS-!=2"T:39
M%(HD(,DC=?ESP #RV>,9 !ZE17E6ESW6H:/X$,^HWA>>\N()F2Y<&1%68 '!
MY.%'S=?0U(^IRZ';:O9+=W$>FQ>(H+5Y7F9FM[>18V<!R<J,DC.>-QQ0!ZC1
M7">(WB\-6MY-9:G-%!=7-H+B,N6CLXF?:SK@@J&'7D=R,'FM?0M,?3M;NW35
MXY[>YA21;*)&V1$''F*2[8W>G .,]C0!TE%>?:W'+9>)-4TKS[G;K]F#I["=
MQY-PIVL$.?E&'60X[*U7/"%P_B"TM&N?.CETRW:SNU65US<YVOD@YR F1_UU
M'>@#IK74'^PVTNI6XL+F=_+%NTHD(8DX (X.0,__ *JKZ3KG]IZIJ]B;5X'T
MZ9(F+.#OW('!XZ<$5YY80C4/#OP_FO))IY7U*1&E>9BQ!6;J<YSP.>O%6-4L
MXY3\1;M9[F.2S6.>W:&X9-KK:(RM\I&3P.N?U- 'IUP\L5M+)##YTJH62+<%
MWL!PN3P,],U##>C99I=*+>[N4R+<N&(8+EAD<''KT_.LK5)9;CP#=7#2R),V
MFM+YD3E&#>7NR"N".:Y:TMH;GQ!X#N+@NTDFBRL[F5@252$C)S[D^_>@#TBH
MGN88KB*W>11--N,:=V Z_ED?G7#:/=75EXCT^UU:!Y#=RS-9:K;3%HKL%68)
M*A^ZP7IU'RX&!5O6+.WD^*&A2R!LFPNB3YC#[K1D=#TY- '9T5YQH@GU_2]-
MUMM=2TO8KW_2@J.7+;RK6[#S,8.0 -O'!%1V.FBYT7Q3J$M_J9N+"]U".V87
MTHV*%P!PW...N>@H ]+HKS2VM"+CP)(+V_#:G:&.\(NI/WJBVW@=>.1U&#UY
MI]I'J7V#6M-TRX60V>NE+>UNYVQ-$(ED,&\Y('+$9R.,'B@#TBJ&H:A<6D]O
M#;:=->/*&8['50@7')+$==PZ5E>$=3MKK3)_W-Q8S)>/!-:W<FYHI< E%;/S
M+@@C'8^U=)0!R^E^,)=6M$N[?0[S[,;DVS/YD>48/L)(W9QN[_C6EX<UL>(-
M'74!;-;YEEB,;,&(*.R=1_NYK$^&?_(K3?\ 81N__1K5RUA";3PII.JP7%RE
MTOB$Q#;.P3RWO'5EV [2""<Y&?R% 'K5%>=2"?Q&_B%7UR/3;S3[YE20AO,M
M8TVE& W@;6&2<C!R<Y[=)XIN8XM*L8YKFX1[F\@B1(/D-PQ;/EDG[JM@Y]L]
M>A .AH) &2<"O*-0NKNW\/>+XQ</"UCJEOY"PW#$0!C#O56X.WYFXX')XK;U
MPB;Q?K=DTTC6[>'3(\ E;;O\QAG&>#@#ZB@#H+GQ)#%J.A6\$!N(-7+>5<JX
M"J!&9 <=3D#]:W*\OM+*!].^&T"O*BRIND*2L&R;,YP<Y7\,8[8IO]HW.E6U
MYIL=S<+8#Q1'8M(TS%H;=T1RH<G(!8XSGC=0!ZE56_GNK>!7M+,W<AD13&)
MF%) 9LGT&3COBN$U\7.F:MK]A8SW$=@_A^6]*1S,OV>=20K(0<KN / X.WZU
M'J&GC3_!ND:E!>ZA]JN[C33,S7DA#Y9 ?ESC!#'(QCIZ4 >DT5PGB"U_M;7S
MH&EW%TEW*RW&HWB7#C[)#QA5 . [XP!C@9:LGQ9=HFE>([K2KR>1].2W"3O<
M%1:L%4JL74L6!!8G&=V,G&  >F?:8?M9M?,7SPGF%.X7.,_GG\JBT^>ZN;))
M;RS-G.2VZ R"3;@D#YAP<C!_&N4M;*UD^*FKNV\%M,MVW+,R_,7D4]#[ >W:
ML/0M3NGTGP9875Q.]I?W=XES,\K%I&1I#&C-G)R>V>=N.F: /4:*\J\2R7MA
M9>,K"VN[I+*T%I/:LD[ P/(V'C!SDKCG:>!NZ=*Z2SC&E?$F>UBN;C[+/I/V
MF99IV<&19=N_YB<<''&!0!V-%-CD26-9(W5T895E.01Z@TZ@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "H+RRM=0M)+6\MXY[>08>.10RG\*GJ*YN8;2 S7$BQQ@@9/J3@ >I)X [
MT 5X=)T^"VFMTM(S%.,3!QO\T8QABV2PQQSVI++1M.TX'[):I$2GE@C)(3^Z
M">B^PXJL_BG1([&6]DU"*.WAD\J9W!7RG_NN",J>1UQUJ['J5G)/<0K.OF6Z
MAI@P(\L$9&2>G'- %3_A&M%^Q_8_[-@^S>;YWE;?EWYSNQZYYSZUS6I^$IK[
M7KRYOO#NCZM',R^1<2W#0R1(% ", C9P03G.>?I756NMZ;>W,EO!=H9HXQ*T
M; J=AZ. 0,K_ +0XJ-/$>D2-(JWJ$QP^>1M89BZ;UX^9?]H9% %6R\):3%;V
M8N[&WN;BV1DCDD3>40L6V MDE1G STP*M)X;T2.*RB32K01V3%K9?*'[HGJ5
M],U*-;TUC9 7D9^W)OM3VF7;NRI[\<_2L)_%VG:IH&I7,&J_V2L$S0+=S19V
ME6QG:XP22",=: -Q-"TJ.&[A6P@\J\):Y0ID3$]2P/4^YHBT/3(;6:W2T3RI
MT$<H;+%U'123R1R>.G)I][JUCIQ"W5P%;89"H4L0@ZL0 2%]SQ4,_B+1K8VP
MFU.U4W2&2#]X#YB 9W#U&.] #ET#2D:S*V,0-D,6N!_J1C&%]....W%37VFV
M6II&EY;I,(W#QD_>1O52.0?<4:;JEEJ]F+O3[E+B L5W)V8'!!'4$>AI+W5+
M/3FC6YFVO(&*(JEW8+]XA5!.!QD]LT 1S:'I=QIITZ:QA>S)W- RY5CG))'<
MYYY[\U=BB2")8HQA%& ,YQ6=)XET2)+1GU2U"WB&2W/F#]XH!)(]L \T^VU[
M2KO3'U*"^A:S1BKRYP%8'!4YY!SQCKR* (SX:T8W4MS_ &="LLS;I=HVK(?5
ME'#'Z@U9O=*L=0$/VJV20P'="W1HSC'RL.1QQQ6%H^NSZAXYU:P6Z,EE;VD,
MB1-#Y;1.S."#D!N@4\^M=)<W4%G;O<7,J10H,L[G % %270]+F@MH)+&$Q6S
M^9 FW C?^\/1N3SUY-,E\/:1-)<R26$+O=%6G8CF0J05)]2"!CT[5CZ9X@DN
M_&VKV;7H.GVME#,$DB\LPL6?=NR W10>>QK4?6[.]@O8+"]5;V& RA60A@N#
MAPK 97WZ4 32:%I<]A/8S644MO<'=,D@W^81C!8GDD8&"3Q@>E,B\-:+!YAB
MTRV0R1>0[+& 6CY^7/7')SZYYK%T36Y;[0/"MQ>ZU';WMZB221&-"UV2A)4#
M'R\\Y'ICO6[!KNF7,%W/#=J\=FQ6X8 _NF R0>."!U':@!#X>T=H+.!M-MFB
MLVW6R,@(B/3Y?3Z5"?"?A\N[G1K(L\PN&)A',G7=]:FN]>TNPA$MS=K'&4$I
M8JWR(>C-Q\J^YP*AO?%>@:=(\=WJUK$Z(LC R9(5CA3QZ_\ UZ )&\.:.]O=
M6[:? T-T_F7$9&5E;U8=S]?2IAH^FB_AOOL4)NX8_*CG*Y=4] >N.3^9J.#7
M]+N;&ZO8;Q'MK4LL\H!Q&5^\#QV[^G>KZ.)8E>,\.N5)'K[4 5KK2=/OKN"[
MNK.&6XM\^3*Z LF>N#VZ"JP\-:*+1+0:= +=)?.6(+\JR9SN ]<\YK \.^,K
M15N;37=8MQ>_VG<6L(DVH2J2%4& ,#.._6NGM]7L+N]NK."X62YM,>?$H.Z/
M/3/'?MZ]J *D_A70+F6YEGTBSD>Y(,S/$"7((()]\@?E5N/2-.BU$ZA'8VZ7
MAC$7G+& VT=!FIK.\M[^UCNK602P2#*. <,/45@#6;O6?%5]HNG3"VM]-2,W
MER$#.TCC*H@.5& ,DD'TQWH V)M'TZXOFO9;2)[EHC TK#YC&>J?[OM2V6DV
M&GMNM;98V""-3DG:@_A7/1?8<56@_M*RU&;[;>13:8MOO69T".C _-O(PN,<
M@@#H<U+!KNF7$DD:7D8>./SF63*'R_[XW8RO^T.* &:IX;T76YX9]3TNUNY8
M?]6\L88@>GN/;I4[:/I[7[7QM8Q=M%Y)F'#;/[N?3VJI;>*M!O;FVM[;5+:6
M6Z!, 5L[\9X!Z9X)QZ<U9_MK3_M0MA<9E9VC4!&(9E!+*IQ@L IR <C!H A'
MAG11:V]J--@%O;2>;!$%^6)^NY1V/N/6I;K0],O9UGN;..298_*WG.63^ZQ_
MB7V.135\0:2]I;7:WT1M[J7R(91G:\F[;MSZ[@1CU%8:^))=-\0>*SJ=RSZ=
MIEO;3Q(D0R@=9"PX&3]T=?3MS0!T+Z1I\E]!>M:1&YMUVPRXYC7T7T'M4%QX
M;T6[U:/5;C2[66_CQMN&C!88Z<]R.WI45OXFTZ73;.[EE\MKF+S%B",SX !;
M  R0,C)QBI9/$FB0K:&35+4"[C,MO^\'[Q ,EA[8'6@!+WPUHFHZE#J-[I=K
M/>0XV321@L,=/KCMGI277AC0[ZYN;BZTFTFFN5"3.\0)<#@9_#O52^\9Z/:Z
M/#J<-P+F":Y2U3RE)^<N%(/'RXSDY_J*WHI$FB25#E'&0<8XH SYO#VCSRK)
M)IUOO6,0Y5=N8QT0XZK_ +)R*GGTFPN;FVN9K6-YK7/D.1S%G@[?3CBHI]=T
MNUN/(GO(T82")B<[5<]%9ONACD8!.>1ZUC:OKSOXJ@\.V]])9,]I),UQ'"'8
M/N144!E(Q\Q)X[#D4 :J^&M$36CK"Z7:C43R;D1C?GIG/K[]:L:CH^G:N(1J
M%E!<B%]\?FH&VMZBF-=-H^@_:M6N!*UM!NN)HHB-Y Y(09//I7,S>+GGO?"=
M[#=BVTW41(UU%(@XQ 9 -Q&>#CIUH L:_P"$XI;:&+3-&TJ>V-TUS>64X\H7
M#%2 P8*<$$D].?:C2/!>GQQW*W.B6-G:W,8CDL(96FCDP00S9 &X8XP.,GD\
M8O7_ (@TV[\.2WUGK\%E$9!$MYM5MCAAE=K?Q'I@C/-:5UK%A93&*XN C+MW
M?*Q";CA=Q PN3TSUH KKX9T-/.V:5:+YT(@EVQ@;X_[I]1Z^O>I8]!TN*:VF
MCLHEDMH_*@<9S$G]U?0>U:-<KXR\4S^'!9200^;"LJRW[8SY5MN"%OKN8$>R
MMZ4 :J^&]'C55CL(H]LC3*8\J5=OO,"#D$]R.M22Z#I,\%M!+IUL\5J_F0JT
M8(1NY'N<G/K5N>[M[6U>ZGFCCMT7<TC, H'KFJ'_  DNBB6:&34K>&:%=\D4
M[>6Z+C.2K8.,=\4 :%Q;P7=O);W,,<T,@VO'(H96'H0>M4['0=+TUE:TLTC*
M#"<D[!_LY/R_ABH;;Q3H=Z)#;:G;R^7''(VUL_*_W/KGL!SGBIX-<TRYM9KF
M*\C,<#^7+NRK1OQ\K*>0>1P1DY% !)H6ES7KWCV,)GD*F1L?ZPK]TL.C$=B<
MXIS:/I[WLMZ;5/M4T?E22\AF3^Z3Z>U5SXGT1+6:YDU*&..&00R^:2C(YZ*5
M.""<\#%,/BS00URO]J6^ZVQYB@Y/.<8'\70],]* )$\-:-%'%'%811+"ACC$
M1*;4)R5&#]T]QT-/N?#^D7CVCW&FVTC6@VV^8Q^[7C@#TX''3BGKK6G/I\%_
M'=I);7 S"\>7\SC/R@9). > .QJ#_A*-"\BVG.JVHCN698B9 -Q7.X>V,'.>
MF.: %7PSHB000)IELL4$OG1*J8V2?WQ_M>_6G7'AW1KJ:[FN-,M99+Q!'<,\
M0)E48P#Z]!^0]*H7_C31K3P_<ZQ#<BZAAD\DB($GS<@!3QE>HY/8UO0S1W$*
MRQ$E&&02"/T- &6/"N@J&"Z1:#?#]G;$0&Z/).T^H.3GUJPNAZ8DUI,MG&)+
M-2ELW>)3U"^@[8I)->TN&\%K)>(LOFB#H=HE(R$+8P&((^4G/(JO=>+?#]D\
MZW&K6J-;N$F&_.PGUQT]_3O0!>L=*L-,\[[#9PVWG.9)/*0+N8]2<?4_G55O
M#6BO!/ ^FP-%<2^=,A7(DD_O,.YX')]!4][JEG:(JR7(225"T813(VT=6V@$
MX&1D].167X%U2ZUKPA9ZA>W"W$\KS RJH4,%E=5P!QT H UH])L8]0_M!+9!
M>>6(O/Y+E/[N?3VJ"[\.Z-?WCW=WIEK/<21&%Y)(P2R=,'\S4$_B.T7Q*/#Z
MLZW;6QF+^62%RP51TP<Y)]L>]9/@[Q;!?:+IL6K:G"^K74DRA2 I<K(X P!@
M':HP.IQWH V+OPGX?OX+6&ZT>SEBM!B!6B&(QZ#V]JEU3P[HVM+ NI:9:W0@
M_P!5YD8.SV'M[=*==:[IEE<K;W-Y'&Y=8\MG:KM]U2W0$Y& 2"<BM!F5$9W8
M*JC)). !0!2NM'T^]6W$]I&WV;_4,HVM%QCY2,%>..*;-H6E3PVT4EA 8[5M
M\";<")O[R^AZ\]>:J1>,?#D]S:V\6LVCRW3%8 LF=Y!*X!Z=00/7M5J\UW3-
M/F\J[O(XFW*C%L[49ONAFZ*3QC)&: %O]"TK5+F&YOK"">> $1R.N6 /49[C
MVZ57'A/P^L5M$-&L@EJS-"ODCY">I_'OZT3>*M!M[PV<NJVPN!*L!C#Y(D;H
MO'?_ .MZUAZ=K]QKEU?7<.L+8VVG7[QR0R0*8I+>/ 8LS %6))(.[CC@T ;\
M7AG1(/)\G2[:/R96FBV)MV.W5ACH3ZU)_8.D^7>1G3X&2]YN59<B8^K ]32P
MZ[IDQG O(T:W022K+F-D0]&(;!V^_2J*^-?#3=-:L_N(X^?J&.%QZY- %NS\
M/:-I^F2Z;:Z9:Q64N?,@$8VOG@[AW_&GZ3H>EZ#;O!I5A!:1.VYEB7&X^I]:
MJGQ;H ^T_P#$TM\VV/- ))&<XP.K X/(ST-63KNF?9;6Y6[22*[7=;F(&0RC
M&25"@DX'7CB@"Y);02SPSR1(TL))B<CE,C!QZ9'%-CL[>))DBA5%F<O)L&-S
M'J3CO5%O$NB)#:3-JEH([P$V[&08D !)(]A@YJ2TU[2K[3Y;^WOH7M86*2R;
ML!&'4-GH>1U]10 P^&]%.G1:<=+M39Q2>;' 8P41_4#MU/YGUI3X>TAA=@V$
M)%X,7(QQ-V^;UXXY[4^#6]-N$NF2[0?9<?:%DRC19&1N#8(R.F>M/L=6L=2D
MGBM;@/+ 0)8F4JZ9Y&5(!&>QQS0 ]M.M'TXZ>T"&S*>683]W9_=^G;%0-H&D
MLEDC:=;LMB<VH9 ?)_W?0<#CV'I5NZN[>RA\ZYE6-,A03W)X  ZDGL!R:H2^
M(=.72KR_BG$J6@82H 0R,!G:RXRIZ=1WH EM=$TVQE66VM(XV3<4QG"%OO%1
MT4GN1UJ6[TJPO[BVN+NSAGFM6+0/(@)C)ZD>G0?D*P_"EWJ.L6MCK#ZKYMO<
MV:M/9M;JHCF8*WR, #M )&#N[<T_4=;NI_%</AK3&2*;[,;N[N67=Y4>[:JJ
M.A<GUX &<&@"^GAK1(M9;5X]+M5U%LDW C ?)ZG/K[]:DBT+2X+:ZMHK*)(;
MMBUP@'$I/4MZD]_6HHX=7M=5ME-X+O3V5Q*98E$JO@%3E< KU_ASG')J6'7=
M+N+N.UBO(VEEW>4.0)=OWMC'AL=\$XH !H.E*;,BQB!LABUX_P!2.GR^G'''
M;BF'PYHY\S_0(@9)A.[#()D P'SUW>_6H7\7^'HR0VKVGRS_ &=B'R!)QP2.
MGWASTYJY=ZQ86,K1W-P$90"_RL0@)P-Q PN3TSC- #3H>F-';HUE"PMY_M,6
MX9*R\_/D\EN3R>:O.@="C9P1@X.*HMK>FK]NW72@V !N@0<P@C(+#' QSGTY
MK)U#6+E?%7AF.SO%;3=12=I%" B0+%N5@W7'.>* -FPTC3]*@>"PM([:*0EF
M2(;02>IQZ^]5QX:T46BV@TZ 6Z2^<L6WY1)G.X#USSFJVF^+M*U&#4;@3>3!
M93M"\DJE0=N 3R/[QP!U/'K5H^(](2TNKJ6_BABM#MN#-F,Q$C(#*V",@\<<
MT )=>&=$O=4BU.YTNUFOHL;)WC!88Z<]\=L]*M:CIECJUH;74+6*Y@+!MDBY
M (Z'V-5K?Q'H]W=36UOJ$,L\,7G/&AR0G<CUP>#CH>*RT\02^)?"-Q?^'YVM
MKDLPB:2V,APLA4?(<9+!?PSSTH U%\-Z(L=VBZ59JEV@CN%$0 D4# !]L 46
MGAS1;&9)K;3+6.5(O)5Q&"P3))&3ZY.?6GOJL-A;0_VE*D=R8?,E6-68+@#<
MW .%![GBK\<B31)+&P9'4,I'<'I0!EP>&=$MA;"#3+:(6K%X-B8\MCU*XZ''
M'TXJ4:!I(ANX3I\#1WAW7*,F1,?5@>I]Z6]US3-/D=+N[2(I@R$@E8@>A<CA
M >V[%8-_XF&C^.);?4M2BATG^S!<*KJ!B0R;>"!D\#I]: -Y=#TQ;2>U^QQM
M#.NV96RQD7&,,3R1CC!HET+2Y[""QELHGM("#%"PRJ$=,#MCMZ5C:YKLF/#5
MWI%_&]E?ZE' [1A766-E<\'MRO;WK2L]0MVU+5V.M0W$5L4WP84"SPO.YAUS
M@GGI0 \^'-',TTW]GP^;.VZ5P,&0],MZU'+X4\/SR2/+H]F[2Q"%R8A\R 8
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M\T>U@@E2VD?RI(\[XV4 E22V>1SBMKX<I)#X+M8)K:>WDCEGS'-$T9 ,SL,
MCD8(Y%=510!R=V9+/XFP7DEM<M;3:28%ECA9U#B4,02!A?EYY_G7+V4$\7@;
MPQ";&\6>'75FEC^RR;D03NQ9AMR!M8<^]>J44 >:)#!]IUG0-=T;5;R6YOI9
M[;RS-]GN8W?>F64[4V\ YQC:*]+'2BD8$H0K;21P<=* /)K"U36OA>NC6D#M
MJ,NHN8V$1'EL+HDR[L8P%!YSVV]>*T7B@CU+7=$U[1]6O/MUX\]MY!F,%S&V
M"JDJ=JE<8.[& !7:>'M%BT#24L(+F6XA5WD5I=N?G8L?N@#JQK4)"C)( ]30
M!R'AZ+R_&_BB22UE1)!:^7(\+[7"18.UB/FP:YY[/4;OPIXA2SL[IIEU][X6
M[PLC7,*S*^%W 9R!QZXQ7J-% '%W8&K>+=/UJR2=;6TT^X2YD:!U+[]NR/!&
M200Q(QQ^-836DH^">G60T^Y^UJ+9'MQ:OY@*SHSY7&>@)S7J-% '( @?%![S
M[//Y']BK&)_L[[=WFEMN[&,[3G%<YX=EN+'2O"]M<:9>VX5;M'NDL7>:%C)D
M1@%3L#C!W$=%[=1ZE10!Y1HL%Q'I?@RWFTZ^1[+5;AIQ):O^[!\[!)QTRR\]
M.>O!J:_M]1\[Q!=V>GW4RV^NVU_Y A93<PQI'NV9 #'*D\=UKU&D!!) (R.H
M]* ."UV4Z[HESJFB:-=&1)[6>8M UO/=K%(&,:Y 8[0#@^O S6MX:;2]0U&;
M5K#3=1AD>%8I;F_\U7;!R$ D/..<D<=@3SCJ*0$'H0>W% '+>+HKN+4_#NJ1
MPRSV=A>,UU%$A=@KQL@DVCD[2V>.>:H26LDFK>*M:@BF%E=:=';H!$V;B55?
M+*N,G 95!QSSZ5W-)D;L9&>N* ,3P;N7P9HL4D<D4L-E#%)'+&4965 """ >
MM8VHVUQH'Q#_ .$C-M/<:;>V0M+EH(S(UNZME7*KDE2.. <=Z[6B@#$O;M];
MTF]M=*\T/-;2HERZ-&J.5(7!(&3DCITP<]@>4C@GU?PSX4TN*SN+;4M.NK5I
MU>%E^SB$8<[B,8(! P?FW#WKT:B@#RS4K:>7P?X^ACL;MI[O4)&@06K[I@5C
M"E>.1E6Y'I6CXB6Z74KW4M"ENTOS'$LEA/;,]OJ*;1@<CY6&2"0>,<X'->@[
MEW!=PW$9QGFEH \]U)YK+6O&<4EE>.^I6$9M?*MW=9-L+JPW ;00?4CJ*6U6
M87WP]+6EVHMK21)]ULX\EC $ ?CY?F!'->@T4 >:>;=:?HGB.W;1KBXD_MUY
MR)+-Y%6)IE82J,?O"!\P"Y^[S56_CN)(/'J)::I.;^QA^S22VCAISY3+P HP
M<D#& ?:O5:* .)12?&GAF6.VN!#'I<T3O]G<*A/E[58XP#\K<'TJW\/!+!X3
MAL+BVN(+BUEE259H63DRN1@D?,,$'(R.:ZNB@#B_%MO*=6%WIUY>:?JD%G^Z
ME6W::WN5W$^2ZX()R.,<_-QFNHTEYY-&L7NK9;:X:WC,L"](FVC*CV!XJY10
M!P, ET\^,-,U.TN)GO[B6XM62%G6YCDC"J@(&,KMVD'&.#TYJ+1K&X\.^(='
M;58YF$7AZ.S:X6%I%\Y7R4RH/..GKBO0@0>A![<4M 'F*Z3=:9I>@H;.X1'\
M2O?+!'"S?9K=C+M#!0=N RY],U8U*V6XF^(BW-O>BWN+:(H\<+ R;8<'82,-
M@\5Z*2 0"1D]/>J6KZ7#K.FR6-Q)-&CE6#POL=65@RD'U! - '$Z9JMI>Z[%
M>W+3OJD>FO9P6CV$UND[??;YI% R=@PO;GKVJZ-)/-KO@Z[^P:A&D=M<031?
M87BBM'9$Q&H*C"C!&XDYQU[#N+'19;>6.6]U:]U%HCF(7 B4(<$9Q&BY.">N
M:UJ /*C'<K\+&TMM/OOMEOJ0WQ_99"3_ *9YF5X^8;.<C(KH;.5]*\5^(SJ=
MO<26NHB*:UE6!I%D01[&BX!PP(^Z>NZNTHH \S\/:3>Z/J?@NVOK>=I+/3KI
M9G\IG6%G*%$+ $ @ KU[4VRLA/I#Q3-JFF7"ZW>3VMY#;N#!N9RK,I7!C96(
MYXYQ7IU("&&001ZB@#%\)RZE-H*'58HTNA-*I>.,QB90YQ)L/*[OO8]ZVZ**
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?;^8Q9U5<;6Y)P2>,\YZ4 7+/Q/=W^MW>GV^ASE+.[%O<3-.@" H&#XSSU'
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MB"< 8'%7X]#UQ]8UO49UT]3J-A';K$DSGRW7?U;;R/GZX'TH S-#UG4[/3_
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M^S(JHC1,S '&3DJ.?K^$.M^(=9LK3QN;:^"OI(A>U9H4)4-$'(Z8/)[YH ]
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M.B.2"&'X5IVE_?MJS6%[8I$/)\U)XI2Z2?-@C! ((R/S'-:896S@@XX.#TH
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M'8+ T<BR$F02!CSD#'W1QS]:T;A[U;ZT6".!K5B_VEG<AU^7Y=@Q@\]<D<4
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M 'F7'4]\$ ]\UL[[W^U2AC@^P>1D/O/F>9NY&W&-N,<YSFK(92Q ()'49Z4
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M=_9YG2VC5O*E4;<LW&&8<8 .1GIS5+PC;75K<^(/M5I- +G5)+F$R 8>-E0
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MI\YN7O&A,Z0PVTDC.H(!VX'S'GH.G).*CMO%VCWNG6=Y:SO,+R4P01*A$C2
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MI9 2UO,073DCG!(]_P :MT %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 5G:OHUKK44$=V9=D$R3H(W
MVX=3E3^!K1HH 0#  R3[FEHHH **** ,R#0;"WUJXU94E:[FZL\S,J\ ?*I.
M%R .@K3HHH **** "BBB@ HHHH *9Y,?G^?L7S0NP/CD#KBGT4 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% &=)HMK+KL6LLTWVN*(P(0_RA"02,=.2 ?PK1HHH *:Z"2-D;.U@0<'!_
M.G44 9VCZ)8Z%:&VL4D"D[F>65I'8].68DG X'I6C110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 9L^A65
MSJ8OIO/D<;#Y33,8MR'*MLSMR#SG%:5%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
0% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>37
<FILENAME>exhibit1018-arvinasxcons005.jpg
<TEXT>
begin 644 exhibit1018-arvinasxcons005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=S",;5)QT!/ &3FL-M(UFQN+2\CTJ6Z,&O7=X88I8@QBD2158;F _C'&<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M\$Y4%25)Y!Z\#HAHFO\ ]K'7=)O+6RDU*"+[?9WD+2JDBJ &0@J=P'&#P<4
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M;O*#[L;<GK@G'3'!%>X\':A<>'-=TO[7:JVJ7[78DVL1$&96VX[_ '0,\=:
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;2PFEC$T/B +<1/P4'VQFPW_  'GZ<U>UH%-7\:6VBHAE?3+1A!;8!DVL^\
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M7I-% 'F'ABXT35[;0K:\N[UM:TKB6Q=%1H'"[92YV#Y#R22><CJ369:C3(/
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MO;@:O$TMKY4.<[5W$')X/;T]2!S3#XXL%TH:@]E?HBWOV&=&1 UO+N"X?YL
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M/;3JH4[6WC*G&?P&1Z6[;1-=CUS2KN^5+MFT8Z?>SI*%V2%U8O@]>AZ#KZ4
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MR[AR-P&:EN$O-=TZYLIK.;3X)X)(G,S(TAW*5^4(S 8SG.>V,=ZY^'0M6O\
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MX_\ KGWJW10 4444 %9ZZ%I::W)K*V47]HR((VN",MM Q^'''%:%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110!E:CX<TG5;M+N\LPURB[%F1VC?;UQN4@D>U7[6TM[
M&W6"UA2*)>BJ,?4^Y]ZFHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML0O%E&4,99<LA'"DJ0"">V0,T ;M%%% !1156>>YCOK6&*S,MO+O\Z<2 "'
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M:/X0LKZ[F-I?WE['/-)*VZ1D>3RT9R<\GMGG:!TXKTF&SM[>.6.&%8UE=I)
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M':@#D=)GN;?7K*PUF"5VO&F-IJ=K<,T5XI5FVR+G*,%Y';C P*H:=?W+^#O
M=P]]<&YFU..*5S.VZ5?WF0W/S#('7/2O0+30]-L94DMK1(VCW>6 21'N^]M!
M.%SWQC-55\(^'D8L-'L\^?\ :,&,$"3GYL?B3]30!P?B6%)M(^)>\$[)87&"
M1R((\=.M;6N+;F[N;"UGGEDMM(>4PO<LL< );$N[EC)D$#T ZC//5_V%I?\
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M//&&ZI#+_8GCJ\%_J FTV]9[,B[D_=$11L,<\C)Z'(';'-=^/#&B"UM[8:;
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MY3;:5>-;W1-PH8*H4EE'.3\W3(X'7M0!V=(K!AE2"/4&L&W\1SOXA.DW.EO
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M:9O.?$BJCK\OR=3OSSZ5!_PB7B%EM/,FTR6>UU?[<;IV<R7"9? ;Y?E*A\
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MB0(BCHJ@8 _*I*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH *YOQIJ&H:9I=G/IURL$CW]O Y:,.
M&5Y I'/U[<_2NDK-UK18-<MH;>XFGC2*=)U\D@'>AW+G(/0@&@#D-2\4:IX9
MD\4)<W?]H"RMK:XMFEB5-C2LR;3L RH(!]<9YK6O+W5-'\3:-8-?O=VVJK+"
MS21(&AE1-X==H&00""#GMS5^?PII]W>ZC<W;37 U"W6VN(I"NQD7.,8 ((W$
MYSWJ2T\.PVLEO+)>WEU+:Q-%;27#(QA#  D849. !ELG\SD R? MQK6K:/9Z
MQJ6K>>DT4B&V6W1!N$A ?<.<X&,=.?;)35=5OM,\47%I<:C)%8W>G236;+$A
M,4T9^=1\OS':5(!]_:MW0M%M_#^E1:;:RS26\18IYQ!(R22,@#N33]2T:RU:
M:QENXM[V-P+F$YZ. 0,^W.<>H% '.>&-:U'6['2XIKJ2/4(#*-478AP\9V;"
M .,L<C'93SWK%U+4;W4_AS>2W\XFFBUM( X0+\J7BJO ]A7>66C66GWNHWEK
M&4GU"199V'=@H48_+/U)K+/@NP;1I=*-W>_9Y;O[8WSIN\S?YG7;TW#./Z4
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M<SAY?+((*@D8 P3T&3Z\"@#*TK4[B\U#3/#\%S):)%HD-Y)+&JEW+810-P(
M&"3QU(]\TH_%.M_V2[S07,XT[5)K*_GL(5:5HT'RRJA!&/F7< ..<5TA\+6@
MET^XANKJ"\L8/LT=U&4WM%Q\C@J58< \CJ,U*GARV@2W%I<W5M)#))*98V4M
M*TARY?<I#9//3TQC H P+7Q'-J<VF6&G:C)>+<VL]W]L@6-)'59 BKAQM! ;
MYAMSD=N:Z'P]_;']D^7K;1&^1V0R1$?,N?E8@<!L$9 XS6?=>!=*N;6TCCEO
M+2YM)9)HKRUEV3!I"6D.<8PQ/(QCT K<T^PBTZS6WB>60#):29R[NQZLS'J?
M\]* //=+U>^TC1[Q_M\\\][XDDTU))PC"/=-M\SA1DA1TZ9QQCBNFM]1O[#Q
MPFAW%R]Y:75DUU#)(BAXF1@K*=H *D,".,@U(_@O2I+74;:0W+P7UP;IHS,0
M(I2VXO'C[IW#/?\ +(K1LM'BM+UKV6XGN[PQ"'S[C;N" YV@*J@9/)XR>/04
M 8.M)<O\1_#L:7]S%$]K=.8DV;<KY?."IZAB/Y8YSS=O>:GI&A:SJ]E?F..W
M\13*UMY2E9E>Y5&#$@D<-QM(_&N_U+0;74]2L-0DEN(KFRWB-H9-N5?&Y6]0
M=H]^*SW\%V,FD7FF-=WIM[N[^V2_,FXR%PY(.W@;@#CVH H7>IZ[J]QK<.B2
M/#/I]P+>!?W7ENP1')DW M@EB/EQP/6K?C2ZOX?AOJMS  EY]A+-Y39V9'S%
M3[ GGVJ6\\&6-WK+ZHEYJ-I<3(J70M+@Q+<A1@;P!UQQD8-=!Y,7D>1Y:>3M
MV>7CY=N,8QZ8H S?#$5O#X5TF.T"_9Q9Q>7MZ$;!S68+QI/%1\,V$[6-M:V
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MP:*6[MY[*:29+B&7$CO)_K"Q((.[//'TQ0!S4?B37IM#TN1;T1W#:^VFS-)
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M ]>#[T 9$-[XBO/%-OI-SJ*69DT?[1,+6)'\N82!&*,P/'7J#U/&>1FVFO\
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M1F$A&WD;F0@_3;Z <==XUN;*WTRQ2]4LDVH01QJTFR,ONW#S3@_)\O(QSP*
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MY[B&U@>>XFCAB09:21@JJ/<GI0!)134=9$5T8,C %6!R"/6G4 %%%(2 "2<
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MI&OQSVMI?PP2V\\<D#O&\;L#N4;E93\@(!]<'I55/!-\GAZ+2O[4A8Q:G_:
ME:V.>)3+M.&&>>_'TH L>(_%EYH'VZX>U@6WM&BV1R/^\NU;;O9,'Y0N['(.
M2#TI\6HZM)\1+[3P]N;.#3XIHXSN!RSN,D^N5';@54U;P5J.I+K\*:O"EOJQ
MCD.^V+R1L@4!0V[[GRYQCN:UDT*^B\4_VTE_"?-LDMKB,P'YBC,P93N^498Y
M!SP.O>@#+TGQ6&T'3#%I]M;7FHW\]I#;Q'$:LCR;W)P,\(6/ R3VSD.U#QA>
MZ4FO6L]E!)?Z79B^CQ(4CN(2#\PX)4@J01SVY]&P>!YX=$L;8:C&+_3[][ZU
MN5A(7+NS,C+NY4AR.".U6=1\)SZK!K,L]U"E_J=D+'S%C)2"(;N ,Y8DL3GC
MMQQR .M/$FH_V]96-_8P)#?V3W5N8)"S@IMRK @#D..GTYZT_P ,>)G\1B*>
M%[-X&A+31QL1+:RY7$3J><\MS@?=Z4/X<O7U;2+_ .W0J=/LY;8JL)RY<*"P
M.[C&P<<U%%X9N8M476I;BTCU.&RDMVN+>W*_:&;;AY%SSC;D+SUZ]J .JHK.
MT$ZBVBVYU9U>]PPD=8_+#C<=K;?X25P2.Q-:- !1110 4444 %%%% !1110
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M:X';D,"/5?<4 6M-TVUTG3X;&RC,=M"NV-"[-M'H"Q)Q5JBB@ HHHH ****
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M 'OU7/U%9MK)(GASP]=6&L0V6JVVBQHT-ZH:WNDP-T3=U8%>W//0]O4Z* .
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MU&.I*[A^-8>H7VG^*]$U.\\,0R2:LVER6PG$;1M$#R(><#<3G '3';C/?44
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M;'5)+<2VXTE+0O&RJ6E5RY(7/"G./K[<UB:;X:UNPT7PFHM(7NM(N93/$TX
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M"U"&#=:64=PDS[P"#(% P,\XV\_7O0!RNNZ_>:W\/=;NYK:XLGM;_P J,I*
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MH(YM;@CV.^TD"1E8,%8@\K[UIP>*Y1K?B*"[L)HK+28T8R+M<XV%R2 <\C&
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MKZ6NB:I/>I;)<F*)8R=C-MSG?C@@YY[<9K#G\-:S+H>LPI:H+B;7%U.W1I5
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MEO;46ERRYD@$@DV'TW#@T 6:*R/$^N-X<T"XU46IN1!MW1B39P6"YS@^M:]
M!14)NH!>K9F1?M#1F41]]H(!/YD5'837<]NSWEH+642.HC$HDRH8A6R/48..
MV: +5%%% !114-W=165G/=SMMA@C:21O15&2?R% $U%8^DZM?ZC-$TNE^393
MVJW,-RLX?[V/D=< JV#GC(Z\UL4 %%%% !1110 4444 %%%% !1110 4444
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M>V-IJ-L;>]MXKB$D'9(H89'(/U'K47]D:<;&2Q-E UK+DR1,@*N3UW ]<^]
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M\M?[S;0=J\'DX'!]#7GU]'J-OX.\6^'KC2]0FU">XN)K>2*V>1+E)&W*P<#
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M",OMD3( )7&""5P?H.DMY/MGQ'MM2MX9Y+"71-B7(A?RRS2*X&[&,[>?_KT
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M9U-7UI=+N-.M5B\VYU"?R(5+;5&%+$L<'  4]N3CZT :3R)$C/(ZHBC)9C@
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M]<& VS3D&)EW;P3MZJ$;(QVZ]*Y#Q#J.H:UX"\7-J=M:[+2_:&'9(6*%&C
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M!!/H>ASB@#OHIHIXQ)#(DB'HR,"/S%/K%>V&@Z3J%_IVDPF\DS<SVT,I599
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MK=(WFCC9D61BJD@=R ?Y5RV@>*;V?0/#WVN"&75-6BWQ*LQ"LH3>[L=OR@9
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MJV#ZQ;Z#HUN[VCB:]C2X**T[H&98_E.3C'7:,D>^ "_8^%X[)(X7U74[JTC
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MBPANGN6N(_MK-&A\M3TD4AE;++TY(SVS785#=6=M>P^3=V\-Q%G.R5 Z_D:
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M6(JHP =XSU3G[W3KV!- $NF1W\=IG4IH9+IVW.(%(C3H-JYYQQU/4D].@N4
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M:]I_V.\\P()$E1XG*.CJ<JRD=""* .&U+Q!K5KI'C18KRY@DTM(9;5YTB:1
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M;'&*E@\(Z?'I-WIUQ->WL=W$8)9+NY:23R\8V@GH.>U &IIT;P:; DD\D[!
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M8/N:[F74/(T)]2>,MLMC.47OA=V!6?+X2L9H=7A>>Z*:N<W8WCYOE"\<<?*
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M.CZ+;Z)%<1VTDSK<3O</YK!OWCG+$<#J><=*34M#M=2N[2\9Y8+VT+>1<P,
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M.U@IS@^AIY( ))P!7&:5;V>G_%#4[6QBAMXI=*@E>*$!0SB20;B!WQCFKGQ
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MWN(Q)&X[@C-6:Y'X:!QX*ASGRC<W)AS_ ,\_.?'X5UU !1110 4444 %%%%
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M]Q&[LLK2$%>GRJ#P <<"M&U\5:7<)J32/-:_V: URMU$8V12"5;![$ X[\4
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M5DU$!H"%'W2N[+<\#;SG\.I JJ/%6F_:K.%O/1+W=]DG,1\N<@9PI'.2!D9
MW=LT ;$L4<T9CEC61&ZJPR#^% AB4L1&@+@!L*.0.!FN8_X6#HALI;T)J!M(
MDE=YA92%%\MMK G'!SV/;KBK]KXITZ[U%K%%NDF^SFYC\RW<":,$ E./FP2.
MGKQF@#6BMH((?)B@CCBY^1$ 7GKQ4B(L:!$4*JC  & !7-0^/-%F@L;E?M8M
M;YS'#<-;.$+\X7./O':<#\.M7+3Q3IMTFH%C/;/8%1<1W$+(ZAAE"%ZG=VQR
M3QUH U&M+9V9FMXBS=24&30+.V!4BVA!7[IV#CZ5C3^,-,M#?I>+=6TUE;_:
MI87A)<P\C>H7.5R"#Z=\4ZU\6:=>7R6<4=V)9;<W,&^!E$Z#&=A/WB,C\_2@
M#=I B@L0H!8Y;CKVYK%\*:^?$FB1ZB;62W$C/M5Q_"'8#G/)P!GWIU]XGT^P
M%V\@GD@LF"W<\4>Y(#@'YN_ ()P#@'G% &HEM!&C(D$:JXPP" !A[TD=I;10
M>1';Q)#_ ,\U0!?RZ5R_B#6G;Q%H>E1+=O97JS2R/:L5,H5 5VNI!QELG!'0
M5D6;7%[J6L:'<:CKRQZ9'"(+R-CYRDAW+/M^^2-J@$'('J2: /0!:VX,9$$0
M\LDIA!\I/7'I2BW@"(@AC"H=RKM&%/J/0U@Z-K6G1^'M*:TN;V^6[0BU\X[[
MB<#)))..@ZDX'3U%0W7B31]1M-,G%Y?PB34TMD6%60^>K8,4O& N>H)P<<9H
M Z1+>&-F:.&-6;J54 FF16=K#$T45M#'&YRR(@ )]Q65/XKTRWN)(W,QBBND
MLY;A4S'',V,(3U_B7D# SR:IZ9/<'XAZ]:O=326Z6=K)'$[DK&6,F=H[9P*
M.A^Q6O'^C0\=/W8XJ>L&[\1-;>+[/0ELIW$]L\[3*N0,,J@#GI\QR?I3W\5:
M9'Y<CM*+.2?[,MYL_<F3.W;NZXW#&[&W/>@#6CM;>&626*"))).7=4 +?4]Z
M([:")]\<$:-ZJ@!JKK.KVNA:;)J%[Y@MHB-[(NXKDX!QUZD5'-KUC;:K-IUP
M[Q30VAO&9E^3R@<%L^Q[4 7Y8(I@!+$D@'3>H.*;]CM<D_9H<G@_(.:H1^(+
M1DE>>.>VCC@%R7F3"F,]P03^77IQS1::_:76K/I;)/;WHA%PL4Z;2\><;EZ]
M^".H[B@"Z^GV4J*DEI ZJ<@-&" ?RJQ7'ZKJ<NF_$2R5IKR6VDTR=_LD(9PS
MB2, A!WP3S]:LW?B+2-1TC2+X7=_#!=WT44)@5D8R^9M\N3CA=P(8'K@T =%
M):V\TT<TL$3RQ_<=D!*_0]J7[/"9?-\F/S/[^T9_.L]M>M1=-"L<\BI<+:O,
MB91)3C"GG/\ $.<8YQG-6K_4+;3;=9KER [K&BJ,L[L<*JCN2: ++*KJ590R
MD8((R#4/V*UP!]FAP.0/+%9,OBW3+>#47N?M$$FG()+J!X29$0C(8!<Y7@\@
MD<'.*MZ3K=MK0E:UBNE2,(0\T#1K(&&04)X8>XH NFV@-P+@P1F=1M$A0;@/
M3/6ECMX8F+1PQHQZE5 )KAM'\4Q:.WB#^U;B^GA@UEXA,4:5;>,K&%W-T5<D
MUT^I^(K/2EN7E2>5+1!)=-#'O$"'G+?AS@9..<8H U)(XY4V2(KKZ,,BF"UM
MPR,((@4!53L'R@]0/2L*X\:Z1#>&TC%Y<S>1'<!;:U>3=$YPKC Y7W''X\58
M\47EE9:-OOKF]MH6FB7S;/<'#%UP,@< G .>,''>@#7$4:QK&(U"+C:H' QT
MP*=M4,6VC<0 3CD@?_K-8-[XOTVRO;ZS,5[-<V,:RS1PVKL0K9Y''(^4\]/Q
MK.\0^)-W_".K8"YDL]5N$+2P @O$8W<*IR""<+Z'&: .K2V@C?>D$:O_ 'E0
M TD=G;0X\JWA3!)&U ,9Z_G7$:-=R>'M?\5+>:AJ5YI]C:VURJW,AE:!&$K,
M!GDX ]R<=ZZE=?L6OM.M,R>9J,+36Q*?*ZJH8\]B PZ^M &A%!#!GRHDCSUV
M*!FB>WAN8_+GACE3.=LBAAGZ&L@^*M-6YM(G\]8KQS':W)C/E3. 3M4CG)P<
M9&&QQFJL7CK1IE@D3[9Y$UT;3SFMG5$EW; K$CY<L,?EG&: .@-M 8GB,$9C
M?.]-@PV>N1WI4@ACSY<4:Y 4[5 R!T%9.I>*=-TM;F2X,IM[1UCNIXTW) S8
MP&/7^)<X!QD9Q2ZGXFL-*2XEG$[P6I474T4>Y(,@$;N_0@G . 03C- ":AI%
M]>WD,"7D$.BB,":T6W^>0ALX#YP%(P",=,^O%_4M.@U2T-K<J&A8Y=2H.X>G
M/3/3(YQGI3-3U:UTG2)M4GWO:0IYCM"N\A/[V!U&.:@3Q!9R:M:Z8$F%Q=6Y
MN8B4^5HQC)W9QD9''7GTH U:SX-*BM;N[DBV_9[MO-F@9<CS, %AZ9 &1ZC/
M!SG,NM;TZYO-'$DVHV[RWKQP+&K*DSJ&!5R."O#$#/. 1Q7/^(/%-SJ7A#Q:
M]K'>Z?+IDCQ13H=C954)R0>"2QX],4 =[]CM?E_T:'Y?N_(./I4-S8K);R16
MQ6V:4;7EC0!@IZX]_0GI[U3T[Q%97VIG2U%PETL G7SH602QY +(3U&2/S%6
M+_6+?3[JVM&26:[N0[101 %F5 "QY(  R.I[B@"U:6D%A9PVEK$L5O"@CC1>
MBJ!@"IJIZ7J=KK.F0:A92%[:==R,5*GK@@@]"""*N4 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5A
M>*]/AU33K>UN-/GO(&N 7:W?9+;X5B)4.0<AL#CG!/!K=HH \VET7Q%;P:5J
M%S:-KJZ?<W,?V:Y*>?+:R;0KG/RF0;<\\D'L<U;O=.U2&32-?TOP[';M:74K
MRZ7$8TEDBDC"%B0=ID&,XSTXS7?44 <;K\6KZKI.GWZ:1*DEIJD%Y]B#H9C$
MO#9^;;NY)QGH!SFLC5M*US4(O&I31;A3JUK!':J98\EE0@AOFX/(]1UYKTFB
M@#E/$EI?WUIX<-MI\\C6^I07,Z90&-$!W9RV">>V:R[W2=5FLO'D2:9.6U0$
M6?S)^\_<+'_>XY'?'%=_10!YW=F_M->MKBQTG4)+A-(CMKLVC0NR$L2JLKL
M",,003G=R,5U/A3[''X>M[.RM+JSBLQ]G^SW8 D0@#[V"02<@Y!QS3KWPOIE
M]J+:@PNH+MU"R2VEW+ 9 .@;8PW8]ZT[:UAL[=8+= D:]!DDDGDDD\DD\DGD
MT >=Q6'B*XN= O+W1;EKVRU*1[MA/&(]K+(H,2[L!!N7/ /^\:6ZT;6)?!OB
M2Q32K@W5YJ[W,$>^/YXS,CAL[L#A3P>:])HH X[Q5I=U<:SI%[ITGD7-X&TZ
MZ!X9K=U+DC'\2;21[DUURHD$*I&F$1<*BCH!T JA:Z#IUGJ]SJD,#?;+G_62
M/(S8Z9V@G"YP,XQG K2H \VM]&UF/PWI%JVDW GM_$!O94WQ_+#YSONSNP>&
M''6M@66H+XC\5W7]G3F"]LX(K9P4_>,BR C&[(Y<=<=Z[&B@#S325NM(UWP;
M;7=C.+BWT*:":)-K,A4Q G@\C([9ZU++X>U.$6]U'ITKO<>)1JLL*,F8(MI7
MG+8+8P2!GJ?2NVET6SFUN#5W$OVR"-HHV$K!0C8)&W.#G _*M"@#E6M+_2?'
M5YJR6DUW8:C:11,8<%X9(RV 02/E(8\CH>OK7-QZ9<>'M7\(B:!WGFU*_NG@
MB(8QB2-VVCG!V@C./0XSQ7IU9][HMGJ&I65_.)3<63,UNRRLH0L-I. <'(..
M: .*U;PQJEW+JVN6EBCW$NH6UU%I\Y4>?'#'L(;J 6W,1GIA<\]'ZSI][J_@
M_4UL/"8T^YN1"B0 0K-(5D#$L5. H XR<]>!W]"HH :C%XU;8R$C.UNH]C7F
M]MI_B*XO/#M[?:+<F]L[^5KQO/C\L!DD4&)0V @R,\ _[QKTJB@#RZ32?$%O
MX!N_"O\ 8UQ<W,%TK0W4<D?ESQ_:!+NR6!#8SD$=JZ7Q!H=]>:]INI:>OE_:
M(FL-1#, 1;L-V>#]Y2"!CN]=910!QWB&UU>YUB:TBTZ6XTN33C' 8)4C59\D
M8ER02N-N ,CKP3TH:'INKP7O@Z2XTFXB33M*DM+DEXSL<K&!T;G.P]/49]O0
M** /-TT768](@;^RIS+;^)7U$P!X][P,[D%?FQG##@D4GB33_$6KV>NVTNC7
M$LK3PRV1BGC6'RE,9(QN!:3Y6&6'I@@=?0C>6PO5LC<1"Z:,RB'>-Y0'!;'7
M&2!FIZ /.M5^UOXAUHVNCZG+!?6D-M>FQ>&0[MIR#O8;7"N!QD8(/I2S6TBW
M^EZUIWAR34=*6Q_LZ2PE5!/:F)R 0'.#@Y4X/8'-=5/X5TN?49;Y1=V\\Y#3
M?9;R:!92!C+*C $X'7K6M!!%;0I##&L<:#"JHP * ,"*_FT6/2;4: ((+R9D
MD6U*!+0L?E# ?>)SSMX&&/2D\7Z9?7B:3?:?'Y\VF7Z736^X RIAE8*3QNPQ
M(SZ5T+0QO*DC1JSIG8Q'*YZX]*?0!P.OZ)?ZQ-K^JV]C.KW.B'3+:!RJO*[%
MF+$$X &5')SU]L]EI*R+H]FDT3PRK"BO&^,J0 "."15RB@#E/ UL^FP:SIDP
MQ+;ZG.XSU:.0[T;Z$-^8([4>&- O-(U*^@F"_P!F6LTC:8 >BRX=ACMM.5'L
M373&VA-TMSL F"[-X."5]#ZCZ]*EH Y/PXMQHMEXDN]2M9+6)M1N+U#(5.Z(
M@$'@G'W3P:L> M,N-&\":39W2,LZ0EW0]5+L7V_4;L?A6_/;0W*JLR;U5@P4
MG@D=,COSSSWJ6@#S9-&UD:#;P'2;CSD\2#4&3?'Q!]H,F[[V/N]NN:D\0^'=
M8U>]\5?9+1X_M<%D;221E"2O Y=E.#D9X'(KT6B@#C(VU75/&>B:H^A7EI!#
M9W$,_G/%^[=S'CHQR/E/(_*L33]*UV#P_P"%-+;0[GS-'U)&N'\R/:Z*)!N3
MYN1A@><=0.>WIU06MY;7L;26MQ%.BNT;-&X8!E."..X- '(>'DU[1#<:!)H[
MSPB[EEMM1\Q/)\IY"^7&=VX%CP!R<<@<U2U?1]6NHO'B0Z9.QU2.)+,[D E(
MB"'^+CD=\<5W=Y?6FGP^=>W4-O%D+OE<*"3T&3WJQ0!Q\]K=GQ9I&H36,B6-
MOI<T-Q+(R!8V;8<'YNF$.2.*Y_06DM+30AJF@ZU'9Z<WF6K 1/%#O!52S!][
M*JM@?*#W(]/3)X(KJWEMYXUDAE0I(C#(92,$'VQ638>%=+TYT, NVCC(,4,U
M[-+%'CIM1F*C';CCM0 WQ5I\6IZ;!:W&G37L#7"ES ^R2# 8B5#D'(;;TYP3
MP>E<P^D^((-,TF:=+O4SINLF>-7*?:7M=C(I;) +@MGKG&,\\5Z'10!YM>Z'
MX@OI/$5W;Z:T%PVHV>HV232IMF,*QY0D'@_+],]^]:FOMK7B3P7J\$>@7%I-
M<6QAB@FDC,LCGOD-@*/<Y.>@[]K10!R@M+Z3QUI6H?8)EM(M,EMY)&*?([,C
M $;L_P )Z4SQCYZ:MH5Q8V4]U?6TLLJBV9/,6/9M;Y7(!4EE!Y&.,<FNG>\M
MHKN&TDN(EN9E9HHF<!G"XW$#J<9%4M4\/:=K$\-Q<I,ES "L<]O.\,B@]1N0
M@X..G2@#BCI\]Y81MINF:A#J>GZO'J]S:WVQ'NMY<-M*L4Z;@.>-HSZUT=II
MDM_XTDU^6VDM[<::+%8Y@ TA,F]B0"< 8 YZY/;KN6.G6VG1&.W5_F.6>61I
M'<_[3,23^)JU0!Q_AKPW>V%M?Z?>/BUMO-M--<'+"!SOR?<95?\ MG[U1\+6
M%]:06.F:AX1MH[K3@JG4@L31R*@P'3'S[V ]!C))/:N^HH \]BT?5O\ A5FL
M:0VF3K?SM=B*$NGS>9([*<[L=&&<FM-K6_/B_0]0&G7'V:VTV:&9LI\KL8R%
MQNY^X>G'2NOHH \WM-%UB'P5X7L'TJ?[58ZI'<7$8>/Y(UD9B<[L'AAP.:EU
MKP]J^IZEXK:VLROVJ.Q>S><KY<SV[%RA&<@'@<BO0ZKVU]:7IF%K=0SF%_+E
M\IPVQL9VG'0\CB@#BKFTO-6\,ZP(/!RZ7>3:?+:JI$(ED=Q@*K*?N ]22,\<
M<5<6QU!O$?A2Y.GSK#96,T-RY9/W;.L8 /S9/*'IGM78T4 <SX$L[_3/#$.F
MZA9/;2VKR)N9U829D9MR[2>,$=<'VK,ATS5--M?%.DG3Y+M-3N+BXM)U9=A\
MY<%'R<KM/?'(Z9/%=S10!Q*Z)?:;K/@Z&*UFN;72;.6WGN5*@ F-%4X)R<E3
MT'%7-+M[ZV\7>)KV73KA;:[6W^SR90^9LC(;C=D<],XKJJ* /,M+TCQ!H6E>
M%-03299YM,MYK2]L5D3S-DA4[T.[:<%1QGFMS7X-6U2QT65=)D1X]7@NW@5T
M+0Q(<DN=V"W?"D]<<XS78T4 >;Z]IWB#4H]3CET>YGECU.&>U:.:-8FMUD0C
M:NX9DP&R6'XXP*Z'3+2^3QYJU_-8RQ6MS9V\<<I92"Z%RPX.?XASBM^ZOK2Q
M$9N[J& 2.(T\UPNYB<!1GJ3Z41WUI->2VD5U"]S" TD2N"R ]"1U&<4 8&J6
M5^OCK2]2@LY)[7[%/:R/&ZCRF9T8,<D'&%/3)]JY^+P[JLOP]/@JXLY!,D@A
M%Z"OE-")0XE!SG.W^'&=WMS7H]5YKZTM[F"VFNH8YYR1#$[@-(0,G:.IX!H
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MW\A05R",\'H>E=\CK(BNC!E89# Y!'K2T 5_LL<FG_8YXXVB:+RG15PA!&"
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M5U*^%X7:UR4.Y&(P&&<E!Z8&>O6NCUG2(==T*YTN\8A+B/8SQ_*5/4,O7&"
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M:-CMR5"YR#R<4VXMK]_%&K^'+34+Q+6XTI;N"7[0Y>UGWL@VOG=M.,X)QP:
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M&Q;JVQE_B4D]/RZG,LEU=V>E>$-9LK^ZN)K^YMH;M7F9TG29<N=I.%*GYAM
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M UQ-[!<WOB'QC;OJNI1PVME;S0)#=-&(W*2'(VX(Y XZ'N#@4ZRU&^N[_P
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M0!Z#16'X2U"WU'0$FMWO"%FE1TO<^=$X=LQMDDY7.WJ> *W* "BBB@ HHHH
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M]+BLTO'U&U%M)DI*)05;'7![X[TR?Q#HMK&DD^K64:21><A:=0&C_O#GD>]
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M>>RBGFMUD4/ED#$[,Y'7-:KZQIJ7RV+W]NMT[;5B,@W%L9VX]<<XZXH S_\
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MY$#L(WD'1S'G:6R <XSD ]JU*HPZSIEQ=?98;^V>?YB(UD!)VG#8]<'KZ=Z
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MT]Q>L80%RTH\N,+M[L-P;&.X->K44 >8^*;U+M/$]I#!-#+-HZF.2&!I&O\
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M2&."V*&WFBEW[U8'AACY6&,X]&'XV-:MYKO0[^UMT#336[Q(&; RRD#)].:
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MHV]B>3TP!SQE:9X<\01ZGX<OKNTL?M-CYR7L_P!J9Y+@NFWS,[/;(7MG' H
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MWK-YFU=BAL(NQ1O[#'7N>;,&A:I'=>#G:WBVZ1 \5T?-'),(C^7CD9&><<4
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MLJ'*$,#@YP5P1[T 1'QU:C3K.\_LV^9;J_?3U1 A*RJS+S\W0[#C'XXJG?\
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M** "J>I:K9:/:-=ZA<+;VRD!I7!VKG@9/;GUJY7'_%/_ ))IK/\ N1_^C%H
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MHRS/_JQGL<*Y(_W:WJ (9[NWMI($GF2-KB3RH@QQO?!; ]\*3^%0:EI&G:Q
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MRO73PK<33A8KUS;:G'Y0S#,"4'/\(,HV\]NG0T =I?ZM8Z9):QWDXB>[F6"
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MJ^1;06ZVY41322;=[-NY 7)VX'0#/>@#T.J5WJUC8WUG9W$^RXO'*0)M)WD
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MMHIBS/YB1*#N/4Y ZGN>]36MG:V,;1VEO% CNTC+$@4%F.23CN3WH GHHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MMY<NW<L;_*.H!Y&>1T[T =)17,^"M4U/5]*N+G4E@W"\GC5HG)^[*RXP0,
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MW1B/*\<<#/Z>]=510!Y397DTK7&J65YX;N8Y+V2ZCM;AY8YM^XA08U8J)<
M';NS@\FMO5/!^LZK!KD8OK1(]5:*9#/$S2P[=I\K(.-@*YX]3QSFNT%G:K<F
MY6VA$YZRB,;C^/6IZ .=@T34K7Q3=:PES:NEW:1131F-E.^/?C:<G"G?WR>*
MR;#P5?:=IGA\Q7=N=3T1Y0C$-Y<\<F=ZMW4\C!YP1[UW%% '&ZMX.N]3L=9;
MSK>/4-5EMVD;YBD20E2JCC+'@Y/'WNG%7+O1-5E\27&L6T]K!))IGV*,'<VQ
MPY<.>!D9.,>G.>U=-10!SFA^&AI>NWVJK#;6?VN)$DM;0DQLZDDR'('S'('
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M:REOAS%'>3(\D$I$I"ED!M.BY&/ID'\:[8^'K!M2OK]Q*\M]"+>X5I#M>,9
M7';&X]/6JUMX0TRU;3&B:[SIF?LI>X9MF5VD<YR-ORXZ =* .7M_$6I6MO\
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MV^L+ZTNQ-,M^5^U2&0AY0O0$C& /08'7U.;%]H5IJ0L/M+W#&QE$\#"4@B0
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MWXRA;G9P.BYQ[XK0JI<:;#<ZC9WSO,);3?Y824JAW#!W*.&XZ9Z5;H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M:BL&'Q;IT]S:QJEP(;NYDM8+DH/+DE3=N4<[A]QL$@ XJK)X\TJ.*XG-O?\
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M<5M;ERX7&0OJ>1Q3+WQ=I]A:O=SPW0LXG6.XN!&-L#-CAP3NXW ' .">>AH
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M]8L]=TR+4+%V:&0D89=K*P.&4CL0015^@ HHHH **** "BBB@ HHHH ****
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ME0!ER, \=&.33KS0=;G\(>*[!-*E^TZAJ;W%LAFB^9&9""3OP/NG@^U>C44
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M2:S^T>8WEFV5MFS^'(8YSZ\UYO<W>IWWP\EN;^YBN9?[<14Q&4Y6\"]<GC@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=]=6=E*^NRV\<JW#1H\:E5D4_<VJ23DCMD\YJ1O$&CK8?;FU*U6V$GE&1I
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MCZCK76HK)$JEB[!<;CP6/K0!PWA&^.E^'Y8X+26X>;6[JVB1,[5_>OR[<[5
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M/7-*\1ZE>V7V6]MM5BB$_GRF)XI439N "D$$<XXYH L_#PD_#W0B3DFS3)K
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M>Z%X3L=,U#R/M%N&4F%RRD%B1U YYK?H **** "BBB@ HHHH **** "BBB@
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MC3XG:UNI@;B"7R1$L!)&5(._>O'7@G/ H ZS4+^WTNQDO+HN(8R WEQLYY(
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M;MKV2>V2W>VO9K0HDA<'RVQG.!U^E;- '-Q>#+2'3M&L4O[X0Z1*LUMS'DD
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M7EP$M[C58PT4 ;/.PN0/4  \_P"-.\/ZW-K$NK1SVR0-87S6@"2%PX"(V[)
MZ[NF* &1Z/>PZ_972:IJ$D$-NT<Z32J8YB22&V@#Y\D<C    '/$NN: -<-M
MNU34+(6[[U%HZ*&;L3N4YQVK8HH R]*T8Z7!.AU/4+R28Y\Z[D5W0 8 7"@
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M;A;I(29"#@= S8SDDD<X&1U=5;22]>6Z%W!%%&LN(&CD+%X\#EA@8.<\<]*
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M'V=')W9 QG&><9QGM72T4 <E-\/[&2RO=/CU+48--NYA.UG$Z;(WWAR4)4L
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MWH;3Y_M*/O5FED((+.64YX8],#GCH*WJ@O;RWT^RGO+J416\"&21VZ*H&2:
M.7UW0&LM,U^ZL_[1O)M6:,7$43(&1>$+1@ $D(/NY.<>]0Z!;WQU"%K/5O$$
MMI\PN$U2S2(*"IQMS&K%MVWID8!SVKK;.:6XM4FFA,#.-PC8Y90>@;W]1V]3
MUJ#4]372EBGN%'V-G6.27/\ JBQ 4D?W<D GMD=LD &1#X*LK?1['3HKZ^'V
M"Z-W;3ED+QR$L3_#M(^=N".]6;GPK:7FFZG:3W-RTFIKLNKD%!(Z@8"CY=H
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M?'1],(F!TVSQ/_K?W"_O/][CG\:2?1=*NH8(KC3+.:. YA22!6$?^Z"./PH
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M/,:J5P64XZG-6=%M[B/QQXDNI+:9+>Y6V\F5D(638C!L?0D=>O:J?B+3GO\
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MU'/).]O'(&.T+M"LHSC+Y)'3 SQP;-MKMAH]C';WVISW0MY!;3:A+"=GF9P
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MNJ)8#_2,+(C$;95X/!]"1@CO3DU74%\2Z/8ZIH^GK>W%O=.D\4Q<Q["OR@E
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MC$/M^HK8R1^:?W>96CW XY^[G''6K'AO4M5OO$'B*&\: V]I=B&,(3E!Y:,
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M=Y):3+$Y9"R8Y4D X((ZT[6=;&FW=E91(7NKO>R?([A50#<Q" D\LHQQUZT
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MOQ:@:[BME=M$E/F09^;]]'P<\\>O?VH [:BBB@ HHHH **** "BBB@ HHHH
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MIZV0C*L=A!8[L]_OGCCIUKI:* .1L?"=]9R>%B;NW==#MW@/R,#,&0)GK\N
M,]ZKGP;JBAY(M1M1)_;+:H$>%FC;<,;&&X9QP0?4=*[:LVPUNWU#5M2TV.*=
M)M/,8E,B@*V\%AMYYX'M0!S5QX)U*;1-=TTZI;'^U+X7@D^SD>6<H6&-W/*
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M;E<9^;[@YXZUJ2:)?OXI;6A/;#=IWV+RMK==V_=GTSQC'XUMV=P;NR@N3!-
M98U?RIEVNF1G##L1WJ:@#C;7P??6VC^&; 7MNW]B7"S%_+;]\ K*!C/R\.?7
MI7944V1_+C9]K/M&=JCD^PH XJ+P5J4&B:=I:ZE:O%8:DMY"Q@8$JLC2!6^;
MJ2V,]L=#5G4/!DNJW?B%[F\6.'5HH%3RE.^!X22C9SSR0<<=*WM#UBWU_1K;
M5+1)4@N 2BR@!L D<@$^E:% &+H=EKT!WZYJ=O=NB>7&+: Q!NF7?).6X[8
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M#PPZ5V=I ;6R@MVE>4Q1JAD?[SX&,GW-4+GP[I]W/<R3+,RW3H\\/G-Y<A4
M+E<XZ*N<=<<YH Y.]U/4(M)\?%+ZX#::Q:T;?S%^X5\ ]QN)ZYIVO:Q?V"K=
M7IOAI3V,0%]8ODV4Q!+/+&.64@J<\@8Z<YKH;_P?HVI75]/<PS$W\8CN46X=
M8Y<+M!* X+ < XR,#N*E?PMICH\>+D12P+;RQ_:9"LD8! 5@3SP2,]2#C.*
M.=$6IZ_XG\26$/B*^MK>"*UDM3!L&PNCGKMY7(Z=3ZU2\/>(M6\41Z;97#B.
M>321=R%+@V[2N9&CW@JI.!L!P,#Y^<\5K66@2S>-/$%Q<6MW;6-S#;Q0R13;
M%D5%8,,*V1U&#@'K@BM;4_"&BZJEDLUJT36*[+:2VE:%XEQC:&0@XP.E '.+
M_P ) FM>&=*U#76:6XM[Q+M[/:%=HRH4@E<AL-@^^<8JOI^OZ@$L-%FOIF,V
MNW6GF\<CS###N8#/]YL!<]<9[\UV(\-Z6MW8720R)+8(T=L5F<!%;&[C."3@
M9)R35:3P9H<MA-9O;2F.6Z-X6^T2;TG)SYBMG*MGT(H Y"YOI?#6M^,IX+AR
M3)ID2RW#[O)60E"2Q!X 8D$Y[=:T-=O==\)V.JZD;R$VCV\8@@EN&G>&8R*A
MD!91\@#@D'/('3-=#'X/T53?F2WEN#?Q+%=?:+B23S548&=S'D=CU':DL?!V
MB6&G7%@ML\UO<1^5(MS,\Q*=D!8D@#T&* ,>>Q^Q?$SP_BZN9P]A=Y\^0O\
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M4NT1RA..2OMZ5C7_ (-T34M474KBWE^U;!'(\<[IYRCH) I&\?6MX *H50
M, #M0!YO<WDVAZSX]U:&:>26SAMWC220L@)B)Y'H"<XK6FMM<MFEO8M62.QE
ML9/E^U&=VE"[EDCW( . <@<8Z 5OOX=TN34[K4'MBT]W$(;@&1C'*H!4;DSM
M)P2,XS@U3TWP5HFE6\\%I#<+'+&8MK74C>7&>JIEOD!]L4 <D\FLP>!]$UP>
M(=0:YOCIZRHVPI\[*&P-N>0W//.*U8[;4)?&&K:&==U(6GV*&[5@Z^8CLSJ0
MK;>%^4' [^V0=]_"VDR:-:Z0T4WV*T9&AC^T2 J4(*_-NR<8&,GM4PT&Q&J3
MZD!.+N>$022"X?E!G QG P23D<\T 4_!.I7.K^"M(O[Q_,N9K96D?&-QZ9_'
M%5[N_EOO'8\/M-+!;1Z;]L/E.4:5C)L'S#G"@=!U+<]*VM)TJST338=.L(VC
MM81B-&D9]H],L2:CO]$LM1N[>\E61+NVW"*>&0HZ@]5R.H/H<B@#SW6;J]U+
MX?ZQ!J%Q-)+IFLI9).#M,Z+/%M9@."0&Q]1FO3X(1!"L0>1PO\4C;F/U-9EU
MX8TF\TC^RIK=_L?F>:R),ZEWW;]S,#ECNYR3UK51!&@0%B ,98Y/YT <=!;$
M_%+5G-Q<$+I<#A/-.WEY!C'3''3UYKGO#$E[IGASP'=0ZC<&.\F6TEMB1Y1C
M9)#TQG(*@YSZ]N*]!N= T^ZU;^TY(Y5N_)\@O'.Z!DR2 0" <$D@D<9JM'X1
MT>&STZTCAF6#39!+:)]ID_=L,@'[W/4]<]: .?6]UV0>+(+.Y>[N+7484MXY
M)%C)B*1L\:M@!206 /J?QK9\(ZK!J=O?^6]\DL5QMEM+\'S;4[%^0DDY!P6!
MR<[JM'PMI>Z]8)<*]Y,EQ,RW,@)D0C:P.[Y2-HZ8Z5>L=-MK!IY(0QEN'#S2
MNQ9I" %&2?0 #'2@!FKWYTW2I[I(_-F4!88LX\R1CM1?Q8@?C7!VB2^%/&FE
M7,EE<VUIJT0L+R6<QXDNAETD.QV^9B7'..M=[?Z5:ZD]LUSYI-O()8]DS( P
MZ$A2,_C46M:#I_B"UCMM2BDDACD$JJDSQX8=#E2#Q0!SVMWU\->U6TEGNH(4
MTU9=.-J&):;+[B=O5LA %/!&>#S5!U\0/J'A/3K[6KZWGU"QN&OA&(@RR*B'
MY2$P""Q'?IZ\U+JVA3S>)+J>YT;5KB)HXHK:ZTS4O*8HHZ2@RH2VYFYYXQWS
MG<TWPS$G]G7=_)=37UCYGV=Y+MW:-'/W2<@/Q@$D'.* ,)&UW6HM7MM.U+RK
MO3+D6L,\UR5*[$0[Y(PA#[\DG/KQC%/-UK?B276X-/O8K:[L94A@=+EE6,^6
MC[R@0AU8LWWNPX .2=V^\&Z)J&L'5)[9Q=.H68QS.BS@=!(JD!Q]?I1J'@[1
M-3U8:G<6T@NBH21H9WC$RCHKA2 P^OTZ4 84;:GJ?B76+&;6[F.%-,MIT^R,
MJJKMYF2AVYVY4'U/'..*I:;JFK-IW@G69M5N99=3FCM[J%MHB96B<YV@<-E0
M<^Y[<5V@\/Z>NHW5^J3+<W40AE99W *#. !G QD],=:KIX2T>.STZT2&80:;
M();1!<R?NV (!^]SP2.<]: .>L+K7=?T^'6K*^@MFCO7\T2W+>6(DD93$T>S
M .T=<YSSG'%9>H7^LP^'?%NJ+KE[YVD:FXME^0*541':P"\K\Q&..OK79Q^#
M=#BUJ358[5TN))/.D19G$3R?WS'G:6[YQUYZ\TLGA#1I;'4+*2&9K?493-=(
M;F3]XYQDYW9'0=,=!0!E:?;EOBIK+FXN"%L+9PAE.WEI1C'3''3UYKLJR)_#
M>G2WK7YBF-T;;[,6%S(N]!G ;!P2,G!()&<U+H&E#1-%M].5V=8=VW<Y?:"Q
M(7<W) !QD^G:@#F=69E^,/A_[2<6QT^X%KNZ>?GYL>^S%=A>O#%!YTJ!S%EX
MU/4L >![XR*@U71K#6K98+^#S%1Q)&P8H\;CHRLI!4^X-%GI,%FZR>;<W$BC
M"O<SM(5^F3@'WZT <.VMZDO@+3/&$-[+)=R2PO/;ALQ2))*$,03H,;A@CG*\
MD\U%J=UJ_P!@\;72:Y?(^D3%[4(4 &(4?:WR\KDD8]^<UV=MX6TFT<>3 ZPK
M/]H2V\UC"DF<[@F<#GG'0'D#-))X4TB6'4XGBF,>IG=>+]HD_>G&/[W'  XQ
MQ0!SFO:W>V-PUW?B]BTF6WB\N^L7W+9RD9;SHP<E3E>3G ]#S3Y]1O1-X[B2
M]G\NQMXYK0A^8F,!?*GTW<X/'X5T+^%],D26-Q<&*:-8IHC<.4E11@!@3SQP
M?4<'--OO"6D:A>W-U/#*'NH?(N%CG=$E4 @;E!PQ )P2.* .>$TMYX@\!332
M,TLVG7+N_<L88B3^=4/#[-9^%"PU2ZB>?6YH-NXR23@3OF-"3\K,!RV>.3D=
M:[.+PQI<,^FS1Q3!],C,5IFXD(C4@ C!;G@ <YZ"J\O@K0I8I8S;3*'NOM@*
M7,BF*;).Z/#?(22<[<9S0!R-[K&LP^&?$OEW]S;RZ?JT,,!9Q(ZQN8<HS')/
MWVYSGW-7]3:]M-7\1:2VJ7L]N^AF]5I) 'CDW.IV%0-H( X%;TG@C098KR)K
M:;9>2)+.HNI?G=<8;[W7*J2>Y SFKK>'M.DU*34)(Y)+F6V^R.SS.0T7/RE<
MXZDGIGF@"MX,A$/@S1@))'W64#_.V[&8UX'H/:MVJ6E:5::+I\=C9+(MO&,(
M))6D( & ,L2<   #L!5V@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "L'Q3J]YH\.F2VGD%;C4;>UF
M$JDG9(X4E<$8/US6]7(_$-(VT33VG4&VCU6T><L/E6,2#<6]%QU)H Z:UOK.
M^1WM+J"X5&VNT4@<*?0XZ&DM=0LKXR"TN[>X,9P_E2!]I]\'BO-=?T\F_P#$
M%_X7@5K,Z5$ER+(#9/()@Q5<<,WE!@>OW@.].U.73M?TC5=6\,WU[J.J?V6T
M#;%";8]P8QL%5?GQNP.O6@#TFVU"RO'D2UNX)WC^^L4@8K]<'BD@U"RNII(;
M>\MYI8_OI'*K,O;D \5PU_?Z5XET*_OO":&76%TF2WC>$,I@0X/E$= ^>@Z\
M''%$DMEK$W@R;1'B\ZWD_?HF,P6WE$2)(/X1D*N#WH [?^U=.\R./[?:^9*Y
M2-?.7+L.H SR1Z5);WUI=O*EM=03/"VV58Y Q0^C8Z'ZUY'-'I8^'&JR(MJ)
M%UYC&R[0RK]K!&#U VY/';-:OB%-OB;7;701$ES-X: CBML*782/P /XMIX^
MHH ]%M]1L;N26.VO+>9XO]8L<JL4^H!XI;:_L[TL+6[@G*8W"*0-MSTS@UY]
M%=>%O$%M-J,.HW\TD.ESP7 C18VM8"AW*X5%&01P.>1D< UK>$KN^_MRYL;R
M>RU,)9QM%JUH-OF1[F"I( 2 W+$8[9H Z'6-=T_0H[=[^XCB^T3I!$&8 LS,
M!W[#.2>P%9=GXF_XJ76K2_N[&+3[2*VDMY]VP-YH<\L6P?NC&,5!\0'CAT_1
M[F8A8(-8M))9&^ZB!^6)[#WK$F;2[WQ-XSDF-M(G]EV^PR <#9)G&>G5<_44
M >@W5]:64(FN[J"WB/1Y9 B_F:E1TDC62-E=&&593D$>HKRO3]9ATX>&+G5M
M0EM-,GT&*WCN@JNBSC'F(Y96VD@+Z?=Q7>^%;*RT_P .VMMIOVC[$NXP&X^\
M5+$@]!@'.1[8H T)]0LK698KB\MX96Y5))0I/T!-!U&Q$<LAO;<)$=LC>:N$
M/H3G@UPGB:YET_6=4O-/NK:]&Z!+[1;D8>7A=C0,.=V",#!&0>]4]9O;2RE^
M(]E<RK'<W5L)((2/FE7[*%+*.X!!R1TQS0!UDGB)[7QE-I]W<6<6F+IJWBS,
M=A!,FS!8MC''MUK4O;J0_8'L[VRCCEG7>9CGS8R#\L9!'S'C'6N&M6TF3Q;I
M<^J?9#:2>'8TB>["^6SASN W<;@">.N#5.WTTV&C^& T)CA_X2=FL5=<-';,
M9B@YY (P<>XH ],DU"RANX[26\MTN9/N0M*H=OH,Y-+-J%E;W$=O/=V\4\G"
M1O(%9OH"<FO-1/IEY+K/A[Q#>7L6H-J<DT5I&BA[@;]T+Q-LW= H^]QMYP*M
M6^H:0UUXC\/^)8G>^N-2::*W8-ONHLJ8?+(Y.-H'!XQSCF@#M;3Q!IE]K%WI
M=O=Q275IM$BAQ]XY)4>I '/IFM%W2*-I)&5$499F. !ZDUR.AS0P_$7Q3;2$
M)//]EDB0CEE$."P]@1C/KQWJ7QZ\\.F:;<JC/90:G;RWX49_<!LDD=P&VD^P
MH Z&/4["6U>YCOK9[>,X>595*J?<YP*P/#6NZAXC2SU2WGT]M-G1S-;#/G0<
MGR^02"2!R"![55@>WE^(5WJMG<0MI9TE5O)D<&)I1)E,GH6";OH"/45-\,Y(
MG^'FC"-E+) %< \@Y/!]Z .ENKZSL$#WEU!;JW ::0(#^=+)?6D.SS;J!/,4
MLFZ0#<H&21ZC'-<GXBO[.'QA;6DNVVN9=-E"74@+^8I=<PQIT+D@'H3C P<\
M<IX>?3KS_A7"S^1(Z6MQ'() .HC& <]<'I[CU% 'J7]K:;]GBN/[0M/(FXCD
M\Y=K_0YP:G^TP?:!;^='YY7<(]XW;?7'7%>=Z3I$&O\ AOQ1IUG)$DT.M3S6
M3(1B&12K1L/0;@?P)KI/"5U/K=NVOWEJUM/<1K D+CF,)G?^<A?Z@+0!KZM-
M/!I[/;75I;2[T DNQ^[QN&1U')&0.>N*DN-3T^T\S[3?6T/E;3)YDJKLSTSD
M\9P<5S/Q,, \&R--Y8=;JU,9;&0?/CSC_@.?PS67)'I$WC;Q:TRV;J=+@.6V
MD$XEW'ZX*Y^HH [PWUF+A+<W4 G<96/S!N8>H'4T&_LU29S=P!(3B5C(,1GT
M;T_&O.H=UMX"\(>*+93/<:/!$)U0;F>!D"2K]1PV/]FK_B&2;1(=!U*_::"T
M^VO/J4L*!S#)(C!&((.54D+G'  ]J .T&I6+68O%O;8VIZ3B5=AYQ][..M4K
MSQ/HUC-81RZA;9OI&2$B5<':"2V<]!MQGU(%<=);:0UJEYHFO2VLMSJ9N;>_
MG56MY;CRF##;A1M*Y!(_BZ'(J#^TBQ\)W^I6MM9+#J]U'-)"28'<I*-Z$_PN
MQ)'N: /0;6>=]1OUDN[22!"GE1Q?ZR(;>?,Y[GD<#BI8-1L;IBMO>6\S#M'*
MK']#7G5X+.:?XE01W/V='MX69H%RP_<?,=HY//!^IJ72]1T76/$<.K&]TN>[
MM-):W2QLYO,ED8?,2N0I& "!CGYCTH [Z/5-/FDECBOK9WB!:15F4E .I(SP
M*RH_$=MK.B->Z+J=BA$_E^9<ME !(5.0"#\P5MOKD5Q6AZE8S:]X(EMIHEMS
M9W,"V\(9EM\I'B)G.2SCG.?3.!GFHUQ8_P#"H_LTC1"[M-4 =&&&B;[<3CV.
MS)^GM0!ZQ=:A96107=W;P%^%$L@7=],GFEGO;6V8+/<PQ$J7 DD"Y4<D\]A7
M&VUY9P^+/%-OK\D*0WD4+6S3D!)K;R\%4)ZX8MD#NV>]8.BV0@U+P%;:VD;7
MBV%T)%N -X'R&)6![@= >X/I0!ZG;W$%W D]M-'-"XRLD;!E8>Q'!IMS=VUE
M%YMU<101YQOE<*,_4URWP]D@.G:Q#;O&8HM8NPB(1A4,A(P!T'I1J=W_ &?\
M2K"XU%UBTR339(;>:0X1+CS 6!)X!* 8]<$4 =0U[:+%%*UU"(Y2!&YD&')Z
M8/?-.M[F"[@6>VFCFA?[LD;AE/;@BO)KFTMH+6S^T"$:=+XM$EBLF-HMSG=M
MS_RS+;O;!]#7K%K:VUE;K!:0100*25CB0*HR<G ''))/XT 13:KIULVV>_M8
MF#B/#S*IW'HO)Z^U.N-1L;-BMS>V\!5=Q$LJK@9QGD],D#\:\W>T\/R7WCZV
MU&&T+F4>7&RC?S;I_JQUW%O3DG'M3M$TRU?QAI5AKD%K<7@\-11W$<ZJY:4.
M,A@>K ?CB@#T:34+**Z2UDO+=+A_NPM*H=OH,Y-+=7]G9%!=W<%N7.$\V0)N
M^F3S7FC.DW@;Q/H^H8_M_P"UW#)"3B664MN@>,=2/N!2.@7VJY'J-E8:_K>E
M>,7 .H6END+R*Q6XC$062-"O.?,+G YRV10!WUUJ%E8A#>7EO;ASA/.E";C[
M9/-+=ZA96"*]Y=V]NKG"F:0("?;)KSN[O-.L/$&H:;KUQ<Z9I]]8016:NBLK
MQ!"KQ;F5CN#$\9R<TQKG3]%UF33M9O+VPTNZTN""QDN$5@\:A@\3ED.'Y!QP
M3^ H ]&N[VVLX/,GN[>W#<(\SA5)Q[D9KG= U[4=8\-Z;J$MSIUO/-?212[E
M(62-973;&-WWB%7')[\5B:7=6/A[Q=;6^H226VF-I$<.ERW[8& YWH2>CD;.
M#@X ':L33I;!/!_A( PHT'B-@-P"E%\Z4]^@P5_,4 >K3:KIUL6$]_:Q%7",
M'F5<,>@.3U/I4ES>VMDH:ZN88%.<&60*#CZUYEJ,.E./B86CM&<0CR\A<AOL
MP^[[[QV[CUJQ/K=CI6M:1?W=_:,ESH(A*7<A2/[P.0^""2<AAZ*#Z"@#TF.6
M.9=T3JZ^JG(K-F\0:>NN?V(EY NHF RA&8';R H(R"2<YQUP#5+P+96.G^#M
M/M=/O;:]BCCPUS;D%9'[GCTZ<\\"J%S<VUE\5XWNI$B6;1MD3/P'83$D#W .
M3Z#GI0!>\)>)!K6@V$^H7%I'J-T)3Y$;;2P61ERJDDXPM;1U&R%X+,WEN+H]
M(?-7>>,_=SGI7D^FG3X?!/@^Y4VZ7 UU"\F0'QYL@.3UQM(_#%3:EJMC*T31
M.EH+;Q3')/:X9I%/FX:61CG:&[ 8&#C)[ 'I%AX@TS4]1O;&TNXI9[-PDBJX
M/S8!./7&0#[\5HR2QPQ-+*ZI&HRS,< #U)KD/"]Q!'XP\5VK$+<27D<R1E2&
M,9@C&['ID$9]:D\=W;:?#HU_*COIEMJ*27VQ2VV/:P5V ZJKE6_ 4 =+#?6=
MQ;-<P7<$MNN=TJ2!E&.N2..*8FJ:?);-<I?VK6Z':TJS*54^A.<5PFO7&FS6
M4>LZ)$9=-?5[:XU6XBW-',B\%@#U"D1EL#''J#2:];G4M7\2W>CLMQ:3^&Y8
M9V@(9);@[O+&1P7"Y]P"/44 >@?:[=I5@2YA\YTWHF\$L/4#.2*QO#&N3ZGH
M]W>:F]O&UO>7$#.@*(%C<J#R3C@>M<M9ZSIU[XB\"/;7<<J)8W,;NARJMY<7
MRD] W'(ZCC/6LN#4$M]&L[IW#Z5#XGN)+\I\P1#)(8W;'\ 8JV?8&@#NM%U^
M75/%.M6"S6D]E9Q6[P26_)._S-P8Y()&P=,5+XOU>\T/03?V0A+K/#&PE4L"
MKR*AQ@C!^;-8_AN]L+KXC>)9;*>&5+BULW62(@K(0) 2".#C(&:L_$F6./P9
M*'=5W75KC)QG$\9/Z G\* .DN=0LK)XTNKRW@>0X19954L?;)YHN-1LK25(K
MF\MX9'^XDDJJ6YQP">>:\^U&^TS_ (2+Q%I/B2_GMK?4A&;7;&K)<P&)5VHV
MQCN#;N <Y;(YK.\3W5FFF>*-+C5[2YCTJ ,MQF2XNPL9*D9R J9(8@=<DD8R
M0#U&^O;>SAS-=VUL[Y$;7#@ GZ$C/YUG>#]7N=>\)Z?JEVL:W%PA9Q$"%!W$
M<9)]*YG3];LH?&E^VL7$:6][IUL--EGX26,!O-52>"2Q!QU(QUXK4^&,D;_#
MO2!&?N1LI'H=QXH VO\ A(-,.OG11=Q&^6(2M'O&1DX ^IY./0>XJU'J%E+=
MM:QWEN]RF=T*R@N/J,YKC=5D>'XAZE';NL=]=: J61(^_*))>GN,J3Z#GI67
M"\.I^$?"%MIQ"ZU9W=L'BZ30,O%P7'4#&[.>N1ZB@#TUW6.-G=@J*"68G  ]
M:YW1=8U/Q+9?VII_V6TTZ1F%M]HA:22902-YPR[ 2#@<G'/M6SJEF=0TF\L@
M^PW$#Q!O[NY2,_K7)>!M;LM,\,6FB:M<0Z?J>G)]GGM[F01D[20&7.-RD8.1
MQS0!TMAJ,XTMKC65@L94ED1QYG[L .0I#-CJN#^-6Q?V9M4N1=P?9Y" DOF#
M8Q)P,'.#S7)ZUJ)B\7^'-0N@T6CXN(Q+*-J),P 1FSTR P4GU]ZY;7;:!;37
M[@&+^RI]<LGLR2-I;='Y[)[$YR1Z-0!ZK!?V=R)C!=P2B%BLOER!O+(ZAL=#
M]:B76-,:-I%U&T,:D L)UP">@SGO@UP>H)I">*?$UH9TM+*?18%E:UV@K\\@
M+ #@D*5_"J.LW&I77A7Q59WOV349H;2WD&IV*\7$8<D!U&0'4!CQV(]J /4'
MN8WDDMH;B#[6J;O+)#%?0E0<XY%<OHGC:VE\-Z)>ZS<6T%YJ;,JQJ=JY!;)Y
M/"@+U/?'K52WUK3+WXGP7=K>0RVS:&X6=3E&_?*>&Z' !^F#Z5SND7-M#X0\
M 74TB+!!J+K-(3Q&2DP 8]N2/S% 'J3:E8K=+:M>VXN'QMB,J[VSR,#.:2?5
M=.MBPGO[6(HP1O,F5=K'H#D]3Z5Y?KFJV,L.H^2RV;6WB&"6:W8,921)&#.Y
M;[B$ 8P ..O.*L7D>DSS_$ES':L3:H8]RC()MN<9Z'=CWS[T =_)X@TR+7X]
M%>[B%\\)F\LN 0-R@ ^YW<#V--\3:A=:3X8U/4;/RC/:6TDZB92RG:I." 1Z
M>M<EI%Y;IXR\/3SRKBZ\.B*)SSYDOF1DJ#W/4G\:ZCQE&\W@C78XD9Y'T^=5
M51DD[#P!0!;TO5;:_@B075N]YY*230QR LF0#RN<CKWJ=-0LI;QK..\MWND&
M6A652ZCW7.:\^6QLKR]\*W'AD6OVZ""1KB:VVX6,PD8D([F0K@'G.3V-0^&;
MC2M7L]#M9+R]/B'2^#9,BH\$P7;(SD(#L/)))YR.I- 'I U"R:\-FMW;FZ R
M81(-X_X#G-(=0LA>"S-Y;_:CTA\T;_7[N<UP7A#4-&U#2=&TR]A=O$6FS$R6
MS!A+%/R'E;'8Y+$G@Y]<"LP,][\,'TAV"^*H;S_5$XG%UY^X2#O@@[MW3;GL
M* /3KC5-.M?,^T7]K#Y94/YDRKM+= <GC.#CZ4];^S>\-FMW UT%WF$2 N%]
M=O7'O7GLD6EOKWQ \Y+1B+.'.X+U\E@WXYQGWQ4.GM80'X;2QFW25XF$K@@,
M<VI!W'W? Y[T =]9WI2.[DOK^Q=%NF2-HFVA%XVHY)/S\\].HXJW;WMI=M*M
MM=0S-$VR01R!BC>AQT->2WC:<?"'B",&VVKXH!C4$<*9HLD>@VANG8&MN^CL
M%\5^)K2UG2TBF\/)N:U4$J09?F"KU8*1P.<8H [R'4K&XD,<%[;RN.JI*K$?
M@#5JO,_#=[HVN:]X=G;4M(^U:?IYMTMH9@[RN0O0$# 7:2 ,G)/ID]5X[%^W
M@;5QIBR-=FW.U8_O%<C<!COMW4 ,N/$A/C'2-+LKJRN+6[2X,_EG=)&T:@CD
M-@ Y].U;8U"TEN9+."]MFO$4DQ>8&9?<J#G%<#=ZOI&I^*_"D^A7-LQ^QWD4
M1CQ^[)C38C?W2#_">E1>%;C1]7AT"VN+N^.NZ40'LBBH\$@7;(7(0'8>223S
MD=2: .I\)^)1K&B6<NHW-G'J-P\X$$;;2P25T!5223PM;;ZC91W:VCWENMRW
MW86E4.?HN<UY1;Z=87GP]BLK6&#_ (29=28PA0!<12"Z)#'^)0$Y)/&VIM?U
M2Q>/4UB9+-[7Q#!)/;G+2L5EC!G<G.U" -N,#@<\XH ]0?4K"*;R9+VV27>$
MV-*H;<>0,9ZG!XHBU.PG<I%?6TC!#(5252=@."W7ID$9KB]#MM#O?'/BUY[>
MQF"26LR>:BG9B$;F /0@]3Z]:P-,MK:'X36.I6-HDDUO<*;Q[:)6F\A;G<Z\
M@Y&T [3Q@=,4 >JVM_9WT;26EW!<(AVLT4@<*?0D5A1^)&N?'%OI-K<V5Q8R
M6,L[-"=SJZN@P2&QC#=,5R&N2Z=J&B:QK?AZ[O-4>:.!;^2-0%:%9 67"JN6
MV;\]PN<]16JFLZ+=_$G3+^QN[:6 Z-.IFA.1P\;!21T(&3CJ* ._HJEI.K6.
MN:;%J.FW"W%I+G9(H(S@X/!P1R.]7: "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***J:AJ,&G0QO-
MN9I9!%%&F-TCG. ,D#H">2  ": +0 48   ["@ #H ._%<S-XXL(+'5+F2RO
MM^EN%O;=$1I(E(R'X;!4CG()[YZ5H1^([%[>]NVWI8V:!Y+LE3$PVACM())P
M".W7B@#6  Z #//% 4 D@ $]?>L-M;BOKB?29;2_L[A[-KA"^%W)G!(9&.U@
M2.#@\UD>#=?6+PWX3LKS[3+=:E:DQSL0P9E0LVXDYS@>E ':45A1^*[![6[F
M:.X1K:]^P&%E7?)-\N%4 D'.X=_7. *Q+'5_LWCSQ!->_;+6UM].@D:*XDWA
M26?)0!F'(QPO?MF@#MPH&< #/6@*%Z #OQ6$OB[3TU"XLKY)K":&U-X?M&S:
MT(.&8%68<=P<'VK%O=4FN_'GA,I!J%K#.ERVV5\1RKY65R@8@$9S\P!Y_( [
MBBBL6U\1PWJQ26UE=RV\X<PSKLV2;<Y'WL@G!QD#I0!LD!A@@$>]+6!!XOT^
MXL=%O8X;G[/J\@BMV*K\K$$@,,Y'"GIFIX/$4%S.JP6MU+ UQ+;"X0*4\R/=
MN!&[<.48#CDX]10!KE02"0,CH:"H)R0"<8KDD^(FE-;VMVUGJ4=C/.;<W;VX
M$44F\H YSD9(Z@$<C.#Q5_5/%^GZ3'<3SQ7#V=M*(;FYC"E(6) Y!8,0-PR5
M!Q^!P ;Q4-U /?FL:XT.XOM6AN+Z^6:SM;D75K;K!M:-PC)@OGYA\Q/0'..<
M<52O/&]E:2:K&-/U*<Z6%:Z,4*X5"N[>"6&1MY]?0'FM";7;622*UM8I[V:>
MV^TB.V(4K$> Q+,N,]!SG@^AP :V!G.!D=Z,#(.!D=ZXCP/K@B\$Z69S=75W
M<S77EQN^97"SR9+%R.@P"2>X'4BMBT\8:;>VD<L"3M<273V8L]J^:)DR74\[
M> "2<XQWH Z"BN/\(74UQXD\5K(+M%CNX52&YDWM'F%20.2 "22,''-:=[XJ
ML[*.^F%O=3VM@^R[N(55EA( +9!(8[003M!Q^!H W  HP  /04M<Y>^,K*UU
M#[#!9:A?3FT%Y&+.$.)(BP&5.1GK_DXK6O\ 5(;!K:-DDEN+ERD$$8&]R 6/
M4@   DDD#\Q0!=Q16%#XKL9K8/Y-TEP;QK(6CH!*TRC)4<[2, MNSC'>J]WX
MVTZQL-4N;FWO(Y=+*_:K;8ID0-RK##;2I]0: -35[+4;Z&%-.U5M.99,RNL"
MRETP05&[[IZ'/M5NTM8K*SAM8%VQ0H(T!.> ,"LF#Q/!/JMQIHL+]+J.V-U$
MDD:K]HC!VDIEO4@8;:>12V/B>UU'1K'4[6VN7BO9?*BCP@?.2#D;N,;3GG(P
M>* -NBN9L-=TFW_MNY3[:AAOQ#.DY+%IBJ!5C4DX!W* ..34&N^-3INCZW+#
MIETM_IL*R-#,$ PX.U]P8@KD'(!SQTH ZWK00",'D5CS^(%MU$9L+N2[$/GO
M:H8]Z)D@$DOMY(. "2<'T-0VWBO3M2MK%]-6:]:^@:>**'"L(P<%F+$!<,=O
M7.>G0T ;NU=NW QTQBEP,8Q7)_#RXENO#US)*]PQ_M&Z5?M#EI%42L I)).0
M..M2>,]:N].72M-T^3R;S5KQ;59\ ^2G5W /!('3/<T ;&M::VKZ3-9)=RVC
M.5(FC )!#!N0>"#C!'<$BJMIH]\US!/JVH6]XUNV^(0VGDC=@C+99B3@GH0*
M;=>'B+118:A?PW*.C^8]W(XDPP)5@Q(P0,<#C/%)>^*[*RBO;C[/=36EC)Y=
MW<PJK)"0 6R,[CM!&=H./P. #=P/2BN>N/%]I%J4NGV]E?WMPEJMVHMHU(DC
M8D JQ8#L>N/;-2V_BJQOK?3I;&.>Y;4+=KF")-JML7;N)W,!D%@,9_0$T ;9
M4'&0#CIFEK&M?$EM=:E;V"VMTD]Q8_;XQ(JC*94%3\W# L!@_G7/:[K<>L:-
MX?U.P>[MT?7;>!E+E"0)]CJP4X(RIZYH [JD(##! (]#7+Q^+S'JWB*.]L9H
M+'1U0O-\K<%"Y) ;/((P #[XZ5;_ .$KM4DO8KBSO()[2T6]:)D5F>(Y&Y=K
M$'E2",CI0!O45SECXRL[^ZTZ%;*_B&I6YGM))8U59<('*#YLA@#W !QP34GA
M/7[CQ#ITUW/8R6NVXFB7<R$$)(RXX).1MYXQGIF@"32-"FTS5]7OI;N.<:A.
MLVQ8"AC(0)C.XYX4=A6W6/#KT%[<+##;7+P27$EI]I3;L$B;MP.&W#E&&<=<
M>H-<MX3\3)IFBP0WT>H3)-JD]J+Q_G1&:=U169FW'L,@$#N10!Z!M&[=@9]:
M" 2"0#CI6#=^+K&SFN \%TUO;74=G/<JJ[(Y'VX!R=Q'SKD@$<_6LV/S'\>>
M(K8W%SY)TR!U43N-C%I 2O/R]!TQ0!V! .,@''(S00#C(!QSS7.>!+B6;P!H
MMQ.\DTK6:L[,2S,<>O<U4TWQ3H]AH&G7$$.IM;7U]):Q>:#+()#(X.[))QD-
M@<\=J .N(!QD XYYI0,# KEV\;VZKJ*G2-5-SIV&N;81(71"NX/G?M((SP#G
M@\<58?Q?8_:[&VM[:\NI+ZT-Y;>3$,2)\O&20 ?F'7 ]2* .@K!O=$U-M9FU
M'3]82 3QI')!<VOGH N<;<,I7[QSR15-/'NGO8PWIL=12U:X^S3RO"H%M+OV
M;9/F_O<97<!FKFJ^++'24NY98;B:WLF"W<T(4B$D \@L&. P)V@X!H TM.T]
M-/A=0_F2RN999-H7>Y &<#@< #\.YYJY7-ZYKT$NFZI;64=W<O!:&266S<+Y
M.Y2RG=N!SCYL+DXQZC.9X?U&T:S\#PWAOGU"XTW?#(';RV/DJ7\SGYCC&,@\
MF@#MZ,#TKG[;Q=8W5S8QI;W2PWTLL-K<,JA)'CW9'WMPSM;&0,X^E5M'\7->
M6NI7-]8S6L=O?O9Q*2C%V#! G#<L6_ 9ZX&: .IHZUQ'B;Q%#J'A;Q19P_:[
M'4M/LFE9#($< J2CJT;$$''K[$5M6.O0KJ5AHDL%R+F:R%PDS!?+=0 &P=V2
M02.,9YSTYH W  !@# ]*  HP  /053LM22^MYYXX)E2*62+Y@,N4)4E<$Y&0
M1^%8=IX[TZ\CTZ=++4$M;^X-K'<20@(LNYE"M\V>2IY ([$@\4 =0% Z "E(
MR,'I6#>^*[*RBO+@P74UG8R>5=7,*J4A88W9&=Q"Y&=H..?0XAC\32S>+Y=)
MBL99+6.Q2Z$\;(P<.Q 8?-G;\I'J2>F,&@#HP .@ ^E+7G^H:^EM\-A?:#%J
M/E37/DB2:0&6/=<['R6;(SE@N,XXZ5L:/=6=AXEN-)2VU2WN+N'[8(KJ57B1
M1A3LPYP<D9 ^O% '3D D$@$CI2X'I6;#K4$NDW6I&&:."W,N=X7+",D,1@GC
M*G'K6%X2CG\2:!!KNJW-T9[[,L<,-S)%'!&2=JJ$(R<8)8\Y- '7$ XR <=*
M4# P.E84%PV@0V^G75Q<:C>7,\QMER#*Z9+\DX "@@9)';N0*@G\;:9;:7=7
MTL-VIL[E;6YM_+!DA=B -P!Q@[A@@D'/% '24FT D@#)ZFN>/B^+^T;G3AI.
MJ&^BB$Z0>4FZ:,DC>IW8 R/XBI[8SQ48\<Z6]OI,T,%],-55S;+'!EMR EE/
M/#<$?_6YH Z:D*JQ!*@D="1TKF[7QOIMU922BWO(KF.\6R>REB"S+,Q^52,[
M<'KG.,=Z6X\:Z?:Z7>WT]M>(+&Z%I<1>6&=')7'0D$'>O(/>@#HR 1@@$'L:
M7I7/CQ;;^?J-NVG:BEQ90"Y,+1*'FB)(WH-W/W3P<'VS5FW\0VUU8Z3=P03R
M1ZH1Y 79E04+Y;YN!M!SC/IUH UZ0*%&  ![4IZ<5Y_JNG2:;XG\(Z:NJ:K)
M%>/<)=EM0FS-LA+ _?\ E^;GC% '?A0.@ [<4M<)JL4N@^+O#2QW6I744DMV
M?(,[RLP\K*KAFP<$G!/0'D\9J[J/B?2=0\+3WEW!J4,$5XMK<11_)-#*LB@
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M\*ODJV[9D_-NV[OEW8QGOCFHKWQI:6=UJMNNG:E<2Z6JR7(AA7 1@6W E@"
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M5K/4O"TL^GNL>G:0UG<,)8SB0B,<?-R/D//N*[JB@#SN;P_K4G@K5=-&FO\
M:KG5VNXU,T>/+-P)>3NZX&,>OYU:72M9TSQ!J1AT"SU.RU*?[3'/-*B-;.5
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MH&D3<V69B[$-M RP Y)X-7M3TK4I+OPUK-K;%[C2PZ3V32*&=)$"MM.=NX$
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MPQN+C:,!\,,*V.,@>G%7;;P\;7Q(=72[)7[$ED(63/R*Q8'=G);+')__ %T
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MYMY:1QJ5D? #,C')C) YQS^F "A>>(?$1N_$T5H=.B72(8[B/SH78N&C+E&
M<8/&-P/&.ASPMMJNIZGXVT-XKF*&SNM%:\-NT1;&YXL\AAD\X!Z#G@YK4;PL
MQN=>E6^"C6(4A=?)_P!4JH4&WYN3@GKW_*DMO";6MYHUU%J4BRZ=9_86VQ+B
M:+*D YSM/R#)'OTH Z2BJFG6MS:6[QW=\]X[2NZR.BH54G(7 ]!QFK= !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MY!I&E:CHM^AAGU*WMW9%#!T:4(Z\C@]1ZBK.GZC?2>.]9TV:XWVD%I;S0Q[
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MKKVLP+<KJL]K!Y@5/D5MJYP,#OR>IS0!VM%<Y#J-Z/B'=:9)<[K%=+CNDCV
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M=K.CG4XW:*#S&0"1&!.'9%P,<EMO0<\XZU;AUW2[BSENX[R,PPR>5*3E2CY
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M P!'()!'/H01^%3T %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !12$@$ D9/3WI: "BB
MB@ HHHH ***0$$ @@@]"* %HHI P)(!!P<'':@!:*** "N1\%QM8W/BJWN,B
M5=9FN",9)CD5'0^_''X5UU5C8P_;Q>KE)]GEN5_Y:*,D!O7!)([C)]3D X32
M]UG\%M0CNK>:&1+6]4Q31,C99Y-HP0#SN7'UKLO#MI-8>&=*L[C_ %\%G#%)
MG^\J ']15FZLHKUHO/R\<;B01G[K,#E2?7!&1VSSV%6-RY R,GH,T +1110
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MP=W@B9>)D0KR<@C.#C/([5ZA10!Y1-:WG]@>)HUL-2=AKL%ZOF6[[Y(@T!+
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M)$8Q,H<XEV'[N[[V/?WK<I 0PR""/:EH **** "BBB@ HHHH **** "BBB@
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M,9E8A_+W[2H[8!P?;H*DNM#U'5=135+R*TBN;:RFM[>&.=F4O+C<S-L!  4
M#!ZFJ=KX7U:WL_"$#&R)T3'GD3/^\'E&/Y?D]\\X]/>@#6T?Q&=;:*6UMHWL
MY'DC,J3[GB9<\2)CY2<=,FMZN/L/"UTGB2QUJ6&SL[R-76^ELY&Q>Y7 W)M
MSGYL\G(QSV["@#GO%FIRV<.FV-L[1SZI>QV@D4X9$.6=A[[5(![$@TR[N+&S
M\6Z-8#20TYMKAK6X4J/+50N]0/?*]<4GC&PDGCTG4X49VTJ_CNI%49)BY63
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M.2RMO!*C<25YSC&>K55M_"7B*QT/0/LMSIRZKH>Z*(,SF&XB9=K!S@%20 >
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MFM+?7+[2;2/4((]9AG,<Z6T@9E@=#YRL.J@KC!(Z[?6NS5510J@!0, #H!0
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M=YY8<%LG 5LXP<5:N[K6[KQ;K&EV^KFTMX+"*YA*6Z,R,Q<=6!R/E&<CZ8H
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M[F^C-I=/=6TOG!FA=BV0-P((^=N"#UJQ=^%+&]TK4+">6X;^T2/M=QN7S9<
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M76D07UU%->/)/'"XDBMW(\M7'1L ?,1VW$X/(YJ_N& <C!Z'- 8-G!!P<<4
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MUX'/ J]IMQJ\MU*+^VMEMFC22&:%SG)^\C*?3CYN^>@K3+*O5@.W)H P=/\
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M5W=Z=>3J%N'M67;.!TWJZLI(]<9]ZDO?#=CJ6F2V5Z9IS*RNT[/B4.IRK*0
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M-8%Y="[>U%J?N;0@)8<;>N23_P#6XJ70]&M_#^D0Z9:R3/;PYV>:06 ))QD
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M#)I;62)-I<Z@VY4!QNCV=/;.*PX%A?X;Z!*VTLGB%=K9Z9O6S^E>G0:5IUJ
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MW+6L)G7I*8QN'X]: . 5'TKQ#!*;>TU/2I]6,4-Q'\MU93Y*;&_O(,$>H7V
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M&,*"QR<#ZFO,YM$T6^L?'SWD2>;:7DDD#[CN@;R$*LG/!+#MUQBO5@ H
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MX,$AD)8?PYR%&?[O.!0!UR^)+#[3/:S"XM[F&#[089(6WM%TW*!G<,]0.1W
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M3=2M-8TV#4+"99K6==\<@XR/QZ'VJU6+ISS6"Z=81Z&+6"997<6VP16O.0K
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M10 4444 %%%% !1110 4444 %%%% #(X8XF=HT56D;<Y Y8^II]%% !1110
M4444 %%%% !1110 4444 9NK:%8ZUY#7:RB6W8M#-!,\4D9(P<,I!Y'4=#4N
MGZ7;::K>29I)'P&EN)GE=@.@W,2<<GCIR:NT4 %%%% !1110 4444 %,BAC@
M4K$BH"2QP.I/4GWI]% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 9VJ:+:ZO)9R7+3!K.87$/EOMVR
M $!O?@GKQS6C110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
B4444 %%%% !1110 4444 %%%% !1110 4444 %%%% '_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>38
<FILENAME>exhibit1018-arvinasxcons006.jpg
<TEXT>
begin 644 exhibit1018-arvinasxcons006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=S",;5)QT!/ &3FL-M(UFQN+2\CTJ6Z,&O7=X88I8@QBD2158;F _C'&<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M5V[W+1-:2I#/%)$ZR*[XV#81D[LC& <]JEA\0Z9-;WLQN#$+)_+N5E1D:-B
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M['&#ZT ;=%4=-U>SU87!LWD<02>6Y:)D&< Y&X#<,$<C(-7J "BBB@ HHHH
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M>V,9#26\VY1(H/4@-G'7K4_B;1KW5(O%6IV=G<D7VFQ65O#Y3*\S@L2Q4C(
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M#)(7!ZU<\./+X;M-!\+W=K<R2_8PIO%4&$2*"3'G.<X4XXZ 5U=1F"(W G*
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *0@,""
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MW*@R'7+AF5AG*.J%/PVD5U]9-]I%PU]]NTN]6RN7*"XWPB5)T7. RY!!Y/S
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M>1Q/<WMS;VR<G+><Y5>.G!7&<=17>U7N;..[,0E+%(W$FP=&92"I/?@@'\*
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MRP2%BN&#<8)!89&<8Y&:@7PQK<6BWT":9 CIKZ:G!#%.N)(Q(K%5X & .^*
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MO7DE?N=#GK4\?B3Q!:W.N:5>QZ;+J%C#%<V]PN887B=B"SAF.-N&/WN<=NM
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M,G (P<$Y%:E !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MNSLK^3SKNR1$97<C#%6(RF['..?3'&.IHH YN3PJTDOB!Q?!1K42Q2+Y/^J
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M^GN;>.)K6S-TS3(CJ) FQ"<,_/7 YQU-2I<PR7,MNDBM-$JLZ#JH;.,_7!H
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M=1W<,JJ&PZYX(/48)JB?"LAGUV4ZB6.L0)!)NA&4"H4!&",G!.>V?0<5TE%
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M.@Z7=S)-/9H\JQ^3O)(9H_[C'/S+['(JU/9VUS:BUF@C> ;?W97Y?E(*\>Q
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MM[(UR4D<GRU8Y5,'IA< @=\U4O\ 2[ZY>+1H+2S3P^8T$KM(QDP&R8PF,8(
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M;>YMY--@>*YE$TRL"0\G]\_[7'7K2KX9T-%NE72;,+=(L<X\D8D4= ?R'Y4
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MB,CJ&5A@J1D$>E $37%NUF;@RQFV*;_,R"I7&<Y],5Q]J?\ A(=8\4VE[//
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MYKF6T$.GV\IN$=B8R4FRP7.&(QP".W%-TQIX_%45EYD\-K<Z TQ3[6S.["1
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M ,)%J-K%+<&T\0PAM)D,SMMVG9*4R>!@^:,=A7I$D:2Q/'(H9'!5E(X(/45
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M$N,LYP.3@#ZD\5+7+>-H;PPZ/>VT,L\%AJ45S=0Q*68Q ,"P4<MM)#8'I[4
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M*^<TLZ*>R/(S+^A!_&H%:+3O'GB">_M9C!>6=LL#"W:03;1('08!!/*_+WH
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MK<65WYNIZ;";810-(KE8I%9=P&T$$CJ1UH V[[6IQXK\.1VEXC:7J,%Q*X5
M0X5%96#=<?-GBK.E^+]*U.QN+Q9O*AAN&@S(I4L0VP8!&<D\ =>E<SIJS"^^
M'NZUNT^S:?+'/OMW7RF,** V1\N2I'/I56WN+C3M EMI-)N7DA\02/+(UF\G
MV=&F9EF08^<@8P1G&03Z$ [IO$FC)927DFHP1P1R^0[2-M*R?W"#R&Y'&,\T
MU?$^BR17TD6H12BQ3?<"++%%YP<#J#@],UYSJ,-P^A^,K;[%J4S7.HVTT7FV
MCEID_<Y. O\ LL<8XQR!TKI;Z*2X\=W[06\QCF\/F!)!$P1GWL0N[&,X.<4
M=-H6L0:]HUKJ5N"J3QJ^QNJDJ#C]:T:Y[P-(6\%:1"\$\,EO:102)/"T9#J@
M### 'KWZ5T- !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M2*Q;CQ])8VNMB_T2:"_TJ);AK83JPEB;.'5_3C!&./>@#LU544*JA548  P
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M':V!C'')'%077BJXALEN4T>>-18?;9?MK& 1_P#3+.TCS.#P<=N>: .DW $
MD9/0>M!8*,L0!TYKSZYU(W7C7P_K.EZ<;F:^T6:5(RZQDAFB8;V/3 /O4>N:
MU#XC\/Z=<O9-:WEGX@M;:>"4AFAE$R[@&'4$$<CJ#0!Z-17+:OXTAT[[<T%O
M'=)82".X07 69C@$^6F#OP&'4CG('2MV[N4_LB:Z6!KB,P%_*X!=<9QS[>M
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MK*TEN9BPBB4NY1"Y '7@ D_A0!SVH>&[J]\3W=YO@.G7^F"PN59F$B@,YRH
MP<AR.2,=>>E5+;POJ<VC:/HFIR6CVNF3Q/\ :(G8O.L/^K!0KA3PN?F/0^O'
M4Z=?P:KIMMJ%JQ:WN8EEC+#!*L,CBH=,UBSU@WGV-I&^R7!MI=\;(0X )&&
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M2:1<:<VG:C-]HD6ZW^9;2E0K%,##@X!P2*Z2[AF?3)H(2KS-$44RM@$D8R2
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M$BNK2$G]W"5*!\,0%!ZD@'DFO4JQY+3P_H=S'>FSL+.XN)E@29(%5WD<X"Y
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M=MS'W)H Y;Q1J6H6MS>I9Z@8_(TYIXX+:-7D$@+?/)O4J(\  <@GYL9Q5?\
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M.K1%@RL/4JP/'<,<<@ TI? >F2"9/M6H)%)>B_6)+C"Q3;MY91CN>QSC/&*
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M/\R;O,W^9G.WIN ./Z4MUX+L+G69-42[U&UFG55NDM;@QI=;1@;P!UQQD8H
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M <I;>*M7;PEH>K7:W4EM()EU"YL(5>1"C;5?80?E.&+8''';BM#3];N[C7]
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M=(&E1V(&QE Y7 /.T]>H[@&]X.N]4OM,N+C4YS-_I,L=NYB5/,B5B%DX_O
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M_EJOR17.<N5'0':%8X]0>];-W<:7?_$@K%+:7"SZ!,C;2K"1O-0@>YQSCTH
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M:ZT,.-RC8%9HUS_ 7#KCI^5=;X7GAUTR^)UM_+-[&D4&],.L2=<^Y<O]0%H
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M,>O%7'\46,,<8E2X-PULUTT*0-O6-3AG(/09Z=SVS0!LHB1QJD:JJ*,*JC
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MXEC/F.ZYW+M/0KM;.<8Q6-XCUX7N@:9J.D7T\2-JUO!(%&PG]\$=&!&1W!%
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M_M?V3SXOM.SS/)WC?LSC=CKC/&: .%CMO$%M=>%-4U*SGOI[5+N"Z^SJ@?\
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M%S&&XW@=,UQ6IZ-JTUAXU@M]&OL:G';FT\R179R$52"2Q.<@GDX'KT%>I44
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M>G2,J1.[N(U522Y( 4>O-9N@Z98:;8N=-G::VNI&N@YD$@9G.XL#Z$G/IZ4
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M.#YB[P"!CJ#TQUKIIM8O)O#>I:N+.UFL1;O-:Q2,09X@N<OP0 1G P>",XY
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M12EA?RB58C]V$D#?C_>8;C^% '+7GB+46\.O/86UGI\H\0"QG$>2&_?JK-D
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M^S7=LTOF!S_HKX!57YRX.>J@<C\:C\"7^H:KX/L+_49(Y)KA#)N7.3DG.?\
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MYA8LCKGY@0Q!QBM#4/#>JZII]FEWJL#7<5]#>.ZVY$?[M@P1%W9 R.223S]
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M10 @    P!T I:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]M#- TCM'_"SD.H&1S@#C/4T =)1679:E)%I*7&N&VLI_,=&!DPG#L%P6ZY
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M@=J]/HH \_T?3]2M/$MUH]U"39WTB:R[*!LC?/[R('_KH(S[C=5'6/M%Q?\
MCZ/3U::X*63"*,Y:5$'[Q5]3MRN/?%>G44 >7:M)8^(]$U?5/#$NH7NK'3&M
MV<JR;(]P8Q$;0"^-V ,D<^HS?.LZ1JOC'P;<Z8P>)(;J,A(SF',: (W'RD=,
M'I7H5,E3S8GCW,NY2NY3@C/<'UH \ETR]T6>UT;1;[6+.)=-U:2=6N0Z32X>
M3"LK*%4DOR=QZ=,GBZ)=.N)M9\.>(6U 7TNHR3PVT:$?:E+[XF1@O8!1G(QM
MYP!7667AF^M[%-,N=<DNM,2,0B%K9%=HP,;6<=1C@D 'WKI* /.WGGL?$F=.
MNXK^TN=5"W6EW"_O[>3=@S1,.=HQNP1C&>>M>B444 >2:C/"O@3Q1I\N1<C7
M78Q,A!*FZ1@>G.5R?H">U:6OW%E:^*-<:*R2\MV\-!6M8#M$V)'^7*_[)[<@
M5Z310!YE9W27?BZ1X+AKI;KPZT<316[+&6#D[$XZ 'N3R<9[5U/@&YBN/ NC
M)&6+06<4,@*D;75 &'/H>*Z2B@#D?%<RVGBOPE>3!EMXKFX5W"%@"T#!1QW)
MX%<EJ@M)?"?Q#<")KB2_8Q' +-\D>W;W/S!L8[@UZW10!YQJ&I6$'B?5[;7K
MFZBT_5;:$6<L2%XYX]A5X\A2<[BQQ_M5W6D6\=IHUE;0QRQ110(B1S-EU4
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MI)K76V\&R:046XLY@UR@&#;6XB82)(/X>=JX/?Z5A1BRB\!*\:PK,OB(2 @
M, +O(;UQLYSZ5Z]10 @(90000>01WKSU)Y['Q,@TZ[BU"QN=699]-G7$]I*6
M(:6,CG9U;!&,'@\UZ'10!Y.\D\>A7\4<4S_8O%#W=_ L;$FV\_=G&.1C:V.X
M!K0\1V]UK6KZI?>&9A,'T"6"66W;*RR%LQJ"."^-_N,CID5Z110!PUGK7AW6
MK%+VSMBMW::?)"Y:-H_L:E1F-L@#.X  =>"1Q61X U(Z4ND6NKLCK>:?$+"Z
MZ>3M50]NP_A.><\;NAY %>H44 !Q@YZ5Y=8K:3:/J4:ZH=,E'B6XDM;I%5DB
M?YBK,#P48!AZ'(YKU&B@#GO!UW>7FDW#7\%LDZ7<B&:USY5SC'[U,]CS^(-9
M?C462^)O",M\L/DB]E#M*!@#R7QG/;.*[6L;5M$EU+6-)OTNUA_LZ5Y5C,6[
M>60H<G<,<,?QH X#6=.":7XUO=.A_P")5-=6,L0A7*,T;HTSH!U'J1W4^E:&
MI7T&K^*]9?3]]REQX8:.%XXV*R-ODX4XYZ_GQ7I%% 'FEC9V.H6_@@Z.D'V^
MQ:-[N2%0&AB$)$JR$="S$#!Y)SZ&L^_EMY?A[XO7<CLVN2O&.I(,Z$$>N0"<
MCL#7K=% 'G\^K:?8>+]?M/$"LUEJT$(LI/+:1)XO+*M$I4'G<6.!UW9JU"8(
M?B/I$*QBW1-"DB6%CDQGS(RJ'WP#^1KMJCG1Y;>6.*4PR,A59  2A(X.#P<>
M] '$:+IUU9:_-X6,)_LFRG&I6\G\/E.24A_X#*&8>R"N[K,T;2I=-@<W=])?
MWLN/.NI$5"V!@ *HP .>/4D]ZTZ /)=9DA7PAX]T^92+IM2EF2-D.2&\O:1Q
MWYQZX/H:Z75[C2M.U[0OLUM!:K<),T>H11%@IVH-BA>"[ #!8'A< '-=K10!
MY!H5_P#V;8>$;F\$R:59W=_'=/)$P6"9G<1,_''!89Z#=VJ6ZN69_%%WI\4\
MUM'K5I=S"VC.9(%2,NR\8;D;O?&>E>M44 >6ZTVGZCHNI:WX?-]J(E:V_M&7
M8P$T*2 L@7 W$+G.!TX/6M>VU?3-0^)UI?V,RSP/HDJ>=$A(SYJ,%) Z@ \=
MJ[NB@"KINHVNK:=!?V4ADMIUW1L4*DCZ$ BK5%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<OXX
MUN[TG3;&VT]Q'>ZI?16$,Q&?*+GE\'K@ X]\5U%8'B[P\_B+288[:98+^SN8
M[RSE<9594.1NQV/(/UH 6[\,1-IDD-G>7L%V4PMR;J1F9O\ ;R?F![CWXQQ3
MKWQ/!:C4'AL[J[ATXXNY( I$9VAB "06(4@D#U[GBI+:]UJYA6*;2?L=QC#S
M-.DD0]2N#N;V!"UCV^CZMI%SXBMK:V6[M=6F>Z@D,JKY,CH%99 >=N0""H)Q
MVH NOXPMGU**QL;&\OI9['[=;M $V2QD@##,PQ][^+'YD"G6?B^RU"STR:T@
MF>745D:&!MJ./+.'!R<9!XP"?RR:S-&\-W>A>(-,:*%I[&QT7^SS*'4,\F]6
MR%)Z':?Q/IS5&S\*W#^&=/TC6-$%S'#)<R,T,ZK+"[2[XWC;<.S,#R.1W% '
M3P>)89M3L=/>QO(9[RV>YC$BH  A 96PV0PW#V]ZY[Q+K46M>%K>^M!=VQAU
MF"V97?8=RW"HX(5B".O7-/@T3Q%I]UX;OY NJ75G;3VMT9)PK8D*E6+$?-@*
M 3U/7FJO_"-:Z/"LNGO:0M<-K?VX;)Q@Q_:/-YSC!QP!S[XH VX_%4J>(M?M
M;JQF2QTJWCE,J[6."KL6(!SR%   )XYQFK,/BJ%[J6UET^\AN%L1?I&P0EXL
MXXPV P/4''7O69>:3XABUKQ'=Z6L$;:G91"WN'DP898T< %<')RPYZ#WZ53L
M]"UF'75U+^R((5DTA[25?M8>4RE@VYF(^8G'4GIW[4 :^G^-K6_ETC&G7\,&
MK(6M;B54"LP0OL(W9!P#R1@XX)J;PKKUUKT>H27-C);""]EMURR$81MN.#G.
M02>,<\$UBV?A_5H-,\%V[V?SZ.X-UB5<8$31_+SSRV>W%;/A73=0TE]6M[N&
M(02ZA/=0RK+DNLC[A\N.,9P: '7&HZ=#XS$$T-TE['ILDPG+_N?)#KN&T-RV
M<<[>W6K>EZXNJFW:.SG2"XM_M$,[%&1ER./E8X;Y@<5FWVG:DWC=-4M[96MT
MTN6U5V=?]8SJPXSG;\N#]:J^'/#D^E:^;RSM)-*L);=A=6'G!X6G+*0T2@G:
M -V3QG(XZT ;^H:N+*^M[&*TGN;JXC>1$CP %3&268@#E@ />LZV\9V%V-#>
M&UO##K.X6\I5 J,H)*/ELAOE/0'.*-<L]7N->L'AMHKS21%(LUM)-Y:B4D;7
M88.]0 1CGDYQTK%L_"NKI\-K32GC@AU?3I1/9LLFY?,20LI)QP""5QZ&@#>M
MO%EO=6>HSI87JO877V22!O+\QI"5 "_/C!W+C)&<TV[\76MG)*9+.[^S07<=
ME-<;5"I(^W'!.2 74$@=^,U1L?",]AXJ2]CG5K&:!9;Q3UFNT)"N1[[R3[HM
M9>N>'O$>IKJD<EE;74G]H17%E<27.-L"R(PC5<?*<*<GC.>] '0GQ;&=;NM*
MBTK499;26*.>1$39&L@R')W?= Y/?VXIL7C;39;[3H-DBPZDQ2TN-R%7;&0"
M VY=PY&1]<5%INDW_P#PD?B.XO;;RK;4XH$1TE#8V1E&]^IXX^N.E5O"UAXB
MTV"TT>_TVP$%B!&-2CE!,T:\+B/;D,0 "2?4\T =)J>J0:7'"90[R7$RP011
MXW2.<X R0.@)))P #6:WB=635;=+*X34M/B$CVKE,LI!VNIW;2O![YX(QFF^
M*M'O-0;2K_3MC7>F7@N5A=MHF7!5USV)!.#ZU7DT>\NM7U777M&CGGTU;"WM
M2Z[B 68LQ!*C)8#@GA??% $7@BT6^TC2M>GCNX[^6Q032/*-MT6 8N5#'/.<
M9P0#C&*Z+5=3BTC3I+R:.61595"1+N9F9@J@#W)'7BN>TV75_#GAGPWI[:6D
MKQ^3977^D*"@P%WH!G=SSCC@'ZUJ^*(-6N=#>/1F NO,C++YGEF2,,"Z!_X2
M5R,]J *=UXSM;&SUF:YL;M9-(V&YA4(S;67<K*=V",>^>.E6+7Q3;S:PVG7%
MG=6;&U-W%+<!0DL2D!B,,2N,CA@#S7*7OA;6I;;Q;#;Z7:P1ZQ:PI D=P/D9
M5*D-P/7)/\^M:NK>'[_6-:@=K=H;5]'N+"63>I9'EV\@ \@;30!5UW6&U+4/
M"%U;6U[#:W.IH8YF?:DL9C<C*!N_RL,C.!VZ5U.OZW#X=TF34KBVN)H(F42>
M0%)0$XW'<PX!(S7)II/B>?3O#%E<:9;+)HU[$TLPNALE1(W3<HQD9R#@C.?T
M[B_LH-2TZYL;E=T%Q$T4@]588/\ .@"@GB"%O$4NB-:W"7$=J+L2-LV/'G;E
M3NSUXZ5GC6;"^UWP\TUA?PW5W#-+:,[A55=H+;PKD$D;<9!QGL<UB1^"=6>S
MT:>XNXVU6%C:WLH/#V93RRH]\*K>S%C6_JNFWD_C#P_?6]L&M+%+A9F#J,>8
MJJN!GG&WG],T <;J!E7X>^,B+FYW0:S,(W\]]P >, 9SDC!Q@UZC<3I;6\L\
MI(CB0NQ R< 9/ ZUP-WX;UFX\(^)]-6R N=2U)[FW!E7;L9U8;CG@@*>.>H_
M#MK\7D^CW2V+"WOG@<0&3!$<A4[2<9'!QZT 9-OXCM]5GCTZ2TO+5[VQ-Y 7
M8*6CX!Y5LJPW+Q[]:YWP9XN2R\+>&K?4;/4!'=QI NHR*#$TS9PI.[=R>,D8
M)[]ZL:3H.M1^(-)U*?3;>$I82VMY(UWYDC.Q0[V./FSM..?RZ4:;X9U.3PKH
MOAR^MEA33YXI)[D2JRRK$VX",#YN2!G<!@9ZT :EMKND65SXCNVBN[=[2>-;
MLRL6WN479Y:[CU!4 #&2>E9[:C(OQ-@DNX;JRA319Y9%GF#1X$D?S *Q (&<
M_P!:KZGX4U?4AXH\I$MY;R\MKRQ>1P59H508<#D9*?K^%37FBZWXAUI;B]TZ
M.PMYM(N-/FS<AV1I"O("CGIZC\* -BU\8V%SJ]CIS12Q/?QL]H[,A$FT9((5
MB5..<$#\^*H^-)VL]8\+W""Y<_V@4,,+$^8/)D.-N<$Y Y/3U J7PS#XBA6V
ML]6TNPMQ:)L>]AF#FYP, JNT%<\$DGMC'/%KQ/IM[>7.BWME"LYTZ]^T20[P
MK.AC=#M)XS\V>2.G6@"F_C^SATW4[JXTK4HIM+=5O+0I'YL2M]U_O[2A]03W
MK?\ [33^TK:Q6"9VG@:?S%*E(U! ^8[L\EAC .>?2LJST42:IK.J:I$D:ZI'
M';?9G8'$2AAAB."S%VX!(QCDU3\&Z?>:=X=N+@RB_G"M!9,S;?,MXBPA!/OR
M<_[5 '7G@=,UYGX@\07FL^!=?N);6YLFL]1$$;)*!PDR(5.ULL?O9!&.>,UW
M>AW]QJ>C6]Y=VPMIY P>)7WJ"&(RK=P<9!]"*XV]\-:Z_AOQ#I$5G"YO-3:[
MMY1.!N5IEDY!'& "/KCMS0!TL/BJU-_?V=[;7.GO9VWVPM<A</!DC>-K'&"I
MR#@^U-L_%ME<ZW;:4\,L$]W$TUL79&$@7!8?*Q*L <X/:LO6O#E[KOB#47>%
MH+.]T1M/\TNI9)"Q;)4'H,_G[<U>\.+XA)ABUC2K"T-NNV2Y@F$AN3C&57:-
M@[G)SVQSP 7M;\10Z)<V%O+9W=P]]*88?(53\X4M@Y(QG!]O4BJ%QXUMK:RE
MGDT^[66W@$]U;LT:R0@@G!!89; )P,\8]1F7Q'I]]>ZMX?N+2V\V.QO#/,=Z
MK\IC9.,GD_-G\*S[O3=<TSQ9?:AIVFV>J66IK&9$FG$36\B+LSDJ<J0!TYX_
M, TE\6V=PCOI\$]\D=K'=OY.T$1R E2%8@G@9/\ CQ55?%=PFO>(+:;3+@VF
ME0Q/NB,98Y5V+8+#J ,#GISC-4/$'AF^U1C)'9^5JT$*+8ZM:2B$QOCY@XSD
MQ[LG&&X)X[F>?1M8BUGQ)+';17$&JV42)()0I#K&R8VGU+ YSTSWXH 9J'BN
MPU'PZ+N]T;5UTV3[+(DHVQ[S(Z[,$.#@-M!^O<&MK4?$L-@;X16=U>?V>BO=
M_9PI,8(W8P2"S;?FP.Q'J*Q=0T/5;CX::?HD=H/MT*6B.IE7:/)=&8YST.PX
M^HZ5(EEXBT;Q/J=UIMA;WMCJS1S$37/E-:RA AW<'<I"@\<\4 6[?Q+<W/B^
M?2X].G:UBL8[E9 4!;>6P2"P('RXQUSU J/0M?TJ+P[IKZ?;W@2]GEBM;65]
MTS,'<ODLQP!M8Y)X''H*?'IFJ6GC:35!%'<VT^G16\D@<(P=&=CA>^=W'/%8
M>G>%M9L-,\.W2VZ?VAH]W<N]L91MFBF9MVUNFX!AC..0?K0!NW7C:RLM-U>Y
MN+.[6;22/M=J AD4,,JP^;!4CH<U-'XLM1J5Q97=G>69BM&O4DG5=LL*G#,
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M3;>>"/RK":Y!59=^9#&06\L%,@'U.<# H W+[6H]1L/$&F-#<VEY96?F./,
M.UT8JRLC>JGTZ5!H6O16/A+P[ X:XO)M+AF$?F*I*B-,L6<@=2!ZG\"11M]
MU:#4M>N(])MX(-1TV.&...X!99%$@PW R3O!)S^)-11:#K^E1^'[^ST^WO9[
M33$TV]L9IE3<%QAT?D=0>O8T ==H.N6?B+2(=2L2_DR%E*R##(RD@J1Z@BM*
MJFFK<K9(;R*&*=B6:*$Y2//10<#..YQR<U;H **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK%\1:R
M^E#3K> )]IU&\2TB9QE4R"2Q'&<!3@9ZXH VJS8-?TNXU%=/BNU:Y=6>-2K
M2!3ABC$8;!ZX)Q6-_:^I1^(-1\/3S1-*+ 7UI=B+^#=L977.,@]",<'IQ1\.
MH9/^$$T22=XY#]D0Q$1X* CD9R<_I0!U=%<AK'B>:P\1/IDUS'IV\1_89+B$
MF&Z)^^OF9PK#H!QV/.<4R[U[Q!>C4I= LA.UC=FV2%A&%F*8WAF+@J>3C [
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M2RY SR 1Z>M<9;>)?$4$'A?5;YK&;3]9,$$L$,+*\+RIE7#%CD9ZC QTYZT
M=\44L&*@LO0XY%+7%V6O^(M5ATW5--L/.L;JXQ+$PC4);DD;PWF9+# )&.>1
M@=:AL];\57=IK%]#]AG&FW5W;K:QV[;[@QCY,'?P<XXYSSSTH [JBN%7QP@T
M:[O[2^AOOWEO;0Q21&*6&>1RI$J]0!D'MG!&>]:-SK&J:9XEM]'GE@G6_M99
M;6<PD&.6/!964-RI# CD'MSUH ZFBN!TGQ1KLUIX4U*\DLFMM9D$$MO'"0R,
M8W8,&+>J=,=#WZUU^M-J$>BW<FE>4;](F>%94+*[ 9"D CKTZT 7ZIW&JV-K
MJ-II\URB7=WN\B(_>?:I8_D :Y.U\92SZMX;/VB Z=JMIOD;RB&BFVDJI;.
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M<,SK][KA>OL..:QM8U"_USPYX:UEY8DMKO6+*1;81\HAF&SYL\MTSVY. ,4
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MFJS(J2W,"NZI]T-WQ[9K8H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[:;RPLB[T*$LP^]@'C@>IR:>?"L-U<O<ZE<FZG:Q>P\P1B-FB?&XMCJW YX
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MNY0<9XSUH C\/:,GA[0K728IWFBMEV([@!B/?'%:=%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M8'BV&^GL+5-.>V:X%TK"UN6*I=@*Q,1(Z<#=Z97GBM^JUYI]IJ,:)>6\<RQN
M)$WC.Q@" P]#R>1ZT >=Q:Y'/+HVGO&VEVT]Y=PW5O?9D1+A0I6(D, RG<Q7
MG!P!CBIRPT/4=(T>ZUC[5I5UJ4ZR$@HD1\L-';EBQRNXD@$^@Z<5VUQH6DW>
MFG3KC3K:6S+;S"\892V<[N>^23GK2/H&CRZ0NDOIEHVG*,+;&(>6._ ]<]Z
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M+H>EI-:RKI]L)+1=MNXC&81Z+Z#Z5+>:98:@\#WEG!</;OOA:6,,8V]1GH:
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M_1Y=735I-,M&U!,;;DQ#>,=.?7WI6T#2'%T&TVU(N_\ CY!B'[[_ '_[WXT
M4]5D>X\"W<S22+*VG-)OC<HP;R\Y!&".:Y2V@^VZEX%AGN+HQ76BR&=%N'42
M;8X<9 /^T>1R>]=^VGV;Z>;!K:(V93RS 5&S;_=QZ>U5X]!TF*2VDCTZV5[5
M-D#+& 8E]%]!["@#S>_B67X8:Q!,SRI8:T]O;F20L4C6[50N2<G XYKIXTAN
M_'EYH5Y'_H-OIT<MI;LQVON=A(_7D@[0#V[8S6\WAK1&M9+5M)LS;R2>:\1A
M&UGZ[B.A/O4USHVG7GD?:+.&0P9\IBOS(#U /4 ]QWH \WMS>WMMX;M[V]O'
MC77+FR247#J;BW190I8@\GY<;NO'7O6O;Z!9CQS>:(9+Q].31H6$#WDK#)ED
M&<EL] .^*[&;1=+N!:B73[9Q:X^S@Q#]SCIM_N_A2MI&G->R7K64!NI$\MYM
M@WLO]TGKCVH \VTKS5\,^!]9:[NGU":_AMI9GG<[XCO4H1G&, =NHSUJ>[O%
M-UINI6-Q(RR^)! ;J:7$LBEV5X@HZ1#& ">V<#K7>#PYHJVT%L-+M!!;OYD,
M8B&V-_[RCL?<4Q_"^@R232/HUBSS2B:5C I+N#G<>.N>: .,LK.UBM?B#)"6
MBE6XF,;Q2LC#_1T;((.>O-6-'NFOM8\-Z3J!+V,GAU+F-'/RSS_(&S_>*KS@
M_P!XFNQDT/2I9[J>33K5I;M!'<.8ANE4=F/<<#@^E$FAZ5+:V]JUA;^3;',"
M! /*[?+C[O''% 'G4K7ILH;22\N_L]KXL2SM91.P9H"1E"<_-M)*@G.-OM73
M^&(A8^,/$^FP/+]DB^RRQQO*S[&=&W$%B3SM!K?FT32Y[>WMY=/MGAMVWPQF
M,;8V_O*.Q]ZD@TNPMKV:]@M(8[J< 2S*@#28Z;CWQ0!P5[_Q+/%'CK4;&$'4
M(--MYH.Y,FR;G'?H./:K$G^BP>#-4T>:1YKZXAAN#YA;[5$\3,[/_>(V[LGD
M<UVS:98-J2ZBUG ;Y4\L7!C'F!?3=UQR?SJ*ST73-/E\VSL(('YP8T VY.3C
MTR>N.M &1XBD@FU[1[!BTT\BSR+:.X6"10H!:3@D[<\  \GVR.-TV6:^\/\
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M"-=J1QJ%51Z #I4M !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %8_B+Q!!X=LH;B>*:0S7$=NBQQLW
M+L%R< XZY]^@YK8KF?'=O<3Z# ]O;S7!M[^UG>.%"[[$E4L0HY. .@H I?\
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MU9H\!$7@! ?XN<^O8,N+2_'PTUG2/[+OS>+J$A5%MF/F!KKS 5P/F&WG(XH
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %5M1LEU+3KBR>62)+B-HV>/
M&X C!QD$=/:K-% %32]/32M+M=/BEEEBMHEB1I<;MJC S@ =!Z5;HHH ****
M "BBB@ HHHH **** "BBB@"KJ-E_:.GSVAN;BV\U=OG6TFR1/=6[&DT[3X=,
MLEMH6D< EFDE<N\C$Y+,QZDU;HH **** &R(9(V19&C)& ZXR/<9!'Z5GZ#H
ML'A[1K?2[::>6" %8S,5+ 9SC( K2HH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@#/US1X=?T:YTNYFFB@N%V2&$J&*]QD@U<@B,%O'$9'DV*%WOC)^N !^E24
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%5I;Z"*Y%N2SS;#(412Q5/4@>I&!
MW)Z=#0!9HK)T[Q'IVIZ?9W\#R+;7;M'$\B%<L&*X/H20<9Z].IQ6M0 4444
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MT37X]%/F_;)(&N%_=D+L4@'YNA.6' K0H ***1F5!EF"C(&2<<G@4 +1110
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MDC>\%\L:73*L4V[<64=LGG^6*G?PE820ZO$T]V4U88NQY@^8;0G!QQ\H _\
MKT 8]FUS=_$N&8WMPD;Z''<>2-I0%I<%0"O .!SU]Z["^E:#3[F998HFCB9A
M)-]Q" 3EO8=ZSH_#5C'J5GJ DN?M-K;BV5A*0)(P<@.!@'!Y_GFM&]LX-0L;
MBRND\RWN(VBD3.-RL,$?D: .%MO$NHZ?J<1GN+F\M6T.:^<RQJ@FDCV'=&
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MP*^?W=S"8I!@XY4\BK5%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %87C#7)_#7AF[UB"WCN/LP4
MM$[%=P+!>" <=?2MVN.^*KJGPTUG<P7*(!DXR?,6@"YJ'B.]T.ZTQ=4LX#:W
M]REHL]O,28Y7^Z"I494XZ@\>E=$TT2N$:5 Q(&TL,Y/0?H:\U\7"VM+SP_?:
M3J+ZEJ<=[&L&GRW'VA)%/#.%))4J.=_:M#1]'T>^^('BO[19VLSV]Q:31AE!
M\M_*!+ =CGJ>] &MJ.N:MI::3Y\5A(UYJ@LY#"[$(C%MI&?XL+SVS721RQS+
MNBD1USC*L",UY);I9MX,T6-_*%FGBEU<9PBIYTHP?08(_.K&M67]CW/BF7P[
M 8M*%K:F[BLU 3S!+^]"*.,^3U '<9H ]2CN(959HYHW5#ABK @'WI!=6Y;:
M)XLC'&\5YIJL'AF^T3Q%JFF:M]O>31)4E2/RO)7:"8RZHHQ)G(7/. ?2M"[\
M)V,_@NTU+1K"V&KP1V]]#*J F>2-0<,?XMPR/J<T =\'0N4#+O')7/(ILEQ#
M"R+++&C.<*&8 L?;UK#\+RQZO'+XD\@QG4500AUPZP*/E!^K%V^C#TKD?&]Y
MI\LWBVUW00WD>DJ'-TVYI1MD91"F1C!Y+#/...,T >ER3119\R1$PI8[F P!
MU/TH::)(O-:1%C SO+ #'KFO/+"#2=8\>V+SQVMVDWAU7?>%=9&$H&6'1L<]
M?2LGPYJ45O9^"$OY4&CYO(P\C?NQ.KD1!B>!A=VW/?Z4 =_X<UNXUBXUB.>.
M!!8WIMXS"Q8.NQ&!)/?YJN:]JHT71+O4/*:9XD_=0KUDD/"J/JQ _&N;\!R6
M/]I^*X;&2 Q_VJ9%2%AC!BCY&.Q.:TK^675?$D5E8W-L#IBBXG$JEQYCAE08
M##H-YY]5H U=&U2#6]%L]3MC^YNHEE49Z9'(/N#Q^%6EN(6=46:,NP)"AAD@
M=37">$'BT;6=<\&ZA);/&C&]M4QA#!+DN@4DX"MG@]C7/:';6%MX2^'NH11P
MI>/J,<37 QYC*5E!4MUQT&.E 'I?]L1ZA::F-'GMI+NT9X09F_=B4*#\Q'.!
MN ./0UI0EVAC,A0N5!;8<KGOCVKRJ:+2U\(_$.V:.T6YCN;QUC*J'5=B%3CJ
M!G&/?I7:PMXA:VTYM+_LIK VT18W!D\SH,XV\=.E $D>O7&J:S>Z=I$4)2P8
M1W-W.24$A&?+51]X@=3D8R.M7=/O;^6^O+6^M(X?(6-DECD++*&W9(R!C&WI
MS]3Q7*>#)HO#^N>(]$U.5(+JXU.6_MFE;:+B*3&"I/4C&"!TJWXXU,/H4<EL
MQET^'4+;^T9(^5^S[_W@R.H&!N]B<]Z .NBGBG3?#*DB XW(P(_2D%S P.)H
MS@ \,._3\^U<'K%M;OXIU![(0-I\NA2F_5,&)F!_=,>V[&[!]!6)<:1HL7PU
M\+WZVMLES/)IBRW(P';#+G+=> 6'L/I0!ZPEQ!)G9-&V,YVL#C'6E$L94,)%
M*DX!SP37"W-KHWAOXA:.T<5GIUG+I]VN<+&C.7C8CTSC)Q7+VRZ9<Z-X?$OD
M&-?%-Q"X.%VHQG(0]P#\O!ZT >K:AK-AIFDSZG<W,8M(5)9PP.<=AZDGC'K3
MWENFU&U$+VALG1_-+,?,+#&W9C@CKG/M7EGB/2+:QLO'4>G6\::2L-K)Y4:C
MRX[@'Y]@Z*=FTG'J*Z2\:P/Q \.S:5]D)DT^]$;0[=KX*;>1U&=WZT =N)XC
M,81*GF@9*;ANQZXH>XAC.'EC4[@N"P')Z#ZUY8A^V_#339;8@>)X;Z,9/$XN
M_.Q(&[\J7)SQM]J;JFG:7+8?$F1K:V9[=B\)*@^4_P!G0Y7^Z=W<<DB@#U>3
M?Y;>5MWX^7=TS[UP4'Q"OH_"=KXGO]*@72Y)S#-Y-P6DA D,>[!4!AN'3(/-
M=IITPDTFTF:0-N@1BY/7Y1SFO/\ P!H-CX@^'^F+?7$UQ:Q74TOV0.HB+"=R
MN[ R1T."<>U 'HYGB5PAE0,2  6&<GH*KV$UT;3=J+V@F\UU_P!'8E,;B%'/
M.[&,^^:X[1-'T:^\>^+#/9VLSV]U:RQ!E!\MO(4E@.Q)SD]^]<Y;0V$G@[PT
MC+"47Q.T:X(&%,\O /8$8_2@#UV.6.52T<BN 2"5.<$=JB>?SK6=K*6"2958
M)N;*!\<!L=!GK7F&K%=)E\<P:7"([:%]/EFM[50N(B!YV%'3* Y]JW;T^%=2
MTS7;[29+:Y,NDLD[0.&A554E P' ?DXR,@#M0!V-M.XL;=[R2W$[1!I#$W[O
M=C+%2>=O]*RO$VN3Z/IEK>6<<$Z37<$#%V.-LCA<C'7KZUQ=G9Z9>ZKX!2]A
MMY8Y]#=&60 K*52$A2.C8Y.#FJLMLFF^%]1AA8)I0\3P?806^4)YL>X)_LA@
M_P"1H ]8>>*)T225$9SA%9@"Q]O6A[B&.18WEC61N54L 3]!7FVH2Z/?ZUXF
MTCQ-JK6,LLJ-;AO+4R0;%V&)F0DD,&X4_>/3)-/U5IM-OKJ^B,.K6*3V:WUE
M=8%W!(%CV.C#@DY5MN.N['4T >E5')<0Q.B22QH[G"*S %OIZU7L]5L-0N+N
M"TNXIIK23RKA$;)C;T/^>QKS?QU>V$B^,K='AAO(K.$2?:&W22D(73R5R-H&
M<EAGG/ QF@#T9M8L5U9M,-P@NEA\]TW#Y$S@$^F>?R-%AK%AJ6G#4+:YC:U)
M;$I8 $!BN<^AQQ7'V[Z5<_$M99OLDJW>APF)F"MYS^:X)7^\<8Z=JPO#U_HU
MMX1\)V\AM4NC=.#)(X6*&51)S,!U.,[5)'..10!ZP)8VB\T2*8\9W@\8]<UA
M^)->FTG3;2\L5M[B.:\@MV9G) 5Y A(QU//K7GMCJUO8V,7VB>-](M_$]P+W
M8,1QHV_RBR\[8]Y#<\<"M?Q*N@G0)IM(F1[>ZUJSDFEBFS$TAE3=L(.,X )V
M]_<' !Z.DL<N[RY%?:=K;3G!]#[TD4\4V[RI4DVG:VU@<'T->8:T@TK5/&4&
MBPK#_P 2VTF>"T4*2-[B0A1_%LS^E+J<FF3:3JNM^$=8FO-3.DM&8[3RPJ1Y
M!!=40%9 -VW//7CB@#L[[7Y;?Q9H^E0"VD@O?/$KAR7C:--V,#@=NM/\1:S=
M:/-HX@AADCO=0CM)"Y.5#9.0!WXKE&O/#TOC#P/<:3-9"-H;B-3$R@A3$-JG
MWSG@]\^]:_CX0NOAR*<KL?6[<%2<9&'R* .MCECE4M'(KJ"02IR,BFI<P2QM
M)'-&\:YW,K @8ZY->6ZFT>DW'C.'3XQ#8P7>GRW,%H@^6$A?.(0#'*CGCD9S
M3O$%MX<NO#7B?4]+U7^T&FTS$P0Q&!&7_5DA%&).2!WP/I0!ZB;B ([F:,+'
M]]MPPOU]*JWNL6&GI:M/<Q@74JPP88?O&;T]L<GV%</K$>E:#>>';G]W8:3=
MES=7<:(4,_EJ(GD+ @Y&_P"8]SG/>J6H6&@V-CHLUG=B[TUO$:R-<3F,PKO1
M]PC*@*(]WX9S0!Z>\\,;(KRQJTG" L 6^GK4E>=6[V%X/&MKK8A$H<O#YF!B
MT\I?*,>>P(8\=&)[UT>CS7EK\/;6?61.UU%IP>Y"Y\TD)DCUWX_6@#>CN(97
M=(Y8W9#AU5@2I]_2A+B&5V2.6-V4X958$@^]>6:3J&FIK_AF6"[M8K:31IX@
MEL^708C*HSY^>0<GH.<\=ZV?"37%AK=AIURME?PMISFPU6S&UG@5D^65?7[N
M"#CKWS0!N^(=>O=(U31[2VMH)AJ5P;<-(Y7RR%+9X!R.*OVUSJ27C1W\-HEO
MY>X2PRDX;(&""!C.>#[&N8\?-;G7?"$=Q/Y*'46)82F,@>6W.X$$<D?G6G&^
M@6=Q?0RZBMW%<P>;/'<7'GK%$@PQ8L3A3N''KGWP =$9D(Q')&S,#M&[K6+X
M6UZ36])6YO%@AN6N9X1'&W!\N1EXSR>!FN7\'1V^A^($TG4(]F^!I-"><@E;
M8L6:+ID.,J3UR,>AK$B@L$\&6FIJD'VR/Q)\EQQO4?;#P&Z@;2>.G)/>@#T/
M7-4U32=/UN_CCL98;.S^T01EV#DJK%]_MP,8]ZTM-OEOK&WE+Q^<\*2.BG[N
MY0>G4"N U9(5U/XDQP*@>318V94 RS>5-DX'?I3[;2M-&J^#;O1(H!=O&3>R
M08/F6YA.XRD?>^?: 3W- '8MK']F6?FZU/:1M)>"VA$#$AM[[8P<_P 6""?3
M!K1N))%M))+?RV<*63<?E/Y5Y-Y=BO@Y'9+<6UOXMY) V1Q_:N?8+C'MBO56
MDMQI9DA:,6PARC+@(%QP1VQB@#D[7QIJ<O@B+Q7)I=LUF8C/+!'<$2)&"02,
MKAB,9QQ]:["TN8KVS@NH23%-&LB$C&5(R/YUX[96^ER_!&V>;6I(9X[9G2W^
MT[DDD#$K&8B2&!( VX[UZ=H>KB73M(M]2\FTU:ZLUF-F/E(P!NPO8#/3M^%
M&U1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !3)
M88I@!+$D@'3>H.*?10!'%;PPDF*&.,GKM4"D6V@5V=8(PS9#$(,G/7-2T4 0
MBTMA$\0MXO+?[R;!AOJ.]/BAB@B6*&-(XUX"(H 'X"GT4 0)96L<31);0K&Q
MW%%C !/KCUJAJNGZE<);P:5?PZ?!EA<8M][%2/X#D!6'/.#U]L'6HH CMX(K
M6VBMX4"11($11T"@8 H>WADD\QX8V?:4W%03M/49]*DHH A^R6V<_9X<XQG8
M.F,8_+BD:RM6A:%K:$Q,<E#&-I/TJ>B@!D<4<0(CC5 3D[1C)I%@A20R)$BR
M-U8* 3^-244 0M:6SN7:WB9CU)0$FD^Q6N /LT.!R!Y8J>B@")K:!RY:&-B^
M-V5!W8Z9]:>B+&@1%"J.@48 IU% $-Q:6UX@2YMXIT!R%E0, ?QJ18T6,1JB
MA ,!0.,>F*=10!#'9VL,!@CMH4B)R8U0!2?I0;2V*!#;Q% <A=@P*FHH CDM
MX)1&)(8W$9#)N4':1T(]*P]?T"759M)^S_9HX;&\%V\;J<2?*RE<#@9WDYY^
ME=!10!'';P10>1'#&D.,>6J@+CTQTI/LMON5O(BW( %.P9&.F*EHH B%K;K<
M&X$$0G88,H0;B/3/6F_8[4[O]&A^;K\@YJ>B@!GDQ>5Y7EIY>,;-HQ^5)%!#
M!GRHDCSUV*!FI** (EMH%9F6",,P(8A!DYZYIOV&TQC[+!CT\L5/10!&EO!&
MY=(8U=NK!0"::EG;10F&.WA2(G)14 4GUQ4U% '.W_AQKSQ-IVH;+3[%:02P
MM;NF=_F%23TP,;1QW]JW6MH'C6-H(V1.%4H"!]!4M% $3VMO))&[P1,\7^K8
MH"4^GI2-:6S7"W#6\1G7I(4&X?CUJ:B@"I;:=!:WEU=J!Y]SMWL% X7.T<?[
MQY///T G>W@D=G>&-F9=A8J"2OI]/:I** &>5'O1_+3<@PIVC*CT%--K;LFP
MP1%=V_!08W>OU]ZEHH C,$)21#%&4D)+J5&&SUSZTW[);>4D7V>+RTX5-@PO
MT':IJ* (DMH(Y/,2&-7_ +P4 _G1#;06P800QQ!CN8(H7)]3BI:* ((K.U@;
M=%;0QMDG*(!R>I_&GRP0SX\V*.3'3>H.*DHH C2W@1V=(8U9NK!0":8EE:1P
M^2EM"L6=VQ8P%SZXJ>B@")K:!X# \,;0D8,94%2/ITI?(A,*PF*/REQA-HVC
M'3BI** (I+6WFECEE@B>2,Y1V0$K]#VJ6BB@"%+6W0*$@B4+G: @&,]<?6B&
MUM[9G:"WBB+G+E$"[C[XZU-10!D:CH]Q?79FCU(P+M "?9HGQ^+*358>'KY5
M95UMP&X8"R@Y^OR5T%% & WA^_<J6UR1BHPN;* X'H/DIO\ PCE[MQ_;38ZX
M^Q0?_$5T-% & F@ZA'(9$UZ57/5A9P _GMI(?#]_;AQ#KDD8<Y?990#<??"<
MUT%% '/CP_?B-HQKD@1OO*+*#!^HV5(^BZI(A1_$,[(>JM:0D?\ H-;E% '/
MIX>OHV#1ZXZ,.A6R@!_] K7M+5X8H_M,WVJX0$>>\:JV"<XX  [?E5FB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***9--%;Q-+/*D4:\L[L% ^I- #Z*9+-%;Q-+-(D<:#+.
M[ !1ZDFD@N(;J%9K>6.6)ONO&P93]"* )**** "BBB@ HHJF-6TTW'V<:A:F
M?.WR_.7=GTQG- %RBBFNZ1HSNP5%&69C@ >IH =14-M=VUY%YMK<13QYQOB<
M,,^F14U !1110 4456CU"RFLS>17EN]J,DS+*"@QU^;..* +-%4K;5],O)A#
M:ZC:3RL"0D4ZLQ .#P#V-7: "BBB@ HJ&VN[:]@$]I<13PL2!)$X93@X/(J:
M@ HHHH **** "BJ7]L:9]I:V_M&T\]20T7GKN&.N1G-7 0P!!!!Y!% "T444
M %%%5[R^M-.MS<7MU#;0@X,DSA%SZ9- %BBBB@ HHHH ***KWE]::=;-<WMS
M#;0+]Z29PBC\30!8HHZTC,$4LQ 4#))/ % "T51&M:4;:&Y&I6A@FD\J*03+
MMD?=MVJ<\G/&!WJ]0 45#]LMOMHLOM$7VHQ^;Y.\;]F<;L=<9XS4U !15>\O
MK33K<W%[=0VT(.#),X1<^F35B@ HHHH ***A^V6WV[[%]HB^U>7YOD[QOV9Q
MNQUQGC- $U%4VU73TOTL'OK9;Q\[8#*-[8&>!UZ<U<H **** "BBH+R]M-/M
MGN;VYAMH$^]),X11^)H GHH!!&1T-5Q?6C7S6*W4)NU3S# '&\+D#<5ZXY'/
MO0!8HHJO>7UIIUN;B]NH;:$<&29PB_F: +%%-DD2*-I)'5$499F. !ZDU':W
M5O>VR7-K/'/!(,I)&P96'L1UH FHJO-?6EM<06\]U#'/.=L,;N TAZX4=35B
M@ HHHH ***KB^M#??81=0F[">88 XWA,@;MO7'(Y]Z +%%%% !1110 457DO
MK2&\AM);J%+F?/E0LX#O@$G ZG !JQ0 4444 %%4_P"U],^TM;?VC:?:%.#%
MYZ[@?IG-6U8,H92"I&01T- "T444 %%%% !1110 4444 %%%% !15>\OK33X
M1->7,-O&2%#RN%!)Z#GO5B@ HJ$WEL+T61N(OM1C,HAWC>4SC=CKC/&:FH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N1^)D$4O@._:2)':-HF
M0LH)4^:G(]*ZZL?Q1HDGB+0)]+CNEMA,5W2-%YF K!N!N'I0!D^*IGE\6^$-
M,;_CUN+N::5>S-%$60'_ (%@_4#TI="G>+XA>*;!"?LVRUN0HZ+(Z$,?QVJ?
MPK7U;1CJBV,QF6*^L9A/!,(\J&P58%<YVLI((S^/%5DT"[MX=6N;344AUC47
M1GN_LX9(P@"JH0GH%!ZGJQ/M0!OT4#.!DY-% !1110 5Y5 !_P -'7)P,_V:
M#_XZM>JUY"-9\-0_$>7Q4WB1_,,7V=K7^Q[G 4 #[V.O'7% $U[\2_$%MIWB
M2]CLM,:+0]0%H^X2 S*9"G S\I[YR?I723^,+V^\8V?A[2(K9'>P^W7$URK,
M%4XVH I'/(R><9Z&O/KC_A%KG2?$5@WBN4#6[T7<CC1+G]T0Y?:!WYQ6G)K/
MAF+Q'IVO:?XEDM[Z"S%E<;]'N'29 .H&!M;\2.!^(,K>!?% \*?#"6Z$*/<7
M.M-:PHQ.P.P7EL<X !/'7':NGU7Q[JFF>'_$5X+.&2;298?*F:"1(;J.0@94
M$Y!4DYY/3WXXR&#P:O@F;P]-XHNWD-Y]N@NDTFX5HI<8Z;>1CZ=:V=7\1Z+X
M@\'W6B:IXNEDGN?+5[A-$N%551@W"8^\2!DY^@% &U;^-/$4OBO3M#:UTL-J
M>FK>P.#)B$D$D-S\_P!T\#;U'-4#\3]4_P"%8MXG%E9_;(;S[++$0WEMSU7G
M(ZCKFJ$6L>&8O%.D:[_PDKF33M/%B(O[&N<. &&XGM][I[5D"+PJ/ D_A<^+
M)O+FO/M1G_L2XR.GRX^HZT >@:;XLU:Z\8ZIX;O[:Q5HM/%Y#)$&8#.W*OD_
M-][J,=/>O.-6OS>? RUFL+.UTVTDU'9+;0[V#'=D<LQ/49(.>V,8KHH-=\-0
M>,KKQ'_PDCF6XL!9&'^QKG P%^;/U7./3CWK%,?A4^ HO"O_  EDOE1W?VGS
M_P"Q+G<>ORX^IZT =4O]GZ'\7+6"32=.2YGTZ2]GOX4='#'?OXW$')4G.,X.
M*UO#WBS7O$*Z1JEKIEO)HVH2SI)M.);548JC,2V&S@Y '''-<Y=:_P"%;WQQ
M:^))_$#L(;,V;VHT>YPZG=D[L<?>/:H/">MZ!X3,ME;>+[J31O-:6*U;1Y_,
M3/\ #YFT\?AS[<T ;3_$35+;6-%M[W3X+?\ M"_:SEL7!\^W!8!'+!B#G.<%
M1[>M-TK5M=U#XE>*;22YM#;V$"1I$\+%0A!88 8<DGDGKCMQ7'6\/AJ&'3E;
MQK>2R6&I'4(W?1)CN8D$[CMRS':.2?PK?@U_PO9^+M8URT\23HNJ1*DL#Z1<
M-M95P"&VCCN1C\10 GA;QK%IW@KP_!IFE6EG<ZOJ36L,*EVBB^<!I#EMS?>'
M&1^&*V+OXAWMKI?BI3;VK:EH$J _*PCG1FP#C=E3UR,FN2L/^$.L- TJP'B2
M>2[TF^^VVER='N ,[@2C+CD''8CM5BXN_!]SI7B*%_$,RW^O2J]Q<#2;@K&J
MG*JJX[<\D]Z .JT7QQJUUXLT72M0M+)8-6TM;Z,P%MT9*DX))P1\I[<9ZG'/
MH%>0:1=>''\8>&KR'Q')+/I]G'ID4']D7"";(* ECPI.[OP*]4TZ"]M[9DO[
MQ;N4RNRR+$(\(22JX!/08&>] BW7(_$O4[K3/!<[6<K0S7$T5MYRG!C5V 9@
M>QQD9]ZZZJ&M:/9Z_H]SI=^A>VN%VL <$=P0>Q! (^E #3H.F-H1T4V<1T\Q
M>5Y.WC;C^??/7/-9D>J7MQ?:AI.C_9S)I,422/<@GS9&3<%&"-O&,MSRW3BK
M%CIVO6]LEI<ZS!/$@VB?[*5G9?<[RN[WV_A40\.W%EK]YJNDWL<!OHHTN8IX
MC*&9!M20'<#G'!SG/% &3:>-K[5Y/#XTVQMU35H+AR;B1LPR1$!E.!R 2?KC
MMUI5\;S0:&MUJ,<%K)'J<NG7=R$9X(2A8>81D':2%')&"W)XJ[:>#1I][H,M
ME>*D&DPS1B.2'<TQEP78L&&#D9Z=S2V'AG4-.BN$BU2WD%QJ$UY+'):'9(LN
M=T9&_ID@@^W0T ">(KY-1\/V\@LIHM4EN(S+;L2NU%=T=3D@AE5>.V3S6#XJ
MU>?5_ ?BV*YBB#:?>BU5HP<. 8F#8.<'Y_TK53P,UC;:<=+OH;:ZL;Z:[CW6
MY:$"4,&C"!@0H#<?-V]Z9/X'N[C1=>TYM80_VO="Y:1K7)C/R9& PS]P?3WH
M M&^U4_$F:P$\+646F+<+#Y9R=TA4\[L;ODZ] .W4F&P\5:A)K>F:==06GFW
M]O,[0Q,<VLL84^6[@E6.&P< $$=.:OW?ARYN?$/]K)J7DF6P^PW")#RP#%@R
M-N^4Y8]0>/SK.T_P9J-E+H$C:U"YT:*2",+9;1)&RA>?G/S?*,GOZ \T 5;'
MQGK,^F:-JMQ8V*6E[J'V&5$=BZDRM&K*>F 5&0>OMTK3\,7NJ7FO^(TO;F&2
M"VO1#&B1D;1Y:, /F/'S'/J>>.E5XO!-U%X=TW21JL)^PZ@+X2FU/SD2F3;C
M?QRQ&<]*UM+T*;3-<U6]6]5[;4)5G,'DX9) BH?GSR,*#C ^M %[6+Z33-&O
M;Z*W>YDMX6D6%.KD#.*X;Q/K(UWX;>(+B*\L;ZR%JABFM@5._<=RLI8E2,+U
M]:[V_@GN;":&UN?LT[+B.;;NV'L<9&?IFN5U'P(=1@UH_:[:UN=6@C@F:WMB
M$^4DERN_ESG&<\ =Z +L&NZI%XEETB[L[9]^GM>VPMW.[Y6"F-BW!)W#G@5#
MI/BB[NO$%GI5XEJS75D]PWV?)^SR*5#1%LD/C=C(QR.G-3W_ (7N=0UAK^34
MEBW:9+IS+% 0P#D$NK;^""!CBJVG>$=0L]0T>\EUB&1M-M'LPD=EL5T.W'\9
MP?D&>Q[!>M '+0JO_"M=*X'R^(EQQT_TYJ]7KCD\$W2>&K;1QJL7[C4!?"7[
M*>3YQEVXW_WCC.>E=@,X&2">^* .>EU6Y7QN^EQV5H3_ &6US%.S$.Q\P+L)
MQPN3GO6/I?C+5[JS\-:E=65DEEK,HMRD;L9(W*NRMSQCY",=>^>U;TVA7+^+
M#KD5[$F+$V:PM 6QE@^XMN'<=,=*R[;P5<VVB>'M-75(B-&N5G60VIS+M#
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M#/,\=N)E.#&'<*6!['!//O6YI%EJ%K$[ZIJ(O;I\ M'#Y4:@9P%7)]3DYY_
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M#N:=I00[%@PP223TZFH9_!=S<:)XATUM4B UFY>=I!:G]UN55( W\\(.>.]
M#KG7M?N/$.I:1I-EIY>VMHKB.2YE?#!]W! '7Y?H/7M3+#Q=>:OH^EW]O;P6
M4=U'+YTER=XCF1MGE*@(9B2&P1V7IS5.R:Z/Q+U>&UO[,3KIELC[XBP9@9.0
M X(QGID]:OVW@N33+O2IM,U/RA96TMO(LT D\SS'#NZ\@*Y8=<$<XQB@"K:^
M--2U"V\+2VNGVH.M+*'$DK?NW1&;C Z97Z]O>DD\7:S#X>U2^:TM&GTB_:VO
M @<JT0VDR(,YX5\D'T/-3:5X(NM,C\/1_P!KQRIHSRL@-K@R!U*XX?C 8\\\
M_E4RQV/A"+4YM;U".2WUB^9P@M6^^Z >7@%LY">@H V;?49;O67@@:&2SCMD
MD>0 DEW)V@'./NC/XCUJY>2S06-Q-;P&XFCC9HX0P4R,!D+D\#)XS6/X-T4:
M%X;M[4B42-^\<2MEU! "H3_LH%3_ (#6CK.G?VOHE[IOGO!]J@>'S8_O)N&,
MB@#GK+Q5?3:O+IK)97$HTTWJO"65%<,%:,ME@V"1\P]#Q4&E^+]6N4\,W=W9
MV:6>M#9B)V,D;^6S@\\8.TC'7W[58M_"6I1:E;W\FLP--%IS:>R)9;4*D@@@
M;^.1SSSVQ2V_@ZYM]/\ #=H-3B(T20.K?93^^PC( ?GXX8^O- &'XLU>ZU_P
M!<ZG;+;#3'O(DC5E)D9%N57?NS@99?NXZ=\\5Z37#2> KY=!O- M=:CBTF6X
M$\"/:;Y(/WHD*!MX!7(..,\]:[= P10[!F Y(& 3]* .?FU.Y/C@Z1';6B%M
M+>XBNF!9\B15VD<?+DYP#S@=*Y_1O%M[9>!=$U75KF$+J$NV6\>%BEONWMEP
M#T+ *.@&1Z5U+:),WC&/7A=H$2R:S^S^2<D%P^[=NZY [5G:3X7U'1]$L]+A
MU:":"U+((Y;3Y983GY'&_D\_>Z<=.N0#=TFYFO--CGG:W=W+8>V;=&Z[CM93
MD]5P>O>KM9/AW0H?#VE?886!0S23;47:B%V+;47)PHS@#-:U !1110 4444
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MI/HVJ>/M0MSMEBCL</C.P%-I;\ 2?PH ] O;G['93W7E22B)"Y2/&Y@!GC)
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M_!6GSWD[SS_O(VED.68)(R@D]SA1S724 %%%% !1110 4444 %%%% !1110
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M]\ N#'F!U;=Z98@'/>ND\#2>5_;EE)'*DZ:O=2,'C8#:TA*G)&#D'(Q76T4
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M;SPV<LKRQB?=N;<<EL-RH)R0/Q[UM444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5RWCK6;O2]-L
M+6PD\F\U6_AL(YL9\G>>7 /< ''N:ZFL'Q;X>/B/28H89Q;WMK<)=V<S#(29
M#E<CTZ@_6@ N_"UH^F206DMQ;W13"W0G<R,W^VV<L#W!HO/$\<"ZC);64]Y#
MIAVW;Q%?E(4,RJ"?F*J02..N!D\5-;76NW$*Q7&FPV<V,/,MP)$'J4&,GV!
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M+"XO;RU>*WBCAD2994>.42,54!@<<'&<\#(.2*TK"]ENVG2:T>W:)@ 2P99
M0#N4CJ.<<XY!KD;/PK<Z<=2_L[38HM.NHHE;1[B8/"S^9F4J.0@*9 ]3V&*U
M?">@2Z"^H)&)8--ED1K2REE\PV^%^?!R< GHH)QCWQ0 [QUK\_AOPC>:A:*I
MN_EB@W#(#NP4$_3.?PJ9/"UJ-,\B2XNVO6CVO?B=A.7(Y8-GCGG;T[8Q4WB?
M0(?$_AV[TF>0Q"=1LE49,;@@JWX$"H=/N?$8M4MK[3K;[4J[6NDN,PN?[VW&
MX>NW'MGO0 +J[VI;2[:VDU"]L;:-[KRV"XR#@ L>6;:2!^9&1FHOCBRN#H_V
M&RO+M=6CD>W:,(.8Q\R-EAA@>#GCKS20Z3J>C^*]1U2UC6^M]3AA$RF01O'-
M&NT-SQM(ZXY!'0UGZ=X2OM(O?#'E+'-%IYNI+N0/C+S\G8#U )/7'&* -2V\
M96L^GQS/;26]R]^VG&WF=1MG7)*E@2,84D$9SQCDU8;Q*(+K3;>ZTZYA>_N9
M+5,E3L= QR>?ND*2"/4=*Q(/#E\;#4[34-(M;VTOM7ENY('E!)A=3C![.&"]
MQ[&H5\+:S8Z=I+6Y^UOINJ/<P6MS<?,MNRL@C\P@Y90V?3MDXH 7QIK,>J^!
MO%D"13P3:9^Z<[\9;:K @J>1AAU_*M@Z_>+XV7119$VB:?\ :6E#*2<N%SCK
M@8(P.3GI6'?>&->O-'\7VS068EUF17@VSG"_NT4[LKT&WKU/H*V+C2M8/BR/
M5K2.W1)=+^QN9)/F@</N#8 (8<^U $]EXMCNKS3[=]/N8?[2@DN+3?MW.$P2
M&7/RD@@C/'N*J6OCR"ZM]/N_[)OHK*\NS9^?)LQ'+O9%! ;)!*]1D#/7K69I
MOAWQ!#J?AW4+JRLOM%BDT=[+]J+R7#.JCS,E><E3A2>,XX%$/AG6H_".F:8;
M:$W-KJPO7Q,-IC$YEP#CK@XZ=: -[0==O=4U[7+.>R,4-C<+#&V]3_ K<]\G
M=GT%;\SO'"[QQF5P,A 0"WMD\5@:+I>HZ=XEUV>2. V5_.EQ'()#O!$:H5*X
M]5SG/_UN@=F6-F5"[ <*#C- 'F6C:O##H>D^)]4TR]DOI+UX!<P2+F0RRN@5
MP&RRKP "#C Q780>))9YTLAI-S%J3(\K6LLB I&K;0Q8$C#'IC.>>PS7.P^&
M=;C\$:3I!M8#=V>H1W3D3C846<RX!QG.#CI6Y=Z5?VWC*+Q#91+<1RV7V.ZM
MBX5UPQ=74G@\D@C(]10 P^.;$V-C<QV5Y)]JOO[/>,*N^"<$Y1QNZ\'ID=.>
M:8WC1U&J1_V#?F[TS#W, >+Y8RNX.&W8.0#P"3D5GR>$]1A@M'ACBDN'U_\
MMB[4285 <C8I(Y.-OH"0>E76T;4_[5\5W(MD,>J6T<5M^]&=RQLAW>@RV>_
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MN-V]%B:/(R!R=V<>@Z^B:GX8UB\TOQA:QV\(?6)E>V+3#"@(BG=QQ]S/&>M
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M650.-Y!^5L?KS6;'XF\0KX;MM9FNK1A;ZD+&XA6WQYZ_:/)+9S\IZ$ >G?.
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M(0X&%*@L".1Z$]Z@N-0\5V U-UT^6[MDMEEMG=8O.\S=ATV(Q#?+\PZ<C'-
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MN<$@\$ ]0:L.',;"-E5\?*6&0#[C(S^=>?VOBC7KGP_X7NUFLQ/J>H/:W!:
MXP#+@@;N !&..I]10!Z%17#KX@URUMO$-NZG4+G2[N%!);08D:"14=B(\X+*
MK-CUP*H:KK<VK:!8W6FZ\)[>37;2$.D05PA>/Y)%(&&#9)&!D8[4 >CUD?\
M"+: ;]K[^Q[+[2S;VD\E<EO[Q]3[]:Q1>>([SQ9J.CV^IVD,-G#:S"4VFYF#
ME]PQNQDA>O;CBJ:>*=6/A&UU,RPFX.L?8I/W7RO']I,73L<?K0!WM-=UC1G8
MX51D_2N674]:UJ/5IM%GMHI+"^-I%!.OR2E"N\R-@D9R<;>F 3G-5;"74SXQ
M\6E=1#"VCM_)22(,B@QLP'!!P"3WYS0!UMC?6^I6$%[:.7MYT#QL5*Y!Z<$
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MT^&\^V16-LEULV><L2A]OINQG'M3;71],LI6EM=/M8)&SEHXE4\\GH.YZ^M
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MRU[;V%H+X1[%F,85MO9=P&<>U-TG2X]+MI$5O,FGE:>>4C'F2,>3CL.@ [
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MJ"W@M;=(+>&.&%!A(XU"JH] !TH \PBL_L^@>+M9MC<R:EINH7PM',[L8AM
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M9?8K*<R37EG<VZ2(46Y6)8]Z@GCJA'O]* -V+79;KXCVEC!=70LWTR69[::
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MOV)B+K=)&Y=D4A=N"N5&3D'GIQS?\.ZKJFH>(?$%O>);BWL[I88]DA)4>6K
M8*\YW9)R.>,4 =/2;@#C(SZ4M<EX[T./6[738DD^S7OVU?L]XBCS(6"NP(/7
M&0,CO0!UA8+U('UI:\_36O[=TD:7KEK#'KNG:A9I=0,H(8&XC E3/5&'\\5N
MS^(KESJW]DV$5U'I+>7,'F*&1P@=D3"GD CD]^/>@#HZ9'-',I:*1'4$J2K
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MQ>Z$EYID5O:ZS;&6"1;C>Z,L8D(9=H !&<$$].<9P #J99HX5#2R)&I(4%F
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MY3P/81R^&M"U.YL[=;U=.CCCN$<L[1LJL=Q(')/)'//?FNKH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ K%\4:-/K>DI!:S1Q74%S#=0M*"4+QN& ;'.#C'%;5% '%7?A/6;V7Q!-
M->V._6-.6S*+&P$1 <9!SR!O/U]JM3^&+N\O]%EN'M_(L;*:SG16;,@D55)!
MQQ@)^M=710!PD7A#7TTG1])?4K![;2;V&:"=HG,DD<>=JLN0 0,#@\^W>[8^
M'->TG4+NWL-4M1HMU</<%9(6,\!<[G6,@XP2203G&>AKKJ* ,+1-'O-.UG6[
MR=X&CU&X6=%C)RF$5,'(YX7-&OZ+=ZE?:/?6-Q#%/IUPTN)D+*RLC(>A!S\V
M16[10!Q=SX2U*XTOQ39F>U!UN0NKY;]T"BIR,<\+GMUJZ=!U,^(8M46:VC,>
ME-8 *6)#E@V\<= 5''_ZJZ>B@#F=*\,O:^)3KDL=I:W#VI@N%L\A;IRP/F,"
M!@C!QU/S'GBM"_T^ZO=8L)6%N]A;%G:)R=S2$;0W3& "W'?.>,5K44 <QJGA
MRZ?Q5I6MZ4;2W-I')%<(P(^T1OCY3@<8(R#SSVKE6N&N]6U:\MM0\-M"]\2U
MMJ#R12!HB%7>BM@G*Y!*DG@^@'J-8^J7VEZ7J.GM=6FZZO;@6T,RP D.02,M
MVX!_*@"EIFG:C-XF7Q%<)# ESIL5N]MN8O&P)?K@9Y8C'MGVJMHWAS7M%F;3
MK?5+4Z")FEB#0M]IC5F+&,-G;C)(W8S@_3'744 <CIGAS7M'NY[*SU2U_L*6
MX>=5>%C<0AV+-&C [<9)P2,C-1S^$]1GTGQ39>=:@ZW,\B-EOW09%3!XYX7/
M;K78,ZH5#, 6.%!/4]<#\C5#2M:M=8EOX[99E:RN#;2^:FWYPH;@=<884 8]
MWX;N[_5],N;AK?[/;6,UG-&KMEQ*%!(..,;?UI/#^C>)-)A@T^[U2SN=.LUV
MV[)$R3RJ!A%D;)  XR0,G'USU5% '$0>#]3A\-:/I7GVC2:?J2WQDRP$@$K2
M;<8X^]C//3WK2@T/5]/U+7[NQN[,#42)X1+$Q,<HC5/FP>5^4'CGFKZ^(;2:
M>:.SBN;P0.8YI+>+<B,.JY_B([A<D5;TW4K75K);RS=GA9G0%D*G*L5;(.".
M5/6@"> 2BWC$[(TP4>84&%+8YP/3-4-6L[R[EL&M?(Q;W(G?S6(W *PP, _W
MNOMTK3HH YWQ!X3MM:U72]51S!?6%Q&_F+_RUB5PQC;U&1D>A%1)X>U#3M3U
MF72Y[?[-JS>:Z3[LV\VW:SKC[X( .TXY'6NGHH Y2#PC+I6H:%-I-Q$L.FV3
MV3I.I)=&*'<".C93Z<_A5(^#]3/AE]*\^T\QM3^W^9EL8\[S=N,>O&?QKN**
M .3N_#6HW-]XEG62U5=8L4M$!9LQ%5==QXY^^3CCI2C0+Z"Z\-WDDEOY>BVT
MD<P4L3+NC"$KQQ@+G'.<X]ZZNL[3-;L]6N+Z"V\X2V4QAF66)D.>>1GJIP<$
M>E 'G.C7=REM!J5G<^&[]6F>ZAM?-D2?>Y)PL89D67#%>%ZD^YKO?%NCS^(/
M#%[I-M)'$]TH3S),X49!S@=>E::6=K%.T\=M"DS?>D5 &/U/6IZ .6U+PQ<:
MQKTEW=M MI/I4NFS1HY+XD()8'&.,8_7VIVAZ9XGL8([;4=3L;J"U0I T<31
MR3\84RDD@8'8#DXY]>GHH XR'P9>#P%I^A&_CAO]-=);6[B4LHD1LJ2I[<D$
M?_JJS>Z+X@UCPQJ5AJ=[8&[O+<VZBW1UBC!&"W))9C^ X^I/07E\EG97-R(I
M;DVZDM#;KOD) SM"]S@CCWJ*\U6&R%LK1RR7%T2(+= !(Y"EB.2 , '.2/S(
MH R8-#U&+Q-::NS6I6#3#8F(.V68LK;L[>F5QCW_  JUX3T>YT#0(].N9(I'
MCEE</%G!#R,_0^F['X5/HFNQ:[#++%97]LL;!?\ 3+<Q%CCG;GK@Y!]Q6I0!
MR<WA:YO-<LM3N5LUN[*Z>5+R#<LLL1W!87&.F" 3D_=X S5,>#]3'AE-*\^T
M\Q=3^W^9EL8\[S=N,>O&?QKN*1'61%=&#(PRK Y!'K0!PVI>#=9O8M9A74++
M9?7D5W')+$S2+L9&$1.?N#9QCU/3-:\6BZC%XFU#5C):N+FQCM0N67#(6.[H
M>"7/';'4UT=% &/X5TF?0?#-AI5Q)')):1"+S(\X8#O@]*Q+CPGJ,^D^*;+S
M[53K<S2(V6_=!D5,'CGA<]NM=%J6LPZ=*L AGNKIHGG%O;J&D,:8#-@D#JP&
M,Y.> :5]7B&D0:E%:WD\4PC*QQP$R .0 2IP1C.3Z &@#+AT34(_%%KJ[-:E
M(=--B8@[9+%E;=G;TRN,>^?:LQ?!^IKX5MM'\^T\R'4A>^;EL$"<S;<8]3C/
MXUV]% '*3>%[N[O?$\DT\"0ZU9I;+LRS1;49,G@9SOSVZ5N:):W=EH]K:WTD
M,D\,:QEH5(7  '<Y[5?HH Y;3?#^I>&[J[CT:2TFTRYF:X%K<ED:W=OO!&4'
M*D\X(X]:FUCP[>:FEA>+>QKJEA="ZA8H?*Z;6CQG.TJ3SUSS[5T=% ''ZQX2
MN]9MM:FEDMHM0U*S2Q7!9D@B!)ZX!8DL3T'8=LFS=:%JD^N6FIQ3VT+V^G2V
M8PS$AWVD...@*CBNGHH X[_A"C<WFI74JVMC)J&G265P++.V9G_Y:LI P1S@
M<GYCDT67AK7%U'P]=WE[8?\ $IAE@*11O^\5D50<D\$[?P]ZZ]G52H9@"QPH
M)ZG&<#\ ?RJO;WHN+N[M_L]Q']F95\R2/:DF5!RA_B S@^] ')_\(=J/]@2V
M?VJU6Y&K_P!J0OABF?.\S8PX..V13-8\&ZSJBZ_$=2LBFJP1H))(6+Q%5 *+
M\W"$@MWQD]3S7<T4 <U;Z)JD7B6ZU>62SD,VGQVFQ=R_,K,V[H>"7(Q[5GZ?
MX.U+3[3PNL=Y:^?HJRPLS(S+*CKC('&",#CI[UVM9UEK5K?ZMJ.FPK,)]/\
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M2>!]%EAO8BMT([V5)IU^U.=[IMP>3URJDGJ<<U8O--33[RX\06]O=7VI+:B
M1)* 94!R% .%SDDY_P#U4 8WAS6;S6K?2;-[F6/4+-I!JP!&=\?R%3QQO8AA
MC^%36WKD-Y::-?SZ-&'U&0JP#2 &3D J&;@';D+V!(I- T\PR7^J3V2VEYJ4
MJRRQ9!9%50JJQ'!. 2<=V/)ZUH:A80ZE9M:SF149E;=$Y1@58,"".1R!0!B^
M$M8AU47X2:^$L,JK)97Z;9K4E?NGU!P2#D]>M5C<W_B#5?$5A::E)83:<T<-
MML .':,/YC@_>!)QCIA3WKH+'2X+&>XN%+R7-R5,TTA!9]HPHX   '8#N?6L
M[4/"&E:EJ_\ :D@N8;ID$<S6UR\0G0=%D"D;A0!C37FM:Y?ZQING7T45Q80P
MK%-'-Y8,CQAQ*5V-N4DXQG& ?K42G7M1\5+I,VO26V=&ANI#9+&RB;S"K%"R
MYVG;WY^E;NI>#M(U/4HM09;FVNDC$)>SN'@,D8Z(VPC(JW#H%C;ZRNJPB1+A
M;86JJKX01 Y"A>F >?6@#A(9+_3O!WC?4+75+M;JVO[LQNQ5_N;<'E3V&/IT
MQ6MK-O)<^-/!SF\N$:6&Y)V%?E(B4Y&1W[UMS>$-)FAU2$K<+#J;,US&L[!6
M+8W8&<+G SBIY?#MG->Z=>/+<F?3D9+9O-^Z&&ULCH<@ <YH Y6\\2ZCI<OB
MD/>M(+?4+2UMY)57%NDRQY;@ ';O)Y]!G-:^K1ZAHUIJ=P/$:PV\ENGD?:HO
M,>&3< S#'+9W* N#\Q&.N*OOX4TF8:JMQ$\Z:K@W:2N2KD  $?W2 !C&.@J!
M/!.D#1[C3)OMES#.JJSW%T\DBA3N4*Q.5 (!&,<T <QJ>H:A)9^-M/>XOH8+
M;24NK<2NOFH2DF?F&3@[!QG(YZ=*T;>[O5FT/0;:X<B;3#=,[S^6[XV*%5@A
MX&XG &>G.,@[2>#](6>ZF=;F:2[M?LEP9KF1_-3!'S9/)PQ&>W;%177@G1[O
M3[&UD^UAK$YMKE+IQ/'P <29SC  QTX% %WPY'JT&E"#6KFWN;V*1E,L+9RN
M<KN^5?FP1GCW[UR<FNZG>^!]4\4VU])#=6<T[QVQ \L1Q.5\MUQR65<D]<MP
M0.*[FPL8--LTM;8,(TSR[EV8GDEF.223R2:S6\*:69;HA)5M[N7SKFU60B&6
M3C+%?? R!@'N#0!@QQO>?%"QN?M%S%YNAF?R\CY?WT?R=.GKWK4\<WMYIWA]
M+NQNGMY5N[=&VA3N5Y55@<@]F/3%:;:':MKZZUOG%XL/V<$2?+Y>0Q7;TZC.
M>M.UC1K77+(6=[YIA$BR;8W*Y92&7D>A /X4 <K>2ZM=^(?%=FFMW=O!96<$
M]N(DC!1F64XR5Z949[GCGU=HNNWGB*ZTO3Y[M[9I="AU&5H,*TLDAVD@]@I&
M<#NP["N@/ARR-YJ%WYESY^H1+#<-YGWD4$  =!@$\CU-4Y_ ^CS6VG1+]K@?
M3H_*MI[>Y>.5(\8V;U.2N!WH HVM[J4GB'3_  S?:GYLD>FR75S=VZB,W#B4
M1@#KMQR3COCH,BL:?7==^R?9!J4B3V?B.+33<B-#Y\+E2-PQ]X!@#C&<>]=I
M/X:TZ4V+QI);SV((MYX9"'0-]X$G.X'ONSD\]:9<>%=,N+."U99E2&Z%X&24
MAFF!W;V;J3GGT_(4 <\UMK*^,(O#_P#PDVH&VDTR6X:4QP^:&\Y0,'9CH<9(
M/&<8SQ2T7Q)J]S>Z;X=O[MC,VH7MI->HH5ITMP",=@6W#)'/RGOS6S>Z;=7/
MQ'M;Q5O(K:+3'@^U18 $AD5MIR""-H/;&<=ZUI?"VE2V-K:B%X_LLQG@FCD(
ME20DDONZDDDYSG.><T <;K>N:WIUGXHL(=1E#Z9-9O:W112QCG8 QOQSCG!&
M#@CFMVYAOK/5+?3VUV^O3.L\_P!G146?^  [@ JQJ=W7J6 YZ5IW?A73+[3;
MFQN!.Z7<JRW,GFD23,N-I+#GC:N , 8J2\\.6%_J%K?S&Y%U;1F$2Q3M&70X
M)5MI&1D T <-8WE_KW_"O;R\O[A9[C[1YIB(4,RPN-V,8S_B<8S5W4?$VIZ1
M_P ):QNVF^RWEK;VK2HN(!*J9/  (!<GGT&:Z*'P3HMO8V%I%'<I'82M+;E;
MF0,A8$, V<[2"1CI4Y\+:5(=5\^)YTU7'VN.5R5? "C _AP  ,8Z"@#*O[G4
M=(\5Z=IL5_<2VFJ6MQDR;6>"6)0P=21T.<$$8SC&*Q='U761IO@K5KC5[BX;
M5)A;W,#H@C8-&[9 "YW J.<_IQ79V_A^UMSO,US-,L)MXYII=SQQG&0I[9P,
MGJ<#).!5>+PAID-EIEI&;E8-+D$MHOG']VP! Y[\$CG/6@#>K@1IM[J7C?Q;
M'9:O<:;(L=F5>!4)+>6^-VX'Y?4#&?6NGT/1SI+Z@WG3,EU<M.L<LS2;,]<$
M],GG X'%%QX<L;C4;F^#W,,UW&L=SY,S*)E4$ $=L D9&#SUH Y'3O$>JM9>
M%?$6H7;II]\OV6^B 41I*<B.7ID*6&#SCYA4NN//<Z)HM[/-(ZW?B"TFA5\?
MNXC,-@''=<'GN<=JVM;LI+^)?"\6B$Z3+#&KW.Y!#&@;E N=V["C&!@$@]JU
M=4T2SU>&VAN?,5+:9)XA$^S:Z'*GCT/;I0!R'B+6M1LAJ-[9ZA+,;74;>$"%
M0((49HU:)\_?8[B21G&1R.E3ZM?:G8:[K6F-J5PK7MDL^D, G[N7=L:,9'/S
MM&><\-6M=>!]%O#?"5;H)>RK/-&ERZIYH(.\*#@-E1S[5JS:/8W%UI]S-#OF
MT\L;9V))3<NT\GKQZT <QH>L7^NZ1:SVMT\=W:V#_:DE(VFZR4"OQT#)(3C'
M&WL:E\)ZU)>ZG+8WKZA:ZG#;*UQ87H!YS@RQN.&4GC@X'' K>BT+3H;74;:*
M#9'J,DDER%."[.,,<]LBJESX9M9;:Y#O=7$\MJ;597N"KK&3G:' R.0"3R3C
MG- &Q<S"VM9IRI81HS[1U.!G%<"^NZI'X)TGQ='>R2S32P-<6N 8GCED"&-1
MC@KN&#UXYS7<:7:/8:3:6<LS3O!"L;2.22Y QDD\G\:S[7PII=GLCA246L<_
MVB*T,A,,<F<[E7MR<@= >0 : ,C0AJNI>(M9\_7+K[/IVI;(X0D8#H8E.UOE
MZ9;C&#ZY[:>O7$JZIIEI%>2J)1*S6EL )I\ 8(8X"JI.221DE1WP;VG:):Z7
M=WMU;M-YE[)YL^^0L&? &0.W  X]*9J7A^QU6_M+Z?STN;0,L<D$[1-M;&Y2
M5(R#@?E0!Q%EK>NW^B^$7_M66&:^OI[2Y=8HR75/- ;[OWOD'MGJ#TJ'5-6\
M0:+;^)-.769YFT^:RDM;N6-"Y2>0*T;X4 XYP1@UJZMX5BT^?P[9Z3;7HM+;
M4GNI6CD9O(#*_()/ W-]T>^1R<V?&/A\OX1U"UL+:XN[V^N())7!S))LD0DE
MN ,*O & .U "12ZMI'C==+N-4GU&QU"PEN )T0-!(A4'!4#Y2&'!_.L?0KV\
ML?!GP^^RW3Q1W-Q%;SQ@*1(ACD;DD9'*CH:[F#1K8227327$ES-"(?/E;]XD
M?7:.!MYZ\9)QG.!52/PAID5CIEFAN5@TR42VB^<?W; $#GO@$CG/6@#+LKK4
M?$-IJ-]:ZN;":SU*2!490T21Q/AE=>Y903DGC<,8Q5'7=:U&S>[O+34)9S;Z
MM!!^Z4""*-FC5H6!^^_S$DC.,CD8Q70MX.T@ZU-JBI<1R3N))X8[AUAF<=&>
M,':Q^O7O4=SX'T6Z-[YB702\G%S)&EU(J"4$'>J@X#$J.: .?&GW]]XH\:&P
MUBXTV6*2W=&A1"&<6ZXW[@<K[#%)IVK3ZQKO@C5;J/;/<:3=2R*HP"<19('H
M>H^M=5+X6TZ2[NKA6N8C=HL=TD<[!9PJ[1NYSG'&1@D=:GDT&Q?5+'4 KQS6
M,;16ZQMM1$; *[>F#@?D* .8T6[\1:U8Z'K]M>VT<%Q(KW<4EQE&B8D%%7R^
M'4X ^;DC!)S5GXJ?\DUUC_=C_P#1J5HV'@O1],U-[VT2XC#2&86OVA_LZR'J
MXCSM!_#CMBK^N:)9^(=,DT[4/-:UEQYB1N4W8((R1SU H QOB.+4_#K6_MFW
M9]E.S=_ST_@Q[[MM<[JC:GXC\/6OA^SXU[2[*UU&>:4\QW 4,B =V8JV2>!G
MOFNT;PSITT\$MX+B]:W8/$MU.\B(PZ-M)VDCL2,BH[[PGIU[K7]L![NUOFC$
M4DMK<-%YJ#H&P>?KU]Z ,'P=?MKGV6\TRZN+>V57DU:.5%+R79(&QF*Y! 4Y
MQCC8 !3OAT7^T^+/M6?MW]N3>;NZ[,+Y?_ <=*U$\#:'!JGV^VBN+9W \Z*"
MY=([C'0R*#ASZYZ]\YK1N-"M9=0?4(7FM+V1 DDUNVTR*.@8$%6QV)&1V- '
M-V0D'QGU0V^?LQT>'[5CIYWF'9GWV9_"M+6KR]M_&GANUANY$M;O[2LT(5<,
M5B+*<XSP??'M6QIVE6FEI*+:,[YG\R:5V+O*W3+,>3Z>PX&!4=[HMK?ZI8ZC
M*TPN+'>8"CX"[AALCH<CCF@#@FU37(?#E[K+:W<O+8:XUJL12,)+%]I6+#@+
MS\I[8Q^M:^IZW=Z=XF:#5)+RSLY;N$65[" ]L5^3=#*.JLS;AD^HP1BM=O!V
MEOI=QIK&Y-K<7/VN1?..6EW[]V>OW@#CIQ5B3PW93R2F:2XDAFF2>6!Y,QO(
MNW:<=N54X& 2.0: .1OM:U:#P?XRN8]1F%QIFH21VLN%RB!8R%Z8(^8]:TY?
M[6U#QU?Z9'KEU:VD5E;W2+%''D,7<$9*_=(7G//OC@Z-]X)T;4)-1,ZW/E:B
M0US EPZQNP &_:#C=@#GVSUYJ]:Z!9V>KOJD37!N7@6W8O,S@QKDJ#GT))SU
MYZT <E#K6HKJF@21ZC-=PWVH3V\TZJJV\J;9"HC4\C;M W=#@\MFJ5SJFN0^
M'=;U?^V[II=,UEX(HRD822,3(FU\+S\K'ICUKJ8? FAP);)&MVL=K<&XMT^U
MR;86.<A1GA3N/%2OX.TN33+W3G-R;:]N#=7"^<<O(6#$YZCD X''% %'[3J'
MB'4?$5G9ZG)83Z=(D%ML4$*QC5_,<'[P)8C'3"^M5IKS6]=OM9T_3+Z**XL(
MX4AE2;8ID>(.)"NQMRDG&,XPI[\UL7O@[2K_ %4:E)]JCNFC6*=H+EXA<J.@
MD"D!O\CI1J7@[2-2U./466YMKI8Q$SV=P\'FQCHC[",B@"X\EZ?#!EEN(TOA
M:;GFML,@D"Y)3<.1GID=*X>TU'7[72/"&OOK,]W_ &E+;6UW:21H(RLJXW+@
M9# \DYYYZ#BN^OXQ%HMQ#!"2%@:..*)?]G  'Y5S_@[P\+?PWH:ZBEU]IL(5
MVV]PV5AEV[6('?J<$D@9XQ0!C2>(-4N?A]<>,;>]DCN899)5M"!Y7E)*4\IA
MC.2H^]UR?3BM2T+S_$/6F1W@=](M2& &Y"6E]01D>XK7'A32UDGVI*MM<3_:
M)K02'R7DR#N*^Y ) X)Z@U/_ &%:C5[K5%>=;JYA$$C"3C8,X '08R>?>@#D
MO#OB&_U6S\)V%W>2++J5E-=7$ZX5Y2A4! <<?>)..<+5S5)M9T:VT2%];:XD
M?6X[:5EC0%X7)(1^/O ;>1C-:,G@?19-'L=-"W,<>GMNLYHYV66 GKM<<_Y]
MA5J;PMITUI96S?:-EG<"YC;SF+F4<AV8Y+'D]<]: .>>\\0Z]'JMQI%Y;VL]
MCJ#V\0FGVQJ(V 82)Y9R&&3G.1D8QBGW.N7EGXE%MJLEW9PW%Y&MC=PX>UE3
MY1Y+X'RL3N&3SGOCBMBX\%Z/<:U+JA2YCFGP;B.&X=(K@CIYB X;\>O?-67\
M.V4DS-(]Q)"]P+IK=Y,Q^:"&#8ZC! . <9&<4 4O'U[>:;X'U6^T^Z>UN8(M
MZ2(%)ZCCY@?7ZU3NVU*]\?3Z0FL75M9-I2W 6%8PR.92ORDJ>P'7/X5T6L:1
M:Z[I<VFWH=K6<;9%1RI8>F1S4"Z!:KJYU037/VPVPM3(9/\ EF#D#'3.3G/6
M@"KX(U*ZU?P9I=]>R"2YDB(D? &XABN<#UQFM^J&C:1:Z%ID6G6(D%M%GRU=
MRQ4$YQD\]2:OT %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 5E>(==M_#VE&]G1Y69UA@@3[TTK'"H/
MJ?TS6K7&_$:QNIM,TK4K:&2X&DZG!?30QC+/&A.[ [D Y_ T :EW=>(K/3)+
MTV]A<2*FYK2+>"OKASG>1Z;5S[5L2W=M!+'%-<11R2'"([@%OH#UJC#XCTBZ
MM8Y[._@NA*/W202!G<^@7.<_7IWQBN/66TD_X3BP\0&-;F29WC$V,O;&("+9
MGK@ANG1CZF@#OY;JW@SYT\4>U2YWN!A1U//;D<TV2\M88%GEN84A?&V1G 4Y
MZ8/2O-]#LXG\8:-%KT=O)?\ _"- W2SA2QD$B??!ZL!GKZ&JV@%Y?"WAUM*U
M:SM]2MS?"W@N_F@GC$V&C;G((79@CD#/:@#U);NV=MJ7$3-MW8#@\>OTK%\2
MZ[/I6F6MYI_V:=9+V"W<L2PVO($.,'J,UREAJMG%K?A#4[N"'2;:73+J%5D<
M!%8-'A0QX((!*^HK,6\M/^$#<":--OBCE6.TJ/MF[D'IQS0!Z=;ZWI]UJ]UI
M<-S&]U:JC2H&'!;=@?4!<D=LBK,%[:W0<V]S#,(SA_+D#;?KCI7GE_>:9I_B
M'QTUY#YIDT^"1((CMEF3RI Y0CD>[#I56"]TV;Q/('O+":VG\-LBK#CRCM?(
M0$D[BHSDG\A0!Z:E[:RR+''<PN[)Y@59 25_O8]/>LE_$,6H:/J-QH4]G//:
MLT:F>7;$67J21D[>O/?'XUPFCQZ;;6'PVN(A;1W$GR2R# 9P;9@0QZGG P?8
M5TWP_>T6+6[6,Q"ZBU:[,D:@;D4RDKD=@1T_2@#H[34@=)LKK4?+L9IXD9XI
M7 V.5!*Y.,D&KRLKJ&5@RL,@@Y!%<=XM%PFL07&FZA91W\-G)NL=0 \FZA)&
MX YRI!4<].1GBM.VN+B\\ 1SZ;:R6ES)IFZV@8_-$_E_(O/H<4 ;,=W;2W#V
M\=Q$\T?WXU<%E^HZBDBO+6>:2&&YADEC^^B."R_4#I7">'M4\,:CI6C3PH\V
MK:;9R*UO"6$T!\O$HD4$=2,9;JQ!'-9.BW^F7&N>"F@GM!:RV5S +:,[_+!2
M,B*1C]]\YR#CGMW(!ZB+VT:5(ENH3))DH@D&6QP<#OC!H:\M4N5MFN81<,,K
M$7&X_AUKR"PTO3;GX:Z4^G16XU]-1"VKQX\Y7%R<C/4*(\DCICFK>O:KI[+J
M!AFAM'MO$<#SQ2,6F++)&IF))^2/ P.,8QSSB@#U66[MH)HX9;B*.60X1'<
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MVJKIFN:=J^G&_L[J-[8,X,FX8PK%<_0[20?2N2\)WOAK6;+P\J*)-8L8&C>
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%17%S!9P-/
M<SQPQ+]YY&"J/Q- $M%-=TBC:21E1%&69C@ >I-)#-%<01S0R))%(H9'1LJR
MGD$$=10 ^BBB@ HHHH ***S9?$.B03-#-K&GQRIPR/<H&'U!- &E15:SU"RU
M&)I;&\M[J-6VEX) X!],@]>15F@ HHJO!?6ES<3V\%U#+/;D+-&D@9HR>0&
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M)_:#H*VEXMO#H\JRQ(T)D,A"E?F.X=03[YYH IZQXJU'2;MS)%:")=0AMA;
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MW=ZRU_:^(EM4";(H?L*R",=\%FZGN?H* ,?3;>XM?B!HFC74QG73/#N]7/\
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M3;%3#<NC9'FX)<'<2,=S@]\U!H^JWFO/H6F7EV ;C08KL;Y'0SRDD.<HP)(
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MT;D$J1D'U'%>4&SBA^'FI>4\RL?$/EC,K-M O5 (#$C/OCGOF@#UZ@D $DX
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M%?:K9V\D:AW228 J"< D=LDT .MO#^E6=P)K>S2-A(954$[$<YRRIG:K')Y
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M55'4_4D#% #KKPQHE[)>R7.F6\KWJA;@LO\ K ,8S[\#GKP/2HCX1\/D3?\
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M&YI=1L)+ZT\R)7B1@N"9%"DG(. VWIFM^L'QEI-[KGAF?3K 0^?+)$P,SE5
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M5L-EW#9M<&UFD'R$+D@D9!Q[=:Y>XO+MO%7A"_>R>6]FL+DF-)!^\.R,@DG
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MA[3M0LKV_P!3N;H>3 6@:*=X_L^!G<H4@%L\Y(.>!6A87^HS:_J=G<V]L+.
M(UO-#(68Y!RK@C ;C.!V(]1FAK4/B:XU:,V5CI<^GPX>-+B[="TG7<P$9''8
M9Z\]<8 ,:SGU*]UCPMH&M,7==*:]OXV_Y;2#:BJ_K@DDCH3CTJQH</\ ;7]N
M:#>3SM9Z;J3(JI*REX60.L98'=M!8]^@ Z9SHR:1JDFI:3KTJ6IU2VCE@N8(
MG(C>)SG"L1G*D*>0,\].*K+HFNZ9IE\^F"S?4]3O6N;IY)V18E. %1@A)(4
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M0 4444 %%%% !1110 4444 %9NH>'M&U:=)]1TFRNYD&%DG@5V ],D=*TJ*
M&QQI#&L<:*D: *JJ, #T IU%% !1110 4444 %%%% !1110 4444 51IMB-2
M.HBSM_MQ3RS<^6/,V^F[KBK5%% !1110 4444 %%%% !1110!%<VUO>6[V]U
M!'/!(,/'*@96'N#P:JZ;HFE:.'&FZ;:6>_[WD0JF[ZX'-7Z* "BBB@ HHHH
M**** "BBB@ QCI1110 4444 %!&1@T44 %%%% !1110 4444 %%%% !1110
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MK2=(AB-98%8(/;(XZ"FIHNE1V<EHFF6:VTI!DA6!0CD="5Q@]!^5 %ZBBB@
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MD5]X:2VVE?)73W"8/4;=V,4",$1_9/B/JVFZ;$BZ0^@![B&-0(M^,(V.FXC
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M5M;3^$?AA)=0Q2(^IM%*TJ@@H;CE6)[=>#6[>O)8?$?Q8V@HB/'X;+VJVX
M.(\%0.,XZ8]JZC_A&?%ILQ9F3PG]E#[Q#_9;; WKMW8S[T]/#_C*.]-XESX6
M6Z/6==-<.>WWMV: ./T<RVM[\,Y-+'^D7T,_V\IUF3Y2QD_O8)<Y/>N8OK6W
M3P/XKOE0+=6OB#;;R D&(;OX/[OX>@]!7JUMX=\86<[S6L_A:"60$.\6FNK,
M"<G)#<\\U%_PB?BCRFB_XI#RW8,R_P!E-@D="1NZ\G\Z .MU>YBB\+7MS<W,
MMO$MF[R3P_?C&PY9?<=1[UX_X5U"V/Q"\'M9SPI;SZ?+#)AU\R4!7V^?MP-Y
M(!QR1QR3S7H TSQX+?[.-2\.>3MV>7]ADV[<8QC=C&.U5H_#?B^(P&.7PHGV
M?/D[=,8>5GKM^;C/M0(\JO[2W7P1XLOE0"YM?$&VWD!(,0W?P?W?P]!Z"N[G
MDAU#XNWL&O\ EO9PZ()+);@@("=A9UST;._D<\>U:W_")^*/*:+_ (I#RW8,
MR_V4V"1T)&[KR?SJ2?PWXON6MVGF\*RM;?Z@OIC-Y7^[EOE_"@97^"1!^'$
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M9JVY;?\ LMO+!]=N[&: .:M='T[_ (6MI5A]G4VEWX?22YB).V=OFYDY^<\
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M>F:]*KGO#.E:OICW?]I-I&V4AU&G6AA);G)?).3TKH:!!1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MB"B, !0O0#MCVKSWQ1<RV&KZI>6%U;7@_<I?Z-=##R@ ;&@8<AN1@8(R#WH
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M6[1*98V."#@,1@A@<Y[U;MO%%G-JEU83075G+;V_VK==($62'."XY) !'(8
MCTH V\ ]NE'2L*'Q592:I9V$T%S;/>Q-+:23!0LP49;&&)4@'.& .*P/$6N_
MV@_ABXL4OX[6?6(%2Y5]L4Z9/!4-D@XR-R\X]^0#K=6M=0N[-8]-U+^SYQ(K
M&8P++E1U7:?7UJ:PLX]/LHK6-F94'+O]YV)RS'W)))]S5FN2N/B%IEM#=SM8
MZHUM9W+6UU,MME8",99N<XY[ GVZ9 .MI,#G@<]:YZZ\8V=OJDFG0V.HWEPD
M,<^+6#>&C=MH8'/(&.?ZT^Y\7:?:V[WCQ7!TV.?[/)?*JF)&#;#GG=M#?*6
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M!+ '&T_7MFK0\1V4\.GM:+-=R:C!]HMXH0 QBP"7.X@*!N4<GJ0* -<*%S@
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MX+E9Q;N@2,R[=JJ"06QMP3@9ZXYK);P]K7]BW(73S]H3Q'_:D<)F0&2+SM^
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M=Z'+IYG+H2DCMG[H;. /U_.NRJK!J=E=7US96]U%+<VH4SQHV3'NSC/IG!H
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ME/;26"3(S%%D,PE8,['/ 8L,Y ]L8XH S(/&.L7>A>&KZ&"R674[UK.=75P
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MV*.GV8L!MSM&"HQ@5<LUU&XTSQ1;65[_ *2FO[(%NYW*NH6%O)+9)"L,K^-
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M UW-,0\Z'S0R;!P(UV@#//R@X%;^HN\7Q4T/R3_KM.N4G _N*R%<_P# C^M
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M6D3-N98EQN/J?6FWFA:7J%W'=WEC#-<1 B.1QED!ZX/;/M6C10!GPZ%I<"W
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M0 4444 %%)D$D9&1U%!(&,D<]* %HHHH **** "BBD+* 26  Z\]* %HHHH
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MMNWEP^1\F,<8_P XKEY]*OM)T/P_H$KZ4=36^FNH?,N'164,[_+(%#*P,BC
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M0?H0:T:PO!VD7>@^%;+2[TP-/;AE+0.65@6)SR >];M !1110 4444 %%%%
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MD_EZ8JWXTU'4-+T>WN=.N%AD:]MX6+1A]RO(JD<^QH Z.BN+1]>E\5ZGH/\
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M#.,$''(Q6V&4L5##<.HSR*Q/$VN3:':VDT$$4WG7D%NX>0J461PNX #GK[4
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M2J"RNX;^QM[RW8M#<1++&2,95AD?H:GH **** "BBB@ HHHH **** "BBB@
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M#LOA9I.J75L6N+M8+5YEEV;\S@A9'.0(\@;N#QD5ZI+9VTTOFRVT,DFPIN=
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MKBNA\)2W$6LZII^HZ9:6NHQ0P/)/8G]Q<(=X1@.JMPP(/H.U=,-.L54J+.W
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M1GETW4([MK<, 94 96"YXW88D9]* +9\4Z9'#J+SM/"^G)YEU"\+&2-,9#8
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M9+JUAO)#]HMT5MLF;=G "@9;YL8ZYKI;/Q-IM[I\]XCRQK!/]FECEB99%ER
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M);I'V**[\Z3RGNA9-^Z;=%,6"['7&5.2.M8B6.HV6L^'M;6RGDAATYK"\MP
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M:JL7E&[MTF\LG.TD9QGZUYYJ][J6I?#OQ+-J3P3&'5#"FQ2-NRX10!D\# H
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MX8L>C#&68GOBNEN;?[592VTC8\V,QL5'J,'%344 <?;^$-0BL/#MK)JUN_\
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
#'__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>39
<FILENAME>exhibit1018-arvinasxcons007.jpg
<TEXT>
begin 644 exhibit1018-arvinasxcons007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=S",;5)QT!/ &3FL-M(UFQN+2\CTJ6Z,&O7=X88I8@QBD2158;F _C'&<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MX!'R@  #D\5VYUVXA\8)HES:Q103VS7%M<^:292I 9-N.",@]3Q6*_@O4?\
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M&#G/4'MVK3KA;C3GN_B/>VL=_=VP&A0#S87 D/[V7'S$'Z^_\\ZQU75]9L?
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M]: *TG@_1I=/OK!X)FMK^8W%RAN9/WDA().=V1T' XXJTV@:>VK)JACE^V+
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MNEP^-D+2J';/H,Y-8FM>)$MM>L]"MKVTM[JXBDD:6<AA%MV[5V[ARQ<=^@-
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MJ/[N0Y';'/2NAMKNS@\4^*K7Q!)$D5XD36[3D!9K;R\%4SUPV[('=O>NZI"
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MIE[;WD#ZZ+[4CIN)3!"6)"\C+!3M;D>IQ1XE&@7O@SQ1JVFWDE\;R.'S+B0
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M'X&\/W*M;+<#Q$K-)D!P/M3Y)/7&P_D:[7XC$#P;)*?]7'=6LCMU"J)T)/T
MYKK** .%:?2K_P"*/F2O:S0_V&"IDP5_UK'//^R<_0YZ&N9T754TSP]X-OKN
M[F@TF*.ZMYKB)0XMY2X\LOE6P-H90<<;O0U[!00",$9% &!X1M=-M]+G?29)
MY;.XN7G667HY;!9D&!A<YQ@8ZD<&N>\"WEKX4L;KPUK5Q%975K=2O"]PX1;F
M)FW*Z,>&ZX('(QS7H%(55OO ''/(H XWQAJ!EM-(OX5=])M]5A>\D RK1 '#
M^Z*Y4Y]L]!FLC7X[>YU+Q7J%I)#+I<OA\I<.I#1R77S[,'H6"X]^5]J]*I
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MC<^,[TP#@#/7.,XJEI?A[7K#2/!V_3XVN-'DD2>$7"\JT;(&STZG.!DX]^*
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MKZ.V\H-,K."BL""%R._K0!?U3Q';Z9<S6_V6ZN98+4WDJP*OR1 D9RS#)X/
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MXVC8C)1B"5/IP2*?0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=:FM?#5Y'KEMK%[K<MS<P6CVN$MT175B&R1SSE1T_3I6_-<PVYB$TBH97$:
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M5_/;S75NLLELV^%B3F-O4>A]Z;'HVG13WDRV<?F7HQ<DC/G#&/F!Z\<<]N*
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MI5HMI86Z6]NI)6).%7/7 [56G\/:/<SW<\VG6[2WB".X?;S*N,8;U& ![X%
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M2+S_ 'E]* .LO]3LM+CCDOKA($D<1HS]&8]%^IIL>KV$M]<64=PK75LH::(
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MF2.0L-D\91U()!!4]#D5?H **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ I"P4$L0 .I-+7)?$N*.3P/
M=,Z*S)/;,A(Y4^?&,C\"1^- '6;ANVY&[&<9YQ2USLNI6,/CEK>>P$=S'I;S
M_;V8?ZD2+E,=<9.>?2GV?B&YNY=-D&DS?V?J*,\5RK;C$NW<IE7&$##IR><
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MIM[XBUH'28I[Z*#R4DED:.-HUVG<0H)!R>@SG'%=E3)98X(7FFD6.)%+.[G
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M>IS_ &?[-?K (PDC%U\M2.05 YSZU"VBZG!XIU;4K4VCVVH6D4165V5T>,.
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M (]?F3CY=GS?+S\I(_\ K\T <_'XEU33X-4L;BZ:\N(=9AT^"Y=$1]DJHV2
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M4)Y-/B:"+SI\@QMCY&  ! VCZ]\U!'X TV*VAM([[4EL;>Z6ZM[43C9 ZMN
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M>2 !S\QZ8'?&>: ,#1]2O;;1/".DPW%S))?Z:+@R#R@ZJD<?R+N&W^/.2"<
M_4+>W_BO3[/2H;J]ABN)]:6S\P1H[26[!F4N ,!^.0N!^=:LO@33)M'L-/-U
MJ"MI[ VEVEQB># "X5L8QM &,8./7FK,OA.TFMK&%[R^+6ETMVLS2AI))@,!
MG+ YXXQP,<8X% %&.YUC3?%NAZ3=:J;V&XM;F29FMTC+LC+M/RCC ?'&.E4+
M;7]536=!5K_[7#?WD]O.8HE%M@*[*(F(#DKM )Y!YYKJ;G1(+K7;/5WGG%Q:
M1O'&BE=FU\;LC&3G:._:LFV\!:9:)81QW>H^7I\YFM4-SQ%D,"@X^[AC[^]
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M3CI6GJYGT_7+G4GAL]6TXZA;"YC'RW5C./+"[#_$N=IV\'YCZF@#T0NH8*6
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MRPA(W,I0J!CC'% 'J190<%AGIC-+FN!\/Z!H^H>*?%#75C!.UMJ:-$'&1&3
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M)3&P<^87R=P(QC&,8.?6O)KF[T^^^&7VW46MQKL>J1F[,I ECF%T 0<\@!.
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M/;N1S"PCB(*?W3GN*Z)=/L;3XA:0MO!$@O\ 2KC[5M'-QAHR"Y_B/)Y.3R:
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MQ;H]SK_A^73;5X4>62)R\I. $D5^@'.=N/QK<HH KVEG;V<6V"U@M]W+K"H
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MH **** "BBJT^H65M,D-Q>6\4K_=22559OH">: +-%(K*XRK C)&0>XX-+0
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MX]RDS6Q*.'WY4KOSG]X><]JZB_@NI[!HK.Y6"Y^4I*Z;@"""<J",@X((R.M
M'#^+]2_MGX;:W<":QO+011M;W-J<JYW#(().UAZ9[_@-^#7]2C\1W.DWEA"7
M^P&^MA;REF8!MI1L@#=DCD<<UFWO@,W=AKL4$UK8R:P(ED6&$F)-A)+A<C+-
MGD\=!UZG0U#PS>:AK<VH'44@\W2Y-.(BB(="Y!\Q6W<$$<#'XT 1Z5XGN+O7
M[;2+R&UWW-BURRPON-NZE0T3]0Q&_J,=.E<C)%&/A-=_(OR:V=G'W?\ 3P./
M3BNITSPGJ=EJ6CWLNIVC'3[-[,QQ6A170[,$?.<'Y!D]/0#K4;>"KUO",^A?
MVE!NEOOM?G?9SQ^^\[;MW>HQG/2@#LZQM3UF:P\1:+IRPQO#J+RHSDD-&4C+
MY'8YQBEA.KCQ1*LD\4FEFU'[L0%3'+D?QD_-D%N.V!Z\QZ_HEUJ5YI5_874,
M%YIT[2)Y\1='5T*," 0>AR#GM0!C7?C2^M=)U6[&GP2OI^K+IY42E=X8Q@.,
MCK^\Z9'3K3W\97>CZK?V?B*R@MTAL7U""6TE,BO&APR'<!\XR/8YK%\4Z-<:
M%X3UA[C4X)6U#5[:Z4F'9L8RQ _Q<C"9QQ]3UKJ+OPLFN7-U<ZQ)')Y]BUBB
M0 @)&YRS9/5B0N/3'>@!DGB.^L+K1O[1M8!;:LXAC:)CF"9E+*C9^\#@C<,8
M(Z5F'QKJZ:9/JDFF6:VEIJAL+A1.Q<@3"+<GR@'!(/.,^@ZG4MO#5Y)'H\.J
MWL-S%I+B6$I$5:9U0HC/R<8#$X'4X/'2J4O@N]E\.:CI)U*W!O-2-_YOV<_)
MF82[<;N>1C.>E '3ZK=RV&DW=Y#$DLD$+2"-W*AL#.,@''3TKFK7Q9JATK3[
M^]L+:--46 62PN\C[W0N^]0N<!5)&,YZ<=1TNHVLM]I%S:)(D<L\+1;RI*J6
M&"<9&>OK6!<^$;BX\(Z5I2ZD(+_2O):UO8XN \:[02A)R""01GO0 L/B/6&@
MU%'T9S-:S1)%<,CPPRQOC,GSX("#.X<].O-5QXW,6GZ]-+%%-_9,\49GM]QC
M=) A\S')PH8DX)X7@U/?>&];U71Q'>ZS U^MQ#.NRV(M\1MN"-'NRP)ZG/8>
ME+;^&]7M;_6+Z+5[?SM1DMY2/LA"JT856!&_E652,=1GJ: '-XJ:'3([K=9W
MGVN\BM+"2VD_=SEP,$]=N#OR.>%]Z2Y\37NG:E?Z7=6MO+=PV#7]LZ.4CF13
MAE.02K X]<@]JJ2> (9+>^:&:*QN9KV&_MQ;1_NK>:,8#!<C.>=W3.?;-:,_
MAVYO[B[O[NXMQ?RV#6,)CC/EQ*QRS8)R23CTQC'J: *6F>*]2N;OPY]LL+:.
MUUNW+QF*5F>-Q$).01C!&?TIR^++N/6-,L[RUMXOM]S+;FV#YFM]H8HSD$@[
M@F<<8SWQ4D'A2\A_X18?;X"-"C,9_<']\/*\O^]\O'/?FJ-IX(U2VATF$ZU
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MP:9J,YN+B!H-TD<C??,3[@!NQW!Q3G\,ZO9Z_>WNBZS':VFH,LEU;S6WFE9
MH4O&=PP2 .N1D9YZ4 ;MSJ<%EHLNJ7*R100VYN)%9<,JA=Q!'K[5AMXGO;/^
MP[F_M85LM7D2%?*8E[>209C#9X8'H2,8/K6]>:=;W^DSZ9<;GMYX&@DRV6*E
M=IY]<=ZPK3PO=FTT>QU*^BN;7294EA9(BKRE 1'OY(&,Y..I /'0@&?I-O/J
MOC'Q9::I#9W-H)+9'B=2PP(@R@ \=3GZDUH>)M0U2U\0^&[2QDA2&[N9%E#@
MY?;"[ '';C/U JYI6B76G^(-9U.6ZAE34GC?REB*F/8@0<Y.<@#L*77M$N-4
MO-)O+2[CM[C3KAIE,L1D5@R,C# 8<X;CGM0!R(U+4-!U+QSJ&GV=K+%:7$5Q
M,LLA3<HMT+!0 ><9.3^N>.CO?$\TEQ+:Z7!YD\5I'<MOADD!,FXHGR X)VG)
M/3(X/.(+CPC>3P>*(CJ$ _MT;<^0?W/[L1_WOFX&>W--E\*ZO;:E;:EH^KP6
MUW]DCM+Q)K8R13JF=KA=P(89/?O^8!T.DWTVI:-;7LME+9SS1AFMIP5:-NZG
MCU[XKE[/QEJDFDW.LW>FVD6G6LD\,@CG9I&D238@4;<$$\9.#[>O7VT,EO:)
M$\[32JOS2R=6;J3@=.>PZ=*YRU\&G_A%-2T&_O%ECO9II1+#&8VC,CE^,D\J
MQX^E #6\3ZI:7%ZMQH\]Q!#8O=QS06\L8+KUA.]?O'L1U]!56^\4WMSX-UG5
MM*N].N(X+(S07,!)P^&+*R$Y#* N,^O(XQ6E8Z1XD6PFBU#Q!#-<+ T5M+#:
M^7AB,"20;CN(]!@=?;%67P2EV=;ED>WM9M5L39RBTC*H6^;]ZP)Y;YOR'4YH
M 9-K^N6<V@Z;#9V=Q<:C;2LLLD[* R(&^;Y2<'(Y&?H.M/7Q$UCKFI#5M/M+
M=[+2([V>XMV+LRY?<F2H. 5; ]_>IT\.:DVIZ!?7&HVSOI<<D;JELRB4.H7C
MYSMP%'KDYZ=*?=^%CJ&OZG>W5PC6=_IPT]X%C(8+ECNW9Z_.>WI0!-;:AKT\
MUH3I]O\ 9KNV:7S%D_X]7P"JOGEP<]5 Z?C7,V7B+4O^%;V.L:E:V>H&XNHP
MRR$@#?<;0<$$':2,#C&!SQ70^'M%UO2XX+;4=:CO+2T79;B.W,;N , R-N(;
M ] .>3FLU?!-^G@V/PZ-5@,<-PDD4IMCD(DOF $;^23@9X&.U &L=>G@\72Z
M/>1P0VYLS=V]QN/[P*<.ISP"N03[&JY\27>;*T\A4O[JV:[($,DBQ1Y 4%5&
M<G/L!@^V;>O^&XM?;39)9C%+9S[RR#_61LI62/\ W6!P?I4.O^'[Z]U:SUG1
MM12RU&VC:%O.B\R*:)B"58 @\$ @@T 7O#VIW6K:1'=7VGRV%SN9)()%(Y!Q
MD9 .T]1QWK4JKI]O<6UHJ7=T;FX)+22[=H)/]U<G:!T Y]R3DU:H **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHKG?%>J26#Z-:K*T$6H:@EK+,IP54JS8![%BH7/7DXYQ0!T5%<1
MKMQ>>&H/)BU:>6+4-4M8!YIW/90R-M;#L23G:V">F?:IW6[M_&K:%%>7AT^_
MTUY\F=FDMI$<+N5R2P!W#@G&1]: .PHKB/"U_=ZI:V.E75S/_:.ESRIJ3B5L
MN8SM7//1]RN.V%(JOI-QK&OZ;8:[;ZC':N+PFX#W3LAC#E6A,6W:#C !ZY .
M3F@#OZ*\LU"ZU2+PWXMU-=:U#S]*U1Q:CS<* HC.U@!\R\D8/'MFM/QCJ%W%
M%XCGL-0NGGT^SCD189#%'9L 6^;!_>,W!VD$ #G&: /0*9)+'%L\QU7>P5<G
MJ3V%<;+]LU+QW'8/JE]#:3:*+AHK>78 _F 9! R/KU]\9%8%M)/K.E^ KB_N
MKF6=M0FA>03NA<*LR@G:1\V%'/7KZF@#U2BN$NM3N].\2B/5?MJ6=Q?HEEJ%
MM.7@QD+Y$J _*201N(.2>O%=W0 45Q_F7'B+6_$NF#4KBQFL/*BM3!(5,>Z,
M/YI4$;\L<8/&%]S265W+KGB?4M)N+^<0V5C;-"]M(83.T@8M+E3[* .0.: .
MQIDLL<$3RRNJ1H-S,QP *\UL-6UG4T\)I<ZE<Q/-?7=G</#A1<+$L@#XQU.T
M>V>15;63/+X.\365Q>W<Z:?K4,,#R3L7V,\)VLP.6 WMC.>WH* /5JJSW3Q7
M]K;+9SRI/O+3H!LAVC(W9.>>@P#7'^)IIH3J\-CJ-Z\ECI1E6*.=D%LWSL)'
MDW9<MMX4@_=.< U*-1OYM>\%,U[,$O[*9[B)2 CL(58-C'JQ]J .UHKRR6[U
M2'PSJ>L?VUJ#W.GZ\T$*M+\C1BY6/:R@?,-I[].V*VKB75?$6H^(K*RO?L=S
MI\Z0V["Z>,PCRU<.T84AP6+?>XP,<=2 =K/*88))1&\A12VQ,;F]AD@?K5/0
M]7AU[1+35;=)$ANHQ(BR8W 'UQ7-V%Y/X@US6=/NKZ1!IUK;+&;25HP[R1[V
MEX/S#.  <C@\<U<^''_).M"_Z]5H WK.[DNGN5>TGMQ#,8E,N,2@ '>N"?E.
M>^#P:M5YCJ&I:I%X.\8S)JMV)[+6#%!+O&Y4_<_*..!\QZ8ZUT5B;JP^(LVF
MG4+NYM9]+^U,EQ)N"R"7;E>R@@]!@<4 =2\L<;QJ[JK2-M0$_>."<#\ 3^%9
MVD:W#J]QJ,,=O-"]A<_9I!+MY;:K9&">,,*P?%%HEQXZ\([Y)U#270(CG=!Q
M"Q!^4CGWZXXZ5SNH+<V]AX^U.TU"[M9[*^,T0@DVJ66&(_,/XAVP>* /2FNY
M%U..T%I.8WB:0W(QY:D$#:><Y.<].U6JY*6]O!\0+.(7DBVTVC33F%C^[5P\
M8#8_$]:J^%M3NEUN#3-:2_M=6%HY823&6VO<%,RQMG (_NX& _M0!T^HZO#I
MT]M;>5-<7=T6$-O"%W,%&6.6(  R.21U'<T:;J\>I374 MKFWFM6598YT ()
M&1@@D$8[@D5D^*M!76[FP-GJ<FFZW:"2:RN(QN^7Y0X93PRG*9'TKG9/%^LZ
M?I&O0:O:VUOK6FBV62[MS^ZEBEDVB49!QM!8X(/3IVH ](HK@M:N-:\,66K:
MQ#>QM;?V>6BM'N7N2LH8#S5+@': PRO3IZUJW6F;(9KB+7+N2TN-/=?(:=F,
MKXW"57W93CLN!R.E &W<:AY<%M-;6\MY'/*D>Z#:0BM_&<D?*.^,FKM>:637
M&G> ? TEG>747GW5@DRB4D.K@97G.%XZ# ]JU8KFZU\^*B;ZYL[C3;E[>T$,
MI01!8U8.5'#;F)/S C Q0!VU%>=:9J.I^(=8\.FYO[RUCU#0WN)X('V N&C&
MY>,C.XG.<C/!KH? EY=7GA=#>7$EQ+#<W$'FR'+NJ2LJECW. .: -*ZURTM-
M<L-(D6;[3?!S$1&=GR+N.6Z=.PR:JZWXG@T1V4V&HWIC3S)OL5OY@A3GECD>
MAX&3QTJAK_\ R/OA#_>O/_1-;>J736\!AM$5[^X!$*'H3C&]O]E>,GZ#J0"
M3Z??VNJ:?;W]E*);:X021N.X-3)+'(TBHZLT;;7 /W3@'!_ @_C5'0M+M]#T
M.STJV??%:1"+<>I(ZD^Y//XUY[%>R>'M"\5W]K-<++_;S6OFR3-((D=HE+X8
MD9 )P3[=N* /4Z*Y.22ZT?QWI-A;W%Q-8ZE;3^;%/*TOE/$%(<%B2,[MI&<=
M*N>()B=5TJS2[G#3&5OL5NQ1IP%')D# HJD@GUR!@T ;SQI( '16QTW#-*
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MW3LC)O*M"8MNU2. #UR!R<T =_17.^+M4FTVVTR.%UC%[?QVKR&0IM5@Q^\
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M+ MOHUFB-(P\E3F21G/('=B35^@ HHHH **** "BBB@ HHHH **** "BBB@
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M0X>4LP$9&0> O..?F'ISIZ7J832XY=4U?39Y9)FC$UNP2,L6P$7+')'3US0
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ML;^W2XM9EVR1N."/\]ZRX?!F@P:/<:4MFYL[@ 3*UQ(S.!T4L6W8'IG%;U%
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M7=Y);-]HNXA%.RRNN]0"!D @9P2,]<$C.*U:* ,B/PSI,1TTI;R#^S!ML_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MS.%5F#,SJ5^]@8';/.<#5\2:I?:7X/O]5MHXHKNVM6G\N9=Z@A<E3M(^F<T
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M,K9!*Y(R@XZ5UU8B:^U]J5W9:3:"[-F_EW,[R^7$DF,[ <$LP!&<# SR<\4
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+CNHE%S)F.4QRDL&SGDHI//.*ENHX=%M/#K"[>&#5Y8UOKB[E>2-F$#;%(W
M*&;' (!P >.*[670-(FDN))=-M7>Y4).S1@F51T#>H]C4DVCZ;<:7_9DUC;R
M6&T*+=HP4 '0 =.* .,GM8=(@^P2:S)=I=ZM#Y%G -D:LP+>06+-B,[=Q7L.
M #N -73_ .T+G2_$&GV=W:I<0ZYMM[>61C"RA8W: 'J%)W#TYQCG%=M_PC>B
M?V4FE_V39_8$8.MOY*[ WKCU]Z7_ (1S1,2@:59J)61I-L*C<5&%/ ZCMZ4
M<*=<;R;*R-E<Z4LNNI:ZG;M+N6(F(,J(X_Y9N=G3'4CH:EUY)].O/%MA92S1
MZ<-!-\%CE91;W'[P (0?E#!,D=..G-=V='TYK&6Q>R@>VE.Z2)T#!SZMGJ>!
MR?2D&BZ8+*:S-C UO-_K8V3(DXQ\V?O<<<T <99QKI7B7PK/'<7 %]IDYO#)
M,SB38D3*2"2!C)Z#OBJ>D7037?!]Q;7$GV:_2Z+3339FNT\LL'E XZ@$#G'M
MTKOET32UFMIET^V$EJNRW?RQF)?13V'TJ"#PQH-JT30:-8QM%+YT92!1L?\
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MV5Q.]P85$20,_F9M5&PD @'GN<<Y]: .JO?%>A:?-Y-QJ4*R^1]H"+ER8\@
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M6,2^5)$\;,A.-RA@-RY[C(KC-5TO4=1U'QS!9VTZ27EK;+:O)$R),R*VY0Y
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MIM#A1R0IR#C)PU5]>T2^O[#QMJ%G:7#)J,=LMO!Y95Y3$!N8(>>>@XR=OTH
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M BT^01VKN]M.I4MN0#< < 9 ZJ*JO:WS>#+^#^R]069_$1N$C^RN6,?VH/N
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M3*8CY9!)& W0MQTH Y:?P==PZ#I>GV4MN\MMJ2:C<2RED$CB0R,  #C).!Z
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M/?/M5G2-&O=,\0:S=&:W>RU"=;A0 ?,5O+5"#VQ\N<^];U)N4N5##< "1GD
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MN"S%"0>>QZ#C&.,XSS38_!VG1:7ING1SW:VVFSBXMAY@RKC.,G'(&3P?7Z4
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M32[E[:VC5$*ED16W/N!)#$D8XX''/-;5IX?2VC2&34=0NK9,;8+B4,HQT!.
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M1<M,CVLXGADAD*,K@$=1[$C\:IMX5LF;5R9[K_B;1B.Z&\?,H78 ../EX_\
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M#,HD>/!&P8 "C#-T ZD]>:!X:M1=:5<?:+DR:7&T=MEEP%8!3GCG( 'X>O-
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MG@<<=S@D=S0!G:1/XCO6T35ENXGL+J(/>1R2+M(=05,0"Y!!.,$G(ZY/-/\
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M^A6+3A,KJEIM9N"N95S@]N,T =8;JW".YGB"1G:[%QA3Z'TISRQQ1F2214C
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MV@G!^AJ_YZPVR27,L4? W-NPN?8FO*WCTL> _'MN8[47,5Y?MLVKN0;LIQU
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M%\H.6QV#<]A4^L7&CZ;9V5WIT[IH$NLM+?W$)$D09XVPPR&7RQ)MS@8##U%
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MEG:S0B&6VA>('(1D!4'Z5-659Z_:7TD/E),(9XFFAN&4".1%QD@YXZCKC(H
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MXEAU7X?ZAJ.CWEU;36T\<4@PT,L3^8BLC#J.&_6@#M);2VG\OS;>*3RSE-Z
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MRVC:I=,JZG<1FRU8!^!;,@S@^H*9_P!Z0UNW=G>#X@Z=?QV,K6,&GS0/*I7
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M6T^B6AL[>:W@C3R5@F7#Q[#L*D9/(*D=3TJM/X4TJ;4);Y1=V\\[!IOLMY-
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M[I.OM:6U^5>\@>V60F0*%+QG("L0!G@C/;M5I?#EQ%KFHZC%?QA;NSCM%C>
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MZ:TK>482QDWKM/S;ACCV- '"ZS>:GJ'P[\;/J-Q#,(;R:! D97;L9%&,L<#
MZ>O.:[*RUK4AXO?1-0@M522R-Y \#,2H#A"K9ZGY@<C'>L^\\$7-SI&OZ6FK
M)':ZM</< &UW-$7(+#.\;N1QTQDYSQC6&AW)\60:[)>Q'R[)K-H5@(W!F5BP
M;=QRHXP>* (O$&MZCINKZ-86-I;3?VC))%NFD*["L;,.@Z<<_P JP;GQQK&G
MZ5KJW>G69U31YX$D6.1O*ECE(".N><\]">W6K?C&8KXL\()%<P0S_:YF!E&1
MCR6'(R.O3ZFI]3\&2:GINK1-J$<=[JDT,D\_V<LJK$5V(J[AP-O4GJ3]  3_
M -M:O%JUMHUS'8)J%V99HWB+ND=N@7!8':2Y9L8! [^U8>N^*M5?0M6MHS#:
M:GIM_;VMRRJ662.5TVLG.5RK=#G&"/0UTNJZ!+?:EIFK6]VD&I6(90YB+1RH
MXPR,NX'' (.>".]4K_P:+_2M5A:]":AJ5S%<RW0ARJM$4V )G[H$8&,YY)S0
M Z_\07\=W>:?9)'+>V4"22'[)+(DCL&*H A^3A>I)Z]#@TMKXAU#59X[*TLT
MLK];!+NXCO%+>4SDA8\ C)RK9.> !P<\,N_"^JC6AK&EZZMI>30K#>A[0213
M[2=K!=P*D9(')X_')>^%+X:O;:MI&M-:WR6PM;E[B 3+<)DL"RY7# DG(]<=
M* *L^J>()/$WA>WF6"P-W;W$MS:$>9MD15!!96P1\_'ZY[17GBR^T_2?%M]%
MIUD)])N-N Q E'EHVYCC).& [=.M;%WX;N)M1T:_AU-EN-.$RN\L0<S"7&_N
M IRN1U ],51O/!=S>:?XDM#JD2C6Y1(S"U/[GY57 ^?GA1Z4 6K77=23Q4-*
MU"VMA%/8M>0-;LS,NUE4JV>I^8$$8]*SK?QCJ5U;>';V&UM'@UN5HTB+,'@P
M&8989W<*0>!@UIW6DW-MK</B*2Z$OV+3Y(&MH;4EY02&)7Y^N4&!@]:X[PW/
M-";.73=<T34;LD&2T_L\K<@N09 6#Y0]<L5 XY% '7^/[Z^TWP7?W6GSK#,@
M52[*20K,%..1@\]:S+\:BOQ)T\6_V1[UM&G!=U98Q^^CYP"2?IG\:Z/Q)HP\
M0^'KS2C.8/M"@"4+NVD$,#COR!51- OSXDM=:FU*"26&R>U9!:E0VY@Q8?/Q
M@J,#GCN>M &=8>,YKW1])9[=(M0OI9XF"1O,D9A9E=@J_,PR!@<?>Z\5L^'=
M3U#4;:Y_M*Q:VF@G:)7\MD6=!RLBJW(!ST/0BL%? =U#I%C#;:UY&I6%W-<V
MMXEMP/-9BZ,A8[E.XCJ.@KJ-+M+NTMC]OOOMETYW/((_+0=@%7)P/Q)R30!R
MWAB4ZQX[\3WUY\\FGS)96B-R(4VY8KZ%CR3[ 5KZY+8>&(-1\3?9P9VACBD5
M,+YS;L1@GUR^,^A]J;<>&Y[?Q#/K>C7L=I<72*EY#-"9(I]O"M@,I5@.,@].
MU3:GX=.O:+>:?J]T9/M483,"F-8B"&#*"3R" <DGIVH @EUS4--\1:?I-_':
MR_VE%(;:6$,@66-=Q1@2>".0P]#Q6);^--<ET/1]8>PL/(O;T63PK(X<,TK1
MJP;&  0,\'/7CI700Z%>37]A?:I?0W-SI\3K;M';E!O<!3(PW')P,8&!R?;&
M9%X)NHO#>F:0-5A/V"_6]$IM#\Y64R!<;^.21G/2@!ESXKU?3XO$T5U:64EU
MI%JEY&8G=4D1E<X.<G(V'ZY'2I+?Q/K$&N:/;ZI8VBV.L(1;R6\C%XI F_:^
M>#D9Z=#Z]:J>+M'DL=+\7ZS-?0E+[2C;B'RMI4HC[<-N.22YXQZ5HZ7HSZK:
MZ)?7E]%-'9VV;;[.FWYVCV;R=QY"D@ =R3Z8 (;/Q7J#:YI.GWEO:K)J G5X
M(V):T=%+!7<$JQ('( !%4O\ A,]:72I=5EL;!;2UU0V%PBR.79?.$6Y3TX)!
MYZ^W>SIW@B_L3H.[7(W&C-((L687S$=2IW?.?GY^]T]J=)X)NI/#M[I)U6'_
M $K43?F7[(?E)E$NW&_^\,9STH O#Q#<6OB;4M,U/[/!;PV?VRUF56S)&"0Y
M//5#C('7(/%6!I7]NV6DW>L6UNMY;NER (LM$X(8*K$DKR #CKC'2LG5TTOQ
M3XBTZPBE>2]TFY+WC1HRJD>SYHV)&"'.P8R<@'T-=E0!RP\423>);G1XY;2&
MY@N$06EP"LLT)"EI4;(!QEN #]W\*E^( !^'VO9 /^A2G_QVDU+PO+J\\?VZ
M[@DAAO4N[=_LY$\&U@VQ7W="1C..A(]"-+Q%I+Z[X>OM*2X6W^UQ-$93'OV@
M\'C(Y_&@#)FUZ>.9-+T]5^TPV,5P[O;2S+\V0BXCY&=C9)/''![);>)[^[FT
M.RDT\Z=?ZE!--*ETI80F/ *@ @L26!'(XYHO?"NI'4K35=*UI++4([5;2X+6
MOF17$:G(RA8$$$G!SWQ6/XK*VVIZ18W6N0V300R3_:]2M1)#-(Q X.5"N/FX
M!& P ![ $TGB[49O![ZM<:78MLU!;1HV=F4XG$1< KS\W(Y_'BM&VO=6E^(>
MJ67VB!K2WL89(X2C#[QD[YZY49..F./6E%I-_P"(_"SZ6U]IZ6\=Q"]O=VED
MR1R(C*X"H7Z;EQD'![5N#0KF/Q5+K4-^B">U2WFA,&=Q0L58-NX'S'(P?J*
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MIU.PGEF!.3GT].0#IJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ P#VHHHH **** "BBB@ HHHH *,444 %%%% !1110 4444 %%
M%% !C-%%% !1110 4444 %%%% !01GK110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MY-3LUBN!NA<SJ!(,9)4YY&.>*:WB'1DLHKUM4LQ:RJ7CF\Y=K*#@D'T'<]J
M-*BJ-WK.F6*JUU?VT*NGF*7D !3^]_N\CGI4EUJ5E90I+<W4,4;_ '&=P-W&
M>/7CF@"U17+ZKXB:T\0^'Q%?6G]CWR7#RR\$$)'N#"3.-O\ G-;]C?V>IVB7
M=A=0W-N^=LL+AE..#R* +-%<CH_BV&.\U>VU[5+&"2'4WM;4.PBWJ$1@ "<D
MY;KGO72)J=@^H/IZ7MLUZB[FMQ*ID4>I7.0* +5%06UY:WD;R6MS#.B.49HG
M#!6'4$CN.XKG]#UG4/%4$NI6$T-II?FO':LT7F/.%.TN>0 I(.!C/&<]J .G
MHK+LKV[M[6ZDUQ[: Q3E$E3*1NF%VD;B>23C&3SQS4O]N:4+"2^.I6@M(F*R
M3-,H5&'4$YX/L: +]%4K76-,OKR:SM-0MI[F 9EBCE#,@]P.E,77=)82$:E:
M8CC\UR9E 5,XW=?NY[]* -"BJBZKISR6L:W]J7NTWVRB5<S+C.4&?F&.<CM7
M+VOC Z=I?B._UR>(IIVI26L(C39O 1"J@9/)+'G/Z"@#LZ*SYM=TFWA2:74K
M1(W4NKF5<%0<%LYZ ]3T%.N=;TJS95N=2M(6:,R@/,H)0?Q=>GO0!>HK#O\
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MU'/I@\U)%%'!"D,*+'%&H5$48"@<  >E #Z*** "BBB@!KNL:%W8*JC)8G
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M/][\<]ZW:** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M^F7RHMQ;(4;RWW*>2<@_C0!!'K%W?>,]1T*2R864-K$_F+( 3O+Y8X.0/EP
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M$]M<18W1OT[@@@@D$'J*U** .=OO"%MJ6G:I;7-W<&;5%5+JY0*'**,*JC&
M!SVSR>:LGP^#KMMJYO[@W%O:M:JNU-I5B"21MZY4'\*7Q!K<FB)I[I:K.MW?
M0VC$R;3'YC!=V,'./3BKT,MXU_=1S6R1VJ!/(F$NXRD@[LKCY<''<YS0!SZ6
M]OX/T*+25MM2U:*YDE542 2'+EF(<J %4ECR>.:U?#>C1^'_  [8Z7&!^XB
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M>#+>'3-$L$U"[\K1YEFMR0F6*J5 ;Y>1ACTQ735C:OK<FEZKH]F+598]1N#
M9?,P8R$9_NXY^[ZB@"A?>"+:_DU6234+Q9-1FAG+)L'E218V%?E[;1P<YIX\
M&6SRZO)<ZC?7']K6HMKH.R -A67<,*,'#'@<>U=+4=Q<0VEM+<7$BQPQ(7=V
M. J@9)- '-77@J.X@TUX]8U"#4=/4QPW\902%" "C+MVE>!QCMGUSOZ?9+I]
MHL FEG;)9YIFR\C'JS'_  P!P!@"IXI%FA25#E'4,I]C3Z ,F;0EE\2)K@O)
MTG2U:U6,!2@1F#$\C.<@=ZS(O!%O#HNFZ6FI7GDZ?=B\B8B/<7#%@&^7&,L>
MPKJ:* .>E\'V%Q/K)GFN)+75P/M-J2HCW; FX$#<#A1WQGG%,L?"36MA/:W&
MN:E>AX6MXGN&0F%",'&%Y;'\39/ZYZ2B@#G;CP?977A6TT":ZNC'9"/[-<JP
M6:)HQA&! QD#CI4D'AR:*T"R:W?S7OF(YO'V;\+G"[0NW;R<C&3D\TGB#Q/'
MI'A[4=5LXDO38/Y<L?F[ &XR,X/(W#CZUOT <W<>#+.YL[N-KF>.YNKV.^>Y
MB"JRS)MVD*05Q\HX(.><]:DOO"R:C!=VEWJ%S-97>SSX) AR5"C*G&5SM&?T
MQ7044 4[>RD@U&\NFO;B6.XV;+=R-D.T8.SC//4Y)JY110!GRZ69=;M]3:[F
M_<1/&EOA?+^;&6Z9S\HYSTSZFJFI>&X]0\0Z=K0OKFWN;%71%B";75\;@V5)
M(X]>*U+N\M[&-)+F58U>5(5)[N[!5'XDBF>;>?VIY/V9/L7D[OM'F_-YF[&S
M9CICG.?;% &#/X)MKC2=:TZ34;SR=7G,]P0$W*Q"@A?EX&%'7-1:U;P^(KVW
M\/W%A>R_8[B*XEO)8=D151D[6Z,6SL('9F]*ZVB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M KE?'&H-90Z-%)(8K&[U.*"\DS@",ACM)[ L%!]B1WKJJAN[2VOK62VN[>*X
MMY!AXI4#*P]P>#0!P:65E;>,/%]O:JL"-I,#E(6*;3^]Z8^[V/'K[U!:Q:C<
M>%/"=Q8Q6FIR1:4'FTN[?;]H4K'ET8Y =3QD_P!\],UV\'A[1;966#2;&-7C
M\I@MNHW)_=/'(Y/%..@Z0T<,9TNSV0 K$H@4",'J%XX![XZT <':1Z=KWB#P
MS&OVP:=<Z'+_ */-.X+!&C #8/)ZYQUQWJE;QRV-E8P&>1K2S\7"ULYI')(M
M^FS<>2H;*\^GM78WWAJ2\\7Z=?FTL7TVTLY+<1LQW*6*D%5VX& N.O>MR;2M
M.N=._LZ>QMI++ 'V=HE,>!R/EQB@#SC7Q;7,'Q+A!CECBM89%0$%5<1,20.Q
MW#/UK1N9[)->TC1I9;"WTV;36>%+B+?#+/N7<,;E&X*01GU/K7:1:-I<'F^3
MIUI'YL8BDVPJ-Z 8"GCD8XQTID_A_1KG3HM/GTJRDLHCF.W:!2B'V7&!0!6\
M*VBV.@0VD>I/J,<+.B7#=P&/R@Y.0OW<Y[5QUAIX%MXQU2 7$VI:9J%VUANG
M=MC_ &=<#&><YZ'/;TKTB**."%(88TCB10J(@P% Z  =!4%KIMC8O*]G96]N
M\QW2-#$J%SZG Y- '&>'8+"\O=$UFPUNVWR0,CPVT9#764R?.RY)92,Y(SGC
MO69HMC-K-IX> E#7D%W(^H7T=T!]JB^?H5;<P8[" 1P!VXSWL6A:?8_:YM+L
MK.QO+E2&N(K=0Q8]"<8SSSBN5L? S,D,-_HGAZ*6/;G4K56^T,1_& 4&USUS
MN.#ZT 9.J7=NUS%J-E/AE\310-<SR#SR?,5)(UQC;$!D8).1SCO6I8Z;;7OC
M+Q5.RS7+V,UK<VD?VA]HD\G<,8/()['CFNMD\/Z+++/))I%@\EPP:9FMT)D(
M.06..2",\U8@TVPM;J6ZM[*VBN)O];+'$JN_^\0,G\: /,"UEJ/@SPCK,CI+
MJ,VL6C7%P3\YD,OSJWL#T7H !CI6K>K_ ,3'XBH)I@JZ?#(N)FRA\F4\'/ S
MV'%=@?#6A-<27#:-IYFE<22.;9,LPYR3CDU,VBZ4[W#MIEFSW(VSL8%)E'HW
M'S#ZT <1I=K'8:[X'GMVD66_T^5;IC(S><!"C+G)['IZ55M+*?6;:UM_.5]0
MBUJ1[G4([D+YT D;<H(8/@KA N."H[ &O0/[%TQ6MWCTZS22V7;;N(%S#_N\
M<?A7'0>!9IX3;:GH_AV65L[]5C0BX=B<F3;L&')YSOP#T]* .D\8V\4W@C6X
MY(UD06$Q"L,\A"0?P(!KDOL=E+<_#ZVB5%AD24R+"VW)-IDY(]>,^H->CM&K
M1F-U#(1M(;G(]ZHQZ#H\(M_*TJQ3[-GR-MN@\K/7;Q\OX4 >="_;1M&U&V2?
MR-+A\4&TD:3<R06Y16P>00F\@'D##$=*[#PUI]O8ZGJ9M-3AN(9_+E-K;)MA
MMS@C*C<<;L9(]L]ZV$T;2XX;B%--LUBN23.BP*!+G^\,?-^-/T_3;'2K46VG
M6<%I "6\N",(N3WP.] '&ZQ+#J7C/4M%U.[M+>(V,3V:W<9(8$N)'0[U <';
MSU&!C'-5=;T^XM]'T6^T:\EU+6K*)BDA0'[9 %(9G!.#P1M;G)(_O5W&HZ-I
M>K^5_:6G6MYY1W1_:(5?:?;(XJ;[#:"Y-R+6#SS'Y1E\L;BG]W/7'M0!PVMM
MILG@CP_<Z-*_V,ZC9&)A(06!E4-OYY/7.>^:-=DGT[7[K4;FVBU+2?MMN'FA
M;;<Z?(/+PN#]Z,G:2!@_.>M=@/#^BBV%L-(L! K^8(A;)M#?WL8QGWJ0Z/IA
MNS=G3[7[065C+Y2[B5X4DXY(P,'M0!YW<%-'/Q!O=/BCBO89D,;1J-ZJT,;.
M5[YQN;ZC-:4=CITC3ZCI^M6[1W.F2 VVGJ8UE4#(E;#DA@<#=P><&NV73K);
MV6]6SMQ=RH(Y)Q&-[J.Q;&2/:J]KX?T:QAN(;32;&"*Y_P!<D=NJB3_> '/X
MT <#HMLEF/AU?0O*+F\@\JX=I6/FI]F+;3D] 0"/2KGAR73-;TFSU#4;UX-=
MM]2;SS'(%F\T2,HA(Z[""!MZ8_.NT70])46X72[(?9O]1BW7]U_N\?+^%*NB
MZ6FJ-J::=:+?L,&Y$*^81T^]C- ' 6QAUZ"]FO-9M[#5K+5) S"(_:8MLI\M
M%._E63: H7!R>IYKJO'M]>:;X(U2[L#(L\<:_/']Y$+ .P]PI8Y[8K5?1=*D
MU1=3?3;1K]1A;DPJ9!V^]C-76574JP!4C!!'!% '%W5K%9^,?#G]BX2TU"&X
M6[2!B%EB$8*R''\08J-W7YNM,^&VE6I\.V6KMYTE\?M$/FO.[?)Y[\8)Q_".
M<9Z^M=7::/IE@KK::?:P*Z[6$<2J"OIP.G/2I;+3[+3H?)L;2"UBSG9!&$7/
MK@4 <Q=W$5]\21H^I*CVBZ8)[:"7E)9"Y#M@\,0 ,>@)/>N3TGR;;P]X9:%P
M%3Q/+#Y@?)V&2?@GN#\O7KQ7I]_I&FZJ(AJ%A;7?E-NC\^)7V'U&1Q43:#H[
MV$EBVEV1M)'WO 8%V,V<Y(Q@G/>@#SO7I8WL?B2L$Y"PK"Z"&4@*WDC.,'^]
MG(]<YK=O]-TG3M0T:TC662YU":2<PSW!,$[+#AFEW9S@$$ #EL'MD=.?#^C%
M)4.DV)255613;H0X4 *",<@   =L5)<:-I=W;P6]SIUI-# 0T,<D*LL9'0J"
M,#\* /+8UM[WPGHB7+0W(M_% A0GY@L1N'  R3A<# YZ#%=%>R36/C759-*R
M\B>&_.MHE8LA<.X7:.@SM4<5US:)I+VT]L^F6;03R>;-$8%*R/G.YAC!.>YJ
M5-,L([W[:EC;+=;-GGK$H?;Z;L9Q[4 < I4>'?!NM:3(6U&YN;:.>56RURKC
M]\LG][&&//W2O&,5EZG9QIX3\:Z@))S=:?J\CVLIG<F%E$1!&3UYQ].*]0M]
M(TVTN6N;:PMH9V))DCB56)/4Y []_6F'0=',,T)TFQ,4[;Y4-NFV1O5ACD^Y
MH 76Y[JUT#4;BQ3?=Q6LCP+C.YPI*C'?G%<,-JZ%X+UG2)"U_=7-M'/*K9:Y
M1U/G"3^\1AFYZ%>U>C1QI%&L<:*B*,*JC  ] *J6VD:;9W#7%M86T,S$DR1Q
M*I)/7D#OW]: .8\.6%E'\0O%;QVT*R1-:E"%&5W0G./3-7/$LEI+KVC6$W[V
M>19Y$MYG MV55 9I 0=Q7/R@>IZ=:W8-+T^VNY;J"QMHKF7_ %DT<2J[_4@9
M-+>Z98:B83?65M<F%M\1FB5]C>HR.#0!SOPXN6N/!-ION!.\<DZ;MV[Y1,X7
MN>,  >PK GT;3M4U/QW+?O(GV:9)(Y4G9/)86R$.,$#(QU/I7HEK96EBCI:6
MT-NCN9&6) H9CU8XZD^M0S:-IEQ>?;)M/M9+GC]Z\2ECCISCMV]* //K#3WU
MW7]"M]?^T/)<^&R]W$9W3<^^(9(!&#SDXQS01!K8UR&]UB#3M0L-0=8Y#&3<
MP1HP\HQDO]UE X ^8D]2:]$;3;%[];Y[*W:\4;5N#$ID ] V,U'-HNE7&I1Z
MC/IMI)?1?<N'A4R+CIAL9H \Z\5W<#VNOW]I.?M-GJ-M&;B>0"2*0&+,<(&"
MJ8)))/)+<'K6K)-IFM^(?$^F:W=I#Y*1?8W:4(8H#&#YL1/ ;>6RP] #T%=;
M/H.CW4\\]QI5C+-<*$FD>W5FD48P&)'(X'7T%.NM#TF]GMY[K3+.>6VP(7D@
M5C'CIM)'% ')-IMGJWQ#%M=>;<6S>'HLB5RID'G-R^,9/?ZUJ_#RXFNO &CR
MSRM+)Y)4NYR2%8@9/T K<?2]/DO&NWL+5KET\MIC"I<KZ%L9Q[5)9V-II]N+
M>RM8;: $D1PQA%!^@XH X6*2?3?%%O)?6T5]976J2K::I;-B6*1BZ^3,IY*K
M\R@@X&T<5ARVL4/A75M7C,BWUKXFD,,HD8;,WBJ0!G&"&.?6O4(M'TR&Y:YB
MT^U2=G9S(L2@EF^\V<=3DY/4U'_PC^C?9WM_[(L/(=_,:/[,FUF_O$8P3[T
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M)+B6V$T0\EV>9 !\P"KR3D< 9YZ4OB^*6X\&ZS;P0R33SV4L4<<:EF9F0@#
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M>,-"2>,] C>WN:W?$Z75MXBTO6UTR]U'3OLTEM/#:AO.B+,K*X3()'RX([4
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M&*ZNHF::-66\1U5MLV!EAM.%&>>3QC&0#LK*_M]0B>2W+D(YC8/&R$,.H(8
MU7?7+!+K[.9)"_G" LL+L@D.,*6 V@\CO5#PBFJQZ;<QZK*T[)<LMO<R0^5)
M/$ -K.O&&ZCH,@ UA7%A?0>)#>Z*M_;RS:@HO;*:%GM;B/< 9E8C"-M .0<D
MKC![@$NB^+(-/EUR/7-2ED\G6'MXI'A+"*/;'M#%%VH,D@%L9.:Z+4/$FE:7
M+/'=W+*;=%DG*1.XA5B0I<J"%!P>OIGI7$7]A?S>#_&UK'I]XUQ?:E)+;1_9
MVS*I$8!''3Y&_*IO%<>IZHGB:SCTB^*3V"?8VMH=@N#L.?-;@EE)("'MV.:
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MA:2:%T4A50DDD8!RQXZX ..:F/BG1T^V"6Y>%K.(3SI-!)&ZQG^/:5!*\'D
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "HY8(IS&94#>6VY0>@(Z''M^E244 %%%% !1110 4444 %%%% !1110
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MP19Q';3FYMY/./F0R$DEE;KR2<@\')JQ-X:TVYTV_L;F-YDO_P#CZD=SOE.
M 2PZ8 &,8 Q0!IV\1@@6,RR2E?XY""Q^N *Y/Q)#)+X]\**MW<1(_P!JRL;
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *:[I&C.[!449+,<
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MS;1ZGXJM;4Q+%'JI9(HB,*#%'G '3G/XYIOVF*'XCZI#K1B6WGT^(6)GP$9
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M<LK!25&,G'0CN:OZI:Z-IOA?PW#9W#26/]NV[02717YD,N6V\#Y.N.,8]L4
M=MI]_<0AX]9N]-$DDI^RO ^P31D#!VL3@Y)'!-:4MU;V^[SIXH]JESO<#"C@
MGGMR.:\P\:WVG,GC"RA,%M<KIT6X2$L]R C,GE+G"JN>2 ><],9K2M_[(U'X
MD6<LGV2X67P_O8OM8.1*N"<]>,X/I0!W8O;4O$@N82\PW1+Y@RX]5]1]*62[
MMH9XX);B%)9/N1LX#-]!WKR*S33(/A]H-Y']E6XBUY%68%=RJ+M@ #U "=NF
M*TKF?2+Z^\1:)XDU.YM;J6]\R&%%0//%\IA,1*%B>,84\$>] 'J-1SSPVT1E
MGECBC'5Y&"@?B:IV>KV%QJ$^E17:O?VD:-/"3\Z!AD$]CVZ>M<[K^H1Z?\0-
M#?5)%ATIK:=8993B-;HE<;B> =FX#/J<4 3Z7K^IZMI&LS1R:;%<6>H/:PRR
M;O)*+L.YCG.2&/3VKI)KRUMY%CGN88G?E5=PI;Z UY'>RZ6W@#QBL3VI1->,
MD0!7"YDBPR_4;L$=LUO^*KF2TU'5=0L;BSU"$0PK?Z3<<.Z 91X&'.3NX&,$
M@XYH [V:]M+?=Y]U#%M(!WR!<$].OK@TMQ>6UHBO<W$,*L< R.%!/XUYZ+#P
M[<^,O&<>L068C,%M(5G"@J#$VY@#_%TY'/2J&F7 L[+1--U<K;ZH= =3->$L
M6C9L"%$)P9,!<]2, 8.> #U*2Y@A"F6>- P)!9P,@#)_3FF-J%DC0JUW K3
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M] &OY:9)V+DG<>.I]:YJ/P[JT-S<*NJ64]G/,\I^U:?YDR;CG:'WA2!T&5.
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M#'/((Y!Z4 :WEIQ\B\=.*/*C$ID"+YA&"V.<>F:CM;@7=I%<".2,2H'"2##
M'U'8UE>(;VRM9=)CO)+V,S7\20&V+*&DYPKD<;3SD'KB@#9$:#.$49ZX%)'%
M'$"(XU0$Y(48R?6N;A\7+_:VOPWEG-;6>D*IDG;:1C87).#GD$8 'UQG%;5E
MJ7VRYFMVM+BWDB1'(F"X96W8P5)!^Z: +A4'&0#@Y&>U-,49E$IC4R 8#XY
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MW MYW6V;9$2NX,Q[+CN:>OBNP-Y90217,27ZLUG.\8V7&!NPN"2"1R 0,]J
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MNU))H+VWDT^$7$L<MN0S1'.'4#)(^4^A&.0* -T1H#D(H([XH6-%QM11MSC
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M3WVCTYV** "F+%&I<K&@WG+8'WC[^M/HH ;Y:;=NQ<>F*-B\?*/EZ<=*=10
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M1B0.2>.0>O/MCFL37O#7B+6?[<CE33I4O[-8[5Y)W/V-MA#(HV<[C_'P?4<
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MK9I>/&3L*HX.U>A^<[6POMR1D9K7NF>(=.\57.K:&MC=6^H11I<V]W*T9C=
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M_<SVZ]\9(!:MO&EI/I4%S)#]FNI;J2S^S3RJNR6,MO!?IM&TG/TXR<5=\/\
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MD1_-\O'3/&:H75MJ<_B'R=.MK">ZL],BM+Q%OV@D&[)VDA#N7&"#@$;C@\\
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M-IA:W-WIKWMS-$JDDJXC 0,"!DDDY!X&.^1:_M36X;S3]"O)%DU"2">>:XL
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M2[6.-[Z]25X_-8A%6,#). 3U91^)]* ($\+PQWVHW@U"^,U_;I;S%C&?E4$
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MM+BMI-2U4636DVJ7'GM$XPZJ%"KN'8GEB.Q<U;US0X==@MH9KFX@6WN([E#
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M%B?E( "@9K!\)Z%YGAOPZ^H2WCO86\;):W$800RB/:<C:"2N6 SZ]S@UU]%
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M/+,HMXEFN,6[GR$8D*7&,KG!Z\X&>E)>>+-(LKV:RDEG>ZBA$[0PVTDC&,G
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M+!U='Z-N"X&,GYN<8-5K[3=0G\'^-K./3[HW&H7\LEK'Y1S*K*@!'I]T]<4
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M2Z1>LDU@@LC HC64[/F\TY#%@V0%.1CH.]:^LZ;JDS:%K.DV[PZA&OV2=),
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MN8NQ#+D[A@8(/H35&R\0ZCJ<&GZC8Z:D^F7DYCRLF)(XN0)B#QCC[HYP1]*
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M -M\L<MQT& ,GKQC&;X?1?V+<V,5])%(;X75I,HYM4$A=47V&^0?\#-=K10
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MFB"D0L_3@L&(]P#^-6-2\;V6F^(HM"^P7]S>SVWVJ$6Z(RR)ST)88/RGK@4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %<[XXT^]U;PE>:?I]L9[F8Q[5WJH&'5CDL1V!KHJ* ,;5- M];EMKJ>?4
M;2:%&5?LUTT) ;!(.P\_='Y5A>'-"U3PII6LS06]SJ%Y-?2R06TU]P\9DX;<
MV0&*DDGJ<<UVU% !1110 4444 %<5K.E)XCTSQ+I5W$L$=ZP>VF>:,C>L:!3
M@,2/F3\J[6N6;X<>#G<LWA^S+,<D[3R?SH XOQ=X.OKKX<:)X<TORKJ[M98Y
MKB5[E%!(1@W+-D\L /8"MG5-.O[WXF:)KT5M&+*ULI(93)<19#LK@<!N1\PS
M6U_PK;P;_P!"]9_]\G_&C_A6W@W_ *%ZS_[Y/^- '%6'@647^J)9DZ-IVIZ9
M)%=6KW221"X88!C"L3M'7G!QP.N!K^'K+6Y_ \WA36;:TM EG+9K?+>(X=2I
M52JCD8R,YQP/?C>_X5MX-_Z%ZS_[Y/\ C1_PK;P;_P!"]9_]\G_&@#F_".D7
M>GZ+%9ZGX?TR.^L(9(HK]9XG>8%2!LYRI((!)(X'OQ@6_A'6XO!GAG2VM83<
MZ;JINY\746-FXG@[N3S^E>A_\*V\&_\ 0O6?_?)_QH_X5MX-_P"A>L_^^3_C
M0!PWB_P[XG\1CQ%$T-C)%+-$VGD7J( BGGY.A<C&68CH0.*VYM+U&3XCZ3KI
MMHOLEKI)M9=MS&2)"'. "PR/F S_ $YK>_X5MX-_Z%ZS_P"^3_C1_P *V\&_
M]"]9_P#?)_QH \ZM_ ^M0^ -+M1':'5-+U,WBVTES&4G0XXR#CL.N.]=!KOA
MEM9TBRO;+2M/TJ^M;^*\:SCFCW3A?O!G7"[N>.>W)YXZ7_A6W@W_ *%ZS_[Y
M/^-'_"MO!O\ T+UG_P!\G_&@#FI?"MWJ>H>-=5EDAM9=9M!:VEO),A(VQA=S
ME20,E1T)[UGZ/H.N)K7@FZNK&""#1K=[>X_TR)FR5*[L XQR#P2>OX]K_P *
MV\&_]"]9_P#?)_QH_P"%;>#?^A>L_P#OD_XT <SH_AF:Q\?6FN648TJ*593J
MD0NHV@G)'RE%#$\D[B" !CCWT_BEIEWXF\)C2]*6*:=ITD),Z(JA<]22/6M/
M_A6W@W_H7K/_ +Y/^-'_  K;P;_T+UG_ -\G_&@#9L+N*/2K<2;(Y4B :(R(
M3D#ID''ZUQOP\T&XTCP7J&C:OY5M+<SS-E)T?*NH&00>HQ6S_P *V\&_]"]9
M_P#?)_QH_P"%;>#?^A>L_P#OD_XT <1:>#-2?0O#7AVY,$4.DZD]U/>"="DD
M8=F78 =V3NQR!C%=-?>&$E^)=MX@MKR&.RFMMFH()%_>LC*8_P R%_!,=ZT?
M^%;>#?\ H7K/_OD_XT?\*V\&_P#0O6?_ 'R?\: ,"]TB_;XCZQK:6=M<V-QI
M#V<:RW$>V63 (5ANR%.,?C6/!X-O=/TSQ39:2)(=-U"T"6VGW%W$Q6<GYB"&
M("@<9)R?PKM_^%;>#?\ H7K/_OD_XT?\*V\&_P#0O6?_ 'R?\: .5TKPY?Z3
MK'A;6S$DSV&E?V?=VJ7$6]2 VUE)8*02?7-9$O@75;?P'IVFQ&WGOSK/]IW*
M+<H%B&TKM!)&3C'3OG\?0?\ A6W@W_H7K/\ [Y/^-'_"MO!O_0O6?_?)_P :
M .;CT6^7QAXNU*:PMKBRU2WCCABEN8\2A0JLK8;*Y .#VJ;P?H>I^$UUYM)M
MIKFP<QO8:7<7D>\-_&=P+*HYX[G'/J=[_A6W@W_H7K/_ +Y/^-:.C^%-!T"X
MDGTG2X+261-CM&""5SG'Z4 ;(Z<C!HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "J8U".35'L(5\R2) \[9P(@V=H/JQP>/09..,W*X7PY=B'3?&]]>7#V[1
M:K=^9.HRT<:1J%('?"@$"@#N)"XC8QJ&<#Y5)P"?KVJOI^H0:E:^?#N&UVCD
M1QAHW4X96'J#_B,BN(T"6:W\9:3"KR1VUUHK2LDEP7>8AX]LD@Z!SN/0GJ>3
M6GX:=U\=^,[=<_9UFM9%'82- -_\EH ZZBBB@ HHHH KWUR;.PN+D0O,8HV<
M11XW.0,[1GN>E8/_  E=U_;RZ*=!NOMIM#>;//BQY88)UW8SD]*Z:N-;_DL\
M?_8O-_Z4+0!IV'B9KW7X-)DTV>V>6P:\+2NN5VNJ%"!GD%NN>W>M6]GNH! ;
M6S-T7F5) ) GEH>K\]<>@Y-<KJ5C#J/Q0@MKAI1$VAR[ECE:,L//CX)4@X^A
MK#M+N[D\$>$9GO;II5UU+9G\YLR1BX= K\_-PJ]<]* /4**X'4;JZTWQ$]SJ
M$#W6ESZA$L.H6LQ#VC;D40R1_P!PL.W'S9(R17>LP52S$  9)/:@#*N_$-C9
M^)+#0I7(N[V*22/T&WL?J-V/]TUK5YIX@L=7U30KCQ#9V4!NHKE-3LI3.=XB
MB'R)LV=&3<=N[JYK;UO5VU/0?#^IZ?*6L;N\@>>)&P\L3 DH!W(."5'4*WN*
M .PHKS36]/OK+PGXRU#[1?V]NP+Z<GVJ5#&@5<X3=A07W8& <>W%7]3B31]4
MT2Q6]ECMM6ED>XDO)GD1Y5C78GWA@-\QV@@$@#&.* .\HKSJZ:XT V&ES:ZD
MUE=:L\<DDBN$MP8BZ6Y;?DKNQ_%T(!XXJ/7M/N='T&\CCUV:7_B:6CQQP,Z"
MV5Y4#1Y+MN4C)VG@9Z<B@#TFBN$CT>"3Q[J>CM<7QT^738;IX?MDO,ID=2V=
MV>@'&<=\<"LG0]9N[_3?!UCJ%\HBOK*<F2YW,+B9&555B&4D[2QY/)]3B@#U
M&HKJYALK66ZN9%C@A0O([=%4#)->>7NGW&GIX?L3KUU=C^W# 7BE>/;$T;MY
M1^8[MN  Q.1TX(K-\0VZQ>&/'^F>9/):64\$ENDLSN8R\<;$9))(R2<'B@#U
MJD)P"<9]JCMH8K>!8H<^6N0,L6/7U/-<-'=76G>*8/[4@>>UN=2D6SU.UF)&
MYMZB"9.P7E01D94'@Y- '4>'];_MVTNIOLK6QM[N6U9&<,<QMM)X]ZUJ\E>$
MVWAC6-8AN+F.\M?$DGE%)V55!NU5@5!P00Q!R#5WQC>L+7Q+?6%U.T]A-;KY
MSS%!:N-AV1 =<YRQ. =V.<< ':G72/%;:%]C?<+$WBS;QA@'"[0/J>IQ3O#F
MMCQ!HZZ@+9K?,LL1C9@Q!1V3J/\ =S642#\64P<_\2-O_1XH^'?_ "*0_P"O
MV[_]*)* -1-<W>+)-!-JZE+,78G+C# OMP!]<]:UZXC4M+M]7^)SVMT\XA.A
M@LL,S1%OWYZE2#^&:Q-+U2_":+I%]J!:REO;ZVBNKK<WVE8FVQ!B&7.1O[\E
M1UH ]2HK#\,6$NF6EW9R:J=0"73E,J1]G4@,(LEF)"YXR>AQVK+UDRR>,);:
MY$UQ8OI1,,-N26CFWD%B!R"1@*W;:W(YH ["BO/;-=2T^[\(:#K4\[F[@GDO
M&>X>3SIU12$+$GC!8[0<$CI36TW4=1B\8Z#:7ERJ64L;Z9,)F#1R-&)#%NSG
M:"0,'H&^E 'HE%<'_;TVJ^%K[Q1IR2))9Z6ZPQ9.%GV;GRO1MA"@>^\5/I>G
M)<7FF:G;>( UK=VSQO# 9,W>5R'+&0E77!^8<\XH [6BO(5LW'P:77_[1U(Z
ME)91AIOMLG/[T?PYQT)'3G)SFM[49+GP_P"*M7&FRW,A;P_+>^5+,TH:='PK
M88G!YQ@8'M0!Z!61KFN?V+)IBFU>9;Z]CM-P<*(R_0GN>AKE[%)%M]-\1V&M
MI,&LY";:-7;[<WEE@&S(<,I4G.,]16:X@O\ PUX'UIKAY[RZU2T>>8R$[W;<
M74C.,!L@#^'&!B@#T?4KPZ?IEU>"%IO(B:3RU(!; SC)XIFCZ@-6T6QU(1F(
M7=O'.(R<[=RAL9[]:9KO_(O:E_UZR_\ H!KS^PT]]-TKP)J6GW=Y]KO/LMM<
M0M<.T<L+0DL-A.T;0N1@#&* /4**\]3S].U;5/"#S7+/J,RW%C.TKLRV[?ZT
M!B<@Q[6QS_$M=\QCMK<DG9'&F23S@ 4 245YII%RZZYX1E@N9VMM0ANM\\TY
M\V[7R]P>11PO/(Y) ...E4=DL/A2XU9;Z^:\L_$!BA=[N1@J?:Q&5()PP*D@
MYR: /3M3O3IVEW5Z(6F^SQ-+Y:D L ,]3Q2:3?C5=&L=1$9C%W;QSA"<[=RA
ML9[XS7%7,R:[_P )O'?R2"73PT-O$)"ODQ^3N#@ ]68L<]P .E=1X0_Y$K0?
M^P=;_P#HM: -FBN"L'@\06VM7%]J=Q9WUAJLB>9%*5:WCC<;%"]-K*.>/FW'
MK2Q.==/C 7UQ-!=6%R\5L4E9#;1K$K)(N#P2=S9[].@Q0!WE%>;:6UWKNN^'
M#JL]VAO= >:Z@CN'C5WW1<X!&W.<G&/0\<4W2WUBY\(Z:+-DU&2TO;M6LKJX
M*M=0QR.@7>>I4%<;N.!Z4 >C2W,,$L$<LBJ\[F.)3U=MI; _!2?PJ6O,0=/U
MC4O!-PD=Y&ANKV)X[F5A)$523<A.>S#&<\@"M30])BU/Q-XB-U=W\B66I*8$
M^V2;5!A0D8W<CYCP>!VQSD [JBO+],O[A_"'P^N)+V<W,^H1QRN9FW2KMDW!
MN?F&0O7VJS!]H\0VNI7C:['IU_8:G*K/L=GMU24A4V[P"K( ,8P<GJ: .XUO
M4_[&T2]U+[.UP+6%IFC5@I(49/)]A5BRN?MMA;7039YT2R;<YQD X_6O.]1F
M37O#GCV6^DD^TV#W-O#&)"ODQI%E" #_ !<DG^+..@Q7>:'SX?TW_KUB_P#0
M!0!?HKS*2^)NM$U*QNYI(KG7W@:[EF(>9"9 T>P<>6NT 9Y^4' SFJ^J0.=&
M\=W?VZ_\[3KMI+1A=R?NF$,;#'//)Z'( Z8YH ]3D9EC9E0NP&0H(!)].:S/
M#FM+XAT"UU58&@6X#$1,VXKABO7\*P;2Z&N>--2TS47<16MA;R6T(<H'\S<7
ME&",D$*H/;MC-3_#0 ?#S20"6PL@R3G/[QJ .LHK@+H2^(]9\2Z;+JR6%Q9N
MBVY.\/!&8E82KAU'WBV3CL 3CBEBL!JGC6XL;S4+RXMGT.WE;RYY(E=R[@N%
M#?+G .T<>N: .OU;58M)MH9)%+R3SQVT* XW2.V%&>P[D^@/7I2Z7>7EW%/]
MNT]K*6*9HPOF"19 ,$.K#&0<]P#P>*\Y);5_ ?@.[OY99KB34+1'D,C L,L.
M<'D\#GK70VB)K/BKQ%I%\\RPV$5O':(LS*41HR3(I!SNW9&[J-H]\@'9T5Y7
MILM]KJ^!QJEY>!KR*]CN/*N'C$Z(I",0I')&#D<\]:UK2"VU2^\1Z)>:A<VS
MZ8L,-J_V@B2"$1*1,&)Y8MNRQ] #0!WU(Y*HQ52Q R%'?VK@9F?Q!KVKZ-)J
MH@,-G UHT@=7VLF3.NUU^8-U.., <9J72IVU/Q2-%U.^:]BM=)@EA<9C%TS$
MAYL \GA<>F21UH Z7PYK0\0Z'#J8MVMQ*\B>4S!BNR1DZC_=S5L3W7]J&W^Q
MG[((0XNO,'+[B-FWKTYSTYKG/AHH3P'9(&+!9KD;F.2?W\G4]Z1U=_B9>6IN
M+D02:(LAC$[@*QF92R\_*< =,=* .NHKRK1/.AT'P%J_VV\>]N[I+>=Y+EV$
MD;1R$J5)V]5!SC.1GK7H/B6[AL?#.I7,]W+:1QV[DW$(R\?&,J/7TH U**\T
M>_U#1-9U<6B&,Q^'#=Q6WGF7,JLP5V'3>1UQG/J:U[1;5-*T[7]-U*XFN7T^
M0K#YI=;U_+W9<'/S J?3&<>U ':45Q/A\6M]I'A_7XM4N'O)(#YJK-D7DK)E
MD<<_=8$@#&W'85B_;;N?X:V'BFVN)FUW[1&S$2-^\=IQ&T++G&WD@+CC [T
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MQZ]>3@T =_16-X8M);#1ELYM5.IM!(Z"X92#C/"DDG=M^[G/;U%;- !1110
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MB@".7PWHL^L)J\NEVKZ@F,7!C&_(Z'/J.QZBI+K0]+O;HW5Q9123,@C=R/\
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ML4B0*"3U)QU-,DT?3Y;][Y[5#=/%Y+3<[BG]W/I[5&FOZ5))8HEXC-?KOM0
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M$H5(XU"JH] !4M0VMU!?6L=S;2K+#(,HZ]"*FH **** "BBB@ HHHH ****
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M"TA0-%(H)503C) _&L*\BEE_X6*1976Z\MU6#_1GS,?LVS"\?-\W'&:]'HH
M\U$SZ7JUG=ZG8ZM+IU[I-M;K):)-NAECW;D=$PW._N.HKN=!L[>PT.UMK2R:
MRMT4^7;NQ9HU)) .2>>>1GCIVK1I 0PR"".G% 'F]Q)<V]OXSE72)KL2ZE#(
MD<MH[*R!8E,BKCY]I4G _NU=T*U%[XJ\30W4&H36>I6=LHFNK=HQ*H617ZJ
M/O ;< ^W>N\HH \NCL/$EMINE:I]FDEU#0;C^SXH3_R]P%C&TGT(\H\]/+)[
MUO:]I*0IH\$.H7MA?VT4IAU*&$R)O.S>)5P00Y.[G'*\&NSHH R?#,M]/X;L
M9-2MDMKQH_WD2*5 .3@A3R,C!P>F<5Q8MKI?!WB;PW>V=Q+J=Q/=&W_=,5N?
M-8M'(&QC )&<GY=O.*]*HH XLQ3VOCKP\DRW$WV;2Y8)KD0N4\PF/&6QC)VL
M>M:?CNTN+[P)K5M:PO-/):N$C099CCH!W-= 2%!)( '4FEH XF:X%[XV\,7J
M6EX+>.RN@TDEK(H0MY>W.1\I.UNN/UKGXHKZTTV#4/[.U&6ULO$%Y/<6\,<D
M<IAD\P+(@&"0-^>.Q/O7JH((R"#]*6@# \,1:<PO+_3K"[MH[MU=Y;OS!).P
M&-VV0[@,8&3C/TP35\1II&K74VC^(-+>:Q$"2Q7)@=E#DL& =1\C *I[9S74
MT4 >6_V?JMOX#>*47]Y:VFM0RV1EB9K@V:2H02N-QQAB.,XQQBI_%4]QJ \4
M6L6EWT+7&F*;<P63;KWY&/SOMXVDX"$@\GKG%>ETA(&,D#/ H X>U:9/&>CW
MIM+U8;C1#:K)]F?Y)/,0X?CY. 3\V.E9WA>&WEM=*T75M%U5M8TN9"3*TWV=
M60X$ZOG9C&2!W)QBO2J* .;\>65]?^$KF+3HFFG22*;R%ZS*DBLR#Z@'COTJ
MHX&M>--$UBQ2=+>RM;C[5))"T>0X4)&00"2""Q';'/45U]% '*> MZZ;J22P
M3PLVJ74JK-"T9*-*65AN R"#5;6[.YTCQ_9>*H[::YLGL6T^\6",R/"-^]9
MHY89X..G6NTHH RAJ2ZI \6F^<2\;#[0T3(L9P<'+ 9.<<#\<=^'BL[K4/A]
MI'AS[)<6^M6=S;HX:)@(3%("TN_&""H)!!YW8ZUZ;29&<9&3SB@#S:_@EDLO
MB,JV5TSW@Q;XMGS-_HZH-O'S?,".*T=.)_X3K3KI[:Y$2>'_ "C*UNX"R>8I
MVDD<-@'CK7< AAD$$>HHR,D9&1SB@#R;3DO-,T#PQ?SZ=J;6=E->Q7D,$<L<
MT0DD)CDVC#$ #MV:M.[B333I/B#2M%O_ .S8M2EN;N$K(\\GF1%#/Y;9;@D\
M=<<XYKT>B@#@O$/EW_ALZAIND7$4)U2UNY-MJRS3!9$+R&/&X\#N,G&<8Q4U
M\EQ?>/#);17,(FT"6".=X'54D:12H)Q@''.#R*[>DR,XR,]<4 <1X1OH[K3M
M%TN[T&YBU32HEAD:XM2J6Y5-A=9",'<!QM))SZ9-<^IN(?"EKI!T[4&O++Q
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M^*I9+:94E^R^7*\#!7V1D-M8C!P?2MC0-#C\/Z<UE#<S3QF624&4+D%V+-T
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MAF48\Q&V9 ("^G3O5ZW\/ZI!K^A7LMQ#<QZ?ISVD\TDC"65VV9?&TCJG<]Z
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M&VU?3+;4+-R]M<1B2-BI!*GIP>E<G:)<OX\\5[[^Y>**SMML+;-N&64[?NY
M!R>#GGG-9/A:]U32]&\"D7_F66H(+62T\E0JCRF96#?>W97GG!ST% 'IE%</
M:ZOXAUJSM]6TLD1F\=7@E,0A,"R,C#/WP^%SG.,]L5V[ LA 8J2,!AC(]^:
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MZM>:9"[FZLU1YE:-E #YVX)&#]T]*GOK^VTVT:YNY1%$I S@DDDX  ')))
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M[*9C'D9&["<9'(J[9ZO8:C8/?6-TES;INW-"=Q!'48'.?;K7-^&_^2C^-O\
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MO?S;3'&N[!+/D8=0,@!>N/>NKABC@ACAB0)'&H5%'0 # %/I&8*I9B !U)H
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M;29)9(WB9]V-K$ Y[@C!_&@"&Y\/65_IEU8ZB9+U+I DSS$;F Y&-H 7!Y&
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MVT?2XH'OQ9M>?Z02$(W;57CN3GGMCH<U/J6N0Z)X>.JZK&82D:EX(SYC>8V
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MR00223VQCC&,5N&1 &)=0$^\2>GUK.&HRZAIEK?:-]GGBFD0[IG*J8BV&9<
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M4],D;37M;S2(=]M:$>4Q#R#'7YF"_P 6!QC@5W4>EZ?%YGEV-LGF*5?;"HW
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M^]>A)86<<XG2T@691M$BQ@,!C&,XSTHM["SM)99;:T@ADF.9'CC"ESZD@<T
M<3X6;PQJ]GX?O(9HY-46W:.6-'!D=F3$OGKU89!)+=\>HSS8@TU/@Q?B*.V6
MYBNV,NP*'4B\(7=CGID#/:O6H+"SMIY9X+2"*:8YEDCC"LY]R.3^--?3;"1'
M1[*V9)'\QU,2D,W]X\<GWH Y9!!J'Q!US3M:ABEA%E UC'.H*F([O-90>^[
M)ZX KF=,M6O%\")J>Z?==7L4;RL=TMN(Y/+W'N"NWZ@^]>GW&FV-TD27%E;3
M)%_JUDB5@GTR.*?+96D\D<DUK#(\?W&>,$K]">E '+^!(H;27Q+96RK';6^K
MR+#"@PL:F.-B%'89)X%5O%,$.C>*K#7!8K<QW\+Z9<Q! ?,=ANAS]64H2?[P
M]*[&"RM;5G:WMH86?EC'&%+?7'6I71),;T5L$,,C.".AH \^\':>\<J^&;VV
MC<^'[EY3+Y?RR!QF$C/L[^X,8K&U.VM?^$$\<IY412'76900"$Y@R1Z<$_K7
MK0C179PBAFQN8#DXZ9J!-.L8TE2.SMU288D58E ?Z\<_C0!QMQ8Z3J'Q$TZU
M$%K-8?V-/B%0#$W[Y.-HX(SGCID>U:'PX;_BB;:,-E(I[F).<[56=PH^@  K
MH?[-L/,63[%;;U78K>4N0N,8!QTQ4EO:6UHA2VMXH4)R5B0*"?PH \M\7WMA
M)!XDN+>6&*ZM=0ME:2Y<&?>IB_U0X*( 2<\Y^?@=:U)M,TG5O&WB87$$%U ^
ME6\H#?,A)\WY\=,XQ@]NU=W)IUC-)+)+9V[O*H21FB4EU'0$XY%(=-L&D>1K
M*V+N,.QB7+#T)QS0!YU'"8O WA+Q@(Q/=Z3;1/<,1N:2W*;9/J5!W#_=/K7;
M^';91:3:DT(CN-2E-S)\N&VD8C!]P@7/OGUJ+4-'O;B6.RM);*UT1T*W4"P'
MS'YY"D$* PX/&>3^&[0!P\VE:=J'Q1U"WO+6&>&31H7DBD&Y6/FR#)4\$X ^
MG%<UI5K;1>$? FJJB_V@VIPVYNB<R&,F1=FX\[< #;TKU1M/LGF:9[.W:5QM
M9S$I9ATP3BF?V3IOEK'_ &?:;$.Y5\E< ^H&* /,M6O].:X6]M9H(7B\3Q+(
M]Q(#<$B14?GC9&!D '/R^G2KYM-*DUSQ_&UO9M-)!&\*E%+-FVW$K]2,Y'>O
M0&TVP9Y7:RMBTI#2$Q+ER.A/'..U2_9H!<-<>3'Y[+L,FT;BOIGKCVH \PMK
M[3;33/!44D]I;:3/9%9Y-B-%]K\J(KYG;=C?U[T^_P!)TFWL?#\%I>F]LW\1
MJ$?<-BJZN6CC*\>7GC [Y':O1VTVP>R^QM96S6I_Y8&)2G7/W<8ZT/IMA+'%
M')96SI$,1JT2D(/88XH 2QT^VTG34LM-MT@@B#>5$OW022?YFO,EW7GPPMM3
MA 'BF*]4>;C$_P!K\_:R-WP02-O3;CL*]8JL-/LEO#>+9VXNCP9Q$-Y_X%C-
M '&Z3HNF7WQ"\3O<6T<KVMQ9SP@D_NY/*SN ]<U>\?7ILK#2?.;9ILNIPQW[
MG[HA.>&]%+!0>V#@]:Z:*RM()WGBM88YG^](D8#-]3U-230Q7$+PS1I)$XPR
M.H(8>A!ZT >?1Q:2OCGQ-!;?91'-H\+-'$5 8@R9.![;:JZ?;7ESX2\'R::]
MC<7<.EEO[.OA^[N4VQAB#_"Z\ ''\1SQFO0XM*TZ&,QQ6%K&A3RRJPJ 5SG;
MC'3D\4CZ1ILD21/IUHT<>=B-"I"YZX&.* /.[2'2-<\0>$O,L/*L[G1IT%I.
MV<A#& A[,!@D>HYJDEI'INFVXR!IEEXN1;*20Y$4&0" QZ('W#\*[K4?#KW_
M (KT_47ALY+"UMI+<P2C).\J<@;<<;.GOVK<DLK66S^R26T+VVT+Y+1@I@=!
MMZ8H \PUEM/NV^)20FWE!T^&557# LL4F6'N#W]:NSWNE0ZMH5G<7%C;:-/I
MS>2[1HUNUQE=P.?E#;>A/J1WKT*.RM80XBMH4WJ$;;&!N4# !]0!Q3)=,L)K
M-;.6QMI+5<;87B4H/HN,4 9OA*SM=/\ #\-K87TM[9QNXAFD((*[CPI'50<@
M>P]*W*1$6-%1%"JHP% P *6@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "J>HZG:Z5#%)<L09I5@B1
M1EI)&Z*!Z]?RJY6!XK.I+:V)T^TEN(_MB?:A!M\U8L')3<1@YP,CD G&.H %
MF\8Z/;Z3<ZC/+-'!:W'V6X#0MNBER!M; X^\O/3D<U7F\0:9?7NF*;C5+20W
MS0Q1_9Y(EG=4)*ON7E,'(Z9Q[5RESHVL#PUXHL(]%NQ)>:M%=6ZF1'+IF$GY
MMQY C;.3U[FNI\36]U>:GX9FMK.>6.VOQ<3E5'[M/+=<G)]6' H U5UVTDNU
M@19G5IVMA,L9,?FKG<N>V-I&3QD8SFLJ'Q+HVFZ?K.IR7]_+;6]\T<_GQ.WD
M283Y%7:"J<CKQDGFLR/2+Z#Q.E_I,-]8O+J#G4+:0[K6>'+?OADD*Y 4\8.3
MR,9-4-0TG59_"_C&TCTRY:>_U/S[5, >8A\KYNO'W&ZX[4 =I9>(].OM2N+"
M-IH[B"(3$3PM&'C)QO4L!E<C&:@3Q=I3RV*!KG;J&39NMN[+.!U*[02!CG)Q
MQSTYK-NX)7\<OJ,]G*--_L1[>2:3"(&+ARI)/'R@\]!ZU@>'Y&MD\.KJVC:W
M#%IJA+5W@C,41D&P;V5R6 #;0=HZY(] #T+5=3MM&TV?4+PNMM I>1D0L54=
M3@<U"^NV*:C#8,TOGSV[7,0$3$.BXR1@=1N''7FH?%FGW&K>$=7T^U4-<7%I
M)'$I.,L5.!GZUSUM_:=UXIT#4FT2]@MK;3YX)C+LW(Q\O^$-T^4@8Y/ICF@#
M6M/'&B7IL##)<F*^E,,$S6SK&9,D!"Q& QVG /-4_&WB!;;POK@L)[M+FS@8
M-/:H2(9-N54MV/(SCH",XK$M-)U6+P7X:LGTRY%S9ZPES/'@92,3.Y;.<'AA
MP.:+K3]:M-"\8:%_9-U=/J,ES<6=S"5*.LHX5LL"&4\8[]J .P;7K>PTZ$SB
MXGE2U2>988S(R)C[S8]<'W.#@'!JO<^-M$MS %FGN#<6INX1;VTDGFQC'*X'
M)YZ#ISG%<_)9:AINNB^N?#$NJV=]8P1/&@B>6UEC!&TAFV[2&Z@]JT(-.NK?
MQGHLZ:4+>S@TZ:!Q;*!% SNC*HQC. IR0,9H Z:\U&.STF;43%-)''"9=B(=
MY&,XP>_U_&N,N_$UQ=P^#-6\RZM(KV=?M%NJMMD#0,^ ,9<9QC'6NUU.![K2
MKRWB ,DL#HN3CDJ0*X:ULM5.F>!HI-(NXGTN1%N@VP[ L#1EN&/&X\=\<XH
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M3/:SMG&()1\S>Y5@K >U0>%_#MUHNK7ULZ@:3:RN^F MD@2X9Q_P$A@#Z.:
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M'EQHL_F;E8'YB0, #G)YQ3]0TJYUG5O'MA9E5N)H++RB_P!TLJ%@#[' !^M
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MQ+=S^&-,FO9%DFDM8G+KG)R@.3GOZUK4 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5C>(]!&NVMJ(
M[@VUW9W*75K/MW!)%]5R,J02",CK6S10!B0:+<#5;G6+B>!M1DM5M8MD9\N)
M Q;IG+$L<GD= /<O\+:+-X=\.6>DRW*7/V5/+658RFX9/49-;%% '$S^"-2D
M2YB36H1$VK+JD1>T+.'#A]KMO&Y1C Q@X YQQ5R7PI>2/XF8ZC#_ ,3N%8N;
M<YAQ%Y>?O?-QSVYKJJ* .%URWLKG2+#P<U^6UR!;=X&MT97CV,!YPZA0%#9Y
M]NXKMK>"*UMHK>! D42!$4=%4# 'Y4_ SG'/K2T <P?"TUUJ^G:A?W%O)/I\
M[RQW,4)29T(8"-CD_* PSZ[1P.:SG\#ZC_9QTV/6($LH]2%_;@VI+@^;YNUS
MOPPR2. /Z5W%% '*)X7U2RUJ^N=+UI+:QU&0374#6V]DDP S1-N^4L .H./>
MK'_"-W2ZSK%_'>PA=0M([98VA8F,(& ).[YOOGTKHZ* ,O0=+FT7PY8Z6TZ3
M26ENL"RB,J&VC )7)]/6L"'P5>0^&=+T@:G 387ZWHE^S'Y]LID"XW\<G&<]
M*[.B@#C]7\&7>JW.NRC5$@&J6T, "P$F/RF+#)W?,#D@C X-2KX3OIM3U&\O
M-4A8:AIPLIHX;78%QO *Y8X'SG@Y.>X'%=710!R2^$]1%CX>7^UH/MFC/\DO
MV0['3RC%@KOSG!SG/7MCBEB\+:K8:M?-INN"#2[^9KB>W>WW2)(WWS&^1MW=
M>0<'I7644 8FFZ)<6'B75]5>[BDBU 1 0B(@Q^6I4?-N.<@^@HUS07U*_P!,
MU.TN%M]0TV1FA=TWHZN-KHPR.",<]B :VZ* .1U7P9+JFF:U&U]%%?:NT7G3
MB$LD:1XVJJ[@>QY)ZL?85UD8?RE$I5GQ\Q48!/L*=10!PG_"!ZE%X??P];:S
M NEQW*3VOF6I:6)5E$FPG> P!'' -;#^'K\ZYJFJ1:G%%+>V"VD>VW.867<5
M?.[GER<>PYKHZ* //O%.@)I^@^*-;G>UBN;K29+>1;:/RTE;#'>P).6.<#T'
M<YK:TK29=1&A:E>W4$R6$&ZW6!" SL@7>Q)/120 .Y)S73,JL,, 1Z$4 !1@
M  >@H XA/ ^I1Z=:::FL6ZV=CJ0OK8?9"7P)#)M<[^>6QQBKMWX,-]=>(%GO
MA]AUE4,D218DCD5 @8/G&/E#8QU[XZ]710!A:%IFN6A7^V=:COQ$NR+RK?RM
MW^U)\QW-CTP.3UXQ%JGAV\O/$7]IVVI)#')8M92Q20>854L6W1G<-K'.#D$<
M#CBNBHH Y#3?!]]8OX9+ZG!*-$ADAP+8KYH9 G]_C 4>N3GITJ&7P+<R6=QC
M5(X[W^UFU:TG2W.(I#U1E+'<N,CJ.M=K10!SVEZ%J-MXEN]:O;^VE>ZMHH'A
MAMV0 H6(()<_WC_]:H-6\+7M_K&H7<&J1PP7]A]BECDM_,:,?-S&VX!<[N00
M>GY=110!RMAX5OK2_P!#NI-2@E.EV+6>T6Q7S P49SOXQL'KW_"L(--\*Z%=
M:9K]]%<1ZK<W#)&D# RF4EFC !;)^; _"NSI" <9'3I0!C^%=(?1/#5E93.\
MEPL8:=W;<S.1SD]\=/H!5&]\-ZE'XEGUG1-6BLVO(TCO(9[?SE?9PKK\PPP!
MQZ5T]% &!-X>N'\0Z5J:WX,=A;26Y22,L\N_;EBV0 ?D';N:Q[#P1J=FNAHV
MM02#2+B22,_9"&E5U96WG?R_S?>Z9Y(-=O10!QMWX*O+O1_$>GG4X%&M7/GE
M_LQ/DY"@C&_YN$'/'>M1]#O)/%5KK9O(/W%D]J81"?FW,K%L[N.5'&*WJ* ,
M7PSHDV@:9)9S74=P7N)9PZ1%,>8Y<C!)Z$UDW?@R\GT_Q'I\6J1):ZS*\H#6
MQ9HF=5#<[AN'R\<#KSFNPHH YJY\,W=UK%K?MJ*1^3I\MD1%"0QW[<NK;N""
MHQP:IZ9X.U*RNO#\TVK6SC1X9+<)'9E!)&P49^^<-\@R>G/3O78T4 8GAK0[
MCP_9SV;WB7%OY\LL $.QD#NSD,<G<<MC( Z=*IZCX6FU:\@>]N+=UMKU;NWG
M6$B>%5;=Y8;/0],^AQCH:Z>B@#B=2\$7]Y::_I\&K0PV&KSFY(-L6DCD(4,-
MV[!7Y,XQGWJY/X9U:'Q!-J^DZS#;27L4<=]'+:F1)&0861!N&UL<8)(KJJ*
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M5O4?!%_>6>O:=!JT,-AJUQ]I(-L6DCD.W<-V[!7Y,XQGGK7:JJJ,* !["EH
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6BBB@ HHHH **** "BBB@ HHHH __V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>40
<FILENAME>exhibit1018-arvinasxcons008.jpg
<TEXT>
begin 644 exhibit1018-arvinasxcons008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=S",;5)QT!/ &3FL-M(UFQN+2\CTJ6Z,&O7=X88I8@QBD2158;F _C'&<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 5S\NKW%]<:O%I\JQ1Z8A1Y2F_?/LW;<>B@KGU)[8.>@KB
MO"UO-##XRLI%)N#JUS*%[E9$5D/Y''X4 7/"?BVQU;2M)M[K5;5]9N+..:6
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MRS[=JLX! X[C(]LYKGHM1N-'\8^+;N#2Y;IUM+.>6))5 7"2%OF;J?0#K[4
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M%$TC+&#@N0H) 'K0!S5KX8UB#3_!]NR69;16'V@B=L.!$T?R_)S][/.*H?\
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M \@$D \]: ,_2]6\1ZM!HVK6<;&TO=KW,4WDB*.)QP4*MO+*<<'KSP.E9?\
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M[ ,#CGFKJG=\5U;UT+/_ )'I]_X%LM0;51+J&HK%JD:K=1)(@5V50H?[N0<
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MK:9I99GA%PX%O\L?S&0'[Q ;Y1QSW&*A^&UQ')X8D@2>.7R+VY0",\*GG/M
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M[.K /G[P!Z ]*U_AC'91>$D2W2W2X$\XG$8 ?B>0+NQSTZ9H ZI'O3JDJ/%
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M-9U0V5I+%9J'MU\]@73:-Q;Y>"#G '4=Q701OO13QD@$CTKRS7$2/2OB='&
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M L'DQ*[$ #;@9.">E0QZ[ITVH_8(IFDN#:_:U"1L0\60-RMC#<D=#63<^-[
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MS5^^LKR-M,\1:1X:>W%I>F::PVHEQ.C1M&SD XW#=P"<X'OBNZ6_LW^S[;N
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M%TW0L?FW') 1LDGVR36MKVDW^L^)-86UAFBCO/#YLHKAT*IYI=VVGN.&'/\
M6N\HH \]5]5OYO!Y;0+^"739R+M650J?N63(.[!7)SD=O?BJEK;:W<7?AN\N
M]$OENK2_E-VB;%AC#)(H\M0V-O(^;&3W)->FT4 >9WNEZJ?!'BK2!I5TUS<:
MA/+ 5 *S+)-O4KS_ '>N<8Z=:WXTG'C^^U$V=T+2328H5D\EOF=7=BN.N<,*
MZVB@#RNP@OM&TOP<?[*OVU.PMITECAB61D0[00T99<@DJ0P/!7OFNP\&-:1Z
M=<6T%O?P3B=Y[A+Z'RI&>1BQ8#IM)R!@GIBKVI^';+5+Z*^:2[MKR-/*$]K<
M-$Q3.=IP<$9YY%7;&P@T^$QP^8Q8Y>261I'<],EF))H X#5M-U3^S/'6GQZ7
M=2OJ,AEM9$ *2!HD4 <YSE3GCC'TJ]JNF7FJ>(+3RK>XBADT2YLVG:,@122;
M-H/_ 'R:[%]0LHKQ+.2\MTNI!E(6D =OHN<FBWU"RNIY8+>\MYI8?]9''(&9
M/J >* ./\+0RRMIUO?\ A%K/4+!=LMY*B&,$+M+1,#DEOH, G)Z9TO$=O<2^
M)_#$\-K-+#:W,LD[QH2(U:)D!/XD=*Z>B@#@+JSN-/\ %.L)>^&9M9L=4=)8
M)H51PI\M8VCD#$87Y0<],&KNGV=Q9>+]1G;3Y(K7^RK>WC,$1\O>A?*)[#<,
M5UL=S!+-+#'-&\L) D16!9,C(R.V1SS4M 'FUEINHP^$_ ]H^GW0N-/OHI+I
M/+.8E5)%)/KRPZ9J.2VUR[;2)[G1+[[79ZX9ITB*+ L7[P QKN .0RDL1G).
M37IM% 'F>L:9J5QH_C6"+3;IY;^]BDM5$9_>J%C!(]/N-UQ703)/_P +!&I"
MSNC9_P!CM!YHA;'F&0.%QUS@?TZUT\ES!#+%%+/&DDI(C1G +D#) '?BI: /
M-=#TS4;6T\!13Z?=(^F^<+O,9_=9B9!GUR2.F:9>V5S'INNM)I][Y\WB&.\L
M1&H#M@1X=%8@-C8YVG!P.W4>FUG:OHMGK<,4=V)5:"3S89896CDC?!&592".
M"1^- &#X8NH9O$&HW%Q9:G:ZG?QHS?:[7R49(AM 3#,.-^3DY^;T'$=S=K:?
M%C>\,\BG0P"88S(1^_/4#)_2NDT_2(-.)=9;FXF(V^;<SM*P'H,]!P.F,X&:
MKSZ;86>M-XAN;MH9A!]F9I9%6,1[MV.1_>YSUH X[3]!O]-U'P]*UC-L&J7M
M].D:[A;),KA%)'&1N7.,XYK9M(;W0_%'B&2XL;B[M-3:.XMI(4WY81A&B;^[
MT&"?EP>HKJOM,'VK[+YT?VC9YGE;AOVYQNQUQGC-$MS! \:331QM*VV,.X!=
MO09ZF@#A!X5U31_ _A\62+/K>B.LJ(&X<,2)8MWIM8C/^R*T/$NEW,>B:):6
MT$UU+!J=M<3M&F20LF^1S]3DX]ZZN*Y@G:589HY&B;9($8$HV,X..AP1Q[U+
M0!P=QIE['XC_ +0T:._L[F6_7[9;2*6M+J'< 9>>%;:,Y!!R.AZU0NM%U>XA
MUJ>VLIO.B\00ZI!"XV?:HXQ&" 3QD[3@''05Z710!Q&JV-QJ^LSZS!:74<4.
MCSVBK)$4DFDD((4*><#'7IEA@\&H+2QOH_\ A  UC<@Z= 4N_P!V?W)^S^7S
M_P "],^O2N^HH X/PQIE[IVL61TZ._M=*EA=KS3KQ24LY, @0L>Q;/ )&/3B
MM+5+6]L?'=CKJ02W-@UB]C.L*EVA)<.'VCD@XP<9[5U5% 'F^J:%J \*^(FA
MLIWGU;5$NH;5%RRHKQ\MV!(0MSZ@=:]!F!N;&41@@R1L%#@J>1W!Z4EW?V>G
MQB2]NX+9"<!II @)],FIP00"""#T(H \WTVRU--*\#V\VDWD3Z7.!=;D!V@0
MNF[@GC+#W[XQ3-8TO4KG1?'$$.G73R:A=QO:*(S^]4)&"1Z<HW7%>F44 <%X
MATZ\N-4NM2T2+4;+6 L:Q,$+6U\F!\LRG@8RPR<$#H3TKK=:N[JRT>XFLK:2
MXN]A6&.-=WSGH3[#J:T*1F5%+,0% R23P!0!P?B;PD4\(PMI$FH3:C8/'<V*
MN[-F53GE3TR"P.<=:76;^Y_MW0]7MM)U'[:MG,)XHH5E:-6*?(\9=3C<,A@?
MX>^>.X@GAN85F@E26)QE7C8,K#V(K#U/2]&O[Z74GU"2TNK5!!/<6UZ8BJ_>
M"28./XL\CO0!RL=O&^F>'[73=.U3-AK2W-XES;E9$W!V9R.F"9!@+G]*OZI:
MW.G>,;^ZN?#T^LZ=J4,01K=4=H70%2K*Q'RD8.>E=;9)86'EVD,ZF68&4"2;
M?)-C +98DM@;1GMP/2KU 'G<FG7&AZ^\TWA9K_3+ZTAC6&P1&^R.FX>7M) V
M$-UZ9%:-A8367C:RN%TLVME%HSV^VWCS'$YE5Q&,=< 'D#&?RKLZ* /,XM,U
M)? 6G6)TV[^U1:T+EXO+.1&+HR[O3[I'\JG@T^>UU#5=*U#PJ^J1WEY+<VMV
M41H"DC;\2[CE=I/H3QP.F?1:K0ZA97-S+;07EO+/%_K(DD#,GU .10!P]YI]
M]);>/XTL+DG48]EF!$?WI^SB/CT^8=\>M7=-M;^V\7Z=>-I]R;>71(K1I, "
M*19"6#Y.1P??/:NTHH Y;7;2]M_%^BZ[#!+<V<$4UM<QQ#<\8?:1(%ZMRH!Q
MSCUKG]7T._DAUJ_ALKACJ6K6<\5LJ?,(X3'N=AV)VL<'GIWXKTFHC<P"Y%L9
MXQ<%2XBWC<5'!..N.1S0!(K!E##.",\C!I:** "BBB@ HHHH **** "BBB@
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M[3C'()&.HP2*LZ/;:M#&\FL7L%Q<N  MM$8XD ST!)))SR<^G'')X@T>/7]
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M_.>U:2>'[V/Q-9ZN;U)OL]E):L)$.Z1G97+9!P.5X&.!0!;\,:T^OZ#!J$L
M@F9Y(I8U;<%='9&P>XRN:UZQ?"VBSZ!HYL9YXYSY\LP=%*_ZQV?&"3T+8K:H
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;@O!SG.3Z=JQ?B8A;P!J9$DD94(?W;E<_.H(..HYZ53NM.:?XE16:7UW"O\
M8;[I8Y/WI'GC^(@X_P#K4 =S17G&A^(-3U2R\-Z=//OEN[>[>65IS TYAD"*
M RJ3G!+'&,XZXR#U_AN#4[73I+;5KV*[N(IW59$;<PC."BN<#+ $<XYX- ":
MEXC@TZ:XACL[R^EM8TEN$M$#M$CDA202"?NL<+DX'3IG8!R >>?6O.I9GT3Q
M'XZU:%[B:6RLK>=(VD)5CY<APP[@?I5ZYO+_ $Q/"NH6^H7%T-3N(K6[1VW+
M)YL9;S%'1"I&<+@8[4 =Q17F46I:K9^&=6\03:W>2R6-_<VJ1R%!%L\X1AW
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MU8) !)( '<T <UK]I?:W?6NGK82Q6UK?6UW]L:1"CK&V\J!G<#D8Z=\U:O\
MPCH^I7E[<W$,Q>]A\FY5+AU24;2H+*#@D \$CCCT%6M.OMNFVK:AJ%A+<2[A
MYMNVV.0@G[H)/0#GGL:E&L:8;5;D:C:&W=BJRB==A([ YQF@"K:^&=+L]0M[
MZ".=;BWM_LL3&YD8+%D';@L01D#KZ4UO"VE-)>R>7<![V9)YV6ZD!,B8VL/F
M^4C:.F.F*TS=VRS+";B(2LF\(7&2OKCT]ZJOJ<%S8W4FF7EI/+"A.5<2*IQD
M;@I_K0!5NO"FD7UG<6]W;M-]HE6>25I&\SS% "L'!RI   QC'XFHU\'Z.K7C
M,EU))>P"WN9)+R5FEC&1@G=[GGWJ#1-9OM5T#P[J$ES8P27J+)<1NI!D!0G;
M'\W7.#WX!I/&GB0^'] N[BRNK(:A"%98)SDL"P!PH8'H<_A0!/>>#-$O8+"*
M2"=&L$\NVFBN9$E1,8V[PVXC'8FK,WAO2II-/=K8JVGAA;F.5TVJV-RG!&X'
M R#G..:UJKW%]9VA/VFZ@APA<^9(%PHZGGMR.: ,S_A$]&^Q7]H]J\D%_,;B
MX629VW2<?."3E3P.1CH*E;PWITEM=PSK/-]KA\B>22=S(\?/R;LY Y/ QU-7
M1J%D8(IQ>6_DS$"*3S5VN3TVG//X5&VKZ8EK'<OJ-HMO+GRY3.H1\=<'.#0!
M53PUIB7&FSK'-YFF(8[0FXD/EJ1@C&[YN !SGI5S3-,MM(L4L[02"%69@))&
M<Y9BQY8D]2:R=6UNYT_Q-H-HCVPL+X3F9W!W+Y<9<$-G 'X=JO7NH";2!=:9
MJ.GJ'=0EQ,P>$C< PR",G&0.>M %N^LH=1LIK.Y#F&9"CA'*$J1@C((-)]@M
MFT\V$D?G6S1F-DF)?<I&""3DGCUK#M?$C1>)M=L=4NK*WM++[-]GD8^7GS%<
MD,6;!/RCIBM:ZN)4U*R5+RSCMV60RQ2_ZR3"Y4H<]!R3P>/2@"&?PYIL\6GK
MY3QOIZ[+66*1EDB7;MP&!R00 "#D&FW'AG2KG3!I\EN_DB<7(99763S0V[?O
M!W;L]\YIVE^(]*UBTGNK.]A>""1T=_,& %)!;KPI(.#WJ[!?V=S:M=07<$MN
MN=TL<@9!CKD@XXH BETFQFGL9Y+=6EL"3;,Q),9*[3]>#WI;72[.R%W]FA$/
MVN9IYBA(+.P +9['@5CZ;XADU#QG?:9%/9W%C%91W$<D')W,[*0S9(.-O;'6
MMZYNK>SB\VZN(H(\XWRN%&?J: ,A?!VBII5IIJ6\RVUG/]HMPMS('C?G)#[M
MW\3<9[FG-X2T=X=2A,,WEZG_ ,?:_:9,2<;?[W'  XQQ6F;ZT$,4QNH/*F($
M;^8-KD] #WS[4L5[:SVGVJ&YADML$^<D@*<<'D<4 9K^%M,D22-EN#%-$L,T
M1N7*RHHP P)YXX/<C@YI+SPGHNH7-Y/<VA=KV$07"B5PDB@$#*@XR 2 V,CL
M:T1J%DPA(O+<B<XA(E7]X?\ 9YY_"FOJNG1NJ/?VJNTODA6F4$R<?+U^]R..
MO- &4/!>B"4RF*Y>9K8VC2O>2L[Q'L26R>IY[=JGC\+Z5$VELD4X.EKML_\
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M#IZ6&GI)';(241Y6DVY))P6)/4FIEU*Q:(2K>VYC,@B#B5<%ST7.>O/2JHU
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MQ8>*8A<NNS @$9 =6'8O$4!_VB:]&Q10!YM<0Z2_B?QYYT=F2-/@QO"\'RY
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M]I /FIL</Y>>O8?+WQ6?HMJ^F:E\/;;4ML=^EI=HZRD>8JE1Y:-]!QCU!KU
M@$@D D=*6@#R.*_%CX9C(>98]/\ $4\FIK!'N>&(R2[692",!BC=#TR.E6=6
METQ;0ZYI5S=7^FSZK:3:M<;08FC3<"0JJ <$1EL#GC/>O4Z0  8  'I0!Q&D
M:AIU[\4M0GL+B">.?28")86#+(1))GYAP<# _#VJSK%T=/\ B)I%UJ#B/2WL
MIH897.(X[DLIY/0$H"!GW ZUUP '0 ?2@@,,$ CT- 'D5]:VT4:O-Y(TN?Q9
M%)9!\;?*./-9?]@MNZ<=^AKU>UM+6SMQ#9P0P09+!(D"KDG).!QR234]% 'C
M^GZE91^#_!U@TZ_:K+6XUN8L?- 0\O#C^'\>M-U&/2QX+\?21+:^<NJ2&%E"
M[AQ$5V_B#C'<&O8=HSG ZYI: /-=2U'3/^$EU_3O$&HSVUGJ<47V1D16CN8#
M&%*(VQCD/N. <_-D4^PM-'C\;WD$\</EQ:#;J5N]I<$%P=Y/\>W&3[UZ,0#C
M(!QTI: /)K.\M?\ A"?AT);B+>FH0!@SC*A8Y5.?0 D#\16Q#<V<=WXST_7V
MC5[IS)")2/W]L8@J"/\ O8(88'1CZFO0:0@$@D D=/:@#R[1=/A?Q1X<LO$$
M5O/>GPZT=Q'<!6+/OCPK ]6VYZ^AJSI-]H[IJ7AW7X&;5EU62=+7:P>?]YNA
M="/X0H49S@!><"O2:3 SG SZT >7>?IMY-K/A[Q#>WT6H/J4DT5I&BA[A=^Z
M%HFV%N@49W<;><"JVNZI9/'J"Q,MFUKXB@DGMR&:4D2Q@SN3G:A ^7&!TY.<
M5ZU@9S@9'>EP/2@#S*6'1)]2\;QZM!;O+<,C01S(/-D4VZ >6#\Q.X8&.X]:
M6U2^M-=T"QGG4:O'X9FA.YQD3?N\ GUR#]<&O2\ D$@9'0TM 'FOA2YT76!H
M$;WE\VM:6NUK(QJC6S[=LF_" [>O4\\=ZVOB*UNFE:6\QC5DU:T9&?&0!*I8
MC\.OM77X )( R>II: /+[R+29=0^([.MFQ^R1["0IY-N<X]]V.G?%=UX9F6?
MPII,HD$FZSBRP.<G8,_CFM:B@#S+0I9XY;33;:XMM9TV?3YQ97"C%S:+M!\N
M4#@@_*N>#D<U4TG5K";3_AS#'<(\MI((KA5R3"XMW4JW]UL]CS7JX !)  )Z
MT!0.@% 'G'AC4-(N].M-$UJ)G\0V.HM,]L0PD\\2,1-D=5PV<],<>E8U\VGM
MX*\770:V-R->9HY<@N/WZ%2#UZ;CQ[U[!@9S@9]:6@"M>+%<Z9.&"2Q21'KA
ME88_6O,](N;?3M-^&NH7LJ6]I';31O/*=J(S0C:"3P,X->C:I:7]VL2V5_':
MJ"PF5[?S1(I&,?>!4CKG]*DTS3;?2=*M--ME/V>UB6*/=R<*, GWXH \GNI]
M.N--O?/,6#XQ1\2KM(C+IN//(& <_2NJU"#2]/\ B-X92TBM;8-;WI9855,E
M@A'3U.['KS7<XQTHH \GMKC5+?3OL&C74&L0R:3<_P!EW40VW5H-JD1R <')
M"@'@[AS4Z:OHEY)X -C-#OMIS%)&/OP'R&!1QU4[@.#UQFO4  "2  3UH"@'
M( SUH \E-U'9Z;K-Q;()+"U\6"XO8H!N_P!&"IEMHZJ& /\ P$UI^*I]$U+P
MCK^K:,HF$[VDES=Q[BDFR5.F>,JHY('U]O2*0  8  'I0!P&HW,-SX_CETF:
M#[5/X?N5@D4@;G+ILY[],CV&1Q6?"\6I^#O"5KIY"ZW9W=L'BZ30NO$Y<=0,
M;\YZY'J*]0I, $G R>IH \=ODTM? _C6:);43+K+F)EV[A\\97;^3$8]Z]2M
M==TN^U6YTRVO(Y;RV19)8ESPK %2#T(P1T)ZBM&JZV<8OFO"6:4IY:DXPB\$
M@?4@$_0>@H Y;Q"]M'\1?"+.T2S$7:DD@-@QX _/I[TOP_GA%CJEF& N8-4N
MS+'CE 9F*Y],@Y'K7844 >=^)+F73];U.[T^ZMKU3) M]HUR,22'";'@8<[L
M$<8(R#WK-U8:=<6WQ,DD^S22[0(F;:6R+90-O_ ACCN*]5P"02!D=#2T >4Z
MWJEE=66MVRND-W+X>3]XV9'O1Y<A"QCD *2=Q )Y[8S6I8:A:S^+?",@N4(.
MBS#);&2?*]?7:?K@UZ%BB@#@O!_B#2=*\.N][?11+<:S<PQGDY=YG*CC.,CG
M)XK<\<7-M:^#M0EO+0W5N @>(,RC!=1EBO.T=3CL#6S=V<=[$(IBQBW!F08P
M^.<'V_GTZ58H \K>ZL+O7/%*76L$0WEC9,M[;QX08=QYB]044E<DD\<9KJ?"
M%Y?SWVJV^H_8[F> PC^TK(8CN@5.,C) =0!G!_B'M75XI  HP  /04 <#K$D
MT7CC78;1_+U&[T%%L>Q>4-+]WW!(SZ53CDM]4T'P5'I+*NIV=U;B2)>);=%4
MB<..JC (.>I(]17I=(  20!D]30!@>,(X9=*MTDU,Z;+]JC:WNRH9(Y1EEW@
M\%3C'XBN-NM2F:PTR^U6&TM_L/B5/M5Y;$_9Y1Y1'G G[HRRJ>P(/->I$9'-
M)M7;MP,>F* /)=4U 2ZCXLN[-7N;5-0TVYN8XE),ULJ(9,#^)<#Z$>QK0\7Z
MAX?U3P9XEU31V2:2ZM(XIKI"P20@_(@SP6 )Z#(XSVKTO%(  ,  #T% '%0-
MI\'Q3M%LFMD271'&(BH#'S4*].IQN(]LU9\;1H;SPM(44R+K<(#8Y *29&:Z
MVL6XT.XOM6AN;Z^6:SMKD75K;B#:T;A"F"^?F'S$] <XYQQ0!Y]KE[:VOA[X
MB:7-*JWTUV\\=OCYVC:*+#@?W<@\]*W+&#1=3^)>H"2&SN5DTJV=5=58,P=R
M3@]P-I]>E=]M!.<#-+0!Y;8BRETW6(8-6CTR5?$TKVMPH5HTDV@KN4\%#AA]
M<4@UJYBO=#OM:M[:WTZWU6YCO;FV)-M)-Y8$4_/12Q89/ 8$]:]3(!&#R*3:
M-NW QTQ0!Y!K=QIMSI?Q)\A[>2.0P20E<%78P)\RGN2V>1US6]+K.F6/B[4X
MO$$J+8:GI\"6,S@F.2,!A)&I'<ELX')R/:O0@ .@I" <9 ..10!P=L;#3O'^
MFQ-";6TDT$6]M%.#DXE&$YR<A<$@\@9STK TJY6UTC0[D,AT>U\071O-GW8@
MSR")VQT4$J<]!P:]<HZT >2>,X89;7QK?6S1/IL]E;@,I!22[!.2AZ%@FT$C
MU'I70-<Z3IOQ*@GADMH;8:%*TABQ@@2HPZ=?EW$>V:[H  8 P!V%#J61E#%2
M1C(QD?G0!5TS4K/6-.@U#3YUGM9UW1R*",C..AY'(/6K=0VEK%96RP0@A 2Q
M).22222?<DD_C4U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %<EX^E:VL-(N$DG4IJ]H&$+-\ZF09
M!5?O?3!KK:P/%VEWFJ:;9_88TDFM;^WN_+9]N]8W#%03QD@<9XH BMO&E@\N
MH07MM>:=<V,8FDANT 9XV.%9-I(8$\<'.>*M:?XFM;[6Y='>&:WO4@%RJ2%&
M$D>=N049AP>"#S6#KWA6_P#$TVHW^T6%P]C':V<<Q5CN243;GVDC!95& 3QD
M]\5L>'SJ\S^;J>B6>EE$VD0S+*96XY! ^5>#P22<]L<@%BY\00PWEU;16MQ<
MO:>7]H\G9^[W\C@L"1CDD#IZ\U%>^*;6T2_F2UNKFWTYMMW- JD1$ ,PP6!;
M:""< X^O%8WB7P[>:IJ<]Y8V<EIJL1C%CJMO.J?+A=RS+G+*#NXP<CTIT.C:
MMI8\2:?!:"[MM5GEN;:?S541/*N&60$YP",@J&R* .BO];M;#P_+K6)+BSC@
M^T9@ 8M'C=D9([<U1L_%MK=:E;V<EE>VOVJV:ZMI9T4+,JX+ 88L"-PX('M4
M=[H,UO\ #F;P]8@W$PTTV41)"[F\O8"<G@=ZH3Z3K+ZGX<N;>U$;6&GSP2.[
MH0DCHBJ< \@%.?8T :=EXMM;VYL819WD7]H6[W-FTBK^^1<$C ;(.&!P<=?P
MK-_X6+8_V*^L#2-7.GI&[F?R4V@K)L*_>ZYY],9YX(JAIVB>($UCP[J=UI4?
MVBSAGBOY6NU>29W51OSCIE3A<\9Q\HH_X1S63\)KCP\;(#47,BJOFIMPTQ<'
M=GI@_G^= '2)XGC>=;8Z;?QW4LKI!!*BJTR*H8R#+8"?,!DX.3C&>*KR>-M/
MBL7NGM;P&&\6RN8MJ![:1B -^6QM.X?,"1S3=6TW4&\2:/XAL[8RM;PR6]S9
MEU#F-\'*DG;D,HXSR.]0Q^$_[0MO$[7Z^4VNL!Y0()A58PB$D<;LC=QQTZXH
M U$\1VS:MJ6FO;7$4VGP+<2-)L"NC9P5.[G[IZ@8QSBL0WLLGQ!TZY2*]59]
M$FF-F\G.1)'@;=VT-@XZ_4U6C\(:M-/HVH74\?\ :$J&#6B#Q+"54[!ZX,:K
M_P "8UM7.GWK>/[/55MR;*+3Y;9Y-ZC#,Z,.,YQA3^= $MGXKM;_ $&WU:"T
MNS'<3BW2 A!+OW[,$;L#!!SSD $UH:EJL&F_9U=7EGN9?*@@CQOD;!)QD@8
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ME4F2)3\O[O&0^, DG Z\]#N>+-'EUOP]<6ULP2^C*SVDAXV3(=R'/;D8^A-
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MVZXBD(&T'[W4@[L#GBNG\374D6F?9(%N?.O7%N)((6<PJQPSDJ#C"DD$]\4
M9OAWQ5-JOB75--N8A%&%6ZTYO^>UL?D+_P#?2Y^CBMV]UBPTYV6ZN C+&97
M4L4C'5VP#M7W/%<;XFTJZT"^T'7+&34;^2PF%L]O';*Y-JXVN (HP>,*1GCB
MF:[?QV/BV_FC6]"7^EQQ2O\ V?+.H^:0*0$&5(!;*MC.1Z&@#J9?%WAV&..1
M]9LBDB,Z%)0VY5ZD8S4DOB;1H((IY+^(02(CB7!**K_<+-C"@YXW8S7(VB61
MU?P,NF+=W=A807,!N&M9/W9\M4&_*_(25(P<4V9(;76]>TG7-'U:\@U&X\ZU
M:U$K0SHR(OEMM(52NW'S8&,<XH [:_US3-+)%[=I$% +L02L8)P"Y PH)[G
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MSPW95A+O;'ECY6X&",]LCD\UUVL7<]AHU[>6T4<LT$+R*DC%5) SR0#0!<)
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M+8RY!;[@SC:>..N<]@MMXVMY[_3HC!']EU!28IHK@2-%A=P\U /DR/<\\'%
M'4DA1DD#MS2UYWXEU1M;M/#&HQ6"BQEUNT:WN&D_>;?,X8KCA6 R.2>F0.WH
ME !17,V_BUGU32[2YTY[8:FTRVXDDQ*NP,<O&0-H(4D8)[5+IOB@:G$+JWMD
MDL=TJO)'-NDB*9X=-ORD[>F3VH +3PI]AW0V^N:JE@69OLGF1E1N)) <IY@&
M2?XL^];T*QI"B0A1$J@(%Z =L>U8%AXB;5M,%Y%81SV4UHTZ/!<"3/3]VV0
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M%M8VHB@BBM[>,<(BA$4?0<"LS_A*M(^RM=^=,;-06-T+:0PX'</MVD>^<>]
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MQLA$BXR,, >]7Z ,OP]=ZC>Z+#/JL5O'>%G5_LQ8Q, Q 9=W." ",U3OM(U
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M?,F[S-_F9SMZ;N<?TH Q;=M8BUOQQ+875Q=W5N\*VUO)Y>"3"K #Y>,%C@9
M]<\FMKPIKD>LR7NR^NI&AV+)9WL"Q3VK\Y# *,@\8//0\U8F\*6<M_J%XMU?
M12WXC,PBFVC>@ 5P,<-@#VXZ9JY8Z/#97UQ?&66XO+A$CDFEV@E$SM&% '5F
M/3O]* *FO7=S#?:;!!>^0DS2;XX4#7$N%^41@J5 !.6)P!QR,URMKXDUZ[T+
MPQ.+U(I[W5);&X+0*=ZJ90"0. ?W8Z<9SVKL-4\/VVJZA8W[W%U;W5GO$<EO
M)M)5\;E/!R#@>_'!%9]OX'TZUALX8;N_6.SO&O8%,H;;(Q8GJIX^=OSYS0!B
M/XGU32O[7TV>\%W<Q:K;6%K=2Q*I43JARP4 ';N;L,X%7K2WGMOBPZS7DMT#
MHF5:54#+^^&1\H ([].]:%UX+TR^&K"ZDN91J;I+-EP"CH $9" "I  _*IK'
MPO!9ZS'JTFH:A=WB6WV7?<2KADW;N0J@9S0 GBC6)=)ATV&W(2;4;^*R64C/
ME[LDM@\$X4@9XR1UZ5S7BC4K^T7Q+H%U<-=VTN@3WL$SHJO&0"C(=H (Y!!Q
MGJ.:[36-&L]=L#9WBML#K(CQMM>-U.5=3V(-5CX;LYH[T7TD][+>6WV2::8J
M&,7/R#8% 'S$\#.?H* .;L[O6]%U#PP)M16\T[5$%NUL8%3R&$1=60CDCY2#
MN)_PSHM1OM)\$Z_?:?<"&:/Q!.N2@;*M=!".?9C7:V/AV"SEM9)+JZNWLXS'
M:FX*'R01@XVJ,G QDY.._)S3?P58R:->:4UY>FWN[HW<IW)N,A<.<';P-P!Q
M0!1UO7+VWUG5K-KW^SDM].6XL6V(?M$GS;OO YP0@VC!^;W&&KJ&N/::4EW?
M-!=W&GM/+;6\*_:!,=O4,"JQKD@DD<X'M575K2YD\4WDL_\ PDUKF.**"XTL
MAXYT4$Y88(5MS,,8 []ZU;+PLUP]IJ.HWVH#4(H7MV<2JKRP%RRI+L&-P&.5
MQSGDT <_::CJ&NWO@"]FOYX'O;>>69(0@0NL7WL%3R<D>P/&*MW/BO4M.C\1
MB6=)I+?5(+*T9HP%B$JQ\G'7&\GGKBMFV\$:;:6FDV\-S?K_ &6S&WD$_P ^
MUAM9"<?=(XXP>.N>:ED\'Z9/%J\5TT]Q%JKB2X21A@,  K*0 01M7'T% %#4
M-2U72/$L&E_;GN8-0LIY8998DWP2Q $_= !4AAP1U[]JS-(US73!X-U"[U/S
MX]8'E7%OY"*H)B9PX(&=V5YYQST%=5'X>B#M+/>W=S<_9VMDN)BF^-&QN"X4
M#)P,D@DX%5HO!]E!:Z-;I=W@CTAMUJ-R<':5&[Y>?E)'XT 9FD^(;J7Q+'I>
MJ7-S8W_G3$6DT*^3=1#=M,,@7)P-I()SUXKH?$-U/9Z#=SVUU;VLRJ-L]QDH
MF2!G !R>>!@Y.!4$'AJVBFLWENKJY6RD:6VCF92(F(*Y!"@G 9@ 20,^PQ:U
MO1K77])ETZ\,JQ2%6WQ-M=&5@RL#V((!H XZY\0ZQ!!XQCBNIU.F6$=Y:274
M$8D&Y)"00 !C*#&1D9.:M_VEK5I-I%M-J+W4NL#S%$<,4;0!(MS*A/!R2#EL
MX /X:$O@BPF;4'DOM1=]1M5M;IFG!\Q0&&<8P#AB.!@9X -6=2\)V.JZ19Z?
M<3W8:R*M;7<4@2>)E& 0P&,XXZ<T 2>'?[:6"ZBUID=TG;[/)E?,:$_=WA?E
M##D<<&LW4[K5I/'5MI%MJ1M;2?3I9VV0(SJRNBY!8'GYCU!'M6[I>F1Z5:F%
M)[BX=FW23W,F^20],D_0 8  J&;0X9M?BUG[3<)<Q0-;HJE=@1B">"O7(!Z]
MJ .4TGQ3J5[:>'=.GN +W4+N[@FNUC4$K;E^0N-H9MJ]L=>*S_%FJZHNC^+=
M%FOIF-C';S0W2*JO)%*<&-\#'!!&0!D?CGJX_!6G1:=!:+/=AK:Z:[M[C>OF
MPRL26*G;C!+'(((YJQ<^%=/O=-U*SNWGF;4@!<W#,!(VT +@@ #;C@ 8Z^IH
M V((WAA6-YI)F'620*&;Z[0!^0KA]8U_5;&Z>>&_$RIK$-JT4$2F%(79%*.S
M#=YGS$G:3CC.*[:UM_LMM'#YTLQ48,DS;F8^I/\ D5SL_@33)Q=I]KU".*YO
M!?>5'/A8YMP8LHQW(Z'(],4 4Y_$-U;>*CIVI7-SIWFWB+9,T*M;747&4#[2
M1(?FX)'.,4FG>(;N3Q,FEZG=7%A?&>;9;30+Y%U" VPPN%R2!L)!;/#<5M/X
M8M92$FNKN:V%RMT+:1U9!(K;@<[=V-P!QNZ_4Y6+PU;)+:M+=W=PEI,T]O',
MR$1.0PR"%!. S8!) S[# !S47B76(_"\UW-.)'CUQ[*:Z$2CR+<3;"^,8X Z
MG.,Y.<4V^UK78;+Q?=6FJ>99Z;;A[*X,",'?R][#<  VTC'3^+GD5:UKP\=+
MT9+2S35KFVGU+[7<R6LB^?"22^]  -V7VY'. 20.*6PT*?5;:\LY]1U]])N[
M9H9EU(1K(6)'W/D# ;=P.1W&.] $EKJ6KVGB?2[:ZU);FWU'3I9S&\2HL,D>
MPY4@9P0YSDFJ^DZ]JAU_P_;3WQO(-1MIVFD6)5A9T"L#"<!RO)&3D$8()ZUO
M2^%K2>[LKB>YNI&M+9[5%9E"M&X 8-A>X4<\=*JV7@BPL9M*E6]U*1M+#);>
M9<9"H0!L( 'RX ]^.210!QND7>MZ'\/=/UVTU%6M+>Z99=/,"XEC:Y9#\_WM
MV6R,'';'KK7.KOH6N^.=0C56DC-@B[N@9U" GIP"V>W2NCM/"-A9PQ6JSW4E
MA#/]HBLY&4QH^[>#]W<0&.0"Q&?H*=+X3TZXN-8DNFFN$U=%2ZAD(V$*,+MP
M 1@>_OUH CTL:_%K\BW;M)I4EOE3<F+S4F!Y \L %2/7D$53\?B1K+1!$ZI(
M=:M K,NX [^"1D9_.M/0_#<&A\K?ZA>L$\N-KVX\PQ)_=7@8' ]^!SQ5K6-&
MMM;M(X+AI8S%,D\4D38:.1#E6&<CCT((H Y4S^)X=:U;P\FL"XN3IXOK"[:W
MC5D;<5\MP!M() YQG&:T-!UV;Q ND26US*@6V,VH(R)D/G8(VXX.]9.F/N>]
M7YH(_#]O=ZL+>_U6]<(DAC57G=0<!54;5 &XG QW/)H\-Z4EA%>WAM!:W&I7
M+74L7&4SP <9&<#)P<;F:@#&^*TT\'P]OS"S(CO%'.R]1$SJ&_3CZ&NOCA@%
MHL"1I]GV!%0#Y=N,8QZ8I+JU@OK26UNHDFMYD*21N,AE/4&LFQ\-+86ZVD6K
M:DU@@VI:R2(55?[H?;YF/^!4 4+:\N=3UW5]$L+U["'28;>.-HD1RS2(6!.\
M'*@;1@8SSSTQBZ=XFUS6Y/"P6Z2R.HI>17:I"K#?#\NY"W3)!([=,YKK9_#E
MLVJG4[2XN+&Z>$02M;%0)4'W0RLI&1V(P1TSBHT\*V$-UI,]N\\ TI'2VCC8
M;<.,-NR"23ZY]^M '.V^OZZF@73M]IOWL-8EL[F:UA3SVMTS\ZIC:6R5! '3
M.!FI;?Q'/<2^&I;'63>VM_?S02LT*J2@21E5AM!5UVJ#TZ=.:VK?PI!:>8;?
M4+^-WOFORX9,^:RE6XV8VD'H1Z8IL_@[3YK2*))[J">.]:^6[B=1+YS9#-]W
M;R"1C&,4 <MXEU&\O/!WCZUNIS,EE)Y4!*J"$,<;8. ,\L:V&%R?BB1_:$ZP
MIHPF6([/+&9<$<KD [02<YXZXXJY)X'TV6QU:T:YOS'JK!KHF8$D@ <9!QG:
M/>KESX8L[O4XK^:>Z:9;4VDF) HFC)SAP ._/&/RH Y[3-=U9M<T&VDOS=1:
ME;7!EE6%1 9$"L&A. Q7DC+9!&"">M4;+7O$']@Z+K,^JB7SM7^Q36XMT59(
MVN&BR3C(8 #&"!QR#UKHK/P/863Z6Z7^IN^F*R6I>XSL1@!LQC!  'OQ@DCB
MGIX*L4T>VTQ;R]%O;7?VR/YDW"3>9.3MZ;B3B@"IX52Y/BGQ4TU_<S)%?(BQ
MR;,8,*$=%!&,X&#CUR>:N>,;^^TC3[75+6Y:.UMKJ,WR!%;= S!6/()!&0>.
MV:OV>@VUCK-[J<,UP)+PJTT1D_=EPH7=MQUP![>U7;ZSAU&PN+*Y3?!<1M%(
MOJK#!_G0!Q<?B*_&N:_I9OI'<HATES'& 26\INB\[9>#GM^9O37NIKXON]'.
MI2?9AHHN$=8T#K)O*EL[<9X],<]*UHO#.EQ3Z1,D'[S28FBM3G[JLH4Y]3@?
MG3SH5NWB%]:::<SO;?9#&2OE^7DMC&,]23G- 'GUHEU)X1^'KF]D>>:^B<23
M*K;"8)>F ,^O))]ZU'\4:II0U73I[O[5<1:O;:?;W<L2J56=4;<P4!3M#-C@
M9XS6W;^";"VM-,MH[W4/*TR836RM*K;" 0!RO0!B/QYS4L_@W3+H:L+I[B9=
M3=)9@S@;70 (R$ %2-HQ]* ,O5=6U71];N=,^W23Q7&ES7EM.\<?F0R18R#A
M0I4Y'49S^A;ZYJ<TG@<M=D#5[9FNU$:89OL_F;AQP=WIQ[5T$&@6ZS23W<T]
M]/);FV,MP5R(CR5 55 R>2<9.!Z"LZS\#V%G)I3_ &_4ICI9/V02SC"*5V[.
M . ./7U)XH K_#U;AM&O);B^N+ECJ-TG[[;_  S,,Y"@Y./IZ 4GB)+E_'OA
M:*._N88I%NF,<>S;N6,8."IYPQ'/;ICFMO2-"MM%:[^RRW!CN9WG,4DF4C9S
MN;:.P))/.:-4T*VU6]L+R66XAN+%G,3P2;20XPRGV(QZ'T(H X#[;J>D:+XJ
MUBPO_)%GKTK&W\I668%HPP8D$@8/&W!'O717^IZUJFH:Y9:-))#/IS)%#M\K
M8TAC63,F_)VG<!\N. 3]+LO@NQFTK4]-DO+TV^I7)N;CYDR7)!.#MX&5''M2
MWW@VRO=7_M1+[4K2[>-8KA[2X\K[2J]/, '7W&#0!N63SR6%N]TD:7#1*95C
M;<H?'(![C-<=\-':>T\075SS?R:S<+<%OO K@*OT Q@5VL4200I%$H2-%"JH
MZ #@"L>7PS;_ -K3:G8WEWIUU< ?:#:LFV;' +(ZLN?< 'WH K^)=1&C260M
M L5WJU]!9--C.P'<=V#P3M4@9[XZ@8K*U/6=7TG5=9TH7IFVZ.^I6ES)$F^)
MD)5D8  ,,X(./7K70WWANQU+36L[LS2LTBS?:"^)5D4Y5U8=".V!CVYIC^&[
M>>&]%Q=74]Q>6_V66Y<H)!%S\JX4*!\QZ#O[# !S<.HZ^;SPH#K.Y=;M6\Y3
M;1XB80B3>G&=W4<DCGIVJM-XAU^WTB[C345DN;/Q!'IPN)8%S+$S1_>   .'
M(R .G:NJ3PM:I+HT@N[O.D(4MN4Z%=AW?+S\O'_U^:Y[Q3X;^R:6Z6)U&YDO
MM8M[R?8F\H0Z[W&U>,*H_*@!;C5M?T;6]6TFXU>UG5M+:_M+R[B6);=@X0J^
MP<KR".,]N:&U[5HKW7[2.[N"MOI"WUM+=VZ*ZM\X/R@#Y3L'# $<UO7GA/3]
M4M;Y+^6YN9+V%87FD(5U13N4+M4!<-\W3KUSBHF\%V;W%Q<R:AJ4EQ<67V*:
M1YP2Z<\D8QGYCT&.<XSS0!D:=JFMC4/"OVG5#/%K5DYFC$"*(G6$.'0@9SUS
MG(YZ#I3].UG57@N]#NK]SKT.HK;B81(,PM^\60+MQCR@W_ E(K:'ABU@;1YE
MN;QVT:-DM5!3D%-I#?+R=O';\^:@T6W75M>?Q+/I-QI\WV5;2)+M0LQ&XLQ(
M!.!G '?KV(H VIK7;(]Y&/,NT@:.+S#@#/./;)"Y^@KFO"GB";4M1^QWUW=P
MZE#;9NM-O(%1E?*CS(RJC<GWAG)ZBNLN($N;:6W?(25"C8ZX(Q6=9Z##:WT-
M[+<W-W<P0&WBDN"I*(2"1\JC).U>3D\>YR 4/&6HZCIMIICZ;<I#)/J5O;/O
MB#AE=PI'_P"KGZ5@:AK'B+0[OQ#ILVJ"[:'1WU2SNFMT5HRI(,9 &",@$''3
MUK8\>VT]YIVEPV\5T[+JEM*[6T;.T:*X+-P#C YJ_/X9M+RWU!;FYNI9=0M_
MLTUPVT2>3@_(,* H^9NV<GZ4 <_>7WB#3M&TG47UH3?;[VQ1HOLJ*$21E#J#
MWSGJ>1VJZNJ:GK9\1M87QLVTN=K:WC$:,'=$5BTFX$X);'!' ]:U;OPS;7ND
MV&G2W=WY5C)%+$ZLFXM&04R=N#C [<]Z;-X7M7O[V[ANKNU:^0)>) RA9\#&
M3E25;'&5(- ',66OZYXFU+2HK+41ID6HZ(UZ0+=9#%*'1<C=U'S'KV/K@CO9
M8I7M&B2X:.8IM$RJ"0<=<'(_"LV+PW9P:S:ZE;R30M:VOV.*%"HC6+(.W&,]
M57OVK8H \U7Q;JD&F:+<7=])YUO?/::TBQ1X4+)Y9<G;\HW-&>.JM[9K3UO5
M=9M[6UO;+4=D=YK4%K$DD*,!"SA#V!()#-G.<$8(ZUNS^%=)G76@\!_XG*A;
ML@]<)L&/0]_KS3M1\.6FHV-A9F6>W@L98IH! 5&&CQLZ@],4 9!GUK3?%.A:
M3<:PUW#>17;2N;>-&)3:4Z#' ?'OBN4 OS\/1.=8OB[Z]Y;9\OYA]L*G)V9Y
MZXSCCICBO1[K0X;O6[#5I+BX$]BCI$JE=I#X#9&WG.!W[<5G-X)TUM,O-/\
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M<?V5!:R6UG?_ &.X65BKL %+R*1QP6^Z1S@\BLB>*R?Q/X3NO#ZPB*>*43B
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M,YVNH(_6GT4 5Q868;<+2#=C;GRQG&,8Z>E20P0VZ%((HXE)SA%"C/X5)10
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M %%%0&\M1>"S-S#]J9"XAWC>5'4[>N.1S0!/1110 44V21(HVDD=411EF8X
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M]B(K#!8KO^9C]0!V')K1GTJ^DL[*W^TVDL<4)AN89K<F.X!  XW?+C'^UU-
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M2XR<F)3D;2P!^;(P :X__A(=3L+;4K*2XECW>((-/CE>7S6MHI51F^=NI&6
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MUN4(?9$RYQ&RC';DIG/-58M3UA/"^KR1W=Q.T'B![:20G,HMA,JLJ8_BV\
M9YXYQ0!Z+17GVH?VO#:^,+ZWU#4H=.M[ R6!D8@B41,SXWC<0"%YSW('M+97
M%YI_B+PRTFJ7<T6I:=,]TMQ)N0,B1L& Z*?F.3W[YZT =Y3(Y8Y0QC=7"L5.
M#G!'45Y]I=_>G6_"X6_O+FUU**Y$UQ+(5%UA-ZNL63Y8],8.#TK-TXS:9X'@
MN[2[NXYCKYA9C<NP*&\*D$$X.0>3WH ]6HK@=<O[^#5/&,5O?W,2VVBI=0A9
M,^7)B4DKG.,[5Z4T37M@OAZ)M3N[AM<V><;FZ,:JRPE@B,JDIN)'3D[>O)H
M] I  HP  /05B^';34;$7UM?WR7*^=YENGFM(\,;#A&=@"W(."><5S[6>H:W
MXL\4:<=>U*UAMX[9[<02!/+9T<]ATR.G?OGB@#NZ*\WTK6-0U[1M)>YO;E[Z
M329)9+6W<P?-OVK</(I& =IPH!R23CCBQIVL:E>Z=X,FO9IVM+VS=KR2WW!W
ME\M2A.SY@OWB2.,XS0!Z!17G5M?:WI]EI-KJ%S<DZGJ<T*M=3&)Q HD,2E@N
MY&;"^_;@FNI\/6FHV$M_;W]\EQ&91);Q&5I7@1A]UG8 L,@X)YH W*I:EJ<.
MF)!Y@9Y;F8001)C,CD$X&<#H"?H*YZ">;Q#XE\1Z;+=W5JNG>3%;BWE:,J7C
MW>8<'YLDX .1A>G)KG!=7'B+2_ 6HZD\RW<]\T<IBE:,-MCF&\ $ $XSD=CC
MI0!Z)I>H-J-FTTEE<V3I(T;Q7*A6!4XR,$@J>Q!P:K3^(+:'6-*TX12R'4T=
MX)TVF/"+N.3G/3&..]1>+80W@K64WRKLL)B&61E;(0D<@Y[?C7)"R#7GP^@C
MN+B,26LY+B4LXS;KD MG'X=.V* .^U"[DLK1IX[2>[8,J^5 !N.6 SR0,#.3
M["K5>8W&HZG;^"=:V:I>>;INNBTBF:3,C1&>-=K,>3PY&>O2M37]4N]+UZ>7
M4OMJZ0TT @O[*8E;4_+N2:,$<,<_-@\.!Z4 =U6>^MV*>((M$:;%_);M<K'_
M + 8+^>2?R-7G=8T9W8*JC)). !7E^O-?1V=OXRCTF\%U9WGVXRDQX-F1L*8
MW[A^[ 8C'#9H ]2HKF-=U&9KSP[);2RMI%W,WVA[8MO8&(M'C;\VW/)(]!GC
M-<W?-K]EX7NKJ35-1@+:U%%9F0@-]F,RJN01NY#'J<D 9H ]+HKB)%NH/$X\
M-I?7=S&UF]ZK7%^T4C,TA4@.BY(0#@?[7.<#$%K<ZP-3T[PUJ%_'>3BRFE>:
M.Z>W,[+(% WHN2RKU QD\GI0!WH &< #/6EKSXIK=KJWA;3+W7II7EGNX;A[
M=P-ZK$S*&..6 P,^V>O-9UW)J4'ACQ=.FMZEYFB7D@LV,^2 $1P'/5Q\Q&&S
MQ0!ZE17#SW6H^(=9UG2[:X^SRVD$/D,EV\)1I(]WF;54[QN.,$X^7&.345O'
MJ6H>+X],O-<NFB?0XYI392>6CR^85+H0,@'&>.??'% '=/+'&T:NZJ9&VH"?
MO'!.!^ )_"G,P52S$  9)/:O+;&6?6X/A[=7]U<R3R37$<DBS,A;;%* QVD?
M-\O7KU]:ZCXE7,UK\/=6>%F5G1(F8'D([JC?^.L: .BL;V/4+9;F$-Y#\QNP
MQYB]F'L>U6:YC7;Y[;Q#X;T*)GM[2^:?S&B8H2(H\K&&'(R3GCGY<5R^OZGJ
M^G:?XPT^WU&Z6/33:S6EQOS(@E/S1ECR0,'!SG!ZT >GT52TW3FTZ.96OKN[
M,LIEW7+ABF0/E7 &%XSCMDU=H **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ JI?Z;;:DL(N5DS!*)8F
MCE:-D?!7(*D'HQ&.G-6ZBN+F"TB,MQ-'#&" 7D8*,GIR: ,UO#&D.;<M;.6M
MYS<QMY\@/FGJY(;YCR1DYXXZ5%<^$-#NQ=^?:.YNY4GF;[1)DR)C:X.[*D8
M!&..*T(]6TV9H5BU"T<SDK$%F4F0CJ%YYQ@]*?'J%E*D[QWENZ0$B9EE4B,C
MDAN>/QH RSX.T$K?+]A.+]!'=?OY,R@#')W=2!R>I[YJT- TT7ME>>5*;BRC
M,5NYGD.Q3C(QNP<X'7/05E>*O$IL_"&HZKH=[93S6FW<<B51D@$':PP<'//Y
M5O6VI6-Y<3V]K>V\\UN=LT<4JLT9]& /'XT -U+2[/5[3[-?0^;$'5UPQ5E9
M3D,K @@@]P:9%HNGQ07,1M_-6Z79<&=C*TJXQABQ)(P3QTY-6+J\M;*(27=Q
M%!&3@-*X4$^G-9VI^)](TNSL[J>^@,5Y,D,#+("'+,!D'I@ Y)]!0 :)X6T?
MP[O_ +,M#$6&W+2O)M7KM7<3M'L,"IM6T'3M::V>]@9I;9R\$T4KQ21D\':Z
M$,,]^>:Q[7Q2D7B36K?4]0L(=-MH[5[:9F$8/FASRQ;#'Y1C&/I70W6HV5C
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ML:SI9N5MAJ5H9VD,2Q>>NXN!DJ!G.0"#B@"AI/@_0M#N))M.L!"SAAM,CLJ
M]0JL2%!]@*AB\#>'H!"L=E(L<$_VF"+[3+Y<4G/*+NPO4\  5KP:II]U=/;6
M]];37$8R\4<JLRC.,D Y'-)#JVG7!<07]K(8TWN$F4[5]3@\#WH ?J&GVNJZ
M?/87T(FM9U*21DD;A]1R*I/X:TMVM7$,J36J%(IH[B19 IY(+AMS GDY)YYZ
MU=M=0LKXN+2[@N#'C>(I VW/3..E-NM5T^QD6.[OK:W=@"%EE5203@<$^O%
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M'&3ZU8EFB@B:6:1(XU&6=V  'J2: ,[_ (1W2OM&HS-:^8^HJ%NQ)(SK* ,
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MGQ +&WN9(K0-"]S#($"R#&<<@L%)P>W7K@UV%]J5MI&D-?7;$11JN0HRS$X
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MT=XI+:XD'REAQ)D?W65GX^E6->T'4(DT6\T%89KG22RBVN7VK<1LH5@6QPW
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MIM[I.B+9WMQ+,R2R&+S9/,=(BQ*(S?Q$+@9K:H **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK*U^
M\N;*R@>VF@A#W"1RR2\E4)YV+_$YX 'J>_2@#2BAC@B$<2*B#HJC %$TT=O"
M\TKA(T!9F/85@^$]9NM6CU6.[^9K'4'M4<Q^6SH%1@67LWSX[=.@J-]4O-5U
MS6-,L+A+9=,BC#.T>\R2R*6 .>B 8SCDD]1CD W-/O[75+"&^LI1-;3KNCD
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M%MLBNJ\X(RN">/UK%M?$OB.&Q\+:S>RV4UAJ[V]O/;10%7B:5?E</NYYZC'
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M58 \,,$XR,'&>*U* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MJ]WIMPUW+ VGW'VB,(JD,VTK\V1TPQZ8K6JK?S7<%L'LK1;J;>@\MI?+&TL
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M6Y63XFUE_#WAR]U9+7[3]EC,AB\S9D?7!_E0!H6L+V]E# \[SO'&J--)C<Y
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M9=0N-FBL#;DHN7PA0;N.?E)'&*Z6B@#E[KP/9WRZNMS>7+?VE/'<%D(1H)4
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MJUC260-&57:Q(&">O0]* ,"[L-7T:'5=8T_["^KZC<Q.\,N]D*(@58D(P2Q
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MELP)%NR?O4=<DJK?*!GN17:U%';6\4TLT<$22RX\QU0!GQTR>] %;6+.XO\
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M6?+FC61,C!P1D?SJ.QODOX9)$AGB"2O$1/$4)*G&0#U!QP>] &9X/T:[\/\
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M(( ]^* .2M_$&NW.BZ!(-1:*>?6Y=.G9H8R7C5I0"0!C=\@^[@55\17FI_\
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MW+)!>7-Q#/%M4AU E8<D9!RHZ&KLOB?4K6YU*R:[+O)KT.F6LSHF8$DC1B<
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M+"^QXY%Z,#^)_.N<UWPM'9Z=?R:?;:C>/J%Q UXL5X1*%0KEX\L,O\B]_P#
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M(C.VX)QN4@ ')( [CMP>J&@0+J]SJBW-R+JY@6WD8,N-BY(P-O!!)/XUF2>
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MM-9GBCU*V"S;HHV*@6VX;25[$<9S[YKL+?PQ90FW,TMQ=_9H'MX/M#AO+1@
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M>!M*,=Q&LU\J3W:7KC[06_>K@AOFSW4'WQ5R;PQ8W%[J%U<//*VH6OV2X5F
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M0J_@"03[ T 4])\4P:KXFU71EB*/9!6B<])UR5=E]E=2M;DUQ!;A3/-'$&.
M78+D^G-><^(+2Y\'3>'_ !#-=VKV^G.ME<^7"T;/!)@%F)=MQ#8;ZDFK/B#5
M-.L_&4LEW?6$L%YHWE)%<W"1JN7;D%C@JW?&2-@X/% '?2310@&21$SG&Y@.
M@R?TIC7=LAB#7$0,W^K!<?/]/6O,(-#T2UOO .GN^FWJ&&YCEFB"%+@^5SG'
MWAN]>M.G30?M_B#P[KU^VF*9(Q:0JL:[[81H(Q"60G(8-PIZ]LDT >G2W,$+
MHDLT<;2'"*[ %CZ#UHEN8( QEGCC"@%M[@8!X!->97$FDSZGK^B>*-5N+)IU
MB^S_ &@1AY8/*0+L9D)+APY(4_>)P*MV>G:3-XRUV"[ABF4:1:EQ=A2Y;$@+
M..F_&,GW]Z /0_/A\X0^;'YI7<$W#<1ZX]*0W, N!;F:/SR-PCW#=CUQUKRK
M2H[&#P[\.K]! M[)=Q1R7&1YC*89%*ENI'"C'L!4VD/I&K0PV>KZK<P^(+34
MVD:S01K.9A(2"N4W,A4CG.-O< 4 >GFZMU<(T\08OL +C);KCZ^U5H=8L;C5
M[G2XKA&N[9$>5 1\N_=@?7"DX]"/6O*;ZUTN/P5XSNXXK59[;6Y#!* NZ(B2
M,C8?X>_2NOTEK&+XH:^K^0L\]M:/;@@;GXEW,OK[D4 =C-<06R!YYHXE)P"[
M!03Z<T37$%M'YD\T<29QN=@HS]37$:EJ6F6GCS4;3Q++##976FQI9/<L%B*Y
M<3*&/ 8DKGN0![5'IK6=IXSM[*Y0QZ6=&1-+%V200&/F#YOXBNPD'G:!0!WK
M2QKMW.HWG"Y/7OQ5&_UO3M-TTW]Q=1?9]P165P=[$X"CU.:\QL[&#S?#$-XD
M3VAUR\CL?-P<V>R38O/5#Q@="".U)JD=C#HGB^")+=+:UUZUD"*!MB4M!O('
M8?>S^- 'K+WEK&8P]S"IE_U89P-_T]:B9[P:O'&&M?L1@8LI)\XN",$#IMP3
MGOG%>9^+M1TBXM_%L%G):Q2+ID?+MN-PH5F3R%S@*,Y+#//88S6Q;RZ==_$/
M39B]M*MSX>D\QR5(E'F1]?48!_#- '=+=6[R+&L\3.X)50X)('4@4"ZMS.8!
M/$9AUC#C<._3K7D>BPZ=;>#_  #?1+;QW;:I'&TXQO*D2@J6ZXZ#'3I6[ILT
MUAXAT]5:TU;2[K4;C[-,ORW5G,PD+J_]Y1\X)X(XSVH [6[UBRL]1M-/FG1;
MJZW&*,L 2%&23[=!]36?X;U^758;W[?]FAGAU&>SC6-B _EG&1GDFLKQ,;*#
MX@>%I[P0)&T5VF^4#!;;'M&3U/7 _*N2O8]//@WQ+J6+<WD/B-VBN#@O'_I2
M8VMU'!/3U- 'KDES!#)''+-&CR'"*S %C[#O4I( R>!7F%]-H]_JWB71_$NJ
MR64TUPKP)B,&6#8OEF)F0DD,&X4]<\9)KHO&LTUEX/@FS<FVAGMVO3M#R^0'
M7>2,$'CJ,$$9[4 =.EW;2P-/'<1/"N=TBN"HQUR:1[RUC69GN(E6 9F)<?NQ
MC.6]./6O+/%$'AVY\)^)M4TW5#J!GMHO.<&,PJZL-A^50!)@GWQUQQ6S=VFG
M6_CZ:VLX;=%N?#TS/'&!^]82KM)'\1Y;D\]: .JBU5M4T_3;_29K0VUQ(C2&
MX)!,3 G"X_C^[@'WK3-Q )!&9H_,+;0NX9SC.,>N.:\JM9=+?PC\/)('M3-'
MJ%HDCIMRK>2VX$^N<9'TJW::7:7'_"=3:=:6\FJVMW*]B44%XI#;K@IZ$MGI
MU(]J /28[F"61XXYHWDC.'56!*_4=J<9H@[(9$WJ,E=PR!ZUP/A=_#FKZCHF
MH:=JL\M_;6SQFUC$:F-"OS+,JH#@,!C)^]C&<U>U>YM-.^)NE75[-#;0RZ7<
M1"65@JLPDC.W)[XR<4 =>)X2JL)4*L=JG<,$^@HBGAGC\R*5)$Y&Y&!''7FO
M(+ :9=:5X7CD%NQ7Q)<QLC8!"%ISM(Z@'Y>#[5-J4\6ER^)K>U5(])BURR:^
MA@'RI;E(_-.T=B1AO;- '>VOB"2Z\:2Z/']EDLUL!=)-$^YBWF;"#V[&MN.Y
M@F:18IXW,9PX5P=I]_2O,-?O+>3Q3K<GAZ>WDNYO#9\LVCJ6D82'[NWJVSIC
MGI5E/^$5UBVEU/3]4:[D72I8I+=5B5(XMN0)E5!C# 8![].] 'HAO;4(SFYA
MV(H9F\P84'H3[&JUWKFG6<UE%-=Q![V0QP .#N(4L3] !U^GK7!:?I%B/!'A
M6\TRYLM/U:9+8QW$D89+B587_=R]R,%_<$#'05 UW:ROX7NM2T^ST]8-9NH+
MDA@8"^R7)5C_  LY) /?([4 >GFZMQ<"W,\7GD9$>\;B/7'6A[JWC.'GB4[@
MF&<#YCT'UKRC5=5TV0^=;S06OD>)XFFCE?,X82A6D8D_(F. ,8QCGG%&I6>D
M3:9\2)O(M6:)B\)*C]VWV=#E?[I+=QR2/:@#U6[N4MH23+#&[?+'YS[06["L
M'P]K>I:YH&AZIML8?M98W2,6!V_-@1^K9 Z]LUA:;JED_B_4(M?G@\N;2[;[
M URPV21%3YVTG@DL1GN0!Z5A^'I+)M&^&\BO 94NIHBV1N \N7*_GCCZ4 >L
MFZMU<(T\08OL +C);T^OM2RW$$+(LLT<;.<(&8 L?;UKQ^^M=+C\$^,;N.*U
M6>VUR0P2@+NB(DC(V'^'OTK9\17FGQ^(/$]C=ZCIQ.IZ;#%"+RY6(0':X'WN
MJY(?*Y(/:@#TNHH[F"622..:-WC.'57!*_4=JYF]M)M/^&$]KX?DCEGBTXK!
M+:@ 2-MY==O&2<GCN:R'-E>S>";OP^8A-Y@6018R+7RCY@<#L&"CGHQ'>@#<
MAU^_U;4;N/1_L+PV-\MK-'.QWR+M5G=&!P,;\ $'.T\C-7;WQ!;QOJ=I9RPR
MZA8VPG:)VX&0Q ..<X0G'H1ZUB^!$LO[0\4FW6WWIK$J@Q@9"^7'QQVR#5"=
M["T\:^,%G-O%/+IL#PA\!F^2;>5_J?SH ZWP]J_]L:#IEY,T*W=U9Q7+PH?N
M[E!. 3G&36@+F W!MQ-&9@-QCW#<!ZXZUYAH\-C:+\-;FV6WCN9[<I+(,!I,
MVIX8]2-P'!Z8%+X:?1]7MM&BU#5;E/$5A>;Y;-!&LXG!(DW?)N*$$ECG&._%
M 'J+R)'C>ZKGIDXSQG^0-,6Y@>W^T+/&8<9\P.-N/KTKCO&5M83>+_"!OXH6
MB>YN(G,H&&!@;"GU!...ASBN=D33M#O]71(431)=;LULQOV6T-P$W2,V.-@8
M#(Z;ACC' !ZFMS;O )TGB:$_\M X*_G5.;7=-@U&UL&NXC<W)<(BN"?E'S$\
M\8/'U->4ZE/82^'O%T,MU:RLNMVTR,F$ #&#+H,_*#\W(///)KJ=5T_0]&\=
M>&&CM+&TMIEO"2L:JKR%8]OU8XX_2@#LK.6[+WGVQ[0HDQ$/D$Y6/:"/,ST;
MKTXQBIX[JWE@,\<\3PC.9%<%1CKS7E4EQ%8:5XC> [+"'Q0KWHMU#;(-D>YM
MN"" V"1@]#6G-::#=VFJWFE>)'W7DMJ9+L>4]LDRN/+R%"J22 &'H1G'% 'H
M<,\-Q'O@E25/[R,&'Z4"X@,HB$T9D)("[AG(Z\>V17.>#[JYG.KV]_8VL%[!
M=@7$MH28;AC&GSKGD';M!!Z?C7'6NFVK>%_&%[I=G#)J=IJ5Z+=X%!DB0X#"
M,C[N5+8 ]: /4XKF"=G6&:.0H<.$8':?0XZ4L=Q!,[I%-&[(<.%8$J??TKSZ
MT_X1S5O.U31M?G-S_94L+- L:BWB*Y!D5$!!4] >>N!UJIX>?1M9O_"UQ]JT
M@S:38,C01W$<LDS[5V[5'(V[2W.""?J: /2TNK>2=X4GB:5/O1JX++]1VI5N
M('D$:S1ESGY0PSQP>/:O)])U/2Y=4\%3V\]K%:-)=)Y!??)&'C<[9G)Y=FQQ
M@<^O6HH;*UA^&FLZGIEI$]];WMS'YT"@RQVYN/G52.0/+R<#W- 'H$GB&3_A
M,K'2(#:RVMQ;S2-(C[G5XR@QQP/OUJ:?/<FQ1M1EL_M#2,N;9CY9^8A0-W.<
M8S[YKBFO/#]S\1/#TNGSV#P3:9<Q9B9=K+^[*J1]-W'UKG["+3IO"7@M'%NR
MC7Y8P,C[A>?*_P"Z?EXZ'B@#UZ*>&:,R12I(@)!9&!&1UYHAN(;E-\$T<J@X
MW(P89_"O+=2CM;:T^(-G:7%O96\4]K($7Y8P2D>Y2!T#D;2?<YK?\/\ ]D:Q
MXWNM>M;K2Y)391P)!!/'-*I!;=(2I.!A@O'4#G' H ZJ6:ZCU2,>9:+8^0[2
M!V(EW@C!';;C.?PIEAKFG:EIHU"WNXC:%F42LX X8KG/H<<5SMXEK_PMFP#+
M#YDNCSK("!EQYD> ?7C/ZUS/AU8I_!GAZ+2]2L;/6;:>5DCN$#1RR R QR <
MAMI)'<8H ]61TD0/&RLIZ%3D&HEOK1@Q6Z@.TX;$@X/H:YS0[R*[\!W$L]J=
M,15N4F2W;<J$,X=HSW&<D5R-X+M=!UO2+N&QU!E\/RO::G8KCS85X59$Y ;/
M(P<'G'>@#U*:?".D+Q&?865&;^>.<5D^%->.O>'=.OKDP17=W#YIAC;H,D<
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M3[)+&) [,!A2,C/IUKG/"7E7GPGTY$V3#^S A48;Y@G3ZYKFM!OK6.T\ $O
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M"2IXX;*D8ZY]N:9J'B6WNM&N_LL.HB9;/SY5CC*2VP925W D$-P3M&3@=.E
M'2(B1H$155%& JC  IK01.26B1BV,DJ#G'2L3PG=S2> M'O)S-<SMI\4CG.Y
MY&V GDGDGW-0:'XOBU/P_8:E<6LT,M\Y6W@ !:4_,0%Y[*,DG X)XH Z(6\"
ML&$,88="%'%"00QR/(D2*[\NRJ 6^I[U3TS6;757NH8?,CN;201W%O*NUXF(
MR,CH01R""0?6HI=>MH[N6!8;B80SQV\TD2@K'(^W:#SGHZDD @9H U&574JR
MAE(P01D&HX+:"U0I;PQQ*3G;&@49_"L67Q?IL&DZEJ,B7*P:;.;>Z'E@M&P
M)XSR/F'(SUJQJ7B*STS[5OCGG^R0B>Z\A WD1G)W-DCL"<#)P.E &FMO"L[3
M+#&)6&&<*-Q'N:3[+;X(\B+!Z_(*XLZ^+7QU=31RWU[8RZ-#=0V\ :0$M(^6
M5>@^4#GC\S77Z=J-KJNF6^HV<F^VN(Q+&Y&,J1GD=J )/LEMYB2?9XMZ?=;8
M,K]#VI7MH)'+O#&SLNPL5!)7T^E9,?B>TE@6XCMKMK=[9[N*4(I66)=N2.?1
M@0#@D=J<GB33[C^QU0SA=9C+VD@7 /[LO@]U.T9H UO)B,GF>6F_^]M&?SII
MMX&&##&1DG!4=3U-<%X7\8VVFZ'#'J\NH2;K^X@:^EC=XT/GNJ*\AZ<8'H..
ME=%;ZMID6N:\[7=X)+..%KI)]WE1##;3&I]<'..O'6@#;^S6_/[B+GK\@YK!
MO] U%]7DO+&\L#!+&D9M;VS,JQ[23E"K+C.>0<YJP/%6G1WEQ:7OFV$T%L;L
MBZ4*&A!P7!!(X/4=1Z5!=^,+2T6[1[.\%U!9-?);N@5I8AP67G P<9!P1Z4
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M1%&TDD99602$A@K'!^8=,CW[5Z9534]-MM7TZ>PO%=[:=2DB*[)N4]1D$'%
M'(W.C7/BA=!W6TUG%9VTC232%<[GA\L*N"<_>W$].!Z\)X7L]1MH;.RO_"-K
M!=6"A7U!?*990HP&CQ\VYL#K@#)Y[5VMM;QVEK%;Q;O+B4*NYBQP.G)Y-2T
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MY2 #D=.>*AETC4-)\137)\,6NKV5];PJ8X/*7[)*B[2H$F/W9&.1Z=*] HH
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MPLOL#R26^4GA!R 5# @@C((/K0!!!XUO)18H]K EQ_;)TB]CY(5PK-O0YZ$
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M(QG(P.W% &C;:YXBDTJRU&Y@TN&UO! XE\QO]'1D+.SAB-W.T *?XN^.:?\
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M7"KM52[%BJKD[5&< 9-:M !1110 4444 %%%% !1110 4444 %%%% !1110
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MK5\9ZK+I&AQS12"(2W<$$DQ;:(T>0!F)[<<9[9S0!O331V\$DTKA(XU+NQZ
M 9)KG1XPC5;>673+Q+:\CB>SG^4K,TC*J(>?E8[@<'MDYX-9>I:3>VVF^(A=
M:DSV<^G/+%:"ZE=HG53E@Y.[:<C*]/UK,U#38!X+\$GS+KY[W3L_Z7+_ !!<
MX^;CIQCIVQ0!WVF7\]\D_P!HT^>REAE,167!#X (9&'WE.>OKD=JO5PDPO\
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M:F75X()# ^W<C9R#Z]!UKG-1UB^\.#Q9;6]]=/!;SV0BEN)3*ULL^!(P9LG
MY(SP": /3:CAFBN(5EA=7C;E64Y!KC-72?3?%%EIUO<W<FGZG8W0N(GN9',;
M1JI616)W+G=M."!R.]7_ (=P)#X T1E:0F2TC9M\C-@[1TR3@>PP* -.#6XY
M_$MUHGV:9);>W2X,C;=KJS%1C!)ZJ>N*U:X:\TL:M\2M2MVO;VU3^QX"6M)C
M$Y/FRX^8<\?_ *\UEZ%K>JZD=&T>_NBYDAO,3M.\#79BF"*=R<YV9.!UZ]J
M/3:*Q_#5M>V6E-:7^HB_FAE=1+DE@N<JK$\L0#C/>MB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MJ>IZ59:S9&SOX3-;LP8Q[V4$@Y&<$=" ?PJY4<\\-M"TT\J11(,L[L% ^I-
M&?+X=TN>[FNIK=I)IK8VDCM,YWPG.4//3D_B<]:5?#^EB*>)[8S+/!]GD\^5
MY28N?DRQ) YZ"IX=6TZ>UENHKZW>WA)6602#;&1U#'L?K3%UO2FM9KH:C:^1
M <32&90L9]&.>/QH HW?@SP]?65K9W.FH\5H<P'>X=/7#@[NP[]A4UUX7T:\
MALHY;%5%C_Q[-"[1-%Q@A60@@'N,\U9M=:TN^O'L[74;6>YC0.\,<JLZJ>Y
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MTN8_MD,2R.I8#EB<*/4X!)].* ,NUTC5;2\^V1Z7H[7>W8+B:\FED"^@=T)
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MF.%-0MQ,()!+$0S*R..X92".M26FJ6%](T=I>03NJAF6-P2%/0X]#C@]ZMT
M8?\ PAV@ .$TY(P]PMT1&[H/-'1N",$8_/FK#^'=)EN+V>6T$KWL8BN?,=G$
MJ#H""<<9./3-9GB?Q6?#^I:5#Y.^VFG5;V7M;QOE$8^F7(_!6K?NK^SL1&;N
MZA@\UQ''YKA=[$X"C/4^U &;8^$M$TZZMKFWLB)[9#'#)),\AC4X^4;F/''
M[=JT[VRMM1LI;.\@2>VF7;)'(,AA5./Q%HDMK/=)J]BUO;OLFE%PNV-O1CG
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M;-OJ^F7:3O;:A:S+;Y$QCF5A'CKNP>/QH IWOA/0M1NKJYN].CEENXQ%.2S
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M5.'8# ^@%;U !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)9[?^^%_B ;##']WVK3\33Z;JWA/5]4T>SE=9IK.2>Z6!U,_ERIG (!(51U
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M6UNTBZH R!7&8UV%BS?3&#CN0*J6MA=V'C#5-8O&@2QGM((1*TH!!C+$EAC
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M>I73Z7O%MYIC^ZR[2&(0%N.,GGWK3UC1(M6EL9_M$UO<V,QF@EBVG#%2I!#
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M\LX65LR.LB!7)SDMACSUYK&T_3$M] \!ZUI\DW]K3S6L,S^<S&:%D/F*1G&
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MUZ,^FV,EZ+Q[*W:Z"[1.8E+@>F[&<5%;Z%I%H83;:58PF%F>(QVZ+Y;-PQ7
MX)[D=: /+[."SA^%6F/;K'%<+JD7F>4=I(^V%1N Z\9 S71PI;ZWJ?C"VUG
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M9CCH<GU->KQ7UI/<R6T5U#)<1*&DB20%D!Z$CJ :K7'A_1KJZDNKC2;&:XD
M5Y9+=&9@.Q)&320:+9V^M2ZI'!!'.\(AS'$$)7C[Q'+?= 'H!@=Z ,WQ^N?
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M91V/ERH4:;&[<Y4\CA@HR,\'MC)X(M=1^S22ZJZRS66[38)0<^9'$Y!D]BQ
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MAF6>)XI"C(Z]"".1U/YU5E\+Z<]W<7,9N('NHEAN1#,5$ZJ,#=[@<;A@X[T
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M[+<3+//()2'E=<;2S#TVK@# &!0!?TRRGL;>2.XU"XOF:1G$DX4,H/\ #\H
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M>O(G,'AV5O*F8<3*RXMR/7:C.#Z%5H [NLG4]8CATG49M/N;2:[M8))1&7#
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M&*^MD"7$#7?DJ\D2N"4) /*YR!7F>I7D5W>^,D@O(;R2[\.JT9M4PDI E'R
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MHSJ#D!D?.WRMV#G'3;].:LR:S9)>>,;+6RL.H7,>;6&X'S26Y@&U4'\6&WY
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M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %!
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MSQV=R+6Z9"L4YC$GEMV.T]?I4.DZ=)I]LXN+HW5W,_F7%P4">8V .%'
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MK0!8(!QD X.1FC:N,8&,YZ5PGAF^5M,T/6[V34SJ=_;B,6XF#)>.R[RX3<0
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MB!(&W, "I91U[C&1S6Q97:7UC!=HDB),@<)(N&7(Z$=C0!-M!SD#G@T!0.@
MXQTJEJFJV^DQ0-.LCO<3K;PQQ@%GD;. ,D ="<D@<5E2^-=,@L'NIH;Q/*OA
M82Q^5N:.4D#!P2,?,IR"<YXH Z%41,[$5<G)P,9-*54J5*@@]1CK6'!XMTZ1
MM36Y2XL6TU%EG%U'M/EL"5<8)R#M/OGC%9$NI7%Q\1]"C\G4+2*6RN7>*=\)
M)C9M.T,1D9/7!&: .S50JA5  '  [4$ ]16'XHUZ;0;2RD@LY+EKF]AMOE*@
M+O< ]2.2,@>_7 K!37)-*\9^(I9H-3N(4LK6<6L9\TPY$A<@%MJ]!D \]LT
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M>]\9R_V;+MU.UCCM?WL?SL(BA'WN.3W[5UE_J5EI=M]IO[J&VAR%WRN%!)Z
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M&#($Q@%@3]TYX[UAQ>'-7A\'ZIX1-F9(YY9EMK_S$\ORI7+;G!.[<NYN #G
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M+KP4?#<M[,4-J+;[0% ;   .!QV''>H[#PW=6WB*/6KG5WN)_L0M)(Q;HB.
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M7]G.T@L&+??SU X]/SK-M?!#VFDZ#:0ZJZS:-*SPSB ?,K*RD%22,X8\_I0
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MNTC=TW$_A^= #-7\5:EI5X?,2T$8U*&U%L%:20PR%5$C.K80DL2%8=![U5D
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M*[F))&2>I[UFZU>W>E^(9KG4([B;2'O(/*O;.X8&S(V#RI8\C*,W4C/#\]J
M.]HKSN!K_P 16>HWT>M+I][8:E*K/N<^0L<A 1D#!2K(!U'.<]: ;[Q%!K-Q
M'K2Z=>:?J,J"3<Y-ND;_ "@H&"E60<Y'.X^E '7:7KBZGJFK6(M9(7TZ5(G+
ML#OW('!&,\8(JX]Q<+J<5LMF[6S1,[7.]=J," %V]22"3GIQ7G$VHFT\<Z_:
M7336VEWFH6T=Q?0R%&B?[/&40D$% YXW=NG&<CI+A7C^(]A9I<W0MI=)G+1?
M:'V[A)& W7[V">>M '6T5Y5I+W<7AKP?K!U+4);R?5%MI6ENG97B9Y%*E<[3
MT!R1GCK6AJ$>M:A%K]O!)>G5EU-%L9K>1UBCA_=G:64[5PI?<#SD]SB@#T6B
MLC7XV@\):BL4\Z-#92%)5E82 JA(.[.<\=:XVVMYOM/@9QJ6H[M4M&CO/]+?
M$JBWWCC.%.1U7!Y/.>: /2:*\O75;O38KC2UN[G[&?%":?YSS,SQ0,BOMWD[
MAECMSG(#=>E6O$4E[I>H>(M/L[N[2R.@27Z8G?=;SJ2HVMG(# 9QG&5/O0!Z
M-17GB276D:SX>N+:ZO+B2^TFXDGBFG>197CCC9"%)PIR2/E ZU)H5O<ZQ8:#
MKJZ\%2= MTJR2'[477#(1NPK*V2"H&W!Z"@#NX+B*YC,D$BR(&9-RGC*L58?
M@01^%25Y?X96"W\%>'K=+J[6:\OI56VCF;_2-KS'823\B #<2.NW&"3BHC=:
M@^C+$VH7<+P^+%LU,5T[;8C*OR;C]Y1GC<* /5:*X35+9?!6J:5J_P#:&H2:
M1O>VO5N;R258O,.8Y2&..&^7)[,/2NG\/P31Z6L]RTWGW3M<,DLC,8MYR$&2
M<;00,#C(- #?$FN+X=T2?4WM9+A(BH9(V (RP7/)Z9(Z9K6KR?5Y_P"W_A?J
M^LW<\WVT7C*T8F8+"$N JQ[<XQM )R.2<]<5>\87\Z6OB2^T^]NGFL)8!YGG
MF)+1AL)1%'WR=V6R /FQDXP #TJBN&FLVU'QMXAL9[Z_%JNGV\J117<B!')D
M!*[2".@X''J#65IEQ>#2O FLOJ%[)>WT\=O<F2X8I(C1.<%,[<Y4'.,YY))H
M ].HKS7[?-]LT'4;*]N9X+K7)(&NI9ROGH?-!01<KL7: "<'Y<XYS4EU%K6I
M0:M!#+>_VLNLA;>>"5UB6WW+D;E.T 1[@5Z[O?% 'HU%<!)'=Z_J'B+2TU4V
M5QITB16[&:0/!'Y2,LO# -EBV2<YQ@U%J%_?:=?B]U-I[W2GDM<:C8S,AM6
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M6>*T$<DL0A=D=ER@Z+P>@[>E-7PUI"6]G;K9@0V3^9;(';$+>J\\=_S-:M%
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%(2 ,DX'O2T %%&1G&: <C(Z4 %%%%
M !1110 4444 %%&<44 %%%% !1110 4444 %%%("#T(- "T444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !10"#T-% !1110 4444 %%%% !1110 4
M49 QSUHH **** "BBB@ HHHH **** "BBB@ HHHH ***,C.,\T %%%&><4 %
M%%% !1110 449!_"B@ HI,C&<C%+0 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M./B#2F8-\[F"Z1EVL"=H*D@ ]" 10!)_PG\']GI<#3;B20:DNG2)%(K*KL0
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M+.L.=B?[*D\D#U/4YZ=!:H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M#/JT2VNG:I);^2MJO[V/RD(4G.1@MG/7KGM@ Z^BBB@ HHHH **** "BBB@
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M#''(&; 'EYC5AQNSD8Y&.>FO>>$K"_\ #EKHMQ-=&.T\LVUPL@6:)D&%96
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M]2&V=7AF#)YB8;<!G;@C/J#P<4RX\':;=V]VEP\[W%U<1W370*K(LL8 1EP
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M6H7#-*DDTT\BL\P4Y"-\N-G^R .I]3D'A6P_M#5;EGG>+54V7=HQ7R7^7;G
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MU]_+ ;W,@KOFC1V1G169#N0D9*G!&1Z'!(_$T+'&C.R(JESN<@8W' &3ZG
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MMX8X8E^ZD:A5'T J*;3K*XMTMY[.WEA3&R-XE95^@(P*GCC2) D:*B*,!5&
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MND@*K-J\WD.>?+D$494Y^OZ9%:_A>>/Q3;PZM=V:Q-!;?8C&R;2DO_+8#V!
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M ACYL3'[I9L<*>=W(&#6=<:=J,GA+7+9=-NS/<:^;J*/RCEHOM"/N_[Y4^]
M'<6/B/3-0N+RWBF=);-1),L\+Q80YPXW@97@\CCBHHO%6DRW5G;K+,)+Y-]K
MFWDQ,O'S*=O3D=<8!!Z&L/4;<R>+=:O+FSG;39=!%NTC#RU<AI&9=QQM^5AR
M>*S?#]QMN_#QUC3]:ADT^#[);236.R-6D"I\[JS9/ 4'"CGD<\ &YX8U:2.W
M\02ZG?23):ZQ+;QO(,L%P@5 %')RV  .2:W-/UJRU.YNK6!W6YM2HF@EC:-T
MW#*G!'0]B.*X272-6FT?6WM].E>=/$']I16TPV"ZA&S@$],@'&>X%=3X;$%S
M/-J$/AZ72BZ+&SW4:I-(1VP"?E'OUSQTY ->]U*VL&A29F,LY*Q11H7=R!DX
M [ =3T%9TOB[1(=+.HR7A6V6?[,Y,3YCER%VN,90Y(^]CK5+6[6]M?&6CZ[%
M!+<V44$UK<)$I9XMY4B0*.6&5 ..>E<]K&AW\FGZ]>0V5PQU/5;2>&V5/F$<
M31[G8?PEMC'!YZ=^* .^TS5+;5K=Y[7S=B2-$WFPM&=R]>& -9%[XYT#3Y+N
M.>ZFW6;A+D):RMY61G+87A<$?-TYKHE8.H89P1GD8/Y5P-M<;?$?CRU%E<7+
MSO"B)'$660FV0;2>B]>K8'/7K0!U%WXFTJS +3M+FV^V'R(VEQ!_ST.T'Y?Y
M\XZ5%>^+M%L#;":Y=C=0&XMQ% \GFQ@ DKM!SP0<#GFN2&CZQIUE!H4EA<W$
M$>AK;QSV>%\R<!@RR/D,%'&!T.3U/%6-(M+]+_P,TVF7<2V.FRV]R7C_ -4Y
M2-5SC/4HWT[XH WM.\7VFIZQJ-E'!=K%:0Q2"4VTGS;U9NF.!@+C."3G&:=I
M6NZ9!H.E-'J5UJ"W@*VLLB%IKC&23@*.@!YP.!5:QBN[#QUX@N);&X:UO(;=
MXIT4,OR(P8=<YSCC'>L#1K?6--\->$K*32;SRX1+'?>3&!/"V/D )(VJV3EE
M/8<CF@#8\2Z]]J\,V&J:-?RI&^HV\+%%VE@9@CHP89'<$<5V->7QZ7JD?@@:
M>VDWJSQZZ)]A&\F,7/F%L@G("]SU[9KTN9#<6LB*Q0R(0&Q@KD=: ,U?$VEM
M>6UMYSAKHLMO(T3".9EY(1\8)P..>>V:9;^+-'NMPAGF9TN_L;)]FE#B;&[:
M5*YZ G/3'>N7\*V<T-MINDZEX3D2_P!,V*;YT5H,(,"1&SDL0. !D$\\5)-:
MW]IXH@\6VFFSM]JD-I=V0A_>"$<+-_OC'/JI ZCD ZG4O$>FZ3YS7<L@C@V^
M?(D+.D.>F\@$+U!]@03Q5>X\8:+;:A)8M<2M<QF/<D=O(^!(<*V0N-O^UTY'
M/(KFY+2>Q\0:S;W_ (8N-7L]3F%Q;3Q*K+\R*ICE#$;0"O4YX-:FC6=Q:^.M
M4E>R>*VDL+6"*1(R(MT>_<JGT&X8H UG\3:5'=00-<,//N#:Q2^6WE/-S\@?
M&,Y!'7J".O%5[+6--CFUFX_M.YF6"Y2.:.9"! Y50$0;03DD>N2W%8GA,ZKI
MEA;^&[[0KB2>RG.V^95-N\>\L) V<[L'IC.?3G$9TYIF\7I?:1>7%I?7T#HB
M*5:2,+&A=#URI4L._P M '6KKEB8;B5VEB%O(L4BR0LK;V VJ!C+$[AC&<YI
M=.UJRU2>ZM[=W%Q:,%GAEC9'CR,J2".A'0]#7"W.C^(3I%PL1N=6MM/U""ZL
MUO5\NXN8E4^9&Q(!.,\%ADD?2NI\-K!<2W%_#X?ETKS%5&:YC5)I2,]0"?E'
M;)YR?Q -:]U*VL'ACF9C+.2(HHT+N^!DX [ =3T%8>N>+K:V\&:GK.F.TTEL
MDB*IA;,<R@\2+C*X/7=CMZBFZU:WEIXTTC78X);FRCMYK2X2)2[Q;RK"0*.2
M,J <<]*Q-4T.^?PWXTGAM)S+K3_Z+:JGSX$:H&(_A+$$\]!C//% '5:%;2 M
M?#4+^:">)!]GNT(V./O,NX!@#Z=/2G7'BC2;:Y>&2X;]W<):R2")C''*V-J,
MP& 3N7Z9&<5HV3^98P-L=#L&5=2I!QT(->=^(;76=0@UB%M&O6ECU.":W%L%
M6&2%9(SOX(WN0ISG.,#IB@#K;SQCHUC<7UO--<&:Q57N(X[65RBD$[L!?NX!
M)/0<<\U:7Q%I;ZC96*7#-/?0^?;;8G*R)C.0V-O0COW%<Y]GNSKOBZX:PNEC
MO+"".#,1.]U20,HQGD%@/3TXJO=:=>6_PYT&]BA:+6-#A@DCBD&TLRJ$DB/^
M^,KQU.* .VM;^WO9;F.!G+6TOE2[HV4!L X!(P>".1FJU_KMCISS).TI,$0F
MF\J%I/+0YP6V@XSM;\C4FD63V&EPP2L&G.9)W'1I&)9S]-Q-<IXLTRYN-3NK
MW2DU&TUB*V5;>>!"\%Y]XB&53E< GJV,;NO% '3'Q!IPGU*'S9/-TU%DND\A
M\HK D$<?,"%/W<]*!K^GO:V=Q#*\RWL7GVZ11,SR1X!W;<9 P1UQU ZFN7N8
M-4L_$/B%WTNYN#JNFP)%);J#&)$20,K$GCE@1ZCID\51TR'6?#[^&]4DT6]N
M8$T9--NK>$*TT#J5(?;GD'&#SQ@9H T]3\313:OX3U#3]3E;2KV2X61(T)$N
MV)R!MQN+!AC;ZCIFNGTG6;+6[5[BR=V6.5H9%DC:-XW7JK*P!!Z=?6N<OH+R
M?7O"ET-+E@BM[BXEFCCCR(%>-E7=MXW$D9QG!)^M6_"-O<6][XC:>VFA6XU1
M[B$R(5#H4101^*GWH T-2\3Z5I-\ME=S2BZ>(RI#' \C.H(!VA0=QY' YI+3
MQ1H]]I$6J6UWYEM+)Y*81MYDSC9LQNW>V/?I6+K-RMK\3=$D>*5U_LZZ!\J,
MN5^>+G Y]N!WK('AW5+*>'78+21E&O2ZB]BN-_DR)Y>[;_?Q\^WK\V.O% '7
MR>+-'ALKZ[FGEC2P(%VC0/YD.1D%D S@CG.,8[U837M/DU:'3%DE^US0?:(T
M,#@-'Q\V[&.XXSGFL:UT8:IXHUC5)[>2/3[RPCL?+E0HTV"Y=BIY PP49&>O
M;&>>B\/>)H-,TJ_4;M7TBX^PVZLV5DM<F(R,/4@JY]HQ0!W(UZP>!)8VF?S'
M>-(U@?>Y0X;"XS@$=>GOS5,^,]!6TM+DWC>7=RM!%B"0DR#.4(VY#<'Y3S6/
MXATRXTK4M#O[72I]5TZSMI+.>WAPTJJVPK(H)&XY3!^M0WU@Y'AZ6RT"6SA3
M6!>RP1Q#<B>6ZEY-N1N)8' )./<&@#L].OX-4L(;VV\SR91E?,C9&ZXY5@".
ME1:OK5AH5F+O49C# 76/?L9@&8X&<#CD]3Q4;ZQY?B./2'L;H"6 RI=[1Y1(
M/*9SG..>E9?CVVN+SPS]GM+::XF-U;N(XDW':DR.Q_)30 ]O$&EZCJ.E+'J%
M_;R/=211P_9WC6=E1MRON3H!R.1T%6[SQ3I%@)VGN'$5O,()I4A=TCD.,(2
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M^@N[AHF 9MI1UVDJPYXY^HH ZZBLW6]731K%)VC,DDLR011C/S.YP.@)QW.
M3@'@UDP:_K4[:I;1:-ON+6-9;:1UDAAN@0<J"R_*P(QW'(H W[^PMM4L)[&\
MB$MM.A21"2,@^XY%4+#P[;6,B.UWJ%WY9S&MW=/*J'L<$\GW.2*HZ#XJ;6M/
M?4S;K!I\%ONG=RP=)@"9(]I'1,<GUX[&HK3Q5J%U>Z:%TB5[34$+"18Y1]F.
MW<OF,4VX/3(Z'UZT =72$A5+,0 !DD]JXJR\:ZC+H;ZY=Z3;Q:>AEB(2Y+2-
M,LWE(H!4##'C)QWXQUV6O]9CGO(+K2H)(4M//CF2;$;MR#$V1G..<XP0>@H
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MNQ\1W\GB&RTZ^L((8K^S>YMGBF+L-FW<KC  X<'@G\>M &F=$MSXA&M^;/\
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M_P!DDBCT;4+<1W-CAB3)MVF16SP2N ?7&<YI/#^A>(-(BAL+K6;>ZTVS7;;
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MI.CW^BV6N'[7;>;>74UY"_EL5B9QP&&?F ('IFM/1'U"31;9M4V&]VGS"B%
MW)PVT\KD8..V<5%KGB"UT'2;G49DEGBMV5)5@ 9E)QC.2/[R_G6K0!S^AZ'>
MZ39:M#)/;RO>WD]TA52 AD.=I]<>O>N5U2R?0=%\,>'IM5TZWFM2SI<WL3+
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M;S6K=)EE9=I1N&087(7C.,]S4=YJUW8>)O*U;[;#:7%]&ME?VTA>WQE1Y$J
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M*'L0S6MMKUO<W$5J S>2%C+LJX(.",GC^$T >H6E]9W\;26=W!<HK;6:&0.
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M:L-8A_X1S3]2U*YM[;[1;1R.\CA$W,@8XR?K7&>;:QM\2EC>)5* @*0 3]E
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M#D%@Q )&2 <?@<&F>(+F_P#%FKZ4UA*EO9+"%FW(02X9MQ^;."-N  >G.,T
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MI=Y3#C?\OS C_P#6*L:QXKM=%MM0N+FTO'@L6C662)58$OC 'S9XW+G..HH
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M]A=B_L(+L0RPB9!((Y@ Z@C(R 3@_C6*_C+3H[BR5HYQ;7MQ]F@N_D,;R'(
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MM& 22[ #D@=>?P.,B'QYI=S%I3VUO>S_ -IM*D*I$,J\88LC<\'Y2/3OG'-
M&SJUI?7EFL6G:D=.F$BL9A LN5'5<-QSZU/8V<>GV45K$698Q]YSEF)Y+'W)
M))]S7+:EXX*>&+K4K+3;K[1;WJV,T$^Q6@D+*O/S$'[ZD8)SD=!G&@^HVC>+
M;2"2SU!-2-A++&A<"/8&7<I ?:6SMP?UH Z&CK7&:?X[8^%UUO4M*O(X6NW@
MW1&-E0><T:Y^<<# !) Y/I723:JL5_)9K:W,LD=M]I8QA2 ,D!>N=Q(..,'!
MYH OT57L;HWUA!=&WGMS-&'\F==LB9'1AV(JQ0 4444 %%%% !1110 4444
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M)XKT'4/L+BWM+*:&8F1,JS[,<;N?N'\Q6_J&IV.E0I-?74=O&[K&I<XW,3@
M>IIW]H6G]IG3?/7[8(?/\GOY>=N[Z9XH X'_ (1G78['[7!8PO>VNM7.H1VE
MQ(NRXAEW KD9"MAN_ (K1UC3=9U?PWY:Z+!9SO=V\HM8ID)18Y%=BS\ DX(
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MMP[PM@?+E259<>Q!% $>B7\VJ:/;WEQ:_99I =\0<.%()'##A@<9![@BK]
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MU&Q@U33;JPN5W07,312#V88-8\/@^PBFT.;?(\NDHZJ['F;<!DOZG< _UYH
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M>!Z<#$6G^"7L9=#=M;NI?['5XH%\J-08F4+M.!UP!S_+K0!R^DZOK?A[P/\
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M"@(YZ[2>O?\ *LW6+.UN-'M?!+"[GNUB@\NXC@=%C5& $GF#Y590N>O)X[T
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MR>N*Z&[>9+&9X2BS+&67>"RYQWP1D5S[^$)(];O+[3]9N[&WOV#WMK$B%9'
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M#AB.,"NNCD2:-9(W5T89#*<@_C0 ZBBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
.4444 %%%% !1110!_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>41
<FILENAME>exhibit1018-arvinasxcons009.jpg
<TEXT>
begin 644 exhibit1018-arvinasxcons009.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=S",;5)QT!/ &3FL-M(UFQN+2\CTJ6Z,&O7=X88I8@QBD2158;F _C'&<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M:XL93(B2-%(&4JT;KPRLI ((]#1?:I;:>RI+YKRLI<10Q-(Y4=3M4$XY'YT
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MK?7#P1"=9%C64K+ \>48D C<!GH?IWH O457O;ZVT^W\^ZDV(6"+P268G 4
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M3M(\0V\&CSRROK+W2MY2.&A>56WQACAG"Y(!'!'X5Z!)/#"T:RRQHTK;(PS
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M5D]"5_GCK4OA2PO]-U::WAN+Z?0A;*81J,9$MO)N_P!6K, S+M^H'&#7844
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MR1J0\[1J5C+ \+C.3@G) Z=*M:7H]]I^N:YJ+26\@U*2.1(QN'EE(P@!/?.
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M9164$^N=V<<8Q0 _P)_R(&@?]>$/_H KH:R_#FF2Z+X<T_2YI$E>T@6'S$!
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MUH^CROL8J<2+)&H?IRV">N:YK3=0U=?#OAG69=9O)IY]7%I+&Y7RWC:9T((
MY. ,'MCB@#U"BO/]:OM;D;Q+#;S7D>J6\L0TI+<$HRE5(R,;6)8MNW=!@\#!
MKN[:.2*UBCEE>615 9WQEC[X 'Z"@#/DUZW_ +0FL+2"XOKF#'GI;A<19Y 9
MF(7..<9S[5)8ZE::REW$L4F;>7R9XKB(J0VU6Q@]1AAR.#VS7,?"YF_L+5$N
M#_Q,%U6Y^V _>\S=W_#%:7BK5#IATZ"U<0RZEJ4%G/,F-R*P)S[$A=H/O[4
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MQ@(-0N[5H-.M'5X' <L$E()8@GM^-2V&N:CKDFB6#2 27.B1W\I6Y:W:21L
MD,JD_+UP,?>YSB@#OJ*RO#L>I0:+#!J]Y#>7L19))X>C8)QG@?-C /'6M6@
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M.[M(X7$GFPR#][+Q\OE\]N2>#QZ4XZMIJR1QG4+0/)(8D4S+EG'50,\GD<4
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MMK3QYKRZU+"EI>VEN;&2=AY<D*JWF(">/O-DCN"#7;4A /4 T >3Z58I;2^
M+;540R+)>;$N -ZPE7\E6SST*X![\=:WO"NKZ7I$/B>:>YBAM$UQPNP9 WB,
M# 7L6)]LYKNZ,9H **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M64PC[3$4*L&VC<#T#'H>AR/45I5Q6D3W.N_#"_.IW!N)I$O8GE90I(6215.
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M@\@#;"=_3@9]><UN#5-2L3XLT^37"/L+6YMKV[B5FC$J@E<(H#'.0HQU('-
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M444 %%%% !1110 4444 %%%% !115'5-6LM&MDGO9EB225(4R1EG9@H _/\
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M.<8QC.><_P!.*I77B&2/Q?I6DV[6LMM=I.975]SHT84XX.!][OZ5JZA)=QI
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M4 %%%% !7(?$981X?LY[A8_*AU.T9W<#"+YRY))Z#UKKZ1D5U*NH93U!&0:
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M&BCNMD>-Y92H.T.,]1DCUKTY(HX_N1JO 'RC' Z"D:WA>'R6AC:+^X5!7\J
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M^T^2VN2I\F^L3,8=J@80JZ_+U.#W)YYH O>&+&UT_P +Z=9VDUO<0QVZ+Y\
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MO#LLWE!TURTV.^,K\_.#].M=7';00G,4,:'D_*H'7K^>!3WBCDQO16QTW#-
M'F-]8Z1<:M\1?.@M',=I$XW!3L8P-EAZ-G'/7-=SX:=;SPAI+2,LPEL8=Y;Y
M@V4&<^M:?V>')/DQ\]?E'-/5510J*%4=@,4 >27%E>V.EW&G6MIND\(WK7T#
ME,^; 3O2,'OE&D!QWC7UK4\70VDW@@ZI=11QRW^HVMR&D 5U0RHJC/4$1@9]
M/FKT?8IW?*/FZ\=::T4;@!T5@.@(SB@#A]:T_2-*\6>#Q96MG:;[Z=L1(J9W
M0/GIZG'Z5E(NF)H/Q$M)5M1<+/=OY3!=RIY*;3CL,XQ[]*]-,,3%28T.W@94
M<4&*-MV8T.[&[*CG'3- 'G$<&FWGB'P()TMI?,TB4,&P=X"1;0?4 YP#[UGQ
MSVMKX/N"EY;P6ECXI<K"[A8FC%P2(R>BKSN!/' KU;[/""#Y,?'3Y1Q63K>B
MW%_':MIUW#:2V\WF[);<213?*1AU!!(YR.>#@T 8_A&+2KOQ'KVN65WIL\EZ
M\>([65)7A4( 2Q7."S#..G [UF>,KW3VU77K-VA@O/[$*EKD[C.A\PA(4SUS
MU;GMQQFNLTK19+6\^W7ALFN_+,0-G:^2@4D$YRS%CE1U/;IUK7:*-G#LBE@"
M Q'(![4 >;6%UI[^(/!-Y/+;LDVC21B5R#YDH$/R@]VSGCKUK<^(8@72M*N+
MD1B&'6+-I)) -J)YHW$D]!ZUUGE1@( BX3[O'W>W'I3G19%*NH93U!&0: //
M)8='U+QIXB$Z6D]NNC6YC#[2H'[WD \=".?0^]96F:O!;6?@V75]0:UTR71_
M*CN6"-&MQ\F0Y=2 2@(!..X[FO53!"228D)/4[1S2-;0/$8GAC:,\E"H(_*@
M#'\(V5A8>'XX-*N)[BP$CM!),0=REL_)@ ;,DXXZ=.,5NT  # & ** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH *P_%&O/X?T^WGCM)+AY[J&W 7&%WN%R<D>O'OCZUN5SOC33[S4
M-$A%C;FXFM[VWN?)5E5G5)59@"Q S@'J10 \:G9-XL6%GU%+Y=.:8VQ#>5Y>
M]>=HX9\G'&>XJM%X]T>:VL;H1WRVE[*88KAK9MGF9("GODE3C /IUXI/LVHM
MX_@U9M-F6T&DM;LPDC.)#(K[<;L]!C/3/?O6#:Z'K47@GP[I[:5-]JLM6CN9
MXQ+%\L:S,Y.=^#P1P* .MM/%.G7(U'S!<6CZ<%:X2YB*,JL"58#G(.#COQC%
M2VFOVMUJ[Z4\5Q;7RPBX6*=0#)'G&Y2"1UX(ZCTKE=9\.:MJVI>*Q#:F%+ZU
MM5M)I60H\D+,V" 20"2!R/6MGPXMU<7 N+GPK;Z+)'&4D?,3,[''"%/X>O)Q
MVXH V;[5(+&>"V*R375QN,4$0!9PO+'D@ #(Y) Y ZD5S^O^+TC\#ZOJVDB5
MKFU62%E9,-;RJ.=ZGT.#WSD=0:FUC3[^W\8Z9K]I;O=P1VTMG<PQL Z*Q5@Z
M@D \K@C.<=,UC:IX;U*;PUXN>"R=KW7),PVH= 44(J L2VT$[23@GJ* .GT/
M3_):2^$^I 7$:!K:[F,BJRYRZY)()[X...E1V_BS3KFYM(D$_E7DTEO;7!0>
M7+)'NW*.<C[K8) !QQ6O:,[6D1DB>)]HRCD$J?P)'ZUYXFF^)+FXT.[OM&F>
M^LM3>2ZD^T1^64*R*#$N[A &7/ ;V8Y- '?ZAJ$&FVPFG)PTB1(J]7=F"JH]
MR2*S+OQ9I^GVXEOHKNW_ -+2S*M"6(D8*1DKD8PPYS],U+XFLDU'1VM)M,.H
MP2R()8%<*P7/WE)(P5X/7/'%<1JEGJFDZ#;17,EW=VZ>(+-K!;IU:X,>]/E9
MLX^]N R<XQG% '86/C#2KR34(I/M%G-8()9XKR$Q.(ST< ]0<5-'XFL/[0EL
M;I9K*>.W-T!=*%#0CJX()''<'!'I7.Z]X8OO$M]J]]%&;-Y-+6QMA/C,CB3S
M<L 3A<A5YYY;C&,H-)OO$>A7]E/X8MM"N9;.2!IR8V+.RXPA3)V9Y)./3!Z@
M Z.W\364]_#9M%=0RW%NUS;^9%_KHUQDJ!DYY'RD \]*YS4/$267PTDU+1)=
M0G621HX[BY.Z1"T^QB2QR,$D+Z8%;/A_4->N;>"'4]#:Q>VCVSR-,CB9@,8C
M"GH3SEL8Z<]1S9T/6O\ A5+:*-)F.HFZ+^3YL7W?M/FYW;\?=]^M &S:QV-C
MXMLD:]UU+F]CEDALKB=W@7: ')R3D]#C<<$]!FM-O%6G+/:J1-]GNKDVD-T$
MS$\W(V@YSU4C.,9'6J>IVE_=>-?#M_%83?9;6*Y6>0N@\LR! O&[)^Z>F:H^
M$HO$.BV4'ARYTG=':2%4U+SD,4D.XD';G=OP<8QC/.: .LU"_MM,LI+N[DV0
MI@$@$DDG   Y))(  ZDURMMJD[_$JYBD74(8$T<3-:RDL-WFXW*JD@D@8XYX
M-:'C72[_ %/18&TQ%EO+*\AO8X&;:)O+;.S)X&??N!5*T&J7/CH:U)HEW;VA
MTG[/B62+>)/,WXP'/;_(H N:)K>G+H&E&QDOKU;P.+83MNGE"DEBQ<CICN?2
MI+CQAIML]C')%>^=>B0PPK;,68IG<N!_%QT_/ KFM/\ #5PW@O0M)UC1KP2V
MWFEIK6=%FM)-V5=&5^002.,]LBFXU;3]9\#KJHEO+Y#?!RNWS"FWY2W."P7;
MG!ZYQGN ='!XWTF?3?MP6Z1%NULIHY(MLD$S,%"NIY')'//6K-]XFMK*35(/
ML]Q+<Z=:BZ>)5'SH<X*G./X3^5<QJ?AG4KC3]>U&"S/VJ]U*UO(K/>H8QP&/
M@G.T,P5CC/<=ZM-IVKZEX@UR[;2I;6#4-'6UA,LL9*R#S.&"L<'YATR/?L #
M:TSQ']KT/3+J:TF^V7L"R);1@;G^0,Q7)P%&>I(Z@=2*O:/K-GKEDUS9L^$E
M:&5)%VO'(IPR,.Q!KB7TK6HM/\+Z@?#XNY-,M#97>G321%V4K&/,0Y*Y#1],
MY(/:M]=0NM%T^UF3PVL$=W>*DL%N\:FV5\*'?'#L3CA?4#)QR ;&LZO:Z%I-
MQJ5[YOV>!=S^7&7./H*JV7B:QO=6.FJES#,8/M,9GA*++&" 64GK@D?GGI47
MC6RN]3\&ZK86-NT]U<V[11QJRKDGW8@5E7^D:AJ/B2PD-E/#:G2+BSEGWQYB
M>39C@-DXVGI[4 :Z>*].=[(D3I:W\GE6EVZ 13.<X .<C.#@D 'MFKFMZU:>
M'])FU*^,HMX0-YCC+D9..@_F>*Y"'0]6O_">B^'+VP>WET^>W$UT'4QF.$@A
MD(.26"@8P,9.>G.I\2_^2=:UCKY(_P#0UH NVOB_2[G5IM-87-M/'";A#<P-
M&LT0ZNA/4"G6/BJPO[BVA2.YC-U:F[M6>/B>(8RRX).?F4X(!YZ5G:E8:EJ^
MO66JVUF;673;.Y$7VDK^\GE4*J_*3\HP23[C&>:RM+T[6QK_ (>U2YT6Z62&
MSF@O9)KF)F\Q@AR &P$RK;0,=>BCF@#0NOB)8_V#=ZGI^GZC<I#;RS*YMBD>
M8VVE68\ YYQUQ[\5K0>)83>:987-M=0W=_&SQ;T 5MHRW.>PYQUQ7/V.@ZJ_
MPHU'0Y;)H-0DCNECCDD0AB[NR\JQ'1AUJWXAM;N[\%V]\+=K+5=-,=S:QRLK
M,)5XV':2/G!*X!/WA0!TUI?QWLUW'''(/LTOE.S 89L _*<\\$?RZ@U5EUZV
MCNY8$AN)A#<1VTTL2@K'(^W /.>CJ20"!FK&DV3:?ID-O(P>;!>9QT>1B6=O
MQ8DUR>KZ'?S>(9=3TFUN[#5!<Q#[1'*OV>\A&W=YJ;NH&X= >!CV ([+Q,FA
M:KXJ;4)-0N;6UODY56E%O&8D))_NKDDX'OQQ70ZCXJT[37NPZSS+9P+<W3PH
M&$,;9PQR1GA6.%R<"N;O=&U>?3O'4*:9,7U4G['^\C_>?N5C_O<<@]<<5%K6
MF>(=2LM6T^329I89M*6*Q"SQHB2^6P<2#=EFW8V]1TZ<F@#;OKF7_A8.@+#=
MS?9;JRNG:(2'RVV^7M;;TS\QY]Z=X)FGEAUQ)[F:?R=8N8HS-(7*HI&%!/85
M6BL=4?Q)X7O'TR6.&TL)H;@F2,^6SB, '#<_<.<9_&KOA"RO;$:T+VSDM_M&
MJ3W,6]D;=&Y&#\I..G0T 94FO-HWCK7EG&I7ENMG;2I;6Z/-Y>3)N(7HHX&:
MZ*'Q)87=E9W5@9+T7D1E@C@ W.@QN/S$ 8) .2.3CK6:;?4--\;ZGJ:Z=/=6
MUY9P1Q- R</&7R&W,,9W#!Z5ST?A74_#D>B746E0:TL$$\-Y9J4RAEE\W='O
MP#M)*]LC] #N]'UBSUS3DOK%V:)F9"&4JR,IPRL#T((K.@\8Z;<ZA+9Q0WS-
M!<-;SR&V8)"P3=EV/W5QW-:&BPM#IXWZ?!IY=B_V:$+^[S_>*\%NYQQVYQD\
M]INBW\]OXPL[JVDM$U6XE:"9F1LH\*QYPK$@Y4GF@#7@\3V,NI6=DZ7$#WT;
M26;S)A;@*,G;SD'!SA@#BHY/%NGQ_8Y/*NFM;VX6VMKI8P8Y)&; QSG'7YB,
M$#@GC.%H6G:E<646G7_A>UTZZ@@:&345\I@YV%0T6WYLG@\XP,UD2G5[3P_X
M4T?4](>U?3]6L;<W'FHT<P1MJLF#NY !.0,4 =M+XKT^&RU:Z=+@)I3E+M=@
MRF%#9'/(P0>*;+J6GOXHL83/?"Z>RDFCB4,(7CRN21T9AQC&2,FN9U?2-:$/
MC73[;29;@:NIEMKA98U3F%4*G+;@V5XXP<]16J+'4CXMT*_;39A;VVFRP3-Y
MD9V.VP@?>Y^X>1[4 7++QMI-_&TT4=ZMLJRL]Q):LL:F-MK*3_>ST'4_7BK4
M7B:P.H7%C="6RN(+?[6R7("YAS@N""1@'KSD=Q7,VOAS5KKX;:AHLEM]DOWN
M9IX5F9&5B9S*@.TG@\ _C2SZ1?\ B3PYJ5F?#5OH-U-9O!YC&,L\AQ\JE,G9
MQR3ZCB@"Q>ZU+=^-O"8MQJ%O;77VABLA*1SH(25)4'J#@X8 \CBMKQ3KS^'M
M-AN8[22X>:YBMP%QA=[A<G)'KQ[X^M8*KKNI:SX5N[C0+FV.GM,+S=+$5!:(
MIE</RN3['':MCQKI]YJ.@(EA;FXGAO+>X\E652ZI*K$ L0,X!ZD4 79]>AAE
M:!+6ZGN8X1/-!"@+Q(<X+<XR<' !).#@5;T[4;35M.@O[&99K:==\;KW']#[
M5S=K;:GI7B_4M5.G3W%IJUO 2D3H7MY8P5V$%@,$'J"0#GMS6CX0T670?#<%
ME.5\XO)-(JG*H7=GVCV&['X4 12>,]-BTN]U"2&[6"RN?LMQF,;HY,@<C/3+
M#GISGIS5Z_U^STS[2UX)8H[6V^U32%<JB9( X).<@\=\5@:EX2FU#Q'J43X&
MAZM;*]XH/)G0%!@>X*-GUC'K26NG>)K/P%=X\J7Q&\(C&2""$PBX+<9*@MSQ
MN<T ;D'B"UN+B\LY(;JWN;:!9Y(7CRYC;.&783GE2..016?IGB/2[31=!$3Z
MA<6VHD0VEQ<?.[L<D!V)X) /7TK/TK3]2M_%UUJ?]BW<5K<:7'%F:YC>7S%=
MR0WSG+'<,<D8[CI3;+PS?S_"FTT6>%K35K2%6@RRDQSQG<A!4D8R!^!- '4S
M:U:V\ETLJRJ+9D1FVY#.^-J+@Y+'(X]QZTW3M=M=1U"[T\1S6]]:!6EMYU 8
M*WW6!!((.#T/UK UC0M5OO!T1CA@DUA;F+4);>0_NY9 P8Q$GMCY 3_=%:?A
MU997DNI/#D6BY0(4/EF60]^4XVCMGDYZ#'(!)?7UE'XKTVUDFOEO&AF>**/<
M(9% 7=N[,1QCTS[U2T?Q@FH:=<7ES93VX6^:SAC(7+L)-BJ.<;LCGL/7C-2:
MK97LWCK0+Z&SD>TM8;E)I@R *9 FW@G)^Z>@K%M=$O!H6I:1J>@27=K)JDTQ
MVS("\;R,ZR1G<""N0><'TS0!VEC?+?+-B&:%X9#$Z3* 0V >Q((P1R#65+XN
MT]-8N-+2WOYKJWDBCE$5J[!/,SAB<?=XY/3Z\TGA*QU+3K*[M[ZYN9[=;@_8
MFNV#3B':O#D=?FW8SSC&?01:39WT'CCQ#>S64B6EW';+!,70AS&K!N V1]X8
MR* #3=>TBVTK4]06ZO6MXK^2*3[5N+"4L%\M%/(&X@!:-0\06]W%JVE(+VUU
M&WM&E8;""@*DJPD7*\X..>Q%<Y=:9>P^%->MKO3)1<7NMM<64?GQJ[[I59&0
MAB-P +8..G/&:MVTEQ-<ZJUUH>JQ:MJ%D88WN##L<(IPBE'PO+$\]>>>@H N
M^$_%,$ND>'-/NOMC7EWIT;)<2QMMG=8@S@.>K=3[\\UI>&?$,GB!+Z1[*:V6
MWNY;=?,Q_ =I!P3SD'V^M8-GI&K11^ E?3)@=)B*7G[R/]V?LYB_O<_,>V>*
MU_"-E?Z:VKVMY9M$CZE<7,4Q=2LJ2/N7 !)'!YR!^/8 G/B*3_A-/[!%C-L6
MT%PT^!@Y?:".>@PV?>G#Q7IN;61A,MG=S>1;WA0>3(^2  <Y&2" 2 #V)R*H
MWVF7[^.VO$M9'LKK2OL33I(H\EO,+9()ST;C //IUK'A\/ZM=^"+#PE>6+12
MVLT,;W@=3$8HI P=>=V2J@8QD$\\<T =MJFIVVD6+7=VQ$894 49+,S!54#U
M)(%1:;K-OJ=Q>6R1RPW-DZI/#* &0LH93D$@@@YR#57Q4-5.B_\ $GA::<3Q
M&2-&59&B#C>$+<!L9P3T^N*S/"^G7UCXGUZXFTR6UL[W[/)"\DZR-E8]I#88
MG=GDGD>YH T[^]LX_%6EVLDU\+QX9VAAC+"&4 +NW?PL1QCTS[TS_A+M-_LE
M=3*W MC=_8V/E\I)YGEX(STW<9&:IZT"?B)X5(&<07Q/M\L5<[<:-KR^'K[1
M8M&FE==9^V).)HPDL1N1*-N6SNQU! '!Y[4 =9-XOL(]6N=,CM=0N+JVDB25
M8;5F"^9G:Q/]WCKTY^N);7Q38WFBS:K%%<^1%,8&1H\2;PVPKMSG.XXQUJIH
M]G?P^-=?OI[&6*UO([80RLZ$,8U8,,!B1]X=JJ1:+-%X_N4AD3^RYECU*X@[
MK<C*+^#8#_[T5 '0:WJO]C:#>ZH;:2?[- TQB0C)P,GOCZ_UK)7QG:V]KI8O
M;6]%Y?P&6.&*W+ERJ!F"XSGV&<^N.M:GB*RFU+PSJMC;@&>YLY88P3@%F0@<
M_4US4-EJ\NJ>#KF31[B*/3X98[G=+$3&6B5!T?GD'IGC'?@ &I::WID^NW$Q
MFU&"9--CN)8+E7CBCB))#;#_ !]02/3':K6G^)++5+N&S1+F&2ZM?M=N9% \
MV'(&Y2"<?>7@X//2LJ^L=9_X3'5=1L;+A]%%M:S2LFQIU>1@"-V<?,O;UK/T
M?3M97Q/HVJ7&C72;=.EM[N2>YC9Q*3&<\,?E.T[0OY** -CP%//<>&W:YN)K
MB1;ZZC$DSEVVK,X R?0 "MW4;62]LGMXKF6V9RN98CA@ P)P>Q(!'XUS7AF/
M5]#\.&&31IGN'U*5C%YT8VQ23,V_(8CA6R1UKKZ .$L[6XN?'>M:0^K:HMK;
MV<$D06Z;<K/NR<]^@ZTD6K3Z%XQU2&[FU'4$ATNVD\J)6D^;,@=PO1<[036C
MIMCJ$7Q&UC4I;"5+&YM8(8IRZ$%DW9X#9 Y]*0V.H)XSUJ_&GS-:SZ=%!#('
MC^=U+DC&[(^^.N* +5QK6E7EUX<F6ZO<7SF6S\C<L<N8V.).Q&,G!YR*NPZ]
M;3W<<,4-P\<EQ);+<*H,?F)NW \Y&"C#)&,BN2T_1-8M]+\#02:9,)-*?-V/
M,C_=CRF3/WN>6'3/%68-#OX?%$6I:9:W>FR2WTAU"(RJUK<PY;$NW<<.1M/
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MBL=,TZ]U$7=AIDJ2VZF#;(VS_5AVW$';QT SM'OGJ** ,KQ)H[>(/#U[I*W
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M!,DTI +'J6/8<YX' JQ10!YQX1TL^(/"$]C+?0MITFHW#S0I'F0J+AF"[MV
M&P#TS@\>M:NI>![F^CUJWCUHQ6VIW*76TVP=XY%V<;MW*?(., CU]>RHH P[
M'0KFT\37FL27Z3?:K>*!XO(VD>7NPV[=U.XYX]*S9?!<[Z)KNDIJH6VU2::5
M<VV3#YK;G&=PW<].F.^:ZZB@#EK[PK?OJEMJNEZU]@U!+9;6Y;[,)(KA%.1E
M"W!!)P<]\59O?#UU=VKVCW\5Q:S6WDS17EMYN]\L3(,,H!^;H!C@8Q@5T%%
M&3INDW.F/900Z@S:;:V2VPMGC!9G7 $A?KT&,=.]:U%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHJ&YNX+01&>14\V18HP?XG;H!0!-1110 4444 %%(2%!)(
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M?$FGV[2"T6&TG6)I&<*[B0,1DGKM&?I6X/#NBK8PV(TJR^RP-OBA\A=B-_>
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MB:7)>F]?3[9KEB"TIB&YB.A/J1V)Z4FHZ#I&KS0RZCIEI=R0G,;3PJY7Z9%
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MA 5@)%P"<$C!(!&1U'<5B^+?$PMH+%=,U"2.5M3@MI"D.Z.0&0*Z;RI7(&>
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MSDRHF#EEXQP<9S@XKB[ZSOGT+QY;1Z9JCO>NCVQD@=FFS$@X]3D'CMC!QTH
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MCDD,3DNF\1J-IR^W!P<<D#/7%:+7]8G\92V*6,0M4TR.Z6%YBDF78CYAM(W
MKC&<#DY.<4 =0;>(W(N"N954HK$D[0>N!T&>/R%2UQFG^.KB[TBRU2;13!:W
MXCCM#]I5FEG=]HC(QP.^[T!XJW>>+I=-N=1LKW3@+VUL6OXDBGW)/$O#88J,
M,#U!'<4 =134=) 2C*P!*G!S@CJ*YFP\67-SJ6D6]SI/V>'5K5I[607 =MRJ
MK%67 QPW!R>G(%5](\1VD=@XM=)2UNKG5I[-+9)!B292Q=V8#@85F)P>G>@#
ML**SM*O[R\>\BO=.>SDMY?+#;]\<RX!#(V!D<X/'!%<Z?$NK6^M^*O-LH)K3
M288W2-+@AB/+9\\K@D]^1C Z]: .SHKEK3Q/JMU:VER?#S1PW@B:"4W(**K(
M79I"%R@7 '0Y+#ISBL/'F[2[>\CTPS,^J_V7(L5PI4/OV[E8@;@>HZ?A0!V5
M%<FWC1K.+7!J>GK;3Z482X2?S$9)>$;=M! '.[@XP3S4FH^*[G3-(?47TV*X
MA^T0Q1O;70=)5D95#JQ4="V,>W6@#J*:SHA4,R@L<*">IZX%<R/$NK-K5YHZ
MZ%']NB@2ZA!O1Y;Q,67YFV95LKC ##WQS55/$UGJ\?A.^?2!(-1G/DO*XS:R
M!'SCCG[K#/% '945SVF^)SJMTRVMM#)!%<RV\^V?,T!3>,O'MX#%..?XA3=&
M\32:]9QW=I9P36DUN\H:.YW,CC;B*0;1M8ACW.-IH Z%'21 \;*R,,AE.0:=
M7(:#XDM)-$T"WTK3(K>348'EM[,2;4AC3[Q+!?4@<#DGZFFW/CHVMK<[]+<W
MMG?Q65U;+,/E,A 1U8@;E(8$9 ]\4 =C2$A022 !R2>U8FDZ]<7NMZAI-[8+
M:7-I'',NR;S5DC?< <X&""I!'/U-5KF].H>/(=%/_'K9V7VV9>TDC/MC!]AA
MFQZ[3VH Z-71F9592RG# 'D=^:=7$W7BB'1D\6ZA#H2BXTV2,W)64*USF,%6
M)QQA2!WK1'BM[;6;BRU6P%E"EB^H1S"829B0@.& 'RL,@X!8>] %S4?#L=]J
M:ZE#J%_878B$+26LBX= 20&5U93@D\XSS5[3[2&T@812O.SMF2:1]S.PXR3^
M&,# &.E9MKK%[>W%E%<:*PL=0@:03+)YGE# (65=H"Y![%N01[US/@O6/['\
M)>&;,6JO#?WEQ:JPDVF,^9*P^7'(PI[B@#T.F[T#[-PWXSMSSCUKFG\8QP-J
M\=Q:%9;"[BLXTCEW?:))0I0#(&,[QGTYK*1KE/BC=RW&G6ZS'02=L,NX3?O1
MU)5>>W(Z8^E '8WMG:ZQI<]G/^]M+J(QOL?&Y2,'!%4;+P]]E=/M&K:E?QQD
M-''=R*54CD$[5!8@\_,3SSUK!TOQ6D6E^%X-,T%8X-6B?R(4G55@VH7V].1Q
MR?KU/!MP^-?^)7--=:?Y-]%JBZ4;=9MR&9BH4A\#Y<.#G&>O% '645A:9K\]
M]XAU+1YK 0R6"QM)*DV]6#@E<< ]FSZ8INK>)18WL]C:Q0374$"SR)-<>4,,
M6VJ#M;+':W;CCUH W2ZJRJ6 9N@)Y-.K@S?V^J>-/!^KI;/;-<V%ZSK,FV10
M!'\K?0DUH0>-TN+C3'CLUDL=1D"1RQ2EY(\C*-(FWY5/KN.,C- '645SMKXD
MN[Z/3[RTTEY]-OI"D<Z2Y=%YVR.FW 0XZY) (X[5AV?C35K7P]>:M?Z=%<!-
M4>T"P7'*_OO*  *C@<?7VH [ZBN=A\0ZA+J*Z4^E10ZFT<D_E/=Y1858*KE@
MI.6)X7'8\^M ^.\VUHT>E2O<2:F=+N(/.4&&8 G@GA@0,@\<$=* .O=UC1G=
M@J*,EF. !3NM<7J'BGS- \31ZKH<<DFE*!<V@N \<L;('!#%1V/3':M5M=E,
MDEEI.GI<7%K9QW$L32^6J!P=B A3ECM/8 <>M &_02 "2< 52@U R:*FHS6L
M\!,'G/;R+^\3Y<E2/7M6-:^)&U;19+Z.PMKJQDLVF!ANA(&( S$^5&TX/OT-
M '2HZR(KHP96&0P.014=S;Q7EI-;3J6AF1HW4$C*D8/(Y'!KFM+\10?V=X:L
M]/TZ.&34[/SX+?S-L<$:HI(W!3G&Y0..?:JJ^/)VL+>Z_L1\RZH-,9%N5)63
M<58C(&1D''3/'2@#7L?"Z6:QPOJNIW=I'@);7$JE !T!(4,P'HQ/O6[7,0^*
MKLC6H)M%D.H:88O]&MI?-\X2CY"#M!'?/'&">:H:KXSNX])\3K:6]J+_ $>W
M67<MP9(R&5CD':#N&T_*1V'/- ';45SEEK]X-6T[2;NRB$UU8O<K+'<%Q\A4
M8.4'7<#5$>.9FL-/N$T=G>\U*33MBW PKJ7&<E1D'8>PQ0!V-%<E-XPNH()X
MWTRW34;6$2W-H][T)R0B,%.YBHST ^8#UQM+K E\-C68;68@VWV@02?(X^7.
MTYZ&@#3K+UC0X=:DL'FNKF$V5RMU$(2G+J"!G<IXP3Q6!:^.;ESH<]WH;VVG
M:P$2"Y%PKE977<JLN!@'D Y^H%$/CJ<Z?=ZG<Z*T.FVDL\,\PN59A)&^Q55<
M#=N;C.1@_G0!V=%8/_"12VFN6>EZK9);-?1N]M+%,959D&61OE&#CD=0<&LZ
M/QM)-;:+>1:7OM-8F,5LWVC#@X)7>NW R%)X)QTH Z^BN2MO%^I7;:@\/AV:
M2WT^XGMYVCN%9R8TW#8F,L6.!CMD=><21^+I1?WUA-I\?VNVL!?>7#<[QC)!
M1B5&U@?8]: .IHKCH/&M[,NA2MH>(-:A#6Y6Z!99#'YFUAM "X!^;)/'W>U/
M'C<065ZVHV<5G=6=^EC*K7&85+A65S)M&%PPY*]>* .NHJGIUU<7<#O<6Z0L
MKE5\N7S%D7 (96P,@Y]*P[SQ=)87T$=QIOE03ZBNGQF2;;*Y)VB54*\IN/7/
M3GVH ZBBN,O?&][:PZY/'H7F1:--MN2UT%+)L5RRC:<G#=#@>_:M:;6OM][<
M:9I]E%>M%;)-<">38@$F=B?=;)(!/3 &/6@#;1UD7<C!E/<'(IU<G\,_^2<Z
M+QC]RW'I\[5UE !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %<C\0C(-(TORMGF_P!L6>S><+GS1C/M
M7757NK"SO@@O+2"X"'<HFC#[3ZC/2@#E]:\+:GK+ZE?+=066HS6:6=L(W9D5
M!)YC[FP#\_W3@<#US56Y\):U<2:RZOI<*:GI(L/)B#A82 XXXY WYZ#IC ZU
MW( 4    < "EH Y?4?#^HW>BZ#%#):I>Z5<PSD.S&.38A0C.,C(;/2JM]X/O
M-4O?$1NKB&.'5;6"%)(2V^)XMQ#[2,?>;.,]NM=E10!S-I:>+WL)$U&\THW*
M1[8?(1]DK9'S29Z# (V@=SSTIWAWPR-%U;4;V*&WLH+Q8\V5JY:(2+NW2#(4
M G(& !]W/?CI** .*U_PIK&JW6OB*ZLFM]3M!!"UP&+VV%P54#C:QY)]>QP*
MR]16\N/$CV\5SHAN[/3X[:YCN+B6V)WY8@,ARZ8V]1@'.,$FNYO=9M+#4]/T
M^<RBXOW9(,1DJ2JECEN@X!]ZFNM,T^^D22\L;:X=/N--"KE?H2.* .5L+#4=
M4O?#NII;:=;6^E>?"8[>9FCD5E" Q'8/E '&?I[U.-"\1:9KVH3:->V']G:C
M*)Y8[M'+V\I4*S)MX8' ."1S76    # '0"FS2K!"\KABJ DA%+'\ .3^% '
M*+H/B'2M=O9]%OK%K#4'66=+U'+PRA0A=-O#9"@D''(K=U?3&U/PW?:4)R&N
M;22W\UQDY9"NXX^N:AMO$FG76B6FK1.YM[PJMNI7#R,QPJ@>IQ_4XJSI>J0Z
MM;/-#'/$8Y6ADCGC*,CKU!!Z_49% &!;Z!K(U3P[>W+6!_LNVE@D6-W&[>J+
MD97MLSVZX[9-&/PEKD.QDFL'4:O/J#VTCN8I5DS@-\O5"<CC!(SQBNK?6;2/
M78=&8R_;)H6G4>6=I52 ?FZ9^8<"M"@#A!X-UE=/GC^UV#SKK@U:#Y756^?<
M5;J1^&>G4]NMOXKZ72FCMVMS=D+GS5/E-R-P(Y.",COUJ]10!P5SX#N#HGB&
MRT];.Q35A&$M$E8P0,,[G'RCEN.  /E%0ZVUQ?>+IX[6?1EN;6Q2"XBNKJ6!
MOG)8@,F"Z8V]1@'IR37H=5;K3-/OI$>\L;:X=/N--$KE?ID<4 <KI]AJ&J7O
MA[4DMM.MK?2O/A,=O,S1R*RA 8CL'R@#O]/<PGPEK:QS^7-8'S-:?4FMY'<Q
MS1L,>6_R]CAAP02!QQ7<@     #H!2T <))X-UA]-U6#[78&6XU:/4X"$=5W
M*8R5;K@?)CC/6K]QH.M#7[W4+::P*ZC8QVUSYF\&-TWX* ?>!WXY(Z9]JZO<
MI8KN&X $C/(!_P#U&EH XO2O"NK6$_A5I9;)TT:TDMI=K,"^]47*_+VV=^N>
MU31:%XBTO6M0.DWUA_9>H3FY<7*,9;>1@ Y3'# XS@XP?UWH-9M+C6[G2(S+
M]KMHEFD#1E5VL2!@GKT/2M"@#D-4\*7.JZE!<S)9I<6MVDMMJ,;L+A(E8$QD
M!<-D;EY;&&Z<<Z/BO0KC7+"T^Q7"07UC=QWEL\@)0NF1M8#G:02.*WJ* .'O
MO"&JZ[?ZG<:E/9VR7VFQVFVU9W:*1'9U8$A<C)!Z#T]SJ6-GXIEL)XM9N=->
M00-%&+4.HE8C&]R1Q] ._P!*Z2B@#C+7PMJEO9^$H"]F3H9_>D2-^\'E&/Y?
MEXX.>?I[UIW'AKS?&4.MI/LA, 2Y@QQ,Z',3'_=W/^2UT%8MYXGL=/TV>_NH
MKR*"&Y^S'=;,"6W!01Q]TDC#=#0!FR:'XAT[Q'?WNAWFG_8M299;B&\1R89
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M0ZA'$+M;Y6W+(B[!(NSKD 94XZ=:M'0]3M_%0U:VN+>:-].2SE%P6#ED9F#
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ML2E@T;K&8^P(QR#^&,<Y'6T4 <E<^'M7?1_#MO%+9,^F%!<6\K,8;@+'L!)
MSD'# $8SCTJ@/!VM+ T1N-/D']O#5@1O3(#[RO0X)/'M[UWE% '*OH>KIK>N
MZC ; C4$MD2.5F(VQ$[E;Y>C*S#V]ZRYO ETFFZE:Z<MG9Q7EY;7*VBRN88/
M*968K\O5R.@  P*Z>_\ $=CI\[Q2+<2^2\:3M!$7$!?[N['//L#@$$XR*UZ
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M]Q$8OE^7CKGGZ>]/C\/:K%>ZS,8]-G@U*\2=[>=F*O$(Q&4;Y#SP#G!KKJ*
M,+PKX?\ ^$=L;JV4JD,MR\T-LCETMU( V*3@XR">@^\:P+GPAKTWFC[7I\C#
M6(]1CGE#F21%D#+&_H%' QD8QTKO** .+N/"NJSZ=XKMC)9;M;8F-M[8CS&L
M?(V_[.?QQ[U-:^']:TOQ!)JEA)8NM];0PWL$SN-KQ#:KH0O/!Y4@?6NNHH P
MO!^C7?A_PM9:7>RPRS6ZE2T(.T@DGO\ 6MVBB@ HHHH **** "BBB@ HHHH
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M6Y86_FYSO\OIG//IG''%$G@W3I=*OM->>[-M?7)NIQY@RTA8,2#C@9 .!Z4
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M=75A+<SRQ%(VD*2",8R"!U+' ],8&:ZSPZ-732A%K<L$U['(RF2(CYDSE2P
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M,@ATK^SG:6>$QF-S/(79P1@Y/TK%MO VEVS:>PGU!SIZ/';F2Z8[8V &S_=
M X]N<T 4?"VO7-YJR:?JL]Y:ZK':L;BPNHE"R/E?WL+J,,GWAU/4<<9K0U^[
MNUU6.UMK^2,&SED%M:HIF+@@!R6&U4'/4C)..>E7K+P_;6=S:W#3W-S+:0M!
M;M<,&,2-C(! !).U>3D\>YI+_P -V.H:Q%JDCW,5RD!MV,$Q021DYVMCJ,\\
M8H Y.PUS6]6/@S_B9M;C5K&:2Z\N%#ET12&7(.#\Q]1[5T'@V_O;W3K^*^N3
M<RV6HW%H)V4*TBHV%+!0!G![ =*6P\&:=IKZ6UM/>#^S$=+8/+N"JX 8'(]
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M;%Z+G/..M7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBN7B3^VO&FIF1G:TTV"*V2,2,$,[?O') /)"F,?B: .HHK@DTQ
MI/'5KI":GJLD%G8-<WS?VC./-DD;:@(#_+]UVP,#I4!O+?P]XFO)KFXO[NVT
M73V+@R/-(SR.TA)W-SLC51DG^,#J10!Z)16=+K5LCPQ1K)-/+#YZPH &$?\
M>;<0%';DC/;H:ETW4X-6TBWU*T61H;B(2QJR[6((R.#_ /JH N45SUEXRTR^
MCMY42Z2&5)9&FDBQ'"L><EWSA<XR.>A![BI6\4V:3>6]O=)NM'O$+(!OB0@$
MX)ROWA]X"@#<HKG+;QKI=U/:11Q7FZZM3<Q$P_> *@KP?O9=1CIGC.015FT\
M3V%[I%CJ,*S$7S%+> H/-D8$Y &<<;22<X &<T ;5%<W=^+;$Z+JUWLOHDL)
M3:SNB+O20@?=R<,064=QGUJ4^(+;2K@:1<&]N;RWLUF:0HK-,/NYX/WB58]
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M]DO$NI+9KI4= /W8(&3SP23@ X/J!0!L45SEEXUTN_.E^1%=E=2=HX6,7"L
MS88YXRJDC&>""<9%9^EZAGQ9KE\L5S<(]RFGV\41#8\I<R/@L !N?:3_ +(%
M '9T5R\Z?:OB+9QPM(@M+)[FY D.&9SY<:D9QT60_@*ZB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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D4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>42
<FILENAME>exhibit1018-arvinasxcons010.jpg
<TEXT>
begin 644 exhibit1018-arvinasxcons010.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=S",;5)QT!/ &3FL-M(UFQN+2\CTJ6Z,&O7=X88I8@QBD2158;F _C'&<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBN3\3WVH6OBCPS:VFH2P6]]<217$:HAW!8RPY921R.U '645P4OB7
M4?#OC"YAU:X:X\/2RQP)=2*@-I,R!@'*J/D;=C)Z$<FNFMGN3XJOX7O)7MDM
M8)8X2J;59VE!Y"Y/W%ZF@#7HKD_$VH:CH_B7P]<+?2)I%U=&TNH0B$;V4^4<
ME=P!88//I4.BZQ=K\1M<T*\U*2YA2".>S1HT4(,#S%)"@DC<AZ]#0!V5%>?^
M(=4UFP^'MUKEKJ]PL[W"O;,8HB%A>8*@QLYRA!YYR:T/%PUC2?#FLZM;:[=1
MM;6^^WB6*$J,*,ELQDDDYZ$#&* .PHKD+NWUF#PY/J<?B*\)&FO-AXH#ME"A
ME(Q&./O @^U+X:\0W>JV5YI&JL;/Q!8IB<1@?O%Q\LT>1@JWTX/'I0!UU%>?
MZEJVJ6UCX-D_MJ>+^TI(TO)"D/S!HBY/*87D=JW?M%S"-1FT[5GU:2WLW86K
MB,_O<9CP44==I!!/<4 ='17#>&]5D\0Z=8WNF>(IKBZ22,ZC9S+&"O(WKMV@
MICG&#R!W/-$6NM?^*]6T:\UJ?2=0BE"V%N%0)+%M&'&Y3YA)W9&> .,<F@#N
M:*J:<EV-(M([Z3-X($$[KC_6;1N([=<UQ-KJFM'2/&%A<ZU*FK:3*\D%P88O
M]24WQ$J$P<X(/&>.* /0:*XW3=:NM;\$Z%<6U_-'?W[Q1O,$3<&4DS @KM&
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MBH!8A=N2N&7YNG(YYH V**RH/$FEW5A;WEK<-<1W&X1+%$S.Q7[PV8R,'@Y
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MZCXFAO-0AN;*>Z"6XMG,#HI=45@5P,;02V<@Y!QD =-I]W'8/]KDU'4[E;J
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M(K[,^^W%<SJMN=:\*ZS+8^%+RRO9K!K4&XA FD8D$(N"3L!R23@=,=Z]'HH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !15:_OH=-T^XOKEML-O&TCD=< 9X]ZR?!GB>+Q=X8MM6C18Y'RDL0.?+<'!
M'\C]"* -^BN"TOQ9KVK>,M=\/PKIL;:8H9)7B<B7., X?Y>O7GZ4_P />.-0
M\4^#]2U#3]/BCU6P=XVMG)>.1E&<*1@\]/8T =U17(>#/&)\4>"Y-;G>VMY8
MC()U5"5A*\\_-D_+@]NM;^DS7[Z1!<:L((;EHP\J1@JL?&<$DGIWH T**Y0^
M/;*:9TTO2]7U:-"5,]E:[HLCJ [$ _A3SXQN ?\ D4O$7_@/'_\ '*OV<NQ'
M/$ZBBN?L/$\][?16S>&];M5D./.N(8PB\=R')_2N67QGK%EJTT.IL422&\D@
MVPHT,PCRR>3*I;D*IW!P#[>LR3CN4FGL>DT5Q<'CPR75M"NF2/;R7,5DURTR
M@B9X1*?DQD@*1SW.> .:IV_Q.#Z0+^XT2:+SK2&ZM8TF\TRB218@#M7(^=AT
M!)';/%(+GH%%<#JOQ O%\/3SV.C7$-\MA<7;K=?N_($9V[@' +@M@@8&1[\5
M<UGQ)JUCJ7A>"QMXKIM2BG:6%G$>\I$'&&.=O.>QH'<[*BN.L/B!;ZE=65M;
MV+^???9Y+>-Y0&:&1&9I",<;/+<$<Y('/-=7:O/);(]S"L,Q'S1J^\+^.!G\
MJ )J*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BL:[\7>';&X:WN=
M;L8YE.&0SJ2I]"!T-0?\)UX6SC^WK'_OZ*KDEV)YX]SH**Q[/Q5H>I2/#I^I
M07<ZHS^5 ^YR!UP*YW3/B1#J%C<W;VEK%'#!',P6]#M&6?;Y<J!=Z.,C^$KV
MSQ4M-;C33V.ZHKG)?'.A17-W"T\V;5)GD<6[["(1F7:^,,5Z$ GGBHV\?^'5
MM9YVNIU\F983$UK()79AN7:FW<P*@D$#&!F@9T]%<KJ7C_1[.&V:U:2^:X$#
MIY,;E%260(I=PI"=20&P3M(J?6_&5AX?UJ.QU".58GM6N3.B,X0!U4[@H.%&
M[)8\#% '1T5BIXKTJ1BD4LLL@FFA\N.)F?=&I=OE SC&,'H=RX^\*V(Y!+$D
M@# .H8!@01GU!Z&@!U%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M._L(IUME*PAL_(" #C'L *U*YS0O%*ZWXH\0Z3'$!%I+Q1^;SEV8,6!^A7%
M$T/A>TB\31:SNYMK/[':6ZQJJ0)QG&!DYP ,\ 9QUK6L[.WL+2.UM8A%!&,(
M@Z 5/2%@HR2!SCF@!:*JSZE86MW#:7%[;17,YQ%#)*JO(?\ 94G)_"K5 !11
M10 445S(\5;_ (D'PK'"K*FFF\DEYW*V\*%],8.?RH Z:BC-% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M23FKU !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG?!#&+F!)@A.=NY0<9_&@+%.6_D;?Y4TZ9W;<Z;*<9 QVYP<GWSVJS_:EO\
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M (2(?] C5_\ P$/^-;5% &+_ ,)$/^@1J_\ X"'_ !H_X2(?] C5_P#P$/\
MC6U10!B_\)$/^@1J_P#X"'_&C_A(A_T"-7_\!#_C6U10!B_\)$/^@1J__@(?
M\:/^$B'_ $"-7_\  0_XUM44 8O_  D0_P"@1J__ ("'_&C_ (2(?] C5_\
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MD0_Z!&K_ /@(?\:/^$B'_0(U?_P$/^-;5% &+_PD0_Z!&K_^ A_QH_X2(?\
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MZOG9C!)QW)QCFN@\(!UU;Q07AFC$NJ&6,R1,H=/*C7<I(Y&5/3TH ZNBBB@
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M%% !1110 4444 %%%% !12,P52S$!0,DGM4%A?6VIV$%]9S+-;3H'CD7HP-
M%BBJ&L:Q9Z%8&]OFD6 .J;DC9^6( S@<<D#)XJS=W45E:2W4Y811(7<HA<@#
MKP 2?PH FHJMIU_!JFFVM_:L6M[F)9HR1@E6&1QVX-6: "BBB@ HHJAJ^M:?
MH-F+O4KCR(2X0'8S$L<\ *"3T/Y4 7Z*JZ=J-KJUA%?64C26\H)1F1D)P<=&
M /;TJI<^(M-M;B>%Y)G:WQY[0V\DBPY&?F95('&#ST!R>* -6BH;2ZAOK."[
MMW#P3QK+&X'WE89!_(U'>7\5B;82I,WVB98$\J)GPQS@MCHO'4\"@"U1110
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MRP((P<8Q@8&.E '/S>)KA="TW4[6\N]2TMY9OM=Y90(9XUW'9NC*]%'#87/
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M\I8 ?1A^= '34444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M*VL? 2>)K>S8F2."5+>8X($CH,''<!Z!G345C7OBC3;#Q'INA7#R+>Z@C/"
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH *CN/^/:7_</\JDIDJ%X70=64@4(
M#!\"_P#(CZ1_U[C^9KH:YOP%(K>"]/C!^>!6@D&,%75B""/J*Z2KJ?&R*?PH
MS)=:L7TG4+V"[C,=EYJ3.#_JGCSN!]QBO'_#?AW4M/MI[2?1+^YU?4=*BM+2
MZ9";:VCE5FE)?HI#.25ZG@#J:]4O_!FA:EJ8O[FS)E+!Y461ECG88P9$!VN1
M@8R*WZ@L\BOO!6M6D>J>$=*AE_LS58;?&I$C;$L4(1U?_:<HG08PQ].)M7D\
M7^(O W]DP>'VLS9VT;7ANA\UQ)$5;R[=0><E/O'CL.N:]7HH \PDT+6;U8?&
ML^FROJZ:@EU'IQ($B6BJ4$7.!OVNSXS]XXKL]#U/5=6N[JXN--DT_3E"I;QW
M2XGD;G<Y )"KT !Y.">*W** .1^)MD+[P#J ,1F6!HKEX^<.D<BNX('7Y0W!
MJ#73;RZ/X=UC0XV%K8ZC"T:V\14&!B8GPH'W=KYR.,#(XZ]K10!Y1=:/J%UX
MJ\86ATB\>]UK;9PZB\9\B"R,0#D/TR#GY1R3CT)JO=>#]0FU36_"$5G=PZ5J
MUU%=-J*_<$*Q#*;L8W>8@&#V.:]?HH%8\SOXO$<G@*73M9T,M?K&MMIHT_,K
M1W"(=EP7!_=@MMP>-O<\TVTM-=_X0OQMI: MK[2N^%&/-WPQC<O3[VU\>XKT
MZDP,DX&3U- SR;_A%I-;\.-#I>CW.FV6FZ-<V=E#=QF*6XGG1=Y93R "HY.,
ML2>@YE_L#7-;T=/$D^GRQZG;75I-9:=. KB" \KR<*[Y<_\ ?(KU6B@+'&W6
MMZUJ6D:[<C3;G2+&WTZ4P27 "7#S;2=P )VJN._4GCI6KX,OKS4O!6BWNH$F
M[GLXY)&(P6)4?-^/7\:L^(=+N-9TB33X+L6J3D)._E[F:+^-5Y&"1QGGJ>*T
MHXTAB2*-%2-%"JJC  '0"@#C++2]/O?BUK.HSVT,EW96-HD#,N2FXRDL/0D
M#/M5OQA#>VUYHVO:?ITVH3:=+*KVT&-[)+&5XR1T<1D^V3VK?@TVUM]1N[^*
M+;<W:HLSY/S! 0OTQDU;H \O\/CQ;X52_P!%317U"_OKC[;'?,0+5))5!E\Q
MLYPK@X R2,5U5Q/J>KOJOAZYTMA;_P!GF-]08!89Y70#;&A))7ELY/&,<]:Z
M:B@#R?P]97M[#X4\(3Q%(]'A6]U>,D':ZD^3&<>K?/CT4>M>AZCJE[:ZOIMC
M::5/=1W3-Y]T"%BMT ZL>Y/8=ZL:=I&GZ2LRZ?9PVXGD,LOEK@NYZDGN:NT
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MXZ_S%-^S0;Y'\F/=*,2':,O]?6G"*-6W*BAN>0.>>O\ (?E0 ^BBB@ HHHH
M***C6>%VVK+&Q] P- $E%1M/"LZ0-*@E<$K&6&Y@.I [U)0 45']H@#;?.CS
MTQN%1WEE;ZA;&"Y0O$2#@,5Z>X(- %BBL7_A$]%_Y]7_ / B3_XJC_A$]%_Y
M]7_\")/_ (J@#:HK%_X1/1?^?5__  (D_P#BJ/\ A$]%_P"?5_\ P(D_^*H
MVJ*Q?^$3T7_GU?\ \")/_BJ/^$3T7_GU?_P(D_\ BJ -JBL7_A$]%_Y]7_\
M B3_ .*H_P"$3T7_ )]7_P# B3_XJ@#:HK%_X1/1?^?5_P#P(D_^*H_X1/1?
M^?5__ B3_P"*H VJ*S[#1;#3)FEM(61V7:297;C\2:T* "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M)FAN87()5USD<@'@]ORZ5;76TM+4?;[9[HW*R7;-"=AC_B2-=V5[8))[D]:
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M1_:3$=XQRQ7OD=/KFW_9U[?^*/&ILM8N=.EBDMWC: )@N+92-^X'*^PQW]L
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MH*$?+[5+_P (WIHO=.NTCE233E9+;;*P"AOO9&?FS@9)S6O10 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MS(<O!\VUPI.,D8ZD5JJFMW_B[2-8FT&:UBM[.>&='N(F8.Q0C;ACD?*<'CW
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH HSZ/87&I)J,D)^UJBH)5D925!+ '! (R2
M<'UJ]110 4444 5KVPM]1@\BY5VCSG"R,F>,<[2,CGI3[6U@LK2&TMHQ'!"@
MCC1>BJ!@#\JFHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI+=RP5F1DR58J>& /4&K=9^AZ8FC:#8::AR+:!(BW]X@<G\3D_C6A0 4444
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M[:*[DM+6[6>ZGFB8+MB4L@S@*<OLX7@;>U=;10 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
*444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>43
<FILENAME>exhibit1018-arvinasxcons011.jpg
<TEXT>
begin 644 exhibit1018-arvinasxcons011.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=S",;5)QT!/ &3FL-M(UFQN+2\CTJ6Z,&O7=X88I8@QBD2158;F _C'&<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MG%6=:^&^DZQX<T_0$GN++3K%Q)%'!M)+8;DE@<_>)^IH&:'C*VA3P;XCN%C
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M6O=/L3+;Z5=>?.QE1=PW1G"@GDX0]<5U4(NSXEFE>PE6UDM8XQ,SI@,K.2"
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MG@+,@=#QE201^8- %JBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MK]*V=+TN/2K4PI/<7#LVZ2>YDWR2'IDGZ #  %8^F^(M4U34]7LH-,LU.FW
M@9GO&&\E0P(Q&<<&I[SQ(^GV=@ES9?\ $UOYC!;V4<N0S G+;R!\@ W%L=#T
MSQ0!7OO NF7_ /::O<W\<.HRK/-!%/M02C;\X&.ORCKD<=.E74\-6\>HWE\M
MY>>==VZVTA+JWR+G&,KG/S'D^M0WNOW.B3VAUFV@CL[J98!<V\I812-]T."H
M^4GC<.^,@=:W\C)&1D=10!S0\$:?';:4EO=WUO/I:&*UNHI%$BQG@HV5*LO
MZ@UHZ)H%KH2W@MIKF3[7<-<RF>3=\[=<>E:C.J+N9@H]2<49 QDCGI0!Q=EI
MEQ=>./$\C2:E9V]S';HDD<6U9@J$-AF4\@G&00>>*VU\,6,6HZ9>6[S0?V;
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M8%DP5*A3N^7GY0!_]>K&CZ%:Z)]I%I+<&.>9YO*DDW+&68LP4=@22><UJ44
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MJNX9<@$DL,]>0,"@#I/%6NQ6^BZS#:R77VJUM&>26U3/V<E25)/KT.!D@<G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^Q BX_V:WK*.XBL8([N=9[E8U$LJIL#MCDA>V3VJ>B@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH *Y[Q#>ZYIUGJ>H6;V"6EE9M.J30-(\KJK,1
MD.H4< =#WKH:P_&4B1^"M;#L 7L9T4$_>8HP 'J3Z4 9B:MXD/A==:,NF-')
MIC7@5;5U,4FP.H.9#N7J.W:M;P_KMMJFG6"27MJ^I26<5Q-;I(N]=R D[,Y
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M3$QSC"<_,<^E>?:+9266H?#^VU=5^V0V5T)!, 63(3RU;/0@# ]P:IWJ68\
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M#]Y:2W&GR;#O^<, 5!( (.,L0#TX[UU5MJ5A>3SV]M>VT\UN<31QRJS1GT8
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M%BKR<+D=!D=2>3C.>*:L*6?PP\-ZC9VA(MOL;Z@;6(&;RT&6R,9)5SNP?0T
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M0GBFE,4^G7+%?,;:<&/!VYP#\QYI_@0O]DUM&DDD$>LW:*9'+D*'P!DDG@4
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M#8N!TX[^M7* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MK!8]C1':#M((XS@$'ZUV5% 'FVB:+?Z->>!K6ZMKAVL;6[%Q(D3.D)D"E5+
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MEK-G;21?:+TR>7;.8RA,3,Q#9./N]N>PK.%],WA_P=I=SI5]975AJEG;SB>
MHFY 5RK='!QG*Y]Z]3K+UG0X=;^Q>=<W$/V.Y2ZC\DKRZ],[E/')XH X36H+
MZ+3?'>E+I=_-<:A*T]LT5NS)(C1(O#XQD%2-N<^@K>_?'Q[I%X;.\6W32)8W
MD-N^$=FC(4D#&<*>*[&B@#S>RTO4Y_A-<6-M97$>HQW,DXMYD:%I,7)E"@D#
M[R@#/O1J-C_PE/A[5Y-)T/4[/4Y=/:W\[4MZ2'+!O)7>3D'#9/3D<\G'I%%
M'!MJ$NL>*?"5[%H^IP);K<K<B6S>,0,T8 !) &,\9&16IXQMKTS:'J5K!+<P
MZ=?K-<01*68QE60LJCEBN[.!SUKJ** ..CM9)?%.LZ_%!<I9OID=J%,#J\\@
M9V+!"-QP"HSCN?2K_@2.6W\#Z/;7$$T$\%JD<D<T;(RL!@C! KHJ* .(MIGL
M_B7K-]-9ZA]EELH(HYDLIG5F4L6 *J?44P:=?:IXHU#Q/=V<]M:P:<UE90,F
M9I<DLTA09(] .O<@5W5% ')^&;J30_ASI+3Z;?M-;6T4,EK%;-YP;A3\AP2
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %87B37_[&BAB2"[DFN"0)(+22<1#NS! ?P'<
M^V36[10!S.F:WIUCX=EN+:PU1;.U<(?,LY!-*[,-S!" S<MDMCJ3Z&NFHHH
M*\V^(6EW<?C/POXD%I/=Z=I\I%RL$9D:+D$/M')'T_NUZ310!C?VV=1L;F31
MX)IG2!VCDDA:-2^/E4;P-Q)].!W->8:7X>U'6_"N@:,(;@7%QJ#:GK5U,A4H
M58_*2?XSP .O&>AKVBB@#P_7],U74SXRUL:9>27-[<QZ580FW;_5C :3&,[2
MHX/3)-:VE:2/#OCZ6YN+*Y&G>']$6-+HQ$)(VS<[[CP>,K@<].P->M5E>(]$
M7Q'H=QI4EW-;0W VR/"!N*]QR#C- 'D6DZ#/XG\#V&GQP%KW6]3;4M2N=A @
MBW'JQ[D8VCON)Z<UK6]E/K?BWQ5:Z\FI(US<+;PQ0VK_ +VT4DJJRXVHC<%N
MF?6O4M,L4TS2[6PC<O';1+"C$ $JHP.G'05:H \CU/3+N;Q-XIUE-,N3;:/I
MBV&EV_D'$K8SE1CY@K>GM36\.QGX9Z-H>V]T[4[6#^TK:Y,3*$N02=K<<$EF
M !YXZ<8KUZB@#R:[GUN;7/!AU71KED2WDOKF&WA.U[S:=I?'"D'#<]"QK!%I
MJ5Q\,3"^GWR7?B+6P]^PMGS&C.23C&<?(IZ8^8CUKW>B@#S1H;VY^*DT\.F7
M*Q:1H_E6"M$1'YKKG.[[O0[.#U^AK!TSP]J6N>$M#T7R;@7=WJ+:CK=U,A4Q
M[7(VL3_&1MP/;/ ->TT4 >,:SI^I7LGCSQ(VF7DLI"Z;I]N;=B67A#(JXR1S
MN!Z9R>PQVFDWS>%M+\*Z!'HU_,MS$(7F2/Y8" ,L_IDDG!P0,]QBNSHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH ***\Z\9WUPD'B>XL+^[>XT^VB8;)FA2S8#=@8/[QFR"01C'&>U
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M96:/' .,>HZ'OFN8A6:R\,7&KVU[=Q7$'B.151)V6,JUWM960<,"&/4$^F*
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M&Q*65OK5N+RYC\S7UB0(Q:2;*1GR]Q((R 1NSP!0!W<TT=O"\TKA(XU+.S=
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M6\N !++YC$R < ')P<=O2M"N9CU'6+KQ)K&FPW-G''91121-);LV2X)PV''
MQVH V;K2+&]O[6]N(2]S:DF"3>P\O/!Q@]QP?45'>:%IM]>?:Y[<_:/+\II(
MY&C9T_NMM(W+['(JKX:U[^V_#4.K7$:6VX-YGS?(-I()!/;C-:-OJ5E=B8P7
M44GD_P"MPP^3C//IQ0 L^GV=UIKZ=-;1M9O'Y30[<+LQC;@=!BF:CI5EJUE]
MCOH!+;Y#>7N*@D'(Z$=" ?PIUMJ5E>/(EM=12M& S*K D ]#]#ZTD&JV%S*8
MH+R"1PN_:KC.W^\/4>_2@"K>>&](O[Z*]N;-7NHH_*$N]@S)_=8@_,/9LBJ\
MW@WP[<:/;Z3)I4!LK=MT,8R"A]0P.0??-7$U_2))88DU.T9YV*1*LRDN0<8'
M//((J:YU.QLY!'<W<,3''#N!C)P,^F3P,T 5+CPSHMUI=OILNGQ?9+=@\*+E
M3&P_B5@00>3R#GDU-IVA:9I,UQ-8VB0RW!!F<$EG(&,DGZ4"X,FLS01:E;DK
M;C_1-H+HV?ODYSCD#'ZUCZ3K%S>^%K"[N]3MK2ZFN2A=T&),3%=BJ2.2 !W-
M &U=Z-I]_?6U[<VJ27-MD0R'(*@XST^@/U&:J_\ "+:,;%K(V?\ HSS>>T?F
MO@R9W;NO7//UYJ[/JEA:S>3/>0QR94%6<#&[A<^F>V>M5_[>L/[<?23.@N(X
MA*^YL 9/ ]SP3[4 5[KPAH%[+=2W.F12O=A?/+%OG(Q@GG[W'WNOO5M=#TQ=
M1AU!;*);J&(0QR 8*H.@QTXR<>F:;I][$-+-U/JEM=1"1_\ 24PJ8W$!>"1Q
MPON14PU?3C:RW/VZW$$)VRNT@ 0^C9Z'ZT 375I;WUK):W<$<]O*NUXY%#*P
M]"#5*R\/Z;I[(;>*7$?^K66XDD6/_=5F(7\ *GMM6TZ\NGM;:^MY;A%WM&D@
M+!?7%7* ,RX\/:5=7DUU+: RS@+/M=E68#H)%!P^.GS \5*^CV+ZF=2,+"\\
MKR/-61@1'UVC!X&>?KS6;8>(VN_%5YI4D6R$1;[27_GKM8K+^3<?AFMBZOK6
MQ4-=7$<0()&XXR!U/X4 4(?#&D6\-O%;VSPI;%S#Y4\B&/><M@AL@$C)%.N?
M#6CW=K:6\UBABLVW0!6*F,GK@@@\YY]>^:+CQ%IMOJ%C9FYC9[Q2\;!QMV 9
MSGISD ?6M1F5%+,P50,DDX % &.?">A?8KBS&FQ+;7,WGS1H2H=\YR<'L<$#
MH,"K,VA:9<7\5]/9QRW4<7D+*^6)3T.>O?KGK4L&J6-TSK!=PR,B[V"N,A?[
MWT]^E8FFZO<Z[>SO8ZA;QI:WK1-;E0XDA7 +9Z@DDX/3IQ0!:MO!WA^T>U>#
M2X4>U+&!LL3'GK@D]/0=!VQ4@\+:,+%;(6?^C+-YXB\U\"3.[=UZYY^O-'BC
M4;O2?#=[J%D(C-;QEP)02/R!%+K&JO81Z?%%M^T7UPENC,,JF06+$=^ <#U(
MH LQZ-I\6JOJB6J"]D0(\W.6 &!GWQQGKBEU+2+#5XX4O[5)UAD$L>[/RL,C
M(Q[$C\:R)=>N]/N=8LIXA=7%E9_;;<HNTS)@C:1ZAEQQU!'%2:;K,MW>Z>D-
MU#?6]W;-,\D2;?)(QCN>"21@\Y!YX- %UO#VEO->RFV.^^C$=R1(X\U ,!3S
MT )'T)'>D7P]I:M8,+8@Z>-MI^]?]R,8PO/IQ]..E9%GX@N=8\136VG:GIBV
M]O+LDMI(V,[*IPQ!W 8)S@X/&*ZB66."%YI6"1QJ69CT ')- &:?#6CM;7UN
M]BDD-^V^Z21F<2M_>()// YZ\#TJ.V\*:'9Z1-I5OIZ1V4_$L89OW@Z88YR1
MCC!-5WUVY72K+4OLL[PWLR!4AA,C11,"58@=S\N>PW=\<V(==19-6:^BFM8=
M/.6>2(A"F"=RM_%G&>.F0* *VHZ=?7;QZ%'I]O\ V$T:>;<27!9\*V3&$(.<
M@ 9SP"?0"NBKE]"U;5O%%L^I6_EZ?IS,5M@\?F2R@'&YN0 ,]AS[U%>>)[_2
MK>PT^Y@@N-?OIGCBACRD84.0'/)(7 !]3S0!J:EX3T'5]1CU"_TR">ZC&T2-
MD$CT;!PP]CFKATFR.K#5/)/VT1>2)=[?<SG;C.,9YQZ\USVH>(+_ $#Q-HNG
MWLL-U!J9,9*1;&B<$ $<G*DL.#S[TFH>(=2'CH:'9SVD=JEF;FYFEB+&'K_M
M 8^[^= &MIWA/0=)U&74+#3(+>ZD))= < GKM&<+GV I;/PKH>GZK)J=IIL,
M5Y(Q9I%S]X]2!G )[D $UD>'?%=YJO@R]UF^ACMFM_-VR*AV2*JYW $YQU'7
MM6+%XXUZ#1]!U*ZBLI3JER8OLD<3*^S. RG<?Y=Q0!V;>&-&+7+?845KF83R
MLC,I,@.=P(/!R <C'(S5VSL+:P606\94ROOD9F+,[8 RS$DDX ')Z "I+FXB
MM+=YYFVQH,DXS^ '<GH!WKD]-\2ZGXB\,7VJ:7'##,EVR6\<L9?<BA>" ?O$
MD^PS[9H VM4\+Z)K=Y#=ZCIT-Q<0KM21L@[?[IP?F'L<BK%YHNGWT\$\T!$\
M"E(I8I&B=5/50R$''MTJLKZTVJWD8>V%L(D: ^6WR/W5C_$#STZ#'K5O2=2C
MU;38KR)2F_*NA/*."0RGZ$$4 2QV-K%8BQCMXUM0AC\H+A=IZC%,?2[&32O[
M+DM8GL?*$/D,N5V 8 Q]!3[Z^MM-L9[V[E$5O A>1SV KE;GQ<9I?"][9W=O
M'IVHR,+I7P2@\AI,%LX7&!GB@#6M?!^@66E3Z9;Z=''9W'$T8=OW@[ G.2/;
M.*LW?A[2KZWM(+JT$J6;;K<L[;HSC'#9STXQFIK76--OK!K^UO[:6T0D-,D@
M**1UR>V*?9:G8ZD)?L=U%.8FV2!&R4/7!'4?C0!S.O>$K<:>EOI.B6,]M)>?
M:;RT9S$9N#@HV#M(8@XX'4<9.9?#_AB&SFGE.E_8+6:!H9;)[MKA9<D<L"2H
MP 1QG(8YJWKFO36NL:;H>G)&VHW^]]\H)2")!EG8 @GT R,GN,589-;M;ZQ
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M AW8^T[MV,9QMYSZ5IQ7=M;:CKFE:S93W'V^Y\ZW"P-(MS&44*H(&!MVXY(
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M(IE:>XAGB8Q-M9/(1<AL8Z@CK76T4 <GXE:>R\7>'-4F5SI</VB*=U!(A=U
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M U+_ *]9?_0#7(Z#I=YKGA7P:D\"0VUA';7AD$FXRE(OW84=N2"<],8&<YH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M*I7FKV-C/';SS'[1("R01(TDC*.IV*"<>^,5=KB/ 4C7FM^,+VZYO1J[VW/5
M88P!&![8)- '5V6JV.HR31VEPLDD./-CP0T9.<!E/*G@\'FKE<]XFU"/P]92
MZG;PQ_;KN2WLU9Q\N6<JI;'4+O8^^,56GU/4],\56VC27*W,6H6DLMM/+$-T
M4L>-P8+M!4AACH<]S0!U) .,@''-+7G-EXC\1RZ)X4U9[VU;^UITM98#;?*I
M=7(?(.<@KTX!''O4FI>)->TK2O%\?VRWGNM'\J2&X>WQN61 VTJ#C(YP?TH
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M"@;@1M 7)XR<CD8Y .EHKS[_ (2S5SX?@U>9HXDT_4FL=76.,$%%?894SD@
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MKI=C/>WDOEV\"%Y'VEMJCJ< $U9KS><WLEA\1C<7\DZ0I+&J,J@ ?9E8 8'
M&3_,\T >B6\\=U;17$+;HI4#H<8R",BI*X;2M4U/2[_PY:W5U%-8W^F._E+#
MM,)BC1AALY;(8@Y[^G2IM+U?Q%JL>BZM:V[/97I5[J&3R@D43C(9&#;RR\9!
MZ\\+TH [.BBN-NO$D]OXJ;2[VZ?37>ZB6R$T(,%W$=NX"3'^LSO&,C^'@]:
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ME>2VEM,YN(HUE:.2)XR4;HPW 94^HK2JEI,4D6EVPEF,S^6OSE0IQC@<5=H
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MV$US<6,,MW:_9+AUR\'F!]A]-PX/X58H **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "O.[.72M:&NKK5X;?5+/57"ND@2>)%
M<&$1YYVLH P!\Q9NYKT2J4FD:9+J2:C)I]H]]&,)<M"ID4>S8S0!QL:P:U/X
MSBUC"W5G,5@9CAK:#R@8W0_PY.YLCO\ 2JCSW6G:5X2\9:HC>='$D&J$KR4E
M4!9"/[RMM]_F(KOKG2=.O+E;BZL+6>=!M622)68#.<9(Z9YJS+#%<1&*:-)(
MVZJXR#^% '!ZS(=)705O3!9VNI7LLE\T\>Z(2,C-'&X! (!XY.,J":SM8TRV
MLM%2&UU9KB%M>M&"VS%(K;?(NZ-,,<#OC/&>V:])N[.UO[9[:\MHKBW?AHID
M#JWU!XJN=#T@V4-D=+LC:PG,4!MU*(?4+C H X_5-.T6QU?^Q[:-5V:=/<F&
M[E+6\2N_,@5LDR9! P0 ,\C(S0L-1:;0O <]W=1W5NT++=6TDJ[I6\D;6.X@
M-M[@G^('DXKT.?2]/N;B"XGL;:6:W_U,DD2LT?\ NDC(_"N?UKPN\TMDNGZ=
MHD^G6\;K_9MY!MB#,0=ZE58 \$?=[GUH YN:.;P[X;BGGN$ALKW6\3%Y#,EO
M:,7\M&PV H.P$ XP<'(KH]"CTS0[C5KH:W9FSE,4CQ1[8K:V8@K\OS$ MP2,
M]<'O5W1?#-II]M=I+I^GPI>!1+9VL7[C SV(^8G/)P,@ 8XJS<>'-+DT.32(
M+"R@LI.L*VRE <YR%Z;NX)SSCK0!JD!T(SP1V.*\G6,/X'T\&:8;?$_EAA,P
M.TW9&,YYX]:]5CACBMT@1?W2($"GG@#&*I?V!HWD"'^R;#R@_F!/LR;0_P#>
MQCK[T <!JLDOAV?QQ'H_FPI%96EP$B8DH6+B5U]&VC.?49KJ=,M_#_\ :7V_
M1KM2T]C@PVT@,3H"")& _CYQN/)R?2MV/3+"*YDN8[&V2XE7;)*L2AG'H3C)
M%1VFBZ580306>F6=O%.<RQQ0*JR?[P Y_&@#SG0BL.@_#2;(3=(8F?.,@PR8
M4GZCIZU:MU:^7Q5::=?VL,AUJ+[.LQW0R$)&WEL!_"Q!!QZ_A7=2:%I$NGC3
MY-+LFL@VX6YMU\L'UVXQFE.B:2R2HVF6124AI%,"X<C@$\<XP,>E 'G>K7(F
M\":VCZ<^E7UIJ5N+BWCFS$'9X>4*X!5D(.#ZFMWQ"X\->,++7D@,EO?Q/8S1
MJ/\ EO\ >B(]V(*9]UKJ7T;2Y+3[))IUH]MNW^4T*E-WK@C&?>K+V\+QI&\,
M;)&59%*C"E>01Z8[4 <'J2Q:3K.A:+?36<-C/:SLS7,.Z":ZW(3D;E&<%RH/
M'. .F.D\)V<6GZ,;6#4FU"".9Q'+_"HSG8IR<JIR!R<8QVK2O]-L=4MOLVH6
M=O=P9SY<\8=<^N#4T,$5M D$$2111@*D<:A54#L .@H X%1#K,7C4:L=E[8W
M$BP.3A[:$1 Q.AZKDAFR.IS4!MSJ6I?#V?6K2)[ZY@E^T^;&,N1;$_,/KSCL
M:[VXTG3KNZ6YN;"UFG4;5EDB5F SD#)'KS3KC3-/N[B.XN;&VFGB_P!7))$K
M,GT)&10!G^+;JVL?"6ISW<US!;K;L&DM2!*N>/E)X!YZ]JX^'RX/$^MV"M;6
M\,NA)*;>SE(4.&DYR,9;:!D@#C'UKT>:&*Y@>">))8I%*O&ZAE8'J"#U%4DT
M'1XE58])L458C" MN@ C)R4Z?=SSCI0!Y_HMI#:#X=7L6\7%Y;^5<2-(294-
MJ6VMD\@$ @=JN):G3-:U+P<(6-OJTJW=K)@G; ?]>F>VW;A?3S%KMAHFE*(-
MNF60^S\P8MU_=?[O''X53TBQU4W;7^N263W:HT,*V:L$1"V2<MSN;"9[#:*
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M^Q9E3<PABD6,S$ '."-V<$=3TKJ/#MC8P:]<7>GZK:S1W-LI>TL8PL (/$F
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M0T]Q 9&*S2+*%#.,_,<,>M=8^A:1(DJ2:58NLQ4RJUNA#E1A<\<X' STI_\
M9.F_:1<_V?:>>$\L2^2NX+TVYQG'M0!YOHE]+_9G@RPNW9]+GOKVWF,C$JQC
M:001L3U'' /4J*9XDAELM-\<V=ME=-M5M9[91TMY6P9 G]T8VM@=-WO7I(T7
M2EL7L5TRS%HYW- (%"$^I7&,U*FGV45F]FEI MLX(:$1@(P/7(Z'/>@#DYY+
M6X^)[0I,A270I/,$<F-Q\U,$X/7;W]*YO0[:.VT'X>ZK&T@OKBZ2"68R,2\;
M12DJ<GIE1QZUZ1#H&CVRHL&E6,:HAC4);H %/)4<=#GD4X:%I"QPQC2K$) V
MZ)1;IB,^JC'!^E '->!+6QMK_P 2B&&WBG&L3J B@,$VQG'KC)_6G^,!%H^L
M:1XEDCW6\4AM+T!=V8I1M5B.^U]H^C$5U,5C:074UU#:P1W$^/-F2,!Y,=-Q
M')Q[U++#%/'Y<T:R)D':PR,@Y!_ @&@#SKPW;2K>W'A._M%4Q7:ZF>,@6[?.
MJ;CU*R?)[JI[5#K%O%):_$Z%U\U(X$D19"7VM]FW9&>GS<^U>EB&(3M,(U$K
M*$+X^8J"2!GT&3^9JNFEZ?%+<2QV-JDER,3LL*@RCT8X^;\: .'N++3[C7/
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?.AEW928#!('^T <D4[Q/XJM_#7]GQO;R7%Q?W*V\42$#&2!N)/0 LH_X$*
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M9)'.C6!>643N3;KEI!R&/'7KS[U,^B:7)>M>OI]LURQ!:0QC+$="?4CL3TH
MY#1)[C7?$,NG>(XB9(]'M)8[=^ 7<'SG _O!L+GMCC&36;H]W?._@Z2\N)9"
M-3O+5;AW.Z>%4E$>X_Q?=&,]<9[UZ)>Z5I^HR1R7EG#/)%G8[H"R@]0#UP>X
M[TEYH^FZA91V5Y86T]K&5*0R1@JA'3 [8H \QUL077A7QLK,)8K?6HO*!;*Q
M\P9QZ#EOS->K6\4,,"Q0!1$F0 IX'//ZU4&@Z0L-S"-+LQ'= "=/)7$H P W
M'(  JY!;PVL$<%O$D4,:A4C10JJ/0 =* ."\6Z?<3W&J:MIZ[M3T>6WO;<#J
MX5#O3Z,F1COQ6?XBN5UO2M*\1!66*\UBQ2T5Q@K"LF<X[%F+'W 7TKT>'3K*
MWNIKJ&TACN)O];*J ,_U/>H[K1=+O8((+K3K6:&#'DQR1*RQXZ;01QCVH X/
MQM<121^+)+:9VNK"RB+232[1:/M9D\D#G<V02<CL.>@MW&GP:[X\@M;R>Y>V
MGT+S)(X[ET4N)5&1M(Q^&.176S^'M&NKAKBXTJSEF:+R&D>%68QXQMR1TQQ3
MX=$TJWNHKF#3K6.>*,11R)"H9$'100.![4 <;ISV&N6NK2ZGJ$MKJ5CJLB^9
M'+MF@5)/W:)G/RLH P!\Q8]2:I:M80W=[\19Y&E$EM!%-"4E9-CK:[@W!&2"
M!U_J:[Z30=(EU9-5DTRT;4$&%N3"ID'I\V,T-H6DNUTS:;:%KL8N28E_?#_;
MX^;\: ':+/)<Z%I\\K;I);:-W8]R5!)K"\5?\C-X0_[",G_HB2NFM[>&TMX[
M>WB2*&,;4C1<*H] .U0W6EV%]/#/=V4$\L)S$\D88H?52>E &;X@\-:'XE:.
M+4HPUU A:&2.8I+""?O*0>.0.>G%1>%+V>/PQ8C5[Y)+AI)((IY6"FY4.PC8
M>I9 K>^<UI7NAZ3J-W%=WNG6MQ<1+M226(,P7TR>WM3-7T2TUF.UCN8HF6WF
M69"T89E*G(VG^$]L^GY@ TZYF\N=.UG4[5Y;RW%CIUQYH+2#]]<#*KCV4D_5
ML>ASTKHKHR.H96&"#T(K&@\(>&K:XCN(- TR*:-@Z2):(&5AR"#C@T <MIY&
MFZ3\0X[SY9%O+FY(;O')"I0_B 1^%:VCW,NB^"]#TIY(H]6:PC14F8 1$( 6
M;V7T[GCO717&EV%W<)<7%G!+,F '= 3P<C\CR/0U6O\ PUH>JW/VG4-'L+N?
M 7S)[=7; Z#)% '':OIEE#-X)TNTN6;1[>^>.26.3K,(V*98?Q%MW3N>,&MS
MPVU];^*/$&ER7,]SI]L8)+9YW,CQLZDO'O/) P",\@,*W$T?38]-&FI86R6*
M]+=8@(QSGA>@YY^M3VUK;V<9CMX4B0DL0HQDGJ3ZGWH P?$\L#:CHEC(7DFN
M+B0Q6I<+#/MC8GS3@_*,Y  .3CCTY;2CJ-[X76"QN;2YGM=:N5CL[F0^5=1*
MTF(L\X 'S+G(^0=A7H.H:5I^JQQIJ%E;W:1OO19XPX5O49J$^'M&VLHTNT :
M;[0=L*@^;TWY'\7)YZ\T 4O!U[#>:"?*M)[-X;F:.:VG;<89-Y+*&Z%03QCM
MBL/Q=);W.HZM LC23VNCM(RS2;8K<$OB1!C)D)&,Y& !SS@]M;VT%I (;>)(
MH@20J# R3DGZD\U6NM%TN^O$O+O3K6>YC0HDLL*LP4]@2.G)_.@#AK=?[6U?
MP2+JZN)5N]&E>Y47#@2,$A/(!Z_,<^N>>*W? +.-$O;8R.\=IJ=W;P[V+%8U
ME8*N3R<#BMF'0-'MWMWATNSC:V4I R0J#$IZA>.!]*GLM-LM-21+&T@MED<N
MXA0*&8]2<=3[T <]JS>5\1_#JABJ3VEX)%S@2%1&1D=\9/ZUR/FF?0H/+O;A
M8QXO:!'AN& $1G("C!P1C&/3M7IFH:1IVK+$NHV-O=K$V^,31A]I]1FL#Q)X
M56]M;.#2].L$0:G%?7:OA!*%8LV<*=Q.3UH S[&VN_#_ (TU>RT.&6[M&T^*
MZ^R373;4G,C+P[;MNY06]\4WQN;S4/AW?S:QID5E<1SPB.-;GSAM,L8W9 'J
M1CVKMK2QMK)&%M;I%O.Y]HY8XQDGJ>..:;?:=9:I;_9[^T@NH<Y\N9 ZY^AH
M X[5=&M+KQ]I^ENUPEC+I5P7@CN713B2/'0\=2>,56A5-5TWQC]NEDBO=-N9
M8K:3S"'M8DC!B=3G(S@L3_%SG-=O_8^F_;(KS[!;_:H5VQS>6-Z+Z ]0*2XT
M73+N[^U7%A;RS[0ID>,$L!R ?4 ],]* .&TV&?6_$^BC6&N-]UX<\ZZ@$SHK
M2;X\Y4'CKR!CWK-M88[[PYX(:\S.T>MRVP>5BS>6IG4+D^R*/P%>G2:5I\M]
M]NDLH&N]GE^>8QOV_P!W=UQ[5!_PCNBFQ%B=)LC:"3S1!Y"[ _\ >VXQGWH
MT$V^6NS!3 VXZ8KS$ :-IWCZ_P!.B*7-K=D1NF2T:>3%N(^@)/X5Z@    ,
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MDNU+085L28&2 <8SCG'7':K0US3S=+;+,[2.[QH1$Y5G0$LH;&"1M;@'L17
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M66W7^L16AC6"/;'%([8QE<E@N.2>O:G>(KG6=!CL)7UHO!+JUK$SO%&I\EV
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MV($<%CM!P,L*R7M;ZU\2_:M&^W(MQJ0%]IMU;LT#KNPUQ&Y&%. &X.">.O4
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M5('S[< JV>. <^M;#>(-*2Y2W:[ 9YO(5RC>69?[F_&W=G(QG.1BN3ATMO\
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M2/%B*)W<LGW@% W'&1R!CD5P-Y;WLWAGQ+"VDZAYESK\=Q'%]E9B\?F0DL,
MY&$;\JW_ !.UQ8^)]-UEK'4;S3&M)+:46/F>; S,K!BB$,0=N#Z8% '66&H6
MFJ645Y8SI/;RC*2(<@]C^.>,59K)\.VMM:Z4!::?)802R-*L,N=_S')9@22"
M3SCWYYR*UJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHKC+KQOJ$46LS6WAR2XBTB<QW)^U*I*!%<LHP<G#9V^W7M0!V=
M%<O<^,[=HBVF1P7+"SCO-LT_D[ED!**ORMEB >. ,CGFH&\:7<]S86^G:#-/
M-?6#WD233"$@J5!1L@X/S8SZ^W- '62310@&61$!. 68#)]*?7!3B75O'.I6
M6L6-I)IZ:3$9(I9RPC1GDW,/D^\=HS@C[HYK1B\6I::5I6H-I_E:)>/'##/Y
MQ:2-7XC9T(X4\?Q$C(SWP =917+VWB?4K[5[ZQM-!,BV-T+>>5KM5P"@<,!C
MGJ 1[]ZI6WCRZGTS1M3.A,++4YQ;*5NE,BR$L%^7 !4E<9+#&>F.2 =K17,0
M^*KLC6X+C1I/M^EB-OLUK+YWG+("4VG:#V.>.,=Z;_PF#(^NP/91/<Z3;+<L
MMO<AUD4ACC<5&UAL.01Z4 7[_P .)=ZJ=2M]2U"PNGC6*1K61=LBJ25!5U8<
M;FY !Y-:-E91V,)1&D=F;=))(VYW; &2?H /0  #BN?T_P 6W%SJ.CP76E?9
MH-6MFGMI?M <AE0.59<# P>#D].0*GM/$EU?+I]W:Z2\VF7TIC2>.3+HO.V1
MDVX"''7=D CCL #HJ*Y*3QQ&)+>6"T6XL9KK[,7BFW3+\Q7S#&%^YD==V<$'
M':NMH **R]5U2XL;BWA@LQ*)4D=[B:0QPPA0/OOM."21@8['TK$C\<FXTO0+
MZVTJ24:O,T"IYRCRW ?(SW&4//''Y4 =?2;UWA-PWD9"YYQZUR\/C,1V6IMJ
M%@;>]L+M+,VT4WF"620+Y81B%^]O'4#'-4;07!^+A>ZLX+>5M#)+0R[Q)^^7
MJ2JG(Z=/3\ #M7=(T+NRJHZEC@4ZL#QI?6VG>%KJYO--34;92@DMW8!2"X )
MR#T.#27OB4Q:S=:5:6\,]W;P),89+CRY)5;/^K7:=V,<^_% '04U'20$HRL
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ME177[#,<,,C(0D'\Z -E65U#*05(R"#P12UQWAS7[B >'=(NM.\F&]TX-;7
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MFU7PKXIM[.PBNK:R@E@FEEEV_O!'N;8NTYVY!R2.1@=*Z?0O^1>TW_KUB_\
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MP:CI]TLMKDAG(*E".H8'!4CT-5]&\4Z1K\TL6FSS2M$NYB]K+&N.G!=0#^%
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M2KH,:R&>0QECYS_-D*W?MCO4C^#[R'3=(M[:6W>:VU7^U+IY&9!(Y+EE4 '
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M#).%VNXR 58,,X^F*V** .9O/#<WB"[%QK:P1*EE/:1PVTA<#S@!(Y8JO.
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MNF.Y_*4A%_V5SS@>IZ\GCI5JBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MV4RQP6J3M.0,'<Q&>O"C:>?7]9$\5:<UY9V[+<1K?*S6<SQ_)<;1D[<<YQR
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M(;EH_+<K*<@C!'*CCH>^>* ._HKSY]2O;?1O!WBFYO;C[,\4":FGFLL9$L8
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MB+11)<QG5K$/:KNG4W"YB&<9;GCGCF@""'PGH5OK,FKQ:=&E[(_F,X9MI?\
MO;<[=WOC-#^%=&DM+ZU>T=H+Z3S;I#/)B5N.3\WL/R'I5I=;TIK6VN5U*T,%
MR=L$GG+ME/3"G/)^E%IK>DW]I-=V>IV<]M"2)9HYE9$QR=Q!P* +L<:Q1+&N
M[:HP-S%C^9Y-8;^"_#LCR,^F1DR7 N2-[8$N<[E&<*2>N,9[UH1ZUI<L$\R:
MC:F*WQYS^:H$>>1NYXR/6FV^NZ1=7+6UOJ=G+.L0F:-)E+!",[B,],$<^XH
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MY"2/'<1F)4,8V _,"IXXZYKTFB@#B;6*&#XD6$(C,:IH!@*NVXJWF(0A;NV
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M806L+S2;1D[5!)P/H*PH_%5P=4TNQETHAM3MFN8&CN V%4 L&R!@@,O3(]Z
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M0>(K/[,;00R!W612%WA3@E=H;/'3/I777^I0:?Y2R!WFF)6&&-=SR$ L<#V
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MI\V/PS[5CZ7X3U[3+/P[!YNG3QZ;%)%-!([F,LQ!65?EY9>1@XZG!&<UWE%
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M\2;?[+B36-.CM4BC9PL#*CKC[O*X?.<#.,8'6M%-!U/^V/#5XWV01Z7:RP3
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M%Y DL9O*+Q=0C8ZJ.W<4 <MXAUB?0/$F@W^HE+BYBTNX2>6!2(U<O"K.>I"
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M<I+>P+;R!2NT(N=H4;>,;C^=5X_!^G16^CQ)->+_ &2&2V=9=K!& 4H2!R"
M/?CK0!F0W>O:B_B^QM=2*7=E.J6+^5'A285<*01@@EL9/-2:9XDDU/2K+4X9
MY3%;Z>UU>Q;4RT@R A^7@[DDSC'W1ZUNZ=HD&FZAJ%[%-.\M_())A(01N"A0
M1@#'  _"G:;HEAI*WBVD(5;RX>XF!Y#._P![\/:@#GM(NO$=\VB:JDZ/8740
M>\CE:,)AU!4Q;1N!!.,,3D>])\4L_P#" W> "?M%MC/_ %W2M#1O!FG:'<A[
M2XOS;HQ:"SEN2T$!.>43\3USC-7M?T&V\1Z:=/O)9TMV=7986"EBI##D@]"
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M6&WG=2H=?NDD*&;'4;F//-1R^$[*9-91[F[VZP,78W+R-NSCY>/E&/\ Z_-
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MBV>Z$9,4<A. K-]2!GH#P2#0!H?V=8@*/L5OA3E?W2\?3BGFTMC="Z-O%]H
MVB;8-^/3/7%9,GBS38;V^LY!<+<V0C,L1A.Y@[;4*#^/)XXS1?\ BS3=.U Z
M?*EX][]G^T"WAM7D=DR!\N!R>>W3!S0!LS0Q7$>R:))$Z[74$?K4"Z98(P9;
M&V5E.01$H(/Y5CCQQH3:=I]\EQ,\%_*88"D#L3(,Y0@#AN#QU/;-3?\ "4V)
ML1=);WS8A\^2$6S"6*/)&YE.".5; ZG!P#B@#5^Q6GG&;[+#YI.2_EC=^=$-
MG:V[%H+:&(L,$H@7/Y5FMXGTUK=)[9I;N-K87>;=-Q$)SAB.O.#P.>#QQ4ES
MXAL[9I1LGE$$2RSF*/=Y2MG:6[\X/3.!R<"@"_;VEM9HR6UO% K'<5B0*"?7
MBBWM+:T#BVMXH0[;F$:!=Q]3CJ:YD:A/9_$#5DEGNIK.+2H;D6ZY8*QDD!*J
M.^%'O6M;^(["ZTJPU*#SI+>^=4@*QG+%LXXZ@<'Z=Z +K:?9-&L;6=N44DJI
MC& 3UP,5.45BI*@E3E21T.,<?@3^=5KW4(; P)('>6XD\N&)!EI&VEB!GC@*
M3R>U5UUVU>UAF1)VDG=XXX/+(D9D)##!Z8*GD\=.>10!=N+2VO$"75O%.@.X
M+*@8 ^O-2X&,8&.F*Y6]\<V:6FGS6,$]Q]JU 6#KY9#0.#\ZL#R& !P/QZ5N
M:MJ)T[1+J_6&1VBA:0(%R<@9Y'\Z )5TRP5@RV-L&'0B)<_RJ>2*.:)HY45X
MV&&5AD$>XKCO#U\!I^D:S=WVIM=7]I'&UFY++<3,@<O&A^[@;NF%QUZ5JS^,
M='M=*O=0GDFC2QD\JZC,+&2%SC 90. <C#=#GK0!M);01G*01J2@3*H!\HZ#
MZ>U,>QM);46LEK ]N.D31@H/PZ5SEWXW@CU#3[6WL+]_M-XULSO;,@PL9?*Y
MP6SQC';-9]KXG31=>\5_VE<7]Q:VMQ"5VQM*+>,PJS$X&%7)/_U\4 ==>:7;
M7K6@EC39;2+*BA!PRD%<'L 0#QUP.V0;M1//&+4W +-%LWYC4L2,9X R3^%<
MWIWB?1K#0M&87M_=07V8[6>>-Y))3R?F('7@X'4^E '3>5&%"^6FU3N QP#Z
MTR2UMYI5EEMXGD7[KL@)'T-4]'URSUN.X-J)D>VE,,T4\9C>-L X(/J""/K7
M,ZCJ)@^)?]FW>M2V>G/I/VD(TXC7S?.V\$_[/:@#K_[/LL./L=OA_O?NE^;Z
M\<U/'%'#&(XD5$7HJC 'X5SL6M6.D:#=ZQ)J-SJ&F"9F6=5\XQJOR-RHY4,K
M'//7TJS=ZM#?Z;J<5E+.DD-KYGGQC 4LFY<-T)P0?;(]10!JI:6T=R]REO$L
M\@P\JH S#W/4TALK4W8NS;0FY P)O+&_'INZUR_A'Q3;7&D>'K"[ENGOKRPC
M99Y8FVS.L89P'/#-U)_&LWQ%JT?_  A_B"]TG5M266VU%$E:5F0Q/OB#(N0"
M$PW3U)H [EK"S9W=K2 L_P!]C&,M]?6G+9VJ+&JVT(6-MR (,*?4>AK*L?%>
MF7^HW&GI]JBNX8O.\J>UDC:2/.-Z C+#/IS6/%XJM-.T#0I+ ZAJ4&HW?V>.
MXN 6DQN8DMG!SA6 &.P]* .J.G6)# V5O\QRW[I>3[\4JV-HDBR):P*ZC"L(
MP"/H:SO%$\T/A#5;NWEE@G@LI9XG4X965"P_4=#6)!;:W+X(L]6T_6[HZF;&
M.Y*7 22*9B@8JPVY /3*D$4 =8EC9QN72U@5C)YI(C ._IN^O)YIQM+9KI;I
MK>(W"C:)2@W@>F>M9OAK7HO$/A>QUH*(4N(=[J3PA&0PSZ @TRR\5:;?SVT4
M/GC[7 UQ:,T1 N(UQDI^8.#@\]* -IE#*58 @C!![U!)8VDUJ+:6U@>W&,1-
M&"@QTXZ5R/\ PGY/A6361I=T#]L-JB&/@9F,0).?89 [G'O6W>^*M/L//$RW
M):VMQ=7*K$28(CG#,/\ @+<#)X/% &RB+&BHBA448"J, "E9%8J64$J<J2.A
MQC(_ G\ZS;K7;.VV*GFW,CPFX$=NFYO*_O\ L/3N>V:YN^\1Q2>*/#%_97US
M-IE]:74GDPJS"4J$V_(!DGYCUZ>V* .QN;2VO(Q'=6\4Z [@LJ!@#ZX--N+&
MTNMOVBU@FV_=\R,-CZ9JA:>)=.O=+COX6E*R3-;K"T9$OF@D&/8>=PP<^@!/
M3FF0^*=+EM;R9I9(6LYA!/!)&1(DC8VKM'4MD8QG.>* -=H8G>-VC1GCSL8J
M"5SZ>E-FMX+E0L\,<J@Y =0P!_&N5TO4[BZ^)&HVK/>);IIL4GV:XX5',C E
M0.#D!>1GO[TFIZK+IOQ%M4>>\EM9-*ED^R0J7W2"2, A .3@GGZ]* .G_L^R
MW%OL=ODC!/E+R/3I4L,$5NFR&)(TSG:B@#]*S;;Q)IU[I5IJ%J\DL=VQ2"-4
M/F.PSN7:>A&ULYX&*IMXVT2.S6YDEG0&\^PNA@?=%-D#8X ^7K^/;- &V+*U
M#,PMH06<2$^6.7'\7U]Z4VEL;H71MXC<!=HE*#>!Z9ZXK+B\36D]LLL5M?/*
MP=OLQMF64*C;22K8P,]/7MFJ+^-;.:_T*+3XIKNVU59)%GC0D!44Y '7=NQD
M=L&@#HGM+:2Y2Y>WB:=!A)2@+*/8]123V5K<R1R3VT,KQG,;21ABA]B>E9EY
MXITRR$\DS2_9;:40W%TL9,4+\<,?;(R1D#N16R"" 000>A% $3VEM).)WMXF
ME7&)"@+#'O236-I<2B6>U@ED52H=XPQ"GJ,GM52;6[6#6HM)=9OM<T+31@1G
M:ZKUPW3(R..O(J"U\3Z?>Z6NHVZW#0-<?9@/*(;S-VS&T\C#<?KTYH TS:V[
M/&Y@B+Q#;&Q090>@]*:-/L@4(M+?,8 0^6/E Z8XXKB])\4Q:-/XC_M:ZO9X
M;?5VC$IC:1;>,QQXW$#"KDG]?>NC-[9'QBEG]KO!>K8M)]F^80&/>HW\C!;)
M R#P,T :*V-FD4D26L"QR##H(P P]QWIZ6T$5N+>.&-( -HC5 %QZ8Z8K*C\
M3Z;<7=G;+)*HO]XM)S'A)RHR=I^G()&#VS7.^%?%<-KI:0:I<7L\LNJ3VJW,
MD;.BGSF6-6?&!G@ ?3ID4 =O;VT%I"(;:&.&(=$C0*H_ 5(R*X 90P!!&1GD
M=ZY_QU/<6O@?6+FUN9;>>&U>1)(FVL"!GK3OMUI_;NBVTUY>I>R6TCQPKN$,
MPVKN+G&&(XQSD9]Z -X(H8L% 9NIQR:A2QM(UD5+6!5D&'"Q@!AZ'UJA!XAM
M+EH_)BN9(YE=H95BRLH3KM/\LXSVR*H:'XOAU;0[74)+6>)[N9XK>'9\TA!?
M !S@D*A).<<&@#=-A9E@QM(-P&T'RQD#&,=.F*?#;06RE8(8XE)R1&H4'\JC
ML+Z/4+7[1$LB+O="LJ%6#*Q4@CZ@UFQ>*M,ENH(5:7R[BX>UAN/+_=R3)G<@
M/K\K<D8.#@F@#36QM%N?M*VL N#G]Z(QN_/K0UC:/+)*]K TD@ =S&"6 Y&3
MWQ@5QAN[X2>/HO[0NO\ 0U5K9M_,/^CA_E]/F-=/X<FDG\+:1//(TDLEE"[N
MYR6)0$DGUH O2VEM<21236\4DD1S&SH"4/J">E(]C:22M*]K"TC#!<Q@DC&.
MOTK-B\3Z;)?6=MNE07V?LDSQD1SX&3M;Z<C.,CD9J.X\6:9;*DK_ &AK:2X%
MLERD):-I2VT*#]>,]/>@#9A@AMD*00QQ+G.U%"C/X5@^'_#C:;=ZE<WL5G-+
M=7TEY%(JY:+> -N2.VWJ/7I5I_$VGQKJQ;S@=) :[7RCE 5WY'J-O/%02ZMI
MT^NZ*!>7JS7-O+-;PHK"*9"H)+\8) Q@9R,^] &R;2W-Q]H-O$9O^>FP;OSZ
MTU+&SC"A+6!0I) $8&">I_'O7-6GCRT;2;_5+ZTN[:TM;M[<MY);:%;9EL9_
MBZ^F171-J,2:A;V)27SIXFE7"Y 5< Y/;EE'XT +_9MALV?8K;;G./*7&?RJ
MR %    '  I:* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "O/[_P_J]X/&6GQ6A0ZA-'<VER[+Y3E4CPAYSD
MLA!XQCOZ^@44 <3:1SW^G7DO_"&KI5VMG)"S%(M[NPQLC*GE<\DG';CN(+S2
M]3D^&&BZ6FG3F^M_L2RP97*^4Z%SG.,84XYYKO:* .62"[7XA7>IFQN/L;:5
M' LN!S(LCN5QG/1A7.Z?X<G;PGX?L-2TW4K2\LXIMM[9R 36DFX8 VD[E8$^
MH^7G%>ET4 8.B7.M6]EH]GJMF\UU) QNKJ,H$B9<8# 'J<_P\9![51\>V5]J
M&F:?#864UU)%J-O<.L9481'RQ^8C\JZ7[;:"]%E]IA^UE#((-XW[1C+;>N.1
MS[U/0!BB]GDU*%XM$NHR5(FN)0@VH 2% #$DEL =ADGZ\]#8:KIWB>#Q);Z9
M(_\ :A,6HV:A UN@QL<'/+# W8)SGCH*[NB@#B-,77-#U+5]+.BR7D%[?2W=
MI>JZ>2@D.XB4$AAM.>@)/:J[Z;>:=XBU>"Y\*QZU::E/]HM[K$1"$JJLDN_D
M*"N<C/!Z'I7?T4 <-87#:?\ $+78Q9238TZS7;:QC:"/,PH&> >W88Y(JKIW
MAK4] 3P=LLFNOL'VL7*0.O[HS98?>(RH)QD>G2NRM]%M+;6;K5HS+]KND5)2
M9"595SM&WH,9/YUHT 8'BLZF+:P.G6LMQ&+M/M:P%1,(L')0L1@YP"00<$XQ
MUKF+/0[C[#KECJ7A^[>SN]7^TKLG4R*AC3#JP?.]63)Y^FZO1J* .?\ "5KJ
MEE874&HW-Q<Q+<M]CENL>>T.U<>9CJ<[N3SC&:YRPTJ\L;R_TB]\)P:BDUY+
M/;:BZ1/%LD<O^]W'=E23P <X&/6O0Z* .'\1Z;JE[J:>(=/L&&H:1*([6!@F
M;R)L>9EL\#D[?0J3_%PZ6^9/B?:3M9W/[S0FW1JH9X_WR]0#^'&?RYKMJSCH
MMH=>&M9E^VB#[.#YAV^7G.W;TZC/K0!Q2^'M2LXM)D6PE9W\12:K/%&5/V>)
MQ( #S@D!ER!GG.*O:O8WEAXQN=1;P[_;FGW]O%&1&L;26\B;AC#D#:P;KGM7
M<44 <%K6@2S"%[33KG3-1MK(?8[G2B B.68^0RY *_=Z@*<GD5'K6C:K<N;V
MV@N[/Q)%;1)'=VC#[/=-M&Z.52<;0Q;D@<$8SC%>@T4 <Q:VEZOQ%N[^2TD%
MK)ID-N)QC:9%=V('.>C#M53PYHT]EXFU&U#HVD6$[362#_EG),H9E]MH+8]I
MJZN\M(K^RGM)PQAG0QN%8J<$8.".1^%5-$M]+L[%K329(WAMY&CDVR^8PD'W
M@[$DENF<G- %'Q7IL.J6UI;W-E=31";?]HLWV36K!3MD4@YZ\<9Z]*Y>;2O$
M5O!HNIWM@=<-C)=02VTHC$TEO(R^7)@_+Y@"*2.ISZYKTBD9E1"[L%51DDG
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MT/R_O2(!'QSQ\WKCBMS1[&9O!5EIUPCVTXL$MY V,HPC"GH<=:VZ0D*I9B
M,DGM0!P7A>PO$M['2]0\)06U[8*(VU/9$T9"C DC(^;>P]AC)R>QQ9QJNF^!
M]+T'4=)FADT_4;.(W>]##,HN%VLF#N)(QP0,<\]J]1M+RVOX!/:7$5Q"25$D
M3AE)!P1D>A!%5M7T:TUNVCM[SS#%'*LRB.0I\ZG*G(]" : .1U6PU6+4/&<,
M&E7%RFL6:_9IHV0("(#&5;)R#G&, YS5B"PU+^V/!<KZ;.B6%E-%=$E"(F:-
M% .&.>5/3-=J!A0,DX[FEH Y'P[H\YT[7M&U;3W6VN;ZZ?S&92DT<KDC;@D]
M#SD#!I_@:SOHM->?4YEGGC)LH95_C@A9E5OJQR2>_%;FL:39:Q8_9[_S/)1Q
M+F.9HB"O^TI!Q4NFRV,NGPG39()+-!Y<9@8,@"G;@$<<$8_"@"U1110 445#
M%=VTUS/;17$3SP;?.C5P6CW#(W#MD<C- $U%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 5R&I^*[[2[Y%GM[9(VU**S6
MW+;I6B<A1-D'"C)X4CG'7-=?7%7/@>_FCO(4UN-89=474XM]IN=7#AMK-O&Y
M1C Q@CCG Q0!/>^)M3L[GQ%:F&T^T:=;I=VBD-_I,;!O?KN7;QWQZU<T_7[C
M5+;3[FR2&XCFL#>2JH*MD@;$&3@$G<.?[AJ>_P##D-_KVF:K),XDLT9'4# G
M!*LH;_==0P]Q5?3O",&FZ-JVFV]U*BW[S;)%X:W1\X5/0*68CW)H JZ9XHOK
MG7;;2[B*S>:YL7N<0L<02J5#1,V6#8W=1Z=.:I6/C35G\-+XAOK"R2RD5HXX
MHIF\UY_.\M%Y& I[GJ,9QV%O3_".I6=_I%Y)K%N[Z=9O9A([+8KH=N#C><'Y
M!GL>P'6EB\#[O A\,76H;]K%XKJ&+8T;>89%."QSAO?D4 5PM\OQ5T[[:;9B
M=(G*O A7_EI'D$$G./7OGH*WM=UE]+FTRVBC4S:A=BV1WSLC^5F)/KPN ,C)
M-4;3P]J__"16.LZCJMK-+;6LELR0VA02!BISRYP<J/;VJIX^N(UBTJUFOX;"
M.2Y,IN;JW\RW&Q3A7Y&"6*D<C[IYXP0"M>^--7LM&\279T^RD?19O)W>:X$O
M"G=MP<<..-W7O6M/J>O6C1B\@TVWAFG8?:?-+I#'M!4,I*EG+?+\IQW]JP[?
M2[WQ)X;U30TU/29+&Y0%;^PLV";BV6&-Y#MP#D'OSUKH=5T*_O\ 4M(U&#48
MH;FP\P,KVY>.0.H!(7<"K#'!R>IZT 8\?C;4)]!T2_AT^W:6_P!2.GRHTK*%
M8.Z[AQG!V9YY&>AJOK7B?6X_#OBZ$BUM]2TB-2LT(9D9'3<" 3D,.1GIGG':
MK<'@>\M].L+(:Q&Z66JG449[7ELL[;#AQSESD_3@=[-[X.DOV\3B;4$$>N0I
M'A("#"53:#G=\WKT% '1V'G_ &&'[2\;R[1EHU(!_,FN8A\5WRZWI5E>6]M&
M;^>:%[=&W26I569-S E26"YQ@$9[XKIK""Y@L(H;NX2>=5P\D<?EJ?HN3C\S
M7)6/@?4+./18SKD;KI-T\T1^QX:17#AMYW\O\Y^;@>H- "WWC.^BTV_U.UM+
M>2"SU/\ LXV\A82.=ZQ[]PSCYF!V[3QWYJT==\03^)KO1[2QTX-:PV\[22SO
M@J[,& PO7Y3CCZURMO>>?JM[>VVN:,E[)>/*NGW^GEKI64[4&U7#$[0,$+G!
MZFNVTS1KV/Q%<:[<SQ*UY:0PR6BQ',93)^_NYY<]O2@#.B\6W]X+&]L-.>ZL
M+FY\IHTMI=Z1;BOF^9C81QDKZ'KQ1)XMOYD%[IFG/>6@O&MV@2VE,C(KE&D6
M3&S@@G;Z#J#Q4FD>%-2T:X:TMM=/]A><9H[0VX\V,%MQC$F?N9SVS@XSWHLO
M"FI:9J%S'8ZZ8M%N9VN&LS;@R1ECEU23/RJ23VR,\8/- %6]\5ZY''XF>WL;
M#&AMN;S)7/FH(A(0, 8;!Z]![]:N0>);\:[I5O>6UM'8ZK;23P&-V,D6Q5;#
MY&#D-VZ$=^M$WA.ZEB\3I_:,(&NC:?\ 1C^Y'E"/^_\ -P/;FI?^$8N6U#0+
MF2^A9=)@DA9/LY_?!U"DYW_+PH]: *MGXKU*^;2;NUTU[C3]0< JMO*KVZ,,
MI(SD;6'3('3/!.*I-XTUF/2[K5)+"Q6TLM4-C<()6+LHF$6Y. ."0>>OH.^C
MH7A;5-#,=BFO&718'W6]L;<"55SE4,F>5!]LD<9QQ4$O@F[E\.ZEI)U6$?;=
M1-^9?LI^0F42E<;^>0!G/2@!8M6U>/QAXF5F2XM=/LX)(K6.,[VRLK *<_>)
M !./3BM#PSX@/B!/M$-U8W5J8E):W!5XI.\;J22"/4XSSP*23P[>C7-3U*UU
M18#J%HD$BB#+)(BN%=6W< ;\XQV'-0'PW<VU]?ZU'=V]MJDUD;;SK:T.UFSG
MS&3)WMG&!Z9ZT =37"/XMO;+PWK&I0Z79+-::NUF\:.0'_>(F_.!N8EL\XKK
M])^VG2+3^T2IO?*7SBJ[06QSP#Q]!7,S>";N;0]5TTZK"/[0U+[>9/LI^0^8
MK[<;^>4'/UH DE\6W6D:CK%OK=O;K'9:>-1C:U9FRFYE*'=C+97KP#GM6K9W
M.N-J,$=Y96S64]N9&EA;!@DX_=D$Y<$$_, .G2J6H>$CJVLWUW?7:-;7NF?V
M=) D)5@NYFW!MQYRQ[>E2Z%HNM:=%'%J.N+?);1^7;@6WED\8#2'<=Y XXP.
M_)P0 <UX5U>?1O!?A=(8HGBO=2DLW# @J&EE.X'VV],=ZV;KQB^G3>(DNK>-
MQI<EO' (R5,S3*-JG.<<L!GZGVJ*/P3=0>%]-TN+5(OM6FWOVVWN&MCL+;V;
M:R;\D?.PX([4ESX$EU%=>%_JN\ZMY#[HH-A@EB VLOS'C(Z'MW/6@"-UU!/B
MCIIN_LKN=)N"C0JR G?'E3DG@<<^_05';^+KZ/PQI=];Z79(]WJQL9(4D*JF
M9V3(XY)QDDXY.<'I6I;>'M8.OV&L7^K6LT]K:R6Q6*S*"0,5.X_.<'*CV]A5
M2+P3=Q:'8::-5A)M-3_M$2?93\Q\TR;,;^.6(SGI0 __ (2V\T]/$RZI9PO+
MHL*7(^RLV)4=&8#YNA!4@G\<58M]?U,^)=/TJ6"SECO+(WGG1,R^6 5!7'S;
MOO#!R,\U3UW3KC1XO$^N&])&H6L< 6&U+-!M!0/U.0-Y)XZ"J/A662#4K:/3
M=6T#5;9E$4PL+0I)%& 2,L'8* ?X3CKQ0!TOB7Q GA^*RDF>.""XG\F2[F0M
M'!\I(+ $=2 O4 9ZUC:EJVMMJ'A9(;FR1;V[F60Q NDJK'(4((;[I !QZXYX
MKI=3L[J[,/V>>%8U+":&>+S$F0C&TC(QZYY^G-<_%X'-E9:1'I]^EO+IU[+=
M)F#='B3>&14W#: 'XY.,=Z )I_$M_/9:U?Z7!;RP:3-)"\4F0]PT8!DVL#A,
M9(&0<D=J?;^)YM==H]!2$LEA#>EKD$@^:&,<> 1@D*<G/''![(/"ES;/K,-A
MJ*16.K.TLT<D.YXI'7:[(<@?-UP0<'GGI44O@^YL=4MK[PYJ::<4M([*:&:W
M\Z.2-/N'&X$,,GG- &7JVL+I_C#PUJ6K0"RN)--N%>#>KD2LT($88'!.XX!S
MCZ5V^G&_:S1M1$"W##+) #M7VR3S]>*P-2\&KJVH6<M[=I<6L-I+:RPS0[FF
M\PJ68L& !RH(P..W:M7P_IU_I6DQ66H:D-0>$;$G,6QRHZ;OF.3[\9H S)O$
M5_=1ZU<:3!;R1:3*T+1S9W7$B*&=5(/R8S@$@Y.>@JG'XOU+5M2L;71+.T,=
M]I?V^&6ZE8;?F488 =MV.,\]Q5W_ (1BYM;S5VTW4(X+75F,D\4D)<Q2E=K.
MAW#J ."#R,^U8HM8]+^(^DZ7I<]O"+70GA6.;YLJ)$P."#GC/O@_6@"*;Q9K
M&IV&C&)8+&[_ +<_LR_BP7'F(&;Y6R/E.T'WSC/KM2^)!INOZXM_:6Z1:=IL
M=VUQ%S)(N7X.?]TX'/7K1/X,8Z=:QVU^L=]#JG]J/</!N668[MP*!AA<-@#/
M  Y-33>%/MFL:I=7MVDUKJ-@MC+ (=K;1N^;=NZG>>WI0!%)XDO["31)M0M[
M?[)J\B0+Y6[=;RNNY%8GAP<$9 7![5FR>--:BTN^U1]/L1:Z?J9LIT$K%W42
MK'E. ,C=GGKZ#OK6OA>Z\C2+74M0CN[?29%E@VPE'D9%*H7.XC@'L!D@'CI5
M.;P3=S>'=6TDZK"/[0U WIE%J?D)D$A7&_GE0,YH ZC4KU=-TN[OW1I$MH7F
M9$ZL%4G ]^*YNW\3:I)J.@6_V6RECUFU:Y5E=E\D*JL03AMW#C!^7D>];>NW
M<FG^&[^Z_>-+';L08(]S;L=0O/0\]ZXGPN\MK<V<>E:UX?U50JPR):6969(\
M\DL'.T#[Q! R1CJ10!K:9XD\2:EI]WJ$6DV,D5M)=0^0EPPDDDC8JNTD;<''
M)./I4MOXKNVO]4L0ME=R6NGK>Q30EDC?)8%"?FS@KU'7VI4\&S_\(CJVA2:H
M,W\LTJSQ0%#&9'+D$%CN&3CJ,CBE'A74WU2XU";5[<RW&F_89$2SVH,%B&4;
M\@?,>,]>X'% $&F>*]6N9O#,EW9V:6NN0;D\IV+QR>5YF3GC:<$8ZCCFK7@N
M^U34(M6EU&XAE\O4KB!=B%<;&VC&2<# Z?J:;;^$KJ"+PQ'_ &E"1H2[0?LQ
M_?#RS'_?^7@^_-:&@Z'/HD^I9O5FMKN[ENXX_)VM&TC;F!;)W<].![Y[ %#Q
M/XDO]#34)T@MD@M+47$0F;<UV1N+J@4Y7: ,L01\WH*LR:_/<ZW:Z38I%'-/
MIYO_ #)P67&X*$ !&3DY)SQQP<\4]7\(7>I7NN21:LL-OJ]F+66-[?>\>U64
M;&W#"G<21@]\$9S6#KV+;6;"PO-?TZREL; (LNI6?[F<N<'RSO7! 0 C<>"/
M>@#1@\;:O=:)H&H1Z7:(VK7GV4(UPQV</@_='=#Z\8ZYJY)XBUA3<6'D6QU6
MSMUEG$,,TT3NV[:BE0"N0N23TST/-0VVDZGKMCI,DMW80KI=\)X'M[-ECN$5
M-HVJ7^4?.P[@[01P:O:GX;U%O$)UK1-76PGFA6"[BEM_.CF52=K8W AADC.:
M (5\57EV8;6&R>SU V27<\5Q;2S>46+*J$(,]4;DXX X.>(H_%6M3W/A^V.C
MQV<^J0SM)'=.P:%XP,@C'3G(]1Z=:GO_  KJ']J6NK:1K1M=0CM_LUP]Q )D
MN4W%LLH*X8,21CUQTJS)X<NI-9T746U(2-IRS!Q)#EIFE W'(8!0,<#!QTH
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MRK(T>J6;B+9YFV=3MWC*YYXR.GK4PU33S9?;1?6QM22HF$HV$YQC.<9SQ]:
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MJJS2#RSC&?O<\$CG/6L?0_$-WJOAJWO+C5M/M;B34G@$K(-DR+,5"("W5@
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M6>>"8:C)<17"PQDPQ,BLR^7)QNQMPW7G/3I5*3Q/XBBT34-8>ZLC'IVKM9O
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M2WN4(B^=9!(JY))P1R>,"N8TK4]>L_AE;ZY%??:6BFDGNE>$,[0^<WFE3_>
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M/S8X& 5/![ 'H=%<G+J.M6VK1:)+<K<W4\<UWYUK;HACB5D54"N^"<L<G)X
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MFD6"1HD$D@4E$+;0QQP,]JJPW^R+3X]05+:]NQM%NK[\.$+,H..0 #S_ (T
M9=OX5,.K3:H^KWLUW-:"UE9Q& P!8AL!0 1N/ X]<U#'X+@BT?1=,34+H1:1
M.D\#83<Q4$*&^7D88],5JZ_JC:)H=YJ@MQ.MI$TSQ[]I*J,G!P>:RI_%ES8:
M-#K-_HTJZ<\:RR26TPE:%& .YEP#@9YVYQ0!N:G8C4]+NK!I7B2YB:)G0#<
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M2;N]CA$S6\32^67V[MHSC.#CIZ4W1[\ZKH>GZB8_*-W;1S^7G.W<H;&>^,T
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M&D;E5@G8-E5P> 0H8KTYZ<UIZA#8:%JOAZ"1GCTW59G:]>:9F2681#RP^XX
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MB4+'I%@H$)@ %N@_=DY*=/NY).* .$T:W2SG^'EY"\HN+VU,=R[2LWFK]EW
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MT?3'^S;M.M&^RC%OF%3Y(_V./E_"@#S#5K6WC\'^+[$H&M;'6X?LR.2PA#-
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M0H,)'&H55'H .E24 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MJ.6\U2T:R06,UW 8[EF^8M$<@%\#!!(ZMCF@#L+OQ?HEAL%Y>-!(\+3"-X)
M^Q>IV[<_ITYZ5*GB?2)+6]N4NB8K%5>Y/DOF-2NX$C&<;><^E8DDDM[XY\/7
MZZ??);I97".\ELP\MG,>T-Q\N=K=>G?%9NKQ7MO?^.K==,OIVU6S5K1X8"R/
MBW\LC=T!!'0\GC - '9W&N:?;6\4[S.Z2Q><@AA>1C'@'=M4$@<CG%(==TTV
MEK<1W0ECO%W6_D*9&E&,DJJ@D@#KQQWKB56]TG4M-O[S1]6N;&XTFWM'6S#F
M6VFC+'#(I!VG?U]15B*UF\/>)M(U&+1+F+1VT^6S%O:Q&5K-VE\P%E7)^8
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M40S20,%)5&#8;&#@D=^>V:Y:--2C\"Z7H,VC:B=2TW4+?SMENS(ZI,&,BO\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M/Y^E-'C(VU]+'J-EY=HEF]T;J!GD1-@RR/E%P<<CUH ZJBL*VUC5IKFT5M&
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MYJE]HT]JT"KI]X+IQ*Q!?Y&7:, X^\3GVK2L;]+W3X+PQ3VRS=([I/+D4YP
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M.H :A<QJ9%57Q\P4Y /L<"N-U3PGJUS)XGAL[NS2TUR+DRJQDC?RA&1QQM.
M<]1SP:[2JL-Z)K^ZM!;W"&W"$RO&1')N!/R-_%C'/I0!A6F@ZE;>([/5'DM)
M5@TO["5!9"S;@V[H<#Y<8_'VK.@\(:I#X<T;3/.LVDT_4Q?,^Y@' D:3:/EX
M/SXS[>_'2W.NV5KJNF:>QD:74M_V=T3*':A<Y;IT%:= ',G0M6MM=UV_L;RU
M1=2BC*"2-BT<J1[!GL5Z'U[>]5(O#MWHLNKZMIBZ?IMS=6Z(+=-[VYE#$F5@
M IW$'& .W?-=;+.D2L6)+*I?8HRQ ] .3531M6MM=TBWU.SW_9[A2R>8NUL
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MJ* .'A\'ZI%X8TS2O.LS)9:F+\R;FPX$S2[<;>#\V,^V?:K4/A_Q!IFL7_\
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M-'EEDECN+?)V,TIE4X('W6(^N.U:]GXBCN]8;2SINIP3IDNTMO\ NU  (_>
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MK;JAHNL6NO:3#J5F)!!*7"^8NUOE8J<CMRIJ_0 4444 %%%% !1110 4444
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M9EBN(+<VL0C8!$B.#M"XQU _(5)H^CVNAV1L[,R^29'DQ(^XAF)9N?<DG\:
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M1N;"W0+;W!^6"79M8@8YZL 23@'C%:/_  BFE-;ZI;S1R3P:I)YEU'*^0[X
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M3[4L4MX+YE^T,?WH.X$9)QSS[GKFI[K3TTFYOM?M;:[OM0DA2-X$D4&55/
M. ,;B?SH R?#FM7>O0Z1#]IFBN[17.JI\N1(A\ORVXXW/EAC'"'UK7\174L+
M:;#%>- 9[G:T,2YFN%",=B?W>0"6., 'D4OA_3?LQOM1FLUM+O4I_/FB!!*
M*%521P3@9..,L>O6I]7T*SUI[22Y,R36DAE@E@E:-T)&#R.Q!P: .(?7M</A
M:25-0EAN;?Q + .Z1LS1>>J!7P,$@'&01G'6MAY-4BU]/#BZG/<M]D>\,\LB
M12L&DVA05C(POL!U';BKY\$:/]FFME^UK%-=B]=1<L?WH.X,,DXY&?<]<U9U
MKPOI^O/:S737,5W:Y\FZMIFBE3/4;EQP?2@";P\NJQZ+#%K=Q;W&H1EDEEMS
ME6P>">!@XQGCK7GTEQJ&F:'XLUBQU&:![/7976%$0I+\T88/D$D$''!&*]-L
MK*#3[..UMU811CC<Q9B2<DDGDDDDDGDDUCR>#M,FTW4-/D>Z:VU"<W%ROF\O
M(2"3GJ,D#@8Z4 9M]=ZUK6K:]IVE72VLVG".. ^:%P[1AP[#8VY<G&.F%/?F
MJ[/KVH^*XM*?77M ^C1W4ALTC95F\S:Q0LN2IQWYQZ5M:AX.TO4M3CU*1[R&
M\$8BEFMKEX3.@_A?81D5<CT"RAUM-6B\U+A+86JJK801 Y"[>G7GUH YB*]\
M1:Y9SZGI=Y;P/;ZA+'LGGQ$(HI"C(Z^63DJ-V<Y!(Q@<52%GJ4^I>-KC3M9G
MT^6VNUEC$<:,KN+>,_/N!RO'08[]:Z<^"](&M3:F@NHGGD$L]O'<NL$SC^)X
MP<,?T/>IYO"^GS7=[/NN$6_Q]LA28B.? "\CMP #@C(ZYH YV#Q#?Q7'AG7=
M0NGBTG5K18YX"%$<%PR!D;.-VUL,.3UQ74Z UU+I:W5W+*[W+-,BR  Q1L<H
MG '1<9SWS6;KEK)K,H\.OHK'3#Y4DEVY3R@BL&**N=V[Y0.G&<]N>EH XZTN
M]2\0VVJ7EIJWV":RU*2W1&0-$B1. P<=26 )SGC(QC'*1W^H:\WB9K;4);*3
M3+AK:U5 N RQJV]P0=P8DC'3 XYYK3?P;I+ZU-J:BYC>X8/<017#I#.PZ,Z
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
)10 4444 ?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>44
<FILENAME>exhibit1018-arvinasxcons012.jpg
<TEXT>
begin 644 exhibit1018-arvinasxcons012.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M5=S",;5)QT!/ &3FL-M(UFQN+2\CTJ6Z,&O7=X88I8@QBD2158;F _C'&<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA>HSD\9&<5J]1P>O<4 +17)>&-9>+2M6N-6OGE$&KW%LDD@RQ DVHH"CD]
M!R36L/$VE"*^>2>2(V""2YCDA=7C4C(;;C)& >1D<'TH UZ*Q;#Q7H^I7MM:
M6UQ(9;F'SX"\#HLJ@ G:Q #$ C(!R*)_%FCVV&EN7\MIS;+*L+LC2C(* @')
MR"/J".HH VJ*R=0\2Z7I@D>ZFD6.(J)I5A=DAW8QO8#"]0>>@()P#4-SXOT6
MUU"2PDN9#<QF,.B6\CX$APIX7[N>_0<>HH W**ANKJ"RM9+FYE6*&)=SNQP
M*H0>(]+FGNX3<&"6TB$\R7$;1%(SGY_F ^7@\]L<T :M%9=OXATZXNUM!)+'
M.\1FC26!XS*@ZE=P&['&0.1GI5.W\;:#=-:>3=R,EW,;>*3[/($\P,5V%BN%
M8D' ."?Q% '045SL'BJVN]3UJP:.Z@33@JO-]G?J5W$C@CH1C/7KR*;9^)='
ML=*T9)=4N+D7T7^BSS1,SW&%+9.%^\0.F 3Z9H Z2BLBW\3Z1<Z5<:DMRR6U
MM(89O-B='CD! V%" V[)&!C)R/6G0>(],GOY['SGCNK=/,FCEA=/+7&0Q)&
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MS7<EJZL9@P0AE"_*=Q Z8S0!T5%<^GBJV/B/4M):WNE%C!'*\HMY&#%MY.,
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M>TLYK9$GNDB:1\EHB8$!8 <-]#CD=30!V%CJ(U70[?4K!0PN;=9H5E.W[RY
M)&<=?>N8C\=3-IFA7LME!$NHWIL;A&G.ZUD#,N#\O/S+CMR1ZUU>FV$&E:9:
MZ?; B"UA6&,$\[5&!G\JYJ[\"072^(4-PP35,O F.+:0A2SCW+HC?\!H =XD
MUV2W\/:M=S:3:7UC;7"0K'-)D2C<H+$%2/E<XQZJ>1Q4C:CJ<WQ$ETAUMVTY
M=-6?86.3OD*DD8P3\N,=,'KS4NM>&IM0\&'0;>Y19'$8>XE4G<RN'9B!U+$'
M\ZEET6^_X2U-=@N;=0UB+2:!T)SM<N"K9XY8@Y!XH Y/P?K=YHOA3P\AL(3I
MMS?R67F"8B16>:3:0FW&W(QUS[5U7CC4;[2/!>JW^GM&MS# S*[Y^7W&._I6
M5!X-U"#PWH^E?:[5FT[45O3+M8"0"1I-N.WWB,Y/2NB\1Z0=?\-ZAI/G>2;N
M!HQ)C.TGH<=Z .8U/[:GCSPY-':6S:A)878/[TA#@Q8+-MS@?0\G\:O6?C-K
MC2K5Y;01ZC/>S6)A0LZ*\1;>V0NXKA,],\@<=:L?V'JDFOZ1JMS<VCO8V\L,
MB1HRAS)MY&2<8V#KG//2LS_A"=133@;?4H;?4[?4YM1M9UC+(#(6W1NIZJ0Q
M&10!O>']8N]5^VQWFGRVLMK-Y8<HZQSJ1D.FX ^Q'8BL+2Y!X@^(^OB^42V^
MBK!#:0.,JK.I9Y,=-W& >P^M=/I,&I10,^K74$]TY&1;QE(D Z!023]23S^%
M9EWX=NK?Q++K^BW$,5Q<Q+%>6]PI,=P%^ZV1RK <9Y&.U $FJ1:5X:^W>)WB
M$/DVK"=8E \T @KQ_>SQGW]JCD\0WMAJVF66I6<,:ZF&6"2*4L(Y0N[RWR.X
MSAAW'2I]2T.7Q!HU[8:O,BQW4)B\NWSMCSSNR?O," >@''3K5>'0=0NI])EU
M>XMYFTK+Q&($>?+L*!VS]W )X&>3G/&* ,H>.-3&BQZP^CP"T6_-E.BW1,@/
MG>4"GR@'G'4COTZU>?Q3J-I>:S9WFFVPN;&Q&H1+%<L5DC)8%2Q0$,"A[$<U
M5/@W4#X5DT;[7:[WU'[;YNUL#]_YVW'UXSFI/$&D74=QKNNRS0"&31'M#$,Y
M7:'?=GZL1B@!MKXQU(7.@R:CI$4&G:TJ)!-'<;WCE9-P#KM  /.,$].?2IT\
M6W,>KZ99W=E%!_:%Q+ (#-F>':&*.XZ88)GVR.M0>'](N-6T#PI-?20?9;""
M&YB6+),L@BVH6S]T*&)P,Y..G2H+3P7K%O%I,;ZM:/\ V;?O=+(;9B\X8."7
M.[E_G_2@!;CQOJD&FZMJ)TBV^RZ5?FUN?]*)9E!0%D^3D_-GG'IS6X->GB\7
M2:+=VT4,+6IN;:X\TGS0#AQC  *Y!/)X(-8]SX.U"Y\/>(=+^UVRMJ]ZUT)-
MK$1!BORX_B^X.>.M+XECT[Q)J-AHZ7BC6+2X5ITMVRT4+(?-#>BLAV_5EH Z
M;1[V?4=*@O)X%A:==ZHK%OD/W2<@<D8..V<5>JG<17YOK(VLT$=FA;[3&\9+
M.-ORA3GY<'K5R@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MA>1SV _G0!:HK%B\1(T]C%<:=?VOVYMMNTJ(58[2V"58[3@$X;%;5 !1110
M45DWGB&ULO$6GZ))#=-<7R.\<B19C4*,G<W;_/K6M0 4444 %%%(S!5+,0 !
MDD]J %HKG+'QC:ZN\S:/I]_J-K"Y1[N!$$18=0I=U+X_V0:U=)U6VUJP%[:"
M41&1X\2QE&#(Q5@5/(Y!ZT 7J*** "BBB@ HK%@\3V,_BR?PV(YUOX8/M#%E
M&PID#((/^T.U:EM=V]X)#;RK*(I&B<J<@.O4?A0!-1110 45";NW%ZMEYJ_:
M6C,HCSSL! )^F2*FH ***AN[A+.SGN9%=DAC:1@B[F( SP.Y]J )J*Y3_A8&
MDC3]$O9+>^CBUF806V^( JY;: PSQZY&1BM'3?%%CJ?B#4M$ACG2\T[:9A(H
M"X;H003GB@#:HHHH **** "BH;N[M[&W-Q=2K%$"%+,>Y( 'U)('XUGR^(;6
M'Q1!X?:&Z-U/;FX6419B"@D8+>O'\O44 :U%%% !1110 445#:7=O?6RW%K*
MLL+$A74Y!P2#C\0: )J*** "BBB@ HHHH **AGN[>VEMXII522X?RXE)Y=L%
ML#\%)_"LNP\3V.H>)-1T&))TO;!5>;>HVD-@@@@G/!% &U1110 4444 %%(3
M@$^GI65X=\06OB;21J-I#<PQ&1H]MS'L;*G!X]* -:BH;N[M[&W,]U*L40*K
MN8]R0 /J20*SY?$-K%XI@\/M#=&ZFMS<K*(LQ!02,%O7C^7K0!K4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M#RN#<RN\BK^\Y"H#PS<C(&>?QKU>/PWI46O/K:VS?VD\?E-.9G)*<?*03C'
M[52'@/PR-*N-+&E1_8;A_,DA\Q\;LY^7GY>>RXH Y#PYJNHR>-O%>E2S7L=G
M'81W$5O/<,[P,44G#%B5)W9P&.#]*Y;2=<UM= \%:N^MZE+<W>L&VG62X9D>
M+?C:5Z'OR<GGV&/7+3P9X>L;N6ZM--2">6#[.[QNZDIC&.#UQ_%U]ZA7P%X:
M2SL[1-.*V]G,9[=!<2XCD)!W#YNN10!R>CV:S?'CQ#OFNL0V<,B 7#@<B,X.
M#RN2?E/'M7J%9;>'-)?7?[;-FO\ :.P1F8,PW*.FX9PV,#!(XP/2M2@#R34Y
M->M/'&N>&(-1U!FU6U6YTF4W,G^CD'+ '/ X?_OE1WJSX5UB^U[X?W>HSW%]
M'=:=ITUM(YN)%+7"[F+'GE@ AS_M$=J])?3[634HM0:%3=Q1-"DO<(Q!(_-1
M_DFH%T33DTVZT]+8):W32/,B,5WF0DOR#GDD_P J /&[F^NM2\'?#6[O;B6X
MN9-84O+*Q9FQ,0,D^P%=9X4_Y+-XU_ZYV_\ Z *Z;_A!O#GV*QL_[/;[/82&
M6U07$N(G)SD?-USS5ZS\.:5I^L76K6ULR7UV,3RF9V\STR"<<=N.* -"XD,-
MM+*J%V1"P4=6P.E>;> I=3\5:7I7B4Z_<1W$=U.-0MMQ:*4$_)&$)VI@;<8&
M?FKTVL&P\%^'M,U:74[+3DAN97WMM=MF[^\$SM!]P* /*O\ A+=<'@5O%WVR
MZ_M/^W/*%OYK>5Y6/]3Y>=N/?&?>M?7+O49_B!XLL%U?4H+2VT-KN*&&Y9 L
M@5"".>.3GC'Y9%>@_P#"(Z%]L^T_8!N^T_:_+\QO*\_&/,\O.W=[XHG\):)<
MZE>:C+9L;N]@-O<2">0&2,@ K@-C' Z4 >3:Y>76L_#GP%>7UU<23S:E'%*_
MFL"X#, 3@\M\H^;KUYYKL)KF[LOC/I>CPW]Z=/DTEI'@DN7=68%QN.2>< <^
MU=,_@SP_)H<&BOIX.GV\GFPQ>:^8WR3E6W;AU/0]ZF_X1;1O[8@U86C"^@B\
MF*832 JG/R@;L8Y/XG/6@#Q637-<A\"WFM#7=3-W9^(3;1!KIBOEA0=I'\0]
MCG]3GO-5U"^C^,<>FK?726,NBO,T"S,$WY<;@,\'"CD5T!^'_AAM-DTXZ83:
M23_:7B-Q+AI<8W'YNN*N:CX3T35K^VOKZR\VYMXS$DAE<$H>JM@_,.3PV>I]
M: /*;'QAK,/PLT*XFU"X>6_U?[-<W<DQ#K%N)(#]5R!C/89KT[PQ:ZS97.J1
M:G,CVK3"6R0W#321(P.59F&<9''7OZ4]?!/AQ?#[Z"-,0Z8[[S TCL WJ"3E
M3]"*T-)T:QT2S%K80F.+OND9V/;EF))_/B@"EXT4MX(UTAY$9;"9U:-RI!"$
MCD<]J\OMK^\T7X7>$8M/N+J$ZO>16]Q,)W/EH6;(3)^3/^SCH:]HG@BN;>2"
M>-9(I5*.C#(92,$'VQ6/%X.T"'13HZ:>HL=P<1F1R58'(*L3N7!R1@C&3CK0
M!@>%=5O5^(OBCP\TTT^GV8AEMS-(9&B+(I9=S$D@DG )XQ7<NH>-D)(# @[2
M0?P(Z52TW1K#26N'LX"LMR_F3RN[.\C8P"S,23CMZ5?H \"M_$FN-\-]%OVU
MB_-V_B#[,\IN&W-&5SM//(X'6NH\3ZUJFA>.I9-4:].@W4L$=M=V=PP6T< $
MJZ [3N).0PR0>.F*ZP_#KPHRLITD;3/]I"B>0!)/50&^7Z# X'H*T;CPQI%W
M=O<W%N\CR2I-(C3R>6[H %9DW;20%7J.PH X$ZEXC\2>(/%MIIEV;>^TRYBC
ML@]TT4<2*QW%D (<. <YSU%>IQ,S0HS[=Q4$[3D9]C6+=^#= OM;_MB?3U-\
M5"O(LCJ) .SJ" PX'4'I6[0!YAXQM%NOC%X1A>:Y6.6&?(CN'3:0C<J5(VGU
M(QGO6!K$4H\=?$6X@O;NUDM=+CFC:WF,;%EB0C+#G''3//>O6M4\.Z3K-W:7
M5_9K-/:$F"3<RLN>HRI&0>X/%5IO!V@SW>H74EDQGU&/RKM_/D'FIQ\IPW3@
M#CMQ0!P3^*]5GL/A[:2W$A&K(6NY!*8FG90 J[QR,DC..O%=YX3MM8L]*EMM
M:N(YYXKAQ$ZRF1A$<% [$ E@#CZ8I+KP5X>O=$MM'N-.#V-J=T"&5]T1_P!E
ML[A^=:UA86VF6B6MI'Y<2]BQ8D^I)))/N30!R_Q/UV^\/>"+F\T]S%.\B0^:
MHYC#'EA[XX_&H[+1]:N6U>WDU.2WTR]MT>P>._>6>!PH!<.>2I.#C)'YUU>H
MZ=9ZMI\UA?VZ7%K,NV2-QPP_SWK-LO".B:?I,NF6MK)':S+L=?M$A8K_ '=V
M[<%Y/ ..3ZT <=\,M4N=:M;^UU>_NI-4TU3;NOVF3$B,6(FZ\DYP#V"@CK6!
MHVJ^*]1^%=EJ%E<W.H7D.I.]Q"UPPFN(5ZHK [O0X'/UZ'U*/PIHT.L3:M%:
MNE_-%Y4DZW$@9DP!@_-Z ?D#4=IX,T*PL8K.SM)+>"&8SQ"*YE4I(5*D@[LC
M@D>G- 'EGB34[;Q!X1\)7EM<Z@8Y-;$;QW$[EXR7)*$Y^8KP%;KC'3FNMEN;
MNR^,^FZ-%?WIT^32#(\$ER[AGRXW')/.%'-=1/X/T&YT>'2IM/1K.&7SXUWL
M&63)._>#NW9)YSGFI/\ A%M&&L0ZL+1A?01>3',)I 53GY0-V,<G\3F@#Q5M
M<UR+P+<ZV-=U,W=IXA-M$&NF*^7M!VL/XA['/ZG/;^);C6_^$PUJ"6;4%LUT
M=GTI+%I.9^!DB/DMNR!NXQ^-=*?A_P"&#ILFG'3";.2?[2\7VB7!EQC=][KB
MN?U_P5>:EXMN]0$VM6T#V\,44FDWJ(S[0<^;YC Y!/&/J>:!G5>#K?4K;PII
MZ:P\S:B8@UQYLA=@Q[$DG\N@K<K$\)Z=J>E^'XK35KV6\N%=RLDS[W"%CL#-
M_$P&,GUK;H$%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 5B^*_$UGX2\/SZM>!G5,+'$IP9'/11_GH#
M6U7!_%OPU?>)O!9ATY&EN;6=;E85ZR !E('OAL_A0!JZ;/XMO-&CU*4Z7'<3
M1B6.P\E_E!&0K2[_ +WJ=N!Z5HQZY;6FE6$^L7-O8W-Q KM'*X3#;07 !YXY
MSZ5FZ)XSTB\T6U=[D1WHB59+$J?M"N!@KY?WCS[5SFJF6P^+"ZMJN8=,FT5X
MH'F(V))G+1D]-V,\=\\9H [VXUG2[.*WEN=2M(8[D@0/),JB7/3:2>?PJK_P
MEGAW[//<?VYIWDP.$E?[2F$8] >>IP?R->+W>FW]K\)/"EIJ4,@D.L+,()%)
M9(/GZCL.<_\  A6Q?10'QK\1Y/+39)HY2!MO#-Y*@A3W.>,#O0,]8FUW2+9;
M9I]4LHEN@#;EYU42@]-N3\W4=/6G6&LZ9JD$D]AJ%M=0Q$K(\,JL$(]2.E>*
M7K(G@WX9"Y4E8]059492Q #C(*]>G:M>,Q7'B3XAZQ#:37V@RV2QLML2HN9
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M/'RP^*O#NGZ/=:;?6>I7#0SLA+O%M*\@JV.=QZCM7<3316\+S32+'$@+,[G
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MFVP'[0O[PYQ@<\\\5PNL65G:?&?PI##;0Q65K8R(%5 (XCMDVCT!SC%<!);
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MRE7>DG/RLI/L>F>GO4EM\0;!U\0"\LKNSET-0]S%)M9F4@D;=I()..F>XYH
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MC]DC$VM7WVBV_?+A5,F[YO0X],UZ=IVIV.KV@N].NX;JW)*B2%PRY'49%6Z
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M(+N>SC4(/W:),R#C:T@&>G&0 ?>H=4\&6]]J]YJEM=R6=S?636-T44,)(SW
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M:P +*)X6.&:3',?/3.W/09ZUJZAXHU/4/%(\.Z,\5K<C26OQ)(H;?*<!(^>
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M+:_+XE@TZ_M[D-:M8K)<IL&?.8XP#VP5?(_W?QI66E6?PXTVY:%=3U&UU#4
MSQK&)3!OX+' R5&!GKVXYK5\&>'K;PUH M+6%HEFFDN"C?>7>V54^X7:OX4
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M5.+B+:%9GD!SEB1SDDGC'6@#G;CQ;XIAO/&6GB_LR^AP"ZCN/LG+C9NV;=V
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M[P]K=^-0L5L97:0,?+NIE\P M_>("KU[\]Z .Z\*^*X?%*:B8K62W:PNFM9
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MRQYZD[LGOC':@#VZBJ&G:WINK3WD-A>17$EG+Y5PJ'F-_0_D?R-7Z "BBB@
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MVEQ!!CR8Y(E(CXQA?3@=J6XT'1[H6HN-+LY1: "WWPJ?)QC&SCY>@Z>E:-%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
L* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@#_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>45
<FILENAME>exhibit108-arvinasxformo001.jpg
<TEXT>
begin 644 exhibit108-arvinasxformo001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 !Z5P
M7_"#>*/^BC:M_P" L/\ A7>T4 <%_P (-XH_Z*-JW_@+#_A1_P (-XH_Z*-J
MW_@+#_A7>T4 <%_P@WBC_HHVK?\ @+#_ (4?\(-XH_Z*-JW_ ("P_P"%=[10
M!P7_  @WBC_HHVK?^ L/^%'_  @WBC_HHVK?^ L/^%=[10!P7_"#>*/^BC:M
M_P" L/\ A1_P@WBC_HHVK?\ @+#_ (5WM% '!?\ "#>*/^BC:M_X"P_X4?\
M"#>*/^BC:M_X"P_X5WM% '!?\(-XH_Z*-JW_ ("P_P"%'_"#>*/^BC:M_P"
ML/\ A7>T4 9/A[2K_2-.:WU#6;C5IC(7%Q/&J,%( VX7C P3^-:U%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M5'6=172=(N;XH9&B3]W&.LCDX1![LQ 'UJ]7*ZYG6O$MAHI%_!;6X-Y+<10.
MJ-*N!&@DV[>,LYYZJM %3X=:SJ5U;:IHFO3"76](NVBG<?\ +2-R7C<>Q!('
MLM7KKQ[HEKJEWII%]+=VDD4<T<5E*Q7S/NG[OW>GS=.1R<US>IV-QX3^)NDZ
MQ9IJNH6^HP/::FRP//Y:@@Q2$JN.#D>N,UJ>'?,'Q.\6SO:W<<%S%9B":2VD
M6.0HC!\,1@X)% &YIWBK3=4M=3N+;[1LTV5X;H20E"CJ,L,'K@8]N:IS:OI%
MWXH\/B2;4H;^>":6T@V21QR(4!8R#&TD#& >03TK'U+0M0A^(,J6<!;1_$-N
MO]I,.D3PD9S_ -=(SL_7M5KQ$LK?$[PA,EK=206\=X)IH[=VCC+HH3<P&!D@
M]Z )YOB1X>AMKVXS?/%87#6]VR6,I\@@#+/\N54;NIZX.,XK6OO$UA97:6BB
M:ZNGMC=B&V3>PA!QO],9.!W/8&O/Q#=-X,^)-N-/U#SKZ^NWM8S9R[IE>)%4
MJ-O()!J^M[>'5]*LKC3-3CL7T6,1S6EHZR2SYP89)  T0& <$J,G).* .PC\
M4:9<V&G7=E(]VNI*7M$A7YI% R3@XQ@=<X].O%7M-U&#5;%;NW$JQL[IME0H
MP9&*,"#R.5->4Z'I<-W\/O"FG:K::YI5[:1S"+4(()(Y+252.N <*P8CYA@[
M<>]=/HWB;4-"\.:=_P )-:WMS/<7TEJMW;V94&/>0D\J\>6&&">,\]* .VGA
M6XA>)V=588)C<HP^A!!%>;^ _%46E?":V\2>(K^^N"\DHFGD\R<\3,B\#(4<
M 9X'K7I$\R6\+RN'*J,G8A<_@ "3^%>+6=E?K^SG-H[:5J0U,,R_9#92^82;
MDN,#;R-O.: /4;#Q9I>H:Z^CQ&YCNQ"9X_.MWC6:,$ M&S !@"1T]<C(J-_&
M>CQSVBO)*+>[N?L=O=^6?)DFR1L#>Y! /0D=:PM826^^)6AS007JP?V9=0M<
MBUD"1-)LV9;;@'@]?2J?@?5;RST'3O">H>'+X:MIQ6 O);$VVU#Q,)3\N-O/
M')/ ]: /2:*S[#5DO[[4+5;2\A-E*(VDGAV)+E<YC/\ $.<9K0H **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MI+L7,,-W(B2A(@RY4,!P?S[T =]17/>+XF;3K)DN+J!O[0M(R;>X>(LKSHK
M[2,@@D5R7BJ\UOPIXQ_MC2I+R]TFULDEU/3GN'ES&SL#+&&)PR[0<#&1GWH
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M&FW"OO)9-T9."2/F-2^#?$5Y=RW7A+Q,3'X@L$^:1&*"\AZ+,A&#SWQT/IT
M!W%%<;X?T,ZKX>T6XNM4U5D2!VE5=0G5IG8K@LX<,0 #@9QS6%X(TN?7M*UY
MY]9UE;JUUJZM[:7^TYR(TC8;%*E\,.QR"2.] 'I]%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4CL$1F.<*,G )/Y#K2U%<VZ7=K);R-*J2*5+12-&X'
MLRD$'W!H \ET;P=+KFG>*%DM;K3-7/B"YU/2KZ:U>-DR5,; D<J>05]#TK>U
M35]3U_X6ZQ:WNB:C;:W)92VTEJMI(P>4J5S&P!!4GD'/ ZUT'_"&Z=_S_:[_
M .#N[_\ CE'_  ANG?\ /]KO_@[N_P#XY0!D:;JMM:>#M(@FT35;C4+*U@"6
MXTV=2)E0#&\H%'.1G.,9J[J-[%=7&H:/XCT2:ZTTK&4E2R>>)R4&Y<*&((/(
M)'?KD5:_X0W3O^?[7?\ P=W?_P <H_X0W3O^?[7?_!W=_P#QR@#(^&FAW&A:
M=JL"QW4&D27[R:9;761)%"0.H;E06R0#SW/)J+PC'<Q_$CQI=S6-[#;7SVAM
MII;9T241Q%6P2.Q]>O:MS_A#=._Y_M=_\'=W_P#'*/\ A#=._P"?[7?_  =W
M?_QR@#G/$&G+J?Q8TI[K2;FZTM=-GMIY&M'>(,YX!.,= >?>K/A,:EX1OY_"
MU];7MUI,7SZ5J"0M*%B)_P!3(5!PR] 3P1Z<5M?\(;IW_/\ :[_X.[O_ ..4
M?\(;IW_/]KO_ (.[O_XY0!R6@:'+K ^(&EWUI>VD.L7DI@FFMG0,C(%#@D <
M$9Q6KX/UFZT/P_9:!X@TS48+_3XEMA+;V4MQ#<(@VJZ/&I'*@9!P0>U;'_"&
MZ=_S_:[_ .#N[_\ CE'_  ANG?\ /]KO_@[N_P#XY0!KVMQ-+;-/<6[0#)*Q
MGYG"^X&>3R<#/8=:X[X9PW-J/$Z7=E>6IN==NKR'[1;O&'B?;M8$@=<'CK6U
M_P (;IW_ #_:[_X.[O\ ^.4?\(;IW_/]KO\ X.[O_P".4 <XLDEI\8=2U2?3
M]2-@^E1VRW"6$TBM()"Q VJ>QZ]/>M/4+T77AWQ%;:?I%_%;FUE$>ZSE1[B>
M16R$0C=C.,D@#+>U:'_"&Z=_S_:[_P"#N[_^.4?\(;IW_/\ :[_X.[O_ ..4
M 8?A;6+K1_A[I%A'H>K7&K6UE'";0V<D0\P*!@R. @&>^?SK2^'WA>Y\+>'9
M(K^5)-2OKJ2^O&C^Z)9,9 ]@ !^=6O\ A#=._P"?[7?_  =W?_QRC_A#=._Y
M_M=_\'=W_P#'* *VJWMM=WFIZ/X@T2XNM*.PPRBR>>.3*#<N$!((/.<=^#D5
M2^&FB7.@Z7JEN$NH=*>_>33+:ZSYD4! Z@\J"<D \]SR:UO^$-T[_G^UW_P=
MW?\ \<H_X0W3O^?[7?\ P=W?_P <H P_"$=S'\1/&EU-8WL-O?2VK6TLMLZ)
M*$B*M@D=CZ]>U/?2KKPS\2;_ ,1QVTUSI6LV\<=W]GC,DEO-&,*Q1<L4*\<
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M@>AW43SVTD<=Q+;LPXEB"[E^FX$?F* ,2W\7VMW?645O8W\MG>2R0PW\<0:
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MI_V>W673V!*@;5<D<?+@'/'(]Q7?:GK*Z;=6MLMA>WDUPKLJ6J*VT)MR6+$
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M//?F@#9HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MR!N(!7[M;&HRZM=?%(:)%K=W:Z?-HKW)CA2/<CB95RC%3@X[G.,G&,Y$M_\
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MD+*>5.1D9 SR#Q6[)X"T^.;1I=-N[W3)-*A>WA:V93OB?&Y7WJV<D9SUSDT
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M;>]=I+J>,IYLSLVYF8E2,D^@&!P,"M"3199)-+?^U[]?L#EF5&51<C;C$@
M('7C'- &M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M1P,C)YJ/5?&UCIVK:#91QW%RFK;W2:"WDE3RA$S@J5!W$D+P,X!).!0!U%%
M.0#10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M83"ST_X57\T<WV>SAD@N&2)G,4C6NP*P4$@[N,8KO?\ A&;O_H:]=_[ZM_\
MXU1_PC-W_P!#7KO_ 'U;_P#QJ@#H%.5!P1D=#2TB*515+%B!C<>I]Z6@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "N;U&
MPM]3\7V]O=J\D*V#N$$C*-WF*,\$=JZ2L5_^1WA_[!LG_HQ* (+S0?#6G6S7
M%Z(K:!>LL]VZ*/Q+8IT/AWP[<6J74$:2V[KO69+IV1E]00V"/>MF\19+*='4
M,K1L"I&01CI7DO@^[N/AO#HUK?S/)X5UF")[>XD.?L%RZ!FC8]D8DD'L?Q-
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M<1-,ZEA&I0948P=QS]X<'&: -W_A$]%_Y]&_[_R?_%54U'1O"^DVHNM05;:
MNL>^2XD W,<*/O=R:JZ?XOO-9;2;&WTYM/U2\LGO;B*^C;_145@A!7Y2Q+'
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M975<[C@GY2,#'!)Z\8 -ZVT;PO>7MY9VZK+<V;*MQ&MQ(3$6&Y0?F[CFK?\
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M^3_XJC_A$]%_Y]&_[_R?_%5M44 8O_")Z+_SZ-_W_D_^*H_X1/1?^?1O^_\
M)_\ %5M44 8O_")Z+_SZ-_W_ )/_ (JLKQ/X<TNR\)ZS=6T$D<\-C/)&ZSR9
M5A&Q!'S=B*Z^L7QC_P B1K__ &#;C_T6U !_PB>B_P#/HW_?^3_XJC_A$]%_
MY]&_[_R?_%5M44 8O_")Z+_SZ-_W_D_^*H_X1/1?^?1O^_\ )_\ %5M44 8O
M_")Z+_SZ-_W_ )/_ (JC_A$]%_Y]&_[_ ,G_ ,56U10!B_\ ")Z+_P ^C?\
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M5% &+_PB>B_\^C?]_P"3_P"*H_X1/1?^?1O^_P#)_P#%5M44 8O_  B>B_\
M/HW_ '_D_P#BJ/\ A$]%_P"?1O\ O_)_\56U10!B_P#")Z+_ ,^C?]_Y/_BJ
M/^$3T7_GT;_O_)_\56U10!B_\(GHO_/HW_?^3_XJC_A$]%_Y]&_[_P G_P 5
M6U10!B_\(GHO_/HW_?\ D_\ BJ/^$3T7_GT;_O\ R?\ Q5;5% &+_P (GHO_
M #Z-_P!_Y/\ XJC_ (1/1?\ GT;_ +_R?_%5M44 8O\ PB>B_P#/HW_?^3_X
MJC_A$]%_Y]&_[_R?_%5M44 <_P"'[6*QUC7+6W#+!'-$40NS;<Q*3C)/>N@K
M%TK_ )&/7_\ KK#_ .BEK:H **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%?\ Y'>'_L&R?^C$K:KF
M=2TZ'4O&=LDTMU&$T^0@V]U)"3^\3J489_&@#?O1.UE,MJD;S,A""5RJY]R
M3^E8UKX<2\\$0>'=>M[>:,6B6LRQN65MJ@;@2 0<C(].*E_X1:Q_Y^]8_P#!
MM<__ !RJUQI&AVDR0W.L7\,K_=236[A6;Z R<T 8'_"!:O9^ [#0;+4H;F>R
MU+[43>%O+NXA*SB.4@$\@KG@C*U+_P (GXB-_P"++IYM+(UVRCA5%,B^4ZQM
M'C.#\HW9SC)QT7/'1+X9T]@2M[JY ..-7N?_ (Y2_P#"+6/_ #]ZQ_X-KG_X
MY0!S\WA/6WT?P;9K_9^_09H))B9WQ+Y<1CPOR=\YYZ=.>M.OO!-WJ^M>*GOG
MMDT_6[**U0Q2,TL1C#88@J >6SC/;O6]_P (M8_\_>L?^#:Y_P#CE'_"+6/_
M #]ZQ_X-KG_XY0!G^&[+QG"UO!XBO]+DM[48$MF)/-NL# ,F[ 7U(&<D#H,Y
ML>,?#<WB*PLFL[A+?4=.O([VTDD!*>8F?E<#G:02#BK'_"+6/_/WK'_@VN?_
M (Y4$FAZ/"Y275=21QU5M:N 1_Y$H 9#H=]>^)[;Q!JD5K%/96CV]K;P3-(H
M9R"[LY1>R@ ;?4]\!O@S0]3T&'58]0^R,+S49[Y#;RLVWS&SM(*CISS^E6H_
M#>G2IOCOM6=3W75[DC_T93O^$6L?^?O6/_!M<_\ QR@"GKFAZG?^,O#NKVOV
M3[-I?G^8LLK*[^:@3@!2.,9Y//M5#4O#WB;3_&%UKWABZTUH]1CC2^M-1WA=
MT8VK(C("<[>"/;\MO_A%K'_G[UC_ ,&US_\ '*/^$6L?^?O6/_!M<_\ QR@#
M"U?PMXA75]*\0Z-J-G)K5K ]M=I>*R0W,3MO(&W)3:WW>O&,GCF7Q%X<U_7?
M"BV,ES8OJ$EY#<RDLZ0QB-U8(G#$CY<9..23[5L?\(M8_P#/WK'_ (-KG_XY
M1_PBUC_S]ZQ_X-KG_P".4 <R[ZBGQIN&M+>VE?\ X1Z+S(Y9V0#]^_1@ISS[
M#^E&I>!-0G\&7^EVLUF=0U/4QJ5W+([+&K^:LFU<*20 BJ,XZ9]JV%^'GA]-
M6;5574AJ#+L:Y&J7.\K_ '<^9T]JO?\ "+6/_/WK'_@VN?\ XY0!B:GX>\36
MGBQ_$/AJXTT/?6\<.H65^S^62F=KHRC.0"1R!D?I-?\ AW6[K6O#&H-<6=PV
MERS37+.[1^8TB,I5%"MA5W<9.< #WK5_X1:Q_P"?O6/_  ;7/_QRC_A%K'_G
M[UC_ ,&US_\ '* .<N_!6JWZ^-XYI;.)/$$:B!DD9C$5B$8W J.#@'@\>]==
MHL.H6^D6T.I_9OM2(%86Q8H, #@M@GIGH.OXU4_X1:Q_Y^]8_P#!M<__ !RC
M_A%K'_G[UC_P;7/_ ,<H RO!]@WA_7/$>D2\+=7[ZI:,>CQRA=P'NK@@^FY?
M45BS>!-?;P!K?A5+C33'=W$KVTS-("$DE\S+_*<$=,#.>N>.>L?PCILC(SSZ
MJS1G<A.JW)*GID?O..":?_PBUC_S]ZQ_X-KG_P".4 9U_P"']4U#QCHFKR1V
M2VME:SV\\7GN6;S0H.WY,8&WOC.>U9_AKPWXP\/PQ:#_ &GILN@6[8@N=K_;
M!#G(CQ]S./EW9X';TZ'_ (1:Q_Y^]8_\&US_ /'*/^$6L?\ G[UC_P &US_\
M<H VZKWUY#86,UU/-!#%$N6DGE$:+_O,>@]ZS/\ A%K'_G[UC_P;7/\ \<H/
MA6P(P;K5R/0ZM<__ !R@#D/ >K:/X:T_4+74?%'AIS<W\UXK6^IHV/,(.TA@
M.GK3=3U;3YO&CZM9^+_"[V<UA]DVW5\I>U;<27C4'!W C(RO0<\5U_\ PB.F
M_P#/?5?_  :W/_Q='_"(Z;_SWU7_ ,&MS_\ %T >;6)M;30_!]B_BOPE(^@W
M0F<C5 H=0K(%'!YPQ.>/3'>NAUG6=&N/&6CZ]IWBSPV!:P36TZ7%^GW9"IW+
M@\D%>AQ]:ZC_ (1'3?\ GOJO_@UN?_BZ/^$1TW_GOJO_ (-;G_XN@#@;F/P_
MJTOC.'4?%?AV.T\0"+RF@U)&>%HT"J2#@'E0W!]O>M7P]XLE00IXA\9>$G6U
M3"FROQNNFQ@-(6.%'<@ \X.1C!ZG_A$=-_Y[ZK_X-;G_ .+H_P"$1TW_ )[Z
MK_X-;G_XN@#RC7K[3]/^%_B'3SX@T"YN[O5!>PI9WZRG#W*.01P?EYZ=AVKK
MKC6-$UGQ!I^J:CXH\.VG]FPS"V6VU-)2995V%R6"X"KG P<D^U;NI?#SP]K%
MM]FU&/4+J#.?+EU.X9<_3?5F/P;I<4:QI-JH11@#^U;G@?\ ?R@#S6S"0V'A
MN"3QAX-\W1KXSM(+_<;D%74R,<CYSNR1W.3N%:D=[IJQ>,T/B?PMG7BQ@QJR
M_N\Q"+YOE]L\?3WKN?\ A$=-_P">^J_^#6Y_^+H_X1'3?^>^J_\ @UN?_BZ
M.#CNM/@D\&W-OXM\+"YT.T>SG5]15D=6C1-ZXP21LSM..N,]Z]9!R,BL+_A$
M=-_Y[ZK_ .#6Y_\ BZ=_PBUC_P _>L?^#:Y_^.4 9?C.P;7]3\/:/$,B+4(]
M1NCV2&+)&?\ ><JH]?F]#6_:#5_[7U WALO[-_=_81%N\T?+\_F9XZ],=NM4
M4\(Z;&[ND^JJTAR[#5;D%CTY_><\4_\ X1:Q_P"?O6/_  ;7/_QR@#;HK$_X
M1:Q_Y^]8_P#!M<__ !RC_A%K'_G[UC_P;7/_ ,<H VZ*Q/\ A%K'_G[UC_P;
M7/\ \<H_X1:Q_P"?O6/_  ;7/_QR@#;HK$_X1:Q_Y^]8_P#!M<__ !RC_A%K
M'_G[UC_P;7/_ ,<H VZ*Q/\ A%K'_G[UC_P;7/\ \<H_X1:Q_P"?O6/_  ;7
M/_QR@#;K%\8_\B1K_P#V#;C_ -%M2?\ "+6/_/WK'_@VN?\ XY61XK\-V<'@
M[6Y5NM59DL)V ?5+AE)$;'D%\$>QH [*BL3_ (1:Q_Y^]8_\&US_ /'*/^$6
ML?\ G[UC_P &US_\<H VZ*Q/^$6L?^?O6/\ P;7/_P <H_X1:Q_Y^]8_\&US
M_P#'* -NBL3_ (1:Q_Y^]8_\&US_ /'*/^$6L?\ G[UC_P &US_\<H VZ*Q/
M^$6L?^?O6/\ P;7/_P <H_X1:Q_Y^]8_\&US_P#'* -NBL3_ (1:Q_Y^]8_\
M&US_ /'*/^$6L?\ G[UC_P &US_\<H VZ*Q/^$6L?^?O6/\ P;7/_P <H_X1
M:Q_Y^]8_\&US_P#'* -NBL3_ (1:Q_Y^]8_\&US_ /'*/^$6L?\ G[UC_P &
MUS_\<H VZ*Q/^$6L?^?O6/\ P;7/_P <H_X1:Q_Y^]8_\&US_P#'* -NBL3_
M (1:Q_Y^]8_\&US_ /'*/^$6L?\ G[UC_P &US_\<H VZ*Q/^$6L?^?O6/\
MP;7/_P <H_X1:Q_Y^]8_\&US_P#'* -NBL3_ (1:Q_Y^]8_\&US_ /'*/^$6
ML?\ G[UC_P &US_\<H VZ*Q/^$6L?^?O6/\ P;7/_P <H_X1:Q_Y^]8_\&US
M_P#'* -NBL3_ (1:Q_Y^]8_\&US_ /'*/^$6L?\ G[UC_P &US_\<H VZ*Q/
M^$6L?^?O6/\ P;7/_P <H_X1:Q_Y^]8_\&US_P#'* -NBL3_ (1:Q_Y^]8_\
M&US_ /'*/^$6L?\ G[UC_P &US_\<H VZ*Q/^$6L?^?O6/\ P;7/_P <H_X1
M:Q_Y^]8_\&US_P#'* -NBL3_ (1:Q_Y^]8_\&US_ /'*/^$6L?\ G[UC_P &
MUS_\<H VZ*Q/^$6L?^?O6/\ P;7/_P <H_X1:Q_Y^]8_\&US_P#'* -NBL3_
M (1:Q_Y^]8_\&US_ /'*/^$6L?\ G[UC_P &US_\<H VZ*Q/^$6L?^?O6/\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !6+XQ_Y$C7_P#L&W'_ *+:MJL7QC_R)&O_ /8-N/\ T6U &U11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MR_CBVAD^(G@4-&"L]S<+,.TH6+*AA_$ 1QFM_P :6EO<Z/:B:)7VZC9*"1R
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M=?\ 0R:Q^<'_ ,:K;HH Q/[ NO\ H9-8_.#_ .-4?V!=?]#)K'YP?_&JVZ*
M,3^P+K_H9-8_.#_XU1_8%U_T,FL?G!_\:K;HH Q/[ NO^ADUC\X/_C5']@77
M_0R:Q^<'_P :K;HH Q/[ NO^ADUC\X/_ (U1_8%U_P!#)K'YP?\ QJMNB@#$
M_L"Z_P"ADUC\X/\ XU1_8%U_T,FL?G!_\:K;HH Q/[ NO^ADUC\X/_C5']@7
M7_0R:Q^<'_QJMNB@#$_L"Z_Z&36/S@_^-4?V!=?]#)K'YP?_ !JMNB@#G?#M
ML]IK6O127<]TPFA/FS[=Q_=+Q\H _2NBK%TK_D8]?_ZZP_\ HI:VJ "BBB@
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MB_[Z;_&C_A!O#7_0)B_[Z;_&@#%\'2:OX5\+VOA_4-!O[BZL T,<UIY;17"
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MV[$*W%G83>3=,EPBR@@@,4C/+!2<'D=#C.*TIO$,5_>2Z9I=FNINMJEQ<!I
MD:QR [%)(.68 D#&,#DC(SS6F6GBGPSJVJ:9!X>@U33[R]EN[.^-RD8@\UBS
M)*I^8A6)Y4'/\K-OIVN^&_'VJZE#ILFK:?K,-OYCV\D:/;S1)LY5V4;&'/!.
M/2@"E\-]0GTWX6Z9+9Z1<W1>_GB^SQ%5:)6N9 6.3C"CK_DUZ37!>#X/$?AK
MP1;6DF@&:]%_)OA%V@VQ23,QDST^4-TZGVKO: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ K%\8_P#(D:__ -@VX_\ 1;5M5B^,?^1(U_\ [!MQ
M_P"BVH VJ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** ,72O^1CU_\ ZZP_^BEK:K%TK_D8]?\ ^NL/_HI:
MVJ "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH *YK4K6YNO&=LMMJ$UDPT^0EHD1BP\Q./G4UTM8K_\
M([P_]@V3_P!&)0!4U3PG/K6FSZ=J.NW=Q:3KMDB:W@P><CHF000"".A%9NG?
M#J339DD'BS7[KRB#$E[.LZ1D="%=2,CL<9':NJU:RBO],N+>8RA60_-%*T;
MX/(92"#7GGP\\2:E8BP\+>*YVFGO+1+G2[]R?]+B90QC8G_EHN<>I'X$@';?
MV/JO_0RWW_@/;_\ QNC^Q]5_Z&6^_P# >W_^-UA6.LVGA7P]>ZE>)>S0'5IX
M&<2>:8P;EHXQ\[9"C*C Z5OR>([6+Q*=">"Y%U]C:\1@@9'C5@IQ@YSDCC%
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MYD)F!#Y!.%P5RPV]!W .M_L?5?\ H9;[_P ![?\ ^-T?V/JO_0RWW_@/;_\
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MO_0RWW_@/;__ !NMJB@#%_L?5?\ H9;[_P ![?\ ^-T?V/JO_0RWW_@/;_\
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M^J_]#+??^ ]O_P#&Z/['U7_H9;[_ ,![?_XW6U10!B_V/JO_ $,M]_X#V_\
M\;H_L?5?^AEOO_ >W_\ C=;5% &+_8^J_P#0RWW_ (#V_P#\;H_L?5?^AEOO
M_ >W_P#C=;5% &+_ &/JO_0RWW_@/;__ !NC^Q]5_P"AEOO_  'M_P#XW6U1
M0!B_V/JO_0RWW_@/;_\ QNC^Q]5_Z&6^_P# >W_^-UM44 8O]CZK_P!#+??^
M ]O_ /&Z/['U7_H9;[_P'M__ (W6U10!B_V/JO\ T,M]_P" ]O\ _&Z/['U7
M_H9;[_P'M_\ XW6U10!B_P!CZK_T,M]_X#V__P ;H_L?5?\ H9;[_P ![?\
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M% !1110 4444 %%%% !6+XQ_Y$C7_P#L&W'_ *+:MJL7QC_R)&O_ /8-N/\
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MQ0!0TWPWK.F(^SQ")YI,>9/<VADD?&< DR< 9. , 9/')J]]@\0?]!VV_P#
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M.Z>W\Z%IH&1+A%P&,;'[V,C\\C(H F^P>(/^@[;?^ '_ -G1]@\0?]!VV_\
M #_[.H+CQGI-K+;F;[0MI<7'V6*^\K]PTN2 N[J,D$;L;<]ZJ>+/$%JNAZ[:
MV_VZ26SM7^T3V6X?9F*;ERRD'(X)"Y(!!(P: -+[!X@_Z#MM_P" '_V='V#Q
M!_T';;_P _\ LZQ_"'B*WB\/^#],O'G-]J6F1R0NREA*4B5GRWK@YYZYH\1Z
M[;:OX*\6K8S7=O=:7;3I(59H7CE6(N,,IY['@X- &Q]@\0?]!VV_\ /_ +.C
M[!X@_P"@[;?^ '_V=5M'UB.T\+: DHFN;RYL(FCAB&Z23$:EFY(  R,DD#)
MSDBE3QMI$GA^?68OM4D-O<?99X8[=FFBEW!2C(.002,^U %C[!X@_P"@[;?^
M '_V='V#Q!_T';;_ , /_LZVJ* ,7[!X@_Z#MM_X ?\ V='V#Q!_T';;_P
M/_LZVJ* ,7[!X@_Z#MM_X ?_ &=9'BNRUQ/!^MM+K-O)&+"<N@L=I8>6V1G?
MQ]:[&L7QC_R)&O\ _8-N/_1;4 'V#Q!_T';;_P  /_LZ/L'B#_H.VW_@!_\
M9UM44 8OV#Q!_P!!VV_\ /\ [.C[!X@_Z#MM_P" '_V=;5% &+]@\0?]!VV_
M\ /_ +.C[!X@_P"@[;?^ '_V=;5% &+]@\0?]!VV_P# #_[.C[!X@_Z#MM_X
M ?\ V=;5% &+]@\0?]!VV_\  #_[.C[!X@_Z#MM_X ?_ &=;5% &+]@\0?\
M0=MO_ #_ .SH^P>(/^@[;?\ @!_]G6U10!B_8/$'_0=MO_ #_P"SH^P>(/\
MH.VW_@!_]G6U10!B_8/$'_0=MO\ P _^SH^P>(/^@[;?^ '_ -G6U10!B_8/
M$'_0=MO_   _^SH^P>(/^@[;?^ '_P!G6U10!B_8/$'_ $';;_P _P#LZ/L'
MB#_H.VW_ ( ?_9UM44 8OV#Q!_T';;_P _\ LZ/L'B#_ *#MM_X ?_9UM44
M8OV#Q!_T';;_ , /_LZ/L'B#_H.VW_@!_P#9UM44 8OV#Q!_T';;_P  /_LZ
M/L'B#_H.VW_@!_\ 9UM44 8OV#Q!_P!!VV_\ /\ [.C[!X@_Z#MM_P" '_V=
M;5% &+]@\0?]!VV_\ /_ +.C[!X@_P"@[;?^ '_V=;5% &+]@\0?]!VV_P#
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M=P*OPW-]X,\<ZK)=Z)?76F:O!;&WDTRV:989(H_+,14<J.,@]/UQUWE>*/\
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M ([1Y7BC_G]T?_P$E_\ CM 'G#VD@\ :X+G3M4CG'B1[NU"6K+(-UP&CD5&
M\P8YVCD]..HZ+PSJNFZAXUEU"[&I1:Q=VJVD*W6ERVD?EH6<JN_.6))8_-T'
M X-7O$'AKQ)K\%J/[:LK*XM)Q<6]Q:VSAD<*5Z-(5888C!'>DT_P]XNMYTN-
M1\26>IS19,1GL=BQDC!(6-E&<$C)SP3C&30!8\;Z?8ZI#I]K?PZDJ^<7AO\
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ML3RO%'_/[H__ ("2_P#QVCRO%'_/[H__ ("2_P#QV@#;HK$\KQ1_S^Z/_P"
MDO\ \=H\KQ1_S^Z/_P" DO\ \=H VZ*Q/*\4?\_NC_\ @)+_ /':/*\4?\_N
MC_\ @)+_ /': -NBL3RO%'_/[H__ ("2_P#QVCRO%'_/[H__ ("2_P#QV@#;
MHK$\KQ1_S^Z/_P" DO\ \=H\KQ1_S^Z/_P" DO\ \=H VZ*Q/*\4?\_NC_\
M@)+_ /':/*\4?\_NC_\ @)+_ /': -NBL3RO%'_/[H__ ("2_P#QVCRO%'_/
M[H__ ("2_P#QV@#;HK$\KQ1_S^Z/_P" DO\ \=H\KQ1_S^Z/_P" DO\ \=H
MVZ*Q/*\4?\_NC_\ @)+_ /':/*\4?\_NC_\ @)+_ /': -NBL3RO%'_/[H__
M ("2_P#QVCRO%'_/[H__ ("2_P#QV@#;HK$\KQ1_S^Z/_P" DO\ \=H\KQ1_
MS^Z/_P" DO\ \=H VZ*Q/*\4?\_NC_\ @)+_ /':/*\4?\_NC_\ @)+_ /':
M -NBL3RO%'_/[H__ ("2_P#QVCRO%'_/[H__ ("2_P#QV@#;HK$\KQ1_S^Z/
M_P" DO\ \=H\KQ1_S^Z/_P" DO\ \=H VZ*Q/*\4?\_NC_\ @)+_ /':/*\4
M?\_NC_\ @)+_ /': -NBL3RO%'_/[H__ ("2_P#QVCRO%'_/[H__ ("2_P#Q
MV@#;HK$\KQ1_S^Z/_P" DO\ \=H\KQ1_S^Z/_P" DO\ \=H VZ*Q/*\4?\_N
MC_\ @)+_ /':/*\4?\_NC_\ @)+_ /': -NBL3RO%'_/[H__ ("2_P#QVCRO
M%'_/[H__ ("2_P#QV@#;HK$\KQ1_S^Z/_P" DO\ \=H\KQ1_S^Z/_P" DO\
M\=H VZ*Q/*\4?\_NC_\ @)+_ /':/*\4?\_NC_\ @)+_ /': %TK_D8]?_ZZ
MP_\ HI:VJYWPZMXNM:\+Z2"2?SH<M A1<>4N."2?UKHJ "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "L7QC_ ,B1K_\ V#;C_P!%M6U6+XQ_Y$C7_P#L&W'_ *+:@#:H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH Q=*_Y&/7_P#KK#_Z*6MJL72O^1CU_P#ZZP_^BEK:H **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ K$U&TU5->AU'3K>SN%%JT#I<7+0D$LK C$;YZ>U;=% &+]I\3?]
M C2/_!I)_P#(]'VGQ-_T"-(_\&DG_P CUM44 8OVGQ-_T"-(_P#!I)_\CT?:
M?$W_ $"-(_\ !I)_\CUM44 8OVGQ-_T"-(_\&DG_ ,CT?:?$W_0(TC_P:2?_
M "/6U10!B_:?$W_0(TC_ ,&DG_R/6'XATSQIJLVGW6G#2M/N[&1I(]UZ\T3[
MEVG>A@&>"<$$$9/K7;44 <;IUGXT6[CO=8@T.]NHD9(O(NY(8XPV,D PL23@
M<EOPK8^T^)O^@1I'_@TD_P#D>MJB@#%^T^)O^@1I'_@TD_\ D>C[3XF_Z!&D
M?^#23_Y'K:HH Q?M/B;_ *!&D?\ @TD_^1Z/M/B;_H$:1_X-)/\ Y'K:HH Q
M?M/B;_H$:1_X-)/_ )'H^T^)O^@1I'_@TD_^1ZVJ* ,7[3XF_P"@1I'_ (-)
M/_D>C[3XF_Z!&D?^#23_ .1ZVJ* ,7[3XF_Z!&D?^#23_P"1Z/M/B;_H$:1_
MX-)/_D>MJB@#%^T^)O\ H$:1_P"#23_Y'H^T^)O^@1I'_@TD_P#D>MJB@#%^
MT^)O^@1I'_@TD_\ D>C[3XF_Z!&D?^#23_Y'K:HH Q?M/B;_ *!&D?\ @TD_
M^1Z/M/B;_H$:1_X-)/\ Y'K:HH Q?M/B;_H$:1_X-)/_ )'H^T^)O^@1I'_@
MTD_^1ZVJ* ,7[3XF_P"@1I'_ (-)/_D>C[3XF_Z!&D?^#23_ .1ZVJ* ,7[3
MXF_Z!&D?^#23_P"1Z/M/B;_H$:1_X-)/_D>MJB@#%^T^)O\ H$:1_P"#23_Y
M'H^T^)O^@1I'_@TD_P#D>MJB@#%^T^)O^@1I'_@TD_\ D>C[3XF_Z!&D?^#2
M3_Y'K:HH Q?M/B;_ *!&D?\ @TD_^1Z/M/B;_H$:1_X-)/\ Y'K:HH Q?M/B
M;_H$:1_X-)/_ )'H^T^)O^@1I'_@TD_^1ZVJ* ,7[3XF_P"@1I'_ (-)/_D>
MC[3XF_Z!&D?^#23_ .1ZVJ* ,7[3XF_Z!&D?^#23_P"1Z/M/B;_H$:1_X-)/
M_D>MJB@#%^T^)O\ H$:1_P"#23_Y'H^T^)O^@1I'_@TD_P#D>MJB@#%^T^)O
M^@1I'_@TD_\ D>C[3XF_Z!&D?^#23_Y'K:HH Q?M/B;_ *!&D?\ @TD_^1ZI
M:Q!XFU;1+_3?[-TB+[7;20>9_:4C;-ZE<X\@9QGIFNGHH Q?M/B;_H$:1_X-
M)/\ Y'H^T^)O^@1I'_@TD_\ D>MJB@#%^T^)O^@1I'_@TD_^1Z/M/B;_ *!&
MD?\ @TD_^1ZVJ* ,7[3XF_Z!&D?^#23_ .1Z/M/B;_H$:1_X-)/_ )'K:HH
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M3XF_Z!&D?^#23_Y'H^T^)O\ H$:1_P"#23_Y'K:HH Q?M/B;_H$:1_X-)/\
MY'H^T^)O^@1I'_@TD_\ D>MJB@#%^T^)O^@1I'_@TD_^1Z/M/B;_ *!&D?\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5SVHV[:AXJM[-[
MN\B@%D\NVWN'BRV]1D[2,\$UT-8K_P#([P_]@V3_ -&)0 ?\(S;?\_\ J_\
MX,IO_BJ/^$9MO^?_ %?_ ,&4W_Q5;5% &+_PC-M_S_ZO_P"#*;_XJC_A&;;_
M )_]7_\ !E-_\56U10!B_P#",VW_ #_ZO_X,IO\ XJC_ (1FV_Y_]7_\&4W_
M ,56U10!B_\ ",VW_/\ ZO\ ^#*;_P"*H_X1FV_Y_P#5_P#P93?_ !5;5% &
M+_PC-M_S_P"K_P#@RF_^*H_X1FV_Y_\ 5_\ P93?_%5M44 8O_",VW_/_J__
M (,IO_BJ/^$9MO\ G_U?_P &4W_Q5;5% &+_ ,(S;?\ /_J__@RF_P#BJ/\
MA&;;_G_U?_P93?\ Q5;5% &+_P (S;?\_P#J_P#X,IO_ (JC_A&;;_G_ -7_
M /!E-_\ %5M44 8O_",VW_/_ *O_ .#*;_XJC_A&;;_G_P!7_P#!E-_\56U1
M0!B_\(S;?\_^K_\ @RF_^*H_X1FV_P"?_5__  93?_%5M44 8O\ PC-M_P _
M^K_^#*;_ .*H_P"$9MO^?_5__!E-_P#%5M44 8O_  C-M_S_ .K_ /@RF_\
MBJ/^$9MO^?\ U?\ \&4W_P 56U10!B_\(S;?\_\ J_\ X,IO_BJ/^$9MO^?_
M %?_ ,&4W_Q5;5% &+_PC-M_S_ZO_P"#*;_XJC_A&;;_ )_]7_\ !E-_\56U
M10!B_P#",VW_ #_ZO_X,IO\ XJC_ (1FV_Y_]7_\&4W_ ,56U10!B_\ ",VW
M_/\ ZO\ ^#*;_P"*H_X1FV_Y_P#5_P#P93?_ !5;5% &+_PC-M_S_P"K_P#@
MRF_^*H_X1FV_Y_\ 5_\ P93?_%5M44 8O_",VW_/_J__ (,IO_BJ/^$9MO\
MG_U?_P &4W_Q5;5% &+_ ,(S;?\ /_J__@RF_P#BJ/\ A&;;_G_U?_P93?\
MQ5;5% &+_P (S;?\_P#J_P#X,IO_ (JC_A&;;_G_ -7_ /!E-_\ %5M44 8O
M_",VW_/_ *O_ .#*;_XJC_A&;;_G_P!7_P#!E-_\56U10!B_\(S;?\_^K_\
M@RF_^*H_X1FV_P"?_5__  93?_%5M44 8O\ PC-M_P _^K_^#*;_ .*H_P"$
M9MO^?_5__!E-_P#%5M44 8O_  C-M_S_ .K_ /@RF_\ BJ/^$9MO^?\ U?\
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MMJB@#%_X1FV_Y_\ 5_\ P93?_%4?\(S;?\_^K_\ @RF_^*K:HH Q?^$9MO\
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MFV_Y_P#5_P#P93?_ !5'_",VW_/_ *O_ .#*;_XJMJB@#%_X1FV_Y_\ 5_\
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M /0TZQ_W[M?_ (Q0!MT5B?V'?_\ 0TZQ_P!^[7_XQ1_8=_\ ]#3K'_?NU_\
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M /0TZQ_W[M?_ (Q0!MT5B?V'?_\ 0TZQ_P!^[7_XQ1_8=_\ ]#3K'_?NU_\
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M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !6*__ ".\/_8-D_\
M1B5M5BO_ ,CO#_V#9/\ T8E &U1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !6+XQ_Y$C7_ /L&W'_HMJVJQ?&/
M_(D:_P#]@VX_]%M0!M4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 8NE?\C'K_ /UUA_\ 12UM5BZ5_P C
M'K__ %UA_P#12UM4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 5S6I07L_C.V6RO5M7&GR%F:$29'F
M)QC(Q72UBO\ \CO#_P!@V3_T8E !_9^O?]!Z'_P!'_Q5']GZ]_T'H?\ P!'_
M ,56U10!B_V?KW_0>A_\ 1_\51_9^O?]!Z'_ , 1_P#%5M44 8O]GZ]_T'H?
M_ $?_%4?V?KW_0>A_P# $?\ Q5;5% &+_9^O?]!Z'_P!'_Q5']GZ]_T'H?\
MP!'_ ,56U10!B_V?KW_0>A_\ 1_\51_9^O?]!Z'_ , 1_P#%5M44 8O]GZ]_
MT'H?_ $?_%4?V?KW_0>A_P# $?\ Q5;5% &+_9^O?]!Z'_P!'_Q5']GZ]_T'
MH?\ P!'_ ,56U10!B_V?KW_0>A_\ 1_\51_9^O?]!Z'_ , 1_P#%5M44 8O]
MGZ]_T'H?_ $?_%4?V?KW_0>A_P# $?\ Q5;5% &+_9^O?]!Z'_P!'_Q5']GZ
M]_T'H?\ P!'_ ,56U10!B_V?KW_0>A_\ 1_\51_9^O?]!Z'_ , 1_P#%5M44
M 8O]GZ]_T'H?_ $?_%4?V?KW_0>A_P# $?\ Q5;5% &+_9^O?]!Z'_P!'_Q5
M']GZ]_T'H?\ P!'_ ,56U10!B_V?KW_0>A_\ 1_\51_9^O?]!Z'_ , 1_P#%
M5M44 8O]GZ]_T'H?_ $?_%4?V?KW_0>A_P# $?\ Q5;5% &+_9^O?]!Z'_P!
M'_Q5']GZ]_T'H?\ P!'_ ,56U10!B_V?KW_0>A_\ 1_\51_9^O?]!Z'_ , 1
M_P#%5M44 8O]GZ]_T'H?_ $?_%4?V?KW_0>A_P# $?\ Q5;5% &+_9^O?]!Z
M'_P!'_Q5']GZ]_T'H?\ P!'_ ,56U10!B_V?KW_0>A_\ 1_\51_9^O?]!Z'_
M , 1_P#%5M44 8O]GZ]_T'H?_ $?_%4?V?KW_0>A_P# $?\ Q5;5% &+_9^O
M?]!Z'_P!'_Q5']GZ]_T'H?\ P!'_ ,56U10!B_V?KW_0>A_\ 1_\51_9^O?]
M!Z'_ , 1_P#%5M44 8O]GZ]_T'H?_ $?_%4?V?KW_0>A_P# $?\ Q5;5% &+
M_9^O?]!Z'_P!'_Q59'BNQUI/!^MM+K44D8L)RZ"R"[AY;9&=W'UKL:Q?&/\
MR)&O_P#8-N/_ $6U !_9^O?]!Z'_ , 1_P#%4?V?KW_0>A_\ 1_\56U10!B_
MV?KW_0>A_P# $?\ Q5']GZ]_T'H?_ $?_%5M44 8O]GZ]_T'H?\ P!'_ ,51
M_9^O?]!Z'_P!'_Q5;5% &+_9^O?]!Z'_ , 1_P#%4?V?KW_0>A_\ 1_\56U1
M0!B_V?KW_0>A_P# $?\ Q5']GZ]_T'H?_ $?_%5M44 8O]GZ]_T'H?\ P!'_
M ,51_9^O?]!Z'_P!'_Q5;5% &+_9^O?]!Z'_ , 1_P#%4?V?KW_0>A_\ 1_\
M56U10!B_V?KW_0>A_P# $?\ Q5']GZ]_T'H?_ $?_%5M44 8O]GZ]_T'H?\
MP!'_ ,51_9^O?]!Z'_P!'_Q5;5% &+_9^O?]!Z'_ , 1_P#%4?V?KW_0>A_\
M 1_\56U10!B_V?KW_0>A_P# $?\ Q5']GZ]_T'H?_ $?_%5M44 8O]GZ]_T'
MH?\ P!'_ ,51_9^O?]!Z'_P!'_Q5;5% &+_9^O?]!Z'_ , 1_P#%4?V?KW_0
M>A_\ 1_\56U10!B_V?KW_0>A_P# $?\ Q5']GZ]_T'H?_ $?_%5M44 8O]GZ
M]_T'H?\ P!'_ ,51_9^O?]!Z'_P!'_Q5;5% &+_9^O?]!Z'_ , 1_P#%4?V?
MKW_0>A_\ 1_\56U10!B_V?KW_0>A_P# $?\ Q5']GZ]_T'H?_ $?_%5M44 8
MO]GZ]_T'H?\ P!'_ ,51_9^O?]!Z'_P!'_Q5;5% &+_9^O?]!Z'_ , 1_P#%
M4?V?KW_0>A_\ 1_\56U10!B_V?KW_0>A_P# $?\ Q5']GZ]_T'H?_ $?_%5M
M44 8O]GZ]_T'H?\ P!'_ ,51_9^O?]!Z'_P!'_Q5;5% &+_9^O?]!Z'_ , 1
M_P#%4?V?KW_0>A_\ 1_\56U10!B_V?KW_0>A_P# $?\ Q5']GZ]_T'H?_ $?
M_%5M44 8O]GZ]_T'H?\ P!'_ ,51_9^O?]!Z'_P!'_Q5;5% &+_9^O?]!Z'_
M , 1_P#%4?V?KW_0>A_\ 1_\56U10!SOAV*YAUK7DN[E;B;SH<R+'L!'E+VR
M:Z*L72O^1CU__KK#_P"BEK:H **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K%?_ )'>'_L&R?\ HQ*V
MJYG4DU%_&=L-.GM8I/[/DW&XA:0$>8G0*RX- '345B>1XH_Z"&C_ /@#+_\
M'J/(\4?]!#1__ &7_P"/4 ;=%8GD>*/^@AH__@#+_P#'J/(\4?\ 00T?_P
M9?\ X]0!MT5B>1XH_P"@AH__ ( R_P#QZCR/%'_00T?_ , 9?_CU &W16)Y'
MBC_H(:/_ . ,O_QZCR/%'_00T?\ \ 9?_CU &W16)Y'BC_H(:/\ ^ ,O_P >
MH\CQ1_T$-'_\ 9?_ (]0!MT5B>1XH_Z"&C_^ ,O_ ,>H\CQ1_P!!#1__  !E
M_P#CU &W16)Y'BC_ *"&C_\ @#+_ /'J/(\4?]!#1_\ P!E_^/4 ;=%8GD>*
M/^@AH_\ X R__'J/(\4?]!#1_P#P!E_^/4 ;=%8GD>*/^@AH_P#X R__ !ZC
MR/%'_00T?_P!E_\ CU &W16)Y'BC_H(:/_X R_\ QZCR/%'_ $$-'_\  &7_
M ./4 ;=%8GD>*/\ H(:/_P" ,O\ \>H\CQ1_T$-'_P# &7_X]0!MT5B>1XH_
MZ"&C_P#@#+_\>H\CQ1_T$-'_ / &7_X]0!MT5B>1XH_Z"&C_ /@#+_\ 'J/(
M\4?]!#1__ &7_P"/4 ;=%8GD>*/^@AH__@#+_P#'J/(\4?\ 00T?_P  9?\
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M *"&C_\ @#+_ /'J -NBL3R/%'_00T?_ , 9?_CU'D>*/^@AH_\ X R__'J
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MP(6=9D6/:8U*@_,I_AZG.>] %SX>^(#)\-=&U'5[Z:XN+DR*)&#223-YCX
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MNY)5E5QF,@J64D_*01T/O7+'4SX=U/P?XAO(9Y-%.B?V?--%$TGV24^6VYE
M)&=FT\=15GQO<65Y\.;J;3M.-M%=:E;S1*MN8WN<31L\I3 ;G#')&2!GN* .
MNU+QIX?TB^FLKS452ZAB$KPI&[OM)P,!0<GKP.>">QI\'B[0;G1+;6+?44FL
MKJ010/&K,TDA. @0#<6X/&,\&N8N-2L+/XV>?=7$,44GAM/+F<@)_P ?#G[W
M09'YU@0"3P]IKWCZ>8M.U3Q1+=07#VID-C"RX694(.TL5."1@!P<=J /16\8
M:"FE7NI27WE6UC(8KHR1.KPN!DJR$;@<$'I19^,-"U#5$TVVOM]U)$9HU\EP
MLJCKL8C:Q&>0"2*\RN) NA_$ZU$=^SW0#P&X@<--N@4#J!R3T7K[ "NAO)X6
M\6?#B2-@8XH;D2,HXCW6X50Q_ARPQSW&* .E\+^+K?Q/-J:P6]S"+2[DMU\V
MWD3(0*"22,!MQ/RYSC&15G5_%NAZ%>)::C?K#</$TJQ^6S$JHR<;0>>G'4YK
M ^'TOV>^\4Z=-%/'<_VY=W.'A8+Y;LI1MQ&#D=.>QI/$4D0^*_A!FY$4%Z';
M&1&SJ@7)Z G! SUH WI/%^B1Z?'?"YEDMY+=;K=#;2R%86&0[!5)4'!^\!T/
MH:)_&/A^WEL8GU.(O?Q&:UV!G$J!=V00#VZ#J<@#DUQ>I7]GH'Q!UQ?$D.II
MIVK+ ]E<VQG:-ML81XF$1ZY&0".]22V]E8>,/A_!:6#6%I;QWV(&R?LZN@V!
MR?NEO0GKD=J .D/Q#\+C3Y;[^T'\J&1HYE%K*9(2N-V]-NY ,CE@!6I<^(=,
MM?L@:X,KWD9EMTMXVF>5  2P5 3MP1STY'K7!VDT(;XFG( G9C%Q_K1]G"?+
M_>^;(X[U!I6K+:P>";.X@EM8SHBQMJ$-H99_-"H#;*0I*$XR>,G  P>: .NU
MCQ!H5_X8M+_^WY[.QNIXQ#=69*N[!P-GW21DC:01Z@XJ[?>,-"T[4I=.N+[%
M[%#YS6\<3R.5SC@*#N.>PR>#Z&O*XG*?!6*P:"Y2YAUD;HI(7#<7I<]1SA>2
M1G%=J+FW_P"%TO<^8GD_\(\(Q-_!N\\OMW=,[><>G- &CJ_B+0=1\*VNHC7Y
M[.PNYH_)N[0LKLP<#9]TD9(VD$>H.*O7WB_0M.U*73;F^Q>Q0^>UND3NY3..
M H.XY[#)X/H:\N9Q_P *>GM@K^=_;N]8@AW[?MF_.W&<;><^E=D+FW/QI-SY
MB>3_ ,(\(Q-_!N\_=MW=,[><>G- '20^)]&N-!BUR*_1M.F(6.4*V68MM"A<
M;MV[C;C.>,46?B;2+[59-+ANB+^+_66TD3HZC&02& X(Y![UY9$8(_ABD\K3
MPS6/B0W4++ T@C;[2Q1G0#<4*MVZY&*ZOPCK&@ZQXTU+4X-6CEU2\MHXA:+#
M)$$BCSR/,52YRV2<<# ]Z .RU'5[+2O(%W*5>XD\N&-$9WD;!.%502> 2>.
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MF^(H9_#FH27%K>:PR7^@7:;S"3*=\\1/S(H(+_W3GKT%=1\4/^28^(O^O-Z
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M ?2__!G)_P#&* -JBL7[7XE_Z ^E_P#@SD_^,4?:_$O_ $!]+_\ !G)_\8H
MVJ*Q?M?B7_H#Z7_X,Y/_ (Q1]K\2_P#0'TO_ ,&<G_QB@#:HK%^U^)?^@/I?
M_@SD_P#C%'VOQ+_T!]+_ /!G)_\ &* -JBL7[7XE_P"@/I?_ (,Y/_C%'VOQ
M+_T!]+_\&<G_ ,8H VJ*Q?M?B7_H#Z7_ .#.3_XQ1]K\2_\ 0'TO_P &<G_Q
MB@#:HK%^U^)?^@/I?_@SD_\ C%'VOQ+_ - ?2_\ P9R?_&* -JBL7[7XE_Z
M^E_^#.3_ .,4?:_$O_0'TO\ \&<G_P 8H VJ*Q?M?B7_ * ^E_\ @SD_^,4?
M:_$O_0'TO_P9R?\ QB@#:HK%^U^)?^@/I?\ X,Y/_C%'VOQ+_P! ?2__  9R
M?_&* -JBL7[7XE_Z ^E_^#.3_P",4?:_$O\ T!]+_P#!G)_\8H VJ*Q?M?B7
M_H#Z7_X,Y/\ XQ1]K\2_] ?2_P#P9R?_ !B@#:HK%^U^)?\ H#Z7_P"#.3_X
MQ1]K\2_] ?2__!G)_P#&* -JBL7[7XE_Z ^E_P#@SD_^,4?:_$O_ $!]+_\
M!G)_\8H VJ*Q?M?B7_H#Z7_X,Y/_ (Q1]K\2_P#0'TO_ ,&<G_QB@#:HK%^U
M^)?^@/I?_@SD_P#C%'VOQ+_T!]+_ /!G)_\ &* -JBL7[7XE_P"@/I?_ (,Y
M/_C%'VOQ+_T!]+_\&<G_ ,8H VJ*Q?M?B7_H#Z7_ .#.3_XQ1]K\2_\ 0'TO
M_P &<G_QB@#:HK%^U^)?^@/I?_@SD_\ C%'VOQ+_ - ?2_\ P9R?_&* -JBL
M7[7XE_Z ^E_^#.3_ .,4?:_$O_0'TO\ \&<G_P 8H VJ*Q?M?B7_ * ^E_\
M@SD_^,4?:_$O_0'TO_P9R?\ QB@#:HK%^U^)?^@/I?\ X,Y/_C%'VOQ+_P!
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M*Q?M?B7_ * ^E_\ @SD_^,4?:_$O_0'TO_P9R?\ QB@#:HK%^U^)?^@/I?\
MX,Y/_C%'VOQ+_P! ?2__  9R?_&* #2O^1CU_P#ZZP_^BEK:K&T6TU"*^U.\
MU&&VA>ZD1DC@G:4 *@7DE%]/2MF@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHH
MH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
M HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHK
MGM<CUQ7OKRUU1;2S@M-\<0MU=GD 8L23T&-HQ]: .AHKA?"%UXFU[PSH>N2:
MPA^UION8/LJ !2&&4/4$':><YP:3P/XS@N- LD\0:W:G5KJ[N(8EE9(WEVS.
MB@*,=E 'K]: .[HK'%U')XO^SIKL19+,E])4(6!WC]\3]X<$+CIS5B#7=*N;
MQ;2&_MWN'W;(U<9?;][;ZX[XZ4 :%%17%S!9V\EQ<S1PP1KN>21@JJ/4D]*H
M1^)=$DG: :M9K.F2T,DRHX &[)4X.,<].G- &I16/;^*_#UW*L5OK>GRNT+3
M@)<*<QJ2&?K]T$'GV-36GB#2+YIEMM1MI&AC$L@\P JAZ.<_PG^]TH TJ*Q8
M_%_AR6:TACUS3WDO&*VRK<*3*0Q7Y>>?F!'N145OXOTJY\67?AZ.XC^UVT:,
M^6QEV+?(/4@+DXZ9^M &_145S<P6=N]Q=31PPH,M)(P55^I-5+;7-+O(;F6W
MO[=TM?\ CXPX!BXS\PZKQSS0!H45P/A[7+[QA.U]IWB".V-MJ4J/8"..1)+5
M'V<\;@S 9#9P">F*M>,]6U;3?$/AFSTZ_P#L\6J7;6TP,*/M 3<"N1P>.^:
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M+2ZU*VAN'<1A'D .X]%/H3V!Y- &E161>>*O#^GM<K=ZU80M:[1.'G4&,MG
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MHK&^@GD@($L:/\R9Z9'4 ]CWJ]0 4444 %%%% !1110 4444 %%%% !1110
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M*\(7YU/P?I-Y]A^P"6U0BV'2,8P /; X]L5YS-<V9\._%I1-!CS9\#<.IME
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MV<$T%Y*@++;2O&%1F Z8^9<]MQ]:W?&-[H-W\,O%M_H\<*V]Y$2UVJ[5NYL
M97/WL8 R."<^AH [6Z\3:'I6R"_UFTCF$'G$2RJK%!CYR.P.1^)XI]KXFT.]
MT5M9MM4M9-.4X:X60;0<XP?0Y(XZ\CUKBM0O-.7XC^";FXGMO);2[GRI78;=
MV(\8/3/6L6[DM-&_X2W6%LH)M#OM;LA;22 FWBD4+YMR0N,HLGH>2N,T >H1
M>)-'EM[R?^T(8X[+'VKSCY1@R,C>&P5R.F>M0VOB[P]?7]K8VVKVLMU=1B6"
M)7YD4KNX]]ISCKCFO/+75+$>)O'I?5/M2W.CP/'<.H595$<H+*0 "N2 #TY
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ME5KB7S2Z/'MXPQ(.[.!R3QS0!ZIJ/B'2=)=DOKZ* H TA;)$:DX!<CA 3W;
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M8FE\W<@+#@L%!)] 1ZT 1^%]7O?&/EZK:Z[):O#?S"2R$*O$]LLC($.0"&(
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M?&SSQ<0%?^$<78S$ @^>S=^AVG/T.>E '9Q:WID^D1ZK%?0/82@&.=6RKY.
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M:XLEM]ELK>6W:!P2T@DVY.>@QM''?VKI-J[=N!MQC&.*6B@!,#T%&!Z"EHH
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M>6F_?L7?C&['.*=10 @4 D@ $\GWI:** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBFR2)%&TDC!44%F8G  '4T .H
MJ*VN(;NUBN;>198)D$D;J<AE(R"/J*EH ***I?VM8_VU_8_GC^T/L_VKR=I_
MU6[;NSC'7C&<T 7:*** "BBB@ HJO?7UKIMI)=WDRPV\8R\C_=4>I/8>]-T_
M4K/5;-+NPN$N+9^4ECY5AZ@]Q0!:HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MN@>VQP9U#()?KY;%?Q-#:#?CX@-XD22V,']F_8%@)8-_K/,W$XQUXQCWSVH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M.2[NY1%!'C<QYY)P  .222  .23B@#&_X3GPY_T$#_WXD_\ B:/^$Y\.?]!
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MW.BWRWEM<-9Y0A=XVL@<$\.>=PH T]/U;5)O'&L:!-<QM#;6,%Q#*L(#!W+
MYYP1\O%<W#XU\1W/@OPCJL3V NM6U1;&X5H&VX+R %?FXX09'/7J*Z6;PMJ2
M>+/[<L-8CA,]G':7JRVH=G"$D.A# *WS'J"/8UD6OPZO[7PUX?T==<@(T?4%
MOTD:R)\PAG8(?W@X^<\_2@"T=8UZWU6/PY<W:W%^MJUY-=V5H =C2%8P$9L#
M[IR>>@'?-;?A.\UN]T7=XAL1:7\<KQG;@"5 ?ED !.W([9Z@UG^(_"5_J.MV
M6OZ)K']EZO;0FW=V@\V*>$G=L9"1T/(.:WM)LKBQLMEY>M>W3L7FG9 @9NGR
MJ.%    ]N23DD Y^WUC5/$>HZ_;Z1=PV::5/]DC+P^9YLX0,Q?)X0%@,#!X)
MSVKDO$'B"[\6_#GP_JZ,MD\NK6L5Q;[-X$JW 4X.>@9<X[\5V<?A>]TSQ%JF
MJ:)J$%O'JFU[FWN+<R*LJC'F)AEQD=0>N.HJG?\ @'?X4TK0-,U!;6&PNH[H
MRS0>:TKH_F9.&4#<V2?KQB@#K[:.6.!5GE668#YI FW=^':O*-#^WW-M\1].
ML-(DOI;O5[J%2TD:1*6C5?GW,#@9SP#7K*B7R<,R&7'W@I"Y^F?ZUS?A7PO=
M^';[6IYM1ANDU2]>]9$MC&8W; P#O;(P!0!D:99:MX1T/P]X?DU&&*WAM'2:
MZ1?-FDG!!6.*,@EEP6/ )PHZ5GKXX\077@3PSK-O]A2[O]52PN4>%MK S-'E
M?F^7.SG@]?:NIU7PU?77BZS\0:?JJ6LD5H]G+%+;^:&C9@V4^8;7R!SR.!QQ
M6'!\.;^W\-Z9HR:]$R:?J@U"*22RR3B1I I <=V.3], =P"MJJ>*(/&O@^RO
M=>@D:>XO7!@L]B?+"VTLI8Y(5B.N/K6G+XOO=+\0^+8]1,,NGZ-I\5["L,91
MR&#D@DDY/R@9X'M6KK_ANZU?5=#U2TU%+2\TN21@6@\Q761-CC&X8..AR<>A
MJLW@TW/B#7KZ^O8Y[/6+)+*6V$!5E10PSOW=3O/\([4 26$GBB6XT:],UG/8
MW<1>_AV[/L^4W(8CU;G@[NO7BN=N?&'B"#PEXUU#S;$WFB7TL,!^SML,:HA^
M[OSGYCSD_2MKPUX5UO1DMK*_\2&_TRR 6UA%J(Y" ,()'R=P48Q@#) )]*Y_
MQ9X?G\/_  \\=SW%_#<+J9DO-JP&/RV8*NW)8Y&%'I0!H3:_XGT3Q%X?;5)K
M&YTG6Y1;>5! 4>UE*[DPQ)W@X.3@?05#>^+=9TZ]TTW$]LTUSK2Z?/8PQ^9'
M#"[E4)E'23&UL$]_NBMNRT&XU0Z#>ZI>P7$.G*)[>."$H))2FT.Q+'H&. .Y
MSGM6+'\-]4BT:RTM?$:?9]/U-=0M&:QR^1(9,2G?\YRQY&WWSV )WU?Q3?\
MB;Q7I-I?Z?;1Z9%;RV\IM"[?.CMM(+X/( +>W YXR)M=U?Q"?AQJ$=ZMF-2=
MWFA2+<GF"!SNY.2.N!GOGG KJ[3PM?VFO^(-475(';5X88MCVI_=>6K*I)#_
M #9W$G@?A6=;_#^\M-$\,6=OK,2W>@2EH;AK,E9$*LA#)OZX;KG\* .Y4$*
MQR<<G'6EI$!5%4L6(&"QQD^_%+0 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110!#!:6UL6,%O%$6.6\M N?KBIJ** "BBB@ HHHH **** "
MBBB@ HHHH **** "BBB@ J*>V@ND"7$,<J YVR*&&?QJ6B@!D44<$:QQ1K'&
MO14& /PI]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M_P"-5/;>*+&?4[?39(KRUO;@,T,5S;.F]5&20V-O'IG(R..:V0ZL6"L"5.&
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MX332?^>&L_\ @DO/_C5=#10!SW_"::3_ ,\-9_\ !)>?_&J/^$TTG_GAK/\
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M\:KH:* .>_X332?^>&L_^"2\_P#C5'_"::3_ ,\-9_\ !)>?_&JZ&B@#GO\
MA--)_P">&L_^"2\_^-4?\)II/_/#6?\ P27G_P :KH:P=7\6V&CM=!X+NY6S
M"&\:UB\S[.'^Z6&<GCG"@D#DC!% #/\ A--)_P">&L_^"2\_^-4?\)II/_/#
M6?\ P27G_P :K7OM2L],T^2_OKF.WM8UW/+(< #M^/;'6LQO%FG0M ;R.\LH
M9V"13W=LT<;,>@)(^0GMNQGIUH C_P"$TTG_ )X:S_X)+S_XU1_PFFD_\\-9
M_P#!)>?_ !JM74M3MM*@CDN"<RRK##&HRTLC?=5?<_D "3@"LBW\9V-RICCL
M[\7XGD@^P/$%F+QJ&;&3M( (.[=@Y'.2!0 [_A--)_YX:S_X)+S_ .-4?\)I
MI/\ SPUG_P $EY_\:J7P[XIM/$RW#V=IJ$"0;06N[5H0Q.<A<]2I4@XZ&MR@
M#GO^$TTG_GAK/_@DO/\ XU1_PFFD_P#/#6?_  27G_QJNAHH Y[_ (332?\
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M (U1_P )II/_ #PUG_P27G_QJNAHH Y[_A--)_YX:S_X)+S_ .-4?\)II/\
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M+3Q!=Z[=313:A<V\=LS00^4FQ"2"1N8EB3U)Z  8[[E !1110 4444 %%%%
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MTP.*Z/7O##:Q=:-+#>):1Z5<K<PQ+!N#,%*@'D87!(P/SHO/#=Q=^+=/U_\
MM%4>R@D@2#[/E6#XW$G=G.5&/3WH Y^;QCJ.C7_CZ6^D2ZMM$AMY;2%8PGWX
MV;:3R3DX&3Z5N6T/B*"^TV^?5H;K3GMW;4(I(U7:VT%&@VKG&<@AF/&.2:8O
M@N&74_$EQ?7(N;;7HDBN+?RMNQ40H-K9ST//OR,4SPYX1OM%%O#>^([O5+*S
M&VSMYH43RQC:-[ 9D(!P,\>V<8 ,6QUOQ=K>E:/KVDP7#I=2I+-9R_9A;_9V
M/(5MWF!P,<D\G/ Z"?3+KQ1K'C#7[%==AM[72;^WPJV2L98FC#M&<G*YSC=D
MGZ=#8T?X?SZ).UI:>([T>'O-,J:28D(7)W%!+C=LS_",9'&>3G7T;PY+I.OZ
MSJC7PG_M61))(O)VB,HH0;3N/&T#.>_I0!OT444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M+A;>Y@!)&RYB,;C'L:M444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M.JJN\YP."2!R<4>$]+M?[1UGQ)#9R6K:Q,C(LJ%',:(%#%3RI8[FQP<;<\T
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
?%%%% !1110 4444 %%%% !1110 4444 %%%% '__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>46
<FILENAME>exhibit108-arvinasxformo002.jpg
<TEXT>
begin 644 exhibit108-arvinasxformo002.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH ***P/&&J#3M#,:W(MY[V1;2*4G'EE_O/_ ,!0,W_ : -:
MPO[34[-+NQG2>W<L%D0Y!*DJ?U!%6:\R^'%W8Z)XIUWP?97"2:>&_M'3"K9
MB? DC!_V6_GFM-=7\6:EXRU_1;"ZTJ"'33:2))+;.Q9) S,I&_K@?>]NG.0
M=U5*XU6TM=5LM-E9Q<WHD,*B-B"$ +98#"\$=2,URFG^*-5BF\5:?JLEN=1T
MMU-HL,)4312+^Y."QRS-\I .,U:NM9UK3_&/AC1KB6SEAU&"X:Y9(&5O,B0'
MY26.%);IC/'6@#KJ*\QG\5>+6T'Q;J45QI2?V!?3QA3:N?M$<:(VW[_R<$\Y
M.2>V.>@U+7-3>6S>":WL+*YL//CD*>=-).<$1K&/F*A>20#]10!UU%><K\0Y
MO^$/\,:WJ&-/M=34_;;V.$R);,!\HQSM#-W.<=.^1VF@W,]YHT-Q<75K=O(S
ME9[3_52)O.QAR>J[<\GG- %Z>9+>!YI Y1!D[$+G\@"35+1M>TWQ#9_;-*N?
MM-MD@3*C!6(X."0,X([5HUXUX8UO4?#G[.\&KZ6;?[1;/*<3QE@0;EE.,$8/
MS9[].E 'LM%<:->UG2_',&EZM/936-[837<?D0LC6[1%<J6+'>,-UP.1T'2C
M3-7\2ZWI6C:]IZV;VE],KS64B[3%:MGY@^>9 ,$C&#DC'&: .RHHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "L:32KZ;Q7!JDEW UG;V[Q16WDG<K.5+/OW8S\H'W> 3ZFMFB@#E?$?A
M6]U;Q/H>N:?J,%E<:69/OVYD,R. &0D,.,#\#S4^E>';W3_&&LZY+>P21:FD
M*F!8"IC\I2!\VXYSN.>*Z.B@#G=1\)V]_P",=-\0F9D>TA>&6(=)QN#1[O\
M<;+#WQ1JOAZZU#QAHFN1WD,<6EK.OD-"6,GFJ%/S;AC&T8X-=%10!Q \#ZA_
M8/BK3&U2V_XG]Q-.9!;-^X\Q A&-_P V HQTJ2'P=JUMKEGJ5OK4"%=,33;A
M&M"V54Y#Q9?Y&/ON''0UV=% '%Z!X1UGP_X?TK2H]6M+N&RCEAEAFM2L<\;$
M%0?F.",'GG.2,5!'X>U7PKH^FV/AZ_AC)U)IY[86NY)(Y'RT:#/[M%!Z^WJ<
M'NZ* (YQ,87$#(LN/E,BDJ#[@$9_.O/X/AQ?P_"^7P5_;-NRLQ*W?V0Y ,OF
M$%=_)SQUZ5Z)10!S-WX:O+WQ=IFMS7EMY=G:RVTEN(&_>"3;N.[=Q]T8&#6=
MX=\%ZSX?5-)C\0B3P[#(7@MS;?Z0J;MPB,N[&S/MDCCBNWHH S["WU.&^U"2
M]OX[BVEE#6D2PA# FWE2<_-SSG_(T*** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M]_:RVB9W3QS*R+CKE@<#%<+XO\1V+Q>$-;@U$Q^'9+PF:\@"LL1:)A$6#*0
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MAMJVMK%93SV%X\XD^15=H8SCGIWXH ]$N]7TVPF2&\U"TMY9,;$FF5&;)P,
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M1Z$;ZB'AS7 H4:YIX"IY8']D)PG]W[_3VH \VT^.S@^#7@BY18$E_MFT<R
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M]]]-C\.:Y%=O=QZWIZ7,G#S+I"!V^IWY- &#I]MI\GQ#^(?FPVS%;2T!W*O
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M.3@9(..V,'OQT&F>(=7?Q7J/A_4K.Q6YBLTOK5K>9RC(S,FUR5R"&7J!T[4
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M-NX4YPHP3WJVGB;Q-?>*M9T6PTK3?^)9):EY)KE\-'*"6QA?O8' Q@8/)R*
M.VHK@+KQ]?M8+J^EZ9)?V(N3$;6&TF:>2(.4,J.!L[%MOIW!X%K5O&5Z&U@:
M+:+</I;^6T3VTTAN9 @=D5D&$.& !.<G/ ') .UHJII=Z=2TJTOFMIK9KB%9
M#!.I5XR1DJP/0CI7(+XVU&WU/0X-1M+6!M5NFMVL-_\ I-H,,49SDA@0O(P,
M9X)Q0!W5%<?:^+I]3UV]T^Q>Q%Q97PMIK";*W'E;E#3#G!&"6 QC ZYXKL*
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MXNN3&7<L,DN_<4! )"XP <=O>NUDM3>Z7):7X1_/A,<XCR%.X88#/..:M44
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MAK6)=5\'W>+$+HB2+<+Y[Y<M%Y?R?)VZ\X]/>MGQ;I=UKGA/5-)LC"L][;/
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MX%I]DU1;<1JDK&1/*0KR"H'.<]>/>KMCX0\-Z9??;;#0M.MKG)(EBMD5E^A
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ KDOB?_R3'Q%_UY/76U5O
M].LM5M6M=0M(+JW;[T4\8=3]0>* (X;JWLM%@N;JXB@@2%"TLKA57@#DG@5>
MZU1N-&TRZTDZ5<6%O)IY 4VS1@QX!R!MZ<$ U= "@   #@ 4 +1110 4444
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ IC31(</(BGT+
M4^O._B1:6T_B7P,TMO$['654ED!)&PG'TR ?PH ]$!R,CI17)W/BR_7Q/?>'
MM/T!KBYM;5+E&>Z6-'5B1R<':/E/8GV YK4\+:_%XH\-V6LPP/ MPK9B<Y*,
MK%67/?!4\T ;%%<S?>*;H#5VT?23J2Z2=ER!,49Y H<QQ*%;>P5AUQR0/7$S
M>)GN=2@TS3;$R7[V2WLL5U(8!!&QPH?"L0Y.1MQQM.3TR =!17#7/Q(B@\-7
M&J#29VN+._&GWMH95!@E+JG7^('<""!R#VK0M/%T_P#PDMWHVJ:2]C)'8G4(
M76<2^9"&VMD ?*P)' )'/6@#J:B@N8+I&>WGCF16*%HW# ,#@CCN#QBL#0O$
MUQKL-E>06$+Z?>6S3QSV]UYA1AMQ&XV@*QW'N<%2*S-&\7:9;>%+C4H='%AN
MU.2SCLH2NZ>Y,NSJ !EFY)[#)SQ0!V1N8%N5MC-&)V4NL1<;BHZD#KCD5+7G
M'F7"?&FRFU"PMK-_[$G9I89O,60"2/JQ53D8[CICGTO?\+*M/-TF806\FGZG
M.D$3PW@>>+?]QI(0ORJ>_P Q(R,CM0!W-%<=IOC/4M5U:\L[7PU,8K'4?L=W
M,UT@\M=H;S /XNOW0<]/7%%KXXF>^T**\TAK2'6GD2V$DQ\^,JI8>9$5&W('
M8G!Q0!V!( ))  ZDTRWN(;N!)[::.:&0922-@RL/4$<&N+\/>(=;U"\\5_;K
M"VE@L+QX$ABN,G"Q(=H#* 0<DDDCKC%2:+XLL%\)^&WTW2H[:35_W=AIT;!5
M3 9FR0.%55)) /T.: .THKE/^$S>WO-8TV]TPQZIIUI]M6"*<.EQ!S\Z.0O0
M@@@@8/K5.R\?W-P/#=S<Z$]MIVN[(X;@W*LR2O&752@'W3@@-D'CH* .WHJA
MK6L6F@:+=ZK?N5MK6,N^T9)] !W). /<UD2^*KC3M7TJRUK3%LXM4;RK:>*X
M\T+-C(CD&U=I(S@@L,@CWH W;O4;'3_+^VWEO;>8=J>=*J;CZ#)Y-6:\YTZ.
MZU[XA>,--U?3K.YL?(L[>2-[AF$<121@%&P9R3D\K@XY.*ZK6M;M?#4&F6P2
M%?M<ZV=N)I?*B4A&8;GP<<)@<')('O0!N45S=UXJ.FVD1U.TAM+R>[:U@BDN
M0(W(4MO,A483:"<XST&,G%8LOQ,2#2O$-PVF":YT0*\J6MTLD,T;#(=)2!GT
M(QD'UH [ZBN(U/QQJ^DZ5+JUYX8,.G)+"JS/?+DQR8'F%0I*A20"#SSWYQT<
MVJ7"ZPMA!9K.!:FXE=9L%#G"+@C!W$-@Y'W6]L@%^WN8+N!9[:>.:%L[9(G#
M*<'!P1[@U+7$>'?%FGGP;HMSIVCI9-J=S);V>FQ,JJ'#R;B2!@#",Y(!_$XS
M??Q>^GV^L2:UI<MC_9SQ(L@?=#=>9@)Y<C!03N(4Y VGJ: .HHKC(?B#;IK%
MUI][!!^ZL7ODGL+H7,;JF=R$[5VN ,@=".]:NAZ_<ZR;6865O]ANK4W$5U;7
M7G*""HV-\HPV&]3]TT ;U%<]XI\3OX:.E[=-EO!J%['9+Y<BKM9\XZ]>A]!Z
MD53;QE<6Y@L]0T^TT[5Y4DE-M=ZBBQI&K;5;S ISN[ +V.<8Y .MHK@D^)J2
MZ+IU_%HUQ(UUJJZ5-$LR_NI2<?*W1P1R", Y'(K2L?&>-0UNRUNP&F2:5;K>
M.XG$R/ P8[L@#!&T@CGV)H Z::Y@MS&)YHXC(X1-[A=S'H!GJ?:I:\O\67UW
MJMQX&U"?1XK>"?6[:2&8S!ID5E8A77:-N1S@,0",5M:U\1;;3(M0N+:&UNX-
M/G,-Q']M5+ARI ?RXL'=M)QR5R0<=B0#MJ*XN\\<WIUV32='\.S:C.=.348"
M;E(1+&S;1RWW>_7GIQU(;K'Q$@TV#4+B"WM;A-.D\NYA:^5)V88WB./!W[<X
MY*Y(./4@';5%!<P749DMYHYD#%2T;!@"."..XK!_X29=4O?[.T>TBOI#9I=S
M_:)3%&D<@/EJ?E8[F )QC@#GL#C_  DX\$O^X\C_ (F-W^YX_=_OF^7CCCI0
M!W=%<EX@\97&B)K-PNCM)9Z0D;SS33&'SMPW$0_*0Y ]QSQ3[_QC-!X@TW2;
M/1Y;I]1M'NH)3,L:G:%X/7 ^89/Y T =541N8%N5MFFC$[J66(L-S =2!UQ7
M*6?CV&7P]=ZA>V$EO>VNH'2VLDD$A>YW!51&P 0=R\X&!GTK*_TMOC7I;WNG
M6UK,VCW!\R";S!(-\?!)53D?3H1SV !Z+17)_$'6M4T/1+6;2XX2\]];V\CR
M2%2JO(H^7"GKTSVSGGI5V3Q!=-JXT6ULK>;5$M1=7"-<E8H5)*J-^PDDD' V
M] 2<<9 -^HA<P-<M;+-&9U4.T0<;@IZ$CKBLKPSXC@\265Q(L#VUU:7#VEW;
M2$%H94ZC(X(Y!![@UQ\\]YIGQ;UM]&T9;ZZETBW=HA,L"D^9)EF8]S@#H?RY
MH ]*HKC+'XBV%[H=I>&$6M[<7<EBUI=S"/R9XP3(KOT  &<X.<@8R<5?\,>+
M8_$-]JE@T$<5WISHLA@G\Z&57&59),#/0@C P>* .DHKE=<\6WNF>)8-"LM"
MEO[JXM)+F!A<+&KE",J2<XZ]3^1JIJ'C_P"QVUXR6=I]JT^)6O+2?4%CD$A0
M.T4>%/F, 1SP"3@'K@ [6BN,7QZ]YJNF6.F:+/<_VEIQOK>2298A@%1M8<E<
M;N3[< T^S\>PS>')-0N;"2"^34#I9L5D#EKH/L"*_ (/7.!@9/:@#JS<P"Y%
ML9HQ<,A<1;QN*@X)QUQR.?>I:\XCEFB^-<=QJ%C;6;#P_*[RPS>8KJ)DY+%5
M.1@]1TQSZ7E^)%J;G1W^SV[V&JS+#"\%X))XBXRAEB"_*#W.X[<C- '<T5QN
MG^-=0U/4[VV@\.2""PU V=Y<27<:B% @;S,?Q=>5!Z8YYP(/^%E6GFZ3,(+>
M33M3G2")X;L//%O^X\D(7Y5/?YB1D9&>* .WDD2&-I)75(U&69C@ >I-$4L<
MT22Q.LD;J&1U.0P/0@]Q7!>+];?6_!OBN.PTR&\L;*"XMI9I9MI,BH=YC7:<
M[">I(Y!QTS73>$L_\(5H>!D_V=;X_P"_:T ;-%<!H7C2^BTOQ1J_B&*WBLM-
MU">#]Q,SLOE[$$:J5&<GOD9+=!6S)XIN-.UG2['6M-6S35&,5M/%<>:%EQD1
MR#:NTD9P1N!((H Z:HGN8(YXH))HTFESY<;. SX&3@=\"N:^(^M:CX?\!:IJ
M6EK%]HBBP'D<CRPQV[E !RPR, X'\CA^)6N8?B+X(O&TV%M19+]#%!*&W?NE
MV@R,J\#.>G'.,]P#T:BN/L_'L)T?4[K5++[#=Z=?"PEM_/#JTK%=FUR -IWC
MD@8YSTJ?1O&<>I>)Y]!FAMQ<+;"ZBGL[K[1#(F[:06VKM<'L1TYH ZFH([VU
ME>1([F%VC^^JR E?KZ5Q'C_4)[GQ)X5\)12R0V^L7$CWC1L59X8E#&/(Y ;H
M<=A[UT&K>$-&U/1FTY;&WM@JX@DAB"&%AT*XQCZ=QP: -ZBN?F\17-QJ6I6&
MC:?'?3::$^T&6X\D%V7<(T.ULMMP3G &1SUQDGXC6TVF^'[^PTRXNH=8NOL@
M!=4:&7YLHP/<%&'8>] ';45QEOXQUFYU+5M(C\- ZMIXCD\K[<ODO&X)5O,V
MY!X(QM//?'-1'XC))HGAO4[71KJ=-<E\A$6108Y,-\O/4Y0C/ [DB@#N**XN
MQ\>3&[UK3]6T&YLM4TRU^V"UAD%P;F'G#1D 9.1C&.I^N+ECXLN)?$::'>Z8
MD%W+IYOXEAN?,X! *,"J[6^8>HZ\T =117GT?Q+N6\/PZ\_AV2/3!>&UNI&N
MEW1?OO*#*H'S\XSTQGC-=!%XDF_X3>3PW<6"PYM3=P7)GR)T#!2 NWJ">1GT
M/- '0TUY$BC:21U1%&69C@ >YK/T34Y=6M);E[988A/)%$5EW^8J,5W]!@$@
MD=>,&J_C"&*X\%ZW'-&DB?89SM=01D(2#0!KQ2QSPI-#(DD4BAD=&!5@>001
MU%/KS3P[XRN]#\.>$(-1T*:'2+NUM;2/41.K;96C4+NC'*J3T.?J!73Z5XJD
MO=7UW3;VRCL9M)"LQ>XW"1&4LL@^487 //8@C% '24V22.&-I)75(U&69C@
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MOG2JF[Z9/-6$DCE!,;JX'7:<]L_R(H Y'POI6KV%YXJ>>V^RG4;Y[JTE9T<
M&-4&X G!RN?2N:L_#/BK'A>YN-(M/[0TV],E]</>AGNB4=3*6VYQ\V<<D=
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M#S.,'('K0!Q7PNMAJ'A&#Q'J(6YU;5R\]Q<.,G;O(6-<]$50 %''6M*Y73/
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M-I+RB]?[8SO<,\1C:8MLR23S@Y)SC(JY+X1O;_Q'IFLG38M-UBVO=]SJ-M,
MMU; GY&48+,PV@Y''.">A .N\1Z[;>&?#M]K-VKO!:1[V1/O,<X 'U) K(?Q
M3J5MXIT_0KG2(#+?6[7$<L5WE5"D;U.4&2,@CU]JL^.G7_A#-1@Q:O+=1BUA
MCNON222$*J_4DC'IU/ KG-(.L:/K%C/JWA3;E5L(KT:P+IXE)X4(RJ<$@9(Y
MP,G(% %_1_&NL:N;B>/PRWV*TNKFVNG2[#R*T(.-B;07W$8[<D=>:GL?&=T^
MO:/I6H:9';3:K9O=11I<%I8"JJQ25"HVG#=?4$=LU7\/Z#KVG^&?$ECF*RO[
MZ[O+FSG23>$,Q)0GC@J2,\&LS3O#/B2+5O"5^^EZ=;_V7'<17:K=EWD:1$4R
MD[?F8E2<$YYY/H 33?$?4XM"U;6!X<0VFD7TMK>9O1NVQL%9HQL^8\DX.T8Z
M$]M&?7-9;XI6FD6\=JVFMI+W6&F96;,L:ES\IY'("^YR1TK'E\):]+X%\7:-
M]EA6[UC4+FYMSYXV*DKAAN..",<X![5LR:+K2>-])UVWMK9HAI;:?<I+/M,)
M,B/O& =_W2,<?A0!5O?B5#;VJ:E;6]M=Z<;GR&6*ZS=;-^PRB(*<C(SC.=O/
M'2M'4==FU3^W+#2].M[V+3D,5RT\VQ7E*;C&@VMD@$9)P,D#U(R?#VC^,_#:
M/X<MXM/FT997-IJ;SD2P1,Q;:8MIWL,G'('3/I4MKH7B'0/$'B :=:6M]I>M
M2FZ5I+CRGMIF4*X8;3N4X!&* +WPN_Y)AX=_Z\U_K5'1_%>HQZEXPNM;%K'I
MND3[2T4S,8T6)7PJE1N)SDG(Y.,=*V? >DZAH7@G2]*U..%+JTA$;"&0NI Z
M<X'/MS]:PY?!FHWMSXRTVY%NNEZ\WFQW2RDR(QB5,;,=F4'.>GUX -&?QC=:
M:-&NM5TM+?3M5E2!)8[C>]O)(,QB1=H&#T)!.#ZCFM3Q?J5]H_A#5M2TY(6N
MK6UDF3SB0HVJ3G@')XZ<9]17/-X?UO7=$T/1=:M885T^X@FNKF.8.MP(?N[!
MC(W$#.[&!G&:Z?Q)ILNL^%]6TN%U26\LY8$9^@9D*@GVR: . UN>]EM/AU?W
M=I'+?M?Q;3'+O:0&W<\LRK@D\D<CW-=%:^.3 GB-==L$LKC0_+>98)_.25)%
MW)M8JO)Z8('-9\VA>(KJR\'+-86R2:/<QRW"I<[LHD1CX) RQ))QTQCFFZCX
M+U'6M2\:+.%M;;6X+9+6=9 S1O"#@LH[;L'@]!VH U;'QH\_BBST:>VM76]A
M>2&XL;K[0L;(,E)/E&TXY![XQ5#XT(K_  FUPLH.T0D9'0^<E:OAR7QE</#'
MXAL]/M$MQB2:UG,ANVQ@$*5&Q?XNI.0!P,U'\2-#U'Q+X'O]$TN*-KF[V /+
M)L1 KJQSU/\ #V% '.7FG_:?B3X8N_#&FSVBVZ2?VK<K:-;Q-"5&V-LJ [9S
M@<D=:VY?'-S:W&E->Z1]EM]3U$V$4<TQ6Y7YF59#&5^Z2O8\!@><UUUJTK6L
M9FB\F7;\R;@V#]1UKS >$?%SZ9ID=Q9Z=/J%CK4=_/>O=G?>JKL03\GR *P&
M.<8P!0!T2^+]:NO$FK:-I_AQ)WTR>W2:1[X(#'*N[>/EZ@8.WV//0'/T/Q+K
M-UX=\67^JZ?9WD5E=W<1@2X.&6(!3& R8VX!Y[DG@9K8\/Z3JEEXU\2ZG=V\
M:6NIFW,+)*"08H]AW#MD\CD^]9MAX=UVPT?Q?I9MK62/4KF\GM)5G.7,_0,"
M/E"Y.3D^PH TM/\ $Z2Z9X<M=-T^%+O5+!;J*U#[(K:$(I.2%Z NJ@ <^PSC
M/U_Q5<6_@75-1UCPJ)/L=U]GFL[EP8I@'4+*A9?F0EE(^4=#Z52;POXDTRU\
M)ZKI4-K+JNC6 T^[LI9]J7,6U0=KX."&4$9'\L'1\5:-XC\2> -0T^2"U34K
MYXRD"SYBMU5U;!<J"Q^4\XZG'09H MZGXLU*V\7-X<T_0UN[DZ>;V*5[H1H1
MO"8;Y25'7GD]..217TKQW<ZMHK2Q:#<#5H=2&F75EOW+;R9Y=G"G]V!SNQ[>
M]4KJYNXOC1;2PV+3,?#C>9"LBAU'V@="3M/..XX_(PW?@_7H].FN;1;>:ZO]
M;&HZA8&8I'+!C:(-^.< *3D8)SVX(!H_\)](ND^*+C^SH9KGP^294@NLQRKY
M?F95]O!QD$8X(J6T\9W[ZSH-I>Z,EM:ZW"S6LRW6]U=8_,(=-N ",X()Z<@=
M!C2^%/$31^.(A9:>B:]:I';+%<'$;>0(MI!4<#U[XX'/&C-H.L27W@B<6D>W
M15;[6#,.IA,7R>O//..* +'@?6=:UB\\1?VG':B*UU:6V0Q3,WE[$C 4*5&1
MU.[(Y)X%=C7$:5IGB/PZ?%;6UI83K=WLVH6;R7)7>SJH",-OR@;3DY_Q'3:#
M?W&J:#97UW;K;W$\0=XU;<H/L>X/4>QH Q]-\6S:S<R#3[2VF@@OGL[A1<GS
MX-K,N]X]O )7(&>A!]0*P\<7'_"/>)]3.E1^9H%S-!)#]J.)A&BN6#;.,ANF
M.W6L^Y\(WNH^(M.U<Z;%IVL6M_OFU*VF 6YM0Q^1U&"S,NT$$8'/S=J@O?#'
MB2.S\;:396EG+:ZX\US!=/<;2K21!#&4QURO7.,'/;! &:G>W$GQ'\-ZGINF
M)/>7>B3N(FE$8Y,1&]\9P,]0"?:K5QX[^U>#?$<VI^'$:]T8F+4-+FF5XV7;
MN#!BI#*1R.*L+H.N66L>&M7%I;W#Z?IKV-U;PW&&RVS#(64!A\G(..O>L_Q1
MH<UAX$\=ZM>;!?:M TDD4;;EB1(PD:9[G R3ZDXZ4 =%>^+(+.:TT^W^PQ7<
MMFMUMNKGR8HT/"C(4DDG(  Z*?8&KI?CU=5T[33#ISQZI?W,MLEI+)A5:(%G
M??CE N""!SN QSQ4U'1?$FGZWIGB/P_!;7<O]G)87NGW,IBWHIW*RO@X8$L.
M1TIVO:#XHOAHGB"U:R.O:9/)+]B,A$#12*%>(/C.< '<1USP!@4 5_%WBOQ%
M8^!_$5RFE"POK"00B=Y&,<B/@"6$[1D_-T.,'N<8KO+9KEK56NHH8[CG*12E
MU'I\Q4']*Y#Q#HOB+Q7X#U>QO(K2SO[R-!!:),9$BVL&^:3:,LV.PP./<GK;
M![R6RC>^@B@N6&7BBD,BI[;L#/Y?XT <-H7C._MM(\5:SXA2 6FFZE/ /L\K
M,P*;$6-%*@$$]\C);H,UM3>*;O2]9TFRUK3HK:'57,,$\%P9!'-C(C<%5ZC.
M",\C'O7/R^!-5U#0O%_A^Z-M#:ZIJ$M_:7:2EF#LR.@9,< ,G)SSVK6GT?6/
M$L_A\ZU9Q68TJZ6]G9)@XFF12J^7CHN6+$M@\ 8YR "S\1M7U'0O 6K:CI?E
M"YAA.'D8CRP>-RX'+#/ .!_(X/B-[Q/'?@2Z;3X'U _;E$<4V0W[CC,C*#CN
M>..< ]^H\;Z)<^(_!6K:1:-&MS=0%(S(<+NR",G\*R;O2M>U#Q-X3U:>PMXE
MTW[0;J-+G=M\R/8 I(&XCJ>GH,T /L_'@72=8GU>R2SO-*O5LI88Y_,21WV^
M65<A>&WCD@8YS4^D^,&OO%+:'/;6Q+6WVB&ZLK@SQ'!PR,=HVL.ON/3I6#=^
M"=9U*'Q8FZ*RGU"_AU#3I_,#[)(@FT.!TR4[9X/M73^'I_%=XZOX@L;'3UB7
M:4M;@S&=_P"]R!L4<\9))/48Y */C;6=8TO4?#=MIJ6YBOM26"4R2LC-A68+
MD*<*=O)Y],<T:OXW-C)J,%I%82W6FHIN(9[WRB\A0/Y<?RDL=I') &2!ZXL>
M,]&U+4WT*[TN*":;3-22Z:&:7RPZ;'4@-@X/S ].U93:7XNT#Q7J&H:-::?J
M-CJ_ERW$$UR83;3J@0LK;3N0A1QC/';N 2R^/KR>[T6VTO07N'U>QDNK<3W
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M=Z[+9; XLY0[,Y4JI0@E< \_E]: -NRUO2M2NI;:RU&UN9X@&DCBE5F4'H2
M>GO5^N)MK];"7P[ VF6#>(+^U-O;2(QQ';(BNQ9]H; ./E Y)'(Y(6?QQ=62
M>([2YTV$ZKHEK]M,2SE8[F#:6#HVTD'@@@C@]^] ':U5;4K%-133VO(!>R*7
M2W,@\PJ.IV]<>]>=^(_%OBS_ (0.;6(=-L["WGAM&AF^U%Y,3,JL-H7Y2-PP
M<\ ^O M:Z^H1_$WPO)'9VTFH/I]Z"@F*QYS'@E]N< ?[)/M0!Z)5=[^SCOXK
M![J%;R5&DC@+@.ZKC) ZD#(K'\(^(9_$%C?&\M([:]L+Z6QN$BD+H73'S*2
M<$,#R*AO-9:'X@Z?H[:9;,T]C--%>E_WBA2H*8V_*"2.YZ=* -.?0--N=;M]
M8EAD:_MU*12B>0;%/4!0V,' R,<UIUYQ-\1-:C\/ZOK8T"U%KH]_+:W:F])9
MEC<*QC^3D\D_-M_&O0V=FMR\(5G*Y0,< G'&3S@4 0W^I6.E6C76H7D%I;KU
MEGD"*/Q-6J\8U75-6USX%>(+W5Q;R,TTP5XV)(*W6W 4C@#  Y/ KO;;Q+J<
M?C"#0]1TRW@2\M)+FSDCN"[?(5!60;0 <,#P2.V3UH Z"WO+#5(KA;>>"ZCC
MD:WF",'"N.&1O<=P:M 8&!TK@K3QQ#9^&=7U:?3+:P^RZR]A*(Y,QA_,5&F=
M@HXRVXG&<"NIT>^O+X3M<1VQA!4V]S:R[XYT*YW#TYR,9/3KS0!/<ZQIEE-Y
M-UJ-I!*!G9+.JG\B:L6]S!=Q"6VFCFC/1XV# _B*\^\>26]O\2O ,]Q$TD:-
M?[@D+2L1Y(Z*H)//H*9X @&I^,M=\5Z1&+;PW?Q)%!&,+]HF0X:78/N=".<$
MYR10!Z317!WWQ#DAL6U2PL$O;".Y,+0Q,[7+H'V-(BA2#@@G;GE1G(Z5?D\7
M37&N:GI>FQ6DEWISQJ]I-,4FF1E5C(@Q]T!O?)4\CB@#K::[K&C.[!44$LS'
M  ]37%V&KZ_<?$G7].V6;V=G:VQAB,S+@/YAS]TY8D#/H ,9[QZ!XPU_Q#H<
M>L)X>LTL'AN"P>^.[?&[*%QL.5(7&?7/ &,@'9V=Y;:A9Q7=G<1W%M,NZ.6)
M@RL/4$5/7%Z-XN2Y\/\ AA;'3H(+S682]O:JVV*!$7<Q) Z 8  ')(Z<D9_B
M_P 3>);+P+KEQ_9T=A>6=RML)S(2DT3LJB2+C(/S]^A!Y- 'H4D8EC:-BP##
M!*L5/X$<BJ.C:'I_A^Q%CID#06P8L(S*[@$DDXW$XR23^-9.H>)I[*_ATEEL
MH]3:W-S*7D<Q1IN*KC"[F+$'L,8/L#0L/'LE]IFF@Z4\&L7]Y)9QVDS%4W1@
ML\@8KDQA1N!QSD#WH ZN'4K&XOI[*"\@ENH &FA20%XP>FX#D9P>M275W;V5
MN]Q=W$5O G+22N$5?J3P*X7PW]K_ .%M^)Q>PP1RBPM/F@8E9!F3#<C(/;'/
M3K5OX@V>M[M%UK1K%=3.DW+3S::S8,ZE"NY?]M<DCW/X4 ;5]:>'/&>F"SNC
M9ZI9EA*$28."5/4%3VS^M:\$$-K;QV]O$D4,2A(XT7"JH&  !T%</X8U_0?%
M&HZAK.A1K;:\MKY%Y97D9BD5@<J9 .3@Y&1GKCBJWA;QGJ"?#[1]4U6.*XOM
M5N5@M$24CS99)'X;(^10 3QG"K]!0!Z+17*GQ:^F>(WT;7H8;<M9O>V]U"Y,
M<B)_K%((RK*.>X(].E%GXCUF[&BWT>B"33-4(.8Y,RVR,NY))!C&",9 /RYZ
MF@#H++4K'4A,;&\@N1#(8I##('". "5..AP1Q[U99E12S$*H&22< "O,_"NJ
MMI^H>+;#38(;G5)_$,[16K/L 39$&D8@':HSUQR< 9)KTJ+S3$OG!!)CY@A)
M&?;- &9<G0?$UK-IL\EAJ4+C]Y!O63H>N >,'O5/1]'\+Z3J)ATT6HOD!78U
MR994'< ,Q*CU Q6#\-41-8\<E5 )\039P/\ 94_U-;+N]KXPU^ZM[>.6=-(L
MV"LVS?B2ZX+8..GH: .GJO'?V<M_-8QW4+7<**\L <%T5LX)'4 X-<-8_$#5
M)].\,ZM<Z+;PZ9K5Q%:Y6Z+2QR29VG;MP5R,=<\YP.E:L.N7$OB[Q#ID&EV4
M5Y9V<,L=TTA)G#;]H?"@@#!XYZGF@#K**Y/X;ZIJ>L^"-/U'5#$\MRAE$B.2
M6RS$Y!'R^P!/%:'BJ[:'2EL8)O)NM1E%I%)G!3<"7<>ZH'8>X [T ;,4L<\2
M2Q2+)&ZAD=#D,#T(/<4^N ^%]VUC;:KX0N)O-GT&Y,<+ELF2U?YHFS]"1[8%
M6M1\;W,5EXDU"PL(I[7P_*8ITEE*/,54/)MX(4 -QG.X@].M ':T5Q%WXSUE
M+_0;&VT.TDGUFUFGA)O3M0HH8!CY8X(93G&>HQWI]QXROT%Q:)9V4>J65M')
M=P2SL5\UEW>4A53GC'S'^\.#S@ [2BN-A\=I>VVF+!:_8[V]M&NWBOMR?9U#
M;<, ,DEL@=. 3Z T3\1+]=#L+UM!*S2ZPFE3Q/,5PS, )(BRC>I!R"=O6@#T
M"BN+C\4>(G\2WWAUM&T\:@EJEY;R"]8PF)F*_.?+W;@1T"G/M26'Q 2\\.:9
M>RVJ6^H7UU+9BW>4E$DB+^8Q8#)4!"1QDY [YH [6BO/[KXA:A9:+XCN7T:.
M6?1@D@D65T@NHV&=R,4SD="OZUI0^*M43Q1INE:AI5O!#JMM+-9R1W)=PT85
MBL@VX&0W\);'O0!UU-DD2&-I)75(T!9F8X 'J37'_#_5M9UB'6)M5^SL(]3N
M(%,3M\OEL$"A2.%P.N<GTYIVK7[:A\2='\.9_P!&@LY-5N$[2%7$<0/L&);'
MJJ^E '6^;&(O-+J(]N[<3@8]<U%8W]GJ=L+FQNH;JW+%1+"X=20<$ CC@@BN
M3M-6UJX^*6IZ5(+4Z=;V,,BQ^8P(#LV6QC!8[>G  _&N4\*>)-0\+^ (+Y-,
MMY=)BU6:&XD:X*R@/=,FY$"D$ L.I!//'>@#U?[?9_VB-.^U0_;3%Y_V?>/,
M\O.W=MZXSQFK%<R-:/\ PLA]%DTRW5AI1NTOE;=(R>:%\O&T8&<G&3VJ+PQX
MLG\30V5[:16<EC<AO.$4Q,MHP!(21<=>,'I@^N<T :TNB:3%K8UZ5&2_$8@^
MT-<.!L+9V8W;<%L<8ZUIB6,RM$'4R* Q3/(!Z''X'\JQ?$VC:CJ\5@VEZJ-.
MN;2Z$XD: 3*Z[65E*GV8X/8T:7HVHV'B/5KV751/IUZRR16A@ :)]H4G?U88
M48';^8!LF6-95B,BB1P65">2!C) ]LC\Q3Z\F\8ZG/;:[;^.(+HFRT.^%B]N
MK#Y[=CLN),=20Y _[99KOO$GB.'P_H0U(1_:3++%# BMA7>1@JY;G"\Y)YX]
M: -F2-)4*2(KH>JL,@TZN4C\2ZL/&<OAI]-M))DLA?+<"Y9%9"2H&W8V#O&#
MST.?:LK2/B#J5YX:7Q-?:+!;:,()GD=+K?*)$D**BKM (8C&<CG/ &,@'H%%
M<=;^,[A/$5OI]]9PM:W,$DHN[1G=+=D&XI(2HP",X;C.,8JM'X_GD?1KJ+3E
MGT_4YDCVP,[3VZN,I(XVXV]-V#\N>IH [JLJ\\-Z1J&JIJ=U9+)>)&(@Y9@&
M0-N"LH.& ;G!!YKE9?'.NMIWB2[MM"LC_8-S)'.LEZV)$CC5SL(3EB">H ''
M7G%R/QG?_P!J>'S<:5#%I6N_+;2BX+3(QC,B[TV[0" 1PQQ^E '9T5PNJ?$"
M6WM+R_TVQCOK:SN6MWMU=OM$P1]CM& I'!!P">0.U6&\6:U=^)=1T32]'M7E
MM[2*ZBFN+ID5ED+8W (2I^7H ?<B@#LJJMJ>GI)<QO?6RO:H'N%,J@PJ1D%Q
MGY1CG)KS^_\ &NK:KX<\':KI<$-LFKZG%;W$4LIW!@7)0,!]W,9!/4CMR:Z=
M_"-A<ZK?:I<V5D;F]LS:SH(LK+D+N\P_QCY% X& #Z\ &Y!>VMUM^SW,,NZ,
M2KY;ALH>C#'4'UJ>N!\562>"?A]!?Z8 )M"=)X]HVAT:0>;'CLK*S<=L+Z U
MW'VA6L_M,:M(IC\Q50<L,9 'O0!-17%V7C6].NZ#INH:?!;RZS%(ZVXF/GVA
M5-X652.XSSQ@C'-4)_'^N#2/$.I0Z!9F+0KR6"Y#7I_>)&JL2GR<MAB>0 ..
MO. #T,G R:K66HV6I1R26-W!=)%(8G:&0.%< $J2.XR.*QI/$K7FL6ND:5%'
M)<S60OI'G)"0Q$X7(')9CGCC@$YZ XOPN,IM/$YGA2&;_A(;O?'&VY5;Y,@'
M R/P% ':-?V::A'8-=0K>21F5("XWL@."P'7 )%6*YFYUEH_B'::,=+MF>73
MI;B*],G[S"LH*8V_*"2#U/0<5STOQ&UF/PYJ&O'0;466F7TEM>*;PERJ2!"8
M_D^;KGYMM 'H]5;_ %*QTNW^T:A>06L.<;YY @SV&3WJ>0R>0[0A6DVDH')"
MD]LG!P*\:U35-5USX$:CJ.KK!)(]WE'C8DY%_C&"/E P .3P* /:**Y6V\4W
M\/B]]$U?3[>UCDL7OK>:*X,F$1@K+("HPW(/&1[FLY/B!-(='O(=/6XT[4ID
MCVP%VGMT?[DKKMQMZ;@#\N>IH [NJ$VN:3;7GV.?5+**ZX'DR7"*_/3Y2<U@
M_$W7[KPS\.]7U2R8K=1QK'$X_@9W";OJ-V?PK3\.Z%9:3X9M=-2%)$:$>>SC
M<9W(^=W)^\6.2<^M &PDB2KNC=77)&5.1D'!'X$$4ZN52:W\*-I/A32(4>>Z
M:>2WCD;:D$(8NQ.,G WJH'?U')JE<>.[JRM/$L-QID1U708/M,D(N"([B$J6
M#HVTD< @J1P>,]Z .WHKAF\::U#?: DVAVQM];C(MMEW\Z2^7YGS@K@*1GH6
M( [GB@^.=2M-.\5&]TFV.H^'D666*&Z;RI8VC\Q2K%,@X!&".HH [FBN$7QS
MJUIJ6@G5M#BMM)UMT@M[F.YWR1S.N5$B[0 &YQ@G'?TJ34O'%[I4L$UYIL5O
M;3:H-/2":4K<.A?8)U7&"N><>G.>U ';T5Q\WBC7)O%&L:#INCV;SV-O%/'-
M/>%4</NZX0D'Y>@!'7D=Z9^(5R_ACP[XABTR)=/U.:."Z>6<@V;,VS<<+\R[
MAC/'4>O !W;,%4LQ 4#))/ %16MW;7]LES9W$5Q _*2PN'5NW!'!K/%]+>:_
M>:5]EADLH;9&FE9B27?=^[VXP?E&3ST8<<UBS-I_PV\*)Y4=O%!)>*I('E00
MM*^-Q SM1<_IUYS0!V%5+[5-/TM$?4+^UM$<[4:XF6,,?09(S4&CWMY>Q7#7
M<5N$64"":WD+I/&45@X].21CG[O4U6U?0- NC=:EK=G:W*+ 5=[M%=8H@"2%
MR/E'4DCD_@, &SYD?E>;O7R]N[?GC'KGTJ&SO[/4(3-97<%S$#M+PR!USZ9%
M>2/:7VC_  ]\&>'KKS4AU/6HH9892=RVK2/(L+=_NA 1]1757=P^G?&;38(/
MEBU/2I5N$' +1-E&/N S+GT- ':BXA-P;<31F<+O,>X;@O3..N/>H;O4]/L&
M1;V^MK9G&5$TJH6^F3S7'Z5;06WQFUWR(8XO-TFVDDV*!N8R2 D^IX'-9'B?
M7KCP3XSU6_N+5-0TW5;2(.XR38%<HOF@ D0L23G'7=@&@#U$$$9'(HK'\*6"
M:7X3TJQBO1?1PVJ*MR#D2C'!'MZ>V*V* "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ K
M!\::7>ZYX/U32=/6$W-Y T"F:0HJ[AC)(!/Z5O4R::*WA>::1(HD4L[NP55
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M^%SX9?5O)C%I87=PLMMIZREUMAM ;!Z#<V3@<#BH_$MMXMN]6A&F66CSZ7"
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M!Z\"@"AX4T/_ (1KPO8:/YOFFV0J6&<9)+8&><#.![ 5LT44 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !7,>/M&U/6_"[P:08C>PSPW,<,_P#JY_+<-Y;>QQ].E=/6
M5KUMJES;6QT>:"*ZAN4E/GYV,@!#*<<\@X]NO:@#D= \6Z3XH\365OJNFS:+
MXLT\.1:7289U9"&$;_Q+T;_@.<8YJ/1?%VH:;IGC+6M?E@EM-,U*>+;"&#91
M(E5$!XP<CKW)-;%YX>U'7_$VB:GJ=K96::1(\R&"=II)69=NW)1=J=SU)P.!
M6<_@&]O=.\7:)>W%J-+UJ[DO(9HRQF1V"$!E( PK(#P3GVH U+SQ-J6AZGHL
M6M6ML+35IQ:K);LV;:=AE$;/WP<$;AMY'2HV\4:Q?Z9/J^A:7%?6<-VUNEOO
MQ-<JDGENZDD*N"&P#G(7.1G%(V@:UKBZ#%X@%DBZ5<I>226TK.;F:-2$."HV
M#)W'D],>]4M(\,^*_#MU?:7IEYIIT&YN9+B&:7?]IM!(=S(J@;6P2<$GODYZ
M4 59M6BTGXL:_C:]Y<:9:1VEN/O3RYEPH'X9)Z  DUW]@;TV:'4! MR1EU@)
M**?0$\GZX'TKA-=\ 7NN^(]8OY?LL:3VL*6$Z7#B>WGA+,DGW..6P<$\9ZYK
MLM"&L+I,":[]D.H(H622T=F20C^+!48SZ4 <D@Q\?IRJ@M_PC*XSQ_R\FJL_
MQ \01^'M;UI=&L!!HM_-;7*&Z8M(D;!6V?+UY)R<?2MI?#^L+\4)?$VRQ-BV
MF#3Q'Y[^9Q)OWXV8]L9_&LB3P5KTO@OQ7HI.G"XUJ^N+F)Q<.5C65@<-^[SD
M8[=?:@#I9M>N;[6Y](T9(#/;VB74\UR"57S,^6@4$$D[6).>!CKGBC_PE]ZM
MKH]M=Z:=/UC4(I99+>4-,+=8R S$1\MDLN!QP>2,8JE=>&_$^G^)(?$&@OIC
M3W%E'::A97<KB-BF=LB.JYR,D8(Z5+KGAGQ%--H^MZ5J-FVOZ?YJRK<*RV]Q
M'*06CXRR@8&WKTYH IW7Q UBS\-7=_-H.VXM-12S?S/,B29'=566(,H)!W="
M1CUK6M?$6MMXMN_#M[96$-PVGF^LY8I7=  ^PK)D D@D'C'%5/$'A_Q/XA\*
M&TN9=-&H2W4$S(LCK!"D;J^U3M)8G:<D@=?:K_\ 8FJO\18?$++9K9KI9L60
M3,9-QD#[@-F".,=??VH Y/3_ !=K5K\%AXFO[6RU)V!D9)69<[IR#D8(."1@
M<<#K78:CXAO=-\;:3I$T%N-/U-)!%<DG<)47<8R.G(R0?8C%<Q_P@OB+_A4\
M_@WS=+,@Q'!/YL@!02^9N;Y.#C VCZY[5U'B[P_=>)/#L<-O+'::M;317=I-
MDNL,R'.<X&1C<.G0T 0WGBN6PMIIY88G2;4?[/L-@;]XPSN9L G"E9.@.=GO
MP_P_XBU#4->O]*OK!PD$:S07\=O+'#,IX*X<<.#VR<CFH_$OA&;4?#.GV.CW
M@M+_ $J>*YL9Y1N7S(P1\_<A@S _7/-7] 3Q(^Z?Q$VGQ2!=B6^GEV3W9F<
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M^&"VA,AG_P")L/WFV(Q?)\OOGG'I[T =7/X%TB>PU>U-G8A-3F$DJBT78N.
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M'IF(*,^JYZUN>(M#UB[\0Z'J6F&QEMK#S!+9W;LB98 +(NU3\RX.,CN<$9H
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M\D'&#G-8L7@75].T;PK#8W5K/=:)>23;+F5]AC<.-BOM+'8' &1SM[4 7?\
MA)_$MUXIU?0]/TG3G?31:N99;I@KI)N+?P\-@<#IP>3P*2#QLME;^+;S4-.A
M@_LB[6$K;/N:X9D39EB!R2RCIQ^%7M&T/5K'QSKFLW7V)K348;>-?*E;>IB#
M#)4KCG<>-QQCO6/-X#O]4L_&-EJ$MM!#KDZW%O+;R,[0LBJ%W JO= >#[>]
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MSCYBI# @C)SZT =O5&76-.AU:#2I+V$:A.K/';[OG90,DX["O./$?B/QA/\
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M?!7BBVO-4FU"RO#)+%!-&J_9U=BS*&'+<L3D^U '<2W$,%NUQ+-''"HW&1F
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M+,DBW"@KD$9 9?3D8Z5Z7:6OD[IYH[;[;* )YH8MGF8SMSDD\ ]R: +5%%%
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MV.3%/&'4GZ'B@#B]&_X2#3]5FL;RPT&2>_B9C/9WDSRY5<*93(I;9_"#DX)
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MUIT4 <+'I%QXH^$C^')76UU%;);"X#C/ES1@ Y]B0"#W5@1G-6;C0->O=?\
M"^JW+Z=OTGSS.D;N YDCV87*GIUR>O3 K5C\3>'GU=[5-0M1=MLCWY $A+,%
M0/T9LJPVYSG-7=0UK3=+=4OKR*!F4N%8\A1U8^BC(RQX'K0!QUUX!O\ 4H?%
M,-S=P6QU:[BO+2>W9F>WEC"["05&>4!_$CWK>\/6WBS>K^);S3&\I=J)IR.!
M*W]]RWM_"!C))],="K*Z*Z,&5AD$'((JA?:YI>FSB&\OH89"N\JS?=7.-S?W
M5SQDX% &A7->.;RVA\.S6<^IZ9827BF.-]0NA"IQ@G'')'I[UN7M_::=;^?=
MSI#&6"@L?O,>@ [D]@.32V=[:ZA;"XM9XYH22-RG."#@@^A!X(/(H XKQ+JW
M@?Q;X>?3=2\3:+%(</%+#J,9:WE'W71L@Y!^F>16)--X>CT[PC<67C/P]_;/
MAV%8E,E^@BN$,8CD0D'(R!D'!QZ5Z98:GI^J+.VGW<%TL$IAE:%PX5P 2I([
M@$?G5O ]!0!YG+?^%]3NM<U'4/%GA^&^U+3O[-C6'4$D2"+#?Q':6)9\G@=
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MP72$\MAUR,,<#C!Y.>,:7AOP]?Z#JNMNUW;RZ??WTE]&@C(E5W"Y!.<8&WC
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M&WS%*@[@1C*G'(ZBJ(\!SV-OX7MM.N(&CT:Z>[F>;*M<2.&W= =N2['OC@4
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MA2XW#VRO7VP<B3QMXJC\"WOB)AI0;1[J2WNX1"Y^U>7+L8J=P\OCD<-SZ=*
M/4J*XCQ!XQDT[Q&VCF]M-+>6T66PFOH28KN4E@4+[@%QA.,Y^;\#VD)<PQF4
M 2%1N ]<<T /HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M5K^HW&@:];VNF:G.;FYMKBU\UH96^^\1R!ENN&R >QKN** (XH5AMT@!9U1
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M\T85<,@/0 DKP2,J<5J7>EZ=J#H][86MRZ?<::%7*_3(XJT %4*H  & !VH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?6M.M!8:M?>0AN9;)HVD*@G:JL0,^F6)_&@"2'Q+H-Q*(X-;TV60@D*ETC'
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M+?O5E<!L,&]1@CTKK** ,*TLM3OM:AU+5(K:V2UC=+>VAE,I+/C+NQ5<8"X
M /4G/3&!<>#[_4]=TK5+NUL+74[&]$KZG:RL))[<$XC9=HR67"G)(')'I7:W
MEW;Z?93WEW*L-M!&TDLC=$4#))_"G6]Q#=VL5S;R+)!,@DC=3PRD9!'U% %3
M6HM0FTQTTU+9[@NF8[HD1R)N&]20#C*[AT/)KAY/A]=Q:-XLM=*@L]/CUN!8
MHK 3MY,+[6#R<+P3D?*HQ\HYYP/2** .,G\.ZS/KOA"_V6*QZ-'*EROVA\L7
MB$?R?)SC&><5@CP3XL_LBSLY)-(EN++6DU(W;RR>9>A9"P\SY/E(! _BX  Q
MCGTZ66.")Y99%CC12S.YP% ZDGL*SK/Q)HFH3I!9ZM93S/\ <CCG4LW!.0,Y
M(P"<^QH R;31-6@^(%_KTBV;6MQI\5JH65@^Y&9LE=N "6QU./>I/ NAZCX=
MT!]/U'[,9?M4TRM;R,X(DD9\'*K@C=BNFJE#K&G7&JS:7#>P27T""26!'!:-
M2< L!T_&@#'\9^&KCQ%96+6%U]CU*QNTGM[D=4'W9!^*,W'<@5!XJ\+7E[8:
M1+X=G@L]2T682V0G!,3+L*-&V.0I4XR*ZRB@#ET@\77.DRRWJZ2+YVC462.Y
MMS$&_>!G*DEF4D?=P,#KS6 ?AS+_ &'XML;%;?3(=:A5;>QCD+PP2 '<_0;=
MQ(R%' 4?0=T^L:='JT>E->PC4)$,BVV\%RHZG'85=H I:0M^FEP+J26Z72J
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MNH[JUD+!)HCE6VDJ<'OR"* ,+PGH6J:#?:Y'<M:/8WFHSWT#QLQD_>L#M8$
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MW&<#(P>]+10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %<#\6M3N;/PYIVGV\SP#6-3
M@T^:9#ADB<DO@]L@8^A-=]6)XL\,6?B[P_-I-XSQAB)(IH_OPR+RKK[C^1-
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M!%EN?3<VU1Z\^AH Z^BL^S&KC5=0-ZUF=.)C^PB$-YH&WY_,SQ][ICMUK0H
MXGX@?8M:AC\*7>I0V,5[#)-<2O*$(11A ,GJ9"I]PC"I/AOXAFU_P- \K1RZ
MG8EK*Z!DX::/C)89X8;3D ]:U-(TN^34]4OM7ALGENI5\DQ2-)LA5<*AW*.A
MWMGU<UE:7X;UC1O'>M:O9KIXTK4U0O:^<ZL)4&!(/DP,CJ/QSQ0!CP_$'Q W
MA*U\33:9IR6 OOLUU&LKF0J;@P[DXQQQUZ\\"NE3Q!?P_$ ^'[Z.VCM)[0W-
ME,H;=-M(#H<G 9<@^X.>*YW_ (077?\ A6K>%_,T[[2;W[1YWG/LV_://QC9
MG/\ #^OM5[QQ:V?B$:7IUOJ45OK\%['Y8M90TL*LO[[/<+Y1<Y(&<+ZT =+X
M?U"ZU73/MMP(1'+*YMS$I&^$,0CG)/W@ WT(KE)SJK_&I(DEM#&NA,RHZ-@1
MFX4-W^\<#GIQTKO((8[:"."% D4:A$1>BJ!@ 5S3Z'JO_"QQXB469LAIOV#R
MS,PD_P!:'W_<Q[8S^- &9X;U[7[^6\MK'1-)MM.TK4IK&:**5@2B*"/* 4#.
M3WP.>V":?9>,]1'B'0-,U&"R275DE\VUB8^=8.L?F!7.XAL@$=%YJWX?\-ZM
MIMGXE@N+BVA?5;VXNX)K:1F: R* ,@J.5P#FL;3_  7XEMSX2:6?1HVT)Y%<
M1"1O.5XRAD)(&7.<D<<Y.[F@#6'B;7-3TJ76= TZWO;..[:W2U8[9KA$D\MY
M%<L%3D,0"#D#J,X$.EZAKEQ\3O$5F]Q:O9VEM:F*$HPPK>:1SD_,3U.#P!@<
M5#I'A;Q3X?N;W2],U'3O^$?N;F2>.257^U6HD.YD0#Y3R3@D\$Y(/2M6#0-4
MLO'FHZW;36C66H6T,<J2[O,5HMV ,<8.[DGIZ&@#*T_QW(/"IU"?3[>.]FUA
M]+M[:%R$>8RE 2Q'3@L3CL>*TV\1ZCIOBVT\/ZG%:ROJ-O++87,(:)7DC&7C
M=26(X(.X$_2L./X>ZE-X1GTVXNK6#4(M7;5K&XA9I$27S"ZA@0#CDKQZY]JW
MQHFHZEXATW7-5BLXI]+@F6UM[>=G5I90 S,Y12!A< 8/WB?:@#FX/B#X@?PE
M8^)IM,TY+!K[[-=1K*YDVFX,.Y.,<<=>O/2MCQ3XJU30DUBY6"SM[73[<30&
M[))OVVEG6/##;M  R0W)Z8%90\"ZZ/AJGA?S-.^TK>_:/.\Y]FW[1Y^,;,Y_
MA_7VJQJO@_Q#?WWB@QW6F_9]<L1;H\^]I+7]T4,:X !0DEL\8))VF@!VM7:Z
MAXV^'-ZJ%1<?:Y0IZ@-:YQ^M=/XHUO\ X1SPY>:L8C(+<*2,$A06"EB!SA0=
MQQV!KGQX7UPWW@VYD?3F.AQR+<!9'7S-T7E_+\IZ#G)QGT%=1K$6H3:8Z:6U
MNMWOC*BXR(V4.I=3@$\J&'3O0!QOB?4Y]5^&OBF8W.GWM@=,=K:[LL[9,JVX
M$;FP1@=^_P" L:5XAU>QUCPUI-]:68L=6LV%NT4C&6)HH@_SY&#E?3H>YZU3
MG^'US_9_BJ/3H=/TXZY;+ +.&5C!&V&#2_<'S'<!@*!\O7GC3F\-ZQ-K7A&^
MQ8JNBQRK.OG.3(7B\OY?D[=>?I[T 5KSQKJ>FWNF_;;6S@%[JJV'V!F_TB.-
MG*),6#$8) .-O0]:E_X23Q->^+=:T33=-TS&FM:OYL]P_P \<FXMT7[V!QQ@
M8/)R*QQX$\4#1K6P:]TF1[/64U-;EQ(9+K$A?,IQPP!QQNS@#(Q73:-H6J6/
MC77-8N39M;:E';HHCD;>IB5AD@KCG=G&>,=Z ,B[\>:D^GG5](TN6_LTNC%]
MDBLIWFFC60HTB2 ;,\%@N#P.H/ NS>+YY_$>I:-92V,5]9/&([*[#++=(RJQ
MD0[@,#<PQ@\KR1GBGI/A?Q;X?N+G2=,U/33X=FGDEBDF1_M5JKL69$ ^4\DX
M)/&<X/2I?%/@Z_\ %$=U:W4.G%?/233]1\QEN;,#;G "<G(8CY@#D9Z4 ==J
MES/9Z5=W5M%'+-#$TBI(Y56(&<$@''Y5Q6G^-];/AFT\1:CIUBEA>VT MHH)
M':9KF5U15(VGY#NSQD@#H3Q7:ZG!/<:3=6]L(VFEA:-/-8JN2,9) /\ *N27
MP1>W/POM/"]U=Q6U_9QQ"WN[<EU62(AD?! [CD?K0 ]/%VKVNI:A;W6D3WEK
M#I[WL-W;V,T"LZ9S 1(#\QQP0>?2I=&\3WFMZ:VH6%YI5[:&S:82P*P,,PVG
MRG4N3T)YX/'3UEL+3QM-IUU_:]]I,5XML\=K]A638TI7"R2%NP/\('<]>,5[
M#P:Z^*I==EM;+3I)[%[:ZCL)&9;IV(.]LJH&W!QP2=W)XY ($\;WS^&?".LB
MUMP-;N[>VFB.[]WYN?F4Y[8Z$=ZCA:XC^*'BQ[1HEN!I%H8VE4LH;,N"0""?
MSJA!X'\4KX=\.Z-)=:0(]#U""XBD7S"9XXRV"PP-IP0,#/KD8P>DM/#^HQ^.
M-7UB9K7['?V<5LH21O,79N^8@KCG<>,\8[T <M8>*M;T_P"#MAXANXK+49)?
M)9_.W*?WDH4L1R&.Y@<?*.*Z34/$6MKXZ/ANPLK$A]-:]CN)Y6X(D5/F '3D
M\#KQR*Q3X&\0M\+H_"+7&F-+"T2Q3!I%4I'*),GY3\QV@8Z#KD]*WVT356^(
M47B+;9?9UTLV)B\]M^XR"3=]S&,C'Z^U &9;_$"X_P"$-AU*YLHEU)]3_LEH
MT<^2LWF^7OSUV?Q>O;WK2L/$.K/XZNO#=U;6<D<%JEW]KC9T)1B5 \LAAD,I
M_BZ<^U<KJ.C7VB>$)=!O;C2!=ZQK32VZSLS0N'D,S(Q(4J0%(##G.,8)%;GA
M[^W-)\0I:ZKIVC%[]27N+&\FFG 125+^:-Q3^$'/!8>M "?%Q[R/X=Z@UM)&
MB%H5EW EB&FC&!@^_.>U+J^L:UI7BK1]/M],TB?4-6AG4W9+1X\I=RAN"=HW
M>I[\#.:T_'FA7_B;PI<Z/I[6T<L[QDR7#L H217Z!3G.W';K46J:)J^H>+_#
MFLJEBD6F+<":,SN6?S5"_*=G;&>>O3CK0 VRU_6=2U*XT6%-/@U/3K6&74)&
M#RQ":0$K&@RIQA22Q/&1P:R&^(U]+HNFW=OI4 NGUM=&O[>28_N9=^UMI ^8
M=P3C&1P:V'\/:EIGC:]\0Z.;6:/4X(XKVUN96B^>,821656_A.""/?/:LJZ\
M!WZ:58PV<MH]W_;RZY>R2NR*\F_<40!3QC"@G^[GO0!:B\1>*)/%&H>'&L]*
M%Y':QWEO<"23REC9F4AQC<S!E[8!'/'0['@WQ!+XF\,6^I7%NEO<%Y(IHT;<
MH>-V0X)[$KD?6JL>B:K'\0;GQ#MLS;2Z:EDL?G-OW*[.&/R8P2V/UYZ5)X'T
M*_\ #GA\Z=?M;/(+F:96@=F!$DC/@Y4=-V/PH S=-O\ 6KCXJ:W8RW-N;"UM
M+9DB\MLJKF0\'/WB1R?0#BN5\)^(=6\-_#K2[^.SLY-)74I()][MYQ$EVZ;D
M &!@L.#G//2NW&@ZK:>/;[7;.6S>TO;2*&6.8L)%:,MC;@8P=W)/3T-<^/ N
MNCX;1>&/,T[[0EZ+GSO.?85^T>=C&S.?X?U]J -G5_%EZ+W5K31H%DGTQ5#*
M]G-,)Y2@?RP8QA/E*\G/)Z<9/0Z)J,NK:)9W\UE/8S3Q!WMIU*O$W=2" >#[
M5RUSX=\4Z;XKO=9\.76E^1JBQM>VE_YA6.5%"[XV09/ &0<9Q^78V<,MO9Q1
M3W!GF"_O)2,;F[D#L,]!V'% '%W'C74["^TE;^ULX/[0U,6)T\M_I,*,S+'*
M6#$$':#C:.&Z\42>)_%=]K?B+2M'TK2S/I#1;6N+A]LH>/>!P!\QR/0#U-9D
M7@3Q2FC:;8/>Z3))IVLKJ0N7$ADN\.S9D..&PV.^<#D8JSHCZLGQ(\=BPALI
MF+60)GE:/:_V<8. K9'MQTZ^@ 6WQ&U#5;?PI-I>DVY_MWSXV2><J898E;<I
MPOW0R]>3@=,T]?$VIZAI_C#P]KUG;6^IZ?8/*'M69HIX7C;#+NY&,8(-9M]H
M4GA?5_ASI.GM'<3P7%X2TQ*+*[0LTAX!VY+-C@XXKI9/"]]</XCU*4VHU/5K
M06<48D8Q01JK 9;;DDEBQ^7T';) ,FPURYT3P+\/5BL[:>*^-A9N\K'=%OC'
MS*,<G /.>/>MNY\0:M?S:Y'X>M[:5M(;RBDX)-S/L#F-2& 3AE&XYY/3 R<V
MX\(ZU)X8\(:6C6'G:'<VLTK&9]LHA7;A?DX+9SST]ZD;PWXGT?Q5J>H^';O3
M#8:LZRW,%^LA,$P4*7CV_>R ,@D=.HH N:EXAUFW6)C9VNF1_P!GBY>:^;>O
MV@_\NPVL/F&#EAGM@&L#4/%6L:Q8>!-0TYX+.'6+I#/"ZLYW>6S;<@CY05^I
MXZ=#KW/AC7E\4KJ-O?V=S;OIHLF:]#&2!LDM(BKP=V1D97H.<#%9MKX'UZT\
M*^%;,76FO?Z#=K* =XBDC"LA&[&=V&ST [>] &XOB.>#QW=Z1?6UI%!;Z0+X
MW:,2Q&\J0<C@##''/;FLVY\<:C:^$;;QD]G;MHLA222V ;SX[=VVK)NSM8\A
MBFT=2-W&:OMX9O[GQS<:O>&SDL+C2!ILJ*[!V^<L6QMP =Q&-W'K69;^"=7_
M .$+_P"$*N[BTETE6$0O5D83M;APP0Q[=H; V[MV,<X[4 79/$NOWGBW4]!T
MNRTW_1[2*Y@N)YG*L'+ ;@!G^'H/KGL=?P?K[>*/">GZR\ @DN4.^('(5E8J
MV#Z94U1M-!U.S\<ZEKB)9&TN+**UBB\Y@R^66()^3 !W8[XQWJ?P)H5[X9\(
MVFCW[V[S6QD_>0,Q5@SL_<#'WL?A0! OB'5-7FUL:!%:,NDSFU(N0Q-S.JAF
M0$$; -P7<0W.>..>7\3>(YO%'@_PEK&EF.&UOM8L@T4RDLL@F^Z<$94,O/KC
MM716/AW6/#VN:W<:,;*>QU:;[68[J5XVM[@C#L-JMO4X!Q\I&,>]4KOP)=VO
MA3PYH6CR6SII-]!>R2W+LAE9'+M@*IQN8GZ>] '9VEJL >=X;=;R8 W$D,>W
MS& P,]S@<#)KCHO&NIPZMH-MJ-M9POJMP\$E@K$W%G\K,A<AB&R%YX7KQG%=
MLZRRVK(6\J5D(W(=VPD=1D#.*\XL_ WBB'3O#EO)=Z/YFC7YN#*!*QN05<&1
MSQ\YW9([G)W"@"W<>,?$KKXJ-GINEJ=!D.XRS.PE01"3 P!\Q!ZG ''7J+T_
MC"]CO/"ES]GMX]&UY4!F?<7@E>/>B'G!W?=!]>U11^%M91/&0/V G72Q@Q,_
M[O,0B^;Y/09X^GO5;7+"TM_AC'X7U6\M4U6"PBCMHX)LR/-'A8GC!PV2ZKV[
MXS0!UFF:A=7VJ:HA$/V*UF$$3JIW.^T%\G., G;]0?2M6L_1--.DZ-:V3R>;
M,BYFE(YEE8[G?_@3%C^-:% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<SX
MW\0W_AK1[>]L+6"X:2\AMW69B.)'"\8[\]R/QH Z:BN%7Q?K.B>*SI7BBVL%
MM;FSFO+2YL2YVB(;I(W#=2%YR,?3GA+;Q?KMQ/H=U#IC75CJ3HL\,=A.CVBN
M,JYE;Y'4<!L >HXH [NBN#TKQ3XDU"ZU::6WTB#3M'U.:VO'+2%VA2-6)3_:
M&<\\'..,9-_3]:\2ZC:Z'JUM86<VFZD4>6W&5EM8'7<LA<MAR!C*A>_'3- '
M6T5P%[XVU>:PN=3T+3S>Q6]V\*V0L)W>Y1)#&[+,/D4Y#$#!X')R<"TWB+Q)
M>^+M3T+3K?381;V<-U#-="1B-Y88=01D_+T!&/4]* .RDBCEV^9&K[&#KN&<
M,.A'O3Z\MN_%>M:]X>\#ZG:S6]C_ &GJB074/E,X+KYG?<#LW1YQU/'/'.WX
MG\4:WH,&K7!73X8K"T6:W\]2S:@P4M($57R@7&.0W7/04 =O17*S^*9Y]7\/
MZ99Q10RZM:/>&6=2ZQJJJ=H (W,2X[\ &LJQ\>:A_9&HW&H6EL)[?5O['A%N
M)")9MX4OMP3MP=V!D\$=: ._HZUP_P#PEFO6=SK"7&D2WUM:Z<][:W4-C-;+
M)(N<P,LF3NZ$$=NV:TO"WB&3Q#BZMM1TW4=.:$-YMI&T;QRYY1U+L1QSS@]?
MQ .EV+_='Y4;%_NC\JYW7=>O-*\3^'=/B2![75)Y(9-RG>A6-G!!SCMC&*RK
MCQIJ%D_C)9;2*?\ L+R3$88VRZR(')89.=N><=0#TH [?8O]T?E1L7^Z/RKC
M4\:>3X?U+7C>:?JNF0PQ-;36*E"\K,5,; LQ4Y,?O\QXXI8?%&KVNO)!J%H9
MM)>UDFDOH]/GMQ:L@W%7\S.X$ X(QSVH Z+5-7TO18HI=2NH;9)9%BCW]7<G
M   Y/)J]L7^Z/RKRKQAJFK:[X!TG666TBL+W4+*9+;RV\V.-IE*$ONP21C(V
MC&[KQSZI+Y@B?R0ADP=H<X&??% &?976D>)]&%Q;?9[_ $ZY#+\T>4D 8J00
MPYY!'([4W2_#.A:([OI6C6%D[C#-;VZH6'H2!TKC(O'NLM\/M#U^*PL#<7^H
M+:30[F"*&G:,;?? ZD]><=JWM(U[5SXVO?#NL1V19;)+^WEM X 1G9"C;B<D
M$=1C/H* .IV+_='Y50AU?2[G5Y])ANH9+^WC$DL*\E%)P">P^E<W\0;S5;6;
MPU'IUY%;QW>LP03*\)<M]YADAA\N4Y'?U'?-E&K_ /"V]133FLOMIT&WW37"
M-Y8/FR<[ <G)[;N/4XY /1=B_P!T?E1L7^Z/RKA-,\?S:CX<\/SM;I#J6JO-
M&RI#).D7DEA(P1?F8948&1][D\5L^%M9U;4Y]3M=5T]X3:2J(+L6TD$=U&PR
M&5)/F!&,$9/;UH OW&O:):ZI'IEQJ-G%?R?<MGD D?Z+U-3:CJFF:0D;ZC=V
M]JDKA(VF8*&8] ,]_:N0^)]I-9V6F^+[*,O>^'KC[0RKUDMF^69?^^>?P-;,
MES!XBUW2DMW6:QMH5U-G'(9G!6 ?^C']BJT =$%0@$*,'VI=B_W1^5<3JGB_
M4Y/[9_L*V$TFERF!8'L)YOM4BJ&90Z86/[VT9SR,G IMYXXF75+33G:UT:ZN
M].CN[>/58FQ-*V[,.X,H5EPH/4G=P..0#N-B_P!T?E5*TU/3[^\O;2UF22>Q
MD$=R@4YC8J& /'H>U<C<7NO2?%#1[(WEO#;MI$EP]N8"P#[XP^2'&3Z'H.>#
MG-._X2_5DM?&TGV.Q\[026B4,VV11#YGS'J3CC@"@#NJ8D4:.[I&JO(078#!
M8@8Y]>*X:S\6Z\NH>%&U"WTX6&O1XVP;_-AD\GS <DX(.",8X]33-2\<:G'H
MWBC5[""S\C0;M[9K>X5M\^P*7;<& 7.[Y>#T]^ #OZR;GQ/H=G=26USJEK%+
M$0LF^0 1D] S=%)R."1UJYILUQ<:;;SW21I-(@=ECS@9Y[\]*\Q.J:G\-IM2
MLO$6D/J7A6\NIIUU.V3S&B$K$LLZ=QSC/\^@ /5()XKFWCN()%DAE0.CJ<AE
M(R"/PJIJFM:;HL<+ZC>1VZSRK#%O/+NQP  .3R16#;:W!&= \/\ AV:"9;C3
M_/BNI071+:,*H;:""Q8LHQD8Y)Z8//\ C6YUN;P0O]LV$,-Y!KMM'$87^2XC
M$Z;) ,DIN_NDDC% 'IM4X=(TVWU.?4H;"VCOK@!9KE(E$D@'0%L9/0?E7+IX
MMU'2O$>K:=K\=F8+72CJT<MF'!6)6961MQ^8C'!&,^@IEKXJUV74=&8::US8
M:@0+A8K">-K+<,JQD?Y9%[$@+Z^U '5:KJ^GZ'ITE_J=W':VL?WI)#P/\3["
MK:.LD:R(<JP!!]0:\M\8ZYJ/B;X4>(=6L39II3)-%%')&QDEC1RC2;PP"DE2
M0-IX YYXZBRUV^3QC:>'BMN;:31OMJ2;&WJP=4P?FP1SGM0!NZOK6FZ!I[W^
MJWD=K;(0#)(>YZ  <D^PJ_7E'BO7;KQ!\&O%,UY'"DMM>26?[D$*PCN%4-@D
MXSC/6NPU;Q).FO3:+IY$=Q!:I<2S/9372C>6"+MCP1]QB23Z8!R< '3T5B^%
M=5U#6?#\%YJFF2Z=?$LDUO(I&"#C<N[G:1@C/K6)#XPN+[Q+>:1;7&GP7EI?
M)"VGW,;+-+;Y7=*C;@#\I9@ IZ<]: .FL=:TW4[R\M+*\CGGLF5+A8SGRV(R
M 3TSQ5^O+TN=:L_&7Q$N=%6Q\V VDS&\#,K;;8': I'7'7/'H>W0IXIU"_TC
M0-1MHK2RL]1M!<W%W='>ENQ52L87<I8L6.#G^'IS0!T&K:UINAVJW.IWD=M$
MSA%9S]YB<  #DFA]:TU-:CT=KR/^T9(S*MN#EM@ZD^G7O7G'B/Q#-XG^"TNI
M7,,<5Q]OAAD6/(4M'>(F0#R <9P>F<5T&K?\E@\-_P#8,O/_ $*.@#I]6UK3
M="L_M>J7D=K!N"!G/4DX  ')-7ZXGXMY'PSU,@9(EML#_MXCI&\4Z[HOBZRT
MWQ%;:<-/U..9K6>S9R87C7>R2;OO?*#A@!TZ4 =O17 P>--:NXM&U*RTR2ZL
M-0EC$MM'83K);PN,K+YI^1L#!( [\$XR>D\6ZM=Z%X3U/5K**&6>SMWG"3$A
M2%!)Z<]O:@#:HKAF\5:_8V-E<:E;Z9NUB:UM],BA9]R/(I+F7/&% S\O7IGO
M5P>(=4LO%R>&]0-HTM[:/<6%Y%"RJ60_.CH7)R 0<AN10!UM%>>P^.]3F\!^
M'/$0M[19-2O8;:>':Q $DOEY4[N".O.:N2>(?$UYXJ\0:)IT&E1G3H()H9KC
MS'!\P.<, 1DG:.A&.>M ';50L]:TW4-0O;"TO(YKJQV"YC0Y\HMG:">F?E/%
M<MIOCN;6=(\+?9;>&+4]>C>3$F6C@6-<R-@$%N< #(^]UXK&L-8G\.>+?B)J
MFJB*=[6"P8?9U*"7*.$&"6()) ZGU]J /4:H:KK6FZ);I/J5Y';1R.(T+G[S
M$X  ')ZUSD'B?6+?Q!!;WUF9]*FMY));R+3Y[<6;(N[#F3(92,X(QR.G-<SX
MRU75=?\ AO::SMM(M.O+VTE2W,;>:D1G38Q?=@L>"1MXW=>.0#UBJ&I:UIND
M/:I?WD<#W<RP0*QYDD8X"@#W-3:C?P:5IEWJ%TQ6WM87FE(&2%4$G]!7FWBJ
M]UC5-%\':G="SCM;S6["86R(WF0AGW)E]V&.#@_*.3QTY /4J*Y./7]6UN;7
M!H L@NE7#6@%U&SFXF50S+D,-@&X+G#<Y...<VV\?W&H6WA+5[>""+1]:F-K
M<>:K&2WG^8*H((!!=2N2/0]\4 =I?Z;8ZK:-::C9V]W;MR8IXPZG\#4.E:%I
M.AQ/%I.F6EBCG+BVA6/<?? YKEK'QG?27?BRRN6LC=:.0+988FQ.&!V=7Y.\
M%"!T8=:EGU_Q*OC*'PW%%I7F2:4;PW#"3:KB14/RYY7D\9R>.1TH [2BN=\%
MZ_=>(=">XOX88KVWNIK2<09\LO&Y4E<\X.,\UD1WVKGXM7]I)J%N-.MM*CG6
M)H#\JM(P;G?][Y!\V,8P,=R =S17 3>-M5_X0K_A-+:VM9-)!,ILBC"<VX?;
MO$F[;NQ\VW;CMGO7;B8WFG">RE13-$'AD="RC(R"5R"1[9% $&K:UINA6HN=
M3O([:%G"*SG[S$X  ')-7Z\5N;W5-2^ !U#4KJ.ZEN+J*0;8BC;OMPSD[B#S
MTP!@<<UW4/B;5+#QC<:/K:6(MCIKZE#+:A\QJCA61MQ^;J#N 7ITH ["BN#M
M_&.MW)T.^MM,>ZL-2DC$UO'83K):QR#*R&4_(X'&[ '7@D<UO^,]9O/#WA'4
MM7L88)9[2$RA)R0I Z].3^GUH W:*XRW\2ZY!XKT.PU*"P^QZS;RO#]GW^9"
M\:*YW$G# @]@,'UZFB?'.KW=A9ZQI.FO>V4]P%-G'83F7R"Q7S%F^X3@;MN,
M<XSQF@#T&J-IHNF6-]/>VMC!#=7&/.F1 &DQTW'O^-<?XK\::OX<MM6OWAL8
MH;&5/L]I+EYKR+Y=\@*O\@RQ RIY7GKQ:UCQ#XD7QJ?#NCVVEDR:6U[#-=M)
M@,)%7#!>W/0>N<\8(!TMWHNF7]Y!>7=C!/<V_,,LB M'Z[3V_"K]<)>^+]9D
M@U4Z3;12W6F/Y#0"QN)A=3*BLZK(F @RVT9R<C) %.O/'$RZI::<[6NC75WI
MT=W;QZK$V)I6W!H=P90K+A0>I.[@<<@'<T5P;WNO2?%33+)KRWBMSHKW#VY@
M+ -YD8<9#C)XX/0#/!SFM_QCJ>J:+X6OM4TF&">XLXS,T,RL0Z+RV,$8(&3^
M&.] &[5#4=:TW29+2._O(X)+N9;>W1CS)(QP% 'O7-MXPF7QEH.FK/92:;K%
MF;B&98FW[MNY5^]@!@&(/^R1SUK&\87U]?Z-X>O)%MY WBBU^R*@*!XQ(P1F
M)+?>QG([$<4 >F45Q$7C*^TG5/$5IXB2T*:78IJ*2V2L-T1W94AB?F!7 /?/
M047OBS5]&T[1=:U*&S?3-0EABGBA1A):>;]QMY8AP"0#\J^H]* .HM-:TV^U
M.\TZUO(YKNR"FXB0Y,>[.,]L\'BK]>?6^HP:-\0O'FIW.?(M--LYY-O4JJ2D
MX]^*N6OBC7GU?2%;36N;"_XN/*L)XFLB1E29'^61>Q("^OM0!VM%<UX[U^_\
M,>%IM6L(+>:2*2)66<G&'D5. .I^;U%5K;7M=C\;MX?U&/3U6YL'O+66W5R8
MBKA2CY(W_>!R-OTH ZZBO/$\>:J_PWT[Q/\ 9[,3S7BV\T.UMI!N##E3NR#C
MGG-:4VO>(;GQKJ?AZPBTR(6]E%<PSSAW^\S#YE!&?N] 1CKD]* .QK$1_#>I
M>*7"I8W.N:?$-S^6&E@1B<#=CCOQGU]:XY/'WB%O!5CXK>RTU+-;A;>]MP7:
M1_W_ )+-&V0%^;D AN.]2W']M?\ "U]>70A8"Z.DVIWWN\HOSR?PKR<_48]^
ME 'H]%<!IGQ#GO\ 2K&*:S%MK4U]/87$2QO.D,D )D8*GS,,;<#C[W)P,U!J
M7C?Q)I?AGQ)?2Z3$9M**-;W4UO+!#=QMW"-\P93P1G'O0!Z-165HSZY(UR^L
M)8)$S*UJMJ7+*A'(DW<$@]QP:S%UW4M8UC6;#0VLHO[**1/)=1M()9F7=M&U
MEVJ 5!//)/''(!T=Q<PVEM)<7,J10QJ6>1S@*/4FJ>F:]INKSW5O97.^>T8+
M<0O&T<D1(R-RL 0".AQ@UYSXH\27/BKX6V>J6OEV7F:A;P7=M(A=EE6Y12H8
M,. PSTY!'2O3K2V:(&6X%N]XX EFAA\O>!G'!)/&>Y/>@"S1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !7#?%?S#X1MA$RK*=4L]A<9 /G+C(]*[FL;Q(?#\6GBX\1P6;V<+;M
M]Y )$C/KR"%[<T 4+CPS+KFMIJ6N+;JD%G-:06UO(S@>=@2.6*KR5 4#''/)
MSQ1\,^'/%NBQVVD7>MV-QHED5$$J0NMW)&I^2-CG:!P 2 20,=\UO:?XET&]
MN(K&RU*U,S)NB@#;69 .JJ<$C'I5K4=8L-*,2WEP$DF)$42JSR28Z[44%CCO
M@<4 8?A[PS=V \1PZD;:6VUB]ENBL+-E!(JH4.0,\+U]^E4O"_AKQ3H4%MHU
MSK-E-H=DP^SR)$XNGC4Y6-CG: . 2 <@8XSFNAB\3:+<65S>0ZA#+;VO_'PZ
M9;R>,D.!RI '(/3O5G3M7L-6L!?:?<"XM6!*RQJ2K ?W>.?PH Y&P\*>*-"U
M*^M=&UFQ30;VX>XVW$#-<6A<Y<1$':1DDC=TST/?3M= U&T\;:CKJM;/!<V4
M5K'$TK;QY98AF.T]=W/I[UMZ=JUCJR2O8SB98G,;D*0%<'!7D=01R.U7: /.
MK7P%J]IX0\/:9'>V/V[1-2^VI(P<QS#,A*D<$'$A]>GOQ-J7@O7KRZ\3A-4L
M6M]=LE@:26!S)"1$4*J <!"26]LG@]:[^L_5]<TW0;476JW:6EOG'FR9" ]@
M3T'XT >?:Q;ZB-1\-Z#'J>B#5M,L#.RW:R1(V<1JT;JP?("N#@XYR1TQ9BT3
M4/$GA^^\/3MI5A<6,L-U97VCLSQ1SAF?YE;G>",MR<B0'K78:K;:#J>F+>:O
M86MW9QJ7#7=H) @[G#*2![XJWI#Z=)I<#Z2D26)7,(ACV)M/(*C X^E &%9:
M?XRETZZ.J:KIJ:@+=HK7[%$XB#G&))-QRQX' P!D]<\)I'A1K7QA-XCDM[*R
MGFL_LTT-DS%;ARP;S'RJ\C&!P3R<FNKHH YKQ9H&H:K<Z-J.E36T=]I5T9T2
MZ#>7(K(4925Y!P>#[5G67ACQ'8ZKXBU./5+#[3JCVTD8\EPJM$JA@>?ND!AC
MDXYR*[:B@#@)OAO!J3>('G2WTQ=8M8X'@L&+()48N)SE5RV=O&!]T\G/&CI6
MB^*+JT>R\5:I87-H(7A_T&)T>X#*5+2DG'0GA1C.#GBM_6-:T_P_IDNHZI<K
M;VD7WY"I./P )-7D=9$5U.589!]J /-6\"^*6\(6_A<ZII;VEC<0O:W3QR>:
MT<<@95=1P" ,9!YQVZUZ.?.6#C8\P7W52WZD#\ZDHH \ZA\!ZQ#X$TCP]]IL
M6ET_4%O#-N<*X68RA<8X))Q^&>_'01:%J ^(3^(I&MA;/IJV!B5V+@B0R;L[
M<=3C'XY[5TM% '.^+] O-=M]+>PG@ANM.U&*^C\]24?8&!4XY'#'\J@M=!U6
M#QQ<^())+.5)M.CL]@9D)9&9MW0X!+$8YP.YKJ:* /-H/AYK-GX9T:&SU.UM
M];T6ZGN+6Y"LT4BRLQ>-UX(!#8XSTKL]#M]9CADGUV[M9;R3 \NS1EAB49^[
MN)))R<D^PQQ5G3=6LM72Y>QF\U;:X>VE.QEVR(<,O(&<>HXJ[0!'<0175M+;
MSH)(94*.C=&4C!!_"N>\#>$U\': =.^TM=2&9F\UCD[ =L:^V$"C'KFNEHH
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M9557QR%;<!^.!_*J<6L6$VJ2Z;'/NO8E#20[&RJG.">.AP<'OCBKU !1110
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MH2:9:7,%L//CF:65"_W&#  #'4CKFF:YX6N[_6-,\0:9=PV&MV@,4KE"\5Q
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M@BDVRRR)A8G13R/G4'VP>P- '6:3?7E_J6J%F@.GV\_V>W*1D.S*!YA+;B"
MQ*]!RIK.U'7-4T_QYINDR-:+I>IV\WV>0PL9%N$ .PG?C!7+#@'@CWK:T?3E
MTG2+6Q60R&% 'E;K(_5G/NS$D^YK.\7>&AXGTRWMTNGM+BVNXKF&XC^]&5/S
M8]RA8?C0!S^A>,]5U?1-2'FZ>=8MM3%A$J6[B-@6&R3:7R5*$OD$< ]<5L6F
MN:BWQ$N_#]PMJ;6+3([R-XT8.6:0H0<DC'RG\Z6W\&VMIXU&OV[^5$+-(/LB
MC"^8F523ZB-F0>QIR:!?)X_N/$?GVYAET];)8,,&&UV<-NZ=6QC% 'GTG_)"
MO&'_ %^W_P#Z/->OVO\ QYP?]<U_E7#?\()J1\ :SX::^M/,U&XFE%P(VQ&)
M'WD;<\XZ#G_Z_<VD<L=G#'/L,JH%8IG:2/3- 'EOC'6]2\4?"'7=:M)+6+3)
M5D2&%XF+R0I)L+E]V Q*E@,8 P.^1U%UXCNGU.?1M-<0RV=G#+),UC+<@O(&
MVKA", !,DD\YXZ&L5_AWK<'A/5?"-CJ]D-#N2YM3- QFMU=MQCR&P0"3@]>?
MRTK_ ,)>((-=@UW0=9LX-0>U2UOXKFV9H+@)G:X4-N5AD]_QZY ,K6-1U'5M
M.\ WFKZ:VG:@^O1B>V;^%A',,CV.,CZUT=OKFK7/CG6= !LXXK:QBN+:7RF8
M[G9A\XW#(&WH,4S5_"VIZC'H'_$QBEFTR_6_FEF0CSG 8%5 /R+\YQUP .M6
MK30+R#QY?^('G@-O=6D=J(0#N4(6(;/0YW'B@#*T/Q7J^J^%M\HLHO$"ZDVG
M2P"%C''(K_-QOR0(P7SGI1J/BK5KAM:CT-%>?2Y# D;6$TPN9E179=RD! =P
M49R0>3Q6I9^$H;/QQ?\ B))SLNX4S;8^43 %6E^I0*O_ 'UZUFS^%/$&G>)[
M_4_#6M6EM::HRR7EK>6QE"2 !3)'AAR0!P>,C\@"M/XF\57?B*PTBQM+"RFO
M=':^V7J.S6\H9 5?:1D L1QCKGM@]7J3ZC#X8N9$G@AU&.U+&58R\:R!<DA2
M1D9SC)],YK*7PS?1^--/UM;R.2"TT]K%EF!,LH9E8N6' .5Z8_+MT=W;K=V<
M]LS%5FC:,D=@1B@#SWP[XCU&P\$^#X)9X+G4M;$45N[Q,!&/+WN[_-\Y !Z;
M<DCI6_8>(+^W\<2^%]5$$K26?VVSNH(R@= VUD923\P.#D'!![5DP^ -17PO
MHEC)JMN-3T&6.33[F.W(3"#;MD4L20R\'!';'3GH+'0IW\2MXAU-H#>K:"SA
MB@R4B3=N8Y/)+''88 QZF@#(\?W.JP:CX5AL+Z.WANM6CBE1X2^\[7<9PP^4
M%1QQDXYXK.V:P_Q5UV/3)[**[.CVFZ>XB9T!W2=$# \G_:X]ZZ7Q9X>NM=72
M9K&[AM[K3;]+R,S1ET?"LI4@$'HWKVJ&S\/ZG:>,K_7FN;6475E%:B/:RD&,
ML0Q//4L>.WK0!D:7X^N-4\/^&I3"D.H:PDS/Y<#S+&(3B0JB_,<MMP,\9R2<
M8.[X5U36;]M1@UBQ,1MI]MO="!H5NHB,A@C$E2.A%<U!\.=4LO#.A6]EK,-O
MK6AS3/:78A)CD25B71T)Z'('![5V>B6FJV\#RZU?0W5[+C<+:,QPQ@= BDD]
MR22<GZ "@#D/&$S0?%GP+*D$L["+4/W<6W<?W2],D#]:@TO2_$6DZMXT\56N
MDI#)J)B^Q:;-.B[B@VM+(0VU<Y+8SGKWKH-9\-ZCJ/C?0]?AN;5(=)6=1 ZL
M6E\U0IR1]W&..#5[QAH,WB;PM>:3;W?V66;85E*[ERKAMK#NIQ@CT- &-I7B
MF_O/%6H:&ES97BQZ<E[;7D<+(A)=D*GYB'7(R"I]1U%<^/$OC/6/AA=>)Q<Z
M590-I4\X$,+M,LBDX*DM@ @'U(X//0=);>&=>C\7'Q#/J6GO+)IHLI(([9E4
M$.6&TEB0,GG.3].QI/@RXM/AE+X/N[V)RUI-:K<Q(1PX;#%2>HW>O.* *<FM
MZSH6A>#1OLKA-1N[6RE;R65E1TSQ\Y^;Y3R?7H*OR:YKFL'7CX=6S#:3.;6.
M.Y0L;F=45V7.Y0B_,%!YYR>G%5[OPEK5[H_ANTGU"Q:;2+V"[9EA95D$2E0@
M&21D$DMZ]J#X3U_3/$VHZAX=UBTMK+57$MW;W5L93%+C!DBPPY( X;C/KTH
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MO""O8WGV;=>6T4N$W%U>55*YSP.>?7IQ0!T;:]IR^((]",S#49(6N%B\ML%
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M6^?(R#\J_2J<GBWQ%J.D_P!M:!8O=H+IDCL?LW$T*R%&/FEAA\ MTP.F#UH
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ME"O)RAP1@\CKD]* .QHKS&7Q5XMD\-^*]4BN=+C?0;^YC"_97(GCB56V_?\
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M36T4#*\;O"7#ARWJO3;P#CGK5SP;+JL_C'Q=]LU%)XK>^2()Y.W"^4I4*=W
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M4;A;>T@7=)*P)"C..W/4BL/2?B'X5US4X=-TW51/=S;C''Y$JYP"3R5 Z T
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MP*42'!W*44D\A@#DGG'8<5#'X;U"^GT>37K^WN_[)?SHO)A*>=,%*K(^6.,
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ML6_X1O31'*D4AUBR".XR%/FC!(R,XZXS76V&J6^I2WL<"S!K.<V\GF1,@+
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MW<=8-'M1:IZ>?-AY/Q"+%_WV:Z6LS0]).DVDZ23">>XN9;F:4+MW,[$@8R>
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MZ9R<CCWJC>^ ?/T-+"WU)8IGU0:K=7#V^\S3!P_W0PVC( QD\ #WH @74/%
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MBC1&TZ2>2V<2QS0W$7WX71@P9?0\$?C0!RNC>+=3O[/Q'9/>QOJMI?K:V3"
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M:>% ==BE/A]65-UECS08_+QP_'R_7GGIQ6O?>&IY_&=GXBM=2^S/%:-9SPF
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MOA:W%HULKI #O+%0,-F/9@Y8]^E=WXDUN/PWX9U#6)D,JV<#2[!QO(' ]LG
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M_NF21@JEO89R?85S6J6E[:_%7P7]JU*2]5H+_'F1(A5A&F[&T#@\<')&.IH
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MOJ0LY[)K972 %G#;0,/F,)SEO7IQ0!ZC12*"% 8@MCD@8R:6@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "LCQ/HK^(O#E[HZW0MEO(S%)+Y>\A3UP,CGWK7HH
M Y?4/"#WT.B3C4!#J^C'-K>)!\I!4*ZNF[E6 YP1[$5,GAARVK7DUXDFJ:E
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M^\<DYZ#'0"M*3PGJ5[X>U+3]4\0/>WE_;-:M=&U5%BC8$$)&I !.<DDG.!V
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M>GE_N_I7;44 8/BCPX_B.TL;>.\6T6TO(KL'R=^YHVW*/O# SU_I4<OAF?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M&<C@<'H0#T2BO-;6Y\57WA_Q;INGZW.^K:1?/'8W3PQ%YE\M7$;C;M).XC(
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MW'E?OKF-))%"Q(JG,C;5Z#IN/%2:5?\ B/6M'\76%IJ-S!J.G7C1Z?+-'$9
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MKH%[;7$EK'H:.EK;QJI3:R;"#D9^Z,#!%1IX+LWOO$,]Y<2W46O(B7=NZJ%
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MU:L;I;[3[:\12J3Q+*JMU 8 X/YT 9%_X9%[XGTW7!?RPR:?')%# J+Y>V0
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M+^#1]5DTYEWK="),.G]X1EO,(QR/DR>PK5TO48-7TJTU*UW?9[N%)X]PP=K
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M0!S/C!-3TCP[X;75KPZK<VWB6V8/#$!)(@9BBD< OMP.V?UKJ_!]ZVO:>/$
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M47:1JCQS%1A6*LIPP'&01GOFM+2M(CTP3R&XGNKJX8-/<SD;W(& ,*   .@
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MC+87\]S$+9@H9TMT8;\@[AP!CIUZ\8]2T:[DO]#T^\EQYD]M'*^!QEE!/\Z
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M!YY[GN>] 'MD;;XU?&-P!IU<$)=0T7XA:%;'5;R[MM4L;EIX)BI1'B",IC4
M;?O$8].N3S6?ID_BKQ-X=TKQ-IE[;V\\LHN)?.OG\@P[CNB,0C*C XW9W9&2
M: /3:*IZM9RW^E7-K;W4MI/)&1%/$V&C;'#>^#VKB_"NKW7B#1-#L9KFYCU.
MVED352)CO#0':X8_[;LAQ_=)QC% 'H%%>:1S^*/%NCWNIZ+>16E]%?S16S27
MKK'$L4I79)"(RK95<DDD_-P0,"CQ+K]YI6KW?]N2:A8Z;<1Q"PU:PD9K>V<J
M-PE5?5R<,P.5(QC&: /1_/B^T?9_,7SMF_9GG;G&?IFJVFWMQ?1W#7&GSV1B
MN'B19BI,BJ<"08)X/;/-<7IMF)?C'KL@O+O TVUD7$Y*\M)P!TV]P.G?O6%>
MZWKD7PM\6WR:U>"^T_6+B"*X^3<8UF5 OW< 8/\ #B@#UZBN'234=(^)VFV+
M:M=WEKJ=A/+-#<%2B21LF&0 #;PQ&/YGFN<.LZ[?^'K>2'4KR#Q6=9-O<643
M [(O-*E1&P*A!%AMY7MG)S0!ZW6+XD\1Q^&X+*66SGN$N[R*T#1%0(VD8*"V
M3G'/8&K6J7W]B>';V_D+W'V&T>9MV TFQ">< #)QV%>::_%<7_@;PEKEUJ-S
M-=WFI:=<3KYA\EO,=6VJGW5"Y !'/').30!ZW4;3Q)-'"TBB60$HA/+ =<?3
M(_.O-/&VK:C9V?BJ^LM5NYKG3UC>W%HVR*QPJDK+D[9&8DDC#$ C@9%6[NV-
MY\7M#F>YND\S19I2D<S*H(>/@#L#W]>/2@#T2BO,X9_%/BS09M8T6]AM+Y;V
M58&EO76&-(YBOER0B,@Y5>223DY! P!Z4A+1JQVY(!.TY'X4 8_B+Q''X=&F
MF6SGG6^OHK)7C*@1M(P4%LG..O0'IVK:KBOB5_QX>'?^QAL/_1M5;JYUKQ/J
MWB6PTZX^SOILB6ULR7KP&-S$KB1E5&W@LV,-QA>F<F@#OZ*\WUK6-<T5-.N/
M$4=W<Z<EALOKO1)&_P!'N@Q#2LHPQ3 ], @Y!XHUC7KG3[;1]0FDU'4O#;::
MOFZCI;D21S<?OW52&*%1GN <Y!H ](HK/T&>.Z\/:=/%?"^1[:,BZ'_+;Y1\
M_P"/6O.[W6M2M9-'O;;5+J]>?Q$EG/=QMMM'A>5D\E4)P=HP-ZCJI^8G- 'J
ME%><16>L^(/%_C'23XHU.TM[)[;[*;?8K(SP[^NW[H)Z#!/&36/I?B'Q'KMK
MX#,NL3VDVH37EK>F%$VRF)9!Y@ROWCMS_=!YQQ0!ZGJNH#2M)N]0:WEG6VB:
M5HX=NY@HR<;B!T]ZS[;Q!)?:%HNJV>EW%Q'J?DLR(RYMXY%W;VR1D+QG'-<;
M;SZKIE[XU\,WNI7.IV<&E_;+2>Z(:6,.CAD9@!GE>*8M[?6'@+X:R6=]-;I/
M<Z;;3QIMVRQLG(/&>PZ$4 >HT5P\,UYXMU+Q59Q:G<6$NFS"SL_(<KY3^6&\
MUP"-^6;[IXPO3))HU&2]?4K2PGUB>\F72LO;::3"[39P;AF# *G! 4GKGAL<
M &]K/B./1M6T>PDLYY#J=P;>.92NQ&VEOFYST4]!^-:.H7?V#3[B\\B6<01F
M0QQ;=S #)QN('YFO*#?ZAXB\,_#.\NKQTOKJ^_>7*(N[/E2@L 1C.!Z8SV[5
MM6DFJ:-XH\0>&;G5+K4[!]'.H6\MV0TL)+,C(6 &0<9'IB@#M- UB/Q!X?L-
M7AB>*.\A694<Y*@C.#BM*O*_#^JW<7A3X?:':$+_ &E8L\A\\PEUBC4[ X4E
M<[L\<X4\BNQ\*V6O:?)J5OK-Y#<6_G"2Q G::6*,@Y5V*J3@C@G)ZY/% &^9
MXEN$@,BB9U9U3/)52 3^&Y?S%25P%Q9>;\<8";J[4?V$TH19B%!$Z# '3!P,
MCO65<:UJ5K+H-[;ZI=7K7/B!;.XNT;;:2Q.[KY21D\[0 -ZCJI^8T >J45YG
MXKOM3\.^+HH1K$PTO6XA;AY)3_Q+)2X'FC_9;.!NXW<9QD5MZS?7B>)])\,6
MDCF.6RFN9&DNVADFV,BA?,52W\3,<8/ Y R" =C17G=PGC/1O#SI<DZMY.I[
MS#97)-TUB0QV;RJDR XY'+ 'FM_P3JUEK.DW-S8:A=74/VEE\N\#":V("YB<
M-SD'/7L>IZT =+1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5E^(=
M!M/$NBRZ7>O,D4C(XD@;:Z,K!E920>00.U:E% '/KX3@&O6>LG4M0>[M+=K=
M-[HP96(+;LIG)(!ZC&,# XK/D^'.FR6,]L=1U,-)J?\ :R3K(@DAN>[(0F,'
M)X((KL** .9M_ VFP7FKW+W6H7#:O;K;WB37&5D 0INX P<$CT'8"M30=%BT
M#2(--ANKJYBA4(CW4@9PH  '  P  .!^O-:5% &7J_A[3];NM,N+V(O)IMR+
MJW(.,. 1S[<@X]0*J>)_"%AXH%G)<3W=G>V3E[6]LI?+FB)&" <$8/&016_1
M0!S\?A.&&SM(HM4U-;FWN/M)O&F5Y9G*%#O+*01M.,8 &!C&*ANO VEWFCWE
MA+-=![R\6^ENT=5E\]2I5QA=HQL48QC ]>:Z:B@#E-7\!6.JWMGJ":EJMCJ=
MK%Y/VZTN LLL9.2KD@AADD].,\5+J/@;3+^TTU$N+VUN]-D:6UOH)OWZLWWR
M68$-N_BR#FNFHH P=&\*6VBZSJ.JI?7US=Z@(_M#7$BD,47:#A5 !QGVYX %
M2ZQX;M-8O['4?.GM-1L2WV>[MBH=58892&!5E/H1],5LT4 <S?\ @?3M2T/4
MM+N+F\(U.027MRK()9R,  G;@ !5   P![G-F;PQ#<:_INLRZA>O=:?$\40S
M&%97QNW )SG Z8Z<8K=HH S]5TH:HEL!>7-I);3B>.6V*A@P5EP=P(((8Y&*
MRKOP/I=_I.K6-W)<R/JLJ37-R&592Z;=C+@ #;L7'';G.372T4 <U:>"K2WU
MV#6I]1U*\OH[5K1GN)5(E0MN(90H'4#@8''0DDU7T3X?:;H-T#:7^J-81RF:
M#39+G=;0OG.57&>#R 20#SUYKK:* .7'@>S%CKUI_:.H&+7'=[S+19RZ[&V_
M)QE0!_\ 7K>TRQ32],M;".666.VB6)'EQN*J,#. !T]JM44 <5/\,]+DL]4T
M^'4M4MM*U)FDFT^&5!$KL<DIE"RY/. <>U7)/ FGOJCWRW^IQ/-:+:721W&%
MN47.TN<;LC)Y4BNIHH Y-/A]IL6CZ-IT=]J:?V1*)+2Y$X\U?E*[<[<;=IQ@
M ?GS27_P_P!/N]>?6+74M6TRYF18[K[!=&,7(48&_())QQD$'W[UUM% '-RZ
M!-'XKTF]L;J^M[.SMS!):B8?9GCVL%&SJ7W%3N]%Q65\58WN?"UM;1I</(^H
MVS8MXV=U595+,, XP.<UW-% &$OAFRNYIKR_N+C499[1K023[5V0O]Y5"*H&
M[C)QG@=ABLNU^'.G6IT8G5=8E;1V/V,R7(^1"NSR^%'R[3C/WO>NQHH XNV^
MS>,?%.GZJVC7MLFB&<)-?6YB9Y6PH" _>4 %L^NW'.<:E_X1L[[Q&NN"\O[:
MY-N+69+:;8D\8)8!N,C!)Y4@^]=!10!R-O\ #S2[30M,TNWO=13^RY_M%G<F
M96DA;!&!E=I&&(P5_7FM6#PY;PK?R-=7,E[?((Y[U]GF[0"%4#;M4#)P O4D
M\DYK9HH Y&?X=:1<>%K#07N;\1Z<X>RNTE5+BW8="KJH_4'^5;6B:''HELZ"
M\O+V>0@RW5[+YDKXZ G   YP  .3W)-:E% &7KWA_3_$FGI9:E$9(4GCG !Q
M\R,&'X'D'V)H7P_IZ^)W\0B+&H/:"T+]O+#;OSSW] *U** ,:'PW;P^*KGQ
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M4W#&<@D]"!Z@UFR?#S3I?#VJ:))J.I-::G=-=W!WQ[R[,&;!V< L ?PKKJ*
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M\(6WV&[@BU#4+>>\NUO+B[MY1'+(Z[>"5  7"A< =/?)KH:* "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MQNP:!LL=CJ/O,%P,'=@DCUJCH$[^&[_Q;IFM6UR_VS49K^T=('D6ZBE4812
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M.6@D*@XP3E6/8]?1NO+X:\7:;>6GBK2[F&ZMKB>*WE%I()2JNP1X7"G=D '
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M:EK-XHG=90%+<,H()P.!U.1@<U9T/Q%IWB&.Y-BTP>UE\F>&>%HI(VP#AE8
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MKGAXYTE)G2Y2\M5^S+=1230$+/&S!04(SR2RC:<-\PXH Z6BN=LO&-G>:_\
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M:WH5_I4[LD5Y;O [IU4,I&1[\USS>#+V1/#WG:YYLFBRB5&:T \PA/+ (##
MVD^IR<Y[4 9'_"7ZMH$7C*WU&Y34I=&DMOLL[1+&6^T*-JN%P,*QZ\9%;6GR
M>*XO%-LDT-S/HLT+?:)+O[.CP2CE2GE-DJ>F""1QS23^!(+^\\3/J-WY]MK\
M<230I%L,7EKM0JVX\CKR.H'TJ?P[X9U72I(CJOB:ZUB.V7;:I) D6SC&7*\N
MV,C)/<\9YH R/C3_ ,DFUKZV_P#Z/CJ;4O#VJ^(O'GA_6+BVBL+'1?-D!,H>
M6=W &T!> HQU)R?2M?QIX8;QAX;GT0WOV2"X*&5UBWM\K!ACD <J/6MR!)5M
MU6XD624##.B; ?H,G'YT >=R^*-:L;W0VFU".YEO-9-A>6]O$&M8T8N%"2[0
M2ZA5R-QYW9 XJW:W?BG6/&?B+2H-<M[2VTNXM&0K9*Y='3>R<GC@XSR>F,<Y
M;!\-+BWTC2],7Q+<_9])OUO++_1H\I@L=K$_>/S'GCZ&N@T?PY-I?B76=8;4
M!/\ VH8C)%Y&W88TV+@[O3KQUZ8H X[PW<ZQ9>"/&&J1ZO+-=VM[J!C:YB1P
M6B)PQP <D*!C.!V%;6G^([_59O#.D+=&"ZO]'&I7=TJ+N( 0;4!!4$LY)X.
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M^9MQXXQ@#)XYXK^'/!>H:$8+6X\3WE_I%H1]DLI8$4H!]T/(/F<+V''0>F*
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M1L!?Z=^ZC!"+D2IPHW,#MP.>"*;JNH>(-&E\&PS:D7DOKY;>_4PQ_/F-G(!
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M-E<_[YP.G SGH<^ZU763X8^(_AS6[L7\VE:>[PWHB6,RQ2P.RAE7C(P1QUH
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M"94,-QR0.>.E 'IU%<#KVH:[X3CMI]3U._O]*EN97NKRSLHQ)9IM7RU*@-E
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MY<YC.><=#TYH P#X&MX)?#O]GW;6L&@ES;Q&,/YA=2K%R3SD$],<DFNLHHH
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M,.H36%YIMQY\$T:*XR5*L"K<$$$UC3?#H2V/B*S.N7C1:XP:?S(T)4[55B,
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MH-4T:+R8+M8@1)&5"E)$S\P( Z$8/(Q3Y3I?@JUU'7M6NI'EO)HS=W2P,V2
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ML7MVEUJ8MOLL4@AV1Q)G<<)DG)(!)W=AC%5-$\*SZ'I&HZ?#JAE%[/-<&62
M;D>4Y;&#@CDX'\^E.M/'&D7%YI]K,+NREU%=UD;N HL_&<*W(S@C@D'FKFE>
M(K75]8U;3(8+B*?2WC28S* &+KN4KR<C&.N.M &+)X!$OP\7P:VJ/]C5%B$X
MA'F;%;<!UQG('..GYU-K7@R;4=:M-=L-;N-+UF&#[-+<V\*ND\6<[6C?(Z\@
M]ORQUE% '):QX$AU.STTP:K?6FJZ=(\MOJ:E6E+/]_>",,&[K@#@ 8'%)J/@
MB75?#CZ7>:Y<S7$TT<UQ>O$F]S&P9 JC"HH*C@#U[DFNNJI;ZC!=W=Q;V^Z0
M6[;)9!]Q7X.S/<@$9QT^O% %6]TV_N+NRN[;4Q!-;QR1R(8-\4P?;G<NX$8*
M\8/>L"3PK>:/8Z59Z!J5S;-'J#75PD<2^7.'?=('[(H!;"CV')YKM** *.LZ
M3::]HUWI5_&7M;J,QR '!P>X/8CJ/I7+Q^ KQ_[%6\\47MPNCSB6V/D1*Q 4
MJ QP=QP<9_3/-=A=74-E:375S((X(4,DCG^%0,DU"-1C^T6]N8Y1<31F41$#
M<BC&2W.!R0/J?8X ,#_A#7\[Q+)_:9SKZ!9OW _=8C\L;.?[OKGGGVJ2Y\%6
MM_X'M_"]]=3216T4<<%U$/+EC,>-C@\C<,#GO3[3QG:7U_?V5KIVI37%A*(;
ME5B7]VQ&0,[L'CTHU'QK8Z9H)U>>SOQ"MR+9X_) >-RX0;@2,#)'.>AH AM?
M!CS:7=V7B+6KO7!<V[6NZ9$B"1G&0 @'S$@'<<G@=*=X<\)W>B&!+WQ%?:K!
M:+LLX9T11$,;<L5&78+D9)[GBMN74&BUBWT\6-VZS1/(;I$!ACVX^5FSP3G@
M8[&KM '&1_#FQ_X1R^T&XU"[FL)YWGMU^56M&,ADRC 9)#'.3GT]<ZEOX=G;
M4;34M3U 7U[8PO%:/Y C5"X 9RH)RQ  Z@8S@#-:-QJ+6^JVUB+&[E6>.1S<
MQQ@Q1;<?*QSP3GCCG!JMX>\0VWB.VNY[6&XA%K=R6<B3J%;?&<-P">,T 9^D
M>$'TGPSJ&B)JLS+=M,ZW"QA9(6E)+$=C@G(_K2OX9D-_/K-UJ).IC3WL8KFV
MM@C1HQW%]N6WOD CMZ#FKUSXBM;7Q18Z!)!<?:;V*26*4*/+P@&X9SG/([=Z
MV* ,CPQ;:E:>'K6#5KJ2ZO$WAII0 [KO.S=CC=LVY]\]:UZ** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH *YSQ=K4^E+I%I;2"&;5-1CLA.0#Y08,S$ \;L*0
M,Y&2.#C%='6-XG\-67BO1_[/O'FBVR+-!/ VV2"5>5=3V(_K0!SWB/4]9\#:
M%XBUF74$U"RCAC:PAG7]Y%(Q"'<0!N3<RGUZCBG:W?:KX5U7PW-_:<]_::E>
MIIUW%,J??D!VRIM4;<%3D<C!_&M.#P=#-H][8:YJ-WK1O(?(EENMJD)V"A
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M=-I?AJPTC6]7U6U5A/JDB23 GY5*J!\H[9ZGU-4!X-07WB"[75+Q)=:$?FE
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M.,UU&B^&ET;4]7OEOIYVU283S1R*H57"A?EP <8 '.:KV7A!89]'DOM1FO\
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MKY^$<6KC4V74;?4!:2SK$G[]1=>3D@C )7TQS74MJ%WKWB_6]#@OY;"+2[:
MAH N^264,=Q+ _*H4<#J2<]J@/P[MSX2D\.?VM>_97N_M9DVQ[]WF>;C.W&-
M_/2K.K^"1J&NPZY8ZS?:5J@@%O//:A"+B,'.&5@1D=CCC\J .?URWUC^W?A[
M;ZAJ$#:J)[I)KNWB^4MY# LJGC./48SVQQ6YX,O]1;6?$VBW]_+?KIEY&L%Q
M,JB0I)$K[6V@ X)/.*MW/@^":_T.[CO[J-M':22(':_FNX(=I"1DDY/3'))J
MSI'AQ-)UO5]46]FFDU1TDFC=5"JR*%7;@9^Z!US0!2U^XO/^$AM+--2DBMY+
M21A:62@W4DNY0'R056-1GDD#<0#GI7(1>*/$5_X#\$:FFJ>1>ZCJD5E=,($*
MR*7D4DC'!^0'@@<FNVU'PHM[XHAU^WU.\LKE;7[',L&PK-%NW '<IVG)/(P:
MR;?X;V]KH>DZ3%K.H>1I=\+ZW+",D.&9E4_+RHW-[G/7I@ A-SK%KX@C\*MJ
M=_J$B63WTET@ABF<-*51>0%PN#G R21T'!Z#PD-?31C%XC:.2]BF=$E0KF2+
MJC.%X#8."!QQ5;Q)X-BUZ_LM4M]3O-+U:S4I'>6A7+(>J,K AESS@]ZV-*TU
M=*LA!]HGNI68O+<7# R2N>K-@ =@,     =* .-N=3\0>(F\0IHDMS;SZ?=O
M9VAB>$1B1$4YE#@D@LW/;;C'.32WCW<GQ%\"/J"1I>MIUZ9UB;*"39%N"GN,
MYQ6A>^ UD\1W.LZ9KFIZ2][M^W0VC)LG(& V&4[6QQN'/XU?G\*02:_H^JQ7
M<T/]DPO!;VZA2A1P P8D9/"COVH Y^RU[7HH?'I21]2NM*F(L(FC4?\ + .%
MPH&>3]35>RUC5+W7/",>F:_-=VVHVCSZEM2)_+VHI#'Y?W89B4(X]N0:T-8T
M)_#VA^*]1M9=1OI]6!>6*W4>9&Q41[H]HS\J\XY/R^M8^@/<BZLTT#QEJ.IH
MDD:R6EQI:*GE @-O?RU*$+G&3G( P>E ":GJ6HW?AKXH6=]>O<QV,4L5ON15
MV(;;=CY0,\GK3OM/B#PRG@_41K3WMAJ,UM87%@\"*D8D3Y6C(&X;<<Y)S741
M^"K7;XC2XO;F>+7P?M2$*NS*;/D(''R^N:ELO"@B.FC4-1FU"/2\&S22-$"L
M%VAVV@;F"D@'@<DXSS0!R)UQ_#=_\3=7C17DMI[8H&^[N,"*"?8$@FNAL8?%
M,'B>QD\V>71Y8G6]6]DA+!\91XO+'<\$=,=*LQ^";)I_$+7EQ-=P:[C[5!(%
M"C"!!M( (^4#N>1FF^'/!TF@R0^?K^IZG!:@K9PW;+M@&,9RH!8[20"3P"<"
M@#-^*$<SZ7H?E7EQ;AM;LT81$ -F48)R#G!&0.F>H-68=0N]5\::CX<74;F"
M#2[*%Y)4V"6>27<=Q.W "A1P ,D\\<5L^)?#T/B72TLY;F:V>*XCN89X<;HY
M(V#*<,"#R.A%5)O"2_VW!K=GJ5Q;ZFEO]EGF95<7,><_O%P!D'D%<8Z=.* *
M_@36[_5K+5;35'66\TG49;![A5"B<)@J^!P"0PR!WK*O&\0:I\0]6T*U\1SV
M%K'I\%U$8[>)FC=I&! RO(.WG//N*Z_1M&MM$LY(+<N[33/<3S2$;Y97.6=L
M #)]@   !TJI!X;6#QA<^(A?3M-<6ZVSP%5\L(I)7'&<Y)YSWH Y0ZIXI\2:
M7?W^@2317<%]+!:HSPBWVQ2%"LBGYCN"DGH1D8Z<Z4.H:GXFUCQ#IMOJ#Z;)
MI<<,40@VM^^DBW[V)!RH)  X!P<YR,//P^BAUN]O=/US5+"SU"4S7MA;NHCE
M<_>()&Y-W<J0?<5+J/@6.?Q"=:TK6+[1KJ:)8+H680K.B\+E74@,!P".@H J
M2ZMK4FMV/AJ>5Y+Q-+%W>3:>R1F1]_E_*7Z*"&)P,Y*]!D'-U;4/%^B^"K>;
M4;\1:A'JT-OYD:QL9[=Y54;\+A6PV#MQT]ZWM:\"6NI2:;=6&HWNE:CIR&*"
M\MG#.R'[RON!#@GGGOD]ZDU'P5%J6@0Z7-JEZ2MREW+=-L:6:5"&!;*X RHX
M  P * *NI:GJ&B?$;3([S49#H6J6\L4<3*@2&Z3YAEMN<,@; )Z@U6N-=U2W
MAT.W%Q<23:]>2M$<1J\-N$:147( #%0F=V3RW?%=%XB\-67BC28M/U+<R1SQ
M3ATX.Y&!X],C*GV8U'XH\+6?BG38;6>:>UFMIEGM;JV;;)!(O1E/XXQ0!7\,
MQ^(K?4=4AU=S)IQ9'T]YG1IU!'SJ^P8(!Z'K@\U6\175\-=^RPZG)'$;!I(K
M2Q4&Y,N[_6,6&U8P.!D@$Y'/%:^A:)+I$4C7>J7>IWDH >YN=H.T9PH50  ,
MGMDD\DU3OO",=WXG;7(=3O;22:U%I<Q0E-LT8)(Y925/)Y4@_2@#DQXGUMO
MGA'Q;-J#QV[2P+JZ)&FUXG;89.5)7#%2<8X)JS!XIO;+Q;XFTZZOKFY@%L)M
M(#)&H=@?+DC4A>6$I51G/7\3T&G>"K*Q\#2>$Y;JXN[)X'M]\^W<J," !@ <
M=O>I&\%Z4TOA^0HY;0\_9R3DOE<'=ZG(5L_WE!H S+]M5MK^STV;79YF&G,3
M'9QH+J:XW &5OEV+&!TR5&3@YKGX_$_B'4?!_@+48]4^SW.K7L=K=E84*R K
M(2V".#\@.!@<UV=]X32[\4#7H-3O;.9[46EQ' 4VS1ABP'S*2IR3RN#]*R[7
MX<06FCZ'ID>LWYAT:[%W;%EC)W#< I^7[H#-[\]>E $=G<:G_P )9%X0FUNY
MG^RV#7US>>6B33[Y2L:<# "C.2!D\=.0<#09]9TGPWXLDT];K4+B'Q1-]H,"
M)]HDA'E[RBXVE]O8#UQCBNVUGPDFI:]9Z]9ZC<Z;JMM$;<SP*K"6$G)1U8$$
M9Y'H:JV'@;^S8[O[+KNHB:YU$ZD9&$1Q(1@C&WH1P1^6* )_!6M6FNV-[=66
MKRW\ N-JQW";)K7"*#$XP#D,&.3Z]34!U'4!\56T?[;(=/DT5KH0[4^27S@F
MX'&>G8DBM?2-!ATJ]U&_,GFWNHR))<R! @.U0J@*.@ '<DY)YJIJWA;^T/$5
MIKEKJEUI]Y# UK(T"HPEA9@VTAU(!R,@B@#AY?$OB(^ _M\>L.+R+Q";'S6A
MC.^+[3Y8# *.W<8/O6RVMZCX9\8ZQ:7^IW&I6$.A-J^V9(U:-D<JRIL4?*0.
MAS]:M#X;VJZ$^D+J]^+=]1_M')V,RR>9O !*YQG&<Y)]:U9O"<-UXFDUNYNY
M9FET\Z=+;,B^4\1;<<\9R3[T </XB_M#4?!7A/6[O4Y9);W4]/N);=57R0)'
M5@JC&1MR!G.3@YSVVKK4]>\0S^(H=%ENK>;3KDVEH87A""18U;=('!)!9L8Z
M;1QS4B_#15TBVT?_ (2/5/[,L[F.XM(=L1:'8VY5WE"6 /3/0>O&+E[X#$GB
M&;6=,U[4]*GNU5;Y+4IMN=HP&(92%;'&0* ,B[N?%-YXNTC1I-9.FO>:+)-<
MK;11R"*=2BDQEASR3USQGH<$=E?P7">&+B!KZ?[2EH5:[C"I(S!>6'& 21G@
M<9XJD/"<">)-/UF&\GB-C:FSBMP%*&,X)R2-Q.5'.>U;TT23PR12#*.I5A['
MB@#QLPW"_![P4_VR26274--9#,%81GS!TP 2,^IS[UT<NOZGX7\1^)+6[U"?
M5+6TT3^UHA<(BLCAG#("BK\IVCJ.*T$^'<*>'=.T3^V]0>VT^YBN+=F$>Y?+
M;,:_=Q@'KW/KVK3D\)6]QXDNM9NKJ6<W5A_9\ULR+Y;19)QTSG+'OWH QM/;
MQ9-?:'J,$TDME.H.HI<R0^6R,H(:()RI!/ SR.N3S6C\2O\ DFGB/_KPE_E4
M7A[P(/#\D40U[5+S3+8YM+"X=3'#Z9(&Y@O8$X'!QD UL^(]$7Q'H-WI$MS+
M;P749CE>(*6VGJ!D$#\J .,7PQJOBJP\%F[%G::;I1M[XM%,TDTSH@V* 44*
M/7D_I4EC-<6_BSXES6EQ;6UQ&MJT4]T<11L+489S_=!Y-=QI-@=+TJUL/M#S
MK;Q+$LC@!BJ@ 9QQGBN>NO 5G?/XE^U7UU)'X@1$N4 5?+V+M4H0., #KG.*
M ,K1M9U(^-[+2OM][/97FCO<&6YB5=TRL@\R,;0P!W'A@!TP*P1KWB:/X=MX
MID\03O<66I-$8/(B$<\?VKRB'^7/W3QM*XP.,\UVEMX)>'6=.U>;7]2N+ZRM
MGMM\@C D0D$ @*,8*@\<GN<5 WP[MV\'3^&3JUY]DFN3<-)MC\S<9/-(!VXQ
MNYZ4 =-K-Z^G:'J%\B[GMK:291ZE5)_I7'>&I;NS^"UG=VE_:VM])8&Z-Y>G
M]VLLF79W/U8GOS7<O LUHUO<8E5T*29&-P(P>/>N+L/":7/@6?P+JCSI' IB
MAN8S@R0A]T3J>F5^4$>H]""0"/1]7U&3Q[-HBWM^UA-HPO(Y+N)%D$@EV%U!
M4$ @_=8=1TQ7.V6O^)1X T#Q5/K\TL[ZBD$UMY$:Q31M<F,[OESNQT(( P..
MY[:V\&/!XA@UV77M0GU".R-F[R+&%D7=N&5"@#!&>,9[YYS53X=VZ>$+3PTN
MK7GV2UN1<))MC\PL)/, )VXQN/I0!U6H6%MJFG7-A>1"6VN8VBE0DC<I&",C
MD5B0>!=!MY-%DCMYO,T8,MHYN') /4,<_,,\\UT:@A0&.X@<G&,TR>0Q022!
M7<HI;:@RQP.@'<T >;^%#JO_  G'CS^SA9D?VA%N^T%ASY0QC;5CQ[]L_P"%
M3)_:00:@9;$W03IYGGQ;L>V:@T^WFTO5-5U"T'BI)M3F$UP#IT)7<!@;<C@8
MHU*T75M!N=+N[?Q7(;JZ2YFN38Q^8Q0J54#&T*-B\ =O<T ;U]J6HV_Q1T?3
M5O7_ +/NK"XE>VV+C>A0 YQN_B/&:Y;5/%&NOX?UZ[M]0DMM?L]6-K:Z:JH=
MT>]510C EMR$ON_+@8K8GF%SXIT_7Y-/\2>?90/ L0L%V.KXW$\YR=HZ'BN)
MMO$$HU:XCAU7Q?INIW5U+*U@-'2X\HLQ(4,R9(QCOC XXH ]"N[[5;#XB>'-
M+;4Y9K.ZLKEIHWC0;WC"8;(4'^(\=/:N1TVTUX>'O&.IZ/KTEA)8ZWJ,\=NL
M"-',5<L1(6!)! P,$8Z\UM13W5YJVAZ[J6G>(!J6GVK1/%#8*(G9POF9Y)Y*
MC&#Q4*V4<<>JVD=IXH73-5N)+FZM19)DM(<R*K_>"MT(Z\\$4 2QZFVM>-OA
M[JKQ^4][I%U<,@_A+QPMC]:9#JWBOQ)H*:YH+2I<&Z<PPRR0BU:))2A1Q@OG
M:IR>N[I@5;N&@F\1:3J\6D^(H/[+A>""VCL%\O8X 8'G/11C!&,5E0:-!9ZI
M=RV47C"VTJ\F:>YTJ.V7R7=OO8)^95;N 1GZ4 >J#D"BF0R>;#')L=-ZAMKC
M#+D=".QI] !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %97B/7[?PQHL^K7D%Q+
M:VXW2F *2HR!G!(SU[5JUQOQ8_Y)9X@_Z]O_ &84 7K;QKITFIV.G7EO>:=<
MZ@A>S%W& L^!DA64LN<$<$@UTE<%)X7U/Q+?>%;W4&L[73]'*7:1P2-+)-(%
M&W)*J%48R1SFLO5-=U6R>TO8-5GO)&\01VDLL  M!"\NSR<-]Y@O5E!PP.6[
M4 >HU"UPFV?R_P!Z\/#QH06W8#!?J01U]17">7K>L?$'Q#I">)+ZTM+6&SGA
M$,<64+%R5R5^Z=O.>3QS@8-;PA:W,8\=S1ZK?+-%JUPB.SJ^"(HB&PRD$CIZ
M8XQ0!W^F7DFH:9;W<MG/9R3(&:WG #QGT;!(S1JEY)I^F7%W%9SWLD2%EM[<
M O(?1<D#-<!H?B74=0TKP'IMQ>R+/K5K+/=70P)'$:!BJG'!8L,D<@ XQU%O
MQ0NO^'/ 7B:X3Q!(\MONN+&0(IEBB[(Y8'=SNPW7WH [V-B\:N49"P!*MU'L
M:=7 :K<:S<^-O#^E6^N75I:7^FS2S")(RP9-GS*2IPQW'KD#L*S;+6-<LK;Q
M1H%]X@ ETF^M4AU.>/=*\$VUO+ 4?-+MRHP,DL..E 'J-%><6>KZJ=0\;:<E
MW?VT5C8PW5D;G9)+"S)(3R=V02@.&R1D]*IV.I:Y:Z=\/]9FUR[N6U>2WMKN
MVD5!$RR0LV[ &=P*@YSR2>@XH ]%U+58=-L+VZ\J>Z:TC\Q[>U3S)3QD +W)
MK&A\<6%Q/HL4=CJ6W5XV>"5K8B.-P#^[D;/ROP1CGI6+X*L6;Q3XU\R_O9 N
MHB/#3=084YR.01G P1CC%=LFF6<?V39"%6T&(%!.V/C&0.F<9&>N"?4T )I^
MI6^I12/#N5XI#%-$XP\3CJK#UY!]""""00:;J^K6NB:<][=EO+5E15499W9@
MJJ/<L0/QKE;:XDM/C;?V$9/D7VA17DJ_]-(YC&#_ -\G'X"H_BK;&;0M,<7$
M\>-6LUVQL #F9>3QU':@#I])UB;4;J^M;C2KRQFM&4$SJ#'*&&0T;@D-TY[@
M]:U:XS[=/>^.V\*_;KJ.ULM-6[DD5]LL[NY498#(50.V,D\].>5U7Q-XAMO"
M7B6W75)5O]#U:&UCO!&F;B&22,*'X^\%?DKMZ"@#UVBLW1]-NM-2Y6ZU:ZU$
MS3&56N%0&,$#Y%V@<9!/XUP'C+7=5TS3?$>I6>JSSW6GW47D"U $%K'F/,<N
M[AW.6R!N(W+]V@#U&BN%U"35;OXI'18];O+;3Y=%:Y,<*QAD?S@N58KQQW.>
M^,9XQ8M0\2WWPRN;^UU2ZEU/1KZX1F4*&O(892&5N/O%!P0,Y'O0!ZI17,Z5
MJB^(M<@O=-O96TJ&Q1V"D;9I)<,H/NJ#)'_31?2J?C^]U2Q/AS^S-2ELS=ZS
M!:3!41@R.&)SD9_A'0@>N: .RHK@?,U2W\21^$QJ=[?^78M?O/).D,T@>4JJ
M[E7HF.P&<CMQ2))XCL-)TNRU[681<'4'B<6N7N;R':61%VJ,/T+$  *N<CF@
M#OZ*\STW6_$MQX5\1BT2ZN[O3=::WCA9D^T&V4QLR!AD%PK. <D^Y-12>.HH
M_#EW=:/J5VT\^HVU@(-0C(FTUI"%;>K<G #,"<C/&2!B@#U&BN(U"[U#P]XX
MT'3XK^ZN=/UI9X)$F8.\$J)O61"1WY!!X[@5R;ZOXBB^'-[XF;Q%>/=Z=J;Q
MI'LC$<J"Y$9$@"\Y4GI@#C [D ]CHJIJE\NF:3>W[(76U@>8H.K!5)Q^E>=:
MAKFLV/PRL/'46I2RWGEP7=S:DCR)8Y&4-$%Q\NT-PPY^7DG- 'J%%>>[-;UG
MX@:_I,?B2_L[.VM[2XA6*.+<A8N2O*_=.WG//3G P=OXAWE[IW@'6+_3KR2T
MNK:W:5)8PI.1V^8'_'WH Z>BN!2ZU;2_'/AB&76+F\M]9M;C[1!*J"-&C1'4
MQ@#*]2.2<]R36=#KFKZU\,+OQO9ZG-;WT:W%W!;\&%8HG8>4R8^;*IR3SD\$
M# H ]/HJAI=Z=8T"ROP'MVO+6.8 8+1[U![C&1GN*\UTC6-=M?A_=>,KS7KN
M[EL!>H+1XT$4I65D0OA0<@@'@@8 &!SD ]9HKC+.T\3PZ_IEY'>!]+DC9;]+
MFZ$GF$KE'B 0!3GJ 0"#TK!AUW5;:_\ "LRZI/??;]2>UO+E !:3@K(0(E//
MR[1AE&#@\F@#U&BO.'\17-KXM.F:[<:AI=S+J0%A<8S9W<&\;8@1PKE>#G!W
M=\'%6=/OM2\6V'B6]MM3N+&>QOY[.Q6$@+&8@,,ZD?/N;DANQ &.M '?45Y9
M9>)M:\1W?@*>+4I]/CUJUNC=PQ1H1OC0?,NY21R21G(Z<5T?@6]OY+CQ%I=[
M?37HTS4F@@GGQYAC*(X#$ 9P6/.* .PHI'7>C+DC(QE3@CZ5Y)?ZSX@M/#'B
M/3$U6]E\2:5J.+9EV;[B!AYJ9&,8,2R=!U0_2@#URL_3M4-YI,5_=VD^FER5
M,%WM#H=VT9P2.>,<]Q6-I&H?\)+=QWVG:A<QZ<MA'C8RG=+*-PSN!^9$VGT^
M?D<5P5Q>:CKGPI\)7]_J=T]U-K<"32(P7S/]*902 ,<8&!T&!QP* /31XCA/
MC$^&C:W"W'V(WHF;;Y;('"8&#G.3W Z5LUYW?:?-<?%ZVLXM1NK?_BG'#W";
M3*1]H7H2" >G./ICJ-CX>:E?:EX:E&H7+75Q:7US:>>X :18Y"JEL<9QB@#K
M**XVVO[CQ+XQ\1Z0;VYL[;2%MXHQ;.$=I)$+F0G'.. !TX.0>W*_\)1XCOO#
MVADZF]O?Q^)1HUW+%$FRX568%\$<9P. 0,YXQ0!ZY16?I&G3Z;IWV6YU.ZU!
M][G[1<;1)@DD#Y0!QTZ5YS?:GK]MI7BS0X]6O7\065VCZ9(H0O-#(-T:XQ@X
M"R!CC^$F@#U:L^PU0W6F/>W=G/IP1W5DNMH8!6(W<$C!QD?6L'0=6_X2E].O
MM/OKF.R735DE"L&W2R?=!R#\R!7S[LM</J5YJ.K_  <CN[_4[J6Y761$TJL$
M,BB\V ,  , =NG XXH ]-E\1PQ>+K?PZUK<">>V>Y2<[?+*J0".N<Y8=JV:\
M\UBPFD^*6@V<6H7,3?V1=!K@;3+C?'T)& ??!X]^1FVWBW5K'PZ;"6_DFNF\
M4G08K^55,BQ%_OMQM+!<@'&,XR#0!ZK17$7-U?Z)\0-*T07MS<Z9K5M/A97W
M26\L0#%E?KA@<8.<'ICI7/0^(]:?X1:)K3:G/_:+ZBD,DV%_>(;HQD,,8^[Q
MTH ]5\Z/SO)WKYNW?LSSC.,X]*?7 Z9:2-\9=>8WUV533[5PAD^7!:3Y<8X7
MV'<D]ZV?%NLSZ?/H>GV\WV=]5U!;5K@ 9C3:S';GC<=H4?7- '2T5QVIV^LZ
M'I?B"5?$T,%L\:/827J[VLSTD);DN"2-H(/) YZ51TK4;Y_'>H:)Y^I)I\FC
MI>1"[8>:K^8R%E/+*" /E;&".@H [^BO*K;Q'K,WPT\%ZPVI3?;KO4K6&YD
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MDT]!J']G_P"OB/E1[&P/F*#Y\X]OH0#T>JE[J$5G;74H1YWMHO->&$J7V\]
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MNS;-H;YMG(4\<'IBM6^TNWO]+GMI= \5+=S7J7[WZ+;B;STQL8?/MP  H&,
M#UYKTNB@#S--,VW^IWIT[QDUQJ5HMK<NPMOGVA@'QNP#AB, ;1GIG%!TU3IF
M@V TKQ<(=#ECEM2([3)**57=SR I([5V-CXCCO?%6IZ#]CGAEL(8IFED*[9
MY;!7!/'R]\'VK;H XO0+98_%M_J$6F^(;,:BPEFCN1"+82*FW=\K%LD #&2,
M]NF.S9@JEB< #)-+10!S>CZ2\OBK4_$US&T;W$,=G:1N,,D"$L21V+.Q..H
M7.#D"UXE\-P^)[.WM;B]N[:.&X2X'V8H"70[ESN5N 1FMJJ6L:K::'I%UJE\
MY2VMHS)(0,G [ =R3P/K0!G:AX7AO-8L]9AO;FUU6VB,'VJ((3+$3DHZE<$9
MY' P:J:AX$T_4/#]SI#WE[&EW<B[NKB,IYL\H96#,2I Y5>  ,*!TK2TW5[R
M[U2YL;S1KJS,4:RQSLP>*56[!AT88Y7^8J75M:@TO2=1OQ%)=?V?&SSPP%=X
MPN\CYB!G:0>O0T :$:LD:JTC2,!@NP&6]S@ 5QM]\-=.OX-;M6U35(K'5YC<
MSVL<J!%F)!+J=N[DJ."2OMTQU&D:@NKZ+8ZDD9C2[MXYU1CDJ'4-@_G5R@#G
MXO"D47B2/7?[4U![N.R^PX<QE63=N)/R9W;N>N.V,<50B2P^'6F^1_Q.-1CO
M[V1PL=L)V$DA+-_JU& 3ZUU]9VH:H\&D27VG6<FILK!5AMW4,_S[3@L0..3^
M% %'P9X?B\-^&X;..V6V>1WN)8E.0CN=VW/<*"%'LHJ7Q#X;A\1'3C/>W=M]
M@NTO(OL^SF1,[2=RG(Y/%;5% '->(_!EKXAO++4%O[[3M4L@5AO;*0))L/56
MR"&4^A%1W7@6TN$TN1-4U*"_TZ9YX[]9%::1G7:^_>I4Y&!C&   , 8KJ:*
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M[U:\&IZG)=:K"D-S+)*A)"J5! V[0<$]L#/ % &!IFJ7E[X1\$R76JW#2WL
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M+>6<0NABV<,6PGR],D]<D=B* *?AC3\_$KQQMO;U3'):[3YQ;&^#/1L@X).
M1@>E9>@^)]3E\'>$[>ZU"9KG6-5N+6>]<C?L228X!Z ML51CH#Q@XKN(?"MI
M;>(KW6[:[O8;B\C19HUE!C9D78KD$'+!>.21WQFLW_A7.C-X33PY+/>R6L,Y
MN;>8RJLUO*6+;T=5&#EF/.>M $6JVFHZ#I/B"0>*OLUK,L;V372M,]ET5\,2
M6DW$C:.<$@#-0^']1O4^(]_I)-^FGMI45W'!?2^8ZN9&0L"68@$ ?*3VZ"M&
M7P'IUWX>N])O[[4[TW6PR7EQ<;K@%&W)M8 !=IY  QDG.<FI;3P9:6FO+K8U
M+5)=0^R?9'EEG!$BY)#%=N,@GH %]LT ><R?\FX:E_U\S_\ I<:[7Q)=7>@>
M,M#U62]N?[$O)#8W4!D/EPS,/W4F/0D%3VY!ZU8_X5[II\'3>%S?ZB=.FD,C
M?/'OR7\PC=LZ%N?_ *U0^*676XIO!4FF:E=M=11^9>R6^(%3<"S^8,#>H!(
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M2V,?[.$TPGG=Y9USYLA< B_Z@$]^_K7:/>7_ (>^(C6KZG>W]G<:-/>R0W#
MA98W7!0 #:"&(P.*O-\.-+/ANYT!;_4UTZ:;S?*$RGR_WGF;5RIP-_/K[XK5
M?PS!+XDMM=DO;Q[NWMFM54^7L9&(+ @)W(!Z_2@#DM)_X2G6=*\.^([*_MXF
MG,5Q>^;?.T,L+C+QB+9M1AG (.1CDGK7I%<AI'PZTK1+[S;.^U46*R^?'I;7
M6;6-\Y!5,9X/(!)&><5U] !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !535-4LM%TRXU'4;A+
M>TMTWR2/T _J>P'<U;KSCXREU\/:(\G_ !X)K=JU\>PBR?O>V=OZ4 =.OB.]
M-@=1;P[J L]GF!=T?G[<9SY6[T[9W>V>*U].O4U+3+2^B4K'<PI,H;J R@C/
MYU9ZUQ7VX:K\09/#:S2P:99:4ES'':S-%YK.^T'<A!VJH  !QECGH, ':T5X
M[JNMZ[!X/\2VG]K7@GT768;6WO%;#RPO)'A7;J2%<@GC/&:W[BRO(/B9!HZ:
M[JQL=1TR6>X1KDD[TD4 H?\ EGD-@[,>V* /0Z*\=N]5UFW^'6NB'6KX3Z7X
MB-A!<-)ND:'SXU =CRW#GN#6],FI>%OB1HUNNN7U[IVLP77VF.^E#K \2!Q(
MO "@YP0,#], 'HE%>56&IZA;ZOX+EAU*_O(=0GFBN;R:1EBO@8V<,D)8[%!
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MH7LN_;YF/;?4^H>&+&^U*SU.*2>QU"TC,,5Q:%5;RCUC(8%67O@@X/3%;5%
M'.7O@K2[[09-'D>Y6WFN/M,[I(!)-+N#[F8CKN /&.@'08JU)X;MY?$-MKCW
M=V;VWMS;H=R;=A(+ C;W(!_EBMFB@#S/QSX6CTWP-JMGIJ:G>2ZGJ4-Y+''&
MTK%S,C2.-BY7A<^G'%=E;^'K.6X^W7<US?S/;-;H]V #'$V-RA55<9P,DC/
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M"YN%B$]O!(T\DI7"!@A(R<'GG@ XQTKK** .=\+Z6D,VJZV]@;*ZUBX$SQ.
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M!8WQF55E2:.6"39)%(ARK*>Q%:M% ',)X%TR.]OKQ;K4?M-]:BUN)&NBQD4
MC<<Y&[#$>@SP!2GP1IYT[1K#[7>B#1I4ELP'7*,@(7)V_-@$CGUYKIJ* ..
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MD\Y@W[QSEB, =3VZ>E:U% !1110 4444 %%%% !1110 4444 %%%% !1110
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M+-<S6;2$J4!)W,21\HSGICFM+Q#H'V77/ ^GV,6IFQTR64-/"CN;=/)*1Y<
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MB@#$\"Z;<:E>ZI?WFM:M*VFZ]>0P1&[;RVC'RA77^(#/&>F!COF_\17NX_\
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MC1VK3W+NZI^Z8*S$Y< N<;L]O05Z+IWA7>^CZCJMW>3:IIJ2+!(\P)57/(?
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M[D7*"=MDNVW#*67."023G%<G=#4/^$!\8ZO_ &[J_P!LTC5KH63"\<!!&Z@
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M.]*GUOPG>IJ?A3RS<SZ->'(CA(W,87[#!)P?_'JU6ALM6^+NB:BJSJMUH#W
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MK1[2Q,\MP\,2H\TSEWD;'+$DD\G)H SO"WB*7Q%'JQFLEM'T_49; J)?,W;
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M+"5%!&#\IZ=,9QSD$@@'H=%>9PVM]XIN/$VE17QBGTV<65K(]U*LMLHB0I*
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M?<6EP;BWDMHVBF8$&12HPQSW/6@"]1110 4444 %%%% !1110 4444 %%%%
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MUU=RK%"I5=Q[EB%4?4D@?C5F@#FU\#:,FGIIH^V_V8@ ^PM>2-"0.Q!.=O\
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MIX3=S$.Y.22=^>3R>>:36? WA[7WM)-1LGDGM%V0SK<2)*%_NEU8,1]2>IH
MXRYTN\M-2\ Z7>>(+O4)!<W=K<744SQ><J1R8! 8_,,;2WWN#R#6;K%G%;^&
MOBAHH,KV%AY<UK%+*S^4SP*YP22<;N<5Z=+X4T6673)#:,C:6"+,1321B'(P
M<!6 .1P<YS31X2T3?JKM:.YU9-E\))Y'$PV[>06(&!P,8P* +6@VL-IH=E'
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M,([V=IF8SJUL6(;)QC(! [=J /4Z*\AL?"]AKVG^.A?7-YOL]6N?LLANY/\
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M;4;NZ@A\311>;++F1,B0[ XQ]W.T8Y&,9R*U?"EK%I/Q'\4Z79!H[$6]I<+
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MHM[IEO+IJ@!+?;M5,=-N,%2/45)HN@Z7X=L?L>E6BVT!;<P#%BS=,LS$DG
MY/:M*B@#(U?PQH^NW5M=:A:;[FUSY,\<KQ2)GJ Z$'!],XJ"+P7X<ATR^TU-
M(M_L=_(TES$02)&)SGD\<],=.V*WJ* ,71O".@Z!83V.FZ;%%;W VS(Y,GF+
MC&UBY)(P3QTY-0Z)X'\.>'))Y-(TQ+6292C.DCDJIY(4DG8,\_+CH/2N@HH
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M+F,203QM'(AZ,K#!'Y&IJ* ,RR\/Z;I\RS00NTB1&%&FG>8I&<95=[':#@9
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
end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>47
<FILENAME>exhibit108-arvinasxformo003.jpg
<TEXT>
begin 644 exhibit108-arvinasxformo003.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !7/MX9N68G_A)]
M<&3G DAP/_(==!10!SW_  C%S_T-&N_]_(?_ (U1_P (Q<_]#1KO_?R'_P"-
M5T-% '/?\(Q<_P#0T:[_ -_(?_C5'_",7/\ T-&N_P#?R'_XU70T4 <]_P (
MQ<_]#1KO_?R'_P"-4?\ ",7/_0T:[_W\A_\ C5=#10!SW_",7/\ T-&N_P#?
MR'_XU1_PC%S_ -#1KO\ W\A_^-5T-% '/?\ ",7/_0T:[_W\A_\ C5'_  C%
MS_T-&N_]_(?_ (U70T4 <]_PC%S_ -#1KO\ W\A_^-4?\(Q<_P#0T:[_ -_(
M?_C5=#10!SW_  C%S_T-&N_]_(?_ (U1_P (Q<_]#1KO_?R'_P"-5T-% '/?
M\(Q<_P#0T:[_ -_(?_C5'_",7/\ T-&N_P#?R'_XU70T4 <]_P (Q<_]#1KO
M_?R'_P"-4?\ ",7/_0T:[_W\A_\ C5=#10!SW_",7/\ T-&N_P#?R'_XU1_P
MC%S_ -#1KO\ W\A_^-5T-% '/?\ ",7/_0T:[_W\A_\ C5'_  C%S_T-&N_]
M_(?_ (U70T4 <]_PC%S_ -#1KO\ W\A_^-4?\(Q<_P#0T:[_ -_(?_C5=#10
M @& !DG'<TM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MQ1J5IKJ6]SJYC=)(]/,C6[(H084L=^5&,8ZG\*Z31OM_]B6/]J%3?^0GV@J
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M22>< < 4 7DC\3V6J7&9[74-/-D7C:4"*1;D'A/E&/+([G)'J:Y_2_%.J?\
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M-]FO$NEN3]_"MC9UX'E?N_IS0 S5?$.NZ?H&B:E'=0,-1U>"$K);_,+:63"
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M#))'R[<#!YH ZJ;Q!8P>([;07,WVZYA>:,>4VPJN,_,>#U' S6K7 W<ES/\
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M7D'H,>]:H  P !]* %HHHH Y4>#YX=4U^ZM=6:.'6 &DMVMPP23RQ&6SD$C
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M-"3NV.N5/#<@AA^-6K'2+L:F-2U6_2[NHXVBA6&#R8HE8@L0I9B6.U>2QX'
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MF(-1NK5)=<AB=(=F&RKL&.Y3D@J, \>QXQM6OAI_[>L]9U*\2[O;.V>VAD2
M1$JY&XOR=Q^7C& ,GCGB7Q-X<'B*WL56\EL[BQO([R":-%;#J",$'@@AC0!R
MDEE?W/Q9U.VL]5DLY/["M@UT(4>0XEDY (V D]?E^@':/1O&NJZEX;\*Q2[W
MU+5I+F.::V2,.1 7#% Y"!FVKUX +8'2NHM_#,]MXIN->74S)--9)9E)801M
M0DJQ((RV22>@]A6,/AI /"MAHZ:O<Q7.FW+W5CJ$*!9879F8Y'1@=Q&.,C%
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M06SVW]HW<MV(9 08D9B43!^[QSM[%B*N^+/#W_"5>';K17NS:P72A972/<V
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "J6JZK::+I[WM[(4B5E0!5+,[,0%
M55')8D@ #UJ[7/\ C'P_%XFT+^S3?/8W)F26TN4^]',AW*0._0\>F: );?Q-
M;R:K;:9<V-_97ET&:%+B$8=5&2=ZEEX],YY'%;*R([.J.K,AVN <[3@'!]."
M#^-><Z/XFUW3_$NF^'?'.FP_:Y7;^SM7M#^YG<(001_"Q4G\^@ZUEZ=K5WX3
M\,^/]?:]NKV2RUBXBCBN"I5GQ$B,Q"@\9 P"!@< 4 >N45PVM:AJWA74?#=P
M=3FU"UU&^CTZ[BF1 -\@.V5-JC;@CD<@@^O-,T^\U[Q;H%QK.D:NME="^DCM
MK>1%,"Q12E"L@VEB652<@C!(QB@#I;/Q%:WOB6_T)(;A+JRBCFD>1 $97) V
MG.3]T]JUZ\JUC7UT3XIZN@D\F;4+&RM(;IU_=0.S2X=S@C'H#U.!P,D>F6%M
M-:6:0SWLUY*H^::945F/T4 #\J )Q(AE:(.ID4!F7/(!S@X]\'\C3J\SLKN;
M1O&?Q#U6:_O;B'3(()_L[%"KJ+=WV?=R "3C!'OFGZGKVMZ/X$TCQI_:3W)<
M6TU]9F-/*>*8J"L>!N4J7&#DYQSF@#TFBJ6L2SP:+?36L]M!<);NT4MT<1(P
M4X9S_=!Y/M7%:/K>IGQIIFEG4+NYL[[29)FFN(44-,A0>9$-H8*=QX(P>"*
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MV>7Q)JWCS4M$@\02:= FFV]VGE6\4AB=G8%02/F7Y>_/IBHCJOBGQ'IE_?\
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MR2!0VT@9!P00:\[_ .$A\03>$? %]%JQCN=6NH(+MF@1A)OC=B2,#'*C@$4
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M,INMK"0L"QR&.-I7'O7:7^JZIJ_B36]'TY[R :;%"%>T:$-YDBEPS>9U &
M!V;.>, ';45E^'&U=_#UF=?2!=5";;GR&RA8$C(^H ..V:U* "BBB@ HHHH
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MBW$5Q;OY:;F:/[@;C!')Z8S72:I8'4]+GL_M,MNTJ@">' =#G(9<Y&<BKE%
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M$4E@0-N<@DGK0!QFE>(/$4_PMT+6&2]U21KJ0ZG]D"BX> /*N8P,<@A.%P<
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MS+Y<J@VKR-N8QD+GD^I..V,G(!U%%,AC,,$<1D>0HH7>YRS8'4^]/H ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHKB_B)XD.A6%I"+R]TY+J0^=J-M9F
MX^RQJ,Y(P0,G:.>V[TH [2BL/PDK'0(I_P#A('UU)R98[UE1<J>  $ '&#[Y
MS6Y0 4444 %%%% !117GT4NJ7OQ0UK13KU_;V%O80W,21>5\CN2#RR'(X[T
M>@T5Q'P\\3WVM:!JD^KSQSII]_-:Q:@B!%NHDQB3 X_+BM/0M7TBT\'6E^FN
M7&H:>698[Z[):69C(5 ^Z"QW?* !DX&,T =)16!)XDTO4GO=*M-1D@U*.,[H
MO*:.6/Y<@X=?3D'&#VKGO 7C:PG\+>'+75-4>75;Z$+OE5V$DAR=IDQM#8_A
M)STXH ] HKFM/\96=_XHUC1O)N8AIJQ[YI;>15W,K,Q+$850H7!)&<G&1BM*
MQ\0:=J-W':V\DWFR0FXC$EO)&'C!4%E+* 1EEZ>HH TZ*I:CJUEI20M>3;#/
M((H45&=Y'()VJJ@DG )X'0$U6M_$VD76FS:A%=Y@@F-O+F-PZ2[@OEE"-V_)
M VXR<C'6@#6HJE8:M::F]PELTOF6[!)4EA>-D)&1D, >A!J'4?$&FZ5<?9[J
M:0S^2TYBAA>9Q&#@N50$A<\9- &G15>QO;;4K&"]LYDGMIT$D4J'(93R"*X6
M'Q NI^/=9T#4];NM)N[=T73;:-EC$T90'S 6!$C%B?E.0 !QUH ]"HKC;WQ)
M=^#_  _IBZV;B_U"ZU!;3SH[<D,&F(#D(,+\AR%').  >:W[GQ!IUKY2R/.9
M98O.6".UE>4)_>,:J64=N0.>.M &G169'XATF71XM6BOHI+&4@1RIEM[$X"@
M#DMGC;C.>,9KG/%OB6"\\#>)9=%U.>VU#3+=FD"QF*:%MNY=RNH(!'(..>QH
M [:BL6QUJU$6FZ?-/,U_<6:386)W." "Q8 @<]R:Y'POXTL])M]<3Q#K,SM#
MKMS;1RS*S^7&&"IN*KA%SQDX&<T >D450OM9L=.FCAGDD:>1"ZPP0O-(5&,M
MM0$X&0,XQD@=ZY+Q]K_VCX77^M^']6DCV!#'/;-@_P"L564Y&0>2"."#0!WE
M%4-0U>RTZ2*">63SYPQCBAB:61@.K!5!.!D<XQR/6N3\ >(//T'6[_4-3FN;
M>+6;F&":?)8QAE6-0N <G( 4#.3C&: .[HK"_P"$RT$0:A-+?>0-. -VD\+Q
M21 C()1E#8(Z$#FIM'\4:-KUS/;Z9>BXE@CCDD C90%<$J<D 'H>G0C!H UZ
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M=@IMC=QU#< *P#?)T^6NG_X1F[_Z&O7?^^K?_P"-4?\ ",W?_0UZ[_WU;_\
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M&>_N((HI(I)+8E@2G0DC<#@'(V\XKTW_ (1F[_Z&O7?^^K?_ .-4?\(S=_\
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M!*W'E@MM.0JD<XR3@]*-5\5ZM:^&K'5-)U/3-2BNM6AMHIQ'Q)#(RJ!E3\K
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M0N?E;:<XR>1CO0!Z317.VFM2:OJFE#2[M9+"2Q^V7#F,$LKX$0S_  EB'/\
MP BNBH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M_P#A#M8?7KO69/$2K=76EFP?R;,($;+%73YR0 6S@DDD=0.!OV?B"POM>O\
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MEI%;(69(T" N=S-CN3W)[FN0M_ +6FAW?AR#5-OAVYD<_93!F6*-VW/$DF[
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M$VG:"5!.#GWQC$=MXSU:UT+6I+NXBGO4\2'1[21H@J1JS1JK$#J!N9NO/3-
M'I!.%)P3CTJII.HKJVEP7Z6UU;+,"1%=1&.1>2/F4].E9<%CXBMM6N@=7CN=
M,DM1Y+W$2^?%<9YX154IMYYYS[5Q<'BWQ+<> ?!>JQ7UN+W5=2BM;EI+<$,'
M=QT&,#Y0..?<=: /5**\]MM7\3Z-XQU#P]?:E;:F)]*DU#3[F>%8!$ZG:4DV
M?P9(.>N*32?$6J_\)9H>G-J;WUOJ.G322RR6ZK%YT80[H2%4LGS'KD$8P>M
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MA7C;@,K D'GC&01Z5YKXGUO4/$'P:\3_ &^<Q7VDW4NGW1@11'<M'(@W8()
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MYOD1+R*:W\Z&8H,*^ RD, <9#8/I72T4 8MMH+I%J$EU?R7%_?1>3)<A @1
M&VJBCH 68\DG).35:V\+R-K6FZMJ=\EY=Z;#)#!*EN(F;> &,AW'<<#H-HR2
M<=,='10!GZ+8WFFZ7%:WVIRZE<*6+74L:HS L2!A>. 0/PK0HHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M;V\;2RN03M51DGCV%+:7<%_907EK()+>>-98G (W*PR#S[&@":BBB@ HHHH
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MVKG^(X% &G14<$\5S;QSP2+)#*H='0Y#*1D$'N"*DH ***I7FK6-A>V5G=7
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MF_T33[9(_/U6[-NLTH)2(!"Y) (R3MP!D=?;!P&\7^((E\8HUOILC^'HBZR
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M9JWB+2=#:!=3O%MC.P2(NK8=C_""!@GVZUEZ!JNNW&OWUCJ-FSZ>D2RVM_\
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "L'QAX?D\3>')=-@N5MI_-BF
MBE=-ZAHW5QD9&0=N.O>MZB@#ECX=U63QAIVOSWUI(;6SDM7C6%EWEV#%AR<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MPC!MC_-RIP,$'VH [FBFQR)+&LD;*Z. RLIR"#T(-.H **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MU%8,NFQPZ5X-N[77-(DUGP[&$>-[Q5CN%:,1RJ&[$@9!Q0!UND>)9;GQ+?\
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M>P&VM(%U%6100=TCOM!R2W0 _='J: -/_A)8].MM(TJ%K87DNGK<%KF0HB(
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M+)-M$;F*,9<8SM'!XR3R..M6[3P=J^@ZGH$>G"TO]*T_3OL@CNY6C\F?=DW
M4*P8D<8X([$9- #U^(L\_AKPSK-KHPD36KQ;,Q?:0&B<E@<?+AA\C<Y':IQX
MNUDCQ/83Z;96^JZ1:K=1;;AI89$=6().Q3D;3D8&?4=:Q=/\%^);3PMX7TJ2
M+3VDT?5Q>R,MPP$D8:0\?+]X^9TZ<=>>-T^&]4G\5^);V1+>.SU73H[.)A*6
M=64.,LN.AW]CVH TO UYJ&H>"M'O-2\MIYK.&3S%D+&3* [FR!@DD\#/UKH:
MP/!=AJFD^%-.TW58K:.>RMX[8?9Y3(&"*%W$E1C..F./4]M^@ HHHH ****
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M8D#) Q@#C)(Z<D./BS5$O=;T4Z?;R:YIUJ+RW17817D)S@KP2K9!7!SSCDT
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "N:\:Z-JFM:=8QZ6]LS6][%<36UT[+%=1KG,;$
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M'!KTZ]-J+&X-Z(C:"-C,)0"FS'S;@>V,UB>'_#GA2".#5M"TO3T69!)!<01
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MC?(<9X'7MUH YBS\,:S9>+-&U%Y[>[@L-'_LZ6:69A-,Y*$R8VD=4]>]9/\
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M]\+^)+5_#^L:++IZZOIUC]@NK:X=S!<1?+P'"Y!#+D<=_;GK]'CU1;,R:O)
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M$%AVP,YK8@T#Q%HOC'4-9TT:==6VL1Q&]@GF>(PS1KMWH0K;E(Z@X/O7;T4
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M['1U7.0&(Y'3].QTV*[AL8UOYTFNSEI6C4A 2<X4'G:.@SS@<\U:HH Y#1=
MUBQ^(.OZ[<I9?8]4C@1%CG9I(_*4C)!0 YSZ\>]3^+-&U?4M0T.[TPVD\-C<
M-+<6-Y(R1SY7"MD*W*'D9!YY["NHJIJ6IV.CV,E[J5W#:VL?WI9G"J/S[^U
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MW(RJC)P",^U:E<WXST/4M<L+!-,FMEDM;Z*Z>"Z+"&Y1<_(^T$XR0>AY4<4
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MT]Q+;6R0-</]YRJ@;C[G&:X"V\"^*8M(T*RDO=(:72=5%Z9R)2UU]_+OZ/\
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M2@8 L-H8!3CHM1W/P]U358O%<>H:C:QG6)8+BWEMD;=!+$J;20>V5Z=2.XH
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M3A@1GH!@]SU,4GCG5[G3H-9T?37OK-[G9]BCL)S*\.\J9%F^YG W;<8QQG-
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MGKP.*N5Q]_K^OGQZ_AO3X-.6-M,^VQW$^]BI\P)\RC&>_ (Z]>,')?QSKO\
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M\PZX.<5VXX%-=Q&C.V<*,G )/Y"L&/QSX7D9@-<LUVR>2S.^Q5?^Z2< 'VH
MQW^'-M-'XI@FN-UMK!<VT6.+5I ID8>YD56_X"/>M*;PW=GX>W'AZ.Y26\N;
M*2":YF)PTDBGS)#@9Y9F;'\JZ8$$9!R** .*G\):L1X1N+:[LH[W0D:%Q(K/
M'(K1",L,8.> 0/PS4D'AG58=5\67ADLV&MQQK$N]AY12+R\M\O.1SQ]/>NQJ
ME::M97NH7UA;S;[FQ9%N4V,-A9=R\D8.1Z9H J>%-*N-"\*Z9I-T\4DME;I
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M6[W#KEWMO]6W/!7D\$8(Y-9-QHNJM%!!)<6FIVS0R)>V]\A"SNS!MPP"% Y
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M5UNRU/59H8VT^&5+9+4M_K)%VM*2W0A<@+SC)Y/%<Y:> ->M]-\.V;:U8?\
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M=6_;UVN,C\JMZ@]Q%IUS):M&LZ1LR&52RY SR 02/Q%< /&?B"7PAX+U6'[
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M%H\&JZ;(TEG/N\MV0J3M8J>#R.0: .1UN/0_&GBG2+6SO$N+W2;N0WOV=O\
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ME+:5H(F'4-(%*C'?GCH: (;CP[>W'C73O$!O8%2TM)+9K<0'+[RI8AMW'*C
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M>WT5X;2)((WB@\H;$ 5<@LV6P.3G'L*@;QMH:),SS7:>3;-=LLEA.A,2XW.
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MJ[74&M6<=M=0I;+'AD# ,IR< ;L@<G(&2: -)3XBT[4;:YN[VUNM*-M(]_E
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M'7(K]1#::>;!;9H"S,A96)+[NN5':@#D-!U+7=/^'/BG6DU1;B[M+F_D4W,
M8$QNW/!'4+@#H/3M711^);R_U30-#AF$-U>Z7_:-U<A 2J * $!XR68\D$
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M:^^RK:O-=P"6.)2Y'E&0_@H!)/TK*\6:Y+H>F6SV\>^YO+R&SAX!PTC8S@D
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MY(;[NW QUK1M-:U'7_$U]HT<SZ6=,M+>2[\L))(9YE+! 6#+M4#G Y)Z@#D
MW-!UZR\1Z9_:&GF4VYE>(>;&4;*,5/!Y'(/6M.N&^$PD7P05F=7E&H7@=E&
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MNMO>));F2&X5>5;:'4AAS@[NG%4KSP$DVD6MC;Z@89(]4&JW$[P[VGN ^_)
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M"8RW<KSZ$<8??>!7_P"$B?6M"UNZT6>XB2"\2"*.1)U080X<$*P' //';KD
MR-3AUE_'O@B&_P!6EANI+.[-PMGL\D2HB99 Z'KN(^;.!TQSGI/'YG3X?Z_+
M;7<UK+%832+)"0&^5"<9(. <8XP?0BFZAX/BNK[1+RUU&ZLY])$J(ZA7:5)
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MQTS4[BVL]/DDDEA5%(NM^XD-Q\HW,2 /IZ5T= !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MH)( ZG'%-36]+ETF/58[^!["0#9.K@JV3@ >ISQCKGCK0!?HKBO&7B4/\/\
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MEQG*XZC'.15B+4;2>_GL8Y@UU JM+'@Y0-T)^N#CZ&@"U1110 4444 %%%%
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MTNEPQ_+8C?+GS206WDG/) .XX7C-=GX6ET^Z^*'CC#6\DC-8E0<%B%AYQ]&
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MT(0+D?WBU-US1M6U>^CACU:.WT62(QWEJ+<-)-D\@29^4$?*>.F>YR-\
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MC&5ZCJ!U'K6A)K%C"ED\DK*+YPEO^Z?YV(+ 8QQP"><< GM7%^&H+#5_$WQ
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MDE5+,S-C+,S%F8XP,EB3P .>*M5Q_P /+N[NK+75O+R>Z:WUN[MXWG?<P1&
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M8OM!)Q@'G Z=3T')J&+Q?HT^FV]];S7$\4\331K#:RO)L!P6*!=P&01R![4
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MG=VEGN'4 RR,<EL#@#L!V  [5?K'L?%&CZEHSZM;7F;..0Q.SQLC)(#M*%"
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MNPHK/++;&..-%+,['H !R3722V44]Y!<REF:#)B0GY58@@MCUP2.>Q/J:LT
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MA8#:A]U0(G_ :Y[5I&L?BYH][+!<-;S:5/:I)%"S@RF5&"D@'' )R<"NXHH
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M>-(I)E:U,Y182&.P)"?D= NW)P3U.>AK3\53:A:>)?!%JE_>0+>W#0WL<<[
M2A8]V#@\<CJ,9S65XFAT+QEX46[U/2[VT\3QV^;8Q6DJ7(G ^780/F0MC')
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M#%8R-'=+<Q-"\+  X96 (X(QQSFN3U"]%_XC^']Y#:7P@ADG:5WM)%\L&W*
ML"N5!8XYQZ].:R-5T_4M2;XA)IUG<23R7ME=VT;1O&MTL(C+JK$#/*$<=\4
M>C67B73K[5WTD&>"_6'SU@N8&B9X\XWKN'(SP>X[@5>O]1MM.CC:X9MTK^7%
M&BEGD;!.%4<DX!/L 2>!7(^%[W1=>U6WU"P\/ZA!=V\3++<:A#)&UOD<QJ7^
M\2>H7C .3TRWXAQW5K?>']<6PNK^PT^>47L%IN,H21-HD4*03M(YQV- &P?'
M&AKI=_J$DUPD6G2>7>QFVD,EN<9^= "0,<[L8QWJY:^)--O9XX;9YY6DM%O%
M*6[D>4V=ISC )P<#J<=*YW3]0T:WTS4]8T[P_="*]\N+,UM()+U\%1N5@6"
M$#<PQC=V'-+P1;7'@O7KOPG<P2S6DRK=6=]%;OY:DC#0,W.-N/ER?NX&<T ;
M7AOQQ::WI%[J=Q#/9P6]Q+$/-A<?*K[%&<8+D_PC)R<=:NIXPT@SWUO,]Q;W
M%E +F:":V=9/*Z>8JXRRYXR,X[XKSF.RU4^ M0L+;2[Z6_TO7GOY;4Q/']HC
M6Y,@5&P Q*\C:3T]QGH;.\T35[74-5TS0=0BF33I89+J\MI5E7(XA4-DMSDG
M;D#'O0!NV7CWP_?W&FQ07$Y74@/LLS6TBQ2,5W;-Y&W=@'Y<YXQUXHT7Q='K
M/B?6=(6TNHAI[I$'>!P&8KN))QA1@C .">O>N)"3+X%^&T!M+OSK/4;-[F/[
M-)NA5(W5RPQ\H!(Y/K72^&S+9_$?Q=!/:72B]FMYX)?(;RG00*I._&WAAC&<
MY[=: -/Q1XK3PY=:1;&UN)GU&[6 /'"SJ@P2>G5L X Y[]JY]/$*Z3\2==^U
M7.HSVITVVGAM$CDF92S/N*Q $KP!GCCO5_X@K+'/X6OEM[B:"SUF.6X-O"TK
M(ACD7=M4$XR1T'>H=,N-OQ4UN]DM[J*WDTNV59'MW"EE+EESC!(##@&@#I8?
M$NE7.D66J6UP9[:^Q]E\I&9YB03@+C.< Y],'.,&GZ/K^GZZES]BD?S+64PW
M$,L922)QV93R/8]#VKR/2H+[3/!?@K5)])U&XM=+ENXM1M(HI$GC65CMD"<,
M0N ?HU>E>$AI=Q]MU+2M)GLX;HINGN8GCEN64'DJ_P V " ">O/8 D QO%LE
MV/B3X0TV#4KZVM-36\^U1P3E0_E1*R8].3VZU7\/>*Y],\2>,--UC5#=:-H@
MBE34)@-T>]<M$Q4?,0>!QGC'-+XTABO/B=X+\^QENK*U%[]J8VK211[XE";C
M@CDBMKQ9;IH'@/4AH6@VDQ4!A916BLC990S>6!\Q RV.^V@#1M_%&FW%W=6A
M^TPW5M MS)!+;N'\HY =5QEAD$<9(/!K#N?BCH T:XU"P%Y>K'927B>5:2!7
M53@_.5P,'&<G@=:Q],N5C^)K:DL6LSV=QH(07EU:RC>XF+'@J-G';"@]@<C+
M=!L;N?\ 9[GTM+.X6_&EW,/V9X623>0^%VD Y.1CUS0!OW&OZ;J%AX:GU&ZU
M*QGNKN$P)#%+$LTQ7/EM\N#&<DX)P<=\5KZKXKTK1_M7VF29ELU#W;0PM(+=
M3R"Y4<<<XZXYQBN*UB[-_P"'? ;0V=__ */JUG),&LY R(D;!V(VY"@G&3^'
M'-2V&J/X7\3>)=)UK2-0NH-5O3>64UO:-.EPKHJF(X! (VX^; QUP* .FN=4
MT>?Q7HJ?VE>"[EMY9;6"$O\ 9[B,J"6; VM@8(YR,^]5+GXF^%K6*:62\N#%
M!<&WN'6SE(@8$ ^9\OR#)QDXR0<9P:HZH)?^%C^"G:RDC6"TNTG\J)FB@9TC
M"J6 VCE2!]*Q-&O;4^'OB#IC02SW-SK&H1Q6Z0LQG+@* O&#SU].IP.: ._O
M?%&F64Z0>9)<3-;&\$=K&93Y ./,X[>GKVS4%QXV\/VUKI=S)?'R-5Q]CD6%
MRLF1D<@8!P.AP?:N.M8KW1KS2O#M_9W@2#08H%NK&V9GNIAPT1F491%QD#*C
MG).*RM(\]?"7PV@DL+^.2QU!3<J]I(#&H212QXX7+ 9- '?MXZTEM&UC4(([
MV1])4FYM6M7CF7Y=PRC $ CG)XQ]*TO#6L'7?#UCJ+12123P1NZM$R#<R!CM
MW#E>>#TKAY[:XN_$/Q+BAM;AC>Z7#%;$PL%F=8)5(5B,$@LHX]:ZSP/<BX\%
MZ0OD7,+06<,+K<0M$P=44,,, < Y&>AQQ0!S-GXFBT#QOXU74KO4+BUMC:/%
M"B27!A0Q%G(50=JY.2>!T]JZ^7Q/I21Z<T4S7+:C$9K2.W0NTL84,6 [  CD
MXZ@=:Y*S8Q^+/B',]O<B*X@MQ"YMWQ+M@*L$./FPQQQ63H5[=6.E>";"[TZ_
MM[8:8T4UU#8N]PDPVCR,A2T0;&21C.T8(QF@#T*W\5:3=Z1::E;3O-#=RF&!
M4C;S'D&[*;2,@C8V<]-I)XJ[IVIV^J0RR6XE'E2F&198FC97&,C!&>_7H>U>
M5:+I]M/X%MM*U>TUJPDBUJX:.\BCD26SD+RLDF[!R,?*6Y7Y^3Z=QX$DUE]+
MO8]9F%VT-X\=M?>3Y37<05<2,OKU7/?;WZD LWOC31K'5+K3'>ZDO[:(2O;P
MVDLCE2< J OS#@\C('>IX?%.CW&B66KP7?FVEZ0ML41B\K'/RJN,[N#D8XP<
MXP:P+:3ROB_JUR\,ZVYTB&(3&!]A=9'9E#8P2 1Q7&Z#:ZCI^@^!]7:QO#;Z
M1?WHO[;[.XDC29I LNS&2%#9X!X;ZT >EOXPTP6&JW""Y>?2TW75GY#"=.,C
MY3V(Z-TZ\\&IO"NN?\)%X:L-3:&2&2XMXY'1HV0!F4,=NX?,.>HXKE+K3)]:
M\7:]KFGQR&S?P\=.1BA47,Y9F^7/4*-HSTRV.QK=^'MP9? >BPM;W,$EK90V
M\JW$#1$.B , & )P1UZ>AH 34/B#X>TZYO[::>Y>XL-OVF**SE=D# G=@+]T
M 9+=!D<\BII_'/AV"VTNY-\7AU3_ (\WBA=Q+P3@$#[W!&WKGC&:Y[2M4L].
M^*7CC[674/'8E2(F?=B)OE& >>>!U/;.*Y^PT:ZT'2_ 5K<V5RK0ZM->2Q)"
MSBUBD$I4-M!"XWJ#Z'/I0!Z+!XNTRZT^WN[9;R;SXWD2!+5_.VJVUB4QE1D8
MYZ]LU&/'/A][;2KF.\DD@U63R;22.WD97DR1L)"_*W!X;!X/I7->)IO["^(?
M]JZIIVH7>C7UA';"XLDD<V\L;N<,J<[6#]?6KFH^&8=7^'=Q:Z-IC:5,)#?:
M=&R[)$G1MZ.P/W68CD'D!N><B@#I=2UK3[<WUG<RW,9@M?/F>&&0^7&V0&#*
M#SPV,<_*?2JFEZSI-EX5T>:&^NKJVN8HTLWGW27%SE<CC&XL0"3QP 2< 51L
M)+JY\$W^M:C:R07VIVK3/;A2S1KY>U(P.N<<X_O,U<CIUO?Z?I/PVUI[2[:T
MTFW>VU"$0/YD!DB"!RF,X4@YXX!H ] 7Q?HYLM2N6EF3^S.;V%H'\V 8W99,
M9QCD$9!'2I6\3Z4LND1F>3.KJ&LF\E]LF5WXSC"G;S@XKCM0T>YUS7?%NKZ=
M%(;6Z\/G3H<H5^TSD.<KG&0 57/3D@=#6;#J)OHOAR(-.U,C3I5CNR;&4>2P
MMRA!!7)P>I&0/6@#T/\ X273C<K"OVAU:Y-HLRP,8S*"5*[@,#!!!/3((SGB
MN:TG6#I/B[QY+J%Y>2Z?8&TD56WS>2K0EFVJ,D#)).!_*LE;>ZL/$B7GAJ>]
MC%UJY34=#NX6:(CS2'N(RP^0<>9N!P<COP=SPTI;XB^-FEMYA!<M:>4\D+!)
M0L.U]I(PV#P: .@'B73&T>QU5))GM+YHUMV6!RS[_N?+C(!]Q6C=74%E:RW5
MS*L4$2EW=C@*!WK@?!VCW]CX@N=!G7=H_A^=YM/D+9+"9<QH?^N:M*.?[R^E
M;OQ"TZ_U3P/J%OID1FO%,4T<(.#+Y<BN4S[A2/QH N0>*M,GU*33C]JBO4@^
MT+;S6SH\D><;D!'S<]AR.XJ*P\:Z'JEK:W%E//,EU<O:Q!;63<9%!+ KMRN
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MO6PFC*):2.MQNF+B17 *D'=ZYS^%>PKYE[H6+<R02RV^$,B%&1BN 2",@@T
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M)1W.?D)_A;@\''0^E '245275(&UE]*"RFX2%9V.SY C$@?-ZDJW'L:Q=?\
M%C:-XFT+2%L;F;^T7E+R1Q[@%2-FPOJV=OT&: .GHKS:Q\1Q>'_&OC?[9)J=
MU;V[6DD<,:R7!A0P[G('.U<DGL/2NT;Q%8-:6-Q;-)=_;XO.M8[==SRI@'<
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<?\
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MB:11F-"!G.5R0,D &N+L;+4K;X8Z LFCZDDFC>(5NKF$V[&3RA<R,2J]7PK
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M &>%I3#'C<V!G')Q^M8FB>,$NO".D:MJ-O-#<7\<*Q0JH)GE= V(P#TZ\G&
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M?(B7AA0SK']T28&X#VSF@"S1110 4444 %%%% !1110 4444 %%%% !1110
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M )VC)XZ<C-S2=5L]<TFUU/3YA+:7,8DB?&,@^W8]L4 7:*** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ KDOB1I][J/@V6.PM9+J>*YMI_)BY=U29&;:.YP#Q76T4
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ME0T8&[:0QY X/7%=S10!Y+JWAO4D\,ZU/'I]R]QJ^OQ7\=K''N:.%)(SE@.
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M5'Q%8W]CX^T3Q-!;37=C%;2V-Y' I>2)7(99%0<L,@ XYQV-=FJJJA5   P
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MA5<[RN8V.&8CJ>. !B@#LM7UB#2([8RJTDMU<+;01J0"\C D#)( X4GKV[G
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MOW@410-O*#?\V<9'4 @9QG.0+<MM>2?%>RU1;&Y^P+H\ELTY3"K(TBN 1UZ
M\XQ7&>';6Y\2? VV\-6UC<>?>%XO.=/W2)]H9C)NZ< 'Y?O9'3'- '?ZMXVM
M-*DU8"QO+J/2(DEOI(0@$2L-PQN8%B%^8X[>_%.O_&EG9:O8:9'8W]U/J%N]
MQ;&"-2LBJ < EA@_,.N ,\D5R?BC3O$&IKXJTF;1[R]@>R\O1V21!;J/*P2P
M+#,F_ID$],8&35VVM-4D\5>#+V72+N&&RTV:"Y+!3Y3NL84'!/\ </3.,C-
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MPL5QSM9CN';=Z_2H;GQS#%JNKZ9;:+JMW>:8D<DL<,: .KAB"I9P,87O@G/
M/.(O'EG>WLOAK['93W(M-:@NYS& =D2!PQY//WAP.:AT^WO;;Q[XLU"33[H6
MEW;6J6\H3(E:-7# #.>K#KC- &K;^,;"^L]'GL(YKE]7A::UA!5&** 6SN(
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ME$CF+L<YP>",8/\ 6@#O+_Q9;6EWJ=M!:7-[)I<"SWH@V_NU8%@!N8;FV@G
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MZ9JSJ?BU+,:FUIIUSJ":4 ;UH"OR':&**"?G<*02/<<YXH Z.D#*Q(!!*G!
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MTEO R&#R8W4^:ISDDHHPN,[CS@<UZ?10 @&  .U+110 4444 %%%% !1110
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M:Q.N!=!F.QXY^J8!  R , >U>C7>NP:"MAI :WEOC:[P)9Q#&$3"EBQSC).
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M*@CMU%<7X=\+7.F^++34]+TRYT*RFAD.JV#3HUN\A V&-58@$-DY  P.Q)%
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M^(/^$7O?[(BG>*\G\]-T 60H6"=7 QDXX&>IP: .D_X03PG_ -"YIG_@,O\
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M.#_<"@$DMVYQGBH[7XC::)]:AU(0P-I5N+IY;:X%Q%+$>Z, #NS@;2 <D=:
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M6M])="/[+YIRRR)C<P!R1MZ^HSQZ#10!R+Z5J?\ PLZRU?[,\EA%I3V3W!=
M3(TBOG;G./E].IZ5R/ABTU+7?A5?:!:V# 7MU>0"\>1/*1&G?<Q&=V1\V %Y
M..1DX]:=!)&R$L PQE3@CZ'M6=H>@:?X<L39:9'+';EVDV/,\F&8DL06)(R2
M30!Q6K^&M>FO=:L$TZ&_TV73%M=*EFN55;,B(HV4()WDG.X#I@9 I]CH>O)?
M> 9KC2]BZ+:2PWFRX1MI:%8QCD9Y7)QT'0FO1:* /-+SPIK>H:/X^L_L8A?6
MI?-LS)*A#8C5<'!.TDK].:[[2'O)-+@:^M!:7&P!H1*)-O'=AQGZ5=HH X6U
MTK6[76O&E\NDI*NIM UI%-+&4F"1B-D<9.,X/4=#^%/\)>%I-"\2WMUIUG<:
M5HEQ;#=ILLRNHN-V2Z*K,$&W@\C)/3BNWHH Y+Q-IFI7GB_PM?V=DT]MIT\T
MEPXD1<!XB@P"0203GZ53U:Q\2Z)XVGU[0=-BU:SU&WCAN[1KE8'C>,MM=6;@
MC#$$=:[FB@#@M8TOQ1%K>A>*+2RM[Z^MXIK>\T])Q&/*D(($;L "4*C).-WM
MVR;73K[Q#J'Q/TYXXK:]O8+:)4\S<J,UKA06QSVS@>O6O3;F[MK* SW=Q%!"
M.#)*X51^)K+L])T;2?$%U=0RF/4]4 >5)+IF:8( ,A&;^$$#@<4 <G%IGBB]
MUGP7?3Z'%:)I F2Y1[Q&/S0^7N&W/&>1U)[X[I-X>UN2P^($(TQ]^N;A9_OH
M^<PB+YOFXY&?I[\5Z/10!PVM:!K=]X*T'^SXX[?6]&D@N8X)W!21XT*,A921
MA@S8/TZ=F:SI7B3QWX,U73=3L(=#DG@"P0_:1.6E5E<,S*,!<J!@9/))["NV
M^UVWVS[)]HB^T[/,\G>-^W.-VWKC)'/O1=7=M96[7%W<16\*_>DE<(H^I/%
M'!7-OXMUO5/"E[=^'X[673+IY+LM>QE6S$R;DVY.W)SSSVQWKI?&VD7.O^"M
M8TJSV?:;JV9(@YP"W8$]JWJ* ."N-'U[^W/#WBF+35^TVEL]G>:<MPA<Q, 0
M58X7<&&<9P1WK7T'1+B+Q/K?B.\A-O+J(AABMRP9HXXU(RQ4D;B2> 3@ <]:
MZ:B@#DM=TS4D\<:+K]G9&]MK6VGMIHHI$64>84(8!R%(^7GD'ZUBZUX)U/5O
M#OB^=4BCU77)()8[<N-J+!L\M&;IN(0Y/0%L9(&:]'HH X:*R\1:AX_T;7KG
M1H[.UAL9K>:-[M7>,NR'G;D'[IP!^)'07/ &E:KH.BS:3J-I'$D%U.\4RS!_
M.5Y6<$ ?=&&QSS73M=VR7:6C7$2W,BETA+@.RC&2!U(&1S[U-0!Q-[I>MZ/\
M1)O$.F6 U*QU&T2VNH%F2.2%T)VN-Y *X.",Y[US\?@OQ')HLLIM;:#4K/Q)
M)K5G";C<LZER2A8#Y<J3@_3(%>K44 <1J7AFY\7:VE_J%I+IMO#IES91QR.C
M2L\X"LWR,PVJHXYR2>V.3PHWC:UMK+1-6TJTABL@L3ZJET'%Q&G VQ8W!F
M).,<GT%=N2 "2< 5%;75O>0">UGBGA)($D3AE)!P1D>A!'X4 >?)X4OIO$VF
MZW:Z2^C:LEWG4KF"=/(O(!G(9%8EF;Y>JC!)Y.!70?$'2K[7/ NJZ5IL'G7=
MW$(XU+JH'(.221QQ7344 <9J.EZG?>-?#.I#3I%L[*VN8KDM+'E3*J 8 ;G&
MTYQZ\9K'L/#&O6/P^O? ALQ+&RRVMMJ?FIY7D2,3N=<[PZAB,!2"0.>X]+HH
M XJ/P]J.D^/M-O["T2XTQ-&32V=Y@K0[) P8CJV5]._7'6M#QQHFHZUHD!T>
M6)-3L+N*^M1-]QWC/W6]B"16_<7=M:!#<W$4(D<1H9'"[F)P%&>I)[5-0!S.
MGZGXKN;*XO+[P]%9S10E8;!;U)6GE..2X 5%&/4DY/' !R++0-:\/>++?5-/
M@EN[?5(B=;C:1$VS]5E0%NHR5*CC:!R37>T4 >?:59^,?"^I:CI=CI5IJ.E7
M=Y+=6E[)=B/[+YK%F61,%F 8DC;U]>>'?V=XI\->,M4O]*TV+6M/U@1/*&NE
MMWMYD0(6.1RK  \ D>G'/?U#=7=M96[7%W<16\*_>DE<(H^I/% ''ZWI>O)X
MC\,Z[!9QZE-917$-Y%%*L6/-"X9-V 5!7'KC'4UA7/A#Q)>^$/&VG26=M'<Z
MIJ)O;4"X!#C,9VYQQ_JSR<=>@KU.B@#@M6L_%=OXCL/%FE:3#<S/9FROM*:[
M5&";RZ,LA&W<"3GMS@9ZUU^DOJ4MEYVJ1107$C;OL\3[Q"N  N[ W'C)..IP
M.!FK<DL<*;Y9%1?5C@4D5Q!.3Y4T<F.NQ@<4 <I:Z;J^F?$/6]4CL%N-/U*V
MML2K,JLC1*X*[3U)W#'0>]<U#X5\01?"W1M .F$ZA::A'/*HGCV[%N#+D'=S
MP<?7\Z]4HH X$6GBSPWXKU6YTG1X=6TK6)4N2CW:P/:3;%1MV0=RD*.F3Q^?
M;VHN([.,73K+<A,R&,84MWV@]O3-3U#;7=M>1F2UN(IXPQ0M$X8!@<$9'<'@
MB@#A_#=EKVB:]XGO)=!FECU.^^T6^RXAX4*%^;+\=.V:M:1X2OIO$&J^)==D
M@&I7UK]BMX+=B\=I!UV[B!N8GDG 'I79NZQHSNP55&2Q. !ZTRWN(;NWCN+:
M:.:"10R21L&5@>A!'!% 'EEOX=\6_P#"*>%-'?184DT+4K>661KQ")DBW?,N
M.@((Z\Y/3N.J\/Z;J=IXZ\4:C=6+16FI?9C;R>8C?ZN/8V0#D9/3VZXKK:*
M/)3X:\77%AI#7NCV]QJ]AK4=Y=7KWB[KJ-78C9QE5 8?*<8QPIKIK.QUO1?&
M'B74(])^VPZM]GD@>&X15C:.$1E9-Q! R,Y4-QVSQ7:44 >;MX,U+2='\&Z=
M9P?;3I6I?;KR5'5 =WF%]H8@GYI#@>@JS;V?BWPQXDU=-+TBWU;2=4NC>1R/
M>"!K65@ X<$$LN1D;037?T4 01>?#9)YQ^T7"1C>4 7S& YP"<#)]37-Z-X=
M@OX[N_\ $.AV_P#:=S<O(_GB.7"9Q&JL,\! H[<[CWKJZ* ///"OAO6-+T[Q
M)X<DL#;:/=2SMIDAE1O)20'*,H)( )R,9ZG-4(-#\63:-X*LI-#AA;0;N#SR
M]ZA\Q8XF3>N,X!R..N3TXS7J5% 'GTWA+4[W4?&NG3P(FFZ\%:*]$H)0^2$Q
MLZY# 'TQW[4LFA:WK_AG1?#^KZ=]E-E/;M>78F1HY5A(/[L [LN5'WE7&3UP
M,^@44 </9Z3JT&N>-KQ]-D\K51%]DQ+'E]D(C.?FXY&?I[\5F'PWKJ^"O!.F
M#3&-UH]]:SW2B:/&R($-M.[DG/'ZXKT6XN[:T5&N;B*$.XC0R.%W,3@*,]23
MVJ:@#RGQ-X7\4ZWIWBNRETN"\N+N;?IU[+=*!'!E"L**?NL-IR> <DDG KI'
MTW7%^(MEKZZ?"UO-I7V*X N1_H[>;YF>F6XXX'7T'-=E10!YC/X,UO4M$\6V
MGE"QN[W5QJ>G2R2*RY7RRH;:3CF/\,]ZZWP_?>)M197UK1X=)2),-&MTL[3/
MZC:,*@Y/)R<CICG;DN[:&XAMY;B))Y]WE1LX#28&3M'4X')Q4=]J>GZ8J-?W
MUM:*YVH9Y5C#'T&3S0!1UN368;C3YM*MENHTF;[7"91&6C*'[I/&X-M(!P.O
M(KG/^$7DUCQ[%XA?2GTB*.QFMK@N\?FWADP!D1LPPHR<DY)QQ@5W8((!!R#1
M0!P'A*W\:Z+96OAF[TRT:TLL0Q:RMT,- OW?W.-V_:,<\=^<<W])TW5++QKX
MLU273I/LNH+;?9BLL9+F*,J01NXR3QG\<5V%([K&C.[!549+$X % '!>&/ E
MO<> =&T;Q3IA:XTY77:+@@9+$Y!C;D8QUJQJ_AJ[L-<\)7>@:?'+9Z1]IB>!
MKC:465  VYLD@$<]3SQFNRM[B"[@2>VFCFA<922-@RL/4$<&I* .&T?2M;\*
MZAXAM[;3CJ-EJ5Y)J%K*DR+Y4D@&]) Q!"@@$%0W&>,\4[2_A?H,/AG2-+U6
MV^VS:?;^5YHFDC!)8LV K#C<3C-=O10!'!!';6\4$*[8HD"(N<X & .:DHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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MY_A3PH=#\37U_864FDZ3<VRA]-,JLAN-V3(BJ2JC;QP1G/08J#QI+/#X_P#
MLEO;FXD6>\_=!@I8>0<X)XSC.,X^HZT ,/Q(N;;3/$9U#0'M]6T)%EGLA=!E
MDB8$JZR;1D8![9%&O^*[N+PCJ&I:SX/CFTQ?L[11S74;B=9&'++M.TJQ7C!_
M2HM;\)ZIJUIXMOUM52_UFS2QM;=I5_=1J#\TC XR68G S@ >^-#Q;HNK:W\-
M#HMK9J-0EC@0H\JA4*.C'+=Q\IQCU'2@#8N]?D_M]M#TRVBN;Z.V%S,9IC''
M$A)502%8EB0>,= 3Z X%Q\25A\/-J*:/,]S;ZDNF7MIYRAH)2X7@X^<?,""
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M$\-X!>;W9I%0&4G;\Q)4GJ2>Y%;G@O1]6T.76;2]@@%K-J5Q=P3I-N:197W
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MC348O&K,A0D9*MC(]N.*=0 4444 %%%% !1110 4444 %%%% !1110 4444
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M=:3>-)=R_:W=KLM&R&9CLSGG.#DGU&*V;+1-?TBY\306MO:31ZO>/=6]TTY
MA+HJ$.FW)QMSQG/3CK7;T4 <(W@Z[TR]\$PZ7''-8Z )!,\LNUWW1&/(&#SD
MECR*98:/XQ\-ZOJ5GI*:9=Z-?W<EW#/<RLDEFTAW."@!W@$D@ CW(KOJ* (U
M#Q6X7+2NB8RV 7('?MS7FUMX1\3VG@>PTI(K-YK;56N[FU-R1%>0-([F,MMX
MY9<@C!V]^E>B7^HV6EV;W>H7<%K;)]Z6>0(H_$U.CK)&LB,&1@"I'<&@#D?#
M.A:QIWBOQ#?WT%A'9ZGY#HL$K,4*1!-F"HXXZ\9].>,/_A6U]%X4O["&[C-[
M:W7FZ'(W2V2.4RQ*3ZY9E)]-OI7H.HZG8:19M=ZE>06ELO66>0(OTR>]6^HS
M0!5TVQ73=-M[-&+B% I<]7/=C[DY)]S7/7&C:M#\1QK]I%:S64VFK9S"24J\
M961GR!M(;(;'48/Z]710!YA-X,\03?#;7/#WV>T%[?W\EQ&WVC]V%>82<G;G
M( QTK5O=)\5:5XNN->T"WL;N#5(8DOK&ZN#&8Y(QM5T<*>,'!&.WY=5<Z]H]
MG=?9;K5K&"X&/W4MPBOSTX)S5V*6.=-\4B2)DKN1@1D'!'X$$?A0!#I\=W'8
MQ+?2I+='+2-&,*"3G"]\#.!GG YKE_#^B:O8_$#Q+K5U;0+9:L+81;)MSIY4
M97YACOGL378T4 <KXMTK6;_4]#N=.BMKRSM)I&N["YF,:397",2%;.PY."#U
MSU KE[OP5XFF\(>*M&$6G&75=4:]@D6=@H#.CG<-O&-F.^<]L<^I44 <KXPT
M?5-:L=%GL(8/MFGZG!?-;S3%5<(&!7> <'YNN.U0OH.J7/Q!76+J"W^P/HS:
M=-LF.[>T@<D C[O&.N?:NPHH X+PGH_C'0+*W\-S_P!GOI5FVV+4UE;SG@!R
M$\K;@-CY<YP!ZXY;?:/J5E>>/M6N(85L]2TY1 5ERX\J%U.X8XSGCDUW]5[Z
MRM]1LIK.Z1GMYE*2('*[E/4$@@X- 'GVB:/J'B;P#X.T^YMH[>QMXK*ZFF\T
M-YJ1HK(JC&020N<XQSC/6JVL^#O%6HZ5XDL3%IL\U[?+<VU]+<,)&A65'2'&
MWY0H7'7'MR37I&G:=:Z580V-E&8K:%0D<9=F"*. !DG@>E)<ZI86=W;VES>V
M\5S<MM@A>0!Y#_LKU/2@#G(-)UE?B))X@FM;?[,^D)9%8Y\MYBR-)P"!\OS8
MSUXSBL"'P7X@B\$:?I_DV9U#3];75$C-P?+E43M+MW;<J<-CIVKTVD9E12S,
M%51DDG  H 9 9C!&;A468J"ZQDE0?0$XR/? ^@KBW\ +=:]X@^U2JVBZG&94
MM@/N7,D9CED^NT#'N[>E=(?$FB#2WU0ZO8C3T8HUSYZ^6&'!&[.,UI>8GE^9
MN&S&[<3QCUH YCP_H>I:1X'-C>2)>:Q) 1/)NP))-@1>?9549]JP&\(Z\/A[
MX8T-8+4WFEW=M-,3<81EA;=\IVYR?I7?6&I6.JP-/I]W!=0JYC,D+AUW#J,C
MCBK5 '*KI&IGXFC7S!$+ Z2+$_O?W@?S?,SMQC';K3_&GAV[UVUTVYTV6)-2
MTN]CO;83$A)"N048@$@$$\X]*Z>B@#F+?1KO4O&%KXBU&W2T^Q6;V]O;B02,
M6<@NS$<8PH '/4DXZ5D2?#L7=WXGM[J93I.I[Y;2 #/D3RH!+)]=R KZ;F]:
M[ZB@#BI?!M]J/PTDT*^OP-8N(TFFO!S_ *2K*X/N 55?HM7_  Z_C"X>/_A(
MK?3K1(%PQLYFD-R^,9P0-B]\<DG'0#G=.HV8U-=--U$+YHC.+?>-YC!QNQUQ
MGC-+?7]GIEH]W?W4-K;H,M+-($4?4F@#!\;:)J&LZ?IK:8L#W-AJ=O?"*:0H
ML@C8DKN ."0>N*Q=4\.^)[[6M9E>+3;B#4-.%O;22SM_H#[&60(NWY@Q;.[Y
M2<#/0"N]BE2:))8F#QNH96'0@]#3Z .*T_P_JUQX9T3PYK-K:_V=#9)#?B&X
M+&4H@54^Z/E.-S8QV7D9)SX_!_B*[\"W?AF\NHHY+299-'O_ #=[A8Y \(E&
M.HV@$C/'N.>ZBU2PGU&;3X;VWDO(5#RP)("\8/ + <C\:MT <GI[^-[O3[DZ
ME;Z78W45NZP+;S-*L\^W"LV5^1 >W).?;!J:%X2>P\8C7+73HM&BEM7COK6W
MFW1W,Q*E6"@  +AOFP"<].M=O10!ROBW2M9O]3T.YT^*VO+.TFD:[L+F8QI-
ME<(Q(5L[#DX(/KU KFY? _B&Y\'^+M'D_L]9M3U)[ZU=96VL2Z/M;Y?E'R8[
M]>V.?18]1LYM0GL([J)[R!%>6!7!=%;.TD=LX-6: *]B]W)9QO?0Q0W+#+QQ
M2%U3VW$#/UP*X<>$+Z\\1Z3K4FGVVG:O:W&Z]O[6;B[AP1L90!N9OESD<8."
M>!7H%% 'F-_X1\3'0_&&@VEO8/;:Q=3W<%W)<$$>;@E"FWJ"#\V<8['I5Z;0
MO%6C^)8=?T>WT^[>ZL8K34;&6Y9%W1YV2))LYP"1@K_/CT"B@#C-8T/7K_4?
M"]VXMIY-.O'NKLB0H/F1EV1@CG&[J<9Q[U:T'1]2LO&OB;5;J&);34S;F K+
MN8>5'L.X8XSU&":Z"_U&RTJS>[U"[@M+9/O2SR!%'XFFMJ=BEY:V;W<*W-TC
M/!$7 :55 )*CO@$4 9?C/0'\2>%KNP@<1W@ FLY>GESH=R-GMR /H35#6O"5
MUJ7@9=)@O5AU6-TNX[HK\OVI7\TL1Z%\_0'VKKJ* .4L7\;7FG73ZC;:78W<
M=LZV\<$S2K-.1\KL2ORH#_#R>>>G-#1_!K6GBBXU:TL(]%@NK)X;RT@EWQSS
M$C#A1@ *-W. 3GH.<]U10!YDWA#Q*_PIMO"KV]A]KMG@1'6Y8HR12A]Q)3@D
M+@#!^O:NA.DZJ?B0GB#[+%]B&D&R*^=^\\PR"3.,8QQCK7644 >4W.B:GIO@
MQM!NK?3GU#4M;>>UA>Y8"16E,Q"N!E'50?FQQVY(K>\.RZI8>(MFK>&XK6XU
M%=IOH]2^U.WEJ2%8,H*J!GIQD\\MFNIU?1-,UZS%KJMC#=PA@ZK*N=K#H0>H
M/N*9I7A_2M$#_P!G64<+.,,^2SL/0LQ)Q[9H Q/&6@:GJ&H:'KFB&!M2T:=W
M6"=RB3QR+MD7< =IQT.*QKOPYXNO]5\2:C;_ &/3)M3TR*VMW2Z9WAD3=W"#
MKNQD=.V<5Z-10!P&E^'->@\6:)JS:;I=E:VVGR6<]O#<,Q3<R-N!V#<3M/'X
MDFJ<7@;7SX.N]$\ZSM;FTU)M0TR[61GWR><94+KM&T<[3][KGMSZ710!S_A^
M3Q1=/YOB"UL+$1IL$-I,9?-?CYR2!M QPO/7D\55\3^'[^Z\0:'XBTGRGO=+
M:1'MY7V+/#(H# -@X88!';UKJJKWM_::=!Y]Y<1P19QND;&3UP/4\'\J .-U
M/PKJ.ICQ/J9@ACU#5=,_LRU@,O$4>UOF=@.I9\X&<!1R<TDOAW6G;P01;6__
M !),&Z_?]?W)B^3CGKGG%=G8WUIJ=E%>6-S%<VTHS'+"X96'L15B@##\9:-/
MXB\':MI%LZ)/=VS1QM)]T-VSCM6)=:-X@OM:\(ZC/96<?]E-*US&ER6QOB\L
M!25&X]ST].>M=O10!YQ?>"-8U1O%VYX;*34KJWO-/G63>8Y(0FW>,<9*=L\&
MNE\/2>++IU?Q#;:?9+$NW99S-*9W_O'(&Q>O'))/48YZ*JFHZI8:1:FYU&]M
M[2#./,GD" GTYZGVH X_XC-.FH^#6MHUEE&N(51FVAOW4G&<''%)K7@:7Q==
M:W>:GBS:]TQ=-M8U8.T:AS)O?'&=^W@'HO7GCJM2T'3M7GM9[Z!Y9+23S8")
MG3RW_O#:1SR>:TJ .)DT+6M?M- L]<M[> :7=Q7=Q-%-O%P\0.W8, @%B&.<
M8QCG.1<\)Z/J>EZQXCN+Z"%(=2OOM4!CEW$#8JX88&#\N>,]:Z6YNK>S@::Z
MGB@B7J\KA5'XFJUIK.EW\OE6>I6=S)C.R&=7./H#0!PT'A+Q#!\.M=\+F&Q9
MK@W*6LPN&^<3.S!F&WY<!L8&[/MWOOX<U>TUW0O$=E%#)=VNG_V;?6;2X\R+
M(8&-L8R&&><9![5W%% 'G.N^"=4U30_%TD4=NNJ^(C"@C:7"01Q*%0%L<GAB
M<#JV.V:V+W2-6O/&WAS6!:PI;:?;SQ7 ,_S9E"CY1CD#;ZCK7756L=1L]3@:
M>QNHKF)7:,O$X8!E.&&1W!H P_&WARY\1:3:?8)HXM1TZ]BO[1I<[#)&3A6Q
MS@@D5&-'OM6\5:9K^HVB6G]EVTR06ZS"1GEE"AB2!@*%7 [G<2<8YZ:66.")
MY975(T4LSL<!0.22:CL[RVU"SAO+.>.>VF4/'+&V593T(- '-^"M(U31AK2Z
ME!"@OM4N+Z(Q3;\+(00IX'(Q]*=XHT75+SQ%X;UC2X[:9M,FG\V*>4QAEECV
M9!"MTZXQS74T4 <1;:#K,.M^,KUK:W9-8BB6V GY!2'RSNXX!//&>*RH/"7B
MC1M-\+W^DK9/J^D61T^ZM)IB(KJ$[?NN!P05!&1_+GTRB@#.T;^U6M&FU@6\
M=U*V[R+=BZ0KCA=Q +'J2<#KCM7&:]X6\2:C?^*HTCL+FWU2R\BQN;B=@]HI
MB*M&$VGAFYR".N3G&*]$HH XO5?#&K:IX'TFU1[:UUW37MY[>16+QQR1X!Y(
M!(*[@>.]%MX&^P>-+74K2?;IHLT6ZA8Y:>XBR(I&]3AV)/JJUTD^NZ3;:C%I
M\^I6L=W*P1(7E 9F(R%QZD<XZUH4 >>Z[X8\1ZCJGBA4CL+FVU2Q^SV-Q<3,
M&LP8BK($VG[S'.01[YP!4MMX>U]=9\&WD]K9A-'LY;>Z"7!)RZ(@VY49QLR<
MXZ\9QSV5GJEAJ,EQ'97MO<M;OY<PAD#^6W7!QT/M5N@#BCHFNZ)X]U36M)@M
M;ZQUF.$7,,UP86@EC78K [6RI7J.N:N?#_1=3\/>%DTW5$MQ,D\TBF"0N"'D
M9^<@8/S8[UU-% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %<A\2=4U32?"PGT
MMXHW>Z@AD=R=P5Y%4A<="<]>PSWKKZYSQQH5YXB\+RV-@\*W8FAGB\\D(QCD
M5\$@$C.W&<4 <]J[ZE'\5=$:"VMI-0;1KD8,I6('S(^2V"V![#.?3J+UCX^9
M_#SW5]9QQ:E'JCZ2T$<A:-IU8@D-C.W:"W3/!%6'T77)_'6EZ_-%IXAM["6V
ME1+A]VYV5OERG(&W&3C/7 Z5AMX#UV71-21+JRM-3_MY];TZ5)&D16)X20%0
M<8)!QGK0!H-XXU.W37TDTE)VTRR-]#<)YD4%P@!+)EE.UQCISG/:G67C/5FO
MO#)O]+M8;#7HP(GCN"TL<GE>8-R[<;3@@8)/3/I4\UAXNUKPSJUMJJZ7!=W5
ME+:PV]M*YCW.I!D=RN?H .!GDYXK2>%];:'P4@2PSH14W.;A_GQ$8_D^3GKG
MG'I0!TWB._O]+\/WFH:;9QWEQ;1-*+=W*^8%&2 0#SCIQ5*R\12ZG:>'Y[%+
M>4:I%Y\GS'$<00%F''.&9%P<<L/2NAKE?!WA)_"[ZBC7 EMC.XT^,=+>W9C)
ML^N]V_!5]* ,NX^(<_V.#5;#3_MNG/<^4884D:X,6\KYJX7:>F=OIW!X&@/%
MT]YKVHZ7IZV37-A=1PR6<TA6>2-@A:91_= 8X&#G;U&:S?#_ (>\8>'%;0+6
MYTR30%E<VUX[/]I@B9BQ39C:S#) ).!UYZ4_Q)X/O_$DS?:+2QBO(;M9-/U>
M&4K/;Q!PV" HR<;@!D@Y&<'F@!VF^(-4C\;>,/[2EMAI>DQ6[$*6S''Y;R9
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M*/YB2S[>26?. . HZU7F\*ZX^D>"[14L/,T*:&2X)N'P_EQ&/"?N^^<\X]*
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M7(D*7&5='=W."RJ<@-Z=LUH?#_2;G2O"-I]NGDN+ZX199I95PY&T*@([$(J
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M2+R_G^3C/7C-8L'@KQ-I.C^%[K2I].&MZ);-9RPR2.8+J%L9&[:"IRH(XZT
M6)OB'JEOH+WDF@XN(-433Y TCHDJNX598MRC<#GH2,'O6M:>)-9?Q/J'A^]L
M+&&\6P%_:/%.TD90N4VOE0<@@=.HJIK^@^)_$'AV"&X;31?_ &^"Z>)976&%
M(G#;%;:2S'!R2!U]JOC0]4;XC_V^Z6BV+:5]@*B9C(&\S?NQLQCMUH B^&NI
MZGK/@>PU+5'BDEN5:4.A.22[9R#T] !VK/\ $<VJ_P#"U/#$-N+4Q?9KQXED
MD8 G;&"6P.HR0,>IK6\ Z)JOAOPO;Z-J9M&%GF.&2W=F\Q=S'<V0-IY P,].
MO. W5=%U:Z\>Z+K5O'9FRT^">)Q).RR,90O( 0CC;Z\YH S=)US5O[<U30]'
M\.:9;6NEWT27!6Y*+Y<H\QG4!!EOFR0<?4YJ2;QS>'PI)XNM-/AGT2-V8Q^8
M1.\"N5:5>-O8L%/4=P>*O^']#U.P\4^)=0O4M/LFJRQ21"*9F=0D83# J!SC
M/!K%LO!FMV'@N]\$QO:/IDOFPV]\TI\R.WD8DJT>WEP&8 YP>.G2@#2?Q;J=
MWXK.B:5I]G*DNEKJ-M=2W+!65GVC< F1WX&<\<BLAOB)K*^#W\2-HEHMM8W#
M0:A&;HER5E\MC%A<$#K\Q'<8[G9M/#5_8>.X]5MHK4:7#HR:9$AG;S,J^X$C
M9C';K[UB2^"-?E^&VM>&_P#B7+=W]Y+/')]H<HJO+YG/[O.1TZ<T >CRF3R7
M,(0R[3L#DA<]LX[5XWJ6IZKK7P"U34-6,$LDEPQ5HR<Y%[C&#T P .3P!7LD
M)D,*&5%23 W*K;@#[' S^5>:/X&\2'X:7_A%3I9+7#-;SF>0;D-QYV6&SY3V
MP,^N: .CM_$^HP>,?[$U>QM;:&>R>\MIH9RY548!EDRH&<,#QD=N>M9R>/[J
M5=(O[?3?M.FZC,D9CA20SP1O]V5OEVD="0.F>IJ_?^']3U#QQI^KRQ6@L8M/
MFM)T\]BY,A4DJ-F"!MQU'6J'A?0_&>A6]OX?FNM,ET6T(2&^!?[28 >$*8VA
ML?+NSP/4T =1XE ;PKJX(R#939!_W#7D2:=/K_PS\$V6A:==?VU"UO*E^+9X
MTME'WV,I !'L"<U[#KMM=7N@W]I9K$UQ<0/$GFN44%E(R2 3W]*H>"M)OM!\
M(:;I&H"W\^S@6$M!(75L=^5!% &/XH\:W_AVVU:_DL(([/3Y$6-+F79)? A2
MYB[<;L=#D@]*FUCQ3K4'BN/0=)TFTN9)].>]@EFNB@)5E7##;QU[9R2.G)&-
MKO@OQ+J<'BZR233)8]8.ZVO)Y'\V) %Q!M"X"@J2"#W)P2>-J'0M</CG3==N
M$T_R(-,>RF6.=]P9G5LJ"G(&W')&>O'2@"KH&K^([SQ_X@LKQ+(16EK9D6ZR
MMB,NLK<';R2>"<#@#@T:1XU#>&8;S^RH+>\N]6DTZ"TAD^1IO,8$EMHXPK,3
MC/!XS6A;:'JUAX_U;6+?[')8:G;VZOOD821O$'  4+@@[NN>/0USJ^ ==/A!
M;-;FRMM8LM8?5K&5)&DB+EV8(^5!QAR#C- '3-J^NP#6HKW1H)%L[<36]PLI
M2&Z!4ED.0Q4C!'0@Y'2L9/&][!H/@^>RT.V9=<"1K"D_EB%C&7"@;<;>.O;T
M-;,%OXGO]'OO[633H;J6W:&"UMIG,8)&"[N5SZ8 ' SUSQQ^I:9J>@Z9\-]+
MDCM9+ZROTAPLK>6^V!QG<5R,CVH WK'QKJ\=]KFD:KH2G6=.M!>V\%C,9%O(
MCD#86 (.[Y3D5:T[Q9>3^+'\.W$5C)='3C>J;>8XC<,%:*3@D'+#YOTJGK'A
M+6-9DU[5([J+3M5O=.73[+RY"?)C#%R68 '+$D<#@ =33=.\.>(;?Q9IFM-:
M:-:P6^EO8O:6\KD1Y=7!4[!G)7'08S_%W *<'Q%UE_"]GXDET2TCTYKW[+=*
M+IFD4&<P[D&W! ..I!// &"=2QU76KCXIZMILC6QT^ULH'2,,P*AV?+=.6.W
MV  'OG(_X0CQ!_PK$>&<:;]L%[]H\S[2_E[?M/GX_P!7G/\ #T]ZZ&'0]7MO
MB#<:Y$+,V5[90P3AI&\R)HV8_*-N&!W8R2,=<'H0#1\0Z\FAQ62+$)KN_NDM
M+6(MM#.V3EC@X4 $G@]/>J$'B2]A\4R>&]0M[=;V6T-W8W$;,(IP#AE8')5@
M<>N0<^U/\9>'+G7K73KC3YHX=2TN\2]M3-GRW9<@H^.0K D9'2FPZ+?7OBJ'
MQ'J,$$$MI9O;6MM',7^9R"[,VT8^Z   >"3[  P_AW;S:MI>I/JUK97,:ZW=
M3*SY=EF68X8 C QC@]>!5_Q#JNM0?$/PWIEFUL+.YBN961V8%V10/F('0!^!
MZ]>U7/ ^B:IH&FWMKJ2VFZ:^GND:WF9QB1RV#E5Y&<4GB'0]4N_%?A_6],-H
MW]GK<131W+LORRJHW+M!R1MZ<9]1UH Y2UU/5M&UGXA7NDV%K<"UNTN)1<3&
M,%5MU8JH53EB >N!TZ]NHE\:1SC2XK)8TN+^P74 9PS+%&V-H(49))..PX)S
MT!HQ^%];5?&H*6&==S]FQ</\F81%\_R<=,\9]/>J?_")^)]*3P[JFC2:<VJZ
M=IB:9>6L\C^3<1+C!5PN00PST[_F =3X2U^X\0Z1)<W>G2V-S#.]O)&X;:Q7
M^-"P!*$$$''MVK=JAI$>I)9;]6D@:\D;>Z6^?+B&  JD\D<9R>I)X X%^@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBLO7K^^L+*%]/LQ<2RW$<3,YPD"$_
M-*_(RJC)P.OMUH U**X.+QU>-I?BV2*&QO9_#Z^:LL,C)#<(8O,!'WB" ",9
M()[BD/C'Q!#/X;DETS3WMM=0)$B3L'CE,7F L2"-IP<@9(]^E '>T5PT?CN?
M2X?%0\16]NLN@+%*S6;,5F2524 #<ALC;Z<U;O?$NJ:%?Z*-9M[0V>K3K:!K
M?<&M9W&45LD[U)!&X!>>U '745PX\9ZC_P (WXMU V]K]HT"ZGB"X;;.L<:O
MGKE2=V.^/>GW'BW6#KF@Z;9Z=9M_:U@]TLDL[#8RJA(("]!O[9)]NM ':T5Y
M;K_C#7;GX:>(KE!:V>IZ9?MIUR\6YE8;T4M'G!7(D'7IS7IEJ+@6Z"[:)I^=
MQB!"]>, DGIB@":J]Y>VUA!YUU,L29"@GJQ/0 =2?8<UR$GC+4KGPO?>*=+M
M;:?2K1Y2('+"6XBB8J\BOG"GY6(4J<@#D9XS]?U*\U3QCX!N],GMS9WGVBYM
MA*C<YMB06 /]UCC'3- '>:9JEAK-DM[IUW%=6S$@21MD9'!!]"/2K=9\ZC2-
M)O)[#3DEG5)+C[-;*$,\N"3_ ,"8]SZUSFF^+K^3Q5;:%=+833W-@]UBW8J;
M>5"H:&3EL_>^\,'C[M '9T5YHOQ"U\>$QXEETK3TL;>^-M=1B=S(5\_RLQ\8
MXR#SUYX'&>E_X2"_M_B GA^]BMH[.YM&N+*==VZ9E(#Q]<!E!W=\CTH Z:BL
MK0-0NM4L)+R=81$\T@MC&"-\2L55SDG[P&1[$5SNEZEK<WQ,\2VDLT$EE96U
MJ8X%0AMK"5N.<;B>I/' ]* .WHKAK/QIJ(U_0-.U&WLXY=7$HDM(V/G6++&9
M%60Y(;(&.B\^M)+XNURV\37?AR>QM1J+B-],8*_E741/[QV.?EV '(Y[8SD9
M .ZHI@\P1#=M:0+SCY03^N!^=<+I7C/7;V'4-3NM.TZWTG2KN[@OW$[M(%A!
M^:,;<'D=\9ST&,D [6^L;;4K*6SNX_-MY5*R1DD!U/4''4'THL;&VTVRBL[.
M+RK>)0L<8)(11T ST ]*Y&V\7ZN^IZ-NTJ2>QU([9/(M)PUD2,J7=AM=>Q(V
MX]ZAU+QKJ8\&ZAXLTNWLGTVU\PPPS[M]PB,4+[@<(,@D#!R .1G@ [RJFI:G
M9:/827^HW,=M:Q8WRR'"KD@#/XD"L.#Q%>2>-HM!:*#RI]).H)* =RL'5-I&
M>1\V<\?UK!O?'>H+\/\ 5M<;3+*>6PU![*2)W8(P681[P,'/)!QD?6@#M=2T
M+2=9EM9=2T^VNWM7\R S1AO+;U&?H/R%:%<=K7B37X/&*>'M)TZPE>;3I+N&
M:XG8#<KJN& 7@<]LYR.G-5KWQEJQMM2;3;&.:ZTLB*:W6WGF%S,$5G2-T&%Q
MNV@D')Z@#D@'<LP52S$  9)/:JFFZMI^L023Z=>0W4,<AB:2%@RAQU&1P<9K
M!@\476KZI;:7IML+2Z;3TO[K[=&Q-L'X6,H"I+DAL\C 7OFL_P"%IF.DZ\;E
M$2<Z]>^8L9RH;?R >XS0!W5%<2=1UIOBY+IOVFV&G0Z2MRL91N TVUB3GEOD
MX/0#MU)BF\;Z@WA"3QC9V=O-HT;,_P!F.X3O;JY4RAL[0< ML(Z?Q9H [B::
M*WA>::1(XD&YG=@%4>I)Z5!IVHV>K6,=]I]S'<VLN?+FC.5;!(.#WY!J6UN8
MKRTANH&WPS1K)&WJI&0?R->/>%?$NO>%?A5I.KII=G<:#:EQ=8F;[3L,[ NJ
MXVX!/0G)QVH ]FHKC=4\7W;7&JP:)"DTFFJH(>UFE%Q(4$GEJ8QA/E9>3GD]
M.,GH]'U"75M#M+][2:QFN(0[6]PA#Q,1RK X/!^F: +]%>=W7CS5[/PIXAU*
M6TL1J&AWIMYK4E@'3*[6!SGY@P8<<]*Z>'5[J\U"TBL&M+FW>P%W+(0RYW<1
M8.3@-AST. AZYH TM-U.QU>R6\T^ZCN;=F91)&<@E25(_ @TT:OIS:P=(6]@
M;41$9C;!P75 0-Q'89(Z^M><:CXLUC4/A?8ZO8QVFG37&IBUFCC!8!?M1C(4
M\=<<G'<],\:&H'5$^+>G_9H[22_;P_,I9RRQ+^_3D]6(]O?J.M ';ZEJ^G:/
M%')J-[!:K*XCC\UP-[$X  [GZ5=KRCQ+X@N?$/PP:ZN[6.*^M=;AM)XX6RAD
MBNE4E2>Q]_6NHM_%=_9>*=0TG7K>SBBATTZI'-:NS;8E8JRMN R1UR /I0!U
M]4K'5].U.6YBL+V"Y>U?RYQ$X;RVQG!([UREOXRU:6[T2==)DN+#4W5)$ALY
MQ)9AQE7=R-CKTW$8QG@D5GZ;K=KX;U/XCZQ>!OL]I>12,J]6/D)A1[DD#\:
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MR75M)!(S-'Y94,KY !X8'(^G/6LY/'6IW$&E:I9:5+=Z;?S(K016<_G0PO\
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MNT7^TF"6F0?WI*[@!QZ#/- &)9:'K-KXVU/79!8217=E#;JJRNK;H]QR1M.
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M/K6H7$GF6&IVX5K/'RB4H8Y)/J8]H_%O6K'ASPY=>'O!J:3]I6\OA$5>XE)
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MB6Z8A8R5CSNVC)P<C ZXZCK7067A?5]"N=<AT>>S;3]6G>Z47#,'M)I!AR
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M]A57.5&P#).T;N2.>.<L>#-8/A3Q7I#2V/F:Y=W%PD@D?$0FP""-O)&/Q]J
M+:>)]9A\4Z#:7EM8_P!GZY'*;=8B_FP,D?F#>QX8$9Z 8/KWRI?&GBA] \3Z
MI!9Z2G]@WT\+HYD;SHXE5B 01AL$\].@QWK8N?#>K7&K>$[X-9*-$63S4\U_
MWI>+ROE^7C YY^GO5-/!VL#PWXNTMI;'?KUS<3QN)'Q")D"$'Y>< 9[9SVH
MG3Q5K,7B+P]%=VUB-,UU7$*QEC- PC\P;F/RMD @@ 8/<TUO%NK7_A_5?$.C
M0V<EC82S*EO,K>9=)"2'8.&PA)#;1M;H,]>);CPQJTUWX1G#60_L/)F'F/\
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MWWC'6]#TQ=(C33UM9DEN$D.Y)-VY3@]<+P>@QWSD ':RRI!"\TC;8XU+,<=
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M!>OJ46GZ;,T+P179E.$<JV67;R6'MQUJ/R]1C^,^EK?W%M./[%N#&\,)C/\
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MXD_[!L__ * :QM)UW6]-U;PGIEX+!]/U>T9(EB1Q+ T<(<%G)PP(!Z*,>_<
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
**** "BBB@#__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>48
<FILENAME>exhibit108-arvinasxformo004.jpg
<TEXT>
begin 644 exhibit108-arvinasxformo004.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M(<'_ ,AUOT4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !115>:]@ANH;9GS/-DI&HR2!C+'T R.3QR!U(H
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MJNI4X&P<\^M8-U#HM[X+TW0Y]1U)+W2UB^P:E!H=TCPO& %;:5.>!R,X.>U
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M+#Q!YU_>C4=;MQ:S7*Z%=[(H@I4*B;<_Q,<EN2?3 "RSV4M]X7NCJEV#H2L
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MU74AJ-XI;?<B 0[P6)'RC@8&!^% %V6*.:,I(@="02"..#FN$O\ _DNND?\
M8#G_ /1HKOJYBY\+7<_CVU\3KJ4*K;VK6@M3:D[D9MQ._?USCM^% &1XP@E3
MQYX(2P\F&9[B^(9U)4,8"2Q (SU)QD9/>H8/&>JZ7IWB.#47AOK[3-1ALK>9
M(O+$OG;-A9<XX+\X(R!VZUTFL^';C5/$VAZQ%?Q0+I32L(6MR_FF1-ARV\8X
M/''6LFX^'JZA'XFAU'41)#KDL<W[B QO;R(%",K;CG&U3T'- %O2KOQ.OBG[
M-=VLT^BRVY?[3.D4;PS _=PC'<I'3C(/<UE_& E?!ML0I8C5+0@#J?W@K<\/
M:'KE@ZOKOB(ZLT*[( MJL ';<^"=S8X[ 9/'.:;XT\+W'BS2H+"+4([)([B.
MX+-;F4DH<@?>7 S0!E3:#JNL_$W2_$DME_9]GI5K+$JRRH9;EW!&"$+ (,YY
M.<]JJ6GBS6(=;\-V]Y=07$FI7$MO?001;H;=PC,!'*!@E=N&!+=^E=]) ]Q8
MR6\\GS21E&>(;,9&,CDX_.N&L_AWJ=M9^';=_$BL-"GW6Q2P5=T>QDPV6.7P
MWWNGJIH =I&H^+=<UW6K5-4T^WM]+U,0'%D6,L1C5BHR_P I&[KDY/H!@X^@
M:KKNG?"76M=34TN+RWDO9E-S &R4EDR>".N..P],5VOA[PY<Z)JNM7DM_%<I
MJES]I,:VYC,;;0N,[SD84=NM9,7@*[@\)ZSX<36U^QW[3^26M,F!96+,#\_S
MGYC@\#V- %F+7[S4]9TW0X)Q;32Z2NI75PJ!FP2%54!X&6W$D@X  QSD4-<U
MKQ9H'A&UNKV33Q?C4HK:5HXRPEA>4(K#D!6(.2.1]*L:AX'OY9]'U/2]<6PU
MK3K7[&UR+7?%<0\?*T9;U&1\W7\,6=9\'WFL>'8M-DUG-S]KCNY[J6VW>8Z,
M& "!E"K\H&.>!W.30!3OM3\3WGCV_P##NG:A8VD":='=QSO:&1XRSLN,;L,?
MEZ\ #L:I:1XNUW4?#@-V]E9WMCJ[Z9JESG"@)_%$ISEF)0 <\D\=J7-X_P :
MKU;.]M$G7081(LL1<,?.?H P((X/4\'\:O3_  _D2WTV33]6\C4K349=2DN)
M;?S$N)I00Y:/<,<-@8/ 'XT 8\WC37(_!7C"]@FB-WH=T\<$UQ:E6DCVJPW)
ME</\W7&./NUKIK&OV7C+0["]O+6>UUJUG=8X[?:;:2-58$-G+@AL'..G;I4-
MQ\.[R?3?$]B?$&8]>D$CE[,$QDJJL>&&?NC'3&><]:UKCPO>W/B#P]JSZG #
MH\4L?EK:G]]YBJK'._Y>%&.OXT 9OPR;4)]-U6>^U%[L_P!JW<9WQ@$E9"N<
MCV XZ"M/7]0U&WUB&VCO8[*S>U=T>*,37$LX(PHCP24"Y)('IR*E\,^&I_#D
MNHH-1^T6=U=RW44/D!3$9&W,"V3NP>G ZG.>,1:AX7O9_&*:_8ZO]EWV7V*>
M%K<2Y0.6#(21L;)[AATXH Q=$\;7^NZ3X1A_=6^H:Y#-+-,JY$:PCYRBG^(D
MKC.0,GKC%4_'ZZW%\,?$<6M/;S+'=0"TGB&&DA\^(@NH& P.1QP<=*L0_#*Y
MM/#NB6EKXA>+5=$E=["_%J,*C_>1DS\P(X//^%:>L>#=1UWPG=Z3?:\LEY>/
M&T]V;3Y0$<,JI&&&T97N2>3[8 +FAZM=>)FGU73[^)-)^:&VB:(,[2*2&=^0
M5&>B<-QDD9P.-A\8>*QX%L_%4]Y8E(]0^SW%JEJ1YR&Y,)^8M\I QC&>G).<
M#K;'PI>Z5XGO=7T_4X(+>_16N['[(3&\XZS+^\^5CQD=\<Y/-9G_  KR[_X0
M+_A%O[:AV?:OM/VC[$<_Z[SL;?,_O<9ST_.@#2CU>^U[Q-KFD:=>"QCTA84:
M41+(TDTBE^0W&P#' Y))Y&*YW_A.M8E\*V.NOY-LMEJO]GZW&L>Y542;&D0G
MD $J><\$^E=,?"]Y9^)[K7M*U""WGOX8X[^&:V,D4K(,)(H#@JP&1C)!'OS4
MT'@^PA\(7?AYRTL-ZLWVF5@-TDDI)=_8Y.1Z8'I0!C0^+;BT\;>(=*U&]#6=
MI9"ZM#'" 2 /WJY_B92R8 _O<\U7UE;Y?$OPZ_M.1)+XW,YG*+M4.;9R0!Z#
MI^%:9\ 63P>&EEN97FT64RM,?O7)89?=S_$^UCUZ8J_KGAVXU?7]#U.*_CMQ
MI4KRB)K<OYI="AYW#'!/;K0!S]WXC\2ZK:ZI=^'+:226RO9+:WMS%&8I_*?:
M^]F<,"2&QC&!CK6G:ZWJ&O\ B34-(M93IO\ 9EM ]T=BR2>?,I8)SE=J@<XY
M)/!&.:R^"-5T_7M0NM#\32:?INI3FXNK,VJRE96^^T3D_(6]P>:L2^#KNR\5
M2:[H&JI9-=01V][;W%N9TF$8PCCYU(<#C.2* .2\+:[>Z#\,M(*>7Y][KLEC
M+<;?D@$ES(&DP?I@9.,L,YK=?Q5JVD:YXIBO9X;K2]#LDO WV?$TA9&;RRX8
M*""O]SD$=.^/K.CCPEX1T_P]=^(D@BO-3>4WUQ9J;=!N:4I*"<$,Q Y(R?8$
M5H^'X)M0:ZT-]7T+7-%O+>5+LZ7:"#R2P Y9'926!QCKWZ T :%GJ7BUM7TB
M7[')<Z==J1?AXXHUM\KE7C(<L5SP0<G'-5_"_BZ?7-7ALY]16UU.*20:AHUS
M (WC4!MIB.,L,[<G+9!SQTJ]X;\)ZWHWV>TO_%$NHZ79X%M;FU6.3 ^Z)) 2
M6"\=AD@9]*=#X/N9[[0[K5]0@O)]'8M#<1VICFE^0IAV+GCG) ZD#IW -7Q+
M>7UCHYGL)+6%O.C66>Z<*D,18!WYX) S@=SCKTKE;?Q9JS1^-;>&X25]%MX[
MBTN+NT*,X:)GVN@V]T." .#T-=)XL\.R^)-/M(;>_P#L5S9WD5[#*8O,7?&<
M@,F1N'/J.U9!\#Z@UYXCN7U]6?7;-+>8&R&$949-PPW3#' SGIDGN 9]EXC\
M1PR^"[V]O+2:TUU$BFMH[?:8V: R!P^>3D<C '.!ZU'K6KZAXH\"^,-0L[Q+
M:RMH[RUAA\H-YRQH5=G)Y!8[MN,8X)STK8;P5>-9^%;<:M /^$?9&5OL9_?[
M8S&,_O/E^4^_/Y55?P!?V\'B#3M+UR.WTC6O.=[:6T\QX))5(<QOO&%).<$'
MVQUH Z/PG_R)VA_]@^#_ -%K7(WOBS6=.O=-:>ZMWFN-;73[BRAC\R&&%W*K
M^] XEQM8@GO]T5V^B:=)I&AV.G27'VAK6!(?-V;-P4  XR<<"N+3X;:C%HUG
MI:>)?]&T_4UU"S+60+ B0R8D._Y^6/(V^^>P!<U#Q%J4VL>*[*VN8['^P[.*
M>#?&&%P6C9RS9_@&W;\N#D'GI6<WBCQ5)8>"YA-I\,NNOB9#9NOE;HBXZR'.
M,=.,^JUEZM<6^H>,=7=_%NCZ;-:F.U%MKEA%(Q"J"7C+,F$9F)XSDC/H!T<6
MC:UXFCT'4[S4K.*;2[MYD>.S?9=##(& +@H"I/KZC@T "ZMK_P#:+>'7NGGO
M[.S2>ZO;*UC&]I'<( CM@ !.>N<\;:BM?$_B-HM%TG5-.>SUJ[2XDN/LXC<B
M.(J R MM!;>IY)Q@\=*T?$'A"^O?$4'B#0M;.DZFL'V:<M;B>*>+)8!D)'()
M.#FHM8\#W6H0:7=VNO3VVOZ=(\D>I-"KB0N '5H^!L(  '8 4 9\_B7Q3H_A
MZ[N=9TZ=$M]06+[;#"KR&S/68Q*6 9>A[<YQQBNE\*ZHNL:;->0ZM;ZI:/.?
MLUQ" #Y>U?E<#HP;=G@=N!4,>AZW'9P.WB 2ZFMP)IIWM?W4B!67RA&&&U?F
MSU)SS])O#OAJ+09]4N5:+SM2N?M$J01^7$AVA<*N3UQDG/))- &[1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !2,RHI9B%4#)). *6N(^*C72>#U>UO9K;-];(XB"_O%:9%(.0
M>.<\=>_&10!T3^(;%/$T7A\^=]OEMVN%!B8)L4@'YCP>2.F:U:\\U>VOC\5-
M#M[>_P!MP='N@;J2)68#S(^0HPN?T]CTI=,\1Z[<^%+XSW]FEWI^M/IUQ?S*
M(P84D 9U7!7S"IP%Q@GL>E 'H5(K*ZAE(92,@@Y!%>:R^(-6O-*\?V U"Z0Z
M3:K-:7;P+%/M> R89=H Y7@[0<'UYKK/!,4L7@G1?-N9)RUC P+JHV@QK\HP
M!P/?F@#?HK+\275W8^&=3O+&2..YM[62:-I$WKE5)Z9'I7%V7B#Q'!_P@^H7
MFI0W%MKBQPW%JMLJ!6> R!PW7.1R.G/ % 'I%(652 2 6. ">IKA8-<UGQ%H
MVO:OI-^+4V%U/!9VYA5TE\GKYI(W?,0?NE<#'4UD0:S>>*/%O@?4H+^YL[?4
M--N;@VRA"L;J$!QE>?O$9/;IC)H ]2HKSJYU[7K0^+]+?4O^)I8+'<:6WV=/
MWT<@Q&NW'S$R90GUQC'?5\/:_<^)+3P_<65\^V6R-U>[HT/S?="'C@[P_3'$
M;#WH Z+3]5AU&*ZD2*X@6VGD@<W$1CR4ZLN>J^C=#4%WXAL+/Q!I^B3&87M^
MLC08B;80B[F^;IT[=>17FWB'6]:U/X3>,IKG42EQ8ZC<68>WC5 \2NJ;<<D
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M\077A/3]<M;M(KZZU?[!)IKVZNL0,K1[<</O50&.6QUX Q@ ]1HJAJ6H#1=
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MO$NOZ9XE^"'B6^TRWFMCEUNK:9=KPS[U+JP]><_C7IVG$?V5:'MY"?\ H(H
M;I6J6FM:;#J%B\CVLZAXW>)X]RD9! 8 X/KBKE>;GQ#-X=\#>#IY3=V^DR6,
M0O;ZU@$K6_[I=A(*MA2<Y.#C ]:[/PY=M?:%;W3:C!J(D+LEU  %D3>VTX'
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 5B^*O#R^)] ETPW36K-)'+'.J!BCHX=3@]1E>E;5% '-?\(Q>
M-XIL-=EU999K2T>U*-;8\P.0S'(88Y QQP/7K62_PZG:PGA37#'<MK1UN&9;
M48CF)R5*EOF7GID'WKNZ* .0@\#.+_Q#<7>LW%PFNVJV]S'Y*)@B,Q[@1['@
M?F343Z%X@TG1M"T_3O$$TDMG-$CXLDV3PJ%78Q_@ 4$DYR3TYP!VE-+JK*K,
M S<*">3]* *>LV#ZKHM[IZ3" W4#PF0IOVA@03C(YP:YYO!5P;'PQ:C54 T!
MHVB;[+_KMD9C&[Y^/E)SCO\ E716FI+=ZA?68M;N(V;(IEEB*QR[EW9C;^(#
MH?0U=H Y.+P;/83:Q'I6J_9+#5Y'FGMVM_,:*1QAVB;<-N>N"& /Y4ZX\$PK
M>^'[C2KU]/&C0/;1HL8DWPNJ@CGHWR@[N?H:ZJB@##OO"]G?^*]-\02.ZW%E
M#)#L'W90Q!7=Z[2"0/4Y[4GAWPO:>&FU1K-F/VZ[>YPPXB#<[%_V0Q8X_P!H
MUNUDVGB*RO?$=]H<27 N[*))92\95"KD@;2>O0]L>] &#_PK\2^%O$.A76IF
M2/6;J6Z:5(-AB>1@QP-QR 0./UJY+X5OKG6]!U6YUD37&DB8<VH F,JA6Z,-
MH  Q^N:ZBB@#DK;PA?V<^K7%MK:Q3ZA?)?;A:\(R@ KC?RI50#T/)YJ.[\ 6
MVH6'B2*ZN56YU^-$N);:'RU78"%(4DY.2223S[5V-% '(R>#]1;6M-UA?$4J
MW]M:O:3R?94*S1LP;Y5Z(<J.?FZ<YJA#\.)H/#]GI":Z[0VFIC48FDM5)!$A
MD"G##/S,<GOQC%=S/+Y%O+,4=Q&A;9&NYFP,X [GVJ+3KT:CIUM>K!/;B>-9
M!%<1[)$R,X9>Q]J ,"Z\'#4/$E_JE]=I-;WVF_V;-:B J#%ECD-NZY8]NGYU
MDK\/-2.DZ5I4WBB22STF\AN;,FS7S0(C\B.V[#8X .!TY!KOJ* .;B\,W4'B
MC5-<CU)#)?6L=MY;6V0@3.TY##)^8YZ?A67'\/I8O"6B: FKKY>DW<5U',;7
M+.8VW*"-_J>?7VKMF=5*AF +'"@GJ<9P/P!_*G4 >1ZO>6UYXSU9Y_&%EHES
M#(D$=KJNGQ2;@BCYXC(00K,20 3Z]\#T7PU/J-QHL;ZI(DT^]@LZ0F$3("=K
M["25R.V??O6L54D$J"1T)'2JFHZE;Z9I]U>3EVCM8S)*L2EW  S]T<]* , >
M#IX;_P 0SVNKM'!K/S/ UN&$<AC$9;.02,#...>YZ5 ? T_]C>&=.&K(%T&>
M*:)_LO,IC4HH;Y^.&.<=_2NFTG4H-9T>RU.V#B"\@2>,2##!6 (R/7!JY0!Q
M?_""WUGKU_>:+XFNM-L-1F,]Y9);I)F0_>:-V_U9;OP>?PQV"1"&W6&$!%1
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MEC5-R .K G;SEB.GU/0T4 <U9^"]/B\/ZKI5X[7?]KRRS7\I 0R22<$J!]T
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M.BN?#4MWXIT_79KY2]G;R6_D"#Y)%?&_.6)S\HQZ>]9>B> )="F%K;^(K]M
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MOFU[2-9U'Q'<7=UIL4L2[;:.-9%?;G=P?[O./PQWZV@ HHHH **** "BBB@
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M]W>SZ?Y:&1E=4&WS. ,DDX&<XQ@9K:\)#Q!'ID\/B)D>XCN76WERN^2#@H9
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M4L'GC"(;A4N0JLXVXR!@X'&1R#7K;R?V=IKRS2RSBWB+O(X&]P!D] !GZ 4
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MWUSDGO6]10!PD/PT2/2]-TQO$.I-9Z9>1W5B@6(&'8257.WYN3U;/ Z5;N_
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M%O?0.&D(;[X?<"'#'DY[_4UN:/I?]E61B>[GO)W;S)KFX(WRO@#)   X
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MCY1\N<<5J1>%6B\2V^NG5;F6YAL38XD1"'0L&+' 'S;@#Q@=L5T3,J*68A5
MR23@ 5BZAXFM=/UG1M-:WGE.K.RP3Q[3&-J%SDYST'8=Z ,<_#RW;P]>:2VJ
M7>+C4/[22<*@>*?S!)D<8(W#H176V\!BM4@EE>X(7#R2XRY[DX 'X  5-10!
MR%MX!M;;29-"6_N&\/M-YHT]E4[5W;S$'Z^7N[=<<9Q6E#X;$/C&?Q$+Z4R3
M6RVK6^Q=@C4EEQQG.2><UHZIJMCHNG3:AJ-PEO:Q#+NWY  #DDG@ <FLB\\7
M)IVES:I?:)J]O8Q1F1IFB1B% SRBN7'XJ,=\4 :FM:/9>(-&N])U",R6EU&8
MY%!P?8@]B#@CW%9&A>$9-,C$>HZW?ZS''&88$O FV-",'(4#<Q'&YLG&<8R<
M]*"" 1T-+0!R5IX#M[72HM$?4+B?0H)EEBLI%4D!7WK&S]60, 0.O !)'%78
M/#+6WB/5=;BU&43ZC%'$Z&-2L80$*5[Y^8]<YKH** .+_P"%>0CP78>%UU:Z
M6SLI4ECE")YAV/O4$XQ@-[5:U_P7_;.I66KVVKW>F:S:QF$7EH%_>1DY*.C
M@C/(]ZZJB@#EKSP4EVFD9U6[\W3;L7HF<*[SS8(W.2.F"1@8 & ,8%=3110!
MPU[\-8;RPUK3?[;OXM+U6=[E[5%3$<CL&<AMNX@D< G SWJ@8Y?^%S"*VU8K
M+%H"0F65$<2N)F)5@-HW8PV!CZ8KTBB@#E;GP'IEQH:Z>9KA+A+W^T5OU(\X
M76[=YO3&><8QC'%78?#C?;9M2NKYI]3DM?LB7'E*JPQYR0J^I."22>@[#%;M
M% '&I\/HH_#.C:$FJW(M])NH[J"3RTWLT;;D#<8(!ST S75W5K'>V,]I/DQS
MQ-%)C@D,,'^=3T4 <:O@ #1-%TMM<OI(](N8KBV=TCS^Z&(U.% V@=>Y]:O/
MX.MKC7=4U*\N7N$U.S%E<6K( AB&< $<@_,><]ZZ2B@#D_#O@E] >&.3Q!J>
MH6-IQ9VER4VP\8&2 "^!P,G ],@8U/$^@KXGT"ZT>6ZDMH+I=DKQ*"VW.<#/
M Z>E;%5-4U*TT?2[G4KZ7RK6VC,DCXS@#V[GVH 73;-M/TVWLVG:?R(UC$C*
M 6 &!G'&>*X]_AG VF2Z:FNZE'9?;A?VT*B,BWD\SS#@E<L,YP&R.>AK4D\9
M1VEU);:AI&HVDA:%;8NB,ERTK;517#%=V>H)&!STYJ72_$]QJ&L2Z;+X=U:S
M:'>)+B>-?)R-N-KACNW!N,>AS0 ZP\,?8?%-WKHU&>62Z@CMY(G5=NU,[3D#
M.>3D]\U%:^$5L;S6YK75+N.+5I&F>W*H4CE90K..,DX4<$X'I4FE^*HM7T[6
MKJUTZ],FE7,MJ]LRKYDLD:*Q"@,1SN '-;5I.US9P7#P20-+&KF&4 /&2,[6
MQW'0T <A+\.+1_#>CZ7'J=Y!=:,V[3]0BVB6+C&#QA@1P1CFKMYX-&H>%K[1
MKW5[RXEOUVW5[($\QU]%  51Z #N3U)-=+++'!'OE=43(&YC@9)P/U(I] 'F
M^L1/%\4/"MK%J8CGMM/N8S*R*06.S:KK_M '@$'CBMN_\!6E_IMQ$]]<QZA/
M?1ZBU^@7S!/'C80",;5  "^GOS76T4 <DO@;;J&JWQUR_>?5+-;6Y+K'AMH9
M0X 48(#$ #CN0:#X&0Z5X>T\:I<"+0I8Y;9O+3+F-2JA^.1M)'&*WM6U>VT>
M"&2<,SW$Z6\$28W22,>%&2!ZGD] :CT;5WU:.Z\[3;RPFMIS"\=R@&X@ [D8
M$AE((Y% %6P\,QZ=XEU+6(+^Z"Z@R236AV^7YBH$W9QNZ <9QGGTPW6_"XU;
M6M,U>#4KJPO;!9(U> (P>-\;E(=2/X1@XI_B#Q1:>'M+349(9KJ!KA;8M;[3
ML=GV<Y(X#<'&:W* .';X;6YT.]TA=9OQ;76H?;SN",R/Y@DP"5Y&X DG)-:M
MUH:6GB0^++B_G9[73VMGACA!5HL[V( !8ME>WTQ71T4 <9X>@TWQ#XLG\96=
MK,D3626D,LT31&8Y+,VU@#P"JAL<_,.E=G110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5Q
M_P 2;_4M+\*K>:7?O:7"WEO&2J*P=7E5"#D9Q@]B#[UV%8WB;PY#XHTH:?<7
M=S;0B5)2UOLW%D8,OWE/< T <QXB76O#:Z%L\1WUT+WQ#;Q2B:.(9AD/,?"C
MC*]L=2*?K&M7(\4:_I]_J;Z5;VVG1SZ8ZN$\UB&\R3)^^58(-O(YZ<UT.N^&
MH_$$>FK<7]W$=/NX[R-H=@+RI]TME3QR>!BN)UB1&\::I)=ZSXCT&?\ =00?
M9K4S174:KD.I\MQG<[#:".F>IX (=1.MWGA_X>SZO=3+JMSJ\,DK30H&A9H9
M. JJH&.N""1GG-6;BXU-(?B)H<^LWUQ%I]A'<VUP[*LR>9#(S+N51QE.P& :
MV[7PS>:Y8Z7-K&KZ@\FFWINK.5H8XI)  0IE39P<,PQP<$9 .:TAX/M#JNN7
MTMY=R_VU;K;W4+% @1595VX4$$!F[GK0!RL5WJ>A^ /"=U#'J=_IAM8GU!;,
M@W$<9@7;L P2@;DXY]\9KL/"&HVVJ^&X+RTU5M4AD>4I<N,,5\QBJL,##*"%
M/ Z55L/"#:99Z9!:Z[J6_3HVBB>7RVWQD*H1EV $ (N,8.1DDUJ:)HEKH5G+
M;VQ9C-/)<S2/C,DCMN9L  #D] * ./O]2U'2_%'B'2KS5KM8;G3A>Z2ZA"T3
M E7C7CYFWE" <\-BG^$M:U#7]*T*VFO+B/4[:28:ORN[="=C(W&!N=D(QCY0
M<5U.J^'=/UC5-)U&[0M/IDS2P8/!)7&#ZC(5OJHHTOP[8:1JVK:E:QE9]4E2
M6?TRJA>/U)]R: //M5O=3O?"'Q*M[K5;J3^SY94MW!5&5! K;/E XR>>YJQK
M%I,A^'4,5[-YCW>1-(%9DS;-T&,<=L@^^>E=1'X(L5M_$-O->7D\6O%S=*Y0
M;2R;"4PHQP!USTIG_"$1,-$,NLZG+)H\GF0.YB)<[=GS?)C&WC QZ\GF@"#P
M?=WZ>)O%.AWFH3W\.G3V[6\UQM\P++$'*DJ " <XX[U#XLGU;_A.?#.EV.LW
M%E:ZBEVLZQ)&<;(P0RDJ3GD]<CH<5NZ9X;BTSQ!JVLI>W4LVJ&,SQR;-B^6N
MU=N%!'''4TFI^&HM3\1:5K3WUU%/IGF>3''LV'S %;=E23D#U% '+QS:WJ&H
MZOX>@U"\FET>W@A%TDR12/*\>_S7&TYZ@8Z<'.<\1ZGK?B+0[#1KCQ+%<R6:
MVTB:E=:-\WDSA@%D8 9V;0Q.!@$G(/%;NM>!K?4]?77+/5=2TC4&B$,\MC(H
M$\8Z!PRD$CL?_K5>'AO[//!+8:G=VOE6_D,GRR+*-Q;<^X$E\DG=GN<YS0!R
M5SJ6J76L>"++3?%$LEGJMI<^?=111GS3'&I$BY7ACN/!X!Q\O&*H_P#"4:[X
M9D\2Z)=Z@^H265U8QV5].JAU2Z;;\Y "DIR02.>_'%6-6T:UT;QCX"TG3+F6
MU@L([T&90&V%T7&_(VC>=W'&<\8XKK)_!6E7VEZM9:CYEXVK,&O)W(#L5 ";
M< !0N!M Z8R<DG(!B7EUXE\+R:IK,S&?18--EF-M=7 DD%P@+ H0H^4@<C/'
M48K1TVRUFX30M7C\0,\,T&^_CD4%)MZ J8AC"$,1CU'7/>?1_!D6GV\L.H:M
MJ6M(\+6ZC4) X2)AAE  &21P6.3].:B\/>!8/#TD*)K&J7=C;$FTLKF8-%!U
MQC !; .!N) ^O- &;\,;:2.W\0227MU/MUN\BQ,X;.UP Q.,YP/6D\0VLLWQ
M;\,@7UW$CV5V=D;@*I7R^@(QSGD]:Z+0_#,&@WVI7%K>7;Q7US)=&VD93''(
MY!<K@ \D=R<=L9.36/#,&KZSIFJF\N[6ZL!(B-;LHWI( &1L@\':.1@CL10!
MS=EJ.I^*M$\1:I::I<65Q9WEQ;V,<>W9'Y/ WJ0=VXC)ST!P,=:Z;PAK<GB/
MPAI6L31"*6[MUD=!T#=\>V>GM5,^"[>*ZU1['4;RRMM58R7EM#LV,Y&&=25)
M1F'4@^_!YK?L[2WT^R@L[2)8K>"-8XHUZ*H& !^% 'FM_KVK64VF7<6JS7DD
MWB%+*>6!0+/R7E*>4 V,LHQEE!PP(+=J[GQ7K+>'?"FJ:Q'$)9+.V>5$/1F
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M;4)IX&MEN;J1&>&-NH4;<9.!DD$G K6T#1X_#^AVFDPW$\\%I&(HGGV[M@&
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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ML=@3R<'M@D Z.BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M3(EG*?+:3[I;Y>%Z?-TY&,UNW^H6NEV;W=Y*(H4P"<$DDG   Y))(  Y).*
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M\D\JI\Y 'T))Z#UH VJ*P[7Q?HUWIEQ?K<LB6T_V6>*2-EECFR (RF,EB2
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MJ%KXSMKC2?EB\11?V;J.&VE-H+"8?[0C$B_]\UW\420Q)%$@2-%"JJC  '
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MT"^XS1\2>$+#7'NM)T"UN+9=3G$FJ7<<LJ6R+D%RJ9\MY6QC@''))'&?2:*
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MY)'1"1G[OTIU_9:GK1\?G3=-O3)/=6-Y:+/;O"MRL*Q,R@L!R=N,=>17L-%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<#N:N+=:C;CPC:2Z7JBZ;_9GEW$MK:/YZ3A4 B<XW1(<')&,D#G - &IK'Q
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MJ[#DE3@ DG%5-5\<B,^&)-*L9[VUUN4;)DVCY-A?: S [CCOP!GG.* .SHK
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M-+N3L=V\IOEC4L2<= !R:\O33M1C^&?@FP;3+[[78ZC9R7,(MG+1+&^7)XZ
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M% !1110 4444 %8VE>'(-(UC5-3BN[N6;4W62=92FW<JA05PH(P !UK9HH *
M*** "BBB@ HHHH ;(@DC9"6 8$94X(^A[5D^'_#=KX=MY(X;F^O)I,![F^N#
M-*P&=J[C_",G '')]36Q10 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MC:5E!(1,9;V&2!^9H ?161X8\00>*?#MKK-M!+!#<%]L<N-PVNR<X)'\-:]
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M!W.H7T.F:=<WUP2(;>-I7P,G &>/4UY'J<EQX9U+P_XRN-.O;:X2=HM<EDC
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M"2*EQLQ(H7Y@1Q@8 XP.N=KP_I3^'GC$6E^-+N" $6EO=W%J\=MD$?(/,&2
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MWDNR",AF7'R\<8.6'^T2:M:MX9LM6\+/X=:2:WL'A6W(@*AA&  %!8'L!VH
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M]5N[$0/$944R[00" BK@C<3\N/89K"T2VE46</A_Q-XMFF@,:_9-1L2L"*"
M5D+PJ  ,]&SZ9- %O[3XF\6:?JMYHET+6]M]1FM[5FNRL<0BDV[9(@A#;@,G
M.3\W&*;XF\07VEZC<?VY)?V&G7%M$MEJVGL7M[64K\_F@<X+$8+ C&,8.36Y
M-\/-/;7;O4[74]6L8[Y_,O;*TN=D%PW<L,9!/<J1FKU_X2@OQJ4+:C>QV6I(
M([FS3R_+*A A"Y0E<J #@_3!H W)46[M&1965)4P)(FP<$=5/]:\3B@=?V=+
M><W,TDDUQ ?WKEPI^VCD#WZGGFO;H8HX(8X8E"1QJ%11T  P!7(#X;Z:OAE_
M#RZGJJZ<9A*D?FH?*Q)Y@5<I]T-SSD]B<4 06UQJ.D_$R32I-8N;JSNM'>](
MNRI6*5)57*X VKAN1[5D:=K.IPZ]X."ZE=WD6IM/%>73\6]V1$SAHD/*@$<$
M*H(]<UV%UX1M+W7AJ]S>7DDWV%[!XB4$;Q,06! 7.20#D$>U9EK\-["VCT9#
MK&LR_P!CR%K,O<*-B;2OE\*/EVG&?O?[5 %3X<VACU+Q=(UW=2E-=GBQ+*6!
M 2+!.>_;Z<4_QI#)/X^\#117#V[M/>CS4 +*/LYSC.1G'J#]#70:7X9M='UC
M4M0M;J\QJ$QN);9I 8EE( 9P,9R0HZDCTQ3M4\-P:KKFE:M)>7<4^F,[0)$4
MV$NNUMP*DG*G'6@#AO\ A)M4\/:;XMM&U"6[;3]4MK6UN;M@7C2?R^6;&#MW
ML02#VSD5TVEV'B2R\5+-+<I_8LUN4DMY[QIY!.#D.A*# (SE<X[@5*W@32IU
MUY+R6ZO(=<*M=Q3,FW*@!2NU000 ,<]@:E\.^$8O#[!WU?5=3:-/+@.H7 D\
ME/10 !G@<G)XH Z*BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **
M** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHKE?'.M7&E0:+:VTK0
M-JNJP6#SKUC1LEMN>C$+M![9SVH ZJBN&FFOM&^(MAHD%]>2:;K%E.^V64RO
M;2Q8.]6?<<$,!@Y&:@^&,&HZGX;TKQ#J.O:E=3R131O!)(/);]ZP#%<9+#'7
M/?'3 H ] K$U+Q&NF^)M%T5[*9SJAE"7 90B&-"Y!&<YX],<]:QO&NHZCI>H
M65X;'4+W0TAD%XFF2LD\+DKLD(4AF4 ., ]\G.!6#>RQ:OJWPV>QUB:YBF^U
MA;\?ZR0?9R">1PW!!XX- 'J5%>5'Q%J7AW3/%UH-0GN!8:K;6MK<WDN]X4G\
MO)9R#D+O8@D'MUZ5U.F:7K^G^*EN'O8ET>>W,<EI+?RW+^<.0\9= 1P#E<X[
MXH ZRBL_1=-DTC2XK*74+O4'0L3<7;!I&RQ."0!TS@>PIGB2]FTWPOJ]];_Z
MZVLIIH_]Y4)'ZB@ CU@745])86SW26N] 58 32KUC0G@X(VDG@'CL<,_MO[/
M;:=-J5I)9"\"(V]@P@F;&(W(XY)V@]">.,C/-:(DMI\#[.2SNI;>==$%RLT>
M-PD,7F$\@]6)J/46DU/X"27%W,\L[^'Q<M*[98R+"'#$^NX YH [YR51F"EB
M!D*,9/MS6-X7\1)XFTN6^CM9;41W,MN8I6!8&-BISCCJ/4U-X:O9M2\*Z1?7
M'^ON;*&:3_>9 3^IKR5&OM+^&VL^(++5;VWN+#6KAXH8GVQ,#=;6#KCY\@GK
MTXQWR >W45YYXON[H3^)3;:G>RS6>F"6""RD,(L7".WF2L& <MA2%()PO3!S
M46I:[J\6D^'=9N[34+[2)=,62_\ [+E*30S.J,)2JD%DQOX' Y..!0!Z1165
MX9NH+[PQIMQ:Z@VH0O;KMNV^]+@8W'/?(Y]\UQ.A#4KJZ\3:A=Z_JLL>B:Q.
M8;=9%5942)6\MP%Y7GH,8Z]30!Z717G&DQ^)M8TOPYXCL]2MXFF,5Q?&74)'
MBGA<?/&(=FU&!.%P<C&"3UJCK^KZA9V]QJ=EJMY=RQ:['$;B)REM'$950V_E
MEL.0#@L%ZY^;(Q0!ZE*[1Q.ZQM(R@D(I +>PR0/S-9/A7Q!'XI\.6NLQ6\EO
M'<&0"*0@LNUV3G''\.:Q;.\E\3>,_$FG37=U;VVD"""&.VG:)B\B;VD8J03V
M !XX/!S4?PB!7X8Z2K,6(:X!8]_W\G- '73WJ1_:$B4SW$$8E:",C>0<[>I
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MU7VV\&KPV9TV3[.]N97NUD4HC@@>7C[Q)R3G&.*KC6+J.TOKJZTBYACM+AT
M#*[2PJ!^^4#J.OR_>X/!. <6:[OD^+UM8B^N#8RZ++-]FR-BN)44,!CDX)ZY
MZTO@"\O;I?$L=[>SW9MM=N+>)YB"5C54PHP  !D]!WH ZRWN(;NVBN;>5)8)
M4#QR(<JRD9!!],5D6'B-+_Q5JF@_8IH9-/BBE,LC*1()-V"H!/'R]\'VK!^%
M<\C>&M0LF),6GZM=VD'_ %S63('T&['X52&EOJWQ3\46PU"\LD.G6>7M)/+<
MG]YCYNHQUXZ_3B@#T:BO,=!UR^UGP;X+N+[5+@W%V)//M;;*W%^45@,."NP
M@,QR!ZGGENEZGXDNO!NKK:"XO;K3]>FMO(:YQ/);1N"T2R]WVDC=G.!US0!Z
MA6)'XC5_&DGAHV4R2)8_;1<,R['7>$P "3USUQTK/\#:S8ZQ:ZC)9W.H%DN<
M2V>H[O/LFV*/+;<2<9!8<G[Q]*QM6TY]5^,1M5O[NR5O#OSR6CA)"/M!X#$'
M'X<\4 >B45Y+I_B77+.U_P"$>N;YKJ5/$;:2E_-)Y;R0B(R@,X4X<\)D#//&
M#S6CJ]SXD\&:;K=]-?P&QG-NME%+>/<26K/(D<C[Y$R4&_=SNP<<8- 'I-%<
M;;:-XAM?$/FC4A;Z3<6S12P-?R7,GG<E9(C(GRG .1TQSCBN-TS4-:7P+X,\
M2RZ]J,UY<ZC;V\\;R_NI(Y)2C!EQR<=SDCM@<4 >R45E^)&F3PSJDEO<26\T
M=K(Z2Q8W*0I(QD$=J\_M[S5-)\":%KSZ[?W%WK$5A:.+F8"&'S"NZ0?*=K;2
M1N.>3D@T >J45P-WIWB72GUJZ751;Z:^F2/%!]N>YFBN$!.]&E3A2.".>>1B
MN?>?7M+\)>$/%T?B#4;JXG-C'>6<S@PS1RA5("X^_D@[LDDY^E 'KU%>=Z1:
MZEJWC3Q-#<>(M56WTK4+:2"**15# Q*[(WR\H<XP,>^3C%72I?$WB?PWI7B;
M3M0M[6XDE%S*TNH2>08@QWQ-#LV# &,]01G- 'IU%>:ZCKESIGBF2W\0/J=C
M!/J41T_4[>5FM&C#+^XD4'",<,I+#G).<"GM)X@\7Q^(&TJ\%I=V6HRV=I(+
M^2)8#$0!NB5"KANIW9X;C&* /1ZCGN(;6+S9Y%C3(7<QP,D@ ?B2!^->?XU;
M4?B-%I5UKEU';3>'EN9H[&4*GF^:%8QMC(!['KCN,US=Y-=ZM\.M%.H7UW/-
M:^)H[/SC,RM(BW10%]I&Y@ .3W&>M 'M%%<+/->ZIXKU/P[;RRB#3K.!D_XF
M,MO*S2;\R;U5F?&U1R<9SD'(Q3M+_7DU7PQX1UO4XY+N6"XGOKJRD*F<1'"(
M&P"IY!;&#\ON: .KT?Q&NKZYK6E_8IK>32I(HW,K*?,WKN!&TGC&._?M5Z[O
M+JWO[&"'3Y;B&X=EFG5U"VX"Y!8$Y.3QQ7'^"+7[%X]\=0"::95N+0JTSEVP
M8 0"QY.,XR><"KGB:[O;7Q[X.A@OIX[6[GN4GMU("2;8&8$\9//OCB@#L:*\
MIF&K7L/Q +^(M53^R96>S\J4)L(@$@!P.5S_  \ \YSV]"\.7LVI^%M)OK@Y
MGNK*&:0@8^9D!/ZF@!-:UZ#2-%U34EB>[&FHSSQ0LNY=J!R/F('W2#]#5O3+
MT:EI-G?JAC6Y@28(3DKN4''ZUY7IMBD'@?XG2":Z<I=:G"!+<.X($*\D$G+>
M_6K^G-?:/J/P^DCU6]EBU.W^SW-M(_[G:+;>NU,84@J.>I[DT >GT5YE;R>)
M?%V@3ZOI%_%9WZ7THADDOY%BB2.8KY<D(0J047DG)RV<@8 [W5FF.@7CQ7#0
M3"V9EEAP2I"YR,@C]* -"BO&VN?$&G_#[PWXU3Q#J-Q=_P"B_:;25P89XY&5
M"NW'WOF!W9)Z^V.@TNTU+6/'?B>TG\1:K';:9>6DD$4,BJ"#$'9&^7E#DC Q
M[YXP >B45YAIDWB;Q3X9T_Q+IE_!:7+SFX9IM0D\GR@Y#0M"$V !1C/WLC.:
MF@T_5O$7BOQEI;>)]6M8;*:W%J;>14,;/"'Y('W03T&,]R>* /2:*\O\/:_J
M/B#P]X4FU&_N&NIX[E9[&R)CEO&C8QB3>K+L48+'D E@/05GOK>NR_#"UNAJ
M]W#>PZX+(RA@S/']J\L!SC+87C@C..<T >P5'/<0VL#33R+'&O5F. .U<7>V
M$NDZGIVGMX@U:_6YEN)S9&7_ $B?Y5 "R*4V1H<GD@98#T%<=J%S>:Q\++9]
M1N[J2>V\0K:A_/8,R+=A '(QN('<]P#UYH ]<N+RZBU6SM8]/EEMIUD,MTKJ
M%@*@;003D[LD<>E7:XK4I;O3OB1X3L(-0NS8W-M>>;;R2[E8QJA4DGEC\QZD
M]JR+34-0\2^ ]:\2Q:G=VFHP2W3VJQRD1P"%F"(T?W6R%^8L"?F/3C !Z917
MF-KJFJ>(_$_A<MJ=[8VVK:"]W/;0,%"O^[^Z<9'WCR<D#IBM[X>7EY<:9J]I
M>7DUV=.U>YLHIIVW2-&C#;N;N><9H ["BF2H9(G19&C+ @.N,K[C((KQNTO]
M;C^&>C^*'\0:E+?1:F(BC2CRY8S>-$5=<?-D'OTP,8H ]GHK@+J?5O$^M^)M
M-LK@V[Z:\=O;%+^2W:)FB5Q(51#ORS$88XPO3KDN;_6+34_"UCX@OXULY;>9
M+Z[LY6CCDND V@N-I48#G'&2,=L4 =_17DZZWK^C>$YKBYU"];[?KRZ;87%R
M%)BM&EVK,,KDDKNP6SGY3]=[4)+O0?'N@Z9;WEY-IFMQ7$,\,UP\C0O&F\2(
M[$LN1D$ XZ'K0!UEYJ+1Z5=7>GVYU"6 .%@B< R.I(* G@'((_"K<+M)#&[Q
MF-V4%D)!*G'3CCBO(-%2XTWX$:MJ-AJ-];W<?VV19!.6(*3R8QNSC/<C!/K7
M67<\UWJ.D6K:A>3&32S(=/LY&BE9R5'GO*&7"CD8)Y)X!(H [*>XAMD5YI%C
M5G6,%CU9B%4?4D@?C59KRZ&M1V0T^5K1H#*;T.NQ7# "/;G.2#G/3BO)GN;O
MQ#X"^'>H:E>7,EW+K<,,LB3,F\!Y%R=I +?(.>HY]:[![N\L?BK;V OKN73_
M .P99OLSON&]944-ZLV,\DD\GUH [:BO*AJ^J:C\)7\<V^IW$6K*DEZJ"4F
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MYNX'XUMUYZ^G)I_QET<1W%U)&^CW/RW$[2[2'CR06)//'&<<?6O0J "BBB@
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M1QW&Q+@*NP,P4#Y@#CC ]0:GLO"$.FQ6:6.JZI ;6U%HK>:C[XQTW!U(R.V
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M&UB\D7MG=%)I(\YVNQ!W#.3^-2ZCX'TK4+;3462\M+G3'+VE[;S8G1F^^2S
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M^6DZK %8JSH1D'(RI!_2O1:PO%_B/_A%/#EQK!L9+Q(2@9$<)C<P4$D]LD=
M: *\_@;2'GTF:T:[T]]+A:W@-G-LS$<91N#D'&<]<\YS53_A7&D+I$FEQWFI
M):R7OVW:+@-MDW[QC<#@!N?4]R:["B@#!U7PI::MJ>GZG)=WT%]8HT:SVTHC
M:1&QN5\#!!P#QC';%4%^'>BIH-[HRRWXM;JZ^UY-R2T,F_>"A/3#<\Y)[DUT
M'VJ\_ML6G]GM]A^S^9]M\U<>9NQY>SKTYST[5=H P9/"MK+K.E:H][?-<Z8D
MB0;I%8$/C?NRN26P._&.,5 W@C3A)J2P7-[;66IN9+VRAD413,PPYY4LNX==
MK#-=+10!B2>&+-_$%GK*3W$,]G;FVABCV"-8SC*[=OL._:L?4/ R1^']4L=.
MU#5EFU"\-Z9(KE8F6=CDL6"C"$@9 SP.!FNSHH B2*06BQ-.QD"!3* ,YQ][
M!R,]ZY<?#[3%\+1>'1>ZA_9\4_VA1YB;@WF>9][9TW\__6K4\5Z__P (OX:O
M=9^QR7:VJ;VB1PIQZY/;\S[5JP2^=;QRXQO4-CTR* .9U7P%IVIZVNLI?ZII
M^H&-8IY["Y\DW*CH),#!^HP?R%87BRQA@\0:9"\'B*PTZSL6CM[[1!)(=S,-
MT;A Q  13DJ<D]>.?1Z* .(TGPV-8T?4M-U:YU?4-%NEC\@:L EPK@DLPPJL
MH^YC< 00>W7?L?#T-K?0WUS>7>H7=O$88)KLH3$C8W8VJHR=HRQ!)QUK8HH
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M;2#AG21@&V\@XY ..QK'^'M_>:EJ4FGZOJ=Q+>:-$8XL3R!=0B9SMNB"<."
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M321Q'JB%N$'T'IZ# !Q"MJ</AGX?:Q'KVJ_;=2GM+2Y9KDLCQRQ,6RARI8$
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MDE^>)RQ;<KC!!W$G\3VXH R;BQ\5Z'IWB>6RO8I#+9F;3;-[M[F2"55PQ#R
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M<,^EW))2XD3[KQXZ$8')R.A[YH Z+PUXC?7Y]9ADL?LCZ;?-9D>;OWX56W<
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MM!=LG).#@ *QZ=J?HMWJMU%<KJVFI930SF-#%,)$G3 (=> 1G.,$9&* ,_\
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M < 58_X0_1VGU>6:&2?^V%5;Y)I"RRA1M7CM@<#&*W$+%%+J%8CD YP?K3J
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MM?>#M#U+5Y=4N;1VN9X1!/MGD1)D'0.@(5\9XR#4D'A;1[?PP_AR.U)TMX3
MT3R,Y*$8QN))Z=.>,#'04 >?6&I2VNOZ_I :8)K\:SZ(\DS/A&;RG*Y/ '$P
M Z*:UM?M;=]2U+3[2:YO9++1P/LSSLD=EG>1*9.6,K8XX)^7DC-=L^C:?)?6
M%XUK'Y]@CI:L!CRE8!6 _  50OO!^B:EK#ZK<VKM=20^1,5G=$FC'19$4A7
MR>H- ' ^;=ZO8?#"2YU&^#W\>R[:.Y=/.'V9F);!^\>?F^]SP16G!8B7Q5?>
M$%FWV>GZ?"]M#>7$K.XD9]\FX,"Q!V*"?N]L9-=)!X#\/VT.EQ0VUPBZ6Q:T
MQ=RYC)&,_>YXXYSQQTJ7Q!X+T/Q-<VUUJ5JYNK8$17$$SPR*IZKN0@X]O<T
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MXGXM/);_  TUB[MYIH+F"-7BEAD9&0[U'!4CM75:5!';:7;1Q[MHB7EF+$G
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MLK D,K#L0016;JOC73]*@O[IK6\N;+3Y!%>7-NBLD+<9!!8,VW<,[0<?4$4
M=)16/<^(H([YK*SM;G4;M(%N)(K79F.-L[22[*,M@X&<\'M69-\0M$CT;3M5
M07<UM?W:V:^7 2T4I;:5D7JI!SD<GC@'B@#JZ*YNS\:Z?/<:M;W5M>Z=+I<
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M0!F'S<=^!@\YQ6OJGBNWTR&]E&GWUVFGH'O3;",_9QMW$'+C)"D,0N>"/49
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M,,_Q 'GV. #TBBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M6'0]!D>G,26/B-]-\))J<=[?S6.NFX:X,!\S[(HD5'D _B(921U]1G->IT4
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M%8'(/(]:P+CPSJ=CHEHXL+AY[SQ:NM2V\2;S;P^;N.['&0H!('<D#.*]9HH
MX"]@N_\ A/=>U!='N+NTET 6\:O"0EQ*K2,8N?4,!SQSBH?#6@W>EZU-;:(^
MIQ^&YK&3?9:DK 6DY(V+$7YQC=D E1CJ<BO1:* /(8K#6!\,_"VE2:%J*7FF
M:A:-/'Y8)*Q29=A@GC&,>N>,UU7C"&\C\1^$]>MM/N[VVT^><7$=M'NE5982
MBMM.#@'KZ5VE% 'DMYX?U_6;?QRD6D2V\UY>6M[9"Z*>7,8EC;RSSU.S!_AS
MWK6M;9O%.C7]I;>#6\/7,MC-;R7-U;1QE9'0J%B*_,PR<EL 8'3GCT2C.>E
M'D=PVNWO@KPUH[^&-434=(O[$7*B-?+*PL,LCEL,"%SQT[XKT&R\0-=>);S1
M9=+O+4P1++%<2@>7.OR[MI!/0L!^?I6WWQ4,=K#%<2W"I^^E #N222!T'/0#
M)X'')]: .4\?6UU=R>&?LMI<7'V;6[>ZG\J,MY<2!@S''IN''7VJ'38KFV^(
M7BR_EL;L6ES:VJ02B!B)6C5PP''JP^O:NWHH \CTO2-8L/"'P_9]'O7GT>\;
M[9;(@\Q 4D4$ D C+#D'O]:N/:W6A>+M8.H^#)M<LM6F6ZMKBW@BF>%RBJT4
MF\C:H*\'./Z>H44 <']AO(?B'X=N/[+:*UM],FMYC:PGR()'*%4! Z?*1D#'
MTJ*PU%;#XM^+#);W4JO96/S6\#2X($F 0H)&<GGIQR1Q7H-8MEX:AL?$VH:Z
ME[>/<7Z1QS1.8_+VIG;@! 1C<>_?F@#@(?#>I:3I_A5&T^X:5=?DU2[B@3>+
M6.3S, D<$KO4$#/?&:U?$]G=:7X\77I/#<FOZ5=V*6LT<$*2S6TB.S*P1NJD
M.0<>GTSZ)10!YWKNG7QL/#%_9^'6MX[365NY;"TC3S(HBCKE@#M+98$X/&>^
M,U4N+:[T7QGJUSJ'@V;6[#6#%<02V\$4TEO((U1HGW$ #Y0<YQ]><>GT=* /
M.9;/5/#OCG3M?&B/+IT^E?V?/;:;&'-DXD,BX48RO."0.HSQP*TO -OJ%O=>
M)WO=,NK-+O6);J!I]HWHR(!T)/\ "?;WKM** .#\1#6;OQ/?V,VE7MUI<NG@
M67V4JL33'=O\X[ATR, Y&,\$UB:78:K'IGPXCGT>_A;2G(NPT6?+7R6CW'&>
MK'IUQSBO5Z* /)]>\-ZOKLGQ#MK.TGB?43926,DJ%$G,*KN7)Z9*XYQG.>E:
M-Y?:IK_B7P;J*>&M6@%E/.UXLT2IY1:$IU+#(R>O0CISQ7H]% !1110 4444
M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M G1B0#'\_/((YQC'-1:=XRM=5\.Z?K-I87KQ7\X@AA_=B3.2"2-^ !M8GG(
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MN*(^8A5#$ H7*MDMD$GC'/!/%=-H?BR$76BZ'<:=?6S7EGNM+F55$<YC12X
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MKM4#OU)XSBN/M=,\1+X&\+:'_P (W??:M%U6VDN6+QA76.0L3&=WS#'.3@4
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M<:"1]LMXBC':4WAE)(!&TY['VJ"#XA0G5M+M+S1M1LK;50!8WDP3RY9"N=F
MVY2>VX#- '94A900"0"3@ GK7"W'Q,2.RU.\A\-ZO/;Z5=26]\R"/]R$QN;[
M_P W4\+G &3C(J'5I[+4?B-\/]5LRLD=W#>NDP'WT, *_P _U- 'H 92S*&!
M*]0#TI:Y#3M>T*UU7Q==M82:=+I[1-J=Q+C][B/*L-I/&S&._/3-7X/$[G6+
M/3[S2+VT^VP//;RL ZX4 E7VYV-@@XY'OGB@#H*0,I) ()!P0#TKE;'QQ!>7
M.BA].N8+76C(ME,Y&254M\Z]5R 2.OOBN2T#7F\*OXS>UT"^OK6#7)I9S:!
M(8_+CR0&8;CU.%S@=<<9 /5RRJ0"0"3@9/4TM>>:S=6.K>-OAUK%D5DBNGN6
MCE P60VS$ _GT[5JZSX_L=(M[V\^SO<6-A-Y-U+'*@92" Q5"<L%)P>G0XSB
M@#KJ*A%W;FR%X)4^S&/S?-)^79C.<^F.:Y^#QBLTVDO_ &5>BPU9MMI=!0W5
M=REU'**P&03^(% '345RUWXW@M].O=6AT^YNM)L97BN+J(KQL.'95SEE4Y!/
ML< TMUXU@CUVUTFSTR\OI;NR-[;20&/RYDRH&&+#'WLY; ],Y% '44SSHB6
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MK%:W,C*0'8919%!RA8=.OH<&J5S\0O*&N>1X>U.<Z*^+L Q+M4('+ E\'CD
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MS:/;M(BX W(5) [=>E<MX.N?%EMIVGZ!J>@_9GL$2"743.C0RQIP"B@[BS
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
G **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>49
<FILENAME>exhibit108-arvinasxformo005.jpg
<TEXT>
begin 644 exhibit108-arvinasxformo005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MI8E00.2/SK+UCPUJ/@WQ+HWCKPAI%S<03QK#J6FPVS!QE0&(3&5SCTX8 ]Z
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M]!U]*ZN/2+O49/$5G;ZQJ-N5U.%$D%VY:*$1P2NJ9)P3N<9_VO2N,^'D-QX
M\7>*['7;&_CBOKE9K.ZAM))HYE#/T**<'##CZUZ;X>BG/]IW\T$D O[SSXXI
M1AU01QQJ6'8D1[L=1D X.10!YB;C4!\>U\+_ -L:M_9!L_,\C[?+G=Y>[.[=
MNZ^]7/'OB?6? 6AZ9X>T[4)+K5]5O)4M[VZ/F/#"7&,YZL-ZJ,^AJLUK>_\
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M\0:FXM]0AM+%/[1DC;,DCH H##<?N]<]*]KL+2/1])BMPSNL*?.^TEI&ZLQ
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MOMR2F.VMWDP@1P22H(')'YU6^(?A#4O$?A[PSKVB6TDNI:*$<VDB&-Y%^0D
M, =P*=.^3WP* -KQQI^H>%O T^LZ-K6I?VEIJK*TES=/,EP 0'#HQ*\@D_*!
MCMBLS5M5UCQ[\.M!U?PU?W.F:O>R-'MAN&1"Z1RET(SCEH\ GID5H>/-:E\2
M^!+G1]"TS49]3U-5A$$EI)%Y )!8R,P"K@ CD]>F:FT?15\$>'_!^B,ES<O:
MW327$MO;22JI>*;<Q*J<+OD Y[8H Y_PQX^F\6>!-7TS4[BYL/%&D0.9O+D:
M&1RG&_C'.>&'3/U%>O11+#"D2ERJC +N6/XD\G\:\F^*/PZGO=3M_%OAU7CU
M%&5+Z&'@W$)^5F '4A201W'N.?7* "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MS_T/WC#_ ,#U_P#B*[VB@#@O^%:7/_0_>,/_  /7_P"(H_X5I<_]#]XP_P#
M]?\ XBN]HH X+_A6ES_T/WC#_P #U_\ B*/^%:7/_0_>,/\ P/7_ .(KO:*
M."_X5I<_]#]XP_\  ]?_ (BC_A6ES_T/WC#_ ,#U_P#B*[VB@#@O^%:7/_0_
M>,/_  /7_P"(H_X5I<_]#]XP_P# ]?\ XBN]HH X+_A6ES_T/WC#_P #U_\
MB*/^%:7/_0_>,/\ P/7_ .(KO:* ."_X5I<_]#]XP_\  ]?_ (BC_A6ES_T/
MWC#_ ,#U_P#B*[VB@#@O^%:7/_0_>,/_  /7_P"(H_X5I<_]#]XP_P# ]?\
MXBN]HH X+_A6ES_T/WC#_P #U_\ B*/^%:7/_0_>,/\ P/7_ .(KO:* ."_X
M5I<_]#]XP_\  ]?_ (BC_A6ES_T/WC#_ ,#U_P#B*[VB@#@O^%:7/_0_>,/_
M  /7_P"(H_X5I<_]#]XP_P# ]?\ XBN]HH X+_A6ES_T/WC#_P #U_\ B*/^
M%:7/_0_>,/\ P/7_ .(KO:* ."_X5I<_]#]XP_\  ]?_ (BC_A6ES_T/WC#_
M ,#U_P#B*[VB@#@O^%:7/_0_>,/_  /7_P"(H_X5I<_]#]XP_P# ]?\ XBN]
MHH X+_A6ES_T/WC#_P #U_\ B*/^%:7/_0_>,/\ P/7_ .(KO:* ."_X5I<_
M]#]XP_\  ]?_ (BC_A6ES_T/WC#_ ,#U_P#B*[VB@#@O^%:7/_0_>,/_  /7
M_P"(H_X5I<_]#]XP_P# ]?\ XBN]HH X+_A6ES_T/WC#_P #U_\ B*/^%:7/
M_0_>,/\ P/7_ .(KO:* ."_X5I<_]#]XP_\  ]?_ (BC_A6ES_T/WC#_ ,#U
M_P#B*[VB@#@O^%:7/_0_>,/_  /7_P"(H_X5I<_]#]XP_P# ]?\ XBN]HH X
M+_A6ES_T/WC#_P #U_\ B*/^%:7/_0_>,/\ P/7_ .(KO:* ."_X5I<_]#]X
MP_\  ]?_ (BC_A6ES_T/WC#_ ,#U_P#B*[VB@#@O^%:7/_0_>,/_  /7_P"(
MH_X5I<_]#]XP_P# ]?\ XBN]HH X+_A6ES_T/WC#_P #U_\ B*/^%:7/_0_>
M,/\ P/7_ .(KO:* ."_X5I<_]#]XP_\  ]?_ (BNNT73&T?28+!]0O+]HMV;
MF]D#ROEB?F( SC.![ 5?HH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MXCC9V#$*,G:I8_@!R: /,O VM1Z)X-\0ZUJ<VH7<=GJEVA+2/.ZQ(W &XG
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MUO!]G8,Z/<*X8<8QM!//^%;OC#2HM7U1KVW@UG3]6M[)6L-4L(9"7)+'R9%
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MF[N&@BVDA2,0%"68D^P&,\DXKNJ* /,]%\-:GJ'P;O\ PW/;2V.HR?:=BSC
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MZ<4Y52)$C4*B@;54< 8[ 4 <)X9AO;+X@>,]2N=-O8[/4#:M:R&+_6".(JW
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M +1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M;$*JJ'@F)(*.I.=PVGID<=>0: -'_A!O#7_0*C_[[?\ QH_X0;PU_P! J/\
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MLA,<J X).1T. <4:CXI:W;5%T_39M1_LI UYY;A2#MW[$'.]]N#C@<@9SQ0
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M@/7!(SV!..IS8HHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *YGX@6%
M]JW@;5M,TVS>ZN[N Q1HKHH!/<EB!BNFHH X'4=+UFY3P08]'N,Z7<)+=J98
M<Q@0E#_'SR>W84G]EZQ%XD\9WIT W=KJ26B01321%;A8U*2*06XR&.,_C7?
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M-C R.36-;Z%K@\%^.M/;2)ENM6O+V6S0S1?.LRX4D[\#'?/ZUZ502 ,DX H
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M#SS20.B1H5!8D$#EB!^M<MIWA6XU+X0P^%=5@>SN3IRVC[F5]KJHPP*D@C<
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ML8W'=Q@KD^U3KI?B+^U-&6XTF.\TN+2HX#;2W2*EM=*<&1UY#C &" Q'H,T
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M_P"6D2L)$ '?)W(?]ES1X+\*W7AV[U-+AU:RBGD32D'_ "RMW;S6'_?;;?\
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MW2RBZ(&!L4#*@G!);IT YR !/ .O:MX@TV\N]3MX8]M[/$ICE+!=DA7:!M'
M Z]^N!775R7@72]5T.VU'3[^S2.$7]Q/#<+,&\Y9)"ZX4<C /.:ZV@ HHHH
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MXR4< ;U(((;'.:AOO$UUY^K0Z-I8U%]*0&X4SF,NY7?Y<8"MN?;CK@98#/7
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MJ   <#).> &2V?BO6?$OA35;O1+:S_LQYS= WH8$O%LRNT'CG([]CCK7?T4
M<WX]T2[\1^"-3TJP\O[5.BF(2-M4E75L9[9VXK-NM(UQ/%^F>+X;&-YS9-87
M^GI."PB+[U9&;"E@>H.!Z&NVHH YSPYH4UEK6O:[=H(KK6)HF\@,&\J.*,(@
M)'!8\DXXYQDXS65XS\-OXDFN(+G0Q=!( =.OX)TBFMI^<Y8D$+G:>,]^#Q7<
M44 >?2:!XI&KVZWB6NL6XTF.V6:>?8MO<@$22[-IW%N,,.>,<9-4[/PMXDM?
M"_@I#8VK7VA7(,MO]JP'C\MDW;MN ?FSCGBO3:* .._LK61\0KS6UM46"31E
MLHY!(I_?*[/G'7;\V,]?:J&C>%+BS\6V>NV>E'1"8)!JUO!.IANY"HV[$4XR
M&R=Q"GZY./0** .3\$Z9J6D'71J5IY O=5N+Z%A*K#9(5P#@\-Q]/>J/@[P\
M=.\3Z[)'<"32[6Z=-/A X@:4)).![!L >GS#UKK=6TFQUW2Y],U*W%Q9W "R
M1%BNX @CD$$<@=*?IVG6>DV$-C86Z6]K"-J1H.!W_//.>] &=XQTBXU[P;J^
ME6K(+B[M7BC+G"[B.,FN?N=*U^]U+P=>S:7''_9<CO=(ERK;0T1C !.,G)R>
MV.YKNZ* /-M1\&:QJ]QXSVJMD^ISVEUIT[.K!9(%3&\ DC+(/7@^O%=+X>N_
M%=\Z'7M+L],2%<.(+GSC</TR!CY%ZG&2<X]#GI** .5\8:?K-[>:+)I]O%?:
M?!.[7]A)-Y0G4KA"21@A6Y*G@\>E8NG>'/$%EX?\::?+I]KOU:YN9K007 *_
MO8E0 Y PJXZ]3Z5Z)10!Y]K7A_6[_P"$MGX<@L!_:,<-I"X>9 @,+1ECNST.
MPXXSZXK3\0Z;J>I^(_"VH6U@WDZ=<R37(>5 RAHV0 #/)YS]*ZZB@#D_#>F:
MEI_BGQ3?W5D4M]1GCFMR)$8D)&$((SP3C(_7%<W+X2U^7X7:[X>^P*+^^O)I
MHLSIL"R3>8,G/&!P>.M>H44 <AJ6F:I>^.O#FKQ6+):V-O<1SEY$W*TH4# !
MY *\_IFN7C\+>+I-/T/[5IEC+J>GZPEY=WCWF7O%'F#=G;E5 <8!Z8P!7J]%
M '(:7I6L:5XY\1ZB;2&;3]3\B9)$F <-'"$*;2.I(!R2!BHO"'A:>#X9IX7U
MZV56:.>&94<.K+(['*D>S>W(KM** .-T/PE??\(%>:+KMT);^^M7M)[A.<($
M\I,?\! 8_P"TS>M-\+?\)M##::3K-A8PPV85'U**YWFY1> %CVY4G R2?7 S
MC':44 <OX\\/7OB'0(4TR6./4;&[AOK7S<A&DC;(5L=CS^E93:9XBUKQGI&K
MWNC0V5I%8W%K<HUZ'=3)MY&U2#]WC]<5WM% ' >%++QKH=G;>&;FSL7T^S(B
MBUA;CYC #P/)VYW[>,DX'7G'-^ST?41\0-=U&XLBNG:A9PVR2"52V4WY)&>
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M99-^6&WY<#C'.3Z=:W+S1M6N_%_A?5/LD2VVG6]Q%<@S#=F557Y1CD#;[=:
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 5$
M+:$7+7(C43,H1G'!8#D ^N.<>F3ZFI:* &N@D1D;.&!!P2#^8I(H8X(4BAC6
M.-!M5$& H] *?10!%';0PS2RQQJCRD&0KQN(&,GWQQGV'I4CJ'1D;.&&#@X/
MYBEHH 9##%;PI##&L<:#"H@P /0"GT44 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 5FZQH&E>(+>.#5;&&Z2-M\9<?,C>JL.5/T-:5% &=I6A
M:9HB.NGVB0E\;WR6=L=,LQ)./<UHT44 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MSZ(8+JYA,L40D<K&TJ$@J2.VX8- &G14=N9FMHC<*B3E 9%0Y4-CD ]QFI*
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M6K1RG$0)!VIL"C;T(.>IK+U_59-+^(7BDS1NNCW$>GP:G=Q<O;0LDHW >A.
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MW_GDY]:Y:.UMX/V9$EBB1))H8#(P'+$7*XS7K@\/:4->?6Q9H-1=!&TP8_,
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M'&,FNFTCP_I6@K.NEV:6RSN9'"L2,DDG&2<#))P,#DT:CX?TS5+V"]N8'%Y
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M7S01@\ X&0 #C&>^:<?">C,NFJ;:3&F8^Q_Z3+^YP,#'S>G'/;CI0!M4444
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MEP\I _/%4?#^D6VL:3X6\3P:W9P3QO"TES;VI$UTS *\,K^8=Q+$YR.",\4
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M49)-1,T6Z(RNCND3@%<KN(4<\[!G/- 'I=5M0U"UTK3KB_O9EBMK>,R22,>
MH&:X&Y\*3Z?9:_8Z9KEG%->RVL\5@;<QVL+[Q\FT,V%FVE6'?GCFN>UR:TOO
M /C>RO?#B:3J]G;12W-J KP[L-LFB(&.<-[C'KF@#UBZEU&0Z?)IJ6K022@W
M1N&8,(2IY3'5LXZ\=:T*\Y\2V-G97?@+[%#';J-6C0QP_(G,3L?E'&20#G&:
MHCP_INJ^+OB);WT+7$$<5JZ1R2L55C QW 9ZYY![9.,4 >J45Y397%[>>&/A
MM<W3O>V;*/MMK]][@^0=CE>KA"-Q'/8X)%=+X)\/S:7J.O7TEN]M:W=XQL8'
M8CRX<#/R9P@+ D+@$#TSB@#I+MM3&H6(LTM6LRS_ &PRLPD5=OR^6 ,$[NN>
MU7:X?Q7&H^)/@24%PS3W:D;S@@6[D<=/QK#NFFT3Q%]HUG38-1TFZUD-:ZU:
MD>?:2&7:L4H/)4,-F0<8'KB@#N?%VL77A_PIJ6KV<$,\UG TVR9RJD*,GH.?
MIQ]:T]/N&N].M;EP \L*2,%Z D U@?$?_DFWB/\ [!\W_H)KD;W0+;0]0\$:
MQHHFBU2\O(;:[(E9C<P-$6DW@DYVA<CT_*@#U6BO&;UK9[30]:TK+13>*8U7
M4KAQ]JN T[(Z\ 8CQE0"3D <"M+Q0\NCZOJFK:GIL&L>'I;F)GO;<C[7IC*$
M&,'J@(#87^\V>O(!ZI2'(!QC/N:\S:S7QEK_ (OTC4+FQ2YMIEB@6XMC)+;P
M&)"DD1WKM^8LV0.N,GH _2Y(]0\=V'A_5;P:K9VN@QSVK7"?+>2%]K3%3D,=
MH&.O5B.M '4>$=?N]?AU<WMO!!)8:I-8A86+ B/;SD]2<GL*Z*N$^%]M#9VG
MB>VMUV0Q>(;M$4'[H&S HC:'7/BEKFD:S;QW%M::?;O8VTZAD97+>;(%/!.=
MJY[ 8[F@#NZ*\1N8[F3PG]BN)[E[?3O&26-C*9FW?9Q,H SGYMI+*">FWVKL
M-&L+;1/B]J-AIT?D6MSHL5U+$K$AYO.==YS_ !8ZGO0!V5_J=II@MS=2A#<S
MI;PKW=V.  /S/T!K(M/$%Y-X_P!0\/S6\"6UO8QW<<J,2[;G9><X ^Z>.?K6
M+\2K"SN[SP>US:03$Z]!$3)&&RC(^5Y[$@9'? JL^B:9JOQ9U&QN[5);%=!M
ME%OTC(\V0 %1P0.PZ#\!0!Z-17B^B:M,O@_P)87EW$EA=7EW;2R7BF2-C&TB
MPQN-PR#@8!/51Z5Z!X5T!/#^J:S#%J4<L=P\=P+""#RHK0D$'8-S8#[<X]O>
M@#J**\YU;1K+5_C(ME?+)+:S>'G>6 S,$D(N$&",].G'L*P=,C@T[3+_ ,/W
M,]Y-IT'BA;32[82#$W ?[.[-G]T#G/7H1R>* /9**\ITZSNI)OB%HEM=VNF,
M;BU6W6(GR(9)8D)4#CAFP#@#.2<=J?9O+=P>(]"GTV'PQXBELH59H2#:3+O9
M4D0KC 9F*G/.,=<4 >IT5Y*-6L]/T[Q1::_I<WAK44TV,W+Z4RF.:+<R+) 0
M.&+.5YYZ<\<:6AP/IOQ8CM4M+;3X9O#YD:UMFR"RS*JL^  7P2,@>V30!Z11
M7C]CH-]KGAC2+<VTDFMQ:PTEYJB$A9H1,_F-YH(W*RX4*#G@< #-:C64?BGQ
M3XJT"]GL5:T6**UBNK<RR10&%2)(CO&#O+$L!G(7)X% 'IE%9?AR$V_AVP@.
MHOJ7E1!/MCC!F X#=\YQUR<]>]>:6:1:_P#"#6?$-_\ N_$,!O+A[O.)K6>)
MW*(K=5 "H-HXP?>@#T37-<?3]1TC2K8)]MU6:2.)Y%+)&$C9V8@$$\ #&1UZ
MU/I-UJ8TN277XK2UN(7<.\$F8FC4\2<\J".<$\>M<%J5E#JWB?X;7.L:;:O>
MWD$[7JR0*=S_ &7=M8$<@-G /2NX\56MO/X.U>":"*2'[%+^[= 5X0D<'C@@
M?E0 ]]0O-2T.RU'P^+6477DS*;LLJF%L$GCG=M/'O6M7C]]8V=O\&_"$MM#'
M!(TFER/Y/R;V8Q@LP'WB?4YK<FT:QU+XPZG:7L)N+670X9)()'8HS&9QRN<$
M8 XZ< T >B45X4VG6\7P6?61YC:EI=^4L;EY69[=4O-BJA)X&WC'>NONXU\3
M>/?$6@ZA+8$06T'V2"\MC*?*9"7DC^=<'>2"P&>%YXH ]&HK'\*VAL/#-E9M
MJCZH;=3%]L=<&7:Q'/)SC&,YYQGO7 Z=#;^)O ?BC4]44+K-O=7H-P>);)XL
MF,(W5 H"G QU/J: /5J1F5%+,P50,DDX %>1PV1\3>)/!?\ ;\<KR:AX?F>]
MB,C*)#B/J 1CKG QS7I-[IEE%X7FTP6Z/916AA6&4>8-BK@ [LYZ#K0!BZ]X
MQ>TT/1]6TB*"ZM-0OX+;S)6(^220+N4#KZ\D=NM==7BJ65I'\&/!WD0QPO<7
M^G-,\*A&8F4#<2.<^];%Y&?"OC3Q2F@0^23X9-^(5)8/<J\@#X/5C@9]: /4
MJ*\UT/1;2_A\,>)K36K.!ALS):VQ$E[O4!HI6,A+G.2<C(()XP:Z3QW-9)X=
M2&]EN52ZO(((XK9@K3NT@Q$2> K8PV>V?I0!TU-<N(V\L*S@':&. 3VR><5Y
M#/>ZCX>N?B0=.CM[6:WTZVN(K>TYC@D*2;F48'S8 ).!G'2NPTK1O#IN?#VO
M:;<M#(\#1Q&!QB^#ID^;QF0C:6R3D')- %_P5K]UXE\.C4;R"&"?[3/"8X22
MH\N1D')Z_=K49M3_ +;152U_LK[.2S%F\[SMPP .FW;GWS7BQTVUB^$DVO(C
M#4[/67>VN-YW0_Z=M(7G@$$Y]<\UW<Z&'XUQR1!F=_#TK;"Y(+"= ,#H/PH
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MMW>[M%*03-,Y:-3U R>_?U[TRP\,Z1ICP-:6A06V?(1I7=(<C!**Q(4D$C(
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MRLK?3K**SM4,=O"H2--Q;:HZ 9/0>E3*Z.2%96VG!P<X-!D0'!=0<[>O?TH
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M5AF\Q@44]0 #@ ]QW[UH$ @@@$'J#2%T5E4LH9N@)Y-4UU:RDUJ32$F#7D4
MGD0'[BDX&?0G!_*@#-3P1X;CL([&/2HH[6.83I$C,H$@.0W!ZCMZ=L5?CT'3
M8]8.K+;G[>8O),[2N6,?7:<GD9YQZ\]:T<@=:,T 8&E^"?#6B:K)J>FZ-:VU
MY)G,D:GC/7:.BY]@*T=6T?3]=T][#5+2.ZM7()C?U!R"".01ZBKBR(S,JNI9
M>H!Y%<YX:U^^U;6?$5C>Q6\8TR[6"(P[OF4QA\DGO\WH* +MGX5T'3[UKRUT
MJVBN7A$#2!,EDYX.>O4Y/4YYJ'1_!?AS0+B>?2=)@M)IP5=XL@@'J%.?E'LN
M.@]*WLBFET#A"RACR%SR: ,3_A#?#_\ 9+Z5_9X_L]Y/-:W\U]A?.<XSZ\_7
MFK8T#31J\>J^0QOXXO)6=I7+"/\ N\GD9YQW//6M*FAT+E REAU /(H PH?!
M'AF#7VUV+1K5-29BYG"G[Q_BV]-W7G&:U[FPM;N>UGN($DEM9#+ S#F-RI7(
M_!B/QK"U37+^3Q')X>T8VD=]'IYO3+=QL\9R^Q$PK*1DALG/&!P<U?GUD:/X
M9&JZ_P"3:210JUPD;[E#X^ZI.,Y/ H 77?#>C>)K1+76=/AO(4;>@D!!0^H(
MP1^!J)_"6A/I=IIG]G1K96CB2"%&951P<AN",MGG)YR2:J:CK]]9^/-$T58K
M8V.H07$C2'<9 8@IX[ ?,/7I72*RNH92&4]"#F@#-_L#3?[6.J^0_P!O,/D&
MX\Y]WE_W<YZ9YQZ\]:KCP?X?_L>XT@Z9"^GW+F26WD+,K,3DMR>#GG(YSS6R
MCI("496 .,@YYIU &#;>"_#MGH<NBV^E0QZ=,<RPJS8D/^T<Y;H.I[59/AO2
M6NK"Z:V9I[!2MK(9G)A!&"%Y[C@^HXZ5JT4 9UCH.E:;J%W?6=C##=7CEYY$
M'+L>I]LX&<=<<UHT44 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %<5\2;Z6SL-#C8E=/NM9M
MK>_;.!Y))R&/92P4'V..]=K4%[96NHV<MG>V\5Q;2KMDBE4,K#W!H XBXT]-
M-^*^FV^F6\<=EJ6FW']I6T: 1,J%0CLO3.6VY[CBD^&.FV%O_P )+/!96T<R
M:]>PK(D2AEC#C" @<+[=*["QT73M-606EL(VD4(SEBSE1T7<23@9.!GC/%)I
MFAZ9HQF.G6<=MYSF241Y =CU8CN3CKUH XWQEIEGJ'Q+\&0W4>^.XCODE3<0
M)%$2D*<'D<GCN"1T)KE+]9/!W_"<66DL]OH,%UISLB[F6V$K#[0% .<%2,@$
M8##I7<^*-"N]7\;^&;S^S7N-/T\7/VB02HA4R(H0K\P;(*YR,8[9KIX-)T^W
ML9;*.TB^S3;C-&R[A*6^\7S]XGN3G- '&P^'-,767U*'4[)EO=->)K+3[<1P
MW$8Y$C ,<D9 #>X'>LSP+X7T27X76.K3Z?#/?3:0T<DTPWEESN (/'!48XXQ
M7;Z7X/\ #VBV]U!IFD6MI'=<3B)=ID'H3UQUXZ<U:M] TJTTAM)M[*.+3V!!
MMTR$P>HQV!]* /*K0PZ9\-/ *QV\,%CJ5W9Q:I)&@7S4*D@2$=5+8!SVX/6N
MCO--CLOBA%9Z? D>GZCI$SZC;1C;&2C )(5' 8[MN>X'M781^'='CT=](73K
M?^S67:;5ES'CK@*>!SSQ3K;0M,M()HH;4*LRA)6+,SNHZ*6)S@9.!GC)H \D
MTOPWI#? .76WLU;4SH4Z_:69BV!N8#KC *C'IBM6[T+3(=;^'LL5JL<M\DD-
MW(C$/<1_9BVV1@<L,@<'C''2O0H_#6C1:*VCQZ="NFMG-J!B,@]1MZ8]J&\-
M:.[63-81EK$8M22<P?[G/'IQVXH \UG72-"_X65ITGGV.BQR6>V#3R(RC31*
M"$_A7<Q /;!-:FFVB1?%74+">WL;:"Y\/QO-9VG$8(F91NZ;FVG&<#@@8]>S
MD\+:%*;\RZ9;R'4%"W>]=WG@=-V>N.WIVID'A#P[;2Q2P:/:12Q0F".1(P&5
M#U /7G)_,^M 'DVE:99V_P ,_ .M10*NIC5;1/M>29-C3%63=UVD$_+T]JZN
MQBTKQ3JWC?2_$31_:H;GR5\P@/;VGEJ8WC)^[SN;([G)[5U__"):!_9]OI_]
MEP?8[>3S88,'9&_7<HZ YY_.C4O"'AW6-0@O]1T>SNKN  1RRQAFP.@/KCWS
M0!QIFM]0\<KH=U=VLEH=%MWTY=4@\_[0I+B1AEERY 3/? [<UUG@S38M'\-0
M:;;ZG)J4-L[QI<..P8_*#SD*<KU[8[5:UOPQH?B2.*/6=+MKU83F/S4R4]<'
MJ*T;:V@L[:*VMH8X8(E"1QQJ%5%'0 #H* /,M4T^?4K_ ,=Z=):#4[NZ6-+"
M9&4_9V,0V1DDCRRC8?\ X%GJ<58CM/[.\:^$_#.I+')8+I,LBJ1F.XO5V[FP
M>I"[F&>F[-1WO@Z2^UW49]:\$:;K$MQ<L\6H)=+%^ZX"*ZD!@54 $C=GK776
M'A/3T\/6>EW]M'.EK(TL(+LWD$L6 C<_,-H.T'@X';I0!P%Z;32)?'>D7#W4
M?AX7-D+>&T<)LGFVEXD)X5&.W<.@#GUK<\-(UE\5]<M2EG;"33+:5[:TXC5]
MSCVRVW'.!QCBNQE\/:1-I$VE2Z=;R6,Q+2PNFX2-G.YL\EL@')YS4-MX5T&S
MN4N;72;2&=(#;K+'&%98R22 1SW//7F@#SKPY8WU_P#";PVFESV8OHM0GFBM
MKT$PW962?,;8]LL#V* ]JZSP1K%@VE7_ )NGKH5Q#J#07=G+(NQ+@JIQ&PP"
M&R"/<FMA/">A16$-C%ID,=M!+Y\,<>5$4G/S)@_*?F/(QU-5M<\':5K&@-H[
M65OY$DOFLS@LR.0090>K2<G!)[Y.<8(!T5<#\)?^1>U?_L-WG_H==X\:R1M&
MV=K#!P2#^=4-*T+2]#21-+LHK1)&+NL0P&8]21TS[T <EXZ@M=#\0Z#XRDBB
M$-M.;+4)"@X@F&T.Q_V7V_@QKG="MOLVIZQX.N=.C@CU^9-2MXQ%]RUD),L;
M>A0(5'HSC':O6;NSMK^U>VNX4F@?&Z-QD'!R./J!0UG;M>I>M"AN8XVB67'S
M!&()7/H2JG\* .+BM8+7XWH((EC#>'#E5&!Q<*!Q] !^%<_'_P DO^)?_82U
M6O3&T336U?\ M8VB?VAY?E?:.=^S^[GT[XZ9JLGA;0X[&[LETV$6MVY>XAYV
MRL>I8=R>^>M %C0O^1>TS_KTB_\ 0!7DMYH^GWW@[XF7US;)+<VFK7DEO(_)
MA=8HV#)_=;/<<G %>R6MK!96L=K;1B.")=J(#PH]![5FCPIH2VUW;#38?(O7
M+W,?.V9CU+C/S$]\]: .0NFLM9UR"&54N]07P^LEP+X@VT$3GEPF,M(Q&#R!
M@#)Z9PX=.?4_@GX<UZ*);O5=#CCO8MXW-(D;'?&3UP4!X]0*]+?PIH$MS9W$
MNDVLDUG'Y5N[Q[C&@.0HSV!Z#MVJUIFCZ;HU@+'3;&"UM02?*B0*N3UXH X7
M7-1^U^"_$7C72$_>S68BLYT3$@MU^^X/4'+2'KT135O2=&TM]?T/Q!I^KV*"
M2%XHHM.MA&MY&R9Q)\S9VXR#V/7K7;6UE:VEA%8V\$<=K%&(DA5?E5 ,!<>F
M*S=&\)>'_#US/<Z1H]I933\2/#& 2,YQ[#V'% &'\0-12RN_#,-ZX31[K4Q%
M>LQPC#8QC5^VTN%)SQQSQ6-XVAL_"WAKQ1>:!--%/=&UDO8K=\);1E@C.BJ/
MD9DW9(YXSVKT34=-L=7L);'4;6*ZM91AXI5#*?PJOIOA[1]'TMM,T_3;:WLG
MSO@2,;7R,'=_>R..: ./U[3[?3/%W@ZY\/P0P&[G>UN$ME"I/:^66)8#J%P"
M#VS[UQ]QHFFM\+_&]VUJC7-CJU\UI*<EK<I(-I0_P]!TQGO7K^G^'M)TH@V-
ME'"50QH02?+0_P *Y/RKP.!@<"H1X3T$6%S8C3(/LEU)YL\.#LE<]689Y)[Y
MZT <?<Z99:;\1?!<]G L,^HV]XE[*OW[D"%6'F-U8YYR:YJ#PMHNH?#[QG>W
M,6+K3]1U%[2X\PAK9HV+)LY^7D#/<\>U>LR>'M),]I=&P22>Q4BU;)+1#'(0
MD\9Z5S/@WPC]GCU9M;TCRY;G59[Q \JNDB.^Y-RJQ!9?]H<=J ,33;JYUKQ+
M!I/B*6R6Z?0;.6&#4+;S5D9@WGE064;MV >IP.V#4-UH%C9S^ --&H2ZG##J
M-Q;"Y=BI:,1R?)D'E0?EZ]!BO1M<\+Z'XD2)=9TNVO1"<QF9,E?7!ZX]J?-X
M=T>X:R,FGP'[" +0*NT08&/D ^[QQQ0!YY;:1%%?_$3P_IEQ#I-JTED+=53$
M,4DL:Y&T< .V 0/6HIM5M;'2_%=GXFTB30]073X?M4ND2+LN8B[(CQ''RDLQ
M4[NV,]./1'\+:'*]Z\FFP.U]M%T6!/G[?N[_ %QCC/2G_P#".Z0;6ZMI+&*:
M*Z01SB;,AD4=%)8DD#)P.V>* .(TJTC@^+$MA/::?;V]QX=!ELK<!HSB<*H?
M@!S@D9VC@XKEX]/L!^S+<3);0)<-;M([HH5F*SL 21R<<CGWKUNR\*:!IUS;
M7-GH]G#/:H8X9$B&Y%/7!_K3?^$0\/"PN;$:/9K:74GFSPK& LC9S\P'7GG'
M2@#G9IEOOBU!I.IQ))9)HOGV<,JAHWE,F)&P>"P7 ]0"?4UQ6O6C0>"?'&G@
M,=,T[6;==.Y.(=\D)DC3T52Y ';)%>OW>@:7?Q6L=S9I)]D.;=\D/$<8^5P=
MPXXX--N/#FC7>EKID^G026(;?]G*_(6SG)'<YYR>_- ')P:99:+\8[./3K=+
M9;S1IGN0G_+9EE3#O_>;D_,>>>M3_%N&.3P%-(Z@O%=VI0^A,\8/Z$BNH_L'
M3/[2AU(VB&]A3RXYR275/[H.>GM4FJ:1I^M6OV74K2.ZM]P;RI1E21T./:@#
MB+_1M.U'XU>3>6L<\,OAYGEBDY20BX4#<O1A['C@>@KF-/U!=,\*:)87,GEZ
M'_PE%Q97&YOD6$/)Y<;$_P &X+G/&!@\5ZS_ &!I?]I#4?LB_;1%Y N-QW^7
M_=W9SCOCUYJ)/"VA)I=SI@TJV-C<L7FMRF4=B<EB#WSSGK0!Q/C>"T\+^&O%
M=_X=FFBN[J.WDNX;9L);Q[@C2(JCY&*;B3U^7/:K7B"PMM,\2^#+WP[##"]U
M=FUE6V 59[0QLS%L?>"[003T)]Z['2_#VCZ+IKZ=INFVUM9OG?"D8VOD8.[^
M]QQS2:=X=TG265K&QCA*H8TQD^6AZJF3\J\#@8' H \FDT+2YO 'Q%GELXWE
MLM5OWM7;DP,JJ5*?W3D#D=< 5O2:?::?XS^']_:PK'>7Z7"WEP/OW(-MN_>-
MU;Y@",]*[9?"NAK:7=H--A%O>.9+F+G;,QZEAGYB>Y/6GMX;T=Y+*1K",O8C
M%JQ))@'^SSQZ<=N* /--/L[;Q=X7U"XU+6+2QU.TU"9[JX6W_P!,M)(YB5 <
MOD#:%4#&,<=:]"\97=]8>!M:N]/+?;8;&5XF4?,&"GY@/4=?PI\WA#P[<:ZF
MMRZ-9OJ:D,+DQ#=N'1O<CUZUMD @@C(- 'G&E:5IES<>'?$FG:M9JRQLD$=C
M;[&O R9,<IWL6Q@DYY!!)KEM3?3]9^ %UKER()M8F(>XN7 \Y9S, RYZK@':
M%_N\=*]6TKPAX=T._FOM+T:SM+J8$/+%$%.#R0/0>PKF?'7@*RO?#NL'0- M
M3K6HA09D"1DG>K,26( R <XY- $J0V\?QKO5,<2I-X=1Y 5 #_OV!)]>, UR
M_AR73G\#>';*17FDGUZY^QVR2!(9F664@2D@CRP.< $Y"X%>FWOA_2-<GM+[
M4])AENK<?NS.H9H\]5."01[<BH9/!OAN6P^POHED;;SOM&SRA_K>?GSUW<GG
MWH \^L\P>%/BE9[X D3W16* ;8T)M@6VKDX&3S[UZ/X6_P"11T7_ *\(/_1:
MTP>$_#ZK>*FCV:+>HJ7(2(*)5 P%..V ..E:5G9V^GVD5I:1"*WB4+'&O10.
M@'M0!Y&JC1- ^)>H:-:00ZE;7\R6\D42AXU\J,G:0,C W-@>F:UM<L[2RT_P
M1J_AN..*ZEO[6%9(1@W%O*I,BN1]X$#<2<X()KO8M#TJ#5+G4XM/MDOKE0L\
MXC&^0=,$_@/R%1:?X;T;2YEEL=/AA9-WEA0=L6[[VP=$SWVXS0!E?$J"*?X;
M>(1-$D@2PE=0Z@[6"D@C/0CUKF-7TZP+?#NTA@BCMY+O,D< V!B;5B<[<=>_
MJ#7IMQ;PW=M+;W$22P2H4DC<95U(P01W!%9*>$M BCLXX]*MT2R.ZV"+CRCW
M*XZ'WZT >::C*?"\/Q)M]'C^QV5K/82"*W4A84E1/.957&/EW'C'X5UVD:'I
MT/BG3]<L=6LA]HM6B6VTVW$<5U'C<'8!FSMXPWN!WKIH= TJWNKRZCL81->K
MMNG(R9QC&'S][CCGM4&B>%-!\./.^C:3:V3S_P"L:%,%O;/I[=* .<^,%K;3
M_#;4I9H(I)(6A,;N@)3,T8.">F1Q3M6L]('C'2](M+* W45A/.EI(JK9PQ,Z
MJTA0#YGSP ,<%LD5U>J:/I^MVAM-3M([JV)!,4HRI(Z9'0U7N_#&B7\MI+>:
M9;W,EID0/,N\H#U&3V]C0!Y+&$G^!NB/(XEDM]6C2-MWW5^VE0!STVC ]A73
MZEX=TG6_C%>66HVBW%M-X?226)F(5V\\C)P>H &/3 ]!77'P?X=-DUE_8]H+
M5IC<-$(\*9,YW$=S_*K2:#I<>JC55LT^WB/ROM!)+[/[N<]/:@#.\<6T+_#W
M7HF0;(]-G*CT*QD@_A@5P<^AZ;"GPVNXK81W-V8X+F=&*R31M:DE'8'++P."
M< <#BO5KVQMM2LY;.\A6:WE7;)&W1QW!]1[51;PQHKI9(VGQ%;''V49/[C'3
M9S\OIQ0!YTZZ1X=O?B7:-YVGZ+%:VDABTX!&C:2-E8QCHK,0OMZU>TFU6T^*
MMO:/;V5I#<>'6$EK;'*X$R*N\C 9L$C.!UP,UV[^&=%DFOII--@>2_3R[MG7
M=YZ] &SU [9Z=JBMO!_AVSDMY+;1K.*2V1HX9$C 9 W7!ZY]^M 'GG@[P]I7
M_"J[G63:JVHPV^IQ1SLQ+(ADE!4<]..GJ2>YJ7X>7%O>S:)8>([.(7T&DV\F
MBEP&BD@,2;V3(_UH(^8=AC'&2?1+?PWHUII<VF6VGPQ6,V?,MTR$;/7(]^_K
M3&\*:$T=C&=,@*V&?L@P?W'3[G]WH.GI0!YW;V=MXPT_Q+#JNJV5E>VNISB:
M9X/])M%23,3)(7&U0@7! QUZDFM;2+"P_P"%O:C-+;P23#1[24320*KF0NX+
M].&/'OVKJ[SP?X=U#68M8N]&LYM1C(*W#Q MD="?4CL3TJY-HFEW&KPZM-86
M[ZA"GEQW+("ZKG. ?Q/YF@#'\?>&E\4>$KRTCC1KZ)?.LW902LJ_,HY['&T^
MQK)T76-.\3Z:WBZ>+[/;6.FM&'1,/ Y7?/MXS\N%48[AQ7>U6@T^SM;1K2"V
MB2W<NS1!1M)<EFX]RQ)^M 'E6E)!:>)_AS/9QQ6MK=6UT$)<-<3P_9]X:=A@
M$DX8C! .>34MY#'/IGQ<5XUDV[W4,N<,+,$$>X-=W;>"O#%F+;[/H5C']FE\
MZ'$(^1_4?YXJ[;:#I5G->36]C$DE[G[2<9\[M\^?O<<<T <#.;<ZQ\+) 8C.
MT;#<,;BGV0]^N,UG:?9VWB_PSJ4^I:Q:6.I6FHS/=7 M_P#2[22.8E,.7R!M
M"J!C&..M>A6O@GPQ9" 6^AV2"WD,L68@=C=,C/IV].U/F\(>';C74UN;1K-]
M30AA<F(;MPZ'W(]>M "^*KN^L/!FKW>G!FOH;&62'"\[PA(./7OBN!U6VMH?
M /A+7M!51JOGV7DSQ_ZRX,I59$=NK;LL6SW&>U>L5E67AK1=.N%GM-.AA=79
MT"CY8V;[Q1>BDY.2 ,Y- ')PZ3IK?&^\8Z?:%AHL5P"85R)?/?Y^GWNG/6I_
MB_;P3?#74GFACD,3P,A=0=A\Y 2,]."1]":ZE=!TM=7;5ELT&H,NQKD$[RN<
M[2<],]NE6;ZPM-3L9K*^MX[BUF7;)%(NY6'N* .#\0:5ILWQ'\':<+6 6(M=
M0!MXU"QGB,E2HX()SD=#WKFOMG_"/^%_$=K;,MKI-OXL6WE 4F.WM6,1<;01
MA,G! (X8CO7J<?AC1(KBSGBTV".6R4I;.@P8E/4+CIGOZ]Z=!X<T:WBO8H].
M@$5\2;I&7<LY/4N#]XGU- &%H6A6>G^+WU.UU2U+7MB UE8P".&1588F(#-\
MWS;<]P?:NQK*T/PSHGAN*6+1M,M[)96W2>2F"Y[9/4XK5H **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ ILDB11M)(ZHBC+,QP /K3JYKQM8W6H:;8PZ?>VUMJ"
MWJ2VJ7:%H;AT5F\MP.<$ GV*@T 1^-O$5YH7AH:II3VDI6Y@B?S 7!6214XP
M1S\V:Z9)HI'=$D1FC.'56!*GW]*\=UV^%[\.M?MKC1QI.HP:S:+?V\4F8S*9
M(#OC88X9=I]<G\:WI+;3?#WQ6G:V@2RM'\-RSW0MEVERDP^<XZL 3SUH ]"2
MYMY9GACGB>5/OHK@LOU':E-Q"'"&:,.6VA=PSNQG'UQS7D&G-:P:U\-KBU^S
MVUE*ESY*LX:=H3;LVZ9Q@$DX)&,!NYK1\*^'M-DNO&5Y%ID$M]8:Y/)893_5
M2"%"-H[9)Y]<#T% 'IHN(#<&W$T9F R8PPW >N.M!N8!.8#/&)0 3'O&[GIQ
M7E/ANUT?Q#X:\+ZJ^O)%?VD\,A\F-%N6N3\LD;G[S;F)W9ZCGI5AVNM"UN&6
M]M+36-!O-<+6VH0_+=65P\Q7:X/WE#93(Y X]!0!ZG4<5Q!.SK%-'(R'#A&!
M*GT/I7*?%&\O;#X<ZM<6!D61502-%G<L1=1(1C_8+<]NM9OB&TM[3Q-X(OO#
MT<,4DUT;=OLP"K+9F(LV<=5&%(ST)'K0!HW7B#5]5U?6M-\.RZ>ESI7D@+>*
MS+<.Z[RN58;0%(&<'GZ5O:GK=EHT=F;^9(Y+NXCMHD#<O(Y P,XR!DD^PKDO
M!^G6$7Q%\;-%9VR-!<VHB*Q*#'FW7.WCC.3G%2?$NVMIG\)-/!%)GQ#:QDR(
M#\I#Y7GL>.* -*'Q%>#XA7NB7+VBZ=%IB7T<H!5AND*?,Q.,?+V ZUT_F1^5
MYN]?+QNWYXQZYKSUM+TO5/C!<6]S:6US9KX>@V0NH:+'GR ?+]TX[<<5RND:
ME]A\%>"8;NZ6WTAM5N[>:690\:%7F$"OGC:"!C/ *@]J /:X9HKB(2PR))&W
M1D8$'\17/ZYXF>RURP\/Z9 ESJ]ZC2@2,1'!"O61\<D9X '4]QUJOX4T?3]*
MUK6Y;'5/M1O&BGGMXE5887P1E0O 9@,GZ ]Q6%>_\23X\6FI7[;++5=(-C;3
M/PHG60/Y>>Q(''J30!U%Q=>(M.N+'S4L+ZVGN$BGDAB>%H%;C=M+/N&<#J,9
MS@UN/<01S)"\T:RO]U"P#-]!WIL]U#;M$LCX:5PD:CDL?8>PR3Z $UY7IL=K
MKGPR\6W&LHG]K0W-ZUU*_$D$L9)BP>J[5";?I0!ZN\L:$!W5202 3C@=:9]K
MMO*CE^T1>7(0$;>,,?0'O7EME8?VGXS\%R:[:1RWUSX>D:]65/\ 6N/*^^._
M)/![UFC0=)?P#\1]UA W]GW]^MD&0$6P6-7 C'\'S'/RX_2@#V=Y8X_OR*O!
M/S'' ZFA9HGA$RR(T1&X.&!7'KFO+I-,L-8^('A/^TK>*Y^U>'Y&G649$Y'E
M$;Q_%W.#FLR&WT[0XO$FCO',VAGQ%:0:;;1R[(_/8([1,Q! B#8W#!X!XS0!
M['#<0W$7FP31RQ_WT8,/S%(MS [JB31L[)O50P)*^H]O>O*8XHGU;XGV5V;*
M16L+=S#"N(Q)Y$N<*2?F&T9/!^7.!45KIECI^F?"S4K6VCBOIY;>.6Y4?O)$
M:U;*LW4C@<'@8P* /75FB?.V1#CDX8<5A>)-5U;3SI<ND06-U#-=I#<I-(1(
M48@?NL<%AR3G@ '\.0OU;P1XSU&VTZT00^*8@;/;%E8[X81@0/X2&#G/]UJ]
M#TK2[71]*M-.LXPEO:Q+%& .P&,_4]30!/+<P0.J2SQQLV=H=P"<=<5+7F/C
M2&]LK[7M6CM;/7-%:W2+5;"0[+BU5$W;HF/!&UMV/7ISFNYU2]N'\)WM]IBL
M;EK%YK52OS%]A*#'KG'% &BMQ T[0+-&9E&6C##<!ZD4/<0),D+S1K*_W4+
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M6=K+<W,J0P1*7DD=L*JCJ2:Y+6?%]PFG^%=2T@V[V6LW]K!()D)=8YANR,'
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M(3UP<#BNBGMM,TGXA1>'<V6F::=+\S3X)8%:%I&E<S!0W&X_+QZ>U 'I@(8
M@@@\@BHVN8$F$+SQK*1D(7 8CZ5A>"=+L]%\.KI^GZA+?VD$TBQRO@@#=DHI
M'!53D>V".U<=K376AZI>ZI<6EIK?AR?58I994^6[T^=71!U^^H95  P<'TH
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MM@;/ .TOC/<T >LI+'+&)(W5XV&0RG((^M<O#XDNIOB.NAQR6<NFOI;WBR1
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M@0RAE(((R".]1O<P1S"%YXUE89",X#$>N*Y#X3.TGPQT;>Q;8LL:DG.%65U
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M\=3B@#OZ*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M?16Z@5+?Z98ZI"D5_:0W*1N)$$JAMCC.&'H1D\CGFIA<P&X-N)XS.!DQ[QN
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M.B:5>6L%K<Z;:2P6^/)C>%2L6!@;1CY>..*MV]O!:0)!;0QPPH,)'&H55'H
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M!+65=#MYDCMD"A7 D!<*/X@O\JDUB30WT?X:7>GM:^4-4MEAD4C(0Q/O&?\
M>"[O?KS7ID6D:;!?/?1:?:1WD@P]PD*B1AZ%L9-4XO"?AR"0O#H.F1N91-E;
M1 ?, (#=.O)Y]S0!F?$FYN;3X?:K<6OF;D6,R>5RWD^8OFX_[9[ZS=-T[PSJ
MOB/3]6M-;74)I+)X!;PB'RY;<C/[U%4':#C&>A(%=XRAE*L 5(P0>AK.L?#N
MB:8EPEAI%A:I<?ZY8;=$$G^]@<_C0!XU;:7IX^!GA^_6VB6[348-ERHQ(O\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ K)\0^(]-\,:;]MU*X2)6=8XU9@#(['  _/GT&36M7$?%?8O@@
MR2;0B7]FS,W11YZ9)]!0!/<^)IX?']A9"_LSH=QIDUV7 '#(RC)DSC')Z8_&
MNG34;&2P^WI>V[617=]H653'CUW9QBN'U&.PU+XN: "MO<V_]DW3*.&0D2)S
MCH<$'\17.6-WIFG>';^WN8$:$>-9(+-#*8H89!('0N1T12"<=^![@ ]2G\0Z
M/;Z1<:J^IVAL+<$RSI*K*N.HR#U]NM/T76+37=(MM1LY$>.>-7(5PQ0E0VUL
M=",C(KR]+F&6[^*L!OK6ZFDL(W'D *KL+5PQ5<GH0 >3TYKO_!%Q;7'@G1?L
MTL4@2Q@5_+8'#>4N0<=^E &K=ZII]A+'%>7]K;R2_P"K2:94+]N 3S3KS4++
M3HA+?7EO:QDX#SRJ@)^I-><:=J.@W-YXYT/Q=<V\,\U^_F)=2^6TEH441;#D
M$@ '[O0G/4U?TBX$?Q6N+2[C>*%]$@_LI)\Y$8)\U>?X\[=W?"C/2@#N7OK2
M.WCN)+J!(92HCD:0!7+=,'H<]JA&M:44NG&IV16T.+AA.N(3_M\_+^->-W>G
MI%X3O(WC0Z;'XQ1=,R.$A,R!A&>R;MXX]#77_P!DZ8OQK6 6-J(SX?\ ,,0B
M4*6$^T-MZ9 ) /I0!W0U&Q:TBNA>6YMIB!',)5V.2<#!S@Y/2DM-2L;]YDL[
MVVN&A;9*L,JN8V]&P>#]:\4FM[+_ (5TB2I$+>U\7F.,\ 0Q_:N0I_A&#VKI
M-=T4Z9\0?-\*6L=K=-X?N_M,=J@121@0$@<;B^<=\+[4 >C1:KIT]\]C%?VL
MEV@)>!)E,BX]5SD4R36M*A($NIV29E\@;IU&9./DZ_>Y''7D5YOX;/ACQ#I7
MA.X_X2"XDO[%X_(L8V@66.7;MD1E"!ROWMV3R!G/>LJ72M,/P]^)LOV.V+PZ
MI?"-O+&8]JH0%],'GB@#V&[U*PL"@O+VVMB_W!-*J;OID\TVZU;3;"..2\U"
MTMXY!E&FF5 P]B3S7G^LKJJ3/K&BW5E?2IHT U/2+[I/!AV#(_\ "3F0<\'O
M41UK2;_5%-ND>G7$GAN)Y)+]R<6[Y*Q(A(!;/5OH,'L =OK'BK2-#FTZ&\O8
M$DU"41P R 9&,E\_W0!U]P.]31S32>(FVZK:O9FT#+8JH,H;=_K=V<[2"!C&
M/>O*M,N[5_"'PLFDN(2D-ZD4KLXPA\B3"L>W;@UTD@V_%K5)=*6'[3+X762(
MH!AW\YMI/K_#S]* .Z&JZ<;_ .P"_M3>?\^_G+YGK]W.:2YU;3;/S?M6H6L'
MDJ&E\V95V \ MD\ ^]>3S&+4OV?K-[7=_;$#1"(C_7K?B8!O<.6+9[X8UOZ=
MI=A<_%W7EN[.UE?^RK5W5HP5+DR!FP>Y'?K@^] 'H<4L<T22Q.LD;@,KH<A@
M>A![BLZ&6<:]?"35+62U6&,I9JH$D!YR[-G.#VR!TKG?A(V[X7Z+\VX*LJCG
M. )7 'X 8JE8VMF?BCXQA:"$QRZ9:-*A488GS,DCOVH [6/6=+EG@@CU*S>:
MX4M#&LZEI .I49Y'!Z>E.N]4T^PDCCO+^UMGD^XLTRH6[< GFO&].LK*W^%W
MP\OHX(4NCK-CF<* YS*5.6Z].,>@KH=/U+0I]4\=:)XMN;>":>\.Y;J7RS)9
MF-1'L)(.!ANG0G/4T >BWFH66G1"6^N[>UC)P'GD" GZDTKW]G';)<O=P+!)
M@)*T@"MGI@]#GM7"Z3.L/Q46TN(Y(K9]"A&DI/G(4-^]7G^/[F[OA1FN/U&P
M2+PCK*&-#ID7BR,:;D<1H9HQ((SV7=O''H: /9!K6E$71&IV9%IQ<D3K^Y_W
M^?E_&IX[ZTFLA>Q74+VA7>)UD!0KZ[NF/>N#?2=,7XUV\ L;41GP\[F(1*%+
M+<*%.WID D"N4CO%TKPB7\U[?1[3QE.ETT"*P@@$C[3M((VARAZ'M0![+9:C
M9:E$TMA>6]U&K;2\$JN ?3(/6K-<5HB^&[37M6\06GB%KUY;1'OY_.A-NB)]
MUF,:@!L;NO8'VKL;>XAN[:*YMY4E@E0/'(ARKJ1D$'N"* )**** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M0 4444 %%%58=2L;F]GLH+R"6ZMP#-"D@9XP<XW <C.#U]* +5%%% !1110
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MY!=0$E?,AD#KD=1D=QZ5:H **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[F[D(@MG&W]T6 Y;+'TX4GGI4?BG0I-?E>SOM&LM4TEX %227RY89LM\RG'
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M[.BL[O3HQY-YO)BF1ESOC&,[EZ8/ /.3TKL]*>ZDTRW:\6)9B@R(G+C&.N2
M<_A7-:KHOB'Q/X+UFPU,V5G>7UL88+>&1I(XCR<LY ))/7 P !C/-='HXOUT
MNW74HH(;H( T<$AD5<#'WB!GUZ#KCG&2 <[-XPO9])U76=)TZ&ZT_3998V5Y
MBLEP(O\ 6,G! P0V,_>QVK(\4ZU=:M>^!;S21!)87U\EQ%YLK(7;R9& 8!3@
M '/?D=.]6M/\,:YH6FZYH5@EK/I]_+-+9W$DQ4VPE^\KKM.X*22,'GH<=:DO
MO"%]:KX.M-(CMY+/095>1IYBCR 1F/@!3R<D]10!UUA86]BDK06D%O)<2&>X
M$"X#RD#<Q.!D\#D\G%6Z09(&1@]Q2T %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 445F:[?WVGV<+:
M?9?:II;B.$DG"0HQ^:5_]E1DD#K[=: +MU=6]C;27-W/%!;QC<\LKA54>I)X
M%4V\0Z.EO83MJ=JL>H,BV9,@'GEL;0@_BSD=*YJV\3MKVF>+].E^RROID31_
M:+5LQ3J\)<$#)P1R",GIUKG)@#\,_AD<=-1TK'Y4 >M5GWFNZ1I]Q]GO=4LK
M>;&[RY9U5L>N">GO47B;4Y-%\*ZMJD*AI;.SEG13T+*A(S[9%8OPRLD@\!Z9
M>NQEO=1A6]N[A^7FDD^8ECWQD >@% '56]U;W2%[>>.90<%HW# ' /;V(/XU
M+7+7DUEX,6.VTZV3[1K6IA;>WSL1974;V.!PH",QQU)QWI(_$>HQ>)Y_#5Y!
M:_V@]F;RQN$W"*=0=K*R\E6!QT)X.?:@#JJ*X[1O%][K'A.VU!+:WBU2:]-D
M]DQ8B*19"KJ3URJAG/'05%JWC6]C75FT>S2[;2Y#$T)AE9KJ15#.J% 0I&<#
M.<G/ &"0#MJ*X:Y\8Z[<:]::5I.B6_FWFD'48?ML[1LAW*-DB[<J1N(P,\XZ
M<T7_ (VU);;4GTZPBGN-,/ES6PCFD-Q*J*SI&RK@8W;02#D]@.2 =PS!5+,0
M% R2>U5=/U2PU:!Y].O(+J%)#&TD+AUW#J,CCBL*#Q1<:OJ=OIFEVX@N6L([
M^Y-ZC9MU?A(R@(.\D-GD8 [YQ6;\+#,=%ULW$:1S'7;WS$1MRJWF<@' R,T
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MKT92,@C\*DKB-/\ $7]GZ%X8TFW"_;+G28YR[Q/(L4:(@R509))8 #@=3G@
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MM1L+#7K?3KB^G)%I%<(K2G ).WN!P?:M!4TCPSI#E5M--TZ %FP%BC3U)[4
M8MWH>KW?CC0];*6*6]C:S0S)]H<N3)MY7Y,$#;W(SGM4WC31=4UO3;*/2Y+;
M?;WL5Q+;73,L5U&N<QN5!.,D'H1D#BM^TNH+ZS@O+602V\\:RQ2#HRL,@_B#
M4U 'GDOA#Q'+)XT9I-*QXAM$BC"O(OE.(?*P?E/ SG/?'1<\6Y?#&MO)X,8+
MI_\ Q(_^/C_2'^?]T8OD_=^^><>GO7<51TW6-.U@7#:=>0W2V\Q@E:)MP5P
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MN,D@\J".O2H-8\/7X\9V'BG2&@>YBM6L;JVG<HLT!;>-K '#*W/(P?:NJHH
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MK;0/\^E &=X/T.;PWX6LM)GN#.]N& .XL%4L65 3R0H(4$]AT'2L33_#.MZ
M->T_2S93:=J<\MS \\K(]J\H^<%0I#J#R.0>Q]:[2*5)HDEC;<CJ&4CN#TI]
M '"WW@N]M]/\(Z;HWV1K70;J*=VN9F1I=J,I "HPR=Q/6NY&2@W !B.0#D T
MM% 'F2^!?$B?#6/PGYFE,UO<QM#-YT@#(D_FY;Y#ACP,#('7)Z5O7OAG4-1\
M;C5;A+,:=)H\FFS1K.QD^=@Q(&S&.,=??VKKZAN[NWL;62ZNYXX+>)=TDLC!
M54>I)H XWPOHOC31X+71+Z^TN72++:D5Y'O^TRQ+]U"I&T'  )R>/?FND\1Z
M#9^)_#U[HU^#]GNH]C%>JG.0P]P0#^%7+&]MM2L8+VSF6:VG0212+T93R"*L
M4 <MHT?B_3K&'3KR'2[XP*(TO_M3QF11P&>/RSAL=<-@^HJ+5O#.I'Q!HWB+
M3KF&?4;&.2"YCN"8TN8I.2 0&VE6Y7@^A/>NNHH X/5?!FHZGIWBN<&S35=>
M@2U"&5O*@B1"H^;;ECDLQ^4=0.V3:N_#NM7&L^$+Y4L NC"3[0IN'RY>(Q_)
M^[YQG/./3WKLJ* /+O%>AZEIWA_XCZG=BT^SZI;"2(13,SILB"88% .<9X-;
M\.B:CKR>&9-3CM8+72V2\ AE9VFE$95.JC:HW%CU.<#WKJ-1TVSU:R>SO[=;
MBVD^_$_W6]B.X]JEMK:&SMH[>W39#&NU%R3M'IS0!YHO@?Q7_9%E923Z1+/9
M:TFI&[>23S+P+(6S)\ORL <?Q= ,@"N@LM UJU\2^*-4==/>/5H((X5$[J5:
M)&7+#8< [L\$XQWKHK+6-.U&\N[2RO8;B>S95N$C;=Y9.< ^_!XJ]0!Y^-%L
M])^$P\+>)KNS1X[!H\PR[B^WD.@8*2P.T@8ZXKIO">F7.D^&[2"_E,VHNOG7
MDK=7F;EOR/ ]@*MW>B:7J%_:W]YI]M<7=H2;>:6(,T1/]TGITJ_0!EZ[;W]U
M:PQV,-G<(9?])M[PD)-"58%<[6YR5/3'%9G@WPM_PC":HL:QVUK=W7GP6,,A
M>.V&T A20.I!; &!G Z5N7FJ6.GW%I;W=RD4MY+Y-NK'F1\$X'X U;H ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M?#N;PMJ=XUR]S"T4]T/O'@*A'^ZJH!_NT )>^*=5T0:'>ZM;VC:?JD\=M((
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M0N>>>U<S9>#]8TC2-9\/Z?/9-I-_),UO-*["6T67.]=@4AP"21\R]>: (?\
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M9A"U[;/ )2NX(6&,X[T <I;>)]>T.Z\.0ZMI]C_8VJ&*S@EMY6::"4IE!)D
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MH0:IILMK+9S^7'/]GDACNHR,AT609'H1DX]>:Y:V^'^O:=X9\-IIVH6,.NZ
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MO>*SKQ%)A=JD'GUSQZ&M33_'$VL6?A:*TAAAU#7+9KEO,!>.!$4%S@$%LL0
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M!,%IIUE/(%ZD+'*2![\5>M?$NOOK&D*VG_:K"^!%P8K">(V1(RI+O\LBYX)
M7U]J .THHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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MUP7;<26;\@,8'4FNOHH XN3PIJKCPAB6S!T'!D^9OWV(C%Q\OR\'/?T]ZO\
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M=5X42,6P .,X&3CD]<]C10 4444 %%%% !1110 4444 %%%% !1110 4444
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH ***Y#QAX@U?1-9\.VM@UEY.J7PM)//@9V08)W AQZ=,4 =?14
M<DJ6\!EN)41$&7=CM4>_/2H3J5B%@8WMOBX.(3YJ_O#_ +///X4 6J*J7&JZ
M=:"8W-_:PB';YOF3*NS=G;NR>,X.,]<5+-=VUO;&YFN(H[< ,97<!0#WR>*
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MU>SUY]3N?LDD*01F HT!7D2HB [0<8!QAB!79VFE:=8,[6=A:VY=0K&&%4W
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MG?\ ;A9R&'R_O [?X??&<>]7CX?T4VZ6YTBP,$;%TC^S)M5O4#& :T  JA5
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M'\M"'7/(^7;D=OK7->*]3TY]6\:64<EO97::0D=U+</N>Z!CD*)$A. !NP2
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M'TJCJEM97/QJTV.^A@E0Z%-Y2SJ""XF3H#U.,_K0!US:]HZ64-Z^JV*VL_\
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MMM:M;..6X4E'"O\ ;$*GY$)(P3D'(STJ6[U_1K 2F\U>PM_*=4D\ZY1-C'.
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MG+1HEF-J_NF8'DCKD\_-5VUU_1[W47TZUU2SFO402-;QS*TBJ>Y4'..1^8H
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M^U"VMCMWGSI0N%_O'/0>]59[I7\2V$4>NP1 P2,VF[4+W&<8<'.X!>>@P<T
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MK<7MQ(9[F94VAY#@<#)PH 50,GA1R:LWUE;:E87%C>1+-;7$;1RQMT92,$4
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M"%YDF:*-I4!".5!9<]<'M0!XUIFI62>$/A;=R7<*VUM=K%-,[@)&WD.-K,>
M>U=1X=OX8O'7C&VUB2)'N?)N+=K@A5EL_+P-N>JJ=V?0L<]:[S[+;^2L/D1>
M4I!5-@V@CD8%-N+*UNRAN;:&8QG*&2,-M/J,]* /%[*S6U\,_#Z#4@GEG7W-
MLEQ]X6Q\TQ@Y[8*X]B*]JM[:WM(!#;010Q DA(D"J"3D\#U))HEM;><@S012
M$< N@./SJ6@#RWQ3-=Z1J7B/5]'O;74+19(AK&AW8PQ;RXP&A8<ABFS (P2.
M.>*[CQ6VH-X+UAM+60:@;&4P!?OA]AQC_:]/>M)[&SDN5N7M8&G4Y65HP6'T
M/6K% 'C>H:]X>N_!?P]-I>V:_9M5T_?&74/!M!5]PZK@]2:G34=$DU'Q?X?\
M6:U+8-<WLD@@<HJW5LZJ(RC%"6.T!<*<C Q7JJZ?9)(TB6ENLC/YC,(P"6_O
M$XZ\GGWITMI;3S1S2V\4DL7,;N@+)]#VH \QUJ"XTLW=]X?U"'S+/2((]2T7
M5^?M%NJ,5.[.5?!=2>A/7WORW<%S\2_!-SY(M9;C2+ES!(?G3<L9"GOD<C\#
M7>S6-G<2I+/:P2R(<J[QABI]03TI[6T#RB5H(VD'1R@)'XT >,W4VE7>E>+/
M"4WB#2(/MFM22?:;R\6*6+,BL^8VY)4J54YP<#H.O53QZ<WQHTC:+9@N@RM&
M0%//FIM(_#./;-3V?A;Q!;JUI=GP]J,)D=OMUW:,T[!F)^=,[6/..& X%=5I
MVBV&FV%K:0V\;+;Q+$CLB[L 8]/Y<4 >46&J:9IWARX$\5L\8\9S1VTLLA6"
MS?S"R2OM(^48) R 21R.M#WD$Z?%F"*_2]EFL$E1D 'FC[)@LH7^'/&>>W)Z
MGU_[!9F)XC:0>6^-R>6,-CID=ZE6&)79UB0,X 8A1D@= : /*;_Q#9VK>!=3
MDU1H=$6UDMIKVW*ND%PT<>S<2& X#KGMD].:K^(/[(T[1EU;1KJ>^T:;Q#:W
M6LW08/#(H.78;0 5#"/=@8SQU!KUMK2V:U-JUO$;<C'E%!LQZ8Z4Y8(4MQ L
M4:PA=HC"@+CTQTQ0!Y\NK:3=_&S3YK2_LYO-T&6,212JP=O.1@N0>3C)QZ5Z
M+4$%E:6NW[/:PP[5VCRXPN!G...V:GH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *Y+X@ZGJ
M&D:-8W>GWK6S'4;:&7"*V^-Y%5@<@XX/45UM</\ %94/A"!IE4VZ:E:/,6&5
M6,3+N+>V.N: .AT_Q5H&JFZ%AK-C<?9.;CRYU/ECU//3WZ467BK0-2NH[:RU
MBRN)I(FF1(Y@Q9%."P]L@\US%S#97GQ2TC5=*>W,%GIUPNI7,3#R]C;?*1F'
M&<AF [ 9]*Y32+)]0_9QG30XXY-2^SSJ?) ,A!F)=>.<L@QCOQ[4 >KV?B#2
M+^[%K:ZA;RSLGF(BORZ?WE_O+[C(KG/"_B&:,>*I=>U16M].U=[:.>8)&L<>
MR,J#@ =6Z^]9NNW=EXGD\#7/AZ:*2YCU**Y A8;H;4(WG!@/NC&U2#WP*Y6V
MUC^R?$6OZ[+-#>>'[7Q#)]NME(+1%DB6.Y !^<*P(QSCJ.1D 'L5UK6FV=M'
M<7%W'''*"8R>K@=2!U(%0OXFT*.WM+A]8L1#>?\ 'LYG7$O^[SS[^E<1K?B'
M3M.^(=KJ.I:I);:)J&E+%9ZA!)^Y\U9&9E+ $#<I4Y_V16;K,'AS3],\&Q::
M0FFR>)HYXS<OD2*4DW.H;D(6/';H1P10!Z*GBS0);*&\BU:VEMYPYB:)]^\(
M<,0!S@=SVJX=7TX:;'J/VV V4H4QSB0%'W<+M(ZY) &.M<=K&IZ5IOQ"M-/_
M -&TJ>33'=;\J-TJM*,PQ*?E+EAN/#$\8'.:XO2K^R@^$7@R]?4(H9-,U=6(
MGR(BX>7*2, =GRDG.#@XXY% 'L%GX@TB_N7M;;4K62Z3.^W\T"5,==R'YACW
M%%GX@TC4+TV=IJ-O+<[/,$:ORR=-R_WE]QD5YM<^1KNE>/=2T'5]/OM4U.SC
M"V6GW E9$C3;SP"68$CIZ#FM;P_J?A'Q7K&B:C87MW>ZI9JYCA:1@UF&3#B0
M8  X"\]3C'K0!W5_JNGZ6L1O[VWMO.D$<7FR!=[DX"KGJ>>@JMI?B71-;FN(
MM+U6SO)+8XF6&4,4]SCM[]*YCXLFW7PK9-=!/(75K,R%Q\H7S1G/MC-9VOQ6
M9\?QZOIMLEW#9:%=_P!I):XQ-&0/*B)'\1PV!UP* .YM/$6CW]RMM:ZC;RRL
MAD15?_6(."RG^(#U&154^-/#(D5/[>T]F9WC4+.K;F098#'4@$?RKS;3=:TV
M?Q)\.;J+4;8VPM[F);>V'[JTS H6'=RQ?H"&.20#@9KI?AJ-.N;CQ7)']FEF
M7Q%=2!EVLP' # ^G+8/N: -K1_'N@:KH4>K-J%O;02R%$$T@5C\[*G![L!G'
MO6KI_B#1]6O+FTT_4K6ZN+;_ %T<4@8I]<5XTNH:>_[/=E8R7$!N+:[@CGA<
MC,;?;,E6!Z':"<>G/2NNU65&^*Y@TZX@2[E\+3Q0;' ^?S5,8'ZD>V: .V3Q
M%H\FHIIZZE;FZ<L$CW_?*_>"GH2.X'(J&/Q;X=FNXK6+6["2>6=K>-$G5B\@
M )48/) (_.O._"M]X6U[1_#>G7=S>OK>ERPXTQG99+>XB&UF*@#Y!\Q)/&/?
MBMSX=?V==:GXP=/LLTZ^()I 1M9@-B ,/Q+\_6@#T&BJ.D:QI^O:<FH:7<K<
MVCLRK(H(!*DJ>HSU!J]0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %! (((R#U!HHH 9'#%%'Y<<2(G]U5 'Y4Y55?NJ!]!2T4
M1I!%$SM'$B,YRQ50"Q]_6G>7'_<7\J=10!&\$4L?ER1(Z==K*"/RIQ1&QE5.
M/44ZB@!I1&96*J67[I(Z?2L'Q%HNIW\NG7.D7UM;R64CN;:Z@,D$^Y=OS $$
M$9."/4\5T%% &!I.AW,6H)J>I_V=]LCB:*-;&V,:JK$%LL22Q^4>@'/!ZUN)
M#%&SM'&B,YRQ50"Q]3ZT^B@#F_&>@WOB+3;.TLY+>(PWL-TS3$\^6X8* !WQ
MU[>]=!!$D,05(HXL\LL8XSW[#-244 ,6*-0 L: *21A1P32JBK]U0/H*=10
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MO.<8W2DG'0GA1UP<\5JZS;:C<BV^P-:LBR'[3;W0.R>,J05R <<D'.#TZ<T
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M9<$CTZURL'@[5+CP]IOAS5[NUN--L)8F\^,,);F.(@QHRD87[JY()S@\#.0
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M!E*%B"3C');IV]Z .3\&Z^=#^&^APP(CWFHZK/96P?.U6:XE)9L<D*H)P.O
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M!R,]QZ4 =K5./2=-@OWOXM/M4O'^_<) HD;ZL!DUP<_BCQ9+:^+Y;:728O[
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M2WWBTW=S;3PC7IUD3[,06<)%A@2YP, <8/3K3_BO_P @CP__ -C!9?\ H1H
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M^&K75$3P_=O)MB,!,T$4A)>)&W8P<M@D9&>]=G;P16MM%;P($AB0(B#HJ@8
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M^QW2O"3#<Q9W#@-E2#R#D^E7-'\.0:=;:DMPRW4^J3//>N4VK(6 7:%R<*%
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MI:1Z3'#YTIB$C/-*I95P> H4#/<EN",<ZVC6%[96K'4M0^W7LK;I91'Y:#C
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M)M+B^M#:7<D*M-;E@WE.1\RY'7!JY4-K;BTM(K<222>6H7?(<LWN3W)ZU-0
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M?4/$NH^.==T&UU2UM+>VM()X)1:;W0N7XP6P3\HR3QCH.<BKH7C;4-<T;PA
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MB3IVC+-!_9]UI\\^SR?F#HR $MGD?-T&* .JJL]E9"8W;6D)F7YO,$0+\>A
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M=J#1WIAOHK)V^TQ(!\ZH22 <@9(]\5YS<I>#X??#-C=>?-)J6FO&9D&$S V
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MZ3K7G/+:R6@E:&212',;[AA3UVD'V(ZUU>B::^CZ'8Z:]R;DVL"0B4H%+!0
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M+!A@?,<DYSQCH!5ZW\&W;^)(-;U77&O9DL7L9(EM$CCE1F#'(Y(S@9Y_(<4
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M.9;G8,*Y5AA7QQD#\.N0"*SU[6]2UW2_#EYC2]1&E_VAJ+0;)"#O$:I&3N4
MG<Q//  ]ZC^&L<T-QXPCN)S/*NO2AI2H4O\ NX\$@<9QUQQ5Z_\ !&_5=-U?
M2=5FL-3LH#;-/)&)Q<Q,=S+(I(R2V6R".2:N>&?##^'KC5IWU.:\;4;LW;AX
MD0*Y !Q@>BC_  H RH;I]0^,MS;2',.EZ0IB0]!)-)\S?7:BC\_6I+/5-4\4
MW?B)--U)M/72[MK&W"Q(X>54!9I-RDE=S8 7' /.3Q8O]-.F>/(/$RJ3:W%D
M;"]P/]7AM\<A_P!G[RD]L@] 2)%\*SV.N:EJ6BZF+)=4VM=P26_FKY@&/,C^
M8;6(ZYW XZ4 <I;>-=>U^S\$W5C/!8'6)I[>[C, ?:\:N"RDGIE,@?3)ZUZ+
MI-O?6FEP0:E?B_O$7$ER(1%YASUVC@<8Z5SK>!88&\.)IMY]EM]"9GAC:+S#
M*S*58N=PZAB>.YS5^ZMM7/C6QN;;49AIBP,EU9- /+Z-AP_7?NV# Z '.,C(
M!6\?7NK:3X6GU;2;AHWL66:>-8U?S( 1Y@&X'!"Y(/M66?%KVWQ&ALYM4+Z%
M=Z>T\#^6@19E4.R%\9/[HAQSW[UW,T,=Q!)!,@>*12CJW1@1@@UQZ_#;2AX7
MTG0GFFDCTZY2X69CEY-O!5C_ '2AV8_NX':@"IJFK^(-+TSPK<-??/J6KP07
M,<L";Q%*20F0  0H )QG.>1Q3M%CO)/BYXG#ZI=/##;696%A'MVMYIV?=R #
MD\$'GDFM[Q-X=D\0G2]MZ+8:??1WR_N=^]TSM!Y'R\G/?W%1_P#",2P^+;O7
M[34WA:[MXXI[<PAD=H]VQL]0/F.0#SZT ><^'-1UO0?ACH&L6FHHMHFI&"2R
M\A2)8Y+MT;+GY@WS9&,#CD&O7]0,ZZ=<M;2+',(V*.R;@IQZ9&:X]?AY(G@F
MU\,#6/W%O="Y68VWSDB7S0#\V/O'\OSKL;F&:>PD@65$E>,KYFS(!(QG;G],
MT >;Z9XE\2P> K+Q;?ZI#=?;+:&&.Q6T10L\DRHLA?(S@$Y7@>XZUMI<>,[3
M5;HQ6MQ>:<UA(\?VXVZR)=*"44>4>4;@<C(/>K-MX%M/^%?#P=?W3W5FL0B2
M94\MU .Y3U(W @$'V'%&G>$M5AL+BWU3Q5>:E(;=X+:5H$B,&Y2N_P"7EW _
MB)]?4T 97AWQ5-K:70MM<E6_MK%S=Z=J-HL<UM.-N&VA5)7[PZD<CFL3_A*/
M&%GX$T3QO/JMO<6K>1]MT\6BJ'C=PA8/UWY(X&![''/87>@"WNG\0ZO?V\MU
M9Z?+;),D @!5L$F0[CD_*,= ,GCGCGO &B'Q!\,_#MM>:E%<:9$L4KVT<0#L
MR-N6-WW$;0P!QM!X )ZY +UWK?B/6UUUO#RW23Z==O:6J(MN89'C"[A+YC;^
M22/EQ@8/)J]::OJVO:Y=Z,)SI%Q86%O-<^2$D?SY@QV@L&4HNWL,DGJ,<I/X
M&NX?$=YJFB>)+S28=08/?6L<,<JR.!@NA<'8Q Y.#3M2\#2/K=MK&@ZU/HU[
M';+9RE8EG2>%?NAE?^(=FZT 8FMQ>(3K'@&#5=5\B^DN9DN18!3"SK#(0X#I
MDG'8\#)P.]=OX@$Z^&=1,%W-;SI:NRSQ[=ZD*3D9!&>/2LS4O!WVR/16M]4N
M8+S2KAKA+ID61I6=6$FX$8RVXG@8'88XKH+BU2ZL);.5F9)8C$[9Y((P3]:
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M22"6P ,<#U.1D>$-:N/[%\">&K6=K;[9I1NIYT52X1% "KN!&23R<'@<=<@
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M,,A(R,CT(Y!'!K@++6?$-LW@34+K66NHM;6.&ZM3;QJ@+0%PZD#<&R.><'/
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MB!@L<9/OQ0!R-M\2O#EQIL.I-+>0:=-+Y2WD]I(L(?=MPS8PO(QDX&:ZX$$
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M6L83R+@(HD0K()%)['# =NGYUU-G="]M4N$BDC1^4$B[6*]CCJ,^AP?4"K%
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MI4%OX+8>(H];O]9NKVY^PM8S(\4:QRHS;B"H' Z<#!]2:Z=Y8XV17=5:1MJ
MG!8X)P/7@$_A3Z ./\/^!&T!XK:/7]0N-&MY/,M=-E";8CG(!?&]E4\@9QP.
MM6K?P?\ 8[K79+75+E(=7=IGMRB%8Y'4(S@XR>%& 3@>AKIJ8)8VE:(.ID0
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M]A/>W/FZPP-]=J$$D@ "A1QA5   &/7N2:Z&S@:ULX;=IGF,:!?,< %L=S@
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M>4BP*)("X*8&X$$=2QS[#BJ6F:7K.H7OCE])UZ;2YH=7D>(11(RO((8R/,W
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M Z*GS(2I(R6.,YQQQGF@#U&BN0\ WM],FOZ??7LU[_9FK2VL$\^#(8]J, Q
M&2-QYJAXSURZT36FDU(:G!H#VBK'J&GY86<^YMSRJ.2N-F,@C@\'- '=M-&L
MR0M(HE=2RH3R0,9(^F1^=/KS>. WGQ9T:5=5N9HW\/-,LD4OR/\ O8N5'3#<
M$^O%-MM6U3Q%X!U;Q5:ZG<6E] ]U):0J1Y4:0LP6-TZ-N"<D\_-QC H ]*K%
MU?Q'#H^K:1I\MI<2-J<Y@CF3;L1@I;YLG/0'H*YK0O$=QXUU6.TDFGL(%T:U
MOFBMW*.\DX)SNZ[4 &!W+<YXK+\6SZCH%GX*FU:=M9O['4)&F>UB"O.5AE(
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M;>=H$?\ <JC7*!8PO3Y>/F^\2.N#BO7+V1HK"XD2:*%DB9A++]Q"!U;V'4T
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MG)L*!Q()-H.W<%W '&?QY-%UX/@OHKBUNM0O)M/N+H74EF^PIN#A]H.W<%W
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MVJVAGV?)(,[?F"@D+N.!GTZXKHZ* ,_7=(BU_1+O2IYYH8+N)HI6A*AMI&"
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M@L@+!@"3TQWKIKWP)I&H^'#HUZ]Y.OFBX^V23DW/G#I+YG]X#@=@.,8XI8?
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MHE8)\)V:Z]J&L07=[!<7\:I.D4H\MBJ[%?:0?F"G'/'?&>: /-/#S7^D> ?
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MC.<T >T4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M@P"[EB?J3R?QI]%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M[6DM["(KJ.*Y9(YP%*J70'#$ XYXH XJWN+^]@^%S/JVH*=0MF6[*7+#SO\
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MGHZ6\MQ?2.55L @\\C Z'\<T <)>7FH)\-/B!*NJZ@)['5[I+>?[2_F(B^6
MH;.<8)XKH?*GT;XC^&DAU&_F35;.Z^V)<7#2([1JC*P0G:AY/W0!BMIO FC/
MI.J:8YNVM-4G:XO$-P<R2-C<<]1G X&!Q5N7PQ92ZGINIO)=27>FQLEJS3'
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M91E@&VKT .>1T.!Q76'P!H7D:M"$NU35@!> 74G[T!0O.3U('+=3DY/-9/Q
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MJDWA.WB\1Z)?6"S6L.EVYMU1)R(FBVLHC\O."<D'<?[HZ]@#IJ*** "BBB@
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MX4@=Q@X/6L[2]8MM=\3^'=$CNY[C1#X?^V1-(S*UW('6/]YW8JH8D'N<GH*
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MO+[Y!L(R00@S_#VQDUT/A.SOM.\-VUCJ.JC5+JW+1/=X(+X8@ Y)R0."?44
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MB>.09 8,A!'!(Z]ZA@\+Z7;:K<:G!'/'=W$*P2.MS( 47[J@;L#&3C K9HH
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M8L""QW?-DDY//6IW\.Z=)KMOK3I.U_;PF".0W#X"'J-N<'. 3D5JT4 <U:^
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M8\'IM'45T5% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M^SK,;B0_N\YVX+8(R >1UYJ36-$T_7[#[%J=OY\&]9  [(5=3E6#*000>X-
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MVX9F))&"1CH,F@#S.31_[$T3P+X@TJYO5U2>:PMIU:Y=UN8I$ 9"A.T #D8
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M[;R6CR',8=A],#KMX!S5O0_%]EXB-DVG6US+%=6HNC+^[VP*20%?#9#$J1@
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M_MUIBFEZA:PHD<D4]S&%2=7!.4()SC'.<=1ZT ;-%1W$CPV\DD<+3NJDK$A
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M &/XJT"+Q1X6U'1)G\M;N$H'QG8W56QWPP!K'\-ZQJ^GZ1:Z5K>A7XU&UC6
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MQI^H)>1Z3=,A>:$(R,K<E0Y#D@9.,#OQ7?*Z.6"LI*G! /0TZ@#SG4H;O6O
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M:HRL'(^4[0<]JO:KINK2>*O!=X-,WQ:>]R]XUL4$</F1% HR06 )Z@=!GVH
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MHUCHL-Y=:?IC6DMXWGS6J.,>8%Q@#.Q2<<XP">37FOB/7+OQ7\#];U'4M/\
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MKDR!E^;@;3SNP<]CV .ZL_%:W'B@:%<Z7>64LMNUS:RS[-LZ*0&P Q*GD'#
M''7'2H/B-JE[H_@'6+NP23SUMG EC8*8<C&_DCI[<U6OK/4;KXDZ#JJ:9<"Q
MM[&XAFE9D'EM(4*@C=D_=.< U;^(5C>ZIX#U?3M.M)+J[NH#%'&C*O)[DL0
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M:SCO@5^SM"7R)<YR,*?NXSD?C0!H^);^XNOB-H6DR:6U[IS6MS,82T92=L(
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MY"L<?=/![&H/AWHMYI\=V+RY%S!I\DFF:;)U/V=)"22?7.$/_7$4 =U1110
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M[^GT %2USMOXI-[<2FRL?M%K#?FPFD28;XY ^QF9,<*#WSGOC'-="20I(!)
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M[3@'L 35NB@#S73?"NIZ5JUQ>>&+*XT*"XL)_/L+F9'MQ=D#RFC568#!SDC
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M^T1Q36LT:[0?F.TJ1C.#U'Y^@44 5=.%T+"+[:D27)!9TB.53))V@\9P"!G
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
80 4444 %%%% !1110 4444 %%%% '__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>50
<FILENAME>exhibit108-arvinasxformo006.jpg
<TEXT>
begin 644 exhibit108-arvinasxformo006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M9J'F22%XR$.<,-P&Y3@\C(JGH&LZ1!X8M[NWUB\U*TFN)(X;BX#232OYC90
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M<W4*VRJL+'9(JY(?CY>G>NLUF:.WT6]DE<*H@<9/<[3@#U/M0!@_#2^O=5\
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ME25+,%(3/7GMSTYKA494^'_PUB*L);;4K-ITVG="%1PY8?P@$C)/K5NQU/\
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M^[0#8I&<[2%++_=YQUKU522H+#!(Y&>E "T444 %%%% !1110 4444 %%%%
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M+\NXJKD;2P'49R.G7B@#HZ*Y6X^(GANV2^=KFY<6$IBNO+LIF,) !+. N54
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M8132+G<JOC!/RMCL<'&: -^BN:?QYX?74Y-.%S.UU%<QVLB+:2G9(_W=WR\
MY'S=.>M6)O%^C6]U;Q2SR)'<3_9HKDPOY#RY(V"3&W.01UQD$9S0!NT5D2^)
M=.AN3"3.P6Y2T:5(':-9F( 0L!@<L!GH"<$YXK4FFBMH))YY%CBC4N[N<!5
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M/%%%!)(94&/N;5.X\C@9-6M$UVP\0Z=]NTZ5GB$C1.'C9'C=3AE96 *D'L:
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MA^(N6?PL%AFE\G7K:>3RH6DV1J'RYP#@#(YKL+*S@T^Q@L[9-D$$:QQKG.%
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M21N 6!$0\SEAG).. 0/6NQHH XCQJ3_PEW@Q_)FD2"^DDF:.%G$:F)E#,0"
M-Q'6LW7KD>'OB)=:AJ]AJ4^D:E9PQQ75DLK^1+&7RCK'S@[\@X//XUZ310!Y
M9/Y?A;7_  UK<6A75IX>6WNK=H(8&=[1I75ED>-<L-VWGC(S@\\56ECFUY?B
MM'8VTYFNH(!#"\961C]D&!M/()[ \\\@&O7*P='\.RZ7XBUK5WOEF.JO&[Q"
M';Y9C0(N#N/8<Y[^E '&+JJ:IXF^'MU:V6HM;VJ7"3R&RE41L;<+@@KGAL G
M&/?K4,GF-I'Q206USNO#+]F7[.^9\VP0;./F^88XKU>B@#S;7X;V3X<^%[VQ
ML;JZ_LN6UN+FSB5DF>-(RCJJ\'<-V<>U4M;LK7Q?X.U^;PKH]ZE[/8B$W5W'
M)')-AU8PKYG+# 8'MD@ G)QZM10!YAJ7B"'Q!K'@B\L]/U)?L]\S741L)0;8
MF%E*M\O8GMGUKK_'09O 6OQ(CR22Z?/%&D:%F=F0@  <DDFN@HH \R+,=7^&
M3^1<;+:WE%PWD/B$FV" /Q\OS<<XK7\&EO\ A,O&;F*9$GO8I(7>)E611"JD
MJ2,$9!'%=M10!Y_K^H3^%_B7#KM[9W<^C7FF"R:>V@:8V\JR%QN503A@W7'4
M5!K@N8]3\)^)K72)X-)L;RX-Q:I 1(D<R;!.T8&1@EF(QD!N1G./1Z* /,]9
MM&U#7_$WB&S25K ^'&T]66)O])G)=AL&,M@;1D=VQV-5WWC1?ABGV>YWVDL!
MN5\A\P@6[(=_'RX8@<UZI10!Y8F\Z1\3T^SW.Z[DG-NOV=\S@VX0;./FRP(X
MJIY[Z)>>&=9U+3]2GT>708;"9K5)=]I.AW9=%PV#G'3J*]>HH \LU2(:.WAW
MQ/I'A^[CTBTU">:ZM8X6\]DFBV?:&C/S9!R<=<$$XR<7/&,O_"3_  U\33:-
MI%P!<P(4=K5HI;IE().P@,0   2.><< 9]'HH \_\2WR:EKG@B]MK>\,"Z@\
MKLUK(I1#$ZAF!&5&2!SC\JC\/W#>&]1\6Z;K=O<-]LU&:_M76%I%NHI5 "+@
M'++MVE>O3M7HE% 'D>C:-?>'Y_AC87\4S36*7ANF6-G6#S(FVJS $#E@O7M7
M3>#2P\8>,V,4R)/?120L\3*LBB%5)4D8(R".*[:B@#CO'UG>1)I'B+2[5[G4
M-(O%801_>FAD_=RH/J"#_P !K&TSP[JVE^-9=-D#3Z7JHBU:\GYVK<QG]XJ^
MS/Y38_NJ17I5% '$_-_PNL3>5-Y/]@^1YWE-Y?F>?NV;L8SMYQFN)E6Y7X'Z
MAH3:?J']HP7S*\/V23))O?,^7CYOD^;*Y&/PKVRB@#AKJ3S?B]H]S'',UO\
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MF/BMXID:*98I[:S2*5H6"2,@?<%8C!QN'>NXHH XKXAK?VAT#7+2SGO8-*U
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M&#*.3TR.:W** $0,$4.0S8Y(& 3]*6BB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MAIKLL(?+B+*2HR<D<# YYQ6C0 45E>(M?L_#&AW&KWZ3M;6XRX@C+M^7;ZG
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M[B68J_(4.20@_P!D#@#_ !K'T/P#+H4RVL'B*_DT&*3S8=*=$*H<[@OF8WE
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M3+'+*LA&Y4)ZJ,=3S6HOA5&\3ZGK$]R)HM1M5LYK5HOE\M=V!G.<_,<^N>U
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MUXZCYTFJB(3P^1M5?+7:FTYR.#SG.:Z2@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
MQ_$?B*U\,Z?'>WD-Q+$\R0_N$#;6=@H)R1@9(K8KB/BON/@9MA ;[=9X)&0#
M]H2@#MZ*XBTO=8T[XBW6BSZL]];3Z0;^/[3&BB&59=A **/DP1P<GCK67IOB
M#5X_$7A&W?5);Z+5%N([V41J+:218BX: [0VT$8!Q@@]S0!Z717G]IKNJ:7K
M'BG1M3U":ZNX5CN-*+)&ADBE^1%&U0"1+\I)SU%69]1U1_$(\,I=7TTEIIL=
MQ/<VYACEF=V9<_,-H V9PHZL,].0#MZ*Q/"G]O#08H_$GE-J4;LCR1$?O%S\
MK$#@,1C('&:Y2+_A*=>\1>+M+M?$\EDNG30BT=+6(D%X0X5LK]W)Y[GCGU /
M1J*\GT_Q7XB\06G@.:/438/J[75O>K'"C M$CC>N0<'*Y Z9QP1P=J.\UJ;5
M[OPT-1O[F73+.%I;RW$$4LLDI<AF#\8 5< #DYSVH [ZH;N<VMG/<"&68Q1L
M_E0KN=\#.U1W)Z"O/=3U+Q=H7AO0=9UJ^$+6MVD.M16RQLCPLY42Y*DJ1E"0
M"!R>E;>J7FI-IWB?4[+4I88;2V=+0".-E$L:%G<97)&[Y,$GE&]: .FL;DWM
MA;W1@FMS-&LGDSKMDCR,[6'8CH14]>?V/B6_OQX)T@W;QW&K:9]MO+I57>VV
M)3M7(P"S-DG' '&,Y&=K7B37='B\9Z2-2E:?2K%-1L+TQQE]C _NW&W:<,.#
MC)% 'J-%<5=ZQJ</BSP3;I>O]FU2&X-W#L3:Y2 .ISC(.3V.*H:1XGNI?%4&
MD:S?7FEZN+N8_8[B)1;WL'S[/)?;S@%#U!R"#F@#K=%\16NN7FJ6MO#<12:;
M<"WF\Y N6*ALCD\8(ZXK7KSK1K:_N]3^(<.EWS65^=07R)PBL%?[.F,A@01G
MKQ5K0/$5[XCTGPY##>SPZ@S.=4RD>]/)^65&&W )D* 8 ."2.E '=T5C^*KF
M[M/#5Y/97]K83J%Q<W7W(P6 8XP<M@G:,'+8XKD(O%]YH^L>*%N7O+G3]/TJ
M/48([Q%27/S@C@ @-M'##(YX% '8:YXBM= DTU+J&X?^T+R.RB:) 561S@;B
M2,#K^5:]>5^(HM0N-)\"ZI>:I+/+=:U82S0[$$67^8; !D!>@Y.1UR>:WM/U
M#4_%L_B7['JDVG'3;Y]/M%B1"-\:*3(^Y3N!9L8X&!Z\T =M2$@ DG '4FO*
MK'Q?K_B1? LUM?#3O[96[CO(U@5P'B1AN7<,]02!G'3.<$&KK>H:];:)X]\-
MZCK-Q='3K!;RTOE1(Y7C=6S&^T8ZKC(P2,]* /7D=9(U=&#(P!5E.00>XIU<
M$FI7UM<:!X=M[B]G:XTYKR25#"LNU?+544D!0/G))QNX'O5>36O%&BV-GI6J
MS*+W4M8%E97C>6TB6S MN<*-GF *5'&"2#@X.0#KD\16LGBR3PYY-PMVEG]L
M\QD C,>\)P<Y)S[=JUZ\_L;2:S^-LJ27L]TK>'MR&;;N0?:.1D 9&>>?7Z5O
M^*+NZMI-+2'44LX);DK.J*6N)UV,0D*A6R<@$\<*"<B@#H:*\EO/%/B%/AKX
MLOH]0FAOM'U62U@EEBB,AC#1X5\ J2!(1D>@KI8[O6-+^)&GZ;<ZM)>V>IV,
M\S0R1(BPR1LF#'M (7#$88L?<T =K16%XKNKJTTRW>VU"&Q#7<232NI9VC+?
M,D2A6S(W0#!ZUQK>(]:CTCX@1K?7<4FB1B>QEGCC\U T'F!6&"",^HS@\\T
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M6TD*P1QJ%E5L%O?)*C'(KSS19Y7@W6/C#6;+4Y6>5]+ETE9I8I'8L8R6C#,
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MQQZ5I4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M;B)K9IF'RM<L01@]]ORK]7.>E 'I-%9VMZ[IOAS2Y-2U:[2VM(R 78$Y)Z
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M,%/0D;6X'H?2O6J* ///C;87>H?"_4(K.WDGD22*0I$I9MH<9.!Z=:Y/XEW
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 5!>7EMI]J]U=S)# GWG<X [ ?4G@#O4]>:^)]0DO\
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MHKNP4,0IY YVX)P?I4!^(WBJ/2/!&O2W-F;;6;H6MQ9I;XR VPOO)SDX)P,
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MKSRUDU-5B7RP?+??'\_OU'!]/>@#U'0]>TSQ)IB:CI-TMS:LQ4.%*X8'!!#
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M&8G@8/&,'WYX[#Q#\0M;T_3?!_BB*1(?#^JF)-0C\H,UN6P258]L;NO]WWH
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M'H >FZIJEEHNF7&I:C.(+2W3?+(03M'T')_"ETW4;35]-M]0L)A-:7$8DBD
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M ;JR>W!)(!X#Y^Z<GC;GWJMX/^'VI^#GEL+7Q*\F@&<SQVC6P$J\YV^9NZ'
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M2(H PT9;V]<<GUXM>*_ -QXN\)IHE]KLAD:X6XFNC;@EF P J!@$7VY_,DT
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% ",H92K $'J#2(BQ
MJ%10JCH ,"G44 ,>&*0Y>-&([LH-/    & *** "BBB@ I" P(8 @\$'O2T4
M      P!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%<WXE\2MIFI:1HEB$?5M
M6E9( XRL4:C=)(P'7 Z#(R?QH Z2BN-76-17XDKIG]N:6^F16.9;)B/M9E'.
M_ '3&#QQ[50T+7?$5YX;UO4AK&CZM<V5U));QV)RCQ*N?)<XRK$=#R0<9R.*
M /0:*S?#^N6?B70+/6+!B;:ZC#KGJIZ%3[@@@_2N!\2>+=>TWXQZ)X5M;Y5T
M[485FD+0(9$R9 0IQT^0=0>M 'J%%)D*N2> .2:R+7Q5H-[J,5A;:K:R74RE
MXHU?_6@=2AZ-WZ9H V**PKOQGX:L+BZM[O7+&&>T&9XGF >,<=5Z]Q^=-/C?
MPN#8@Z_I_P#IV/LW[\?O,G QZ<@CGN"* -^BD9@JECP ,FN<?X@>$(XED;Q'
MIH1I/*!^T+]_T/IU'YT =)15'4=8T[2HX7OKN*$3-LB!.6D;T4#EC]*S=6\:
M:#I'A>3Q%+?Q3:>H.QX6#^8_]Q<?Q9&,=N^,&@#H**Q?"OB*U\4>'K/4[>2)
MGEA1IHXWW>5(RABA]QFI-3\3Z)HSNFHZG;V[(%,@=O\ 5ACA2V/N@]B<9H U
MJ*RKSQ+HFGSVD%WJMI#+> &V5I!F8$X&S^]G(Z>HI(O$^ASWMU90ZI;275HK
M-<0J^7B ZEAU% &M165<^)=%M+2&ZFU&!89XS-$0<EXQU< <E1D<].:)?$VA
MPZ+'K,FJVBZ9+C9=F4>6<\?>Z=>/K0!JT5EVGB71+^_DL;35;2>ZC@%P\4<H
M)6,X(8^W(_,>M.T[Q#I&KSM#I^H07$JIYFU&Y9,XWK_>7(QN&10!I456O[^S
MTNRDO+^YBMK:(9>65PJK^)JK;^(M'NK6ZN8=0@:*T_X^<MM,/&?G!Y7CGD4
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MB@ HHHH **** "BBB@ HHHH **** "O+M?CEC_:(\*3RY\B73)XX2>F]1(6
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M@8]>.M,T:XLK6\^,OVYXD$IF$8D(!D_UXPN>OS%1QW(KW9+2VC"!+>)1&,(
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MDV+O(VEL<D>F:C%G:B9)A;0^;&NU'V#<H] >PH \?M[34='^,'@]]=EVQ)H
MMTFD;Y//6,^8,GC=W]P17)16>H/\ _&$YCD-C/JHGM!C@QB5-SK_ +/'Z&OH
M^>V@NHO+N(8YH\YVR*&'Y&GF.,Q>447R\;=F.,>F/2@#P:PU6PO_ (Q_#I[2
M[BF2+1!"[HV5#^3+\N>F<D#'KQ6Y\.KB&R^+WQ M+F18KFYNXVAB?AI!F0Y
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1
M110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%
M1W%Q#:6\EQ<2I##&-SR2,%51ZDGI0!)16<FO:4^KQZ2M_!_:$D/VA;8MB0Q_
MWL577Q;X??3+W4DU>T:RL9#%<S"0%8F! P??)'USQ0!LT54M=4L+UHUMKN&5
MI(5GC",#OC;HX]5]Q5EW6-&=CA5&3QF@!U%9&F^*="UB[DM--U6UN[B/_61P
MR!F3_> Z=.]:] !1110 4444 %%%4=5UG3=#M1<ZI>P6=N3M\V9]JY],F@"]
M13(9H[B&.:%U>*10Z.IR&!&013Z "BBDR-P7(R1G% "T50TS6],UH7!TR^@N
MQ;2F&;RGW;''4&K] !1110 44UG50<L!@9/TJEI6MZ7KD,DVE7]O>1Q/Y;M!
M(&"MUP<=^: +]%4+S6],T_4;/3[N^@AN[TE;:%WPTI'7 J_0 45!>7EO86LE
MS=RK#!&-SR-T4>I]!532?$&D:]&\FDZC;WL:'#/ ^]0?3(XSR.* -*BBB@ H
MI,@$ D9/04M !1110 4453U+5M/T?3I=0U&[BMK2'_632-A5YQ_/B@"Y14<$
M\5S;QSP2+)#*H='0Y#*1D$'N"*DH ***@O+RVT^RFO+R=(+:%"\DLAPJJ.I)
MH GHJO87]IJEA#?6-Q'<6LZ[XY8SE6'M5B@ HHHH **** "BBLZQU_2=2OKB
MQLM0MY[NV_U\"."\?;YAU% &C15>]OK73;.6\OKF*VMHEW22RN%51[DU7TO7
M-,UH3G3KR.X-O)Y<RKD-&WHRGD'ZT :%%5=2U*RT?3YK_4;F.VM(1F260X51
MG _4@?C4D%U!=6L-U!,DEO,JO'(K95U;H0>^<B@":BL\Z[I0UH:,=0MQJ;+O
M%J7'F%<9R%ZXP#6A0 4444 %%%5=0U&STJS>\O[F.VMH_ORR'"K]3VH M457
MLKZUU*RBO+*XCN+:5=T<L;;E8>H-6* "BBB@ HI 020""0<'VI: "BBB@ HH
MHH **** "BD) (!(R>@]:6@ HHK(O_%.A:9?"RO=5MH+C<BE'?[A?.P,>BYP
M<9QG% &O1110 444R::.WA>:5PD:*69CT '4T /HJEI>L:=K=G]KTN^@O+?<
M4\V!PZ[AU&1]:NT %%%% !1110 4444 %%%9XUW2CK7]C?VA;_VEMW_9=X\S
M;C.=O7&* -"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ KSCQ5J4FH?%WPGX68G["L;ZE<)VE90_E ^RLF['KCTKT>O/O%^DO
M8?$/PUXT52UI:![*_(_Y91N&"2'_ &59SN/8'/3- %5]6<?'L:4=.TLR-I9D
MCO\ [.WVA1S\I;?@C(] <'%<?9>)#)\)_&E\-!T%!:ZEY<ULMJXAN<N@+,/,
MR&R000>,#BO0I/!NH/\ %5/&<=S:-;K9_95MR6W,,'YMV,=3TQ7/6OPIU>W\
M#>(_#IU&Q9M9NUN?/"N!%\RL1MQS]T#J.M ">,]4EL/A+X8\6V,,-K>Z>+.Y
MBC@7:BHZ!7B _N$-C'L/2O5K>=+JUBN(\[)4#KGT(R*\R\7^';R_\">'_A_$
M\<M](;>*>2+)6.WA'S3'/0?*H /4G S7IJQ_9[58K=%Q&@6-6.!P, 9P: /&
M_@O_ ,C_ /$3_K_'_HV:O2/&&LZKHFE03Z3IIO99+E(I6QE;>(YW2L,C( 'J
M!SR0*Y_P'X#U/PCXDU_4[F[M+B/69O.=(]RF$[G; R/F^_CMTK2^(GA+4/&.
MAVUAI^II9&*Z2>194+QS*N?E8#J,X..AQ0!C^$_'FH:WKOBG1GEL;@Z6@DM+
MZ&,A)5()&Y=QSVY!&:Y+_A;GBT?#RU\8R6VCB :C]DEM4BDW2+@G(8O\O3'?
MU]J[+1/ .KZ-XN\0:XVJ6=S_ &M;!"GV=H\2!<<8)VKGZG'YUSS_  =U9OAB
MG@[^U++<M_\ ;/M.QL8VD;=OKD]<T =!8>,M=B^*T?A354L'M[NP^V0M;(RM
M">?E)).[[IYP,\' Z5T_B[5=4T7PW<WNC:6^I7R%1';KSU(!8CJ0!S@?IUK
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M7(N-VZW?Y@SK@'?G>QP2O)ZT 5KGXHW&IQ>#K70H(8;WQ$2SO<J9%MD4[7P
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M !1110 4444 %%%>??&C4M2TKX:W]SIMY]F8LD4K*F69'8*0IS\O7K@_AUH
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MX+\8OX-^!NDSV\:/>7NHO:0>8"41F=B78#D@ '@=3B@#WA$6-%1%"JHP% P
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M'H^U>*?^@-H__@UE_P#D>@#;HK$^U>*?^@-H_P#X-I?_ )'H^U>*?^@-H_\
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M %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
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MBL3=XI_YY:/_ -_9?_B:-WBG_GEH_P#W]E_^)H VZ*Q-WBG_ )Y:/_W]E_\
MB:-WBG_GCH__ ']E_P#B: -NBL3=XI_YY:/_ -_9?_B:-WBG_GEH_P#W]E_^
M)H VZ*Q-WBG_ )Y:/_W]E_\ B:-WBG_GEH__ ']E_P#B: -NBL3=XI_YXZ/_
M -_9?_B:-WBG_GEH_P#W]E_^)H VZ*Q-WBG_ )Y:/_W]E_\ B:-WBG_GEH__
M ']E_P#B: -NBL3=XI_YXZ/_ -_9?_B:-WBG_GEH_P#W]E_^)H VZ*Q-WBG_
M )Y:/_W]E_\ B:-WBG_GEH__ ']E_P#B: -NBL3=XI_YY:/_ -_9?_B:-WBG
M_GCH_P#W]E_^)H VZ*Q-WBG_ )Y:/_W]E_\ B:-WBG_GEH__ ']E_P#B: -N
MBLB!O$?VB/[1%I0AW#>8Y)"V.^,KC-:] !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M<-T5ELEWW,4T3Q21KC(8HX#8('7&*M:7J=GK.F6^HZ?.)[2X7?%( 0&'T/-
M%NBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MRK9$%;F0<O$^<C=@^V<[>V* .UTJYOKNP6;4=/\ L%R7<&#SA+@!B%.X<<@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MJI;(;;D!<YZ'K6EXCM=3\#:1XDU>QU:)%GLU:/3[:!@MNP=4:= 68#Y7R0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MIY"-*M);N_D:0DW$KXCB$A_C<9D;GI[4 >B57NKZVLO)^T2A#/*L,0/5W/0
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MVV%QT91G@CMCID^M1ZGX*\-:SJD6IZEHUI<WL0 6:1,D@=-W]['OFMZB@!"
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MW>MWFBZ+]G^U6=L)IYIP61'?/E1D YR<%B>P X.[@ E_MS4?^A4U?_O[:?\
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M I!<3[8II)5+>8^ 2X50 !@C))ZX(Z7PKI,>B^'X+2.[6[!9Y3*@PA+N6(0
MD*@)P .@ J6^\-:)J>HQZA>Z7:W%W&FQ9I(P6V]=I]1[&K]RDQLIDM'2*<QL
M(F9<JK8X)'H#B@#S.ZT[4-57QI:26?\ :6L3W36]A<;U,-I$47R\-G]VR9+,
M!\Q.#@Y%37.A%?%/A/PY;2N\MA;27]]=M(S/T$:G+$GYG+D#. 5!QQBG2^!V
MO;#>='N++Q,T6)-9@O\ RU:;',I*,&?GG:4]N!7?V^GP07!NS&CWKPI#+<[
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M>2".:=IF@B.-L>]N6Q@GGIG'.,UHC2=/&K-JOV.'[>T8B-QM&_:,X&?Q/YT
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ML8&O3#]G\\H-_E\_+GL.3^=%GHFFZ>\;VEG%"8D,<04<1(<95!T4' X&!P*
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M9-@-_J*-([<;((@993GMP@4_[U=7:Z5865Y=7EM:0Q7-VP>XE1 &D(& 2>_
MI+O2=/O[RTN[NSAGN+-F:WDD0$Q$XR5].@_*@#A?%RJ_B:QOYE6^T+4A_8DN
MS_66-P9&42Q^A+':Q'(VJ>U>B1QK%&D:#"( JCT JA%H.E03B:*QB1Q*TXP/
ME\ULYDV]-YR?FQGGK6C0 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %5M1NA9:9=7;2I
M$L$32L[KN"A1DDC(ST]15FN0^)$CS^&8]%A<K/K=W%IRE>H1VS(?PC5Z -3P
MAJ&H:KX3TR_U40K?74"SR)$I55#_ #*,$DCY2.];18 @$@$]!ZUYOJEA::'X
MUM]0T.Q5%T;2;J?4C",&<%!Y,;MU9B59N<G SW%,T/29/$N@:#J&JW5F)+R6
M'4);I)/,N)Y 1(L2' \I%(QA2>%(XR30!W[W-\-:CMEL5:P:!G>[\X K(" $
MV8R<C)SGM5S(XY'/%>7VVI6-G;?$+Q48H&!D:WAAV@B18%V D=]\Q<>^/:J>
MG^'(],U#X?:)=[1?VB-?7#[N80J[0B_[TLHS_>(]   #UPLJD D#/3)ZTM>6
M3Z7?:NOC>Q^R1ZGJUU=-;VUXTB&*TA9%\M<DY0QY+$*,YP><\>@Z%I$6A:);
M:?$S/Y,8#R$DF1\?,W)/4\T :)8+C) SP,TN1G'>O*='@F\?>$I=2U.:S@CU
M6X='G=]\MO$)"JP1(1A&P!\V2=Q)P3C%[Q'#IT/Q!T&>+"6=^DFGZE+$0$FW
M)YL*NPZDF,Y[[6YX;D ]'R",Y&/6@$, 000>XKSH2"[\:-X;TRULETG2-.BG
M@LY93'%*TA.'*A3O5 .!TRV>N,0V=I';:_HWA-+X2V-XMUJUX\?R1W3^8,1(
M >(P6)*@G(49R"<@'I892I8,,#OFEKS3QYHVF+X>N[*R<F37=3MK+8''E0MP
MK;5& -J*Y[\\]ABS;ZG;:E\1[J[>15TO0-+VPY;[[R_,S@=P(XQ^# ]Z .WM
M=3M+Z[N[:VE$KVCB.8KR%<C.W/J 02.V15H,"2 02.H]*\:T^;^Q_ NC-8Q0
M6>H>)]547<\1$30QS%I0@<#Y#Y>Q1Z;LCG%;6OHWA.WU+7[5[&VU+[/#IMM;
M6PS%;B64 22D@%VR=V2!P,<Y)(!U/C?6KW0_#<EUI;6YU!IHH+>.9"X=Y'"*
M,!@>^<^QKHD#!%#-N8#DXQDUYG<V6E/\0?#6B6X65M-62_O+R5@7FD&$0,W5
MF+MN/NHQTXZCX@7PT_P)J\OE++(\'D0QL 0TLA")P?\ :84 ;&EW-]<V9EU&
MQ6RG\QU$2S"4%0Q"MN '48..V:N @YP>G6O,M3TB*74/ ?A733$ZV"&\EN5
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MR&Y;3KVQNW999[>%XFBQ&SK\I=@P)4#.1].<BIX>\0ZKJGC/Q'HUT+,6^CM
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M-S#U ZXH 9I^FV.DVBVFG6<%I;*25B@C"*">O XJ >']&62ZD&E60>[&+EA
MN9A_M\?-^-5--\7:'JK7WV?4;8I:7!MV<S* S *21STRV,^H-:OVRU\^.#[3
M#YTB[DCWC<P]0.XX- %(^&M":VM[8Z-IY@MVWPQ&V3;$WJHQ@'W%-F\+Z!<7
M%U<3Z+I\D]TGEW$CVR%I5]&..1P/R%7?[1L?.6'[9;^:TAB">:NXN!DKC/4
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MU67[4<C!$> L2GT(C"Y'J6KGKDVD/QO@>X\A-_A]MK28&Y_M*XQGJ?UKO0
M !@#M5:XTZQN[F&YN;*WFG@SY4LD2LT>>NTD9&?:@#Q?4-/LI/A=\0+Y[:%K
MN+6KUHYRH+H1."-K=1SZ>M=1=:C:_P#"R=0L=;U7[!'<:9!]A,HB\N:/Y_-4
M&12,DD9 Z@#.<"NW'AW1!;R6XT;3Q!*V^2+[*FUV]2,8)]Z6\T#1M1MH;:]T
MFQN8(/\ 5136Z.L?^Z",#\* */@O3M/TGPI9V.E7ES>6$.]8)[APS.N\]"
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MJ#:) \(B&&,NR7!&/XLX_2KWA?4?!^NZ1X2E@D@FU&RB5;6WBEQ- _E[9=R
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MT^2#=A--CWF7<I4AW*)\N&/RX.3@YXYZ>'3;"WMI+:&RMHX),AXDB4*V>#D
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M3:V=O-"9ML2QL[.""QZGY1W_  KK&U&Q2P6_>\MULV4,LYD'ED'H0W0YR,4
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M@\B_L[>[ASGRYXED7/T(Q7+>(O$=Q;ZQX5DTW4K=M+U"]:&=D"NLB"-VR'Y
M&5[?G71V6MZ3J5E+>V.IV=S:Q$B2:&=71".3E@<# YH FLM/LM-@\BPL[>UA
MSGRX(E1<_0#%,@TC3;6Y-S;Z=:0W!SF6.%58YZ\@9IEIK>E7XF-IJ5I/Y"AI
M?+F5M@/()YX!]:;:^(-&OKA+>TU:QGF>,RI'%<*S,@.TL #R 01GVH T:B^S
M6YB,7D1>66+E-@P6+;B<>N><^O-5;+6]*U*XDM['4K2YFC4,\<,RLRJ>AP#T
M]Z6VUK2[RZ^RVNHVDUQ@MY4<RLQ ."< ] >,T 2W6GV5]L^V6=O<;.5\Z)7V
M_3(XIG]D:;YSS?V=:>:X*L_DKN8'@@G'(K+\:>)HO"7A2_U5FA,\43&WBE<+
MYLF. .YYZ@=J@TN\EMI9-2N_%-G?:++&JH7$2F.?/(5TP"I_NG)SWH W$TO3
MX[.2S2PM5M9,[X5A4(WU7&#2+I&F+8K8KIUH+-3E;<0KY8/LN,4P:YI)TUM2
M&IV?V%<AKGSU\L$=06S@4^RU;3M1FGALKZVN9+<@3)#*KF,D9 8 \9]Z $&C
MZ8'B<:=:!X<")O(7*?[O''X5;DC2:-HY45XV&&5AD$>A%8B>+M'D\5R^'5O(
M?ML40D<&0#YF. @'=N"2!TX]:NP:[I-S>BR@U.SENCNQ"DRECM^]@9YQW]*
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MYQOB<,,_455FUW2;:]%E/J=G'=%E00O,H;<W1<9ZGL.] %]55%"JH50,  8
M%5K[3;#5(1#J%E;7<0.0EQ$LB@_0@U!=Z_H]A),EYJME;O!'YDJRSJIC7( 9
M@3P,D#FIUU.P?31J2WMN;$IY@N1*OEE?7=G&* 'VEG:V%NMO9VT-O OW8X4"
M*/H!Q45OI.G6MW)=V^GVL-S+GS)HX55WSURP&37,:1XDGU+XDZCID.I6]WID
M6FQW$:0JO[N0R,I!89).%'Y]*ZN[OK2PC62\N8H$9MJF1PN3UP,]3P?RH B_
ML?3-TK?V=9YF&)3Y"_/SGYN.>?6FG1-):)(CI=D8T)*(;=,*3U(&.*<-7TTZ
M<-0&H6ILF.!<"5?+)SCALX/(Q]:R]8\:Z%I'AN37#J%M<6H.R,PRAA+)G 0$
M=\]?3DGI0!G:+X1EB\4:_J6L:?I4\%_/'-;8)E>+;&J8(:, 9V@\&NJN+&SN
MY(7N;6"9X6WQ-)&&,;>JYZ'Z5B7/CC0+?6=/TS^T[1Y;U7D5Q.NQ47N6SC)/
M '?GTJOX;U;4KSQAXKTV]N5F@T^6W6V"QA-BO%O(]3R>Y[4 ;SZ-I<B;)--L
MV3>9-K0*1O/5NG4]S45WID<<,]UIEEIZ:J(F%O--"  ^,+N*C=MZ9QVIUKKN
MD7MS);6NIV<\\:;WCCG5F5?[V >GO4/_  E'A_?;K_;>G;KES' /M2?O6!P0
MO/)SQQWXH CT#3M2@\^_UN6UDU6Y5%E^R*PBC1 =J)NY(RS-D]V/I6U5&UUK
M2KZ_N+&TU*TN+NV_UT$4RL\?;YE!R.:0ZYI(U%=..I6@O6)5;?SEWDCD@+G.
M<=J )5TVP2R:R6RMA:/G= (E$9SURN,4^SL;33X!!96L%M"#GRX8PBY^@JC=
M>)] LEE:ZUO3H1%((I#)<HNQST4Y/!]JK:KXPT;2-9TW2[J]@2>^W,I>4*J(
MJEMY)XP2 !ZY]J -ZBCI5"TUO2K^Y:VL]2M+B=5WF.*96;;TS@'IGO0!?HK@
M[GQ-)KWB?5] T?Q#:Z=/900_9I%,4OVB=]Y92&SE5"J"%P>3STKN(!,+>(7#
M(TP0>8R#"EL<D#L,T 24444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 5S_C;0W\0^$;^Q@.V["":
MT<=4G0[HR/3Y@!]":Z"B@#Q]M?U)]0T/XA6UC)Y6H0C2)+39AG9AE&/<?O\
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MM;RSM;&.^?R[**3>;1&BD&V1V)8N3QS@$Y !QFO:C!$TRS-$AE4$*Y4;@#U
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M(QM;ZCO0;&S:02&U@+@ !C&,C' YH \6OI+9?AAXL@#Q"%/%;HB C:%^U1G
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MMJK\J]AA1]3D]\5>N+"SO'C>YM()WB.8VEC#%#[9Z4 >-Z19O;:7\,(=<4&
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MO&[6:"[^!-_H=[C^WH?-MY;1C^_-X92R$#J2S%6!'7->MV*S6^D6RW\JM/'
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ML^(-=LO#>AW6K:A)LM[="Q Y+'LH'J:Y+3IFE^*GC*"RNK>.];3K182_SA7
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MB8*[%2-QQE5!..<]JY"[O[(^$?BC;F_6XD:<RJTFU2X:*,*V  ,$]"!SCC-
M'K]IXAT:_P!3DTVTU2TGOHDWO;QR@NJ^I'XCZ9I\>NZ5+?)9)?P-<N[(D8?E
MV4$L%]2,'..F.:X>\FL(O'GPZ%O+;HIM+Q5$;* 5,*8'';(XJEH5S<Z1JN@Q
MZ??V^N>'+Z\D%K%(!]KTZ0I(6Y!^95!<'/(SB@#T,>(=':_6Q&I6QN6D,2IY
M@^:0=4!Z%AW7K2ZAKVDZ4^R_U&VMF #$22 ;03@%O[HSQD\5X[<:]I5WHGAR
MXM[FWT^W@\3Q2/IJG+6@\Y]SSLV2K$DG^$8;'.,UT.GZ]H=CK?C'0_%TL<+W
M]X9XEN5(^UVKQJJ*G=B-I&T<Y/'.: .RF\8Z3!XNA\.M<QBZDM6N"2V OS(J
M)[LV\G'HON*GT6[BN+C5I4U^'4HEN/N)LVV8"C,99>OKSSS7)BYL]+^+.C><
MHL()O#;6]M#*<'?Y\9$0]6 [#)XKG-1%Q>^'/BC;Z*PFNCJ*L8H6RSQA(O,
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MP;?)@BCVY V(!C/7IZU+10!']G@-P+CR8_. QYFT;L>F>M/(# @@$'J#2T4
M1_9X<8\F/'IM%)+;03!!+!'($.4WH#M/MZ5+10 UT61=KJ&'7!&:AOHYI;"X
MBMPAE>,JOF,0N2,<D U8HH Y[P9X>?PYX9L-.NEMGNK2$0&XA'^L4=#D@$?3
MFMV2"&61))(HW>,Y1F4$J?8]JDHH 88HR^\QJ6_O8YI/(BR3Y29/4[1S4E%
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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MO+!@V"N!SS7&:MJNG:CXU^'UU!.DEN&NFWL" ,P84\]BW /<]*P=2^T747Q
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MT7G"'R7YC_O!L;<9XSGKQ2G7M-"7;M.RK:S""7=$X_>'&%7(^8G(P%SG(]:
M-*BL+_A,M %KJ%Q)?^2FG8^UI/#)')#D9!*,H;!'(..>U3:/XGT?7KFXM],O
M!<2VZ(\H$;* K@E2"0 >AZ9QC!H KS:'J5YXB-W>:SYNCH\<L&FK;*NV11P6
MDSEAN^8#CD#TYWZP)K[31XUBMVUFX2^CL7<Z<&_=&/<N96&,;AP!ST)XJO\
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MW 8$$CI5>\D7Q-\-] T&RC>+7()K.-K8H5DLGA9?,=AU50%;!/7(QU%>L44
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M>R(<PQIN.'5=N"QY&03TJ&V^(?AF\&GM!?2/%?R^3!/]FE$1D)("%]NU6)'
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M6E\6P\WPSUBUACDFN)XU2**)"[.=ZG@ 9Z5MZ%I.BQ6]OJ-CIUI%</ J&9(
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M:VD6*0[=VT.5V[L?PYS^-<;93+%XL\6S"/5)8+S1H3#<W-M(/-*K*">5&.2
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MV$$;I-&T;*RQ@$$, >HH Y#2I+R]\1>-K>[\2:A9VFES1K;2^<NVW5H]Q)W
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MNO#</B""2:33IF58W6!BS%G"#"XW<L0.E7]5U)-)T>ZU*2&:5+>(RF.)-SL
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M!#,/0\$] >"16/XN\0-!XH\.:*$O#:7LLSW)MXWS*J0EE567DC<03@]N>,T
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M#(4KD]>1VP<XQ0!T]%8.H>,-*TZWFN9?M+V]NJO<RQ6[LMN& 8;\#(.""1U
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MS):R2QLBSQ8WQDC 89XR.M '!:'HE[8>-KWP^$4^'[:<:S;X/W&EW 0X[*)
M\@_W17;:Y!)=>']2MX5+RRVLJ(H[L4( J'0M%_L6T=);ZXO[N4AI[NYQOD(
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M8'C2X\N--RJS  Y*E>O?TKUJB@#C])\5-XBB2:V\.7T=];P.9A?6IA$3[?\
M5*[#YB6 ''&!DXX!XNTGN[NY\#:C)I6L">VNW6]A6PDBAM6:%U$:1X "@G&[
M!X^\U>R44 >;Z7*VE'QO87FG7DEQ?:C//:P+;.PN8WB15VMC;@D$')X[X%5H
M=%O-!O?AII\T-Q.VF),MW-# \D<1: J,L!@#<<#->HT4 >2V*V^F7^L^'O$/
MA?4=0EN+^>>TEBMVEANXY7+@,V=JD$X.[ 'K7I%]Y]GX:N?LEE%/<0V;>5:#
M[CN$.(_H2 *TJ* /(M.FN+GQ'X#U,Z?K+F*.XBN]]E)%';R-"%$:QX"HH.1N
M Q@#+'!K8U#PQ>3^,=8T987'A_Q!"EW=RH<".1!L=![O^Z)]@U>BT4 <#X0M
M]>M_"EY=:I9>?JMC:OIUM"_2X6#< W/_ #T;&?4*IKGM/GN;G7/ 6J-IVLLT
M GCO ;&2**VD:#:(TCP%50>-P&,#ECBO7Z* ///"MI=W.F^.;..&ZM+B]U2[
MDMI)X'B#*\:JCJ6 R,@]/2N;GOKF?X6Z-H+:+JL>K:7<V45S;"QD; BE7+A@
MNU@0N1@GK7L]% &9KL]S'X9U&XL;(7ER+21X;61.)6VG"%??IC\*\ZTV6>X\
M8>"]2%CK4JBTN8;F2:SDB2*1DCP@3 6-1@C( !QU8@UZQ01D$>M 'BCW&F+I
MVM>'+_\ M>VT:;5Y9F0:3-,VU9@S!9DRNTNA.<$@$CKR.OAN4O/B[9ZG;17$
MNGS:!Y<=VENYA9FF5U&_&.5YZUH:9X/O](A2QM?%6I#2X\B.W:*%I%4G.T2E
M-V/?K[UT]M;Q6EK%;0($AB0(BC^%0, 4 >7@PZ+XE\0Z7XA\.ZEJ$&I7C7-G
M<6MN\T<Z2*H,38X!&,?-QCK@=5N4'A7Q>T^J>'KR71[_ $^VAA.G1/,MG)$&
M!B*ISMPW!Q_7'JE% 'FMU9I::[X$^PZ%<6%E;W5U*T$-LQ6W1XW"E]H(4L2"
M1G@D^E3Z>9(_%/Q!G>TO%AN4M_(<VDF)ML&QMGR_-AN.*]#HH \8LX;S1M$\
M#ZO>Z+J-W86>FR6%_;QP.)K9FV$/Y?#$93!]OPK4\26]M<>#&FT;P]>6J76J
MVL^Q;-_.F"2(SRN@!8# /WN3CW%>IT4 <0/,?XR1W:VUU]E;03!YYMW$?F&8
M,%W8QG;SC-+\*A/;> ['3+JRN[6ZL=\4RW$#1C=YCGY21\PQ@Y&1SUKMJ* .
M)A$G_"Y[JX-K="W;1([=;@V[^49!,[%=^-N<$'K7.VWD:3K&O:'XA\,ZEJ!O
M;^:YLY8+=IH;J*5MP1B#M4@G!W8 %>L44 ><6-S<>$O'^IB^TJ\-EJMK9K9R
M6-N\\<31(4:$[1E>22"0!BN=LHKB3X8:5?16EQ*MAXH-[<1Q(9)%B2[<L0JY
M)QGMFO9W#%&"$*^/E)&0#].]8OA7PZ?#&DOIXO#=1F>2<.T>P@NQ9AP>1DG%
M '-Z7>M<_%74-3%AJ,=A-HT*1SR6<BJQ61R>",@X/ (!/IR,\O:6]Y%\*?"U
MI)IFHBYM]<CFF@^Q2ETC6Z=RQ7;G&T@_C7M%% 'GOC0RZ;XMT?Q#-I=YJ.C_
M &26SN5M8V>2W+LCK)L')'RX/I^5=)X5BL?L5Q=:?H[Z;;W4QE"RQ&.28X&9
M'4\@D^O.!GO6]10!P\33:=\6M5GGLKQK>]TVW6&:*W9XR49]X+ 8! (."<GM
MDD"N0^S7G_"DFT_^S=1^V_VIY@M_L4OF;?MOF9V[<XV<YKV>B@#R^]FCT7QU
MK4FM:'J5_IFL"&:SN;2WDE (B6-HG5>0?ER,CO7H&AVT5GHMK!#IZ:?$J?):
M)C]T"20IQQGGG'&<]:T** /-O!XD^'L^I^']5MKH:?)>R76GW\4#RQ/&^#Y;
ME0=K@COC/:M/QS;:AXN\!ZQ9:/;RAGB1H#,IC,[*ZN5"L 0"%QDXSGTYKMJ*
M . U9SXTO?"4EC:W<$MEJ"7]V9[=XS;HB-NC8L!\Q8JN!UP3TYK'CBN3X*^)
M,'V"_$U[>WK6L9LY0TP>)50H-O()!Z5ZO10!YM>"9[[X<.MG>E;4DW!%I)^Y
M!MRGS_+\OS''-4]#OK==+^(6GO;3W$]QK%ZD<$<#/YQ:-5"@@8SGKSP#DX'-
M>J'.#C@]LUA>&_#K^'Y-48WOVD:C>R7S@Q;-DCX! Y/R_*, \^] '&Z?;ZAH
M-WH?A[4+*],$&AQQ?:M/MV9IYP<-"TRC*(N 1RH.<DXXK(TB*\3P1\/+632]
M22:PU9&N4:RDS&JB4%C\O"Y9>:]GHH XC18G;XH>*WEM+@6US:VD<<DENXCE
M**X<!B,'&X=^]4_!>CW]CKEUHER ^E>'IW.G2%LEA,H9%/O&C.OTD'I7;:O8
MSZEI5Q:6U_/832J ES  7C.0<C(QVQ^--T?2DTBQ\@3S7,KL9)KF<@R3.>K-
M@ =@  ,   =* ,OQ_9W.H?#_ %ZTM(7FN);*18XT&6<[>@'<^U<Q/-=)K_A#
MQ.ME?MI4%I+97*M;.)+<NJXD,>-VW<NTG'&,],&O2J* ..\.Z?+-X\\1>(DC
MDBL;R&VMX=Z%#.T:G<^#@X&0H/?!QQ3O']C>&QT[7-+MGN-2T:\2YCAC^]-&
MWR2QCZHQ_P"^177T4 >:V/AO5].\:FU<--INLQQZAJ4N252YA;+*OLY:,8_N
MJ?2M6=9?^%SVMQ]FN3;C1)+<SB!S&)#,C!=^-N< GK7:T4 >-S0WJ?"?Q;H9
MTO4C?_:[O;&MG(1)OF+)L('S @YR,@=\<9Z;4G>7X@^#+N.UO&MX+2[6:46L
MFV,NB!0QV_*25/!]*[ZB@#QFZM;R7X0^+K)--U W=SJEQ)!!]CEWR*\X96"[
M<D$<YKJ+>6;1/B5J>J7D-RVE:S96_P!GN5@=A"\08&-P!E2=Q89 !Z=:[ZB@
M#Q[5=#O[7X;>)"MC>-)J^O?;[:TCMW>1(C/&>4 )7*H6P>F<'FM\7DWA_P")
M^IZC?VE[+IFLV=NMK<P6LDHB>/<#&RJ"RD[BW(KT*B@#B?A@L\?AV^BN+.ZM
MG_M.ZD"W$+1DJTK,",CD8/:L7Q;9W":WJ^J^'IM1L=?B\M#;&W:6UU9?+7 *
MD;2>2F0?EQSCK7J%% '"V+SI\6-3O+BTNDA;1X(C*+>0QF17=F56VX) (Z5S
M'A^YU'2?!GA*UGTK4(81?72WLZZ>[W%H"\A38I4LN_< 6 X!(X)KV&B@#Q.\
MM+T?#_X@:9'I&K^?=:H\UM&]M)(\J-Y6W!Y+'"L3R<8YQD5U_CI;DIX<U^VT
MVZU&QL+AFN[2&-A,8I(RF\)P<KG..O/UKO:* /.9[?P]J_A_4KI?#.HQ6%[)
M;QS3K;R1W4A#\2!<%\1_*0<=CC@<Z?@9=8M[O5K*]OYM4TV Q"PU"YBV32 @
MED8X&_;Q\WJQ]P.SHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
@@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>51
<FILENAME>exhibit108-arvinasxformo007.jpg
<TEXT>
begin 644 exhibit108-arvinasxformo007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" 55!!\# 2(  A$! Q$!_\0
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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MV38S.A56R!M) )P<&N3NL2?"+QQ;I&YGN-6NGBB"'?(&F!0JN,D$#((]#Z4
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M7$UI)H+0K<+;2!-WGA@"Q7 X!Y/&>.M '<7VI6NG+$;AV#3/Y<21QL[R-@G
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MGKVSM1F3Q;X6\+:=I\<D>J6]]:2S0%"LECY7^L+@_=P 0,]<C&<UK:?<1?\
M"Y-8;=A'TNWA5R"%:19'+*#T+#<..M '4FYCT32;4:C>R3R(L<!F,>7GDX&0
MJCEB>< 54F\7Z+;64MW<7,T,$-P+65I+653'*=N%8%<C.]<$\'(YJIXYMM/O
M-'MK?49KNU1[M/*O;5BKVLH#%9,@' !&"3Q\W-</JYUZ\^''B*WO675?L5_;
M/#J-K!M-[$CQ.S[5X8J 02.#MQVH ]0&M6!UW^Q?/(U#R#<"$QL,Q@@%@V-I
MY('!JF/%NB&]MK7[80UU*8+>4PN(I9!G*K)C83P> ><'%<;<WZZ[\2H;C2Q=
M&"Y\.W%M!=_9I%02-(I4Y(X'!Y.!QUI_@C7K*XT#1/#5]HEP==TKRH9+6>S;
M; T?R^>)"NP<9((.23@=: ':'XPM=#O_ !6NOZM=2Q6VJF.)GC>4PQ>6AY"*
M=B9)Y( KT9'2:)7C<,CKE64\$'N#7E*R1MH'Q23!+W4MSY VG,P-N$79_>RP
M(&.]>@>%9%;P?H[$_=L80V>"I" $'T((.: .,TF?4[_5?&D5QXHOK*#2KD);
M2GRBL*F/=EMR'< ?7M4VD^,/$-_\%'\3&R#:T+61T58^)-K$"0+]!NQW[<&N
M>M_"UGXPUCQU;DB"]DU".XTZ[:/^)$&&7(^=-PP1R/TKK]+\;7#^%)IKS2YX
MM;T\K%=Z>D+%G(<*QA ^^"#E<9Z@4 ,T.X37K#3=5\,^*KN_A$\1OHIG1S(F
M?F#*1F)AUPN 0",'(I=/O-0?XO:KI4FHW+Z=;Z=%<QVQ(VJ[-@\XR1QT)[US
MNN:1HTGB;2=:\$.;?Q!)>QBZ@M%9%> G,AGCP-F!W(!)]3C&W>/_ ,(Y\6YM
M9U%6BTK4=+2W6[VDQQS(Y.UR/NY4Y!.!0!T&I?:/^$PT>*.]N([>6*X>6!&&
MV0ILVYXR/O'H1FK47B32YKR"UCFE9[B5X87^SR>7(Z!BP$FW:<!&[]C5"WO8
M=>\56=WIY::RLK:99+D*1&TDACVJC'AN%8DC(''K7'Z,)],U[2W\.W\MUIE[
M>M]JT.\3=)IY8.7EC8C<B@YZ\'=P3N% 'JM96I>(],TFX-O=32&=8#<-%# \
MK+$#@N0@) SW/7!QTINB>)-/\0/?)9&8/93F"99HFC(89&1GJ#@X/L:Y;Q#J
M/_%;76G36MQ;+)I8$-S:VK/+>DLV8O,"G:J]<#!RV<@=0#I+GQCX?M(M.EFU
M.)8]27=:. 2)1MW9R!QP.^*ETKQ/H^LP7DUG=_+9,5N1/&\+0G&?F5P"!CG.
M,5Y?I$ZGPW\,$>*9&M+L>>)867RP(G7<<CA=Q STS]*E\1V5]JUS\3[32D=[
MJZM['R%4']^(T_>JI_B. 5('<XH Z#6O$RW7C;P;%IM_?1V]W<2^9"87BBN(
MQ$Q# LHWC..A(Z''(->A5Y?J?B2PU_7_  ->Z?!=LL-Y(9XQ:2;K<F%EVM\O
M!!(!_/IS7J% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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M)I(H'=(Y&V[58@<'YE]AD9Q3=5\4Z7HPN&NGG*6H#7,D,#R+ ",Y<J#CCGU
M.>G- &S17$ZI?2M\2_"1M-0F:QOK2[D:))289 J(4; X/WCS4G@VXNG\3^,;
M:>\N+B.VU"-(1-(6\M3"K$+GH,D\"@#LJ*Y_QEXG7PGH#Z@;:6=S(D4:I&6
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ME9C.XM%#7+0P/((<C(W%0<<<^PP3@<T :]%%% !1110 4444 %%%% !1110
M4444 <Q<>&]7BUV]U+2?$36J7I1IK>XM%N%!50HV'<I48'3)&<GO6UINGC3X
MI-TSSSSOYL\[@ R/@+G   P%4 #L!U/-7:* "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** *UK9
M16LD\JEGEG;=)(YR6P, >@ '  _F239HHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ KCOB?;SS^"93;V\L[0W=K,R0H7;8DR,Q"CDX )X]*[&B@#@I[M;KXK
M:)?)!=+;?V5<(9)+9U"LSH5#9'RDA2<'!KE&MM1/A_5;RUTZ]N/L7B^74I+1
M$>.2XMB2,Q]">&R,?W:]HHH \UN)]&U?PWXBU/1]&OUEETF:V:ZN8)1+*S*=
ML2A\LW/7' .,9YPW5K:^E^%7ABXL+&YN9-+-E<7-DBM',Z1H%D0#@[AG./\
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M+MK=+=FB95F*V[*P5B,'#$#BMSX=7'F> M%@:WN89;6SBMY5N(&B(D5 & #
M$X(ZCCWKJ:* /+/$$%S::WJ6J^&;F\M]7-TB7.D3PF2VU+[J[U!'!VXRZGC:
M<XZTUIK;1?%'B+2_$FCZK=6^J71N;.:UBFEBN$=%4Q$)QD;<<CIUXQ7JM% '
MGMW!]E\>>!HXM/DMK>TLKJ)XXHV>.VW)&$0N!@?=('/:CP_:W-[KWCF""YO-
M-DNKZ*2WNT@P2JQH"R;U*L,J1WZUZ%10!YUXUT/5;3X=7\4NI7^N3"ZMI\O
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M4 9EMK*2ZP=)DMKF.[2U6YD?RCY(R<;0_0L#V]*TZ** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
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M Q>9$3C>N>V>.<'VJ(>,],%YIT4L=S#!J;^78WDD8$-PV,@ YR,CD;@-W;-
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MDD%U/%IVBR64]TD#M$LA\O W8QCY3].,UZ310!6U%]FFW+;'?$3?+&A9CQT
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M3-<N$WNQR<Y R <9YQ6]##>Z;\4]5O7TZZELK[3[=8[F)-R*8R^X-SG.&&
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M1V)6;S/NJ &R03N^7IG%=:/!2[[-_P"W]=B^S111>5;WICB;8H&2F.^.?7-
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M\TG0;W0?%/@VT:WN9X=-T>6SN+I(F,:R-LP,XZ?*?IQG%>E4 %%%% !1110
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M;69E>"5E!>-@<.C(Q!&>#SD&J7@C5HM/^''A6-DEN+JZLT6&"/&^0A-S'+$
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M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M$YX]^-YKW5O%7AS5HAHEUIB36,L$<=\46625E(& K'"CID]<]!CGK** .?\
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MT9\?Z=;7^HV6IP2V<]E8MJ)&]95E@7.XJ5)^8$8*G'MD5KZ?K$M[>+;RZ?+
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M<RH5 C#Q,@X)!/)[ \53L;#4X/$OCF\?2[D0:BD'V1LI^]*0>60!NXY]<<4
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MCRW%W,+>V@CQNE<@G R0   22>@%9L?C" 76IV%S874.I:?;BZ>T!1FFA/\
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M8E$IDVX#9Z'&>F>_>N9F\/:]+\(]>T1=&N1J-W?32PPEX_F1Y_,!SNP/E]Z
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MLDC*V0TKN""I(Z,*3Q=8:D_B7PKJ]CI\M]'I]S/Y\4+HK@21% PWD# )YYH
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M)'4>M<39>';V+Q-I^L:1IU[HM[-=DZS;B0?9+B+#;GVAB-Y.W&.1DY'4T =
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M88OE9FP(\\;_ 'P2..]<_P")99(OB)X'U!]+;[<RWZ&&(JSOB(;1NX&.<\G
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MZVT6S,3-.R$L,]VR<+GKBMW3?%?VOQ%=Z)?:9<:=<PVHO(_.D1Q)"6*ELJ2
M01R* .CHKBY/B%$FF:5JJ:3=3Z=JUR+6S>*1/,9V)";E<J%#;3@[O3(&:[-2
M2H)4J2.AZB@"&\MK>]LI[2[C62VGC:*5&Z,K#!!^H-8-AX)TZP5(A>ZK/9H
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M1CS\W8D>_:K/BW3=0FU[PSJ]E9O>1Z9=2O/#$ZK(5>)DRNX@'!.2,_2NLHH
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MR)(P*C(? /UQ]:M?#C3=0T7P)I>E:I9O:W=I$8W5G1P3N)R"I/;%=22%!)(
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M[G[8LMS"=IDBV97:QW+D^Q]JZ'QS8WFJ>"-8T[3[9KB[N[5X8HU95Y88R2Q
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ML5W) 9!&70*ZG!;C/S \T 8"376G?%C6Y-.T=;F]FT>VD>".58U+[WR6<CV
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M=2"-WN,UC:YX-U>[\,^)GM[+?J>NZA!<BW$J 0QQ/&5#,3C=M0DXSRV.<9H
MZFQ\42W/BM_#]_I$ME)):&[MW>59!+&&"L&"_=8$CC)X/6JWAO4&M/%VN^%F
M),%HL5W9 _PPR#YD^BN#CT# =!1/I^IS?$S3M9&G2K81:;):R2-)'E7=U8<!
MLD#;@X[^M4]/MKN7Q[XL\0V=N+CR+2/3[2,OL$\J*7==QZ ,57/8Y]* .ZHJ
MMI\MU/IUM->VPM;MXE:: 2!Q&Y'*[AP<'C-6: "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *RO^$=T_P#X2/\ M_;/
M_:/D?9_,\]]OEYW;=N=N,\]*U:* "BBB@ HHHH **** "BBB@ HHHH ****
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M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
4@ HHHH **** "BBB@ HHHH __]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cover - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Feb. 20, 2026</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38672<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">ARVINAS, INC.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-2566120<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">5 Science Park<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine2', window );">Entity Address, Address Line Two</a></td>
<td class="text">395 Winchester Ave<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">New Haven<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">CT<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">06511<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">203<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">535-1456<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">ARVN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFinStmtErrorCorrectionFlag', window );">Document Financial Statement Error Correction</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 469.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">63,960,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentsIncorporatedByReferenceTextBlock', window );">Documents Incorporated by Reference</a></td>
<td class="text"><div style="margin-top:2pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%">Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant&#8217;s 2026 Annual Meeting of Stockholders, which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#8217;s fiscal year ended December&#160;31, 2025.</span></div><span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001655759<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFinStmtErrorCorrectionFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates whether any of the financial statement period in the filing include a restatement due to error correction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 402<br> -Subsection w<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 4: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFinStmtErrorCorrectionFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentsIncorporatedByReferenceTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Documents incorporated by reference.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentsIncorporatedByReferenceTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 2 such as Street or Suite number</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Audit Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AuditInformationAbstract', window );"><strong>Audit Information [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Deloitte & Touche LLP<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Boston, Massachusetts<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">34<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AuditInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Audit Information</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AuditInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 142.9<span></span>
</td>
<td class="nump">$ 100.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesCurrent', window );">Marketable securities</a></td>
<td class="nump">542.5<span></span>
</td>
<td class="nump">938.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Accounts receivable</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherReceivablesNetCurrent', window );">Other receivables</a></td>
<td class="nump">5.4<span></span>
</td>
<td class="nump">8.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">8.9<span></span>
</td>
<td class="nump">14.2<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">700.7<span></span>
</td>
<td class="nump">1,067.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and leasehold improvements, net</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Operating lease right of use assets</a></td>
<td class="nump">8.2<span></span>
</td>
<td class="nump">9.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">717.9<span></span>
</td>
<td class="nump">1,091.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">69.5<span></span>
</td>
<td class="nump">71.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityCurrent', window );">Deferred revenue</a></td>
<td class="nump">71.3<span></span>
</td>
<td class="nump">156.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current portion of operating lease liability</a></td>
<td class="nump">1.7<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">142.5<span></span>
</td>
<td class="nump">229.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityNoncurrent', window );">Deferred revenue</a></td>
<td class="nump">134.3<span></span>
</td>
<td class="nump">292.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Long term debt</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Operating lease liability</a></td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">7.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">284.0<span></span>
</td>
<td class="nump">529.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and contingencies (Note 12)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock, $0.001 par value, zero shares issued and outstanding as of December&#160;31, 2025 and 2024, respectively</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value, 73.5 shares issued and 63.5 shares outstanding as of December&#160;31, 2025, and 68.8 shares issued and outstanding as of December&#160;31, 2024</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(1,612.4)<span></span>
</td>
<td class="num">(1,531.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">2,136.9<span></span>
</td>
<td class="nump">2,092.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive income</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonValue', window );">Treasury Stock, at cost (10.0 and zero shares at December&#160;31, 2025 and December&#160;31, 2024, respectively)</a></td>
<td class="num">(91.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">433.9<span></span>
</td>
<td class="nump">561.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 717.9<span></span>
</td>
<td class="nump">$ 1,091.4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborationContractAssetAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Contract Asset And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborationContractAssetAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 815<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480870/815-30-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-14<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 13: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 19: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 20: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 35: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 37: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset recognized for present right to economic benefit, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(15))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 64<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481620/480-10-55-64<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-25<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br><br>Reference 23: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481404/852-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in marketable security, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherReceivablesNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherReceivablesNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (01)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(21))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated undistributed earnings (deficit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480016/944-40-65-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-11<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(17))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>Statement of Financial Position [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding (in shares)</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">73,500,000<span></span>
</td>
<td class="nump">68,800,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">63,500,000<span></span>
</td>
<td class="nump">68,800,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Treasury stock, shares (in shares)</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations and Comprehensive Loss - USD ($)<br> shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementAbstract', window );"><strong>Consolidated Statements of Operations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 262.6<span></span>
</td>
<td class="nump">$ 263.4<span></span>
</td>
<td class="nump">$ 78.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">285.2<span></span>
</td>
<td class="nump">348.2<span></span>
</td>
<td class="nump">379.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">95.9<span></span>
</td>
<td class="nump">165.4<span></span>
</td>
<td class="nump">100.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">381.1<span></span>
</td>
<td class="nump">513.6<span></span>
</td>
<td class="nump">480.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(118.5)<span></span>
</td>
<td class="num">(250.2)<span></span>
</td>
<td class="num">(401.5)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract', window );"><strong>Other income (expense)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other expense, net</a></td>
<td class="num">(0.4)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
<td class="num">(1.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">38.4<span></span>
</td>
<td class="nump">54.8<span></span>
</td>
<td class="nump">38.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpense', window );">Total other income</a></td>
<td class="nump">38.0<span></span>
</td>
<td class="nump">51.9<span></span>
</td>
<td class="nump">37.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments', window );">Net loss before income taxes and loss from equity method investment</a></td>
<td class="num">(80.5)<span></span>
</td>
<td class="num">(198.3)<span></span>
</td>
<td class="num">(363.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="num">(0.3)<span></span>
</td>
<td class="num">(0.6)<span></span>
</td>
<td class="num">(0.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(2.5)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (80.8)<span></span>
</td>
<td class="num">$ (198.9)<span></span>
</td>
<td class="num">$ (367.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
<td class="num">$ (6.62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
<td class="num">$ (6.62)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract', window );"><strong>Weighted-average common shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted-average common shares outstanding - basic (in shares)</a></td>
<td class="nump">70.9<span></span>
</td>
<td class="nump">71.9<span></span>
</td>
<td class="nump">55.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">70.9<span></span>
</td>
<td class="nump">71.9<span></span>
</td>
<td class="nump">55.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract', window );"><strong>Consolidated Statements of Comprehensive Loss</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (80.8)<span></span>
</td>
<td class="num">$ (198.9)<span></span>
</td>
<td class="num">$ (367.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Other comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on available-for-sale securities</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Comprehensive loss</a></td>
<td class="num">$ (80.6)<span></span>
</td>
<td class="num">$ (194.8)<span></span>
</td>
<td class="num">$ (351.2)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Total</div></th>
<th class="th"><div>Common</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Loss (Income)</div></th>
<th class="th"><div>Treasury</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Beginning balance (in shares) at Dec. 31, 2022</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Beginning balance at Dec. 31, 2022</a></td>
<td class="nump">$ 564.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (965.4)<span></span>
</td>
<td class="nump">$ 1,549.4<span></span>
</td>
<td class="num">$ (19.2)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">71.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">71.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(367.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(367.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued, net of issuance costs</a></td>
<td class="nump">370.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on available-for-sale securities</a></td>
<td class="nump">16.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">16.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2023</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">68,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2023</a></td>
<td class="nump">660.0<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">(1,332.7)<span></span>
</td>
<td class="nump">1,995.7<span></span>
</td>
<td class="num">(3.1)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">88.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">88.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(198.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(198.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on available-for-sale securities</a></td>
<td class="nump">$ 4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">68,800,000<span></span>
</td>
<td class="nump">68,800,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Dec. 31, 2024</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2024</a></td>
<td class="nump">$ 561.7<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">(1,531.6)<span></span>
</td>
<td class="nump">2,092.2<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Equity [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation</a></td>
<td class="nump">44.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(80.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(80.8)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation', window );">Issuance of common stock under equity incentive plans (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation', window );">Issuance of common stock under equity incentive plans</a></td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common stock for pre-funded warrants (in shares)</a></td>
<td class="nump">3,422,186<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Share repurchases (Treasury Stock) (in shares)</a></td>
<td class="nump">10,009,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockValueAcquiredCostMethod', window );">Share repurchases (Treasury stock)</a></td>
<td class="num">$ (91.9)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (91.9)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent', window );">Unrealized gain on available-for-sale securities</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">63,500,000<span></span>
</td>
<td class="nump">73,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockCommonShares', window );">Ending balance (in shares) at Dec. 31, 2025</a></td>
<td class="nump">10,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000.0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Ending balance at Dec. 31, 2025</a></td>
<td class="nump">$ 433.9<span></span>
</td>
<td class="nump">$ 0.1<span></span>
</td>
<td class="num">$ (1,612.4)<span></span>
</td>
<td class="nump">$ 2,136.9<span></span>
</td>
<td class="nump">$ 1.2<span></span>
</td>
<td class="num">$ (91.9)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 810<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-19<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 20<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481231/810-10-45-20<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(3)<br> -SubTopic 10<br> -Topic 810<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-12<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.6-05(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-2<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(7))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 16: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480418/310-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockCommonShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of previously issued common shares repurchased by the issuing entity and held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockCommonShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockValueAcquiredCostMethod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockValueAcquiredCostMethod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>Statement of Stockholders' Equity [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts', window );">Issuance of common stock, offering costs</a></td>
<td class="nump">$ 17.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (80.8)<span></span>
</td>
<td class="num">$ (198.9)<span></span>
</td>
<td class="num">$ (367.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">3.0<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">4.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Net accretion of bond discounts/premiums</a></td>
<td class="num">(12.8)<span></span>
</td>
<td class="num">(21.8)<span></span>
</td>
<td class="num">(16.6)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss', window );">Loss on sale of marketable securities</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense', window );">Amortization of right-of-use assets</a></td>
<td class="nump">2.2<span></span>
</td>
<td class="nump">2.0<span></span>
</td>
<td class="nump">1.9<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostAmortization', window );">Amortization of collaboration contract asset</a></td>
<td class="nump">4.3<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">1.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Net loss on disposal of property, equipment and leasehold improvements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">44.0<span></span>
</td>
<td class="nump">88.2<span></span>
</td>
<td class="nump">71.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsReceivable', window );">Accounts receivable</a></td>
<td class="nump">4.7<span></span>
</td>
<td class="num">(5.7)<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherReceivables', window );">Other receivables</a></td>
<td class="nump">2.6<span></span>
</td>
<td class="num">(0.8)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="num">(7.0)<span></span>
</td>
<td class="nump">14.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset', window );">Collaboration contract asset</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(3.0)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable and accrued liabilities</a></td>
<td class="num">(1.7)<span></span>
</td>
<td class="num">(21.2)<span></span>
</td>
<td class="nump">17.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability', window );">Operating lease liabilities</a></td>
<td class="num">(2.0)<span></span>
</td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(2.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability', window );">Deferred revenue</a></td>
<td class="num">(242.6)<span></span>
</td>
<td class="num">(101.0)<span></span>
</td>
<td class="num">(74.6)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(273.8)<span></span>
</td>
<td class="num">(259.3)<span></span>
</td>
<td class="num">(347.8)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchase of marketable securities</a></td>
<td class="num">(354.2)<span></span>
</td>
<td class="num">(652.1)<span></span>
</td>
<td class="num">(956.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromMaturitiesOfMarketableSecurities', window );">Maturities of marketable securities</a></td>
<td class="nump">731.1<span></span>
</td>
<td class="nump">644.0<span></span>
</td>
<td class="nump">1,103.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromSaleOfMarketableSecurities', window );">Sale of marketable securities</a></td>
<td class="nump">32.6<span></span>
</td>
<td class="nump">44.5<span></span>
</td>
<td class="nump">58.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchase of property, equipment and leasehold improvements</a></td>
<td class="num">(1.9)<span></span>
</td>
<td class="num">(1.8)<span></span>
</td>
<td class="num">(2.9)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Proceeds from disposal of property, equipment and leasehold improvements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">407.6<span></span>
</td>
<td class="nump">34.7<span></span>
</td>
<td class="nump">203.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfLongTermDebt', window );">Repayments of long-term debt</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.4)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common stock and pre-funded warrants</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">387.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Payment of common stock offering costs</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(17.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRepurchaseOfCommonStock', window );">Repurchase of common shares, net</a></td>
<td class="num">(91.9)<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares', window );">Proceeds from exercise of stock options and issuance of ESPP shares</a></td>
<td class="nump">0.7<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash (used in) provided by financing activities</a></td>
<td class="num">(91.4)<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">374.7<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash, cash equivalents and restricted cash</a></td>
<td class="nump">42.4<span></span>
</td>
<td class="num">(216.7)<span></span>
</td>
<td class="nump">230.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, beginning of the period</a></td>
<td class="nump">100.5<span></span>
</td>
<td class="nump">317.2<span></span>
</td>
<td class="nump">86.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash, end of the period</a></td>
<td class="nump">142.9<span></span>
</td>
<td class="nump">100.5<span></span>
</td>
<td class="nump">317.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosure of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid', window );">Purchases of property, equipment and leasehold improvements unpaid at period end</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock And Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromMaturitiesOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from maturities of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromMaturitiesOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromSaleOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from sale of marketable securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromSaleOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalExpendituresIncurredButNotYetPaid">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future cash outflow to pay for purchases of fixed assets that have occurred.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalExpendituresIncurredButNotYetPaid</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -SubTopic 230<br> -Topic 830<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477401/830-230-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 912<br> -SubTopic 310<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478345/912-310-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in obligation for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -SubTopic 20<br> -Topic 842<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in receivables classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRepurchaseOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow to reacquire common stock during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRepurchaseOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-11<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfLongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfLongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock', window );">Nature of Business and Basis of Presentation</a></td>
<td class="text">Nature of Business and Basis of Presentation<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Nature of Business</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins. Arvinas, Inc. has four wholly owned subsidiaries; Arvinas Operations, Inc. formed in 2013, Arvinas Androgen Receptor, Inc. formed in 2015, Arvinas Estrogen Receptor, Inc. formed in 2016, and Arvinas Winchester, Inc. formed in 2018 (collectively, "Arvinas" or the "Company").</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and include the accounts of Arvinas, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated upon consolidation. The accounting policies used to prepare the Company's consolidated financial statements are the same as those used to prepare the consolidated financial statements in prior years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and notes. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements and notes are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the Company&#8217;s revenue recognition, uncertain tax positions and research and development expenses.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 205<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/205/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text">Summary of Significant Accounting Policies <span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents and are considered Level 1 financial instruments. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount which was canceled in connection with a lease termination agreement the Company entered into with 101 College Street LLC in August 2024.</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total amounts shown on the consolidated statements of cash flows for the years ended December 31, 2025, 2024 and 2023:</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">311.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protect its proprietary technology. If the Company does not successfully obtain regulatory approval for its product candidates, it will be unable to generate revenue from product sales or achieve profitability. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of assets and equity, proceeds from collaborations and a licensing arrangement, grant funding and debt financing. The Company had cash, cash equivalents and marketable securities of approximately $685.4 million as of December&#160;31, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company maintains its cash in financial institution accounts that may at times exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000. Cash may also be maintained at commercial institutions that are not insured by the FDIC. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, one collaborator represented 92.0%, 62.0% and 97% of the Company's revenue, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's marketable securities are classified as available-for-sale securities and are carried at their fair value based on the quoted market prices of the securities, with unrealized gains and losses reported as accumulated other comprehensive income (loss), a separate component of stockholders' equity. Realized gains and losses on available-for-sale securities are included in other income in the period earned or incurred. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Equipment, and Leasehold Improvements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from three years for office equipment to five years for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation is removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease and Rent Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases under Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use ("ROU") assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of the term of the lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the lease term unless there is reasonable certainty of renewal.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">similar term, in a similar economic environment. The Company's weighted average incremental borrowing rate at December&#160;31, 2025 totaled 7.0%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease payments are not included within the lease right-of-use asset and lease liability on the consolidated balance sheet, and instead are reflected as expense in the period they are incurred.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company monitors its long-lived assets for indicators of impairment. If such indicators are present, the Company assesses the recoverability of affected assets by determining whether the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found not to be recoverable, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, with the fair value generally determined based on the present value of the expected future cash flows associated with the assets. No such impairments were recorded during 2025, 2024 or 2023.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition and Deferred Revenue </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues from Contracts </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s revenue is primarily generated through research collaborations and licensing arrangements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Under ASC 606, the Company evaluates whether the license agreement, research and development services and participation in research and development steering committees represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent combined single performance obligations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also generated revenue through the sale of assets based on fair value.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research collaboration and license agreements may include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company continually assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized ratably over the Company&#8217;s expected performance period under each respective arrangement. Management makes its best estimate of the period over which the Company expects to fulfill its performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. Management evaluates changes in the duration of the performance period at each reporting period and adjusts revenue as necessary. Changes are accounted for prospectively as a change in accounting estimate. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, the transaction price allocated to the combined performance obligation identified under the individual research collaboration and license agreements was recognized as revenue on either a straight-line basis over the estimated performance period under the arrangement or over the estimated performance period based on the Company&#8217;s best estimate of costs to be incurred. Straight-line basis was considered the best measure of progress for certain agreements in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. For agreements accounted for under the costs to be incurred method, revenue is recognized as program costs are incurred by measuring actual costs incurred to date compared to the total expected costs to satisfy the performance obligations. Management evaluates estimates of expected costs to satisfy the performance obligations at each reporting period and adjusts revenue as necessary. Changes are accounted for prospectively as a change in accounting estimate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale, or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by customers from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liabilities in the Company&#8217;s accompanying consolidated balance sheets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses direct and incremental costs to obtaining and fulfilling a contract as and when incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as collaboration contract assets and amortized as general and administrative expenses over the total estimated period of performance of each underlying contract.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Method Investments </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Equity Method and Joint Ventures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company recognizes its pro-rata share of income and losses in the investment in &#8220;Loss from equity method investment&#8221; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment in the consolidated balance sheet until such investment is reduced to zero. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. The Company provides a valuation allowance to the extent that it is more likely than not that all or a portion of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the authoritative guidance under ASC 740 for recognizing and measuring uncertainty in income tax positions taken or expected to be taken in a tax return. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures employee and board of director equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards. Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies equity-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">401(k) Savings Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Under the 401(k) Plan, the Company made discretionary matching contributions on behalf of eligible employees </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">totaling $2.6&#160;million, $3.4&#160;million and $3.1&#160;million for the years ended December&#160;31, 2025, 2024 and 2023, respectively.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include (i) employee-related expenses, including salaries, benefits, stock-based compensation expense and travel; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites and consultants; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into consulting, research and other agreements with commercial entities, researchers, universities and others for the provision of goods and services. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#8217;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Inputs used in the valuation techniques to determine fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below, with Level 1 having the highest priority and Level 3 having the lowest. The three levels of the fair value hierarchy are as follows: </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;&#160;&#160;&#160;&#160;Inputs are based upon observable or quoted prices (unadjusted) for identical instruments traded in active markets. The Company&#8217;s Level 1 financial instruments consist of cash equivalents.</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;&#160;&#160;&#160;&#160;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#8217;s Level 2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;&#160;&#160;&#160;&#160;Inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models and similar techniques. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Common Share </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common shares.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average number of common shares included in the computation of basic and diluted net loss per common share gives effect to pre-funded warrants. See Note 9,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note 13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. </span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2023, the FASB issued ASU No. 2023-09, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted the new standard on January 1, 2025 and presented disclosures on a retrospective basis. The adoption of the standard did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In November 2024, the FASB issued ASU No. 2024-03, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," which requires disaggregation and disclosure of specified information about certain costs and expenses in the notes to the financial statements. The requirements of the ASU are effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact ASU No. 2024-03 will have on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/235/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract', window );"><strong>Research Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CollaborativeArrangementDisclosureTextBlock', window );">Research Collaboration and License Agreements</a></td>
<td class="text">Research Collaboration and License Agreements<div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Vepdegestrant (ARV-471) Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2021, the Company entered into a collaboration agreement with Pfizer (the &#8220;Vepdegestrant (ARV-471) Collaboration Agreement&#8221;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#8217;s proprietary compound vepdegestrant (the &#8220;Licensed Products&#8221;). Under the Vepdegestrant (ARV-471) Collaboration Agreement, the Company received an upfront, non-refundable payment of $650.0&#160;million. In addition, the Company will be eligible to receive up to an additional $1.4&#160;billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400.0&#160;million in regulatory milestones are related to marketing approvals and $1.0&#160;billion are related to sales-based milestones. There were no regulatory or sales-based milestone payments received through December&#160;31, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company and Pfizer share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company will be the marketing authorization applicant in the United States and, subject to approval, can book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In addition, in connection with the execution of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant (ARV-471)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Collaboration Agreement, the Company and Pfizer entered into a Stock Purchase Agreement (the "Pfizer Stock Purchase Agreement") for the sale and issuance of 3,457,815 shares of the Company&#8217;s common stock (the &#8220;Shares&#8221;) to Pfizer at a price of $101.22 per share, for an aggregate purchase price of $350.0&#160;million (the &#8220;Pfizer Equity Transaction&#8221;), less financial advisor fees of $4.6&#160;million, which was consummated in September 2021. Pursuant to terms of the Pfizer Stock Purchase Agreement, Pfizer has agreed not to sell or transfer the Shares without prior written approval of the Company for a specified time period, subject to specified exceptions.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant (ARV-471) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement and the Pfizer Equity Transaction entered into with Pfizer concurrently should be evaluated as a combined contract in accordance with Accounting Standards Codification (&#8220;ASC&#8221;) 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined the fair value of the shares sold under the Pfizer Equity Transaction to be $85.4&#160;million less than the contractual purchase price stipulated in the agreement. In accordance with the applicable accounting guidance in ASC 815-40, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Contracts in Entity&#8217;s Own Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company determined that the sale of stock should be recorded at fair value and therefore allocated the excess consideration received under the Pfizer Equity Transaction to the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant (ARV-471) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement, which, along with the non-refundable payment of $650.0&#160;million, is being recognized as revenue over the total estimated period of performance based on the Company&#8217;s best estimate of costs to be incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant (ARV-471) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $12.9&#160;million. In accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $12.9&#160;million in collaboration contract asset and other assets in the consolidated balance sheet, which is being amortized as general and administrative expense over the total estimated period of performance under the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Vepdegestrant (ARV-471) </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Collaboration Agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the Company announced that the Company and Pfizer have agreed to jointly select a third party for the commercialization and potential further development of vepdegestrant. The announcement did not have an effect on revenue recognition for the year ended December 31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Pfizer Research Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the "Pfizer Research Collaboration Agreement"). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in 2018 in exchange for use of the Company&#8217;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized over the total estimated period of performance. As of December&#160;31, 2025, there remains a single target under the Pfizer Research Collaboration Agreement, and, in accordance with the terms of such Agreement, the Company is eligible to receive up to an additional $3.8 million in non-refundable option payments if Pfizer exercises its option for such target protein under the Pfizer Research Collaboration Agreement. </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. There were no sales-based milestone payments or royalties received through December&#160;31, 2025.</span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Novartis License and Asset Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In April 2024, the Company entered into a transaction (the "Novartis Transaction"), including both a license agreement (the "Novartis License Agreement") and an asset purchase agreement (the "Novartis Asset Agreement") with Novartis Pharma AG ("Novartis") for the worldwide development, manufacture and commercialization of luxdegalutamide (ARV-766), the Company's second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer and for the sale of the Company's preclinical AR-V7 program. Under the terms of the agreements, Novartis is responsible for worldwide clinical development and commercialization of luxdegalutamide (ARV-766) and has all research, development, manufacturing, and commercialization rights with respect to the Company&#8217;s PROTAC protein degrader targeting AR-V7, a splice variant of the AR. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In May 2024, Novartis paid to the Company a one-time, upfront payment in the aggregate amount of $150.0&#160;million in accordance with the terms of the Novartis License Agreement and the Novartis Asset Agreement. Under the terms of the Novartis License Agreement, the Company is eligible to receive up to an additional $1.01&#160;billion as contingent payments based on specified development, regulatory and commercial milestones for luxdegalutamide (ARV-766) being met, as well as tiered royalties based on worldwide net sales of luxdegalutamide (ARV-766), subject to reduction under certain circumstances as provided in the Novartis License Agreement. During the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025, the Company recognized as revenue $20.0&#160;million upon the achievemen</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">t of a development m</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ilestone pursuant to the terms of the Novartis License </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Agreement. There were no development, regulatory or commercial milestone payments, or sales-based royalties received during the year ended December&#160;31, 2024.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Novartis License Agreement will continue on a country-by-country basis (or, in certain cases, a region-by-region basis) until the expiration of the applicable royalty term for such country (or region, as applicable). The Novartis License Agreement contains customary termination provisions, including that either party may terminate the Novartis License Agreement (a) upon the material breach of the other party or (b) in the event the other party experiences an insolvency event. Additionally, Novartis may terminate the Novartis License Agreement for convenience or upon a safety or regulatory issue.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determined that the Novartis License Agreement and the Novartis Asset Agreement entered into with Novartis concurrently should be accounted for as a combined contract in accordance with ASC 606, </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company determined the fair value of the assets sold under the Novartis Asset Agreement to be $20.0&#160;million, which was recognized at the time of sale as revenue</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and the fair value of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis License Agreement to be $130.0&#160;million, which was recognized as revenue over the total estimated period of performance during the technology transfer period, as defined in the agreement, based on the cost incurred input method. Under the Novartis License Agreement, Novartis will also reimburse the Company for development costs incurred during the technology transfer period, which will be recognized as revenue as costs are incurred. As of December 31, 2024, the technology transfer period ended as the Company completed the transition of its ongoing and planned clinical trials of luxdegalutamide (ARV-766) to Novartis.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a direct result of the Company&#8217;s entry into the Novartis Transaction, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $3.0&#160;million. In accordance with ASC 340, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Other Assets and Deferred Costs</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company recognized an asset of $3.0&#160;million in collaboration contract asset and other assets in the consolidated balance sheet at inception of the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis License Agreement and the Novartis Asset Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, which was amortized as general and administrative expense over the total estimated period of performance under the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Novartis License Agreement and the Novartis Asset Agreement</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Genentech Modification</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the "Genentech Modification") with Genentech, Inc. and F. Hoffman-La Roche Ltd (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Genentech Modification, the Company received upfront, non-refundable payments of $34.5 million (in addition to $11.0 million received under the previous agreement in 2015) to fund Genentech-related research. Upfront non-refundable payments were recognized as revenue over the total estimated period of performance, which concluded during the first quarter of 2023. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is eligible to receive up to $44.0 million per target in development milestone payments, $52.5 million in regulatory milestone payments and $60.0 million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received through December&#160;31, 2025.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Bayer Collaboration Agreement</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the "Bayer Collaboration Agreement") setting forth the Company&#8217;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras, or PROTAC targeted protein degraders, that mediate for degradation of target proteins ("Targets"), using the Company&#8217;s proprietary platform technology, which Targets were selected by Bayer AG, subject to certain exclusions and limitations. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $17.5 million in exchange for the use of the Company&#8217;s technology license. The Company also received an additional $12.0 million from Bayer AG from inception through 2023, including $1.5 million received during the year ended December 31, 2023. These payments were recognized over the total estimated period of performance.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to notice from Bayer AG in accordance with the terms of the Bayer Collaboration Agreement, the Bayer Collaboration Agreement was terminated effective August 12, 2024.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company was also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated Targets. In addition, the Company was eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which were subject to reductions. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There were no development or sales-based milestone payments or royalties received through August 12, 2024, the termination date of the agreement.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's contract balances were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(25.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts payable related to collaborations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(34.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(56.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">448.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">549.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">130.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(242.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(101.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances not held at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(130.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">205.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">448.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, the Company updated its estimate to satisfy the performance obligations under the Vepdegestrant (ARV-471) Collaboration Agreement due to the removal of the first-line Phase 3 combination trial with Pfizer&#8217;s novel investigational CDK4 inhibitor, atirmociclib, and the removal of the second-line Phase 3 combination trial with a CDK4/6 inhibitor from the development plan. The change in accounting estimate resulted in an increase in revenue of $150.2&#160;million, an increase in operating expenses of $2.6&#160;million, a decrease in net loss of $147.6&#160;million, and a decrease in basic and diluted loss per share of $2.08 for the year ended December 31, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2025, the Company also changed its estimate of the duration of the performance period under the Pfizer Research Collaboration Agreement as a result of updated research timelines. The change in accounting estimate resulted in a decrease of $6.6&#160;million in revenue, an increase in net loss, and an increase in basic and diluted loss per share of $0.09 for the year ended December 31, 2025. The reversed revenue will continue to be recognized in future periods as the Company continues to advance on the performance obligation under the updated collaboration timeline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company changed its estimate of the duration of the performance period under the Pfizer Research Collaboration Agreement as a result of updated research timelines. The changes in accounting estimate resulted in a decrease in revenue and an increase in net loss of $2.4&#160;million, respectively, and an increase in net loss per share of $0.03 for the year ended December 31, 2024. The reversed revenue will be recognized in subsequent periods as the Company continues to advance on the performance obligation under the updated collaboration timeline.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the fourth quarter of 2023, the Company had a change to its estimate to satisfy the performance obligations under the Vepdegestrant (ARV-471) Collaboration Agreement due to the expansion of the development programs. The changes in accounting estimate resulted in a decrease in revenue and increase in net loss of $35.0&#160;million, respectively, and an increase in net loss per share of $0.63 for the year ended December 31, 2023. The reversed revenue will continue to be recognized in future periods as the Company continues to advance on the performance obligation under the collaboration.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company also changed its estimate of the duration of the performance period under the Bayer Collaboration Agreement and Pfizer Research Collaboration Agreement as a result of updated research timelines. The changes in accounting estimate resulted in a decrease in revenue and an increase in net loss of $10.6&#160;million, respectively, and an increase in net loss per share of $0.19 for the year ended December 31, 2023. The reversed revenue was recognized in subsequent periods as the Company continued to advance on the performance obligation under the updated collaboration timelines.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of December&#160;31, 2025 totaled $205.6&#160;million, which is expected to be recognized in the following periods: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">114.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">205.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CollaborativeArrangementDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 808<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 808<br> -Publisher FASB<br> -URI https://asc.fasb.org/808/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CollaborativeArrangementDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Marketable Securities and Fair Value Measurements</a></td>
<td class="text">Marketable Securities and Fair Value Measurements<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available for sale marketable securities measured at fair value on a recurring basis.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hierarchy</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hierarchy</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The carrying value of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities approximate their </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">fair values due to the short-term nature of these assets and liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 107<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-107<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6A<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 940<br> -SubTopic 820<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478119/940-820-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property, Equipment and Leasehold Improvements</a></td>
<td class="text">Property, Equipment and Leasehold Improvements <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(28.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(25.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense totaled $3.0 million, $4.6 million, and $4.8 million for the years ended December&#160;31, 2025, 2024 and 2023, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2024, the Company wrote-off leasehold improvements totaling $2.4&#160;million resulting from the termination of the Terminated Lease, as discussed below in Note 6, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Right-of-Use Assets and Liabilities.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/360/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of Use Assets and Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Right of Use Assets and Liabilities</a></td>
<td class="text">Right-of-Use Assets and Liabilities<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2024, the Company entered into a Lease Termination Agreement with 101 College Street LLC (the "Landlord"). Under the terms of the Lease Termination Agreement, the lease, by and between the Company and the Landlord, dated May 4, 2021 (as amended, the "Terminated Lease"), for certain leased premises of approximately 160,000 square feet of laboratory and office space, was terminated in full, effective August 15, 2024. The leased premises were expected to be occupied by the Company in 2025. In connection with the Lease Termination Agreement and as consideration for the Landlord&#8217;s agreement to terminate the lease for its laboratory and office space at 101 College Street in full, the Company agreed to pay to the Landlord a one-time cash termination fee in the amount of $41.5&#160;million and wrote-off $1.9&#160;million of prepaid rent, both of which were recognized in general and administrative operating expenses on the consolidated statements of operations. The Company also cancelled its previously issued letter of credit in the amount of $5.5 million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has operating leases for its corpor</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ate office, laboratories and certain</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> equipment, which expire no later than December 2029. The leases have a weighted-average remaining term of 4.0 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In December 2024, the Company, entered into a Seventh Amendment and an Eighth Amendment to its lease (collectively the &#8220;Seventh and Eighth Building 5 Lease Amendments") with Science Park Development Corporation for certain premises in New Haven, Connecticut (the &#8220;Building 5 Premises&#8221;). The Seventh and Eighth Building 5 Lease Amendments extend the term of the original lease to December 31, 2029, resulting in an increase in the Company's ROU assets of $8.5&#160;million, and, effective on January 1 2025, expand the Building 5 Premises to include approximately 11,200 square feet of additional laboratory and office space resulting in an increase in the Company's ROU assets of $1.5&#160;million. The annual base rent during the extended term will range from $2.2&#160;million to $2.6&#160;million.</span></div><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of December&#160;31, 2025 were as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/842-20/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accounts Payable and Accrued Liabilities</a></td>
<td class="text">Accounts Payable and Accrued Liabilities <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative and commercial expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(24))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 720<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483384/720-30-45-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Long-Term Debt</a></td>
<td class="text">Long-Term Debt <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt obligations consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Assistance Agreement Debt</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current installments included within Accounts Payable and Accrued Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2018, the Company entered into an Assistance Agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. In September 2018, the Company borrowed $2.0&#160;million under the 2018 Assistance Agreement, of which $1.0&#160;million was forgiven by the State of Connecticut in April 2021 as the Company met certain employment conditions, as defined in the agreement. Borrowings under the 2018 Assistance Agreement bear an interest rate of 3.25% per annum, with interest-only payments required for the first 60 months, and mature in </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">September 2028</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028 with a default penalty of repayment of the full original funding amount of $2.0&#160;million plus liquidated damages of 7.5% of the total amount of funding received.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt as of December&#160;31, 2025 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the years ended December&#160;31, 2025, 2024 and 2023, interest expense was immaterial.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 405<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477092/405-40-50-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 470<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/470/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Equity</a></td>
<td class="text">Equity <div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Preferred Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025 and 2024, the Company had authorized 5,000,000 shares of preferred stock, at a $0.001 par value per share. Preferred stock may be issued in one or more series upon authorization of the Company's board of directors. The board of directors is authorized to fix the designations, powers, preferences and the relative, participating, optional or other special rights and any qualifications, limitations and restrictions of the shares of each series of preferred stock. The authorized shares of the Company's preferred stock are available for issuance without further action by the Company's stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Common Stock</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025 and 2024, the Company had authorized 200,000,000 shares of common stock, at a $0.001 par value per share. The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. The holders of shares of common stock are entitled to receive dividends, if and when declared by the board of directors. No dividends have been declared or paid by the Company since its inception.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company completed a private placement offering with certain institutional investors in which the Company issued and sold 12,963,542 shares of common stock at a price of $21.36 per share and, to one investor, in lieu of common stock, pre-funded warrants to purchase up to 3,422,380 shares of common stock at a price of $21.359 per pre-funded warrant. Each pre-funded warrant has an exercise price of $0.001 per share, is exercisable immediately and is exercisable until exercised in full. The aggregate gross </span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">proceeds from the issuance of common stock and pre-funded warrants totaled approximately $350.0&#160;million,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> before deducting placement agent fees and offering costs of approximately </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$15.9&#160;million</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of December 31, 2025, all outstanding</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pre-funded warrants had been cashless exercised for no consideration and the Company issued 3,422,186 shares of common stock to the holders.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Share Repurchase Program</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On September 17, 2025, the Company announced that its board of directors authorized and approved a share repurchase program for the repurchase of up to $100.0&#160;million of the then-currently outstanding shares of the Company&#8217;s common stock. Share repurchases under the share repurchase program may be made from time to time through a variety of methods, which may include open market purchases, privately negotiated block trades, accelerated share repurchases, other privately negotiated transactions or any combination of these methods. Repurchases may also be made under a Rule 10b5-1 plan, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws. The share repurchase program is funded using the Company's working capital. The share repurchase program has no time limit and can be modified, suspended or discontinued at any time without prior notice. Repurchased shares are recorded as treasury stock, at cost, and are eligible to be reissued under the Company's stock plans and for other corporate purposes.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, the Company repurchased 10,009,758 shares of its common stock, at an average price of $9.09 per share, for an aggregate purchase price of $91.0&#160;million, plus commissions and excise tax of $0.9&#160;million. As of December&#160;31, 2025, the Company has </span><span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%">suspended the program and has no further plans to repurchase additional shares</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Distribution Agreements</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In August 2021, the Company entered into an Equity Distribution Agreement with Piper Sandler &amp; Company (&#8220;Piper Sandler&#8221;) and Cantor Fitzgerald &amp; Co. (&#8220;Cantor&#8221;), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to $300.0&#160;million of the common stock registered under a universal shelf registration statement pursuant to one or more &#8220;at-the-market" offerings. During the year ended December 31, 2023, the Company issued 1,449,275 shares of common stock under this agreement resulting in gross proceeds of approximately $37.2&#160;million, less offering costs of approximately $1.1&#160;million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In November 2023, the Company amended and restated the Equity Distribution Agreement with Piper Sandler and Cantor, pursuant to which the Company may offer and sell from time to time, through the agents, up to approximately </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$262.8&#160;million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> of the common stock registered under a universal shelf registration statement pursuant to one or more &#8220;at-the-market&#8221; offerings. During the years ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025 and 2024</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, no shares were issued under this amended and restated agreement.</span></div><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Stock-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Employee Stock Purchase Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the "2018 ESPP"), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company's common stock. The number of shares of the Company's common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to 1% of the Company&#8217;s then-outstanding common stock, effective as of January 1 of each year. As of December&#160;31, 2025, 3,577,025 shares remained available for purchase. During the years ended December&#160;31, 2025, 2024 and 2023, the Company issued 110,412, 120,834 and 78,528 shares, respectively, of common stock under the 2018 ESPP.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">2018 Stock Incentive Plan</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2018, the Company&#8217;s board of directors adopted, and the Company&#8217;s stockholders approved, the 2018 Stock Incentive Plan (the "2018 Plan"), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#8217;s initial public offering. The number of common shares initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181 shares) issued in respect of incentive units granted under the Incentive Plan that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each year beginning with the year ended December 31, 2019 and continuing to, and including, the year ending December 31, 2028, equal to the lesser of 4,989,593 shares of the Company&#8217;s common stock, 4% of the number of shares of the Company&#8217;s common stock outstanding on the first day of the year or an amount determined by the Company&#8217;s board of directors. As of December&#160;31, 2025, 2,966,406 shares are available for issuance under the 2018 Plan. Common shares subject to outstanding equity awards that expire or are terminated, surrendered, or cancelled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Compensation Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In connection with the strategic restructuring actions initiated by the Company in the second and third quarters of 2025, as further discussed below in Note 14, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Restructuring Activity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, the Company modified the vesting terms of certain restricted stock units previously granted to employees. The incremental impact of the modification for the year ended December 31, 2025 totaled $5.3&#160;million, as a decrease to compensation expense.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, the Company recognized compensation expense of $44.0 million, $88.2&#160;million and $71.6 million, respectively, related to the issuance of incentive awards, including $0.5&#160;million, $0.7&#160;million and $0.8&#160;million, respectively, related to the 2018 ESPP.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As of December&#160;31, 2025, there was $30.4 million of compensation expense that is expected to be recognized over a weighted-average period of approximately 1.5 years.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Stock Options</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during each of the years ended December&#160;31, 2025, 2024 and 2023 was determined using the Black-Scholes option pricing model at the grant date with the following range of assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.1% - 80.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0% - 75.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.3% - 75.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 5.7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 - 5.5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 7.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7% - 4.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5% - 4.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4% - 4.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.61 - $17.70</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$24.19 - $47.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.21 - $36.27</span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Expected term is calculated based on the Company's historical experience.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December 31, 2023, the Company calculated volatility of its common stock by utilizing a weighted-average of a collection of peer company volatilities and its own common stock volatility as the Company&#8217;s common stock had not been trading for a sufficient period of time. The expected term was calculated utilizing the simplified method.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the 2018 Plan as of December&#160;31, 2025 is presented below. Included in the table are stock options granted to employees, directors and consultants under the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">except weighted-average exercise price)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term (Years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,892,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,515,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,631,075&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and exercisable as of December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,607,194&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and expected to vest as of December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,304,964&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2025, 2024 and 2023 was $8.15, $27.35 and $21.99, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2024 and 2023 was $3.6 million and $1.4 million, respectively. There were no options exercised during the year ended December&#160;31, 2025.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Restricted Stock Units</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit ("RSU") activity under the 2018 Plan for the year ended December&#160;31, 2025 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing 170,365 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested RSUs as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,311,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,253,564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(874,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested RSUs as of December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,624,051&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average grant date fair value of RSUs granted during the years ended December&#160;31, 2025, 2024 and 2023 was $12.34, $44.43 and $32.27, respectively. The total intrinsic value of RSUs released during the years ended December&#160;31, 2025, 2024 and 2023 was $17.7 million, $13.2 million and $4.3 million, respectively. The total fair value of RSUs vested during the years ended December&#160;31, 2025, 2024 and 2023 was $44.3 million, $13.1 million and $6.9 million, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract', window );"><strong>Equity Method Investments and Joint Ventures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock', window );">Equity Method Investments</a></td>
<td class="text">Equity Method Investments<div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In July 2019, the Company and Bayer CropScience LP ("Bayer LP") formed Oerth Bio, a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. Pursuant to the terms of the joint venture agreement, the Company made an in-kind intellectual property contribution to Oerth Bio in the form of a license to certain of the Company&#8217;s proprietary technology and Bayer LP committed and subsequently made cash contributions to Oerth Bio totaling $56.0&#160;million, as well as an in-kind intellectual property contribution. The Company and Bayer LP each held an initial ownership interest in Oerth Bio representing 50% of the ownership interests. A 15% ownership interest of Oerth Bio was </span></div><div style="margin-top:6pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled 42.9%, 43.6% and 45.0% as of December&#160;31, 2025, 2024 and 2023, respectively, as a result of vested incentive units.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Under the joint venture agreement, the Company has no obligation to provide additional funding and the Company&#8217;s ownership interest will not be diluted from future contributions from Bayer LP. The activities of Oerth Bio are controlled by a management board under the joint control of the Company and Bayer LP. As Oerth Bio is jointly controlled by the Company and Bayer LP, the Company accounts for its interest using the equity method of accounting. The Company determined that Oerth Bio is a variable interest entity and, accordingly, the Company has evaluated the significant activities of Oerth Bio under the variable interest entity model and concluded that the significant activities consist primarily of research and development activities and, as the Company does not have the sole power to direct such activities, the Company is not the primary beneficiary.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating expenses and net loss of Oerth Bio for the years ended December 31, 2025, 2024 and 2023 totaled </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$1.1 million</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, $3.7 million and $8.3 million, respectively. The Company recognized no equity method losses for the years ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025 and </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2024</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company recognized equity method losses of $2.5&#160;million for the year ended </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December 31, 2023</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. As of </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">December&#160;31, 2025</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and 2024, the Company&#8217;s carrying value of the investment was zero.</span></div><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also provides Oerth Bio with compensated research and development and administrative services through a separate agreement. The se</span>rvices rendered by the Company during the years ended December&#160;31, 2025, 2024 and 2023 were immaterial.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478156/740-323-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 323<br> -Publisher FASB<br> -URI https://asc.fasb.org/323/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text">Income Taxes <div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, income tax expense totaled </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.3&#160;million, $0.6&#160;million and $0.9&#160;million, respectively, and consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generated a taxable loss for the year ended December&#160;31, 2025 primarily due to losses from operations. The Company has not recorded any income tax benefits for the net operating losses incurred in the period due to its uncertainty of realizing a benefit from those items.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generated a taxable income for the year ended December 31, 2024 primarily due to the Novartis License Agreement, the Novartis Asset Agreement and the required capitalization of research and development expenses. The taxable income for federal purposes has been partially offset by losses from operations.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company generated a taxable loss for the year ended December 31, 2023 primarily due to losses from operations. The Company has not recorded any income tax benefits for the net operating losses incurred in the period due to its uncertainty of realizing a benefit from those items.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On July 4, 2025, H.R.1, commonly referred to as the One Big Beautiful Bill Act, was signed into law in the U.S., which includes a broad range of tax reform provisions, including extending and modifying certain key Tax Cuts and Jobs Act provisions, and provisions allowing accelerated tax deductions for qualified property and research expenditures. The tax impacts of this legislation do not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All of the Company&#8217;s losses before income taxes were generated in the United States.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2025, 2024 and 2023 were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:30.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Federal statutory tax rate</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State and local income taxes, net of federal income tax effect</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.6</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.9</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nontaxable or nondeductible items</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective tax rate</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the year ended December&#160;31, 2025, state and local income taxes in Connecticut, Massachusetts, and New York comprised the majority of the state and local income taxes, net of federal effect. For the year ended December&#160;31, 2024, state and local income taxes in Connecticut comprised the majority of the state and local income taxes, net of federal effect. For the year ended December&#160;31, 2023, state and local income taxes in New York comprised the majority of the state and local income taxes, net of federal effect.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes income taxes paid, net of refunds received for the years ended December&#160;31, 2025, 2024 and 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US federal &#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US state and local &#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York City</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income taxes paid, net of refunds received &#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The amount of income taxes paid during the year does not meet the 5% disaggregation threshold.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and tax reporting purposes. Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities were as follows as of December&#160;31, 2025 and 2024: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(471.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred income tax liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company has provided a valuation allowance against the full amount of the deferred tax assets since</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> it is more likely than not that the benefits will not be realized. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This assessment is based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">All, or a portion of, the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to utilize these potential tax benefits. The valuation allowance increased by $10.0 million and $63.5 million in 2025 and 2024, respectively, due to increases in net operating loss carryforwards, revenue recognition for tax purposes from the Vepdegestrant (ARV-471) Collaboration Agreement and the mandatory capitalization of qualified research and development costs in 2024.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company had $533.6&#160;million and $111.0 million of federal net operating loss carryforwards as of December&#160;31, 2025 and 2024, respectively. Federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such carryforwards is limited to 80% of the Company&#8217;s taxable income in the year in which carryforwards are used. The Company had $563.2 million and $129.0 million of state and local net operating loss carryforwards as of December&#160;31, 2025 and 2024, respectively, which expire at various dates beginning in 2035. The Company had $44.7 million and $37.7 million of federal tax credit carryforwards as of December&#160;31, 2025 and 2024, respectively. The Company had $22.3 million and $22.4 million of state tax credit carryforwards as of December&#160;31, 2025 and 2024, respectively, which expire at various dates beginning in 2035.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company has performed a Section 382 analysis through December 31, 2024 to determine whether an ownership change occurred for tax purposes. Based on this analysis, the Company determined that ownership changes occurred on July 31, 2018 and December 31, 2020 due to various equity offerings, vesting of restricted stock awards and stock option exercises. These ownership changes resulted in Section 382 limitations on the Company&#8217;s net operating loss and tax credit carryforwards generated before these dates. However, because the amount of the Section 382 limitations (including carryover of the unused Section 382 limitations and realized built-in gains) exceeds the amount of the Company&#8217;s carryforwards generated before these dates, the limitations will not affect the Company's ability to fully utilize these carryforwards.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company complies with the provisions of ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. As of December&#160;31, 2025 and 2024, the Company recorded net uncertain tax positions of $5.9 million and $5.4 million, respectively, relating primarily to state income tax filing positions in various jurisdictions. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's gross unrecognized tax benefits were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period balance - gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for tax positions taken during the current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period balance - gross</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense. The Company's accrual for interest and penalties as of December&#160;31, 2025 and 2024 totaled $1.6&#160;million and $1.0&#160;million, respectively.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is required to file income tax returns in the U.S. Federal and various state jurisdictions. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As a result of the Company&#8217;s net operating loss carryforwards, the Company&#8217;s federal and state statutes of limitations generally remain open for all tax years until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization. The Company is currently under federal income tax examination for the year ended December 31, 2023, and state income tax examination with the state of New York for the years ended December 31, 2021 through December 31, 2023.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477617/942-740-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 740<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478822/944-740-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12C<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12B<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 270<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477891/740-270-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.5.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480990/946-20-50-13<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/740/tableOfContent<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-14<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-21<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482603/740-30-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text">Commitments and Contingencies <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the&#160;ordinary&#160;course&#160;of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount, which could differ materially. Legal fees and other costs associated with such actions are expensed as incurred.&#160;As of December&#160;31, 2025, 2024 and 2023, the Company accrued zero, $5.0&#160;million and $15.2&#160;million, respectively, for such matters, related to the Amended License Agreement with Yale University ("Yale"), as further described below.</span></div><div style="margin-top:12pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Clinical and Preclinical Development and Licensing Arrangements</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%">In addition, under licensing and related arrangements to which the Company is a party, the Company may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Yale University License Agreement</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In June 2024, the Company entered into an Amended and Restated License Agreement (the &#8220;Amended License Agreement&#8221;) with Yale pursuant to which the parties amended and restated the license agreement dated July 5, 2013, as amended to date (the "Original Agreement"). In connection with the signing of the Amended License Agreement, the Company made a payment of $14.95&#160;million to Yale, comprising both an upfront payment connected to the Amended License Agreement and an amount related to the collaboration income under the Novartis License Agreement and Novartis Asset Agreement (see Note 3, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Research </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Collaboration and License Agreements,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for a description of the agreements</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company made another $5.0&#160;million payment in June 2025 on the first anniversary of signing. Thereafter, the Company will also pay to Yale (1) up to $15.0&#160;million if it secures approval of the first and second royalty products (as defined in the Amended License Agreement), (2) a low single digit percentage royalty on certain, more narrowly defined &#8220;collaboration products,&#8221; and (3) a lower single digit royalty on its aggregate worldwide net sales of certain newly defined &#8220;meaningfully involved products.&#8221; </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s obligations under the Original Agreement to pay Yale minimum annual royalties and certain other annual fees have been eliminated and Yale has agreed to release all claims arising previously under the Original Agreement. Other provisions of the Original Agreement remain materially unchanged under the Amended License Agreement, including the </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">requirement to pay to Yale a minimum license maintenance royalty totaling</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> $0.1 million per year until the first sale to a third party of any licensed product, followed by success-based milestones for the first two licensed products for the development of the protein degradation technologies totaling approximately $3.0&#160;million for the first licensed product and approximately $1.5&#160;million for the second licensed product, certain of which milestones have already been satisfied, and low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to minimum royalty payments that range from $0.2 million to $0.5 million. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During each of the years ended December&#160;31, 2025, 2024 and 2023, the Comp</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">any recognized expenses </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">under the license agreement totaling</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.7&#160;million, zero and $0.3&#160;million, respectively, under the license agreement. The payment made in the year ended December 31, 2024 included the payment made in connection with signing the Amended License Agreement, as summarized above.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 405<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/405-30/tableOfContent<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 450<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/450/tableOfContent<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 954<br> -SubTopic 440<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478522/954-440-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 440<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482648/440-10-50-4<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 440<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/440/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss Per Share</a></td>
<td class="text">Net Loss Per Share <div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share was calculated as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;- basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per common share<br/>&#160;- basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.77)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.62)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Treasury shares are not considered outstanding and are excluded from the calculation of basic and diluted loss per common share.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average number of common shares included in the computation of basic and diluted net loss per common share for the years ended December 31, 2024 and 2023 gave effect to pre-funded warrants which allowed holders to acquire a specified number of common shares at a nominal exercise price of </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.001</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> per share and were classified as equity. The shares underlying the pre-funded warrants were exercisable for little or no consideration and therefore the underlying shares were considered outstanding at the issuance of the pre-funded warrants for purposes of calculating the weighted-average number of common shares outstanding in basic and diluted net loss per share for common share. As of December&#160;31, 2025, all outstanding</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">pre-funded warrants had been cashless exercised for no consideration. See Note 9,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity.</span></div><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported net losses for each of the years ended December 31, 2025, 2024 and 2023, and therefore excluded all stock options and RSUs from the computation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(shares in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/260/tableOfContent<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>74
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Activity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesAbstract', window );"><strong>Restructuring and Related Activities [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock', window );">Restructuring Activity</a></td>
<td class="text">Restructuring Activity<div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the second quarter of 2025, the Company committed to and approved a reduction of the Company&#8217;s workforce by approximately 33% across all areas of the Company, as part of the Company&#8217;s decision to streamline operations across the organization and enable the efficient progression of the Company&#8217;s portfolio. This decision was made following a strategic review aimed at reducing internal costs while minimally impacting the Company's targeted clinical stage programs to drive value over the next several years by aligning the Company's operations with long-term program development objectives. As of June 30, 2025, these restructuring activities were substantially completed.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In September 2025, the Company announced an update on its collaboration with Pfizer and further actions to support value creation by optimizing organizational and cost structures and streamlining operations in advance of multiple anticipated upcoming value inflection points, including: further limiting additional expenditures on the vepdegestrant program supporting activities required for commercialization readiness and identification, with Pfizer, of a third party for the commercialization and potential further development of vepdegestrant; reducing the Company's workforce by an additional 15% to streamline operations, with the most significant reductions being roles related to vepdegestrant commercialization; and proactively managing pipeline cost by seeking strategic business development opportunities and by identifying further efficiencies across the business. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The September 2025 workforce reduction was substantially completed in the first quarter of 2026.</span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Components of Restructuring Charges</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">During the year ended December&#160;31, 2025, the Company recognized net restructuring charges of $3.7&#160;million, including $15.3&#160;million of cash severance and other one-time employee related termination benefit related to the workforce reduction, partially offset by a reversal of $11.6&#160;million of non-cash stock compensation and bonus expenses, of which $2.3&#160;million of charges are reflected in <span style="-sec-ix-hidden:f-937">research and development expenses</span> and $1.3&#160;million of a reversal of previously recognized expense reflected in <span style="-sec-ix-hidden:f-939">general and administrative expenses</span> in the accompanying consolidated statement of operations. The Company recognized no restructuring charges during the years ended December 31, 2024 and 2023.</span></div>The Company's restructuring accrual totaled $4.4&#160;million and zero as of December&#160;31, 2025 and 2024, respectively.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/420/tableOfContent<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingDisclosureTextBlock', window );">Segment Information</a></td>
<td class="text">Segment Information <div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's operations are organized into one operating and reportable segment focused on </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">the discovery, development and commercialization of therapies that degrade disease-causing proteins. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The segment develops protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing protein through the Company's PROTAC (PROteolysis TArgeting Chimera) protein degrader platform. The Company is progressing multiple product candidates through clinical development programs, including </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ARV-102, targeting the leucine-rich repeat kinase 2 protein for the treatment of neurodegenerative diseases; ARV-806, targeting Kirsten rat sarcoma G12D protein for cancers with the G12D mutation, including pancreatic, colorectal and non-small cell lung cancers; ARV-393, targeting the B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyQ-AR in skeletal muscle and specifically selected for potent </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">in vitro</span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div style="margin-top:6pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">reduction of cytosolic and nuclear polyQ-AR and for favorable skeletal muscle exposure following oral administration; and vepdegestrant, targeting the estrogen receptor for the treatment of locally advanced or metastatic ER positive / human epidermal growth factor receptor 2 negative breast cancer</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The Company's tangible assets are held in the United States and all of the Company's revenue has been generated in the United States. The Company manages all business activities on a consolidated basis. The Company's chief operating decision maker is the Chief Executive Officer. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The operating segment's revenue is primarily generated through research collaborations and licensing arrangements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Revenue is recognized ratably over the Company&#8217;s expected performance period under each respective arrangement. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also generated revenue through the sale of assets based on fair value. </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company does not have intra-entity sales or transfers.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The accounting policies of the operating segment are the same as those described in Note 2, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Summary of Significant Accounting Policies</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The chief operating decision maker evaluates the performance of the operating segment and allocates resources based on net income/ loss that also is reported on the consolidated income statement as net loss. The measure of the operating segment assets is reported on the consolidated balance sheet as total assets.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The chief operating decision maker uses net loss to monitor budget versus actual results and to analyze cash flows in assessing performance of the segment and allocating resources.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the reportable segment's financial information: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">262.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">263.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Program-specific external expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vepdegestrant (ARV-471) (*)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-102</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-806</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-393</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Bavdegalutamide (ARV-110)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Luxdegalutamide (ARV-766)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non program-specific external expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Compensation and related personnel expense</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(including stock-based compensation)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">145.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">134.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total research and development expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">285.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">348.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">379.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">95.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">165.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other segment expense, net (**)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Loss from equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Plus:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(80.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(198.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(367.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*)&#160;&#160;&#160;&#160;Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.</span></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(**)&#160;&#160;&#160;&#160;Includes loss on disposal of fixed assets, realized gains/ losses on sale of marketable securities and refundable research and development credits from the State of Connecticut.  </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Depreciation and amortization expense totaled $3.0 million, $4.6 million, and $4.8 million for the years ended December&#160;31, 2025, 2024 and 2023, respectively.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-21<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 31<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-31<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-15<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 13: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 14: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 16: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 17: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 34<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-34<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/280/tableOfContent<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Arrangements<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_TradingArrByIndTable', window );"><strong>Trading Arrangements, by Individual</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrAdoptedFlag', window );">Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrAdoptedFlag', window );">Non-Rule 10b5-1 Arrangement Adopted</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_Rule10b51ArrTrmntdFlag', window );">Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_NonRule10b51ArrTrmntdFlag', window );">Non-Rule 10b5-1 Arrangement Terminated</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_NonRule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_NonRule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_Rule10b51ArrTrmntdFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_Rule10b51ArrTrmntdFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_TradingArrByIndTable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection a<br> -Paragraph 2<br> -Subparagraph A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_TradingArrByIndTable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Insider Trading Policies and Procedures<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTradingPoliciesProcLineItems', window );"><strong>Insider Trading Policies and Procedures [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ecd_InsiderTrdPoliciesProcAdoptedFlag', window );">Insider Trading Policies and Procedures Adopted</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTradingPoliciesProcLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTradingPoliciesProcLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ecd_InsiderTrdPoliciesProcAdoptedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Number 229<br> -Section 408<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16<br> -Subsection J<br> -Paragraph a<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ecd_InsiderTrdPoliciesProcAdoptedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ecd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>78
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Cybersecurity Risk Management and Strategy Disclosure<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems', window );"><strong>Cybersecurity Risk Management, Strategy, and Governance [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock', window );">Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">We have processes for assessing, identifying and managing cybersecurity risks, which are built into our information technology function and are designed to provide protection for our information assets and operations from internal and external cyber threats, including protecting employee and patient information from unauthorized access or attack, as well as secure our networks and systems. These processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine reviews of our policies and procedures to identify risks and enhance our practices. As part of our overall risk mitigation strategy, we maintain cyber insurance coverage; however, such insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches. We have engaged external parties, including consultants, computer security firms and risk management, and legal and governance experts, to enhance our cybersecurity oversight. We also employ processes to identify material risks from cybersecurity threats associated with our use of third-party service providers.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Based on an assessment using the previously described risk mitigation strategy, we do not believe there are currently any risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. See &#8220;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Our internal computer systems and those of our collaborators, CROs, CDMOs contractors, consultants and other third parties are vulnerable to cyber attacks, cyber intrusions and security breaches, which could not only materially disrupt our business operations and result in the loss of confidential information, but could also damage the integrity of our clinical trials, impact our regulatory filings, compromise our ability to protect our intellectual property, and subject us to regulatory actions that could result in significant fines or other penalties&#8221;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> in Part I, Item 1A. &#8220;Risk Factors&#8221; for additional information.</span></div>In an effort to deter and detect cyber threats, we periodically provide our workforce, including all employees and contingent staff, with a privacy, data protection, cybersecurity and incident response, and prevention education and awareness program, which includes annual and supplemental training covering a range of timely and relevant topics. Past topics have included social engineering, phishing, password protection, confidential data protection, asset use, and mobile security. This education and awareness program functions to educate employees on the importance of reporting all incidents immediately. In addition, we perform monthly phishing test campaigns to reinforce identification and reporting training. We automatically assign online reinforcement training upon initial phish test failure and may follow-up one-on-one as needed, including providing additional training. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs. Lastly, we perform annual penetration tests conducted by independent, third-party cybersecurity firms and ongoing vulnerability assessments conducted by the internal security team<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag', window );">Cybersecurity Risk Management Processes Integrated [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock', window );">Cybersecurity Risk Management Processes Integrated [Text Block]</a></td>
<td class="text">We have processes for assessing, identifying and managing cybersecurity risks, which are built into our information technology function and are designed to provide protection for our information assets and operations from internal and external cyber threats, including protecting employee and patient information from unauthorized access or attack, as well as secure our networks and systems. These processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine reviews of our policies and procedures to identify risks and enhance our practices.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag', window );">Cybersecurity Risk Management Third Party Engaged [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag', window );">Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag', window );">Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock', window );">Cybersecurity Risk Board of Directors Oversight [Text Block]</a></td>
<td class="text">Our Audit Committee of our board of directors, or the Audit Committee, provides direct cybersecurity risk oversight, and provides regular updates to the board of directors regarding such oversight. The Audit Committee receives quarterly updates from management and the Cybersecurity Board, as discussed in further detail below, regarding cybersecurity matters, and is notified between such updates regarding significant new cybersecurity risks, threats or incidents. We also provide updates to the full board of directors regarding cybersecurity risks, threat landscape and risks, as appropriate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">Our Audit Committee of our board of directors, or the Audit Committee, provides direct cybersecurity risk oversight, and provides regular updates to the board of directors regarding such oversight.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock', window );">Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]</a></td>
<td class="text">The Audit Committee receives quarterly updates from management and the Cybersecurity Board, as discussed in further detail below, regarding cybersecurity matters, and is notified between such updates regarding significant new cybersecurity risks, threats or incidents. We also provide updates to the full board of directors regarding cybersecurity risks, threat landscape and risks, as appropriate.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskRoleOfManagementTextBlock', window );">Cybersecurity Risk Role of Management [Text Block]</a></td>
<td class="text">We have a cross-functional Cybersecurity Board led by our Senior Vice President, Information Technology Systems &amp; Security, or SVP ITSS, serving as the chair and consisting of executive-level and non-executive level leaders, including among others, our chief financial officer and general counsel. This board is responsible for reviewing, engaging and making decisions related to the execution and continuous improvement of cybersecurity strategy, processes and governance impacting our information systems, employees, partners and patients. Our SVP, ITSS, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Management Positions or Committees Responsible [Text Block]</a></td>
<td class="text">We have a cross-functional Cybersecurity Board led by our Senior Vice President, Information Technology Systems &amp; Security, or SVP ITSS, serving as the chair and consisting of executive-level and non-executive level leaders, including among others, our chief financial officer and general counsel.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock', window );">Cybersecurity Risk Management Expertise of Management Responsible [Text Block]</a></td>
<td class="text">Our SVP, ITSS, is an experienced senior leader with more than 25 years of experience in information technology within the pharmaceutical industry leading a team of employees and consultants with a breadth of experience including security management experience along with Certified Information Systems Security Professional, or CISSP certification.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock', window );">Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]</a></td>
<td class="text">This board is responsible for reviewing, engaging and making decisions related to the execution and continuous improvement of cybersecurity strategy, processes and governance impacting our information systems, employees, partners and patients. Our SVP, ITSS, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag', window );">Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]</a></td>
<td class="text">true<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph i<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskManagementThirdPartyEngagedFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskManagementThirdPartyEngagedFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 1<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br> -Subparagraph ii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskRoleOfManagementTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection c<br> -Paragraph 2<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection c<br> -Paragraph 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskRoleOfManagementTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-K<br> -Section 106<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Section 16K<br> -Subsection b<br> -Paragraph 1<br> -Subparagraph iii<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>cyd_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>i:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>79
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Basis of Presentation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company's consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and include the accounts of Arvinas, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated upon consolidation. The accounting policies used to prepare the Company's consolidated financial statements are the same as those used to prepare the consolidated financial statements in prior years.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConsolidationPolicyTextBlock', window );">Consolidation</a></td>
<td class="text">All intercompany transactions have been eliminated upon consolidation. The accounting policies used to prepare the Company's consolidated financial statements are the same as those used to prepare the consolidated financial statements in prior years.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The preparation of the Company&#8217;s consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and notes. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements and notes are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the Company&#8217;s revenue recognition, uncertain tax positions and research and development expenses.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Cash and Cash Equivalents </span></div>The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents and are considered Level 1 financial instruments.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Restricted Cash</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount which was canceled in connection with a lease termination agreement the Company entered into with 101 College Street LLC in August 2024.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk and Other Risks and Uncertainties</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Concentration of Credit Risk and Other Risks and Uncertainties</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company&#8217;s products and protect its proprietary technology. If the Company does not successfully obtain regulatory approval for its product candidates, it will be unable to generate revenue from product sales or achieve profitability. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of assets and equity, proceeds from collaborations and a licensing arrangement, grant funding and debt financing. The Company had cash, cash equivalents and marketable securities of approximately $685.4 million as of December&#160;31, 2025.</span></div>The Company maintains its cash in financial institution accounts that may at times exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000. Cash may also be maintained at commercial institutions that are not insured by the FDIC.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Marketable Securities </span></div>The Company's marketable securities are classified as available-for-sale securities and are carried at their fair value based on the quoted market prices of the securities, with unrealized gains and losses reported as accumulated other comprehensive income (loss), a separate component of stockholders' equity. Realized gains and losses on available-for-sale securities are included in other income in the period earned or incurred.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Equipment, and Leasehold Improvements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Property, Equipment, and Leasehold Improvements </span></div>Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from three years for office equipment to five years for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation is removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeasesPolicyTextBlock', window );">Lease and Rent Expense</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Lease and Rent Expense</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for leases under Accounting Standards Codification (&#8220;ASC&#8221;) 842, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Leases</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use ("ROU") assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of the term of the lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the lease term unless there is reasonable certainty of renewal.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a </span></div><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">similar term, in a similar economic environment. The Company's weighted average incremental borrowing rate at December&#160;31, 2025 totaled 7.0%.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Variable lease payments are not included within the lease right-of-use asset and lease liability on the consolidated balance sheet, and instead are reflected as expense in the period they are incurred.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock', window );">Impairment of Long-Lived Assets</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Impairment of Long-Lived Assets </span></div>The Company monitors its long-lived assets for indicators of impairment. If such indicators are present, the Company assesses the recoverability of affected assets by determining whether the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found not to be recoverable, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, with the fair value generally determined based on the present value of the expected future cash flows associated with the assets.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock', window );">Revenue Recognition and Deferred Revenue</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Revenue Recognition and Deferred Revenue </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues from Contracts </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company recognizes revenue under ASC 606, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Revenue from Contracts with Customers.</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> The Company&#8217;s revenue is primarily generated through research collaborations and licensing arrangements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Under ASC 606, the Company evaluates whether the license agreement, research and development services and participation in research and development steering committees represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent combined single performance obligations. </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company also generated revenue through the sale of assets based on fair value.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The research collaboration and license agreements may include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company continually assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Revenue is recognized ratably over the Company&#8217;s expected performance period under each respective arrangement. Management makes its best estimate of the period over which the Company expects to fulfill its performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. Management evaluates changes in the duration of the performance period at each reporting period and adjusts revenue as necessary. Changes are accounted for prospectively as a change in accounting estimate. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, the transaction price allocated to the combined performance obligation identified under the individual research collaboration and license agreements was recognized as revenue on either a straight-line basis over the estimated performance period under the arrangement or over the estimated performance period based on the Company&#8217;s best estimate of costs to be incurred. Straight-line basis was considered the best measure of progress for certain agreements in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. For agreements accounted for under the costs to be incurred method, revenue is recognized as program costs are incurred by measuring actual costs incurred to date compared to the total expected costs to satisfy the performance obligations. Management evaluates estimates of expected costs to satisfy the performance obligations at each reporting period and adjusts revenue as necessary. Changes are accounted for prospectively as a change in accounting estimate.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company&#8217;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale, or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by customers from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liabilities in the Company&#8217;s accompanying consolidated balance sheets. </span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company expenses direct and incremental costs to obtaining and fulfilling a contract as and when incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as collaboration contract assets and amortized as general and administrative expenses over the total estimated period of performance of each underlying contract.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentsPolicy', window );">Equity Method Investments</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity Method Investments </span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Investments &#8211; Equity Method and Joint Ventures</span>. The Company recognizes its pro-rata share of income and losses in the investment in &#8220;Loss from equity method investment&#8221; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment in the consolidated balance sheet until such investment is reduced to zero.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Income Taxes </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Accounting for Income Taxes</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. The Company provides a valuation allowance to the extent that it is more likely than not that all or a portion of the deferred tax assets will not be realized.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company follows the authoritative guidance under ASC 740 for recognizing and measuring uncertainty in income tax positions taken or expected to be taken in a tax return. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Equity-based Compensation</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Equity-based Compensation</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company measures employee and board of director equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards. Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company classifies equity-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#8217;s salary and related costs are classified or in which the award recipient&#8217;s service payments are classified.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DefinedContributionPlanPolicyPolicyTextBlock', window );">401(k) Savings Plan</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">401(k) Savings Plan</span></div>The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the &#8220;401(k) Plan&#8221;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expenses</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Research and Development Expenses</span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Research and development expenses include (i) employee-related expenses, including salaries, benefits, stock-based compensation expense and travel; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites and consultants; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company enters into consulting, research and other agreements with commercial entities, researchers, universities and others for the provision of goods and services. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#8217;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#8217;s estimates of the work performed under service agreements, milestones achieved and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.</span></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Fair Value Measurements </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Inputs used in the valuation techniques to determine fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below, with Level 1 having the highest priority and Level 3 having the lowest. The three levels of the fair value hierarchy are as follows: </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 1&#8212;&#160;&#160;&#160;&#160;Inputs are based upon observable or quoted prices (unadjusted) for identical instruments traded in active markets. The Company&#8217;s Level 1 financial instruments consist of cash equivalents.</span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 2&#8212;&#160;&#160;&#160;&#160;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#8217;s Level 2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. </span></div><div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Level 3&#8212;&#160;&#160;&#160;&#160;Inputs are generally unobservable and typically reflect management&#8217;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models and similar techniques. </span></div>In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Common Share</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Net Loss per Common Share </span></div><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common shares.</span></div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The weighted-average number of common shares included in the computation of basic and diluted net loss per common share gives effect to pre-funded warrants. See Note 9,</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"> Equity</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, and Note 13, </span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Net Loss Per Share</span>.<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements</a></td>
<td class="text"><div style="margin-top:18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%">New Accounting Pronouncements </span></div><div style="margin-top:6pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Adopted Accounting Pronouncements </span></div><div style="margin-top:12pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Taxes (Topic 740)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In December 2023, the FASB issued ASU No. 2023-09, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Improvements to Income Tax Disclosures</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted the new standard on January 1, 2025 and presented disclosures on a retrospective basis. The adoption of the standard did not have a material impact on the Company's consolidated financial statements.</span></div><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Recently Issued Accounting Pronouncements Not Yet Adopted</span></div><div style="margin-top:6pt;text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - In November 2024, the FASB issued ASU No. 2024-03, "</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Disaggregation of Income Statement Expenses</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">," which requires disaggregation and disclosure of specified information about certain costs and expenses in the notes to the financial statements. The requirements of the ASU are effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact ASU No. 2024-03 will have on its consolidated financial statements.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DefinedContributionPlanPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Defined Contribution Plan, Policy</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DefinedContributionPlanPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-21<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConsolidationPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481203/810-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConsolidationPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 21D<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-21D<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.CC)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 4<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482338/360-10-05-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-20<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-25<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(h)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-17<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-28<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeasesPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for leasing arrangement entered into by lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeasesPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477268/942-320-50-5<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-6<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -SubTopic 360<br> -Topic 958<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477798/958-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 05<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483044/730-10-05-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for revenue from contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 17<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-17<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 19<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-19<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-18<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-20<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483426/235-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/606/tableOfContent<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-5<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-3<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-4<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479953/718-10-S50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.C.Q3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.1.Q5)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.3.Q2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -Name Accounting Standards Codification<br> -Publisher FASB<br> -URI https://asc.fasb.org/718/tableOfContent<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-12<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-9<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482836/275-10-55-6<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-6<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-4<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -SubTopic 10<br> -Topic 275<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>80
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock', window );">Schedule of cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total amounts shown on the consolidated statements of cash flows for the years ended December 31, 2025, 2024 and 2023:</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">311.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock', window );">Schedule of restrictions on cash and cash equivalents</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total amounts shown on the consolidated statements of cash flows for the years ended December 31, 2025, 2024 and 2023:</span></div><div style="margin-top:6pt;text-indent:36pt"><span><br/></span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Cash and cash equivalents</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">311.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Restricted cash</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Cash, cash equivalents and restricted cash</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">317.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of cash and cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>81
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract', window );"><strong>Research Collaboration And License Agreements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock', window );">Schedule of Contract Balances</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's contract balances were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:67.990%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.053%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts receivable</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments received</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(25.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(6.7)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Accounts payable related to collaborations</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">46.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">48.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Payments made</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(34.9)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(56.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">16.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract assets: Collaboration contract asset</span></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Amortization</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(4.6)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Contract liabilities: Deferred revenue</span></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Beginning balance</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">448.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">549.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Additions to collaboration agreements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">130.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances held at the beginning of the period</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(242.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(101.0)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Revenue recognized from balances not held at the beginning of the period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(130.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Ending balance</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">205.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">448.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock', window );">Schedule of Transaction Price Allocated to Performance Obligations</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of December&#160;31, 2025 totaled $205.6&#160;million, which is expected to be recognized in the following periods: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">114.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">205.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of expected timing for satisfying remaining performance obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>82
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Disclosures [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock', window );">Schedule of Available-for-Sale Marketable Securities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following is a summary of the Company&#8217;s available for sale marketable securities measured at fair value on a recurring basis.</span></div><div style="margin-top:6pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2025</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hierarchy</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">528.0&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">529.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">13.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">541.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">542.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:31.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.085%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31, 2024</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Valuation </span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Hierarchy</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Amortized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Cost</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gains</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Gross</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Unrealized</span></div><div style="margin-top:0.75pt;text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%">Losses</span></div></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Fair <br/>Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Corporate bonds</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">934.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">935.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Government securities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Level 2</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">937.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.7&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.7)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">938.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-9<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aaa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>83
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property, Plant and Equipment [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Schedule of Property, Equipment and Leasehold Improvements</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Property, equipment and leasehold improvements consist of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Laboratory equipment</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">20.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Office equipment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">33.4&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">32.6&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: accumulated depreciation and amortization</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(28.2)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(25.6)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Property, equipment and leasehold improvements, net</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.2&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">7.0&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>84
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of Use Assets and Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeaseCostTableTextBlock', window );">Schedule of Components of Lease Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The components of lease expense were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December&#160;31,</span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating lease cost</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.9&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.1&#160;</span></td><td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock', window );">Schedule of Supplemental Cash Flow Information Related to Leases</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supplemental cash flow information related to leases was as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.263%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.557%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Cash paid for amounts included in the measurement of lease liabilities:</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#160;</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Operating cash flows from operating leases</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Supplemental non-cash information:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:0.75pt;padding-left:13.5pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">Right-of-use assets obtained in exchange for new lease obligations</span></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of Maturities of Operating Lease Liabilities</a></td>
<td class="text"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Maturities of operating lease liabilities as of December&#160;31, 2025 were as follows:</span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2029</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total lease payments</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">9.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: imputed interest</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(1.3)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.5&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental cash flow information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeaseCostTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeaseCostTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>85
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Schedule of Components of Accounts Payable and Accrued Liabilities</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Accounts payable and accrued liabilities consisted of the following: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accrued liabilities</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Research and development expenses</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">18.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">25.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Employee expenses</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">17.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">22.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Income taxes</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">General and administrative and commercial expenses</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">3.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">5.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Professional fees</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Accounts payable and accrued liabilities</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">69.5&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">71.8&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>86
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock', window );">Schedule of Long-Term Debt</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Debt obligations consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:36.475%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.051%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:14.054%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Maturity Date</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Interest Rate</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2018 Assistance Agreement Debt</span></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">09/28</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.25%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.8&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less: current installments included within Accounts Payable and Accrued Liabilities</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total long-term debt</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.4&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock', window );">Schedule of Minimum Future Payments on Long-Term Debt</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Minimum future principal payments on long-term debt as of December&#160;31, 2025 are as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:84.809%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.991%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2026</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2027</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2028</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDebtInstrumentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 470<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477734/942-470-50-3<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-8<br><br>Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-6<br><br>Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-7<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDebtInstrumentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of maturity and sinking fund requirement for long-term debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>87
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Share-Based Payment Arrangement [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The fair value of the stock options granted during each of the years ended December&#160;31, 2025, 2024 and 2023 was determined using the Black-Scholes option pricing model at the grant date with the following range of assumptions:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:39.960%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.021%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:2.678%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:16.024%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected volatility</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.1% - 80.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">72.0% - 75.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.3% - 75.0%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Expected term (years)</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 5.7</span></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.4 - 5.5</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.5 - 7.0</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Risk free interest rate</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.7% - 4.4%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.5% - 4.6%</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.4% - 4.8%</span></div></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Expected dividend yield</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Exercise price</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$6.61 - $17.70</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$24.19 - $47.00</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:right"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$16.21 - $36.27</span></div></td></tr></table></div><div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;Expected term is calculated based on the Company's historical experience.</span></div><div style="padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> &#160;&#160;&#160;&#160;Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Schedule of Stock Option Activity</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of the stock option activity under the 2018 Plan as of December&#160;31, 2025 is presented below. Included in the table are stock options granted to employees, directors and consultants under the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:40.112%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.994%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions, </span></div><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">except weighted-average exercise price)</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Options</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Exercise Price</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Remaining</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Contractual</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Term (Years)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Aggregate<br/>Intrinsic Value</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,892,330&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.16&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.7</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,253,860&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.41&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,515,115)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">46.07&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Outstanding as of December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,631,075&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">35.89&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.5</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and exercisable as of December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,607,194&#160;</span></td><td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44.41&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.3</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Vested and expected to vest as of December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8,304,964&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36.55&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">6.4</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock', window );">Schedule of Restricted Stock Grant Activity</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A summary of restricted stock unit ("RSU") activity under the 2018 Plan for the year ended December&#160;31, 2025 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing 170,365 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:69.506%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Shares</span></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Weighted-Average Grant</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Date</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Fair Value Per</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Share</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested RSUs as of December&#160;31, 2024</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2,311,291&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">42.25&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Granted</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,440,614&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.34&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Released</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,253,564)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">40.06&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Forfeited</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(874,290)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.81&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Unvested RSUs as of December&#160;31, 2025</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,624,051&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">18.59&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the changes in outstanding nonvested restricted stock shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Subparagraph (c)<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -SubTopic 10<br> -Topic 718<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (f)(2)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>88
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Tax Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock', window );">Schedule of Income Tax Expense</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the years ended December&#160;31, 2025, 2024 and 2023, income tax expense totaled </span><span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">$0.3&#160;million, $0.6&#160;million and $0.9&#160;million, respectively, and consisted of the following:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Year Ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.7)</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total current</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred:</span></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">U.S.:</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Federal</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">State and local</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A reconciliation of the U.S. federal statutory income tax rate to the Company&#8217;s effective income tax rate for the years ended December&#160;31, 2025, 2024 and 2023 were as follows: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"><tr><td style="width:1.0%"></td><td style="width:30.918%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.558%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.673%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:9.683%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></div></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Amount</span></div></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Percent</span></div></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">U.S. Federal statutory tax rate</span></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(41.6)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(76.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">21.0</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">State and local income taxes, net of federal income tax effect</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.1</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.3</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.6</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Tax credits</span></div></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development tax credit</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.8)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.5</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.1)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.6</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(28.0)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.6</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Changes in valuation allowance</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20.6</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">43.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(22.1</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">98.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.9</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Nontaxable or nondeductible items</span></div></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(9.3</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.2</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.1</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.2</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Effective tax rate</span></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.3</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">%)</span></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock', window );">Schedule of Income Tax Paid, Net of Refunds</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes income taxes paid, net of refunds received for the years ended December&#160;31, 2025, 2024 and 2023:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US federal &#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">US state and local &#160;</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">California</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Massachusetts</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New York City</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.5&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">New Jersey</span></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Pennsylvania</span></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="text-align:center"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*</span></div></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.0&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total income taxes paid, net of refunds received &#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.4)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11.1&#160;</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</span><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The amount of income taxes paid during the year does not meet the 5% disaggregation threshold.</span></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Income Tax Benefits and Liabilities</a></td>
<td class="text">Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities were as follows as of December&#160;31, 2025 and 2024: <div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:70.112%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.992%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred income tax assets:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Loss carryforwards</span></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Capitalized research and development</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">131.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">161.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred revenue</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">81.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">155.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Tax credits</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">62.1&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock compensation</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">60.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred income tax assets</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">482.3&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">472.8&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Deferred income tax liabilities:</span></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property, equipment and leasehold improvements</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total deferred income tax liabilities</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.4)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Less valuation allowance</span></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(481.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(471.4)</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net deferred income tax liability</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock', window );">Schedule of Unrecognized Tax Benefits</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Changes in the Company's gross unrecognized tax benefits were as follows:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Beginning of period balance - gross</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4.1&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Increases for tax positions taken during the current period</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End of period balance - gross</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</span></td><td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of supplemental cash flow information for the periods presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the change in unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>89
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock', window );">Schedule of Basic and Diluted Loss per Common Share</a></td>
<td class="text"><div style="margin-top:6pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Basic and diluted loss per common share was calculated as follows: </span></div><div style="margin-top:12pt;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars and shares in millions, except per common share amounts)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(80.8)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(198.9)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(367.3)</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Weighted-average common shares outstanding</span></div><div style="padding-left:9pt;text-indent:-9pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;- basic and diluted</span></div></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">70.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">71.9&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55.5&#160;</span></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net loss per common share<br/>&#160;- basic and diluted</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.14)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(2.77)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(6.62)</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Securities Excluded From Computation of Diluted Net Loss Per Common Share</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:34.7pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company reported net losses for each of the years ended December 31, 2025, 2024 and 2023, and therefore excluded all stock options and RSUs from the computation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:</span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:55.415%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.990%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.993%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">Year ended December 31,</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(shares in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Stock options</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.9&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">RSUs</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%">9.1&#160;</span></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>90
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2025</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock', window );">Schedule of Reportable Segment Financial Information</a></td>
<td class="text"><div style="margin-top:12pt;text-indent:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table summarizes the reportable segment's financial information: </span></div><div style="margin-top:12pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:58.142%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.081%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.406%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.084%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%">Years Ended December 31,</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%">(dollars in millions)</span></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2025</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2024</span></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%">2023</span></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Revenue</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">262.6&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">263.4&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">78.5&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Less:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Research and development expense</span></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Program-specific external expense:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-top:12pt;padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Vepdegestrant (ARV-471) (*)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">76.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">104.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-102</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">21.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-806</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.3&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">ARV-393</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">6.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Bavdegalutamide (ARV-110)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.7&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">8.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">26.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Luxdegalutamide (ARV-766)</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">19.7&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">24.2&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other programs</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">4.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Non program-specific external expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">49.1&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">62.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">72.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Compensation and related personnel expense</span></div><div style="padding-left:36pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(including stock-based compensation)</span></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">109.6&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">145.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">134.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Other research and development expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">11.0&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">12.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">13.8&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Total research and development expense</span></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">285.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">348.2&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">379.7&#160;</span></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="padding-left:12pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">General and administrative expense</span></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">95.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">165.4&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">100.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Other segment expense, net (**)</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.9&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">1.2&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Income tax expense</span></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.3&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.6&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">0.9&#160;</span></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Loss from equity method investment</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">&#8212;&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">2.5&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">Plus:</span></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%">Interest income, net</span></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38.4&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">54.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">38.8&#160;</span></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Segment net loss</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(80.8)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(198.9)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">$</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%">(367.3)</span></td><td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"><span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(*)&#160;&#160;&#160;&#160;Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.</span></div>(**)&#160;&#160;&#160;&#160;Includes loss on disposal of fixed assets, realized gains/ losses on sale of marketable securities and refundable research and development credits from the State of Connecticut.<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 25<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>91
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of Business and Basis of Presentation (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2025 </div>
<div>subsidiary</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Organization, Consolidation and Presentation of Financial Statements [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_NumberOfWhollyOwnedSubsidiaries', window );">Number of wholly owned subsidiaries</a></td>
<td class="nump">4<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NumberOfWhollyOwnedSubsidiaries">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of wholly owned subsidiaries.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NumberOfWhollyOwnedSubsidiaries</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>92
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Cash Reconciliation (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 142.9<span></span>
</td>
<td class="nump">$ 100.5<span></span>
</td>
<td class="nump">$ 311.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashCurrent', window );">Restricted cash</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash, cash equivalents and restricted cash</a></td>
<td class="nump">$ 142.9<span></span>
</td>
<td class="nump">$ 100.5<span></span>
</td>
<td class="nump">$ 317.2<span></span>
</td>
<td class="nump">$ 86.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483467/210-10-45-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 24<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-24<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>93
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities', window );">Cash, cash equivalents, restricted cash and marketable securities</a></td>
<td class="nump">$ 685,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Operating lease, weighted average discount rate, percent</a></td>
<td class="nump">7.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment of long lived assets</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanCostRecognized', window );">Discretionary matching contributions</a></td>
<td class="nump">2,600,000<span></span>
</td>
<td class="nump">$ 3,400,000<span></span>
</td>
<td class="nump">$ 3,100,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense', window );">Federal deposit insurance corporation premium expense</a></td>
<td class="nump">$ 250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property and equipment, estimated useful life</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember', window );">Customer Concentration Risk | Revenue | Collaborator One</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems', window );"><strong>Summary Of Significant Accounting Policies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskPercentage1', window );">Concentration risk, percentage</a></td>
<td class="nump">92.00%<span></span>
</td>
<td class="nump">62.00%<span></span>
</td>
<td class="nump">97.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash, Cash Equivalents, Restricted Cash and Marketable Securities</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_SummaryOfSignificantAccountingPoliciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Summary of significant accounting policies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_SummaryOfSignificantAccountingPoliciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskPercentage1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the "benchmark" (or denominator) in the equation, this concept represents the concentration percentage derived from the division.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 20<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-20<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 275<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482861/275-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskPercentage1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanCostRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost for defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 715<br> -SubTopic 70<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480794/715-70-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanCostRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FederalDepositInsuranceCorporationPremiumExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FederalDepositInsuranceCorporationPremiumExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482130/360-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByTypeAxis=us-gaap_CustomerConcentrationRiskMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskByBenchmarkAxis=us-gaap_SalesRevenueNetMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorOneMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_CollaboratorOneMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>94
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Additional Information (Details) - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="3">1 Months Ended</th>
<th class="th" colspan="1">4 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2021</div></th>
<th class="th"><div>Jul. 31, 2021</div></th>
<th class="th"><div>Nov. 30, 2017</div></th>
<th class="th"><div>Dec. 31, 2015</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Dec. 31, 2018</div></th>
<th class="th"><div>May 31, 2024</div></th>
<th class="th"><div>Apr. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2019</div></th>
<th class="th"><div>Dec. 31, 2017</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 205.6<span></span>
</td>
<td class="nump">$ 448.2<span></span>
</td>
<td class="nump">$ 549.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">205.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued, net of issuance costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.8<span></span>
</td>
<td class="nump">8.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">262.6<span></span>
</td>
<td class="nump">263.4<span></span>
</td>
<td class="nump">78.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">381.1<span></span>
</td>
<td class="nump">513.6<span></span>
</td>
<td class="nump">480.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (80.8)<span></span>
</td>
<td class="num">$ (198.9)<span></span>
</td>
<td class="num">$ (367.3)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
<td class="num">$ (6.62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
<td class="num">$ (6.62)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_UpdatedResearchTimelinesMember', window );">Updated Research Timelines</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (6.6)<span></span>
</td>
<td class="num">$ (2.4)<span></span>
</td>
<td class="num">$ (10.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 6.6<span></span>
</td>
<td class="num">$ (2.4)<span></span>
</td>
<td class="num">$ (10.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.09<span></span>
</td>
<td class="nump">$ 0.03<span></span>
</td>
<td class="nump">$ 0.19<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_ExpansionOfDevelopmentProgramsMember', window );">Expansion of Development Programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (35.0)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.63<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_RemovalOfCombinationTrialsMember', window );">Removal Of Combination Trials</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 147.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.08<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of issuance costs (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_NovartisPharmaAGMember', window );">Novartis Pharma AG | License</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Contract with customer, liability</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 150.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_RevenueRemainingPerformanceObligationContingentPayments', window );">Contingent payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,010.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax', window );">Revenue recognized</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 20.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CapitalizedContractCostGross', window );">Capitalized costs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 28.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Collaboration Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract', window );">Collaboration agreement direct and incremental costs incurred</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborationContractAssetAndOtherAssets', window );">Collaboration contract asset and other assets</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">12.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Regulatory Milestone Related to Marketing Approvals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Sales-based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Stock Purchase Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">650.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SaleOfStockFairValueOfSharesSold', window );">Fair value of the shares sold</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">85.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Stock Purchase Agreement | Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of issuance costs (in shares)</a></td>
<td class="nump">3,457,815<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Share price, issued and sold (in usd per share)</a></td>
<td class="nump">$ 101.22<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued, net of issuance costs</a></td>
<td class="nump">$ 350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForBrokerageFees', window );">Financial advisor fees</a></td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Maximum | Regulatory and Sales Based Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,400.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Maximum | Option Payments To License Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Maximum | Sales-based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">550.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember', window );">Pfizer, Inc. | Maximum | Development Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 225.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer | Research Funding Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer | Maximum | Sales-based Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">490.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerAGMember', window );">Bayer | Maximum | Development Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 197.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromCollaborators', window );">Payments received</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 34.5<span></span>
</td>
<td class="nump">$ 11.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech | Regulatory Milestone Related to Marketing Approvals</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">52.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech | Commercial Milestones</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">60.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember', window );">Genentech | Maximum | Development Milestone Payments</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems', window );"><strong>Research Collaboration And License Agreements [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Contract revenue receivable if milestones achieved</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborationContractAssetAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaboration Contract Asset And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborationContractAssetAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DirectAndIncrementalCostsIncurredToObtainTheContract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Direct And Incremental Costs Incurred To Obtain The Contract</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DirectAndIncrementalCostsIncurredToObtainTheContract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchCollaborationAndLicenseAgreementsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research collaboration and license agreements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchCollaborationAndLicenseAgreementsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_RevenueRemainingPerformanceObligationContingentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Revenue, Remaining Performance Obligation, Contingent Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_RevenueRemainingPerformanceObligationContingentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_SaleOfStockFairValueOfSharesSold">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sale of stock, fair value of shares sold.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_SaleOfStockFairValueOfSharesSold</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CapitalizedContractCostGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 340<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479483/340-40-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CapitalizedContractCostGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForBrokerageFees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for brokerage fees during the current period. This element is intended to represent the brokerage fees paid by and between financial industry participants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForBrokerageFees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromCollaborators">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash received from collaborators during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromCollaborators</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-7<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 924<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 11.L)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479941/924-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 5<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-5<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_UpdatedResearchTimelinesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_UpdatedResearchTimelinesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_ExpansionOfDevelopmentProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_ExpansionOfDevelopmentProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_RemovalOfCombinationTrialsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ChangeInAccountingEstimateByTypeAxis=arvn_RemovalOfCombinationTrialsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_NovartisPharmaAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_NovartisPharmaAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=us-gaap_LicenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=us-gaap_LicenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PfizerIncorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_CollaborationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_CollaborationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_RegulatoryMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_StockPurchaseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_StockPurchaseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_RegulatoryAndSalesBasedMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_RegulatoryAndSalesBasedMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_OptionPaymentsToLicenseAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SalesBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_DevelopmentMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerAGMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerAGMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_ResearchFundingPaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_CommercialMilestonesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>95
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Schedule of Contract Balances (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward', window );"><strong>Accounts receivable</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Beginning balance</a></td>
<td class="nump">$ 5.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions', window );">Additions</a></td>
<td class="nump">21.1<span></span>
</td>
<td class="nump">12.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived', window );">Payments received</a></td>
<td class="num">(25.8)<span></span>
</td>
<td class="num">(6.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsReceivableNetCurrent', window );">Ending balance</a></td>
<td class="nump">1.0<span></span>
</td>
<td class="nump">5.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward', window );"><strong>Accounts payable related to collaborations</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrent', window );">Beginning balance</a></td>
<td class="nump">5.3<span></span>
</td>
<td class="nump">13.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrentAdditions', window );">Additions</a></td>
<td class="nump">46.4<span></span>
</td>
<td class="nump">48.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrentPayments', window );">Payments made</a></td>
<td class="num">(34.9)<span></span>
</td>
<td class="num">(56.7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccountsPayableContractBalancesCurrent', window );">Ending balance</a></td>
<td class="nump">16.8<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward', window );"><strong>Contract assets: Collaboration contract asset</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Beginning balance</a></td>
<td class="nump">7.8<span></span>
</td>
<td class="nump">9.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements', window );">Additions</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">3.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CapitalizedContractCostAmortizationDuringPeriod', window );">Amortization</a></td>
<td class="num">(4.3)<span></span>
</td>
<td class="num">(4.6)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerAssetNet', window );">Ending balance</a></td>
<td class="nump">3.5<span></span>
</td>
<td class="nump">7.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ChangeInContractWithCustomerLiabilityRollForward', window );"><strong>Contract liabilities: Deferred revenue</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Beginning balance</a></td>
<td class="nump">448.2<span></span>
</td>
<td class="nump">549.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements', window );">Additions to collaboration agreements</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">130.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized', window );">Revenue recognized from balances held at the beginning of the period</a></td>
<td class="num">(242.6)<span></span>
</td>
<td class="num">(101.0)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration', window );">Revenue recognized from balances not held at the beginning of the period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(130.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ContractWithCustomerLiability', window );">Ending balance</a></td>
<td class="nump">$ 205.6<span></span>
</td>
<td class="nump">$ 448.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsPayableContractBalancesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Contract Balances, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsPayableContractBalancesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsPayableContractBalancesCurrentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Contract Balances, Current Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsPayableContractBalancesCurrentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsPayableContractBalancesCurrentPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Payable, Contract Balances, Current Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsPayableContractBalancesCurrentPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, After Allowance For Credit Loss, Current, Additions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CapitalizedContractCostAmortizationDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Capitalized Contract Cost, Amortization During Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CapitalizedContractCostAmortizationDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Accounts Payable, after Allowance for Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Accounts Receivable, after Allowance for Credit Loss</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Collaboration Contract Asset And Other Assets</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ChangeInContractWithCustomerLiabilityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Change in Contract with Customer, Liability</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ChangeInContractWithCustomerLiabilityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contract with Customer, Liability, Revenue Recognized From New Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsReceivableNetCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 310<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481990/310-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsReceivableNetCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerAssetNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-3<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerAssetNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-11<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479837/606-10-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ContractWithCustomerLiabilityRevenueRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 606<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-8<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ContractWithCustomerLiabilityRevenueRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>96
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Research Collaboration and License Agreements - Schedule of Transaction Price Allocated to Performance Obligations (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 205.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2026-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 71.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2027-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 20.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2028-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligation', window );">Revenue, remaining performance obligation</a></td>
<td class="nump">$ 114.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2029-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2029-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2030-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2030-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2031-01-01', window );">Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2031-01-01</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems', window );"><strong>Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1', window );">Revenue, remaining performance obligation, expected timing of satisfaction, period</a></td>
<td class="text">1 year<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transaction price allocated to performance obligation that has not been recognized as revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)(1)<br> -SubTopic 10<br> -Topic 606<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479806/606-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2026-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2027-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2028-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2029-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2029-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2030-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2030-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2031-01-01">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis=2031-01-01</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>97
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Marketable Securities and Fair Value Measurements (Details) - Level 2 - Fair Value, Measurements, Recurring - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">$ 541.3<span></span>
</td>
<td class="nump">$ 937.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.2<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">542.5<span></span>
</td>
<td class="nump">938.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">528.0<span></span>
</td>
<td class="nump">934.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">1.1<span></span>
</td>
<td class="nump">1.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="num">(0.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">529.1<span></span>
</td>
<td class="nump">935.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member', window );">Government securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems', window );"><strong>Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis', window );">Amortized Cost</a></td>
<td class="nump">13.3<span></span>
</td>
<td class="nump">3.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gains</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Losses</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities', window );">Fair Value</a></td>
<td class="nump">$ 13.4<span></span>
</td>
<td class="nump">$ 3.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -SubTopic 10<br> -Topic 825<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-10<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482736/825-10-45-1A<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-11<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-10<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482881/825-10-55-12<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 103<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-103<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (aa)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481800/320-10-50-2<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 326<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479130/326-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 100<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482078/820-10-55-100<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 820<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482106/820-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementFrequencyAxis=us-gaap_FairValueMeasurementsRecurringMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateBondSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>98
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and leasehold improvements</a></td>
<td class="nump">$ 33.4<span></span>
</td>
<td class="nump">$ 32.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(28.2)<span></span>
</td>
<td class="num">(25.6)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property, equipment and leasehold improvements, net</a></td>
<td class="nump">5.2<span></span>
</td>
<td class="nump">7.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember', window );">Laboratory equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and leasehold improvements</a></td>
<td class="nump">21.3<span></span>
</td>
<td class="nump">20.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and leasehold improvements</a></td>
<td class="nump">9.1<span></span>
</td>
<td class="nump">9.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember', window );">Office equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Total property, equipment and leasehold improvements</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 2.7<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 360<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 360<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 360<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478451/942-360-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=arvn_LaboratoryEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_OfficeEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>99
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property, Equipment and Leasehold Improvements - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_A101CollegeStreetLLCMember', window );">101 College Street LLC | Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property Plant And Equipment [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PropertyPlantAndEquipmentWriteoff', window );">Leasehold improvement written-off</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PropertyPlantAndEquipmentWriteoff">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Property, Plant And Equipment, Writeoff</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PropertyPlantAndEquipmentWriteoff</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_A101CollegeStreetLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_A101CollegeStreetLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>100
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of Use Assets and Liabilities - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Aug. 15, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>ft&#178;</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 31, 2021 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>May 04, 2021 </div>
<div>ft&#178;</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LandSubjectToGroundLeases', window );">Lease for laboratory and office space (in sq feet) | ft&#178;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">160,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Operating lease, weighted average remaining lease term (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new lease obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PledgedStatusAxis=us-gaap_AssetPledgedAsCollateralMember', window );">Asset Pledged as Collateral | Letter of Credit</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecurities', window );">Debt securities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ContractTerminationAxis=arvn_OneTimeCashTerminationFeeMember', window );">One-Time Cash Termination Fee</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Lease termination costs</a></td>
<td class="nump">$ 41.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ContractTerminationAxis=arvn_WriteoffOfPrepaidRentMember', window );">Writeoff Of Prepaid Rent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeLeaseDescriptionLineItems', window );"><strong>Lessee Lease Description [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnContractTermination', window );">Lease termination costs</a></td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-14<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 80<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480078/944-80-55-9<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 320<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481830/320-10-45-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(1)(6))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnContractTermination">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnContractTermination</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LandSubjectToGroundLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area of land subject to a ground lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LandSubjectToGroundLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:areaItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeLeaseDescriptionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeLeaseDescriptionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgedStatusAxis=us-gaap_AssetPledgedAsCollateralMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgedStatusAxis=us-gaap_AssetPledgedAsCollateralMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PledgingPurposeAxis=us-gaap_LetterOfCreditMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractTerminationAxis=arvn_OneTimeCashTerminationFeeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractTerminationAxis=arvn_OneTimeCashTerminationFeeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ContractTerminationAxis=arvn_WriteoffOfPrepaidRentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ContractTerminationAxis=arvn_WriteoffOfPrepaidRentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>101
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of Use Assets and Liabilities - Schedule of Components of Lease Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseCost', window );">Operating lease cost</a></td>
<td class="nump">$ 2.9<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 2.1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>102
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract', window );"><strong>Cash paid for amounts included in the measurement of lease liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows from operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="nump">$ 1.9<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract', window );"><strong>Supplemental non-cash information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-of-use assets obtained in exchange for new lease obligations</a></td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 1.5<span></span>
</td>
<td class="nump">$ 8.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cash paid for amounts included in the measurement of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_SupplementalNonCashInformationRelatedToLeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental non-cash information related to leases.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_SupplementalNonCashInformationRelatedToLeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-5<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 53<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479589/842-20-55-53<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>103
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)<br> $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 2.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2027</a></td>
<td class="nump">2.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2028</a></td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2029</a></td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total lease payments</a></td>
<td class="nump">9.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: imputed interest</a></td>
<td class="num">(1.3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Total</a></td>
<td class="nump">$ 8.5<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478964/842-20-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 842<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479041/842-20-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>104
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accounts Payable and Accrued Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PayablesAndAccrualsAbstract', window );"><strong>Payables and Accruals [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">$ 24.4<span></span>
</td>
<td class="nump">$ 13.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract', window );"><strong>Accrued liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccruedResearchAndDevelopmentExpenseCurrent', window );">Research and development expenses</a></td>
<td class="nump">18.2<span></span>
</td>
<td class="nump">25.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Employee expenses</a></td>
<td class="nump">17.5<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedIncomeTaxesCurrent', window );">Income taxes</a></td>
<td class="nump">4.8<span></span>
</td>
<td class="nump">3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent', window );">General and administrative and commercial expenses</a></td>
<td class="nump">3.7<span></span>
</td>
<td class="nump">5.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Professional fees</a></td>
<td class="nump">0.9<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent', window );">Accounts payable and accrued liabilities</a></td>
<td class="nump">$ 69.5<span></span>
</td>
<td class="nump">$ 71.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued General And Administrative And Commercial, Current</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AccruedResearchAndDevelopmentExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accrued research and development expense current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AccruedResearchAndDevelopmentExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(19)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 852<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481372/852-10-55-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedIncomeTaxesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedIncomeTaxesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PayablesAndAccrualsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PayablesAndAccrualsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>105
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Long Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Interest Rate</a></td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtCurrent', window );">Less: current installments included within Accounts Payable and Accrued Liabilities</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="num">(0.2)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtNoncurrent', window );">Total long-term debt</a></td>
<td class="nump">$ 0.4<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>106
<FILENAME>R54.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Long-Term Debt - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Apr. 30, 2021</div></th>
<th class="th"><div>Sep. 30, 2018</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument bearing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember', window );">2018 Assistance Agreement | State of Connecticut</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentLineItems', window );"><strong>Debt Instrument [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Debt instrument face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DebtInstrumentLoanForgiveness', window );">Loan forgiveness</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentInterestRateStatedPercentage', window );">Debt instrument bearing interest rate</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3.25%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_DebtInstrumentInterestPaymentsTerm', window );">Debt instrument interest payments term (in months)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">60 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PercentageOfLiquidatedDamages', window );">Percentage of liquidated damages</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">7.50%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentInterestPaymentsTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt instrument interest payments term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentInterestPaymentsTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_DebtInstrumentLoanForgiveness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Debt Instrument Loan Forgiveness</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_DebtInstrumentLoanForgiveness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PercentageOfLiquidatedDamages">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of liquidated damages.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PercentageOfLiquidatedDamages</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentInterestRateStatedPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contractual interest rate for funds borrowed, under the debt agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22)(a)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentInterestRateStatedPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69E<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69E<br><br>Reference 12: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69F<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69F<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 15: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1F<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1F<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I<br><br>Reference 30: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482925/835-30-45-2<br><br>Reference 31: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482900/835-30-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentAxis=arvn_TwoThousandAndEighteenAssistanceAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StatementGeographicalAxis=stpr_CT">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StatementGeographicalAxis=stpr_CT</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>107
<FILENAME>R55.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Debt Disclosure [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths', window );">2026</a></td>
<td class="nump">$ 0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo', window );">2027</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree', window );">2028</a></td>
<td class="nump">0.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Total</a></td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -SubTopic 10<br> -Topic 210<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 835<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482949/835-30-55-8<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69B<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 69C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481568/470-20-55-69C<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1D<br><br>Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 944<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16)(a)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-4<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.12-04(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-3<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -SubTopic 10<br> -Topic 470<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481544/470-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>108
<FILENAME>R56.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Additional Information (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="4">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Nov. 30, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 30, 2018 </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2019 </div>
<div>shares</div>
</th>
<th class="th">
<div>Sep. 17, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Aug. 31, 2021 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="nump">200,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_NumberOfVotesPerCommonStockShareHeld', window );">Number of votes per common stock share held | vote</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common stock and pre-funded warrants | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 387.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Fees and expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">17.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common stock for pre-funded warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,422,186<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_StockRepurchaseProgramAuthorizedAmount1', window );">Share repurchase program, authorized amount | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockSharesAcquired', window );">Share repurchases (Treasury Stock) (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,009,758<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare', window );">Share repurchase program, average price (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9.09<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions', window );">Share repurchase program, acquired, value net of commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 91.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ShareRepurchaseProgramCommissionsAndExciseTax', window );">Share repurchase program, commissions and excise tax | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">370.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost', window );">Decrease in compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">44.0<span></span>
</td>
<td class="nump">$ 88.2<span></span>
</td>
<td class="nump">$ 71.6<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Compensation expense not yet recognized | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 30.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants', window );">Inducement grants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">255,611<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value of options granted (in usd per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 8.15<span></span>
</td>
<td class="nump">$ 27.35<span></span>
</td>
<td class="nump">$ 21.99<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Intrinsic value of options exercised | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 3.6<span></span>
</td>
<td class="nump">$ 1.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_WeightedAverageMember', window );">Weighted Average</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense not yet recognized, period of recognition (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 6 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,067,007<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares remained available for purchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,966,406<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum', window );">Annual increase in reserved shares as percentage of outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,277,181<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod', window );">Annual increase in reserved shares of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,989,593<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Common stock reserved for issuance (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">311,850<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock', window );">Common stock reserved for issuance represented as percentage on outstanding common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Common stock, shares remained available for purchase (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,577,025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Common stock, shares issued (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">110,412<span></span>
</td>
<td class="nump">120,834<span></span>
</td>
<td class="nump">78,528<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember', window );">ESPP | 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Compensation expense | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5<span></span>
</td>
<td class="nump">$ 0.7<span></span>
</td>
<td class="nump">$ 0.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants', window );">Number of inducement grants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">170,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.34<span></span>
</td>
<td class="nump">$ 44.43<span></span>
</td>
<td class="nump">$ 32.27<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod', window );">Total intrinsic value of RSUs released | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 17.7<span></span>
</td>
<td class="nump">$ 13.2<span></span>
</td>
<td class="nump">$ 4.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue', window );">Total fair value of RSUs vested | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 44.3<span></span>
</td>
<td class="nump">$ 13.1<span></span>
</td>
<td class="nump">$ 6.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs | 2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share) | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=arvn_PreFundedWarrantMember', window );">Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember', window );">Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants', window );">Proceeds from issuance of common stock and pre-funded warrants | $</a></td>
<td class="nump">$ 350.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Fees and expenses | $</a></td>
<td class="nump">15.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember', window );">At-the-Market Offering | Piper Sandler and Cantor | Equity Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_MaximumAggregateOfferingPriceOfCommonStock', window );">Common stock aggregate offering price | $</a></td>
<td class="nump">$ 262.8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of issuance costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants', window );">Issuance of common stock for pre-funded warrants (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of issuance costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">14,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Piper Sandler and Cantor | Equity Distribution Agreement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Fees and expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_MaximumAggregateOfferingPriceOfCommonStock', window );">Common stock aggregate offering price | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Common stock issued, net of issuance costs (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,449,275<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueNewIssues', window );">Common stock issued, net of issuance costs | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 37.2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Private Placement</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction', window );">Number of shares issued in transaction (in shares) | shares</a></td>
<td class="nump">12,963,542<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 21.36<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember', window );">Common Shares | Private Placement | Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SaleOfStockPricePerShare', window );">Sale of stock, price (in usd per share) | $ / shares</a></td>
<td class="nump">$ 21.359<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Warrants to be purchased (in shares) | shares</a></td>
<td class="nump">3,422,380<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_MaximumAggregateOfferingPriceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum Aggregate Offering Price Of Common Stock</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_MaximumAggregateOfferingPriceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NumberOfVotesPerCommonStockShareHeld">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of votes per common stock share held</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NumberOfVotesPerCommonStockShareHeld</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ProceedsFromIssuanceOfCommonStockAndWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds From Issuance Of Common Stock And Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ProceedsFromIssuanceOfCommonStockAndWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareRepurchaseProgramCommissionsAndExciseTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Repurchase Program Commissions And Excise Tax</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareRepurchaseProgramCommissionsAndExciseTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Stock Issued During Period, Shares, Exercise Of Warrants</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Treasury Stock, Value, Acquired, Cost Method, Net of Commissions</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_StockRepurchaseProgramAuthorizedAmount1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 505<br> -SubTopic 30<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481520/505-30-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_StockRepurchaseProgramAuthorizedAmount1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>srt_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479983/718-10-S45-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479830/718-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-13<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-04(16)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued or sold by the subsidiary or equity method investee per stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SaleOfStockPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SaleOfStockPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>An excess of the fair value of the modified award over the fair value of the award immediately before the modification.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-03(i)(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479886/946-10-S99-3<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-11<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 205<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478009/946-205-45-4<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 505<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478448/946-505-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(4)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockAcquiredAverageCostPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total cost of shares repurchased divided by the total number of shares repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481549/505-30-45-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockAcquiredAverageCostPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TreasuryStockSharesAcquired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares that have been repurchased during the period and are being held in treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -SubTopic 10<br> -Topic 505<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-2<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TreasuryStockSharesAcquired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_WeightedAverageMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_WeightedAverageMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=arvn_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=arvn_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=arvn_AtTheMarketOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_PiperSandlerAndCantorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_PiperSandlerAndCantorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_EquityDistributionAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_EquityDistributionAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>109
<FILENAME>R57.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details) - Stock options - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum', window );">Expected volatility, minimum (percentage)</a></td>
<td class="nump">72.10%<span></span>
</td>
<td class="nump">72.00%<span></span>
</td>
<td class="nump">71.30%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum', window );">Expected volatility, maximum (percentage)</a></td>
<td class="nump">80.40%<span></span>
</td>
<td class="nump">75.60%<span></span>
</td>
<td class="nump">75.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum', window );">Risk free interest rate, minimum (percentage)</a></td>
<td class="nump">3.70%<span></span>
</td>
<td class="nump">3.50%<span></span>
</td>
<td class="nump">3.40%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum', window );">Risk free interest rate, maximum (percentage)</a></td>
<td class="nump">4.40%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">4.80%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Expected dividend yield (percentage)</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 4 months 24 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.61<span></span>
</td>
<td class="nump">$ 24.19<span></span>
</td>
<td class="nump">$ 16.21<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Share Based Compensation Arrangement By Share Based Payment Award [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (years)</a></td>
<td class="text">5 years 8 months 12 days<span></span>
</td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">7 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice', window );">Exercise price (in dollars per share)</a></td>
<td class="nump">$ 17.70<span></span>
</td>
<td class="nump">$ 47.00<span></span>
</td>
<td class="nump">$ 36.27<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The minimum risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 1D<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 35<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480483/718-10-35-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(04)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(02)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>110
<FILENAME>R58.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Stock Option Activity (Details) - 2018 Plan - USD ($)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Options</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">7,892,330<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">2,253,860<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(1,515,115)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">8,631,075<span></span>
</td>
<td class="nump">7,892,330<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Vested and exercisable, ending balance (in shares)</a></td>
<td class="nump">5,607,194<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">8,304,964<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract', window );"><strong>Weighted-Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 44.16<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="nump">12.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">46.07<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Ending balance (in dollars per share)</a></td>
<td class="nump">35.89<span></span>
</td>
<td class="nump">$ 44.16<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Vested and exercisable (in dollars per share)</a></td>
<td class="nump">44.41<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest (in dollars per share)</a></td>
<td class="nump">$ 36.55<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted-Average Remaining Contractual Term (Years)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">6 years 6 months<span></span>
</td>
<td class="text">6 years 8 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Vested and exercisable (in years)</a></td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest (in Years)</a></td>
<td class="text">6 years 4 months 24 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AggregateIntrinsicValueAbstract', window );"><strong>Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding</a></td>
<td class="nump">$ 5.3<span></span>
</td>
<td class="nump">$ 3.2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1', window );">Vested and exercisable</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue', window );">Vested and expected to vest</a></td>
<td class="nump">$ 4.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AggregateIntrinsicValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate Intrinsic Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AggregateIntrinsicValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 718<br> -SubTopic 10<br> -Subparagraph (e)(1)<br> -Name Accounting Standards Codification<br> -Paragraph 2<br> -Section 50<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>111
<FILENAME>R59.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity - Schedule of Restricted Stock (Details) - RSUs - $ / shares<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">$ 12.34<span></span>
</td>
<td class="nump">$ 44.43<span></span>
</td>
<td class="nump">$ 32.27<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember', window );">2018 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward', window );"><strong>Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Beginning balance (in shares)</a></td>
<td class="nump">2,311,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted (in shares)</a></td>
<td class="nump">3,440,614<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod', window );">Released (in shares)</a></td>
<td class="num">(1,253,564)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(874,290)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Ending balance (in shares)</a></td>
<td class="nump">3,624,051<span></span>
</td>
<td class="nump">2,311,291<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward', window );"><strong>Weighted-Average Grant Date Fair Value Per Share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Beginning balance (in dollars per share)</a></td>
<td class="nump">$ 42.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted (in dollars per share)</a></td>
<td class="nump">12.34<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue', window );">Released (in dollars per share)</a></td>
<td class="nump">40.06<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue', window );">Forfeited (in dollars per share)</a></td>
<td class="nump">22.81<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Ending balance (in in dollars per share)</a></td>
<td class="nump">$ 18.59<span></span>
</td>
<td class="nump">$ 42.25<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Released In Period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Released, Weighted Average Grant Date Fair Value</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(03)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(01)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(ii)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480429/718-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=arvn_TwoThousandEighteenStockIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>112
<FILENAME>R60.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Equity Method Investments (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Jul. 31, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">$ 381,100,000<span></span>
</td>
<td class="nump">$ 513,600,000<span></span>
</td>
<td class="nump">$ 480,000,000.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(80,800,000)<span></span>
</td>
<td class="num">(198,900,000)<span></span>
</td>
<td class="num">(367,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LegalEntityAxis=arvn_OerthBioLimitedLiabilityCorporationMember', window );">Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Operating expenses</a></td>
<td class="nump">1,100,000<span></span>
</td>
<td class="nump">3,700,000<span></span>
</td>
<td class="nump">8,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (1,100,000)<span></span>
</td>
<td class="num">$ (3,700,000)<span></span>
</td>
<td class="num">$ (8,300,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember', window );">Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest, percentage</a></td>
<td class="nump">42.90%<span></span>
</td>
<td class="nump">43.60%<span></span>
</td>
<td class="nump">45.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage', window );">Future grant of incentive units to service providers, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (2,500,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestments', window );">Equity method investments</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember', window );">Bayer LP | Oerth</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems', window );"><strong>Schedule Of Equity Method Investments [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentAggregateCost', window );">Equity interest</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EquityMethodInvestmentOwnershipPercentage', window );">Ownership interest, percentage</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">50.00%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Future grant of incentive units to service providers, percentage.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentAggregateCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This element represents the aggregate cost of investments accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentAggregateCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestmentOwnershipPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestmentOwnershipPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 25<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEquityMethodInvestmentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEquityMethodInvestmentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LegalEntityAxis=arvn_OerthBioLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LegalEntityAxis=arvn_OerthBioLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis=arvn_OerthBioLimitedLiabilityCorporationMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_BayerCropScienceLPMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>113
<FILENAME>R61.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Additional Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_UnrecognizedTaxBenefitsNet', window );">Net uncertain tax positions</a></td>
<td class="nump">5.9<span></span>
</td>
<td class="nump">5.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued', window );">Unrecognized tax benefits, income tax penalties and interest accrued</a></td>
<td class="nump">1.6<span></span>
</td>
<td class="nump">1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Jurisdiction</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">$ 533.6<span></span>
</td>
<td class="nump">111.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage', window );">Operating losses carry forward, maximum deductibility percentage</a></td>
<td class="nump">80.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Federal tax credit carryforwards</a></td>
<td class="nump">$ 44.7<span></span>
</td>
<td class="nump">37.7<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">US state and local &#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">563.2<span></span>
</td>
<td class="nump">129.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAmount', window );">Federal tax credit carryforwards</a></td>
<td class="nump">22.3<span></span>
</td>
<td class="nump">22.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember', window );">Research and Development Tax Credits</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_IncomeTaxDisclosureLineItems', window );"><strong>Income Tax Disclosure [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">(Decrease) increase in valuation allowance</a></td>
<td class="nump">$ 10.0<span></span>
</td>
<td class="nump">$ 63.5<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_IncomeTaxDisclosureLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Income tax disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_IncomeTaxDisclosureLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Operating losses carry forward, maximum deductibility as a percentage of taxable income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_UnrecognizedTaxBenefitsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Unrecognized Tax Benefits, Net</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_UnrecognizedTaxBenefitsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TaxCreditCarryforwardAxis=us-gaap_ResearchMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>114
<FILENAME>R62.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Expense (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Current:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentFederalTaxExpenseBenefit', window );">Federal</a></td>
<td class="num">$ (0.3)<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="num">$ (1.7)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">2.6<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CurrentIncomeTaxExpenseBenefit', window );">Total current</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract', window );"><strong>Deferred:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit', window );">Federal</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit', window );">State and local</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Total deferred</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentFederalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentFederalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CurrentStateAndLocalTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CurrentStateAndLocalTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredFederalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredFederalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-9<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>115
<FILENAME>R63.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract', window );"><strong>Amount</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal statutory tax rate</a></td>
<td class="num">$ (16.9)<span></span>
</td>
<td class="num">$ (41.6)<span></span>
</td>
<td class="num">$ (76.4)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes, net of federal income tax effect</a></td>
<td class="nump">0.1<span></span>
</td>
<td class="nump">4.6<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch', window );">Research and development tax credit</a></td>
<td class="num">(6.8)<span></span>
</td>
<td class="num">(9.1)<span></span>
</td>
<td class="num">(28.0)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="nump">16.6<span></span>
</td>
<td class="nump">43.8<span></span>
</td>
<td class="nump">98.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">7.5<span></span>
</td>
<td class="nump">2.1<span></span>
</td>
<td class="nump">4.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="num">(0.2)<span></span>
</td>
<td class="nump">0.8<span></span>
</td>
<td class="nump">0.5<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.6<span></span>
</td>
<td class="nump">$ 0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Percent</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">U.S. Federal statutory tax rate</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State and local income taxes, net of federal income tax effect</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(2.30%)<span></span>
</td>
<td class="num">(0.60%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development tax credit</a></td>
<td class="nump">8.50%<span></span>
</td>
<td class="nump">4.60%<span></span>
</td>
<td class="nump">7.60%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Changes in valuation allowance</a></td>
<td class="num">(20.60%)<span></span>
</td>
<td class="num">(22.10%)<span></span>
</td>
<td class="num">(26.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost', window );">Research and development tax credit</a></td>
<td class="num">(9.30%)<span></span>
</td>
<td class="num">(1.10%)<span></span>
</td>
<td class="num">(1.20%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther', window );">Other</a></td>
<td class="nump">0.10%<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.20%)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Effective tax rate</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
<td class="num">(0.30%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.1.Q1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(6)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (a)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12A<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12A<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>116
<FILENAME>R64.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Income Tax Paid, Net of Refunds (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidFederalAfterRefundReceived', window );">US federal &#160;</a></td>
<td class="num">$ (400)<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxesPaidNet', window );">Total income taxes paid, net of refunds received &#160;</a></td>
<td class="num">(400)<span></span>
</td>
<td class="nump">2,300<span></span>
</td>
<td class="nump">11,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA', window );">California</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">US state and local &#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_MA', window );">Massachusetts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">US state and local &#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NY', window );">New York</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">US state and local &#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">800<span></span>
</td>
<td class="nump">2,400<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=arvn_NewYorkCityMember', window );">New York City</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">US state and local &#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">500<span></span>
</td>
<td class="nump">2,200<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NJ', window );">New Jersey</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">US state and local &#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,100<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=stpr_PA', window );">Pennsylvania</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">US state and local &#160;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,900<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignTaxJurisdictionOtherMember', window );">Other</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems', window );"><strong>Income Tax Paid, by Individual Jurisdiction [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived', window );">US state and local &#160;</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidFederalAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidFederalAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxesPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2A<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 23<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-22<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482913/230-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxesPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_CA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_CA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_MA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_MA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NY">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_NY</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=arvn_NewYorkCityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=arvn_NewYorkCityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_NJ">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_NJ</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=stpr_PA">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=stpr_PA</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignTaxJurisdictionOtherMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_ForeignTaxJurisdictionOtherMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>117
<FILENAME>R65.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred income tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Loss carryforwards</a></td>
<td class="nump">$ 145.4<span></span>
</td>
<td class="nump">$ 31.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment', window );">Capitalized research and development</a></td>
<td class="nump">131.9<span></span>
</td>
<td class="nump">161.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsDeferredIncome', window );">Deferred revenue</a></td>
<td class="nump">81.9<span></span>
</td>
<td class="nump">155.6<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards', window );">Tax credits</a></td>
<td class="nump">62.1<span></span>
</td>
<td class="nump">55.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock compensation</a></td>
<td class="nump">56.6<span></span>
</td>
<td class="nump">60.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOther', window );">Other</a></td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">8.3<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Total deferred income tax assets</a></td>
<td class="nump">482.3<span></span>
</td>
<td class="nump">472.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred income tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment', window );">Property, equipment and leasehold improvements</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Total deferred income tax liabilities</a></td>
<td class="num">(0.9)<span></span>
</td>
<td class="num">(1.4)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less valuation allowance</a></td>
<td class="num">(481.4)<span></span>
</td>
<td class="num">(471.4)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred income tax liability</a></td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 210<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 210<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsDeferredIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsDeferredIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>118
<FILENAME>R66.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Schedule of Unrecognized Tax Benefits (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward', window );"><strong>Unrecognized Tax Benefits [Roll Forward]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Beginning of period balance - gross</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 4.1<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions', window );">Increases for tax positions taken during the current period</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">1.8<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">End of period balance - gross</a></td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
<td class="nump">$ 5.9<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482525/740-10-45-10B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 217<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-217<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-15A<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>119
<FILENAME>R67.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies (Details)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Jul. 05, 2013 </div>
<div>USD ($) </div>
<div>product</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2025 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LossContingencyAccrualAtCarryingValue', window );">Loss contingency</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 15,200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 700<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 300<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payment</a></td>
<td class="nump">$ 500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_AnnualLicenseFeePayment', window );">Annual payment for license</a></td>
<td class="nump">$ 100<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_NumberOfLicensedProducts', window );">Number of licensed products | product</a></td>
<td class="nump">2<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsForRoyalties', window );">Royalty payment</a></td>
<td class="nump">$ 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University | Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_PaymentsForCollaboration', window );">Payments for collaboration</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,950<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University | Milestone Payment On First Anniversary Of Signing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment the Company will make</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University | Milestone Payment Upon Approval Of First And Second Royalty Products | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment', window );">Milestone payment the Company will make</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University | Success-Based Milestone Payments | License, First Licensed Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_RequiredMilestonePayments', window );">Required milestone payments</a></td>
<td class="nump">3,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember', window );">Yale University | Success-Based Milestone Payments | License, Second Licensed Product</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_CommitmentsAndContingenciesLineItems', window );"><strong>Commitments And Contingencies [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_RequiredMilestonePayments', window );">Required milestone payments</a></td>
<td class="nump">$ 1,500<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_AnnualLicenseFeePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Annual license fee payment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_AnnualLicenseFeePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Collaborative Arrangement, Rights And Obligations, Milestone Payment</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_CommitmentsAndContingenciesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_CommitmentsAndContingenciesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_NumberOfLicensedProducts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of Licensed Products</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_NumberOfLicensedProducts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_PaymentsForCollaboration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Payments For Collaboration</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_PaymentsForCollaboration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_RequiredMilestonePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Required Milestone Payments</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_RequiredMilestonePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LossContingencyAccrualAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss contingency liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 450<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483076/450-20-50-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LossContingencyAccrualAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsForRoyalties">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash paid for royalties during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (g)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-25<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsForRoyalties</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=arvn_YaleUniversityMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=arvn_YaleUniversityMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TypeOfArrangementAxis=arvn_SuccessBasedMilestonePaymentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TypeOfArrangementAxis=arvn_SuccessBasedMilestonePaymentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_LicenseFirstLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_LicenseFirstLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_LicenseSecondLicensedProductMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_LicenseSecondLicensedProductMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>120
<FILENAME>R68.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Schedule of Basic and Diluted Loss per Common Share (Details) - USD ($)<br> $ / shares in Units, shares in Millions, $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Earnings Per Share [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (80.8)<span></span>
</td>
<td class="num">$ (198.9)<span></span>
</td>
<td class="num">$ (367.3)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Weighted average common shares outstanding - basic (in shares)</a></td>
<td class="nump">70.9<span></span>
</td>
<td class="nump">71.9<span></span>
</td>
<td class="nump">55.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Weighted-average common shares outstanding - diluted (in shares)</a></td>
<td class="nump">70.9<span></span>
</td>
<td class="nump">71.9<span></span>
</td>
<td class="nump">55.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per common share - basic (in usd per share)</a></td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
<td class="num">$ (6.62)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Net loss per common share - diluted (in dollars per share)</a></td>
<td class="num">$ (1.14)<span></span>
</td>
<td class="num">$ (2.77)<span></span>
</td>
<td class="num">$ (6.62)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 52<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-52<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 15<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482635/260-10-55-15<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-7<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-2<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-7<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 16<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-16<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-10<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>121
<FILENAME>R69.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Net Loss Per Share - Additional Information (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
<th class="th"><div>Nov. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=arvn_PreFundedWarrantMember', window );">Pre-Funded Warrant</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Warrant exercise price (in usd per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 505<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481112/505-10-50-3<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=arvn_PreFundedWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=arvn_PreFundedWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>122
<FILENAME>R70.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss Per Share - Securities Excluded from the Computations of Diluted Net Loss Per Share (Details) - shares<br> shares in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</a></td>
<td class="nump">12.2<span></span>
</td>
<td class="nump">10.2<span></span>
</td>
<td class="nump">9.1<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</a></td>
<td class="nump">8.6<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
<td class="nump">7.9<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per common share (in shares)</a></td>
<td class="nump">3.6<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482662/260-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>123
<FILENAME>R71.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Restructuring Activity (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Sep. 30, 2025</div></th>
<th class="th"><div>Jun. 30, 2025</div></th>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent', window );">Reduction in workforce (as a percent)</a></td>
<td class="nump">15.00%<span></span>
</td>
<td class="nump">33.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.7<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringReserve', window );">Restructuring accrual</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.4<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">Research and development<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration', window );">Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">General and administrative<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember', window );">Employee Severance</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveAxis=arvn_StockCompensationAndBonusExpenseMember', window );">Non Cash Stock Compensation And Bonus Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCostAndReserveLineItems', window );"><strong>Restructuring Cost and Reserve [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestructuringCharges', window );">Restructuring charges</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">$ (11.6)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCharges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482047/420-10-45-3<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 5.P.3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 21<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-21<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476148/220-40-50-6<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCharges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of income or comprehensive income that includes restructuring charges.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/recommendedDisclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringReserve">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 5.P.4.b.2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479823/420-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 420<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482017/420-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringReserve</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=us-gaap_EmployeeSeveranceMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestructuringCostAndReserveAxis=arvn_StockCompensationAndBonusExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestructuringCostAndReserveAxis=arvn_StockCompensationAndBonusExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>124
<FILENAME>R72.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Additional Information (Details)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2025 </div>
<div>USD ($) </div>
<div>segment</div>
</th>
<th class="th">
<div>Dec. 31, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingAbstract', window );"><strong>Segment Reporting [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfReportableSegments', window );">Number of reportable segments</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationAndAmortization', window );">Depreciation and amortization | $</a></td>
<td class="nump">$ 3.0<span></span>
</td>
<td class="nump">$ 4.6<span></span>
</td>
<td class="nump">$ 4.8<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482099/360-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 49<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-49<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfReportableSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 47<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-47<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 54<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-54<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-18<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfReportableSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>125
<FILENAME>R73.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.4</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Segment Information - Schedule of Financial Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2025</div></th>
<th class="th"><div>Dec. 31, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">$ 262.6<span></span>
</td>
<td class="nump">$ 263.4<span></span>
</td>
<td class="nump">$ 78.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expense</a></td>
<td class="nump">285.2<span></span>
</td>
<td class="nump">348.2<span></span>
</td>
<td class="nump">379.7<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">95.9<span></span>
</td>
<td class="nump">165.4<span></span>
</td>
<td class="nump">100.3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">38.4<span></span>
</td>
<td class="nump">54.8<span></span>
</td>
<td class="nump">38.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Segment net loss</a></td>
<td class="num">(80.8)<span></span>
</td>
<td class="num">(198.9)<span></span>
</td>
<td class="num">(367.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingInformationLineItems', window );"><strong>Segment Reporting Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Revenues', window );">Revenue</a></td>
<td class="nump">262.6<span></span>
</td>
<td class="nump">263.4<span></span>
</td>
<td class="nump">78.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific', window );">Non program-specific external expense</a></td>
<td class="nump">49.1<span></span>
</td>
<td class="nump">62.8<span></span>
</td>
<td class="nump">72.4<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LaborAndRelatedExpense', window );">Compensation and related personnel expense (including stock-based compensation)</a></td>
<td class="nump">109.6<span></span>
</td>
<td class="nump">145.4<span></span>
</td>
<td class="nump">134.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherResearchAndDevelopmentExpense', window );">Other research and development expense</a></td>
<td class="nump">11.0<span></span>
</td>
<td class="nump">12.8<span></span>
</td>
<td class="nump">13.8<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Total research and development expense</a></td>
<td class="nump">285.2<span></span>
</td>
<td class="nump">348.2<span></span>
</td>
<td class="nump">379.7<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative expense</a></td>
<td class="nump">95.9<span></span>
</td>
<td class="nump">165.4<span></span>
</td>
<td class="nump">100.3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SegmentReportingOtherItemAmount', window );">Other segment expense, net</a></td>
<td class="nump">0.4<span></span>
</td>
<td class="nump">2.9<span></span>
</td>
<td class="nump">1.2<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax expense</a></td>
<td class="nump">0.3<span></span>
</td>
<td class="nump">0.6<span></span>
</td>
<td class="nump">0.9<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeLossFromEquityMethodInvestments', window );">Loss from equity method investment</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">2.5<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentIncomeInterest', window );">Interest income, net</a></td>
<td class="nump">38.4<span></span>
</td>
<td class="nump">54.8<span></span>
</td>
<td class="nump">38.8<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Segment net loss</a></td>
<td class="num">(80.8)<span></span>
</td>
<td class="num">(198.9)<span></span>
</td>
<td class="num">(367.3)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | Vepdegestrant ARV-471</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense:</a></td>
<td class="nump">62.7<span></span>
</td>
<td class="nump">76.9<span></span>
</td>
<td class="nump">104.8<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | ARV-102</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense:</a></td>
<td class="nump">21.0<span></span>
</td>
<td class="nump">13.0<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | ARV-806</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense:</a></td>
<td class="nump">13.5<span></span>
</td>
<td class="nump">2.3<span></span>
</td>
<td class="nump">0.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | ARV-393</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense:</a></td>
<td class="nump">11.1<span></span>
</td>
<td class="nump">6.8<span></span>
</td>
<td class="nump">1.4<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | Bavdegalutamide (ARV-110)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense:</a></td>
<td class="nump">2.7<span></span>
</td>
<td class="nump">8.5<span></span>
</td>
<td class="nump">26.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | Luxdegalutamide (ARV-766)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense:</a></td>
<td class="nump">0.0<span></span>
</td>
<td class="nump">19.7<span></span>
</td>
<td class="nump">24.2<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember', window );">Reportable Segment | Other programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract', window );"><strong>Less:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific', window );">Program-specific external expense:</a></td>
<td class="nump">$ 4.5<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchAndDevelopmentExpenseNonProgramSpecific">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Non-Program Specific</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchAndDevelopmentExpenseNonProgramSpecific</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_arvn_ResearchAndDevelopmentExpenseProgramSpecific">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research And Development Expense, Program Specific</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">arvn_ResearchAndDevelopmentExpenseProgramSpecific</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>arvn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(2)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromEquityMethodInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) for proportionate share of equity method investee's income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -SubTopic 10<br> -Topic 230<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(10))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481664/323-10-45-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(12))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(13)(f))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromEquityMethodInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 12<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-12<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 231<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482663/740-10-55-231<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479360/740-10-S99-1<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482685/740-10-50-10<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -SubTopic 20<br> -Topic 740<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482659/740-20-45-2<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -SubTopic 10<br> -Topic 235<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentIncomeInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(7)(b))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentIncomeInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LaborAndRelatedExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(4))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(14)(a))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LaborAndRelatedExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 946<br> -SubTopic 830<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 10<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479168/946-830-55-10<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-4<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 21<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-21<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(k)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-4<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479857/480-10-S50-3<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S45<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479887/480-10-S45-3<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 480<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3A<br> -Subparagraph (24)(d)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480244/480-10-S99-3A<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 105<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 9<br> -Subparagraph (e)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479343/105-10-65-9<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 718<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 17<br> -Subparagraph (d)(1)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480336/718-10-65-17<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-6<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 9<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-9<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 805<br> -SubTopic 60<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476176/805-60-65-1<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 740<br> -SubTopic 323<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(3)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478666/740-323-65-2<br><br>Reference 19: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 6<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482765/220-10-50-6<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-3<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-1<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 815<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480175/815-40-65-1<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 8<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-8<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 250<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483443/250-10-50-11<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479105/946-220-45-7<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 944<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.6-07(9))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-1<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 946<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 3<br> -Subparagraph (SX 210.6-09(1)(d))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479134/946-220-S99-3<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 34: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 36: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 37: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 38: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 39: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 40: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 41: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 42: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 43: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 260<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482689/260-10-45-60B<br><br>Reference 44: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 205<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 7<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483499/205-20-50-7<br><br>Reference 45: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 230<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 28<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482740/230-10-45-28<br><br>Reference 46: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A<br><br>Reference 47: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B<br><br>Reference 48: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (f)(4)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481538/470-20-65-4<br><br>Reference 49: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Topic 942<br> -SubTopic 220<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478524/942-220-S99-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other research and development expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 18<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-18<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 220<br> -SubTopic 40<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147476153/220-40-55-14<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 985<br> -SubTopic 20<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 2<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481283/985-20-50-2<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 730<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482916/730-10-50-1<br><br>Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 912<br> -SubTopic 730<br> -Name Accounting Standards Codification<br> -Section 25<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147479532/912-730-25-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Revenues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 815<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 4A<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480434/815-10-50-4A<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 942<br> -SubTopic 235<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 41<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-41<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 42<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-42<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S50<br> -Paragraph 1<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 825<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482907/825-10-50-28<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 14<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-14<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 944<br> -SubTopic 605<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 11<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147477548/944-605-55-11<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 14: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 15: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 235<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 323<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147481687/323-10-50-3<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 19: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 470<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-30<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (b)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 40<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-40<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (a)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-22<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 220<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(1))<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147483621/220-10-S99-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Revenues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SegmentReportingOtherItemAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 55<br> -Paragraph 48<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482785/280-10-55-48<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 270<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (i)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482964/270-10-50-1<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (ee)<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-32<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26C<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 280<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 50<br> -Paragraph 26B<br> -Publisher FASB<br> -URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SegmentReportingOtherItemAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementBusinessSegmentsAxis=arvn_ReportableSegmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_ARV471Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_ARV471Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_ARV102Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_ARV102Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_ARV806Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_ARV806Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_ARV393Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_ARV393Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_ARV110Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_ARV110Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_ARV766Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_ARV766Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_ProductOrServiceAxis=arvn_OtherProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_ProductOrServiceAxis=arvn_OtherProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>126
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>127
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>129
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>234</ContextCount>
  <ElementCount>398</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>87</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>9</UnitCount>
  <MyReports>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/Cover</Role>
      <ShortName>Cover</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>0000002 - Document - Audit Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AuditInformation</Role>
      <ShortName>Audit Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>9952151 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ConsolidatedBalanceSheets</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>9952152 - Statement - Consolidated Balance Sheets (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical</Role>
      <ShortName>Consolidated Balance Sheets (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss</Role>
      <ShortName>Consolidated Statements of Operations and Comprehensive Loss</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>9952154 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>9952155 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>9952156 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>9952157 - Disclosure - Nature of Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation</Role>
      <ShortName>Nature of Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>9952158 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>9952159 - Disclosure - Research Collaboration and License Agreements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements</Role>
      <ShortName>Research Collaboration and License Agreements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>9952160 - Disclosure - Marketable Securities and Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements</Role>
      <ShortName>Marketable Securities and Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>9952161 - Disclosure - Property, Equipment and Leasehold Improvements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements</Role>
      <ShortName>Property, Equipment and Leasehold Improvements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>9952162 - Disclosure - Right of Use Assets and Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilities</Role>
      <ShortName>Right of Use Assets and Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>9952163 - Disclosure - Accounts Payable and Accrued Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities</Role>
      <ShortName>Accounts Payable and Accrued Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>9952164 - Disclosure - Long-Term Debt</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebt</Role>
      <ShortName>Long-Term Debt</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>9952165 - Disclosure - Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/Equity</Role>
      <ShortName>Equity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>9952166 - Disclosure - Equity Method Investments</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestments</Role>
      <ShortName>Equity Method Investments</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>9952167 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>9952168 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CommitmentsandContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>9952169 - Disclosure - Net Loss Per Share</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShare</Role>
      <ShortName>Net Loss Per Share</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>9952170 - Disclosure - Restructuring Activity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RestructuringActivity</Role>
      <ShortName>Restructuring Activity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>9952171 - Disclosure - Segment Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SegmentInformation</Role>
      <ShortName>Segment Information</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>995445 - Disclosure - Insider Trading Arrangements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements</Role>
      <ShortName>Insider Trading Arrangements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>995447 - Disclosure - Insider Trading Policies and Procedures</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc</Role>
      <ShortName>Insider Trading Policies and Procedures</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>25</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure</Role>
      <ShortName>Cybersecurity Risk Management and Strategy Disclosure</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>9955513 - Disclosure - Research Collaboration and License Agreements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables</Role>
      <ShortName>Research Collaboration and License Agreements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>9955514 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>9955515 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables</Role>
      <ShortName>Property, Equipment and Leasehold Improvements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>9955516 - Disclosure - Right of Use Assets and Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables</Role>
      <ShortName>Right of Use Assets and Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/RightofUseAssetsandLiabilities</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>9955517 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities</ParentRole>
      <Position>33</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>9955518 - Disclosure - Long-Term Debt (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtTables</Role>
      <ShortName>Long-Term Debt (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/LongTermDebt</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>9955519 - Disclosure - Equity (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityTables</Role>
      <ShortName>Equity (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/Equity</ParentRole>
      <Position>35</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>9955520 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/IncomeTaxes</ParentRole>
      <Position>36</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>9955521 - Disclosure - Net Loss Per Share (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShareTables</Role>
      <ShortName>Net Loss Per Share (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/NetLossPerShare</ParentRole>
      <Position>37</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>9955522 - Disclosure - Segment Information (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SegmentInformationTables</Role>
      <ShortName>Segment Information (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/SegmentInformation</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>9955523 - Disclosure - Nature of Business and Basis of Presentation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails</Role>
      <ShortName>Nature of Business and Basis of Presentation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>9955524 - Disclosure - Summary of Significant Accounting Policies - Cash Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Cash Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>40</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>9955525 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>41</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>9955526 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>9955527 - Disclosure - Research Collaboration and License Agreements - Schedule of Contract Balances (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Schedule of Contract Balances (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>9955528 - Disclosure - Research Collaboration and License Agreements - Schedule of Transaction Price Allocated to Performance Obligations (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails</Role>
      <ShortName>Research Collaboration and License Agreements - Schedule of Transaction Price Allocated to Performance Obligations (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>9955529 - Disclosure - Marketable Securities and Fair Value Measurements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails</Role>
      <ShortName>Marketable Securities and Fair Value Measurements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>9955530 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails</Role>
      <ShortName>Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>46</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>9955531 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails</Role>
      <ShortName>Property, Equipment and Leasehold Improvements - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>9955532 - Disclosure - Right of Use Assets and Liabilities - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails</Role>
      <ShortName>Right of Use Assets and Liabilities - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>9955533 - Disclosure - Right of Use Assets and Liabilities - Schedule of Components of Lease Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofComponentsofLeaseExpenseDetails</Role>
      <ShortName>Right of Use Assets and Liabilities - Schedule of Components of Lease Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>9955534 - Disclosure - Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails</Role>
      <ShortName>Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>9955535 - Disclosure - Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails</Role>
      <ShortName>Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>9955536 - Disclosure - Accounts Payable and Accrued Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails</Role>
      <ShortName>Accounts Payable and Accrued Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables</ParentRole>
      <Position>52</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>9955537 - Disclosure - Long-Term Debt - Schedule of Long Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Long Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>53</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R54.htm</HtmlFileName>
      <LongName>9955538 - Disclosure - Long-Term Debt - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails</Role>
      <ShortName>Long-Term Debt - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>54</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R55.htm</HtmlFileName>
      <LongName>9955539 - Disclosure - Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails</Role>
      <ShortName>Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>55</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R56.htm</HtmlFileName>
      <LongName>9955540 - Disclosure - Equity - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityAdditionalInformationDetails</Role>
      <ShortName>Equity - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>56</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R57.htm</HtmlFileName>
      <LongName>9955541 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails</Role>
      <ShortName>Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>57</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R58.htm</HtmlFileName>
      <LongName>9955542 - Disclosure - Equity - Schedule of Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails</Role>
      <ShortName>Equity - Schedule of Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>58</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R59.htm</HtmlFileName>
      <LongName>9955543 - Disclosure - Equity - Schedule of Restricted Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails</Role>
      <ShortName>Equity - Schedule of Restricted Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>59</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R60.htm</HtmlFileName>
      <LongName>9955544 - Disclosure - Equity Method Investments (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/EquityMethodInvestmentsDetails</Role>
      <ShortName>Equity Method Investments (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/EquityMethodInvestments</ParentRole>
      <Position>60</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R61.htm</HtmlFileName>
      <LongName>9955545 - Disclosure - Income Taxes - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails</Role>
      <ShortName>Income Taxes - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>61</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R62.htm</HtmlFileName>
      <LongName>9955546 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>62</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R63.htm</HtmlFileName>
      <LongName>9955547 - Disclosure - Income Taxes - Schedule of Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails</Role>
      <ShortName>Income Taxes - Schedule of Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>63</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R64.htm</HtmlFileName>
      <LongName>9955548 - Disclosure - Income Taxes - Schedule of Income Tax Paid, Net of Refunds (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails</Role>
      <ShortName>Income Taxes - Schedule of Income Tax Paid, Net of Refunds (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>64</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R65.htm</HtmlFileName>
      <LongName>9955549 - Disclosure - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails</Role>
      <ShortName>Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>65</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R66.htm</HtmlFileName>
      <LongName>9955550 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails</Role>
      <ShortName>Income Taxes - Schedule of Unrecognized Tax Benefits (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>66</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R67.htm</HtmlFileName>
      <LongName>9955551 - Disclosure - Commitments and Contingencies (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/CommitmentsandContingenciesDetails</Role>
      <ShortName>Commitments and Contingencies (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/CommitmentsandContingencies</ParentRole>
      <Position>67</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R68.htm</HtmlFileName>
      <LongName>9955552 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Loss per Common Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShareScheduleofBasicandDilutedLossperCommonShareDetails</Role>
      <ShortName>Net Loss Per Share - Schedule of Basic and Diluted Loss per Common Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>68</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R69.htm</HtmlFileName>
      <LongName>9955553 - Disclosure - Net Loss Per Share - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShareAdditionalInformationDetails</Role>
      <ShortName>Net Loss Per Share - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>69</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R70.htm</HtmlFileName>
      <LongName>9955554 - Disclosure - Net Loss Per Share - Securities Excluded from the Computations of Diluted Net Loss Per Share (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails</Role>
      <ShortName>Net Loss Per Share - Securities Excluded from the Computations of Diluted Net Loss Per Share (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>70</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R71.htm</HtmlFileName>
      <LongName>9955555 - Disclosure - Restructuring Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/RestructuringActivityDetails</Role>
      <ShortName>Restructuring Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.arvinas.com/role/RestructuringActivity</ParentRole>
      <Position>71</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R72.htm</HtmlFileName>
      <LongName>9955556 - Disclosure - Segment Information - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails</Role>
      <ShortName>Segment Information - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>72</Position>
    </Report>
    <Report instance="arvn-20251231.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R73.htm</HtmlFileName>
      <LongName>9955557 - Disclosure - Segment Information - Schedule of Financial Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails</Role>
      <ShortName>Segment Information - Schedule of Financial Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>73</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" isDefinitelyFs="true" isUsgaap="true" original="arvn-20251231.htm">arvn-20251231.htm</File>
    <File>arvn-20251231.xsd</File>
    <File>arvn-20251231_cal.xml</File>
    <File>arvn-20251231_def.xml</File>
    <File>arvn-20251231_lab.xml</File>
    <File>arvn-20251231_pre.xml</File>
  </InputFiles>
  <SupplementalFiles>
    <File>arvn-20251231_g1.jpg</File>
    <File>arvn-20251231_g2.jpg</File>
    <File>arvn-20251231_g3.jpg</File>
    <File>arvn-20251231_g4.jpg</File>
    <File>arvn-20251231_g5.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="1">http://fasb.org/srt/2025</BaseTaxonomy>
    <BaseTaxonomy items="843">http://fasb.org/us-gaap/2025</BaseTaxonomy>
    <BaseTaxonomy items="15">http://xbrl.sec.gov/cyd/2025</BaseTaxonomy>
    <BaseTaxonomy items="39">http://xbrl.sec.gov/dei/2025</BaseTaxonomy>
    <BaseTaxonomy items="5">http://xbrl.sec.gov/ecd/2025</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>132
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "arvn-20251231.htm": {
   "nsprefix": "arvn",
   "nsuri": "http://www.arvinas.com/20251231",
   "dts": {
    "inline": {
     "local": [
      "arvn-20251231.htm"
     ]
    },
    "schema": {
     "local": [
      "arvn-20251231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2024-01-31/types.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-roles-2025.xsd",
      "https://xbrl.fasb.org/srt/2025/elts/srt-types-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-gaap-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-roles-2025.xsd",
      "https://xbrl.fasb.org/us-gaap/2025/elts/us-types-2025.xsd",
      "https://xbrl.sec.gov/country/2025/country-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-2025.xsd",
      "https://xbrl.sec.gov/cyd/2025/cyd-af-sub-2025.xsd",
      "https://xbrl.sec.gov/dei/2025/dei-2025.xsd",
      "https://xbrl.sec.gov/ecd/2025/ecd-2025.xsd",
      "https://xbrl.sec.gov/stpr/2025/stpr-2025.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "arvn-20251231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "arvn-20251231_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "arvn-20251231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "arvn-20251231_pre.xml"
     ]
    }
   },
   "keyStandard": 350,
   "keyCustom": 48,
   "axisStandard": 29,
   "axisCustom": 1,
   "memberStandard": 37,
   "memberCustom": 47,
   "hidden": {
    "total": 12,
    "http://fasb.org/us-gaap/2025": 8,
    "http://xbrl.sec.gov/dei/2025": 4
   },
   "contextCount": 234,
   "entityCount": 1,
   "segmentCount": 87,
   "elementCount": 737,
   "unitCount": 9,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2025": 843,
    "http://xbrl.sec.gov/dei/2025": 39,
    "http://xbrl.sec.gov/cyd/2025": 15,
    "http://xbrl.sec.gov/ecd/2025": 5,
    "http://fasb.org/srt/2025": 1
   },
   "report": {
    "R1": {
     "role": "http://www.arvinas.com/role/Cover",
     "longName": "0000001 - Document - Cover",
     "shortName": "Cover",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R2": {
     "role": "http://www.arvinas.com/role/AuditInformation",
     "longName": "0000002 - Document - Audit Information",
     "shortName": "Audit Information",
     "isDefault": "false",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "2",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:AuditorName",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
     "longName": "9952151 - Statement - Consolidated Balance Sheets",
     "shortName": "Consolidated Balance Sheets",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:MarketableSecuritiesCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical",
     "longName": "9952152 - Statement - Consolidated Balance Sheets (Parenthetical)",
     "shortName": "Consolidated Balance Sheets (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockSharesIssued",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:PreferredStockSharesOutstanding",
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
     "longName": "9952153 - Statement - Consolidated Statements of Operations and Comprehensive Loss",
     "shortName": "Consolidated Statements of Operations and Comprehensive Loss",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
     "longName": "9952154 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-9",
      "name": "us-gaap:CommonStockSharesOutstanding",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical",
     "longName": "9952155 - Statement - Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "7",
     "firstAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-8",
      "name": "us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
     "longName": "9952156 - Statement - Consolidated Statements of Cash Flows",
     "shortName": "Consolidated Statements of Cash Flows",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "8",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation",
     "longName": "9952157 - Disclosure - Nature of Business and Basis of Presentation",
     "shortName": "Nature of Business and Basis of Presentation",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies",
     "longName": "9952158 - Disclosure - Summary of Significant Accounting Policies",
     "shortName": "Summary of Significant Accounting Policies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements",
     "longName": "9952159 - Disclosure - Research Collaboration and License Agreements",
     "shortName": "Research Collaboration and License Agreements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CollaborativeArrangementDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements",
     "longName": "9952160 - Disclosure - Marketable Securities and Fair Value Measurements",
     "shortName": "Marketable Securities and Fair Value Measurements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements",
     "longName": "9952161 - Disclosure - Property, Equipment and Leasehold Improvements",
     "shortName": "Property, Equipment and Leasehold Improvements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilities",
     "longName": "9952162 - Disclosure - Right of Use Assets and Liabilities",
     "shortName": "Right of Use Assets and Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities",
     "longName": "9952163 - Disclosure - Accounts Payable and Accrued Liabilities",
     "shortName": "Accounts Payable and Accrued Liabilities",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.arvinas.com/role/LongTermDebt",
     "longName": "9952164 - Disclosure - Long-Term Debt",
     "shortName": "Long-Term Debt",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.arvinas.com/role/Equity",
     "longName": "9952165 - Disclosure - Equity",
     "shortName": "Equity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "17",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.arvinas.com/role/EquityMethodInvestments",
     "longName": "9952166 - Disclosure - Equity Method Investments",
     "shortName": "Equity Method Investments",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "18",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EquityMethodInvestmentsDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.arvinas.com/role/IncomeTaxes",
     "longName": "9952167 - Disclosure - Income Taxes",
     "shortName": "Income Taxes",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "19",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.arvinas.com/role/CommitmentsandContingencies",
     "longName": "9952168 - Disclosure - Commitments and Contingencies",
     "shortName": "Commitments and Contingencies",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "20",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.arvinas.com/role/NetLossPerShare",
     "longName": "9952169 - Disclosure - Net Loss Per Share",
     "shortName": "Net Loss Per Share",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "21",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.arvinas.com/role/RestructuringActivity",
     "longName": "9952170 - Disclosure - Restructuring Activity",
     "shortName": "Restructuring Activity",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "22",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.arvinas.com/role/SegmentInformation",
     "longName": "9952171 - Disclosure - Segment Information",
     "shortName": "Segment Information",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "23",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:SegmentReportingDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
     "longName": "995445 - Disclosure - Insider Trading Arrangements",
     "shortName": "Insider Trading Arrangements",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "24",
     "firstAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-4",
      "name": "ecd:Rule10b51ArrAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ecd:NonRule10b51ArrAdoptedFlag",
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R25": {
     "role": "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc",
     "longName": "995447 - Disclosure - Insider Trading Policies and Procedures",
     "shortName": "Insider Trading Policies and Procedures",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "25",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "ecd:InsiderTrdPoliciesProcAdoptedFlag",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R26": {
     "role": "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure",
     "longName": "995550 - Disclosure - Cybersecurity Risk Management and Strategy Disclosure",
     "shortName": "Cybersecurity Risk Management and Strategy Disclosure",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "26",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies",
     "longName": "9955511 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "27",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables",
     "longName": "9955512 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "28",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables",
     "longName": "9955513 - Disclosure - Research Collaboration and License Agreements (Tables)",
     "shortName": "Research Collaboration and License Agreements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "29",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables",
     "longName": "9955514 - Disclosure - Marketable Securities and Fair Value Measurements (Tables)",
     "shortName": "Marketable Securities and Fair Value Measurements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "30",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R31": {
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables",
     "longName": "9955515 - Disclosure - Property, Equipment and Leasehold Improvements (Tables)",
     "shortName": "Property, Equipment and Leasehold Improvements (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "31",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R32": {
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables",
     "longName": "9955516 - Disclosure - Right of Use Assets and Liabilities (Tables)",
     "shortName": "Right of Use Assets and Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "32",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:LeaseCostTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R33": {
     "role": "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables",
     "longName": "9955517 - Disclosure - Accounts Payable and Accrued Liabilities (Tables)",
     "shortName": "Accounts Payable and Accrued Liabilities (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "33",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R34": {
     "role": "http://www.arvinas.com/role/LongTermDebtTables",
     "longName": "9955518 - Disclosure - Long-Term Debt (Tables)",
     "shortName": "Long-Term Debt (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "34",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R35": {
     "role": "http://www.arvinas.com/role/EquityTables",
     "longName": "9955519 - Disclosure - Equity (Tables)",
     "shortName": "Equity (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "35",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R36": {
     "role": "http://www.arvinas.com/role/IncomeTaxesTables",
     "longName": "9955520 - Disclosure - Income Taxes (Tables)",
     "shortName": "Income Taxes (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "36",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R37": {
     "role": "http://www.arvinas.com/role/NetLossPerShareTables",
     "longName": "9955521 - Disclosure - Net Loss Per Share (Tables)",
     "shortName": "Net Loss Per Share (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "37",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R38": {
     "role": "http://www.arvinas.com/role/SegmentInformationTables",
     "longName": "9955522 - Disclosure - Segment Information (Tables)",
     "shortName": "Segment Information (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "38",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R39": {
     "role": "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails",
     "longName": "9955523 - Disclosure - Nature of Business and Basis of Presentation (Details)",
     "shortName": "Nature of Business and Basis of Presentation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "39",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "arvn:NumberOfWhollyOwnedSubsidiaries",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "arvn:NumberOfWhollyOwnedSubsidiaries",
      "unitRef": "subsidiary",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R40": {
     "role": "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails",
     "longName": "9955524 - Disclosure - Summary of Significant Accounting Policies - Cash Reconciliation (Details)",
     "shortName": "Summary of Significant Accounting Policies - Cash Reconciliation (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "40",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
       "us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R41": {
     "role": "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails",
     "longName": "9955525 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "41",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "us-gaap:ConcentrationRiskCreditRisk",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R42": {
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
     "longName": "9955526 - Disclosure - Research Collaboration and License Agreements - Additional Information (Details)",
     "shortName": "Research Collaboration and License Agreements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "42",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:ContractWithCustomerLiability",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-83",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R43": {
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails",
     "longName": "9955527 - Disclosure - Research Collaboration and License Agreements - Schedule of Contract Balances (Details)",
     "shortName": "Research Collaboration and License Agreements - Schedule of Contract Balances (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "43",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:AccountsReceivableNetCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R44": {
     "role": "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails",
     "longName": "9955528 - Disclosure - Research Collaboration and License Agreements - Schedule of Transaction Price Allocated to Performance Obligations (Details)",
     "shortName": "Research Collaboration and License Agreements - Schedule of Transaction Price Allocated to Performance Obligations (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "44",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-48",
      "name": "us-gaap:RevenueRemainingPerformanceObligation",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R45": {
     "role": "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails",
     "longName": "9955529 - Disclosure - Marketable Securities and Fair Value Measurements (Details)",
     "shortName": "Marketable Securities and Fair Value Measurements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "45",
     "firstAnchor": {
      "contextRef": "c-89",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-89",
      "name": "us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R46": {
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails",
     "longName": "9955530 - Disclosure - Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)",
     "shortName": "Property, Equipment and Leasehold Improvements - Schedule of Property, Equipment and Leasehold Improvements (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "46",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R47": {
     "role": "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
     "longName": "9955531 - Disclosure - Property, Equipment and Leasehold Improvements - Additional Information (Details)",
     "shortName": "Property, Equipment and Leasehold Improvements - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "47",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:DepreciationAndAmortization",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-97",
      "name": "arvn:PropertyPlantAndEquipmentWriteoff",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R48": {
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
     "longName": "9955532 - Disclosure - Right of Use Assets and Liabilities - Additional Information (Details)",
     "shortName": "Right of Use Assets and Liabilities - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "48",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:LandSubjectToGroundLeases",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-98",
      "name": "us-gaap:LandSubjectToGroundLeases",
      "unitRef": "sqft",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R49": {
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofComponentsofLeaseExpenseDetails",
     "longName": "9955533 - Disclosure - Right of Use Assets and Liabilities - Schedule of Components of Lease Expense (Details)",
     "shortName": "Right of Use Assets and Liabilities - Schedule of Components of Lease Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "49",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeaseCost",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LeaseCostTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R50": {
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails",
     "longName": "9955534 - Disclosure - Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "shortName": "Right of Use Assets and Liabilities - Schedule of Supplemental Cash Flow Information Related to Leases (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "50",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingLeasePayments",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R51": {
     "role": "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails",
     "longName": "9955535 - Disclosure - Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)",
     "shortName": "Right of Use Assets and Liabilities - Schedule of Maturities of Lease Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "51",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R52": {
     "role": "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails",
     "longName": "9955536 - Disclosure - Accounts Payable and Accrued Liabilities (Details)",
     "shortName": "Accounts Payable and Accrued Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "52",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:AccountsPayableCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R53": {
     "role": "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails",
     "longName": "9955537 - Disclosure - Long-Term Debt - Schedule of Long Term Debt (Details)",
     "shortName": "Long-Term Debt - Schedule of Long Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "53",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LongTermDebtCurrent",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R54": {
     "role": "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
     "longName": "9955538 - Disclosure - Long-Term Debt - Additional Information (Details)",
     "shortName": "Long-Term Debt - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "54",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DebtInstrumentInterestRateStatedPercentage",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfDebtInstrumentsTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-105",
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R55": {
     "role": "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails",
     "longName": "9955539 - Disclosure - Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)",
     "shortName": "Long-Term Debt - Schedule of Minimum Future Payments on Long-Term Debt (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "55",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R56": {
     "role": "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
     "longName": "9955540 - Disclosure - Equity - Additional Information (Details)",
     "shortName": "Equity - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "56",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R57": {
     "role": "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
     "longName": "9955541 - Disclosure - Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)",
     "shortName": "Equity - Schedule of Assumptions Used to Determine Fair Value of and Stock Options Granted (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "57",
     "firstAnchor": {
      "contextRef": "c-134",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-134",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "span",
       "div",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R58": {
     "role": "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails",
     "longName": "9955542 - Disclosure - Equity - Schedule of Stock Option Activity (Details)",
     "shortName": "Equity - Schedule of Stock Option Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "58",
     "firstAnchor": {
      "contextRef": "c-149",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-151",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R59": {
     "role": "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails",
     "longName": "9955543 - Disclosure - Equity - Schedule of Restricted Stock (Details)",
     "shortName": "Equity - Schedule of Restricted Stock (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "59",
     "firstAnchor": {
      "contextRef": "c-152",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-154",
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R60": {
     "role": "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
     "longName": "9955544 - Disclosure - Equity Method Investments (Details)",
     "shortName": "Equity Method Investments (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "60",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-163",
      "name": "us-gaap:OperatingExpenses",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "us-gaap:NetIncomeLoss",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R61": {
     "role": "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails",
     "longName": "9955545 - Disclosure - Income Taxes - Additional Information (Details)",
     "shortName": "Income Taxes - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "61",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "arvn:UnrecognizedTaxBenefitsNet",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R62": {
     "role": "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails",
     "longName": "9955546 - Disclosure - Income Taxes - Schedule of Income Tax Expense (Details)",
     "shortName": "Income Taxes - Schedule of Income Tax Expense (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "62",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:CurrentFederalTaxExpenseBenefit",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R63": {
     "role": "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails",
     "longName": "9955547 - Disclosure - Income Taxes - Schedule of Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "shortName": "Income Taxes - Schedule of Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "63",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R64": {
     "role": "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails",
     "longName": "9955548 - Disclosure - Income Taxes - Schedule of Income Tax Paid, Net of Refunds (Details)",
     "shortName": "Income Taxes - Schedule of Income Tax Paid, Net of Refunds (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "64",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:IncomeTaxPaidFederalAfterRefundReceived",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-3",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R65": {
     "role": "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails",
     "longName": "9955549 - Disclosure - Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)",
     "shortName": "Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "65",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R66": {
     "role": "http://www.arvinas.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails",
     "longName": "9955550 - Disclosure - Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "shortName": "Income Taxes - Schedule of Unrecognized Tax Benefits (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "66",
     "firstAnchor": {
      "contextRef": "c-6",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-13",
      "name": "us-gaap:UnrecognizedTaxBenefits",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    },
    "R67": {
     "role": "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
     "longName": "9955551 - Disclosure - Commitments and Contingencies (Details)",
     "shortName": "Commitments and Contingencies (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "67",
     "firstAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-5",
      "name": "us-gaap:LossContingencyAccrualAtCarryingValue",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R68": {
     "role": "http://www.arvinas.com/role/NetLossPerShareScheduleofBasicandDilutedLossperCommonShareDetails",
     "longName": "9955552 - Disclosure - Net Loss Per Share - Schedule of Basic and Diluted Loss per Common Share (Details)",
     "shortName": "Net Loss Per Share - Schedule of Basic and Diluted Loss per Common Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "68",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NetIncomeLoss",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R69": {
     "role": "http://www.arvinas.com/role/NetLossPerShareAdditionalInformationDetails",
     "longName": "9955553 - Disclosure - Net Loss Per Share - Additional Information (Details)",
     "shortName": "Net Loss Per Share - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "69",
     "firstAnchor": {
      "contextRef": "c-22",
      "name": "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
      "unitRef": "usdPerShare",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "3",
      "ancestors": [
       "us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": null
    },
    "R70": {
     "role": "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails",
     "longName": "9955554 - Disclosure - Net Loss Per Share - Securities Excluded from the Computations of Diluted Net Loss Per Share (Details)",
     "shortName": "Net Loss Per Share - Securities Excluded from the Computations of Diluted Net Loss Per Share (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "70",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "unitRef": "shares",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "ix:continuation",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R71": {
     "role": "http://www.arvinas.com/role/RestructuringActivityDetails",
     "longName": "9955555 - Disclosure - Restructuring Activity (Details)",
     "shortName": "Restructuring Activity (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "71",
     "firstAnchor": {
      "contextRef": "c-206",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-206",
      "name": "us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
      "unitRef": "number",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "2",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R72": {
     "role": "http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails",
     "longName": "9955556 - Disclosure - Segment Information - Additional Information (Details)",
     "shortName": "Segment Information - Additional Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "72",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:NumberOfOperatingSegments",
      "unitRef": "segment",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "INF",
      "ancestors": [
       "span",
       "div",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true,
      "unique": true
     }
    },
    "R73": {
     "role": "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails",
     "longName": "9955557 - Disclosure - Segment Information - Schedule of Financial Information (Details)",
     "shortName": "Segment Information - Schedule of Financial Information (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "73",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "c-211",
      "name": "us-gaap:Revenues",
      "unitRef": "usd",
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": "-5",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "div",
       "us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock",
       "ix:continuation",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "arvn-20251231.htm",
      "unique": true
     }
    }
   },
   "tag": {
    "arvn_A101CollegeStreetLLCMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "A101CollegeStreetLLCMember",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "101 College Street LLC",
        "label": "101 College Street LLC [Member]",
        "documentation": "101 College Street LLC"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ARV102Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ARV102Member",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARV-102",
        "label": "ARV-102 [Member]",
        "documentation": "ARV-102"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ARV110Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ARV110Member",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bavdegalutamide (ARV-110)",
        "label": "ARV-110 [Member]",
        "documentation": "ARV-110"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ARV393Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ARV393Member",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARV-393",
        "label": "ARV-393 [Member]",
        "documentation": "ARV-393"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ARV471Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ARV471Member",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vepdegestrant ARV-471",
        "label": "ARV-471 [Member]",
        "documentation": "ARV-471"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ARV766Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ARV766Member",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Luxdegalutamide (ARV-766)",
        "label": "ARV-766 [Member]",
        "documentation": "ARV-766"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ARV806Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ARV806Member",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ARV-806",
        "label": "ARV-806 [Member]",
        "documentation": "ARV-806"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounting Policies [Abstract]",
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails",
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "totalLabel": "Accounts payable and accrued liabilities",
        "label": "Accounts Payable and Accrued Liabilities, Current",
        "documentation": "Sum of the carrying values as of the balance sheet date of obligations incurred through that date and due within one year (or the operating cycle, if longer), including liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received, taxes, interest, rent and utilities, accrued salaries and bonuses, payroll taxes and fringe benefits."
       }
      }
     },
     "auth_ref": [
      "r46",
      "r47"
     ]
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts Payable and Accrued Liabilities",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r47",
      "r51",
      "r1250"
     ]
    },
    "arvn_AccountsPayableContractBalancesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "AccountsPayableContractBalancesCurrent",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Accounts Payable, Contract Balances, Current",
        "documentation": "Accounts Payable, Contract Balances, Current"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_AccountsPayableContractBalancesCurrentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "AccountsPayableContractBalancesCurrentAdditions",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Accounts Payable, Contract Balances, Current Additions",
        "documentation": "Accounts Payable, Contract Balances, Current Additions"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_AccountsPayableContractBalancesCurrentPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "AccountsPayableContractBalancesCurrentPayments",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments made",
        "label": "Accounts Payable, Contract Balances, Current Payments",
        "documentation": "Accounts Payable, Contract Balances, Current Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsPayableCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsPayableCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable",
        "label": "Accounts Payable, Current",
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r45",
      "r929"
     ]
    },
    "arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Accounts Receivable, After Allowance For Credit Loss, Current, Additions",
        "documentation": "Accounts Receivable, After Allowance For Credit Loss, Current, Additions"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Payments received",
        "label": "Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received",
        "documentation": "Accounts Receivable, After Allowance For Credit Loss, Current, Payments Received"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccountsReceivableNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccountsReceivableNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Accounts Receivable, after Allowance for Credit Loss, Current",
        "documentation": "Amount, after allowance for credit loss, of right to consideration from customer for product sold and service rendered in normal course of business, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1184"
     ]
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Net accretion of bond discounts/premiums",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "arvn_AccruedGeneralAndAdministrativeAndCommercialCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "AccruedGeneralAndAdministrativeAndCommercialCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative and commercial expenses",
        "label": "Accrued General And Administrative And Commercial, Current",
        "documentation": "Accrued General And Administrative And Commercial, Current"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedIncomeTaxesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedIncomeTaxesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income taxes",
        "label": "Accrued Income Taxes, Current",
        "documentation": "Carrying amount as of the balance sheet date of the unpaid sum of the known and estimated amounts payable to satisfy all currently due domestic and foreign income tax obligations."
       }
      }
     },
     "auth_ref": [
      "r47",
      "r94"
     ]
    },
    "us-gaap_AccruedLiabilitiesCurrentAndNoncurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedLiabilitiesCurrentAndNoncurrentAbstract",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accrued liabilities",
        "label": "Accrued Liabilities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccruedProfessionalFeesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Professional fees",
        "label": "Accrued Professional Fees, Current",
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "arvn_AccruedResearchAndDevelopmentExpenseCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "AccruedResearchAndDevelopmentExpenseCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development expenses",
        "label": "Accrued Research And Development Expense Current",
        "documentation": "Accrued research and development expense current."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: accumulated depreciation and amortization",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services."
       }
      }
     },
     "auth_ref": [
      "r34",
      "r161",
      "r722"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated other comprehensive income",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "documentation": "Amount, after tax, of accumulated increase (decrease) in equity from transaction and other event and circumstance from nonowner source."
       }
      }
     },
     "auth_ref": [
      "r17",
      "r18",
      "r63",
      "r165",
      "r718",
      "r759",
      "r760",
      "r1271"
     ]
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Other Comprehensive Loss (Income)",
        "label": "AOCI Attributable to Parent [Member]",
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r2",
      "r10",
      "r18",
      "r558",
      "r561",
      "r626",
      "r755",
      "r756",
      "r1108",
      "r1109",
      "r1110",
      "r1168",
      "r1169",
      "r1170",
      "r1171"
     ]
    },
    "ecd_Additional402vDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Additional402vDisclosureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional 402(v) Disclosure",
        "label": "Additional 402(v) Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1012"
     ]
    },
    "us-gaap_AdditionalPaidInCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional paid-in capital",
        "label": "Additional Paid in Capital",
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock."
       }
      }
     },
     "auth_ref": [
      "r58",
      "r929",
      "r1334"
     ]
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdditionalPaidInCapitalMember",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additional Paid-in Capital",
        "label": "Additional Paid-in Capital [Member]",
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders."
       }
      }
     },
     "auth_ref": [
      "r771",
      "r1168",
      "r1169",
      "r1170",
      "r1171",
      "r1272",
      "r1336"
     ]
    },
    "ecd_AdjToCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation, Amount",
        "label": "Adjustment to Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AdjToCompAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToCompAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Compensation:",
        "label": "Adjustment to Compensation [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AdjToNonPeoNeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToNonPeoNeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment to Non-PEO NEO Compensation Footnote",
        "label": "Adjustment to Non-PEO NEO Compensation Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AdjToPeoCompFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AdjToPeoCompFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustment To PEO Compensation, Footnote",
        "label": "Adjustment To PEO Compensation, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "APIC, Share-Based Payment Arrangement, Increase for Cost Recognition",
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r445"
     ]
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquityParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock, offering costs",
        "label": "Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs",
        "documentation": "Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r86"
     ]
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_AggregateIntrinsicValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "AggregateIntrinsicValueAbstract",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Intrinsic Value",
        "label": "Aggregate Intrinsic Value [Abstract]",
        "documentation": "Aggregate Intrinsic Value"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_AggtChngPnsnValInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtChngPnsnValInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table",
        "label": "Aggregate Change in Present Value of Accumulated Benefit for All Pension Plans Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1070"
     ]
    },
    "ecd_AggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Amount",
        "label": "Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r994",
      "r1004",
      "r1037"
     ]
    },
    "ecd_AggtErrCompNotYetDeterminedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtErrCompNotYetDeterminedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Erroneous Compensation Not Yet Determined",
        "label": "Aggregate Erroneous Compensation Not Yet Determined [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r986",
      "r997",
      "r1007",
      "r1040"
     ]
    },
    "ecd_AggtPnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AggtPnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Pension Adjustments Service Cost",
        "label": "Aggregate Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1071"
     ]
    },
    "ecd_AllAdjToCompMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllAdjToCompMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Adjustments to Compensation",
        "label": "All Adjustments to Compensation [Member]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_AllExecutiveCategoriesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllExecutiveCategoriesMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Executive Categories",
        "label": "All Executive Categories [Member]"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_AllIndividualsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllIndividualsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Individuals",
        "label": "All Individuals [Member]"
       }
      }
     },
     "auth_ref": [
      "r987",
      "r998",
      "r1008",
      "r1032",
      "r1041",
      "r1045",
      "r1053"
     ]
    },
    "ecd_AllTradingArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AllTradingArrangementsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "All Trading Arrangements",
        "label": "All Trading Arrangements [Member]"
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AllocatedShareBasedCompensationExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense",
        "label": "Share-Based Payment Arrangement, Expense",
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized."
       }
      }
     },
     "auth_ref": [
      "r477",
      "r484",
      "r493"
     ]
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_AnnualLicenseFeePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "AnnualLicenseFeePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual payment for license",
        "label": "Annual License Fee Payment",
        "documentation": "Annual license fee payment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per common share (in shares)",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities [Axis]",
        "label": "Antidilutive Securities [Axis]",
        "documentation": "Information by type of antidilutive security."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareAdditionalInformationDetails",
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities Excluded From Computation Of Earnings Per Share [Line Items]",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AntidilutiveSecuritiesNameDomain",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Antidilutive Securities, Name [Domain]",
        "label": "Antidilutive Securities, Name [Domain]",
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_ArrangementsAndNonarrangementTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ArrangementsAndNonarrangementTransactionsMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Domain]",
        "documentation": "Collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_AssetPledgedAsCollateralMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetPledgedAsCollateralMember",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Asset Pledged as Collateral",
        "label": "Asset Pledged as Collateral [Member]",
        "documentation": "Asset pledged as collateral."
       }
      }
     },
     "auth_ref": [
      "r548",
      "r780",
      "r911",
      "r1159",
      "r1161",
      "r1297"
     ]
    },
    "us-gaap_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total assets",
        "label": "Assets",
        "documentation": "Amount of asset recognized for present right to economic benefit."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r105",
      "r162",
      "r187",
      "r191",
      "r192",
      "r228",
      "r240",
      "r258",
      "r262",
      "r307",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r548",
      "r550",
      "r598",
      "r703",
      "r704",
      "r714",
      "r800",
      "r880",
      "r881",
      "r893",
      "r929",
      "r946",
      "r947",
      "r961",
      "r1214",
      "r1215",
      "r1289"
     ]
    },
    "us-gaap_AssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Assets",
        "label": "Assets [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_AssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current assets",
        "label": "Assets, Current",
        "documentation": "Amount of asset recognized for present right to economic benefit, classified as current."
       }
      }
     },
     "auth_ref": [
      "r157",
      "r166",
      "r187",
      "r191",
      "r192",
      "r307",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r548",
      "r550",
      "r598",
      "r929",
      "r1214",
      "r1215",
      "r1289"
     ]
    },
    "us-gaap_AssetsCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AssetsCurrentAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Current assets:",
        "label": "Assets, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_AtTheMarketOfferingMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "AtTheMarketOfferingMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "At-the-Market Offering",
        "label": "At The Market Offering [Member]",
        "documentation": "At the market offering."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_AuditInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "AuditInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Audit Information [Abstract]",
        "documentation": "Audit Information"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AuditorFirmId": {
     "xbrltype": "nonemptySequenceNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorFirmId",
     "presentation": [
      "http://www.arvinas.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Firm ID",
        "label": "Auditor Firm ID",
        "documentation": "PCAOB issued Audit Firm Identifier"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r990"
     ]
    },
    "dei_AuditorLocation": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorLocation",
     "presentation": [
      "http://www.arvinas.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Location",
        "label": "Auditor Location"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r990"
     ]
    },
    "dei_AuditorName": {
     "xbrltype": "internationalNameItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "AuditorName",
     "presentation": [
      "http://www.arvinas.com/role/AuditInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Auditor Name",
        "label": "Auditor Name"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r990"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Gross Unrealized Gains",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Gain, before Tax",
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r276"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Gross Unrealized Losses",
        "label": "Debt Securities, Available-for-Sale, Accumulated Gross Unrealized Loss, before Tax",
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r277"
     ]
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleDebtSecuritiesAmortizedCostBasis",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Amortized Cost",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost",
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r273",
      "r316",
      "r713"
     ]
    },
    "us-gaap_AvailableForSaleSecuritiesDebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AvailableForSaleSecuritiesDebtSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails": {
       "parentTag": "us-gaap_AvailableForSaleDebtSecuritiesAmortizedCostBasis",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value",
        "label": "Debt Securities, Available-for-Sale",
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r274",
      "r316",
      "r572",
      "r591",
      "r592",
      "r593",
      "r594",
      "r699",
      "r858",
      "r915",
      "r919",
      "r926",
      "r1185",
      "r1276",
      "r1277",
      "r1278"
     ]
    },
    "ecd_AwardExrcPrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardExrcPrice",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise Price",
        "label": "Award Exercise Price"
       }
      }
     },
     "auth_ref": [
      "r1048"
     ]
    },
    "ecd_AwardGrantDateFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardGrantDateFairValue",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value as of Grant Date",
        "label": "Award Grant Date Fair Value"
       }
      }
     },
     "auth_ref": [
      "r1049"
     ]
    },
    "ecd_AwardTmgDiscLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgDiscLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Award Timing Disclosures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "ecd_AwardTmgHowMnpiCnsdrdTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgHowMnpiCnsdrdTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing, How MNPI Considered",
        "label": "Award Timing, How MNPI Considered [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "ecd_AwardTmgMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Method",
        "label": "Award Timing Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "ecd_AwardTmgMnpiCnsdrdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiCnsdrdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Considered",
        "label": "Award Timing MNPI Considered [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "ecd_AwardTmgMnpiDiscTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgMnpiDiscTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing MNPI Disclosure",
        "label": "Award Timing MNPI Disclosure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "ecd_AwardTmgPredtrmndFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardTmgPredtrmndFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Timing Predetermined",
        "label": "Award Timing Predetermined [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "us-gaap_AwardTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "AwardTypeAxis",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Axis]",
        "label": "Award Type [Axis]",
        "documentation": "Information by type of award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "ecd_AwardUndrlygSecuritiesAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardUndrlygSecuritiesAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Securities",
        "label": "Award Underlying Securities Amount"
       }
      }
     },
     "auth_ref": [
      "r1047"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Awards Close in Time to MNPI Disclosures, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1046"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures",
        "label": "Awards Close in Time to MNPI Disclosures [Table]"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "ecd_AwardsCloseToMnpiDiscTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "AwardsCloseToMnpiDiscTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Awards Close in Time to MNPI Disclosures, Table",
        "label": "Awards Close in Time to MNPI Disclosures [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1045"
     ]
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Basis of Presentation",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1158"
     ]
    },
    "arvn_BayerAGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "BayerAGMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bayer",
        "label": "Bayer A G [Member]",
        "documentation": "Bayer AG."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_BayerCropScienceLPMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "BayerCropScienceLPMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Bayer LP",
        "label": "Bayer Crop Science L P [Member]",
        "documentation": "Bayer CropScience LP."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_BusinessDescriptionAndBasisOfPresentationTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "BusinessDescriptionAndBasisOfPresentationTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Nature of Business and Basis of Presentation",
        "label": "Business Description and Basis of Presentation [Text Block]",
        "documentation": "The entire disclosure for the business description and basis of presentation concepts. Business description describes the nature and type of organization including but not limited to organizational structure as may be applicable to holding companies, parent and subsidiary relationships, business divisions, business units, business segments, affiliates and information about significant ownership of the reporting entity. Basis of presentation describes the underlying basis used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS)."
       }
      }
     },
     "auth_ref": [
      "r1094",
      "r1158"
     ]
    },
    "stpr_CA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "CA",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "California",
        "label": "CALIFORNIA"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_CT": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "CT",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State of Connecticut",
        "label": "CONNECTICUT"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalExpendituresIncurredButNotYetPaid": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalExpendituresIncurredButNotYetPaid",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Purchases of property, equipment and leasehold improvements unpaid at period end",
        "label": "Capital Expenditures Incurred but Not yet Paid",
        "documentation": "Future cash outflow to pay for purchases of fixed assets that have occurred."
       }
      }
     },
     "auth_ref": [
      "r24",
      "r25",
      "r26"
     ]
    },
    "us-gaap_CapitalizedContractCostAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of collaboration contract asset",
        "label": "Capitalized Contract Cost, Amortization",
        "documentation": "Amount of amortization expense for asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r179",
      "r180",
      "r320"
     ]
    },
    "arvn_CapitalizedContractCostAmortizationDuringPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "CapitalizedContractCostAmortizationDuringPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Amortization",
        "label": "Capitalized Contract Cost, Amortization During Period",
        "documentation": "Capitalized Contract Cost, Amortization During Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CapitalizedContractCostGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CapitalizedContractCostGross",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized costs",
        "label": "Capitalized Contract Cost, Gross",
        "documentation": "Amount, before accumulated amortization and accumulated impairment loss, of asset recognized from cost incurred to obtain or fulfill contract with customer."
       }
      }
     },
     "auth_ref": [
      "r1204"
     ]
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents",
        "label": "Cash and Cash Equivalent",
        "documentation": "Amount of cash and cash equivalent. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r159",
      "r861"
     ]
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash and Cash Equivalents",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value."
       }
      }
     },
     "auth_ref": [
      "r22"
     ]
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restricted Cash",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits."
       }
      }
     },
     "auth_ref": [
      "r22",
      "r91"
     ]
    },
    "arvn_CashCashEquivalentsRestrictedCashAndMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "CashCashEquivalentsRestrictedCashAndMarketableSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash, cash equivalents, restricted cash and marketable securities",
        "label": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities",
        "documentation": "Cash, Cash Equivalents, Restricted Cash and Marketable Securities"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Cash, cash equivalents and restricted cash, beginning of the period",
        "periodEndLabel": "Cash, cash equivalents and restricted cash, end of the period",
        "totalLabel": "Cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Continuing Operation",
        "documentation": "Amount of cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; attributable to continuing operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r21",
      "r73",
      "r184"
     ]
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net increase (decrease) in cash, cash equivalents and restricted cash",
        "label": "Cash, Cash Equivalent, Restricted Cash, and Restricted Cash Equivalent, Period Increase (Decrease), Including Exchange Rate Effect and Discontinued Operation",
        "documentation": "Amount of increase (decrease) in cash and cash equivalent, and cash and cash equivalent restricted to withdrawal or usage; including effect from exchange rate change and including, but not limited to, discontinued operation. Cash includes, but is not limited to, currency on hand, demand deposit with financial institution, and account with general characteristic of demand deposit. Cash equivalent includes, but is not limited to, short-term, highly liquid investment that is both readily convertible to known amount of cash and so near maturity that it presents insignificant risk of change in value because of change in interest rate."
       }
      }
     },
     "auth_ref": [
      "r1",
      "r73"
     ]
    },
    "arvn_CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "CashPaidForAmountsIncludedInMeasurementOfLeaseLiabilitiesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash paid for amounts included in the measurement of lease liabilities:",
        "label": "Cash Paid For Amounts Included In Measurement Of Lease Liabilities [Abstract]",
        "documentation": "Cash paid for amounts included in the measurement of lease liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ChangeInAccountingEstimateByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingEstimateByTypeAxis",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Estimate by Type [Axis]",
        "label": "Effect of Change in Accounting Estimate, Type [Axis]",
        "documentation": "Information by type of effect from change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r209",
      "r703",
      "r705"
     ]
    },
    "us-gaap_ChangeInAccountingEstimateTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ChangeInAccountingEstimateTypeDomain",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Accounting Estimate, Type [Domain]",
        "label": "Effect of Change in Accounting Estimate, Type [Domain]",
        "documentation": "Type of effect from change in accounting estimate."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r209",
      "r703",
      "r705"
     ]
    },
    "arvn_ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ChangeInAccountsPayableAfterAllowanceForCreditLossRollForward",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable related to collaborations",
        "label": "Change in Accounts Payable, after Allowance for Credit Loss [Roll Forward]",
        "documentation": "Change in Accounts Payable, after Allowance for Credit Loss"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ChangeInAccountsReceivableAfterAllowanceForCreditLossRollForward",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts receivable",
        "label": "Change in Accounts Receivable, after Allowance for Credit Loss [Roll Forward]",
        "documentation": "Change in Accounts Receivable, after Allowance for Credit Loss"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ChangeInCollaborationContractAssetAndOtherAssetsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ChangeInCollaborationContractAssetAndOtherAssetsRollForward",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract assets: Collaboration contract asset",
        "label": "Change in Collaboration Contract Asset And Other Assets [Roll Forward]",
        "documentation": "Change in Collaboration Contract Asset And Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ChangeInContractWithCustomerLiabilityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ChangeInContractWithCustomerLiabilityRollForward",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract liabilities: Deferred revenue",
        "label": "Change in Contract with Customer, Liability [Roll Forward]",
        "documentation": "Change in Contract with Customer, Liability"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_ChangedPeerGroupFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChangedPeerGroupFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changed Peer Group, Footnote",
        "label": "Changed Peer Group, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValAsOfVstngDtOfPrrYrEqtyAwrdsVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year",
        "label": "Change in Fair Value as of Vesting Date of Prior Year Equity Awards Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1020"
     ]
    },
    "ecd_ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ChngInFrValOfOutsdngAndUnvstdEqtyAwrdsGrntdInPrrYrsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested",
        "label": "Year-over-Year Change in Fair Value of Equity Awards Granted in Prior Years That are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1018"
     ]
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightAxis",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/NetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Axis]",
        "label": "Class of Warrant or Right [Axis]",
        "documentation": "Information by type of warrant or right issued."
       }
      }
     },
     "auth_ref": [
      "r1217"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightDomain",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/NetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Class of Warrant or Right [Domain]",
        "label": "Class of Warrant or Right [Domain]",
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/NetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrant exercise price (in usd per share)",
        "label": "Class of Warrant or Right, Exercise Price of Warrants or Rights",
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r194",
      "r412"
     ]
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Warrants to be purchased (in shares)",
        "label": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights",
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares."
       }
      }
     },
     "auth_ref": [
      "r412"
     ]
    },
    "ecd_CoSelectedMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Amount",
        "label": "Company Selected Measure Amount"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_CoSelectedMeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CoSelectedMeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Company Selected Measure Name",
        "label": "Company Selected Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "arvn_CollaborationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "CollaborationAgreementMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration Agreement",
        "label": "Collaboration Agreement [Member]",
        "documentation": "Collaboration Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_CollaborationContractAssetAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "CollaborationContractAssetAndOtherAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration contract asset and other assets",
        "label": "Collaboration Contract Asset And Other Assets",
        "documentation": "Collaboration Contract Asset And Other Assets"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CollaborativeArrangementDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CollaborativeArrangementDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Collaboration and License Agreements",
        "label": "Collaborative Arrangement Disclosure [Text Block]",
        "documentation": "The entire disclosure for collaborative arrangements in which the entity is a participant, including a) information about the nature and purpose of such arrangements; b) its rights and obligations thereunder; c) the accounting policy for collaborative arrangements; and d) the income statement classification and amounts attributable to transactions arising from the collaborative arrangement between participants."
       }
      }
     },
     "auth_ref": [
      "r118",
      "r545",
      "r546"
     ]
    },
    "arvn_CollaborativeArrangementRightsAndObligationsMilestonePayment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "CollaborativeArrangementRightsAndObligationsMilestonePayment",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone payment the Company will make",
        "label": "Collaborative Arrangement, Rights And Obligations, Milestone Payment",
        "documentation": "Collaborative Arrangement, Rights And Obligations, Milestone Payment"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_CollaboratorOneMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "CollaboratorOneMember",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborator One",
        "label": "Collaborator One [Member]",
        "documentation": "Collaborator one."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_CommercialMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "CommercialMilestonesMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commercial Milestones",
        "label": "Commercial Milestones [Member]",
        "documentation": "Commercial milestones."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingencies": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingencies",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and contingencies (Note 12)",
        "label": "Commitments and Contingencies",
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur."
       }
      }
     },
     "auth_ref": [
      "r52",
      "r97",
      "r715",
      "r787"
     ]
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies Disclosure [Abstract]",
        "label": "Commitments and Contingencies Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingencies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments and Contingencies",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "documentation": "The entire disclosure for commitments and contingencies."
       }
      }
     },
     "auth_ref": [
      "r82",
      "r352",
      "r353",
      "r844",
      "r1205",
      "r1211"
     ]
    },
    "arvn_CommitmentsAndContingenciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "CommitmentsAndContingenciesLineItems",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Line Items]",
        "label": "Commitments And Contingencies [Line Items]",
        "documentation": "Commitments and contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_CommitmentsAndContingenciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "CommitmentsAndContingenciesTable",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Commitments And Contingencies [Table]",
        "label": "Commitments And Contingencies [Table]",
        "documentation": "Commitments and contingencies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for issuance (in shares)",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "documentation": "Aggregate number of common shares reserved for future issuance."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_CommonStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockMember",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Common",
        "terseLabel": "Common Shares",
        "label": "Common Stock [Member]",
        "documentation": "Stock that is subordinate to all other stock of the issuer."
       }
      }
     },
     "auth_ref": [
      "r951",
      "r952",
      "r953",
      "r955",
      "r956",
      "r957",
      "r958",
      "r1168",
      "r1169",
      "r1171",
      "r1272",
      "r1333",
      "r1336"
     ]
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, par value (in dollars per share)",
        "label": "Common Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of common stock."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesAuthorized",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares authorized (in shares)",
        "label": "Common Stock, Shares Authorized",
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r788"
     ]
    },
    "us-gaap_CommonStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesIssued",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Common Stock, Shares, Issued",
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury."
       }
      }
     },
     "auth_ref": [
      "r57"
     ]
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockSharesOutstanding",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares outstanding (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Common Stock, Shares, Outstanding",
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r57",
      "r788",
      "r806",
      "r1336",
      "r1337"
     ]
    },
    "us-gaap_CommonStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CommonStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, $0.001 par value, 73.5 shares issued and 63.5 shares outstanding as of December\u00a031, 2025, and 68.8 shares issued and outstanding as of December\u00a031, 2024",
        "label": "Common Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r401",
      "r407",
      "r717",
      "r929"
     ]
    },
    "ecd_CompActuallyPaidVsCoSelectedMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsCoSelectedMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Company Selected Measure",
        "label": "Compensation Actually Paid vs. Company Selected Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1029"
     ]
    },
    "ecd_CompActuallyPaidVsNetIncomeTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsNetIncomeTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Net Income",
        "label": "Compensation Actually Paid vs. Net Income [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1028"
     ]
    },
    "ecd_CompActuallyPaidVsOtherMeasureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsOtherMeasureTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Other Measure",
        "label": "Compensation Actually Paid vs. Other Measure [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "ecd_CompActuallyPaidVsTotalShareholderRtnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "CompActuallyPaidVsTotalShareholderRtnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Actually Paid vs. Total Shareholder Return",
        "label": "Compensation Actually Paid vs. Total Shareholder Return [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1027"
     ]
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ComprehensiveIncomeNetOfTax",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Comprehensive loss",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners."
       }
      }
     },
     "auth_ref": [
      "r19",
      "r168",
      "r170",
      "r176",
      "r701",
      "r728",
      "r729"
     ]
    },
    "us-gaap_ConcentrationRiskBenchmarkDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskBenchmarkDomain",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Domain]",
        "label": "Concentration Risk Benchmark [Domain]",
        "documentation": "The denominator in a calculation of a disclosed concentration risk percentage."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r269",
      "r763",
      "r764",
      "r843",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178"
     ]
    },
    "us-gaap_ConcentrationRiskByBenchmarkAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByBenchmarkAxis",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Benchmark [Axis]",
        "label": "Concentration Risk Benchmark [Axis]",
        "documentation": "Information by benchmark of concentration risk."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r269",
      "r763",
      "r764",
      "r843",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178"
     ]
    },
    "us-gaap_ConcentrationRiskByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskByTypeAxis",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Axis]",
        "label": "Concentration Risk Type [Axis]",
        "documentation": "Information by type of concentration risk, for example, but not limited to, asset, liability, net assets, geographic, customer, employees, supplier, lender."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r269",
      "r763",
      "r764",
      "r843",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178"
     ]
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskCreditRisk",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration of Credit Risk and Other Risks and Uncertainties",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for credit risk. Includes, but is not limited to, policy for entering into master netting arrangement or similar agreement to mitigate credit risk of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r595",
      "r596"
     ]
    },
    "us-gaap_ConcentrationRiskPercentage1": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskPercentage1",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration risk, percentage",
        "label": "Concentration Risk, Percentage",
        "documentation": "For an entity that discloses a concentration risk in relation to quantitative amount, which serves as the \"benchmark\" (or denominator) in the equation, this concept represents the concentration percentage derived from the division."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r269",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178"
     ]
    },
    "us-gaap_ConcentrationRiskTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConcentrationRiskTypeDomain",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Concentration Risk Type [Domain]",
        "label": "Concentration Risk Type [Domain]",
        "documentation": "For an entity that discloses a concentration risk as a percentage of some financial balance or benchmark, identifies the type (for example, asset, liability, net assets, geographic, customer, employees, supplier, lender) of the concentration."
       }
      }
     },
     "auth_ref": [
      "r231",
      "r269",
      "r763",
      "r764",
      "r843",
      "r1174",
      "r1175",
      "r1176",
      "r1177",
      "r1178"
     ]
    },
    "us-gaap_ConsolidationPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ConsolidationPolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidation",
        "label": "Consolidation, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r870"
     ]
    },
    "arvn_ContractTerminationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ContractTerminationAxis",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Termination [Axis]",
        "label": "Contract Termination [Axis]",
        "documentation": "Contract Termination"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ContractTerminationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ContractTerminationDomain",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract Termination [Domain]",
        "label": "Contract Termination [Domain]",
        "documentation": "Contract Termination [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerAssetAndLiabilityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetAndLiabilityTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Contract Balances",
        "label": "Contract with Customer, Contract Asset, Contract Liability, and Receivable [Table Text Block]",
        "documentation": "Tabular disclosure of receivable, contract asset, and contract liability from contract with customer. Includes, but is not limited to, change in contract asset and contract liability."
       }
      }
     },
     "auth_ref": [
      "r1219"
     ]
    },
    "us-gaap_ContractWithCustomerAssetNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerAssetNet",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract revenue receivable if milestones achieved",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Contract with Customer, Asset, after Allowance for Credit Loss",
        "documentation": "Amount, after allowance for credit loss, of right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r416",
      "r417",
      "r429"
     ]
    },
    "arvn_ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions",
        "label": "Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements",
        "documentation": "Contract With Customer, Assets, Increase (Decrease) For Additions To Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contract with customer, liability",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Contract with Customer, Liability",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r417",
      "r429"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Current",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as current."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r417",
      "r429"
     ]
    },
    "arvn_ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Additions to collaboration agreements",
        "label": "Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements",
        "documentation": "Contract With Customer, Liability, Increase (Decrease) For Additions To Collaboration Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ContractWithCustomerLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Contract with Customer, Liability, Noncurrent",
        "documentation": "Amount of obligation to transfer good or service to customer for which consideration has been received or is receivable, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r414",
      "r415",
      "r417",
      "r429"
     ]
    },
    "us-gaap_ContractWithCustomerLiabilityRevenueRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ContractWithCustomerLiabilityRevenueRecognized",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Revenue recognized from balances held at the beginning of the period",
        "label": "Contract with Customer, Liability, Revenue Recognized",
        "documentation": "Amount of revenue recognized that was previously included in balance of obligation to transfer good or service to customer for which consideration from customer has been received or is due."
       }
      }
     },
     "auth_ref": [
      "r430"
     ]
    },
    "arvn_ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofContractBalancesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized from balances not held at the beginning of the period",
        "label": "Contract with Customer, Liability, Revenue Recognized From New Collaboration",
        "documentation": "Contract with Customer, Liability, Revenue Recognized From New Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CorporateBondSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CorporateBondSecuritiesMember",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Corporate bonds",
        "label": "Corporate Bond Securities [Member]",
        "documentation": "This category includes information about long-term debt securities that are issued by either a domestic or foreign corporate business entity with a date certain promise of repayment and a return to the holder for the time value of money (for example, variable or fixed interest, original issue discount)."
       }
      }
     },
     "auth_ref": []
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Axis]",
        "label": "Counterparty Name [Axis]",
        "documentation": "Information by name of counterparty. A counterparty is the other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r187",
      "r196",
      "r197",
      "r374",
      "r410",
      "r627",
      "r645",
      "r711",
      "r862",
      "r863",
      "r864",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1267",
      "r1268",
      "r1269",
      "r1270"
     ]
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentFederalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentFederalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Current Federal Tax Expense (Benefit)",
        "documentation": "Amount of current federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1159",
      "r1165",
      "r1260"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current Fiscal Year End Date",
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current",
        "label": "Current Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) pertaining to taxable income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r526",
      "r1159",
      "r1165"
     ]
    },
    "us-gaap_CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current:",
        "label": "Current Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_CurrentStateAndLocalTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CurrentStateAndLocalTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_CurrentIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local",
        "label": "Current State and Local Tax Expense (Benefit)",
        "documentation": "Amount of current state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, current regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1085",
      "r1159",
      "r1165",
      "r1260"
     ]
    },
    "us-gaap_CustomerConcentrationRiskMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "CustomerConcentrationRiskMember",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Customer Concentration Risk",
        "label": "Customer Concentration Risk [Member]",
        "documentation": "Reflects the percentage that revenues in the period from one or more significant customers is to net revenues, as defined by the entity, such as total net revenues, product line revenues, segment revenues. The risk is the materially adverse effects of loss of a significant customer."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r1175"
     ]
    },
    "cyd_CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r1064"
     ]
    },
    "cyd_CybersecurityRiskBoardOfDirectorsOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskBoardOfDirectorsOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Board of Directors Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r1064"
     ]
    },
    "cyd_CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Expertise of Management Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r1066"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Flag]"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r1066"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]"
       }
      }
     },
     "auth_ref": [
      "r979",
      "r1068"
     ]
    },
    "cyd_CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Positions or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r977",
      "r1066"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r970",
      "r1059"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r1060"
     ]
    },
    "cyd_CybersecurityRiskManagementProcessesIntegratedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementProcessesIntegratedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Processes Integrated [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r971",
      "r1060"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Abstract]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r1058"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceLineItems",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r1058"
     ]
    },
    "cyd_CybersecurityRiskManagementStrategyAndGovernanceTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementStrategyAndGovernanceTable",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management, Strategy, and Governance [Table]"
       }
      }
     },
     "auth_ref": [
      "r969",
      "r1058"
     ]
    },
    "cyd_CybersecurityRiskManagementThirdPartyEngagedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskManagementThirdPartyEngagedFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Management Third Party Engaged [Flag]"
       }
      }
     },
     "auth_ref": [
      "r972",
      "r1061"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r1063"
     ]
    },
    "cyd_CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r974",
      "r1063"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r975",
      "r1064"
     ]
    },
    "cyd_CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r978",
      "r1067"
     ]
    },
    "cyd_CybersecurityRiskRoleOfManagementTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskRoleOfManagementTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Role of Management [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r976",
      "r1065"
     ]
    },
    "cyd_CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/cyd/2025",
     "localname": "CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag",
     "presentation": [
      "http://xbrl.sec.gov/cyd/role/CybersecurityRiskManagementAndStrategyDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]"
       }
      }
     },
     "auth_ref": [
      "r973",
      "r1062"
     ]
    },
    "us-gaap_DebtDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Disclosure [Abstract]",
        "label": "Debt Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebt"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Term Debt",
        "label": "Debt Disclosure [Text Block]",
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants."
       }
      }
     },
     "auth_ref": [
      "r83",
      "r187",
      "r190",
      "r334",
      "r335",
      "r336",
      "r337",
      "r338",
      "r359",
      "r360",
      "r370",
      "r376",
      "r377",
      "r378",
      "r379",
      "r380",
      "r381",
      "r386",
      "r393",
      "r394",
      "r396",
      "r556",
      "r608"
     ]
    },
    "us-gaap_DebtInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentAxis",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Axis]",
        "label": "Debt Instrument [Axis]",
        "documentation": "Information by type of debt instrument, including, but not limited to, draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r46",
      "r47",
      "r93",
      "r96",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r927",
      "r1159",
      "r1160",
      "r1162",
      "r1167",
      "r1206",
      "r1207",
      "r1208",
      "r1284",
      "r1285",
      "r1299"
     ]
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentFaceAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument face amount",
        "label": "Debt Instrument, Face Amount",
        "documentation": "Face (par) amount of debt instrument at time of issuance."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r608",
      "r609",
      "r889",
      "r890",
      "r927"
     ]
    },
    "arvn_DebtInstrumentInterestPaymentsTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "DebtInstrumentInterestPaymentsTerm",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt instrument interest payments term (in months)",
        "label": "Debt Instrument Interest Payments Term",
        "documentation": "Debt instrument interest payments term."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentInterestRateStatedPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentInterestRateStatedPercentage",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails",
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Interest Rate",
        "terseLabel": "Debt instrument bearing interest rate",
        "label": "Debt Instrument, Interest Rate, Stated Percentage",
        "documentation": "Contractual interest rate for funds borrowed, under the debt agreement."
       }
      }
     },
     "auth_ref": [
      "r49",
      "r372"
     ]
    },
    "us-gaap_DebtInstrumentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentLineItems",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Line Items]",
        "label": "Debt Instrument [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r556",
      "r707",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r927",
      "r1159",
      "r1160",
      "r1162",
      "r1167",
      "r1284",
      "r1285"
     ]
    },
    "arvn_DebtInstrumentLoanForgiveness": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "DebtInstrumentLoanForgiveness",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loan forgiveness",
        "label": "Debt Instrument Loan Forgiveness",
        "documentation": "Debt Instrument Loan Forgiveness"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DebtInstrumentNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentNameDomain",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument, Name [Domain]",
        "label": "Debt Instrument, Name [Domain]",
        "documentation": "The name for the particular debt instrument or borrowing that distinguishes it from other debt instruments or borrowings, including draws against credit facilities."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r927",
      "r1159",
      "r1160",
      "r1162",
      "r1167",
      "r1206",
      "r1207",
      "r1208",
      "r1284",
      "r1285",
      "r1299"
     ]
    },
    "us-gaap_DebtInstrumentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtInstrumentTable",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt Instrument [Table]",
        "label": "Schedule of Long-Term Debt Instruments [Table]",
        "documentation": "Disclosure of information about long-term debt instrument or arrangement."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r35",
      "r36",
      "r43",
      "r84",
      "r85",
      "r371",
      "r372",
      "r373",
      "r374",
      "r375",
      "r377",
      "r382",
      "r383",
      "r384",
      "r385",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r395",
      "r556",
      "r707",
      "r888",
      "r889",
      "r890",
      "r891",
      "r892",
      "r927",
      "r1159",
      "r1160",
      "r1162",
      "r1167",
      "r1284",
      "r1285"
     ]
    },
    "us-gaap_DebtSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecurities",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Debt securities",
        "label": "Debt Securities",
        "documentation": "Amount, after allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), investment in debt security measured at amortized cost (held-to-maturity), and investment in debt security measured at fair value with change in fair value recognized in net income (trading)."
       }
      }
     },
     "auth_ref": [
      "r271",
      "r711",
      "r712",
      "r948",
      "r950"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGainLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleRealizedGainLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Loss on sale of marketable securities",
        "label": "Debt Securities, Available-for-Sale, Realized Gain (Loss)",
        "documentation": "Amount of realized gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1198"
     ]
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DebtSecuritiesAvailableForSaleTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Available-for-Sale Marketable Securities",
        "label": "Debt Securities, Available-for-Sale [Table Text Block]",
        "documentation": "Tabular disclosure of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale)."
       }
      }
     },
     "auth_ref": [
      "r1187",
      "r1188",
      "r1189",
      "r1190",
      "r1191",
      "r1192",
      "r1193",
      "r1194",
      "r1195",
      "r1196",
      "r1197",
      "r1198"
     ]
    },
    "us-gaap_DeferredFederalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredFederalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal",
        "label": "Deferred Federal Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred federal tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred national tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1165",
      "r1259",
      "r1260"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred",
        "label": "Deferred Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r114",
      "r1159",
      "r1165"
     ]
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxExpenseBenefitContinuingOperationsAbstract",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred:",
        "label": "Deferred Income Tax Expense (Benefit), Continuing Operations [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredIncomeTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Total deferred income tax liabilities",
        "label": "Deferred Tax Liabilities, Gross",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences."
       }
      }
     },
     "auth_ref": [
      "r53",
      "r54",
      "r95",
      "r517"
     ]
    },
    "us-gaap_DeferredStateAndLocalIncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredStateAndLocalIncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local",
        "label": "Deferred State and Local Income Tax Expense (Benefit)",
        "documentation": "Amount of deferred state and local tax expense (benefit) attributable to income (loss) from continuing operations. Includes, but is not limited to, deferred regional, territorial, and provincial tax expense (benefit) for non-US (United States of America) jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r1159",
      "r1165",
      "r1259",
      "r1260"
     ]
    },
    "us-gaap_DeferredTaxAssetsDeferredIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsDeferredIncome",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Deferred Tax Assets, Deferred Income",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from deferred income."
       }
      }
     },
     "auth_ref": [
      "r1257"
     ]
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total deferred income tax assets",
        "label": "Deferred Tax Assets, Gross",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards."
       }
      }
     },
     "auth_ref": [
      "r518"
     ]
    },
    "us-gaap_DeferredTaxAssetsInProcessResearchAndDevelopment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsInProcessResearchAndDevelopment",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Capitalized research and development",
        "label": "Deferred Tax Asset, In-Process Research and Development",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary difference from in-process research and development cost acquired in business combination or from joint venture formation or both."
       }
      }
     },
     "auth_ref": [
      "r1257"
     ]
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsNetAbstract",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax assets:",
        "label": "Deferred Tax Assets, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss carryforwards",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1257"
     ]
    },
    "us-gaap_DeferredTaxAssetsOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsOther",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Deferred Tax Assets, Other",
        "documentation": "Amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other."
       }
      }
     },
     "auth_ref": [
      "r1257"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxCreditCarryforwards",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax credits",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards",
        "documentation": "Amount, before allocation of a valuation allowances, of deferred tax assets attributable to deductible tax credit carryforwards including, but not limited to, research, foreign, general business, alternative minimum tax, and other deductible tax credit carryforwards."
       }
      }
     },
     "auth_ref": [
      "r1257"
     ]
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-Based Compensation Cost",
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation."
       }
      }
     },
     "auth_ref": [
      "r1257"
     ]
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxAssetsValuationAllowance",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less valuation allowance",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized."
       }
      }
     },
     "auth_ref": [
      "r519"
     ]
    },
    "us-gaap_DeferredTaxLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTotalLabel": "Net deferred income tax liability",
        "label": "Deferred Tax Liabilities, Net",
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting."
       }
      }
     },
     "auth_ref": [
      "r1254"
     ]
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred income tax liabilities:",
        "label": "Deferred Tax Liabilities, Net [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DeferredTaxLiabilitiesPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DeferredTaxLiabilitiesPropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails": {
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofDeferredIncomeTaxAssetsandLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Property, equipment and leasehold improvements",
        "label": "Deferred Tax Liabilities, Property, Plant and Equipment",
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from property, plant, and equipment."
       }
      }
     },
     "auth_ref": [
      "r1257"
     ]
    },
    "us-gaap_DefinedContributionPlanCostRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DefinedContributionPlanCostRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Discretionary matching contributions",
        "label": "Defined Contribution Plan, Cost",
        "documentation": "Amount of cost for defined contribution plan."
       }
      }
     },
     "auth_ref": [
      "r441"
     ]
    },
    "arvn_DefinedContributionPlanPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "DefinedContributionPlanPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "401(k) Savings Plan",
        "label": "Defined Contribution Plan, Policy [Policy Text Block]",
        "documentation": "Defined Contribution Plan, Policy"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DepreciationAndAmortization": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DepreciationAndAmortization",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Depreciation and amortization",
        "label": "Depreciation, Depletion and Amortization, Nonproduction",
        "documentation": "The current period expense charged against earnings on long-lived, physical assets not used in production, and which are not intended for resale, to allocate or recognize the cost of such assets over their useful lives; or to record the reduction in book value of an intangible asset over the benefit period of such asset; or to reflect consumption during the period of an asset that is not used in production."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r33"
     ]
    },
    "arvn_DevelopmentMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "DevelopmentMilestonePaymentsMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Development Milestone Payments",
        "label": "Development Milestone Payments [Member]",
        "documentation": "Development milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_DirectAndIncrementalCostsIncurredToObtainTheContract": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "DirectAndIncrementalCostsIncurredToObtainTheContract",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaboration agreement direct and incremental costs incurred",
        "label": "Direct And Incremental Costs Incurred To Obtain The Contract",
        "documentation": "Direct And Incremental Costs Incurred To Obtain The Contract"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/Equity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity",
        "label": "Share-Based Payment Arrangement [Text Block]",
        "documentation": "The entire disclosure for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r447",
      "r478",
      "r479",
      "r482",
      "r904"
     ]
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share-based Payment Arrangement [Abstract]",
        "label": "Share-Based Payment Arrangement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentAnnualReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentAnnualReport",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Annual Report",
        "label": "Document Annual Report",
        "documentation": "Boolean flag that is true only for a form used as an annual report."
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r990"
     ]
    },
    "dei_DocumentFinStmtErrorCorrectionFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFinStmtErrorCorrectionFlag",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Financial Statement Error Correction",
        "label": "Document Financial Statement Error Correction [Flag]",
        "documentation": "Indicates whether any of the financial statement period in the filing include a restatement due to error correction."
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r990",
      "r1033"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Period Focus",
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Fiscal Year Focus",
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentTransitionReport": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentTransitionReport",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Transition Report",
        "label": "Document Transition Report",
        "documentation": "Boolean flag that is true only for a form used as a transition report."
       }
      }
     },
     "auth_ref": [
      "r1011"
     ]
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentType",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentsIncorporatedByReferenceTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "DocumentsIncorporatedByReferenceTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Documents Incorporated by Reference",
        "label": "Documents Incorporated by Reference [Text Block]",
        "documentation": "Documents incorporated by reference."
       }
      }
     },
     "auth_ref": [
      "r964"
     ]
    },
    "us-gaap_DomesticCountryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "DomesticCountryMember",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Domestic Tax Jurisdiction",
        "label": "Domestic Tax Jurisdiction [Member]",
        "documentation": "Designated federal jurisdiction entitled to levy and collect income tax in country of domicile. Includes, but is not limited to, national jurisdiction for non-U.S. jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "ecd_DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "DvddsOrOthrErngsPdOnEqtyAwrdsNtOthrwsRflctdInTtlCompForCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year",
        "label": "Dividends or Other Earnings Paid on Equity Awards not Otherwise Reflected in Total Compensation for Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1022"
     ]
    },
    "us-gaap_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share",
        "label": "Earnings Per Share [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EarningsPerShareBasic": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareBasic",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/NetLossPerShareScheduleofBasicandDilutedLossperCommonShareDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share - basic (in dollars per share)",
        "verboseLabel": "Net loss per common share - basic (in usd per share)",
        "label": "Earnings Per Share, Basic",
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r177",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r216",
      "r218",
      "r220",
      "r221",
      "r222",
      "r227",
      "r399",
      "r483",
      "r539",
      "r544",
      "r569",
      "r570",
      "r702",
      "r730",
      "r871"
     ]
    },
    "us-gaap_EarningsPerShareDiluted": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareDiluted",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/NetLossPerShareScheduleofBasicandDilutedLossperCommonShareDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net loss per common share - diluted (in dollars per share)",
        "label": "Earnings Per Share, Diluted",
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r154",
      "r177",
      "r204",
      "r205",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r211",
      "r218",
      "r220",
      "r221",
      "r222",
      "r227",
      "r399",
      "r483",
      "r539",
      "r544",
      "r569",
      "r570",
      "r702",
      "r730",
      "r871"
     ]
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerSharePolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss per Common Share",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r27",
      "r28",
      "r224"
     ]
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EarningsPerShareTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net Loss Per Share",
        "label": "Earnings Per Share [Text Block]",
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r215",
      "r223",
      "r225",
      "r226"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Effective tax rate",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r906"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percent",
        "label": "Effective Income Tax Rate Reconciliation, Percent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss)."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r193",
      "r502",
      "r529",
      "r906"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r906",
      "r1159",
      "r1166",
      "r1252"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r1159",
      "r1166",
      "r1252",
      "r1253"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development tax credit",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Percent",
        "documentation": "Percentage of difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r1159",
      "r1166",
      "r1252",
      "r1253"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local income taxes, net of federal income tax effect",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r906",
      "r1159",
      "r1166",
      "r1252"
     ]
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development tax credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r1159",
      "r1166",
      "r1252",
      "r1253"
     ]
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails": {
       "parentTag": "us-gaap_AccountsPayableAndAccruedLiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee expenses",
        "label": "Employee-related Liabilities, Current",
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer)."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense not yet recognized",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount",
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation expense not yet recognized, period of recognition (in years)",
        "label": "Share-Based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition",
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r481"
     ]
    },
    "us-gaap_EmployeeSeveranceMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeSeveranceMember",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Employee Severance",
        "label": "Employee Severance [Member]",
        "documentation": "Termination of an employee associated with exit from or disposal of business activities or restructurings pursuant to a plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ESPP",
        "label": "Employee Stock [Member]",
        "documentation": "An Employee Stock Purchase Plan is a tax-efficient means by which employees of a corporation can purchase the corporation's stock."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EmployeeStockOptionMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock options",
        "label": "Share-Based Payment Arrangement, Option [Member]",
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248"
     ]
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine2": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressAddressLine2",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line Two",
        "label": "Entity Address, Address Line Two",
        "documentation": "Address Line 2 such as Street or Suite number"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCommonStockSharesOutstanding",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Common Stock Shares Outstanding",
        "label": "Entity Common Stock, Shares Outstanding",
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCurrentReportingStatus": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityCurrentReportingStatus",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Current Reporting Status",
        "label": "Entity Current Reporting Status",
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityDomain",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity [Domain]",
        "label": "Entity [Domain]",
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity File Number",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityFilerCategory": {
     "xbrltype": "filerCategoryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityFilerCategory",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Category",
        "label": "Entity Filer Category",
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityInteractiveDataCurrent": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityInteractiveDataCurrent",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Interactive Data Current",
        "label": "Entity Interactive Data Current",
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)."
       }
      }
     },
     "auth_ref": [
      "r1073"
     ]
    },
    "dei_EntityPublicFloat": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityPublicFloat",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Public Float",
        "label": "Entity Public Float",
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "dei_EntityShellCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityShellCompany",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Shell Company",
        "label": "Entity Shell Company",
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "dei_EntitySmallBusiness": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntitySmallBusiness",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Small Business",
        "label": "Entity Small Business",
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r963"
     ]
    },
    "dei_EntityVoluntaryFilers": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityVoluntaryFilers",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Voluntary Filers",
        "label": "Entity Voluntary Filers",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "xbrltype": "yesNoItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "EntityWellKnownSeasonedIssuer",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Well-known Seasoned Issuer",
        "label": "Entity Well-known Seasoned Issuer",
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A."
       }
      }
     },
     "auth_ref": [
      "r1074"
     ]
    },
    "ecd_EqtyAwrdsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Footnote",
        "label": "Equity Awards Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsExclgValRprtdInSummryCompstnTblMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments, Excluding Value Reported in Compensation Table",
        "label": "Equity Awards Adjustments, Excluding Value Reported in the Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_EqtyAwrdsAdjsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsAdjsMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Awards Adjustments",
        "label": "Equity Awards Adjustments [Member]"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "ecd_EqtyAwrdsInSummryCompstnTblForAplblYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EqtyAwrdsInSummryCompstnTblForAplblYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table",
        "label": "Aggregate Grant Date Fair Value of Equity Award Amounts Reported in Summary Compensation Table [Member]"
       }
      }
     },
     "auth_ref": [
      "r1069"
     ]
    },
    "us-gaap_EquityComponentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityComponentDomain",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Component [Domain]",
        "label": "Equity Component [Domain]",
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r152",
      "r153",
      "r154",
      "r172",
      "r173",
      "r174",
      "r199",
      "r200",
      "r201",
      "r203",
      "r210",
      "r212",
      "r214",
      "r229",
      "r309",
      "r310",
      "r331",
      "r398",
      "r413",
      "r483",
      "r527",
      "r528",
      "r536",
      "r537",
      "r538",
      "r540",
      "r543",
      "r544",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r610",
      "r612",
      "r626",
      "r726",
      "r755",
      "r756",
      "r757",
      "r771",
      "r825"
     ]
    },
    "arvn_EquityDistributionAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "EquityDistributionAgreementMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Distribution Agreement",
        "label": "Equity Distribution Agreement [Member]",
        "documentation": "Equity Distribution Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "srt_EquityMethodInvesteeNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "EquityMethodInvesteeNameDomain",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Domain]",
        "label": "Investment, Name [Domain]",
        "documentation": "Name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r306",
      "r535",
      "r598",
      "r1078",
      "r1079",
      "r1080",
      "r1261",
      "r1262",
      "r1263",
      "r1264"
     ]
    },
    "us-gaap_EquityMethodInvestmentAggregateCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentAggregateCost",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity interest",
        "label": "Equity Method Investment, Aggregate Cost",
        "documentation": "This element represents the aggregate cost of investments accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r44"
     ]
    },
    "us-gaap_EquityMethodInvestmentOwnershipPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentOwnershipPercentage",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Ownership interest, percentage",
        "label": "Equity Method Investment, Ownership Percentage",
        "documentation": "The percentage of ownership of common stock or equity participation in the investee accounted for under the equity method of accounting."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r598"
     ]
    },
    "us-gaap_EquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestments",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity method investments",
        "label": "Equity Method Investments",
        "documentation": "This item represents the carrying amount on the entity's balance sheet of its investment in common stock of an equity method investee. This is not an indicator of the fair value of the investment, rather it is the initial cost adjusted for the entity's share of earnings and losses of the investee, adjusted for any distributions (dividends) and other than temporary impairment (OTTI) losses recognized."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r250",
      "r262",
      "r302",
      "r1096",
      "r1202"
     ]
    },
    "us-gaap_EquityMethodInvestmentsAndJointVenturesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsAndJointVenturesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments and Joint Ventures [Abstract]",
        "label": "Equity Method Investments and Joint Ventures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_EquityMethodInvestmentsDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments",
        "label": "Equity Method Investments and Joint Ventures Disclosure [Text Block]",
        "documentation": "The entire disclosure for equity method investments and joint ventures. Equity method investments are investments that give the investor the ability to exercise significant influence over the operating and financial policies of an investee. Joint ventures are entities owned and operated by a small group of businesses as a separate and specific business or project for the mutual benefit of the members of the group."
       }
      }
     },
     "auth_ref": [
      "r116",
      "r305",
      "r308",
      "r1080"
     ]
    },
    "us-gaap_EquityMethodInvestmentsPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "EquityMethodInvestmentsPolicy",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Method Investments",
        "label": "Equity Method Investments [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for equity method of accounting for investments and other interests. Investment includes, but is not limited to, unconsolidated subsidiary, corporate joint venture, noncontrolling interest in real estate venture, limited partnership, and limited liability company. Information includes, but is not limited to, ownership percentage, reason equity method is or is not considered appropriate, and accounting policy election for distribution received."
       }
      }
     },
     "auth_ref": [
      "r4",
      "r304",
      "r598"
     ]
    },
    "ecd_EquityValuationAssumptionDifferenceFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "EquityValuationAssumptionDifferenceFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Valuation Assumption Difference, Footnote",
        "label": "Equity Valuation Assumption Difference, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1026"
     ]
    },
    "ecd_ErrCompAnalysisTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompAnalysisTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneous Compensation Analysis",
        "label": "Erroneous Compensation Analysis [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r983",
      "r994",
      "r1004",
      "r1037"
     ]
    },
    "ecd_ErrCompRecoveryTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ErrCompRecoveryTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Erroneously Awarded Compensation Recovery",
        "label": "Erroneously Awarded Compensation Recovery [Table]"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r991",
      "r1001",
      "r1034"
     ]
    },
    "ecd_ExecutiveCategoryAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ExecutiveCategoryAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Executive Category:",
        "label": "Executive Category [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "arvn_ExpansionOfDevelopmentProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ExpansionOfDevelopmentProgramsMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expansion of Development Programs",
        "label": "Expansion Of Development Programs [Member]",
        "documentation": "Expansion Of Development Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisLineItems",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]",
        "label": "Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r573",
      "r583",
      "r915"
     ]
    },
    "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTable",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Table]",
        "label": "Fair Value, Recurring and Nonrecurring [Table]",
        "documentation": "Disclosure of information about asset and liability measured at fair value on recurring and nonrecurring basis."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r573",
      "r583",
      "r915"
     ]
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Axis]",
        "label": "Fair Value Hierarchy and NAV [Axis]",
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r571",
      "r573",
      "r574",
      "r575",
      "r576",
      "r582",
      "r583",
      "r585",
      "r592",
      "r631",
      "r632",
      "r633",
      "r858",
      "r889",
      "r890",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r915",
      "r919",
      "r926"
     ]
    },
    "us-gaap_FairValueByMeasurementFrequencyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueByMeasurementFrequencyAxis",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Axis]",
        "label": "Measurement Frequency [Axis]",
        "documentation": "Information by measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r573",
      "r574",
      "r576",
      "r915",
      "r1277",
      "r1280"
     ]
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueDisclosuresTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities and Fair Value Measurements",
        "label": "Fair Value Disclosures [Text Block]",
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information."
       }
      }
     },
     "auth_ref": [
      "r574",
      "r578",
      "r580",
      "r581",
      "r582",
      "r585",
      "r586",
      "r587",
      "r588",
      "r589",
      "r698",
      "r915",
      "r920"
     ]
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueInputsLevel2Member",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Level 2",
        "label": "Fair Value, Inputs, Level 2 [Member]",
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r432",
      "r437",
      "r438",
      "r440",
      "r573",
      "r574",
      "r583",
      "r592",
      "r632",
      "r858",
      "r889",
      "r890",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r915",
      "r926"
     ]
    },
    "us-gaap_FairValueMeasurementFrequencyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementFrequencyDomain",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measurement Frequency [Domain]",
        "label": "Measurement Frequency [Domain]",
        "documentation": "Measurement frequency."
       }
      }
     },
     "auth_ref": [
      "r572",
      "r573",
      "r574",
      "r576",
      "r915",
      "r1277",
      "r1280"
     ]
    },
    "us-gaap_FairValueMeasurementPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Measurements",
        "label": "Fair Value Measurement, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for fair value measurements of financial and non-financial assets, liabilities and instruments classified in shareholders' equity. Disclosures include, but are not limited to, how an entity that manages a group of financial assets and liabilities on the basis of its net exposure measures the fair value of those assets and liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value Hierarchy and NAV [Domain]",
        "label": "Fair Value Hierarchy and NAV [Domain]",
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value."
       }
      }
     },
     "auth_ref": [
      "r384",
      "r432",
      "r433",
      "r434",
      "r435",
      "r436",
      "r437",
      "r438",
      "r439",
      "r571",
      "r573",
      "r574",
      "r575",
      "r576",
      "r582",
      "r583",
      "r585",
      "r592",
      "r631",
      "r632",
      "r633",
      "r858",
      "r889",
      "r890",
      "r898",
      "r899",
      "r900",
      "r901",
      "r902",
      "r915",
      "r919",
      "r926"
     ]
    },
    "us-gaap_FairValueMeasurementsRecurringMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FairValueMeasurementsRecurringMember",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair Value, Measurements, Recurring",
        "label": "Fair Value, Recurring [Member]",
        "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value."
       }
      }
     },
     "auth_ref": [
      "r915",
      "r1274",
      "r1275",
      "r1276",
      "r1277",
      "r1278",
      "r1280"
     ]
    },
    "us-gaap_FederalDepositInsuranceCorporationPremiumExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FederalDepositInsuranceCorporationPremiumExpense",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal deposit insurance corporation premium expense",
        "label": "Federal Deposit Insurance Corporation Premium Expense",
        "documentation": "Amount of expense for Federal Deposit Insurance Corporation (FDIC) insurance."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "us-gaap_FinancialInstrumentAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "FinancialInstrumentAxis",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instrument [Axis]",
        "label": "Financial Instrument [Axis]",
        "documentation": "Information by type of financial instrument."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r311",
      "r312",
      "r313",
      "r314",
      "r315",
      "r317",
      "r318",
      "r319",
      "r395",
      "r411",
      "r556",
      "r567",
      "r590",
      "r597",
      "r600",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r643",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r710",
      "r727",
      "r886",
      "r915",
      "r917",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r931",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1273",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282"
     ]
    },
    "us-gaap_ForeignTaxJurisdictionOtherMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ForeignTaxJurisdictionOtherMember",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Foreign Tax Jurisdiction, Other [Member]",
        "documentation": "Designated foreign jurisdiction entitled to levy and collect income tax outside country of domicile, classified as other."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r1156",
      "r1255"
     ]
    },
    "ecd_ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToDisqualificationOfTaxBenefitsAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Disqualification of Tax Benefits, Amount",
        "label": "Forgone Recovery due to Disqualification of Tax Benefits, Amount"
       }
      }
     },
     "auth_ref": [
      "r987",
      "r998",
      "r1008",
      "r1041"
     ]
    },
    "ecd_ForgoneRecoveryDueToExpenseOfEnforcementAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToExpenseOfEnforcementAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Expense of Enforcement, Amount",
        "label": "Forgone Recovery due to Expense of Enforcement, Amount"
       }
      }
     },
     "auth_ref": [
      "r987",
      "r998",
      "r1008",
      "r1041"
     ]
    },
    "ecd_ForgoneRecoveryDueToViolationOfHomeCountryLawAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryDueToViolationOfHomeCountryLawAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery due to Violation of Home Country Law, Amount",
        "label": "Forgone Recovery due to Violation of Home Country Law, Amount"
       }
      }
     },
     "auth_ref": [
      "r987",
      "r998",
      "r1008",
      "r1041"
     ]
    },
    "ecd_ForgoneRecoveryExplanationOfImpracticabilityTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryExplanationOfImpracticabilityTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forgone Recovery, Explanation of Impracticability",
        "label": "Forgone Recovery, Explanation of Impracticability [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r987",
      "r998",
      "r1008",
      "r1041"
     ]
    },
    "ecd_ForgoneRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "ForgoneRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Forgone Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r987",
      "r998",
      "r1008",
      "r1041"
     ]
    },
    "ecd_FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "FrValAsOfPrrYrEndOfEqtyAwrdsGrntdInPrrYrsFldVstngCondsDrngCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year",
        "label": "Prior Year End Fair Value of Equity Awards Granted in Any Prior Year that Fail to Meet Applicable Vesting Conditions During Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1021"
     ]
    },
    "arvn_FutureGrantOfIncentiveUnitsToServiceProvidersPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "FutureGrantOfIncentiveUnitsToServiceProvidersPercentage",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Future grant of incentive units to service providers, percentage",
        "label": "Future Grant Of Incentive Units To Service Providers Percentage",
        "documentation": "Future grant of incentive units to service providers, percentage."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GainLossOnContractTermination": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnContractTermination",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Lease termination costs",
        "label": "Gain (Loss) on Contract Termination",
        "documentation": "Gain (loss) related to the termination of a contract between the parties. The termination may be due to many causes including early termination of a lease by a lessee, a breach of contract by one party, or a failure to perform."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Net loss on disposal of property, equipment and leasehold improvements",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property."
       }
      }
     },
     "auth_ref": [
      "r7"
     ]
    },
    "arvn_GenentechIncorporationAndFHoffmanLaRocheLimitedMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "GenentechIncorporationAndFHoffmanLaRocheLimitedMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Genentech",
        "label": "Genentech Incorporation And F Hoffman La Roche Limited [Member]",
        "documentation": "Genentech, Incorporation. and F. Hoffman-La Roche Limited."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and administrative",
        "verboseLabel": "General and administrative expense",
        "label": "General and Administrative Expense",
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line."
       }
      }
     },
     "auth_ref": [
      "r66",
      "r809"
     ]
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "GeneralAndAdministrativeExpenseMember",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "General and Administrative Expense",
        "label": "General and Administrative Expense [Member]",
        "documentation": "Primary financial statement caption encompassing general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "dei_IcfrAuditorAttestationFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "IcfrAuditorAttestationFlag",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "ICFR Auditor Attestation Flag",
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "auth_ref": [
      "r966",
      "r967",
      "r990"
     ]
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of long lived assets",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r79",
      "r916"
     ]
    },
    "us-gaap_ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Impairment of Long-Lived Assets",
        "label": "Impairment or Disposal of Long-Lived Assets, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for recognizing and measuring the impairment of long-lived assets. An entity also may disclose its accounting policy for long-lived assets to be sold. This policy excludes goodwill and intangible assets."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r81"
     ]
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss before income taxes and loss from equity method investment",
        "label": "Income (Loss) from Continuing Operations before Equity Method Investments, Income Taxes, Noncontrolling Interest",
        "documentation": "Amount of income (loss) from continuing operations before deduction of income tax expense (benefit) and income (loss) attributable to noncontrolling interest, and addition of income (loss) from equity method investments."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r731",
      "r875",
      "r946",
      "r947",
      "r1173",
      "r1180",
      "r1181",
      "r1182",
      "r1183"
     ]
    },
    "us-gaap_IncomeLossFromEquityMethodInvestments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeLossFromEquityMethodInvestments",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss from equity method investment",
        "negatedLabel": "Loss from equity method investment",
        "label": "Income (Loss) from Equity Method Investments",
        "documentation": "Amount of income (loss) for proportionate share of equity method investee's income (loss)."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r64",
      "r99",
      "r228",
      "r247",
      "r262",
      "r302",
      "r724"
     ]
    },
    "us-gaap_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Statements of Operations",
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_IncomeStatementAndStatementOfComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "IncomeStatementAndStatementOfComprehensiveIncomeAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement And Statement Of Comprehensive Income [Abstract]",
        "documentation": "Income Statement And Statement Of Comprehensive Income"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationAxis",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Axis]",
        "label": "Statement of Income Location, Balance [Axis]",
        "documentation": "Information by location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r332",
      "r339",
      "r344",
      "r552",
      "r553",
      "r554",
      "r555",
      "r577",
      "r579",
      "r584",
      "r599",
      "r600",
      "r601",
      "r752",
      "r754",
      "r810",
      "r856",
      "r858",
      "r907",
      "r908",
      "r913",
      "r914",
      "r918",
      "r926",
      "r1265",
      "r1266",
      "r1304"
     ]
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeStatementLocationDomain",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Income Location, Balance [Domain]",
        "label": "Statement of Income Location, Balance [Domain]",
        "documentation": "Location in statement of income where disaggregated amount is reported."
       }
      }
     },
     "auth_ref": [
      "r339",
      "r344",
      "r552",
      "r553",
      "r554",
      "r555",
      "r577",
      "r579",
      "r584",
      "r599",
      "r600",
      "r601",
      "r752",
      "r754",
      "r810",
      "r856",
      "r858",
      "r907",
      "r908",
      "r913",
      "r914",
      "r918",
      "r926",
      "r1265",
      "r1266",
      "r1304"
     ]
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityAxis",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Axis]",
        "label": "Income Tax Jurisdiction [Axis]",
        "documentation": "Information by income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r502",
      "r503",
      "r511",
      "r523",
      "r906",
      "r1256"
     ]
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxAuthorityDomain",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Jurisdiction [Domain]",
        "label": "Income Tax Jurisdiction [Domain]",
        "documentation": "Income tax jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r502",
      "r503",
      "r511",
      "r523",
      "r906",
      "r1256"
     ]
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Abstract]",
        "label": "Income Tax Disclosure [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_IncomeTaxDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "IncomeTaxDisclosureLineItems",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Line Items]",
        "label": "Income Tax Disclosure [Line Items]",
        "documentation": "Income tax disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_IncomeTaxDisclosureTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "IncomeTaxDisclosureTable",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Disclosure [Table]",
        "label": "Income Tax Disclosure [Table]",
        "documentation": "Income tax disclosure."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxes"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax Disclosure [Text Block]",
        "documentation": "The entire disclosure for income tax."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r193",
      "r497",
      "r502",
      "r507",
      "r508",
      "r509",
      "r514",
      "r521",
      "r530",
      "r532",
      "r533",
      "r534",
      "r709",
      "r762",
      "r770",
      "r906"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefit",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      },
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxExpenseDetails",
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails",
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Income tax expense",
        "terseLabel": "Income tax expense",
        "totalLabel": "Income tax expense",
        "verboseLabel": "Income tax expense",
        "label": "Income Tax Expense (Benefit)",
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations."
       }
      }
     },
     "auth_ref": [
      "r106",
      "r115",
      "r187",
      "r213",
      "r214",
      "r228",
      "r248",
      "r262",
      "r501",
      "r502",
      "r531",
      "r732",
      "r866",
      "r868",
      "r869",
      "r906"
     ]
    },
    "us-gaap_IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxExpenseBenefitContinuingOperationsIncomeTaxReconciliationAbstract",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amount",
        "label": "Income Tax Expense (Benefit), Effective Income Tax Rate Reconciliation, Amount [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncomeTaxPaidByIndividualJurisdictionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidByIndividualJurisdictionLineItems",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Paid, by Individual Jurisdiction [Line Items]",
        "label": "Income Tax Paid, by Individual Jurisdiction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r523"
     ]
    },
    "us-gaap_IncomeTaxPaidByIndividualJurisdictionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidByIndividualJurisdictionTable",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Tax Paid, by Individual Jurisdiction [Table]",
        "label": "Income Tax Paid, by Individual Jurisdiction [Table]",
        "documentation": "Disclosure of information about income tax paid by jurisdiction."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r523"
     ]
    },
    "us-gaap_IncomeTaxPaidFederalAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidFederalAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US federal",
        "label": "Income Tax Paid, Federal, after Refund Received",
        "documentation": "Amount, after income tax refund received, of cash paid to federal (national) tax jurisdiction for tax on income."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r522"
     ]
    },
    "us-gaap_IncomeTaxPaidStateAndLocalAfterRefundReceived": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPaidStateAndLocalAfterRefundReceived",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails": {
       "parentTag": "us-gaap_IncomeTaxesPaidNet",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US state and local",
        "label": "Income Tax Paid, State and Local, after Refund Received",
        "documentation": "Amount, after income tax refund received, of cash paid to state and local tax jurisdictions for tax on income."
       }
      }
     },
     "auth_ref": [
      "r183",
      "r522"
     ]
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxPolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Income Taxes",
        "label": "Income Tax, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements."
       }
      }
     },
     "auth_ref": [
      "r171",
      "r499",
      "r500",
      "r514",
      "r515",
      "r520",
      "r525",
      "r766"
     ]
    },
    "us-gaap_IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in valuation allowance",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to increase (decrease) in the valuation allowance for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r506",
      "r906",
      "r1252"
     ]
    },
    "us-gaap_IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "U.S. Federal statutory tax rate",
        "label": "Effective Income Tax Rate Reconciliation at Federal Statutory Income Tax Rate, Amount",
        "documentation": "The amount of income tax expense or benefit for the period computed by applying the domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r502",
      "r906"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseOther": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseOther",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Other, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to other nondeductible expenses."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r1252",
      "r1253"
     ]
    },
    "us-gaap_IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock compensation",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Share-Based Payment Arrangement, Amount",
        "documentation": "Amount of reported income tax expense (benefit) in excess of (less than) expected income tax expense (benefit) computed by applying domestic federal statutory income tax rate to pretax income (loss) from continuing operation, attributable to nondeductible expense for award under share-based payment arrangement. Includes, but is not limited to, expense determined to be nondeductible upon grant or after for award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r1252",
      "r1253"
     ]
    },
    "us-gaap_IncomeTaxReconciliationStateAndLocalIncomeTaxes": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationStateAndLocalIncomeTaxes",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "State and local income taxes, net of federal income tax effect",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to state and local income tax expense (benefit)."
       }
      }
     },
     "auth_ref": [
      "r505",
      "r906",
      "r1252"
     ]
    },
    "us-gaap_IncomeTaxReconciliationTaxCreditsResearch": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxReconciliationTaxCreditsResearch",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails": {
       "parentTag": "us-gaap_IncomeTaxExpenseBenefit",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofReconciliationoftheUSFederalStatutoryIncomeTaxRatetoEffectiveIncomeTaxRateDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Research and development tax credit",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Amount",
        "documentation": "Amount of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit."
       }
      }
     },
     "auth_ref": [
      "r906",
      "r1252",
      "r1253"
     ]
    },
    "us-gaap_IncomeTaxesPaidNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncomeTaxesPaidNet",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total income taxes paid, net of refunds received",
        "label": "Income Taxes Paid, Net",
        "documentation": "Amount, after refund, of cash paid to foreign, federal, state, and local jurisdictions as income tax."
       }
      }
     },
     "auth_ref": [
      "r23",
      "r183",
      "r522",
      "r523"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 13.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accounts payable and accrued liabilities",
        "label": "Increase (Decrease) in Accounts Payable and Accrued Liabilities",
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInAccountsReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInAccountsReceivable",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Accounts receivable",
        "label": "Increase (Decrease) in Accounts Receivable",
        "documentation": "The increase (decrease) during the reporting period in amount due within one year (or one business cycle) from customers for the credit sale of goods and services."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerAsset",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 12.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Collaboration contract asset",
        "label": "Increase (Decrease) in Contract with Customer, Asset",
        "documentation": "Amount of increase (decrease) in right to consideration in exchange for good or service transferred to customer when right is conditioned on something other than passage of time."
       }
      }
     },
     "auth_ref": [
      "r1154"
     ]
    },
    "us-gaap_IncreaseDecreaseInContractWithCustomerLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInContractWithCustomerLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 15.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Deferred revenue",
        "label": "Increase (Decrease) in Contract with Customer, Liability",
        "documentation": "Amount of increase (decrease) in obligation to transfer good or service to customer for which consideration has been received or is receivable."
       }
      }
     },
     "auth_ref": [
      "r662",
      "r1154"
     ]
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Changes in operating assets and liabilities:",
        "label": "Adjustment to Reconcile Net Income to Cash Provided by (Used in) Operating Activity, Increase (Decrease) in Operating Capital [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_IncreaseDecreaseInOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOperatingLeaseLiability",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 14.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liabilities",
        "label": "Increase (Decrease) in Operating Lease Liability",
        "documentation": "Amount of increase (decrease) in obligation for operating lease."
       }
      }
     },
     "auth_ref": [
      "r1084",
      "r1154"
     ]
    },
    "us-gaap_IncreaseDecreaseInOtherReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInOtherReceivables",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 10.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Other receivables",
        "label": "Increase (Decrease) in Other Receivables",
        "documentation": "Amount of increase (decrease) in receivables classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0,
       "order": 11.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Prepaid expenses and other assets",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock reserved for issuance represented as percentage on outstanding common stock",
        "label": "Increase In Capital Shares Reserved For Future Issuance Represented As Percentage On Outstanding Common Stock",
        "documentation": "Increase in capital shares reserved for future issuance represented as percentage on outstanding common stock."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_IndividualAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "IndividualAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure",
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure",
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements",
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Individual:",
        "label": "Individual [Axis]"
       }
      }
     },
     "auth_ref": [
      "r987",
      "r998",
      "r1008",
      "r1032",
      "r1041",
      "r1045",
      "r1053"
     ]
    },
    "ecd_InsiderTradingArrLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingArrLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Arrangements [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "ecd_InsiderTradingPoliciesProcLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTradingPoliciesProcLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Insider Trading Policies and Procedures [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1057"
     ]
    },
    "ecd_InsiderTrdPoliciesProcAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Adopted",
        "label": "Insider Trading Policies and Procedures Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1057"
     ]
    },
    "ecd_InsiderTrdPoliciesProcNotAdoptedTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "InsiderTrdPoliciesProcNotAdoptedTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingPoliciesProc"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Insider Trading Policies and Procedures Not Adopted",
        "label": "Insider Trading Policies and Procedures Not Adopted [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r968",
      "r1057"
     ]
    },
    "us-gaap_InvestmentIncomeInterest": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "InvestmentIncomeInterest",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Interest income, net",
        "verboseLabel": "Interest income, net",
        "label": "Investment Income, Interest",
        "documentation": "Amount before accretion (amortization) of purchase discount (premium) of interest income on nonoperating securities."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r243",
      "r262",
      "r880",
      "r1112"
     ]
    },
    "us-gaap_LaborAndRelatedExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LaborAndRelatedExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Compensation and related personnel expense (including stock-based compensation)",
        "label": "Labor and Related Expense",
        "documentation": "Amount of expense for salary, wage, profit sharing; incentive and equity-based compensation; and other employee benefit."
       }
      }
     },
     "auth_ref": [
      "r700",
      "r868",
      "r1111"
     ]
    },
    "arvn_LaboratoryEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "LaboratoryEquipmentMember",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Laboratory equipment",
        "label": "Laboratory Equipment [Member]",
        "documentation": "Laboratory equipment."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LandSubjectToGroundLeases": {
     "xbrltype": "areaItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LandSubjectToGroundLeases",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease for laboratory and office space (in sq feet)",
        "label": "Land Subject to Ground Leases",
        "documentation": "Area of land subject to a ground lease."
       }
      }
     },
     "auth_ref": [
      "r1286"
     ]
    },
    "us-gaap_LeaseCostTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseCostTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Lease Expense",
        "label": "Lease, Cost [Table Text Block]",
        "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income."
       }
      }
     },
     "auth_ref": [
      "r1287"
     ]
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeaseholdImprovementsMember",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvements",
        "label": "Leasehold Improvements [Member]",
        "documentation": "Additions or improvements to assets held under a lease arrangement."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r624"
     ]
    },
    "us-gaap_LeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LeasesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leases [Abstract]",
        "label": "Leases [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LegalEntityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LegalEntityAxis",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Legal Entity [Axis]",
        "label": "Legal Entity [Axis]",
        "documentation": "The set of legal entities associated with a report."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LesseeLeaseDescriptionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionLineItems",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Line Items]",
        "label": "Lessee, Lease, Description [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r625"
     ]
    },
    "us-gaap_LesseeLeaseDescriptionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeaseDescriptionTable",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lessee Lease Description [Table]",
        "label": "Lessee, Lease, Description [Table]",
        "documentation": "Disclosure of information about lessee's leases."
       }
      }
     },
     "auth_ref": [
      "r617",
      "r625"
     ]
    },
    "us-gaap_LesseeLeasesPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeLeasesPolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Lease and Rent Expense",
        "label": "Lessee, Leases [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for leasing arrangement entered into by lessee."
       }
      }
     },
     "auth_ref": [
      "r616"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Maturities of Operating Lease Liabilities",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Maturity [Table Text Block]",
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position."
       }
      }
     },
     "auth_ref": [
      "r1288"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total lease payments",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r1160",
      "r1167",
      "r1299"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r1160",
      "r1167",
      "r1299"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2029",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r1160",
      "r1167",
      "r1299"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r1160",
      "r1167",
      "r1299"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r623",
      "r1160",
      "r1167",
      "r1299"
     ]
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: imputed interest",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease."
       }
      }
     },
     "auth_ref": [
      "r623"
     ]
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LesseeOperatingLeasesTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilities"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right of Use Assets and Liabilities",
        "label": "Lessee, Operating Leases [Text Block]",
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r611"
     ]
    },
    "us-gaap_LetterOfCreditMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LetterOfCreditMember",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Letter of Credit",
        "label": "Letter of Credit [Member]",
        "documentation": "A document typically issued by a financial institution which acts as a guarantee of payment to a beneficiary, or as the source of payment for a specific transaction (for example, wiring funds to a foreign exporter if and when specified merchandise is accepted pursuant to the terms of the letter of credit)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities",
        "label": "Liabilities",
        "documentation": "Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r46",
      "r47",
      "r48",
      "r50",
      "r51",
      "r52",
      "r55",
      "r187",
      "r191",
      "r192",
      "r307",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r549",
      "r550",
      "r551",
      "r598",
      "r786",
      "r874",
      "r893",
      "r961",
      "r1214",
      "r1289",
      "r1290"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total liabilities and stockholders' equity",
        "label": "Liabilities and Equity",
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any."
       }
      }
     },
     "auth_ref": [
      "r62",
      "r98",
      "r720",
      "r929",
      "r946",
      "r947",
      "r1159",
      "r1164",
      "r1203",
      "r1283"
     ]
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Liabilities and stockholders' equity",
        "label": "Liabilities and Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LiabilitiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total current liabilities",
        "label": "Liabilities, Current",
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r48",
      "r158",
      "r187",
      "r191",
      "r192",
      "r307",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r549",
      "r550",
      "r551",
      "r598",
      "r929",
      "r1214",
      "r1289",
      "r1290"
     ]
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LiabilitiesCurrentAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current liabilities:",
        "label": "Liabilities, Current [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_LicenseFirstLicensedProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "LicenseFirstLicensedProductMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, First Licensed Product",
        "label": "License, First Licensed Product [Member]",
        "documentation": "License, First Licensed Product"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LicenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LicenseMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License",
        "label": "License [Member]",
        "documentation": "Right to use intangible asset. Intangible asset includes, but is not limited to, patent, copyright, technology, manufacturing process, software or trademark."
       }
      }
     },
     "auth_ref": [
      "r1220",
      "r1221"
     ]
    },
    "arvn_LicenseSecondLicensedProductMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "LicenseSecondLicensedProductMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "License, Second Licensed Product",
        "label": "License, Second Licensed Product [Member]",
        "documentation": "License, Second Licensed Product"
       }
      }
     },
     "auth_ref": []
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_LongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails",
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total",
        "label": "Long-Term Debt",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r96",
      "r188",
      "r198",
      "r383",
      "r397",
      "r707",
      "r889",
      "r890",
      "r927",
      "r1301"
     ]
    },
    "us-gaap_LongTermDebtCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Less: current installments included within Accounts Payable and Accrued Liabilities",
        "label": "Long-Term Debt, Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as current. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r163"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2026",
        "label": "Long-Term Debt, Maturity, Year One",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r188",
      "r198",
      "r388",
      "r707"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2028",
        "label": "Long-Term Debt, Maturity, Year Three",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r188",
      "r198",
      "r388",
      "r707"
     ]
    },
    "us-gaap_LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtScheduleofMinimumFuturePaymentsonLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2027",
        "label": "Long-Term Debt, Maturity, Year Two",
        "documentation": "Amount of long-term debt payable, sinking fund requirement, and other securities issued that are redeemable by holder at fixed or determinable price and date, maturing in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach)."
       }
      }
     },
     "auth_ref": [
      "r9",
      "r188",
      "r198",
      "r388",
      "r707"
     ]
    },
    "us-gaap_LongTermDebtNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LongTermDebtNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails": {
       "parentTag": "us-gaap_LongTermDebt",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
      "http://www.arvinas.com/role/LongTermDebtScheduleofLongTermDebtDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long term debt",
        "verboseLabel": "Total long-term debt",
        "label": "Long-Term Debt, Excluding Current Maturities",
        "documentation": "Amount, after deduction of unamortized premium (discount) and debt issuance cost, of long-term debt classified as noncurrent. Excludes lease obligation."
       }
      }
     },
     "auth_ref": [
      "r164"
     ]
    },
    "us-gaap_LossContingencyAccrualAtCarryingValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "LossContingencyAccrualAtCarryingValue",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Loss contingency",
        "label": "Loss Contingency Accrual",
        "documentation": "Amount of loss contingency liability."
       }
      }
     },
     "auth_ref": [
      "r354",
      "r1077"
     ]
    },
    "stpr_MA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "MA",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Massachusetts",
        "label": "MASSACHUSETTS"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_MarketableSecuritiesCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable securities",
        "label": "Marketable Securities, Current",
        "documentation": "Amount of investment in marketable security, classified as current."
       }
      }
     },
     "auth_ref": [
      "r1097"
     ]
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "MarketableSecuritiesPolicy",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Marketable Securities",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for investment classified as marketable security."
       }
      }
     },
     "auth_ref": [
      "r42"
     ]
    },
    "arvn_MaximumAggregateOfferingPriceOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "MaximumAggregateOfferingPriceOfCommonStock",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock aggregate offering price",
        "label": "Maximum Aggregate Offering Price Of Common Stock",
        "documentation": "Maximum Aggregate Offering Price Of Common Stock"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MaximumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MaximumMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maximum",
        "label": "Maximum [Member]",
        "documentation": "Upper limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r123",
      "r124",
      "r126",
      "r143",
      "r145",
      "r146",
      "r150",
      "r151",
      "r235",
      "r355",
      "r356",
      "r357",
      "r358",
      "r442",
      "r473",
      "r474",
      "r475",
      "r494",
      "r576",
      "r661",
      "r751",
      "r753",
      "r761",
      "r777",
      "r778",
      "r828",
      "r830",
      "r832",
      "r833",
      "r835",
      "r838",
      "r839",
      "r841",
      "r842",
      "r854",
      "r855",
      "r885",
      "r894",
      "r903",
      "r907",
      "r909",
      "r910",
      "r919",
      "r920",
      "r924",
      "r925",
      "r941",
      "r1216",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296"
     ]
    },
    "ecd_MeasureAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Measure:",
        "label": "Measure [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_MeasureName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MeasureName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Measure Name"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "arvn_MilestonePaymentOnFirstAnniversaryOfSigningMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "MilestonePaymentOnFirstAnniversaryOfSigningMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment On First Anniversary Of Signing",
        "label": "Milestone Payment On First Anniversary Of Signing [Member]",
        "documentation": "Milestone Payment On First Anniversary Of Signing"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Milestone Payment Upon Approval Of First And Second Royalty Products",
        "label": "Milestone Payment Upon Approval Of First And Second Royalty Products [Member]",
        "documentation": "Milestone Payment Upon Approval Of First And Second Royalty Products"
       }
      }
     },
     "auth_ref": []
    },
    "srt_MinimumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "MinimumMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Minimum",
        "label": "Minimum [Member]",
        "documentation": "Lower limit of the provided range."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r123",
      "r124",
      "r126",
      "r143",
      "r145",
      "r146",
      "r150",
      "r151",
      "r235",
      "r355",
      "r356",
      "r357",
      "r358",
      "r442",
      "r473",
      "r474",
      "r475",
      "r494",
      "r576",
      "r661",
      "r751",
      "r753",
      "r761",
      "r777",
      "r778",
      "r828",
      "r830",
      "r832",
      "r833",
      "r835",
      "r838",
      "r839",
      "r841",
      "r842",
      "r854",
      "r855",
      "r885",
      "r894",
      "r903",
      "r907",
      "r909",
      "r910",
      "r919",
      "r920",
      "r924",
      "r941",
      "r1216",
      "r1291",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296"
     ]
    },
    "ecd_MnpiDiscTimedForCompValFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MnpiDiscTimedForCompValFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "MNPI Disclosure Timed for Compensation Value",
        "label": "MNPI Disclosure Timed for Compensation Value [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1044"
     ]
    },
    "ecd_MtrlTermsOfTrdArrTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "MtrlTermsOfTrdArrTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Material Terms of Trading Arrangement",
        "label": "Material Terms of Trading Arrangement [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "stpr_NJ": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "NJ",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Jersey",
        "label": "NEW JERSEY"
       }
      }
     },
     "auth_ref": []
    },
    "stpr_NY": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "NY",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York",
        "label": "NEW YORK"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NamedExecutiveOfficersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NamedExecutiveOfficersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Named Executive Officers, Footnote",
        "label": "Named Executive Officers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash (used in) provided by financing activities",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from financing activity, including, but not limited to, discontinued operation. Financing activity includes, but is not limited to, obtaining resource from owner and providing return on, and return of, their investment; borrowing money and repaying amount borrowed, or settling obligation; and obtaining and paying for other resource obtained from creditor on long-term credit."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from financing activities:",
        "label": "Cash Provided by (Used in) Financing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash provided by investing activities",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from investing activity, including, but not limited to, discontinued operation. Investing activity includes, but is not limited to, making and collecting loan, acquiring and disposing of debt and equity instruments, property, plant, and equipment, and other productive assets."
       }
      }
     },
     "auth_ref": [
      "r182"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from investing activities:",
        "label": "Cash Provided by (Used in) Investing Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net cash used in operating activities",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation",
        "documentation": "Amount of cash inflow (outflow) from operating activity, including, but not limited to, discontinued operation. Operating activity includes, but is not limited to, transaction, adjustment, and change in value not defined as investing or financing activity."
       }
      }
     },
     "auth_ref": [
      "r73",
      "r74",
      "r76"
     ]
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cash flows from operating activities:",
        "label": "Cash Provided by (Used in) Operating Activity, Including Discontinued Operation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NetIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NetIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
      "http://www.arvinas.com/role/NetLossPerShareScheduleofBasicandDilutedLossperCommonShareDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Net loss",
        "terseLabel": "Net loss",
        "verboseLabel": "Segment net loss",
        "label": "Net Income (Loss) Attributable to Parent",
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r76",
      "r101",
      "r154",
      "r156",
      "r167",
      "r169",
      "r174",
      "r187",
      "r191",
      "r192",
      "r195",
      "r202",
      "r206",
      "r207",
      "r208",
      "r209",
      "r210",
      "r213",
      "r214",
      "r219",
      "r307",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r399",
      "r402",
      "r404",
      "r408",
      "r483",
      "r539",
      "r544",
      "r570",
      "r598",
      "r725",
      "r807",
      "r823",
      "r824",
      "r866",
      "r868",
      "r869",
      "r959",
      "r1214"
     ]
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New Accounting Pronouncements",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_NewYorkCityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "NewYorkCityMember",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "New York City",
        "label": "New York City [Member]",
        "documentation": "New York City"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_NonGaapMeasureDescriptionTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonGaapMeasureDescriptionTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-GAAP Measure Description",
        "label": "Non-GAAP Measure Description [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "ecd_NonNeosMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonNeosMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-NEOs",
        "label": "Non-NEOs [Member]"
       }
      }
     },
     "auth_ref": [
      "r987",
      "r998",
      "r1008",
      "r1032",
      "r1041"
     ]
    },
    "ecd_NonPeoNeoAvgCompActuallyPaidAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgCompActuallyPaidAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Compensation Actually Paid Amount",
        "label": "Non-PEO NEO Average Compensation Actually Paid Amount"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_NonPeoNeoAvgTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoAvgTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO Average Total Compensation Amount",
        "label": "Non-PEO NEO Average Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "ecd_NonPeoNeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonPeoNeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-PEO NEO",
        "label": "Non-PEO NEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_NonRule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Adopted",
        "label": "Non-Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "ecd_NonRule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "NonRule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non-Rule 10b5-1 Arrangement Terminated",
        "label": "Non-Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "us-gaap_NonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total other income",
        "label": "Nonoperating Income (Expense)",
        "documentation": "The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business)."
       }
      }
     },
     "auth_ref": [
      "r67"
     ]
    },
    "us-gaap_NonvestedRestrictedStockSharesActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NonvestedRestrictedStockSharesActivityTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Restricted Stock Grant Activity",
        "label": "Nonvested Restricted Stock Shares Activity [Table Text Block]",
        "documentation": "Tabular disclosure of the changes in outstanding nonvested restricted stock shares."
       }
      }
     },
     "auth_ref": [
      "r15"
     ]
    },
    "arvn_NovartisPharmaAGMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "NovartisPharmaAGMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Novartis Pharma AG",
        "label": "Novartis Pharma AG [Member]",
        "documentation": "Novartis Pharma AG"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_NumberOfLicensedProducts": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "NumberOfLicensedProducts",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of licensed products",
        "label": "Number of Licensed Products",
        "documentation": "Number of Licensed Products"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_NumberOfOperatingSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfOperatingSegments",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of operating segments",
        "label": "Number of Operating Segments",
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues."
       }
      }
     },
     "auth_ref": [
      "r881",
      "r1179"
     ]
    },
    "us-gaap_NumberOfReportableSegments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "NumberOfReportableSegments",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of reportable segments",
        "label": "Number of Reportable Segments",
        "documentation": "Number of segments reported by the entity. A reportable segment is a component of an entity for which there is an accounting requirement to report separate financial information on that component in the entity's financial statements."
       }
      }
     },
     "auth_ref": [
      "r876",
      "r884",
      "r1179"
     ]
    },
    "arvn_NumberOfVotesPerCommonStockShareHeld": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "NumberOfVotesPerCommonStockShareHeld",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of votes per common stock share held",
        "label": "Number of votes per common stock share held",
        "documentation": "Number of votes per common stock share held"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_NumberOfWhollyOwnedSubsidiaries": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "NumberOfWhollyOwnedSubsidiaries",
     "presentation": [
      "http://www.arvinas.com/role/NatureofBusinessandBasisofPresentationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of wholly owned subsidiaries",
        "label": "Number Of Wholly Owned Subsidiaries",
        "documentation": "Number of wholly owned subsidiaries."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_OerthBioLimitedLiabilityCorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "OerthBioLimitedLiabilityCorporationMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Oerth",
        "label": "Oerth Bio Limited Liability Corporation [Member]",
        "documentation": "Oerth Bio LLC."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OfficeEquipmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OfficeEquipmentMember",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Office equipment",
        "label": "Office Equipment [Member]",
        "documentation": "Tangible personal property used in an office setting. Examples include, but are not limited to, computers, copiers and fax machine."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_OneTimeCashTerminationFeeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "OneTimeCashTerminationFeeMember",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "One-Time Cash Termination Fee",
        "label": "One-Time Cash Termination Fee [Member]",
        "documentation": "One-Time Cash Termination Fee"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total operating expenses",
        "terseLabel": "Operating expenses",
        "label": "Operating Expenses",
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense."
       }
      }
     },
     "auth_ref": [
      "r869"
     ]
    },
    "us-gaap_OperatingExpensesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingExpensesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating expenses:",
        "label": "Operating Expenses [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OperatingIncomeLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingIncomeLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Loss from operations",
        "label": "Operating Income (Loss)",
        "documentation": "The net result for the period of deducting operating expenses from operating revenues."
       }
      }
     },
     "auth_ref": [
      "r104",
      "r866",
      "r869",
      "r875",
      "r1173",
      "r1180",
      "r1181",
      "r1182",
      "r1183"
     ]
    },
    "us-gaap_OperatingLeaseCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseCost",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofComponentsofLeaseExpenseDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease cost",
        "label": "Operating Lease, Cost",
        "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability."
       }
      }
     },
     "auth_ref": [
      "r618",
      "r928"
     ]
    },
    "us-gaap_OperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiability",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails_1": {
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofMaturitiesofLeaseLiabilitiesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total",
        "label": "Operating Lease, Liability",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityCurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Current portion of operating lease liability",
        "label": "Operating Lease, Liability, Current",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease liability",
        "label": "Operating Lease, Liability, Noncurrent",
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent."
       }
      }
     },
     "auth_ref": [
      "r614"
     ]
    },
    "us-gaap_OperatingLeasePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeasePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating cash flows from operating leases",
        "label": "Operating Lease, Payments",
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use."
       }
      }
     },
     "auth_ref": [
      "r615",
      "r619"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAsset",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease right of use assets",
        "label": "Operating Lease, Right-of-Use Asset",
        "documentation": "Amount of lessee's right to use underlying asset under operating lease."
       }
      }
     },
     "auth_ref": [
      "r613"
     ]
    },
    "us-gaap_OperatingLeaseRightOfUseAssetAmortizationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseRightOfUseAssetAmortizationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amortization of right-of-use assets",
        "label": "Operating Lease, Right-of-Use Asset, Periodic Reduction",
        "documentation": "Amount of periodic reduction over lease term of carrying amount of right-of-use asset from operating lease."
       }
      }
     },
     "auth_ref": [
      "r1155"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, weighted average discount rate, percent",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "documentation": "Weighted average discount rate for operating lease calculated at point in time."
       }
      }
     },
     "auth_ref": [
      "r622",
      "r928"
     ]
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating lease, weighted average remaining lease term (in years)",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r621",
      "r928"
     ]
    },
    "us-gaap_OperatingLossCarryforwards": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OperatingLossCarryforwards",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal net operating loss carryforwards",
        "label": "Operating Loss Carryforwards",
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "arvn_OperatingLossesCarryForwardMaximumDeductibilityPercentage": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "OperatingLossesCarryForwardMaximumDeductibilityPercentage",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Operating losses carry forward, maximum deductibility percentage",
        "label": "Operating Losses Carry Forward Maximum Deductibility Percentage",
        "documentation": "Operating losses carry forward, maximum deductibility as a percentage of taxable income."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_OptionPaymentsToLicenseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "OptionPaymentsToLicenseAgreementMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Option Payments To License Agreement",
        "label": "Option Payments To License Agreement [Member]",
        "documentation": "Option payments to license agreement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Organization, Consolidation and Presentation of Financial Statements [Abstract]",
        "label": "Organization, Consolidation and Presentation of Financial Statements [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrealized gain on available-for-sale securities",
        "label": "Other Comprehensive Income (Loss), Available-for-Sale Securities Adjustment, Net of Tax, Portion Attributable to Parent",
        "documentation": "Amount, after tax and reclassification adjustment, of gain (loss) in value of unsold investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), attributable to parent."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r10",
      "r90"
     ]
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other comprehensive loss:",
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_NonoperatingIncomeExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other expense, net",
        "label": "Other Nonoperating Income (Expense)",
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other."
       }
      }
     },
     "auth_ref": [
      "r68",
      "r912"
     ]
    },
    "us-gaap_OtherNonoperatingIncomeExpenseAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherNonoperatingIncomeExpenseAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other income (expense)",
        "label": "Other Nonoperating Income (Expense) [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_OtherPerfMeasureAmt": {
     "xbrltype": "decimalItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OtherPerfMeasureAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other Performance Measure, Amount",
        "label": "Other Performance Measure, Amount"
       }
      }
     },
     "auth_ref": [
      "r1024"
     ]
    },
    "arvn_OtherProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "OtherProgramsMember",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other programs",
        "label": "Other Programs [Member]",
        "documentation": "Other Programs"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherReceivablesNetCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherReceivablesNetCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other receivables",
        "label": "Other Receivables, Net, Current",
        "documentation": "Amount, after allowance, of receivables classified as other, due within one year or the operating cycle, if longer."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_OtherResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "OtherResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other research and development expense",
        "label": "Other Research and Development Expense",
        "documentation": "Amount of other research and development expense."
       }
      }
     },
     "auth_ref": [
      "r1251"
     ]
    },
    "ecd_OutstandingAggtErrCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingAggtErrCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding Aggregate Erroneous Compensation Amount",
        "label": "Outstanding Aggregate Erroneous Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r985",
      "r996",
      "r1006",
      "r1039"
     ]
    },
    "ecd_OutstandingRecoveryCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Compensation Amount",
        "label": "Outstanding Recovery Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r988",
      "r999",
      "r1009",
      "r1042"
     ]
    },
    "ecd_OutstandingRecoveryIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "OutstandingRecoveryIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Outstanding Recovery, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r988",
      "r999",
      "r1009",
      "r1042"
     ]
    },
    "stpr_PA": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/stpr/2025",
     "localname": "PA",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pennsylvania",
        "label": "PENNSYLVANIA"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PayVsPerformanceDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PayVsPerformanceDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Pay vs Performance Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "us-gaap_PayablesAndAccrualsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PayablesAndAccrualsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payables and Accruals [Abstract]",
        "label": "Payables and Accruals [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForBrokerageFees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForBrokerageFees",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial advisor fees",
        "label": "Payments for Brokerage Fees",
        "documentation": "The amount of cash paid for brokerage fees during the current period. This element is intended to represent the brokerage fees paid by and between financial industry participants."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "arvn_PaymentsForCollaboration": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "PaymentsForCollaboration",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments for collaboration",
        "label": "Payments For Collaboration",
        "documentation": "Payments For Collaboration"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PaymentsForRepurchaseOfCommonStock": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRepurchaseOfCommonStock",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repurchase of common shares, net",
        "label": "Payments for Repurchase of Common Stock",
        "documentation": "The cash outflow to reacquire common stock during the period."
       }
      }
     },
     "auth_ref": [
      "r71"
     ]
    },
    "us-gaap_PaymentsForRoyalties": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsForRoyalties",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Royalty payment",
        "label": "Payments for Royalties",
        "documentation": "The amount of cash paid for royalties during the current period."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsOfStockIssuanceCosts",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Payment of common stock offering costs",
        "terseLabel": "Fees and expenses",
        "label": "Payments of Stock Issuance Costs",
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security."
       }
      }
     },
     "auth_ref": [
      "r20"
     ]
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquireMarketableSecurities",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of marketable securities",
        "label": "Payments to Acquire Marketable Securities",
        "documentation": "Amount of cash outflow for purchase of marketable security."
       }
      }
     },
     "auth_ref": [
      "r1186"
     ]
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Purchase of property, equipment and leasehold improvements",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets."
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ecd_PeerGroupIssuersFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupIssuersFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Issuers, Footnote",
        "label": "Peer Group Issuers, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_PeerGroupTotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeerGroupTotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Peer Group Total Shareholder Return Amount",
        "label": "Peer Group Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_PeoActuallyPaidCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoActuallyPaidCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Actually Paid Compensation Amount",
        "label": "PEO Actually Paid Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "ecd_PeoMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO",
        "label": "PEO [Member]"
       }
      }
     },
     "auth_ref": [
      "r1032"
     ]
    },
    "ecd_PeoName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Name",
        "label": "PEO Name"
       }
      }
     },
     "auth_ref": [
      "r1025"
     ]
    },
    "ecd_PeoTotalCompAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PeoTotalCompAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "PEO Total Compensation Amount",
        "label": "PEO Total Compensation Amount"
       }
      }
     },
     "auth_ref": [
      "r1014"
     ]
    },
    "arvn_PercentageOfLiquidatedDamages": {
     "xbrltype": "percentItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "PercentageOfLiquidatedDamages",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Percentage of liquidated damages",
        "label": "Percentage Of Liquidated Damages",
        "documentation": "Percentage of liquidated damages."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_PfizerIncorporationMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "PfizerIncorporationMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pfizer, Inc.",
        "label": "Pfizer Incorporation [Member]",
        "documentation": "Pfizer, Incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_PiperSandlerAndCantorMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "PiperSandlerAndCantorMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Piper Sandler and Cantor",
        "label": "Piper Sandler And Cantor [Member]",
        "documentation": "Piper sandler and cantor."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PlanNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameAxis",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails",
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Axis]",
        "label": "Plan Name [Axis]",
        "documentation": "Information by plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248"
     ]
    },
    "us-gaap_PlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PlanNameDomain",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails",
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Plan Name [Domain]",
        "label": "Plan Name [Domain]",
        "documentation": "Plan name for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248"
     ]
    },
    "us-gaap_PledgedStatusAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PledgedStatusAxis",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pledged Status [Axis]",
        "label": "Pledged Status [Axis]",
        "documentation": "Information by pledged or not pledged status of asset owned by entity."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r189",
      "r548",
      "r780",
      "r911"
     ]
    },
    "us-gaap_PledgedStatusDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PledgedStatusDomain",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pledged Status [Domain]",
        "label": "Pledged Status [Domain]",
        "documentation": "Pledged or not pledged status of asset owned by entity."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r189",
      "r548",
      "r780",
      "r911"
     ]
    },
    "us-gaap_PledgingPurposeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PledgingPurposeAxis",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pledging Purpose [Axis]",
        "label": "Pledging Purpose [Axis]",
        "documentation": "Information by pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r189",
      "r642",
      "r911",
      "r930",
      "r1081"
     ]
    },
    "us-gaap_PledgingPurposeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PledgingPurposeDomain",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pledging Purpose [Domain]",
        "label": "Pledging Purpose [Domain]",
        "documentation": "Pledging purpose of pledged asset owned."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r189",
      "r642",
      "r911",
      "r930",
      "r1081"
     ]
    },
    "ecd_PnsnAdjsPrrSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsPrrSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Prior Service Cost",
        "label": "Pension Adjustments Prior Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1016"
     ]
    },
    "ecd_PnsnAdjsSvcCstMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnAdjsSvcCstMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Adjustments Service Cost",
        "label": "Pension Adjustments Service Cost [Member]"
       }
      }
     },
     "auth_ref": [
      "r1072"
     ]
    },
    "ecd_PnsnBnftsAdjFnTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PnsnBnftsAdjFnTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pension Benefits Adjustments, Footnote",
        "label": "Pension Benefits Adjustments, Footnote [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1015"
     ]
    },
    "arvn_PreFundedWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "PreFundedWarrantMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/NetLossPerShareAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-Funded Warrant",
        "label": "Pre-Funded Warrant [Member]",
        "documentation": "Pre-Funded Warrant"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockParOrStatedValuePerShare",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock par value (in dollars per share)",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r409"
     ]
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesAuthorized",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares authorized (in shares)",
        "label": "Preferred Stock, Shares Authorized",
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r788"
     ]
    },
    "us-gaap_PreferredStockSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesIssued",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares issued (in shares)",
        "label": "Preferred Stock, Shares Issued",
        "documentation": "Number of shares issued for nonredeemable preferred shares and preferred shares redeemable solely at option of issuer. Includes, but is not limited to, preferred shares issued, repurchased, and held as treasury shares. Excludes preferred shares classified as debt."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r409"
     ]
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockSharesOutstanding",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, shares outstanding (in shares)",
        "label": "Preferred Stock, Shares Outstanding",
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r788",
      "r806",
      "r1336",
      "r1337"
     ]
    },
    "us-gaap_PreferredStockValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PreferredStockValue",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Preferred stock, $0.001 par value, zero shares issued and outstanding as of December\u00a031, 2025 and 2024, respectively",
        "label": "Preferred Stock, Value, Issued",
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity."
       }
      }
     },
     "auth_ref": [
      "r56",
      "r401",
      "r406",
      "r716",
      "r929"
     ]
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Prepaid expenses and other current assets",
        "label": "Prepaid Expense and Other Assets, Current",
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r1098"
     ]
    },
    "us-gaap_PrivatePlacementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PrivatePlacementMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Private Placement",
        "label": "Private Placement [Member]",
        "documentation": "A private placement is a direct offering of securities to a limited number of sophisticated investors such as insurance companies, pension funds, mezzanine funds, stock funds and trusts."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromCollaborators": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromCollaborators",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Payments received",
        "label": "Proceeds from Collaborators",
        "documentation": "Cash received from collaborators during the current period."
       }
      }
     },
     "auth_ref": [
      "r75"
     ]
    },
    "arvn_ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from exercise of stock options and issuance of ESPP shares",
        "label": "Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares",
        "documentation": "Proceeds From Exercise Of Stock Options And Issuance Of Employee Stock Shares"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ProceedsFromIssuanceOfCommonStockAndWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ProceedsFromIssuanceOfCommonStockAndWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from issuance of common stock and pre-funded warrants",
        "label": "Proceeds From Issuance Of Common Stock And Warrants",
        "documentation": "Proceeds From Issuance Of Common Stock And Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ProceedsFromMaturitiesOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ProceedsFromMaturitiesOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Maturities of marketable securities",
        "label": "Proceeds From Maturities Of Marketable Securities",
        "documentation": "Proceeds from maturities of marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ProceedsFromSaleOfMarketableSecurities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ProceedsFromSaleOfMarketableSecurities",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of marketable securities",
        "label": "Proceeds From Sale Of Marketable Securities",
        "documentation": "Proceeds from sale of marketable securities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Proceeds from disposal of property, equipment and leasehold improvements",
        "label": "Proceeds from Sale of Property, Plant, and Equipment",
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r69"
     ]
    },
    "srt_ProductOrServiceAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductOrServiceAxis",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Axis]",
        "label": "Product and Service [Axis]",
        "documentation": "Information by product and service, or group of similar products and similar services."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r149",
      "r265",
      "r663",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r859",
      "r865",
      "r868",
      "r869",
      "r895",
      "r896",
      "r940",
      "r941",
      "r942",
      "r945",
      "r949",
      "r1083",
      "r1093",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1212",
      "r1213",
      "r1303",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332"
     ]
    },
    "srt_ProductsAndServicesDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ProductsAndServicesDomain",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Product and Service [Domain]",
        "label": "Product and Service [Domain]",
        "documentation": "Product or service, or a group of similar products or similar services."
       }
      }
     },
     "auth_ref": [
      "r128",
      "r129",
      "r130",
      "r131",
      "r132",
      "r133",
      "r149",
      "r265",
      "r663",
      "r744",
      "r745",
      "r746",
      "r747",
      "r748",
      "r749",
      "r750",
      "r859",
      "r865",
      "r868",
      "r869",
      "r895",
      "r896",
      "r940",
      "r941",
      "r942",
      "r945",
      "r949",
      "r1083",
      "r1093",
      "r1113",
      "r1114",
      "r1115",
      "r1116",
      "r1117",
      "r1118",
      "r1119",
      "r1120",
      "r1121",
      "r1122",
      "r1123",
      "r1124",
      "r1125",
      "r1126",
      "r1127",
      "r1128",
      "r1129",
      "r1130",
      "r1131",
      "r1132",
      "r1133",
      "r1134",
      "r1135",
      "r1136",
      "r1137",
      "r1138",
      "r1139",
      "r1140",
      "r1141",
      "r1142",
      "r1143",
      "r1144",
      "r1145",
      "r1146",
      "r1147",
      "r1148",
      "r1149",
      "r1150",
      "r1151",
      "r1152",
      "r1153",
      "r1212",
      "r1213",
      "r1303",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Plant and Equipment [Abstract]",
        "label": "Property, Plant and Equipment [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Axis]",
        "label": "Long-Lived Tangible Asset [Axis]",
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r624"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Equipment and Leasehold Improvements",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r78",
      "r109",
      "r112",
      "r113"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentGross",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total property, equipment and leasehold improvements",
        "label": "Property, Plant and Equipment, Gross",
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r160",
      "r723"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentLineItems",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property Plant And Equipment [Line Items]",
        "label": "Property, Plant and Equipment [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r624"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentNet",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_Assets",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, equipment and leasehold improvements, net",
        "totalLabel": "Property, equipment and leasehold improvements, net",
        "label": "Property, Plant and Equipment, Net",
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r624",
      "r708",
      "r723",
      "r929"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property, Equipment, and Leasehold Improvements",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r109",
      "r112",
      "r721"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Property, Equipment and Leasehold Improvements",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Long-Lived Tangible Asset [Domain]",
        "label": "Long-Lived Tangible Asset [Domain]",
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software."
       }
      }
     },
     "auth_ref": [
      "r80",
      "r624"
     ]
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Property and equipment, estimated useful life",
        "label": "Property, Plant and Equipment, Useful Life",
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_PropertyPlantAndEquipmentWriteoff": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "PropertyPlantAndEquipmentWriteoff",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Leasehold improvement written-off",
        "label": "Property, Plant And Equipment, Writeoff",
        "documentation": "Property, Plant And Equipment, Writeoff"
       }
      }
     },
     "auth_ref": []
    },
    "ecd_PvpTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure",
        "label": "Pay vs Performance Disclosure [Table]"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "ecd_PvpTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "PvpTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pay vs Performance Disclosure, Table",
        "label": "Pay vs Performance [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1013"
     ]
    },
    "srt_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Axis]",
        "label": "Statistical Measurement [Axis]",
        "documentation": "Information by statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r123",
      "r124",
      "r126",
      "r143",
      "r145",
      "r146",
      "r150",
      "r151",
      "r235",
      "r355",
      "r356",
      "r357",
      "r358",
      "r431",
      "r442",
      "r473",
      "r474",
      "r475",
      "r482",
      "r494",
      "r576",
      "r634",
      "r644",
      "r661",
      "r751",
      "r753",
      "r761",
      "r777",
      "r778",
      "r828",
      "r830",
      "r832",
      "r833",
      "r835",
      "r838",
      "r839",
      "r841",
      "r842",
      "r854",
      "r855",
      "r885",
      "r894",
      "r903",
      "r907",
      "r909",
      "r910",
      "r919",
      "r920",
      "r924",
      "r925",
      "r941",
      "r953",
      "r1209",
      "r1216",
      "r1277",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296"
     ]
    },
    "srt_RangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RangeMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statistical Measurement [Domain]",
        "label": "Statistical Measurement [Domain]",
        "documentation": "Statistical measurement. Includes, but is not limited to, minimum, maximum, weighted average, arithmetic average, and median."
       }
      }
     },
     "auth_ref": [
      "r119",
      "r121",
      "r123",
      "r124",
      "r126",
      "r143",
      "r145",
      "r146",
      "r150",
      "r151",
      "r235",
      "r355",
      "r356",
      "r357",
      "r358",
      "r431",
      "r442",
      "r473",
      "r474",
      "r475",
      "r482",
      "r494",
      "r576",
      "r634",
      "r644",
      "r661",
      "r751",
      "r753",
      "r761",
      "r777",
      "r778",
      "r828",
      "r830",
      "r832",
      "r833",
      "r835",
      "r838",
      "r839",
      "r841",
      "r842",
      "r854",
      "r855",
      "r885",
      "r894",
      "r903",
      "r907",
      "r909",
      "r910",
      "r919",
      "r920",
      "r924",
      "r925",
      "r941",
      "r953",
      "r1209",
      "r1216",
      "r1277",
      "r1292",
      "r1293",
      "r1294",
      "r1295",
      "r1296"
     ]
    },
    "us-gaap_ReconciliationFromSegmentTotalsToConsolidatedAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationFromSegmentTotalsToConsolidatedAbstract",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Less:",
        "label": "Segment Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ReconciliationOfUnrecognizedTaxBenefitsExcludingAmountsPertainingToExaminedTaxReturnsRollForward",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized Tax Benefits [Roll Forward]",
        "label": "Unrecognized Tax Benefits [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_RecoveryOfErrCompDisclosureLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RecoveryOfErrCompDisclosureLineItems",
     "lang": {
      "en-us": {
       "role": {
        "label": "Recovery of Erroneously Awarded Compensation Disclosure [Line Items]"
       }
      }
     },
     "auth_ref": [
      "r980",
      "r991",
      "r1001",
      "r1034"
     ]
    },
    "arvn_RegulatoryAndSalesBasedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "RegulatoryAndSalesBasedMilestonesMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory and Sales Based Milestones",
        "label": "Regulatory And Sales Based Milestones [Member]",
        "documentation": "Regulatory And Sales Based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_RegulatoryMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "RegulatoryMilestonePaymentsMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Regulatory Milestone Related to Marketing Approvals",
        "label": "Regulatory Milestone Payments [Member]",
        "documentation": "Regulatory milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_RemovalOfCombinationTrialsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "RemovalOfCombinationTrialsMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Removal Of Combination Trials",
        "label": "Removal Of Combination Trials [Member]",
        "documentation": "Removal Of Combination Trials"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RepaymentsOfLongTermDebt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RepaymentsOfLongTermDebt",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Repayments of long-term debt",
        "label": "Repayments of Long-Term Debt",
        "documentation": "The cash outflow for debt initially having maturity due after one year or beyond the normal operating cycle, if longer."
       }
      }
     },
     "auth_ref": [
      "r72",
      "r768"
     ]
    },
    "arvn_ReportableSegmentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ReportableSegmentMember",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reportable Segment",
        "label": "Reportable Segment [Member]",
        "documentation": "Reportable Segment"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Counterparty Name [Domain]",
        "label": "Counterparty Name [Domain]",
        "documentation": "Named other party that participates in a financial transaction. Examples include, but not limited to, the name of the financial institution."
       }
      }
     },
     "auth_ref": [
      "r147",
      "r148",
      "r187",
      "r196",
      "r197",
      "r374",
      "r410",
      "r627",
      "r645",
      "r711",
      "r862",
      "r863",
      "r864",
      "r1099",
      "r1100",
      "r1101",
      "r1102",
      "r1103",
      "r1104",
      "r1105",
      "r1106",
      "r1107",
      "r1267",
      "r1268",
      "r1269",
      "r1270"
     ]
    },
    "arvn_RequiredMilestonePayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "RequiredMilestonePayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Required milestone payments",
        "label": "Required Milestone Payments",
        "documentation": "Required Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and development",
        "totalLabel": "Total research and development expense",
        "label": "Research and Development Expense",
        "documentation": "Amount of expense for research and development. Includes, but is not limited to, cost for computer software product to be sold, leased, or otherwise marketed and writeoff of research and development assets acquired in transaction other than business combination or joint venture formation or both. Excludes write-down of intangible asset acquired in business combination or from joint venture formation or both, used in research and development activity."
       }
      }
     },
     "auth_ref": [
      "r496",
      "r856",
      "r866",
      "r867",
      "r880",
      "r1298"
     ]
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpenseMember",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expense",
        "label": "Research and Development Expense [Member]",
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ResearchAndDevelopmentExpenseNonProgramSpecific": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseNonProgramSpecific",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non program-specific external expense",
        "label": "Research And Development Expense, Non-Program Specific",
        "documentation": "Research And Development Expense, Non-Program Specific"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Expenses",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process."
       }
      }
     },
     "auth_ref": [
      "r495"
     ]
    },
    "arvn_ResearchAndDevelopmentExpenseProgramSpecific": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ResearchAndDevelopmentExpenseProgramSpecific",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails": {
       "parentTag": "us-gaap_ResearchAndDevelopmentExpense",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Program-specific external expense:",
        "label": "Research And Development Expense, Program Specific",
        "documentation": "Research And Development Expense, Program Specific"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ResearchCollaborationAndLicenseAgreementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Collaboration And License Agreements [Abstract]",
        "label": "Research Collaboration And License Agreements [Abstract]",
        "documentation": "Research collaboration and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ResearchCollaborationAndLicenseAgreementsLineItems",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Collaboration And License Agreements [Line Items]",
        "label": "Research Collaboration And License Agreements [Line Items]",
        "documentation": "Research collaboration and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ResearchCollaborationAndLicenseAgreementsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ResearchCollaborationAndLicenseAgreementsTable",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Collaboration And License Agreements [Table]",
        "label": "Research Collaboration And License Agreements [Table]",
        "documentation": "Research collaboration and license agreements."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ResearchFundingPaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ResearchFundingPaymentsMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research Funding Payments",
        "label": "Research Funding Payments [Member]",
        "documentation": "Research funding payments."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ResearchMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ResearchMember",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Research and Development Tax Credits",
        "label": "Research Tax Credit Carryforward [Member]",
        "documentation": "Research tax credit carryforwards arising from certain qualifying expenditures incurred to develop new products and processes."
       }
      }
     },
     "auth_ref": [
      "r1256"
     ]
    },
    "ecd_RestatementDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDateAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date:",
        "label": "Restatement Determination Date [Axis]"
       }
      }
     },
     "auth_ref": [
      "r981",
      "r992",
      "r1002",
      "r1035"
     ]
    },
    "ecd_RestatementDeterminationDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDeterminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement Determination Date",
        "label": "Restatement Determination Date"
       }
      }
     },
     "auth_ref": [
      "r982",
      "r993",
      "r1003",
      "r1036"
     ]
    },
    "ecd_RestatementDoesNotRequireRecoveryTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "RestatementDoesNotRequireRecoveryTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restatement does not require Recovery",
        "label": "Restatement Does Not Require Recovery [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r989",
      "r1000",
      "r1010",
      "r1043"
     ]
    },
    "us-gaap_RestrictedCashCurrent": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedCashCurrent",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails": {
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesCashReconciliationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Restricted cash",
        "label": "Restricted Cash, Current",
        "documentation": "Amount of cash restricted as to withdrawal or usage, classified as current. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits."
       }
      }
     },
     "auth_ref": [
      "r1095",
      "r1157"
     ]
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestrictedStockUnitsRSUMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails",
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "RSUs",
        "label": "Restricted Stock Units (RSUs) [Member]",
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248"
     ]
    },
    "us-gaap_RestructuringAndRelatedActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Restructuring and Related Activities [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringAndRelatedActivitiesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedActivitiesDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Activity",
        "label": "Restructuring and Related Activities Disclosure [Text Block]",
        "documentation": "The entire disclosure for restructuring and related activities. Description of restructuring activities such as exit and disposal activities, include facts and circumstances leading to the plan, the expected plan completion date, the major types of costs associated with the plan activities, total expected costs, the accrual balance at the end of the period, and the periods over which the remaining accrual will be settled."
       }
      }
     },
     "auth_ref": [
      "r340",
      "r341",
      "r343",
      "r346",
      "r351"
     ]
    },
    "us-gaap_RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Reduction in workforce (as a percent)",
        "label": "Restructuring and Related Cost, Number of Positions Eliminated, Period Percent",
        "documentation": "The number of positions eliminated during the period as a percentage of total positions eliminated during the period in connection with the restructuring plan(s)."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RestructuringCharges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCharges",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring charges",
        "label": "Restructuring Charges",
        "documentation": "Amount of expenses associated with exit or disposal activities pursuant to an authorized plan. Excludes expenses related to a discontinued operation or an asset retirement obligation."
       }
      }
     },
     "auth_ref": [
      "r7",
      "r178",
      "r181",
      "r347",
      "r348",
      "r867",
      "r1210"
     ]
    },
    "us-gaap_RestructuringCostAndReserveAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveAxis",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Type [Axis]",
        "label": "Restructuring Type [Axis]",
        "documentation": "Information by type of restructuring cost."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r181",
      "r342",
      "r343",
      "r348",
      "r349",
      "r867"
     ]
    },
    "us-gaap_RestructuringCostAndReserveLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringCostAndReserveLineItems",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost and Reserve [Line Items]",
        "label": "Restructuring Cost and Reserve [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r348",
      "r349",
      "r350"
     ]
    },
    "us-gaap_RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration": {
     "xbrltype": "enumerationSetItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "label": "Restructuring Charges, Statement of Income or Comprehensive Income [Extensible Enumeration]",
        "documentation": "Indicates line item in statement of income or comprehensive income that includes restructuring charges."
       }
      }
     },
     "auth_ref": [
      "r1075",
      "r1076"
     ]
    },
    "us-gaap_RestructuringReserve": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RestructuringReserve",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring accrual",
        "label": "Restructuring Reserve",
        "documentation": "Carrying amount (including both current and noncurrent portions of the accrual) as of the balance sheet date pertaining to a specified type of cost associated with exit from or disposal of business activities or restructuring pursuant to a duly authorized plan."
       }
      }
     },
     "auth_ref": [
      "r343",
      "r349"
     ]
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsAccumulatedDeficit",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated deficit",
        "label": "Retained Earnings (Accumulated Deficit)",
        "documentation": "Amount of accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r59",
      "r86",
      "r719",
      "r758",
      "r760",
      "r769",
      "r789",
      "r929"
     ]
    },
    "us-gaap_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Accumulated Deficit",
        "label": "Retained Earnings [Member]",
        "documentation": "Accumulated undistributed earnings (deficit)."
       }
      }
     },
     "auth_ref": [
      "r152",
      "r153",
      "r154",
      "r199",
      "r200",
      "r201",
      "r203",
      "r210",
      "r212",
      "r214",
      "r309",
      "r310",
      "r331",
      "r398",
      "r483",
      "r527",
      "r528",
      "r536",
      "r537",
      "r538",
      "r540",
      "r543",
      "r544",
      "r557",
      "r559",
      "r560",
      "r562",
      "r568",
      "r610",
      "r612",
      "r755",
      "r757",
      "r771",
      "r1336"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue from Contract with Customer [Abstract]",
        "label": "Revenue from Contract with Customer [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerExcludingAssessedTax",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue recognized",
        "label": "Revenue from Contract with Customer, Excluding Assessed Tax",
        "documentation": "Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r228",
      "r241",
      "r242",
      "r256",
      "r262",
      "r265",
      "r267",
      "r269",
      "r426",
      "r427",
      "r428",
      "r663",
      "r866",
      "r869"
     ]
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Recognition and Deferred Revenue",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for revenue from contract with customer."
       }
      }
     },
     "auth_ref": [
      "r117",
      "r418",
      "r419",
      "r420",
      "r421",
      "r422",
      "r423",
      "r424",
      "r425",
      "r857"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligation",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation",
        "label": "Revenue, Remaining Performance Obligation, Amount",
        "documentation": "Amount of transaction price allocated to performance obligation that has not been recognized as revenue."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "arvn_RevenueRemainingPerformanceObligationContingentPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "RevenueRemainingPerformanceObligationContingentPayments",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Contingent payments",
        "label": "Revenue, Remaining Performance Obligation, Contingent Payments",
        "documentation": "Revenue, Remaining Performance Obligation, Contingent Payments"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionLineItems",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Line Items]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, remaining performance obligation, expected timing of satisfaction, period",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Period",
        "documentation": "Period in which remaining performance obligation is expected to be recognized as revenue, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]",
        "documentation": "Start date of time band for expected timing of satisfaction of remaining performance obligation, in YYYY-MM-DD format."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTable",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsScheduleofTransactionPriceAllocatedtoPerformanceObligationsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue Remaining Performance Obligation Expected Timing Of Satisfaction [Table]",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table]",
        "documentation": "Disclosure of information about expected timing for satisfying remaining performance obligation."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Transaction Price Allocated to Performance Obligations",
        "label": "Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction [Table Text Block]",
        "documentation": "Tabular disclosure of expected timing for satisfying remaining performance obligation."
       }
      }
     },
     "auth_ref": [
      "r1082"
     ]
    },
    "us-gaap_Revenues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "Revenues",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss": {
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "verboseLabel": "Revenue",
        "label": "Revenues",
        "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss)."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r175",
      "r187",
      "r191",
      "r192",
      "r228",
      "r241",
      "r242",
      "r256",
      "r262",
      "r265",
      "r267",
      "r269",
      "r307",
      "r361",
      "r362",
      "r363",
      "r364",
      "r365",
      "r366",
      "r367",
      "r368",
      "r369",
      "r598",
      "r703",
      "r705",
      "r880",
      "r912",
      "r946",
      "r947",
      "r1214"
     ]
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails",
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Right-of-use assets obtained in exchange for new lease obligations",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability."
       }
      }
     },
     "auth_ref": [
      "r620",
      "r928"
     ]
    },
    "ecd_Rule10b51ArrAdoptedFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrAdoptedFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Adopted",
        "label": "Rule 10b5-1 Arrangement Adopted [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "ecd_Rule10b51ArrTrmntdFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "Rule10b51ArrTrmntdFlag",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Rule 10b5-1 Arrangement Terminated",
        "label": "Rule 10b5-1 Arrangement Terminated [Flag]"
       }
      }
     },
     "auth_ref": [
      "r1052"
     ]
    },
    "arvn_SaleOfStockFairValueOfSharesSold": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "SaleOfStockFairValueOfSharesSold",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Fair value of the shares sold",
        "label": "Sale Of Stock Fair Value Of Shares Sold",
        "documentation": "Sale of stock, fair value of shares sold."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNameOfTransactionDomain",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Domain]",
        "label": "Sale of Stock [Domain]",
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockNumberOfSharesIssuedInTransaction": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockNumberOfSharesIssuedInTransaction",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of shares issued in transaction (in shares)",
        "label": "Sale of Stock, Number of Shares Issued in Transaction",
        "documentation": "The number of shares issued or sold by the subsidiary or equity method investee per stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SaleOfStockPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SaleOfStockPricePerShare",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of stock, price (in usd per share)",
        "label": "Sale of Stock, Price Per Share",
        "documentation": "Per share amount received by subsidiary or equity investee for each share of common stock issued or sold in the stock transaction."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_SalesBasedMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "SalesBasedMilestonePaymentsMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-based Milestone Payments",
        "label": "Sales Based Milestone Payments [Member]",
        "documentation": "Sales-based milestone payments."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_SalesBasedMilestonesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "SalesBasedMilestonesMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sales-based Milestones",
        "label": "Sales Based Milestones [Member]",
        "documentation": "Sales Based Milestones"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SalesRevenueNetMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SalesRevenueNetMember",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Revenue",
        "label": "Revenue Benchmark [Member]",
        "documentation": "Revenue from sale of product and rendering of service and other sources of income, when it serves as benchmark in concentration of risk calculation."
       }
      }
     },
     "auth_ref": [
      "r269",
      "r1175",
      "r1176"
     ]
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/AccountsPayableandAccruedLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Components of Accounts Payable and Accrued Liabilities",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of accrued liabilities."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareAdditionalInformationDetails",
      "http://www.arvinas.com/role/NetLossPerShareSecuritiesExcludedfromtheComputationsofDilutedNetLossPerShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Antidilutive Securities Excluded From Computation Of Earnings Per Share [Table]",
        "label": "Antidilutive Security, Excluded EPS Calculation [Table]",
        "documentation": "Disclosure of information about security that could potentially dilute basic earnings per share (EPS) in future that was not included in calculation of diluted EPS."
       }
      }
     },
     "auth_ref": [
      "r223"
     ]
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Securities Excluded From Computation of Diluted Net Loss Per Common Share",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities."
       }
      }
     },
     "auth_ref": [
      "r27"
     ]
    },
    "us-gaap_ScheduleOfCashAndCashEquivalentsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashAndCashEquivalentsTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of cash and cash equivalents",
        "label": "Schedule of Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of the components of cash and cash equivalents."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax Paid, Net of Refunds",
        "label": "Schedule of Cash Flow, Supplemental Disclosures [Table Text Block]",
        "documentation": "Tabular disclosure of supplemental cash flow information for the periods presented."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Income Tax Expense",
        "label": "Schedule of Components of Income Tax Expense (Benefit) [Table Text Block]",
        "documentation": "Tabular disclosure of the components of income tax expense attributable to continuing operations for each year presented including, but not limited to: current tax expense (benefit), deferred tax expense (benefit), investment tax credits, government grants, the benefits of operating loss carryforwards, tax expense that results from allocating certain tax benefits either directly to contributed capital or to reduce goodwill or other noncurrent intangible assets of an acquired entity, adjustments of a deferred tax liability or asset for enacted changes in tax laws or rates or a change in the tax status of the entity, and adjustments of the beginning-of-the-year balances of a valuation allowance because of a change in circumstances that causes a change in judgment about the realizability of the related deferred tax asset in future years."
       }
      }
     },
     "auth_ref": [
      "r1258"
     ]
    },
    "us-gaap_ScheduleOfDebtInstrumentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDebtInstrumentsTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Long-Term Debt",
        "label": "Schedule of Long-Term Debt Instruments [Table Text Block]",
        "documentation": "Tabular disclosure of long-debt instruments or arrangements, including identification, terms, features, collateral requirements and other information necessary to a fair presentation. These are debt arrangements that originally required repayment more than twelve months after issuance or greater than the normal operating cycle of the entity, if longer."
       }
      }
     },
     "auth_ref": [
      "r16",
      "r35",
      "r36",
      "r43",
      "r84",
      "r85",
      "r889",
      "r891",
      "r1160",
      "r1167",
      "r1284",
      "r1299"
     ]
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Deferred Income Tax Benefits and Liabilities",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets."
       }
      }
     },
     "auth_ref": [
      "r1254"
     ]
    },
    "us-gaap_ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/NetLossPerShareTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Basic and Diluted Loss per Common Share",
        "label": "Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]",
        "documentation": "Tabular disclosure of an entity's basic and diluted earnings per share calculations, including a reconciliation of numerators and denominators of the basic and diluted per-share computations for income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r1172"
     ]
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reconciliation of the U.S. Federal Statutory Income Tax Rate to Effective Income Tax Rate",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations."
       }
      }
     },
     "auth_ref": [
      "r504",
      "r906",
      "r1252"
     ]
    },
    "srt_ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails",
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Investment, Name [Axis]",
        "label": "Investment, Name [Axis]",
        "documentation": "Information by name of investment including named security. Excludes entity that is consolidated."
       }
      }
     },
     "auth_ref": [
      "r303",
      "r304",
      "r306",
      "r535",
      "r598",
      "r1078",
      "r1079",
      "r1080",
      "r1261",
      "r1262",
      "r1263",
      "r1264"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsLineItems",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Equity Method Investments [Line Items]",
        "label": "Schedule of Equity Method Investments [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r187",
      "r192",
      "r303",
      "r304",
      "r306",
      "r307",
      "r598"
     ]
    },
    "us-gaap_ScheduleOfEquityMethodInvestmentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfEquityMethodInvestmentsTable",
     "presentation": [
      "http://www.arvinas.com/role/EquityMethodInvestmentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Equity Method Investments [Table]",
        "label": "Equity Method Investment [Table]",
        "documentation": "Disclosure of information about equity method investment. Includes, but is not limited to, name of investee or group of investees, percentage ownership, difference between investment and value of underlying equity in net assets."
       }
      }
     },
     "auth_ref": [
      "r156",
      "r187",
      "r192",
      "r303",
      "r304",
      "r306",
      "r307",
      "r598"
     ]
    },
    "us-gaap_ScheduleOfMaturitiesOfLongTermDebtTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfMaturitiesOfLongTermDebtTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Minimum Future Payments on Long-Term Debt",
        "label": "Schedule of Maturities of Long-Term Debt [Table Text Block]",
        "documentation": "Tabular disclosure of maturity and sinking fund requirement for long-term debt."
       }
      }
     },
     "auth_ref": [
      "r9"
     ]
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "presentation": [
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsAdditionalInformationDetails",
      "http://www.arvinas.com/role/PropertyEquipmentandLeaseholdImprovementsScheduleofPropertyEquipmentandLeaseholdImprovementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Property Plant And Equipment [Table]",
        "label": "Property, Plant and Equipment [Table]",
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation."
       }
      }
     },
     "auth_ref": [
      "r8",
      "r624"
     ]
    },
    "us-gaap_ScheduleOfRestrictedCashAndCashEquivalentsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestrictedCashAndCashEquivalentsTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of restrictions on cash and cash equivalents",
        "label": "Restrictions on Cash and Cash Equivalents [Table Text Block]",
        "documentation": "Tabular disclosure of cash and cash equivalents restricted as to withdrawal or usage."
       }
      }
     },
     "auth_ref": [
      "r14",
      "r91",
      "r1302"
     ]
    },
    "us-gaap_ScheduleOfRestructuringAndRelatedCostsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfRestructuringAndRelatedCostsTable",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Restructuring Cost [Table]",
        "label": "Restructuring Cost [Table]",
        "documentation": "Disclosure of information about restructuring cost. Includes, but is not limited to, expected cost, cost incurred, statement of income caption that includes restructuring cost recognized, and amount of restructuring reserve."
       }
      }
     },
     "auth_ref": [
      "r342",
      "r343",
      "r344",
      "r345",
      "r348",
      "r349",
      "r350"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTable",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Segment Reporting Information, by Segment [Table]",
        "label": "Schedule of Segment Reporting Information, by Segment [Table]",
        "documentation": "Disclosure of information about profit (loss) and total assets by reportable segment."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ScheduleOfSegmentReportingInformationBySegmentTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfSegmentReportingInformationBySegmentTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Reportable Segment Financial Information",
        "label": "Schedule of Segment Reporting Information, by Segment [Table Text Block]",
        "documentation": "Tabular disclosure of the profit or loss and total assets for each reportable segment. An entity discloses certain information on each reportable segment if the amounts (a) are included in the measure of segment profit or loss reviewed by the chief operating decision maker or (b) are otherwise regularly provided to the chief operating decision maker, even if not included in that measure of segment profit or loss."
       }
      }
     },
     "auth_ref": [
      "r30",
      "r31",
      "r32"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails",
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule Of Share Based Compensation Arrangements By Share Based Payment Award [Table]",
        "label": "Schedule of Share-Based Compensation Arrangements by Share-Based Payment Award [Table]",
        "documentation": "Disclosure of information about share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r446",
      "r448",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r482"
     ]
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Stock Option Activity",
        "label": "Share-Based Payment Arrangement, Option, Activity [Table Text Block]",
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value."
       }
      }
     },
     "auth_ref": [
      "r12",
      "r13",
      "r87"
     ]
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/EquityTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Assumptions Used to Determine Fair Value of Stock Options Granted",
        "label": "Schedule of Share-Based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions."
       }
      }
     },
     "auth_ref": [
      "r89"
     ]
    },
    "arvn_ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Supplemental Cash Flow Information Related to Leases",
        "label": "Schedule Of Supplemental Cash Flow Information Related To Leases Table [Table Text Block]",
        "documentation": "Supplemental cash flow information related to leases."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Schedule of Unrecognized Tax Benefits",
        "label": "Schedule of Unrecognized Tax Benefits Roll Forward [Table Text Block]",
        "documentation": "Tabular disclosure of the change in unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r512",
      "r905"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r962"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r965"
     ]
    },
    "us-gaap_SegmentDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentDomain",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Domain]",
        "label": "Segments [Domain]",
        "documentation": "Components of an entity that engage in business activities from which they may earn revenue and incur expenses, including transactions with other components of the same entity."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r228",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r269",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r345",
      "r350",
      "r541",
      "r542",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r877",
      "r880",
      "r881",
      "r887",
      "r944",
      "r1303",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332"
     ]
    },
    "srt_SegmentGeographicalDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "SegmentGeographicalDomain",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Domain]",
        "label": "Geographical [Domain]",
        "documentation": "Geographical area."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r122",
      "r125",
      "r127",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r144",
      "r145",
      "r146",
      "r232",
      "r267",
      "r268",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r703",
      "r704",
      "r705",
      "r706",
      "r774",
      "r775",
      "r776",
      "r829",
      "r831",
      "r834",
      "r836",
      "r838",
      "r840",
      "r841",
      "r842",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r860",
      "r872",
      "r895",
      "r897",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r943",
      "r953",
      "r1303",
      "r1305",
      "r1306",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332"
     ]
    },
    "us-gaap_SegmentReportingAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Segment Reporting [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingDisclosureTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Information",
        "label": "Segment Reporting Disclosure [Text Block]",
        "documentation": "The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments."
       }
      }
     },
     "auth_ref": [
      "r105",
      "r228",
      "r236",
      "r237",
      "r238",
      "r239",
      "r240",
      "r252",
      "r254",
      "r255",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r269",
      "r876",
      "r878",
      "r879",
      "r880",
      "r882",
      "r883",
      "r884"
     ]
    },
    "us-gaap_SegmentReportingInformationLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingInformationLineItems",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segment Reporting Information [Line Items]",
        "label": "Segment Reporting Information [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SegmentReportingOtherItemAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SegmentReportingOtherItemAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Other segment expense, net",
        "label": "Segment Reporting, Other Segment Item, Amount",
        "documentation": "Amount of other expense (income) and loss (gain) calculated as difference between segment revenue and separately disclosed expense category to arrive at segment profit (loss)."
       }
      }
     },
     "auth_ref": [
      "r228",
      "r254",
      "r255",
      "r262",
      "r880"
     ]
    },
    "us-gaap_ShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensation",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows": {
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock-based compensation",
        "label": "Share-Based Payment Arrangement, Noncash Expense",
        "documentation": "Amount of noncash expense for share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total intrinsic value of RSUs released",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Aggregate Intrinsic Value, Released In Period"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeited in Period",
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that were forfeited during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Forfeitures, Weighted Average Grant Date Fair Value",
        "documentation": "Weighted average fair value as of the grant date of equity-based award plans other than stock (unit) option plans that were not exercised or put into effect as a result of the occurrence of a terminating event."
       }
      }
     },
     "auth_ref": [
      "r465"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period",
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in dollars per share)",
        "terseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan)."
       }
      }
     },
     "auth_ref": [
      "r463"
     ]
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Number of inducement grants (in shares)",
        "label": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants",
        "documentation": "Share-Based Compensation Arrangement By Share-Based Payment Award, Equity Instruments Other Than Options, Inducement Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number",
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedRollForward",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Shares",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value",
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options."
       }
      }
     },
     "auth_ref": [
      "r460",
      "r461"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValueRollForward",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Grant Date Fair Value Per Share",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Released (in shares)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Released In Period",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Released In Period"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Released (in dollars per share)",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Released, Weighted Average Grant Date Fair Value",
        "documentation": "Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options, Released, Weighted Average Grant Date Fair Value"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total fair value of RSUs vested",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Equity Instruments Other than Options, Vested in Period, Fair Value",
        "documentation": "Fair value of share-based awards for which the grantee gained the right by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Exercise price (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Exercise Price",
        "documentation": "Agreed-upon price for the exchange of the underlying asset relating to the share-based payment award."
       }
      }
     },
     "auth_ref": [
      "r1243"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected dividend yield (percentage)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Dividend Rate",
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term."
       }
      }
     },
     "auth_ref": [
      "r474"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, maximum (percentage)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Maximum",
        "documentation": "The estimated measure of the maximum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected volatility, minimum (percentage)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Volatility Rate, Minimum",
        "documentation": "The estimated measure of the minimum percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period."
       }
      }
     },
     "auth_ref": [
      "r473"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate, maximum (percentage)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Maximum",
        "documentation": "The maximum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Risk free interest rate, minimum (percentage)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Risk Free Interest Rate, Minimum",
        "documentation": "The minimum risk-free interest rate assumption that is used in valuing an option on its own shares."
       }
      }
     },
     "auth_ref": [
      "r475"
     ]
    },
    "arvn_ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Inducement grants (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants",
        "documentation": "Share-Based Compensation Arrangement by Share-Based Payment Award, Inducement Grants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails",
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share Based Compensation Arrangement By Share Based Payment Award [Line Items]",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r444",
      "r446",
      "r448",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r471",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476",
      "r482"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares remained available for purchase (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant",
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-Average Remaining Contractual Term (Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Additional Disclosures [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodEndLabel": "Vested and exercisable, ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Number",
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and exercisable (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Exercise Price",
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r454"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Intrinsic value of options exercised",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares."
       }
      }
     },
     "auth_ref": [
      "r467"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Forfeited (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Forfeitures in Period",
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Gross",
        "documentation": "Gross number of share options (or share units) granted during the period."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted average grant date fair value of options granted (in usd per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology."
       }
      }
     },
     "auth_ref": [
      "r466"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual increase in reserved shares of common stock (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Other Increases (Decreases) in Period",
        "documentation": "The addition or reduction in the number of reserved shares that could potentially be issued under the option plan attributable to reasons other than grants, exercises, forfeitures, and expirations during the reporting period."
       }
      }
     },
     "auth_ref": [
      "r1228"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Intrinsic Value",
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Number",
        "documentation": "Number of options outstanding, including both vested and non-vested options."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Options",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding [Roll Forward]",
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning balance (in dollars per share)",
        "periodEndLabel": "Ending balance (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan."
       }
      }
     },
     "auth_ref": [
      "r452",
      "r453"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Aggregate Intrinsic Value",
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in shares)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Number",
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in dollars per share)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Exercise Price",
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum": {
     "xbrltype": "percentItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Annual increase in reserved shares as percentage of outstanding common stock",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Percentage of Outstanding Stock Maximum",
        "documentation": "Maximum number of shares that may be issued in accordance with the plan as a proportion of outstanding capital stock."
       }
      }
     },
     "auth_ref": [
      "r1249"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Decrease in compensation expense",
        "label": "Share-Based Payment Arrangement, Plan Modification, Incremental Cost",
        "documentation": "An excess of the fair value of the modified award over the fair value of the award immediately before the modification."
       }
      }
     },
     "auth_ref": [
      "r480"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails",
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails",
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Award Type [Domain]",
        "label": "Award Type [Domain]",
        "documentation": "Award under share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r448",
      "r449",
      "r450",
      "r452",
      "r453",
      "r454",
      "r455",
      "r456",
      "r457",
      "r458",
      "r459",
      "r460",
      "r461",
      "r462",
      "r463",
      "r464",
      "r465",
      "r466",
      "r467",
      "r468",
      "r469",
      "r472",
      "r473",
      "r474",
      "r475",
      "r476"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Forfeited (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated."
       }
      }
     },
     "auth_ref": [
      "r458"
     ]
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Granted (in dollars per share)",
        "label": "Share-Based Compensation Arrangements by Share-Based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options."
       }
      }
     },
     "auth_ref": [
      "r456"
     ]
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity-based Compensation",
        "label": "Share-Based Payment Arrangement [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost."
       }
      }
     },
     "auth_ref": [
      "r443",
      "r451",
      "r470",
      "r471",
      "r472",
      "r473",
      "r476",
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492"
     ]
    },
    "arvn_ShareRepurchaseProgramCommissionsAndExciseTax": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "ShareRepurchaseProgramCommissionsAndExciseTax",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program, commissions and excise tax",
        "label": "Share Repurchase Program Commissions And Excise Tax",
        "documentation": "Share Repurchase Program Commissions And Excise Tax"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofAssumptionsUsedtoDetermineFairValueofandStockOptionsGrantedDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expected term (years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Fair Value Assumptions, Expected Term",
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r472"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and exercisable",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Intrinsic Value",
        "documentation": "Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and exercisable (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Exercisable, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r39"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedWeightedAverageGrantDateFairValueAbstract",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "verboseLabel": "Weighted-Average Exercise Price",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Nonvested, Weighted Average Grant Date Fair Value [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Outstanding (in years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days."
       }
      }
     },
     "auth_ref": [
      "r88"
     ]
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "xbrltype": "durationItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "presentation": [
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vested and expected to vest (in Years)",
        "label": "Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Vested and Expected to Vest, Outstanding, Weighted Average Remaining Contractual Term",
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur."
       }
      }
     },
     "auth_ref": [
      "r468"
     ]
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SharesIssuedPricePerShare",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share price, issued and sold (in usd per share)",
        "label": "Shares Issued, Price Per Share",
        "documentation": "Per share or per unit amount of equity securities issued."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SignificantAccountingPoliciesTextBlock",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary of Significant Accounting Policies",
        "label": "Significant Accounting Policies [Text Block]",
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity."
       }
      }
     },
     "auth_ref": [
      "r185",
      "r186"
     ]
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StateAndLocalJurisdictionMember",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails",
      "http://www.arvinas.com/role/IncomeTaxesScheduleofIncomeTaxPaidNetofRefundsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "US state and local",
        "label": "State and Local Jurisdiction [Member]",
        "documentation": "Designated state or local jurisdiction entitled to levy and collect income tax."
       }
      }
     },
     "auth_ref": [
      "r502"
     ]
    },
    "us-gaap_StatementBusinessSegmentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementBusinessSegmentsAxis",
     "presentation": [
      "http://www.arvinas.com/role/SegmentInformationScheduleofFinancialInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Segments [Axis]",
        "label": "Segments [Axis]",
        "documentation": "Information by business segments."
       }
      }
     },
     "auth_ref": [
      "r102",
      "r103",
      "r104",
      "r105",
      "r155",
      "r228",
      "r237",
      "r240",
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r250",
      "r251",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r258",
      "r259",
      "r260",
      "r262",
      "r263",
      "r264",
      "r269",
      "r321",
      "r322",
      "r323",
      "r324",
      "r325",
      "r326",
      "r327",
      "r328",
      "r329",
      "r330",
      "r333",
      "r345",
      "r350",
      "r541",
      "r542",
      "r733",
      "r734",
      "r735",
      "r736",
      "r737",
      "r738",
      "r739",
      "r740",
      "r741",
      "r742",
      "r743",
      "r877",
      "r880",
      "r881",
      "r887",
      "r944",
      "r1303",
      "r1305",
      "r1306",
      "r1307",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332"
     ]
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementEquityComponentsAxis",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Equity Components [Axis]",
        "label": "Equity Components [Axis]",
        "documentation": "Information by component of equity."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r57",
      "r60",
      "r61",
      "r152",
      "r153",
      "r154",
      "r172",
      "r173",
      "r174",
      "r199",
      "r200",
      "r201",
      "r203",
      "r210",
      "r212",
      "r214",
      "r229",
      "r309",
      "r310",
      "r331",
      "r398",
      "r413",
      "r483",
      "r527",
      "r528",
      "r536",
      "r537",
      "r538",
      "r540",
      "r543",
      "r544",
      "r557",
      "r558",
      "r559",
      "r560",
      "r561",
      "r562",
      "r563",
      "r564",
      "r565",
      "r566",
      "r568",
      "r602",
      "r603",
      "r604",
      "r605",
      "r606",
      "r607",
      "r610",
      "r612",
      "r626",
      "r726",
      "r755",
      "r756",
      "r757",
      "r771",
      "r825"
     ]
    },
    "srt_StatementGeographicalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StatementGeographicalAxis",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Geographical [Axis]",
        "label": "Geographical [Axis]",
        "documentation": "Information by geographical components."
       }
      }
     },
     "auth_ref": [
      "r120",
      "r122",
      "r125",
      "r127",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r142",
      "r144",
      "r145",
      "r146",
      "r232",
      "r267",
      "r268",
      "r664",
      "r665",
      "r666",
      "r667",
      "r668",
      "r669",
      "r670",
      "r671",
      "r672",
      "r673",
      "r674",
      "r675",
      "r676",
      "r677",
      "r678",
      "r679",
      "r680",
      "r681",
      "r682",
      "r683",
      "r684",
      "r685",
      "r686",
      "r687",
      "r688",
      "r689",
      "r690",
      "r691",
      "r692",
      "r693",
      "r694",
      "r695",
      "r696",
      "r697",
      "r703",
      "r704",
      "r705",
      "r706",
      "r774",
      "r775",
      "r776",
      "r829",
      "r831",
      "r834",
      "r836",
      "r838",
      "r840",
      "r841",
      "r842",
      "r845",
      "r846",
      "r847",
      "r848",
      "r849",
      "r850",
      "r851",
      "r852",
      "r853",
      "r860",
      "r872",
      "r895",
      "r897",
      "r932",
      "r933",
      "r934",
      "r935",
      "r936",
      "r937",
      "r938",
      "r939",
      "r943",
      "r953",
      "r1303",
      "r1305",
      "r1306",
      "r1308",
      "r1309",
      "r1310",
      "r1311",
      "r1312",
      "r1313",
      "r1314",
      "r1315",
      "r1316",
      "r1317",
      "r1318",
      "r1319",
      "r1320",
      "r1321",
      "r1322",
      "r1323",
      "r1324",
      "r1325",
      "r1326",
      "r1327",
      "r1328",
      "r1329",
      "r1330",
      "r1331",
      "r1332"
     ]
    },
    "us-gaap_StatementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementLineItems",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Line Items]",
        "label": "Statement [Line Items]",
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r229",
      "r400",
      "r401",
      "r403",
      "r405",
      "r612",
      "r663",
      "r765",
      "r772",
      "r773",
      "r779",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r788",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r808",
      "r809",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r825",
      "r868",
      "r869",
      "r954",
      "r1335"
     ]
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Cash Flows [Abstract]",
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Financial Position [Abstract]",
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfIncomeAndComprehensiveIncomeAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfIncomeAndComprehensiveIncomeAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Consolidated Statements of Comprehensive Loss",
        "label": "Statement of Comprehensive Income [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementOfStockholdersEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement of Stockholders' Equity [Abstract]",
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StatementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StatementTable",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Statement [Table]",
        "label": "Statement [Table]",
        "documentation": "Presentation of information about comprehensive income, income, other comprehensive income, financial position, cash flows, and shareholders' equity."
       }
      }
     },
     "auth_ref": [
      "r199",
      "r200",
      "r201",
      "r229",
      "r270",
      "r400",
      "r401",
      "r403",
      "r405",
      "r612",
      "r663",
      "r765",
      "r772",
      "r773",
      "r779",
      "r781",
      "r782",
      "r783",
      "r784",
      "r785",
      "r788",
      "r791",
      "r792",
      "r793",
      "r794",
      "r795",
      "r796",
      "r797",
      "r798",
      "r799",
      "r801",
      "r802",
      "r803",
      "r804",
      "r805",
      "r808",
      "r809",
      "r811",
      "r812",
      "r813",
      "r814",
      "r815",
      "r816",
      "r817",
      "r818",
      "r819",
      "r820",
      "r821",
      "r822",
      "r825",
      "r868",
      "r869",
      "r954",
      "r1335"
     ]
    },
    "ecd_StkPrcOrTsrEstimationMethodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "StkPrcOrTsrEstimationMethodTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/ErrCompDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Price or TSR Estimation Method",
        "label": "Stock Price or TSR Estimation Method [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r984",
      "r995",
      "r1005",
      "r1038"
     ]
    },
    "us-gaap_StockAppreciationRightsSARSMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockAppreciationRightsSARSMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Appreciation Rights (SARs)",
        "label": "Stock Appreciation Rights (SARs) [Member]",
        "documentation": "Right to receive cash or shares equal to appreciation of predetermined number of grantor's shares during predetermined time period."
       }
      }
     },
     "auth_ref": [
      "r1222",
      "r1223",
      "r1224",
      "r1225",
      "r1226",
      "r1227",
      "r1228",
      "r1229",
      "r1230",
      "r1231",
      "r1232",
      "r1233",
      "r1234",
      "r1235",
      "r1236",
      "r1237",
      "r1238",
      "r1239",
      "r1240",
      "r1241",
      "r1242",
      "r1244",
      "r1245",
      "r1246",
      "r1247",
      "r1248"
     ]
    },
    "arvn_StockCompensationAndBonusExpenseMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "StockCompensationAndBonusExpenseMember",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Non Cash Stock Compensation And Bonus Expense",
        "label": "Stock Compensation And Bonus Expense [Member]",
        "documentation": "Stock Compensation And Bonus Expense"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock, shares issued (in shares)",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r56",
      "r57",
      "r86"
     ]
    },
    "arvn_StockIssuedDuringPeriodSharesExerciseOfWarrants": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "StockIssuedDuringPeriodSharesExerciseOfWarrants",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock for pre-funded warrants (in shares)",
        "label": "Stock Issued During Period, Shares, Exercise Of Warrants",
        "documentation": "Stock Issued During Period, Shares, Exercise Of Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued, net of issuance costs (in shares)",
        "label": "Stock Issued During Period, Shares, New Issues",
        "documentation": "Number of new stock issued during the period."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r56",
      "r57",
      "r86",
      "r767",
      "r825",
      "r837"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodSharesShareBasedCompensation": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodSharesShareBasedCompensation",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under equity incentive plans (in shares)",
        "label": "Shares Issued, Shares, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Number, after forfeiture, of shares or units issued under share-based payment arrangement. Excludes shares or units issued under employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r56",
      "r57",
      "r86"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Common stock issued, net of issuance costs",
        "label": "Stock Issued During Period, Value, New Issues",
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r56",
      "r57",
      "r86",
      "r771",
      "r825",
      "r837",
      "r960"
     ]
    },
    "us-gaap_StockIssuedDuringPeriodValueShareBasedCompensation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockIssuedDuringPeriodValueShareBasedCompensation",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Issuance of common stock under equity incentive plans",
        "label": "Shares Issued, Value, Share-Based Payment Arrangement, after Forfeiture",
        "documentation": "Value, after forfeiture, of shares issued under share-based payment arrangement. Excludes employee stock ownership plan (ESOP)."
       }
      }
     },
     "auth_ref": [
      "r40",
      "r56",
      "r57",
      "r86"
     ]
    },
    "arvn_StockPurchaseAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "StockPurchaseAgreementMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stock Purchase Agreement",
        "label": "Stock Purchase Agreement [Member]",
        "documentation": "Stock purchase agreement."
       }
      }
     },
     "auth_ref": []
    },
    "srt_StockRepurchaseProgramAuthorizedAmount1": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "StockRepurchaseProgramAuthorizedAmount1",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program, authorized amount",
        "label": "Share Repurchase Program, Authorized, Amount",
        "documentation": "Amount authorized for purchase of share under share repurchase plan. Includes, but is not limited to, repurchase of stock and unit of ownership."
       }
      }
     },
     "auth_ref": [
      "r1218"
     ]
    },
    "us-gaap_StockholdersEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquity",
     "crdr": "credit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "totalLabel": "Total stockholders' equity",
        "periodStartLabel": "Beginning balance",
        "periodEndLabel": "Ending balance",
        "label": "Equity, Attributable to Parent",
        "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest."
       }
      }
     },
     "auth_ref": [
      "r57",
      "r60",
      "r61",
      "r77",
      "r790",
      "r806",
      "r826",
      "r827",
      "r929",
      "r961",
      "r1159",
      "r1163",
      "r1164",
      "r1203",
      "r1283",
      "r1336"
     ]
    },
    "us-gaap_StockholdersEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "StockholdersEquityAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Stockholders' equity:",
        "label": "Equity, Attributable to Parent [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SubsidiarySaleOfStockAxis",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Sale of Stock [Axis]",
        "label": "Sale of Stock [Axis]",
        "documentation": "Information by type of sale of the entity's stock."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_SuccessBasedMilestonePaymentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "SuccessBasedMilestonePaymentsMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Success-Based Milestone Payments",
        "label": "Success-Based Milestone Payments [Member]",
        "documentation": "Success-Based Milestone Payments"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_SummaryOfSignificantAccountingPoliciesLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "SummaryOfSignificantAccountingPoliciesLineItems",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Line Items]",
        "label": "Summary Of Significant Accounting Policies [Line Items]",
        "documentation": "Summary of significant accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_SummaryOfSignificantAccountingPoliciesTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "SummaryOfSignificantAccountingPoliciesTable",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Summary Of Significant Accounting Policies [Table]",
        "label": "Summary Of Significant Accounting Policies [Table]",
        "documentation": "Summary of significant of accounting policies."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "SupplementalCashFlowInformationAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental disclosure of cash flow information:",
        "label": "Supplemental Cash Flow Information [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_SupplementalNonCashInformationRelatedToLeasesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "SupplementalNonCashInformationRelatedToLeasesAbstract",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesScheduleofSupplementalCashFlowInformationRelatedtoLeasesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Supplemental non-cash information:",
        "label": "Supplemental Non Cash Information Related To Leases [Abstract]",
        "documentation": "Supplemental non-cash information related to leases."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_TabularListTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TabularListTableTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tabular List, Table",
        "label": "Tabular List [Table Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1031"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAmount",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Federal tax credit carryforwards",
        "label": "Tax Credit Carryforward, Amount",
        "documentation": "The amount of the tax credit carryforward, before tax effects, available to reduce future taxable income under enacted tax laws."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_TaxCreditCarryforwardAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardAxis",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward [Axis]",
        "label": "Tax Credit Carryforward [Axis]",
        "documentation": "Information by specific tax credit related to an unused tax credit."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "us-gaap_TaxCreditCarryforwardNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TaxCreditCarryforwardNameDomain",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Tax Credit Carryforward, Name [Domain]",
        "label": "Tax Credit Carryforward, Name [Domain]",
        "documentation": "The name of the tax credit carryforward."
       }
      }
     },
     "auth_ref": [
      "r524"
     ]
    },
    "ecd_TotalShareholderRtnAmt": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Amount",
        "label": "Total Shareholder Return Amount"
       }
      }
     },
     "auth_ref": [
      "r1023"
     ]
    },
    "ecd_TotalShareholderRtnVsPeerGroupTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TotalShareholderRtnVsPeerGroupTextBlock",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Total Shareholder Return Vs Peer Group",
        "label": "Total Shareholder Return Vs Peer Group [Text Block]"
       }
      }
     },
     "auth_ref": [
      "r1030"
     ]
    },
    "ecd_TradingArrAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrAxis",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangement:",
        "label": "Trading Arrangement [Axis]"
       }
      }
     },
     "auth_ref": [
      "r1051"
     ]
    },
    "ecd_TradingArrByIndTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TradingArrByIndTable",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Arrangements, by Individual",
        "label": "Trading Arrangements, by Individual [Table]"
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2025",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.arvinas.com/role/Cover"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Financial Instruments [Domain]",
        "label": "Financial Instruments [Domain]",
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms."
       }
      }
     },
     "auth_ref": [
      "r272",
      "r273",
      "r274",
      "r275",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r295",
      "r296",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301",
      "r395",
      "r411",
      "r556",
      "r567",
      "r590",
      "r597",
      "r600",
      "r628",
      "r629",
      "r630",
      "r631",
      "r632",
      "r633",
      "r634",
      "r635",
      "r636",
      "r637",
      "r638",
      "r639",
      "r640",
      "r641",
      "r643",
      "r646",
      "r647",
      "r648",
      "r649",
      "r650",
      "r651",
      "r652",
      "r653",
      "r654",
      "r655",
      "r656",
      "r657",
      "r658",
      "r659",
      "r660",
      "r710",
      "r727",
      "r915",
      "r917",
      "r919",
      "r920",
      "r921",
      "r922",
      "r923",
      "r924",
      "r925",
      "r931",
      "r1086",
      "r1087",
      "r1088",
      "r1089",
      "r1090",
      "r1091",
      "r1092",
      "r1198",
      "r1199",
      "r1200",
      "r1201",
      "r1273",
      "r1276",
      "r1277",
      "r1278",
      "r1279",
      "r1280",
      "r1281",
      "r1282"
     ]
    },
    "ecd_TrdArrAdoptionDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrAdoptionDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Adoption Date",
        "label": "Trading Arrangement Adoption Date"
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "ecd_TrdArrDuration": {
     "xbrltype": "durationItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrDuration",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Arrangement Duration",
        "label": "Trading Arrangement Duration"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_TrdArrExpirationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrExpirationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Expiration Date",
        "label": "Trading Arrangement Expiration Date"
       }
      }
     },
     "auth_ref": [
      "r1055"
     ]
    },
    "ecd_TrdArrIndName": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndName",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Name",
        "label": "Trading Arrangement, Individual Name"
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "ecd_TrdArrIndTitle": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrIndTitle",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title",
        "label": "Trading Arrangement, Individual Title"
       }
      }
     },
     "auth_ref": [
      "r1053"
     ]
    },
    "ecd_TrdArrSecuritiesAggAvailAmt": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrSecuritiesAggAvailAmt",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Aggregate Available",
        "label": "Trading Arrangement, Securities Aggregate Available Amount"
       }
      }
     },
     "auth_ref": [
      "r1056"
     ]
    },
    "ecd_TrdArrTerminationDate": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "TrdArrTerminationDate",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/InsiderTradingArrangements"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Termination Date",
        "label": "Trading Arrangement Termination Date"
       }
      }
     },
     "auth_ref": [
      "r1054"
     ]
    },
    "us-gaap_TreasuryStockAcquiredAverageCostPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockAcquiredAverageCostPerShare",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program, average price (in dollars per share)",
        "label": "Shares Acquired, Average Cost Per Share",
        "documentation": "Total cost of shares repurchased divided by the total number of shares repurchased."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_TreasuryStockCommonMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonMember",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury",
        "label": "Treasury Stock, Common [Member]",
        "documentation": "Previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_TreasuryStockCommonShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonShares",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheetsParenthetical",
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Treasury stock, shares (in shares)",
        "periodStartLabel": "Beginning balance (in shares)",
        "periodEndLabel": "Ending balance (in shares)",
        "label": "Treasury Stock, Common, Shares",
        "documentation": "Number of previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "us-gaap_TreasuryStockCommonValue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockCommonValue",
     "crdr": "debit",
     "calculation": {
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets": {
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedBalanceSheets"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedLabel": "Treasury Stock, at cost (10.0 and zero shares at December\u00a031, 2025 and December\u00a031, 2024, respectively)",
        "label": "Treasury Stock, Common, Value",
        "documentation": "Amount allocated to previously issued common shares repurchased by the issuing entity and held in treasury."
       }
      }
     },
     "auth_ref": [
      "r37",
      "r38",
      "r60"
     ]
    },
    "us-gaap_TreasuryStockSharesAcquired": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockSharesAcquired",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchases (Treasury Stock) (in shares)",
        "label": "Treasury Stock, Shares, Acquired",
        "documentation": "Number of shares that have been repurchased during the period and are being held in treasury."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r57",
      "r86"
     ]
    },
    "us-gaap_TreasuryStockValueAcquiredCostMethod": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TreasuryStockValueAcquiredCostMethod",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofChangesinStockholdersEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "negatedTerseLabel": "Share repurchases (Treasury stock)",
        "label": "Treasury Stock, Value, Acquired, Cost Method",
        "documentation": "Equity impact of the cost of common and preferred stock that were repurchased during the period. Recorded using the cost method."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r37",
      "r86"
     ]
    },
    "arvn_TreasuryStockValueAcquiredCostMethodNetOfCommissions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "TreasuryStockValueAcquiredCostMethodNetOfCommissions",
     "crdr": "debit",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Share repurchase program, acquired, value net of commissions",
        "label": "Treasury Stock, Value, Acquired, Cost Method, Net Of Commissions",
        "documentation": "Treasury Stock, Value, Acquired, Cost Method, Net of Commissions"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_TwoThousandAndEighteenAssistanceAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "TwoThousandAndEighteenAssistanceAgreementMember",
     "presentation": [
      "http://www.arvinas.com/role/LongTermDebtAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 Assistance Agreement",
        "label": "Two Thousand And Eighteen Assistance Agreement [Member]",
        "documentation": "Two thousand and eighteen assistance agreement."
       }
      }
     },
     "auth_ref": []
    },
    "arvn_TwoThousandEighteenStockIncentivePlanMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "TwoThousandEighteenStockIncentivePlanMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/EquityScheduleofRestrictedStockDetails",
      "http://www.arvinas.com/role/EquityScheduleofStockOptionActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "2018 Plan",
        "verboseLabel": "2018 Plan",
        "label": "Two Thousand Eighteen Stock Incentive Plan [Member]",
        "documentation": "Two thousand eighteen stock incentive plan."
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_TypeOfArrangementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfArrangementAxis",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails",
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails",
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "label": "Collaborative Arrangement and Arrangement Other than Collaborative [Axis]",
        "documentation": "Information by collaborative arrangement and arrangement other than collaborative applicable to revenue-generating activity or operations."
       }
      }
     },
     "auth_ref": [
      "r547"
     ]
    },
    "us-gaap_TypeOfRestructuringDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "TypeOfRestructuringDomain",
     "presentation": [
      "http://www.arvinas.com/role/RestructuringActivityDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Type of Restructuring [Domain]",
        "label": "Type of Restructuring [Domain]",
        "documentation": "Identification of the types of restructuring costs."
       }
      }
     },
     "auth_ref": [
      "r178",
      "r181",
      "r342",
      "r343",
      "r348",
      "r349",
      "r867"
     ]
    },
    "us-gaap_USGovernmentDebtSecuritiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "USGovernmentDebtSecuritiesMember",
     "presentation": [
      "http://www.arvinas.com/role/MarketableSecuritiesandFairValueMeasurementsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Government securities",
        "label": "US Government Debt Securities [Member]",
        "documentation": "Debt securities issued by the United States government."
       }
      }
     },
     "auth_ref": [
      "r1300"
     ]
    },
    "ecd_UndrlygSecurityMktPriceChngPct": {
     "xbrltype": "pureItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "UndrlygSecurityMktPriceChngPct",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/AwardTimingDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Underlying Security Market Price Change",
        "label": "Underlying Security Market Price Change, Percent"
       }
      }
     },
     "auth_ref": [
      "r1050"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefits",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "periodStartLabel": "Beginning of period balance - gross",
        "periodEndLabel": "End of period balance - gross",
        "label": "Unrecognized Tax Benefits",
        "documentation": "Amount of unrecognized tax benefits."
       }
      }
     },
     "auth_ref": [
      "r498",
      "r512",
      "r905"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Unrecognized tax benefits, income tax penalties and interest accrued",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Accrued",
        "documentation": "Amount accrued for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return."
       }
      }
     },
     "auth_ref": [
      "r510",
      "r905"
     ]
    },
    "us-gaap_UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesScheduleofUnrecognizedTaxBenefitsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Increases for tax positions taken during the current period",
        "label": "Unrecognized Tax Benefits, Increase Resulting from Current Period Tax Positions",
        "documentation": "Amount of increase in unrecognized tax benefits resulting from tax positions that have been or will be taken in current period tax return."
       }
      }
     },
     "auth_ref": [
      "r513",
      "r905"
     ]
    },
    "arvn_UnrecognizedTaxBenefitsNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "UnrecognizedTaxBenefitsNet",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Net uncertain tax positions",
        "label": "Unrecognized Tax Benefits, Net",
        "documentation": "Unrecognized Tax Benefits, Net"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_UpdatedResearchTimelinesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "UpdatedResearchTimelinesMember",
     "presentation": [
      "http://www.arvinas.com/role/ResearchCollaborationandLicenseAgreementsAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Updated Research Timelines",
        "label": "Updated Research Timelines [Member]",
        "documentation": "Updated Research Timelines"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements",
        "label": "Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements [Member]",
        "documentation": "Upfront Payment For Amended License Agreement And Novartis License And Asset Agreements"
       }
      }
     },
     "auth_ref": []
    },
    "us-gaap_UseOfEstimates": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "UseOfEstimates",
     "presentation": [
      "http://www.arvinas.com/role/SummaryofSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Use of Estimates",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles."
       }
      }
     },
     "auth_ref": [
      "r107",
      "r108",
      "r230",
      "r233",
      "r234",
      "r235",
      "r703",
      "r705",
      "r873"
     ]
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "crdr": "credit",
     "presentation": [
      "http://www.arvinas.com/role/IncomeTaxesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "(Decrease) increase in valuation allowance",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset."
       }
      }
     },
     "auth_ref": [
      "r516"
     ]
    },
    "ecd_VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "VstngDtFrValOfEqtyAwrdsGrntdAndVstdInCvrdYrMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year",
        "label": "Vesting Date Fair Value of Equity Awards Granted and Vested in Covered Year [Member]"
       }
      }
     },
     "auth_ref": [
      "r1019"
     ]
    },
    "srt_WeightedAverageMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2025",
     "localname": "WeightedAverageMember",
     "presentation": [
      "http://www.arvinas.com/role/EquityAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted Average",
        "label": "Weighted Average [Member]",
        "documentation": "Average of a range of values, calculated with consideration of proportional relevance."
       }
      }
     },
     "auth_ref": [
      "r473",
      "r474",
      "r576",
      "r644",
      "r854",
      "r855",
      "r919",
      "r1291",
      "r1293",
      "r1296"
     ]
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/NetLossPerShareScheduleofBasicandDilutedLossperCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding - diluted (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period."
       }
      }
     },
     "auth_ref": [
      "r217",
      "r222"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss",
      "http://www.arvinas.com/role/NetLossPerShareScheduleofBasicandDilutedLossperCommonShareDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding - basic (in shares)",
        "verboseLabel": "Weighted average common shares outstanding - basic (in shares)",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period."
       }
      }
     },
     "auth_ref": [
      "r216",
      "r222"
     ]
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/us-gaap/2025",
     "localname": "WeightedAverageNumberOfSharesOutstandingDilutedDisclosureItemsAbstract",
     "presentation": [
      "http://www.arvinas.com/role/ConsolidatedStatementsofOperationsandComprehensiveLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Weighted-average common shares outstanding",
        "label": "Weighted Average Number of Shares Outstanding Reconciliation [Abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_WriteoffOfPrepaidRentMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "WriteoffOfPrepaidRentMember",
     "presentation": [
      "http://www.arvinas.com/role/RightofUseAssetsandLiabilitiesAdditionalInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Writeoff Of Prepaid Rent",
        "label": "Writeoff Of Prepaid Rent [Member]",
        "documentation": "Writeoff Of Prepaid Rent"
       }
      }
     },
     "auth_ref": []
    },
    "arvn_YaleUniversityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.arvinas.com/20251231",
     "localname": "YaleUniversityMember",
     "presentation": [
      "http://www.arvinas.com/role/CommitmentsandContingenciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Yale University",
        "label": "Yale University [Member]",
        "documentation": "Yale University."
       }
      }
     },
     "auth_ref": []
    },
    "ecd_YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/ecd/2025",
     "localname": "YrEndFrValOfEqtyAwrdsGrntdInCvrdYrOutsdngAndUnvstdMember",
     "presentation": [
      "http://xbrl.sec.gov/ecd/role/PvpDisclosure"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested",
        "label": "Year-end Fair Value of Equity Awards Granted in Covered Year that are Outstanding and Unvested [Member]"
       }
      }
     },
     "auth_ref": [
      "r1017"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "4",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482338/360-10-05-4"
  },
  "r1": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "SubTopic": "230",
   "Topic": "830",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477401/830-230-45-1"
  },
  "r2": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10A",
   "SubTopic": "10",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-10A"
  },
  "r3": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-20"
  },
  "r4": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "21D",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-21D"
  },
  "r5": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(g)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r6": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r7": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r8": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "360",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r9": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "SubTopic": "10",
   "Topic": "470",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-1"
  },
  "r10": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)(3)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1A"
  },
  "r11": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "505",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-2"
  },
  "r12": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r13": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r14": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "SubTopic": "10",
   "Topic": "230",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r15": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Subparagraph": "(c)",
   "Paragraph": "2",
   "SubTopic": "10",
   "Topic": "718",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r16": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "SubTopic": "10",
   "Topic": "210",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r17": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14"
  },
  "r18": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-14A"
  },
  "r19": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "220",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-5"
  },
  "r20": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r21": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-4"
  },
  "r22": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-1"
  },
  "r23": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2"
  },
  "r24": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-3"
  },
  "r25": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-4"
  },
  "r26": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "230",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-5"
  },
  "r27": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r28": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "260",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r29": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "270",
   "SubTopic": "10",
   "Section": "45",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482989/270-10-45-14"
  },
  "r30": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r31": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r32": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "280",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r33": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r34": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "360",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r35": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r36": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-8"
  },
  "r37": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481549/505-30-45-1"
  },
  "r38": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "505",
   "SubTopic": "30",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r39": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r40": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "718",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r41": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "810",
   "SubTopic": "10",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-1"
  },
  "r42": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "320",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-5"
  },
  "r43": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Name": "Accounting Standards Codification",
   "Topic": "942",
   "SubTopic": "470",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477734/942-470-50-3"
  },
  "r44": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r45": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r46": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r47": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r48": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r49": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r50": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r51": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r52": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r53": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r54": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r55": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r56": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(28))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r57": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(29))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r58": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r59": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r60": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r61": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(31))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r62": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(32))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r63": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-11"
  },
  "r64": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r65": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r66": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r67": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r68": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r69": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "12",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-12"
  },
  "r70": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-13"
  },
  "r71": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r72": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-15"
  },
  "r73": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r74": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r75": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-25"
  },
  "r76": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r77": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 4.E)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480418/310-10-S99-2"
  },
  "r78": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/360/tableOfContent"
  },
  "r79": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482130/360-10-45-15"
  },
  "r80": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-1"
  },
  "r81": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.CC)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480091/360-10-S99-2"
  },
  "r82": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "440",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/440/tableOfContent"
  },
  "r83": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "470",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/470/tableOfContent"
  },
  "r84": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-6"
  },
  "r85": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-7"
  },
  "r86": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r87": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r88": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r89": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "718",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Section": "50",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r90": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-19"
  },
  "r91": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r92": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r93": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r94": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r95": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r96": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(16))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r97": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r98": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r99": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(13)(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r100": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r101": {
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r102": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r103": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r104": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r105": {
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "SubTopic": "20",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482659/740-20-45-2"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "SubTopic": "10",
   "Topic": "275",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-1"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-1"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-6"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "SubTopic": "360",
   "Topic": "958",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477798/958-360-50-7"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h))",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "323",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/323/tableOfContent"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/606/tableOfContent"
  },
  "r118": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Accounting Standards Codification",
   "Topic": "808",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/808/tableOfContent"
  },
  "r119": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r120": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12",
   "Paragraph": "Column C",
   "Footnote": "5",
   "Publisher": "SEC"
  },
  "r121": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r122": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12A",
   "Paragraph": "Column C",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r123": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(a)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r124": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column A",
   "Subparagraph": "(b)",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r125": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "12B",
   "Paragraph": "Column C",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r126": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r127": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "14",
   "Paragraph": "Column F",
   "Footnote": "7",
   "Publisher": "SEC"
  },
  "r128": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column A",
   "Publisher": "SEC"
  },
  "r129": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r130": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r131": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r132": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r133": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "17",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r134": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column A",
   "Footnote": "2",
   "Publisher": "SEC"
  },
  "r135": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r136": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r137": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column D",
   "Publisher": "SEC"
  },
  "r138": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column E",
   "Publisher": "SEC"
  },
  "r139": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column F",
   "Publisher": "SEC"
  },
  "r140": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column G",
   "Publisher": "SEC"
  },
  "r141": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column H",
   "Publisher": "SEC"
  },
  "r142": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "28",
   "Paragraph": "Column I",
   "Publisher": "SEC"
  },
  "r143": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "3",
   "Publisher": "SEC"
  },
  "r144": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column A",
   "Footnote": "4",
   "Publisher": "SEC"
  },
  "r145": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column B",
   "Publisher": "SEC"
  },
  "r146": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "12",
   "Subsection": "29",
   "Paragraph": "Column C",
   "Publisher": "SEC"
  },
  "r147": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(1)(iii)",
   "Publisher": "SEC"
  },
  "r148": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Regulation S-X (SX)",
   "Number": "210",
   "Section": "4",
   "Subsection": "08",
   "Paragraph": "m",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r149": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 11",
   "Section": "L",
   "Publisher": "SEC"
  },
  "r150": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r151": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 4",
   "Publisher": "SEC"
  },
  "r152": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-6"
  },
  "r153": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r154": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "105",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "9",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479343/105-10-65-9"
  },
  "r155": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-1"
  },
  "r156": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "205",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483499/205-20-50-7"
  },
  "r157": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r158": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-5"
  },
  "r159": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r160": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(13))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r161": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r162": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r163": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r164": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r165": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r166": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r167": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r168": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1A"
  },
  "r169": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r170": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482790/220-10-45-1B"
  },
  "r171": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-1"
  },
  "r172": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r173": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r174": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r175": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r176": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(24))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r177": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r178": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r179": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r180": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r181": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r182": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-24"
  },
  "r183": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r184": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r185": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/235/tableOfContent"
  },
  "r186": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-1"
  },
  "r187": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r188": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r189": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r190": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r191": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r192": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r193": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r194": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r195": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(k)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r196": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r197": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r198": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r199": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r200": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r201": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r202": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r203": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r204": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r205": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-1"
  },
  "r206": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r207": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-11"
  },
  "r208": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-3"
  },
  "r209": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-4"
  },
  "r210": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r211": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r212": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-7"
  },
  "r213": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-8"
  },
  "r214": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-9"
  },
  "r215": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/260/tableOfContent"
  },
  "r216": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-10"
  },
  "r217": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-16"
  },
  "r218": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-2"
  },
  "r219": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r220": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "60B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-60B"
  },
  "r221": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482689/260-10-45-7"
  },
  "r222": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r223": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r224": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r225": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-2"
  },
  "r226": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-3"
  },
  "r227": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-15"
  },
  "r228": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r229": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "272",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483014/272-10-45-1"
  },
  "r230": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-12"
  },
  "r231": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r232": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-20"
  },
  "r233": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-4"
  },
  "r234": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-6"
  },
  "r235": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-9"
  },
  "r236": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/280/tableOfContent"
  },
  "r237": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-15"
  },
  "r238": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r239": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-21"
  },
  "r240": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r241": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r242": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r243": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r244": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r245": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r246": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r247": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r248": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r249": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r250": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r251": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-25"
  },
  "r252": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26"
  },
  "r253": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26A"
  },
  "r254": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26B"
  },
  "r255": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "26C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-26C"
  },
  "r256": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r257": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r258": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r259": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r260": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r261": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r262": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r263": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r264": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "34",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-34"
  },
  "r265": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "40",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-40"
  },
  "r266": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r267": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r268": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "41",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-41"
  },
  "r269": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "42",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-42"
  },
  "r270": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-13"
  },
  "r271": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r272": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r273": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r274": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r275": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r276": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r277": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r278": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r279": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r280": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r281": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r282": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r283": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r284": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r285": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r286": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r287": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r288": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r289": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r290": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r291": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r292": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r293": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5"
  },
  "r294": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r295": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r296": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5A"
  },
  "r297": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r298": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r299": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r300": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r301": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-5B"
  },
  "r302": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481664/323-10-45-1"
  },
  "r303": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r304": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r305": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r306": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r307": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r308": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r309": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-4"
  },
  "r310": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "5",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479654/326-10-65-5"
  },
  "r311": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-11"
  },
  "r312": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-13"
  },
  "r313": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-14"
  },
  "r314": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-16"
  },
  "r315": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479319/326-20-50-5"
  },
  "r316": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479130/326-30-45-1"
  },
  "r317": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-4"
  },
  "r318": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-7"
  },
  "r319": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479106/326-30-50-9"
  },
  "r320": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r321": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r322": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r323": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r324": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r325": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r326": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r327": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r328": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r329": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482573/350-20-50-1"
  },
  "r330": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482665/350-30-50-3"
  },
  "r331": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "350",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476166/350-60-65-1"
  },
  "r332": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r333": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "360",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482099/360-10-50-3"
  },
  "r334": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r335": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r336": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r337": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r338": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r339": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r340": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/420/tableOfContent"
  },
  "r341": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r342": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r343": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r344": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r345": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r346": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r347": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.P.3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-1"
  },
  "r348": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r349": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.b.2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r350": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r351": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r352": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r353": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "440",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482648/440-10-50-4"
  },
  "r354": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-1"
  },
  "r355": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-4"
  },
  "r356": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r357": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r358": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r359": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r360": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481544/470-10-50-6"
  },
  "r361": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r362": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r363": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r364": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r365": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r366": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r367": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r368": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r369": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1B",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1B"
  },
  "r370": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r371": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r372": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r373": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r374": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r375": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r376": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r377": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r378": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r379": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r380": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r381": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1C"
  },
  "r382": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r383": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r384": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1D",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1D"
  },
  "r385": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r386": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r387": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r388": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1E",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1E"
  },
  "r389": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r390": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r391": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r392": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1F",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1F"
  },
  "r393": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r394": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r395": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r396": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1I",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1I"
  },
  "r397": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-4"
  },
  "r398": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r399": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "4",
   "Subparagraph": "(f)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481538/470-20-65-4"
  },
  "r400": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-1"
  },
  "r401": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-2"
  },
  "r402": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479887/480-10-S45-3"
  },
  "r403": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-1"
  },
  "r404": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479857/480-10-S50-3"
  },
  "r405": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r406": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r407": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(01)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-1"
  },
  "r408": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3A",
   "Subparagraph": "(24)(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480244/480-10-S99-3A"
  },
  "r409": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r410": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r411": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-18"
  },
  "r412": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r413": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.3-04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480008/505-10-S99-1"
  },
  "r414": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-1"
  },
  "r415": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-2"
  },
  "r416": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479837/606-10-45-3"
  },
  "r417": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-11"
  },
  "r418": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-17"
  },
  "r419": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r420": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-18"
  },
  "r421": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-19"
  },
  "r422": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r423": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r424": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r425": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-20"
  },
  "r426": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-4"
  },
  "r427": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r428": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-7"
  },
  "r429": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r430": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-8"
  },
  "r431": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r432": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r433": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r434": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r435": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r436": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r437": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r438": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r439": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r440": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r441": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "70",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480794/715-70-50-1"
  },
  "r442": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480576/715-80-50-5"
  },
  "r443": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/718/tableOfContent"
  },
  "r444": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-1D"
  },
  "r445": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-2"
  },
  "r446": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480483/718-10-35-3"
  },
  "r447": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r448": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r449": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r450": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r451": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r452": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r453": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r454": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r455": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r456": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r457": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r458": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r459": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r460": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r461": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r462": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r463": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r464": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r465": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r466": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r467": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r468": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r469": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r470": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r471": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r472": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r473": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r474": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r475": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r476": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r477": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r478": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r479": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r480": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r481": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r482": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r483": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "17",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480336/718-10-65-17"
  },
  "r484": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479983/718-10-S45-1"
  },
  "r485": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-2"
  },
  "r486": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-3"
  },
  "r487": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-4"
  },
  "r488": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479953/718-10-S50-5"
  },
  "r489": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.C.Q3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r490": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.1.Q5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r491": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r492": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.D.3.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r493": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 14.F)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479830/718-10-S99-1"
  },
  "r494": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "720",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483359/720-20-50-1"
  },
  "r495": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "05",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483044/730-10-05-1"
  },
  "r496": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r497": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/740/tableOfContent"
  },
  "r498": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-10B"
  },
  "r499": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-25"
  },
  "r500": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482525/740-10-45-28"
  },
  "r501": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-10"
  },
  "r502": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r503": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r504": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r505": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r506": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r507": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12B"
  },
  "r508": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12C"
  },
  "r509": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-14"
  },
  "r510": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r511": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15"
  },
  "r512": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r513": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "15A",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-15A"
  },
  "r514": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-17"
  },
  "r515": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-19"
  },
  "r516": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r517": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r518": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r519": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r520": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-20"
  },
  "r521": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-21"
  },
  "r522": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-22"
  },
  "r523": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r524": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r525": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r526": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r527": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r528": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(d)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482615/740-10-65-8"
  },
  "r529": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.1.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r530": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.5.Q1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r531": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r532": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 11.C)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-2"
  },
  "r533": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "270",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477891/740-270-50-1"
  },
  "r534": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482603/740-30-50-2"
  },
  "r535": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478758/740-323-25-1"
  },
  "r536": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r537": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r538": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r539": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r540": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478666/740-323-65-2"
  },
  "r541": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-1"
  },
  "r542": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479581/805-30-50-2"
  },
  "r543": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r544": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "805",
   "SubTopic": "60",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476176/805-60-65-1"
  },
  "r545": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r546": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r547": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "808",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479402/808-10-50-1"
  },
  "r548": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r549": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r550": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r551": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r552": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r553": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4C"
  },
  "r554": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4D"
  },
  "r555": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4F",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4F"
  },
  "r556": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8A"
  },
  "r557": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r558": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r559": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r560": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r561": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(h)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r562": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "6",
   "Subparagraph": "(i)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480528/815-20-65-6"
  },
  "r563": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r564": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r565": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r566": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r567": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480237/815-40-50-5"
  },
  "r568": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r569": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r570": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r571": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r572": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r573": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r574": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r575": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r576": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r577": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r578": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r579": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r580": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r581": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r582": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r583": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r584": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-3"
  },
  "r585": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r586": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r587": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r588": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r589": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r590": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6B"
  },
  "r591": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482736/825-10-45-1A"
  },
  "r592": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r593": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r594": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r595": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r596": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-21"
  },
  "r597": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r598": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r599": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-30"
  },
  "r600": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-32"
  },
  "r601": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "825",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482804/825-20-50-1"
  },
  "r602": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-17"
  },
  "r603": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r604": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r605": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r606": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "20",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481694/830-30-45-20"
  },
  "r607": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "830",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481674/830-30-50-1"
  },
  "r608": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r609": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r610": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479832/842-10-65-8"
  },
  "r611": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/842-20/tableOfContent"
  },
  "r612": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "12A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479165/842-20-35-12A"
  },
  "r613": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r614": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-1"
  },
  "r615": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479041/842-20-45-5"
  },
  "r616": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-1"
  },
  "r617": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r618": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r619": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r620": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r621": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r622": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r623": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r624": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r625": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-7A"
  },
  "r626": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "848",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483550/848-10-65-2"
  },
  "r627": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "850",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483326/850-10-50-3"
  },
  "r628": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r629": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r630": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r631": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r632": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r633": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r634": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r635": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r636": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r637": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r638": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r639": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r640": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r641": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481444/860-30-45-1"
  },
  "r642": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r643": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r644": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-7"
  },
  "r645": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-9"
  },
  "r646": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r647": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r648": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r649": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(4)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-3"
  },
  "r650": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r651": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r652": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r653": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r654": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r655": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r656": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)(7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r657": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r658": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r659": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r660": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "860",
   "SubTopic": "50",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481229/860-50-50-4"
  },
  "r661": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "910",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482546/910-10-50-6"
  },
  "r662": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "912",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478345/912-310-45-11"
  },
  "r663": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "924",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 11.L)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479941/924-10-S99-1"
  },
  "r664": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478934/932-220-50-1"
  },
  "r665": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r666": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r667": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-18"
  },
  "r668": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "19",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-19"
  },
  "r669": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r670": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "20",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-20"
  },
  "r671": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r672": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r673": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r674": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r675": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r676": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-23"
  },
  "r677": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r678": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-28"
  },
  "r679": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r680": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r681": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r682": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r683": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r684": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-31"
  },
  "r685": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r686": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r687": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r688": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r689": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r690": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-5"
  },
  "r691": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-6"
  },
  "r692": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-7"
  },
  "r693": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r694": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r695": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-8"
  },
  "r696": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "280",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478657/932-280-50-1"
  },
  "r697": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "932",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478988/932-323-50-1"
  },
  "r698": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "940",
   "SubTopic": "820",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478119/940-820-50-1"
  },
  "r699": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-03(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478546/942-210-S99-1"
  },
  "r700": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(14)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r701": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(26))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r702": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-04(27))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478524/942-220-S99-1"
  },
  "r703": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478671/942-235-S50-1"
  },
  "r704": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r705": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r706": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.9-05(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-1"
  },
  "r707": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r708": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478451/942-360-50-1"
  },
  "r709": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477617/942-740-50-1"
  },
  "r710": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "942",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478898/942-825-50-1"
  },
  "r711": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r712": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r713": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r714": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r715": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r716": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(21))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r717": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r718": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r719": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r720": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r721": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r722": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r723": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r724": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r725": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r726": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r727": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r728": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(20))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r729": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(22))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r730": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(23))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r731": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r732": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-04(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477250/944-220-S99-1"
  },
  "r733": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r734": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r735": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r736": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r737": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r738": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r739": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r740": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r741": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r742": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column J))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r743": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-16(Column K))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-1"
  },
  "r744": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column A))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r745": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r746": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r747": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r748": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r749": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-17(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477965/944-235-S99-2"
  },
  "r750": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4E"
  },
  "r751": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r752": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r753": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r754": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-9"
  },
  "r755": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r756": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r757": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r758": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r759": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(g)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r760": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "2",
   "Subparagraph": "(h)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480016/944-40-65-2"
  },
  "r761": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.W.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479583/944-40-S99-1"
  },
  "r762": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "740",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478822/944-740-50-1"
  },
  "r763": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r764": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "944",
   "SubTopic": "825",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477351/944-825-50-1B"
  },
  "r765": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r766": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(h)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r767": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r768": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-03(i)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479886/946-10-S99-3"
  },
  "r769": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-11"
  },
  "r770": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480990/946-20-50-13"
  },
  "r771": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r772": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-6"
  },
  "r773": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477796/946-210-45-4"
  },
  "r774": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r775": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-2"
  },
  "r776": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r777": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r778": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r779": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r780": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(11))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r781": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r782": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r783": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(12)(b)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r784": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r785": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(13)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r786": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(14))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r787": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(15))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r788": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(16)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r789": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(17))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r790": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(19))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r791": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r792": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(2)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r793": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r794": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r795": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(3)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r796": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r797": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r798": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r799": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(6)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r800": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(8))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r801": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r802": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(c))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r803": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r804": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(9)(e))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r805": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r806": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.6-05(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-2"
  },
  "r807": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "7",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-7"
  },
  "r808": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r809": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r810": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(2)(g)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r811": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r812": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r813": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r814": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r815": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r816": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(a)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r817": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r818": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r819": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r820": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r821": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r822": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(7)(c)(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r823": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-07(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-1"
  },
  "r824": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(1)(d))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r825": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r826": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(6))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r827": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r828": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r829": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column C)(Footnote 5))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r830": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r831": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column C)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r832": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r833": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r834": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column C)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r835": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r836": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column F)(Footnote 7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r837": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "946",
   "SubTopic": "505",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478448/946-505-50-2"
  },
  "r838": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478322/948-310-S50-2"
  },
  "r839": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 3))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r840": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column A)(Footnote 4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r841": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r842": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "948",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-29(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479628/948-310-S99-1"
  },
  "r843": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478785/954-310-50-2"
  },
  "r844": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "954",
   "SubTopic": "440",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478522/954-440-50-1"
  },
  "r845": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r846": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column B))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r847": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column C))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r848": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column D))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r849": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column E))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r850": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column F))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r851": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column G))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r852": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column H))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r853": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "970",
   "SubTopic": "360",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-28(Column I))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478979/970-360-S99-1"
  },
  "r854": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "976",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477332/976-310-50-1"
  },
  "r855": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "978",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479230/978-310-50-1"
  },
  "r856": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Topic": "985",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481283/985-20-50-2"
  },
  "r857": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(e)",
   "SubTopic": "10",
   "Topic": "235",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r858": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "SubTopic": "10",
   "Topic": "825",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-10"
  },
  "r859": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r860": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "13H",
   "Subparagraph": "(b)",
   "SubTopic": "40",
   "Topic": "944",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-13H"
  },
  "r861": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483467/210-10-45-1"
  },
  "r862": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "16",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-16"
  },
  "r863": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-21"
  },
  "r864": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-22"
  },
  "r865": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-11"
  },
  "r866": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-14"
  },
  "r867": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-18"
  },
  "r868": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-21"
  },
  "r869": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476153/220-40-55-4"
  },
  "r870": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r871": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "52",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482635/260-10-55-52"
  },
  "r872": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-18"
  },
  "r873": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482836/275-10-55-6"
  },
  "r874": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r875": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-31"
  },
  "r876": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r877": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r878": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r879": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-47"
  },
  "r880": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "48",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-48"
  },
  "r881": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "49",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-49"
  },
  "r882": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r883": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r884": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "54",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482785/280-10-55-54"
  },
  "r885": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481933/310-10-55-12A"
  },
  "r886": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "326",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479081/326-30-55-8"
  },
  "r887": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "350",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482548/350-20-55-24"
  },
  "r888": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r889": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69B"
  },
  "r890": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69C"
  },
  "r891": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69E"
  },
  "r892": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "69F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481568/470-20-55-69F"
  },
  "r893": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "480",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "64",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481620/480-10-55-64"
  },
  "r894": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-13"
  },
  "r895": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r896": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r897": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r898": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r899": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(d)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-1"
  },
  "r900": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r901": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480506/715-20-50-5"
  },
  "r902": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480482/715-20-55-17"
  },
  "r903": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "715",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480547/715-80-55-8"
  },
  "r904": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r905": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "217",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-217"
  },
  "r906": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "231",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482663/740-10-55-231"
  },
  "r907": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-8"
  },
  "r908": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "41",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-41"
  },
  "r909": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "43",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-43"
  },
  "r910": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "47",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479303/805-10-55-47"
  },
  "r911": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "810",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(bb)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481203/810-10-50-3"
  },
  "r912": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-4A"
  },
  "r913": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "182",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-182"
  },
  "r914": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "184",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480401/815-10-55-184"
  },
  "r915": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r916": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "100",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-100"
  },
  "r917": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "101",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-101"
  },
  "r918": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "102",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-102"
  },
  "r919": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "103",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-103"
  },
  "r920": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r921": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r922": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r923": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r924": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r925": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "107",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482078/820-10-55-107"
  },
  "r926": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482881/825-10-55-12"
  },
  "r927": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482949/835-30-55-8"
  },
  "r928": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "53",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479589/842-20-55-53"
  },
  "r929": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481372/852-10-55-10"
  },
  "r930": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r931": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481395/860-30-55-4"
  },
  "r932": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "17",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-17"
  },
  "r933": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-21"
  },
  "r934": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "29",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-29"
  },
  "r935": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477215/932-235-50-3"
  },
  "r936": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-2"
  },
  "r937": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-4"
  },
  "r938": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-5"
  },
  "r939": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "932",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477916/932-235-55-6"
  },
  "r940": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479401/944-30-55-2"
  },
  "r941": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-29F"
  },
  "r942": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r943": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r944": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9C",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9C"
  },
  "r945": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480046/944-40-55-9E"
  },
  "r946": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-11"
  },
  "r947": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "605",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477548/944-605-55-14"
  },
  "r948": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "14",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-14"
  },
  "r949": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-18"
  },
  "r950": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480078/944-80-55-9"
  },
  "r951": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-1"
  },
  "r952": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478795/946-210-50-6"
  },
  "r953": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477439/946-210-55-1"
  },
  "r954": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477802/946-310-45-1"
  },
  "r955": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-1"
  },
  "r956": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-2"
  },
  "r957": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-3"
  },
  "r958": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "6",
   "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477271/946-320-S99-6"
  },
  "r959": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-10"
  },
  "r960": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-11"
  },
  "r961": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Topic": "946",
   "SubTopic": "830",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479168/946-830-55-12"
  },
  "r962": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r963": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r964": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-23"
  },
  "r965": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r966": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 10-K",
   "Number": "249",
   "Section": "310"
  },
  "r967": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Number": "249",
   "Section": "220",
   "Subsection": "f"
  },
  "r968": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16",
   "Subsection": "J",
   "Paragraph": "a"
  },
  "r969": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K"
  },
  "r970": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r971": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r972": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r973": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r974": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r975": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r976": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r977": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r978": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r979": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "16K",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r980": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1"
  },
  "r981": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r982": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r983": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r984": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r985": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r986": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r987": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r988": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r989": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 20-F",
   "Section": "6",
   "Subsection": "F",
   "Paragraph": "2"
  },
  "r990": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Number": "249",
   "Section": "240",
   "Subsection": "f"
  },
  "r991": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a"
  },
  "r992": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r993": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r994": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r995": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r996": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r997": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r998": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r999": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1000": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form 40-F",
   "Section": "19",
   "Paragraph": "b"
  },
  "r1001": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a"
  },
  "r1002": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1"
  },
  "r1003": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "i"
  },
  "r1004": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "ii"
  },
  "r1005": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iii"
  },
  "r1006": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "iv"
  },
  "r1007": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "1",
   "Sentence": "v"
  },
  "r1008": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "2"
  },
  "r1009": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "a",
   "Subparagraph": "3"
  },
  "r1010": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Form N-CSR",
   "Section": "18",
   "Paragraph": "b"
  },
  "r1011": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r1012": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v"
  },
  "r1013": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "1"
  },
  "r1014": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1015": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1016": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1017": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "i"
  },
  "r1018": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "ii"
  },
  "r1019": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iii"
  },
  "r1020": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "iv"
  },
  "r1021": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "v"
  },
  "r1022": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1",
   "Subclause": "vi"
  },
  "r1023": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iv"
  },
  "r1024": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "vi"
  },
  "r1025": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "3"
  },
  "r1026": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "4"
  },
  "r1027": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "i"
  },
  "r1028": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "ii"
  },
  "r1029": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iii"
  },
  "r1030": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "5",
   "Subparagraph": "iv"
  },
  "r1031": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6"
  },
  "r1032": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "6",
   "Subparagraph": "i"
  },
  "r1033": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w"
  },
  "r1034": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1"
  },
  "r1035": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1036": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "A"
  },
  "r1037": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "B"
  },
  "r1038": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "C"
  },
  "r1039": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "D"
  },
  "r1040": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "i",
   "Sentence": "E"
  },
  "r1041": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1042": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1043": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "w",
   "Paragraph": "2"
  },
  "r1044": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "1"
  },
  "r1045": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2"
  },
  "r1046": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "A"
  },
  "r1047": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "C"
  },
  "r1048": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "D"
  },
  "r1049": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "E"
  },
  "r1050": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "402",
   "Subsection": "x",
   "Paragraph": "2",
   "Subparagraph": "ii",
   "Sentence": "F"
  },
  "r1051": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a"
  },
  "r1052": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "1"
  },
  "r1053": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "A"
  },
  "r1054": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "B"
  },
  "r1055": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "C"
  },
  "r1056": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "a",
   "Paragraph": "2",
   "Subparagraph": "D"
  },
  "r1057": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Number": "229",
   "Section": "408",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1058": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106"
  },
  "r1059": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1"
  },
  "r1060": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "i"
  },
  "r1061": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "ii"
  },
  "r1062": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "1",
   "Subparagraph": "iii"
  },
  "r1063": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "b",
   "Paragraph": "2"
  },
  "r1064": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "1"
  },
  "r1065": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2"
  },
  "r1066": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "i"
  },
  "r1067": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "ii"
  },
  "r1068": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "106",
   "Subsection": "c",
   "Paragraph": "2",
   "Subparagraph": "iii"
  },
  "r1069": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Number": "229",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "C",
   "Clause": "1"
  },
  "r1070": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "A",
   "Number": "229"
  },
  "r1071": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Number": "229"
  },
  "r1072": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-K",
   "Section": "402",
   "Subsection": "v",
   "Paragraph": "2",
   "Subparagraph": "iii",
   "Sentence": "B",
   "Clause": "1",
   "Subclause": "i",
   "Number": "229"
  },
  "r1073": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Regulation S-T",
   "Number": "232",
   "Section": "405"
  },
  "r1074": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "405"
  },
  "r1075": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482017/420-10-50-1"
  },
  "r1076": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SAB Topic 5.P.4.c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479823/420-10-S99-2"
  },
  "r1077": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-10"
  },
  "r1078": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1079": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1080": {
   "role": "http://www.xbrl.org/2003/role/recommendedDisclosureRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-2"
  },
  "r1081": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "25",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "810",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481231/810-10-45-25"
  },
  "r1082": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "13",
   "Subparagraph": "(b)(1)",
   "SubTopic": "10",
   "Topic": "606",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-13"
  },
  "r1083": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(a)",
   "SubTopic": "40",
   "Topic": "220",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1084": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(g)(1)",
   "SubTopic": "20",
   "Topic": "842",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1085": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "SubTopic": "10",
   "Topic": "740",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1086": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "a",
   "Publisher": "SEC"
  },
  "r1087": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(1)",
   "Publisher": "SEC"
  },
  "r1088": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(2)",
   "Publisher": "SEC"
  },
  "r1089": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "b",
   "Subparagraph": "(3)",
   "Publisher": "SEC"
  },
  "r1090": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(i)",
   "Publisher": "SEC"
  },
  "r1091": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(ii)",
   "Publisher": "SEC"
  },
  "r1092": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Section": "1402",
   "Paragraph": "c",
   "Subparagraph": "(2)(iii)",
   "Publisher": "SEC"
  },
  "r1093": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "Staff Accounting Bulletin (SAB)",
   "Number": "Topic 5",
   "Section": "Y",
   "Paragraph": "Question 2",
   "Publisher": "SEC"
  },
  "r1094": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "205",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/205/tableOfContent"
  },
  "r1095": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1096": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(10))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1097": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1098": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.5-02(9))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480566/210-10-S99-1"
  },
  "r1099": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1100": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1101": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1102": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1103": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1104": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1105": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483466/210-20-50-3"
  },
  "r1106": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-10"
  },
  "r1107": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "210",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483444/210-20-55-12"
  },
  "r1108": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-4"
  },
  "r1109": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-5"
  },
  "r1110": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482765/220-10-50-6"
  },
  "r1111": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(4))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1112": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Subparagraph": "(SX 210.5-03(7)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483621/220-10-S99-2"
  },
  "r1113": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1114": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1115": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1116": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1117": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "21",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-21"
  },
  "r1126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(g)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1132": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(h)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1133": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1134": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(j)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1135": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(k)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1136": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(l)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1137": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(m)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1138": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(n)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1139": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(o)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1140": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(p)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1141": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(q)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1142": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(r)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1143": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(s)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1144": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(t)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1145": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Subparagraph": "(u)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-22"
  },
  "r1146": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-30"
  },
  "r1147": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "31",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-31"
  },
  "r1148": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-32"
  },
  "r1149": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "33",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-33"
  },
  "r1150": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1151": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1152": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1153": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "220",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(e)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147476148/220-40-50-6"
  },
  "r1154": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1155": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "28",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482740/230-10-45-28"
  },
  "r1156": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-2A"
  },
  "r1157": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "230",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482913/230-10-50-8"
  },
  "r1158": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483426/235-10-50-4"
  },
  "r1159": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-1"
  },
  "r1160": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480738/235-10-S50-4"
  },
  "r1161": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1162": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(f))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1163": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(i))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1164": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1165": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1166": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-1"
  },
  "r1167": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "235",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.12-04(a))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480678/235-10-S99-3"
  },
  "r1168": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "23",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-23"
  },
  "r1169": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "24",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-24"
  },
  "r1170": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483421/250-10-45-5"
  },
  "r1171": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "250",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483443/250-10-50-6"
  },
  "r1172": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "260",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482662/260-10-50-1"
  },
  "r1173": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "270",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482964/270-10-50-1"
  },
  "r1174": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1175": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1176": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1177": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1178": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "275",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482861/275-10-50-18"
  },
  "r1179": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "18",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-18"
  },
  "r1180": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "22",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-22"
  },
  "r1181": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "30",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-30"
  },
  "r1182": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(ee)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1183": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "280",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "32",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482810/280-10-50-32"
  },
  "r1184": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "310",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481990/310-10-45-2"
  },
  "r1185": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-1"
  },
  "r1186": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "11",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481830/320-10-45-11"
  },
  "r1187": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1188": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1189": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(aaa)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1190": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1191": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1192": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-2"
  },
  "r1193": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1194": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1195": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1196": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1197": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-3"
  },
  "r1198": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "320",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481800/320-10-50-9"
  },
  "r1199": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1200": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1201": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "321",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479536/321-10-50-3"
  },
  "r1202": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1203": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "323",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481687/323-10-50-3"
  },
  "r1204": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "340",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479483/340-40-50-3"
  },
  "r1205": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/405-30/tableOfContent"
  },
  "r1206": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1207": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1208": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "405",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477092/405-40-50-1"
  },
  "r1209": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "410",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481931/410-30-50-10"
  },
  "r1210": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "420",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482047/420-10-45-3"
  },
  "r1211": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/450/tableOfContent"
  },
  "r1212": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483076/450-20-50-9"
  },
  "r1213": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "450",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480102/450-20-S99-1"
  },
  "r1214": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1215": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1A",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480097/470-10-S99-1A"
  },
  "r1216": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "470",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1B",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481139/470-20-50-1B"
  },
  "r1217": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481112/505-10-50-3"
  },
  "r1218": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "505",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481520/505-30-50-4"
  },
  "r1219": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-10"
  },
  "r1220": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479806/606-10-50-5"
  },
  "r1221": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "606",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "55",
   "Paragraph": "91",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479777/606-10-55-91"
  },
  "r1222": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1223": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1224": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1225": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1226": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1227": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1228": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1229": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1230": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1231": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1232": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1233": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1234": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1235": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1236": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1237": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1238": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1239": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1240": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(d)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1241": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1242": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1243": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1244": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1245": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(ii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1246": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iii)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1247": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(iv)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1248": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(f)(2)(v)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-2"
  },
  "r1249": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "718",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480429/718-10-50-4"
  },
  "r1250": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "720",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147483384/720-30-45-1"
  },
  "r1251": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "730",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482916/730-10-50-1"
  },
  "r1252": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12"
  },
  "r1253": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "12A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-12A"
  },
  "r1254": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-2"
  },
  "r1255": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "23",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-23"
  },
  "r1256": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-3"
  },
  "r1257": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-6"
  },
  "r1258": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1259": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "9",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482685/740-10-50-9"
  },
  "r1260": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479360/740-10-S99-1"
  },
  "r1261": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1262": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1263": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1264": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "740",
   "SubTopic": "323",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478156/740-323-50-1A"
  },
  "r1265": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-2"
  },
  "r1266": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "805",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479328/805-10-50-3"
  },
  "r1267": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-7A"
  },
  "r1268": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1269": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1270": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "8",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480434/815-10-50-8"
  },
  "r1271": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480870/815-30-50-2"
  },
  "r1272": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "815",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "65",
   "Paragraph": "1",
   "Subparagraph": "(e)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480175/815-40-65-1"
  },
  "r1273": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "35",
   "Paragraph": "54B",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482134/820-10-35-54B"
  },
  "r1274": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1275": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1276": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1277": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1278": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(bbb)(2)(i)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2"
  },
  "r1279": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2E",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-2E"
  },
  "r1280": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "820",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482106/820-10-50-6A"
  },
  "r1281": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "10",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-10"
  },
  "r1282": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "11",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-11"
  },
  "r1283": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "825",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "28",
   "Subparagraph": "(f)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482907/825-10-50-28"
  },
  "r1284": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482925/835-30-45-2"
  },
  "r1285": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "835",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147482900/835-30-50-1"
  },
  "r1286": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-3"
  },
  "r1287": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-4"
  },
  "r1288": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "842",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478964/842-20-50-6"
  },
  "r1289": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1290": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "852",
   "SubTopic": "10",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481404/852-10-50-7"
  },
  "r1291": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1292": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1293": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(c)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-3"
  },
  "r1294": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1295": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1296": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "20",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481326/860-20-50-4"
  },
  "r1297": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "860",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "1A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147481420/860-30-50-1A"
  },
  "r1298": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "912",
   "SubTopic": "730",
   "Name": "Accounting Standards Codification",
   "Section": "25",
   "Paragraph": "1",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479532/912-730-25-1"
  },
  "r1299": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "235",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "2",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477314/942-235-S99-2"
  },
  "r1300": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "942",
   "SubTopic": "320",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477268/942-320-50-2"
  },
  "r1301": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(16)(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1302": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.7-03(a)(2))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478777/944-210-S99-1"
  },
  "r1303": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "30",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479432/944-30-50-2B"
  },
  "r1304": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "310",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "3",
   "Subparagraph": "(a)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147477363/944-310-50-3"
  },
  "r1305": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1306": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4B"
  },
  "r1307": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4C",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4C"
  },
  "r1308": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4D",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4D"
  },
  "r1309": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "4G",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-4G"
  },
  "r1310": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1311": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1312": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1313": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "5",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-5"
  },
  "r1314": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1315": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1316": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1317": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1318": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(4)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1319": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(5)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1320": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(b)(6)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1321": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "6",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-6"
  },
  "r1322": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1323": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(1)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1324": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(2)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1325": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(b)(3)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1326": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1327": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7A",
   "Subparagraph": "(d)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7A"
  },
  "r1328": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1329": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1330": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "40",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "7B",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480081/944-40-50-7B"
  },
  "r1331": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1332": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "944",
   "SubTopic": "80",
   "Name": "Accounting Standards Codification",
   "Section": "50",
   "Paragraph": "2",
   "Subparagraph": "(c)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147480109/944-80-50-2"
  },
  "r1333": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "205",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "4",
   "Subparagraph": "(a)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147478009/946-205-45-4"
  },
  "r1334": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "210",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "1",
   "Subparagraph": "(SX 210.6-04(18))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479170/946-210-S99-1"
  },
  "r1335": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "45",
   "Paragraph": "3",
   "Subparagraph": "(b)",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479105/946-220-45-3"
  },
  "r1336": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(4)(b))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  },
  "r1337": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Topic": "946",
   "SubTopic": "220",
   "Name": "Accounting Standards Codification",
   "Section": "S99",
   "Paragraph": "3",
   "Subparagraph": "(SX 210.6-09(7))",
   "Publisher": "FASB",
   "URI": "https://asc.fasb.org/1943274/2147479134/946-220-S99-3"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>133
<FILENAME>0001628280-26-011226-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001628280-26-011226-xbrl.zip
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MZ^WVUN<&G)_=G9V]G8-?/N7N^H*'&%EZYH:V\/XIA3J#3\+D,9VMS_CZRWK
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MP>F^&R[)4)).=Y)Q0/%F!Y1. 2GF34*7A9./L4605O6>0.V$^DOZ(8L]S'K
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MYZ[9W*]DYB;2;E_+S%9E<VZ8S 3*7:E@C/LI*R-STPY=LWE0"<P-I!T6Z)'
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M(3.(&0PKX._[?684%.(D#$48(*S&Q/+<.^GI6,34]59<V;TE80S\&]S-)'"
MH7>C%Z,$02 +,\5:.ZEF"6.756U&AR,S>!&.1:?@$FR%+0U$4P:>2?!M'H;2
MI[MR=UH:!P%^2?A)6EA,IJV%%- *=O4A&E;,5 YFPDJCW[K=JXPF<'UL^=)H
M9D3I2-Q)JOGT&-G4F]2HS E88RB],6I&:BF]QX9$%2*J%W9Z66Z4)N\)A">,
MR'0CNRP8(9"+]L;);QACZC*#Q"H5+<2WJ\KZ->:.C/'0MP;8S>Y3QML3#Z9?
MF;KX,%1"0*D5]N;R8LMC&;DDC4U\8S[@ZQR U\^_]-2GSR_]U<I?O+D#._[/
M(+88?Q=5AO,L"*P!:W ".\[ 4C](MG#ZKL<%\U+/G['(K7L._'HT]F0D/99)
M.M8GN2V:2G[8]^3GH,@CU%X*/^%ON",[YYZ\UW; ]OMJ!WS-DZ*32@0US4'I
M0&E_3P>I'3>TO2#DIB*R#Y]"H 9.GZ2'#SD:GF 3UQ..D>=2/4#PW*VVT16.
M,QWHN*Q[C5R-M\::.*FRS@2Y+)2JGGDG7-;\EXJ>!I&FTWDGMZT_M3C0D-%.
MIOX:4S1HG>B[V8*R<(+QM%(T:O.[!<#G<QW.^K:Z,O8:/#3KC)]HJF-#:6N(
M6"U0-(J[WBVVF<2\+8V"I_;S.?3^9(,NGR0I2%=B""7[!(N7KRI(38&,/2_L
MOV*7912F.R560\(_@'I&=(4:;<_"%X&?T%NQM9BAWH07N!F8YG]*LU,B#&-$
ML(4-"7H@?#D/#,2*QPY7W3R%!P\<C_4WJ+=T4)+@$<1X[+DV^5!@:6W(GCPW
M:4)X89".FT@CTH3,9XIL(X1*2LJ 1\(AG$XW&;\=F2P<_0R^BC7\"2GJ!"82
MUYVY,=V,T.$MSB(Y<1BI"8Y<@#73MWJ\!>%<Q*,>HJ+TF;CC5#YY[LB-#/B.
MD:,$2,#"1+(XA74,T&YC@<J;AA]2@R>O!86=V8%MZ]Q/?/%DS(1^R-0*TFW3
MV64#$YTZ2XFE5/"5QB#G70IS ,L</]<1)VG+,!3*18#,F 9:4(L1]["F163I
MU \VH# NM6T=JR ,ZPQ.PFZ>&YIY";@]":K-$.P^8-XZ_M?*(@<3J@/V%^9^
MKSLND"DVYD@HG/6 ?/>L,LDHCV-\:7]F#$=7W2/FQLRXBYEQ'W%Z#>ZF_A2X
M)?E8BYT$5X/.)>R4D4(A'YP'-Y0U5 8(OAQ89@&,)T4MI#RE@OJ8J2,*I\.X
MC@LDDU1DSX+1)V#O49"TGA&B3/:Y*/_ULVM3B[9Z@6Y(99[(:%1:F;;T9<%U
MA R07?2FL(TTR[9\,>(3[06#@(X0H=,AS@J>XE#+L$4F_-!N23BRH4G-IK?A
MS!U/Y+;23VAGP09#4R7P!UK(LE!%HX"G_=P$'KI0&.AC1&7,T $=IVY/?](+
MZ;4H/3?E17-^<!]0,*KH(5!W&2%_[X;X<S0\/' J.$0%FA2A6]"SXU.(AZRY
MUSFRN(NIL]\"PVPRZ@4(4-Z+$VSY9*N,U,I->N%V#DF@>\#@V$-BS"P*FFK+
M (1CS7!G/_80L,N #3+R5E[1UX@H"CDA-$CXYB\6W-GK"; K4/K^H7QBN\DN
MU@8+OP<]">W-0)D=2X%*#67QF#7WCK)WRA$5?IMG&=P:\*AAV[52!M$P=,>T
M_20-X,EP+#6&&?QZC+)#T36H3D+0Z#46&>E")HN=VM>>"Y:Q\,U<QH4GSZQ5
MNEQF<X!P['(*/K5].,?$H[^PX!^+'&GT%?HJL_FA;&8Q-QDKS<L;GX:0Z&83
MCS0 *Y1FJ)@B7!4[#@FX'U4'GJ 7^%E\9IZ4*_E':M]/^U.>%SS J@^KB.82
M(IH9MSPFL9]%* 4G'ZLU@'=LJ>USM$Z()?Z4.BC 8M>.5;Z\(^4N?1="7 6>
M]:@1"DGIHWT1@A>-'7\3T :FY&0"7]'5.HQ'I9RZR!,8N(]9,DI/L-?LRV2I
MU+\(;_'O^XWM?41B],AR__?FP?[V@?F;GO+O[=V][7;RD4'*XV6P/CD!8QL/
M'>BEW<91NUG#TI,=^M\.VT+PKW;-E%51_F6[&G*U3+9D/M"(3M+)MS>9^EWN
M;\JS3D\FG.+)BBC+(@K;4%+[$V;:9+;D+-:A>8XHX+0^!K],1CN"4]U'<PSU
M2*S3T8&E!'@T24U8)HU=,T&HGDPC,1AR S,&3!)R_/$((FH8F6:(D^*C"4@F
MF\9^KR7,DFWX3R W,X/(9CH'9+^/$"P+V3H5"SW#0M= 9FJYR)1U:YHCC3G2
MZKA>;()U7*<:V'?#P',H?JFP*]75ADW*5DA#S1]HKB)+25@3AD"'QE8WSI7!
MCM<#L&;[ "IB+X/8J)L30';M;*'EB); I&@:PRPATI 4$DX/)<I@_R<XN"Y"
M)F--@Z3:")<@X._@!FY$T7G,!I"IHB>A6GH*B:S1S%@*3F06PS'%.^"@81!0
MZ *\3PR]L:FK+^7FH8E9=\4VRU(SVB/F<LET@[.,D9;0]:34P/_WP"H<ZY@2
MXMLK>3.ZSR$*+]=>P"]=0Z%LD:;-;HZ<TP=E\IB*XD4YGX#T+@6H'4*S#H-:
MOGC5U*9E/%%$*)=.=3J6<3I.5#S(B:I,?L23_B :3I*,K4]0R4!>FWQ_JJ*
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MRAC.L3^2/"+C"3-J)?CJKW] FBW44+Y.8]&TA7L-1E0CB*1L-2=CEFA9 =S
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M(YO-]95RSRS:M/LR[=FT\EM@3A1PISD]9F)F=KYWVF>8 &R@$"-.S]8&:.\
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MSIQE<@R<*P921?0M%>"@F3-3@5/1<9ET-+6+A]9U8FUG3N.S-O?3;F+B 61
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M"T;O'2U(7B)&P//SU!X KJV1$EZ,I5, Z=EVXYA.D$$:@#'L3*FU&S%CQ<G
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M,K$K[L(M,D/_U+7<?[@1U_+!XP???6[TX"XW>JOEK)[3KN7T9R5JV>-D6(I
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M8FR=X[;H8:1K6135A1GMKM+=+D:TBO2LA5X=63Y>);ZNS:*96>VVK8*2?YV
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M#V;.;@>Q 'PQ;0E7J+':6N<UC]+/U)OZT(T6LWG-R>:BK0<][]XN#2TK%71
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M>0#TUZ9MFC%@W!8S57.9+*4Z@J2:%@T@./!/2^GQ^L8&H Z+94._06K6R3+
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M=+@7M3!_'%F&LAMA6WOC@R.^[,&WI))@HPC.^V-?S_F'A]^2GN&:'V%M#;/
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MJLLLF!-D]2DDVP.@CAZMT7WM>-1:1"T_MR:O>X,K^7&:O*YH+"L*L$@"H"^
M 'F^+C@+2I3#*>6_!8B4?,%-M:=S3@]C@?3\^2Q74XJ*%Q&4BQ!NB,^?'8FB
M$BB^:\P9*AQI#?><(3V'ND\O$:MU$V2#53/@=_.*/KY929I[Q3_[]<E\)Q>*
M-F@.%THU0S<<>^$\%\F4.?HUIFORE/=3M8K<'^CM3-QX(*Q&BNW0;I)33,5B
MN"[=7EG?D\E8I,"TWP[YX),)Z&IOVE3N]G9UNTO3L^0I)O6>6VLO%9N<:_Y/
ME%ARTCEF1V.&:&14]UT.8<;8ZVC>IAF'_DPQ1 :UU<:>WU"]0BFOV$T!N0N4
MSM@/AYQIC&4FNOP\$!\\T7W?'X]^)_LCZ!6=V!^C7#XK'BI6E;75!QMAEL5=
M)$,Y]^/'#JJ/8+QSP+#(0Q:<8BH+YDGF<N.);$#:=^A$3'^J('KY_+@Y-"F0
M/+6H;/7FJ1@@0P^M29J5.%+M/R,J8B>\P"QT$.?.+H2VAQ[:="H)<EXG!H17
MQ*;MO%4 9$^/"DII<0-T]WST^[OO6^?Q[V#K*$#7$%RG7E_& VN*LY)E2K6Z
MTTL_!?=1:S5SN.(],_<J. >% N@V2]=9-TB6GEAE.3,"B)5H==-!SKF&Z<UN
M.3??P+*?/ U4J&S4^$2AXCZ 0O+)+G>PWDAKJ"C'(HSK8E0FQH6F#-W.4%U#
M<F1_K2='.EOW^-UJZ+V3E@HM$(/C1S1K@"U2MH)V@=3T]$2:E8@M<6@=U^87
MP<-H+_V48(F41XZ]JC(M,8,&?0$.K&7(%E&=\5AF'<O8 @AX(@S+?R*\?E3H
M7=2;T<__+.EQ>[*/(FM0R(()1.IO#*^0AOS?TH-Z-)J_<?[??C>&Y@," !,O
M6 ,".:PVAME<A[8-<%X*!B@VI[5K1(W>KEE^W:9=;A.TW:>K61,\,4&&Q!VT
MF,2?Q+[V"B>22[I&FHY>\:R[&GG&BL($=LH&M4N%\5H78W]<2U<$%ZL43W,7
M4PET76MYAW=;U,N*:_\ZP**\\T& M6DZ5C!5AV9C%C*CC[F],NRO:/>5Y#]P
M?45753KYTVMH14W;A4X=S3N:,&OZ5L7/57S$T>-9(;3LX)QX=7=U;LJNE/NZ
M%!O"?9%/JEU733N?]!%H+G9GQ1.Q0]L7UH0"S/GL!W/ZYN5DB!TH%FF.G6_-
M[MEA9WFI=73M0V5@RL7/"GODV;&JJ\^_5L7G895N[&1(8ZM(9[;;0BD<M2Z6
M#5+0?C_L#/@! ,Y<2D["-@NS"VKM"YK@"7;78Q8&'/BEUB50Y?3%!"3,SMY
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M0C@%7FXJZ69]<O%RGAG$3F2OM"5> LF)U,ZM)W;64>8P8!@SML <=:'JHH9
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MP\/>QA!V9GO8),@BXEL8.Z;'X?1\47P=Q;)[R#TQIWB7FFTM-ODY?)NMGC$
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M@%3K6&L/H'TA%[#2G\_:]=E>6\OL"^AVY)TO[2.13[OU?[;!O;&I Q=P,=Q
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MJD/IQ1DXWW!V>7HZLCU_?YJB:'E=;P&9O%7:(9".H[WANL)B3H_7DY/($ E
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M9.2_^..71A<?]H2[>6+\OGC\)<U*?5-WY5;N+9#5[&L(X22GV(=.+K42ZHD
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MU'LZ#Q&/M^?M"M?^CR(;$3K?'MZ3SJA_$#V@5LV120TPW\-0/ZZ8$FY!2IY
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M ?8IKF%R96F<ZVI2V=?OC#SRZ)$?OU59L[NKEQ('RONK-5_O1U2]>]<D5ZC
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M41DN^6J%IX&[%#QOJYHSY5HS@5@Z<U[>%QTLW,IO,TG82@2, HZ\S;9W'()
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M.[8@BD$>-6[/Z=V<]RQ.W'IWL/6*T+S9F7:K_K%>N1BZ/:]@7K:$$<J#XL3
MV7?<>">&=2_<FON:;ROD,G--2Y4WQM+7?DG43>7RV'*=;!V<*KI5#G6GTFK5
MZ6',!*5>O6O!,4Q_/3?1+6L>5J%0(=W>MZ".JF]//_<=F^A3J5$^^C1KE)]M
MY'_.1OY"B&Z-;0U7D6-ZM\5F@7-:PTSEAZQAZ<'4[^OET4UC=3B0"4F,E/Q-
MM*J@!\S$RJHV]_^V.)654,E/9R2,A%U+C):;-"V[ZCWB);:X?==_/KI_D66I
M2PD5NZTT$%F)S]9H+@Z^J9?7.X@2"[7GTW1HM%OP?.&8MCRO_L[/;W$^<[R5
MWOSVN+F2BCI*'G3BHD?PU=>SR_/OSU^AXPSXWX??/."5'G[SU5R0\O2447P,
M,"0-".>>%YSG1*Z W8ACLMK;Y_7SRYFU[XD6'01/H2:ERZ#IA%1@BQ;DSJ,F
M<X"0;=3@2!%OVR8[0F]KO/H.J3?SHWK!INW.2+W0HD^MB9P+@3$CL] R9K%_
M>*"/>WNUVU#:@9C5R/P^+YI?_"RD^'EZ<3OIKTF!';%]13+Z;<0OO_0?O+1U
M\/J(8OFN%JN3.ZA>:K(H%!%YNJ[3$EGQS3+]*+;JE 7D5YZFR%J,X*L:OG(Z
MEUU\S:/GR>O:WRY]BSB6.#19B\"SBJIN&9UND"IN2#BUR.KPK"/IWZF]UP10
M<AJXA;ESCW$Y! &17%XWFU6:7^\>&#LB6=52"@/IAKLCJQD&U:)[+;O,8^K_
MH]KNO_4[SEYK<4ZPY,]?SXW-X\<?7\\+O$G 5OFNSLD[KHBU3@YH>B0;("\H
M.3-*/8D?VZ)P2>NI5C*Q1#@+",UIP525+$91BD:-M0/T0AL.T9&]5:1RC:I#
M+^P\:0SYIM'$;6G?TFS+)DIO"Y7[7FAQ/IN/7\!\5,FE;:_:8Q^SSJ$$,LZK
M6A+(OO_!3+/MU0(F5[1NLER;\U<A)Y\&LET<.^UZQ &58^6)5'M1/53,5(,-
M27S&_6 ,_%[ 7'/!#!38#]JZH69LT3T1"]X\MX?ZLM(DZT;K7;M!;-05Q?"K
M8]KA&%@?O,XQE@Q?JU3CT=U0M??CS 9K<0$'FQ'SI>G.UO)#MJTP52?*%-E<
M,3K*'.%[Y%DIIGL^N_!H#PGA,.VXYJ9=6M!G+T#=<!>S)S2HG&C!9:0'D5P7
M<S2.I(P0 N\L&^T[@*UD^NYL(I[N1A4,:TFUN"W*N *'$+>1'GUKP.!8:F<'
M#:=6\$R=\-OM48O>Z_OVGNACK\MC:3#!#.K <7Z/:&S*MYG/]$N\$ B58TZB
M4_,*,.GM_2BU/CM%"3#@ YAG7J.;ZW8F^\G!(.[(1Z!<)IHM.[11Z<$$>6DC
M7\>-?N83AB2)]&J/:JDT#WHF4(^#N>#.J<%#FVJT ^QA37LM+.WC3I%0AUNA
MY._I%8MGMHSOV6\HDA:H</7:OR\EY%-TK#*?P09:CZ@"P@&'(?UP$^FC,YUX
MH.Z;3Q*9*XEX#6LVS[4<;7,W($7KK(!WG9=AF-9I+P[L-$_\W<4@%,63\]:Q
MTNLF2@YBQ6_M*O3C\I=M=U69!'/HZ"M>0O(6*^I'IU,DV6&BH8OW0CAIT0\@
M5.QO<G. M.P%QL>;ZYJOJ)+YD.D<W;[D'37H2)TFDJYI8-CQFT#1)*_UQBJ)
M<;Q=0?4;[U_=#I]" "X^H(+2\<T$X(!\& &G:Y"]8DCD]>NNL+8 DL\<F!83
M29>=Y5&%M<;+3&E#G3D=DT$I[9=Y9T1X(8, RSD1AM5N>DE)8#'8)IUX(,PY
M2;+R' "RDPD&]'8,2O-VA";.7$Y2#WN)!]H")GSKCBE!6:*-*)@!&I;(\I-Y
MCWI;#EG[,S/'W1<?\]E."LJ<14%-WF'QG(K(F'<)\^"D175$KOMJP^QUA#D:
M>--(9>A\21N3'+-M;=E/$Z!JPOA6]5;0)(?ZCM4YO1[#%IH/'5!;Q:5HE;)]
MP();(DL>1K)78VP0>OA14$V!+-41)M!J@<W<^B%JSSP4W:RL'J(?S!X$Y%9.
ME;H YFEDQ(4>MI47&(\1XO32G8!CR)FAY-)LG&3%M PGN&*%'(8=(;DDJJB_
MT&3,4VD^C>@3I]8!/YE<=.!QJ_7UH,0?.+2#GS#&3KK?,.XQ"; 31P37D/4[
M90OJ$9?PGY5#D<,BUW _<CS)#SEV:M^5#EU,&6\O3393Q]QXYQ5KV/N#V#MA
MA#+3/P:EF7KY9=<W3RQ9.Q)/?=8O_&__X^O'GWS=^;<_E][0)A/8;[3K(R\^
M]\4I@+H2SD"-AS7S,)_(9V4/-[9&T#6)WGQL&UJWRZ/ZO^ [9!1[/OLA7(C?
M%D&!&#A;AI-J%VA W H>1@ZJ^(SF90]R5\O:7:2Y(+0-'<ET2-SH@50CQV-0
M/C@T!^]98W05?"48X=8AL>4-\XD:![I-[B02)LJ.$7[-/@4?(PYVY7''TY<-
M$\Q,N0):<<-\?3FZK*M1'#_W*=PV4T[V6&O<>##!)[;S5)O:6AY&#MQYCN)]
MG$.<\?C<D&-<F+!GBDQ'@_3Y[*E&<+G&]>'H$0?M 3.K?E-L^)@BK'2'2MEE
MP6A1+<#1@3/%I'?&W@D AWT_-;3BT4\][J+.BW?(,G1??-TWHU[ W/\WQA63
M2Z1'Z5/I<*4;-VWD=7VCG*JY4&X6Q!K8R[016ZZ;=O"IO=ZY+&S9!G=Z "QE
MV=58O(KIFF',-8^1O&ZPF-WA"O9$1S2OTCAU@O?H%VX6_%TMD10./6?C\*,'
M#U5WY.+R@LH JE@2A $BKYDV.EE/<UIB-KUYO<F*4H=ZP-<UR*@TKBVN=U=&
M*][UXGB%1K<T1)6_^.ZXNJH/:.;F*W9- _Q]"I!DX":SLW),[!5PS$!!;'2*
M,ZS!'_''7]KT]+/7(BH&UC\0]=:BV0*<P&'VRGZ;!E;U;XTBK@ TI\@%R08,
M8*4_\UO25!L7QK\]/'\$XL'-)E(&R\Y+#_<X_9.$<"H$@FDZ[JP)3< I'M!!
MY<Z( Y&;ZYJKJSIOZ]R+GFF13;(\C(Y!\KMA/</.;>_[U3>O.00T%%_!4C *
M\;E-3^H)LZ*2D0L5QM?]Z-^1-4T!5(_MC0DXR?:4EM-%LD,;F2##FREA="#[
MR%/W^$&H[5^V78K%WC5=.IDND+Q[56^:>BT'O4.3G'VW(*&Z>/7T]0?:B7]7
M>QTNYL46KE"ZXYOJ?7H):1;D@<,>>C2]AR2<7DV_0ULD98T\4['E1F,Z)S3_
MAN02QG1;[;'(V9JB)1L(I]>,.CYH&2R(WN_32_F 7HNO_;%1Q@+/\E$/'CV:
M"[3!WD<X\GH1Y"PYQ?/+E"U][K+1*61[Z"W[']"36:60^%9@-5_]N_;!H&W\
M975[=M&?_:_V>/9#&U;8@]D7+R_^UP\OOK1!U:+?>+AI38[0MNLAD^\D4X#>
MMHY?P<-^E>R/F#6I/Q2:58>XV%_5_3*YRR\W(AZ@5#YZF*0A@PU$O8+AC(B,
MNAQJA^IMO0N&QVCFP)&B/&5WSY3;VNA[M.MUGPXS:OUE9AY[#U\]_.:Q+0!A
M9Y>)3B;R]"F8GZ*<X*#@S!44#"P,XR,M^]ZP&GWM6SP<"&FW(D-1B;F/%^C%
MM.(*Z3\>_JN0@SQ\E#;IZT;:\X?KZ_)B1+@QUP@2(>^QEKZ/.?SNNFM%$DZV
MI? (] 6GD,"NC>95X "U>M/I/\%O.:9B$M^LX/N12',XVF3Q9Y='30#\I5T$
M+:B'?YBP,7=+U3V:Z^^<$$D&J\8^"'9I@QBT":&WD.65:GL^#K#I\[.-,6Y(
M#=MV%KA'U8$#<8;BS=8I52(J0 O7<R1+H#Z3%31$N.Y/*EX V.?KXQX9!%'>
M8A7Q+\<4ESX40;Z'Z*'KH7M!7]98,(>E);9^:MY!N)?S.IDQ9X:4<*E:F"E_
M32M>LBJFG^4<,2S("&[BEX1//?JH]3_[51%;O.5?&U<PH5$*Q+;T"'Q>T07;
MO*T%6V7[3O? <9=>*Q(P=)))=F2E;\O;AQPX?Q*3.[C'B[0,OFNN9M_5R3]N
MUL=-^M=FXX[@B^^^^T[^@?/@N.%A\'78%5DA4')$*/SJ",9LD'@@'&2;1A+O
MP.OLKK&*V<J];8Y;"DHO\52(=Z^KC1*?Z*58;)"0&B[;MM5^4+/DRVIOOIP0
M4RW2YC;&GV1)I%%#L3NH='72V\TL428MJ7?IQ!$6!8C:.!550=1Q+P$O+YD.
M%$S+::&-WQ.FY<T@EQLZ_LO\2Q]HSA9!T(?]^$IT#*>:FP4DKD<1^IG.B@R3
M2^9R(B.7E@7-ZK(XV)H=<6]UB90MD@3&8SU%F94-@.CXL6HY':N(R61*L8"#
M$S<W2$DQA377&K\A_IPYS<6/+->E" Z'[04J 4MFRW'-XF.NM(YR9-;K/PDB
M^75M?%DM^5633UGN-OL9*BMB"TJ[QJBOOA)Q!Q4I0@P$9W4PS<4.B'",DX:W
M]VOG]1RXH#7>"EC@3^/]O%'RI=QVY2B1G91YFBVKW!OV4975GDJ<-N;?TPSN
M/D#(\JG46K_ZY&NMO_;YN&U7]48ZY[L,L9>P/IGN;(#1)SC[+N>UJ$=@)L-0
M)&=&M\6LP]"D:Q(!5JD_:&EQCUX6EYPRP _A+]7JG3AW 7B:PY22Q?XACEPH
M>%-UYCK=X1V<5A=X*,BT9+?= &.1S*&XD]UM4 R!/9R7$=V?+-:Y?/[:;' 5
MM[>P;Z53$ K6Y[-_P%W&]P@/MAA.AH=+\ Q7S>-&\9KU^_VF[11EMO<X-_+N
M2X,.#6[Q)D:O:3#U"K&CT*[T!R^E/_#_3'$3T8E(&B-KF(9[MF!:DN+S_TJ)
MBJ)$D];<B^6AS8H,T.VRZC]@7OLC8:7#]UPI8Y"SV7H%S9DP"$XC UGZJ:6J
M_OC@J]FS+1H8Q-:'+K"&'X<#>.J(9BKWLMJ!D)?O?]+KI(B]$WPA7^'9%&4]
M4SI53V"4'M\KH\JEOS7LG=,<@VB07;]Z?C&GO#T=#)!<X'XY%T!8VFG=<%?G
M)HFR9 #$5<$7E+ 0#\0[I0NLIC, :2OBW2$Y*R[1!$NZ=D[HF[-L>A->1P1Z
MA*FFCKB9FJ]-,,.QW 8A^#XMVV959<4@Y%)Q&UX%\#I'TN5[ZOL2;W[7W@BG
M<U0+&BV,B;6@.#.I$\#.6)I8L<'&$1H ^&CPKY.-TE&K1@-U;PR3*;J;A-#4
M9SJ,3K*EO"/+:?9,/4N BE@(#^@X6A7SG(##2Y9)IB CX&P4\' 6X *^KDM?
M5;L&9O_[**FD0RVXD1+:*1CBNC[P99F27,]W^KQ*"T_.CJ_#"]WMVB//'#?,
M/ G9-!T)G9R:/-GV/1[XN--WYC.WZM*:=MR 'K'UF892 FRI#[DE2Q4Z,M94
M!&# -%&OV$7G,!::)]-#97\/*;!$*U7S80W YMGTQ+6NP1BW\<A2_ZJ9XV<O
MYSY#LA08OEA6MJ\Y1PA;568$_/']P::_V9FAS0^=@1J+6\\O+3?IL%O?#ADX
MYYI LA2B+2<Q!GJ9+$&K1E=?U( =O$_;5O,_$B9+Q-QLV3'W<>F>W[S>YMD^
M'(8\]"@P5\5#Q?-F@?<X:.-D7S*6MP5:6IXUH_X^6DUJRP"\) D ^C-/YD:S
M%MG:K JFE[UUXA-I&T"A[+@CS"EW6^1:31/PW8NL/Q"/>MG[M$B6=-2DA3(U
MQQDHO# R2790/3"M/)&\@"I/01>-7V5_[':V!Z;BK%V?$:F&-!-\7S5Z)YXS
MT[O5I#P'^55SU1!$+26+FH[O0 !BI 3U2$YS8;%,&PW (U/2WJTWUIIO$YA+
MA8]H29Y!Y2,KJJ'J*5/KV=YT[^*.CQ_=DVWQPE$V#[^QJ>*TO#H!!L)"PKN.
M>3EJPFY=R'G*;W_B$B0B[B >8J84%_Y!9U^SYCLZGALQ4.4%+X2A#>EH\?^&
M<0*614/NYGJKIYFY0_*SAE**&,VFBF*F[?&0<WO!7^7*MR3[>?(8Q_E'F[G3
M' WFM C C>I25^QOVNDVWM57[<%*QURP_F!?+-*<[W8Z;DB<?#EW(4D/<%'W
M7N3K(*%6T"U7^V]=,-;V\2 CJ3.8$Y/^%IVX.BTQ'7!4X #R'[/'CVU??2'^
MU^I8FZ[(E]_&TJ;R<LCU'1=X5>W=2.2:/"LU+I2'OVD5A'\>3=#77\J"Q3O9
MHZOA(#=[#>XZ]H!#$3,=".*1;HP.SVG#^Z+P:F;9VL"9SX:3U)M39T?)/'OB
MZNH(..5?*>9\'61AY@9_0X.:T)N/5G,HC@6%5U]@8..Q-:OI75W6,1^#;"^Y
MT7=7F_JL3P'54L^D"!8=4!W'"BM0Q0(85G@X^^33#Y4-6S7J2R*&T_M#ENTY
M$Q_2^66/$ ://O+K-'-G['22K<_L$,_(V]$F2SZ@<*KK-I\KFZ\<.@^_CF1M
M^A.YJ'S_#_.I[WS'T';\[3_.%;OQT;_XD\RU*BL]F8#JJ@2IXX]COURE+V_6
MT9UH^D BJ:UJ-S4[9/VD3\=*FM9.DV?U>T4;BN<U7&>:H!H<\Z?+N5+T3]=]
M;"'3:=25??6K^;#<*Q =1E?HFGA/ACL!4DYAF;E;7&"A[9(#I >,U+B,']Z]
MU@%XT_5^Y$<C?U,H4;=&>YK5F+FXL\P )A.D52@NX^5 GT&3#T->C7CWQ6TF
MVZKT%43M)[2B;50,7-W42HJ)X5A2J,BV>M]LCUO<6G>\(44R6I-SKU@QX?N;
M/'L@9,+7M0YR2\7 5=E]\G16NE([$S,,?>1</%'-R.$@IN^_$[UCE;&L]J%_
M?)"O3&<G'.1]NWQ;'\S?8/\/6_R0"=ARZO[MJWFRZ&GJB>"27?F5I'8)2Y*4
MT^@TI/S>OST*O[TG7JI$+_ BEK=+Z7,I_"0[;'UB892TI/]3_J)G)@6DO<RH
M]/Z(UGUU^A\SC6)NL:3&OI+ ,6=.)1+V%M"#C[",E":<.CL1/+>DOB"A00BF
M$)2RYT9J\YK<BLU2JZ9:U ?V#2679)<.O+?-"BR[:DZU%GU=']-Z:1N<9\EW
M2=?IC1S 8 /BXV X,@IM%667V:F*Q#=%ZE"Q4E]+\C^FF6I]1/6ZRS-);A>H
MQW1GV:OL43!93;_OSZV;7W_]R9<3895^92/4]'<N2\LO@"6AV0N,2XVX\55Q
M>[7+Y;&S9BNURSLANPW'8_0?PYV1\3"N/V_LSCO57<=RR_[A7RKR>*$PS6^L
M:O&\[I9OE4;PLCV?SY[MEN=S4[GSPI#IW5D]C :K3X,X&#9S&E:D8;W70#YP
MNA39#P>'TOD"#A$!R*Z7&JDX,T/9*B;"FS5X<-%+%,&\A%==!L I,*P+HKUW
M%'>PSOMN*"V5?WU=63/@I3#6U,*T./7Y=UW3']K-[#DE$5\GQVFQP)_1F:GX
M':F67?2'>K-)/K.4W69_>VUOX:?V79O^ITMGTUO]*"W.-.V[08FN#[_ ^/MA
M">]2B\4,L"_0T_!_)P=J6<W^>O[RG&_TN[:^QK9*C_$L_>\F+9OM]%W$'9,5
MXCJ,>!')%VM)ZW7L3/C&A))*H*\1_DVLJG/^ VFQS/!TTSKP#O4:[M8T)?OC
MH0YP))52I+H>G$EQ4:Z46T?OF N1@MY,:Q\J=%HY/)\]1YCIA[M<4GC,&,*D
M<*Q&4>)%KA,_?F!>3EAD1^&8NN#7LY-%LIK9)9C6&A(G44Z \C971U>/D]:<
M<A#2U*==6U:<NOMFK\7JV=VLBOWS1U@,KMI%5T2&JB/4 MH?YQ\]Q/)N7?U/
M\>J&Z].M1Q83'+>>#)S%7,\: \C5V%CQ6 R((0_+MG&DWHRJB7JZ?=$)EQ=U
M[L?L:HGEK/PAS>3[&IWBL=$_>7@;H=)J5WV1I2UB&T8P^GS(A/#>%419]'$B
M:Z*<:QJ&(B1K!NW_D.)VE'BS>]=NWJF%Z^N 6ABW3#"KC3/3^S0^&B[^+W9^
MRB[4X.;K$TA,Q)PE"%/S:2Q5]98Y17M4&GB]U]X51\ &=/)T0W@.D(?W88?(
MH8^YV%"X=/Q4Z%BWRI4_A2]_B<O :E/&4'@(^S7JSBAQ(P#;8L8*7!'.!F=P
MH$LW472>]:W2Z0G?^&$&,C+KP-*JNI? C:Z *S %_K.^6A)0;R-",>W :F"H
MW18Z;J9J/E[GX]D4VR#VYO%7#[X+C7]%&I=\0*Z=B@][X]:;2IH;69"\;Z-$
MGE7+Y"A()"7L3DSA:JP7ZBN:&COD7\8_@F[N$+A+6D>J&],B"=J=\8(M=^G?
MJW\>^\,$@$QA9;+H!B9BN*9S,I*=$+/UT5$Y9AFLET\9K3E+&(]]8(KPL:61
M4Y]KG^FC6Z>RH"U+QJ;9:1,M#A):I'J?9G@/QZ8$@!1<E81<9*L5A5/_,<C-
M#_W9<<HB5%7F4ROJ1+L]EPN3O B,C0-7$WVXC#-HTF$!N&.V;3?ITALGR,S%
MMMZ2CQ6_'FC,,_%#T X##@M:I*9#SR-N2TY?2P"4A-P?'@!Y6?8;Z^YOM:.'
M/2)2Y  ABS"CN")N(YU*%8^9_E">BGRSA[X\';TW[E_ID D48_2H'C[ZT%D3
M7+*A </*8FUVV-LRSN$:OW-#5M6)LXCL(5P6)QM<1O<WZW#*#B*A>(2"2;(_
M@+^?*?S];*?1"NS0]S_-+5=.7HA^HB]E]#C2TJ*C3P/FV<35Z!Q]K@KK</L3
M3V&8(>VBUYQCHP+6UG^JU;*I#HMA(#4Y'8(MV2=G[6AF5B]=\CVU2HM9$9*B
M.CXR(BU/IQES:S3]K@:QKX+?'MA*PW"4JM* ;]F10/$QW$ P>B1K;W?25;CH
M])P1BVLGM?%*%75#*RQZYZ(DB*F_+?J$09'74T'65R%WY/%!J4+AKJUE!)G(
MR2)1O'*CW6.9[8-#.M=(ZN2<8"ID6>H:M=S2"-=.S(0J"WO5IU*A J^W!7[;
M4N[GLCUSOD1.U!-9O**!A];*IY=/K"DSG;YMCR6Y1?'#Z[K\W@]/7E).$S65
MY#L4C"K?//CW(F.2OAN^>C[[CC!P^F[U.\;[5EPQ[I388.J7??2(HPMO,?04
M].F1^O6M9.O2.8(V&:L!%>@8#XIMQREI20HZ-JCG6 $ZM[=*$"+;/P<^RM8:
M9,#Q0-QWS#7AE2HD :P,MM"#;S".:G[_Y\IS85Y;YCTOU=N'=QXOFYJR7YC,
MAW\XK2>0-NF!:].QCH%CSK@SPF$V>^HF]D5GCNFJWE8A6J=QS;>02G%A>MQ!
M2+&\^73SV=6QHCQS77P7>RD%3)O;LTV5%LRUUH^"2Y2L\;';!1(698U+:X+*
MR[B=,V2X"QFXRZ7TR1,O"+)B%X2!6&U5II7)M".8E2W?$R4:TM;:'S>1_/E6
MS OLEP"0Y9P8G6-HPSR42!""?ZQBMBO/]C4##.$"S"CN?-##%,1APZW0'P@.
MBYZAE[R-U!QY8I6@^>;!;$7.DP@8.A1L2&+\B8J47E4(<)H3#" _MG2[H9\(
M!?FN1W7>7$" M%8K8@H\.2+#)7<UVF0%.)-"3;TF!+*932R]=UB797 N_]YT
M!]'BR5S/_1W:&CQ8&,L8!**Z@@A"[8+@$^8G\,4R-QEQ/ @&O:VJ\"28=O.N
M"4E*?#,/N_A-=]SN9[[B^<]7[\^OVG?@TKVI%RG8K,OD1(03WNUGV>^#"(NC
M&^3(RQ';P@Z.\;/G%@EK&1Y,UUVNWD1)\Z-,\:=2[_SFTZQW_M9IPMPE^#A4
M^3--$T)9D?0J4RVQIWWV;+=KWVD<Y*XWFGG VG5&",N^V;2YE;ZTKI79N>Q-
MZPXSRP9EFFT=$#L.KAL ]_#1HZ__W5FD@3PH G&33I!A" H0RN=BQU5"[H=-
MNTC[][LTE&OPCXI_2P%!C->K@[ !S[T)=8@>U 3#X/H__/7%=T\SZ?4/1Z7=
MY-'EE[C0DM,KD3CD'2\9I4T@KT_=Z6\7KYZ<IX#*"@'^:LJ7,2<;>K26TC=T
M4SM4*B8XFG59N4;CBKP404?5!0DQ7Q309(=1CVR@H,\O/O3+@E)QEQ$\/OK8
MMIX><^"O:UB!>" M@G]+"S\%3,*[J-"X'%#@2Q[?G(HL!M__HLK=3=!B$.'=
MJ2? 59TX<?00*2+^\ESJL/3.D)P[UG;P3+\J%35%#1G@+X2<H17QL9VJS@-=
M[CGE/G,P\Z"G(H/)K&:H8""^9RY;(9@J<0?R5RZU^P$UNQ"72T7(X(_.)[KC
M1G(C9+[L>V69LM1O 3V4>D(F2H@+-3";.('M=,TD,Y<,N;/;S$DR8,47,8F&
M486[,F.*[4$SIK5/"_.)T2P+A#E=9-.2[I^K*7*M%)S9\ZS,A?+JO'C0]/7D
M +/[(513B.H=R#()>O:X>1OBD4^#BN,B4#?+VI/6 N=\,X6V"1SP1/^VVAE^
MF?J?Y/=N=G$U98["-/5H-?O_V'O3Y3:N+&OT51"^U;>E^)*T2(TNW^X(6I)=
M*I<LM21WQ?W5D0 29)822'8F0!KU]-_9:P]GGQQ 2J8EH<3Z4:9(((<S[+.'
MM=?:T85V>58'DR,-76&JID0 22F46M=(D>BTY5-*H(WR1W\E_"I)MSXY+\AY
M.\G11!U*JD%F@DQXM&^%-K ZTW*N*=99,0?O<5*J0UPY4I%E)EWD'T4?MHDP
ML\YQ!;SV*.N46WZIF&I"(6S,S(EV"ZU1;4"5= ISQF\:E^A %WA4"R/[M^&>
M+5BF>N4_'_,6?R^@QZ.J/J[JT&>?<D_.99_XP":JDO);,U-\-DF4!_GEF-4?
M@>-2ZW_Y>H"1W:LV)/I8Z4#V]::RY'XQ:Z@<OL-#Z85[J'87!R0F$WA,]X7;
M[4WL1#_1.KO24*,)]G4G,_3\US_$"N Z?Z;-6LZN\=C_*O6_GN 6NP^)HE8X
M!RBW8[ZTK^M0R"'-TLRPP*T3KB'%>%5IBB^"O^D<*LIU=_.V0_Y$JM(1%0X$
M;I$I @/\=!3=J18I;T_X8(-5\# 6,(!K&D2HD)I&A?2]23#L! -9ZA#98SU(
M.]P=P7")=)\(8 5;PEB2UC%V"!V#R3/YH>24JQ!0" QE#?R-BG&9PI?R6"1!
MF(VNTW2$I$2OME7'6(X.J=QI*--5CQ\?2+7H^:^91BHEMZYJ:T9W&%,UVXXF
M9&G8"_\(R01S:&^#I' X1W-PP4@U)?[;M5C0]YXK]JQ(3:8HQ@EO!TL@V)]]
MRO#"N!28XT2>D8@5A@3:[-F-4VK7([)8G9>\Y::]254#'BO)\WP]I@6GM^.'
M>O[KM\\W!  ,W[)2WDF86IR[SY^?9*B=<MZX";L".6J_(Q&;TMI<FA6.1[EB
M*7OSTQ/ZL<TGZY,%]BBAT]UV>M)Q'2<N7G<@]!_E</(79=CRS(]]A9+^5W4!
MG5+JO]K^WH6D"RB>^^%7L[,5@6"V@*VW[0?PK7[VP/K-P!302EX55DSN[-E8
MXRZ@HSHXBT!+U8PT(8Z''#V,\/\:IFK 7;"N.X?$=1]#^GJQ8\.\AF UGZV[
MRTH7K&[.MHNL,^8V,5SX=%S-NY=E]%,<HIR;@EM!"RZ+B0B8#P-;T*RN") 0
M#.2 OD^+< DP:Q"[>TFD,"ACAS>L52*]B$=18;M,=2O9OHGV((*'HJH.)(=!
M=^C:<0K\3=C6 1V38[9CWSTO$R>HO #IBW6GKW/-,'O"R)=1^3(1="_ Q=,Y
MR/*QHYIMV\QA>4C^&[X E6CE1!K_.I^F5/%W-Y1SS[^G<#?P980:MZVK>9S^
M+TA._ .=VU_JU8&MA;>\>O:"9SEY<%OV%((Q51>?G%W-5C'9J"Q?E$V-< Z.
M'L-Z%RADS\X*Y+L%N*/X1ND1H>KM)+G]'=6/#4/S6SG3+]RUYU)",CD8.2YU
MJO16M_WI;Z_IA%O-J ,=1H,ZRTCLCSCTR= \8X!T.)6.[]U[\.W1O6^?/YW<
M$=XAV+A+:ATGL&VP<E)&MQQBU H>L&8HE1Y]/RD.3P^S29//R_J@EY @[9U6
MF83X,^!,0T"Z:0 1NXN6DGBS+!P7_=D*)T-XWC\FT3.Z"X87$UJ]@FG\]$DG
M&),O9@@N/L,(9+8[B/%G13DCV\(9D264:\)L9E ?"J$K?J+$M%CBK[X(__CK
M+,)_1@YC(BPM+X3@=$:K<I<5U_0?ET8I\N=F88Z]F*P-L$3EUM3.$I%!U&C)
MIY\[L9@&767D,ABRN)K>I><S=DI*H5:%N,X?!Q#=1Z&)ISHV[R H;@G)O7!^
M'-'#_2-/$)>^53MY$VD4[SS_]6YP6R8/[S_Z]OC>T0/N+G[W9EB11\(:1PAF
M" 'Z6N<VB5-R%"X?G!*Y_C.1XGKW9L)]N8!+!\>'V3$YO2[M7::LTTW(<3JA
M5]3LYQ>\2QXQ%/#I:NIU7DD3OY1@^AF.H90% A?)UB&@2#_!JE*I;\=B%Y3,
MH1#V):?5$/%I$&5YFQ .2O@2QMM_,B,L B#H/A=D=*_"U^1B(#8?28+(Q5ME
MRV)TOO&I.X\O7%'P+:Q/)L1NW7%&9;A"2TU+Z13)3-I;O;1VCA.PE_(+OI3X
M+&$8[(RF\G%FXQ&A+$X_6$Y(F\A@9OLD. B8>821$J3>7I/VC13X_CRA6;=6
MR'DR]7%)7X1SQ%9'@=0)2#YY'7\3QNTUSUT>;'@>0OZ\+;[)XE>4RJ*>;4S@
M<8HV+-IV$OT:1:W;0/8L3DY&MGJ)K".MF4X%%,')V/PS],<E+@?VK27<L#//
M.VR7O:UL;)>HVTI]\+)&K!*.1T"S7@!9A M'ZNAP:1K$Y#W2S<KD4^Z!^(-T
ML72X)+LL%U;#@I<E!+#DD,>2(>$CO:5OS2GYJF\/DI3'D/GRF@7\F)D0OX6P
MD=:95 5:Z>[A04I'J:7%P0E[4LS*4>T<^OYA>&;0LL^+?,Z9L<A(9QDHO["2
M&>X\NI]P-GA-79F)M=12L3ZC+353R6 [)MS%X]I*6]%Y]7-&,"Z'E7IAX$!;
MJ ,V^,*6NM;^0^[[G1M7<ZQ:*WI.[A(V_YZDD?6(5]X#D:=GCZ&P)FWG)TJ9
M/ZTH2J&#G8Q8.E,:\K@K;/PC??WPN9 V;G663]EVS^[#R8O%R">3\YTK./0D
MW<V8=9[4[U_2/Z:M82C_WD[&*"A4G\$<206Q4UWI/ZF1$Y('DKHNE#"'.P$V
MHKX=D.G@[#A"!F+TI/RQ227(?D/W<V=/,=VPZ910HR4^1U3II9-)W(]U3#G@
ME@Q%CJ81P4/#^>1>0JX-:D,G9CHL)5YI]>JT5M]VR'?2W=XU*G3C"T$\/^U\
MAR9_T,:#$-/.ESOEW8D1]7=#!$\O\NX9C/R=,GQ!2V*]SWODJ/SROA7PXJ[2
M!78&WMTQK\ <FF?:6>??OR7(<0PCB$*XZM[[X>'D1)8BG> X=='/W1FK.YY>
MB0YE&3B@CS U=Q-&/<?$+&G_#G'#_MCAU\PPI38"T%#EZ.V,$IF:;+PL=4Z(
MTJX5=.&!BQ'7^M- ] EIICU)";Q^\^+E\\FS2/7J7G(OT@(OJ-.:Q'1"?/^(
MC7\(N6*#EJ'@L<=(RB.?E56Y9CQ?3.=$?(L'H4$A1.M[!/1;$$$E\05GSB L
MBDN&PM#MF_P<JY%)8, 2'!8$6\TPVGQPOWPNH2++_- D9).6:C %H_&COF#$
M)@LK;WQF2L41IH4>?K-:AB &%8Y<L#6ND;(%A+HJ6$LP]2^M%A*<=U9=55U6
MD(-A#VC;C#CR1D2-PY@"+A&Q,(_R, +;X,J X.) %%GFY6:)29YS5U^PWJT,
MQ=N7SX%3VG)&<+&5BFM#^$\)[4R9B1>O#!LR#Q7UC3>Q=?"0])4,+HQ1:-C!
M-0F,X8E'7I.O[WB0/3B92OQ@)R L9<%*H 4:XF7<\YD :ZPR/P^#69]N7-84
MV8%%P\0!3O&44?"I)>+G\&!JOQ:T\Z*H5'8%T96;]6M4E).5 4QKB(E;4 ?U
M(Z9#E=KB]N?PT4)[^6D'4C212P:KR:'?4VR:Z-B&S_Q[B[X2]J5HGO^R6<8\
MB@-'<E[M+R]?\P_)=TZ4@>F=[CW^T,F[#,=?C&)Y=L*F2=:-V0/F=M!69:QO
MD\#JH ""^0^/;VV6\8'0IA&.[,G[<O;^H%XL5%M'C1!C MI4XE6!U4AYP/\J
MPDP2_() 8;0JRC!%T,\CO'##/,QJZERCJ\H!:'>.1E]^H7!ZT]8D%XI/L5>^
M^K+2DZ^^K/0%>"1A]^>4+U%HQG[X(7\OE*XFGOPQB4_$]_I:5IAZP9N4B9N8
MO@/_:NA*^MW>]S(/S?,ZA,8:$^)AWY=CL5&$GHWC@]3[ZV3J[;1$L.X1)EU$
M!WBLM#/!MVD07//ER8$I,+S.[<U>@ M+V41>5SG7!EZ3<AFZ8_&<%:-1BLA_
M$<?FO#XWO1.G1T7F$=RGH*^81S#R@<7\EWF)1!6E!G*B.I!_HRHY1Z.JY"&H
MJD$IA;JQ;-O@B\(S>?%:<G/,=<:.@ ./,C59-3H/+E\, A8*%>?U)28H*7 ]
M18'KZ#N4H.Z)!]S6!T(HX48Y?NT+@F[M- 4O;7!.DL'9"X/PSC#,8W.<P./%
MH0YAES^<48_J=R%H06Q%\#^5;>,+Y,/^^"01#=;*%7F?NK+-P[%UU_G&:'YO
ML#1U9UX,/PC>@>@_ &XY797I>F=0XYO7=\F+&ALYB@\HF23;6EFRXBCYK+HK
MC^[:.1TNLH^RFK\Z2XD4?P>.]_'&\L7KF[6$=X[N[K*&=X[O=BPB,F?W[_YN
MH[@?.:5W8W%M7"6:[V-63A29I)JX&WL;SU:$#0(,EN;^BW _BMK -88//S^9
MW"D/0SRMF:=8:'P18CMT-O^M+&9G86>&O2J4G;_43?!)PQYZ321<.6=J!U;_
MXV,"1MP3MNWA-T8=8!E654LF"91&NEQBVT2,BUU+ M$JX!-B0"0K-RUKZQ_0
MED^"]2 %IUD#C;J97TATB88:-HR!EW,OVR&49X\\3RK\$J(;R-71T>GT)CRA
MIIG'XB9=&D')=PQ^DR[?L&=V$T\B"0!YCO0%C3N(^*T1\7+Z!NR+/JO>G_!6
MR"!P0V/7IA2)D8&-+Q2QRJQNJ&B,\8_FVKG BL=B/20;L1(D?;C>IA7LL R^
M5(N9)'T_S,FONY-E@F/ZR\O7K)B*,Z2D2A*S%5M>FV>%.3TZ,("8FY!:12M*
MW934/NAD?,"C@"0CUAH67\DR#;X[+KW%LIZCAT18&AJN 8D>8<T4W5+S'+&
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MRI9B/OWMK*H\O 87Z  5@F^EIA5%.6U:]#3?Z]I%^B.)]C#I_)C$N(BAHY=
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MN?WCDE#TL</,#_43:%^.')TNE6>)17H)1%,$@Z)QT7Q!0FP R"_""1#0T><
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M5N*_4R0!?J8)6C 9CG F2;3HSK)C3"]& O)Z&OU+G32OR"0'PW!\'_'\(SX
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M^,7Y<>*J\3E87D$R0!*F<%()JO=TA,7,(YT**F3) :[TC'-"6L,K0K>Z]+.
M<+BP(<N3 MM@.L-B*1$N<<S.7]1T'Z!$F2JS:WT*9K8"SD_9),&J0VGPN2),
M0-PI)IXJ>G\7HI(UY:,=C*O>#-!$MQ;[V4L+/W61HB7KA>=%=!?H[-+^>/O-
MOGOW@I'HBLU+=(RK.0-<;C5E/O#&PW(#-F58LZO3VA"-5;XBI[ +\99%.[28
MHF]X\N:_#X[N';.S\OK-JW<G3[FO!M)<IT1#VB1UVS7EJGC>__;FS<_'^ND,
MEWIR[]$'7^KG-R=O)S\='3_#REINUMC*,]J@5&.@R][_[OY'/>$/3__V*'W
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M$.^I^VA5+U33SFF^\!NH4PY5O!+QT@$C>:T1^NQYRQ<KPHQGFN9!:Y]6_G3
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M+4;CKVR=#K$P@-^B@VYTHH%1AJF .,-Z5ZW3#A3%4GC)0Y=U^.!%$ZS4QE2
M8+44M(? 0F.25M/;QI0Z;_)E#L.'4.2]M TM(Q<JV+Z8@Z/:&[Z(V*=K"8)K
M)W4$UR7%DO&A%PV3]1F0TLJU8:+U=!@42^)O*#+EKTI@!,-"GM>?^NZC9EH&
M<U)QG&"([[:&S+LR9W,MFE-G]+MZ18N@#MX0O8#_*U^YX5>0^CZEVHIF96+:
MMU6,&[$I4TEO7\TN<]L/\T?/!6V241'=VW3-S>/2T[6=J%@VFO0-ANG<E&,2
M)8#@Y4R;.I^SN[-F_1A2DJ+PKIC?SM0?,E,L\YM/B\KR7\+TWR; 5-$&2MJ
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MJ;>0=2/V,:2". 9:P:R)WK9:[X]\8,+;+AV$;!H=<;N472.Y&#DK# X#O\<
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M7A"H; @%P<DZ:<F@=A,B@2-@,\$XC.80%T,78/!CF4#.3.S@L(Q%/(5ZT1&
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M0<1!P %^_/W3.(KXX-'WG-(*R_]DM:)4UYL"V)TPRF%2PB7N'?R\)UQG+QU
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MHQ$JYO\2E+BE0W*U(W&NQX(L$HT0<7'#,+?8HL.WY_:,%=-Y[BCX>%,=C89
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M\>4?OWO<C_(!E[K0LQD!JV@X)<"<H_3[\%=^)<G0[X8+Y(GD!<-XP))P1D_
MA,@5<(,EC .<Z)CLVT[528 O+D;0N@R,A>?!-WT0.=I-5OI_/VC\</;$1.1,
MVA5215Q+6=!M.(]S*,,--_=\F0467.8.*1A2E@DSU*!2Y+A?4W@[!6K0;LV
MYF6/CS'S9=H*L!9=%GE^?C1ZE+.V70OXBV\:@L'PWD7*QJ8Y%>2/?PS;&SXG
ME6VC6M'):^,UZ-H/OOY/7Z-VO/Q(F%1O0W 6G8%42,&&,G8B.9++)GXY57P\
M?0WN 53#._35I[&L?VH6KZK]02;RBR*;;4_UT0K")M0-2/)^6AU:^N8#_2**
M_EV)$C--'!7(#L(RTPN$*_9#8 /PP0)]LW)!#K4L'5ZJ\2E&Z [T&^.#7@?T
MHD4"<WF,&V2DPC'7"Y4\$U8FHH'Q6&B'!OW6WIZ%FEE\C\N=<N[K S+.)5&9
MRX N&&-R-M ^J((]P,J5*X0_9YJFI!D7[YJ\0*H&&9;9\^]_U':(>I5R+!B/
M9]ZLW5\\4360$Z8*"+^!SF'"[35(C+T*+N_YXN_!;V(C]K<R+/@BB@2LDWVN
MH,Y7HM[^\/.'_NW3:;SJU.&8\Y>A)Q3_'$K^MNU8H'H?+\Y!3;21 ( /$3:V
M>K8(ZZNV\H_LH^.>>?C%?SI#'6TAS<6*JL<XQ'2I15^05LRSL,T1DWU?+3NM
MU'WI$H )R(F0#&[E/TN\E:<6C3P-+EN["Z[?BY9@$XO'*\>"*]&42&W&/4E\
MV5PSD_5"+WQ1LB8/'9&M+'"P,'SV;8A8:W*/RRU^\>#;9)_J6<3O?[RGV []
MT/W%#^'9+J:F(6YP8_R2QZ+TN]Z"Z_>"WHGAX:>XGKG-,6W26T775D>,@3"&
M17$(Q&;])V;"TKIX=$,PS%MT[/@J?$2#A' 9+XO*^M1W1JL0GRLN*'8P5PWV
MA+9!"TR14\%5EZ2<1)&+TC@(+41X71(KRL,^1_V+%%K%E63./?KFX>[[#$%>
MG&021'7EI:>!Z'P];-\VRE<Q95L[*HQ@!*;2](]_)3F8SK;MTA@IY,T!@\%Y
MO2/00J7;7W*C$L2)O& Q1GP7)YE$YR',4R'RNMD$QY:-)>=Y8K;#4$L)2<2V
M#.OJ7.>%9\DI1&;N$?NJT3@WVP-/!UW:/@"I &[!.U:4"D YAI-AT@&U\0<!
M#DQVMGKC54"""@M6*DY27%0KKT@/,EC_&MI#22V5@PAUJET]E&\KEWW*YJ;0
MZ"5W9X2#@<9\#JZA\2PAX*,O)(D#%[P>]>D3W4KBH3$?@C_M^%7$!-2= WB<
M[L;X=_3L+2/3S_=PJQVJM:-[V[*'K:W5P1/&Z!Z86,(VY"9,S8%P28?+2A!P
M2=\WXX<12$;#71$&3"\O^'D4#>G3Z-:F4E^A5HN6C?!-'HR7R+)JIC[#UB2:
M&[%+&JC&[DY1 +)U:&ED/7+D1MORDB#]P]9U.MF[1Z.[&<&K[%?I0+2=IE=:
MLXUG51N+L$-#FT<*K3W3$YH9C+8O>N%T.8)4+.O6J<?%J@\;GA7-NJ_\3DZ(
M(O*2%%.=WC$7N<&\MR'XZ[<"4L^"9%+;IK>$)2"^Q7"E\S"1D_0?83O9LT3%
MMS)B>, UJ8/'(=!UOCGRJ#M=!^X$9F&E4?7,'O<["K .VJ+QA.UZ98G4OX0=
M4@[TIV=>\?85-<N #I1PJ\]>%9RI!%":6I3(CZAW$#/:8@G18G,!-F+DKMI4
MG31*2UU;'-/'X93=UE@W+\.7"W5/>3S# @[/P%\P<:WP$&)@4R,,#1F6==:1
MY,'](@38X>'/ %YUJL1&A%">G5$ZFOALE\=$*,PNM"79X[6BTO ([!/0'R(I
M0;48O1"   PH!EG-&GC60[V-R:0'GQ7<!U#>U2^_?O0IUR\_TKFIO"IJ*>[Q
M,79@&.4%=9^6NPK&JHS:EG*VP1[I67F=TY&,M2/UE?Y7=M>PJ9.00A6)<7 X
M>D6[U1"O34?$B>.^<- %_7C*QFQ4">'NY$7!>B0^W AOG]/%PI=,Q]"NQ< (
MIJ.["%NP08N9HV%MNS1.2(XC!(1GP7@N6VF<6%;'MO'RC?Z4(C.[7J.3:4]&
MGEN]"/@?!E<L[[Y$Y0D],2.SJ^02;Z@D' X>BH2 Z #-$*(JH2[ZI)S,*0XN
M#/5WP:MC,_ZU983[A=]2AF;]+IR"Z/60I [/U6,1DOB>&P;^F[J+8EHIYEHH
M8H(C2;JPY:6<0S^]>OKDGR^?XBH\>>@1Z2> - K&!^G01+*+%A&T:+GA8L:U
M KJ&L@FLL_*7)T^"?_%/V[+) Q3SX%\)Y?Y0_S$L%T0X$I>G]Z4E;^Q,88(N
MT(AH(-TE=3:&1_@V7"A<*:9["\$B2)LHI0S*2.QB["-R9 \H$?^J.WL=L=*_
MJ=[L6_I^>#IZ/"AZA@"C;-C]*%6XDE'&O^;^7"%(I]V2A0UAMRQW%^<PK$>:
M-^AK'<@)ZC$:_(&C^C09'U$7[(.'7W[V SP=>(YB.Y^3'TM&[(F_DSUFS4Z3
MRS^)=Q:>YJ_/%G\-6S=X8/BQ@NO?APO=+Q;_.*S#?X,+2X?**OXQR9^R+7\>
MOOR:5+7=%Q,1,?4'Z?U^'OZ_VOPY'D=O,DOJ8A7&)%CUF1U1:([YZ%+,R;4+
M:6!BKAT)L:S'4_)O&A(HNJY<;.&<4F:)'\X-.O%D#?MUZ=I@\A.5]I \DA)$
M;"I!_ZXEKQ]\7CA+XZZ8>/AZ8WH2P\WRN*[YQ1_O]V$6>'E1*WZYI$!%JN[A
M%&);Q8XRO1EE+ZVA"D:2.HE64K]$'E\:UW0=!7/G6EHX-M9S+PPPX+6,)I7(
M:P1(B7MA6[_!J:7ZE<Y"K*X9;4:3B.]1G_*V[;4BE$"^W.4+2R%=UGTD>;6^
M@V"2LTCBX'&@?\Y(BGURP^M[(:U5=>J&Q +A"-]@:ZBO/)OIR/=P:=4;8?+X
M2*<W,0P.S::\:)G;PQ^0EN=H\MEQ166+FRI:AM3S(+ <_0V<5DT?3A0^5E++
M2JNR)VB"]\$R<,^<>L6%LD!Q<GB')O-YJK<_ -5%P>M*F5^J]1\%U^'XG#1(
M/,6+)TU6\-,[Y[&G6?72RZUDGD@9 ODN426K/P1[J@CY<0?)24"/([4:CU]\
M+&4;E1>(V ]?+MP[VH@T@0CH(A_-&<YG,H6_E@SK][E9GHT+,'TQ7?S)&<K5
MJ22#V%5IM8HJ#YM(WSE-97=5FNQNNR+MW01*T9?]U6#[S"2$TXG'@W(QE-V3
M&TFNR"%V)2U[2+*^LMLU3_IN&M_O)NP]713U^G__1_WP\T?EE^47ZW)958_*
MK\JO-\MO'CW\:EE]^76Y^NS1H__[]<-'_W$UGN_;23[G0Q'HY7%\+TGZ9?%2
MH$C: ##I1 M#1%1[0I"T>!)W]"U12U2=G9-L[>H%]!GF/736T.%!/ .,%3T7
MXL@*2M%5%>DR5.B'##REC<^/P76NRP96\T!%3"25(\GWOCRV78KDE99@*DMA
MY>YV0T..3*R<CCCC1>GR>M2-'UT+_=G[F(NF;:HP2EL0!<B\G)5IM?C&9V24
MWS<>4[I7QP&>"%2KQ[(ZKW:X:+GGI#ZAFB13Q+\M8'<AA.:94.8>@?V =;LB
MA5HA[,[)M"'%9@^$ OW,Z NL2Q<YK&R(B2G'M*7J-^J@-J0)<3=K,1^2)N4%
M$HR#$.=9Y:S<JKYK_+H4CIA%D_O]7E^QQ4YIG6_,PYKLEQ)<*U1S9HY0)M>,
M;4SD9;0)QHS#67I*9?XXM'=B6>]-^*6B35M*1XACWEU?A"4$EH.R%R9 J5TY
M^MJXKN^TLM[;C%!A(&P3Y35"8"\Q/%B(J96$W:X38)>1OW@WB1]P$L<\IF&N
MDKA4J"'++=CMDNBSHY3GW32\M[UD@E.RF9"!H(V40K#OML8'G!,Z_<,? "F.
M@'FBVA*O,!Q#^R%6\0B%T7 "-;AIFAHA,) YE-P-5O6KKEY6ZG/IQT],W:>"
M*/CBTT(4W.W,7[<S@SVLFK/#><)!6;B084TFLUZ"AT;Y">\LXWL;__(BQ--)
M#W&,C5<@5SWC8\SBPJZJ=TNB\:)#ZFXFWMM,'$C'[$Q=[HPF1*UMAGQ&I?)<
M1LIT-R/O94:4"943&>(DA BU1>!*58%]?],*LI_0<$MG@Z.=X!38T(_3/N1X
MG558^XZYC%-E5W$$_;YRU;FVF2@;&D_ : H@1"==I$6:3-.T\&: H? D<R?J
MG%*AO#QG\."1:;PED79+,LP_FU)LA+PH!2?&,%&<JYM-5X9U-K 4$+T]/MPD
ME"22@.748?PR >N].T+:8'4[:ON-FI&O8_5@FK\W45F=%OJWX1<%II7+B<\K
MS>)U_?-._*=T 54U]@XX.;<7TM\E;-T)26!LPYG67Q,49EPROP-\[3/*1O4'
MI8N[K%S;\\%1#Q.=JXZA[A5B$-FT*RJ8%ZJH$6Z]GHQQX;:H\HHD6@6$DY&S
M1 K_TYK;?#Y-J^.)@)\!Z$<:M]8MFFD%($N3MH5?\NI_L0GOU<F.@=0:/?(O
M;<V]BQ610:>RQ,;5/'V7-*&[X<:@L7)*\BZW1H%,(,=E,\% C.;FTC.!DTT!
M8(0'7*AMT$3_3LOLYE99=BVEQNB$3AEWP)6X(+.'.\FSM6NR\9;'\W%T*$S7
MS46[O= O9'?C5>?AJ#P7GKD;:ALZT!OC'W(AYERO>VG64EY\P@'>(S[D86?-
MGD[1U-MK;LM4IN69ALWI@$^&EAYS]%A(&YI9S[\O/;MK^33L)0@B[7 A_!,8
MZG7M89]3MWQ)YQ_3W@Z-%IOKK2@6=I7JOT^7DK:W*>-NM=F@ZU+Z4 EHM952
M)4U>F-OP+LS_H."X+8&Q:O@_ E$FS$C=,(XX J*&+COO)FIS6ZS']UQBY*W"
MT+38F:;C-U$,3+Q>&0[:"@(#O:M(OK?224(9*'NR8*,A$")F/M8<"!>/V750
M.I9B\:9I+[?5^JR"-Z^=H.Q2KD\OY&_OIO(]I5'B5(;)P='# Q^%L"([010=
M=WE]:D&M"(M(N+7,A,^5 !P?G6[:NUE]7[.Z#2&$(LI%::#S<JI _J/JR3CK
MT9Q[=K']<$#WV@&]*K$0&@(E0R H<R@CS^&4<%_JVX,X"^8%$/@0B:"[N7X/
M<SU0JV%P*J L..FG+_N^73$\E5L'J%8J7$,T?JP ?,B:6N\NWQ[%[!,)HNLZ
MQLQY@-9V&EOX@IZQZW1$[SNOV"'4+JE"J#Y/ K[$A0'$"U99N4X9^49M(=NC
M;-\M$3%QB,6N(82G,AH#4R7E2R-KB=F,L4;3B6P9AD/H>:XU(N,GFI>3%J<X
M3N Z1&HMTIO@&<'C(^O&.#?YU,!4+#(^R/? <P]#>-A6B@-GR1L<<LDC%D(#
MIZRPDXY;#W - Q<B=L0PCJU'E:[X2@>$]!)G\A18.)IXJ>8-;8_*"R3)N>MG
M-MWD4!RA6:KH_X)%9Y2AFLZ3RY3]^@SIK4DF*_!9#$;DF)Z1($_R3)(-B[KG
M4U8/W[VCQ'ZNX2 %U28EPO!Q@O^O>#\P*_2*VPU@583+E## J=)QAIWH5B2D
M7Y]722^&-)%3DT0FA4+(9![/(BVXIH/H-1?C7%W07KVLUY!;C%1ZT@:''^\O
MGBC9(G4'L8/JNT=HOE-:*&Z_P*KXY&$L7][!6#[P]K'<8L+$0&)IQ%3G=-8D
M:>A9)J//"+HW1RW/$5^R\>XO7I&1B[QDRA/AU2.U#,0X2<[I80\NX4U!AX53
MG[RUJ6SVK&$-3KNR6E@UFZ!.I\Q NV:*V_#,M&[24E,,,4BK,H4"]-S7#IIE
M"V=3BX$K" .K@Q#TR3N;7[1T"@G<0\NP@E$_H(X_L(N]-5;>LW-?(7;9XS3"
M%@1VLG68.8P;GDXEWH64O= @FUFW)N4V'556BG5GEC1'0(G=>M1BPRB31/'
M\R&TS8^P(X[D\:+5.E^BX^1KYNW!8>@ TF*AB]C"O4S.7%YRDZ.$4]'<AYS)
M.;O#W#7-TS-M@;0Z(LDMRT]<Q0G3OK3HP;?OH\\^\BZL!<0H=;%5TH?@ @/O
M6CZ0'DLCGTX=FBR<')5PTXPPS5WP28;].*5,6]L11^6\FTI<HSDG?6X>;TMR
M^:=TG*[C\B4N-@MR^ 89P?$K"&/,YW@-7)C6"'OG6)9. CBBG/G&R\J9!*PF
M+^H5?<8HE1<6SP7=5F1&PM:/W$-L8WS$'ZS+7QT_BA-+X0K6N"$L-G&=NH_\
MC@Q/&"&A$W(W);G %?5.2/8I@E08;8%7WY='*=?XHD\ZFNC%"N] .K_UKD1?
MK4R4=>2Z4:H]DUSX8G6IPK'H@B?[%QZ9:0[>:5BD3!S"P=W^8"<%C"D?O<LC
M[V;$='Z9 &MH,L'3M>+,8H+E><8]_**3<O9.#\M!!AUJS!)!MI..[IC94YF4
M\'0[#B&)(+2BT)RX4RDG"*LE1-5@!>&&"5[[)"AP7F[)L)I4%O\Y_+H[DV8T
M[>.+R) G\XZ^%PJ*.V*$%=&DQWBOKZ.UX\T':ZV783?$^OIF[]N'P>^Y*^Y(
M(D/CCV59$(S]51VE(F][KHESN;_X*7IL2!74C?U[WN0DR0@EQE4B+:143C@[
ML10L/D9D"5:&!()&,#7VJ6!-1F)FI#5*BMZ0]X$VUS*O-*]HW+0E@LJI_PB1
MN\2_-IQFTWY&-BCCK)B>Z\GI<(WSY-IS>CL.5$8GR$+QW:VY<.+JF'U[C+VI
M4*<0 5O]HMP(_HOUFU(6%+MIZ(@-U2,R#B+SU'I6Y*P0F-R6=RI9/E4&RQ'(
MWE\\#T_0 D!4A7A;*7"YG7;V)2/ITXZ(;#B?R7?3DWU?UFP(:_ ]A773<S((
M'X4#*0[B!6ILRG+N 5!1%CAAY::#%WKU ]O7X-52CMG1$1;2]3:&PD44PS/A
M4LT=N4G>Q?J,B49IR=! \9XLQ6C]Z+ KJD@>XU*WVW;@G@Y'3=G@)$X-;6?\
MX4CRE"H7IN0-@HRUJ=5#-I*Z5 =!/"I[%&P"8XUDS2W!7-R.0T=Y]W(;CMXU
M@<!X+7."'BX$JZSH"[%@3QM6:B>LRU2I4*Z1<!JSIQ=)OK2&<'_Q8V4G*OV9
MKVLV.I@9Y6PG(6I:W_%(AL5;"HF 6//PT=..HX3%<.E<[__RZ.NW9*'?&FZ*
M:)IY@5(<RK@N8[PR]O&-//M(T<)TE(YF4-HM9=1E-.7=N>J11?6]GCHV;8A9
M&^[W!P7Z<S@8Y(SH/A5*<^#Q>/B3*(OR +(\#B UIK3Z*&LKO$SWP0B2 "3"
M6.Y -":6_CH'%B]G# Y$,N(LW2,N+M98&,^,NCUF/F>K/IXI)O(RYQEC)KIB
MQ234+(DK3/FE"&BKCH(_"I/ !A>&VO V1T1S:^H(+RSII.-!RW\@:LN2*#=Z
M%,]YN#G'-B@%-(&U6 ^,B5'KI 1IWD<>G)BMZ=&.D1F^);G_X&"ROE1C"M=&
M +N?#"V(Y]7@.&(>U9HX"=H\'X)1G$A1 ,Y/YZX^!N(!Y>#&HPCNSF:!8;XS
M9=5D"IYYQ%[B)*Z)"7'MH.2Z6%;;LM8RYWR5U&XK*AUU\\O0)36\D^L+2JAE
MM]Y*\G%'[ 5* P_7(#@^5-$JW.#+DSGEY+KY\QV(XSV .-:5:B(XDKR91)2?
M_,R:NT-0O1<$%?(99FM'-N-NC-_'&#/I:GG)9:-\"R=@Z<'@%K[73;.L7OVG
M5+;P)8!OR_:M,86772/U(68A%;%"NA!OLS38G)_<3Z6"^]5=!?=N[Y[>NP2%
M&AAK5C5=2RF*M.K)V>EZ7TK<F6[V$Q^^LZWOI1G;Y> XE0+<&EQ.+E1NA2O[
M4)_!%MZ-^_MI@H_N]HXX&)&)"D?0FC6LLGM#>1;OIN!]3,&VY9!&:O%W@_H^
M!A7AY5&9IKMJ/QQB_ZHW-J;!226\,N)@[Z;A?4R#YG<CV#B*!Y8,P$:ZD9C!
M4\V;!6C4JK/C7>?%S?1.G<*1Y)-#MZ.T]WA+RA%GY_ST7%+.).: \@">0W/;
MCHN82Z6:YK8Z#V5^?<[3#Q*R5U9^5N8&TR>XS@,0%N6R$FD^+BIE4G\NM\=?
MOG8?.-7!)O>L>WU( #!BA3R^2UHYMC'-O0"J?6A(QL=9D8&K@HV"0_RX,@Z!
M*S-Q:*R'MNSJOLKEA:])Y/[EPW\'(G>JSCSS5= 74@6])06'$^+1'O=!;B4W
M$Y ZC*4[:"T[M9BR<34BECPX> U+5-0G%U*I9%KNG-G6*FY8\LNN+=>%PBW1
M+4BE*64%X/(3U_.]O9Q[**W8T\/1"N(-#$>DCSWSS@R?P&*<>GDMR^[V)15&
MBRG]MN\1":]5^=X=%0GA%-8MJ;W\-.1X\@73V'M0XY@M=WZY130A@0NZNM*^
M4UT[6?:,^"TO>IVRAH@5MFO.3"0,;5]5;Z3P>D A<_1=(TQ8'A<D@XJB.S__
MWFD^7?&L5'+IUTK Y4I2=+NF)2R3/:06]7+G"(G]4)5^R[4MND!8276/O&1X
M9J?HZWO2HK;2AG>&(#KT);T*)>^^2L^1N"W#S?XUU*LW5)(:^-5%XK&#\&*R
M9;#WA*%II]( 0[^HPDMI2UA6J&>T.R)NQMF79.0)%7794(///6E@8U!_E73B
M61DJ&*+@\:[E4C,3QR<G3YTBYFVYW2*HE3/(?;5B<(Y2,UW!SW+*JFUJ0?WH
M=2MX:+'%D= F55]+2UMFTD[Y*WB0+7 I#:#&^/1VJ[)A  69=IC1_W!AEF>;
M%_GF*/=FS@B8!]L+"GIB]))G41H.U,8>>U!J6OHMQ.R<19L<=7ZM6B](W:V&
M70^)!2ZX2L>FB;YUZ'=P6%^AC \[M^3F6C$Z?KC%V<P,+"-%G:\8=TTO/7"L
M;FL&4<=/-XVT&R3$8Z]C@[/@SF7S )3BY]4M%EL;##^I&O#OK'F*96YIM9$*
M=7/0)E-2F2?^&O(&JSY.U[OU*?Z^-I_3($L%^#"G:<M-Q$]S PAY)F$!GH=+
M$R*I$46_0CNT>J%M>$M]AT(:M1'YO'\-A'50T?OSDE4$1!Q*F-N6JFVLO3%4
MXA^@N:KYWE&S-U-&7&)F)K;1%H _3K'&>P5@]"3I*6T/(IRNE\L@M!+BJ:<#
M^=^E;3X24=1J7^^6NF,IV54A*%WSU;4O0F_%*(]ENSXR0!1 L?0@H#L0"O/^
MX@4)2#J%1V#E:#M%FJ\>?BV42L/M"0A%9S0#RK8EM;51]PT7)'F&W$4* 93]
M1M>"G/W#<4]K:2LS8<J7+-+^X&O*-Q_.M2^.[4LAUI?-%D"DP$"+Y7V=4!P(
M2H4X>1*=R3#DE^?"'ZH4 R046G?]@:W2&_X--1DU_," BD3I/%*R7^MASO1;
M8IGBD0T6&=$<G3.!>BJDS\#W%6<&IQCW1TRB%J&WB<\YZE3#2_0DJD?*/8B!
MBL5%"!W6X&$08Z?K, UAZ'-#I%[EF\L>H>D;[W5&">H;NT[CW&+1_1?]'1VU
M907$*GL_C%KUF]29)8<;*1CBVC((7MQ\C#!?P<<UIH#.6D\"UDR9 +S+-^?P
M4@^'B-01?T2M,'ZWZ\5#(VU0HH_2.1M_Z-H!!))M-30D^!#*3!'NV91=UUZF
M@:^;1><-?/+8@*\_>6S Q_="HD<:6Y%=$VR9=G:%LUQ,&GTH1)6].II=35YX
M=] S/-U1+V(\_YHD)REV6_Q$>9[*.I?^^>K%ZY_TD%%G@A.U8=J)6XINB]BD
M(CO7*XX>9!G&84FGQ%ZW /4K -2,G[N*_ 2!8A59LMR;R[_EAQ_O!I/I5!X_
MW.QS,SP:E0_W6*M=^N.M6<#]R8U]TGB'4YFS@7P2A^.3JBL/OOIV='BUB9G6
M7V[D0*#DA:'&M0^PU)@?4EA@E+.55[A'8C] /5+)47"-*S'&LL)P$H?'**9'
M;,&RZ%/>H9/Y/P^EE-,<>;UU'=QIU05?#!3CB7ZVM@: <*C@A@H]DB>TB*ZG
M9I$H["58>+TT\6S7VA7I&QC<:XZ<=DG6DJ5=$[%[EXB#.,]'NC;1M>'/OEGG
ME/QN(*#AM]5*(+&&*5E7+J 1A\"8A9HS'37&K\/+*R+9U'@<5!4R_"'E GQW
M3J&/;IA_RKBZ-,0C7Q=-RV W "MIG_=W=\)&Q2X9VE(/@*=#5KH'Z1[/LF8/
M[B^>NL;]ZSS(:-*I:%SV,;-@33CH5L.?$><+MQDYX^C'EI[@07*V@'*&@"ZL
M!:*.BNNP,&_29R#5I=Q7R>I)5.ASM_!>I_$0LEOM+R\'I.7ND;QAE_::D<G2
M:K;T?*X>D:B0>;_7&Q:,6-,V]]P&YT3);5G6KUU8)!S-O'RD^K-J:2%SQI%;
M6_#:$I2=U_M)+(5.@R2:BI6<:ZS;R)PL)UI4@ UVJC-4%6<%-N@7>Y=X^_[B
ME8AJ\]5'/0\+A1A5;_F]Y8TVQ 5/>;96.J9B>(5'D?X)#MDXYH!UM8-MS7Q?
M6PKJ;7@H19(-UY1:@@PS]PF-"V$',K@N;AMZ T*G 5R^QI:OKQ2\1^A^:*4<
MNERDEH;=)^IN]Q=_)1*<$=T!"%>L1U'I\Y-&5FWYX09;Z^957VB#)M0<NXFN
M(7U$>G\F7+<>"^:KJ=[NB=Q(<L9TNIZW';D%G&(9?XG;"3V;^RB]<%VK3/V1
MFW9;MS[OEI@_US4;TW!8C=2J?")2OU95]=:TWKF$PBB+(/_$KMYW85085\$^
MS%49@7 Y2=,*"^CR*&5A]9S3UDY?8?Q5GLM'+P1+K"?\@I[K3HG#!'>#/FI-
M85FC(B.,^^#)D61)Y/5(ZAK.9T^+1I(\%8.G=!  *T<MH[2^%TYY+]CQX,MB
M\?"S!P\X@_>/JCP_WGNUHXWRF!K;5F5PFR\PM8]7!PM>D\_1[R_+'EA&[<<.
MBXDEMD>?C(Z;%\5.(->R,,-%T@,G+E/5 EC9&N;=BZW>1^XJ1QUR61[S(]A-
MZC+69B]?U_NZ]/]KC=_5K%9KF$S/GB6&>A5"LHY?1U@91]*L8OLG(\J/8JRJ
ML1OQHO)CY!+_8\+BV<LFRLE%S ;?4\<C[*Q[2 ;'$:7"R J%"DUP$K;A.0J&
MLH8^#S9;B0.(/Z>.7LXV>-[AT"T/D=W+47^-UTADH)5N)6FBCILA%K],AB9W
M(;PL627C\?X=;TS$X3%J>9<F<T.J(A>>:PC_GM5Q=BA8H'5K5%"14 G=*'"U
M:&?0X7;8BFPP)[W(=(.%18[V= 44W(N<36 I=2&MJ?8-!]2IU \\M."9'+ 7
M@=G0?886#&%*(G\.!B<II?#:7:0[!GF]'2&IA58D7C=U+&5&_*C<EA#CL3%2
MTJ8SAJY7 PFO5(LGY-53K7/1#5OFWX#B.IHI> A0W!H50B.S%I-*:.!2"8H$
M@ <+9C@\XW7>0\Z"?73=-E8:F+JXD3:(R!UX$Z8P 117JO)-U>CE8B9-(Y7@
M$':]OT(?5I&F V0WB@B0\+7M@^,<Z\$#2 "=,54208J(L F/U8%7X:KNN;Q3
MKM<=;-"S<0)70:S.K!P5DT6MXXISFL+"1B <3NN [QAU[:5KK*WX6*:9!34]
MZIF3VQD$+''9S.2TB$L%DGA;5OQWE=;^PDCPA- <AHW]I&W.:$[D4*O66.<R
MC6J4)?-N=787!>$Z?$['8JHQ4#!3<9B:H2'FMA#Q8MV"*K8T\29>JC/SB\ J
M5L_0 \@R3!#GB2PVXR2C@WA[0M!DG61P"6. 0'_L@^-'Y[(6V) 0P^YM#GJY
MPY%W:SCOF_4NWAV9-$H64[_OT$E4I >B48LJ H->_9.O^GUS5_5[^*%)G9O4
M%(:5G '*L.F$IZ^NX'I\"A)Y(C&-67*5T5Y9LW$BFY39_,G&C6T&C*)N._+T
M#7/^CE"OCY]<,.;#2:W2^'U\^-\E1M"GT*.MW*3UMB)6[&98V;P7O:PBLK/(
MR>X-342^WY*\PY-1GEY]L&QD\5N&$J3?0(;@$\[3@YJ?4 "2 ./05W,4W_ 7
MDR^SXVWSQ+'!5;/DCEV&?HO[3DT=?1C(@U$!A4>'CN3:[FI]%!* &'+3"IYR
M"7E7C8,B$16EM,^,W?4ROI#PFEF&):TT-C..<@R-"JA#D9_.36XKIHD%)MAR
M\<@O3@K/W#6%+#C/Q]7);QK40S=4;E5(^;K7\63OG04;NVI#S%N:%$<\SJ5R
MUF>-V7%FDXJI:BU\213/JKR>GDE6I"HJH[-M=)$Z>NE)O3Q6%+AARRKA/N#D
MZ1X."6OW*&-91LXL 83%FD*1J2@D0"O*^\A0Q0KB935BO.9EE=@V/]^ %5*?
M.]'*5VMKYTLZ@U"6:WJ*O(?>3@:JIMPBW9A12Z(BK+-F)X.[YDBN9S#NBE6Z
ML@S&(H4T_;U7XMD>/=Z>!9(<M/Y6' */D_P)Z.Q;I+:R1V(D.!T!0,RYC[X'
MF$BU>T'"QY&TLJ<_1BN"V/WX/5JF#&88>F]NN%HWTY"$*JE_K2P4A3I;3B(T
M^53I*Z>$G!Y)VHB5 OU'^E8D(& ?X :Y\YGU^EY78G$C6<#;$=Y3=MW)D%!'
MQ2I,6^P9\!B?_%Q(@HAZ8]*F*E&'4E)D1>)X_YNU%Y4;GPZ!5A3+C=C0* 18
MHIN:6!P][[)B%@%41YDZ0!P,74AD9E8L_W+M=_$=WN@2H815TF!4'@YXO0OD
M*-J./G!*YC>IM3T?O;4;')@57H%9W @+PX5]OAXJ,17!&=H2)3V11C-7/.W%
M<T^^T-EP6FNYMR_C)E?)W"<:W/FN\'$/ZWY+N#1LW*8Z:P^UR]$'%Z*F746G
MM$U(->K/R$_+N#+@A($RS(-^]K3!4NYX:T[OUQ-5/U%3JZ35Q@,F)[XR2T4X
MG!XMDE,KGJ,6X=*,=1&SY1;AN]S;U8:2"P,B:O]K.JD^^IE_1><Q.)I=_L'2
MWPO7!,3-I@H\1!#(XHRT_T:,YM>4G\1VZLW 3$]V[4N> #:KY/,QMY_KN6-9
M$;9^4C3(K2 7#TBBY<H^,Y$Q83>3(DHBJ>V3:NU%@L=FKGJ'"S;G/OI9OA0V
M 6330]R!LO]+%<K<R$IM,9;_ #8SF'O:LD+J8*(4&:]0-]:*-X*GW0X?*,V@
MJ1\L^ M%%V,[%9I#9%M7=O7($J= <2Y Z=J<]39F" 0BWCMNIOGU/MN,0,]T
MM_*OL_*%D3\Y=26?D,FF^625J2U,BDIME]:4Q.\5!;IQ2>EQ_Z[V4VF#@&!I
M.]<<W562F2S$S2*"<,F]GZ;MIF<\(P-,-#SP:JUNGZ8D$R3EM./BM5=;F?8*
M],[/8)=%,/9H/Z0D327]G<(TWIJOT0-7L8L:M:[1=M3-H'\!-M-Z<$>T[$,O
MT:/[ZCR=TE\JYL?/@5$HMWJ@1E/ B;BZ3V5JF@E!Z1DHV-[V1#^ID[??:CR4
MIY*X:D9UZB:%R_&2/U4=9_>/YH/O-T2 3>)[Z,W$14KZ]D\<"Y](G?*;S^[J
ME!_]U(_T5!L*+1DAQ8EB8O[E%BO%YHI+PX@3J4,DB3-+ZI^.LBZK6"5[]_R8
MDSZM?*M'F2BNGW ?'(0OSZUBA$G'^'B62'F'A&YB8JJ8JT='_/AFL?O*&K@H
ML]DV][1QH8H YW PC1E\(/7#@9EG>4@,DF'7D1]%.L/NQ-0@WK5:'G4E4&('
M\=H*\,4Q3IU3%C&^RB5)1Z-QF=QY *[>I "-BW==[L+V3^*;<'K1Q^0OG*L+
MAJ]KJJ.U1&XJ,KZCE1V>'K$Z03TY4Z-K>&TU+TJ];FH!^HS.>:WD<4O4, /9
MG]< X7(SYZ9Y&'O),B295 .>CA*R>NAOCSGA^"=.AB2\-5XTH:2J1#W+LT]Y
MQBGX!=0KV).X128:3M,=VI!@!+*"K1WEA6]-HHG-H%(7(84G>#9D_I=;"69Z
M;1U=347GY_("4C;B3PJ!1->5LJYZ17DD52?;'MNVKY)\;%HSD3CIEN63?N9]
M:=8<])B5J61UW'$9;6YY%F(Y;$*,U7^7RCDEG3:]M=K 1Z/M7DIB]&3(J37-
M%R]_>OWX2?!8NS,46 $3J0GH%R(4OE1R?+PF;.3TX6A::*;7=5@N&H]>E5\&
MT19-'I]?]3:\/-6.I7<YA+'ML=QR+4TI1V,NPJ_,<+&A5Q&C:RQE;U69)0[E
M@Q!_UYNZ\L_"N,^"!]YR\Y:VQGDCK>05 T?C6::%,3:;!B8<G;BY/"#'(I()
M'&G#(B>7@*OS$PW$Q+W$G?AOE4MD:KJ580NJL%XX[X=^PK HVQ5O\Y76\YP1
MECSOUN1B$RM.&$50G3%[4DDBAW7%F5"5O(SB3]OZ#5VH$KP+[8B8VD_K4M>T
M(#',9K095F9L(YNNFMN1HWJ="OT(\M[;X]B8'N>]E]D3K@("?Q%F#JO5<6,Q
M()N#--O4400RI0X(.Z!FL4JM\%0 V[%,;2,&S%T&<P0!KTUYT7:IP^B5YF#Q
MKWPLOWE3?J]X..2W1-LEMNQQ[%Z@/-!9ZV LU_!UC#QTTKCY[M7DB7 A&[K?
MK#KXT9?M"*W/E9&64TMO^AF5UW$5-D)7?"9"V+?1C-:#'HU7/*^:F16 7M8Q
M0:EC3)3<6 <F\1U5+/>T6FO-9Q%UFG*PI= P>IR#\I1YRQC7IU9LXM/.HD=<
MR,2U/#[.:AR"S"S _4LHVSFCQF\?'\WOG&#>S[$HTR<7"3>YV+ G;HYRYSZ0
M.U&YI#B],V8X[GW4YL5=,XUC2S'Y\J]Z>'YP(GM)SP^.@-A=?EG%XQ<P%W&F
M)KJ?\W3.)S)F4/)-8H_;T[8A/6COPOKI>@M X%DUYG(EK74;77MNE:T%+7;E
MPL;5:'%?GE>"YN 'P]2Z- D?/!$FL&HGC8EQA:(>.EFXA4N>BM<57N-P'A9
M,+4C=L>X?.$FF1L'!VRFZW"4@<WL $(9&A&J6:$-[L&#@;N=2X-=G)GSMHT9
M9@+)!H>+.4/,T[(LPM@AJU0M8()?3<G8K1>WB(RM;K9_Q?QZ1KY;$P'_G",G
M4PZ,,9<UUX,,:X%&HK" VF-5]8SV#8=&*7RW#3!"8F-/)"?FP!DP?7@2.!WH
MNSNO]UPWX;-1>MS*WH!Z,[CRVQ(>\VA2A:L. >Y \A=H0:W0/!XBM7;H*6+@
M08?>]M#4M %$D#C""=A#2XMIE):;X;P=.Y8^O4A?:P^2/7)_0"(1TTJ=+(#
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MWMH(FL.K(L^<&&!STJ;@>?9J.*.=WU>R6M$,XD8?TG\)G19WU&KOG%'1QCE
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M0]YD5"F(I7B0=_=U9U3>G/HRR8:I=C'6>)G9$#.RHGW8],21W$_Q8O#D#?7
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M(P,HGDBEC% 0M><D3I]AY/*C=T/'(PZ;MZ(G:=-/69[N.L_AW1Y7<+AJCCB
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MMP1_.K N]ODE0LKJL+K_Q\5EV.V1]"AZ-%_B@/H<KMC?AF"V']F)17G.< J
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MX^+^"QF4PWG7#F?G.&/+_;%8?%^&07S=!4<1D_""DF2TS%\BIBG2&^4&MH#
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M.)T'KXP55CQ[1NE3$YMVC"L^0G-GNDC_35Q9IGTE5Y;ZN1$ZEI0L(YQ;4UX
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M"0_^(R5E)!>IMZ/S#>3\2=7D)?=8/6F:M\%T)YDA<DQ88M5U?$TM@LFWC&E
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M]BZ]Y'>2R</2L7.2U]3AH #H\=:(?1N@)Z'(.6%(S0%,V);&[G6:+LM7VGK
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M'E<^1OAH>O#PX(EKX4V*!=0@$[-D]$O3IITJNAC-)#X1 J8-X4S#A@V;F'/
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MZQ&I,&K1G?, \$SC*2X"-AO"'VWK4K5Q?P="2Q EIW^#2%&8[*)5J2F6"U+
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MZ7Q[.45*172 SR6F*CC3N1-*OA18!W+4Y)8[$:SB5&.5W_F##ENA(9"^S_B
MPZ)SDJ5)^Y6P02RT)GJCI>.%&&1CQL-(T DKND^4QH4"@C,M"2V8';M-I!!C
MLFYJO&7@@9 _(;C(2:?V32,X#43,3!E<7R53,UYINI[B8]NX8W59"VDF^#?J
M\[)N.YDY[F'>V02=6/9FYZ1=US+;N&(0>H(ET(E8/9>E(T=76C.X\L;\_#>
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MKVB'T ";OIES\AR]ZO1Q8F?/%%3O?I9N<6=$SV#;&NJ/DL64U@3SA]'HY N
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M73%X;CF%=RT6K*1+;8<T>J=DN=QCY![^ZC%RGWK3?IB)&FU7;Z9&TGO>]R&
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MNU8N_5*TQZPQ<!/'RS$D&Z&W)%3PV#'EQ[>;%TCIX!$;JAD-=!A6*G36364
MX<VUQ1QT:^$SG78_##,Y(]7OM%',U'DFA1\IXQ8NOJ$!ICA*?% 2CK3[08C%
MGM&+HQ7YVIS..$Y =K=;9A-/%D>8X-O:;8SJ?8L&\Y&.'49VQX4'KS.EA7D\
MT98X?,M[A_-6CF!5TV#1$20:66-D8JDBF\?G:PU] DED$NX8W^2-E*QM1"T$
M42>B*:)%OG=;;P>94FGAP_&P1*T8\'39/(AN,VS_DB=O?H4D:Y6JN4WXNO>S
M=0NS%8\KH9"</B5)J%2,;IP\T2JZGYU/8P-9_@?JVE'SCIWLP:D&+''3$62?
M'6F6F<UA[\AU2QPIJ()QCW%-PA)KB5XZ$RJ[G]Z/A>EG..70M;5NV'5PE6(O
M/E7$R(]>;J$S6U7$53R>1RTBG9?SL+4'8@3)K@Z_NVPIZ\AZ/F%&[B?V%JTJ
M%5D0HU "<VK#W8_V[7@<ZF?LBF2H(DQ=%[.OYE5>OPW^1K%X^Q4%'ZN"^!DT
MK/(576H4Y$X-JJ UV\$&M62\!*&@7+YHF.ZE*L.^UE31D@1.J>3L!.G0WA&\
M5LBEMFIGTQ@O8ASF5-;FRH 5QX,9$.Q-B,B(I6(3XDF%WC!/-+X+>1: N:DB
M)=!%JNS'7#FEW2.7\NR\Z;@3E['>(5[W"LT2L,',Q##>@PV8/H3P"Q@C[K+<
M=8S<@[5N_2@IDJH+6);$W--$][.JR,.A\BW7>YERNS<P,55:1K5B7810+ZL*
M41WH@ 7)"28NG+\%E7(WQ4*D(&/8KZF(<XA7TJ<Y:717L&$OFK;@3@A-F5P:
M][TJI0$3IRE.8Y=AMAO> Z).X ;EM=3-C@X>Z&18DO0G04^>N)3;7_)+-5)Z
MOG>1IT9J^HS^?Z>-MH?3A7TV56(+X,A3=DY$[#B%3?\ >F K!4BO[HS0&F)"
M,U2'E>G9M)Y=ZBW&%!@"?EHQ+\L/?EJ2_  =*&>@**48GUG2[ETT/N",IBR9
M(!<YS+DSF?;G*P^W:EJ/H66X(*D!D,W=;.=5V9U'S43>E,SA/:<#+$4E,8(1
M56 ^'"EKOA1]4I :!4O!'"Z;L!@:L&[EK;*ZZ&38CY)V%!D%F3:0^2> Q3N"
MLGG#2YBE*"(EPA1W1<HG(#U54;92YT 2P3)[T]!/FT2>L"VWAZ9*%PE.U;Y(
MFY_YUTGIX$/GDP!V"0O+NEFJ0N2DJH4^E\Q\Y&C0=74/LGET#[+YQ'N6E1B4
MEG *EUU6IH(^A<R.".RA50, 5\"X9LC"5D2FN>4B@^D@VZ9<0"4!VS)G>DC>
MT?H@T62SB6B@-\N=_JUPU+'QK BE0Y[#/('N1F0IVRA#I=+?MZURU\4RCW^G
MIAT::L!C^>7NSO&8TH310+J\<=\0OM"[$E)6 _5? TI,H9SA$<QN5$C3(RU8
MPQ0D%6O0B3DMZ92&/Q5,Z1TY 5^$./!]D%#-+$+_)$;*U([3<E/;3'0^J+\4
M"$\JU2CO*2)/C]*.98+=U4_KYJ+-LXAM1#0A:,Y(;\FU6J&F%55T]$MNU#5U
M$XXS>A@RB1C4Z-F8>I8!\93@P6\5.A<\6]4_>6]5]FX$04::FNRWT:A84ZIK
M&/#+I]DD8L18)YJ!(56Z7G 8:4'\DOM%Q+&)_>9RM6SGI0Q?X#H0?/]"4Q/N
M'P5N6(+1:F/L"EKC0\#2"VM1W7&DL:GR6OBGBG<DU\+.%EA-Z67964-Y\E]\
MU"B111L&NJR]P2;IUWC0ZFJ,VO9G0.[T9KA_2* >[F!(]@R#&ABU  6NLA]4
MT[GC EM 1LB-;SJ+R%Y# Q;@4'"L1I $"9L5Q7KFI'I4O5>MQ0X[''G@J"-0
MI=MS.78'AYR"?'A 1AMTTLO_T(/Q2]BL HRH!&=%I)50 Q.2W-GK'T_"^(>U
M1R$"96[.BVI%SH>08S8B2K@6-;]GP<.?O=Y[(!X&RKR=S'ZS(E0HRY97E5RD
MH.@^78JCC.NRF/?)(E\6\/#!["P&%=M#99(O07C=2_$1:XG.;_K_T*\GFT0/
ME/AE*TA]4BL/3[)(8Q=$D\T5:/ NK]$P(2< +DEF+:]NBLN[P:Q_)I7CY_7L
M>'M&Q:2C@Z-#%MNL>8)@]<(#_LA[]RG-?CGGXOLQ$;=A_K%J3DNB"W\=QHY8
M ?\C7V]^(#)*0F?!>B5_9WMU$N8C_.59V?_SC-)92_O:/K["?P>D/3\3J20W
MC;S4+L55^_2ZR8?9PX??9T??/IJZ]6>:2^<:#=VBO-\+2W=/[)FM>VTV$\F-
M&K8.++ J#^':<W[SX/'^P7_\/X>/#WY8$T2MJ?=O<]R//BS(_ +&.^R=GT,$
M!S<G[)X'G-M=L^J >C%,:Q3,Q@=OH[A+=BQ].JL&]G5D^RAJ:2%!SOU9O).V
M&Q'[=0Y3.MF??D?]YNCQT?YWR?KZ@N9:?:ED8[G3+#J#-SPW=YU)4KM+-JQ6
M[VS?[L^>;EO%6E*N?<:+[M//VM-B@0W \_8@G"!A)WQ)1C%$E*27P<N?]J9U
M2LCN5-IJWA^R'[-9W:@Y16>A5'QYFED903][1QR_U^HJ^[#:Z1A?$U='5=+H
MOT^A1CYT$WA =K(?PA6^2G; 5[;VE>DM1D4 9SN<M12TAT]W5Q)7?RO&3?W2
MM>ZB:^Y:SV-?K&L7IPH\JG^<!UFH(Z:X? >(QIWFAAE;<CQ#==]DF>B)0B$K
MJ:8[K<LR^. E0E)AAM6RIU0X\2$GG7,G,ES'4\-W64S,@^AVY N5]$G4W87=
MT(+8<HF"'%^&YP@!?:%WX83!Z[R=YW71[;U\5Q57L^,%9O?HX. (JS[],^<E
MGS;+Y=ZSEC L?Z-:_>N^I5SVJX+*+^Q*D.(ER0>=BO0*^1\+26M692<)<8<=
M#/>DI_DY[Y;Y/V8_5<T\+(770$?/7K GZ522HN*-LQ+MMBI&&DEC!3C2/=I6
M9_"5I%(6@M",11N*&1&A-<A_^Z>KTQD:2+*2<4<.W>P]],^+6OG"HXJ-4XF$
MQH$G91 YGQLL[)?C7CRA;U4&4=U9^80)Q@FD?AN2+--[;'\6(0>[%^3H/>Q2
MDW:#;[ACKB2YM.L#G$-80^6Z61=>5Y,I!,)+[4%M=:V[@Y[A[DB9G;J#26$9
M#P\> J4QV(BT-^,G#.KAC>MJV]8HXZKRFYRC;N6(D,E05&J&&JYG $1%HSZ#
M@G:^."^+BV35(*28>A[6NC4 1 .(!1E^:<W#)!47>;55#8X;/XO7$(S[QS'U
MS,.>D 7 :^&<T*KU&=[CN7!'<?D9SXL#JBX$6N2.Q"5T5/HBWLT1L!AFK3)E
M7\HT$V#:"_^R+EA+1?<MX+,%Z9@4@HVC#"X./6H2$1H-':'[(O;C7WT1^Y.K
M*2%"609C0I*<Z+J\X:[,XLX)X>J&8:]KP*#LNV('F!76)=JS</JBN[F(F02I
M84@KKIZ1U)VX9<D]<4%UNT@Z),KFY?I ?*HGQH.?2TF=89M6S0>9PZ=%MRG%
M<@EKL31& O_EE-S,P+"PG;+"$'T$:79'+?*;&T#J'S//(N^B\0^&WAEC8 3H
M %>-/Y\#4('W\('\;8U9R:B\,JII3*H8,O6O(7S"[EOX@N8(&<##[JZ.&A3S
MS4IU9J%'!%(@PLVC7U^R0<Y-9H=8&>F]X+D(["F<20)0L !3V^8+[ZI8;-AI
MGNN6).^_@,CNY?L:IZ6IIXO5YI/PHG#13L[I3&\-W@6^6/J'P4(UE&/X"N3(
M+E"TDD;E,7.*"1/,B_X28CM19"N)G&?O?7*M'8[?0,7-EJ6L*^H#[TU1?4!_
M*SCEL#+8%Y]Z$<'1N3Y E8RIR,-W6G*YXEM62D07 HF.E2J7@DQ]'8,5B;,.
MOW_P@.L.G,K5JN?BO)$Z/3_+J,N;>SMVJ4IY>3.(J$*I4EK39W\/40LV0'Q/
MFQZ%VDK]T7%Y14:U* 4:DS7)%-Z)N/OC[I"RV[DY: 6YXKJLED04;S;'Z1>%
M!HO@NJY8WDY7EUMYY/50;3^LEG*Y#5,;GFRY)?MW&1L?)J=2D@=^0H=]Z9*)
M!ON!QULZOHK)AP*MH2-/M/W@LV\W 9NS9F.L1MSH.W0NT MX:FL:S0^;QFPF
M\[7[_29>ZKVD%0JGO5*!V"% WUP H=$B[R98-(+[_3+S:'#URT*;[("')VO$
M] \PA9Y#BX[U2@3:=?UF'VYF.PJZ,KW#:ALBL+ <H*?=4[I"^,;F$'[/]%"Y
M:T:9RF-LDG._.R)]9S3(\]:O'YCF@4'F1LQMVOU,?LNR<U;\@\WVQ%X?&V\-
MGU,B%7X:$T'VFUK.\%]^Q_W9<5QFA%TDZAQ>4D:T2._.X;J-^8W881A6$1R^
MF#"$7G1!*N.+(F? %3/U",VO0+PX:QHKEIK+ZII%"3<2(XY5"&8E)Q^+)^M'
MO/K9^U5)$_G1";[6_=G/18DK6R+MFC7)WJQ<GB=.CQ52M.<A8$'HZ#"W?'!
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MMR4J.^*PE34_"QRE*$:F538^R.%2$0*$:^1*#+:)*!]M7/&78[IT3A5$D1'
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MC BJ=5R5.8*X)X:?!_=*?)8D&1U??T?.HFDGD]6C_?:ZL):3C](\LC.'NKL
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M9)#\3RDHUS*IL\PB([;H,V*..&+8]@UM<UZ@)/=V1HT#%1?7Y'JL+JA3N]T
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M3S]NRTD-)4Z5BQK1LBDZI>!%9\B\J(L5$WVP[C'I)9+$310#.R\JY#+KAF1
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MUO*7L/P&'[FZA'_,BIQDKCD@_ *$ZJ,."6P&_3LTTQ45;&R6K_%2W6 [<!H
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M>IZ_%?K9G'RJ,L&I&TB 7LM$?T1$;U*DC.W]F59SLM"D[1A_@LJ9J3@C\K%
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M'5MB8FL03.KWXUK #[MU3W)%(H\[J'0UT9C2<O"&,:RTPEGW+Q0RY&X!8]#
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M>ER:'D8@S)==2H\OW-UR#C,+UKJN@ >E!8\Q,J?BQC%+#@UB;-8#Y/33)#V
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MQ*)T1CM BUO(<=K*$M1*>@K]PIGJV5(7/E+M;@0B+S_^\<JC:*"L5VY:VZQ
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M2T'[B[/!H-/S9G9'<W_!B&<O?_D^]6BTE?=ZQV!FM_,$O(N< -7IXX;5:(=
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M%,/AHKVZ$27I89SF+=/U7"( ]"X7(;N&9*L4<G8M; ES+6W/!JG8V1(Q/1(
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M=A(JIQ: !UV3=YC,-&[_ADR1/;!W8\\19::&*3N>EJZT/5JTJW\3UEO$>;K
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M#[>,8\$I+"8[/<,Q4]XL@1T76 M X^.I?RZ6F$>+MAB)/CD#;ZDI*S>K BU
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M("U6I1B;3H/<A$U_/HQODNB&''HWH:(H5P(/.J*$JR=@20HD8PM?BF93)X3
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M9=;O]DY?ZT(6QUL<8C8X:4XCP#3T22F*P@!X6=(#<H=95A!:C[$L<QF_3UK
M)EO#TSYH47[*Q M?FB6Q )=2O,T;%;0A1WM_X*:SCA2:5QPJ)>P1[]F;C9GL
M 2=6X,3?"B!F0(BSUX94>ZW!\+@UZ V:0 CJ"M>OG/^\'IR#O@W\'V!V+S#[
M P3S3 CYK$K(/H DBI+;-OWG!A1\U.KW3UK]DT9PKZ?8WI&-\QTH]H&A?P6:
M"(._;:,@H'QT+07W6T=G@];QX*0)I&B$QN2<[W??^'D;Y'!;PI4:9^C'WIOU
MT#\^<FM3#\!_4.!7 /Z-I'_<.CKIM8;]TSN3_O"XNQ'I'X!_KY0/T.^])G"2
M%PD@,6@-CTY:I[VC%4);2BK7B^RC:BG@1N&/N\'O"9)N]@#4I):UO1+$!ZZ*
M-AR>@<QNA'8S@__!LH;UB'!B-?&GH.T#;JQ1_THXT6^='0]:1\-&TXM< :EJ
MHZ< XZ;D1,C)RSDOTH!KC$$<]%N#T^XJS$)/S0WBS#SR TZ(V(RIK$<F_*^#
ML+@'+#D'&$441+<H<G[9_OM)J:^$315H3'5!R%)QN+>-,-@D.?F)BKD_Q%Z)
MA,AIY\\XO8*K4ZEA#KNGWK&WZBT&CL-14=>JX/'+H3Z%<]C\%6PV@O_]#W\V
M?^-1BD>LO>DQ-@%X'^;_OL;X]]@\TZG;[!,!HE6J8S=:*H:D2$:QHJJB2-R)
MX8P3M^!_6\81R]T_%"58%G,J)"@Y*I^@5@W;]92+ G?HTG6*4HFI ]O&C('4
M) ^A.["(0\EUSZ8JFLA#XIDV+:5*,,3>!!A41-Y>IWQHHU*K(%G'>\N9WM4<
M]<<'VYJL^!T"(:9F:/%\"T#3=IW3#J>.F_E;M8$X7<^_'YQ-BW.RWR,632%*
MBJ!+5MPW])5I8#T428%/B*5TFZ31^!8KH(.D334*&4UQP5V2VB3Y1SK-9H:1
M#$P"539L%L!!_9!RA9"HX.\@F%6.^6EHO2/RE"NP.]Z?!HY;GK"E-S[SQQCY
M 88(G!/_'B=QJE#OH]"/A)S$?;.YL?=LDG[.GGW2SPY$UB^PP.E]E-SN28'F
M1R!O+,IJT?^E,.<-*-ZQA#WKRT5,0O_QJ5MJ2:5?/="Y=8C5)RMJ^\HM#$;[
MF#24@Q3@ #$&?KV1'VG74:D*@#[L]@&\TX?WHWP1ZX/88TH:"(.FF&$.PK_1
M\@5XZF04/&@AO3P(NCJ76UK2F?RNUQN?'8XJG]1LDIK>4@+ /%.O]3_>8%%0
MY"]>AS$=@5YZ(XL);T7&4NEY2S?+/UN>T^DRWY'6[_)E^;D#/_VX_/>CTTYO
MV*_]J=OIU?Z]::E>O],]K7^E::GFOP^[Q]_YIH8KEUK3PW_%7#06J0_91?IT
MHR;2]?VCS5EZ1[MYF"5I18>IJZF@XJ32^>X.M(?N@WZZO6N4SOURC'PJI=14
MD1E9\T 5IP7]A@,"=QCD* +O\:3K1BU^%Q<V/%S8=A<VV(9_[/&4S#]4SII5
MD7&6O"V$]+FQ>KC%H):+]^^[[R\VGD+Z_4R?N,O!=W' Q,O^R:!SNB1([O/<
M#SE.1;:SU3B5 \[N/<X>G74&!YP]X.P>X>Q@>+*#?/9[F Z_1L^1>MTQ-P2E
MAO$K=9U@>03BWDPZ''9/=(>S!DQ[&":WX2C)O;G'P5#WJ#Q<X[>,0NT.UDS>
MW)'QNKO,OUZ*H?:JQ,E,Z=QVG&RM-K+S./7RK-<9;BU'=T"W^RZA<;+U=,(#
M0!Y6<IVL$UT/!I+M?.X;3S0'W?>QZN7I!I'QFC%++W5?PU<T7Z,YZDS]-,.
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MU&$BP?W !FPW\JH8!HY3H#&VO/#>Q7"+'/84M=.!W[(49(@U:J6.*GB W'U
M#C1*/8 M\.>E#)P5X#Q,<;F7RP?K[(OX]DAM)*^G+R-0T?M30Q]D"V1%@/'_
M21')%-)(@9E0434?$D@'U1\#*5\P?30(.59-BJ2TO]0N)S#-,QRC&+G*?0JP
MBO7H8#',IR&%8H#JOJB%IP"@R4*1$Q<CX!FF@(395"NO/F>(M"SNZ'^2TS>3
M]\9NK_HPGJ2@NJ: 3C)J-O*+F,;VZG[%-N_$L5!0_9K0<N2 U9YYFE/.N761
M=/L.X\K42KH1<M0>Q.QC85P%S.QTMGS=Q4-X \=F)VE>'<!*\ZQE^F/@C!/
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M@R>$;[T*&]_C :J=+["">9#GA_O'X-9F=!(*;3WL&LJB5,073=J3;]H5\*1
ML(.F,I_.>6Y24&P\Q]H57_3_B@XY!%2<<43A>WQ/$KUOH',>,>>]&SS\%V'
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MYIFBA6[,[M*7<[LZ+;W326.BRUN6?/3\^&A/\M%SYJ-=K:<;GX:]9KO77!C
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MJTE^ -*O'>=*JV?CP#HM8*V6'QQE.<G\$5@=<6&A",]K8&039\9DT<TO4)Y
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M+;E,1RL!^O;:AG9\]#7:N/&'T#("V+O.@"4O,F,3U0<TX,)8A]!/0E,KE<7
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M/R6I2%(I(ZED51HWD@JVF&QWBG#L'BV:<?PDT ,FE!Y_@7O8;/!U0 ^\*O;
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MB&4KP$#(*[$FZ/&]&#GNA4?07TS-N6OY%MUNJ&_5&BL4V.*%T>F"0XDSUGX
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MB /]F6-^/#&%C:+O'Y2[QGI*_+2D]N<RVE U*KO1IN5E_4_1F2[I*,""$X1
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MW6QJ;'B-S;2IL:%J&E.-S;# _>^?9K2$>;>J\ /8N96L[D!H,7\%O@KS[IW
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MY.S&P_NHZ;3C6NDD@'\C'N3?UUIDU:,P8[$ P@:G"E\,MLB#*/WY3-_I8C)
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MNH_ 8BRT/#^R'" H;V%%OA4RU[7P4XYWS\*(!L=;Z\#Q _QKP.:8PI4CS9W
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MG,L?;9<@QV69^+!9XK!===B.?MAP1""8(\% (*!=UW] NVFG_O!88*8,D+-
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M0+UX8(M'<1 /Z%@!2^<'6US^S0+?Q!L##!A/>MW>VYKPQ][P576 T] [4Y.
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M)W-2F&/@,(G)HNG\[Z#8H>4G&Y!,%^IX<XQ68AY"5]V44F/!2KU(?8,N.1/
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MF..EKFA+I:S**['@WIDS\S7]YA,6$UN0@@UII$):EX)1]S\,7BJ5@.E.>UC
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M0J''XUW3 T5_L\.%_1?<EURG !ID/^:,4XB#1#+W@P7!#Q/VH/C29X<CK]\
M3UG#47_X:O[ZU>#USOB:YX([..BTN]U>W9#K>NWIM!P88K.HFBVJ$N#!/:*
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MZ%7MS"%Q?QMXN13E9<VA:1=D>6O8';:ZW2R<60;.OB3-US$.^_PL(=/&ZLA
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M\[U[LLGB)].#Z8ZW@(Z/N]T=0<='IS9I$ICC07R('* :V<5Z=7'S[?>+U\4
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MN <V^!KX]PYR]9;=@*=H )SYR70_L,'X?M"JW$6Q"ADK1.( &XO7?NC@!]Z
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MJSQ65%-^,Z?\]C;H<H53?@F_7<M =<^?\EM_5;!+H4?3990N?YT-_.)H_PJ
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M%!I\DX%!1I*QDU,D6[RKY/#!YWME$/=V.D]T*J#$\2S$<?_3YU3+S@%"2$7
MPVHS_4H2E21>JB2.*I+$J>LM=/]_-ZP?_MW4^L',VS^9YV9):*<!T@B"VOGY
MJJ3TU B')W6[-Q/<V1M964/$J33F::'UU+M4%)K6N?O_ 9X,NM*Q]"IJ; [
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M:X^&C1TB/:I>@G,++U.I(&+P=J>IE:N4A\T'YJ3>$M"'#T0<X%$#].-[BQO
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M>D@%[&O2U_ J34'^;0U,LEE;^G?=)(>$[FB%OA[A;$3BN+H7?NF]:/:'#Q$
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MGGNQM0YBBT0D3PHIP1.?TY-=8MB348D\1]F\>O/\(SS[V!'IZ#C#;H%@N:A
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M :%V18)BDH7I$D$E%7=EQVKU@7';"7+PLGE@XE 6@;I$$T<G47^,;*9!/*S
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MGC<^-$N-0I1#"DZ>MYH(BK: !6&Z"=[BPS=-R!+8EI^T>;  <K,E@EB!=M>
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M]P1VW3PIBYUNO5O)+S/.S(89(?TP?696:Q6P#L/E^4F(7RJ4>OID!:*3J>6
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MW49KQLS5P(M":8CGV;GM[(!>070Y9WN6M^OOT7/U:2 [+JXVQG?T++^VU9^
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M'/LRYWS-L&W#Q-5C ;5:W#*ZD];8Q.?-&T1]@4_X4SQ#7W[Z?U!+ P04
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M_68 F2ET=*T?@L20LB@F5.[CA7O XVA!1P]^M5PT6F8DQS1[@9<&;UVDH,6
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MT[%O1556#D+?E[K\[5*FJ6+!&$:B*:6!?*#$L1")9AE,X,YZT:D"SR/QYO6
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M+8T&;2!:Q^@]M=DKNR$AU@SU+*A00\VU[W8?X"9E+HA2$0$$:((  [&28@@
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MCB*<A>'@4ZN8 A]_5U:V^2W-/<PQDL!%)J!$B#XJ;F(W9V%+ *?)E[V9I(>
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MSI0J-JB8A/H(A?_3#Z]@+8,C]\1%&XF(ADF;95"^=K9))V G3IKJMJF8S+H
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M9FBD0*2)[?J(4%G,1!FFH@X^Z>I-<9]RWD+?S-G$'#TPYJ&K5?3('/#R%"4
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MI0NP[ZS:V5PK2+7S0?:MA?.E_SR8^N&,]N]A N,OD%XWX]=7TZLQ+$Y1S[7
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MJ^&05JVYHX./F+C$).L)X21- N4$UF+S#H2VD6FCO;'=O,0U UP4^RV,V+R
MR7TUQW59\F0F-Y$[RXMTP#"0$X,HP<=BR*<)*F!PA8=NR3KK1K@H:IN8L74E
M]8_XG_O!>,4;TAO%"W<BE_JZE5</M4!,B@'C)L2@F';+K:37D+MVB(MBMXTA
M>RBGON!S/.1#T'QO9,XJ,XO@F(XDN6S!U??@SJN:GJ59":TK]*W"<2D*:&;K
MHU0X_PWOZH[C XX_?0ECO,IY>L5P^^NPC,9?IZ[% >>1=[G\X0>3]YY,HQKF
M5R2B/+B]K]X:;?COQX-*^MN_TNT]7?P="9!4]^W^;@KDNKP-XYKO]HCW_>+A
M]R@YJ0U+0+ )+<0@')#L8@T*R"ACXUNR%?:#ZXG.RM!?EP,1/59B7K1D4;4S
M2<[ /:KDD^/.A,:6;#N#8]5//XEV7]0T/1WYIS[W/3?!+[=A,KDN_YIFPMU=
MCZ=;O7GUX&>&31E"<0@\Y-J8(SG#>&,IKP5SJAKLIQ3(J ^B>HCGK@3V5'!X
M*[2>SH1M@'6:\U^-".PBBP.L?UJ!%"O 2Q% I>(DHI,IMSY3>G1A;#G'=7)=
M;#1ZZXCOAS&^NZ^^[PS94U&_14@*'<2(&3032CAKZ(?9YOQON/[Q<\V;V7_4
MUG@]G!9?.=6W?]%3=C#!#^-!PL=?3F:_G?!ET(:,$ (G2RB!KM@8E6_=WV4O
MH"<XIG .KG'_I*Y58H_QAI?FK.:_^X(+%IV,RC^J]3$O_>=V<8DF,)K'+]H;
MY^SB'$5%DY( 7EAM15V+?OK(0'DMN)?&9_QOG*/33D;[I*,-&I(W9$E:2L!E
MXR"KK+U56J-OO3E\[7&.';3;<YQC%_+/)<YQX,3?_%A]@8?<2Z:"X3R *)B
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M!5ML!G(RIGTV#<2L+#AM#/?",Z^[M2-:O.HE<+6?B7JXKQPS"_D RH0$.;D
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MT?.-M^KLZ_HCA@G^S]_^'U!+ P04    " !8BEA<V6P)?$!O  !\<P  %
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M.@_8E%FXH &:-4'B,W?9JHMGSP#\)ZM'IYR_=^=1MQ@W6WQQUHAQP3&?Z[_
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M)<;@;<I4@77<W>ZK-.<('A.8T:QI4BVG:=*"L,?L6L4&65L<RV&T!7YXS-B
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M%4@8]B&RP^TG9"I1+D#[,E\O54^O4LUUJY?AW1]+EG"]5++I9&EQ%!.HLAW
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MJ'NU/=8#J!)-JV;*A.O1T%8?!_1)IU-:/GU@;<H.BL%XZ+#6V<:,8,=FWI'
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MCP*2+_^?BJ_^_R7LI[G_ U!+ P04    " !8BEA<7YX.F4&2   MM   %
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MHS:%0 XC AQ@9EW5TB#H_T@T^8D8X\IAIA.I)ORSM%6!2G@P31-A4(30\)<
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M'9,3._.HHVLB(0%U]R;K@!?1'A,@A;>Z'6YK$GS'6Y,!)V,%(RVN$#[W-41
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MWO<?8[S>5$9E,IG9^7HFYD#8C0,J$BZAHF:O^[!*F3KI92\W+<!E4%5@[OJ
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M6"@U3JSE^(%O8S;M[)2WEP'ZY<0;#ET5Y"N+Y]$<."__>@'?4"V<2[X=%3A
M:5DSYF;SEW7VM0!GUI]Z/N\W;3I_J-Y[PK5C?H<C^F#L97+?'8-Y"8/NBGDF
M(;LJFRF+M4---ST2L_-!";%VGI9ZE*)"*,U:*>6U7IBG,^U_9O1&!G*M*L#:
M-F(,U5.W^U"3[0/V\.3#Y &9&NFEX+#KRKJQT0RJ,L$BK8QTN#1M=$!8A5>R
M\4QQ$7A2NX#B7O3W+DU\Z&G":W(^']B-X4 Q7*=A:H=)/_.LJ;HE:*+XXY3-
M+2AB*'';35^B\8)W<E_WR[G1[?DJ$P3\F]V<8W7?SG5>*]Z]=L!7Y2W:JY5?
MM.873%RRTD^"1X?P*_9I?0Q]F[-#VN$U>>OGOIZ*!B)X027NT7JJ;Q "7Z;N
M\#5'JX3>Z+*V1".30IVR'^E6!MW=]W<Q.Z;MAZ0&>-TX1R&FK\%'8E-*_:Q>
M,KF%?&L!\-R)Q(L=TN$Q'I,@1O4LY:_:# F"HMBW0=]HNO5</K'VW8@$VDE$
M@GQ58*R<H.&9102>=X/VK?1)X<6)6"S$P0@MA@+'4D7#((O^HZL3$:>APB0R
MD6"8@K<@<8Y\%.*$QA2ZVO&90>%=<EUF"+='1C$&I%J%J(@D_'J;XV>/=%6O
MXGA.?1Q\E_<:)*<<EX JOGW/C!T);H0/ZG/+5$0^+F!K1/,UW;JUW$#R&YB^
M7LIYX09LRMX 'BB N1)RA_W'@VE>1_''XCB!_?X>L:W:>B2![5J8\YRWC*,J
MV STI/%[];"CT+MGR9()XWI\KW=L'/.7><E)\C3P:IA[=@FK"^8-W%8N1U<A
M]8[4U,\;;@3=%;2-3':.-+]6.U(LHXIAVP!/9*N>G6^Z4GP8!%A2-:K*;,3C
M%7[5\\PS\JV%:*9M!=(+:&<LFT2YRV(^6JOP:P9L!KUR&RUMO.@O_ZM"LY]E
M0V%ZZ3#I]*M[G;Q[E%J\3]09-3-D4-$>6=CBKAUYWQPN$]438'[X-**-H]2!
M(^&-DTA,D[3@:@Y9[&V7=HOUX_;#-S)7#^@UMDTVUKJDIQZY;M\%K$X!F .R
MD<M.VJ3_ZT;*X2MC^PFM=P3S)'N6F^%SEF=?23,H67;OI#X_S:PP$]-%:E6B
M**L&MV2L!N>J]RZ^#AJ@H2MSEK^M'_&C_A,W@/XA-NBLQ+5V'7]G6*:(7L/,
M3:<TX]EV6'3"D4%!V4M5=] M5=YP<\J[,-G/9R*O?*:"_RL*:7[W7_[PSP-:
M8;AY R40 V*7<69_YIWX:&C+F87-Q._-XK6ZBT]O-77J]_K \+=9VQ'[\JN(
MPV5G-.R7V%'J+2V:C?4 BE>-@KAB]@C4*EZ&,J88XEMD=.TS9NU5Q+,L:<Y6
M*5LPBBHX%6N_C*O5T8FN,'X9=]G'G#WGTQ*?>5WY A3G*1(%7749@.[\G)U7
M_5U&V3XX4O9X.]O+GB)I#N)H$\!NQ/5>M/O\/95X_/C8?> Z3;]N+,2QWC+G
MRX_>XK4?I8Y[M&!!FKKM[:/J_I<'6\901TOHQX"N_A,A&CQLQ[85A-[49B<"
MOQ:^$('9CXB6N-^D@UUAD9;<Z0>?)HO?#5QT\[CYM51]V99,:W/1<9M*-WIH
M$>.9PI"1L@N1I7F^57EMXN"L^$SPH:/(Y,U_R &57<_\0<#Z2Q(!AC:,\RF#
M@N3I41K^KY^P67C#"1%\' 1\+X$-.X^+^ *+LD WCQ1WU$E\;HSM[SO*8)F\
MS^#3O4HEOY)K/PX9G4A\5.6%/8RA??G>9(J&SO%T=**3:FS@M#*&8'TH2.AJ
M@8J=C*,C?C-8-H'O+6KVF-<=?+(GAS.<\%5MB^(S,<!(Y/UUQVG54'>LW\_M
M>NQ5$2D:KO.)^',]F:X!8L8";/9P.4U'=IBE1(_JBOA5[]R?WGWHNG(X[TK>
M%<)$!Q&0/HF'6KT )9UNXDQ^$Z'[.U"Q#7<<$9@WR9K_^%)&'K;I,7D2HW![
M+)^6K2*^4SC66KS5[G2(;"/>EQ=I[X(RX=&$^+T]N*TFL4W-U"LQ^%5#^VZT
M"7VF ZBJ%/&S<5%@G%-[">JG=/YW\YV'MI8JFA"!^[%11""0U!*>.ZG?&.WQ
MKU(YGC*O<GGI1)7Z2OI56GF3X/XJ) [CU<G(X*W1T]YWV!-0X&W>[5Q)+SVA
MN_)FC$4VQ$>>]]CEDTW<UC?G/<D:*JP*ZQ%XIC\>-#^6(4$$LCH?$@'$#6B8
MP!]1T[@2U3[QLM9M-L:XRTBU#4ZYY5^==O)M\GN.;=;-H_HG^9/&JEZR1=;T
M.5$-UX3K]&.0)\U1SV-5A89U_W ?[._<-TUJX+7BLLT<E$SA"<T":4LFU=."
M1,"JG&)G*EA/\HTC_;ZLJFZEYKC6<!4D_I)E=#RKISJP_ >:U]!_A^8'VK8]
M_48G-]MHML72I:KD;9&AQ?3 P<#^&VV]Y5[G>KF:Y7FC4=F#C9+VOG&1V^XT
M8VM>\6M8XR Y)'6(LMORR[>!T(^=[\?)A1*B_XA/3/_? 1P_AK6;<;0BKS)4
M^M9*I3WA?EP^H\'F=/EJ/5LK[S5IZ;%FW@,N^'PFWT.4X_TV62E5B8:9MU L
MSYM%_^V?$&'7:XS3[J]4%U2QHW)'*5.A_TCR-L3?)[DU!,'NWLO:EJS ?6L8
MMEV\(R(UKA7[XN2FPV:LG/^WYB!@89;MEXEWZNBRB1K]U/59TY;RW.@4VI4M
MH5MC/")\75V'V2<0'GS/MC*ICR 8'I;/@_^NB-4FMG/[EYIII!8GMMMY3G7!
M'0S(5U>\>G"H!+Q17F=^>^!Q0^0SC7N=GLC("Z[>9&#/P8#@/R4X_YV$NEEP
M9>SQ;1$$7'/<T-^S^-79$L0,39VP7[!!(%*DD @TQN'^+!R@OW/,K  D<9AD
M/%6\W8EI1C[A&/2GD9N(P-];V3^@1/L)$0@0P&1ON?IFGJP2@1B!R6>SRV!7
MQLUHD5U$0R8Y$?@SDX_SL0$XCJ_^YW$2A3BE7<*D?F.&R<=W)L]_1/R,T3=<
MWDDZA0P1_@O3R$H"HFS;E(53I8UW_PB2QOS1PD4'ZV&&_*+P?>P<IW'&X#OD
M,"Y/>QR,HKW-G-<<HDX$X@H0N*_.>&E8F\ Q93,1"":5,(S^CAPWX4MBUQ?L
M'-!&MB*'&X:BX]?!>Z<N1 ":AH>D33PZ@998^#>N$&S#H*VB>&4B\/FE (Y-
M@ BPJ?ZYV#;BGR?;D6AJ!*FCS=R(.\'/+JA6? AP8UTZ!.TIBA&X#%&,I^3/
MB4!3 8E,?@7-)P62$OR7+"/^7!P1B(1Y_#$7+ZR0@B?MY=#991(9OY/3NO$A
M4[*&"'R<!Z-_()B@JSQ4! I5(M!.TH.N"$-%"/X.G7L*Q>O[97O'Z3X41^Y]
MC<WYV<0XFD)@D= D0$M .WO0&/[!%P<_M5.FB,!/- QG#7X#VJ</)0)GLHD
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MF?FJJZNKNZOJ[:[NP=_<V85J[,KN&:Z?OLW+6A<^%;SW*-.IE#KZ_9.6M,M
MCWT41W3B32;%(AL_U,CRMTD9!YR1!92^/&\)>$9R/E*([ZY)U/W:"N<%>X;J
MK@RMFIR[LV?,& F$$0[V"X00<L1S#PE^J1?U/%)%Z]3'8AS5[L7Y7E_%[K3J
M8!<.B-+#<I&WX4:I<(@\3)5T7'?UGG$ 6Y6?&VW!,Z^RN1?]22O,]HK195D7
M*8FPC8[B0WVZ :4:N?@U)VGJ1U/WPC9Z'I.^&":F:(TG#9@?RAAT<%.J/)@(
MY!=@XJ3U?MS#I"]^P^W@.(449]?_2]ZW5 0X;3V9I-C_>];Y(9.,FM.>'F&G
M"WO5'A?!W1=TSPSS;]T<O/!Y!8$_G^<!DO'>4:ZK&7A2.GS0.O@FJS1*R33Y
M9,EW^"669"9YWOLF+F#-6%6Q:((KP\0B=5GI*V>ETM>*\NI/-CTKO713;0:S
MPQE#^=-7%_4[GX?-!"8^S'BV +K90Q/FDD+*CU#:C7"6:9,0&!5BNLE1547_
MAOYYAN.:^$PD<8B= F&8OVN%0NMV'5\L(FTW6&?D$!R\D>G\;'H-:3CWC3_?
MX;Y%1$$C7WK$5T4BPB62N88V<5P/+!RXH72T%*\R86@[QT.ZQZ[>=]@@DBP2
MB. YE;JY+9/FHCECXL?@9\;$%-01,B]7CB]H5<72FIW/)&(%X+TEK:)*FB7U
MC"]1GGWLKIFJ-VU9C0E?Y*RM6_W,@K<TV?6)@RY00)T(;M05MWAPRP+.G<A[
M<,J9$BL$E[X==R :^$RC*KQS@[T;YZG302NP7"H$\HZ#ZJT$"97UVS#H5<&?
M1^<^ML*-Z]5_3#UFQGNN@\7%X+92;SUMD4(:?P#S=&V-SK0H'5^-C:T>/8(&
M<@^]?/:&7,G6,4YZ4O3P2<OL"=@?>Z!$".8MP>%<]"3N2T4R:^60&'$ZXO7X
MJ5*VSMFM(TH[]J2V*Y0E%0?M'40DUNO5/-@K-DZSRU6+O4[VJ5+S@07NMM8%
M!;5^[)Q+G\;EB?)K4&HM7J**=!.&.TT.'O+S3BW*VE0W=,N'8S]28#4IXT)W
M'KMNW<)! YXZF1J\O!>HI+U?2X>8'@MB[27'[8HTP\?6A'T:'.,=TS*=G0P&
M;,M;JM[5Y]G9,[-%AW^,25B^AF MIET0&I79;6L^,KI5&B<_R-Q0).B<[V#S
MX"0E=HKI&M'-=JLO)_T/2BYGR'_MN+2!,:&R@'OQG*K/VVN8Z*FPBYFE)JY9
MS5(X_M%G*QE5-[YTQ?Y%9W6 _"O@) >I:EBWY*\G0<!4=QV.9DBG50L% @7*
ME>F8-DW]*.,O1A#FO<:1T(\X>V=RM9TQ$9++DT*:V-90='D2J5T[Y)#G(3<_
MOJ-;.KQ5=.!?]IC?/=O$^&J\U$IN&I]GMH*9K;W1QEP!^;%T>3+?EN.Q<93B
MPV#QO?L%])#9"T+J7MNW]0[4OI],^O'HJ:(!UN"BT\694]SG(]%HX"O;!JI*
M!.4E.;(2: ANZX+ML*RH/X(:P_<%SMI.AK3ZW+R^E]/B&,[_I)1I72E9;CB(
MG#V1.2]Z #5Z.@_Q';V7%8S<$F_)C,SFN1>A/5&99^HI&KMQ,LR1O%RV0">J
M^&VT/WYAGG/T*&:@EID1,_[ZK_7BK6$,NRYW[DI*X7P:%!HT<''6%^=5:RH9
MS2>O+U2<7-M7.S^N?5:7I0QI3&(Y;?EQI.TP^) 2*PUNCI(THD4#19K(J-K6
M.M'Y7J1G[4TT8)1UPND2:I_, 7V*D5<!4Q3XTX,U[LZ&!B*GVU#X&-\I9.J\
M@)*;TD?5FV(\:[<U\C]^!SS]G4N3'7G/YX]J#YOXZ)Y6AJOQ?:@>YH;+%5R/
MR^SH^Z:?:&34ZF*"!L3Z,&&UNO-&XZA>>H6K7_19@0;77I?G5@=92/36N;53
M4S6'$?, :TDP3DI7^/FQN#)@6%X>U#%]AU6*\69H;MKG'(N_[49(6/P/7^!Q
MYJ/)4H\$IQ11P&W?%;$LB%KK^?L8M\:+CR196F=]+:(6_+CP<5R'30Y7!$]N
M^B.HIL6M*_/RBN/F2J+YZ5O*;DSLO(6)5H:P]JY#=J%M>KUA0@R=$!*9E(*1
MT,(UZ"V]%EO<_"@5H/Q*?TBT3VC+XEEZ(I9F[RP+!:+U[M)H+5/!FJ.:L\[#
M_A$^_6#+EV;5T"KRV_EF'6)//!VK3D;9&>?K2Z=L43,H<;D-\!$&RZT#)PS&
M"*V%&0IG8QT:>MR"F/,9S^5^D_+!#OWFZ\H8Y$6/HSW!0/NYBW)+0P$O%VFX
M*S3J)13\KO^-&P,_J?:(X&US,Y'8"A&*)N*V<;$AQT<-S6[0R$JO=J$CYI]5
M>!]U*@]M)8_OC0GPS^S(V)%%,JQ?9/.4>!3%?ZOWB 5>GAE*U)>1X9=!-#',
M3OR*T^1*2.L#VF-&OJOL%HQPK4R$2*YS<>'TZ)>".5M2P]Z4-KM/BF+&:\^G
M7Q^+<,@U4^U]NS[O= >?K;Z,6L^BY(RV/$1W<P_5Q78^,K.]U7IS*RB1X0G
M\(7I,T:MO2$H,JM2ZVG>P8,9O/3]=9T1"F=P<\4.Y:M5Q_Z+#2$79%H^IX>0
MX;%TK>3D3^G,S@3P"X936XZK^H:FVM*C@9=B(W;Z9'EK74OO% H=:ZZ(AF@
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MSR0\'.V?RF&_?(,&WFD^QAA1LY5S!'@WA2B>3Q]%IFR"\HJ#',]AC&'X+]R
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MUY#7T ([2 \8_EV, _#/GNCY]%>C :/F/T::9ON;F2?)9E],I3O;SN[FNPZ
M3W ,P:,8J-C'0S^Y7U7/ME[<L<J!<Y75C 9Y%;);(F1[L@H[;L1 2?N_+=C6
M16ZZ\3C>@R%TZ:'( ^.S.3#&GOSM[ZH'/"6D9B1M&+-+R*Z-!I*#,0Y$X/O<
M^?-'G:M2LZ:[XLK44INIW]8Q-M-D?6:_'[SC^\,:F%K]\6'O<?E9$>UZJ>[J
M7GE%I-792P<.%L%"T%*B\7!>T9IR"UN&],TI=HP3\(W, _=B[%@]S7?[]Z=/
M?.\_Q41*=#"%%:&HY0K0@#@-"F&\FZ$:,%YZSX=M-M&C!5/-XEH_&L@WSO[T
M5?R]*!,D7,PESQG\L)^[/(9J.^66TH>&3O?ZNGOQ&*,W9X\(1KEA6+^-0_(I
M_1HV/W'>FTI:05X'DX%[+6 [ Q@Y6':KD!AB\4\8HZ*$HFKHEPS;1]&  F K
M9<;':]]59X#"A,W)_> 9S*PGF%U-(?F?_)[4>!>_N<"ZV8BKO*0FAOZ2R,L+
M0DR4R4U#!/[-8%J'4':#^M(@/DU&"C$KO5LJV)=!P>-51>^,]T2_H8$O&/N(
MEQ_."/XZD0<>[8*<TJ60Y*%H8JLPCO(%&L#X<_@C<./>*&@E%(+QTBC>VOD@
MX ",,-);0<)+OSO@WY($"3L-,#()@S'! ")W/X@'&Z/].1=KR'YK+\8!_TAN
M%."W1SEC0L/O7GT^KX</_S$<!S9^-=W2JM1*141AJT,_ZSAAID\-OP1CI/]4
M8_BOE>E\')<<&>EOWA=ORFYZ</[X%*[1AY_VSXLDJDLRA_^=D* YEPW(?N-/
M\8SL_B604?\<T3W+UQLPPR!$3-\IWU^T7+EKU0P]K2E)NE,^X24F^BB:[9"6
M[ROCZ. ]R.E.VRE!ZF+;\D?WLOT'6_O"H1.N"^)V6Y(L=^7A^,VNCI4V['"?
MSH(U%'?%[J01M?.S&0>SLS+K3!P7WS'"[F5SBXF@Y5J!!0_[1C#)&WZ)B18=
MG=<SSD7J@X?Z-34?V!*4[\?.I:G>DN4CB\B=K11_5?FU* ]<6D"\6W?&"9N0
M=GFVT6$L8GOLM'#GJ%N>*S1+F6GHM>7(:\Y!O$IYJ#07>^HK^2Z/'@OLY0D(
M@_O](6HW<[B[\&W+9,*ZT?$%A3#"][7)##GD3+W>E3RYC*R+*[3YQF0(J&;8
MQ/P1U*Y(U'C*^?:#X8(W?&5A2L_W63G'V,Q.8AC8X2>E+1Y/J1/,<9[=R=]:
M"#79D^9X (2??<#>/GN3V9[^K9NMG3,T/^K:<RHG+T6RY.Q++$X3&8 S%Q3N
MHU&*&$Q=<S7*>S.295S6M_-F(Q.JX-B.=WRS*?QN<0R;@>_ZW0O0>LKQ2<.W
M79I2UH(C<:K6N0$94.PNN?WM&SKL!:[P@<WX_:WG'=^F9DG+:'6ZOJR*F(@Y
MK@3%\YAXWXB4BV1=#4B5/)Q5P^]$4<"7)HTN(]S2NN',RA0*"8WA.8KS= ])
M.4:+ ^(V?:<>H#;)6Q2FIRX51L^_K2E$)!QI#)2?2Y^N-(TWMV<:S2B;?F+S
MG&RI"WCB6#A8&]941%=D9X.OY&8&M;G>4C"@*O14^*NZ\=WK-+3$R>=6D[OR
M]H1-@I:"US.,[E+>^BPNA>\MGHW=N".F-5]YN!,8GQPS+QKJI+*;&8US:O21
M\N8MJ]N*%CVF4;(&GR>Q@0]T^&L&VPEPG69J(_*Z^J%:#=NRLYW-;S8OR\XZ
MK[Z<K4GZ<*\4EZR!$+@Q0)1Y<;G^?44IM-2PX@BN7WAAGJ>1",OS#A,PZZKU
M:!<50TESF2OF681!TF!S1?&[]Z>5K;3GF'$ )G%NTX/;8"87DXD>W' D@7;D
ML(!7=R&*C*H_V+61XTD-TY3F2WG\J$JNNI46"$$9*</&T7AA?IR&P4034[5<
M=$P(VR0'8F*0<T&RK3J$F2_=@[=5P<1WT\:(=E(A4I! B_'-DYN>\MG+!6KX
M7K+P^//#[MOWH_6#SUX;,TU;.E$SZ/10$T157ZC\:N!B*O+VKE";)8@:Q;J:
M#/0AY84K3L^/8+/G,CK4T;JL83WS4_,7X>^P/MA$!E_E%K5O>W :=W:K<\O&
MX4C4MEQ81'6QZ,.WM=A6%5'-@9[I*[1*SFIR&9>O/7FA.41R!Q]C=]HUG!.T
M!\6,%_@@Q @$POMT78#P6R'LR-GL9OZH1G[P.RP&K';F!$]QOC($!*[Y"*$'
MN5SF4JO6B@:4=U%)$H'BIW+<U94NG(J&DFI,@9<B\/ 9"8X[/5A4RP)D<7W3
MR2Y<5$B159/Z.DO2!BF06% NK8V_6WAMJY SA$J1R]?P/7,*^2VL;1[L%2;\
M^:( I#P\6NVS,;E01D5TSCK9Y%H4PQMO:XLG79?HP84N#Q,K0/YWMAX;74*,
M%5@940\C9;,1C>=;^BK%(1/W7]2NVJY K&N5!GAN:,ET-BY&?RVRL?5,IDEX
M%+7L./22G_[(0_9-^W58?UK51UW3&$FL$IEZO$TB^'BAL_SLJ#_RBO-U]1TA
M2PI5^H?L6I'/%5XTX>UI.7KJ\-96*'Y9]I1X&]X6[Q_\?)<Q?B<8]!E6ZFZ>
M9WEU_L+17G5CA3+TEM<2C6C'B:>)5ZME+!J@<%=E&FX+89O(LZY(QH'IZ^^P
M\D[),G]F#UM-6<"[P?%E=H'=QUA7(CA+T>;(?#!_>@(R65Y-N?@$6=FFPONF
MS/M6!FL@0=;[#!/L2^?];81; YYBQE_J62#S!6%9-O,%1@)D%D>:'-6F1^,A
M%+T,[=@<?MI>THMX7!*W:L)3A$;=#88R$>:[W"TZTXQ[!V-E_"0Z@XTIICX=
MX9?VDE. .X7C34HE Y\L\E\4Y#][/MEN0]"<4:>@=LMC/3P8R6^R$$ZPCF(>
M:O97&>9/'IB5/F,Q(6)D;IOVE'@-0Z3.1Q]-B3;5BQM?GIBL>-=DJ*1@O'E[
M:O+#LB<NE@(/-@[HEI/8""2XGA41W3B>%61#TUJ263J7ET"HS"U3XTUQO;XD
MWRP]PH9H6<Y)TN2+]$?QC54E?NHFE3)]:S<^BZ<X=Q_Y2IK3-B62Z'OUZL4:
M2@RX?2U<*H-&;5^^KT-*7A;I,\1'%HF@!TY>L]!M3./V(YTKWG)6U\# +,))
MCG&ET@P/2F/>G\R6S-^8Y''$Q9.Z4 Z>NPO72IJ.%-I.RUH7N6DIP14_J :U
M>)D^AJ-6QK 48D-^0>%));%7I+&<1)P)WV3-F+[H9+;B6*K&<_5^@X5E[+[E
M8 ^NU@':.>_6D8LFVO?#>*BTJ.IW 2+ S6O$4\(9@Q5KVJJ?QX[XMSH>ZXP7
M^1YL.?+5J;.6*EE..RBF!L*+15(;;?&MGR27;X(OU:JRA+QE7J,OTS0VN*35
MGS'D?6DL<HS!+GSQY:.Y.#]:]H(WT'N&,8O\Q"TQY<W7O&\S?L[+D>I78*<]
M6M.4)7*$<ZC+1=[WY&VC]]7"3@%>X0(203PI%\H@*"D:X\-VV %!=P$W&HB0
M'3U_;7M^P:N@E_QO2QTY+V$+R\;'X?O9>2G'WX\[7JA-:(D'!VZYZSID6$)U
M1*CUYB^81<12=R9*D,I^65BU'K'(56DM6W<3<3-(^V0Q4L\R4%!V)G@)AX#2
MM7A;M4K(-8CWX83-E"^ENJ3WO\D2+5:K\[:AL7Q=\?";,;./6'O,7:_?)?MC
M%X$&RMV94H2#,S]>5XS6J)9PZ"H8*D:QI!2L_[A2Z/<'>]GO'R]=SOO*L,-2
MX(H&-E/1 &>> AHHU,0@_LP4TNK"%\U[%%7R[BPIQT?9X%+YXT$,HJ8/U[CS
M88')0]Q7<](#Q@OTH;I99E1'D18__[<&V1TAL__OJW^+5U:]8SZZG9=>8>=H
M-$%I\VW:)O8*:/X\A7H440QC7S=7- V*>PG1P)@&N+$,$[:GQ&/">]!YS"N1
M:[+-*4^(VZ!ULI5G;[7*(?;#BSE(-."U"MXMN 9;Y8(=]V+B;'D,X!(XO51T
MOH_AH9/\4F(FAB$<NB0+>?7_-G7\]/H-RXIEMYPT;U;)Z46LZ#X/*X]%S$#.
M&3LF-=<\@6'W80"+GBZX3QF\ T%UA".T8XT/*(S/5M! 29'8=^V(L-AVQ/QU
M79((F^?I+%M""Y":/T2[)\PENS;D^*FW\O4C%/C+03@54J(<3A46AU,=4:&O
M$&+5(K6/W]FKOG8Z*H3!<?(8H)*"P<TSQ1C HFW;XA-*V(2/2OJ^.LF_,GKP
M(_?(& ,_V3'HJ<\!O//MMS-5OWS.^RH",1X(Q9"GR!=A@K;(0?#J/=CQY@\,
M][</6HL,O45K<OL;IVKX_[^0U3HKS7G$^1U^%4@=]NULJR'#P;ZK :KUL$HN
MW_5KTAXNW.$8>:<J6'!%V6>IG9O%;;K2]MT+U=!->]0,RG,X<L&1O:6Z K2R
MK'I^L0\_]=^XH?\:&60W77#FE)3T[ B$R-UCPG1GFLMA"NG'A+\TN$6L?Y4U
MZRDQ\WN"4XR[/&+C$Y)_2"B@/,_:RSK3 FZU9R#C=YUYMI%=Z_!KCRK5>O5O
MX!1>% 3#%V()H/</6BF'5909ZC<1?FI8N2K*K1]]XWG;+C,^8Q^^CCW<MF$$
M/ :S@..FLXS?Y!B9?KXT&3:AGA >03U+W:HL# Z>)H;6#[^8::;.W'@ OGY$
M2;*%O7.IN,)G_R6K#>.^D<,\R-OU.+!6UZ702MO5*)6ZQL3,.L\R-'=*BH@8
MZ^F>RY-+$7[X1%@X;B-EF+E1JY[AK-D\XHI78&.>O5[/%V=X+4J,V2&M.A9J
M^8@ZM*-0I%!A2Y(!"F%VI[/,1\@U"*F_$5/EZ/\VJ9\FZ)8VYV,7X41<N4YJ
MH!WG5\]M43V5U*2:_4U_:J+%WDGPQN1);FQ?%UPPX_,=HG<BQRJR+ICXI9[(
M&=( =^9:)TP2WD8#]T?+^>66Z;)B(K=V1/ (V2]TL^'A\Q\'B(6,:&>="5F+
M&%WN$^Q4?C[0<T0LHQFLF:15;)]A-"4X*%FY*"'\Y*!G'3AL1F3,715R8^)W
M.),!NQ8+U;)"(-V&<*(%K(\N! H<CEF(FGE;7W=<L1O._@;E \_CN9+OK'#;
MMZ;CO0+$+LBIOCQ<L=F]/C\S+YSVEO]%N0#Q.GUY?2$[1+W2:S.9(U1+&^=\
M,N'A [5$D]0U0_.0>B9#YX36D@U%H9+F:3I8/Q6G066LHP9+UE1CA 6VO H"
M.MNM-Z%=60J_#A&OCZ'O=N-MWVL,4=#IA5]E]=1AC0PK:W\K@+C%=-&:=)Y!
M=K"[O72?9 OES!#RUDADN^U.FXJKS@>$_Y'M4'DWH4IQN$9IN1L+P=HX[XOI
MW&/A.$6[*!T<N0GA1?>FNWDCD(ON\NE6]#I!@@4@V7*X>'*J>->1DVM,]Z1(
M('^ECYO*NJZI6IXW%H,4TRKVIV+$^9S/0I)YTVE8CDE6&U8QJB=I";3FO<R_
MKDJK7NF+$QEE-U*=C>)P?F9,9K#*ES\1^FS,S)*?]M9GLI!V;SG:[$5/%3ZO
MT7IB:V:VS_"3JLI!#330O/# [":?BYU01>,"A[DEK^.(35L#A&Y]AIQM5,C&
M:N2H9V!%,VI:KOI#L=\R?A!/,^W>PMXQ\-BTXG8\L,6R$/Y.B)A0%];G<'Y;
M)TZYE*:7KG(O;2\0N/M:8EE%!) 4TYZ$D;O?M,VVTB;?$%YSRI0^ILG9IX+*
M2F[K%I==3B>_G4C6XF)4=29N51WN+5A'/GW42%<@1L/MIWL4X?<\"I_DAL3*
M=L(,5Y%S^.Q.H!#DLG/=YO5K@H;L!@,[_->O^"WK&,JY/'T\'__XP5;H(&,U
MX^<O*22%H' T0&+&RATB./ PD%HDN2@T*VOJ+BVXIE=O4TQJGNEV8_S#T^1B
M-Y*DIWABG8$3!)?N8$]&20*O[8V4YF%>-*?;"?,3;FX)%SF'D5=,YKXR181?
M?TS7;N)U+/$TQ%7'&@YJ</4/1MY-;\GHM6'.2<=,V((2H^T][BB\WK@KC+XO
MDB7OW+F30F*.@<%E7,$9^LZZ[G>S+:N31F"YP@F44%7>)JS[_-P?J)3P:+4(
M).^^4J6:0I2VH9AWV22G68>O##0W?-13:WYJ5Q4(S,G)8=!E+6:^(60*!8*O
MN:OG3#V6S5&:EQ^U+> G%+R9]4TY5Y[A,J'(U/-G>"XYJ'ON0G#;9@O?V,#<
M!MMT \LX;1%AS2GE%S@# /GK9W01/)/UNJR,*_' 9CDHL)ZJO[SRP*W[]0B_
MBD*L606=X[<O)=%EET4 A5X#.P.,5Z^_N\I"MNDNY)':S:!G36I/IU]%I'G_
MF70S+CO)JUNOG/$EAC4;9DB1ZK.VU-/*IJ>RV\%Y&3[&G:\'^+MK)B8XB(IY
M:%\U8.%$ED6/5.V0NA/#<>YQOSNPT3A6#>IM6M N4PH6<8QR<\LV#67!(2[,
M5)%36"@ 7(G#6XVQU[5/8UJ@@0<GK(-/1'0T=JZ8O!,>O*YP$L$L<EV^S@JA
MV6;$ N\2>;U*7U"?'1MU,6M/L>N%G"2KIPNC3U]8S )]^!<0%2*KL7]-KV4D
MT)HK9L[%72BS//Q#YVN.&SZ"7[S*;'S?2B4_3AS-MY @A2@@?.=M/-+]-ZL+
M8B$VC HW.D8V6)]-?78JE'B/-?)W$.3'\^=,<-WR=#2P=Q&#HPJ_QRUJ0E7S
M.G_L)_"/(MT[47"4 ]4;YMD?)8FF[_5?H2^TC:CX4%4E2:+SS76_C6G#M5*5
M GD="N<.MG&0BWE:/BXQ2A!F;G;7V+9H($<_IT ([_Q(>4Z) 48YQ1TH])['
M/^E>0_WFI7%IT:K#+<,"5BQ) !=X@M5'H*<\^5'IXR3/IZ#[N+]AK?$WX V:
M[WLPOT(LUU]W?5?$%%\V8C!?Q)_ S@_ 4_9/]D]'_\D[H/'O./V+$*K2@79J
M6?015-S_<R[,/ [E EW2V^LFOTOB"=$,7[>$6$)1\RAKE"!6W)$+>"7A[2./
MY._ITS%6'IDS9\$G18C^HP3PML R;$&2#OQ;>?FQI>\)W"?:6>,V:* 2%O_]
MH/'_Y?._/1^==-PW"2ER%T,K0=N/9GXR$+J2+%@1*UT92AF+C<].EV)MW[B=
M$KUU"QEZ'&[K&OPU^BST1"<3%E(+8J 29KW\"NS @A@$SPGM'B-/2,\.61 C
MHQ[AFN.])W3+R?<AD[8=X6RJVR)+1G%HX%*1/VSE*W@F^\?Y:V5W<30@(8,Z
MET<)&AZ16H,6S>-=R,%V,%ZQ0%#E3(RK,9*KGAD-0*Z@@;=I/^XU^%LE_4[?
MQ//10&2RY:+B>2LR>X\#M?!6:PV\&X]P0[G[GY^&_S@?/MHTL[\(VAD"+\C.
M/#DJ1<FY9$5R'S/LI?W6C Q,<&T]MW.RQW*\#H*GH2B,2<&]$6@ IH[1*(V'
MSY]:D<1([A)\5K$NJI/^2Z$,9L'=L\NX 9@YGOFG4HWN.AJG-'X70B ET6W]
M?%W(C]^;Y(&[(,"P%D^<^5%P7,^HR9[.V2<W-'@/[DV:C<R+Q2"VNE1P7Q7I
M^1X$J?S,Q=:^O?9',>:'WR6H,T=1'_FB >E%T'$'&"X(;ISN@ZT:^*-.5%%<
M7LS*B^T_%&'Z71$;H%UHF< I#49U]1B[$9CV:U&LQ>D?+,.Y?G3-][N/W:0Q
M1NHUR]D2"!$/FK.U,#ZX+H,&W+/0 (7D_TS>C+V-"F-BML]T%5A ZJ@F;?G0
M!4?X\WSI*(E!;E9PA34F\(!3/!@]W' 3-:06532="GQ_78= U8PY1K@ 3M$X
M0A_37=>3:#1_EXX#7-KZ^LML8G3R$-;L+S),8620:4 #!X1HH-T9AAE[>LP8
M"YUBC%)JP4R8>8G_=8FO8N;_3(R;$Y*?%!\#]@4PSF+^QU0Q1XBBO& G_"R(
M/OR5FG_8IAQ>)/Z+.\'5\"=.?T-[64%5.1B?\_T8Y0<T8 $B1^0VS>-EV::H
MSM\2Q,QD-& EQ>PO9DE)$>S/_&85#6Q<YMU+(9>\0Y="FLY31%:-.,G5XPXX
MO"A8PZ34E,S<O^G $"IUG8ZS+FH9@.>KQS2&-IL6SXIDYQW/T""EYCKK3.3@
M3,D^&=85(Q5Q%:6$5<D]ILER(5<:7?S4.B2U-&O$G%)(C5-"F*V;WPB$C1^'
M;+X19:*0^BQQ!78OM5*_\R-;19CH59R7CS9GXIXKIV2WJK@^8F:!.P4<['P;
M&&RNH.%%<?HTV3I#10I-FX,K8_E]*CU);C=\Z0;<"JCF=2#D2.64*56.ZML;
M;Z_X-%*/YSVV'"47+PLYYB2\IN]$3;A/?DL!5W)-N[?UK-]N=IY&SH9%EZ@4
MX:EXIY@B\)WT&,-SD_>+B4IE+QE<^_"+U8TTOV\IMP\<B)XEW=1@.+?7''A.
M>(6?TC'X5:ODS<X;T+,ZZ",0'DIH'4QQR)-6O7OV>.TXWFK=$1HI?T.AX0D.
M>5E KD$>'NXE?/P!3W%[ND^UA*U@<C&E>=#E51.5$FCQ;ATDO$#PZLN1K9%M
M\]#PCQ^^C#][+FJ7"(_BM25VMQSB%RS"\2]5,F37L?9-T!V]GA%)K55K$3O3
M_>A+I#\?C+!?"M/T.EKN<O>S=/=G\.68N2GM%;7!LJ1GJ(4VTKG06QR5SK'B
M R7A-[;.<GP732,3CW)!9.YV\X+#YJ4E1-5+X:%BXN8<V&H.91\S?-Q:JPS2
M[R?+BQ8GUZKA#U#JO$?(+U!GY"%ZVAKC*R*M+?.(Y=4&;4W+DI(OC^S*WQ*[
M[ZG@\-Z4D8IUE'L.%F(D "\*%NP,X"\[4R4V<GZPKY7<VP,69^:+"ZB^8URW
M%^*XF/S)4\+[4RV[*F*TB.62O(3O)_UU,HNWU"6CASK#1=]4V908*L.$"??K
MOR7&O;CP2G2X&+[SN&IH>X??'62!HBP=/CB_;IWS\N/+;T;RA!S!S)/N?@XX
M%+UW4DA??(KQ&V$?#'H ?+]4]:\>/D4TL$CF@ 8,$C"!7?[XK[DT<+XBQ$G<
M^0)RG3=V R5AA@:<T<"]H&K25[^5KQUM!E,X@$@WZ#.CA1,A+QR,-YO(KG%<
M>T4(!C51#MB:*&C&R%LD.>;-FY4/S0_D/SMSS&.=?*K=V B9B82]<W,0JIJ8
MKMK!1>BCR J$0IL20K573Z!Q_)VBR6,'3'RIJ1,IJC&B]S&5R3W]+;]1^+?-
M!: ?@3&_K )$X-$<E**1B5'2K[L,5;WD^I\Q$2@'SZ=2I!0_DEZ\J]HB9)IM
M6YWG*ZL#[6$*H9/3JV\3BG9V;$U$)O:BC "O7V"N@37OL;'YF7@PZ:0+9(.#
M99K]L[CO:WKE[S^"6V13WT\7_*!$RRV@33'KX)3TP<$- /./$1#]X^ ]ON5N
M,$K>C07!\F/!+OR$P<'V] 0#(&2$BOZC-X)8OK\GW__=@]_]5X;L/_IQ Q;;
M]=_R[SSA_HVDA(C]QX:JNF55L?N;L*>.T+IXW-@9.UM>63FL48Y=#^O^(GYF
M%T5@0;QX5?P\%W;T(CGT%!P*O&:?Z_5KIA_"5_0<WQ#N&YO1CW#/>1H$NBXX
MT8>K@L=W20('(208N$D<.EG_9M> H;UHV:TLZH*[=W3L=,TM1T_G]L,B)51W
M=#],%9YV)JPJ=PYJ]12;5O5Z2Q3]H'BP-4%,;<Q U9[H\W17M'_B\BLSXJI8
MF>/WB?2K&,N+O>IJ[AW=*'QT,9E)2>ZS/GESMI<7[BT5.V_K[+_G>8?0U@=%
M7U:B[_RL/C2J0;"YVE#:MHR_6FGY4Z#3R[D>J1Z[M@>%;R\Z2XY;QOIUK.7G
MLW3K:WK<#'(1FQ%UWZ@AAW[<7RJQ-PH_3^!.>PM9D/]= RZ+(%QW%OR@MH X
M)9.<@DGH6O6RG-_=)>FHZF;]9W%$3D_LX_MWP4VA%%^B'KPQJ_6F5KW*_[PN
MUH+UX8JI>BF55/(7MS>%G3_E#-\<$V<X^'Z;T?X$Q!MUN0:N!J>,?P$9ESX1
MND&]+G6Q1A* =!"7=GT!*NZF)\Q"WV65#VPQ=RR<@51L=K\%M\O60.YT$45N
M3W!QB/K-6O>A@5+3 ]O![[L8/Q220D+VEMS9T$&_3O*QXLKD>K]UU)6JZ Z:
M_I47'1\;B]M[\$A=5<F05W:S@D%E83F9#'Y# C:'A'ZZ4W2%K,H17PDB'N4>
MM&5:U_Y#I\VA\)WO'NCSWSZ3F#,IJXU"B:;7?7P9LD=<4O.0P8W&.*;$A9;)
M5]%\5[^1_H4KHZ.>R5AFL+50:/S$Y%<OFR7.9.XF]U7%'H8[0JO@L1)7D364
M(/AY^^I,%L9K)ZP;7T#2Y+9EM4G$L;68F3''%S<X75,2SP>_IO/^O*_F*NP*
MT=2G0-[9W6JTXCEUW1P2F!W:IC+T= MPAUWU(V5PST8PNI=_^\FP_V<G2E(I
MMG,<"L;8_H/V<V3U_[Z!O.K:_Z!,@O=:L-_+@'Z^NY!!]:_SB_EEO> 1RV^*
M$++9FEP;)<,]&2/P=$NJQ."0IL(_]F.S$K[H=46+$FKZ/9/O@2"U;J.H4.48
M-)&%.E-%\4*KQ2&6)"LBLF\@NT6'12>'H./Q'TOLL!'8RO<K!RV_)Z:]81Y@
MZGF9;;"J31.?49$F7J+D]B+C:8S?@POV+8[@?U+089+J<4&Z_1L=C%<@^/$K
M6Y#OEQ!F_<ADXSNW1GFHGA]AA**1VKHRN;Q:&/V+<.$(G=-1Y"GD; N$R+WN
M,RY3U3WXVXET0YH_E^9UQM;5T;!1P4*=8D0PQ"_SMQ?Y=<7"#1**Q,I%Q#WH
MFZNXG![[V>5UH&DK"4TF5J^,@1/R*NEEL&LO"@VPH+@^BUF^[!7_5$>(HO0/
M -69HP%P.";XEO^%R(O93=:5YI>OPA$:S*RH0\@Y"H14!ESJDD+K(:0Q-@12
MS(KC/MC<.3EY?; Y!6>?LQ'P,0(-?,<D$7#\8PPPVX&C@7D+[%Z+(DSL[WME
MGG1'%Z.^!330W(]1FDPSR_3W!+PV#'Q((?W/!//D^2<;V:X@SWJ:#69Z.'_Y
M87_%#?D:I[@KW#'LF>(;A"T@(G>9'(2_6K5WF_NMGNW09=:OUQ3$R@&7%JHQ
M#(A+@X/.L3%#[QH8J<6RFXU4Q?AV-( ,_GZ5H"2CV;\]#3>25Y4"HP,0&F#[
M/O@D61C^TNO]1RGJ[6 [#HV(PB_FQ4=4^EN#X%XYY+JRZKG3PCFNG<1-1$**
M,_W>2*=&_+*-]+IP/!^3Q(!23I=UDX+&#05)YTGG7DJL,8]JVY/5F226EPDH
M5Y&5QT9,<)7H^6Z"7MT!V[G:P>N#[B(7OQ'W7&Q8O/SZHICW#<MZ'KBR_SLQ
MH;R-N)YNDPS]NNZOGOB16G(J-.(>V=C@WX18/7LSL]\/NY<>IRZ4[X3;;'>/
MSR_"%R"+3#RWW.*5#QU@6V%Q\=P8\.3_M7J#G9!:XRQGBJ9CO9[L[8K8,Y%\
MOFJ9JF$\&K&])B&=5C1P^8VM?Y,*:M0M[7K:;?WQ!C-KSJZ2ZE1'K,L4C=Y@
M F!#8DH$>6#;$P[%6")QAOU\$*DSY '<R-<L?TVG>,H2&EA_J6&BTIRVH0'G
MLA1^A!ROC;Y>>7]9S93TLWV9Y[Y+2J:WOM[\QK88O37B*53_*[-<;XMO*=.I
MB:9766\NB%\UC6$#OF[0<@,U6-%KW8#>ST;_E""W+""?*DDK\(O&%W(//IIF
MU*U!=[93:2M2KG--=1\EZ.,XN_V,J<^?>PGWDBVPTW\M7 4B1\KN'OL@9>:Z
M276&J'LUX$0[-IG-7YN5V3P?;&,3#CFT*K;08*)Y<4N,$\5IS^:!\P^_CW_G
M*'7IO)'Q]FT3PLU+[2V  ^0WQ<I/9**!Y-"384TV0-$!(&Z.NL,,>Z!Z3SQ[
MVLKF]07A.3_N3%)7 'JT!EM)>_OF9Z_8)]/#_9+F:T3/\KC?^+6B/(2?5ZI!
MZ@./)&ZYT*VZC8Q=<8V0R/2\]FLG:HFM(M,$XI/5UL_\^A$#9<4IN.FR^+2<
MGCVN:KA%/U69]G.T%CN0\U*K;1T_BHP^8%KWBYDGOFW@YU)V+CV]Q^>R6!$S
M'W$Y*K4I]8#5FQAX\7?U4%M,'5T+Z(4Z]GU)=%T82*T;VCR8X,OKS,M^4EX>
MT"U6.'O-SE/Q^0$M3A]>^$\%]/_60@<955C%\(N"G6LK8>L#\T*Q5S_9=*PW
ML?JL2E%]_'[)8:*[.8OO\-2A_.",!H/.S8!8=3+<TJ:73]LR@#?&?Z=34)GL
MXD?W;\C4$>4%VY6!/*F\B4FK.$<"#@I]><:PS7=R,BLO1U?;ENYB9S&78>7]
MJN-'MYN+73(?-QOO]U5.G!QDL><'T3V^E>RK(I5""/JM(IV'V]4VS5YAA])?
MDE\Y+I?D_8)E,&ZU:QF^7,K8\VGK,ZW7WO<UF8=HX-T9QEQ#*GZN\.0S_ %P
MIK\>>22*,K$@N<=[D>?0'RM5++L0:]#^T<SWY1^A'G79"+<[CO= "-5RR,F9
M[<]%'XD1\,H6;.<]QBM8)Z:;/])^_B0W[9KB+*GK-9^QIN(!<*-' ;AW CQS
MZ3<7<>D(XQ] -C]7B8PTS7(G$6=J$;J*G$7^_!!K@ROCQV'W<I._BB8?CGEY
M!;V\2L5[,RR4+^F?"?;@*\2<I$W^[YD_2!8?T1UBJ&BX<Y:#J7Q41"7XW,I#
MEEIJ<^[;YEL.1*=VG^ YN3Y?&N&DI)$&F<J"[R'^T"@N!M];-\\<D-F>'6,,
M-(4A32OH! =ABZH+WWNPU_$%GKQB\G<D\DC^(@IPGRQL9Q*,5+8;4F,OQOC&
M\GG;TXO0\[/PWY;21@-AJVPSQ]L@%%?E^B7 -!%KL@__+SA!_L;)I3>@5H;:
MRR)$K=?AMHOCT=IQNOW@[G%&W\%9)55A.5W7Z#YI$B5J^\H8I9OK<0JI[']2
M*P_V?R87#_8PBLE=:E1HATI/S\CHH\V,XR*/#^BJN.<VKKESUKQYP)L9,BOA
M/N,2&<KM@'J]5]B7\?ET81=ABTX8UEYH8)58E_D.QJ=#,>%@T4?0P6U)>LAN
M12UF=DM18^("N]]BB7&XR#F./NJ\[7NW,,D"CJ!_?YHQC(/&2?@;S;]R.MG>
M.$Y[EZ8U>(9:P+_<ELR2OM#?-@NO_Y-N9ED\7=+1^VL7Y<FQ*^UBENO",=/3
M$!-Y23U:Q5XAO8BD&[Z.-)[-@Y"ORKYIC38:*3P8CA,^$J&A:.+/5RV;^P"T
M51)75UV9#:>W!N]^?"#&8O^I-]=97[.LNA1:<;.!?T$EDY+$U$24:O+^!Q9G
MKS5C(W5)9BUXENI0D1CW7 (#F(3X;?^VB;*4<G&U]>-F;I+/_H8K;VFB?:<2
M[8PTT]P91FME4RW)G"&RL*JHIKG#J<2;!EU-G4/U \NXK,)$J<(Q=^]L_KCE
M<%&5P5T$?KTF:]UN0X)\Q%UJ7C1/_%)9DHI(EZ,2N<Q1Y10TM&#Y6DBG#^S5
M1M#ASCCA_:%R99,O(D?"TZS)H\I#A::U"4T,;R<(Q/-:\VMJJ)^0CM0Y":KA
M=\\0UY-9%8%W3T$4J_;M61;5+W/[91RX"+Z.6ASY+5X9'WS?2=';'3U2.;0K
M$"9DR-WV>@*A<BQ=/>S.;F_-&9./=W%&[4RCA.UF9$C/9>B.RJU+19]74T@3
M:^5WBQ[7PEE"Q.1)8IQ/,::AG[N_,%9[,K:=J62*MO45S84G2'N?Q)'C+9%/
MULSL^OP@E=V:#<>HQ].;==[?)CMM[<OO\^0MLX8[<7??G8"&E6\=J.%WW1MM
MM+UL?:H3<&@C_P!6#1>"^0F2I?>8V]X4NOC^8\?3XF6\UH69K ?*JG/+16YP
M/M7JFMWD+)=Y!C"S?)[BO/)8.:H#.+$BV0ZZ:"Q@VR$EOK%VRH/=4B_N?FNH
MGL,YK^FJ&5%0;/7S[/YUPA ]HV?XY<_<*#C J84LJ@B'!5NJ#7JGX,-0$F71
MYFG6@?+^;&D#$Y5;>FVX254O9^S"F29'AS!*[=1T=FIF%H2:#=?>G2\@52G?
M?0M)_[IVH?,:--(@[RLU$QJH#5\Z*9$[Y*9*RW1VTXY3W\W8":EG-C)>LTQG
MT.?GDY-9LASUWOKP$$X'>FT:W/EB<;/INO7:PWY)ENO6:( $J6)2*A*OM8EB
M8>8<O5[TXDDI3<C\<[P1>Y+#:1@8GQO7J^6-,>V;C2*BM^VOOM6.EQ^V0(],
M.::@T1X\(GVA(3+NA8^VSJ831_N$C-" :ODP?VC=5IF.XU),EV:* Z>"V1WQ
M!B#\%0_V4K?.W$[ 2^+#D="Y AW97<ID=N^E6B'QS\GV!&-EKY6.-+EYS'E:
M1.S+*H@?8^P@ITO^.^]]U1$APUNC#7KOM5G&GTS4ZNR\Z;6E#378,M4\JXW2
MDEP1.KS"D1@=O:$HR<(OT#1#;64D4%P%I[?.<^"L#^8,2WOZ#'I+KTRM[2B@
MJU5J,9JW'<;KA"_N^FB$!:]Q;,;9SIW%P0P;*64HC;)XWV;KEED651WS:LQ4
MZPFM7<C\_]/>=88UF6WK#U!0$5"*"BI!P0$$1$% $ A5FA(C0NBA#<4(L: &
M*1\S2!0$@B(@<"B*!*0J$$,31CHB1EIHHQBJAF)""4%"<@(S]\@]]_K,G//<
M^YSSX_S8?[Z]]EJ[9']YU_K>O79MYN-P_4OZ8G1>%J;KR'3-H1]P[GB4O\A0
MX<R=.'^MZ8O17=9>RS]=*1C?7#\C\*&2.YTA KU9-$3D]+!AA8N5#2V#X%FR
MBO=&:X[7IYFD*9L)I=<F+H:*\TR PH%6!;#P73=/W7WBC+%!G)&<\2BOQK5A
MT+KW<UK;/K;-\W\AUQP9HH!W',EL4)"IZD ;_TSSTO%?<;$:;P<QQ/BV*_=>
MS"=CR/ )KP 5I!M\;4'U@0PVJ;%/!QI)6.6K[W;NA^%]53PG"Y,OM:BFS@\N
MI\Q! GTO&2H_JO8NP43\$J9"UXO#)Z=N;LY0G0E1OF_?_[;^Q&GUY]5QFD+Q
M.\W;2-83M8G<.3!E)E.<N/XC)ASC:?6N:]*TFBXQ,Y'VV$7L4/F+45C,R4)O
MD]>%Q6_X*=BW/"2(08C@F1^@$;4[<,9)00MY"PMQD@&><V.AE7;*E2=.1MR
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MTE1O+TH>L;$A-TC.9.]B1,G;PGMK\=6I"NM7_*P5X6[*;E8< TJ#KO(4R+9
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MY!^P/<B^UO]5W^L]WJW:N@@Q_Y43J A8>5= "-SG""[G4U7Q;?RII-.E=TJ
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MBX^9\GWH[IY3*!S)1L'?R$:1F!_;"%&[)&Y/V#1K]T<NP[*RCA'FS[IW1]0
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M:5E5/KP/P?\5QNT7<^:[,_3;O&%$LK*%3RJ+-)G=#3DZ.5(7/*O9F_KV\D=
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M."06CE8/'#S7C?KWLA 0/>>Y-8^V1S"V4GO)BVFB,GT='Q:@%&]IA-]4DU!
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M,:;@Q96J_K@_K13L/:PUJDR_O0<#3BQ_CLALZSH?/;5R?FG^W^_E4G[O9GN
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MQ)>(4M%".F2I4:W/Z5="]H(>.7L%H;MQ.ZX0VN Z2MZ0L/MD-V$*W(0T'!'
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M98_3R_R>/Y!14P(]JIE&ZA@)QB4;-5GZFUOQ'&\B09L;059J</"2Y#1=#X\
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M/#UENZ/\<O[^2A<OI3GAB+L 9'+YXM4.TB2ZCL.,XK7X !_%Q+6,O?-*JB\
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MF*LY.5'Z'N.%GL?+TA8#6@%,MB]A?AV3JK=&Q/ZAI.:4=$1-4X5RHCR*O]D
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M]=EB2F?@]]I)\8RSRNG8"\!R:<<1FM;_K13C4,8I])1G0)J+?V)"[7#L4+6
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M-^_3^0I%DY3UM/C;$B_CD+8ZR B6R2QQ;,7WY#;ZD.#D^L?4\!()993!790
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M1C:D]+==MI;"1[/^X%45R^:29X#V-W( P+R;.8GA,C@'[U[IL'@? ^L6M=?
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M^ CHSDZ*#>UD8N=%]Z!,'?*(JBVQO)CBHA"X: ,XK<1E6ITQU+U+62*]*TI
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M>*[<V4?W%L##H8!3DT!;(FYJ<@*[1&2<978-MF'Y_D@H;=EP(=1Y_0I M3=
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M&9YOK/TYD0T_$'K6SWTX__.ACVJ/\C,@E2,UA WXE!VW&3K?YS-?YD]L)EP
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MMDZW6L;%\U8/A:6B/+JHF;3]S?WF+P!3<GCISQ0EZH8LN!1V^BWZBP;][LP
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MM[*U3,[,6S=;GD7]",=8X"+I+5\,2!7%J$=51LMR4JT_E?=)(?5YM*UA+"X
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M/HLX9 [/JY9]?GI9Z7IHZ\IRG[O;FWR^*IIK34.0UT.;$IIB#-):%;4_1WY
MA$$:AOHREI#MHD< IG>@[]! 'J9XN0[H9;(MW_SE)>4XI_"N^7;XU)YO"[?/
M9UAE5O#3[K>M;2)N[V?)'.V>)R')2%?\F0#A5/U-+8O.E/+PE/_@JTY75E8>
M3V;)@2 WT,!-+#E@06ED9:+TP9/I]7CCKHDW79Y6MW2D!=)W6F2.4T?':^ZX
M]M8=6TZNU)2'FM\A\9=2%Q;#+97')&5$%^?FUDB:$O!%!P\=985HQQF33B\G
MP=L=":T"7^,?WQ&KCPNX)G]#Q3X^0DO'0W.3]K%YKVL:\:@=>1VN?&C21]>&
M%8[T?/1 (UH.$C*G0E-F=.>V_CZ&QI:=NQQ9M(;E3LU?3_&?]?*#V7&ZSJ2M
MB,E^'AB03S"YH^N:T#3Y]4&M,G_LO!,#V1OW)O"__\CRGA>(^OPNV<P.=S0,
MN/Y%X/-B@&N#@J:*%?&T#>L4:D,\RP^ICC2C=C$V$^:X%C_^0I6W^KE'VKP[
M5[#3D(I\0RBO#V<>BIC:<O)R2C(V4![\85S7+V^L=+_NX1.-"X#"[6M2:*IE
M5GG]].3 :@9I:..$@X2FU(1)(T1X12=D6.)7.OS8_)GTDV.# !\F]<FLU$+I
MAG>9S)5B\I+_JJTUJ1)+1KX:J0;9Y>Q]"-6LCIGE(E(3"@! @(L?R#Q"@,/%
MTXHWOI+V4=:7MO\?-]Y[9V6CZ,VIA?E+P%.P/'+B53GO61S&&A+B_4^/_$/K
M=CUB8FTV@2-L,<4D\D]>'%>2)^UKP67%"$P[U$S;C-BEE<0U&&B_?:0U*V09
M 3=\6U:LU=\S#NL_4A0ZJZJNDP1C7\YS)796SAA!"MNO_*RTXA;W E@]''&$
M[Q>!Z<M%D):Q6%ED:$I4/+@=PZI5N7IT2PI_I6SZ-K""YB:FMFO>8.;.!+UV
MP(WRV*\_?]/,.*>LQBB.ZEU7)E5!H'+YM=&L&E>]RZJM[,P4&DO&3V:.J2>1
M;7MG3?S?"E#/R*Y6/S]0\G9X/<[O@RHN &ADRPJR5;F:?* Q$%2;\,H:73=F
M$_**C2.0]1(;YZ[X<-/(H><9*HO,E ^/[!^?[DCI;T XE4L":TZ?(AA'IYM.
M[L9596AD@";LEZ*C.5\#-0Q;C=R:4S!-M>IMZF7<GPIS\K9/#H;\?N\YA?)4
M);<C@^H3[!69B:5EWPN8'PG/&3GRZ2F\:"SI=!V<CS@6:<&Q^#XF0@\'R9@B
M>+>NPX.>)2MT\'F?8.>B6 ?>F5V430\(I)IK/LOZ5;# Z756L_2WM+D!Y_&]
MR50@&5A9[65V.+*MR<-*MK7'U0"W#/ 7 )Y)._:0Y'_%^N9C+0;CGRE=&;TI
M134A\B A)B)M_@MH322VR&3>H./=)5ZRDPZ \0*P6FG@I:1D:E"=QIMM1<?;
M)#E3#T>H:DI[@F915/ 74E R/S1,+,<Q7I^-2V4Z(042VZ-"N3V!1]&<66<@
M=^G'CL:8)ZM $%3"UJ\=L@/YG.9A[PZCEE-5+WH!,^\KM/#=L9F!@B1KDG1-
M?S:@6K?P#3YT#:=P]I=V(E,Y43M4O)9_]0\>?F)[4+,?;02VBYT&M9U+$H-S
M1YOIB67I2Y RB#TQMSU6OBB/F+.4^X9:#. :<:H>$1JK);UX],O4R4^04MK<
M=*Y4PISKZ.2QKE^+-O><UNI>P6RND<28I@;:4#<1+&34JU%4EPM4W6V# \02
M;Z8T=_^:WKMK4U_I64FAO#:YKBAZ!!>L6>8LT-<Y;^VNRZR]AZ(0K-V*/2E>
M+X;NW?IG]WNWG'%V5&D&:V;,57V2KE%"_(2Y)H/$^F\E#4K7M4AJN?DJ*ZY[
M@4IHLAJ)H\V<F[A<L[ 3>;)<B[,)@="4]'VJG;CTPC>,Z/7^3OR=[=]0K<3_
M0=U[1S45??^"01!4JM)K5$ 0!$2J5!%I(B @H"!$1'KO04(1I)=(5RD1Z372
M>T)O2B^!T$,OP80:2 C/[W]OWELS\WZSUJR9=]?ZW/_N6>?<>_8^G\^^Y^R]
MX^_Q**1#5WJT=)U=0TA("%K5." $5[*?1OSY^3, *I7V<V\R'>[F'""^A-/C
M#ZTV2VYVW&IH&+H$6#(.N4?\ZE>Y$CQQI@G<EF3([J[>/(!K3!MFD*_[<XBH
M$:5IJ/S(T^JP0<3:SZQ#E8#[7JZ"8D2!BH;TM2Z)M3BHW*SG7$O;J:I"\".0
M$]MUHN1 0<5Q3A%CA%A^/0)W4;WDA'"?S4/'.0SGCC+)NU#3WQ[H8-VY!%2+
M(U><0V)S1,)-)TG&OG@SBWC=@$O =:LOS1_@+!!L(DM2)[YV.2?V(8"Z3?4_
M11TG5+L98\SENH'TX,'##A6)"3'R8$;2;,&: 7 DOGLO3SZI8^!VF/QJ*L&2
M^*CALXK@ DD=[QY72?)=?6PMBP?I.:1[/OGLJOC^J:8?*2\+8,"#GS!F?UK(
MGC0X/*+1]C?0:@Y"UF3JG"Z*WGR^LVN57@='7 (DOGF?P+ZY^#!>V9%"IEE;
MK^KQ;>P_?73KCLI"WXS4?9(H;1]:9K&): &V6OQM.:FD_!"7L'H!UTM<6+]M
MJ76  1>\X-G<W_S4OZDRL(J\NHV\";E32G WNY6M:AC:Q?^$*!!_;*8>'FE*
M\>EV_*>.;0LV4ZRC/16]4H,8BU.D8[3$'4KN3 !=3A& T>G .OK5<K)YI>WI
M'/GZ]G!XUIR['G >LHI?7=E/P4TL+WXJ<+R+41.*._K=TO)[(![%GB'A$VD1
MDW6QS7/@ =@#  #!XWQW6PE /(T^(:'00L<+O0CU7HEY'R-G=T0-,X#X"/3S
M/=*6-UZ*#[JO(?\>W:"PL7C^-S#D2U&D/BEQSF*P;UA%GN#HBUM=;NC\^JZN
M<<H&I]]2M,M5C>ZU^S;V[.>.K0FG%Y]?"H Y-+C.?M4]L98Q 4%7C5/])%/&
MR+*#WLC]<) @XMMDP?VZ\OV_I2#R1?0K*MK#Y9J')E1'YVRQACU.18(!]]"H
M3?@?/FZM:RT:^;#U,SY!? -9%]0^0J1=N@1L,T]!T>*V&48$/6N>KVVPWFGF
M9Z$?4F,$ PQ&Q=54L6;5J,>E8&:#:8AG+OCGOD6,N[1%X%>7BH;B,-FLV\EO
M;3R#8G[=FKF![=5W?-JLSPZZX8SR0SXJTJ@358V!CP5':6FPF-V<9L5+8$>(
M0KJ85\V$F.5=H-RK!/\==% S"75-=;V98BJ4V%5"J90$<C6T!+\U>2%H8@HC
M/?X=T]7%JC<!(TD2;%> [$YD2CQO3L-/*YVB'3]WQ&/C8U/>&TE?U);#PT%%
MH!I5;-0/B$-UE,Y4CC)[3](/1D=^4@;'SFBR5U>3\2&#]Q<YH,I%F:JU=JN%
MS"4@CLS;P5M???;]KSJ5@)D>28\!K*7LAROB>9<3H@(OEV%D<*JVL)R;W_Z>
M5@Z3-N;7>*#_F).&ZB;(50'\=B=#VC(?<;R[  1R8KQB6ZO-XHBP(KO@;;J'
M5#SA_7=3W)P/)9;A6")F"=!'G8DI-HBM35W%TA'=F0*K,"\"EW.P(%N(PD65
M"@=$(_(.8_2[<??7WO:E-]UOJX3[TX4LB($$8WY[RMO_U=QMGCR/5[&.ZI;P
M,PW*B:I-I:E[V+-M.+>3[N\ IY]\)$H_J)ZH5?'ZD.6 U_,8_N HNK74(_Z&
M2\;#OM]#7"&M[6:LJ["$16J"-^4 AO'6Z]>/+@&_V5,Y+2XF@5+!@"G-1YGK
ML2WWC.)9U_82Y^$_*N4P[CTA]! !W-YY7W2=</E*/%-2^I]DQ*.;[&621T"K
MT.]GBI@E$DOPN/!F%8XZ&>6U5CQ9QWJ?B:^,X\Z<"E'R+XB%L(EACT8(.AN4
M$E),8*]:']\8SWI@\Q@=*V^X!X#_[%BK*Y,1(>^%  E U4:<YYL>$9U>:.LE
M@)$@]#-X[!)0BVC GUI2=&TO\M1YN4HOSZ=,_$GA8>N0YV6Y1:TC,'.1?@FP
MPZJO;L;G,9>AP>8#X3OL37.M'X(W5,U<R)1"$\HT>Q-$3@)TU792H;Z&APS$
M>65E#K"[H$+V.HL:B!]<CP:VSR7S(%=Q<E$^%I82ST=7)RHJO@C8H;6TEFT\
M7?Z3X4< !8_O&VTW/J_G#A&'X0PD:,,J$DJ.XS47@T*6>=.C?LX0W+6JQVM_
MO]ZKW94WI0T$FUWG$FX'!(D<>V!QAX83#%CF'JZ$0I4]]L]O>X[.FHIA5OBB
M* /2"Y_7,G/6_[PAEP4V9<?&#1D!T87*ELR?'XM;<E4%]B$XFY$6KO9:[J*6
M$]6C6<LO8#W,'\-).TV$DD(HU>_*Y9A5%=TWS,0.STN $O[X[_;0VS&R$#CP
MM??U-C9VW=\6($9!%/E\]4!F4]0Z'WSZ&B4S1\$$V0N[*O_>K/P/HF+F/%BF
M_/;Z_I"+[>-BXFA@3@KNM#=F58])?^N7$Q-,?&?!8-ZM._#F*,H0)+-U?C$2
MIJ3&5G*EIHM<N4-Q"1#C'U&-WA'=:E-\V3#E\JZU+LVN(9LRKZ3_]D3WV(G4
MA/TOZ]W U[O-#\8T6/M]_P]12./6<5>)_0IQH8@/.6._.S=+;SWT))@,"@-^
MQO[7 (== AQ&KAK@=[M4[N&&0B6HD^P.>W^/6^!:\IX$5863CS_V02&&XN'6
M](4Y/X.<7[K?'0:>0,U4!A^7(1AQ?ZQ81E>J-0_M-G1C1A;3C7]+*I]=B!:F
M+E"75DSW*;\N'9@(]%5E%-L7]\DD%,7DH _0+[=FNC1WO!BKJ,SVW-O=8]*1
M;&1VA^"[H3^'I"G<[JB32VW/+(,_?>K]&,]W?$8D^D 84E;<>P(3O#J7[*.4
MGF%]*30ZNU2I'2Y4\.+*F>CRX&Y@[0V2*+X&[/VZ49+@;_'EJO^[6^C-GU4C
M3Y:O"DW>D0>@T';2IC:?$^\F5CB3G<_W((E7RMK?%SRM'#$XL-\^7>0QYE1V
M'.U/C-WRYZ<+$WG:@DC#:<VQ"EC10WR)EMO?83$^J/$'KK9-<@WIN-_K=%\Q
MAY12,.M:^UV0W:/W316@]F:_*N_-$2;[8[@694PB&[PV6;[*1S"ZJ/];!TD$
MEU#F," P_?L@E#DQU"ROHT -<#$ODC=C4J'X/$JWGJDS\Z4?J_WORH_'V8Y-
M;[?R](S"8M[<GL,:"X!+KKR*XW/.6ER]*=)Y3_A5S_.R1+V[3^ANG)V>S!+J
M870(.B?9DX.(J;H?/D03F@WNCD7RG+'GR&G].:K5"5U1'U?T=FGQ^1?SN=QD
M'8%WI:7_K!Y'TQ:L09Y$\JP3MO'BJR\;[+E8$W==%>ZMWH=]?^LG_N04S<*G
M$?C&E!Y3=;UNO\_LG+__#UZ77BW_8ML!^>>0D0[L=]JSR#_Q3]JQ-2(GQ6WJ
MPF0X!1?"H)N@!KYKN KXIU;>GX2/ T_1V^F>YO<4/[^4(B3!>A'4EX P;Q)C
MREN\'JK;59^1D.%H75$[NDVN7H_D4\OISX>6$<VV"OSM&PN,2G-Y\Y!EEP!^
MJ&!7LT^VH[M8&R/31:7*XUU0S26@JT*TVYPW.^*X9[B*]7/5SK7]L'N1CAR5
M?4;<DH#K EY@N#@^ VN!=UZ)K%M1A+. &9^F/,.;/QX_PBH<J ?QP(2U"].@
M&2V/-/69.6R&U2A__NO:9X*B%1[9$<35U]4LG@NWZL-<$PITE9W:%WC=TS:8
M(1*:_:,Z_FC-5 YKN0RZ!8[<798?KZ77?47^,YGGO&KK*- YI5;_6_L5;_BZ
MFS[-8) HC\##_6Q!H_N'CZW(NOJ%,R4H$Q%YG3*ON8WC+3>"_TD,(6H%!OW.
MWH6,"0:.BC%WRR(=)O9]KMMZTS*M/2C4O)-H\T'QZ6'8(^&,DPA"'%X7XQ[;
M*H&+4\?MH4,B!8C*Y"J,XSU)75E+O]X[[SS><%#VW]&1IS+5Z@NA),297]2H
MW'+^&!Q>8K4U_?"9>!UWH [?XGQ,X7N!+_2E'FIKB7G3OY0HV.-#;%7C0+>2
M=__IJQ@EQY616XM!2 ,D;N%;LZWK075^:-"B(+K[Z/Z7:S+/TZYWO/ILIACK
MZ-.V=_[7[7-S6I[<=9V#^S+!]74H_?7=$337X:K6WBX^3Q-/G<06_H\AT\T:
M.!?/MJ]U]VU:]G,D/QQK3DI)?+Q1K<)*@@#_.<'W(U',L]MYYGBV*M] V\+7
M4EBM%.S$>M8Q^E$>9?)K!H5H"#\.U'L(>4 X7=4+5&NNPC,FWLG>@ZC>XA0W
MI.TG"/_([FY\B0R\IL,3NZ&D1E0$_^X!5C-V1L1UR64HH"+=W0L1N(5QY;8_
MHWK^_$PL*Y\Z<]L[T&N)3RKKZ$2M!NI^#]<B8)0DB=S!S1A0J\ZAEPIL$910
MI]RE32#B1=MA;!#!Y4M ["(01V(CBUZ5QJIW025?VW'PO0I[ZL_TA@7;SMU!
M%?N9/'H)N*4B3'J)MX\,9G90X8:]P-7F:)R48.X7WO<4MK-,"GAF(\@C[D_9
M(!#ZI%)B1:@+%G4*NZDDJ1)%?$SHZC*KS[CO+5N%H<TL<PZD>?+&DBKE(8RN
M%("6REJ-=>\JP&?LP?&!F%=R(8P0W54@ SC]%'L>G+OR6[6.R7^PO_I=:*MN
MY  52S\5UT::"'N& +M"8LSLO;]EU2G;XV0_!7[3NKPAH?[%'6R%+%)D=WWM
M(V-"B(,[+U@40],Q0N?TD3JIR))0;<A0X[9W2N^RZ"6T_T'GRM'[ /K)CZ:P
M;@DT)0@'Q1HNAT2FURNXH-F:WC68L3-KW6G6$O- \M/<H-DW"RLJV2Q4VCQ)
M&(-X8_1LEE$]@1)7G/S9%7A1L!*"$^KB[L$"9&9!D\DVYM4[#^1]?IF8 .=5
M9"RH7JMKA.\M21G5JKA2!D[(9PQQZ-1>CG^Q:#L\7_Y@1 J0OPGPW;%C$1Z\
MX2H1Z8_"WL.B]D5\=WKUKR-C92<*,[9/TRX!]@8<CO_(#UF>/)$C,,6983#^
M%RY>.//H#]O!,M9P(::=<C)V*_^B!"'9@QL+?B 71GJDPL?9=\Z.%E* ?;$]
M^)Q9\XM^WMXM$-LG,TQ@7 ;%MIJL M&!+YK'_AZ]AF@IC_YK$&LE+/YU84C
MEC>2DW$@_>VR;)!H+(Z]TX#>084E7 ,/W9M=M0SL8UO_&;C+69G<N;>O^/I/
M#14TGC%->U5YM_YEUZNL(L$_%PO2<VG^J:YP2]>9U?@JIK!XD,AIR]^A+3)6
M/(@";W!2-NVJ9+L,I 7?0CV)_-OS7<E\WAP>)P0NQT2^W)!6O*88G="2\^8)
MC<P^D*X.R.%DQ<&XFGVO2QNU^FT5?-3TI_[@1^\LLT :C:IO$P<<AE DV'3Q
M:^#Z(NI&/EGQX]F2;',[T]D1;$/SYR[(1YE/=]29<IDRWG<TV#ORY]2<".)
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M1E6U3\HBY7D5H$Z1+UU]#KGU.--EQ5+7@D0/2^M$-41-@@_]M285F)I=G<^
MNA N5,&DSGSWOW=J5HD: E'4?;,ZE^^XHSF_MBJOA!JO.WW+:VK4/IRZ,/^!
MO'DA=;BW ZWJ:1'[MZ# 6Y28_DNZK\S)/#LGP48&>S'/)NM1>>8F_N%F']=Y
MS2T T/PL#Q-"8N%?07Y:2T:ILUM)(0U1!MU^/\XY,^%3)A$^8UVFW8I&<?;*
M+AHB-XX_)!U?93U+PUP""/?9NRM<!OBBK// ;I39B5]D_NP>.S)T70(@-PZP
MH),V0D]%E1R?RN2J$!G2[;=T?M^TK3F 0>3Y@2/D$M"/W\RVSLLWMM^3824,
MPVHW>Z+G'Q*B,+>T3N'ST/[OVT? .?]5V7!AZ]7K$JM_62_RF:E)S]V GUCS
M&T-NGM@A@0=W'Z_3M()6_O&:!-:SS64#PGU$F]TV>[R2D&U)3Q9W]CW3AB^,
M1M!6R7-6>"F"-7@:1J\B7E=7GP:_!RO3]ZM,*_WD[F%!+$LV&2'&.P]VVS:6
M/VI=*?(MV7[YY^%,E(.NU8CZ3/'/V$/&9__CR:K_=X#0OPAM]<1(<&V#F(#=
M7"<%E<KUI3&43G)>^N^-*M+TUK \##2L$_KA)<]]C0FNA*S#\EQ3EN\$. 'X
M>@PD,[S$:'RR4L] OJ?*!-.]0[VEGWR7J.@)/?Y4?\7SU-][NI+0<K*"DXN
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MQ3YCQCN*:]J<1\?;BRT&T>;4L(IM*]%?R%_0WY&!+66FB5.N.=>-!ME-7WS
M*GH$=(4G2\4;R(G^.G.K_-A'NM6'&>KY8R5$\ V43!;UX4+DE =CTJ\K0%UJ
M7:%&?6W!GVIM."EQ\ $)PKT_-4)8Q7=)S-5ZXKCG-*=/*2\!N5?A*"HE,UB,
M:;&?H?^GPR*L,U':G&2':]EI?G6=,:YV*Z8^%8)T5!N(&,G==%3F. ;4ASPJ
MWS]FI-M].3_7BO8KL?80T +D_WJ>\"5@[=$O4D_P\J-WY^&@K*6&OQW2N)!X
M,9)K03O_A&_#P5]6]AL93S[(U1]3P7S>!SB=*Z7P3"+*#+=._E&7S9IX+N==
MZ5.+2\"WDZ*]-GPG,/$20/N@[MOS>PU.P0,E[;"N1T<>RKP>73M:3L=H4MY%
MI(J$7)=$@JEYT%0'5 //($V,L.M\D$]>OP10GWEO;2#-1 >&'L)>=<OWK7R$
M'YSQ%5K&GD]1K>/%. PU6-?X?OPOI6[Z[TJ5#4#TIK!',-JW,NT,B0^-B8M+
M@X@'J.^ZQ+/-J@C^!BV*+A7)R4^[(.W@<:O;1/JTMF\"HG>"&<W/C%^W!+0^
MZIR,60OP'UG/2N7]! R%1X_L#)OP/V<[@^5_D%9.9T8?IPC!7DF^88U\E=:Z
M,!$@ED7GJ3?QH B1,11!516>W!Z[=O0AR6W\)<_3T!IY*\G$-/^NCQ4]Y*KH
M^G(WD@B^!S)1ZRB/OG"?/)>>MY@\/UUF_^S&A>;5I:;UZ%9(BGPO^>GHKQ7^
M+:C34L%5L6,:\X[]CV+:$R4ZBJ5Y+JSH$5TFC2[-Y]@B;N_ D;;9,Q6;Z'0A
MYOLZ9U=9#*U6-O[7?UI)8#F)5F"+9;&6[2TS2_R':',Q$1H,'P.7/9DBZ308
M?]0GTQ,\ ZMG 5UW+<1E?+9/#.'0_VS@ _"9>)7(P$BMGD/1SVM@#?J^7J?*
MZOPVL\+"%)$![)&>Z._#/^A&3:PW&30\K^?7/K*\!"P#'W^UR^DA<G']1KH3
MA#SQ@2>?\ V]"]HC&$LKG0=3,5%Z#2J6Y<H*MY=S:(2$%JN4KOY;6V',\."A
ME0J&7>,[8:W]+=;QEX Z?FNS+7WG7=@L\>1Z=(=K)4GS8B^1*LG!4X55$?IX
MDM1WD29_+#8:!/NYQ<;'-['\:WSOW:^:3WX:5UN=HN.V ,N,UE:)_/)Y$59]
MUUFPIR$=\AYG)BZZ)XW?9$*09 H<* RYG+7(/_DST9T9G#RB39/B;GN],237
M3H3BG)IUE\N Q(Q<P2;?;YT\;GOZ C*WS_],:.;!.W+=L4?4)/D5PN@C,TC9
M6+;W50AOF[0R.L#NUG>"Q&[)(3^Y/81V\>Y/,3UNXBYX%IBCM?VV(5IU.<N*
MI>7I/]JP@_:)(@=_]K^F$BH"G$9T'TP0:SE2SV,''Z>+B^_DD88$,U8^E&_G
M'4KT70)^@;I5KVN(#2=/!PO5OOA2#U]_:X.RP1.HA="(P*DC2X,NA:QT\^RT
MZ8SBI\$.XC\=\M7GPBA8B2[6_$4R79#G!*D5B3@NBS=@J%8D+N*N8D*+W>?S
MO$0S5"(C!%43.5*J,7>3NW(WY( $%;J9;)S<1F,_BR6'?,,9M*O.I?2J7M\(
MUT>M9_;D< &$DKSON;T#O<Y7#EEP@18$)T$D"64K\'@^CG!+7._/C&DW0++4
MP1#EJ0YSZ:_-F6.J1.=#X$GDQ1>2&LZZ<*IV.L42]VMM081\/A,R8<*+G./Y
M&-$_D@FY2^C J(8A).I0)$7PF,)#=K;XOH$6:*N7A(=FP XC/W4;G28H\H\C
M$2+Z'!1^;,G9%=7W_B'SB7PJFF16Y!.,&K/RQ8FN!D?@5SN8G-&*9\:Y!W 7
MWAK!<N2"N\TDWRJ>=:L.SWI_,#7K7OG8R<,L)PU]ANT(%K,A6,-FG.\(-82^
M'HDCUX3D+LE6N=]LGG"S6C2*?*QCV:_6<=LS9ZJ0+Z[;)$$ ZV^C<&QRPZMX
M:B](2 ,LU!?"LLNENA=0[)S.5;">7BMMP:F9ZZZH)>_OH/[0P^OZ_'QXCAX8
M!JT;H=Y%5MMW*IMAA@LP%T_T9(^:QMSXDS?>( ,.7TP OU[E#<9A+5]YZ)<:
M(1+?-HNVP=>\37I%7'N7[#/-;-N@35MP04(!49=@L^(>ZPJ1O)=928!UI\QE
MPO=@]#-Q+=$_.17GW5Y2LV39RW/V7I-9#Y:X*)26@"(!*B(24;42-[=''<^E
M.RT6C(;E?TA\^IHVKL7=?CM-7OYQ^?;R[BO#E(2?6'A95<$+2V$Y/N<!D('Z
MSH[HRL@L_*06!^MTGUWM_&A754!()BMR"C4@)H\NI =L[04RC)4\!T0?)?3*
MFJ);&E5:S>:X-"OLX=NRYCDPA8775NT9LH=%"\ER+P>[9L(85XUC.B<[AWIU
M=6MA@8R,,471L9X?9V5;WC9H0*#$#\'C.>($O57@M2TR6[C9A$T@]-'Y=FUC
M0?VDS3TE-<I^;N_X7^]:M!=;SSU@]2/=TGC3!)Q_=_+6^5+$.\OW.UK5*"Q]
MQ?Q3N7#QL;!NNBMJ([=1)CSU!2"[N>IL+,KYZ+!JQ *H#ZO5L>Q<M( %C%D!
MEY'HPXX<*?P%]#-#-H:7TFC2YM!GVW=(<>_7TGVJLF>Z;%T O_27#)*HV %"
M!-&+I$2PQRPQ$;Q?UZ$8BO*TDQ3FT-V['G]RD3XO\GXH9<QAOV^\?J .NQO>
M!C]0X!,/@RI^KU^2VG(2[878$\W 4AUE*XTJ0^6[S4O1#S#(ZM%:74EOR/LD
M]3L?Z  "?)G5'IY9IO!.(%JB$\99)V:L,XZ9/$H(><%=>>3JAMI#>8H_31=-
MYZ *#>@7L.=D9:0U?WB2R-!3KL&NHB'H/>D %R'8$K7^];&ABS>DSUPCI\P]
MWP'NR?M'[E=O354DZ[<3D?Y!KTK)=)Y-^=TWYB%8SV5%9'@4QJ1CT@=[;5'F
ML]^IZ>Y)B3WOS9N\GP2N!)\^T>D5/J\(;#Q0+'*'60?9):1LF#K]8P7H8GA.
MZV.B(\&[.T=U',*50XU?CVPI'KB5SXY^YODUSTM2*6Z3[76H8ASVMO"]5IIE
M6*^RXHHJ%HC'Z&(5WZ+<W'W+D/QZHR[?]S$:B?O++=A^"D/M 0$;5?.=2$MS
MP\SD&AWIEEV;[^!SPU0C?[U9!/KM!>7/UJBG%\4D5@PH_'M?=[;\TOP66E]C
M_6O$U35]65($+7:85UOQE]KN6]<^[#;NA%Y\Q$1/J,>,ZT&O_.94[GBX^9O!
MW4;U!YGX#8HI8W]U%.L(#]]=O0*:O(8_BZ^;;^HT5?B> ;4-K2PQ<+149PXK
M'A1:*Z1[H6G ]=E5_*!7VCDH\25_BU395<5)7$6/'B8$BN#%P7I!C!#IMKK)
M3"N46,147;?DG3J3>R\IJSS:-]BV\KT>[\9/\Y4UM#2[KS5(^VY+U$U)9,X<
M-8MB0BC(,SGBR(L\DDF!$Q\O/KADQ;;A[N\NT^]46H832Q" KD*\P@^ZLP=8
M<I7\)K1>!,]A_M4T3;]T[67W1'?ARMB,<"4(8]:=3;,B]UE"21>C6^-8:+Y\
M*]9RS4_^E0;O:QA>'O!]#<%"'E.0Z\D.. IT9R# NE!+[Q52:3&\4GMEWBZ<
M[']BPA]:?S/>87"6'RT15HA5V=EQV#6.GY(]#F(T^8D(FE1U15Y1*]WYXH@V
MB(6H%SH:!?B?[T/SO^V)Z7OH#C0R22VY,;K$;BEY$U^"_3L0=U+4:W&GL23+
M$G5WWJEN%>ZQQ<T]?#.-T7HL1=IM?)9]%D\L:@<<E[]\3$8:JU:\K(%LG8B(
M;DH 22ZXD3[@K!9&O&4E,.;/R^T&ME,VE#9_8T/*.T5+-64U*B9MI<../F6B
M+ DT%GR3W ]DE#AN/.:>E;!OJZVMF1 SW\!@#.K??HG.2V0U,*)A+9HL#112
M#)R?KV](^T-N,$ ++RVL;[21]H(L-<!+75!T1N<EX*:2WR)=BA:>_3/)<.W;
MZH227E&<3L'+EL117F246'A\J/8VZ"'D%J&GB"1\D:^B.!!8N/O]>&B_SD_L
M:(AZH')?X.;"/'M0$T#D/J= O/VNF0&%J9._J:?.7-M"3(YL*L^#_4RGBW+H
MJ(+HAFKL$G>K%'[D1(,040E^C_'DD2U<Q$QCJ?S9_K8QH%YJK_%=$^ +6 X=
M";T$<$!D</8GBCC9-DSF1MA,SP.FKEMG*?.J:,%.S>QAFE\ +PVM?P-4<59Q
M<[.PL*PT0]TGZEL06UM1R&QHT1:<B^!)? 4VQ@C%8W"9VU9W<$71;K>)&A70
M&)]+0+7R9*"_&Y1NEEN-7[Z?AK,G4,SK58&"1/K/&@7'J0B3(9K_[ +]X/3O
M!O@?P8J#[M'@N3N#KTT$WU''J#)OH:EJ=HIQ?:5.-RVD8RG#7BG2?<*"_,UH
MY=I#(OV9E:I)BKC\ZOZ>[*5G]0^Z#W0$'\LL1<'ULT522X4<+=SY8]LXA\M%
M.N!^Q#.85!!B[C^U9).V&NK-;EJ]F=]Z[R!^VP/_F_MUDYDISZ,O:E0>:O <
MDAC^5M _&U4B!%T"KON%+X<P[J+G+P'.$R2UHJ6W3J9Q3:\BDCG,'VEKF#*H
M7;W.[:5S\3!E!1YI%%+_QL'<[5N9ENT%S+WTS1L-UJER15D1C=N6_:6M  9J
M!;/?BRP7&60IB"(.&$VB^+&;0]6*ZVT00 3GE5B\C;NH%I]6-'G.7.O96']]
M.5$4W64C_%PV/=W0_$RN<L@QJ#R (U[0H:7/HDE9:7S"IX_TBC#@B3-;,>M
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MMVI:RM-W\R/JB[*9WYQ%7AZGK=S14-VU0]I57P%V4@-+M\8A ^V^KAZ%"5<
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MKV1I-.5=Q+-;S(E*?I,2KPK5EG9'4>/U.R CBN-BR7PK[/XDW JXON*^<P7
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M%7U46=@ .W4LJHPIJ3^LB;0'0UL"AC:A=:KG/"TA'VJE2ZLTWZ8T9403AZX
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M&@%ND7,8@2C\M(']UM211A.-3#.B</ZT@!S3UPR2#"/U!/$I(,8J*J;<R5G
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MFC2XFR0WH<P+L1CZC\W=]])B@S@6EFXO*YU;)7697HM@,WM'KGDJV]]DH9L
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M7.5[0<#_ \C2"3FK6KK1"+KC?:H5;\_R^0[V2T#+A?XE8%6$D<1$*$=[TJY
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M );H*CH8;PU6G,RRS<@P( \4SNI%VVH3E_Z.Q[T+FX=]YI1R"C,+Z;0WWO0
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M%8_OOF9949[[PAF,LD2-,;.!>*S-M7(:J0LBW(?I7:([O :-E ?N*3P'TVO
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M\_H/I>_J7L+K-]T,QR84F6$\$K)K?J^.!D4.H3H2K]FV(D8_]+R/8/*I>_E
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MEOHI4X+N3WN[ 2K<X+ 8EV-#Y:MBE=>VEKY_'Q4'ZZ/Z=WRTQXO0N!_^XG>
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M2W@\,J+J@+]%6;6VV5D7<M5LIR3GR[_##:+64.C.KM?^5LU/S^=^."9AC+9
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M[<R?CZI^&A=/-7!=B?F-[?6GAI%KH1\4P8&N&.<.7(I([(J>X)K5DQ&GZJ1
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M+!21L.K/%' <PMN5>$@N)7YB15AI^?;NRT4#^R+DD-M;^:.*;Y!'5+7V*0K
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M%RLS2R]_%0B1$;:["@(Z!ZE<!GMFQ;L?F>^.@'IU"G],#IOIW->V3/7@UN'
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M/)$A'Z:!:?^VLA\TJ/+D67M<OXB8 G=<(=Z$\VYWTF.9<T?"<]* %0^>MF0
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M30*VS[:X'H[\&G.TY/ I/N*Q($D,IHK;II1W=CA2Q*5>QE:COM8^VSXW3S;
M?$/UN47VV26T]@)670$NG=[<EC8[3_]& Y_%C&-%U5!_SSUM^C\]9<30X_ ^
MIB*-OJ<J6S%MP' 8.QZU;"M^!:!9+-W[CA#,OEW1>CGR>CL_IJN@NZP&Q4PD
MA[IBZ9IC6!5+;2LKC;I[:V?\$/.F[6*'OT]8>;E^$1^@3&$L4(UA!2&\<%M[
M'5ES1N^6<P\B@Y5<4AE=>>UN18S.^ON$DLA-AB?H;,[%%ILMT)%1N3E)5X#U
MZ++P1TB&D]8&"*X$SX7B5&!8V/+L_F9:SG?T)@Y_N1UM,?@1O7:.'FF,#Y](
M-'Q74*3H;J6?9M\RFM%/X"._!FW?;NX^\\(I$V=E?54KY4M*\[/P2_W+^"N
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M*V_</\;W-/%:OQB%H,@K !D9OI,(P.LQ!S_?:F@T;N\W]]1O4[+_\RR.B!5
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MQ1<C)O_N:8WWB.,YQ3(-9B\*#PL[D$KL8NL'@8N,#79%L$X0TTG](-..E]%
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M)6U<- 6B#[YN:S\^5Q['V;1?WM@QQ9Q=/(F.-V9*^$Q],4'Z,0CT)LV+V]<
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M%Z&%.?HXM0,(I+!#H1.U"CPL+7'YZP<'I=+N6OG:[5/./TSN7(^[VA.AU+A
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M(]]K6@\.Y<_*"J;6Y3,J$'T,:9 GYCTBF87<[1FAAX%>Q<=5)3<-"R:#\)?
MI1^L(;GB:UMSJJQF$E7_6YKE?Q*F/OBY/J&V /LTG\K<,2AWT >I<2?V547M
M9YWW;E]W\_\W@U,GSTLPR=2>W=3TV#FY/C.SSK0BA5RDWW21-E[:(,+$H!$
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M=BH>D]8WO46W,\.S+14'AH:9M-, IA8!#\L01L%E-%BD]5CE0-GK@KIM:['
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M[PJ5V3KA,"=UY%J<O]$,_2Q  U[Z6HWLW&3JGN.$:;MB45-3N@.[,O?\WWF
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MNC8D)S%4)CPU56GA3)=_*O98@2_]3/#"\E/\H8]ANA@OP:F@1I/AQ5J"2/-
M<Q(E,G [5J+JQ+$'"POLNMU?RN'%PX]N^AAW3XTTTH!DU-C9DH;BS9$#6:]M
MG7B2/$'?*R)<B(!JA\?"V>1@MOC5-9N77;<R1J7HA4BUXA]\V-]O_+S:&BC.
MEO98H,(%G[Y^V'*@'J/JY-L$*%*^ <JF'..K?/B5NF6E"7ANW\^4<,^B1YV;
MNI:,;ZQZ-$ ;F834]I!R9/%*BU(HM,QE;:-N?&A#\*++ST&P4H\"SZU;RDQN
M I-*O;X,Q$A25/A9&XI^*OJ7FJ@BTC*)U1@K7?@SN<#MZ_D'[RXT.GG7R"FB
M<5JCU>T6F:G7Y9RV2JL];:'NJZ[">M+%18$N9?D#4F%;%7DSX2,M:B1X.:FO
MP\8JND40WJ: M85PVF=N_>Z_[>P/ZL^GGG^ZOIDG/KL(603+S10\=6#D+Q;C
MI.-7WW)H/VQ(FDA(@FU;8+8 P30>C%0VJ1:Z#CW(=#_Y,TDDW UKR>_,]'2R
MG@9$YO!1[/%6:*6U[!,CJ"JDT8;-=R-J[PERGHN!3.UM9Y"RFV\"82S5_D6!
MAM^>Y_MM+X('#7C<;7FSQ#QC/T22=";LL. <N7K8R,0/@=?M:VG P"_NOLF[
M.4_@U6QMJ&<*-*!@3?"-*WJ2<N_)E_*]G[CG;$T,2G*^-$"N9ZR._G#8WDJ@
M2JR%BU22JK L.1PDT;[;=<->-5/:<MV2KZY.3*J^#>X[IWOW0F<#>-(1IT#:
M)2!L"0^,O(]F7C14)D/+\@T]!RZ_?_XVPF@:31_LVUUN?-O#8&(H8U"#LA^P
M[6IA,[RX<4YW35;'WO3A0<*KNO4U\DU>B1R2@9@P#1ACV4>2658U')+Q!L3X
MYM$=.,E0.4:Y5$"N!E737#=9P!+\":RBV)VS=5(OV/0P<CT/!X]P#CSQ==Z*
MCC+Y3/H[FPY7=R:B1>K>H\X\CD!ER21NNA0C[=[[00;$4E+AO"E74 Y:$!2G
MTUY*RG"J'RD'5V\XD:_%V)5Z!L6]T^K" ,)D9JGH4K![7=/0S$Y=^O/+S=(:
MH>22LG3;O;T<?>H 9 +$";XWQQ!4VJ[AW!4!T\Q?=9F<:TLUEGQR?W&X1_A#
MOA%$,M-;Z^E9<:VQ=I4?<!ZP&R@&(L0[HN6.#2WS8+&49ZU*4C^EWZD6['VN
M?)U3C>,-IU)O\*+_O1+C!&'G&12JKZ*D)Z9$L/H6P@E5V'^8/]<N/OFW#T.T
MK!T\1V%$:$"4#.FP03KN12RBB.=X@3RI'3^I$XM[CPZ;@&V=ZQ-=L[@RV%G[
MEX\)3SNHO/BCC?-9\M90TQ-0G^,J+#Q/SFR/>W9]O_WI8 1CS1"WB+[EGYN?
M<YNZY(=9?6_N RV@(,J:+I*-W< \.LHP1CSHB9_M :@UFV\XGUW$YFIHR?29
MCO/<E3=+&PN$T[5.,.^002(4#3A)6LCM.+[1-3%\YC0-:(,<XCO2O4=M^V:[
MG@EK,3^;<%BY*'-X1+R_%WU0YG7"T<B !_YA&L[UR :.#]FV2='0)T4_='D&
MKA#J.BMAM\&<7+;W<%>4[. >0FY&LXX*J8OK/PF5R8GUQ/*+\^9>R2M?1[<"
MMBK\#ZS7HA3>-M0MF3I_W!@GRQ!]\%I,Q.I#;HK?RNALZVH+J?WPLBZC!N5:
MD_0S]'7:G26M<^^96%N[,HI$%&$>)*@_#CX>-6I2P7?8$#'%-1T)DQR>+(I"
M2@ZS3_:<FDT@WRXY]@/-,4@WVJ(YK*,5M&:!KXB#7?0O?ZWLQ;6*^+!*;!L\
MHF;U8$7<T$[,6:C@"M+0+"G+(R>">H'4B'F9C+TNWQY27#G49.!)U+:<V;B7
M)9<WN5:S%S..-1"P [WJQZ?9I=UP]H>&R(,U*ZTS/.2$R[__VH7COY"5,&-Q
M,#6R>5UD"P?,B11:MJ*C635T3= UQE,\-)B7.R;Y?,SG!XQ2_D$3C7*7^'3H
MW6WDVRHF2HFQ@_X;RD%#5_NU]+P=?5WD'+Y WNJK;R^=L=%*8^T,DUDR@4\Y
MXCPKHLVOQ'>-Q=Y]SN)_>G*N[QB?&WH6\OH-G'?]UW<H P:^<9&@-/\]I]B:
M!$9O%-I"IL/*%QV^SR[TR %R-F[3RX"?"F>;A;>WI?'*Y.:D9K-GT9=Z;,F[
MS,8 #Z+]AT]KVQ=1L;,2O^UE+ \#S6^1='<0I\0U(,2WGZ*<&#=3>U\<719?
M_*&PY8 ABU&X'E<4D+IQI7F8K6A1KGK;D>:<4Q6;^8\<X]@OWA66\\[Z1@\8
M>;:H$2"XP,1PM=4 C>A$_XJ-TD;I:[P_PUX>4SWEB;XO<3-X4U=EA/(/M]<!
M%I%WS!8B4]=*IT:G]@M2WJSH5VCMVBO;[D.\7B/(^A3'5%Q?QT%@Y]&)#V5R
MKT]5(V%><;,JS(]C5M&L7:E/T P1,M_6*DD%!*^.'$$M ]YFG*P5V=$B;L*3
M$[<^H!N3]CHM !W7;-_0&5RN\^EL5PJS*C(I)&4Y,VWK47Z<C/F%/W]QI6(0
M%"NJ3+J'7\;,K:.P")#[[)D1?WOQ]I?IGV1K8_KC'<\'$#T_X4)E8!_$SW'/
MSV\R>D,R1\9(4]B^..KI'RT"@UIZI2(&-_ CKRH'<U4)!D0W^OQG7Z5ET6Z*
MZ)ST,N^QW#5CP1\5\(RJ,?V/!0+NI<@6<HXG]3N</Y=4YTV^3=$=VV&L']KR
MXR]JZ!]<*>"<['#WR]9]K;\H*WS/Y/%S([& (I@4 ?Y$"T(^!0M*;P6SH3"0
MJ2MWUWR]#I ZA<2H"U6LGVXRWW6ZZ]\+TYNOB->1(07FD3(-\,0/?AN:Z-J<
M>R.'+9H1\57 I_7I56-O\80\IJ6UP1P,.$%4'@]^IF6 \>2RALHRH15B=C7!
MI\\RKM)!FE;OJ$LX&ZKT:'$]O*$!%?(@6J[\[%])4I!XT6B\+SO3A]3A"Z+?
MQHRM1V*.K<,<YVD (ZF@0V,1%2?JQ7]8+.\9E94M&(D95KZM4YAJX/_,J:85
MUW?P_@,2'IF#1#P.EX=I#^43= D\KU%UT:9S >F($T?DF(/O+K)6BWO9T0 N
MQZ1P#5(\(;0#Q2MDH'-NY/N[3WJY596)GMC'8L_\+*R3#>YU"\S[?BY_>NV@
M2.?,CTEPI'*C/,]U+U?,'4%[8=D/0AL"R3@Q0\?9K[>L[#\8MG:J\YL<MS#)
MJIEJ'KL.H\X'93S4BE5.^W  ?A<F11#_C#H!=Y][$JY)0F%0;!Y@MB;[O*_;
MJY4WILKD7<64XRZV.J9N2U^IIWSU8?4#U? E4D$D\#QD??.P97&G 2Q'-K6D
MZ&K@&VN)2NN//3W5$JX6A:]7.&0&K4(7V6)SD/(=X 0-]@&8+9:<96HT^U'E
M30#>UD#\[-<M]GROUH6C?6*BN5:ZF+ZIISC79TW:A3]"3!/#>PI77E;=L=$]
M2'.BVBGD7K7O/>X8>5/12,O'/<P261 8JE:D-& SVEQN->KN8//P9:WM+-FA
M*UJ7L<Z\BY&C:<BPE5-]N%J)*P(0,=(NW9$GBHUHJ;SWL*$![0?BF-HB_%#7
M2BZ+ITG'$]?&^FT@05/9B@,[_87DS7_D!GCB: O]2)-!"31;O'FL0FYF-[2G
MKB5C]8*XHV9#P"-NH,A;:A$X.5YA/P+W1"1^&HM>&'C8!(<]<$I +PF%!KG*
M]%/WQ#E=YP*@I3SZ_IANH;"M?;A2)JLEMVNO?#?<9"&8*48Y9YT5?FM(9XAU
M>;S<N99\O?%ADGV254CVJG?R.E0G3@8I_."P,M__3T\F#Y=V%U'\L/LJ)H72
M $@*_$<L=#T313\1/A[B&DL1+YX^-:I%1Y#;DSR/ZPT[!YU@R=7B.:)6W+KV
M$+G7/I\C!(6<A%D4!:6VUZ$F)D>SETR@%6<E?HZ7W JH/Q<DX<-FL]9TBFP
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M;_CAM9TM2&3#TJA!_"C[E0<*O4JO@+6#N]4J#60#63E> #5-6 16;?3![,A
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M"*IC/V8[!.?EBDPL1SZ*<5U;L:^-FN=]9AXU=:K5IWZW,*0-6*H]'.+/.T4
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M!"W[WMM)?)J6L6)2/&8)7AI:G%$8CF]5YCU<8>)SB75;*/!,%&G6?97*02C
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MD!EYY[FAH\&KP#.@)X[NU9:=(UTJ707,(3T#ID/3#" ;9[)&T%E)+AN=090
M^A4[<Y)M#M17J^OB[=/:2-$;+ZFE@J)?"+KS*FC,_DAD=YLPOJX9JWE;A='H
M_8D./2FR?2Q+E'D8G1XO=2$RA/JC^WG>M$_Z2D ?_TXTBMI?(7BZL>Y&A5F-
M!OLJJL;]]'3VJM\5(&%7OUO%3P@2I:=[I;2WBSJ"L?BS9S0%=?Z%VV<\)7=#
M5FL/]-1F"4)$(6Q24%AS<>$XM/P6>)LKZF/@$8![62;O7FG/1^P1P.2_5L89
MUW;9_Y__$?J_?_U)JO8LD-T!3;M%L5WK?RBQ)G8Z=U-,/+D8 ,BENMFQ>&K=
ME\QB9YC"VYD1SV 31Y9C>^.)JNKM'WXT,)8UHXA"*)*2>//R$4!I$'Z'P[+P
M"9O>AS8T@_3L,?E\CP]IE:5M]1.HMV;NDRA0==;58'G3D2W7RI/P[:VXG( '
MJ_KK,18W_L"Q2F%X9H]S>AT<M[ FGKU$8B<$3XGU.5_"DP>F&#AXMCTXV[W[
M<W;,K!B").-+9>7T8E)UC8+0$X%9,' S21A'"JBC&_X4+"I1>54Z/NS:1,15
MK%%*Y2WN=U>T6:B02N.$$,WJ(>'2=Y(",BBPL6E%<:2G(\8$D.-)[AYPOH&W
MHH!R3]IX&%5$Y=\'9$=%T8+!5LM#[&=1W_2L,N1=\KC2GBA_B7EZKI76TA0J
MLL9RC';7QI>XN4](J2+L7K$/5V-U9K[;F_*SRA6\-.@SL8W<U_XXT#3G>H;@
MU+D33RC&G]MH%9N<7K0X._.Y?\NV(H;5R"7:^[,JN?=ZP\RV32J *0V7EDFX
M<W '%HO9KLN4J*-UEC[0F>)8VJ7B.7TQV"4L8&9KUE$^4BNHYY-#H4L3UO3E
M]C/HWM8TPY+LQZ=TDET](R(VR2WLX?'WPY_<6H%P+9;O1P5O;U#!O>I\TLKQ
MY*_6"S9L$-5<;Y%\-FPDNE@OTK*_,,9C/31@?X=+ZBMV'1,*'F_M:V_0HLL5
MTP'PX61/)>Z9[M0I H^)5 GN.RS_"- B788H1QS_85PI3BI:V#JH&4*N%M"4
M$%7QJ+9 =B)<E(+31 NV]GD"0_68=A.!*+HED.JFB?%8=#U/0*OA%T+6O&HI
MM[UHA!>\XV0SKCXM-J#\3'W^4CB=P,.Z9X?1/V3O(AG@-_+9Q^_B&?&- (Q1
MR57R\O42PO#WM]\O'>\8UC\.-\K,]KQ*Y2;89JCEP1+TV6U?Q@I5:3Z,L>JC
M:[YF9*+ %*4SV#O\W'^T.+_N'"Y -D05K_W.]L$;M3C0N><*27?QD1%8$%43
M5D&6)!?!8&;A5=-@/%(YH7[_?&M_\HMP]@Z"']ZU$<'$<%@CE%>8+:A)%7Y;
M4%7AH S/4^B!JN2.^YFY$"I" L+NM$'.YA^'D\>6*\5+8V+N;/GKW;/]9;V!
M&PH.!#$H\F49NI2?R)L M*GXWJ\3W(<0LBQL$#MM_,+ ;9G6PO3JPJB$:4_5
M1@N$T7P<3@;SNA2!C2I!0)$ES?[]==?8JHHZ8GF!L5S0\T0+_'P2/F<+?1':
M@5&XN?VRO+A?1.+YD/=.\#U;$< $GT#_+:M)S:VS;1Y+^P(+($I"$]:^E9:)
M4'70Y'^UGZB0L2B;Y+BSK]V=&DM5&Q(KF%SUR".NAY]U5C(3@WY-NH(>]I<#
M]^3XO"'8B8YI[M%'E0!O8*J"]O8B%$F^SQ*%613$6Y$72XM.KY!8^B3/"\]5
MXIE&2TJAGB9WGQC9*9O1*;I]YR::6D$N3</RC/"UR-7I@A53T..!]>W7B3Y$
M5)3/Q?2H."6RY[*4:7BJG1!\:VP>(<$8M_%J8UN;5W,@D?;&=)-^60*GO]V@
MABN5*VT .56 6V"W0T6A7Y(*'#\+>L4MBV=IC:(F&#96$;FY/P_52')G\<6.
MM+D[3]2\;/^#_A7V/9V)#=^T;L,B&8X C63':9#>T+9&_+R56,.GQ'N/+ZKG
M?#_5[W'_U(;.;*6N*J$: Z2##1T_*>O_)8'[<O'T3MA-ZK#2M%/U[FEF 3Z
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M" )Y#JF+!,1W5^/I.G ;IF5]<-VLT0X?VC$79I'2[$>J0=ZG"W5P3\M.4>K
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M],^\/$>Y7NUN=FXFF&S.^M:G<>(%W(2IHFR\C3<L56ST,)/ZIW#+&">M@%,
M&IX<HZ.T53AZ8KRD_3FT#W?@P0V8J?+ %A4^'Q:F5_F]T":U?GHZ/X\RK3W(
M]+YQU"V^:^0ONBP0H[&-N]Q\88:5 ]L'G;=<(S.90]RR$_JQR<7.*]P3D1HD
M8<*2]<>3&D(33YLW2%+;%>_T<AT-:QQ#ADH*.7&I6?>9&KW3S79,=$G[,6:M
MZ V\*15S6X;/A8QOEO$(<-'_VQ0C7BUTV^HI>-*I!65K//!8XF"6IF">G%BJ
M5ZD@'C'2<^O'<-;OX/);RWIR-_ZQ<;T=#Q0([CVZ.*%$:R<[$7)+A:X7CC:3
M N(A/)#)GV*@$&>/L;;5D)G#!RB'(P"J1LWVT[(IC;=P'#3[;*GYZR. 6?%;
M&9?ZLB<@RAV3WPRD]SNU" ?^Z=-_%-31.0S5R??"+1)8V@SZ/.-Z9UZUIVHI
M2S]XY]R!2/YYGGL0@35M&J<-M::OPLUG>3^S?^"^V(=Z&1HCJDK-(IA_\PVM
MSF#-256OL_@GG&4V..!BO7"?&;::R_XQ#1]K].\&C^1VT(7G* >] $1\\)2W
M'ZKT,]SQ^BZIX*$T9&HVO.JES=-*(V]E#CF?NLY:_$*&8M,>*#592<SK _]F
MH#N_\1LY5N2?__ +DC-'@* JM8!M--/R4W<KRRZL5A%JJN5I.SX//GT#D$&U
MF4HAV0 <96E(M1DOS,#R?>>>71/"# ZT]W<N@)9WUHG>]E.UKT_N'W>8?BE[
M;Q,+:7R&9"?UD;AYILW[2@40-*]BS7N]Q\,TXLV_YM[+<"ICA6>5>!;6'@%L
MT>3237E(\ORQ=//)*:'#P>,$B[YPX;TORU-E$" #[0X=_)V"?[?N[*K_@O>D
M 1+KDD51<RUO&T,/K*KLO</.D\;(]'-JTS%?3=U ,HM-Y4P_(+1U;!H>!R:P
M\58&!]-$NSB[),&%JJ ,K:3W] ;F-H+GYBYIM;?O-:R?]3M]8M?W_=E_U/,9
M5JV#'OP*^)U>>\4'5HB.)D+Y"O0(\/'-\.+L[XP;EJM:Y[JO@!_Y=F&<+4KY
M5.O%8S_W?0SJ=FB=%]5(FO=7[H44%?S&%:;]QHZ#[-[B^RC(',(#="F[:'CH
MI/M*8AUHDD<L6K?_P<2TOW]2]:BF-"T/(N(.OQ$#TM&0D\(YN[_"SZ+H)[H2
M^<;(=&7E=T_\+AJP>]/F&9-,=\5_4H8>^ITT7F3H8+:=T%^/U7A;_^1J''"<
M4"PPW8-,]+3?$-C>/NF&B9 +&<P] @@<O-\[J^)?=V*7FO7D?]IFVX<Y[!VB
M4KO-:<>CV?1SB?ZA$87?S7RU.@*36_3E/ZJ2TG61?^G_?X,]8[R5M8H^$.G$
MGWZ&8(2E3Z;C!IRKQGI;V0]#/): :+PGI^FDT$GUO+5.1?-+SQTS 0)FO,&L
M0]=L]%ZS4]_(G@&0WS8P5CVI+O(*Y_[DB.9AAQ:'UP=5%0QN,OOWP)4#OXY\
M\PCW;/QCM)W?^4MGRYSON3\.AW?%)IGT3VKIN&%WOS_Y9:_QR</)^I_4)7XQ
M-^*D"K+RIOW3FWN>7!G"U2%_Q&O;JAL9)_5N+%9-(\;'L>X_HH2P0LSJ_P";
M?_)G5"]7,?H/D^[_H0S@CPKAO-_]N_>*.>QD2<\VXCZ[V=SL/L]Y/(-9KF>&
MVI;9^KD?:X\1L?TO1/S?B(C_$0LM_;K!Y4;)[QA41*YJ["VIW5$]][/A;6EM
MP#^D]:7TZJ>90KP.O]6>?%F97A/(?QGW/]^X_VG;[Y^*%I)_M[A:CD;$3T#9
M3"0D0-3_P*1T[/'69XD%"L5'O<4JC"8+A4QJ%D> -X^F<<##\\;+&06(=C'7
M/PH;;J";$C(D,O%M@YRU3$&S1?2TE 1#_8' LXG7VD-NS=]IQ$_')ON2698W
MB3!!37U;L]((D6Z*&=3Z5G>G+/C;OU( KW%)B\S["<SFVN08-#=1"6QJ%:G4
M%JW8N]Y969IQ&FSJN<AAH2!;6^2JE;>?&J'B0S],-"R E;28Q*?R16F6]KV&
M#8'54R@W&QZ*D7/YY/;#-?%4!)8[>)[V:#[33U,DR=?J%??"I2^M+:I]51/:
M\]F0^_ VZ66,Z5INV)PSM+][[+%W?F+UG'XR^.E&1LR\QM+PU_WU9Y),C7!E
MO$D:U /3)7Z[RJS("_SB8";TX %K1P-YU#O.68*VM]=*7[-R@49_U AJ6MMX
M:\^"E!5K2"MKA#& ..U8>3X=7BC_H&]-*]W<PZ#[:6HYK,ABS+KIZ25=6@X5
M1]:+D5GSL\B#A6QYTP>YA*1FV=VP-;C,QTFU]$ZNT,DI2PDJ<5XZ1;V"UE.V
MW#4'IK&ZLFG&UO2QOGRE0[LH5+\]WCQC,"?6]..:C(H0V'<):KT/K1I;2HU6
M\1&*:G'6TL0A7R&-U M1$5<W5IV6JPU,^++Y:)7S8:U*7 (>#=Z)@_.9+KMU
M(OU>RGJH[CAG3G#:K9ESAA4SLS),M8)#$3[*C/TNUJ%CJ(*QY=30C3OLE59.
M-Y.7)=[Z66WI:O'W%EC%9_FI,)I^@6'^L5I8A:F+<-#*7[_/YXWM6?NVF7]:
M1+IS[H5,-VU6IHU%J>C6G$E&J<E\J4-WK8IF8DUJFX:*FR^PV5'8:\_3V4,=
M03LM> X#'P^*E[J=G#)S:N3@B9_ I_[M0W'3Z-GB 6>11[?CM7R&E#,F3KN9
MZ[?T%A91>*%2(U<R4Y S4#"516#I;-^N19YBN2GDM6_HMY 6=LGF-VK,10\$
M$X#+^L)Z[V7:OIY:>*/&)+E3^6DIMHUF/@WJ*(%TEYDWLML_[5/@AY*J?!M7
M>Z\V[NZ>C]4A5:G),T*(9N3&:E'.:&;/N\L_+3QI:[:L*KMULRP@!'6)DFR_
MP /-GK71MM&:K4V/I7*9K#7'(X#8&EIOQQ@4MSN>YA_:58$7CG;TWC'?!E]S
M*2EOC\$P;2Z5)@]9HND]M1!,*:?!T5PCVJVFGO3GNN5KUKN/ (]-#%OTLEP<
M,PO*5T;Z6)T&%5FE,W>6)I:R\Q6HFJ-RC@!.J GFG9MF$Q)756HC[RMOVX^3
M\O?SW 74= 97O6!C6E3CST8&,*E3QF_^'_;>.ZS);=L;C<N""H(B*!V4)H0F
MO6,#! 2DEU!$0(00>@\0!0%!BG0,3>DMB930BW3I0B"A]QI:0N_Y6.=^=Y^S
M][GK[G77<^[S?-_Y]A_O'\EX,N?XC3GFF&.,=\R1B\O/N9"I=N[4SM"3M#1-
M;6ZE;/'!A"DQ%/Q7A2*[D")?"^_[&)7IZ]G6*%MX3#=$C%'M&]41A@)_K##9
M.$=$,,W=B?4I%;NF(I[PL4[Q)>;D<39^H%9?.CY[/K^+LW:5G2KORG??RW,J
MLHHSWFA3+81]BR?UL]Y<*[NO[Z[Q::(0KXBB<7.4$(R_L?'120^6 <61"X&;
M^4R.^D:6AWT#HU8\L:4F8W;ZB7=^_3;00X/OH+O(44P&>,52'_?9*T2UVLB8
M6:/7.NA2#-W&K0">Y7:R=W[JX'7;&FB7N8B"M9;YA(\W XV>G(P19M=K4HU\
M%3R,"09[)SQJT+[6^L;.3.97V83 UO&Q*A8OH]<=/:81>;CVU0$/O1YJD'UU
MNU-ULBXLXGII(L?KS97QJ8SO9>F,R]7UH2P%\*#:.T57-LM>A+U^+8(^LP=:
MEMM%A=="6&*G4Y^"^I%\NW<J'A:4-"3?>1&6Q8Q8GD2G%+NQJV 7U3D6<JWS
MLYSB%_2T%VS+,U&>WX:P?&F\_6Y=H>LHL4_D:A]<JWDVHIE=?_[DEKN*4./I
MZ4FY+70A*\+D/8;C3;W903L)P,E];FY]%$YIXA>7Z%-*NOG F"BQ4>/#'!+@
M:7^G\/"B8>X3EX421TW=!IWEO@,-7XESPI5X$N!],0E U(4UN<XT'-&)HDYN
M1)$ 8:A845->B*=A,0;2R=\Z3QQKL^)X8/,JD\,F'+Z);GCG<Q:5B_=\B&=0
MRCNRVZQ!?Z^V@7.VJ5CS/FS3D)YVAA\6,#U->FW!&^?4J2HS4H\[B<I"-1_Z
M,SCG@F[.3N(JH/XVU23 W\^9>78[_08)\*LQ&S9M#SO1\\4167^$S.R5VKYR
M])]:&FGW7/0V,YMH#1YWD&J;K#\%QA4!B4J"-_1U[?I5U=QA6Q+?FNE>J$MB
MLXTJZ\I( )%5$N"?XOS\H$@!>T0";*_XK4V=:G\C 13,QZ-0),",%&'JE(+!
MX.S*N7!;M4B :WW!),#RJX$&@KC"&6^]\O?B=-V&\A)T>)>K\_UFFE?OJX;?
M97)'JM!BO%9GT@H)>V.JR3KP7JV\4 HPF.=S3D]-(-.%$\MO<C?<GH86HWE4
M:YU6FL1KL)U'['!?L<!<?5%KTWS5/6/3,7T_SG^<+NH?@>AM7?9A^4:0,1TH
M^X+<V"Q+$I@I R\-C&Z>\CW[FB C/O>.RJ>:226RE4=:TIV3>=?GMGF(D*0-
M+>@F)F',#KITPBW/2 )\"U0E 7X,G\NI0.'O 1O\I!T;]7THX4_1+[:Y_@FD
MN2ZS6#+B(YOWZH=K77;'W/S9I@^<23V\I8I7]W9)#2Y[8'6Q7^\ 3!:LY0X6
M\[3.!4E@.D26_Q/?_VD!8M @JK4ZU<6^]3O[_L^"%>2']ENYJ";U-Z@0;@JW
M3J[ZLX+%$Z[LKY_YI7CZV\0OK(\;0MKF4B"KFP,QL[Z6'_"\UW_9RGDX[)VD
M_3@ 7\V][C\R:8O.63G?#7#Y.!+@PU(S;$?(UOR D94$H%7^3[@/02WU-$.^
M]SPO(U'@/96E]PZ6F@_-W>R?D_%J2.DT+H5U%!4XF_'&I?"^5$%&KL Q,R;\
MAOF8HE$_/;A\PY\8_[>PJ-WZAI,C<Z@H":";!^O#[;/_.<W,/'4\5T3YQ,GF
MORDF,H/8$')I^S9JY16UD/\8JRRL3OL?]Q'J,["0F/B>ZH.;XPWSTXIUV)CX
MZ\VNK7)O69ZQU';/R=5VC?A^%I[6H0_XMK RZOH:TQ%_;ME*RVNJ3KF\O5MU
M99.=FX0_);K?PI9( - YF+[L_=+,_R^[YRU6EM(M_<);%LYC1[B8$5?4VJ2^
M+(J_<\G#WWZ][W&4S\*JW;C.IZ^#=EHJ96FG#-7'&*'L9CKCE<[4-P,0R)",
M0BNK^3\U(.^-L?4LQP8A@F*P=3EIP=+GQ:<!1GL3:C'R5E&LPA'C*7OR\3=G
M:]65!M\B;D/KHEUG3,1$4PKE3,M--0M@_PS#HXR_+5"/PA OZ_;NZ<]S2_(/
M3+ 24@X<SX)O $F BY8DP&SA_/5UW,R5.K[)NV$7(<[<'U]OKW]PF*I^1),0
MR_OPW8\4FV][?>HL7&VS@FM.>/UR''ZM?F_-57^FZ [+)+8F8K.N&MA0!4Q_
M!OM_!^\EE_AC0F/OAO;TZNAE=$ZJE_V;ZLH:MX^=M->NMSX<:MJ.?%S$>OM$
M'%O+,POBI\9+YE35C>P90:;<=!PAF>";,L2?K-&T& .Y[N7F44WRC75H_=Z)
M<7&/)GL76'.D^3;RV-M\RV9@ZA_@Y?VCVIA+'FS.F)42SHXUT750<(?@_M4;
MGTJ#K5]E>[]TC9%L]^G'UE]=]:%,='=WA64Q%JHYNSKG*'M7XQ\<QR2UL[2O
MP!UENP=SR8*PC)LYB2=HZ@[A=CKUUV5I8V!$@QR5WY]2T^V_V?@=$N /EPIL
M/-$(<TB\@U%VOA3(PZ=!;^@3("E&U/-,IY#G'O>Z3P"9)*8K?VGPOJMSZ^S\
MYUJ3-4Z^A@78ERV-2H(%*ZOSSI:2>IB,I>#DN$1E'*;[R"<LH.UH2J<T&(^U
M.O>L*&/N_;30P2VKY ,147VCSA[0SR.P]A36#:H%'5UQ<^(2V7'@H>Y05CW7
M,W\:&BU%E<=_YR?_/SPO)_S.(:YFD #2\&_5Q^=V!*=XYJYU$"T\# ][D/_@
MSY2X\-XB 5A#SJJB%NWL/L#:9T@ I.4A/&^7<X<K(XQ7]4^5N"_7GMLRMH_G
MK&0U'#TL3$5^:H9M78TZJU8C 3(9ZBA86_H4[A(RM<,>H'2W?\M;-=^B2/Z_
M6K[6Z;JC#J^HDP 7SA<BR-K@P&7G35R]Y%%FBS_OBG3N)S%3LB<E85X(%AU7
M9^C\W6#^K^L3P^EU6[&]BI9X?WHB=["LYS?PUF3?[%-V/_C">AF1/E+@RZLO
MEWQ;YN<VPG;QP.E5:]W5P7@;[MYQ8T\/D_+RQ-+5:GQ?529<-U-#5-> 5UW,
MVK,'N@I&)LM_)#XEM-8:S9( #&*G$:WU<]5-&XIN3Y9D _M#+LJ!,PF]B7ZS
MZ4$2QI3YN5VY9JV,(%ZU"Q\?FL,E+@)NI5A%3A_ALK1TE+DSE;1C8-0QB?MQ
MJ;L[(_*M^CVK^N&O<4VS<_.SB%SD9C=Q,XA!H"+O(.R&LFE)52F#8L"(\:<D
MN%Q+C+"P5-/\[0U@C>-E%992@?P[#45?U&I#;?@7(8_99CP@QYER<H4Y&15-
M"V7?=_1X)+A2-_8;NCJ[YBU"N^UF@=+%JCR%1A#']-2I[L-11RH['=N[+R<.
MP*!*XJ<)[T^%#QSY7D4=OJ5\^ ZF 48E])D0;"+6=H\CA#>-U>H$9$#-%JS)
M][L+DB/)\A_W:6AF^PS1-FJR!_%;:FUSP3U A?CC"D^/71F\C6MA5GZA3 YR
MSZ/?0[6S@X55HOG4T8A@$(HR[EC?O:'Y\F[_L +U)8IV5O/4RKW]0F.60/G2
M.1B5N6T]715AJ#R=_M@J%G3XFU+CC+)^KW-:I>P.ZDU&OI6;Y0,5E17P>J&V
M2]UZ#@KDQKGDGDVOV J&.F;8*H-7,P;.HT># 5;IO^O$O$@"L,0G-Y:_U\!*
M?S"4[)4W0#W/J"0FP1 S2T_V%O6K<!]:_/1K@:,GR#W9BA:6*S7];@C7%H:@
MU8-<HV/Z +&$<66&-LV>+9XE0.SA$8Z=,#,3.ZL4R(^>-U#C+,IXZIB+R&#W
MMG_A>V'Q5IOAL<$O&H-H':X/A9A"59,"?AF[,=O)_<6A.G1#]*I.+U>>;K:V
MA(NZ^;,8.RRZ3,V/?]%WY#3"&D(P&S.('! ;;"@C.]*?2K_P\:)\BALRX\R/
M2I6X%-8>SL=1 ZU+?S5Q(:[6B]W>RLVQ6B0Z_%;TU.ART;UH7E796.,'FXPY
M S&0PE5_QUA3]:4TZ4@3@D\5!"B:_$E%QM;!//6(16N&^7J?WL'[.9G<THB-
M=9;QD;+56/+XUU?))-DRMM?-7#/>$EY\'YG")][Q&36S&E;.O":@MG$\Z?&8
MO?[:W"\<IDRG,%JG(*.JW,51&272H,*OW[F.NJ?=QZW>L;61D5"HH>=0[",W
M&7J8+N[[.%4 [4C#V1YMX<G<OU6$>4'%WV+1@/WRLY."@N#DBJ$=./1Y$TN4
M>%8]Q#<GCH.;<(F#84(J3DX7G:AZH@>WS2847[@ ==W]LB<P6+EDGW,V!KJZ
M7++3S."Y:VLQ8!5/%=N-0W-0@US4A:%U)-)7:@YVG^=-D._S39?/NV\#Q6&F
MZ-$5,VF"3<A.W5.]_K+#3/2527KU[/)&8.J8WM.;Y((]L1M28BMBRCJ_UMR_
M\+/L77""<-YNHH\<<A)B!$S/38G5"E=7>D-5;VOHEQ>/&=FE[AR@];%CA4F:
M(MD?HTH15S*A*_P[D1$@\Q#E@6,9.G-:"'+CC!7\T+"PKEFI@<^23U<ZD76_
M%[]MJFI*94S@7)._C<E65P72)1"G*ZPZR;27VP^2V3FV?\CNH=PSJIV_.&+Q
M4MO&Q 4?T]TAF>5=G+)K,EG2J3X\A']=P!J1J,Y07J@NIB^KJ1;[#"<+F>$F
M!'T"H>'%@QR1M^F>_6"TDF1,WJ38'Y>2^[[^S>, EJDI2SV^_ L<Q7GB_)LK
MBS('Y?"X L/1_; 9;VYAS[Q8SU%QXZV=AGWW3<_BT5*D/H+,&K+@F2L!@D$U
ML'@OP[.^(;'T.W;R].7'\@'5EX@OB$VOPU0\4BYK7Z&Z6&&YJH(XL).!!4J+
M]::^84^P94LX>OMZ<I.%:2&$"&C5H&(&3KPM.&L)SY3W7N7DS"C1T#@"+E<;
M'ZWF-91GTS]NDU9LQ6^ZTT),T7Z.CM';B\E9[>ZY7O"Y1T-OAA9C7VR-&Z_<
M[^7S_OB<48,<0B%T-R4-;#SD"T1Y<1WA% <DP'>.9.BGUEKLW4>?OY$5_4)_
MR8K@!#4H[U>EY[#(%2Y55W"O&_,TB+5=12+/GJ:Y\ZQV;L#!DVI6\:D9L<:V
M&<73M_&CL!.@W!4@H]K;.;4\C%9M0G.W(>=5I3UMH24*;ZF=HJY'GZ91'PMI
M2 #;0+] CHQA$#"0Y_##TR"R2/GXG7C:\!)Z]1S\^EUF]DD!A1Z'BDW_<K%(
M*!U7//]\-M$C)G%K*KL"76VRN(.B'2$![(T.W#C6??FH%U+8MH:<KESK=<64
M2ZV:R_N>>T@QL0A8'>M9F.K1&]RSXI)!E-C55^10SXK>I.(WKS(!+EYT:T+
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M6O7;:=K#JCG+D^<*2:C*GR(=%E;?*T.\Y-(=#UBCB5)[*DPOS("4"+'J31*
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M"3!ZIV+65A/8V'O3)5F]@ZLJ8WW3N$]]'4$"7,1P'.3/&):1 .7E*-:1\!Z
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MX3@OZF?':DS.VTP7WK>YCB*7%:A9]EON&BL59Y4'.M\HKKDAUO0SYV& VDV
MF=1J&R4X0RJ-6CN<76X=PHP> QF9=R\E&'T*M^:^@?+3VYE2FQC[N9Z'DCE
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MHDR6;E=L)EV]N[#?NDZ]JC]@W6\=J)E4)L@61S/"[D!!)N=C&0!44@BO#NK
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M0WHX "??S-=$FYG92G=2?96SMI*+-9_5=KZR7/8I M>O"Q:1T&PMU7$X@+#
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MF,KP:21.';7[3,XZ?)'%TK:E]Q@H[:P9+,HU>:UTY=0.K[JDD)?SH ^7!)6
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M _M=?717#GU]/&^T /KGUI>'%5])42HZ=1\\T[*ZK[18X@G:V?+,FJG#,N7
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M.\?J[M'<1]M?OR4_.( 1A9C?OO/P1,BJ@:MC)]OZ[GL7XU>IPYZ@W+'CWW7
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M#6#$^18L=UT#R+VN 8F!*T"R!>QPA[Z76'@[Z\2(I7)J6$9;_-/[=W^Q34S
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M7;;=#,<:[CM+/5KD3>G'T4E%!NUF]./XM]_SDG/ EZ4G$ZGO%@L_$ZGV4X'
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M!:!9T]A%((EMD@/*Q"??Z"%,(/\:H&)T$_QM70+T-.S]IZ[.F41IH']+!5L
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M2[A0O-MOW"*X.J2W50DR<1T3K1:'4%7VN_L/4=X%/]NWL,E0_Z33'=-!(7(
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M-!ZO"TI=+$ADE8#$AI%<DU?]G6EFT]4-_XKQ&N<B4#?,%2#:USW#ZA(\7%0
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M>FKE\0:>3'4_M$U:_D7#.,\**JWETW+L.Q^[X_&4!7,&_VBQ8<20\@K:P%;
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MRD#F^]+MX5XVJ_%=I\_V[+%CQ]XH(/3C412A,D-#P09-==+W^K&C:[7H,?(
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M:8]]U*Q,,)EHCPZ9ATUCPD"5T;/^MK8KP(N:V'FX9=6'69&>G%A%-:C?1OL
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M@@.^0+[(XJ$WO$N[()\\IQKX+)2]+/M?6VWSC_3S9Q77 IEM].89F-4G61U
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M;4*_+@I6E33W>0&/AN9=JJP>[ %]R>-M/\_)(M^<BQE-DNH^#M*D>'H]M)6
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M@:Q8W*%V0JS;(JH!HX.8B9#I@Q,HC*U6>:Y$'@^)C2Y6N'*?J[N,GZ5;UV*
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M .AZJ18JR,]JNRM H,(58-EM8USOH,)+ZP]+:0VUQS.XK&(:L$'%9A<T?%<
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MS(J+\XE@#@AE+Z2^FOY_ %!+ P04    " !8BEA<C-<^?C1& 0"UK0$ %
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MD#LH<>;T7T=JZPV:KN&W%:]2OG X+5^@I^J'%^/^:_,'WPT!%VN)_SXO.TW
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M" 3&W-W _C4C-\_Q V AM9BE]R:DU1PLD(9?EJ<J,<I5P0<;!Z"WOA5'73;
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M24)S-HQ5&G'%HWCR!3A.WD%M_F:0,EFQ](2NV-GD27?'5=^NS%"[I3^U'_]
M9*=:4;,8\@5(!A76,;^YDT"#H*;X*-!Q8QTA_7OAS?K(4H?CSK4;4 ..]EO:
M=GO*:5<2C[KW,@>-PS&UJ!$TKV['I$SC1D0J3N>=PI$4;GN=J@););2XR5'Q
M#T6J>R$_!(;+)2)2]@&R&R:KG =\0?/\AN%47^PL.T<[2W&K8279IU:1M_0J
M,CR>'%2QS;!83Q?H-7OQG@M(^/:/;-ET0G A1/UT& *: ^7]0N89@_#9S 5[
M"A9SVX577G2+5]9A<WUB]]KUDN3-FS&<I!]H:5;<GL&&YZ9CI.CNA-RE":I$
ML<],/S3NRLMYNKMA48%W]EO._ F500GS<8T[96\21P5)"I =KG7]Y;XQEIPN
M4!&Z,QA)<Z+;@I4;,*$@:8>&D%M/TL.C21?9V#WKO7H^'1K\(V;Z;'>O[85+
M;S^>8$0Z3XQ8F7*GX+-8[14:U/A>3XZPF/Y^ 1<G/ORWP=-TSK-K[[5"VN]B
M^>-WM;N"9$OS#"H2$])H$):HCA!2+)F'R#-ZP&D]C<J3@5+P=%#KK&*TUB3Y
M?G)4/=MPP3@\\)"-)9_KRW-QY(@4+-DS%[=+S9JYZK2\2)6,$-F^*'</+NX0
M$AD5B4!$''2[$UO%GC-ZYNV[X6>($.08<I/)6QI9,TGVHC8P7[UX1$ +>YG5
M]X:^F6:4NN.FMI=4U!=>/F<*O6OMRJ5:4XIJ\C5*(N[]&%/9**B_ZG<!Q;7R
MPY#M+P_?P^'4=3<_G.F8S2$KW\=BW+;K\$*,()VCFH7!E<5PFZ$BYS=V%HV+
MDP8."'R-?LGI;1KIP%6+PYV"O+'2LMOY#>E(>O= G4?R[R2\@"E$F:^CBZ4Q
M^?$;C2$; V6W@PCZZ>Q,;Q.?U)G/.2:WG]?TY5R1D,JS4@I4=>-*=0B#Z5F8
MYS.:L(1T:'OQ. -VNI^!"8O>!U)N41\]K;Z\W6M>OF=MUG(^[XJ'<_PSFJR?
M8-TN^SF;M5PF/QLM$OFO"0JE"X#H>+7D$ J'VX<#T65.YS]LAJB]*!+PUXUV
MXUBON7*IZ;J @MP/Z,IMID 0(8+?(RYB"-L2_J(._#$NU]3)VY/=<?M1H]3'
MI"I\Q/<U^]K\/*WQ&T!HWIGD"982$D@HE1!8*WX8)H6TFM9M^)6R,!U7@#^G
ML[ 0.W=)*LXE7?5I=/Z%PE=G@+\K5 :C[=C4TA3U2BXU<9H."6JZ/%#G'QR]
MTC>> CP^HOOB0OGQO^X/40LP\@6,%.H=JVV3'G;"(<Z!#G7!L3 QG=#O>C_K
M?YU4R9EXW^95(#HL!NIVYYV0;19D 1U$K>P#[;;C4TM&(U@(4Y1^<;;?JC$8
M5UZ:<+RTUNG+Y-4("1WO)I9.G*WZ@UK)8Z5WAB98OLAEOP_<=V9.HJD<L]B?
M[PX M_7'(:!.+ND4V>?W"%;&-)8F[%1-5Z8X$I^D/ N^]52N[/,+[V]Z\]=:
M[&8"K#.LY1.53@(O;2F93 %-F@M=OV7&'#9%@[Q&D!&CQDE#%=]NO7_^>5ON
M_MD&RAM) 8$HU< ]Y5Z#%@43X4"6V']&)&!D)WR:J)6,FY/\5D8&#X#VAU^'
M:2'HDM]YK["N.(TT2I*9=S5I%M()YN'G+M4 4!)L.VBRLSZH63:UDTTV6=^=
M@*3B(;JF3KX;Q#:<6NTMZKA);)?#/?RGBY^>9^7,?V19R@(;FAU%U6<\\@5I
ME7&*<]XO"MW:.XQOKFY8)IYK< AW4U>)J+L%LGK8Q9I@(RC9H7DY]W+J#&YA
MT7+V8/D5K)9IB8XUFUF;"IKVI1<#ZL!8Y,\0&<Y(09XD0.[")3NPHB'&78UU
M\'=U0>?_M"UYC0GLAN3!/AR.S3YN+M-^_<0)H)0I<)5BO+L!IXL[$;#CV@PU
M$SZZ6V.09__"X3?>NKA-NYZ'XPT6.A(#;"J/W6<P'76L7K!YB55%KX/^8>1%
M0GCS!E8B[KE=:_NLC@[AON?@,*]T]*Q-=BHB7U*%\&+U%2[DTQ2H)4VO[*.&
M[ /-<.%]8"O5\R<$U,"0ZBASA)NY@Q'+N^OHT5=,Q<"UH^2U$J8*Y<=2PU00
MA\R5A)2AI99Z@X&/)P43#;*^ U^CH:#6(BF*C&"5ZF24,&H5TZ:(61> *> G
M0FJV2XX__V)H[E<ODG='];5R=6^$\ZLWC7T\*1$85F)X"I-C=22L"I#T%&F:
M;R[H;0]+[LPV&X!^3?W3%5<<1LE7<YD]7N3RJ8 ;'6.FG<AH_PE++A=E- Q
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M#F#EU9JXPM$I_J_&CF_L_/H-WGT:EWCV0+[FCXW=EY?<B::%A,6= S1%YM2
MBN(1\!3-'+QM.S\76_A,(*:<*$A&OE!#!+;Q\5Q5B)SMVP=8Y$N0J4B_0D[
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MLSA"3G@%2L1W#5\: @J>#N9WN,_"R1=(<";?*LTFCK;^))N"'2T_3&[J)$9
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MY'E&_!I%/;'E[PGA."3<MR: 7U3R>,#-XOE5]J;6@2#[&[S&AP(W[!>_4PD
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M0OK \S54'\"<!,[PU'ZDNSJP;Y=:X19P:@@OW9$W"$?B)_389 HM"-YJ;QL
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MQ"#N5F"-O3 PVC^Q.6OX^IC6Q'GPD9[+[G?,@@5,^AH%@:K_Y.7<;F'@ #2
MXZ5?(WDXH240-[<^+*SU/W2*/S?]9;O=:8.DVIJAKQ9TP=!(0,/'[+"KZ4_8
M8OW,PBB3SYJF\OU!IE9$V%:W6GOA%RDA"K_[]2/GIB*;0IF+#Z?MY]W['ZKN
MT27!U*<4CYGGXOG[J'3B:)11OHG;L8U)@B[GN79I;SRMA6T7UK2W,T;FIK[M
MG-&#Q._75_K7 \BJ&;H^25O#1OO\F O!Z )= L]1963-UIA5'+4F3!=OIP8
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MHTE#?O#N;SD(<.1:6Z+"%,4O!^E#4^SV#DOZM=<NI50\NE%KN66.2F:N, 6
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M4_)9/_Z@^]^46YQ^'%\O]\*1Q?,$__ZW*#>NVRH_GFILU4Z@F+.!$'@Q9EZ
ML@$> BL8825<\:U@5N\M(_38='[I[C&FJZGE2!M]\6Y2RSK_Y8CH\E,1#BJL
M#B< T7+[ZLTH>+>N.&KO]R.(7%Y(Z77M:SAD>2@Q+D74T,]IRGDDVOK%_2N.
MQO(Q'E7,+,(5_& L.3>S#C]H0H)'JA\5_WYWPZPS[OPGES(<7=C2;4R_LE!>
MJ)8S,$<JV>]]S5MY+29<'T!=HG+2,,QW&&_L-M"E%E><>5MG-V66A M?>>?K
M>>-$)^J8K_:B(&(KZIW)ZWN1G+&/SBPFP57Y2DN8.80KWM@#Z,YJ"68)YK*U
MN@EN^_2@=*+ ?=0^,E]8:4G?<N:CUOPWK7!_-2/_#</2.Q4%YS$9KB\%GJ %
M61\A6*G8C!BL/\',8P-7"0(@IGY;@/"ILB(*]^UEF;/$I*"DIP,^@3=T-QP4
M63NOLGJ6=,J9E??_3[DO88=P+%-8,X'&@6'R>Y2#]FQ OJ.>0-M0Q 8Z=]NI
MS'>P@5W8<2(=(+#"BD>^;V&(<2$1Z1PVF.DG+_D'_PH=49TC?/&O8@-X)4)"
M;F1S 1MX/+K*JDQA72E1 E(B?RV]P7"R@?>_(=>_?[034#44...N E3I &%Y
M#R1"OUH-$7*1[_.#V( =OYNE]P/,EPM0R_*X;N]W(RX)A+#>X9=$-?0R,>]U
M!=;)A/?G/__R0=M8,G*-;YH-K*QCEH5M17]^_/4SNRV/QC.B5PDK$^+?-/(O
MT)!+VJ-LH.\)\L,GKL8_<)7A=A8W&WATDK!"UV2%0JT9PZQM-&$#R$+,M$7^
M_]/EB+)F]!MLH"457&75J+"!5[G^2#["EP30GU5CB5M74 YEEK&!+YT,:&@O
MBK.!3[T5^%#BTFF&-O2LC& */>&HT!<YR_$7B>MO=;>W$1 QT_^E]!>]N_!C
MUR&O\JNU)(W#UL14,+-W<O>T4[&,*''"2LVG3>W:K.,43)\HZT1&ULW%->Y:
M2'*LUG@3?YF,JW[?,[<S&,8B(%AW/1SS?W[\=4[_D]XHR[:Q#(.(ZTM1:XF_
M+OQ0XH1]O]AI<SR+< 7Z1CE0<R"3N.,^9I;FS>3] ^KX8Y6M<"_,FCI&E@WT
M;V(#RQIYLR1_1NSW2Q3Z>;O9P,GT:X12.",1CL7,;6 #ZY)]OI0*EC$N'#.W
MR8T-I)R[K>GZ5^(<_V9_^W_]F,:?>Z?\4]^S.!U_M9I"E!,;^*UQD7E-(]VZ
M&G)1CQU76>\D@;(_VXF>K2^@-X'PV4CHZYK_7V+^MQ(7_#[FBTHJ)/)?H2:9
M7K7\B^=?KHCC9]UQ&L"\7X0TT<$,<_#75>![<@)AK.-"4#USQ'51J#UW(*46
M5&&BVR&5M_QUG?PQ!1K^KM/($Z=-L8%80^HB\S:2#>C9+%2+8UH.4J#'7/CR
MJ;-<\W_-OOW-[OX16_L7O?NI[Q"Q^M5J_NQ&BG(TF^!+>QV@.CB/B:O_8"]>
M=1.^P+B9/L@O>]Q_.=:WF:K""%W&K#/AZSR0R_OIZ=<#AG_4G3=!*FLRBYC9
M5I5)UU]7 "AM^3W_^P=4\H<DH/0?N(RG=:QA2&-=64?9P%L^-C#M8=]7M[BV
M"RT#/8MFLNZ? D;^FD'Z&QW^0];VI^[]##Y>\D?^:C7_[DAZGUX!FUGZ4<3U
M,=<-DS_:BO-:_HR0,4AXE!FAIG_ OT.->U2-A9Q>)L28(-_YES_\NG/_27M$
ML<YL0*YJD1FHSVC_=1WX$P+ZVV[X%Y32*A(]BBDVJ*(KHD1*J<@[*,GD'51D
M1.5Q-Q(;V/SU8.%FY\_[3:ZZ13XZZ2YXOU8JNF>XHE3 (Z-=W9*JT=CP^G%*
MG+]?S=DC\K&?SG(WPB5U?-C )A,F%KV]G7X&90CF4^ADKOLIS[QTD&-1,'Z-
M.Z7%+N<?#=ISEAN<&/@0\E+1P\EM&3:(IXU2#4,9G)0*/6;\LI2,53-,*OT.
M:DOB]"5/9U=*LTYI*6^XSX74.+7S,++BY&:+RE):&)CS_;Q1ERC(KCEA!VQF
MC%CB%]S-5!J](WWPZQIU^K^U,%]DYI-=%,['2W!SLJR_[<(U+?)-CT(R??<M
MJRV9O^N-Y9!^EXX@?L#5;Z!5?\*M^^7Q9++&@UL4)4[#\^ \_2JZ$2E:R>]&
MMV><H."Q:-CW;7""KD(!6(-/\,+]E?#L#SRWM91%8KCJ-S1/<FR/J3B&+J3E
M,3-TM8=9WXE$!!NX[-=YE>&<ZWI]=O1[,*%[GQ@+UO7X@_LL+V[T]-*&EYJ<
MNQ^'#S_',L3EA>EB_5%(D,D&0D-3,2Y.BX'T+TU$E%<Z>%J*!;M!/4MD V^@
M3.T,B$$MS'X)[$VBSD^BBSB**;&T,&96]296S[KXW$.Z<T!X_:AB2+.-13OQ
MMD[@*[<K-<-V0_OI4=K/U,PN*'Y(QU2&[$7RK#BCOG^N'5LP5W$#>ZTQS5.,
MO4$C2>C5QR7='QF'QC5H1R%78N?2Y'V_6@5TSK!&@GIC"\7C$OLS72=+.B\_
MM!DY\47;6^YN /GV$<+O4ACD070/H0C3B!5E?:S>3YDLI<N#]7I%%5TV1U8\
M9B.V',HI0_OSWL!FYD(J44<0GN6GU-<_0,G<XOETM653/'98 ?!;MH0SY,L)
M3%YQPFI7)QO@V8^'[$+H(G.YB"-?'P(+=28YD#U[!=40O ]&B9F!8)$2Y!2(
M)G^:Y?A[E 6L?U3B5IO9Q$@P8^8K2O/Z1UIGSC$)?Z6-2QX(EI ]DA7*1Z1_
M_6[]F]G O7@KR/6=6&6MV\!)"CV0C3T+.;+JN#_-)X#&OIAU$17,8GKJ/UW!
MGZ C]L__]::#=S;Q8=X+^6N@U^0UK\N.TVVW36XRE#AS4O+9P(_5_U#H3RL.
M/U3_4YN^SW_\<Y3\D7SK_2B]Q88-Y;3,&R]'CFN&[7]E&1&B7$ *;@=N2O[@
M&B]8.LCUG/LHC^1Q.""HM$7B6L#LN9^5Y=^FPG_4&,,_:PM$GT6Q/VD,YI^Z
MK.Q?P 6[C+(\]X,S6E=C KPF#\JT7#9P_A#N?=P&\U]BO?Y7EOT)2OV49QU7
M/IE2O;N\',D_7%A5Y/Z)R[Z50R<1F)G^1S*!_V,* C^!]3SSNO+)5(],8VE=
MJ;+G4@G;R]7&A$;@WZ<B_MLMX%^6S'6SR5UX)9?>>_]HEL5[-Z/Z()]CXED_
MDK=)(KB;#=3B!@FT<) #5HL=\&(#IPNU1EA$,3OB3*[KDMM,&C-!PB):_KKF
MN,3Y/=>E(]=/10(@EH0(9P-C><2-NK"O.+YJL>\DM_#CPU=?Q<A2RE*F)F:\
MJ16JWPH6FO=^;"A4E8\QUI@F%OO/55&GQJ=NL[:CW"F6^20F][A+O?6K'D\A
MA&I14E3"Q8?><WPW=MPU.*U\W2^/1ZH-W_7Y+'>S)+X&,^1"ZP7Q8Q[XP54(
ML8>B-HT)  %W]Z&16Z<35VE/.R(T#A_?)G9M0^.&B8+,R?JWVJ5<9RH@B)I0
MK5-+-P!=:(/,QY<[]Z.<4EVON^HJ4$HCO"1'AY!=R7I[F@J5F,,M.X?YKEV[
M]]RPF)60<EO7##2D:[,^XV3@'OQ\M IF 0,.O7;+\3'3/9/=-;*<GWSUT)X+
M7E;.C1,?P,T?S"?.$D;T0G?'KY?_:]KJ?]NT%5(4W4ND7("8 7Y0H &V 4Z"
MNE6*>5O=P@:$D: )NFUJK??1,.8U73[);ZT"3?TX3'V^%75&12 D(]-Z0-,S
MJ>_+K3(#DX2I_OCPFNZI1+MV!^63755?ND;P!V>)/\]\,/H^07I51>CO?>@!
M"5SZI%?"EQ'(,_2JOIN"4<D>"[ !1=H=-A"6SL3IP*E$EJ#*G,H\L1@B;#GS
M;,!]22>I+)<-]*[Y+(Q,>-%3I?(_JOG47[FPU]F05ZWB%%TCLUVFC,!#Y=(+
MN_# 5]9(LQ6G+INKZ6%@.H=[/+ULIN\/T_K7%-P_S12<LG:CK@H%=Z?(#64X
MCA3^.JB+ S[T#:;/^5&:5P(WFZUU>2KXG7?:W6*P9SY1W>KC(!M@B"21MN)S
M3$GP@;9:W=T@/O?DD"R,Z^O6WFL$;ZV%8_DIF)**YM^R,8Z8VE/5.M_R I+J
M<)O4C<L'W53YO6UX;^6<ZB\UC^;<M5W6QPXO<>K,Y^ZDI:'%(>K1K"_;!SV2
MQ,9/P)>I@T@E^1FXA51@,AL81\ "I$C5$2P%,'1\GXI>]SA]M;R*X4?E_%I^
M@BLXAPIG\>I1-6MPVPF>*I*,DZ ;^;!OL!!S3JS#K-221S4*41)F6G%;GD?.
M]^,!G\>/CN,_8S=A:@^Q 1=395N$!.,"U@9,(BM,%.,B;A7.2*_LO'CUA/A1
MD=2+P$$'/?I9R$-*+.,'Y<;CBJF8D^"L-\G#U&*?$/%8$<6F72:EUHV_6C1N
MYL#QI=*+.YKF;CS *6O67]D^I_;@8FD5/J\CIV#-8R8XD_,*8U]]0M%,+W[?
MQ?$/8Y^]V\6=MW]KF4>[M!:Y#Z8NQ1#<"6,QF"4L#O*LJZ)LH+MX M7V"GKY
M1D*)I^0L2[*T;>A@<REKF]V46Q-F'+0:AA<@YIB0E2BFZP9@Q@P9"H0A0C\2
MLAOW\?VZD%7JNV&'>?U-?JBT?6@UVF_JP=B-RX%>FMQ13V8-6AISNWMG"X]B
M! ,*P[_-Q23#.&V3W5-B[0IME-H=EB)MBR=O'85LWSGT@7^9@__5YF!/=4Z.
MFXW8BT/X/'<_FE_<M$-03EG<X7&DY94=' NN_6Z'YJ)$K&X']'T_Y4K+S68(
M/$C22>QK( JJ\*6B=+J09Z=>[M,B;RN;J1T"A"/?LX;8P-VGJ,!Q/4I'J"ZO
M:^S-BIYTR=$BD67G^SY>F=)/40=TKI3)JD7Y9082%F;!N>JKM%>/G,8WZ9AF
M-:YDK2%?1Q?&0$)MO6Q)(*L(@.;&20Y4@PJ7C/ZAO*^+W@LQVU-EWRP<,UO1
M&!N%P.O=6,9FK<_56T&)5!!+SJB2&+S)!CA<%WVWN!0:7_<1RLS)OK;G*">+
MIY 2;M7SBNHR+S7N+<*PZDWQ_*KYH-C?XS"2$.LF<:$3WN\Y'NM )7EO#D#4
M#*H[2%.LPM3G88C;CE(R^UNU YS6Y2\J,;(Q)3WS$**[ ^]4:<BYQA) WUJ"
M5/0:&QC*5/A^F\VW/L;5BO$^)B]RXTUCPDB?[]O,I1('W0=IO=A0PE@2;,/6
M8O$'Z".SLG)@-M[ GU^ON;Q^1$]B(7]HR\GLZ0?2O.MBD1[<^A6?*XFKQ8Q#
M2/G=/EQ:@M?JLCYAW3V>,J;>$#^>SGP9X%_/$NFZ] FE\LKZ:\FAV1(^9;[S
M84K-*2F 2/ FNY3(&6.%RP$Q3]*&O.8@H7!4_1W0E_,'5BY^2#JIOZO'5GR_
MNZ*OQ.GWU]:!?EQ/R?\ILN/7Y?_W%J$AGO>KU?Q9LVTL_GWU_B5?X@^S1F>_
M_CFLXP^L@<:S3JS#F6@<<R-DRGYZ^@-1"3^P_ZL_A'6H<^3_&0$/3-WM%2\K
M2Y"+UM@G'UVSYTZ+?/+=V\.^HB2B$&$L!5/05S_OQ!*4$6_REU6G\@F]!6_4
M6.Y[/7*J_G6(P$(]9U/OM>"<1(AN05YHDS"X2">$LH&--P5")=4)_K94)JGJ
M<P*<(/,$OA?!:AB076G;Z\RW5/M-M[-O<;K:4[9G;XCJ$]%3+>="Z!8P!:;P
M:CH;\&K$&1&1UFYQU]TEGWZQI%%>!68F'XN(U(IIOGVT/0")_7YB,J%0)52C
MA.)]Q[?=A"P>L288@"%-/EM/^W@+\P:[JL<=\NW+K>]]%HZM']6IQ-HQ<]&'
M ^K)Z>1WL73XN<^2]48/F[53"THN"B</11R6$%U(!L!+E''2F<AJ:=!ES%3N
M6/[V]KS'F<U>#PS]-G.-+UPW-:46^YWBZ[!:W2<^VO;E_0&,2+J#?2K]'6;L
MW!E/S-!;M$L(ILX3&H:=('4)E"-EANENG2Y@CI@WQLM9]+3ZW2R)V)SJ?3X^
M0VN]OPO2<X) I456/1DQB"5G1E7O=??178EJN)5:FU''>CMPK/4QEF:B1K?J
M_&Q^0>MZ;\Z-E:&%3O2&0-;^F(G:)G7Q55%HJ.Z4S&"^]"ZIZ8B/P3A1FIW"
M]4@!E%3Z]"T4YGJ;T=OHT1W!?DU 1Y5'I[ZO?,H;K-B-%\9EIB/5^&LID;MC
M_K7L_L_BY-?X6'R;Z+;H3Y ^,Y0)H!EL&_PMH10#<<)B#-G"S7=J#>ZX1!@G
M[SXT_^TR_=W'A1MWL/>%6;QE].!FU'H,ZE9#UPY##*A?E'=L6I5F9_4PJN/
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MOGY]_N*$8H%Q"<MHT6,*]AU3ID[]&Z:<=[' D'(Q[@@L<II08#A7YNN48=J
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MSOP-QS9[:40R:&N]7SN9NUD&7\Q!V2EN*60QIY>W1<^'/(%I[J;-E,$ZY!!
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M?EJD^JS:=?PCOX=[CV;$\3A+]^0CTZ<]^Y\]Z!09 LO:R4QA0VY+PY["CQ0
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MN@;!%#CFK*_>J+EJTN:*J-)C0_S=4UZU;RBUW#2=0\2Y'WYQJT9,1,MO>'K
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MN<1S%"2&(;CU["WYP[7'_1[I'(<?O'-X::8M3N823_LP*.9*YV>U]Z RYPV
M9Z^?7;K[R&CQS=@>24F-QZ[#\W_ SU6IB0H5O]B,ZRH7=.=&GMH@.TJN9AA4
M?2GX,E4KRFH'=FGPHV("; C0W1K8;''Y_:G>-A\YKAW]:'7*\?97M9!O7-G\
M8]U:WN.?7]D>@SN%90EJ^VN)%XQ]RVY6,->KTSIL<;G^OSR2_4]Z)-MD0ZAE
MVSM_K"YL:?2A^>3\!#:$>R,R%>Y-C!'EM[KKYDD-I]D$]28V$&Y=C-S:$3D0
MX_?3+_+1A]X5*<47Q[HW0YV(R[33JHR#2%.,+L4QB()K./5*G,\QWD;\"LIR
MLBZ^_BJS>;>B;CUNK* 4YX@<::$&,O-*^J*^:IPZ8KW25+E<OU4L8Q%W*Z!I
MMZ<B=/G=><%?AU,L/L]=?(S-_6F0X3)P=M3Z5V/W+QO;WT0OW(CF=W1[MNN!
M)F$0)/RE1HP#@W6LTWU88MA"7 %0ST_4]T7W'GDNB5JX^^)8W=M'FXLPM9B*
MRP]VO)VJ07XB>!U3V!L/M)<!1,3'<O6+.%$,;A.+-$:D8+EPA"QXB<_":R*M
M=C<+U"_X2O5?A.R!AN_BD8]7(^CH:)@M &O=@JJ[$I]3$/X!9VA-Y 82YNEM
MRF ]4L1R/MF6L3?JS$,'-Z>[X0^ZSR_%[H3JC3<1% 35[Q8(E"1^9+1/ZSW:
M^#E[_WTD4>F_&2W&\ "<$(0;NFB[E<10 5Y/9"YBR<$D.&8D=RWQ#Y$S6R._
MCGN64;MKROKSF,(+_J]5#TRKP1<UWEDDI/T:6W!$VXP0#0>J?C)60$(<S!'X
M?NP"&S+^B5*STX&U7^,U"+W8.28L^]$?W!U$RW'M#<85QA34YBW.X1]THC 7
MB%"G]:UJ1M+DAH.(%Z@"\5C4)(Z#Z\QJ//1_MZ^Y_Y'GS#_&=/E3#*-_/#++
M[UX\"<#F+E"]0A0#,V9@A;C "OV&6Z>KLD+_#:%B_OC%2=A?>J3Y@OA+GV:7
M14K^>Y&>_FYK_RTQ3/_4./X_MMSTC[&>_N7,_0PEC!!6C\'4'DCZBA>HACKD
MS?;<_>!CS"!?$,0?C@H#5;CA*U W8BT/+0_4*4>8'^$.\@(&E"HJ-RTB9\[<
M,V#C(K>W:MO^"RO#)]5R:2T;>F&S3^^H6LQR\H\^;5<0U&^6H_@WS6&_]? [
M[BM;"#"CGP;J[FB(HEA4^#-P!1^)3^.BJ)D$IAGH]B<8)M]X\-L;ENNUKET:
M-VY-#H86E+C+RZKLU2E8D$M/VY,.Y?WQY6Z<SC='L6#NB0/VDG0+D$O  2?<
M\/!WL(V"*( NW1@L6S9VIN> 0^4NZ L]A;)'1Q\0GBOR)UTHB+8?9/% P58D
M];67%0'U2'*=4QNOKFSD"?461>>5H^M"X85L2.*K?'SNK>)C#[KB@6]48!Q(
M9^R[<*:?IAR(^\;4>%\M234 E]8S5A=0FO?!&O',NVL!<4APU7/<_8Z6?O#E
MB7K\XW&_E*QV2)O48)5%@G6HK;HV3YSSYBL]Q:AB<+$7[?]/&#+HOQR!_OLY
M G7L**V9K$Y,>B!>J!=Z*E*+-__#K6#HK@/#6"U(P&VZ%5 G6BL4<+TJB2BY
M,)C=1$ >%D_SL]2J>#02H?E-ZM!4B1MIGZ"4PH:BC\5+ACPX-Z/0 [!"@:BW
MM#-T5(!ZOW>@BH:^@7=P*3G\J&]<!U9ND^OC+4*:;5P93F<^E?:.G#1>WHS=
M8T1 1-;R?AY4SL7@G /Y"'G17-=@RAY*#1]Y+QVP+SW:E9R<$84I"6-=KQ&J
M=K5[V&&'/@4/@8EJ'$3_2#N :69#N!B>CGF6YW9ECE)DJ^)2XYM_HK#,1,C&
M42\[;_2C ">P:G;H'["BY2@L"<LX1">>RYX:D9<,2YXU7Q?K) D?88Y.!  Y
MSSW.[SPHO,"&.!;09"S"5%+-T/SHGV@1Y&Y:[#"BV" O\"6IQ%FSSB;\S71)
MP+KDF91XAZ,W<Q.EGGL_>#B-,:,FY<S/!7573F4NX0XMZ4G5)N7,^DV]V5W\
MWL5\(]''6*9L\'&Q3%S[T[N*1?&"![Z)A9A+?_OY]?^6&'[_0+CL_[6H2]L_
MA!A0APBXG=M$;AEOJ0.@J)6-!A_8?@TIYV1'5N'MCR*ZLLJ38QM*OF]C(K%5
M=XP@3BKK'0$;='O&268D<!\:@^!%"[+ZA).&J[7X.];QP=4**NW=(W-A=]2(
M9F9#)X-VI'YJ@/ND3NIPQ05P,&-PMT%T#] OPM'D?_<G%4HZAF@8?JJZF&X=
M<+L,9Z7VFI\BH]#T^H0XI]L#33&U =RBJFHDX"8_0M=G/DUJ\1L()<!X4<>J
MC4DS#'BV2D9SL4R"S TKM8^KW$_B)8\'$KI&C9- 81?\!01V3N!>5TCM$2;(
M5IQ@87Z20:SC*)OFX4?V1RO(::_YHUQV7QG/LS_/;W[+3/]6\.-T^=%[7%]H
MGKAZ/-D&(SH\WT;U53,CVS=OZ!Z$K>?R4LF5'Y>N:IT@%2DL7A:Z:!$J#R>D
M(,I5&XQ"$7P,;Z((/A0K^*ZV%]%PD54@NS)365HDUJ12_%W_Y/>[,3P3TW*Z
MEV[(C_136AB'98%QR6WP<X1R.'-U]-UL'DXLD%%8Z1ZQT4**51P+,D7[+R#U
MZ*(@LN0KD<Y%4-IL>F7>TXZ1 @6N5NG^Q.OG.<<\+&HI#[W!/>S5>?\?BW=$
MP(\8-E"]*=[3C=!H%K1/V7(M\6+,2TR8Z)E,S,-)X[: K/-3H!@;M\/$:C=
M^;@&9:* 6T,343<'OQGY019G_F1]^T?SZ-]=^?]'INW] ZA7Z-L@#F,/CVJ+
M?G23XRRYI\O+Y6R; I$V^J-!]N]N_/^NN?9_I?Y-ZI_$GT83"=C:-P00%-@0
MX79R7D'DW=X/KOM,AI7IUY]\>G[0QV/B!Y?%7UYKV4:V_^3I]I?H)JP&6/'&
MHGO&65K,N*=[GKB-3+5!1F@DE9>/P^V %'1)1Y WQ5UM,..O+)HSI$KO&QB^
M*;8+$SI?E;[J:D+;]L('\HM@H[EB5S8$6GJ3A'P6I1 _=RITLO@WR<1DWJ0B
MP$KLU)Z1BC=+@P-L2)$JXW 6J'SGII>3F?F9:BK$UL-<Y('"B\]>TYG)]D<(
M_KSP72]V)E-;>AG.)P4G!F2L+&^_S-/=Y6?1BBC59AS<^14NE)^OYD7&F/16
M"Q$?.\BU29MCC"J3\NW%V1"31M)TN,/'TXV@IIU'6.5TLY[$KF:P(1GR_>C=
MC+4YAI\&&S(5B-5".]*N4B>87^"W8 =' DXP/S,DLUV3N9%R#58I>_)YK]+R
MEB)&'KWU*KHVILAQMWF8CB%H+W*!\G?X9KTK"1J".[P68\ZYEUKE6'[&ZUX+
M32+B,R7MR[>Z9M.XCH=W5A:N'?#"^4&=96^"TO)"SPN5V5_KPG^(&O7'>P7&
M%-FLJ)N:E?Z+UOW$ S"%@[^"M0OS=RJ]_0/KKB\JIKPK#F_Z-!2ZDG3_7,MQ
MAWD3YC_9)/MW3_>RKLW+1:'AEQ"4SI@[KSKI]86\?I.O+&#YZ%XXEYJB5<!5
MNG' I2+'^6-=X>X':M]<KU#QS#(!>-R<50OG2BRZ+DXS#NM33<E4-)YNAC(Q
MJ.CZZ9Y9">K"IX?R+VV[?ZYBM0I?6_[,<'QS4ZP4\Q0I #>Z()8?3E#HI3GK
M+SE*F8FV8FVZ$7OG ;(-&_+$SU=A5A@65;J;ZYD!S[ R/&K4@PUI<6V N[ A
M-!D$AJ48 /]"<R?[_U9-[JC]$".:FVN@N#?K:;3@^R'LZ;/T=L&R\X(3:95"
M$@[6+G)'<ZMFG(^J6ZEC[)E5.$(>N%KVH:5G 5!;=#K_B.E&0YH=I"69?ME<
M7+(R%/U^$+Z_)S:,PRO8=1X8"J&^I3G0+0,4RFD)Y!'C-8Q93Y8G->8B24A!
MAVOJT_G;WY:X"'E^D@MM=$.&,?-%[2E-"FP\-K<P_("+GUOCF\ KO!--4JR<
M4=.52],SA;;J88D'KL0F8.Q9N"R'')3E%^M+V)H7%AAT)U"R$0IWQNYT3I,E
M"S0&<MOCK?=X,-0V;M2LA[ AAQ\VQEKI' >5W;.H#C^C/UXB0/";I,P:U+MT
MB/H;7%+Z:]M]EUW_S-> _@_=,7KMZDI,(+[))O7+AGXMBVX]\611.N$))\3[
MT3_CE9'_C*G_O[GFPF&O3;=!@Y-KW_:E:^@,&95EU;\&W8]"&-.!I]5VXR/O
M]K'BO%;BNRMV\=^)J#"RB]0TX1"MT(($M&X'KC@V]HZBW\"&' %<@&&O)NR1
M?(:8%Q7+,VL]^NF(GW?,M^-Y#3;U"C)MH2=^KN\\3G H8>;@[N#WL'J%N\+0
M)YW3U ;5#I%PW/IB*-?F6N$X\ZE1<<'X/?S/AMYY/ P[9NG$.UZ3%@DAPX>Z
MJ <+:5<I+AO42%H%);T1=@A]8M0YQ*", @M_'RFX-J\VT>"*%&CE(Z4V'DI)
M<?]%KUGYYW/H_3>_0@:(Z<<C@'DJDLE3]C=!.O^AG2U>1#B,+V /Q::^7(.;
M%C<NO0^I6V5KY) ]$K$_K5UIP]*;]ZSFQ'Y7PO:U!++N<A1\1X Y^@)0!T<?
MGS/W*0O]('HTX<;*4KI]QO'4V*$?:PH&?;Q''GHBWI58W#L$BZC#><YL&)DR
MC3](&;[Y05.E;@?;K4^]9,>&A*K3D30-4OTP,^7]<&"@\D:DPG&2@'DC,JC2
M\3G_]"7C:ZX_<(2W"+()_!D6PA+,#"(7- HC(]2LB/H<<L]E/$R(PYVC6W;?
MO^G< H*45D6-OE\ 9V)PQRR>>PTWM CFZPKJ*D %STU8SHQ)E(4W,:-;GJ]V
M8A6N?K-\(]7N?R"9\:K@PU?'5T=;D@Z^)19\0C[")YE6Q^:8.@]L+"+%J-JL
M/?T@+>4EER^ZCI^OWDO:X[[6!7,V#UDL@X1B3"(N[Y[Z!6.@-7(,M;^CMM"X
M-"@W"M?(XJ"H8V+4!/)_S2;GOWY8_!,QK&.B<_=FPT[FQ?TZ%W;7CM-LZ'>
MNMN LSP?4*])MFG8/^I,:9TX9M[;,'"C23SR[$__],)8-'6,0[W2_$+BY72+
M8>,7#ER,SE8%L_IABZBB5;A1=D$GDF:&)=MA1%)<\0=BXZH9>,KYGCSJ-*NZ
MC_4":  E?ZZ]DDBU,]V)F29 ITZW).>26$,?-.'6J_#BT]JDQJL3(PI4!9L.
M6+I*:'Z "<UQ_(E1!/KDC/7C'_J!51;/C@)X-VD"G/80WHP3\*)(4K\>3)QD
M0XA67H%=P'KYGN11<'R"@7WN%#9DC_SBOGR[U=7 ,*UG>#'6[I4[F(^3QK1"
MU;40J),6$OYUJ]R660K<A?,M"6<M*A$>M&VDAS0.])[?^N31LO8OI.D#JZZ2
M0]J'KFG5WG!<-C8NT#-A/78W+%^ZXQ&<=J)K(2)S,="B*>U"GPU,L2O7YEK8
MC%B9"5S)+C:,#=GUE!GR*%JD*U2@,H'W=D&UKA]<)^,R('5!\?SR!=QO25-'
M&O(_M0S""27P0KD$[&<7UJG^L^?IT+ A+S8$2+Y(*NVBR2TO3+M9HKS&!6+D
M%7Z,G<KX M]H[[&HN0^0#?$_,0TCZ#KZ.9J'08W&J,<& IO2D;SP"#Z$I7J2
MO\'(L0P(V2S(N*Z$7/K!:=6R273P5&S?%-,:\=SK]N"U (./;$B=W\ <LI &
MIUI^^1+7*::J(=4 ,XJ3M8%O])NS(6$EK%\L>38DWI5^9(\/&Y++AD2(9@6"
M %)=/3CS[$VZL[ ,W*E[+==5APVI<-_1##^UXU/W^D(9?+=0P,1/?SW]^VC)
M:56&2@OC2$@S8P9>?*9'=05.C$S&(UF[]0!KC59P+L]3< =_I9[D(BW/G*,#
MRRFMB'1E8V8N-T/0S[4?L0YUJ]2"I>#)S0#9RDADE0@=SIX]P2*S(4^GEGC]
M[W2>A$O!QW]@RYRB.M&GT$-$DY8-+$6A#UFYSH98=T_AKMU/IR.%8$'7-.(T
MUR-396JUI],PX.CL[TE&E* *J&^K*^Y=B'-C2!5BZ;-+"+BM!>(=V#%[</?\
M;X@TP@\S/%%?'\KFRQXW03\;[80+TQ]'1CA9?=C(9DW@Q"7#/VUAI<#1N ;\
M]->50C(4B/N,=CDMCIUXZ;6^$E )C@9-0F#AQ/AB9@L5U>LH/48WKJ[H&NQ\
MG3N6G>][3W!SV1SA?ZH_>ZNXHP3^$T^]3I[BBZ,KTXZ<,VXL&'>U.@I\3=V+
M+L52-JA23"SN/C2T'.#U[H+,)IM\472N3,-D-NW:"FP^6]1L=BV0Y_<K8//*
MYOJ'PJ/[^D8'7ZNMU"RA>5A],!#9&Y>'X$3OE@9DQ$6?3\GFN3M@Q7/G-K\F
M*@(2-[^G0>^@:\$)[[=MZ?@( Z/ILXXL+SJ\L\M+_'@?^*PF)W>W[$W;[::^
MA5 [O@LZ*_#J7_M+-[*:8:%8/O1IEUH!HW![WM[UH Q75]^LO71/R;B+^5=Y
MF;LU"82[1WF6I$<:*4<DROAO!D\FF>,,6WZCW'PA4^)4QX9L6U^& GN7L]QM
M")CF&*^&0:FQN^>&FRKM&S]=Y$0QLC27?.*6;9&,TPB:3-="[BI#A98J'U/R
MQB/QQ]QL=G;T(V/.K0@!YL\B;8<QG$YV_GFG\YWVUF7)B^)8QL$C)S-[!OL8
MLR J@#U0(E O:P+G90W BDK*DH2&5ZV;/#.Z@OJKW[ST/+&ER(<J"*!M^T/U
M8D9J2/H^'@[#R*M)^TI 2BG74G[D^[.VE,2/^Q=';EVR)U.#B*F*!H<:MXZE
MI3N>;2Q+HK8J&ZIWUW%1^ D /XZ0""M4;4(J$A%/XVA^*]>)J_7ELH[%&L^C
MZS:;76IJC<-9IR2YQN3FEX"W7C<2Y\;"*FC:+1I[:$$9<E4$N*"SWVB4@_M4
M0K:VUP$V)*BY$5V:BTBSEP-'2!RU\36Y&)5%M65F%2BW_61#2,/J5HXEKR]A
MUJJN8K^?L$*07P%UKFR(HT(,LF%0%-XC6SNO_L'OVW.^#R6<2(78)>W5=+KJ
M/AOF6#7B1<T@N!;47YPBZR__8)Y\7POY?=NCJ[MDVT6\-NX^8FC5O#M_W#WI
MYHS/R2MYR\@'8G=;LEXUUS[_O:N.,J/19WT?LX[1IC,L[5J#J+#]B;T3O,!3
MH?IT[(90;G*M%:9A_J+'Z$ NN4(QW?Q2^LA,]N+VF:/ELIM<>IJ0J?+-*^,O
M^]:.QW)_E'[R[;\.RO[/'93]=WY*U8AQ*"^*WB PMI>2&>K^<=8ZM5@3N.TC
MB)J*"9/27I_CWG4KDH'>=CL$U%UB&-%/HE*KG0E?\KWA$!>?\Y]QM^P-%*^I
MV=C"F#L,HW?S"7K13]EN-&'VTOR;<?O6L3RH8NWR/N41NL2SE<ZYLZU2HF\Q
M?:)OGVB?K)$I5\Q-,JL<D/=F>JMDF)MF3*"UP3) O$AE23+S&8:URI0/%A>=
MGBBWI2#PV6<DLDZFN>=UL<(DM;AVRJ"80>2PIVH*!!BO)4V^SH^_['6&<V(;
M9VCHA]MBSU2.GH8-?A1/B'>1YZ 9-=ASDNVWG6QSS21N>21E6;9POHP!LX7N
MB(9P31F9Z$HF6/?=LWIIVYPW%F<C/Y]MEBM5M +V3W7O7]F,_4_9CNU,H861
M@7'MIESH0E<D;%\)?/\5 1>)PHRF!S>9/7-Z6,]@Z2DV)!)/OH;X.4_D>NTS
MON^2-3EP9"+W?F5<X@[\HM8#<=(0#YI_/96_]ZI09 / XQZP1B^34Y'<]WJS
MP1=<[N^993BGW(\JR*%+U S%^D^(!6G ,T-7GBYQMD=3DK'OB;JG,1O2 $)(
M':C0.^)^H7\@.&P:*]UQ L(O.R.>'_:SFYUNY3HV9)D,0D85&U(Z;7'=X'Q7
M1RZ\!HC+*D>2=+$' \Z DV(2W3EV9B5/0XJVLU'T\)< 9-HON7<N:15WA^0G
M#Q1DL ZS!O#%VLW+4O!0-D0D0#W'U@ C]Q7Q2=4)OK8L-Z1-+.F*Q!<)++10
MJCH2B#YU4.B<Q2&G]C[.\."%:5;:B1%YECI".< ,+$J(U94FL2JO<8CQ&X4K
MU$/DU/'*/=G666]Y1DXQKC_#T+0: 155$$OE5Z%47Q]$!'6=?Q.L.B^H6'*Z
M,!-Q@>2]I%P4]GKYU+Z+>!N^G!!6J@K'Y)F6NS)& QF@\ @N0@_#BM=_^:DN
M.M)EDF(L)4<,8IH39'"+7([Q0@"!0W-]69OZV]S\LX_":;I#S';U$&#G=>:Q
M][5&OR-E(C.&=7SS<:UT?RF6VZZ6P\#KNN(5FQ_Z'G<A0,DXG&<+/LZ&-'6%
M8OD7X*4:@HQK/QB:D!L=$I@<+<]B)B%:#^L08LM/1GU2I=P:;%M7>B&YK_M'
MMQ9_^^7?;1W^Z+S_C]&X?OSC\6]_MRWZN\8M9O\&LZ+_V%@%?PX^]F\X[OW[
M1DO_:-0R\"O_>HR=)_6OF^ _.#O^OSC!?[(&^X<!7($!UNQ$((R%,V(%N]XI
M_//CW_]K)+6YS:0DOL&X.)*XQ_33YR[!1][JX6H'3+HOBXI0;%A[JN@"#/M5
M#Y7EH&'[5!\)HY'J2U5&SQ7F1FY)Q0)X\X(4]'%PW?.6,.5O@!P;0WW,?+=N
M)[JR&^^\NPI9\[(FWSW:#8N0C4$_,;9;4[J.ANF8/EY81\1T.%A_>NPTM<P0
M@Y-MH$-&J=+67VA!'VS63;]@K YR_.!\)3NE,.3)R+6IPY-M<$(H23/1(\QL
MX-ZE4<4MM< <@V,39:_5@6ZY9N""%OJ9N5%T "<!&>YG]8,!$#JD;8LN=&06
M9&EY"< 7OGVP,*(F"I?3F[AQY^D%K#WV P=I[VNM14^0LU@\+^F' BP.V(PP
M[,,N5R<(%5',JBQ?;'T?"EMY/EAS/YD:1G0_I^[4X->?^<[I;+OJ8U5I&4/U
MJV>.LW;7NO]NA!7.C*R5\"V_B A:KC[C*Z%;0>Y\WRWGCYXR%K_L+R6+DBL'
M,WDPTS7XYDQ0251#9HYC6<JQ-L[V06'3">BXXHC2IS#FY&4_T=-;M<8(FK<M
MS%FZH ;]KNV*C=Y8UHQJ% ,QCH'0[M";TY0'W4LZI*^7.2\O+TWL.:J0/1G!
M2M4]SIN 2#L U+G)$IFY&?T6];QH@?:H6WAPI1CQB$2Q(:Q>9B<]=])HV(CZ
MGEFHYN4H_Q4Z+$^4R/.$A95*V.1)4'O.'^U,V:F@TSW58J;H01\ZIED@7. O
M/SYW>+8\O.3-\,BI4=]4Y<^%^F-]K##&"2((A*"4/Z*A3+:O^EW*%W7=!IR/
M;TMY7NC:'/=Q0F1W03..)HEE'#9J@A=!PUM"& [4/)NO%Z/I!24_.V<?S4)M
MHA[HP)9;GHL4\"H"5TI@-*GE!?X"=RW:5%F\0DL2\!;?A,D5/,<J)3@4N=T[
M4AQ]<E(T1II)'4KI/[M^0I:_>\V,?](:NMA!/TI+N-\+.&,YSSB$VG2@1>X8
M94HXJ@S?APMH'*;E(ADG0<6A6OVCQWG$9]<;!MC,%I6I[Z'W XQ=)]IM[Y9K
M7]6"!"OR:<YH\3\/_B]:^']M(.6__L$4@+K?X"!9% 3)XMDQ9;*M^; 39JW-
MS1+Q>8]HEG"L;#Z4%21I)LDEA6* WP_5HEQB'?%AG %HFJ7R-#U<26T=,Y3J
M0,64.(F<8U7,QGK%NF[MRQ?M&G=J2*1M^E+<JX6RL ?S(XXESR.<1%%/TBQ\
MQJ/76X1:^)<=*R9M]PD8NKY^M ),/.IIU$MQ6]=XQ'P.LM<X_,Y:(88"@G8?
MR_435=YDG2R3'#8L[H7,XO7<):+3"FN2-%<_RZ6>";*378G,X-+VR@#^^.:K
M _K0_?@LUL5[4G"I+8W(U>G7#M-F7</*^'L]].A4ZYBQZ1:_9<:!O=1+_0^'
M/2I(=F?9$.Z2@;</X,N+5=B!+S7^+&YI<CX)3HY&_Q ]7DR:I*,3.#OAR\^B
M5#::^#\H17>*F &7X.T9]D5S:"\8[:1J,X8K%<^+<^/8<_-%9Y*70P@;XI8O
MWC* H?G@&/Q1=3#58/ -MK0^)>,+92P;M\EG&8DNW5+2<F66QR:UM,E;OF/>
MR;)#:T^K,H[#R79LR [@FT"SDZ7.)IRBV+WD Z7[WVC9!*GP/C&0(I61)1G1
M<([8XL^...++6)(/BT-'B68QTW$8<+V&.,:#9(V6SXF.JA-K2:MO6*+@?.#<
M0W:"'0+NQ.W7?+V'W)SKT)+OZ+1S_N8LGFQO,WK.\S8),V3BZJN]U5Q&T32'
M43OU;P"4.>;!;)5CTOK]A'.596^0W@?FCS5*S6^>/8DI<.RAD=LF)4*&3?P;
M*!IB/P!"%:XXK[.;B'RJH5PDN2QRJN3+3M96LAK+# 0CLA7^9Y3E"/-= 0JC
M-SJXR!)]/+*^PHO-\.^LH2NS.M%G?@7HD_?6^07=;K-'V?=<W2RY.\A? -1=
M8$/N0 ]ZL'XPWU2KBXYW_12+'UQ9.::@7=KJ5'.AX!IVZNA/G^X7RC#:F>4%
M,:+Z^Q;JL]X[LL-LB&%U:4M?!T_DHC(,?**:4#3Z?[ ASO([#9<W;H/R.K/_
M+IR\^[GJK+T!6(XH&W);UL'GIX:(BY_5[8&&QB1WC.>T[BE/OPW&_@:J*6Y4
M(HS$AAR=74+/I5[IN=]"&*C#4>;4TW35L\YO?0!7<]FQ=:>?%V'1#!C1&SI>
MP#];&7[[Y3G5[HXX-@0B49*[2MK>)N6B65]31%E0D_K<N2<Y-YZ9!,!RC/Z?
M]MX[JJEO:Q?>"HA([YTH15!$+" @2$0%1(2(2A>B($V:B$@+"46Z@(" B!(5
M%&E&NM)"1P0$ 4&"0!*:]!V4L"7MQC/&=^\YY_O&^'[GW/>/]WWO_6/_D9%D
M[[76GO.9S[/F6G/!%I+Z64"\/G-,@9\%9-R@N27<PY2P@ OX=RS@"V*_VG:V
M/3Q>=*L3UW'JF60U"^#XY9Y$9VN;N*/L6WZ$1+'\S*^FMCQ;DDS1O \;IXZ&
M"L'B+["_XUH$50/+)KK_H.FSZ4]73*G6>BBI)/^O$[\$7?*'3'_TB_]F/YF?
MC6E<F:"J@A(C*_6M$FT%Q1]L&/'30PTVE :A=%:#B-._V1JEXG'\=<;ZM@HC
M#KZ^9)8$KSB: <FY+2K#;(N'!N;1#T:#_U*\YOR! 9U9 ._'-K@XNF\[Y86<
M7@7EF&7@KQ E>A52FSD-!ZVPLLQOVX\,)0</^=T5Y/Q6V;,K:3@N>^,V?.R:
M."F!*29MO=RC5_Z.#D\K=C(I"W7].@FO'[CS(K9DSKT,G8CNQ-0MM+  0J;=
MF $723WWURH2@<]WE)6_>#_S<M5D9\=9-HBGK:NU&B@8)N(68MH4-"GP2!3"
M=0;!M5QWTKWT];4RJB0U0RQ#6@QDW\CROHB $>Z;)J2*H8N=;8?53,=)MJ*U
MLB<N4IBYOGDTKGU*(S-6_?WOV2%L9JEPU@TA,_];J4W3^ZQ=T!J>B#Z+BZ>B
M?]TS?/8R27W!\M)?4,+_60^E_0_/8?WM^KM]):_LF]F&F^ZRQ7PO WSXN\J^
M G\?,O^%)::)F%G- K;D660WR<+'YI\^_PN[&?ZW#VXV!FY ,Z2<]H'$,(VQ
M^$8,\9FF75539&?@KA<W,[C/''V0_C!B]][H'9S"R/0_A;O9UI;XYQQET;H4
M TGQST5$?LL%"<D5WI[7Y[N3O=D1YKG9E\C6=@',S5+]3J80V)W6>#2"B)?Q
MM"'D9Q5/:$E2)0/B4SV_W2G$.#^/--F-0VCT+;MM^M4D3V)R<FL.#KW25/I-
M^3/W@YA9%_WVM[F?ST4E2\'J?^9^W&:?F!BHP<:> YF1ZE1>)L\T.\BN@]TK
MB:182E&*8NT('5,\X<)DG [Y]?%;H*\?YI?>R0HI*:O/12NVM!UT04;V9DI@
M=[-(+=;JZR;O;W)%\TA+J-;$J>^.'9A?!PQ_\G&T+/QXLM[_LR[9^5/<P^5)
M%M!"[U<GGRIJD&=S4=PSO3-_Q7::M1FOYRF(U5@:Q@OS+@-:=QALY""E<=0E
M&43 XC=W5;\?=<MP2^)5S3*\(21R;E:P49I6<HR1A92C&UB1$)#&>MK*YNN-
MO$[XKD/^6H&J"G?.!OCSEFP_[=S7LI*R>%IJ^[_4,ED2"Q!"[V1.L&D_7?(-
M'4Y)ZX9S?/<**_\0396B:VNY#3Z\+7U->+BBM!;&"_?OE^B2AYV#MH@A9:N*
M=KZ*F>V6?>EJA,C,D4A@( S8WID$(B';:9"M<+=U-7=B2(=_8=K^I#_BV9&I
M-424!? $/Q<,>]DHR13?HHO!F:F\+5C(O D&XO#$%VRPNNW,R0+:G'YP3+W!
ML<$K]F^'U[. @FA0E2FR;DI77X?4, PYR2@XF!,&;)6HMV)(2$PK&Z!_$!MY
MV'&Z@<UY]M"8>V LP)2+B*"K3$6>6OI+K7+Y!X";Q0I.,Z?"<*O\9-C]418@
MV[CW25SF<X+S=R=\W$^^]$\=!]]PW+Z1:D9N&/BG>^]8OVK+IF___(2"?^PR
M$/Y5G(C_YW[_O[I\6F'3.$3S'_L-_Z<N#W(W63GS_G._T_[/;-8_3#<YZ__S
MX]_#Q]F:G/H3JB$FXT4@S$SP_4/$NC&<3[[Z-/]:H/*Q1^Y<)B<R/\I[<BS?
M^@^TKO^<-O^?M%5_?QYA"/X?'S7;K-])BT =@8QP$/M[:($X46IQL+4H?VJX
MW=@MW8ACC]UUA?!![I&_E\E(_1#'-B1X*26P7<:OQINRU4+I#+W!1RG,EW+Y
M]#8J4G=&5QOSW\P1_NLVJR+D[[<9H3(I?G\\%I1,H?.2RAW9'GM8E7*BD6IS
M;"+$GX<S6I%6R'?,ED-*;BSTOYD?_-=M5>G?"03*]#_>=+,50O]YH5\QGOY"
M]/UUT"2)<T3KV:XA*GF5KO/X9JK-/NO3LC%\=Q!B.S9K_MM;^W_E9JTX_T-:
M:P.Q0L'00ND.H/%T(@I.:6B3N.VX/%:+$%^/V]++D+YP?&>!K-FL0,W4?V%K
MOX?G0FG3+#S#:E:FY9M50L*O584'21SY03CK:'!Y;>YQ?H&<2^0IB?\O\='H
M2BUA)*-4:1>]#>6AQ-<A/Z^!B%3ZOD,I))P,=,O8,>_N0Y?SRC:R[K$?/LD%
MW7AZ/(X:IL;!ELD>\&\7NDF"G:73!'7R0E>:$,H"B@]ZS7]BH@.MF*3F.ESV
M,Y._O!&IK)\:+&1Y)Z N<&WKT__/;/I>T#\*Y72#Y@4-D[GF8PS"#K\@,DZ.
M]EI=-_C@GO*M7B LTGOLQU^<N/YS;0A^*VII/@Q%@-C+7PR\G@\4.?7/\%]>
MTCT,\ WVZ-U$"Y[1$U_^]==%M', S0FZTH'68SQ!N9)@NQ=%II=LM_6-/3P
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M^I8(\C33^9/G*GIF?Q_1Z>TRNJIB;^2$OQYB0QVP!'?EO;DE&6#DORN-+W-
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M<9[D- :A@&$[A>9*%I GL>1$Q@BGV"Y/^#2QR4.+/=)!I6A?Z*FSHVZ; CR
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MM)C)=G1'Q?!6-]^O7P+N*]&G$-4WRMRLGZ\5F;5:K^FL[@?]'BW"2,(0YC'
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MGR0/>80Q5XOGD /(4K6,IA0"A&*!A2Z(QJSZ4!O2G7P1+46E4W,J\216 XV
MS\+.3"<G0,1.6[=%I_3QIF##PE[\;,>&SXP(*[F]94>849TY4\(*BL.L";O;
MSS_ZM\AE'C$$(X"3/ 60D C0A&' DQ0E".O0&K-)C.H/;J7[]IE0#IW:]D0W
MTVI7@>Q4=_\PWC0'[WQO5?6'?K6C=B>WIHY=XQ26?A++LBG2]&NQ%$HG5V(3
MZ-G4#6"0<X$$0$+W/10B 9BF*> Y3C.>AQ0RH[*_AO0FGU&W# 1;#K9!5ZMX
MZRAR1B%HGWC8AJ"'H' I&6" B54,VB<VKC'H'4;W6XPV 6A_L6=324=BSZ/#
MS!E[-I7I1>S9^#;[V/,G<4N6[YM:Z<UB-,<123A+0 XCH4P;RY5IXQ+PE*,P
MDDS$Q*C&TY&Q)\]Z4=2"EIS5JOP8#.-!Y3.$LW04+.2RBB"?D, I;OQRK-FB
MQ2>$Z,>(3UWB&,2J:[&N%US-\0D-]<YTD@ 8LTQORB @8LXBD0G)\LS&BVZ'
MG<-_#DA#RC)BU4IM&*JREL4R1C4L@'U@:H]?7Q&I=M!Y0U%[@AS$H/9_=7"-
MVRJ$[XJZ/7"A.]7<5J(Y -_Y,C)+$HBDFCERP0%$7#<#%R&((LY1"BE)F5&V
MEAFYB6>4KE1FGX%@RX&%#S@.FX%;[!4,.WT;Q,'%*1X'Q,(G]@J,FTOL]J+8
M.<3&8@[ZP^.CS.<.&TNTYPV;WV5GX.IJW8W=;GI]7#TI5ULTQSW>E?>D6"U2
M3@07*0,$PAS B.: $IP!FG)*48Y#&B4FQFV<U,2&K26H(;MHSOX$WUJRACIL
M -6P0?,+@)TQLY?=6$_-Q1KR,=0H/?]"_;7S+0P(S**^YH)N5-?B#L=Z6'>D
M$F](+;@^B"A6==NW]J%KI_=1R:-6 $]"%V*OK\MEP9X7-)(X8Q2#)(/*8X&4
M*F<%<9#*G L<PS@75AMD#CS,XL$H*Z5X"OI,61;-<@#7;*DP,61VIJ%A!C3<
M;&)^>VUNO[4,3%2BV!T)7Z6X'#B8MT*7.T0'A;O.&,H^R'93$=UBZNOS/2V7
M"QJ2*"0A!Z&@"8 RX@ C%*G5DH0"1U(B#DU#;'LC3VQ,.EI!2\P\MK8O_7AD
MS5DF.VTW%,<JI':4=:> VOY(LX73C@K0#Z8=OV#ZTEP?U&-<P(2F,LJA4AH1
MZN@" Y2)!.12IFD:,JP0G*HREV9@8@53+P">KC!7@Z#9K#PE+K;!;X>R7)JE
MUZG*U0?C%8IR->1_V)I<?7#.*<FU-XY#%/.+[E%6"7ZPF;:0(>.9$ 10D2@C
MPQ !),(8((:P#+$DF)COZY\D,[$5V= ]LCEK$:([#9)!K-*+Z':&8BOU61D,
MIZ6V"$AZD=XM$.F"@ET8<E2XP?#CZ;OG"SN.2K 7;AR_VC&)E]1W:J&A_Z<7
MZ4]DJ0=MBEP4NO[I\=\W@0M*TR@A.< 2$@!Q1 %)0PDX13&+$QHB8A2(],',
MY-9LPT13]-HRV_<<D,U<I;F@L[.&37UPW=J@^= C?!&\ /3$55VD8]*(AP_H
M?*46G\/*O/G&'D [2$+V,::#(_;V3H?6/JX&DZ"_E,OEA[+2YR<6422(\L$8
MB"5$RC_#$F <(1!1F3(D(8^E^>ZR+?6)#=TVE7]3 *00]5\"M],.;N@:.'93
M8F9IX1I.@F(5C)Z!"+YICH*.)9M]:FL(+;S$*:%T<QXM(/7D3+IB,.AC6@\Z
MG^OI*N^>1^H\B/U^^%=QJU^COXKRMB(/=P4CRVY_ES(,TU2MCWD>YP#F. )8
M$ I$)B!G-$MX8I0F.DAE8HO;)^BP WX:G&%#ZDUD.X-I)ZW5GO>H-&=L=Y\>
M>[:=[E'Q^IO<XQ>[K1??2RG8>EM:]X;\\86LQ1>A^5<:WUCZC678. WJHC;G
M[V]D^=A<<;E<EM^)DGC!0B["G%( ,[6.A%FN%!BC"$12Q%$88YDBH]:7$_$W
MM;/5<*+;PP5/&]H!V1"W6V3Z?C)FZ\Y7Q-O.[FP9[3=3UKP&^\Q>!#O_8^OU
MZFM;EH,MS\&6Z0M=5H5Y/=DZ$:R>EJF^N9MUY3H1M"\7LU.1<5G?DH=B39;%
M/W660>NLO2WK]>6]KO[XSX;.NZ:<;5NW1E> IDG(0T!3F0 4ZK9]&&.UO$VX
M2'C$) [-NG&ZD#<R >>TZ>P3MEF$6:)HLHR= !G'.-V6D=VB2[-R$?29"5IN
MNBI2$V)GLWZ=#D/'Y:M7+"T7LFY@#*]C+<><<1GK)NW^*M9Q##?O>3L7M$'+
M784K$I,PPS@%4:I]X3!&@,0R B+! N=)F$AIE(LU1FAB?W;G6MFV+CZ)C)D;
MZD->.Y.Y$W6>78HQ"3VY=B?)S.JCC0G[TMD:O=XQF7NMQOA8UX^"]XU D[19
M'T_=7, H3U+,(Y")' ,84P)(CD(09U&:TU!I=6X4D3J#AZF57#&C75)=-5S!
M?J_FLEHS&3RN%+2!: \A%9O4U>!!YZXVU83KAFG#:L+G/ 0SHS$QM';VI*4:
MM.Q<!.V?W?]/YX)?!$3JY@,?RDJ*8OU8>6S]<08\WIHRVW,P<Z]F9X@.6SB[
M#V6?"=X=0^=<#5Z_51^OJIOR^VH1(I1Q$64 "9(!R&D$""(YB&2($44T#<US
MPD_0F-@Z=04*.K(7@2:L8 DT:?-<\5/X#!L63U);!K9<!+;*)A\1R2FO_-28
MLV68CPC5SS4?N]3-N=#UH;X*IG1=;[$O!$0YE6D&*-3'UJ'0.UE9"C*:T#R!
MDE([OV%_^(F5KJD'7V^IV4WP+X PF[O=Q;/3KD:RK^.26<^NQP7P-'&^&'S6
M.?&X8"^GNQ-7N:G29['624'75?E4<,'?//^F9LJ/JVT:]Z4.Q#:$+FG=K/$7
M:CZ#*681B$FB)SI) :9, L:$4'\@ J55ZJ(]"U-O+>E<.KDLO]>!?D:]_CYD
MR\I?[!35 68S99X6/-M0J,)MPTE GX.?-#-J.?-S[_!'Q]#SA=Y,6CXVY[?>
M%;72$/6S\N VEZJET;<-RQYC >YX>;(O#@S,:H/< 7III\X8:;H-=O5EV_A,
M)T<*1>)N(024+!'*?0BA;D\62Y"3C(*$"BR2B%%"^&;/YL;O=OHA-PY;.#=.
M*=D-M29UF/>J :[)'P%SZ#CH"+V9C9L0R8GWP_4/+5M-UG;#URMM>9\&:,:=
M[2-,_' ;V*>!<MFG'AC-,;#:9B=]$4T#PM7MU?I.5!_7XO[ROGS4)>/3$)$8
M<Y!!S@&D$ /,,PXH2@7'B&6$&AV ,Z0WL2O64%/+HX:'0/RA SCB(E@)2_LT
MAIIAU-,?%I81S@Z +>6+H$5F\X-FHMDD??1I5PSE]16R'*$V;WC23/2#4*3A
M;<YM(_3$T;K'7XKZ]S?/VQ8D5#>#R",!J"[6!YF, &5*[PD3B&1AAIFP.U!V
MFM;4RZ\^Y4"3=F_3,H28F<Y[PL%R)>4&@4L7B#'A_'5^.$EI[FX/8R(?Z? P
M>HN=0NL&39_+U;4H/XOR\NE6;TVHY= C62Z?=16$R_NU::^RD6$FUE5%'5R_
MOPH^J_\NG]3"[E;L%:D*-NPTQ1W&)BAKC(95V#,\=BKL%QFKUF>&,CNU0!L;
M>[96:(9"]ENBF=YR3H+2U[5: F@7X)-^1#H%JCU0$D:8P8P0(/.8 R22!)!(
M0I"F.,Q(2D.,N'V6T@EJ$RO]EJI.8^B6P!L&+H(W9-FD.-@=QS%#T6S*]H:-
MI9/N!Q;']*81<;WF.)VB]0J)3B-B'\]V&KO)S0#L3ELW"0F_K?2B_^MO73GD
M*&.$1!R!7*8,0!1)90"2%$ 1IYPF0F9VO1('J4UL !0=RXW*86S,U-J;Q'9J
MW:NVT- -&L+!3QJ$G\=+9UNKLY&8GM1YF-:LZFPD]DMU-KO)WC=_Z1W\K6X6
M\K\*4C]6PKJ?L.%PDZ^K3WJ?3_6?NX!2QY.YBVX*U;BK/@%*MJMN<X FZ%AL
M*;^3^VY*8S8WWE+HOCMO>ZO+\:_N7(-N2E>L^IYHS"(&21B"*$,(0((9(+J)
M'.,13%(9L2PSJF,Y3&;Z2%M[QJ9'V-)O'X%I6.O]"6\=7IM8;IM36#[D=SQO
MY82#Y;FJ,?&&3U"=O'O&LU)C$NR?BAJ]VC7E^/V]J&Z+U>U?J_+[^DY;/[)Z
M7C .)8X)!3F5$, <$9#'* 8R1$C$&<M):A3W'Z$SL27J,G$WI(.6=M 1MTT^
M/H[4L"WR*+^=,7(4W2$->5"P,U*1CX\[<SKRH'"'*<G#ESL6P^ZUK_V5K+L$
MS2]B4[OU2EY7Q8H5#V3Y<:7+X-XHT,6")E0P@BA $D;*E0@30!G!0+ \11!3
MJM39JB2V$QL3*[AZ;7+WML\6:)K%$J;'R,X([+>2O@@ZGIZ[<M@-]6D:3-M+
M/T$K:@LF7JUIM3U00^VM'49S]1O>-@<-FP!)>R3JZG%=K\E*I]XN,LZ2%*<,
MI!'2W?Z2#) H"O5AZE1PBB*<&C70,2,WCQ?1<M!%Z[K#@3TF;+V)0?Q,G0I?
MJ#CY%GU +FP0<7 R3 0]P]<8''YFE\-$U$//P^@NQQV(XO9N?25_JT53"^>*
MKM6Z0^=<O_^#-?5R/I35B0+]BRAG)&88 PJI6D=D@@,J: ABGLL\QPF&*;7:
MGW#G9>K="\T9*"5XK$7723<H._9TZ2K1,1C(L@I6XGNPU-RI2Y;%;;.>L]W[
M...I&.Z,S(.UY;[)!F;%5EL!++CJH?R^C_*+WB ^JY1ZQ,C7ILL9G,R[)7,^
M9 <;-AZ&]-E=L%</X,WS[I*N7,"E+K[:=A3K6^G/C\VN)2(1CWF6*-<I80"F
M201H#CG(2(3T&? DAV3QT!Y%7Y-J;68WO?-IH^$ON356]C="+:976H%IE^?@
M7K3"^X-*(Y:C1!(@PUSYN%!2-<EQ"'!.6<YHDH1AUCVH]ZN1LFP_T&/:\&KA
M#?(?] F937.OBKG=Y->O/;*_K=AK1DF?C]<HT2SK?ED-TQ=]1_TB:!F?NF>E
M!TPG[6AY#G\_0+]+#_":=</T0<@A>^)N=?MQ]:'Z&UE>UE?R;_5Z=?MNK:,;
MU3^J]_^Y?K[\7O%:?:WF_;=/%?]'U>4!F:93.(X_]6[JMOCM!U)43;5;O;[0
MV8!_$W7CW;[3AP35W]?*?E=M:*]K/-\\B[JYL/6/WY9/0M?/U1=99&.X0C]L
M@>="W7(;=S+ /:9U^8#.+=7#E>A\N1]GPK*7#'+N6&ZK"OWB->_=Q]6#LJ"?
M]%'JN%,IEF*&9(0 BJE:'TA" .'*[4P92<(\CB"U:_$U0&MBR]:0"F([+W$(
M&C-_SY/ =D9E9TITA0I-]R+HY)\@V=- 1$^.U!"E65TB Y%?.C<FM]COCKSK
M<F8^%*NOZ_OU^ZHJJ[=E5>DSW>7JPY+<+CB!,699#KCN404SC@&)0@%8'A,9
MXC!BU"C+RXS<Q%J\82!0'*@%8$&6P>[(0L-.L./'?)/$ ,;Q31*_X-AIO!4N
MP3?-C <+8">UTXZ)P?"S[9B8B]K?,;&XZ\RJTOM5&YKG?[GB^GS(<GN-J)MC
M7+H4+<@ICP B/ 4YDZ$NA443E.0IBJQR-2SI3VPA&K)-31C]WBYU(5I]B&FM
M23=%%[0K+86"=^_'0#2%,!RK5ALB;^8R3(BGY<ZK<8V8'>@-=[WK->B^2SHX
M N2[1+8A]=>IG&T'S<F"VI;#.-:\:E:SOXKU7:E6-D]J-=LUNV8Y)"%* 4Y0
M""!'&5!?9 !ERGSE6":26&WGGJ S=4)'NU:_;\@JB[.E:UF=Z@1(9C;%@^B6
MMJ.5NJ48?#20VKYBU+!,ODI"G: R;\VG85$/BCJ-7&X?#OVXJ@MUY4W%FQ+[
MA:BOJY)]+M>7O'QHZK=9'B<S'G!B[>SX"&XJTFPL;;AI)C/-DN"/.M-(<19T
MK)E',LU1&P]=3@*8G4X[8#7!$3-K()PBC^949@LU6@O>CRW:W^Q:WFDH49-
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M[;\(IMREZGG7!<ZAV\[PB!.;^7[[&:XX"5;E6MGXMO[#AAFW%CPC2 W;[NE
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MC#*?\]Q/?7_Q6&=V?]O0<@.(EN;@'Z*7QU(8J^:OXKY8U2YJ3M4_,/$*0^K
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MX'&.TXR&.$T2F8DDI#1/8>;"A.SD%J/+:Z@T%^B1ENA)TZ\K)[CNFU962+V
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ML=+N"?<.RF!.P@!,9KZ &^%ARGI2[BO4D$5_MO\_R3X_+JZC[7R T*R[]KC
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M29!GH0Q$;.S;&Q"<>*=M.< U"_LK8-0Q 5!*$_0,C))C3&#V:0P.F]C !!>
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MEIG%N^8;P$Q96_DUZH7Z)7%<=>0Y7G[:%CL7A#OIF7/I.4NW1_^"W^EN5[I
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MY#2)>*Q,$$["JJ(E1"3Q"1(RCE))LB"71HW?KF=E9)/5,J9'9759J\I!6N:
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M! 1G,VLY%GHPDZBYT+!5?"CSM\.QYJ4>TE#AV&''8:F!!0BNR@4@I*=-^;<
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MH31&F.:Y3V,1" *:I3<>JR/O/RTM[UD3JWI^<OW%B[J)5Y68#^U;/=YG,W/
M?XR/ =N_*H90W</O8 1TAVV/OGK=YQK6Z]'1-Y[FWJO8]SK\WWB[3UR)X# W
M8G287>5(C,?HM+D2HP-^DC,Q/L5K!KW=M4T1JJ%3NVN4WU9<G63T<4?P]]^9
M>K3)$."<)4)2B2+!4X1SSM6A(LP1#E@:T"P*)0[F*Z%V,V'8KMF*#R,KDM=6
MI,N-L3'17/W-6^@<EJJ/OMH7U+YL,Q8.BK"9@1X/M:M&R>T8:H?*[7BZ\;I<
M>35;SI,WKH+%Z0 Z* ]O,)K.$J;S0^ML%W.9^/5]4<[CT-=A#Q]%,E-N:103
M1$-EJB3!$?9%Q&@$&CQUD=+(7N6%?"?O#TT;.)_R,EIFQL8)!C"#8BF^HVRO
MCFBCYGII.C] IE='7+,\K^X+5S:%%:7N!OE9;-J+7($BRGR4D@2C+ LD8D22
M((])EH01I,G9*0F0RMIV-ZO[FNED3:$.@%43TU4]G:RH&ESJ&NVZQ>5US5_W
MP)DI\75PP+1WW\95E$TCU\\]$S;MN[2>R.*Z%>N>P-OT6ST1\&)3U=,G+>NH
MI11LLQN,IE;^HMSG+T)SKK;TZOCR>;WB@F_58W39-E*K)JLU2IQ1)' >HC0A
M%&4D#E 6A@Q'"4\(!F5=7\7-R%MT10-867T5N&:*/AED,)NP8\O;6P=/<^8=
MLJ9,19<YK^%.G2TT?S=M9Q*'I=@N\')5G7T5+],6;+N [:2&V\FB#@:BU:TM
M9NS?VT71=*7WB10HU!Y)FLE<#_B*4.R3* HCDF8^J&-$#ZV1C59=\%6(9_7?
MOZF36NG]=#BYZ2^.IE8=(6AXTG"#"_"L<32YJJ9[X[641YI==5Z\,:97'5%Z
MN_E5YT7NG6!UX14[%;]=%\_Z'DZ\4S9D7[?69!B2F%$<YPS1E#&$,0\127F
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MIS[S*<HY#1$6?HCR!$O=Z(FF8<I(@HUF;QM3'#O#H&5!']:[,P=;+@"6TPA
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MHPQ[S--&M)]A6J:5<C\2":4LIS[(B#X!:&3)?3]?DB73KR[A3_/UJD!20".
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M74E4A^2N"K2'=//YMQW>J(4XV/,SP@*;^H!>=MF@WJ#I5\S"(S0>2YWYAD9
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MW2PPF84'/S0I,IW=_N;$^319?7<4TWBT^M0+OUC.75B.#"5<9V]!*L=!!*?
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MV@.)C8+!8UCX!,IZ D)0="QYCJ Y[@8E:0AZ7\WI,5#J0-8P7:7[PU1M330
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M+C^S@JJ:Q."V ^&.O1R]ERHS\(:6][M!@V7.@G3(=U2*BE"[4=^!)+;6_VS
M<_PXM36 RNXYLU%@@>F,_"2AT&,.-H(3$H4:6:;<J)BK]Q?O3MVP/N7Y2Y+[
M4%JU(=/5X;BNC=HNR)"2]P&94S$X$(YR,%S$TFV0*QJU(K3VB7TXE8V,B3G3
MPXM:ZFK /J(7?/-&;MV?YG<W_R.M>F[<%42-HK&<E>E),AD.@GE3O! +R:.?
M[(1B-M6.:3H1UN1#C6KHF/6MJD'S/JM6F"@[%$E<O$;A_NZ6UTR\S]M9RR2D
M' SD7%P/33@&9<9"T-9&YY5T>2/KLZ,MZ2&K-OF*HC;$^M7%T.UO[S.VKNC8
MRI)2ECN2,]"5*T%, L.DAJ@B#TXXXR@[&%Z[UVOR+KEW8%62?XLGYX,RH8MI
MO*L4XLPEXZP$3U.9+48=./12P8:HJ0W<D^J]1KM3UV1D<;8SM([2FKA >;S-
M=C-';(R66U$2FAH$U;GL-0N$>N*\%RR8VD'% >0-FYD^-R1[4EL#)K*[)$>4
MJN0<<J:(""!,I& L;KYR3T2=2$Y4;RG3G;IA$]-GQF-/2FLW^?)Z/'73L".+
M92F1(7&PCI5;=)[ >^O!!YD=U]3K=*:<X!XJA_4DSYU\J:6N!NSCQ_3MVA]Y
MG]_.IE\^I_EE>8J&?.00J(G &,/]JU/9NB1 3#(&3ZC"(+\R[';1TF2*I1H&
M9CTH9/@*AD=1UTUW*]RB=YU/T;.X'3&BI FF6'+F$UIR+\1UB;KF.EJF#6<;
MY?\=8M^G5FTRM5(;6OWJH@$C]N%VQ]RV4[MKI$9S,(2AU8\AX[Y1SH"+*4'T
M*>E( N74UHXS]M#39,ZE+V-633%M1+?7W+R>S=%*7\W#5[=XN(>NV^G'#)QJ
M!UJ($K%'=#8\>KPT4QVJ3Q1ZFJHFTRM]0ZZ2DAH\2>_&<ZW8>?^M:+*TN;@S
MZ[]=?IO,?J9TK[WX"..C[!*SH$M&21AAP4>BP"22E7<NN?QD\\5*M#297.G]
MU#V#WAHXB[M+=R2TB(H%#8Q' L(*!H:A:%,I)O(6=ZBLW:ZV.W5-)ESZ,IH]
M*:V!A$MAJ_RO)#"_NTE:O=]"B8T#&N?R#[C_'G[CWD^NAX$]+D\+DZLRIN&W
M'V'5*/LC&OK?<DZH! 1<)D9&T%)F5$+$(,W@9O4Y6R:D]('7/O_/R^&POD1O
MB9Z&8?+<-]&(:>6D5Q*H\QR$+&_68L*(,H>2).:2N]H!V$D$#^N=M GQ@Y1X
MXJ@'E,!\V0!N@V":"FN!E9=KPN$A9S1W0*.RSD@N0ZY='=X_;GOS6!K%[2%*
M;&76S=6W;Y.5*-WD1I1OIGDVOUPK\[:GAR/.*"+ H.,'0K&$6U(ZR#'AT9*-
M3KEZOY1NI W[:J$W)/:AF 8BMNNG'*LWO'&\O$)UH>]R52AY<;5\-UO^[[0L
M,RM&-";)2S4G=:5=F](4K"<<MQ8UAD46O:W=E+HK;0-WW>\#&-M[EM754J.#
M0]Z5TL\TRR^N%N-I6BS<-+YPB_%BEC_<6^ A$]VFAW3\Y!HC1(YAHM(<D??S
M+VYZW<CN;I+)NK/S_<7?Y^L(O\RAN1ER<HM6Q9P*3GB(T90^_$Z"+5TGDHG,
M"XS\/:M=H%6%\%/MX8W"7J5%F(^_72^_TMW[![K[C.IZ,2D99<J4MC8KD%II
M$(S:DE%.0(,/B=$L<_7JRL.I'-9&GA^3FQ:T9[TV:DL_75U>NOG/6?XT_C(=
MYW$H!7WK]^=EW#VJ(91LYQ&VM.,GU["EQS!1R98^7N86C,Y9ZJ,E$&*@(*(U
MX 7^D;+V)MB@I:P=(.ZFYN2H8Y]D[W:$B":Z0 VP2",(@MP[PSU0&4O;OQP%
MJ]TEOQME \]SJ(.21Q%'?:4T:J8P@D](U->7LPF"<S9??1ZZ3&_'8=59Z,L\
MK8^"8RQ5]P^O8:R.9.5$>[6Z;MRZ],66I>]"$F_,ZD US"@0E)<33N/?F+/,
M9SQ6:;>JJX.7/GVN^>U"W]-%*5SZLEJ@#'Z8S!;H>]]M$,>T]CZ632?+L =G
MP>N8P<2D2K-QD5GU:YGNY UCNLX F,<SS_M16:,V;=L3,[0#K]UX_I]N<I5^
M7PWH/MZL'?3Y-2S;\0Q5<L9N5[I#S!TR>5!1QNA!V9+XB,:!]T%"PEA!&$F,
M8+5']NVCYU3[MNVS[T4F(0M'*#H4,N,?23FPG'$,A+PCTHJ4?6W?<R]!P[I?
MU7"Q:;'J*:%1&W7ST.OV@5=Q5,KU=1F'_.;RVWSV_7@#U?W#:UBG(UFI9)IV
MOIB[Q:$P1'.1\1R3)B .16E;Q"E$8:DLF0:E:H=.3Q)5X<'G]@6V'NDD,DLC
M!\U6#_:U )=\!.0\!F:S\+IZ"X\#Z!O6A-7%SY87GOWHJ5&SMAH^-+L=/K18
MA5]W;2>/B2'W?V*5P/$ HBM9K95]O#LJ=0I&BEB<>V% "!-+CS4.-EA"77 ^
M^MHW? \I.-4>O4THN?2PG>&] ULGKQQ)NC@ MCQ>EF C[BAK:/*,H2M@:K^E
MW$_1L#;G!.UO&IB*@F_4I&PT;75;^]D>85@Z?6X-\W(X [5<H_6"BYL^MVYR
MWSGGL4PLA, 0>$)) I9P"T838RW&^G@2U7\PLXN<"J-GGVSLN^W$S2HP$JP$
MJ<K1;A0%[_ /K9TQC#%N8VTI'$GJP$Y2)21MF2';N]X:-6L/'EH?8;X>/]0^
MT4SM)JB2.2H??*?,6_QD0P.1,8)1IDQ4E1XPB&= '4M:!NU"JIT^VDY)C4'!
MV\":4E0F&0N.RY*R$'B\:Y. ))I-CD3E5#MEM(.488U(!?UO&]Y[JL@;M0\E
M4ES^/,8R7/]F#9NPC8A:UN!6;:M'HK?S[3ZF27F_N7JJO'J)Y\L$O)O7I??:
MW'#M&;JSQ+H((A1WF?(,--B4DE9$\=I)G=,H/MFZ=%W]Q?W5[^5,R_A4[A4X
MF7";L=+&PEH/7'K* LV$QNIF]C22![96Y\/G(ZMV1E4W;?U^3\NOY8%7:3]U
M=#)\UT?5LX]/D%G)8.Y8"WWF_WLVGB[_$[]X</TBHO+4X/%'E"@E>T0A G6$
MI+S51%KM0^V[]P-)/-4D[EANFT-@C.7*EQ[TV1L0-#*,3QB%;(1.N%^2-K6/
MB^[4#6OH^L35IF7K26.-&K'UX.#/[L=Q":K[OU[#6.TDIY*!NOW\+4Z^0(5%
MY? 0E+(\_Z$"//,"F.&$HHM/HNUAHNHN<BK,N]G\Z#O@2D9"$GC4.V+QY&<L
M@R=90[22)$\%4;2VJ=E'S^!#8ZM@8LOHFCH::-1TE+8YX[5Q=--8QO*,IU_2
M]-B2\7T?5\.T=":WDJFYM][%QGI;@$89T41K#]J7HT31@)XQ1]RES UW"L^Q
MZN_G#B'P](K,#HO=2YYB#."CDN Y*\D1K\$9$R%[GD0PVFDAAA!'(R:K/VP]
M+LOL36^-FK5W:?EVMBB-.U;QZS&F;/,CJCP9W$=6K?#-S:>HWMM%[NY/I/:N
M.-#>)E2K,0XLP@8L858ZQ3AJMW9HLH.6DP.RC<^]EY U$H]S3H%1RD%80W";
MY(SL.J&=+;,U:YO@G<0,'&[5P,&CN*J*X!LU&JLF$U>A3*6Y[8AU5&)\^P=5
M>GKR%(F5S,C#E4H'CE5.<$M?LM)M42CG,&)F$;0N=R"&>,B.,4\3)X:'RENN
M,W&G=\]^8J%MY^>&0*PM O$6I-5&T1B");4SX,?0.:QYZ@=?CYMM]ZR_1DW9
MI_2EN'OW>E0<8\>V?$J5Q[Y/$%?)@ETO\S%]F\U70R5NKTRT)YH;!9&6AIN*
M&[#628AN]?+(*"*K]]790<O)CWHW/G<;G#63VL3,@6:RFI)J,6C 0S]SP9R)
MD=)8NRJ[ UD#-W2I@8U'CWDK*Z-5V]+IK7[_C0<&:$ P5"."TI 5CSD'B$P!
M(OI2Q"(=>(W@X9PZ\XP:$5PWY-A8X.?ZSP>GL.=$L?($5>$I3 CRS 20R#"D
MP+/8V=K3FKI1UFPC@D-0\JAW2GVEM-#Y['X?FFV\N-446V$L\I(X.&HTK":M
MJ,1ME-7;ENZA9]A))3W!JIH"&@#3/TIG]]\6RS'ZK*5M^\U6D"0*T#%D\ F9
M283B-Y2B5M5VJQY2,.R@D9X <X*0&X#(=;?2S?;16W&?5.FP;D!3*4K#F%S&
M' LFLE"$U'X,T(FP85M_]V6!JJND69P]ZIJ[E>D1)]8((B@HG32&( [-+@FX
MN[S*0N".4J[VX+=3Z!VV6_=94=F# EL ZVP:D/IUZYF/X\4?+Y&&\;+\;:1E
M2"92#SX75H1DX#0+X'P6!#U*0U7]OCT[R1FVP79_+E@5\3> I&WM::[WA&>.
M1:XR<"\<B.0LV(R<Y#+.C@3%LJGMS.^F9MCVV#WAJ)+P&X#1SEX)FUY!=IGE
MB(96$%_$98M7D )$)A*54J)K>K9^%L?X:N:90:P7Q30 N/7;^?63^4U6.(U2
M2VW 4I% !%Z>T&L"@F5F-?[A<NTTUQYR.L'*/C-8U1)_ TAZ<_G-C>>KV0?S
M5^/%M]G"3=9CA-^.OZ>X;BNRR2-3AGI-(R SR".G!DS*&8+"OVN:O+>UL\?'
MT-DMKTJ>&?AZUU@#J/R8OJ?I52HS$$MQ89'9/\?+KR^O%LO999IO<B<Y^@1&
ME;ER%G>:2^A_>F4PG"$T!"9CE/4GCQ]"83<D/K<4?X]::@"#.U[\7'NHA N-
MH0X#2F29F6$S6(YNJLXLD>2$E^1,S[(.B!#H<\OVU]-! X"Z??GQ:&-8+R,E
MZ#*8\NI510+.>0DZ,NJTR=GGWIX8'66HGML=0!7)-X"@NZ?3]Q]7O[\93/%F
ME9=!)Z"$.S>;)) <I506C%0!PYMB?P-/D!.3BO%L JD=#AQ!9C?</;>K@K[U
M-2 D5[W 7Z4\GJ;5^X_YV%^MKF21E>TW_<$$:9QCP"(::B$T,D8M!^]\R+C]
M(@\;0-S1-_Z05;OAZKDD^_L5>@,&[J:Y/&Z.5^A<3F:K9,UJ@MDB76\0R:0A
M@5$@SA:;74:*<AT@!<EL%#G8Z@_B.Y#5#6C/+=5?6Q\-0&Q;Z_GM>R=I2440
M I@(9%V?9'SP0(,D*6K)G:M]J]Z9N&YP>VXW OWHI@'0;;YRVF1'Z:R3-@ZD
M+O<=A2=+3(1DI=/2L\AR[<NF)TCJ!K#G=A]04P\-P.I=^O.>H.:S*?XUI'LA
M\B/^T!^@'D/DQ$5)25O<-IQ'R!FCY>!CT+[V@,9#:>P&O.=V8]"KIIYU6?_G
M57O6_HKZKS__?"7]VQCJOZ"?Z$"X)Q@VNC)8A*9R((H 0?$0N<\\4?=L"OH_
MA:\I7DW2>ASWX[*EE8CO97&,RLGA#HF9H-76+H-7W@"1I0EYCC'[ZN^1#J*P
MV0+_0U#S*+G1GY(:.%KON'NJAN[>)9N/DK!LP)&23?24EU;2 E0I!:6>!.OZ
MPV%G,IM]%E 'C/VHJ]$CMO/@R.-/V4.7..L\S![.VB.''!(1+(U10C"\7+#;
MTD8^1=!1T8R^6A+R25$/-17S\=7MJHC@XFZ8S,]-8RZ,]%H:=$=+0Y^ %MVR
MXJ=2FTG2.@E?^\'S$60^JRF9AP!H2T5NKRILX#R^KC7XF"[=N(3P&,&O'OMC
M%/7>3\9?5@(NB<EB^3^/+_%'WN=/^-U%1L&4$>T/V4_&<$43!^E#1G$7]H,.
M$&-@03C%):F=<:G,PC#G^ #H'E+UC9[[AXQ5/?[H/V*5<\^,[3'8WCLAE/ 4
MB+<,04/*_'3$$'Z"!F>3RRJ$P%CM6_4^)\>6:11WPK[X[L:3(MC7L_DG])HW
M]L_Z"65B8".SH*4L?GI,X*-A,7*6"*W=GND0^AJ>*WL(:K8-#.E%18V:N,ZS
M68^W;X<N<=:1LSU:MJ<'A\H<3!(I0Z+6H'.('J(13$!"X:6@:8BZMG\_W.#9
M>[7[D3AO9 93NCD+YQ7XI'"[ZF!HH,+37+NN_6FJ6A\R>PA6.K_/.4XGC9JR
M_5-:3TC-=/G<_L?,]FBI-L:-<L99L($!,=3B^2D8.&(0><2(D!@&%+3^,-:Z
MPV;QT\H4G(WS.CIAB4"09Q)Q#SF'CH%&%\%JDCP7/&15^P'##E*:&B][B+X?
MO]$Z7=1#UU?>9;4_77U#@[#R%R8EH?UZ,OOS7KO#ZRZ4GV?74W17+#_DF]E@
M<R0,A#2DU)5R<#*4FYB<E;,D!,>>,CBUB1KV*J("V ;54@-9N6TSG&\3CK^[
MTB7U4>(Q^<RI#P:,5<@8L66P<\ -F'S(/F5*>>VRNB/('+874E4[V*^*&O6Y
MNHRN/M[S.N#3SS6'N\]X<<\,92(5-887;%@/0OARB>H(K/JS>Y,9NNZU0Z;^
MIG'?F?(= KY764]]]J5/@*()]Z1UJH0] ;AQ7E##7$BU7;;NU+4[<_L0O.R^
MY*^JG48MV/VIUL=;JBV?4GOD=H^69\?@Y4@2CTZB@[1ZMD>T J\L 1JXSU8D
M_-?:EW?]#-Z^0W3Y_#?3TEM^8R2JSB)P037H4)Y7&$LQ5(FA5)V27'J3.%L[
MV_XT54V.XSX$%;M-2Q5%-.":WW%T[>2AD5RWB7BP;^_=&43F:$P<37$IO[+6
ME/(K!MR6@>3!:QJJ-[$_D,9AX\5>8=>#DAH]U]9O^H\_T1[\?KU1R'V>8J<-
MY$[26T.I 2(2NDPT>_#<E-H)HKV/7GK_UQH8?R^ALCDK_.)/-X^?EK@5UJ^H
M%^6N=6T!%HNKR_7W'M5[I*A95A"CPSU39B6XH#($RD5"=Q W3>V6D'4Y>-;C
MY ]![V[S>'8@-'6";^\C<)_[F\E=&QSG&'5.>!BADQ*08^TP[L+3 X\LQ;-Q
MG)T%^H=1/? IWQ;<>U1X Q!_-ULU]4GQKFI_Q>2*_UT\"L^BB@8]K*B11R,T
M^&0CH(]0-G).LGK]T3%T#IM!'A#&O2NU4<?VWI3ZX[W;QQ]2P\5]@K1*?NZ^
MD>G,T]*#,(*RC@,JE(()44,0B26=E52Y]DFTAYR*#Q1Q;\VF9>^\S[<+7C?(
M>)&F*8\W0SB,UP2W&"7*6"[VHO2E\-Y#8D&)Z(WVKK^$SL'D#NM[UD+4GK>+
MO>JO@2/VCM7?<D[%^*9;/C_B4? QA=DTC"=CMZ547M&0J-09M%&\%%\E\-9'
ML ;MOPM.:EH[]#R%WF$]Q_[!VK,&FT+K3?W$_9J*>S75CPN>@U!6HGP5>BF,
M:'"<6$BK'E?2QAAZ-*J'D#JL6W@&@]J;WIJ"YZMK E"4ZYK(B\<UD?>N(WGB
MPH8(7)DRR]PZ\$IKH*7OI";),-)?''X0J<..;.H?GOWIK2EX_F,ZQU/ARW3\
M7RM6KSV9Q<?99/)Z-B^YL\VR2&VR2HY!4KP,8RS2C=Q"EC+&1 P1NG95UO'4
M#CO!J7^0]JJ]1J/G=VGY=K:X[<QU? 2]_8-J1-$=2*P426_V*;O%EU!&,%MF
M/%,>4-&>@*$<(Q!'M?'&,D=KMQC914O%P&1CA3(Z-I26D^/)5:F7?8AU&FP,
MF4C(.AD067MP%K'NN>6!FAQ=JEUQ=B2IP\;.53"T)Q;I36E-':07T^4X%I8P
MZKI[?OG;CS"YPFV^'GUP^>UJK=;'4KF3@*-6Y\!RR<<+$$)(%+B@P ,>%1ZC
M-.UKORVKS\6P 7;/B!Y$U8V>QI_2EQ*ZW7N\<$*?OEV?5:4G7R="*QW+UXM]
M3-]F\U),?W==$J7,B3C@3I:6$E: BTI L#Y806BTH7KGKQVT5+QUWECAGHQ?
M_+S^QWNADO::*QW )(J>+Z$&K+(4@B.22<=P0_:7*CR(U&&/Y2H8VG-SW)O2
M&K54[TKA7)KE%U>+\30MRMO4XHHL9OG#O05>I:4;3XZ+)PY:H$J<<3Q+E0S=
M^_D7A]'G:IV7L^EB-AG'FR8_]VEXGU\CZ=,P=I-/^)V-IC^6L2 5IV7XP*I8
MD8,/1@!C)##!I/:DMJ=>A?"3WFR^N[KT:?X^__,K1NL_W_\Y3?'3E5^@9^'F
MZ$Z,@J"1X:8KC[<\>L*!@&<R@67*<NZ$%BH^!<DN"PUKY<X/H =/,FLJH5&[
MUZT9<<G&/[P?.L$2GKKD^7HP=V2[_[;,CB-J26:EX2U=-Y0WOO3;2PK/=NX=
MGO.536!_;9FW-U2]6+YT\_E/7&_5]VA$7-:4* =$*%URD0X,1O>EQQK)N)F3
MJ%[IT8FP9ILP'X*11YT?JZOD:'/W/<W]K-X<H'M-?%]>S8N(1\'&C*%SA)22
M!!&I D^8 :FU#S$)ZE0/DW\>$])L!^53D'2ZR)M SHKXA[OA44?HA]^X]Y.C
M2)U1AGET,PJ[N%W *%\&&E&*,5@*DM9.TIU$\+#%!#W:M/.H\'C7;K9TDX%=
MNXL8QZN^V)-[,7[OWMW>5<_GX'5GOG\?3VJ+R%(>+&4)A&2E9XLF$*+CF<8H
MI&U_],:ZD\U:]N\[##@9!>5)H(I"SD:!8(&!S:*<$<)H*:7@J5O#\P,6;=:%
M.P0"#WL']23Q!N[0,.POXTW7S:$_CA=_O/CY&7_UXL=X,>(Z$\.B N*<0",=
M45[E2Y>TY,%*;DWML&@/.0/VB>]-_X\[Q%=11HNX*HR\FI7FX*.8I:'9EY&Y
MKM1FHP=@@TC  F$J4^.,JQY[[B9G6'-53>5/0>E(^;< I>M9"8]8^CV5_.&(
M6ZM=8@0R5V4(FT W4J@,CD:/(N11ZE@;3OM):@Q2QZI^$U(5]= "K![OO!=I
M&KZBI?]CM?V\E500%0!#%5G2SVC)#0V@/1$\(#.A>KO/IV@:<)K$@&?@\6II
M$F8WW%QO21NH94HXD$3;$GI3\#*@?^J(Y$9EE6SMFMZG:&K,?IV$@"?A=8(Z
M&H!7&2NPN)Z]\BXMKTUQEH%Z12AP5](YCA"PCB0PPH0LLU(DUPYVMQ+2&I!.
MT?5F,<?)@A\0/8OY\GZ1Z*JUSN]I^746WZQ>A:_FQS_Z;DKOW.7:-;7*\=4H
M;^*"0<DQA1;>6+ RLDB,*++L C DY!ZX\*L[8)U*XS!9U[.<E6=5W\ PW<7'
M]19.SLF4F009D7X1'(J/HT/KLW39DF"S[U2]\@00]U,QC)D[+PIFO:ADZ-[M
M=[/19O/WTW1CQ7WIU&89,%GJX&,9EA&2AZBD42%D'\/&!(,=6=.M'S\<6FHJ
M;E95B@UX4CNGG-S+R"0\P%W"0YT:J4OC=SS9"5?@>-".DB*HLTW<.3 S6OTU
MZ%FCPMK*:1EO]],U2++EQ$-0HE3 109.IP!$$Z8=,4;:ZGV[GR:KT5E'QT*A
M\[2CX_32 -3>9]R9Z9:1:_N<'-IA9AADS2.:>^O!J2Q!>>J9S-:'6+L;PU9"
M&H73L>J>U9;]T#[2VYNC_><F%S+*((66X+Q"AT&C,3=%0HDD//DSI41TNUW>
MN<2P15Q]8:.B6 >.SCZZZ9>UR55$4J\UA:"U+BUL"%CJ RB:RTLZ:QSO-/7K
MB4#L=L%AN@N<+;P_3K MH.$:Q#25KJWE467I<R",B^"$SI"M)H&1K(FMAH>A
MXZHCE;6I[B,D-[#"?W<_QI=7ES>'FD$&LS) ;+E<S!H=+A($.F$B!XPM:="=
MWE<^H?('BPZL]&-4-JLAOZ&=@FXV\.UXFMXLTR5ZY%+8F/%<+(U"44*& YYE
M$B3AN;A"POB:A6BW"W?"AWJ6QT3O>A@:8UU*C+>-H1]E%:(V+@ 3DI5[G0"6
MV B4,R<"11GG;J_WCJ6@^5JU(P$Q.[=V&@B>7R?4EIN\2M]FBW$9.G,U=].0
M7L[FWV;KJ\4/\W0YOKJ\[D<Z8BPK$70$'4P&H80!ERQZ\RY'EW/B-M2^T#^4
MQN;K2$[#YUE4UP T'UUP?TCS\@WW)=&1,,3Z3 QXAM$I\I+!2N* RJ10@CHK
M7[TL;@\]S5_'UH%<-94T *^=Z8]_+%*^FKP=YS2RVID<RO,=4HRY+*6%S@O0
MRE"E5222GRU#?4=6\S<B=<!66T$-8.[A"-Q_IC+3/L6+[_C=+ZFT<BR"+/V4
MK_?52"5%#><.<BPU/!'C+Y^"!T]=4DBA=;[V(X5#:6P^554'C;VJK@%HOKG\
MYL;SLKW6P]_>CK\C>ZOVM)]G+PJ'Z&:D^#Z/2/*>6&JA=.XN#XT<^(S&/C >
M.8F"1EK;*'8FKOF N X8^U%6 RC<7N>S&)41+%Y(!^C XF8J+00<9267D!)!
MQ]5941MS.TCIA##][!%60Q$-X.E5RBB.B'XKAN[^:A44H3M11@]]O&UO/ K)
M<Z-+QS-&) B+T9'+CH"4@GA*(@]*5T97)\(Z8<T\>ZS55U*C_9(^XJ<@45_O
M*LK*\_'2_#V4 /WBRSQ==Y^J_*Z^SL(UGM;W(()*K^NOJ]W7/5:GJS?5_QPO
MO]Z\"[M]9QV$#])*#U0HM'LT"G!XQ(+@C@M"DHY&5#86'4D[*1V]53$76Q2S
M3NEGRFU2H?2'C!AX>97!>\9*9Q9F%1<ZNFXW'H>M.VPU31\0>9!U[E$) ]^E
MOBPG1YJCG)<_;TNTG3>!N'*G*#0!$;)!^G.$R(3C*7!C1*=F2D]<J6Y;>\ [
MC#Z5/*LH\:'++=*W*Y22NR>1399N'CJ5Q^*.$B#2E\1C#*72/T$4*"B=73"D
M4\>DIXHQNA(TW*W]Z3J?]:V H:]=W\V^(_7CQ8>O#IV*B_^XJ7&@44F,9, 8
M7US,K,OS[H"2DMQ$ZD/N>*FZ_?,'+.3H1XNSNB(=&A4?,L88\S)5Y_;R[)H+
MG4(B-@042/:EBQ@&-E(1B%+;9+6+7K).P-BYQ##7E6?"1AW!#@V/%^XGNG<W
MP":<!VN9 A^X*MWE$C@2,R@40Z)99NYR)T@\^-AAKA#/!(/C!3BTZO\CE<FL
M*7Q]@&%TUU[_CUG.EV[ZUGV<A:_I[?ARO$SQYG48]X+J1$N=6P)AO0$;30#J
M+?>!,4&][ 21HY8?YH+P3%#J7R$#.[X?YK-X%9;OYY_2_#O&!.MN25XZ12P'
M$YG$+8,GJJ>2X[ZQ*"\C)$:9%7S<;6L/6$YSIE#I9(FW@9@R1_*:@\7U+B/&
M44T0]MZ7,4#<.'#."-!,"&J5*H6W]6#SF(#A_-[3=?H8("<*N('[D.N-<VT4
M#<U9.^Y*7US<+XH%,#9S\-K+F+GETM1^\/N @,'1<:I"9[6D.W2NY?:)!VX"
MDR,UH&0IJ"D-$[SC&:1CEA&CNQ:<5'WHU$_AW)D.E^-DVP(@;G"<M,V.6^!.
MK*(U"<Y&#<FK2 DWFJ=.G>*>UUNG@Y2UXZW3(9)KZJT33RPD+00DLGK &PA8
M%6(9VY"\%LQQW>GQ]/-[ZW20RG:^=3I$?@UX!>7![_M\,9\70123M]H!@@2&
MO)>!SLJ4"W=;*L4I*&$,!DV1!56[S=I60@8L=SW#$5%/!PT Z1[YQ;5Z-YNZ
MN^]\QK\M7"@B7%SODS)3D')6FEB4^PDG#+I(U$.V1#.>25"B]F.2 TD<]L*Y
M BAFY]/0T*FZA[OT9F]>,Q)*5BGS -(G"\*((C1M@<K@RR BY\-&K/-DUZO'
MJPP\'*!/W6[OB'6BH(=&S,?TY6JRZE)1 L'2\_*%6Z3X^QC_MIQ-TXVD=#:4
ME%".)(.&'=T_\-DR"(0PDPRA<7/D_<YJETX+#CS=Z5PXZD/\[4#JEHT/[N=*
MEC?B4B[JTGXNL$A 1!-+AL&#4B$X1TQVTAP(IAU+#3R:Z?PPJB'RH0&T9Q\0
M:CTO/1,23PJ0(0]&D 0Q22E"2DYNCC7<U6;@-,M3W=D^.V0J"7EPK"QGX8\/
MFS=N-U=>PBBJ,?S046/H*:0%D[/"(]DZRK.SU'0[M/:M,LSKK_/CI9:@AT;,
M^V^K\OIK\_AYMAG)WCAQ5)#H2VLN88NT#,:TW <(FCI/? YN\^'K#NQT6V^8
M9UMG1U$/PA\:3UL,Z<;9R[0)GB2THKPX;TPPL"%;(,6@JB 8_L"QA]81[D[U
MIUDMG%TGB'QH +U*W]-DMFX0N(.=Z(E0A&2PJN1D!2_9U&Q L4RTD*+4#G5"
MT--K#?/BZNP0JBSTH3%TDZ9]?36-Y77:0TZ<U(E(A6(1#CEQV8$3WH%-CA(K
M#4L\=(+/WF4Z(<<^>^34$_70H'DYN[Q,\S!VDT<A0%)$R(R1HHV^S$O)'IPA
MMC1RTB'2J"7M]KAI]QK=,H7DV>.EDI0;N-OXA.I)=U,GD+%OL^E*?JM'%CQ)
M2DV$$"@!D7D&'TD$R1+^7^&4UF[4L9>@ ;MRG/'2K)Y.&@#8!@\W8RN0?4>U
M!\E78RN( N?Q,&8Z&<8Y%4S5?FZZE9!AKS8J*GIKHX-3I-X =(J5G4U728J;
M"@2JI!=HH5E(#H2R%ES&K66"%4EQ(JVL?7G_B(AA(5-!L8^ZGYTBY19@\K4<
M\6^F=XT<?ELLQY>XM>Y-E] !CWJCT0!K)= >2P\^I0349R<H,R'$3J\I#T%.
M![H&[.QSQ@.MNH::1MW]00/%Z[.&EF&%&#EPJ<$8W%C<Z:!%Y);)VJ7(7>@:
M>,1C=31TAMN1JADZJ/O'MXC$QYL=^WE\F?#G;D,.FR,+) O(+)ORZ(B"=\Y#
MD#):+X-/FY-#=P1V^]=I%37'*G76CX2'!LMO/[YAH(M:>9_O)<0^S&=?YN[R
MAB&JN3#2<]!,EL9&%K>7QL->NQ"\IMQ+J3M!ILMJP]9]] N<ZM(>&CX?T^7L
MNYN\S^@7^O%TI:;/\[&;W+M)#HQK#L2H!+H,SK 1'0$E:- Q,R%8MYX"3ZTT
M;)U'O["I*N7A(=/1DWQ[VUB-,D=35 J(+CN".84[(F10UF1&A)!R<]+,J8V6
MWAXT7:*?5H=G<+G/H9 6O.\MC:K>CIT?3S ZOBEV*8E<'P"W8KDSC&4B%W$J
MQF!8KMWY<"]!SZ$MTY%0>-Q*O9)>AC=JJZYH:*C1T)<[H31?->R;AO3>3\9?
M5H(L[.*_E1/_^LKH$8\A@&<\0Y+<!Q<DTZ&;,WXD <_A7?MI6#N;>AJP<T_T
MYOOM1YA<E1O+TB49_S]^=C]N6 S ,E/H.AB4J0D*<C#4L<0RE[4O;8X@\SD\
MD:UC$_O683LPW;\;-YF2&$6;9#703+0F7FMF:D\WZ438<WB*5Q6*%?74 /A>
MNF_CI9N4=LHW^ZLT6?Z/^6RQV.2%R 0N&(&[B7AI(D5!UAZ8O(^>YW"!7<D3
MK*65%A"VK2UNF4OP+BWO>%&4,-PMPH*7(N(?,F<5I-;=AJ:>&&S<T/,<;I3Z
MBS6.TDH#"%M=O[Y9+*Y2?'4U7UOF\2Q^^HI27[Q+?Z[^Z=Z^L81ET&76F=>,
M@$C>.^6-E]4#VVZ4/8>D2AW4]:"I%O"W(G_-UH<Y2@ZY6GUODQ&Q*GXD&I@Q
MW(G(7)2UG;:=Q PX.>+<**NBCQ: M7V[_*>;7*6=NR4P!S:8 #QH*DP67KK:
MY6"="!NF_+DALW:"GAH WTW6Y_5L_F(^^V,UU.QU>LP'\QQ=3YH@!$F2H,(F
M5;LN8Q<M Y5,#X&Q*NH8.B]<WBF]SZOM\MJ-YZL-@E^O[/6GV23>,1.LDH!N
MI@:CI(9,>-949D;=1OIMS\NP?2MU0\ZSOE:H+_&AX?-J/$^AS/U\,PWSE8C<
MI,3%"_SZJA#S>?;>+]UX^OEKN@EP-ADLXZ*\SAX\3\P07M[Z=X/4,:MW@]GS
MOU'H73-#0^^!$&\X6 7,R/3[Y=?KZ'FQR92D&4Q4>-3+2)VV,HA$.\&MZXK=
M(/:L+P/ZTT +?M9\%E**B_45QPV/L_D]1K+F$7!G<+ V"Y#2A*RC58&DVH[6
M+F*ZH>POD>>OHY &D'5]87%+=P239#&T7(*GO&16K/$L2^5#IY;?A]\==<3-
M7R)I?Y2X&X#)[1CKWWY\*W)9;-;/947!*>D@1NLP3&4Q;HZJ.!DOCXCH!IR_
M1"[^- 4T@*!W:5DF;URFM_?NIV[@GU8=]54 YIF/&&"XE&J74#P@H!MR_A+Y
M].,%WP!J?G/S<HV^N,G.OG"+<=AD(G ")L<(&(Y&GID-HML R$,>MVXCI!N*
M_A+Y\M,5T2":7HTG5\L4-]G F+*4 %.P-'"1 S$DUJYAV$%*-T3])1+B-93Q
MW =V?PI?4[R:I%F^"59?N$DI%EJ<8VKWTZN?=73W@<(X<7[W89"_G=&\1F<D
MX&7FZ*U[!X[D")P@X%W2RM%N3:4.7OJTU-3#QS:+CRFD\??R".(BXUZXF$QF
M?Q91OY[-7^(>&B^+L_ 12<-O_.GF<9-OYLMK=>- &,69R<A>[-9#]%1*GD.I
M_U%H>9C(.J>^&CB9'_.);NO+DA6>/I(B%1Z<CQG06U59&Q/XYBS5T]O][Z%G
M0 2>%Q:;,P!JZ>AHO'U;5P(MW7QY>K;^(!E>LWD1\>O2WVJ37UD&%*/74R:W
M^,"R)5YT>U]W$AD#OD49!(IG5MS0%TK'<'I3 [#^G?1(SM$2L"(ED,QH*5DR
M(HG>D+I)S8"/4IX78$]2X^&XM6O<3M.7TJ7A\R#GNO,6K*8$I)$R(O:<;>]<
M[^?VZMF<ZWMU=.*Y_MLT5KB#WY D[J/CQ1B=!1^U ZD5I<2P&#K:RI/(> XO
M3.N'./UIJI5C_)K#S>S&CJW&$P.CK )!8_:1>YW980?U_O4:"F-Z5/VV<[BB
M'MH*9?8SMML'+G,FG29 B/$TTY3<YNW;24AK,5QI"G+':>9YF+6-Q@"WK 4F
MP:2LP%A-#'$B>=JMZ.VP=1N*.)K"W%%Z&3ZP.,&02V+ :&= <*J5ICD'T:V1
M5L4#]3SQ0U-(.T@/+<407:M)]\B21 .6"@J)$VT=$QB-=1M;<P(1SZ'S1[WX
MH6\M-7 [TN$A]BTO!ET&X[P&17-,4?M(^,;-W/#/X_L-*WI'Q.'OY+NIIXUH
M8B<[B]7##;=(K]+ZORB\6]?U\VS[>-]'#@9?70UY!C%3%XVB4O!NT49EPAJ(
M1LZ%U,'U.G2LLJ-9RL7E;+X<_]>*L_NO<A^=2H+AWXP&E&\62MN4=4?,'K9P
M ]'*>3'9HUY.#5;.?G2+P,!E](X5DA)LI$E4KZ$_^>CN-X!I^>C>JYZVXI8]
M/4+W2(X7!ATGD$*,A$07'/,'!BO=5GX.#>%J1B@]Z*/1L&2S%^U=15!Q?+7U
M$*(DR4F#N[)VRY%6>P3W"X0C.@1WTTJ[X<@M/U4\5X.'A9') 7Z3>4-%]H(?
M'9&<1EL304F/*&U!I:V;SMLFHF'V95I<XT?E'3F 3X1@J*4B43+[=-Y^ZX\H
M;")N&=JXGJ:W1NY6#N.PO']_E_Y\L"LWN;82MZ'2'*)V3F<AN O=9M^<3DL3
M(<V@YK2^REHWGX\<=L[P+, O,S621BX<L=6'PIWL>?;3WJ =XWB05JI&TX._
M[;LW&'O5:K+<R(9BLI>SK?W!S_SX[VCR!GH=6$><PSP?S(;F;*($IRT#H9T
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M-M" 683!X#"$$(D(7B>K?'#5']I6(?SYG[H-"_WC43!\DX-]O-_R?5<*HQS
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MU&A0=:3^N\+K<&4T *VMZY1? 8F(X]5X&_A^!>N&?MMC;_8R/Z+!N^1X+EM
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M^%'('"GPH2_5/O\Y_?QU>EU>!U],TNMEZU&87,SGX_G"3R)<?)G!\A'[>EA
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ME)ELB,KE(EBBI$)0C&230!L''KDY]D#GW;#S\NI'-W7%V< >=</+^G+W%YA
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M]R+-]5D0T,*'2D1K&8@L79 ]!$:R84HGSVG,U6_=]Q'3(A:/U?GN_7L5!32
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M#1P_#,>[VF'#V,?SS/&VD:08,"]30HKR_<3KRJ['6(12]0]]A;^G1H6 A6I
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MQ6*77+09Y]#H>APC]+Y8/!0US2".[^W+0KLE97"?:\0"GZ$S7L]IEKW=TE0
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MU=EL=O9*TVQTH7R'7+P#QT,(Z\3FU]@.OBVRE"L#;LN"3[@=O-/,!-O![6:
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M&P._AW^"F;A 1RL?B.D)]!5%(H0!)-1R)9^6+7*RS4>  >;'N5$0_Y,G4/^
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MG5!2#L/--=UZ%G,WK-BYP[MSP1'\,0N][?(/CV^JS_))TH%]@O474$L#!!0
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M-93F4.59$$_.^COAU'Z?_ M02P,$%     @ 6(I87-##&MW-*0  [98  !P
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M@Y:C4+!SW&TJ"FE3P>;HW(;,BG\"Q<NE:=C8$=P#'D&N0,B051MDO,@ CEE
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M;= 3P?S=2)8)Z:0[D-J:$ABQ60#Z(4JO1E=T03O&C<!.MIJ<$K"LE =E?;,
MP\>22@)+@HHJR_2%<T#\"/AAFO&F*FX$3Z"FZ>H-Z/^,/7P,&.VQV&[@?3;[
M[VC"/A '?0?+/4B-N<B)^ P4D<K)A:/UT/0R?^(J 7-";H%?T2OW,KS W.XT
MV,1T"!+&D.F^S0=081*F< <'1"BP;*<6)V@OK!DNOZ.UR6K!0G4U,6OC*ES&
M,Z_)H#PC(;0@'-J2T6(P$-&7@Q%(M>@(I!"%4_D%(2IXN@)X60EFU+Q"IQD8
M(HSO9F^] B8&0L_W0@SK:!)NST(YL#8"SD%>4 5)*1+A:5[W(E]@Z/#L9*I
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MI+S1GGRX)W>?VC;%P,DK_#F"[;"Y:2+1ND+*4+:#1CR6VGTZ6T*+$D_<K=N
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M7XHPH0/8-QU;RD-^#Z:*9GL;'2UX= U."J+W0)#'>O+LKZB(3&F7Q!$;-+G
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M1"TE%IP#4X5#"/?D E!=&-6$8=V78(3Q$V'1(_5P*+@>7O.:5<L'WXIIP8P
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M</CDZ"#=_P:XAC%@;>VSM=+>Q^_+ S8&5&V9-D0DW:&9.5\D8;CM 2Z3:X%
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MPO82CP9Y=M&;V+FJ^&096XP(8M%(]'/D1I-2K8PAB@EA81Z7N[F@Z(1\*7N
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MKBU8*1R#R($4;:+)IDHX5^8)H]7E#9.%;G@$<0-;&)HF<K<8;M%/1563\J1
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M.Q@L$D+1R)KZ4F2UE:$K#<]A9'U I+#")EQJM@OXTGU+&.EKK[!1!1=6LMT
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M+FAT;5!+ 0(4 Q0    ( %B*6%S!>+H=_!4  .#_   1              "
M ?AN! !A<G9N+3(P,C4Q,C,Q+GAS9%!+ 0(4 Q0    ( %B*6%Q:LM:4R"$
M *55 0 5              "  2.%! !A<G9N+3(P,C4Q,C,Q7V-A;"YX;6Q0
M2P$"% ,4    " !8BEA<,_0WC&9A  #S8P0 %0              @ $>IP0
M87)V;BTR,#(U,3(S,5]D968N>&UL4$L! A0#%     @ 6(I87-EL"7Q ;P
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M,C R-3$R,S%?9S0N:G!G4$L! A0#%     @ 6(I87(S7/GXT1@$ M:T! !0
M             ( !5C<* &%R=FXM,C R-3$R,S%?9S4N:G!G4$L! A0#%
M  @ 6(I87._\RNI#0 $ I90, !4              ( !O'T+ &%R=FXM,C R
M-3$R,S%?;&%B+GAM;%!+ 0(4 Q0    ( %B*6%P>!F#*S+4  !28"  5
M          "  3*^# !A<G9N+3(P,C4Q,C,Q7W!R92YX;6Q02P$"% ,4
M" !8BEA<9'V^/'H"   +$   '               @ $Q= T 87)V;BTR,#(U
M,3(S,7@Q,&MX97@R,5\Q+FAT;5!+ 0(4 Q0    ( %B*6%RD<M5W$@@   DH
M   ;              "  >5V#0!A<G9N+3(P,C4Q,C,Q>#$P:WAE>#,Q,2YH
M=&U02P$"% ,4    " !8BEA<!_;WKP4(   -*   &P              @ $P
M?PT 87)V;BTR,#(U,3(S,7@Q,&MX97@S,3(N:'1M4$L! A0#%     @ 6(I8
M7(ACO%V%!   U!(  !L              ( !;H<- &%R=FXM,C R-3$R,S%X
M,3!K>&5X,S(Q+FAT;5!+ 0(4 Q0    ( %B*6%RDLO=X?@0  ,@2   ;
M          "  2R,#0!A<G9N+3(P,C4Q,C,Q>#$P:WAE>#,R,BYH=&U02P$"
M% ,4    " !8BEA<\=.<FCD#  "F"   %P              @ 'CD T 8V]N
M<V5N="UF;W)M,3!K9GDR-2YH=&U02P$"% ,4    " !8BEA<T,,:W<TI  #M
ME@  '               @ %1E T 97AH:6)I=#$P,38M87)V:6YA<WAA;65N
M+FAT;5!+ 0(4 Q0    ( %B*6%S\VPVJJ3(  ,RO   <              "
M 5B^#0!E>&AI8FET,3 Q."UA<G9I;F%S>&-O;G,N:'1M4$L! A0#%     @
M6(I87'B8&;?_%   8$4  !P              ( !._$- &5X:&EB:70Q,#@M
G87)V:6YA<WAF;W)M;RYH=&U02P4&     !0 % !E!0  = 8.

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>134
<FILENAME>arvn-20251231_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:arvn="http://www.arvinas.com/20251231"
  xmlns:cyd="http://xbrl.sec.gov/cyd/2025"
  xmlns:dei="http://xbrl.sec.gov/dei/2025"
  xmlns:ecd="http://xbrl.sec.gov/ecd/2025"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2025"
  xmlns:stpr="http://xbrl.sec.gov/stpr/2025"
  xmlns:us-gaap="http://fasb.org/us-gaap/2025"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="arvn-20251231.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-2">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-3">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2026-02-20</instant>
        </period>
    </context>
    <context id="c-4">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2025-10-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-5">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-6">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-7">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-8">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-9">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-10">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-11">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-12">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-13">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="c-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-15">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-16">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-17">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-18">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-19">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-20">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-21">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-22">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-24">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-25">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-26">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-27">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-28">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-29">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-32">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-33">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-34">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-35">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-36">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-37">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-38">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-39">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-40">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-41">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:TreasuryStockCommonMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-42">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-43">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-44">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-45">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:CollaboratorOneMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByBenchmarkAxis">us-gaap:SalesRevenueNetMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ConcentrationRiskByTypeAxis">us-gaap:CustomerConcentrationRiskMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-46">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-47">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-48">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2026-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-49">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2027-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-50">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2028-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-51">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2029-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-52">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2030-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-53">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:typedMember dimension="us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis">
                    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>2031-01-01</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionStartDateAxis.domain>
                </xbrldi:typedMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-54">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c-55">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryAndSalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c-56">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c-57">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c-58">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-09-01</startDate>
            <endDate>2021-09-30</endDate>
        </period>
    </context>
    <context id="c-59">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-09-30</instant>
        </period>
    </context>
    <context id="c-60">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-07-01</startDate>
            <endDate>2021-07-31</endDate>
        </period>
    </context>
    <context id="c-61">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:StockPurchaseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-07-31</instant>
        </period>
    </context>
    <context id="c-62">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-63">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CollaborationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-64">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="c-65">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:OptionPaymentsToLicenseAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-66">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-67">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PfizerIncorporationMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2017-12-31</instant>
        </period>
    </context>
    <context id="c-68">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-05-31</instant>
        </period>
    </context>
    <context id="c-69">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-70">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-71">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:NovartisPharmaAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">us-gaap:LicenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-30</instant>
        </period>
    </context>
    <context id="c-72">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-11-01</startDate>
            <endDate>2017-11-30</endDate>
        </period>
    </context>
    <context id="c-73">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-09-01</startDate>
            <endDate>2015-12-31</endDate>
        </period>
    </context>
    <context id="c-74">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-75">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:RegulatoryMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-76">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:GenentechIncorporationAndFHoffmanLaRocheLimitedMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:CommercialMilestonesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-77">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c-78">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-79">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:ResearchFundingPaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-80">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:DevelopmentMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c-81">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerAGMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SalesBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-06-30</instant>
        </period>
    </context>
    <context id="c-82">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:RemovalOfCombinationTrialsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-83">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:UpdatedResearchTimelinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-84">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:UpdatedResearchTimelinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-85">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:ExpansionOfDevelopmentProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-86">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ChangeInAccountingEstimateByTypeAxis">arvn:UpdatedResearchTimelinesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-87">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-88">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-89">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-90">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateBondSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-91">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-92">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementFrequencyAxis">us-gaap:FairValueMeasurementsRecurringMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-93">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">arvn:LaboratoryEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-94">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-95">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-96">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-97">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:A101CollegeStreetLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-98">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2021-05-04</instant>
        </period>
    </context>
    <context id="c-99">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="arvn:ContractTerminationAxis">arvn:OneTimeCashTerminationFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c-100">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="arvn:ContractTerminationAxis">arvn:WriteoffOfPrepaidRentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-15</startDate>
            <endDate>2024-08-15</endDate>
        </period>
    </context>
    <context id="c-101">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PledgedStatusAxis">us-gaap:AssetPledgedAsCollateralMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PledgingPurposeAxis">us-gaap:LetterOfCreditMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-05-31</instant>
        </period>
    </context>
    <context id="c-102">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-103">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-104">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-12-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-105">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c-106">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-01</startDate>
            <endDate>2021-04-30</endDate>
        </period>
    </context>
    <context id="c-107">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:StatementGeographicalAxis">stpr:CT</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">arvn:TwoThousandAndEighteenAssistanceAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c-108">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-109">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-110">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arvn:PreFundedWarrantMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-111">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arvn:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-112">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:PrivatePlacementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-11-01</startDate>
            <endDate>2023-11-30</endDate>
        </period>
    </context>
    <context id="c-113">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <instant>2025-09-17</instant>
        </period>
    </context>
    <context id="c-114">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-08-31</instant>
        </period>
    </context>
    <context id="c-115">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-116">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-11-30</instant>
        </period>
    </context>
    <context id="c-117">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-118">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:PiperSandlerAndCantorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">arvn:AtTheMarketOfferingMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:EquityDistributionAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-119">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c-120">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-09-01</startDate>
            <endDate>2018-09-30</endDate>
        </period>
    </context>
    <context id="c-121">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-122">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-123">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-124">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-125">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c-126">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-09-30</instant>
        </period>
    </context>
    <context id="c-127">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-128">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-01-01</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="c-129">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-130">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-131">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-132">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-133">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:WeightedAverageMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-134">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-135">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-136">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-137">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-138">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-139">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-140">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-141">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-142">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-143">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-144">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-145">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-146">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-147">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-148">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-149">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-150">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-151">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-152">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-153">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-154">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-155">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">arvn:TwoThousandEighteenStockIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-156">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-157">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-158">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:BayerCropScienceLPMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="c-159">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-07-31</instant>
        </period>
    </context>
    <context id="c-160">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-161">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-162">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="c-163">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-164">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-165">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="dei:LegalEntityAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-166">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-167">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-168">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ScheduleOfEquityMethodInvestmentEquityMethodInvesteeNameAxis">arvn:OerthBioLimitedLiabilityCorporationMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-169">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:CA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-170">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:MA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-171">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-172">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NY</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-173">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">arvn:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-174">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">arvn:NewYorkCityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-175">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:NJ</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-176">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">stpr:PA</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-177">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-178">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-179">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:ForeignTaxJurisdictionOtherMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-180">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-181">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TaxCreditCarryforwardAxis">us-gaap:ResearchMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-182">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-183">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-184">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-185">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-12-31</instant>
        </period>
    </context>
    <context id="c-186">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-187">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:UpfrontPaymentForAmendedLicenseAgreementAndNovartisLicenseAndAssetAgreementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="c-188">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:MilestonePaymentOnFirstAnniversaryOfSigningMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-189">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:MilestonePaymentUponApprovalOfFirstAndSecondRoyaltyProductsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2025-06-30</instant>
        </period>
    </context>
    <context id="c-190">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-05</startDate>
            <endDate>2013-07-05</endDate>
        </period>
    </context>
    <context id="c-191">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2013-07-05</instant>
        </period>
    </context>
    <context id="c-192">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:LicenseFirstLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-05</startDate>
            <endDate>2013-07-05</endDate>
        </period>
    </context>
    <context id="c-193">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:LicenseSecondLicensedProductMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">arvn:SuccessBasedMilestonePaymentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-05</startDate>
            <endDate>2013-07-05</endDate>
        </period>
    </context>
    <context id="c-194">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2013-07-05</startDate>
            <endDate>2013-07-05</endDate>
        </period>
    </context>
    <context id="c-195">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-196">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-197">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">arvn:YaleUniversityMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-198">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">arvn:PreFundedWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-12-31</instant>
        </period>
    </context>
    <context id="c-199">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-200">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-201">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-202">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-203">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-204">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-205">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2025-04-01</startDate>
            <endDate>2025-06-30</endDate>
        </period>
    </context>
    <context id="c-206">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
        </entity>
        <period>
            <startDate>2025-09-01</startDate>
            <endDate>2025-09-30</endDate>
        </period>
    </context>
    <context id="c-207">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">us-gaap:EmployeeSeveranceMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-208">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:RestructuringCostAndReserveAxis">arvn:StockCompensationAndBonusExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-209">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-210">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-211">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-212">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-213">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-214">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-215">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-216">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV471Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-217">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-218">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-219">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV102Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-220">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-221">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-222">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV806Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-223">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-224">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-225">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV393Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-226">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-227">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-228">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV110Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-229">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-230">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-231">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:ARV766Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <context id="c-232">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2025-01-01</startDate>
            <endDate>2025-12-31</endDate>
        </period>
    </context>
    <context id="c-233">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-12-31</endDate>
        </period>
    </context>
    <context id="c-234">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001655759</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">arvn:OtherProgramsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementBusinessSegmentsAxis">arvn:ReportableSegmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-12-31</endDate>
        </period>
    </context>
    <unit id="usd">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="shares">
        <measure>shares</measure>
    </unit>
    <unit id="usdPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="subsidiary">
        <measure>arvn:subsidiary</measure>
    </unit>
    <unit id="number">
        <measure>pure</measure>
    </unit>
    <unit id="sqft">
        <measure>utr:sqft</measure>
    </unit>
    <unit id="vote">
        <measure>arvn:vote</measure>
    </unit>
    <unit id="product">
        <measure>arvn:product</measure>
    </unit>
    <unit id="segment">
        <measure>arvn:segment</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-33">0001655759</dei:EntityCentralIndexKey>
    <dei:DocumentFiscalYearFocus contextRef="c-1" id="f-34">2025</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="c-1" id="f-35">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag contextRef="c-1" id="f-36">false</dei:AmendmentFlag>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-48" id="f-393">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-49" id="f-394">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-50" id="f-395">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-51" id="f-396">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-52" id="f-397">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1 contextRef="c-53" id="f-398">P1Y</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionPeriod1>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-209" id="f-937">http://fasb.org/us-gaap/2025#ResearchAndDevelopmentExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration contextRef="c-210" id="f-939">http://fasb.org/us-gaap/2025#GeneralAndAdministrativeExpense</us-gaap:RestructuringIncurredCostStatementOfIncomeOrComprehensiveIncomeExtensibleEnumeration>
    <dei:DocumentType contextRef="c-1" id="f-1">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="c-1" id="f-2">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-3">2025-12-31</dei:DocumentPeriodEndDate>
    <dei:CurrentFiscalYearEndDate contextRef="c-1" id="f-4">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentTransitionReport contextRef="c-1" id="f-5">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="c-1" id="f-6">001-38672</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="c-1" id="f-7">ARVINAS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-8">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-9">47-2566120</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-10">5 Science Park</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="c-1" id="f-11">395 Winchester Ave</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-12">New Haven</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-13">CT</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-14">06511</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-15">203</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-16">535-1456</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-17">Common stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-18">ARVN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-19">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="c-1" id="f-20">Yes</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="c-1" id="f-21">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="c-1" id="f-22">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="c-1" id="f-23">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="c-1" id="f-24">Accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="c-1" id="f-25">false</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-26">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="c-1" id="f-27">true</dei:IcfrAuditorAttestationFlag>
    <dei:DocumentFinStmtErrorCorrectionFlag contextRef="c-1" id="f-28">false</dei:DocumentFinStmtErrorCorrectionFlag>
    <dei:EntityShellCompany contextRef="c-1" id="f-29">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="c-2" decimals="-5" id="f-30" unitRef="usd">469000000.0</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="c-3" decimals="INF" id="f-31" unitRef="shares">63960997</dei:EntityCommonStockSharesOutstanding>
    <dei:DocumentsIncorporatedByReferenceTextBlock contextRef="c-1" id="f-32">&lt;div style="margin-top:2pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:120%"&gt;Part III of this Annual Report incorporates by reference information from the definitive Proxy Statement for the registrant&#x2019;s 2026 Annual Meeting of Stockholders, which is expected to be filed with the Securities and Exchange Commission not later than 120 days after the registrant&#x2019;s fiscal year ended December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;</dei:DocumentsIncorporatedByReferenceTextBlock>
    <cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock contextRef="c-1" id="f-39">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;We have processes for assessing, identifying and managing cybersecurity risks, which are built into our information technology function and are designed to provide protection for our information assets and operations from internal and external cyber threats, including protecting employee and patient information from unauthorized access or attack, as well as secure our networks and systems. These processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine reviews of our policies and procedures to identify risks and enhance our practices. As part of our overall risk mitigation strategy, we maintain cyber insurance coverage; however, such insurance may not be sufficient in type or amount to cover us against claims related to security breaches, cyber-attacks and other related breaches. We have engaged external parties, including consultants, computer security firms and risk management, and legal and governance experts, to enhance our cybersecurity oversight. We also employ processes to identify material risks from cybersecurity threats associated with our use of third-party service providers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Based on an assessment using the previously described risk mitigation strategy, we do not believe there are currently any risks from known cybersecurity threats, including as a result of any prior cybersecurity incidents, that have materially affected or are reasonably likely to materially affect us, including our business strategy, results of operations, or financial condition. See &#x201c;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Our internal computer systems and those of our collaborators, CROs, CDMOs contractors, consultants and other third parties are vulnerable to cyber attacks, cyber intrusions and security breaches, which could not only materially disrupt our business operations and result in the loss of confidential information, but could also damage the integrity of our clinical trials, impact our regulatory filings, compromise our ability to protect our intellectual property, and subject us to regulatory actions that could result in significant fines or other penalties&#x201d;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in Part I, Item 1A. &#x201c;Risk Factors&#x201d; for additional information.&lt;/span&gt;&lt;/div&gt;In an effort to deter and detect cyber threats, we periodically provide our workforce, including all employees and contingent staff, with a privacy, data protection, cybersecurity and incident response, and prevention education and awareness program, which includes annual and supplemental training covering a range of timely and relevant topics. Past topics have included social engineering, phishing, password protection, confidential data protection, asset use, and mobile security. This education and awareness program functions to educate employees on the importance of reporting all incidents immediately. In addition, we perform monthly phishing test campaigns to reinforce identification and reporting training. We automatically assign online reinforcement training upon initial phish test failure and may follow-up one-on-one as needed, including providing additional training. We also use technology-based tools to mitigate cybersecurity risks and to bolster our employee-based cybersecurity programs. Lastly, we perform annual penetration tests conducted by independent, third-party cybersecurity firms and ongoing vulnerability assessments conducted by the internal security team</cyd:CybersecurityRiskManagementProcessesForAssessingIdentifyingAndManagingThreatsTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock contextRef="c-1" id="f-37">We have processes for assessing, identifying and managing cybersecurity risks, which are built into our information technology function and are designed to provide protection for our information assets and operations from internal and external cyber threats, including protecting employee and patient information from unauthorized access or attack, as well as secure our networks and systems. These processes include physical, procedural and technical safeguards, response plans, regular tests on our systems, incident simulations and routine reviews of our policies and procedures to identify risks and enhance our practices.</cyd:CybersecurityRiskManagementProcessesIntegratedTextBlock>
    <cyd:CybersecurityRiskManagementProcessesIntegratedFlag contextRef="c-1" id="f-38">true</cyd:CybersecurityRiskManagementProcessesIntegratedFlag>
    <cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag contextRef="c-1" id="f-40">true</cyd:CybersecurityRiskThirdPartyOversightAndIdentificationProcessesFlag>
    <cyd:CybersecurityRiskManagementThirdPartyEngagedFlag contextRef="c-1" id="f-41">true</cyd:CybersecurityRiskManagementThirdPartyEngagedFlag>
    <cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag contextRef="c-1" id="f-42">false</cyd:CybersecurityRiskMateriallyAffectedOrReasonablyLikelyToMateriallyAffectRegistrantFlag>
    <cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock contextRef="c-1" id="f-44">Our Audit Committee of our board of directors, or the Audit Committee, provides direct cybersecurity risk oversight, and provides regular updates to the board of directors regarding such oversight. The Audit Committee receives quarterly updates from management and the Cybersecurity Board, as discussed in further detail below, regarding cybersecurity matters, and is notified between such updates regarding significant new cybersecurity risks, threats or incidents. We also provide updates to the full board of directors regarding cybersecurity risks, threat landscape and risks, as appropriate.</cyd:CybersecurityRiskBoardOfDirectorsOversightTextBlock>
    <cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-43">Our Audit Committee of our board of directors, or the Audit Committee, provides direct cybersecurity risk oversight, and provides regular updates to the board of directors regarding such oversight.</cyd:CybersecurityRiskBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag contextRef="c-1" id="f-45">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleReportToBoardFlag>
    <cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock contextRef="c-1" id="f-46">The Audit Committee receives quarterly updates from management and the Cybersecurity Board, as discussed in further detail below, regarding cybersecurity matters, and is notified between such updates regarding significant new cybersecurity risks, threats or incidents. We also provide updates to the full board of directors regarding cybersecurity risks, threat landscape and risks, as appropriate.</cyd:CybersecurityRiskProcessForInformingBoardCommitteeOrSubcommitteeResponsibleForOversightTextBlock>
    <cyd:CybersecurityRiskRoleOfManagementTextBlock contextRef="c-1" id="f-48">We have a cross-functional Cybersecurity Board led by our Senior Vice President, Information Technology Systems &amp;amp; Security, or SVP ITSS, serving as the chair and consisting of executive-level and non-executive level leaders, including among others, our chief financial officer and general counsel. This board is responsible for reviewing, engaging and making decisions related to the execution and continuous improvement of cybersecurity strategy, processes and governance impacting our information systems, employees, partners and patients. Our SVP, ITSS, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks.</cyd:CybersecurityRiskRoleOfManagementTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-47">We have a cross-functional Cybersecurity Board led by our Senior Vice President, Information Technology Systems &amp;amp; Security, or SVP ITSS, serving as the chair and consisting of executive-level and non-executive level leaders, including among others, our chief financial officer and general counsel.</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag contextRef="c-1" id="f-49">true</cyd:CybersecurityRiskManagementPositionsOrCommitteesResponsibleFlag>
    <cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock contextRef="c-1" id="f-50">This board is responsible for reviewing, engaging and making decisions related to the execution and continuous improvement of cybersecurity strategy, processes and governance impacting our information systems, employees, partners and patients. Our SVP, ITSS, leads the operational oversight of company-wide cybersecurity strategy, policy, standards and processes and works across relevant departments to assess and help prepare us and our employees to address cybersecurity risks.</cyd:CybersecurityRiskProcessForInformingManagementOrCommitteesResponsibleTextBlock>
    <cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock contextRef="c-1" id="f-51">Our SVP, ITSS, is an experienced senior leader with more than 25 years of experience in information technology within the pharmaceutical industry leading a team of employees and consultants with a breadth of experience including security management experience along with Certified Information Systems Security Professional, or CISSP certification.</cyd:CybersecurityRiskManagementExpertiseOfManagementResponsibleTextBlock>
    <ecd:NonRule10b51ArrAdoptedFlag contextRef="c-4" id="f-52">false</ecd:NonRule10b51ArrAdoptedFlag>
    <ecd:Rule10b51ArrAdoptedFlag contextRef="c-4" id="f-53">false</ecd:Rule10b51ArrAdoptedFlag>
    <ecd:NonRule10b51ArrTrmntdFlag contextRef="c-4" id="f-54">false</ecd:NonRule10b51ArrTrmntdFlag>
    <ecd:Rule10b51ArrTrmntdFlag contextRef="c-4" id="f-55">false</ecd:Rule10b51ArrTrmntdFlag>
    <ecd:InsiderTrdPoliciesProcAdoptedFlag contextRef="c-1" id="f-56">true</ecd:InsiderTrdPoliciesProcAdoptedFlag>
    <dei:AuditorFirmId contextRef="c-1" id="f-57">34</dei:AuditorFirmId>
    <dei:AuditorName contextRef="c-1" id="f-58">Deloitte &amp; Touche LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="c-1" id="f-59">Boston, Massachusetts</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-5" id="f-60" unitRef="usd">142900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-5" id="f-61" unitRef="usd">100500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-5" decimals="-5" id="f-62" unitRef="usd">542500000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:MarketableSecuritiesCurrent contextRef="c-6" decimals="-5" id="f-63" unitRef="usd">938900000</us-gaap:MarketableSecuritiesCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-5" id="f-64" unitRef="usd">1000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="-5" id="f-65" unitRef="usd">5700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-5" decimals="-5" id="f-66" unitRef="usd">5400000</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:OtherReceivablesNetCurrent contextRef="c-6" decimals="-5" id="f-67" unitRef="usd">8000000.0</us-gaap:OtherReceivablesNetCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-5" decimals="-5" id="f-68" unitRef="usd">8900000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent contextRef="c-6" decimals="-5" id="f-69" unitRef="usd">14200000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-5" decimals="-5" id="f-70" unitRef="usd">700700000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="c-6" decimals="-5" id="f-71" unitRef="usd">1067300000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-5" id="f-72" unitRef="usd">5200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-5" id="f-73" unitRef="usd">7000000.0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-5" decimals="-5" id="f-74" unitRef="usd">8200000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="c-6" decimals="-5" id="f-75" unitRef="usd">9000000.0</us-gaap:OperatingLeaseRightOfUseAsset>
    <arvn:CollaborationContractAssetAndOtherAssets contextRef="c-5" decimals="-5" id="f-76" unitRef="usd">3800000</arvn:CollaborationContractAssetAndOtherAssets>
    <arvn:CollaborationContractAssetAndOtherAssets contextRef="c-6" decimals="-5" id="f-77" unitRef="usd">8100000</arvn:CollaborationContractAssetAndOtherAssets>
    <us-gaap:Assets contextRef="c-5" decimals="-5" id="f-78" unitRef="usd">717900000</us-gaap:Assets>
    <us-gaap:Assets contextRef="c-6" decimals="-5" id="f-79" unitRef="usd">1091400000</us-gaap:Assets>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-80" unitRef="usd">69500000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-6" decimals="-5" id="f-81" unitRef="usd">71800000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-5" decimals="-5" id="f-82" unitRef="usd">71300000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="c-6" decimals="-5" id="f-83" unitRef="usd">156200000</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-5" decimals="-5" id="f-84" unitRef="usd">1700000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="c-6" decimals="-5" id="f-85" unitRef="usd">1800000</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-86" unitRef="usd">142500000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="c-6" decimals="-5" id="f-87" unitRef="usd">229800000</us-gaap:LiabilitiesCurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-5" decimals="-5" id="f-88" unitRef="usd">134300000</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:ContractWithCustomerLiabilityNoncurrent contextRef="c-6" decimals="-5" id="f-89" unitRef="usd">292000000.0</us-gaap:ContractWithCustomerLiabilityNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-5" id="f-90" unitRef="usd">400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-6" decimals="-5" id="f-91" unitRef="usd">600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-5" decimals="-5" id="f-92" unitRef="usd">6800000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="c-6" decimals="-5" id="f-93" unitRef="usd">7300000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities contextRef="c-5" decimals="-5" id="f-94" unitRef="usd">284000000.0</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="c-6" decimals="-5" id="f-95" unitRef="usd">529700000</us-gaap:Liabilities>
    <us-gaap:CommitmentsAndContingencies contextRef="c-5" id="f-96" unitRef="usd" xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies contextRef="c-6" id="f-97" unitRef="usd" xsi:nil="true"/>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-98"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-99"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-6" decimals="-5" id="f-100" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="c-5" decimals="-5" id="f-101" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="c-6" decimals="-5" id="f-102" unitRef="shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="c-5" decimals="-5" id="f-103" unitRef="shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockValue contextRef="c-5" decimals="-5" id="f-104" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:PreferredStockValue contextRef="c-6" decimals="-5" id="f-105" unitRef="usd">0</us-gaap:PreferredStockValue>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-106"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-107"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued contextRef="c-5" decimals="-5" id="f-108" unitRef="shares">73500000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-5" decimals="-5" id="f-109" unitRef="shares">63500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-6" decimals="-5" id="f-110" unitRef="shares">68800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="c-6" decimals="-5" id="f-111" unitRef="shares">68800000</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockValue contextRef="c-5" decimals="-5" id="f-112" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="c-6" decimals="-5" id="f-113" unitRef="usd">100000</us-gaap:CommonStockValue>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-5" decimals="-5" id="f-114" unitRef="usd">-1612400000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="c-6" decimals="-5" id="f-115" unitRef="usd">-1531600000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:AdditionalPaidInCapital contextRef="c-5" decimals="-5" id="f-116" unitRef="usd">2136900000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital contextRef="c-6" decimals="-5" id="f-117" unitRef="usd">2092200000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-5" decimals="-5" id="f-118" unitRef="usd">1200000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax contextRef="c-6" decimals="-5" id="f-119" unitRef="usd">1000000.0</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:TreasuryStockCommonShares contextRef="c-5" decimals="-5" id="f-120" unitRef="shares">10000000.0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonShares contextRef="c-6" decimals="INF" id="f-121" unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:TreasuryStockCommonValue contextRef="c-5" decimals="-5" id="f-122" unitRef="usd">91900000</us-gaap:TreasuryStockCommonValue>
    <us-gaap:TreasuryStockCommonValue contextRef="c-6" decimals="-5" id="f-123" unitRef="usd">0</us-gaap:TreasuryStockCommonValue>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-5" id="f-124" unitRef="usd">433900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-5" id="f-125" unitRef="usd">561700000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-5" decimals="-5" id="f-126" unitRef="usd">717900000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="c-6" decimals="-5" id="f-127" unitRef="usd">1091400000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:Revenues contextRef="c-1" decimals="-5" id="f-128" unitRef="usd">262600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-7" decimals="-5" id="f-129" unitRef="usd">263400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-8" decimals="-5" id="f-130" unitRef="usd">78500000</us-gaap:Revenues>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-1" decimals="-5" id="f-131" unitRef="usd">285200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-7" decimals="-5" id="f-132" unitRef="usd">348200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-8" decimals="-5" id="f-133" unitRef="usd">379700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-1" decimals="-5" id="f-134" unitRef="usd">95900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-7" decimals="-5" id="f-135" unitRef="usd">165400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-8" decimals="-5" id="f-136" unitRef="usd">100300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses contextRef="c-1" decimals="-5" id="f-137" unitRef="usd">381100000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-7" decimals="-5" id="f-138" unitRef="usd">513600000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-8" decimals="-5" id="f-139" unitRef="usd">480000000.0</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss contextRef="c-1" decimals="-5" id="f-140" unitRef="usd">-118500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-7" decimals="-5" id="f-141" unitRef="usd">-250200000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss contextRef="c-8" decimals="-5" id="f-142" unitRef="usd">-401500000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-143" unitRef="usd">-400000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-7" decimals="-5" id="f-144" unitRef="usd">-2900000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense contextRef="c-8" decimals="-5" id="f-145" unitRef="usd">-1200000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:InvestmentIncomeInterest contextRef="c-1" decimals="-5" id="f-146" unitRef="usd">38400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-7" decimals="-5" id="f-147" unitRef="usd">54800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-8" decimals="-5" id="f-148" unitRef="usd">38800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-1" decimals="-5" id="f-149" unitRef="usd">38000000.0</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-7" decimals="-5" id="f-150" unitRef="usd">51900000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense contextRef="c-8" decimals="-5" id="f-151" unitRef="usd">37600000</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-5" id="f-152" unitRef="usd">-80500000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-7" decimals="-5" id="f-153" unitRef="usd">-198300000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments contextRef="c-8" decimals="-5" id="f-154" unitRef="usd">-363900000</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-155" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-156" unitRef="usd">600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-8" decimals="-5" id="f-157" unitRef="usd">900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-1" decimals="-5" id="f-158" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-7" decimals="-5" id="f-159" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-8" decimals="-5" id="f-160" unitRef="usd">-2500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-161" unitRef="usd">-80800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-5" id="f-162" unitRef="usd">-198900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-5" id="f-163" unitRef="usd">-367300000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-164"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-165"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-166"
      unitRef="usdPerShare">-2.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-167"
      unitRef="usdPerShare">-2.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-8"
      decimals="2"
      id="f-168"
      unitRef="usdPerShare">-6.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-8"
      decimals="2"
      id="f-169"
      unitRef="usdPerShare">-6.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-170" unitRef="shares">70900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-171" unitRef="shares">70900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-5" id="f-172" unitRef="shares">71900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-5" id="f-173" unitRef="shares">71900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-8" decimals="-5" id="f-174" unitRef="shares">55500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-8" decimals="-5" id="f-175" unitRef="shares">55500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-176" unitRef="usd">-80800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-5" id="f-177" unitRef="usd">-198900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-5" id="f-178" unitRef="usd">-367300000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-179" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-5" id="f-180" unitRef="usd">4100000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-8" decimals="-5" id="f-181" unitRef="usd">16100000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-1" decimals="-5" id="f-182" unitRef="usd">-80600000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-7" decimals="-5" id="f-183" unitRef="usd">-194800000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax contextRef="c-8" decimals="-5" id="f-184" unitRef="usd">-351200000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-9" decimals="-5" id="f-185" unitRef="shares">53200000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-9" decimals="-5" id="f-186" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-10" decimals="-5" id="f-187" unitRef="usd">-965400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-11" decimals="-5" id="f-188" unitRef="usd">1549400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-12" decimals="-5" id="f-189" unitRef="usd">-19200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-13" decimals="-5" id="f-190" unitRef="usd">564900000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-14" decimals="-5" id="f-191" unitRef="usd">71600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-8" decimals="-5" id="f-192" unitRef="usd">71600000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-15" decimals="-5" id="f-193" unitRef="usd">-367300000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-5" id="f-194" unitRef="usd">-367300000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-16" decimals="-5" id="f-195" unitRef="shares">400000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-14" decimals="-5" id="f-196" unitRef="usd">4500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-8" decimals="-5" id="f-197" unitRef="usd">4500000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts contextRef="c-8" decimals="-5" id="f-198" unitRef="usd">17000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues contextRef="c-16" decimals="-5" id="f-199" unitRef="shares">14400000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-14" decimals="-5" id="f-200" unitRef="usd">370200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-8" decimals="-5" id="f-201" unitRef="usd">370200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-17" decimals="-5" id="f-202" unitRef="usd">16100000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-8" decimals="-5" id="f-203" unitRef="usd">16100000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-18" decimals="-5" id="f-204" unitRef="shares">68000000.0</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-18" decimals="-5" id="f-205" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-19" decimals="-5" id="f-206" unitRef="usd">-1332700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-20" decimals="-5" id="f-207" unitRef="usd">1995700000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-21" decimals="-5" id="f-208" unitRef="usd">-3100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-22" decimals="-5" id="f-209" unitRef="usd">660000000.0</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-23" decimals="-5" id="f-210" unitRef="usd">88200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-7" decimals="-5" id="f-211" unitRef="usd">88200000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-24" decimals="-5" id="f-212" unitRef="usd">-198900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-5" id="f-213" unitRef="usd">-198900000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-25" decimals="-5" id="f-214" unitRef="shares">800000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-23" decimals="-5" id="f-215" unitRef="usd">8300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-7" decimals="-5" id="f-216" unitRef="usd">8300000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-26" decimals="-5" id="f-217" unitRef="usd">4100000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-7" decimals="-5" id="f-218" unitRef="usd">4100000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-27" decimals="-5" id="f-219" unitRef="shares">68800000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-27" decimals="-5" id="f-220" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-28" decimals="-5" id="f-221" unitRef="usd">-1531600000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-29" decimals="-5" id="f-222" unitRef="usd">2092200000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-30" decimals="-5" id="f-223" unitRef="usd">1000000.0</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-31" decimals="-5" id="f-224" unitRef="shares">0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-31" decimals="-5" id="f-225" unitRef="usd">0</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-6" decimals="-5" id="f-226" unitRef="usd">561700000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-32" decimals="-5" id="f-227" unitRef="usd">44000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue contextRef="c-1" decimals="-5" id="f-228" unitRef="usd">44000000.0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss contextRef="c-33" decimals="-5" id="f-229" unitRef="usd">-80800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-230" unitRef="usd">-80800000</us-gaap:NetIncomeLoss>
    <us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation contextRef="c-34" decimals="-5" id="f-231" unitRef="shares">1300000</us-gaap:StockIssuedDuringPeriodSharesShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-32" decimals="-5" id="f-232" unitRef="usd">700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation contextRef="c-1" decimals="-5" id="f-233" unitRef="usd">700000</us-gaap:StockIssuedDuringPeriodValueShareBasedCompensation>
    <arvn:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="c-34" decimals="-5" id="f-234" unitRef="shares">3400000</arvn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-35" decimals="-5" id="f-235" unitRef="shares">10000000.0</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-35" decimals="-5" id="f-236" unitRef="usd">91900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:TreasuryStockValueAcquiredCostMethod contextRef="c-1" decimals="-5" id="f-237" unitRef="usd">91900000</us-gaap:TreasuryStockValueAcquiredCostMethod>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-36" decimals="-5" id="f-238" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent contextRef="c-1" decimals="-5" id="f-239" unitRef="usd">200000</us-gaap:OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent>
    <us-gaap:CommonStockSharesOutstanding contextRef="c-37" decimals="-5" id="f-240" unitRef="shares">73500000</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity contextRef="c-37" decimals="-5" id="f-241" unitRef="usd">100000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-38" decimals="-5" id="f-242" unitRef="usd">-1612400000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-39" decimals="-5" id="f-243" unitRef="usd">2136900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-40" decimals="-5" id="f-244" unitRef="usd">1200000</us-gaap:StockholdersEquity>
    <us-gaap:TreasuryStockCommonShares contextRef="c-41" decimals="-5" id="f-245" unitRef="shares">10000000.0</us-gaap:TreasuryStockCommonShares>
    <us-gaap:StockholdersEquity contextRef="c-41" decimals="-5" id="f-246" unitRef="usd">-91900000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="c-5" decimals="-5" id="f-247" unitRef="usd">433900000</us-gaap:StockholdersEquity>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-248" unitRef="usd">-80800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-5" id="f-249" unitRef="usd">-198900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-5" id="f-250" unitRef="usd">-367300000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-5" id="f-251" unitRef="usd">3000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-7" decimals="-5" id="f-252" unitRef="usd">4600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-8" decimals="-5" id="f-253" unitRef="usd">4800000</us-gaap:DepreciationAndAmortization>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-1" decimals="-5" id="f-254" unitRef="usd">12800000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-7" decimals="-5" id="f-255" unitRef="usd">21800000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments contextRef="c-8" decimals="-5" id="f-256" unitRef="usd">16600000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-1" decimals="-5" id="f-257" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-7" decimals="-5" id="f-258" unitRef="usd">0</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss contextRef="c-8" decimals="-5" id="f-259" unitRef="usd">-900000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGainLoss>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-1" decimals="-5" id="f-260" unitRef="usd">2200000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-7" decimals="-5" id="f-261" unitRef="usd">2000000.0</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense contextRef="c-8" decimals="-5" id="f-262" unitRef="usd">1900000</us-gaap:OperatingLeaseRightOfUseAssetAmortizationExpense>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-1" decimals="-5" id="f-263" unitRef="usd">4300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-7" decimals="-5" id="f-264" unitRef="usd">4600000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:CapitalizedContractCostAmortization contextRef="c-8" decimals="-5" id="f-265" unitRef="usd">1300000</us-gaap:CapitalizedContractCostAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-1" decimals="-5" id="f-266" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-7" decimals="-5" id="f-267" unitRef="usd">-2600000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment contextRef="c-8" decimals="-5" id="f-268" unitRef="usd">0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation contextRef="c-1" decimals="-5" id="f-269" unitRef="usd">44000000.0</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-7" decimals="-5" id="f-270" unitRef="usd">88200000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation contextRef="c-8" decimals="-5" id="f-271" unitRef="usd">71600000</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-1" decimals="-5" id="f-272" unitRef="usd">-4700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-7" decimals="-5" id="f-273" unitRef="usd">5700000</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable contextRef="c-8" decimals="-5" id="f-274" unitRef="usd">-1000000.0</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-1" decimals="-5" id="f-275" unitRef="usd">-2600000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-7" decimals="-5" id="f-276" unitRef="usd">800000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInOtherReceivables contextRef="c-8" decimals="-5" id="f-277" unitRef="usd">200000</us-gaap:IncreaseDecreaseInOtherReceivables>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-1" decimals="-5" id="f-278" unitRef="usd">-5300000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-7" decimals="-5" id="f-279" unitRef="usd">7000000.0</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets contextRef="c-8" decimals="-5" id="f-280" unitRef="usd">-14100000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-1" decimals="-5" id="f-281" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-7" decimals="-5" id="f-282" unitRef="usd">3000000.0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInContractWithCustomerAsset contextRef="c-8" decimals="-5" id="f-283" unitRef="usd">0</us-gaap:IncreaseDecreaseInContractWithCustomerAsset>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-1" decimals="-5" id="f-284" unitRef="usd">-1700000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-7" decimals="-5" id="f-285" unitRef="usd">-21200000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities contextRef="c-8" decimals="-5" id="f-286" unitRef="usd">17300000</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-1" decimals="-5" id="f-287" unitRef="usd">-2000000.0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-7" decimals="-5" id="f-288" unitRef="usd">-1900000</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability contextRef="c-8" decimals="-5" id="f-289" unitRef="usd">-2000000.0</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-1" decimals="-5" id="f-290" unitRef="usd">-242600000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-7" decimals="-5" id="f-291" unitRef="usd">-101000000.0</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:IncreaseDecreaseInContractWithCustomerLiability contextRef="c-8" decimals="-5" id="f-292" unitRef="usd">-74600000</us-gaap:IncreaseDecreaseInContractWithCustomerLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-1" decimals="-5" id="f-293" unitRef="usd">-273800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-7" decimals="-5" id="f-294" unitRef="usd">-259300000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities contextRef="c-8" decimals="-5" id="f-295" unitRef="usd">-347800000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-1" decimals="-5" id="f-296" unitRef="usd">354200000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-7" decimals="-5" id="f-297" unitRef="usd">652100000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities contextRef="c-8" decimals="-5" id="f-298" unitRef="usd">956300000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities contextRef="c-1" decimals="-5" id="f-299" unitRef="usd">731100000</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities contextRef="c-7" decimals="-5" id="f-300" unitRef="usd">644000000.0</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <arvn:ProceedsFromMaturitiesOfMarketableSecurities contextRef="c-8" decimals="-5" id="f-301" unitRef="usd">1103900000</arvn:ProceedsFromMaturitiesOfMarketableSecurities>
    <arvn:ProceedsFromSaleOfMarketableSecurities contextRef="c-1" decimals="-5" id="f-302" unitRef="usd">32600000</arvn:ProceedsFromSaleOfMarketableSecurities>
    <arvn:ProceedsFromSaleOfMarketableSecurities contextRef="c-7" decimals="-5" id="f-303" unitRef="usd">44500000</arvn:ProceedsFromSaleOfMarketableSecurities>
    <arvn:ProceedsFromSaleOfMarketableSecurities contextRef="c-8" decimals="-5" id="f-304" unitRef="usd">58800000</arvn:ProceedsFromSaleOfMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-305" unitRef="usd">1900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-7" decimals="-5" id="f-306" unitRef="usd">1800000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment contextRef="c-8" decimals="-5" id="f-307" unitRef="usd">2900000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-1" decimals="-5" id="f-308" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-7" decimals="-5" id="f-309" unitRef="usd">100000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment contextRef="c-8" decimals="-5" id="f-310" unitRef="usd">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-1" decimals="-5" id="f-311" unitRef="usd">407600000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-7" decimals="-5" id="f-312" unitRef="usd">34700000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities contextRef="c-8" decimals="-5" id="f-313" unitRef="usd">203500000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-1" decimals="-5" id="f-314" unitRef="usd">200000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-7" decimals="-5" id="f-315" unitRef="usd">400000</us-gaap:RepaymentsOfLongTermDebt>
    <us-gaap:RepaymentsOfLongTermDebt contextRef="c-8" decimals="-5" id="f-316" unitRef="usd">0</us-gaap:RepaymentsOfLongTermDebt>
    <arvn:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="c-1" decimals="-5" id="f-317" unitRef="usd">0</arvn:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <arvn:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="c-7" decimals="-5" id="f-318" unitRef="usd">0</arvn:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <arvn:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="c-8" decimals="-5" id="f-319" unitRef="usd">387200000</arvn:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-1" decimals="-5" id="f-320" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-7" decimals="-5" id="f-321" unitRef="usd">0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-8" decimals="-5" id="f-322" unitRef="usd">17000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-1" decimals="-5" id="f-323" unitRef="usd">91900000</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-7" decimals="-5" id="f-324" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <us-gaap:PaymentsForRepurchaseOfCommonStock contextRef="c-8" decimals="-5" id="f-325" unitRef="usd">0</us-gaap:PaymentsForRepurchaseOfCommonStock>
    <arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares contextRef="c-1" decimals="-5" id="f-326" unitRef="usd">700000</arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares>
    <arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares contextRef="c-7" decimals="-5" id="f-327" unitRef="usd">8300000</arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares>
    <arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares contextRef="c-8" decimals="-5" id="f-328" unitRef="usd">4500000</arvn:ProceedsFromExerciseOfStockOptionsAndIssuanceOfEmployeeStockShares>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-1" decimals="-5" id="f-329" unitRef="usd">-91400000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-7" decimals="-5" id="f-330" unitRef="usd">7900000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities contextRef="c-8" decimals="-5" id="f-331" unitRef="usd">374700000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-1" decimals="-5" id="f-332" unitRef="usd">42400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-7" decimals="-5" id="f-333" unitRef="usd">-216700000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect contextRef="c-8" decimals="-5" id="f-334" unitRef="usd">230400000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-5" id="f-335" unitRef="usd">100500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-5" id="f-336" unitRef="usd">317200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-13" decimals="-5" id="f-337" unitRef="usd">86800000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-5" id="f-338" unitRef="usd">142900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-5" id="f-339" unitRef="usd">100500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-5" id="f-340" unitRef="usd">317200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-1" decimals="-5" id="f-341" unitRef="usd">300000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-7" decimals="-5" id="f-342" unitRef="usd">900000</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:CapitalExpendituresIncurredButNotYetPaid contextRef="c-8" decimals="-5" id="f-343" unitRef="usd">0</us-gaap:CapitalExpendituresIncurredButNotYetPaid>
    <us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock contextRef="c-1" id="f-344">Nature of Business and Basis of Presentation&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Nature of Business&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arvinas, Inc. is a clinical-stage biotechnology company dedicated to improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development and commercialization of therapies that degrade disease-causing proteins. Arvinas, Inc. has four wholly owned subsidiaries; Arvinas Operations, Inc. formed in 2013, Arvinas Androgen Receptor, Inc. formed in 2015, Arvinas Estrogen Receptor, Inc. formed in 2016, and Arvinas Winchester, Inc. formed in 2018 (collectively, "Arvinas" or the "Company").&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and include the accounts of Arvinas, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated upon consolidation. The accounting policies used to prepare the Company's consolidated financial statements are the same as those used to prepare the consolidated financial statements in prior years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and notes. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements and notes are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the Company&#x2019;s revenue recognition, uncertain tax positions and research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:BusinessDescriptionAndBasisOfPresentationTextBlock>
    <arvn:NumberOfWhollyOwnedSubsidiaries
      contextRef="c-1"
      decimals="INF"
      id="f-345"
      unitRef="subsidiary">4</arvn:NumberOfWhollyOwnedSubsidiaries>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="c-1" id="f-346">&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Basis of Presentation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's consolidated financial statements are prepared in conformity with accounting principles generally accepted in the United States of America ("U.S. GAAP") and include the accounts of Arvinas, Inc. and its wholly owned subsidiaries. All intercompany transactions have been eliminated upon consolidation. The accounting policies used to prepare the Company's consolidated financial statements are the same as those used to prepare the consolidated financial statements in prior years.&lt;/span&gt;&lt;/div&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:ConsolidationPolicyTextBlock contextRef="c-1" id="f-347">All intercompany transactions have been eliminated upon consolidation. The accounting policies used to prepare the Company's consolidated financial statements are the same as those used to prepare the consolidated financial statements in prior years.</us-gaap:ConsolidationPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="c-1" id="f-348">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The preparation of the Company&#x2019;s consolidated financial statements in conformity with U.S. GAAP requires management to make certain estimates and assumptions that affect the reported amounts and disclosures in the consolidated financial statements and notes. While management believes that estimates and assumptions used in the preparation of the consolidated financial statements and notes are appropriate, actual results could differ from those estimates. The most significant estimates are those used in the determination of the Company&#x2019;s revenue recognition, uncertain tax positions and research and development expenses.&lt;/span&gt;&lt;/div&gt;</us-gaap:UseOfEstimates>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="c-1" id="f-349">Summary of Significant Accounting Policies &lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents and are considered Level 1 financial instruments. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount which was canceled in connection with a lease termination agreement the Company entered into with 101 College Street LLC in August 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total amounts shown on the consolidated statements of cash flows for the years ended December 31, 2025, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;311.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protect its proprietary technology. If the Company does not successfully obtain regulatory approval for its product candidates, it will be unable to generate revenue from product sales or achieve profitability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of assets and equity, proceeds from collaborations and a licensing arrangement, grant funding and debt financing. The Company had cash, cash equivalents and marketable securities of approximately $685.4 million as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company maintains its cash in financial institution accounts that may at times exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000. Cash may also be maintained at commercial institutions that are not insured by the FDIC. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025, 2024 and 2023, one collaborator represented 92.0%, 62.0% and 97% of the Company's revenue, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable Securities &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's marketable securities are classified as available-for-sale securities and are carried at their fair value based on the quoted market prices of the securities, with unrealized gains and losses reported as accumulated other comprehensive income (loss), a separate component of stockholders' equity. Realized gains and losses on available-for-sale securities are included in other income in the period earned or incurred. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Equipment, and Leasehold Improvements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from three years for office equipment to five years for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation is removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease and Rent Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for leases under Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use ("ROU") assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of the term of the lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the lease term unless there is reasonable certainty of renewal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;similar term, in a similar economic environment. The Company's weighted average incremental borrowing rate at December&#160;31, 2025 totaled 7.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease payments are not included within the lease right-of-use asset and lease liability on the consolidated balance sheet, and instead are reflected as expense in the period they are incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company monitors its long-lived assets for indicators of impairment. If such indicators are present, the Company assesses the recoverability of affected assets by determining whether the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found not to be recoverable, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, with the fair value generally determined based on the present value of the expected future cash flows associated with the assets. No such impairments were recorded during 2025, 2024 or 2023.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition and Deferred Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenues from Contracts &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s revenue is primarily generated through research collaborations and licensing arrangements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Under ASC 606, the Company evaluates whether the license agreement, research and development services and participation in research and development steering committees represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent combined single performance obligations. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also generated revenue through the sale of assets based on fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The research collaboration and license agreements may include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company continually assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized ratably over the Company&#x2019;s expected performance period under each respective arrangement. Management makes its best estimate of the period over which the Company expects to fulfill its performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. Management evaluates changes in the duration of the performance period at each reporting period and adjusts revenue as necessary. Changes are accounted for prospectively as a change in accounting estimate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025, 2024 and 2023, the transaction price allocated to the combined performance obligation identified under the individual research collaboration and license agreements was recognized as revenue on either a straight-line basis over the estimated performance period under the arrangement or over the estimated performance period based on the Company&#x2019;s best estimate of costs to be incurred. Straight-line basis was considered the best measure of progress for certain agreements in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. For agreements accounted for under the costs to be incurred method, revenue is recognized as program costs are incurred by measuring actual costs incurred to date compared to the total expected costs to satisfy the performance obligations. Management evaluates estimates of expected costs to satisfy the performance obligations at each reporting period and adjusts revenue as necessary. Changes are accounted for prospectively as a change in accounting estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale, or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by customers from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liabilities in the Company&#x2019;s accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses direct and incremental costs to obtaining and fulfilling a contract as and when incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as collaboration contract assets and amortized as general and administrative expenses over the total estimated period of performance of each underlying contract.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Method Investments &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments &#x2013; Equity Method and Joint Ventures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company recognizes its pro-rata share of income and losses in the investment in &#x201c;Loss from equity method investment&#x201d; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment in the consolidated balance sheet until such investment is reduced to zero. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. The Company provides a valuation allowance to the extent that it is more likely than not that all or a portion of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the authoritative guidance under ASC 740 for recognizing and measuring uncertainty in income tax positions taken or expected to be taken in a tax return. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures employee and board of director equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards. Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies equity-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;401(k) Savings Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis. Under the 401(k) Plan, the Company made discretionary matching contributions on behalf of eligible employees &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;totaling $2.6&#160;million, $3.4&#160;million and $3.1&#160;million for the years ended December&#160;31, 2025, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include (i) employee-related expenses, including salaries, benefits, stock-based compensation expense and travel; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites and consultants; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into consulting, research and other agreements with commercial entities, researchers, universities and others for the provision of goods and services. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#x2019;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#x2019;s estimates of the work performed under service agreements, milestones achieved and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Inputs used in the valuation techniques to determine fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below, with Level 1 having the highest priority and Level 3 having the lowest. The three levels of the fair value hierarchy are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;&#160;&#160;&#160;&#160;Inputs are based upon observable or quoted prices (unadjusted) for identical instruments traded in active markets. The Company&#x2019;s Level 1 financial instruments consist of cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;&#160;&#160;&#160;&#160;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#x2019;s Level 2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;&#160;&#160;&#160;&#160;Inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models and similar techniques. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss per Common Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common shares.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average number of common shares included in the computation of basic and diluted net loss per common share gives effect to pre-funded warrants. See Note 9,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and Note 13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In December 2023, the FASB issued ASU No. 2023-09, "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted the new standard on January 1, 2025 and presented disclosures on a retrospective basis. The adoption of the standard did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In November 2024, the FASB issued ASU No. 2024-03, "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;," which requires disaggregation and disclosure of specified information about certain costs and expenses in the notes to the financial statements. The requirements of the ASU are effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact ASU No. 2024-03 will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="c-1" id="f-350">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Cash and Cash Equivalents &lt;/span&gt;&lt;/div&gt;The Company classifies as cash and cash equivalents amounts on deposit in banks and cash invested temporarily in various instruments, primarily money market accounts, with original maturities of three months or less at time of purchase. The carrying amounts reported in the consolidated balance sheets represent the fair values of cash and cash equivalents and are considered Level 1 financial instruments.</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy contextRef="c-1" id="f-351">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Restricted Cash&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Restricted cash represents a letter of credit collateralized by a certificate of deposit in the same amount which was canceled in connection with a lease termination agreement the Company entered into with 101 College Street LLC in August 2024.&lt;/span&gt;&lt;/div&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock contextRef="c-1" id="f-353">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total amounts shown on the consolidated statements of cash flows for the years ended December 31, 2025, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;311.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashAndCashEquivalentsTableTextBlock>
    <us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock contextRef="c-1" id="f-352">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table provides a reconciliation of cash, cash equivalents and restricted cash reported within the consolidated balance sheets to the total amounts shown on the consolidated statements of cash flows for the years ended December 31, 2025, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span&gt;&lt;br/&gt;&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Cash and cash equivalents&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;311.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Cash, cash equivalents and restricted cash&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;142.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;100.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;317.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfRestrictedCashAndCashEquivalentsTextBlock>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-5" decimals="-5" id="f-354" unitRef="usd">142900000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-6" decimals="-5" id="f-355" unitRef="usd">100500000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="c-22" decimals="-5" id="f-356" unitRef="usd">311700000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:RestrictedCashCurrent contextRef="c-5" decimals="-5" id="f-357" unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-6" decimals="-5" id="f-358" unitRef="usd">0</us-gaap:RestrictedCashCurrent>
    <us-gaap:RestrictedCashCurrent contextRef="c-22" decimals="-5" id="f-359" unitRef="usd">5500000</us-gaap:RestrictedCashCurrent>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-5" decimals="-5" id="f-360" unitRef="usd">142900000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-6" decimals="-5" id="f-361" unitRef="usd">100500000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="c-22" decimals="-5" id="f-362" unitRef="usd">317200000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="c-1" id="f-363">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Concentration of Credit Risk and Other Risks and Uncertainties&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is subject to a number of risks similar to other biotechnology companies in a similar stage, including, but not limited to, the need to obtain adequate additional funding, possible failure of preclinical testing or clinical trials, the need to obtain marketing approval for its product candidates, competitors developing new technological innovations, and the need to successfully commercialize and gain market acceptance of the Company&#x2019;s products and protect its proprietary technology. If the Company does not successfully obtain regulatory approval for its product candidates, it will be unable to generate revenue from product sales or achieve profitability. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;To date, the Company has not generated any revenue from product sales and expects to incur additional operating losses and negative operating cash flows for the foreseeable future. The Company has financed its operations primarily through sales of assets and equity, proceeds from collaborations and a licensing arrangement, grant funding and debt financing. The Company had cash, cash equivalents and marketable securities of approximately $685.4 million as of December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;The Company maintains its cash in financial institution accounts that may at times exceed federally insured limits. The cash balances in the financial institutions are insured by the Federal Deposit Insurance Corporation ("FDIC") up to $250,000. Cash may also be maintained at commercial institutions that are not insured by the FDIC.</us-gaap:ConcentrationRiskCreditRisk>
    <arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities contextRef="c-5" decimals="-5" id="f-364" unitRef="usd">685400000</arvn:CashCashEquivalentsRestrictedCashAndMarketableSecurities>
    <us-gaap:FederalDepositInsuranceCorporationPremiumExpense contextRef="c-42" decimals="-3" id="f-365" unitRef="usd">250000</us-gaap:FederalDepositInsuranceCorporationPremiumExpense>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-43" decimals="3" id="f-366" unitRef="number">0.920</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-44" decimals="3" id="f-367" unitRef="number">0.620</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:ConcentrationRiskPercentage1 contextRef="c-45" decimals="2" id="f-368" unitRef="number">0.97</us-gaap:ConcentrationRiskPercentage1>
    <us-gaap:MarketableSecuritiesPolicy contextRef="c-1" id="f-369">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Marketable Securities &lt;/span&gt;&lt;/div&gt;The Company's marketable securities are classified as available-for-sale securities and are carried at their fair value based on the quoted market prices of the securities, with unrealized gains and losses reported as accumulated other comprehensive income (loss), a separate component of stockholders' equity. Realized gains and losses on available-for-sale securities are included in other income in the period earned or incurred.</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="c-1" id="f-370">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Property, Equipment, and Leasehold Improvements &lt;/span&gt;&lt;/div&gt;Property and equipment are recorded at cost. Depreciation is calculated using the straight-line method over the estimated useful lives, which range from three years for office equipment to five years for laboratory equipment. Maintenance and repairs which do not extend the lives of the assets are charged directly to expense as incurred. Upon retirement or disposal, cost and related accumulated depreciation is removed from the related accounts, and any resulting gain or loss is recognized as a component of income or loss for the period. Leasehold improvements are recorded at cost and amortized using the straight-line method over the shorter of the lease term or the useful life of the asset.</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-46" id="f-371">P3Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife contextRef="c-47" id="f-372">P5Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="c-1" id="f-373">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Lease and Rent Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for leases under Accounting Standards Codification (&#x201c;ASC&#x201d;) 842, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Leases&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. At the inception of an arrangement, the Company determines whether the arrangement is or contains a lease based on the unique facts and circumstances present in the arrangement. Leases with a term greater than one year are recognized on the balance sheet as right-of-use ("ROU") assets and short-term and long-term lease liabilities, as applicable. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. The Company has elected not to recognize leases with an original term of one year or less on the balance sheet. The Company typically only includes an initial lease term in its assessment of the term of the lease arrangement. It also considers termination options and factors those into the determination of lease payments. Options to renew a lease are not included in the lease term unless there is reasonable certainty of renewal.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating lease liabilities and their corresponding ROU assets are recorded based on the present value of lease payments over the expected remaining lease term. Certain adjustments to the ROU asset may be required for items such as incentives received. The interest rate implicit in lease contracts is typically not readily determinable. As a result, the Company utilizes its incremental borrowing rate, which reflects the fixed rate at which it could borrow on a collateralized basis the amount of the lease payments in the same currency, for a &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;similar term, in a similar economic environment. The Company's weighted average incremental borrowing rate at December&#160;31, 2025 totaled 7.0%.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Variable lease payments are not included within the lease right-of-use asset and lease liability on the consolidated balance sheet, and instead are reflected as expense in the period they are incurred.&lt;/span&gt;&lt;/div&gt;</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent contextRef="c-5" decimals="3" id="f-374" unitRef="number">0.070</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock contextRef="c-1" id="f-375">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Impairment of Long-Lived Assets &lt;/span&gt;&lt;/div&gt;The Company monitors its long-lived assets for indicators of impairment. If such indicators are present, the Company assesses the recoverability of affected assets by determining whether the carrying value of such assets is less than the sum of the undiscounted future cash flows of the assets. If such assets are found not to be recoverable, the Company measures the amount of such impairment by comparing the carrying value of the assets to the fair value of the assets, with the fair value generally determined based on the present value of the expected future cash flows associated with the assets.</us-gaap:ImpairmentOrDisposalOfLongLivedAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c-1" decimals="INF" id="f-376" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c-7" decimals="INF" id="f-377" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf contextRef="c-8" decimals="INF" id="f-378" unitRef="usd">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:RevenueFromContractWithCustomerPolicyTextBlock contextRef="c-1" id="f-379">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Revenue Recognition and Deferred Revenue &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Revenues from Contracts &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes revenue under ASC 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers.&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company&#x2019;s revenue is primarily generated through research collaborations and licensing arrangements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Under ASC 606, the Company evaluates whether the license agreement, research and development services and participation in research and development steering committees represent separate or combined performance obligations. The Company has determined that these services within its existing contracts represent combined single performance obligations. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also generated revenue through the sale of assets based on fair value.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The research collaboration and license agreements may include contingent milestone payments related to specified preclinical and clinical development milestones and regulatory milestones. These milestone payments represent variable consideration to be included within the transaction price using the most likely amount method. The Company continually assesses the probability of significant reversals for any amounts that become likely to be realized prior to recognizing the variable consideration associated with these payments within the transaction price.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Revenue is recognized ratably over the Company&#x2019;s expected performance period under each respective arrangement. Management makes its best estimate of the period over which the Company expects to fulfill its performance obligations, which includes access to technology through the license agreement and research activities. Given the uncertainties of these collaboration arrangements, significant judgment is required to determine the duration of the performance period. Management evaluates changes in the duration of the performance period at each reporting period and adjusts revenue as necessary. Changes are accounted for prospectively as a change in accounting estimate. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025, 2024 and 2023, the transaction price allocated to the combined performance obligation identified under the individual research collaboration and license agreements was recognized as revenue on either a straight-line basis over the estimated performance period under the arrangement or over the estimated performance period based on the Company&#x2019;s best estimate of costs to be incurred. Straight-line basis was considered the best measure of progress for certain agreements in which control of the combined obligation transfers to the customers, due to the contract containing license rights to technology, research and development services, and joint committee participation, which in totality are expected to occur ratably over the performance period. For agreements accounted for under the costs to be incurred method, revenue is recognized as program costs are incurred by measuring actual costs incurred to date compared to the total expected costs to satisfy the performance obligations. Management evaluates estimates of expected costs to satisfy the performance obligations at each reporting period and adjusts revenue as necessary. Changes are accounted for prospectively as a change in accounting estimate.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s contracts may also call for certain sales-based milestone and royalty payments upon successful commercialization of a target. The Company recognizes revenues from sales-based milestone and royalty payments at the later of a) the occurrence of the subsequent sale, or b) the performance obligation to which some or all of the sales-based milestone or royalty payments has been allocated has been satisfied (or partially satisfied). The Company anticipates recognizing these milestones and royalty payments if and when subsequent sales are generated by customers from the use of the technology. To date, no revenue from these sales-based milestone and royalty payments has been recognized for any periods. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Amounts received prior to satisfying the above revenue recognition criteria are recorded as contract liabilities in the Company&#x2019;s accompanying consolidated balance sheets. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company expenses direct and incremental costs to obtaining and fulfilling a contract as and when incurred if the expected amortization period of the asset that would be recognized is one year or less, or if the amount of the asset is immaterial. Otherwise, such costs are capitalized as collaboration contract assets and amortized as general and administrative expenses over the total estimated period of performance of each underlying contract.&lt;/span&gt;&lt;/div&gt;</us-gaap:RevenueFromContractWithCustomerPolicyTextBlock>
    <us-gaap:EquityMethodInvestmentsPolicy contextRef="c-1" id="f-380">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Method Investments &lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company accounts for investments for which it does not have a controlling interest in accordance with ASC 323, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Investments &#x2013; Equity Method and Joint Ventures&lt;/span&gt;. The Company recognizes its pro-rata share of income and losses in the investment in &#x201c;Loss from equity method investment&#x201d; on the consolidated statement of operations and comprehensive loss, with a corresponding change to the investment in equity method investment in the consolidated balance sheet until such investment is reduced to zero.</us-gaap:EquityMethodInvestmentsPolicy>
    <us-gaap:EquityMethodInvestments contextRef="c-5" decimals="INF" id="f-381" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="c-1" id="f-382">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Income Taxes &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Arvinas, Inc. and its wholly owned subsidiaries use the asset and liability method of accounting for income taxes, as set forth in ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. Under this method, deferred tax assets and liabilities are recognized for the expected future tax consequence of temporary differences between the carrying amounts and the tax basis of assets and liabilities and net operating loss carry forwards, all calculated using presently enacted tax rates. A valuation allowance is established to reduce deferred tax assets to their estimated realizable value. The Company provides a valuation allowance to the extent that it is more likely than not that all or a portion of the deferred tax assets will not be realized.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company follows the authoritative guidance under ASC 740 for recognizing and measuring uncertainty in income tax positions taken or expected to be taken in a tax return. The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="c-1" id="f-383">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company measures employee and board of director equity-based compensation for stock option and restricted stock grants based on the grant date fair value of the equity awards. Equity-based compensation expense is recognized over the requisite service period of the awards, net of estimated forfeitures. Estimated forfeitures are updated on a periodic basis based on actual experience. For equity awards that have a performance condition, the Company recognizes compensation expense based on its assessment of the probability that the performance condition will be achieved.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company classifies equity-based compensation expense in its consolidated statements of operations in the same manner in which the award recipient&#x2019;s salary and related costs are classified or in which the award recipient&#x2019;s service payments are classified.&lt;/span&gt;&lt;/div&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <arvn:DefinedContributionPlanPolicyPolicyTextBlock contextRef="c-1" id="f-384">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;401(k) Savings Plan&lt;/span&gt;&lt;/div&gt;The Company has a defined-contribution savings plan under Section 401(k) of the Internal Revenue Code (the &#x201c;401(k) Plan&#x201d;). The 401(k) Plan covers all employees who meet defined minimum age and service requirements and allows participants to defer a portion of their annual compensation on a pretax basis.</arvn:DefinedContributionPlanPolicyPolicyTextBlock>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-1" decimals="-5" id="f-385" unitRef="usd">2600000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-7" decimals="-5" id="f-386" unitRef="usd">3400000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:DefinedContributionPlanCostRecognized contextRef="c-8" decimals="-5" id="f-387" unitRef="usd">3100000</us-gaap:DefinedContributionPlanCostRecognized>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="c-1" id="f-388">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Research and Development Expenses&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Research and development expenses include (i) employee-related expenses, including salaries, benefits, stock-based compensation expense and travel; (ii) external research and development expenses incurred under arrangements with third parties, such as contract research organization agreements, investigational sites and consultants; (iii) the cost of acquiring, developing and manufacturing clinical study materials; (iv) costs associated with preclinical and clinical activities and regulatory operations; and (v) costs incurred in development of intellectual property. Costs incurred in connection with research and development activities are expensed as incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company enters into consulting, research and other agreements with commercial entities, researchers, universities and others for the provision of goods and services. Such arrangements are generally cancellable upon reasonable notice and payment of costs incurred. Costs are considered incurred based on an evaluation of the progress to completion of specific tasks under each contract using information and data provided by the respective vendors, including the Company&#x2019;s clinical sites. These costs consist of direct and indirect costs associated with specific projects, as well as fees paid to various entities that perform certain research on behalf of the Company. Depending upon the timing of payments to the service providers, the Company recognizes prepaid expenses or accrued expenses related to these costs. These accrued or prepaid expenses are based on management&#x2019;s estimates of the work performed under service agreements, milestones achieved and experience with similar contracts. The Company monitors each of these factors and adjusts estimates accordingly.&lt;/span&gt;&lt;/div&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:FairValueMeasurementPolicyPolicyTextBlock contextRef="c-1" id="f-389">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Fair Value Measurements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Inputs used in the valuation techniques to determine fair values are classified based on a three-level hierarchy. The basis for fair value measurements for each level within the hierarchy is described below, with Level 1 having the highest priority and Level 3 having the lowest. The three levels of the fair value hierarchy are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 1&#x2014;&#160;&#160;&#160;&#160;Inputs are based upon observable or quoted prices (unadjusted) for identical instruments traded in active markets. The Company&#x2019;s Level 1 financial instruments consist of cash equivalents.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 2&#x2014;&#160;&#160;&#160;&#160;Inputs are based upon quoted prices for similar instruments in active markets, quoted prices for identical or similar instruments in markets that are not active and model-based valuation techniques for which all significant assumptions are observable in the market or can be corroborated by observable market data for substantially the full term of the assets or liabilities. The Company&#x2019;s Level 2 investments consist primarily of corporate notes and bonds and U.S. government and agency securities. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:90pt;text-indent:-54pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Level 3&#x2014;&#160;&#160;&#160;&#160;Inputs are generally unobservable and typically reflect management&#x2019;s estimates of assumptions that market participants would use in pricing the asset or liability. The fair values are therefore determined using model-based techniques that include option pricing models, discounted cash flow models and similar techniques. &lt;/span&gt;&lt;/div&gt;In determining fair value, the Company utilizes valuation techniques that maximize the use of observable inputs and minimize the use of unobservable inputs to the extent possible as well as considers counterparty credit risk in its assessment of fair value.</us-gaap:FairValueMeasurementPolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="c-1" id="f-390">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Net Loss per Common Share &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic net loss per common share is computed by dividing net loss by the weighted-average number of common shares outstanding during the period. Diluted net loss per common share is computed using the weighted-average number of common shares outstanding during the period and, if dilutive, the weighted-average number of potential shares of common shares.&lt;/span&gt;&lt;/div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average number of common shares included in the computation of basic and diluted net loss per common share gives effect to pre-funded warrants. See Note 9,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and Note 13, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Net Loss Per Share&lt;/span&gt;.</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="c-1" id="f-391">&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;New Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Adopted Accounting Pronouncements &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Taxes (Topic 740)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In December 2023, the FASB issued ASU No. 2023-09, "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Improvements to Income Tax Disclosures&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;," which requires enhanced income tax disclosures, including specific categories and disaggregation of information in the effective tax rate reconciliation, disaggregated information related to income taxes paid, income or loss from continuing operations before income tax expense or benefit and income tax expense or benefit from continuing operations. The requirements of the ASU are effective for annual periods beginning after December 15, 2024, with early adoption permitted. The Company adopted the new standard on January 1, 2025 and presented disclosures on a retrospective basis. The adoption of the standard did not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Recently Issued Accounting Pronouncements Not Yet Adopted&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-align:justify;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Income Statement - Reporting Comprehensive Income - Expense Disaggregation Disclosures (Subtopic 220-40)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; - In November 2024, the FASB issued ASU No. 2024-03, "&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Disaggregation of Income Statement Expenses&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;," which requires disaggregation and disclosure of specified information about certain costs and expenses in the notes to the financial statements. The requirements of the ASU are effective for annual periods beginning after December 15, 2026, and interim reporting periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact ASU No. 2024-03 will have on its consolidated financial statements.&lt;/span&gt;&lt;/div&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:CollaborativeArrangementDisclosureTextBlock contextRef="c-1" id="f-392">Research Collaboration and License Agreements&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Vepdegestrant (ARV-471) Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2021, the Company entered into a collaboration agreement with Pfizer (the &#x201c;Vepdegestrant (ARV-471) Collaboration Agreement&#x201d;) pursuant to which the Company granted Pfizer worldwide co-exclusive rights to develop and commercialize products containing the Company&#x2019;s proprietary compound vepdegestrant (the &#x201c;Licensed Products&#x201d;). Under the Vepdegestrant (ARV-471) Collaboration Agreement, the Company received an upfront, non-refundable payment of $650.0&#160;million. In addition, the Company will be eligible to receive up to an additional $1.4&#160;billion in contingent payments based on specific regulatory and sales-based milestones for the Licensed Products. Of the total contingent payments, $400.0&#160;million in regulatory milestones are related to marketing approvals and $1.0&#160;billion are related to sales-based milestones. There were no regulatory or sales-based milestone payments received through December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company and Pfizer share equally all development costs, including costs of conducting clinical trials, for the Licensed Products, subject to certain exceptions. Except for certain regions described below, the parties will also share equally all profits and losses in commercialization and medical affairs activities for the Licensed Products in all other countries, subject to certain exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company will be the marketing authorization applicant in the United States and, subject to approval, can book sales in the United States, while Pfizer will hold marketing authorizations outside the United States. The parties will determine which, if any, regions within the world will be solely commercialized by one party, and in such region the parties will adjust their share of profits and losses for the Licensed Products based on the role each party will be performing.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In addition, in connection with the execution of the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vepdegestrant (ARV-471)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; Collaboration Agreement, the Company and Pfizer entered into a Stock Purchase Agreement (the "Pfizer Stock Purchase Agreement") for the sale and issuance of 3,457,815 shares of the Company&#x2019;s common stock (the &#x201c;Shares&#x201d;) to Pfizer at a price of $101.22 per share, for an aggregate purchase price of $350.0&#160;million (the &#x201c;Pfizer Equity Transaction&#x201d;), less financial advisor fees of $4.6&#160;million, which was consummated in September 2021. Pursuant to terms of the Pfizer Stock Purchase Agreement, Pfizer has agreed not to sell or transfer the Shares without prior written approval of the Company for a specified time period, subject to specified exceptions.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vepdegestrant (ARV-471) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration Agreement and the Pfizer Equity Transaction entered into with Pfizer concurrently should be evaluated as a combined contract in accordance with Accounting Standards Codification (&#x201c;ASC&#x201d;) 606, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company determined the fair value of the shares sold under the Pfizer Equity Transaction to be $85.4&#160;million less than the contractual purchase price stipulated in the agreement. In accordance with the applicable accounting guidance in ASC 815-40, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Contracts in Entity&#x2019;s Own Equity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company determined that the sale of stock should be recorded at fair value and therefore allocated the excess consideration received under the Pfizer Equity Transaction to the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vepdegestrant (ARV-471) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration Agreement, which, along with the non-refundable payment of $650.0&#160;million, is being recognized as revenue over the total estimated period of performance based on the Company&#x2019;s best estimate of costs to be incurred.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a direct result of the Company&#x2019;s entry into the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vepdegestrant (ARV-471) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration Agreement, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $12.9&#160;million. In accordance with ASC 340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized an asset of $12.9&#160;million in collaboration contract asset and other assets in the consolidated balance sheet, which is being amortized as general and administrative expense over the total estimated period of performance under the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Vepdegestrant (ARV-471) &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Collaboration Agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the Company announced that the Company and Pfizer have agreed to jointly select a third party for the commercialization and potential further development of vepdegestrant. The announcement did not have an effect on revenue recognition for the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Pfizer Research Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2017, the Company entered into a Research Collaboration and License Agreement with Pfizer (the "Pfizer Research Collaboration Agreement"). Under the terms of the Pfizer Research Collaboration Agreement, the Company received an upfront, non-refundable payment and certain additional payments totaling $28.0 million in 2018 in exchange for use of the Company&#x2019;s technology license and to fund Pfizer-related research as defined within the Pfizer Research Collaboration Agreement. These payments are being recognized over the total estimated period of performance. As of December&#160;31, 2025, there remains a single target under the Pfizer Research Collaboration Agreement, and, in accordance with the terms of such Agreement, the Company is eligible to receive up to an additional $3.8 million in non-refundable option payments if Pfizer exercises its option for such target protein under the Pfizer Research Collaboration Agreement. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is also entitled to receive up to $225.0 million in development milestone payments and up to $550.0 million in sales-based milestone payments for all designated targets under the Pfizer Research Collaboration Agreement, as well as tiered royalties based on sales. There were no sales-based milestone payments or royalties received through December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Novartis License and Asset Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In April 2024, the Company entered into a transaction (the "Novartis Transaction"), including both a license agreement (the "Novartis License Agreement") and an asset purchase agreement (the "Novartis Asset Agreement") with Novartis Pharma AG ("Novartis") for the worldwide development, manufacture and commercialization of luxdegalutamide (ARV-766), the Company's second generation PROTAC androgen receptor (AR) degrader for patients with prostate cancer and for the sale of the Company's preclinical AR-V7 program. Under the terms of the agreements, Novartis is responsible for worldwide clinical development and commercialization of luxdegalutamide (ARV-766) and has all research, development, manufacturing, and commercialization rights with respect to the Company&#x2019;s PROTAC protein degrader targeting AR-V7, a splice variant of the AR. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In May 2024, Novartis paid to the Company a one-time, upfront payment in the aggregate amount of $150.0&#160;million in accordance with the terms of the Novartis License Agreement and the Novartis Asset Agreement. Under the terms of the Novartis License Agreement, the Company is eligible to receive up to an additional $1.01&#160;billion as contingent payments based on specified development, regulatory and commercial milestones for luxdegalutamide (ARV-766) being met, as well as tiered royalties based on worldwide net sales of luxdegalutamide (ARV-766), subject to reduction under certain circumstances as provided in the Novartis License Agreement. During the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2025, the Company recognized as revenue $20.0&#160;million upon the achievemen&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;t of a development m&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ilestone pursuant to the terms of the Novartis License &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Agreement. There were no development, regulatory or commercial milestone payments, or sales-based royalties received during the year ended December&#160;31, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Novartis License Agreement will continue on a country-by-country basis (or, in certain cases, a region-by-region basis) until the expiration of the applicable royalty term for such country (or region, as applicable). The Novartis License Agreement contains customary termination provisions, including that either party may terminate the Novartis License Agreement (a) upon the material breach of the other party or (b) in the event the other party experiences an insolvency event. Additionally, Novartis may terminate the Novartis License Agreement for convenience or upon a safety or regulatory issue.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company determined that the Novartis License Agreement and the Novartis Asset Agreement entered into with Novartis concurrently should be accounted for as a combined contract in accordance with ASC 606, &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Revenue from Contracts with Customers&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company determined the fair value of the assets sold under the Novartis Asset Agreement to be $20.0&#160;million, which was recognized at the time of sale as revenue&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and the fair value of the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis License Agreement to be $130.0&#160;million, which was recognized as revenue over the total estimated period of performance during the technology transfer period, as defined in the agreement, based on the cost incurred input method. Under the Novartis License Agreement, Novartis will also reimburse the Company for development costs incurred during the technology transfer period, which will be recognized as revenue as costs are incurred. As of December 31, 2024, the technology transfer period ended as the Company completed the transition of its ongoing and planned clinical trials of luxdegalutamide (ARV-766) to Novartis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a direct result of the Company&#x2019;s entry into the Novartis Transaction, the Company incurred direct and incremental costs to obtain the contract, paid to a financial advisor, totaling $3.0&#160;million. In accordance with ASC 340, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Other Assets and Deferred Costs&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company recognized an asset of $3.0&#160;million in collaboration contract asset and other assets in the consolidated balance sheet at inception of the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis License Agreement and the Novartis Asset Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, which was amortized as general and administrative expense over the total estimated period of performance under the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Novartis License Agreement and the Novartis Asset Agreement&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Genentech Modification&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2017, the Company entered into an Amended and Restated Option, License, and Collaboration Agreement (the "Genentech Modification") with Genentech, Inc. and F. Hoffman-La Roche Ltd (together "Genentech"), amending a previous Genentech agreement entered into in September 2015. Under the Genentech Modification, the Company received upfront, non-refundable payments of $34.5 million (in addition to $11.0 million received under the previous agreement in 2015) to fund Genentech-related research. Upfront non-refundable payments were recognized as revenue over the total estimated period of performance, which concluded during the first quarter of 2023. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is eligible to receive up to $44.0 million per target in development milestone payments, $52.5 million in regulatory milestone payments and $60.0 million in commercial milestone payments based on sales as well as tiered royalties based on sales. There were no development, regulatory or commercial milestone payments or royalties received through December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Bayer Collaboration Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2019, the Company and Bayer AG entered into a Collaboration and License Agreement (the "Bayer Collaboration Agreement") setting forth the Company&#x2019;s collaboration with Bayer AG to identify or optimize proteolysis targeting chimeras, or PROTAC targeted protein degraders, that mediate for degradation of target proteins ("Targets"), using the Company&#x2019;s proprietary platform technology, which Targets were selected by Bayer AG, subject to certain exclusions and limitations. Under the terms of the Bayer Collaboration Agreement, the Company received an upfront, non-refundable payment of $17.5 million in exchange for the use of the Company&#x2019;s technology license. The Company also received an additional $12.0 million from Bayer AG from inception through 2023, including $1.5 million received during the year ended December 31, 2023. These payments were recognized over the total estimated period of performance.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Pursuant to notice from Bayer AG in accordance with the terms of the Bayer Collaboration Agreement, the Bayer Collaboration Agreement was terminated effective August 12, 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company was also eligible to receive up to $197.5 million in development milestone payments and up to $490.0 million in sales-based milestone payments for all designated Targets. In addition, the Company was eligible to receive, on net sales of PROTAC targeted protein degrader-related products, mid-single digit to low-double digit tiered royalties, which were subject to reductions. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;There were no development or sales-based milestone payments or royalties received through August 12, 2024, the termination date of the agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's contract balances were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(25.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts payable related to collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(34.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(56.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract assets: Collaboration contract asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract liabilities: Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;448.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;549.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions to collaboration agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(242.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(101.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances not held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(130.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;205.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;448.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2025, the Company updated its estimate to satisfy the performance obligations under the Vepdegestrant (ARV-471) Collaboration Agreement due to the removal of the first-line Phase 3 combination trial with Pfizer&#x2019;s novel investigational CDK4 inhibitor, atirmociclib, and the removal of the second-line Phase 3 combination trial with a CDK4/6 inhibitor from the development plan. The change in accounting estimate resulted in an increase in revenue of $150.2&#160;million, an increase in operating expenses of $2.6&#160;million, a decrease in net loss of $147.6&#160;million, and a decrease in basic and diluted loss per share of $2.08 for the year ended December 31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2025, the Company also changed its estimate of the duration of the performance period under the Pfizer Research Collaboration Agreement as a result of updated research timelines. The change in accounting estimate resulted in a decrease of $6.6&#160;million in revenue, an increase in net loss, and an increase in basic and diluted loss per share of $0.09 for the year ended December 31, 2025. The reversed revenue will continue to be recognized in future periods as the Company continues to advance on the performance obligation under the updated collaboration timeline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2024, the Company changed its estimate of the duration of the performance period under the Pfizer Research Collaboration Agreement as a result of updated research timelines. The changes in accounting estimate resulted in a decrease in revenue and an increase in net loss of $2.4&#160;million, respectively, and an increase in net loss per share of $0.03 for the year ended December 31, 2024. The reversed revenue will be recognized in subsequent periods as the Company continues to advance on the performance obligation under the updated collaboration timeline.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the fourth quarter of 2023, the Company had a change to its estimate to satisfy the performance obligations under the Vepdegestrant (ARV-471) Collaboration Agreement due to the expansion of the development programs. The changes in accounting estimate resulted in a decrease in revenue and increase in net loss of $35.0&#160;million, respectively, and an increase in net loss per share of $0.63 for the year ended December 31, 2023. The reversed revenue will continue to be recognized in future periods as the Company continues to advance on the performance obligation under the collaboration.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company also changed its estimate of the duration of the performance period under the Bayer Collaboration Agreement and Pfizer Research Collaboration Agreement as a result of updated research timelines. The changes in accounting estimate resulted in a decrease in revenue and an increase in net loss of $10.6&#160;million, respectively, and an increase in net loss per share of $0.19 for the year ended December 31, 2023. The reversed revenue was recognized in subsequent periods as the Company continued to advance on the performance obligation under the updated collaboration timelines.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of December&#160;31, 2025 totaled $205.6&#160;million, which is expected to be recognized in the following periods: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;114.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;205.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:CollaborativeArrangementDisclosureTextBlock>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-54" decimals="-5" id="f-399" unitRef="usd">650000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-55" decimals="-8" id="f-400" unitRef="usd">1400000000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-56" decimals="-5" id="f-401" unitRef="usd">400000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-57" decimals="-8" id="f-402" unitRef="usd">1000000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-58"
      decimals="INF"
      id="f-403"
      unitRef="shares">3457815</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="c-59"
      decimals="2"
      id="f-404"
      unitRef="usdPerShare">101.22</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-58" decimals="-5" id="f-405" unitRef="usd">350000000.0</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsForBrokerageFees contextRef="c-58" decimals="-5" id="f-406" unitRef="usd">4600000</us-gaap:PaymentsForBrokerageFees>
    <arvn:SaleOfStockFairValueOfSharesSold contextRef="c-60" decimals="-5" id="f-407" unitRef="usd">85400000</arvn:SaleOfStockFairValueOfSharesSold>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-61" decimals="-5" id="f-408" unitRef="usd">650000000.0</us-gaap:ContractWithCustomerAssetNet>
    <arvn:DirectAndIncrementalCostsIncurredToObtainTheContract contextRef="c-62" decimals="-5" id="f-409" unitRef="usd">12900000</arvn:DirectAndIncrementalCostsIncurredToObtainTheContract>
    <arvn:CollaborationContractAssetAndOtherAssets contextRef="c-63" decimals="-5" id="f-410" unitRef="usd">12900000</arvn:CollaborationContractAssetAndOtherAssets>
    <us-gaap:ProceedsFromCollaborators contextRef="c-64" decimals="-5" id="f-411" unitRef="usd">28000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-65" decimals="-5" id="f-412" unitRef="usd">3800000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-66" decimals="-5" id="f-413" unitRef="usd">225000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-67" decimals="-5" id="f-414" unitRef="usd">550000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability contextRef="c-68" decimals="-5" id="f-415" unitRef="usd">150000000.0</us-gaap:ContractWithCustomerLiability>
    <arvn:RevenueRemainingPerformanceObligationContingentPayments contextRef="c-68" decimals="-7" id="f-416" unitRef="usd">1010000000.00</arvn:RevenueRemainingPerformanceObligationContingentPayments>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-69" decimals="-5" id="f-417" unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax contextRef="c-69" decimals="-5" id="f-418" unitRef="usd">20000000.0</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-70" decimals="-5" id="f-419" unitRef="usd">130000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CapitalizedContractCostGross contextRef="c-71" decimals="-5" id="f-420" unitRef="usd">3000000.0</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross contextRef="c-71" decimals="-5" id="f-421" unitRef="usd">3000000.0</us-gaap:CapitalizedContractCostGross>
    <us-gaap:ProceedsFromCollaborators contextRef="c-72" decimals="-5" id="f-422" unitRef="usd">34500000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ProceedsFromCollaborators contextRef="c-73" decimals="-5" id="f-423" unitRef="usd">11000000.0</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-74" decimals="-5" id="f-424" unitRef="usd">44000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-75" decimals="-5" id="f-425" unitRef="usd">52500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-76" decimals="-5" id="f-426" unitRef="usd">60000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-77" decimals="-5" id="f-427" unitRef="usd">17500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-78" decimals="-5" id="f-428" unitRef="usd">12000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ProceedsFromCollaborators contextRef="c-79" decimals="-5" id="f-429" unitRef="usd">1500000</us-gaap:ProceedsFromCollaborators>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-80" decimals="-5" id="f-430" unitRef="usd">197500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-81" decimals="-5" id="f-431" unitRef="usd">490000000.0</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="c-1" id="f-432">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's contract balances were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:67.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.053%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts receivable&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments received&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(25.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(6.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Accounts payable related to collaborations&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;46.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;48.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Payments made&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(34.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(56.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;16.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract assets: Collaboration contract asset&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(4.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Contract liabilities: Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Beginning balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;448.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;549.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Additions to collaboration agreements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;130.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(242.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(101.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Revenue recognized from balances not held at the beginning of the period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(130.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Ending balance&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;205.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;448.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="-5" id="f-433" unitRef="usd">5700000</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-22" decimals="-5" id="f-434" unitRef="usd">0</us-gaap:AccountsReceivableNetCurrent>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions contextRef="c-1" decimals="-5" id="f-435" unitRef="usd">21100000</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions contextRef="c-7" decimals="-5" id="f-436" unitRef="usd">12400000</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentAdditions>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived contextRef="c-1" decimals="-5" id="f-437" unitRef="usd">25800000</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived>
    <arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived contextRef="c-7" decimals="-5" id="f-438" unitRef="usd">6700000</arvn:AccountsReceivableAfterAllowanceForCreditLossCurrentPaymentsReceived>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-5" decimals="-5" id="f-439" unitRef="usd">1000000.0</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="c-6" decimals="-5" id="f-440" unitRef="usd">5700000</us-gaap:AccountsReceivableNetCurrent>
    <arvn:AccountsPayableContractBalancesCurrent contextRef="c-6" decimals="-5" id="f-441" unitRef="usd">5300000</arvn:AccountsPayableContractBalancesCurrent>
    <arvn:AccountsPayableContractBalancesCurrent contextRef="c-22" decimals="-5" id="f-442" unitRef="usd">13100000</arvn:AccountsPayableContractBalancesCurrent>
    <arvn:AccountsPayableContractBalancesCurrentAdditions contextRef="c-1" decimals="-5" id="f-443" unitRef="usd">46400000</arvn:AccountsPayableContractBalancesCurrentAdditions>
    <arvn:AccountsPayableContractBalancesCurrentAdditions contextRef="c-7" decimals="-5" id="f-444" unitRef="usd">48900000</arvn:AccountsPayableContractBalancesCurrentAdditions>
    <arvn:AccountsPayableContractBalancesCurrentPayments contextRef="c-1" decimals="-5" id="f-445" unitRef="usd">34900000</arvn:AccountsPayableContractBalancesCurrentPayments>
    <arvn:AccountsPayableContractBalancesCurrentPayments contextRef="c-7" decimals="-5" id="f-446" unitRef="usd">56700000</arvn:AccountsPayableContractBalancesCurrentPayments>
    <arvn:AccountsPayableContractBalancesCurrent contextRef="c-5" decimals="-5" id="f-447" unitRef="usd">16800000</arvn:AccountsPayableContractBalancesCurrent>
    <arvn:AccountsPayableContractBalancesCurrent contextRef="c-6" decimals="-5" id="f-448" unitRef="usd">5300000</arvn:AccountsPayableContractBalancesCurrent>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-6" decimals="-5" id="f-449" unitRef="usd">7800000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-22" decimals="-5" id="f-450" unitRef="usd">9400000</us-gaap:ContractWithCustomerAssetNet>
    <arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements contextRef="c-1" decimals="-5" id="f-451" unitRef="usd">0</arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements contextRef="c-7" decimals="-5" id="f-452" unitRef="usd">3000000.0</arvn:ContractWithCustomerAssetsIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <arvn:CapitalizedContractCostAmortizationDuringPeriod contextRef="c-1" decimals="-5" id="f-453" unitRef="usd">4300000</arvn:CapitalizedContractCostAmortizationDuringPeriod>
    <arvn:CapitalizedContractCostAmortizationDuringPeriod contextRef="c-7" decimals="-5" id="f-454" unitRef="usd">4600000</arvn:CapitalizedContractCostAmortizationDuringPeriod>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-5" decimals="-5" id="f-455" unitRef="usd">3500000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerAssetNet contextRef="c-6" decimals="-5" id="f-456" unitRef="usd">7800000</us-gaap:ContractWithCustomerAssetNet>
    <us-gaap:ContractWithCustomerLiability contextRef="c-6" decimals="-5" id="f-457" unitRef="usd">448200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-22" decimals="-5" id="f-458" unitRef="usd">549200000</us-gaap:ContractWithCustomerLiability>
    <arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements contextRef="c-1" decimals="-5" id="f-459" unitRef="usd">0</arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements contextRef="c-7" decimals="-5" id="f-460" unitRef="usd">130000000.0</arvn:ContractWithCustomerLiabilityIncreaseDecreaseForAdditionsToCollaborationAgreements>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-1" decimals="-5" id="f-461" unitRef="usd">242600000</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized contextRef="c-7" decimals="-5" id="f-462" unitRef="usd">101000000.0</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <arvn:ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration contextRef="c-1" decimals="-5" id="f-463" unitRef="usd">0</arvn:ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration>
    <arvn:ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration contextRef="c-7" decimals="-5" id="f-464" unitRef="usd">-130000000.0</arvn:ContractWithCustomerLiabilityRevenueRecognizedFromNewCollaboration>
    <us-gaap:ContractWithCustomerLiability contextRef="c-5" decimals="-5" id="f-465" unitRef="usd">205600000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability contextRef="c-6" decimals="-5" id="f-466" unitRef="usd">448200000</us-gaap:ContractWithCustomerLiability>
    <us-gaap:Revenues contextRef="c-82" decimals="-5" id="f-467" unitRef="usd">150200000</us-gaap:Revenues>
    <us-gaap:OperatingExpenses contextRef="c-82" decimals="-5" id="f-468" unitRef="usd">2600000</us-gaap:OperatingExpenses>
    <us-gaap:NetIncomeLoss contextRef="c-82" decimals="-5" id="f-469" unitRef="usd">147600000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-82"
      decimals="2"
      id="f-470"
      unitRef="usdPerShare">2.08</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-82"
      decimals="2"
      id="f-471"
      unitRef="usdPerShare">2.08</us-gaap:EarningsPerShareDiluted>
    <us-gaap:Revenues contextRef="c-83" decimals="-5" id="f-472" unitRef="usd">-6600000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss contextRef="c-83" decimals="-5" id="f-473" unitRef="usd">6600000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-83"
      decimals="2"
      id="f-474"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-83"
      decimals="2"
      id="f-475"
      unitRef="usdPerShare">0.09</us-gaap:EarningsPerShareBasic>
    <us-gaap:NetIncomeLoss contextRef="c-84" decimals="-5" id="f-476" unitRef="usd">-2400000</us-gaap:NetIncomeLoss>
    <us-gaap:Revenues contextRef="c-84" decimals="-5" id="f-477" unitRef="usd">-2400000</us-gaap:Revenues>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-84"
      decimals="2"
      id="f-478"
      unitRef="usdPerShare">0.03</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-84"
      decimals="2"
      id="f-479"
      unitRef="usdPerShare">0.03</us-gaap:EarningsPerShareBasic>
    <us-gaap:Revenues contextRef="c-85" decimals="-5" id="f-480" unitRef="usd">-35000000.0</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss contextRef="c-85" decimals="-5" id="f-481" unitRef="usd">-35000000.0</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-85"
      decimals="2"
      id="f-482"
      unitRef="usdPerShare">0.63</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-85"
      decimals="2"
      id="f-483"
      unitRef="usdPerShare">0.63</us-gaap:EarningsPerShareBasic>
    <us-gaap:Revenues contextRef="c-86" decimals="-5" id="f-484" unitRef="usd">-10600000</us-gaap:Revenues>
    <us-gaap:NetIncomeLoss contextRef="c-86" decimals="-5" id="f-485" unitRef="usd">-10600000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-86"
      decimals="2"
      id="f-486"
      unitRef="usdPerShare">0.19</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-86"
      decimals="2"
      id="f-487"
      unitRef="usdPerShare">0.19</us-gaap:EarningsPerShareBasic>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock contextRef="c-1" id="f-488">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The aggregate amount of the transaction price allocated to performance obligations that were unsatisfied as of December&#160;31, 2025 totaled $205.6&#160;million, which is expected to be recognized in the following periods: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;114.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;205.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-5" decimals="-5" id="f-489" unitRef="usd">205600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-48" decimals="-5" id="f-490" unitRef="usd">71300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-49" decimals="-5" id="f-491" unitRef="usd">20300000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-50" decimals="-5" id="f-492" unitRef="usd">114000000.0</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="c-5" decimals="-5" id="f-493" unitRef="usd">205600000</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:FairValueDisclosuresTextBlock contextRef="c-1" id="f-494">Marketable Securities and Fair Value Measurements&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available for sale marketable securities measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generally does not intend to sell any investments prior to recovery of their amortized cost basis for any investment in an unrealized loss position. As such, the Company has classified these losses as temporary in nature.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The carrying value of cash and cash equivalents, accounts receivable and accounts payable and accrued liabilities approximate their &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;fair values due to the short-term nature of these assets and liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock contextRef="c-1" id="f-495">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following is a summary of the Company&#x2019;s available for sale marketable securities measured at fair value on a recurring basis.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2025&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;528.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;529.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;541.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;542.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:31.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:11.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.085%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="27" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31, 2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Valuation &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Hierarchy&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Amortized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Cost&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gains&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Gross&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Unrealized&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:0.75pt;text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:115%"&gt;Losses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Fair &lt;br/&gt;Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Corporate bonds&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;934.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;935.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Government securities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Level 2&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;937.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;938.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:DebtSecuritiesAvailableForSaleTableTextBlock>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-87" decimals="-5" id="f-496" unitRef="usd">528000000.0</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-87" decimals="-5" id="f-497" unitRef="usd">1100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-87" decimals="-5" id="f-498" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-87" decimals="-5" id="f-499" unitRef="usd">529100000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-88" decimals="-5" id="f-500" unitRef="usd">13300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-88" decimals="-5" id="f-501" unitRef="usd">100000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-88" decimals="-5" id="f-502" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-88" decimals="-5" id="f-503" unitRef="usd">13400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-89" decimals="-5" id="f-504" unitRef="usd">541300000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-89" decimals="-5" id="f-505" unitRef="usd">1200000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-89" decimals="-5" id="f-506" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-89" decimals="-5" id="f-507" unitRef="usd">542500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-90" decimals="-5" id="f-508" unitRef="usd">934400000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-90" decimals="-5" id="f-509" unitRef="usd">1700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-90" decimals="-5" id="f-510" unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-90" decimals="-5" id="f-511" unitRef="usd">935400000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-91" decimals="-5" id="f-512" unitRef="usd">3500000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-91" decimals="-5" id="f-513" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-91" decimals="-5" id="f-514" unitRef="usd">0</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-91" decimals="-5" id="f-515" unitRef="usd">3500000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis contextRef="c-92" decimals="-5" id="f-516" unitRef="usd">937900000</us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax contextRef="c-92" decimals="-5" id="f-517" unitRef="usd">1700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax contextRef="c-92" decimals="-5" id="f-518" unitRef="usd">700000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:AvailableForSaleSecuritiesDebtSecurities contextRef="c-92" decimals="-5" id="f-519" unitRef="usd">938900000</us-gaap:AvailableForSaleSecuritiesDebtSecurities>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="c-1" id="f-520">Property, Equipment and Leasehold Improvements &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and leasehold improvements consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(25.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Property, equipment and leasehold improvements, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense totaled $3.0 million, $4.6 million, and $4.8 million for the years ended December&#160;31, 2025, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2024, the Company wrote-off leasehold improvements totaling $2.4&#160;million resulting from the termination of the Terminated Lease, as discussed below in Note 6, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Right-of-Use Assets and Liabilities.&lt;/span&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="c-1" id="f-521">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Property, equipment and leasehold improvements consist of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Laboratory equipment&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;20.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Office equipment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;33.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;32.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: accumulated depreciation and amortization&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(28.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(25.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Property, equipment and leasehold improvements, net&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;7.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-47" decimals="-5" id="f-522" unitRef="usd">21300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-93" decimals="-5" id="f-523" unitRef="usd">20600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-94" decimals="-5" id="f-524" unitRef="usd">9100000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-95" decimals="-5" id="f-525" unitRef="usd">9300000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-46" decimals="-5" id="f-526" unitRef="usd">3000000.0</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-96" decimals="-5" id="f-527" unitRef="usd">2700000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-5" decimals="-5" id="f-528" unitRef="usd">33400000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="c-6" decimals="-5" id="f-529" unitRef="usd">32600000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-5" decimals="-5" id="f-530" unitRef="usd">28200000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="c-6" decimals="-5" id="f-531" unitRef="usd">25600000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-5" decimals="-5" id="f-532" unitRef="usd">5200000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="c-6" decimals="-5" id="f-533" unitRef="usd">7000000.0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-5" id="f-534" unitRef="usd">3000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-7" decimals="-5" id="f-535" unitRef="usd">4600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-8" decimals="-5" id="f-536" unitRef="usd">4800000</us-gaap:DepreciationAndAmortization>
    <arvn:PropertyPlantAndEquipmentWriteoff contextRef="c-97" decimals="-5" id="f-537" unitRef="usd">2400000</arvn:PropertyPlantAndEquipmentWriteoff>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="c-1" id="f-538">Right-of-Use Assets and Liabilities&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2024, the Company entered into a Lease Termination Agreement with 101 College Street LLC (the "Landlord"). Under the terms of the Lease Termination Agreement, the lease, by and between the Company and the Landlord, dated May 4, 2021 (as amended, the "Terminated Lease"), for certain leased premises of approximately 160,000 square feet of laboratory and office space, was terminated in full, effective August 15, 2024. The leased premises were expected to be occupied by the Company in 2025. In connection with the Lease Termination Agreement and as consideration for the Landlord&#x2019;s agreement to terminate the lease for its laboratory and office space at 101 College Street in full, the Company agreed to pay to the Landlord a one-time cash termination fee in the amount of $41.5&#160;million and wrote-off $1.9&#160;million of prepaid rent, both of which were recognized in general and administrative operating expenses on the consolidated statements of operations. The Company also cancelled its previously issued letter of credit in the amount of $5.5 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has operating leases for its corpor&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ate office, laboratories and certain&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; equipment, which expire no later than December 2029. The leases have a weighted-average remaining term of 4.0 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Supplemental non-cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets obtained in exchange for new lease obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In December 2024, the Company, entered into a Seventh Amendment and an Eighth Amendment to its lease (collectively the &#x201c;Seventh and Eighth Building 5 Lease Amendments") with Science Park Development Corporation for certain premises in New Haven, Connecticut (the &#x201c;Building 5 Premises&#x201d;). The Seventh and Eighth Building 5 Lease Amendments extend the term of the original lease to December 31, 2029, resulting in an increase in the Company's ROU assets of $8.5&#160;million, and, effective on January 1 2025, expand the Building 5 Premises to include approximately 11,200 square feet of additional laboratory and office space resulting in an increase in the Company's ROU assets of $1.5&#160;million. The annual base rent during the extended term will range from $2.2&#160;million to $2.6&#160;million.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of December&#160;31, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-98" decimals="-3" id="f-539" unitRef="sqft">160000</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:GainLossOnContractTermination contextRef="c-99" decimals="-5" id="f-540" unitRef="usd">-41500000</us-gaap:GainLossOnContractTermination>
    <us-gaap:GainLossOnContractTermination contextRef="c-100" decimals="-5" id="f-541" unitRef="usd">-1900000</us-gaap:GainLossOnContractTermination>
    <us-gaap:DebtSecurities contextRef="c-101" decimals="-5" id="f-542" unitRef="usd">5500000</us-gaap:DebtSecurities>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1 contextRef="c-5" id="f-543">P4Y</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:LeaseCostTableTextBlock contextRef="c-1" id="f-544">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The components of lease expense were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December&#160;31,&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating lease cost&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LeaseCostTableTextBlock>
    <us-gaap:OperatingLeaseCost contextRef="c-1" decimals="-5" id="f-545" unitRef="usd">2900000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-7" decimals="-5" id="f-546" unitRef="usd">1900000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-8" decimals="-5" id="f-547" unitRef="usd">2100000</us-gaap:OperatingLeaseCost>
    <arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock contextRef="c-1" id="f-548">&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Supplemental cash flow information related to leases was as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.263%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.557%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:0.75pt solid #000000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Operating cash flows from operating leases&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Supplemental non-cash information:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:0.75pt;padding-left:13.5pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;Right-of-use assets obtained in exchange for new lease obligations&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</arvn:ScheduleOfSupplementalCashFlowInformationRelatedToLeasesTableTableTextBlock>
    <us-gaap:OperatingLeasePayments contextRef="c-1" decimals="-5" id="f-549" unitRef="usd">2000000.0</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-7" decimals="-5" id="f-550" unitRef="usd">1900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeasePayments contextRef="c-8" decimals="-5" id="f-551" unitRef="usd">2000000.0</us-gaap:OperatingLeasePayments>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-1" decimals="-5" id="f-552" unitRef="usd">1500000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-7" decimals="-5" id="f-553" unitRef="usd">8500000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-8" decimals="-5" id="f-554" unitRef="usd">0</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-7" decimals="-5" id="f-555" unitRef="usd">8500000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:LandSubjectToGroundLeases contextRef="c-6" decimals="-2" id="f-556" unitRef="sqft">11200</us-gaap:LandSubjectToGroundLeases>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability contextRef="c-102" decimals="-5" id="f-557" unitRef="usd">1500000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <us-gaap:OperatingLeaseCost contextRef="c-103" decimals="-5" id="f-558" unitRef="usd">2200000</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost contextRef="c-104" decimals="-5" id="f-559" unitRef="usd">2600000</us-gaap:OperatingLeaseCost>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="c-1" id="f-560">&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Maturities of operating lease liabilities as of December&#160;31, 2025 were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2029&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total lease payments&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;9.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: imputed interest&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(1.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:0.75pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="c-5" decimals="-5" id="f-561" unitRef="usd">2300000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="c-5" decimals="-5" id="f-562" unitRef="usd">2400000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="c-5" decimals="-5" id="f-563" unitRef="usd">2500000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour contextRef="c-5" decimals="-5" id="f-564" unitRef="usd">2600000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="c-5" decimals="-5" id="f-565" unitRef="usd">9800000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="c-5" decimals="-5" id="f-566" unitRef="usd">1300000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability contextRef="c-5" decimals="-5" id="f-567" unitRef="usd">8500000</us-gaap:OperatingLeaseLiability>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock contextRef="c-1" id="f-568">Accounts Payable and Accrued Liabilities &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative and commercial expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock contextRef="c-1" id="f-569">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Accounts payable and accrued liabilities consisted of the following: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts payable&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Research and development expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;18.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;25.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Employee expenses&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;17.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;22.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Income taxes&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;General and administrative and commercial expenses&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;3.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;5.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Professional fees&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Accounts payable and accrued liabilities&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;69.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;71.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:AccountsPayableCurrent contextRef="c-5" decimals="-5" id="f-570" unitRef="usd">24400000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="c-6" decimals="-5" id="f-571" unitRef="usd">13400000</us-gaap:AccountsPayableCurrent>
    <arvn:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-5" decimals="-5" id="f-572" unitRef="usd">18200000</arvn:AccruedResearchAndDevelopmentExpenseCurrent>
    <arvn:AccruedResearchAndDevelopmentExpenseCurrent contextRef="c-6" decimals="-5" id="f-573" unitRef="usd">25900000</arvn:AccruedResearchAndDevelopmentExpenseCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-574" unitRef="usd">17500000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent contextRef="c-6" decimals="-5" id="f-575" unitRef="usd">22400000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-5" decimals="-5" id="f-576" unitRef="usd">4800000</us-gaap:AccruedIncomeTaxesCurrent>
    <us-gaap:AccruedIncomeTaxesCurrent contextRef="c-6" decimals="-5" id="f-577" unitRef="usd">3200000</us-gaap:AccruedIncomeTaxesCurrent>
    <arvn:AccruedGeneralAndAdministrativeAndCommercialCurrent contextRef="c-5" decimals="-5" id="f-578" unitRef="usd">3700000</arvn:AccruedGeneralAndAdministrativeAndCommercialCurrent>
    <arvn:AccruedGeneralAndAdministrativeAndCommercialCurrent contextRef="c-6" decimals="-5" id="f-579" unitRef="usd">5100000</arvn:AccruedGeneralAndAdministrativeAndCommercialCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-5" decimals="-5" id="f-580" unitRef="usd">900000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent contextRef="c-6" decimals="-5" id="f-581" unitRef="usd">1800000</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-5" decimals="-5" id="f-582" unitRef="usd">69500000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent contextRef="c-6" decimals="-5" id="f-583" unitRef="usd">71800000</us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent>
    <us-gaap:DebtDisclosureTextBlock contextRef="c-1" id="f-584">Long-Term Debt &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt obligations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2018 Assistance Agreement Debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;09/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: current installments included within Accounts Payable and Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2018, the Company entered into an Assistance Agreement with the State of Connecticut (the "2018 Assistance Agreement") to provide funding for the expansion and renovation of laboratory and office space. In September 2018, the Company borrowed $2.0&#160;million under the 2018 Assistance Agreement, of which $1.0&#160;million was forgiven by the State of Connecticut in April 2021 as the Company met certain employment conditions, as defined in the agreement. Borrowings under the 2018 Assistance Agreement bear an interest rate of 3.25% per annum, with interest-only payments required for the first 60 months, and mature in &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;September 2028&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The 2018 Assistance Agreement requires that the Company be located in the State of Connecticut through September 2028 with a default penalty of repayment of the full original funding amount of $2.0&#160;million plus liquidated damages of 7.5% of the total amount of funding received.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum future principal payments on long-term debt as of December&#160;31, 2025 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:34.7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the years ended December&#160;31, 2025, 2024 and 2023, interest expense was immaterial.&lt;/span&gt;&lt;/div&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:ScheduleOfDebtInstrumentsTextBlock contextRef="c-1" id="f-585">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Debt obligations consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:36.475%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.051%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:14.054%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Maturity Date&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Interest Rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2018 Assistance Agreement Debt&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;09/28&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.25%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less: current installments included within Accounts Payable and Accrued Liabilities&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total long-term debt&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDebtInstrumentsTextBlock>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage contextRef="c-5" decimals="INF" id="f-586" unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <us-gaap:LongTermDebt contextRef="c-5" decimals="-5" id="f-587" unitRef="usd">600000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebt contextRef="c-6" decimals="-5" id="f-588" unitRef="usd">800000</us-gaap:LongTermDebt>
    <us-gaap:LongTermDebtCurrent contextRef="c-5" decimals="-5" id="f-589" unitRef="usd">200000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtCurrent contextRef="c-6" decimals="-5" id="f-590" unitRef="usd">200000</us-gaap:LongTermDebtCurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-5" decimals="-5" id="f-591" unitRef="usd">400000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:LongTermDebtNoncurrent contextRef="c-6" decimals="-5" id="f-592" unitRef="usd">600000</us-gaap:LongTermDebtNoncurrent>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-105" decimals="-5" id="f-593" unitRef="usd">2000000.0</us-gaap:DebtInstrumentFaceAmount>
    <arvn:DebtInstrumentLoanForgiveness contextRef="c-106" decimals="-5" id="f-594" unitRef="usd">1000000.0</arvn:DebtInstrumentLoanForgiveness>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="c-105"
      decimals="INF"
      id="f-595"
      unitRef="number">0.0325</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <arvn:DebtInstrumentInterestPaymentsTerm contextRef="c-107" id="f-596">P60M</arvn:DebtInstrumentInterestPaymentsTerm>
    <us-gaap:DebtInstrumentFaceAmount contextRef="c-105" decimals="-5" id="f-597" unitRef="usd">2000000.0</us-gaap:DebtInstrumentFaceAmount>
    <arvn:PercentageOfLiquidatedDamages
      contextRef="c-107"
      decimals="INF"
      id="f-598"
      unitRef="number">0.075</arvn:PercentageOfLiquidatedDamages>
    <us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock contextRef="c-1" id="f-599">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Minimum future principal payments on long-term debt as of December&#160;31, 2025 are as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:84.809%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.991%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2026&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2027&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2028&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfMaturitiesOfLongTermDebtTableTextBlock>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths contextRef="c-5" decimals="-5" id="f-600" unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo contextRef="c-5" decimals="-5" id="f-601" unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo>
    <us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree contextRef="c-5" decimals="-5" id="f-602" unitRef="usd">200000</us-gaap:LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree>
    <us-gaap:LongTermDebt contextRef="c-5" decimals="-5" id="f-603" unitRef="usd">600000</us-gaap:LongTermDebt>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="c-1" id="f-604">Equity &lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Preferred Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2025 and 2024, the Company had authorized 5,000,000 shares of preferred stock, at a $0.001 par value per share. Preferred stock may be issued in one or more series upon authorization of the Company's board of directors. The board of directors is authorized to fix the designations, powers, preferences and the relative, participating, optional or other special rights and any qualifications, limitations and restrictions of the shares of each series of preferred stock. The authorized shares of the Company's preferred stock are available for issuance without further action by the Company's stockholders, unless such action is required by applicable law or the rules of any stock exchange on which our securities may be listed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Common Stock&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2025 and 2024, the Company had authorized 200,000,000 shares of common stock, at a $0.001 par value per share. The holders of shares of common stock are entitled to one vote for each share of common stock held at all meetings of stockholders and written actions in lieu of meetings. The holders of shares of common stock are entitled to receive dividends, if and when declared by the board of directors. No dividends have been declared or paid by the Company since its inception.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Company completed a private placement offering with certain institutional investors in which the Company issued and sold 12,963,542 shares of common stock at a price of $21.36 per share and, to one investor, in lieu of common stock, pre-funded warrants to purchase up to 3,422,380 shares of common stock at a price of $21.359 per pre-funded warrant. Each pre-funded warrant has an exercise price of $0.001 per share, is exercisable immediately and is exercisable until exercised in full. The aggregate gross &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;proceeds from the issuance of common stock and pre-funded warrants totaled approximately $350.0&#160;million,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; before deducting placement agent fees and offering costs of approximately &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$15.9&#160;million&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of December 31, 2025, all outstanding&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pre-funded warrants had been cashless exercised for no consideration and the Company issued 3,422,186 shares of common stock to the holders.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Share Repurchase Program&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On September 17, 2025, the Company announced that its board of directors authorized and approved a share repurchase program for the repurchase of up to $100.0&#160;million of the then-currently outstanding shares of the Company&#x2019;s common stock. Share repurchases under the share repurchase program may be made from time to time through a variety of methods, which may include open market purchases, privately negotiated block trades, accelerated share repurchases, other privately negotiated transactions or any combination of these methods. Repurchases may also be made under a Rule 10b5-1 plan, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws. The share repurchase program is funded using the Company's working capital. The share repurchase program has no time limit and can be modified, suspended or discontinued at any time without prior notice. Repurchased shares are recorded as treasury stock, at cost, and are eligible to be reissued under the Company's stock plans and for other corporate purposes.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2025, the Company repurchased 10,009,758 shares of its common stock, at an average price of $9.09 per share, for an aggregate purchase price of $91.0&#160;million, plus commissions and excise tax of $0.9&#160;million. As of December&#160;31, 2025, the Company has &lt;/span&gt;&lt;span style="color:#000000;font-family:'Calibri',sans-serif;font-size:12pt;font-weight:400;line-height:120%"&gt;suspended the program and has no further plans to repurchase additional shares&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Equity Distribution Agreements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In August 2021, the Company entered into an Equity Distribution Agreement with Piper Sandler &amp;amp; Company (&#x201c;Piper Sandler&#x201d;) and Cantor Fitzgerald &amp;amp; Co. (&#x201c;Cantor&#x201d;), as agents, pursuant to which the Company may offer and sell from time to time, through the agents, up to $300.0&#160;million of the common stock registered under a universal shelf registration statement pursuant to one or more &#x201c;at-the-market" offerings. During the year ended December 31, 2023, the Company issued 1,449,275 shares of common stock under this agreement resulting in gross proceeds of approximately $37.2&#160;million, less offering costs of approximately $1.1&#160;million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In November 2023, the Company amended and restated the Equity Distribution Agreement with Piper Sandler and Cantor, pursuant to which the Company may offer and sell from time to time, through the agents, up to approximately &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$262.8&#160;million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; of the common stock registered under a universal shelf registration statement pursuant to one or more &#x201c;at-the-market&#x201d; offerings. During the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2025 and 2024&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, no shares were issued under this amended and restated agreement.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Stock-based Compensation&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Employee Stock Purchase Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company adopted the 2018 Employee Stock Purchase Plan (the "2018 ESPP"), with the first offering period under the 2018 ESPP commencing on January 1, 2020, by initially providing participating employees with the opportunity to purchase an aggregate of 311,850 shares of the Company's common stock. The number of shares of the Company's common stock reserved for issuance under the 2018 ESPP increased, pursuant to the terms of the 2018 ESPP, by additional shares equal to 1% of the Company&#x2019;s then-outstanding common stock, effective as of January 1 of each year. As of December&#160;31, 2025, 3,577,025 shares remained available for purchase. During the years ended December&#160;31, 2025, 2024 and 2023, the Company issued 110,412, 120,834 and 78,528 shares, respectively, of common stock under the 2018 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;2018 Stock Incentive Plan&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2018, the Company&#x2019;s board of directors adopted, and the Company&#x2019;s stockholders approved, the 2018 Stock Incentive Plan (the "2018 Plan"), which became effective upon the effectiveness of the registration statement on Form S-1 for the Company&#x2019;s initial public offering. The number of common shares initially available for issuance under the 2018 Plan equaled the sum of (1) 4,067,007 shares of common stock; plus (2) the number of shares of common stock (up to 1,277,181 shares) issued in respect of incentive units granted under the Incentive Plan that were subject to vesting immediately prior to the effectiveness of the registration statement that expire, terminate or are otherwise surrendered, cancelled, forfeited or repurchased by the Company at their original issuance price pursuant to a contractual repurchase right; plus (3) an annual increase on the first day of each year beginning with the year ended December 31, 2019 and continuing to, and including, the year ending December 31, 2028, equal to the lesser of 4,989,593 shares of the Company&#x2019;s common stock, 4% of the number of shares of the Company&#x2019;s common stock outstanding on the first day of the year or an amount determined by the Company&#x2019;s board of directors. As of December&#160;31, 2025, 2,966,406 shares are available for issuance under the 2018 Plan. Common shares subject to outstanding equity awards that expire or are terminated, surrendered, or cancelled without having been fully exercised or are forfeited in whole or in part are available for future grants of awards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Compensation Expense&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In connection with the strategic restructuring actions initiated by the Company in the second and third quarters of 2025, as further discussed below in Note 14, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Restructuring Activity&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, the Company modified the vesting terms of certain restricted stock units previously granted to employees. The incremental impact of the modification for the year ended December 31, 2025 totaled $5.3&#160;million, as a decrease to compensation expense.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025, 2024 and 2023, the Company recognized compensation expense of $44.0 million, $88.2&#160;million and $71.6 million, respectively, related to the issuance of incentive awards, including $0.5&#160;million, $0.7&#160;million and $0.8&#160;million, respectively, related to the 2018 ESPP.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As of December&#160;31, 2025, there was $30.4 million of compensation expense that is expected to be recognized over a weighted-average period of approximately 1.5 years.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Stock Options&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted during each of the years ended December&#160;31, 2025, 2024 and 2023 was determined using the Black-Scholes option pricing model at the grant date with the following range of assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.024%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.1% - 80.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0% - 75.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.3% - 75.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 - 5.7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4 - 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7% - 4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5% - 4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4% - 4.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.61 - $17.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$24.19 - $47.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.21 - $36.27&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;Expected term is calculated based on the Company's historical experience.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &#160;&#160;&#160;&#160;Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December 31, 2023, the Company calculated volatility of its common stock by utilizing a weighted-average of a collection of peer company volatilities and its own common stock volatility as the Company&#x2019;s common stock had not been trading for a sufficient period of time. The expected term was calculated utilizing the simplified method.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the 2018 Plan as of December&#160;31, 2025 is presented below. Included in the table are stock options granted to employees, directors and consultants under the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;except weighted-average exercise price)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,892,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,515,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,631,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested and exercisable as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,607,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested and expected to vest as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,304,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of options granted during the years ended December&#160;31, 2025, 2024 and 2023 was $8.15, $27.35 and $21.99, respectively. The total intrinsic value of options exercised during the years ended December&#160;31, 2024 and 2023 was $3.6 million and $1.4 million, respectively. There were no options exercised during the year ended December&#160;31, 2025.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Restricted Stock Units&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock unit ("RSU") activity under the 2018 Plan for the year ended December&#160;31, 2025 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing 170,365 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested RSUs as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,311,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,440,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,253,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(874,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested RSUs as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,624,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average grant date fair value of RSUs granted during the years ended December&#160;31, 2025, 2024 and 2023 was $12.34, $44.43 and $32.27, respectively. The total intrinsic value of RSUs released during the years ended December&#160;31, 2025, 2024 and 2023 was $17.7 million, $13.2 million and $4.3 million, respectively. The total fair value of RSUs vested during the years ended December&#160;31, 2025, 2024 and 2023 was $44.3 million, $13.1 million and $6.9 million, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-605" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-606" unitRef="shares">5000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-607"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-608"
      unitRef="usdPerShare">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-6" decimals="INF" id="f-609" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="c-5" decimals="INF" id="f-610" unitRef="shares">200000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-5"
      decimals="INF"
      id="f-611"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="c-6"
      decimals="INF"
      id="f-612"
      unitRef="usdPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <arvn:NumberOfVotesPerCommonStockShareHeld contextRef="c-5" decimals="INF" id="f-613" unitRef="vote">1</arvn:NumberOfVotesPerCommonStockShareHeld>
    <us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction
      contextRef="c-108"
      decimals="INF"
      id="f-614"
      unitRef="shares">12963542</us-gaap:SaleOfStockNumberOfSharesIssuedInTransaction>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-109"
      decimals="INF"
      id="f-615"
      unitRef="usdPerShare">21.36</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="c-110"
      decimals="INF"
      id="f-616"
      unitRef="shares">3422380</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:SaleOfStockPricePerShare
      contextRef="c-110"
      decimals="INF"
      id="f-617"
      unitRef="usdPerShare">21.359</us-gaap:SaleOfStockPricePerShare>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-111"
      decimals="INF"
      id="f-618"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <arvn:ProceedsFromIssuanceOfCommonStockAndWarrants contextRef="c-112" decimals="-5" id="f-619" unitRef="usd">350000000.0</arvn:ProceedsFromIssuanceOfCommonStockAndWarrants>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-112" decimals="-5" id="f-620" unitRef="usd">15900000</us-gaap:PaymentsOfStockIssuanceCosts>
    <arvn:StockIssuedDuringPeriodSharesExerciseOfWarrants contextRef="c-1" decimals="INF" id="f-621" unitRef="shares">3422186</arvn:StockIssuedDuringPeriodSharesExerciseOfWarrants>
    <srt:StockRepurchaseProgramAuthorizedAmount1 contextRef="c-113" decimals="-5" id="f-622" unitRef="usd">100000000.0</srt:StockRepurchaseProgramAuthorizedAmount1>
    <us-gaap:TreasuryStockSharesAcquired contextRef="c-1" decimals="INF" id="f-623" unitRef="shares">10009758</us-gaap:TreasuryStockSharesAcquired>
    <us-gaap:TreasuryStockAcquiredAverageCostPerShare
      contextRef="c-1"
      decimals="2"
      id="f-624"
      unitRef="usdPerShare">9.09</us-gaap:TreasuryStockAcquiredAverageCostPerShare>
    <arvn:TreasuryStockValueAcquiredCostMethodNetOfCommissions contextRef="c-1" decimals="-5" id="f-625" unitRef="usd">91000000.0</arvn:TreasuryStockValueAcquiredCostMethodNetOfCommissions>
    <arvn:ShareRepurchaseProgramCommissionsAndExciseTax contextRef="c-1" decimals="-5" id="f-626" unitRef="usd">900000</arvn:ShareRepurchaseProgramCommissionsAndExciseTax>
    <arvn:MaximumAggregateOfferingPriceOfCommonStock contextRef="c-114" decimals="-5" id="f-627" unitRef="usd">300000000.0</arvn:MaximumAggregateOfferingPriceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-115"
      decimals="INF"
      id="f-628"
      unitRef="shares">1449275</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodValueNewIssues contextRef="c-115" decimals="-5" id="f-629" unitRef="usd">37200000</us-gaap:StockIssuedDuringPeriodValueNewIssues>
    <us-gaap:PaymentsOfStockIssuanceCosts contextRef="c-115" decimals="-5" id="f-630" unitRef="usd">1100000</us-gaap:PaymentsOfStockIssuanceCosts>
    <arvn:MaximumAggregateOfferingPriceOfCommonStock contextRef="c-116" decimals="-5" id="f-631" unitRef="usd">262800000</arvn:MaximumAggregateOfferingPriceOfCommonStock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-117"
      decimals="INF"
      id="f-632"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="c-118"
      decimals="INF"
      id="f-633"
      unitRef="shares">0</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-119"
      decimals="INF"
      id="f-634"
      unitRef="shares">311850</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock contextRef="c-120" decimals="2" id="f-635" unitRef="number">0.01</arvn:IncreaseInCapitalSharesReservedForFutureIssuanceRepresentedAsPercentageOnOutstandingCommonStock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-121"
      decimals="INF"
      id="f-636"
      unitRef="shares">3577025</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-122"
      decimals="INF"
      id="f-637"
      unitRef="shares">110412</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-123"
      decimals="INF"
      id="f-638"
      unitRef="shares">120834</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="c-124"
      decimals="INF"
      id="f-639"
      unitRef="shares">78528</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-125"
      decimals="INF"
      id="f-640"
      unitRef="shares">4067007</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="c-126"
      decimals="INF"
      id="f-641"
      unitRef="shares">1277181</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod
      contextRef="c-127"
      decimals="INF"
      id="f-642"
      unitRef="shares">4989593</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOtherIncreasesDecreasesInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum contextRef="c-128" decimals="2" id="f-643" unitRef="number">0.04</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPercentageOfOutstandingStockMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="c-129"
      decimals="INF"
      id="f-644"
      unitRef="shares">2966406</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost contextRef="c-1" decimals="-5" id="f-645" unitRef="usd">5300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-1" decimals="-5" id="f-646" unitRef="usd">44000000.0</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-7" decimals="-5" id="f-647" unitRef="usd">88200000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-8" decimals="-5" id="f-648" unitRef="usd">71600000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-130" decimals="-5" id="f-649" unitRef="usd">500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-131" decimals="-5" id="f-650" unitRef="usd">700000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense contextRef="c-132" decimals="-5" id="f-651" unitRef="usd">800000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized contextRef="c-5" decimals="-5" id="f-652" unitRef="usd">30400000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="c-133" id="f-653">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="c-1" id="f-654">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The fair value of the stock options granted during each of the years ended December&#160;31, 2025, 2024 and 2023 was determined using the Black-Scholes option pricing model at the grant date with the following range of assumptions:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:39.960%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.021%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:2.678%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:16.024%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="24" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected volatility&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.1% - 80.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;72.0% - 75.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.3% - 75.0%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Expected term (years)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 - 5.7&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.4 - 5.5&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.5 - 7.0&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Risk free interest rate&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.7% - 4.4%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.5% - 4.6%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.4% - 4.8%&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Expected dividend yield&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Exercise price&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$6.61 - $17.70&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$24.19 - $47.00&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:right"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$16.21 - $36.27&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(1)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#160;&#160;&#160;&#160;Expected volatility is calculated by utilizing the Company's historical volatility of its stock price over a period equal to the expected term.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(2)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt;&#160;&#160;&#160;&#160;Expected term is calculated based on the Company's historical experience.&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:6.5pt;font-weight:400;line-height:115%;position:relative;top:-3.5pt;vertical-align:baseline"&gt;(3)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:115%"&gt; &#160;&#160;&#160;&#160;Risk free interest rate is based on an interpolation of U.S. Treasury rates to reflect the expected term at the date of grant.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-134" decimals="3" id="f-655" unitRef="number">0.721</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-134" decimals="3" id="f-656" unitRef="number">0.804</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-135" decimals="3" id="f-657" unitRef="number">0.720</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-135" decimals="3" id="f-658" unitRef="number">0.756</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum contextRef="c-136" decimals="3" id="f-659" unitRef="number">0.713</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum contextRef="c-136" decimals="3" id="f-660" unitRef="number">0.750</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRateMaximum>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-137" id="f-661">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-138" id="f-662">P5Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-139" id="f-663">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-140" id="f-664">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-141" id="f-665">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1 contextRef="c-142" id="f-666">P7Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-134" decimals="3" id="f-667" unitRef="number">0.037</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-134" decimals="3" id="f-668" unitRef="number">0.044</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-135" decimals="3" id="f-669" unitRef="number">0.035</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-135" decimals="3" id="f-670" unitRef="number">0.046</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum contextRef="c-136" decimals="3" id="f-671" unitRef="number">0.034</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMinimum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum contextRef="c-136" decimals="3" id="f-672" unitRef="number">0.048</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRateMaximum>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-134" decimals="2" id="f-673" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-135" decimals="2" id="f-674" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate contextRef="c-136" decimals="2" id="f-675" unitRef="number">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-143"
      decimals="2"
      id="f-676"
      unitRef="usdPerShare">6.61</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-144"
      decimals="2"
      id="f-677"
      unitRef="usdPerShare">17.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-145"
      decimals="2"
      id="f-678"
      unitRef="usdPerShare">24.19</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-146"
      decimals="2"
      id="f-679"
      unitRef="usdPerShare">47.00</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-147"
      decimals="2"
      id="f-680"
      unitRef="usdPerShare">16.21</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice
      contextRef="c-148"
      decimals="2"
      id="f-681"
      unitRef="usdPerShare">36.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-683">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the 2018 Plan as of December&#160;31, 2025 is presented below. Included in the table are stock options granted to employees, directors and consultants under the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;except weighted-average exercise price)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,892,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,515,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,631,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested and exercisable as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,607,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested and expected to vest as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,304,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="c-1" id="f-682">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of the stock option activity under the 2018 Plan as of December&#160;31, 2025 is presented below. Included in the table are stock options granted to employees, directors and consultants under the 2018 Plan, as well as options to purchase 255,611 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:40.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.994%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions, &lt;/span&gt;&lt;/div&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;except weighted-average exercise price)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Exercise Price&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Remaining&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Contractual&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Term (Years)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Aggregate&lt;br/&gt;Intrinsic Value&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7,892,330&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.16&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,253,860&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,515,115)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;46.07&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Outstanding as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,631,075&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;35.89&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested and exercisable as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5,607,194&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;44.41&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.3&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Vested and expected to vest as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8,304,964&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:3pt double #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;36.55&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;6.4&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants contextRef="c-1" decimals="INF" id="f-684" unitRef="shares">255611</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardInducementGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-149"
      decimals="INF"
      id="f-685"
      unitRef="shares">7892330</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-149"
      decimals="2"
      id="f-686"
      unitRef="usdPerShare">44.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-150" id="f-687">P6Y8M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-149" decimals="-5" id="f-688" unitRef="usd">3200000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="c-151"
      decimals="INF"
      id="f-689"
      unitRef="shares">2253860</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="c-151"
      decimals="2"
      id="f-690"
      unitRef="usdPerShare">12.41</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="c-151"
      decimals="INF"
      id="f-691"
      unitRef="shares">1515115</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="c-151"
      decimals="2"
      id="f-692"
      unitRef="usdPerShare">46.07</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="c-129"
      decimals="INF"
      id="f-693"
      unitRef="shares">8631075</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="c-129"
      decimals="2"
      id="f-694"
      unitRef="usdPerShare">35.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="c-151" id="f-695">P6Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue contextRef="c-129" decimals="-5" id="f-696" unitRef="usd">5300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="c-129"
      decimals="INF"
      id="f-697"
      unitRef="shares">5607194</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="c-129"
      decimals="2"
      id="f-698"
      unitRef="usdPerShare">44.41</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="c-151" id="f-699">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1 contextRef="c-129" decimals="-5" id="f-700" unitRef="usd">0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="c-129"
      decimals="INF"
      id="f-701"
      unitRef="shares">8304964</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="c-129"
      decimals="2"
      id="f-702"
      unitRef="usdPerShare">36.55</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="c-151" id="f-703">P6Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="c-129" decimals="-5" id="f-704" unitRef="usd">4900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-1"
      decimals="2"
      id="f-705"
      unitRef="usdPerShare">8.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-7"
      decimals="2"
      id="f-706"
      unitRef="usdPerShare">27.35</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-8"
      decimals="2"
      id="f-707"
      unitRef="usdPerShare">21.99</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-7" decimals="-5" id="f-708" unitRef="usd">3600000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-8" decimals="-5" id="f-709" unitRef="usd">1400000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue contextRef="c-1" decimals="-5" id="f-710" unitRef="usd">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock contextRef="c-1" id="f-711">&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A summary of restricted stock unit ("RSU") activity under the 2018 Plan for the year ended December&#160;31, 2025 is presented below. Included in the table are RSUs granted to employees and directors under the 2018 Plan, as well as RSUs representing 170,365 shares of common stock granted to certain employees pursuant to the Nasdaq inducement grant exception in accordance with Nasdaq Listing Rule 5635(c)(4).&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:69.506%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Shares&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Weighted-Average Grant&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Date&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Fair Value Per&lt;/span&gt;&lt;/div&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Share&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested RSUs as of December&#160;31, 2024&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2,311,291&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;42.25&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Granted&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,440,614&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.34&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Released&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1,253,564)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;40.06&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Forfeited&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(874,290)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;22.81&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Unvested RSUs as of December&#160;31, 2025&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3,624,051&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;18.59&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:NonvestedRestrictedStockSharesActivityTableTextBlock>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants
      contextRef="c-152"
      decimals="INF"
      id="f-712"
      unitRef="shares">170365</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsInducementGrants>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-153"
      decimals="INF"
      id="f-713"
      unitRef="shares">2311291</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-153"
      decimals="2"
      id="f-714"
      unitRef="usdPerShare">42.25</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="c-154"
      decimals="INF"
      id="f-715"
      unitRef="shares">3440614</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-154"
      decimals="2"
      id="f-716"
      unitRef="usdPerShare">12.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod
      contextRef="c-154"
      decimals="INF"
      id="f-717"
      unitRef="shares">1253564</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedInPeriod>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue
      contextRef="c-154"
      decimals="2"
      id="f-718"
      unitRef="usdPerShare">40.06</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsReleasedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod
      contextRef="c-154"
      decimals="INF"
      id="f-719"
      unitRef="shares">874290</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
      contextRef="c-154"
      decimals="2"
      id="f-720"
      unitRef="usdPerShare">22.81</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="c-155"
      decimals="INF"
      id="f-721"
      unitRef="shares">3624051</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="c-155"
      decimals="2"
      id="f-722"
      unitRef="usdPerShare">18.59</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-152"
      decimals="2"
      id="f-723"
      unitRef="usdPerShare">12.34</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-156"
      decimals="2"
      id="f-724"
      unitRef="usdPerShare">44.43</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="c-157"
      decimals="2"
      id="f-725"
      unitRef="usdPerShare">32.27</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod contextRef="c-152" decimals="-5" id="f-726" unitRef="usd">17700000</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod contextRef="c-156" decimals="-5" id="f-727" unitRef="usd">13200000</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod>
    <arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod contextRef="c-157" decimals="-5" id="f-728" unitRef="usd">4300000</arvn:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueReleasedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-152" decimals="-5" id="f-729" unitRef="usd">44300000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-156" decimals="-5" id="f-730" unitRef="usd">13100000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue contextRef="c-157" decimals="-5" id="f-731" unitRef="usd">6900000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="c-1" id="f-732">Equity Method Investments&lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In July 2019, the Company and Bayer CropScience LP ("Bayer LP") formed Oerth Bio, a joint venture to research, develop and commercialize PROTAC targeted protein degraders for applications in the field of agriculture. Pursuant to the terms of the joint venture agreement, the Company made an in-kind intellectual property contribution to Oerth Bio in the form of a license to certain of the Company&#x2019;s proprietary technology and Bayer LP committed and subsequently made cash contributions to Oerth Bio totaling $56.0&#160;million, as well as an in-kind intellectual property contribution. The Company and Bayer LP each held an initial ownership interest in Oerth Bio representing 50% of the ownership interests. A 15% ownership interest of Oerth Bio was &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reserved for the future grants of incentive units to employees and service providers and, as a result, the Company's ownership interest totaled 42.9%, 43.6% and 45.0% as of December&#160;31, 2025, 2024 and 2023, respectively, as a result of vested incentive units.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Under the joint venture agreement, the Company has no obligation to provide additional funding and the Company&#x2019;s ownership interest will not be diluted from future contributions from Bayer LP. The activities of Oerth Bio are controlled by a management board under the joint control of the Company and Bayer LP. As Oerth Bio is jointly controlled by the Company and Bayer LP, the Company accounts for its interest using the equity method of accounting. The Company determined that Oerth Bio is a variable interest entity and, accordingly, the Company has evaluated the significant activities of Oerth Bio under the variable interest entity model and concluded that the significant activities consist primarily of research and development activities and, as the Company does not have the sole power to direct such activities, the Company is not the primary beneficiary.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Operating expenses and net loss of Oerth Bio for the years ended December 31, 2025, 2024 and 2023 totaled &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$1.1 million&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, $3.7 million and $8.3 million, respectively. The Company recognized no equity method losses for the years ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2025 and &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;2024&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;.&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; The Company recognized equity method losses of $2.5&#160;million for the year ended &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December 31, 2023&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. As of &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;December&#160;31, 2025&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;, and 2024, the Company&#x2019;s carrying value of the investment was zero.&lt;/span&gt;&lt;/div&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also provides Oerth Bio with compensated research and development and administrative services through a separate agreement. The se&lt;/span&gt;rvices rendered by the Company during the years ended December&#160;31, 2025, 2024 and 2023 were immaterial.</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:EquityMethodInvestmentAggregateCost contextRef="c-158" decimals="-5" id="f-733" unitRef="usd">56000000.0</us-gaap:EquityMethodInvestmentAggregateCost>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-158" decimals="2" id="f-734" unitRef="number">0.50</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage contextRef="c-159" decimals="2" id="f-735" unitRef="number">0.15</arvn:FutureGrantOfIncentiveUnitsToServiceProvidersPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-160" decimals="3" id="f-736" unitRef="number">0.429</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-161" decimals="3" id="f-737" unitRef="number">0.436</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:EquityMethodInvestmentOwnershipPercentage contextRef="c-162" decimals="3" id="f-738" unitRef="number">0.450</us-gaap:EquityMethodInvestmentOwnershipPercentage>
    <us-gaap:NetIncomeLoss contextRef="c-163" decimals="-5" id="f-739" unitRef="usd">-1100000</us-gaap:NetIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="c-163" decimals="-5" id="f-740" unitRef="usd">1100000</us-gaap:OperatingExpenses>
    <us-gaap:NetIncomeLoss contextRef="c-164" decimals="-5" id="f-741" unitRef="usd">-3700000</us-gaap:NetIncomeLoss>
    <us-gaap:OperatingExpenses contextRef="c-164" decimals="-5" id="f-742" unitRef="usd">3700000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses contextRef="c-165" decimals="-5" id="f-743" unitRef="usd">8300000</us-gaap:OperatingExpenses>
    <us-gaap:NetIncomeLoss contextRef="c-165" decimals="-5" id="f-744" unitRef="usd">-8300000</us-gaap:NetIncomeLoss>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-166" decimals="-5" id="f-745" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-167" decimals="-5" id="f-746" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-168" decimals="-5" id="f-747" unitRef="usd">-2500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-160" decimals="-5" id="f-748" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:EquityMethodInvestments contextRef="c-161" decimals="-5" id="f-749" unitRef="usd">0</us-gaap:EquityMethodInvestments>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="c-1" id="f-750">Income Taxes &lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025, 2024 and 2023, income tax expense totaled &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.3&#160;million, $0.6&#160;million and $0.9&#160;million, respectively, and consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generated a taxable loss for the year ended December&#160;31, 2025 primarily due to losses from operations. The Company has not recorded any income tax benefits for the net operating losses incurred in the period due to its uncertainty of realizing a benefit from those items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generated a taxable income for the year ended December 31, 2024 primarily due to the Novartis License Agreement, the Novartis Asset Agreement and the required capitalization of research and development expenses. The taxable income for federal purposes has been partially offset by losses from operations.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company generated a taxable loss for the year ended December 31, 2023 primarily due to losses from operations. The Company has not recorded any income tax benefits for the net operating losses incurred in the period due to its uncertainty of realizing a benefit from those items.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;On July 4, 2025, H.R.1, commonly referred to as the One Big Beautiful Bill Act, was signed into law in the U.S., which includes a broad range of tax reform provisions, including extending and modifying certain key Tax Cuts and Jobs Act provisions, and provisions allowing accelerated tax deductions for qualified property and research expenditures. The tax impacts of this legislation do not have a material impact on the Company's consolidated financial statements.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All of the Company&#x2019;s losses before income taxes were generated in the United States.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate for the years ended December&#160;31, 2025, 2024 and 2023 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.918%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.558%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.558%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Federal statutory tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;State and local income taxes, net of federal income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the year ended December&#160;31, 2025, state and local income taxes in Connecticut, Massachusetts, and New York comprised the majority of the state and local income taxes, net of federal effect. For the year ended December&#160;31, 2024, state and local income taxes in Connecticut comprised the majority of the state and local income taxes, net of federal effect. For the year ended December&#160;31, 2023, state and local income taxes in New York comprised the majority of the state and local income taxes, net of federal effect.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes income taxes paid, net of refunds received for the years ended December&#160;31, 2025, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US federal &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US state and local &#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Massachusetts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New York&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New York City&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New Jersey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pennsylvania&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total income taxes paid, net of refunds received &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The amount of income taxes paid during the year does not meet the 5% disaggregation threshold.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Deferred income taxes represent the tax effect of transactions that are reported in different periods for financial and tax reporting purposes. Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities were as follows as of December&#160;31, 2025 and 2024: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(471.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A valuation allowance is established when it is more likely than not that some portion or all of a deferred tax asset will not be realized. The realization of deferred tax assets depends on the generation of future taxable income during the period in which related temporary differences become deductible. The Company has provided a valuation allowance against the full amount of the deferred tax assets since&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; it is more likely than not that the benefits will not be realized. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;This assessment is based on the Company's historical cumulative losses, which provide strong objective evidence that cannot be overcome with projections of income, as well as the fact the Company expects continuing losses in the future.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;All, or a portion of, the remaining valuation allowance may be reduced in future years based on an assessment of earnings sufficient to utilize these potential tax benefits. The valuation allowance increased by $10.0 million and $63.5 million in 2025 and 2024, respectively, due to increases in net operating loss carryforwards, revenue recognition for tax purposes from the Vepdegestrant (ARV-471) Collaboration Agreement and the mandatory capitalization of qualified research and development costs in 2024.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company had $533.6&#160;million and $111.0 million of federal net operating loss carryforwards as of December&#160;31, 2025 and 2024, respectively. Federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such carryforwards is limited to 80% of the Company&#x2019;s taxable income in the year in which carryforwards are used. The Company had $563.2 million and $129.0 million of state and local net operating loss carryforwards as of December&#160;31, 2025 and 2024, respectively, which expire at various dates beginning in 2035. The Company had $44.7 million and $37.7 million of federal tax credit carryforwards as of December&#160;31, 2025 and 2024, respectively. The Company had $22.3 million and $22.4 million of state tax credit carryforwards as of December&#160;31, 2025 and 2024, respectively, which expire at various dates beginning in 2035.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company has performed a Section 382 analysis through December 31, 2024 to determine whether an ownership change occurred for tax purposes. Based on this analysis, the Company determined that ownership changes occurred on July 31, 2018 and December 31, 2020 due to various equity offerings, vesting of restricted stock awards and stock option exercises. These ownership changes resulted in Section 382 limitations on the Company&#x2019;s net operating loss and tax credit carryforwards generated before these dates. However, because the amount of the Section 382 limitations (including carryover of the unused Section 382 limitations and realized built-in gains) exceeds the amount of the Company&#x2019;s carryforwards generated before these dates, the limitations will not affect the Company's ability to fully utilize these carryforwards.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company complies with the provisions of ASC 740, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Accounting for Income Taxes,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; in accounting for its uncertain tax positions. ASC 740 addresses the determination of whether tax benefits claimed or expected to be claimed on a tax return should be recorded in the financial statements. Under ASC 740, the Company may recognize the tax benefit from an uncertain tax position only if it is more likely than not that the tax position will be sustained on examination by the taxing authorities, based on the technical merits of the position. As of December&#160;31, 2025 and 2024, the Company recorded net uncertain tax positions of $5.9 million and $5.4 million, respectively, relating primarily to state income tax filing positions in various jurisdictions. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's gross unrecognized tax benefits were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning of period balance - gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for tax positions taken during the current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;End of period balance - gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company recognizes interest accrued related to unrecognized tax benefits and penalties in tax expense. The Company's accrual for interest and penalties as of December&#160;31, 2025 and 2024 totaled $1.6&#160;million and $1.0&#160;million, respectively.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company is required to file income tax returns in the U.S. Federal and various state jurisdictions. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;As a result of the Company&#x2019;s net operating loss carryforwards, the Company&#x2019;s federal and state statutes of limitations generally remain open for all tax years until its net operating loss and tax credit carryforwards are utilized or expire prior to utilization. The Company is currently under federal income tax examination for the year ended December 31, 2023, and state income tax examination with the state of New York for the years ended December 31, 2021 through December 31, 2023.&lt;/span&gt;&lt;/div&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock contextRef="c-1" id="f-751">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;For the years ended December&#160;31, 2025, 2024 and 2023, income tax expense totaled &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.3&#160;million, $0.6&#160;million and $0.9&#160;million, respectively, and consisted of the following:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Year Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Current:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.7)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total current&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;U.S.:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Federal&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;State and local&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 19pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfComponentsOfIncomeTaxExpenseBenefitTableTextBlock>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-752" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-753" unitRef="usd">600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-8" decimals="-5" id="f-754" unitRef="usd">900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-755" unitRef="usd">-300000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-756" unitRef="usd">0</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentFederalTaxExpenseBenefit contextRef="c-8" decimals="-5" id="f-757" unitRef="usd">-1700000</us-gaap:CurrentFederalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-758" unitRef="usd">600000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-759" unitRef="usd">600000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentStateAndLocalTaxExpenseBenefit contextRef="c-8" decimals="-5" id="f-760" unitRef="usd">2600000</us-gaap:CurrentStateAndLocalTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-761" unitRef="usd">300000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-762" unitRef="usd">600000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:CurrentIncomeTaxExpenseBenefit contextRef="c-8" decimals="-5" id="f-763" unitRef="usd">900000</us-gaap:CurrentIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-764" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-765" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredFederalIncomeTaxExpenseBenefit contextRef="c-8" decimals="-5" id="f-766" unitRef="usd">0</us-gaap:DeferredFederalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-767" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-768" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit contextRef="c-8" decimals="-5" id="f-769" unitRef="usd">0</us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-770" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-771" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit contextRef="c-8" decimals="-5" id="f-772" unitRef="usd">0</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-773" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-774" unitRef="usd">600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-8" decimals="-5" id="f-775" unitRef="usd">900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="c-1" id="f-776">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;A reconciliation of the U.S. federal statutory income tax rate to the Company&#x2019;s effective income tax rate for the years ended December&#160;31, 2025, 2024 and 2023 were as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.848%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:30.918%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.558%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.558%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.673%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:9.683%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="33" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Amount&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Percent&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;U.S. Federal statutory tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(16.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(41.6)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(76.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;21.0&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;State and local income taxes, net of federal income tax effect&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Research and development tax credit&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.5&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.1)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(28.0)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Changes in valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;16.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(20.6&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;43.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(22.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;98.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(26.9&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Nontaxable or nondeductible items&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(9.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.1&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.2&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Effective tax rate&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.3&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;%)&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="-5" id="f-777" unitRef="usd">-16900000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-1" decimals="3" id="f-778" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-7" decimals="-5" id="f-779" unitRef="usd">-41600000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-7" decimals="3" id="f-780" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate contextRef="c-8" decimals="-5" id="f-781" unitRef="usd">-76400000</us-gaap:IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate contextRef="c-8" decimals="3" id="f-782" unitRef="number">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="-5" id="f-783" unitRef="usd">100000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-1" decimals="3" id="f-784" unitRef="number">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-7" decimals="-5" id="f-785" unitRef="usd">4600000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-7" decimals="3" id="f-786" unitRef="number">-0.023</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes contextRef="c-8" decimals="-5" id="f-787" unitRef="usd">2100000</us-gaap:IncomeTaxReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes contextRef="c-8" decimals="3" id="f-788" unitRef="number">-0.006</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-1" decimals="-5" id="f-789" unitRef="usd">6800000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-1" decimals="3" id="f-790" unitRef="number">-0.085</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-7" decimals="-5" id="f-791" unitRef="usd">9100000</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-7" decimals="3" id="f-792" unitRef="number">-0.046</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationTaxCreditsResearch contextRef="c-8" decimals="-5" id="f-793" unitRef="usd">28000000.0</us-gaap:IncomeTaxReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch contextRef="c-8" decimals="3" id="f-794" unitRef="number">-0.076</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="-5" id="f-795" unitRef="usd">16600000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-1" decimals="3" id="f-796" unitRef="number">-0.206</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="-5" id="f-797" unitRef="usd">43800000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-7" decimals="3" id="f-798" unitRef="number">-0.221</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="-5" id="f-799" unitRef="usd">98200000</us-gaap:IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance contextRef="c-8" decimals="3" id="f-800" unitRef="number">-0.269</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="-5" id="f-801" unitRef="usd">7500000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-1" decimals="3" id="f-802" unitRef="number">-0.093</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-7" decimals="-5" id="f-803" unitRef="usd">2100000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-7" decimals="3" id="f-804" unitRef="number">-0.011</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-8" decimals="-5" id="f-805" unitRef="usd">4500000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost contextRef="c-8" decimals="3" id="f-806" unitRef="number">-0.012</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseShareBasedCompensationCost>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="-5" id="f-807" unitRef="usd">-200000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-1" decimals="3" id="f-808" unitRef="number">0.001</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-7" decimals="-5" id="f-809" unitRef="usd">800000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-7" decimals="3" id="f-810" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther contextRef="c-8" decimals="-5" id="f-811" unitRef="usd">500000</us-gaap:IncomeTaxReconciliationNondeductibleExpenseOther>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther contextRef="c-8" decimals="3" id="f-812" unitRef="number">-0.002</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpenseOther>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-1" decimals="-5" id="f-813" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-1" decimals="3" id="f-814" unitRef="number">-0.004</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-7" decimals="-5" id="f-815" unitRef="usd">600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-7" decimals="3" id="f-816" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-8" decimals="-5" id="f-817" unitRef="usd">900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations contextRef="c-8" decimals="3" id="f-818" unitRef="number">-0.003</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock contextRef="c-1" id="f-819">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes income taxes paid, net of refunds received for the years ended December&#160;31, 2025, 2024 and 2023:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:400;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US federal &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;US state and local &#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;California&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Massachusetts&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New York&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New York City&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;New Jersey&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Pennsylvania&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="text-align:center"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;*&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total income taxes paid, net of refunds received &#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:36pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;&#x2022;&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt"&gt;The amount of income taxes paid during the year does not meet the 5% disaggregation threshold.&lt;/span&gt;&lt;/div&gt;</us-gaap:ScheduleOfCashFlowSupplementalDisclosuresTableTextBlock>
    <us-gaap:IncomeTaxPaidFederalAfterRefundReceived contextRef="c-1" decimals="-3" id="f-820" unitRef="usd">-400000</us-gaap:IncomeTaxPaidFederalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidFederalAfterRefundReceived contextRef="c-7" decimals="-3" id="f-821" unitRef="usd">700000</us-gaap:IncomeTaxPaidFederalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidFederalAfterRefundReceived contextRef="c-8" decimals="-3" id="f-822" unitRef="usd">0</us-gaap:IncomeTaxPaidFederalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-169" decimals="-3" id="f-823" unitRef="usd">1300000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-170" decimals="-3" id="f-824" unitRef="usd">1200000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-171" decimals="-3" id="f-825" unitRef="usd">800000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-172" decimals="-3" id="f-826" unitRef="usd">2400000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-173" decimals="-3" id="f-827" unitRef="usd">500000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-174" decimals="-3" id="f-828" unitRef="usd">2200000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-175" decimals="-3" id="f-829" unitRef="usd">1100000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-176" decimals="-3" id="f-830" unitRef="usd">1900000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-177" decimals="-3" id="f-831" unitRef="usd">0</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-178" decimals="-3" id="f-832" unitRef="usd">300000</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived contextRef="c-179" decimals="-3" id="f-833" unitRef="usd">1000000.0</us-gaap:IncomeTaxPaidStateAndLocalAfterRefundReceived>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-1" decimals="-3" id="f-834" unitRef="usd">-400000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-7" decimals="-3" id="f-835" unitRef="usd">2300000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:IncomeTaxesPaidNet contextRef="c-8" decimals="-3" id="f-836" unitRef="usd">11100000</us-gaap:IncomeTaxesPaidNet>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="c-1" id="f-837">Temporary differences and carryforwards that give rise to a significant portion of the deferred income tax benefits and liabilities were as follows as of December&#160;31, 2025 and 2024: &lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:70.112%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.992%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred income tax assets:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Loss carryforwards&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;145.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;31.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Capitalized research and development&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;131.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;161.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Deferred revenue&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;81.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;155.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Tax credits&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;62.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock compensation&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;56.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;60.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Other&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred income tax assets&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;482.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;472.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Deferred income tax liabilities:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Property, equipment and leasehold improvements&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Total deferred income tax liabilities&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(0.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Less valuation allowance&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(481.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(471.4)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net deferred income tax liability&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-5" decimals="-5" id="f-838" unitRef="usd">145400000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards contextRef="c-6" decimals="-5" id="f-839" unitRef="usd">31700000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-5" decimals="-5" id="f-840" unitRef="usd">131900000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment contextRef="c-6" decimals="-5" id="f-841" unitRef="usd">161300000</us-gaap:DeferredTaxAssetsInProcessResearchAndDevelopment>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-5" decimals="-5" id="f-842" unitRef="usd">81900000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsDeferredIncome contextRef="c-6" decimals="-5" id="f-843" unitRef="usd">155600000</us-gaap:DeferredTaxAssetsDeferredIncome>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-5" decimals="-5" id="f-844" unitRef="usd">62100000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwards contextRef="c-6" decimals="-5" id="f-845" unitRef="usd">55800000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-5" decimals="-5" id="f-846" unitRef="usd">56600000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost contextRef="c-6" decimals="-5" id="f-847" unitRef="usd">60100000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-5" decimals="-5" id="f-848" unitRef="usd">4400000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsOther contextRef="c-6" decimals="-5" id="f-849" unitRef="usd">8300000</us-gaap:DeferredTaxAssetsOther>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-5" decimals="-5" id="f-850" unitRef="usd">482300000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross contextRef="c-6" decimals="-5" id="f-851" unitRef="usd">472800000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-5" decimals="-5" id="f-852" unitRef="usd">900000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment contextRef="c-6" decimals="-5" id="f-853" unitRef="usd">1400000</us-gaap:DeferredTaxLiabilitiesPropertyPlantAndEquipment>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-5" decimals="-5" id="f-854" unitRef="usd">900000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities contextRef="c-6" decimals="-5" id="f-855" unitRef="usd">1400000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-5" decimals="-5" id="f-856" unitRef="usd">481400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance contextRef="c-6" decimals="-5" id="f-857" unitRef="usd">471400000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxLiabilities contextRef="c-5" decimals="-5" id="f-858" unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities contextRef="c-6" decimals="-5" id="f-859" unitRef="usd">0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-180" decimals="-5" id="f-860" unitRef="usd">10000000.0</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount contextRef="c-181" decimals="-5" id="f-861" unitRef="usd">63500000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:OperatingLossCarryforwards contextRef="c-182" decimals="-5" id="f-862" unitRef="usd">533600000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-183" decimals="-5" id="f-863" unitRef="usd">111000000.0</us-gaap:OperatingLossCarryforwards>
    <arvn:OperatingLossesCarryForwardMaximumDeductibilityPercentage contextRef="c-184" decimals="2" id="f-864" unitRef="number">0.80</arvn:OperatingLossesCarryForwardMaximumDeductibilityPercentage>
    <us-gaap:OperatingLossCarryforwards contextRef="c-185" decimals="-5" id="f-865" unitRef="usd">563200000</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards contextRef="c-186" decimals="-5" id="f-866" unitRef="usd">129000000.0</us-gaap:OperatingLossCarryforwards>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-182" decimals="-5" id="f-867" unitRef="usd">44700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-183" decimals="-5" id="f-868" unitRef="usd">37700000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-185" decimals="-5" id="f-869" unitRef="usd">22300000</us-gaap:TaxCreditCarryforwardAmount>
    <us-gaap:TaxCreditCarryforwardAmount contextRef="c-186" decimals="-5" id="f-870" unitRef="usd">22400000</us-gaap:TaxCreditCarryforwardAmount>
    <arvn:UnrecognizedTaxBenefitsNet contextRef="c-5" decimals="-5" id="f-871" unitRef="usd">5900000</arvn:UnrecognizedTaxBenefitsNet>
    <arvn:UnrecognizedTaxBenefitsNet contextRef="c-6" decimals="-5" id="f-872" unitRef="usd">5400000</arvn:UnrecognizedTaxBenefitsNet>
    <us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock contextRef="c-1" id="f-873">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Changes in the Company's gross unrecognized tax benefits were as follows:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Beginning of period balance - gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;4.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Increases for tax positions taken during the current period&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;End of period balance - gross&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;5.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfUnrecognizedTaxBenefitsRollForwardTableTextBlock>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-5" id="f-874" unitRef="usd">5900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-22" decimals="-5" id="f-875" unitRef="usd">5900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-13" decimals="-5" id="f-876" unitRef="usd">4100000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-1" decimals="-5" id="f-877" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-7" decimals="-5" id="f-878" unitRef="usd">0</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions contextRef="c-8" decimals="-5" id="f-879" unitRef="usd">1800000</us-gaap:UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-5" decimals="-5" id="f-880" unitRef="usd">5900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-6" decimals="-5" id="f-881" unitRef="usd">5900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefits contextRef="c-22" decimals="-5" id="f-882" unitRef="usd">5900000</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-5" decimals="-5" id="f-883" unitRef="usd">1600000</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued contextRef="c-6" decimals="-5" id="f-884" unitRef="usd">1000000.0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="c-1" id="f-885">Commitments and Contingencies &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company may be subject to legal proceedings, claims and disputes that arise in the&#160;ordinary&#160;course&#160;of business. The Company accrues a liability for such matters when it is probable that future expenditures will be made and that such expenditures can be reasonably estimated. Significant judgment is required to determine both probability and the estimated amount, which could differ materially. Legal fees and other costs associated with such actions are expensed as incurred.&#160;As of December&#160;31, 2025, 2024 and 2023, the Company accrued zero, $5.0&#160;million and $15.2&#160;million, respectively, for such matters, related to the Amended License Agreement with Yale University ("Yale"), as further described below.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:120%"&gt;Clinical and Preclinical Development and Licensing Arrangements&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;From time to time, the Company enters into contracts in the normal course of business with various third parties who support its clinical trials, preclinical research studies and other services related to its development activities. The scope of the services under these agreements can generally be modified at any time, and the agreement can be terminated by either party after a period of notice and receipt of written notice.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:112%"&gt;In addition, under licensing and related arrangements to which the Company is a party, the Company may be obligated to make milestone payments to third parties. The payment obligations under these arrangements are contingent upon future events, such as achievement of specified milestones or generation of product sales, and the amount, timing and likelihood of such payments are not known.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Yale University License Agreement&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In June 2024, the Company entered into an Amended and Restated License Agreement (the &#x201c;Amended License Agreement&#x201d;) with Yale pursuant to which the parties amended and restated the license agreement dated July 5, 2013, as amended to date (the "Original Agreement"). In connection with the signing of the Amended License Agreement, the Company made a payment of $14.95&#160;million to Yale, comprising both an upfront payment connected to the Amended License Agreement and an amount related to the collaboration income under the Novartis License Agreement and Novartis Asset Agreement (see Note 3, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Research &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Collaboration and License Agreements,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; for a description of the agreements&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;)&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company made another $5.0&#160;million payment in June 2025 on the first anniversary of signing. Thereafter, the Company will also pay to Yale (1) up to $15.0&#160;million if it secures approval of the first and second royalty products (as defined in the Amended License Agreement), (2) a low single digit percentage royalty on certain, more narrowly defined &#x201c;collaboration products,&#x201d; and (3) a lower single digit royalty on its aggregate worldwide net sales of certain newly defined &#x201c;meaningfully involved products.&#x201d; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company&#x2019;s obligations under the Original Agreement to pay Yale minimum annual royalties and certain other annual fees have been eliminated and Yale has agreed to release all claims arising previously under the Original Agreement. Other provisions of the Original Agreement remain materially unchanged under the Amended License Agreement, including the &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;requirement to pay to Yale a minimum license maintenance royalty totaling&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; $0.1 million per year until the first sale to a third party of any licensed product, followed by success-based milestones for the first two licensed products for the development of the protein degradation technologies totaling approximately $3.0&#160;million for the first licensed product and approximately $1.5&#160;million for the second licensed product, certain of which milestones have already been satisfied, and low single-digit royalties on aggregate worldwide net sales of certain licensed products, which may be subject to reductions, and subject to minimum royalty payments that range from $0.2 million to $0.5 million. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During each of the years ended December&#160;31, 2025, 2024 and 2023, the Comp&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;any recognized expenses &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;under the license agreement totaling&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.7&#160;million, zero and $0.3&#160;million, respectively, under the license agreement. The payment made in the year ended December 31, 2024 included the payment made in connection with signing the Amended License Agreement, as summarized above.&lt;/span&gt;&lt;/div&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-5" decimals="-5" id="f-886" unitRef="usd">0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-6" decimals="-5" id="f-887" unitRef="usd">5000000.0</us-gaap:LossContingencyAccrualAtCarryingValue>
    <us-gaap:LossContingencyAccrualAtCarryingValue contextRef="c-22" decimals="-5" id="f-888" unitRef="usd">15200000</us-gaap:LossContingencyAccrualAtCarryingValue>
    <arvn:PaymentsForCollaboration contextRef="c-187" decimals="-4" id="f-889" unitRef="usd">14950000</arvn:PaymentsForCollaboration>
    <arvn:CollaborativeArrangementRightsAndObligationsMilestonePayment contextRef="c-188" decimals="-5" id="f-890" unitRef="usd">5000000.0</arvn:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <arvn:CollaborativeArrangementRightsAndObligationsMilestonePayment contextRef="c-189" decimals="-5" id="f-891" unitRef="usd">15000000.0</arvn:CollaborativeArrangementRightsAndObligationsMilestonePayment>
    <arvn:AnnualLicenseFeePayment contextRef="c-190" decimals="-5" id="f-892" unitRef="usd">100000</arvn:AnnualLicenseFeePayment>
    <arvn:NumberOfLicensedProducts
      contextRef="c-191"
      decimals="INF"
      id="f-893"
      unitRef="product">2</arvn:NumberOfLicensedProducts>
    <arvn:RequiredMilestonePayments contextRef="c-192" decimals="-5" id="f-894" unitRef="usd">3000000.0</arvn:RequiredMilestonePayments>
    <arvn:RequiredMilestonePayments contextRef="c-193" decimals="-5" id="f-895" unitRef="usd">1500000</arvn:RequiredMilestonePayments>
    <us-gaap:PaymentsForRoyalties contextRef="c-190" decimals="-5" id="f-896" unitRef="usd">200000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="c-194" decimals="-5" id="f-897" unitRef="usd">500000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="c-195" decimals="-5" id="f-898" unitRef="usd">700000</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="c-196" decimals="-5" id="f-899" unitRef="usd">0</us-gaap:PaymentsForRoyalties>
    <us-gaap:PaymentsForRoyalties contextRef="c-197" decimals="-5" id="f-900" unitRef="usd">300000</us-gaap:PaymentsForRoyalties>
    <us-gaap:EarningsPerShareTextBlock contextRef="c-1" id="f-901">Net Loss Per Share &lt;div style="margin-top:6pt;text-indent:34.7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per common share was calculated as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars and shares in millions, except per common share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(367.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;- basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss per common share&lt;br/&gt;&#160;- basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Treasury shares are not considered outstanding and are excluded from the calculation of basic and diluted loss per common share.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The weighted-average number of common shares included in the computation of basic and diluted net loss per common share for the years ended December 31, 2024 and 2023 gave effect to pre-funded warrants which allowed holders to acquire a specified number of common shares at a nominal exercise price of &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;$0.001&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; per share and were classified as equity. The shares underlying the pre-funded warrants were exercisable for little or no consideration and therefore the underlying shares were considered outstanding at the issuance of the pre-funded warrants for purposes of calculating the weighted-average number of common shares outstanding in basic and diluted net loss per share for common share. As of December&#160;31, 2025, all outstanding&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;pre-funded warrants had been cashless exercised for no consideration. See Note 9,&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt; Equity.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:34.7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported net losses for each of the years ended December 31, 2025, 2024 and 2023, and therefore excluded all stock options and RSUs from the computation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock contextRef="c-1" id="f-902">&lt;div style="margin-top:6pt;text-indent:34.7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Basic and diluted loss per common share was calculated as follows: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-align:center"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars and shares in millions, except per common share amounts)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(80.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(198.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(367.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Weighted-average common shares outstanding&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:9pt;text-indent:-9pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;&#160;- basic and diluted&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;70.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;71.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;55.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Net loss per common share&lt;br/&gt;&#160;- basic and diluted&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(1.14)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(2.77)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;(6.62)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfEarningsPerShareBasicAndDilutedTableTextBlock>
    <us-gaap:NetIncomeLoss contextRef="c-1" decimals="-5" id="f-903" unitRef="usd">-80800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-7" decimals="-5" id="f-904" unitRef="usd">-198900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-8" decimals="-5" id="f-905" unitRef="usd">-367300000</us-gaap:NetIncomeLoss>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-1" decimals="-5" id="f-906" unitRef="shares">70900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-1" decimals="-5" id="f-907" unitRef="shares">70900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-7" decimals="-5" id="f-908" unitRef="shares">71900000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-7" decimals="-5" id="f-909" unitRef="shares">71900000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding contextRef="c-8" decimals="-5" id="f-910" unitRef="shares">55500000</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic contextRef="c-8" decimals="-5" id="f-911" unitRef="shares">55500000</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-1"
      decimals="2"
      id="f-912"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-1"
      decimals="2"
      id="f-913"
      unitRef="usdPerShare">-1.14</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-7"
      decimals="2"
      id="f-914"
      unitRef="usdPerShare">-2.77</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-7"
      decimals="2"
      id="f-915"
      unitRef="usdPerShare">-2.77</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="c-8"
      decimals="2"
      id="f-916"
      unitRef="usdPerShare">-6.62</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="c-8"
      decimals="2"
      id="f-917"
      unitRef="usdPerShare">-6.62</us-gaap:EarningsPerShareBasic>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-198"
      decimals="3"
      id="f-918"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="c-22"
      decimals="3"
      id="f-919"
      unitRef="usdPerShare">0.001</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="c-1" id="f-920">&lt;div style="margin-top:12pt;text-indent:34.7pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company reported net losses for each of the years ended December 31, 2025, 2024 and 2023, and therefore excluded all stock options and RSUs from the computation of diluted net loss per common share as their inclusion would have had an anti-dilutive effect, as summarized below:&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:55.415%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.990%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.993%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;Year ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(shares in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;Stock options&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;8.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;7.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;RSUs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;3.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;12.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;10.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:100%"&gt;9.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-199"
      decimals="-5"
      id="f-921"
      unitRef="shares">8600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-200"
      decimals="-5"
      id="f-922"
      unitRef="shares">7900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-201"
      decimals="-5"
      id="f-923"
      unitRef="shares">7900000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-202"
      decimals="-5"
      id="f-924"
      unitRef="shares">3600000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-203"
      decimals="-5"
      id="f-925"
      unitRef="shares">2300000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="c-204"
      decimals="-5"
      id="f-926"
      unitRef="shares">1200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-1" decimals="-5" id="f-927" unitRef="shares">12200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-7" decimals="-5" id="f-928" unitRef="shares">10200000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount contextRef="c-8" decimals="-5" id="f-929" unitRef="shares">9100000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock contextRef="c-1" id="f-930">Restructuring Activity&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In the second quarter of 2025, the Company committed to and approved a reduction of the Company&#x2019;s workforce by approximately 33% across all areas of the Company, as part of the Company&#x2019;s decision to streamline operations across the organization and enable the efficient progression of the Company&#x2019;s portfolio. This decision was made following a strategic review aimed at reducing internal costs while minimally impacting the Company's targeted clinical stage programs to drive value over the next several years by aligning the Company's operations with long-term program development objectives. As of June 30, 2025, these restructuring activities were substantially completed.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;In September 2025, the Company announced an update on its collaboration with Pfizer and further actions to support value creation by optimizing organizational and cost structures and streamlining operations in advance of multiple anticipated upcoming value inflection points, including: further limiting additional expenditures on the vepdegestrant program supporting activities required for commercialization readiness and identification, with Pfizer, of a third party for the commercialization and potential further development of vepdegestrant; reducing the Company's workforce by an additional 15% to streamline operations, with the most significant reductions being roles related to vepdegestrant commercialization; and proactively managing pipeline cost by seeking strategic business development opportunities and by identifying further efficiencies across the business. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The September 2025 workforce reduction was substantially completed in the first quarter of 2026.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%"&gt;Components of Restructuring Charges&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;During the year ended December&#160;31, 2025, the Company recognized net restructuring charges of $3.7&#160;million, including $15.3&#160;million of cash severance and other one-time employee related termination benefit related to the workforce reduction, partially offset by a reversal of $11.6&#160;million of non-cash stock compensation and bonus expenses, of which $2.3&#160;million of charges are reflected in &lt;span style="-sec-ix-hidden:f-937"&gt;research and development expenses&lt;/span&gt; and $1.3&#160;million of a reversal of previously recognized expense reflected in &lt;span style="-sec-ix-hidden:f-939"&gt;general and administrative expenses&lt;/span&gt; in the accompanying consolidated statement of operations. The Company recognized no restructuring charges during the years ended December 31, 2024 and 2023.&lt;/span&gt;&lt;/div&gt;The Company's restructuring accrual totaled $4.4&#160;million and zero as of December&#160;31, 2025 and 2024, respectively.</us-gaap:RestructuringAndRelatedActivitiesDisclosureTextBlock>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-205" decimals="2" id="f-931" unitRef="number">0.33</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent contextRef="c-206" decimals="2" id="f-932" unitRef="number">0.15</us-gaap:RestructuringAndRelatedCostNumberOfPositionsEliminatedPeriodPercent>
    <us-gaap:RestructuringCharges contextRef="c-1" decimals="-5" id="f-933" unitRef="usd">3700000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-207" decimals="-5" id="f-934" unitRef="usd">15300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-208" decimals="-5" id="f-935" unitRef="usd">-11600000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-209" decimals="-5" id="f-936" unitRef="usd">2300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-210" decimals="-5" id="f-938" unitRef="usd">1300000</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-7" decimals="-5" id="f-940" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringCharges contextRef="c-8" decimals="-5" id="f-941" unitRef="usd">0</us-gaap:RestructuringCharges>
    <us-gaap:RestructuringReserve contextRef="c-5" decimals="-5" id="f-942" unitRef="usd">4400000</us-gaap:RestructuringReserve>
    <us-gaap:RestructuringReserve contextRef="c-6" decimals="-5" id="f-943" unitRef="usd">0</us-gaap:RestructuringReserve>
    <us-gaap:SegmentReportingDisclosureTextBlock contextRef="c-1" id="f-944">Segment Information &lt;div style="margin-top:6pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company's operations are organized into one operating and reportable segment focused on &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;the discovery, development and commercialization of therapies that degrade disease-causing proteins. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The segment develops protein degradation therapies designed to harness the body's natural protein disposal system to selectively and efficiently degrade and remove disease-causing protein through the Company's PROTAC (PROteolysis TArgeting Chimera) protein degrader platform. The Company is progressing multiple product candidates through clinical development programs, including &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;ARV-102, targeting the leucine-rich repeat kinase 2 protein for the treatment of neurodegenerative diseases; ARV-806, targeting Kirsten rat sarcoma G12D protein for cancers with the G12D mutation, including pancreatic, colorectal and non-small cell lung cancers; ARV-393, targeting the B-cell lymphoma 6 protein for the treatment of relapsed/refractory non-Hodgkin Lymphoma; ARV-027, targeting the polyQ-AR in skeletal muscle and specifically selected for potent &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;in vitro&lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt; &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt"&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;reduction of cytosolic and nuclear polyQ-AR and for favorable skeletal muscle exposure following oral administration; and vepdegestrant, targeting the estrogen receptor for the treatment of locally advanced or metastatic ER positive / human epidermal growth factor receptor 2 negative breast cancer&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The Company's tangible assets are held in the United States and all of the Company's revenue has been generated in the United States. The Company manages all business activities on a consolidated basis. The Company's chief operating decision maker is the Chief Executive Officer. &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The operating segment's revenue is primarily generated through research collaborations and licensing arrangements with pharmaceutical partners. The terms of these agreements contain multiple goods and services which may include (i) licenses, (ii) research and development activities, and (iii) participation in joint research and development steering committees. The terms of these agreements may include non-refundable, upfront license or option fees, payments for research and development activities, payments upon the achievement of certain milestones and royalty payments based on product sales derived from the collaboration. Revenue is recognized ratably over the Company&#x2019;s expected performance period under each respective arrangement. &lt;/span&gt;&lt;span style="background-color:#ffffff;color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company also generated revenue through the sale of assets based on fair value. &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The Company does not have intra-entity sales or transfers.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The accounting policies of the operating segment are the same as those described in Note 2, &lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%"&gt;Summary of Significant Accounting Policies&lt;/span&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;. The chief operating decision maker evaluates the performance of the operating segment and allocates resources based on net income/ loss that also is reported on the consolidated income statement as net loss. The measure of the operating segment assets is reported on the consolidated balance sheet as total assets.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The chief operating decision maker uses net loss to monitor budget versus actual results and to analyze cash flows in assessing performance of the segment and allocating resources.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the reportable segment's financial information: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;262.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;263.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Program-specific external expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vepdegestrant (ARV-471) (*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ARV-102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ARV-806&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ARV-393&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Bavdegalutamide (ARV-110)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Luxdegalutamide (ARV-766)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non program-specific external expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Compensation and related personnel expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(including stock-based compensation)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;145.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;285.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;348.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;379.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;95.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;165.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Other segment expense, net (**)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Loss from equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Plus:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(80.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(198.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(367.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(*)&#160;&#160;&#160;&#160;Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.&lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(**)&#160;&#160;&#160;&#160;Includes loss on disposal of fixed assets, realized gains/ losses on sale of marketable securities and refundable research and development credits from the State of Connecticut.  &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;Depreciation and amortization expense totaled $3.0 million, $4.6 million, and $4.8 million for the years ended December&#160;31, 2025, 2024 and 2023, respectively.&lt;/span&gt;&lt;/div&gt;</us-gaap:SegmentReportingDisclosureTextBlock>
    <us-gaap:NumberOfOperatingSegments
      contextRef="c-1"
      decimals="INF"
      id="f-945"
      unitRef="segment">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:NumberOfReportableSegments
      contextRef="c-1"
      decimals="INF"
      id="f-946"
      unitRef="segment">1</us-gaap:NumberOfReportableSegments>
    <us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock contextRef="c-1" id="f-947">&lt;div style="margin-top:12pt;text-indent:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;The following table summarizes the reportable segment's financial information: &lt;/span&gt;&lt;/div&gt;&lt;div style="margin-top:12pt"&gt;&lt;table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"&gt;&lt;tr&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:58.142%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.081%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:0.406%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td style="width:1.0%"&gt;&lt;/td&gt;&lt;td style="width:12.084%"&gt;&lt;/td&gt;&lt;td style="width:0.1%"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="15" style="padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:114%"&gt;Years Ended December 31,&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-style:italic;font-weight:400;line-height:114%"&gt;(dollars in millions)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2025&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2024&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:8pt;font-weight:700;line-height:100%"&gt;2023&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Revenue&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;262.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;263.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;78.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Less:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 25pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Program-specific external expense:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="margin-top:12pt;padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Vepdegestrant (ARV-471) (*)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;76.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;104.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ARV-102&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;21.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ARV-806&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;ARV-393&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;6.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Bavdegalutamide (ARV-110)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;8.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;26.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Luxdegalutamide (ARV-766)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;19.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;24.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other programs&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;4.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Non program-specific external expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;49.1&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;62.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;72.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Compensation and related personnel expense&lt;/span&gt;&lt;/div&gt;&lt;div style="padding-left:36pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(including stock-based compensation)&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;109.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;145.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;134.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 37pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Other research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;11.0&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;12.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;13.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 49pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Total research and development expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;285.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;348.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;379.7&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;div style="padding-left:12pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;General and administrative expense&lt;/span&gt;&lt;/div&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;95.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;165.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;100.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Other segment expense, net (**)&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;1.2&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Income tax expense&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.3&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.6&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;0.9&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Loss from equity method investment&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;&#x2014;&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;2.5&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;Plus:&lt;/span&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 14.5pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:114%"&gt;Interest income, net&lt;/span&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38.4&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;54.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#cceeff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;38.8&#160;&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:700;line-height:100%"&gt;Segment net loss&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(80.8)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(198.9)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="background-color:#ffffff;padding:0 1pt"&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;$&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:114%"&gt;(367.3)&lt;/span&gt;&lt;/td&gt;&lt;td style="background-color:#ffffff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"&gt;&lt;/td&gt;&lt;td colspan="3" style="display:none"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;div style="margin-top:6pt;padding-left:18pt;text-indent:-18pt"&gt;&lt;span style="color:#000000;font-family:'Arial',sans-serif;font-size:10pt;font-weight:400;line-height:120%"&gt;(*)&#160;&#160;&#160;&#160;Includes net reimbursement to and from Pfizer pursuant to the Vepdegestrant (ARV-471) Collaboration Agreement which are accounted for pursuant to ASC 808 and are recorded as an offset or an increase to research and development expenses.&lt;/span&gt;&lt;/div&gt;(**)&#160;&#160;&#160;&#160;Includes loss on disposal of fixed assets, realized gains/ losses on sale of marketable securities and refundable research and development credits from the State of Connecticut.</us-gaap:ScheduleOfSegmentReportingInformationBySegmentTextBlock>
    <us-gaap:Revenues contextRef="c-211" decimals="-5" id="f-948" unitRef="usd">262600000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-212" decimals="-5" id="f-949" unitRef="usd">263400000</us-gaap:Revenues>
    <us-gaap:Revenues contextRef="c-213" decimals="-5" id="f-950" unitRef="usd">78500000</us-gaap:Revenues>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-214" decimals="-5" id="f-951" unitRef="usd">62700000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-215" decimals="-5" id="f-952" unitRef="usd">76900000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-216" decimals="-5" id="f-953" unitRef="usd">104800000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-217" decimals="-5" id="f-954" unitRef="usd">21000000.0</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-218" decimals="-5" id="f-955" unitRef="usd">13000000.0</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-219" decimals="-5" id="f-956" unitRef="usd">2300000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-220" decimals="-5" id="f-957" unitRef="usd">13500000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-221" decimals="-5" id="f-958" unitRef="usd">2300000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-222" decimals="-5" id="f-959" unitRef="usd">0</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-223" decimals="-5" id="f-960" unitRef="usd">11100000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-224" decimals="-5" id="f-961" unitRef="usd">6800000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-225" decimals="-5" id="f-962" unitRef="usd">1400000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-226" decimals="-5" id="f-963" unitRef="usd">2700000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-227" decimals="-5" id="f-964" unitRef="usd">8500000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-228" decimals="-5" id="f-965" unitRef="usd">26600000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-229" decimals="-5" id="f-966" unitRef="usd">0</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-230" decimals="-5" id="f-967" unitRef="usd">19700000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-231" decimals="-5" id="f-968" unitRef="usd">24200000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-232" decimals="-5" id="f-969" unitRef="usd">4500000</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-233" decimals="-5" id="f-970" unitRef="usd">0</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseProgramSpecific contextRef="c-234" decimals="-5" id="f-971" unitRef="usd">0</arvn:ResearchAndDevelopmentExpenseProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseNonProgramSpecific contextRef="c-211" decimals="-5" id="f-972" unitRef="usd">49100000</arvn:ResearchAndDevelopmentExpenseNonProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseNonProgramSpecific contextRef="c-212" decimals="-5" id="f-973" unitRef="usd">62800000</arvn:ResearchAndDevelopmentExpenseNonProgramSpecific>
    <arvn:ResearchAndDevelopmentExpenseNonProgramSpecific contextRef="c-213" decimals="-5" id="f-974" unitRef="usd">72400000</arvn:ResearchAndDevelopmentExpenseNonProgramSpecific>
    <us-gaap:LaborAndRelatedExpense contextRef="c-211" decimals="-5" id="f-975" unitRef="usd">109600000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-212" decimals="-5" id="f-976" unitRef="usd">145400000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:LaborAndRelatedExpense contextRef="c-213" decimals="-5" id="f-977" unitRef="usd">134200000</us-gaap:LaborAndRelatedExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-211" decimals="-5" id="f-978" unitRef="usd">11000000.0</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-212" decimals="-5" id="f-979" unitRef="usd">12800000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:OtherResearchAndDevelopmentExpense contextRef="c-213" decimals="-5" id="f-980" unitRef="usd">13800000</us-gaap:OtherResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-211" decimals="-5" id="f-981" unitRef="usd">285200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-212" decimals="-5" id="f-982" unitRef="usd">348200000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense contextRef="c-213" decimals="-5" id="f-983" unitRef="usd">379700000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-211" decimals="-5" id="f-984" unitRef="usd">95900000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-212" decimals="-5" id="f-985" unitRef="usd">165400000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense contextRef="c-213" decimals="-5" id="f-986" unitRef="usd">100300000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-211" decimals="-5" id="f-987" unitRef="usd">400000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-212" decimals="-5" id="f-988" unitRef="usd">2900000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:SegmentReportingOtherItemAmount contextRef="c-213" decimals="-5" id="f-989" unitRef="usd">1200000</us-gaap:SegmentReportingOtherItemAmount>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-211" decimals="-5" id="f-990" unitRef="usd">300000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-212" decimals="-5" id="f-991" unitRef="usd">600000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit contextRef="c-213" decimals="-5" id="f-992" unitRef="usd">900000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-211" decimals="-5" id="f-993" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-212" decimals="-5" id="f-994" unitRef="usd">0</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:IncomeLossFromEquityMethodInvestments contextRef="c-213" decimals="-5" id="f-995" unitRef="usd">-2500000</us-gaap:IncomeLossFromEquityMethodInvestments>
    <us-gaap:InvestmentIncomeInterest contextRef="c-211" decimals="-5" id="f-996" unitRef="usd">38400000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-212" decimals="-5" id="f-997" unitRef="usd">54800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:InvestmentIncomeInterest contextRef="c-213" decimals="-5" id="f-998" unitRef="usd">38800000</us-gaap:InvestmentIncomeInterest>
    <us-gaap:NetIncomeLoss contextRef="c-211" decimals="-5" id="f-999" unitRef="usd">-80800000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-212" decimals="-5" id="f-1000" unitRef="usd">-198900000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss contextRef="c-213" decimals="-5" id="f-1001" unitRef="usd">-367300000</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationAndAmortization contextRef="c-1" decimals="-5" id="f-1002" unitRef="usd">3000000.0</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-7" decimals="-5" id="f-1003" unitRef="usd">4600000</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization contextRef="c-8" decimals="-5" id="f-1004" unitRef="usd">4800000</us-gaap:DepreciationAndAmortization>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
